The	O
dogma	O
of	O
exclusive	O
T	O
cell	O
recognition	O
of	O
peptide	B
-	O
major	O
histocompatibility	O
complex	O
(	O
pMHC	O
)	O
antigens	B
has	O
recently	O
been	O
challenged	O
(	O
Kaufmann	O
1996	O
;	O
Melian	O
et	O
al.	O
1996	O
;	O
Porcelli	O
et	O
al.	O
1996	O
;	O
Carbone	O
and	O
Gleeson	O
1997	O
;	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
.	O

Cells	O
presenting	O
nonpeptidic	O
or	O
modified	O
peptide	B
antigens	B
(	O
e.g.	O
,	O
glycopeptides	B
and	O
glycolipids	B
bound	O
to	O
class	O
I	O
and	O
II	O
MHC	O
,	O
and	O
MHC	O
class	O
I	O
–	O
like	O
CD1	O
molecules	O
,	O
respectively	O
)	O
can	O
also	O
be	O
recognized	O
by	O
cytotoxic	O
T	O
cells	O
(	O
CTL	O
)	O
bearing	O
α	O
/	O
β	O
or	O
γ	O
/	O
δ	O
T	O
cell	O
receptors	O
(	O
TCR	O
)	O
(	O
Beckman	O
et	O
al.	O
1994	O
;	O
Davis	O
and	O
Chien	O
1995	O
;	O
Sieling	O
et	O
al.	O
1995	O
;	O
Chien	O
et	O
al.	O
1996	O
;	O
Kaufmann	O
1996	O
;	O
reviewed	O
by	O
Porcelli	O
et	O
al.	O
1998	O
)	O
.	O

However	O
,	O
the	O
structural	O
properties	O
of	O
these	O
unconventional	O
TCR	O
ligands	O
are	O
currently	O
undetermined	O
except	O
for	O
the	O
crystal	O
structure	O
of	O
mouse	O
CD1	O
(	O
Zeng	O
et	O
al.	O
1997	O
)	O
.	O

Conventional	O
T	O
cell	O
recognition	O
of	O
pMHC	O
has	O
been	O
widely	O
studied	O
(	O
Eisen	O
et	O
al.	O
1996	O
;	O
Davis	O
et	O
al.	O
1998	O
)	O
and	O
now	O
includes	O
the	O
recent	O
high	O
-	O
resolution	O
crystal	O
structures	O
of	O
intact	O
α	O
/	O
β	O
TCR	O
-	O
pMHC	O
complexes	O
(	O
Garboczi	O
et	O
al.	O
1996	O
;	O
Garcia	O
et	O
al.	O
1996	O
,	O
Garcia	O
et	O
al.	O
1998	O
;	O
Ding	O
et	O
al.	O
1998	O
)	O
.	O

The	O
TCR	O
binds	O
the	O
pMHC	O
surface	O
in	O
a	O
diagonal	O
orientation	O
in	O
which	O
a	O
majority	O
of	O
the	O
intermolecular	O
interactions	O
are	O
derived	O
from	O
contact	O
of	O
CDRs	O
1	O
and	O
2	O
of	O
both	O
TCR	O
polypeptide	O
chains	O
with	O
highly	O
conserved	O
MHC	O
α1	O
and	O
α2	O
helical	O
residues	O
.	O

The	O
TCR	O
α	O
and	O
β	O
chain	O
hypervariable	O
CDR3	O
loops	O
are	O
ideally	O
positioned	O
within	O
the	O
MHC	O
helices	O
to	O
examine	O
the	O
contents	O
of	O
the	O
peptide	O
binding	O
groove	O
and	O
hence	O
are	O
well	O
suited	O
for	O
their	O
role	O
in	O
peptide	O
-	O
antigen	B
recognition	O
.	O

The	O
consistent	O
diagonal	O
orientation	O
of	O
the	O
TCRs	O
over	O
the	O
pMHC	O
so	O
far	O
observed	O
allows	O
more	O
accurate	O
prediction	O
of	O
the	O
structural	O
determinants	O
of	O
MHC	O
-	O
bound	O
ligands	O
that	O
are	O
likely	O
to	O
be	O
responsible	O
for	O
T	O
cell	O
recognition	O
(	O
reviewed	O
by	O
Wilson	O
and	O
Garcia	O
1997	O
)	O
.	O

The	O
biological	O
role	O
of	O
antigen	B
ligation	O
by	O
γ	O
/	O
δ	O
TCR	O
in	O
T	O
cell	O
–	O
mediated	O
immunity	O
is	O
far	O
less	O
understood	O
.	O

Indeed	O
,	O
MHC	O
-	O
independent	O
recognition	O
of	O
ligands	O
by	O
γ	O
/	O
δ	O
TCRs	O
was	O
anticipated	O
after	O
analysis	O
of	O
their	O
primary	O
structures	O
.	O

Similar	O
to	O
the	O
comparison	O
between	O
immunoglobin	O
(	O
Ig	O
)	O
VH	O
and	O
VL	O
CDR3	O
loops	O
,	O
the	O
TCR	O
δ	O
chain	O
CDR3s	O
are	O
significantly	O
longer	O
and	O
more	O
heterogenous	O
in	O
length	O
than	O
those	O
of	O
the	O
γ	O
chain	O
(	O
Rock	O
et	O
al.	O
1994	O
)	O
.	O

The	O
TCR	O
α	O
and	O
β	O
chain	O
CDR3s	O
are	O
both	O
long	O
and	O
homogeneous	O
in	O
length	O
.	O

Therefore	O
,	O
the	O
γ	O
and	O
δ	O
chain	O
pairings	O
suggest	O
γ	O
/	O
δ	O
TCR	O
antigen	B
binding	O
is	O
more	O
closely	O
related	O
to	O
that	O
of	O
Ig	O
molecules	O
than	O
to	O
α	O
/	O
β	O
TCR	O
(	O
Rock	O
et	O
al.	O
1994	O
;	O
Davis	O
and	O
Chien	O
1995	O
)	O
.	O

Many	O
γ	O
/	O
δ	O
T	O
cell	O
effector	O
functions	O
overlap	O
with	O
those	O
of	O
α	O
/	O
β	O
T	O
cells	O
;	O
however	O
,	O
γ	O
/	O
δ	O
T	O
cells	O
differ	O
in	O
their	O
antigens	O
and	O
mode	O
of	O
ligand	O
recognition	O
that	O
may	O
be	O
reflected	O
in	O
their	O
localization	O
,	O
relative	O
population	O
,	O
and	O
activation	O
kinetics	O
(	O
Kaufmann	O
1996	O
;	O
Boismenu	O
and	O
Havran	O
1997	O
)	O
.	O

Glycosylation	O
is	O
a	O
common	O
posttranslational	O
modification	O
of	O
proteins	O
to	O
be	O
secreted	O
or	O
transported	O
to	O
the	O
cell	O
surface	O
(	O
Varki	O
1993	O
)	O
.	O

Nevertheless	O
,	O
evidence	O
for	O
the	O
processing	O
of	O
glycoproteins	O
to	O
glycopeptides	B
and	O
subsequent	O
glycopeptide	B
presentation	O
by	O
MHC	O
class	O
I	O
(	O
MHC	O
I	O
)	O
or	O
II	O
(	O
MHC	O
II	O
)	O
receptors	O
during	O
normal	O
immune	O
responses	O
is	O
scarce	O
(	O
Carbone	O
and	O
Gleeson	O
1997	O
;	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
.	O

Glycosylated	O
fragments	O
of	O
collagen	O
type	O
II	O
presented	O
by	O
MHC	O
II	O
I	O
-	O
Aq	O
(	O
Broddefalk	O
et	O
al.	O
1998	O
)	O
and	O
the	O
O	O
-	O
linked	O
glycosylation	O
of	O
cytosolic	O
and	O
nuclear	O
proteins	O
with	O
a	O
single	O
N	B
-	I
acetylglucosamine	I
(	O
GlcNAc	B
)	O
(	O
Hart	O
et	O
al.	O
1989	O
;	O
Haurum	O
et	O
al.	O
1994	O
)	O
represent	O
two	O
possible	O
sources	O
of	O
natural	O
glycopeptides	B
for	O
T	O
cell	O
recognition	O
.	O

Studies	O
using	O
synthetic	O
glycopeptides	B
have	O
enhanced	O
our	O
understanding	O
of	O
oligosaccharide	B
recognition	O
by	O
T	O
cells	O
(	O
Carbone	O
and	O
Gleeson	O
1997	O
;	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
recognize	O
carbohydrates	B
has	O
important	O
implications	O
,	O
as	O
some	O
glycoprotein	O
and	O
glycolipid	B
-	O
associated	O
oligosaccharides	B
have	O
been	O
identified	O
as	O
tumor	O
-	O
associated	O
antigens	B
(	O
TAA	O
;	O
Hakomori	O
1989	O
)	O
.	O

In	O
the	O
first	O
demonstration	O
of	O
a	O
T	O
cell	O
response	O
to	O
a	O
naturally	O
occuring	O
glycan	B
,	O
immunization	O
with	O
synthetic	O
MHC	O
I	O
restricted	O
peptides	B
conjugated	O
with	O
GlcNAc	B
generated	O
glycopeptide	B
-	O
specific	O
CTL	O
(	O
Haurum	O
et	O
al.	O
1994	O
)	O
.	O

Although	O
many	O
studies	O
have	O
demonstrated	O
the	O
fine	O
specificity	O
of	O
helper	O
T	O
cells	O
and	O
CTL	O
for	O
glycopeptide	B
versus	O
carrier	O
peptide	B
,	O
they	O
have	O
not	O
convincingly	O
demonstrated	O
TCR	O
recognition	O
of	O
the	O
carbohydrate	B
hapten	I
moiety	O
independent	O
of	O
the	O
restricting	O
MHC	O
background	O
or	O
carrier	O
peptide	B
.	O

We	O
have	O
found	O
that	O
immunization	O
with	O
MHC	O
I	O
H-2Kb	O
restricted	O
glycopeptide	B
RGY8	B
-	I
6H	I
-	I
Gal2	I
(	O
Figure	O
1	O
)	O
can	O
generate	O
polyclonal	O
CTL	O
that	O
specifically	O
kill	O
cells	O
presenting	O
the	O
glycopeptide	B
-	O
MHC	O
complex	O
(	O
gpMHC	O
)	O
as	O
well	O
as	O
a	O
glycolipid	B
with	O
the	O
galabiose	B
oligosaccharide	B
as	O
the	O
hydrophilic	O
head	O
group	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

Fractionation	O
of	O
the	O
CTL	O
population	O
by	O
TCR	O
expression	O
has	O
shown	O
glycopeptide	B
-	O
specific	O
killing	O
is	O
mediated	O
by	O
α	O
/	O
β	O
T	O
cells	O
(	O
60	O
%	O
of	O
the	O
CTL	O
)	O
,	O
and	O
glycolipid	B
-	O
specific	O
killing	O
by	O
γ	O
/	O
δ	O
T	O
cells	O
(	O
10%–15	O
%	O
of	O
the	O
CTL	O
)	O
.	O

The	O
MHC	O
-	O
restricted	O
α	O
/	O
β	O
T	O
cell	O
response	O
to	O
the	O
glycopeptide	B
,	O
and	O
gpMHC	O
-	O
unrestricted	O
,	O
hapten	O
-	O
specific	O
response	O
of	O
γ	O
/	O
δ	O
T	O
cells	O
correlate	O
well	O
with	O
the	O
antigen	B
recognition	O
abilities	O
of	O
each	O
T	O
cell	O
subset	O
.	O

Although	O
their	O
biological	O
properties	O
have	O
been	O
elucidated	O
,	O
the	O
structures	O
of	O
MHC	O
-	O
presented	O
glycopeptides	B
have	O
not	O
.	O

Structural	O
analysis	O
is	O
essential	O
since	O
a	O
majority	O
of	O
the	O
synthetic	O
glycopeptides	B
that	O
have	O
been	O
tested	O
have	O
failed	O
to	O
generate	O
carbohydrate	B
-	O
specific	O
T	O
cell	O
responses	O
(	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
.	O

Glycopeptides	B
with	O
centrally	O
located	O
oligosaccharides	B
,	O
such	O
as	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
,	O
have	O
clearly	O
been	O
the	O
most	O
immunogenic	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

Therefore	O
,	O
we	O
determined	O
the	O
crystal	O
structure	O
of	O
the	O
H-2Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
complex	O
at	O
2.2	O
Å	O
resolution	O
to	O
identify	O
the	O
structural	O
determinants	O
critical	O
for	O
T	O
cell	O
activation	O
.	O

The	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
glycopeptide	B
structure	O
shows	O
that	O
glycan	B
position	O
,	O
linker	O
length	O
,	O
and	O
carbohydrate	B
size	O
are	O
important	O
for	O
recognition	O
and	O
discrimination	O
by	O
the	O
different	O
T	O
cells	O
and	O
can	O
be	O
rationalized	O
with	O
the	O
recently	O
determined	O
footprint	O
of	O
the	O
α	O
/	O
β	O
T	O
cell	O
receptor	O
over	O
the	O
pMHC	O
(	O
Garboczi	O
et	O
al.	O
1996	O
;	O
Garcia	O
et	O
al.	O
1996	O
,	O
Garcia	O
et	O
al.	O
1998	O
;	O
Ding	O
et	O
al.	O
1998	O
)	O
.	O

Results	O
Chemical	O
Characteristics	O
of	O
the	O
Glycopeptides	B
and	O
Glycolipids	B
The	O
known	O
MHC	O
allele	O
-	O
specific	O
motifs	O
(	O
Rammensee	O
et	O
al.	O
1995	O
)	O
and	O
available	O
crystal	O
structures	O
of	O
Kb	O
(	O
Fremont	O
et	O
al.	O
1992	O
)	O
and	O
Db	O
(	O
Young	O
et	O
al.	O
1994	O
)	O
were	O
utilized	O
in	O
glycopeptide	B
synthesis	O
and	O
design	O
(	O
Figure	O
1	O
)	O
.	O

The	O
Db	O
-binding	O
peptides	B
were	O
ASNENMETM	B
from	O
PR8	O
influenza	O
virus	O
nucleoprotein	O
(	O
NP	O
)	O
(	O
van	O
Bleek	O
and	O
Nathenson	O
1990	O
)	O
and	O
SGPSNTPPEI	B
from	O
adenovirus	O
Ad5EI	O
protein	O
(	O
Rammensee	O
et	O
al.	O
1993	O
)	O
.	O

The	O
Kb	O
-binding	O
peptides	B
were	O
FAPGNYPAL	B
from	O
Sendai	O
virus	O
NP	O
(	O
Schumacher	O
et	O
al.	O
1991	O
)	O
and	O
RGYVYQGL	B
from	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
NP	O
(	O
van	O
Bleek	O
and	O
Nathenson	O
1990	O
)	O
.	O

The	O
allele	O
-	O
specific	O
anchor	O
residues	O
for	O
Kb	O
and	O
Db	O
are	O
centrally	O
located	O
at	O
P5	O
for	O
Db	O
and	O
P5	O
(	O
8-mer	O
)	O
or	O
P6	O
(	O
9-mer	O
)	O
for	O
Kb	O
(	O
Figure	O
1	O
)	O
.	O

Five	O
carbohydrates	B
differing	O
in	O
size	O
and	O
chemical	O
structure	O
were	O
coupled	O
either	O
to	O
serine	B
,	O
cysteine	B
,	O
or	O
homocysteine	B
(	O
Figure	O
1	O
)	O
.	O

Oligosaccharide	B
CD77	B
is	O
the	O
Burkitt	O
lymphoma	O
TAA	B
(	O
Nudelman	O
et	O
al.	O
1983	O
)	O
.	O

Lactose	B
and	O
GM3-lactam	B
are	O
also	O
tumor	O
-	O
associated	O
saccharides	B
(	O
Holmes	O
et	O
al.	O
1987	O
;	O
Nores	O
et	O
al.	O
1987	O
)	O
.	O

Galabiose	B
(	O
Gal	B
-	I
α	I
(	I
1,4	I
)	I
-Galβ	I
or	O
Gal2	B
)	O
is	O
an	O
integral	O
part	O
of	O
several	O
natural	O
glycolipid	B
head	O
groups	O
and	O
is	O
the	O
terminal	O
disaccharide	B
of	O
CD77	B
(	O
Figure	O
1	O
)	O
.	O

The	O
amino	B
acid	I
glycans	B
replaced	O
upward	O
-	O
pointed	O
residues	O
flanking	O
the	O
central	O
anchor	O
in	O
the	O
Kb	O
or	O
Db	O
peptides	O
or	O
were	O
added	O
to	O
their	O
termini	O
(	O
Figure	O
1	O
;	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1995	O
,	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

Peptide	B
binding	O
to	O
MHC	O
I	O
was	O
unaffected	O
by	O
the	O
glycan	B
modifications	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
,	O
and	O
the	O
stability	O
of	O
the	O
glycopeptides	B
in	O
vivo	O
has	O
been	O
previously	O
demonstrated	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1993	O
)	O
.	O

Monoclonal	O
antibody	O
(	O
MAb	O
)	O
detection	O
of	O
the	O
peptide	B
-	I
linked	I
carbohydrates	I
on	O
the	O
cell	O
surface	O
differed	O
depending	O
on	O
the	O
position	O
of	O
the	O
glycan	B
substitution	O
on	O
the	O
peptide	B
and	O
linker	O
length	O
.	O

Thus	O
,	O
antibody	O
binding	O
to	O
the	O
peptide	B
glycans	I
provided	O
a	O
measure	O
of	O
the	O
carbohydrate	B
exposure	O
in	O
the	O
various	O
pMHC	O
complexes	O
.	O

Carbohydrates	B
attached	O
at	O
internal	O
positions	O
in	O
the	O
peptide	B
by	O
the	O
serine	B
linker	O
were	O
poorly	O
detected	O
by	O
anti	O
-	O
carbohydrate	B
MAb	O
.	O

In	O
contrast	O
,	O
high	O
carbohydrate	B
exposure	O
was	O
detected	O
for	O
all	O
of	O
the	O
glycopeptides	B
that	O
had	O
N	O
-	O
terminal	O
cysteine	B
-	O
ethylene	B
extensions	O
or	O
with	O
the	O
homocysteine	B
linker	O
at	O
internal	O
positions	O
with	O
one	O
exception	O
(	O
ASN9	O
-	O
6H	O
-	O
CD77Table	O
1	O
)	O
.	O

The	O
anti	O
-	O
CD77	O
MAb	O
is	O
of	O
the	O
IgM	O
type	O
and	O
may	O
not	O
be	O
optimal	O
for	O
binding	O
to	O
CD77	O
in	O
the	O
context	O
of	O
the	O
pMHC	O
.	O

Carbohydrate	B
headgroups	O
in	O
all	O
of	O
the	O
glycolipids	B
,	O
after	O
liposomal	O
transfer	O
to	O
EL-4	O
target	O
cells	O
,	O
were	O
highly	O
exposed	O
at	O
the	O
cell	O
surface	O
and	O
stable	O
for	O
at	O
least	O
24	O
hr	O
under	O
tissue	O
culture	O
conditions	O
,	O
as	O
detected	O
with	O
the	O
corresponding	O
anti	O
-	O
carbohydrate	B
MAb	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

Specificity	O
of	O
α	O
/	O
β	O
and	O
γ	O
/	O
δ	O
CTL	O
toward	O
Glycopeptides	B
and	O
Glycolipids	B
Immunizations	O
with	O
the	O
glycopeptide	B
panel	O
produced	O
a	O
wide	O
range	O
of	O
T	O
cell	O
responses	O
(	O
Table	O
1	O
;	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

Glycosylation	O
of	O
the	O
peptide	B
termini	O
,	O
glycopeptides	B
with	O
internal	O
serine	B
-	O
coupled	O
oligosaccharides	B
,	O
and	O
Db	O
-binding	O
glycopeptides	B
produced	O
low	O
CTL	O
responses	O
in	O
general	O
with	O
no	O
evidence	O
for	O
any	O
carbohydrate	B
specificity	O
.	O

In	O
contrast	O
,	O
Kb	O
-binding	O
glycopeptides	B
,	O
RGY8	B
-	I
4H	I
-	I
Gal2	I
and	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
,	O
with	O
central	O
homocysteine	B
-	O
coupled	O
galabiose	B
generated	O
strong	O
bulk	O
CTL	O
responses	O
that	O
specifically	O
killed	O
glycopeptide	B
-	O
coated	O
target	O
cells	O
(	O
Table	O
1	O
;	O
Figure	O
1	O
)	O
.	O

Fractionation	O
of	O
the	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
generated	O
T	O
cell	O
population	O
based	O
on	O
α	O
/	O
β	O
or	O
γ	O
/	O
δ	O
TCR	O
expression	O
determined	O
glycopeptide	B
-	O
specific	O
killing	O
was	O
primarily	O
by	O
the	O
α	O
/	O
β	O
T	O
cells	O
(	O
Table	O
1	O
)	O
.	O

Interestingly	O
,	O
the	O
bulk	O
CTL	O
generated	O
with	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
also	O
killed	O
target	O
cells	O
coated	O
with	O
Db	O
-binding	O
glycopeptides	B
containing	O
homocysteine	B
-	O
coupled	O
galabiose	B
(	O
e.g.	O
,	O
ASN9	B
-	I
6H	I
-	I
Gal2	I
)	O
,	O
and	O
suggested	O
a	O
strict	O
carbohydrate	B
specificity	O
independent	O
of	O
the	O
pMHC	O
background	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

MHC	O
-	O
unrestricted	O
carbohydrate	B
specificity	O
was	O
unambiguously	O
determined	O
by	O
fusing	O
liposomes	O
composed	O
of	O
galabiose	B
containing	O
glycolipid	B
(	O
Figure	O
1C	O
)	O
with	O
EL-4	O
,	O
YAC	O
-	O
I	O
,	O
and	O
P815	O
cells	O
.	O

These	O
glycolipid	B
-	O
coated	O
target	O
cells	O
were	O
specifically	O
killed	O
by	O
a	O
small	O
γ	O
/	O
δ	O
T	O
cell	O
subpopulation	O
present	O
in	O
the	O
bulk	O
CTL	O
generated	O
against	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
(	O
Table	O
1	O
)	O
.	O

These	O
data	O
suggest	O
that	O
the	O
α	O
/	O
β	O
and	O
γ	O
/	O
δ	O
T	O
cells	O
recognized	O
different	O
portions	O
of	O
the	O
same	O
gpMHC	O
antigen	B
that	O
correlates	O
with	O
their	O
specific	O
killing	O
of	O
glycopeptide	B
-	O
coated	O
or	O
glycolipid	B
-	O
coated	O
target	O
cells	O
,	O
respectively	O
.	O

Thus	O
,	O
we	O
determined	O
the	O
H-2Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
crystal	O
structure	O
to	O
improve	O
our	O
understanding	O
of	O
carbohydrate	B
recognition	O
by	O
T	O
cells	O
.	O

RGY8	B
-	I
6H	I
-	I
Gal2	I
Glycopeptide	B
Structure	O
The	O
crystal	O
structure	O
of	O
Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
was	O
determined	O
using	O
well	O
-	O
developed	O
procedures	O
for	O
Kb	O
pMHC	O
complexes	O
(	O
see	O
Experimental	O
Procedures	O
)	O
.	O

The	O
final	O
model	O
included	O
the	O
H-2Kb	O
/glycopeptide	O
complex	O
,	O
four	O
well	O
-	O
ordered	O
N	B
-	I
linked	I
carbohydrates	I
to	O
the	O
MHC	O
,	O
and	O
108	O
waters	B
(	O
Rcryst	O
22.4	O
%	O
,	O
Rfree	O
27.9	O
%	O
)	O
.	O

Electron	O
density	O
for	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
was	O
continuous	O
and	O
well	O
resolved	O
,	O
allowing	O
unambiguous	O
modeling	O
of	O
the	O
glycosylated	B
peptide	I
(	O
Figure	O
2	O
)	O
.	O

The	O
glycopeptide	B
structure	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
Kb	O
-bound	O
VSV-8	B
for	O
the	O
common	O
residues	O
(	O
P1-P5	O
,	O
P7-P8	O
)	O
(	O
Fremont	O
et	O
al.	O
1992	O
)	O
.	O

The	O
root	O
-	O
mean	O
-	O
square	O
deviation	O
(	O
r.m.s.d	O
)	O
is	O
only	O
0.19	O
Å	O
for	O
the	O
equivalent	O
polyalanine	B
atoms	O
between	O
VSV-8	B
and	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
after	O
the	O
Cα	B
atoms	I
of	O
the	O
Kb	O
α1	O
α2	O
superdomains	O
are	O
aligned	O
.	O

Many	O
interactions	O
between	O
the	O
glycopeptide	B
and	O
MHC	O
heavy	O
chain	O
,	O
including	O
water	B
-	O
mediated	O
hydrogen	B
bonds	I
,	O
are	O
also	O
shared	O
with	O
the	O
Kb	O
/VSV-8	O
complex	O
(	O
Table	O
2	O
)	O
;	O
however	O
,	O
the	O
glycosidic	O
modification	O
makes	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
the	O
largest	O
MHC	O
I	O
bound	O
antigen	B
to	O
have	O
its	O
structure	O
determined	O
to	O
date	O
.	O

The	O
homocysteine	B
galabiose	I
glycan	B
at	O
position	O
6	O
of	O
the	O
peptide	B
(	O
HggP6	B
)	O
extends	O
12	O
Å	O
above	O
the	O
peptide	B
backbone	O
(	O
Figure	O
3A	O
and	O
Figure	O
3B	O
)	O
.	O

Arginine	B
,	O
the	O
longest	O
unmodified	O
amino	B
acid	I
,	O
can	O
only	O
extend	O
approximately	O
7	O
Å	O
out	O
from	O
the	O
peptide	B
backbone	O
(	O
e.g.	O
,	O
see	O
ArgP1	O
in	O
Figure	O
2	O
and	O
Figure	O
3	O
)	O
.	O

Interestingly	O
,	O
there	O
are	O
no	O
significant	O
alterations	O
of	O
the	O
Kb	O
structure	O
as	O
a	O
result	O
of	O
glycopeptide	B
binding	O
.	O

The	O
conformation	O
of	O
the	O
galabiose	B
thioether	I
linker	O
loosely	O
matches	O
that	O
of	O
VSV-8	B
GlnP6	B
for	O
the	O
first	O
few	O
equivalent	O
atom	O
positions	O
and	O
orients	O
HggP6	B
toward	O
the	O
α2	O
helix	O
(	O
Figure	O
3B	O
)	O
.	O

HggP6	B
""""	O
leans	O
""""	O
on	O
the	O
α2	O
helix	O
,	O
creating	O
several	O
contacts	O
unique	O
to	O
the	O
glycopeptide	B
(	O
Table	O
2	O
)	O
,	O
but	O
does	O
not	O
make	O
any	O
hydrogen	B
bonds	I
.	O

In	O
the	O
absence	O
of	O
T	O
cell	O
receptor	O
ligation	O
or	O
any	O
direct	O
hydrogen	O
bonds	O
to	O
the	O
linker	O
or	O
sugars	B
from	O
the	O
Kb	O
α1	O
α2	O
domains	O
,	O
the	O
polar	O
and	O
hydrophobic	O
contacts	O
are	O
the	O
only	O
interactions	O
stabilizing	O
the	O
placement	O
of	O
the	O
glycosidic	O
modification	O
adjacent	O
to	O
the	O
α2	O
helix	O
.	O

The	O
contacts	O
between	O
the	O
disaccharide	B
and	O
Kb	O
are	O
mainly	O
with	O
the	O
internal	O
galactose	O
residue	O
.	O

Only	O
a	O
single	O
contact	O
exists	O
between	O
the	O
Kb	O
α2	O
domain	O
and	O
the	O
terminal	O
galactose	B
(	O
Table	O
2	O
)	O
;	O
in	O
fact	O
,	O
both	O
sugars	B
of	O
the	O
galabiose	B
are	O
clasped	O
between	O
the	O
MHC	O
α2	O
helix	O
and	O
the	O
β2	O
m	O
subunit	O
of	O
a	O
neighboring	O
Kb	O
molecule	O
in	O
the	O
crystal	O
lattice	O
.	O

The	O
neighboring	O
β2	O
m	O
is	O
on	O
the	O
opposite	O
side	O
of	O
galabiose	B
from	O
the	O
α2	O
helix	O
.	O

Two	O
hydrogen	O
bonds	O
and	O
several	O
polar	O
interactions	O
between	O
HggP6	B
and	O
neighboring	O
β2	O
m	O
residues	O
Leuβ40	B
,	O
Glyβ43	B
,	O
Argβ81	B
,	O
and	O
Lysβ83	B
are	O
a	O
result	O
of	O
the	O
galabiose	B
entrapment	O
(	O
Table	O
2	O
)	O
.	O

These	O
interactions	O
may	O
be	O
preventing	O
the	O
formation	O
of	O
other	O
hydrogen	B
bonds	I
between	O
galabiose	B
and	O
Kb	O
.	O

The	O
peptide	B
-	O
conjugated	O
galabiose	B
retains	O
a	O
structure	O
very	O
similar	O
to	O
that	O
of	O
the	O
free	O
disaccharide	B
(	O
Svensson	O
et	O
al.	O
1986	O
)	O
.	O

Superposition	O
of	O
the	O
small	O
molecule	O
galabiose	B
crystal	O
structure	O
with	O
the	O
HggP6-linked	B
disaccharide	B
structure	O
gives	O
an	O
r.m.s.d	O
of	O
only	O
0.78	O
Å.	O
The	O
two	O
galabiose	B
structures	O
differ	O
mainly	O
due	O
to	O
a	O
46	O
°	O
difference	O
between	O
their	O
internal	O
glycosidic	O
dihedral	O
angles	O
,	O
presumably	O
due	O
to	O
contact	O
of	O
the	O
HggP6	B
galabiose	B
with	O
the	O
neighboring	O
β2	O
m	O
molecule	O
;	O
the	O
terminal	O
galactose	B
in	O
HggP6	B
must	O
rotate	O
away	O
from	O
the	O
neighboring	O
β2	O
m	O
molecule	O
to	O
avoid	O
forming	O
energetically	O
unfavorable	O
close	O
contacts	O
.	O

Disaccharide	B
Exposure	O
and	O
Mobility	O
The	O
galabiose	B
disaccharide	B
is	O
71	O
%	O
exposed	O
to	O
solvent	B
in	O
the	O
crystal	O
structure	O
.	O

The	O
orientation	O
adopted	O
by	O
HggP6	B
places	O
most	O
of	O
its	O
mass	O
into	O
the	O
open	O
space	O
between	O
the	O
α1	O
α2	O
helices	O
.	O

Thus	O
,	O
the	O
overall	O
exposed	O
surface	O
area	O
of	O
the	O
glycopeptide	B
is	O
substantially	O
greater	O
than	O
that	O
of	O
normal	O
peptides	B
bound	O
by	O
Kb	O
and	O
other	O
MHC	O
I	O
antigens	B
(	O
see	O
Figure	O
3D	O
and	O
Figure	O
3E	O
)	O
.	O

Contact	O
between	O
glycopeptide	B
residue	O
HggP6	B
and	O
the	O
α2	O
helix	O
also	O
contributes	O
to	O
significantly	O
more	O
Kb	O
-buried	O
surface	O
in	O
the	O
glycopeptide	B
complex	O
(	O
952	O
Å2	O
)	O
than	O
in	O
Kb	O
/VSV-8	O
(	O
843	O
Å2	O
)	O
.	O

Modeling	O
studies	O
of	O
this	O
complex	O
show	O
that	O
the	O
galabiose	B
exposure	O
could	O
be	O
even	O
greater	O
.	O

Torsion	O
angles	O
for	O
the	O
relatively	O
long	O
thioether	B
-	O
hydrocarbon	B
linker	O
are	O
largely	O
unrestricted	O
.	O

Small	O
rotations	O
(	O
<	O
20	O
°	O
)	O
of	O
just	O
two	O
of	O
the	O
linker	O
torsion	O
angles	O
can	O
free	O
the	O
galabiose	B
from	O
any	O
contact	O
with	O
the	O
Kb	O
α2	O
helix	O
(	O
Figure	O
3C	O
)	O
.	O

The	O
repositioned	O
galabiose	B
would	O
be	O
100	O
%	O
solvent	B
accessible	O
giving	O
the	O
glycopeptide	B
nearly	O
double	O
the	O
exposed	O
peptide	B
surface	O
area	O
of	O
other	O
MHC	O
-	O
bound	O
peptides	B
(	O
383	O
Å2	O
versus	O
150–220	O
Å2	O
)	O
.	O

Galabiose	B
-	O
specific	O
monoclonal	O
antibodies	O
strongly	O
recognize	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
treated	O
RMA	O
-	O
S	O
cells	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
,	O
providing	O
further	O
evidence	O
for	O
the	O
high	O
exposure	O
of	O
the	O
glycopeptide	B
-	O
attached	O
galabiose	B
.	O

The	O
MAb	O
could	O
possibly	O
recognize	O
the	O
galabiose	B
in	O
close	O
proximity	O
to	O
the	O
MHC	O
helices	O
,	O
but	O
small	O
haptens	B
are	O
more	O
commonly	O
buried	O
deep	O
within	O
the	O
immunoglobin	O
combining	O
site	O
(	O
reviewed	O
by	O
Wilson	O
and	O
Stanfield	O
1994	O
)	O
.	O

The	O
unrestricted	O
access	O
to	O
the	O
galabiose	B
is	O
compatible	O
with	O
antibody	O
binding	O
of	O
small	O
haptens	B
and	O
therefore	O
supports	O
the	O
likelihood	O
of	O
HggP6	B
conformations	O
that	O
fully	O
expose	O
the	O
carbohydrates	B
(	O
e.g.	O

Figure	O
3C	O
)	O
.	O

Carbohydrate	B
Dominance	O
of	O
the	O
TCR	O
Footprint	O
An	O
extended	O
glycan	B
linker	O
,	O
such	O
as	O
that	O
observed	O
in	O
the	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
crystal	O
structure	O
,	O
will	O
place	O
the	O
galabiose	B
well	O
above	O
the	O
peptide	B
backbone	O
in	O
the	O
pMHC	O
region	O
normally	O
covered	O
by	O
the	O
α	O
/	O
β	O
TCR	O
CDR3	O
loops	O
(	O
Garboczi	O
et	O
al.	O
1996	O
;	O
Garcia	O
et	O
al.	O
1996	O
,	O
Garcia	O
et	O
al.	O
1998	O
;	O
Ding	O
et	O
al.	O
1998	O
)	O
.	O

Torsion	O
angle	O
rotations	O
of	O
the	O
linker	O
can	O
result	O
in	O
large	O
lateral	O
movements	O
of	O
the	O
galabiose	O
;	O
however	O
,	O
the	O
central	O
peptide	O
attachment	O
site	O
,	O
combined	O
with	O
the	O
diagonal	O
orientation	O
of	O
the	O
TCR	O
over	O
the	O
MHC	O
binding	O
groove	O
,	O
still	O
keeps	O
the	O
galabiose	O
within	O
the	O
CDR3	O
region	O
of	O
the	O
TCR	O
footprint	O
.	O

Therefore	O
,	O
direct	O
interactions	O
between	O
the	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
carbohydrates	B
and	O
the	O
TCR	O
CDR3	O
loops	O
are	O
relatively	O
convincing	O
.	O

The	O
current	O
position	O
of	O
the	O
disaccharide	O
in	O
the	O
Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
crystal	O
structure	O
would	O
place	O
it	O
under	O
the	O
CDR3β	O
loop	O
and	O
next	O
to	O
a	O
key	O
β	O
chain	O
contact	O
patch	O
on	O
the	O
MHC	O
α2	O
helix	O
(	O
residues	O
149–158	O
)	O
.	O

TCR	O
recognition	O
of	O
the	O
galabiose	B
,	O
therefore	O
,	O
would	O
predominantly	O
involve	O
the	O
β	O
subunit	O
.	O

The	O
area	O
between	O
the	O
glycopeptide	B
and	O
the	O
α1	O
helix	O
is	O
more	O
accessible	O
and	O
could	O
allow	O
TCR	O
α	O
and	O
β	O
subunit	O
contacts	O
directly	O
to	O
the	O
peptide	B
backbone	O
as	O
well	O
as	O
to	O
the	O
side	O
chains	O
.	O

TCR	O
corecognition	O
of	O
glycopeptide	B
and	O
MHC	O
residues	O
in	O
this	O
manner	O
favors	O
an	O
MHC	O
-	O
restricted	O
,	O
glycopeptide	B
-	O
specific	O
α	O
/	O
β	O
T	O
cell	O
response	O
,	O
and	O
may	O
explain	O
the	O
low	O
-	O
level	O
bulk	O
CTL	O
cross	O
-	O
reactivity	O
to	O
the	O
carrier	O
peptide	B
stripped	O
of	O
carbohydrate	B
.	O

The	O
highly	O
exposed	O
galabiose	B
also	O
closely	O
matches	O
the	O
attributes	O
of	O
preferred	O
γ	O
/	O
δ	O
T	O
cell	O
antigens	B
that	O
supports	O
the	O
dichotomy	O
of	O
the	O
anti	O
-	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
T	O
cell	O
response	O
.	O

Direct	O
,	O
immunoglobin	O
-	O
like	O
recognition	O
of	O
the	O
galabiose	B
,	O
either	O
as	O
a	O
highly	O
exposed	O
glycopeptide	B
hapten	B
or	O
glycolipid	B
headgroup	O
,	O
is	O
easily	O
conceivable	O
.	O

Complete	O
carbohydrate	B
exposure	O
can	O
be	O
achieved	O
by	O
varying	O
the	O
HggP6	B
conformation	O
(	O
e.g.	O

Figure	O
3C	O
)	O
or	O
may	O
be	O
induced	O
through	O
TCR	O
binding	O
.	O

A	O
great	O
variety	O
of	O
TCR	O
docking	O
scenarios	O
and	O
HggP6	B
conformations	O
appear	O
feasible	O
,	O
and	O
could	O
potentially	O
coexist	O
in	O
vivo	O
,	O
which	O
would	O
explain	O
the	O
simultaneous	O
generation	O
of	O
carbohydrate	B
-	O
specific	O
γ	O
/	O
δ	O
CTL	O
and	O
glycopeptide	B
-	O
specific	O
α	O
/	O
β	O
CTL	O
by	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
.	O

Discussion	O
Important	O
Structural	O
Features	O
of	O
the	O
Kb	O
/Glycopeptide	O
Complex	O

The	O
crystal	O
structure	O
of	O
H-2Kb	O
-bound	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
reveals	O
the	O
VSV-8	O
carrier	O
peptide	B
and	O
Kb	O
structures	O
are	O
unaffected	O
by	O
the	O
peptide	B
glycosylation	O
;	O
thus	O
,	O
the	O
novel	O
features	O
of	O
the	O
glycopeptide	B
presentation	O
are	O
specifically	O
localized	O
to	O
the	O
carbohydrate	B
portion	O
of	O
the	O
ligand	O
.	O

Indeed	O
,	O
the	O
glycan	B
modification	O
places	O
the	O
galabiose	B
disaccharide	B
at	O
the	O
outer	O
limits	O
of	O
the	O
MHC	O
peptide	B
binding	O
groove	O
where	O
it	O
abuts	O
the	O
apex	O
of	O
the	O
α2	O
helix	O
,	O
well	O
beyond	O
the	O
reach	O
of	O
normal	O
peptide	B
side	B
chains	I
.	O

The	O
galabiose	B
is	O
secured	O
at	O
this	O
position	O
more	O
by	O
intermolecular	O
crystal	O
contacts	O
to	O
a	O
neighboring	O
β2	O
m	O
molecule	O
than	O
by	O
intramolecular	O
contacts	O
to	O
the	O
MHC	O
receptor	O
,	O
suggesting	O
that	O
HggP6	B
may	O
have	O
significantly	O
more	O
conformational	O
freedom	O
in	O
solution	O
.	O

The	O
chemical	O
structure	O
,	O
P6	O
substitution	O
site	O
,	O
and	O
size	O
of	O
the	O
Hgg	B
linker	B
favor	O
a	O
highly	O
exposed	O
hapten	B
moiety	O
in	O
virtually	O
any	O
linker	O
conformation	O
.	O

This	O
unusual	O
access	O
to	O
an	O
MHC	O
I	O
bound	O
ligand	O
allows	O
for	O
direct	O
TCR	O
interactions	O
with	O
the	O
galabiose	B
,	O
which	O
is	O
considerably	O
larger	O
than	O
an	O
amino	B
acid	I
side	B
chain	I
.	O

Alterations	O
in	O
the	O
shape	O
of	O
the	O
TCR	O
combining	O
site	O
,	O
such	O
as	O
large	O
conformational	O
adjustments	O
of	O
the	O
CDR3	O
loops	O
,	O
may	O
be	O
required	O
for	O
a	O
TCR	O
to	O
bind	O
the	O
Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
disaccharide	B
compared	O
to	O
a	O
pMHC	O
.	O

Movements	O
of	O
up	O
to	O
several	O
angstroms	O
by	O
CDRs	O
1α	O
,	O
3α	O
,	O
and	O
3β	O
were	O
observed	O
in	O
comparisons	O
between	O
the	O
free	O
and	O
bound	O
structures	O
of	O
the	O
murine	O
2C	O
TCR	O
(	O
Garcia	O
et	O
al.	O
1998	O
)	O
.	O

It	O
is	O
likely	O
that	O
CDR	O
flexibility	O
is	O
also	O
involved	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
the	O
high	O
-	O
affinity	O
allorecognition	O
of	O
the	O
H-2Ld	O
/QL9	O
peptide	O
complex	O
by	O
the	O
2C	O
TCR	O
.	O

A	O
model	O
of	O
the	O
2C	O
/	O
Ld	O
interaction	O
(	O
Speir	O
et	O
al.	O
1998	O
)	O
reveals	O
that	O
a	O
bulge	O
near	O
the	O
QL9	O
C	O
terminus	O
,	O
as	O
a	O
result	O
of	O
a	O
ridge	O
in	O
the	O
Ld	O
binding	O
groove	O
floor	O
,	O
is	O
likely	O
to	O
greatly	O
increase	O
the	O
TCR	O
contact	O
with	O
the	O
QL9	O
peptide	B
and	O
require	O
different	O
conformations	O
of	O
the	O
2C	O
CDRs	O
for	O
optimal	O
binding	O
compared	O
to	O
the	O
syngeneic	O
2C	O
/	O
dEV8	O
/	O
Kb	O
complex	O
.	O

Alternatively	O
,	O
HggP6	B
may	O
adopt	O
a	O
conformation	O
that	O
places	O
the	O
carbohydrate	B
into	O
a	O
cavity	O
between	O
the	O
TCR	O
α	O
and	O
β	O
chains	O
(	O
Garcia	O
et	O
al.	O
1996	O
)	O
or	O
generally	O
between	O
the	O
TCR	O
and	O
pMHC	O
,	O
requiring	O
little	O
to	O
no	O
structural	O
adjustments	O
of	O
either	O
receptor	O
.	O

Indeed	O
,	O
the	O
TCR	O
-	O
pMHC	O
interfaces	O
are	O
extensive	O
but	O
exhibit	O
poor	O
shape	O
complementarity	O
,	O
leaving	O
large	O
cavities	O
between	O
the	O
contacting	O
surfaces	O
(	O
Garboczi	O
et	O
al.	O
1996	O
;	O
Ding	O
et	O
al.	O
1998	O
;	O
Garcia	O
et	O
al.	O
1998	O
)	O
.	O

Regardless	O
of	O
the	O
poorly	O
formed	O
TCR	O
-	O
pMHC	O
interface	O
,	O
central	O
modifications	O
of	O
the	O
peptide	B
antigen	B
that	O
extend	O
outward	O
from	O
the	O
MHC	O
binding	O
groove	O
will	O
create	O
new	O
and	O
more	O
numerous	O
contacts	O
with	O
the	O
TCR	O
.	O

Glycopeptide	B
Structure	O
-	O
Function	O
Relationships	O
:	O

A	O
Beginning	O
MHC	O
I	O
and	O
II	O
bound	O
peptide	B
immunogens	O
with	O
glycosylation	O
sites	O
outside	O
of	O
the	O
central	O
peptide	B
residues	I
normally	O
fail	O
to	O
generate	O
glycopeptide	B
-	O
specific	O
CTL	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
;	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
.	O

It	O
is	O
now	O
apparent	O
that	O
glycans	B
at	O
these	O
positions	O
would	O
not	O
promote	O
contact	O
between	O
carbohydate	B
haptens	B
and	O
the	O
hypervariable	O
CDR3	O
loops	O
of	O
an	O
α	O
/	O
β	O
TCR	O
,	O
leading	O
to	O
the	O
killing	O
of	O
both	O
carrier	O
peptide	B
and	O
glycopeptide	B
coated	O
target	O
cells	O
by	O
the	O
CTL	O
generated	O
against	O
glycopeptides	B
with	O
noncentral	O
glycan	B
modifications	O
(	O
Ishioka	O
et	O
al.	O
1992	O
;	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
;	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
.	O

Glycosylation	O
of	O
the	O
central	O
peptide	B
residues	I
places	O
the	O
carbohydrates	B
within	O
the	O
expected	O
TCR	O
CDR3α	O
and	O
3β	O
footprint	O
and	O
yields	O
glycopeptides	B
whose	O
immunogenicity	O
is	O
dependent	O
upon	O
the	O
linker	O
length	O
and	O
carbohydrate	B
size	O
.	O

Glycopeptides	B
incorporating	O
disaccharides	B
or	O
larger	O
carbohydrates	B
linked	I
to	I
serine	I
showed	O
weak	O
CTL	O
immunogenicity	O
,	O
as	O
well	O
as	O
poor	O
detection	O
by	O
carbohydrate	B
-	O
specific	O
MAb	O
on	O
the	O
cell	O
surface	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

In	O
contrast	O
,	O
GlcNAc	B
monosaccharides	B
coupled	O
to	O
peptides	B
with	O
serine	B
linkers	O
generate	O
CTL	O
that	O
are	O
able	O
to	O
discriminate	O
between	O
the	O
glycosylated	B
and	O
native	O
peptides	B
,	O
as	O
well	O
as	O
between	O
chemically	O
similar	O
glycopeptides	B
(	O
Haurum	O
et	O
al.	O
1994	O
)	O
.	O

The	O
fine	O
specificity	O
demonstrated	O
in	O
T	O
cell	O
recognition	O
of	O
the	O
GlcNAc	B
-	B
based	I
glycopeptides	I
suggests	O
monosaccharides	B
attached	O
to	O
short	O
linkers	O
near	O
the	O
peptide	B
center	O
are	O
better	O
suited	O
for	O
glycopeptide	B
-	O
specific	O
α	O
/	O
β	O
TCR	O
recognition	O
.	O

From	O
the	O
Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
structure	O
,	O
it	O
appears	O
the	O
greater	O
mass	O
of	O
the	O
serine	B
-	I
linked	I
disaccharides	I
and	O
larger	O
carbohydrates	B
will	O
be	O
confined	O
to	O
the	O
limited	O
space	O
between	O
the	O
MHC	O
helices	O
and	O
thus	O
may	O
interfere	O
with	O
TCR	O
-	O
MHC	O
interactions	O
and/or	O
hinder	O
specific	O
-	O
recognition	O
of	O
the	O
carbohydrates	B
by	O
the	O
TCR	O
.	O

The	O
smaller	O
size	O
of	O
monosaccharides	B
is	O
less	O
likely	O
to	O
disrupt	O
α	O
/	O
β	O
TCR	O
interactions	O
within	O
the	O
MHC	O
binding	O
site	O
,	O
but	O
their	O
relatively	O
low	O
exposure	O
disfavors	O
a	O
carbohydrate	B
-	O
specific	O
γ	O
/	O
δ	O
T	O
cell	O
response	O
(	O
Figure	O
4	O
)	O
.	O

Longer	O
oligosaccharide	B
tethers	O
,	O
such	O
as	O
homocysteine	B
,	O
can	O
fully	O
expose	O
bound	O
carbohydrates	B
(	O
Figure	O
3	O
and	O
Figure	O
4	O
)	O
.	O

The	O
greater	O
exposure	O
results	O
in	O
facilitated	O
MAb	O
detection	O
of	O
the	O
sugars	B
and	O
strong	O
generation	O
of	O
carbohydrate	B
-	O
specific	O
CTL	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
,	O
presumably	O
through	O
direct	O
interaction	O
between	O
TCRs	O
and	O
the	O
carbohydrates	B
.	O

Furthermore	O
,	O
the	O
unobstructed	O
access	O
to	O
the	O
glycan	B
is	O
probably	O
a	O
key	O
factor	O
in	O
generating	O
an	O
MHC	O
-	O
unrestricted	O
γ	O
/	O
δ	O
T	O
cell	O
response	O
.	O

Several	O
cross	O
-	O
reactive	O
T	O
cell	O
clones	O
to	O
MHC	O
bound	O
peptides	B
with	O
chemically	O
TNP	B
-	O
modified	O
lysine	B
residues	O
have	O
been	O
described	O
(	O
Martin	O
et	O
al.	O
1992	O
)	O
.	O

TNP	B
exposure	O
,	O
when	O
attached	O
to	O
lysine	B
,	O
would	O
be	O
equivalent	O
to	O
that	O
of	O
homocysteine	B
-	B
linked	I
galabiose	I
,	O
and	O
could	O
be	O
responsible	O
for	O
the	O
immunodominance	O
of	O
the	O
TNP	B
epitopes	B
and	O
restriction	O
of	O
the	O
responding	O
T	O
cell	O
repertoire	O
(	O
Hochgeschwender	O
et	O
al.	O
1987	O
)	O
.	O

Furthermore	O
,	O
the	O
specificity	O
of	O
the	O
cross	O
-	O
reactive	O
T	O
cells	O
only	O
for	O
TNP	B
-	I
lysine	I
located	O
near	O
the	O
center	O
of	O
the	O
peptide	B
,	O
and	O
the	O
freedom	O
of	O
one	O
TNP	B
-	O
specific	O
T	O
cell	O
hybridoma	O
from	O
class	O
II	O
polymophism	O
,	O
mirrors	O
the	O
behavior	O
of	O
carbohydrate	B
-	O
specific	O
CTL	O
(	O
Martin	O
et	O
al.	O
1992	O
;	O
Kohler	O
et	O
al.	O
1997	O
)	O
.	O

Thus	O
,	O
central	O
placement	O
and	O
extensive	O
exposure	O
are	O
common	O
factors	O
in	O
MHC	O
antigens	O
that	O
produce	O
enhanced	O
cross	O
-	O
reactivity	O
,	O
reduced	O
MHC	O
restriction	O
,	O
and	O
hapten	O
-	O
specfic	O
recognition	O
by	O
the	O
responding	O
T	O
cell	O
population	O
.	O

Poor	O
or	O
Diminished	O
CTL	O
Reactivity	O
to	O
Large	O
Oligosaccharides	B
and	O
Db	O
-Bound	O
Galabiose	B
Db	O
-bound	O
glycopeptides	B
with	O
homocysteine	B
linked	O
galabiose	B
(	O
e.g.	O

Figure	O
3F	O
)	O
are	O
poorly	O
immunogenic	O
,	O
and	O
Kb	O
-bound	O
glycopeptides	B
presenting	O
homocysteine	B
-	O
linked	O
CD77	B
or	O
GM3-lactam	B
are	O
less	O
immunogenic	O
than	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
(	O
Table	O
1	O
;	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

Interestingly	O
,	O
these	O
glycopeptide	B
designs	O
could	O
place	O
carbohydrate	B
structures	O
further	O
above	O
the	O
MHC	O
α1	O
α2	O
helices	O
than	O
observed	O
in	O
Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
(	O
Figure	O
4	O
)	O
,	O
as	O
CD77	B
and	O
GM3-lactam	B
are	O
larger	O
than	O
galabiose	B
by	O
one	O
sugar	B
unit	O
or	O
more	O
.	O

In	O
addition	O
,	O
the	O
Db	O
-binding	O
glycopeptides	B
have	O
a	O
large	O
arch	O
in	O
the	O
peptide	B
backbone	O
near	O
the	O
C	O
terminus	O
that	O
would	O
futher	O
elevate	O
glycans	B
attached	O
to	O
the	O
bulged	O
residues	O
(	O
Figure	O
3F	O
and	O
Figure	O
4	O
;	O
Young	O
et	O
al.	O
1994	O
)	O
.	O

Peptide	B
antigen	B
recognition	O
by	O
α	O
/	O
β	O
TCR	O
normally	O
occurs	O
within	O
the	O
α1	O
α2	O
helices	O
and	O
may	O
,	O
therefore	O
,	O
fail	O
to	O
entirely	O
encompass	O
these	O
large	O
glycans	B
.	O

Furthermore	O
,	O
carbohydrates	B
outside	O
or	O
atop	O
the	O
α1	O
α2	O
helices	O
are	O
likely	O
to	O
disrupt	O
conserved	O
TCR	O
-	O
MHC	O
interactions	O
that	O
are	O
important	O
to	O
the	O
docking	O
,	O
orientation	O
,	O
and	O
proper	O
register	O
of	O
the	O
TCR	O
on	O
the	O
pMHC	O
molecule	O
and	O
hence	O
can	O
explain	O
the	O
reduced	O
,	O
poor	O
,	O
or	O
lack	O
of	O
CTL	O
reactivity	O
to	O
these	O
glycopeptides	B
(	O
Table	O
1	O
)	O
.	O

γ	O
/	O
δ	O
T	O
Cell	O
Response	O
to	O
Glycolipid	B
The	O
Kb	O
/RGY8	O
-	B
6H	I
-	I
Gal2	I
crystal	O
structure	O
supports	O
the	O
possibility	O
of	O
distinct	O
γ	O
/	O
δ	O
CTL	O
stimulation	O
through	O
MHC	O
-	O
unrestricted	O
γ	O
/	O
δ	O
TCR	O
recognition	O
of	O
the	O
exposed	O
carbohydrate	B
haptens	B
.	O

Indeed	O
,	O
the	O
γ	O
/	O
δ	O
T	O
cells	O
may	O
be	O
directly	O
triggered	O
by	O
corresponding	O
galabiose	B
-	O
presenting	O
glycolipids	B
fused	O
with	O
target	O
cells	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
MHC	O
-	O
unrestricted	O
antigen	B
binding	B
by	O
γ	O
/	O
δ	O
TCR	O
allows	O
triggering	O
and	O
clonal	O
expansion	O
of	O
γ	O
/	O
δ	O
CTL	O
in	O
the	O
present	O
system	O
.	O

Less	O
exposed	O
oligosaccharides	B
may	O
also	O
be	O
capable	O
of	O
generating	O
γ	O
/	O
δ	O
CTL	O
,	O
but	O
peptide	B
and	O
MHC	O
residues	O
are	O
more	O
likely	O
to	O
be	O
in	O
close	O
proximity	O
to	O
these	O
carbohydrates	B
and	O
may	O
inhibit	O
γ	O
/	O
δ	O
TCR	O
binding	O
.	O

Interestingly	O
,	O
the	O
inherent	O
linker	O
flexibility	O
of	O
HggP6	B
in	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
may	O
provide	O
the	O
glycan	B
with	O
the	O
ability	O
to	O
switch	O
between	O
the	O
positions	O
and/or	O
structures	O
best	O
recognized	O
by	O
the	O
two	O
types	O
of	O
TCR	O
,	O
providing	O
a	O
rationale	O
for	O
the	O
concurrent	O
generation	O
of	O
glycopeptide	B
-	O
specific	O
α	O
/	O
β	O
CTL	O
and	O
carbohydrate	B
-	O
specific	O
γ	O
/	O
δ	O
CTL	O
.	O

Implications	O
for	O
T	O
Cell	O
Recognition	O
of	O
Natural	O
Glycopeptides	B
Glycosylation	O
of	O
secreted	O
,	O
cell	O
surface	O
,	O
nuclear	O
,	O
and	O
cytoplasmic	O
proteins	O
(	O
Hart	O
et	O
al.	O
1989	O
)	O
is	O
a	O
common	O
posttranslational	O
modification	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
molecular	O
structure	O
and	O
stability	O
,	O
masking	O
of	O
microorganism	O
target	O
epitopes	B
,	O
and	O
modulation	O
of	O
specific	O
protein	O
functions	O
(	O
Varki	O
1993	O
)	O
.	O

The	O
small	O
number	O
of	O
natural	O
MHC	O
I	O
bound	O
glycopeptides	B
that	O
have	O
been	O
identified	O
may	O
reflect	O
their	O
limited	O
numbers	O
at	O
the	O
cell	O
surface	O
or	O
the	O
technical	O
difficulties	O
in	O
their	O
detection	O
(	O
Haurum	O
et	O
al.	O
1994	O
)	O
,	O
but	O
not	O
necessarily	O
their	O
importance	O
in	O
the	O
cellular	O
immune	O
response	O
since	O
T	O
cell	O
avidity	O
for	O
pMHC	O
antigens	O
widely	O
varies	O
.	O

Our	O
results	O
,	O
together	O
with	O
those	O
from	O
other	O
studies	O
of	O
glycopeptide	B
immunogenicity	O
,	O
suggest	O
small	O
carbohydrates	B
(	O
mono	B
or	O
disaccharides	B
)	O
attached	O
to	O
short	O
,	O
centrally	O
placed	O
linkers	O
satisfy	O
α	O
/	O
β	O
TCR	O
antigen	B
binding	O
preferences	O
,	O
and	O
that	O
carbohydrates	B
of	O
the	O
same	O
size	O
attached	O
to	O
slightly	O
longer	O
linkers	O
may	O
also	O
satisfy	O
the	O
requirements	O
for	O
γ	O
/	O
δ	O
TCR	O
antigen	B
binding	O
(	O
Figure	O
4	O
)	O
,	O
leading	O
to	O
glycopeptide	B
and	O
carbohydrate	B
-	O
specific	O
T	O
cell	O
responses	O
.	O

Asparagine	B
-	O
linked	O
glycans	B
have	O
a	O
pentasaccharide	B
core	O
decorated	O
by	O
further	O
carbohydrate	B
additions	O
(	O
Kornfeld	O
and	O
Kornfeld	O
1985	O
)	O
;	O
therefore	O
,	O
the	O
corresponding	O
glycopeptides	B
would	O
not	O
be	O
well	O
suited	O
for	O
carbohydrate	B
-	O
specific	O
CTL	O
.	O

In	O
contrast	O
,	O
many	O
mucins	O
and	O
other	O
O	B
-	I
linked	I
glycoconjugates	I
found	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
are	O
composed	O
of	O
mono-	B
or	O
disaccharides	B
attached	O
to	O
serine	B
,	O
threonine	B
,	O
hydroxylysine	B
or	O
tyrosine	B
(	O
Hart	O
et	O
al.	O
1989	O
;	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
and	O
,	O
therefore	O
,	O
are	O
more	O
promising	O
natural	O
glycan	B
antigens	B
for	O
T	O
cells	O
.	O

The	O
mucins	O
,	O
that	O
include	O
the	O
Tn	B
and	O
sialyl	B
Tn	I
epitopes	I
that	O
are	O
present	O
on	O
cancer	O
cells	O
and	O
HIV	O
envelope	O
glycoprotein	O
gp120	O
(	O
Hansen	O
et	O
al.	O
1990	O
)	O
,	O
can	O
be	O
recognized	O
by	O
T	O
cells	O
(	O
Galli	O
-	O
Stampino	O
et	O
al.	O
1997	O
)	O
.	O

Carbohydrate	B
structures	O
that	O
are	O
not	O
well	O
represented	O
or	O
are	O
poorly	O
immunogenic	O
in	O
normal	O
antigen	B
presentation	O
could	O
also	O
be	O
used	O
in	O
synthetic	O
peptide	B
immunogens	O
to	O
activate	O
defined	O
,	O
carbohydrate	O
-	O
specific	O
T	O
cell	O
populations	O
.	O

The	O
ability	O
to	O
generate	O
or	O
enhance	O
the	O
Ig	O
-	O
like	O
,	O
MHC	O
-	O
unrestricted	O
γ	O
/	O
δ	O
T	O
cell	O
responses	O
to	O
the	O
glycopeptide	B
could	O
further	O
augment	O
T	O
cell	O
surveillance	O
and	O
CTL	O
effector	O
functions	O
against	O
cells	O
presenting	O
the	O
corresponding	O
carbohydrate	B
hapten	B
.	O

Indeed	O
,	O
peptide	B
-	O
based	O
vaccines	O
able	O
to	O
generate	O
carbohydrate	B
-	O
specific	O
CTL	O
have	O
potential	O
clinical	O
applications	O
for	O
treatment	O
of	O
various	O
types	O
of	O
cancer	O
and	O
parasitic	O
infections	O
(	O
Lanzavecchia	O
1993	O
;	O
Chesnut	O
et	O
al.	O
1995	O
)	O
by	O
targeting	O
abnormal	O
glycosylation	O
produced	O
by	O
malignant	O
cells	O
or	O
oligosaccharide	B
structures	O
unique	O
to	O
microorganisms	O
(	O
Kaufmann	O
1996	O
)	O
.	O

Experimental	O
Procedures	O
Carbohydrates	B
,	O
Glycopeptides	B
,	O
and	O
Glycolipids	B
Galabiose	B
(	O
Gal	B
-	I
α	I
(	I
1,4	I
)	I
Gal	I
-	I
β	I
or	I
Gal2	I
)	O
,	O
CD77	B
(	O
Gal	B
-	I
α	I
(	I
1,4	I
)	I
Gal	I
-	I
β	I
(	I
1,4	I
)	I
Glc	I
-	I
β	I
)	O
,	O
lactose	B
(	O
Gal	B
-	I
β	I
(	I
1,4	I
)	I
-Glc	I
-	I
β	I
)	O
,	O
GM3	B
(	B
NeuAc	I
-	I
α	I
(	I
3	I
)	I
-GalN	I
-	I
β	I
(	I
1,4	I
)	I
Glc	I
-	I
β	I
)	O
,	O
and	O
GM3-lactam	B
were	O
synthesized	O
as	O
described	O
(	O
Figure	O
1	O
;	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1995	O
;	O
Kihlberg	O
and	O
Elofsson	O
1997	O
)	O
.	O

Monoclonal	O
antibodies	O
specific	O
for	O
the	O
carbohydrates	B
were	O
used	O
to	O
test	O
the	O
expression	O
of	O
carbohydrates	B
on	O
the	O
surface	O
of	O
glycopeptide	B
-	O
treated	O
RMA	O
-	O
S	O
cells	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

Glycopeptides	B
and	O
glycolipids	B
were	O
synthesized	O
and	O
tested	O
for	O
Kb	O
and	O
Db	O
-binding	O
capacity	O
,	O
carbohydrate	B
presentation	O
,	O
and	O
stability	O
in	O
vivo	O
as	O
described	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1995	O
,	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1996	O
)	O
.	O

CTL	O
Generation	O
,	O
Assay	O
,	O
and	O
Fractionation	O
CTL	O
were	O
generated	O
by	O
immunization	O
of	O
C57BL	O
/	O
6	O
mice	O
with	O
100	O
μg	O
glycopeptide	B
in	O
Freund	O
's	O
incomplete	O
adjuvant	O
at	O
the	O
base	O
of	O
the	O
tail	O
followed	O
by	O
in	O
vitro	O
restimulation	O
of	O
harvested	O
spleen	O
cells	O
,	O
as	O
described	O
(	O
Zhou	O
et	O
al.	O
1992	O
)	O
.	O

CTL	O
were	O
tested	O
in	O
a	O
short	O
-	O
term	O
4	O
hr	O
51	O
Cr	O
-	O
release	O
assay	O
against	O
peptide-	B
,	O
glycopeptide-	B
or	O
glycolipid	B
-	O
treated	O
target	O
cells	O
.	O

Glycolipid	B
-	O
expressing	O
target	O
cells	O
were	O
produced	O
by	O
treatment	O
of	O
target	O
cells	O
with	O
liposomes	O
containing	O
the	O
different	O
glycolipids	B
as	O
described	O
(	O
Abdel	O
-	O
Motal	O
et	O
al.	O
1995	O
)	O
.	O

CTL	O
populations	O
were	O
fractionated	O
using	O
either	O
anti	O
-	O
α	O
/	O
β	O
or	O
γ	O
/	O
δ	O
framework	O
MAb	O
on	O
magnetic	O
Dynabeads	O
(	O
Dynal	O
A.	O
S.	O
,	O
Norway	O
)	O
.	O

Preparation	O
and	O
Crystallization	O
of	O
the	O
Kb	O
-Glycopeptide	O
Complex	O
Purified	O
H-2Kb	O
was	O
incubated	O
with	O
a	O
5-fold	O
molar	O
excess	O
of	O
RGY8	B
-	I
6H	I
-	I
Gal2	I
for	O
5	O
hr	O
at	O
room	O
temperature	O
(	O
see	O
Stura	O
et	O
al.	O
1992	O
)	O
.	O

Centricon	O
10	O
ultrafiltration	O
was	O
used	O
to	O
concentrate	O
the	O
MHC	O
complex	O
and	O
clear	O
any	O
free	O
peptide	B
simultaneously	O
.	O

An	O
exchange	O
of	O
bound	O
peptides	B
was	O
apparent	O
from	O
notable	O
band	O
shifts	O
between	O
treated	O
and	O
untreated	O
samples	O
subjected	O
to	O
IEF	O
electrophoresis	O
(	O
data	O
not	O
shown	O
;	O
see	O
also	O
Stura	O
et	O
al.	O
1992	O
)	O
.	O

Large	O
single	O
crystals	O
were	O
grown	O
from	O
18	O
mg	O
/	O
ml	O
H-2Kb	O
in	O
2.3	O
M	O
Na	B
/	I
K	I
PO4	I
,	O
2	O
%	O
2-methyl-2,4-pentanediol	B
(	O
pH	O
6.4	O
)	O
,	O
with	O
diffraction	O
to	O
approximately	O
2.0	O
Å	O
resolution	O
.	O

Data	O
Collection	O
and	O
Processing	O
Diffraction	O
data	O
were	O
collected	O
in	O
house	O
from	O
a	O
flash	O
-	O
cooled	O
(	O
130	O
K	O
,	O
25	O
%	O
glycerol	B
)	O
single	O
crystal	O
(	O
0.5	O
×	O
0.5	O
×	O
0.3	O
mm	O
)	O
with	O
a	O
30	O
cm	O
MAR	O
image	O
plate	O
mounted	O
on	O
a	O
Siemens	O
M18X	O
CuKα	O
x	O
-	O
ray	O
generator	O
(	O
300	O
μm	O
focal	O
cup	O
,	O
50	O
kV	O
,	O
80	O
mA	O
)	O
fitted	O
with	O
Supper	O
long	O
double	O
-	O
mirror	O
focusing	O
optics	O
.	O

The	O
data	O
were	O
indexed	O
and	O
integrated	O
with	O
the	O
program	O
DENZO	O
(	O
Otwinowski	O
and	O
Minor	O
1997	O
)	O
.	O

The	O
crystals	O
are	O
orthorhombic	O
,	O
P21	O
21	O
2	O
,	O
with	O
unit	O
cell	O
dimensions	O
a	O
=	O
135.9	O
Å	O
,	O
b	O
=	O
86.8	O
Å	O
,	O
and	O
c	O
=	O
45.0	O
Å.	O
The	O
Vm	O
(	O
Matthews	O
1968	O
)	O
of	O
2.86	O
Å3	O
Da−1	O
indicated	O
one	O
molecule	O
per	O
asymmetric	O
unit	O
with	O
a	O
solvent	O
content	O
of	O
57	O
%	O
.	O

The	O
data	O
were	O
merged	O
,	O
scaled	O
,	O
and	O
reduced	O
to	O
a	O
unique	O
reflection	O
set	O
using	O
the	O
program	O
SCALEPACK	O
(	O
Table	O
3	O
;	O
Otwinowski	O
and	O
Minor	O
1997	O
)	O
.	O

Model	O
Refinement	O
A	O
random	O
set	O
of	O
10	O
%	O
of	O
the	O
reflections	O
between	O
18–2.1	O
Å	O
were	O
excluded	O
from	O
refinement	O
to	O
monitor	O
Rfree	O
(	O
Brünger	O
1997	O
)	O
.	O

Only	O
procedures	O
that	O
minimized	O
both	O
Rcryst	O
and	O
Rfree	O
were	O
utilized	O
.	O

Kb	O
/VSV-8	O
coordinates	O
(	O
Fremont	O
et	O
al.	O
1992	O
)	O
stripped	O
of	O
peptide	B
were	O
directly	O
refined	O
against	O
the	O
glycopeptide	B
data	O
using	O
X	O
-	O
PLOR	O
v3.851	O
(	O
Brünger	O
et	O
al.	O
1987	O
)	O
.	O

Rigid	O
body	O
refinement	O
from	O
8–2.1	O
Å	O
resolution	O
(	O
F	O
/	O
σF	O
>	O
2	O
)	O
gave	O
an	O
Rcryst	O
of	O
36.6	O
%	O
and	O
an	O
Rfree	O
of	O
35.7	O
%	O
.	O

One	O
round	O
of	O
refinement	O
,	O
bulk	O
-	O
solvent	O
correction	O
,	O
and	O
model	O
rebuilding	O
was	O
performed	O
using	O
positional	O
minimization	O
and	O
iterative	O
slow	O
-	O
cooled	O
molecular	O
dynamics	O
as	O
implemented	O
in	O
X	O
-	O
PLOR	O
(	O
serial	O
slow	O
coolKleywegt	O
and	O
Jones	O
1997	O
)	O
before	O
the	O
peptide	B
was	O
traced	O
(	O
Rcryst	O
27.5	O
%	O
,	O
Rfree	O
32.5	O
%	O
)	O
.	O

3Fo	O
-2Fc	O
,	O
2Fo	O
-Fc	O
shake	O
omit	O
(	O
McRee	O
1993	O
)	O
,	O
and	O
shaken	O
,	O
σA	O
-weighted	O
(	O
Read	O
1986	O
)	O
2Fo	O
-Fc	O
and	O
Fo	O
-Fc	O
electron	O
density	O
maps	O
were	O
computed	O
to	O
reduce	O
phase	O
bias	O
for	O
model	O
rebuilding	O
.	O

Strong	O
density	O
in	O
shaken	O
,	O
σA	O
-weighted	O
Fo	O
-Fc	O
maps	O
was	O
located	O
within	O
the	O
peptide	B
binding	O
groove	O
and	O
included	O
the	O
entire	O
glycosylated	B
homocysteine	I
at	O
position	O
six	O
(	O
HggP6	B
;	O
Figure	O
2	O
)	O
.	O

HggP6	B
was	O
constructed	O
with	O
the	O
help	O
of	O
the	O
hetero	O
-	O
compound	O
libraries	O
(	O
e.g.	O
,	O
homocysteine	B
and	O
galactose	B
)	O
provided	O
by	O
G.	O
Kleywegt	O
's	O
web	O
site	O
(	O
http://alpha2.bmc.uu.se/hicup	O
;	O
Kleywegt	O
1995	O
)	O
.	O

The	O
Rfree	O
for	O
the	O
outer	O
reflection	O
bin	O
failed	O
to	O
decline	O
,	O
probably	O
due	O
to	O
limited	O
data	O
completeness	O
;	O
therefore	O
,	O
the	O
high	O
resolution	O
limit	O
was	O
reduced	O
to	O
2.2	O
Å	O
(	O
Table	O
3	O
)	O
.	O

The	O
coordinates	O
and	O
reflection	O
data	O
(	O
keeping	O
the	O
same	O
Rfree	O
data	O
partition	O
)	O
were	O
converted	O
for	O
use	O
in	O
the	O
SHELXL	O
automated	O
water	B
divining	O
routine	O
(	O
Sheldrick	O
and	O
Schneider	O
1997	O
)	O
and	O
108	O
waters	B
were	O
retained	O
after	O
manual	O
inspection	O
.	O

The	O
final	O
rounds	O
of	O
positional	O
and	O
B	O
-	O
value	O
refinement	O
in	O
X	O
-	O
PLOR	O
gave	O
an	O
Rcryst	O
of	O
22.4	O
%	O
and	O
an	O
Rfree	O
of	O
27.9	O
%	O
(	O
Table	O
3	O
)	O
.	O

Structural	O
Analysis	O
and	O
Illustrations	O
The	O
H-2Kb	O
glycopeptide	B
structure	O
was	O
compared	O
with	O
other	O
Kb	O
/peptide	O
complexes	O
(	O
PDB	O
accession	O
codes	O
2VAA	O
,	O
2VAB	O
;	O
Fremont	O
et	O
al.	O
1992	O
)	O
,	O
the	O
H-2Db	O
/peptide	O
complex	O
(	O
1HOCYoung	O
et	O
al.	O
1994	O
)	O
,	O
the	O
H-2Ld	O
/peptide	O
complex	O
(	O
1LDPSpeir	O
et	O
al.	O
1998	O
)	O
,	O
the	O
HLA	O
-	O
A2	O
/	O
Influenza	O
M1	O
peptide	B
complex	O
(	O
1HHIMadden	O
et	O
al.	O
1993	O
)	O
,	O
and	O
various	O
complexes	O
of	O
HIV	O
-	O
derived	O
peptides	B
bound	O
to	O
HLA	O
molecules	O
B35	B
,	O
B53	B
,	O
and	O
B8	B
(	O
1AGEReid	O
et	O
al.	O
1996	O
;	O
1A1MSmith	O
et	O
al.	O
1996a	O
;	O
1A1NSmith	O
et	O
al.	O
1996b	O
)	O
.	O

PROCHECK	O
(	O
Laskowski	O
et	O
al.	O
1993	O
)	O
was	O
used	O
to	O
examine	O
polypeptide	B
geometry	O
,	O
PROMOTIF	O
to	O
identify	O
secondary	O
structure	O
elements	O
(	O
Hutchinson	O
and	O
Thornton	O
1996	O
)	O
,	O
CONTACSYM	O
(	O
Sheriff	O
et	O
al.	O
1987	O
)	O
to	O
identify	O
van	O
der	O
Waals	O
contacts	O
up	O
to	O
4	O
Å	O
apart	O
,	O
and	O
HBPLUS	O
(	O
McDonald	O
and	O
Thornton	O
1994	O
)	O
to	O
locate	O
hydrogen	B
bond	I
pairs	O
using	O
both	O
distance	O
and	O
geometry	O
criteria	O
.	O

Buried	O
surface	O
areas	O
were	O
computed	O
with	O
MS	O
(	O
Connolly	O
1983	O
)	O
using	O
a	O
1.4	O
Å	O
radius	O
probe	O
.	O

Figure	O
2	O
was	O
created	O
using	O
programs	O
O	O
(	O
Jones	O
et	O
al.	O
1991	O
)	O
and	O
MolView	O
(	O
Smith	O
1995	O
)	O
.	O

Figure	O
3	O
was	O
created	O
using	O
MIDAS	O
(	O
Ferrin	O
et	O
al.	O
1988	O
)	O
.§	O

To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
(	O
email	O
:	O
mikael.jondal@mtc.ki.se	O
[	O
M.	O
J.	O
]	O
,	O
wilson@scripps.edu	O
[	O
I.	O
A.	O
W.	O
]	O
)	O
.	O

Acknowledgements	O

We	O
thank	O
Wendy	O
Havran	O
for	O
critically	O
reading	O
the	O
manuscript	O
and	O
helpful	O
discussions	O
,	O
Andreas	O
Heine	O
for	O
assistance	O
with	O
program	O
SHELXL	O
,	O
and	O
David	O
Jewell	O
for	O
technical	O
assistance	O
.	O

This	O
study	O
was	O
supported	O
by	O
National	O
Institutes	O
of	O
Health	O
grants	O
CA58896	O
(	O
I.	O
A.	O
W.	O
)	O
,	O
AI42266	O
(	O
I.	O
A.	O
W.	O
)	O
,	O
and	O
a	O
postdoctoral	O
fellowship	O
from	O
National	O
Institutes	O
of	O
Health	O
training	O
grant	O
MH19185	O
(	O
J.	O
A.	O
S.	O
)	O
.	O

This	O
is	O
manuscript	O
#	O
11737-MB	O
from	O
The	O
Scripps	O
Research	O
Institute	O
.	O

3,4-Dihydroxyphenylalanine	O
(	O
Dopa	O
)	O
decarboxylase	O
is	O
a	O
stereospecific	O
pyridoxal	O
5'-phosphate	O
(	O
PLP	O
)	O
-dependent	O
alpha	O
-	O
decarboxylase	O
that	O
converts	O
L	B
-	I
aromatic	I
amino	I
acids	I
into	O
their	O
corresponding	O
amines	B
.	O

We	O
now	O
report	O
that	O
reaction	O
of	O
the	O
enzyme	O
with	O
D-5-hydroxytryptophan	B
or	O
D	B
-	I
Dopa	I
results	O
in	O
a	O
time	O
-	O
dependent	O
inactivation	O
and	O
conversion	O
of	O
the	O
PLP	B
coenzyme	O
to	O
pyridoxamine	B
5'-phosphate	I
and	O
PLP	B
-	I
D	I
-	I
amino	I
acid	I
Pictet	I
-	I
Spengler	I
adducts	I
,	I
which	O
have	O
been	O
identified	O
by	O
high	O
performance	O
liquid	O
chromatography	O
.	O

We	O
also	O
show	O
that	O
the	O
reaction	O
specificity	O
of	O
Dopa	O
decarboxylase	O
toward	O
aromatic	B
amines	I
depends	O
on	O
the	O
experimental	O
conditions	O
.	O

Whereas	O
oxidative	O
deamination	O
occurs	O
under	O
aerobic	O
conditions	O
(	O
Bertoldi	O
,	O
M.	O
,	O
Moore	O
,	O
P.	O
S.	O
,	O
Maras	O
,	O
B.	O
,	O
Dominici	O
,	O
P.	O
,	O
and	O
Borri	O
Voltattorni	O
,	O
C.	O
(	O
1996	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O
271	O
,	O
23954	O
-	O
23959	O
;	O
Bertoldi	O
,	O
M.	O
,	O
Dominici	O
,	O
P.	O
,	O
Moore	O
,	O
P.	O
S.	O
,	O
Maras	O
,	O
B.	O
,	O
and	O
Borri	O
Voltattorni	O
,	O
C.	O
(	O
1998	O
)	O
Biochemistry	O
37	O
,	O
6552	O
-	O
6561	O
)	O
,	O
half	O
-	O
transamination	O
and	O
Pictet	O
-	O
Spengler	O
reactions	O
take	O
place	O
under	O
anaerobic	O
conditions	O
.	O

Moreover	O
,	O
we	O
examined	O
the	O
reaction	O
specificity	O
of	O
nicked	O
Dopa	O
decarboxylase	O
,	O
obtained	O
by	O
selective	O
tryptic	O
cleavage	O
of	O
the	O
native	O
enzyme	O
between	O
Lys334	B
and	O
His335	B
.	O

Although	O
this	O
enzymatic	O
species	O
does	O
not	O
exhibit	O
either	O
decarboxylase	O
or	O
oxidative	O
deamination	O
activities	O
,	O
it	O
retains	O
a	O
large	O
percentage	O
of	O
the	O
native	O
transaminase	O
activity	O
toward	O
D	B
-	I
aromatic	I
amino	I
acids	I
and	O
displays	O
a	O
slow	O
transaminase	O
activity	O
toward	O
aromatic	B
amines	I
.	O

These	O
transamination	O
reactions	O
occur	O
concomitantly	O
with	O
the	O
formation	O
of	O
cyclic	B
coenzyme	I
-	I
substrate	I
adducts	I
.	I

Together	O
with	O
additional	O
data	O
,	O
we	O
thus	O
suggest	O
that	O
native	O
Dopa	O
decarboxylase	O
can	O
exist	O
as	O
an	O
equilibrium	O
among	O
""""	O
open	O
,	O
""""	O
""""	O
half	O
-	O
open	O
,	O
""""	O
and	O
""""	O
closed	O
""""	O
forms	O
.	O

Diazaborine	B
and	O
isoniazid	B
are	O
,	O
at	O
first	O
sight	O
,	O
unrelated	O
anti	O
-	O
bacterial	O
agents	O
that	O
inhibit	O
the	O
enoyl	O
-	O
ACP	O
reductase	O
(	O
ENR	O
)	O
of	O
Escherichia	O
coli	O
and	O
Mycobacterium	O
tuberculosis	O
respectively	O
.	O

The	O
crystal	O
structures	O
of	O
these	O
enzymes	O
including	O
that	O
of	O
the	O
diazaborine	B
-	O
inhibited	O
E.	O
coli	O
ENR	O
have	O
been	O
obtained	O
at	O
high	O
resolution	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
was	O
used	O
to	O
study	O
the	O
importance	O
of	O
amino	B
acid	I
residues	O
in	O
diazaborine	B
susceptibility	O
and	O
enzyme	O
function	O
.	O

The	O
results	O
show	O
that	O
drug	O
binding	O
and	O
inhibition	O
require	O
the	O
presence	O
of	O
a	O
glycine	B
residue	O
at	O
position	O
93	O
of	O
E.	O
coli	O
ENR	O
or	O
at	O
the	O
structurally	O
equivalent	O
position	O
in	O
the	O
plant	O
homologue	O
,	O
which	O
is	O
naturally	O
resistant	O
to	O
the	O
drug	O
.	O

The	O
data	O
confirm	O
the	O
hypothesis	O
that	O
any	O
amino	B
acid	I
side	O
-	O
chain	O
other	O
than	O
hydrogen	B
at	O
this	O
position	O
within	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
these	O
enzymes	O
will	O
affect	O
diazaborine	B
resistance	O
by	O
encroaching	O
into	O
the	O
drug	O
binding	O
site	O
.	O

Substitutions	O
of	O
Gly-93	B
by	O
amino	B
acids	I
with	O
small	O
side	O
-	O
chains	O
,	O
such	O
as	O
serine	B
,	O
alanine	B
,	O
cysteine	B
and	O
valine	B
,	O
hardly	O
affected	O
the	O
catalytic	O
parameters	O
and	O
rendered	O
the	O
bacterial	O
host	O
resistant	O
to	O
the	O
drug	O
.	O

Larger	O
amino	B
acid	I
side	O
-	O
chains	O
,	O
such	O
as	O
that	O
of	O
arginine	B
,	O
histidine	B
,	O
lysine	B
and	O
glutamine	B
,	O
completely	O
inactivated	O
the	O
activity	O
of	O
the	O
enzyme	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
exposure	O
-	O
response	O
relationships	O
in	O
the	O
occurrence	O
of	O
symptoms	O
of	O
the	O
eyes	O
and	O
airways	O
in	O
workers	O
exposed	O
to	O
methyltetrahydrophthalic	B
anhydride	I
(	O
MTHPA	B
)	O
.	O

METHODS	O
:	O
A	O
population	O
of	O
111	O
workers	O
from	O
2	O
condenser	O
plants	O
(	O
A	O
and	O
B	O
)	O
using	O
epoxy	B
resin	I
with	O
MTHPA	B
underwent	O
a	O
questionnaire	O
survey	O
and	O
serology	O
investigations	O
,	O
and	O
data	O
obtained	O
on	O
95	O
subjects	O
in	O
assembly	O
and	O
inspection	O
lines	O
were	O
analyzed	O
for	O
this	O
study	O
.	O

RESULTS	O
:	O
In	O
all	O
,	O
24	O
(	O
65	O
%	O
)	O
of	O
37	O
workers	O
in	O
plant	O
A	O
and	O
38	O
(	O
66	O
%	O
)	O
of	O
58	O
workers	O
in	O
plant	O
B	O
had	O
positive	O
MTHPA	B
-	O
specific	O
IgE.	O
The	O
air	O
levels	O
of	O
MTHPA	B
detected	O
in	O
assembly	O
and	O
inspection	O
lines	O
were	O
higher	O
in	O
plant	O
A	O
than	O
in	O
plant	O
B	O
(	O
geometric	O
mean	O
25.5	O
-	O
63.9	O
and	O
4.93	O
-	O
5.49	O
microg	O
/	O
m3	O
,	O
respectively	O
)	O
.	O

IgE	O
-	O
sensitized	O
workers	O
in	O
each	O
plant	O
had	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
complaints	O
regarding	O
the	O
eyes	O
and	O
nose	O
than	O
did	O
unsensitized	O
workers	O
,	O
suggesting	O
that	O
there	O
is	O
an	O
IgE	O
-	O
mediated	O
mechanism	O
in	O
most	O
of	O
these	O
symptoms	O
.	O

The	O
sensitized	O
workers	O
in	O
plant	O
A	O
had	O
higher	O
frequencies	O
for	O
symptoms	O
of	O
the	O
eyes	O
,	O
nose	O
,	O
and	O
pharynx	O
than	O
did	O
those	O
in	O
plant	O
B	O
(	O
P	O
<	O
0.02	O
)	O
.	O

Furthermore	O
,	O
only	O
15	O
%	O
of	O
persons	O
often	O
displayed	O
work	O
-	O
related	O
symptoms	O
among	O
the	O
20	O
symptomatic	O
workers	O
in	O
plant	O
B	O
as	O
compared	O
with	O
73	O
%	O
of	O
the	O
26	O
symptomatic	O
workers	O
in	O
plant	O
A	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

These	O
results	O
can	O
be	O
explained	O
by	O
the	O
difference	O
in	O
the	O
MTHPA	B
levels	O
measured	O
in	O
the	O
lines	O
between	O
the	O
two	O
plants	O
.	O

In	O
plant	O
B	O
the	O
minimal	O
level	O
of	O
MTHPA	B
that	O
was	O
associated	O
with	O
work	O
-	O
related	O
symptoms	O
was	O
15	O
-	O
22	O
microg	O
/	O
m3	O
,	O
which	O
was	O
lower	O
than	O
the	O
geometric	O
mean	O
levels	O
detected	O
in	O
assembly	O
and	O
inspection	O
lines	O
in	O
plant	O
A.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
MTHPA	B
exposure	O
at	O
levels	O
above	O
15	O
microg	O
/	O
m3	O
should	O
be	O
avoided	O
to	O
prevent	O
the	O
development	O
of	O
occupational	O
allergic	O
diseases	O
in	O
most	O
workers	O
.	O

We	O
investigated	O
the	O
protective	O
effect	O
of	O
fluvastatin	B
sodium	I
on	O
the	O
oxidation	O
of	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
induced	O
in	O
vitro	O
by	O
copper	B
ions	O
.	O

The	O
extent	O
of	O
lipid	O
peroxidation	O
was	O
assessed	O
by	O
monitoring	O
the	O
increase	O
of	O
UV	O
absorbance	O
at	O
234	O
nm	O
,	O
which	O
is	O
the	O
peak	O
absorbance	O
of	O
a	O
conjugated	B
diene	I
.	O

Fluvastatin	B
sodium	I
(	O
1	O
-	O
30	O
microM	O
)	O
not	O
only	O
prolonged	O
the	O
lag	O
time	O
of	O
oxidation	O
in	O
the	O
initiation	O
step	O
,	O
but	O
also	O
decreased	O
the	O
rate	O
of	O
oxidation	O
in	O
the	O
propagation	O
step	O
,	O
both	O
concentration	O
dependently	O
.	O

Fluvastatin	B
sodium	I
and	O
alpha	B
-	I
tocopherol	I
showed	O
an	O
additive	O
effect	O
when	O
both	O
compounds	O
were	O
added	O
before	O
oxidation	O
.	O

However	O
,	O
when	O
the	O
lag	O
time	O
was	O
prolonged	O
initially	O
by	O
alpha	B
-	I
tocopherol	I
,	O
and	O
fluvastatin	B
sodium	I
and	O
alpha	B
-	I
tocopherol	I
,	O
were	O
further	O
added	O
into	O
the	O
reaction	O
mixture	O
at	O
the	O
end	O
point	O
of	O
the	O
lag	O
phase	O
,	O
fluvastatin	B
sodium	I
still	O
showed	O
an	O
antioxidative	O
effect	O
,	O
whereas	O
alpha	B
-	I
tocopherol	I
showed	O
a	O
pro	O
-	O
oxidative	O
effect	O
.	O

Therefore	O
,	O
the	O
antioxidative	O
property	O
of	O
fluvastatin	B
sodium	I
differs	O
from	O
that	O
of	O
alpha	B
-	I
tocopherol	I
.	O

In	O
this	O
experiment	O
,	O
as	O
neither	O
the	O
double	O
bond	O
-	O
reduced	O
derivative	O
of	O
fluvastatin	B
sodium	I
nor	O
pravastatin	B
sodium	I
showed	O
any	O
protective	O
effect	O
,	O
we	O
concluded	O
that	O
the	O
antioxidative	O
effect	O
of	O
fluvastatin	B
sodium	I
is	O
not	O
a	O
common	O
property	O
of	O
3-hydroxy-3-methylglutaryl	O
coenzyme	O
A	O
(	O
HMG	O
-	O
CoA	O
)	O
reductase	O
inhibitors	O
,	O
but	O
may	O
be	O
derived	O
from	O
its	O
unique	O
chemical	O
structure	O
.	O

Since	O
the	O
oxidative	O
modification	O
of	O
LDL	O
plays	O
an	O
important	O
role	O
in	O
the	O
genesis	O
of	O
atherosclerosis	O
,	O
fluvastatin	B
sodium	I
may	O
help	O
reduce	O
the	O
risk	O
of	O
atherosclerosis	O
,	O
not	O
only	O
by	O
reducing	O
plasma	O
LDL	O
levels	O
but	O
also	O
by	O
protecting	O
LDL	O
from	O
oxidative	O
modification	O
.	O

Oxaliplatin	B
(	O
4	O
mg	O
/	O
kg	O
)	O
,	O
cisplatin	B
(	O
2	O
mg	O
/	O
kg	O
with	O
20	O
mg	O
/	O
kg	O
mannitol	B
)	O
and	O
ormaplatin	B
(	O
2	O
mg	O
/	O
kg	O
)	O
were	O
administered	O
i.p	O
.	O

twice	O
weekly	O
for	O
4.5	O
weeks	O
.	O

Lactose	B
injections	O
(	O
0.9	O
%	O
)	O
were	O
used	O
as	O
a	O
control	O
for	O
oxaliplatin	B
and	O
0.9	O
%	O
saline	B
injections	O
were	O
used	O
as	O
a	O
control	O
for	O
cisplatin	B
and	O
ormaplatin	B
.	O

Morphometric	O
changes	O
to	O
dorsal	O
root	O
ganglia	O
L4-L6	O
were	O
quantitated	O
as	O
a	O
measure	O
of	O
neurotoxicity	O
.	O

Drug	O
treatment	O
resulted	O
in	O
a	O
decrease	O
in	O
cell	O
and	O
nuclear	O
area	O
and	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
cells	O
with	O
eccentric	O
nucleoli	O
for	O
neuronal	O
cell	O
bodies	O
in	O
the	O
DRG	O
.	O

Immediately	O
following	O
treatment	O
the	O
order	O
of	O
morphometric	O
changes	O
was	O
ormaplatin	B
>	O
cisplatin	B
>	O
or	O
=	O
oxaliplatin	B
.	O

The	O
accumulation	O
of	O
platinum	B
in	O
the	O
DRG	O
was	O
measured	O
by	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
.	O

The	O
order	O
of	O
accumulation	O
was	O
cisplatin	B
>	O
oxaliplatin	B
>	O
ormaplatin	B
.	O

Following	O
an	O
8-week	O
recovery	O
period	O
the	O
order	O
of	O
morphometric	O
changes	O
to	O
the	O
DRG	O
was	O
ormaplatin	B
approximately	O
equal	O
to	O
oxaliplatin	B
>	O
cisplatin	B
.	O

This	O
correlated	O
with	O
a	O
greater	O
retention	O
of	O
platinum	B
by	O
the	O
DRG	O
for	O
ormaplatin	B
and	O
oxaliplatin	B
than	O
for	O
cisplatin	B
.	O

The	O
results	O
suggest	O
that	O
ormaplatin	B
is	O
uniquely	O
neurotoxic	O
immediately	O
following	O
treatment	O
in	O
the	O
Wistar	O
rat	O
model	O
.	O

However	O
,	O
following	O
an	O
8-week	O
recovery	O
period	O
both	O
ormaplatin	B
and	O
oxaliplatin	B
are	O
more	O
neurotoxic	O
than	O
cisplatin	B
and	O
this	O
neurotoxicity	O
correlates	O
with	O
a	O
greater	O
retention	O
of	O
platinum	B
by	O
the	O
DRG	O
.	O

1,2-Dichlorobenzene	B
(	O
1,2-DCB	B
)	O
is	O
a	O
potent	O
hepatotoxicant	O
in	O
male	O
Fischer	O
344	O
(	O
F344	O
)	O
rats	O
and	O
previous	O
studies	O
have	O
suggested	O
that	O
reactive	B
oxygen	I
species	I
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatotoxicity	O
.	O

Since	O
reactive	B
oxygen	I
species	I
can	O
damage	O
lipid	O
membranes	O
,	O
this	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
extent	O
of	O
lipid	O
peroxidation	O
after	O
administration	O
of	O
1,2-DCB	B
by	O
immuno	O
-	O
histochemical	O
analysis	O
of	O
4-hydroxynonenal	B
(	O
4-HNE	B
)	O
protein	O
adduct	O
formation	O
in	O
liver	O
and	O
conjugated	B
diene	I
formation	O
in	O
liver	O
and	O
serum	O
.	O

The	O
contribution	O
of	O
Kupffer	O
cells	O
to	O
the	O
lipid	O
peroxidation	O
was	O
also	O
investigated	O
.	O

Male	O
F344	O
rats	O
were	O
administered	O
1,2-DCB	B
(	O
3.6	O
mmol	O
/	O
kg	O
i.p	O
.	O

in	O
corn	B
oil	I
)	O
and	O
killed	O
at	O
selected	O
times	O
between	O
3	O
and	O
48	O
h.	O
Time	O
course	O
studies	O
revealed	O
the	O
greatest	O
abundance	O
of	O
4-HNE	B
protein	O
adducts	O
in	O
the	O
centrilobular	O
regions	O
of	O
the	O
liver	O
24	O
h	O
after	O
1,2-DCB	B
administration	O
,	O
with	O
much	O
lower	O
levels	O
at	O
16	O
h.	O
Adducts	O
were	O
present	O
in	O
necrotic	O
and	O
vacuolized	O
centrilobular	O
hepatocytes	O
of	O
1,2-DCB	B
treated	O
rats	O
but	O
not	O
in	O
livers	O
of	O
controls	O
.	O

Further	O
,	O
conjugated	B
dienes	I
were	O
significantly	O
increased	O
in	O
liver	O
and	O
serum	O
16	O
and	O
24	O
h	O
after	O
1,2-DCB	B
administration	O
,	O
peaking	O
at	O
24	O
h.	O
These	O
data	O
correlated	O
with	O
hepatocellular	O
injury	O
,	O
determined	O
by	O
serum	O
alanine	O
aminotransferase	O
activity	O
and	O
histopathological	O
evaluation	O
,	O
which	O
was	O
markedly	O
elevated	O
within	O
16	O
h	O
and	O
peaked	O
at	O
24	O
h.	O
When	O
rats	O
were	O
pretreated	O
with	O
gadolinium	B
chloride	I
(	O
GdCl3	B
;	I
10	O
mg	O
/	O
kg	O
i.v	O
.	O

24	O
h	O
prior	O
to	O
1,2-DCB	O
)	O
,	O
an	O
inhibitor	O
of	O
Kupffer	O
cells	O
,	O
hepatotoxicity	O
was	O
decreased	O
by	O
89	O
and	O
86	O
%	O
,	O
at	O
16	O
and	O
24	O
h	O
,	O
respectively	O
.	O

Conjugated	B
diene	I
concentrations	O
were	O
decreased	O
to	O
control	O
values	O
at	O
these	O
times	O
after	O
1,2-DCB	B
administration	O
.	O

Moreover	O
,	O
no	O
4-HNE	B
protein	O
adducts	O
were	O
detected	O
in	O
livers	O
of	O
1,2-DCB	B
-	O
treated	O
rats	O
pretreated	O
with	O
GdCl3	B
.	O

Finally	O
,	O
Kupffer	O
cells	O
isolated	O
from	O
1,2-DCB	B
-	O
treated	O
rats	O
produced	O
significantly	O
more	O
superoxide	B
anion	I
than	O
Kupffer	O
cells	O
isolated	O
from	O
vehicle	O
controls	O
.	O

These	O
data	O
,	O
along	O
with	O
previous	O
findings	O
,	O
suggest	O
that	O
lipid	O
peroxidation	O
associated	O
with	O
1,2-DCB	B
is	O
mediated	O
in	O
part	O
by	O
Kupffer	O
cell	O
-	O
derived	O
reactive	B
oxygen	I
species	I
.	O

The	O
crystal	O
structure	O
of	O
gliclazide	B
,	O
N-	B
[	I
(	I
perhydrocyclopenta	I
[	I
c	I
]	I
pyrrol-2-yl	I
)	I
aminocarbonyl	I
]	I
-p	I
-	I
toluenesulfonamide	I
,	O
C15H21B3O3S	O
,	O
a	O
second	O
-	O
generation	O
oral	O
hypoglycemic	B
agent	I
,	O
contains	O
discrete	O
molecules	B
with	O
normal	O
molecular	O
dimensions	O
.	O

Both	O
of	O
the	O
five	O
-	O
membered	O
fused	O
rings	O
adopt	O
envelope	O
conformations	O
.	O

The	O
molecules	O
are	O
linked	O
into	O
chains	O
by	O
intermolecular	O
hydrogen	B
bonds	O
involving	O
amino	B
-	O
H	B
atoms	I
,	O
with	O
N	O
...	O
O	O
separations	O
of	O
2.967	O
(	O
3	O
)	O
and	O
2.949	O
(	O
3	O
)	O
A.	O

By	O
assaying	O
lactate	B
dehydrogenase	O
and	O
malondialdehyde	B
leakage	O
from	O
LLC	O
-	O
PK1	O
cells	O
in	O
culture	O
,	O
a	O
study	O
was	O
conducted	O
to	O
clarify	O
whether	O
flavonoid	B
compounds	O
ameliorate	O
renal	O
cellular	O
injury	O
.	O

The	O
cells	O
were	O
cultured	O
with	O
various	O
concentrations	O
of	O
samples	O
under	O
routine	O
conditions	O
.	O

The	O
results	O
demonstrated	O
that	O
baicalin	B
,	O
cirsimaritin	B
,	O
6-hydroxyluteolin	B
,	O
luteolin	B
,	O
plantaginin	B
,	O
rhoifolin	B
,	O
sorbarin	B
,	O
afzelin	B
,	O
hyperin	B
,	O
isoquercitrin	B
,	O
isorhamnetin	B
,	O
kaempferitrin	B
,	O
kaempferol-7-glucoside	B
,	O
oxyayanin	B
A	I
,	O
quercetin	B
,	O
quercitrin	B
,	O
rhamnetin	B
and	O
rutin	B
exerted	O
marked	O
protective	O
effects	O
on	O
the	O
cells	O
,	O
whereas	O
acacetin	B
,	O
apigenin	B
,	O
apiin	B
,	O
cirsilineol	B
,	O
genkwanin	B
,	O
pectolinarin	B
and	O
tetramethylquercitin	B
had	O
virtually	O
no	O
effect	O
.	O

In	O
the	O
light	O
of	O
these	O
findings	O
,	O
we	O
propose	O
that	O
the	O
general	O
capability	O
of	O
these	O
compounds	O
is	O
largely	O
decided	O
by	O
the	O
number	O
and	O
position	O
of	O
phenolic	B
hydroxyl	I
groups	I
linked	O
to	O
the	O
structural	O
backbone	O
.	O

Dopamine	O
D4-like	O
binding	O
sites	O
are	O
abundant	O
in	O
human	O
cerebral	O
cortex	O
as	O
detected	O
by	O
[	B
3H	I
]	I
nemonapride	I
.	O

The	O
extremely	O
low	O
density	O
of	O
D4	O
mRNA	O
in	O
human	O
cerebral	O
cortex	O
is	O
inconsistent	O
with	O
the	O
high	O
amount	O
of	O
D4-like	O
binding	O
sites	O
.	O

To	O
investigate	O
the	O
nature	O
of	O
the	O
D4-like	O
receptors	O
,	O
[	O
3H	O
]	O
nemonapride	O
binding	O
sites	O
in	O
the	O
nonhuman	O
primate	O
cerebral	O
cortex	O
were	O
characterized	O
.	O

Although	O
[	O
3H	O
]	O
nemonapride	O
binding	O
sites	O
were	O
D4-like	O
,	O
displaceable	O
by	O
clozapine	B
but	O
not	O
raclopride	B
,	O
[	B
3H	I
]	I
nemonapride	I
binding	O
was	O
not	O
displaced	O
by	O
selective	O
D4	B
antagonists	I
but	O
was	O
displaced	O
by	O
the	O
selective	O
5-HT2A	O
antagonist	O
MDL100907	B
.	O

Using	O
[	B
3H	I
]	I
ketanserin	I
as	O
a	O
5-HT2A	O
ligand	O
,	O
nemonapride	B
showed	O
high	O
affinity	O
for	O
monkey	O
(	O
Ki	O
=	O
10.4	O
nM	O
)	O
and	O
cloned	O
human	O
(	O
Ki	O
=	O
9.4	O
nM	O
)	O
5-HT2A	O
receptors	O
,	O
while	O
its	O
affinity	O
for	O
rat	O
receptors	O
was	O
lower	O
(	O
Ki	O
=	O
140	O
nM	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
cerebral	O
cortical	O
D4-like	O
binding	O
sites	O
labeled	O
by	O
[	B
3H	I
]	I
nemonapride	I
in	O
nonhuman	O
primates	O
consist	O
of	O
a	O
very	O
small	O
portion	O
of	O
D4	O
,	O
but	O
a	O
substantial	O
portion	O
of	O
5-HT2A	O
receptors	O
.	O

The	O
unexpectedly	O
high	O
affinity	O
of	O
nemonapride	B
for	O
primate	O
5-HT2A	O
receptor	O
suggests	O
reconsidering	O
previous	O
data	O
from	O
other	O
studies	O
using	O
[	B
3H	I
]	I
nemonapride	I
,	O
particularly	O
those	O
on	O
D4-like	O
receptors	O
.	O

The	O
concentrations	O
of	O
adrenaline	B
,	O
noradrenaline	B
,	O
dopamine	B
,	O
aldosterone	B
,	O
the	O
atrial	O
natriuretic	O
hormone	O
,	O
and	O
plasma	O
renin	O
activity	O
were	O
investigated	O
in	O
50	O
patients	O
with	O
mild	O
chronic	O
heart	O
failure	O
.	O

The	O
patients	O
received	O
oral	O
digoxin	B
chronically	O
in	O
a	O
daily	O
dose	O
of	O
0.125	O
mg	O
.	O

On	O
the	O
basis	O
of	O
the	O
estimate	O
of	O
the	O
dosing	O
of	O
digoxin	B
these	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
the	O
first	O
with	O
therapeutic	O
and	O
the	O
second	O
with	O
subtherapeutic	O
concentrations	O
of	O
digoxin	B
in	O
serum	O
.	O

The	O
therapeutic	O
concentration	O
of	O
digoxin	B
in	O
serum	O
was	O
found	O
in	O
23	O
patients	O
(	O
46	O
%	O
)	O
,	O
while	O
subtherapeutic	O
levels	O
were	O
found	O
in	O
27	O
patients	O
(	O
54	O
%	O
)	O
.	O

The	O
concentrations	O
of	O
noradrenaline	B
,	O
dopamine	B
,	O
the	O
renin	O
activity	O
of	O
plasma	O
,	O
aldosterone	B
and	O
the	O
atrial	O
natriuretic	O
hormone	O
in	O
the	O
blood	O
serum	O
in	O
the	O
group	O
of	O
patients	O
in	O
whom	O
the	O
presence	O
of	O
subtherapeutic	O
concentrations	O
of	O
digoxin	B
was	O
found	O
,	O
did	O
not	O
differ	O
essentially	O
from	O
the	O
concentration	O
that	O
was	O
observed	O
in	O
the	O
group	O
with	O
therapeutic	O
concentrations	O
.	O

Only	O
the	O
concentration	O
of	O
adrenaline	B
was	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
in	O
the	O
group	O
of	O
patients	O
with	O
therapeutic	O
concentrations	O
of	O
digoxin	B
.	O

The	O
above	O
results	O
reveal	O
that	O
the	O
neuroendocrine	O
activity	O
of	O
plasma	O
(	O
except	O
for	O
the	O
concentration	O
of	O
adrenaline	B
)	O
is	O
alike	O
in	O
both	O
ranges	O
of	O
digoxin	B
concentrations	O
in	O
serum	O
.	O

Three	O
series	O
of	O
cycloalkanecarboxylic	B
esters	I
derived	O
from	O
the	O
naturally	O
occurring	O
clavine	B
alkaloids	I
lysergol	B
,	O
dihydrolysergol	B
-	I
I	I
,	O
and	O
elymoclavine	B
were	O
synthesized	O
to	O
study	O
their	O
interaction	O
with	O
5-HT2A	O
receptors	O
and	O
alpha1-adrenoceptors	O
in	O
rat	O
tail	O
artery	O
and	O
aorta	O
,	O
respectively	O
.	O

Especially	O
cycloalkanecarboxylic	B
esters	I
derived	O
from	O
lysergol	B
showed	O
complex	O
behavior	O
as	O
partial	O
agonists	O
and	O
antagonists	O
of	O
the	O
contractile	O
effect	O
of	O
5-HT	B
.	O

Within	O
this	O
group	O
,	O
partial	O
5-HT2A	O
receptor	O
agonist	O
activity	O
was	O
most	O
potent	O
for	O
cyclopropanecarboxylic	B
ester	I
6a	I
(	O
pKP	O
=	O
7.67	O
,	O
alpha	O
=	O
0.21	O
)	O
and	O
decreased	O
as	O
the	O
volume	O
requirement	O
of	O
the	O
alicyclic	B
ring	I
increased	O
.	O

This	O
tendency	O
was	O
echoed	O
in	O
experiments	O
where	O
the	O
compounds	O
were	O
used	O
as	O
antagonists	O
of	O
the	O
contractile	O
effect	O
of	O
5-HT	B
.	O

From	O
the	O
structure	O
-	O
activity	O
study	O
,	O
the	O
N-1-isopropyl	B
homologue	I
of	I
6a	I
,	O
compound	B
6b	I
,	O
emerged	O
as	O
the	O
ligand	O
with	O
the	O
highest	O
affinity	O
for	O
rat	O
5-HT2A	O
receptors	O
(	O
pA2	O
=	O
8.74	O
)	O
.	O

For	O
cycloalkanecarboxylic	B
esters	I
derived	O
from	O
dihydrolysergol	B
-	I
I	I
and	O
elymoclavine	B
,	O
no	O
clear	O
structure	O
-	O
affinity	O
relationship	O
could	O
be	O
deduced	O
,	O
although	O
those	O
compounds	O
that	O
had	O
smaller	O
cycloalkyl	B
rings	I
in	O
the	O
acyl	B
portion	O
and	O
an	O
isopropyl	B
substituent	O
at	O
N-1	O
showed	O
the	O
highest	O
5-HT2A	O
receptor	O
affinity	O
.	O

On	O
the	O
other	O
hand	O
,	O
cycloalkanecarboxylic	B
esters	I
derived	O
from	O
lysergol	B
,	O
dihydrolysergol	B
-	I
I	I
,	B
and	O
elymoclavine	B
displayed	O
low	O
or	O
marginal	O
affinity	O
at	O
alpha1-adrenoceptors	O
.	O

A	O
further	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
to	O
what	O
extent	O
the	O
complete	O
removal	O
of	O
the	O
acyl	B
portion	O
of	O
the	O
esters	B
would	O
affect	O
5-HT2A	O
receptor	O
affinity	O
.	O

The	O
parent	O
alcohols	B
of	O
the	O
three	O
series	O
of	O
N-1-isopropyl	B
homologues	I
,	O
1-isopropyllysergol	B
(	O
1b	B
)	O
,	O
1-isopropyldihydrolysergol	B
-	I
I	I
(	O
2b	B
)	O
,	O
and	O
1-isopropylelymoclavine	B
(	O
3b	B
)	O
,	O
displayed	O
higher	O
affinity	O
for	O
5-HT2A	O
receptors	O
(	O
pA2	O
=	O
9.15	O
,	O
8.50	O
,	O
9.14	O
)	O
than	O
the	O
corresponding	O
esters	B
.	O

Compounds	B
1b-3b	I
had	O
no	O
contractile	O
effects	O
by	O
themselves	O
and	O
displayed	O
low	O
affinity	O
at	O
guinea	O
-	O
pig	O
5-HT1B	O
receptors	O
and	O
rat	O
alpha1-adrenoceptors	O
.	O

The	O
high	O
affinity	O
for	O
rat	O
5-HT2A	O
receptors	O
was	O
retained	O
when	O
clavines	B
even	O
more	O
simple	O
in	O
structure	O
than	O
1b-3b	B
,	O
compounds	O
4b	B
and	O
5b	B
,	O
were	O
examined	O
as	O
5-HT2A	O
receptor	O
antagonists	O
.	O

The	O
nanomolar	O
antagonist	O
activity	O
of	O
simple	O
clavines	B
(	O
1b-5b	B
)	O
in	O
the	O
rat	O
suggests	O
that	O
the	O
indolo	B
[	I
4,3-fg	I
]	I
quinoline	I
system	O
of	O
the	O
ergolines	O
is	O
the	O
molecular	O
fragment	O
that	O
is	O
responsible	O
for	O
5-HT2A	O
receptor	O
affinity	O
,	O
and	O
not	O
the	O
substituent	O
at	O
position	O
C-8	O
.	O

Exposure	O
of	O
Clone	O
9	O
cells	O
,	O
a	O
nontransformed	O
rat	O
liver	O
cell	O
line	O
expressing	O
only	O
the	O
Glutl	O
glucose	O
transporter	O
isoform	O
,	O
to	O
the	O
guanylyl	O
cyclase	O
inhibitor	O
LY-83583	B
was	O
found	O
to	O
stimulate	O
the	O
rate	O
of	O
glucose	B
transport	O
(	O
approximately	O
7-	O
to	O
8-fold	O
in	O
1	O
h	O
)	O
.	O

A	O
similar	O
response	O
to	O
LY-83583	B
was	O
found	O
in	O
NIH	O
3T3	O
fibroblasts	O
,	O
3T3-L1	O
pre	O
-	O
adipocytes	O
,	O
and	O
C2C12	O
myoblasts	O
.	O

Neither	O
the	O
rate	O
of	O
glucose	B
transport	O
in	O
cells	O
under	O
control	O
conditions	O
nor	O
the	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
was	O
altered	O
by	O
10	O
,	O
50	O
,	O
or	O
100	O
microM	O
8-bromo	B
-	I
cGMP	I
or	O
by	O
addition	O
of	O
cGMP	B
phosphodiesterase	O
inhibitors	O
,	O
zaprinast	B
,	O
or	O
dipyridamole	B
suggesting	O
that	O
glucose	B
transport	O
and	O
the	O
response	O
to	O
LY-83583	B
is	O
independent	O
of	O
cGMP	B
levels	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
was	O
not	O
mediated	O
by	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
,	O
since	O
exposure	O
to	O
the	O
agent	O
resulted	O
in	O
no	O
increase	O
in	O
lactate	O
production	O
.	O

Incubation	O
of	O
Clone	O
9	O
cells	O
in	O
the	O
presence	O
of	O
the	O
phospholipase	O
C	O
inhibitor	O
U73122	B
,	O
however	O
,	O
attenuated	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
.	O

Moreover	O
,	O
exposure	O
to	O
LY-83583	B
resulted	O
in	O
a	O
rise	O
in	O
cell	O
diacylglycerol	B
content	O
,	O
and	O
preincubation	O
with	O
U73122	B
significantly	O
diminished	O
this	O
rise	O
as	O
well	O
as	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
.	O

The	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
was	O
significantly	O
blocked	O
by	O
thapsigargin	B
.	O

Down	O
-	O
regulation	O
of	O
protein	O
kinase	O
C	O
activity	O
,	O
resulting	O
from	O
24	O
h	O
pre	O
-	O
incubation	O
in	O
the	O
presence	O
of	O
160	O
nM	O
phorbol-12-myristate	B
13-acetate	I
,	O
did	O
not	O
attenuate	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
.	O

It	O
is	O
concluded	O
that	O
the	O
stimulation	O
of	O
glucose	B
transport	O
in	O
response	O
to	O
LY-83583	B
is	O
independent	O
of	O
changes	O
in	O
cGMP	B
levels	O
,	O
is	O
not	O
mediated	O
by	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
,	O
and	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
stimulation	O
of	O
the	O
phospholipase	O
C	O
pathway	O
.	O

Facilitative	O
transport	O
of	O
glucose	B
across	O
plasma	O
membranes	O
is	O
mediated	O
by	O
members	O
of	O
the	O
Na+	B
-independent	O
family	O
of	O
glucose	O
transporter	O
molecules	O
(	O
Glut	O
)	O
which	O
are	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
(	O
Muekler	O
,	O
1990	O
;	O
Pessin	O
and	O
Bell	O
,	O
1992	O
;	O
Ismail	O
-	O
Beigi	O
,	O
1993	O
)	O
.	O

Among	O
the	O
glucose	O
transporters	O
,	O
glucose	O
transporter-1	O
is	O
present	O
in	O
varying	O
amounts	O
in	O
most	O
tissues	O
and	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
brain	O
,	O
retina	O
,	O
placenta	O
,	O
human	O
erythrocytes	O
,	O
and	O
a	O
variety	O
of	O
cells	O
in	O
culture	O
(	O
Muekler	O
et	O
al.	O
,	O
1985	O
;	O
Birnbaum	O
et	O
al.	O
,	O
1986	O
;	O
Pessin	O
and	O
Bell	O
,	O
1992	O
)	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
reported	O
that	O
the	O
rate	O
of	O
glucose	B
transport	O
in	O
Clone	O
9	O
cells	O
,	O
a	O
nontransformed	O
rat	O
liver	O
cell	O
line	O
expressing	O
only	O
the	O
glucose	O
transporter-1	O
isoform	O
,	O
is	O
markedly	O
augmented	O
in	O
response	O
to	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
by	O
sodium	B
azide	I
or	O
cyanide	B
(	O
Mercado	O
et	O
al.	O
,	O
1989	O
;	O
Shetty	O
et	O
al.	O
,	O
1992	O
;	O
Becker	O
et	O
al.	O
,	O
1996	O
;	O
Behrooz	O
and	O
Ismail	O
-	O
Beigi	O
,	O
1997	O
)	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
azide	B
and	O
other	O
inhibitors	O
of	O
oxidative	O
phosphorylation	O
increase	O
nitric	B
oxide	I
(	O
NO	B
)	O
levels	O
(	O
Schulz	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Since	O
NO	B
donors	O
,	O
such	O
as	O
sodium	B
nitroprusside	I
,	O
have	O
been	O
reported	O
to	O
stimulate	O
the	O
rate	O
of	O
glucose	B
transport	O
(	O
Balon	O
and	O
Nadler	O
,	O
1997	O
;	O
Young	O
et	O
al.	O
,	O
1997	O
)	O
,	O
we	O
tested	O
the	O
possibility	O
that	O
the	O
stimulation	O
of	O
glucose	B
transport	O
in	O
response	O
to	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
is	O
mediated	O
through	O
NO	B
signalling	O
mechanisms	O
.	O

Results	O
of	O
initial	O
studies	O
on	O
Clone	O
9	O
cells	O
indicated	O
that	O
glucose	B
transport	O
was	O
enhanced	O
2-	O
to	O
3-fold	O
by	O
sodium	B
nitroprusside	I
(	O
Prasad	O
and	O
Ismail	O
-	O
Beigi	O
,	O
unpublished	O
observations	O
)	O
,	O
presumably	O
through	O
generation	O
of	O
NO	B
.	O

Since	O
it	O
is	O
well	O
-	O
known	O
that	O
many	O
actions	O
of	O
NO	B
are	O
mediated	O
by	O
stimulation	O
of	O
guanylyl	O
cyclase	O
activity	O
resulting	O
in	O
increased	O
cGMP	B
levels	O
,	O
we	O
tested	O
the	O
effect	O
of	O
LY-83583—a	B
well	O
documented	O
and	O
specific	O
inhibitor	O
of	O
guanylyl	O
cyclase	O
activity	O
(	O
Mulsch	O
et	O
al.	O
,	O
1988	O
;	O
Stuart	O
-	O
Smith	O
et	O
al.	O
,	O
1998	O
)	O
—on	O
the	O
stimulation	O
of	O
glucose	B
transport	O
in	O
response	O
to	O
sodium	B
nitroprusside	I
.	O

The	O
experimental	O
results	O
yielded	O
an	O
unexpected	O
finding	O
,	O
namely	O
that	O
exposure	O
to	O
LY-83583	B
alone	O
resulted	O
in	O
a	O
marked	O
(	O
∼7	O
fold	O
)	O
stimulation	O
of	O
glucose	B
transport	O
.	O

Studies	O
were	O
hence	O
performed	O
to	O
further	O
characterize	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
.	O

A	O
preliminary	O
report	O
of	O
some	O
of	O
the	O
findings	O
has	O
been	O
presented	O
(	O
Prasad	O
et	O
al.	O
,	O
1998	O
)	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Clone	O
9	O
,	O
C2	O
C12	O
,	O
NIH	O
3T3	O
,	O
and	O
3T3-L1	O
cells	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
Rockville	O
,	O
MD	O
)	O
.	O

Dulbecco	B
's	I
modified	I
Eagle	I
's	I
medium	I
(	O
DMEM	B
)	O
,	O
Hank	B
's	I
balanced	I
salt	I
solution	I
(	O
HBSS	B
)	O
,	O
calf	O
serum	O
,	O
and	O
fetal	O
bovine	O
serum	O
were	O
purchased	O
from	O
Gibco	O
BRL	O
(	O
Grand	O
Island	O
,	O
NY	O
)	O
.	O

Plastic	O
culture	O
dishes	O
were	O
obtained	O
from	O
Corning	O
Glass	O
Works	O
(	O
Medfield	O
,	O
MA	O
)	O
.	O

3-O	B
-Methyl	I
-	I
d	I
-	I
[	I
3	I
H	I
]	I
glucose	I
(	O
[	B
3	I
H	I
]	I
3-O	I
-methyl	I
glucose	I
)	O
(	O
3.4	O
mCi	O
mmol−1	O
)	O
,	O
and	O
sn	B
-1,2-diacylglycerol	I
assay	O
kit	O
were	O
purchased	O
from	O
Amersham	O
(	O
Arlington	O
Heights	O
,	O
IL	O
)	O
.	O

[	B
32	I
P	I
]	I
γ	I
-	I
ATP	I
(	O
4500	O
Ci	O
mmol−1	O
)	O
was	O
purchased	O
from	O
ICN	O
Biochemicals	O
(	O
Irvine	O
,	O
CA	O
)	O
.	O

LY-83583	B
and	O
U73122	B
(	O
Fig.	O
1	O
)	O
,	O
dipyridamole	B
,	O
zaprinast	B
,	O
8-bromo	B
-	I
cGMP	I
,	O
and	O
phorbol-12-myristate	B
13-acetate	I
(	O
PMA	B
)	O
were	O
purchased	O
from	O
CalBiochem	O
(	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

Lactate	B
assay	O
kit	O
,	O
sodium	B
azide	I
,	O
cytochalasin	B
-	I
B	I
,	O
sodium	B
nitroprusside	I
,	O
trichloroacetic	B
acid	I
,	O
gamma	O
globulin	O
,	O
thapsigargin	B
,	O
phloretin	B
,	O
thin	O
-	O
layer	O
chromatography	O
plates	O
(	O
silica	B
gel	I
)	O
,	O
and	O
standard	O
chemical	O
compounds	O
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
.	O

Horse	O
anti	O
-	O
cGMP	O
antibody	O
and	O
[	B
125	I
I	I
]	I
cGMP	I
were	O
obtained	O
as	O
a	O
gift	O
from	O
Dr.	O
Chung	O
-	O
Ho	O
Chang	O
(	O
Chang	O
and	O
Song	O
,	O
1993	O
)	O
.	O

Dimethyl	B
sulfoxide	I
(	O
DMSO	B
)	O
,	O
and	O
hydrochloric	B
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Fairlawn	O
,	O
NJ	O
)	O
.	O

2.2	O
Cell	O
culture	O
Clone	O
9	O
cells	O
were	O
maintained	O
in	O
Dulbecco	B
's	I
modified	I
eagle	I
medium	I
(	O
DMEM	B
;	O
5.6	O
mM	O
glucose	O
)	O
containing	O
10	O
%	O
calf	O
serum	O
at	O
37	O
°	O
C	O
with	O
8	O
%	O
CO2	B
and	O
reached	O
confluence	O
after	O
∼4	O
days	O
.	O

Cells	O
were	O
used	O
between	O
passages	O
27	O
and	O
53	O
.	O

NIH-3T3	O
cells	O
,	O
3T3-L1	O
cells	O
,	O
and	O
C2	O
C12	O
cells	O
were	O
grown	O
in	O
DMEM	B
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
.	O

After	O
confluence	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
serum	O
-	O
free	O
DMEM	B
24	O
h	O
prior	O
to	O
initiation	O
of	O
all	O
experiments	O
.	O

Sodium	B
azide	I
and	O
8-bromo	B
-	I
cGMP	I
dissolved	O
in	O
40	O
μl	O
of	O
DMEM	B
,	O
and	O
LY-83583	B
,	O
thapsigargin	B
,	O
and	O
U73122	B
dissolved	O
in	O
10	O
μl	O
DMSO	B
were	O
added	O
directly	O
to	O
culture	O
dishes	O
at	O
appropriate	O
times	O
.	O

2.3	O
Measurement	O
of	O
[	B
3	I
H	I
]	I
3-O	I
-	I
methyl	I
glucose	I
uptake	O
Cells	O
were	O
grown	O
on	O
60-mm	O
culture	O
dishes	O
.	O

Uptake	O
assay	O
was	O
performed	O
in	O
replicate	O
dishes	O
for	O
a	O
1.0	O
to	O
1.5	O
min	O
interval	O
,	O
as	O
described	O
previously	O
,	O
in	O
the	O
absence	O
and	O
presence	O
of	O
50	O
μM	O
cytochalasin	B
B	I
(	O
Mercado	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Cytochalasin	B
B	I
-	O
inhibitable	O
[	B
3	I
H	I
]	I
3-O	I
-methyl	I
-	I
d	I
-glucose	I
(	O
[	B
3	I
H	I
]	I
3-OMG	I
)	O
uptake	O
was	O
calculated	O
as	O
the	O
difference	O
in	O
uptake	O
in	O
the	O
absence	O
and	O
presence	O
of	O
cytochalasin	B
B	I
assayed	O
in	O
parallel	O
.	O

2.4	O
Measurement	O
of	O
cGMP	B
Cells	O
grown	O
on	O
100-mm	O
culture	O
dishes	O
were	O
exposed	O
to	O
various	O
reagents	O
for	O
indicated	O
times	O
in	O
the	O
presence	O
of	O
10	O
μM	O
dipyridamole	B
,	O
a	O
cGMP	O
phosphodiesterase	O
inhibitor	O
(	O
Beavo	O
and	O
Reifsnyder	O
,	O
1990	O
)	O
.	O

Immediately	O
following	O
exposure	O
to	O
the	O
indicated	O
stimuli	O
,	O
cells	O
in	O
each	O
dish	O
were	O
washed	O
four	O
times	O
with	O
10	O
ml	O
of	O
ice	O
-	O
cold	O
phosphate	B
-	I
buffered	I
saline	I
.	O

Following	O
complete	O
drainage	O
,	O
250	O
μl	O
of	O
ice	O
-	O
cold	O
10	O
%	O
trichloroacetic	B
acid	I
was	O
added	O
to	O
each	O
dish	O
and	O
dishes	O
were	O
immediately	O
placed	O
in	O
−80	O
°	O
C	O
for	O
1	O
h.	O
After	O
thawing	O
,	O
cells	O
were	O
scraped	O
and	O
centrifuged	O
at	O
14,000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
and	O
the	O
resulting	O
supernatants	O
were	O
placed	O
in	O
glass	O
tubes	O
.	O

50	O
μl	O
of	O
1	O
M	O
HCl	B
was	O
added	O
to	O
each	O
tube	O
,	O
and	O
the	O
aqueous	B
phase	O
was	O
extracted	O
3	O
times	O
with	O
2	O
ml	O
of	O
ethyl	B
ether	I
.	O

The	O
aqueous	B
phase	O
was	O
placed	O
in	O
uncapped	O
tubes	O
for	O
16	O
h	O
at	O
room	O
temperature	O
to	O
allow	O
the	O
remaining	O
ether	B
to	O
evaporate	O
.	O

Next	O
,	O
50	O
μl	O
of	O
1	O
M	O
sodium	B
acetate	I
,	O
40	O
μl	O
of	O
1	O
M	O
NaOH	B
,	O
and	O
10	O
μl	O
of	O
triethanolamine	B
:	O
acetic	B
anhydride	I
(	O
2:1	O
,	O
v	O
/	O
v	O
)	O
were	O
sequentially	O
added	O
to	O
each	O
tube	O
with	O
brief	O
mixing	O
after	O
each	O
addition	O
.	O

100	O
μl	O
of	O
antibody	O
against	O
cGMP	B
and	O
100	O
μl	O
of	O
[	B
125	I

I	B
]	I
cGMP	I
was	O
added	O
,	O
and	O
the	O
tubes	O
were	O
gently	O
shaken	O
for	O
4	O
h	O
at	O
4	O
°	O
C	O
.	O

Next	O
,	O
50	O
μl	O
of	O
rabbit	O
gamma	O
globulin	O
was	O
added	O
to	O
each	O
sample	O
.	O

Following	O
the	O
addition	O
of	O
2	O
ml	O
isopropanol	B
to	O
each	O
sample	O
,	O
tubes	O
were	O
centrifuged	O
at	O
2700	O
×	O
g	O
for	O
30	O
min	O
at	O
4	O
°	O
C	O
.	O

Supernatants	O
were	O
decanted	O
and	O
pellets	O
were	O
dried	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Finally	O
,	O
samples	O
were	O
counted	O
in	O
a	O
gamma	O
counter	O
.	O

cGMP	B
content	O
in	O
samples	O
was	O
determined	O
using	O
cGMP	B
standards	O
assayed	O
in	O
parallel	O
(	O
Chang	O
and	O
Song	O
,	O
1993	O
)	O
.	O

2.5	O
Measurement	O
of	O
lactate	B
Lactate	B
concentration	O
in	O
the	O
medium	O
was	O
measured	O
in	O
cells	O
grown	O
in	O
60-mm	O
dishes	O
that	O
had	O
been	O
washed	O
once	O
with	O
4	O
ml	O
of	O
Hank	B
's	I
balanced	I
salt	I
solution	I
and	O
incubated	O
in	O
the	O
presence	O
of	O
1	O
ml	O
of	O
DMEM	B
for	O
1	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
sodium	B
azide	I
or	O
LY-83583	B
.	O

Samples	O
of	O
the	O
medium	O
were	O
analyzed	O
for	O
lactate	B
as	O
described	O
previously	O
and	O
in	O
the	O
kit	O
's	O
instruction	O
guide	O
(	O
Becker	O
et	O
al.	O
,	O
1996	O
)	O
.	O

2.6	O
Assay	O
of	O
sn-1,2-diacylglycerol	B
After	O
addition	O
of	O
the	O
indicated	O
reagents	O
to	O
cells	O
,	O
plates	O
were	O
washed	O
twice	O
with	O
ice	O
-	O
cold	O
phosphate	B
-	I
buffered	I
saline	I
(	O
PBS	B
)	O
,	O
harvested	O
in	O
5	O
ml	O
of	O
ice	O
-	O
cold	O
PBS	B
,	O
placed	O
in	O
15	O
ml	O
Falcon	O
Blue	O
Max	O
Jr.	O
tubes	O
,	O
and	O
centrifuged	O
for	O
5	O
min	O
at	O
720	O
×	O
g	O
.	O

Pellets	O
were	O
resuspended	O
in	O
0.8	O
ml	O
of	O
1	O
M	O
NaCl	B
and	O
3	O
ml	O
of	O
a	O
chloroform	B
:	O
methanol	B
(	O
1:2	O
,	O
v	O
/	O
v	O
)	O
was	O
added	O
,	O
and	O
the	O
tubes	O
were	O
shaken	O
vigorously	O
.	O

Then	O
,	O
1	O
ml	O
of	O
1	O
M	O
NaCl	B
and	O
1	O
ml	O
of	O
chloroform	B
were	O
then	O
added	O
,	O
tubes	O
were	O
capped	O
,	O
vortexed	O
,	O
and	O
centrifuged	O
for	O
2	O
min	O
at	O
2350	O
×	O
g	O
.	O

Next	O
,	O
200	O
μl	O
of	O
the	O
chloroform	B
phase	O
was	O
transferred	O
to	O
2	O
ml	O
microfuge	O
tubes	O
,	O
and	O
samples	O
were	O
evaporated	O
to	O
dryness	O
in	O
a	O
speed	O
-	O
vac	O
for	O
1	O
h.	O
Subsequent	O
steps	O
,	O
including	O
measurement	O
of	O
diacylglycerol	B
by	O
its	O
quantitative	O
conversion	O
to	O
[	B
32	I
P	I
]	I
phosphatidic	I
acid	I
in	O
the	O
presence	O
of	O
[	B
32	I
P	I
]	I
-γ	I
-	I
ATP	I
,	O
were	O
according	O
to	O
the	O
kit	O
's	O
instructions	O
.	O

Following	O
the	O
reaction	O
and	O
extraction	O
procedures	O
,	O
radioactivity	O
in	O
phosphatidic	B
acid	I
was	O
determined	O
by	O
thin	O
layer	O
chromatography	O
using	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Bands	O
corresponding	O
to	O
[	B
32	I
P	I
]	I
phosphatidic	I
acid	I
(	O
detected	O
by	O
autoradiography	O
)	O
were	O
cut	O
-	O
out	O
and	O
counted	O
.	O

Diacylglycerol	B
content	O
in	O
samples	O
were	O
determined	O
using	O
diacylglycerol	B
standards	O
assayed	O
in	O
parallel	O
.	O

2.7	O
Statistical	O
methods	O
All	O
values	O
are	O
expressed	O
as	O
means±S.E.	O
Student	O
's	O
unpaired	O
two	O
-	O
tailed	O
t	O
-test	O
was	O
used	O
,	O
and	O
a	O
P	O
value	O
of	O
<	O
0.05	O
was	O
taken	O
to	O
be	O
significant	O
(	O
Snedecor	O
and	O
Cochran	O
,	O
1976	O
)	O
.	O

3	O
Results	O
3.1	O
Enhancement	O
of	O
glucose	B
transport	O
in	O
Clone	O
9	O
and	O
other	O
cells	O
in	O
response	O
to	O
LY-83583	B
Exposure	O
of	O
Clone	O
9	O
cells	O
to	O
10	O
μM	O
LY-83583	B
for	O
1	O
h	O
stimulated	O
the	O
rate	O
of	O
cytochalasin	B
B	I
-	O
inhibitable	O
3-O	B
-methyl	I
glucose	I
transport	O
7.4±0.3	O
fold	O
(	O
Fig.	O
2	O
)	O
.	O

As	O
a	O
comparison	O
,	O
treatment	O
of	O
cells	O
with	O
10	O
mM	O
sodium	B
azide	I
for	O
1	O
h	O
,	O
an	O
inhibitor	O
of	O
oxidative	O
phosphorylation	O
known	O
to	O
stimulate	O
glucose	B
transport	O
in	O
the	O
cells	O
(	O
Shetty	O
et	O
al.	O
,	O
1992	O
)	O
,	O
resulted	O
in	O
a	O
4.1±0.3-fold	O
increase	O
in	O
the	O
rate	O
of	O
glucose	B
uptake	O
.	O

To	O
determine	O
the	O
concentration	O
–	O
response	O
relationship	O
to	O
LY-83583	B
,	O
Clone	O
9	O
cells	O
were	O
exposed	O
to	O
0	O
,	O
1	O
,	O
3	O
,	O
10	O
,	O
and	O
33	O
μM	O
LY-83583	B
for	O
1	O
h	O
prior	O
to	O
measurement	O
of	O
cytochalasin	B
B	I
-	O
inhibitable	O
[	B
3	I
H	I
]	I
3-O	I
-methyl	I
-	I
d	I
-glucose	I
(	O
[	B
3	I
H	I
]	I
3-OMG	I
)	O
uptake	O
;	O
rates	O
of	O
uptake	O
were	O
half	O
-	O
maximally	O
and	O
maximally	O
stimulated	O
at	O
∼0.8	O
and	O
∼10	O
μM	O
LY-83583	B
,	O
respectively	O
(	O
Fig.	O
3	O
A	O
)	O
.	O

The	O
time	O
-	O
course	O
of	O
the	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
was	O
also	O
determined	O
(	O
Fig.	O
3	O
B	O
)	O
.	O

Rate	O
of	O
[	B
3	I
H	I
]	I
3-OMG	I
uptake	O
was	O
significantly	O
stimulated	O
after	O
10	O
min	O
exposure	O
to	O
10	O
μM	O
LY-83583	B
,	O
and	O
reached	O
near	O
-	O
maximal	O
levels	O
at	O
90	O
min	O
.	O

To	O
determine	O
whether	O
the	O
observed	O
stimulation	O
of	O
glucose	B
transport	O
in	O
response	O
to	O
LY-83583	B
is	O
specific	O
to	O
Clone	O
9	O
cells	O
,	O
we	O
measured	O
the	O
effect	O
of	O
LY-83583	B
on	O
the	O
rate	O
of	O
[	B
3	I
H	I
]	I
3-OMG	I
uptake	O
in	O
three	O
additional	O
cell	O
types	O
,	O
all	O
of	O
which	O
express	O
only	O
the	O
glucose	O
transporter-1	O
isoform	O
(	O
Harrison	O
et	O
al.	O
,	O
1991	O
;	O
Kotliar	O
and	O
Pilch	O
,	O
1992	O
;	O
Ismail	O
-	O
Beigi	O
,	O
unpublished	O
observations	O
)	O
;	O
the	O
results	O
are	O
shown	O
in	O
Table	O
1	O
.	O

In	O
response	O
to	O
exposure	O
to	O
10	O
μM	O
LY-83583	B
,	O
cytochalasin	B
B	I
-	O
inhibitable	O
[	B
3	I
H	I
]	I
3-OMG	I
uptake	O
was	O
stimulated	O
4.3-	O
,	O
5.0-	O
,	O
and	O
3.7-fold	O
in	O
NIH	O
3T3	O
fibroblasts	O
,	O
3T3-L1	O
preadipocytes	O
,	O
and	O
C2	O
C12	O
myoblasts	O
,	O
respectively	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
LY-83583	B
evokes	O
a	O
marked	O
and	O
rapid	O
stimulation	O
of	O
glucose	B
transport	O
that	O
is	O
manifest	O
in	O
the	O
variety	O
of	O
cell	O
types	O
examined	O
.	O

3.2	O
Effect	O
of	O
LY-83583	B
on	O
intracellular	O
cGMP	B
levels	O
and	O
glucose	B
transport	O
The	O
observed	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
the	O
rate	O
of	O
glucose	B
transport	O
in	O
conjunction	O
with	O
its	O
known	O
inhibitory	O
action	O
on	O
guanylyl	O
cyclase	O
activity	O
leading	O
to	O
a	O
reduction	O
of	O
cellular	O
cGMP	B
levels	O
(	O
Diamond	O
and	O
Chu	O
,	O
1985	O
;	O
Schmidt	O
et	O
al.	O
,	O
1985	O
)	O
,	O
raised	O
the	O
possibility	O
that	O
a	O
decrease	O
in	O
cell	O
cGMP	B
levels	O
mediates	O
the	O
enhancement	O
of	O
glucose	B
transport	O
.	O

If	O
this	O
were	O
the	O
case	O
,	O
then	O
an	O
increase	O
in	O
cellular	O
cGMP	B
levels	O
should	O
abrogate	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
.	O

To	O
test	O
this	O
possibility	O
,	O
Clone	O
9	O
cells	O
were	O
exposed	O
to	O
the	O
membrane	O
-	O
permeant	O
cGMP	B
analog	O
,	O
8-bromo	B
-	I
cGMP	I
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
LY-83583	B
(	O
Fig.	O
4	O
)	O
.	O

In	O
comparison	O
with	O
control	O
cells	O
,	O
and	O
as	O
already	O
noted	O
,	O
exposure	O
to	O
10	O
μM	O
LY-83583	B
alone	O
for	O
1	O
h	O
resulted	O
in	O
7.1±0.3-fold	O
increase	O
in	O
the	O
rate	O
of	O
[	B
3	I
H	I
]	I
3-OMG	I
uptake	O
.	O

10	O
μM	O
LY-83583	B
in	O
the	O
presence	O
of	O
10	O
μM	O
8-bromo	B
-	I
cGMP	I
also	O
resulted	O
in	O
a	O
7.0±0.2-fold	O
increase	O
in	O
the	O
rate	O
of	O
uptake	O
,	O
while	O
exposure	O
to	O
10	O
μM	O
8-bromo	B
-	I
cGMP	I
alone	O
had	O
no	O
effect	O
on	O
the	O
rate	O
of	O
glucose	B
transport	O
.	O

In	O
additional	O
experiments	O
,	O
exposure	O
to	O
50	O
or	O
100	O
μM	O
8-bromo	B
-	I
cGMP	I
had	O
no	O
effect	O
on	O
either	O
the	O
basal	O
or	O
LY-83583-stimulated	B
rate	O
of	O
glucose	B
transport	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
an	O
alternative	O
method	O
of	O
increasing	O
cellular	O
cGMP	B
levels	O
,	O
zaprinast	B
or	O
dipyridamole	B
,	O
cGMP	O
phosphodiesterase	O
inhibitors	O
,	O
were	O
employed	O
(	O
Beavo	O
and	O
Reifsnyder	O
,	O
1990	O
)	O
.	O

The	O
stimulatory	O
effect	O
of	O
10	O
μM	O
LY-83583	B
was	O
largely	O
unaffected	O
by	O
the	O
presence	O
of	O
zaprinast	B
or	O
dipyridamole	B
,	O
and	O
zaprinast	B
and	O
dipyridamole	B
alone	O
had	O
no	O
significant	O
effect	O
of	O
the	O
basal	O
rate	O
of	O
glucose	B
uptake	O
(	O
Fig.	O
4	O
)	O
.	O

To	O
verify	O
that	O
addition	O
of	O
8-bromo	B
-	I
cGMP	I
to	O
the	O
culture	O
dishes	O
resulted	O
in	O
elevated	O
intracellular	O
cGMP	B
levels	O
,	O
cell	O
cGMP	B
content	O
was	O
measured	O
by	O
radioimmunoassay	O
(	O
Fig.	O
5	O
)	O
.	O

To	O
obtain	O
measurable	O
levels	O
of	O
cGMP	B
,	O
all	O
cells	O
were	O
exposed	O
to	O
10	O
μM	O
dipyridamole	B
in	O
addition	O
to	O
the	O
test	O
agents	O
.	O

Addition	O
of	O
1	O
μM	O
or	O
10	O
μM	O
8-bromo	B
-	I
cGMP	I
resulted	O
in	O
significant	O
increases	O
in	O
cGMP	B
content	O
of	O
Clone	O
9	O
cells	O
.	O

(	O
It	O
should	O
be	O
noted	O
that	O
cells	O
were	O
washed	O
four	O
times	O
to	O
remove	O
all	O
traces	O
of	O
external	O
8-bromo	B
-	I
cGMP	I
prior	O
to	O
lysis	O
of	O
the	O
cells	O
,	O
and	O
in	O
preliminary	O
experiments	O
,	O
cellular	O
cGMP	B
levels	O
were	O
the	O
same	O
after	O
two	O
versus	O
four	O
washes	O
prior	O
to	O
harvest	O
.	O
)	O

cGMP	B
levels	O
remained	O
unchanged	O
in	O
the	O
presence	O
of	O
10	O
μM	O
LY-83583	B
in	O
conjunction	O
with	O
dipyridamole	B
.	O

As	O
a	O
positive	O
control	O
,	O
exposure	O
of	O
cells	O
to	O
5	O
mM	O
sodium	B
nitroprusside	I
resulted	O
in	O
a	O
significant	O
increase	O
in	O
cGMP	B
levels	I
,	O
and	O
this	O
effect	O
was	O
partially	O
blocked	O
by	O
LY-83583	B
.	O

Taken	O
together	O
,	O
the	O
above	O
results	O
suggested	O
that	O
the	O
stimulation	O
of	O
glucose	B
transport	O
in	O
response	O
to	O
LY-83583	B
is	O
independent	O
of	O
changes	O
in	O
intracellular	O
cGMP	B
levels	O
.	O

3.3	O
Effect	O
of	O
LY-83583	B
on	O
lactate	B
production	O
in	O
Clone	O
9	O
cells	O
Other	O
potential	O
pathways	O
that	O
could	O
mediate	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
were	O
examined	O
.	O

We	O
have	O
previously	O
shown	O
that	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
by	O
cyanide	B
or	O
azide	B
results	O
in	O
a	O
rapid	O
stimulation	O
of	O
glucose	B
transport	O
in	O
these	O
cells	O
(	O
Mercado	O
et	O
al.	O
,	O
1989	O
;	O
Shetty	O
et	O
al.	O
,	O
1992	O
;	O
Becker	O
et	O
al.	O
,	O
1996	O
)	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
leads	O
to	O
an	O
increase	O
in	O
cytosolic	O
NADH	B
/	O
NAD+	B
and	O
lactate	B
/	O
pyruvate	B
ratios	O
and	O
results	O
in	O
a	O
marked	O
increase	O
in	O
the	O
rate	O
of	O
lactate	B
production	O
(	O
LaNoue	O
and	O
Schoolwerth	O
,	O
1979	O
;	O
Becker	O
et	O
al.	O
,	O
1996	O
)	O
.	O

To	O
discern	O
whether	O
LY-83583	B
's	O
stimulatory	O
effect	O
on	O
glucose	B
transport	O
is	O
in	O
response	O
to	O
a	O
potential	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
by	O
the	O
agent	O
,	O
we	O
measured	O
the	O
rate	O
of	O
lactate	B
production	O
in	O
Clone	O
9	O
cells	O
exposed	O
to	O
LY-83583	B
(	O
Table	O
2	O
)	O
;	O
lactate	B
produced	O
by	O
cells	O
treated	O
with	O
azide	B
served	O
as	O
a	O
positive	O
control	O
.	O

In	O
cells	O
treated	O
with	O
10	O
μM	O
LY-83583	B
for	O
1	O
h	O
,	O
the	O
rate	O
of	O
lactate	B
production	O
averaged	O
2.1±0.15	O
nmol	O
(	O
mg	O
protein	O
)	O
−1	O
h−1	O
which	O
was	O
not	O
different	O
than	O
the	O
rate	O
in	O
control	O
cells	O
.	O

3.4	O
Role	O
of	O
activation	O
of	O
phospholipase	O
C	O
in	O
the	O
stimulation	O
of	O
glucose	B
transport	O
in	O
response	O
to	O
LY-83583	B
The	O
possibility	O
that	O
activation	O
of	O
phospholipase	O
C	O
,	O
a	O
well	O
characterized	O
upstream	O
mediator	O
of	O
many	O
signalling	O
pathways	O
,	O
is	O
involved	O
in	O
LY-83583	B
's	O
stimulation	O
of	O
glucose	B
transport	O
was	O
explored	O
.	O

We	O
first	O
investigated	O
the	O
effect	O
of	O
U73122	B
on	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
;	O
U73122	B
is	O
a	O
potent	O
inhibitor	O
of	O
phospholipase	O
C	O
with	O
an	O
IC50	O
of	O
∼10	O
μM	O
for	O
phospholipase	O
C	O
in	O
many	O
cell	O
types	O
(	O
De	O
Moel	O
et	O
al.	O
,	O
1995	O
;	O
Wang	O
et	O
al.	O
,	O
1997	O
)	O
,	O
although	O
lower	O
IC50	O
values	O
have	O
also	O
been	O
reported	O
(	O
Zheng	O
et	O
al.	O
,	O
1995	O
)	O
.	O

In	O
the	O
presence	O
of	O
10	O
μM	O
U73122	B
,	O
the	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
in	O
Clone	O
9	O
cells	O
was	O
reduced	O
by	O
45	O
%	O
(	O
Fig.	O
6	O
)	O
;	O
cells	O
treated	O
with	O
10	O
μM	O
U73122	B
alone	O
exhibited	O
a	O
slight	O
(	O
1.3±0.1	O
fold	O
)	O
increase	O
in	O
transport	O
,	O
which	O
was	O
not	O
significant	O
.	O

A	O
presumed	O
stimulation	O
of	O
phospholipase	O
C	O
activity	O
by	O
LY-83583	B
would	O
be	O
predicted	O
to	O
increase	O
cellular	O
levels	O
of	O
sn	B
-1,2-diacylglycerol	I
,	O
a	O
product	O
of	O
the	O
reaction	O
catalyzed	O
by	O
phospholipase	O
C.	O
The	O
effect	O
of	O
LY-83583	B
on	O
cellular	O
diacylglycerol	B
content	O
was	O
hence	O
assayed	O
by	O
measuring	O
the	O
production	O
of	O
[	B
32	I
P	I
]	I
phosphatidic	I
acid	I
in	O
the	O
presence	O
of	O
exogenously	O
added	O
32	B
P	I
-labeled	I
ATP	I
and	O
diacylglycerol	O
kinase	O
(	O
see	O
Methods	O
)	O
.	O

Clone	O
9	O
cells	O
exposed	O
to	O
10	O
μM	O
LY-83583	B
for	O
30	O
min	O
exhibited	O
3.0±0.1-fold	O
increase	O
in	O
diacylglycerol	B
content	O
compared	O
to	O
untreated	O
control	O
cells	O
(	O
473±37	O
to	O
1438±13	O
pmol	O
(	O
mg	O
protein	O
)	O
−1	O
)	O
(	O
Table	O
3	O
)	O
.	O

In	O
contrast	O
,	O
cells	O
preincubated	O
with	O
10	O
μM	O
U73122	B
for	O
10	O
min	O
prior	O
to	O
the	O
30	O
min	O
exposure	O
to	O
LY-83583	B
manifest	O
only	O
a	O
1.4±0.2-fold	O
increase	O
in	O
diacylglycerol	B
content	O
.	O

Exposure	O
to	O
10	O
μM	O
U73122	B
alone	O
also	O
increased	O
cell	O
diacylglycerol	B
content	O
;	O
the	O
reasons	O
for	O
this	O
unexpected	O
finding	O
is	O
not	O
known	O
.	O

Activation	O
of	O
phospholipase	O
C	O
by	O
LY-83583	O
would	O
be	O
expected	O
to	O
results	O
in	O
an	O
inositol	B
1,4,5-trisphosphate	I
-	O
induced	O
release	O
of	O
Ca2	B
+	I
from	O
microsomal	O
stores	O
.	O

Moreover	O
,	O
the	O
presumed	O
release	O
of	O
Ca2	B
+	I
induced	O
by	O
LY-83583	B
could	O
be	O
linked	O
to	O
the	O
LY-83583-induced	B
stimulation	O
of	O
glucose	B
transport	O
.	O

To	O
examine	O
this	O
possibility	O
,	O
we	O
employed	O
thapsigargin	B
,	O
a	O
potent	O
inhibitor	O
of	O
microsomal	O
Ca2	O
+	O
-ATPase	O
which	O
results	O
in	O
a	O
rapid	O
and	O
near	O
-	O
complete	O
depletion	O
of	O
microsomal	O
Ca2	B
+	I
stores	O
in	O
a	O
variety	O
of	O
cells	O
(	O
Moore	O
et	O
al.	O
,	O
1991	O
;	O
Tsukamoto	O
and	O
Kaneko	O
,	O
1993	O
)	O
.	O

The	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
was	O
significantly	O
reduced	O
in	O
cells	O
preincubated	O
for	O
10	O
min	O
with	O
thapsigargin	B
(	O
Fig.	O
7	O
)	O
;	O
10	O
μM	O
thapsigargin	B
alone	O
caused	O
a	O
slight	O
increase	O
in	O
the	O
rate	O
of	O
transport	O
.	O

We	O
also	O
explored	O
the	O
possibility	O
that	O
stimulation	O
of	O
protein	O
kinase	O
C	O
activity	O
(	O
perhaps	O
secondary	O
to	O
phospholipase	O
C	O
activation	O
)	O
mediates	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
.	O

Accordingly	O
,	O
cells	O
were	O
preincubated	O
for	O
24	O
h	O
in	O
the	O
presence	O
of	O
diluent	O
(	O
DMSO	B
)	O
or	O
160	O
nM	O
phorbol-12-myristate	B
13-acetate	I
(	O
PMA	B
)	O
to	O
`	O
down	O
-	O
regulate	O
'	O
protein	O
kinase	O
C	O
activity	O
.	O

Following	O
this	O
treatment	O
,	O
cells	O
were	O
exposed	O
to	O
diluent	O
,	O
fresh	O
PMA	B
,	O
or	O
LY-83583	B
(	O
Fig.	O
8	O
)	O
.	O

The	O
results	O
showed	O
that	O
exposure	O
to	O
LY-83583	B
was	O
associated	O
with	O
a	O
large	O
stimulation	O
of	O
glucose	B
transport	O
in	O
both	O
control	O
cells	O
and	O
in	O
cells	O
pre	O
-	O
exposed	O
to	O
PMA	O
.	O

4	O
Discussion	O
The	O
experimental	O
results	O
obtained	O
in	O
this	O
study	O
present	O
several	O
novel	O
findings	O
.	O

First	O
,	O
LY-83583	B
was	O
found	O
to	O
dramatically	O
enhance	O
the	O
rate	O
of	O
glucose	B
transport	O
,	O
and	O
the	O
response	O
was	O
observed	O
in	O
several	O
cell	O
systems	O
examined	O
;	O
Second	O
,	O
LY-83583	B
's	O
effect	O
on	O
glucose	B
transport	O
appeared	O
to	O
be	O
independent	O
of	O
its	O
inhibitory	O
actions	O
on	O
guanylyl	O
cyclase	O
or	O
a	O
reduction	O
in	O
cellular	O
cGMP	B
levels	O
.	O

This	O
important	O
inference	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
was	O
not	O
blocked	O
by	O
10	O
to	O
100	O
μM	O
8-bromo	B
-	I
cGMP	I
.	O

Moreover	O
,	O
addition	O
of	O
8-bromo	B
-	I
cGMP	I
(	O
up	O
to	O
100	O
μM	O
)	O
did	O
not	O
alter	O
the	O
basal	O
rate	O
of	O
transport	O
;	O
Third	O
,	O
LY-83583	B
's	O
effect	O
on	O
glucose	B
transport	O
was	O
shown	O
not	O
to	O
be	O
secondary	O
to	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
;	O
and	O
Fourth	O
,	O
the	O
results	O
suggest	O
that	O
the	O
stimulation	O
of	O
transport	O
in	O
response	O
to	O
LY-83583	B
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activation	O
of	O
phospholipase	O
C.	O
The	O
present	O
studies	O
were	O
initiated	O
to	O
better	O
define	O
the	O
mechanisms	O
underlying	O
stimulation	O
of	O
glucose	O
transport	O
in	O
response	O
to	O
inhibition	O
of	O
oxidative	O
phosphorylation	O
by	O
azide	B
(	O
Shetty	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Potential	O
signalling	O
pathways	O
considered	O
were	O
those	O
linked	O
to	O
nitric	B
oxide	I
generation	O
,	O
because	O
exposure	O
of	O
cells	O
to	O
azide	B
has	O
been	O
shown	O
to	O
stimulate	O
NO	B
production	O
(	O
Schulz	O
et	O
al.	O
,	O
1997	O
)	O
,	O
and	O
NO	B
has	O
been	O
proposed	O
to	O
stimulate	O
the	O
rate	O
of	O
glucose	B
transport	O
(	O
Balon	O
and	O
Nadler	O
,	O
1997	O
;	O
Young	O
et	O
al.	O
,	O
1997	O
)	O
.	O

To	O
test	O
the	O
possibility	O
that	O
stimulation	O
of	O
guanylyl	O
cyclase	O
activity	O
mediates	O
the	O
stimulation	O
of	O
glucose	B
transport	O
in	O
response	O
to	O
LY-83583	B
,	O
we	O
measured	O
the	O
effect	O
of	O
a	O
known	O
inhibitor	O
of	O
guanylyl	O
cyclase	O
activity	O
(	O
LY-83583	B
)	O
on	O
sodium	B
nitroprusside	I
-	O
induced	O
enhancement	O
of	O
glucose	B
transport	O
.	O

The	O
experimental	O
results	O
identified	O
an	O
unexpected	O
and	O
novel	O
finding	O
,	O
namely	O
that	O
exposure	O
to	O
LY-83583	B
alone	O
resulted	O
in	O
a	O
dramatic	O
stimulation	O
of	O
glucose	B
transport	O
.	O

It	O
is	O
well	O
-	O
documented	O
that	O
LY-83583	B
is	O
a	O
potent	O
and	O
specific	O
inhibitor	O
of	O
guanylyl	O
cyclase	O
(	O
Diamond	O
and	O
Chu	O
,	O
1985	O
;	O
Schmidt	O
et	O
al.	O
,	O
1985	O
;	O
Mulsch	O
et	O
al.	O
,	O
1988	O
;	O
Stuart	O
-	O
Smith	O
et	O
al.	O
,	O
1998	O
)	O
.	O

If	O
a	O
reduction	O
in	O
cell	O
cGMP	B
level	O
mediates	O
the	O
transport	O
response	O
to	O
LY-83583	B
,	O
then	O
elevation	O
of	O
cGMP	B
levels	O
by	O
addition	O
of	O
8-bromo	B
-	I
cGMP	I
to	O
the	O
external	O
medium	O
,	O
or	O
prevention	O
of	O
endogenous	O
cGMP	B
hydrolysis	O
by	O
cGMP	B
-	O
specific	O
phosphodiesterase	O
inhibitors	O
(	O
such	O
as	O
zaprinast	B
or	O
dipyridamole	B
)	O
,	O
would	O
be	O
expected	O
to	O
significantly	O
attenuate	O
the	O
response	O
.	O

It	O
was	O
found	O
,	O
however	O
,	O
that	O
addition	O
of	O
exogenous	O
8-bromo	B
-	I
cGMP	I
(	O
up	O
to	O
100	O
μM	O
)	O
or	O
zaprinast	B
or	O
dipyridamole	B
did	O
not	O
inhibit	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
.	O

To	O
verify	O
that	O
the	O
addition	O
of	O
8-bromo	B
-	I
cGMP	I
resulted	O
in	O
increased	O
intracellular	O
cGMP	B
levels	O
,	O
assays	O
were	O
performed	O
to	O
measure	O
cGMP	B
levels	O
directly	O
.	O

The	O
results	O
indicated	O
that	O
exposure	O
to	O
10	O
μM	O
8-bromo	B
-	I
cGMP	I
resulted	O
in	O
elevated	O
cell	O
8-bromo	B
-	I
cGMP	I
levels	O
,	O
as	O
compared	O
to	O
control	O
cells	O
.	O

In	O
this	O
series	O
of	O
experiments	O
,	O
we	O
could	O
not	O
demonstrate	O
a	O
reduction	O
of	O
cGMP	B
levels	O
in	O
the	O
presence	O
of	O
LY-83583	B
alone	O
.	O

While	O
this	O
latter	O
finding	O
remains	O
unexplained	O
,	O
it	O
is	O
possible	O
that	O
the	O
addition	O
of	O
dipyridamole	B
(	O
a	O
cGMP	O
phosphodiesterase	O
inhibitor	O
)	O
prior	O
to	O
exposure	O
to	O
LY-83583	B
may	O
have	O
obscured	O
the	O
expected	O
decrease	O
in	O
intracellular	O
cGMP	B
concentration	O
.	O

(	O
The	O
very	O
low	O
levels	O
of	O
cGMP	B
in	O
cells	O
under	O
basal	O
conditions	O
in	O
the	O
absence	O
of	O
dipyridamole	B
were	O
unreliable	O
by	O
the	O
assay	O
employed	O
.	O
)	O

Taken	O
together	O
,	O
the	O
above	O
results	O
suggest	O
that	O
the	O
stimulation	O
of	O
glucose	B
transport	O
by	O
LY-83583	B
is	O
independent	O
of	O
changes	O
in	O
intracellular	O
cGMP	B
concentration	O
.	O

It	O
has	O
been	O
reported	O
that	O
in	O
addition	O
to	O
LY-83583	B
's	O
well	O
-	O
known	O
inhibitory	O
actions	O
on	O
guanylyl	O
cyclase	O
activity	O
,	O
LY-83583	B
also	O
stimulates	O
intracellular	O
superoxide	B
formation	O
(	O
Baas	O
and	O
Berk	O
,	O
1995	O
)	O
.	O

Reactive	B
oxygen	I
species	I
such	O
as	O
superoxide	B
and	O
hydrogen	B
peroxide	I
have	O
been	O
shown	O
not	O
only	O
to	O
stimulate	O
glucose	B
transport	O
(	O
Fischer	O
et	O
al.	O
,	O
1993	O
;	O
Kozlovsky	O
et	O
al.	O
,	O
1997	O
)	O
,	O
but	O
also	O
to	O
enhance	O
phospholipase	O
C	O
activity	O
(	O
Kontos	O
and	O
Hess	O
,	O
1983	O
)	O
.	O

We	O
hence	O
explored	O
the	O
possibility	O
that	O
the	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
is	O
mediated	O
through	O
activation	O
of	O
phospholipase	O
C.	O
The	O
following	O
experimental	O
results	O
are	O
consistent	O
with	O
the	O
above	O
possibility	O
,	O
namely	O
:	O
(	O
i	O
)	O
exposure	O
to	O
LY-83583	B
resulted	O
in	O
a	O
significant	O
rise	O
in	O
cell	O
diacylglycerol	B
content	O
,	O
and	O
the	O
increase	O
in	O
diacylglycerol	B
was	O
diminished	O
by	O
U73122	B
,	O
an	O
inhibitor	O
of	O
phospholipase	O
C	O
activity	O
;	O
(	O
ii	O
)	O
U73122	B
attenuated	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
;	O
and	O
(	O
iii	O
)	O
the	O
stimulatory	O
effect	O
of	O
LY-83583	B
on	O
glucose	B
transport	O
was	O
significantly	O
blocked	O
by	O
thapsigargin	B
,	O
a	O
specific	O
inhibitor	O
of	O
microsomal	O
Ca2	O
+	O
-ATPase	O
,	O
which	O
leads	O
to	O
a	O
depletion	O
of	O
Ca2	B
+	I
stores	O
from	O
the	O
microsomal	O
compartment	O
.	O

This	O
latter	O
result	O
is	O
consistent	O
with	O
other	O
reports	O
suggesting	O
that	O
the	O
downstream	O
effects	O
of	O
phospholipase	O
C	O
activation	O
and	O
the	O
attendant	O
increase	O
in	O
cell	O
inositol-1,4,5-triphosphate	B
levels	O
require	O
the	O
presence	O
of	O
normal	O
microsomal	O
calcium	B
stores	O
(	O
Daniell	O
and	O
Harris	O
,	O
1988	O
)	O
.	O

The	O
observation	O
that	O
thapsigargin	B
only	O
partially	O
attenuated	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
suggests	O
that	O
other	O
sources	O
of	O
calcium	B
(	O
perhaps	O
from	O
the	O
extracellular	O
compartment	O
)	O
are	O
also	O
involved	O
in	O
the	O
response	O
.	O

Further	O
studies	O
are	O
required	O
to	O
delineate	O
the	O
relative	O
importance	O
of	O
various	O
calcium	B
sources	O
in	O
the	O
stimulation	O
of	O
glucose	B
transport	O
by	O
LY-83583	B
.	O

Stimulation	O
of	O
phospholipase	B
C	I
activity	O
and	O
the	O
resultant	O
increase	O
in	O
diacylglycerol	B
and	O
intracellular	O
Ca2	B
+	I
would	O
be	O
expected	O
to	O
lead	O
to	O
stimulation	O
of	O
protein	O
kinase	O
C	O
activity	O
.	O

It	O
is	O
also	O
well	O
established	O
that	O
prolonged	O
exposure	O
of	O
cells	O
to	O
phorbol	B
esters	I
(	O
such	O
as	O
PMA	B
)	O
results	O
in	O
`	O
down	O
-	O
regulation	O
'	O
of	O
protein	O
kinase	O
C	O
activity	O
(	O
Bandyopadhyay	O
et	O
al.	O
,	O
1997	O
;	O
Formisano	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Results	O
of	O
experiments	O
reported	O
herein	O
indicate	O
that	O
LY-83583	B
's	O
effect	O
to	O
stimulate	O
glucose	B
transport	O
is	O
unaffected	O
in	O
cells	O
pre	O
-	O
exposed	O
to	O
PMA	B
.	O

However	O
,	O
since	O
not	O
all	O
protein	O
kinase	O
C	O
isoforms	O
are	O
`	O
down	O
-	O
regulated	O
'	O
by	O
this	O
treatment	O
(	O
Bandyopadhyay	O
et	O
al.	O
,	O
1997	O
;	O
Formisano	O
et	O
al.	O
,	O
1998	O
)	O
it	O
is	O
possible	O
that	O
the	O
effect	O
of	O
phospholipase	O
C	O
is	O
mediated	O
by	O
these	O
diacylglycerol	B
-	O
insensitive	O
protein	O
kinase	O
C	O
isoforms	O
.	O

Further	O
studies	O
are	O
required	O
to	O
verify	O
the	O
mediating	O
role	O
of	O
the	O
phospholipase	O
C	O
pathway	O
in	O
the	O
glucose	B
transport	O
response	O
to	O
LY-83583	B
,	O
and	O
to	O
determine	O
the	O
intermediate	O
steps	O
linking	O
phospholipase	O
C	O
activation	O
to	O
the	O
observed	O
stimulation	O
of	O
glucose	B
transport	O
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Dr.	O
Amir	O
Hamrahian	O
for	O
his	O
help	O
in	O
performance	O
of	O
some	O
of	O
the	O
assays	O
.	O

This	O
study	O
was	O
supported	O
in	O
part	O
by	O
a	O
grant	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
#	O
DK45945	O
)	O
.	O

Retinaldehyde	B
(	O
RAL	B
)	O
,	O
a	O
key	O
intermediate	O
in	O
retinoid	B
metabolism	O
,	O
acts	O
as	O
a	O
retinoic	B
acid	I
(	O
RA	B
)	O
precursor	O
,	O
but	O
is	O
also	O
reduced	O
to	O
retinol	B
(	O
ROH	B
)	O
,	O
which	O
can	O
subsequently	O
be	O
esterified	O
to	O
retinyl	B
esters	I
,	O
the	O
storage	O
form	O
of	O
vitamin	B
A.	I
Limited	O
information	O
is	O
available	O
on	O
the	O
metabolism	O
of	O
geometric	O
isomers	O
of	O
RAL	B
as	O
well	O
as	O
on	O
the	O
transplacental	O
distribution	O
of	O
their	O
metabolites	O
,	O
including	O
RA	B
isomers	O
.	O

Such	O
information	O
would	O
be	O
very	O
helpful	O
for	O
the	O
assessment	O
of	O
the	O
teratogenic	O
potency	O
of	O
RAL	B
isomers	I
,	O
as	O
teratogenesis	O
represents	O
a	O
major	O
side	O
effect	O
of	O
retinoid	B
use	O
in	O
pharmacotherapy	O
.	O

In	O
the	O
present	O
study	O
we	O
examined	O
concentrations	O
of	O
retinoids	B
in	O
plasma	O
,	O
maternal	O
tissues	O
,	O
and	O
embryos	O
of	O
pregnant	O
rats	O
2	O
h	O
after	O
a	O
single	O
oral	O
dose	O
(	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
of	O
all	B
-	I
trans-	I
,	O
13-cis-	B
,	O
or	O
9-cis	B
-	I
RAL	I
on	O
gestational	O
day	O
13	O
.	O

The	O
main	O
findings	O
of	O
this	O
study	O
were	O
the	O
very	O
similar	O
patterns	O
of	O
retinoid	B
metabolites	I
(	O
consisting	O
of	O
retinoids	B
with	O
mainly	O
the	O
all	O
-	O
trans	O
-	O
configuration	O
)	O
after	O
administration	O
of	O
all	B
-	I
trans-	I
and	O
13-cis	B
-	I
RAL	I
,	O
and	O
the	O
high	O
concentrations	O
of	O
9-cis	B
-	I
RA	I
,	O
9,13-dicis	B
-	I
RA	I
,	O
and	O
9-cis	B
-	I
retinoyl	I
-	I
beta	I
-	I
D	I
-	I
glucuronide	I
after	O
dosing	O
with	O
9-cis	B
-	I
RAL	I
.	O

In	O
addition	O
,	O
all	B
-	I
trans	I
-	I
RA	I
as	O
a	O
RAL	B
metabolite	O
reached	O
the	O
embryos	O
to	O
a	O
much	O
greater	O
extent	O
than	O
any	O
of	O
its	O
cis	B
-	I
isomers	I
.	O

The	O
results	O
are	O
discussed	O
in	O
view	O
of	O
in	O
vitro	O
data	O
on	O
enzymes	O
involved	O
in	O
the	O
biotransformation	O
of	O
RAL	B
isomers	I
.	O

UDP	O
-	O
glucose	O
:	O
anthocyanin	O
5-O	O
-	O
glucosyltransferase	O
(	O
5-GT	O
)	O
is	O
responsible	O
for	O
the	O
modification	O
of	O
anthocyanins	B
to	O
more	O
stable	O
molecules	B
in	O
complexes	O
for	O
co	O
-	O
pigmentation	O
,	O
supposedly	O
resulting	O
in	O
a	O
purple	O
hue	O
.	O

The	O
cDNA	O
encoding	O
5-GT	O
was	O
isolated	O
by	O
a	O
differential	O
display	O
applied	O
to	O
two	O
different	O
forms	O
of	O
anthocyanin	B
production	O
in	O
Perilla	O
frutescens	O
var	O
.	O

crispa	O
.	O

Differential	O
display	O
was	O
carried	O
out	O
for	O
mRNA	O
from	O
the	O
leaves	O
of	O
reddish	O
-	O
purple	O
and	O
green	O
forms	O
of	O
P.	O
frutescens	O
,	O
resulting	O
in	O
the	O
isolation	O
of	O
five	O
cDNA	O
clones	O
predominantly	O
expressed	O
in	O
the	O
red	O
form	O
.	O

The	O
cDNA	O
encoded	O
a	O
polypeptide	O
of	O
460	O
amino	B
acids	I
,	O
exhibiting	O
a	O
low	O
homology	O
with	O
the	O
sequences	O
of	O
several	O
glucosyltransferases	O
including	O
UDP	O
-	O
glucose	O
:	O
anthocyanidin	O
3-O	O
-	O
glucosyltransferase	O
.	O

By	O
using	O
this	O
cDNA	O
as	O
the	O
probe	O
,	O
we	O
also	O
isolated	O
a	O
homologous	O
cDNA	O
clone	O
from	O
a	O
petal	O
cDNA	O
library	O
of	O
Verbena	O
hybrida	O
.	O

To	O
identify	O
the	O
biochemical	O
function	O
of	O
the	O
encoded	O
proteins	O
,	O
these	O
cDNAs	O
were	O
expressed	O
in	O
Saccharomyces	O
cerevisiae	O
cells	O
.	O

The	O
recombinant	O
proteins	O
in	O
the	O
yeast	O
extracts	O
catalyzed	O
the	O
conversion	O
of	O
anthocyanidin	B
3-O	I
-	I
glucosides	I
into	O
the	O
corresponding	O
anthocyanidin	B
3,5-di	I
-	I
O	I
-	I
glucosides	I
using	O
UDP	B
-	I
glucose	I
as	O
a	O
cofactor	O
,	O
indicating	O
the	O
identity	O
of	O
the	O
cDNAs	O
encoding	O
5-GT	O
.	O

Several	O
biochemical	O
properties	O
(	O
optimum	O
pH	O
,	O
Km	O
values	O
,	O
and	O
sensitivity	O
to	O
inhibitors	O
)	O
were	O
similar	O
to	O
those	O
reported	O
previously	O
for	O
5-GTs	O
.	O

Southern	O
blot	O
analysis	O
indicated	O
the	O
presence	O
of	O
two	O
copies	O
of	O
5-GT	O
genes	O
in	O
the	O
genome	O
of	O
both	O
red	O
and	O
green	O
forms	O
of	O
P.	O
frutescens	O
.	O

The	O
mRNA	O
accumulation	O
of	O
the	O
5-GT	O
gene	O
was	O
detected	O
in	O
the	O
leaves	O
of	O
the	O
red	O
form	O
but	O
not	O
in	O
those	O
of	O
the	O
green	O
form	O
and	O
was	O
induced	O
by	O
illumination	O
of	O
light	O
,	O
as	O
observed	O
for	O
other	O
structural	O
genes	O
for	O
anthocyanin	B
biosynthesis	O
in	O
P.	O
frutescens	O
.	O

The	O
cephalosporins	B
are	O
a	O
large	O
group	O
of	O
related	O
beta	B
-	I
lactam	I
antimicrobial	O
agents	O
.	O

Favorable	O
attributes	O
of	O
the	O
cephalosporins	B
include	O
low	O
rates	O
of	O
toxicity	O
,	O
relatively	O
broad	O
spectrum	O
of	O
activity	O
,	O
and	O
ease	O
of	O
administration	O
.	O

Various	O
cephalosporins	B
are	O
effective	O
for	O
treatment	O
of	O
many	O
conditions	O
,	O
including	O
pneumonia	O
,	O
skin	O
and	O
soft	O
tissue	O
infections	O
,	O
bacteremia	O
,	O
and	O
meningitis	O
.	O

Differences	O
among	O
the	O
numerous	O
cephalosporin	B
antimicrobial	O
agents	O
are	O
sometimes	O
subtle	O
;	O
however	O
,	O
an	O
understanding	O
of	O
these	O
differences	O
is	O
essential	O
for	O
optimal	O
use	O
of	O
these	O
agents	O
.	O

As	O
a	O
result	O
of	O
widespread	O
use	O
of	O
cephalosporins	B
,	O
bacterial	O
resistance	O
to	O
these	O
drugs	O
is	O
increasingly	O
common	O
.	O

New	O
,	O
fourth	O
-	O
generation	O
agents	O
(	O
such	O
as	O
cefepime	B
)	O
offer	O
an	O
alternative	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
some	O
drug	O
-	O
resistant	O
microorganisms	O
.	O

A	O
comparative	O
study	O
of	O
various	O
procedures	O
for	O
tryptophanyl	O
peptide	O
bond	O
cleavage	O
by	O
BNPS	B
-	I
skatole	I
[	O
2-	B
(	I
2-nitrophenyl	I
)	I
-3-methyl-3-bromoindolenine	I
]	O
was	O
carried	O
out	O
on	O
native	O
and	O
on	O
reduced	O
and	O
alkylated	O
bovine	O
beta	O
-	O
lactoglobulin	O
(	O
BLG	O
)	O
.	O

The	O
reaction	O
yield	O
and	O
the	O
composition	O
of	O
the	O
derived	O
products	O
were	O
studied	O
in	O
acetic	B
acid	I
,	O
trifluoroacetic	B
acid	I
(	O
TFA	B
)	O
,	O
and	O
ethanol	B
/	O
TFA	B
.	O

For	O
BNPS	B
-	I
skatole	I
removal	O
,	O
extraction	O
by	O
water	B
or	O
ethyl	B
ether	I
was	O
compared	O
with	O
dialysis	O
and	O
gel	O
filtration	O
.	O

The	O
three	O
expected	O
peptides	B
(	O
1	O
-	O
19	O
,	O
20	O
-	O
61	O
,	O
62	O
-	O
162	O
)	O
and	O
incomplete	O
cleaved	O
fragments	O
(	O
1	O
-	O
61	O
,	O
20	O
-	O
162	O
)	O
were	O
separated	O
and	O
characterized	O
by	O
electrophoresis	O
,	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
,	O
and	O
mass	O
spectrometry	O
.	O

The	O
highest	O
hydrolysis	O
yield	O
(	O
67.4	O
%	O
)	O
occurred	O
with	O
native	O
BLG	O
cleaved	O
in	O
88	O
%	O
acetic	B
acid	I
at	O
47	O
degrees	O
C	O
for	O
60	O
min	O
.	O

Subsequent	O
water	B
extraction	O
and	O
gel	O
filtration	O
led	O
to	O
total	O
recovery	O
of	O
the	O
material	O
,	O
but	O
reagent	O
elimination	O
was	O
only	O
quantitative	O
after	O
gel	O
filtration	O
.	O

Cleavage	O
specificity	O
was	O
ensured	O
by	O
mass	O
spectrometry	O
and	O
the	O
amino	B
acid	I
composition	O
of	O
peptides	B
1	O
-	O
19	O
and	O
62	O
-	O
162	O
.	O

The	O
chemical	O
side	O
reactions	O
identified	O
are	O
discussed	O
.	O

We	O
conducted	O
a	O
study	O
of	O
the	O
patterns	O
and	O
dynamics	O
of	O
oxidized	B
fatty	I
acid	I
derivatives	I
(	O
oxylipins	B
)	O
in	O
potato	O
leaves	O
infected	O
with	O
the	O
late	O
-	O
blight	O
pathogen	O
Phytophthora	O
infestans	O
.	O

Two	O
18-carbon	B
divinyl	I
ether	I
fatty	I
acids	I
,	O
colneleic	B
acid	I
and	O
colnelenic	B
acid	I
,	O
accumulated	O
during	O
disease	O
development	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
reports	O
that	O
such	O
compounds	O
have	O
been	O
detected	O
in	O
higher	O
plants	O
.	O

The	O
divinyl	B
ether	I
fatty	I
acids	I
accumulate	O
more	O
rapidly	O
in	O
potato	O
cultivar	O
Matilda	O
(	O
a	O
cultivar	O
with	O
increased	O
resistance	O
to	O
late	O
blight	O
)	O
than	O
in	O
cultivar	O
Bintje	O
,	O
a	O
susceptible	O
cultivar	O
.	O

Colnelenic	B
acid	I
reached	O
levels	O
of	O
up	O
to	O
approximately	O
24	O
nmol	O
(	O
7	O
microgram	O
)	O
per	O
g	O
fresh	O
weight	O
of	O
tissue	O
in	O
infected	O
leaves	O
.	O

By	O
contrast	O
,	O
levels	O
of	O
members	O
of	O
the	O
jasmonic	B
acid	I
family	O
did	O
not	O
change	O
significantly	O
during	O
pathogenesis	O
.	O

The	O
divinyl	B
ethers	I
also	O
accumulated	O
during	O
the	O
incompatible	O
interaction	O
of	O
tobacco	O
with	O
tobacco	O
mosaic	O
virus	O
.	O

Colneleic	B
and	O
colnelenic	B
acids	I
were	O
found	O
to	O
be	O
inhibitory	O
to	O
P.	O
infestans	O
,	O
suggesting	O
a	O
function	O
in	O
plant	O
defense	O
for	O
divinyl	B
ethers	I
,	O
which	O
are	O
unstable	O
compounds	O
rarely	O
encountered	O
in	O
biological	O
systems	O
.	O

Tyrosinaemia	O
type	O
I	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
fumarylacetoacetate	B
hydrolase	O
and	O
mainly	O
affects	O
the	O
liver	O
.	O

This	O
disease	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
high	O
level	O
of	O
succinylacetone	B
.	O

This	O
metabolite	O
has	O
been	O
used	O
for	O
prenatal	O
diagnosis	O
from	O
amniotic	O
fluid	O
samples	O
.	O

One	O
case	O
with	O
a	O
normal	O
level	O
of	O
succinylacetone	B
in	O
amniotic	O
fluid	O
has	O
recently	O
been	O
described	O
(	O
Grenier	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
this	O
patient	O
is	O
a	O
compound	O
heterozygote	O
for	O
two	O
known	O
mutations	O
:	O
E364X	O
and	O
IVS6	O
-	O
1g-->t	O
.	O

The	O
low	O
level	O
of	O
succinylacetone	B
can	O
not	O
be	O
explained	O
by	O
these	O
mutations	O
.	O

An	O
aminotransferase	O
which	O
catalyzes	O
the	O
final	O
step	O
in	O
methionine	B
recycling	O
from	O
methylthioadenosine	B
,	O
the	O
conversion	O
of	O
alpha	B
-	I
ketomethiobutyrate	I
to	O
methionine	B
,	O
has	O
been	O
purified	O
from	O
Klebsiella	O
pneumoniae	O
and	O
characterized	O
.	O

The	O
enzyme	O
was	O
found	O
to	O
be	O
a	O
homodimer	O
of	O
45-kDa	O
subunits	O
,	O
and	O
it	O
catalyzed	O
methionine	B
formation	O
primarily	O
using	O
aromatic	B
amino	I
acids	I
and	O
glutamate	B
as	O
the	O
amino	O
donors	O
.	O

Histidine	B
,	O
leucine	B
,	O
asparagine	B
,	I
and	O
arginine	B
were	O
also	O
functional	O
amino	O
donors	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

The	O
N	B
-	I
terminal	I
amino	I
acid	I
sequence	O
of	O
the	O
enzyme	O
was	O
determined	O
and	O
found	O
to	O
be	O
almost	O
identical	O
to	O
the	O
N	O
-	O
terminal	O
sequence	O
of	O
both	O
the	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
tyrosine	O
aminotransferases	O
(	O
tyrB	O
gene	O
products	O
)	O
.	O

The	O
structural	O
gene	O
for	O
the	O
tyrosine	O
aminotransferase	O
was	O
cloned	O
from	O
K.	O
pneumoniae	O
and	O
expressed	O
in	O
E.	O
coli	O
.	O

The	O
deduced	O
amino	B
acid	I
sequence	O
displayed	O
83	O
,	O
80	O
,	O
38	O
,	O
and	O
34	O
%	O
identity	O
to	O
the	O
tyrosine	O
aminotransferases	O
from	O
E.	O
coli	O
,	O
S.	O
typhimurium	O
,	O
Paracoccus	O
denitrificans	O
,	O
and	O
Rhizobium	O
meliloti	O
,	O
respectively	O
,	O
but	O
it	O
showed	O
less	O
than	O
13	O
%	O
identity	O
to	O
any	O
characterized	O
eukaryotic	O
tyrosine	O
aminotransferase	O
.	O

Structural	O
motifs	O
around	O
key	O
invariant	O
residues	O
placed	O
the	O
K.	O
pneumoniae	O
enzyme	O
within	O
the	O
Ia	O
subfamily	O
of	O
aminotransferases	O
.	O

Kinetic	O
analysis	O
of	O
the	O
aminotransferase	O
showed	O
that	O
reactions	O
of	O
an	O
aromatic	B
amino	I
acid	I
with	O
alpha	B
-	I
ketomethiobutyrate	I
and	O
of	O
glutamate	B
with	O
alpha	B
-	I
ketomethiobutyrate	I
proceed	O
as	O
favorably	O
as	O
the	O
well	O
-	O
known	O
reactions	O
of	O
tyrosine	B
with	O
alpha	B
-	I
ketoglutarate	I
and	O
tyrosine	B
with	O
oxaloacetate	B
normally	O
associated	O
with	O
tyrosine	O
aminotransferases	O
.	O

The	O
aminotransferase	O
was	O
inhibited	O
by	O
the	O
aminooxy	B
compounds	I
canaline	B
and	O
carboxymethoxylamine	B
but	O
not	O
by	O
substrate	O
analogues	O
,	O
such	O
as	O
nitrotyrosine	B
or	O
nitrophenylalanine	B
.	O

Casimiroa	O
edulis	O
de	O
la	O
Llave	O
and	O
Lexarza	O
(	O
Rutaceae	O
)	O
,	O
commonly	O
known	O
as	O
'	O
zapote	O
blanco	O
'	O
is	O
a	O
tree	O
indigenous	O
to	O
Mexico	O
,	O
used	O
by	O
local	O
herbalists	O
in	O
the	O
treatment	O
of	O
hypertension	O
(	O
Lozoya	O
et	O
al.	O
,	O
1987	O
)	O
.	O

The	O
hypotensive	O
activity	O
of	O
the	O
plant	O
was	O
first	O
recognized	O
a	O
hundred	O
years	O
ago	O
(	O
Anonymous	O
,	O
1897	O
)	O
and	O
later	O
confirmed	O
in	O
animals	O
(	O
De	O
Lille	O
1934	O
,	O
Ramı́rez	O
and	O
Rivero	O
1935	O
,	O
Lozoya	O
et	O
al.	O
1977	O
,	O
Magos	O
and	O
Vidrio	O
1991	O
)	O
and	O
humans	O
(	O
Flores	O
Montalvo	O
1936	O
,	O
Cruz	O
y	O
Corro	O
1939	O
)	O
.	O

We	O
recently	O
found	O
that	O
the	O
methanolic	B
extract	O
of	O
'	O
zapote	O
blanco	O
'	O
seeds	O
exerts	O
its	O
hypotensive	O
action	O
apparently	O
by	O
peripheral	O
vasodilation	O
mediated	O
through	O
histamine	O
H1	O
-receptors	O
and	O
that	O
it	O
also	O
produces	O
α	O
-adrenergic	O
vasoconstriction	O
(	O
Magos	O
and	O
Vidrio	O
1991	O
,	O
Vidrio	O
and	O
Magos	O
1991	O
,	O
Magos	O
et	O
al.	O
1995	O
)	O
.	O

Hypotension	O
produced	O
by	O
'	O
zapote	O
blanco	O
'	O
was	O
previously	O
attributed	O
solely	O
to	O
N	B
,	I
N	I
-dimethylhistamine	I
(	O
Major	O
and	O
Dürsch	O
1958	O
,	O
Lozoya	O
et	O
al.	O
1978	O
)	O
,	O
a	O
histamine	B
derivative	B
present	O
in	O
the	O
plant	O
,	O
which	O
shares	O
the	O
hypotensive	O
effects	O
of	O
the	O
parent	O
compound	O
(	O
Vartiainen	O
1935	O
,	O
Bertaccini	O
and	O
Vitali	O
1964	O
)	O
.	O

No	O
detailed	O
pharmacology	O
of	O
other	O
possible	O
vasoactive	O
components	O
of	O
the	O
seed	O
has	O
been	O
described	O
.	O

In	O
this	O
work	O
we	O
report	O
the	O
hypotensive	O
effects	O
of	O
several	O
compounds	O
present	O
in	O
the	O
methanolic	B
extract	O
of	O
'	O
zapote	O
blanco	O
'	O
seeds	O
,	O
potentially	O
jointly	O
responsible	O
for	O
the	O
action	O
of	O
the	O
plant	O
on	O
blood	O
pressure	O
.	O

Particular	O
attention	O
is	O
given	O
to	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
above	O
mentioned	O
histamine	B
derivative	B
,	O
as	O
well	O
as	O
of	O
its	O
N	B
-monomethyl	I
analog	I
.	O

Of	O
the	O
other	O
compounds	O
,	O
some	O
were	O
previously	O
reported	O
for	O
this	O
plant	O
and	O
some	O
are	O
described	O
for	O
the	O
first	O
time	O
.	O

Detailed	O
chemical	O
work	O
leading	O
to	O
the	O
structural	O
characterization	O
of	O
these	O
compounds	O
will	O
be	O
published	O
elsewhere	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Plant	O
material	O
Seeds	O
of	O
ripe	O
fruits	O
of	O
C.	O
edulis	O
were	O
collected	O
in	O
Texcoco	O
,	O
Mexico	O
State	O
.	O

The	O
botanical	O
identity	O
of	O
the	O
plant	O
was	O
verified	O
and	O
vouched	O
at	O
the	O
herbarium	O
of	O
the	O
Botanical	O
Center	O
of	O
the	O
Graduate	O
College	O
of	O
Chapingo	O
.	O

The	O
specimen	O
deposited	O
as	O
Collection	O
No.	O
1	O
of	O
G.A.	O
Magos	O
,	O
was	O
authenticated	O
by	O
José	O
Garcı́a	O
Pérez	O
,	O
botanist	O
in	O
charge	O
of	O
the	O
herbarium	O
.	O

2.2	O
Sample	O
preparation	O
The	O
dry	O
ground	O
kernels	O
(	O
1	O
kg	O
)	O
were	O
extracted	O
by	O
maceration	O
at	O
room	O
temperature	O
with	O
methanol	B
.	O

The	O
solvent	B
was	O
eliminated	O
by	O
drying	O
in	O
vacuum	O
and	O
a	O
portion	O
of	O
the	O
extracted	O
material	O
(	O
25	O
g	O
)	O
was	O
subjected	O
to	O
column	O
chromatography	O
(	O
CC	O
)	O
on	O
silica	B
gel	I
60	I
(	O
500	O
g	O
)	O
.	O

Fractions	O
obtained	O
by	O
discontinuous	O
gradient	O
elution	O
with	O
acetonitrile	B
-	O
methanol	B
(	O
60:40	O
v	O
/	O
v	O
)	O
and	O
n	B
-	I
propanol	I
-	O
water	B
(	O
100:50	O
v	O
/	O
v	O
)	O
,	O
both	O
in	O
1	O
%	O
ammonium	B
hydroxide	I
,	O
were	O
grouped	O
on	O
the	O
basis	O
of	O
thin	O
layer	O
chromatography	O
(	O
TLC	O
)	O
and	O
hypotensive	O
activity	O
.	O

The	O
active	O
fractions	O
were	O
rechromatographed	O
by	O
CC	O
and	O
preparative	O
TLC	O
.	O

2.3	O
Compound	O
identification	O
The	O
seven	O
compounds	O
found	O
in	O
the	O
active	O
fractions	O
were	O
identified	O
by	O
IR	O
,	O
NMR	O
and	O
MS	O
spectra	O
.	O

IR	O
spectra	O
were	O
obtained	O
in	O
Kbr	B
or	O
as	O
a	O
film	O
with	O
a	O
Perkin	O
-	O
Elmer	O
283-B	O
or	O
a	O
Nicolet	O
FT	O
-	O
J.RSX	O
spectrometer	O
.	O

1	O
H	O
NMR	O
spectra	O
were	O
obtained	O
in	O
methanol	B
or	O
D2	B
O	I
using	O
a	O
Varian	O
XL	O
300	O
Mhz	O
spectrometer	O
.	O

MS	O
spectra	O
were	O
obtained	O
with	O
a	O
Jeol	O
JMS	O
-	O
SX102A	O
mass	O
spectrometer	O
operating	O
at	O
70	O
eV.	O
Compounds	O
in	O
the	O
fraction	O
of	O
higher	O
polarity	O
designated	O
as	O
the	O
MP	O
zone	O
(	O
see	O
below	O
)	O
were	O
identified	O
by	O
1	O
H	O
and	O
DEPT	O
NMR	O
spectra	O
in	O
conjuction	O
with	O
COSY	O
,	O
TOCSY	O
,	O
HMQC	O
and	O
HMBC	O
NMR	O
using	O
a	O
500	O
Mhz	O
instrument	O
.	O

2.4	O
Preparation	O
of	O
anesthetized	O
rats	O
and	O
guinea	O
pigs	O
Male	O
Wistar	O
rats	O
weighing	O
250–300	O
g	O
and	O
male	O
guinea	O
pigs	O
of	O
mixed	O
breed	O
weighing	O
300–400	O
g	O
,	O
were	O
anesthetized	O
with	O
sodium	B
pentobarbital	I
(	O
30	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

After	O
cannulation	O
of	O
the	O
trachea	O
for	O
artificial	O
respiration	O
,	O
polyethylene	B
cannulas	O
were	O
inserted	O
in	O
a	O
femoral	O
artery	O
and	O
vein	O
in	O
rats	O
or	O
in	O
a	O
carotid	O
artery	O
and	O
a	O
jugular	O
vein	O
in	O
guinea	O
pigs	O
,	O
for	O
continuous	O
recording	O
of	O
blood	O
pressure	O
and	O
drug	O
administration	O
,	O
respectively	O
.	O

Mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
was	O
recorded	O
with	O
a	O
pressure	O
transducer	O
connected	O
to	O
the	O
arterial	O
cannula	O
.	O

The	O
signal	O
from	O
the	O
transducer	O
was	O
electronically	O
dampened	O
and	O
inscribed	O
on	O
a	O
Model	O
79	O
Grass	O
polygraph	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
was	O
recorded	O
with	O
a	O
tachograph	O
driven	O
by	O
the	O
undampened	O
pulse	O
signal	O
of	O
the	O
transducer	O
.	O

In	O
all	O
experiments	O
,	O
groups	O
of	O
six	O
animals	O
were	O
used	O
and	O
pretreatments	O
were	O
carried	O
out	O
i.v	O
.	O

10	O
min	O
before	O
administration	O
of	O
the	O
test	O
compounds	O
.	O

2.5	O
Drugs	O
Micronized	O
loratadine	B
was	O
supplied	O
by	O
Schering	O
Plough	O
,	O
Mexico	O
.	O

The	O
hydrochlorides	B
of	B
histamine	B
,	O
prazosin	B
,	O
dl	B
-propranolol	I
,	O
l	B
-phenylephrine	I
and	O
N	B
ω	I
-	I
nitro	I
-	I
l	I
-arginine	I
methyl	I
ester	I
,	O
as	O
well	O
as	O
atropine	B
sulfate	I
,	O
(	B
±	I
)	I
-synephrine	I
and	O
cimetidine	B
free	I
bases	I
,	O
γ	B
-aminobutyric	I
acid	I
,	O
l	B
-proline	I
and	O
N	B
-methyl	I
-	I
l	I
-proline	I
were	O
obtained	O
from	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
.	O

Loratadine	B
and	O
casimiroedine	B
were	O
used	O
as	O
resuspensions	O
in	O
distilled	O
water	B
;	O
all	O
other	O
drugs	B
were	O
dissolved	O
in	O
isotonic	O
saline	B
solution	O
.	O

In	O
all	O
cases	O
the	O
volume	O
injected	O
was	O
1	O
ml	O
/	O
kg	O
.	O

2.6	O
Statistical	O
analysis	O
Baseline	O
MAP	O
and	O
HR	O
values	O
,	O
as	O
well	O
as	O
changes	O
in	O
these	O
parameters	O
in	O
response	O
to	O
the	O
test	O
compounds	O
at	O
different	O
doses	O
or	O
times	O
were	O
compared	O
in	O
control	O
and	O
pretreated	O
groups	O
by	O
unpaired	O
or	O
paired	O
Student	O
's	O
t	O
-test	O
as	O
indicated	O
.	O

Comparison	O
of	O
two	O
treatment	O
groups	O
with	O
the	O
same	O
control	O
was	O
carried	O
out	O
by	O
analysis	O
of	O
variance	O
followed	O
by	O
Dunnett	O
's	O
test	O
.	O

A	O
probability	O
level	O
of	O
less	O
than	O
0.05	O
was	O
considered	O
as	O
indicating	O
statistical	O
significance	O
of	O
the	O
differences	O
observed	O
.	O

3	O
Results	O
The	O
bioassay	O
-	O
guided	O
fractionation	O
of	O
the	O
methanolic	B
extract	O
of	O
'	O
zapote	O
blanco	O
'	O
seeds	O
led	O
to	O
identification	O
of	O
a	O
chromatographic	O
zone	O
from	O
which	O
several	O
compounds	O
with	O
cardiovascular	O
activity	O
were	O
isolated	O
.	O

These	O
were	O
identified	O
as	O
the	O
histamine	B
(	O
H	B
)	O
derivatives	B
N	B
-momomethylhistamine	I
(	O
MMH	B
)	O
and	O
N	B
,	I
N	I
-dimethylhistamine	I
(	O
DMH	B
)	O
,	O
and	O
the	O
imidazolic	B
glucoalkaloid	I
casimiroedine	B
(	O
CAS	B
)	O
,	O
all	O
producing	O
hypotension	O
,	O
as	O
well	O
as	O
the	O
phenethylamine	B
derivative	B
synephrine	B
acetonide	I
(	O
SA	B
)	O
,	O
which	O
increased	O
MAP	O
and	O
HR	O
.	O

Silica	B
gel	I
rechromatography	O
of	O
the	O
methanolic	B
extract	O
produced	O
in	O
0.09	O
%	O
yield	O
a	O
homogeneous	O
fraction	O
of	O
higher	O
polarity	O
(	O
MP	O
zone	O
)	O
also	O
eliciting	O
hypotension	O
.	O

High	O
field	O
and	O
bidimensional	O
NMR	O
revealed	O
the	O
presence	O
of	O
the	O
amino	B
acids	I
N	B
-methylproline	I
(	O
MP	B
,	O
70	O
%	O
)	O
,	O
proline	B
(	O
P	B
,	O
18	O
%	O
)	O
,	O
γ	B
-aminobutyric	I
acid	I
(	O
GABA	B
,	O
12	O
%	O
)	O
and	O
other	O
unidentified	O
components	O
(	O
<	O
1	O
%	O
)	O
.	O

The	O
structures	O
of	O
the	O
seven	O
compounds	O
identified	O
appear	O
in	O
Fig.	O
1	O
.	O

3.1	O
Studies	O
of	O
histamine	B
derivatives	I
Both	O
MMH	B
and	O
DMH	B
,	O
as	O
well	O
as	O
H	B
,	O
produced	O
short	O
-	O
lasting	O
,	O
dose	O
-	O
related	O
decreases	O
in	O
MAP	O
(	O
Fig.	O
2	O
)	O
.	O

The	O
derivatives	O
were	O
respectively	O
two	O
and	O
ten	O
times	O
less	O
potent	O
than	O
H.	B
Responses	O
were	O
significantly	O
inhibited	O
by	O
the	O
peripheral	O
H1	O
-antagonist	O
loratadine	B
but	O
not	O
by	O
the	O
H2	O
-blocker	O
cimetidine	B
.	O

In	O
contrast	O
to	O
H	B
,	O
which	O
did	O
not	O
modify	O
HR	O
at	O
any	O
dose	O
,	O
both	O
derivatives	O
elicited	O
positive	O
chronotropic	O
effects	O
which	O
were	O
not	O
affected	O
by	O
H1	O
-	O
or	O
H2	O
-blockade	O
.	O

In	O
another	O
series	O
,	O
dose	O
-	O
response	O
curves	O
to	O
H	B
,	O
MMH	B
and	O
DMH	B
were	O
obtained	O
in	O
rats	O
receiving	O
a	O
continuous	O
infusion	O
of	O
phenylephrine	B
and	O
subsequently	O
pretreated	O
with	O
the	O
nitric	B
oxide	I
synthesis	O
inhibitor	O
Nω	B
-nitro	I
-	I
l	I
-arginine	I
methylester	I
(	O
l	B
-NAME	I
)	O
.	O

Phenylephrine	B
significantly	O
increased	O
MAP	O
from	O
123±2	O
to	O
155±2	O
mmHg	O
and	O
decreased	O
HR	O
from	O
427±6	O
to	O
395±8	O
beats	O
/	O
min	O
.	O

These	O
values	O
were	O
not	O
changed	O
further	O
after	O
l	B
-NAME	I
,	O
MAP	O
being	O
156±5	O
mmHg	O
and	O
HR	O
400±7	O
beats	O
/	O
min	O
.	O

Hypotensive	O
responses	O
to	O
H	B
were	O
similar	O
to	O
those	O
of	O
animals	O
not	O
receiving	O
the	O
vasoconstrictor	O
,	O
whereas	O
around	O
10-fold	O
higher	O
doses	O
of	O
the	O
derivatives	O
were	O
required	O
to	O
induce	O
equivalent	O
depressor	O
effects	O
.	O

Additional	O
pretreatment	O
with	O
l	B
-NAME	I
significantly	O
antagonized	O
responses	O
to	O
H	B
and	O
DMH	B
,	O
but	O
not	O
to	O
MMH	B
.	O

In	O
this	O
model	O
,	O
H	B
and	O
its	O
two	O
analogs	O
increased	O
HR	O
;	O
this	O
effect	O
was	O
inhibited	O
by	O
l	B
-NAME	I
only	O
in	O
the	O
case	O
of	O
DMH	B
(	O
Fig.	O
3	O
)	O
.	O

3.2	O
Studies	O
of	O
synephrine	B
acetonide	I
All	O
experiments	O
in	O
this	O
series	O
were	O
carried	O
out	O
after	O
pretreatment	O
with	O
atropine	B
,	O
in	O
order	O
to	O
block	O
baroreflex	O
-	O
induced	O
vagal	O
bradycardia	O
.	O

The	O
cyclized	B
phenethylamine	I
derivative	I
SA	B
produced	O
transient	O
,	O
dose	O
-	O
related	O
increases	O
in	O
MAP	O
and	O
HR	O
identical	O
to	O
those	O
elicited	O
by	O
the	O
reference	O
drug	B
synephrine	B
(	O
S	B
,	O
Fig.	O
4	O
)	O
.	O

Pressor	O
responses	O
to	O
both	O
agents	O
were	O
significantly	O
inhibited	O
by	O
the	O
α	O
-adrenergic	O
antagonist	O
prazosin	B
,	O
but	O
were	O
unaffected	O
by	O
the	O
β	O
-adrenergic	O
blocker	O
propranolol	B
.	O

In	O
contrast	O
,	O
tachycardia	O
after	O
SA	O
and	O
S	O
was	O
partially	O
inhibited	O
by	O
both	O
antagonists	O
.	O

3.3	O
Studies	O
of	O
the	O
MP	B
zone	O
and	O
casimiroedine	B
The	O
MP	B
zone	O
,	O
tested	O
in	O
rats	O
at	O
a	O
single	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
,	O
elicited	O
marked	O
hypotension	O
lasting	O
more	O
than	O
60	O
min	O
,	O
without	O
affecting	O
HR	O
(	O
Fig.	O
5	O
A	O
)	O
.	O

The	O
constituent	O
amino	B
acids	I
,	O
administered	O
either	O
separately	O
or	O
as	O
a	O
mixture	O
,	O
had	O
no	O
effects	O
on	O
MAP	O
or	O
HR	O
(	O
results	O
not	O
shown	O
)	O
.	O

The	O
glucoalkaloid	B
CAS	B
lacked	O
hypotensive	O
activity	O
in	O
rats	O
,	O
but	O
produced	O
a	O
prolonged	O
fall	O
in	O
MAP	O
,	O
also	O
with	O
no	O
appreciable	O
change	O
in	O
HR	O
,	O
when	O
tested	O
in	O
guinea	O
pigs	O
(	O
Fig.	O
5	O
B	O
)	O
.	O

It	O
shoud	O
be	O
noted	O
that	O
baseline	O
MAP	O
in	O
these	O
animals	O
was	O
67±1	O
mmHg	O
,	O
so	O
that	O
the	O
20	O
mmHg	O
decrease	O
observed	O
after	O
CAS	O
corresponds	O
to	O
a	O
30	O
%	O
fall	O
,	O
i.e.	O
similar	O
to	O
that	O
produced	O
in	O
rats	O
by	O
the	O
MP	B
zone	O
.	O

4	O
Discussion	O
Of	O
the	O
seven	O
compounds	O
identified	O
in	O
the	O
present	O
study	O
,	O
CAS	B
(	O
Power	O
and	O
Callan	O
,	O
1911	O
)	O
and	O
DMH	B
(	O
Major	O
and	O
Dürsch	O
,	O
1958	O
)	O
have	O
been	O
reported	O
as	O
constituents	O
of	O
C.	O
edulis	O
.	O

MMH	B
,	O
MP	B
,	O
P	B
and	O
GABA	B
are	O
known	O
compounds	O
not	O
previously	O
described	O
in	O
the	O
plant	O
,	O
while	O
SA	B
is	O
an	O
entirely	O
new	O
chemical	O
entity	O
.	O

The	O
identity	O
of	O
these	O
active	O
compounds	B
was	O
confirmed	O
by	O
comparison	O
of	O
their	O
spectral	O
parameters	O
with	O
those	O
reported	O
in	O
the	O
literature	O
(	O
Panzica	O
and	O
Townsed	O
1973	O
,	O
Lozoya	O
et	O
al.	O
1978	O
,	O
Toscano	O
et	O
al.	O
1997	O
)	O
,	O
as	O
well	O
as	O
by	O
TLC	O
's	O
ran	O
in	O
parallel	O
with	O
standard	O
samples	O
.	O

The	O
new	O
compound	O
SA	B
was	O
also	O
characterized	O
by	O
various	O
physicochemical	O
methods	O
(	O
Enrı́quez	O
et	O
al.	O
,	O
unpublished	O
)	O
.	O

The	O
present	O
results	O
show	O
that	O
in	O
the	O
rat	O
,	O
MMH	B
and	O
DMH	B
elicit	O
transient	O
hypotensive	O
responses	O
lasting	O
less	O
than	O
3	O
min	O
and	O
entirely	O
similar	O
to	O
those	O
produced	O
by	O
H	B
,	O
thus	O
confirming	O
previous	O
reports	O
(	O
Vartiainen	O
1935	O
,	O
Bertaccini	O
and	O
Vitali	O
1964	O
)	O
.	O

These	O
compounds	O
can	O
not	O
therefore	O
be	O
solely	O
responsible	O
for	O
the	O
long	O
-	O
lasting	O
decrease	O
in	O
MAP	O
produced	O
by	O
Casimiroa	O
extracts	O
,	O
a	O
possibility	O
which	O
we	O
have	O
suggested	O
previously	O
(	O
Magos	O
and	O
Vidrio	O
,	O
1991	O
)	O
.	O

Results	O
of	O
experiments	O
with	O
H	O
-	O
antagonists	O
indicate	O
that	O
hypotension	O
is	O
mediated	O
by	O
activation	O
of	O
peripheral	O
,	O
presumably	O
vascular	O
,	O
H1	O
-receptors	O
;	O
blockade	O
by	O
loratadine	B
,	O
an	O
H1	O
-antagonist	O
which	O
does	O
not	O
penetrate	O
into	O
the	O
central	O
nervous	O
system	O
(	O
Simons	O
and	O
Simons	O
,	O
1994	O
)	O
,	O
precludes	O
involvement	O
of	O
central	O
H1	O
-receptors	O
in	O
this	O
response	O
.	O

In	O
contrast	O
to	O
H	B
,	O
which	O
in	O
the	O
rat	O
is	O
devoid	O
of	O
effects	O
on	O
HR	O
(	O
Levi	O
et	O
al.	O
,	O
1982	O
)	O
and	O
was	O
so	O
found	O
in	O
the	O
present	O
experiments	O
,	O
both	O
MMH	B
and	O
DMH	B
produced	O
tachycardia	O
.	O

This	O
response	O
is	O
apparently	O
not	O
mediated	O
through	O
H1	O
-	O
or	O
H2	O
-receptors	O
,	O
since	O
it	O
is	O
not	O
blocked	O
by	O
the	O
corresponding	O
antagonists	O
.	O

Stimulation	O
of	O
cardiac	O
β	O
-	O
adrenegic	O
receptors	O
,	O
such	O
as	O
that	O
produced	O
by	O
high	O
concentrations	O
of	O
H	B
in	O
rat	O
atria	O
(	O
Cakici	O
et	O
al.	O
,	O
1992	O
)	O
,	O
could	O
explain	O
this	O
finding	O
.	O

Since	O
vascular	O
relaxation	O
by	O
H	B
in	O
rat	O
aortic	O
rings	O
is	O
endothelium	O
-	O
dependent	O
(	O
van	O
de	O
Voorde	O
and	O
Leusen	O
,	O
1983	O
)	O
,	O
the	O
role	O
of	O
nitric	B
oxide	I
as	O
the	O
endothelium	O
-	O
derived	O
relaxing	O
factor	O
in	O
the	O
hypotensive	O
effects	O
of	O
H	B
,	O
MMH	B
and	O
DMH	B
was	O
explored	O
in	O
rats	O
pretreated	O
with	O
the	O
nitric	B
oxide	I
synthesis	O
inhibitor	O
l	B
-NAME	I
.	O

In	O
preliminary	O
experiments	O
,	O
even	O
high	O
doses	O
of	O
this	O
agent	O
did	O
not	O
affect	O
depressor	O
responses	O
to	O
H	B
,	O
a	O
finding	O
similar	O
to	O
that	O
reported	O
by	O
others	O
(	O
Conrad	O
and	O
Whittemore	O
1992	O
,	O
Nakahara	O
et	O
al.	O
1995	O
)	O
.	O

Blockade	O
of	O
hypotension	O
induced	O
by	O
acetylcholine	B
,	O
another	O
endothelium	O
-	O
dependent	O
vasodilator	O
,	O
could	O
be	O
achieved	O
by	O
nitric	B
oxide	I
synthesis	O
inhibition	O
in	O
rabbits	O
previously	O
subjected	O
to	O
vasoconstriction	O
with	O
phenylephrine	B
(	O
Rees	O
et	O
al.	O
,	O
1989	O
)	O
.	O

It	O
was	O
therefore	O
reasoned	O
that	O
an	O
increase	O
in	O
vascular	O
tone	O
would	O
enhance	O
nitric	B
oxide	I
release	O
(	O
Vargas	O
et	O
al.	O
,	O
1990	O
)	O
and	O
amplify	O
the	O
consequences	O
of	O
nitric	B
oxide	I
synthesis	O
inhibition	O
.	O

Experiments	O
in	O
phenylephrine	B
-	O
vasoconstricted	O
rats	O
show	O
that	O
hypotension	O
induced	O
by	O
H	B
and	O
DMH	B
,	O
but	O
surprisingly	O
not	O
by	O
MMH	B
,	O
is	O
nitric	B
oxide	I
-	O
dependent	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
preliminary	O
results	O
in	O
rat	O
aortic	O
rigs	O
indicate	O
that	O
removal	O
of	O
endothelium	O
prevents	O
relaxation	O
by	O
H	B
and	O
DMH	B
,	O
but	O
not	O
by	O
MMH	B
(	O
Magos	O
et	O
al.	O
,	O
unpublished	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
vasodilatation	O
by	O
H	B
and	O
DMH	B
is	O
the	O
result	O
of	O
stimulation	O
of	O
H1	O
-receptors	O
in	O
vascular	O
endothelium	O
(	O
Van	O
de	O
Voorde	O
and	O
Leusen	O
,	O
1983	O
)	O
,	O
which	O
leads	O
to	O
the	O
release	O
of	O
nitric	B
oxide	I
and	O
vascular	O
smooth	O
muscle	O
relaxation	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
action	O
of	O
MMH	B
appears	O
to	O
be	O
exerted	O
on	O
H1	O
-receptors	O
located	O
in	O
vascular	O
smooth	O
muscle	O
.	O

It	O
should	O
be	O
noted	O
that	O
H	B
elicits	O
endothelium	O
-	O
independent	O
vasodilatation	O
in	O
the	O
rat	O
femoral	O
artery	O
by	O
activation	O
of	O
smooth	O
muscle	O
H	O
receptors	O
,	O
although	O
these	O
have	O
been	O
identified	O
as	O
H2	O
-	O
(	O
Krstic	O
et	O
al.	O
,	O
1991	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
H1	O
-relaxation	O
of	O
dog	O
mesenteric	O
and	O
gastroepiploic	O
arteries	O
has	O
been	O
attributed	O
to	O
release	O
of	O
prostaglandin	B
I2	I
(	O
Toda	O
et	O
al.	O
,	O
1982	O
)	O
.	O

In	O
any	O
event	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
elucidate	O
the	O
nature	O
of	O
MMH	B
-	O
induced	O
vasodilatation	O
.	O

Tachycardia	O
produced	O
by	O
DMH	B
,	O
but	O
not	O
by	O
H	B
or	O
MMH	B
,	O
was	O
partially	O
inhibited	O
by	O
l	B
-NAME	I
,	O
suggesting	O
involvement	O
of	O
nitric	B
oxide	I
in	O
this	O
response	O
.	O

In	O
keeping	O
with	O
the	O
above	O
postulated	O
β	O
-adrenergic	O
mechanism	O
of	O
DMH	B
-	O
induced	O
tachycardia	O
,	O
l	B
-NAME	I
has	O
been	O
shown	O
to	O
decrease	O
chronotropic	O
responses	O
to	O
β	O
-	O
adrenergic	O
stimulation	O
(	O
Reid	O
et	O
al.	O
,	O
1994	O
)	O
,	O
as	O
well	O
as	O
to	O
antagonize	O
the	O
facilitation	O
by	O
angiotensin	O
of	O
norepinephrine	B
release	O
from	O
atrial	O
sympathetic	O
nerve	O
endings	O
(	O
Gironacci	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
cardiovascular	O
effects	O
of	O
the	O
new	O
compound	O
SA	B
,	O
i.e.	O
,	O
transient	O
hypertension	O
and	O
tachycardia	O
,	O
are	O
identical	O
to	O
those	O
of	O
the	O
reference	O
drug	B
S	B
,	O
which	O
has	O
been	O
described	O
as	O
an	O
adrenergic	O
receptor	O
agonsit	O
with	O
much	O
less	O
affinity	O
for	O
β	O
1	O
-	O
than	O
for	O
α	O
1	O
-	O
receptors	O
(	O
Jordan	O
et	O
al.	O
1957	O
,	O
Brown	O
et	O
al.	O
1988	O
)	O
.	O

The	O
α	O
1	O
-	O
nature	O
of	O
the	O
pressor	O
effect	O
of	O
SA	B
and	O
S	B
is	O
clearly	O
demonstrated	O
by	O
its	O
blockade	O
by	O
the	O
specific	O
antagonist	O
prazosin	B
,	O
an	O
interaction	O
found	O
previously	O
with	O
crude	O
Casimiroa	O
extract	O
in	O
rat	O
aortic	O
rings	O
(	O
Magos	O
et	O
al.	O
,	O
1995	O
)	O
.	O

Their	O
positive	O
chronotropic	O
action	O
appears	O
to	O
be	O
mediated	O
by	O
both	O
α	O
-	O
and	O
β	O
-receptors	O
,	O
since	O
it	O
is	O
partially	O
antagonized	O
by	O
prazosin	B
and	O
propranolol	B
.	O

Tachycardia	O
paradoxically	O
produced	O
by	O
α	O
-receptor	O
activation	O
has	O
been	O
reported	O
with	O
phenylephrine	B
,	O
the	O
m	B
-	I
OH	I
isomer	I
of	I
S	I
(	O
Williamson	O
et	O
al.	O
,	O
1994	O
)	O
.	O

It	O
is	O
interesting	O
that	O
the	O
hypotensive	O
fraction	O
of	O
Casimiroa	O
methanolic	B
extract	O
contains	O
a	O
compound	O
eliciting	O
an	O
opposite	O
effect	O
on	O
MAP	O
,	O
thus	O
theoretically	O
preventing	O
an	O
excessive	O
depressor	O
response	O
to	O
the	O
extract	O
.	O

This	O
constitutes	O
another	O
example	O
of	O
antagonistic	O
actions	O
of	O
constituents	O
of	O
the	O
same	O
plant	O
(	O
Izaddosst	O
and	O
Robinson	O
,	O
1991	O
)	O
.	O

In	O
contrast	O
to	O
the	O
transient	O
hypotension	O
produced	O
by	O
the	O
H	B
derivatives	I
,	O
the	O
mixture	O
of	O
amino	B
acids	I
designated	O
as	O
the	O
MP	B
zone	O
elicits	O
a	O
long	O
-	O
lasting	O
fall	O
in	O
MAP	O
and	O
could	O
thus	O
be	O
responsible	O
for	O
the	O
persistent	O
hypotensive	O
action	O
of	O
Casimiroa	O
crude	O
extract	O
in	O
the	O
dog	O
(	O
Vidrio	O
and	O
Magos	O
,	O
1991	O
)	O
.	O

Although	O
peripherally	O
administered	O
GABA	B
lowers	O
blood	O
pressure	O
in	O
the	O
rat	O
(	O
Billingsley	O
and	O
Suria	O
,	O
1982	O
)	O
,	O
its	O
effects	O
are	O
short	O
-	O
lived	O
and	O
can	O
not	O
account	O
for	O
the	O
prolonged	O
MAP	O
response	O
to	O
the	O
MP	B
zone	O
.	O

The	O
other	O
major	O
components	O
,	O
P	B
and	O
MP	B
,	O
are	O
devoid	O
of	O
hypotensive	O
activity	O
either	O
by	O
themselves	O
or	O
as	O
a	O
mixture	O
with	O
GABA	B
.	O

The	O
nature	O
of	O
the	O
blood	O
pressure	O
effect	O
of	O
the	O
MP	B
zone	O
remains	O
unexplained	O
,	O
although	O
it	O
is	O
possible	O
that	O
the	O
amino	B
acids	I
found	O
are	O
in	O
effect	O
residues	O
of	O
a	O
peptide	B
responsible	O
for	O
this	O
effect	O
.	O

In	O
this	O
connection	O
,	O
it	O
should	O
be	O
mentioned	O
that	O
P	B
is	O
a	O
constituent	O
of	O
the	O
potent	O
vasodilator	O
peptides	B
kallidin	B
and	O
bradykinin	B
(	O
Trifilieff	O
et	O
al.	O
,	O
1993	O
)	O
.	O

CAS	B
,	O
the	O
main	O
component	O
of	O
Casimiroa	O
seeds	O
(	O
Kincl	O
et	O
al.	O
,	O
1956	O
)	O
,	O
is	O
devoid	O
of	O
blood	O
pressure	O
effects	O
in	O
rats	O
,	O
but	O
elicits	O
long	O
-	O
lasting	O
hypotension	O
in	O
guinea	O
pigs	O
and	O
could	O
therefore	O
be	O
another	O
constituent	O
of	O
Casimiroa	O
extract	O
contributing	O
to	O
its	O
depressor	O
effect	O
.	O

Although	O
in	O
the	O
present	O
study	O
the	O
mechanism	O
of	O
CAS	B
hypotension	O
was	O
not	O
investigated	O
,	O
stimulation	O
of	O
histaminergic	O
H3	O
-receptors	O
is	O
an	O
interesting	O
possibility	O
,	O
considering	O
the	O
imidazolic	O
nature	O
of	O
the	O
compound	O
.	O

These	O
receptors	O
,	O
located	O
in	O
sympathetic	O
nerve	O
terminals	O
,	O
inhibit	O
the	O
release	O
of	O
norepinephrine	O
and	O
thus	O
lead	O
to	O
vasodilatation	O
and	O
lowering	O
of	O
blood	O
pressure	O
(	O
McLeod	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
lack	O
of	O
effect	O
of	O
CAS	B
on	O
the	O
blood	O
pressure	O
of	O
rats	O
as	O
compared	O
to	O
guinea	O
pigs	O
parallels	O
the	O
species	O
differences	O
found	O
for	O
the	O
prototypic	O
H3	O
-agonist	O
R	B
-	I
α	I
-methylhistamine	I
(	O
McLeod	O
et	O
al.	O
,	O
1994	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
findings	O
indicate	O
that	O
hypotension	O
after	O
C.	O
edulis	O
is	O
due	O
to	O
several	O
active	O
components	O
.	O

Immediate	O
,	O
transitory	O
effects	O
can	O
be	O
attributed	O
to	O
MMH	B
and	O
DMH	B
,	O
acting	O
through	O
H1	O
-histaminergic	O
receptors	O
located	O
in	O
vascular	O
smooth	O
muscle	O
and	O
vascular	O
endothelium	O
,	O
respectively	O
.	O

More	O
prolonged	O
hypotension	O
would	O
be	O
produced	O
by	O
a	O
mixture	O
of	O
the	O
amino	B
acids	I
MP	B
,	O
P	B
and	O
GABA	B
through	O
an	O
unknown	O
mechanism	O
,	O
as	O
well	O
as	O
by	O
CAS	B
,	O
possibly	O
by	O
activation	O
of	O
H3	O
-histaminergic	O
receptors	O
.	O

Coexisting	O
with	O
these	O
hypotensive	O
components	O
is	O
SA	B
,	O
which	O
increases	O
blood	O
pressure	O
and	O
heart	O
rate	O
by	O
α	O
-	O
and	O
β	O
-	O
adrenergic	O
mechanisms	O
Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
the	O
National	O
University	O
of	O
Mexico	O
for	O
financial	O
support	O
through	O
projects	O
IN214094	O
and	O
FM-012314	O
of	O
Dirección	O
General	O
de	O
Asuntos	O
del	O
Personal	O
Académico	O
and	O
Coordinación	O
General	O
de	O
Estudios	O
de	O
Posgrado	O
,	O
respectively	O
.	O

Three	O
novel	O
triterpene	B
alcohols	I
,	O
camelliols	B
A	B
(	O
1	O
)	O
,	O
B	B
(	O
3	O
)	O
,	O
and	O
C	B
(	O
5	O
)	O
,	O
possessing	O
a	O
mono-	O
,	O
bi-	O
,	O
and	O
tricyclic	O
ring	O
system	O
,	O
respectively	O
,	O
have	O
been	O
isolated	O
,	O
along	O
with	O
achilleol	B
A	I
,	O
a	O
known	O
monocyclic	B
triterpene	I
alcohol	I
,	O
from	O
the	O
nonsaponifiable	O
lipids	O
of	O
sasanqua	O
oil	O
(	O
Camellia	O
sasanqua	O
)	O
.	O

The	O
structures	O
of	O
these	O
new	O
alcohols	B
were	O
determined	O
on	O
the	O
basis	O
of	O
spectroscopic	O
methods	O
.	O

A	O
new	O
natural	O
product	O
,	O
4-epifriedelin	B
(	O
1	O
)	O
,	O
and	O
12	O
known	O
terpenoids	B
have	O
been	O
isolated	O
from	O
the	O
leaves	O
of	O
Syzygium	O
formosanum	O
.	O

The	O
known	O
compounds	O
include	O
caryophyllene	B
oxide	I
,	O
friedelin	B
,	O
canophyllal	B
,	O
glutinol	B
,	O
alpha	B
-	I
terpineol	I
,	O
phytol	B
,	O
betulinic	B
acid	I
,	O
uvaol	B
,	I
lupeol	B
,	O
betulin	B
,	O
ursolic	B
acid	I
,	O
and	O
oleanolic	B
acid	I
.	I

All	O
of	O
these	O
compounds	O
are	O
reported	O
for	O
the	O
first	O
time	O
from	O
S.	O
formosanum	O
.	O

Two	O
new	O
jaspamide	B
derivatives	I
(	O
1	B
and	O
2	B
)	O
along	O
with	O
jaspamide	B
have	O
been	O
isolated	O
from	O
the	O
marine	O
sponge	O
Jaspis	O
splendans	O
collected	O
in	O
Vanuatu	O
.	O

Their	O
chemical	O
structures	O
were	O
determined	O
from	O
1D	O
and	O
2D	O
NMR	O
studies	O
and	O
MS	O
data	O
.	O

These	O
two	O
compounds	O
inhibited	O
the	O
in	O
vitro	O
growth	O
of	O
the	O
NSCLC	O
-	O
N6	O
human	O
tumor	O
cell	O
lines	O
with	O
IC50	O
values	O
in	O
the	O
microg	O
/	O
mL	O
range	O
.	O

7-Epiclusianone	B
,	O
isolated	O
from	O
Rheedia	O
gardneriana	O
,	O
was	O
tested	O
in	O
several	O
biological	O
assays	O
.	O

It	O
was	O
active	O
in	O
vitro	O
against	O
trypomastigotes	O
of	O
Trypanosoma	O
cruzi	O
but	O
inactive	O
in	O
vivo	O
in	O
experimentally	O
infected	O
mice	O
.	O

It	O
was	O
also	O
active	O
against	O
Artemia	O
salina	O
,	O
but	O
inactive	O
against	O
the	O
fungus	O
Cladosporium	O
sphaerospermum	O
and	O
the	O
snail	O
Biomphalaria	O
glabrata	O
.	O

Prolyl	O
endopeptidase	O
(	O
PEP	O
,	O
EC	O
3.4.21.26	O
)	O
is	O
an	O
enzyme	O
which	O
plays	O
a	O
role	O
in	O
the	O
metabolism	O
of	O
proline	B
-	B
containing	I
neuropeptides	I
,	O
e.g.	O
,	O
vasopressin	B
,	O
substance	B
P	I
and	O
thyrotropin	B
-	I
releasing	I
hormone	I
(	O
TRH	B
)	I
,	O
which	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
learning	O
and	O
memory	O
processes	O
.	O

In	O
our	O
systematic	O
screening	O
for	O
PEP	O
inhibitors	O
from	O
traditional	O
Chinese	O
medicines	O
,	O
we	O
found	O
that	O
MeOH	B
extract	O
from	O
the	O
underground	O
part	O
of	O
Rhodiola	O
sacra	O
S.	O
H.	O
Fu	O
shows	O
significant	O
inhibitory	O
activity	O
against	O
PEP	O
from	O
Flavobacterium	O
meningosepticum	O
.	O

Examination	O
of	O
the	O
constituents	O
of	O
the	O
extract	O
resulted	O
in	O
the	O
isolation	O
of	O
nineteen	O
known	O
compounds	O
,	O
identified	O
as	O
hydroquinone	B
(	O
1	O
)	O
,	O
4-hydroxybenzoic	B
acid	I
(	O
2	O
)	O
,	O
caffeic	B
acid	I
(	O
3	O
)	O
,	O
4-hydroxycinnamic	B
acid	I
(	O
4	O
)	O
,	O
suberic	B
acid	I
(	O
5	O
)	O
,	O
protocatechuic	B
acid	I
(	O
6	O
)	O
,	O
gallic	B
acid	I
(	O
7	O
)	O
,	O
(	O
-	B
)	I
-epigallocatechin	I
3-O	I
-	I
gallate	I
(	O
8)	O
,	O
2-phenylethyl	B
beta	I
-	I
D	I
-	I
glucopyranoside	I
(	O
9	O
)	O
,	O
3-O	B
-	I
galloylepigallocatechin-	I
(	I
4beta-->8	I
)	I
-epigallocatechin+	I
+	I
+	I
3-O	I
-	I
gallate	I
(	O
10	O
)	O
,	O
2-phenylethyl	B
alpha	I
-	I
L	I
-	I
arabinopyranosyl-	I
(	I
1	I
-	I
->6	I
)	I
-beta	I
-	I
D	I
-	I
glucopyranoside	I
(	O
11	O
)	O
,	O
sacranoside	B
A	I
(	O
12	O
)	O
,	O
beta	B
-	I
D	I
-	I
glucopyranosyl	I
4-hydroxybenzoate	I
(	O
13	O
)	O
,	O
rhodiocyanoside	B
A	I
(	O
14	O
)	O
,	O
rhodiooctanoside	B
(	O
15	O
)	O
,	O
sarmentosin	B
(	O
16	O
)	O
,	O
heterodendrin	B
(	O
17	O
)	O
,	O
arbutin	B
(	O
18	O
)	O
and	O
4-O-	B
(	I
beta	I
-	I
D	I
-	I
glucopyranosyl	I
)	I
-gallic	I
acid	I
(	O
19	O
)	O
.	O

Among	O
these	O
,	O
1	B
,	O
2	B
,	O
5	B
,	O
8	B
-	I
10	I
,	O
13	B
,	O
16	B
,	O
18	B
and	O
19	B
have	O
been	O
isolated	O
for	O
the	O
first	O
time	O
from	O
R.	O
sacra	O
,	O
among	O
which	O
5	B
,	O
9	B
,	O
10	B
,	O
13	B
,	O
16	B
,	O
18	B
and	O
19	B
have	O
been	O
isolated	O
from	O
Rhodiola	O
plants	O
for	O
the	O
first	O
time	O
.	O

On	O
the	O
PEP	O
inhibition	O
,	O
seven	O
compounds	O
(	O
6	B
-	I
8	I
,	O
10	B
,	O
12	B
,	O
18	B
,	O
19	B
)	O
showed	O
inhibition	O
with	O
an	O
1C50	O
of	O
27.8	O
,	O
487	O
,	O
1.47	O
,	O
0.437	O
,	O
348	O
,	O
391	O
and	O
215	O
microM	O
,	O
respectively	O
.	O

The	O
kinetic	O
study	O
of	O
these	O
inhibitors	O
indicated	O
that	O
they	O
are	O
noncompetitive	O
inhibitors	O
,	O
except	O
for	O
6	B
which	O
is	O
a	O
competitive	O
inhibitor	O
.	O

The	O
growth	O
-	O
promoting	O
effects	O
of	O
estrogens	B
in	O
hormone	O
-	O
dependent	O
tumor	O
tissues	O
involve	O
receptor	O
-	O
mediated	O
pathways	O
that	O
are	O
well	O
-	O
recognized	O
;	O
however	O
,	O
the	O
role	O
of	O
estrogens	B
in	O
tumor	O
initiation	O
remains	O
controversial	O
.	O

Estrogen	B
metabolites	B
,	O
primarily	O
the	O
catechol	B
estrogens	I
(	O
CE	B
's	I
)	O
,	O
have	O
been	O
implicated	O
in	O
tumor	O
initiation	O
via	O
a	O
redox	O
cycling	O
mechanism	O
.	O

We	O
have	O
developed	O
metabolically	O
stable	O
CE	B
analogues	I
for	O
the	O
study	O
of	O
receptor	O
versus	O
redox	O
cycling	O
effects	O
on	O
DNA	O
damage	O
.	O

Comparisons	O
between	O
hydroxy	B
estradiols	I
(	O
HE2	B
's	I
)	O
,	O
methoxy	B
estradiols	I
(	O
ME2	B
's	I
)	O
,	O
and	O
hydroxymethyl	B
estradiols	I
(	O
HME2	O
)	O
in	O
potentiometric	O
and	O
DNA	O
damaging	O
studies	O
were	O
made	O
.	O

DNA	O
damage	O
was	O
assessed	O
in	O
calf	O
thymus	O
DNA	O
using	O
8-oxo-2'-deoxyguanosine	B
(	O
8-oxo	B
-	I
dG	I
)	O
as	O
a	O
genotoxic	O
marker	O
for	O
oxidative	O
stress	O
.	O

Increases	O
in	O
the	O
number	O
of	O
8-oxo	B
-	I
dG	I
/	O
10	O
(	O
5	O
)	O
dG	O
were	O
significant	O
for	O
each	O
2-HE2	B
and	O
4-HE2	B
.	O

Cu	B
(	I
II	I
)	I
SO4	I
,	O
a	O
transition	B
metal	I
known	O
to	O
catalyze	O
the	O
redox	O
cycling	O
of	O
o	B
-	I
quinones	I
,	O
substantially	O
increased	O
the	O
amount	O
of	O
DNA	O
damage	O
caused	O
by	O
both	O
CE	B
's	I
.	O

However	O
,	O
DNA	O
damage	O
was	O
only	O
observed	O
at	O
concentrations	O
of	O
10	O
microM	O
or	O
higher	O
,	O
much	O
greater	O
than	O
what	O
is	O
found	O
under	O
physiologic	O
conditions	O
.	O

Furthermore	O
,	O
the	O
presence	O
of	O
endogenous	O
antioxidants	O
such	O
as	O
glutathione	B
,	O
SOD	O
,	O
and	O
catalase	O
drastically	O
reduced	O
the	O
amount	O
of	O
DNA	O
damage	O
induced	O
by	O
high	O
concentrations	O
of	O
2-HE2	B
.	O

There	O
was	O
no	O
DNA	O
damage	O
observed	O
for	O
the	O
non	O
-	O
redox	O
cycling	O
HME2	B
's	I
,	O
making	O
these	O
compounds	O
useful	O
probes	O
in	O
the	O
study	O
of	O
receptor	O
-	O
mediated	O
carcinogenesis	O
.	O

Thus	O
,	O
both	O
2-HE2	B
and	O
4-HE2	B
are	O
capable	O
of	O
producing	O
oxidative	O
DNA	O
damage	O
at	O
micromolar	O
concentrations	O
in	O
vitro	O
.	O

However	O
,	O
since	O
the	O
amount	O
of	O
CE	B
's	I
has	O
not	O
been	O
shown	O
to	O
surpass	O
nanomolar	O
levels	O
in	O
vivo	O
,	O
it	O
is	O
unlikely	O
that	O
free	O
radical	O
production	O
via	O
redox	O
cycling	O
of	O
CE	B
's	I
is	O
a	O
causative	O
factor	O
in	O
human	O
tumorigenesis	O
.	O

In	O
addition	O
to	O
effects	O
in	O
the	O
periphery	O
through	O
inhibition	O
of	O
prostaglandin	B
synthesis	O
,	O
several	O
lines	O
of	O
evidence	O
suggest	O
that	O
nonsteroidal	B
anti	I
-	I
inflammatory	I
drugs	I
(	O
NSAIDs	B
)	O
act	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
possibility	O
that	O
the	O
central	O
action	O
of	O
NSAIDs	B
involves	O
regulation	O
of	O
opioid	O
receptors	O
was	O
investigated	O
by	O
quantitative	O
autoradiography	O
of	O
mu	O
,	O
delta	O
,	O
and	O
kappa	O
sites	O
in	O
rat	O
brain	O
slices	O
.	O

Increased	O
(	O
p	O
<	O
0.05	O
)	O
labeling	O
of	O
mu	O
receptors	O
was	O
observed	O
in	O
thalamic	O
nuclei	O
,	O
gyrus	O
dentate	O
,	O
and	O
layers	O
of	O
the	O
parietal	O
cortex	O
of	O
rats	O
treated	O
for	O
10	O
days	O
with	O
lysine	B
clonixinate	B
.	O

Labeling	O
of	O
delta	O
receptors	O
was	O
lower	O
in	O
the	O
lateral	O
septum	O
,	O
and	O
kappa	O
sites	O
decreased	O
in	O
thalamic	O
nuclei	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
through	O
direct	O
interaction	O
with	O
opioid	O
-	O
binding	O
sites	O
,	O
since	O
receptor	O
-	O
binding	O
assays	O
using	O
rat	O
brain	O
membranes	O
confirmed	O
that	O
clonixinate	B
up	O
to	O
1	O
x	O
10	O
(	O
-4	O
)	O
mol	O
/	O
l	O
does	O
not	O
inhibit	O
mu	O
,	O
delta	O
,	O
and	O
kappa	O
receptor	O
specific	O
binding	O
.	O

Central	O
effects	O
of	O
NSAIDs	B
might	O
,	O
therefore	O
,	O
involve	O
interaction	O
with	O
the	O
opioid	O
receptor	O
system	O
through	O
indirect	O
mechanisms	O
.	O

1	O
.	O

Quantitative	O
relationships	O
between	O
molecular	O
physico	O
-	O
chemical	O
properties	O
of	O
22	O
substituted	O
benzoic	B
acids	I
and	O
the	O
extent	O
of	O
excretion	O
of	O
their	O
metabolites	O
in	O
rat	O
urine	O
have	O
been	O
investigated	O
using	O
computational	O
chemistry	O
and	O
multivariate	O
statistics	O
.	O

2	O
.	O

A	O
data	O
set	O
of	O
34	O
theoretically	O
derived	O
physico	O
-	O
chemical	O
descriptors	O
calculated	O
was	O
used	O
to	O
classify	O
the	O
benzoic	B
acids	I
according	O
to	O
their	O
predominant	O
urinary	O
metabolic	O
fate	O
.	O

3	O
.	O

Quantitative	O
structure	O
-	O
metabolism	O
relationships	O
were	O
obtained	O
by	O
linear	O
regression	O
using	O
combinations	O
of	O
physico	O
-	O
chemical	O
descriptors	O
allowing	O
the	O
prediction	O
of	O
%	O
urinary	O
excretion	O
of	O
glycine	B
(	O
r	O
=	O
0.73	O
)	O
and	O
glucuronide	B
conjugates	I
(	O
r	O
=	O
0.82	O
)	O
and	O
%	O
urinary	O
excretion	O
of	O
the	O
parent	O
compound	O
(	O
r	O
=	O
0.91	O
)	O
.	O

A	O
novel	O
phospholipid	B
has	O
been	O
purified	O
from	O
strain	O
Dm	O
28c	O
of	O
Trypanosoma	O
cruzi	O
,	O
and	O
characterized	O
by	O
fast	O
atom	O
bombardment	O
mass	O
spectrometry	O
and	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
as	O
a	O
plasmenylethanolamine	B
with	O
a	O
hexadec	B
-	I
l	I
-	I
enyl	I
group	I
in	O
the	O
sn-1	O
position	O
and	O
an	O
approximately	O
equimolar	O
mixture	O
of	O
octadecenoate	B
and	O
octadecadienoate	B
esterified	O
to	O
the	O
sn-2	O
hydroxyl	O
.	O

The	O
purified	O
plasmenylethanolamine	B
reacted	O
positively	O
when	O
probed	O
with	O
sera	O
from	O
patients	O
with	O
chronic	O
Chagas	O
'	O
disease	O
.	O

Since	O
plasmenylethanolamines	B
of	O
similar	O
structure	O
are	O
abundant	O
in	O
mammalian	O
cardiac	O
and	O
neuronal	O
tissues	O
,	O
cross	O
reactions	O
between	O
these	O
epitopes	O
may	O
be	O
a	O
factor	O
in	O
the	O
mechanism	O
of	O
autoimmune	O
pathology	O
in	O
the	O
chronic	O
phase	O
of	O
Chagas	O
'	O
disease	O
.	O

Trypanosoma	O
cruzi	O
is	O
the	O
causative	O
agent	O
of	O
Chagas	O
'	O
disease	O
,	O
which	O
is	O
still	O
endemic	O
throughout	O
much	O
of	O
Central	O
and	O
South	O
America	O
[	O
1	O
]	O
.	O

The	O
parasite	O
has	O
a	O
complex	O
life	O
-	O
cycle	O
in	O
which	O
several	O
morphologically	O
distinct	O
forms	O
alternate	O
between	O
blood	O
-	O
sucking	O
insects	O
and	O
mammalian	O
hosts	O
[	O
2,3	O
]	O
.	O

These	O
various	O
developmental	O
stages	O
are	O
confronted	O
with	O
a	O
range	O
of	O
environments	O
,	O
some	O
extremely	O
hostile	O
.	O

Epimastigotes	O
must	O
resist	O
the	O
hydrolytic	O
action	O
of	O
digestive	O
enzymes	O
in	O
the	O
insect	O
intestinal	O
tract	O
,	O
bloodstream	O
trypomastigotes	O
have	O
to	O
evade	O
complement	O
-	O
mediated	O
lysis	O
and	O
other	O
immune	O
defence	O
mechanisms	O
,	O
and	O
amastigotes	O
need	O
to	O
survive	O
and	O
replicate	O
inside	O
their	O
host	O
cells	O
.	O

Components	O
of	O
the	O
parasite	O
cell	O
surface	O
provide	O
crucial	O
protection	O
against	O
these	O
hostile	O
environments	O
,	O
and	O
actively	O
mediate	O
processes	O
such	O
as	O
cellular	O
invasion	O
and	O
intracellular	O
survival	O
[	O
4	O
]	O
.	O

The	O
immunological	O
properties	O
of	O
surface	O
molecules	B
of	O
T.	O
cruzi	O
are	O
likely	O
to	O
be	O
of	O
particular	O
relevance	O
,	O
since	O
many	O
of	O
the	O
pathological	O
features	O
of	O
chronic	O
Chagas	O
'	O
disease	O
may	O
result	O
from	O
autoimmune	O
processes	O
,	O
perhaps	O
originating	O
from	O
molecular	O
mimicry	O
between	O
parasite	O
antigens	B
and	O
host	O
tissues	O
[	O
5	O
]	O
.	O

Surface	O
molecules	B
of	O
T.	O
cruzi	O
which	O
have	O
been	O
characterized	O
include	O
trans	O
-	O
sialidase	O
[	O
6	O
]	O
,	O
mucin	O
-	O
like	O
glycoproteins	O
[	O
7	O
]	O
,	O
glycoinositol	B
phospholipids	I
[	O
8	O
]	O
,	O
inositol	B
phosphoceramides	I
[	O
9	O
]	O
,	O
and	O
glycosphingolipids	B
[	O
10	O
]	O
.	O

Surprisingly	O
little	O
recent	O
attention	O
has	O
,	O
however	O
,	O
been	O
devoted	O
to	O
the	O
phospholipids	B
of	O
Trypanosoma	O
cruzi	O
,	O
even	O
though	O
it	O
is	O
increasingly	O
recognised	O
that	O
membrane	O
lipids	B
are	O
not	O
simply	O
structural	O
components	O
,	O
but	O
are	O
active	O
participants	O
in	O
processes	O
such	O
as	O
signal	O
transduction	O
and	O
are	O
the	O
precursors	O
of	O
biologically	O
active	O
molecules	O
including	O
diacylglycerols	B
,	O
platelet	B
activating	I
factor	I
(	O
PAF	B
)	O
,	O
and	O
eicosanoids	B
.	O

In	O
the	O
present	O
paper	O
we	O
report	O
the	O
characterization	O
of	O
a	O
major	O
phospholipid	B
from	O
the	O
Dm	O
28c	O
clone	O
of	O
T.	O
cruzi	O
by	O
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
,	O
gas	O
-	O
chromatography	O
mass	O
spectrometry	O
(	O
GC	O
/	O
MS	O
)	O
,	O
fast	O
atom	O
bombardment	O
mass	O
spectrometry	O
(	O
FAB	O
MS	O
)	O
and	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
All	O
solvents	O
were	O
of	O
reagent	O
grade	O
and	O
were	O
obtained	O
from	O
Merck	O
and	O
re	O
-	O
distilled	O
before	O
use	O
.	O

Phospholipid	B
standards	O
and	O
phospholipase	O
A2	O
were	O
purchased	O
from	O
Sigma	O
.	O

Silica	B
gel	I
60	I
and	O
high	O
performance	O
thin	O
-	O
layer	O
chromatography	O
(	O
HPTLC	O
)	O
plates	O
were	O
obtained	O
from	O
Merck	O
.	O

Human	O
sera	O
were	O
obtained	O
from	O
five	O
confirmed	O
cases	O
of	O
chronic	O
Chagas	O
'	O
disease	O
and	O
from	O
two	O
healthy	O
controls	O
.	O

2.2	O
Culture	O
of	O
parasites	O
The	O
Dm	O
28c	O
clone	O
of	O
Trypanosoma	O
cruzi	O
[	O
11	O
]	O
was	O
obtained	O
from	O
the	O
Department	O
of	O
Protozoology	O
,	O
FIOCRUZ	O
,	O
Rio	O
de	O
Janeiro	O
,	O
Brazil	O
.	O

Parasites	O
were	O
grown	O
at	O
25	O
°	O
C	O
in	O
brain	O
heart	O
infusion	O
medium	O
(	O
Becton	O
Dickinson	O
,	O
USA	O
)	O
,	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
foetal	O
calf	O
serum	O
(	O
Fazenda	O
Pigue	O
,	O
Brazil	O
)	O
and	O
10	O
mg	O
l−1	O
haemin	B
.	O

Epimastigotes	O
were	O
harvested	O
by	O
centrifugation	O
in	O
early	O
stationary	O
phase	O
(	O
7	O
days	O
growth	O
)	O
,	O
washed	O
three	O
times	O
with	O
isotonic	O
buffered	O
saline	B
and	O
stored	O
at	O
−20	O
°	O
C	O
.	O

2.3	O
Extraction	O
and	O
purification	O
of	O
phospholipids	B
Epimastigote	O
cells	O
(	O
100	O
g	O
,	O
wet	O
weight	O
)	O
were	O
extracted	O
for	O
24	O
h	O
at	O
−10	O
°	O
C	O
with	O
100	O
ml	O
of	O
acetone	O
,	O
then	O
for	O
2	O
h	O
at	O
room	O
temperature	O
with	O
successive	O
volumes	O
of	O
chloroform	B
/	O
methanol	B
(	O
2:1	O
and	O
1:2	O
v	O
/	O
v	O
)	O
.	O

Crude	O
lipid	B
was	O
obtained	O
by	O
evaporation	O
of	O
the	O
combined	O
extracts	O
,	O
and	O
was	O
partitioned	O
according	O
to	O
Folch	O
et	O
al.	O
[	O
12	O
]	O
.	O

Material	O
recovered	O
from	O
the	O
lower	O
phase	O
was	O
separated	O
by	O
silica	B
gel	I
60	I
chromatography	O
into	O
neutral	O
,	O
glyco-	B
and	O
phospholipid	B
fractions	O
as	O
previously	O
described	O
[	O
13	O
]	O
.	O

The	O
resulting	O
phospholipids	B
were	O
applied	O
to	O
a	O
column	O
of	O
silica	B
gel	I
60	I
and	O
eluted	O
with	O
200	O
ml	O
volumes	O
of	O
chloroform	B
/	O
methanol	B
(	O
95:5	O
,	O
90:10	O
,	O
80:20	O
,	O
and	O
50:50	O
(	O
v	O
/	O
v	O
)	O
and	O
finally	O
with	O
methanol	B
.	O

The	O
methanol	B
fractions	O
were	O
pooled	O
and	O
subjected	O
to	O
a	O
final	O
purification	O
on	O
silica	B
gel	I
60	I
in	O
which	O
the	O
column	O
was	O
sequentially	O
eluted	O
with	O
100	O
ml	O
portions	O
of	O
chloroform	B
/	O
methanol	B
(	O
80:20	O
and	O
50:50	O
v	O
/	O
v	O
)	O
and	O
lastly	O
with	O
methanol	B
.	O

Fractions	O
(	O
5	O
ml	O
)	O
were	O
collected	O
and	O
monitored	O
by	O
TLC	O
.	O

The	O
major	O
phospholipid	B
was	O
obtained	O
as	O
a	O
single	O
component	O
in	O
fractions	O
12	O
and	O
13	O
of	O
the	O
50:50	O
chloroform	B
/	O
methanol	B
eluate	O
.	O

2.4	O
Thin	O
layer	O
chromatography	O
Analytical	O
TLC	O
was	O
performed	O
on	O
silica	B
gel	I
G	I
plates	O
(	O
Merck	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
.	O

developed	O
with	O
chloroform	B
/	O
methanol	B
/	O
water	B
(	O
65:25:4	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
.	O

The	O
separated	O
components	O
were	O
visualized	O
with	O
iodine	B
vapour	O
,	O
ninhydrin	B
[	O
14	O
]	O
,	O
and	O
ammonium	B
molybdate	I
reagent	O
[	O
15	O
]	O
.	O

For	O
two	O
dimensional	O
TLC	O
the	O
first	O
dimension	O
was	O
developed	O
with	O
chloroform	B
/	O
methanol	B
/	O
28	O
%	O
ammonium	B
hydroxide	I
(	O
65:35:5	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
and	O
the	O
second	O
with	O
chloroform	B
:	O
acetone	B
:	O
methanol	B
:	O
acetic	B
acid	I
:	O
water	B
(	O
5:2:1:1:0.5	O
,	O
v	O
/	O
v	O
/	O
v	O
/	O
v	O
/	O
v	O
)	O
[	O
16	O
]	O
.	O

The	O
separated	O
phospholipids	B
were	O
visualized	O
by	O
spraying	O
with	O
ammonium	B
molybdate	I
.	O

2.5	O
High	O
performance	O
thin	O
layer	O
chromatography	O
immunostaining	O
The	O
total	O
lipid	B
fraction	O
was	O
separated	O
by	O
HPTLC	O
using	O
chloroform	B
/	O
methanol	B
/	O
water	B
(	O
65:25:4	O
v	O
/	O
v	O
)	O
as	O
solvent	O
system	O
.	O

The	O
developed	O
plates	O
were	O
soaked	O
in	O
0.5	O
%	O
polymethacrylate	B
in	O
diethyl	B
ether	I
,	O
blocked	O
for	O
2	O
h	O
with	O
10	O
%	O
skimmed	O
milk	O
in	O
phosphate	O
-	O
buffered	O
saline	B
and	O
incubated	O
overnight	O
with	O
sera	O
from	O
either	O
chagasic	O
patients	O
or	O
healthy	O
volunteers	O
,	O
followed	O
by	O
sequential	O
treatment	O
with	O
peroxidase	O
-	O
conjugated	O
goat	O
anti	O
-	O
human	O
IgG	O
(	O
2	O
h	O
)	O
and	O
diaminobenzidine	B
,	O
as	O
described	O
by	O
Straus	O
et	O
al.	O
[	O
17	O
]	O
.	O

The	O
reaction	O
was	O
terminated	O
after	O
5	O
min	O
by	O
washing	O
with	O
distilled	O
water	B
.	O

Reactive	O
components	O
were	O
indicated	O
by	O
the	O
development	O
of	O
brown	O
bands	O
on	O
the	O
HPTLC	O
plates	O
.	O

2.6	O
Acid	B
methanolysis	O
The	O
purified	O
phospholipid	B
was	O
methanolysed	O
overnight	O
at	O
80	O
°	O
C	O
in	O
1	O
M	O
methanol	B
:	O
HCl	B
made	O
10	O
M	O
with	O
respect	O
to	O
water	B
[	O
18	O
]	O
,	O
cooled	O
and	O
extracted	O
twice	O
with	O
an	O
equal	O
volume	O
of	O
hexane	B
.	O

The	O
combined	O
hexane	B
extracts	O
were	O
dried	O
and	O
analysed	O
by	O
GC	O
/	O
MS	O
.	O

2.7	O
Phospholipase	O
A2	O
digestion	O
.	O

The	O
purified	O
phospholipid	B
(	O
0.15	O
mg	O
)	O
was	O
dissolved	O
in	O
2	O
ml	O
of	O
diethyl	B
ether	I
/	O
methanol	B
(	O
98:2	O
)	O
and	O
10	O
units	O
of	O
Crotalus	O
atrox	O
phospholipase	O
A2	O
(	O
Sigma	O
P-3770	O
)	O
in	O
0.5	O
ml	O
of	O
borate	B
buffer	I
pH	O
8.9	O
was	O
added	O
[	O
19	O
]	O
.	O

Dipalmitoyl	B
phosphatidylethanolamine	I
was	O
used	O
as	O
a	O
positive	O
control	O
.	O

After	O
incubation	O
overnight	O
(	O
37	O
°	O
C	O
,	O
with	O
agitation	O
)	O
the	O
ether	B
was	O
removed	O
by	O
vacuum	O
centrifugation	O
,	O
and	O
the	O
digestion	O
products	O
were	O
recovered	O
by	O
Bligh	O
-	O
Dyer	O
extraction	O
and	O
analysed	O
by	O
FAB	O
MS	O
.	O

2.8	O
Gas	O
chromatography	O
mass	O
spectrometry	O
GC	O
/	O
MS	O
was	O
performed	O
with	O
a	O
Kratos	O
MS80	O
RFA	O
spectrometer	O
(	O
Kratos	O
Manchester	O
,	O
UK	O
)	O
interfaced	O
to	O
a	O
Carlo	O
Erba	O
5160	O
chromatograph	O
fitted	O
with	O
a	O
BPX-5	O
fused	B
silica	I
column	O
(	O
25	O
m	O
by	O
0.2	O
mm	O
;	O
SGE	O
,	O
Milton	O
Keynes	O
,	O
UK	O
)	O
.	O

Helium	B
(	O
0.7	O
ml	O
min−1	O
)	O
was	O
the	O
carrier	O
gas	O
,	O
and	O
samples	O
were	O
introduced	O
by	O
'	O
splitless	O
'	O
injection	O
.	O

Electron	O
ionization	O
spectra	O
were	O
recorded	O
at	O
an	O
ionization	O
energy	O
of	O
70	O
eV	O
,	O
trap	O
current	O
of	O
100	O
μA	O
,	O
and	O
source	O
temperature	O
of	O
220	O
°	O
C	O
.	O

Chemical	O
ionization	O
spectra	O
were	O
obtained	O
using	O
isobutane	B
reagent	O
gas	O
and	O
an	O
emission	O
current	O
of	O
250	O
mA.	O
2.9	O
Fast	O
atom	O
bombardment	O
-	O
mass	O
spectrometry	O
Fast	O
atom	O
bombardment	O
(	O
FAB	O
)	O
spectra	O
were	O
obtained	O
in	O
positive	O
and	O
negative	O
ion	O
modes	O
with	O
a	O
Kratos	O
MS80	O
spectrometer	O
,	O
fitted	O
with	O
an	O
IonTech	O
saddle	O
-	O
field	O
atom	O
gun	O
supplied	O
with	O
high	O
-	O
purity	O
xenon	B
gas	O
.	O

Approximately	O
10	O
μg	O
of	O
sample	O
was	O
loaded	O
into	O
3-nitrobenzyl	B
alcohol	I
matrix	O
.	O

Collision	O
induced	O
dissociation	O
was	O
achieved	O
by	O
admitting	O
helium	B
into	O
a	O
collision	O
cell	O
in	O
the	O
field	O
-	O
free	O
region	O
between	O
source	O
and	O
electrostatic	O
analyser	O
so	O
as	O
to	O
attenuate	O
the	O
ion	O
beam	O
by	O
50	O
%	O
.	O

Constant	O
neutral	O
loss	O
and	O
daughter	O
ion	O
spectra	O
were	O
recorded	O
by	O
means	O
of	O
computer	O
generated	O
linked	O
scans	O
.	O

2.10	O
Nuclear	O
magnetic	O
resonance	O
spectroscopy	O
Proton	O
(	O
500	O
MHz	O
,	O
25	O
°	O
C	O
)	O
and	O
13	O
C	O
NMR	O
spectra	O
(	O
125	O
MHz	O
,	O
25	O
°	O
C	O
)	O
were	O
acquired	O
on	O
a	O
Varian	O
Unity	O
500	O
MHz	O
spectrometer	O
using	O
the	O
manufacturer	O
's	O
standard	O
pulse	O
sequences	O
.	O

Samples	O
were	O
dissolved	O
in	O
CDCl3	B
containing	O
a	O
trace	O
of	O
CD3	B
OD	I
or	O
CDCl3	B
and	O
CD3	B
OD	I
(	O
1:2	O
v	O
/	O
v	O
)	O
.	O

1	O
H	O
and	O
13	O
C	O
chemical	O
shifts	O
are	O
reported	O
relative	O
to	O
tetramethylsilane	B
at	O
0	O
ppm	O
.	O

3	O
Results	O
3.1	O
Isolation	O
of	O
phospholipids	B
Phospholipids	B
were	O
extracted	O
from	O
epimastigotes	O
of	O
the	O
Dm	O
28c	O
clone	O
of	O
T.	O
cruzi	O
with	O
chloroform	B
/	O
methanol	B
,	O
and	O
were	O
purified	O
by	O
Folch	O
partition	O
and	O
silica	B
chromatography	O
.	O

Twenty	O
milligrams	O
of	O
purified	O
material	O
were	O
obtained	O
from	O
100	O
g	O
(	O
wet	O
weight	O
)	O
of	O
biomass	O
.	O

The	O
unknown	O
phospholipid	B
was	O
similar	O
in	O
one	O
-	O
dimensional	O
TLC	O
mobility	O
to	O
a	O
phosphatidylethanolamine	B
(	O
PE	B
)	O
standard	O
(	O
Fig.	O
1	O
A	O
and	O
B	O
)	O
and	O
stained	O
positively	O
with	O
ninhydrin	B
,	O
iodine	B
,	O
and	O
ammonium	B
molybdate	I
reagents	O
.	O

Two	O
dimensional	O
TLC	O
,	O
however	O
,	O
resolved	O
the	O
compound	O
from	O
phosphatidylethanolamine	B
(	O
Fig.	O
1	O
C	O
)	O
.	O

The	O
phospholipid	B
was	O
derived	O
from	O
the	O
T.	O
cruzi	O
biomass	O
,	O
since	O
it	O
was	O
not	O
detected	O
in	O
control	O
extractions	O
of	O
the	O
culture	O
medium	O
alone	O
.	O

3.2	O
Gas	O
chromotography	O
mass	O
spectrometry	O
analysis	O
of	O
the	O
methanolysed	B
phospholipid	I
The	O
phospholipid	B
was	O
methanolysed	O
under	O
acid	B
conditions	O
,	O
and	O
the	O
products	O
were	O
analysed	O
by	O
GC	O
/	O
MS	O
.	O

Four	O
peaks	O
(	O
I	O
–	O
IV	O
)	O
were	O
observed	O
in	O
the	O
chromatogram	O
in	O
an	O
intensity	O
ratio	O
of	O
≈1:0.2:1:1	O
;	O
two	O
of	O
these	O
(	O
III	O
and	O
IV	O
)	O
were	O
late	O
-	O
eluting	O
and	O
poorly	O
resolved	O
under	O
the	O
conditions	O
used	O
.	O

The	O
minor	O
peak	O
(	O
II	O
)	O
was	O
intermediate	O
in	O
retention	O
time	O
between	O
peak	O
I	O
and	O
peaks	O
III	O
and	O
IV	O
.	O

The	O
pair	O
of	O
late	O
-	O
eluting	O
peaks	O
had	O
mass	O
spectra	O
typical	O
of	O
methyl	B
esters	I
of	I
unsaturated	I
long	I
chain	I
fatty	I
acids	I
.	O

The	O
earlier	O
-	O
eluting	O
of	O
the	O
two	O
(	O
III	O
)	O
had	O
a	O
molecular	O
ion	O
(	O
M+	O
)	O
at	O
m	O
/z	O
294	O
,	O
and	O
an	O
ion	O
at	O
m	O
/z	O
263	O
(	O
M-31	O
)	O
,	O
the	O
latter	O
comparable	O
in	O
intensity	O
to	O
M+	O
.	O

The	O
low	O
mass	O
end	O
of	O
the	O
spectrum	O
was	O
dominated	O
by	O
a	O
series	O
of	O
ions	O
at	O
m	O
/z	O
67	O
(	O
base	O
peak	O
)	O
,	O
m	O
/z	O
81	O
,	O
m	O
/z	O
95	O
etc	O
.	O

The	O
spectrum	O
thus	O
confirmed	O
the	O
identity	O
of	O
this	O
component	O
as	O
octadecadienoic	B
acid	I
[	O
20	O
]	O
.	O

Peak	O
IV	O
had	O
an	O
M+	O
at	O
m	O
/z	O
296	O
,	O
an	O
M-32	O
ion	O
at	O
m	O
/z	O
264	O
,	O
(	O
more	O
abundant	O
than	O
the	O
molecular	O
ion	O
)	O
,	O
and	O
a	O
low	O
mass	O
ion	O
series	O
at	O
m	O
/z	O
55	O
(	O
base	O
peak	O
)	O
,	O
m	O
/z	O
69	O
,	O
m	O
/z	O
83	O
etc	O
.	O

which	O
identified	O
it	O
as	O
octadecenoic	B
acid	I
.	O

No	O
attempt	O
was	O
made	O
to	O
determine	O
the	O
locations	O
of	O
the	O
double	B
bonds	I
in	O
either	O
compound	O
.	O

The	O
spectrum	O
of	O
peak	O
II	O
was	O
consistent	O
with	O
the	O
methyl	B
ester	I
of	I
a	I
saturated	I
fatty	I
acid	I
(	O
M+	O
at	O
m	O
/z	O
270	O
,	O
ions	O
at	O
m	O
/z	O
241	O
,	O
239	O
,	O
and	O
227	O
;	O
base	O
peak	O
at	O
m	O
/z	O
74	O
,	O
and	O
was	O
assigned	O
as	O
methyl	B
hexadecanoate	I
.	O

The	O
mass	O
spectrum	O
of	O
the	O
other	O
major	O
peak	O
in	O
the	O
methanolysate	O
did	O
not	O
resemble	O
that	O
of	O
a	O
fatty	B
acid	I
but	O
was	O
consistent	O
with	O
a	O
long	B
chain	I
aldehyde	I
as	O
would	O
be	O
obtained	O
from	O
hydrolysis	O
of	O
a	O
plasmenyl	O
linkage	O
(	O
Fig.	O
2	O
A	O
)	O
.	O

A	O
weak	O
ion	O
was	O
observed	O
at	O
m	O
/z	O
240	O
,	O
the	O
mass	O
of	O
hexadecanal	B
,	O
and	O
was	O
accompanied	O
by	O
fragments	O
at	O
m	O
/z	O
222	O
,	O
212	O
,	O
and	O
296	O
(	O
loss	O
of	O
H2	B
O	B
,	O
CO	B
,	O
and	O
CH3	B
CO	I
,	O
respectively	O
)	O
,	O
all	O
fragmentation	O
processes	O
characteristic	O
of	O
aliphatic	B
aldehydes	I
[	O
21	O
]	O
.	O

In	O
the	O
corresponding	O
chemical	O
ionization	O
spectrum	O
,	O
the	O
base	O
peak	O
was	O
observed	O
at	O
m	O
/z	O
241	O
,	O
consistent	O
with	O
the	O
protonated	O
molecule	O
of	O
hexadecanal	B
(	O
Fig.	O
2	O
B	O
)	O
.	O

The	O
electron	O
ionization	O
and	O
chemical	O
ionizaton	O
spectra	O
obtained	O
from	O
a	O
tetradecanal	B
standard	O
of	O
were	O
similar	O
except	O
that	O
the	O
corresponding	O
protonated	O
molecules	O
and	O
fragment	O
ions	O
were	O
observed	O
28	O
m	O
/z	O
units	O
lower	O
in	O
mass	O
.	O

3.3	O
Fast	O
atom	O
bombardment	O
mass	O
spectroscopy	O
analysis	O
A	O
doublet	O
of	O
de	O
-	O
protonated	O
molecules	O
(	O
[	O
M	O
-	O
H	O
]	O
−	O
)	O
,	O
approximately	O
equal	O
in	O
abundance	O
,	O
was	O
observed	O
at	O
m	O
/z	O
698	O
and	O
700	O
in	O
the	O
negative	O
ion	O
FAB	O
spectrum	O
of	O
the	O
intact	O
phospholipid	O
(	O
Fig.	O
3	O
)	O
,	O
together	O
with	O
a	O
pair	O
of	O
signals	O
at	O
m	O
/z	O
279	O
and	O
281	O
,	O
also	O
similar	O
to	O
each	O
other	O
in	O
intensity	O
.	O

The	O
latter	O
were	O
consistent	O
with	O
carboxylate	B
anions	I
derived	B
from	I
octadecenoic	B
(	I
18:1	I
)	I
and	O
octadecadienoic	B
(	I
18:2	I
)	I
substituents	I
.	O

In	O
the	O
positive	O
ion	O
FAB	O
spectrum	O
,	O
corresponding	O
[	O
M+H	O
]	O
+	O
ions	O
were	O
present	O
at	O
m	O
/z	O
700	O
and	O
702	O
,	O
but	O
were	O
accompanied	O
by	O
more	O
abundant	O
[	O
M+Na	O
]	O
+	O
and	O
[	O
M	O
-	O
H+Na2	O
]	O
+	O
signals	O
at	O
m	O
/z	O
722	O
/	O
744	O
,	O
and	O
744	O
/	O
746	O
,	O
respectively	O
.	O

A	O
doublet	O
of	O
fragment	O
ions	O
at	O
m	O
/z	O
561	O
and	O
559	O
was	O
consistent	O
with	O
loss	O
of	O
an	O
ethanolamine	B
phosphate	I
headgroup	O
(	O
141	O
)	O
from	O
the	O
protonated	B
molecules	I
.	O

This	O
was	O
verified	O
by	O
a	O
constant	O
neutral	O
loss	O
scan	O
,	O
which	O
confirmed	O
that	O
the	O
peaks	O
at	O
m	O
/z	O
559	O
and	O
561	O
originated	O
by	O
elimination	O
of	O
141	O
from	O
the	O
protonated	B
molecules	I
at	O
m	O
/z	O
700	O
and	O
702	O
.	O

The	O
data	O
thus	O
indicate	O
the	O
presence	O
of	O
both	O
phosphoethanolamine	B
and	I
hydroxyester	I
-	I
linked	I
C18:1	I
and	I
C18:2	I
fatty	I
acids	I
.	O

The	O
observed	O
[	O
M+H	O
]	O
+	O
is	O
not	O
,	O
however	O
,	O
consistent	O
with	O
a	O
phosphatidyl	B
ethanolamine	I
having	O
this	O
substitution	O
pattern	O
,	O
for	O
which	O
the	O
calculated	O
mass	O
would	O
be	O
742	O
.	O

The	O
spectra	O
are	O
more	O
compatible	O
with	O
a	O
plasmenyl	B
ethanolamine	I
,	O
in	O
which	O
carbon	O
1	O
of	O
sn	B
-glycero-3-phosphoethanolamine	I
bears	O
an	O
O	B
-	I
(	I
1-hexadecenyl	I
)	I
residue	I
,	O
and	O
the	O
sn	O
-2	O
position	O
is	O
esterified	O
with	O
a	O
mixture	O
of	O
octadecenoic	B
and	O
octadecadienoic	B
acids	I
.	O

This	O
structure	O
would	O
yield	O
on	O
hydrolysis	O
an	O
equimolar	O
mixture	O
of	O
hexadecanal	B
,	O
octadecanoate	B
,	O
and	O
octadecadienoate	B
acid	I
,	O
in	O
agreement	O
with	O
the	O
results	O
of	O
the	O
GC	O
/	O
MS	O
experiments	O
.	O

The	O
acid	B
lability	O
of	O
the	O
compound	O
similarly	O
excludes	O
an	O
alkylglycerol	B
structure	O
,	O
which	O
would	O
be	O
stable	O
to	O
the	O
acid	B
hydrolysis	O
conditions	O
employed	O
.	O

When	O
the	O
compound	O
was	O
treated	O
with	O
phospholipase	O
A2	O
,	O
and	O
reanalysed	O
by	O
negative	O
ion	O
FAB	O
MS	O
,	O
the	O
doublet	O
at	O
m	O
/z	O
698	O
/	O
700	O
disappeared	O
,	O
and	O
was	O
replaced	O
by	O
a	O
singlet	O
at	O
m	O
/z	O
436.3	O
,	O
consistent	O
with	O
removal	O
of	O
octadecanoate	B
and	O
octadecadienoate	B
,	O
thus	O
establishing	O
an	O
sn	B
-1,2-diradyl	I
glycerol	I
stereochemisty	O
.	O

Further	O
confirmation	O
of	O
the	O
structure	O
was	O
provided	O
by	O
the	O
helium	B
collisional	O
activation	O
spectrum	O
of	O
the	O
protonated	B
molecules	I
at	O
m	O
/z	O
700	O
and	O
702	O
(	O
both	O
ions	O
fell	O
within	O
the	O
precursor	O
ion	O
window	O
because	O
of	O
the	O
poor	O
parent	O
-	O
ion	O
resolution	O
of	O
the	O
B	O
/	O
E	O
scan	O
on	O
a	O
two	O
sector	O
instrument	O
)	O
.	O

In	O
addition	O
to	O
daughter	O
ions	O
at	O
m	O
/z	O
559	O
and	O
561	O
,	O
attributable	O
to	O
loss	O
of	O
the	O
phosphoethanolamine	B
head	O
group	O
,	O
a	O
further	O
doublet	O
of	O
fragment	O
ions	O
was	O
observed	O
at	O
m	O
/z	O
337	O
and	O
339	O
,	O
which	O
were	O
the	O
result	O
of	O
cleavage	O
of	O
the	O
sn	B
-1	I
O	I
-	I
CH	I
bond	I
(	O
with	O
hydrogen	B
transfer	O
to	O
glycerol	B
)	O
combined	O
with	O
loss	O
of	O
ethanolamine	B
phosphate	I
.	O

Consistent	O
with	O
previous	O
reports	O
of	O
the	O
FAB	O
spectra	O
of	O
plasmalogens	B
,	O
both	O
in	O
-	O
source	O
and	O
collision	O
-	O
induced	O
loss	O
of	O
phosphoethanolamine	B
was	O
considerably	O
less	O
facile	O
than	O
in	O
the	O
spectra	O
of	O
phosphatidylethanolamines	B
[	O
22,23	O
]	O
.	O

3.4	O
Nuclear	O
magnetic	O
resonance	O
analysis	O
of	O
the	O
phospholipid	B
Proton	O
and	O
carbon	O
spectra	O
were	O
assigned	O
using	O
two	O
-	O
dimensional	O
NMR	O
techniques	O
;	O
double	O
quantum	O
filtered	O
correlation	O
spectroscopy	O
(	O
DQCOSY	O
)	O
and	O
total	O
correlation	O
spectroscopy	O
(	O
TOCSY	O
)	O
for	O
the	O
1	O
H	O
spectrum	O
and	O
heteronuclear	O
multiple	O
quantum	O
correlated	O
spectroscopy	O
(	O
HMQC	O
)	O
for	O
the	O
13	O
C	O
spectrum	O
.	O

The	O
chemical	O
shifts	O
listed	O
in	O
Table	O
1	O
were	O
obtained	O
in	O
CDCl3	B
at	O
25	O
°	O
C	O
:	O
Both	O
the	O
1	O
H	O
and	O
13	O
C	O
spectra	O
are	O
consistent	O
with	O
the	O
structure	O
deduced	O
from	O
the	O
mass	O
spectrometric	O
analysis	O
and	O
the	O
chemical	O
shifts	O
were	O
in	O
agreement	O
with	O
the	O
published	O
values	O
of	O
a	O
synthetic	O
plasmenylcholine	B
model	O
system	O
[	O
24	O
]	O
,	O
except	O
for	O
differences	O
attributable	O
to	O
the	O
presence	O
of	O
a	O
phosphoethanolamine	B
rather	O
than	O
a	O
phosphocholine	B
polar	I
head	I
group	I
.	O

The	O
relative	O
positions	O
of	O
the	O
double	B
bonds	I
in	O
octadecadienoic	B
acid	I
are	O
revealed	O
by	O
the	O
chemical	O
shift	O
of	O
signals	O
from	O
protons	B
attached	O
to	O
carbon	B
32	O
(	O
arbitrary	O
numbering	O
;	O
Fig.	O
4	O
)	O
,	O
consistent	O
with	O
a	O
bisallylic	B
methylene	I
;	O
which	O
are	O
correlated	O
by	O
COSY	O
cross	O
-	O
peaks	O
to	O
the	O
envelope	O
of	O
methine	B
resonances	O
at	O
5.35	O
ppm	O
.	O

3.5	O
High	O
performance	O
thin	O
layer	O
chromatography	O
immunostaining	O
Immunostaining	O
of	O
the	O
HPTLC	O
-	O
separated	O
total	O
lipid	B
extract	O
showed	O
that	O
only	O
the	O
band	O
corresponding	O
to	O
the	O
plasmenyl	B
ethanolamine	I
was	O
recognised	O
by	O
sera	O
from	O
patients	O
with	O
Chagas	O
'	O
disease	O
(	O
Fig.	O
5	O
)	O
.	O

4	O
Discussion	O
This	O
study	O
describes	O
the	O
purification	O
and	O
molecular	O
characterization	O
of	O
a	O
novel	O
phospholipid	B
from	O
T.	O
cruzi	O
strain	O
Dm	O
28c	O
,	O
which	O
we	O
show	O
by	O
FAB	O
MS	O
and	O
NMR	O
is	O
a	O
plasmenylethanolamine	B
with	O
a	O
hexadec-1-enyl	B
group	I
in	O
the	O
sn	O
-1	O
position	O
and	O
an	O
approximately	O
equimolar	O
mixture	O
of	O
octadecenoate	B
and	O
octadecadienoate	B
esterified	O
to	O
the	O
sn	B
-2	I
hydroxyl	I
.	O

Plasmalogens	B
are	O
a	O
unique	O
class	O
of	O
glycerophospholipids	B
with	O
an	O
alk-1-enyl	B
ether	I
substituent	I
on	O
the	O
sn	B
-1	I
position	I
of	I
glycerol	I
[	O
25	O
]	O
.	O

The	O
molecular	O
geometry	O
of	O
the	O
alk-1-enyl	B
ether	I
linkage	I
is	O
significantly	O
different	O
to	O
that	O
found	O
in	O
diacyl	B
phospholipids	I
,	O
resulting	O
in	O
altered	O
packing	O
within	O
the	O
lipid	B
bilayer	O
[	O
26	O
]	O
,	O
and	O
modifying	O
the	O
phase	O
transition	O
behaviour	O
of	O
the	O
membrane	O
[	O
27	O
]	O
.	O

In	O
activated	O
neutrophils	O
plasmenylethanolamine	B
catabolism	O
can	O
result	O
in	O
enhanced	O
production	O
of	O
platelet	B
activating	I
factor	I
(	O
PAF	B
)	O
via	O
a	O
novel	O
remodelling	O
pathway	O
[	O
28	O
]	O
.	O

Plasmalogen	B
catabolism	O
in	O
activated	O
neutrophils	O
has	O
also	O
been	O
shown	O
to	O
lead	O
to	O
the	O
production	O
of	O
a	O
plasmenyl	B
analogue	I
of	I
PAF	I
[	O
29	O
]	O
,	O
though	O
this	O
compound	O
is	O
apparently	O
about	O
five	O
times	O
less	O
active	O
than	O
PAF	B
[	O
30	O
]	O
,	O
and	O
its	O
role	O
remains	O
to	O
be	O
determined	O
.	O

Plasmalogens	B
have	O
previously	O
been	O
reported	O
in	O
rumen	O
protozoa	O
[	O
31–33	O
]	O
,	O
and	O
in	O
the	O
trypanosomatids	O
Blastocrithidia	O
culicis	O
[	O
34	O
]	O
,	O
Leishmania	O
[	O
35	O
]	O
,	O
and	O
Trypanosoma	O
brucei	O
[	O
36	O
]	O
.	O

In	O
the	O
latter	O
organism	O
≈60	O
%	O
of	O
the	O
glycerophosphoethanolamine	B
fraction	O
belonged	O
to	O
the	O
alk-1-enyl-2-acyl	B
class	O
,	O
of	O
which	O
,	O
in	O
bloodstream	O
forms	O
,	O
plasmenylethanolamine	B
comprised	O
a	O
single	O
molecular	O
species	O
,	O
which	O
was	O
substituted	O
with	O
octadecanoic	B
and	O
octadecadienoic	B
acids	I
in	O
the	O
sn	O
-1	O
and	O
sn	O
-2	O
positions	O
,	O
respectively	O
[	O
36	O
]	O
.	O

Most	O
reports	O
of	O
the	O
phospholipid	B
composition	O
of	O
T.	O
cruzi	O
have	O
made	O
no	O
mention	O
of	O
plasmalogens	B
[	O
37–40	O
]	O
,	O
though	O
an	O
early	O
paper	O
provided	O
indirect	O
evidence	O
for	O
the	O
presence	O
of	O
plasmenylethanolamine	B
in	O
the	O
Tulahuen	O
strain	O
[	O
41	O
]	O
.	O

The	O
present	O
study	O
is	O
therefore	O
the	O
first	O
instance	O
of	O
detailed	O
chemical	O
characterization	O
of	O
plasmalogens	B
from	O
this	O
organism	O
.	O

No	O
convincing	O
function	O
has	O
yet	O
been	O
assigned	O
to	O
the	O
plasmalogens	B
of	O
protozoa	O
.	O

In	O
contrast	O
to	O
mammalian	O
plasmalogens	B
,	O
those	O
of	O
protozoa	O
are	O
not	O
usually	O
enriched	O
in	O
arachidonate	B
,	O
and	O
thus	O
their	O
hydrolysis	O
may	O
not	O
result	O
in	O
the	O
release	O
of	O
biologically	O
active	O
eicosanoids	B
.	O

It	O
may	O
however	O
be	O
significant	O
that	O
plasmenylethanolamine	B
can	O
enhance	O
PAF	B
production	O
,	O
since	O
it	O
has	O
been	O
shown	O
that	O
PAF	B
encourages	O
cell	O
differentiation	O
in	O
T.	O
cruzi	O
strain	O
Dm28c	O
[	O
42	O
]	O
and	O
in	O
Herpetomonas	O
muscarum	O
[	O
43	O
]	O
,	O
and	O
that	O
both	O
parasites	O
have	O
specific	O
receptors	O
for	O
PAF	B
.	O

It	O
is	O
possible	O
that	O
parasite	O
plasmalogens	B
have	O
a	O
protective	O
function	O
,	O
since	O
they	O
have	O
been	O
shown	O
to	O
be	O
effective	O
scavengers	O
of	O
reactive	B
oxygen	I
species	I
[	O
44,45	O
]	O
and	O
might	O
thus	O
prevent	O
killing	O
by	O
the	O
oxidative	O
burst	O
.	O

In	O
the	O
present	O
study	O
we	O
show	O
that	O
the	O
major	O
plasmenylethanolamine	B
of	O
the	O
Dm28c	O
clone	O
of	O
T.	O
cruzi	O
is	O
recognised	O
by	O
antibodies	O
in	O
human	O
serum	O
which	O
are	O
present	O
at	O
elevated	O
levels	O
in	O
patients	O
with	O
chronic	O
Chagas	O
'	O
disease	O
.	O

Anti	O
-	O
phospholipid	B
antibodies	O
have	O
been	O
associated	O
with	O
infection	O
[	O
44	O
]	O
,	O
inflammation	O
,	O
immunological	O
diseases	O
,	O
and	O
conditions	O
such	O
as	O
pregnancy	O
and	O
ageing	O
[	O
45	O
]	O
.	O

In	O
general	O
antibodies	O
are	O
directed	O
against	O
cardiolipin	B
,	O
or	O
more	O
rarely	O
phosphatidylcholine	B
[	O
46	O
]	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
detection	O
of	O
anti	O
-	O
plasmenylethanolamine	B
antibodies	O
.	O

Most	O
morbidity	O
and	O
mortality	O
in	O
Chagas	O
'	O
disease	O
is	O
a	O
consequence	O
of	O
the	O
cardiac	O
myopathy	O
associated	O
with	O
the	O
chronic	O
phase	O
of	O
the	O
disease	O
,	O
which	O
affects	O
20–30	O
%	O
of	O
seropositive	O
patients	O
years	O
after	O
their	O
initial	O
infection	O
.	O

It	O
has	O
been	O
suggested	O
the	O
mechanism	O
of	O
cardiac	O
damage	O
is	O
autoimmune	O
in	O
nature	O
,	O
as	O
is	O
the	O
associated	O
destruction	O
of	O
the	O
autonomic	O
nerve	O
supply	O
to	O
the	O
affected	O
organs	O
.	O

Cross	O
reactive	O
antibodies	O
have	O
been	O
described	O
between	O
T.	O
cruzi	O
epitopes	B
and	O
a	O
43	O
kDa	O
muscle	O
protein	O
[	O
47	O
]	O
,	O
laminin	O
[	O
48	O
]	O
,	O
tubulin	O
[	O
49	O
]	O
,	O
muscle	O
sarcoplasmatic	O
reticulum	O
antigen	B
[	O
50	O
]	O
,	O
ribosomal	O
proteins	O
[	O
51	O
]	O
,	O
antigens	B
of	O
nervous	O
tissues	O
[	O
52	O
]	O
cholesterol	B
sulphate	I
[	O
53	O
]	O
,	O
cardiac	O
glycosphingolipids	B
[	O
54	O
]	O
,	O
and	O
the	O
AAALDK	B
motif	O
of	O
cardiac	O
myosin	O
heavy	O
chain	O
[	O
55	O
]	O
.	O

Many	O
of	O
these	O
are	O
of	O
dubious	O
clinical	O
relevance	O
,	O
because	O
of	O
poor	O
correlation	O
with	O
the	O
different	O
forms	O
of	O
chronic	O
disease	O
,	O
lack	O
of	O
specificity	O
of	O
self	O
-	O
antigen	B
to	O
the	O
target	O
organs	O
,	O
or	O
because	O
the	O
cross	O
reactive	O
antigens	B
are	O
also	O
present	O
in	O
sera	O
from	O
uninfected	O
individuals	O
.	O

The	O
observation	O
that	O
the	O
plasmenylethanolamine	B
characterized	O
in	O
the	O
present	O
study	O
is	O
recognised	O
by	O
chagasic	O
serum	O
is	O
intriguing	O
,	O
because	O
plasmalogens	B
are	O
relatively	O
minor	O
constituents	O
of	O
most	O
mammalian	O
cell	O
types	O
but	O
are	O
abundant	O
in	O
the	O
cardiac	O
and	O
neuronal	O
tissues	O
that	O
are	O
the	O
main	O
sites	O
of	O
damage	O
in	O
chronic	O
Chagas	O
'	O
disease	O
.	O

In	O
most	O
mammalian	O
species	O
heart	O
muscle	O
is	O
markedly	O
enriched	O
in	O
plasmalogens	B
,	O
(	O
over	O
30	O
%	O
of	O
total	O
phospholipid	B
in	O
ox	O
,	O
rabbit	O
,	O
dog	O
,	O
and	O
humans	O
[	O
24	O
]	O
)	O
.	O

In	O
human	O
heart	O
the	O
most	O
abundant	O
plasmalogen	B
species	O
are	O
plasmenylethanolamines	B
with	O
predominantly	O
hexadec-1-enyl	B
substituents	O
in	O
the	O
sn	O
-1	O
position	O
and	O
a	O
mixture	O
of	O
octadecenoyl	B
,	O
eicosenoyl	B
,	O
and	O
arachidonoyl	B
acyl	B
groups	I
on	O
sn	O
-2	O
.	O

The	O
presence	O
of	O
these	O
epitopes	B
shared	O
by	O
parasite	O
and	O
host	O
may	O
thus	O
provide	O
an	O
additional	O
route	O
for	O
the	O
development	O
of	O
the	O
characteristic	O
myopathy	O
of	O
chronic	O
Chagas	O
'	O
disease	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Conselho	O
Nacional	O
de	O
Desenvolvimento	O
Cientı́fico	O
e	O
Tecnológico	O
(	O
CNPq	O
)	O
,	O
Financiadora	O
de	O
Estudos	O
e	O
Projetos	O
(	O
FINEP	O
)	O
,	O
Conselho	O
de	O
Ensino	O
e	O
Pesquisa	O
da	O
UFRJ	O
(	O
CEPG	O
)	O
,	O
and	O
Programa	O
de	O
Núcleos	O
de	O
Excelência	O
(	O
PRONEX	O
)	O
.	O

We	O
thank	O
Dr	O
Barbara	O
Mulloy	O
(	O
National	O
Institute	O
for	O
Biological	O
Standards	O
and	O
Control	O
,	O
UK	O
)	O
for	O
the	O
NMR	O
spectroscopy	O
and	O
Maria	O
de	O
Fátima	O
Ferreira	O
Soares	O
for	O
technical	O
assistance	O
.	O

The	O
radioligand	O
[	B
3	I
H	I
]	I
{	I
1-	I
[	I
2-	I
(	I
diphenylmethoxy	I
)	I
ethyl	I
]	I
-4-	I
(	I
3-phenylpropyl	I
)	I
piperazine	I
dihydrochloride	I
}	I
(	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
)	O
labels	O
the	O
neuronal	O
dopamine	B
uptake	O
site	O
and	O
functions	O
as	O
a	O
marker	O
for	O
dopaminergic	O
neuron	O
terminals	O
in	O
brain	O
.	O

[	B
3	I
H	I
]	I
GBR	I
12935	I
also	O
recognizes	O
a	O
`	O
piperazine	O
acceptor	O
site	O
'	O
in	O
brain	O
.	O

The	O
designation	O
implies	O
that	O
this	O
site	O
is	O
recognized	O
by	O
piperazine	B
derivatives	I
such	O
as	O
flupenthixol	B
and	O
piflutixol	B
(	O
Andersen	O
,	O
1987	O
)	O
.	O

Also	O
in	O
human	O
platelet	O
membranes	O
,	O
the	O
binding	O
of	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
has	O
yielded	O
characteristics	O
indicating	O
that	O
part	O
of	O
the	O
binding	O
is	O
to	O
a	O
piperazine	O
acceptor	O
site	O
(	O
Gordon	O
et	O
al.	O
,	O
1994	O
)	O
.	O

The	O
molecular	O
identity	O
and	O
functional	O
significance	O
of	O
the	O
piperazine	O
acceptor	O
site	O
have	O
not	O
yet	O
been	O
established	O
.	O

Some	O
data	O
indicate	O
that	O
there	O
might	O
be	O
an	O
association	O
with	O
the	O
cytochrome	O
P	O
-450	O
(	O
CYP450	O
)	O
system	O
;	O
in	O
canine	O
brain	O
the	O
piperazine	O
acceptor	O
site	O
has	O
been	O
identified	O
as	O
CYP4502D1	O
,	O
which	O
corresponds	O
to	O
human	O
CYP4502D6	O
(	O
Niznik	O
et	O
al.	O
,	O
1990	O
;	O
Tyndale	O
et	O
al.	O
,	O
1991	O
)	O
,	O
and	O
in	O
human	O
brain	O
an	O
association	O
between	O
the	O
piperazine	O
acceptor	O
site	O
and	O
CYP4502D6	O
has	O
been	O
demonstrated	O
(	O
Allard	O
et	O
al.	O
,	O
1994	O
)	O
.	O

In	O
human	O
platelets	O
,	O
the	O
pharmacological	O
characteristics	O
of	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
were	O
recently	O
investigated	O
.	O

Part	O
of	O
the	O
binding	O
was	O
inhibited	O
by	O
compounds	O
known	O
as	O
inhibitors	O
of	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
to	O
CYP4502D6	O
in	O
liver	O
and	O
brain	O
,	O
suggesting	O
that	O
this	O
binding	O
fraction	O
in	O
platelets	O
is	O
associated	O
with	O
CYP4502D6	O
(	O
Norlén	O
and	O
Allard	O
,	O
1997	O
)	O
.	O

In	O
humans	O
,	O
CYP4502D6	O
(	O
debrisoquine-4-hydroxylase	O
)	O
has	O
been	O
demonstrated	O
mainly	O
in	O
liver	O
.	O

The	O
enzyme	O
is	O
responsible	O
for	O
the	O
metabolism	O
of	O
more	O
than	O
40	O
different	O
drugs	B
,	O
such	O
as	O
antidepressants	O
,	O
neuroleptics	O
and	O
antiarrhythmics	O
.	O

The	O
CYP4502D6	O
gene	O
on	O
human	O
chromosome	O
22	O
is	O
highly	O
polymorphic	O
.	O

At	O
least	O
20	O
different	O
alleles	O
have	O
been	O
described	O
(	O
Stüven	O
et	O
al.	O
,	O
1996	O
)	O
,	O
some	O
of	O
them	O
harbouring	O
mutations	O
leading	O
to	O
the	O
poor	O
metabolizer	O
phenotype	O
.	O

This	O
autosomal	O
recessive	O
metabolic	O
deficiency	O
affects	O
5–10	O
%	O
of	O
Caucasians	O
and	O
may	O
lead	O
to	O
adverse	O
reactions	O
upon	O
administration	O
of	O
drugs	B
in	O
standard	O
doses	O
.	O

According	O
to	O
our	O
previous	O
study	O
(	O
Norlén	O
and	O
Allard	O
,	O
1997	O
)	O
,	O
part	O
of	O
the	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
in	O
platelets	O
might	O
be	O
to	O
CYP4502D6	O
.	O

Therefore	O
,	O
possible	O
differences	O
in	O
binding	O
characteristics	O
in	O
platelets	O
from	O
CYP4502D6	O
poor	O
and	O
extensive	O
metabolizers	O
respectively	O
,	O
were	O
investigated	O
in	O
the	O
present	O
study	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Subjects	O
Thirty	O
-	O
four	O
subjects	O
took	O
part	O
in	O
the	O
investigation	O
,	O
which	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
at	O
the	O
University	O
of	O
Umeå	O
.	O

All	O
subjects	O
were	O
healthy	O
,	O
as	O
assessed	O
by	O
medical	O
history	O
,	O
physical	O
examination	O
and	O
routine	O
blood	O
chemistry	O
tests	O
.	O

They	O
were	O
recruited	O
from	O
a	O
population	O
of	O
more	O
than	O
500	O
volunteers	O
phenotyped	O
with	O
respect	O
to	O
the	O
CYP4502D6	O
polymorphism	O
by	O
means	O
of	O
the	O
test	O
drug	B
dextromethorphan	B
.	O

The	O
34	O
subjects	O
included	O
16	O
(	O
11	O
men	O
and	O
5	O
women	O
)	O
poor	O
metabolizers	O
of	O
dextromethorphan	B
and	O
18	O
(	O
10	O
men	O
and	O
8	O
women	O
)	O
extensive	O
metabolizers	O
of	O
dextromethorphan	B
.	O

The	O
mean	O
age	O
of	O
the	O
extensive	O
metabolizer	O
group	O
was	O
38±2	O
years	O
(	O
mean±S.E.M.	O
)	O
(	O
range	O
23–51	O
years	O
)	O
and	O
of	O
the	O
poor	O
metabolizer	O
group	O
29±2	O
years	O
(	O
range	O
23–43	O
years	O
)	O
(	O
P	O
=	O
0.006	O
)	O
.	O

When	O
dividing	O
the	O
subjects	O
with	O
respect	O
to	O
gender	O
,	O
the	O
mean	O
age	O
of	O
the	O
men	O
was	O
30±2	O
years	O
(	O
mean±S.E.M.	O
)	O
(	O
range	O
23–50	O
years	O
)	O
and	O
of	O
the	O
women	O
40±3	O
years	O
(	O
range	O
23–51	O
years	O
)	O
(	O
P	O
=	O
0.002	O
)	O
.	O

The	O
body	O
weight	O
was	O
70±3	O
kg	O
(	O
mean±S.E.M.	O
)	O
in	O
the	O
extensive	O
metabolizer	O
group	O
and	O
71±3	O
kg	O
in	O
the	O
poor	O
metabolizer	O
group	O
.	O

As	O
expected	O
,	O
the	O
mean	O
body	O
weight	O
was	O
significantly	O
higher	O
in	O
males	O
than	O
in	O
females	O
(	O
77±2	O
and	O
60±2	O
kg	O
,	O
respectively	O
)	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

All	O
individuals	O
had	O
been	O
entirely	O
drug	O
-	O
free	O
for	O
at	O
least	O
2	O
weeks	O
.	O

2.2	O
CYP4502D6	O
phenotyping	O
After	O
intake	O
of	O
50	O
mg	O
dextromethorphan	B
hydrobromide	I
(	O
Tussidyl	O
mixture	O
,	O
2	O
mg	O
/	O
ml	O
,	O
TIKA	O
,	O
Lund	O
,	O
Sweden	O
)	O
,	O
urine	O
was	O
collected	O
for	O
10	O
h.	O
Dextromethorphan	B
and	O
its	O
O	B
-demethylated	I
metabolite	I
dextrorphan	B
were	O
analyzed	O
by	O
a	O
capillary	O
gas	O
chromatography	O
method	O
published	O
earlier	O
(	O
Spigset	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Dextromethorphan	B
/	O
dextrorphan	B
ratios	O
>	O
0.90	O
defined	O
the	O
CYP4502D6	O
poor	O
metabolizers	O
,	O
whereas	O
ratios	O
<	O
0.90	O
defined	O
the	O
CYP4502D6	O
extensive	O
metabolizers	O
.	O

The	O
poor	O
metabolizers	O
had	O
metabolic	O
ratios	O
between	O
0.92	O
and	O
77.11	O
,	O
whereas	O
the	O
extensive	O
metabolizers	O
had	O
metabolic	O
ratios	O
between	O
0.02	O
and	O
0.86	O
.	O

2.3	O
Tissue	O
preparation	O
A	O
total	O
of	O
75	O
ml	O
whole	O
blood	O
was	O
collected	O
from	O
each	O
individual	O
.	O

The	O
samples	O
were	O
centrifuged	O
at	O
180	O
×	O
g	O
for	O
15	O
min	O
at	O
20	O
°	O
C	O
.	O

Assay	B
buffer	I
(	O
50	O
mM	O
Tris·HCl	B
,	O
120	O
mM	O
NaCl	B
,	O
5	O
mM	O
KCl	B
,	O
pH	O
7.4	O
)	O
was	O
then	O
added	O
1:1	O
to	O
the	O
supernatant	O
,	O
which	O
was	O
then	O
centrifuged	O
at	O
3000	O
×	O
g	O
for	O
20	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
pellets	O
were	O
washed	O
with	O
20	O
ml	O
of	O
assay	B
buffer	I
and	O
then	O
recentrifuged	O
at	O
3000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
pellets	O
were	O
homogenized	O
with	O
10	O
+	O
10	O
ml	O
of	O
assay	B
buffer	I
using	O
a	O
Kinematica	O
Polytron	O
homogenizer	O
(	O
Luzern	O
,	O
Switzerland	O
)	O
,	O
at	O
a	O
setting	O
of	O
6	O
,	O
for	O
7	O
s.	O
The	O
pellets	O
were	O
centrifuged	O
at	O
15	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
and	O
frozen	O
at	O
−70	O
°	O
C	O
until	O
assay	O
.	O

On	O
the	O
day	O
of	O
experiment	O
,	O
the	O
tissue	O
was	O
washed	O
in	O
10	O
+	O
10	O
ml	O
assay	B
buffer	I
and	O
centrifuged	O
at	O
18	O
000	O
×	O
g	O
for	O
10	O
min	O
.	O

The	O
pellets	O
were	O
finally	O
homogenized	O
at	O
a	O
setting	O
of	O
4	O
,	O
for	O
10	O
s	O
,	O
and	O
then	O
resuspended	O
in	O
the	O
assay	B
buffer	I
to	O
a	O
mean	O
final	O
protein	O
concentration	O
of	O
470	O
μg	O
protein	O
/	O
ml	O
(	O
range	O
270–710	O
μg	O
protein	O
/	O
ml	O
)	O
.	O

2.4	O
Compounds	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
(	O
40–45.7	O
Ci	O
/	O
mmol	O
)	O
was	O
purchased	O
from	O
New	O
England	O
Nuclear	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
.	O

cis	B
-	I
(	I
Z	I
)	I
-Flupenthixol	I
was	O
obtained	O
as	O
a	O
gift	O
from	O
H.	O
Lundbeck	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O

2.5	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
The	O
binding	O
of	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
was	O
carried	O
out	O
for	O
60	O
min	O
at	O
25	O
°	O
C	O
in	O
a	O
total	O
volume	O
of	O
2.0	O
ml	O
.	O

The	O
incubation	O
volume	O
contained	O
250	O
μl	O
of	O
tissue	O
homogenate	O
,	O
250	O
μl	O
of	O
radioligand	B
,	O
250	O
μl	O
of	O
displacing	O
drug	B
or	O
buffer	B
and	O
1250	O
μl	O
assay	B
buffer	I
(	O
50	O
mM	O
Tris·HCl	B
,	O
120	O
mM	O
NaCl	B
,	O
0.01	O
%	O
bovine	O
serum	O
albumin	O
,	O
pH	O
7.4	O
)	O
.	O

The	O
concentrations	O
of	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
ranged	O
from	O
0.25	O
to	O
30	O
nM.	O
The	O
experiments	O
were	O
carried	O
out	O
in	O
duplicate	O
.	O

After	O
the	O
addition	O
of	O
6	O
ml	O
of	O
ice	O
-	O
cold	O
assay	B
buffer	I
,	O
the	O
homogenates	O
were	O
filtered	O
through	O
Whatman	O
GF	O
/	O
C	O
filters	O
using	O
a	O
24-channel	O
cell	O
harvester	O
(	O
Brandel	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
Finally	O
,	O
the	O
filters	O
were	O
washed	O
with	O
three	O
6-ml	O
rinses	O
of	O
the	O
buffer	B
and	O
the	O
radioactivity	O
determined	O
by	O
liquid	O
scintillation	O
spectroscopy	O
.	O

Specific	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
to	O
the	O
piperazine	O
acceptor	O
site	O
was	O
defined	O
as	O
the	O
difference	O
between	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
in	O
the	O
absence	O
and	O
presence	O
of	O
0.3	O
μM	O
cis	B
-flupenthixol	I
(	O
Norlén	O
and	O
Allard	O
,	O
1997	O
)	O
.	O

Protein	O
determination	O
was	O
performed	O
according	O
to	O
Markwell	O
et	O
al.	O
(	O
1978	O
)	O
.	O

2.6	O
Data	O
analysis	O
and	O
statistics	O
B	O
max	O
and	O
K	O
d	O
values	O
were	O
determined	O
by	O
least	O
squares	O
linear	O
regression	O
analysis	O
of	O
Scatchard	O
plots	O
derived	O
from	O
the	O
saturation	O
experiments	O
.	O

Student	O
's	O
t	O
-test	O
and	O
covariate	O
analysis	O
were	O
used	O
for	O
comparisons	O
between	O
groups	O
.	O

The	O
criterion	O
for	O
statistical	O
significance	O
was	O
P	O
<	O
0.05	O
.	O

3	O
Results	O
B	O
max	O
was	O
680±74	O
fmol	O
/	O
mg	O
protein	O
(	O
mean±S.E.M.	O
)	O
in	O
the	O
poor	O
metabolizer	O
group	O
and	O
648±78	O
fmol	O
/	O
mg	O
protein	O
in	O
the	O
extensive	O
metabolizer	O
group	O
(	O
P	O
=	O
0.772	O
)	O
.	O

K	O
d	O
was	O
5.77±0.81	O
nM	O
in	O
the	O
poor	O
metabolizer	O
group	O
and	O
4.29±0.52	O
nM	O
in	O
the	O
extensive	O
metabolizer	O
group	O
(	O
Fig.	O
1	O
A	O
)	O
,	O
indicating	O
a	O
lower	O
binding	O
affinity	O
in	O
the	O
poor	O
metabolizer	O
group	O
.	O

The	O
difference	O
was	O
,	O
however	O
,	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.126	O
)	O
.	O

Representative	O
Scatchard	O
plots	O
,	O
one	O
from	O
each	O
group	O
,	O
are	O
depicted	O
in	O
Fig.	O
2	O
.	O

There	O
were	O
no	O
correlations	O
between	O
age	O
and	O
the	O
B	O
max	O
or	O
K	O
d	O
values	O
(	O
r	O
=	O
−0.19	O
and	O
−0.28	O
,	O
respectively	O
)	O
.	O

Neither	O
were	O
there	O
any	O
correlations	O
between	O
body	O
weight	O
and	O
the	O
B	O
max	O
or	O
K	O
d	O
values	O
(	O
r	O
=	O
0.25	O
and	O
0.31	O
,	O
respectively	O
)	O
.	O

When	O
analyzing	O
possible	O
gender	O
differences	O
in	O
binding	O
parameters	O
,	O
no	O
significant	O
differences	O
in	O
density	O
of	O
binding	O
sites	O
were	O
found	O
;	O
in	O
male	O
subjects	O
(	O
poor	O
metabolizers	O
plus	O
extensive	O
metabolizers	O
)	O
,	O
B	O
max	O
was	O
725±78	O
fmol	O
/	O
mg	O
protein	O
and	O
in	O
female	O
subjects	O
(	O
poor	O
metabolizers	O
plus	O
extensive	O
metabolizers	O
)	O
,	O
B	O
max	O
was	O
564±49	O
fmol	O
/	O
mg	O
protein	O
(	O
P	O
=	O
0.144	O
)	O
.	O

In	O
contrast	O
,	O
significant	O
differences	O
in	O
binding	O
affinity	O
were	O
found	O
;	O
K	O
d	O
for	O
male	O
subjects	O
was	O
5.73±0.66	O
nM	O
,	O
and	O
for	O
female	O
subjects	O
3.78±0.56	O
nM	O
(	O
P	O
=	O
0.048	O
)	O
(	O
Fig.	O
1	O
B	O
)	O
.	O

After	O
correction	O
for	O
gender	O
using	O
covariance	O
analysis	O
,	O
the	O
differences	O
in	O
K	O
d	O
between	O
the	O
poor	O
metabolizers	O
and	O
the	O
extensive	O
metabolizers	O
remained	O
grossly	O
unchanged	O
(	O
P	O
=	O
0.19	O
)	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
concentrations	O
of	O
tissue	O
protein	O
and	O
the	O
K	O
d	O
values	O
(	O
r	O
=	O
−0.28	O
)	O
.	O

4	O
Discussion	O
The	O
principal	O
finding	O
in	O
this	O
study	O
was	O
that	O
males	O
had	O
significantly	O
lower	O
binding	O
affinity	O
for	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
than	O
females	O
.	O

This	O
discrepancy	O
seems	O
not	O
to	O
be	O
related	O
to	O
differences	O
in	O
CYP4502D6	O
activity	O
since	O
the	O
metabolism	O
of	O
debrisoquine	B
is	O
not	O
affected	O
by	O
gender	O
(	O
Hietanen	O
et	O
al.	O
,	O
1991	O
;	O
Bock	O
et	O
al.	O
,	O
1994	O
)	O
.	O

The	O
observed	O
gender	O
difference	O
could	O
imply	O
that	O
the	O
binding	O
is	O
influenced	O
in	O
a	O
competitive	O
manner	O
by	O
hormonal	O
factors	O
not	O
yet	O
identified	O
,	O
or	O
that	O
the	O
properties	O
of	O
the	O
piperazine	O
acceptor	O
ligand	O
binding	O
sites	O
are	O
differently	O
developed	O
secondary	O
to	O
unknown	O
gender	O
-	O
related	O
factors	O
.	O

No	O
significant	O
differences	O
in	O
binding	O
parameters	O
were	O
obtained	O
between	O
the	O
poor	O
metabolizer	O
and	O
the	O
extensive	O
metabolizer	O
groups	O
,	O
although	O
higher	O
K	O
d	O
values	O
were	O
found	O
in	O
the	O
poor	O
metabolizer	O
group	O
,	O
a	O
tendency	O
that	O
persisted	O
after	O
correction	O
for	O
gender	O
.	O

Although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
,	O
some	O
possibilities	O
favouring	O
that	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
could	O
be	O
associated	O
with	O
CYP4502D6	O
can	O
be	O
stated	O
.	O

The	O
reduced	O
binding	O
affinity	O
in	O
poor	O
metabolizers	O
could	O
in	O
fact	O
indicate	O
impairments	O
in	O
enzymatic	O
function	O
among	O
the	O
poor	O
metabolizers	O
or	O
,	O
alternatively	O
,	O
that	O
CYP4502D6	O
is	O
not	O
completely	O
expressed	O
in	O
platelets	O
.	O

Further	O
possibilities	O
that	O
could	O
be	O
accounted	O
for	O
might	O
be	O
that	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binds	O
to	O
CYP450	O
isoenzymes	O
other	O
than	O
CYP4502D6	O
,	O
several	O
of	O
which	O
are	O
gender	O
-	O
specific	O
(	O
Fletcher	O
et	O
al.	O
,	O
1994	O
;	O
Gleiter	O
and	O
Gundert	O
-	O
Remy	O
,	O
1996	O
)	O
,	O
or	O
that	O
mutant	O
CYP4502D6	O
alleles	O
in	O
poor	O
metabolizers	O
might	O
produce	O
enzymes	O
not	O
metabolically	O
active	O
but	O
still	O
harbouring	O
piperazine	O
acceptor	O
sites	O
.	O

A	O
shortcoming	O
to	O
the	O
study	O
might	O
be	O
the	O
age	O
differences	O
with	O
respect	O
to	O
gender	O
and	O
metabolic	O
capacity	O
;	O
women	O
being	O
significantly	O
older	O
than	O
men	O
,	O
and	O
the	O
extensive	O
metabolizers	O
being	O
significantly	O
older	O
than	O
the	O
poor	O
metabolizers	O
.	O

Age	O
was	O
,	O
however	O
,	O
not	O
significantly	O
correlated	O
to	O
either	O
the	O
K	O
d	O
or	O
the	O
B	O
max	O
values	O
and	O
,	O
consequently	O
,	O
the	O
age	O
differences	O
appear	O
not	O
to	O
influence	O
the	O
binding	O
parameters	O
.	O

The	O
function	O
and	O
significance	O
of	O
the	O
piperazine	O
acceptor	O
site	O
are	O
incompletely	O
known	O
.	O

The	O
present	O
study	O
revealed	O
,	O
as	O
a	O
conclusion	O
,	O
that	O
there	O
was	O
a	O
significant	O
gender	O
difference	O
in	O
the	O
affinity	O
of	O
piperazine	O
acceptor	O
sites	O
for	O
the	O
binding	O
of	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
.	O

There	O
was	O
also	O
a	O
tendency	O
towards	O
reduced	O
affinity	O
for	O
[	B
3	I
H	I
]	I
GBR	I
12935	I
binding	O
to	O
piperazine	O
acceptor	O
sites	O
among	O
poor	O
metabolizers	O
compared	O
with	O
extensive	O
metabolizers	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

The	O
association	O
between	O
the	O
piperazine	O
acceptor	O
site	O
and	O
CYP4502D6	O
in	O
platelets	O
has	O
not	O
been	O
convincingly	O
demonstrated	O
.	O

If	O
such	O
a	O
connection	O
exists	O
,	O
it	O
should	O
be	O
taken	O
into	O
account	O
that	O
gender	O
-	O
related	O
factors	O
probably	O
exert	O
an	O
important	O
influence	O
upon	O
that	O
link	O
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Professor	O
Svante	O
B.	O
Ross	O
,	O
Astra	O
,	O
Södertälje	O
,	O
Sweden	O
for	O
generous	O
donation	O
of	O
radioligand	O
;	O
H.	O
Lundbeck	O
,	O
Copenhagen	O
,	O
Denmark	O
for	O
generous	O
donation	O
of	O
displacing	O
drug	O
;	O
Kerstin	O
Granberg	O
and	O
Margareta	O
Danielsson	O
for	O
excellent	O
technical	O
assistance	O
.	O

This	O
study	O
was	O
supported	O
by	O
the	O
County	O
Councils	O
of	O
Northern	O
Sweden	O
,	O
Gamla	O
Tjänarinnor	O
Foundation	O
,	O
the	O
Medical	O
Faculty	O
of	O
Umeå	O
University	O
and	O
the	O
Swedish	O
Society	O
for	O
Medicine	O
.	O

We	O
have	O
previously	O
identified	O
two	O
enzyme	O
activities	O
that	O
transfer	O
the	O
acetyl	B
group	I
from	O
platelet	B
-	I
activating	I
factor	I
(	O
PAF	B
)	O
in	O
a	O
CoA	B
-	O
independent	O
manner	O
to	O
lysoplasmalogen	B
or	O
sphingosine	B
in	O
HL-60	O
cells	O
,	O
endothelial	O
cells	O
,	O
and	O
a	O
variety	O
of	O
rat	O
tissues	O
.	O

These	O
were	O
termed	O
as	O
PAF	B
:	O
lysoplasmalogen	B
(	O
lysophospholipid	B
)	I
transacetylase	O
and	O
PAF	B
:	O
sphingosine	B
transacetylase	O
,	O
respectively	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
solubilized	O
and	O
purified	O
this	O
PAF	O
-	O
dependent	O
transacetylase	O
13,700-fold	O
from	O
rat	O
kidney	O
membranes	O
(	O
mitochondrial	O
plus	O
microsomal	O
membranes	O
)	O
based	O
on	O
the	O
PAF	B
:	O
lysoplasmalogen	B
transacetylase	O
activity	O
.	O

The	O
mitochondria	O
and	O
microsomes	O
were	O
prepared	O
and	O
washed	O
three	O
times	O
,	O
then	O
solubilized	O
with	O
0.04	O
%	O
Tween	B
20	I
at	O
a	O
detergent	O
/	O
protein	O
(	O
w	O
/	O
w	O
)	O
ratio	O
of	O
0.1	O
.	O

The	O
solubilized	O
fractions	O
from	O
mitochondria	O
and	O
microsomes	O
were	O
combined	O
and	O
subjected	O
to	O
sequential	O
column	O
chromatographies	O
on	O
DEAE	B
-	O
Sepharose	B
,	O
hydroxyapatite	B
,	O
phenyl	B
-	I
Sepharose	I
,	O
and	O
chromatofocusing	O
.	O

The	O
enzyme	O
was	O
further	O
purified	O
by	O
native	O
-	B
polyacrylamide	I
gel	O
electrophoresis	O
(	O
PAGE	O
)	O
and	O
affinity	O
gel	O
matrix	O
in	O
which	O
the	O
competitive	O
inhibitor	O
of	O
the	O
enzyme	O
,	O
1-O	B
-	I
hexadecyl-2-N	I
-	I
methylcarbamyl	I
-	I
sn	I
-	I
glycero-3-phosphoethanolamine	I
was	O
covalently	O
attached	O
to	O
the	O
CH	O
-	O
Sepharose	B
.	O

On	O
SDS	O
-	O
PAGE	O
,	O
the	O
purified	O
enzyme	O
showed	O
a	O
single	O
homogeneous	O
band	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
40	O
kDa	O
.	O

The	O
purified	O
enzyme	O
catalyzed	O
transacetylation	O
of	O
the	O
acetyl	B
group	I
not	O
only	O
from	O
PAF	B
to	O
lysoplasmalogen	B
forming	O
plasmalogen	B
analogs	O
of	O
PAF	B
,	O
but	O
also	O
to	O
sphingosine	B
producing	O
N	B
-	I
acetylsphingosine	I
(	O
C2-ceramide	B
)	O
.	O

In	O
addition	O
,	O
this	O
enzyme	O
acted	O
as	O
a	O
PAF	O
-	O
acetylhydrolase	O
in	O
the	O
absence	O
of	O
lipid	B
acceptor	O
molecules	O
.	O

These	O
results	O
suggest	O
that	O
PAF	O
-	O
dependent	O
transacetylase	O
is	O
an	O
enzyme	O
that	O
modifies	O
the	O
cellular	O
functions	O
of	O
PAF	O
through	O
generation	O
of	O
other	O
diverse	O
lipid	B
mediators	O
.	O

It	O
has	O
been	O
proposed	O
that	O
cells	O
sense	O
hypoxia	O
by	O
a	O
heme	B
protein	O
,	O
which	O
transmits	O
a	O
signal	O
that	O
activates	O
the	O
heterodimeric	O
transcription	O
factor	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF-1	O
)	O
,	O
thereby	O
inducing	O
a	O
number	O
of	O
physiologically	O
relevant	O
genes	O
such	O
as	O
erythropoietin	O
(	O
Epo	B
)	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
by	O
which	O
two	O
heme	B
-	O
binding	O
ligands	O
,	O
carbon	B
monoxide	I
and	O
nitric	B
oxide	I
,	O
affect	O
oxygen	B
sensing	O
and	O
signaling	O
.	O

Two	O
concentrations	O
of	O
CO	B
(	O
10	O
and	O
80	O
%	O
)	O
suppressed	O
the	O
activation	O
of	O
HIF-1	O
and	O
induction	O
of	O
Epo	O
mRNA	O
by	O
hypoxia	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
CO	B
had	O
no	O
effect	O
on	O
the	O
induction	O
of	O
HIF-1	O
activity	O
and	O
Epo	O
expression	O
by	O
either	O
cobalt	B
chloride	I
or	O
the	O
iron	O
chelator	O
desferrioxamine	B
.	O

The	O
affinity	O
of	O
CO	B
for	O
the	O
putative	O
sensor	O
was	O
much	O
lower	O
than	O
that	O
of	O
oxygen	B
(	O
Haldane	O
coefficient	O
,	O
approximately	O
0.5	O
)	O
.	O

Parallel	O
experiments	O
were	O
done	O
with	O
100	O
microM	O
sodium	B
nitroprusside	I
,	O
a	O
nitric	O
oxide	O
donor	O
.	O

Both	O
NO	B
and	O
CO	B
inhibited	O
HIF-1	O
DNA	O
binding	O
by	O
abrogating	O
hypoxia	O
-	O
induced	O
accumulation	O
of	O
HIF-1alpha	O
protein	O
.	O

Moreover	O
,	O
both	O
NO	B
and	O
CO	B
specifically	O
targeted	O
the	O
internal	O
oxygen	B
-	O
dependent	O
degradation	O
domain	O
of	O
HIF-1alpha	O
,	O
and	O
also	O
repressed	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
of	O
HIF-1alpha	O
.	O

Thus	O
,	O
NO	B
and	O
CO	B
act	O
proximally	O
,	O
presumably	O
as	O
heme	O
ligands	O
binding	O
to	O
the	O
oxygen	B
sensor	O
,	O
whereas	O
desferrioxamine	B
and	O
perhaps	O
cobalt	B
appear	O
to	O
act	O
at	O
a	O
site	O
downstream	O
.	O

Binding	O
of	O
fluorescent	B
fatty	I
acids	I
to	O
bovine	O
liver	O
non	O
-	O
specific	O
lipid	O
-	O
transfer	O
protein	O
(	O
nsL	O
-	O
TP	O
)	O
was	O
assessed	O
by	O
measuring	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
between	O
the	O
single	O
tryptophan	B
residue	O
of	O
nsL	O
-	O
TP	O
and	O
the	O
fluorophore	B
.	O

Upon	O
addition	O
of	O
pyrene	B
dodecanoic	I
acid	I
(	O
Pyr	B
-	I
C12	I
)	O
and	O
cis	B
-	I
parinaric	I
acid	I
to	O
nsL	O
-	O
TP	O
,	O
FRET	O
was	O
observed	O
indicating	O
that	O
these	O
fatty	B
acids	I
were	O
accommodated	O
in	O
the	O
lipid	O
binding	O
site	O
closely	O
positioned	O
to	O
the	O
tryptophan	B
residue	O
.	O

Substantial	O
binding	O
was	O
observed	O
only	O
when	O
these	O
fatty	B
acids	I
were	O
presented	O
in	O
the	O
monomeric	O
form	O
complexed	O
to	O
beta	B
-	I
cyclodextrin	I
.	O

As	O
shown	O
by	O
time	O
-	O
resolved	O
fluorescence	O
measurements	O
,	O
translocation	O
of	O
Pyr	B
-	I
C12	I
from	O
the	O
Pyr	B
-	I
C12-beta	I
-	B
cyclodextrin	I
complex	I
to	O
nsL	O
-	O
TP	O
changed	O
dramatically	O
the	O
direct	O
molecular	O
environment	O
of	O
the	O
pyrene	B
moiety	O
:	O
i.e.	O
the	O
fluorescence	O
lifetime	O
of	O
the	O
directly	O
excited	O
pyrene	B
increased	O
at	O
least	O
by	O
25	O
%	O
and	O
a	O
distinct	O
rotational	O
correlation	O
time	O
of	O
7	O
ns	O
was	O
observed	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
affinity	O
of	O
nsL	O
-	O
TP	O
for	O
intermediates	O
of	O
the	O
beta	O
-	O
oxidation	O
pathway	O
,	O
a	O
binding	O
assay	O
was	O
developed	O
based	O
on	O
the	O
ability	O
of	O
fatty	B
acyl	I
derivatives	I
to	O
displace	O
Pyr	B
-	I
C12	I
from	O
the	O
lipid	O
binding	O
site	O
as	O
reflected	O
by	O
the	O
reduction	O
of	O
FRET	O
.	O

Hexadecanoyl	B
-	I
CoA	I
and	O
2-hexadecenoyl	B
-	I
CoA	I
were	O
found	O
to	O
bind	O
readily	O
to	O
nsL	O
-	O
TP	O
,	O
whereas	O
3-hydroxyhexadecanoyl	B
-	I
CoA	I
and	O
3-ketohexadecanoyl	B
-	I
CoA	I
bound	O
poorly	O
.	O

The	O
highest	O
affinities	O
were	O
observed	O
for	O
the	O
very	B
-	I
long	I
-	I
chain	I
fatty	I
acyl	I
-	I
CoA	I
esters	I
(	O
24:0-CoA	B
,	O
26:0-CoA	B
)	O
and	O
their	O
enoyl	B
derivatives	I
(	O
24:1-CoA	B
,	O
26:1-CoA	B
)	O
.	O

Binding	O
of	O
non	O
-	O
esterified	O
hexadecanoic	B
acid	I
and	O
tetracosanoic	B
acid	I
(	O
24:0	B
)	O
was	O
negligible	O
.	O

Isatin	B
is	O
an	O
endogenous	O
indole	B
and	O
an	O
inhibitor	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
receptors	O
coupled	O
with	O
particulate	O
guanylyl	O
cyclase	O
(	O
GC	O
)	O
.	O

In	O
this	O
study	O
,	O
several	O
isatin	B
analogues	I
were	O
tested	O
as	O
inhibitors	O
of	O
ANP	O
-	O
stimulated	O
GC	O
in	O
rat	O
brain	O
and	O
heart	O
membranes	O
.	O

None	O
of	O
these	O
analogues	O
affected	O
activity	O
in	O
the	O
absence	O
of	O
ANP	O
,	O
or	O
stimulated	O
ANP	O
-	O
induced	O
activity	O
.	O

In	O
both	O
tissues	O
,	O
some	O
5-substituted	B
isatins	I
(	O
5-hydroxyisatin	B
,	O
5-methylisatin	B
,	O
and	O
5-aminoisatin	B
)	O
exhibited	O
more	O
effective	O
inhibitory	O
activity	O
than	O
isatin	O
itself	O
,	O
with	O
IC50	O
values	O
in	O
the	O
range	O
1.3	O
-	O
20	O
microM.	O
The	O
efficacy	O
of	O
other	O
analogues	O
varied	O
and	O
was	O
not	O
consistent	O
between	O
the	O
two	O
tissues	O
,	O
raising	O
the	O
possibility	O
of	O
receptor	O
heterogeneity	O
and	O
relative	O
selectivity	O
of	O
inhibition	O
.	O

Some	O
substituted	O
isatins	B
may	O
have	O
a	O
role	O
as	O
pharmacological	O
tools	O
for	O
investigating	O
the	O
physiological	O
roles	O
of	O
natriuretic	O
peptides	O
and	O
their	O
receptors	O
.	O

It	O
has	O
been	O
shown	O
previously	O
that	O
4-anilino	B
quinazolines	I
compete	O
with	O
the	O
ability	O
of	O
ATP	B
to	O
bind	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGF	O
-	O
R	O
)	O
,	O
inhibit	O
EGF	O
-	O
stimulated	O
autophosphorylation	O
of	O
tyrosine	B
residues	O
in	O
EGF	O
-	O
R	O
,	O
and	O
block	O
EGF	O
-	O
mediated	O
growth	O
.	O

Since	O
millimolar	O
concentrations	O
of	O
ATP	B
in	O
cells	O
could	O
reduce	O
the	O
efficacy	O
of	O
4-anilino	B
quinazolines	I
in	O
cells	O
and	O
the	O
activity	O
of	O
these	O
compounds	O
would	O
not	O
be	O
sustained	O
once	O
they	O
were	O
removed	O
from	O
the	O
body	O
,	O
we	O
reasoned	O
that	O
irreversible	O
inhibitors	O
of	O
EGF	O
-	O
R	O
might	O
improve	O
the	O
activity	O
of	O
this	O
series	O
of	O
compounds	O
in	O
animals	O
.	O

Molecular	O
modeling	O
of	O
the	O
EGF	O
-	O
R	O
kinase	O
domain	O
was	O
used	O
to	O
design	O
irreversible	O
inhibitors	O
.	O

We	O
herein	O
describe	O
one	O
such	O
inhibitor	O
:	O
N-	B
[	I
4-	I
[	I
(	I
3-bromophenyl	I
)	I
amino	I
]	I
-6-quinazolinyl	I
]	I
2-butynamide	I
,	O
known	O
as	O
CL-387,785	B
.	O

This	O
compound	O
covalently	O
bound	O
to	O
EGF	O
-	O
R.	O
It	O
also	O
specifically	O
inhibited	O
kinase	O
activity	O
of	O
the	O
protein	O
(	O
IC50	O
=	O
370+	O
/	O
-120	O
pM	O
)	O
,	O
blocked	O
EGF	O
-	O
stimulated	O
autophosphorylation	O
of	O
the	O
receptor	O
in	O
cells	O
(	O
ic50	O
approximately	O
5	O
nM	O
)	O
,	O
inhibited	O
cell	O
proliferation	O
(	O
IC50	O
=	O
31	O
-	O
125	O
nM	O
)	O
primarily	O
in	O
a	O
cytostatic	O
manner	O
in	O
cell	O
lines	O
that	O
overexpress	O
EGF	O
-	O
R	O
or	O
c	O
-	O
erbB-2	O
,	O
and	O
profoundly	O
blocked	O
the	O
growth	O
of	O
a	O
tumor	O
that	O
overexpresses	O
EGF	O
-	O
R	O
in	O
nude	O
mice	O
(	O
when	O
given	O
orally	O
at	O
80	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
days	O
,	O
daily	O
)	O
.	O

We	O
conclude	O
that	O
CL-387,785	B
is	O
useful	O
for	O
studying	O
the	O
interaction	O
of	O
small	O
molecules	O
with	O
EGF	O
-	O
R	O
and	O
may	O
have	O
clinical	O
utility	O
.	O

Ethylene	B
-	I
di	I
-	I
bromide	I
is	O
a	O
popular	O
fumigant	O
.	O

Delayed	O
long	O
-	O
term	O
effects	O
of	O
this	O
chemical	O
include	O
carcinogenicity	O
and	O
genotoxicity	O
in	O
animals	O
.	O

Only	O
a	O
few	O
cases	O
of	O
acute	O
ethylene	B
-	I
di	I
-	I
bromide	I
toxicity	O
have	O
been	O
reported	O
and	O
all	O
of	O
them	O
have	O
resulted	O
in	O
a	O
fatal	O
outcome	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
ethylene	B
-	I
di	I
-	I
bromide	I
poisoning	O
presenting	O
with	O
acute	O
renal	O
failure	O
and	O
toxic	O
hepatitis	O
that	O
was	O
managed	O
successfully	O
.	O

By	O
using	O
wild	O
-	O
type	O
and	O
deoxystreptamine	B
-	O
negative	O
mutants	O
of	O
Streptomyces	O
fradiae	O
grown	O
in	O
media	O
containing	O
[	B
6	I
(	I
-3	I
)	I
H	I
]	I
glucose	I
or	O
[	B
U-14C	I
]	I
glucose	I
,	O
and	O
by	O
subsequent	O
hydrolysis	O
of	O
the	O
labelled	O
neomycin	B
produced	O
,	O
neamines	B
labelled	O
with	O
3H	B
in	O
both	O
rings	O
I	O
and	O
II	O
,	O
but	O
with	O
14C	B
in	O
ring	O
I	O
only	O
,	O
were	O
prepared	O
.	O

A	O
mixture	O
of	O
these	O
two	O
forms	O
of	O
neamine	B
was	O
converted	O
by	O
deoxystreptamine	B
-	O
negative	O
Streptomyces	O
rimosus	O
forma	O
paromomycinus	O
into	O
neomycin	B
(	O
not	O
paromomycin	B
)	I
with	O
a	O
30	O
%	O
yield	O
.	O

The3H	O
:	O
14C	B
ratio	O
in	O
this	O
neomycin	B
was	O
the	O
same	O
as	O
the	O
measured	O
in	O
neamine	B
produced	O
by	O
hydrolysis	O
of	O
the	O
neomycin	B
,	O
and	O
in	O
unused	O
neamine	B
reisolated	O
from	O
the	O
incubation	O
medium	O
.	O

The	O
3H:14C	B
ratio	O
in	O
the	O
neomycin	B
was	O
not	O
affected	O
by	O
the	O
presence	O
of	O
unlabelled	O
deoxystreptamine	B
during	O
the	O
incubation	O
.	O

The	O
radioactivity	O
in	O
the	O
neomycin	B
was	O
associated	O
with	O
rings	O
I	O
and	O
II	O
only	O
.	O

It	O
is	O
concluded	O
that	O
the	O
added	O
neamine	B
is	O
incorporated	O
into	O
antibiotic	O
intact	O
,	O
without	O
initial	O
hydrolysis	O
,	O
and	O
that	O
the	O
probable	O
first	O
step	O
in	O
the	O
subunit	O
assembly	O
of	O
neomycin	B
is	O
the	O
formation	O
of	O
neamine	B
.	O

Extraction	O
with	O
butan-1-ol	B
of	O
freeze	O
-	O
dried	O
microsomal	O
fractions	O
from	O
livers	O
of	O
3-methyl	B
-	I
cholarthrene	I
-	O
pre	O
-	O
treated	O
hamsters	O
removed	O
about	O
90	O
%	O
of	O
the	O
total	O
lipid	B
content	O
,	O
but	O
the	O
lipid	B
remaining	O
proved	O
sufficient	O
for	O
the	O
cytochrome	O
P-450	O
enzyme	O
system	O
to	O
retain	O
about	O
15	O
-	O
40	O
%	O
of	O
its	O
original	O
catalytic	O
activity	O
for	O
dimethylnitrosamine	B
demethylation	O
.	O

Addition	O
of	O
butan-1-ol	B
-	O
extracted	O
total	O
phospholipid	B
or	O
phosphatidylcholine	B
could	O
not	O
restore	O
any	O
activity	O
,	O
whereas	O
the	O
addition	O
of	O
the	O
synthetic	O
phospholipid	B
dilauroyl	O
phosphatidylcholine	O
was	O
able	O
to	O
restore	O
almost	O
complete	O
activity	O
.	O

Synthetic	O
dipalmitoyl	B
or	O
distearoyl	B
phosphatidylcholine	I
was	O
ineffective	O
in	O
restoring	O
the	O
activity	O
in	O
this	O
reconstituted	O
system	O
.	O

The	O
prevention	O
of	O
cerebral	O
palsy	O
and	O
neuroprotection	O
of	O
the	O
immature	O
brain	O
continue	O
to	O
be	O
health	O
care	O
priorities	O
.	O

The	O
pathophysiology	O
of	O
perinatal	O
brain	O
lesions	O
associated	O
with	O
cerebral	O
palsy	O
seems	O
to	O
be	O
multifactorial	O
and	O
includes	O
pre-	O
and	O
perinatal	O
factors	O
such	O
as	O
preconceptional	O
events	O
,	O
hormone	O
and	O
growth	O
factors	O
deficiencies	O
,	O
maternal	O
infections	O
with	O
production	O
of	O
cytokines	O
,	O
and	O
hypoxic	O
/	O
ischemic	O
perfusion	O
failures	O
.	O

Excitotoxic	O
cascade	O
could	O
represent	O
a	O
common	O
pathway	O
that	O
leads	O
to	O
neural	O
cell	O
death	O
and	O
subsequent	O
brain	O
damage	O
.	O

Brain	O
injuries	O
induced	O
by	O
ibotenate	B
,	O
a	O
glutamatergic	O
analog	O
,	O
which	O
are	O
essentially	O
mediated	O
through	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptor	O
,	O
mimic	O
some	O
aspects	O
of	O
the	O
white	O
matter	O
cysts	O
and	O
transcortical	O
necrosis	O
observed	O
in	O
human	O
perinatal	O
brain	O
damage	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
protective	O
role	O
of	O
several	O
pharmacological	O
agents	O
,	O
administered	O
in	O
conjunction	O
with	O
ibotenate	B
,	O
against	O
induced	O
excitotoxic	O
lesions	O
.	O

We	O
injected	O
ibotenate	B
in	O
the	O
developing	O
mouse	O
brain	O
5	O
d	O
postnatally	O
,	O
after	O
the	O
full	O
settlement	O
of	O
neuronal	O
layers	O
.	O

Co	O
-	O
treatment	O
with	O
kynurenic	B
acid	I
,	O
an	O
antagonist	O
of	O
the	O
facilitating	O
glycine	B
site	O
of	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptor	O
,	O
or	O
with	O
N	B
(	I
G	I
)	I
-nitro	I
-	I
L	I
-	I
arginine	I
,	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthesis	O
,	O
induced	O
a	O
dose	O
-	O
dependent	O
neuroprotective	O
effect	O
.	O

Conversely	O
,	O
zinc	B
gluconate	I
,	I
a	O
blocking	O
agent	O
of	O
the	O
channel	O
linked	O
to	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptor	O
,	O
and	O
a	O
free	O
radical	O
scavenger	O
(	O
U74389F	B
)	O
,	O
were	O
unable	O
to	O
protect	O
the	O
developing	O
brain	O
against	O
excitotoxic	O
attack	O
.	O

These	O
data	O
help	O
to	O
clarify	O
some	O
molecular	O
mechanisms	O
involved	O
in	O
excitotoxic	O
lesions	O
of	O
the	O
developing	O
mouse	O
brain	O
and	O
permit	O
us	O
to	O
envision	O
new	O
strategies	O
in	O
the	O
prevention	O
of	O
cerebral	O
palsy	O
.	O

A	O
novel	O
tricyclic	B
diterpenoid	I
antibiotic	B
,	O
brasilicardin	B
A	I
,	O
was	O
isolated	O
from	O
the	O
culture	O
broth	O
of	O
Nocardia	O
brasiliensis	O
IFM	O
0406	O
.	O

The	O
antibiotic	B
exhibited	O
immunosuppressive	O
activity	O
in	O
a	O
mouse	O
mixed	O
lymphocyte	O
reaction	O
(	O
MLR	O
)	O
assay	O
system	O
and	O
its	O
IC50	O
value	O
was	O
0.057	O
microg	O
/	O
ml	O
.	O

Although	O
the	O
inhibitory	O
activity	O
of	O
cyclosporin	B
A	I
(	O
CyA	B
)	O
against	O
IL-2	O
production	O
was	O
confirmed	O
in	O
the	O
MLR	O
assay	O
system	O
,	O
brasilicardin	B
A	I
did	O
not	O
have	O
the	O
activity	O
.	O

The	O
results	O
of	O
in	O
vitro	O
toxicity	O
testing	O
of	O
brasilicardin	B
A	I
against	O
various	O
human	O
cell	O
lines	O
were	O
compared	O
with	O
those	O
of	O
CyA.	B

IC202A	B
,	O
a	O
new	O
immunosuppressive	O
compound	O
,	O
was	O
isolated	O
from	O
the	O
culture	O
filtrate	O
of	O
Streptoalloteichus	O
sp.	O
1454	O
-	O
19	O
.	O

It	O
showed	O
a	O
suppressive	O
effect	O
on	O
mixed	O
lymphocyte	O
culture	O
reaction	O
with	O
an	O
IC50	O
value	O
of	O
3.6	O
microg	O
/	O
ml	O
and	O
mitogen	O
induced	O
lymphocyte	O
blastogenesis	O
in	O
vitro	O
.	O

A	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
with	O
activity	O
toward	O
1	B
,	I
2-epoxy-2-methyl-3-butene	I
(	O
isoprene	B
monoxide	I
)	O
and	O
cis-1	B
,	I
2-dichloroepoxyethane	I
was	O
purified	O
from	O
the	O
isoprene	B
-	O
utilizing	O
bacterium	O
Rhodococcus	O
sp.	O
strain	O
AD45	O
.	O

The	O
homodimeric	O
enzyme	O
(	O
two	O
subunits	O
of	O
27	O
kDa	O
each	O
)	O
catalyzed	O
the	O
glutathione	B
(	O
GSH	B
)	O
-dependent	O
ring	O
opening	O
of	O
various	O
epoxides	B
.	O

At	O
5	O
mM	O
GSH	B
,	O
the	O
enzyme	O
followed	O
Michaelis	O
-	O
Menten	O
kinetics	O
for	O
isoprene	B
monoxide	I
and	O
cis-1	B
,	I
2-dichloroepoxyethane	I
,	O
with	O
Vmax	O
values	O
of	O
66	O
and	O
2.4	O
micromol	O
min-1	O
mg	O
of	O
protein-1	O
and	O
Km	O
values	O
of	O
0.3	O
and	O
0.1	O
mM	O
for	O
isoprene	B
monoxide	I
and	O
cis-1,2-dichloroepoxyethane	B
,	O
respectively	O
.	O

Activities	O
increased	O
linearly	O
with	O
the	O
GSH	B
concentration	O
up	O
to	O
25	O
mM.	O
1H	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
showed	O
that	O
the	O
product	O
of	O
GSH	B
conjugation	O
to	O
isoprene	B
monoxide	I
was	O
1-hydroxy-2-glutathionyl-2-methyl-3-butene	B
(	O
HGMB	B
)	O
.	O

Thus	O
,	O
nucleophilic	O
attack	O
of	O
GSH	B
occurred	O
on	O
the	O
tertiary	O
carbon	B
atom	O
of	O
the	O
epoxide	B
ring	O
.	O

HGMB	B
was	O
further	O
converted	O
by	O
an	O
NAD+-dependent	B
dehydrogenase	O
,	O
and	O
this	O
enzyme	O
was	O
also	O
purified	O
from	O
isoprene	B
-	O
grown	O
cells	O
.	O

The	O
homodimeric	O
enzyme	O
(	O
two	O
subunits	O
of	O
25	O
kDa	O
each	O
)	O
showed	O
a	O
high	O
activity	O
for	O
HGMB	B
,	O
whereas	O
simple	O
primary	B
and	O
secondary	B
alcohols	I
were	O
not	O
oxidized	O
.	O

The	O
enzyme	O
catalyzed	O
the	O
sequential	O
oxidation	O
of	O
the	O
alcohol	B
function	O
to	O
the	O
corresponding	O
aldehyde	B
and	O
carboxylic	B
acid	I
and	O
followed	O
Michaelis	O
-	O
Menten	O
kinetics	O
with	O
respect	O
to	O
NAD+	B
and	O
HGMB	B
.	O

The	O
results	O
suggest	O
that	O
the	O
initial	O
steps	O
in	O
isoprene	B
metabolism	O
are	O
a	O
monooxygenase	O
-	O
catalyzed	O
conversion	O
to	O
isoprene	B
monoxide	I
,	O
a	O
GST	O
-	O
catalyzed	O
conjugation	O
to	O
HGMB	B
,	O
and	O
a	O
dehydrogenase	O
-	O
catalyzed	O
two	O
-	O
step	O
oxidation	O
to	O
2-glutathionyl-2-methyl-3-butenoic	B
acid	I
.	O

This	O
paper	O
reports	O
the	O
preparation	O
and	O
identification	O
of	O
two	O
monoclonal	O
antibodies	O
against	O
FTB	B
,	O
and	O
the	O
establishment	O
of	O
an	O
indirect	O
competitive	O
ELISA	O
methods	O
for	O
FTB	B
determination	O
in	O
buckwheat	O
,	O
rice	O
,	O
and	O
corn	O
.	O

Two	O
of	O
the	O
hybridoma	O
cell	O
lines	O
(	O
1C9	O
and	O
2D10	O
)	O
,	O
which	O
could	O
produce	O
specific	O
antibodies	O
against	O
fumitremorgin	B
B	I
(	O
FTB	B
)	O
,	O
were	O
selected	O
and	O
developed	O
.	O

The	O
affinity	O
Kaff	O
constants	O
of	O
the	O
monoclonal	O
antibodies	B
with	O
the	O
coating	O
antigen	O
,	O
FTBS	B
-	I
IgG	I
,	O
were	O
found	O
to	O
be	O
6	O
x	O
10	O
(	O
8	O
)	O
M-1	O
and	O
9.8	O
x	O
10	O
M-1	O
,	O
respectively	O
.	O

The	O
isotypes	O
of	O
the	O
monoclonal	O
antibodies	O
are	O
of	O
two	O
isotypes	O
,	O
IgG1	O
and	O
IgM	O
,	O
respectively	O
.	O

The	O
antibody	O
titers	O
were	O
found	O
around	O
1	O
x	O
10	O
(	O
6	O
)	O
and	O
1.5	O
x	O
10	O
(	O
6	O
)	O
.	O

The	O
standard	O
curves	O
showed	O
that	O
as	O
little	O
as	O
5	O
pg	O
of	O
FTB	B
in	O
50	O
mL	O
could	O
be	O
detected	O
,	O
and	O
the	O
linear	O
range	O
of	O
standard	O
curve	O
was	O
from	O
10	O
pg	O
to	O
1000	O
pg	O
of	O
standard	O
FTB	B
.	I

There	O
were	O
no	O
cross	O
-	O
reaction	O
for	O
McAbs	O
in	O
the	O
assay	O
system	O
with	O
some	O
mycotoxins	O
tested	O
.	O

The	O
mean	O
recovery	O
rate	O
from	O
buckwheat	O
spiked	O
with	O
10	O
-	O
60	O
ng	O
/	O
g	O
of	O
FTB	B
was	O
78	O
-	O
88.7	O
%	O
.	O

The	O
reaction	O
of	O
[	B
3H	I
]	I
p	I
-	I
nitrophenyl	I
acetate	I
(	O
NPA	B
)	O
or	O
[	B
14C	I
]	I
methyl	I
acetimidate	I
(	O
MAI	B
)	O
with	O
amino	B
groups	I
of	O
ribosomal	O
pade	O
between	O
the	O
reactivity	O
of	O
the	O
proteins	O
in	O
situ	O
in	O
the	O
ribosomal	O
subunit	O
with	O
that	O
of	O
isolated	O
protein	O
mixtures	O
.	O

In	O
the	O
small	O
subunit	O
reactivity	O
compared	O
with	O
the	O
protein	O
mixture	O
was	O
only	O
10	O
-	O
65	O
%	O
in	O
the	O
case	O
of	O
NPA	B
but	O
45	O
to	O
more	O
than	O
100	O
%	O
in	O
the	O
case	O
of	O
MAI	B
.	O

In	O
the	O
large	O
subunit	O
reactivity	O
to	O
MAI	B
was	O
10	O
-	O
60	O
%	O
that	O
of	O
the	O
isas	O
a	O
denser	O
structure	O
than	O
the	O
small	O
one	O
.	O

In	O
agreement	O
with	O
earlier	O
experiments	O
with	O
iodoacetamide	B
the	O
proteins	O
S2	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
10	O
and	O
13	O
of	O
the	O
small	O
subunit	O
and	O
L15	O
,	O
17	O
,	O
20	O
,	O
24	O
,	O
25	O
,	O
27	O
,	O
29	O
,	O
33	O
,	O
34	O
,	O
35	O
and	O
38	O
in	O
the	O
large	O
subunit	O
are	O
quite	O
accessible	O
while	O
proteins	O
S9	O
,	O
14	O
,	O
19	O
,	O
20	O
,	O
24	O
,	O
25	O
,	O
27	O
,	O
29	O
and	O
30	O
of	O
the	O
small	O
subunit	O
and	O
L1	O
,	O
7	O
,	O
8	O
,	O
10	O
,	O
11	O
,	O
19	O
,	O
28	O
,	O
31	O
,	O
and	O
32	O
of	O
the	O
large	O
one	O
are	O
relatively	O
inaccessible	O
.	O

BACKGROUND	O
:	O
Removal	O
and/or	O
""""	O
neutralization	O
""""	O
of	O
anti	O
-	O
Gal	O
alpha1	O
-	O
3Gal	O
(	O
alphaGal	O
)	O
antibodies	O
can	O
prevent	O
or	O
delay	O
the	O
hyperacute	O
rejection	O
of	O
pig	O
organs	O
transplanted	O
into	O
primates	O
.	O

AIM	O
:	O
To	O
determine	O
variations	O
in	O
(	O
1	O
)	O
cytotoxicity	O
to	O
pig	O
kidney	O
(	O
PK15	O
)	O
cells	O
,	O
(	O
2	O
)	O
anti	O
-	O
alphaGal	O
antibody	O
level	O
,	O
and	O
(	O
3	O
)	O
specificity	O
in	O
adult	O
human	O
(	O
n=46	O
)	O
and	O
baboon	O
(	O
n=38	O
)	O
sera	O
.	O

METHODS	O
:	O
Cytotoxicity	O
to	O
PK15	O
cells	O
was	O
determined	O
by	O
adding	O
rabbit	O
complement	O
to	O
heat	O
-	O
inactivated	O
serum	O
,	O
using	O
a	O
two	O
-	O
color	O
fluorescent	B
dye	I
to	O
distinguish	O
live	O
and	O
dead	O
cells	O
.	O

Anti	O
-	O
alphaGal	O
antibody	O
level	O
was	O
determined	O
by	O
ELISA	O
using	O
alphaGal	O
trisaccharide	O
type	O
2-BSA	O
glycoconjugate	O
as	O
antigen	O
target	O
.	O

Specificity	O
determined	O
by	O
ELISA	O
using	O
four	O
different	O
alphaGal	O
-	O
BSA	O
glycoconjugates	O
:	O
(	O
disaccharide	B
,	O
trisaccharides	B
type	O
2	O
and	O
6	O
,	O
and	O
pentasaccharide	B
)	O
.	O

RESULTS	O
:	O
Cytotoxicity	O
of	O
human	O
AB	O
sera	O
varied	O
from	O
30	O
-	O
100	O
%	O
PK15	O
relative	O
cell	O
damage	O
(	O
%	O
RCD	O
)	O
,	O
although	O
that	O
of	O
baboon	O
sera	O
of	O
all	O
blood	O
groups	O
varied	O
from	O
35	O
-	O
100	O
%	O
RCD	O
.	O

In	O
human	O
AB	O
sera	O
,	O
anti	O
-	O
alphaGal	O
antibody	O
level	O
(	O
at	O
a	O
dilution	O
of	O
1:80	O
)	O
varied	O
from	O
undetectable	O
to	O
0.75	O
(	O
OD	O
at	O
405	O
nm	O
)	O
,	O
although	O
in	O
baboon	O
sera	O
of	O
all	O
blood	O
groups	O
,	O
anti	O
-	O
alphaGal	O
antibody	O
level	O
varied	O
from	O
undetectable	O
to	O
>	O
2.0	O
.	O

There	O
was	O
no	O
correlation	O
between	O
anti	O
-	O
alphaGal	O
antibody	O
level	O
and	O
serum	O
cytotoxicity	O
in	O
either	O
species	O
.	O

Specificity	O
varied	O
among	O
individuals	O
in	O
both	O
human	O
and	O
baboon	O
sera	O
.	O

CONCLUSIONS	O
:	O
These	O
studies	O
have	O
demonstrated	O
(	O
1	O
)	O
considerable	O
variation	O
in	O
cytotoxicity	O
and	O
anti	O
-	O
alphaGal	O
antibody	O
level	O
in	O
human	O
and	O
baboon	O
sera	O
,	O
but	O
a	O
lack	O
of	O
correlation	O
between	O
these	O
two	O
parameters	O
;	O
(	O
2	O
)	O
considerable	O
variation	O
in	O
the	O
specificity	O
of	O
anti	O
-	O
alphaGal	O
antibodies	O
;	O
(	O
3	O
)	O
blood	O
group	O
B	O
human	O
and	O
baboon	O
sera	O
have	O
lower	O
levels	O
of	O
anti	O
-	O
alphaGal	O
antibodies	O
;	O
(	O
4	O
)	O
no	O
relation	O
between	O
blood	O
group	O
and	O
specificity	O
of	O
anti	O
-	O
alphaGal	O
antibodies	O
.	O

Although	O
there	O
are	O
minor	O
differences	O
in	O
the	O
parameters	O
measured	O
,	O
baboons	O
would	O
appear	O
to	O
be	O
suitable	O
surrogates	O
for	O
humans	O
in	O
the	O
pig	O
-	O
to	O
-	O
primate	O
xenograft	O
model	O
.	O

Three	O
novel	O
sesquiterpene	B
esters	B
of	O
aristolochic	B
acid	I
,	O
aristoloterpenate	B
-	B
II	I
(	O
2	O
)	O
,	O
-III	B
(	O
3	O
)	O
,	O
and	O
-	B
IV	I
(	O
4	O
)	O
,	O
together	O
with	O
known	O
aristoloterpenate	B
-	I
I	I
(	O
1	O
)	O
,	O
were	O
isolated	O
and	O
characterized	O
from	O
the	O
root	O
and	O
stem	O
of	O
Aristolochia	O
heterophylla	O
.	O

Their	O
structures	O
were	O
elucidated	O
by	O
spectroscopic	O
methods	O
.	O

The	O
absolute	O
configuration	O
of	O
these	O
compounds	O
at	O
C-4	O
'	O
was	O
determined	O
as	O
R	O
by	O
circular	O
dichroic	O
studies	O
.	O

These	O
compounds	O
showed	O
cytotoxicity	O
against	O
hepatoma	O
G2	O
,	O
2	O
,	O
2	O
,	O
15	O
cells	O
.	O

Raloxifene	B
hydrochloride	I
(	O
HCl	O
)	O
is	O
a	O
selective	O
estrogen	B
receptor	O
modulator	O
with	O
estrogen	B
agonist	O
effects	O
on	O
bone	O
and	O
lipid	O
metabolism	O
and	O
estrogen	B
antagonist	O
effects	O
on	O
reproductive	O
tissues	O
.	O

Animal	O
studies	O
suggest	O
that	O
raloxifene	B
may	O
affect	O
brain	O
function	O
as	O
well	O
,	O
although	O
the	O
effects	O
of	O
raloxifene	B
on	O
the	O
human	O
brain	O
remain	O
to	O
be	O
established	O
.	O

This	O
paper	O
presents	O
an	O
early	O
safety	O
assessment	O
of	O
raloxifene	B
effects	O
on	O
cognition	O
and	O
mood	O
in	O
postmenopausal	O
women	O
participating	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
osteoporosis	O
treatment	O
trial	O
.	O

Psychometric	O
test	O
batteries	O
were	O
administered	O
to	O
postmenopausal	O
women	O
at	O
baseline	O
and	O
1	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
initiating	O
treatment	O
with	O
raloxifene	B
(	O
60	O
and	O
120	O
mg	O
/	O
day	O
)	O
.	O

The	O
Memory	O
Assessment	O
Clinics	O
(	O
MAC	O
)	O
battery	O
and	O
Walter	O
Reed	O
Performance	O
Assessment	O
Battery	O
(	O
PAB	O
)	O
were	O
used	O
to	O
assess	O
multiple	O
and	O
independent	O
aspects	O
of	O
cognitive	O
function	O
,	O
while	O
mood	O
was	O
assessed	O
with	O
the	O
Geriatric	O
Depression	O
Scale	O
(	O
GDS	O
)	O
.	O

After	O
12	O
months	O
of	O
treatment	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
raloxifene	B
groups	O
and	O
placebo	O
on	O
performance	O
in	O
either	O
the	O
MAC	O
battery	O
or	O
the	O
PAB	O
.	O

The	O
only	O
significant	O
difference	O
observed	O
was	O
a	O
slight	O
increase	O
in	O
performance	O
favoring	O
the	O
raloxifene	B
120	O
mg	O
/	O
day	O
group	O
in	O
an	O
assessment	O
of	O
verbal	O
memory	O
on	O
the	O
MAC	O
battery	O
after	O
1	O
month	O
of	O
treatment	O
.	O

Scores	O
on	O
the	O
GDS	O
and	O
the	O
self	O
-	O
reported	O
incidence	O
of	O
mood	O
-	O
related	O
events	O
were	O
not	O
different	O
between	O
treatment	O
groups	O
at	O
any	O
of	O
the	O
assessment	O
periods	O
.	O

These	O
data	O
do	O
not	O
suggest	O
that	O
raloxifene	B
impairs	O
cognition	O
or	O
affects	O
mood	O
in	O
postmenopausal	O
women	O
treated	O
for	O
1	O
year	O
.	O

Studies	O
to	O
further	O
assess	O
the	O
safety	O
and	O
potential	O
efficacy	O
of	O
raloxifene	B
with	O
respect	O
to	O
cognitive	O
function	O
are	O
ongoing	O
.	O

Preclinical	O
studies	O
suggest	O
that	O
estrogenic	O
hormones	B
may	O
affect	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
function	O
(	O
Schneider	O
and	O
Finch	O
,	O
1997	O
)	O
,	O
enhancing	O
cholinergic	O
and	O
serotonergic	O
mechanisms	O
in	O
the	O
rat	O
brain	O
,	O
modulating	O
the	O
growth	O
and	O
maintenance	O
of	O
neuronal	O
cells	O
in	O
vitro	O
,	O
and	O
ameliorating	O
ovariectomy	O
-	O
induced	O
learning	O
deficits	O
in	O
rats	O
.	O

Nevertheless	O
,	O
the	O
effect	O
of	O
estrogen	B
on	O
cognitive	O
function	O
in	O
humans	O
remains	O
a	O
matter	O
of	O
debate	O
(	O
Haskell	O
et	O
al.	O
,	O
1997	O
;	O
Plouffe	O
and	O
Schulkin	O
,	O
1998	O
;	O
Yaffe	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
postmenopausal	O
women	O
,	O
modest	O
improvements	O
in	O
certain	O
aspects	O
of	O
cognitive	O
function	O
,	O
particularly	O
in	O
verbal	O
memory	O
,	O
have	O
been	O
demonstrated	O
with	O
estrogen	B
in	O
some	O
small	O
-	O
scale	O
randomized	O
,	O
placebo	O
-	O
controlled	O
studies	O
(	O
Hackman	O
and	O
Galbraith	O
,	O
1976	O
;	O
Sherwin	O
,	O
1988	O
;	O
Phillips	O
and	O
Sherwin	O
,	O
1992	O
)	O
,	O
but	O
not	O
others	O
(	O
Rauramo	O
et	O
al.	O
,	O
1975	O
;	O
Vanhulle	O
and	O
Demol	O
,	O
1976	O
;	O
Ditkoff	O
et	O
al.	O
,	O
1991	O
;	O
Erkkola	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Also	O
,	O
several	O
epidemiological	O
studies	O
suggest	O
that	O
estrogen	B
replacement	O
therapy	O
(	O
ERT	O
)	O
may	O
delay	O
the	O
onset	O
of	O
Alzhiemer	O
's	O
disease	O
(	O
Paganini	O
-	O
Hill	O
and	O
Henderson	O
,	O
1996	O
;	O
Kawas	O
et	O
al.	O
,	O
1997	O
)	O
,	O
although	O
in	O
other	O
studies	O
no	O
effect	O
was	O
observed	O
(	O
Barrett	O
-	O
Connor	O
and	O
Kritz	O
-	O
Silverstein	O
,	O
1993	O
;	O
Brenner	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Thus	O
,	O
confirmation	O
of	O
any	O
positive	O
effect	O
of	O
estrogen	B
on	O
cognition	O
,	O
as	O
well	O
as	O
clarification	O
of	O
its	O
magnitude	O
and	O
clinical	O
significance	O
,	O
must	O
await	O
completion	O
of	O
a	O
large	O
-	O
scale	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
prospective	O
trial	O
(	O
Yaffe	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Raloxifene	B
is	O
a	O
benzothiophene	B
member	O
of	O
a	O
new	O
class	O
of	O
compounds	O
termed	O
selective	B
estrogen	I
receptor	I
modulators	I
,	O
which	O
bind	O
with	O
high	O
affinity	O
to	O
the	O
estrogen	B
receptor	O
,	O
and	O
can	O
exert	O
either	O
agonist	O
or	O
antagonist	O
effects	O
in	O
a	O
tissue	O
-	O
dependent	O
manner	O
(	O
Mitlak	O
and	O
Cohen	O
,	O
1997	O
)	O
.	O

Studies	O
in	O
animals	O
(	O
Black	O
et	O
al.	O
,	O
1994	O
)	O
and	O
clinical	O
studies	O
in	O
postmenopausal	O
women	O
(	O
Draper	O
et	O
al.	O
,	O
1996	O
;	O
Delmas	O
et	O
al.	O
,	O
1997	O
;	O
Walsh	O
et	O
al.	O
,	O
1998	O
)	O
have	O
demonstrated	O
that	O
raloxifene	B
prevents	O
bone	O
loss	O
caused	O
by	O
loss	O
of	O
endogenous	O
estrogen	B
,	O
favorably	O
alters	O
the	O
serum	O
lipid	B
profile	O
,	O
and	O
does	O
not	O
stimulate	O
breast	O
or	O
uterine	O
tissue	O
.	O

Based	O
on	O
this	O
selective	O
pharmacological	O
profile	O
,	O
raloxifene	B
has	O
been	O
approved	O
for	O
marketing	O
in	O
several	O
countries	O
for	O
the	O
prevention	O
of	O
postmenopausal	O
osteoporosis	O
.	O

Whether	O
raloxifene	B
affects	O
human	O
brain	O
function	O
or	O
cognition	O
is	O
a	O
topic	O
of	O
ongoing	O
research	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
raloxifene	B
does	O
not	O
adversely	O
affect	O
cognition	O
or	O
mood	O
in	O
postmenopausal	O
women	O
,	O
we	O
assessed	O
cognitive	O
and	O
affective	O
function	O
as	O
secondary	O
safety	O
endpoints	O
in	O
a	O
placebo	O
-	O
controlled	O
osteoporosis	O
treatment	O
study	O
with	O
raloxifene	B
.	O

Computerized	O
neuropsychological	O
test	O
batteries	O
long	O
-	O
used	O
in	O
neuropharmacology	O
research	O
were	O
used	O
to	O
monitor	O
cognition	O
and	O
memory	O
in	O
postmenopausal	O
women	O
treated	O
with	O
raloxifene	B
for	O
1	O
year	O
.	O

Although	O
the	O
effect	O
of	O
estrogen	B
on	O
these	O
batteries	O
has	O
not	O
been	O
tested	O
,	O
they	O
were	O
chosen	O
based	O
on	O
their	O
reliability	O
(	O
Youngjohn	O
et	O
al.	O
,	O
1992a	O
)	O
and	O
validity	O
(	O
Youngjohn	O
et	O
al.	O
,	O
1992b	O
)	O
in	O
measuring	O
independent	O
aspects	O
of	O
cognition	O
and	O
memory	O
.	O

In	O
addition	O
,	O
a	O
test	O
of	O
affective	O
function	O
designed	O
specifically	O
for	O
mature	O
adults	O
(	O
Yesavage	O
et	O
al.	O
,	O
1983	O
)	O
was	O
administered	O
.	O

The	O
use	O
of	O
these	O
well	O
-	O
established	O
assessments	O
of	O
cognition	O
and	O
mood	O
is	O
particularly	O
important	O
,	O
because	O
in	O
some	O
previous	O
studies	O
of	O
estrogen	B
and	O
cognition	O
,	O
tests	O
of	O
attention	O
span	O
and	O
reaction	O
time	O
were	O
erroneously	O
used	O
as	O
tests	O
of	O
memory	O
,	O
and	O
potentially	O
important	O
confounding	O
factors	O
such	O
as	O
mood	O
were	O
not	O
assessed	O
(	O
Haskell	O
et	O
al.	O
,	O
1997	O
)	O
.	O

This	O
report	O
is	O
the	O
first	O
of	O
a	O
series	O
of	O
investigations	O
that	O
,	O
together	O
,	O
will	O
determine	O
the	O
long	O
-	O
term	O
effects	O
of	O
raloxifene	B
on	O
cognitive	O
function	O
and	O
mood	O
in	O
postmenopausal	O
women	O
.	O

2	O
Methods	O
2.1	O
Patient	O
population	O
This	O
study	O
included	O
postmenopausal	O
women	O
with	O
established	O
osteoporosis	O
,	O
45–75	O
years	O
of	O
age	O
,	O
who	O
had	O
their	O
last	O
menstrual	O
periods	O
at	O
least	O
5	O
years	O
before	O
the	O
beginning	O
of	O
the	O
study	O
.	O

All	O
subjects	O
were	O
studied	O
at	O
Mayo	O
Clinic	O
Rochester	O
,	O
MN	O
or	O
Mayo	O
Clinic	O
Scottsdale	O
,	O
AZ	O
.	O

Patients	O
were	O
eligible	O
if	O
they	O
were	O
in	O
good	O
health	O
except	O
for	O
osteoporosis	O
,	O
free	O
of	O
any	O
serious	O
acute	O
or	O
chronic	O
medical	O
condition	O
that	O
might	O
affect	O
bone	O
or	O
calcium	B
metabolism	O
,	O
and	O
fully	O
ambulatory	O
.	O

Postmenopausal	O
status	O
was	O
confirmed	O
in	O
women	O
less	O
than	O
60	O
years	O
of	O
age	O
by	O
serum	O
estradiol	B
≤73	O
pmol	O
/	O
l	O
and	O
follicle	O
stimulating	O
hormone	O
≥30	O
IU	O
/	O
l	O
.	O

Osteoporosis	O
was	O
documented	O
by	O
diagnosis	O
of	O
at	O
least	O
one	O
non	O
-	O
traumatic	O
vertebral	O
fracture	O
and	O
a	O
bone	O
mineral	O
density	O
of	O
the	O
lumbar	O
spine	O
or	O
proximal	O
femur	O
of	O
less	O
than	O
the	O
tenth	O
percentile	O
of	O
normal	O
premenopausal	O
women	O
.	O

Patients	O
with	O
bone	O
disorders	O
other	O
than	O
osteoporosis	O
,	O
clinically	O
significant	O
menopausal	O
symptoms	O
(	O
hot	O
flashes	O
,	O
sweating	O
,	O
etc	O
.	O
)	O
,	O
any	O
history	O
of	O
cancer	O
(	O
except	O
superficial	O
basal	O
or	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
skin	O
)	O
within	O
the	O
previous	O
5	O
years	O
,	O
acute	O
or	O
chronic	O
liver	O
disease	O
,	O
history	O
of	O
deep	O
vein	O
thrombosis	O
or	O
cerebral	O
vascular	O
accident	O
,	O
or	O
impaired	O
kidney	O
function	O
were	O
not	O
considered	O
for	O
enrollment	O
in	O
the	O
study	O
.	O

Treatment	O
with	O
estrogen	B
,	O
progestin	B
,	O
calcitonin	B
,	O
androgen	B
,	O
or	O
systemic	O
corticosteroid	B
more	O
recently	O
than	O
6	O
months	O
prior	O
to	O
study	O
was	O
also	O
grounds	O
for	O
exclusion	O
.	O

An	O
informed	O
consent	O
document	O
and	O
study	O
protocol	O
were	O
reviewed	O
and	O
approved	O
by	O
the	O
appropriate	O
ethical	O
review	O
board	O
prior	O
to	O
initiation	O
of	O
the	O
study	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
study	O
participants	O
according	O
to	O
the	O
ethical	O
principles	O
stated	O
in	O
the	O
latest	O
version	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

2.2	O
Study	O
design	O

This	O
was	O
a	O
Phase	O
2	O
,	O
two	O
-	O
site	O
,	O
parallel	O
groups	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
treatment	O
groups	O
;	O
placebo	O
,	O
raloxifene	B
60	O
mg	O
/	O
day	O
,	O
or	O
raloxifene	B
120	O
mg	O
/	O
day	O
.	O

Outcome	O
measures	O
were	O
recorded	O
at	O
baseline	O
and	O
at	O
1	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O

2.3	O
Outcome	O
measures	O
Outcome	O
measures	O
included	O
ten	O
cognitive	O
assessments	O
and	O
one	O
assessment	O
of	O
mood	O
.	O

Seven	O
of	O
the	O
cognitive	O
outcome	O
measures	O
were	O
derived	O
from	O
the	O
MAC	O
computerized	O
psychometric	O
battery	O
while	O
three	O
were	O
derived	O
from	O
the	O
Walter	O
Reed	O
PAB	O
.	O

Both	O
assessments	O
measure	O
components	O
of	O
cognitive	O
function	O
that	O
have	O
been	O
shown	O
to	O
decline	O
with	O
advancing	O
age	O
.	O

The	O
Geriatric	O
Depression	O
Scale	O
(	O
GDS	O
)	O
,	O
a	O
valid	O
and	O
reliable	O
test	O
designed	O
specifically	O
for	O
the	O
assessment	O
of	O
mood	O
in	O
the	O
elderly	O
(	O
Yesavage	O
et	O
al.	O
,	O
1983	O
)	O
,	O
was	O
also	O
administered	O
on	O
each	O
patient	O
visit	O
.	O

The	O
individual	O
cognitive	O
assessments	O
within	O
each	O
battery	O
are	O
outlined	O
below	O
.	O

The	O
test	O
batteries	O
have	O
been	O
described	O
in	O
many	O
previous	O
publications	O
(	O
Thorne	O
et	O
al.	O
,	O
1985	O
;	O
Larrabee	O
and	O
Crook	O
,	O
1988	O
;	O
Crook	O
et	O
al.	O
,	O
1990	O
;	O
Crook	O
,	O
1992	O
)	O
.	O

2.3.1	O
MAC	O
battery	O
This	O
assessment	O
battery	O
was	O
designed	O
to	O
simulate	O
critical	O
cognitive	O
tasks	O
of	O
everyday	O
life	O
and	O
has	O
been	O
shown	O
to	O
be	O
reliable	O
(	O
Youngjohn	O
et	O
al.	O
,	O
1992a	O
)	O
and	O
valid	O
(	O
Crook	O
and	O
West	O
,	O
1990	O
;	O
Youngjohn	O
et	O
al.	O
,	O
1992b	O
)	O
.	O

The	O
independent	O
parameters	O
of	O
learning	O
and	O
memory	O
tested	O
by	O
this	O
battery	O
are	O
as	O
follows:•	O
name	O
–	O
face	O
association	O
:	O
delayed	O
recall	O
and	O
total	O
acquisition	O
(	O
Crook	O
and	O
West	O
,	O
1990	O
)	O
;	O
•	O
first	O
–	O
last	O
names	O
:	O
delayed	O
recall	O
and	O
total	O
acquisition	O
(	O
Youngjohn	O
et	O
al.	O
,	O
1991	O
)	O
;	O
•	O
facial	O
recognition	O
:	O
number	O
before	O
first	O
error	O
(	O
Crook	O
and	O
Larrabee	O
,	O
1992	O
)	O
;	O
•	O
telephone	O
number	O
recall	O
(	O
ten	O
digit	O
)	O
:	O
before	O
interference	O
and	O
after	O
interference	O
(	O
West	O
and	O
Crook	O
,	O
1990	O
)	O
.	O

The	O
name	O
–	O
face	O
association	O
and	O
first	O
–	O
last	O
names	O
recall	O
tests	O
measure	O
primarily	O
verbal	O
memory	O
,	O
the	O
facial	O
recognition	O
test	O
measures	O
primarily	O
visual	O
memory	O
,	O
and	O
the	O
telephone	O
number	O
recall	O
test	O
measures	O
working	O
memory	O
;	O
that	O
is	O
,	O
encoding	O
and	O
manipulation	O
of	O
information	O
for	O
later	O
use	O
.	O

2.3.2	O
Walter	O
Reed	O
performance	O
assessment	O
battery	O
(	O
PAB	O
)	O

The	O
Walter	O
Reed	O
PAB	O
was	O
developed	O
by	O
the	O
United	O
States	O
Army	O
and	O
provides	O
measures	O
of	O
various	O
aspects	O
of	O
attention	O
,	O
information	O
processing	O
speed	O
and	O
efficiency	O
,	O
and	O
reaction	O
time	O
(	O
Thorne	O
et	O
al.	O
,	O
1985	O
)	O
.	O

These	O
tests	O
are	O
particularly	O
suited	O
to	O
detect	O
even	O
subtle	O
influences	O
of	O
drugs	B
on	O
attention	O
,	O
vigilance	O
,	O
and	O
information	O
processing	O
(	O
Newhouse	O
et	O
al.	O
,	O
1989	O
;	O
Snyder	O
and	O
Henningfield	O
,	O
1989	O
)	O
.	O

The	O
three	O
Walter	O
Reed	O
PAB	O
assessments	O
used	O
in	O
this	O
study	O
were:•	O
two	O
-	O
letter	O
search	O
;	O
•	O
six	O
-	O
letter	O
search	O
;	O
•	O
four	O
-	O
choice	O
serial	O
reaction	O
time	O
.	O

Both	O
assessment	O
batteries	O
were	O
administered	O
by	O
a	O
research	O
assistant	O
in	O
a	O
controlled	O
testing	O
environment	O
and	O
required	O
30–40	O
min	O
to	O
complete	O
.	O

Multiple	O
,	O
equivalent	O
forms	O
of	O
both	O
the	O
MAC	O
battery	O
(	O
Crook	O
et	O
al.	O
,	O
1992	O
)	O
and	O
the	O
Walter	O
Reed	O
PAB	O
(	O
Thorne	O
et	O
al.	O
,	O
1985	O
)	O
were	O
administered	O
such	O
that	O
subjects	O
did	O
not	O
see	O
the	O
same	O
stimuli	O
more	O
than	O
once	O
.	O

2.4	O
Evaluation	O
of	O
test	O
batteries	O
for	O
sensitivity	O
to	O
cognitive	O
impairment	O
in	O
healthy	O
older	O
adults	O
Both	O
test	O
batteries	O
employed	O
have	O
been	O
used	O
in	O
multiple	O
studies	O
of	O
drug	B
effects	O
on	O
cognition	O
(	O
Newhouse	O
et	O
al.	O
,	O
1989	O
;	O
Crook	O
and	O
Lakin	O
,	O
1991	O
;	O
Crook	O
et	O
al.	O
,	O
1991	O
)	O
.	O

However	O
,	O
many	O
of	O
these	O
studies	O
were	O
conducted	O
in	O
populations	O
with	O
neurologic	O
or	O
psychiatric	O
impairments	O
.	O

To	O
assure	O
sensitivity	O
to	O
cognitive	O
impairment	O
in	O
the	O
population	O
under	O
study	O
with	O
raloxifene	B
,	O
a	O
preliminary	O
sensitivity	O
study	O
was	O
undertaken	O
in	O
a	O
separate	O
cohort	O
of	O
subjects	O
.	O

The	O
ability	O
of	O
diazepam	B
to	O
induce	O
deficits	O
in	O
memory	O
and	O
cognitive	O
performance	O
is	O
well	O
-	O
established	O
and	O
,	O
thus	O
,	O
was	O
considered	O
appropriate	O
for	O
comparison	O
with	O
placebo	O
in	O
this	O
sensitivity	O
study	O
.	O

Healthy	O
subjects	O
of	O
either	O
sex	O
between	O
55	O
and	O
75	O
years	O
of	O
age	O
(	O
mean	O
age=63	O
)	O
were	O
tested	O
with	O
both	O
the	O
MAC	O
battery	O
and	O
Walter	O
Reed	O
PAB	O
at	O
baseline	O
(	O
day	O
1	O
)	O
.	O

Subjects	O
were	O
treated	O
with	O
diazepam	B
(	O
4	O
×	O
5	O
mg	O
/	O
day	O
)	O
on	O
days	O
2	O
and	O
3	O
.	O

On	O
day	O
4	O
,	O
subjects	O
were	O
retested	O
with	O
both	O
assessment	O
batteries	O
1	O
h	O
after	O
a	O
morning	O
5	O
mg	O
dose	O
of	O
diazepam	B
.	O

Scores	O
obtained	O
on	O
the	O
test	O
batteries	O
at	O
baseline	O
and	O
after	O
diazepam	B
therapy	O
were	O
compared	O
.	O

Diazepam	B
induced	O
clear	O
performance	O
deficits	O
in	O
all	O
of	O
the	O
components	O
of	O
the	O
MAC	O
battery	O
(	O
Fig.	O
1	O
)	O
.	O

Significant	O
performance	O
deficits	O
were	O
also	O
observed	O
in	O
the	O
PAB	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
the	O
test	O
batteries	O
used	O
in	O
this	O
study	O
were	O
considered	O
appropriate	O
for	O
detection	O
of	O
negative	O
drug	B
effects	O
in	O
the	O
population	O
being	O
studied	O
.	O

2.5	O
Data	O
analysis	O
Analysis	O
of	O
drug	B
effects	O
on	O
cognition	O
in	O
this	O
study	O
was	O
based	O
on	O
a	O
univariate	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
in	O
which	O
age	O
and	O
baseline	O
score	O
on	O
each	O
variable	O
were	O
entered	O
as	O
covariates	O
and	O
the	O
single	O
main	O
effect	O
was	O
treatment	O
.	O

Overall	O
ANCOVA	O
comparisons	O
were	O
conducted	O
comparing	O
all	O
three	O
treatment	O
groups	O
on	O
each	O
variable	O
.	O

Data	O
analysis	O
was	O
based	O
on	O
an	O
intent	O
-	O
to	O
-	O
treat	O
principle	O
.	O

Thus	O
,	O
all	O
patients	O
were	O
included	O
in	O
the	O
treatment	O
group	O
to	O
which	O
they	O
were	O
originally	O
randomized	O
.	O

In	O
cases	O
where	O
patients	O
discontinued	O
from	O
the	O
study	O
early	O
,	O
values	O
obtained	O
from	O
the	O
last	O
visit	O
were	O
carried	O
forward	O
to	O
all	O
subsequent	O
analyses	O
.	O

3	O
Results	O
3.1	O
Characteristics	O
and	O
disposition	O
of	O
study	O
subjects	O
Selected	O
characteristics	O
of	O
the	O
study	O
subjects	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Of	O
the	O
143	O
patients	O
randomized	O
,	O
48	O
received	O
placebo	O
,	O
48	O
received	O
raloxifene	B
HCl	I
60	O
mg	O
,	O
and	O
47	O
received	O
raloxifene	B
HCl	I
120	O
mg	O
.	O

The	O
raloxifene	B
60	O
mg	O
group	O
was	O
slightly	O
older	O
than	O
the	O
other	O
groups	O
.	O

This	O
difference	O
was	O
controlled	O
by	O
entering	O
age	O
as	O
a	O
covariate	O
in	O
all	O
comparisons	O
among	O
treatment	O
groups	O
.	O

The	O
overall	O
mean	O
age	O
of	O
study	O
subjects	O
was	O
68	O
years	O
.	O

The	O
incidence	O
of	O
concomitant	O
medication	O
was	O
not	O
significantly	O
different	O
among	O
treatment	O
groups	O
for	O
any	O
specific	O
medication	O
,	O
including	O
benzodiazepines	B
,	O
tricyclic	B
antidepressants	I
,	O
antipsychotics	B
,	O
and	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
.	O

The	O
percentage	O
of	O
women	O
reporting	O
an	O
alcohol	B
consumption	O
of	O
greater	O
than	O
three	O
drinks	O
per	O
week	O
was	O
significantly	O
different	O
among	O
the	O
treatment	O
groups	O
(	O
33	O
,	O
15	O
,	O
and	O
20	O
%	O
in	O
the	O
placebo	O
,	O
raloxifene	B
60	O
mg	O
,	O
and	O
raloxifene	B
120	O
mg	O
,	O
respectively	O
;	O
p	O
=	O
.022	O
)	O
.	O

Thirteen	O
patients	O
(	O
9.1	O
%	O
)	O
discontinued	O
from	O
the	O
study	O
before	O
completing	O
the	O
12	O
month	O
treatment	O
period	O
.	O

The	O
number	O
of	O
discontinuations	O
did	O
not	O
differ	O
significantly	O
among	O
the	O
treatment	O
groups	O
and	O
did	O
not	O
alter	O
the	O
age	O
distribution	O
among	O
groups	O
for	O
the	O
intent	O
-	O
to	O
-	O
treat	O
analyses	O
.	O

One	O
women	O
in	O
the	O
raloxifene	B
60	O
mg	O
group	O
died	O
of	O
unrelated	O
causes	O
(	O
pneumonia	O
)	O
,	O
two	O
discontinued	O
for	O
personal	O
reasons	O
,	O
two	O
for	O
protocol	O
variances	O
,	O
and	O
eight	O
because	O
of	O
adverse	O
events	O
.	O

The	O
percentage	O
of	O
women	O
discontinuing	O
due	O
to	O
an	O
adverse	O
event	O
was	O
not	O
significantly	O
different	O
among	O
treatment	O
groups	O
(	O
6.3	O
,	O
4.2	O
,	O
and	O
6.4	O
%	O
for	O
placebo	O
,	O
raloxifene	B
60	O
mg	O
,	O
and	O
raloxifene	B
120	O
mg	O
,	O
respectively	O
;	O
p	O
=	O
.87	O
)	O
.	O

3.2	O
Baseline	O
cognitive	O
and	O
mood	O
assessment	O
scores	O
Unadjusted	O
mean	O
baseline	O
scores	O
for	O
the	O
cognitive	O
assessments	O
and	O
GDS	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

Baseline	O
performance	O
in	O
all	O
assessments	O
was	O
not	O
significantly	O
different	O
between	O
the	O
raloxifene	B
and	O
placebo	O
groups	O
.	O

3.3	O
Effect	O
of	O
raloxifene	B
on	O
cognitive	O
assessment	O
scores	O
Scores	O
(	O
adjusted	O
for	O
age	O
and	O
baseline	O
performance	O
)	O
for	O
each	O
assessment	O
of	O
the	O
MAC	O
battery	O
at	O
month	O
1	O
,	O
6	O
,	O
and	O
12	O
,	O
are	O
displayed	O
in	O
Fig.	O
2	O
.	O

After	O
12	O
months	O
of	O
treatment	O
with	O
raloxifene	B
,	O
there	O
were	O
no	O
significant	O
differences	O
on	O
any	O
of	O
the	O
seven	O
MAC	O
assessments	O
between	O
the	O
raloxifene	B
groups	O
and	O
placebo	O
.	O

Among	O
all	O
assessments	O
and	O
all	O
time	O
points	O
,	O
only	O
one	O
significant	O
difference	O
between	O
the	O
treatment	O
groups	O
was	O
observed	O
:	O
delayed	O
recall	O
of	O
first	O
–	O
last	O
names	O
after	O
1	O
month	O
of	O
treatment	O
(	O
Fig.	O
2	O
(	O
B	O
)	O
)	O
.	O

This	O
difference	O
resulted	O
from	O
high	O
scores	O
in	O
the	O
raloxifene	B
120	O
mg	O
group	O
.	O

There	O
were	O
also	O
no	O
significant	O
differences	O
between	O
treatment	O
groups	O
at	O
any	O
time	O
point	O
on	O
any	O
of	O
the	O
three	O
Walter	O
Reed	O
PAB	O
assessments	O
tested	O
(	O
Table	O
3	O
)	O
.	O

3.4	O
Effect	O
of	O
raloxifene	B
on	O
mood	O
Patient	O
scores	O
on	O
the	O
Geriatric	O
Depression	O
Scale	O
are	O
shown	O
for	O
each	O
assessment	O
period	O
in	O
Table	O
4	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
raloxifene	B
groups	O
and	O
the	O
placebo	O
group	O
at	O
any	O
of	O
the	O
time	O
points	O
tested	O
.	O

In	O
addition	O
,	O
the	O
only	O
self	O
-	O
reported	O
adverse	O
events	O
related	O
to	O
mood	O
were	O
malaise	O
and	O
anxiety	O
;	O
the	O
incidence	O
of	O
these	O
events	O
was	O
low	O
(	O
<	O
5	O
%	O
)	O
and	O
not	O
significantly	O
different	O
among	O
treatment	O
groups	O
.	O

The	O
incidence	O
of	O
hot	O
flashes	O
,	O
an	O
event	O
that	O
may	O
have	O
secondary	O
effects	O
on	O
mood	O
in	O
postmenopausal	O
women	O
,	O
was	O
not	O
significantly	O
different	O
among	O
treatment	O
groups	O
(	O
10.4	O
,	O
14.6	O
,	O
and	O
12.8	O
%	O
for	O
placebo	O
,	O
raloxifene	B
60	O
mg	O
,	O
and	O
raloxifene	B
120	O
mg	O
,	O
respectively	O
;	O
p	O
=	O
.83	O
)	O
.	O

4	O
Discussion	O
This	O
study	O
was	O
done	O
to	O
obtain	O
preliminary	O
safety	O
assessments	O
of	O
possible	O
effects	O
of	O
raloxifene	B
on	O
cognition	O
and	O
mood	O
in	O
women	O
being	O
studied	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
osteoporosis	O
.	O

In	O
this	O
study	O
,	O
two	O
separate	O
computerized	O
batteries	O
yielded	O
ten	O
separate	O
measures	O
of	O
cognitive	O
function	O
.	O

These	O
batteries	O
were	O
administered	O
on	O
three	O
occasions	O
during	O
the	O
course	O
of	O
the	O
study	O
,	O
providing	O
30	O
separate	O
measures	O
of	O
cognitive	O
abilities	O
for	O
treatment	O
group	O
comparisons	O
.	O

A	O
mood	O
scale	O
brought	O
the	O
total	O
number	O
of	O
comparisons	O
to	O
33	O
.	O

From	O
these	O
33	O
comparisons	O
among	O
the	O
three	O
treatment	O
groups	O
,	O
only	O
one	O
significant	O
difference	O
emerged	O
(	O
first	O
–	O
last	O
names	O
delayed	O
recall	O
at	O
1	O
month	O
)	O
.	O

Beyond	O
that	O
,	O
no	O
consistent	O
or	O
meaningful	O
trends	O
were	O
seen	O
when	O
examining	O
differences	O
among	O
groups	O
.	O

Notably	O
,	O
the	O
only	O
significant	O
difference	O
between	O
raloxifene	B
and	O
placebo	O
observed	O
in	O
this	O
study	O
favored	O
the	O
raloxifene	B
120	O
mg	O
group	O
,	O
and	O
occurred	O
on	O
the	O
test	O
that	O
appears	O
to	O
be	O
most	O
sensitive	O
to	O
drug	B
-	O
induced	O
impairment	O
(	O
first	O
–	O
last	O
names	O
,	O
delayed	O
recall	O
,	O
Fig.	O
2	O
(	O
B	O
)	O
)	O
.	O

Together	O
,	O
these	O
data	O
do	O
not	O
support	O
an	O
effect	O
of	O
raloxifene	O
to	O
impair	O
cognitive	O
function	O
in	O
postmenopausal	O
women	O
treated	O
for	O
up	O
to	O
12	O
months	O
.	O

Assessment	O
of	O
mood	O
by	O
the	O
Geriatric	O
Depression	O
Scale	O
revealed	O
no	O
significant	O
differences	O
between	O
the	O
raloxifene	B
groups	O
and	O
the	O
placebo	O
group	O
at	O
any	O
assessment	O
point	O
.	O

Furthermore	O
,	O
self	O
-	O
reported	O
incidences	O
of	O
adverse	O
events	O
related	O
to	O
mood	O
also	O
did	O
not	O
differ	O
between	O
treatment	O
groups	O
.	O

Mood	O
is	O
known	O
to	O
affect	O
performance	O
on	O
cognitive	O
assessment	O
batteries	O
(	O
Palinkas	O
and	O
Barrett	O
-	O
Connor	O
,	O
1992	O
)	O
,	O
a	O
factor	O
that	O
was	O
not	O
controlled	O
for	O
in	O
some	O
studies	O
of	O
estrogen	O
and	O
cognitive	O
function	O
(	O
Hackman	O
and	O
Galbraith	O
,	O
1976	O
;	O
Sherwin	O
,	O
1988	O
)	O
.	O

Thus	O
,	O
alterations	O
in	O
mood	O
did	O
not	O
confound	O
the	O
assessment	O
of	O
cognitive	O
function	O
in	O
this	O
study	O
.	O

Assessment	O
of	O
cognitive	O
function	O
was	O
a	O
secondary	O
objective	O
in	O
this	O
study	O
with	O
the	O
primary	O
endpoint	O
of	O
determining	O
effects	O
of	O
the	O
raloxifene	B
on	O
bone	O
in	O
osteoporosis	O
.	O

However	O
,	O
the	O
test	O
batteries	O
used	O
to	O
assess	O
cognitive	O
function	O
in	O
this	O
study	O
are	O
well	O
-	O
established	O
and	O
particularly	O
sensitive	O
to	O
impairments	O
in	O
cognitive	O
function	O
(	O
West	O
and	O
Crook	O
,	O
1990	O
;	O
West	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Indeed	O
,	O
diazepam	B
induced	O
rapid	O
and	O
significant	O
impairments	O
in	O
performance	O
on	O
the	O
MAC	O
Battery	O
in	O
a	O
patient	O
cohort	O
with	O
similar	O
baseline	O
variability	O
in	O
cognitive	O
performance	O
,	O
confirming	O
the	O
sensitivity	O
of	O
this	O
battery	O
to	O
drug	B
-	O
induced	O
cognitive	O
impairments	O
.	O

The	O
estrogen	B
agonist	O
and	O
antagonist	O
effects	O
of	O
raloxifene	B
in	O
the	O
CNS	O
are	O
under	O
investigation	O
.	O

In	O
ovariectomized	O
rats	O
,	O
raloxifene	B
antagonized	O
both	O
estrogen	B
-	O
induced	O
changes	O
in	O
serum	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
levels	O
(	O
Clemens	O
et	O
al.	O
,	O
1983	O
)	O
and	O
estrogen	B
-	O
stimulated	O
expression	O
of	O
hypothalamic	O
progesterone	B
receptor	O
message	O
(	O
Shughrue	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Although	O
these	O
data	O
suggest	O
that	O
raloxifene	B
may	O
have	O
antiestrogenic	O
activity	O
at	O
the	O
level	O
of	O
the	O
hypothalamus	O
and/or	O
pituitary	O
in	O
the	O
rat	O
brain	O
,	O
its	O
effect	O
on	O
this	O
brain	O
region	O
in	O
humans	O
remains	O
unclear	O
.	O

In	O
premenopausal	O
women	O
,	O
raloxifene	B
increased	O
gonadotropin	O
levels	O
and	O
decreased	O
prolactin	O
levels	O
(	O
Baker	O
et	O
al.	O
,	O
1998	O
)	O
,	O
suggestive	O
of	O
an	O
estrogen	B
-	O
antagonist	O
effect	O
.	O

Although	O
not	O
evident	O
in	O
the	O
present	O
study	O
,	O
raloxifene	B
was	O
reported	O
to	O
increase	O
the	O
incidence	O
of	O
hot	O
flashes	O
in	O
postmenopausal	O
women	O
(	O
Draper	O
et	O
al.	O
,	O
1996	O
;	O
Walsh	O
et	O
al.	O
,	O
1998	O
)	O
.	O

However	O
,	O
it	O
has	O
not	O
been	O
established	O
that	O
this	O
effect	O
is	O
related	O
to	O
an	O
antiestrogen	O
action	O
of	O
raloxifene	B
in	O
the	O
hypothalamus	O
.	O

Indeed	O
,	O
raloxifene	B
significantly	O
decreases	O
the	O
serum	O
level	O
of	O
follicle	O
stimulating	O
hormone	O
and	O
had	O
no	O
effect	O
on	O
serum	O
LH	O
or	O
prolactin	O
levels	O
in	O
postmenopausal	O
women	O
(	O
unpublished	O
data	O
)	O
,	O
suggestive	O
of	O
either	O
a	O
neutral	O
or	O
weak	O
estrogen	B
agonist	O
effect	O
at	O
the	O
hypothalamic	O
/	O
pituitary	O
axis	O
.	O

Importantly	O
,	O
preliminary	O
results	O
suggest	O
that	O
benzothiophene	B
SERMs	B
similar	O
to	O
raloxifene	B
increase	O
the	O
expression	O
of	O
trkA	O
(	O
a	O
nerve	O
growth	O
factor	O
receptor	O
component	O
)	O
and	O
other	O
estrogen	B
-	O
responsive	O
genes	O
in	O
the	O
hippocampus	O
and	O
cortex	O
of	O
ovariectomized	O
rats	O
,	O
and	O
differential	O
display	O
analysis	O
revealed	O
identical	O
patterns	O
of	O
hippocampal	O
mRNA	O
expression	O
induced	O
by	O
treatment	O
of	O
ovariectomized	O
rats	O
with	O
estrogen	O
and	O
benzothiophene	O
analogs	O
of	O
raloxifene	B
(	O
Bryant	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Similar	O
results	O
have	O
also	O
been	O
observed	O
with	O
raloxifene	B
(	O
H.U.	O
Bryant	O
,	O
personal	O
communication	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
an	O
estrogen	O
agonist	O
-	O
like	O
effect	O
of	O
raloxifene	B
in	O
the	O
rat	O
hippocampus	O
and	O
cortex	O
.	O

Thus	O
,	O
the	O
effects	O
of	O
raloxifene	B
on	O
the	O
brain	O
are	O
likely	O
complex	O
and	O
may	O
not	O
be	O
inferred	O
solely	O
from	O
its	O
actions	O
on	O
the	O
hypothalamic	O
/	O
pituitary	O
axis	O
.	O

The	O
potential	O
of	O
raloxifene	B
to	O
improve	O
cognitive	O
performance	O
,	O
or	O
to	O
alter	O
the	O
time	O
of	O
onset	O
or	O
course	O
of	O
dementing	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
was	O
beyond	O
the	O
scope	O
of	O
this	O
safety	O
study	O
.	O

However	O
,	O
it	O
should	O
be	O
emphasized	O
that	O
,	O
despite	O
many	O
reports	O
in	O
the	O
popular	O
media	O
to	O
the	O
contrary	O
,	O
clinically	O
important	O
effects	O
of	O
estrogen	O
on	O
cognitive	O
function	O
have	O
not	O
been	O
established	O
in	O
clinical	O
trials	O
(	O
Haskell	O
et	O
al.	O
,	O
1997	O
;	O
Yaffe	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Whereas	O
some	O
observational	O
(	O
Kampen	O
and	O
Sherwin	O
,	O
1994	O
)	O
and	O
controlled	O
studies	O
(	O
Hackman	O
and	O
Galbraith	O
,	O
1976	O
;	O
Phillips	O
and	O
Sherwin	O
,	O
1992	O
)	O
suggest	O
that	O
estrogen	B
may	O
improve	O
certain	O
aspects	O
of	O
cognitive	O
function	O
in	O
postmenopausal	O
women	O
,	O
other	O
studies	O
failed	O
to	O
demonstrate	O
any	O
effect	O
of	O
estrogen	B
(	O
Rauramo	O
et	O
al.	O
,	O
1975	O
;	O
Vanhulle	O
and	O
Demol	O
,	O
1976	O
;	O
Ditkoff	O
et	O
al.	O
,	O
1991	O
;	O
Barrett	O
-	O
Connor	O
and	O
Kritz	O
-	O
Silverstein	O
,	O
1993	O
;	O
Erkkola	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Many	O
of	O
these	O
studies	O
are	O
difficult	O
to	O
compare	O
due	O
to	O
different	O
methodologies	O
used	O
to	O
assess	O
cognitive	O
function	O
,	O
variation	O
in	O
study	O
populations	O
,	O
and	O
the	O
failure	O
of	O
some	O
studies	O
to	O
consider	O
the	O
positive	O
effects	O
of	O
estrogen	B
on	O
mood	O
as	O
a	O
contributor	O
to	O
improvements	O
in	O
cognitive	O
function	O
observed	O
.	O

Taken	O
together	O
,	O
the	O
literature	O
suggests	O
that	O
estrogen	B
therapy	O
may	O
produce	O
modest	O
improvements	O
in	O
certain	O
aspects	O
of	O
cognitive	O
function	O
,	O
but	O
detecting	O
these	O
effects	O
experimentally	O
may	O
be	O
dependent	O
upon	O
the	O
patient	O
population	O
studied	O
and	O
the	O
techniques	O
used	O
to	O
assess	O
cognition	O
.	O

Studies	O
to	O
further	O
assess	O
the	O
safety	O
and	O
potential	O
efficacy	O
of	O
raloxifene	B
with	O
respect	O
to	O
cognitive	O
function	O
are	O
ongoing	O
.	O

Acknowledgements	O

The	O
authors	O
thank	O
Sushant	O
D.	O
Hardikar	O
,	O
PhD	O
,	O
for	O
critically	O
reviewing	O
the	O
manuscript	O
.	O

A	O
novel	O
series	O
of	O
nonpeptide	O
small	O
-	O
molecular	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPP	O
-	O
IV	O
)	O
inhibitors	O
with	O
an	O
N	B
-	I
phenylphthalimide	I
skeleton	O
has	O
been	O
developed	O
.	O

Some	O
of	O
the	O
compounds	O
,	O
including	O
4-amino-	B
(	I
2,6-dimethylphenyl	I
)	I
phthalimides	I
(	O
7	O
)	O
,	O
4-	B
and	O
5-hydroxy-	B
(	I
2,6-diethylphenyl	I
)	I
phthalimide	I
(	O
11	B
and	O
14	B
)	O
,	O
4-hydroxy-	B
(	I
2,6-diisopropylphenyl	I
)	I
phthalimide	I
(	O
12	B
)	O
,	O
and	O
thiocarbonyl	B
analogs	I
of	I
(	I
2,6-diisopropylphenyl	I
)	I
phthalimide	I
and	O
their	B
4,5,6,7-tetrafluorinated	I
derivative	I
(	O
18	B
,	O
19	B
and	O
20	B
)	O
,	O
were	O
more	O
potent	O
than	O
the	O
well	O
-	O
known	O
DPP	O
-	O
IV	O
-	O
specific	O
inhibitor	O
,	O
Pro	B
-	I
boroPro	I
(	O
PBP	B
)	O
.	O

Among	O
them	O
,	O
18	B
was	O
revealed	O
to	O
be	O
a	O
DPP	O
-	O
IV	O
-	O
specific	O
inhibitor	O
,	O
while	O
the	O
others	O
also	O
showed	O
inhibitory	O
activity	O
toward	O
another	O
peptidase	O
,	O
aminopeptidase	O
N	O
(	O
APN	O
)	O
.	O

Methyl-	B
and	O
hydroxymethyl	B
derivatives	I
of	I
the	O
highly	O
potent	O
glycosidase	O
inhibitor	O
isofagomine	B
are	O
accessible	O
via	O
aldolase	O
-	O
catalyzed	O
C	O
-	O
C	O
bond	O
formation	O
and	O
competitively	O
inhibit	O
beta	O
-	O
glucosidase	O
at	O
low	O
micromolar	O
concentrations	O
.	O

A	O
kilogram	O
-	O
scale	O
synthesis	O
of	O
(	B
Z	I
)	I
-3-hexen-1-yl	I
acetate	I
,	O
in	O
hexane	B
,	O
on	O
direct	O
esterification	O
of	O
(	B
Z	I
)	I
-3-hexen-1-ol	I
with	O
acetic	B
acid	I
in	O
the	O
presence	O
of	O
2	O
%	O
(	O
w	O
/	O
w	O
reactants	O
)	O
of	O
an	O
immobilized	O
lipase	O
from	O
Candida	O
antarctica	O
(	O
Novozym	O
435	O
)	O
is	O
reported	O
.	O

Conversion	O
yields	O
ranging	O
from	O
92	O
to	O
96	O
%	O
were	O
obtained	O
after	O
optimization	O
of	O
various	O
parameters	O
.	O

In	O
that	O
respect	O
,	O
elimination	O
of	O
the	O
water	B
proved	O
crucial	O
.	O

Using	O
at	O
both	O
the	O
laboratory	O
large	O
scale	O
(	O
preparation	O
of	O
200	O
-	O
400	O
g	O
of	O
ester	B
)	O
and	O
the	O
pilot	O
scale	O
(	O
1	O
-	O
5	O
kg	O
)	O
a	O
""""	O
reflux	O
""""	O
rotary	O
evaporator	O
equipped	O
with	O
a	O
graduated	O
decantation	O
flask	O
,	O
we	O
were	O
able	O
to	O
trap	O
the	O
water	B
evolved	O
during	O
esterification	O
while	O
at	O
the	O
same	O
time	O
monitor	O
the	O
time	O
course	O
of	O
the	O
reaction	O
.	O

As	O
a	O
consequence	O
of	O
both	O
an	O
efficient	O
water	B
trapping	O
and	O
of	O
a	O
gentle	O
dispersion	O
of	O
the	O
immobilized	O
lipase	O
into	O
the	O
reaction	O
medium	O
,	O
the	O
lifetime	O
of	O
the	O
enzyme	O
was	O
significantly	O
prolonged	O
.	O

At	O
the	O
laboratory	O
large	O
scale	O
(	O
LLS	O
)	O
,	O
the	O
yield	O
was	O
still	O
>	O
/=90	O
%	O
after	O
seven	O
consecutive	O
utilizations	O
whereas	O
at	O
the	O
pilot	O
scale	O
(	O
PS	O
)	O
,	O
it	O
reached	O
93	O
%	O
after	O
reusing	O
the	O
enzyme	O
four	O
times	O
.	O

In	O
those	O
conditions	O
,	O
the	O
amount	O
of	O
immobilized	O
enzyme	O
necessary	O
to	O
produce	O
1	O
kg	O
of	O
(	B
Z	I
)	I
-3-hexen-1-yl	I
acetate	I
was	O
18	O
g	O
(	O
1	O
.	O
8	O
%	O
)	O
and	O
60	O
g	O
(	O
6	O
%	O
)	O
at	O
the	O
LLS	O
and	O
the	O
PS	O
,	O
respectively	O
.	O

Copyright	O
1998	O
John	O
Wiley	O
&	O
Sons	O
,	O
Inc.	O

BACKGROUND	O
:	O
Phenylephrine	B
is	O
an	O
alpha1-adrenergic	O
agonist	O
which	O
causes	O
contraction	O
of	O
human	O
internal	O
anal	O
sphincter	O
muscle	O
in	O
vitro	O
.	O

Its	O
intra	O
-	O
arterial	O
administration	O
in	O
animals	O
has	O
been	O
shown	O
to	O
increase	O
resting	O
sphincter	O
pressure	O
in	O
vivo	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
topical	O
application	O
of	O
phenylephrine	B
on	O
resting	O
anal	O
pressure	O
in	O
healthy	O
human	O
volunteers	O
was	O
investigated	O
.	O

METHODS	O
:	O
Twelve	O
healthy	O
volunteers	O
had	O
measurements	O
of	O
maximum	O
resting	O
sphincter	O
pressure	O
(	O
MRP	O
)	O
and	O
anodermal	O
blood	O
flow	O
taken	O
before	O
and	O
after	O
topical	O
application	O
of	O
increasing	O
concentrations	O
of	O
phenylephrine	B
gel	O
to	O
the	O
anus	O
.	O

To	O
determine	O
the	O
duration	O
of	O
effect	O
of	O
the	O
agent	O
,	O
readings	O
were	O
taken	O
throughout	O
the	O
day	O
after	O
a	O
single	O
application	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
dose	O
-	O
dependent	O
rise	O
in	O
the	O
resting	O
anal	O
sphincter	O
pressure	O
,	O
with	O
a	O
small	O
8	O
per	O
cent	O
rise	O
after	O
5	O
per	O
cent	O
phenylephrine	B
(	O
P	O
=	O
0.012	O
)	O
and	O
a	O
larger	O
33	O
per	O
cent	O
rise	O
with	O
10	O
per	O
cent	O
phenylephrine	B
(	O
mean	O
(	O
s.d	O
.	O
)	O

MRP	O
85	O
(	O
12	O
)	O
cmH2O	O
before	O
versus	O
127	O
(	O
12	O
)	O
cmH2O	O
after	O
treatment	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

Thereafter	O
no	O
additional	O
response	O
was	O
noted	O
with	O
higher	O
concentrations	O
of	O
phenylephrine	B
.	O

The	O
median	O
duration	O
of	O
action	O
of	O
a	O
single	O
application	O
of	O
10	O
per	O
cent	O
phenylephrine	B
was	O
7	O
(	O
range	O
from	O
6	O
to	O
more	O
than	O
8)	O
h.	O
CONCLUSION	O
:	O
Topical	O
application	O
of	O
10	O
per	O
cent	O
phenylephrine	B
gel	O
to	O
the	O
anus	O
produces	O
a	O
significant	O
rise	O
in	O
the	O
resting	O
anal	O
sphincter	O
pressure	O
in	O
healthy	O
human	O
volunteers	O
.	O

This	O
represents	O
a	O
potential	O
novel	O
therapeutic	O
approach	O
to	O
the	O
treatment	O
of	O
passive	O
faecal	O
incontinence	O
associated	O
with	O
a	O
low	O
resting	O
anal	O
sphincter	O
pressure	O
.	O

Curcumin	B
,	O
the	O
yellow	O
pigment	O
in	O
turmeric	O
and	O
curry	O
,	O
has	O
antioxidative	O
and	O
anticarcinogenic	O
activities	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
pharmacokinetic	O
properties	O
of	O
curcumin	B
in	O
mice	O
.	O

After	O
i.p	O
.	O

administration	O
of	O
curcumin	B
(	O
0.1	O
g	O
/	O
kg	O
)	O
to	O
mice	O
,	O
about	O
2.25	O
microg	O
/	O
ml	O
of	O
curcumin	B
appeared	O
in	O
the	O
plasma	O
in	O
the	O
first	O
15	O
min	O
.	O

One	O
hour	O
after	O
administration	O
,	O
the	O
levels	O
of	O
curcumin	B
in	O
the	O
intestines	O
,	O
spleen	O
,	O
liver	O
,	O
and	O
kidneys	O
were	O
177.04	O
,	O
26.06	O
,	O
26.90	O
,	O
and	O
7.51	O
microg	O
/	O
g	O
,	O
respectively	O
.	O

Only	O
traces	O
(	O
0.41	O
microg	O
/	O
g	O
)	O
were	O
observed	O
in	O
the	O
brain	O
at	O
1	O
h.	O
To	O
clarify	O
the	O
nature	O
of	O
the	O
metabolites	O
of	O
curcumin	B
,	O
the	O
plasma	O
was	O
analyzed	O
by	O
reversed	O
-	O
phase	O
HPLC	O
,	O
and	O
two	O
putative	B
conjugates	I
were	O
observed	O
.	O

Treatment	O
of	O
the	O
plasma	O
with	O
beta	O
-	O
glucuronidase	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
concentrations	O
of	O
these	O
two	O
putative	O
conjugates	O
and	O
the	O
concomitant	O
appearance	O
of	O
tetrahydrocurcumin	B
(	O
THC	B
)	O
and	O
curcumin	B
,	O
respectively	O
.	O

To	O
investigate	O
the	O
nature	O
of	O
these	O
glucuronide	B
conjugates	I
in	O
vivo	O
,	O
the	O
plasma	O
was	O
analyzed	O
by	O
electrospray	O
.	O

The	O
chemical	O
structures	O
of	O
these	O
metabolites	O
,	O
determined	O
by	O
mass	O
spectrometry	O
/	O
mass	O
spectrometry	O
analysis	O
,	O
suggested	O
that	O
curcumin	B
was	O
first	O
biotransformed	O
to	O
dihydrocurcumin	B
and	O
THC	B
and	O
that	O
these	O
compounds	O
subsequently	O
were	O
converted	O
to	O
monoglucuronide	B
conjugates	O
.	O

Because	O
THC	B
is	O
one	O
of	O
the	O
major	O
metabolites	O
of	O
curcumin	B
,	I
we	O
studied	O
its	O
stability	O
at	O
different	O
pH	O
values	O
.	O

THC	B
was	O
very	O
stable	O
in	O
0.1	O
M	O
phosphate	B
buffers	O
of	O
various	O
pH	O
values	O
.	O

Moreover	O
,	O
THC	B
was	O
more	O
stable	O
than	O
curcumin	B
in	O
0.1	O
M	O
phosphate	B
buffer	O
,	O
pH	O
7.2	O
(	O
37	O
degrees	O
C	O
)	O
.	O

These	O
results	O
,	O
together	O
with	O
previous	O
findings	O
,	O
suggest	O
that	O
curcumin	B
-	I
glucuronoside	I
,	O
dihydrocurcumin	B
-	I
glucuronoside	I
,	O
THC	B
-	I
glucuronoside	I
,	O
and	O
THC	B
are	O
major	O
metabolites	O
of	O
curcumin	B
in	O
vivo	O
.	O

Forty	O
-	O
eight	O
patients	O
with	O
acute	O
proximal	O
deep	O
vein	O
thrombosis	O
(	O
DVT	O
)	O
were	O
randomised	O
to	O
intravenous	O
infusions	O
for	O
4	O
to	O
6	O
days	O
with	O
melagatran	B
,	O
a	O
novel	O
synthetic	O
low	O
molecular	O
weight	O
thrombin	O
inhibitor	O
,	O
or	O
unfractionated	O
heparin	B
adjusted	O
by	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
the	O
safety	O
of	O
melagatran	B
therapy	O
at	O
three	O
different	O
doses	O
.	O

Steady	O
-	O
state	O
plasma	O
concentrations	O
were	O
rapidly	O
achieved	O
and	O
maintained	O
throughout	O
the	O
infusion	O
period	O
.	O

The	O
mean	O
plasma	O
concentrations	O
in	O
the	O
low	O
,	O
medium	O
and	O
high	O
dose	O
groups	O
were	O
0.17	O
,	O
0.31	O
and	O
0.53	O
micromol	O
/	O
l	O
,	O
respectively	O
.	O

The	O
prolongation	O
of	O
APTT	O
was	O
stable	O
during	O
the	O
melagatran	B
infusions	O
and	O
correlated	O
to	O
the	O
plasma	O
concentration	O
.	O

Phlebographically	O
verified	O
regression	O
of	O
thrombus	O
size	O
measured	O
as	O
decrease	O
in	O
Marder	O
score	O
was	O
seen	O
after	O
4	O
to	O
6	O
days	O
in	O
8	O
of	O
12	O
patients	O
,	O
6	O
of	O
12	O
patients	O
and	O
5	O
of	O
11	O
patients	O
in	O
the	O
low	O
,	O
medium	O
and	O
high	O
dose	O
groups	O
of	O
melagatran	B
and	O
in	O
5	O
of	O
the	O
heparin	B
-	O
treated	O
patients	O
.	O

In	O
the	O
low	O
dose	O
group	O
with	O
melagatran	B
,	O
thrombus	O
extension	O
was	O
seen	O
in	O
one	O
patient	O
.	O

At	O
the	O
dose	O
levels	O
studied	O
,	O
melagatran	B
was	O
well	O
tolerated	O
with	O
no	O
clinically	O
significant	O
bleeding	O
problems	O
,	O
suggesting	O
that	O
melagatran	B
could	O
safely	O
be	O
given	O
to	O
patients	O
suffering	O
from	O
DVT	O
.	O

Bacterial	O
strain	O
LW1	O
,	O
which	O
belongs	O
to	O
the	O
family	O
Comamonadaceae	O
,	O
utilizes	O
1-chloro-4-nitrobenzene	B
(	O
1C4NB	B
)	O
as	O
a	O
sole	O
source	O
of	O
carbon	B
,	O
nitrogen	B
,	O
and	O
energy	O
.	O

Suspensions	O
of	O
1C4NB	B
-	O
grown	O
cells	O
removed	O
1C4NB	B
from	O
culture	O
fluids	O
,	O
and	O
there	O
was	O
a	O
concomitant	O
release	O
of	O
ammonia	B
and	O
chloride	B
.	O

Under	O
anaerobic	O
conditions	O
LW1	O
transformed	O
1C4NB	B
into	O
a	O
product	O
which	O
was	O
identified	O
as	O
2-amino-5-chlorophenol	B
by	O
1H	O
and	O
13C	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
and	O
mass	O
spectrometry	O
.	O

This	O
transformation	O
indicated	O
that	O
there	O
was	O
partial	O
reduction	O
of	O
the	O
nitro	B
group	O
to	O
the	O
hydroxylamino	B
substituent	O
,	O
followed	O
by	O
Bamberger	O
rearrangement	O
.	O

In	O
the	O
presence	O
of	O
oxygen	B
but	O
in	O
the	O
absence	O
of	O
NAD	B
,	O
fast	O
transformation	O
of	O
2-amino-5-chlorophenol	B
into	O
a	O
transiently	O
stable	O
yellow	O
product	O
was	O
observed	O
with	O
resting	O
cells	O
and	O
cell	O
extracts	O
.	O

This	O
compound	O
exhibited	O
an	O
absorption	O
maximum	O
at	O
395	O
nm	O
and	O
was	O
further	O
converted	O
to	O
a	O
dead	O
-	O
end	O
product	O
with	O
maxima	O
at	O
226	O
and	O
272	O
nm	O
.	O

The	O
compound	O
formed	O
was	O
subsequently	O
identified	O
by	O
1H	O
and	O
13C	O
NMR	O
spectroscopy	O
and	O
mass	O
spectrometry	O
as	O
5-chloropicolinic	B
acid	I
.	O

In	O
contrast	O
,	O
when	O
NAD	B
was	O
added	O
in	O
the	O
presence	O
of	O
oxygen	B
,	O
only	O
minor	O
amounts	O
of	O
5-chloropicolinic	B
acid	I
were	O
formed	O
,	O
and	O
a	O
new	O
product	O
,	O
which	O
exhibited	O
an	O
absorption	O
maximum	O
at	O
306	O
nm	O
,	O
accumulated	O
.	O

In	O
this	O
article	O
,	O
a	O
cost	O
-	O
minimization	O
model	O
was	O
used	O
to	O
make	O
an	O
economic	O
comparison	O
between	O
cefmetazole	B
and	O
cefoxitin	B
--	O
two	O
drugs	O
with	O
comparable	O
in	O
vitro	O
spectra	O
of	O
activity	O
,	O
clinical	O
efficacy	O
,	O
and	O
safety	O
profiles	O
.	O

Drug	O
acquisition	O
costs	O
were	O
estimated	O
from	O
published	O
information	O
and	O
labor	O
and	O
material	O
costs	O
were	O
calculated	O
based	O
on	O
actual	O
costs	O
at	O
Presbyterian	O
Hospital	O
of	O
Dallas	O
.	O

Costs	O
of	O
the	O
agents	O
were	O
calculated	O
based	O
on	O
the	O
dosage	O
and	O
administration	O
schedules	O
typically	O
used	O
in	O
published	O
clinical	O
trials	O
of	O
cefmetazole	B
and	O
cefoxitin	B
and	O
on	O
the	O
typical	O
dosing	O
patterns	O
of	O
cefoxitin	B
used	O
at	O
Presbyterian	O
Hospital	O
.	O

Results	O
of	O
the	O
cost	O
analysis	O
revealed	O
that	O
an	O
annual	O
savings	O
of	O
$	O
36,015	O
to	O
$	O
59,143	O
could	O
be	O
realized	O
at	O
Presbyterian	O
Hospital	O
if	O
cefmetazole	B
were	O
used	O
in	O
place	O
of	O
cefoxitin	B
for	O
surgical	O
prophylaxis	O
.	O

Furthermore	O
,	O
use	O
of	O
cefmetazole	B
in	O
place	O
of	O
cefoxitin	B
for	O
wound	O
treatment	O
would	O
yield	O
annual	O
savings	O
of	O
$	O
33,242	O
.	O

Aspergillus	O
candidus	O
Link	O
,	O
one	O
of	O
the	O
commonest	O
constituents	O
of	O
cereal	O
mycoflora	O
,	O
produces	O
two	O
kinds	O
of	O
mycotoxins	O
,	O
terphenyllin	B
and	O
xanthoascin	B
,	O
which	O
show	O
different	O
chemical	O
and	O
toxicological	O
properties	O
.	O

The	O
latter	O
,	O
xanthoascin	B
,	O
caused	O
severe	O
hepatic	O
injury	O
with	O
jaundice	O
and	O
focal	O
or	O
confluent	O
necrosis	O
of	O
hepatocytes	O
,	O
when	O
given	O
to	O
mice	O
in	O
doses	O
of	O
6	O
mg	O
/	O
kg	O
b.w	O
.	O

or	O
higher	O
by	O
a	O
single	O
subcutaneous	O
injection	O
.	O

With	O
higher	O
doses	O
above	O
15	O
mg	O
/	O
kg	O
,	O
myocardial	O
degeneration	O
and	O
necrosis	O
was	O
induced	O
after	O
a	O
week	O
or	O
two	O
in	O
addition	O
to	O
the	O
hepatic	O
injury	O
.	O

Vacuolation	O
of	O
the	O
nuclei	O
of	O
the	O
alveolar	O
interstitial	O
cells	O
of	O
the	O
lung	O
and	O
myocardial	O
interstitial	O
cells	O
was	O
another	O
characteristic	O
lesion	O
caused	O
by	O
this	O
mycotoxin	O
.	O

Other	O
organs	O
including	O
the	O
testicles	O
and	O
thymus	O
were	O
widely	O
involved	O
.	O

The	O
unique	O
nature	O
of	O
lesions	O
in	O
the	O
liver	O
and	O
heart	O
may	O
necessitate	O
further	O
investigations	O
in	O
the	O
field	O
of	O
mycotoxicology	O
in	O
relation	O
to	O
human	O
diseases	O
such	O
as	O
nutritional	O
hepatitis	O
and	O
primary	O
myocardial	O
degeneration	O
.	O

1	O
.	O

The	O
central	O
depressant	O
effects	O
of	O
bromvaletone	B
,	O
carbromal	B
and	O
six	O
non	B
-	I
bromo	I
analogues	I
were	O
compared	O
in	O
mice	O
.	O

2	O
.	O

The	O
chloro	B
analogues	I
of	I
bromvaletone	B
and	O
carbromal	B
were	O
slightly	O
less	O
potent	O
as	O
central	O
depressant	O
agents	O
than	O
the	O
bromo	B
compounds	I
.	O

3	O
.	O

The	O
chloro	B
analogue	I
of	I
bromvaletone	I
had	O
the	O
greatest	O
margin	O
between	O
central	O
depressant	O
and	O
lethal	O
doses	O
.	O

4	O
.	O
Lipophilicity	O
(	O
octanol	B
-	O
water	B
partition	O
coefficient	O
)	O
did	O
not	O
provide	O
a	O
unifying	O
relationship	O
for	O
potency	O
within	O
this	O
group	O
of	O
eight	O
acylureas	B
.	O

However	O
,	O
within	O
each	O
of	O
the	O
two	O
subsets	O
of	O
compounds	O
,	O
a	O
linear	O
relationship	O
was	O
found	O
between	O
relative	O
potency	O
and	O
lipophilicity	O
.	O

Isoguanine	B
(	O
2	O
)	O
was	O
found	O
to	O
be	O
an	O
antineoplastic	O
constituent	O
of	O
Prioneris	O
thestylis	O
Dbldy	O
.	O

wings	O
.	O

Three	O
other	O
purine	B
components	I
of	O
the	O
butterfly	O
wings	O
were	O
identified	O
as	O
hypoxanthine	B
(	O
3	O
)	O
,	O
uric	B
acid	I
(	O
4	O
)	O
and	O
xanthine	B
(	O
5	O
)	O
.	O

Isolation	O
of	O
urocanic	B
acid	I
(	O
6	O
)	O
from	O
the	O
same	O
wing	O
material	O
represented	O
the	O
first	O
detection	O
of	O
this	O
interesting	O
histidine	B
derivative	I
in	O
an	O
arthropod	O
.	O

Antiandrogenic	B
chemicals	I
alter	O
sexual	O
differentiation	O
by	O
a	O
variety	O
of	O
mechanisms	O
,	O
and	O
as	O
a	O
consequence	O
,	O
they	O
induce	O
different	O
profiles	O
of	O
effects	O
.	O

For	O
example	O
,	O
in	O
utero	O
treatment	O
with	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
antagonist	O
,	O
flutamide	B
,	O
produces	O
ventral	O
prostate	O
agenesis	O
and	O
testicular	O
nondescent	O
,	O
while	O
in	O
contrast	O
,	O
finasteride	B
,	O
an	O
inhibitor	O
of	O
5	B
alpha	I
-	I
dihydrotestosterone	I
(	O
DHT	B
)	I
synthesis	O
,	O
rarely	O
,	O
if	O
ever	O
,	O
induces	O
such	O
malformations	O
.	O

In	O
this	O
regard	O
,	O
it	O
was	O
recently	O
proposed	O
that	O
dibutyl	B
phthalate	I
(	O
DBP	B
)	O
alters	O
reproductive	O
development	O
by	O
a	O
different	O
mechanism	O
of	O
action	O
than	O
flutamide	B
or	O
vinclozolin	B
(	O
V	B
)	O
,	O
which	O
are	O
AR	O
antagonists	O
,	O
because	O
the	O
male	O
offsprings	O
display	O
an	O
unusually	O
high	O
incidence	O
of	O
testicular	O
and	O
epididymal	O
alterations	O
--	O
effects	O
rarely	O
seen	O
after	O
in	O
utero	O
flutamide	B
or	O
V	B
treatment	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
original	O
data	O
describing	O
the	O
reproductive	O
effects	O
of	O
10	O
known	O
or	O
suspected	O
anti	O
-	O
androgens	O
,	O
including	O
a	O
Leydig	O
cell	O
toxicant	O
ethane	B
dimethane	I
sulphonate	I
(	O
EDS	B
,	O
50	O
mg	O
kg-1	O
day-1	O
)	O
,	O
linuron	B
(	O
L	B
,	O
100	O
mg	O
kg-1	O
day-1	O
)	O
,	O
p	B
,	I
p'-DDE	I
(	O
100	O
mg	O
kg-1	O
day-1	O
)	O
,	O
ketoconazole	B
(	O
12	O
-	O
50	O
mg	O
kg-1	O
day-1	O
)	O
,	O
procymidone	B
(	O
P	B
,	O
100	O
mg	O
kg-1	O
day-1	O
)	O
,	O
chlozolinate	B
(	O
100	O
mg	O
kg-1	O
day-1	O
)	O
,	O
iprodione	B
(	O
100	O
mg	O
kg-1	O
day-1	O
)	O
,	O
DBP	B
(	O
500	O
mg	O
kg-1	O
day-1	O
)	O
,	O
diethylhexyl	B
phthalate	I
(	O
DEHP	B
,	O
750	O
mg	O
kg-1	O
day-1	O
)	O
,	O
and	O
polychlorinated	B
biphenyl	I
(	O
PCB	B
)	O
congener	B
no.	I
169	I
(	O
single	O
dose	O
of	O
1.8	O
mg	O
kg-1	O
)	O
.	O

Our	O
analysis	O
indicates	O
that	O
the	O
chemicals	B
discussed	O
here	O
can	O
be	O
clustered	O
into	O
three	O
or	O
four	O
separate	O
groups	O
,	O
based	O
on	O
the	O
resulting	O
profiles	O
of	O
reproductive	O
effects	O
.	O

Vinclozolin	B
,	O
P	B
,	O
and	O
DDE	B
,	O
known	O
AR	B
ligands	I
,	O
produce	O
similar	O
profiles	O
of	O
toxicity	O
.	O

However	O
,	O
p	B
,	I
p'-DDE	I
is	O
less	O
potent	O
in	O
this	O
regard	O
.	O

DBP	B
and	O
DEHP	B
produce	O
a	O
profile	O
distinct	O
from	O
the	O
above	O
AR	B
ligands	I
.	O

Male	O
offsprings	O
display	O
a	O
higher	O
incidence	O
of	O
epididymal	O
and	O
testicular	O
lesions	O
than	O
generally	O
seen	O
with	O
flutamide	B
,	O
P	B
,	O
or	O
V	B
even	O
at	O
high	O
dosage	O
levels	O
.	O

Linuron	B
treatment	O
induced	O
a	O
level	O
of	O
external	O
effects	O
consistent	O
with	O
its	O
low	O
affinity	O
for	O
AR	O
[	O
reduced	O
anogenital	O
distance	O
(	O
AGD	O
)	O
,	O
retained	O
nipples	O
,	O
and	O
a	O
low	O
incidence	O
of	O
hypospadias	O
]	O
.	O

However	O
,	O
L	B
treatment	O
also	O
induced	O
an	O
unanticipated	O
degree	O
of	O
malformed	O
epididymides	O
and	O
testis	O
atrophy	O
.	O

In	O
fact	O
,	O
the	O
profile	O
of	O
effects	O
induced	O
by	O
L	B
was	O
similar	O
to	O
that	O
seen	O
with	O
DBP	B
.	O

These	O
results	O
suggest	O
that	O
L	B
may	O
display	O
several	O
mechanisms	O
of	O
endocrine	O
toxicity	O
,	O
one	O
of	O
which	O
involves	O
AR	O
binding	O
.	O

Chlozolinate	B
and	O
iprodione	B
did	O
not	O
produce	O
any	O
signs	O
of	O
maternal	O
or	O
fetal	O
endocrine	O
toxicity	O
at	O
100	O
mg	O
kg-1	O
day-1	O
.	O

EDS	B
produced	O
severe	O
maternal	O
toxicity	O
and	O
a	O
45	O
%	O
reduction	O
in	O
size	O
at	O
birth	O
,	O
which	O
resulted	O
in	O
the	O
death	O
of	O
all	O
neonates	O
by	O
5	O
days	O
of	O
age	O
.	O

However	O
,	O
EDS	B
only	O
reduced	O
AGD	O
in	O
male	O
pups	O
by	O
15	O
%	O
.	O

Ketoconazole	B
did	O
not	O
demasculinize	O
or	O
feminize	O
males	O
but	O
rather	O
displayed	O
anti	O
-	O
hormonal	O
activities	O
,	O
apparently	O
by	O
inhibiting	O
ovarian	O
hormone	O
synthesis	O
,	O
which	O
resulted	O
in	O
delayed	O
delivery	O
and	O
whole	O
litter	O
loss	O
.	O

In	O
summary	O
,	O
the	O
above	O
in	O
vivo	O
data	O
suggest	O
that	O
the	O
chemicals	B
we	O
studied	O
alter	O
male	O
sexual	O
differentiation	O
via	O
different	O
mechanisms	O
.	O

The	O
anti	O
-	O
androgens	O
V	B
,	O
P	B
,	O
and	O
p	B
,	I
p'-DDE	I
produce	O
flutamide	B
-	O
like	O
profiles	O
that	O
are	O
distinct	O
from	O
those	O
seen	O
with	O
DBP	B
,	O
DEHP	B
,	O
and	O
L.	B
The	O
effects	O
of	O
PCB	B
169	O
bear	O
little	O
resemblance	O
to	O
those	O
of	O
any	O
known	O
anti	O
-	O
androgen	O
.	O

Only	O
in	O
depth	O
in	O
vitro	O
studies	O
will	O
reveal	O
the	O
degree	O
to	O
which	O
one	O
can	O
rely	O
upon	O
in	O
vivo	O
studies	O
,	O
like	O
those	O
presented	O
here	O
,	O
to	O
predict	O
the	O
cellular	O
and	O
molecular	O
mechanisms	O
of	O
developmental	O
toxicity	O
.	O

Lysine	B
clonixinate	I
(	O
LC	B
)	I
is	O
a	O
drug	O
of	O
antiinflammatory	O
antipyretic	O
and	O
analgesic	O
activity	O
that	O
produces	O
minor	O
digestive	O
side	O
-	O
effects	O
.	O

This	O
fact	O
induced	O
us	O
to	O
think	O
that	O
LC	B
is	O
possibly	O
a	O
weak	O
COX-1	O
inhibitor	O
.	O

In	O
order	O
to	O
investigate	O
our	O
hypothesis	O
we	O
inhibited	O
cyclooxygenase	O
activity	O
with	O
LC	B
or	O
indomethacin	B
(	O
INDO	B
)	O
in	O
rat	O
lung	O
and	O
stomach	O
obtained	O
from	O
rats	O
treated	O
with	O
lipopolysacharide	B
(	O
LPS	B
)	O
and	O
control	O
rats	O
.	O

Rat	O
lung	O
preparations	O
incubated	O
with	O
14C	B
-	I
arachidonic	I
acid	I
synthesise	O
mainly	O
PGE2	B
.	O

LC	B
at	O
2.5	O
and	O
4.1	O
x	O
10	O
(	O
-5	O
)	O
M	O
does	O
not	O
modify	O
the	O
basal	O
production	O
of	O
PGE2	B
(	O
probably	O
COX-1	O
)	O
but	O
at	O
6.8	O
x	O
10	O
(	O
-5	O
)	O
M	O
significantly	O
inhibited	O
PGE2	B
production	O
(	O
approximately	O
48.5	O
%	O
inhibition	O
,	O
P<0.001	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
INDO	B
at	O
10	O
(	O
-6	O
)	O
inhibited	O
the	O
basal	O
production	O
of	O
PGE2	B
by	O
around	O
73	O
%	O
.	O

In	O
LPS	B
-	O
treated	O
rats	O
,	O
the	O
production	O
of	O
PGE2	B
was	O
significantly	O
higher	O
than	O
in	O
the	O
lungs	O
of	O
control	O
rats	O
,	O
probably	O
due	O
to	O
the	O
induction	O
of	O
COX-2	O
.	O

The	O
addition	O
of	O
LC	B
at	O
2.7	O
and	O
4.1	O
x	O
10	O
(	O
-5	O
)	O
M	O
recovered	O
the	O
control	O
values	O
of	O
PGE2	B
inhibiting	O
,	O
probably	O
only	O
from	O
COX-2	O
activity	O
.	O

LC	B
at	O
higher	O
concentrations	O
(	O
6.8	O
x	O
10	O
(	O
-5	O
)	O
M	O
)	O
and	O
INDO	B
10	O
(	O
-6	O
)	O
M	O
inhibited	O
PGE2	B
formed	O
by	O
COX-2	O
and	O
also	O
partly	O
by	O
COX-1	O
activity	O
.	O

The	O
leaves	O
of	O
the	O
composite	O
Solidago	O
canadensis	O
(	O
goldenrod	O
)	O
were	O
shown	O
to	O
contain	O
(	O
-	O
)	O
-alpha	O
-	O
gurjunene	O
synthase	O
activity	O
.	O

This	O
sesquiterpene	B
is	O
likely	O
to	O
be	O
the	O
precursor	O
for	O
cyclocolorenone	B
,	O
a	O
sesquiterpene	B
ketone	I
present	O
in	O
high	O
amounts	O
in	O
S.	O
canadensis	O
leaves	O
.	O

(	O
-	O
)	O
-alpha	O
-	O
Gurjunene	O
synthase	O
was	O
purified	O
to	O
apparent	O
homogeneity	O
(	O
741-fold	O
)	O
by	O
anion	O
-	O
exchange	O
chromatography	O
(	O
on	O
several	O
matrices	O
)	O
,	O
dye	O
ligand	O
chromatography	O
,	O
hydroxylapatite	B
chromatography	O
,	O
and	O
gel	B
filtration	O
.	O

Chromatography	O
on	O
a	O
gel	B
filtration	O
matrix	O
indicated	O
a	O
native	O
molecular	O
mass	O
of	O
48	O
kDa	O
,	O
and	O
SDS	O
-	O
PAGE	O
showed	O
the	O
enzyme	O
to	O
be	O
composed	O
of	O
one	O
subunit	O
with	O
a	O
denatured	O
mass	O
of	O
60	O
kDa	O
.	O

Its	O
maximum	O
activity	O
was	O
observed	O
at	O
pH	O
7.8	O
in	O
the	O
presence	O
of	O
10	O
mM	O
Mg2	B
+	I
and	O
the	O
KM	O
value	O
for	O
the	O
substrate	O
farnesyl	B
diphosphate	I
was	O
5.5	O
microM.	O
Over	O
a	O
range	O
of	O
purification	O
steps	O
(	O
-	O
)	O
-alpha	O
-	O
gurjunene	O
and	O
(	O
+	O
)	O
-gamma	O
-	O
gurjunene	O
synthase	O
activities	O
copurified	O
.	O

In	O
addition	O
,	O
the	O
product	O
ratio	O
of	O
the	O
enzyme	O
activity	O
under	O
several	O
different	O
assay	O
conditions	O
was	O
always	O
91	O
%	O
(	B
-	I
)	I
-alpha	I
-	I
gurjunene	I
and	O
9	O
%	O
(	B
+	I
)	I
-gamma	I
-	I
gurjunene	I
.	O

This	O
suggests	O
that	O
the	O
formation	O
of	O
these	O
two	O
structurally	O
related	O
products	O
is	O
catalyzed	O
by	O
one	O
enzyme	O
.	O

For	O
further	O
confirmation	O
,	O
we	O
carried	O
out	O
a	O
number	O
of	O
mechanistic	O
studies	O
with	O
(	O
-	O
)	O
-alpha	O
-	O
gurjunene	O
synthase	O
,	O
in	O
which	O
an	O
enzyme	O
preparation	O
was	O
incubated	O
with	O
deuterated	B
substrate	I
analogues	I
.	O

Based	O
on	O
mass	O
spectrometry	O
analysis	O
of	O
the	O
products	O
formed	O
,	O
a	O
cyclization	O
mechanism	O
was	O
postulated	O
which	O
makes	O
it	O
plausible	O
that	O
the	O
synthase	O
catalyzes	O
the	O
formation	O
of	O
both	O
sesquiterpenes	B
.	O

The	O
stereochemistry	O
of	O
the	O
alpha	O
-	O
oxidation	O
of	O
3-methyl	B
-	I
branched	I
fatty	I
acids	I
was	O
studied	O
in	O
rat	O
liver	O
.	O

R-	B
and	O
S-3-methylhexadecanoic	B
acid	I
were	O
equally	O
well	O
alpha	O
-	O
oxidized	O
in	O
intact	O
hepatocytes	O
and	O
homogenates	O
.	O

Subcellular	O
fractionation	O
studies	O
showed	O
that	O
alpha	O
-	O
oxidation	O
of	O
both	O
isomers	O
is	O
confined	O
to	O
peroxisomes	O
.	O

Dehydrogenation	O
of	O
2-methylpentadecanal	B
,	O
the	O
end	O
-	O
product	O
of	O
the	O
peroxisomal	O
alpha	O
-	O
oxidation	O
of	O
3-methylhexadecanoic	B
acid	I
,	O
to	O
2-methylpentadecanoic	B
acid	I
,	O
followed	O
by	O
derivatization	O
with	O
R-1-phenylethylamine	B
and	O
subsequent	O
separation	O
of	O
the	O
stereoisomers	O
by	O
gas	O
chromatography	O
,	O
revealed	O
that	O
the	O
configuration	O
of	O
the	O
methyl	O
-	O
branch	O
is	O
preserved	O
throughout	O
the	O
whole	O
alpha	O
-	O
oxidation	O
process	O
.	O

Metabolism	O
and	O
formation	O
of	O
the	O
2-hydroxy-3-methylhexadecanoyl	B
-	I
CoA	I
intermediate	O
were	O
also	O
investigated	O
.	O

Separation	O
of	O
the	O
methyl	B
esters	I
of	O
the	O
four	O
isomers	O
of	B
2-hydroxy-3-methylhexadecanoic	I
acid	I
was	O
achieved	O
by	O
gas	O
chromatography	O
after	O
derivatization	O
of	O
the	O
hydroxy	O
group	O
with	O
R-2-methoxy-2-trifluoromethylphenylacetic	B
acid	I
chloride	I
and	O
the	O
absolute	O
configuration	O
of	O
the	O
four	O
isomers	O
was	O
determined	O
.	O

Although	O
purified	O
peroxisomes	O
are	O
capable	O
of	O
metabolizing	O
all	O
four	O
isomers	O
of	O
2-hydroxy-3-methylhexadecanoyl	B
-	I
CoA	I
,	I
they	O
can	O
only	O
form	O
the	O
(	O
2S,3R	O
)	O
and	O
the	O
(	O
2R,3S	O
)	O
isomers	O
.	O

Our	O
experiments	O
exclude	O
the	O
racemization	O
of	O
the	O
3-methyl	O
branch	O
during	O
the	O
alpha	O
-	O
oxidation	O
process	O
.	O

The	O
configuration	O
of	O
the	O
3-methyl	O
branch	O
does	O
not	O
influence	O
the	O
rate	O
of	O
alpha	O
-	O
oxidation	O
,	O
but	O
determines	O
the	O
side	O
of	O
the	O
2-hydroxylation	O
,	O
hence	O
the	O
configuration	O
of	O
the	O
2-hydroxy-3-methylacyl	B
-	I
CoA	I
intermediates	O
formed	O
during	O
the	O
process	O
.	O

Mass	O
transport	O
of	O
electrolyte	O
species	O
during	O
the	O
redox	O
reaction	O
of	O
conducting	B
polymers	I
,	O
plays	O
an	O
important	O
role	O
in	O
determining	O
their	O
electrochemical	O
characteristics	O
,	O
and	O
has	O
been	O
extensively	O
investigated	O
by	O
many	O
groups	O
[	O
1,2	O
]	O
.	O

In	O
general	O
,	O
the	O
mass	O
transport	O
mechanism	O
is	O
very	O
complex	O
,	O
because	O
dual	O
ion	B
transport	O
,	O
solvent	O
transport	O
,	O
and	O
neutral	O
salt	O
transport	O
are	O
present	O
and	O
they	O
depend	O
on	O
the	O
applied	O
potential	O
.	O

In	O
spite	O
of	O
these	O
complexities	O
,	O
considerable	O
progress	O
has	O
been	O
made	O
in	O
the	O
elucidation	O
of	O
the	O
mass	O
transport	O
mechanism	O
in	O
an	O
aqueous	B
solution	O
.	O

Recently	O
,	O
we	O
reported	O
valuable	O
information	O
on	O
water	B
transport	O
in	O
polypyrrole	B
(	O
PPy	B
)	O
and	O
poly	B
(	I
N	I
-methylpyrrole	I
)	I
(	O
PMPy	B
)	O
films	O
[	O
3,4	O
]	O
.	O

We	O
showed	O
that	O
water	B
transport	O
accompanying	O
cation	B
transport	O
in	O
a	O
PPy	B
film	O
depends	O
on	O
the	O
nature	O
and	O
concentration	O
of	O
the	O
electrolyte	O
solution	O
as	O
well	O
as	O
the	O
applied	O
potential	O
.	O

We	O
also	O
showed	O
that	O
water	B
transport	O
during	O
anion	B
transport	O
in	O
a	O
PMPy	B
film	O
does	O
not	O
change	O
extensively	O
with	O
the	O
concentration	O
of	O
the	O
electrolyte	O
solution	O
and	O
the	O
applied	O
potential	O
.	O

Moreover	O
,	O
it	O
was	O
found	O
that	O
the	O
amount	O
of	O
accompanying	O
water	B
per	O
ion	B
affects	O
the	O
ionic	O
conductivity	O
in	O
the	O
film	O
and	O
the	O
morphology	O
change	O
of	O
a	O
film	O
.	O

Although	O
the	O
mass	O
transport	O
study	O
of	O
conducting	B
polymers	I
in	O
polar	B
aprotic	I
solvents	I
has	O
been	O
an	O
important	O
topic	O
because	O
of	O
Li	B
battery	O
application	O
[	O
5,6	O
]	O
,	O
the	O
study	O
in	O
such	O
solvents	B
has	O
not	O
been	O
performed	O
as	O
extensively	O
as	O
in	O
aqueous	B
solutions	O
.	O

Daifuku	O
et	O
al.	O
[	O
7,8	O
]	O
reported	O
that	O
only	O
anion	B
transport	O
occurs	O
during	O
the	O
redox	O
reaction	O
of	O
polyaniline	B
(	O
PAn	B
)	O
films	O
in	O
acetonitrile	B
(	O
AN	B
)	O
containing	O
LiClO4	B
.	O

Desilvestro	O
et	O
al.	O
[	O
9	O
]	O
showed	O
that	O
some	O
propylene	B
carbonate	I
(	O
PC	B
)	O
molecules	O
move	O
in	O
the	O
same	O
or	O
in	O
the	O
opposite	O
direction	O
with	O
respect	O
to	O
anion	B
transport	O
during	O
the	O
redox	O
reaction	O
of	O
PAn	B
films	O
in	O
a	O
PC	B
solution	O
.	O

Hillman	O
et	O
al.	O
[	O
10	O
]	O
insisted	O
that	O
a	O
neutral	O
salt	O
as	O
well	O
as	O
an	O
anion	B
and	O
a	O
solvent	B
take	O
part	O
in	O
mass	O
transport	O
of	O
polybithiophene	B
films	O
in	O
AN	B
.	O

Schiavon	O
et	O
al.	O
[	O
11	O
]	O
showed	O
that	O
ion	B
transport	O
is	O
anion	B
-	O
specific	O
in	O
the	O
case	O
of	O
poly	B
(	I
N	I
-alkyl	I
-	I
substituted	I
pyrrole	I
)	I
films	O
in	O
an	O
AN	B
solution	O
and	O
that	O
some	O
AN	B
molecules	O
move	O
in	O
the	O
opposite	O
direction	O
to	O
anion	B
transport	O
.	O

Thus	O
,	O
mass	O
transport	O
in	O
an	O
aprotic	B
solvent	I
is	O
very	O
complex	O
,	O
and	O
its	O
mechanism	O
is	O
still	O
far	O
from	O
being	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
the	O
ion	B
and	O
solvent	B
transport	O
behavior	O
for	O
PPy	B
and	O
PMPy	B
films	O
in	O
AN	B
are	O
investigated	O
by	O
using	O
the	O
cyclic	O
electrochemical	O
quartz	B
crystal	O
microbalance	O
(	O
EQCM	O
)	O
technique	O
[	O
12,13	O
]	O
.	O

First	O
,	O
cyclic	O
voltammograms	O
and	O
mass	O
change	O
diagrams	O
are	O
obtained	O
for	O
PPy	B
and	O
PMPy	B
films	O
during	O
the	O
first	O
negative	O
scan	O
as	O
well	O
as	O
the	O
steady	O
-	O
state	O
scan	O
.	O

Second	O
,	O
the	O
identity	O
of	O
charge	O
compensating	O
species	O
in	O
various	O
electrolyte	O
solutions	O
is	O
revealed	O
by	O
quantitative	O
analysis	O
.	O

Finally	O
,	O
the	O
differences	O
in	O
the	O
mass	O
transport	O
behavior	O
between	O
a	O
PPy	B
film	O
and	O
a	O
PMPy	B
film	O
are	O
discussed	O
focusing	O
on	O
solvent	B
transport	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
Pyrrole	B
,	O
N	B
-methylpyrrole	I
,	O
and	O
AN	B
(	O
anhydrous	O
,	O
99.8	O
%	O
)	O
were	O
purchased	O
from	O
Aldrich	O
and	O
used	O
as	O
received	O
.	O

All	O
the	O
electrolytes	O
used	O
in	O
this	O
study	O
are	O
of	O
reagent	O
grade	O
and	O
were	O
dried	O
at	O
80	O
°	O
C	O
under	O
vacuum	O
before	O
use	O
.	O

2.2	O
Electrochemistry	O
and	O
film	O
preparations	O
A	O
standard	O
three	O
-	O
electrode	O
cell	O
was	O
used	O
for	O
all	O
electrochemical	O
measurement	O
with	O
an	O
Ag	B
|	O
Ag+	B
(	O
0.01	O
M	O
AgNO3	B
in	O
AN	B
)	O
reference	O
electrode	O
and	O
a	O
Pt	B
wire	O
counter	O
electrode	O
.	O

All	O
potentials	O
are	O
quoted	O
against	O
the	O
saturated	O
calomel	B
electrode	O
(	O
SCE	O
)	O
.	O

A	O
6	O
MHz	O
AT	O
-	O
cut	O
quartz	B
crystal	O
(	O
Inficon	O
,	O
NY	O
)	O
coated	O
with	O
Au	B
,	O
0.32	O
cm2	O
in	O
area	O
,	O
served	O
as	O
the	O
working	O
electrode	O
.	O

The	O
electromechanical	O
impedance	O
of	O
the	O
quartz	B
crystal	O
was	O
measured	O
using	O
a	O
Hewlett	O
-	O
Packard	O
4285A	O
LCR	O
meter	O
.	O

The	O
experimental	O
setup	O
for	O
the	O
EQCM	O
and	O
the	O
electromechanical	O
impedance	O
experiment	O
was	O
the	O
same	O
as	O
that	O
reported	O
previously	O
[	O
3	O
]	O
.	O

PPy	B
films	O
were	O
prepared	O
galvanostatically	O
at	O
0.2	O
mA	O
cm−2	O
in	O
AN	B
containing	O
0.1	O
M	O
pyrrole	B
and	O
0.1	O
M	O
electrolyte	O
,	O
and	O
PMPy	B
was	O
polymerized	O
from	O
an	O
AN	B
solution	O
containing	O
0.1	O
M	O
N	B
-methylpyrrole	I
and	O
0.1	O
M	O
electrolyte	O
.	O

The	O
electrolyte	O
used	O
in	O
the	O
polymerizations	O
is	O
a	O
salt	O
containing	O
TEA+	B
and	O
the	O
anion	B
to	O
be	O
used	O
in	O
the	O
cyclic	O
EQCM	O
experiment	O
.	O

The	O
charge	O
consumed	O
during	O
the	O
polymerization	O
was	O
300	O
mC	O
cm−2	O
for	O
all	O
the	O
films	O
.	O

After	O
polymerization	O
,	O
the	O
films	O
were	O
washed	O
with	O
pure	O
AN	B
and	O
transferred	O
into	O
an	O
Ar	B
-	O
filled	O
glove	O
box	O
.	O

All	O
the	O
cyclic	O
EQCM	O
experiments	O
were	O
performed	O
in	O
the	O
glove	O
box	O
,	O
and	O
the	O
electromechanical	O
impedance	O
experiments	O
were	O
performed	O
in	O
the	O
atmosphere	O
with	O
a	O
closed	O
cell	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Mass	O
transport	O
behavior	O
in	O
the	O
first	O
cathodic	O
scan	O
Fig.	O
1	O
shows	O
a	O
cyclic	O
voltammogram	O
and	O
a	O
mass	O
change	O
diagram	O
for	O
a	O
PPy	B
film	O
during	O
the	O
first	O
two	O
cycles	O
in	O
AN	B
containing	O
1	O
M	O
LiClO4	B
.	O

The	O
first	O
negative	O
scan	O
exhibits	O
a	O
sharp	O
and	O
large	O
peak	O
at	O
a	O
more	O
negative	O
potential	O
than	O
that	O
in	O
the	O
second	O
scan	O
.	O

As	O
shown	O
in	O
Fig.	O
1	O
b	O
,	O
the	O
mass	O
of	O
a	O
film	O
decreases	O
at	O
first	O
and	O
then	O
increases	O
sharply	O
around	O
the	O
peak	O
potential	O
of	O
the	O
first	O
negative	O
scan	O
.	O

This	O
means	O
that	O
anions	B
initially	O
move	O
out	O
of	O
the	O
film	O
and	O
that	O
cations	B
begin	O
to	O
move	O
into	O
the	O
film	O
around	O
the	O
peak	O
potential	O
.	O

The	O
charge	O
change	O
in	O
the	O
potential	O
region	O
where	O
mass	O
increases	O
is	O
5.6	O
mC	O
,	O
which	O
would	O
correspond	O
to	O
0.4	O
μg	O
if	O
only	O
Li+	B
insertion	O
contributed	O
to	O
the	O
mass	O
increase	O
.	O

However	O
,	O
the	O
actual	O
mass	O
change	O
in	O
this	O
potential	O
region	O
is	O
10.7	O
μg	O
.	O

This	O
large	O
mass	O
change	O
indicates	O
that	O
there	O
is	O
considerable	O
solvent	B
transport	O
in	O
addition	O
to	O
Li+	B
transport	O
during	O
the	O
first	O
negative	O
scan	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
case	O
of	O
a	O
PMPy	B
film	O
,	O
there	O
is	O
no	O
significant	O
difference	O
between	O
the	O
first	O
two	O
cycles	O
in	O
both	O
the	O
cyclic	O
voltammogram	O
and	O
the	O
mass	O
change	O
diagram	O
as	O
shown	O
in	O
Fig.	O
2	O
.	O

Moreover	O
,	O
the	O
mass	O
of	O
a	O
film	O
decreases	O
monotonically	O
in	O
the	O
negative	O
scan	O
and	O
increases	O
in	O
the	O
positive	O
scan	O
.	O

It	O
seems	O
that	O
anion	B
transport	O
is	O
dominant	O
over	O
the	O
whole	O
scan	O
range	O
.	O

The	O
abnormal	O
behavior	O
in	O
the	O
first	O
negative	O
scan	O
has	O
been	O
referred	O
to	O
as	O
the	O
'	O
break	O
-	O
in	O
process	O
.	O
'	O

It	O
is	O
known	O
that	O
the	O
film	O
after	O
its	O
deposition	O
is	O
compact	O
[	O
14	O
]	O
.	O

When	O
a	O
cation	B
with	O
some	O
solvent	B
moves	O
into	O
the	O
compact	O
film	O
in	O
the	O
first	O
negative	O
scan	O
,	O
the	O
break	O
-	O
in	O
process	O
occurs	O
[	O
14,15	O
]	O
.	O

However	O
,	O
when	O
an	O
anion	B
moves	O
out	O
of	O
the	O
compact	O
film	O
,	O
there	O
is	O
no	O
break	O
-	O
in	O
process	O
.	O

We	O
reported	O
previously	O
that	O
,	O
in	O
aqueous	B
solutions	O
,	O
the	O
break	O
-	O
in	O
process	O
is	O
observed	O
for	O
a	O
PPy	B
/	O
copper	B
phthalocyaninetetrasulfonate	I
film	O
where	O
cation	B
transport	O
is	O
dominant	O
[	O
3	O
]	O
,	O
whereas	O
it	O
is	O
not	O
observed	O
for	O
a	O
PMPy	B
film	O
where	O
anion	B
transport	O
is	O
dominant	O
[	O
4	O
]	O
.	O

Thus	O
,	O
the	O
break	O
-	O
in	O
process	O
in	O
AN	B
can	O
be	O
understood	O
in	O
the	O
same	O
way	O
because	O
the	O
break	O
-	O
in	O
process	O
is	O
observed	O
for	O
a	O
PPy	B
film	O
where	O
cation	B
transport	O
is	O
considerable	O
,	O
whereas	O
it	O
is	O
not	O
observed	O
for	O
a	O
PMPy	B
film	O
where	O
only	O
anion	B
transport	O
occurs	O
.	O

3.2	O
Mass	O
transport	O
behavior	O
in	O
the	O
steady	O
state	O
Fig.	O
3	O
a	O
shows	O
a	O
cyclic	O
voltammogram	O
and	O
a	O
mass	O
change	O
diagram	O
for	O
a	O
PPy	B
film	O
in	O
LiClO4	B
after	O
the	O
film	O
has	O
reached	O
its	O
steady	O
state	O
.	O

Similar	O
to	O
the	O
first	O
negative	O
scan	O
(	O
Fig.	O
1	O
)	O
,	O
the	O
mass	O
of	O
a	O
film	O
decreases	O
at	O
first	O
and	O
then	O
increases	O
around	O
the	O
peak	O
potential	O
.	O

This	O
means	O
that	O
anion	B
transport	O
is	O
dominant	O
in	O
the	O
highly	O
oxidized	O
state	O
of	O
the	O
film	O
and	O
that	O
cation	B
transport	O
is	O
dominant	O
in	O
its	O
lightly	O
oxidized	O
state	O
.	O

Moreover	O
,	O
the	O
extent	O
of	O
mass	O
increase	O
is	O
significantly	O
reduced	O
when	O
it	O
is	O
compared	O
with	O
that	O
observed	O
during	O
the	O
first	O
scan	O
.	O

Fig.	O
3	O
b	O
shows	O
the	O
result	O
obtained	O
in	O
TBAClO4	B
.	O

When	O
large	O
TBA+	B
is	O
used	O
as	O
the	O
electrolyte	O
cation	B
instead	O
of	O
small	O
Li+	B
,	O
the	O
shape	O
of	O
the	O
cyclic	O
voltammogram	O
is	O
very	O
different	O
.	O

The	O
mass	O
increase	O
is	O
very	O
small	O
in	O
the	O
lower	O
potential	O
region	O
which	O
means	O
that	O
cation	B
transport	O
is	O
severely	O
suppressed	O
in	O
the	O
case	O
of	O
TBAClO4	B
.	O

Consequently	O
,	O
it	O
is	O
evident	O
that	O
cation	B
transport	O
is	O
considerable	O
during	O
the	O
redox	O
reaction	O
of	O
a	O
PPy	B
film	O
.	O

Fig.	O
4	O
a	O
shows	O
diagrams	O
for	O
a	O
PMPy	B
film	O
in	O
LiClO4	B
.	O

The	O
mass	O
of	O
a	O
film	O
decreases	O
monotonically	O
in	O
the	O
negative	O
scan	O
and	O
increases	O
in	O
the	O
positive	O
scan	O
,	O
similarly	O
to	O
that	O
of	O
the	O
first	O
cycle	O
(	O
Fig.	O
2	O
)	O
.	O

Anion	B
transport	O
seems	O
to	O
be	O
dominant	O
over	O
the	O
whole	O
range	O
,	O
too	O
.	O

Fig.	O

4	O
b	O
shows	O
the	O
result	O
for	O
a	O
PMPy	B
film	O
in	O
TBAClO4	B
.	O

Contrary	O
to	O
PPy	B
films	O
,	O
there	O
is	O
no	O
significant	O
change	O
in	O
the	O
cyclic	O
voltammogram	O
or	O
the	O
mass	O
change	O
diagram	O
when	O
TBA+	B
is	O
used	O
as	O
the	O
electrolyte	O
cation	B
instead	O
of	O
Li+	B
.	O

Therefore	O
,	O
it	O
is	O
evident	O
that	O
cation	B
transport	O
is	O
negligible	O
during	O
the	O
redox	O
reaction	O
of	O
a	O
PMPy	B
film	O
.	O

3.3	O
Quantitative	O
analysis	O
The	O
plots	O
of	O
mass	O
change	O
(	O
ΔM	O
)	O
vs.	O
charge	O
change	O
(	O
ΔQ	O
)	O
during	O
the	O
redox	O
reaction	O
of	O
a	O
PPy	B
film	O
(	O
Fig.	O
3	O
a	O
)	O
and	O
a	O
PMPy	B
film	O
(	O
Fig.	O
4	O
a	O
)	O
in	O
1	O
M	O
LiClO4	B
are	O
shown	O
in	O
Figs.	O
5a	O
,	O
b	O
,	O
respectively	O
.	O

From	O
the	O
slope	O
of	O
the	O
plot	O
,	O
the	O
apparent	O
molar	O
mass	O
(	O
W	O
′	O
)	O
of	O
charge	O
compensating	O
species	O
can	O
be	O
calculated	O
according	O
to	O
Eq.	O
(	O
1	O
)	O
:	O
(	O
1	O
)	O
W′	O
=	O
−	O
zF	O
(	O
Δ	O
M	O
/	O
Δ	O
Q	O
)	O
where	O
F	O
is	O
the	O
Faraday	O
constant	O
and	O
z	O
is	O
the	O
electric	O
charge	O
of	O
the	O
charge	O
compensating	O
species	O
.	O

3.3.1	O
PPy	B
film	O
The	O
ΔM	O
vs.	O
ΔQ	O
plot	O
for	O
a	O
PPy	B
film	O
(	O
Fig.	O
5	O
a	O
)	O
is	O
V	O
-	O
shaped	O
and	O
exhibits	O
'	O
hysteresis	O
behavior	O
'	O
.	O

Thus	O
,	O
we	O
obtained	O
two	O
W	O
′	O
values	O
for	O
the	O
oxidized	O
and	O
the	O
reduced	O
state	O
.	O

Because	O
the	O
value	O
for	O
the	O
oxidized	O
state	O
is	O
mainly	O
related	O
to	O
anion	B
transport	O
,	O
we	O
represented	O
it	O
as	O
W	O
′+	O
.	O

On	O
the	O
contrary	O
,	O
the	O
value	O
for	O
the	O
reduced	O
state	O
is	O
represented	O
as	O
W	O
′−	O
because	O
it	O
is	O
mainly	O
related	O
to	O
cation	B
transport	O
.	O

W	O
′	O
values	O
obtained	O
in	O
various	O
systems	O
are	O
shown	O
in	O
Table	O
1	O
.	O

For	O
a	O
PPy	B
film	O
in	O
1	O
M	O
LiClO4	B
,	O
W	O
′+	O
values	O
both	O
in	O
the	O
first	O
scan	O
and	O
in	O
the	O
steady	O
-	O
state	O
scan	O
are	O
much	O
larger	O
than	O
the	O
molar	O
mass	O
of	O
Li+	B
(	O
W	O
Li+	B
=	O
7	O
)	O
.	O

A	O
similar	O
behavior	O
is	O
observed	O
for	O
PPy	B
films	O
in	O
1	O
and	O
0.1	O
M	O
TEAClO4	B
.	O

Two	O
explanations	O
are	O
possible	O
for	O
the	O
difference	O
between	O
the	O
molar	O
mass	O
of	O
the	O
cation	B
(	O
W	O
+	O
)	O
and	O
the	O
apparent	O
molar	O
mass	O
(	O
W	O
′+	O
)	O
.	O

One	O
is	O
neutral	O
salt	B
transport	O
,	O
and	O
the	O
other	O
is	O
solvent	B
transport	O
.	O

However	O
,	O
the	O
difference	O
for	O
1	O
M	O
TEAClO4	B
in	O
the	O
first	O
scan	O
(	O
177–130=47	O
)	O
is	O
much	O
smaller	O
than	O
that	O
for	O
1	O
M	O
LiClO4	B
(	O
262–7=255	O
)	O
.	O

The	O
same	O
behavior	O
is	O
observed	O
in	O
the	O
steady	O
-	O
state	O
scan	O
.	O

If	O
neutral	O
salt	B
transport	O
occurred	O
,	O
the	O
differences	O
were	O
larger	O
for	O
TEAClO4	B
due	O
to	O
its	O
large	O
molar	O
mass	O
.	O

Moreover	O
,	O
the	O
differences	O
in	O
0.1	O
M	O
TEAClO4	B
are	O
larger	O
than	O
those	O
in	O
1	O
M	O
TEAClO4	B
.	O

However	O
,	O
this	O
would	O
be	O
reversed	O
if	O
neutral	O
salt	B
transport	O
was	O
present	O
because	O
neutral	O
salt	B
transport	O
occurs	O
more	O
extensively	O
in	O
more	O
concentrated	O
electrolyte	O
solutions	O
.	O

Therefore	O
,	O
the	O
difference	O
between	O
W	O
+	O
and	O
W	O
′+	O
is	O
likely	O
to	O
be	O
due	O
to	O
solvent	B
transport	O
.	O

If	O
only	O
cation	B
transport	O
and	O
solvent	B
transport	O
occur	O
,	O
W	O
′+	O
can	O
be	O
expressed	O
as	O
follows:	O
(	O
2	O
)	O
W′	O
+	O
=	O
W+	O
+	O
Y+	O
Ws	O
where	O
W	O
+	O
and	O
W	O
s	O
are	O
the	O
molar	O
masses	O
of	O
a	O
cation	B
and	O
a	O
solvent	B
,	O
respectively	O
,	O
and	O
Y	O
+	O
is	O
the	O
number	O
of	O
accompanying	O
solvent	B
molecules	O
per	O
cation	B
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
Y	O
+	O
values	O
for	O
1	O
M	O
LiClO4	B
are	O
6.2	O
and	O
2.7	O
in	O
the	O
first	O
and	O
in	O
the	O
steady	O
-	O
state	O
scan	O
,	O
respectively	O
.	O

This	O
means	O
the	O
amount	O
of	O
accompanying	O
solvent	B
is	O
larger	O
in	O
the	O
first	O
scan	O
than	O
in	O
the	O
steady	O
-	O
state	O
scan	O
.	O

For	O
1	O
M	O
TEAClO4	B
,	O
Y	O
+	O
values	O
are	O
1.1	O
and	O
0.1	O
,	O
which	O
are	O
much	O
smaller	O
than	O
those	O
for	O
LiClO4	B
This	O
indicates	O
that	O
the	O
amount	O
of	O
accompanying	O
solvent	B
depends	O
on	O
the	O
kind	O
of	O
cation	B
.	O

In	O
addition	O
,	O
the	O
fact	O
that	O
Y	O
+	O
values	O
for	O
0.1	O
M	O
TEAClO4	B
are	O
larger	O
than	O
those	O
for	O
1	O
M	O
TEAClO4	B
means	O
that	O
the	O
amount	O
of	O
accompanying	O
solvent	B
depends	O
on	O
the	O
concentration	O
of	O
the	O
electrolyte	O
solution	O
.	O

The	O
increased	O
Y	O
+	O
in	O
a	O
dilute	O
solution	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
the	O
solvation	O
number	O
of	O
the	O
ion	B
increases	O
due	O
to	O
the	O
increased	O
dielectric	O
constant	O
in	O
a	O
dilute	O
solution	O
[	O
3	O
]	O
.	O

In	O
every	O
PPy	B
film	O
,	O
W	O
′−	O
is	O
smaller	O
than	O
W	O
ClO4	B
−	I
(	O
=	O
99.5	O
)	O
and	O
varies	O
little	O
in	O
comparison	O
with	O
the	O
variation	O
of	O
W	O
′+	O
.	O

It	O
is	O
difficult	O
to	O
give	O
a	O
clear	O
explanation	O
for	O
the	O
smaller	O
value	O
of	O
W	O
′−	O
compared	O
to	O
W	O
ClO4	B
−	I
.	O

In	O
addition	O
to	O
anion	B
transport	O
,	O
cation	B
and	O
solvent	B
transport	O
might	O
occur	O
even	O
in	O
the	O
region	O
where	O
anion	B
transport	O
is	O
dominant	O
.	O

3.3.2	O
PMPy	B
film	O
The	O
ΔM	O
vs.	O
ΔQ	O
plot	O
for	O
a	O
PMPy	B
film	O
(	O
Fig.	O
5	O
b	O
)	O
is	O
linear	O
over	O
the	O
whole	O
charge	O
range	O
,	O
and	O
it	O
shows	O
no	O
hysteresis	O
behavior	O
.	O

Since	O
W	O
′−	O
in	O
the	O
first	O
scan	O
is	O
similar	O
to	O
that	O
in	O
the	O
steady	O
-	O
state	O
scan	O
within	O
the	O
experimental	O
error	O
,	O
only	O
W	O
′−	O
in	O
the	O
steady	O
-	O
state	O
scan	O
is	O
obtained	O
(	O
Table	O
2	O
)	O
.	O

In	O
LiClO4	B
,	O
W	O
′−	O
is	O
76	O
,	O
which	O
is	O
smaller	O
than	O
W	O
ClO4	B
−	I
.	O

All	O
W	O
′−	O
values	O
in	O
other	O
solutions	O
containing	O
ClO4	B
−	I
are	O
smaller	O
than	O
W	O
ClO4	B
−	I
,	O
too	O
.	O

Moreover	O
,	O
W	O
′−	O
values	O
are	O
not	O
significantly	O
affected	O
by	O
the	O
kind	O
of	O
cation	B
nor	O
by	O
the	O
concentration	O
of	O
the	O
electrolyte	O
.	O

It	O
shows	O
that	O
cation	B
or	O
neutral	O
salt	B
transport	O
is	O
negligible	O
in	O
ClO4	B
−	I
-containing	O
solutions	O
.	O

Therefore	O
,	O
the	O
possibility	O
that	O
the	O
smaller	O
W	O
′−	O
is	O
due	O
to	O
cation	B
or	O
neutral	O
salt	B
transport	O
in	O
the	O
opposite	O
direction	O
to	O
anion	B
transport	O
can	O
be	O
excluded	O
.	O

In	O
that	O
case	O
,	O
two	O
possibilities	O
remain	O
.	O

One	O
is	O
that	O
solvent	B
transport	O
occurs	O
in	O
the	O
opposite	O
direction	O
to	O
anion	B
(	O
ClO4	B
−	I
)	O
transport	O
,	O
and	O
the	O
other	O
is	O
that	O
the	O
morphology	O
change	O
of	O
a	O
film	O
results	O
in	O
a	O
miscalculation	O
of	O
ΔM	O
.	O

In	O
order	O
to	O
examine	O
the	O
latter	O
possibility	O
,	O
the	O
electromechanical	O
impedance	O
[	O
16–18	O
]	O
is	O
measured	O
for	O
a	O
PMPy	B
film	O
in	O
1	O
M	O
TEAClO4	B
(	O
Fig.	O
6	O
)	O
.	O

In	O
the	O
electromechanical	O
impedance	O
experiment	O
,	O
the	O
excitation	O
signal	O
(	O
Fig.	O
6	O
a	O
)	O
consists	O
of	O
successive	O
potential	O
steps	O
.	O

The	O
resonance	O
frequency	O
of	O
a	O
quartz	B
crystal	O
(	O
Δf	O
o	O
)	O
,	O
the	O
maximum	O
-	O
conductance	O
frequency	O
(	O
Δf	O
r	O
)	O
,	O
and	O
the	O
total	O
resistance	O
of	O
a	O
quartz	B
crystal	O
(	O
R	O
t	O
)	O
are	O
measured	O
at	O
every	O
step	O
after	O
steady	O
state	O
is	O
established	O
.	O

It	O
has	O
been	O
known	O
that	O
Δf	O
r	O
depends	O
only	O
on	O
ΔM	O
,	O
and	O
R	O
t	O
depends	O
on	O
the	O
morphology	O
change	O
of	O
a	O
film	O
.	O

We	O
previously	O
reported	O
that	O
the	O
comparison	O
between	O
f	O
o	O
and	O
f	O
r	O
enables	O
one	O
to	O
verify	O
the	O
linear	O
relation	O
between	O
ΔM	O
and	O
Δf	O
o	O
[	O
3	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
6	O
b	O
,	O
R	O
t	O
varies	O
within	O
about	O
20	O
Ω	O
,	O
which	O
is	O
very	O
small	O
compared	O
with	O
that	O
for	O
other	O
systems	O
reported	O
previously	O
[	O
3	O
]	O
.	O

It	O
indicates	O
that	O
the	O
morphology	O
change	O
is	O
not	O
significant	O
during	O
the	O
redox	O
reaction	O
of	O
a	O
PMPy	B
film	O
in	O
an	O
AN	B
solution	O
.	O

Moreover	O
,	O
the	O
Δf	O
o	O
behavior	O
is	O
very	O
similar	O
to	O
the	O
Δf	O
r	O
behavior	O
as	O
shown	O
in	O
Fig.	O
6	O

c.	O
Therefore	O
,	O
ΔM	O
can	O
be	O
obtained	O
from	O
Δf	O
o	O
without	O
considering	O
a	O
change	O
in	O
the	O
morphology	O
of	O
the	O
film	O
in	O
this	O
system	O
.	O

Consequently	O
,	O
the	O
smaller	O
value	O
of	O
W	O
′−	O
is	O
related	O
to	O
solvent	B
transport	O
occurring	O
in	O
the	O
opposite	O
direction	O
to	O
anion	B
transport	O
.	O

Assuming	O
that	O
only	O
anion	B
transport	O
and	O
solvent	B
transport	O
take	O
place	O
,	O
W	O
′−	O
can	O
be	O
expressed	O
as	O
below:	O
(	O
3	O
)	O

W′	O
−	O
=	O
W−	O
+	O
Y−	O
Ws	O
where	O
W	O
−	O
and	O
W	O
s	O
are	O
the	O
molar	O
masses	O
of	O
an	O
anion	B
and	O
a	O
solvent	B
,	O
respectively	O
,	O
and	O
Y	O
−	O
is	O
the	O
number	O
of	O
accompanying	O
solvent	B
molecules	O
per	O
anion	B
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
Y	O
−	O
for	O
PMPy	B
films	O
in	O
ClO4	B
−	I
-containing	O
AN	B
is	O
between	O
−0.5	O
and	O
−0.6	O
.	O

This	O
means	O
that	O
some	O
AN	B
molecules	O
(	O
about	O
0.5	O
per	O
ClO4	B
−	I
)	O
move	O
in	O
the	O
opposite	O
direction	O
to	O
ClO4	B
−	I
transport	O
.	O

In	O
order	O
to	O
examine	O
the	O
effect	O
of	O
the	O
anion	B
on	O
the	O
mass	O
transport	O
of	O
a	O
PMPy	B
film	O
,	O
cyclic	O
EQCM	O
experiments	O
were	O
performed	O
in	O
solutions	O
containing	O
BF4	B
−	I
and	O
CF3	B
SO3	I
−	I
.	O

The	O
cyclic	O
voltammograms	O
and	O
mass	O
change	O
diagrams	O
are	O
very	O
similar	O
to	O
those	O
of	O
ClO4	B
−	I
-containing	O
solutions	O
.	O

Table	O
2	O
shows	O
that	O
the	O
W	O
′−	O
value	O
is	O
67	O
in	O
both	O
LiBF4	B
and	O
TBABF4	B
,	O
and	O
that	O
the	O
value	O
is	O
about	O
110	O
in	O
both	O
LiCF3	B
SO3	I
and	O
TBACF3	B
SO3	I
.	O

It	O
shows	O
that	O
W	O
′−	O
values	O
are	O
smaller	O
than	O
W	O
−	O
(	O
W	O
BF4	B
−	I
=	O
86.8	O
and	O
W	O
CF3	B
SO3	I
−	I
=	O
149	O
)	O
and	O
independent	O
of	O
the	O
kind	O
of	O
cation	B
in	O
both	O
solutions	O
containing	O
BF4	B
−	I
and	O
CF3	B
SO3	I
−	I
.	O

Thus	O
,	O
it	O
is	O
evident	O
that	O
cation	B
or	O
neutral	O
salt	B
transport	O
is	O
negligible	O
and	O
that	O
counter	O
flux	O
of	O
the	O
solvent	B
occurs	O
in	O
these	O
solutions	O
.	O

4	O
Conclusions	O
Ion	B
and	O
solvent	B
transport	O
behavior	O
for	O
PPy	B
and	O
PMPy	B
films	O
in	O
AN	B
was	O
investigated	O
with	O
the	O
cyclic	O
EQCM	O
technique	O
.	O

Cations	B
as	O
well	O
as	O
anions	B
take	O
part	O
in	O
ion	B
transport	O
during	O
the	O
redox	O
reaction	O
of	O
PPy	B
films	O
,	O
and	O
AN	B
transport	O
also	O
occurs	O
in	O
the	O
same	O
direction	O
as	O
cation	B
transport	O
.	O

In	O
the	O
first	O
negative	O
scan	O
,	O
the	O
break	O
-	O
in	O
process	O
takes	O
place	O
and	O
AN	B
molecules	O
are	O
inserted	O
into	O
the	O
film	O
.	O

In	O
a	O
TBA+	B
-containing	O
solution	O
,	O
cation	B
transport	O
is	O
suppressed	O
because	O
of	O
the	O
large	O
cation	B
.	O

On	O
the	O
other	O
hand	O
,	O
anion	B
transport	O
is	O
dominant	O
during	O
the	O
redox	O
reaction	O
of	O
PMPy	B
films	O
.	O

AN	B
transport	O
takes	O
place	O
in	O
the	O
opposite	O
direction	O
to	O
anion	B
transport	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
grateful	O
to	O
the	O
Korea	O
Advanced	O
Institute	O
of	O
Science	O
and	O
Technology	O
for	O
financial	O
support	O
of	O
this	O
research	O
.	O

The	O
stable	O
prostacyclin	B
analogue	B
,	O
iloprost	B
relaxes	O
a	O
variety	O
of	O
blood	O
vessels	O
and	O
increases	O
cyclic	B
AMP	I
,	O
although	O
the	O
relationship	O
between	O
adenosine	B
3	I
'	I
:	I
5'-cyclic	I
monophosphate	I
(	O
cyclic	B
AMP	I
)	O
and	O
vasorelaxation	O
remains	O
unclear	O
.	O

We	O
therefore	O
investigated	O
the	O
effect	O
of	O
the	O
adenylyl	O
cyclase	O
inhibitor	O
,	O
9-	B
(	I
tetrahydro-2-furanyl	I
)	I
-9H	I
-	I
purin-6-amine	I
(	O
SQ22536	B
)	O
on	O
iloprost	B
-	O
mediated	O
relaxation	O
and	O
cyclic	B
AMP	I
elevation	O
in	O
endothelium	O
-	O
denuded	O
aortic	O
strips	O
.	O

Iloprost	B
(	O
1	O
-	O
1000	O
nM	O
)	O
caused	O
a	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
phenylephrine	B
(	O
1	O
-	O
6	O
microM	O
)	O
contractions	O
,	O
the	O
responses	O
being	O
unaffected	O
by	O
pre	O
-	O
incubation	O
with	O
SQ22536	B
(	O
100	O
microM	O
)	O
for	O
30	O
min	O
.	O

In	O
other	O
experiments	O
60	O
nM	O
iloprost	B
caused	O
a	O
64	O
%	O
inhibition	O
of	O
phenylephrine	B
contractions	O
concomitant	O
with	O
a	O
3	O
fold	O
rise	O
in	O
cyclic	B
AMP	I
.	O

SQ22536	B
completely	O
abolished	O
the	O
iloprost	B
-	O
induced	O
elevation	O
in	O
cyclic	B
AMP	I
while	O
having	O
no	O
significant	O
effect	O
on	O
relaxation	O
.	O

Our	O
results	O
therefore	O
strongly	O
suggest	O
that	O
cyclic	B
AMP	I
-	O
independent	O
pathways	O
are	O
responsible	O
for	O
the	O
vasorelaxant	O
effects	O
of	O
iloprost	B
in	O
guinea	O
-	O
pig	O
aorta	O
.	O

The	O
photosynthetic	O
organelles	O
(	O
cyanelles	O
)	O
of	O
the	O
protist	O
Cyanophora	O
paradoxa	O
are	O
surrounded	O
by	O
a	O
peptidoglycan	B
wall	O
,	O
modified	O
through	O
amidation	O
with	O
N	B
-	I
acetylputrescine	I
.	O

Cyanelle	O
envelope	O
membrane	O
preparations	O
were	O
shown	O
to	O
catalyze	O
the	O
lipid	B
-	O
linked	O
steps	O
of	O
peptidoglycan	B
biosynthesis	O
as	O
well	O
as	O
the	O
putrescinylation	O
and	O
subsequent	O
acetylation	O
,	O
occurring	O
at	O
the	O
stage	O
of	O
lipid	B
I	I
and/or	O
lipid	B
II	I
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
involvement	O
of	O
cyclooxygenase-1	O
(	O
COX-1	O
)	O
,	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
,	O
and	O
tyrosine	O
kinase	O
on	O
prostaglandin	B
E2	I
(	O
PGE2	B
)	I
production	O
in	O
human	O
gingival	O
fibroblasts	O
stimulated	O
by	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
and/or	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
.	O

The	O
cytokine	O
IL-1beta	O
and	O
to	O
a	O
lesser	O
extent	O
EGF	O
,	O
enhanced	O
COX-2	O
mRNA	O
levels	O
in	O
gingival	O
fibroblasts	O
.	O

Simultaneous	O
treatment	O
with	O
EGF	O
and	O
IL-1beta	O
resulted	O
in	O
enhanced	O
COX-2	O
mRNA	O
levels	O
accompanied	O
by	O
a	O
synergistic	O
stimulation	O
of	O
PGE2	B
biosynthesis	O
compared	O
to	O
the	O
cells	O
treated	O
with	O
IL-1beta	O
or	O
EGF	O
alone	O
.	O

Neither	O
IL-1beta	O
EGF	O
nor	O
the	O
combination	O
of	O
IL-1beta	O
and	O
EGF	O
enhanced	O
COX-1	O
mRNA	O
levels	O
in	O
gingival	O
fibroblasts	O
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
,	O
Herbimycin	B
A	I
and	O
PD	B
153035	I
hydrochloride	I
,	O
reduced	O
COX-2	O
mRNA	O
levels	O
as	O
well	O
as	O
PGE2	B
production	O
induced	O
by	O
IL-1beta	O
or	O
the	O
combination	O
of	O
IL-1beta	O
and	O
EGF	O
whereas	O
COX-1	O
mRNA	O
levels	O
were	O
not	O
affected	O
.	O

Furthermore	O
,	O
the	O
COX-2	O
specific	O
inhibitor	O
,	O
NS-398	B
,	O
abolished	O
the	O
PGE2	B
production	O
induced	O
by	O
IL-1beta	O
,	O
EGF	O
,	O
or	O
the	O
combination	O
.	O

These	O
results	O
indicate	O
that	O
the	O
synergy	O
between	O
IL-1beta	O
and	O
EGF	O
on	O
PGE2	B
production	O
is	O
due	O
to	O
an	O
enhanced	O
gene	O
expression	O
of	O
COX-2	O
and	O
that	O
tyrosine	O
kinase	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
signal	O
transduction	O
of	O
COX-2	O
in	O
gingival	O
fibroblasts	O
.	O

Phosphorothioate	B
oligonucleotides	I
(	O
S	B
-	I
oligos	I
)	O
are	O
nucleic	B
acid	I
derivatives	I
that	O
are	O
commonly	O
used	O
as	O
antisense	B
agents	I
.	O

These	O
compounds	O
,	O
similar	O
to	O
bacterial	O
DNA	O
and	O
CpG	B
oligonucleotides	I
,	O
display	O
a	O
variety	O
of	O
immunological	O
activities	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

To	O
assess	O
further	O
these	O
activities	O
,	O
the	O
antigenicity	O
of	O
a	O
series	O
of	O
S	B
-	I
oligos	I
was	O
assessed	O
in	O
the	O
solid	O
phase	O
using	O
anti	O
-	O
DNA	O
antibodies	O
from	O
sera	O
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

By	O
ELISA	O
,	O
S	B
-	I
oligos	I
bound	O
well	O
to	O
anti	O
-	O
DNA	O
antibodies	O
under	O
the	O
same	O
conditions	O
as	O
calf	O
thymus	O
DNA	O
antigen	O
.	O

The	O
specificity	O
for	O
anti	O
-	O
DNA	O
was	O
established	O
by	O
competition	O
assays	O
showing	O
cross	O
-	O
inhibition	O
of	O
binding	O
by	O
DNA	O
and	O
S	B
-	I
oligos	I
.	O

Reactivity	O
with	O
anti	O
-	O
DNA	O
was	O
observed	O
with	O
S	B
-	I
oligos	I
varying	O
in	O
sequence	O
,	O
suggesting	O
interaction	O
with	O
a	O
conserved	O
determinant	O
not	O
strictly	O
dependent	O
on	O
the	O
bases	O
.	O

Furthermore	O
.	O
in	O
comparison	O
with	O
a	O
phosphodiester	B
oligomer	I
of	O
the	O
same	O
sequence	O
,	O
a	O
phosphorothioate	B
showed	O
dramatically	O
increased	O
activity	O
.	O

These	O
findings	O
indicate	O
that	O
structural	O
features	O
associated	O
with	O
the	O
S	B
-	I
oligo	I
backbone	O
promote	O
specific	O
binding	O
to	O
anti	O
-	O
DNA	O
antibodies	O
and	O
influence	O
the	O
size	O
requirement	O
for	O
antigenicity	O
in	O
the	O
solid	O
phase	O
.	O

These	O
observations	O
thus	O
extend	O
the	O
immunological	O
properties	O
of	O
S	B
-	I
oligos	I
and	O
suggest	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
autoimmune	O
disease	O
.	O

Phosphorothioate	B
oligonucleotides	I
(	O
S	B
-	I
oligos	I
)	O
are	O
nucleic	B
acid	I
derivatives	B
commonly	O
used	O
as	O
antisense	O
agents	O
(	O
Milligan	O
et	O
al.	O
,	O
1993	O
)	O
.	O

These	O
compounds	O
have	O
the	O
replacement	O
of	O
one	O
of	O
non	O
-	O
bridging	O
oxygens	B
by	O
a	O
sulfur	B
in	O
the	O
phosphodiester	B
backbone	O
.	O

While	O
this	O
modification	O
increases	O
nuclease	O
resistance	O
,	O
it	O
also	O
affects	O
helix	O
stability	O
as	O
well	O
as	O
the	O
charge	O
distribution	O
along	O
the	O
backbone	O
(	O
Iyengar	O
et	O
al.	O
,	O
1984	O
;	O
Frey	O
and	O
Sammons	O
,	O
1985	O
;	O
Stein	O
et	O
al.	O
,	O
1988	O
)	O
.	O

In	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
,	O
S	B
-	I
oligos	I
display	O
potent	O
antisense	O
activities	O
and	O
are	O
currently	O
in	O
clinical	O
trials	O
in	O
human	O
disease	O
(	O
Stein	O
and	O
Cheng	O
,	O
1993	O
;	O
Wagner	O
,	O
1994	O
,	O
Wagner	O
,	O
1995	O
)	O
.	O

Despite	O
their	O
effectiveness	O
in	O
blocking	O
gene	O
expression	O
,	O
S	B
-	I
oligos	I
have	O
properties	O
that	O
could	O
affect	O
their	O
use	O
in	O
antisense	O
therapy	O
.	O

These	O
properties	O
include	O
non	O
-	O
specific	O
binding	O
to	O
cellular	O
proteins	O
as	O
well	O
as	O
powerful	O
immunostimulatory	O
activities	O
(	O
Pisetsky	O
and	O
Reich	O
,	O
1993	O
,	O
Pisetsky	O
and	O
Reich	O
,	O
1994a	O
;	O
Brown	O
et	O
al.	O
,	O
1994	O
;	O
Perez	O
et	O
al.	O
,	O
1994	O
;	O
Zhao	O
et	O
al.	O
,	O
1996	O
)	O
.These	O

activities	O
include	O
stimulation	O
of	O
lymphocyte	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
cytokines	O
,	O
including	O
IL-12	O
,	O
IFN	O
-	O
α	O
/	O
β	O
and	O
IL-6	O
(	O
Krieg	O
et	O
al.	O
,	O
1995	O
;	O
Klinman	O
et	O
al.	O
,	O
1996	O
;	O
Lipford	O
et	O
al.	O
,	O
1997	O
)	O
.	O

While	O
sequence	O
dependent	O
,	O
these	O
activities	O
are	O
not	O
antisense	O
effects	O
.	O

Rather	O
,	O
immunostimulation	O
by	O
S	B
-	I
oligos	I
resembles	O
that	O
of	O
bacterial	O
DNA	O
as	O
well	O
as	O
synthetic	O
phosphodiester	B
oligonucleotides	I
containing	O
CpG	B
motifs	O
.	O

These	O
findings	O
suggest	O
that	O
S	B
-	I
oligos	I
exert	O
immunological	O
effects	O
by	O
mimicking	O
foreign	O
DNA	O
in	O
its	O
signaling	O
properties	O
(	O
Pisetsky	O
,	O
1996a	O
,	O
Pisetsky	O
,	O
1996b	O
)	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
have	O
evaluated	O
further	O
the	O
immunological	O
properties	O
of	O
S	B
-	I
oligos	I
by	O
testing	O
their	O
ability	O
to	O
bind	O
to	O
antibodies	O
to	O
DNA	B
(	O
anti	O
-	O
DNA	O
)	O
in	O
the	O
solid	O
phase	O
.	O

These	O
antibodies	O
occur	O
prominently	O
in	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
a	O
prototypic	O
autoimmune	O
disease	O
characterized	O
by	O
the	O
expression	O
of	O
antibodies	O
to	O
components	O
of	O
the	O
cell	O
nucleus	O
(	O
Pisetsky	O
,	O
1992	O
)	O
.	O

Anti	O
-	O
DNA	B
antibodies	O
from	O
lupus	O
patients	O
as	O
well	O
as	O
murine	O
models	O
differ	O
in	O
fine	O
specificity	O
.	O

Some	O
antibodies	O
have	O
preference	O
for	O
certain	O
base	B
sequences	O
and	O
have	O
binding	O
site	O
interactions	O
with	O
exposed	O
bases	B
.	O

Other	O
antibodies	O
bind	O
to	O
conserved	O
determinants	O
found	O
commonly	O
on	O
all	O
natural	O
DNA	B
,	O
both	O
single	O
stranded	O
(	O
ss	O
)	O
and	O
double	O
stranded	O
(	O
ds	O
)	O
,	O
with	O
much	O
less	O
dependence	O
on	O
base	B
sequence	O
(	O
Stollar	O
et	O
al.	O
,	O
1986	O
;	O
Sano	O
et	O
al.	O
,	O
1989	O
;	O
Stollar	O
,	O
1994	O
;	O
Eilat	O
and	O
Anderson	O
,	O
1994	O
;	O
Herrmann	O
et	O
al.	O
,	O
1995	O
;	O
Swanson	O
et	O
al.	O
,	O
1996	O
)	O
.	O

To	O
investigate	O
the	O
antigenicity	O
of	O
S	B
-	I
oligos	I
,	O
we	O
have	O
tested	O
the	O
reactivity	O
of	O
normal	O
and	O
SLE	O
sera	O
to	O
phosphorothioate	B
compounds	B
up	O
to	O
30	O
bases	B
in	O
length	O
.	O

In	O
results	O
presented	O
herein	O
,	O
we	O
show	O
that	O
anti	O
-	O
DNA	O
antibodies	O
in	O
SLE	O
sera	O
bind	O
phosphorothioate	B
oligonucleotides	I
in	O
a	O
solid	O
phase	O
immunoassay	O
.	O

In	O
their	O
reactivity	O
,	O
S	B
-	I
oligos	I
were	O
more	O
potent	O
than	O
phosphodiester	B
oligonucleotides	I
of	O
similar	O
sequence	O
,	O
suggesting	O
that	O
backbone	O
modifications	O
enhance	O
antigenicity	O
.	O

These	O
findings	O
extend	O
the	O
immunological	O
effects	O
of	O
S	B
-	I
oligos	I
to	O
antibody	O
binding	O
and	O
suggest	O
the	O
use	O
for	O
phosphorothioates	B
as	O
antigens	B
in	O
immunological	O
testing	O
.	O

2	O
Experimental	O
2.1	O
Materials	O
and	O
methods	O
2.1.1	O
Antigens	B
Oligonucleotides	B
,	O
synthesized	O
using	O
cyanoethyl	B
phosphoramidite	I
chemistry	O
,	O
were	O
purchased	O
from	O
Midland	O
Certified	O
Reagent	O
Company	O
(	O
Midland	O
,	O
TX	O
)	O
and	O
purified	O
by	O
gel	O
filtration	O
and	O
ethanol	B
precipitation	O
.	O

These	O
compounds	O
were	O
dissolved	O
in	O
distilled	O
water	B
to	O
a	O
final	O
concentration	O
of	O
1	O
mg	O
/	O
ml	O
and	O
filter	O
sterilized	O
through	O
a	O
Millex	O
GV	O
filter	O
(	O
Millipore	O
,	O
Bedford	O
MA	O
)	O
for	O
storage	O
at	O
4	O
°	O
C	O
.	O

Calf	O
thymus	O
(	O
CT	O
)	O
DNA	B
was	O
purchased	O
from	O
the	O
Sigma	O
Chemical	O
Co.	O
(	O
St	O
Louis	O
,	O
MO	O
)	O
and	O
further	O
purified	O
by	O
extraction	O
with	O
phenol	B
:	O
chloroform	B
and	O
ethanol	B
precipitation	O
.	O

To	O
prepare	O
ssDNA	B
antigen	I
,	O
the	O
DNA	B
was	O
boiled	O
for	O
10	O
min	O
and	O
then	O
rapidly	O
cooled	O
in	O
ice	B
.	O

Concentrations	O
were	O
determinated	O
by	O
absorbance	O
at	O
260	O
nm	O
with	O
OD	O
260	O
/	O
280	O
ratios	O
greater	O
than	O
1.8	O
for	O
preparations	O
used	O
.	O

2.1.1.1	O
Sera	O
Sera	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
were	O
obtained	O
from	O
the	O
Clinical	O
Immunology	O
Laboratory	O
of	O
the	O
Duke	O
University	O
Medical	O
Center	O
and	O
were	O
selected	O
on	O
the	O
basis	O
of	O
a	O
high	O
level	O
of	O
anti	B
-	I
DNA	I
in	O
an	O
ELISA	O
for	O
dsDNA	B
(	O
Sanofi	O
Diagnostics	O
Pasteur	O
,	O
Redmond	O
,	O
WA	O
)	O
.	O

Sera	O
from	O
normal	O
human	O
subjects	O
(	O
NHS	O
)	O
were	O
obtained	O
from	O
healthy	O
volunteers	O
at	O
the	O
Durham	O
VA	O
Hospital	O
.	O

2.1.1.2	O
ELISA	O
For	O
antibody	O
assays	O
,	O
96	O
well	O
microtiter	O
plates	O
(	O
Dynatech	O
Laboratories	O
,	O
Chantilly	O
,	O
VA	O
)	O
were	O
coated	O
overnight	O
at	O
4	O
°	O
C	O
with	O
DNA	B
or	O
oligonucleotides	B
diluted	O
to	O
various	O
concentrations	O
in	O
SSC	B
(	O
0.15	O
M	O
NaCl	B
,	O
0.1	O
M	O
Na	B
citrate	I
pH	O
8.0	O
)	O
.	O

Plates	O
were	O
then	O
washed	O
3	O
times	O
with	O
phosphate	B
buffered	I
saline	I
(	O
PBS	B
,	O
pH	O
7.3	O
)	O
containing	O
0.05	O
%	O
Tween	B
20	I
(	O
Sigma	O
)	O
(	O
PBS	B
-	I
T	I
)	O
.	O

Sera	O
starting	O
at	O
1	O
:	O
100	O
dilution	O
were	O
serially	O
diluted	O
in	O
PBS	B
-	I
T	I
containing	O
1	O
%	O
bovine	O
serum	O
albumin	O
(	O
Sigma	O
)	O
and	O
then	O
incubated	O
on	O
plates	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
plates	O
3	O
times	O
with	O
PBS	B
-	I
T	I
,	O
peroxidase	O
-	O
conjugated	O
goat	O
anti	O
-	O
human	O
IgG	O
(	O
gamma	O
chain	O
specific	O
,	O
Sigma	O
)	O
diluted	O
1	O
:	O
1000	O
in	O
PBS	B
-	I
T	I
was	O
then	O
added	O
to	O
the	O
wells	O
and	O
incubated	O
for	O
1	O
h.	O
Plates	O
were	O
then	O
washed	O
3	O
times	O
with	O
PBS	B
-	I
T	I
and	O
substrate	O
solution	O
containing	O
0.015	O
%	O
3,3′,5,5′-tetramethylbenzidine	B
(	O
Sigma	O
)	O
,	O
0.01	O
%	O
hydrogen	B
peroxide	I
in	O
0.1	O
M	O
sodium	B
citrate	I
buffer	I
.	O

pH	O
4	O
was	O
added	O
.	O

After	O
a	O
30	O
min	O
incubation	O
at	O
room	O
temperature	O
,	O
optical	O
densities	O
were	O
determined	O
at	O
380	O
nm	O
using	O
a	O
Titertek	O
plate	O
reader	O
(	O
Flow	O
Laboratories	O
,	O
McLean	O
,	O
VA	O
)	O
.	O

For	O
competition	O
experiments	O
,	O
sera	O
were	O
initially	O
titrated	O
to	O
determine	O
the	O
concentration	O
producing	O
an	O
OD	O
380	O
value	O
of	O
approximately	O
1	O
when	O
uninhibited	O
.	O

This	O
dilution	O
of	O
serum	O
was	O
then	O
mixed	O
with	O
competing	O
oligonucleotides	B
or	O
DNA	B
antigen	I
and	O
incubated	O
for	O
1	O
h	O
prior	O
to	O
transfer	O
to	O
plates	O
.	O

The	O
ELISA	O
was	O
then	O
performed	O
as	O
described	O
.	O

2.2	O
Results	O
As	O
a	O
model	O
to	O
investigate	O
the	O
antigenicity	O
of	O
phosphorothioate	B
oligonucleotides	I
,	O
we	O
initially	O
studied	O
the	O
compound	O
1082	B
which	O
has	O
a	O
sequence	O
complementary	O
to	O
a	O
translation	O
initiation	O
codon	O
region	O
within	O
the	O
UL13	O
open	O
reading	O
frame	O
of	O
the	O
herpes	O
simplex	O
virus	O
(	O
Table	O
1	O
)	O
.	O

This	O
compound	O
is	O
21	O
bases	B
long	O
and	O
has	O
been	O
previously	O
used	O
to	O
assess	O
the	O
immunostimulatory	O
activity	O
of	O
phosphorothioates	B
(	O
Pisetsky	O
and	O
Reich	O
,	O
1994a	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
1	O
,	O
this	O
compound	O
shows	O
reactivity	O
with	O
a	O
lupus	O
serum	O
when	O
coated	O
to	O
microtiter	O
plates	O
under	O
the	O
same	O
conditions	O
as	O
CT	O
ssDNA	B
.	O

Optimal	O
antigenic	O
activity	O
was	O
observed	O
with	O
oligonucleotide	B
concentrations	O
of	O
1–5	O
μg	O
/	O
ml	O
,	O
a	O
value	O
similar	O
to	O
that	O
of	O
CT	O
ssDNA	B
.	O

Under	O
these	O
conditions	O
,	O
the	O
NHS	O
showed	O
no	O
appreciable	O
reactivity	O
,	O
indicating	O
specificity	O
for	O
antibodies	O
in	O
the	O
SLE	O
serum	O
.	O

A	O
panel	O
of	O
SLE	O
sera	O
was	O
next	O
tested	O
for	O
reactivity	O
to	O
plates	O
coated	O
with	O
S	B
-	I
oligo	I
1082	I
at	O
a	O
concentration	O
of	O
5	O
μg	O
/	O
ml	O
.	O

Of	O
12	O
SLE	O
with	O
high	O
levels	O
of	O
anti	O
-	O
DNA	O
binding	O
(	O
OD380	O
greater	O
than	O
2.0	O
at	O
a	O
dilution	O
of	O
1	O
:	O
100	O
)	O
,	O
all	O
but	O
three	O
produced	O
ELISA	O
values	O
greater	O
than	O
1.0	O
using	O
1082	B
as	O
the	O
coating	O
antigen	B
.	O

Fig.	O
2	O
shows	O
representative	O
data	O
of	O
these	O
titrations	O
.	O

These	O
results	O
suggest	O
that	O
binding	O
to	O
S	B
-	I
oligos	I
is	O
a	O
property	O
of	O
some	O
but	O
not	O
all	O
anti	O
-	O
DNA	O
antibodies	O
.	O

To	O
demonstrate	O
further	O
that	O
binding	O
to	O
S	B
-	I
oligos	I
is	O
a	O
property	O
of	O
anti	O
-	O
DNA	O
antibodies	O
,	O
inhibition	O
ELISA	O
were	O
performed	O
using	O
sera	O
that	O
bound	O
both	O
CT	O
ssDNA	B
and	O
1082	B
.	O

As	O
shown	O
in	O
Fig.	O
3	O
,	O
soluble	O
S	B
-	I
oligo	I
effectively	O
competed	O
for	O
binding	O
to	O
surface	O
bound	O
CT	O
ssDNA	B
.	O

Conversely	O
,	O
CT	O
ssDNA	B
effectively	O
competed	O
for	O
binding	O
to	O
1082	B
(	O
Fig.	O
4	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
free	O
oligonucleotide	B
is	O
antigenic	O
and	O
provide	O
further	O
evidence	O
that	O
S	B
-	I
oligo	I
reactivity	O
reflects	O
anti	B
-	I
DNA	I
binding	O
.	O

The	O
relationship	O
of	O
sequence	O
to	O
antigenicity	O
was	O
next	O
assessed	O
by	O
comparing	O
antibody	O
binding	O
by	O
two	O
SLE	O
sera	O
and	O
an	O
NHS	O
serum	O
to	O
a	O
group	O
of	O
S	O
-	O
oligos	O
(	O
Table	O
1	O
)	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
all	O
compounds	O
tested	O
were	O
active	O
in	O
the	O
direct	O
binding	O
ELISA	O
,	O
although	O
the	O
sera	O
varied	O
somewhat	O
in	O
their	O
binding	O
to	O
these	O
compounds	O
;	O
the	O
NHS	O
serum	O
,	O
however	O
,	O
showed	O
binding	O
minimally	O
above	O
background	O
.	O

These	O
results	O
suggest	O
that	O
an	O
important	O
determinant	O
of	O
antigenicity	O
is	O
the	O
phosphorothioate	B
backbone	O
but	O
do	O
not	O
exclude	O
sequence	O
-	O
specific	O
binding	O
.	O

The	O
specificity	O
for	O
backbone	O
determinants	O
was	O
evaluated	O
further	O
by	O
comparing	O
reactivity	O
of	O
phosphorothioate	B
and	O
phosphodiester	B
compounds	O
20	O
bases	B
long	O
synthesized	O
with	O
all	O
four	O
bases	B
at	O
each	O
position	O
to	O
provide	O
a	O
large	O
set	O
of	O
varying	O
sequences	O
(	O
randomers	O
)	O
.	O

Like	O
S	B
-	I
oligos	I
of	O
other	O
sequences	O
,	O
the	O
S	B
-	I
oligo	I
randomer	I
was	O
active	O
when	O
bound	O
to	O
polystyrene	B
plates	O
.	O

Under	O
the	O
same	O
coating	O
and	O
assay	O
conditions	O
,	O
however	O
,	O
the	O
phosphodiester	B
compound	O
was	O
much	O
less	O
active	O
(	O
Fig.	O
5	O
)	O
.	O

These	O
findings	O
suggest	O
the	O
importance	O
of	O
the	O
phosphorothioate	B
backbone	O
to	O
antigenicity	O
.	O

This	O
point	O
was	O
further	O
demonstrated	O
by	O
comparing	O
the	O
activity	O
of	O
the	O
phosphorothioate	B
randomer	I
with	O
the	O
phosphodiester	B
randomer	I
as	O
fluid	O
phase	O
inhibitors	O
.	O

Consistent	O
with	O
direct	O
binding	O
results	O
,	O
the	O
phosphorothioate	B
was	O
a	O
much	O
better	O
inhibitor	O
than	O
the	O
phosphodiester	B
.	O

Thus	O
,	O
at	O
a	O
concentration	O
of	O
50	O
μg	O
/	O
ml	O
,	O
the	O
phosphorothioate	O
randomer	O
inhibited	O
binding	O
in	O
the	O
ELISA	O
67±12	O
%	O
compared	O
to	O
17±11	O
%	O
for	O
the	O
phosphodiester	O
(	O
mean±S.D.	O
for	O
four	O
SLE	O
sera	O
)	O
.	O

In	O
these	O
experiments	O
,	O
the	O
oligonucleotides	O
were	O
all	O
at	O
least	O
18	O
bases	B
in	O
length	O
.	O

To	O
evaluate	O
whether	O
shorter	O
compounds	O
are	O
also	O
antigenic	O
,	O
the	O
activity	O
of	O
a	O
random	O
sequence	O
10-mer	O
was	O
tested	O
.	O

As	O
shown	O
in	O
Fig.	O
6	O
,	O
this	O
compound	O
showed	O
only	O
weak	O
antigenicity	O
with	O
only	O
two	O
of	O
four	O
sera	O
tested	O
producing	O
on	O
OD380	O
value	O
in	O
the	O
ELISA	O
greater	O
than	O
0.5	O
.	O

These	O
results	O
suggest	O
that	O
a	O
sequence	O
somewhere	O
between	O
10	O
and	O
20	O
bases	B
in	O
length	O
is	O
required	O
for	O
antigenicity	O
and	O
that	O
shorter	O
compounds	O
either	O
fail	O
to	O
adhere	O
to	O
plates	O
or	O
present	O
an	O
antigenic	O
epitope	B
.	O

2.3	O
Discussion	O
Results	O
of	O
these	O
studies	O
demonstrate	O
that	O
anti	O
-	O
DNA	O
antibodies	O
in	O
SLE	O
sera	O
can	O
bind	O
solid	O
phase	O
phosphorothioate	B
oligonucleotides	I
in	O
an	O
interaction	O
influenced	O
by	O
the	O
backbone	O
modification	O
.	O

The	O
identity	O
of	O
these	O
antibodies	O
as	O
anti	O
-	O
DNA	O
is	O
established	O
by	O
both	O
direct	O
binding	O
as	O
well	O
as	O
inhibition	O
assays	O
.	O

Thus	O
,	O
soluble	O
CT	O
ssDNA	B
can	O
block	O
antibody	O
binding	O
to	O
solid	O
phase	O
S	B
-	I
oligos	I
while	O
S	B
-	I
oligos	I
can	O
block	O
antibody	O
binding	O
to	O
CT	O
ssDNA	B
.	O

The	O
binding	O
of	O
murine	O
monoclonal	O
anti	O
-	O
DNA	O
antibodies	O
to	O
phosphorothoiate	B
DNA	I
has	O
been	O
previously	O
described	O
,	O
although	O
these	O
antibodies	O
were	O
induced	O
by	O
immunization	O
with	O
modified	O
DNA	B
(	O
Latimer	O
et	O
al.	O
,	O
1995	O
)	O
.	O

Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
spontaneous	O
anti	O
-	O
DNA	O
antibodies	O
in	O
human	O
SLE	O
sera	O
display	O
such	O
reactivity	O
.	O

The	O
binding	O
of	O
lupus	O
sera	O
to	O
S	B
-	I
oligos	I
is	O
notable	O
in	O
view	O
of	O
studies	O
on	O
the	O
influence	O
of	O
DNA	O
size	O
on	O
antigenicity	O
(	O
Papalian	O
et	O
al.	O
,	O
1980	O
;	O
Ali	O
et	O
al.	O
,	O
1985	O
)	O
.	O

Although	O
an	O
antibody	O
binding	O
site	O
can	O
accommodate	O
three	O
to	O
four	O
bases	B
,	O
most	O
SLE	O
sera	O
fail	O
to	O
bind	O
to	O
short	O
oligonucleotides	B
and	O
rather	O
require	O
DNA	B
pieces	O
at	O
least	O
35–45	O
bases	B
in	O
length	O
in	O
fluid	O
phase	O
assays	O
.	O

These	O
findings	O
suggest	O
that	O
lupus	O
anti	O
-	O
DNA	O
bind	O
to	O
DNA	B
by	O
bivalent	O
or	O
monogamous	O
interaction	O
.	O

In	O
this	O
mode	O
of	O
binding	O
,	O
both	O
Fab	O
combining	O
sites	O
contact	O
antigenic	O
determinants	O
along	O
the	O
same	O
continuous	O
stretch	O
of	O
DNA	B
.	O

Because	O
of	O
the	O
distance	O
between	O
antibody	O
combining	O
sites	O
(	O
greater	O
than	O
100Å	O
depending	O
on	O
the	O
angle	O
at	O
the	O
hinge	O
region	O
)	O
,	O
the	O
minimum	O
size	O
piece	O
of	O
DNA	B
to	O
span	O
this	O
distance	O
is	O
approximately	O
35–45	O
bases	B
in	O
length	O
.	O

The	O
requirement	O
for	O
bivalent	O
interaction	O
suggests	O
that	O
the	O
affinity	O
of	O
each	O
Fab	O
combining	O
site	O
is	O
relatively	O
low	O
and	O
insufficient	O
for	O
monovalent	O
binding	O
.	O

The	O
model	O
for	O
bivalent	O
binding	O
is	O
based	O
on	O
studies	O
of	O
fluid	O
phase	O
assays	O
.	O

A	O
recent	O
study	O
assessing	O
anti	O
-	O
DNA	O
binding	O
by	O
ELISA	O
suggested	O
that	O
solid	O
phase	O
interactions	O
impose	O
more	O
drastic	O
requirements	O
for	O
DNA	B
antigenicity	O
(	O
Pisetsky	O
and	O
Reich	O
,	O
1994b	O
)	O
.	O

Thus	O
,	O
ssDNA	B
pieces	O
less	O
than	O
2000	O
bases	B
showed	O
poor	O
antigenicity	O
when	O
adhered	O
to	O
plastic	O
surfaces	O
,	O
although	O
these	O
fragments	O
were	O
nevertheless	O
active	O
in	O
the	O
fluid	O
phase	O
.	O

These	O
results	O
suggest	O
that	O
solid	O
phase	O
binding	O
may	O
limit	O
antibody	O
-	O
antigen	B
interactions	O
because	O
of	O
structural	O
constraints	O
imposed	O
on	O
low	O
molecular	O
weight	O
DNA	B
(	O
1000–2000	O
bases	B
or	O
less	O
)	O
by	O
surface	O
adherence	O
.	O

The	O
surface	O
adherence	O
of	O
DNA	B
in	O
this	O
size	O
range	O
may	O
involve	O
the	O
majority	O
of	O
the	O
molecule	O
;	O
under	O
these	O
conditions	O
,	O
antigenicity	O
may	O
be	O
impaired	O
because	O
extensive	O
surface	O
binding	O
limits	O
the	O
exposure	O
of	O
certain	O
determinants	O
or	O
prevents	O
conformational	O
rearrangements	O
(	O
e.g.	O
,	O
DNA	B
looping	O
)	O
required	O
for	O
antibody	O
binding	O
.	O

In	O
contrast	O
,	O
high	O
molecular	O
DNA	B
may	O
have	O
greater	O
regions	O
that	O
are	O
free	O
in	O
solution	O
and	O
capable	O
of	O
rearranging	O
for	O
bivalent	O
binding	O
.	O

In	O
contrast	O
to	O
phosphodiester	B
oligonucleotides	I
,	O
phosphorothioate	B
oligonucleotides	I
were	O
antigenically	O
active	O
in	O
solid	O
phase	O
form	O
.	O

The	O
results	O
with	O
the	O
ELISA	O
are	O
particularly	O
striking	O
since	O
,	O
as	O
described	O
above	O
,	O
SLE	O
sera	O
fail	O
to	O
bind	O
appreciably	O
to	O
natural	O
DNA	B
fragments	I
much	O
greater	O
in	O
length	O
or	O
,	O
as	O
shown	O
herein	O
,	O
phosphodiester	B
oligonucleotides	I
of	O
the	O
same	O
sequence	O
.	O

These	O
results	O
suggest	O
that	O
lupus	O
anti	O
-	O
DNA	O
bind	O
much	O
more	O
avidly	O
to	O
phosphorothioates	B
than	O
phosphodiester	B
compounds	I
and	O
,	O
as	O
a	O
result	O
,	O
interact	O
with	O
oligonucleotides	B
in	O
solid	O
phase	O
assays	O
.	O

As	O
shown	O
with	O
phosphorothioates	B
in	O
a	O
number	O
of	O
systems	O
,	O
the	O
presence	O
of	O
phosphorothioate	B
linkages	O
increases	O
non	O
-	O
specific	O
protein	O
binding	O
(	O
Brown	O
et	O
al.	O
,	O
1994	O
;	O
Guvakova	O
et	O
al.	O
,	O
1995	O
;	O
Shoeman	O
et	O
al.	O
,	O
1997	O
)	O
.	O

In	O
the	O
case	O
of	O
antibodies	O
,	O
however	O
,	O
binding	O
to	O
phosphorothioates	B
appears	O
to	O
be	O
a	O
specific	O
property	O
of	O
anti	O
-	O
DNA	O
antibodies	O
.	O

Thus	O
,	O
normal	O
sera	O
showed	O
low	O
reactivity	O
with	O
phosphorothioate	B
-	O
coated	O
plates	O
under	O
conditions	O
in	O
which	O
SLE	O
sera	O
bound	O
well	O
in	O
a	O
fashion	O
inhibited	O
by	O
soluble	O
DNA	B
.	O

Enhanced	O
antigenicity	O
of	O
phosphorothioates	B
could	O
relate	O
to	O
the	O
distribution	O
of	O
charge	O
along	O
the	O
backbone	O
since	O
charge	O
–	O
charge	O
interactions	O
are	O
important	O
for	O
lupus	O
anti	O
-	O
DNA	O
.	O

Alternatively	O
,	O
the	O
presence	O
of	O
phosphorothioate	B
groups	I
may	O
enhance	O
binding	O
by	O
altering	O
backbone	O
geometry	O
or	O
flexibility	O
as	O
well	O
as	O
adherence	O
to	O
solid	O
phase	O
supports	O
.	O

Because	O
of	O
the	O
stereochemistry	O
of	O
phosphorothioate	B
bonds	I
,	O
the	O
structure	O
of	O
these	O
compounds	O
has	O
been	O
difficult	O
to	O
determine	O
precisely	O
.	O

Using	O
current	O
synthetic	O
methods	O
,	O
these	O
compounds	O
have	O
chiral	O
centers	O
since	O
the	O
sulfur	B
atom	I
can	O
occur	O
in	O
either	O
of	O
two	O
orientations	O
(	O
R	O
or	O
S	O
)	O
with	O
respect	O
to	O
the	O
phosphate	B
backbone	O
(	O
Milligan	O
et	O
al.	O
,	O
1993	O
;	O
Frey	O
and	O
Sammons	O
,	O
1985	O
)	O
.	O

As	O
a	O
result	O
,	O
S	B
-	I
oligo	I
preparations	O
contain	O
an	O
enormous	O
mixture	O
of	O
stereoisomers	O
,	O
reflecting	O
the	O
occurrence	O
of	O
either	O
isomeric	O
form	O
at	O
every	O
bond	O
position	O
.	O

This	O
complexity	O
,	O
which	O
precludes	O
structural	O
analysis	O
by	O
usual	O
biophysical	O
techniques	O
,	O
also	O
prevents	O
determination	O
of	O
whether	O
enhanced	O
antigenicity	O
characterizes	O
all	O
phosphorothioates	B
or	O
only	O
certain	O
steroisomers	O
.	O

In	O
this	O
regard	O
,	O
we	O
have	O
not	O
as	O
yet	O
tested	O
double	O
stranded	O
oligomers	B
to	O
assess	O
their	O
behavior	O
in	O
these	O
assays	O
;	O
most	O
SLE	O
anti	O
-	O
DNA	O
,	O
however	O
,	O
crossreact	O
with	O
ss	B
and	O
dsDNA	B
.	O

These	O
findings	O
have	O
implications	O
both	O
for	O
the	O
assessment	O
of	O
anti	O
-	O
DNA	O
antibodies	O
as	O
well	O
as	O
the	O
medicinal	O
use	O
of	O
phosphorothioate	B
oligonucleotides	I
.	O

Thus	O
,	O
phosphorothioate	B
oligonucleotides	I
could	O
provide	O
the	O
basis	O
for	O
assays	O
of	O
anti	O
-	O
DNA	O
antibodies	O
(	O
at	O
least	O
to	O
ssDNA	B
)	O
using	O
short	O
compounds	B
synthesized	O
with	O
defined	O
sequence	O
.	O

The	O
application	O
of	O
synthetic	O
compounds	B
should	O
obviate	O
variations	O
in	O
assays	O
resulting	O
from	O
the	O
use	O
of	O
DNA	B
from	O
various	O
species	O
and	O
possible	O
interference	O
from	O
contaminating	O
non	O
-	O
nucleic	B
acid	I
components	O
(	O
Stollar	O
et	O
al.	O
,	O
1962	O
;	O
Casperson	O
and	O
Voss	O
,	O
1983	O
)	O
.	O

The	O
nuclease	O
resistance	O
of	O
phosphorothioates	B
may	O
also	O
improve	O
stability	O
of	O
antigens	B
in	O
sera	O
and	O
performance	O
characteristics	O
of	O
assays	O
.	O

As	O
shown	O
previously	O
,	O
phosphorothioates	B
have	O
immunostimulatory	O
properties	O
that	O
reflect	O
features	O
of	O
the	O
backbone	O
(	O
Pisetsky	O
and	O
Reich	O
,	O
1993	O
;	O
Pisetsky	O
and	O
Reich	O
,	O
1994a	O
;	O
Zhao	O
et	O
al.	O
,	O
1996	O
)	O
.	O

The	O
ability	O
of	O
these	O
compounds	O
to	O
bind	O
anti	O
-	O
DNA	O
suggests	O
that	O
may	O
also	O
have	O
immunogenic	O
potential	O
and	O
promote	O
anti	O
-	O
DNA	O
production	O
in	O
susceptible	O
individuals	O
.	O

This	O
potential	O
,	O
which	O
could	O
reflect	O
their	O
adjuvant	O
properties	O
,	O
nuclease	O
resistance	O
as	O
well	O
as	O
interactions	O
with	O
surface	O
Ig	O
receptors	O
,	O
could	O
limit	O
the	O
use	O
of	O
phosphorothioates	B
in	O
the	O
setting	O
of	O
inflammatory	O
or	O
autoimmune	O
disease	O
(	O
Braun	O
and	O
Lee	O
,	O
1988	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
S	B
-	I
oligo	I
that	O
bound	O
anti	O
-	O
DNA	O
without	O
exerting	O
immunostimulatory	O
effects	O
could	O
block	O
the	O
pathogenic	O
effects	O
of	O
anti	O
-	O
DNA	O
.	O

Studies	O
are	O
therefore	O
in	O
progress	O
to	O
define	O
further	O
the	O
immunological	O
effects	O
of	O
phosphorothioates	B
binding	O
to	O
antibodies	O
and	O
structural	O
basis	O
for	O
antibody	O
interaction	O
.	O

Synthetic	O
benzamide	B
derivatives	I
were	O
investigated	O
for	O
their	O
ability	O
to	O
inhibit	O
histone	O
deacetylase	O
(	O
HDA	O
)	O
.	O

In	O
this	O
study	O
,	O
one	O
of	O
the	O
most	O
active	O
benzamide	B
derivatives	I
,	O
MS-27	B
-	I
275	I
,	I
was	O
examined	O
with	O
regard	O
to	O
its	O
biological	O
properties	O
and	O
antitumor	O
efficacy	O
.	O

MS-27	B
-	I
275	I
inhibited	O
partially	O
purified	O
human	O
HDA	O
and	O
caused	O
hyperacetylation	O
of	O
nuclear	O
histones	O
in	O
various	O
tumor	O
cell	O
lines	O
.	O

It	O
behaved	O
in	O
a	O
manner	O
similar	O
to	O
other	O
HDA	B
inhibitors	I
,	O
such	O
as	O
sodium	B
butyrate	I
and	O
trichostatin	B
A	I
;	O
MS-27	B
-	I
275	I
induced	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
gelsolin	O
and	O
changed	O
the	O
cell	O
cycle	O
distribution	O
,	O
decrease	O
of	O
S	O
-	O
phase	O
cells	O
,	O
and	O
increase	O
of	O
G1-phase	O
cells	O
.	O

The	O
in	O
vitro	O
sensitivity	O
spectrum	O
of	O
MS-27	B
-	I
275	I
against	O
various	O
human	O
tumor	O
cell	O
lines	O
showed	O
a	O
pattern	O
different	O
than	O
that	O
of	O
a	O
commonly	O
used	O
antitumor	B
agent	I
,	O
5-fluorouracil	B
,	O
and	O
,	O
of	O
interest	O
,	O
the	O
accumulation	O
of	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
tended	O
to	O
be	O
faster	O
and	O
greater	O
in	O
the	O
cell	O
lines	O
sensitive	O
to	O
MS-27	B
-	I
275	I
.	O

MS-27	B
-	I
275	I
administered	O
orally	O
strongly	O
inhibited	O
the	O
growth	O
in	O
seven	O
of	O
eight	O
tumor	O
lines	O
implanted	O
into	O
nude	O
mice	O
,	O
although	O
most	O
of	O
these	O
did	O
not	O
respond	O
to	O
5-fluorouracil	B
.	O

A	O
structurally	B
analogous	I
compound	I
to	I
MS-27	I
-	I
275	I
without	O
HDA	O
-	O
inhibiting	O
activity	O
showed	O
neither	O
the	O
biological	O
effects	O
in	O
cell	O
culture	O
nor	O
the	O
in	O
vivo	O
therapeutic	O
efficacy	O
.	O

These	O
results	O
suggest	O
that	O
MS-27	B
-	I
275	I
acts	O
as	O
an	O
antitumor	B
agent	I
through	O
HDA	O
inhibition	O
and	O
may	O
provide	O
a	O
novel	O
chemotherapeutic	O
strategy	O
for	O
cancers	O
insensitive	O
to	O
traditional	O
antitumor	B
agents	I
.	O

Mechanisms	O
leading	O
to	O
down	O
-	O
regulation	O
of	O
activated	O
microglia	O
and	O
astrocytes	O
are	O
poorly	O
understood	O
,	O
in	O
spite	O
of	O
the	O
potentially	O
detrimental	O
role	O
of	O
activated	O
glia	O
in	O
neurodegeneration	O
.	O

Prostaglandins	B
,	O
produced	O
both	O
by	O
neurons	O
and	O
glia	O
,	O
may	O
serve	O
as	O
mediators	O
of	O
glial	O
and	O
neuronal	O
functions	O
.	O

We	O
examined	O
the	O
influence	O
of	O
cyclopentenone	B
prostaglandins	I
and	O
their	O
precursors	B
on	O
activated	O
glia	O
.	O

As	O
models	O
of	O
glial	O
activation	O
,	O
production	O
of	O
inducible	O
nitric	O
-	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
was	O
studied	O
in	O
lipopolysaccharide	B
-	O
stimulated	O
rat	O
microglia	O
,	O
a	O
murine	O
microglial	O
cell	O
line	O
BV-2	O
,	O
and	O
IL-1beta	O
-	O
stimulated	O
rat	O
astrocytes	O
.	O

Cyclopentenone	B
prostaglandins	I
were	O
potent	O
inhibitors	O
of	O
iNOS	O
induction	O
and	O
were	O
more	O
effective	O
than	O
their	O
precursors	O
,	O
prostaglandins	B
E2	B
and	O
D2	B
.	O

15-Deoxy	B
-	I
Delta12,14-prostaglandin	I
J2	I
(	O
15d	B
-	I
PGJ2	I
)	I
was	O
the	O
most	O
potent	O
prostaglandin	B
among	O
those	O
tested	O
.	O

In	O
activated	O
microglia	O
,	O
15d	B
-	I
PGJ2	I
suppressed	O
iNOS	O
promoter	O
activity	O
,	O
iNOS	O
mRNA	O
,	O
and	O
protein	O
levels	O
.	O

The	O
action	O
of	O
15d	B
-	I
PGJ2	I
does	O
not	O
appear	O
to	O
involve	O
its	O
nuclear	O
receptor	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
because	O
troglitazone	B
,	O
a	O
specific	O
ligand	O
of	O
PPARgamma	O
,	O
was	O
unable	O
to	O
inhibit	O
iNOS	O
induction	O
,	O
and	O
neither	O
troglitazone	B
nor	O
15d	B
-	I
PGJ2	I
could	O
stimulate	O
the	O
activity	O
of	O
a	O
PPAR	O
-	O
dependent	O
promoter	O
in	O
the	O
absence	O
of	O
cotransfected	O
PPARgamma	O
.	O

15d	B
-	I
PGJ2	I
did	O
not	O
block	O
nuclear	O
translocation	O
or	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NFkappaB	O
,	O
but	O
it	O
did	O
inhibit	O
the	O
activity	O
of	O
an	O
NFkappaB	O
reporter	O
construct	O
,	O
suggesting	O
that	O
the	O
mechanism	O
of	O
suppression	O
of	O
microglial	O
iNOS	O
by	O
15d	B
-	I
PGJ2	I
may	O
involve	O
interference	O
with	O
NFkappaB	O
transcriptional	O
activity	O
in	O
the	O
nucleus	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
pathway	O
mediated	O
by	O
cyclopentenone	B
prostaglandins	I
,	I
which	O
may	O
represent	O
part	O
of	O
a	O
feedback	O
mechanism	O
leading	O
to	O
the	O
cessation	O
of	O
inflammatory	O
glial	O
responses	O
in	O
the	O
brain	O
.	O

This	O
ongoing	O
study	O
evaluates	O
the	O
efficacy	O
of	O
oral	O
9-nitrocamptothecin	B
(	O
9NC	B
)	I
,	O
or	O
RFS-2000	B
,	O
in	O
the	O
treatment	O
of	O
advanced	O
pancreatic	O
cancer	O
.	O

Patients	O
received	O
9NC	B
orally	O
for	O
5	O
days	O
/	O
week	O
;	O
8	O
weeks	O
of	O
therapy	O
is	O
required	O
to	O
achieve	O
minimum	O
effective	O
dose	O
.	O

Starting	O
dose	O
was	O
1.5	O
mg	O
/	O
m2	O
/	O
day	O
,	O
with	O
adjustments	O
made	O
as	O
necessary	O
.	O

Patients	O
were	O
analyzed	O
for	O
changes	O
in	O
tumor	O
size	O
by	O
CT	O
scan	O
,	O
changes	O
in	O
serum	O
CA	O
19	O
-	O
9	O
tumor	O
marker	O
levels	O
,	O
quality	O
of	O
life	O
,	O
and	O
survival	O
.	O

107	O
consecutive	O
patients	O
with	O
advanced	O
adenocarcinoma	O
of	O
the	O
pancreas	O
were	O
enrolled	O
before	O
November	O
3	O
,	O
1997	O
.	O

Of	O
this	O
group	O
,	O
47	O
patients	O
did	O
not	O
receive	O
the	O
minimum	O
2	O
courses	O
of	O
treatment	O
necessary	O
to	O
induce	O
response	O
,	O
leaving	O
60	O
evaluable	O
patients	O
.	O

Primary	O
dose	O
-	O
limiting	O
toxicities	O
were	O
myelosuppression	O
and	O
interstitial	O
cystitis	O
.	O

No	O
deaths	O
were	O
attributed	O
to	O
9NC	B
.	O

Median	O
survival	O
was	O
6.5	O
months	O
for	O
the	O
107	O
total	O
patients	O
and	O
8.7	O
months	O
for	O
the	O
60	O
evaluable	O
patients	O
,	O
with	O
one	O
patient	O
surviving	O
at	O
44	O
+	O
months	O
.	O

Of	O
the	O
60	O
evaluable	O
patients	O
,	O
31.7	O
%	O
were	O
responders	O
(	O
median	O
survival	O
18.6	O
months	O
;	O
range	O
6.5	O
-	O
44.7	O
+	O
months	O
)	O
,	O
31.7	O
%	O
were	O
stable	O
(	O
median	O
survival	O
9.7	O
months	O
)	O
,	O
and	O
36.6	O
%	O
were	O
non	O
-	O
responders	O
(	O
median	O
survival	O
6.8	O
months	O
)	O
.	O

Fifty	O
-	O
seven	O
previously	O
untreated	O
patients	O
had	O
a	O
median	O
survival	O
of	O
7.3	O
months	O
compared	O
to	O
4.7	O
months	O
for	O
the	O
50	O
previously	O
treated	O
patients	O
.	O

Thirty	O
-	O
three	O
patients	O
who	O
failed	O
gemcitabine	B
therapy	O
prior	O
to	O
9NC	B
treatment	O
had	O
a	O
median	O
survival	O
of	O
4.7	O
months	O
.	O

9NC	B
is	O
safe	O
and	O
efficacious	O
as	O
first	O
-	O
line	O
therapy	O
for	O
the	O
treatment	O
of	O
advanced	O
pancreatic	O
cancer	O
.	O

It	O
also	O
shows	O
some	O
modest	O
success	O
as	O
second	O
-	O
line	O
therapy	O
in	O
treating	O
gemcitabine	B
failures	O
.	O

An	O
efficient	O
solid	O
-	O
phase	O
synthesis	O
of	O
benzisothiazolone-1,1-dioxide	B
-	O
based	O
serine	O
protease	O
inhibitors	O
involving	O
alkylation	O
of	O
carboxylic	B
acids	I
with	O
N-	B
(	I
bromomethyl	I
)	I
benzisothiazolone-1,1-dioxide	I
has	O
been	O
developed	O
.	O

An	O
example	O
using	O
this	O
procedure	O
for	O
preparation	O
of	O
a	O
library	O
of	O
human	O
mast	O
cell	O
tryptase	O
inhibitors	O
is	O
described	O
.	O

We	O
compared	O
effects	O
of	O
alpha	B
-	I
galactosylceramide	I
(	O
alpha	B
-	I
GalCer	I
)	O
and	O
its	O
3alpha-	B
or	O
3beta	B
-	I
galactosylated	I
derivatives	I
on	O
the	O
proliferation	O
of	O
murine	O
spleen	O
cells	O
.	O

The	O
3alpha	B
-	I
galactosylated	I
alpha	I
-	I
GalCer	I
showed	O
stronger	O
proliferative	O
response	O
than	O
the	O
parental	O
alpha	B
-	I
GalCer	I
,	O
but	O
the	O
3beta	B
-	I
galactosylated	I
alpha	I
-	I
GalCer	I
possessed	O
weaker	O
activity	O
than	O
the	O
alpha	B
-	I
GalCer	I
.	O

In	O
addition	O
,	O
alpha	B
-	I
Gal-3-Cer	I
did	O
not	O
show	O
immunostimulatory	O
activity	O
.	O

We	O
previously	O
reported	O
that	O
representative	O
o~-galactosylceramide	B
(	O
oc	B
-	I
GalCer	I
,	O
galactose	B
bound	O
to	O
ceramide	B
in	O
an	O
c~-configuration	B
)	O
,	O
named	O
KRN7000	B
(	O
1	O
)	O
(	O
Fig.	O
1	O
)	O
,	O
has	O
strong	O
immunostimulatory	O
and	O
antitumor	O
activity	O
.	O

1,2	O
KRN7000	B
has	O
also	O
drawn	O
researchers	O
'	O
attention	O
as	O
a	O
ligand	O
for	O
mouse	O
and	O
human	O
natural	O
killer	O
T	O
(	O
NKT	O
)	O
cells.3	O
-	O
8	O
Our	O
structure	O
-	O
activity	O
relationship	O
study	O
using	O
ct	B
-	I
GalCers	I
with	O
different	O
ceramide	B
moieties	O
indicated	O
that	O
the	O
3	B
hydroxyl	I
group	I
(	O
3-OH	B
)	O
in	O
the	O
ceramide	B
plays	O
an	O
essential	O
role	O
in	O
the	O
manifestation	O
of	O
immunostimulatory	O
activity	O
induced	O
by	O
0c	B
-	I
GalCers	I
,	O
demonstrating	O
that	O
ot	B
-	I
GalCer	I
with	O
only	O
the	O
3-OH	B
is	O
the	O
minimal	O
structure	O
to	O
stimulate	O
the	O
immune	O
system	O
through	O
the	O
activation	O
of	O
NKT	O
cells	O
.	O

1,3	O
HO	O
.OH	O
O	O
~	O
/	O
(	O
CH2	O
)	O
24CH3	O
HO	O
.OH	O
?	O

H	O
OH	O
HO	O
QI~,~	O
HN	O
.	O

HO6	O
-	O
v~	O
(	O
CH2	O
)	O
I3CH3	O
v~	O
(	O
cH2	O
)	O

I3cH3	O
OH	O
OH	O
I	O
2	O
Figure	O
1	O
Structures	O
of	O
KRN7000	B
(	O
1	O
)	O
and	O
AGL-506	B
(	O
2	O
)	O
Other	O
researchers	O
also	O
attempted	O
to	O
isolate	O
c~-glycosylceramides	B
from	O
marine	O
sponges	O
,	O
and	O
they	O
succeeded	O
in	O
the	O
isolation	O
of	O
various	O
types	O
of	O
c~-GaICers	B
,	O
monoglycosylated	B
oc	I
-	I
GalCers	I
,	O
and	O
diglycosylated	B
~-	I
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

PII	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00054	O
-	O
2	O
698	O
T.	O
Sakai	O
et	O
al.	O
I	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
697	O
-	O
702	O
GalCers,7	B
-	O
9	O
and	O
it	O
has	O
been	O
reported	O
that	O
several	O
mono-	B
or	O
diglycosylated	B
~-GalCers	I
as	O
well	O
as	O
cGalCers	B
possess	O
immunostimulatory	O
effects.12	O
-	O
14	O
In	O
these	O
studies	O
using	O
mono-	B
or	O
diglycosylated	B
t~-GalCers	I
,	O
it	O
was	O
demonstrated	O
that	O
the	O
"3""-glycosylated"	B
~-GalCer	I
have	O
much	O
less	O
immunostimulatory	O
activity	O
than	O
the	O
parental	O
ct	B
-	I
GalCer.13,14	I
These	O
findings	O
arose	O
a	O
question	O
as	O
to	O
whether	O
the	O
3-glycosylated	B
0~-GalCer	I
also	O
has	O
weaker	O
immunostimulatory	O
activity	O
than	O
the	O
parental	O
ct	B
-	I
GalCer	I
.	O

In	O
order	O
to	O
address	O
this	O
question	O
,	O
we	O
synthesized	O
two	O
kinds	O
of	O
3-galactosylated	B
ct	I
-	I
GalCers	I
,	O
and	O
compared	O
effects	O
among	O
these	O
two	O
compounds	O
and	O
AGL-506	B
(	O
2	O
)	O
l	O
(	O
Fig.	O
1	O
)	O
,	O
the	O
parental	O
ot	B
-	I
GalCer	I
,	O
on	O
the	O
proliferation	O
of	O
murine	O
spleen	O
cells	O
.	O

Chemistry	O
The	O
synthetic	O
procedures	O
of	O
AGL-529	B
(	O
3	B
[	I
3-galactosylated	I
t~-GalCer	I
,	O
3	O
)	O
and	O
AGL-533	B
(	O
3a	B
-	I
galactosylated	I
o~-	I
GalCer	I
,	O
4	O
)	O
are	O
shown	O
in	O
Scheme	O
1	O
.	O

The	O
synthesis	O
of	O
ceramide	B
(	I
5	I
)	I
was	O
reported	O
previously.1	O
The	O
ceramide	B
(	I
5	I
)	I
was	O
glycosylated	O
with	O
3	O
eq.	O
galactosyl	B
donor	I
(	I
6	I
)	I
to	O
give	O
7	O
and	O
8	O
.	O

The	O
mixture	O
of	O
7	O
and	O
8	O
were	O
directly	O
hydrogenated	O
and	O
subsequent	O
acetylated	O
to	O
give	O
9	O
and	O
10	O
.	O

Deacetylation	O
of	O
9	O
and	O
10	O
gave	O
AGL-529	B
(	O
3	O
)	O
j5	O
and	O
AGL-533	B
(	O
4	O
)	O
,16	O
respectively	O
.	O

Scheme	O
I	O
OAc	O
OAc	O
BnO	O
OBn	O
OAc	O
BnO	O
/OBn	O
~	O
-	O
O	O
-	O
L~,~	O
..	O
_\	O
BnO	O
_	O
OBn	O
:	O
u	O
I	O
(	O
O.	O
/	O
/	O
..	O

L	O
..	O

_	O
\~O	O
""""	O
""""	O
~	O
(	O
CH2	O
)	O
21CH3	O
~'~'	O
(	O
CH2	O
)	O
2,CH3	O
BnO~\~F	O
~O	O
""""	O
~	O
""""	O
(	O
CH2	O
)	O
21CH3	O
BnO~	O
,	O
..	O

~t~	O
HIll	O
Ha	O
60Bn	O
BnO	O
,.~	O
l,.w	O
,,~	O
l,~	O
Ha	O

8n~	O
/	O
-	O
7	O
Bnbl	O
..	O
=	O
O	O
~	O
(	O
CH2	O
)	O
14CH3	O
HO~	O
(	O
CH2	O
)	O
12cH3a	O
O	O
V'~,~v	O
/	O
(	O
CH2	O
)	O
'2CH3	O
+	O
IO	O
o.	O
5	O
7	O
"O""~"	O
OBn	O
(	O
)	O
~	O
8	O
oB	O
~	O
OBOn	O
O	O
~	O
H	O
BnO	O
Bn	O
4	O
'	O
o	O
Bn	O
BnO	O
AcO	O
/OAc	O
0	O
?	O

Acc	O
H	O
CH	O
AcO	O
.	O
/	O
OAc	O
O	O
b.	O

L	O
-	O
o	O
L\	O
o	O
H.	O
_	O
'	O
9	O
X	O
OAc	O
o	O
/~	O
.OAc	O

10	O
AcO	O
OAc	O
Ac	O
~	O
J	O
uAc	O
OH	O
HO	O
.OH	O
_	O
--	O
x~	O
HO~--~	O
"O'~""""'"	O
(	O
C	O
H2	O
)	O
210	O
H3	O
HO	O
/	O
HN	O
O~	O
(	O
CH2	O
)	O
12CH3	O
AG	O
L-529	O
(	O
3	O
)	O
Oo-~H	O
Scheme	O
1	O
;	O
Reagents	O
;	O
(	O
a	O
)	O
6	O
(	O
3eq	O
)	O
,	O
SnCI2	B
,	O
AgCIO4	B
,	O
MS4A	B
/	O
THF	B
,	O
-10	O
~C-	O
r.t	O
.	O
,	O
2hr	O
,	O
65	O
%	O
;	O
(	O
b	O
)	O
H2	B
,	O
Pd	B
-	I
black	I
/	O
THF	B
,	O
r.t	O
.	O
,	O
24hr	O
,	O
95	O
%	O
;	O
(	O
c	O
)	O
Ac2O	B
,	O
Et3N	B
/	O
CH2CI2	B
,	O
r.t	O
.	O
,	O
5hr	O
,	O
9	O
(	O
15	O
%	O
)	O
,	O
10	O
(	O
33	O
%	O
)	O
;	O
(	O
d	O
)	O
NaOMe	B
,	O
MeOH	B
,	O
lhr	O
,	O
90	O
%	O
.	O

b	O
,	O
c	O
OH	O
HO	O
.OH	O
HO	O
~.~	O
OHN'~	O
(	O
CH2	O
)	O
21CH3	O
d	O
HO	O
/	O
-	O
Ov	O
/	O
~	O
(	O
cH2	O
)	O
14cH3	O
AGL-533	O
(	O
4	O
)	O
O	O
~	O
H	O
T.	O
Sakai	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
697	O
-	O
702	O
699	O
The	O
synthetic	O
procedures	O
of	O
~-Gal	B
-	I
l	I
-	I
Cer	I
(	O
AGL-517	B
,	O
16	O
)	O
and	O
~-Gal-3-Cer	B
(	O
AGL-553	B
,	O
17	O
)	O
are	O
shown	O
in	O
Scheme	O
2	O
.	O

Briefly	O
,	O
the	O
synthesis	O
of	O
ceramide	B
11	I
was	O
reported	O
previously.13	O
The	O
ceramide	B
11	I
was	O
directly	O
glycosylated	O
with	O
1.2	O
eq	O
(	O
6	O
)	O
to	O
give	O
12	O
and	O
13	O
.	O

The	O
mixture	O
of	O
12	O
and	O
13	O
were	O
directly	O
acetylated	O
to	O
give	O
14	O
and	O
15	O
.	O

Debenzylation	O
and	O
subsequent	O
deacetylation	O
of	O
14	O
and	O
15	O
gave	O
AGL-517	B
(	O
16	O
)	O
1	O
and	O
AGL-	B
553	I
(	O
17	O
)	O
,17	O
respectively	O
.	O

Scheme	O
2	O

O	O
BnO~-~Bn	O
Bn	O
?	O

(	O
...	O
OBn	O
O	O
=	O
O	O
"HN""J~"	O
(	O
cH2	O
)	O
'2OH3	O
B	O
nO	O
""""	O
"31~""~""~""~"	O
F	O
BnO~	O
HN-~	O
(	O
OH2	O
)	O
I2CH3	O
"HN""J~"	O
(	O
oH2	O
)	O
'2OH3	O
--'-	O
~	O
_	O
.:-	O
+	O
HOv~	O
(	O
cH2	O
)	O
14cH3	O
HO~	O
(	O
CH2	O
)	O
14CH3	O
60Bn	O
BnOo	O
""""	O
"~""~"	O
(	O
CH2	O
)	O
14CH3	O
OH	O
a	O
O	O
/~'IOBn	O
13	O
11	O
OH	O
(	O
)	O
~	O
12	O
BnOn~,,y	O
OBn	O
BnO	O
_	O
OBn	O
O	O
BnO	O
HN	O
-	O
JL-.	O
(	O
CH2	O
)	O
,2CH3	O
"HN""~"	O
(	O
CH2	O
)	O
mCH3	O
b	O
""""	O
~	O
(	O
cH2	O
)	O
'4CH3	O
+	O
"AcOx""~""~"	O
(	O
CH2	O
)	O
'4CH30	O
OAc	O
/~	O
.OBn	O

O	O
15	O
14	O
BnO	O
)	O
~'q'~	O
l	O
o	O
c	O
,	O
d	O
HN	O
""""	O
~	O
(	O
CH2	O
)	O
12CH3	O
HO	O
~OH	O
0	O
HO~	O
HN	O
"~""'"	O
(	O
CH2	O
)	O
12CH3	O
HO~	O
(	O
CH2	O
)	O
14CH3	O
HO2	O
~	O
o	O
/	O
~OH	O
O'~oH	O
(	O
CH2	O
)	O
14CH3	O
HOo	O
~	O
OH	O
AGL-517	O
(	O
16	O
)	O
AGL-553	O
(	O
17	O
)	O
Scheme	O
2	O
;	O
Reagents	O
;	O
(	O
a	O
)	O
6	O
(	O
1.2eq	O
)	O
,	O
SnCI2	B
,	O
AgClO4	B
,	O
MS4A	B
/	O
THF	B
,	O
-10	O
~C-	O
r.t	O
.	O
,	O
2hr	O
,	O
65	O
%	O
;	O
(	O
b	O
)	O
Ac20	B
,	O
Et3N	B
/	O
CH2Cl2	B
,	O
r.t	O
.	O
,	O
5hr	O
,	O
14	O
(	O
48	O
%	O
)	O
,	O
15	O
(	O
26	O
%	O
)	O
;	O
(	O
c	O
)	O
H2	B
,	O
Pd	B
-	I
black	I
/	O
THF	B
,	O
r.t	O
.	O
,	O
24hr	O
,	O
95	O
%	O
;	O
(	O
d	O
)	O
NaOMe	B
,	O
MeOH	B
,	O
lhr	O
,	O
90	O
%	O
.	O

Results	O
and	O
Discussion	O
We	O
compared	O
the	O
effects	O
of	O
AGL-506	B
(	O
tx	B
-	I
GalCer	I
,	O
2	O
)	O
,	O
AGL-529	B
(	O
313-galactosylated	B
~-GalCer	I
,	O
3	O
)	O
,	O
and	O
AGL-533	B
(	O
3c~-galactosylated	B
a	I
-	I
GalCer	I
,	O
4	O
)	O
on	O
the	O
proliferation	O
of	O
mouse	O
spleen	O
cells	O
.	O

As	O
shown	O
in	O
Table	O
l	O
,	O
AGL-506	B
stimulated	O
the	O
proliferation	O
of	O
spleen	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
,	O
and	O
significant	O
stimulatory	O
activity	O
was	O
observed	O
from	O
the	O
concentration	O
of	O
1	O
ng	O
/	O
ml	O
.	O

Although	O
AGL-529	B
showed	O
significant	O
enhancement	O
of	O
the	O
proliferative	O
effect	O
from	O
the	O
concentration	O
of	O
10	O
ng	O
/	O
ml	O
,	O
its	O
potency	O
was	O
weaker	O
than	O
that	O
of	O
AGL-506	B
,	O
the	O
parental	O
o~-GalCer	B
.	O

By	O
contrast	O
,	O
AGL-533	B
significantly	O
stimulated	O
the	O
proliferation	O
of	O
spleen	O
cells	O
from	O
the	O
concentration	O
of	O
1	O
ng	O
/	O
ml	O
,	O
and	O
it	O
appeared	O
that	O
AGL-533	B
has	O
stronger	O
irnmunostimulatory	O
activity	O
than	O
AGL-506	B
.	O

It	O
is	O
quite	O
interesting	O
that	O
the	O
configuration	O
of	O
the	O
glycosidic	B
linkage	I
between	O
galactose	B
700	O
T.	O
Sakai	O
et	O
al.	O
/Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
697	O
-	O
702	O
and	O
ceramide	B
in	O
the	O
3-position	O
greatly	O
affects	O
the	O
ct	B
-	I
GalCer	I
induced	O
immunostimulatory	O
effects	O
,	O
i.e.	O
,	O
linkage	O
enhances	O
the	O
immunostimulatory	O
effect	O
of	O
ct	B
-	I
GalCer	I
,	O
but	O
the	O
]	O
3-linkage	O
reduces	O
the	O
activity	O
.	O

Table	O
1	O
.	O

Effects	O
of	O
AGL-506	B
(	O
2	O
)	O
,	O
AGL-529	O
(	O
3	O
)	O
and	O
AGL-533	B
(	O
4	O
)	O
on	O
the	O
proliferation	O
of	O
murine	O
spleen	O
cells	O
.	O

the	O
(	O
x-	O
3H	O
-	O
TdR	O
incorpolation	O
(	O
cpm	O
)	O
Sample	O
1	O
n~	O
/	O
ml	O
10	O
ng	O
/	O
ml	O
100	O
ng	O
/	O
ml	O
Vehicle	O
6962	O
+	O
_	O
758	O
7858	O
_	O
+	O
1065	O
6280	O
_	O
+	O
823	O
AGL-506	O
(	O
2	O
)	O
9454	O
_	O
_	O
_	O
844	O
*	O
20283	O
_	O
+	O
3420	O
*	O
45966	O
_	O
+	O
2196	O
""""	O
AGL-529	O
(	O
3	O
)	O
7892	O
_	O
+	O
1320	O
13195	O
_	O
+	O
1818	O
""""	O
45036	O
+	O
_	O
231	O
""""	O
AGL-533	O
(	O
4	O
)	O
16138	O
_	O
944	O
*	O
34892	O
+	O
1259	O
""""	O
44867	O
_	O
+	O
4529	O
*	O
2.5	O
x	O
105	O
cells	O
/	O
100Bl	O
/	O
well	O
of	O
spleen	O
cells	O
from	O
BALB	O
/	O
c	O
mice	O
suspended	O
in	O
10	O
%	O
FCS	O
RPMI	O
1640	O
medium	O
were	O
plated	O
on	O
a	O
96-well	O
plate	O
.	O

At	O
the	O
same	O
time	O
,	O
various	O
concentrations	O
of	O
samples	O
(	O
10	O
Bl	O
/	O
well	O
)	O
were	O
added	O
into	O
each	O
well	O
,	O
and	O
the	O
cell	O
suspension	O
was	O
cultured	O
at	O
37	O
,	O
5	O
%	O
CO2	O
for	O
2	O
days	O
.	O

Then	O
0.5	O
BCi	O
/	O
well	O
of	O
tritium	B
-	I
thymidine	I
(	O
3H	B
-	I
TdR	I
)	O
was	O
added	O
into	O
each	O
well	O
,	O
and	O
16	O
hours	O
later	O
,	O
the	O
3H	B
-	I
TdR	I
uptake	O
into	O
the	O
cells	O
was	O
measured	O
by	O
a	O
liquid	O
scintillation	O
counter	O
.	O

Each	O
value	O
shows	O
the	O
mean	O
+	O
_	O
S.D.	O
*	O
;	O
p	O
<	O
0.05	O
(	O
vs.	O
vehicle	O
treated	O
group	O
)	O
.	O

Because	O
3tx	B
-	I
galactosylated	I
~-GalCer	I
(	O
AGL-533	B
)	O
showed	O
stronger	O
immunostimulatory	O
activity	O
than	O
the	O
parental	O
~-GalCer	B
(	O
AGL-506	B
)	O
(	O
Table	O
1	O
)	O
,	O
the	O
result	O
arose	O
a	O
question	O
as	O
to	O
whether	O
c~-galactosyl-3-ceramide	B
(	O
~-	B
Gal-3-Cer	I
,	O
galactose	B
bound	O
to	O
ceramide	B
in	O
the	O
3-position	O
)	O
can	O
stimulate	O
the	O
proliferation	O
of	O
spleen	O
cells	O
as	O
ct-	B
Gal	I
-	I
l	I
-	I
Cers	I
such	O
as	O
KRN7000	B
and	O
AGL-506	B
can	O
do	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
synthesized	O
two	O
kinds	O
of	O
c~-GalCers	B
with	O
only	O
the	O
3-OH	O
,	O
ct	B
-	I
Gal	I
-	I
l	I
-	I
Cer	I
(	O
AGL-517	B
,	O
16	O
)	O
and	O
ct	B
-	I
Gal-3-Cer	I
(	O
AGL-553	B
,	O
17	O
)	O
,	O
by	O
the	O
methods	O
shown	O
in	O
Scheme	O
2	O
.	O

Table	O
2	O
,	O
Effects	O
of	O
AGL-517	B
(	O
16	O
)	O
and	O
AGL-553	B
(	O
17	O
)	O
on	O
murine	O
spleen	O
cells	O
.	O

3H	O
-	O
TdR	O
incorpolation	O
(	O
cpm	O
)	O
Sample	O
1	O
n~	O
/	O
ml	O
l0	O
ng	O
/	O
ml	O
100	O
ng	O
/	O
ml	O
Vehicle	O
6962	O
+	O
_	O
758	O
7858	O
_	O
_	O
1065	O
6280	O
_	O
+	O
823	O
AGL-517	B
(	O
16	O
)	O
9018	O
_	O
+	O
541	O
""""	O
44395	O
+	O
2157	O
""""	O
44395	O
_	O
+	O
2157	O
""""	O
AGL-553	B
(	O
17	O
)	O
7722	O
_	O
230	O
7412	O
_	O
+	O
1783	O
6141	O
_	O
_	O
1040	O
The	O
speen	O
cell	O
proliferation	O
assay	O
was	O
done	O
by	O
the	O
same	O
method	O
shown	O
in	O
Table	O
1	O
.	O

Each	O
value	O
shows	O
the	O
mean	O
+	O
S.D.	O
*	O
;	O
p	O
<	O
0.05	O
(	O
vs.	O
vehicle	O
treated	O
group	O
)	O
.	O

We	O
compared	O
the	O
effects	O
of	O
ct	B
-	I
Gal	I
-	I
l	I
-	I
Cer	I
,	O
AGL-517	B
(	O
16	O
)	O
,	O
and	O
ct	B
-	I
Gal-3-Cer	I
,	O
AGL-553	B
(	O
17	O
)	O
,	O
on	O
the	O
proliferation	O
of	O
mouse	O
spleen	O
cells	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
AGL-517	B
stimulated	O
the	O
proliferation	O
of	O
spleen	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
,	O
and	O
significant	O
stimulatory	O
activity	O
was	O
observed	O
from	O
the	O
concentration	O
of	O
1	O
ng	O
/	O
ml	O
.	O

By	O
contrast	O
,	O
AGL-553	B
did	O
not	O
stimulate	O
the	O
proliferation	O
of	O
spleen	O
cells	O
even	O
at	O
the	O
highest	O
concentration	O
of	O
100	O
ng	O
/	O
ml	O
.	O

Although	O
several	O
research	O
groups	O
have	O
published	O
the	O
reports	O
on	O
various	O
types	O
of	O
T.	O
Sakai	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
697	O
-	O
702	O
701	O
cz	B
-	I
GalCers	I
and	O
their	O
derivatives	B
which	O
were	O
isolated	O
from	O
marine	O
sponges9	O
-	O
13,18,19	O
or	O
were	O
totally	O
synthesized	O
,	O
l,14,20	O
all	O
compounds	O
are	O
cz	B
-	I
Gal	I
-	I
l	I
-	I
Cers	I
and	O
their	O
derivatives	B
.	O

Since	O
there	O
is	O
no	O
report	O
on	O
cx	B
-	I
Gal-3-	I
Cer	I
as	O
far	O
as	O
we	O
know	O
,	O
this	O
is	O
the	O
first	O
finding	O
that	O
oc	B
-	I
Gal-3-Cer	I
(	O
at	O
least	O
100	O
ng	O
/	O
ml	O
)	O
has	O
no	O
immunostimulatory	O
effect	O
.	O

The	O
results	O
shown	O
in	O
Table	O
1	O
and	O
2	O
demonstrate	O
that	O
{	O
x	O
-	O
binding	O
of	O
galactose	B
not	O
in	O
the	O
3-position	O
but	O
in	O
the	O
1-position	O
is	O
essential	O
for	O
the	O
manifestation	O
of	O
immunostimulatory	O
activity	O
by	O
cz	B
-	I
GalCers	I
,	O
and	O
that	O
the	O
3-	O
position	O
is	O
a	O
preferable	O
site	O
to	O
enhance	O
the	O
activity	O
by	O
the	O
glycosylation	O
.	O

It	O
was	O
demonstrated	O
that	O
CDld	O
-	O
transfectant	O
cells	O
pretreated	O
with	O
KRN7000	B
activate	O
murine	O
Vczl4	O
positive	O
NKT	O
cell	O
clones	O
and	O
human	O
Vo~24	O
positive	O
NKT	O
cell	O
clones	O
,	O
suggesting	O
that	O
CDld	O
molecule	O
plays	O
an	O
essential	O
role	O
in	O
the	O
activation	O
of	O
these	O
NKT	O
cells.4	O
-	O
8	O
In	O
addition	O
,	O
it	O
was	O
recently	O
proven	O
that	O
radiolabeled	B
KRN700021	I
and	O
biotinylated	B
o~-GalCers22	I
actualy	O
bind	O
to	O
mouse	O
CDI	O
and	O
human	O
CDld	O
molecules	O
.	O

These	O
results	O
suggest	O
that	O
the	O
complex	O
of	O
cz	B
-	I
GalCer	I
and	O
CDld	O
molecule	O
is	O
recognized	O
by	O
Vc~14	O
or	O
Vc~24	O
T	O
cell	O
receptor	O
on	O
NKT	O
cells	O
.	O

Our	O
computer	O
-	O
aided	O
molecular	O
modeling	O
demonstrated	O
that	O
active	O
compounds	O
such	O
as	O
R	B
-	I
GalCer	I
and	O
~-glucosylceramide	B
(	O
o~-GlcCer	B
)	O
share	O
active	O
conformations	O
which	O
are	O
not	O
accessible	O
to	O
[	O
3-GalCer	B
and	O
~-GlcCer.23	B
Furthermore	O
,	O
the	O
crystallographic	O
structure	O
of	O
mouse	O
CD1	O
was	O
recently	O
solved	O
by	O
Zeng	O
et	O
al.24	O
Taken	O
these	O
findings	O
together	O
,	O
it	O
seems	O
to	O
be	O
possible	O
to	O
construct	O
the	O
binding	O
model	O
of	O
CDld	O
/	O
o~-GalCer	B
complex	O
using	O
these	O
data	O
.	O

It	O
is	O
considered	O
that	O
the	O
present	O
study	O
using	O
AGL-506	B
(	O
2	O
)	O
,	O
AGL-529	B
(	O
3	O
)	O
,	O
AGL-	B
533	I
(	O
4	O
)	O
,	O
AGL-517	B
(	O
16	O
)	O
and	O
AGL-553	B
(	O
17	O
)	O
will	O
contribute	O
to	O
the	O
modeling	O
study	O
of	O
CDld	O
/	O
cz	B
-	I
GalCer	I
complex	O
and	O
will	O
be	O
useful	O
to	O
investigate	O
the	O
interaction	O
mechanism	O
among	O
CDId	O
molecules	O
,	O
R	B
-	I
GalCer	I
and	O
T	O
cell	O
receptor	O
.	O

Zonal	O
elution	O
and	O
high	O
-	O
performance	O
affinity	O
chromatography	O
were	O
used	O
to	O
examine	O
interactions	O
of	O
the	O
drugs	O
digitoxin	B
and	O
acetyldigitoxin	B
with	O
the	O
protein	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
.	O

This	O
was	O
done	O
by	O
injecting	O
small	O
amounts	O
of	O
digitoxin	B
and	O
acetyldigitoxin	B
onto	O
an	O
immobilized	O
HSA	O
column	O
in	O
the	O
presence	O
of	O
mobile	O
phases	O
that	O
contained	O
various	O
concentrations	O
of	O
digitoxin	B
,	O
acetyldigitoxin	B
or	O
other	O
solutes	O
as	O
competing	O
agents	O
.	O

A	O
fixed	O
concentration	O
of	O
beta	B
-	I
cyclodextrin	I
was	O
also	O
present	O
in	O
the	O
mobile	O
phase	O
as	O
a	O
solubilising	O
agent	O
.	O

It	O
was	O
found	O
that	O
digitoxin	B
and	O
acetyldigitoxin	B
each	O
had	O
strong	O
interactions	O
at	O
a	O
single	O
common	O
binding	O
site	O
on	O
HSA	O
,	O
but	O
with	O
slightly	O
different	O
equilibrium	O
constants	O
for	O
this	O
region	O
.	O

Neither	O
compound	O
showed	O
any	O
competition	O
with	O
warfarin	B
or	O
L	B
-	I
tryptophan	I
,	O
which	O
were	O
used	O
as	O
probes	O
for	O
binding	O
at	O
the	O
warfarin	B
-	O
azapropazone	B
and	O
indole	B
-	O
benzodiazepine	B
sites	O
of	O
HSA	O
.	O

These	O
results	O
confirmed	O
the	O
presence	O
of	O
a	O
separate	O
binding	O
region	O
on	O
HSA	O
for	O
digitoxin	B
-	I
related	I
compounds	I
.	O

Digitoxin	B
is	O
a	O
common	O
cardiovascular	O
drug	O
used	O
for	O
the	O
treatment	O
of	O
individuals	O
with	O
congestive	O
heart	O
failure	O
or	O
atrial	O
fibrillation	O
[	O
1	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
1	O
,	O
the	O
structure	O
of	O
digitoxin	B
consists	O
of	O
a	O
steroid	B
backbone	O
with	O
a	O
lactone	B
ring	O
at	O
the	O
C-17	O
position	O
and	O
a	O
linear	O
chain	O
of	O
three	O
digitoxose	B
sugar	O
residues	B
attached	O
at	O
the	O
C-3	O
carbon	O
[	O
2	O
]	O
.	O

A	O
closely	O
related	O
molecule	O
is	O
acetyldigitoxin	B
(	O
or	O
digitoxin	B
monoacetate	I
)	O
,	O
in	O
which	O
an	O
acetyl	B
group	I
replaces	O
one	O
of	O
the	O
hydroxyl	B
groups	I
on	O
the	O
digitoxose	B
residues	O
.	O

Acetyldigitoxin	B
is	O
also	O
used	O
in	O
pharmaceutical	O
preparations	O
as	O
a	O
cardiovascular	O
drug	O
[	O
3	O
]	O
.	O

Like	O
many	O
other	O
drugs	O
,	O
both	O
digitoxin	B
and	O
acetyldigitoxin	B
are	O
known	O
to	O
interact	O
with	O
carrier	O
proteins	O
in	O
blood	O
[	O
4–6	O
]	O
.	O

Such	O
binding	O
can	O
play	O
an	O
important	O
role	O
in	O
controlling	O
the	O
distribution	O
,	O
metabolism	O
and	O
excretion	O
of	O
drugs	O
within	O
the	O
body	O
[	O
7	O
]	O
.	O

One	O
important	O
carrier	O
protein	O
is	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
.	O

HSA	O
is	O
the	O
most	O
abundant	O
protein	O
in	O
human	O
blood	O
plasma	O
and	O
is	O
known	O
to	O
bind	O
to	O
a	O
wide	O
range	O
of	O
exogenous	O
and	O
endogenous	O
compounds	O
,	O
including	O
bilirubin	B
,	O
fatty	B
acids	I
,	O
warfarin	B
,	O
tryptophan	B
and	O
benzodiazepines	B
,	O
among	O
others	O
[	O
8	O
]	O
.	O

Some	O
previous	O
studies	O
have	O
reported	O
that	O
both	O
digitoxin	B
and	O
acetyldigitoxin	B
bind	O
to	O
HSA	O
[	O
4,6,9	O
]	O
.	O

This	O
was	O
noted	O
in	O
solution	O
-	O
phase	O
radiolabel	O
studies	O
,	O
in	O
which	O
acetyldigitoxin	B
was	O
found	O
to	O
displace	O
digitoxin	B
from	O
HSA	O
.	O

In	O
the	O
same	O
work	O
,	O
it	O
was	O
found	O
that	O
digitoxin	B
was	O
not	O
displaced	O
from	O
HSA	O
by	O
other	O
compounds	O
that	O
are	O
known	O
to	O
interact	O
with	O
the	O
major	O
binding	O
regions	O
of	O
HSA	O
(	O
i.e.	O
,	O
the	O
warfarin	B
-	O
azapropazone	B
and	O
indole	B
-	O
benzodiazepine	B
binding	O
sites	O
)	O
[	O
6	O
]	O
.	O

It	O
was	O
concluded	O
from	O
these	O
results	O
that	O
a	O
separate	O
binding	O
region	O
exists	O
on	O
HSA	O
,	O
known	O
as	O
the	O
digitoxin	B
site	O
,	O
which	O
is	O
responsible	O
for	O
the	O
interactions	O
of	O
digitoxin	B
and	O
related	O
compounds	O
with	O
this	O
protein	O
[	O
6	O
]	O
.	O

However	O
,	O
the	O
existence	O
of	O
this	O
binding	O
region	O
still	O
remains	O
an	O
area	O
of	O
controversy	O
and	O
little	O
quantitative	O
data	O
is	O
available	O
on	O
the	O
overall	O
strength	O
of	O
binding	O
between	O
digitoxin	B
and	O
acetyldigitoxin	B
with	O
HSA	O
[	O
4,6,9	O
]	O
.	O

The	O
general	O
goal	O
of	O
this	O
study	O
is	O
to	O
perform	O
a	O
detailed	O
examination	O
of	O
the	O
binding	O
between	O
digitoxin	B
and	O
acetyldigitoxin	B
with	O
HSA	O
by	O
using	O
high	O
-	O
performance	O
affinity	O
chromatography	O
(	O
HPAC	O
)	O
and	O
zonal	O
elution	O
competitive	O
binding	O
experiments	O
.	O

In	O
this	O
approach	O
,	O
HSA	O
will	O
be	O
immobilized	O
onto	O
a	O
HPLC	O
-	O
based	O
silica	B
support	O
and	O
packed	O
into	O
a	O
column	O
.	O

The	O
immobilized	O
HSA	O
will	O
then	O
be	O
used	O
as	O
a	O
stationary	O
phase	O
to	O
examine	O
the	O
binding	O
of	O
drugs	O
or	O
other	O
solutes	O
that	O
are	O
applied	O
to	O
the	O
chromatographic	O
system	O
.	O

In	O
previous	O
work	O
,	O
it	O
has	O
been	O
repeatedly	O
shown	O
that	O
there	O
is	O
good	O
correlation	O
between	O
the	O
behaviour	O
observed	O
with	O
these	O
immobilized	O
HSA	O
supports	O
and	O
that	O
seen	O
for	O
solution	O
-	O
phase	O
HSA	O
[	O
10–19	O
]	O
.	O

However	O
,	O
the	O
chromatographic	O
approach	O
has	O
the	O
advantages	O
of	O
being	O
faster	O
,	O
easier	O
to	O
use	O
and	O
more	O
precise	O
than	O
traditional	O
solution	O
-	O
phase	O
methods	O
for	O
the	O
measurement	O
of	O
drug	B
-	O
protein	O
interactions	O
[	O
19	O
]	O
.	O

The	O
immobilized	O
HSA	O
columns	O
in	O
this	O
work	O
will	O
be	O
used	O
to	O
examine	O
the	O
retention	O
of	O
digitoxin	B
and	O
acetyldigitoxin	B
in	O
the	O
presence	O
of	O
various	O
competing	O
agents	O
.	O

The	O
competition	O
of	O
each	O
drug	O
with	O
itself	O
will	O
be	O
used	O
to	O
determine	O
the	O
total	O
number	O
of	O
binding	O
regions	O
for	O
these	O
solutes	O
,	O
while	O
the	O
competition	O
of	O
acetyldigitoxin	B
with	O
digitoxin	B
will	O
be	O
used	O
to	O
examine	O
the	O
number	O
of	O
their	O
common	O
binding	O
sites	O
.	O

Other	O
competing	O
agents	O
,	O
such	O
as	O
warfarin	B
and	O
L	B
-	I
tryptophan	I
,	O
will	O
be	O
employed	O
to	O
determine	O
whether	O
or	O
not	O
digitoxin	B
and	O
acetyldigitoxin	B
really	O
do	O
have	O
sites	O
on	O
HSA	O
that	O
are	O
separate	O
from	O
the	O
major	O
binding	O
regions	O
of	O
this	O
protein	O
.	O

From	O
these	O
studies	O
,	O
data	O
will	O
be	O
obtained	O
that	O
should	O
allow	O
a	O
more	O
complete	O
picture	O
to	O
be	O
developed	O
for	O
the	O
binding	O
of	O
HSA	O
to	O
digitoxin	B
and	O
related	O
compounds	O
.	O

2	O
Theory	O
The	O
binding	O
of	O
digitoxin	B
and	O
acetyldigitoxin	B
to	O
HSA	O
was	O
studied	O
by	O
using	O
the	O
technique	O
of	O
zonal	O
elution	O
[	O
19	O
]	O
.	O

In	O
this	O
method	O
,	O
a	O
known	O
concentration	O
of	O
a	O
competing	O
agent	O
(	O
I	O
)	O
is	O
continuously	O
applied	O
to	O
a	O
column	O
that	O
contains	O
an	O
immobilized	O
ligand	O
(	O
L	O
)	O
(	O
e.g.	O
,	O
HSA	O
)	O
while	O
injections	O
of	O
a	O
small	O
amount	O
of	O
analyte	O
(	O
A	O
)	O
are	O
made	O
.	O

If	O
I	O
and	O
A	O
compete	O
for	O
a	O
single	O
site	O
on	O
L	O
,	O
and	O
A	O
binds	O
to	O
no	O
other	O
type	O
of	O
site	O
on	O
the	O
support	O
,	O
then	O
the	O
following	O
reactions	O
can	O
be	O
used	O
to	O
describe	O
the	O
binding	O
events	O
that	O
take	O
place	O
in	O
the	O
column.	O
(	O
1	O
)	O
A+L	O
⇌	O
KAL	O
A−L	O
(	O
2	O
)	O
I+L	O
⇌	O
KIL	O
I−L	O
In	O
these	O
equations	O
K	O
AL	O
and	O
K	O
IL	O
are	O
the	O
association	O
equilibrium	O
constants	O
for	O
the	O
formation	O
of	O
the	O
complexes	O
A−L	O
and	O
I−L	O
,	O
respectively	O
.	O

It	O
was	O
necessary	O
in	O
this	O
study	O
to	O
also	O
use	O
β	B
-	I
cyclodextrin	I
as	O
a	O
mobile	O
phase	O
additive	O
to	O
help	O
complex	O
and	O
dissolve	O
the	O
digitoxin	B
and	O
acetyldigitoxin	B
in	O
solution	O
.	O

If	O
such	O
a	O
solubilising	O
agent	O
(	O
S	O
)	O
has	O
1:1	O
interactions	O
with	O
A	O
and/or	O
I	O
,	O
then	O
the	O
following	O
additional	O
reactions	O
will	O
occur	O
within	O
the	O
mobile	O
phase	O
during	O
the	O
zonal	O
elution	O
study.	O
(	O
3	O
)	O
A+S	O
⇌	O
KAS	O
A−S	O
(	O
4	O
)	O
I+S	O
⇌	O
KIS	O
I−S	O
In	O
these	O
reactions	O
,	O
K	O
AS	O
and	O
K	O
IS	O
are	O
the	O
association	O
equilibrium	O
constants	O
for	O
the	O
formation	O
of	O
the	O
complexes	O
A−S	O
and	O
I−S	O
,	O
respectively	O
.	O

For	O
the	O
reaction	O
scheme	O
shown	O
in	O
Eqs.	O
(	O
1	O
)	O
–	O
(	O
4	O
)	O
,	O
the	O
following	O
relationship	O
has	O
been	O
previously	O
derived	O
to	O
describe	O
the	O
change	O
in	O
retention	O
for	O
A	O
as	O
the	O
mobile	O
phase	O
concentration	O
of	O
the	O
competing	O
agent	O
is	O
varied	O
[	O
20	O
]	O
.	O
(	O
5	O
)	O
1	O
/	O
kA	O
′=	O
(	O
1+KAS	O
CS	O
)	O
(	O
1+KIS	O
CS	O
)	O
KAL	O
CL	O
(	O
1+KIL	O
CS	O
)	O
+	O
(	O
1+KAS	O
CS	O
)	O
(	O
KIL	O
CI	O
)	O
KAL	O
CL	O
(	O
1+KIL	O
CS	O
)	O
In	O
Eq.	O
(	O
5	O
)	O
,	O
k	O
A	O
′	O
is	O
the	O
capacity	O
factor	O
for	O
the	O
injected	O
solute	O
,	O
or	O
k	O
A	O
′=	O
(	O
t	O
r	O
/t	O
m	O
−1	O
)	O
,	O
where	O
tr	O
is	O
the	O
measured	O
retention	O
time	O
of	O
the	O
analyte	O
and	O
tm	O
is	O
the	O
column	O
void	O
time	O
.	O

The	O
term	O
C	O
L	O
is	O
the	O
total	O
concentration	O
of	O
all	O
active	O
ligand	O
sites	O
in	O
the	O
column	O
,	O
C	O
S	O
is	O
the	O
total	O
mobile	O
phase	O
concentration	O
of	O
the	O
solubilising	O
agent	O
,	O
and	O
C	O
I	O
is	O
the	O
total	O
concentration	O
of	O
competing	O
agent	O
in	O
the	O
mobile	O
phase	O
.	O

It	O
is	O
assumed	O
in	O
Eq.	O
(	O
5	O
)	O
that	O
the	O
amount	O
of	O
A	O
that	O
is	O
injected	O
is	O
much	O
smaller	O
than	O
the	O
amount	O
of	O
competing	O
agent	O
or	O
immobilized	O
ligand	O
in	O
the	O
column	O
(	O
i.e.	O
,	O
linear	O
elution	O
conditions	O
are	O
present	O
)	O
.	O

It	O
is	O
also	O
assumed	O
that	O
the	O
amount	O
of	O
solubilising	O
agent	O
is	O
much	O
larger	O
than	O
the	O
amount	O
of	O
A	O
or	O
I	O
that	O
is	O
complexed	O
by	O
this	O
agent	O
in	O
the	O
mobile	O
phase	O
.	O

For	O
the	O
1:1	O
direct	O
competition	O
of	O
A	O
and	O
I	O
for	O
L	O
,	O
Eq.	O
(	O
5	O
)	O
predicts	O
that	O
a	O
plot	O
of	O
1	O
/	O
k	O
A	O
versus	O
C	O
I	O
should	O
yield	O
a	O
linear	O
relationship	O
,	O
with	O
the	O
ratio	O
of	O
the	O
intercept	O
to	O
the	O
slope	O
for	O
this	O
graph	O
giving	O
a	O
value	O
equal	O
to	O
(	O
1+K	O
IS	O
C	O
S	O
)	O
/K	O
IL	O
.	O

The	O
values	O
for	O
some	O
of	O
the	O
equilibrium	O
constants	O
in	O
this	O
system	O
can	O
be	O
determined	O
by	O
preparing	O
a	O
second	O
plot	O
of	O
the	O
intercept	O
/	O
slope	O
ratio	O
versus	O
the	O
concentration	O
of	O
solubilising	O
agent	O
(	O
C	O
S	O
)	O
that	O
was	O
used	O
in	O
each	O
study	O
.	O

If	O
the	O
test	O
system	O
follows	O
the	O
reaction	O
model	O
shown	O
in	O
Eqs.	O
(	O
1	O
)	O
–	O
(	O
4	O
)	O
,	O
then	O
this	O
second	O
plot	O
should	O
give	O
a	O
linear	O
relationship	O
with	O
an	O
intercept	O
equal	O
to	O
1	O
/	O
K	O
IL	O
and	O
a	O
slope	O
equal	O
to	O
K	O
IS	O
/K	O
IL	O
.	O

By	O
taking	O
the	O
reciprocal	O
of	O
the	O
intercept	O
obtained	O
for	O
this	O
plot	O
,	O
the	O
association	O
equilibrium	O
constant	O
K	O
IL	O
for	O
the	O
binding	O
of	O
I	O
to	O
L	O
can	O
be	O
determined	O
at	O
the	O
site	O
of	O
competition	O
between	O
A	O
and	O
I	O
on	O
the	O
immobilized	O
ligand	O
[	O
20	O
]	O
.	O

3	O
Experimental	O
3.1	O
Reagents	O
Digitoxin	B
and	O
acetyldigitoxin	B
(	O
2:1	O
ratio	O
of	O
α-	B
and	I
β	I
-	I
forms	I
)	O
,	O
β	B
-	I
cyclodextrin	I
,	O
HSA	O
(	O
Cohn	O
fraction	O
V	O
,	O
99	O
%	O
globulin	O
free	O
,	O
fatty	O
acid	O
free	O
)	O
,	O
racemic	B
warfarin	I
and	O
L	B
-	I
tryptophan	I
were	O
obtained	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

The	O
HSA	O
and	O
diol	B
-	O
bonded	O
silica	B
supports	O
were	O
prepared	O
using	O
Nucleosil	O
Si-300	O
silica	B
(	O
7μm	O
particle	O
diameter	O
,	O
300	O
Å	O
pore	O
-	O
size	O
)	O
from	O
Macherey	O
-	O
Nagel	O
(	O
Duren	O
,	O
Germany	O
)	O
.	O

Other	O
chemicals	O
and	O
biochemicals	O
used	O
were	O
of	O
the	O
purest	O
grades	O
available	O
.	O

All	O
aqueous	B
solutions	O
were	O
prepared	O
using	O
water	B
purified	O
by	O
a	O
Nanopure	O
water	B
system	O
(	O
Barnstead	O
,	O
Dubuque	O
,	O
IA	O
,	O
USA	O
)	O
.	O

3.2	O
Apparatus	O
The	O
chromatographic	O
system	O
consisted	O
of	O
a	O
CM3000	O
solvent	O
delivery	O
system	O
from	O
Thermoseparations	O
(	O
Riviera	O
Beach	O
,	O
FL	O
,	O
USA	O
)	O
,	O
a	O
Rheodyne	O
7010	O
injection	O
valve	O
(	O
Cotati	O
,	O
CA	O
,	O
USA	O
)	O
equipped	O
with	O
a	O
20	O
μL	O
sample	O
loop	O
,	O
and	O
a	O
SM3100	O
UV	O
–	O
Vis	O
variable	O
wavelength	O
detector	O
from	O
Thermoseparations	O
.	O

A	O
Winner	O
-	O
on	O
-	O
Windows	O
interface	O
from	O
Thermoseparations	O
was	O
used	O
for	O
data	O
collection	O
.	O

Chromatograms	O
were	O
processed	O
by	O
programs	O
written	O
in	O
Microsoft	O
QuickBASIC	O
(	O
Redmond	O
,	O
WA	O
,	O
USA	O
)	O
.	O

All	O
columns	O
and	O
mobile	O
phases	O
were	O
maintained	O
at	O
37±0.2	O
°	O
C	O
by	O
using	O
an	O
Isotemp	O
9100	O
water	B
bath	O
(	O
Fisher	O
Scientific	O
,	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

The	O
columns	O
were	O
downward	O
slurry	O
-	O
packed	O
using	O
an	O
HPLC	O
column	O
slurry	O
packer	O
from	O
Alltech	O
(	O
Deerfield	O
,	O
IL	O
,	O
USA	O
)	O
.	O

3.3	O
Methods	O
Digitoxin	B
and	O
acetyldigitoxin	B
were	O
placed	O
into	O
pH	O
7.4	O
,	O
0.067	O
M	O
phosphate	B
buffer	I
by	O
using	O
β	B
-	I
cyclodextrin	I
as	O
a	O
solubilising	O
agent	O
.	O

The	O
concentration	O
of	O
this	O
solubilising	O
agent	O
was	O
varied	O
from	O
1.0–2.6	O
mM	O
during	O
the	O
zonal	O
elution	O
studies	O
.	O

Both	O
digitoxin	B
and	O
acetyldigitoxin	B
were	O
found	O
to	O
be	O
stable	O
in	O
this	O
solution	O
for	O
over	O
two	O
weeks	O
at	O
room	O
temperature	O
.	O

Diol	B
-	O
bonded	O
silica	B
was	O
prepared	O
as	O
described	O
previously	O
[	O
21	O
]	O
.	O

The	O
diol	B
coverage	O
of	O
the	O
final	O
Nucleosil	O
support	O
was	O
230±3μmol	O
(	O
±1	O
SD	O
)	O
per	O
gram	O
of	O
silica	B
,	O
as	O
determined	O
in	O
duplicate	O
by	O
an	O
iodometric	O
capillary	O
electrophoresis	O
assay	O
[	O
22	O
]	O
.	O

The	O
Schiff	B
base	I
immobilisation	O
method	O
was	O
used	O
to	O
couple	O
HSA	O
to	O
this	O
diol	B
support	O
[	O
23,24	O
]	O
.	O

A	O
bicinchoninic	B
acid	I
(	O
BCA	B
)	O
protein	O
assay	O
was	O
performed	O
in	O
triplicate	O
on	O
the	O
HSA	O
support	O
using	O
HSA	O
as	O
the	O
standard	O
and	O
diol	B
-	I
bonded	I
silica	I
as	O
the	O
blank	O
[	O
25	O
]	O
,	O
according	O
to	O
previous	O
methods	O
[	O
12	O
]	O
.	O

The	O
final	O
protein	O
content	O
of	O
the	O
HSA	O
support	O
was	O
found	O
to	O
be	O
426±2	O
nmol	O
HSA	O
per	O
gram	O
of	O
silica	B
.	O

A	O
3	O
cm	O
×	O
2	O
mm	O
I.D.	O
stainless	O
steel	O
column	O
was	O
downward	O
slurry	O
-	O
packed	O
at	O
3500	O
p.s.i	O
.	O

with	O
the	O
immobilized	O
HSA	O
silica	B
and	O
enclosed	O
in	O
a	O
water	O
jacket	O
for	O
temperature	O
control	O
.	O

A	O
pH	O
7.4	O
,	O
0.067	O
M	O
potassium	B
phosphate	I
buffer	I
containing	O
1.0–2.6	O
mM	O
β	B
-	I
cyclodextrin	I
was	O
used	O
to	O
prepare	O
all	O
mobile	O
phases	O
.	O

To	O
each	O
of	O
these	O
solutions	O
was	O
added	O
0–10	O
μM	O
of	O
digitoxin	B
,	O
acetyldigitoxin	B
or	O
warfarin	B
,	O
or	O
0–50	O
μM	O
of	O
L	B
-	I
tryptophan	I
as	O
a	O
competing	O
agent	O
.	O

Linear	O
behaviour	O
in	O
plots	O
made	O
according	O
to	O
Eq.	O
(	O
5	O
)	O
was	O
observed	O
when	O
using	O
mobile	O
phase	O
concentrations	O
of	O
0–0.5	O
μM	O
digitoxin	B
or	O
acetyldigitoxin	B
;	O
as	O
discussed	O
later	O
,	O
these	O
were	O
the	O
final	O
conditions	O
selected	O
for	O
use	O
in	O
all	O
equilibrium	O
constant	O
measurements	O
.	O

These	O
concentrations	O
were	O
approximately	O
ten	O
times	O
higher	O
than	O
the	O
therapeutic	O
range	O
of	O
digitoxin	B
(	O
i.e.	O
,	O
26–46	O
nM	O
)	O
[	O
26	O
]	O
,	O
and	O
thus	O
should	O
have	O
provided	O
sufficient	O
amounts	O
of	O
these	O
drugs	O
for	O
the	O
detection	O
of	O
any	O
significant	O
interactions	O
between	O
these	O
compounds	O
and	O
HSA	O
under	O
conditions	O
of	O
normal	O
use	O
.	O

After	O
preparation	O
,	O
each	O
mobile	O
phase	O
was	O
filtered	O
through	O
a	O
0.22	O
μm	O
nylon	O
filter	O
and	O
degassed	O
under	O
vacuum	O
for	O
15	O
min	O
.	O

The	O
samples	O
of	O
acetyldigitoxin	B
or	O
digitoxin	B
to	O
be	O
used	O
as	O
the	O
injected	O
analyte	O
were	O
then	O
prepared	O
in	O
the	O
same	O
mobile	O
phases	O
as	O
employed	O
in	O
each	O
individual	O
zonal	O
elution	O
study	O
.	O

The	O
zonal	O
elution	O
experiments	O
were	O
performed	O
at	O
flow	O
-	O
rates	O
between	O
0.2	O
and	O
0.5	O
ml	O
/	O
min	O
,	O
with	O
the	O
desired	O
analyte	O
being	O
applied	O
in	O
replicate	O
injections	O
.	O

The	O
column	O
back	O
-	O
pressures	O
under	O
these	O
conditions	O
ranged	O
from	O
200–500	O
p.s.i	O
.	O

The	O
elution	O
of	O
the	O
injected	O
acetyldigitoxin	B
and	O
digitoxin	B
was	O
monitored	O
at	O
221	O
nm	O
.	O

The	O
retention	O
time	O
of	O
each	O
probe	O
was	O
calculated	O
by	O
using	O
the	O
first	O
statistical	O
moment	O
of	O
its	O
corresponding	O
peak	O
[	O
27	O
]	O
.	O

The	O
void	O
time	O
of	O
the	O
column	O
was	O
determined	O
by	O
making	O
similar	O
injections	O
with	O
sodium	B
nitrate	I
,	O
a	O
non	O
-	O
retained	O
compound	O
.	O

Tests	O
for	O
non	O
-	O
specific	O
binding	O
between	O
digitoxin	B
and	O
acetyldigitoxin	B
and	O
the	O
support	O
were	O
performed	O
by	O
injecting	O
these	O
compounds	O
onto	O
a	O
diol	B
-	I
bonded	I
silica	I
column	O
;	O
in	O
each	O
case	O
,	O
only	O
negligible	O
interactions	O
were	O
noted	O
.	O

The	O
capacity	O
factors	O
for	O
the	O
injected	O
probe	O
compounds	O
were	O
determined	O
over	O
sample	O
concentrations	O
of	O
0.1–100	O
μM	O
,	O
with	O
0.1	O
μM	O
being	O
the	O
typical	O
level	O
employed	O
.	O

There	O
were	O
no	O
noticeable	O
shifts	O
in	O
the	O
capacity	O
factors	O
over	O
this	O
range	O
of	O
sample	O
concentrations	O
,	O
indicating	O
that	O
linear	O
elution	O
conditions	O
were	O
present	O
,	O
as	O
assumed	O
in	O
Eq.	O
(	O
5	O
)	O
.	O

4	O
Results	O
and	O
discussion	O
4.1	O
General	O
design	O
of	O
zonal	O
elution	O
studies	O
.	O

The	O
binding	O
studies	O
performed	O
in	O
this	O
work	O
were	O
based	O
on	O
the	O
change	O
in	O
retention	O
observed	O
for	O
a	O
small	O
amount	O
of	O
an	O
injected	O
analyte	O
that	O
was	O
passed	O
through	O
an	O
immobilized	O
protein	O
column	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
fixed	O
concentration	O
of	O
a	O
competing	O
agent	O
.	O

If	O
direct	O
competition	O
occurs	O
between	O
the	O
analyte	O
and	O
competing	O
agent	O
,	O
then	O
a	O
decrease	O
in	O
retention	O
should	O
be	O
obtained	O
for	O
the	O
analyte	O
as	O
the	O
competing	O
agent	O
's	O
concentration	O
is	O
increased	O
.	O

If	O
indirect	O
(	O
or	O
allosteric	O
)	O
competition	O
is	O
present	O
,	O
then	O
either	O
an	O
increase	O
or	O
decrease	O
in	O
analyte	O
retention	O
may	O
be	O
seen	O
at	O
higher	O
concentrations	O
of	O
the	O
competing	O
agent	O
,	O
depending	O
on	O
whether	O
the	O
indirect	O
competition	O
is	O
positive	O
or	O
negative	O
in	O
nature	O
.	O

Examples	O
of	O
typical	O
chromatograms	O
and	O
shifts	O
in	O
retention	O
that	O
are	O
obtained	O
in	O
such	O
studies	O
are	O
provided	O
in	O
[	O
10–19	O
]	O
.	O

By	O
analysing	O
the	O
data	O
of	O
these	O
experiments	O
according	O
to	O
equations	O
derived	O
for	O
specific	O
reaction	O
models	O
(	O
e.g.	O
,	O
see	O
Eqs.	O
(	O
1	O
)	O
–	O
(	O
5	O
)	O
for	O
direct	O
1:1	O
competition	O
)	O
,	O
it	O
is	O
possible	O
to	O
not	O
only	O
identify	O
the	O
particular	O
type	O
of	O
interaction	O
that	O
is	O
occurring	O
but	O
also	O
to	O
determine	O
the	O
equilibrium	O
constants	O
that	O
are	O
involved	O
in	O
these	O
binding	O
processes	O
.	O

Several	O
practical	O
factors	O
had	O
to	O
be	O
considered	O
when	O
using	O
these	O
types	O
of	O
zonal	O
elution	O
experiments	O
to	O
examine	O
the	O
interactions	O
of	O
digitoxin	B
and	O
acetyldigitoxin	B
with	O
immobilized	O
HSA	O
.	O

The	O
first	O
problem	O
encountered	O
was	O
the	O
relatively	O
low	O
water	B
solubility	O
of	O
these	O
drugs	O
,	O
which	O
made	O
it	O
difficult	O
to	O
reliably	O
put	O
enough	O
of	O
these	O
compounds	O
in	O
the	O
mobile	O
phase	O
for	O
detection	O
by	O
a	O
standard	O
HPLC	O
absorbance	O
detector	O
or	O
for	O
use	O
as	O
a	O
competing	O
agent	O
in	O
the	O
zonal	O
elution	O
studies	O
.	O

One	O
possible	O
way	O
of	O
enhancing	O
the	O
solubility	O
of	O
these	O
agents	O
would	O
be	O
to	O
add	O
an	O
organic	O
solvent	O
as	O
a	O
modifier	O
to	O
the	O
mobile	O
phase	O
.	O

However	O
,	O
this	O
would	O
also	O
be	O
likely	O
to	O
cause	O
a	O
change	O
in	O
the	O
binding	O
properties	O
and/or	O
structure	O
of	O
the	O
immobilized	O
HSA	O
[	O
28,29	O
]	O
.	O

An	O
alternative	O
approach	O
has	O
recently	O
been	O
developed	O
in	O
which	O
β	B
-	I
cyclodextrin	I
,	O
or	O
a	O
related	O
compound	O
like	O
α-	B
or	O
γ	B
-	I
cyclodextrin	I
,	O
is	O
used	O
as	O
a	O
mobile	O
phase	O
additive	O
to	O
help	O
solubilise	O
non	O
-	O
polar	O
compounds	O
during	O
HPLC	O
-	O
based	O
binding	O
studies	O
[	O
20	O
]	O
.	O

In	O
this	O
present	O
study	O
it	O
was	O
found	O
that	O
a	O
solution	O
of	O
1–2.6	O
mM	O
β	B
-	I
cyclodextrin	I
could	O
easily	O
dissolve	O
acetyldigitoxin	B
and	O
digitoxin	B
in	O
pH	O
7.4	O
,	O
0.067	O
phosphate	B
buffer	I
at	O
concentrations	O
that	O
were	O
compatible	O
with	O
zonal	O
elution	O
experiments	O
(	O
i.e.	O
,	O
0.1–100	O
μM	O
)	O
.	O

Absorbance	O
and	O
light	O
-	O
scattering	O
measurements	O
indicated	O
that	O
were	O
no	O
apparent	O
changes	O
in	O
the	O
solubility	O
of	O
these	O
acetyldigitoxin	B
or	O
digitoxin	B
solutions	O
when	O
stored	O
for	O
several	O
weeks	O
at	O
4–37	O
°	O
C	O
,	O
thus	O
indicating	O
that	O
they	O
were	O
sufficiently	O
stable	O
for	O
use	O
as	O
mobile	O
phases	O
in	O
HPLC	O
studies	O
.	O

β	B
-	I
Cyclodextrin	I
was	O
selected	O
as	O
a	O
solubilising	O
agent	O
for	O
acetyldigitoxin	B
and	O
digitoxin	B
since	O
it	O
is	O
known	O
to	O
bind	O
to	O
many	O
small	O
,	O
non	O
-	O
polar	O
compounds	O
and	O
yet	O
it	O
has	O
no	O
measurable	O
binding	O
to	O
HSA	O
[	O
20,30	O
]	O
.	O

This	O
means	O
that	O
the	O
presence	O
of	O
β	B
-	I
cyclodextrin	I
in	O
the	O
mobile	O
phase	O
should	O
not	O
alter	O
the	O
nature	O
or	O
strength	O
of	O
the	O
binding	O
between	O
immobilized	O
HSA	O
and	O
solutes	O
like	O
acetyldigitoxin	B
and	O
digitoxin	B
.	O

Instead	O
,	O
β	B
-	I
cyclodextrin	I
and	O
HSA	O
would	O
be	O
expected	O
to	O
act	O
as	O
independent	O
ligands	O
for	O
these	O
drugs	O
,	O
with	O
the	O
β	B
-	I
cyclodextrin	I
being	O
used	O
to	O
merely	O
help	O
keep	O
acetyldigitoxin	B
and	O
digitoxin	B
in	O
the	O
mobile	O
phase	O
through	O
the	O
formation	O
of	O
soluble	O
host	O
:	O
guest	O
complexes	O
.	O

This	O
type	O
of	O
behaviour	O
has	O
been	O
confirmed	O
in	O
earlier	O
HPLC	O
experiments	O
that	O
have	O
examined	O
the	O
interactions	O
of	O
cis	B
-	O
and	O
trans	B
-clomiphene	B
with	O
immobilized	O
HSA	O
in	O
the	O
presence	O
of	O
soluble	O
β	B
-	I
cyclodextrin	I
[	O
20	O
]	O
.	O

A	O
second	O
advantage	O
of	O
using	O
β	B
-	I
cyclodextrin	I
as	O
a	O
complexing	O
agent	O
is	O
that	O
it	O
has	O
no	O
absorbance	O
under	O
the	O
UV	O
/	O
Vis	O
detection	O
conditions	O
that	O
are	O
commonly	O
employed	O
to	O
monitor	O
injected	O
solutes	O
in	O
HPLC	O
studies	O
of	O
drug	O
-	O
protein	O
interactions	O
.	O

Although	O
the	O
presence	O
of	O
β	B
-	I
cyclodextrin	I
did	O
help	O
produce	O
sufficient	O
mobile	O
phase	O
concentrations	O
of	O
acetyldigitoxin	B
and	O
digitoxin	B
for	O
HPLC	O
studies	O
,	O
the	O
presence	O
of	O
this	O
secondary	O
ligand	O
did	O
add	O
some	O
complexity	O
to	O
these	O
measurements	O
.	O

This	O
was	O
true	O
even	O
though	O
the	O
β	B
-	I
cyclodextrin	I
did	O
not	O
directly	O
affect	O
the	O
interactions	O
of	O
these	O
compounds	O
with	O
HSA	O
.	O

For	O
example	O
,	O
it	O
was	O
now	O
necessary	O
to	O
consider	O
how	O
the	O
elution	O
of	O
acetyldigitoxin	B
or	O
digitoxin	B
changed	O
as	O
a	O
function	O
of	O
the	O
concentrations	O
of	O
both	O
the	O
solubilising	O
agent	O
(	O
β	B
-	I
cyclodextrin	I
)	O
and	O
any	O
competing	O
agent	O
that	O
was	O
present	O
in	O
the	O
mobile	O
phase	O
(	O
e.g.	O
,	O
acetyldigitoxin	B
,	O
digitoxin	B
,	O
L	B
-	I
tryptophan	I
or	O
R	B
/	I
S	I
-	I
warfarin	I
)	O
.	O

The	O
equations	O
and	O
experiments	O
that	O
were	O
used	O
for	O
this	O
purpose	O
are	O
described	O
in	O
detail	O
in	O
[	O
20	O
]	O
as	O
well	O
as	O
in	O
the	O
Theory	O
and	O
Sections	O
4.2–4.4	O
of	O
this	O
current	O
report	O
.	O

A	O
second	O
complication	O
created	O
by	O
the	O
presence	O
of	O
β	B
-	I
cyclodextrin	I
was	O
the	O
relatively	O
small	O
retention	O
and	O
small	O
changes	O
in	O
retention	O
that	O
now	O
occurred	O
during	O
the	O
zonal	O
elution	O
studies	O
.	O

This	O
was	O
caused	O
by	O
the	O
increased	O
time	O
that	O
the	O
acetyldigitoxin	B
and	O
digitoxin	B
spent	O
in	O
the	O
mobile	O
phase	O
because	O
of	O
their	O
complexation	O
to	O
β	B
-	I
cyclodextrin	I
,	O
which	O
in	O
turn	O
led	O
to	O
a	O
decrease	O
in	O
their	O
observed	O
retention	O
times	O
and	O
capacity	O
factors	O
.	O

Most	O
of	O
the	O
capacity	O
factors	O
measured	O
in	O
this	O
work	O
were	O
in	O
the	O
range	O
of	O
0.10–0.25	O
,	O
with	O
some	O
experimental	O
conditions	O
giving	O
k	O
′	O
values	O
that	O
were	O
even	O
as	O
low	O
as	O
0.03	O
.	O

Non	O
-	O
specific	O
binding	O
did	O
not	O
create	O
a	O
problem	O
at	O
these	O
small	O
retention	O
values	O
because	O
neither	O
acetyldigitoxin	B
or	O
digitoxin	B
were	O
found	O
to	O
have	O
any	O
significant	O
interactions	O
with	O
the	O
diol	B
-	O
bonded	O
support	O
that	O
was	O
used	O
for	O
the	O
immobilisation	O
of	O
HSA	O
.	O

But	O
these	O
small	O
levels	O
of	O
retention	O
did	O
require	O
that	O
several	O
precautions	O
be	O
taken	O
in	O
order	O
to	O
obtain	O
reliable	O
estimates	O
of	O
shifts	O
in	O
k	O
′	O
values	O
as	O
the	O
experimental	O
conditions	O
were	O
changed	O
.	O

For	O
instance	O
,	O
a	O
low	O
injection	O
flow	O
rate	O
(	O
down	O
to	O
0.2	O
ml	O
/	O
min	O
)	O
and	O
a	O
fast	O
data	O
acquisition	O
rate	O
(	O
usually	O
60	O
points	O
per	O
second	O
)	O
were	O
used	O
to	O
obtain	O
good	O
time	O
resolution	O
in	O
the	O
chromatographic	O
data	O
that	O
were	O
generated	O
.	O

This	O
,	O
combined	O
with	O
the	O
use	O
of	O
replicate	O
moments	O
analysis	O
for	O
determining	O
the	O
true	O
center	O
of	O
each	O
peak	O
,	O
provided	O
an	O
estimated	O
precision	O
of	O
±0.001–0.002	O
min	O
(	O
or	O
about	O
±0.05–0.10	O
s	O
)	O
for	O
the	O
retention	O
time	O
measurements	O
performed	O
on	O
any	O
given	O
peak	O
.	O

Replicate	O
injections	O
under	O
each	O
set	O
of	O
experimental	O
conditions	O
gave	O
a	O
typical	O
observed	O
run	O
-	O
to	O
-	O
run	O
variation	O
of	O
±0.002–0.004	O
min	O
(	O
±	O
1	O
SD	O
)	O
.	O

When	O
the	O
retention	O
times	O
from	O
these	O
replicate	O
runs	O
were	O
averaged	O
,	O
the	O
resulting	O
precision	O
for	O
the	O
mean	O
retention	O
time	O
became	O
a	O
value	O
of	O
±0.002	O
/	O
N	O
to	O
0.004	O
/	O
N	O
(	O
or	O
±0.001–0.002	O
min	O
for	O
N=3	O
)	O
.	O

This	O
level	O
of	O
precision	O
was	O
found	O
to	O
be	O
sufficient	O
for	O
examining	O
most	O
of	O
the	O
shifts	O
in	O
k	O
′	O
that	O
occurred	O
throughout	O
this	O
work	O
.	O

In	O
those	O
cases	O
that	O
needed	O
even	O
higher	O
precision	O
(	O
e.g.	O
,	O
the	O
experiments	O
performed	O
at	O
k	O
′=0.03	O
)	O
,	O
a	O
larger	O
of	O
number	O
of	O
replicate	O
injections	O
were	O
used	O
to	O
further	O
decrease	O
the	O
standard	O
deviations	O
of	O
the	O
mean	O
retention	O
times	O
until	O
the	O
precision	O
of	O
the	O
average	O
capacity	O
factors	O
was	O
at	O
an	O
acceptable	O
level	O
.	O

4.2	O
Competitive	O
binding	O
studies	O
using	O
digitoxin	B
as	O
a	O
mobile	O
phase	O
additive	O
.	O

The	O
first	O
set	O
of	O
zonal	O
elution	O
studies	O
in	O
this	O
study	O
examined	O
the	O
competitive	O
binding	O
of	O
injected	O
digitoxin	B
and	O
acetyldigitoxin	B
in	O
the	O
presence	O
of	O
digitoxin	B
as	O
a	O
mobile	O
phase	O
additive	O
.	O

Plots	O
of	O
1	O
/	O
k	O
′A	O
versus	O
C	O
I	O
were	O
initially	O
generated	O
in	O
these	O
experiments	O
over	O
a	O
wide	O
range	O
of	O
competing	O
agent	O
concentrations	O
in	O
the	O
mobile	O
phase	O
.	O

When	O
using	O
1.0–2.6	O
mM	O
β	B
-	I
cyclodextrin	I
as	O
a	O
solubilising	O
agent	O
,	O
a	O
linear	O
region	O
in	O
these	O
plots	O
was	O
generally	O
observed	O
whenever	O
the	O
concentration	O
of	O
digitoxin	B
or	O
acetyldigitoxin	B
in	O
the	O
mobile	O
phase	O
was	O
below	O
0.5	O
μM	O
(	O
see	O
Fig.	O
2	O
)	O
.	O

Similar	O
results	O
have	O
been	O
observed	O
in	O
zonal	O
elution	O
studies	O
of	O
clomiphene	B
binding	O
to	O
HSA	O
in	O
the	O
presence	O
of	O
β	O
-	O
cyclodextrin	O
[	O
20	O
]	O
.	O

Since	O
Eq.	O
(	O
5	O
)	O
assumes	O
that	O
the	O
solubilising	O
agent	O
is	O
present	O
in	O
a	O
large	O
excess	O
versus	O
the	O
competing	O
agent	O
,	O
0–0.5	O
μM	O
digitoxin	B
or	O
acetyldigitoxin	B
was	O
the	O
mobile	O
phase	O
concentration	O
range	O
used	O
for	O
all	O
later	O
zonal	O
elution	O
studies	O
in	O
this	O
work	O
.	O

When	O
using	O
less	O
than	O
0.5	O
μM	O
digitoxin	B
as	O
a	O
competing	O
agent	O
and	O
digitoxin	B
as	O
the	O
injected	O
probe	O
,	O
plots	O
of	O
1	O
/	O
k	O
A	O
′	O
versus	O
[	O
digitoxin	B
]	O
gave	O
linear	O
relationships	O
,	O
as	O
predicted	O
by	O
Eq.	O
(	O
5	O
)	O
for	O
systems	O
with	O
1:1	O
competition	O
.	O

The	O
graphs	O
that	O
were	O
obtained	O
are	O
shown	O
in	O
Figs.	O
2	O
(	O
a	O
)	O
and	O
3	O
(	O
a	O
–	O
c	O
)	O
.	O

The	O
correlation	O
coefficients	O
for	O
all	O
these	O
plots	O
were	O
0.9999	O
over	O
the	O
four	O
data	O
points	O
generated	O
at	O
1.0–2.6	O
mM	O
β	B
-	I
cyclodextrin	I
.	O

A	O
second	O
graph	O
(	O
Fig.	O
4	O
)	O
was	O
made	O
for	O
the	O
digitoxin	B
/	O
digitoxin	B
data	O
by	O
taking	O
the	O
ratio	O
of	O
the	O
intercepts	O
and	O
slopes	O
of	O
the	O
best	O
-	O
fit	O
lines	O
and	O
plotting	O
these	O
values	O
versus	O
the	O
total	O
,	O
or	O
analytical	O
,	O
concentration	O
of	O
β	B
-	I
cyclodextrin	I
that	O
was	O
present	O
in	O
the	O
mobile	O
phase	O
.	O

This	O
graph	O
also	O
gave	O
linear	O
behaviour	O
,	O
with	O
a	O
correlation	O
coefficient	O
of	O
0.9974	O
over	O
the	O
four	O
concentrations	O
of	O
β	B
-	I
cyclodextrin	I
that	O
were	O
used	O
.	O

From	O
the	O
reciprocal	O
of	O
the	O
intercept	O
for	O
the	O
digitoxin	B
/	O
digitoxin	B
data	O
in	O
Fig.	O
4	O
,	O
it	O
was	O
possible	O
to	O
obtain	O
the	O
association	O
equilibrium	O
constant	O
for	O
the	O
competition	O
of	O
digitoxin	B
with	O
itself	O
at	O
its	O
binding	O
regions	O
on	O
HSA	O
.	O

This	O
gave	O
a	O
K	O
IL	O
value	O
for	O
this	O
interaction	O
of	O
5.2	O
(	O
±0.2	O
)	O
×	O
104	O
M−1	O
.	O

The	O
linearity	O
of	O
the	O
graphs	O
in	O
Figs.	O
2–4	O
for	O
the	O
competition	O
of	O
digitoxin	B
with	O
itself	O
supports	O
a	O
model	O
in	O
which	O
digitoxin	B
is	O
interacting	O
at	O
only	O
one	O
type	O
of	O
site	O
on	O
HSA	O
.	O

The	O
size	O
of	O
this	O
association	O
constant	O
is	O
also	O
in	O
good	O
agreement	O
with	O
previous	O
estimates	O
of	O
4–7	O
×	O
104	O
M−1	O
that	O
have	O
been	O
made	O
for	O
the	O
binding	O
of	O
digitoxin	B
to	O
HSA	O
in	O
solution	O
[	O
31	O
]	O
.	O

Similar	O
competitive	O
binding	O
studies	O
were	O
performed	O
between	O
acetyldigitoxin	B
and	O
digitoxin	B
by	O
injecting	O
small	O
amounts	O
of	O
acetyldigitoxin	B
into	O
the	O
presence	O
of	O
digitoxin	B
as	O
a	O
mobile	O
phase	O
additive	O
.	O

Plots	O
of	O
1	O
/	O
k	O
A	O
′	O
versus	O
[	O
digitoxin	O
]	O
for	O
these	O
experiments	O
again	O
gave	O
linear	O
relationships	O
at	O
competing	O
agent	O
concentrations	O
below	O
0.5	O
μM	O
(	O
see	O
Fig.	O
5	O
)	O
,	O
with	O
correlation	O
coefficients	O
ranging	O
from	O
0.9994–0.9999	O
over	O
four	O
data	O
points	O
obtained	O
at	O
each	O
level	O
of	O
β	B
-	I
cyclodextrin	I
.	O

The	O
ratio	O
of	O
the	O
intercepts	O
and	O
slopes	O
from	O
these	O
graphs	O
were	O
then	O
plotted	O
versus	O
the	O
total	O
concentration	O
of	O
β	B
-	I
cyclodextrin	I
in	O
the	O
mobile	O
phase	O
.	O

The	O
result	O
was	O
a	O
linear	O
relationship	O
with	O
a	O
correlation	O
coefficient	O
of	O
0.9988	O
over	O
four	O
levels	O
of	O
β	B
-	I
cyclodextrin	I
(	O
Fig.	O
4	O
)	O
.	O

The	O
reciprocal	O
of	O
the	O
intercept	O
from	O
this	O
plot	O
gave	O
an	O
association	O
equilibrium	O
constant	O
of	O
5.4	O
(	O
±0.2	O
)	O
×	O
10−4	O
M−1	O
for	O
the	O
interaction	O
of	O
digitoxin	B
at	O
the	O
site	O
at	O
which	O
it	O
competes	O
with	O
acetyldigitoxin	B
for	O
HSA	O
binding	O
.	O

This	O
value	O
was	O
statistically	O
identical	O
to	O
that	O
obtained	O
in	O
the	O
previous	O
experiment	O
for	O
the	O
competition	O
of	O
digitoxin	B
with	O
itself	O
,	O
indicating	O
that	O
the	O
same	O
site	O
on	O
HSA	O
was	O
involved	O
in	O
both	O
binding	O
processes	O
.	O

Furthermore	O
,	O
the	O
linearity	O
of	O
the	O
acetyldigitoxin	B
/	O
digitoxin	B
plots	O
in	O
Figs.	O
4–5	O
indicates	O
that	O
digitoxin	B
and	O
acetyldigitoxin	B
had	O
only	O
one	O
region	O
on	O
HSA	O
at	O
which	O
they	O
had	O
competitive	O
binding	O
,	O
as	O
observed	O
for	O
the	O
digitoxin	B
/	O
digitoxin	B
system	O
in	O
Figs.	O
2–4	O
.	O

4.3	O
Competitive	O
binding	O
studies	O
using	O
acetyldigitoxin	B
as	O
a	O
mobile	O
phase	O
additive	O
.	O

The	O
next	O
group	O
of	O
zonal	O
elution	O
studies	O
examined	O
the	O
binding	O
of	O
acetyldigitoxin	B
in	O
the	O
presence	O
of	O
acetyldigitoxin	B
as	O
a	O
mobile	O
phase	O
additive	O
.	O

As	O
seen	O
earlier	O
in	O
the	O
digitoxin	B
studies	O
,	O
linear	O
behaviour	O
was	O
obtained	O
for	O
plots	O
of	O
1	O
/	O
k	O
A	O
′	O
versus	O
[	O
acetyldigitoxin	B
]	O
at	O
competing	O
agent	O
concentrations	O
below	O
0.5	O
μM	O
.	O

The	O
linear	O
region	O
of	O
these	O
curves	O
gave	O
correlation	O
coefficients	O
of	O
0.9980–0.9999	O
over	O
the	O
four	O
data	O
points	O
in	O
this	O
range	O
.	O

The	O
ratio	O
of	O
the	O
intercepts	O
and	O
slopes	O
of	O
these	O
results	O
were	O
then	O
plotted	O
against	O
the	O
concentration	O
of	O
β	B
-	I
cyclodextrin	I
.	O

The	O
result	O
was	O
a	O
linear	O
relationship	O
(	O
correlation	O
coefficient	O
,	O
0.9995	O
)	O
,	O
indicating	O
the	O
presence	O
of	O
single	O
-	O
site	O
binding	O
between	O
acetyldigitoxin	B
and	O
HSA	O
(	O
see	O
Fig.	O
4	O
)	O
.	O

From	O
the	O
reciprocal	O
of	O
the	O
intercept	O
in	O
this	O
graph	O
,	O
an	O
association	O
equilibrium	O
constant	O
of	O
4.8	O
(	O
±0.2	O
)	O
×	O
10−4	O
M−1	O
was	O
obtained	O
for	O
the	O
competition	O
of	O
acetyldigitoxin	B
with	O
itself	O
at	O
its	O
binding	O
regions	O
on	O
HSA	O
.	O

Another	O
zonal	O
elution	O
study	O
examined	O
the	O
competition	O
of	O
injected	O
digitoxin	B
in	O
the	O
presence	O
of	O
acetyldigitoxin	B
as	O
a	O
mobile	O
phase	O
additive	O
.	O

The	O
plots	O
of	O
1	O
/	O
k	O
A	O
′	O
versus	O
various	O
acetyldigitoxin	B
concentrations	O
below	O
0.5	O
μM	O
gave	O
linear	O
relationships	O
with	O
correlation	O
coefficients	O
of	O
0.9995–0.9999	O
over	O
the	O
four	O
data	O
points	O
obtained	O
at	O
each	O
concentration	O
of	O
β	B
-	I
cyclodextrin	I
.	O

The	O
ratio	O
of	O
the	O
intercepts	O
and	O
slopes	O
were	O
plotted	O
against	O
the	O
concentration	O
of	O
β	B
-	I
cyclodextrin	I
,	O
which	O
gave	O
a	O
linear	O
relationship	O
with	O
a	O
correlation	O
coefficient	O
of	O
0.9991	O
(	O
see	O
Fig.	O
4	O
)	O
.	O

From	O
the	O
reciprocal	O
of	O
the	O
intercept	O
in	O
this	O
plot	O
,	O
an	O
association	O
equilibrium	O
constant	O
of	O
4.9	O
(	O
±0.2	O
)	O
×	O
10−4	O
M−1	O
was	O
found	O
for	O
acetyldigitoxin	B
at	O
the	O
site	O
where	O
both	O
it	O
and	O
digitoxin	B
were	O
binding	O
to	O
HSA	O
.	O

This	O
association	O
equilibrium	O
constant	O
was	O
statistically	O
identical	O
to	O
that	O
seen	O
for	O
acetyldigitoxin	B
at	O
its	O
site	O
of	O
competition	O
with	O
itself	O
,	O
again	O
indicating	O
that	O
these	O
two	O
agents	O
each	O
had	O
just	O
one	O
common	O
binding	O
region	O
on	O
HSA	O
.	O

4.4	O
Competitive	O
binding	O
studies	O
using	O
warfarin	B
or	O
L	B
-	I
tryptophan	I
as	O
mobile	O
phase	O
additives	O
.	O

It	O
has	O
previously	O
been	O
proposed	O
in	O
the	O
literature	O
that	O
digitoxin	B
has	O
a	O
distinct	O
site	O
on	O
HSA	O
that	O
is	O
separate	O
from	O
the	O
warfarin	B
and	O
indole	B
binding	O
regions	O
[	O
6	O
]	O
.	O

It	O
has	O
also	O
been	O
reported	O
that	O
digitoxin	B
does	O
not	O
compete	O
with	O
warfarin	B
or	O
diazepam	B
(	O
a	O
marker	O
for	O
the	O
indole	B
site	O
of	O
HSA	O
)	O
in	O
the	O
presence	O
of	O
rat	O
α	O
-	O
fetoprotein	O
,	O
which	O
is	O
closely	O
-	O
related	O
to	O
HSA	O
in	O
its	O
structure	O
[	O
32	O
]	O
.	O

The	O
binding	O
(	O
or	O
lack	O
of	O
binding	O
)	O
of	O
digitoxin	B
and	O
acetyldigitoxin	B
at	O
the	O
warfarin	B
and	O
indole	B
sites	O
of	O
HSA	O
was	O
examined	O
in	O
this	O
study	O
by	O
performing	O
competitive	O
binding	O
zonal	O
elution	O
studies	O
between	O
these	O
drugs	O
and	O
warfarin	B
or	O
L	B
-	I
tryptophan	I
,	O
which	O
are	O
often	O
used	O
as	O
probes	O
for	O
the	O
warfarin	B
and	O
indole	B
sites	O
of	O
HSA	O
.	O

The	O
first	O
zonal	O
elution	O
studies	O
in	O
this	O
section	O
involved	O
the	O
injection	O
of	O
digitoxin	B
or	O
acetyldigitoxin	B
into	O
the	O
presence	O
of	O
warfarin	B
as	O
a	O
mobile	O
phase	O
additive	O
.	O

In	O
these	O
experiments	O
,	O
only	O
random	O
variations	O
of	O
±2–3	O
%	O
were	O
noted	O
in	O
k	O
A	O
′	O
for	O
injections	O
of	O
acetyldigitoxin	B
and	O
digitoxin	B
when	O
0–10	O
μM	O
warfarin	B
was	O
present	O
in	O
the	O
mobile	O
phase	O
.	O

Furthermore	O
,	O
both	O
acetyldigitoxin	B
and	O
digitoxin	B
gave	O
graphs	O
of	O
1	O
/	O
k	O
A	O
′	O
versus	O
[	O
warfarin	B
]	O
that	O
had	O
small	O
correlation	O
coefficients	O
(	O
0.1865–0.1942	O
over	O
seven	O
data	O
points	O
)	O
and	O
best	O
-	O
fit	O
slopes	O
that	O
were	O
statistically	O
equal	O
to	O
zero	O
(	O
i.e.	O
,	O
slopes	O
that	O
overlapped	O
with	O
zero	O
within	O
a	O
range	O
of	O
±1	O
SD	O
)	O
.	O

These	O
results	O
indicated	O
that	O
no	O
competition	O
existed	O
between	O
these	O
compounds	O
and	O
warfarin	B
for	O
binding	O
sites	O
on	O
HSA	O
,	O
in	O
agreement	O
with	O
previous	O
observations	O
[	O
6	O
]	O
.	O

This	O
confirmed	O
that	O
digitoxin	B
and	O
acetyldigitoxin	B
were	O
not	O
binding	O
at	O
the	O
warfarin	B
site	O
of	O
HSA	O
.	O

Competitive	O
binding	O
studies	O
between	O
digitoxin	B
or	O
acetyldigitoxin	B
and	O
L	B
-	I
tryptophan	I
produced	O
similar	O
negative	O
results	O
.	O

For	O
these	O
experiments	O
,	O
random	O
variations	O
of	O
±0.3–0.4	O
%	O
were	O
noted	O
in	O
k	O
A	O
′	O
for	O
injections	O
of	O
acetyldigitoxin	B
and	O
digitoxin	B
when	O
0–50	O
μM	O
L	B
-	I
tryptophan	I
was	O
used	O
as	O
a	O
mobile	O
phase	O
additive	O
.	O

The	O
correlation	O
coefficients	O
for	O
plots	O
of	O
1	O
/	O
k	O
A	O
′	O
versus	O
[	O
L	B
-	I
tryptophan	I
]	O
gave	O
values	O
of	O
only	O
0.0081–0.0417	O
over	O
seven	O
data	O
points	O
,	O
and	O
the	O
best	O
-	O
fit	O
slopes	O
were	O
again	O
statistically	O
equal	O
to	O
zero	O
within	O
a	O
range	O
of	O
±1	O
SD	O
.	O

As	O
in	O
the	O
previous	O
solution	O
-	O
phase	O
studies	O
[	O
6	O
]	O
,	O
this	O
indicated	O
that	O
digitoxin	B
and	O
acetyldigitoxin	B
were	O
not	O
competing	O
with	O
L	B
-	I
tryptophan	I
and	O
did	O
not	O
have	O
any	O
detectable	O
interactions	O
at	O
the	O
indole	B
site	O
of	O
HSA	O
.	O

5	O
Conclusion	O
In	O
this	O
report	O
,	O
HPAC	O
and	O
competitive	O
binding	O
zonal	O
elution	O
studies	O
were	O
used	O
to	O
characterize	O
the	O
binding	O
of	O
digitoxin	B
and	O
acetyldigitoxin	B
to	O
immobilized	O
HSA	O
,	O
with	O
β	B
-	I
cyclodextrin	I
being	O
used	O
in	O
the	O
mobile	O
phase	O
as	O
a	O
solubilising	O
agent	O
.	O

These	O
experiments	O
indicated	O
that	O
digitoxin	B
and	O
acetyldigitoxin	B
each	O
had	O
a	O
single	O
common	O
binding	O
site	O
on	O
HSA	O
,	O
but	O
with	O
slightly	O
different	O
equilibrium	O
constants	O
for	O
this	O
region	O
.	O

The	O
association	O
constants	O
that	O
were	O
measured	O
(	O
see	O
Table	O
1	O
)	O
were	O
in	O
good	O
agreement	O
with	O
earlier	O
solution	O
-	O
phase	O
estimates	O
[	O
31	O
]	O
.	O

Neither	O
digitoxin	B
or	O
acetyldigitoxin	B
showed	O
any	O
competition	O
with	O
warfarin	B
or	O
L	B
-	I
tryptophan	I
,	O
which	O
were	O
used	O
as	O
probes	O
for	O
binding	O
at	O
the	O
warfarin	B
-	O
azapropazone	B
and	O
indole	B
-	O
benzodiazepine	B
sites	O
of	O
HSA	O
.	O

Thus	O
,	O
these	O
data	O
support	O
a	O
model	O
in	O
which	O
HSA	O
has	O
a	O
separate	O
binding	O
region	O
for	O
digitoxin	B
-	B
related	I
compounds	I
,	O
as	O
proposed	O
previously	O
[	O
6	O
]	O
.	O

Similar	O
competitive	O
binding	O
studies	O
could	O
be	O
used	O
to	O
examine	O
the	O
binding	O
of	O
other	O
compounds	O
to	O
HSA	O
,	O
including	O
digitoxin	B
-	O
related	O
cardiovascular	O
drugs	O
or	O
other	O
therapeutic	O
agents	O
that	O
may	O
be	O
co	O
-	O
administered	O
with	O
digitoxin	B
or	O
acetyldigitoxin	B
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
under	O
grant	O
R01	O
GM44931	O
.	O

The	O
cellular	O
responses	O
of	O
plants	O
to	O
numerous	O
extracellular	O
stimuli	O
are	O
mediated	O
by	O
transient	O
elevations	O
in	O
the	O
concentration	O
of	O
cytosolic	O
free	O
calcium	B
(	O
[	O
Ca2+	B
]	O
cyt	O
)	O
.	O

We	O
have	O
addressed	O
the	O
question	O
of	O
how	O
cells	O
can	O
use	O
this	O
apparently	O
ubiquitous	O
system	O
to	O
initiate	O
so	O
many	O
specific	O
and	O
appropriate	O
end	O
responses	O
.	O

We	O
show	O
that	O
the	O
pollutant	O
gas	O
ozone	B
elicits	O
a	O
biphasic	O
Ca2	O
+	O
response	O
in	O
intact	O
Arabidopsis	O
plants	O
and	O
a	O
subsequent	O
increase	O
in	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
antioxidant	O
defence	O
enzyme	O
glutathione	O
-	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
.	O

The	O
second	O
of	O
the	O
two	O
[	O
Ca2+	B
]	O
cyt	O
peaks	O
,	O
but	O
not	O
the	O
first	O
,	O
could	O
be	O
eliminated	O
either	O
by	O
pre	O
-	O
treatment	O
of	O
plants	O
with	O
lanthanum	B
chloride	I
,	O
or	O
by	O
reducing	O
the	O
duration	O
of	O
ozone	B
fumigation	O
.	O

Under	O
these	O
conditions	O
,	O
ozone	B
-	O
induced	O
GST	O
expression	O
was	O
abolished	O
.	O

These	O
data	O
provide	O
a	O
functional	O
dissection	O
of	O
the	O
ozone	B
Ca2	B
+	I
signalling	O
pathway	O
and	O
indicate	O
that	O
the	O
second	O
ozone	B
-	O
induced	O
[	O
Ca2+	B
]	O
cyt	O
peak	O
provides	O
the	O
necessary	O
information	O
to	O
direct	O
expression	O
of	O
GST	O
.	O

Dipiperon	B
drops	O
30	O
-	O
180	O
mg	O
/	O
day	O
were	O
given	O
for	O
eight	O
weeks	O
to	O
29	O
children	O
with	O
character	O
neuroses	O
and	O
behavioural	O
disorders	O
.	O

A	O
16-item	O
rating	O
-	O
scale	O
covering	O
several	O
features	O
of	O
behaviour	O
disorder	O
was	O
completed	O
by	O
a	O
psychologist	O
and	O
a	O
teacher	O
independent	O
from	O
each	O
other	O
.	O

The	O
individual	O
number	O
of	O
pathological	O
scores	O
showed	O
a	O
decrease	O
already	O
within	O
the	O
first	O
treatment	O
week	O
and	O
a	O
further	O
decrease	O
by	O
the	O
end	O
of	O
the	O
trial	O
,	O
especially	O
for	O
the	O
items	O
of	O
capriciousness	O
,	O
obstinacy	O
,	O
irritability	O
and	O
restlessness	O
.	O

The	O
therapeutic	O
benefit	O
was	O
not	O
accompanied	O
by	O
an	O
adverse	O
effect	O
on	O
the	O
school	O
performance	O
of	O
the	O
children	O
.	O

No	O
side	O
-	O
effects	O
were	O
reported	O
or	O
observed	O
.	O

In	O
starfish	O
oocytes	O
,	O
maturation	O
is	O
induced	O
by	O
a	O
hormone	B
,	O
1-methyladenine	B
(	O
1-MA	B
)	O
,	O
that	O
binds	O
to	O
the	O
receptors	O
exposed	O
to	O
the	O
outer	O
surface	O
of	O
the	O
plasma	O
membrane	O
.	O

The	O
signal	O
of	O
1-MA	B
stimulates	O
the	O
heterotrimeric	O
G	O
protein	O
,	O
resulting	O
in	O
dissociation	O
of	O
the	O
betagamma	O
subunit	O
of	O
G	O
protein	O
(	O
Gbetagamma	O
)	O
from	O
a	O
pertussis	O
toxin	O
-	O
sensitive	O
Gi	O
-	O
type	O
alpha	O
subunit	O
.	O

To	O
investigate	O
the	O
targets	O
for	O
Gbetagamma	O
,	O
we	O
analyzed	O
1-MA-	B
or	O
Gbetagamma	O
-	O
dependent	O
phosphorylation	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
systems	O
.	O

A	O
62-kDa	O
protein	O
was	O
phosphorylated	O
immediately	O
after	O
1-MA	B
treatment	O
in	O
intact	O
oocytes	O
.	O

In	O
the	O
cell	O
-	O
free	O
preparations	O
,	O
the	O
62-kDa	O
protein	O
was	O
also	O
phosphorylated	O
on	O
serine	O
residue	O
(	O
s	O
)	O
immediately	O
after	O
addition	O
of	O
1-MA	B
or	O
Gbetagamma	O
.	O

The	O
Gbetagamma	O
-	O
dependent	O
phosphorylation	O
of	O
the	O
62-kDa	O
protein	O
was	O
inhibited	O
by	O
wortmannin	B
or	O
LY294002	B
,	O
which	O
are	O
mechanistically	O
different	O
inhibitors	O
of	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3	O
K	O
)	O
.	O

LY294002	B
also	O
inhibited	O
Gbetagamma-	O
as	O
well	O
as	O
1-MA	B
-	O
induced	O
maturation	O
of	O
oocytes	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
62-kDa	O
protein	O
functions	O
downstream	O
of	O
Gbetagamma	O
and	O
PI3	O
K	O
in	O
the	O
early	O
signaling	O
pathway	O
of	O
1-MA	B
-	O
induced	O
starfish	O
oocyte	O
maturation	O
.	O

The	O
phosphorylation	O
of	O
the	O
62-kDa	O
protein	O
may	O
be	O
required	O
for	O
the	O
activation	O
of	O
maturation	O
-	O
promoting	O
factor	O
.	O

The	O
flavoenzyme	O
d	O
-	O
aspartate	O
oxidase	O
from	O
beef	O
kidney	O
(	O
DASPO	O
,	O
EC	O
1.4	O
.	O
3.1	O
)	O
has	O
been	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

A	O
purification	O
procedure	O
,	O
faster	O
than	O
the	O
one	O
used	O
for	O
the	O
enzyme	O
from	O
the	O
natural	O
source	O
(	O
bDASPO	O
)	O
,	O
has	O
been	O
set	O
up	O
yielding	O
about	O
2	O
mg	O
of	O
pure	O
recombinant	O
protein	O
(	O
rDASPO	O
)	O
per	O
each	O
gram	O
of	O
wet	O
E.	O
coli	O
paste	O
.	O

rDASPO	O
has	O
been	O
shown	O
to	O
possess	O
the	O
same	O
general	O
biochemical	O
properties	O
of	O
bDASPO	O
,	O
except	O
that	O
the	O
former	O
contains	O
only	O
FAD	B
,	O
while	O
the	O
latter	O
is	O
a	O
mixture	O
of	O
two	O
forms	O
,	O
one	O
active	O
containing	O
FAD	B
and	O
one	O
inactive	O
containing	O
6-OH	B
-	I
FAD	I
(	O
9	O
-	O
20	O
%	O
depending	O
on	O
the	O
preparation	O
)	O
.	O

This	O
results	O
in	O
a	O
slightly	O
higher	O
specific	O
activity	O
(	O
about	O
15	O
%	O
)	O
for	O
rDASPO	O
compared	O
to	O
bDASPO	O
and	O
in	O
facilitated	O
procedures	O
for	O
apoprotein	O
preparation	O
and	O
reconstitution	O
.	O

Redox	O
potentials	O
of	O
-97	O
mV	O
and	O
-157	O
mV	O
were	O
determined	O
for	O
free	O
and	O
l-	B
(	I
+	I
)	I
-tartrate	I
complexed	O
DASPO	O
,	O
respectively	O
,	O
in	O
0.1	O
M	O
KPi	O
,	O
pH	O
7.0	O
,	O
25	O
degrees	O
C.	O
The	O
large	O
positive	O
shift	O
in	O
the	O
redox	O
potential	O
of	O
the	O
coenzyme	B
compared	O
to	O
free	O
FAD	B
(	O
-207	O
mV	O
)	O
is	O
in	O
agreement	O
with	O
similar	O
results	O
obtained	O
with	O
other	O
flavooxidases	O
.	O

rDASPO	O
has	O
been	O
used	O
to	O
assess	O
a	O
possible	O
oxidative	O
activity	O
of	O
the	O
enzyme	O
towards	O
a	O
number	O
of	O
compounds	B
used	O
as	O
agonists	O
or	O
antagonists	O
of	O
neurotransmitters	O
,	O
including	O
d	B
-	I
aspartatic	I
acid	I
,	O
d	B
-	I
glutamic	I
acid	I
,	I
N	B
-	I
methyl	I
-	I
d	I
-	I
aspartic	I
acid	I
,	O
d	B
,	I
l	I
-	I
cysteic	I
acid	I
,	O
d	B
-	I
homocysteic	I
acid	I
,	I
d	B
,	I
l-2-amino-3-phosphonopropanoic	I
acid	I
,	O
d	B
-	I
alpha	I
-	I
aminoadipic	I
acid	I
,	O
d	B
-	I
aspartic	I
acid	I
-	I
beta	I
-	I
hydroxamate	I
,	O
glycyl	B
-	I
d	I
-	I
aspartic	I
acid	I
and	O
cis-2	B
,	I
3-piperidine	I
dicarboxylic	I
acid	I
.	O

Kinetic	O
parameters	O
for	O
each	O
substrate	O
in	O
50	O
mM	O
KPi	O
,	O
pH	O
7.4	O
,	O
25	O
degrees	O
C	O
are	O
reported	O
.	O

LD50	O
of	O
karminomycin	B
,	O
rubomycin	B
and	O
adriamycin	B
were	O
determined	O
after	O
their	O
single	O
administration	O
or	O
3-	O
,	O
5-	O
,	O
10-	O
and	O
15-fold	O
administration	O
once	O
a	O
day	O
to	O
540	O
hybrid	O
male	O
mice	O
F1	O
(	O
C57B1	O
X	O
CBA	O
)	O
.	O

Comparison	O
of	O
the	O
cumulative	O
indices	O
for	O
these	O
antibiotics	B
showed	O
that	O
after	O
injections	O
they	O
were	O
close	O
.	O

After	O
5	O
injections	O
the	O
cumulative	O
properties	O
were	O
more	O
pronounced	O
for	O
adriamycin	B
.	O

After	O
10	O
or	O
15	O
injections	O
the	O
cumulative	O
properties	O
were	O
less	O
pronounced	O
for	O
karminomycin	B
.	O

We	O
have	O
compared	O
the	O
minimum	O
local	O
analgesic	O
concentrations	O
(	O
MLAC	O
)	O
of	O
levobupivacaine	B
relative	O
to	O
racemic	B
bupivacaine	I
in	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
sequential	O
allocation	O
study	O
.	O

Women	O
in	O
labour	O
were	O
given	O
a	O
20-ml	O
bolus	O
of	O
epidural	O
levobupivacaine	B
or	O
bupivacaine	B
diluted	O
to	O
a	O
concentration	O
determined	O
by	O
up	O
-	O
down	O
sequential	O
allocation	O
.	O

The	O
initial	O
concentration	O
was	O
0.07	O
%	O
w	O
/	O
v	O
for	O
both	O
drugs	B
.	O

Efficacy	O
was	O
defined	O
using	O
a	O
visual	O
analogue	O
pain	O
score	O
(	O
VAPS	O
)	O
at	O
10	O
mm	O
or	O
less	O
within	O
30	O
min	O
.	O

The	O
MLAC	O
of	O
levobupivacaine	B
was	O
0.083	O
%	O
w	O
/	O
v	O
(	O
95	O
%	O
CI	O
0.065	O
-	O
0.101	O
)	O
and	O
the	O
MLAC	O
of	O
bupivacaine	B
0.081	O
%	O
w	O
/	O
v	O
(	O
95	O
%	O
CI	O
0.055	O
-	O
0.108	O
)	O
.	O

In	O
molar	O
terms	O
,	O
the	O
MLAC	O
of	O
levobupivacaine	B
was	O
2.87	O
mmol	O
litre-1	O
(	O
95	O
%	O
CI	O
2.25	O
-	O
3.49	O
)	O
and	O
the	O
MLAC	O
of	O
bupivacaine	B
2.49	O
mmol	O
litre-1	O
(	O
95	O
%	O
CI	O
1.69	O
-	O
3.32	O
)	O
.	O

With	O
regard	O
to	O
the	O
commercial	O
preparations	O
,	O
the	O
potency	O
ratio	O
levobupivacaine	B
:	O
bupivacaine	B
was	O
0.98	O
(	O
95	O
%	O
CI	O
0.67	O
-	O
1.41	O
)	O
,	O
and	O
this	O
is	O
unlikely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O

In	O
molar	O
terms	O
,	O
the	O
ratio	O
was	O
0.87	O
(	O
95	O
%	O
CI	O
0.60	O
-	O
1.25	O
)	O
.	O

With	O
regard	O
to	O
toxicity	O
,	O
the	O
evidence	O
should	O
be	O
evaluated	O
in	O
the	O
light	O
of	O
a	O
possible	O
13	O
%	O
potency	O
difference	O
in	O
molar	O
concentration	O
in	O
favour	O
of	O
racemic	B
bupivacaine	I
.	O

The	O
expression	O
of	O
the	O
sialyl	B
Lewis	I
x	I
antigen	I
(	O
sLe	B
(	I
x	I
)	I
)	O
on	O
surgical	O
specimens	O
of	O
primary	O
gastric	O
cancer	O
correlates	O
with	O
the	O
degree	O
of	O
differentiation	O
and	O
synchronous	O
and	O
metachronous	O
liver	O
metastasis	O
.	O

Multivariate	O
analysis	O
by	O
means	O
of	O
Quantification	O
theory	O
II	O
revealed	O
that	O
sLe	B
(	I
x	I
)	I
expression	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
liver	O
metastasis	O
from	O
gastric	O
cancer	O
.	O

Novel	O
as	O
well	O
as	O
known	O
5'-N	B
-	I
substituted	I
carboxamidoadenosines	I
were	O
prepared	O
via	O
new	O
routes	O
that	O
provided	O
shorter	O
reaction	O
times	O
and	O
good	O
yields	O
.	O

Binding	O
affinities	O
were	O
determined	O
for	O
rat	O
A1	O
and	O
A2A	O
receptors	O
and	O
human	O
A3	O
receptors	O
.	O

EC50	O
values	O
were	O
determined	O
for	O
cyclic	B
AMP	I
production	O
in	O
CHO	O
cells	O
expressing	O
human	O
A2B	O
receptors	O
.	O

On	O
all	O
receptor	O
subtypes	O
relatively	O
small	O
substituents	O
on	O
the	O
carboxamido	B
moiety	O
were	O
optimal	O
.	O

Selectivity	O
for	O
the	O
A3	O
receptor	O
was	O
found	O
for	O
several	O
analogues	B
(	O
1a	B
,	O
1d	B
,	O
1h	B
,	O
and	O
1k	B
)	O
.	O

On	O
A1	O
receptors	O
a	O
number	O
of	O
compounds	O
,	O
but	O
not	O
5'-N	B
-	I
ethylcarboxamidoadenosine	I
(	O
NECA	B
,	O
1b	B
)	O
,	O
showed	O
small	O
GTP	B
shifts	O
,	O
which	O
could	O
be	O
indicative	O
of	O
lower	O
intrinsic	O
activities	O
at	O
the	O
A1	O
receptor	O
.	O

At	O
the	O
A2B	O
receptor	O
,	O
derivatives	B
1i	I
-	I
k	I
with	O
modified	O
ethyl	B
substituents	I
had	O
reduced	O
activities	O
compared	O
to	O
the	O
A2B	O
reference	O
agonist	O
NECA	B
(	O
1b	B
)	O
.	O

Thiocarboxamido	B
derivatives	I
(	O
8b	B
and	O
8c	B
)	O
displayed	O
considerable	O
although	O
decreased	O
A2B	O
receptor	O
activity	O
.	O

The	O
X	O
-	O
ray	O
structure	O
determination	O
of	O
compound	B
8b	I
was	O
carried	O
out	O
.	O

Due	O
to	O
intramolecular	O
hydrogen	O
bonding	O
between	O
the	O
carboxamido	B
NH	I
and	O
the	O
purine	B
N3	I
in	O
the	O
crystal	O
structure	O
,	O
the	O
ribose	B
moiety	O
of	O
this	O
compound	O
is	O
in	O
a	O
syn	O
conformation	O
.	O

However	O
,	O
theoretical	O
calculations	O
support	O
that	O
NECA	B
(	O
1b	B
)	O
,	O
and	O
less	O
so	O
8b	B
,	O
can	O
readily	O
adopt	O
both	O
the	O
syn	O
and	O
the	O
anti	O
conformation	O
,	O
therefore	O
not	O
excluding	O
the	O
proposed	O
anti	O
mode	O
of	O
binding	O
to	O
the	O
receptor	O
.	O

Calcitriol	B
,	O
also	O
known	O
as	O
1,25-dihydroxy	B
-	I
vitamin	I
D3	I
,	O
is	O
a	O
steroid	B
hormone	I
that	O
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
cytokine	O
production	O
and	O
lymphocyte	O
proliferation	O
.	O

Coadministration	O
of	O
calcitriol	B
with	O
trivalent	O
influenza	O
vaccine	O
in	O
mice	O
enhanced	O
both	O
mucosal	O
and	O
systemic	O
antibody	O
responses	O
.	O

We	O
studied	O
the	O
effects	O
of	O
calcitriol	B
coadministered	O
with	O
a	O
commercially	O
available	O
influenza	O
vaccine	O
in	O
175	O
human	O
volunteers	O
in	O
this	O
double	O
-	O
blind	O
,	O
placebo	O
controlled	O
clinical	O
trial	O
.	O

Subjects	O
that	O
received	O
calcitriol	B
experienced	O
more	O
pain	O
at	O
the	O
injection	O
site	O
compared	O
with	O
placebo	O
recipients	O
.	O

No	O
significant	O
differences	O
in	O
hemagglutination	O
inhibition	O
titers	O
against	O
H1N1	B
,	O
H3N2	B
,	O
or	O
influenza	B
B	I
antigens	I
were	O
detected	O
at	O
1	O
or	O
3	O
months	O
postvaccination	O
.	O

We	O
conclude	O
that	O
coadministration	O
of	O
1.0	O
microg	O
of	O
calcitriol	B
at	O
a	O
site	O
adjacent	O
to	O
influenza	O
vaccination	O
does	O
not	O
enhance	O
humoral	O
immunity	O
in	O
human	O
volunteers	O
.	O

Influenza	O
viruses	O
have	O
been	O
responsible	O
for	O
epidemics	O
of	O
febrile	O
respiratory	O
infections	O
for	O
hundreds	O
of	O
years	O
.	O

Individuals	O
with	O
acute	O
influenza	O
A	O
infection	O
characteristically	O
develop	O
the	O
acute	O
onset	O
of	O
fever	O
,	O
myalgias	O
and	O
headache	O
,	O
followed	O
by	O
a	O
severe	O
upper	O
respiratory	O
illness	O
with	O
cough	O
lasting	O
for	O
days	O
or	O
weeks	O
.	O

Some	O
influenza	O
cases	O
progress	O
to	O
a	O
morbid	O
or	O
fatal	O
lower	O
respiratory	O
infection	O
.	O

During	O
the	O
great	O
pandemic	O
of	O
1918–1919	O
,	O
more	O
persons	O
succumbed	O
to	O
complications	O
of	O
influenza	O
infection	O
than	O
were	O
killed	O
during	O
the	O
four	O
preceding	O
years	O
of	O
World	O
War	O
I	O
[	O
1	O
]	O
.	O

The	O
efficacy	O
of	O
vaccination	O
against	O
influenza	O
viruses	O
has	O
been	O
limited	O
by	O
the	O
ability	O
of	O
the	O
virus	O
to	O
alter	O
its	O
antigenic	O
structure	O
,	O
a	O
relatively	O
short	O
duration	O
of	O
immunity	O
,	O
and	O
incomplete	O
protection	O
provided	O
by	O
tolerable	O
doses	O
of	O
these	O
vaccines	O
.	O

1,25-dihydroxy	B
-	I
vitamin	I
D3	I
,	O
also	O
known	O
as	O
calcitriol	B
,	O
has	O
potent	O
effects	O
on	O
cytokine	O
production	O
and	O
immune	O
functions	O
in	O
animals	O
and	O
humans	O
[	O
2–6	O
]	O
.	O

The	O
addition	O
of	O
calcitriol	B
to	O
a	O
variety	O
of	O
vaccine	O
preparations	O
has	O
been	O
shown	O
to	O
augment	O
induced	O
immunity	O
to	O
herpes	O
simplex	O
virus	O
,	O
tetanus	O
toxoid	O
,	O
hepatitis	O
B	O
surface	O
antigen	B
and	O
HIV	O
gp160	O
[	O
7–9	O
]	O
.	O

Calcitriol	B
coadministered	O
with	O
trivalent	O
influenza	O
vaccine	O
in	O
mice	O
enhanced	O
both	O
mucosal	O
and	O
sytemic	O
antibody	O
responses	O
[	O
10	O
,	O
11	O
]	O
.	O

Coadministration	O
of	O
calcitriol	B
in	O
this	O
study	O
also	O
enhanced	O
the	O
vaccinated	O
animals	O
'	O
ability	O
to	O
neutralize	O
live	O
influenza	O
virus	O
instilled	O
into	O
the	O
nose	O
.	O

Serum	O
influenza	O
hemagglutination	O
inhibition	O
(	O
HAI	O
)	O
titers	O
reflect	O
the	O
ability	O
of	O
the	O
host	O
immune	O
response	O
to	O
neutralize	O
infectivity	O
of	O
the	O
virus	O
.	O

Most	O
importantly	O
,	O
higher	O
HAI	O
titers	O
are	O
correlated	O
with	O
the	O
protection	O
of	O
humans	O
from	O
influenza	O
virus	O
induced	O
respiratory	O
disease	O
[	O
12	O
]	O
.	O

The	O
following	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
clinical	O
trial	O
evaluated	O
calcitriol	B
as	O
a	O
potential	O
vaccine	O
-	O
enhancing	O
agent	O
when	O
coadministered	O
with	O
split	O
-	O
killed	O
influenza	O
vaccine	O
in	O
healthy	O
human	O
volunteers	O
.	O

We	O
hypothesized	O
that	O
calcitriol	B
and	O
influenza	O
vaccine	O
would	O
have	O
a	O
significant	O
enhancing	O
effect	O
on	O
influenza	O
hemagglutination	O
inhibition	O
(	O
HAI	O
)	O
titers	O
compared	O
to	O
a	O
parallel	O
control	O
group	O
that	O
received	O
influenza	O
vaccine	O
and	O
placebo	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Subjects	O
and	O
vaccinations	O
One	O
-	O
hundred	O
seventy	O
-	O
five	O
healthy	O
volunteers	O
were	O
enrolled	O
and	O
vaccinated	O
in	O
the	O
deltoid	O
muscle	O
with	O
0.5	O
ml	O
1996–1997	O
trivalent	O
split	O
-	O
killed	O
influenza	O
vaccine	O
(	O
Fluzone	O
,	O
Connaught	O
Laboratories	O
,	O
Inc.	O
,	O
Swiftwater	O
,	O
PA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

At	O
this	O
time	O
,	O
the	O
vaccinees	O
also	O
received	O
1.0	O
mL	O
(	O
1.0	O
μg	O
)	O
of	O
intramuscular	O
calcitriol	B
(	O
Calcijex	O
,	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
or	O
a	O
matching	O
saline	B
placebo	O
at	O
a	O
site	O
adjacent	O
to	O
and	O
1.0	O
cm	O
distant	O
from	O
the	O
influenza	O
vaccination	O
site	O
.	O

The	O
1.0	O
cm	O
separation	O
of	O
the	O
two	O
injections	O
was	O
chosen	O
to	O
comply	O
with	O
federal	O
regulations	O
yet	O
still	O
allow	O
the	O
in	O
vivo	O
mixing	O
of	O
the	O
two	O
agents	O
necessary	O
for	O
the	O
immunologic	O
effects	O
of	O
calcitriol	B
.	O

The	O
1.0	O
μg	O
dose	O
of	O
calcitriol	B
was	O
chosen	O
based	O
on	O
efficacy	O
in	O
preclinical	O
animal	O
studies	O
and	O
on	O
a	O
study	O
showing	O
a	O
lack	O
of	O
toxicity	O
in	O
normal	O
human	O
volunteers	O
[	O
13	O
,	O
14	O
]	O
.	O

The	O
calcitriol	B
or	O
placebo	O
injections	O
were	O
administered	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
manner	O
at	O
a	O
ratio	O
of	O
1:1	O
.	O

The	O
subjects	O
were	O
vaccinated	O
and	O
observed	O
in	O
the	O
Clinical	O
Research	O
Center	O
within	O
the	O
University	O
of	O
Utah	O
Medical	O
Center	O
.	O

Serum	O
samples	O
were	O
obtained	O
at	O
the	O
time	O
of	O
vaccination	O
and	O
30	O
and	O
90	O
days	O
postvaccination	O
.	O

Serum	O
was	O
stored	O
at	O
−20	O
°	O
C	O
.	O

before	O
thawing	O
and	O
analysis	O
.	O

The	O
study	O
was	O
reviewed	O
and	O
authorized	O
by	O
the	O
University	O
of	O
Utah	O
Institutional	O
Review	O
Board	O
and	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
.	O

The	O
randomization	O
schedule	O
and	O
study	O
drug	O
were	O
prepared	O
by	O
the	O
University	O
of	O
Utah	O
Investigational	O
Pharmacy	O
.	O

The	O
blind	O
was	O
held	O
there	O
until	O
the	O
dataset	O
was	O
finalized	O
.	O

All	O
the	O
subjects	O
were	O
18–49	O
years	O
of	O
age	O
(	O
male	O
or	O
female	O
)	O
,	O
in	O
good	O
physical	O
health	O
and	O
willing	O
to	O
provide	O
written	O
informed	O
consent	O
.	O

Female	O
subjects	O
in	O
their	O
childbearing	O
years	O
were	O
willing	O
to	O
perform	O
an	O
effective	O
method	O
of	O
contraception	O
during	O
the	O
study	O
period	O
.	O

Subjects	O
were	O
excluded	O
if	O
they	O
(	O
1	O
)	O
were	O
pregnant	O
or	O
lactating	O
,	O
(	O
2	O
)	O
had	O
received	O
an	O
investigational	O
drug	O
within	O
the	O
last	O
30	O
days	O
,	O
(	O
3	O
)	O
had	O
a	O
history	O
of	O
malignancy	O
,	O
renal	O
failure	O
,	O
nephrolithiasis	O
,	O
hypercalcemia	O
,	O
hyperparathyroidism	O
,	O
hypervitaminosis	O
D	O
or	O
other	O
serious	O
underlying	O
illnesses	O
,	O
(	O
4	O
)	O
were	O
using	O
oral	O
steroids	B
,	O
had	O
used	O
oral	O
or	O
IV	O
calcitriol	B
within	O
the	O
past	O
2	O
months	O
or	O
calcium	B
supplementation	O
in	O
the	O
past	O
2	O
days	O
,	O
(	O
5	O
)	O
had	O
already	O
received	O
any	O
1996–1997	O
influenza	O
vaccine	O
or	O
(	O
6	O
)	O
had	O
known	O
sensitivity	O
to	O
influenza	O
vaccines	O
,	O
calcitriol	B
or	O
any	O
components	O
of	O
these	O
commercial	O
preparations	O
.	O

Medical	O
histories	O
and	O
physical	O
examinations	O
were	O
performed	O
on	O
all	O
the	O
subjects	O
before	O
inclusion	O
and	O
vaccination	O
.	O

To	O
detect	O
potential	O
hypercalcemia	O
due	O
to	O
intramuscular	O
injection	O
of	O
calcitriol	B
,	O
the	O
first	O
20	O
subjects	O
had	O
serum	O
calcium	B
and	O
phosphorus	B
determinations	O
at	O
the	O
time	O
of	O
vaccination	O
and	O
24	O
h	O
later	O
.	O

The	O
subjects	O
were	O
asked	O
to	O
record	O
daily	O
oral	O
temperatures	O
,	O
general	O
symptoms	O
(	O
malaise	O
,	O
fatigue	O
)	O
and	O
local	O
symptoms	O
(	O
redness	O
,	O
swelling	O
and	O
soreness	O
at	O
the	O
injection	O
sites	O
)	O
the	O
day	O
of	O
and	O
for	O
3	O
days	O
following	O
vaccination	O
.	O

Queries	O
were	O
made	O
about	O
adverse	O
events	O
and	O
concomitant	O
medications	O
at	O
the	O
30-	O
and	O
90-day	O
follow	O
up	O
visits	O
.	O

A	O
brief	O
questionnaire	O
intended	O
to	O
elicit	O
signs	O
and	O
symptoms	O
of	O
clinical	O
influenza	O
was	O
administered	O
at	O
the	O
90-day	O
follow	O
-	O
up	O
visit	O
.	O

2.2	O
Serologies	O
The	O
primary	O
end	O
-	O
point	O
of	O
this	O
study	O
was	O
the	O
comparison	O
of	O
serum	O
hemagglutination	O
inhibition	O
(	O
HAI	O
)	O
titers	O
in	O
the	O
calcitriol	B
/	O
vaccine	O
group	O
compared	O
with	O
the	O
placebo	O
/	O
vaccine	O
group	O
.	O

Sera	O
were	O
thawed	O
,	O
treated	O
overnight	O
at	O
37	O
°	O
C	O
with	O
receptor	O
destroying	O
enzyme	O
(	O
Sigma	O
,	O
Cat	O
#	O
C8772	O
)	O
,	O
diluted	O
1:20	O
and	O
serum	O
HAI	O
titers	O
determined	O
by	O
a	O
standard	O
method	O
[	O
15	O
]	O
.	O

Titers	O
are	O
reported	O
as	O
the	O
highest	O
dilution	O
of	O
sera	O
that	O
showed	O
complete	O
inhibition	O
of	O
agglutination	O
.	O

HAI	O
titers	O
for	O
each	O
of	O
the	O
three	O
1996–1997	O
influenza	O
antigens	B
:	O
H1N1	B
,	O
H3N2	B
and	O
B	B
were	O
compared	O
between	O
the	O
groups	O
in	O
two	O
ways	O
:	O
(	O
1	O
)	O
comparison	O
of	O
the	O
mean	O
and	O
median	O
rises	O
above	O
baseline	O
at	O
30	O
and	O
90	O
days	O
(	O
paired	O
analysis	O
)	O
,	O
(	O
2	O
)	O
comparisons	O
between	O
the	O
groups	O
at	O
0	O
(	O
baseline	O
)	O
,	O
30	O
and	O
90	O
days	O
(	O
unpaired	O
)	O
.	O

Secondary	O
end	O
-	O
points	O
of	O
the	O
trial	O
were	O
comparisons	O
of	O
serum	O
ELISA	O
titers	O
to	O
the	O
influenza	O
antigens	B
H1N1	B
,	O
H3N2	B
and	O
B	B
and	O
the	O
presence	O
of	O
clinical	O
influenza	O
syndrome	O
in	O
the	O
subjects	O
.	O

Antibody	O
to	O
subtype	O
-	O
specific	O
Influenza	O
hemagglutinin	O
is	O
measured	O
by	O
hemagglutination	O
inhibition	O
according	O
to	O
a	O
standard	O
CDC	O
protocol	O
using	O
each	O
of	O
the	O
above	O
three	O
antigens	B
(	O
H1N1	B
,	O
H3N2	B
and	O
B	B
;	O
CDC	O
,	O
Atlanta	O
,	O
GA	O
)	O
.	O

Titers	O
were	O
log2	O
-transformed	O
for	O
analysis	O
as	O
follows	O
:	O
0	O
=	O
no	O
hemagglutinating	O
activity	O
,	O
1=1:10	O
,	O
2=1:20	O
,	O
3=1	O
:	O
40	O
,	O
4=1:80	O
,	O
etc	O
.	O

2.3	O
Statistical	O
analysis	O
We	O
estimated	O
that	O
63	O
evaluable	O
patients	O
per	O
group	O
(	O
126	O
total	O
)	O
would	O
be	O
required	O
to	O
detect	O
a	O
one	O
log2	O
(	O
twofold	O
)	O
increase	O
in	O
postvaccination	O
serum	O
HAI	O
titers	O
between	O
the	O
groups	O
.	O

The	O
group	O
size	O
was	O
determined	O
using	O
an	O
estimated	O
mean	O
HAI	O
titer	O
in	O
the	O
control	O
group	O
of	O
4.0	O
log	O
units	O
,	O
a	O
standard	O
deviation	O
of	O
2.0	O
log	O
units	O
,	O
significance	O
at	O
the	O
p	O
=	O
0.05	O
level	O
and	O
a	O
power	O
to	O
detect	O
of	O
80	O
%	O
(	O
β	O
=	O
0.20	O
)	O
.	O

Demographic	O
parameters	O
,	O
serologic	O
titers	O
and	O
adverse	O
events	O
were	O
compared	O
using	O
the	O
nonparametric	O
Mann	O
–	O
Whitney	O
(	O
unpaired	O
)	O
or	O
Wilcoxan	O
(	O
paired	O
)	O
tests	O
.	O

3	O
Results	O
3.1	O
Demographics	O
A	O
total	O
of	O
175	O
subjects	O
were	O
enrolled	O
and	O
vaccinated	O
during	O
the	O
influenza	O
season	O
beginning	O
in	O
October	O
,	O
1996	O
and	O
ending	O
in	O
January	O
,	O
1997	O
.	O

The	O
distributions	O
of	O
sex	O
,	O
race	O
and	O
age	O
were	O
not	O
significantly	O
different	O
between	O
the	O
placebo	O
and	O
calcitriol	B
groups	O
(	O
Table	O
1	O
)	O
.	O

Most	O
of	O
the	O
subjects	O
were	O
young	O
and	O
white	O
;	O
many	O
were	O
medical	O
students	O
at	O
the	O
University	O
of	O
Utah	O
.	O

3.2	O
Safety	O
analysis	O
None	O
of	O
the	O
calcitriol	B
/	O
vaccine	O
or	O
placebo	O
vaccine	O
recipients	O
experienced	O
laboratory	O
-	O
defined	O
or	O
clinical	O
symptoms	O
of	O
hypercalcemia	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
serum	O
calcium	B
levels	O
between	O
the	O
calcitriol	B
and	O
placebo	O
groups	O
either	O
pretreatment	O
(	O
SCa2	O
+	O
=	O
9.6	O
and	O
9.4	O
mg	O
/	O
dl	O
,	O
respectively	O
)	O
or	O
one	O
day	O
postinjection	O
(	O
SCa2	O
+	O
=	O
9.5	O
and	O
9.4	O
mg	O
/	O
dl	O
,	O
respectively	O
)	O
.	O

Nearly	O
all	O
the	O
subjects	O
experienced	O
some	O
pain	O
at	O
the	O
injection	O
site	O
which	O
declined	O
rapidly	O
over	O
the	O
following	O
few	O
days	O
(	O
Fig.	O
1	O
)	O
.	O

Subjects	O
in	O
the	O
calcitriol+flu	B
vaccine	O
group	O
were	O
more	O
likely	O
to	O
still	O
be	O
experiencing	O
pain	O
at	O
the	O
injection	O
site	O
2	O
and	O
3	O
days	O
postvaccination	O
compared	O
with	O
the	O
placebo+flu	O
vaccine	O
group	O
.	O

Overall	O
,	O
25–50	O
%	O
of	O
the	O
subjects	O
reported	O
some	O
generalized	O
malaise	O
or	O
fatigue	O
on	O
the	O
day	O
of	O
or	O
1–3	O
days	O
after	O
their	O
injections	O
.	O

Those	O
that	O
received	O
calcitriol	B
were	O
more	O
likely	O
to	O
experience	O
malaise	O
and	O
fatigue	O
1–2	O
days	O
after	O
injection	O
(	O
time	O
-	O
course	O
data	O
not	O
shown	O
)	O
,	O
but	O
the	O
overall	O
frequency	O
of	O
these	O
symptoms	O
were	O
not	O
significantly	O
different	O
between	O
the	O
groups	O
.	O

No	O
significant	O
differences	O
in	O
redness	O
or	O
swelling	O
at	O
the	O
injection	O
site	O
were	O
observed	O
between	O
the	O
groups	O
at	O
any	O
time	O
-	O
point	O
.	O

Only	O
a	O
single	O
subject	O
experienced	O
fever	O
postvaccination	O
.	O

3.3	O
Efficacy	O
analysis	O
Among	O
the	O
88	O
subjects	O
enrolled	O
in	O
the	O
placebo	O
group	O
,	O
77	O
(	O
88	O
%	O
)	O
followed	O
through	O
and	O
provided	O
serum	O
for	O
analysis	O
28	O
and	O
90	O
days	O
postvaccination	O
.	O

In	O
the	O
calcitriol	B
group	O
76	O
of	O
87	O
subjects	O
(	O
87	O
%	O
)	O
provided	O
serum	O
for	O
analysis	O
at	O
the	O
subsequent	O
time	O
points	O
.	O

Baseline	O
(	O
day	O
0	O
)	O
influenza	O
HAI	O
titers	O
for	O
all	O
three	O
antigens	B
were	O
similar	O
between	O
the	O
calcitriol	B
and	O
placebo	O
groups	O
(	O
Fig.	O
2	O
)	O
.	O

Including	O
all	O
subjects	O
in	O
both	O
groups	O
,	O
the	O
mean	O
absolute	O
HAI	O
titers	O
prevaccination	O
were	O
H1N1	O
4.3	O
,	O
H3N2	O
2.3	O
and	O
influenza	O
B	O
3.1	O
log2	O
units	O
(	O
Fig.	O
2	O
)	O
.	O

These	O
titers	O
rose	O
significantly	O
to	O
6.2	O
,	O
4.8	O
and	O
4.9	O
log2	O
units	O
,	O
respectively	O
,	O
at	O
28	O
days	O
postvaccination	O
.	O

HAI	O
titers	O
against	O
each	O
antigen	B
decreased	O
slightly	O
between	O
28	O
and	O
90	O
days	O
postvaccination	O
but	O
remained	O
above	O
prevaccination	O
levels	O
.	O

Coinjection	O
of	O
calcitriol	B
with	O
the	O
influenza	O
vaccine	O
failed	O
to	O
significantly	O
increase	O
28	O
day	O
or	O
90	O
day	O
HAI	O
titers	O
against	O
H1N1	B
,	O
H3N2	B
or	O
influenza	B
B	I
antigens	I
.	O

To	O
determine	O
whether	O
preexisting	O
immunity	O
to	O
any	O
of	O
the	O
influenza	B
antigens	I
might	O
influence	O
a	O
calcitriol	B
enhanced	O
response	O
,	O
a	O
censored	O
analysis	O
of	O
the	O
serologic	O
data	O
was	O
performed	O
.	O

Subjects	O
who	O
were	O
relatively	O
naive	O
to	O
influenza	B
antigens	I
,	O
defined	O
as	O
baseline	O
(	O
day	O
0	O
)	O
H1N1	B
,	O
H3N2	B
or	O
influenza	O
B	O
HAI	O
titers	O
≤3	O
log	O
units	O
(	O
1:40	O
or	O
less	O
)	O
were	O
included	O
in	O
this	O
subanalysis	O
.	O

The	O
number	O
of	O
subjects	O
available	O
for	O
these	O
subanalyses	O
were	O
:	O
influenza	O
B	O
,	O
N	O
=	O
49	O
(	O
placebo	O
)	O
,	O
46	O
(	O
calcitriol	B
)	O
;	O
H1N1	O
,	O
N	O
=	O
24	O
,	O
33	O
;	O
H3N2	O
,	O
N	O
=	O
58	O
,	O
58	O
.	O

HAI	O
titers	O
for	O
each	O
of	O
the	O
influenza	B
antigens	I
in	O
these	O
naive	O
subjects	O
were	O
not	O
significantly	O
different	O
at	O
either	O
28	O
or	O
90	O
days	O
postvaccination	O
(	O
data	O
not	O
shown	O
)	O
.	O

Similar	O
nonsignificant	O
results	O
were	O
obtained	O
when	O
responses	O
were	O
analyzed	O
from	O
subjects	O
with	O
baseline	O
HAI	O
titers	O
of	O
≤2	O
log	O
units	O
(	O
1:20	O
or	O
less	O
)	O
.	O

4	O
Discussion	O
This	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
calcitriol	B
coinjected	O
with	O
a	O
commercial	O
influenza	O
vaccine	O
did	O
not	O
confirm	O
the	O
hypothesized	O
immunologic	O
benefit	O
of	O
this	O
compound	O
.	O

Intramuscular	O
calcitriol	B
coinjection	O
did	O
not	O
significantly	O
enhance	O
subsequent	O
serum	O
HAI	O
titers	O
to	O
any	O
of	O
the	O
vaccine	O
antigens	O
compared	O
to	O
a	O
saline	B
placebo	O
.	O

Calcitriol	B
injection	O
was	O
more	O
painful	O
and	O
resulted	O
in	O
more	O
malaise	O
and	O
fatigue	O
than	O
placebo	O
in	O
our	O
subjects	O
.	O

There	O
are	O
several	O
important	O
limitations	O
to	O
the	O
conclusions	O
which	O
may	O
be	O
drawn	O
from	O
this	O
controlled	O
human	O
study	O
.	O

It	O
should	O
be	O
noted	O
that	O
prior	O
exposure	O
and	O
immunity	O
to	O
influenza	O
viruses	O
within	O
the	O
study	O
population	O
,	O
the	O
manner	O
in	O
which	O
calcitriol	B
and	O
the	O
trivalent	O
influenza	O
vaccines	O
were	O
delivered	O
,	O
and	O
the	O
use	O
of	O
systemic	O
HAI	O
titers	O
as	O
the	O
primary	O
endpoint	O
may	O
all	O
have	O
had	O
a	O
masking	O
effect	O
on	O
the	O
immunomodulatory	O
properties	O
of	O
calcitriol	B
.	O

Since	O
HAI	O
titers	O
rather	O
than	O
ELISA	O
are	O
associated	O
with	O
protection	O
from	O
clinical	O
influenza	O
and	O
HAI	O
analysis	O
failed	O
to	O
show	O
a	O
benefit	O
from	O
calcitriol	B
,	O
ELISA	O
was	O
not	O
performed	O
on	O
the	O
serum	O
specimens	O
.	O

The	O
subjects	O
in	O
this	O
study	O
were	O
young	O
(	O
mean	O
age	O
32	O
)	O
and	O
predominantly	O
white	O
.	O

Significant	O
baseline	O
HAI	O
titers	O
against	O
each	O
vaccine	O
antigen	B
were	O
detected	O
in	O
nearly	O
all	O
the	O
subjects	O
(	O
Fig.	O
2	O
)	O
,	O
indicating	O
that	O
the	O
subjects	O
had	O
considerable	O
immunity	O
to	O
influenza	O
before	O
their	O
vaccination	O
.	O

This	O
is	O
understandable	O
in	O
our	O
study	O
population	O
,	O
which	O
included	O
many	O
medical	O
students	O
and	O
members	O
of	O
the	O
hospital	O
staff	O
required	O
to	O
have	O
annual	O
influenza	O
vaccinations	O
.	O

Nevertheless	O
,	O
vaccination	O
of	O
our	O
subjects	O
did	O
result	O
in	O
a	O
4–8-fold	O
(	O
2–3	O
log2	O
units	O
)	O
increase	O
in	O
HAI	O
titers	O
measured	O
one	O
month	O
later	O
.	O

The	O
study	O
was	O
designed	O
to	O
detect	O
a	O
twofold	O
difference	O
(	O
one	O
log2	O
unit	O
)	O
in	O
HAI	O
titers	O
between	O
the	O
treated	O
and	O
control	O
groups	O
postvaccination	O
.	O

It	O
is	O
possible	O
that	O
there	O
was	O
a	O
small	O
positive	O
effect	O
of	O
calcitriol	B
that	O
was	O
undetectable	O
by	O
these	O
methods	O
.	O

However	O
,	O
the	O
nearly	O
identical	O
values	O
of	O
mean	O
HAI	O
titers	O
between	O
the	O
groups	O
at	O
all	O
the	O
timepoints	O
argues	O
against	O
any	O
real	O
effect	O
of	O
calcitriol	B
on	O
humoral	O
immunity	O
in	O
these	O
subjects	O
.	O

Malaise	O
and	O
fatigue	O
were	O
more	O
likely	O
to	O
have	O
been	O
experienced	O
in	O
the	O
calcitriol	B
-	O
injected	O
subjects	O
and	O
were	O
also	O
associated	O
with	O
pain	O
at	O
the	O
injection	O
site	O
2–3	O
days	O
after	O
injection	O
.	O

Malaise	O
,	O
fatigue	O
,	O
redness	O
and	O
swelling	O
were	O
self	O
-	O
reported	O
,	O
necessarily	O
somewhat	O
subjective	O
and	O
probably	O
overreported	O
by	O
the	O
subjects	O
.	O

Since	O
a	O
sham	O
-	O
vaccine	O
group	O
was	O
not	O
included	O
in	O
this	O
trial	O
,	O
it	O
can	O
not	O
be	O
concluded	O
that	O
the	O
vaccine	O
itself	O
caused	O
these	O
subjective	O
symptoms	O
.	O

The	O
increased	O
pain	O
observed	O
in	O
the	O
calcitriol	B
-	O
injected	O
subjects	O
may	O
be	O
related	O
to	O
the	O
relatively	O
large	O
molecular	O
weight	O
of	O
this	O
compound	O
or	O
to	O
its	O
vehicle	O
formulated	O
for	O
intravenous	O
use	O
.	O

The	O
injection	O
of	O
calcitriol	B
next	O
to	O
but	O
1.0	O
cm	O
distant	O
from	O
the	O
site	O
of	O
influenza	O
injection	O
may	O
have	O
limited	O
the	O
in	O
vivo	O
contact	O
of	O
calcitriol	B
with	O
influenza	B
antigens	I
.	O

Adjacent	O
injection	O
rather	O
than	O
direct	O
mixing	O
of	O
the	O
two	O
compounds	O
was	O
necessary	O
to	O
comply	O
with	O
federal	O
regulations	O
and	O
gain	O
FDA	O
approval	O
for	O
the	O
study	O
.	O

It	O
is	O
possible	O
that	O
mixing	O
of	O
calcitriol	B
and	O
influenza	O
vaccine	O
in	O
a	O
single	O
syringe	O
,	O
like	O
in	O
the	O
preliminary	O
animal	O
experiments	O
,	O
might	O
also	O
be	O
effective	O
in	O
humans	O
.	O

Finally	O
,	O
serum	O
rather	O
than	O
mucosal	O
antibody	O
levels	O
were	O
measured	O
in	O
these	O
subjects	O
.	O

Preclinical	O
studies	O
in	O
mice	O
showed	O
that	O
,	O
while	O
serum	O
influenza	O
antibody	O
levels	O
were	O
enhanced	O
by	O
calcitriol	B
,	O
a	O
much	O
more	O
dramatic	O
effect	O
was	O
seen	O
on	O
mucosal	O
antibodies	O
in	O
vaginal	O
fluid	O
[	O
10	O
,	O
11	O
]	O
.	O

Future	O
studies	O
which	O
employ	O
calcitriol	B
as	O
a	O
candidate	O
vaccine	O
immunomodulator	O
should	O
incorporate	O
the	O
measurement	O
of	O
nasal	O
,	O
oral	O
or	O
vaginal	O
mucosal	O
antibodies	O
.	O

In	O
summary	O
,	O
calcitriol	B
had	O
no	O
demonstrable	O
immunologic	O
effects	O
on	O
influenza	O
vaccination	O
at	O
this	O
dose	O
and	O
route	O
in	O
this	O
relatively	O
young	O
healthy	O
population	O
.	O

Side	O
effects	O
,	O
particularly	O
pain	O
at	O
the	O
injection	O
site	O
,	O
were	O
increased	O
by	O
the	O
coadministration	O
of	O
calcitriol	B
with	O
influenza	O
vaccine	O
.	O

Other	O
strategies	O
should	O
be	O
employed	O
to	O
boost	O
the	O
effectiveness	O
and	O
duration	O
of	O
immunity	O
of	O
influenza	O
vaccines	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
Dr.	O
James	O
Kushner	O
and	O
the	O
staff	O
of	O
the	O
University	O
of	O
Utah	O
Clinical	O
Research	O
Center	O
for	O
the	O
use	O
of	O
their	O
facility	O
and	O
expertise	O
in	O
completing	O
this	O
study	O
and	O
Dr.	O
Raymond	O
A.	O
Daynes	O
for	O
reviewing	O
the	O
manuscript	O
.	O

This	O
investigation	O
was	O
supported	O
by	O
research	O
grant	O
number	O
M01-RR00064	O
from	O
the	O
National	O
Center	O
for	O
Research	O
Resources	O
,	O
and	O
by	O
Pharmadigm	O
Biosciences	O
,	O
Inc.	O
,	O
Salt	O
Lake	O
City	O
,	O
UT	O
.	O

In	O
intermediary	O
metabolism	O
,	O
lipoic	B
acid	I
(	O
LA	B
;	O
6,8-thioctic	B
acid	I
)	O
serves	O
as	O
a	O
prosthetic	O
group	O
covalently	O
linked	O
to	O
a	O
lysyl	B
residue	I
of	O
three	O
mitochondrial	O
α	B
-	I
keto	I
acid	I
dehydrogenase	O
complexes	O
;	O
namely	O
,	O
the	O
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	O
)	O
,	O
the	O
α	O
-	O
ketoglutarate	O
dehydrogenase	O
complex	O
,	O
and	O
the	O
branched	O
-	O
chain	O
α	O
-	O
keto	O
acid	O
dehydrogenase	O
complex	O
,	O
and	O
also	O
to	O
H	O
protein	O
of	O
the	O
glycine	O
cleavage	O
system	O
[	O
1,2	O
]	O
.	O

These	O
complexes	O
are	O
involved	O
in	O
the	O
oxidation	O
of	O
carbohydrate	B
and	O
amino	B
acids	I
as	O
well	O
as	O
in	O
cellular	O
oxidative	O
metabolism	O
[	O
1	O
]	O
.	O

Reoxidation	O
of	O
reduced	O
lipoyl	O
moieties	O
of	O
these	O
four	O
complexes	O
is	O
carried	O
out	O
by	O
dihydrolipoamide	O
dehydrogenase	O
(	O
E3	O
)	O
,	O
the	O
common	O
component	O
of	O
the	O
complexes	O
.	O

Additionally	O
,	O
E3	O
recognizes	O
free	O
dihydrolipoamide	B
as	O
a	O
substrate	O
and	O
also	O
catalyzes	O
the	O
reverse	O
reaction	O
using	O
lipoamide	B
and	O
NADH	B
.	O

LA	B
itself	O
is	O
a	O
poor	O
substrate	O
for	O
the	O
reverse	O
reaction	O
of	O
E3	O
[	O
3	O
]	O
.	O

Due	O
to	O
its	O
potent	O
anti	O
-	O
oxidant	O
properties	O
in	O
biological	O
systems	O
,	O
LA	B
has	O
been	O
used	O
as	O
a	O
therapeutic	O
agent	O
against	O
hepatic	O
and	O
neurological	O
disorders	O
.	O

Clinically	O
,	O
decreased	O
levels	O
of	O
endogenous	O
LA	B
were	O
reported	O
in	O
patients	O
with	O
liver	O
cirrhosis	O
,	O
diabetes	O
mellitus	O
,	O
polyneuritis	O
and	O
atherosclerosis	O
[	O
4	O
]	O
.	O

LA	B
has	O
been	O
used	O
in	O
therapeutic	O
treatments	O
for	O
the	O
relief	O
of	O
symptoms	O
of	O
diabetic	O
neuropathy	O
and	O
improvements	O
in	O
overall	O
cellular	O
metabolism	O
,	O
probably	O
via	O
the	O
stimulatory	O
effects	O
on	O
glucose	B
uptake	O
,	O
utlization	O
and	O
disposal	O
in	O
various	O
biological	O
tissues	O
[	O
5–8	O
]	O
.	O

LA	B
is	O
also	O
used	O
as	O
a	O
preventive	O
agent	O
for	O
calcium	B
oxalate	I
stone	O
formation	O
in	O
animals	O
[	O
9,10	O
]	O
.	O

Even	O
though	O
the	O
mechanisms	O
of	O
the	O
actions	O
of	O
LA	B
have	O
not	O
been	O
elucidated	O
,	O
these	O
therapeutic	O
effects	O
might	O
be	O
explained	O
by	O
the	O
free	O
-	O
radical	O
scavenging	O
role	O
of	O
dihydrolipoic	B
acid	I
(	O
DHLA	B
)	O
,	O
formed	O
by	O
intracellular	O
reduction	O
of	O
LA	B
[	O
11	O
]	O
,	O
since	O
exogenous	O
DHLA	B
prevented	O
oxidative	O
damage	O
to	O
membranes	O
,	O
low	O
density	O
lipoproteins	O
,	O
and	O
ischemia	O
reperfusion	O
injury	O
of	O
rat	O
heart	O
and	O
brain	O
[	O
12,13	O
]	O
.	O

Since	O
R	B
-	I
LA	I
is	O
increasingly	O
used	O
as	O
an	O
antioxidant	O
,	O
it	O
is	O
of	O
interest	O
to	O
evaluate	O
its	O
effects	O
on	O
pyruvate	B
metabolism	O
via	O
PDC	O
in	O
the	O
cell	O
.	O

Recently	O
,	O
1,2-diselenolane-3-pentanoic	B
acid	I
(	O
Se	B
-	I
LA	I
,	O
diseleno	B
lipoic	I
acid	I
)	O
,	O
a	O
derivative	O
of	O
LA	B
in	O
which	O
two	O
sulfur	B
atoms	I
are	O
substituted	O
with	O
selenium	B
atoms	I
,	O
was	O
also	O
found	O
to	O
be	O
an	O
effective	O
antioxidant	O
.	O

Although	O
both	O
LA	B
and	O
Se	B
-	I
LA	I
have	O
similar	O
chemical	O
structures	O
except	O
for	O
the	O
larger	O
selenium	B
atoms	I
in	O
the	O
1,2-dithiolane	B
ring	O
of	O
Se	B
-	I
LA	I
,	O
they	O
showed	O
remarkably	O
different	O
anti	O
-	O
oxidant	O
properties	O
against	O
various	O
biological	O
systems	O
[	O
S.	O
Matsugo	O
,	O
L	O
.-	O
J.	O
Yan	O
,	O
H.	O
Ulrich	O
,	O
and	O
L.	O
Packer	O
(	O
unpublished	O
work	O
)	O
]	O
.	O

In	O
that	O
study	O
,	O
Se	B
-	I
LA	I
had	O
no	O
antioxidant	O
effect	O
on	O
protein	O
oxidative	O
modification	O
of	O
human	O
low	O
density	O
lipoprotein	O
,	O
but	O
it	O
showed	O
a	O
protective	O
effect	O
,	O
similar	O
to	O
LA	B
,	O
against	O
the	O
formation	O
of	O
lipid	B
peroxidation	I
products	I
.	O

In	O
earlier	O
works	O
,	O
both	B
enantiomers	I
of	I
lipoic	I
acid	I
(	O
R-	O
and	O
S-	B
forms	I
)	B
and	O
lipoic	B
acid	I
homologues	B
(	O
RS-1,2-dithiolane-3-caproic	B
acid	I
,	O
RS	B
-	I
bisnorlipoic	I
acid	I
and	O
RS	B
-	I
tetranorlipoic	I
acid	I
)	O
were	O
studied	O
for	O
the	O
substrate	O
selectivity	O
for	O
E3	O
[	O
14–17	O
]	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
LA	B
enantiomers	B
and	O
their	O
analogs	B
on	O
the	O
activities	O
of	O
PDC	O
and	O
its	O
catalytic	O
components	O
from	O
different	O
sources	O
have	O
been	O
investigated	O
with	O
variable	O
findings	O
[	O
17	O
]	O
,	O
and	O
the	O
possible	O
effects	O
of	O
Se	B
-	I
LA	I
on	O
PDC	O
have	O
not	O
been	O
reported	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
effects	O
of	O
Se	B
-	I
LA	I
,	O
and	O
both	O
the	O
R-	B
and	O
S-	B
forms	O
of	O
LA	B
,	O
on	O
the	O
reactions	O
catalyzed	O
by	O
mammalian	O
PDC	O
and	O
its	O
individual	O
catalytic	O
components	O
as	O
well	O
as	O
their	O
effects	O
on	O
pyruvate	B
oxidation	O
by	O
intact	O
HepG2	O
cells	O
.	O

Materials	O
and	O
methods	O
Materials	O
Porcine	O
heart	O
PDC	O
and	O
DL	B
-	I
lipoamide	I
were	O
purchased	O
from	O
Sigma	O
Chemical	O
Company	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
.	O

R	B
-	I
LA	I
,	O
S	B
-	I
LA	I
,	O
and	O
Se	B
-	I
LA	I
were	O
kindly	O
provided	O
by	O
ASTA	O
Medica	O
AG	O
,	O
Frankfurt	O
,	O
Germany	O
.	O

DL	B
-	I
Dihydrolipoamide	I
was	O
chemically	O
produced	O
by	O
the	O
reduction	O
of	O
DL	B
-	I
lipoamide	I
with	O
NaBH4	B
[	O
18	O
]	O
.	O

[	B
1	I
-	I
14	I
C	I
]	I
Acetyl	I
-	I
CoA	I
and	O
[	B
1	I
-	I
14	I
C	I
]	I
pyruvate	I
were	O
from	O
ICN	O
Pharmaceutical	O
Inc.	O
(	O
Costa	O
Mesa	O
,	O
CA	O
)	O
.	O

Other	O
chemicals	O
were	O
commercial	O
grade	O
.	O

Activity	O
measurements	O
of	O
PDC	O
and	O
its	O
catalytic	O
components	O
For	O
the	O
preparation	O
of	O
lipoic	B
acid	I
stock	O
solutions	O
,	O
R	B
-	I
LA	I
,	O
S	B
-	I
LA	I
,	O
and	O
Se	B
-	I
LA	I
were	O
dissolved	O
to	O
their	O
desired	O
concentrations	O
(	O
up	O
to	O
200	O
mM	O
)	O
in	O
95	O
%	O
(	O
v	O
/	O
v	O
)	O
ethanol	B
,	O
daily	O
.	O

Experimental	O
assays	O
contained	O
5–40	O
μl	O
of	O
these	O
lipoic	B
compounds	I
,	O
while	O
control	O
assays	O
contained	O
the	O
same	O
volume	O
of	O
95	O
%	O
(	O
v	O
/	O
v	O
)	O
ethanol	B
.	O

For	O
all	O
enzymes	O
in	O
this	O
study	O
,	O
one	O
unit	O
of	O
enzyme	O
activity	O
is	O
defined	O
as	O
the	O
formation	O
of	O
one	O
μmole	O
of	O
product	O
or	O
utilization	O
of	O
1	O
μmole	O
of	O
substrate	O
per	O
min	O
at	O
37	O
°	O
.	O

Porcine	O
heart	O
PDC	O
activity	O
was	O
assayed	O
by	O
measuring	O
the	O
14	B
CO2	I
produced	O
from	O
[	B
1	I
-	I
14	I
C	I
]	I
pyruvate	I
as	O
described	O
previously	O
[	O
19	O
]	O
.	O

The	O
reaction	O
was	O
carried	O
out	O
in	O
the	O
presence	O
of	O
0.5	O
mM	O
[	B
1	I
-	I
14	I
C	I
]	I
pyruvate	I
(	O
200	O
cpm	O
/	O
nmole	O
)	O
,	O
0.2	O
mM	O
thiamine	B
pyrophosphate	I
,	O
0.15	O
mM	O
coenzyme	B
A	I
and	O
2	O
mM	O
NAD+	B
with	O
or	O
without	O
lipoic	B
compounds	I
(	O
0.25–	O
4	O
mM	O
)	O
.	O

The	O
reaction	O
was	O
initiated	O
by	O
adding	O
3.7	O
μg	O
of	O
porcine	O
heart	O
PDC	O
,	O
and	O
stopped	O
with	O
0.1	O
ml	O
of	O
20	O
%	O
(	O
W	O
/	O
V	O
)	O
trichloroacetic	B
acid	I
containing	O
30	O
mM	O
pyruvate	B
after	O
a	O
4	O
min	O
reaction	O
at	O
37	O
°	O
.	O

Released	O
14	B
CO2	I
was	O
absorbed	O
in	O
0.2	O
ml	O
of	O
benzothonium	B
hydroxide	I
(	O
Sigma	O
Chemical	O
Company	O
,	O
St.	O
Louis	O
,	O
MO	O
)	O
for	O
1	O
h	O
,	O
and	O
the	O
radioactivity	O
was	O
measured	O
in	O
a	O
Beckman	O
LS6500	O
scintillation	O
counter	O
.	O

As	O
a	O
blank	O
,	O
radioactivity	O
from	O
control	O
assays	O
which	O
contained	O
buffer	O
in	O
place	O
of	O
enzyme	O
was	O
subtracted	O
from	O
other	O
assays	O
.	O

Recombinant	O
human	O
pyruvate	O
dehydrogenase	O
(	O
E1	O
)	O
was	O
overexpressed	O
and	O
purified	O
according	O
to	O
Korotchkina	O
et	O
al.	O
[	O
20	O
]	O
.	O

The	O
activity	O
of	O
E1	O
was	O
measured	O
using	O
the	O
artificial	O
electron	O
acceptor	O
,	O
2,6-dichlorophenol	B
-	I
indophenol	I
(	O
Sigma	O
Chemical	O
Company	O
,	O
St.	O
Louis	O
,	O
MO	O
)	O
,	O
in	O
the	O
presence	O
of	O
0–4	O
mM	O
lipoic	B
compounds	I
with	O
either	O
0.1	O
or	O
5	O
mM	O
pyruvate	B
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
[	O
21	O
]	O
.	O

The	O
change	O
in	O
absorbance	O
at	O
600	O
nm	O
per	O
minute	O
was	O
measured	O
by	O
a	O
SHIMADZU	O
UV160U	O
spectrophotometer	O
and	O
the	O
μmoles	O
of	O
reduced	B
2,6-dichlorophenol	I
-	I
indo	I
-	I
phenol	I
were	O
calculated	O
using	O
the	O
extinction	O
coefficeint	O
of	O
15,600	O
M−1	O
cm−1	O
.	O

The	O
activity	O
of	O
dihydrolipoamide	O
acetyltransferase	O
(	O
E2	O
)	O
was	O
measured	O
in	O
the	O
reverse	O
direction	O
[	O
22	O
]	O
.	O

The	O
reaction	O
mixture	O
(	O
1	O
ml	O
)	O
contained	O
43.5	O
mM	O
MOPS	B
,	O
pH	O
7.4	O
,	O
0.9	O
mM	O
dithiothreitol	B
,	O
0.13	O
mM	O
NADH	B
,	O
13.9	O
mM	O
DL	B
-	I
dihydrolipoamide	I
,	O
0	O
to	O
4	O
mM	O
lipoic	B
compounds	I
,	O
and	O
about	O
320	O
ng	O
of	O
porcine	O
heart	O
PDC	O
.	O

After	O
preincubation	O
for	O
3	O
min	O
at	O
37	O
°	O
,	O
the	O
reaction	O
was	O
started	O
by	O
the	O
addition	O
of	O
[	B
1	I
-	I
14	I
C	I
]	I
acetyl	I
-	I
CoA	I
(	O
final	O
concentration	O
0.36	O
mM	O
,	O
43,200	O
cpm	O
)	O
,	O
and	O
incubated	O
for	O
up	O
to	O
4.5	O
min	O
.	O

The	O
radioactive	O
product	O
was	O
extracted	O
with	O
benzene	B
,	O
and	O
was	O
counted	O
in	O
a	O
Beckman	O
LS6500	O
scintillation	O
counter	O
.	O

Radioactivity	O
from	O
control	O
samples	O
without	O
added	O
enzyme	O
was	O
subtracted	O
as	O
blank	O
.	O

Recombinant	O
human	O
E3	O
was	O
overexpressed	O
by	O
Escherichia	O
coli	O
XL-1	O
Blue	O
cells	O
with	O
pPROEX-1	O
expression	O
vector	O
(	O
Life	O
Technologies	O
,	O
Inc.	O
;	O
Gaithersburg	O
,	O
MD	O
)	O
containing	O
cloned	O
human	O
E3	O
cDNA	O
(	O
coding	O
region	O
for	O
mature	O
E3	O
protein	O
)	O
[	O
Y.	O
S.	O
Hong	O
and	O
M.	O
S.	O
Patel	O
(	O
unpublished	O
work	O
)	O
]	O
.	O

E3	O
activities	O
in	O
the	O
forward	O
and	O
reverse	O
directions	O
were	O
measured	O
as	O
described	O
[	O
3	O
]	O
.	O

For	O
the	O
forward	O
reaction	O
,	O
the	O
1	O
ml	O
reaction	O
mixture	O
contained	O
100	O
mM	O
potassium	B
phosphate	I
buffer	I
,	O
pH	O
8.0	O
,	O
3	O
mM	O
DL	B
-	I
dihydrolipoamide	I
,	O
3	O
mM	O
NAD+	B
,	O
and	O
1.5	O
mM	O
EDTA	B
.	O

The	O
reverse	O
reaction	O
contained	O
100	O
mM	O
potassium	B
phosphate	I
buffer	I
,	O
pH	O
6.3	O
,	O
3	O
mM	O
lipoamide	B
(	O
or	O
varying	O
levels	O
of	O
other	O
lipoic	B
compounds	I
)	O
,	O
0.2	O
mM	O
NAD+	B
and	O
0.2	O
mM	O
NADH	B
.	O

NAD+	B
was	O
needed	O
to	O
eliminate	O
the	O
initial	O
lag	O
period	O
in	O
the	O
reaction	O
[	O
3	O
]	O
.	O

The	O
reaction	O
was	O
initiated	O
by	O
the	O
addition	O
of	O
E3	O
.	O

The	O
rates	O
of	O
NADH	B
production	O
(	O
forward	O
)	O
or	O
consumption	O
(	O
reverse	O
)	O
per	O
min	O
were	O
measured	O
at	O
340	O
nm	O
.	O

Km	O
s	O
and	O
Vmax	O
s	O
were	O
obtained	O
from	O
double	O
reciprocal	O
plots	O
of	O
each	O
E3	O
reverse	O
reaction	O
obtained	O
by	O
varying	O
concentrations	O
of	O
lipoic	B
compounds	I
(	O
R	B
-	I
LA	I
,	O
0.07–0.3	O
mM	O
;	O
S	B
-	I
LA	I
,	O
0.5–4	O
mM	O
;	O
Se	B
-	I
LA	I
,	O
0.18–0.625	O
mM	O
;	O
DL	B
-	I
dihydrolipoamide	I
,	O
0.48	O
-	O
1.8	O
mM	O
)	O
as	O
substrates	O
.	O

k	O
cat	O
,	O
the	O
number	O
of	O
product	O
molecules	O
per	O
active	O
site	O
of	O
the	O
enzyme	O
per	O
sec	O
,	O
was	O
calculated	O
based	O
on	O
Vmax	O
and	O
2	O
active	O
sites	O
per	O
E3	O
dimer	O
.	O

Pyruvate	B
decarboxylation	O
was	O
carried	O
out	O
using	O
[	B
1	I
-	I
14	I
C	I
]	I
pyruvate	I
with	O
cultured	O
HepG2	O
cells	O
(	O
American	O
Type	O
Culture	O
Collection	O
;	O
Rockville	O
,	O
MD	O
)	O
.	O

HepG2	O
cells	O
were	O
cultured	O
in	O
minimum	O
essential	O
medium	O
(	O
MEM	O
)	O
containing	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
fetal	O
calf	O
serum	O
[	O
24	O
]	O
.	O

Confluent	O
HepG2	O
cells	O
were	O
harvested	O
by	O
trypsinization	O
and	O
separated	O
by	O
centrifugation	O
,	O
and	O
washed	O
with	O
MEM	O
containing	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
fetal	O
calf	O
serum	O
.	O

To	O
convert	O
inactive	O
phosphorylated	O
PDC	O
into	O
the	O
active	O
dephosphorylated	O
form	O
,	O
cells	O
were	O
suspended	O
in	O
MEM	O
with	O
serum	O
containing	O
5	O
mM	O
dichloroacetic	B
acid	I
and	O
incubated	O
at	O
37	O
°	O
for	O
15	O
min	O
.	O

After	O
being	O
collected	O
by	O
centrifugation	O
,	O
cells	O
were	O
washed	O
twice	O
with	O
phosphate	B
buffered	I
saline	I
containing	O
5	O
mM	O
dichloroacetic	B
acid	I
(	O
inhibitor	O
of	O
E1	O
kinases	O
)	O
.	O

Final	O
cell	O
suspensions	O
were	O
made	O
in	O
2.5	O
ml	O
of	O
phosphate	O
buffered	O
saline	O
containing	O
5	O
mM	O
dichloroacetic	B
acid	I
and	O
kept	O
on	O
ice	O
until	O
used	O
.	O

The	O
reaction	O
mixture	O
(	O
100	O
μl	O
)	O
contained	O
94	O
μl	O
(	O
5–10	O
mg	O
/	O
ml	O
total	O
protein	O
)	O
of	O
HepG2	O
cell	O
suspensions	O
,	O
5	O
μl	O
of	O
lipoic	B
compounds	I
(	O
final	O
1–4	O
mM	O
range	O
where	O
indicated	O
)	O
,	O
and	O
1	O
μl	O
of	O
50	O
mM	O
[	B
1	I
-	I
14	I
C	I
]	I
pyruvate	I
(	O
200	O
cpm	O
/	O
nmole	O
)	O
.	O

Cells	O
were	O
incubated	O
at	O
37	O
°	O
for	O
5	O
min	O
in	O
a	O
sealed	O
test	O
tube	O
,	O
and	O
the	O
pyruvate	B
decarboxylation	O
reaction	O
was	O
terminated	O
by	O
injecting	O
0.1	O
ml	O
of	O
20	O
%	O
(	O
w	O
/	O
v	O
)	O
trichloroacetic	B
acid	I
with	O
30	O
mM	O
pyruvate	B
to	O
the	O
reaction	O
mixture	O
.	O

To	O
trap	O
the	O
liberated	O
14	B
CO2	I
,	O
0.2	O
ml	O
of	O
benzothonium	B
hydroxide	I
was	O
injected	O
into	O
a	O
hanging	O
plastic	O
cup	O
in	O
a	O
sealed	O
tube	O
with	O
a	O
rubber	O
stopper	O
,	O
and	O
the	O
evolved	O
14	B
CO2	I
was	O
absorbed	O
for	O
1	O
h	O
and	O
the	O
radioactivity	O
was	O
measured	O
in	O
a	O
Beckman	O
LS6500	O
scintillation	O
counter	O
.	O

Radioactivity	O
from	O
the	O
blank	O
(	O
without	O
cells	O
and	O
lipoic	B
compound	I
)	O
was	O
subtracted	O
from	O
total	O
counts	O
.	O

Pyruvate	B
metabolism	O
via	O
pyruvate	O
carboxylase	O
and	O
subsequent	O
oxidation	O
in	O
the	O
tricarboxylic	B
acid	I
cycle	O
was	O
measured	O
using	O
the	O
protocol	O
described	O
for	O
pyruvate	B
decarboxylation	O
except	O
HepG2	O
cells	O
were	O
treated	O
with	O
1	O
mM	O
n	B
-	I
octanoic	I
acid	I
instead	O
of	O
dichloroacetic	B
acid	I
in	O
both	O
preincubation	O
and	O
incubation	O
of	O
the	O
cells	O
.	O

The	O
oxidation	O
of	O
n	B
-	I
octanoic	I
acid	I
is	O
shown	O
to	O
stimulate	O
E1	O
kinase	O
activity	O
,	O
resulting	O
in	O
the	O
phosphorylation	O
(	O
and	O
hence	O
inactivation	O
)	O
of	O
PDC	O
[	O
25	O
]	O
.	O

Results	O
In	O
a	O
previous	O
study	O
,	O
two	O
enantiomers	B
of	I
LA	I
(	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
)	O
were	O
found	O
to	O
have	O
different	O
effects	O
on	O
the	O
overall	O
activity	O
of	O
PDC	O
from	O
mammalian	O
and	O
prokaryotic	O
sources	O
[	O
17	O
]	O
.	O

We	O
,	O
therefore	O
,	O
reinvestigated	O
the	O
effect	O
of	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
and	O
also	O
investigated	O
the	O
effect	O
of	O
Se	B
-	I
LA	I
on	O
this	O
complex	O
.	O

Overall	O
activity	O
of	O
porcine	O
heart	O
PDC	O
was	O
markedly	O
inhibited	O
by	O
both	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
,	O
showing	O
at	O
least	O
80	O
%	O
inhibition	O
by	O
1	O
mM	O
or	O
higher	O
concentrations	O
of	O
LA	B
(	O
Fig.	O
1	O
)	O
.	O

In	O
comparison	O
,	O
Se	B
-	I
LA	I
-	O
mediated	O
PDC	O
inhibition	O
was	O
weaker	O
,	O
requiring	O
a	O
much	O
higher	O
concentration	O
of	O
Se	B
-	I
LA	I
(	O
4	O
mM	O
)	O
to	O
achieve	O
about	O
65	O
%	O
inhibition	O
(	O
Fig.	O
1	O
)	O
.	O

Since	O
LA	B
-	O
mediated	O
inhibition	O
of	O
overall	O
PDC	O
activity	O
could	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
one	O
or	O
more	O
catalytic	O
components	O
of	O
the	O
complex	O
,	O
the	O
effects	O
of	O
lipoic	B
compounds	I
were	O
tested	O
on	O
the	O
three	O
catalytic	O
components	O
of	O
mammalian	O
PDC	O
.	O

In	O
the	O
forward	O
reaction	O
,	O
the	O
E3	O
component	O
of	O
the	O
complex	O
reoxidizes	O
exogenous	O
DL	B
-	I
dihydrolipoamide	I
as	O
a	O
substrate	O
[	O
3	O
]	O
.	O

The	O
effects	O
of	O
lipoic	B
compounds	I
on	O
the	O
forward	O
reaction	O
of	O
recombinant	O
human	O
E3	O
were	O
examined	O
.	O

Up	O
to	O
1	O
mM	O
,	O
Se	B
-	I
LA	I
was	O
more	O
effective	O
as	O
an	O
effector	O
(	O
approximately	O
25	O
%	O
reduction	O
)	O
than	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
(	O
Fig.	O
2	O
)	O
.	O

However	O
,	O
at	O
higher	O
concentrations	O
,	O
these	O
three	O
compounds	O
affected	O
E3	O
activity	O
similarly	O
,	O
lowering	O
about	O
30–45	O
%	O
at	O
a	O
concentration	O
of	O
4	O
mM	O
(	O
Fig.	O
2	O
)	O
.	O

This	O
low	O
level	O
of	O
E3	O
activity	O
by	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
did	O
not	O
account	O
for	O
the	O
observed	O
high	O
level	O
of	O
inhibition	O
seen	O
on	O
the	O
overall	O
activity	O
of	O
PDC	O
at	O
lower	O
concentrations	O
of	O
these	O
two	O
compounds	O
(	O
Fig.	O
1	O
)	O
.	O

Also	O
,	O
the	O
low	O
level	O
of	O
apparent	O
inhibition	O
implied	O
that	O
NADH	B
,	O
the	O
product	O
of	O
the	O
forward	O
reaction	O
,	O
was	O
probably	O
used	O
as	O
a	O
substrate	O
for	O
the	O
reverse	O
reaction	O
of	O
E3	O
in	O
the	O
presence	O
of	O
added	O
oxidized	B
lipoic	I
compounds	I
.	O

Therefore	O
,	O
the	O
activity	O
of	O
E3	O
in	O
the	O
reverse	O
direction	O
with	O
R	B
-	I
LA	I
,	O
S	B
-	I
LA	I
,	O
Se	B
-	I
LA	I
,	O
and	O
DL	B
-	I
lipoamide	I
as	O
a	O
substrate	O
was	O
determined	O
,	O
and	O
the	O
results	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

E3	O
had	O
a	O
significantly	O
higher	O
affinity	O
for	O
R	B
-	I
LA	I
,	O
the	O
natural	O
enantiomer	O
,	O
than	O
S	B
-	I
LA	I
,	O
but	O
k	O
cat	O
was	O
not	O
significantly	O
different	O
for	O
these	O
two	O
compounds	O
.	O

Km	O
for	O
Se	B
-	I
LA	I
was	O
similar	O
to	O
that	O
of	O
R	B
-	I
LA	I
and	O
the	O
calculated	O
k	O
cat	O
value	O
for	O
Se	B
-	I
LA	I
was	O
comparable	O
to	O
that	O
of	O
R	B
-	I
LA	I
or	O
S	B
-	I
LA	I
.	O

In	O
contrast	O
,	O
DL	B
-	I
lipoamide	I
was	O
the	O
preferred	O
substrate	O
for	O
the	O
reverse	O
reaction	O
of	O
E3	O
(	O
Table	O
1	O
)	O
.	O

The	O
catalytic	O
efficiency	O
(	O
k	O
cat	O
/Km	O
)	O
was	O
highest	O
with	O
DL	B
-	I
lipoamide	I
and	O
lowest	O
with	O
S	B
-	I
LA	I
.	O

These	O
findings	O
suggested	O
that	O
these	O
lipoic	B
compounds	I
could	O
account	O
for	O
a	O
partial	O
reoxidation	O
of	O
NADH	B
at	O
higher	O
concentrations	O
but	O
failed	O
to	O
support	O
a	O
high	O
degree	O
of	O
PDC	O
inhibition	O
observed	O
at	O
lower	O
concentrations	O
of	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
(	O
Fig.	O
1	O
)	O
.	O

E1	O
is	O
the	O
rate	O
-	O
limiting	O
component	O
of	O
the	O
complex	O
[	O
26	O
]	O
.	O

Using	O
a	O
dye	O
assay	O
,	O
E1	O
activity	O
was	O
determined	O
over	O
a	O
range	O
of	O
pyruvate	B
concentrations	O
(	O
0–5	O
mM	O
)	O
with	O
a	O
fixed	O
concentration	O
(	O
4	O
mM	O
)	O
of	O
lipoic	B
compounds	I
.	O

R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
had	O
no	O
significant	O
effect	O
on	O
E1	O
activity	O
over	O
a	O
wide	O
range	O
of	O
substrate	O
concentrations	O
(	O
Fig.	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
4	O
mM	O
Se	B
-	I
LA	I
inhibited	O
E1	O
activity	O
by	O
about	O
70	O
%	O
at	O
0.1	O
and	O
5	O
mM	O
pyruvate	B
.	O

When	O
the	O
effect	O
of	O
varying	O
concentrations	O
of	O
lipoic	B
compounds	I
were	O
investigated	O
on	O
E1	O
activity	O
at	O
two	O
different	O
pyruvate	B
concentrations	O
(	O
0.1	O
and	O
5	O
mM	O
)	O
,	O
only	O
a	O
significant	O
inhibitory	O
effect	O
by	O
Se	B
-	I
LA	I
on	O
E1	O
activity	O
was	O
noted	O
(	O
Fig.	O
3B	O
)	O
,	O
consistent	O
with	O
the	O
results	O
seen	O
in	O
Fig.	O
3A	O
.	O

To	O
examine	O
the	O
effect	O
of	O
lipoic	B
compounds	I
on	O
E2	O
activity	O
,	O
the	O
activity	O
of	O
porcine	O
heart	O
E2	O
was	O
measured	O
in	O
the	O
reverse	O
direction	O
using	O
[	B
1	I
-	I
14	I
C	I
]	I
acetyl	I
-	I
CoA	I
and	O
dihydrolipoamide	B
as	O
substrates	O
.	O

Both	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
displayed	O
similar	O
concentration	O
-	O
dependent	O
inhibitory	O
effects	O
on	O
the	O
E2	O
activity	O
(	O
Fig.	O
4	O
)	O
.	O

At	O
0.5	O
mM	O
and	O
4.0	O
mM	O
R	B
-	I
LA	I
or	O
S	B
-	I
LA	I
,	O
the	O
E2	O
activity	O
was	O
inhibited	O
by	O
approximately	O
45	O
%	O
and	O
80	O
%	O
,	O
respectively	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
a	O
separate	O
experiment	O
in	O
which	O
DL	B
-	I
dihydrolipoamide	I
was	O
omitted	O
from	O
the	O
incubation	O
medium	O
,	O
the	O
acetylation	O
of	O
each	O
lipoic	B
compound	I
added	O
accounted	O
less	O
than	O
10	O
%	O
of	O
the	O
radioactivity	O
extracted	O
in	O
benzene	B
layer	O
compared	O
to	O
that	O
of	O
control	O
with	O
DL	B
-	I
dihydrolipoamide	I
.	O

A	O
significant	O
inhibition	O
of	O
E2	O
activity	O
by	O
R	B
-	I
LA	I
or	O
S	B
-	I
LA	I
at	O
or	O
below	O
0.5	O
mM	O
could	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
observed	O
inhibition	O
of	O
PDC	O
activity	O
by	O
R	B
-	I
LA	I
or	O
S	B
-	I
LA	I
(	O
Fig.	O
1	O
)	O
.	O

At	O
2	O
mM	O
,	O
Se	B
-	I
LA	I
had	O
no	O
significant	O
inhibitory	O
effect	O
on	O
E2	O
activity	O
,	O
and	O
only	O
at	O
higher	O
concentrations	O
(	O
3	O
-	O
4	O
mM	O
)	O
it	O
inhibited	O
(	O
about	O
25	O
%	O
)	O
E2	O
activity	O
(	O
Fig.	O
4	O
)	O
.	O

The	O
findings	O
of	O
the	O
previous	O
studies	O
and	O
the	O
present	O
study	O
show	O
the	O
inhibitory	O
effects	O
of	O
the	O
lipoic	B
compounds	I
on	O
the	O
activities	O
of	O
PDC	O
and	O
its	O
catalytic	O
components	O
.	O

In	O
light	O
of	O
the	O
inhibitory	O
effects	O
of	O
lipoic	B
compounds	I
on	O
purified	O
PDC	O
components	O
,	O
it	O
was	O
of	O
interest	O
to	O
examine	O
the	O
possible	O
effects	O
of	O
these	O
compounds	O
on	O
pyruvate	B
decarboxylation	O
via	O
PDC	O
by	O
intact	O
cells	O
.	O

The	O
inhibition	O
of	O
pyruvate	B
oxidation	O
in	O
intact	O
cells	O
by	O
LA	B
compounds	O
could	O
impair	O
carbohydrate	B
metabolism	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
formation	O
of	O
14	B
CO2	I
from	O
[	B
1	I
-	I
14	I
C	I
]	I
pyruvate	I
in	O
the	O
intact	O
cells	O
occurs	O
via	O
the	O
action	O
of	O
PDC	O
as	O
well	O
as	O
the	O
formation	O
of	O
oxaloacetate	B
by	O
pyruvate	O
carboxylase	O
and	O
the	O
subsequent	O
metabolism	O
of	O
oxaloacetate	B
via	O
the	O
tricarboxylic	B
acid	I
cycle	O
.	O

The	O
results	O
presented	O
for	O
control	O
cells	O
without	O
the	O
addition	O
of	O
any	O
lipoic	B
compounds	I
(	O
Fig.	O
5A	O
,	O
B	O
)	O
show	O
that	O
the	O
formation	O
of	O
14	B
CO2	I
from	O
[	B
1	I
-	I
14	I
C	I
]	I
pyruvate	I
via	O
PDC	O
accounted	O
for	O
the	O
majority	O
(	O
99	O
%	O
)	O
of	O
pyruvate	B
oxidation	O
(	O
Fig.	O
5A	O
)	O
,	O
and	O
the	O
14	B
CO2	I
production	O
from	O
the	O
metabolism	O
of	O
pyruvate	B
via	O
pyruvate	O
carboxylase	O
and	O
the	O
tricarboxylic	B
acid	I
cylce	O
was	O
negligible	O
under	O
our	O
experimental	O
conditions	O
(	O
Fig.	O
5B	O
)	O
.	O

Pyruvate	B
decarboxylation	O
by	O
cultured	O
HepG2	O
cells	O
was	O
not	O
affected	O
in	O
the	O
presence	O
of	O
1–4	O
mM	O
R	B
-	I
LA	I
in	O
the	O
incubation	O
medium	O
compared	O
to	O
that	O
of	O
control	O
(	O
Fig.	O
5A	O
)	O
.	O

However	O
,	O
approximately	O
25–30	O
%	O
decrease	O
in	O
pyruvate	B
decarboxylation	O
was	O
seen	O
in	O
cells	O
treated	O
with	O
either	O
4	O
mM	O
S	B
-	I
LA	I
or	O
DL	B
-	I
dihydrolipoamide	I
and	O
about	O
75	O
%	O
reduction	O
in	O
pyruvate	B
decarboxylation	O
was	O
observed	O
with	O
cells	O
treated	O
with	O
4	O
mM	O
Se	B
-	I
LA	I
(	O
Fig.	O
5A	O
)	O
.	O

Discussion	O
The	O
results	O
presented	O
in	O
this	O
paper	O
for	O
the	O
inhibitory	O
effects	O
of	O
both	O
R-	B
and	O
S	B
-	I
enantiomers	O
of	O
lipoic	B
acid	I
on	O
the	O
overall	O
reaction	O
of	O
PDC	O
from	O
porcine	O
heart	O
support	O
and	O
extend	O
the	O
inhibitory	O
effects	O
of	O
these	O
two	O
compounds	O
on	O
PDC	O
from	O
bovine	O
heart	O
[	O
17	O
]	O
.	O

The	O
degree	O
of	O
inhibition	O
,	O
however	O
,	O
was	O
more	O
pronounced	O
in	O
the	O
present	O
study	O
.	O

For	O
example	O
,	O
1	O
mM	O
of	O
either	O
R	B
-	I
LA	I
or	O
S	B
-	I
LA	I
inhibited	O
pig	O
heart	O
PDC	O
by	O
about	O
80	O
%	O
(	O
Fig.	O
1	O
)	O
as	O
compared	O
to	O
the	O
reported	O
25	O
%	O
and	O
41	O
%	O
inhibition	O
of	O
bovine	O
heart	O
PDC	O
by	O
1	O
mM	O
of	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
,	O
respectively	O
[	O
17	O
]	O
.	O

Loffelhardt	O
et	O
al.	O
[	O
17	O
]	O
also	O
observed	O
that	O
at	O
low	O
concentrations	O
(	O
less	O
than	O
1	O
mM	O
)	O
of	O
both	B
enantiomers	I
of	I
LA	I
,	O
the	O
overall	O
reaction	O
of	O
the	O
PDC	O
from	O
rat	O
kidney	O
was	O
activated	O
.	O

These	O
investigators	O
observed	O
even	O
greater	O
stimulatory	O
effects	O
of	O
these	O
two	O
compounds	O
on	O
the	O
PDC	O
activity	O
from	O
E.	O
coli	O
[	O
17	O
]	O
.	O

These	O
species-	O
and	O
tissue	O
-	O
specific	O
effects	O
of	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
on	O
the	O
PDC	O
activity	O
are	O
difficult	O
to	O
rationalize	O
at	O
the	O
present	O
time	O
and	O
may	O
require	O
a	O
systematic	O
study	O
of	O
highly	O
purified	O
enzyme	O
complexes	O
from	O
different	O
species	O
.	O

There	O
,	O
however	O
,	O
are	O
several	O
important	O
differences	O
in	O
the	O
experimental	O
approaches	O
used	O
between	O
the	O
study	O
reported	O
by	O
Loffelhardt	O
et	O
al.	O
[	O
17	O
]	O
and	O
the	O
present	O
study	O
.	O

First	O
,	O
Loffelhardt	O
et	O
al.	O
studied	O
PDC	O
preparations	O
from	O
several	O
sources	O
at	O
different	O
stages	O
of	O
purification	O
[	O
17	O
]	O
,	O
whereas	O
we	O
have	O
used	O
highly	O
purified	O
porcine	O
heart	O
PDC	O
and	O
overexpressed	O
PDC	O
components	O
in	O
the	O
present	O
study	O
.	O

Second	O
,	O
Loffelhardt	O
et	O
al.	O
[	O
17	O
]	O
examined	O
the	O
effects	O
of	O
LA	B
and	O
its	O
analogs	O
on	O
the	O
E1	O
and	O
E3	O
components	O
of	O
PDC	O
only	O
and	O
did	O
not	O
investigate	O
the	O
effect	O
of	O
lipoic	B
acid	I
enantiomers	B
on	O
the	O
E2	O
component	O
of	O
PDC	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
observed	O
that	O
both	O
R	O
-	O
LA	O
and	O
S	O
-	O
LA	O
at	O
1	O
mM	O
concentration	O
exerted	O
higher	O
inhibitory	O
effect	O
on	O
PDC	O
-	O
E2	O
than	O
on	O
either	O
PDC	O
-	O
E1	O
or	O
E3	O
(	O
compare	O
Fig.	O
4	O
vs	O
Figs.	O
2	O
or	O
3	O
)	O
.	O

Third	O
,	O
there	O
are	O
differences	O
in	O
kinetic	O
parameters	O
for	O
mammalian	O
E3	O
catalyzing	O
the	O
reverse	O
reaction	O
(	O
oxidation	O
of	O
NADH	B
)	O
between	O
the	O
study	O
of	O
Loffelhardt	O
et	O
al.	O
[	O
17	O
]	O
and	O
the	O
present	O
study	O
.	O

In	O
the	O
former	O
study	O
the	O
Km	O
of	O
S	B
-	I
LA	I
was	O
only	O
slightly	O
higher	O
than	O
that	O
of	O
R	B
-	I
LA	I
(	O
5.5	O
mM	O
vs	O
3.7	O
mM	O
)	O
whereas	O
in	O
the	O
present	O
study	O
this	O
difference	O
was	O
about	O
17-fold	O
(	O
K	O
m	O
values	O
of	O
9.10	O
mM	O
and	O
0.53	O
mM	O
for	O
S	B
-	I
LA	I
and	O
R	B
-	I
LA	I
,	O
respectively	O
;	O
Table	O
1	O
)	O
.	O

Similarly	O
,	O
the	O
catalytic	O
efficiency	O
(	O
k	O
cat	O
/K	O
m	O
)	O
of	O
R	B
-	I
LA	I
was	O
higher	O
compared	O
to	O
S	B
-	I
LA	I
by	O
a	O
factor	O
of	O
36	O
in	O
previously	O
reported	O
study	O
[	O
17	O
]	O
whereas	O
this	O
factor	O
was	O
153	O
in	O
the	O
present	O
study	O
.	O

Fourth	O
,	O
E3	O
from	O
human	O
renal	O
carcinoma	O
had	O
a	O
Km	O
value	O
of	O
18	O
mM	O
for	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
was	O
found	O
to	O
be	O
inactive	O
as	O
a	O
substrate	O
by	O
Loffelhardt	O
et	O
al.	O
[	O
17	O
]	O
.	O

In	O
contrast	O
,	O
in	O
the	O
present	O
study	O
we	O
observed	O
both	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
are	O
used	O
as	O
substrates	O
(	O
in	O
the	O
reverse	O
reaction	O
)	O
for	O
human	O
liver	O
E3	O
and	O
Km	O
values	O
for	O
these	O
two	O
enantiomers	O
(	O
0.53	O
mM	O
for	O
R	B
-	I
LA	I
and	O
9.1	O
mM	O
for	O
S	B
-	I
LA	I
)	O
are	O
lower	O
than	O
that	O
reported	O
(	O
18	O
mM	O
for	O
R	B
-	I
LA	I
)	O
for	O
partially	O
purified	O
PDC	O
-	O
E3	O
from	O
human	O
kidney	O
carcinoma	O
[	O
17	O
]	O
.	O

The	O
inhibition	O
of	O
PDC	O
-	O
E2	O
activity	O
by	O
both	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
was	O
the	O
major	O
contribution	O
to	O
the	O
observed	O
inhibition	O
of	O
PDC	O
activity	O
.	O

However	O
,	O
much	O
higher	O
levels	O
of	O
LA	B
(	O
0.5–1	O
mM	O
)	O
than	O
is	O
present	O
physiologically	O
were	O
required	O
to	O
attain	O
a	O
significant	O
inhibition	O
(	O
50	O
%	O
)	O
of	O
this	O
component	O
's	O
activity	O
.	O

If	O
exogenous	O
lipoic	B
acid	I
is	O
provided	O
in	O
large	O
quantities	O
as	O
a	O
daily	O
supplement	O
,	O
it	O
may	O
be	O
possible	O
that	O
intracellular	O
and	O
more	O
importantly	O
intramitochondrial	O
concentrations	O
of	O
LA	B
could	O
be	O
raised	O
to	O
a	O
range	O
that	O
would	O
influence	O
E2	O
activity	O
in	O
the	O
mitochondria	O
.	O

However	O
,	O
the	O
likelihood	O
of	O
this	O
possibility	O
is	O
low	O
(	O
Fig.	O
5	O
)	O
because	O
LA	B
is	O
reduced	O
to	O
dihydrolipoic	B
acid	I
by	O
the	O
action	O
of	O
E3	O
and	O
glutathione	O
reductase	O
,	O
and	O
subsequently	O
dihydrolipoic	B
acid	I
is	O
readily	O
transported	O
out	O
of	O
the	O
cell	O
[	O
11	O
]	O
Furthermore	O
,	O
since	O
both	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
had	O
no	O
significant	O
effect	O
on	O
the	O
activity	O
of	O
E1	O
,	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
overall	O
reaction	O
of	O
PDC	O
,	O
it	O
is	O
suggested	O
that	O
a	O
partial	O
inhibition	O
of	O
E2	O
and	O
E3	O
components	O
may	O
not	O
have	O
any	O
significant	O
effect	O
on	O
the	O
carbon	O
flux	O
through	O
PDC	O
in	O
the	O
cell	O
(	O
Fig.	O
5	O
)	O
.	O

This	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
the	O
site	O
of	O
Se	B
-	I
LA	I
-	O
mediated	O
inhibition	O
of	O
PDC	O
activity	O
is	O
different	O
than	O
that	O
of	O
LA	B
.	O

Inhibition	O
of	O
PDC	O
activity	O
required	O
higher	O
concentrations	O
of	O
Se	B
-	I
LA	I
compared	O
to	O
R	B
-	I
LA	I
or	O
S	B
-	I
LA	I
(	O
Fig.	O
1	O
)	O
.	O

Although	O
Se	B
-	I
LA	I
was	O
as	O
effective	O
as	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
in	O
the	O
inhibition	O
of	O
E3	O
activity	O
in	O
the	O
forward	O
direction	O
(	O
Fig.	O
2	O
)	O
,	O
it	O
inhibited	O
E2	O
activity	O
marginally	O
in	O
comparison	O
to	O
that	O
of	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
(	O
Fig.	O
4	O
)	O
.	O

Since	O
E1	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
overall	O
reaction	O
of	O
the	O
PDC	O
,	O
when	O
there	O
is	O
no	O
inhibition	O
,	O
the	O
rate	O
at	O
which	O
NADH	B
is	O
generated	O
is	O
indirectly	O
controlled	O
by	O
E1	O
activity	O
in	O
the	O
complex	O
.	O

Se	B
-	I
LA	I
inhibited	O
the	O
activity	O
of	O
the	O
E1	O
component	O
(	O
Fig.	O
3	O
)	O
,	O
and	O
the	O
extent	O
of	O
inhibition	O
by	O
Se	B
-	I
LA	I
of	O
this	O
component	O
closely	O
paralleled	O
inhibition	O
of	O
the	O
overall	O
activity	O
of	O
PDC	O
(	O
Fig.	O
1	O
)	O
,	O
indicating	O
that	O
Se	B
-	I
LA	I
and	O
R-	B
or	O
S	B
-	I
LA	I
act	O
on	O
different	O
components	O
of	O
PDC	O
.	O

Since	O
Se	B
-	I
LA	I
was	O
recognized	O
as	O
a	O
substrate	O
for	O
the	O
reverse	O
reaction	O
of	O
E3	O
,	O
we	O
studied	O
the	O
kinetic	O
aspects	O
of	O
these	O
lipoic	B
compounds	I
on	O
the	O
E3	O
reverse	O
direction	O
.	O

Our	O
findings	O
demonstrated	O
that	O
the	O
K	O
m	O
and	O
k	O
cat	O
for	O
DL	B
-	I
lipoamide	I
on	O
the	O
reverse	O
reaction	O
of	O
E3	O
,	O
calculated	O
as	O
1.39	O
mM	O
and	O
719	O
s−1	O
,	O
respectively	O
,	O
are	O
in	O
agreement	O
with	O
the	O
previously	O
published	O
results	O
[	O
3	O
]	O
.	O

Since	O
a	O
mixture	O
of	O
D-	B
and	O
L	B
-	I
forms	O
of	O
lipoamide	B
was	O
used	O
in	O
both	O
experiments	O
,	O
it	O
was	O
not	O
surprising	O
to	O
find	O
a	O
higher	O
Km	O
than	O
that	O
of	O
R	B
-	I
LA	I
.	O

Furthermore	O
,	O
the	O
approximately	O
70	O
fold	O
higher	O
k	O
cat	O
with	O
DL	B
-	I
lipoamide	I
,	O
compared	O
to	O
those	O
for	O
the	O
other	O
lipoic	B
compounds	I
,	O
indicates	O
that	O
DL	B
-	I
lipoamide	I
is	O
the	O
preferred	O
substrate	O
for	O
the	O
reverse	O
reaction	O
of	O
E3	O
among	O
the	O
lipoic	B
compounds	I
tested	O
(	O
Table	O
1	O
)	O
.	O

The	O
differential	O
effect	O
of	O
lipoic	B
compounds	I
on	O
pyruvate	B
oxidation	O
by	O
intact	O
HepG2	O
cells	O
(	O
Fig.	O
5	O
)	O
suggests	O
that	O
PDC	O
as	O
well	O
as	O
its	O
catalytic	O
components	O
are	O
affected	O
based	O
on	O
the	O
stereoselectivity	O
of	O
the	O
lipoic	B
compounds	I
.	O

Our	O
findings	O
also	O
indicate	O
that	O
R	B
-	I
LA	I
is	O
not	O
inhibitory	O
at	O
the	O
extracellular	O
level	O
of	O
up	O
to	O
4	O
mM	O
(	O
Fig.	O
5A	O
)	O
which	O
may	O
not	O
be	O
readily	O
attained	O
by	O
supplementation	O
of	O
R	B
-	I
LA	I
.	O

Blumenthal	O
[	O
27	O
]	O
suggested	O
that	O
the	O
addition	O
of	O
free	O
R	B
,	I
S	I
-	I
lipoic	I
acid	I
caused	O
the	O
sequestration	O
of	O
intramitochondrial	O
free	O
CoA	B
by	O
the	O
formation	O
of	O
lipoyl	B
-	I
CoA	I
and	O
reduction	O
in	O
gluconeogenesis	O
from	O
lactate	B
and	O
pyruvate	B
by	O
rat	O
hepatocytes	O
.	O

Our	O
results	O
,	O
however	O
do	O
not	O
support	O
this	O
suggestion	O
because	O
there	O
was	O
no	O
significant	O
decrease	O
in	O
the	O
rate	O
of	O
pyruvate	B
decarboxylation	O
which	O
requires	O
the	O
participation	O
of	O
free	O
CoA	B
by	O
intact	O
HepG2	O
cells	O
with	O
lipoic	B
acids	I
(	O
Fig.	O
5	O
)	O
.	O

In	O
summary	O
,	O
the	O
influence	O
of	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
on	O
the	O
activity	O
of	O
mammalian	O
PDC	O
components	O
differs	O
from	O
that	O
of	O
Se	B
-	I
LA	I
.	O

Since	O
LA	B
(	O
R	O
and	O
S	O
forms	O
)	O
has	O
very	O
little	O
effect	O
on	O
the	O
activity	O
of	O
the	O
E1	O
component	O
which	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
of	O
the	O
PDC	O
,	O
R	B
-	I
LA	I
,	O
the	O
natural	O
enantiomer	O
,	O
would	O
not	O
be	O
expected	O
to	O
exert	O
any	O
significant	O
effect	O
on	O
pyruvate	B
metabolism	O
via	O
PDC	O
in	O
the	O
cell	O
.	O

Furthermore	O
,	O
the	O
high	O
catalytic	O
efficiency	O
of	O
the	O
E3	O
component	O
and	O
its	O
reversible	O
action	O
provides	O
a	O
means	O
for	O
the	O
conversion	O
of	O
exogenous	O
oxidized	B
LA	I
to	O
DHLA	B
which	O
is	O
a	O
potent	O
reductant	O
(	O
redox	O
modulator	O
)	O
and	O
cellular	O
anti	O
-	O
oxidant	O
.	O

The	O
findings	O
of	O
this	O
study	O
are	O
consistent	O
with	O
the	O
observed	O
improvements	O
in	O
glucose	B
utilization	O
by	O
mammalian	O
tissues	O
in	O
the	O
presence	O
of	O
lipoic	B
acid	I
[	O
6–8	O
]	O
.	O

Our	O
findings	O
clearly	O
show	O
that	O
in	O
contrast	O
to	O
S	B
-	I
LA	I
,	O
R	B
-	I
LA	I
is	O
a	O
better	O
substrate	O
for	O
E3	O
and	O
displays	O
no	O
inhibitory	O
effect	O
on	O
pyruvate	B
decarboxylation	O
by	O
intact	O
cells	O
.	O

It	O
,	O
therefore	O
,	O
is	O
suggested	O
that	O
R	B
-	I
LA	I
,	O
and	O
not	O
a	O
racemic	O
mixture	O
of	O
R-	B
and	O
S	B
-	I
LA	I
,	O
should	O
be	O
considered	O
a	O
choice	O
for	O
therapeutic	O
applications	O
.	O

[	O
23	O
]	O
Acknowledgements	O
We	O
thank	O
Dr.	O
Murray	O
Ettinger	O
of	O
State	O
University	O
of	O
New	O
York	O
at	O
Buffalo	O
and	O
Dr.	O
Thomas	O
E.	O
Roche	O
of	O
Kansas	O
State	O
University	O
for	O
their	O
critical	O
reading	O
of	O
the	O
manuscript	O
.	O

This	O
study	O
was	O
supported	O
in	O
part	O
by	O
USPHS	O
Grants	O
DK42885	O
(	O
MSP	O
)	O
and	O
DK50430	O
(	O
LP	O
)	O
.	O

1	O
.	O

The	O
metabolism	O
of	O
loxtidine	B
(	O
1-methyl-5-	B
[	I
3-	I
[	I
3-	I
[	I
(	I
1-piperidinyl	I
)	I
methyl	I
]	I
phenoxy	I
]	I
propyl	I
]	I
amino-1H-1,2,4-triazole-3-methanol	I
)	O
was	O
studied	O
in	O
freshly	O
isolated	O
rat	O
,	O
dog	O
and	O
human	O
hepatocytes	O
.	O

Metabolism	O
in	O
vitro	O
was	O
comparable	O
with	O
previously	O
available	O
in	O
vivo	O
data	O
in	O
all	O
three	O
species	O
with	O
the	O
marked	O
species	O
differences	O
observed	O
in	O
vivo	O
being	O
reproduced	O
in	O
the	O
hepatocyte	O
model	O
.	O

2	O
.	O

The	O
major	O
route	O
for	O
the	O
metabolism	O
of	O
loxtidine	B
by	O
rat	O
hepatocytes	O
was	O
N	O
-	O
dealkylation	O
to	O
form	O
the	O
propionic	B
acid	I
and	O
hydroxymethyl	B
triazole	I
metabolites	I
.	O

A	O
minor	O
metabolic	O
route	O
was	O
the	O
oxidation	O
of	O
loxtidine	B
to	O
a	O
carboxylic	B
acid	I
metabolite	I
.	O

The	O
major	O
route	O
of	O
metabolism	O
for	O
loxtidine	B
in	O
dog	O
hepatocytes	O
was	O
glucuronidation	O
with	O
oxidation	O
to	O
the	O
carboxylic	B
acid	I
metabolite	I
being	O
of	O
minor	O
importance	O
.	O

Incubation	O
of	O
loxtidine	B
with	O
human	O
hepatocytes	O
resulted	O
in	O
the	O
drug	B
remaining	O
largely	O
unchanged	O
but	O
with	O
the	O
carboxylic	B
acid	I
metabolite	I
being	O
produced	O
in	O
minor	O
amounts	O
.	O

3	O
.	O

In	O
vitro	O
studies	O
were	O
undertaken	O
with	O
rat	O
,	O
dog	O
and	O
human	O
hepatocytes	O
to	O
determine	O
the	O
Michaelis	O
-	O
Menten	O
parameters	O
Vmax	O
and	O
Km	O
for	O
the	O
sum	O
of	O
all	O
the	O
metabolic	O
pathways	O
.	O

These	O
kinetic	O
parameters	O
were	O
used	O
to	O
calculate	O
the	O
intrinsic	O
clearance	O
of	O
loxtidine	B
.	O

Using	O
appropriate	O
scaling	O
factors	O
,	O
the	O
predicted	O
in	O
vivo	O
hepatic	O
clearance	O
was	O
then	O
calculated	O
.	O

The	O
predicted	O
intrinsic	O
clearances	O
were	O
51.4	O
+	O
/-	O

12.4	O
,	O
8.0	O
+	O
/-	O

0.8	O
and	O
1.0	O
+	O
/-	O

0.6	O
ml	O
/	O
min	O
/	O
kg	O
for	O
rat	O
,	O
dog	O
and	O
human	O
hepatocytes	O
respectively	O
.	O

These	O
data	O
were	O
then	O
used	O
to	O
calculate	O
hepatic	O
clearances	O
of	O
24.5	O
,	O
3.1	O
and	O
0.2	O
ml	O
/	O
min	O
/	O
kg	O
for	O
rat	O
,	O
dog	O
and	O
man	O
respectively	O
.	O

4	O
.	O

In	O
vivo	O
hepatic	O
and	O
intrinsic	O
clearances	O
for	O
loxtidine	B
were	O
determined	O
in	O
rat	O
,	O
dog	O
and	O
human	O
volunteers	O
.	O

The	O
hepatic	O
clearances	O
of	O
loxtidine	B
were	O
26.6	O
,	O
6.6	O
and	O
0.4	O
ml	O
/	O
min	O
/	O
kg	O
in	O
rat	O
,	O
dog	O
and	O
man	O
respectively	O
and	O
intrinsic	O
clearances	O
were	O
58.5	O
,	O
18.6	O
and	O
2.0	O
ml	O
/	O
min	O
/	O
kg	O
in	O
rat	O
,	O
dog	O
and	O
man	O
respectively	O
.	O

5	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
the	O
hepatocyte	O
model	O
may	O
be	O
a	O
valuable	O
in	O
vitro	O
tool	O
for	O
predicting	O
both	O
qualitative	O
and	O
quantitative	O
aspects	O
of	O
the	O
metabolism	O
of	O
a	O
drug	B
in	O
animals	O
and	O
man	O
at	O
an	O
early	O
stage	O
of	O
the	O
drug	B
development	O
process	O
.	O

Our	O
development	O
of	O
vaccines	O
to	O
prevent	O
shigellosis	O
is	O
based	O
on	O
the	O
hypothesis	O
that	O
a	O
critical	O
(	O
protective	O
)	O
level	O
of	O
serum	O
IgG	O
to	O
the	O
O	B
-	I
specific	I
polysaccharide	I
(	O
O	B
-	I
SP	I
)	O
domain	O
of	O
Shigella	O
lipopolysaccharide	B
(	O
LPS	B
)	O
confers	O
immunity	O
.	O

The	O
O	B
-	I
SP	I
is	O
a	O
hapten	O
and	O
must	O
be	O
conjugated	O
to	O
a	O
protein	O
to	O
induce	O
serum	O
antibodies	O
.	O

The	O
O	B
-	I
SP	I
of	O
Shigella	O
dysenteriae	O
type	O
1	O
(	O
approximately	O
27	O
tetrasaccharide	B
repeat	O
units	O
)	O
,	O
prepared	O
by	O
acid	B
hydrolysis	O
of	O
the	O
LPS	B
,	O
was	O
bound	O
to	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
by	O
multiple	O
point	O
attachment	O
(	O
O	B
-	I
SP	I
-	O
HSA	O
)	O
:	O
The	O
molar	O
ratio	O
of	O
HSA	O
to	O
O	B
-	I
SP	I
was	O
1.0	O
.	O

Synthetic	O
saccharides	B
,	O
composed	O
of	O
one	O
or	O
multiples	O
of	O
the	O
O	B
-	I
SP	I
tetrasaccharide	B
,	O
equipped	O
with	O
a	O
spacer	O
at	O
their	O
reducing	O
end	O
,	O
were	O
bound	O
to	O
HSA	O
by	O
a	O
single	O
point	O
attachment	O
:	O
The	O
average	O
molar	O
ratios	O
of	O
the	O
saccharides	B
to	O
HSA	O
ranged	O
from	O
4	O
to	O
24	O
.	O

Serum	O
IgG	O
anti	O
-	O
LPS	B
,	O
elicited	O
in	O
mice	O
by	O
O	B
-	I
SP	I
-	O
HSA	O
or	O
synthetic	O
tetra-	B
,	O
octa-	B
,	O
dodeca-	B
,	O
and	O
hexadecasaccharide	B
fragments	O
,	O
was	O
measured	O
by	O
ELISA	O
.	O

Outbred	O
6-week	O
-	O
old	O
female	O
mice	O
were	O
injected	O
s.c	O
.	O

three	O
times	O
at	O
biweekly	O
intervals	O
with	O
2.5	O
micrograms	O
of	O
saccharide	B
as	O
a	O
conjugate	B
and	O
were	O
bled	O
7	O
days	O
after	O
the	O
second	O
and	O
third	O
injections	O
.	O

Excepting	O
the	O
tetramer	B
,	O
conjugates	B
of	I
the	I
octamer	B
,	O
dodecamer	B
and	O
hexadecamer	B
elicited	O
IgG	O
LPS	B
antibodies	O
after	O
the	O
second	O
injection	O
,	O
a	O
statistically	O
significant	O
rise	O
(	O
booster	O
)	O
after	O
the	O
third	O
injection	O
,	O
and	O
higher	O
levels	O
than	O
those	O
vaccinated	O
with	O
O	B
-	I
SP	I
-	O
HSA	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

The	O
highest	O
geometric	O
mean	O
levels	O
of	O
IgG	O
anti	O
-	O
LPS	B
were	O
elicited	O
by	O
the	O
hexadecamer	B
with	O
9	O
chains	O
or	O
9	O
moles	O
of	O
saccharide	B
/	O
HSA	O
(	O
15.5	O
ELISA	O
units	O
)	O
followed	O
by	O
the	O
octamer	B
with	O
20	O
chains	O
(	O
11.1	O
ELISA	O
units	O
)	O
and	O
the	O
dodecamer	B
with	O
10	O
chains	O
(	O
9.52	O
ELISA	O
units	O
)	O
.	O

Clinical	O
evaluation	O
of	O
these	O
synthetic	O
saccharides	B
bound	O
to	O
a	O
medically	O
useful	O
carrier	O
is	O
planned	O
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
pharmacokinetics	O
and	O
metabolism	O
of	O
R	B
(	I
+	I
)	I
-	I
and	O
S	B
(	I
-	I
)	I
-	I
ketorolac	I
in	O
children	O
.	O

METHODS	O
:	O
Children	O
from	O
3	O
to	O
18	O
years	O
old	O
received	O
0.6	O
mg	O
/	O
kg	O
racemic	B
ketorolac	I
intravenously	O
.	O

Serial	O
blood	O
samples	O
were	O
obtained	O
for	O
12	O
hours	O
,	O
and	O
urine	O
was	O
collected	O
for	O
12	O
to	O
24	O
hours	O
.	O

Racemic	B
ketorolac	I
was	O
measured	O
in	O
plasma	O
,	O
and	O
racemic	B
ketorolac	I
,	O
para	B
-	I
hydroxyketorolac	I
,	O
and	O
ketorolac	B
glucuronide	I
were	O
measured	O
in	O
urine	O
by	O
HPLC	O
.	O

S	B
(	I
-	I
)	I
-	I
and	O
R	B
(	I
+	I
)	I
-ketorolac	I
were	O
measured	O
in	O
plasma	O
;	O
S	B
(	I
-	I
)	I
-	I
and	O
R	B
(	I
+	I
)	I
-ketorolac	I
and	O
ketorolac	B
glucuronide	I
were	O
measured	O
in	O
urine	O
by	O
chiral	O
HPLC	O
separation	O
.	O

Plasma	O
pharmacokinetic	O
parameters	O
for	O
racemic	B
drug	I
and	O
both	O
enantiomers	B
were	O
determined	O
for	O
each	O
patient	O
.	O

RESULTS	O
:	O
Clearance	O
of	O
racemic	B
ketorolac	I
in	O
children	O
was	O
approximately	O
2	O
times	O
the	O
clearance	O
reported	O
in	O
adults	O
.	O

Clearance	O
of	O
the	O
S	B
(	I
-	I
)	I
enantiomer	I
was	O
4	O
times	O
that	O
of	O
the	O
R	B
(	I
+	I
)	I
enantiomer	I
.	O

Terminal	O
half	O
-	O
life	O
of	O
S	B
(	I
-	I
)	I
-ketorolac	I
was	O
40	O
%	O
that	O
of	O
the	O
R	B
(	I
+	I
)	I
enantiomer	I
,	O
and	O
the	O
apparent	O
volume	O
of	O
distribution	O
of	O
the	O
S	B
(	I
-	I
)	I
enantiomer	I
was	O
greater	O
than	O
that	O
of	O
the	O
R	B
(	I
+	I
)	I
form	I
.	O

Recovery	O
of	O
S	B
(	I
-	I
)	I
-ketorolac	I
glucuronide	I
was	O
2.3	O
times	O
that	O
of	O
the	O
R	B
(	I
+	I
)	I
enantiomer	I
.	O

CONCLUSION	O
:	O
The	O
higher	O
clearance	O
in	O
children	O
suggests	O
that	O
the	O
weight	O
-	O
adjusted	O
dose	O
of	O
ketorolac	B
may	O
have	O
to	O
be	O
greater	O
for	O
children	O
to	O
achieve	O
plasma	O
concentrations	O
comparable	O
to	O
those	O
of	O
adults	O
.	O

Because	O
of	O
the	O
greater	O
clearance	O
and	O
shorter	O
half	O
-	O
life	O
of	O
S	B
(	I
-	I
)	I
-ketorolac	I
,	O
pharmacokinetic	O
predictions	O
based	O
on	O
racemic	O
assays	O
may	O
overestimate	O
the	O
duration	O
of	O
pharmacologic	O
effect	O
.	O

Enantiomeric	O
pharmacokinetic	O
differences	O
are	O
best	O
explained	O
by	O
stereoselective	O
plasma	O
protein	O
binding	O
.	O

Selective	O
glucuronidation	O
of	O
the	O
S	B
(	I
-	I
)	I
enantiomer	I
suggests	O
that	O
stereoselective	O
metabolism	O
may	O
also	O
be	O
a	O
contributing	O
factor	O
.	O

The	O
antifungal	O
activity	O
of	O
eberconazole	B
,	O
a	O
new	O
imidazole	B
derivative	I
,	O
against	O
124	O
clinical	O
isolates	O
of	O
Candida	O
comprising	O
eight	O
different	O
species	O
and	O
to	O
34	O
isolates	O
of	O
Cryptococcus	O
neoformans	O
was	O
compared	O
to	O
those	O
of	O
clotrimazole	B
and	O
ketoconazole	B
.	O

MICs	O
of	O
eberconazole	B
,	O
determined	O
by	O
the	O
National	O
Committee	O
for	O
Clinical	O
Laboratory	O
Standards	O
standardized	O
microbroth	O
method	O
,	O
were	O
equal	O
to	O
or	O
lower	O
than	O
those	O
of	O
other	O
azoles	B
,	O
especially	O
for	O
Candida	O
krusei	O
and	O
Candida	O
glabrata	O
,	O
which	O
are	O
usually	O
resistant	O
to	O
triazoles	B
.	O

Long	O
-	O
chain	O
fatty	O
acyl	O
-	O
CoA	O
synthetase	O
(	O
FACS	O
)	O
catalyzes	O
esterification	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
LCFAs	O
)	O
with	O
coenzyme	B
A	I
(	O
CoA	B
)	O
,	O
the	O
first	O
step	O
in	O
fatty	B
acid	I
metabolism	O
.	O

FACS	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
LCFA	B
import	O
into	O
bacteria	O
and	O
implicated	O
to	O
function	O
in	O
mammalian	O
cell	O
LCFA	B
import	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
FACS	O
overexpression	O
in	O
fibroblasts	O
increases	O
LCFA	B
uptake	O
,	O
and	O
overexpression	O
of	O
both	O
FACS	O
and	O
the	O
fatty	O
acid	O
transport	O
protein	O
(	O
FATP	O
)	O
have	O
synergistic	O
effects	O
on	O
LCFA	B
uptake	O
.	O

To	O
explore	O
how	O
FACS	O
contributes	O
to	O
LCFA	B
import	O
,	O
we	O
examined	O
the	O
subcellular	O
location	O
of	O
this	O
enzyme	O
in	O
3T3-L1	O
adipocytes	O
which	O
natively	O
express	O
this	O
protein	O
and	O
which	O
efficiently	O
take	O
up	O
LCFAs	B
.	I

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
FACS	O
is	O
an	O
integral	O
membrane	O
protein	O
.	O

Subcellular	O
fractionation	O
of	O
adipocytes	O
by	O
differential	O
density	O
centrifugation	O
reveals	O
immunoreactive	O
and	O
enzymatically	O
active	O
FACS	O
in	O
several	O
membrane	O
fractions	O
,	O
including	O
the	O
plasma	O
membrane	O
.	O

Immunofluorescence	O
studies	O
on	O
adipocyte	O
plasma	O
membrane	O
lawns	O
confirm	O
that	O
FACS	O
resides	O
at	O
the	O
plasma	O
membrane	O
of	O
adipocytes	O
,	O
where	O
it	O
co	O
-	O
distributes	O
with	O
FATP	O
.	O

Taken	O
together	O
,	O
our	O
data	O
support	O
a	O
model	O
in	O
which	O
imported	O
LCFAs	B
are	O
immediately	O
esterified	O
at	O
the	O
plasma	O
membrane	O
upon	O
uptake	O
,	O
and	O
in	O
which	O
FATP	O
and	O
FACS	O
function	O
coordinately	O
to	O
facilitate	O
LCFA	B
movement	O
across	O
the	O
plasma	O
membrane	O
of	O
mammalian	O
cells	O
.	O

On	O
the	O
22nd	O
day	O
of	O
gestation	O
in	O
rats	O
,	O
fetuses	O
of	O
acutely	O
adrenalectomized	O
mothers	O
were	O
injected	O
subcutaneously	O
with	O
0.43	O
muCi	O
4	B
-	I
14C	I
-	I
progesterone	I
in	O
0.05	O
ml	O
saline	B
.	O

Ten	O
and	O
20	O
min	O
after	O
injection	O
to	O
fetuses	O
,	O
samples	O
were	O
taken	O
to	O
determine	O
the	O
14C	B
-	I
progesterone	I
metabolites	B
in	O
the	O
plasma	O
and	O
adrenal	O
glands	O
.	O

After	O
extraction	O
of	O
the	O
samples	O
taken	O
,	O
the	O
metabolites	B
were	O
separated	O
by	O
two	O
-	O
dimensional	O
thin	O
-	O
layer	O
chromatography	O
and	O
identified	O
by	O
autoradiography	O
.	O

11-deoxycorticosterone	B
,	O
18-hydroxy-11-deoxycorticosterone	B
,	O
corticosterone	B
and	O
11beta	B
-	I
hydroxyprogesterone	I
were	O
identified	O
in	O
the	O
plasma	O
of	O
injected	O
fetuses	O
,	O
and	O
,	O
in	O
far	O
smaller	O
amounts	O
,	O
in	O
the	O
plasma	O
of	O
their	O
mothers	O
.	O

The	O
plasma	O
of	O
noninjected	O
fetuses	O
also	O
contained	O
very	O
small	O
amounts	O
of	O
these	O
corticoids	B
.	O

The	O
fetal	O
adrenal	O
glands	O
contained	O
far	O
smaller	O
amounts	O
of	O
radioactive	O
steroids	B
than	O
the	O
fetal	O
plasma	O
did	O
.	O

The	O
results	O
obtained	O
show	O
that	O
steroids	B
of	O
fetal	O
origin	O
can	O
cross	O
the	O
placenta	O
in	O
and	O
out	O
,	O
constituting	O
evidence	O
that	O
the	O
fetal	O
adrenal	O
glands	O
are	O
the	O
only	O
source	O
of	O
the	O
plasma	O
corticoids	B
of	O
their	O
adrenalectomized	O
mothers	O
.	O

Ozone	B
-	O
oxygen	B
mixture	O
(	O
ozone	B
concentration	O
600	O
microg	O
/	O
l	O
)	O
was	O
used	O
in	O
irrigations	O
of	O
the	O
tympanic	O
cavity	O
in	O
52	O
patients	O
with	O
chronic	O
purulent	O
mesotympanitis	O
(	O
CPM	O
)	O
.	O

The	O
course	O
of	O
the	O
treatment	O
consisted	O
of	O
5	O
-	O
7	O
procedures	O
.	O

18	O
CPM	O
controls	O
received	O
standard	O
treatment	O
without	O
the	O
irrigations	O
.	O

The	O
course	O
of	O
the	O
ozone	B
-	I
oxygen	I
irrigations	O
produced	O
good	O
results	O
:	O
ear	O
discharge	O
and	O
tympanic	O
mucosa	O
inflammation	O
stopped	O
in	O
81	O
%	O
of	O
the	O
irrigated	O
patients	O
,	O
levels	O
of	O
myeloperoxidase	O
which	O
marks	O
inflammation	O
reduced	O
significantly	O
,	O
bactericidal	O
effects	O
of	O
the	O
mixture	B
were	O
observed	O
for	O
all	O
the	O
detected	O
pathogens	O
,	O
antibiotic	O
sensitivity	O
of	O
the	O
bacteria	O
rose	O
.	O

Fast	O
antiinflammatory	O
result	O
of	O
ozone	B
therapy	O
was	O
due	O
not	O
only	O
to	O
its	O
bactericidal	O
effect	O
but	O
also	O
via	O
its	O
antihypoxic	O
and	O
immunomodulating	O
mechanisms	O
.	O

Galacto	B
-	I
oligosaccharides	I
,	O
including	O
the	O
oligogalactosylated	B
glucoses	I
,	O
are	O
claimed	O
to	O
be	O
beneficial	O
for	O
human	O
health	O
because	O
they	O
seem	O
to	O
promote	O
the	O
growth	O
of	O
bifidobacteria	O
in	O
the	O
large	O
intestine	O
[	O
1	O
]	O
.	O

Several	O
studies	O
suggest	O
that	O
the	O
volatile	O
fatty	B
acids	I
resulting	O
from	O
the	O
fermentation	O
of	O
galacto	B
-	I
oligosaccharides	I
by	O
the	O
intestinal	O
microflora	O
improve	O
the	O
absorption	O
ability	O
of	O
the	O
intestinal	O
epithelium	O
[	O
2–4	O
]	O
.	O

Oligogalactosylated	B
glucoses	I
can	O
be	O
prepared	O
from	O
lactose	B
through	O
the	O
transgalactosylating	O
activity	O
of	O
β	O
-	O
galactosidase	O
(	O
EC	O
3.2.1.23	O
)	O
.	O

Various	O
parameters	O
such	O
as	O
source	O
of	O
the	O
enzyme	O
,	O
substrate	B
concentration	O
,	O
pH	O
,	O
and	O
temperature	O
can	O
influence	O
the	O
transgalactosylation	O
and	O
thereby	O
the	O
final	O
yields	O
of	O
the	O
different	O
compounds	O
formed	O
[	O
5	O
]	O
.	O

The	O
structures	O
of	O
oligogalactosylated	B
glucoses	I
reported	O
so	O
far	O
range	O
from	O
dimers	B
to	O
pentamers	B
[	O
1,6–9	O
]	O
.	O

Depending	O
on	O
the	O
biological	O
origin	O
of	O
the	O
β	O
-	O
galactosidase	O
applied	O
,	O
different	O
linkages	O
between	O
Gal	B
and	O
the	O
reducing	O
Glc	B
unit	O
have	O
been	O
identified	O
,	O
namely	O
,	O
β	B
-	I
d	I
-Galp	I
-	I
(	I
1→2	I
)	I
-d	I
-Glcp	I
,	O
β	B
-	I
d	I
-Galp	I
-	I
(	I
1→3	I
)	I
-d	I
-Glcp	I
,	O
β	B
-	I
d	I
-Galp	I
-	I
(	I
1→4	I
)	I
-d	I
-Glcp	I
,	O
and	O
β	B
-	I
d	I
-Galp	I
-	I
(	I
1→6	I
)	I
-d	I
-Glcp	I
.	O

Branched	O
Glc	B
residues	O
also	O
occur	O
,	O
whereas	O
the	O
oligogalactose	B
fragments	O
contain	O
mainly	O
(	O
1→4	O
)	O
or	O
(	O
1→6	O
)	O
linkages	O
.	O

So	O
far	O
oligogalactosylated	B
glucose	I
tetramers	B
and	O
pentamers	B
have	O
rarely	O
been	O
observed	O
in	O
large	O
amounts	O
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
novel	O
transgalactosylating	O
activity	O
of	O
β	O
-	O
galactosidase	O
leading	O
to	O
the	O
formation	O
of	O
α	B
-	I
d	I
-Glcp	I
-	I
(	I
1↔1	I
)	I
-β	I
-	I
d	I
-Galp	I
elements	O
in	O
several	O
oligogalactosylated	B
glucoses	I
.	O

2	O
2	O
.	O

Results	O
2.1	O
Purification	O
of	O
oligosaccharides	B
produced	O
by	O
β	B
-	I
galactosidase	I
The	O
oligogalactosylated	B
glucose	I
sample	O
supplied	O
(	O
Borculo	O
Whey	O
Products	O
)	O
was	O
fractionated	O
by	O
gel	O
-	O
permeation	O
chromatography	O
using	O
Fractogel	O
TSK	O
HW-40	O
(	O
S	O
)	O
followed	O
by	O
Bio	O
-	O
Gel	O
P-2	O
.	O

Following	O
this	O
protocol	O
,	O
fractions	O
of	O
different	O
degrees	O
of	O
polymerization	O
were	O
obtained	O
.	O

These	O
pools	O
of	O
oligosaccharides	B
were	O
further	O
fractionated	O
by	O
high	O
-	O
performance	O
anion	O
-	O
exchange	O
chromatography	O
(	O
HPAEC	O
)	O
.	O

In	O
Fig.	O
1	O
HPAEC	O
profiles	O
of	O
the	O
starting	O
oligogalactosylated	B
glucose	I
sample	O
(	O
upper	O
panel	O
)	O
and	O
of	O
five	O
Bio	O
-	O
Gel	O
P-2	O
fractions	O
(	O
dimers	O
to	O
hexamers	O
)	O
are	O
shown	O
.	O

The	O
major	O
components	O
[	O
(	B
β	I
-	I
d	I
-Galp	I
-	I
(	I
1→4	I
)	I
)	I
n	I
-d	I
-Glcp	I
,	O
and	O
(	B
β	I
-	I
d	I
-Galp	I
-	I
(	I
1→6	I
)	I
)	I
n	I
-β	I
-	I
d	I
-Galp	I
-	I
(	I
1→4	I
)	I
-d	I
-Glcp	I
,	O
n	O
=	O
0–5	O
]	O
in	O
each	O
Bio	O
-	O
Gel	O
P-2	O
fraction	O
were	O
characterized	O
using	O
HPAEC	O
retention	O
times	O
and	O
1	O
H	O
NMR	O
spectroscopy	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
oligogalactosylated	B
glucose	I
structures	O
found	O
were	O
in	O
agreement	O
with	O
those	O
reported	O
so	O
far	O
[	O
5	O
]	O
.	O

For	O
the	O
NMR	O
analysis	O
,	O
use	O
was	O
made	O
of	O
the	O
chemical	O
shifts	O
of	O
linear	O
β-	O
(	O
1→4	O
)	O
-linked	O
d	O
-galactobi-	O
to	O
pentaose	O
(	O
see	O
Table	O
1	O
)	O
.	O

The	O
1	O
H	O
and	O
13	O
C	O
chemical	O
shifts	O
of	O
the	O
latter	O
compounds	O
,	O
which	O
have	O
not	O
been	O
reported	O
so	O
far	O
in	O
detail	O
,	O
are	O
shown	O
in	O
Tables	O
1	O
and	O
2	O
,	O
respectively	O
.	O

Additionally	O
to	O
the	O
known	O
oligogalactosylated	B
glucoses	I
,	O
each	O
Bio	O
-	O
Gel	O
P-2	O
fraction	O
contained	O
at	O
least	O
one	O
less	O
retarded	O
component	O
(	O
Fig.	O
1	O
,	O
indicated	O
by	O
its	O
fraction	O
number	O
)	O
whose	O
structure	O
has	O
not	O
yet	O
been	O
reported	O
.	O

The	O
structural	O
characterization	O
of	O
these	O
compounds	O
is	O
described	O
in	O
the	O
following	O
paragraphs	O
.	O

2.2	O
Characterization	O
of	O
Fractions	O
2.1	O
and	O
2.2	O
The	O
pool	O
of	O
disaccharides	B
contained	O
,	O
according	O
to	O
the	O
HPAEC	O
chromatogram	O
,	O
at	O
least	O
six	O
components	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
1	O
H	O
NMR	O
spectrum	O
of	O
Fraction	O
2.2	O
indicated	O
the	O
presence	O
of	O
free	O
Gal	B
and	O
Glc	B
(	O
data	O
not	O
shown	O
)	O
.	O

Fraction	O
2.1	O
contained	O
a	O
disaccharide	B
consisting	O
of	O
Glc	B
and	O
Gal	B
in	O
a	O
molar	O
ratio	O
of	O
1:1	O
.	O

Methylation	B
analysis	O
revealed	O
the	O
presence	O
of	O
equimolar	O
amounts	O
of	O
terminal	O
Galp	B
and	O
terminal	O
Glcp	B
.	O

Electrospray	O
ionization	O
mass	O
spectrometry	O
(	O
ESMS	O
)	O
analysis	O
of	O
the	O
sodium	B
borodeuteride	I
-	O
treated	O
and	O
permethylated	O
Fraction	O
2.1	O
showed	O
an	O
ion	O
at	O
m	O
/	O
z	O
477	O
(	O
data	O
not	O
shown	O
)	O
,	O
corresponding	O
to	O
a	O
sodium	B
-	O
cationized	O
pseudomolecular	O
ion	O
[	O
M+Na	O
]	O
+	O
for	O
nonreduced	B
permethylated	I
Hex2	I
.	O

The	O
[	O
M+H	O
]	O
+	O
ion	O
at	O
m	O
/	O
z	O
455	O
,	O
observed	O
in	O
the	O
FAB	O
mass	O
spectrum	O
was	O
used	O
for	O
a	O
high	O
energy	O
collision	O
experiment	O
applying	O
fast	O
atom	O
bombardment	O
collision	O
induced	O
dissociation	O
tandem	O
mass	O
spectrometry	O
(	O
FAB	O
CID	O
MS	O
-	O
MS	O
)	O
.	O

The	O
most	O
abundant	O
and	O
the	O
only	O
mass	O
spectrometric	O
sequence	O
ion	O
notable	O
in	O
the	O
tandem	O
mass	O
spectrum	O
was	O
the	O
B1	O
ion	O
at	O
m	O
/	O
z	O
219	O
[	O
10	O
]	O
.	O

This	O
ion	O
was	O
accompanied	O
by	O
ions	O
resulting	O
from	O
the	O
loss	O
of	O
one	O
and	O
two	O
methanol	B
molecules	O
from	O
the	O
B1	O
ion	O
(	O
m	O
/	O
z	O
187	O
and	O
155	O
)	O
and	O
the	O
precursor	O
(	O
m	O
/	O
z	O
423	O
and	O
391	O
)	O
.	O

Although	O
the	O
ion	O
at	O
m	O
/	O
z	O
423	O
has	O
the	O
same	O
mass	O
as	O
that	O
expected	O
for	O
a	O
B2	O
ion	O
,	O
its	O
relatively	O
low	O
abundance	O
is	O
not	O
consistent	O
with	O
its	O
assignment	O
as	O
a	O
B2	O
ion	O
.	O

All	O
data	O
are	O
thus	O
consistent	O
with	O
the	O
presence	O
of	O
a	O
(	O
1↔1	O
)	O
-linked	O
disaccharide	O
.	O

1D	O
1	O
H	O
NMR	O
analysis	O
showed	O
two	O
anomeric	O
signals	O
at	O
δ	O
5.230	O
and	O
4.571	O
(	O
Fig.	O
2	O
(	O
A	O
)	O
,	O
Table	O
3	O
)	O
in	O
the	O
intensity	O
ratio	O
of	O
1:1	O
.	O

The	O
signal	O
at	O
δ	O
5.230	O
(	O
3	O
J	O
1,2	O
3.7	O
Hz	O
)	O
had	O
correlations	O
to	O
H-2,3,4,5,6a,6b	O
in	O
the	O
TOCSY	O
spectrum	O
,	O
identifying	O
the	O
α	B
-	I
Glcp	I
residue	O
.	O

The	O
signal	O
at	O
δ	O
4.571	O
(	O
3	O
J	O
1,2	O
7.6	O
Hz	O
)	O
only	O
showed	O
TOCSY	O
cross	O
-	O
peaks	O
to	O
H-2,3,4	O
;	O
combined	O
with	O
the	O
typical	O
peak	O
pattern	O
of	O
H-4	O
and	O
the	O
resemblance	O
of	O
the	O
chemical	O
shifts	O
with	O
those	O
of	O
the	O
nonreducing	O
residues	O
in	O
1	O
–4	O
(	O
Table	O
1	O
)	O
,	O
the	O
β	B
-	I
Galp	I
residue	O
could	O
be	O
assigned	O
.	O

Due	O
to	O
small	O
3	O
J	O
3,4	O
(	O
2	O
Hz	O
)	O
and	O
3	O
J	O
4,5	O
(	O
<	O
1	O
Hz	O
)	O
couplings	O
no	O
correlations	O
to	O
H-5	O
could	O
be	O
seen	O
.	O

Consequently	O
,	O
Fraction	O
2.1	O
contains	O
the	O
following	O
disaccharide:	O
(	O
2.1A	B
)	O
α	B
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p	I

In	O
the	O
ROESY	O
spectrum	O
an	O
intense	O
interresidual	O
contact	O
between	O
the	O
two	O
anomeric	O
protons	B
was	O
visible	O
.	O

The	O
assignments	O
of	O
the	O
carbon	B
atoms	O
as	O
obtained	O
from	O
the	O
seHSQC	O
and	O
HMBC	O
spectra	O
are	O
given	O
in	O
Table	O
4	O
.	O

Notable	O
are	O
the	O
chemical	O
shift	O
values	O
for	O
C-1	O
of	O
Gal	B
(	O
δ	O
104.5	O
)	O
and	O
Glc	O
(	O
δ	O
101.1	O
)	O
,	O
typical	O
for	O
a	O
terminal	O
β	B
-	I
Gal	I
and	O
a	O
terminal	O
α	B
-	I
Glc	I
residue	O
.	O

The	O
HMBC	O
spectrum	O
showed	O
two	O
interresidual	O
contacts	O
(	O
I	O
H-1,II′	O
C-1	O
and	O
II′	O
H-1,I	O
C-1	O
)	O
and	O
the	O
H-1	O
/	O
C-1	O
coupling	O
constants	O
(	O
Glc	B
1	O
J	O
C-1,H-1	O
174	O
Hz	O
,	O
Gal	B
1	O
J	O
C-1,H-1	O
163	O
Hz	O
)	O
,	O
confirming	O
structure	O
2.1A	B
.	O

2.3	O
Characterization	O
of	O
Fraction	O
3.1	O
HPAEC	O
Fraction	O
3.1	O
(	O
Fig.	O
1	O
)	O
contained	O
as	O
the	O
major	O
component	O
compound	O
3.1A	O
:	O
(	O
3.1A	B
)	O
β	B
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p	I
Quantitative	O
monosaccharide	B
analysis	O
of	O
Fraction	O
3.1	O
revealed	O
Glc	B
and	O
Gal	B
in	O
a	O
molar	O
ratio	O
of	O
1.0:1.9	O
.	O

Methylation	B
analysis	O
demonstrated	O
the	O
presence	O
of	O
terminal	O
Galp	B
and	O
4-substituted	B
Glcp	I
residues	O
.	O

In	O
the	O
ESMS	O
spectrum	O
of	O
the	O
sodium	B
borodeuteride	I
-	O
treated	O
and	O
permethylated	O
Fraction	O
3.1	O
,	O
an	O
ion	O
at	O
m	O
/	O
z	O
681	O
was	O
observed	O
,	O
corresponding	O
to	O
[	O
M+Na	O
]	O
+	O
for	O
a	O
nonreduced	O
permethylated	O
Hex3	O
.	O

The	O
most	O
abundant	O
ions	O
observed	O
in	O
the	O
tandem	O
mass	O
spectrum	O
obtained	O
from	O
the	O
protonated	O
derivatized	O
oligosaccharide	B
,	O
m	O
/	O
z	O
659	O
,	O
were	O
the	O
B1	O
and	O
B2	O
ions	O
(	O
m	O
/	O
z	O
219	O
and	O
423	O
)	O
.	O

The	O
intense	O
ion	O
observed	O
at	O
m	O
/	O
z	O
455	O
corresponding	O
in	O
mass	O
to	O
fully	O
methylated	B
Hex2	O
was	O
assigned	O
as	O
resulting	O
from	O
'	O
internal	O
residue	O
loss	O
'	O
[	O
11	O
]	O
.	O

The	O
very	O
low	O
abundance	O
of	O
the	O
ion	O
at	O
m	O
/	O
z	O
627	O
corresponding	O
to	O
the	O
loss	O
of	O
methanol	B
from	O
the	O
precursor	O
and	O
having	O
the	O
same	O
mass	O
as	O
a	O
B3	O
ion	O
was	O
consistent	O
with	O
the	O
presence	O
of	O
a	O
(	O
1↔1	O
)	O
glycosidic	O
linkage	O
in	O
Hex3	O
.	O

1D	O
1	O
H	O
NMR	O
analysis	O
of	O
Fraction	O
3.1	O
(	O
Fig.	O
2	O
(	O
B	O
)	O
)	O
showed	O
three	O
,	O
equally	O
intense	O
,	O
anomeric	O
signals	O
at	O
δ	O
5.228	O
(	O
3	O
J	O
1,2	O
3.4	O
Hz	O
,	O
1	O
J	O
C-1,H-1	O
173	O
Hz	O
)	O
,	O
4.576	O
(	O
3	O
J	O
1,2	O
7.0	O
Hz	O
,	O
1	O
J	O
C-1,H-1	O
160	O
Hz	O
)	O
,	O
and	O
4.443	O
(	O
3	O
J	O
1,2	O
7.9	O
Hz	O
,	O
1	O
J	O
C-1,H-1	O
163	O
Hz	O
)	O
.	O

Taking	O
into	O
account	O
both	O
the	O
3	O
J	O
1,2	O
and	O
1	O
J	O
C-1,H-1	O
(	O
from	O
HMBC	O
)	O
coupling	O
constants	O
,	O
the	O
first	O
signal	O
belonged	O
to	O
an	O
α	B
and	O
the	O
other	O
two	O
to	O
β	B
gluco	B
/	O
galactopyranosyl	B
residues	O
.	O

2D	O
NMR	O
spectroscopy	O
(	O
DQF	O
COSY	O
,	O
TOCSY	O
,	O
and	O
ROESY	O
)	O
together	O
with	O
the	O
chemical	O
shift	O
values	O
of	O
1	O
–4	O
allowed	O
the	O
assignment	O
of	O
all	O
proton	O
resonances	O
,	O
as	O
presented	O
in	O
Table	O
3	O
.	O

In	O
this	O
way	O
,	O
the	O
α	O
anomeric	O
signal	O
could	O
be	O
assigned	O
to	O
the	O
Glcp	B
residue	O
and	O
the	O
β	O
anomeric	O
signals	O
to	O
Galp	B
residues	O
.	O

The	O
linkages	O
between	O
the	O
different	O
monosaccharide	B
units	O
were	O
confirmed	O
by	O
the	O
interresidual	O
ROESY	O
cross	O
-	O
peaks	O
II	O
H-1,I	O
H-4	O
and	O
I	O
H-1,II′	O
H-1	O
,	O
and	O
by	O
the	O
long	O
range	O
HMBC	O
contacts	O
(	O
Fig.	O
3	O
)	O
II	O
H-1,I	O
C-4	O
,	O
I	O
H-4,II	O
C-1	O
,	O
I	O
H-1,II′	O
C-1	O
,	O
and	O
II′	O
H-1,I	O
C-1	O
.	O

The	O
assignments	O
of	O
the	O
carbon	B
chemical	O
shifts	O
as	O
obtained	O
from	O
the	O
HMBC	O
spectrum	O
are	O
shown	O
in	O
Table	O
4	O
.	O

They	O
are	O
in	O
agreement	O
with	O
terminal	O
β	B
-	I
Galp	I
(	O
C-1	O
,	O
δ	O
103.8	O
and	O
104.4	O
)	O
and	O
4-substituted	B
α	I
-	I
Glcp	I
(	O
C-1	O
,	O
δ	O
101.7	O
;	O
C-4	O
,	O
δ	O
79.0	O
)	O
.	O

In	O
the	O
1D	O
1	O
H	O
NMR	O
spectrum	O
of	O
Fraction	O
3.1	O
(	O
Fig.	O
2	O
(	O
B	O
)	O
)	O
some	O
other	O
anomeric	O
signals	O
with	O
much	O
lower	O
intensity	O
(	O
ca	O
.	O
10	O
%	O
)	O
were	O
visible	O
(	O
δ	O
5.45	O
,	O
3	O
J	O
1,2	O
3.4	O
Hz	O
;	O
4.62	O
,	O
7.2	O
Hz	O
;	O
4.53	O
,	O
7.0	O
Hz	O
)	O
,	O
suggesting	O
the	O
presence	O
of	O
compound	O
3.1B	O
:	O
(	O
3.1B	O
)	O
β	O
-d	O
-G	O
II	O
al	O
p-	O
(	O
1→2	O
)	O
-α	O
-d	O
-G	O

I	O
lc	O
p-	O
(	O
1↔1	O
)	O
-β	O
-d	O
-G	O
II′	O
al	O
p	O
A	O
series	O
of	O
1	O
H	O
chemical	O
shift	O
values	O
of	O
low	O
intensity	O
peaks	O
(	O
Table	O
3	O
)	O
could	O
be	O
assigned	O
from	O
the	O
different	O
2D	O
spectra	O
recorded	O
of	O
Fraction	O
3.1	O
.	O

Evidence	O
for	O
structure	O
3.1B	B
was	O
found	O
in	O
the	O
ROESY	O
spectrum	O
,	O
showing	O
a	O
strong	O
ROE	O
I	O
H-1,II′	O
H-1	O
and	O
a	O
weak	O
ROE	O
II	O
H-1,I	O
H-2	O
.	O

The	O
substitution	O
of	O
Glc	B
at	O
O-2	O
is	O
supported	O
by	O
the	O
chemical	O
shift	O
of	O
the	O
anomeric	O
proton	O
of	O
residue	O
I	O
(	O
α	O
H-1	O
,	O
5.45	O
ppm	O
)	O
which	O
is	O
characteristic	O
for	O
a	O
2-substituted	B
α	I
-	I
Glc	I
residue	O
[	O
8	O
]	O
.	O

No	O
2-substituted	B
hexose	I
was	O
found	O
in	O
the	O
methylation	B
analysis	O
,	O
probably	O
because	O
of	O
the	O
small	O
amount	O
of	O
this	O
compound	O
present	O
in	O
Fraction	O
3.1	O
.	O

2.4	O
Characterization	O
of	O
Fraction	O
4.1	O
Monosaccharide	B
analysis	O
of	O
Fraction	O
4.1	O
revealed	O
the	O
presence	O
of	O
Glc	B
and	O
Gal	B
in	O
a	O
molar	O
ratio	O
of	O
1.3:2.7	O
.	O

In	O
the	O
ESMS	O
spectrum	O
of	O
the	O
sodium	B
borodeuteride	I
-	O
treated	O
and	O
permethylated	O
Fraction	O
4.1	O
,	O
an	O
ion	O
at	O
m	O
/	O
z	O
885	O
was	O
observed	O
,	O
corresponding	O
to	O
[	O
M+Na	O
]	O
+	O
for	O
a	O
nonreduced	O
permethylated	O
Hex4	O
.	O

In	O
the	O
1D	O
1	O
H	O
NMR	O
spectrum	O
of	O
Fraction	O
4.1	O
(	O
Fig.	O
4	O
(	O
A	O
)	O
)	O
two	O
almost	O
equally	O
intense	O
H-1α	O
signals	O
around	O
5.22	O
ppm	O
are	O
present	O
.	O

The	O
TOCSY	O
spectrum	O
showed	O
that	O
both	O
signals	O
belong	O
to	O
Glcp	B
residues	O
.	O

Because	O
these	O
oligosaccharides	B
were	O
synthesized	O
by	O
β	O
-	O
galactosidase	O
action	O
,	O
each	O
oligosaccharide	B
can	O
only	O
contain	O
one	O
Glc	B
unit	O
,	O
and	O
,	O
consequently	O
,	O
this	O
fraction	O
contains	O
at	O
least	O
two	O
components	O
.	O

The	O
H-1β	O
signals	O
were	O
assigned	O
to	O
Galp	B
residues	O
based	O
on	O
their	O
TOCSY	O
spin	O
system	O
.	O

The	O
ROESY	O
spectrum	O
showed	O
for	O
each	O
H-1α	O
signal	O
an	O
interresidual	O
contact	O
to	O
a	O
H-1β	O
signal	O
.	O

One	O
of	O
these	O
β	B
-	I
Galp	I
residues	O
(	O
δ	O
4.571	O
)	O
was	O
not	O
substituted	O
whereas	O
the	O
other	O
(	O
δ	O
4.60	O
)	O
was	O
substituted	O
at	O
O-4	O
(	O
H-4	O
at	O
δ	O
4.18	O
instead	O
of	O
∼3.90	O
;	O
see	O
Table	O
1	O
)	O
.	O

In	O
total	O
,	O
two	O
4-substituted	B
Galp	I
residues	O
were	O
found	O
(	O
H-1	O
,	O
δ	O
4.478	O
with	O
H-4	O
,	O
δ	O
4.18	O
;	O
H-1	O
,	O
δ	O
4.60	O
with	O
H-4	O
,	O
δ	O
4.18	O
)	O
.	O

The	O
typical	O
chemical	O
shifts	O
of	O
two	O
H-1β	O
signals	O
below	O
δ	O
4.50	O
(	O
δ	O
4.478	O
and	O
4.439	O
)	O
indicated	O
the	O
presence	O
of	O
two	O
Galp	B
residues	O
linked	O
to	O
O-4	O
of	O
a	O
Glcp	B
residue	O
[	O
8,12	O
]	O
(	O
structure	O
3.1A	B
)	O
.	O

On	O
the	O
basis	O
of	O
the	O
results	O
above	O
,	O
the	O
following	O
two	O
structures	O
,	O
4.1A	O
and	O
4.1B	O
,	O
can	O
be	O
established:	O
(	O
4.1A	O
)	O
β	B
-d	I
-G	I
III	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p	I
(	O
4.1B	O
)	O
β	B
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
III′	I
al	I
p	I
Specific	O
assignments	O
of	O
the	O
1	O
H	O
and	O
13	O
C	O
resonances	O
of	O
these	O
two	O
compounds	O
,	O
as	O
obtained	O
from	O
TOCSY	O
,	O
ROESY	O
,	O
and	O
seHSQC	O
spectra	O
,	O
are	O
shown	O
in	O
Tables	O
3	O
and	O
4	O
,	O
respectively	O
.	O

1D	O
1	O
H	O
NMR	O
analysis	O
of	O
Fraction	O
4.1	O
shows	O
anomeric	O
signals	O
(	O
δ	O
5.26	O
,	O
5.25	O
,	O
4.68	O
,	O
4.64	O
,	O
4.56	O
,	O
and	O
4.52	O
)	O
of	O
some	O
minor	O
components	O
(	O
ca	O
.	O
10	O
%	O
)	O
that	O
could	O
not	O
be	O
assigned	O
due	O
to	O
the	O
low	O
amounts	O
of	O
the	O
individual	O
components	O
.	O

2.5	O
Characterization	O
of	O
Fraction	O
5.1	O
In	O
view	O
of	O
the	O
foregoing	O
,	O
the	O
presence	O
of	O
different	O
compounds	O
with	O
a	O
(	O
1↔1	O
)	O
glycosidic	O
linkage	O
in	O
Fraction	O
5.1	O
can	O
be	O
expected	O
,	O
and	O
evidence	O
is	O
provided	O
for	O
the	O
occurrence	O
of	O
compounds	O
5.1A	B
,	O
5.1B	B
,	O
and	O
5.1C	B
.	O
(	O
5.1A	B
)	O
β	B
-d	I
-G	I
IV	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
III	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p	I
(	O
5.1B	B
)	O
β	B
-d	I
-G	I
III	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
III′	I
al	I
p	I
(	O
5.1C	B
)	O
β	B
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
III′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
IV′	I
al	I
p	I
In	O
the	O
ESMS	O
spectrum	O
of	O
the	O
sodium	B
borodeuteride	I
-	O
treated	O
and	O
permethylated	O
Fraction	O
5.1	O
,	O
an	O
ion	O
at	O
m	O
/	O
z	O
1089	O
was	O
observed	O
,	O
corresponding	O
to	O
[	O
M+Na	O
]	O
+	O
for	O
a	O
nonreduced	O
permethylated	O
Hex5	O
.	O

In	O
the	O
1D	O
1	O
H	O
NMR	O
spectrum	O
(	O
Fig.	O
4	O
(	O
B	O
)	O
)	O
several	O
groups	O
of	O
anomeric	O
signals	O
are	O
visible	O
.	O

In	O
the	O
H-1α	O
region	O
δ	O
5.21–5.23	O
,	O
three	O
overlapping	O
doublets	O
(	O
3	O
J	O
1,2	O
3–4	O
Hz	O
)	O
at	O
δ	O
5.216	O
,	O
5.221	O
,	O
and	O
5.227	O
are	O
present	O
in	O
a	O
relative	O
abundance	O
of	O
1:0.7:1	O
.	O

Based	O
on	O
TOCSY	O
spectra	O
these	O
three	O
doublets	O
were	O
assigned	O
to	O
α	B
-	I
Glcp	I
residues	O
.	O

The	O
resonances	O
in	O
the	O
H-1β	O
region	O
δ	O
4.4–4.5	O
are	O
indicative	O
of	O
β	B
-	I
Galp	I
residues	O
linked	O
to	O
O-4	O
of	O
α	B
-	I
Glcp	I
residues	O
(	O
see	O
above	O
)	O
.	O

In	O
the	O
1D	O
600	O
and	O
750	O
MHz	O
spectra	O
two	O
doublets	O
are	O
visible	O
at	O
δ	O
4.445	O
and	O
δ	O
4.484	O
,	O
respectively	O
,	O
in	O
the	O
relative	O
intensity	O
of	O
1:3	O
.	O

Comparing	O
the	O
relative	O
intensities	O
of	O
these	O
two	O
anomeric	O
signals	O
with	O
those	O
of	O
the	O
three	O
Glc	B
H-1α	O
resonances	O
,	O
it	O
can	O
be	O
concluded	O
that	O
two	O
signals	O
overlap	O
at	O
δ	O
4.484	O
,	O
since	O
at	O
least	O
three	O
compounds	O
are	O
present	O
in	O
this	O
fraction	O
.	O

By	O
comparing	O
the	O
chemical	O
shift	O
values	O
of	O
Fraction	O
5.1	O
with	O
those	O
obtained	O
for	O
Fractions	O
3.1	O
and	O
4.1	O
,	O
the	O
signal	O
at	O
δ	O
4.445	O
was	O
assigned	O
to	O
terminal	O
β	B
-	I
Galp	I
(	O
compound	O
5.1C	B
)	O
and	O
that	O
at	O
δ	O
4.484	O
to	O
4-substituted	B
β	I
-	I
Galp	I
linked	O
to	O
O-4	O
of	O
α	B
-	I
Glcp	I
(	O
compounds	O
5.1A	B
and	O
5.1B	B
)	O
.	O

According	O
to	O
the	O
ROESY	O
and	O
TOCSY	O
data	O
only	O
terminal	O
and	O
4-substituted	B
β	I
-	I
Galp	I
residues	O
occur	O
in	O
this	O
fraction	O
(	O
terminal	O
β	B
-	I
Galp	I
H-4	O
,	O
δ	O
∼3.90	O
;	O
4-substituted	B
β	I
-	I
Galp	I
H-4	O
,	O
δ	O
∼4.20	O
)	O
,	O
and	O
each	O
α	B
-	I
Glc	I
H-1	O
signal	O
(	O
δ	O
5.216	O
,	O
5.221	O
,	O
5.227	O
;	O
Table	O
3	O
)	O
has	O
an	O
interresidual	O
ROESY	O
cross	O
-	O
peak	O
to	O
a	O
β	B
-	I
Galp	I
H-1	O
resonance	O
.	O

The	O
chemical	O
shift	O
of	O
C-1	O
(	O
δ	O
100.6–100.8	O
;	O
Table	O
4	O
)	O
gives	O
supporting	O
evidence	O
for	O
the	O
substitution	O
of	O
the	O
anomeric	O
centers	O
of	O
the	O
α	B
-	I
Glcp	I
residues	O
.	O

Based	O
on	O
the	O
reasoning	O
presented	O
above	O
,	O
the	O
structure	O
with	O
the	O
β	B
-	I
Gal	I
H-1	O
signal	O
at	O
δ	O
4.445	O
is	O
5.1C	B
.	O

The	O
α	B
-	I
Glc	I
H-1	O
doublet	O
at	O
δ	O
5.216	O
has	O
a	O
ROESY	O
cross	O
-	O
peak	O
with	O
a	O
β	B
-	I
Galp	I
H-1	O
signal	O
at	O
δ	O
4.58	O
.	O

According	O
to	O
the	O
TOCSY	O
spectrum	O
this	O
Galp	B
residue	O
occurs	O
in	O
a	O
terminal	O
position	O
(	O
H-4	O
,	O
δ	O
3.90	O
)	O
,	O
thereby	O
indicating	O
structure	O
5.1A	B
.	O

The	O
third	O
component	O
has	O
structural	O
similarities	O
with	O
5.1A	B
and	O
5.1C	B
(	O
i.e.	O
,	O
the	O
presence	O
of	O
the	O
following	O
structural	O
elements	O
:	O
β	B
-	I
Galp	I
-	I
(	I
1→4	I
)	I
-β	I
-	I
Galp	I
and	I
β	I
-	I
Galp	I
-	I
(	I
1→4	I
)	I
-α	I
-	I
Glcp	I
-	I
(	I
1↔1	I
)	I
-β	I
-	I
Galp	I
)	O
giving	O
rise	O
to	O
overlap	O
in	O
the	O
NMR	O
spectra	O
(	O
compare	O
Table	O
1	O
)	O
.	O

These	O
similarities	O
lead	O
to	O
propose	O
the	O
presence	O
of	O
structure	O
5.1B	B
.	O

2.6	O
Characterization	O
of	O
Fraction	O
6.1	O
Structural	O
analysis	O
of	O
Fraction	O
6.1	O
gave	O
evidence	O
for	O
the	O
occurrence	O
of	O
compounds	O
6.1A	B
,	O
6.1B	B
,	O
6.1C	B
,	O
and	O
6.1D	B
.	O
(	O
6.1A	B
)	O

β	B
-d	I
-G	I
V	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
IV	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
III	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I

-α	B
-d	I
-G	I
I	I
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p	I
(	O
6.1B	B
)	O
β	B
-d	I
-G	I
IV	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
III	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
III′	I
al	I
p	I
(	O
6.1C	B
)	O
β	B
-d	I
-G	I
III	I
al	I
p-	I
(	I
1→4	I
)	I
-β	I
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
III′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
IV′	I
al	I
p	I
(	O
6.1D	B
)	O
β	B
-d	I
-G	I
II	I
al	I
p-	I
(	I
1→4	I
)	I
-α	I
-d	I
-G	I

I	B
lc	I
p-	I
(	I
1↔1	I
)	I
-β	I
-d	I
-G	I
II′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
III′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
IV′	I
al	I
p-	I
(	I
4←1	I
)	I
-β	I
-d	I
-G	I
V′	I
al	I
p	I
Monosaccharide	B
analysis	O
revealed	O
the	O
presence	O
of	O
Gal	B
and	O
Glc	B
in	O
a	O
molar	O
ratio	O
of	O
4.9:1.1	O
.	O

Methylation	B
analysis	O
showed	O
the	O
occurrence	O
of	O
terminal	O
Gal	B
,	O
4-substituted	B
Gal	I
,	O
and	O
4-substituted	B
Glc	I
.	O

In	O
the	O
ESMS	O
spectrum	O
of	O
the	O
sodium	B
borodeuteride	I
-	O
treated	O
and	O
permethylated	O
Fraction	O
6.1	O
,	O
an	O
ion	O
at	O
m	O
/	O
z	O
1293	O
was	O
observed	O
,	O
corresponding	O
to	O
[	O
M+Na	O
]	O
+	O
for	O
a	O
nonreduced	O
permethylated	O
Hex6	O
.	O

TOCSY	O
,	O
ROESY	O
,	O
and	O
seHSQC	O
experiments	O
revealed	O
the	O
presence	O
of	O
the	O
structural	O
elements	O
β	B
-	I
Galp	I
-	I
(	I
1→	I
,	I
→4	I
)	I
-β	I
-	I
Galp	I
-	I
(	I
1→	I
,	I
and	I
→4	I
)	I
-α	I
-	I
Glcp	I
-	I
(	I
1→.	I
In	O
the	O
1D	O
1	O
H	O
NMR	O
spectrum	O
of	O
Fraction	O
6.1	O
(	O
Fig.	O
5	O
)	O
the	O
doublet	O
at	O
δ	O
4.429	O
is	O
characteristic	O
for	O
a	O
terminal	O
β	B
-	I
Galp	I
residue	O
(	O
1→4	O
)	O
-linked	O
to	O
α	B
-	I
Glcp	I
(	O
see	O
compounds	O
5.1C	B
and	O
4.1B	B
)	O
and	O
the	O
doublet	O
with	O
the	O
same	O
intensity	O
at	O
δ	O
3.93	O
is	O
typical	O
for	O
H-4	O
of	O
a	O
terminal	O
β	B
-	I
Galp	I
residue	O
,	O
giving	O
rise	O
to	O
structure	O
6.1D	B
.	O

The	O
H-1α	O
region	O
(	O
δ	O
∼5.23	O
)	O
is	O
composed	O
of	O
three	O
doublets	O
with	O
relative	O
intensities	O
1:2:2	O
,	O
as	O
indicated	O
in	O
Fig.	O
5	O
.	O

According	O
to	O
TOCSY	O
and	O
seHSQC	O
data	O
these	O
doublets	O
belong	O
to	O
α	O
-	O
Glcp	O
H-1	O
atoms	O
.	O

Since	O
each	O
compound	O
can	O
only	O
contain	O
one	O
Glc	B
residue	O
,	O
Fraction	O
6.1	O
contains	O
at	O
least	O
three	O
compounds	O
(	O
see	O
above	O
)	O
.	O

The	O
doublet	O
of	O
6.1D	B
II	O
H-1	O
is	O
hidden	O
in	O
the	O
multiplet	O
around	O
δ	O
∼5.23	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
four	O
instead	O
of	O
three	O
compounds	O
is	O
suggested	O
.	O

The	O
H-1β	O
signal	O
at	O
δ	O
4.582	O
is	O
characteristic	O
for	O
terminal	O
β	B
-	I
Galp	I
,	O
(	O
1↔1	O
)	O
-linked	O
to	O
α	B
-	I
Glcp	I
(	O
H-1	O
,	O
δ	O
5.238	O
)	O
leading	O
to	O
structure	O
6.1A	B
.	O

Compounds	O
6.1B	B
and	O
6.1C	B
have	O
structural	O
similarities	O
with	O
parts	O
of	O
6.1A	B
(	O
and	O
the	O
minor	O
component	O
6.1D	B
)	O
and	O
with	O
each	O
other	O
(	O
i.e.	O
,	O
the	O
occurrence	O
of	O
the	O
following	O
structural	O
elements	O
:	O
(	O
β	B
-	I
Galp	I
-	I
(	I
1→4	I
)	I
)	I
n	I
-β	I
-	I
Galp	I
n	O
=	O
0–2	O
and	O
β	B
-	I
Galp	I
-	I
(	I
1→4	I
)	I
-α	I
-	I
Glcp	I
-	I
(	I
1↔1	I
)	I
-β	I
-	I
Galp	I
)	O
giving	O
rise	O
to	O
overlap	O
in	O
the	O
NMR	O
spectra	O
.	O

By	O
consequence	O
,	O
no	O
complete	O
assignment	O
could	O
be	O
established	O
.	O

Exclusive	O
evidence	O
for	O
their	O
presence	O
is	O
the	O
number	O
of	O
Glc	B
H-1α	O
signals	O
.	O

3	O
3	O
.	O

Discussion	O
This	O
structural	O
study	O
of	O
oligosaccharides	B
produced	O
by	O
the	O
transgalactosylation	O
activity	O
of	O
β	O
-	O
galactosidase	O
using	O
lactose	B
as	O
a	O
substrate	O
,	O
revealed	O
the	O
formation	O
of	O
a	O
series	O
of	O
nonreducing	O
oligosaccharides	B
containing	O
one	O
α	B
-	I
Glcp	I
unit	O
and	O
a	O
variable	O
number	O
of	O
β	B
-	I
Galp	I
units	O
having	O
the	O
structural	O
motif	O
α	B
-	I
d	I
-Glcp	I
-	I
(	I
1↔1	I
)	I
-β	I
-	I
d	I
-Galp	I
in	O
common	O
.	O

It	O
would	O
be	O
interesting	O
to	O
investigate	O
the	O
gastrointestinal	O
effect	O
of	O
galactosylated	B
glucoses	I
with	O
respect	O
to	O
the	O
Glc	B
unit	O
being	O
reducing	O
or	O
not	O
.	O

Interestingly	O
,	O
no	O
β	B
-	I
Glcp	I
was	O
found	O
in	O
the	O
nonreducing	O
oligosaccharides	B
described	O
above	O
.	O

This	O
can	O
be	O
explained	O
by	O
the	O
way	O
the	O
enzyme	O
binds	O
to	O
lactose	B
[	O
13	O
]	O
.	O

According	O
to	O
[	O
13	O
]	O
lactose	B
can	O
be	O
positioned	O
on	O
the	O
enzyme	O
via	O
several	O
hydrophobic	O
contacts	O
and	O
intermolecular	O
hydrogen	B
bonds	O
(	O
Fig.	O
6	O
(	O
A	O
)	O
)	O
to	O
Gal	B
(	O
O-2	O
,	O
O-4	O
,	O
and	O
O-6	O
)	O
and	O
Glc	B
(	O
O-2	O
and	O
O-3	O
)	O
.	O

During	O
the	O
transgalactosylation	O
process	O
,	O
the	O
terminal	O
Gal	B
residue	O
of	O
the	O
galactosyl	B
acceptor	O
is	O
located	O
in	O
the	O
same	O
part	O
of	O
the	O
pocket	O
as	O
Glc	B
in	O
a	O
galactosidase	O
reaction	O
(	O
Fig.	O
6	O
(	O
B	O
)	O
)	O
.	O

Presumably	O
the	O
same	O
intermolecular	O
hydrogen	B
bonds	O
are	O
present	O
,	O
as	O
Gal	B
is	O
the	O
C-4	O
epimer	O
of	O
Glc	B
having	O
a	O
similar	O
orientation	O
of	O
O-2	O
and	O
O-3	O
.	O

This	O
might	O
explain	O
the	O
preference	O
of	O
the	O
enzyme	O
for	O
Gal	B
O-4	O
in	O
transgalactosylation	O
reactions	O
.	O

When	O
the	O
anomeric	O
center	O
of	O
Glc	B
enters	O
the	O
active	O
site	O
as	O
galactosyl	B
acceptor	O
,	O
the	O
orientation	O
of	O
Glc	B
O-1,2,3	O
(	O
Fig.	O
6	O
(	O
B	O
)	O
)	O
depends	O
on	O
the	O
anomeric	O
configuration	O
:	O
for	O
α	B
-	I
Glc	I
the	O
orientation	O
is	O
the	O
same	O
as	O
for	O
Gal	B
O-4,3,2	O
.	O

This	O
is	O
probably	O
the	O
reason	O
for	O
the	O
absence	O
of	O
β	B
-	I
Glc	I
-	O
containing	O
nonreducing	O
oligosaccharides	B
.	O

4	O
4	O
.	O

Experimental	O
4.1	O
Model	O
compounds	O
Galactobiose	B
to	O
pentaose	B
(	O
1	O
–4	O
)	O
were	O
generated	O
by	O
a	O
controlled	O
digestion	O
of	O
soy	O
arabinogalactan	B
using	O
endogalactanase	O
from	O
A.	O
niger	O
[	O
14	O
]	O
,	O
then	O
isolated	O
via	O
gel	O
-	O
permeation	O
chromatography	O
on	O
Bio	O
-	O
Gel	O
P-2	O
,	O
when	O
necessary	O
combined	O
with	O
HPAEC	O
on	O
CarboPac	O
PA-100	O
[	O
15	O
]	O
.	O

4.2	O
Trans	O
-	O
galacto	B
-	I
oligosaccharides	I
A	O
mixture	O
of	O
galactosylated	B
glucoses	I
,	O
produced	O
by	O
a	O
pure	O
β	O
-	O
galactosidase	O
using	O
lactose	B
as	O
substrate	O
,	O
was	O
a	O
gift	O
of	O
Borculo	O
Whey	O
Products	O
(	O
Borculo	O
,	O
The	O
Netherlands	O
)	O
.	O

The	O
sample	O
supplied	O
stemmed	O
from	O
an	O
incubation	O
mixture	O
from	O
which	O
most	O
of	O
the	O
free	O
Gal	B
and	O
Glc	B
and	O
some	O
di-	B
and	O
trisaccharide	B
material	O
had	O
been	O
removed	O
by	O
charcoal	B
column	O
chromatography	O
.	O

Inspection	O
of	O
the	O
sample	O
using	O
gel	O
-	O
permeation	O
chromatography	O
on	O
Bio	O
-	O
Gel	O
P-2	O
showed	O
that	O
the	O
material	O
consisted	O
of	O
di-	B
through	O
hexasaccharides	B
in	O
a	O
relative	O
abundance	O
of	O
3	O
,	O
6	O
,	O
17	O
,	O
37	O
,	O
and	O
26	O
%	O
,	O
respectively	O
,	O
whereas	O
11	O
%	O
of	O
the	O
material	O
consisted	O
of	O
larger	O
oligomers	B
.	O

The	O
non	O
-	O
reducing	O
oligosaccharide	B
-	O
containing	O
fractions	O
comprised	O
0.3	O
,	O
0.3	O
,	O
0.5	O
,	O
4.6	O
,	O
2.6	O
%	O
of	O
di-	B
through	O
hexasaccharides	B
,	O
respectively	O
,	O
in	O
the	O
total	O
mixture	O
of	O
oligosaccharides	B
.	O

4.3	O
Purification	O
of	O
the	O
galactosylated	B
glucoses	I
sample	O
The	O
galactosylated	B
glucoses	I
sample	O
was	O
fractionated	O
on	O
two	O
connected	O
columns	O
(	O
each	O
600	O
×	O
26	O
mm	O
)	O
packed	O
with	O
Fractogel	O
TSK	O
HW-40	O
(	O
S	O
)	O
(	O
25–40	O
μm	O
,	O
E.	O
Merck	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
,	O
thermostated	O
at	O
60	O
°	O
C	O
and	O
eluted	O
with	O
water	B
(	O
2	O
mL	O
/	O
min	O
)	O
,	O
using	O
a	O
Pharmacia	O
Hiload	O
system	O
equipped	O
with	O
a	O
Pharmacia	O
P50	O
pump	O
.	O

A	O
Shodex	O
RI-72	O
detector	O
was	O
used	O
to	O
monitor	O
the	O
refractive	O
index	O
.	O

The	O
various	O
fractions	O
were	O
subfractionated	O
on	O
a	O
Bio	O
-	O
Gel	O
P-2	O
column	O
(	O
100	O
×	O
2.8	O
cm	O
)	O
at	O
60	O
°	O
C	O
,	O
eluted	O
with	O
water	B
;	O
the	O
elution	O
profile	O
was	O
established	O
via	O
an	O
auto	O
-	O
analyser	O
(	O
Skalar	O
Analytical	O
BV	O
,	O
Breda	O
,	O
The	O
Netherlands	O
)	O
using	O
the	O
orcinol	O
–	O
H2	O
SO4	O
assay	O
for	O
neutral	O
sugars	B
[	O
16	O
]	O
.	O

Further	O
fractionation	O
of	O
Bio	O
-	O
Gel	O
P-2	O
fractions	O
was	O
performed	O
by	O
HPAEC	O
on	O
a	O
preparative	O
(	O
Fractions	O
2	O
,	O
3	O
,	O
and	O
6	O
)	O
or	O
a	O
semi	O
-	O
analytical	O
(	O
Fractions	O
4	O
and	O
5	O
)	O
scale	O
.	O

Preparative	O
HPAEC	O
was	O
performed	O
using	O
a	O
Spectra	O
Physics	O
P4000	O
pump	O
equipped	O
with	O
a	O
CarboPac	O
PA-100	O
column	O
(	O
250	O
×	O
22	O
mm	O
)	O
and	O
coupled	O
with	O
a	O
Spectra	O
Physics	O
AS3000	O
autosampler	O
(	O
900	O
μL	O
samples	O
;	O
flow	O
rate	O
,	O
20	O
mL	O
/	O
min	O
)	O
and	O
a	O
pulsed	O
electrochemical	O
detector	O
(	O
PED	O
)	O
.	O

Gradients	O
were	O
optimized	O
for	O
each	O
sample	O
using	O
0.2	O
M	O
NaOH	B
,	O
2	O
M	O
NaOAc	B
in	O
0.2	O
M	O
NaOH	B
and	O
Millipore	O
water	B
as	O
eluents	O
.	O

The	O
effluent	O
actually	O
passing	O
the	O
detector	O
was	O
reduced	O
to	O
1	O
mL	O
/	O
min	O
by	O
splitting	O
the	O
effluent	O
post	O
-	O
column	O
,	O
and	O
10	O
mL	O
fractions	O
were	O
collected	O
and	O
immediately	O
neutralized	O
by	O
on	O
-	O
line	O
addition	O
of	O
1	O
M	O
HOAc	B
.	O

Relevant	O
fractions	O
were	O
concentrated	O
and	O
desalted	O
on	O
a	O
Sephadex	O
G-10	O
column	O
(	O
600	O
×	O
50	O
mm	O
)	O
using	O
distilled	O
water	B
as	O
eluent	O
(	O
RI	O
detection	O
)	O
.	O

The	O
purity	O
of	O
the	O
oligosaccharides	B
was	O
checked	O
by	O
analytical	O
HPAEC	O
.	O

Semi	O
-	O
preparative	O
HPAEC	O
was	O
performed	O
using	O
a	O
Dionex	O
LC	O
system	O
with	O
pulsed	O
amperometric	O
detection	O
(	O
PAD	O
)	O
,	O
equipped	O
with	O
a	O
CarboPac	O
PA-1	O
column	O
(	O
250	O
mm	O
×	O
9	O
mm	O
)	O
,	O
eluted	O
with	O
a	O
gradient	O
of	O
NaOAc	B
in	O
0.1	O
M	O
NaOH	B
at	O
a	O
flow	O
rate	O
of	O
4	O
mL	O
/	O
min	O
.	O

PAD	O
-	O
detection	O
was	O
carried	O
out	O
with	O
a	O
gold	B
working	O
electrode	O
and	O
triple	O
-	O
pulse	O
amperometry	O
was	O
used	O
.	O

Immediately	O
after	O
collection	O
,	O
fractions	O
were	O
neutralized	O
manually	O
with	O
aq	O
99	O
%	O
HOAc	B
,	O
followed	O
by	O
desalting	O
on	O
a	O
Dowex	O
AG	O
50W	O
-	O
X12	O
(	O
100–200	O
mesh	O
,	O
H+	O
-form	O
,	O
Bio	O
-	O
Rad	O
)	O
column	O
(	O
RI	O
detection	O
)	O
using	O
distilled	O
water	B
as	O
eluent	O
,	O
and	O
subsequent	O
lyophilization	O
.	O

4.4	O
Gas	O
–	O
liquid	O
chromatography	O
GLC	O
analyses	O
were	O
performed	O
on	O
a	O
Chrompack	O
CP9002	O
gas	O
chromatograph	O
,	O
equipped	O
with	O
a	O
CP	O
-	O
Sil	O
5	O
CB	O
DFc.25	O
(	O
Chrompack	O
)	O
capillary	O
column	O
(	O
25	O
m	O
×	O
0.32	O
mm	O
)	O
using	O
a	O
temperature	O
program	O
of	O
130–230	O
°	O
C	O
at	O
4	O
°	O
C	O
/	O
min	O
.	O

4.5	O
Monosaccharide	B
analysis	O
Oligosaccharides	B
were	O
subjected	O
to	O
methanolysis	B
(	O
methanolic	B
1	O
M	O
HCl	B
,	O
18	O
h	O
,	O
85	O
°	O
C	O
)	O
,	O
and	O
the	O
resulting	O
mixtures	O
of	O
methyl	B
glycosides	I
were	O
trimethylsilylated	B
with	O
1:1:5	O
hexamethyldisilazane	B
–	O
trimethylchlorosilane	B
–	O
pyridine	B
,	O
and	O
quantitatively	O
analyzed	O
by	O
GLC	O
[	O
17	O
]	O
.	O

4.6	O
Methylation	B
analysis	O
Samples	O
were	O
dissolved	O
in	O
0.5	O
M	O
NH4	B
OH	I
(	O
250	O
μL	O
)	O
containing	O
NaBD4	B
(	O
10	O
mg	O
/	O
mL	O
)	O
.	O

After	O
1	O
h	O
,	O
the	O
mixture	O
was	O
neutralized	O
with	O
aq	O
99	O
%	O
HOAc	B
,	O
then	O
concentrated	O
.	O

Boric	B
acid	I
was	O
removed	O
by	O
repetitive	O
co	O
-	O
evaporation	O
with	O
9:1	O
MeOH	B
–	O
HOAc	B
and	O
MeOH	B
.	O

Permethylation	O
was	O
carried	O
out	O
essentially	O
as	O
described	O
[	O
18	O
]	O
.	O

Briefly	O
,	O
freshly	O
ground	O
NaOH	B
pellets	O
(	O
250	O
mg	O
)	O
were	O
added	O
to	O
solutions	O
of	O
samples	O
in	O
Me2	B
SO	I
(	O
200	O
μL	O
)	O
,	O
and	O
portions	O
of	O
MeI	B
(	O
250	O
μL	O
)	O
were	O
added	O
after	O
5	O
,	O
15	O
,	O
and	O
25	O
min	O
.	O

The	O
reaction	O
was	O
stopped	O
after	O
20	O
min	O
by	O
adding	O
aq	O
Na2	B
S2	I
O3	I
(	O
1	O
mL	O
,	O
100	O
mg	O
/	O
mL	O
)	O
and	O
CHCl3	B
(	O
1	O
mL	O
)	O
.	O

The	O
chloroform	B
layer	O
was	O
extracted	O
with	O
water	B
(	O
3	O
×	O
0.5	O
mL	O
)	O
,	O
then	O
concentrated	O
.	O

After	O
hydrolysis	O
with	O
2	O
M	O
CF3	B
COOH	I
(	O
0.3	O
mL	O
;	O
120	O
°	O
C	O
,	O
1	O
h	O
)	O
,	O
reduction	O
(	O
see	O
above	O
)	O
,	O
acetylation	B
with	O
Ac2	B
O	I
(	O
0.5	O
mL	O
;	O
120	O
°	O
C	O
,	O
3	O
h	O
)	O
,	O
quenching	O
with	O
water	B
(	O
0.5	O
mL	O
)	O
,	O
and	O
neutralization	O
with	O
NaHCO3	B
,	O
the	O
partially	B
methylated	I
alditol	I
acetates	I
were	O
extracted	O
with	O
CH2	B
Cl2	I
(	O
3	O
×	O
0.7	O
mL	O
)	O
.	O

After	O
concentration	O
to	O
about	O
20	O
μL	O
(	O
N2	B
)	O
,	O
samples	O
were	O
analyzed	O
by	O
GLC	O
and	O
GLC	O
–	O
EIMS	O
.	O

4.7	O
Gas	O
–	O
liquid	O
chromatography	O
–	O
electron	O
impact	O
mass	O
spectrometry	O
(	O
GLC	O
–	O
EIMS	O
)	O
GLC	O
–	O
EIMS	O
analyses	O
were	O
carried	O
out	O
on	O
a	O
Fisons	O
MD800	O
/	O
8060	O
system	O
(	O
electron	O
energy	O
,	O
70	O
eV	O
;	O
carrier	O
gas	O
,	O
He	B
)	O
equipped	O
with	O
a	O
DB-1	O
fused	O
-	O
silica	B
capillary	O
column	O
(	O
30	O
m	O
×	O
0.32	O
mm	O
,	O
J&W	O
Scientific	O
)	O
using	O
a	O
temperature	O
program	O
of	O
110–240	O
°	O
C	O
at	O
4	O
°	O
C	O
/	O
min	O
followed	O
by	O
isothermal	O
elution	O
for	O
3	O
min	O
.	O

4.8	O
Mass	O
spectrometry	O
Approximately	O
10–25	O
%	O
of	O
the	O
total	O
amount	O
of	O
each	O
fraction	O
was	O
used	O
for	O
mass	O
spectrometric	O
analysis	O
.	O

NaBD4	B
-treated	O
and	O
permethylated	O
carbohydrates	B
were	O
dissolved	O
in	O
1:1	O
MeOH	B
–	O
aq	O
1	O
%	O
HCOOH	B
(	O
100	O
μL	O
)	O
for	O
ESMS	O
.	O

Positive	O
-	O
ion	O
mode	O
ES	O
mass	O
spectra	O
were	O
obtained	O
using	O
a	O
VG	O
Platform	O
II	O
single	O
quadrupole	O
mass	O
spectrometer	O
.	O

Aliquots	O
of	O
10	O
μL	O
of	O
the	O
samples	O
were	O
infused	O
into	O
a	O
mobile	O
phase	O
of	O
1:1	O
MeOH	B
–	O
aq	O
1	O
%	O
HCOOH	B
and	O
introduced	O
into	O
the	O
electrospray	O
source	O
at	O
a	O
flow	O
rate	O
of	O
5	O
μL	O
/	O
min	O
.	O

Spectra	O
were	O
scanned	O
at	O
a	O
speed	O
of	O
8	O
s	O
for	O
m	O
/	O
z	O
200–2000	O
,	O
with	O
a	O
cone	O
voltage	O
of	O
95	O
V	O
,	O
recorded	O
and	O
processed	O
using	O
the	O
MassLynx	O
software	O
,	O
version	O
2.0	O
.	O

Mass	O
calibration	O
was	O
performed	O
by	O
multiple	O
-	O
ion	O
monitoring	O
of	O
peracetylated	B
malto	I
-	I
oligosaccharides	I
.	O

FABMS	O
was	O
carried	O
out	O
using	O
a	O
Jeol	O
JMS	O
-	O
SX	O
/	O
SX102A	O
tandem	O
mass	O
spectrometer	O
(	O
BEBE	O
geometry	O
)	O
at	O
10	O
kV	O
accelerating	O
voltage	O
.	O

A	O
Xe	B
beam	O
of	O
about	O
6	O
kV	O
translational	O
energy	O
(	O
gun	O
current	O
10	O
mA	O
)	O
was	O
used	O
for	O
FAB	O
ionization	O
.	O

The	O
CID	O
tandem	O
mass	O
spectra	O
were	O
obtained	O
by	O
using	O
the	O
collision	O
cell	O
in	O
the	O
third	O
field	O
free	O
region	O
of	O
the	O
mass	O
spectrometer	O
with	O
air	O
as	O
collision	O
gas	O
at	O
a	O
pressure	O
sufficient	O
to	O
reduce	O
the	O
intensity	O
of	O
the	O
selected	O
ion	O
beam	O
by	O
50	O
%	O
.	O

As	O
the	O
collision	O
cell	O
was	O
held	O
at	O
ground	O
potential	O
,	O
the	O
collision	O
energy	O
in	O
the	O
MS	O
-	O
MS	O
experiments	O
was	O
10	O
keV.	O
Spectra	O
were	O
scanned	O
at	O
a	O
speed	O
of	O
30	O
s	O
for	O
the	O
full	O
mass	O
range	O
specified	O
by	O
the	O
accelerating	O
voltage	O
used	O
,	O
recorded	O
and	O
averaged	O
using	O
a	O
Hewlett	O
–	O
Packard	O
HP9000	O
data	O
system	O
running	O
Jeol	O
complement	O
software	O
.	O

NaBD4	B
-treated	O
and	O
permethylated	O
carbohydrates	B
were	O
dissolved	O
in	O
10	O
μL	O
MeOH	B
and	O
about	O
1	O
μL	O
of	O
the	O
solution	O
was	O
mixed	O
with	O
0.8	O
μL	O
thioglycerol	B
matrix	O
on	O
the	O
probe	O
tip	O
.	O

4.9	O
NMR	O
spectroscopy	O
Prior	O
to	O
NMR	O
analysis	O
samples	O
were	O
exchanged	O
twice	O
in	O
D2	B
O	I
(	O
99.9	O
atom%	O
D	O
,	O
Cambridge	O
Isotope	O
Laboratories	O
,	O
MA	O
,	O
USA	O
)	O
and	O
then	O
dissolved	O
in	O
D2	B
O	I
(	O
99.96	O
atom%	O
D	O
,	O
Isotec	O
,	O
USA	O
)	O
.	O

NMR	O
spectra	O
were	O
recorded	O
on	O
Bruker	O
AC-300	O
(	O
Department	O
of	O
Organic	O
Chemistry	O
,	O
Utrecht	O
University	O
)	O
,	O
Bruker	O
AMX-500	O
(	O
Bijvoet	O
Center	O
,	O
Utrecht	O
University	O
)	O
,	O
Bruker	O
AMX-600	O
(	O
Bijvoet	O
Center	O
,	O
Utrecht	O
University	O
or	O
NSR	O
Center	O
,	O
University	O
of	O
Nijmegen	O
)	O
or	O
Varian	O
UNITY	O
-	O
plus	O
750	O
(	O
Bijvoet	O
Center	O
,	O
Utrecht	O
University	O
)	O
instruments	O
at	O
probe	O
temperatures	O
of	O
27	O
or	O
5	O
°	O
C	O
.	O

Chemical	O
shifts	O
for	O
1	O
H	O
are	O
expressed	O
in	O
ppm	O
relative	O
to	O
internal	O
acetone	B
(	O
δ	O
2.225	O
)	O
or	O
acetate	B
(	O
δ	O
1.908	O
)	O
,	O
and	O
for	O
13	O
C	O
to	O
external	O
glucose	B
(	O
δ	O
Glcp	B
C-1α	O
92.9	O
,	O
Glcp	B
C-1β	O
96.7	O
[	O
12	O
]	O
.	O

1D	O
1	O
H	O
NMR	O
spectra	O
were	O
recorded	O
with	O
a	O
sweep	O
width	O
of	O
5000	O
Hz	O
at	O
500	O
MHz	O
or	O
6000	O
Hz	O
at	O
600	O
MHz	O
in	O
data	O
sets	O
of	O
16,384	O
points	O
.	O

Suppression	O
of	O
the	O
HOD	B
signal	O
was	O
achieved	O
by	O
applying	O
the	O
WEFT	O
pulse	O
as	O
described	O
[	O
19	O
]	O
.	O

Proton	O
decoupled	O
13	O
C	O
NMR	O
spectra	O
were	O
acquired	O
at	O
75.469	O
MHz	O
.	O

Typically	O
,	O
50,000	O
transients	O
of	O
16,384	O
data	O
points	O
were	O
recorded	O
.	O

All	O
2D	O
NMR	O
spectra	O
employed	O
the	O
time	O
-	O
proportional	O
phase	O
increment	O
(	O
TPPI	O
)	O
method	O
[	O
20	O
]	O
.	O

Only	O
seHSQC	O
used	O
the	O
STATES	O
-	O
TPPI	O
method	O
[	O
21	O
]	O
.	O

In	O
the	O
2D	O
homonuclear	O
proton	O
NMR	O
spectra	O
the	O
HOD	B
signal	O
was	O
suppressed	O
using	O
presaturation	O
during	O
a	O
relaxation	O
delay	O
for	O
1	O
s.	O
2D	O
TOCSY	O
spectra	O
were	O
acquired	O
using	O
MLEV	O
17	O
mixing	O
sequences	O
of	O
20–100	O
ms	O
preceded	O
by	O
a	O
trim	O
pulse	O
of	O
2.5	O
ms	O
.	O

The	O
spin	O
-	O
lock	O
field	O
strength	O
corresponded	O
with	O
a	O
90	O
°	O
pulse	O
of	O
25–30	O
μs	O
and	O
the	O
spectral	O
width	O
was	O
between	O
4	O
and	O
6	O
ppm	O
in	O
each	O
dimension	O
.	O

Typically	O
,	O
400–512	O
experiments	O
of	O
2048	O
points	O
were	O
acquired	O
with	O
4–32	O
scans	O
per	O
increment	O
.	O

2D	O
DQF	O
-	O
COSY	O
spectra	O
were	O
recorded	O
with	O
a	O
spectral	O
width	O
as	O
in	O
the	O
2D	O
TOCSY	O
spectra	O
.	O

Typically	O
,	O
400–512	O
free	O
induction	O
decays	O
,	O
each	O
acquired	O
as	O
8	O
or	O
16	O
transients	O
of	O
2048	O
data	O
points	O
were	O
recorded	O
.	O

2D	O
ROESY	O
spectra	O
were	O
obtained	O
with	O
a	O
mixing	O
time	O
of	O
200–250	O
ms	O
.	O

The	O
spin	O
-	O
lock	O
field	O
strength	O
was	O
in	O
accordance	O
with	O
a	O
90	O
°	O
pulse	O
of	O
100–120	O
μs	O
.	O

The	O
spectral	O
width	O
corresponded	O
with	O
5–7	O
ppm	O
in	O
each	O
dimension	O
.	O

Typically	O
,	O
400–512	O
experiments	O
of	O
2048	O
points	O
were	O
acquired	O
with	O
32–64	O
scans	O
per	O
increment	O
.	O

The	O
frequency	O
offset	O
was	O
initially	O
placed	O
on	O
the	O
HOD	B
resonance	O
and	O
switched	O
to	O
about	O
5.7	O
ppm	O
just	O
before	O
application	O
of	O
the	O
spin	O
-	O
lock	O
pulse	O
thereby	O
reducing	O
the	O
Hartmann	O
–	O
Hahn	O
transfer	O
during	O
the	O
ROE	O
mixing	O
time	O
[	O
22	O
]	O
.	O

2D	O
sensitivity	O
enhanced	O
HSQC	O
spectra	O
were	O
proton	O
detected	O
and	O
two	O
gradients	O
were	O
applied	O
for	O
13	O
C	O
coherence	O
selection	O
.	O

These	O
spectra	O
were	O
acquired	O
with	O
the	O
proton	O
offset	O
at	O
about	O
4.6	O
ppm	O
and	O
a	O
sweepwidth	O
of	O
about	O
6	O
ppm	O
.	O

In	O
the	O
13	O
C	O
dimension	O
the	O
offset	O
was	O
placed	O
around	O
80	O
ppm	O
and	O
a	O
sweep	O
width	O
of	O
60	O
ppm	O
was	O
used	O
.	O

Typically	O
,	O
300–350	O
free	O
induction	O
decays	O
of	O
1024	O
data	O
points	O
were	O
acquired	O
using	O
128–256	O
scans	O
per	O
decay	O
.	O

2D	O
HMBC	O
spectra	O
were	O
recorded	O
essentially	O
as	O
the	O
2D	O
seHSQC	O
spectra	O
.	O

The	O
delay	O
for	O
the	O
evolution	O
of	O
the	O
long	O
range	O
couplings	O
was	O
40–50	O
ms	O
.	O

NMR	O
data	O
sets	O
were	O
processed	O
using	O
Bruker	O
UXNMR	O
software	O
or	O
the	O
Triton	O
NMR	O
software	O
package	O
(	O
Bijvoet	O
Center	O
,	O
Utrecht	O
University	O
)	O
.	O

Briefly	O
,	O
time	O
domain	O
data	O
were	O
multiplied	O
by	O
phase	O
-	O
shifted	O
(	O
squared-	O
)	O
sine	O
-	O
bell	O
functions	O
or	O
with	O
a	O
Lorentzian	O
-	O
to	O
-	O
Gaussian	O
multiplication	O
.	O

After	O
zerofilling	O
and	O
Fourier	O
transformation	O
datasets	O
of	O
1024	O
×	O
1024	O
or	O
2048	O
×	O
1024	O
points	O
were	O
obtained	O
,	O
which	O
were	O
baseline	O
corrected	O
with	O
a	O
fourth	O
-	O
order	O
polynomial	O
function	O
when	O
necessary	O
.	O

Accurate	O
chemical	O
shift	O
values	O
obtained	O
from	O
1D	O
spectra	O
are	O
represented	O
with	O
three	O
(	O
protons	O
)	O
or	O
two	O
(	O
carbons	O
)	O
decimals	O
,	O
whereas	O
values	O
obtained	O
from	O
2D	O
spectra	O
are	O
depicted	O
with	O
two	O
(	O
protons	O
)	O
or	O
one	O
(	O
carbon	B
)	O
decimals	O
.	O

Acknowledgements	O
The	O
authors	O
thank	O
Dr.	O
R.W.	O
Wechselberger	O
(	O
Bijvoet	O
Center	O
,	O
Department	O
of	O
NMR	O
Spectroscopy	O
,	O
Utrecht	O
University	O
,	O
The	O
Netherlands	O
)	O
for	O
recording	O
the	O
1D	O
1	O
H	O
NMR	O
spectra	O
using	O
the	O
Varian	O
Unity	O
plus	O
750	O
instrument	O
.	O

This	O
research	O
was	O
supported	O
by	O
the	O
Dutch	O
Technology	O
Foundation	O
(	O
NWO	O
/	O
STW	O
)	O
,	O
Gist	O
-	O
brocades	O
,	O
The	O
Product	O
Board	O
for	O
Feeding	O
Stuffs	O
(	O
VVR	O
)	O
,	O
and	O
Borculo	O
Whey	O
Products	O
.	O

Activity	O
-	O
guided	O
fractionation	O
of	O
the	O
roots	O
of	O
Anthriscus	O
sylvestris	O
resulted	O
in	O
the	O
isolation	O
and	O
characterization	O
of	O
five	O
cytotoxic	O
compounds	O
,	O
deoxypodophyllotoxin	B
(	O
1	O
)	O
,	O
falcarindiol	B
(	O
2	O
)	O
,	O
and	O
angeloyl	B
podophyllotoxin	I
(	O
5	O
)	O
from	O
the	O
hexane	B
soluble	O
fraction	O
and	O
morelensin	B
(	O
3	O
)	O
,	O
bursehernin	B
(	O
4	O
)	O
from	O
the	O
chloroform	B
soluble	O
fraction	O
.	O

It	O
is	O
the	O
first	O
report	O
of	O
the	O
occurrence	O
of	O
compound	B
5	I
in	O
nature	O
.	O

BACKGROUND	O
:	O
Vegetarians	O
have	O
lower	O
platelet	O
and	O
plasma	O
concentrations	O
of	O
n-3	B
polyunsaturated	I
fatty	I
acids	I
(	O
PUFAs	B
)	O
than	O
do	O
omnivores	O
.	O

We	O
recently	O
showed	O
that	O
male	O
vegetarians	O
have	O
higher	O
platelet	O
aggregability	O
than	O
do	O
omnivores	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
whether	O
male	O
vegetarians	O
(	O
n	O
=	O
17	O
)	O
who	O
consumed	O
an	O
increased	O
amount	O
of	O
dietary	O
alpha	B
-	I
linolenic	I
acid	I
(	O
ALA	B
)	O
showed	O
any	O
changes	O
in	O
their	O
tissue	O
profile	O
of	O
PUFAs	B
,	O
plasma	O
thromboxane	B
concentrations	O
,	O
platelet	O
aggregability	O
,	O
or	O
hemostatic	O
factors	O
.	O

DESIGN	O
:	O
During	O
the	O
study	O
,	O
all	O
subjects	O
maintained	O
their	O
habitual	O
vegetarian	O
diets	O
except	O
that	O
a	O
proportion	O
of	O
dietary	O
fat	B
was	O
replaced	O
with	O
vegetable	B
oils	I
and	O
margarines	O
that	O
were	O
provided	O
.	O

Initially	O
,	O
all	O
subjects	O
consumed	O
a	O
low	O
-	O
ALA	B
diet	O
(	O
containing	O
safflower	B
oil	I
and	O
safflower	B
oil	I
-	I
based	I
margarine	I
)	O
for	O
14	O
d	O
;	O
they	O
then	O
consumed	O
either	O
a	O
moderate	O
-	O
ALA	B
diet	O
(	O
containing	O
canola	B
oil	I
and	O
canola	B
oil	I
-	I
based	I
margarine	I
)	O
or	O
a	O
high	O
-	O
ALA	B
diet	O
(	O
containing	O
linseed	B
oil	I
and	O
linseed	B
oil	I
-	I
based	I
margarine	I
)	O
for	O
28	O
d.	O
Blood	O
samples	O
were	O
collected	O
at	O
day	O
0	O
(	O
baseline	O
)	O
,	O
day	O
14	O
,	O
and	O
day	O
42	O
.	O

RESULTS	O
:	O
Eicosapentaenoic	B
acid	I
,	O
docosapentaenoic	B
acid	I
,	O
total	O
n-3	B
PUFAs	I
,	O
and	O
the	O
ratio	O
of	O
n-3	B
to	O
n-6	B
PUFAs	I
were	O
significantly	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
the	O
ratio	O
of	O
arachidonic	B
acid	I
to	O
eicosapentaenoic	B
acid	I
was	O
decreased	O
(	O
P	O
<	O
0.05	O
)	O
,	O
in	O
platelet	O
phospholipids	B
,	O
plasma	O
phospholipids	B
,	O
and	O
triacylglycerols	B
after	O
either	O
the	O
moderate	O
-	O
ALA	B
or	O
high	O
-	O
ALA	B
diet	O
compared	O
with	O
the	O
low	O
-	O
ALA	B
diet	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
thrombotic	O
risk	O
factors	O
.	O

CONCLUSION	O
:	O
ALA	B
from	O
vegetable	B
oils	I
(	O
canola	O
and	O
linseed	O
)	O
has	O
a	O
beneficial	O
effect	O
on	O
n-3	B
PUFA	I
concentrations	O
of	O
platelet	O
phospholipids	B
and	O
plasma	O
lipids	B
in	O
vegetarian	O
males	O
.	O

Organic	O
nitrate	B
esters	I
,	I
such	O
as	O
glyceryl	B
trinitrate	I
and	O
isosorbide	B
dinitrate	I
,	O
are	O
a	O
class	O
of	O
compounds	O
used	O
to	O
treat	O
a	O
variety	O
of	O
vascular	O
ailments	O
.	O

Their	O
effectiveness	O
relies	O
on	O
their	O
ability	O
to	O
be	O
bioactivated	O
to	O
nitric	B
oxide	I
(	O
NO	B
)	O
which	O
,	O
in	O
turn	O
,	O
relaxes	O
vascular	O
smooth	O
muscle	O
.	O

Although	O
there	O
have	O
been	O
many	O
biological	O
studies	O
that	O
indicate	O
that	O
NO	B
can	O
be	O
formed	O
from	O
organic	O
nitrate	B
esters	I
in	O
a	O
biological	O
environment	O
,	O
the	O
chemical	O
mechanism	O
by	O
which	O
this	O
occurs	O
has	O
yet	O
to	O
be	O
established	O
.	O

Previous	O
studies	O
have	O
implicated	O
both	O
flavins	B
and	O
thiols	B
in	O
organic	O
nitrate	B
ester	I
bioactivation	O
.	O

Thus	O
,	O
we	O
examined	O
the	O
chemical	O
interactions	O
of	O
flavins	B
and	O
thiols	B
with	O
organic	O
nitrate	B
esters	I
as	O
a	O
means	O
of	O
determining	O
the	O
role	O
these	O
species	O
may	O
play	O
in	O
NO	B
production	O
.	O

Based	O
on	O
these	O
studies	O
we	O
concluded	O
that	O
a	O
reasonable	O
chemical	O
mechanism	O
for	O
organic	O
nitrate	B
ester	I
bioactivation	O
involves	O
reduction	O
to	O
the	O
organic	O
nitrite	B
ester	I
followed	O
by	O
conversion	O
to	O
a	O
nitrosothiol	B
.	O

The	O
release	O
of	O
NO	B
from	O
nitrosothiols	B
can	O
occur	O
via	O
a	O
variety	O
of	O
processes	O
including	O
reaction	O
with	O
dihydroflavins	B
and	O
NADH	B
.	O

Plant	O
cell	O
suspension	O
cultures	O
of	O
Rauwolfia	O
produce	O
within	O
1	O
week	O
approximately	O
250	O
nkat	O
/	O
l	O
of	O
raucaffricine	O
-	O
O	O
-	O
beta	O
-	O
D	O
-	O
glucosidase	O
.	O

A	O
five	O
step	O
procedure	O
using	O
anion	B
exchange	O
chromatography	O
,	O
chromatography	O
on	O
hydroxylapatite	B
,	O
gel	O
filtration	O
and	O
FPLC	O
-	O
chromatography	O
on	O
Mono	B
Q	I
and	O
Mono	B
P	I
delivered	O
in	O
a	O
yield	O
of	O
0.9	O
%	O
approximately	O
1200-fold	O
enriched	O
glucosidase	O
.	O

A	O
short	O
protocol	O
employing	O
DEAE	B
sepharose	I
,	O
TSK	B
55	I
S	I
gel	I
chromatography	O
and	O
purification	O
on	O
Mono	B
Q	I
gave	O
a	O
5	O
%	O
recovery	O
of	O
glucosidase	O
which	O
was	O
340-fold	O
enriched	O
.	O

SDS	O
-	O
PAGE	O
showed	O
a	O
Mr	O
for	O
the	O
enzyme	O
of	O
61	O
kDa	O
.	O

The	O
enzyme	O
is	O
not	O
glycosylated	O
.	O

Structural	O
investigation	O
of	O
the	O
enzyme	O
product	O
,	O
vomilenine	B
,	O
demonstrated	O
that	O
the	O
alkaloid	B
exists	O
in	O
aqueous	B
solutions	I
in	O
an	O
equilibrium	O
of	O
21	B
(	I
R	I
)	I
-	I
and	O
21	B
(	I
S	I
)	I
-vomilenine	I
in	O
a	O
ratio	O
of	O
3.4:1	O
.	O

Proteolysis	O
of	O
the	O
pure	O
enzyme	O
with	O
endoproteinase	O
Lys	O
C	O
revealed	O
six	O
peptide	B
fragments	O
with	O
6	O
-	O
24	O
amino	B
acids	I
which	O
were	O
sequenced	O
.	O

The	O
two	O
largest	O
fragments	O
showed	O
sequences	O
,	O
of	O
which	O
the	O
motif	O
Val	B
-	I
Thr	I
-	I
Glu	I
-	I
Asn	I
-	I
Gly	I
is	O
typical	O
for	O
beta	O
-	O
glucosidases	O
.	O

Sequence	O
alignment	O
of	O
these	O
fragments	O
demonstrated	O
high	O
homologies	O
to	O
linamarase	O
from	O
Manihot	O
esculenta	O
(	O
81	O
%	O
identity	O
)	O
or	O
to	O
beta	O
-	O
glucosidase	O
from	O
Prunus	O
avium	O
(	O
79	O
%	O
identity	O
)	O
.	O

Raucaffricine	O
-	O
O	O
-	O
beta	O
-	O
D	O
-	O
glucosidase	O
seems	O
to	O
be	O
a	O
new	O
member	O
of	O
the	O
family	O
1	O
of	O
glycosyl	O
hydrolases	O
.	O

Glucosidases	O
belong	O
to	O
a	O
group	O
of	O
enzymes	O
which	O
are	O
of	O
widespread	O
distribution	O
and	O
for	O
a	O
long	O
time	O
have	O
been	O
extensively	O
studied	O
from	O
several	O
points	O
of	O
view	O
.	O

These	O
enzymes	O
were	O
investigated	O
not	O
only	O
because	O
of	O
their	O
significant	O
role	O
in	O
cellulose	B
degradation	O
(	O
Beguin	O
,	O
1990	O
)	O
,	O
their	O
involvement	O
in	O
plant	O
defence	O
reactions	O
(	O
Poulton	O
,	O
1990	O
)	O
and	O
activation	O
of	O
phytohormones	B
(	O
Brzobohaty	O
et	O
al.	O
,	O
1993	O
)	O
,	O
but	O
also	O
to	O
elucidate	O
their	O
still	O
unrevealed	O
reaction	O
mechanisms	O
(	O
Withers	O
and	O
Street	O
,	O
1988	O
;	O
Sinnot	O
,	O
1990	O
)	O
or	O
to	O
assign	O
them	O
to	O
the	O
appropriate	O
glycosyl	O
hydrolase	O
families	O
(	O
Henrissat	O
,	O
1991	O
;	O
Henrissat	O
and	O
Bairoch	O
,	O
1993	O
)	O
.	O

Consequently	O
many	O
attempts	O
have	O
been	O
directed	O
towards	O
the	O
purification	O
and	O
characterization	O
of	O
glucosidases	O
from	O
quite	O
different	O
origins	O
and	O
especially	O
in	O
order	O
to	O
gain	O
insight	O
into	O
their	O
substrate	O
acceptance	O
as	O
unspecific	O
and	O
specific	O
enzymes	O
.	O

The	O
use	O
of	O
unnatural	O
substrates	O
,	O
like	O
p	B
-nitrophenyl	I
glucoside	I
,	O
for	O
the	O
enrichment	O
of	O
glucosidases	O
hampered	O
detailed	O
studies	O
of	O
their	O
real	O
substrate	O
specificities	O
and	O
was	O
criticized	O
several	O
times	O
in	O
the	O
literature	O
(	O
Hemscheidt	O
and	O
Zenk	O
,	O
1980	O
;	O
Conn	O
,	O
1993	O
)	O
.	O

Very	O
recent	O
work	O
,	O
however	O
,	O
describes	O
a	O
number	O
of	O
more	O
or	O
less	O
substrate	O
specific	O
plant	O
glucosidases	O
(	O
Gus	O
-	O
Mayer	O
et	O
al.	O
,	O
1994	O
;	O
Falk	O
and	O
Rask	O
,	O
1995	O
)	O
and	O
among	O
them	O
the	O
well	O
characterized	O
β	O
-glucosidases	O
hydrolyzing	O
cyanogenic	B
glucosides	I
(	O
Oxtoby	O
et	O
al.	O
,	O
1991	O
;	O
Li	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Although	O
glucosidases	O
are	O
involved	O
in	O
the	O
metabolism	O
of	O
a	O
broad	O
variety	O
of	O
plant	O
natural	B
products	I
it	O
seems	O
that	O
this	O
type	O
of	O
enzyme	O
has	O
no	O
general	O
significance	O
in	O
alkaloid	B
biosynthesis	O
and	O
this	O
is	O
especially	O
true	O
for	O
one	O
of	O
the	O
largest	O
alkaloid	B
groups	O
,	O
containing	O
the	O
so	O
far	O
known	O
2000	O
monoterpenoid	B
indole	I
alkaloids	I
.	O

Among	O
them	O
less	O
than	O
40	O
are	O
glucoalkaloids	B
(	O
Ruyter	O
et	O
al.	O
,	O
1988	O
)	O
.	O

From	O
two	O
of	O
these	O
glucoalkaloids	B
only	O
the	O
corresponding	O
glucosidases	O
were	O
detected	O
and	O
could	O
be	O
partially	O
characterized	O
from	O
plant	O
cell	O
suspension	O
cultures	O
of	O
Catharanthus	O
roseus	O
G.	O
Don	O
and	O
Rauwolfia	O
serpentina	O
Benth	O
.	O

ex	O
Kurz	O
(	O
Hemscheidt	O
and	O
Zenk	O
,	O
1980	O
;	O
Schubel	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Both	O
of	O
them	O
,	O
the	O
alkaloidal	B
glucoside	I
strictosidine	B
(	O
3	B
)	O
and	O
the	O
alkaloid	B
raucaffricine	B
(	O
6	B
)	O
are	O
,	O
however	O
,	O
of	O
great	O
interest	O
(	O
Fig.	O
1	O
)	O
.	O

Strictosidine	B
(	O
3	B
)	O
,	O
which	O
is	O
the	O
condensation	O
product	O
of	O
the	O
monoterpene	B
glucoside	I
secologanin	B
(	O
2	B
)	O
and	O
the	O
amine	B
tryptamine	B
(	O
1	B
)	O
,	O
occupies	O
a	O
crucial	O
biosynthetic	O
role	O
(	O
Kutchan	O
,	O
1993	O
)	O
.	O

It	O
is	O
most	O
probably	O
the	O
biogenetic	O
progenitor	O
of	O
all	O
monoterpenoid	B
indole	I
alkaloids	I
in	O
nature	O
.	O

This	O
glucoside	B
is	O
therefore	O
an	O
extraordinary	O
example	O
because	O
glucosides	B
of	O
natural	B
products	I
are	O
usually	O
located	O
at	O
the	O
end	O
of	O
biosynthetic	O
routes	O
as	O
water	B
soluble	O
compounds	O
.	O

3	B
is	O
,	O
however	O
,	O
situated	O
at	O
the	O
beginning	O
of	O
pathways	O
and	O
becomes	O
a	O
highly	O
activated	O
and	O
reactive	O
alkaloid	B
precursor	O
on	O
entering	O
these	O
routes	O
after	O
the	O
splitting	O
off	O
the	O
glucosidic	B
bond	O
by	O
strictosidine	O
glucosidase	O
(	O
Hemscheidt	O
and	O
Zenk	O
,	O
1980	O
)	O
.	O

In	O
contrast	O
,	O
the	O
second	O
glucoside	B
,	O
6	B
,	O
might	O
well	O
belong	O
to	O
a	O
group	O
of	O
storage	O
compounds	O
but	O
its	O
precise	O
biosynthetic	O
role	O
is	O
not	O
yet	O
known	O
(	O
Stockigt	O
,	O
1995	O
)	O
.	O

The	O
deglucosylation	O
of	O
6	B
catalyzed	O
by	O
raucaffricine	O
glucosidase	O
(	O
RG	O
;	O
EC	O
3.2.1.125	O
)	O
leads	O
to	O
its	O
aglycone	B
vomilenine	B
(	O
4	B
)	O
.	O

The	O
latter	O
alkaloid	B
is	O
a	O
direct	O
intermediate	O
in	O
the	O
biosynthetic	O
pathway	O
of	O
the	O
antiarrhythmic	O
alkaloid	B
ajmaline	B
(	O
5	B
)	O
(	O
Stockigt	O
,	O
1995	O
)	O
.	O

RG	O
,	O
therefore	O
,	O
might	O
have	O
a	O
fascinating	O
biochemical	O
function	O
,	O
e.g.	O
by	O
channeling	O
a	O
biogenetic	O
precursor	O
into	O
the	O
late	O
stages	O
of	O
ajmaline	B
biosynthesis	O
.	O

Moreover	O
the	O
glucosidase	O
has	O
never	O
been	O
detected	O
in	O
other	O
plants	O
or	O
cell	O
suspension	O
cultures	O
than	O
Rauwolfia	O
and	O
is	O
obviously	O
unique	O
to	O
the	O
co	O
-	O
occurrence	O
of	O
ajmaline	B
type	O
alkaloids	B
.	O

Therefore	O
,	O
for	O
its	O
further	O
investigation	O
,	O
e.g.	O
the	O
elucidation	O
of	O
its	O
reaction	O
mechanism	O
,	O
a	O
pure	O
enzyme	O
and	O
information	O
on	O
its	O
amino	B
acid	I
sequence	O
would	O
be	O
advantageous	O
.	O

The	O
present	O
paper	O
describes	O
the	O
purification	O
,	O
partial	O
sequencing	O
,	O
the	O
structure	O
of	O
the	O
enzyme	O
product	O
4	B
and	O
a	O
comparison	O
of	O
this	O
exceptional	O
enzyme	O
in	O
alkaloid	B
biosynthesis	O
to	O
other	O
plant	O
glucosidases	O
.	O

2	O
Results	O
2.1	O
Cell	O
growth	O
and	O
glucosidase	O
activity	O
Cell	O
growth	O
,	O
protein	O
amount	O
and	O
RG	O
activity	O
of	O
cultivated	O
Rauwolfia	O
cells	O
were	O
dependent	O
on	O
cultivation	O
time	O
.	O

Enzyme	O
activity	O
(	O
nkat	O
/	O
l	O
cell	O
suspension	O
)	O
and	O
protein	O
content	O
(	O
g	O
/	O
l	O
)	O
increased	O
up	O
to	O
the	O
5th	O
/	O
6th	O
day	O
from	O
100	O
to	O
270	O
nkat	O
and	O
0.3	O
to	O
0.6	O
g	O
protein	O
,	O
respectively	O
.	O

Optimum	O
conditions	O
were	O
around	O
5–6	O
days	O
.	O

For	O
cultivation	O
of	O
the	O
Rauwolfia	O
cells	O
usually	O
1	O
week	O
growth	O
period	O
is	O
applied	O
routinely	O
.	O

Because	O
at	O
that	O
time	O
only	O
slight	O
decrease	O
of	O
enzyme	O
activity	O
from	O
270	O
to	O
250	O
nkat	O
/	O
l	O
occurs	O
,	O
cells	O
for	O
isolation	O
of	O
RG	O
were	O
harvested	O
after	O
7	O
days	O
of	O
growth	O
.	O

2.2	O
Purification	O
of	O
RG	O
The	O
results	O
of	O
a	O
typical	O
purification	O
procedure	O
of	O
RG	O
are	O
shown	O
in	O
Table	O
1	O
.	O

The	O
combination	O
of	O
five	O
different	O
steps	O
of	O
enzyme	O
enrichment	O
including	O
HPLC	O
chromatography	O
resulted	O
finally	O
in	O
over	O
1000-fold	O
enzyme	O
purification	O
.	O

The	O
crude	O
protein	O
extract	O
obtained	O
from	O
the	O
Rauwolfia	O
cells	O
was	O
subjected	O
to	O
(	B
NH4	I
)	I
2	I
SO4	I
fractionation	O
followed	O
by	O
anion	O
exchange	O
chromatography	O
on	O
DEAE	O
Sephacel	O
(	O
Fig.	O
2	O
A	O
)	O
.	O

At	O
this	O
stage	O
a	O
3.5-fold	O
enzyme	O
enrichment	O
with	O
an	O
overall	O
yield	O
of	O
43	O
%	O
was	O
obtained	O
.	O

For	O
further	O
purification	O
the	O
glucosidase	O
-	O
containing	O
fractions	O
were	O
added	O
to	O
a	O
hydroxylapatite	B
column	O
which	O
,	O
after	O
elution	O
with	O
a	O
linear	O
KPi	O
gradient	O
,	O
gave	O
a	O
10-fold	O
purification	O
of	O
the	O
RG	O
activity	O
with	O
a	O
specific	O
activity	O
of	O
3.9	O
nkat	O
/	O
mg	O
.	O

As	O
Fig.	O
2	O
(	O
B	O
)	O
illustrates	O
,	O
maximum	O
enzyme	O
activity	O
was	O
separated	O
from	O
the	O
bulk	O
of	O
the	O
protein	O
and	O
this	O
enzyme	O
preparation	O
was	O
then	O
subjected	O
to	O
size	O
exclusion	O
chromatography	O
applying	O
AcA	O
54	O
material	O
after	O
it	O
had	O
been	O
concentrated	O
by	O
ultrafiltration	O
.	O

The	O
maximum	O
glucosidase	O
activity	O
was	O
eluted	O
under	O
the	O
applied	O
conditions	O
after	O
75	O
ml	O
corresponding	O
to	O
a	O
M	O
r	O
of	O
63	O
kDa±10	O
%	O
(	O
Fig.	O
2	O
C	O
)	O
.	O

The	O
remaining	O
glucosidase	O
fractions	O
did	O
not	O
contain	O
the	O
well	O
known	O
Rauwolfia	O
enzyme	O
polyneuridine	O
aldehyde	O
esterase	O
(	O
PNA	O
esterase	O
,	O
data	O
not	O
shown	O
(	O
Pfitzner	O
and	O
Stockigt	O
,	O
1983	O
)	O
)	O
indicating	O
its	O
further	O
purification	O
,	O
which	O
corresponded	O
to	O
a	O
133-fold	O
enrichment	O
.	O

Fractions	O
with	O
the	O
highest	O
enzyme	O
activity	O
were	O
combined	O
,	O
concentrated	O
and	O
were	O
used	O
for	O
the	O
next	O
purification	O
step	O
based	O
on	O
the	O
second	O
ion	O
exchange	O
chromatography	O
in	O
this	O
protocol	O
,	O
on	O
the	O
Mono	O
Q	O
anion	O
exchanger	O
.	O

Although	O
this	O
step	O
did	O
not	O
efficiently	O
resolve	O
the	O
enzyme	O
activity	O
from	O
the	O
major	O
protein	O
peaks	O
(	O
Fig.	O
2	O
D	O
)	O
,	O
the	O
resulting	O
enzyme	O
solution	O
obtained	O
by	O
KCl	B
elution	O
showed	O
a	O
∼600-fold	O
enrichment	O
with	O
a	O
specific	O
enzyme	O
activity	O
of	O
240	O
nkat	O
/	O
mg	O
.	O

Compared	O
with	O
the	O
starting	O
protein	O
amount	O
at	O
this	O
stage	O
a	O
yield	O
of	O
∼4	O
%	O
was	O
determined	O
.	O

After	O
concentration	O
of	O
the	O
protein	O
solution	O
,	O
the	O
remaining	O
enzyme	O
could	O
be	O
finally	O
purified	O
by	O
FPLC	O
isoelectric	O
focusing	O
on	O
a	O
Mono	O
P	O
column	O
(	O
Fig.	O
2	O
E	O
)	O
.	O

The	O
maximum	O
catalytic	O
activity	O
of	O
RG	O
corresponds	O
to	O
an	O
isoelectric	O
point	O
of	O
5.8	O
.	O

In	O
summary	O
,	O
the	O
enzyme	O
was	O
∼1200-fold	O
purified	O
and	O
showed	O
a	O
specific	O
activity	O
of	O
∼470	O
nkat	O
/	O
mg	O
with	O
a	O
0.9	O
%	O
recovery	O
from	O
the	O
crude	O
protein	O
extract	O
.	O

Only	O
about	O
10	O
mg	O
of	O
the	O
enzyme	O
remained	O
.	O

Based	O
on	O
these	O
data	O
a	O
shorter	O
purification	O
protocol	O
for	O
RG	O
could	O
be	O
developed	O
with	O
the	O
aim	O
of	O
obtaining	O
sufficient	O
pure	O
enzyme	O
amounts	O
for	O
protein	O
digestion	O
and	O
partial	O
sequencing	O
.	O

This	O
procedure	O
finally	O
was	O
similar	O
to	O
the	O
just	O
described	O
one	O
but	O
only	O
3	O
steps	O
of	O
column	O
chromatography	O
were	O
applied	O
;	O
DEAE	B
Sepharose	I
(	O
fast	O
flow	O
)	O
,	O
size	O
exclusion	O
on	O
TSK	O
55	O
S	O
and	O
Mono	O
Q	O
chromatography	O
resulted	O
in	O
an	O
enzyme	O
preparation	O
with	O
a	O
specific	O
activity	O
of	O
136	O
nkat	O
/	O
mg	O
which	O
was	O
340-fold	O
enriched	O
with	O
a	O
total	O
recovery	O
of	O
5	O
%	O
.	O

2.3	O
Purity	O
,	O
molecular	O
weight	O
and	O
sugar	B
content	O
of	O
RG	O
The	O
340-fold	O
enriched	O
enzyme	O
preparation	O
showed	O
on	O
SDS	O
-	O
PAGE	O
(	O
Fig.	O
3	O
A	O
,	O
lane	O
A	O
)	O
after	O
Coomassie	O
Blue	O
staining	O
several	O
bands	O
with	O
a	O
major	O
protein	O
at	O
61	O
kDa	O
.	O

Previous	O
determination	O
of	O
M	O
r	O
by	O
gel	O
chromatography	O
on	O
Fractogel	O
TSK	O
3000	O
indicated	O
66	O
kDa	O
(	O
±5	O
%	O
)	O
for	O
the	O
enzyme	O
(	O
Schubel	O
et	O
al.	O
,	O
1986	O
)	O
.	O

In	O
order	O
to	O
finally	O
assign	O
the	O
glucosidase	O
to	O
one	O
of	O
the	O
bands	O
on	O
SDS	O
-	O
PAGE	O
,	O
the	O
same	O
enzyme	O
preparation	O
was	O
subjected	O
three	O
times	O
(	O
lane	O
A	O
–	O
C	O
)	O
to	O
basic	O
native	O
electrophoresis	O
(	O
BNE	O
,	O
Fig.	O
3	O
B	O
)	O
.	O

Lane	O
A	O
was	O
separated	O
and	O
stained	O
with	O
Coomassie	B
Blue	I
,	O
indicating	O
three	O
different	O
protein	O
regions	O
,	O
with	O
one	O
major	O
(	O
a	O
)	O
and	O
with	O
two	O
minor	O
protein	O
amounts	O
(	O
b	O
)	O
and	O
(	O
c	O
)	O
.	O

From	O
the	O
unstained	O
lane	O
B	O
the	O
corresponding	O
regions	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
and	O
(	O
c	O
)	O
were	O
scraped	O
off	O
and	O
analyzed	O
for	O
enzyme	O
activity	O
.	O

Only	O
the	O
major	O
protein	O
band	O
(	O
a	O
)	O
showed	O
RG	O
activity	O
.	O

The	O
third	O
lane	O
C	O
was	O
treated	O
accordingly	O
,	O
but	O
used	O
finally	O
for	O
SDS	O
-	O
PAGE	O
.	O

After	O
staining	O
,	O
this	O
gel	O
clearly	O
exhibited	O
only	O
one	O
protein	O
band	O
at	O
61	O
kDa	O
(	O
Fig.	O
3	O
A	O
,	O
lane	O
B	O
)	O
which	O
was	O
the	O
same	O
as	O
that	O
dominating	O
in	O
the	O
original	O
SDS	O
-	O
PAGE	O
of	O
the	O
340-fold	O
enriched	O
enzyme	O
preparation	O
(	O
Fig.	O
3	O
A	O
,	O
lane	O
A	O
)	O
.	O

Silver	O
staining	O
of	O
this	O
gel	O
also	O
showed	O
only	O
one	O
protein	O
band	O
.	O

This	O
protein	O
,	O
therefore	O
,	O
could	O
be	O
clearly	O
assigned	O
as	O
RG	O
.	O

To	O
obtain	O
knowledge	O
of	O
a	O
glycosylation	O
of	O
this	O
enzyme	O
,	O
an	O
enriched	O
glucosidase	O
fraction	O
(	O
340-fold	O
)	O
was	O
separated	O
on	O
SDS	O
-	O
PAGE	O
with	O
the	O
reference	O
proteins	O
,	O
transferrin	O
as	O
a	O
glycoprotein	O
and	O
creatinase	O
as	O
a	O
non	O
-	O
glycosidic	O
protein	O
.	O

The	O
gel	O
exhibited	O
,	O
after	O
blotting	O
on	O
nitrocellulose	B
membranes	O
and	O
staining	O
with	O
the	O
Dig	O
Glycan	B
Detection	O
Kit	O
,	O
only	O
staining	O
of	O
the	O
glycoprotein	O
transferrin	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
RG	O
is	O
therefore	O
most	O
probably	O
a	O
sugar	B
-	O
free	O
enzyme	O
.	O

2.4	O
MS	O
and	O
NMR	O
identification	O
of	O
the	O
glucosidase	O
product	O
vomilenine	B
The	O
enzyme	O
product	O
4	B
showed	O
identical	O
MS	O
-	O
fragmentation	O
when	O
analyzed	O
by	O
EIMS	O
and	O
the	O
same	O
behaviour	O
as	O
a	O
reference	O
sample	O
when	O
analyzed	O
by	O
coupled	O
GC	O
–	O
MS	O
.	O

When	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
the	O
purified	O
enzyme	O
product	O
4	B
was	O
measured	O
in	O
DMSO	B
-	I
d6	I
several	O
protons	O
appeared	O
as	O
double	O
signals	O
in	O
a	O
ratio	O
3.4:1	O
,	O
like	O
the	O
quartet	O
for	O
H-19	O
,	O
the	O
singlet	O
of	O
H-21	O
or	O
the	O
singlet	O
of	O
H-17	O
.	O

Vomilenine	B
obviously	O
occurs	O
as	O
a	O
mixture	O
of	O
isomers	O
.	O

Analysis	O
of	O
the	O
NMR	O
data	O
indicates	O
that	O
the	O
mixed	O
spectrum	O
consists	O
of	O
the	O
signals	O
for	O
a	O
21a	B
(	I
S	I
)	I
-	I
and	O
a	O
21β	B
(	I
R	I
)	I
-isomer	I
of	I
4	I
,	O
the	O
latter	O
being	O
the	O
main	O
product	O
,	O
but	O
exhibiting	O
the	O
reverse	O
configuration	O
when	O
compared	O
with	O
the	O
enzyme	O
substrate	O
6	B
or	O
with	O
5	B
and	O
all	O
of	O
its	O
natural	B
derivatives	I
.	O

The	O
stability	O
of	O
4	B
can	O
be	O
low	O
due	O
to	O
its	O
carbinol	B
(	O
aminal	B
)	O
structure	O
.	O

Structures	O
could	O
exist	O
in	O
an	O
equilibrium	O
through	O
the	O
open	O
form	O
(	O
aldehyde	B
and	O
free	O
amino	B
group	O
)	O
which	O
leads	O
to	O
the	O
21a-	B
(	O
4b	B
)	O
and	O
21β	B
-isomers	I
(	O
4a	B
)	O
,	O
respectively	O
(	O
Fig.	O
4	O
)	O
.	O

NMR	O
experiments	O
were	O
performed	O
,	O
by	O
measuring	O
1	O
H	O
of	O
4	O
in	O
DMSO	B
-	I
d6	I
in	O
the	O
presence	O
of	O
increasing	O
amounts	O
of	O
D2	B
O.	I
In	O
this	O
series	O
the	O
1	O
H	O
signals	O
of	O
H-17	O
and	O
H-21	O
were	O
measured	O
in	O
DMSO	B
-	I
d6	I
/D2	O
O	B
ratios	O
of	O
100:0	O
,	O
75:25	O
,	O
65:35	O
and	O
50:50	O
(	O
Fig.	O
5	O
)	O
.	O

With	O
increasing	O
amounts	O
of	O
D2	B
O	I
the	O
signal	O
distances	O
of	O
the	O
appropriate	O
proton	O
signals	O
(	O
H-17	O
,	O
H-21	O
)	O
of	O
each	O
isomer	B
decreased	O
and	O
signals	O
overlapped	O
completely	O
at	O
50	O
%	O
D2	B
O.	I
In	O
the	O
presence	O
of	O
water	B
a	O
fast	O
equilibrium	O
between	O
both	O
configuration	O
isomers	B
exists	O
and	O
one	O
spectrum	O
only	O
is	O
obtained	O
due	O
to	O
a	O
short	O
life	O
time	O
of	O
the	O
isomers	B
compared	O
to	O
the	O
NMR	O
-	O
time	O
scale	O
.	O

2.5	O
Partial	O
amino	B
acid	I
sequence	O
of	O
RG	O
Degradation	O
of	O
the	O
enzyme	O
by	O
endoproteinase	O
Lys	O
C	O
,	O
HPLC	O
-	O
analysis	O
of	O
the	O
resultant	O
peptide	B
fragments	O
(	O
PF	B
)	O
and	O
their	O
sequencing	O
delivered	O
6	O
peptide	B
sequences	O
with	O
6	O
to	O
24	O
amino	B
acids	I
(	O
Table	O
2	O
)	O
.	O

Comparison	O
of	O
the	O
six	O
peptide	B
sequences	O
against	O
a	O
protein	O
database	O
(	O
SwissProt	O
)	O
showed	O
a	O
high	O
homology	O
of	O
PF	B
37	I
and	O
PF	B
47	I
with	O
different	O
β	O
-glucosidases	O
from	O
various	O
sources	O
(	O
Table	O
3	O
)	O
while	O
for	O
the	O
other	O
peptides	B
no	O
significant	O
homologies	O
could	O
be	O
found	O
.	O

PF	B
37	I
showed	O
the	O
highest	O
homology	O
(	O
81	O
%	O
)	O
to	O
linamarase	O
from	O
Manihot	O
esculenta	O
(	O
Hughes	O
et	O
al.	O
,	O
1992	O
)	O
while	O
PF	B
47	I
had	O
a	O
79	O
%	O
identity	O
to	O
β	O
-glucosidase	O
from	O
Prunus	O
avium	O
(	O
Wiersma	O
and	O
Fils	O
-	O
Lycaon	O
,	O
1995	O
)	O
.	O

3	O
Discussion	O
The	O
monoterpenoid	B
Rauwolfia	B
alkaloid	I
ajmaline	B
(	O
Gilurytmal	O
®	O
)	O
and	O
its	O
synthetic	O
derivative	O
prajmalium	B
(	O
Neo	O
-	O
Gilurytmal	O
®	O
)	O
are	O
well	O
established	O
in	O
the	O
therapy	O
of	O
heart	O
rhythm	O
disorders	O
.	O

Because	O
of	O
their	O
pronounced	O
quinine	B
related	O
activity	O
they	O
belong	O
to	O
class	O
Ia	O
of	O
antiarrhythmic	B
drugs	I
.	I

Ajmaline	B
(	O
5	B
)	O
has	O
a	O
complicated	O
hexacyclic	O
structure	O
possessing	O
nine	O
chiral	O
carbon	B
centers	O
.	O

For	O
commercial	O
use	O
5	O
is	O
therefore	O
not	O
synthesized	O
but	O
still	O
isolated	O
from	O
Rauwolfia	O
roots	O
.	O

In	O
order	O
to	O
understand	O
the	O
formation	O
of	O
this	O
alkaloid	B
in	O
plant	O
cells	O
we	O
have	O
investigated	O
its	O
biosynthesis	O
in	O
plant	O
cell	O
suspension	O
cultures	O
at	O
the	O
enzyme	B
level	O
and	O
have	O
elucidated	O
the	O
major	O
biochemical	O
reactions	O
of	O
this	O
multi	O
-	O
step	O
pathway	O
(	O
Stockigt	O
,	O
1995	O
)	O
.	O

Enzymatic	O
and	O
phytochemical	O
analysis	O
of	O
Rauwolfia	O
plants	O
and	O
cell	O
suspension	O
cultures	O
showed	O
greater	O
activities	O
of	O
vomilenine	B
UDP	O
glucose	O
transferase	O
and	O
RG	O
when	O
compared	O
with	O
the	O
differentiated	O
tissue	O
(	O
data	O
not	O
shown	O
)	O
and	O
a	O
much	O
higher	O
content	O
of	O
the	O
glucoalkaloid	B
6	B
in	O
the	O
in	O
vitro	O
cell	O
systems	O
exceeding	O
that	O
of	O
the	O
differentiated	O
R.	O
serpentina	O
plant	O
by	O
a	O
factor	O
of	O
67	O
(	O
Ruyter	O
et	O
al.	O
,	O
1991	O
)	O
.	O

The	O
results	O
obtained	O
up	O
to	O
the	O
present	O
point	O
to	O
the	O
most	O
important	O
branchpoint	O
in	O
the	O
ajmaline	B
pathway	O
involving	O
the	O
intermediate	O
4	B
,	O
apart	O
from	O
a	O
number	O
of	O
side	O
routes	O
delivering	O
only	O
minor	O
alkaloid	B
amounts	O
.	O

Both	O
enzymes	O
,	O
the	O
vomilenine	B
glucosylating	O
protein	O
and	O
the	O
glucosidase	O
hydrolyzing	O
raucaffricine	B
(	O
vomilenine	B
-	I
β	I
-d	I
-glucoside	I
)	O
,	O
are	O
therefore	O
of	O
extraordinary	O
interest	O
(	O
Fig.	O
1	O
)	O
.	O

To	O
get	O
a	O
more	O
detailed	O
insight	O
into	O
the	O
properties	O
,	O
structure	O
and	O
mechanism	O
of	O
this	O
outstanding	O
glucosidase	O
in	O
the	O
biosynthesis	O
of	O
Rauwolfia	B
alkaloids	I
we	O
purified	O
the	O
enzyme	O
,	O
investigated	O
the	O
structure	O
of	O
the	O
enzyme	O
product	O
vomilenine	B
and	O
made	O
amino	B
acid	I
sequence	O
alignments	O
of	O
peptide	B
fragments	O
obtained	O
by	O
hydrolyzing	O
the	O
glucosidase	O
.	O

A	O
relatively	O
long	O
purification	O
protocol	O
employing	O
5	O
steps	O
permitted	O
the	O
enrichment	O
of	O
RG	O
to	O
near	O
homogeneity	O
.	O

But	O
in	O
general	O
from	O
1	O
kg	O
of	O
fresh	O
Rauwolfia	O
cell	O
suspension	O
cells	O
only	O
10	O
mg	O
RG	O
remained	O
,	O
an	O
inefficient	O
procedure	O
which	O
did	O
not	O
deliver	O
enough	O
material	O
to	O
allow	O
successful	O
protein	O
sequencing	O
.	O

The	O
whole	O
purification	O
procedure	O
could	O
,	O
however	O
,	O
be	O
optimized	O
with	O
only	O
3	O
steps	O
of	O
column	O
chromatography	O
,	O
including	O
the	O
efficient	O
purification	O
on	O
Mono	O
Q	O
material	O
,	O
to	O
yield	O
enough	O
enzyme	O
(	O
∼550	O
mg	O
protein	O
)	O
but	O
of	O
lower	O
purity	O
.	O

With	O
the	O
higher	O
amount	O
of	O
enzyme	O
several	O
experiments	O
could	O
be	O
performed	O
,	O
like	O
the	O
testing	O
of	O
the	O
enzyme	O
for	O
sugar	B
residues	O
.	O

The	O
result	O
that	O
RG	O
is	O
most	O
probably	O
not	O
glycosylated	O
might	O
be	O
an	O
important	O
prerequisite	O
for	O
a	O
heterologous	O
expression	O
of	O
RG	O
in	O
procaryotic	O
systems	O
in	O
future	O
.	O

Part	O
of	O
the	O
enzyme	O
from	O
an	O
enriched	O
preparation	O
was	O
used	O
to	O
generate	O
the	O
aglycone	B
4	B
from	O
6	B
which	O
was	O
then	O
analysed	O
by	O
MS	O
and	O
NMR	O
spectroscopy	O
.	O

Our	O
previous	O
isolation	O
of	O
this	O
alkaloid	B
from	O
cell	O
suspensions	O
has	O
pointed	O
to	O
the	O
occurrence	O
of	O
an	O
isomer	O
mixture	O
(	O
Stockigt	O
et	O
al.	O
,	O
1981	O
)	O
which	O
is	O
in	O
contrast	O
to	O
the	O
vomilenine	B
structure	O
discussed	O
in	O
earlier	O
literature	O
(	O
Taylor	O
et	O
al.	O
,	O
1962	O
)	O
.	O

A	O
careful	O
and	O
complete	O
analysis	O
of	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
4	O
(	O
the	O
appropriate	O
data	O
only	O
are	O
shown	O
)	O
suggested	O
two	O
C-21	O
epimers	O
.	O

The	O
major	O
epimer	O
exhibited	O
the	O
C-21	O
β	B
-hydroxygroup	I
(	O
S	B
-isomer	I
)	O
whereas	O
the	O
minor	O
showed	O
the	O
C-21	O
a	O
OH	B
.	O

Both	O
(	B
S	I
)	I
-	I
and	O
(	B
R	I
)	I
-isomers	I
occurred	O
in	O
a	O
constant	O
ratio	O
of	O
∼3:1	O
when	O
measured	O
in	O
dry	O
DMSO	B
-	I
d6	I
or	O
pyridine	B
-	I
d5	I
.	O

Since	O
the	O
naturally	O
occurring	O
alkaloids	B
with	O
ajmaline	O
structure	O
are	O
all	O
(	O
R	O
)	O
-configurated	O
at	O
C-21	O
,	O
an	O
equilibrium	O
between	O
both	O
vomilenine	B
isomers	O
can	O
be	O
assumed	O
,	O
from	O
which	O
by	O
enzymatic	O
reduction	O
of	O
two	O
double	O
bonds	O
exclusively	O
(	B
R	I
)	I
-vomilenine	I
is	O
removed	O
leading	O
finally	O
to	O
5	B
.	O

In	O
fact	O
,	O
the	O
existence	O
of	O
such	O
an	O
equilibrium	O
became	O
evident	O
by	O
dynamic	O
NMR	O
experiments	O
.	O

When	O
water	B
(	O
D2	B
O	I
)	O
was	O
added	O
to	O
the	O
NMR	O
sample	O
the	O
interconversion	O
of	O
both	O
isomers	O
became	O
very	O
fast	O
because	O
the	O
signals	O
corresponding	O
to	O
both	O
C-21	O
isomers	O
moved	O
toward	O
each	O
other	O
and	O
finally	O
overlapped	O
.	O

It	O
therefore	O
seems	O
quite	O
clear	O
that	O
the	O
existence	O
of	O
the	O
isomeric	O
4	B
mixture	O
being	O
in	O
equilibrium	O
has	O
no	O
real	O
influence	O
on	O
ajmaline	B
biosynthesis	O
.	O

The	O
comparison	O
of	O
the	O
two	O
longest	O
peptide	B
sequences	O
resulted	O
in	O
the	O
detection	O
of	O
surprisingly	O
high	O
sequence	O
homologies	O
(	O
from	O
73	O
to	O
80	O
%	O
)	O
to	O
more	O
than	O
10	O
plant	O
β	O
-glucosidases	O
such	O
as	O
linamarase	O
from	O
Cassava	O
(	O
Manihot	O
esculenta	O
Crantz	O
,	O
(	O
Hughes	O
et	O
al.	O
,	O
1992	O
)	O
)	O
,	O
which	O
is	O
a	O
major	O
crop	O
plant	O
of	O
tropical	O
Africa	O
or	O
the	O
well	O
investigated	O
amygdalin	O
and	O
prunasin	O
hydrolases	O
from	O
black	O
cherry	O
(	O
Prunus	O
serotina	O
,	O
(	O
Zheng	O
and	O
Poulton	O
,	O
1995	O
)	O
)	O
and	O
dhurrinase	O
from	O
mustard	O
(	O
Sinapis	O
alba	O
,	O
(	O
Xue	O
et	O
al.	O
,	O
1992	O
)	O
)	O
.	O

The	O
amino	B
acid	I
motif	O
Val	B
–	I
Thr	I
–	I
Glu	I
–	I
Asn	I
–	I
Gly	I
in	O
PF	B
37	I
is	O
remarkably	O
similar	O
to	O
conserved	O
sequence	O
motifs	O
in	O
β	O
-glucosidases	O
(	O
Withers	O
et	O
al.	O
,	O
1990	O
;	O
Trimbur	O
et	O
al.	O
,	O
1993	O
)	O
.	O

In	O
some	O
cases	O
the	O
glutamic	B
acid	I
in	O
this	O
motif	O
was	O
identified	O
as	O
the	O
active	O
site	O
nucleophil	O
,	O
e.g.	O
in	O
β	O
-glucosidase	O
from	O
Agrobacterium	O
faecalis	O
(	O
Trimbur	O
et	O
al.	O
,	O
1992	O
)	O
or	O
sweet	O
almond	O
(	O
He	O
and	O
Withers	O
,	O
1997	O
)	O
.	O

From	O
these	O
data	O
,	O
in	O
addition	O
to	O
the	O
catalyzed	O
reaction	O
(	O
chemical	O
identification	O
of	O
the	O
conversion	O
of	O
6	B
to	O
4	B
)	O
,	O
it	O
became	O
evident	O
that	O
the	O
here	O
isolated	O
and	O
purified	O
enzyme	O
was	O
indeed	O
a	O
glucosidase	O
.	O

Moreover	O
its	O
relation	O
to	O
other	O
glucosidases	O
is	O
obvious	O
although	O
the	O
substrate	O
specificity	O
of	O
RG	O
which	O
has	O
been	O
published	O
earlier	O
(	O
Schubel	O
et	O
al.	O
,	O
1986	O
)	O
is	O
completely	O
different	O
to	O
the	O
above	O
mentioned	O
hydrolases	O
.	O

RG	O
is	O
exclusively	O
active	O
towards	O
glucosides	B
derived	O
from	O
6	B
like	O
1.2-dihydro-	B
and	O
1.2.19.20-tetrahydroraucaffricine	B
(	O
Schubel	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Obviously	O
a	O
glucosidic	B
ajmalan	B
-	O
type	O
skeleton	O
is	O
a	O
prerequisite	O
for	O
a	O
glucoside	B
being	O
hydrolyzed	O
by	O
this	O
specific	O
glucosidase	O
.	O

In	O
fact	O
,	O
15	O
other	O
glucosides	B
including	O
the	O
alkaloidal	B
glucosides	I
strictosidine	B
,	O
strictosidine	B
lactam	I
,	O
monoterpenoid	B
glucosides	I
or	O
artificial	O
glucosides	B
used	O
frequently	O
for	O
glucosidase	O
purification	O
(	O
nitrophenyl	B
glucosides	I
)	O
were	O
not	O
accepted	O
by	O
RG	O
(	O
Schubel	O
et	O
al.	O
,	O
1986	O
)	O
.	O

The	O
appropriate	O
binding	O
site	O
at	O
the	O
enzyme	O
is	O
,	O
however	O
,	O
not	O
yet	O
known	O
.	O

The	O
obtained	O
data	O
so	O
far	O
suggest	O
that	O
RG	O
is	O
a	O
new	O
member	O
of	O
the	O
family	O
1	O
of	O
glycosyl	O
hydrolases	O
for	O
which	O
the	O
substrate	O
specificity	O
for	O
β	O
-glucosides	O
and	O
the	O
above	O
mentioned	O
amino	B
acid	I
motif	O
found	O
in	O
PF	B
37	I
are	O
characteristic	O
.	O

On	O
the	O
other	O
hand	O
such	O
sequence	O
information	O
might	O
be	O
very	O
useful	O
in	O
the	O
future	O
search	O
for	O
the	O
corresponding	O
gene	O
in	O
Rauwolfia	O
plant	O
cells	O
and	O
in	O
obtaining	O
enough	O
enzyme	O
by	O
heterologous	O
expression	O
for	O
a	O
much	O
more	O
detailed	O
analysis	O
of	O
this	O
protein	O
.	O

In	O
addition	O
it	O
will	O
be	O
of	O
future	O
interest	O
to	O
further	O
investigate	O
not	O
only	O
the	O
molecular	O
structure	O
of	O
RG	O
but	O
also	O
to	O
extent	O
our	O
understanding	O
of	O
the	O
biochemical	O
and	O
physiological	O
function	O
of	O
the	O
soluble	O
RG	O
especially	O
in	O
connection	O
with	O
the	O
membrane	O
bound	O
vomilenine	B
UDP	O
-	O
glucose	O
transferase	O
(	O
Ruyter	O
and	O
Stockigt	O
,	O
1991	O
)	O
catalyzing	O
the	O
reverse	O
reaction	O
of	O
the	O
glucosidase	O
.	O

Moreover	O
it	O
would	O
be	O
most	O
interesting	O
to	O
find	O
out	O
whether	O
RG	O
can	O
exert	O
direct	O
influence	O
on	O
the	O
biosynthesis	O
of	O
the	O
target	O
compound	O
ajmaline	B
,	O
e.g.	O
by	O
channelling	O
the	O
aglycone	B
4	B
into	O
the	O
biosynthetic	O
pathway	O
or	O
to	O
block	O
the	O
enzyme	O
or	O
the	O
corresponding	O
gene	O
and	O
to	O
analyze	O
the	O
remaining	O
biosynthetic	O
potency	O
of	O
the	O
cells	O
to	O
perform	O
alkaloid	B
biosynthesis	O
(	O
Fig.	O
1	O
)	O
.	O

Appropriate	O
work	O
is	O
now	O
in	O
progress	O
.	O

4	O
Experimental	O
4.1	O
Cell	O
material	O
Cell	O
material	O
used	O
in	O
this	O
report	O
was	O
obtained	O
from	O
cell	O
suspension	O
cultures	O
of	O
R.	O
serpentina	O
grown	O
in	O
1	O
l	O
Erlenmeyer	O
flasks	O
in	O
Linsmair	O
and	O
Skoog	O
medium	O
(	O
Linsmaier	O
and	O
Skoog	O
,	O
1965	O
)	O
for	O
7	O
days	O
under	O
the	O
following	O
conditions	O
;	O
24±2	O
°	O
C	O
,	O
under	O
continuous	O
light	O
(	O
600	O
lx	O
)	O
and	O
shaking	O
(	O
100	O
rpm	O
)	O
.	O

For	O
optimization	O
of	O
enzyme	O
isolation	O
after	O
the	O
transfer	O
of	O
Rauwolfia	O
cells	O
to	O
new	O
nutrition	O
medium	O
,	O
the	O
RG	O
activity	O
and	O
the	O
protein	O
content	O
were	O
measured	O
every	O
day	O
for	O
2	O
weeks	O
.	O

4.2	O
Enzyme	O
assay	O
for	O
RG	O
activity	O
20	O
nmol	O
6	O
(	O
solved	O
in	O
10	O
ml	O
EtOH	B
)	O
and	O
appropriate	O
amounts	O
of	O
enzyme	O
solution	O
(	O
RG	O
with	O
an	O
activity	O
of	O
1–5	O
pkat	O
)	O
were	O
incubated	O
in	O
a	O
total	O
of	O
0.1	O
ml	O
of	O
citrate	B
/	O
NaOH	B
buffer	O
(	O
0.1	O
M	O
,	O
pH	O
5.0	O
)	O
for	O
30	O
min	O
at	O
30	O
°	O
C	O
under	O
shaking	O
(	O
100	O
rpm	O
)	O
.	O

The	O
enzyme	O
reaction	O
was	O
terminated	O
by	O
addition	O
of	O
0.2	O
ml	O
MeOH	B
.	O

After	O
centrifugation	O
at	O
18000	O
×	O
g	O
for	O
5	O
min	O
the	O
supernatant	O
was	O
quantitatively	O
analyzed	O
by	O
HPLC	O
,	O
using	O
a	O
Lichrospher	O
RP	O
-	O
select	O
B	O
column	O
(	O
125	O
×	O
4	O
mm	O
)	O
equipped	O
with	O
a	O
4	O
×	O
4	O
mm	O
pre	O
-	O
column	O
of	O
the	O
same	O
type	O
(	O
Merck	O
,	O
Darmstadt	O
)	O
;	O
solvent	O
system	O
was	O
(	O
a	O
)	O
CH3	B
CN	I
and	O
(	O
b	O
)	O
KPi	O
buffer	O
(	O
20	O
mM	O
,	O
pH	O
4.0	O
)	O
with	O
a	O
gradient	O
of	O
25	O
%	O
(	O
a	O
)	O
at	O
0	O
min	O
,	O
35	O
%	O
(	O
a	O
)	O
at	O
3.0	O
min	O
,	O
80	O
%	O
(	O
a	O
)	O
at	O
3.5–4.5	O
min	O
and	O
25	O
%	O
(	O
a	O
)	O
from	O
5–7	O
min	O
,	O
flow	O
rate	O
was	O
1.5	O
ml	O
/	O
min	O
and	O
detection	O
was	O
at	O
258	O
nm	O
.	O

The	O
substrate	O
6	O
(	O
R	O
t	O
=	O
1	O
min	O
44	O
s	O
)	O
and	O
the	O
enzyme	O
product	O
4	O
(	O
R	O
t	O
=	O
2	O
min	O
41	O
s	O
)	O
were	O
completely	O
separated	O
and	O
quantified	O
using	O
6	O
as	O
an	O
external	O
standard	O
.	O

The	O
used	O
6	O
was	O
isolated	O
from	O
cell	O
suspension	O
cultures	O
of	O
R.	O
serpentina	O
according	O
to	O
a	O
published	O
procedure	O
(	O
Schubel	O
and	O
Stockigt	O
,	O
1984	O
)	O
.	O

4.3	O
Protein	O
determination	O
Protein	O
concentrations	O
were	O
determined	O
as	O
described	O
by	O
Bradford	O
(	O
1976	O
)	O
using	O
Coomassie	O
solution	O
.	O

4.4	O
SDS	O
-	O
Polyacrylamide	B
gel	O
electrophoresis	O
-	O
protein	O
staining	O
SDS	O
gels	O
were	O
stained	O
with	O
Coomassie	B
solution	O
(	O
0.25	O
%	O
Coomasie	B
Brilliant	I
Blue	I
R-250	I
,	O
45	O
%	O
MeOH	B
and	O
9	O
%	O
HOAc	B
in	O
water	B
)	I
;	O
destaining	O
of	O
backgrounds	O
were	O
performed	O
with	O
a	O
solution	O
of	O
5	O
%	O
MeOH	B
and	O
7.5	O
%	O
HOAc	B
in	O
water	B
.	O

Silver	B
staining	O
was	O
performed	O
as	O
published	O
previously	O
(	O
Heukeshoven	O
and	O
Dernick	O
,	O
1985	O
)	O
.	O

Enzyme	O
enrichment	O
during	O
the	O
purification	O
of	O
the	O
glucosidase	O
was	O
followed	O
by	O
SDS	O
-	O
PAGE	O
under	O
denaturing	O
conditions	O
using	O
10	O
%	O
acrylamide	B
.	O

Marker	O
proteins	O
used	O
were	O
the	O
LMW	O
marker	O
mixture	O
(	O
Pharmacia	O
)	O
.	O

4.5	O
Buffers	O
Buffer	O
A	O
:	O
0.1	O
M	O
Tris	B
–	I
HCl	I
,	O
pH	O
7.5	O
,	O
1	O
mM	O
EDTA	B
,	O
20	O
mM	O
β	B
-mercaptoethanol	I
(	O
EtSH	B
)	O
.	O

Buffer	O
B	O
:	O
as	O
for	O
A	O
but	O
20	O
mM	O
Tris	B
–	I
HCl	I
and	O
10	O
mM	O
EtSH	B
.	O

Buffer	O
C	O
:	O
as	O
for	O
B	O
but	O
20	O
mM	O
KPi	O
.	O

Buffer	O
D	O
:	O
20	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
7.0	O
,	O
10	O
mM	O
EtSH	B
.	O

Buffer	O
E	O
:	O
20	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
8.0	O
,	O
0.1	O
M	O
KCl	B
,	O
10	O
mM	O
EtSH	B
.	O

Buffer	O
F	O
:	O
as	O
for	O
buffer	O
D	O
,	O
but	O
pH	O
was	O
7.5	O
.	O

Buffer	O
G	O
:	O
25	O
mM	O
Bis	B
–	I
Tris	I
set	O
to	O
pH	O
7.1	O
with	O
saturated	O
iminodiacetic	B
acid	I
,	I
10	O
mM	O
EtSH	B
.	O

Buffer	O
H	O
:	O
10	O
%	O
polybuffer	O
74	O
(	O
Pharmacia	O
)	O
at	O
pH	O
4.0	O
adjusted	O
with	O
satd	O
.	O

iminodiacetic	B
acid	I
,	O
10	O
mM	O
EtSH	B
.	O

Buffer	O
I	O
:	O
0.1	O
M	O
Tris	B
–	I
HCl	I
,	O
pH	O
7.5	O
,	O
20	O
mM	O
EtSH	B
.	O

Buffer	O
K	O
:	O
20	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
8.0	O
,	O
10	O
mM	O
EtSH	B
.	O

Buffer	O
L	O
:	O
39	O
mM	O
glycine	B
,	O
48	O
mM	O
Tris	B
–	I
HCl	I
,	O
0.0375	O
%	O
SDS	B
,	O
20	O
%	O
MeOH	B
.	O

Buffer	O
M	O
:	O
10	O
mM	O
CAPS	O
,	O
pH	O
11	O
,	O
10	O
%	O
MeOH	B
.	O

4.6	O
MS	O
and	O
GC	O
–	O
MS	O
A	O
Finnigan	O
MAT	O
44S	O
quadrupole	O
instrument	O
was	O
used	O
.	O

Direct	O
inlet	O
mass	O
spectra	O
were	O
obtained	O
under	O
EI	O
-	O
conditions	O
(	O
70	O
eV	O
)	O
at	O
an	O
ion	O
source	O
temperature	O
of	O
200	O
°	O
C	O
and	O
a	O
temperature	O
gradient	O
of	O
50	O
°	O
C	O
/	O
min	O
.	O

GC	O
–	O
MS	O
analyses	O
were	O
performed	O
with	O
the	O
same	O
instrument	O
coupled	O
to	O
a	O
Varian	O
Gaschromatograph	O
type	O
3700	O
,	O
which	O
was	O
equipped	O
with	O
a	O
30	O
m	O
×	O
0.32	O
mm	O
Durabond	O
DB1	O
column	O
.	O

GC	O
–	O
MS	O
analyses	O
for	O
identification	O
of	O
4	O
were	O
carried	O
out	O
with	O
a	O
gas	O
flow	O
of	O
10	O
ml	O
/	O
min	O
under	O
isocratic	O
conditions	O
(	O
320	O
°	O
C	O
)	O
.	O

4.7	O
NMR	O
measurements	O
NMR	O
spectra	O
were	O
recorded	O
on	O
Bruker	O
360	O
MHz	O
(	O
360	O
AM	O
)	O
and	O
400	O
MHz	O
(	O
400	O
ARX	O
)	O
instruments	O
using	O
Bruker	O
standard	O
software	O
and	O
5	O
mm	O
NMR	O
tubes	O
with	O
DMSO	B
-	I
d6	I
;	O
for	O
dynamic	O
NMR	O
spectroscopy	O
mixtures	O
of	O
DMSO	B
-	I
d6	I
and	O
D2	B
O	I
were	O
used	O
.	O

4.8	O
Purification	O
of	O
RG	O
All	O
purification	O
steps	O
were	O
carried	O
out	O
at	O
4	O
°	O
C	O
.	O

4.9	O
Preparation	O
of	O
crude	O
protein	O
extracts	O
Cells	O
of	O
R.	O
serpentina	O
cell	O
suspensions	O
(	O
1.0	O
kg	O
,	O
fr	O
.	O

wt	O
)	O
were	O
frozen	O
with	O
liquid	O
nitrogen	B
,	O
added	O
to	O
1300	O
ml	O
buffer	O
A	O
and	O
the	O
mixture	O
was	O
stirred	O
at	O
35	O
°	O
C	O
until	O
thawed	O
.	O

The	O
mixture	O
was	O
then	O
homogenized	O
in	O
an	O
ultraturrax	O
for	O
2	O
min	O
and	O
filtered	O
through	O
cheese	O
cloth	O
.	O

The	O
resultant	O
solution	O
was	O
centrifuged	O
at	O
10,000	O
×	O
g	O
for	O
30	O
min	O
and	O
the	O
supernatant	O
(	O
1.8	O
l	O
)	O
used	O
for	O
the	O
next	O
purification	O
step	O
.	O

4.10	O
Fractional	O
precipitation	O
with	O
(	B
NH4	I
)	I
2	I
SO4	I
The	O
protein	O
in	O
the	O
resulting	O
supernatant	O
was	O
subjected	O
to	O
(	B
NH4	I
)	I
2	I
SO4	I
precipitation	O
.	O

The	O
precipitated	O
protein	O
between	O
30–75	O
%	O
saturation	O
was	O
collected	O
after	O
centrifugation	O
(	O
30	O
min	O
,	O
10,000	O
×	O
g	O
)	O
,	O
solubilized	O
in	O
150	O
ml	O
buffer	O
B	O
,	O
centrifuged	O
and	O
the	O
supernatant	O
dialyzed	O
overnight	O
against	O
10	O
l	O
of	O
buffer	O
B.	O
Centrifugation	O
(	O
20	O
min	O
,	O
10,000	O
×	O
g	O
)	O
yielded	O
the	O
soluble	O
protein	O
fraction	O
(	O
∼200	O
ml	O
,	O
4.2	O
mg	O
/	O
ml	O
)	O
.	O

4.11	O
Anion	O
exchange	O
chromatography	O
on	O
DEAE	B
-	I
Sephacel	I
The	O
protein	O
solution	O
so	O
obtained	O
was	O
added	O
at	O
a	O
rate	O
of	O
1.5	O
ml	O
/	O
min	O
to	O
a	O
DEAE	B
-	I
Sephacel	I
column	O
(	O
7.8	O
×	O
5	O
cm	O
,	O
XK	O
50	O
/	O
20-column	O
,	O
Pharmacia	O
)	O
which	O
was	O
pre	O
-	O
equilibrated	O
with	O
buffer	O
B.	O
After	O
washing	O
the	O
column	O
with	O
buffer	O
B	O
for	O
200	O
min	O
the	O
enzyme	O
activity	O
was	O
fractionated	O
(	O
10	O
ml	O
per	O
fraction	O
)	O
with	O
a	O
linear	O
KCl	B
gradient	O
(	O
0–0.4	O
M	O
)	O
prepared	O
from	O
buffer	O
B	O
and	O
KCl	B
and	O
applied	O
with	O
the	O
rate	O
of	O
1.5	O
ml	O
/	O
min	O
.	O

Enzyme	O
activity	O
appeared	O
at	O
around	O
0.3	O
M	O
KCl	B
.	O

Fractions	O
containing	O
glucosidase	O
activity	O
>	O
1.3	O
nkat	O
/	O
mg	O
were	O
combined	O
and	O
dialyzed	O
overnight	O
against	O
5	O
l	O
buffer	O
C.	O
4.12	O
Biogel	O
HT	O
-	O
hydroxylapatite	B
chromatography	O
The	O
remaining	O
protein	O
solution	O
from	O
the	O
anion	O
exchange	O
chromatography	O
was	O
added	O
to	O
the	O
top	O
of	O
a	O
Biogel	O
HT	O
-	O
column	O
(	O
1.6	O
×	O
15	O
cm	O
)	O
with	O
a	O
flow	O
rate	O
of	O
0.5	O
ml	O
/	O
min	O
.	O

After	O
washing	O
the	O
column	O
for	O
50	O
min	O
with	O
buffer	O
D	O
(	O
0.5	O
ml	O
/	O
min	O
)	O
proteins	O
were	O
eluted	O
with	O
a	O
gradient	O
of	O
KPi	O
(	O
buffer	O
D	O
and	O
20–500	O
mM	O
KPi	O
)	O
within	O
200	O
min	O
.	O

Fractions	O
of	O
2.5	O
ml	O
were	O
collected	O
and	O
assayed	O
for	O
glucosidase	O
activity	O
.	O

Fractions	O
containing	O
>	O
3.5	O
nkat	O
/	O
mg	O
enzyme	O
were	O
combined	O
(	O
35	O
ml	O
)	O
and	O
conc	O
.	O

to	O
5	O
ml	O
by	O
ultra	O
-	O
filtration	O
(	O
membrane	O
pore	O
size	O
<	O
20	O
kDa	O
,	O
0.1–0.2	O
MPa	O
)	O
.	O

4.13	O
Gel	O
filtration	O
on	O
Ultrogel	O
AcA	O
54	O
For	O
gel	O
filtration	O
the	O
above	O
enzyme	O
solution	O
was	O
chromatographed	O
on	O
a	O
2	O
×	O
90	O
cm	O
column	O
containing	O
the	O
AcA	O
54	O
material	O
(	O
Pharmacia	O
)	O
,	O
which	O
had	O
been	O
equilibrated	O
earlier	O
with	O
buffer	O
E.	O
The	O
same	O
buffer	O
was	O
used	O
for	O
the	O
fractionation	O
of	O
the	O
protein	O
solution	O
(	O
0.33	O
ml	O
/	O
min	O
,	O
3	O
ml	O
/	O
fraction	O
)	O
.	O

Fractions	O
exhibiting	O
glucosidase	O
activity	O
of	O
>	O
47	O
nkat	O
/	O
mg	O
were	O
combined	O
(	O
10	O
ml	O
total	O
)	O
and	O
conc	O
.	O

to	O
0.5	O
ml	O
by	O
filtration	O
through	O
Centrisat	O
I	O
filters	O
(	O
20–30	O
min	O
,	O
2000	O
×	O
g	O
,	O
pore	O
size	O
<	O
20	O
kDa	O
)	O
.	O

4.14	O
Mono	O
Q	O
HR	O
5	O
/	O
5	O
ion	O
exchange	O
chromatography	O
The	O
Mono	O
Q	O
column	O
(	O
0.5	O
×	O
5	O
cm	O
)	O
was	O
equilibrated	O
with	O
buffer	O
F	O
and	O
the	O
above	O
mentioned	O
enzyme	O
solution	O
added	O
to	O
the	O
column	O
.	O

For	O
elution	O
of	O
the	O
enzyme	O
a	O
KCl	B
gradient	O
(	O
prepared	O
by	O
mixing	O
buffer	O
F	O
and	O
buffer	O
G	O
containing	O
1	O
M	O
KCl	B
)	O
was	O
applied	O
(	O
0.5	O
ml	O
/	O
min	O
)	O
:	O
0–5	O
ml	O
buffer	O
F	O
:	O
G=100:0	O
;	O
0.32	O
ml	O
buffer	O
F	O
:	O
G=50:50	O
,	O
35	O
ml	O
buffer	O
F	O
:	O
G=25:75	O
,	O
36	O
ml	O
buffer	O
F	O
:	O
G=100:0	O
.	O

Fractions	O
of	O
0.75	O
ml	O
were	O
collected	O
and	O
were	O
combined	O
with	O
specific	O
glucosidase	O
activities	O
of	O
>	O
220	O
nkat	O
/	O
mg	O
.	O

This	O
enzyme	O
solution	O
was	O
concentrated	O
to	O
0.25	O
ml	O
and	O
equilibrated	O
with	O
the	O
starting	O
buffer	O
of	O
the	O
next	O
step	O
(	O
buffer	O
G	O
)	O
.	O

4.15	O
FPLC	O
-	O
chromatofocusing	O
with	O
Mono	O
P	O
column	O
The	O
protein	O
solution	O
obtained	O
by	O
chromatography	O
on	O
Mono	O
Q	O
was	O
added	O
to	O
the	O
Mono	O
P	O
HR	O
515	O
column	O
.	O

Proteins	O
were	O
fractionated	O
(	O
0.5	O
ml	O
)	O
with	O
20	O
ml	O
buffer	O
H	O
at	O
a	O
flow	O
rate	O
of	O
0.25	O
ml	O
/	O
min	O
generating	O
a	O
pH	O
gradient	O
from	O
pH	O
7.1	O
to	O
4.0	O
.	O

The	O
enzyme	O
was	O
eluted	O
after	O
10	O
ml	O
of	O
buffer	O
H.	O
4.16	O
Short	O
procedure	O
for	O
RG	O
purification	O
A	O
short	O
procedure	O
for	O
the	O
enrichment	O
of	O
RG	O
in	O
higher	O
concentration	O
for	O
proteinase	O
-	O
catalyzed	O
sequencing	O
included	O
the	O
following	O
steps	O
.	O

From	O
1	O
kg	O
frozen	O
R.	O
serpentina	O
cells	O
stirred	O
for	O
ca	O
.	O

60	O
min	O
in	O
buffer	O
I	O
a	O
crude	O
protein	O
solution	O
of	O
1.8	O
l	O
(	O
0.8	O
mg	O
protein	O
/	O
ml	O
)	O
was	O
obtained	O
with	O
a	O
specific	O
enzyme	O
activity	O
of	O
0.4	O
nkat	O
/	O
mg	O
.	O

(	B
NH4	I
)	I
2	I
SO4	I
precipitation	O
(	O
30–75	O
%	O
)	O
and	O
solubilisation	O
of	O
the	O
ppt	O
.	O

in	O
180	O
ml	O
buffer	O
F	O
gave	O
a	O
protein	O
concentration	O
of	O
5.6	O
mg	O
/	O
ml	O
.	O

After	O
dialysis	O
against	O
10	O
l	O
buffer	O
F	O
the	O
final	O
solution	O
of	O
250	O
ml	O
contained	O
4.0	O
mg	O
/	O
ml	O
protein	O
with	O
a	O
specific	O
activity	O
of	O
0.49	O
nkat	O
/	O
mg	O
.	O

This	O
protein	O
solution	O
was	O
added	O
to	O
a	O
15.3	O
×	O
5	O
cm	O
column	O
of	O
DEAE	B
sepharose	I
(	O
fast	O
flow	O
)	O
.	O

After	O
washing	O
the	O
column	O
with	O
900	O
ml	O
buffer	O
B	O
,	O
proteins	O
were	O
fractionated	O
with	O
a	O
linear	O
KCl	B
gradient	O
(	O
0–0.5	O
M	O
,	O
1.5	O
ml	O
/	O
min	O
)	O
.	O

Glucosidase	O
activity	O
appeared	O
between	O
0.2–0.3	O
M	O
KCl	B
.	O

The	O
combined	O
active	O
fractions	O
(	O
190	O
ml	O
)	O
contained	O
200	O
mg	O
protein	O
with	O
a	O
specific	O
activity	O
of	O
1.72	O
nkat	O
/	O
mg	O
(	O
4.3-fold	O
enrichment	O
)	O
.	O

This	O
solution	O
was	O
concentrated	O
to	O
6	O
ml	O
by	O
ultrafiltration	O
(	O
cellulose	B
triacetate	I
membrane	O
<	O
20	O
kDa	O
,	O
0.1–0.2	O
MPa	O
)	O
and	O
was	O
then	O
applied	O
to	O
a	O
TSK	O
55	O
S	O
size	O
exclusion	O
chromatography	O
column	O
(	O
2.5	O
×	O
47	O
cm	O
)	O
.	O

Protein	O
was	O
eluted	O
with	O
buffer	O
K	O
at	O
a	O
flow	O
rate	O
of	O
15	O
ml	O
/	O
h	O
.	O

Fractions	O
between	O
95–115	O
ml	O
were	O
combined	O
and	O
yielded	O
7.6	O
mg	O
protein	O
with	O
a	O
specific	O
activity	O
of	O
18.3	O
nkat	O
/	O
mg	O
(	O
46-fold	O
enrichment	O
)	O
.	O

After	O
concentration	O
of	O
this	O
solution	O
by	O
centriprep	O
(	O
Amicon	O
/	O
Witten	O
)	O
it	O
was	O
added	O
to	O
a	O
Mono	O
Q	O
column	O
which	O
was	O
eluted	O
as	O
described	O
above	O
.	O

Maximum	O
enzyme	O
activity	O
appeared	O
at	O
0.28	O
M	O
KCl	B
.	O

Fractions	O
from	O
23	O
to	O
25.5	O
ml	O
,	O
showing	O
highest	O
enzyme	O
activity	O
,	O
were	O
combined	O
,	O
resulting	O
in	O
2.5	O
ml	O
enzyme	O
solution	O
(	O
0.55	O
mg	O
glucosidase	O
exhibiting	O
a	O
specific	O
activity	O
of	O
136	O
nkat	O
/	O
mg	O
)	O
.	O

The	O
total	O
yield	O
of	O
enzyme	O
isolated	O
was	O
5.2	O
%	O
.	O

4.17	O
Basic	O
-	O
native	O
-	O
electrophoresis	O
of	O
the	O
enriched	O
RG	O
Polyacrylamide	O
gels	O
(	O
Clean	O
Gel	O
,	O
Pharmacia	O
)	O
were	O
treated	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

Electrophoresis	O
was	O
carried	O
out	O
under	O
the	O
following	O
conditions	O
:	O
for	O
10	O
min	O
continuous	O
300	O
V	O
(	O
9	O
mA	O
)	O
reaching	O
after	O
60	O
min	O
900	O
V	O
(	O
25	O
mA	O
)	O
.	O

The	O
gel	O
was	O
cut	O
into	O
several	O
bands	O
;	O
one	O
was	O
used	O
for	O
Coomassie	B
staining	O
,	O
one	O
for	O
cutting	O
into	O
small	O
samples	O
which	O
were	O
eluted	O
and	O
concentrated	O
(	O
Microcon	O
10	O
,	O
Micropur	O
22	O
;	O
gel	O
nebulizer	O
,	O
Amicon	O
)	O
and	O
some	O
gel	O
strips	O
were	O
used	O
directly	O
for	O
enzyme	O
assay	O
revealing	O
the	O
glucosidase	O
activity	O
.	O

The	O
protein	O
band	O
corresponding	O
to	O
ca	O
.	O

61	O
kDa	O
showed	O
RG	O
activity	O
.	O

4.18	O
Protein	O
blotting	O
SDS	B
-	O
gels	O
were	O
blotted	O
by	O
the	O
semi	O
dry	O
blotting	O
procedure	O
(	O
Kyhse	O
-	O
Andersen	O
,	O
1984	O
)	O
for	O
60	O
min	O
at	O
20	O
V.	O
For	O
nitrocellulose	B
membrane	O
blotting	O
the	O
transfer	O
buffer	O
L	O
was	O
applied	O
and	O
for	O
blotting	O
on	O
PVDF	B
membranes	O
buffer	O
M	O
was	O
used	O
.	O

The	O
PVDF	B
membranes	O
had	O
been	O
washed	O
first	O
for	O
1	O
min	O
with	O
MeOH	B
and	O
then	O
equilibrated	O
with	O
buffer	O
M	O
for	O
20	O
min	O
.	O

4.19	O
Investigation	O
of	O
RG	O
for	O
glycosylation	O
A	O
fraction	O
of	O
∼300-fold	O
enriched	O
RG	O
from	O
Mono	O
Q	O
chromatography	O
was	O
separated	O
by	O
SDS	O
-	O
PAGE	O
.	O

The	O
gel	O
was	O
then	O
blotted	O
to	O
a	O
nitrocellulose	B
membrane	O
,	O
which	O
was	O
processed	O
as	O
described	O
in	O
the	O
Dig	O
Glycan	B
Detection	O
Kit	O
(	O
Boehringer	O
Mannheim	O
)	O
for	O
the	O
detection	O
of	O
glycosylated	O
proteins	O
.	O

4.20	O
Formation	O
of	O
the	O
enzyme	O
product	O
vomilenine	B
2	O
mg	O
(	O
3.9	O
mmol	O
)	O
of	O
6	O
were	O
dissolved	O
in	O
0.5	O
ml	O
of	O
100	O
mM	O
KPi	O
buffer	O
(	O
pH	O
8.0	O
)	O
.	O

Purified	O
RG	O
(	O
0.01	O
ml	O
)	O
was	O
added	O
and	O
the	O
mixture	O
was	O
incubated	O
at	O
37	O
°	O
C	O
for	O
2	O
h.	O
The	O
mixture	O
was	O
freeze	O
dried	O
and	O
1	O
ml	O
KPi	O
buffer	O
and	O
1	O
ml	O
CH2	B
Cl2	I
were	O
added	O
and	O
mixed	O
.	O

The	O
organic	B
solvent	I
was	O
separated	O
and	O
after	O
repeating	O
the	O
procedure	O
and	O
combining	O
the	O
CH2	B
Cl2	I
fractions	O
the	O
organic	O
layer	O
was	O
dried	O
,	O
resulting	O
in	O
0.9	O
mg	O
(	O
2.57	O
mmol	O
,	O
yield	O
66	O
%	O
)	O
vomilenine	B
.	O

4.21	O
Sequencing	O
of	O
RG	O
and	O
peptide	B
sequence	O
alignment	O
An	O
enriched	O
protein	O
fraction	O
from	O
step	O
three	O
of	O
the	O
short	O
enzyme	O
purification	O
protocol	O
was	O
separated	O
on	O
SDS	B
and	O
blotted	O
on	O
a	O
PVDF	B
membrane	O
by	O
the	O
semi	O
dry	O
blotting	O
method	O
.	O

Using	O
the	O
Edman	O
degradation	O
several	O
attempts	O
to	O
sequence	O
RG	O
were	O
unsuccessful	O
.	O

The	O
enzyme	O
,	O
therefore	O
,	O
was	O
digested	O
with	O
the	O
endoproteinase	O
Lys	B
C	O
directly	O
in	O
the	O
gel	O
.	O

After	O
separation	O
and	O
fractionation	O
of	O
formed	O
peptide	B
fragments	O
by	O
HPLC	O
on	O
a	O
Supersphere	O
60	O
RP	O
select	O
B	O
column	O
(	O
Merck	O
,	O
Darmstadt	O
)	O
,	O
the	O
peptides	O
were	O
sequenced	O
.	O

Two	O
of	O
the	O
obtained	O
peptide	B
sequences	O
,	O
named	O
peptide	B
37	I
and	O
peptide	B
47	I
,	O
of	O
RG	O
were	O
used	O
for	O
screening	O
the	O
SwissProt	O
protein	O
sequences	O
library	O
by	O
the	O
sequence	O
analysis	O
program	O
BLAST	O
.	O

Acknowledgements	O
We	O
are	O
indebted	O
to	O
Professor	O
Dr.	O
F.	O
Lottspeich	O
,	O
Max	O
Planck	O
Institut	O
für	O
Biochemie	O
(	O
Martinsried	O
,	O
Germany	O
)	O
for	O
performing	O
the	O
amino	B
acid	I
sequencing	O
of	O
the	O
enzyme	O
and	O
Professor	O
Dr.	O
W.E.	O
Court	O
(	O
Mold	O
,	O
Wales	O
)	O
for	O
correcting	O
the	O
English	O
version	O
of	O
the	O
manuscript	O
.	O

We	O
also	O
acknowledge	O
very	O
much	O
the	O
kind	O
support	O
provided	O
by	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
Bonn	O
-	O
Bad	O
Godesberg	O
,	O
Germany	O
)	O
and	O
by	O
the	O
Fonds	O
der	O
Chemischen	O
Industrie	O
(	O
Frankfurt	O
/	O
Main	O
,	O
Germany	O
)	O
.	O

It	O
is	O
shown	O
that	O
6-ketoderivatives	B
of	I
natural	B
sapogenins	I
,	O
viz	O
.	O

agigenin	B
,	O
diosgenin	B
and	O
alliogenin	B
,	O
display	O
the	O
anabolic	O
activity	O
and	O
do	O
not	O
manifest	O
any	O
androgenic	O
properties	O
.	O

The	O
compoud	B
IV	I
/	O
(	B
25	I
R	I
)	I
-5alpha	I
-	I
spirostan-2alpha	I
,	I
3beta	I
,	I
5alpha	I
-	I
triol-6-OH	I
/	O
produces	O
an	O
accelerated	O
gain	O
of	O
weight	O
in	O
rats	O
,	O
and	O
also	O
an	O
increase	O
in	O
the	O
weight	O
of	O
the	O
liver	O
,	O
heart	O
,	O
kidneys	O
,	O
musculus	O
tibiliasis	O
anterior	O
and	O
augments	O
the	O
total	O
amount	O
of	O
protein	O
therein	O
.	O

All	O
of	O
the	O
above	O
-	O
mentioned	O
changes	O
become	O
more	O
pronounced	O
with	O
the	O
study	O
substance	O
introduced	O
to	O
young	O
animals	O
.	O

Castration	O
of	O
sexually	O
immature	O
rats	O
greatly	O
mitigates	O
the	O
anabolic	O
effect	O
of	O
the	O
compound	B
IV	I
.	I

Three	O
triterpenoid	B
saponins	I
were	O
isolated	O
from	O
the	O
methanol	B
extract	O
of	O
the	O
stem	O
bark	O
of	O
Kalopanax	O
pictum	O
Nakai	O
var	O
.	O

magnificum	O
(	O
Araliaceae	O
)	O
.	O

The	O
structures	O
of	O
these	O
saponins	B
were	O
identified	O
as	O
hederagenin	B
3-O	I
-	I
alpha	I
-	I
L	I
-	I
arabinopyranoside	I
,	O
hederagenin-3-O	B
-	I
alpha	I
-	I
L	I
-	I
rhamnopyranosyl	I
(	I
1	I
-	I
->2	I
)	I
-alpha	I
-	I
L	I
-	I
arabinop	I
yranoside	I
and	O
3-O	B
-	I
alpha	I
-	I
L	I
-	I
rhamnopyranosyl	I
(	I
1	I
-	I
->2	I
)	I
-alpha	I
-	I
L	I
-	I
arabinopyranosyl	I
hederagenin	I
28-O	I
-	I
alpha	I
-	I
L	I
-	I
rhamnopyranosyl	I
(	I
1	I
-	I
->4	I
)	I
-beta	I
-	I
D-	I
glucopyranosyl	I
(	I
1	I
-	I
->6	I
)	I
-beta	I
-	I
D	I
-	I
glucopyranosyl	I
ester	I
.	O

A	O
key	O
step	O
in	O
fungal	O
biosynthesis	O
of	O
lysine	B
,	O
enzymatic	O
reduction	O
of	O
alpha	B
-	I
aminoadipate	I
at	O
C6	O
to	O
the	O
semialdehyde	B
,	O
requires	O
two	O
gene	O
products	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
Lys2	O
and	O
Lys5	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
31-kDa	O
Lys5	O
is	O
a	O
specific	O
posttranslational	O
modification	O
catalyst	O
,	O
using	O
coenzyme	B
A	I
(	O
CoASH	B
)	O
as	O
a	O
cosubstrate	O
to	O
phosphopantetheinylate	B
Ser880	B
of	O
the	O
155-kDa	O
Lys2	O
and	O
activate	O
it	O
for	O
catalysis	O
.	O

Lys2	O
was	O
subcloned	O
from	O
S.	O
cerevisiae	O
and	O
expressed	O
in	O
and	O
purified	O
from	O
Escherichia	O
coli	O
as	O
a	O
full	O
-	O
length	O
155-kDa	O
enzyme	O
,	O
as	O
a	O
105-kDa	O
adenylation	O
/	O
peptidyl	O
carrier	O
protein	O
(	O
A	O
/	O
PCP	O
)	O
fragment	O
(	O
residues	O
1	O
-	O
924	O
)	O
,	O
and	O
as	O
a	O
14-kDa	O
PCP	O
fragment	O
(	O
residues	O
809	O
-	O
924	O
)	O
.	O

The	O
apo	O
-	O
PCP	O
fragment	O
was	O
covalently	O
modified	O
to	O
phosphopantetheinylated	O
holo	O
-	O
PCP	O
by	O
pure	O
Lys5	O
and	O
CoASH	B
with	O
a	O
Km	O
of	O
1	O
microM	O
and	O
kcat	O
of	O
3	O
min-1	O
for	O
both	O
the	O
PCP	O
and	O
CoASH	B
substrates	O
.	O

The	O
adenylation	O
domain	O
of	O
the	O
A	O
/	O
PCP	O
fragment	O
activated	O
S	B
-	I
carboxymethyl	I
-	I
L	I
-	I
cysteine	I
(	O
kcat	O
/	O
Km	O
=	O
840	O
mM-1	O
min-1	O
)	O
at	O
16	O
%	O
the	O
efficiency	O
of	O
L	B
-	I
alpha	I
-	I
aminoadipate	I
in	O
[	B
32P	I
]	I
PPi	I
/	O
ATP	B
exchange	O
assays	O
.	O

The	O
holo	O
form	O
of	O
the	O
A	O
/	O
PCP	O
105-kDa	O
fragment	O
of	O
Lys2	O
covalently	O
aminoacylated	O
itself	O
with	O
[	B
35S	I
]	I
S	I
-	I
carboxymethyl	I
-	I
L	I
-	I
cysteine	I
.	O

Addition	O
of	O
NADPH	B
discharged	O
the	O
covalent	O
acyl	O
-	O
S	O
-	O
PCP	O
Lys2	O
,	O
consistent	O
with	O
a	O
reductive	O
cleavage	O
of	O
the	O
acyl	O
-	O
S	O
-	O
enzyme	O
intermediate	O
.	O

These	O
results	O
identify	O
the	O
Lys5	O
/	O
Lys2	O
pair	O
as	O
a	O
two	O
-	O
component	O
system	O
in	O
which	O
Lys5	O
covalently	O
primes	O
Lys2	O
,	O
allowing	O
alpha	O
-	O
aminoadipate	O
reductase	O
activity	O
by	O
holo	O
-	O
Lys2	O
with	O
catalytic	O
cycles	O
of	O
autoaminoacylation	O
and	O
reductive	O
cleavage	O
.	O

This	O
is	O
a	O
novel	O
mechanism	O
for	O
a	O
fungal	O
enzyme	O
essential	O
for	O
amino	B
acid	I
metabolism	O
.	O

Rat	O
liver	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
catalyzes	O
not	O
only	O
the	O
hydrolysis	O
of	O
1-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
,	O
but	O
also	O
the	O
transfer	O
of	O
its	O
acyl	O
chain	O
to	O
a	O
second	O
molecule	O
of	O
1-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
to	O
form	O
phosphatidylcholine	B
(	O
H.	O
Sugimoto	O
,	O
S.	O
Yamashita	O
,	O
J.	O
Biol	O
.	O

Chem	O
.	O
269	O
(	O
1994	O
)	O
6252	O
-	O
6258	O
)	O
.	O

Here	O
we	O
report	O
the	O
detailed	O
characterization	O
of	O
the	O
transacylase	O
activity	O
of	O
the	O
enzyme	O
.	O

The	O
enzyme	O
mediated	O
three	O
types	O
of	O
acyl	O
transfer	O
between	O
donor	O
and	O
acceptor	O
lipids	O
,	O
transferring	O
acyl	O
residues	O
from	O
:	O
(	O
1	O
)	O
the	O
sn-1	O
to	O
-1	O
(	O
3	O
)	O
;	O
(	O
2	O
)	O
sn-1	O
to	O
-2	O
;	O
and	O
(	O
3	O
)	O
sn-2	O
to	O
-1	O
positions	O
.	O

In	O
the	O
sn-1	O
to	O
-1	O
(	O
3	O
)	O
transfer	O
,	O
the	O
sn-1	O
acyl	B
residue	I
of	O
1-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
was	O
transferred	O
to	O
the	O
sn-1	O
(	O
3	O
)	O
positions	O
of	O
glycerol	B
and	O
2-acyl	B
-	I
sn	I
-	I
glycerol	I
,	O
producing	O
1	B
(	I
3	I
)	I
-acyl	I
-	I
sn	I
-	I
glycerol	I
and	O
1,2-diacyl	B
-	I
sn	I
-	I
glycerol	I
,	O
respectively	O
.	O

In	O
the	O
sn-1	O
to	O
-2	O
transfer	O
,	O
the	O
sn-1	O
acyl	O
residue	O
of	O
1-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
was	O
transferred	O
to	O
not	O
only	O
the	O
sn-2	O
positions	O
of	O
1-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
,	O
but	O
also	O
1-acyl	B
-	I
sn	I
-	I
glycero-3-phosphoethanolamine	I
,	O
producing	O
phosphatidylcholine	B
and	O
phosphatidylethanolamine	B
,	O
respectively	O
.	O

1-Acyl	B
-	I
sn	I
-	I
glycero-3-phospho	I
-	I
myo	I
-	I
inositol	I
and	O
1-acyl	B
-	I
sn	I
-	I
glycero-3-phosphoserine	I
were	O
much	O
less	O
effectively	O
transacylated	O
by	O
the	O
enzyme	O
.	O

In	O
the	O
sn-2	O
to	O
-1	O
transfer	O
,	O
the	O
sn-2	O
acyl	B
residue	I
of	O
2-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
was	O
transferred	O
to	O
the	O
sn-1	O
position	O
of	O
2-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
and	O
2-acyl	B
-	I
sn	I
-	I
glycero-3-phosphoethanolamine	I
,	O
producing	O
phosphatidylcholine	B
and	O
phosphatidylethanolamine	B
,	O
respectively	O
.	O

Consistently	O
,	O
the	O
enzyme	O
hydrolyzed	O
the	O
sn-2	O
acyl	B
residue	I
from	O
2-acyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
.	O

By	O
the	O
sn-2	O
to	O
-1	O
transfer	O
activity	O
,	O
arachidonic	B
acid	I
was	O
transferred	O
from	O
the	O
sn-2	O
position	O
of	O
donor	O
lipids	B
to	O
the	O
sn-1	O
position	O
of	O
acceptor	O
lipids	B
,	O
thus	O
producing	O
1-arachidonoyl	B
phosphatidylcholine	I
.	O

When	O
2-arachidonoyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
was	O
used	O
as	O
the	O
sole	O
substrate	O
,	O
diarachidonoyl	B
phosphatidylcholine	I
was	O
synthesized	O
at	O
a	O
rate	O
of	O
0.23	O
micromol	O
/	O
min	O
/	O
mg	O
protein	O
.	O

Thus	O
,	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
may	O
play	O
a	O
role	O
in	O
the	O
synthesis	O
of	O
1-arachidonoyl	B
phosphatidylcholine	I
needed	O
for	O
important	O
cell	O
functions	O
,	O
such	O
as	O
anandamide	B
synthesis	O
.	O

Erbland	O
and	O
Marinetti	O
[	O
1	O
]	O
first	O
demonstrated	O
the	O
presence	O
of	O
transacylase	O
activity	O
in	O
liver	O
supernatant	O
to	O
transfer	O
the	O
acyl	B
group	I
from	O
1-acyl	B
-	I
sn	I
-glycero-3-phosphocholine	I
(	O
1-acyl	B
-	I
GPC	I
)	O
to	O
a	O
second	O
molecule	O
of	O
1-acyl	B
-	I
GPC	I
,	O
producing	O
phosphatidylcholine	B
(	O
PC	B
)	O
.	O

By	O
purifying	O
the	O
enzyme	O
from	O
rat	O
lung	O
,	O
Brumley	O
and	O
van	O
den	O
Bosch	O
[	O
2	O
]	O
demonstrated	O
that	O
the	O
transacylase	O
activity	O
was	O
a	O
second	O
activity	O
of	O
lysophospholipase	O
and	O
responsible	O
for	O
the	O
synthesis	O
of	O
disaturated	O
PC	B
,	O
abundantly	O
found	O
in	O
lung	O
surfactant	O
[	O
3	O
]	O
.	O

Transacylation	O
activity	O
is	O
not	O
associated	O
with	O
all	O
lysophospholipases	O
,	O
but	O
one	O
class	O
of	O
isoform	O
with	O
molecular	O
masses	O
of	O
about	O
60	O
kDa	O
,	O
called	O
lysophospholipase	O
-	O
transacylase	O
.	O

The	O
activity	O
is	O
thought	O
to	O
be	O
due	O
to	O
the	O
intermediate	O
formation	O
of	O
the	O
acyl	O
-	O
enzyme	O
during	O
the	O
enzyme	O
reaction	O
.	O

Lysophospholipase	O
-	O
transacylase	O
was	O
purified	O
from	O
various	O
tissues	O
,	O
such	O
as	O
liver	O
[	O
4	O
]	O
,	O
heart	O
[	O
5	O
]	O
,	O
and	O
lung	O
[	O
2	O
]	O
.	O

We	O
recently	O
cloned	O
cDNA	O
for	O
the	O
hepatic	O
enzyme	O
and	O
showed	O
that	O
it	O
comprised	O
564	O
amino	B
acid	I
residues	O
[	O
6	O
]	O
.	O

The	O
amino	B
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
molecule	O
resembled	O
Escherichia	O
coli	O
asparaginase	O
I	O
[	O
7	O
]	O
with	O
the	O
putative	O
catalytic	O
triad	O
Thr	B
-	I
Asp	I
-	I
Lys	I
,	O
followed	O
by	O
the	O
leucine	B
zipper	O
motif	O
.	O

The	O
carboxyl	B
-	O
terminal	O
region	O
contained	O
the	O
ankyrin	O
repeat	O
[	O
8,9	O
]	O
.	O

This	O
structure	O
is	O
markedly	O
different	O
from	O
the	O
other	O
class	O
of	O
lysophospholipase	O
lacking	O
transacylase	O
activity	O
with	O
a	O
molecular	O
mass	O
of	O
about	O
25	O
kDa	O
,	O
comprising	O
230	O
amino	B
acids	I
with	O
the	O
Gly	O
-	O
X	O
-	O
Ser	O
-	O
X	O
-	O
Gly	O
esterase	O
/	O
lipase	O
consensus	O
and	O
the	O
catalytic	O
triad	O
Ser119	B
-Asp174	O
-His208	O
[	O
10–12	O
]	O
.	O

In	O
the	O
previous	O
study	O
,	O
we	O
showed	O
that	O
rat	O
liver	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
transferred	O
the	O
palmitoyl	B
residue	I
from	O
1-palmitoyl	B
-	I
GPC	I
to	O
a	O
second	O
molecule	O
of	O
1-palmitoyl	B
-	I
GPC	I
,	O
and	O
also	O
to	O
2-palmitoyl	B
-	I
sn	I
-glycerol	I
(	O
hereafter	O
2-palmitoylglycerol	B
)	O
,	O
producing	O
1,2-dipalmitoyl	B
-	I
GPC	I
and	O
1,2-dipalmitoylglycerol	B
,	O
respectively	O
[	O
4	O
]	O
.	O

To	O
extend	O
these	O
findings	O
,	O
we	O
characterized	O
the	O
transacylation	O
activity	O
of	O
the	O
enzyme	O
in	O
more	O
detail	O
.	O

The	O
obtained	O
results	O
indicate	O
that	O
the	O
enzyme	O
can	O
transfer	O
saturated	B
and	O
unsaturated	B
fatty	I
acyl	I
chains	I
from	O
1-acyl	B
-	I
GPC	I
to	O
the	O
sn	O
-1	O
(	O
3	O
)	O
and	O
sn	O
-2	O
positions	O
of	O
acyl	B
acceptors	I
and	O
also	O
from	O
2-acyl	B
-	I
GPC	I
to	O
the	O
sn	O
-1	O
position	O
of	O
acyl	B
acceptors	I
.	O

Notably	O
,	O
the	O
enzyme	O
transferred	O
the	O
arachidonoyl	B
residue	I
from	O
the	O
sn	O
-2	O
position	O
of	O
the	O
donor	B
lipid	I
to	O
the	O
sn	O
-1	O
position	O
of	O
the	O
acceptor	B
lipid	I
.	O

When	O
the	O
enzyme	O
was	O
incubated	O
with	O
2-arachidonoyl	B
-	I
GPC	I
,	O
arachidonic	B
acid	I
was	O
transferred	O
from	O
one	O
molecule	O
of	O
2-arachidonoyl	B
-	I
GPC	I
to	O
another	O
molecule	O
of	O
2-arachidonoyl	B
-	I
GPC	I
,	O
producing	O
1,2-diarachidonoyl	B
-	I
GPC	I
.	O

The	O
present	O
results	O
suggest	O
that	O
60-kDa	O
lysophospholipase	B
-	I
transacylase	I
mediates	O
the	O
synthesis	O
of	O
1-arachidonoyl	B
PC	I
,	O
an	O
important	O
precursor	O
of	O
the	O
intrinsic	O
cannabinol	B
receptor	O
ligand	O
,	O
anandamide	B
[	O
13,14	O
]	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
1-Palmitoyl	B
-	I
GPC	I
was	O
obtained	O
from	O
Bachem	O
Feinchemikalien	O
AG	O
(	O
Bubendorf	O
,	O
Switzerland	O
)	O
.	O

1-Palmitoyl	B
-	I
sn	I
-glycero-3-phosphoethanolamine	I
(	O
1-palmitoyl	B
-	I
GPE	I
)	O
,	O
1-acyl	B
-	I
sn	I
-glycero-3-phospho	I
-	I
myo	I
-inositol	I
(	O
1-acyl	B
-	I
GPI	I
)	O
,	O
and	O
1-acyl	B
-	I
sn	I
-glycero-3-phosphoserine	I
(	O
1-acyl	B
-	I
GPS	I
)	O
were	O
from	O
Avanti	O
Polar	O
Lipids	B
(	O
Alabaster	O
,	O
AL	O
,	O
USA	O
)	O
.	O

1-Stearoyl-2-arachidonoyl	B
-	I
GPC	I
and	O
1	B
(	I
3	I
)	I
-	I
and	O
2-palmitoylglycerol	B
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

Glycerol	B
was	O
purchased	O
from	O
Wako	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

1-	B
[	I
14	I
C	I
]	I
Palmitoyl	I
-	I
GPC	I
(	O
55	O
mCi	O
/	O
mmol	O
)	O
,	O
1-stearoyl-2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
(	O
55	O
mCi	O
/	O
mmol	O
)	O
,	O
and	O
1-palmitoyl-2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
(	O
55	O
mCi	O
/	O
mmol	O
)	O
were	O
from	O
Amersham	O
(	O
UK	O
)	O
.	O

Silica	B
Gel	I
60	O
plates	O
were	O
obtained	O
from	O
Merck	O
(	O
Darmstadt	O
,	O
Germany	O
)	O
.	O

Rhizopus	O
arrhizus	O
lipase	O
was	O
from	O
Boehringer	O
Mannheim	O
(	O
Germany	O
)	O
.	O

2.2	O
Preparation	O
of	O
2-	B
[	I
14	I
C	I
]	I
palmitoyl-	I
and	O
2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
Two	O
hundred	O
nanomoles	O
of	O
1-palmitoyl-2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
(	O
21.6	O
dpm	O
/	O
pmol	O
)	O
or	O
1-stearoyl-2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
(	O
17.7	O
dpm	O
/	O
pmol	O
)	O
was	O
treated	O
with	O
R.	O
arrhizus	O
lipase	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
the	O
presence	O
of	O
2	O
mM	O
CaCl2	B
and	O
0.02	O
%	O
Triton	B
X-100	I
in	O
a	O
total	O
volume	O
of	O
0.6	O
ml	O
.	O

2-	B
[	I
14	I
C	I
]	I
Palmitoyl-	I
and	O
2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
produced	O
were	O
extracted	O
with	O
chloroform	B
/	O
methanol	B
(	O
2:1	O
,	O
by	O
volume	O
)	O
and	O
separated	O
by	O
two	O
-	O
dimensional	O
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
using	O
chloroform	B
/	O
methanol	B
/	O
ammonia	B
/	O
water	B
(	O
65:25:4:1	O
,	O
by	O
volume	O
)	O
as	O
the	O
first	O
solvent	B
and	O
chloroform	B
/	O
acetone	B
/	O
methanol	B
/	O
acetic	B
acid	I
/	O
water	B
(	O
30:40:10:7:5	O
,	O
by	O
volume	O
)	O
as	O
the	O
second	O
solvent	B
.	O

The	O
TLC	O
band	O
containing	O
2-	B
[	I
14	I
C	I
]	I
palmitoyl-	I
or	O
[	B
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
was	O
located	O
by	O
autoradiography	O
,	O
scraped	O
off	O
,	O
extracted	O
with	O
methanol	B
,	O
and	O
dispersed	O
in	O
90	O
μl	O
of	O
distilled	O
water	B
using	O
a	O
Branson	O
B-220	O
sonifier	O
for	O
20	O
s	O
at	O
an	O
output	O
of	O
125	O
W	O
,	O
and	O
then	O
immediately	O
used	O
to	O
minimize	O
acyl	B
migration	O
.	O

2.3	O
Enzyme	O
purification	O
Sixty	O
-	O
kiloDalton	O
lysophospholipase	O
-	O
transacylase	O
was	O
purified	O
from	O
rat	O
liver	O
as	O
described	O
previously	O
[	O
4	O
]	O
with	O
some	O
modification	O
.	O

We	O
found	O
that	O
the	O
G	O
-	O
butyl	B
column	O
chromatography	O
step	O
sometimes	O
gave	O
a	O
poor	O
yield	O
of	O
the	O
enzyme	O
,	O
but	O
could	O
be	O
removed	O
without	O
any	O
serious	O
effect	O
on	O
the	O
purity	O
of	O
the	O
final	O
enzyme	O
preparation	O
.	O

Glycerol	B
(	O
10	O
%	O
)	O
was	O
used	O
instead	O
of	O
dimethylsulfoxide	B
in	O
S-200	O
column	O
chromatography	O
.	O

2.4	O
Lysophospholipase	O
assay	O
The	O
activity	O
was	O
isotopically	O
assayed	O
as	O
described	O
previously	O
[	O
4	O
]	O
.	O

2.5	O
Acyl	B
transfer	O
from	O
the	O
sn-1	O
to	O
the	O
sn-1	O
(	O
3	O
)	O
position	O
The	O
purified	O
enzyme	O
was	O
incubated	O
for	O
40	O
min	O
at	O
37	O
°	O
C	O
in	O
0.1-ml	O
of	O
the	O
indicated	O
buffer	O
containing	O
0.2	O
mM	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
(	O
3	O
500	O
dpm	O
/	O
nmol	O
)	O
as	O
acyl	B
donor	I
,	O
and	O
the	O
indicated	O
concentration	O
of	O
glycerol	B
or	O
2-palmitoylglycerol	B
as	O
acyl	B
acceptor	I
.	O

The	O
reaction	O
was	O
terminated	O
by	O
adding	O
3	O
ml	O
of	O
chloroform	B
/	O
methanol	B
(	O
2:1	O
,	O
by	O
volume	O
)	O
,	O
followed	O
by	O
the	O
addition	O
of	O
0.6	O
ml	O
of	O
distilled	O
water	B
.	O

The	O
mixture	O
was	O
shaken	O
vigorously	O
and	O
centrifuged	O
at	O
2000	O
×	O
g	O
for	O
5	O
min	O
.	O

The	O
lower	O
phase	O
was	O
evaporated	O
to	O
dryness	O
in	O
a	O
CVE-100	O
centrifugal	O
vaporizer	O
(	O
Tokyo	O
Rika	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
dissolved	O
in	O
a	O
minimum	O
volume	O
of	O
chloroform	B
/	O
methanol	B
(	O
2:1	O
,	O
by	O
volume	O
)	O
and	O
separated	O
by	O
two	O
-	O
dimensional	O
TLC	O
.	O

The	O
acylation	B
product	I
of	O
glycerol	B
was	O
developed	O
with	O
solvent	B
system	O
I	O
(	O
first	O
dimension	O
,	O
chloroform	B
/	O
methanol	B
/	O
ammonia	B
/	O
water	B
(	O
65:25:4:1	O
,	O
by	O
volume	O
)	O
;	O
second	O
dimension	O
,	O
chloroform	B
/	O
acetone	B
/	O
methanol	B
/	I
acetic	B
acid	I
/	O
water	B
(	O
30:40:10:7:5	O
,	O
by	O
volume	O
)	O
)	O
.	O

The	O
acylation	B
product	I
of	O
2-palmitoylglycerol	B
was	O
separated	O
with	O
solvent	B
system	O
II	O
(	O
first	O
dimension	O
,	O
n	B
-hexane	I
/	O
diethyl	B
ether	I
/	O
acetic	B
acid	I
(	O
80:20:1	O
,	O
by	O
volume	O
)	O
;	O
second	O
dimension	O
,	O
chloroform	B
/	O
methanol	B
/	O
ammonia	B
/	O
water	B
(	O
65:25:4:1	O
,	O
by	O
volume	O
)	O
)	O
.	O

The	O
lipids	B
were	O
located	O
by	O
autoradiography	O
,	O
scraped	O
off	O
the	O
plate	O
,	O
and	O
quantitated	O
by	O
counting	O
in	O
a	O
toluene	B
/	O
Triton	B
X-100	I
scintillant	O
.	O

The	O
identity	O
of	O
each	O
TLC	O
spot	O
was	O
ascertained	O
by	O
co	O
-	O
chromatography	O
with	O
authentic	O
samples	O
.	O

Steric	O
isomers	O
of	O
palmitoylglycerol	B
were	O
identified	O
on	O
a	O
borate	B
-	O
impregnated	O
silica	B
gel	I
H	O
plate	O
with	O
chloroform	B
/	O
acetone	B
(	O
1:1	O
,	O
by	O
volume	O
)	O
as	O
the	O
developing	O
solvent	B
[	O
15	O
]	O
.	O

2.6	O
Acyl	B
transfer	O
from	O
the	O
sn-1	O
to	O
the	O
sn-2	O
position	O
The	O
enzyme	B
was	O
incubated	O
with	O
0.2	O
mM	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
as	O
acyl	B
donor	I
and	O
0.2	O
mM	O
1-palmitoyl	B
-	I
GPE	I
,	O
1-acyl	B
-	I
GPI	I
,	O
or	O
1-acyl	B
-	I
GPS	I
as	O
acyl	B
acceptor	I
.	O

The	O
other	O
conditions	O
were	O
as	O
described	O
above	O
.	O

The	O
product	O
lipids	B
were	O
extracted	O
and	O
separated	O
by	O
two	O
-	O
dimensional	O
TLC	O
using	O
the	O
solvent	B
system	O
I	O
and	O
counted	O
as	O
above	O
.	O

2.7	O
Acyl	B
transfer	O
from	O
the	O
sn-2	O
to	O
the	O
sn-1	O
position	O
Two	O
methods	O
were	O
used	O
.	O

In	O
method	O
I	O
,	O
the	O
enzyme	O
was	O
incubated	O
with	O
0.2	O
mM	O
2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
(	O
21	O
600	O
dpm	O
/	O
nmol	O
)	O
or	O
2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
(	O
17	O
700	O
dpm	O
/	O
nmol	O
)	O
,	O
and	O
the	O
reaction	O
product	O
was	O
extracted	O
,	O
separated	O
on	O
TLC	O
with	O
the	O
solvent	B
system	O
I	O
,	O
and	O
then	O
quantitated	O
as	O
above	O
.	O

In	O
method	O
II	O
,	O
10	O
nmol	O
each	O
of	O
1-stearoyl-2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
(	O
20	O
000	O
dpm	O
)	O
and	O
1,2-dioleoyl	B
-	I
GPE	I
were	O
preincubated	O
with	O
12.5	O
U	O
of	O
R.	O
arrhizus	O
lipase	O
at	O
37	O
°	O
C	O
in	O
a	O
total	O
volume	O
of	O
50	O
μl	O
containing	O
10	O
mM	O
Tris	B
-	I
HCl	I
(	O
pH	O
7.5	O
)	O
,	O
2	O
mM	O
CaCl2	B
,	O
and	O
0.02	O
%	O
Triton	B
X-100	I
.	O

After	O
20	O
min	O
of	O
incubation	O
,	O
0.1	O
μg	O
of	O
purified	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
and	O
2.5	O
μmol	O
of	O
phosphate	B
buffer	O
(	O
pH	O
6.0	O
)	O
were	O
added	O
and	O
incubated	O
at	O
37	O
°	O
C	O
for	O
40	O
min	O
in	O
a	O
total	O
volume	O
of	O
100	O
μl	O
.	O

Lipids	B
were	O
extracted	O
,	O
separated	O
with	O
the	O
solvent	B
system	O
I	O
,	O
and	O
then	O
quantitated	O
as	O
described	O
above	O
.	O

All	O
the	O
data	O
presented	O
herein	O
were	O
repeated	O
at	O
least	O
twice	O
and	O
the	O
representative	O
data	O
are	O
shown	O
.	O

3	O
Results	O
3.1	O
Acylation	B
of	O
glycerol	B
and	O
2-acylglycerol	B
with	O
1-acyl	B
-	I
GPC	I
(	O
sn-1	O
to	O
-1	O
(	O
3	O
)	O
transfer	O
)	O
When	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
was	O
incubated	O
with	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
,	O
we	O
noted	O
the	O
spot	O
of	O
monoacylglycerol	B
on	O
a	O
two	O
-	O
dimensional	O
TLC	O
plate	O
in	O
addition	O
to	O
those	O
of	O
palmitic	B
acid	I
and	O
dipalmitoyl	B
-	I
GPC	I
(	O
data	O
not	O
shown	O
)	O
.	O

Since	O
the	O
enzyme	O
contained	O
10	O
%	O
glycerol	B
as	O
the	O
stabilizing	O
agent	O
,	O
we	O
thought	O
that	O
the	O
monoacylglycerol	B
was	O
derived	O
from	O
the	O
acylation	B
of	O
glycerol	B
contained	O
in	O
the	O
enzyme	O
preparation	O
.	O

To	O
confirm	O
this	O
,	O
increasing	O
concentrations	O
of	O
glycerol	B
were	O
supplemented	O
to	O
the	O
incubation	O
and	O
monoacylglycerol	B
synthesis	O
was	O
examined	O
.	O

As	O
shown	O
in	O
Fig.	O
1	O
,	O
monoacylglycerol	B
synthesis	O
was	O
stimulated	O
by	O
the	O
substrate	O
glycerol	B
,	O
but	O
inhibited	O
at	O
high	O
concentrations	O
.	O

The	O
optimum	O
pH	O
of	O
monoacylglycerol	B
synthesis	O
was	O
9.0	O
.	O

However	O
,	O
the	O
glycerol	B
concentration	O
required	O
for	O
the	O
maximal	O
monoacylglycerol	B
synthesis	O
(	O
40	O
%	O
)	O
was	O
much	O
higher	O
than	O
the	O
reported	O
glycerol	B
content	O
of	O
rat	O
liver	O
(	O
2.7	O
μg	O
/	O
g	O
wet	O
weight	O
)	O
[	O
16	O
]	O
.	O

Thus	O
,	O
the	O
acylation	B
of	O
glycerol	B
by	O
lysoPC	B
may	O
not	O
have	O
physiological	O
significance	O
in	O
the	O
liver	O
.	O

To	O
determine	O
which	O
carbon	B
of	O
the	O
glycerol	B
backbone	O
was	O
acylated	O
,	O
we	O
separated	O
the	O
palmitoylglycerol	B
formed	O
from	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
and	O
glycerol	B
on	O
a	O
borate	B
-	O
impregnated	O
silicic	B
acid	I
plate	O
[	O
15	O
]	O
to	O
separate	O
sn	B
-1	I
(	I
3	I
)	I
-	O
and	O
2-isomer	B
.	I

1	B
(	I
3	I
)	I
-Palmitoylglycerol	I
migrated	O
more	O
slowly	O
than	O
2-palmitoylglycerol	B
because	O
boric	B
acid	I
complexed	O
with	O
vicinal	O
hydroxy	B
groups	I
.	O

As	O
shown	O
in	O
Fig.	O
2	O
,	O
the	O
product	O
from	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
and	O
glycerol	B
was	O
identified	O
as	O
the	O
1	B
(	I
3	I
)	I
-palmitoylglycerol	I
.	O

Thus	O
glycerol	B
was	O
acylated	B
in	O
a	O
regiospecific	O
manner	O
by	O
the	O
enzyme	O
.	O

When	O
2-palmitoylglycerol	B
was	O
used	O
as	O
acyl	B
acceptor	I
,	O
1,2-dipalmitoylglycerol	B
was	O
produced	O
(	O
Fig.	O
3	O
)	O
.	O

1,3-Dipalmitoylglycerol	B
was	O
not	O
produced	O
(	O
data	O
not	O
shown	O
)	O
.	O

1,2-Dipalmitoylglycerol	B
formation	O
was	O
maximal	O
with	O
0.4	O
mM	O
2-palmitoylglycerol	B
with	O
optimum	O
pH	O
at	O
6.0	O
.	O

The	O
transacylation	O
was	O
slightly	O
stimulated	O
(	O
25	O
%	O
)	O
by	O
2	O
mM	O
Mg2	B
+	I
.	O

In	O
the	O
presence	O
of	O
0.4	O
mM	O
2-palmitoylglycerol	B
and	O
2	O
mM	O
Mg2	B
+	I
at	O
pH	O
6.0	O
,	O
1,2-diacylglycerol	B
formation	O
was	O
40	O
%	O
of	O
PC	B
formation	O
.	O

Thus	O
,	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
catalyzed	O
the	O
following	O
sn	O
-1	O
to	O
-1	O
acyl	B
transfer	O
reactions:1-acyl	O
-	B
GPC+glycerol→1	I
(	B
3	I
)	I
-acylglycerol+GPC	I
1-acyl	B
-	I
GPC+2-acylglycerol→1,2-diacylglycerol+GPC	I
.	O

3.2	O
Acylation	B
of	O
1-acyl	B
lysophospholipids	I
with	O
1-acyl	B
-	I
GPC	I
(	O
sn-1	O
to	O
-2	O
transfer	O
)	O
We	O
examined	O
whether	O
or	O
not	O
the	O
enzyme	O
was	O
able	O
to	O
utilize	O
different	O
1-acyl	B
lysophospholipids	I
as	O
acyl	B
acceptor	I
.	O

The	O
purified	O
enzyme	O
was	O
incubated	O
with	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
and	O
0.2	O
mM	O
1-acyl	B
lysophospholipids	I
(	O
1-palmitoyl	B
-	I
GPE	I
,	O
1-acyl	B
-	I
GPI	I
,	O
or	O
1-acyl	B
-	I
GPS	I
)	O
at	O
pH	O
6.0	O
,	O
and	O
the	O
radioactive	O
products	O
were	O
separated	O
by	O
two	O
-	O
dimensional	O
TLC	O
and	O
quantitated	O
.	O

When	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
was	O
used	O
as	O
the	O
sole	O
substrate	O
,	O
radioactive	O
product	O
was	O
[	B
14	I
C	I
]	I
dipalmitoyl	I
-	I
GPC	I
(	O
Fig.	O
3	O
)	O
.	O

However	O
,	O
when	O
1-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
was	O
incubated	O
with	O
1-palmitoyl	B
-	I
GPE	I
,	O
1-acyl	B
-	I
GPI	I
,	O
or	O
1-acyl	B
-	I
GPS	I
,	O
[	B
14	I
C	I
]	I
PC	I
was	O
decreased	O
,	O
and	O
varying	O
amounts	O
of	O
1-palmitoyl-2	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPE	I
,	O
1-acyl-2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPI	I
,	O
and	O
1-acyl-2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPS	I
were	O
produced	O
.	O

The	O
total	O
acyl	B
transfer	O
(	O
PC+PE	B
,	O
PC+PI	B
,	O
and	O
PC+PS	B
syntheses	O
)	O
varied	O
with	O
the	O
lysophospholipids	B
used	O
,	O
suggesting	O
the	O
modulation	O
of	O
transferase	O
activity	O
by	O
lysophospholipids	B
.	O

The	O
amount	O
of	O
[	B
14	I
C	I
]	I
PE	I
produced	O
was	O
about	O
half	O
the	O
amount	O
of	O
[	B
14	I
C	I
]	I
PC	I
,	O
indicating	O
that	O
1-palmitoyl	B
-	I
GPE	I
was	O
a	O
fairly	O
good	O
acyl	B
acceptor	I
.	O

However	O
,	O
when	O
1-acyl	B
-	I
GPI	I
and	O
1-acyl	B
-	I
GPS	I
were	O
used	O
as	O
acyl	B
acceptor	I
,	O
only	O
low	O
levels	O
of	O
[	B
14	I
C	I
]	I
PI	I
and	O
[	B
14	I
C	I
]	I
PS	I
were	O
produced	O
,	O
indicating	O
that	O
1-acyl	B
-	I
GPI	I
and	O
1-acyl	B
-	I
GPS	I
were	O
rather	O
poor	O
acyl	B
acceptors	I
although	O
the	O
former	O
was	O
somewhat	O
better	O
than	O
the	O
latter	O
.	O

Thus	O
,	O
the	O
effectiveness	O
of	O
lysophospholipids	B
as	O
acyl	B
acceptor	I
was	O
in	O
the	O
order	O
:	O
1-palmitoyl	B
-	I
GPC>1-palmitoyl	I
-	B
GPE>1-acyl	I
-	B
GPI>1-acyl	I
-	B
GPS	I
.	O

This	O
order	O
agreed	O
fairly	O
well	O
with	O
the	O
specificity	O
of	O
the	O
hydrolytic	O
activity	O
of	O
the	O
enzyme	O
[	O
4	O
]	O
.	O

Thus	O
,	O
the	O
enzyme	O
catalyzed	O
the	O
following	O
sn	O
-1	O
to	O
-2	O
transacylation:1-acyl	O
-	B
GPC+1-acyl	I
-	B
GPX	I
(	O
GPC	B
>	O
GPE	B
>	O
GPI	B
>	O
GPS	B
)	O
→1,2-diacyl	O
-	B
GPX	I
(	O
GPC	B
>	O
GPE	B
>	O
GPI	B
>	O
GPS	B
)	O
+GPX	O
(	O
GPC	B
>	O
GPE	B
>	O
GPI	B
>	O
GPS	B
)	O
.	O

3.3	O
Acylation	B
of	O
2-acyl	B
-	I
GPC	I
with	O
2-acyl	B
-	I
GPC	I
(	O
sn-2	O
to	O
-1	O
transfer	O
)	O
We	O
next	O
examined	O
whether	O
or	O
not	O
the	O
enzyme	O
utilized	O
2-acyl	B
-	I
GPC	I
as	O
the	O
substrate	O
.	O

We	O
prepared	O
2-	B
[	I
14	I
C	I
]	I
arachidonoyl-	I
and	O
2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
from	O
1-stearoyl-2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
and	O
1-palmitoyl-2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
,	O
respectively	O
,	O
by	O
treatment	O
with	O
R.	O
arrhizus	O
lipase	O
that	O
specifically	O
cleaved	O
the	O
sn	O
-1	O
acyl	B
residue	I
of	O
phospholipids	B
.	O

The	O
2-acyl	B
-	I
GPCs	I
thus	O
prepared	O
were	O
separated	O
by	O
two	O
-	O
dimensional	O
TLC	O
.	O

Since	O
2-acyl	B
-	I
GPC	I
is	O
known	O
to	O
be	O
gradually	O
converted	O
to	O
the	O
1-acyl	B
isomer	I
via	O
acyl	B
migration	O
in	O
vitro	O
[	O
12,17	O
]	O
,	O
the	O
2-acyl	B
-	I
GPC	I
extracted	O
was	O
immediately	O
used	O
for	O
the	O
assay	O
.	O

The	O
enzyme	O
was	O
incubated	O
with	O
2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
or	O
2-	B
[	I
14	I
C	I
]	I
palmitoyl	I
-	I
GPC	I
at	O
pH	O
6.0	O
,	O
and	O
the	O
reaction	O
products	O
were	O
analyzed	O
by	O
two	O
-	O
dimensional	O
TLC	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
,	O
free	O
fatty	B
acid	I
was	O
released	O
from	O
each	O
substrate	O
,	O
indicating	O
that	O
the	O
enzyme	O
can	O
hydrolyze	O
the	O
ester	B
bond	O
at	O
the	O
sn	O
-2	O
position	O
.	O

The	O
hydrolytic	O
rate	O
for	O
2-palmitoyl	B
-	I
GPC	I
was	O
0.57	O
μmol	O
/	O
min	O
/	O
mg	O
,	O
about	O
one	O
-	O
third	O
the	O
rate	O
for	O
the	O
sn	B
-1	I
isomer	I
.	O

2-Arachidonoyl	B
-	I
GPC	I
was	O
cleaved	O
at	O
a	O
rate	O
of	O
0.4	O
μmol	O
/	O
min	O
/	O
mg	O
.	O

In	O
addition	O
to	O
fatty	B
acid	I
,	O
PC	B
and	O
monoacylglycerol	B
were	O
observed	O
on	O
TLC	O
,	O
indicating	O
that	O
transacylation	O
occurred	O
from	O
2-acyl	B
-	I
GPC	I
to	O
a	O
second	O
molecule	O
of	O
2-acyl	B
-	I
GPC	I
.	O

Monoacylglycerol	B
was	O
formed	O
by	O
transacylation	O
from	O
2-acyl	B
-	I
GPC	I
to	O
glycerol	B
contained	O
in	O
the	O
enzyme	O
.	O

1,2-Diarachidonoyl	B
PC	I
was	O
synthesized	O
from	O
two	O
molecules	O
of	O
2-arachidonoyl	B
-	I
GPC	I
at	O
a	O
rate	O
of	O
0.23	O
μmol	O
/	O
min	O
/	O
mg	O
,	O
almost	O
three	O
times	O
greater	O
than	O
the	O
rate	O
of	O
dipalmitoyl	B
PC	I
synthesis	O
(	O
0.082	O
μmol	O
/	O
min	O
/	O
mg	O
)	O
.	O

To	O
confirm	O
the	O
above	O
results	O
,	O
we	O
used	O
an	O
alternative	O
method	O
,	O
lipase	O
-	O
coupling	O
assay	O
,	O
to	O
determine	O
the	O
sn	O
-2	O
to	O
-1	O
transacylase	O
activity	O
of	O
the	O
enzyme	O
.	O

This	O
method	O
utilized	O
the	O
2-acyl	B
-	I
GPC-	I
and	O
2-acyl	B
-	I
GPE	I
-	O
generating	O
systems	O
as	O
acyl	B
donor	B
and	O
acceptor	B
,	O
respectively	O
.	O

Briefly	O
,	O
1-stearoyl-2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
and	O
1,2-dioleoyl	B
-	I
GPE	I
were	O
mixed	O
with	O
Rhizopus	O
lipase	O
and	O
purified	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
and	O
incubated	O
.	O

Radioactive	O
lipid	B
products	O
were	O
separated	O
by	O
two	O
-	O
dimensional	O
TLC	O
and	O
analyzed	O
.	O

We	O
expected	O
that	O
radioactive	O
PE	B
,	O
easily	O
separable	O
from	O
the	O
substrate	O
PC	B
,	O
would	O
be	O
produced	O
by	O
transacylation	O
from	O
2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
to	O
2-oleoyl	B
-	I
GPE	I
generated	O
from	O
the	O
added	O
PC	B
and	O
PE	B
.	O

Fig.	O
5	O
shows	O
that	O
radioactive	O
PE	B
was	O
indeed	O
formed	O
in	O
the	O
presence	O
of	O
lysophospholipase	O
-	O
transacylase	O
and	O
lipase	B
.	O

However	O
,	O
when	O
lysophospholipase	O
-	O
transacylase	O
was	O
omitted	O
,	O
radioactive	O
PE	B
was	O
not	O
produced	O
.	O

These	O
results	O
confirm	O
the	O
above	O
results	O
that	O
the	O
enzyme	O
mediated	O
the	O
sn	O
-2	O
to	O
-1	O
acyl	B
transfer	O
.	O

Furthermore	O
,	O
the	O
autoradiogram	O
shows	O
that	O
much	O
more	O
[	B
14	I
C	I
]	I
arachidonic	I
acid	I
was	O
released	O
from	O
1-stearoyl-2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
by	O
the	O
combined	O
action	O
of	O
lysophospholipase	O
-	O
transacylase	O
and	O
Rhizopus	O
lipase	O
than	O
lipase	O
alone	O
.	O

Fig.	O
6	O
shows	O
the	O
time	O
course	O
of	O
arachidonic	B
acid	I
release	O
from	O
1-stearoyl-2-	B
[	I
14	I
C	I
]	I
arachidonoyl	I
-	I
GPC	I
in	O
the	O
presence	O
of	O
lysophospholipase	O
-	O
transacylase	O
and	O
Rhizopus	O
lipase	O
.	O

When	O
lysophospholipase	O
-	O
transacylase	O
was	O
omitted	O
,	O
arachidonic	B
acid	I
release	O
decreased	O
greatly	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
above	O
findings	O
that	O
the	O
60-kDa	O
enzyme	O
mediated	O
the	O
cleavage	O
of	O
not	O
only	O
the	O
sn	O
-1	O
,	O
but	O
also	O
sn	O
-2	O
ester	B
bonds	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
rat	O
liver	O
60-kDa	O
lysophospholipase	O
catalyzes	O
the	O
following	O
reactions:2-arachidonoyl	O
(	O
or	O
palmitoyl	B
)	O
-GPC+H2	B
O→arachidonic	B
acid	B
(	O
or	O
palmitic	B
acid	I
)	O
+GPC	O
,	O
2-arachidonoyl	B
or	O
(	O
palmitoyl	B
)	O
-GPC+2-arachidonoyl	B
(	O
or	O
palmitoyl	B
)	O
-GPC→1,2-diarachidonoyl	B
(	O
or	O
dipalmitoyl	B
)	O
-GPC+GPC	B
,	O
2-arachidonoyl	B
(	O
or	O
palmitoyl	B
)	O
-GPC+glycerol→arachidonoylglycerol	B
(	O
or	O
palmitoylglycerol	B
)	O
+GPC	O
,	O
2-arachidonoyl	B
-	I
GPC+2-acyl	I
-	B
GPE→1-arachidonoyl-2-acyl	I
-	B
GPE+GPC	I
.	O

4	O
Discussion	O
Erbland	O
and	O
Marinetti	O
[	O
1	O
]	O
first	O
described	O
the	O
production	O
of	O
PC	B
from	O
two	O
molecules	O
of	O
lysoPC	B
in	O
liver	O
supernatant	O
.	O

This	O
activity	O
was	O
ascribed	O
to	O
a	O
second	O
activity	O
of	O
lysophospholipase	O
by	O
partial	O
purification	O
of	O
the	O
lung	O
enzyme	O
[	O
2	O
]	O
.	O

We	O
previously	O
observed	O
that	O
the	O
lysophospholipase	O
activity	O
of	O
liver	O
supernatant	O
was	O
separated	O
into	O
three	O
peaks	O
by	O
DEAE	B
-	I
cellulose	I
chromatography	O
.	O

The	O
first	O
and	O
second	O
peaks	O
exhibited	O
only	O
hydrolase	O
activity	O
,	O
but	O
the	O
third	O
peak	O
exhibited	O
not	O
only	O
lysophospholipase	O
,	O
but	O
also	O
transacylase	O
activities	O
[	O
4	O
]	O
.	O

We	O
purified	O
and	O
cloned	O
all	O
three	O
enzyme	O
peaks	O
[	O
6,10,18	O
]	O
.	O

The	O
lysophospholipase	O
exhibiting	O
transacylase	O
,	O
named	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
,	O
comprised	O
564	O
amino	B
acid	I
residues	O
with	O
a	O
molecular	O
mass	O
of	O
60	O
794	O
Da	O
.	O

The	O
present	O
investigation	O
showed	O
that	O
the	O
enzyme	O
can	O
catalyze	O
three	O
types	O
of	O
transacylation	O
reactions	O
:	O
(	O
1	O
)	O
acyl	B
transfer	O
from	O
1-acyl	B
-	I
GPC	I
to	O
the	O
sn	O
-1	O
(	O
3	O
)	O
positions	O
of	O
glycerol	B
and	O
2-acylglycerol	B
(	O
sn	O
-1	O
to	O
-1	O
(	O
3	O
)	O
transfer	O
)	O
;	O
(	O
2	O
)	O
acyl	B
transfer	O
from	O
1-acyl	B
-	I
GPC	I
to	O
the	O
sn	O
-2	O
positions	O
of	O
1-acyl	B
-	I
GPC	I
,	O
1-acyl	B
-	I
GPE	I
,	O
and	O
other	O
lysophospholipids	B
(	O
sn	O
-1	O
to	O
-2	O
transfer	O
)	O
;	O
and	O
(	O
3	O
)	O
acyl	B
transfer	O
from	O
2-acyl	B
-	I
GPC	I
to	O
the	O
sn	O
-1	O
position	O
of	O
2-acyl	B
-	I
GPC	I
and	O
2-acyl	B
-	I
GPE	I
(	O
sn	O
-2	O
to	O
-1	O
transfer	O
)	O
.	O

The	O
sn	O
-1	O
to	O
-2	O
transfer	O
from	O
1-acyl	B
lysophospholipid	I
to	O
a	O
second	O
molecule	O
of	O
1-acyl	B
lysophospholipid	I
is	O
a	O
well	O
-	O
known	O
activity	O
of	O
lysophospholipase	O
-	O
transacylase	O
[	O
1,2,4,5	O
]	O
.	O

Since	O
fatty	B
acid	I
esterified	O
at	O
the	O
sn	O
-1	O
position	O
is	O
normally	O
saturated	O
[	O
19	O
]	O
,	O
this	O
activity	O
was	O
thought	O
to	O
be	O
important	O
for	O
the	O
synthesis	O
of	O
disaturated	O
species	O
of	O
phospholipids	B
abundantly	O
found	O
in	O
pulmonary	O
surfactant	O
[	O
3,19	O
]	O
.	O

The	O
other	O
two	O
activities	O
,	O
the	O
sn	O
-1	O
to	O
-1	O
(	O
3	O
)	O
and	O
sn	O
-2	O
to	O
-1	O
transfers	O
,	O
had	O
not	O
been	O
previously	O
described	O
for	O
lysophospholipase	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
cytoplasmic	O
phospholipase	B
A2	I
,	O
which	O
also	O
exhibits	O
lysophospholipase	O
activity	O
,	O
was	O
reported	O
to	O
mediate	O
a	O
similar	O
transacylation	O
reaction	O
,	O
the	O
acylation	O
of	O
glycerol	B
with	O
1-palmitoyl	B
-	I
GPC	I
[	O
20	O
]	O
.	O

The	O
sn	O
-2	O
to	O
-1	O
transfer	O
activity	O
of	O
60-kDa	O
lysophospholipase	O
is	O
of	O
special	O
interest	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
activity	O
had	O
not	O
been	O
reported	O
for	O
any	O
other	O
transacylases	O
.	O

Mammalian	O
cells	O
possess	O
the	O
phospholipid	B
remodeling	O
system	O
to	O
modify	O
the	O
fatty	B
acid	I
composition	O
of	O
the	O
newly	O
synthesized	O
phospholipids	B
.	O

Arachidonic	B
acid	I
is	O
incorporated	O
into	O
phospholipids	B
by	O
such	O
remodeling	O
systems	O
at	O
the	O
sn	O
-2	O
position	O
of	O
the	O
glycerol	B
backbone	O
.	O

All	O
the	O
known	O
transacylases	O
involved	O
in	O
phospholipid	B
remodeling	O
introduce	O
arachidonic	B
acid	I
into	O
the	O
sn	O
-2	O
position	O
to	O
form	O
2-arachidonoyl	B
phospholipids	I
.	O

Lysophospholipid	B
acyltransferase	O
acylates	B
the	O
sn	O
-2	O
position	O
of	O
1-acyl	B
lysophospholipids	I
with	O
arachidonoyl	B
-	I
CoA	I
[	O
21,22	O
]	O
.	O

CoA	B
-	O
dependent	O
transacylase	O
which	O
utilizes	O
the	O
existing	O
diacyl	B
phospholipids	I
as	O
acyl	B
donor	I
also	O
transfers	O
arachidonic	B
acid	I
to	O
the	O
sn	O
-2	O
position	O
of	O
1-acyl	B
lysophospholipids	I
[	O
23,24	O
]	O
.	O

CoA	B
-	O
independent	O
transacylase	O
catalyzes	O
the	O
incorporation	O
of	O
arachidonic	B
acid	I
from	O
the	O
sn	O
-2	O
position	O
of	O
phospholipid	B
to	O
the	O
sn	O
-2	O
position	O
of	O
1-alkyl	B
-	I
GPC	I
[	O
25	O
]	O
or	O
1-alkenyl	B
-	I
GPE	I
[	O
26	O
]	O
.	O

Thus	O
,	O
60-kDa	O
lysophospholipase	O
-	O
transacylase	O
is	O
unique	O
in	O
its	O
ability	O
to	O
synthesize	O
1-arachidonoyl	B
species	O
of	O
phospholipids	B
by	O
transferring	O
the	O
arachidonoyl	B
residue	I
from	O
2-arachidonoyl	B
lysophospholipid	I
to	O
the	O
sn	O
-1	O
position	O
of	O
2-acyl	B
lysophospholipid	I
.	O

Although	O
1-arachidonoyl	B
species	O
of	O
phospholipids	B
are	O
rather	O
rare	O
in	O
mammalian	O
tissues	O
,	O
they	O
may	O
play	O
important	O
roles	O
in	O
cellular	O
functions	O
.	O

For	O
example	O
,	O
1-arachidonoyl	B
PC	I
is	O
required	O
for	O
the	O
synthesis	O
of	O
the	O
intrinsic	O
cannabinol	B
receptor	B
ligand	I
,	O
arachidonoylethanolamide	B
or	O
anandamide	B
which	O
plays	O
crucial	O
roles	O
in	O
brain	O
and	O
other	O
tissues	O
[	O
27	O
]	O
.	O

Anandamide	B
is	O
produced	O
from	O
N	B
-arachidonoyl	I
-	I
PE	I
by	O
the	O
phospholipase	O
D	O
-	O
mediated	O
phosphodiester	B
bond	O
cleavage	O
[	O
13,14,28	O
]	O
.	O

N	B
-Arachidonoyl	I
-	I
PE	I
is	O
synthesized	O
by	O
the	O
transfer	O
of	O
the	O
arachidonoyl	B
residue	I
from	O
1-arachidonoyl	B
PC	I
to	O
the	O
ethanolamine	B
moiety	O
of	O
PE	B
[	O
13,29	O
]	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
1-arachidonoyl	B
PC	I
formation	O
had	O
not	O
been	O
clarified	O
.	O

The	O
present	O
study	O
showed	O
that	O
1-arachidonoyl	B
PC	I
can	O
be	O
produced	O
from	O
2-arachidonoyl	B
-	I
GPC	I
by	O
the	O
sn	O
-2	O
to	O
-1	O
transacylation	O
activity	O
of	O
lysophospholipase	O
-	O
transacylase	O
.	O

Pete	O
et	O
al.	O
[	O
30,31	O
]	O
showed	O
that	O
the	O
brain	O
tissue	O
contained	O
a	O
high	O
level	O
of	O
phospholipase	O
A1	O
and	O
possessed	O
the	O
PC	B
degradation	O
pathway	O
by	O
which	O
PC	B
was	O
sequentially	O
deacylated	O
first	O
by	O
phospholipase	O
A1	O
and	O
then	O
by	O
lysophospholipase	O
.	O

Thus	O
,	O
it	O
is	O
very	O
likely	O
that	O
2-arachidonoyl	B
-	I
GPC	I
is	O
formed	O
as	O
the	O
intermediate	O
of	O
PC	B
degradation	O
in	O
brain	O
and	O
probably	O
in	O
other	O
tissues	O
as	O
well	O
,	O
and	O
utilized	O
for	O
the	O
synthesis	O
of	O
1-arachidonoyl	B
species	O
of	O
PC	B
by	O
lysophospholipase	O
-	O
transacylase	O
.	O

A	O
highly	O
sensitive	O
and	O
specific	O
fluorimetric	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
oxamniquine	B
in	O
biological	O
fluids	O
(	O
urine	O
and	O
plasma	O
)	O
.	O

The	O
proposed	O
method	O
is	O
based	O
on	O
the	O
reduction	O
of	O
oxamniquine	B
using	O
zinc	B
/	O
calcium	B
chloride	I
to	O
obtain	O
its	O
nitroso	B
derivative	I
.	O

The	O
latter	O
is	O
then	O
allowed	O
to	O
react	O
with	O
2-cyanoacetamide	B
to	O
get	O
a	O
highly	O
fluorescent	O
product	O
.	O

The	O
different	O
experimental	O
parameters	O
affecting	O
the	O
intensity	O
of	O
the	O
fluorescence	O
were	O
carefully	O
studied	O
and	O
incorporated	O
into	O
the	O
procedure	O
.	O

Under	O
the	O
described	O
conditions	O
,	O
the	O
method	O
is	O
applicable	O
over	O
the	O
concentration	O
range	O
of	O
0.08	O
-	O
0.88	O
microgram	O
/	O
ml	O
with	O
a	O
minimum	O
detectability	O
(	O
S	O
/	O
N	O
=	O
2	O
)	O
of	O
8	O
ng	O
/	O
ml	O
.	O

The	O
percentage	O
recoveries	O
from	O
spiked	O
urine	O
and	O
plasma	O
were	O
99.75	O
+	O
/-	O

1.58	O
and	O
97.46	O
+	O
/-	O

0.44	O
%	O
,	O
respectively	O
.	O

Up	O
to	O
now	O
,	O
different	O
methods	O
in	O
guinea	O
pig	O
sensitization	O
were	O
used	O
,	O
to	O
assess	O
contact	O
sensitization	O
potential	O
of	O
low	B
molecular	I
weight	I
chemicals	I
.	O

In	O
order	O
to	O
compare	O
the	O
efficiency	O
of	O
the	O
epicutaneous	O
,	O
intradermal	O
and	O
combined	O
sensitization	O
methods	O
,	O
two	O
stronger	O
sensitizers	O
,	O
the	O
water	O
soluble	O
chlormethylimidazoline	B
hydrochloride	I
(	O
CMI	B
)	O
and	O
the	O
lipid	B
soluble	O
1,3-dinitrochlorobenzene	B
(	O
DNCB	B
)	O
were	O
used	O
for	O
the	O
experiments	O
.	O

Eleven	O
modified	O
sensitization	O
methods	O
were	O
performed	O
.	O

In	O
a	O
first	O
trial	O
each	O
substance	O
was	O
tested	O
on	O
10	O
animals	O
.	O

In	O
a	O
further	O
study	O
those	O
techniques	O
which	O
had	O
produced	O
the	O
best	O
results	O
,	O
that	O
is	O
the	O
highest	O
degree	O
of	O
sensitization	O
,	O
were	O
applied	O
to	O
25	O
to	O
30	O
animals	O
.	O

For	O
comparison	O
of	O
the	O
results	O
of	O
the	O
various	O
methods	O
,	O
a	O
mean	O
sensitization	O
index	O
was	O
calculated	O
.	O

The	O
best	O
results	O
were	O
achieved	O
with	O
the	O
Maximization	O
Test	O
of	O
Magnusson	O
&	O
Kligman	O
(	O
1969	O
)	O
and	O
the	O
Split	O
Adjuvant	O
Technique	O
of	O
Maguire	O
&	O
Chase	O
(	O
1967	O
)	O
.	O

Cytochromes	O
P-450	O
(	O
P450	O
)	O
catalyse	O
terminal	O
(	O
ω	O
)	O
and	O
subterminal	O
(	O
ω	O
-1	O
to	O
ω	O
-6	O
)	O
hydroxylations	O
of	O
fatty	B
acids	I
in	O
microorganisms	O
,	O
plants	O
,	O
insects	O
,	O
non	O
-	O
mammalian	O
vertebrates	O
,	O
and	O
mammals	O
.	O

These	O
activities	O
are	O
mediated	O
by	O
several	O
members	O
of	O
the	O
CYP4	O
family	O
in	O
mammals	O
[	O
16	O
]	O
.	O

In	O
addition	O
,	O
some	O
CYP2	O
isoforms	O
are	O
involved	O
in	O
lauric	B
acid	I
subterminal	O
hydroxylations	O
in	O
fish	O
[	O
4	O
]	O
.	O

The	O
CYP4	O
isozymes	O
have	O
been	O
characterized	O
in	O
several	O
organs	O
such	O
as	O
liver	O
,	O
kidney	O
,	O
lung	O
,	O
colon	O
,	O
and	O
small	O
intestine	O
.	O

Cloning	O
and	O
heterologous	O
expression	O
of	O
many	O
of	O
them	O
demonstrate	O
their	O
involvement	O
in	O
the	O
oxidation	O
of	O
fatty	B
acids	I
,	O
prostaglandins	B
and	O
leukotrienes	B
,	O
mainly	O
at	O
the	O
ω	O
position	O
in	O
mammals	O
[	O
16	O
]	O
.	O

The	O
physiological	O
role	O
of	O
fatty	B
acid	I
hydroxylases	O
remains	O
unclear	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
oxygenated	B
polyunsaturated	I
fatty	I
acids	I
act	O
as	O
modulators	O
of	O
various	O
cell	O
functions	O
[	O
24	O
]	O
.	O

Ortiz	O
de	O
Montellano	O
and	O
Reich	O
[	O
25	O
]	O
described	O
fatty	B
acid	I
acetylenic	I
analogues	I
which	O
selectively	O
inhibit	O
P450	O
activities	O
based	O
on	O
their	O
substrate	O
specificity	O
.	O

Such	O
inhibitors	O
have	O
been	O
used	O
successfully	O
to	O
investigate	O
the	O
functional	O
role	O
of	O
several	O
fatty	B
acid	I
hydroxylases	O
[	O
9,40	O
]	O
.	O

P450	O
expression	O
is	O
induced	O
by	O
numerous	O
drugs	B
and	O
chemicals	O
[	O
22	O
]	O
.	O

Peroxisome	O
proliferators	O
,	O
such	O
as	O
hypolipidemic	O
drugs	B
(	O
fibrates	B
)	O
,	O
herbicides	B
(	O
2,4-dichlorophenoxyacetic	B
acid	I
)	O
,	O
and	O
phthalate	B
ester	I
plasticizers	O
(	O
DEHP	B
)	O
induce	O
ω	O
-hydroxylation	O
of	O
fatty	B
acids	I
in	O
rodents	O
and	O
increase	O
expression	O
of	O
several	O
mammalian	O
CYP4	O
genes	O
[	O
2,22,23	O
]	O
.	O

Fatty	O
acid	O
hydroxylase	O
activities	O
from	O
other	O
organisms	O
,	O
such	O
as	O
plants	O
[	O
26	O
]	O
and	O
bacteria	O
[	O
6	O
]	O
,	O
are	O
also	O
sensitive	O
to	O
peroxisome	O
proliferators	O
.	O

Most	O
of	O
the	O
CYP2	O
isozymes	O
are	O
not	O
induced	O
by	O
peroxisome	O
proliferators	O
,	O
but	O
by	O
other	O
class	O
of	O
xenobiotics	B
such	O
as	O
phenobarbital	B
[	O
22	O
]	O
.	O

Most	O
investigations	O
involving	O
fish	O
P450	O
have	O
concerned	O
activities	O
toward	O
environmental	B
pollutants	I
,	O
such	O
as	O
polycyclic	B
aromatic	I
hydrocarbons	I
(	O
PAHs	B
)	O
and	O
polychlorobiphenyls	B
(	O
PCBs	B
)	O
,	O
or	O
endogenous	O
substrates	O
(	O
steroids	B
)	O
.	O

Limited	O
information	O
is	O
available	O
about	O
LAH	O
activities	O
in	O
fish	O
.	O

Previous	O
studies	O
by	O
Lemaire	O
et	O
al.	O
[	O
17	O
]	O
have	O
shown	O
that	O
starvation	O
increases	O
LAH	O
activities	O
in	O
sea	O
bass	O
liver	O
,	O
as	O
reported	O
for	O
rat	O
[	O
11	O
]	O
.	O

A	O
recent	O
report	O
by	O
Buhler	O
et	O
al.	O
[	O
4	O
]	O
indicates	O
that	O
both	O
trout	O
liver	O
microsomes	O
and	O
purified	O
CYP2K1	O
protein	O
hydroxylate	O
lauric	B
acid	I
at	O
several	O
subterminal	O
positions	O
.	O

A	O
cDNA	O
fragment	O
was	O
recently	O
isolated	O
from	O
rainbow	O
trout	O
liver	O
and	O
classified	O
in	O
the	O
CYP4	O
gene	O
family	O
(	O
CYP4T1	O
,	O
[	O
7	O
]	O
)	O
.	O

Surprisingly	O
,	O
Scarano	O
et	O
al.	O
[	O
28	O
]	O
,	O
and	O
Miranda	O
et	O
al.	O
[	O
18	O
]	O
reported	O
that	O
rainbow	O
trout	O
was	O
insensitive	O
to	O
peroxisome	O
proliferators	O
(	O
gemfibrozil	B
,	O
dehydroepiandrosterone	B
)	O
,	O
compounds	O
which	O
are	O
known	O
to	O
induce	O
P450-dependent	O
hydroxylation	O
of	O
fatty	B
acids	I
and	O
peroxisome	O
proliferation	O
in	O
rodents	O
[	O
37	O
]	O
.	O

With	O
the	O
aim	O
of	O
developing	O
new	O
biological	B
markers	I
specific	O
for	O
another	O
class	O
of	O
chemical	O
pollutants	B
(	O
peroxisome	O
proliferators	O
,	O
especially	O
the	O
phthalates	B
)	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
these	O
compounds	O
on	O
the	O
cytochrome	O
P450-dependent	O
LAH	O
activities	O
in	O
sea	O
bass	O
(	O
Dicentrarchus	O
labrax	O
)	O
tissues	O
.	O

LAH	O
activities	O
and	O
the	O
ratios	O
of	O
each	O
metabolite	B
formed	O
were	O
compared	O
for	O
liver	O
,	O
kidney	O
and	O
small	O
intestine	O
microsomes	O
from	O
control	O
or	O
fish	O
treated	O
with	O
peroxisome	O
-	O
proliferators	O
(	O
clofibrate	B
and	O
DEHP	B
)	O
.	O

In	O
addition	O
,	O
microsomes	O
from	O
liver	O
and	O
kidney	O
were	O
incubated	O
with	O
a	O
series	O
of	O
lauric	B
acid	I
analogues	I
containing	O
terminal	O
and	O
internal	O
acetylenes	B
,	O
9-dodecynoic	B
(	O
9-DDYA	B
)	O
,	O
10-dodecynoic	B
(	O
10-DDYA	B
)	O
and	O
11-dodecynoic	B
(	O
11-DDYA	B
)	O
acids	B
,	O
in	O
order	O
to	O
compare	O
inactivation	O
kinetics	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O
Clofibrate	B
,	O
DEHP	B
,	O
NADPH	B
,	O
glucose-6-phosphate	B
(	O
G-6-P	B
)	O
,	O
and	O
yeast	O
glucose-6-phosphate	O
dehydrogenase	O
(	O
G-6-PDH	O
)	O
were	O
purchased	O
from	O
Sigma	O
–	O
Aldrich	O
Chimie	O
(	O
France	O
)	O
.	O

[	B
1	I
-	I
14	I
C	I
]	I
lauric	I
acid	I
(	O
2.19	O
×	O
1012	O
Bq	O
mol−1	O
)	O
was	O
from	O
the	O
Commissariat	O
à	O
l'Energie	O
Atomique	O
(	O
CEA	O
,	O
Gif	O
sur	O
Yvette	O
,	O
France	O
)	O
.	O

Acetonitrile	B
(	O
HPLC	O
grade	O
)	O
and	O
silica	B
gel	I
plates	O
were	O
from	O
Merck	O
(	O
Darmstadt	O
,	O
Germany	O
)	O
.	O

11-DDYA	B
,	O
10-DDYA	B
and	O
9-DDYA	B
were	O
synthesized	O
from	O
1-bromo-6-hexanol	B
,	O
1-bromo-7-heptanol	B
and	O
1-bromo-9-nonanol	B
,	O
respectively	O
,	O
according	O
to	O
Alayrac	O
et	O
al.	O
[	O
1	O
]	O
.	O

2.2	O
Fish	O
Sexually	O
immature	O
sea	O
bass	O
(	O
D.	O
labrax	O
,	O
100–200	O
g	O
)	O
were	O
obtained	O
from	O
the	O
fish	O
farm	O
'	O
Théoule	O
Aquaculture	O
'	O
(	O
France	O
)	O
and	O
placed	O
in	O
aquaria	O
containing	O
120	O
l	O
of	O
artificial	O
sea	O
water	B
(	O
salinity	O
28‰	O
)	O
at	O
18	O
°	O
C	O
.	O

An	O
acclimation	O
period	O
of	O
at	O
least	O
2	O
weeks	O
was	O
needed	O
to	O
reduce	O
stress	O
-	O
related	O
responses	O
.	O

Three	O
groups	O
of	O
ten	O
fish	O
were	O
treated	O
for	O
3	O
days	O
by	O
daily	O
intraperitoneal	O
injection	O
of	O
clofibrate	B
(	O
100	O
mg	O
(	O
kg	O
body	O
weight	O
)	O
−1	O
day−1	O
,	O
in	O
NaCl	B
0.9	O
%	O
)	O
,	O
DEHP	B
(	O
1.5	O
g	O
(	O
kg	O
body	O
weight	O
)	O
−1	O
day−1	O
,	O
in	O
NaCl	B
0.9	O
%	O
)	O
or	O
NaCl	B
0.9	O
%	O
(	O
control	O
)	O
.	O

2.3	O
Sample	O
preparation	O
Fish	O
were	O
sacrificed	O
by	O
severing	O
their	O
spinal	O
cord	O
,	O
and	O
liver	O
,	O
kidney	O
,	O
and	O
intestinal	O
mucosa	O
were	O
collected	O
and	O
rinsed	O
in	O
ice	B
-	O
cold	O
150	O
mM	O
KCl	B
.	O

Tissues	O
were	O
homogenized	O
in	O
5	O
vol	O
.	O

of	O
buffer	O
A	O
(	O
250	O
mM	O
sucrose	B
,	O
10	O
mM	O
Hepes	B
,	O
pH	O
7.4	O
)	O
,	O
containing	O
1	O
mM	O
EDTA	B
,	O
1	O
mM	O
PMSF	B
and	O
1	O
mM	O
DTT	B
.	O

Homogenates	O
were	O
centrifuged	O
at	O
9000	O
×	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
.	O

Resulting	O
supernatants	O
were	O
then	O
centrifuged	O
at	O
100	O
000	O
×	O
g	O
for	O
90	O
min	O
at	O
4	O
°	O
C	O
.	O

Microsomal	O
pellets	O
were	O
resuspended	O
in	O
buffer	O
A	O
containing	O
20	O
%	O
glycerol	B
(	O
v	O
/	O
v	O
)	O
,	O
and	O
stored	O
at	O
−70	O
°	O
C	O
.	O

Protein	O
concentrations	O
were	O
determined	O
according	O
to	O
the	O
Bradford	O
's	O
method	O
,	O
with	O
BSA	O
as	O
a	O
standard	O
.	O

2.4	O
Enzyme	O
activities	O
LAH	O
activities	O
were	O
measured	O
as	O
previously	O
described	O
by	O
Weissbart	O
et	O
al.	O
[	O
35	O
]	O
.	O

All	O
assays	O
were	O
carried	O
out	O
at	O
28	O
°	O
C	O
in	O
a	O
final	O
reaction	O
mixture	O
of	O
0.2	O
ml	O
containing	O
50	O
μM	O
[	B
1	I
-	I
14	I
C	I
]	I
lauric	I
acid	I
,	O
0.02	O
M	O
sodium	B
phosphate	I
buffer	O
pH	O
7.4	O
,	O
0.1–0.2	O
mg	O
microsomal	O
proteins	O
,	O
and	O
1	O
mM	O
NADPH	B
plus	O
a	O
regenerating	O
system	O
(	O
consisting	O
of	O
1	O
mM	O
β	B
-NADP	I
,	O
6.7	O
mM	O
G-6-P	B
,	O
and	O
0.4	O
IU	O
of	O
G-6-PDH	O
final	O
concentrations	O
)	O
.	O

The	O
reaction	O
was	O
stopped	O
after	O
20	O
min	O
by	O
addition	O
of	O
0.2	O
ml	O
of	O
ice	B
-	O
cold	O
acetonitrile	B
containing	O
0.2	O
%	O
acetic	B
acid	I
.	O

Proteins	O
were	O
pelleted	O
by	O
rapid	O
centrifugation	O
(	O
13	O
000	O
×	O
g	O
,	O
2	O
min	O
)	O
and	O
0.1	O
ml	O
of	O
supernatant	O
was	O
injected	O
into	O
a	O
RP	O
-	O
HPLC	O
column	O
or	O
spotted	O
on	O
silica	B
gel	I
plates	O
.	O

Total	O
specific	O
activity	O
(	O
nmol	O
min−1	O
mg−1	O
of	O
microsomal	O
proteins	O
)	O
was	O
calculated	O
by	O
adding	O
the	O
amounts	O
of	O
each	O
metabolite	B
formed	O
.	O

2.5	O
Inactivation	O
with	O
mechanism	O
-	O
based	O
inhibitors	O
Five	O
livers	O
or	O
kidneys	O
from	O
DEHP-	B
or	O
clofibrate	B
-	O
treated	O
fish	O
were	O
pooled	O
and	O
homogenized	O
prior	O
to	O
microsomes	O
preparation	O
.	O

Microsomes	O
were	O
first	O
preincubated	O
at	O
28	O
°	O
C	O
with	O
1	O
mM	O
NADPH	B
and	O
the	O
regenerating	O
system	O
described	O
above	O
,	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
(	O
20	O
,	O
40	O
,	O
60	O
or	O
80	O
μM	O
)	O
of	O
inhibitor	O
(	O
9-DDYA	B
,	O
10-DDYA	B
or	O
11-DDYA	B
)	O
as	O
described	O
by	O
Salaün	O
et	O
al.	O
[	O
27	O
]	O
.	O

Mixtures	O
containing	O
no	O
n	O
-	O
DDYA	B
or	O
no	O
NADPH	B
served	O
as	O
controls	O
.	O

One	O
hundred	O
microliters	O
of	O
aliquots	O
of	O
preincubated	O
microsomes	O
were	O
removed	O
at	O
different	O
intervals	O
(	O
0	O
,	O
6	O
,	O
10	O
,	O
20	O
and	O
30	O
min	O
)	O
and	O
transferred	O
to	O
incubation	O
mixtures	O
containing	O
[	B
1	I
-	I
14	I
C	I
]	I
lauric	I
acid	I
,	O
as	O
described	O
above	O
,	O
in	O
a	O
final	O
volume	O
of	O
0.2	O
ml	O
.	O

Mixtures	O
were	O
further	O
incubated	O
at	O
28	O
°	O
C	O
for	O
5	O
min	O
to	O
measure	O
residual	O
activities	O
of	O
lauric	B
acid	I
hydroxylation	O
,	O
and	O
the	O
reactions	O
were	O
stopped	O
by	O
adding	O
0.2	O
ml	O
of	O
ice	B
-	O
cold	O
acetonitrile	B
containing	O
0.2	O
%	O
acetic	B
acid	I
.	O

Metabolites	B
(	O
100	O
μl	O
aliquots	O
)	O
were	O
resolved	O
by	O
silica	B
thin	O
-	O
layer	O
chromatography	O
developed	O
with	O
diethyl	B
ether	I
/	O
light	B
petroleum	I
(	O
bp	O
40–60	O
°	O
)	O
/	O
formic	B
acid	I
(	O
70:30:1	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
.	O

Radioactive	O
products	O
were	O
located	O
by	O
autoradiography	O
,	O
scraped	O
into	O
counting	O
vials	O
,	O
and	O
the	O
radioactivity	O
was	O
measured	O
with	O
a	O
liquid	O
scintillation	O
counter	O
(	O
Wallac	O
1410	O
,	O
EG&G	O
)	O
.	O

2.6	O
HPLC	O
conditions	O
RP	O
-	O
HPLC	O
analysis	O
was	O
performed	O
using	O
an	O
Alltima	O
C18	O
column	O
(	O
15	O
cm	O
×	O
4.6	O
mm	O
,	O
Alltech	O
)	O
at	O
1.5	O
ml	O
min−1	O
with	O
acetic	B
acid	I
/	O
0.2	O
%	O
water	B
and	O
a	O
linear	O
gradient	O
of	O
acetonitrile	B
from	O
44	O
%	O
to	O
97	O
%	O
over	O
a	O
37-min	O
period	O
.	O

The	O
HPLC	O
eluate	O
containing	O
radioactive	O
metabolites	B
was	O
passed	O
through	O
a	O
Flow	O
-	O
One	O
Beta	O
radioactive	O
flow	O
detector	O
(	O
Radiomatic	O
)	O
to	O
quantify	O
each	O
[	B
1	I
-	I
14	I
C	I
]	I
hydroxylated	I
product	I
formed	O
.	O

2.7	O
GC	O
/	O
MS	O
analysis	O
Compounds	O
isolated	O
by	O
RP	O
-	O
HPLC	O
were	O
chemically	O
hydrogenated	O
(	O
H2	B
and	O
Pd	B
/	O
charcoal	B
)	O
as	O
described	O
by	O
Weissbart	O
et	O
al.	O
[	O
35	O
]	O
,	O
and	O
reanalysed	O
by	O
RP	O
-	O
HPLC	O
to	O
verify	O
peak	O
collection	O
before	O
mass	O
spectra	O
analysis	O
.	O

GC	O
and	O
electron	O
impact	O
(	O
70	O
eV	O
)	O
ionization	O
mass	O
spectrometry	O
analyses	O
were	O
performed	O
as	O
described	O
elsewhere	O
[	O
35	O
]	O
.	O

Characteristic	O
fragment	O
ions	O
generated	O
from	O
positional	O
isomers	O
of	O
n	B
-	I
monohydroxylated	I
lauric	I
acids	I
were	O
identified	O
as	O
previously	O
described	O
[	O
9,17	O
]	O
.	O

2.8	O
Statistical	O
analysis	O
Significance	O
of	O
differences	O
(	O
for	O
each	O
metabolite	B
formed	O
)	O
between	O
controls	O
and	O
treated	O
fish	O
groups	O
was	O
evaluated	O
using	O
the	O
non	O
-	O
parametric	O
Kruskal	O
–	O
Wallis	O
test	O
[	O
15	O
]	O
at	O
P	O
<	O
0.005	O
level	O
.	O

Groups	O
were	O
then	O
compared	O
by	O
pairs	O
using	O
the	O
Mann	O
–	O
Whitney	O
test	O
(	O
P	O
<	O
0.05	O
)	O
.	O

3	O
Results	O
3.1	O
Characterization	O
of	O
lauric	B
acid	I
hydroxylase	O
activities	O
from	O
liver	O
,	O
kidney	O
,	O
and	O
intestinal	O
microsomes	O
Microsomal	O
LAH	O
activities	O
from	O
liver	O
,	O
kidney	O
,	O
and	O
intestinal	O
mucosa	O
were	O
O2	B
-	O
and	O
NADPH	B
-	O
dependent	O
and	O
were	O
inhibited	O
in	O
the	O
presence	O
of	O
a	O
CO	B
/	O
O2	B
mixture	O
suggesting	O
the	O
involvement	O
of	O
cytochrome	O
P-450	O
in	O
these	O
reactions	O
(	O
data	O
not	O
shown	O
)	O
.	O

Products	B
of	I
lauric	I
acid	I
hydroxylation	I
were	O
resolved	O
by	O
RP	O
-	O
HPLC	O
analysis	O
into	O
five	O
radiolabelled	O
metabolites	B
.	O

Retention	O
times	O
were	O
compared	O
with	O
those	O
of	O
standards	O
and	O
methylester	B
trimethylsilylether	B
derivatives	I
of	O
metabolites	B
were	O
further	O
identified	O
by	O
a	O
GC	O
-	O
MS	O
analysis	O
(	O
previously	O
reported	O
by	O
Lemaire	O
et	O
al.	O
[	O
17	O
]	O
)	O
as	O
(	B
ω	I
-1	I
)	I
-	I
,	O
(	B
ω	I
-2	I
)	I
-	I
,	O
(	B
ω	I
-3	I
)	I
-	I
,	O
(	B
ω	I
-4	I
)	I
-	I
and	O
ω	B
-hydroxylauric	I
acids	I
,	O
respectively	O
.	O

Mass	O
spectra	O
of	O
the	O
methyl	B
ester	I
and	O
trimethylsilyl	B
(	O
TMS	B
)	O
derivatives	B
showed	O
typical	O
fragment	O
ions	O
expected	O
from	O
monohydroxylated	B
fatty	I
acids	I
at	O
m	O
/	O
z	O
†287	O
[	O
M-15	O
]	O
+	O
,	O
m	O
/	O
z	O
271	O
[	O
M-31	O
]	O
+	O
,	O
m	O
/	O
z	O
255	O
[	O
M-47	O
]	O
+	O
,	O
m	O
/	O
z	O
146	O
[	O
CH2	B
=	I
C	I
(	I
OSi-	I
(	I
CH3	I
)	I
3	I
)	I
OCH3	I
]	O
+	O
,	O
m	O
/	O
z	O
159	O
[	O
(	B
CH3	I
O	I
=	I
C	I
(	I
OSi-	I
(	I
CH3	I
)	I
3	I
)	I
CH	I
=	I
CH2	I
]	O
+	O
,	O
and	O
the	O
base	O
peak	O
at	O
m	O
/	O
z	O
73	O
(	O
TMS	B
)	O
,	O
which	O
were	O
commonly	O
present	O
in	O
all	O
hydroxylated	B
lauric	I
acid	I
metabolites	B
.	O

The	O
same	O
results	O
were	O
obtained	O
for	O
metabolites	B
generated	O
by	O
the	O
three	O
organs	O
from	O
untreated	O
or	O
clofibrate-	B
and	O
DEHP	B
-	O
treated	O
fish	O
.	O

In	O
all	O
cases	O
,	O
all	O
five	O
hydroxylauric	B
acids	I
are	O
generated	O
,	O
indicating	O
that	O
the	O
site	O
-	O
specific	O
oxidative	O
attack	O
of	O
lauric	B
acid	I
remains	O
unchanged	O
.	O

Only	O
the	O
relative	O
proportion	O
of	O
metabolites	B
was	O
changed	O
in	O
terms	O
of	O
organs	O
and	O
fish	O
treatments	O
.	O

Hence	O
,	O
microsomes	O
from	O
liver	O
,	O
kidney	O
,	O
and	O
intestine	O
catalyzed	O
mainly	O
(	O
ω	O
-1	O
)	O
-	O
and	O
(	O
ω	O
-2	O
)	O
-hydroxylations	O
of	O
lauric	B
acid	I
(	O
Table	O
1	O
)	O
.	O

In	O
intestine	O
,	O
(	B
ω	I
-1	I
)	I
-hydroxylauric	I
acid	I
represents	O
up	O
to	O
72	O
%	O
of	O
the	O
metabolites	B
.	O

Three	O
other	O
metabolites	B
including	O
ω-	B
,	O
(	B
ω	I
-3	I
)	I
-	I
and	O
(	O
ω	O
-4	O
)	O
-hydroxylauric	O
acids	B
were	O
produced	O
to	O
a	O
lesser	O
extent	O
in	O
all	O
tissues	O
.	O

3.2	O
Tissue	O
-	O
specific	O
induction	O
of	O
LAH	O
activities	O
by	O
clofibrate	B
and	O
DEHP	B
The	O
microsomal	O
LAH	O
activities	O
from	O
the	O
three	O
organs	O
were	O
measured	O
in	O
clofibrate-	B
and	O
DEHP	B
-	O
treated	O
sea	O
bass	O
and	O
compared	O
to	O
activities	O
measured	O
in	O
control	O
fish	O
.	O

Intestinal	O
LAH	O
activity	O
was	O
not	O
induced	O
by	O
clofibrate	B
or	O
DEHP	B
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
liver	O
(	O
Fig.	O
1	O
(	O
A	O
)	O
)	O
,	O
clofibrate	B
had	O
no	O
statistically	O
significant	O
effect	O
on	O
metabolites	B
generated	O
from	O
lauric	B
acid	I
.	O

A	O
significant	O
effect	O
was	O
found	O
in	O
hepatic	O
microsomes	O
from	O
DEHP	B
-	O
treated	O
fish	O
:	O
the	O
production	O
of	O
(	B
ω	I
-1	I
)	I
-	I
,	O
(	B
ω	I
-2	I
)	I
-	I
,	O
and	O
(	B
ω	I
-3	I
)	I
-hydroxylauric	I
acid	I
was	O
increased	O
1.9-	O
,	O
2-	O
and	O
2.7-fold	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
LAH	O
activities	O
of	O
kidney	O
microsomes	O
were	O
strongly	O
affected	O
,	O
especially	O
by	O
a	O
DEHP	B
treatment	O
.	O

As	O
in	O
liver	O
microsomes	O
,	O
the	O
production	O
of	O
(	B
ω	I
-1	I
)	I
,	O
(	B
ω	I
-2	I
)	I
,	O
and	O
(	B
ω	I
-3	I
)	I
-hydroxylauric	I
acid	I
was	O
increased	O
,	O
but	O
to	O
higher	O
levels	O
(	O
5.3-	O
,	O
4-	O
and	O
4.9-fold	O
,	O
respectively	O
)	O
.	O

After	O
clofibrate	B
treatment	O
,	O
only	O
the	O
production	O
of	O
(	B
ω	I
-1	I
)	I
-hydroxylauric	I
acid	I
was	O
increased	O
(	O
2.6-fold	O
)	O
.	O

3.3	O
Inactivation	O
of	O
lauric	B
acid	I
hydroxylases	O
by	O
suicide	O
-	O
substrates	O
In	O
order	O
to	O
study	O
the	O
substrate	O
selectivity	O
of	O
sea	O
bass	O
P450s	O
involved	O
in	O
the	O
oxidation	O
of	O
lauric	B
acid	I
,	I
we	O
have	O
evaluated	O
the	O
effects	O
on	O
microsomal	O
LAH	O
activities	O
of	O
three	O
lauric	B
acid	I
analogues	B
containing	O
a	O
triple	O
bond	O
in	O
the	O
vicinity	O
of	O
the	O
carbons	B
preferentially	O
attacked	O
(	O
C10	O
and	O
C11	O
)	O
.	O

Liver	O
microsomes	O
were	O
incubated	O
with	O
9-DDYA	B
,	O
10-DDYA	B
or	O
11-DDYA	B
.	O

10-DDYA	B
was	O
the	O
only	O
analogue	O
tested	O
on	O
sea	O
bass	O
kidney	O
microsomes	O
because	O
of	O
the	O
low	O
amount	O
of	O
biological	O
material	O
obtained	O
from	O
this	O
organ	O
.	O

Preincubation	O
of	O
liver	O
microsomes	O
with	O
10-DDYA	B
resulted	O
in	O
a	O
drastic	O
decrease	O
in	O
total	O
LAH	O
activity	O
.	O

This	O
loss	O
of	O
activity	O
was	O
dependent	O
on	O
incubation	O
time	O
and	O
on	O
the	O
concentration	O
of	O
inhibitor	O
and	O
it	O
occured	O
only	O
in	O
the	O
presence	O
of	O
NADPH	B
.	O

LAH	O
inactivation	O
fitted	O
pseudo	O
-	O
first	O
-	O
order	O
kinetics	O
(	O
Fig.	O
2	O
)	O
.	O

A	O
plot	O
of	O
half	O
-	O
life	O
values	O
(	O
t	O
1	O
/	O
2	O
)	O
against	O
the	O
reciprocal	O
concentrations	O
of	O
inhibitor	O
(	O
Fig.	O
3	O
)	O
allowed	O
for	O
the	O
determination	O
of	O
the	O
apparent	O
binding	O
constant	O
(	O
K	O
i	O
)	O
and	O
half	O
-	O
life	O
of	O
LAH	O
activity	O
at	O
saturating	O
concentration	O
of	O
inhibitor	O
(	O
T	O
1	O
/	O
2	O
)	O
.	O

A	O
pseudo	O
-	O
first	O
-	O
order	O
inactivation	O
constant	O
(	O
k	O
inact	O
)	O
was	O
calculated	O
from	O
the	O
T1	O
/	O
2	O
.	O

The	O
different	O
parameters	O
obtained	O
with	O
10-DDYA	B
and	O
11-DDYA	B
are	O
recapitulated	O
in	O
Table	O
2	O
.	O

On	O
the	O
other	O
hand	O
,	O
80	O
μM	O
of	O
9-DDYA	B
caused	O
only	O
a	O
slight	O
loss	O
of	O
activity	O
(	O
4	O
%	O
)	O
after	O
a	O
30-min	O
preincubation	O
time	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
9-DDYA	B
is	O
a	O
weak	O
inhibitor	O
of	O
LAH	O
activities	O
in	O
liver	O
microsomes	O
.	O

4	O
Discussion	O
The	O
involvement	O
of	O
several	O
mammalian	O
CYP4	O
members	O
in	O
lauric	B
acid	I
hydroxylation	O
is	O
now	O
well	O
documented	O
,	O
but	O
only	O
limited	O
informations	O
are	O
available	O
for	O
fish	O
.	O

Most	O
of	O
the	O
investigations	O
in	O
fish	O
have	O
focused	O
on	O
hepatic	O
P450	O
isoforms	O
.	O

The	O
ω	O
-	O
to	O
(	O
ω	O
-6	O
)	O
-hydroxylation	O
of	O
lauric	B
acid	I
in	O
liver	O
of	O
rainbow	O
trout	O
has	O
been	O
reported	O
,	O
but	O
only	O
CYP2-mediated	O
activities	O
were	O
investigated	O
[	O
4,39	O
]	O
.	O

Very	O
recently	O
,	O
a	O
partial	O
cDNA	O
sequence	O
isolated	O
from	O
rainbow	O
trout	O
liver	O
was	O
identified	O
as	O
a	O
CYP4	O
gene	O
[	O
7	O
]	O
,	O
indicating	O
the	O
existence	O
of	O
a	O
P450	O
belonging	O
to	O
this	O
family	O
in	O
fish	O
.	O

As	O
a	O
first	O
step	O
to	O
develop	O
new	O
biomarkers	O
specific	O
for	O
other	O
classes	O
of	O
marine	O
pollutants	B
(	O
phthalates	B
)	O
,	O
we	O
focused	O
our	O
study	O
on	O
the	O
effect	O
of	O
several	O
CYP4	O
inducers	O
on	O
the	O
cytochrome	O
P450-dependent	O
LAH	O
activities	O
in	O
sea	O
bass	O
tissues	O
.	O

Microsomes	O
from	O
liver	O
,	O
kidney	O
or	O
intestinal	O
mucosa	O
of	O
sea	O
bass	O
catalyzed	O
mainly	O
in	O
-	O
chain	O
hydroxylation	O
(	O
especially	O
(	O
ω	O
-1	O
)	O
-	O
and	O
(	O
ω	O
-2	O
)	O
-hydroxylations	O
)	O
of	O
lauric	B
acid	I
.	I

Such	O
an	O
in	O
-	O
chain	O
hydroxylation	O
of	O
fatty	B
acids	I
(	O
ω	O
-1	O
to	O
ω	O
-4	O
)	O
is	O
also	O
found	O
in	O
bacteria	O
[	O
20	O
]	O
,	O
yeast	O
[	O
29	O
]	O
,	O
fungi	O
[	O
33	O
]	O
,	O
and	O
some	O
plants	O
[	O
27	O
]	O
.	O

In	O
contrast	O
,	O
hydroxylation	O
of	O
fatty	B
acids	I
occurs	O
mainly	O
at	O
the	O
ω	O
position	O
in	O
mammals	O
[	O
16	O
]	O
,	O
amphibians	O
[	O
21	O
]	O
,	O
insects	O
[	O
5	O
]	O
,	O
yeast	O
[	O
29	O
]	O
,	O
and	O
Leguminosae	O
[	O
26	O
]	O
.	O

Kidney	O
microsomes	O
catalyzed	O
lauric	B
acid	I
hydroxylation	O
more	O
efficiently	O
than	O
liver	O
microsomes	O
,	O
as	O
was	O
observed	O
in	O
the	O
trout	O
[	O
36	O
]	O
and	O
in	O
the	O
rat	O
[	O
10	O
]	O
.	O

These	O
results	O
suggests	O
that	O
these	O
P450	O
systems	O
from	O
kidney	O
are	O
rather	O
specialized	O
for	O
fatty	B
acid	I
(	O
ω	O
-1	O
)	O
-hydroxylation	O
.	O

The	O
hydroxylation	O
of	O
lauric	B
acid	I
at	O
different	O
positions	O
in	O
sea	O
bass	O
could	O
be	O
explained	O
both	O
by	O
several	O
CYP2	O
[	O
4,19	O
]	O
and	O
CYP4	O
gene	O
-	O
mediated	O
activities	O
.	O

Buhler	O
et	O
al.	O
[	O
4	O
]	O
have	O
reported	O
that	O
CYP2M1	O
and	O
CYP2K1	O
catalyse	O
some	O
of	O
the	O
lauric	B
acid	I
(	O
ω	O
-1	O
)	O
-	O
to	O
(	O
ω	O
-6	O
)	O
-hydroxylations	O
but	O
several	O
other	O
CYP	O
isozymes	O
may	O
also	O
contribute	O
to	O
this	O
regiospecific	O
fatty	B
acid	I
metabolism	O
.	O

Indeed	O
,	O
a	O
CYP4T1	O
gene	O
has	O
been	O
isolated	O
in	O
trout	O
[	O
7	O
]	O
,	O
and	O
four	O
CYP4A	O
isozymes	O
have	O
been	O
characterized	O
in	O
rat	O
liver	O
.	O

CYP4A2	O
catalyses	O
only	O
ω	O
-hydroxylation	O
whereas	O
CYP4A1	O
and	O
CYP4A3	O
catalyses	O
both	O
ω	O
-	O
and	O
(	O
ω	O
-1	O
)	O
-hydroxylations	O
of	O
lauric	B
acid	I
[	O
13,14	O
]	O
.	O

CYP4A1	O
protein	O
could	O
play	O
two	O
alternative	O
functional	O
roles	O
both	O
in	O
a	O
catabolic	O
process	O
[	O
32	O
]	O
and	O
in	O
the	O
conversion	O
of	O
arachidonate	B
to	O
signal	O
metabolites	B
[	O
30	O
]	O
.	O

The	O
long	B
-	I
chain	I
dicarboxylic	I
acids	I
formed	O
via	O
the	O
CYP4A1	O
pathway	O
seems	O
to	O
regulate	O
the	O
peroxisomal	O
β	O
-oxidation	O
enzymes	O
[	O
12	O
]	O
.	O

Moreover	O
,	O
CYP4A1	O
is	O
regulated	O
by	O
the	O
same	O
mechanism	O
that	O
controls	O
the	O
peroxisomal	O
β	O
-oxidation	O
enzymes	O
:	O
CYP4A1	O
expression	O
is	O
modified	O
by	O
starvation	O
[	O
11	O
]	O
.	O

Lemaire	O
et	O
al.	O
[	O
17	O
]	O
have	O
shown	O
that	O
sea	O
bass	O
starvation	O
also	O
increases	O
LAH	O
activities	O
.	O

However	O
,	O
the	O
physiological	O
significance	O
of	O
in	O
-	O
chain	O
hydroxylation	O
by	O
P450	O
systems	O
in	O
fish	O
is	O
still	O
unknown	O
.	O

Because	O
lipids	B
are	O
a	O
preferential	O
energy	O
source	O
in	O
fish	O
,	O
fatty	B
acid	I
metabolism	O
is	O
a	O
very	O
important	O
biological	O
process	O
for	O
fish	O
[	O
34	O
]	O
.	O

This	O
could	O
explain	O
the	O
great	O
diversity	O
of	O
metabolites	B
formed	O
in	O
sea	O
bass	O
and	O
trout	O
[	O
4	O
]	O
.	O

Several	O
mechanism	O
-	O
based	O
inhibitors	O
of	O
P450	O
which	O
selectively	O
inhibit	O
P450	O
isozymes	O
have	O
been	O
previously	O
described	O
:	O
rat	O
hepatic	O
ω	O
-hydroxylases	O
are	O
inactivated	O
by	O
11-DDYA	B
[	O
25	O
]	O
.	O

The	O
experimental	O
use	O
in	O
vivo	O
of	O
such	O
fatty	B
acid	I
analogues	O
has	O
clarified	O
the	O
functional	O
role	O
of	O
several	O
fatty	B
acid	I
hydroxylases	O
in	O
rat	O
[	O
40	O
]	O
and	O
in	O
plant	O
[	O
9	O
]	O
.	O

Preincubations	O
of	O
liver	O
or	O
kidney	O
microsomes	O
with	O
11-DDYA	B
or	O
10-DDYA	B
in	O
the	O
presence	O
of	O
NADPH	B
resulted	O
in	O
time-	O
and	O
concentration	O
-	O
dependent	O
inhibitions	O
described	O
by	O
pseudo	O
-	O
first	O
order	O
kinetics	O
,	O
which	O
is	O
characteristic	O
of	O
mechanism	O
-	O
based	O
inhibition	O
.	O

9-DDYA	B
was	O
a	O
very	O
weak	O
inhibitor	O
.	O

These	O
data	O
agree	O
with	O
the	O
highly	O
selective	O
oxidation	O
of	O
lauric	B
acid	I
at	O
the	O
subterminal	O
position	O
by	O
sea	O
bass	O
microsomes	O
whatever	O
the	O
tissue	O
.	O

Yang	O
et	O
al.	O
[	O
38	O
]	O
have	O
demonstrated	O
that	O
ciprofibrate	B
induces	O
peroxisome	O
proliferation	O
in	O
rainbow	O
trout	O
liver	O
,	O
but	O
such	O
a	O
response	O
was	O
not	O
observed	O
with	O
gemfibrozil	B
[	O
28	O
]	O
or	O
dehydroepiandrosterone	B
[	O
18	O
]	O
,	O
whereas	O
these	O
compounds	O
are	O
LAH	O
inducers	O
in	O
rodents	O
[	O
24	O
]	O
.	O

Haasch	O
[	O
8	O
]	O
has	O
reported	O
that	O
catfish	O
's	O
and	O
bluegill	O
's	O
liver	O
and	O
kidney	O
showed	O
increased	O
CYP2K1	O
and	O
CYP2M1	O
P450	O
ortholog	O
expression	O
after	O
treatment	O
with	O
fibrates	B
(	O
clofibrate	B
and	O
ciprofibrate	B
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
clofibrate	B
and	O
DEHP	B
on	O
liver	O
,	O
kidney	O
,	O
and	O
intestinal	O
LAH	O
activities	O
of	O
sea	O
bass	O
.	O

Lauric	B
acid	I
(	O
ω	O
-1	O
)	O
-hydroxylation	O
is	O
strongly	O
induced	O
in	O
sea	O
bass	O
kidney	O
treated	O
with	O
DEHP	B
.	O

The	O
amount	O
of	O
ω	B
-hydroxylauric	I
acid	I
remained	O
unchanged	O
in	O
liver	O
and	O
kidney	O
of	O
clofibrate	B
and	O
DEHP	B
-	O
treated	O
fish	O
as	O
compared	O
to	O
control	O
,	O
although	O
this	O
metabolite	B
is	O
strongly	O
increased	O
in	O
rodents	O
treated	O
with	O
peroxisome	O
proliferators	O
[	O
31	O
]	O
.	O

Thus	O
,	O
the	O
site	O
-	O
specificity	O
of	O
lauric	B
acid	I
oxidative	O
attack	O
in	O
sea	O
bass	O
microsomes	O
was	O
not	O
modified	O
by	O
a	O
treatment	O
with	O
peroxisome	O
proliferators	O
.	O

Methylclofenapate	B
(	O
an	O
hypolipidemic	O
drug	O
,	O
such	O
as	O
clofibrate	B
)	O
induced	O
CYP4A	O
mRNA	O
in	O
mice	O
and	O
rat	O
liver	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
kidney	O
[	O
3	O
]	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
significant	O
induction	O
of	O
CYP4A	O
in	O
the	O
liver	O
or	O
kidney	O
of	O
guinea	O
-	O
pigs	O
exposed	O
to	O
methylclofenapate	B
[	O
3	O
]	O
.	O

These	O
data	O
suggested	O
that	O
there	O
is	O
species	O
difference	O
in	O
response	O
to	O
peroxisome	O
proliferators	O
between	O
rodents	O
and	O
guinea	O
pig	O
.	O

As	O
in	O
guinea	O
-	O
pig	O
,	O
LAH	O
activities	O
from	O
clofibrate	B
-	O
treated	O
sea	O
bass	O
showed	O
no	O
significant	O
induction	O
in	O
liver	O
.	O

Both	O
clofibrate	B
(	O
and	O
several	O
other	O
fibrates	B
)	O
and	O
phthalates	O
are	O
potent	O
peroxisome	O
proliferators	O
and	O
CYP4	O
inducers	O
in	O
rodent	O
liver	O
[	O
3	O
]	O
.	O

In	O
contrast	O
,	O
the	O
induction	O
of	O
LAH	O
activity	O
in	O
sea	O
bass	O
is	O
more	O
important	O
in	O
kidney	O
than	O
in	O
liver	O
,	O
and	O
DEHP	B
is	O
by	O
far	O
a	O
more	O
potent	O
inducer	O
of	O
LAH	O
activities	O
than	O
clofibrate	B
.	O

Together	O
,	O
our	O
results	O
are	O
much	O
in	O
favor	O
of	O
the	O
involvement	O
of	O
several	O
P450s	O
in	O
LAH	O
activities	O
in	O
sea	O
bass	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
LAH	O
activities	O
are	O
induced	O
in	O
sea	O
bass	O
kidney	O
by	O
peroxisome	O
proliferators	O
,	O
especially	O
phthalates	B
.	O

Considering	O
that	O
phthalate	B
ester	I
plasticizers	B
represent	O
widely	O
-	O
distributed	O
environmental	B
contaminants	I
,	O
the	O
induction	O
of	O
LAH	O
activities	O
in	O
fish	O
kidney	O
by	O
phthalates	B
could	O
be	O
a	O
first	O
step	O
in	O
the	O
development	O
of	O
efficient	O
biomarkers	O
for	O
this	O
class	O
of	O
marine	O
pollutants	B
.	O

The	O
use	O
of	O
such	O
a	O
biomarker	O
to	O
detect	O
phthalates	B
in	O
sea	O
water	B
will	O
be	O
easier	O
and	O
cheaper	O
than	O
chemical	O
analysis	O
.	O

Moreover	O
,	O
further	O
isolation	O
and	O
cloning	O
of	O
sea	O
bass	O
CYP4	O
genes	O
from	O
this	O
tissue	O
are	O
currently	O
under	O
way	O
to	O
develop	O
molecular	O
tools	O
.	O

Acknowledgements	O
This	O
research	O
was	O
supported	O
by	O
a	O
EEC	O
grant	O
(	O
CEE	O
-	O
BIOMAR	O
EV5V	O
-	O
CT94	O
-	O
0550	O
)	O
.	O

We	O
are	O
very	O
grateful	O
to	O
Drs	O
David	O
Pauron	O
(	O
INRA	O
,	O
Antibes	O
)	O
and	O
René	O
Feyereisen	O
(	O
University	O
of	O
Arizona	O
,	O
Tucson	O
)	O
for	O
critically	O
reading	O
this	O
manuscript	O
.	O

We	O
would	O
like	O
to	O
thank	O
Dr	O
Charles	O
Mioskowski	O
(	O
CNRS	O
-	O
Faculté	O
de	O
Pharmacie	O
,	O
Strasbourg	O
)	O
for	O
providing	O
us	O
with	O
dodecynoic	B
acids	I
.	O

A	O
novel	O
type	O
of	O
NADPH	O
-	O
dependent	O
sepiapterin	O
reductase	O
,	O
which	O
catalysed	O
uniquely	O
the	O
reduction	O
of	O
sepiapterin	B
to	O
l	B
-	I
threo	I
-	I
dihydrobiopterin	I
,	O
was	O
purified	O
533-fold	O
from	O
the	O
cytosolic	O
fraction	O
of	O
Chlorobium	O
tepidum	O
,	O
with	O
an	O
overall	O
yield	O
of	O
3	O
%	O
.	O

The	O
native	O
enzyme	O
had	O
a	O
molecular	O
mass	O
of	O
55	O
kDa	O
and	O
SDS	O
/	O
PAGE	O
revealed	O
that	O
the	O
enzyme	O
consists	O
of	O
two	O
subunits	O
with	O
a	O
molecular	O
mass	O
of	O
26	O
kDa	O
.	O

The	O
enzyme	O
was	O
optimally	O
active	O
at	O
pH8.8	O
and	O
50	O
degrees	O
C.	O
Apparent	O
Km	O
values	O
for	O
sepiapterin	B
and	O
NADPH	B
were	O
21	O
and	O
6.2	O
microM	O
,	O
respectively	O
,	O
and	O
the	O
kcat	O
value	O
was	O
5.0	O
s-1	O
.	O

Diacetyl	B
could	O
also	O
serve	O
as	O
a	O
substrate	O
,	O
with	O
a	O
Km	O
of	O
4.0	O
mM.	O
The	O
inhibitory	O
effects	O
of	O
N	B
-	I
acetylserotonin	I
,	O
N	B
-	I
acetyldopamine	I
and	O
melatonin	B
were	O
very	O
weak	O
.	O

The	O
Ki	O
value	O
of	O
N	B
-	I
acetyldopamine	I
was	O
measured	O
as	O
400	O
microM.	O
The	O
N	B
-	I
terminal	I
amino	I
acid	I
sequence	O
was	O
revealed	O
as	O
Met	B
-	I
Lys	I
-	I
His	I
-	I
Ile	I
-	I
Leu	I
-	I
Leu	I
-	I
Ile	I
-	I
Thr	I
-	I
Gly	I
-	I
Ala	I
-	I
Xaa	I
-	I
Lys	I
-	I
Lys	I
-	I
Ile	I
-	I
Xaa	I
-	I
Arg	I
-	I
Ala	I
-	I
Ile	I
-	I
Ala	I
-	I
Leu	I
-	I
Glu	I
-	I
Xaa	I
-	I
Ala	I
-	I
Arg	I
-	I
Xaa	I
-	I
Xaa	I
-	I
Xaa	I
-	I
His	I
-	I
His	I
-	I
His-	I
,	O
which	O
shared	O
relatively	O
high	O
sequence	O
similarity	O
with	O
other	O
sepiapterin	O
reductases	O
.	O

Stachyose	O
synthase	O
(	O
STS	O
)	O
(	O
EC	O
2.4.1.67	O
)	O
was	O
purified	O
313-fold	O
from	O
mature	O
seeds	O
of	O
lentil	O
.	O

The	O
final	O
preparation	O
had	O
a	O
specific	O
activity	O
of	O
9.09	O
nkat	O
stachyose	B
formed	O
per	O
milligram	O
of	O
protein	O
.	O

The	O
enzyme	O
was	O
a	O
monomeric	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
88.6	O
kDa	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
an	O
isoelectric	O
point	O
of	O
4.8	O
(	O
chromatofocusing	O
)	O
.	O

Western	O
analysis	O
revealed	O
cross	O
-	O
reactivity	O
of	O
polyclonal	O
antibodies	O
raised	O
against	O
STS	O
from	O
adzuki	O
bean	O
with	O
the	O
lentil	O
enzyme	O
.	O

The	O
purified	O
enzyme	O
catalyzed	O
a	O
range	O
of	O
different	O
galactosyl	O
transfer	O
reactions	O
.	O

In	O
addition	O
to	O
the	O
genuine	O
STS	O
reaction	O
(	O
raffinose	B
+	O
galactinol	B
--	O
>	O
stachyose	B
+	O
myo	B
-	I
inositol	I
)	I
,	O
the	O
enzyme	O
catalyzed	O
the	O
reversible	O
galactosyl	O
transfer	O
from	O
galactinol	B
to	O
d	B
-	I
pinitol	I
(	O
1d-3-O	B
-	I
methyl	I
-	I
chiro	I
-	I
inositol	I
)	O
,	O
yielding	O
galactopinitol	B
A	I
(	O
O	B
-	I
alpha	I
-	I
d	I
-	I
galactopyranosyl-	I
(	I
1	I
--	I
>	I
2	I
)	I
-4-O	I
-	I
methyl	I
-	I
d	I
-	I
chiro	I
-	I
inositol	I
)	I
and	O
myo	B
-	I
inositol	I
.	I

Galactopinitol	B
A	I
could	O
be	O
further	O
galactosylated	O
by	O
STS	O
to	O
give	O
ciceritol	B
(	O
O	B
-	I
alpha	I
-	I
d	I
-	I
galactopyranosyl-	I
(	I
1	I
--	I
>	I
6	I
)	I
-O	I
-	I
alpha	I
-	I
d	I
-	I
galactopyranosyl-	I
(	I
1	I
--	I
>	I
2	I
)	I
-4-O	I
-	I
methyl	I
-	I
d	I
-	I
chiro	I
-	I
inositol	I
)	O
.	O

Enzymatic	O
synthesis	O
of	O
galactopinitol	B
A	I
and	O
ciceritol	B
is	O
a	O
new	O
observation	O
.	O

However	O
,	O
STS	O
was	O
not	O
only	O
able	O
to	O
utilize	O
galactopinitol	B
A	I
as	O
galactosyl	O
acceptor	O
,	O
but	O
also	O
as	O
galactosyl	O
donor	O
to	O
form	O
stachyose	B
from	O
raffinose	B
.	O

The	O
role	O
of	O
STS	O
in	O
the	O
metabolism	O
of	O
galactosyl	B
cyclitols	I
and	O
oligosaccharides	B
in	O
plant	O
seeds	O
is	O
discussed	O
.	O

We	O
have	O
identified	O
a	O
series	O
of	O
novel	O
inhibitors	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
integrase	O
by	O
randomly	O
screening	O
natural	O
product	O
extracts	O
using	O
an	O
in	O
vitro	O
biochemical	O
assay	O
designed	O
to	O
identify	O
inhibitors	O
of	O
integrase	O
-	O
catalysed	O
strand	O
transfer	O
.	O

Equisetin	B
recovered	O
from	O
the	O
fungus	O
Fusarium	O
heterosporum	O
and	O
a	O
novel	O
enantiomeric	B
homologue	I
of	I
equisetin	I
from	O
Phoma	O
sp.	O
were	O
isolated	O
as	O
inhibitors	O
of	O
HIV-1	O
integrase	O
in	O
vitro	O
.	O

Two	O
additional	O
analogues	O
,	O
a	O
novel	O
decalin	B
derivative	I
,	O
integric	B
acid	I
,	O
and	O
oteromycin	B
were	O
also	O
discovered	O
to	O
be	O
inhibitors	O
of	O
integrase	O
.	O

Equisetin	B
and	O
related	O
compounds	O
inhibit	O
3	O
'	O
end	O
-	O
processing	O
and	O
strand	O
transfer	O
as	O
well	O
as	O
disintegration	O
catalysed	O
by	O
either	O
the	O
full	O
-	O
length	O
enzyme	O
or	O
the	O
truncated	O
integrase	O
core	O
domain	O
(	O
amino	B
acids	I
50	O
-	O
212	O
)	O
.	O

These	O
compounds	O
also	O
inhibit	O
strand	O
transfer	O
reactions	O
catalysed	O
by	O
stable	O
complexes	O
assembled	O
in	O
vitro	O
and	O
integration	O
reactions	O
catalysed	O
by	O
pre	O
-	O
integration	O
complexes	O
isolated	O
from	O
HIV-1-infected	O
cells	O
.	O

The	O
compounds	O
described	O
in	O
this	O
report	O
are	O
structurally	O
novel	O
and	O
mechanistically	O
distinct	O
from	O
many	O
previously	O
described	O
inhibitors	O
of	O
HIV-1	O
integrase	O
.	O

These	O
results	O
demonstrate	O
the	O
utility	O
of	O
using	O
an	O
appropriately	O
configured	O
assay	O
to	O
identify	O
compounds	O
that	O
are	O
effective	O
post	O
-	O
assembly	O
and	O
the	O
potential	O
of	O
isolating	O
novel	O
integrase	O
inhibitors	O
from	O
complex	O
natural	O
product	O
extracts	O
.	O

AIMS	O
:	O
The	O
present	O
study	O
was	O
conducted	O
to	O
evaluate	O
metabolism	O
of	O
the	O
enantiomers	B
of	I
verapamil	B
and	O
norverapamil	B
using	O
a	O
broad	O
range	O
of	O
cytochrome	O
P450	O
isoforms	O
and	O
measure	O
the	O
kinetic	O
parameters	O
of	O
these	O
processes	O
.	O

METHODS	O
:	O
Cytochrome	O
P450	O
cDNA	O
-	O
expressed	O
cells	O
and	O
microsomes	O
from	O
a	O
P450-expressed	O
lymphoblastoid	O
cell	O
line	O
were	O
incubated	O
with	O
40	O
microm	O
concentrations	O
of	O
R-	B
or	O
S	B
-	I
verapamil	I
and	O
R-	B
or	O
S	B
-	I
norverapamil	I
and	O
metabolite	B
formation	O
measured	O
by	O
h.p.l.c	O
.	O

as	O
an	O
initial	O
screening	O
.	O

Those	O
isoforms	O
exhibiting	O
substantial	O
activity	O
were	O
then	O
studied	O
over	O
a	O
range	O
of	O
substrate	B
concentrations	O
(	O
2.5	O
-	O
450	O
microm	O
)	O
to	O
estimate	O
the	O
kinetic	O
parameters	O
for	O
metabolite	B
formation	O
.	O

RESULTS	O
:	O
P450s	O
3A4	O
,	O
3A5	O
,	O
2C8	O
and	O
to	O
a	O
minor	O
extent	O
2E1	O
were	O
involved	O
in	O
the	O
metabolism	O
of	O
the	O
enantiomers	B
of	I
verapamil	I
.	O

Estimated	O
Km	O
values	O
for	O
the	O
production	O
of	O
D-617	B
and	O
norverapamil	B
by	O
P450	O
s	O
3A4	O
and	O
3A5	O
were	O
similar	O
(	O
range=60	O
-	O
127	O
microm	O
)	O
regardless	O
of	O
the	O
enantiomer	B
of	I
verapamil	I
studied	O
while	O
the	O
Vmax	O
estimates	O
were	O
also	O
similar	O
(	O
range=4	O
-	O
8	O
pmol	O
min-1	O
pmol-1	O
P450	O
)	O
.	O

Only	O
nominal	O
production	O
of	O
D-620	B
by	O
these	O
isoforms	O
was	O
noted	O
.	O

Interestingly	O
,	O
P450	O
2C8	O
readily	O
metabolized	O
both	O
S-	B
and	O
R	B
-	I
verapamil	I
to	O
D-617	B
,	O
norverapamil	B
and	O
PR-22	B
with	O
only	O
slightly	O
higher	O
Km	O
values	O
than	O
noted	O
for	O
P450s	O
3A4	O
and	O
3A5	O
.	O

However	O
,	O
the	O
Vmax	O
estimates	O
for	O
P450	O
2C8	O
metabolism	O
of	O
S-	B
and	O
R	B
-	I
verapamil	I
were	O
in	O
general	O
greater	O
(	O
range=8	O
-	O
15	O
pmol	O
min-1	O
pmol-1	O
P450	O
)	O
than	O
those	O
noted	O
for	O
P450	O
s	O
3A4	O
and	O
3A5	O
with	O
preference	O
noted	O
for	O
metabolism	O
of	O
the	O
S	B
-	I
enantiomer	I
.	O

Similarly	O
,	O
P450	O
s	O
3A4	O
,	O
3A5	O
and	O
2C8	O
also	O
mediated	O
the	O
metabolism	O
of	O
the	O
enantiomers	B
of	I
norverapamil	I
with	O
minor	O
contributions	O
by	O
P450	O
s	O
2D6	O
and	O
2E1	O
.	O

P450s	O
3A4	O
and	O
3A5	O
readily	O
formed	O
the	O
D-620	B
metabolite	I
with	O
generally	O
a	O
lower	O
Km	O
and	O
higher	O
Vmax	O
for	O
S	B
-	I
norverapamil	I
than	O
for	O
the	O
R	B
-	I
enantiomer	I
.	I

In	O
contrast	O
,	O
P450	O
2C8	O
produced	O
both	O
the	O
D-620	B
and	O
PR-22	B
metabolites	I
from	O
the	O
enantiomers	B
of	I
norverapamil	I
,	O
again	O
with	O
stereoselective	O
preference	O
seen	O
for	O
the	O
S	B
-	I
enantiomer	I
.	O

CONCLUSIONS	O
:	O
These	O
results	O
confirm	O
that	O
P450s	O
3A4	O
,	O
3A5	O
and	O
2C8	O
play	O
a	O
major	O
role	O
in	O
verapamil	B
metabolism	O
and	O
demonstrate	O
that	O
norverapamil	B
can	O
also	O
be	O
further	O
metabolized	O
by	O
the	O
P450s	O
.	O

Phenylacetic	B
acids	I
are	O
common	O
intermediates	O
in	O
the	O
microbial	O
metabolism	O
of	O
various	O
aromatic	B
substrates	I
including	O
phenylalanine	B
.	O

In	O
the	O
denitrifying	O
bacterium	O
Thauera	O
aromatica	O
phenylacetate	B
is	O
oxidized	O
,	O
under	O
anoxic	O
conditions	O
,	O
to	O
the	O
common	O
intermediate	O
benzoyl	B
-	I
CoA	I
via	O
the	O
intermediates	O
phenylacetyl	B
-	I
CoA	I
and	O
phenylglyoxylate	B
(	O
benzoylformate	B
)	O
.	O

The	O
enzyme	O
that	O
catalyzes	O
the	O
four	O
-	O
electron	O
oxidation	O
of	O
phenylacetyl	B
-	I
CoA	I
has	O
been	O
purified	O
from	O
this	O
bacterium	O
and	O
studied	O
.	O

The	O
enzyme	O
preparation	O
catalyzes	O
the	O
reaction	O
phenylacetyl	B
-	I
CoA	I
+	O
2	O
quinone	B
+	O
2	O
H2O	B
--	O
>	O
phenylglyoxylate	B
+	O
2	O
quinone	B
H2	B
+	O
CoASH	B
.	O

Phenylacetyl	B
-	I
CoA	I
:	O
acceptor	O
oxidoreductase	O
is	O
a	O
membrane	O
-	O
bound	O
molybdenum	B
-	O
iron	B
-	O
sulfur	B
protein	O
.	O

The	O
purest	O
preparations	O
contained	O
three	O
subunits	O
of	O
93	O
,	O
27	O
,	O
and	O
26	O
kDa	O
.	O

Ubiquinone	B
is	O
most	O
likely	O
to	O
act	O
as	O
the	O
electron	O
acceptor	O
,	O
and	O
the	O
oxygen	B
atom	O
introduced	O
into	O
the	O
product	O
is	O
derived	O
from	O
water	B
.	O

The	O
protein	O
preparations	O
contained	O
0.66	O
mol	O
Mo	B
,	O
30	O
mol	O
Fe	B
,	O
and	O
25	O
mol	O
acid	B
-	O
labile	O
sulfur	B
per	O
mol	O
of	O
native	O
enzyme	O
,	O
assuming	O
a	O
native	O
molecular	O
mass	O
of	O
280	O
kDa	O
.	O

Phenylglyoxylyl	B
-	I
CoA	I
,	O
but	O
not	O
mandelyl	B
-	I
CoA	I
,	O
was	O
observed	O
as	O
a	O
free	O
intermediate	O
.	O

All	O
enzyme	O
preparations	O
also	O
catalyzed	O
the	O
subsequent	O
hydrolytic	O
release	O
of	O
coenzyme	B
A	I
from	O
phenylglyoxylyl	B
-	I
CoA	I
but	O
not	O
from	O
phenylacetyl	B
-	I
CoA.	I
The	O
enzyme	O
is	O
reversibly	O
inactivated	O
by	O
a	O
low	O
concentration	O
of	O
cyanide	B
,	O
but	O
is	O
remarkably	O
stable	O
with	O
respect	O
to	O
oxygen	B
.	O

This	O
new	O
member	O
of	O
the	O
molybdoproteins	O
represents	O
the	O
first	O
example	O
of	O
an	O
enzyme	O
which	O
catalyzes	O
the	O
alpha	O
-	O
oxidation	O
of	O
a	O
CoA	O
-	O
activated	O
carboxylic	O
acid	O
without	O
utilizing	O
molecular	O
oxygen	B
.	O

Phlorisovalerophenone	O
synthase	O
(	O
VPS	O
)	O
,	O
a	O
novel	O
aromatic	O
polyketide	O
synthase	O
,	O
was	O
purified	O
to	O
homogeneity	O
from	O
4.2	O
mg	O
protein	O
extract	O
obtained	O
from	O
hop	O
(	O
Humulus	O
lupulus	O
L.	O
)	O
cone	O
glandular	O
hairs	O
.	O

The	O
enzyme	O
uses	O
isovaleryl	B
-	I
CoA	I
or	O
isobutyryl	B
-	I
CoA	I
and	O
three	O
molecules	O
of	O
malonyl	B
-	I
CoA	I
to	O
form	O
phlorisovalerophenone	B
or	O
phlorisobutyrophenone	B
,	O
intermediates	O
in	O
the	O
biosynthesis	O
of	O
the	O
hop	O
bitter	B
acids	I
(	O
alpha-	B
and	O
beta	B
-	I
acids	I
)	O
.	O

VPS	O
is	O
an	O
homodimeric	O
enzyme	O
,	O
with	O
subunits	O
of	O
45	O
kDa	O
.	O

The	O
pI	O
of	O
the	O
enzyme	O
was	O
6.1	O
.	O

Km	O
values	O
of	O
4	O
microm	O
for	O
isovaleryl	B
-	I
CoA	I
,	O
10	O
microm	O
for	O
isobutyryl	B
-	I
CoA	I
and	O
33	O
microm	O
for	O
malonyl	O
-	O
CoA	O
,	O
were	O
found	O
.	O

The	O
amino	B
-	I
acid	I
sequences	O
of	O
two	O
peptides	B
,	O
obtained	O
by	O
digestion	O
of	O
VPS	O
,	O
showed	O
that	O
the	O
enzyme	O
is	O
highly	O
homologous	O
to	O
plant	O
chalcone	O
synthases	O
.	O

The	O
functional	O
and	O
structural	O
relationship	O
between	O
VPS	O
and	O
other	O
aromatic	O
polyketide	O
synthases	O
is	O
discussed	O
.	O

Supplementation	O
of	O
vegetable	O
proteins	O
with	O
various	O
essential	B
amino	I
acids	I
is	O
an	O
effective	O
means	O
of	O
improving	O
proteins	O
quality	O
.	O

Unfortunately	O
,	O
simple	O
amino	B
acid	I
additions	O
to	O
foods	O
which	O
must	O
be	O
heat	O
processed	O
and	O
cooked	O
is	O
not	O
without	O
consequences	O
.	O

Under	O
these	O
conditions	O
,	O
methionine	B
interacts	O
with	O
reducing	B
sugars	I
yielding	O
methional	B
through	O
the	O
Strecker	O
degradation	O
reaction	O
.	O

This	O
generation	O
of	O
methional	B
during	O
heat	O
treatment	O
imparts	O
undesirable	O
sulfur	B
odors	O
and	O
flavors	O
to	O
the	O
food	O
rendering	O
it	O
organoleptically	O
unacceptable	O
.	O

Similarly	O
,	O
threonine	B
and	O
lysine	B
are	O
also	O
susceptible	O
to	O
interaction	O
with	O
reducing	B
sugars	I
rendering	O
them	O
nutritionally	O
unavailable	O
.	O

Acetylated	B
derivatives	I
of	I
methionine	B
,	O
threonine	B
and	O
lysine	B
have	O
been	O
studied	O
to	O
determine	O
their	O
utility	O
in	O
overcoming	O
the	O
inherent	O
problems	O
associated	O
with	O
each	O
amino	B
acid	I
.	O

To	O
this	O
end	O
,	O
N	B
-	I
acetyl	I
-	I
L	I
-	I
methionine	I
and	O
N	B
-	I
acetyl	I
-	I
L	I
-	I
threonine	I
were	O
found	O
to	O
be	O
fully	O
available	O
to	O
promote	O
growth	O
of	O
rats	O
.	O

To	O
the	O
contrary	O
,	O
neither	O
the	O
alpha	B
nor	O
the	O
epsilon	B
,	I
monoacetylated	I
derivative	I
of	I
L	I
-	I
Lysine	I
nor	O
the	O
alpha	B
,	O
epsilon	B
diacetyl	I
derivative	I
of	I
L	I
-	I
Lysine	I
were	O
effective	O
in	O
significantly	O
promoting	O
the	O
growth	O
of	O
rats	O
.	O

Utilization	O
of	O
N	B
-	I
acetyl	I
-	I
L	I
-	I
methionine	I
by	O
humans	O
has	O
also	O
been	O
studied	O
and	O
shown	O
to	O
be	O
as	O
effective	O
as	O
methionine	B
in	O
improving	O
the	O
quality	O
of	O
vegetable	O
proteins	O
deficient	O
in	O
sulfur	B
amino	I
acids	I
.	O

Nigericin	B
is	O
an	O
ionophore	O
commonly	O
used	O
at	O
the	O
end	O
of	O
experiments	O
to	O
calibrate	O
intracellularly	O
trapped	O
pH	O
-	O
sensitive	O
dyes	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
explore	O
the	O
possibility	O
that	O
residual	O
nigericin	B
from	O
dye	O
calibration	O
in	O
one	O
experiment	O
might	O
interfere	O
with	O
intracellular	O
pH	O
(	O
pHi	O
)	O
changes	O
in	O
the	O
next	O
.	O

Using	O
the	O
pH	O
-	O
sensitive	O
fluorescent	O
dye	O
2	B
'	I
,	I
7'-bis	I
(	I
carboxyethyl	I
)	I
-5,6-carboxyfluorescein	I
(	O
BCECF	B
)	O
,	O
we	O
measured	O
pHi	O
in	O
cultured	O
rat	O
renal	O
mesangial	O
cells	O
.	O

Nigericin	B
contamination	O
caused	O
:	O
(	O
i	O
)	O
an	O
increase	O
in	O
acid	B
loading	O
during	O
the	O
pHi	O
decrease	O
elicited	O
by	O
removing	O
extracellular	O
Na+	B
,	O
(	O
ii	O
)	O
an	O
increase	O
in	O
acid	B
extrusion	O
during	O
the	O
pHi	O
increase	O
caused	O
by	O
elevating	O
extracellular	O
[	O
K+	B
]	O
,	O
and	O
(	O
iii	O
)	O
an	O
acid	B
shift	O
in	O
the	O
pHi	O
dependence	O
of	O
the	O
background	O
intracellular	O
acid	B
loading	O
unmasked	O
by	O
inhibiting	O
Na	B
-	O
H	B
exchange	O
with	O
ethylisopropylamiloride	B
(	O
EIPA	B
)	O
.	O

However	O
,	O
contamination	O
had	O
no	O
effect	O
on	O
the	O
pHi	O
dependence	O
of	O
Na	B
-	O
H	B
exchange	O
,	O
computed	O
by	O
adding	O
the	O
pHi	O
dependencies	O
of	O
total	O
acid	B
extrusion	O
and	O
background	O
acid	B
loading	O
.	O

Nigericin	B
contamination	O
can	O
be	O
conveniently	O
minimized	O
by	O
using	O
a	O
separate	O
line	O
to	O
deliver	O
nigericin	B
to	O
the	O
cells	O
,	O
and	O
by	O
briefly	O
washing	O
the	O
tubing	O
with	O
ethanol	B
and	O
water	B
after	O
each	O
experiment	O
.	O

The	O
fatty	B
acid	I
composition	O
of	O
caprine	O
milk	O
fat	O
was	O
studied	O
using	O
capillary	O
gas	O
chromatography	O
.	O

Milk	O
was	O
obtained	O
from	O
five	O
goat	O
herds	O
belonging	O
to	O
different	O
breeders	O
in	O
the	O
Murcia	O
region	O
(	O
Spain	O
)	O
and	O
collected	O
monthly	O
(	O
from	O
November	O
to	O
May	O
)	O
.	O

The	O
results	O
showed	O
significant	O
differences	O
among	O
herds	O
mainly	O
in	O
long	B
-	I
chain	I
fatty	I
acids	I
(	O
C16:0	B
,	O
C18:0	B
,	O
and	O
C18:2	B
)	O
.	O

There	O
were	O
five	O
branched	B
-	I
chain	I
fatty	I
acids	I
(	O
iso-	B
and	O
anteiso	B
-	I
C15:0	I
,	O
iso-	B
and	O
anteiso	B
-	I
C17:0	I
,	O
and	O
iso	B
-	I
C16:0	I
)	O
with	O
>	O
0.1	O
%	O
of	O
the	O
total	O
fatty	B
acid	I
methyl	I
esters	I
and	O
another	O
31	O
(	O
the	O
most	O
monomethylated	B
)	O
with	O
<	O
0.1	O
%	O
,	O
including	O
4-ethyloctanoate	B
,	O
which	O
is	O
implicated	O
in	O
goat	O
-	O
like	O
flavors	O
.	O

To	O
study	O
the	O
content	O
of	O
trans	B
unsaturated	I
fatty	I
acids	I
,	O
the	O
fatty	B
acid	I
methyl	I
esters	I
were	O
previously	O
fractionated	O
by	O
AgNO3-thin	O
layer	O
chromatography	O
.	O

The	O
mean	O
contents	O
of	O
trans	B
-	I
C16:1	I
and	O
trans	B
-	I
C18:1	I
were	O
0.16	O
and	O
2.12	O
%	O
,	O
respectively	O
.	O

The	O
distribution	O
profile	O
of	O
trans	B
-	I
C18:1	I
was	O
also	O
studied	O
.	O

The	O
nor	O
mutant	O
of	O
Aspergillus	O
flavus	O
has	O
a	O
defective	O
norsolorinic	O
acid	O
reductase	O
,	O
and	O
thus	O
the	O
aflatoxin	B
biosynthetic	O
pathway	O
is	O
blocked	O
,	O
resulting	O
in	O
the	O
accumulation	O
of	O
norsolorinic	B
acid	I
,	O
a	O
bright	O
red	O
-	O
orange	O
pigment	O
.	O

We	O
developed	O
a	O
visual	O
agar	B
plate	O
assay	O
to	O
monitor	O
yeast	O
strains	O
for	O
their	O
ability	O
to	O
inhibit	O
aflatoxin	B
production	O
by	O
visually	O
scoring	O
the	O
accumulation	O
of	O
this	O
pigment	O
of	O
the	O
nor	O
mutant	O
.	O

We	O
identified	O
yeast	O
strains	O
that	O
reduced	O
the	O
red	O
-	O
orange	O
pigment	O
accumulation	O
in	O
the	O
nor	O
mutant	O
.	O

These	O
yeasts	O
also	O
reduced	O
aflatoxin	B
accumulation	O
by	O
a	O
toxigenic	O
strain	O
of	O
A.	O
flavus	O
.	O

These	O
yeasts	O
may	O
be	O
useful	O
for	O
reducing	O
aflatoxin	B
contamination	O
of	O
food	O
commodities	O
.	O

During	O
the	O
course	O
of	O
our	O
screening	O
program	O
for	O
low	O
molecular	O
natural	B
products	I
with	O
their	O
ability	O
to	O
potentiate	O
and/or	O
mimic	O
neurotrophic	O
effect	O
of	O
NGF	O
,	O
a	O
novel	O
fungal	O
metabolite	B
,	O
phenylacetic	B
acid	I
hydrazide	I
derivative	I
NG-061	B
was	O
isolated	O
from	O
the	O
fermentation	O
broth	O
of	O
Penicillium	O
minioluteum	O
F-4627	O
.	O

NG-061	B
enhanced	O
and	O
mimicked	O
neurotrophic	O
effect	O
of	O
NGF	O
on	O
neurite	O
outgrowth	O
in	O
a	O
rat	O
pheochromocytoma	O
cell	O
line	O
PC12	O
.	O

The	O
structure	O
of	O
NG-061	B
,	O
a	O
new	O
potentiator	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
isolated	O
from	O
Penicillium	O
minioluteum	O
F-4627	O
,	O
was	O
determined	O
by	O
spectroscopic	O
analysis	O
and	O
X	O
-	O
ray	O
diffraction	O
method	O
to	O
be	O
phenylacetic	B
acid	I
2-	I
(	I
2-methoxy-4-oxocyclohexa-2,4-dienylidene	I
)	I
-hydrazide	I
.	O

A	O
new	O
antitumor	O
antibiotic	B
gilvusmycin	B
was	O
isolated	O
from	O
the	O
culture	O
broth	O
of	O
Streptomyces	O
sp.	O
QM16	O
.	O

The	O
structure	O
of	O
gilvusmycin	B
was	O
related	O
to	O
CC-1065	B
and	O
determined	O
by	O
NMR	O
spectral	O
analysis	O
.	O

Gilvusmycin	B
exhibited	O
antitumor	O
activity	O
against	O
murine	O
leukemia	O
P388	O
in	O
vivo	O
.	O

Ethylene	B
glycol	I
is	O
a	O
serious	O
toxin	O
that	O
children	O
frequently	O
ingest	O
.	O

Diagnosis	O
and	O
treatment	O
of	O
this	O
poisoning	O
are	O
challenging	O
and	O
frequently	O
involve	O
the	O
use	O
of	O
novel	O
therapies	O
.	O

In	O
the	O
past	O
year	O
,	O
fomepizole	B
(	O
4-methylpyrazole	B
)	O
has	O
been	O
approved	O
for	O
use	O
as	O
an	O
antidote	O
in	O
the	O
treatment	O
of	O
ethylene	B
glycol	I
poisoning	O
in	O
adults	O
,	O
and	O
the	O
first	O
article	O
reporting	O
the	O
use	O
of	O
fomepizole	B
in	O
a	O
pediatric	O
ethylene	B
glycol	I
exposure	O
was	O
published	O
.	O

As	O
a	O
result	O
,	O
the	O
therapy	O
of	O
ethylene	B
glycol	I
poisoning	O
in	O
children	O
is	O
likely	O
to	O
change	O
from	O
the	O
traditional	O
approach	O
of	O
ethanol	B
administration	O
coupled	O
with	O
hemodialysis	O
to	O
the	O
administration	O
of	O
fomepizole	B
with	O
or	O
without	O
hemodialysis	O
.	O

It	O
was	O
studied	O
the	O
amino	B
acids	I
pattern	O
in	O
serum	O
and	O
cerebrospinal	O
fluid	O
of	O
12	O
and	O
8	O
patients	O
,	O
respectively	O
,	O
suffering	O
from	O
optic	O
epidemic	O
neuropathy	O
diagnosed	O
between	O
1995	O
and	O
1997	O
(	O
endemic	O
period	O
)	O
.	O

The	O
cerebrospinal	O
fluid	O
of	O
16	O
patients	O
diagnosed	O
during	O
the	O
epidemic	O
(	O
1992	O
)	O
was	O
also	O
studied	O
.	O

The	O
analysis	O
of	O
amino	B
acids	I
in	O
serum	O
and	O
cerebrospinal	O
fluid	O
was	O
made	O
by	O
high	O
resolution	O
liquid	O
chromatography	O
with	O
fluorescent	O
detection	O
,	O
previous	O
derivation	O
with	O
orthofthallic	B
aldehyde	I
.	O

As	O
in	O
the	O
previous	O
study	O
,	O
no	O
important	O
deficiencies	O
of	O
the	O
essential	O
amino	B
acids	I
were	O
observed	O
in	O
the	O
serum	O
of	O
the	O
studied	O
patients	O
.	O

Lower	O
concentrations	O
of	O
threonine	B
,	O
aspartic	B
acid	I
and	O
taurine	B
were	O
found	O
in	O
the	O
serum	O
of	O
patients	O
with	O
epidemic	O
optic	O
neuropathy	O
diagnosed	O
in	O
the	O
endemic	O
period	O
.	O

Taurine	B
plays	O
an	O
important	O
role	O
in	O
the	O
structure	O
and	O
function	O
of	O
photoreceptors	O
of	O
the	O
retina	O
.	O

It	O
is	O
synthesized	O
in	O
the	O
necessary	O
amounts	O
in	O
man	O
,	O
so	O
it	O
must	O
be	O
supplied	O
in	O
the	O
diet	O
.	O

As	O
it	O
is	O
only	O
present	O
in	O
food	O
of	O
animal	O
origin	O
,	O
it	O
is	O
considered	O
that	O
the	O
deficiency	O
of	O
taurine	B
may	O
contribute	O
to	O
the	O
development	O
of	O
optic	O
epidemic	O
neuritis	O
in	O
our	O
patients	O
.	O

Samples	O
of	O
cerebrospinal	O
fluid	O
were	O
analyzed	O
during	O
the	O
epidemic	O
and	O
endemic	O
periods	O
and	O
it	O
was	O
observed	O
an	O
increase	O
of	O
the	O
glutamic	B
and	O
aspartic	B
acid	I
in	O
the	O
epidemic	O
period	O
and	O
of	O
glutamic	B
acid	I
during	O
the	O
endemic	O
.	O

The	O
excess	O
of	O
excitotoxic	O
amino	B
acids	I
in	O
the	O
cerebrospinal	O
fluid	O
supports	O
the	O
previous	O
neurocognitive	O
studies	O
that	O
suggested	O
the	O
affection	O
of	O
the	O
central	O
nervous	O
system	O
in	O
these	O
patients	O
.	O

The	O
kinetic	O
properties	O
of	O
bacterial	O
and	O
rat	O
liver	O
glutathione	O
S	O
-	O
transferases	O
(	O
GST	O
)	O
active	O
with	O
dichloromethane	B
(	O
DCM	B
)	O
were	O
compared	O
.	O

The	O
theta	O
class	O
glutathione	O
S	O
-	O
transferase	O
(	O
rGSTTI-1	O
)	O
from	O
rat	O
liver	O
had	O
an	O
affinity	O
for	O
dihalomethanes	B
lower	O
by	O
three	O
orders	O
of	O
magnitude	O
(	O
K	O
(	O
app	O
)	O
>	O
50	O
mM	O
)	O
than	O
the	O
bacterial	O
DCM	O
dehalogenase	O
/	O
GST	O
from	O
Methylophilus	O
sp.	O
DM11	O
.	O

Unlike	O
the	O
bacterial	O
DCM	O
dehalogenase	O
,	O
the	O
rat	O
enzyme	O
was	O
unable	O
to	O
support	O
growth	O
of	O
the	O
dehalogenase	O
minus	O
Methylobacterium	O
sp.	O
DM4	O
-	O
2cr	O
mutant	O
with	O
DCM	B
.	O

Moreover	O
,	O
the	O
presence	O
of	O
DCM	B
inhibited	O
growth	O
with	O
methanol	B
of	O
the	O
DM4	O
-	O
2cr	O
transconjugant	O
expressing	O
the	O
rat	O
liver	O
GSTT1	O
-	O
1	O
.	O

In	O
Salmonella	O
typhimurium	O
TA1535	O
,	O
expression	O
of	O
rat	O
and	O
bacterial	O
DCM	B
-	O
active	O
GST	O
from	O
a	O
plasmid	O
in	O
the	O
presence	O
of	O
DCM	B
yielded	O
up	O
to	O
5.3	O
times	O
more	O
reversions	O
to	O
histidine	B
prototrophy	O
in	O
the	O
transconjugant	O
expressing	O
the	O
rat	O
enzyme	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
however	O
,	O
GST	O
-	O
mediated	O
conversion	O
of	O
DCM	B
to	O
formaldehyde	B
was	O
lower	O
in	O
cell	O
-	O
free	O
extracts	O
of	O
the	O
transconjugant	O
expressing	O
the	O
rat	O
GSTT1	O
than	O
in	O
the	O
corresponding	O
strain	O
expressing	O
the	O
bacterial	O
DCM	O
dehalogenase	O
.	O

This	O
provided	O
new	O
evidence	O
that	O
formaldehyde	B
was	O
not	O
the	O
main	O
toxicant	O
associated	O
with	O
GST	O
-	O
mediated	O
DCM	B
conversion	O
,	O
and	O
indicated	O
that	O
an	O
intermediate	O
in	O
the	O
transformation	O
of	O
DCM	B
by	O
GST	O
,	O
presumably	O
S	B
-	I
chloromethylglutathione	I
,	O
was	O
responsible	O
for	O
the	O
observed	O
effects	O
.	O

The	O
marked	O
differences	O
in	O
substrate	O
affinity	O
of	O
rat	O
and	O
bacterial	O
DCM	B
-	O
active	O
GST	O
,	O
as	O
well	O
as	O
in	O
the	O
toxicity	O
and	O
genotoxicity	O
associated	O
with	O
expression	O
of	O
these	O
enzymes	O
in	O
bacteria	O
,	O
suggest	O
that	O
bacterial	O
DCM	B
dehalogenases	O
/	O
GST	O
have	O
evolved	O
to	O
minimise	O
the	O
toxic	O
effects	O
associated	O
with	O
glutathione	B
-	O
mediated	O
catalysis	O
of	O
DCM	B
conversion	O
.	O

Emotional	O
or	O
social	O
stress	O
is	O
consistently	O
viewed	O
as	O
an	O
important	O
factor	O
in	O
voluntary	O
ethanol	B
consumption	O
.	O

Isolation	O
stress	O
was	O
shown	O
to	O
be	O
one	O
of	O
the	O
factors	O
determining	O
the	O
inclination	O
to	O
voluntary	O
ethanol	B
intake	O
.	O

Furthermore	O
,	O
the	O
level	O
of	O
alcohol	B
motivation	O
directly	O
correlated	O
with	O
the	O
degree	O
of	O
stress	O
(	O
1	O
)	O
.	O

Early	O
maternal	O
deprivation	O
may	O
predispose	O
animals	O
to	O
increased	O
ethanol	B
consumption	O
as	O
adults	O
(	O
2	O
)	O
.	O

Also	O
,	O
adult	O
isolated	O
rats	O
drank	O
significantly	O
more	O
alcohol	B
than	O
control	O
rats	O
(	O
3	O
)	O
.	O

Social	O
isolation	O
and	O
loneliness	O
may	O
contribute	O
to	O
ethanol	B
consumption	O
in	O
aged	O
humans	O
.	O

Late	O
-	O
onset	O
drinking	O
,	O
defined	O
as	O
onset	O
of	O
the	O
first	O
alcohol	B
problem	O
at	O
or	O
after	O
age	O
60	O
,	O
is	O
believed	O
to	O
be	O
related	O
to	O
life	O
and	O
social	O
stress	O
of	O
aging	O
particularly	O
when	O
coping	O
with	O
resources	O
or	O
social	O
supports	O
are	O
inadequate	O
(	O
4	O
-	O
5	O
)	O
and	O
was	O
not	O
uncommon	O
(	O
6	O
)	O
.	O

A	O
long	O
-	O
debated	O
""""	O
tension	O
reduction	O
""""	O
hypothesis	O
postulates	O
anti	O
-	O
anxiety	O
effects	O
to	O
be	O
important	O
for	O
ethanol	B
reward	O
,	O
and	O
states	O
that	O
elevated	O
anxiety	O
levels	O
might	O
predispose	O
to	O
ethanol	B
consumption	O
and	O
addiction	O
(	O
7	O
)	O
.	O

Exposure	O
to	O
stress	O
can	O
increase	O
ethanol	B
consumption	O
and	O
ethanol	B
can	O
attenuate	O
the	O
behavioural	O
and	O
biochemical	O
effects	O
of	O
stress	O
(	O
8)	O
.	O

Furthermore	O
,	O
there	O
is	O
a	O
relationship	O
between	O
voluntary	O
ethanol	B
intake	O
and	O
escape	O
from	O
the	O
consequences	O
of	O
stress	O
(	O
9-	O
10	O
)	O
.	O

In	O
rats	O
,	O
previous	O
reports	O
(	O
7	O
)	O
support	O
a	O
relation	O
between	O
experimental	O
anxiety	O
and	O
voluntary	O
alcohol	B
consumption	O
.	O

Since	O
previous	O
reports	O
showed	O
that	O
alprazolam	B
,	O
a	O
benzodiazepine	B
anxiolytic	O
drug	B
,	I
partially	O
reversed	O
many	O
effects	O
of	O
stress	O
in	O
rodents	O
(	O
11	O
-	O
15	O
)	O
,	O
we	O
then	O
postulated	O
that	O
this	O
drug	B
should	O
affect	O
Corresponding	O
Author	O
:	O
Maria	O
J.	O
Nunez	O
.	O

Department	O
of	O
Nursing	O
.	O

E.U.E.	O
Universidad	O
de	O
Santiago	O
de	O
Compostela	O
.	O

Campus	O
Norte	O
.	O

Avda	O
.	O

Xoan	O
XXIII	O
,	O
s	O
/	O
n	O
.	O

15075-Santiago	O
de	O
Compostela	O
.	O

SPAIN	O
PL-214	O
Alprazolam	B
,	O
Ethanol	B
Consumption	O
and	O
Stress	O
Vol	O
.	O

64	O
,	O
No.	O
20,1999	O
the	O
free	O
-	O
choice	O
alcohol	B
consumption	O
in	O
aged	O
rats	O
exposed	O
to	O
stress	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
report	O
we	O
study	O
the	O
effect	O
of	O
alprazolam	B
on	O
the	O
voluntary	O
alcohol	B
consumption	O
in	O
Sprague-	O
Dawley	O
aged	O
rats	O
exposed	O
to	O
isolation	O
stress	O
.	O

Methods	O
Rats	O
Aged	O
(	O
18	O
months	O
)	O
female	O
rats	O
(	O
240	O
10	O
g	O
)	O
of	O
the	O
Sprague	O
-	O
Dawley	O
strain	O
(	O
Interfauna	O
Ibica	O
S.A.	O
,	O
Barcelona	O
,	O
Spain	O
)	O
were	O
used	O
.	O

They	O
were	O
housed	O
,	O
7	O
days	O
before	O
experiments	O
,	O
five	O
per	O
cage	O
in	O
a	O
temperature	O
(	O
22	O
-	O
24C	O
)	O
and	O
humidity	O
controlled	O
animal	O
room	O
,	O
with	O
an	O
alternating	O
12-hr	O
light	O
-	O
dark	O
cycle	O
(	O
lights	O
on	O
at	O
0600	O
,	O
lights	O
off	O
at	O
1800	O
)	O
,	O
with	O
food	O
(	O
Ultrasorb	O
,	O
PANLAB	O
,	O
Barcelona	O
,	O
Spain	O
)	O
and	O
drink	O
ad	O
libitum	O
.	O

Procedure	O
Twenty	O
five	O
rats	O
were	O
randomly	O
assigned	O
,	O
five	O
per	O
group	O
,	O
in	O
the	O
following	O
groups	O
according	O
to	O
the	O
treatment	O
they	O
were	O
submitted	O
to	O
:	O
GROUP	O
A.	O
unstimulated	O
controls	O
,	O
GROUP	O
B.	O
unstimulated	O
rats	O
injected	O
with	O
placebo	B
,	O
GROUP	O
C.	O
unstimulated	O
rats	O
injected	O
with	O
alprazolam	B
,	O
GROUP	O
D.	O
stressed	O
rats	O
injected	O
with	O
placebo	B
,	O
GROUP	O
E.	O
stressed	O
rats	O
injected	O
with	O
alprazolam	B
.	O

Drinking	O
solutions	O
Two	O
drinking	O
solutions	O
were	O
used	O
.	O

One	O
consisted	O
of	O
a	O
0.2	O
%	O
saccharin	B
solution	O
and	O
the	O
other	O
consisted	O
of	O
the	O
same	O
solution	O
containing	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
ethanol	B
.	O

The	O
solutions	O
were	O
prepared	O
on	O
alternate	O
days	O
and	O
stored	O
in	O
air	O
-	O
tight	O
containers	O
until	O
used	O
.	O

Induction	O
of	O
stress	O
Isolation	O
stress	O
(	O
ISOL	O
)	O
was	O
conducted	O
by	O
placing	O
the	O
animals	O
alone	O
in	O
a	O
novel	O
environment	O
alone	O
.	O

Stress	O
periods	O
ranged	O
from	O
1	O
to	O
4	O
hours	O
on	O
a	O
random	O
unpredictable	O
schedule	O
distributed	O
throughout	O
during	O
the	O
day	O
.	O

The	O
total	O
amount	O
of	O
exposure	O
to	O
ISOL	O
was	O
of	O
12	O
hours	O
.	O

Unstimulated	O
rats	O
were	O
exposed	O
only	O
to	O
the	O
normal	O
activity	O
of	O
the	O
animal	O
room	O
.	O

Groups	O
D	O
and	O
E	O
were	O
submitted	O
to	O
the	O
same	O
ISOL	O
exposure	O
.	O

Following	O
a	O
10	O
day	O
baseline	O
period	O
,	O
the	O
animals	O
were	O
given	O
4	O
day	O
of	O
ISOL	O
on	O
an	O
unpredictable	O
schedule	O
,	O
followed	O
by	O
4	O
day	O
recovery	O
period	O
(	O
16	O
)	O
.	O

Cages	O
(	O
Cage	O
FI	O
,	O
Iffa	O
-	O
Credo	O
,	O
Griffa	O
SA	O
,	O
Barcelona	O
,	O
Spain	O
)	O
of	O
305	O
mm	O
depth	O
x	O
180	O
mm	O
width	O
x	O
184	O
mm	O
height	O
internal	O
dimensions	O
were	O
used	O
both	O
for	O
control	O
housing	O
conditions	O
and	O
ISOL	O
.	O

They	O
were	O
always	O
placed	O
in	O
the	O
same	O
animal	O
room	O
.	O

Quantification	O
of	O
alcohol	B
consumption	O
During	O
days	O
1	O
-	O
7	O
,	O
the	O
saccharin	B
solution	O
was	O
presented	O
in	O
both	O
tubes	O
.	O

Following	O
this	O
,	O
saccharin	B
was	O
presented	O
in	O
one	O
tube	O
and	O
ethanol	B
-	O
saccharin	B
in	O
the	O
other	O
tube	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

The	O
volumes	O
remaining	O
in	O
each	O
tube	O
were	O
recorded	O
daily	O
during	O
the	O
period	O
11.00	O
-	O
13.00	O
hours	O
,	O
the	O
tubes	O
were	O
refilled	O
and	O
their	O
positions	O
(	O
left	O
-	O
right	O
)	O
alternated	O
to	O
prevent	O
the	O
development	O
of	O
positional	O
preference	O
(	O
16	O
)	O
.	O

Daily	O
fluid	O
consumption	O
(	O
both	O
ethanol	B
and	O
saccharin	B
)	O
and	O
body	O
weight	O
were	O
monitored	O
and	O
daily	O
ethanol	B
intake	O
in	O
g	O
/	O
Kg	O
per	O
day	O
were	O
calculated	O
(	O
17	O
)	O
.	O

Low	O
,	O
medium	O
and	O
high	O
ethanol	B
consumption	O
were	O
defined	O
by	O
the	O
means	O
of	O
daily	O
ethanol	B
consumption	O
(	O
1.5	O
-	O
2.5	O
;	O
2.5-	O
4.5	O
;	O
4.5	O
-	O
6.0	O
g	O
/	O
Kg	O
/	O
day	O
,	O
respectively	O
)	O
(	O
18	O
)	O
.	O

Drug	B
treatments	O
Alprazolam	B
was	O
intraperitoneally	O
injected	O
at	O
1	O
mg	O
/	O
Kg	O
,	O
in	O
a	O
volume	O
of	O
1	O
ml	O
/	O
kg	O
of	O
1	O
%	O
aqueous	B
solution	O
of	O
carboxymethylcellulose	B
as	O
vehicle	O
.	O

The	O
same	O
volume	O
of	O
diluent	O
was	O
used	O
as	O
placebo	B
.	O

Drugs	B
were	O
daily	O
administerd	O
at	O
09.30	O
a.m.	O
Statistical	O
analysis	O
Mean	O
24	O
hour	O
fluid	O
consumption	O
for	O
each	O
group	O
of	O
animals	O
was	O
computed	O
in	O
g	O
/	O
Kg	O
body	O
weight	O
SEM	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
ANOVA	O
with	O
grouping	O
of	O
means	O
by	O
Student	O
Newman	O
-	O
Keuls	O
multiple	O
range	O
tests	O
with	O
significance	O
set	O
at	O
p	O
<	O
0.05	O
(	O
16	O
)	O
.	O

Vol	O
.	O

64	O
,	O
No.	O
20	O
,	O
1999	O
Alprazolam	B
,	O
Ethanol	B
Consumption	O
and	O
Stress	O
PL-215	O
Results	O
Table	O
1	O
summarizes	O
the	O
data	O
from	O
the	O
study	O
.	O

Isolation	O
stress	O
significantly	O
increased	O
the	O
ethanol	B
consumption	O
of	O
the	O
Sprague	O
-	O
Dawley	O
aged	O
rats	O
.	O

Stress	O
induced	O
high	O
ethanol	B
consumption	O
compared	O
to	O
those	O
of	O
the	O
control	O
and	O
unstressed	O
group	O
rats	O
,	O
which	O
exhibited	O
a	O
medium	O
ethanol	B
intake	O
.	O

Also	O
,	O
at	O
the	O
post	O
-	O
stress	O
period	O
stressed	O
animals	O
exhibited	O
a	O
significantly	O
greater	O
ethanol	B
consumption	O
than	O
control	O
and	O
non	O
-	O
stressed	O
groups	O
.	O

Treatment	O
with	O
alprazolam	B
(	O
1	O
mg	O
/	O
Kg	O
)	O
partially	O
reversed	O
that	O
adverse	O
effect	O
of	O
stress	O
.	O

Treatment	O
with	O
drugs	B
did	O
not	O
affect	O
the	O
free-	O
choice	O
ethanol	B
consumption	O
in	O
unstressed	O
rats	O
.	O

Saccharin	B
consumption	O
was	O
not	O
influenced	O
by	O
ISOL	O
stress	O
.	O

Total	O
fluid	O
consumption	O
was	O
significantly	O
increased	O
in	O
stressed	O
rats	O
,	O
because	O
of	O
the	O
significant	O
increase	O
in	O
ethanol	B
consumption	O
in	O
stressed	O
rats	O
as	O
compared	O
to	O
control	O
and	O
unstressed	O
groups	O
(	O
Table	O
II	O
)	O
.	O

TABLE	O
I	O
Effects	O
of	O
alprazolam	B
on	O
ethanol	B
consumption	O
in	O
stressed	O
rats	O
.	O

Control	O
3.6	O
0.2	O
Placebo	B
Alprazolam	B
Stress	O
+	O
placebo	B
Stress	O
+	O
alprazolam	B
Baseline	O
Isolation	O
Recovery	O
3.4	O
.2	O
3.7	O
.2	O
3.6	O
.3	O
3.8	O
.3	O
3.9	O
.3	O
3.7	O
0.6	O
3.6	O
.1	O
8.2	O
.9	O
'	O

*	O
7.0	O
.2	O
""""	O
*	O
3.4	O
.4	O
5.4.2	O
""""	O
5.5.3	O
'	O
*	O
Each	O
value	O
represents	O
the	O
mean	O
24	O
hour	O
consumption	O
value	O
(	O
g	O
/	O
Kg	O
SD	O
)	O
of	O
5	O
rats	O
over	O
4	O
day	O
periods	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
ANOVA	O
with	O
grouping	O
of	O
means	O
by	O
Student	O
Newman	O
-	O
Keuls	O
multiple	O
range	O
tests	O
with	O
significance	O
set	O
at	O
p	O
<	O
0.05	O
(	O
14	O
)	O
.	O
""""	O

Significant	O
difference	O
from	O
control	O
rats	O
(	O
p	O
<	O
0.01	O
)	O
.	O

*	O
Differences	O
between	O
placebo	B
and	O
alprazolam	B
significant	O
at	O
p	O
<	O
0.01	O
.	O

TABLE	O
II	O
Effects	O
of	O
alprazolam	B
on	O
fluid	O
consumption	O
in	O
stressed	O
rats	O
.	O

Control	O
S	O
11.8	O
.6	O
T	O
15.4	O
.8	O
Baseline	O
Isolation	O
Recovery	O
Placebo	B
S	O
11.5	O
.5	O
12.0	O
.3	O
11.1	O
.5	O
T	O
14.9	O
.7	O
15.7	O
.5	O
14.7	O
.8	O
Alprazolam	B
S	O
12.2	O
.2	O
12.3	O
.4	O
12.0	O
.1	O
T	O
16.0	O
.5	O
16.2	O
.7	O
15.7	O
.7	O
Stress	O
+	O
placebo	O
S	O
12.8	O
.1	O
12.6	O
.7	O
13.0	O
.4	O
T	O
16.4	O
.2	O
20.8	O
.6	O
'	O

*	O

20.0	O
.6	O
""""	O
'	O
Stress	O
+	O
alprazolam	O
S	O
12.4	O
.3	O

11.2	O
.4	O
11.5	O
.7	O

T	O
15.8	O
.7	O
16.6	O
.6	O
'	O

*	O
17.0	O
1.0'-	O
Each	O
value	O
represents	O
the	O
mean	O
24	O
hour	O
consumption	O
value	O
(	O
g	O
/	O
Kg	O
SD	O
)	O
of	O
5	O
rats	O
over	O
4	O
day	O
periods	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
ANOVA	O
with	O
grouping	O
of	O
means	O
by	O
Student	O
Newman	O
-	O
Keuls	O
multiple	O
range	O
tests	O
with	O
significance	O
set	O
at	O
p	O
<	O
0.05	O
(	O
14	O
)	O
.	O
'	O

Significant	O
difference	O
from	O
control	O
rats	O
(	O
p	O
<	O
0.01	O
)	O
.	O

*	O
Differences	O
between	O
placebo	B
and	O
alprazolam	B
significant	O
at	O
p	O
<	O
0.01	O
.	O

(	O
S	O
:	O
Saccharine	B
;	O
T	O
:	O
Total	O
)	O
PL-216	O
Alprazolam	B
,	O
Ethanol	B
Consumption	O
and	O
Stress	O
Vol	O
.	O

64	O
,	O
No.	O
20	O
,	O
1999	O

Discussion	O
The	O
presented	O
data	O
shows	O
that	O
isolation	O
stress	O
powerfully	O
increased	O
the	O
voluntary	O
ethanol	B
consumption	O
in	O
aged	O
rats	O
.	O

Our	O
data	O
is	O
in	O
good	O
agreement	O
with	O
those	O
previously	O
reported	O
in	O
young	O
and	O
adult	O
rats	O
(	O
2	O
,	O
3	O
,	O
7	O
,	O
19	O
)	O
.	O

Stress	O
activates	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenocortical	O
(	O
HPA	O
)	O
axis	O
.	O

At	O
least	O
one	O
of	O
the	O
neuroendocrine	O
responses	O
to	O
stress	O
,	O
i.e.	O
the	O
adrenal	O
corticosterone	B
hypersrion	O
via	O
ACTH	O
secretion	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
stress	O
increased	O
ethanol	B
consumption	O
(	O
20	O
-	O
22	O
)	O
.	O

Firstly	O
,	O
adrenalectomized	O
rats	O
showed	O
neither	O
evidence	O
of	O
enhancement	O
(	O
21	O
)	O
nor	O
did	O
decrease	O
their	O
ethanol	B
intake	O
compared	O
to	O
the	O
sham	O
-	O
operated	O
controls	O
(	O
22	O
)	O
,	O
and	O
the	O
treatment	O
with	O
corticosterone	B
restored	O
the	O
intake	O
of	O
ethanol	B
to	O
the	O
preoperative	O
level	O
(	O
22	O
)	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
aldosterone	B
had	O
no	O
effect	O
on	O
ethanol	B
intake	O
(	O
22	O
)	O
.	O

Secondly	O
,	O
treatment	O
of	O
stressed	O
rats	O
with	O
the	O
enzyme	O
inhibitor	O
cyanoketone	B
,	O
which	O
blocks	O
stress	O
-	O
induced	O
but	O
not	O
basal	O
corticosterone	B
secretion	O
,	O
at	O
least	O
partially	O
prevented	O
the	O
stress	O
-	O
induced	O
increase	O
in	O
ethanol	B
drinking	O
(	O
21	O
)	O
.	O

Also	O
,	O
exposure	O
to	O
repetitive	O
unpredictable	O
stressful	O
stimuli	O
did	O
not	O
induce	O
the	O
free	O
-	O
choice	O
post	O
-	O
stress	O
consumption	O
of	O
ethanol	B
either	O
in	O
hypophysectomized	O
rats	O
or	O
chronic	O
dexamentasone	B
treated	O
rats	O
(	O
20	O
)	O
.	O

Aged	O
rats	O
exposed	O
to	O
unpredictable	O
stressful	O
stimuli	O
increased	O
their	O
ethanol	B
intake	O
during	O
the	O
stress	O
period	O
and	O
maintained	O
this	O
increase	O
throughout	O
the	O
entire	O
post	O
-	O
stress	O
period	O
as	O
compared	O
to	O
non	O
-	O
stressed	O
animals	O
.	O

There	O
is	O
an	O
age	O
-	O
related	O
deficiency	O
in	O
HPA	O
response	O
to	O
stress	O
as	O
well	O
as	O
decline	O
in	O
negative	O
feed	O
-	O
back	O
sensitivity	O
to	O
glucocorticoids	B
(	O
23	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
ethanol	B
stimulates	O
corticosterone	B
secretion	O
in	O
rats	O
(	O
24	O
)	O
.	O

But	O
,	O
whereas	O
young	O
rats	O
exhibit	O
complete	O
tolerance	O
to	O
the	O
stimulatory	O
effects	O
of	O
ethanol	B
on	O
corticosterone	B
levels	O
,	O
impaired	O
adaptation	O
of	O
the	O
hypotalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
to	O
ethanol	B
in	O
aged	O
rats	O
was	O
reported	O
(	O
24	O
)	O
.	O

Thus	O
,	O
the	O
loss	O
in	O
the	O
ability	O
to	O
down	O
-	O
regulate	O
both	O
,	O
stress	O
and	O
ethanol	B
responses	O
,	O
and	O
the	O
elevated	O
glucocorticoids	B
might	O
induce	O
increased	O
ethanol	B
consumption	O
during	O
post	O
-	O
stress	O
period	O
noted	O
in	O
our	O
study	O
.	O

Alprazolam	B
partially	O
reversed	O
the	O
adverse	O
effect	O
of	O
stress	O
on	O
the	O
free	O
-	O
choice	O
alcohol	B
consumption	O
.	O

It	O
has	O
been	O
reported	O
that	O
anxiolytics	O
reduced	O
the	O
response	O
of	O
CRF	O
,	O
ACTH	O
and	O
corticosterone	B
to	O
stress	O
(	O
11	O
,	O
25	O
-	O
26	O
)	O
;	O
so	O
this	O
might	O
be	O
one	O
of	O
the	O
reasons	O
to	O
reverse	O
the	O
increase	O
in	O
alcohol	B
consumption	O
induced	O
by	O
stress	O
This	O
is	O
a	O
benzodiazepine	B
agonist	O
with	O
well	O
-	O
known	O
anxiolytic	O
properties	O
which	O
was	O
found	O
to	O
reduce	O
the	O
stress	O
-	O
induced	O
decrease	O
in	O
the	O
immune	O
function	O
(	O
12	O
-	O
14	O
)	O
,	O
which	O
was	O
associated	O
with	O
a	O
proportional	O
suppression	O
of	O
the	O
stress	O
-	O
induce	O
a	O
increase	O
in	O
plasma	O
ACTH	O
levels	O
(	O
27	O
)	O
which	O
were	O
attributed	O
to	O
activation	O
of	O
GABA	B
-	O
linked	O
BZD	O
receptors	O
in	O
the	O
CNS	O
.	O

Central	O
pharmacological	O
effects	O
related	O
to	O
the	O
central	O
type	O
benzodiazepine	B
(	O
BZD	B
)	O
acting	O
by	O
facilitating	O
inhibitory	O
GABA	B
neurotransmission	O
in	O
CNS	O
may	O
regulate	O
the	O
release	O
of	O
neuroendocrine	O
hormones	O
involved	O
in	O
the	O
response	O
to	O
stress	O
.	O

In	O
summary	O
,	O
the	O
present	O
results	O
suggest	O
that	O
exposure	O
to	O
unpredictable	O
isolation	O
stress	O
produces	O
enhancement	O
of	O
ethanol	B
consumption	O
at	O
the	O
stress	O
and	O
post	O
-	O
stress	O
periods	O
,	O
which	O
are	O
partially	O
reversed	O
by	O
alprazolam	B
.	O

Acknowledgements	O
.	O

To	O
J.A.	O
Veira	O
for	O
his	O
comments	O
on	O
the	O
manuscript	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
tetrahydroswertianolin	B
(	O
THS	B
)	O
,	O
a	O
hepatoprotective	O
agent	O
from	O
Swertia	O
japonica	O
,	O
on	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-dependent	O
hepatic	O
apoptosis	O
induced	O
by	O
D	B
-	I
galactosamine	I
(	O
D	B
-	I
GalN	I
)	O
(	O
700	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
and	O
lipopolysaccharide	B
(	O
LPS	B
)	O
(	O
10	O
microg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
in	O
mice	O
.	O

Apoptotic	O
symptoms	O
were	O
observed	O
at	O
the	O
initial	O
stage	O
of	O
liver	O
damage	O
.	O

By	O
5	O
hr	O
after	O
intoxication	O
,	O
hepatic	O
DNA	O
fragmentation	O
had	O
risen	O
to	O
2123	O
%	O
,	O
with	O
the	O
value	O
in	O
untreated	O
mice	O
set	O
at	O
100	O
%	O
,	O
without	O
a	O
significant	O
elevation	O
of	O
serum	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
activity	O
.	O

There	O
was	O
a	O
parallel	O
increase	O
in	O
hepatocytes	O
undergoing	O
chromatin	O
condensation	O
and	O
apoptotic	O
body	O
formation	O
.	O

By	O
8	O
hr	O
after	O
intoxication	O
,	O
serum	O
ALT	O
activity	O
had	O
risen	O
to	O
3707	O
U	O
/	O
L.	O
Pretreatment	O
with	O
THS	B
(	O
50	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
at	O
18	O
and	O
2	O
hr	O
before	O
intoxication	O
significantly	O
reduced	O
DNA	O
fragmentation	O
to	O
821	O
%	O
of	O
that	O
in	O
untreated	O
mice	O
and	O
prevented	O
the	O
emergence	O
of	O
chromatin	O
condensation	O
and	O
apoptotic	O
body	O
formation	O
.	O

A	O
significant	O
and	O
dose	O
-	O
dependent	O
reduction	O
in	O
serum	O
ALT	O
activity	O
at	O
8	O
hr	O
also	O
was	O
observed	O
with	O
THS	B
pretreatment	O
.	O

These	O
effects	O
of	O
THS	B
were	O
different	O
from	O
those	O
observed	O
from	O
pretreatment	O
with	O
glycyrrhizin	B
(	O
GCR	B
)	O
,	O
which	O
is	O
a	O
clinically	O
used	O
hepatoprotective	O
agent	O
with	O
membrane	O
-	O
stabilizing	O
activity	O
.	O

GCR	B
pretreatment	O
(	O
100	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
did	O
not	O
inhibit	O
hepatic	O
DNA	O
fragmentation	O
(	O
1588	O
%	O
of	O
untreated	O
mice	O
)	O
,	O
although	O
this	O
compound	O
significantly	O
protected	O
against	O
serum	O
ALT	O
elevation	O
(	O
1463	O
U	O
/	O
L	O
)	O
.	O

These	O
data	O
suggest	O
that	O
an	O
inhibitory	O
effect	O
on	O
the	O
progression	O
of	O
hepatic	O
apoptosis	O
prior	O
to	O
liver	O
injury	O
may	O
be	O
involved	O
in	O
the	O
hepatoprotective	O
mechanisms	O
of	O
THS	B
,	O
whereas	O
it	O
appears	O
that	O
GCR	B
affects	O
the	O
processes	O
after	O
apoptosis	O
.	O

In	O
a	O
separate	O
experiment	O
,	O
we	O
found	O
that	O
the	O
concentration	O
of	O
serum	O
TNF	O
-	O
alpha	O
rose	O
to	O
2016	O
pg	O
/	O
mL	O
at	O
1	O
hr	O
after	O
intoxication	O
of	O
mice	O
with	O
D	B
-	I
GalN	I
and	O
LPS	B
,	O
but	O
this	O
increase	O
was	O
suppressed	O
by	O
THS	B
pretreatment	O
(	O
10	O
,	O
50	O
,	O
or	O
200	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
to	O
716	O
,	O
454	O
,	O
or	O
406	O
pg	O
/	O
mL	O
,	O
respectively	O
.	O

Further	O
study	O
with	O
a	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
method	O
showed	O
that	O
THS	B
blocked	O
TNF	O
-	O
alpha	O
production	O
at	O
the	O
transcriptional	O
level	O
.	O

Because	O
TNF	O
-	O
alpha	O
is	O
a	O
critical	O
mediator	O
to	O
elicit	O
apoptosis	O
in	O
this	O
model	O
,	O
the	O
property	O
of	O
suppressing	O
TNF	O
-	O
alpha	O
production	O
may	O
be	O
of	O
prime	O
importance	O
for	O
THS	B
inhibition	O
of	O
hepatic	O
apoptosis	O
.	O

Dinucleoside	B
polyphosphates	I
(	O
Npn	B
N	I
)	O
are	O
molecules	O
of	O
crescent	O
interest	O
in	O
metabolic	O
regulation	O
and	O
cell	O
signaling	O
[	O
1–3	O
]	O
.	O

Diadenosine	B
tetraphosphate	I
(	O
Ap4	B
A	I
)	O
is	O
present	O
at	O
(	O
sub	O
)	O
micromolar	O
concentration	O
in	O
all	O
the	O
prokaryotic	O
and	O
eukaryotic	O
tissues	O
examined	O
[	O
4	O
]	O
.	O

The	O
occurrence	O
of	O
Ap4	B
A	I
,	O
Ap5	B
A	I
and	O
Ap6	B
A	I
has	O
been	O
reported	O
in	O
the	O
dense	O
granules	O
of	O
human	O
blood	O
platelets	O
[	O
5–7	O
]	O
,	O
in	O
some	O
rat	O
brain	O
synaptic	O
terminals	O
[	O
8	O
,	O
9	O
]	O
and	O
in	O
chromaffin	O
granules	O
of	O
bovine	O
adrenal	O
medullary	O
gland	O
[	O
10–13	O
]	O
.	O

The	O
concentration	O
of	O
ATP	B
in	O
both	O
the	O
total	O
adrenal	O
medullary	O
tissue	O
and	O
in	O
chromaffin	O
granules	O
is	O
three	O
orders	O
of	O
magnitude	O
higher	O
than	O
that	O
of	O
Ap4	B
A	I
[	O
13	O
]	O
.	O

Upon	O
liberation	O
from	O
the	O
adrenal	O
medulla	O
,	O
after	O
an	O
appropriate	O
stimulus	O
,	O
the	O
rate	O
of	O
hydrolysis	O
of	O
the	O
secreted	O
ATP	B
is	O
so	O
high	O
that	O
less	O
than	O
1	O
%	O
remains	O
as	O
ATP	B
,	O
whereas	O
the	O
secreted	O
Ap4	B
A	I
was	O
apparently	O
degraded	O
at	O
a	O
much	O
slower	O
rate	O
[	O
12	O
,	O
13	O
]	O
.	O

Probably	O
both	O
ATP	B
and	O
Ap4	B
A	I
are	O
hydrolyzed	O
by	O
phosphodiesterases	O
[	O
14–16	O
]	O
(	O
and	O
phosphatases	O
and	O
nucleotidases	O
for	O
ATP	B
)	O
located	O
in	O
the	O
outer	O
aspect	O
of	O
cell	O
plasma	O
membranes	O
and	O
the	O
ATP	B
itself	O
could	O
be	O
a	O
competitive	O
inhibitor	O
of	O
the	O
degradation	O
of	O
Ap4	B
A	I
in	O
the	O
extracellular	O
fluid	O
[	O
12	O
]	O
.	O

For	O
that	O
reason	O
,	O
the	O
use	O
of	O
Ap4	B
A	I
monitoring	O
as	O
a	O
reliable	O
index	O
of	O
true	O
secretion	O
from	O
chromaffin	O
granules	O
was	O
suggested	O
[	O
12	O
]	O
.	O

The	O
secreted	O
ATP	B
,	O
the	O
diadenosine	B
polyphosphates	I
,	O
and	O
their	O
products	B
of	I
hydrolysis	I
may	O
interact	O
with	O
not	O
yet	O
well	O
defined	O
purine	O
receptors	O
,	O
P2X	O
,	O
P2Y	O
,	O
P2D	O
,	O
P4	O
and	O
P1	O
[	O
17–20	O
]	O
,	O
and	O
modulate	O
a	O
variety	O
of	O
processes	O
such	O
as	O
vascular	O
tone	O
[	O
6	O
,	O
21–23	O
]	O
,	O
cell	O
proliferation	O
[	O
24	O
,	O
25	O
]	O
,	O
cardiac	O
function	O
[	O
26	O
]	O
,	O
neurotransmission	O
[	O
17	O
,	O
27	O
]	O
,	O
platelet	O
aggregation	O
[	O
28	O
]	O
,	O
glucose	B
metabolism	O
[	O
29	O
,	O
30	O
]	O
,	O
cellular	O
pH	O
[	O
31	O
]	O
and	O
neutrophil	O
function	O
[	O
32	O
]	O
.	O

The	O
potential	O
implication	O
of	O
dinucleoside	B
polyphosphates	I
in	O
the	O
pathogenesis	O
of	O
hypertension	O
and	O
atherosclerosis	O
has	O
been	O
suggested	O
[	O
7	O
,	O
23	O
]	O
and	O
their	O
longer	O
stability	O
in	O
vivo	O
in	O
relation	O
to	O
ATP	B
have	O
inspired	O
basic	O
research	O
on	O
the	O
potential	O
clinical	O
utility	O
of	O
some	O
chemical	B
analogues	I
[	O
33	O
]	O
.	O

Of	O
special	O
interest	O
in	O
relation	O
to	O
this	O
paper	O
is	O
the	O
strong	O
vasoconstrictor	O
effect	O
reported	O
for	O
diadenosine	B
hexaphosphate	I
(	O
Ap6	B
A	I
)	O
and	O
diadenosine	B
pentaphosphate	I
(	O
Ap5	B
A	I
)	O
in	O
the	O
isolated	O
perfused	O
rat	O
kidney	O
at	O
concentrations	O
as	O
low	O
as	O
1	O
nM	O
[	O
6	O
]	O
.	O

The	O
synthesis	O
of	O
both	O
Ap6	B
A	I
and	O
Ap5	B
A	I
catalyzed	O
by	O
firefly	O
luciferase	O
has	O
been	O
previously	O
reported	O
[	O
34	O
]	O
.	O

However	O
,	O
this	O
enzyme	O
apparently	O
only	O
exists	O
in	O
the	O
lanterns	O
of	O
fireflies	O
and	O
not	O
in	O
mammals	O
.	O

The	O
synthesis	O
of	O
a	O
variety	O
of	O
mono-	B
and	O
dinucleoside	B
polyphosphates	I
,	O
including	O
adenosine	B
tetraphosphate	I
(	O
p4	B
A	I
)	O
,	O
adenosine	B
pentaphosphate	I
(	O
p5	B
A	I
)	O
,	O
Ap4	B
A	I
,	O
Ap5	B
A	I
,	O
and	O
various	O
heterodinucleoside	B
tetraphosphates	I
(	O
Ap4	B
N	I
)	O
by	O
acyl	O
-	O
CoA	O
synthetase	O
from	O
Pseudomonas	O
fragi	O
has	O
been	O
recently	O
reported	O
[	O
35	O
]	O
.	O

The	O
objet	O
of	O
this	O
report	O
is	O
to	O
present	O
evidence	O
that	O
this	O
enzyme	O
also	O
catalyzes	O
the	O
synthesis	O
of	O
the	O
strong	O
vasoactive	O
diadenosine	B
hexaphosphate	I
(	O
Ap6	B
A	I
)	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
The	O
commercial	O
preparation	O
of	O
Pseudomonas	O
fragi	O
acyl	O
-	O
CoA	O
synthetase	O
was	O
from	O
Boehringer	O
Mannheim	O
(	O
catalogue	O
no.	O
1002406	O
;	O
lot	O
:	O
94110725	O
)	O
.	O

The	O
lyophilyzed	O
powders	O
were	O
dissolved	O
(	O
3.62	O
mg	O
/	O
mL	O
)	O
in	O
25	O
mM	O
Hepes	B
/	O
KOH	B
(	O
pH	O
7.6	O
)	O
,	O
0.1	O
mM	O
dithiothreitol	B
,	O
5	O
%	O
glycerol	B
and	O
0.1	O
%	O
bovine	O
serum	O
albumin	O
.	O

Dithiothreitol	B
,	O
ammonium	B
tetrapolyphosphate	I
(	O
P4	B
)	O
and	O
nucleotides	B
were	O
from	O
Sigma	O
.	O

Bovine	O
serum	O
albumin	O
(	O
fraction	O
V	O
;	O
fatty	O
acids	O
free	O
)	O
,	O
phosphodiesterase	O
from	O
Crotalus	O
durissus	O
(	O
catalogue	O
no.	O
108260	O
)	O
,	O
alkaline	O
phosphatase	O
(	O
EC	O
3.1.3.1	O
)	O
from	O
calf	O
intestine	O
(	O
catalogue	O
no.	O
108138	O
)	O
and	O
inorganic	B
pyrophosphatase	I
(	O
EC	O
3.6.1.1	O
)	O
from	O
yeast	O
(	O
catalogue	O
no.	O
108987	O
)	O
were	O
purchased	O
from	O
Boehringer	O
Mannheim	O
.	O

Asymmetrical	O
dinucleoside	O
tetraphosphatase	O
was	O
purified	O
from	O
rat	O
liver	O
as	O
described	O
by	O
Sillero	O
et	O
al.	O
[	O
36	O
]	O
.	O

Pyrophosphatase	O
was	O
desalted	O
by	O
ultrafiltration	O
using	O
microconcentrators	O
with	O
exclusion	O
limit	O
membranes	O
of	O
30	O
kDa	O
(	O
from	O
Vivascience	O
)	O
[	O
35	O
]	O
.	O

HPLC	O
chromatographs	O
were	O
from	O
Hewlett	O
Packard	O
or	O
from	O
Waters	B
.	O

The	O
Hypersil	O
ODS	O
and	O
Mono	O
Q	O
columns	O
were	O
from	O
Hewlett	O
Packard	O
and	O
Pharmacia	O
,	O
respectively	O
.	O

2.2	O
Methods	O
All	O
the	O
incubations	O
were	O
performed	O
at	O
30	O
°	O
C	O
.	O

2.3	O
Synthesis	O
of	O
Ap6	B
A	I
using	O
ATP	B
and	O
P4	B
as	O
substrates	O
of	O
acyl	O
-	O
CoA	O
synthetase	O
The	O
reaction	O
mixture	O
(	O
0.4	O
mL	O
)	O
contained	O
50	O
mM	O
MES	B
-	O
KOH	B
(	O
pH	O
5.5	O
)	O
,	O
0.1	O
mM	O
dithiothreitol	B
,	O
10	O
mM	O
MgCl2	B
,	O
4.4	O
mM	O
ATP	B
,	O
5	O
mM	O
P4	B
,	O
acyl	O
-	O
CoA	O
synthetase	O
from	O
Pseudomonas	O
fragi	O
(	O
0.325	O
mg	O
protein	O
/	O
mL	O
)	O
and	O
desalted	B
pyrophosphatase	I
(	O
1.2	O
%	O
;	O
v	O
/	O
v	O
)	O
.	O

20	O
μL	O
aliquots	O
were	O
withdrawn	O
at	O
various	O
times	O
of	O
incubation	O
at	O
30	O
°	O
C	O
,	O
diluted	O
with	O
180	O
μL	O
of	O
water	B
,	O
kept	O
at	O
100	O
°	O
C	O
for	O
90	O
s	O
,	O
chilled	O
,	O
filtered	O
and	O
analyzed	O
by	O
HPLC	O
using	O
an	O
Hypersil	O
ODS	O
column	O
(	O
100	O
mm	O
×	O
2.1	O
mm	O
)	O
.	O

Elutions	O
were	O
performed	O
at	O
a	O
constant	O
flow	O
rate	O
(	O
0.5	O
mL	O
/min	O
)	O
with	O
a	O
20-min	O
linear	O
gradient	O
(	O
5–30	O
mM	O
)	O
of	O
sodium	B
phosphate	I
(	O
pH	O
7.5	O
)	O
in	O
20	O
mM	O
tetrabutylammonium	B
bromide	I
/	O
20	O
%	O
methanol	B
(	O
buffer	O
A	O
)	O
,	O
followed	O
by	O
a	O
10-min	O
linear	O
gradient	O
(	O
30–100	O
mM	O
)	O
of	O
sodium	B
phosphate	I
(	O
pH	O
7.5	O
)	O
in	O
buffer	O
A.	O
2.4	O
Purification	O
of	O
the	O
synthesized	O
Ap6	B
A	I
Reaction	O
mixtures	O
were	O
set	O
up	O
as	O
described	O
above	O
.	O

After	O
incubation	O
for	O
40	O
h	O
they	O
were	O
heated	O
at	O
100	O
°	O
C	O
for	O
90	O
s	O
,	O
centrifuged	O
,	O
the	O
supernatant	O
brought	O
to	O
pH	O
7.8	O
with	O
HEPES	B
-	O
KOH	B
mM	O
and	O
treated	O
with	O
25	O
μg	O
of	O
protein	O
/	O
mL	O
alkaline	B
phosphatase	I
during	O
2	O
h.	O
At	O
the	O
end	O
of	O
the	O
incubation	O
,	O
the	O
mixtures	O
were	O
heated	O
at	O
100	O
°	O
C	O
for	O
90	O
s	O
,	O
centrifuged	O
and	O
all	O
the	O
supernatant	O
injected	O
into	O
a	O
Mono	O
Q	O
column	O
(	O
0.5	O
cm	O
×	O
5	O
cm	O
)	O
(	O
Pharmacia	O
)	O
and	O
eluted	O
(	O
HPLC	O
)	O
with	O
40	O
min	O
linear	O
NH4	B
HCO3	I
gradient	O
(	O
0.5–0.7	O
M	O
)	O
.	O

The	O
fractions	O
containing	O
the	O
presumed	O
Ap6	B
A	I
were	O
pooled	O
,	O
an	O
aliquot	O
was	O
rechromatographed	O
in	O
the	O
same	O
conditions	O
to	O
establish	O
the	O
purity	O
of	O
the	O
pool	O
,	O
and	O
the	O
rest	O
concentrated	O
by	O
lyophilization	O
.	O

2.5	O
Characterization	O
of	O
the	O
synthesized	O
Ap6	B
A.	I
Phosphodiesterase	O
treatment	O
The	O
reaction	O
mixture	O
(	O
0.17	O
mL	O
)	O
contained	O
15	O
μM	O
of	O
purified	O
Ap6	B
A	I
,	I
50	O
mM	O
HEPES	B
-	O
KOH	B
(	O
pH	O
7.2	O
)	O
and	O
commercial	O
phosphodiesterase	O
of	O
Crotalus	O
durissus	O
(	O
2.4	O
μg	O
of	O
protein	O
/	O
mL	O
)	O
.	O

Asymmetrical	O
dinucleoside	O
tetraphosphatase	O
treatment	O
:	O
the	O
reaction	O
mixture	O
(	O
0.28	O
mL	O
)	O
contained	O
12	O
μM	O
of	O
purified	O
Ap6	B
A	I
,	O
50	O
mM	O
Tris	B
-	O
HCl	B
(	O
pH	O
7.5	O
)	O
,	O
1	O
mM	O
MgCl2	B
and	O
rat	O
liver	O
asymmetrical	O
dinucleoside	O
tetraphosphatase	O
(	O
0.04	O
mU	O
/	O
mL	O
)	O
.	O

Aliquots	O
were	O
taken	O
at	O
various	O
times	O
of	O
incubation	O
and	O
analyzed	O
by	O
HPLC	O
using	O
an	O
Hypersil	O
ODS	O
column	O
(	O
100	O
mm	O
×	O
4.6	O
mm	O
)	O
and	O
eluting	O
with	O
30	O
mM	O
sodium	B
phosphate	I
(	O
pH	O
7.5	O
)	O
in	O
20	O
mM	O
tetrabutylammonium	B
bromide	I
/	O
20	O
%	O
methanol	B
.	O

The	O
products	O
have	O
been	O
identified	O
by	O
co	O
-	O
elution	O
with	O
appropriate	O
standards	O
.	O

3	O
Results	O
and	O
discussion	O
Although	O
in	O
our	O
view	O
the	O
mechanism	O
of	O
reaction	O
of	O
acyl	O
-	O
CoA	O
synthetase	O
is	O
not	O
yet	O
completely	O
clarified	O
,	O
here	O
it	O
is	O
assumed	O
that	O
the	O
synthesis	O
of	O
Ap4	B
N	I
takes	O
place	O
through	O
reactions	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
with	O
the	O
trace	O
amounts	O
of	O
fatty	B
acid	I
needed	O
being	O
supplied	O
by	O
the	O
proper	O
enzyme	O
preparation	O
or	O
by	O
other	O
component	O
of	O
the	O
reaction	O
mixture	O
(	O
see	O
reference	O
[	O
35	O
]	O
)	O
.	O

E	O
+	O
RCOOH	B
+	O
ATP	B
→	O
E.RCO	B
-	I
AMP	I
+	O
Ppi	B
(	O
1	O
)	O
E.RCO	B
-	I
AMP	I
+	O
NTP	B
→	O
E	O
+	O
RCOOH	B
+	O
Ap4	B
N	I
(	O
2	O
)	O
ATP	B
is	O
the	O
preferred	O
substrate	O
for	O
reaction	O
(	O
1	O
)	O
[	O
35	O
]	O
.	O

The	O
second	O
step	O
is	O
rather	O
unspecific	O
and	O
all	O
the	O
nucleoside	O
triphosphates	O
tested	O
were	O
acceptors	O
of	O
the	O
AMP	B
moiety	O
of	O
the	O
intermediate	O
complex	O
giving	O
rise	O
to	O
a	O
variety	O
of	O
heterodinucleoside	B
polyphosphates	I
(	O
Ap4	B
N	I
)	O
[	O
35	O
]	O
.	O

Tri-	B
and	O
tetrapolyphosphates	B
(	O
P3	B
and	O
P4	B
)	O
are	O
also	O
acceptor	O
substrates	O
for	O
the	O
synthesis	O
of	O
p4	B
A	I
and	O
p5	B
A	I
,	O
respectively	O
[	O
35	O
]	O
.	O

The	O
synthesis	O
of	O
Ap6	B
A	I
could	O
be	O
approached	O
using	O
ATP	B
and	O
p5	B
A	I
as	O
donor	O
and	O
acceptor	O
of	O
AMP	B
,	O
respectively	O
.	O

Unfortunately	O
,	O
p5	B
A	I
is	O
not	O
commercially	O
available	O
.	O

However	O
,	O
as	O
the	O
enzyme	O
synthesizes	O
p5	B
A	I
from	O
ATP	B
and	O
P4	B
[	O
35	O
]	O
,	O
a	O
reaction	O
mixture	O
containing	O
ATP	B
and	O
P4	B
was	O
set	O
up	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
and	O
analyzed	O
by	O
HPLC	O
after	O
different	O
periods	O
of	O
incubation	O
.	O

As	O
expected	O
,	O
a	O
compound	O
corresponding	O
to	O
p5	B
A	I
(	O
figure	O
1	O
,	O
peak	O
5	O
)	O
was	O
firstly	O
synthesized	O
increasing	O
in	O
the	O
first	O
24	O
h	O
of	O
reaction	O
and	O
decreasing	O
thereafter	O
.	O

In	O
the	O
first	O
12	O
h	O
of	O
incubation	O
the	O
average	O
rate	O
of	O
synthesis	O
of	O
p5	B
A	I
was	O
4.2	O
mU	O
/	O
mg	O
of	O
protein	O
;	O
its	O
concentration	O
was	O
1.0	O
mM	O
and	O
1.3	O
mM	O
at	O
time	O
12	O
h	O
and	O
24	O
h	O
,	O
respectively	O
.	O

A	O
new	O
peak	O
(	O
peak	O
d6	O
)	O
,	O
corresponding	O
presumably	O
to	O
Ap6	B
A	I
,	O
appeared	O
along	O
the	O
time	O
of	O
incubation	O
.	O

Between	O
time	O
12	O
h	O
and	O
24	O
h	O
of	O
incubation	O
the	O
average	O
rate	O
of	O
synthesis	O
of	O
Ap6	B
A	I
was	O
0.40	O
mU	O
/	O
mg	O
of	O
protein	O
and	O
its	O
concentration	O
increased	O
from	O
51	O
μM	O
to	O
144	O
μM	O
during	O
that	O
time	O
.	O

Synthesis	O
of	O
Ap4	B
A	I
(	O
peak	O
d4	O
)	O
was	O
also	O
observed	O
due	O
to	O
the	O
dual	O
role	O
of	O
ATP	B
as	O
donor	O
and	O
acceptor	O
of	O
adenylate	B
(	O
figure	O
1	O
)	O
.	O

p4	B
A	I
(	O
peak	O
4	O
)	O
and	O
Ap5	B
A	I
(	O
d5	B
)	O
were	O
also	O
synthesized	O
due	O
to	O
the	O
P3	B
present	O
as	O
product	O
of	O
hydrolysis	O
or	O
contaminating	O
the	O
P4	B
preparations	O
(	O
figure	O
1	O
)	O
.	O

In	O
a	O
control	O
without	O
enzyme	O
only	O
a	O
partial	O
hydrolysis	O
of	O
ATP	B
into	O
ADP	B
(	O
peak	O
2	O
)	O
and	O
AMP	B
(	O
peak	O
1	O
)	O
was	O
observed	O
(	O
results	O
not	O
shown	O
)	O
.	O

The	O
synthesized	O
Ap6	B
A	I
was	O
characterized	O
by	O
its	O
UV	O
spectrum	O
,	O
co	O
-	O
elution	O
with	O
commercial	O
Ap6	B
A	I
and	O
by	O
treatment	O
with	O
hydrolytic	O
enzymes	O
.	O

For	O
that	O
,	O
reaction	O
mixtures	O
similar	O
to	O
the	O
one	O
reported	O
above	O
were	O
treated	O
with	O
alkaline	O
phosphatase	O
and	O
,	O
by	O
chromatography	O
on	O
a	O
Mono	O
Q	O
column	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
,	O
peaks	O
corresponding	O
to	O
adenosine	B
,	O
Ap4	B
A	I
,	O
Ap5	B
A	I
and	O
Ap6	B
A	I
were	O
separated	O
(	O
not	O
shown	O
)	O
.	O

Fractions	O
containing	O
the	O
presumed	O
Ap6	B
A	I
were	O
joined	O
and	O
the	O
purity	O
of	O
the	O
pool	O
checked	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

The	O
remaining	O
of	O
the	O
pool	O
was	O
frozen	O
,	O
dried	O
in	O
vacuum	O
,	O
and	O
a	O
volume	O
of	O
0.23	O
mL	O
of	O
146	O
μM	O
Ap6	B
A	I
was	O
obtained	O
.	O

The	O
purified	O
Ap6	B
A	I
was	O
treated	O
with	O
commercial	O
phosphodiesterase	O
from	O
Crotalus	O
durissus	O
or	O
with	O
asymmetrical	O
dinucleoside	O
tetraphosphatase	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
.	O

Upon	O
phosphodiesterase	O
treatment	O
formation	O
of	O
AMP	B
and	O
p5	B
A	I
was	O
firstly	O
observed	O
and	O
upon	O
asymmetrical	O
dinucleoside	O
tetraphosphatase	O
treatment	O
the	O
only	O
product	O
of	O
hydrolysis	O
was	O
ATP	B
(	O
figure	O
2	O
)	O
.	O

Here	O
we	O
have	O
shown	O
that	O
acyl	O
-	O
CoA	O
synthetase	O
from	O
Pseudomonas	O
fragi	O
catalyzes	O
,	O
in	O
vitro	O
,	O
the	O
synthesis	O
of	O
Ap6	B
A	I
,	O
Ap5	B
A	I
and	O
Ap4	B
A.	I
It	O
has	O
been	O
hypothesized	O
that	O
the	O
enzymes	O
(	O
mainly	O
synthetases	O
and	O
some	O
transferases	O
)	O
able	O
to	O
form	O
an	O
adenylyl	B
intermediate	O
with	O
simultaneous	O
liberation	O
of	O
PPi	B
in	O
the	O
course	O
of	O
the	O
enzyme	O
mechanism	O
would	O
be	O
able	O
to	O
synthesize	O
Ap4	B
N	I
[	O
37	O
]	O
.	O

Probably	O
,	O
these	O
enzymes	O
could	O
also	O
be	O
able	O
to	O
catalyze	O
,	O
at	O
least	O
in	O
vitro	O
,	O
the	O
synthesis	O
of	O
p4	B
A	I
,	O
p5	B
A	I
,	O
Ap5	B
A	I
and	O
Ap6	B
A.	I
It	O
is	O
known	O
since	O
1966	O
that	O
certain	O
aminoacyl	O
-	O
tRNA	O
synthetases	O
catalyze	O
the	O
synthesis	O
of	O
Ap4	B
A	I
using	O
ATP	B
as	O
adenylyl	B
donor	O
and	O
acceptor	O
[	O
38	O
]	O
;	O
it	O
has	O
also	O
been	O
reported	O
that	O
in	O
the	O
presence	O
of	O
ATP	B
and	O
P3	B
lysil	O
-	O
tRNA	O
synthetase	O
from	O
E.	O
coli	O
can	O
catalyze	O
the	O
synthesis	O
of	O
p4	B
A	I
[	O
39	O
]	O
.	O

The	O
synthesis	O
of	O
p4	B
A	I
or	O
p5	B
A	I
from	O
ATP	B
and	O
P3	B
or	O
P4	B
,	O
respectively	O
,	O
has	O
been	O
shown	O
to	O
be	O
catalyzed	O
by	O
yeast	O
acetyl	O
-	O
CoA	O
synthetase	O
[	O
40	O
]	O
and	O
firefly	O
luciferase	O
[	O
34	O
]	O
.	O

The	O
possibility	O
that	O
,	O
in	O
vivo	O
,	O
the	O
synthesis	O
of	O
Ap5	B
A	I
and	O
Ap6	B
A	I
takes	O
place	O
through	O
the	O
mechanism	O
shown	O
to	O
be	O
possible	O
in	O
vitro	O
(	O
this	O
work	O
)	O
is	O
,	O
at	O
present	O
,	O
somewhat	O
speculative	O
and	O
implies	O
the	O
simultaneous	O
presence	O
of	O
those	O
enzymes	O
,	O
the	O
adequate	O
adenylyl	B
donor	O
ATP	B
and	O
an	O
adequate	O
adenylyl	B
acceptor	O
(	O
p4	B
A	I
and	O
p5	B
A	I
or	O
P3	B
and	O
P4	B
)	O
in	O
a	O
particular	O
microenvironment	O
of	O
the	O
cell	O
.	O

Actually	O
,	O
p4	B
A	I
is	O
present	O
in	O
horse	O
and	O
rabbit	O
muscle	O
[	O
41	O
]	O
and	O
in	O
adrenal	O
medullary	O
gland	O
[	O
13	O
]	O
.	O

The	O
occurrence	O
of	O
polyphosphates	B
in	O
mammalian	O
tissues	O
has	O
also	O
been	O
reported	O
[	O
42	O
,	O
43	O
]	O
.	O

The	O
in	O
vivo	O
relative	O
contributions	O
to	O
the	O
synthesis	O
of	O
Ap6	B
A	I
of	O
the	O
different	O
enzymes	O
able	O
to	O
catalyze	O
in	O
vitro	O
the	O
synthesis	O
dinucleoside	O
polyphosphates	O
is	O
beyond	O
the	O
objectives	O
of	O
this	O
paper	O
.	O

From	O
data	O
presented	O
above	O
and	O
in	O
a	O
previous	O
paper	O
[	O
35	O
]	O
it	O
can	O
be	O
inferred	O
that	O
the	O
activity	O
of	O
synthesis	O
of	O
Ap6	B
A	I
catalyzed	O
by	O
acyl	O
-	O
CoA	O
synthetase	O
from	O
Pseudomonas	O
fragi	O
would	O
be	O
three	O
to	O
four	O
orders	O
of	O
magnitude	O
lower	O
than	O
the	O
activity	O
of	O
synthesis	O
of	O
palmitoyl	B
-	I
CoA.	I
Similar	O
orders	O
of	O
magnitude	O
for	O
the	O
synthesis	O
of	O
Ap4	B
A	I
compared	O
to	O
that	O
of	O
aminoacyl	B
-	I
tRNA	I
has	O
also	O
been	O
observed	O
in	O
the	O
cases	O
of	O
valyl	O
and	O
methionyl	O
-	O
tRNA	O
synthetases	O
from	O
E.	O
coli	O
and	O
,	O
however	O
,	O
this	O
low	O
activity	O
did	O
not	O
precluded	O
the	O
induction	O
of	O
in	O
vivo	O
increase	O
concentration	O
of	O
Ap4	B
N	I
by	O
over	O
expression	O
of	O
these	O
enzymes	O
[	O
44	O
]	O
.	O

Acyl	O
-	O
CoA	O
synthetases	O
have	O
been	O
described	O
in	O
the	O
membranes	O
of	O
rat	O
liver	O
peroxisomes	O
,	O
endoplasmic	O
reticulum	O
and	O
mitochondria	O
[	O
45–47	O
]	O
.	O

The	O
association	O
of	O
acyl	O
-	O
CoA	O
synthetases	O
with	O
membranous	O
material	O
supports	O
the	O
speculation	O
that	O
these	O
enzymes	O
could	O
be	O
involved	O
in	O
the	O
synthesis	O
of	O
diadenosine	B
polyphosphates	I
in	O
chromaffin	O
granules	O
and	O
in	O
synaptic	O
terminals	O
of	O
the	O
nervous	O
system	O
.	O

Acknowledgements	O

We	O
thank	O
Isabel	O
de	O
Diego	O
for	O
very	O
able	O
technical	O
assistance	O
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Dirección	O
General	O
de	O
Investigación	O
Científica	O
y	O
Técnica	O
(	O
PM95	O
/	O
13	O
)	O
.	O

R.F.	O
was	O
supported	O
by	O
a	O
Fellowship	O
from	O
Junta	O
Nacional	O
de	O
Investigação	O
Científica	O
e	O
Tecnológica	O
(	O
Portugal	O
)	O
.	O

3-Deoxy	B
-	I
d	I
-glycero	I
-d	I
-galacto	I
-2-nonulosonic	I
acid	I
(	O
Kdn	B
)	O
is	O
a	O
unique	O
deaminated	B
analogue	I
of	I
sialic	I
acid	I
that	O
has	O
recently	O
been	O
isolated	O
from	O
the	O
rainbow	O
trout	O
egg	O
polysialoglycoprotein	O
(	O
PSGP	O
)	O
[	O
1	O
]	O
.	O

Kdn	B
has	O
several	O
forms	O
of	O
glycosylic	B
linkages	O
,	O
such	O
as	O
α-	O
(	O
2→3	O
)	O
,	O
α-	O
(	O
2→6	O
)	O
and	O
α-	O
(	O
2→8	O
)	O
and	O
has	O
been	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
such	O
as	O
fish	O
egg	O
,	O
sperm	O
,	O
amphibian	O
egg	O
,	O
and	O
bacteria	O
[	O
2–5	O
]	O
.	O

To	O
date	O
,	O
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
the	O
Kdn	B
,	O
several	O
studies	O
have	O
been	O
carried	O
out	O
[	O
6	O
]	O
,	O
and	O
consequently	O
,	O
it	O
was	O
deduced	O
that	O
the	O
Kdn	B
may	O
play	O
a	O
role	O
in	O
protecting	O
against	O
sialidase	O
digestion	O
[	O
6	O
]	O
.	O

In	O
order	O
to	O
investigate	O
its	O
further	O
roles	O
,	O
enzymatic	O
incorporation	O
of	O
Kdn	B
and	O
its	O
analogues	B
into	O
intact	O
oligosaccharides	B
in	O
vivo	O
is	O
a	O
potential	O
method	O
as	O
has	O
been	O
demonstrated	O
in	O
the	O
research	O
on	O
N	B
-acetylneuraminic	I
acid	I
(	O
NeuAc	B
)	O
[	O
7	O
]	O
.	O

Although	O
activities	O
of	O
Kdn	B
-	O
transferase	O
have	O
been	O
identified	O
[	O
6	O
]	O
,	O
purification	O
of	O
Kdn	B
-	O
transferase	O
has	O
not	O
been	O
accomplished	O
on	O
a	O
practical	O
scale	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
variety	O
of	O
sialyltransferases	O
have	O
been	O
purified	O
and	O
used	O
in	O
enzymatic	O
syntheses	O
of	O
sialoside	B
,	O
its	O
analogues	B
[	O
8	O
]	O
,	O
and	O
Kdn	B
-	I
α-	I
(	I
2→3	I
)	I
-Gal	I
-	I
β-	I
(	I
1→4	I
)	I
-Glc	I
-	I
β-1-OAll	I
[	O
9	O
]	O
.	O

Recently	O
,	O
bacterial	O
α-	O
(	O
2→6	O
)	O
sialyltransferase	O
[	O
EC	O
2.4.99.1	O
]	O
,	O
which	O
catalyzes	O
the	O
transfer	O
of	O
NeuAc	B
to	O
a	O
variety	O
of	O
sialyl	B
acceptors	O
,	O
has	O
been	O
isolated	O
[	O
10	O
]	O
.	O

Since	O
this	O
enzyme	O
has	O
broad	O
substrate	O
specificity	O
[	O
11	O
]	O
,	O
it	O
is	O
expected	O
to	O
be	O
useful	O
for	O
the	O
syntheses	O
of	O
Kdn	B
oligosaccharides	B
or	O
their	O
analogues	B
.	O

If	O
this	O
enzyme	O
can	O
transfer	O
Kdn	O
from	O
CMP	O
-	O
β	O
-	O
d	O
-Kdn	O
to	O
the	O
corresponding	O
sialyl	O
acceptor	O
,	O
modification	O
of	O
oligosaccharide	O
by	O
Kdn	O
or	O
its	O
analogues	O
in	O
vivo	O
will	O
be	O
developed	O
.	O

We	O
report	O
here	O
enzymatic	O
transfer	O
of	O
Kdn	B
to	O
methyl	B
N	I
-acetyl	I
-	I
β	I
-	I
d	I
-lactosaminide	I
and	O
4-methylumbelliferyl	B
β	I
-	I
d	I
-lactoside	I
by	O
bacterial	O
α-	O
(	O
2→6	O
)	O
-sialyltransferase	O
.	O

2	O
.	O

Results	O
and	O
discussion	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
was	O
prepared	O
by	O
our	O
previously	O
reported	O
method	O
(	O
Scheme	O
1	O
)	O
[	O
12	O
]	O
.	O

This	O
synthetic	O
route	O
,	O
however	O
,	O
afforded	O
a	O
mixture	O
of	O
four	O
isomers	O
of	O
4	O
.	O

The	O
derivatives	O
were	O
rationalized	O
as	O
1:1:0.8:0.8	O
,	O
and	O
this	O
ratio	O
is	O
reproducible	O
.	O

1	O
H	O
NMR	O
data	O
suggested	O
that	O
the	O
phosphite	B
derivatives	B
consist	O
of	O
an	O
anomeric	O
mixture	O
of	O
Kdn	B
because	O
both	O
H-3′	O
and	O
H-4′	O
in	O
the	O
Kdn	B
unit	O
were	O
observed	O
with	O
reasonable	O
chemical	O
shifts	O
(	O
Table	O
2	O
in	O
Ref	O
.	O

[	O
13	O
]	O
)	O
.	O

Since	O
separation	O
of	O
each	O
product	O
proved	O
to	O
be	O
difficult	O
due	O
to	O
their	O
lability	O
on	O
purification	O
,	O
the	O
phosphite	B
4	B
was	O
then	O
used	O
in	O
the	O
next	O
step	O
without	O
further	O
purification	O
.	O

Oxidation	O
of	O
4	B
also	O
afforded	O
a	O
mixture	O
of	O
four	O
kinds	O
of	O
phosphate	B
5	B
in	O
88	O
%	O
yield	O
.	O

After	O
deprotection	O
,	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
the	O
crude	O
product	O
showed	O
that	O
the	O
desired	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
6	B
was	O
obtained	O
in	O
60	O
%	O
purity	O
,	O
and	O
no	O
CMP	B
-	I
α	I
-	I
d	I
-Kdn	I
was	O
observed	O
at	O
all	O
.	O

These	O
results	O
indicated	O
that	O
CMP	B
-	I
α	I
-	I
d	I
-Kdn	I
might	O
be	O
more	O
labile	O
than	O
6	B
.	O

Purification	O
with	O
a	O
gel	O
-	O
permeation	O
column	O
(	O
5	O
mM	O
NH4	B
OH	I
)	O
afforded	O
pure	O
compound	B
6	I
in	O
30	O
%	O
yield	O
,	O
and	O
its	O
1	O
H	O
NMR	O
data	O
are	O
in	O
good	O
agreement	O
with	O
reported	O
data	O
[	O
4,9,14	O
]	O
.	O

Enzymatic	O
synthesis	O
of	O
Kdn	B
-	B
oligosaccharide	I
8	B
using	O
the	O
bacterial	O
α-	O
(	O
2→6	O
)	O
-sialyltransferase	O
was	O
performed	O
under	O
the	O
reported	O
conditions	O
[	O
11	O
]	O
for	O
the	O
preparation	O
of	O
sialoside	B
,	O
except	O
that	O
the	O
pH	O
was	O
adjusted	O
to	O
7.5	O
.	O

The	O
enzyme	O
catalyzed	O
the	O
transfer	O
of	O
Kdn	B
to	O
methyl	B
β	I
-	I
d	I
-N	I
-acetyllactosaminide	I
(	O
7	B
)	O
and	O
afforded	O
the	O
desired	O
Kdn	B
-	I
N	I
-acetyl	I
-	I
β	I
-	I
d	I
-lactosaminide	I
8	O
in	O
77	O
%	O
yield	O
(	O
Scheme	O
2	O
)	O
.	O

The	O
structure	O
was	O
identified	O
by	O
1	O
H	O
and	O
related	O
2D	O
NMR	O
spectra	O
.	O

Enzyme	O
assay	O
using	O
4-methylumbelliferyl	B
β	I
-	I
d	I
-lactoside	I
indicated	O
that	O
the	O
apparent	O
K	O
m	O
value	O
of	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
is	O
880	O
μM	O
,	O
which	O
is	O
27	O
times	O
larger	O
than	O
that	O
of	O
CMP	B
-	I
β	I
-	I
d	I
-NeuAc	I
(	O
33	O
μM	O
)	O
.	O

In	O
addition	O
,	O
the	O
V	O
max	O
value	O
of	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
is	O
15	O
%	O
larger	O
than	O
that	O
of	O
CMP	B
-	I
β	I
-	I
d	I
-NeuAc	I
.	O

Despite	O
the	O
fact	O
that	O
substitution	O
of	O
the	O
acetamido	B
group	I
with	O
a	O
hydroxyl	B
group	I
resulted	O
in	O
a	O
decrease	O
of	O
both	O
binding	O
affinity	O
and	O
transfer	O
velocity	O
,	O
practical	O
enzymatic	O
synthesis	O
could	O
still	O
afford	O
Kdn	B
-	I
N	I
-acetyl	I
-	I
β	I
-	I
d	I
-lactosaminide	I
in	O
good	O
yield	O
.	O

In	O
general	O
,	O
mammalian	O
α-	O
(	O
2→6	O
)	O
-sialyltransferase	O
can	O
not	O
catalyze	O
transfer	O
of	O
NeuAc	B
to	O
both	O
lactose	B
and	O
N	B
-acetyl	I
-	I
β	I
-	I
d	I
-lactosamine	I
.	O

However	O
,	O
bacterial	O
sialyltransferase	O
can	O
transfer	O
even	O
Kdn	B
to	O
both	O
lactose	B
and	O
N	B
-acetyl	I
-	I
β	I
-	I
d	I
-lactosamine	I
.	O

This	O
finding	O
would	O
be	O
useful	O
for	O
the	O
synthesis	O
of	O
several	O
Kdn	B
oligosaccharides	B
.	O

In	O
summary	O
,	O
we	O
found	O
bacterial	O
sialyltransferase	O
catalyzes	O
the	O
transfer	O
of	O
Kdn	B
to	O
both	O
methyl	B
N	I
-acetyl	I
-	I
β	I
-	I
d	I
-lactosaminide	I
and	O
4-methylumbelliferyl	B
β	I
-	I
d	I
-lactoside	I
.	O

A	O
previous	O
report	O
[	O
11,15	O
]	O
showed	O
that	O
this	O
enzyme	O
has	O
broad	O
substrate	O
specificity	O
toward	O
disaccharides	B
and	O
monosaccharides	B
.	O

In	O
addition	O
,	O
the	O
enzyme	O
is	O
now	O
available	O
in	O
large	O
quantity	O
[	O
15	O
]	O
.	O

Therefore	O
,	O
enzymatic	O
synthesis	O
using	O
CMP	B
-	I
modified	I
-	I
Kdn	I
and	O
bacterial	O
sialyltransferase	O
would	O
afford	O
Kdn	B
-	B
oligosaccharide	I
analogues	B
which	O
can	O
be	O
expected	O
to	O
clarify	O
the	O
role	O
of	O
Kdn	B
.	O

Since	O
the	O
Kdn	B
may	O
be	O
resistant	O
to	O
sialidase	O
digestion	O
,	O
the	O
Kdn	B
or	O
its	O
analogues	B
will	O
be	O
expected	O
to	O
be	O
used	O
for	O
masking	O
of	O
galactosides	B
at	O
the	O
nonreducing	O
end	O
of	O
the	O
glycoprotein	O
in	O
order	O
to	O
change	O
the	O
biological	O
response	O
,	O
such	O
as	O
blocking	O
the	O
hepatic	O
clearance	O
[	O
16	O
]	O
.	O

3	O
.	O

Experimental	O
3.1	O
General	O
procedure	O
1	O
H	O
NMR	O
spectra	O
were	O
recorded	O
with	O
either	O
a	O
JEOL	O
EX	O
270	O
or	O
Bruker	O
DMX	O
500	O
instrument	O
.	O

31	O
P	O
NMR	O
spectra	O
were	O
recorded	O
with	O
Bruker	O
DMX	O
500	O
or	O
AC	O
300	O
instrument	O
,	O
and	O
chemical	O
shifts	O
are	O
expressed	O
in	O
ppm	O
and	O
referenced	O
to	O
H3	B
PO4	I
(	O
0	O
ppm	O
)	O
as	O
the	O
external	O
standard	O
.	O

Optical	O
rotations	O
were	O
measured	O
with	O
a	O
JASCO	O
DIP-4	O
.	O

High	O
-	O
resolution	O
mass	O
spectra	O
were	O
recorded	O
using	O
a	O
Shimazu	O
/	O
Kratos	O
concept	O
-	O
IIH	O
under	O
FAB	O
conditions	O
.	O

All	O
reactions	O
were	O
monitored	O
by	O
TLC	O
(	O
Silica	B
Gel	O
60-F254	O
,	O
E.	O
Merck	O
)	O
by	O
charring	O
after	O
spraying	O
with	O
5	O
%	O
H2	B
SO4	I
in	O
MeOH	B
.	O

3.2	O
Methyl	B
4,5,7,8,9-penta	I
-	I
O	I
-	I
acetyl-3-deoxy	I
-	I
d	I
-glycero	I
-	I
β	I
-	I
d	I
-galacto-2-nonulopyranosonate	I
(	O
2	O
)	O
To	O
a	O
solution	O
of	O
thiophenyl	B
glycoside	I
1	O
[	O
13	O
]	O
(	O
682	O
mg	O
,	O
1.17	O
mmol	O
)	O
in	O
10:3	O
acetone	B
–	O
H2	B
O	I
(	O
26	O
mL	O
)	O
was	O
added	O
NBS	B
(	O
609	O
mg	O
)	O
,	O
and	O
the	O
mixture	O
was	O
stirred	O
at	O
0	O
°	O
C	O
.	O

After	O
2	O
h	O
the	O
mixture	O
was	O
diluted	O
with	O
EtOAc	B
and	O
washed	O
with	O
a	O
solution	O
of	O
NaHCO3	B
(	O
2	O
×	O
)	O
.	O

The	O
organic	O
phase	O
was	O
dried	O
with	O
MgSO4	B
and	O
was	O
concentrated	O
in	O
vacuo	O
.	O

Purification	O
of	O
the	O
residue	O
by	O
flash	O
column	O
chromatography	O
(	O
2:1→1:1	O
n	B
-hexane	I
–	O
EtOAc	B
)	O
afforded	O
2	O
(	O
96	O
%	O
,	O
546	O
mg	O
)	O
:	O
[	O
α	O
]	O
D	O
26	O
−1.2	O
°	O
(	O
c	O
0.83	O
,	O
CHCl3	B
)	O
;	O
mp	O
106–108	O
°	O
C	O
;	O
1	O
H	O
NMR	O
(	O
270	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.34–7.52	O
(	O
m	O
,	O
5	O
H	O
,	O
SPh	B
)	O
,	O
5.20	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-7	O
)	O
,	O
5.04	O
(	O
ddd	O
,	O
1	O
H	O
,	O
J	O
7.4	O
Hz	O
,	O
H-8	O
)	O
,	O
5.09	O
(	O
ddd	O
,	O
1	O
H	O
,	O
J	O
11.8	O
Hz	O
,	O
H-4	O
)	O
,	O
4.79	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
7.4	O
Hz	O
,	O
H-5	O
)	O
,	O
4.21	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2.9	O
Hz	O
,	O
H-9	O
)	O
,	O
4.19	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
10.3	O
,	O
2.1	O
Hz	O
,	O
H-6	O
)	O
,	O
3.97	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
12.4	O
,	O
6.0	O
Hz	O
,	O
H-9	O
)	O
,	O
3.66	O
(	O
s	O
,	O
3H	O
,	O
COOMe	B
)	O
,	O
2.15	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
5.1	O
,	O
12.8	O
Hz	O
,	O
H-3eq	O
)	O
,	O
1.83–1.93	O
(	O
m	O
,	O
16	O
H	O
,	O
OAc	O
,	O
H-3ax	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C20	B
H28	I
O14	I
:	O
C	O
,	O
48.78	O
;	O
H	O
,	O
5.73	O
.	O

Found	O
:	O
C	O
,	O
49.10	O
;	O
H	O
,	O
5.50	O
.	O

3.3	O
2-Cyanoethyl	B
(	I
2′,3′-di	I
-	I
O	I
-	I
acetyl	I
-	I
N4	I
-acetylcytidine-5′-yl	I
)	I
(	I
methyl	I
4,5,7,8,9-penta	I
-	I
O	I
-	I
acetyl-3-deoxy	I
-	I
β	I
-	I
d	I
-glycero	I
-	I
β	I
-	I
d	I
-galacto-2-non	I
-	I
ulopyranosid-2′′-yl	I
)	I
phosphite	I
(	O
4	B
)	O
The	O
pentaacetyl	B
-	I
Kdn	I
(	O
2	O
,	O
229	O
mg	O
,	O
470	O
μmol	O
)	O
and	O
cytidine	B
5′-O	I
-amidite	I
(	O
3	O
,	O
784	O
mg	O
,	O
14.0	O
mmol	O
)	O
were	O
separately	O
dried	O
by	O
coevaporating	O
twice	O
with	O
dry	O
toluene	B
.	O

They	O
were	O
then	O
combined	O
in	O
freshly	O
prepared	O
dry	O
MeCN	B
(	O
2.0	O
mL	O
)	O
.	O

To	O
this	O
mixture	O
was	O
added	O
[	B
1H	I
]	I
-tetrazole	I
(	O
59	O
mg	O
,	O
840	O
μmol	O
)	O
at	O
−40	O
°	O
C	O
under	O
an	O
argon	B
atmosphere	O
.	O

After	O
5	O
min	O
,	O
the	O
cold	O
bath	O
was	O
removed	O
.	O

The	O
mixture	O
was	O
further	O
stirred	O
for	O
30	O
min	O
at	O
room	O
temperature	O
(	O
rt	O
)	O
,	O
and	O
then	O
the	O
mixture	O
was	O
diluted	O
with	O
EtOAc	B
.	O

The	O
organic	O
phase	O
was	O
washed	O
with	O
NaHCO3	B
solution	O
,	O
dried	O
with	O
MgSO4	B
,	O
and	O
concentrated	O
in	O
vacuo	O
at	O
40	O
°	O
C	O
.	O

Purification	O
of	O
the	O
residue	O
by	O
gel	O
-	O
permeation	O
column	O
chromatography	O
twice	O
(	O
Sephadex	O
LH-20	O
,	O
2	O
×	O
60	O
cm	O
,	O
MeOH	B
,	O
)	O
afforded	O
phosphite	B
4	I
(	O
403	O
mg	O
,	O
88	O
%	O
,	O
four	O
diastereomers	B
,	O
1:1:0.8:0.8	O
)	O
.	O

1	O
H	O
NMR	O
chemical	O
shifts	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

31	O
P	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
135.0	O
,	O
135.9	O
,	O
137.2	O
,	O
137.3	O
.	O

HRFABMS	O
:	O
Calcd	O
for	O
C38	B
H50	I
N4	I
O23	I
P	I
,	O
961.2604	O
(	O
M+H	O
)	O
;	O
Found	O
:	O
961.2611	O
.	O

Anal	O
.	O

Calcd	O
for	O
C38	B
H49	I
N4	I
O23	I
P	I
:	O
C	O
,	O
47.50	O
;	O
H	O
,	O
5.14	O
;	O
N	O
,	O
5.83	O
,	O
Found	O
:	O
C	O
,	O
47.09	O
;	O
H	O
,	O
5.02	O
;	O
N	O
,	O
6.09	O
.	O
3.4	O
2-Cyanoethyl	B
(	I
2′,3′-di	I
-	I
O	I
-	I
acetyl	I
-	I
N4	I
-acetylcytidine	I
5′-yl	I
)	I
(	I
methyl	I
4,5,7,8,9-penta	I
-	I
O	I
-	I
acetyl-3-deoxy	I
-	I
β	I
-	I
d	I
-glycero	I
-	I
d	I
-galacto-2-nonulo	I
-	I
pyranosid	I
2′′-yl	I
)	I
phosphate	I
(	O
5	O
)	O
To	O
a	O
solution	O
of	O
phosphite	B
4	I
(	O
108	O
mg	O
,	O
110	O
μmol	O
)	O
in	O
MeCN	B
(	O
1.0	O
mL	O
)	O
was	O
added	O
tert	B
-BuOOH	I
(	O
2.5	O
M	O
in	O
toluene	B
,	O
218	O
μL	O
)	O
,	O
and	O
the	O
mixture	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
30	O
min	O
,	O
the	O
mixture	O
was	O
diluted	O
with	O
EtOAc	B
and	O
washed	O
with	O
NaHCO3	B
solution	O
.	O

After	O
drying	O
with	O
MgSO4	B
,	O
the	O
organic	O
phase	O
was	O
concentrated	O
in	O
vacuo	O
at	O
40	O
°	O
C	O
.	O

Purification	O
of	O
the	O
residue	O
by	O
gel	O
-	O
permeation	O
column	O
chromatography	O
(	O
Sephadex	O
LH-20	O
,	O
CH2	B
Cl2	I
)	O
afforded	O
phosphate	B
5	I
(	O
99	O
mg	O
,	O
90	O
%	O
,	O
four	O
diastereomers	B
)	O
.	O

1	O
H	O
NMR	O
:	O
δ	O
9.64	O
(	O
NHAc	B
)	O
,	O
8.00–8.25	O
(	O
H-6	O
)	O
,	O
7.39–7.50	O
(	O
H-5	O
)	O
,	O
6.08–6.20	O
(	O
H-1′	O
)	O
,	O
3.89	O
(	O
COOMe	B
)	O
,	O
2.78–2.88	O
(	O
H-3′′eq	O
)	O
,	O
2.24	O
(	O
NAc	B
)	O
,	O
1.98–2.11	O
(	O
OAc	B
)	O
;	O
31	O
P	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
−6.33	O
,	O
−6.23	O
,	O
−6.23	O
,	O
−6.14	O
.	O

HRFABMS	O
:	O
Calcd	O
for	O
C38	B
H50	I
N4	I
O24	I
P	I
,	O
977.2553	O
(	O
M+H	O
)	O
;	O
Found	O
:	O
977.2552	O
.	O

3.5	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
(	O
6	B
)	O
To	O
a	O
solution	O
of	O
protected	O
CMP	B
-	I
Kdn	I
5	O
(	O
96	O
mg	O
,	O
100	O
μmol	O
)	O
in	O
THF	B
(	O
3.0	O
mL	O
)	O
was	O
added	O
1,8-diazabicyclo-	B
[	I
5.4.0	I
]	I
-7-undecene	I
(	O
2.3	O
mg	O
,	O
15.2	O
μmol	O
)	O
,	O
and	O
the	O
mixture	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
5	O
min	O
,	O
NaOMe	B
(	O
174	O
mg	O
,	O
3.24	O
mmol	O
)	O
and	O
MeOH	B
–	O
H2	B
O	I
(	O
1.2–5.1	O
mL	O
)	O
were	O
added	O
to	O
this	O
mixture	O
.	O

After	O
16	O
h	O
the	O
mixture	O
was	O
lyophilized	O
.	O

Purification	O
of	O
the	O
residue	O
by	O
gel	O
-	O
permeation	O
column	O
chromatography	O
(	O
Sephadex	O
G-15	O
,	O
3	O
×	O
100	O
cm	O
,	O
5	O
mM	O
NH4	B
OH	I
,	O
4	O
°	O
C	O
)	O
afforded	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
6	B
(	O
19	O
mg	O
30	O
%	O
)	O
.	O

1	O
H	O
NMR	O
(	O
HOD=4.81	B
ppm	O
)	O
:	O
δ	O
7.96	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
7.5	O
Hz	O
,	O
H-6	O
)	O
,	O
6.10	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
7.5	O
Hz	O
,	O
H-5	O
)	O
,	O
5.97	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
4.5	O
Hz	O
,	O
H-1′′	O
)	O
,	O
4.33	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-4′	O
)	O
,	O
4.27	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2′	O
)	O
,	O
4.21	O
(	O
d	O
,	O
3	O
H	O
,	O
H-3′	O
,	O
5′a	O
,	O
5′b	O
)	O
,	O
4.06	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
9.6	O
Hz	O
,	O
H-6′′	O
)	O
,	O
4.00	O
(	O
ddd	O
,	O
1	O
H	O
,	O
J	O
4.9	O
,	O
9.6	O
,	O
12.4	O
Hz	O
,	O
H-4′′	O
)	O
,	O
3.92	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
12.1	O
Hz	O
,	O
H-9′′a	O
)	O
,	O
3.88	O
(	O
d	O
,	O
1	O
H	O
,	O
H-7′′	O
)	O
,	O
3.72	O
(	O
m	O
,	O
1	O
H	O
,	O
H-8′′	O
)	O
,	O
3.65	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
6.8	O
,	O
12.1	O
Hz	O
,	O
H-9′′b	O
)	O
,	O
3.57	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
9.6	O
,	O
9.6	O
Hz	O
,	O
H-5′′	O
)	O
,	O
2.41	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
4.9	O
,	O
12.4	O
Hz	O
)	O
,	O
1.57	O
(	O
ddd	O
,	O
1	O
H	O
,	O
J	O
5.9	O
,	O
12.4	O
,	O
12.4	O
Hz	O
,	O
H-3ax	O
)	O
;	O
31	O
P	O
NMR	O
(	O
D2	B
O	I
)	O
:	O
δ	O
−4.43	O
.	O

HRFABMS	O
:	O
Calcd	O
for	O
C18	B
H26	I
N3	I
O16	I
PNa3	I
(	O
M+Na+	O
)	O
,	O
640.0745	O
;	O
Found	O
:	O
640.0754	O
.	O

3.6	O
Methyl	B
(	I
3-deoxy	I
-	I
d	I
-glycero	I
-	I
α	I
-	I
d	I
-galacto-2-nonulopyranosylonic	I
acid	I
)	I
-	I
(	I
2→6	I
)	I
-	I
(	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-2-acetoamido-2-deoxy	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
8	B
)	O
A	O
solution	O
containing	O
the	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
(	O
6.5	O
mg	O
,	O
10.2	O
μmol	O
,	O
2	O
sodium	B
salt	O
)	O
,	O
methyl	B
β	I
-	I
d	I
-lactosaminide	I
7	B
(	O
3.5	O
mg	O
,	O
8.1	O
μmol	O
)	O
,	O
BSA	O
(	O
2	O
mg	O
)	O
,	O
alkaline	O
phosphatase	O
(	O
25	O
u	O
)	O
,	O
purified	O
sialyltransferase	O
(	O
80	O
mu	O
)	O
in	O
HEPES	B
buffer	O
(	O
100	O
mM	O
,	O
pH	O
7.5	O
,	O
200	O
μL	O
)	O
was	O
incubated	O
at	O
37	O
°	O
C	O
for	O
12	O
h.	O
The	O
mixture	O
was	O
concentrated	O
in	O
vacuo	O
.	O

The	O
residue	O
was	O
purified	O
by	O
silica	B
gel	O
column	O
chromatography	O
(	O
Kanto	O
Kagaku	O
Co.	O
,	O
Silica	B
Gel	O
60	O
,	O
Spherical	O
,	O
1	O
×	O
10	O
cm	O
,	O
7:3:1	O
n	B
-PrOH	I
–	O
H2	B
O	I
–	O
NH4	B
OH	I
)	O
,	O
and	O
then	O
the	O
product	O
was	O
further	O
purified	O
on	O
a	O
column	O
of	O
Sephadex	O
G-15	O
(	O
1	O
×	O
50	O
cm	O
,	O
water	B
)	O
to	O
give	O
8	O
(	O
4.0	O
mg	O
,	O
77	O
%	O
)	O
.	O

1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
D2	B
O	I
)	O
:	O
δ	O
4.47	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
8.1	O
Hz	O
,	O
H-1	O
)	O
,	O
4.43	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
7.9	O
Hz	O
,	O
H-1′	O
)	O
,	O
3.99	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2.1	O
,	O
13.0	O
Hz	O
,	O
H-6	O
)	O
,	O
3.98	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
9.5	O
,	O
9.5	O
Hz	O
,	O
H-6′	O
)	O
,	O
3.91	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3.4	O
Hz	O
,	O
H-4′	O
)	O
,	O
3.82	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
5.6	O
,	O
13.0	O
Hz	O
,	O
H-6	O
)	O
,	O
3.52	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
8.0	O
,	O
10.4	O
Hz	O
,	O
H-2′	O
)	O
,	O
3.50	O
(	O
s	O
,	O
3	O
H	O
,	O
OMe	B
)	O
,	O
3.47	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
9.4	O
,	O
9.4	O
Hz	O
,	O
H-5′′	O
)	O
,	O
2.61	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
4.6	O
,	O
12.4	O
Hz	O
,	O
H-3′′eq	O
)	O
,	O
2.05	O
(	O
s	O
,	O
3	O
H	O
,	O
Ac	B
)	O
,	O
1.67	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
12.4	O
,	O
12.4	O
Hz	O
,	O
H-3′′ax	O
)	O
;	O
13	O
C	O
NMR	O
(	O
D2	B
O	I
,	O
dioxane=67.48	B
ppm	O
)	O
:	O
δ	O
175.39	O
,	O
174.36	O
,	O
174.16	O
,	O
104.22	O
,	O
102.51	O
,	O
100.66	O
,	O
81.35	O
,	O
75.39	O
,	O
74.61	O
,	O
74.44	O
,	O
73.36	O
,	O
73.20	O
,	O
72.86	O
,	O
71.52	O
,	O
70.85	O
,	O
69.29	O
,	O
69.00	O
,	O
64.45	O
,	O
63.59	O
,	O
61.12	O
,	O
57.89	O
,	O
55.66	O
,	O
40.45	O
,	O
23.16	O
.	O

HRFABMS	O
:	O
Calcd	O
for	O
C24	B
H41	I
NO19	I
Na	I
(	O
M+H	O
)	O
,	O
670.2171	O
;	O
Found	O
:	O
670.2205	O
.	O

3.7	O
Enzyme	O
assay	O
Sialyltransferase	B
assays	O
were	O
performed	O
with	O
a	O
HEPES	B
buffer	O
solution	O
(	O
pH	O
7.5	O
,	O
100	O
mM	O
,	O
25	O
μL	O
)	O
containing	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
(	O
1.5	O
,	O
3.0	O
,	O
5.0	O
and	O
10.0	O
mM	O
)	O
or	O
CMP	B
-	I
β	I
-	I
d	I
-NeuAc	I
(	O
75.0	O
,	O
100	O
,	O
150	O
,	O
and	O
280	O
μM	O
)	O
,	O
4-methylumbelliferyl	B
β	I
-	I
d	I
-lactoside	I
(	O
1.0	O
mM	O
)	O
,	O
BSA	B
(	O
1	O
μg	O
)	O
,	O
Triton	B
X100	I
(	O
0.02	O
%	O
)	O
and	O
sialyltransferase	O
(	O
for	O
CMP	B
-	I
β	I
-	I
d	I
-Kdn	I
:	O
8.3	O
mU	O
;	O
for	O
CMP	B
-	I
β	I
-	I
d	I
-NeuAc	I
:	O
0.1	O
mU	O
)	O
.	O

The	O
mixture	O
was	O
incubated	O
at	O
37	O
°	O
C	O
.	O

The	O
reaction	O
was	O
followed	O
up	O
to	O
15	O
%	O
consumption	O
of	O
donor	O
substrate	O
.	O

After	O
incubation	O
,	O
the	O
mixture	O
was	O
allowed	O
to	O
cool	O
with	O
dry	B
ice	I
/	O
acetone	B
,	O
and	O
then	O
Kdn	B
or	O
NeuAc	B
transferred	O
were	O
quantitated	O
with	O
HPLC	O
(	O
C18-column	O
:	O
1	O
×	O
25	O
cm	O
,	O
1:4	O
MeCN	B
–	O
H2	B
O	I
)	O
equipped	O
with	O
fluorescence	O
detector	O
(	O
excitation	O
:	O
325	O
nm	O
,	O
emission	O
:	O
378	O
nm	O
)	O
.	O

K	O
m	O
and	O
V	O
max	O
values	O
were	O
estimated	O
using	O
a	O
Lineweaver	O
–	O
Burk	O
plot	O
.	O

The	O
data	O
points	O
are	O
the	O
averages	O
of	O
at	O
least	O
duplicate	O
values	O
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Masayosi	O
Kusama	O
for	O
the	O
mass	O
spectroscopic	O
analyses	O
.	O

The	O
cyclic	B
hydroxamic	I
acids	I
DIBOA	B
(	O
2,4-dihydroxy-1,4-benzoxazin-3-one	B
)	O
and	O
DIMBOA	B
(	O
2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one	B
)	O
play	O
an	O
important	O
role	O
in	O
the	O
chemical	O
defense	O
of	O
cereals	O
against	O
deleterious	O
pests	O
such	O
as	O
insects	O
,	O
pathogenic	O
fungi	O
and	O
bacteria	O
[	O
1	O
]	O
.	O

DIBOA	B
is	O
the	O
main	O
hydroxamic	B
acid	I
in	O
rye	O
,	O
whereas	O
its	O
methoxy	B
derivative	I
DIMBOA	B
is	O
the	O
predominant	O
form	O
in	O
maize	O
and	O
wheat	O
.	O

In	O
maize	O
,	O
a	O
series	O
of	O
five	O
genes	O
that	O
are	O
clustered	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
four	O
,	O
is	O
sufficient	O
to	O
encode	O
the	O
enzymes	O
to	O
synthesise	O
DIBOA	B
[	O
2	O
]	O
.	O

The	O
first	O
gene	O
in	O
the	O
pathway	O
,	O
Bx1	O
,	O
encodes	O
an	O
enzyme	O
resembling	O
a	O
tryptophan	O
synthase	O
α	O
subunit	O
[	O
2	O
,	O
3	O
]	O
that	O
catalyses	O
the	O
formation	O
of	O
free	O
indole	B
[	O
2	O
]	O
and	O
thereby	O
establishes	O
the	O
branchpoint	O
that	O
leads	O
to	O
the	O
secondary	B
metabolites	I
DIBOA	B
and	O
DIMBOA	B
.	O

The	O
next	O
four	O
genes	O
,	O
Bx2–Bx5	O
,	O
encode	O
cytochrome	O
P450-dependent	O
monooxygenases	O
of	O
the	O
CYP71C	O
subfamily	O
[	O
4	O
]	O
,	O
that	O
catalyse	O
four	O
consecutive	O
hydroxylations	O
including	O
one	O
ring	O
-	O
expansion	O
to	O
form	O
the	O
defense	O
compound	O
DIBOA	B
(	O
Fig.	O
1	O
;	O
[	O
2	O
]	O
)	O
.	O

The	O
classic	O
forms	O
of	O
cytochrome	O
P450	O
monooxygenases	O
are	O
membrane	O
-	O
bound	O
heme	B
-	O
containing	O
mixed	O
function	O
oxidases	O
.	O

They	O
utilise	O
NADPH	B
or	O
NADH	B
to	O
reductively	O
cleave	O
molecular	O
oxygen	B
to	O
produce	O
functionalised	B
organic	I
products	I
and	O
a	O
molecule	O
of	O
water	B
.	O

In	O
this	O
generalised	O
reaction	O
,	O
reducing	O
equivalents	O
from	O
NADPH	B
are	O
transferred	O
to	O
the	O
P450	O
enzyme	O
via	O
a	O
flavin	O
-	O
containing	O
NADPH	O
-	O
P450	O
reductase	O
(	O
CPR	O
)	O
.	O

In	O
plants	O
,	O
P450	O
enzymes	O
are	O
involved	O
mainly	O
in	O
hydroxylation	O
or	O
oxidative	O
demethylation	O
reactions	O
[	O
5	O
]	O
of	O
a	O
large	O
variety	O
of	O
primary	B
and	O
secondary	B
metabolites	I
including	O
hormones	B
,	O
phytoalexins	B
,	O
xenobiotics	B
and	O
pharmaceutically	B
relevant	I
compounds	I
.	O

The	O
close	O
genetic	O
linkage	O
and	O
the	O
sequence	O
similarity	O
of	O
the	O
DIBOA	B
-	O
specific	O
P450	O
genes	O
[	O
4	O
]	O
,	O
indicate	O
that	O
these	O
genes	O
most	O
probably	O
arose	O
from	O
gene	O
duplication	O
events	O
.	O

Evolution	O
of	O
these	O
genes	O
generated	O
enzymes	O
of	O
the	O
CYP71C	O
P450	O
subfamily	O
that	O
catalyse	O
consecutive	O
reactions	O
in	O
the	O
pathway	O
leading	O
to	O
DIBOA	B
.	O

In	O
this	O
report	O
we	O
show	O
that	O
this	O
process	O
has	O
resulted	O
in	O
rather	O
specific	O
P450	O
enzymes	O
that	O
predominantly	O
catalyse	O
only	O
one	O
reaction	O
in	O
the	O
DIBOA	B
pathway	O
.	O

The	O
question	O
of	O
enzyme	O
specificity	O
was	O
addressed	O
by	O
heterologous	O
expression	O
of	O
the	O
P450	O
genes	O
in	O
yeast	O
.	O

In	O
this	O
system	O
we	O
also	O
investigated	O
the	O
interaction	O
of	O
the	O
maize	O
P450	O
enzymes	O
with	O
one	O
CPR	O
of	O
yeast	O
and	O
two	O
CPRs	O
of	O
Arabidopsis	O
,	O
indicating	O
that	O
the	O
availability	O
of	O
CPR	O
may	O
limit	O
P450	O
enzyme	O
activity	O
in	O
plants	O
.	O

In	O
order	O
to	O
test	O
whether	O
the	O
DIBOA	B
pathway	O
of	O
maize	O
can	O
be	O
generalised	O
in	O
grasses	O
,	O
microsomes	O
derived	O
from	O
rye	O
and	O
barley	O
seedlings	O
were	O
assayed	O
for	O
the	O
BX2–BX5	O
specific	O
reactions	O
.	O

In	O
rye	O
(	O
high	O
DIBOA	B
content	O
)	O
the	O
enzyme	O
activities	O
were	O
identical	O
with	O
those	O
in	O
maize	O
,	O
whereas	O
in	O
barley	O
(	O
no	O
detectable	O
DIBOA	B
or	O
DIMBOA	B
)	O
no	O
enzymatic	O
activities	O
were	O
observed	O
.	O

2	O
Results	O
2.1	O
Characterization	O
of	O
the	O
enzymatic	O
properties	O
of	O
BX2–BX5	O
by	O
heterologous	O
expression	O
in	O
yeast	O
The	O
cytochrome	O
P450-dependent	O
monooxygenases	O
BX2–BX5	O
convert	O
indole	B
to	O
DIBOA	B
by	O
catalysing	O
a	O
series	O
of	O
four	O
hydroxylations	O
(	O
Fig.	O
1	O
;	O
[	O
2	O
]	O
)	O
.	O

These	O
P450	O
enzymes	O
were	O
expressed	O
in	O
yeast	O
in	O
order	O
to	O
characterise	O
their	O
catalytic	O
properties	O
in	O
more	O
detail	O
.	O

For	O
expression	O
,	O
the	O
Bx2–Bx5	O
cDNAs	O
were	O
inserted	O
into	O
the	O
pYeDP60	O
vector	O
under	O
the	O
control	O
of	O
the	O
galactose	B
inducible	O
GAL10-CYC1	O
promotor	O
[	O
6	O
]	O
.	O

The	O
P450	O
genes	O
were	O
expressed	O
in	O
four	O
different	O
Saccharomyces	O
cerevisiae	O
strains	O
that	O
were	O
isogenic	O
except	O
for	O
their	O
CPR	O
gene	O
locus	O
.	O

Strain	O
W	O
(	O
N	O
)	O
has	O
wild	O
type	O
yeast	O
CPR	O
levels	O
,	O
W	O
(	O
R	O
)	O
overexpresses	O
yeast	O
CPR	O
after	O
induction	O
with	O
galactose	B
[	O
7	O
]	O
.	O

In	O
WAT11	O
and	O
WAT21	O
galactose	B
inducible	O
Arabidopsis	O
thaliana	O
CPRs	O
(	O
ATR1	O
and	O
ATR2	O
,	O
respectively	O
)	O
replace	O
the	O
yeast	O
reductase	O
in	O
the	O
genome	O
[	O
6	O
,	O
8	O
]	O
.	O

Microsomes	O
were	O
isolated	O
from	O
the	O
transgenic	O
yeast	O
strains	O
and	O
tested	O
for	O
the	O
four	O
specific	O
reactions	O
of	O
the	O
DIBOA	B
pathway	O
by	O
HPLC	O
analysis	O
.	O

The	O
concentration	O
of	O
the	O
maize	O
P450	O
proteins	O
in	O
the	O
microsomes	O
was	O
determined	O
by	O
quantitative	O
Western	O
analysis	O
(	O
Table	O
1	O
)	O
.	O

CPR	O
activities	O
were	O
analysed	O
by	O
cytochrome	O
c	O
reduction	O
[	O
9	O
]	O
.	O

The	O
CPR	O
activity	O
was	O
basically	O
independent	O
of	O
the	O
heterologous	O
P450	O
gene	O
and	O
similar	O
to	O
the	O
values	O
obtained	O
by	O
Pompon	O
et	O
al.	O
[	O
5	O
]	O
.	O

In	O
W	O
(	O
R	O
)	O
overexpression	O
of	O
the	O
yeast	O
CPR	O
results	O
in	O
a	O
20-fold	O
stimulation	O
of	O
the	O
basal	O
CPR	O
activity	O
.	O

Overexpression	O
of	O
the	O
CPRs	O
from	O
Arabidopsis	O
leads	O
to	O
a	O
4	O
-	O
5-fold	O
increase	O
over	O
the	O
basal	O
level	O
.	O

The	O
concentration	O
of	O
the	O
maize	O
P450	O
proteins	O
in	O
the	O
transgenic	O
yeast	O
microsomes	O
was	O
in	O
the	O
range	O
of	O
0.2–2.6	O
μ	O
g	O
/	O
mg	O
microsomes	O
(	O
Table	O
1	O
)	O
.	O

Except	O
for	O
BX2	O
,	O
these	O
expression	O
levels	O
are	O
lower	O
than	O
in	O
maize	O
microsomes	O
.	O

It	O
is	O
possible	O
that	O
the	O
relative	O
high	O
GC	O
content	O
(	O
65	O
%	O
)	O
of	O
the	O
maize	O
genes	O
[	O
4	O
]	O
does	O
not	O
permit	O
efficient	O
expression	O
in	O
the	O
yeast	O
system	O
.	O

Heterologous	O
expression	O
of	O
the	O
cinnamate-4-hydroxylase	O
gene	O
from	O
Helianthus	O
tuberosus	O
(	O
48	O
%	O
GC	O
)	O
[	O
10	O
]	O
in	O
the	O
same	O
system	O
resulted	O
in	O
protein	O
expression	O
levels	O
that	O
were	O
in	O
the	O
range	O
of	O
4	O
to	O
10	O
μ	O
g	O
/	O
mg	O
microsomal	O
protein	O
[	O
11	O
]	O
.	O

In	O
general	O
,	O
similar	O
P450	O
activities	O
can	O
be	O
obtained	O
in	O
microsomal	O
preparations	O
derived	O
from	O
the	O
yeast	O
strains	O
as	O
with	O
maize	O
microsomes	O
.	O

The	O
specific	O
activity	O
of	O
the	O
P450	O
enzymes	O
is	O
dependent	O
on	O
the	O
amount	O
and	O
to	O
a	O
certain	O
extend	O
on	O
the	O
nature	O
of	O
the	O
CPRs	O
present	O
in	O
the	O
microsomes	O
(	O
Table	O
1	O
)	O
.	O

In	O
this	O
respect	O
,	O
some	O
individual	O
features	O
were	O
observed	O
.	O

BX2	O
shows	O
little	O
preference	O
for	O
one	O
of	O
the	O
CPRs	O
and	O
has	O
a	O
similar	O
specific	O
activity	O
in	O
all	O
yeast	O
strains	O
which	O
is	O
highest	O
in	O
W	O
(	O
R	O
)	O
.	O

In	O
contrast	O
,	O
the	O
specific	O
activity	O
of	O
BX3	O
is	O
about	O
8	O
times	O
higher	O
in	O
WAT11	O
than	O
in	O
maize	O
microsomes	O
.	O

This	O
suggests	O
a	O
productive	O
interaction	O
of	O
BX3	O
and	O
ATR1	O
and	O
indicates	O
that	O
in	O
this	O
case	O
the	O
amount	O
of	O
CPR	O
limits	O
the	O
in	O
vivo	O
activity	O
of	O
BX3	O
.	O

According	O
to	O
their	O
specific	O
activities	O
,	O
BX4	O
and	O
BX5	O
show	O
a	O
preference	O
for	O
the	O
maize	O
CPR	O
(	O
s	O
)	O
.	O

The	O
question	O
of	O
enzyme	O
specificity	O
was	O
addressed	O
with	O
the	O
yeast	O
expression	O
system	O
.	O

The	O
intermediate	O
metabolites	B
of	O
the	O
DIBOA	B
pathway	O
indole	B
,	O
indolin-2-one	B
,	O
3-hydroxy	B
-	I
indolin-2-on	I
,	O
and	O
HBOA	B
[	O
2	O
]	O
were	O
incubated	O
with	O
microsomal	O
preparations	O
each	O
containing	O
one	O
of	O
the	O
P450	O
enzymes	O
.	O

Enzymatic	O
conversions	O
occured	O
only	O
in	O
the	O
known	O
productive	O
combinations	O
[	O
2	O
]	O
(	O
Fig.	O
1	O
)	O
,	O
no	O
conversions	O
were	O
detectable	O
(	O
the	O
detection	O
limit	O
is	O
0.002	O
nmol	O
×	O
mg−1	O
×min−1	O
)	O
in	O
the	O
other	O
combinations	O
.	O

Each	O
enzyme	O
is	O
therefore	O
specific	O
for	O
the	O
introduction	O
of	O
only	O
one	O
of	O
the	O
oxygen	B
atoms	O
of	O
the	O
DIBOA	B
molecule	O
.	O

In	O
addition	O
to	O
the	O
reactions	O
described	O
above	O
,	O
benzoxazin-3-one	B
and	O
2-hydroxy-7-methoxy-1,4-benzoxazin-3-one	B
(	O
HMBOA	B
,	O
Fig.	O
1	O
)	O
were	O
tested	O
as	O
possible	O
substrates	O
for	O
BX2–BX5	O
.	O

The	O
hydroxylation	O
of	O
benzoxazin-3-one	B
to	O
HBOA	B
(	O
Fig.	O
1	O
)	O
was	O
previously	O
described	O
for	O
maize	O
microsomes	O
[	O
12	O
]	O
.	O

Of	O
the	O
four	O
P450	O
enzymes	O
tested	O
,	O
only	O
BX3	O
catalyses	O
this	O
reaction	O
.	O

Hydroxylation	O
of	O
benzoxazin-3-one	B
is	O
approximately	O
half	O
as	O
efficient	O
as	O
the	O
hydroxylation	O
of	O
indolin-2-one	B
(	O
Table	O
1	O
)	O
.	O

In	O
both	O
cases	O
a	O
C	O
atom	O
at	O
an	O
equivalent	O
position	O
is	O
hydroxylated	O
(	O
Fig.	O
1	O
)	O
.	O

In	O
contrast	O
,	O
for	O
HMBOA	B
,	O
a	O
derivative	B
present	O
in	O
maize	O
seedlings	O
[	O
13	O
]	O
,	O
no	O
enzymatic	O
conversions	O
are	O
detectable	O
with	O
BX2–BX5	O
expressed	O
in	O
yeast	O
or	O
with	O
maize	O
microsomes	O
.	O

In	O
particular	O
,	O
HMBOA	B
is	O
not	O
N	O
-	O
hydroxylated	O
by	O
BX5	O
.	O

This	O
indicates	O
that	O
the	O
7-methoxy	O
group	B
of	O
HMBOA	B
would	O
interfere	O
with	O
BX5	O
action	O
.	O

In	O
a	O
number	O
of	O
species	O
the	O
demethylation	O
of	O
the	O
artificial	O
substrate	O
p	B
-chloro	I
-	I
N	I
-methylaniline	I
(	O
pCMA	B
)	O
in	O
a	O
P450	O
specific	O
reaction	O
has	O
been	O
described	O
.	O

This	O
activity	O
is	O
associated	O
with	O
the	O
first	O
plant	O
P450	O
enzyme	O
that	O
was	O
purified	O
and	O
cloned	O
[	O
14	O
]	O
.	O

This	O
enzyme	O
from	O
avocado	O
(	O
Persea	O
americana	O
)	O
,	O
for	O
which	O
the	O
natural	O
substrate	O
is	O
still	O
unknown	O
,	O
was	O
designated	O
CYP71A1	O
and	O
established	O
the	O
CYP71A	O
subfamily	O
[	O
15	O
]	O
.	O

CYP73A1	O
,	O
the	O
cinnamate-4-hydroxylase	O
from	O
Heliantus	O
tuberosus	O
shows	O
also	O
pCMA	O
demetylase	O
activity	O
[	O
16	O
]	O
.	O

Since	O
BX2–BX5	O
have	O
been	O
grouped	O
into	O
the	O
CYP71	O
family	O
[	O
4	O
]	O
,	O
they	O
were	O
tested	O
for	O
pCMA	O
demethylase	O
activity	O
.	O

While	O
BX3–BX5	O
expressed	O
in	O
WAT11	O
show	O
low	O
pCMA	O
demethylase	O
activity	O
(	O
0.02–0.04	O
nmol	O
×	O
min−1	O
×mg−1	O
microsomes	O
)	O
WAT11	O
yeast	O
microsomes	O
containing	O
the	O
BX2	O
enzyme	O
convert	O
pCMA	B
to	O
p	B
-chloro	I
-	I
aniline	I
with	O
a	O
specific	O
activity	O
of	O
0.74	O
nmol	O
×	O
min−1	O
×mg−1	O
microsomes	O
.	O

This	O
value	O
is	O
about	O
three	O
times	O
the	O
pCMA	O
demethylase	O
activity	O
of	O
CYP71A1	O
expressed	O
in	O
wild	O
type	O
yeast	O
[	O
17	O
]	O
and	O
one	O
third	O
of	O
the	O
activity	O
of	O
CYP73A1	O
expressed	O
in	O
W	O
(	O
R	O
)	O
[	O
16	O
]	O
.	O

The	O
KM	O
values	O
for	O
BX2–BX5	O
are	O
in	O
the	O
range	O
5–38	O
μ	O
M.	O
The	O
concentrations	O
determined	O
for	O
the	O
yeast	O
-	O
expressed	O
enzymes	O
are	O
nearly	O
identical	O
to	O
the	O
values	O
measured	O
in	O
maize	O
microsomes	O
(	O
Table	O
2	O
)	O
.	O

This	O
is	O
an	O
indication	O
for	O
the	O
native	O
conformation	O
of	O
the	O
heterologously	O
expressed	O
P450	O
enzymes	O
.	O

KM	O
values	O
for	O
other	O
plant	O
P450	O
enzymes	O
are	O
in	O
the	O
range	O
of	O
2	O
μ	O
M	O
for	O
protopin-6-hydroxylase	O
[	O
18	O
]	O
and	O
350	O
μ	O
M	O
for	O
tyrosin	O
-	O
N	O
-hydroxylase	O
[	O
19	O
]	O
.	O

2.2	O
DIBOA	B
biosynthetic	O
enzymes	O
in	O
other	O
cereals	O
The	O
hydroxamic	B
acids	I
are	O
widely	O
distributed	O
in	O
grasses	O
[	O
1	O
]	O
,	O
suggesting	O
that	O
the	O
aquisation	O
of	O
this	O
pathway	O
occured	O
relatively	O
early	O
in	O
the	O
evolution	O
of	O
the	O
Gramineae	O
.	O

The	O
activity	O
of	O
the	O
DIBOA	B
specific	O
P450	O
enzymes	O
was	O
assayed	O
in	O
two	O
other	O
cereals	O
,	O
rye	O
(	O
containing	O
hydroxamic	B
acids	I
)	O
and	O
barley	O
(	O
without	O
hydroxamic	B
acids	I
)	O
[	O
1	O
]	O
.	O

These	O
two	O
species	O
are	O
much	O
closer	O
related	O
to	O
each	O
other	O
than	O
either	O
is	O
to	O
maize	O
[	O
20	O
]	O
.	O

The	O
major	O
cyclic	B
hydroxamic	I
acid	I
of	O
rye	O
is	O
DIBOA	B
.	O

As	O
in	O
maize	O
,	O
there	O
are	O
relatively	O
high	O
concentrations	O
(	O
up	O
to	O
1	O
mg	O
/	O
g	O
fresh	O
weight	O
)	O
[	O
21	O
]	O
present	O
in	O
the	O
rye	O
seedling	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
identical	O
cytochrome	O
P450-dependent	O
reactions	O
are	O
associated	O
with	O
DIBOA	B
biosynthesis	O
in	O
rye	O
,	O
microsomes	O
were	O
isolated	O
from	O
seedlings	O
.	O

The	O
CPR	O
activity	O
in	O
rye	O
microsomes	O
is	O
about	O
1.8	O
times	O
higher	O
than	O
in	O
maize	O
.	O

All	O
five	O
substrates	O
tested	O
(	O
Table	O
3	O
)	O
were	O
converted	O
to	O
products	B
that	O
were	O
identical	O
to	O
the	O
products	B
obtained	O
with	O
maize	O
microsomes	O
.	O

No	O
additional	O
products	B
were	O
detected	O
.	O

The	O
reactions	O
were	O
strictly	O
dependent	O
on	O
NADPH	B
(	O
data	O
not	O
shown	O
)	O
indicating	O
true	O
cytochrome	O
P450	O
enzyme	O
reactions	O
.	O

The	O
specific	O
activities	O
determined	O
for	O
the	O
rye	O
microsomes	O
were	O
very	O
similar	O
to	O
the	O
values	O
detected	O
with	O
maize	O
microsomes	O
for	O
the	O
first	O
three	O
reactions	O
in	O
the	O
pathway	O
.	O

The	O
conversion	O
of	O
HBOA	B
to	O
DIBOA	B
was	O
reproducibly	O
lower	O
(	O
a	O
factor	O
of	O
two	O
)	O
in	O
rye	O
microsomes	O
.	O

The	O
identity	O
of	O
the	O
reactions	O
in	O
maize	O
and	O
in	O
rye	O
suggests	O
identical	O
DIBOA	B
biosynthetic	O
pathways	O
for	O
both	O
species	O
.	O

In	O
microsomes	O
prepared	O
from	O
barley	O
seedlings	O
,	O
no	O
activities	O
of	O
the	O
P450	O
enzymes	O
of	O
the	O
DIBOA	B
pathway	O
were	O
detectable	O
,	O
although	O
a	O
total	O
P450	O
content	O
of	O
3	O
μ	O
g	O
/	O
mg	O
microsomal	O
protein	O
and	O
a	O
CPR	O
activity	O
of	O
29	O
nmol	O
×	O
mg−1	O
×min−1	O
was	O
determined	O
(	O
Table	O
3	O
)	O
.	O

3	O
Discussion	O
Heterologous	O
expression	O
in	O
yeast	O
strains	O
overexpressing	O
plant	O
CPRs	O
is	O
a	O
powerful	O
tool	O
for	O
the	O
functional	O
analysis	O
of	O
plant	O
cytochrome	O
P450	O
enzymes	O
[	O
11	O
]	O
.	O

Using	O
this	O
system	O
it	O
was	O
possible	O
to	O
determine	O
the	O
enzymatic	O
properties	O
for	O
BX2–BX5	O
without	O
using	O
radioactively	O
labelled	O
substrates	O
.	O

3.1	O
Enzymatic	O
properties	O
of	O
BX2–BX5	O
Bx2–Bx5	O
have	O
probably	O
evolved	O
by	O
gene	O
duplication	O
events	O
as	O
indicated	O
by	O
clustering	O
of	O
the	O
genes	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
four	O
and	O
the	O
sequence	O
similarity	O
between	O
these	O
genes	O
.	O

They	O
have	O
been	O
grouped	O
into	O
the	O
CYP71C	O
subfamily	O
[	O
4	O
]	O
of	O
cytochrome	O
P450-dependent	O
monooxygenases	O
.	O

The	O
BX3–BX5	O
proteins	O
share	O
an	O
average	O
amino	B
acid	I
identity	O
and	O
similarity	O
of	O
58	O
%	O
and	O
77	O
%	O
,	O
respectively	O
,	O
while	O
the	O
average	O
identity	O
and	O
similarity	O
of	O
these	O
P450	O
enzymes	O
to	O
BX2	B
is	O
only	O
49	O
%	O
and	O
70	O
%	O
respectively	O
[	O
4	O
]	O
.	O

BX2	O
is	O
also	O
distinct	O
in	O
that	O
its	O
expression	O
levels	O
in	O
the	O
yeast	O
strains	O
are	O
much	O
higher	O
than	O
that	O
of	O
the	O
other	O
subfamiliy	O
members	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
the	O
interaction	O
of	O
BX2	O
with	O
different	O
CPRs	O
seems	O
to	O
be	O
less	O
selective	O
than	O
that	O
of	O
BX3–BX5	O
.	O

The	O
specific	O
activity	O
of	O
BX2	O
in	O
the	O
microsomes	O
prepared	O
from	O
transgenic	O
W	O
(	O
R	O
)	O
and	O
WAT11	O
strains	O
are	O
quite	O
similar	O
.	O

In	O
contrast	O
,	O
BX3	O
shows	O
a	O
clear	O
preference	O
for	O
the	O
CPR	O
of	O
Arabidopsis	O
thaliana	O
(	O
ATR1	O
)	O
present	O
in	O
the	O
WAT11	O
yeast	O
strain	O
.	O

BX4	O
and	O
BX5	O
also	O
seem	O
to	O
interact	O
relatively	O
well	O
with	O
ATR1	O
,	O
although	O
their	O
specific	O
activities	O
are	O
lower	O
than	O
in	O
maize	O
microsomes	O
.	O

All	O
heterologous	O
CPRs	O
,	O
however	O
,	O
show	O
a	O
productive	O
interaction	O
with	O
the	O
maize	O
P450	O
enzymes	O
.	O

This	O
is	O
further	O
proof	O
for	O
the	O
well	O
established	O
structural	O
conservation	O
of	O
the	O
interaction	O
of	O
P450	O
enzymes	O
and	O
CPRs	O
[	O
22	O
]	O
.	O

The	O
turn	O
-	O
over	O
rate	O
of	O
BX3	O
expressed	O
in	O
WAT11	O
is	O
about	O
eight	O
times	O
higher	O
than	O
in	O
maize	O
microsomes	O
.	O

This	O
indicates	O
that	O
CPR	O
is	O
a	O
limiting	O
factor	O
for	O
BX3	O
activity	O
in	O
vivo	O
.	O

Overexpression	O
of	O
CPRs	O
in	O
the	O
plant	O
could	O
therefore	O
result	O
in	O
significantly	O
higher	O
enzymatic	O
activities	O
.	O

This	O
could	O
be	O
important	O
for	O
the	O
engineering	O
of	O
metabolic	O
pathways	O
that	O
involve	O
P450	O
enzymes	O
.	O

3.2	O
Specificity	O
of	O
BX2–BX5	O
BX2–BX5	O
show	O
high	O
substrate	O
specificity	O
.	O

Each	O
of	O
the	O
DIMBOA	B
specific	O
enzymatic	O
conversions	O
can	O
be	O
performed	O
only	O
by	O
one	O
enzyme	O
of	O
the	O
subfamily	O
.	O

Such	O
a	O
finding	O
seems	O
to	O
support	O
the	O
idea	O
that	O
plant	O
P450s	O
generally	O
have	O
a	O
much	O
greater	O
substrate	O
specificity	O
than	O
their	O
animal	O
homologues	O
[	O
23	O
]	O
.	O

However	O
,	O
there	O
is	O
emerging	O
evidence	O
that	O
plant	O
P450s	O
in	O
addition	O
to	O
their	O
normal	O
physiological	O
function	O
,	O
can	O
also	O
convert	O
certain	O
xenobiotics	B
with	O
varying	O
efficiencies	O
.	O

The	O
hydroxylation	O
of	O
the	O
herbicide	O
diclofop	B
was	O
shown	O
to	O
occur	O
by	O
a	O
wheat	O
P450	O
enzyme	O
[	O
24	O
]	O
.	O

Other	O
examples	O
include	O
the	O
demethylation	O
of	O
pCMA	B
by	O
CYP71A1	O
[	O
17	O
]	O
and	O
by	O
CYP73A1	O
[	O
16	O
]	O
.	O

The	O
natural	O
substrate	O
for	O
CYP71A1	O
is	O
not	O
known	O
,	O
although	O
geraniol	B
and	O
nerol	B
have	O
been	O
reported	O
as	O
substrates	O
[	O
25	O
]	O
.	O

CYP73A1	O
catalyzes	O
the	O
4-hydroxylation	O
of	O
cinnamic	B
acid	I
,	O
the	O
first	O
oxidative	O
step	O
in	O
the	O
phenylpropan	B
pathway	O
.	O

For	O
CYP73A1	O
the	O
conversion	O
of	O
extra	O
substrates	O
has	O
been	O
investigated	O
in	O
great	O
detail	O
[	O
23	O
]	O
.	O

Furthermore	O
,	O
plant	O
P450	O
enzymes	O
can	O
convert	O
different	O
natural	O
substrates	O
.	O

Two	O
P450	O
enzymes	O
of	O
sorghum	O
that	O
belong	O
to	O
the	O
CYP79	O
family	O
and	O
the	O
CYP71E	O
subfamily	O
respectively	O
[	O
26	O
]	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
the	O
cyanogenic	B
glucoside	I
dhurrin	B
.	O

These	O
enzymes	O
are	O
multifunctional	O
and	O
catalyse	O
four	O
distinct	O
steps	O
[	O
27	O
,	O
28	O
]	O
.	O

Indole	B
appears	O
as	O
the	O
natural	O
substrate	O
for	O
2-hydroxylation	O
by	O
BX2	O
.	O

In	O
addition	O
,	O
BX2	O
shows	O
pCMA	O
demethylase	O
activity	O
like	O
CYP71A1	O
and	O
CYP73A1	O
.	O

Since	O
the	O
other	O
substrates	O
of	O
these	O
P450	O
enzymes	O
have	O
no	O
structural	O
similarity	O
,	O
it	O
is	O
likely	O
that	O
pCMA	B
is	O
a	O
quite	O
reactive	O
molecule	O
in	O
the	O
context	O
of	O
P450	O
catalysed	O
reactions	O
,	O
even	O
if	O
binding	O
of	O
pCMA	B
is	O
not	O
optimal	O
.	O

This	O
is	O
underlined	O
by	O
the	O
fact	O
that	O
demetylation	O
of	O
pCMA	B
is	O
also	O
catalysed	O
by	O
several	O
animal	O
P450	O
enzymes	O
[	O
29	O
]	O
.	O

The	O
structural	O
analogy	O
between	O
2-naphthoic	B
acid	I
and	O
trans	B
-cinnamic	I
acid	I
was	O
shown	O
to	O
be	O
sufficient	O
such	O
that	O
2-naphthoic	B
acid	I
can	O
serve	O
as	O
an	O
excellent	O
substrate	O
for	O
CYP73A1	O
[	O
23	O
]	O
.	O

We	O
have	O
probably	O
observed	O
a	O
similar	O
case	O
for	O
BX3	O
that	O
hydroxylates	O
indolin-2-one	B
and	O
1,4-benzoxazin-3-one	B
at	O
an	O
equivalent	O
carbon	B
atom	O
.	O

Although	O
indolin-2-one	B
is	O
converted	O
about	O
2-fold	O
more	O
efficiently	O
,	O
it	O
seems	O
that	O
1,4-benzoxazin-3-one	B
mimics	O
indolin-2-one	B
in	O
the	O
active	O
site	O
of	O
BX3	O
.	O

HMBOA	B
was	O
found	O
in	O
maize	O
seedlings	O
[	O
13	O
]	O
.	O

It	O
is	O
neither	O
a	O
substrate	O
for	O
BX5	O
nor	O
can	O
it	O
be	O
N	O
-	O
hydroxylated	O
in	O
maize	O
microsomes	O
[	O
30	O
]	O
.	O

It	O
is	O
probably	O
the	O
presence	O
of	O
the	O
7-methoxy	O
group	B
that	O
excludes	O
HMBOA	B
as	O
a	O
substrate	O
for	O
BX5	O
.	O

HMBOA	B
could	O
represent	O
a	O
side	O
product	O
of	O
the	O
DIMBOA	B
pathway	O
,	O
in	O
which	O
the	O
C7-methoxy	O
group	B
was	O
introduced	O
prior	O
to	O
N	O
-	O
hydroxylation	O
by	O
BX5	O
.	O

3.3	O
Evolution	O
of	O
the	O
DIBOA	B
pathway	O
For	O
maize	O
and	O
rye	O
,	O
two	O
distant	O
species	O
among	O
the	O
Gramineae	O
,	O
the	O
same	O
DIBOA	B
biosynthetic	O
pathway	O
exists	O
and	O
therefore	O
a	O
set	O
of	O
proteins	O
homologous	O
to	O
BX2–BX5	O
can	O
be	O
proposed	O
.	O

If	O
this	O
were	O
the	O
case	O
,	O
the	O
duplications	O
responsible	O
for	O
the	O
evolution	O
of	O
the	O
Bx2–Bx5	O
gene	O
cluster	O
must	O
have	O
occurred	O
early	O
in	O
the	O
development	O
of	O
the	O
Gramineae	O
.	O

In	O
maize	O
,	O
the	O
Bx1	O
gene	O
is	O
included	O
in	O
this	O
cluster	O
[	O
2	O
]	O
.	O

Bx1	O
encodes	O
a	O
protein	O
with	O
homology	O
to	O
the	O
trypthophan	O
sythase	O
α	O
subunit	O
that	O
catalyses	O
the	O
first	O
step	O
in	O
DIMBOA	B
biosynthesis	O
.	O

The	O
isolation	O
of	O
genes	O
homologues	O
to	O
Bx1–Bx5	O
from	O
rye	O
and	O
other	O
grasses	O
could	O
give	O
insight	O
into	O
the	O
evolution	O
of	O
the	O
Bx	O
gene	O
cluster	O
.	O

Barley	O
microsomes	O
show	O
no	O
significant	O
DIBOA	B
specific	O
P450	O
activities	O
.	O

It	O
remains	O
to	O
be	O
shown	O
whether	O
the	O
loss	O
of	O
enzyme	O
activity	O
is	O
due	O
to	O
gene	O
inactivation	O
,	O
or	O
whether	O
the	O
whole	O
Bx2–Bx5	O
cluster	O
has	O
been	O
lost	O
.	O

This	O
might	O
have	O
occured	O
during	O
agricultural	O
breeding	O
from	O
wild	O
barley	O
varieties	O
in	O
which	O
DIMBOA	B
is	O
still	O
present	O
[	O
1	O
]	O
.	O

A	O
similar	O
loss	O
of	O
enzyme	O
activity	O
has	O
been	O
observed	O
for	O
the	O
UDP	O
-	O
glucose	O
:	O
DIBOA	O
glycosyltransferase	O
.	O

Glycosylation	O
is	O
required	O
for	O
transport	O
of	O
DIBOA	B
into	O
the	O
vacuole	O
.	O

Glycosyltransferase	O
activity	O
present	O
in	O
wild	O
varieties	O
,	O
was	O
lost	O
during	O
barley	O
cultivation	O
[	O
30	O
]	O
.	O

4	O
Experimental	O
4.1	O
Chemicals	O
DIBOA	B
and	O
HBOA	B
were	O
isolated	O
from	O
etiolated	O
rye	O
seedlings	O
[	O
31	O
]	O
and	O
further	O
purified	O
by	O
HPLC	O
using	O
a	O
Merck	O
LiChroCART	O
RP-18	O
column	O
(	O
10	O
×	O
250	O
mm	O
)	O
.	O

The	O
eluent	O
contained	O
9	O
%	O
HOAc	B
and	O
10	O
%	O
MeOH	B
in	O
H2	B
O	I
(	O
v	O
/	O
v	O
)	O
.	O

4.2	O
Plant	O
materials	O
The	O
maize	O
hybrid	O
Blizzard	O
(	O
Ciba	O
Geigy	O
)	O
,	O
rye	O
seeds	O
Halo	O
(	O
Lochow	O
-	O
Petkus	O
,	O
Germany	O
)	O
and	O
the	O
barley	O
seeds	O
Dissa	O
(	O
original	O
source	O
Seed	O
Union	O
,	O
Germany	O
)	O
were	O
used	O
for	O
preparation	O
of	O
microsomes	O
.	O

Seeds	O
were	O
germinated	O
in	O
the	O
dark	O
on	O
wet	O
filter	O
paper	O
for	O
3	O
(	O
maize	O
)	O
or	O
4	O
(	O
rye	O
and	O
barley	O
)	O
days	O
.	O

Whole	O
seedlings	O
were	O
utilised	O
for	O
microsomal	O
preparations	O
.	O

4.3	O
Expression	O
of	O
BX2–BX5	O
proteins	O
in	O
E.	O
coli	O
and	O
preparation	O
of	O
antibodies	O
The	O
coding	O
region	O
of	O
the	O
four	O
P450	O
genes	O
was	O
obtained	O
by	O
PCR	O
amplification	O
using	O
the	O
cDNA	O
clones	O
[	O
4	O
]	O
as	O
templates	O
.	O

The	O
PCR	O
fragments	O
were	O
inserted	O
into	O
the	O
pET3a	O
expression	O
vector	O
and	O
expressed	O
in	O
E.	O
coli	O
strain	O
BL21	O
(	O
DE3	O
)	O
[	O
32	O
]	O
.	O

1	O
l	O
cultures	O
were	O
harvested	O
,	O
lysed	O
and	O
the	O
overexpressed	O
proteins	O
were	O
recovered	O
as	O
inclusion	O
bodies	O
using	O
a	O
modified	O
protocol	O
of	O
Ito	O
et	O
al.	O
[	O
33	O
]	O
.	O

Final	O
purification	O
was	O
achieved	O
by	O
preparative	O
SDS	O
/	O
PAGE	O
on	O
a	O
BioRad	O
model	O
491	O
Prep	O
Cell	O
using	O
10	O
%	O
SDS	O
/	O
PAGE	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
supplier	O
.	O

Immunisation	O
of	O
rabbits	O
was	O
carried	O
out	O
by	O
EUROGENTECH	O
(	O
Belgium	O
)	O
using	O
0.3	O
mg	O
of	O
the	O
purified	O
proteins	O
per	O
immunisation	O
.	O

4.4	O
Expression	O
of	O
P450	O
proteins	O
in	O
yeast	O
The	O
yeast	O
strains	O
W	O
(	O
N	O
)	O
,	O
W	O
(	O
R	O
)	O
[	O
6	O
]	O
,	O
WAT11	O
and	O
WAT21	O
[	O
6	O
,	O
8	O
]	O
and	O
the	O
plasmid	O
pYeDP60	O
[	O
11	O
]	O
were	O
obtained	O
from	O
P.	O
Urban	O
.	O

The	O
DNA	O
coding	O
sequences	O
for	O
BX2–BX5	O
were	O
excised	O
from	O
the	O
pET3a	O
constructs	O
by	O
cleavage	O
with	O
NdeI	O
and	O
EcoRI	O
.	O

The	O
NdeI	O
site	O
contains	O
the	O
AUG	O
start	O
codon	O
of	O
the	O
genes	O
.	O

The	O
DNA	O
fragments	O
were	O
inserted	O
into	O
pYeDP60	O
which	O
was	O
linearized	O
with	O
EcoRI	O
and	O
BamHI	O
by	O
using	O
an	O
adapter	O
(	O
5′-GATCCAGGTGTCCA-3′	B
,	O
5́-TATGGACACCTG-3́	B
)	O
.	O

Yeast	O
cells	O
were	O
transformed	O
by	O
electroporation	O
[	O
34	O
]	O
and	O
cell	O
culture	O
was	O
performed	O
as	O
described	O
by	O
Urban	O
et	O
al.	O
[	O
11	O
]	O
.	O

4.5	O
Enzyme	O
assays	O
Plant	O
microsomes	O
were	O
prepared	O
according	O
to	O
Bailey	O
and	O
Larson	O
[	O
35	O
]	O
.	O

Yeast	O
microsomes	O
were	O
prepared	O
as	O
described	O
[	O
11	O
]	O
.	O

The	O
total	O
P450	O
content	O
of	O
plant	O
microsomes	O
was	O
measured	O
by	O
carbon	B
monoxide	I
differential	O
spectroscopy	O
[	O
36	O
]	O
.	O

pCMA	O
demethylase	O
activity	O
was	O
determined	O
with	O
NADPH	B
as	O
co	O
-	O
substrate	O
as	O
described	O
[	O
37	O
]	O
.	O

Other	O
hydroxylase	O
assays	O
were	O
performed	O
using	O
a	O
0.2	O
ml	O
reaction	O
mixture	O
containing	O
50	O
mM	O
K	O
-	O
Pi	O
pH	O
7.5	O
,	O
0.8	O
mM	O
NADPH	B
,	O
5	O
μ	O
M	O
to	O
1	O
mM	O
of	O
substrate	O
and	O
1	O
mg	O
microsomes	O
(	O
according	O
to	O
the	O
protein	O
content	O
as	O
determined	O
by	O
Bradford	O
)	O
.	O

After	O
10	O
min	O
incubation	O
at	O
25	O
°	O
C	O
the	O
assays	O
were	O
terminated	O
by	O
the	O
addition	O
of	O
0.2	O
ml	O
MeOH	B
and	O
centrifuged	O
for	O
5	O
min	O
.	O

The	O
supernatant	O
was	O
acidified	O
with	O
0.5	O
ml	O
0.1	O
M	O
HOAc	B
and	O
extracted	O
three	O
times	O
with	O
0.4	O
ml	O
EtOAc	B
.	O

The	O
extracts	O
were	O
lyophilised	O
,	O
dissolved	O
in	O
0.1	O
ml	O
MeOH	B
and	O
an	O
aliquot	O
was	O
loaded	O
onto	O
a	O
Merck	O
LiChroCART	O
RP-18	O
HPLC	O
column	O
(	O
4	O
×	O
125	O
mm	O
)	O
and	O
eluted	O
for	O
5	O
min	O
in	O
isocratic	O
conditions	O
with	O
solvent	B
A	O
(	O
H2	B
O	I
–	O
HOAc	B
,	O
9:1	O
)	O
followed	O
by	O
a	O
linear	O
gradient	O
from	O
solvent	B
A	O
to	O
B	O
(	O
MeOH	B
–	O
H2	B
O	I
–	O
HOAc	B
,	O
70:27:3	O
)	O
for	O
7	O
min	O
.	O

Analytes	O
were	O
detected	O
at	O
254	O
nm	O
.	O

Microsomal	O
NADPH	O
-	O
cytochrome	O
c	O
reductase	O
(	O
CPR	O
)	O
activity	O
was	O
measured	O
as	O
previously	O
described	O
[	O
38	O
]	O
.	O

4.6	O
Determination	O
of	O
BX2–BX5	O
concentration	O
in	O
microsomes	O
Microsomal	O
proteins	O
were	O
separated	O
by	O
10	O
%	O
SDS	O
/	O
PAGE	O
and	O
transferred	O
to	O
nitro	B
-	I
cellulose	I
membranes	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
manufacturer	O
(	O
Amersham	O
)	O
.	O

For	O
immunostaining	O
,	O
the	O
rabbit	O
polyclonal	O
antibodies	O
specific	O
for	O
BX2–BX5	O
were	O
used	O
.	O

The	O
blot	O
was	O
stained	O
with	O
anti	O
-	O
rabbit	O
antibodies	O
linked	O
with	O
Cy5	B
fluorescent	B
dye	I
(	O
Amersham	O
)	O
.	O

The	O
fluorescent	O
signal	O
was	O
quantified	O
using	O
a	O
Storm	O
860	O
imager	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Purified	O
recombinant	O
P450	O
proteins	O
were	O
used	O
as	O
a	O
reference	O
for	O
quantification	O
.	O

Acknowledgements	O

We	O
thank	O
P.	O
Urban	O
and	O
D.	O
Pompon	O
for	O
the	O
yeast	O
expression	O
system	O
and	O
D.	O
Werck	O
-	O
Reichhart	O
for	O
suggestions	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
SFB	O
369	O
)	O
and	O
the	O
Fonds	O
der	O
Chemischen	O
Industrie	O
.	O

Neu2en5Ac	B
(	O
5-acetamido-2,6-anhydro-3,5-dideoxy	B
-	I
d	I
-glycero	I
-d	I
-galacto	I
-non-2-enonic	I
acid	I
,	I
2,3-dehydro-2-deoxy	I
-	I
N	I
-acetylneuraminic	I
acid	I
(	O
1	B
)	O
is	O
a	O
transition	O
-	O
state	O
analog	O
of	O
the	O
hydrolysis	O
of	O
sialoglycoconjugates	B
(	O
2	B
)	O
that	O
liberates	O
Neu5Ac	B
(	O
N	B
-acetylneuraminic	I
acid	I
(	O
3	B
)	O
by	O
sialidase	O
;	O
it	O
acts	O
as	O
an	O
inhibitor	O
against	O
sialidase	O
[	O
1–5	O
]	O
.	O

Neu2en5Ac	B
was	O
first	O
detected	O
in	O
the	O
urine	O
,	O
saliva	O
,	O
and	O
blood	O
of	O
a	O
patient	O
with	O
sialuria	O
[	O
6	O
]	O
.	O

After	O
that	O
,	O
it	O
was	O
found	O
in	O
low	O
concentrations	O
in	O
the	O
serum	O
,	O
saliva	O
,	O
and	O
urine	O
of	O
healthy	O
individuals	O
[	O
7	O
]	O
and	O
was	O
further	O
detected	O
as	O
a	O
metabolite	B
in	O
mammalian	O
brain	O
[	O
8	O
]	O
.	O

Current	O
methods	O
of	O
detecting	O
Neu2en5Ac	B
rely	O
on	O
chemical	O
analysis	O
,	O
TLC	O
,	O
GC	O
or	O
MS	O
[	O
9,10	O
]	O
.	O

If	O
a	O
specific	O
antibody	O
to	O
Neu2en5Ac	B
could	O
be	O
produced	O
,	O
it	O
might	O
facilitate	O
the	O
detection	O
and	O
analysis	O
of	O
Neu2en5Ac	B
in	O
various	O
organisms	O
,	O
and	O
it	O
might	O
also	O
be	O
used	O
for	O
screening	O
for	O
sialuria	O
.	O

Here	O
,	O
we	O
describe	O
the	O
synthesis	O
of	O
an	O
effective	O
hapten	B
that	O
induces	O
antibodies	O
to	O
Neu2en5Ac	B
and	O
the	O
finding	O
of	O
a	O
MAb	O
that	O
recognizes	O
Neu2en5Ac	B
in	O
a	O
specific	O
manner	O
.	O

2	O
.	O

Results	O
and	O
discussion	O
2.1	O
Synthesis	O
of	O
hapten	B
The	O
carboxylate	B
group	I
of	O
Neu5Ac	B
has	O
the	O
special	O
characteristic	O
of	O
exhibiting	O
a	O
negative	O
charge	O
.	O

In	O
order	O
to	O
synthesize	O
a	O
potential	O
hapten	B
,	O
a	O
linker	O
was	O
attached	O
at	O
the	O
9	O
position	O
,	O
which	O
is	O
remote	O
and	O
may	O
have	O
no	O
relation	O
to	O
the	O
characteristic	O
functional	O
group	O
.	O

Hapten	B
8	I
was	O
synthesized	O
from	O
methyl	B
5-acetamido-4,7,8,9-tetra	I
-	I
O	I
-acetyl-2,6-anhydro-3,5-dideoxy	I
-	I
d	I
-glycero	I
-d	I
-galacto	I
-non-2-enonate	I
(	O
4	B
)	O
[	O
11	O
]	O
(	O
Scheme	O
1	O
)	O
.	O

Compound	B
4	I
was	O
treated	O
with	O
NaOMe	B
and	O
then	O
with	O
p	B
-toluenesulfonyl	I
chloride	I
to	O
produce	O
tosyl	B
derivative	I
5	I
in	O
42	O
%	O
yield	O
.	O

Compound	B
5	I
was	O
converted	O
to	O
azide	B
derivative	I
6	I
by	O
treatment	O
with	O
sodium	B
azide	I
,	O
and	O
then	O
saponificated	O
(	O
78	O
%	O
yield	O
)	O
.	O

The	O
reduction	O
of	O
azide	B
derivative	I
6	I
by	O
triphenylphosphine	B
produced	O
amino	B
derivative	I
7	I
in	O
59	O
%	O
yield	O
.	O

In	O
order	O
to	O
attach	O
a	O
linker	O
at	O
C-9	O
,	O
amino	B
derivative	I
7	I
was	O
treated	O
with	O
glutaric	B
anhydride	I
to	O
produce	O
hapten	B
8	I
(	O
59	O
%	O
)	O
.	O

For	O
the	O
coupling	O
of	O
hapten	B
8	I
with	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
or	O
keyhole	O
limpet	O
hemocyanin	O
(	O
KLH	O
)	O
,	O
a	O
mixture	O
of	O
hapten	B
8	I
and	O
either	O
BSA	O
or	O
KLH	O
was	O
treated	O
with	O
1-ethyl-3-	B
(	I
3-diaminopropyl	I
)	I
carbodiimide	I
HCl	I
salt	O
(	O
EDC·HCl	B
)	O
.	O

The	O
conjugate	O
was	O
purified	O
by	O
gel	O
permeation	O
chromatography	O
.	O

2.2	O
Hybridoma	O
Spleen	O
cells	O
from	O
mice	O
immunized	O
with	O
conjugate	O
10	O
were	O
hybridized	O
with	O
myeloma	O
X63-Ag8.653	O
cells	O
[	O
12	O
]	O
and	O
plated	O
directly	O
on	O
0.5	O
%	O
agar	B
plates	O
containing	O
a	O
culture	O
medium	O
with	O
HAT	O
(	O
hypoxanthine	B
,	O
aminopterin	B
,	O
and	O
thymidine	B
)	O
[	O
13	O
]	O
.	O

Colonies	O
grown	O
on	O
the	O
agar	B
plates	O
were	O
isolated	O
and	O
the	O
culture	O
supernatant	O
was	O
assayed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
both	O
conjugate	O
9	O
and	O
fetuin	O
as	O
screening	O
antigens	O
.	O

From	O
394	O
clones	O
isolated	O
from	O
the	O
agar	B
plates	O
of	O
three	O
hybridization	O
trials	O
,	O
24	O
hybridomas	O
were	O
obtained	O
that	O
produced	O
ELISA	O
-	O
positive	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
.	O

Most	O
of	O
the	O
positive	O
clones	O
produced	O
antibodies	O
that	O
also	O
bound	O
to	O
fetuin	O
as	O
well	O
.	O

However	O
,	O
one	O
clone	O
named	O
SIC172	O
produced	O
an	O
antibody	O
that	O
bound	O
strongly	O
to	O
conjugate	O
9	O
but	O
weakly	O
to	O
fetuin	O
.	O

Therefore	O
,	O
SIC172	O
was	O
selected	O
for	O
further	O
study	O
.	O

The	O
SIC172	O
MAb	O
was	O
IgG3	O
(	O
κ	O
)	O
.	O

The	O
recloning	O
of	O
the	O
SIC172	O
hybridoma	O
produced	O
subclones	O
essentially	O
similar	O
to	O
the	O
mother	O
clone	O
:	O
22	O
subclones	O
out	O
of	O
23	O
subclones	O
,	O
isolated	O
as	O
colonies	O
grown	O
on	O
an	O
agar	B
plate	O
,	O
produced	O
MAbs	O
that	O
bound	O
strongly	O
to	O
conjugate	O
9	O
but	O
weakly	O
to	O
fetuin	O
.	O

2.3	O
SIC172	O
MAb	O
in	O
culture	O
supernatant	O
Fig.	O
1	O
shows	O
the	O
binding	O
activities	O
of	O
SIC172	O
MAb	O
at	O
various	O
dilutions	O
to	O
conjugate	O
9	O
and	O
fetuin	O
.	O

For	O
comparison	O
,	O
data	O
obtained	O
with	O
SIC4	O
MAb	O
that	O
bound	O
strongly	O
to	O
conjugate	O
both	O
9	O
and	O
fetuin	O
are	O
included	O
.	O

SIC172	O
MAb	O
shows	O
strong	O
binding	O
to	O
conjugate	O
9	O
,	O
and	O
in	O
a	O
7-level	O
dilution	O
series	O
(	O
i.e.	O
,	O
dilutions	O
of	O
1:1–1:64	O
)	O
,	O
it	O
is	O
beyond	O
the	O
upper	O
limit	O
of	O
the	O
assay	O
(	O
A	O
490	O
of	O
about	O
6	O
)	O
.	O

But	O
it	O
binds	O
a	O
little	O
to	O
fetuin	O
,	O
and	O
no	O
increase	O
is	O
found	O
after	O
dilution	O
,	O
which	O
might	O
dilute	O
out	O
some	O
interfering	O
materials	O
,	O
as	O
seen	O
in	O
the	O
case	O
of	O
the	O
binding	O
of	O
SIC4	O
MAb	O
in	O
both	O
conjugate	O
9	O
and	O
fetuin	O
.	O

The	O
effects	O
of	O
Neu2en5Ac	B
and	O
Neu5Ac	B
on	O
the	O
binding	O
of	O
SIC172	O
MAb	O
in	O
culture	O
supernatant	O
to	O
conjugate	O
9	O
were	O
examined	O
to	O
see	O
if	O
Neu2en5A	B
competes	O
specifically	O
with	O
conjugate	O
9	O
(	O
Fig.	O
2	O
)	O
.	O

High	O
doses	O
of	O
Neu2en5Ac	B
of	O
over	O
10	O
μg	O
/	O
well	O
(	O
0.34	O
mM	O
)	O
interfered	O
with	O
the	O
binding	O
,	O
as	O
expected	O
,	O
and	O
at	O
100	O
μg	O
/	O
well	O
,	O
it	O
almost	O
completely	O
suppressed	O
the	O
binding	O
.	O

However	O
,	O
low	O
doses	O
of	O
Neu2en5Ac	B
,	O
such	O
as	O
1	O
μg	O
/	O
well	O
,	O
increased	O
the	O
binding	O
of	O
SIC172	O
MAb	O
to	O
conjugate	O
9	O
.	O

As	O
for	O
Neu5Ac	B
,	O
it	O
had	O
little	O
effect	O
on	O
binding	O
;	O
and	O
at	O
100	O
μg	O
/	O
well	O
(	O
3.2	O
mM	O
)	O
it	O
slightly	O
increased	O
the	O
binding	O
,	O
just	O
like	O
a	O
low	O
dose	O
of	O
Neu2en5Ac	B
.	O

The	O
increased	O
binding	O
of	O
SIC172	O
MAb	O
to	O
conjugate	O
9	O
at	O
low	O
doses	O
of	O
Neu2en5Ac	B
may	O
be	O
due	O
to	O
the	O
presence	O
,	O
in	O
culture	O
supernatant	O
,	O
of	O
large	O
amounts	O
of	O
materials	O
that	O
can	O
cross	O
-	O
react	O
with	O
the	O
MAb	O
.	O

Since	O
high	O
doses	O
of	O
Neu5Ac	B
also	O
produce	O
a	O
similar	O
phenomenon	O
,	O
sialic	B
acid	I
-	O
containing	O
materials	O
,	O
which	O
might	O
be	O
abundant	O
in	O
culture	O
supernatant	O
,	O
may	O
be	O
the	O
ones	O
—	O
they	O
would	O
trap	O
some	O
of	O
the	O
SIC172	O
MAb	O
in	O
culture	O
supernatant	O
.	O

Low	O
doses	O
of	O
Neu2en5Ac	B
may	O
release	O
such	O
trapped	O
MAb	O
and	O
increase	O
the	O
opportunity	O
to	O
bind	O
to	O
an	O
ELISA	O
antigen	O
plate	O
.	O

Therefore	O
the	O
purification	O
of	O
MAb	O
should	O
eliminate	O
such	O
contradictory	O
effects	O
of	O
hapten	B
;	O
this	O
was	O
found	O
to	O
be	O
true	O
,	O
as	O
described	O
below	O
.	O

2.4	O
Purified	O
SIC172	O
MAb	O
To	O
clarify	O
the	O
binding	O
activity	O
of	O
SIC172	O
MAb	O
,	O
it	O
was	O
purified	O
by	O
using	O
a	O
protein	O
A	O
/	O
G	O
plus	O
-	O
agarose	B
affinity	O
column	O
.	O

The	O
binding	O
activity	O
of	O
the	O
purified	O
SIC172	O
MAb	O
with	O
regard	O
to	O
conjugate	O
9	O
and	O
to	O
fetuin	O
is	O
shown	O
in	O
Fig.	O
3	O
.	O

Purified	O
MAb	O
bound	O
to	O
conjugate	O
9	O
strongly	O
just	O
as	O
MAb	O
in	O
culture	O
supernatant	O
(	O
Fig.	O
3	O
(	O
a	O
)	O
)	O
.	O

Furthermore	O
,	O
as	O
is	O
clearly	O
seen	O
in	O
Fig.	O
3	O
(	O
b	O
)	O
,	O
it	O
also	O
bound	O
well	O
to	O
fetuin	O
.	O

The	O
binding	O
to	O
fetuin	O
is	O
,	O
however	O
,	O
weaker	O
than	O
that	O
to	O
conjugate	O
9	O
,	O
as	O
seen	O
at	O
higher	O
dilutions	O
.	O

The	O
effects	O
of	O
haptens	B
on	O
the	O
binding	O
of	O
purified	O
SIC172	O
MAb	O
both	O
to	O
conjugate	O
9	O
and	O
to	O
fetuin	O
were	O
then	O
examined	O
.	O

In	O
binding	O
to	O
conjugate	O
9	O
(	O
Fig.	O
4	O
(	O
a	O
,	O
b	O
)	O
)	O
,	O
at	O
a	O
high	O
dose	O
(	O
1	O
mM	O
or	O
more	O
)	O
Neu2en5Ac	B
competes	O
strongly	O
with	O
purified	O
SIC172	O
MAb	O
,	O
but	O
Neu5Ac	B
does	O
not	O
.	O

This	O
clearly	O
shows	O
that	O
the	O
binding	O
is	O
specific	O
to	O
Neu2en5Ac	B
.	O

In	O
binding	O
to	O
fetuin	O
(	O
Fig.	O
4	O
(	O
c	O
,	O
d	O
)	O
)	O
,	O
on	O
the	O
other	O
hand	O
,	O
both	O
Neu2en5Ac	B
and	O
Neu5Ac	B
compete	O
with	O
the	O
MAb	O
.	O

But	O
the	O
effect	O
of	O
Neu2en5Ac	B
appears	O
at	O
doses	O
as	O
low	O
as	O
0.01	O
mM	O
,	O
while	O
that	O
of	O
Neu5Ac	B
appears	O
at	O
above	O
0.3	O
mM.	O
To	O
determine	O
more	O
precisely	O
the	O
effect	O
of	O
low	O
doses	O
of	O
haptens	B
on	O
binding	O
to	O
fetuin	O
,	O
IgG	O
and	O
haptens	B
were	O
preincubated	O
with	O
shaking	O
and	O
applied	O
to	O
an	O
ELISA	O
plate	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
BSA	O
used	O
here	O
for	O
the	O
dilution	O
of	O
IgG	O
and	O
the	O
blocking	O
of	O
a	O
fetuin	O
-	O
coated	O
plate	O
was	O
pretreated	O
with	O
dilute	O
HCl	B
in	O
order	O
to	O
remove	O
sialic	B
acids	I
from	O
any	O
sialo	B
-	I
compounds	I
contaminating	O
the	O
BSA	O
.	O

Neu2en5Ac	B
competes	O
strongly	O
and	O
as	O
little	O
as	O
3	O
μM	O
of	O
it	O
had	O
a	O
significant	O
effect	O
,	O
while	O
300	O
μM	O
or	O
more	O
of	O
Neu5Ac	B
was	O
required	O
to	O
get	O
a	O
similar	O
result	O
,	O
as	O
before	O
.	O

The	O
purification	O
of	O
SIC172	O
MAb	O
thus	O
revealed	O
its	O
ability	O
to	O
bind	O
to	O
fetuin	O
.	O

Since	O
it	O
competes	O
with	O
Neu5Ac	B
,	O
SIC172	O
MAb	O
recognizes	O
the	O
Neu5Ac	B
residues	O
present	O
in	O
fetuin	O
.	O

Neu2en5Ac	B
competes	O
about	O
100–300	O
times	O
more	O
strongly	O
than	O
Neu5Ac	B
,	O
indicating	O
that	O
SIC172	O
MAb	O
has	O
more	O
affinity	O
to	O
Neu2en5Ac	B
than	O
to	O
Neu5Ac	B
.	O

Since	O
concentrations	O
of	O
Neu2en5Ac	B
as	O
low	O
as	O
3	O
μM	O
can	O
be	O
detected	O
by	O
this	O
MAb	O
as	O
a	O
competitor	O
in	O
binding	O
to	O
fetuin	O
,	O
this	O
MAb	O
may	O
be	O
useful	O
for	O
the	O
detection	O
of	O
a	O
small	O
amount	O
of	O
Neu2en5Ac	B
in	O
natural	O
biological	O
samples	O
,	O
though	O
adequate	O
separation	O
of	O
Neu2en5Ac	B
from	O
Neu5Ac	B
,	O
such	O
as	O
by	O
TLC	O
on	O
silica	B
gel	I
[	O
7	O
]	O
,	O
is	O
necessary	O
to	O
eliminate	O
possible	O
cross	O
reactions	O
with	O
Neu5Ac	B
,	O
which	O
is	O
usually	O
present	O
at	O
much	O
higher	O
levels	O
than	O
Neu2en5Ac	B
.	O

It	O
is	O
interesting	O
that	O
a	O
terminal	O
Neu5Ac	O
residue	O
,	O
bound	O
to	O
the	O
next	O
residue	O
at	O
the	O
C-2	O
position	O
,	O
in	O
a	O
carbohydrate	B
moiety	O
of	O
fetuin	O
can	O
be	O
recognized	O
by	O
SIC172	O
MAb	O
,	O
which	O
was	O
generated	O
by	O
immunization	O
with	O
Neu2en5Ac	B
that	O
was	O
bound	O
to	O
a	O
linker	O
at	O
the	O
C-9	O
position	O
.	O

Determination	O
of	O
the	O
amino	B
acid	I
sequence	O
of	O
SIC172	O
MAb	O
and	O
3-D	O
modeling	O
of	O
the	O
MAb	O
molecule	O
would	O
offer	O
some	O
clues	O
to	O
this	O
problem	O
.	O

3	O
.	O

Experimental	O
3.1	O
General	O
procedure	O
1	O
H	O
NMR	O
spectra	O
were	O
recorded	O
with	O
a	O
Jeol	O
EX	O
270	O
(	O
Japan	O
)	O
or	O
Bruker	O
DMX	O
500	O
(	O
Germany	O
)	O
instrument	O
at	O
298	O
K.	O
Chemical	O
shifts	O
are	O
expressed	O
in	O
ppm	O
and	O
referenced	O
to	O
HOD	B
(	O
4.81	O
ppm	O
)	O
as	O
an	O
internal	O
standard	O
.	O

Optical	O
rotations	O
were	O
measured	O
with	O
a	O
Jasco	O
DIP-4	O
(	O
Japan	O
)	O
polarimeter	O
.	O

High	O
-	O
resolution	O
mass	O
spectra	O
(	O
HR	O
-	O
MS	O
)	O
were	O
recorded	O
on	O
a	O
Shimadzu	O
/	O
Kratos	O
concept	O
-	O
IIH	O
(	O
Japan	O
/	O
UK	O
)	O
instrument	O
under	O
Fab	O
conditions	O
.	O

All	O
reactions	O
were	O
monitored	O
by	O
TLC	O
(	O
Silica	B
Gel	I
60-F254	O
,	O
E.	O
Merck	O
,	O
Germany	O
)	O
by	O
charring	O
after	O
spraying	O
with	O
5	O
%	O
H2	B
SO4	I
in	O
MeOH	B
.	O

3.2	O
Chemicals	O
5-Acetamido-2,6-anhydro-3,5-dideoxy	B
-	I
d	I
-glycero	I
-d	I
-galacto	I
-non-2-enonic	I
acid	I
,	O
Neu2en5Ac	B
,	O
Neu5Ac	B
,	O
and	O
fetuin	O
were	O
purchased	O
from	O
Sigma	O
(	O
USA	O
)	O
.	O

3.3	O
Methyl	B
5-acetamido-2,6-anhydro-3,5-dideoxy-9-p	I
-	I
toluenesulfonyl	I
-	I
d	I
-glycero	I
-	I
d	I
-galacto	I
-	I
non-2-enonate	I
(	O
5	B
)	O
To	O
a	O
solution	O
of	O
methyl	B
5-acetamido-4,7,8,9-tetra	I
-	I
O	I
-acetyl-2,6-anhydro-3,5-dideoxy	I
-	I
d	I
-glycero	I
-d	I
-galacto	I
-non-2-enonate	I
(	O
4	B
)	O
(	O
1.12	O
g	O
,	O
2.36	O
mmol	O
)	O
[	O
11	O
]	O
in	O
dry	O
MeOH	B
(	O
10	O
mL	O
)	O
was	O
added	O
NaOMe	B
(	O
13	O
mg	O
,	O
0.25	O
mmol	O
)	O
,	O
and	O
the	O
mixture	O
was	O
stirred	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

The	O
mixture	O
was	O
neutralized	O
by	O
the	O
addition	O
of	O
Dowex	B
50W	I
×	I
8	I
resin	I
.	O

To	O
this	O
mixture	O
was	O
added	O
water	B
(	O
2	O
mL	O
)	O
,	O
and	O
then	O
the	O
mixture	O
was	O
filtered	O
and	O
concentrated	O
.	O

The	O
residue	B
was	O
dried	O
in	O
a	O
desiccator	O
overnight	O
.	O

To	O
a	O
solution	O
of	O
this	O
residue	B
in	O
pyridine	B
(	O
20	O
mL	O
)	O
was	O
added	O
p	B
-toluenesulfonyl	I
chloride	I
(	O
415	O
mg	O
,	O
2.17	O
mmol	O
)	O
at	O
room	O
temperature	O
,	O
and	O
the	O
mixture	O
was	O
stirred	O
for	O
4	O
h.	O
Next	O
MeOH	B
(	O
5	O
mL	O
)	O
was	O
added	O
to	O
the	O
mixture	O
,	O
which	O
was	O
then	O
concentrated	O
in	O
vacuo	O
.	O

Purification	O
of	O
the	O
residue	B
on	O
a	O
column	O
of	O
silica	B
gel	I
(	O
19:1	O
EtOAc	B
–	O
MeOH	B
)	O
yielded	O
5	B
(	O
460	O
mg	O
,	O
42	O
%	O
)	O
;	O
[	O
α	O
]	O
D	O
25	O
−12.0	O
°	O
(	O
c	O
0.5	O
,	O
MeOH	B
)	O
;	O
HR	O
-	O
MS	O
m	O
/z	O
Anal	O
.	O

Calcd	O
for	O
C19	B
H25	I
NO10	I
SNa	I
:	O
482.1097	O
[	O
M+Na	O
]	O
+	O
,	O
Found	O
:	O
482.1109	O
.	O

1	O
H	O
NMR	O
data	O
of	O
this	O
and	O
some	O
other	O
compounds	O
are	O
shown	O
in	O
Table	O
1	O
.	O

3.4	O
5-Acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy	B
-	I
d	I
-glycero	I
-	I
d	I
-galacto	I
-	I
non-2-enonic	I
acid	I
(	O
6	B
)	O
To	O
a	O
solution	O
of	O
5	B
(	O
450	O
mg	O
,	O
0.98	O
mmol	O
)	O
in	O
DMF	B
(	O
2	O
mL	O
)	O
was	O
added	O
sodium	B
azide	I
(	O
241	O
mg	O
,	O
3.71	O
mmol	O
)	O
and	O
the	O
mixture	O
was	O
stirred	O
at	O
70	O
°	O
C	O
.	O

After	O
7	O
h	O
,	O
it	O
was	O
allowed	O
to	O
cool	O
to	O
room	O
temperature	O
.	O

Purification	O
of	O
the	O
mixture	O
on	O
a	O
column	O
of	O
silica	B
gel	I
(	O
49:1	O
EtOAc	B
–	O
MeOH	B
)	O
yielded	O
azide	B
derivative	B
6	I
(	O
280	O
mg	O
)	O
,	O
{	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
:	O
δ	O
5.91	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
2.64	O
Hz	O
,	O
H-3	O
)	O
,	O
3.76	O
(	O
s	O
,	O
3	O
H	O
,	O
OMe	B
)	O
,	O
3.54	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2.64	O
,	O
13.2	O
Hz	O
,	O
H-9a	O
)	O
,	O
3.37	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
6.6	O
,	O
13.2	O
Hz	O
,	O
H-9b	O
)	O
,	O
2.03	O
(	O
s	O
,	O
3	O
H	O
,	O
Ac	B
)	O
}	O
.	O
The	O
azide	B
derivative	B
was	O
dissolved	O
in	O
1:1	O
0.3	O
M	O
NaOH	B
–	O
MeOH	B
(	O
8	O
mL	O
)	O
and	O
the	O
mixture	O
was	O
stirred	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

The	O
mixture	O
was	O
neutralized	O
by	O
the	O
addition	O
of	O
Dowex	B
50	I
W	I
×	I
8	I
resin	I
,	O
then	O
filtered	O
.	O

The	O
filtrate	O
was	O
concentrated	O
in	O
vacuo	O
.	O

Purification	O
of	O
the	O
residue	B
on	O
a	O
column	O
of	O
silica	B
gel	I
(	O
1:1	O
EtOAc	B
–	O
MeOH	B
)	O
yielded	O
6	B
(	O
241	O
mg	O
,	O
78	O
%	O
)	O
;	O
[	O
α	O
]	O
D	O
25	O
+	O
33.1	O
°	O
(	O
c	O
0.87	O
,	O
MeOH	B
)	O
;	O
HR	O
-	O
MS	O
m	O
/z	O
Anal	O
.	O

Calcd	O
for	O
C11	B
H16	I
N4	I
O7	I
Na	I
(	O
Na	B
salt	I
)	O
:	O
339.0917	O
[	O
M+H	O
]	O
+	O
,	O
Found	O
:	O
339.0944	O
.	O

3.5	O
5-Acetamido-9-amino-2,6-anhydro-3,5,9-trideoxy	O
-	B
d	I
-glycero	I
-	I
d	I
-galacto	I
-	I
non-2-enonic	I
acid	I
(	O
7	B
)	O
To	O
a	O
solution	O
of	O
azide	B
derivative	B
6	I
(	O
22	O
mg	O
,	O
70	O
μmol	O
)	O
in	O
4:3:1	O
dioxane	B
–	O
MeOH	O
–	O
H2	B
O	I
(	O
400	O
μL	O
)	O
was	O
added	O
triphenylphosphine	B
(	O
27	O
mg	O
,	O
104	O
μmol	O
)	O
and	O
the	O
mixture	O
was	O
stirred	O
at	O
room	O
temperature	O
.	O

After	O
12	O
h	O
,	O
the	O
mixture	O
was	O
concentrated	O
in	O
vacuo	O
.	O

Purification	O
of	O
this	O
residue	B
on	O
a	O
column	O
of	O
silica	B
gel	I
(	O
3:2:1	O
EtOAc	B
–	O
MeOH	B
–	O
H2	B
O	I
)	O
yielded	O
amino	B
derivative	I
7	I
(	O
16	O
mg	O
,	O
80	O
%	O
)	O
;	O
[	O
α	O
]	O
D	O
25	O
+	O
30.0	O
°	O
(	O
c	O
0.6	O
,	O
H2	B
O	I
)	O
;	O
HR	O
-	O
MS	O
m	O
/z	O
Anal	O
.	O

Calcd	O
for	O
C11	B
H19	I
N2	I
O7	I
:	O
291.1192	O
[	O
M+H	O
]	O
+	O
,	O
Found	O
:	O
291.1206	O
.	O

3.6	O
5-Acetamido-2,6-anhydro-9-glutaramido-3,5,9-trideoxy	B
-	I
d	I
-glycero	I
-	I
d	I
-galacto	I
-	I
non-2-enonic	I
acid	I
(	O
8	B
)	O
To	O
a	O
solution	O
of	O
amino	B
derivative	I
7	I
(	O
5	O
mg	O
,	O
17	O
μmol	O
)	O
in	O
300:100:3	O
MeOH	B
–	O
H2	B
O	I
–	O
Et3	B
N	I
(	O
403	O
μL	O
)	O
was	O
added	O
glutaric	B
acid	I
anhydride	I
(	O
3.5	O
mg	O
,	O
30	O
μmol	O
)	O
and	O
the	O
mixture	O
was	O
stirred	O
at	O
room	O
temperature	O
.	O

After	O
20	O
min	O
the	O
mixture	O
was	O
concentrated	O
in	O
vacuo	O
.	O

Purification	O
of	O
this	O
residue	B
on	O
a	O
column	O
of	O
silica	B
gel	I
(	O
3:2:1	O
EtOAc	B
–	O
MeOH	B
–	O
H2	B
O	I
)	O
yielded	O
amino	B
derivative	I
8	I
(	O
4	O
mg	O
,	O
59	O
%	O
)	O
;	O
[	O
α	O
]	O
D	O
25	O
+	O
25.5	O
°	O
(	O
c	O
0.4	O
,	O
MeOH	B
)	O
;	O
HR	O
-	O
MS	O
m	O
/z	O
Anal	O
.	O

Calcd	O
for	O
C16	B
H24	I
N2	I
O10	I
Na	I
(	O
Na	B
salt	I
)	O
:	O
427.1329	O
[	O
M+H	O
]	O
+	O
,	O
Found	O
:	O
427.1354	O
.	O

3.7	O
Conjugate	O
9	O
The	O
reaction	O
was	O
carried	O
out	O
in	O
a	O
centricon	O
tube	O
.	O

Compound	B
8	I
(	O
4	O
mg	O
,	O
10	O
μmol	O
)	O
was	O
dissolved	O
in	O
H2	B
O	I
(	O
250	O
μL	O
)	O
,	O
and	O
the	O
pH	O
of	O
this	O
solution	O
was	O
adjusted	O
to	O
6.0	O
by	O
the	O
addition	O
of	O
aq	O
NaHCO3	B
.	O

To	O
this	O
solution	O
was	O
added	O
BSA	O
(	O
15	O
mg	O
,	O
ca	O
0.2	O
μmol	O
)	O
and	O
EDC·HCl	B
(	O
3	O
mg	O
,	O
16.5	O
μmol	O
)	O
,	O
and	O
the	O
mixture	O
was	O
incubated	O
at	O
room	O
temperature	O
.	O

After	O
12	O
h	O
,	O
the	O
mixture	O
was	O
directly	O
loaded	O
onto	O
a	O
gel	O
permeation	O
column	O
(	O
Sephadex	O
G-50	O
,	O
H2	B
O	I
)	O
.	O

The	O
fraction	O
containing	O
BSA	O
was	O
pooled	O
and	O
lyophilized	O
.	O

3.8	O
Conjugate	O
10	O
Prior	O
to	O
the	O
reaction	O
,	O
KLH	O
was	O
dissolved	O
in	O
H2	B
O	I
(	O
100	O
mg	O
/	O
0.5	O
mL	O
)	O
,	O
and	O
the	O
precipitate	O
was	O
removed	O
by	O
filtration	O
.	O

The	O
filtrate	O
containing	O
KLH	O
was	O
lyophilized	O
and	O
used	O
for	O
the	O
synthesis	O
of	O
conjugate	O
10	O
.	O

The	O
conditions	O
for	O
the	O
reaction	O
were	O
the	O
same	O
as	O
those	O
for	O
conjugate	O
9	O
.	O

3.9	O
Hybridoma	O
Conjugate	O
10	O
(	O
390	O
μg	O
)	O
was	O
dissolved	O
in	O
1	O
mL	O
of	O
PBS	B
and	O
mixed	O
into	O
one	O
vial	O
of	O
GERBU	O
adjuvant	O
containing	O
10	O
μg	O
of	O
GMDP	B
,	O
40	O
μg	O
of	O
N	B
,	I
N	I
′-dimethyl	I
-	I
N	I
,	I
N	I
-dioctadecylammonium	I
chloride	I
,	O
and	O
1.68	O
mg	O
of	O
Zn	B
-	I
proline	I
complex	I
(	O
Gerbu	O
Biotechnik	O
,	O
Germany	O
)	O
.	O

Female	O
MRL	O
/	O
MpJ	O
-	O
lpr	O
/	O
lpr	O
mice	O
[	O
10	O
]	O
(	O
Nihon	O
Slc	O
,	O
Japan	O
)	O
,	O
8-weeks	O
-	O
old	O
,	O
were	O
each	O
immunized	O
subcutaneously	O
with	O
50	O
μL	O
of	O
the	O
antigen	O
–	O
adjuvant	O
mixture	O
,	O
which	O
contained	O
19.5	O
μg	O
of	O
conjugate	O
10	O
.	O

The	O
mice	O
were	O
further	O
immunized	O
with	O
the	O
same	O
dose	O
at	O
2	O
,	O
5	O
,	O
and	O
8	O
weeks	O
after	O
the	O
first	O
immunization	O
.	O

The	O
titer	O
of	O
antibodies	O
that	O
bound	O
to	O
conjugate	O
9	O
,	O
as	O
detected	O
by	O
ELISA	O
,	O
increased	O
gradually	O
after	O
2	O
weeks	O
in	O
all	O
the	O
mice	O
immunized	O
.	O

Three	O
or	O
4	O
days	O
after	O
immunization	O
at	O
5	O
or	O
8	O
weeks	O
,	O
spleen	O
cells	O
from	O
two	O
or	O
three	O
mice	O
were	O
obtained	O
and	O
hybridized	O
with	O
myeloma	O
X63-Ag8.653	O
cells	O
[	O
12	O
]	O
by	O
using	O
polyethylene	B
glycol	I
6000	O
,	O
and	O
were	O
plated	O
on	O
0.5	O
%	O
agar	O
plates	O
containing	O
RPMI	O
medium	O
(	O
in	O
a	O
later	O
experiment	O
,	O
DMEM	O
medium	O
with	O
a	O
high	O
glucose	B
level	O
was	O
used	O
instead	O
of	O
RPMI	O
medium	O
)	O
,	O
HAT	O
(	O
0.1	O
mM	O
hypoxanthine	B
,	O
0.4	O
μM	O
aminopterin	B
,	O
and	O
16	O
μM	O
thymidine	B
,	O
Sigma	O
,	O
USA	O
)	O
and	O
20	O
%	O
FBS	B
[	O
13	O
]	O
.	O

From	O
2	O
weeks	O
to	O
1	O
month	O
later	O
,	O
colonies	O
grown	O
on	O
the	O
agar	B
plates	O
were	O
isolated	O
in	O
liquid	O
culture	O
medium	O
containing	O
HT	O
(	O
0.1	O
mM	O
hypoxanthine	B
and	O
16	O
μM	O
thymidine	B
,	O
Sigma	O
,	O
USA	O
)	O
.	O

Culture	O
supernatants	O
were	O
assayed	O
by	O
ELISA	O
for	O
the	O
presence	O
of	O
MAb	O
that	O
can	O
bind	O
to	O
conjugate	O
9	O
and/or	O
to	O
fetuin	O
.	O

ELISA	O
-	O
positive	O
clones	O
were	O
selected	O
and	O
transfered	O
to	O
normal	O
medium	O
for	O
further	O
study	O
.	O

3.10	O
Typing	O
of	O
immunoglobulin	O
subclass	O
This	O
was	O
done	O
by	O
using	O
a	O
Mouse	O
MonoAB	O
ID	O
Kit	O
(	O
Zymed	O
,	O
USA	O
)	O
.	O

3.11	O
Affinity	O
purification	O
of	O
IgG	O
IgG	O
in	O
the	O
culture	O
supernatant	O
was	O
precipitated	O
with	O
ammonium	B
sulfate	I
at	O
50	O
%	O
,	O
dissolved	O
and	O
dialysed	O
against	O
the	O
application	O
/	O
binding	O
buffer	O
,	O
and	O
applied	O
to	O
a	O
protein	O
A	O
/	O
G	O
plus	O
-	O
agarose	B
affinity	O
column	O
(	O
Calbiochem	O
.	O
,	O
USA	O
)	O
.	O

IgG	O
was	O
eluted	O
with	O
acetate	B
buffer	O
(	O
pH	O
3.0	O
)	O
and	O
glycine	B
–	O
HCl	B
buffer	O
(	O
pH	O
3.0	O
)	O
,	O
and	O
adjusted	O
to	O
a	O
pH	O
of	O
7.0	O
with	O
Tris	B
base	I
.	O

3.12	O
ELISA	O
A	O
total	O
of	O
100	O
μg	O
of	O
conjugate	O
9	O
,	O
or	O
200	O
μg	O
(	O
145	O
μg	O
in	O
a	O
later	O
experiment	O
)	O
of	O
fetuin	O
containing	O
5.5	O
%	O
Neu5Ac	B
,	O
was	O
dissolved	O
in	O
1	O
mL	O
of	O
PBS	B
;	O
100	O
μL	O
of	O
the	O
solution	O
was	O
used	O
to	O
coat	O
each	O
well	O
of	O
a	O
96-well	O
test	O
plate	O
at	O
room	O
temperature	O
for	O
2	O
h.	O
Antigen	O
-	O
coated	O
plates	O
were	O
blocked	O
with	O
1	O
%	O
BSA	O
in	O
PBS	B
,	O
washed	O
with	O
0.1	O
%	O
Tween	B
20	I
in	O
PBS	B
,	O
and	O
used	O
for	O
ELISA	O
.	O

The	O
culture	O
supernatant	O
of	O
hybridoma	O
or	O
purified	O
IgG	O
,	O
undiluted	O
or	O
diluted	O
with	O
0.1	O
%	O
BSA	O
in	O
PBS	B
,	O
was	O
used	O
as	O
the	O
source	O
of	O
MAb	O
.	O

In	O
some	O
experiments	O
,	O
as	O
shown	O
in	O
Fig.	O
5	O
,	O
the	O
BSA	O
used	O
to	O
dilute	O
samples	O
and	O
block	O
ELISA	O
plates	O
was	O
pretreated	O
with	O
0.1	O
M	O
HCl	B
for	O
1	O
h	O
at	O
80	O
°	O
C	O
,	O
and	O
neutralized	O
and	O
dialysed	O
against	O
PBS	B
to	O
remove	O
any	O
sialic	B
acids	I
from	O
sialo	B
-	I
compounds	I
contaminating	O
the	O
BSA	O
.	O

To	O
test	O
the	O
effects	O
of	O
Neu2en5Ac	B
and	O
Neu5Ac	B
,	O
they	O
were	O
dissolved	O
in	O
PBS	B
;	O
and	O
the	O
solution	O
was	O
adjusted	O
to	O
a	O
pH	O
of	O
7.2–7.5	O
with	O
0.1	O
M	O
NaOH	B
by	O
using	O
pHBOY	O
-	O
P2	O
(	O
Shindengen	O
,	O
Japan	O
)	O
,	O
and	O
diluted	O
with	O
PBS	B
.	O

Culture	O
supernatant	O
,	O
purified	O
IgG	O
,	O
or	O
their	O
diluted	O
solutions	O
were	O
preincubated	O
with	O
various	O
concentrations	O
of	O
either	O
Neu2en5Ac	B
or	O
Neu5Ac	B
at	O
37	O
°	O
C	O
for	O
1	O
h	O
(	O
or	O
at	O
room	O
temperature	O
with	O
shaking	O
in	O
the	O
experiments	O
for	O
Fig.	O
5	O
)	O
,	O
and	O
then	O
the	O
mixture	O
was	O
applied	O
to	O
an	O
antigen	O
-	O
coated	O
well	O
.	O

POD	O
-	O
labeled	O
sheep	O
anti	O
-	O
mouse	O
-	O
immunoglobulins	O
antibody	O
was	O
used	O
as	O
a	O
secondary	O
antibody	O
.	O

Peroxidase	O
activity	O
was	O
detected	O
with	O
o	B
-phenylenediamine	I
and	O
H2	B
O2	I
.	O

The	O
absorbance	O
at	O
490	O
nm	O
,	O
A	O
490	O
,	O
was	O
read	O
on	O
a	O
microplate	O
reader	O
(	O
Thermo	O
max	O
,	O
Molecular	O
Devices	O
,	O
USA	O
)	O
.	O

Assays	O
were	O
carried	O
out	O
in	O
duplicate	O
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Mr	O
Masayosi	O
Kusama	O
for	O
the	O
mass	O
spectroscopic	O
analyses	O
.	O

This	O
work	O
was	O
performed	O
as	O
part	O
of	O
the	O
R&D	O
Project	O
of	O
the	O
Industrial	O
Science	O
and	O
Technology	O
Frontier	O
Program	O
supported	O
by	O
NEDO	O
(	O
New	O
Energy	O
and	O
Industrial	O
Technology	O
Development	O
Organization	O
)	O
.	O

LoVoDx	O
cells	O
are	O
derived	O
from	O
initially	O
highly	O
doxorubicin	B
-	O
sensitive	O
LoVo	O
adenocarcinoma	O
cells	O
by	O
incubation	O
and	O
selection	O
on	O
increasing	O
doxorubicin	B
concentrations	O
(	O
Grandi	O
et	O
al.	O
,	O
1986	O
;	O
Rivoltini	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Resistance	O
is	O
based	O
on	O
the	O
expression	O
of	O
multidrug	O
resistance	O
(	O
MDR1	O
)	O
phenotype	O
mediated	O
by	O
the	O
P	O
-	O
glycoprotein	O
drug	B
extrusion	O
mechanism	O
(	O
Rivoltini	O
et	O
al.	O
,	O
1990	O
;	O
Bertram	O
et	O
al.	O
,	O
1995	O
)	O
.	O

Okadaic	B
acid	I
and	O
cantharidic	B
acid	I
are	O
selective	O
inhibitors	O
of	O
ser	O
/	O
thr	O
phosphatases	O
1	O
and	O
2A	O
(	O
Cohen	O
,	O
1989	O
;	O
Honkanen	O
,	O
1993	O
;	O
Honkanen	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Via	O
the	O
inhibition	O
of	O
these	O
enzymes	O
both	O
agents	B
have	O
been	O
shown	O
to	O
induce	O
apoptosis	O
in	O
many	O
human	O
and	O
non	O
-	O
human	O
cell	O
lines	O
(	O
Bøe	O
et	O
al.	O
,	O
1991	O
;	O
Kiguchi	O
et	O
al.	O
,	O
1994	O
;	O
Morana	O
et	O
al.	O
,	O
1996	O
;	O
Laidley	O
et	O
al.	O
,	O
1997	O
;	O
Tergau	O
et	O
al.	O
,	O
1997	O
;	O
von	O
Zezschwitz	O
et	O
al.	O
,	O
1997	O
)	O
.	O

By	O
selection	O
techniques	O
cells	O
could	O
be	O
isolated	O
that	O
were	O
resistant	O
to	O
okadaic	B
acid	I
(	O
Takeda	O
et	O
al.	O
,	O
1994	O
;	O
Ritz	O
et	O
al.	O
,	O
1997	O
)	O
as	O
well	O
as	O
cantharidic	B
acid	I
(	O
Richter	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
some	O
resistant	O
lines	O
,	O
at	O
least	O
in	O
the	O
case	O
of	O
okadaic	B
acid	I
,	O
observations	O
suggested	O
that	O
MDR1	O
expression	O
might	O
be	O
involved	O
(	O
Tohda	O
et	O
al.	O
,	O
1994	O
,	O
1997	O
;	O
Zheng	O
et	O
al.	O
,	O
1994	O
;	O
Wang	O
et	O
al.	O
,	O
1995	O
;	O
Ritz	O
et	O
al.	O
,	O
1997	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
first	O
tested	O
whether	O
LoVo	O
cells	O
respond	O
with	O
apoptosis	O
when	O
they	O
were	O
treated	O
with	O
the	O
phosphatase	O
inhibitors	O
okadaic	B
or	O
cantharidic	B
acid	I
.	O

Next	O
,	O
we	O
compared	O
the	O
response	O
of	O
these	O
cells	O
with	O
that	O
observed	O
in	O
doxorubicin	B
-	O
resistant	O
LoVoDx	O
cells	O
.	O

While	O
okadaic	B
and	O
cantharidic	B
acid	I
effectively	O
killed	O
LoVo	O
cells	O
,	O
LoVoDx	O
cells	O
were	O
resistant	O
to	O
doxorubicin	B
as	O
well	O
as	O
to	O
okadaic	B
acid	I
.	O

On	O
the	O
other	O
hand	O
,	O
LoVoDx	O
cells	O
seemed	O
to	O
be	O
even	O
more	O
sensitive	O
to	O
cantharidic	B
acid	I
.	O

Comparable	O
results	O
were	O
obtained	O
with	O
rat	O
pituitary	O
GH3	O
cells	O
made	O
resistant	O
to	O
150	O
nM	O
okadaic	B
acid	I
.	O

Incubation	O
of	O
LoVoDx	O
cells	O
in	O
medium	O
devoid	O
of	O
doxorubicin	B
for	O
several	O
months	O
resulted	O
in	O
the	O
loss	O
of	O
okadaic	B
acid	I
and	O
doxorubicin	B
resistance	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Doxorubicin	B
was	O
from	O
Sigma	O
(	O
Deisenhofen	O
,	O
Germany	O
)	O
.	O

Okadaic	B
acid	I
and	O
cantharidic	B
acid	I
were	O
purchased	O
from	O
Calbiochem	O
(	O
Bad	O
Soden	O
,	O
Germany	O
)	O
.	O

Cell	O
culture	O
reagents	B
and	O
fetal	O
bovine	O
serum	O
were	O
from	O
Life	O
Technologies	O
(	O
Eggenstein	O
,	O
Germany	O
)	O
.	O

Caspase	O
substrate	O
Ac	B
-	I
DEVD	I
-	I
pNA	I
and	O
the	O
inhibitor	O
Ac	B
-	I
DEVD	I
-	I
CHO	I
were	O
obtained	O
from	O
Bachem	O
(	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

2.2	O
Cell	O
culture	O
and	O
selection	O
of	O
resistant	O
cells	O
LoVo	O
and	O
GH3	O
rat	O
pituitary	O
cells	O
were	O
maintained	O
in	O
monolayer	O
in	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
supplemented	O
with	O
8	O
%	O
fetal	O
calf	O
serum	O
,	O
streptomycin	B
and	O
penicillin	B
at	O
37	O
°	O
C	O
in	O
5	O
%	O
CO2	B
.	O

LoVoDx	O
cells	O
(	O
Rivoltini	O
et	O
al.	O
,	O
1990	O
)	O
were	O
cultured	O
under	O
the	O
same	O
conditions	O
and	O
fed	O
once	O
a	O
week	O
with	O
1	O
μg	O
/	O
ml	O
doxorubicin	B
.	O

Okadaic	B
acid	I
-	O
resistant	O
GH3	O
cells	O
were	O
selected	O
by	O
culturing	O
partially	O
resistant	O
cells	O
(	O
Ritz	O
et	O
al.	O
,	O
1997	O
)	O
for	O
an	O
additional	O
12	O
months	O
in	O
stepwise	O
raised	O
okadaic	B
acid	I
concentrations	O
with	O
subsequent	O
survival	O
at	O
150	O
nM.	O
Okadaic	B
acid	I
(	O
150	O
nM	O
)	O
was	O
added	O
once	O
a	O
week	O
to	O
the	O
incubation	O
medium	O
.	O

2.3	O
Viability	O
assay	O
(	O
MTT	B
conversion	O
assay	O
)	O
Cell	O
suspensions	O
(	O
100	O
μl	O
;	O
7.5–10	O
×	O
103	O
cells	O
/	O
well	O
)	O
were	O
seeded	O
into	O
a	O
96-well	O
microtiter	O
plate	O
and	O
incubated	O
for	O
24	O
h.	O
Then	O
cells	O
were	O
incubated	O
for	O
24–72	O
h	O
with	O
various	O
drug	B
concentrations	O
in	O
serum	O
-	O
free	O
insulin	O
–	O
transferrin	O
–	O
selenite	B
medium	O
followed	O
by	O
the	O
addition	O
of	O
10	O
μl	O
MTT	B
solution	O
(	O
5	O
mg	O
/	O
ml	O
)	O
and	O
incubation	O
for	O
60	O
min	O
.	O

After	O
addition	O
of	O
100	O
μl	O
20	O
%	O
SDS	B
in	O
0.02	O
N	O
HCl	B
cells	O
were	O
incubated	O
for	O
24	O
h	O
and	O
MTT	B
conversion	O
was	O
measured	O
at	O
550	O
and	O
650	O
nm	O
using	O
a	O
Molecular	O
Devices	O
UV	O
max	O
microplate	O
reader	O
(	O
Ritz	O
et	O
al.	O
,	O
1997	O
)	O
.	O

2.4	O
Measurement	O
of	O
caspase-3	O
like	O
activity	O
In	O
order	O
to	O
evaluate	O
if	O
cytotoxicity	O
of	O
the	O
tested	O
drugs	B
is	O
apoptotic	O
and	O
therefore	O
associated	O
with	O
the	O
activation	O
of	O
caspases	O
,	O
cells	O
(	O
2–3	O
×	O
106	O
)	O
were	O
plated	O
on	O
10-cm	O
culture	O
dishes	O
.	O

After	O
24-h	O
incubation	O
with	O
complete	O
medium	O
,	O
cells	O
were	O
incubated	O
for	O
an	O
additional	O
24	O
h	O
with	O
the	O
indicated	O
treatments	O
in	O
serum	O
-	O
free	O
medium	O
.	O

Cells	O
were	O
harvested	O
after	O
the	O
addition	O
of	O
20	O
μl	O
PMSF	B
(	O
100	O
mM	O
)	O
per	O
1	O
ml	O
medium	O
,	O
and	O
centrifuged	O
at	O
360	O
×	O
g	O
for	O
5	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
pellet	O
was	O
transferred	O
to	O
a	O
second	O
vial	O
,	O
washed	O
with	O
PBS	B
supplemented	O
with	O
PMSF	B
(	O
20	O
μl	O
/	O
ml	O
)	O
.	O

After	O
a	O
second	O
centrifugation	O
(	O
600	O
×	O
g	O
,	O
5	O
min	O
,	O
4	O
°	O
C	O
)	O
600	O
μl	O
reaction	O
buffer	O
(	O
10	O
mM	O
HEPES	B
,	O
1	O
%	O
NP-40	B
,	O
Aprotinin	O
10	O
μg	O
/	O
ml	O
at	O
pH	O
7.4	O
)	O
was	O
added	O
and	O
the	O
resuspended	O
pellet	O
frozen	O
in	O
liquid	O
nitrogen	B
.	O

The	O
frozen	O
pellet	O
was	O
stored	O
at	O
−20	O
°	O
C	O
until	O
the	O
assay	O
was	O
performed	O
.	O

After	O
thawing	O
cell	O
disruption	O
was	O
completed	O
by	O
two	O
additional	O
freeze	O
–	O
thaw	O
cycles	O
.	O

Following	O
a	O
centrifugation	O
at	O
5000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
the	O
supernatant	O
was	O
used	O
for	O
protein	O
determination	O
with	O
the	O
BCA	B
assay	O
(	O
Pierce	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

Protein	O
was	O
adjusted	O
to	O
50	O
μg	O
/	O
100	O
μl	O
.	O

Reactions	O
were	O
performed	O
with	O
100	O
μg	O
protein	O
in	O
a	O
final	O
volume	O
of	O
350	O
μl	O
after	O
addition	O
of	O
DTT	B
(	O
final	O
concentration	O
5	O
mM	O
)	O
at	O
37	O
°	O
C	O
.	O

Reactions	O
were	O
started	O
by	O
the	O
addition	O
of	O
the	O
substrate	O
peptide	B
Ac	B
-	I
DEVD	I
-	I
pNA	I
(	O
final	O
concentration	O
25	O
μM	O
)	O
.	O

Caspase-3	O
like	O
activity	O
was	O
quantified	O
by	O
measuring	O
the	O
release	O
of	O
p	B
-nitroanilide	I
at	O
405	O
nm	O
in	O
a	O
microplate	O
reader	O
.	O

Enzyme	B
activity	O
was	O
calculated	O
and	O
expressed	O
as	O
U	O
/	O
mg	O
protein	O
.	O

To	O
account	O
for	O
non	O
-	O
specific	O
proteolytic	O
activity	O
the	O
values	O
presented	O
are	O
the	O
difference	O
of	O
the	O
absolute	O
conversion	O
minus	O
the	O
activity	O
not	O
suppressible	O
by	O
100	O
nM	O
of	O
the	O
DEVDase	O
inhibitor	O
peptide	B
Ac	B
-	I
DEVD	I
-	I
CHO	I
.	O

3	O
Results	O
When	O
LoVo	O
cells	O
were	O
incubated	O
with	O
okadaic	B
acid	I
(	O
100	O
nM	O
)	O
and	O
cantharidic	B
acid	I
(	O
10	O
μM	O
)	O
for	O
24	O
h	O
,	O
both	O
treatments	O
resulted	O
in	O
morphological	O
features	O
like	O
rounding	O
of	O
cells	O
that	O
are	O
indicative	O
of	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
.	O

This	O
hypothesis	O
was	O
confirmed	O
by	O
measuring	O
and	O
comparing	O
caspase	O
activity	O
as	O
evidenced	O
by	O
the	O
cleavage	O
of	O
the	O
substrate	O
Ac	B
-	I
DEVD	I
-	I
pNA	I
with	O
the	O
two	O
phosphatase	O
inhibitors	O
as	O
well	O
as	O
doxorubicin	B
(	O
1	O
μg	O
/	O
ml	O
)	O
.	O

This	O
tetrapeptide	B
is	O
supposed	O
to	O
be	O
mainly	O
a	O
substrate	O
of	O
caspases-3	O
and	O
-7	O
.	O

All	O
treatment	O
regimens	O
resulted	O
in	O
a	O
significant	O
stimulation	O
of	O
DEVDase	O
activity	O
with	O
activity	O
ratios	O
of	O
threefold	O
(	O
doxorubicin	B
1	O
μg	O
/	O
ml	O
)	O
,	O
fivefold	O
(	O
okadaic	B
acid	I
100	O
nM	O
)	O
and	O
sixfold	O
(	O
cantharidic	B
acid	I
10	O
μM	O
)	O
(	O
Fig.	O
1	O
A	O
)	O
.	O

Thus	O
,	O
like	O
many	O
other	O
tumour	O
cells	O
LoVo	O
cells	O
respond	O
with	O
apoptosis	O
when	O
ser	O
/	O
thr	O
phosphatases	O
1	O
and	O
2A	O
,	O
the	O
enzymes	O
predominantly	O
inhibited	O
by	O
okadaic	B
acid	I
and	O
cantharidic	B
acid	I
at	O
these	O
concentrations	O
,	O
are	O
inhibited	O
for	O
a	O
longer	O
period	O
of	O
time	O
(	O
>	O
12	O
h	O
)	O
.	O

Next	O
we	O
tested	O
for	O
the	O
viability	O
loss	O
of	O
LoVo	O
cells	O
treated	O
for	O
24	O
h	O
with	O
doxorubicin	B
(	O
0.33–10	O
μg	O
/	O
ml	O
)	O
,	O
okadaic	B
acid	I
(	O
25–300	O
nM	O
)	O
and	O
cantharidic	B
acid	I
(	O
1–25	O
μM	O
)	O
(	O
Fig.	O
2	O
A	O
–	O
C	O
,	O
filled	O
symbols	O
)	O
.	O

At	O
the	O
most	O
effective	O
concentrations	O
these	O
agents	B
induced	O
a	O
loss	O
in	O
viability	O
of	O
about	O
40–60	O
%	O
.	O

This	O
effect	O
was	O
achieved	O
with	O
10	O
μg	O
/	O
ml	O
doxorubicin	B
,	O
300	O
nM	O
okadaic	B
acid	I
and	O
25	O
μM	O
cantharidic	B
acid	I
.	O

When	O
cells	O
were	O
treated	O
for	O
up	O
to	O
72	O
h	O
(	O
Fig.	O
2	O
A	O
–	O
C	O
,	O
open	O
symbols	O
)	O
toxicity	O
observed	O
with	O
all	O
three	O
agents	B
was	O
significantly	O
more	O
pronounced	O
resulting	O
in	O
overall	O
death	O
rates	O
of	O
80–90	O
%	O
compared	O
to	O
maximally	O
40–60	O
%	O
cells	O
that	O
died	O
after	O
24	O
h	O
(	O
Fig.	O
2	O
B	O
)	O
.	O

With	O
doxorubicin	B
and	O
okadaic	B
acid	I
40	O
%	O
viability	O
loss	O
was	O
observed	O
with	O
1	O
μg	O
/	O
ml	O
and	O
25	O
nM	O
,	O
respectively	O
,	O
while	O
cantharidic	B
acid	I
was	O
about	O
2.5	O
times	O
more	O
effective	O
with	O
40	O
%	O
of	O
cells	O
dying	O
between	O
5	O
and	O
10	O
μM	O
after	O
72	O
h	O
compared	O
to	O
40	O
%	O
of	O
cells	O
dying	O
at	O
25	O
μM	O
after	O
24	O
h.	O
Sensitivity	O
of	O
different	O
strains	O
of	O
tumour	O
cells	O
to	O
the	O
cytotoxicity	O
induced	O
by	O
phosphatase	O
inhibitors	O
was	O
shown	O
to	O
differ	O
substantially	O
(	O
Sakurada	O
et	O
al.	O
,	O
1992	O
)	O
.	O

In	O
order	O
to	O
investigate	O
these	O
aspects	O
in	O
more	O
detail	O
,	O
we	O
studied	O
toxicity	O
of	O
these	O
agents	B
in	O
LoVoDx	O
cells	O
which	O
had	O
become	O
at	O
least	O
10-fold	O
less	O
responsive	O
to	O
doxorubicin	B
(	O
Rivoltini	O
et	O
al.	O
,	O
1990	O
)	O
by	O
culture	O
in	O
increasing	O
concentrations	O
of	O
doxorubicin	B
.	O

Resistance	O
of	O
these	O
cells	O
is	O
mediated	O
via	O
the	O
enhanced	O
expression	O
of	O
P	O
-	O
glycoprotein	O
(	O
Rivoltini	O
et	O
al.	O
,	O
1990	O
;	O
Bertram	O
et	O
al.	O
,	O
1995	O
)	O
resulting	O
in	O
MDR1	O
phenotype	O
(	O
Gottesmann	O
and	O
Pastan	O
,	O
1993	O
)	O
.	O

When	O
either	O
LoVo	O
or	O
LoVoDx	O
cells	O
were	O
cultured	O
for	O
72	O
h	O
with	O
the	O
three	O
drugs	B
we	O
observed	O
substantially	O
different	O
behaviours	O
.	O

While	O
as	O
expected	O
LoVoDx	O
cells	O
were	O
more	O
than	O
10-fold	O
less	O
sensitive	O
to	O
doxorubicin	B
resulting	O
in	O
a	O
rightward	O
shift	O
of	O
the	O
toxicity	O
curve	O
(	O
Fig.	O
3	O
A	O
)	O
,	O
cells	O
treated	O
with	O
okadaic	B
acid	I
also	O
showed	O
such	O
a	O
rightward	O
shift	O
,	O
albeit	O
toxicity	O
was	O
only	O
reduced	O
by	O
a	O
factor	O
of	O
about	O
6–8	O
(	O
Fig.	O
3	O
B	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
LoVoDx	O
cells	O
treated	O
with	O
cantharidic	B
acid	I
displayed	O
a	O
leftward	O
shift	O
of	O
the	O
toxicity	O
curve	O
since	O
these	O
resistant	O
cells	O
were	O
about	O
2-	O
to	O
2.5-fold	O
more	O
sensitive	O
to	O
this	O
agent	B
(	O
Fig.	O
3	O
C	O
)	O
with	O
80	O
%	O
of	O
LoVoDx	O
cells	O
killed	O
at	O
10	O
μM	O
vs.	O
80	O
%	O
LoVo	O
cells	O
killed	O
at	O
25	O
μM.	O
This	O
different	O
behaviour	O
with	O
respect	O
to	O
the	O
response	O
to	O
cantharidic	B
acid	I
vs.	O
that	O
to	O
doxorubicin	B
and	O
okadaic	B
acid	I
was	O
confirmed	O
by	O
measurements	O
of	O
Ac	B
-	I
DEVD	I
-	I
pNA	I
conversion	O
in	O
LoVoDx	O
cells	O
treated	O
with	O
the	O
three	O
agents	B
.	O

While	O
in	O
these	O
cells	O
doxorubicin	B
and	O
okadaic	B
acid	I
showed	O
no	O
increase	O
of	O
caspase	O
3-like	O
activity	O
when	O
compared	O
to	O
untreated	O
LoVoDx	O
cells	O
(	O
Fig.	O
1	O
B	O
)	O
,	O
only	O
in	O
extracts	O
of	O
cantharidic	B
acid	I
-	O
treated	O
cells	O
was	O
caspase	O
activity	O
higher	O
than	O
in	O
extracts	O
from	O
untreated	O
cells	O
(	O
Fig.	O
1	O
B	O
)	O
.	O

Caspase	O
activity	O
in	O
untreated	O
LoVoDx	O
cells	O
was	O
about	O
5.5-fold	O
that	O
observed	O
in	O
untreated	O
LoVo	O
cells	O
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
MDR	O
can	O
protect	O
LoVoDx	O
cells	O
not	O
only	O
from	O
doxorubicin	B
but	O
also	O
,	O
albeit	O
to	O
a	O
lesser	O
extent	O
from	O
okadaic	B
acid	I
toxicity	O
.	O

This	O
is	O
in	O
accordance	O
with	O
observations	O
by	O
various	O
groups	O
(	O
Tohda	O
et	O
al.	O
,	O
1994	O
,	O
1997	O
;	O
Zheng	O
et	O
al.	O
,	O
1994	O
;	O
Wang	O
et	O
al.	O
,	O
1995	O
;	O
Ritz	O
et	O
al.	O
,	O
1997	O
)	O
obtained	O
with	O
okadaic	B
acid	I
-	O
resistant	O
cells	O
selected	O
on	O
increasing	O
concentrations	O
of	O
okadaic	B
acid	I
in	O
the	O
culture	O
medium	O
.	O

This	O
protection	O
has	O
been	O
shown	O
by	O
functional	O
and	O
biochemical	O
data	O
to	O
be	O
the	O
consequence	O
of	O
overexpression	O
of	O
the	O
MDR1	O
mediating	O
P	O
-	O
glycoprotein	O
.	O

On	O
the	O
other	O
hand	O
,	O
cells	O
which	O
showed	O
a	O
reduced	O
sensitivity	O
to	O
okadaic	B
acid	I
mainly	O
by	O
overexpression	O
of	O
the	O
P	O
-	O
glycoprotein	O
displayed	O
no	O
cross	O
resistance	O
to	O
cantharidic	B
acid	I
(	O
Ritz	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Similar	O
results	O
are	O
shown	O
for	O
a	O
okadaic	B
acid	I
-	O
resistant	O
subline	O
of	O
rat	O
pituitary	O
GH3	O
cells	O
that	O
proliferated	O
at	O
150	O
nM	O
okadaic	B
acid	I
which	O
is	O
about	O
15-fold	O
the	O
initially	O
lethal	O
concentration	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
this	O
subline	O
significant	O
okadaic	B
acid	I
toxicity	O
after	O
72	O
h	O
was	O
only	O
seen	O
with	O
a	O
concentration	O
of	O
300	O
nM	O
,	O
while	O
nearly	O
50	O
%	O
of	O
parental	O
cells	O
had	O
already	O
died	O
at	O
25	O
nM	O
okadaic	B
acid	I
(	O
Fig.	O
4	O
B	O
)	O
.	O

In	O
agreement	O
with	O
the	O
hypothesis	O
that	O
MDR1	O
is	O
underlying	O
this	O
loss	O
in	O
sensitivity	O
,	O
these	O
cells	O
were	O
also	O
about	O
10-fold	O
more	O
resistant	O
to	O
doxorubicin	B
toxicity	O
with	O
75	O
%	O
of	O
cells	O
killed	O
at	O
1	O
μg	O
/	O
ml	O
in	O
parental	O
vs.	O
75	O
%	O
killed	O
at	O
10	O
μg	O
/	O
ml	O
in	O
the	O
okadaic	B
acid	I
-	O
resistant	O
cells	O
(	O
Fig.	O
4	O
A	O
)	O
.	O

In	O
accordance	O
with	O
our	O
observations	O
with	O
the	O
LoVo	O
lines	O
cantharidic	B
acid	I
(	O
15	O
μM	O
)	O
toxicity	O
was	O
increased	O
in	O
the	O
resistant	O
GH3	O
lines	O
with	O
only	O
20	O
%	O
of	O
cells	O
surviving	O
after	O
72	O
h	O
compared	O
to	O
about	O
45	O
%	O
in	O
the	O
parental	O
line	O
(	O
Fig.	O
4	O
C	O
)	O
.	O

To	O
further	O
supplement	O
our	O
observations	O
on	O
the	O
responsiveness	O
of	O
LoVo	O
cells	O
and	O
lines	O
derived	O
from	O
these	O
cells	O
we	O
studied	O
the	O
loss	O
of	O
drug	B
resistance	O
by	O
omission	O
of	O
doxorubicin	B
from	O
the	O
culture	O
medium	O
.	O

Four	O
months	O
after	O
removal	O
of	O
doxorubicin	B
the	O
toxicity	O
of	O
okadaic	B
acid	I
and	O
doxorubicin	B
was	O
compared	O
between	O
these	O
cells	O
and	O
LoVoDx	O
as	O
well	O
as	O
parental	O
LoVo	O
cells	O
.	O

Interestingly	O
,	O
sensitivity	O
of	O
these	O
revertant	O
cells	O
for	O
doxorubicin	O
was	O
in	O
between	O
that	O
observed	O
with	O
LoVoDx	O
and	O
LoVo	O
cells	O
(	O
Fig.	O
5	O
A	O
)	O
.	O

Resistance	O
to	O
okadaic	B
acid	I
was	O
completely	O
lost	O
in	O
these	O
revertants	O
,	O
only	O
at	O
the	O
lowest	O
concentrations	O
tested	O
(	O
25	O
nM	O
)	O
was	O
survival	O
slightly	O
higher	O
than	O
in	O
parental	O
LoVo	O
cells	O
(	O
Fig.	O
5	O
B	O
)	O
.	O

Loss	O
of	O
MDR	O
in	O
these	O
cells	O
was	O
also	O
confirmed	O
by	O
measuring	O
the	O
accumulation	O
of	O
the	O
fluorescent	O
dye	O
rhodamine	B
123	I
which	O
as	O
a	O
substrate	O
of	O
the	O
P	O
-	O
glycoprotein	O
achieves	O
lower	O
steady	O
state	O
levels	O
in	O
resistant	O
cells	O
.	O

Omission	O
of	O
doxorubicin	B
in	O
the	O
culture	O
medium	O
resulted	O
in	O
normalization	O
of	O
dye	O
accumulation	O
(	O
data	O
not	O
shown	O
)	O
.	O

4	O
Discussion	O
The	O
data	O
presented	O
in	O
this	O
study	O
confirm	O
our	O
earlier	O
observations	O
as	O
well	O
as	O
those	O
of	O
other	O
groups	O
that	O
inhibition	O
of	O
ser	O
/	O
thr	O
phosphatases	O
,	O
especially	O
PP1	O
and	O
2A	O
,	O
by	O
selective	O
inhibitors	O
like	O
okadaic	B
acid	I
and	O
cantharidic	B
acid	I
,	O
can	O
be	O
considered	O
a	O
new	O
cytotoxic	O
principle	O
for	O
tumour	O
cells	O
(	O
Bøe	O
et	O
al.	O
,	O
1991	O
;	O
Kiguchi	O
et	O
al.	O
,	O
1994	O
;	O
Morana	O
et	O
al.	O
,	O
1996	O
;	O
Laidley	O
et	O
al.	O
,	O
1997	O
;	O
Tergau	O
et	O
al.	O
,	O
1997	O
;	O
von	O
Zezschwitz	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Like	O
doxorubicin	B
,	O
the	O
two	O
tested	O
agents	B
,	O
okadaic	B
acid	I
and	O
cantharidic	B
acid	I
,	O
induced	O
apoptosis	O
in	O
LoVo	O
cells	O
.	O

The	O
extent	O
of	O
cell	O
death	O
was	O
comparable	O
between	O
the	O
three	O
agents	B
.	O

Different	O
cell	O
lines	O
can	O
develop	O
resistance	O
to	O
okadaic	B
acid	I
-	O
induced	O
apoptosis	O
by	O
the	O
development	O
of	O
a	O
MDR1	O
phenotype	O
(	O
Tohda	O
et	O
al.	O
,	O
1994	O
,	O
1997	O
;	O
Zheng	O
et	O
al.	O
,	O
1994	O
;	O
Wang	O
et	O
al.	O
,	O
1995	O
;	O
Ritz	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Here	O
we	O
could	O
show	O
that	O
MDR1	O
expressing	O
LoVo	O
cells	O
resistant	O
to	O
doxorubicin	B
(	O
LoVoDx	O
)	O
displayed	O
a	O
comparable	O
cross	O
resistance	O
to	O
okadaic	B
acid	I
which	O
was	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
an	O
okadaic	B
acid	I
-	O
resistant	O
GH3	O
line	O
revealed	O
a	O
comparably	O
reduced	O
sensitivity	O
to	O
doxorubicin	B
.	O

In	O
accordance	O
with	O
this	O
conclusion	O
reduction	O
of	O
doxorubicin	B
resistance	O
in	O
a	O
revertant	O
LoVoDx	O
line	O
is	O
associated	O
with	O
the	O
loss	O
of	O
okadaic	B
acid	I
resistance	O
.	O

Thus	O
,	O
okadaic	B
acid	I
can	O
be	O
considered	O
a	O
drug	B
that	O
is	O
a	O
substrate	O
of	O
the	O
P	O
-	O
glycoprotein	O
-	O
mediating	O
MDR1	O
.	O

Studying	O
toxicity	O
of	O
this	O
agent	B
and	O
structurally	B
related	I
derivatives	I
should	O
consider	O
the	O
contribution	O
of	O
this	O
drug	B
extrusion	O
mechanism	O
for	O
the	O
correct	O
interpretation	O
of	O
the	O
results	O
.	O

On	O
the	O
other	O
hand	O
,	O
cytotoxicity	O
of	O
cantharidic	B
acid	I
,	I
an	O
inhibitor	O
of	O
PP1	O
and	O
PP2A	O
comparable	O
to	O
okadaic	B
acid	I
,	O
is	O
not	O
reduced	O
but	O
is	O
even	O
slightly	O
enhanced	O
in	O
LoVoDx	O
cells	O
.	O

The	O
potential	O
increased	O
sensitivity	O
of	O
LoVoDx	O
cells	O
was	O
confirmed	O
with	O
the	O
okadaic	O
acid	O
-	O
resistant	O
GH3	O
cells	O
but	O
should	O
be	O
confirmed	O
with	O
other	O
MDR	O
lines	O
before	O
general	O
conclusions	O
can	O
be	O
drawn	O
.	O

Thus	O
,	O
cantharidic	B
acid	I
does	O
not	O
seem	O
to	O
be	O
a	O
substrate	O
of	O
the	O
P	O
-	O
glycoprotein	O
and	O
might	O
therefore	O
be	O
the	O
drug	B
of	O
choice	O
for	O
testing	O
the	O
new	O
cytotoxic	O
principle	O
of	O
ser	O
/	O
thr	O
phosphatase	O
inhibition	O
in	O
MDR1	O
expressing	O
tumour	O
cells	O
.	O

Acknowledgements	O

We	O
thank	O
Dr	O
J.	O
Bertram	O
for	O
providing	O
us	O
with	O
LoVo	O
and	O
LoVoDx	O
cells	O
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
to	O
HJS	O
(	O
Ste	O
422	O
/	O
4	O
-	O
2	O
)	O
.	O

Inborn	O
errors	O
of	O
metabolism	O
can	O
in	O
many	O
cases	O
be	O
identified	O
by	O
the	O
presence	O
of	O
abnormal	O
metabolites	B
in	O
the	O
urine	O
.	O

These	O
compounds	B
are	O
either	O
not	O
present	O
or	O
are	O
present	O
in	O
only	O
very	O
small	O
concentrations	O
in	O
the	O
urine	O
of	O
normal	O
individuals	O
.	O

Many	O
organic	O
acidemias	O
show	O
similar	O
clinical	O
manifestations	O
and	O
a	O
definitive	O
diagnosis	O
can	O
only	O
be	O
made	O
by	O
identification	O
of	O
the	O
abnormal	O
metabolites	B
.	O

The	O
method	O
generally	O
applied	O
is	O
capillary	O
gas	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
GC	O
/	O
MS	O
)	O
.	O

One	O
of	O
the	O
drawbacks	O
of	O
this	O
technique	O
is	O
the	O
relatively	O
long	O
time	O
required	O
for	O
sample	O
preparation	O
and	O
analysis	O
.	O

In	O
sick	O
patients	O
it	O
is	O
sometimes	O
desirable	O
to	O
make	O
a	O
diagnosis	O
within	O
a	O
short	O
period	O
of	O
time	O
.	O

To	O
address	O
these	O
needs	O
,	O
we	O
developed	O
a	O
fast	O
solid	O
-	O
phase	O
extraction	O
method	O
for	O
sample	O
preparation	O
and	O
a	O
GC	O
/	O
MS	O
/	O
MS	O
screening	O
method	O
for	O
14	O
diagnostic	O
marker	O
compounds	B
.	O

MS	O
/	O
MS	O
or	O
tandem	O
mass	O
spectrometry	O
methods	O
are	O
characterized	O
by	O
high	O
specificity	O
and	O
sensitivity	O
due	O
to	O
the	O
effective	O
exclusion	O
of	O
interfering	O
matrix	O
compounds	B
.	O

While	O
to	O
date	O
,	O
in	O
the	O
majority	O
of	O
analytical	O
applications	O
a	O
tandem	O
-	O
in	O
-	O
space	O
MS	O
approach	O
with	O
triple	O
quadrupole	O
or	O
sector	O
MS	O
/	O
MS	O
instruments	O
is	O
used	O
,	O
we	O
applied	O
a	O
tandem	O
-	O
in	O
-	O
time	O
technique	O
,	O
using	O
a	O
bench	O
-	O
top	O
ion	O
trap	O
.	O

In	O
tandem	O
-	O
in	O
-	O
time	O
instruments	O
,	O
the	O
sequential	O
events	O
of	O
tandem	O
MS	O
,	O
i.e.	O
electron	O
impact	O
ionization	O
of	O
the	O
sample	O
molecules	O
,	O
the	O
mass	O
selection	O
of	O
the	O
precursor	O
ions	O
,	O
the	O
collision	O
-	O
induced	O
dissociation	O
(	O
CID	O
)	O
of	O
the	O
precursor	O
ions	O
with	O
neutral	O
gas	O
molecules	O
,	O
and	O
the	O
mass	O
analysis	O
of	O
the	O
product	O
ions	O
,	O
occur	O
in	O
the	O
same	O
space	O
,	O
the	O
ion	O
trap	O
,	O
and	O
are	O
separated	O
by	O
time	O
[	O
1	O
]	O
.	O

With	O
the	O
introduction	O
of	O
the	O
wave	O
-	O
board	O
technology	O
into	O
bench	O
-	O
top	O
ion	O
trap	O
instruments	O
[	O
2–4	O
]	O
,	O
MS	O
/	O
MS	O
experiments	O
can	O
be	O
performed	O
at	O
relatively	O
low	O
cost	O
.	O

Compared	O
to	O
screening	O
methods	O
using	O
quadrupole	O
GC	O
/	O
MS	O
instruments	O
operated	O
in	O
the	O
selected	O
ion	O
monitoring	O
mode	O
,	O
as	O
described	O
by	O
Tuchman	O
et	O
al.	O
[	O
5	O
]	O
for	O
the	O
screening	O
of	O
organic	B
acids	I
,	O
the	O
tandem	O
MS	O
approach	O
described	O
here	O
provides	O
increased	O
specificity	O
.	O

With	O
the	O
help	O
of	O
the	O
Saturn	O
Automatic	O
Method	O
Development	O
(	O
AMD	O
)	O
editor	O
,	O
the	O
development	O
and	O
optimization	O
of	O
tandem	O
MS	O
methods	O
is	O
relatively	O
easy	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
methods	O
for	O
the	O
sample	O
preparation	O
and	O
GC	O
/	O
MS	O
/	O
MS	O
organic	B
acid	I
screening	O
.	O

We	O
also	O
show	O
examples	O
of	O
how	O
diagnostic	O
marker	O
compounds	B
can	O
be	O
identified	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Instrumentation	O
A	O
Varian	O
3400	O
/	O
Saturn	O
2	O
ion	O
trap	O
GC	O
/	O
MS	O
system	O
(	O
Varian	O
,	O
Walnut	O
Creek	O
,	O
CA	O
)	O
,	O
equipped	O
with	O
an	O
MS	O
/	O
MS	O
and	O
SIS	O
(	O
selective	O
ion	O
storage	O
)	O
wave	O
-	O
board	O
,	O
is	O
used	O
.	O

A	O
DB-1	O
fused	O
-	O
silica	B
capillary	O
column	O
(	O
30	O
m	O
×	O
0.25	O
mm	O
×	O
0.25	O
μm	O
)	O
(	O
Alltech	O
,	O
Deerfield	O
,	O
IL	O
)	O
is	O
used	O
.	O

The	O
column	O
is	O
equilibrated	O
at	O
60	O
°	O
C	O
,	O
the	O
temperature	O
is	O
increased	O
to	O
300	O
°	O
C	O
at	O
a	O
rate	O
of	O
24	O
°	O
C	O
/	O
min	O
.	O

The	O
total	O
run	O
time	O
is	O
10.0	O
min	O
.	O

Helium	B
is	O
used	O
as	O
the	O
carrier	O
gas	O
with	O
controlled	O
pressure	O
set	O
at	O
12.5	O
psi	O
.	O

Data	O
is	O
collected	O
from	O
3.40	O
to	O
8.50	O
min	O
.	O

The	O
injector	O
used	O
is	O
a	O
1078	O
Universal	O
Capillary	O
Injector	O
(	O
Varian	O
)	O
with	O
0.34	O
mm	O
I.D.	O
injector	O
port	O
liner	O
.	O

The	O
injection	O
is	O
splitless	O
with	O
no	O
temperature	O
program	O
.	O

The	O
injector	O
temperature	O
is	O
300	O
°	O
C	O
.	O

The	O
split	O
valve	O
is	O
closed	O
at	O
0.01	O
min	O
and	O
reopened	O
at	O
0.30	O
min	O
(	O
split	O
mode	O
,	O
50:1	O
)	O
.	O

A	O
total	O
of	O
2	O
μl	O
of	O
the	O
sample	O
is	O
injected	O
.	O

The	O
transfer	O
line	O
is	O
held	O
at	O
260	O
°	O
C	O
.	O

2.2	O
Chemicals	B
The	O
organic	B
acids	I
were	O
obtained	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
or	O
Aldrich	O
(	O
Milwaukee	O
,	O
WI	O
)	O
.	O

The	O
acylglycines	B
were	O
synthesized	O
from	O
glycine	B
and	O
acylanhydrides	B
or	O
acylchlorides	B
as	O
described	O
in	O
[	O
6,7	O
]	O
.	O

N	B
,	I
O	I
-Bis	I
(	I
trimethylsilyl	I
)	I
trifluoroacetamide	I
(	O
BSTFA	B
)	O
with	O
1	O
%	O
trimethylchlorosilane	B
(	O
TMCS	B
)	O
was	O
obtained	O
from	O
Alltech	O
.	O

2.3	O
Solid	O
-	O
phase	O
extraction	O
columns	O
CHEMELUT	O
extraction	O
columns	O
were	O
obtained	O
from	O
Varian	O
(	O
Harbor	O
City	O
,	O
CA	O
)	O
.	O

A	O
specially	O
modified	O
form	O
of	O
diatomaceous	O
earth	O
,	O
that	O
provides	O
large	O
surface	O
area	O
between	O
the	O
aqueous	O
and	O
the	O
organic	O
phase	O
,	O
was	O
utilized	O
as	O
the	O
packing	O
material	O
.	O

The	O
extraction	O
columns	O
were	O
conditioned	O
on	O
a	O
vacuum	O
manifold	O
with	O
the	O
vacuum	O
pressure	O
set	O
at	O
15	O
mm	O
Hg	B
by	O
sequentially	O
adding	O
2	O
ml	O
of	O
3	O
N	O
HCl	B
saturated	O
with	O
NaCl	B
,	O
10	O
ml	O
of	O
deionized	O
water	B
,	O
5	O
ml	O
of	O
methanol	B
,	O
and	O
5	O
ml	O
of	O
ethylactate	B
.	O

The	O
columns	O
were	O
then	O
dried	O
for	O
approximately	O
30	O
min	O
.	O

2.4	O
Sample	O
preparation	O
Urine	O
equivalent	O
to	O
2.5	O
μmol	O
creatinine	B
is	O
used	O
.	O

If	O
the	O
calculated	O
urine	O
volume	O
exceeds	O
2.0	O
ml	O
,	O
only	O
one	O
-	O
half	O
of	O
the	O
volume	O
is	O
used	O
(	O
internal	O
standard	O
and	O
final	O
volume	O
are	O
also	O
cut	O
into	O
half	O
)	O
.	O

If	O
the	O
urine	O
volume	O
is	O
less	O
than	O
1.0	O
ml	O
,	O
the	O
volume	O
is	O
brought	O
up	O
to	O
1.0	O
ml	O
with	O
deionized	O
water	B
.	O

Fifty	O
μl	O
internal	O
standard	O
2-ketocaproic	B
acid	I
(	O
1	O
mg	O
/	O
ml	O
)	O
and	O
200	O
μl	O
hydroxylamine	B
hydrochloride	I
(	O
7.5	O
mg	O
/	O
dl	O
)	O
are	O
added	O
and	O
the	O
sample	O
is	O
incubated	O
at	O
60	O
°	O
C	O
for	O
20	O
min	O
.	O

Five	O
hundred	O
μl	O
of	O
3	O
N	O
HCl	B
are	O
added	O
.	O

The	O
sample	O
is	O
vortexed	O
for	O
1	O
min	O
and	O
applied	O
to	O
the	O
column	O
.	O

Ten	O
ml	O
ethylacetate	B
is	O
added	O
.	O

Water	B
is	O
removed	O
from	O
the	O
eluate	O
with	O
sodium	B
sulfate	I
,	O
it	O
is	O
dried	O
under	O
a	O
flow	O
of	O
nitrogen	B
at	O
40	O
°	O
C	O
,	O
derivatized	O
with	O
50	O
μl	O
BSTFA+1%TMCS	B
for	O
10	O
min	O
at	O
60	O
°	O
C	O
and	O
the	O
final	O
volume	O
is	O
brought	O
up	O
to	O
1.0	O
ml	O
with	O
hexane	B
.	O

2.5	O
MS	O
/	O
MS	O
method	O
development	O
The	O
following	O
steps	O
were	O
performed	O
for	O
each	O
analyte:1	O
.	O

In	O
the	O
full	O
scan	O
electron	O
ionization	O
mode	O
,	O
the	O
retention	O
time	O
was	O
determined	O
and	O
the	O
identity	O
of	O
the	O
compound	B
was	O
confirmed	O
by	O
comparison	O
of	O
the	O
full	O
scan	O
electron	O
impact	O
with	O
the	O
library	O
spectra	O
(	O
The	O
MS	O
library	O
used	O
was	O
a	O
gift	O
by	O
Denis	O
C.	O
Lehotay	O
from	O
the	O
Hospital	O
for	O
Sick	O
Children	O
Toronto	O
)	O
.	O

2	O
.	O

The	O
candidate	O
precursor	O
ion	O
,	O
which	O
in	O
most	O
cases	O
was	O
the	O
most	O
abundant	O
ion	O
,	O
was	O
isolated	O
in	O
the	O
ion	O
trap	O
without	O
applying	O
a	O
CID	O
voltage	O
.	O

3	O
.	O

If	O
the	O
candidate	O
precursor	O
ion	O
could	O
be	O
isolated	O
successfully	O
,	O
the	O
AMD	O
editor	O
was	O
used	O
to	O
determine	O
the	O
required	O
CID	O
voltage	O
for	O
fragmentation	O
by	O
increasing	O
the	O
voltage	O
in	O
5	O
or	O
0.05	O
V	O
steps	O
for	O
the	O
non	O
-	O
resonant	O
or	O
resonant	O
mode	O
,	O
respectively	O
(	O
Figs.	O
1	O
and	O
2	O
)	O
.	O

The	O
voltage	O
that	O
gave	O
the	O
highest	O
intensity	O
for	O
the	O
product	O
ions	O
was	O
selected	O
.	O

This	O
was	O
done	O
in	O
the	O
non	O
-	O
resonant	O
mode	O
first	O
.	O

If	O
the	O
fragmentation	O
was	O
not	O
satisfying	O
,	O
the	O
resonant	O
mode	O
was	O
chosen	O
or	O
a	O
different	O
precursor	O
ion	O
was	O
selected	O
.	O

4	O
.	O

If	O
the	O
fragmentation	O
pattern	O
was	O
satisfying	O
,	O
but	O
the	O
intensity	O
of	O
the	O
product	O
ion	O
spectrum	O
was	O
relatively	O
low	O
,	O
the	O
storage	O
level	O
of	O
the	O
radiofrequency	O
trapping	O
field	O
and	O
the	O
CID	O
voltage	O
were	O
increased	O
to	O
improve	O
ion	O
intensity	O
.	O

5	O
.	O

A	O
product	O
ion	O
,	O
that	O
was	O
abundant	O
and	O
specific	O
,	O
was	O
selected	O
for	O
analyte	O
detection	O
.	O

3	O
Results	O
Fourteen	O
urinary	O
organic	B
acids	I
that	O
are	O
indicative	O
of	O
various	O
inherited	O
metabolic	O
diseases	O
were	O
chosen	O
for	O
the	O
GC	O
/	O
MS	O
/	O
MS	O
screening	O
(	O
Table	O
1	O
)	O
.	O

The	O
automatic	O
method	O
development	O
(	O
AMD	O
)	O
is	O
illustrated	O
in	O
Figs.	O
1	O
and	O
2	O
for	O
2-ketoisocaproic	B
acid	I
.	O

Fig.	O
1A	O
–	O
D	O
shows	O
the	O
product	O
ion	O
spectra	O
at	O
increasing	O
CID	O
voltages	O
.	O

The	O
ion	O
at	O
m	O
/z	O
200	O
was	O
chosen	O
as	O
the	O
precursor	O
ion	O
.	O

With	O
increasing	O
CID	O
voltage	O
,	O
the	O
precursor	O
ion	O
signal	O
decreases	O
,	O
while	O
the	O
product	O
ions	O
become	O
more	O
abundant	O
.	O

This	O
is	O
further	O
illustrated	O
in	O
the	O
breakdown	O
curve	O
in	O
Fig.	O
2	O
,	O
where	O
the	O
ion	O
intensities	O
of	O
the	O
precursor	O
ion	O
m	O
/z	O
200	O
and	O
the	O
most	O
abundant	O
product	O
ion	O
m	O
/z	O
110	O
are	O
plotted	O
against	O
the	O
CID	O
voltage	O
.	O

It	O
can	O
be	O
concluded	O
that	O
0.30	O
V	O
results	O
in	O
the	O
highest	O
intensity	O
of	O
the	O
product	O
ion	O
m	O
/z	O
110	O
and	O
is	O
therefore	O
the	O
optimum	O
voltage	O
to	O
monitor	O
the	O
product	O
ion	O
.	O

The	O
optimum	O
conditions	O
of	O
the	O
CID	O
process	O
for	O
the	O
other	O
analytes	O
were	O
determined	O
analogously	O
.	O

Table	O
2	O
lists	O
for	O
each	O
of	O
the	O
fourteen	O
analytes	O
the	O
precursor	O
ion	O
,	O
the	O
product	O
ion	O
that	O
was	O
chosen	O
for	O
the	O
detection	O
,	O
and	O
the	O
determined	O
optimum	O
CID	O
conditions	O
,	O
i.e.	O
the	O
CID	O
mode	O
(	O
non	O
-	O
resonant	O
or	O
resonant	O
excitation	O
)	O
,	O
the	O
CID	O
voltage	O
and	O
the	O
excitation	O
storage	O
level	O
.	O

Table	O
3	O
shows	O
the	O
determined	O
response	O
factors	O
and	O
the	O
range	O
of	O
linearity	O
.	O

The	O
response	O
factors	O
were	O
measured	O
as	O
the	O
ratio	O
of	O
the	O
intensity	O
of	O
the	O
product	O
ions	O
and	O
the	O
intensity	O
of	O
the	O
peak	O
of	O
the	O
respective	O
analyte	O
in	O
the	O
full	O
scan	O
chromatogram	O
,	O
based	O
on	O
internal	O
standards	O
.	O

The	O
response	O
factors	O
vary	O
widely	O
because	O
of	O
different	O
ionization	O
and	O
fragmentation	O
efficiencies	O
for	O
the	O
analytes	O
.	O

The	O
linearity	O
of	O
the	O
standard	O
curves	O
,	O
tested	O
for	O
over	O
the	O
range	O
from	O
0.1	O
to	O
10	O
ng	O
/	O
μl	O
,	O
varied	O
between	O
the	O
analytes	O
.	O

For	O
the	O
sample	O
preparation	O
a	O
fast	O
solid	O
-	O
phase	O
extraction	O
that	O
was	O
previously	O
described	O
for	O
the	O
extraction	O
of	O
methylmalonic	B
acid	I
[	O
8	O
]	O
was	O
chosen	O
.	O

The	O
measured	O
extraction	O
efficiencies	O
for	O
the	O
14	O
organic	B
acid	I
markers	O
are	O
between	O
57	O
%	O
(	O
propionylglycine	B
)	O
and	O
106	O
%	O
(	O
glutaric	B
acid	I
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

When	O
the	O
extraction	O
efficiency	O
of	O
the	O
solid	O
phase	O
extraction	O
was	O
compared	O
using	O
a	O
liquid	O
–	O
liquid	O
extraction	O
two	O
times	O
with	O
5	O
ml	O
ethylacetate	B
,	O
the	O
ratios	O
in	O
percent	O
of	O
the	O
area	O
counts	O
after	O
solid	O
phase	O
versus	O
liquid	O
–	O
liquid	O
extraction	O
were	O
between	O
89	O
and	O
145	O
%	O
for	O
the	O
14	O
analytes	O
.	O

For	O
all	O
organic	B
acid	I
markers	O
except	O
sebacic	B
acid	I
the	O
solid	O
-	O
phase	O
extraction	O
showed	O
a	O
higher	O
efficiency	O
compared	O
with	O
the	O
liquid	O
–	O
liquid	O
extraction	O
.	O

In	O
order	O
to	O
test	O
the	O
sensitivity	O
and	O
to	O
establish	O
reference	O
values	O
,	O
we	O
determined	O
the	O
areas	O
of	O
the	O
characteristic	O
product	O
ion	O
peaks	O
for	O
each	O
of	O
the	O
14	O
analytes	O
in	O
30	O
normal	O
urine	O
samples	O
.	O

The	O
samples	O
were	O
run	O
over	O
a	O
period	O
of	O
3	O
days	O
.	O

The	O
averages	O
,	O
expressed	O
as	O
the	O
ratio	O
of	O
the	O
area	O
of	O
the	O
analyte	O
over	O
the	O
area	O
of	O
the	O
internal	O
standard	O
,	O
2-ketocaproic	B
acid	I
,	O
and	O
the	O
standard	O
deviations	O
are	O
listed	O
in	O
Table	O
4	O
.	O

All	O
analytes	O
were	O
detected	O
in	O
at	O
least	O
24	O
of	O
the	O
30	O
samples	O
.	O

Fig.	O
3	O
illustrates	O
how	O
elevations	O
in	O
organic	B
acids	I
can	O
be	O
detected	O
.	O

The	O
product	O
ion	O
chromatograms	O
for	O
all	O
14	O
analytes	O
in	O
a	O
normal	O
urine	O
sample	O
that	O
was	O
spiked	O
with	O
five	O
organic	B
acids	I
are	O
shown	O
(	O
see	O
legend	O
to	O
Fig.	O
3	O
)	O
.	O

The	O
elevations	O
in	O
the	O
five	O
organic	B
acids	I
could	O
all	O
be	O
detected	O
.	O

Table	O
5	O
shows	O
the	O
results	O
from	O
nine	O
patients	O
with	O
various	O
known	O
metabolic	O
diseases	O
that	O
were	O
tested	O
.	O

The	O
elevations	O
in	O
the	O
characteristic	O
analytes	O
were	O
easily	O
detectable	O
.	O

The	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
is	O
considered	O
to	O
be	O
the	O
average	O
of	O
the	O
ratios	O
of	O
the	O
area	O
of	O
the	O
analyte	O
over	O
the	O
area	O
of	O
the	O
internal	O
standard	O
in	O
30	O
normal	O
controls	O
plus	O
two	O
standard	O
deviations	O
.	O

All	O
analytes	O
that	O
are	O
characteristic	O
for	O
the	O
particular	O
disorder	O
were	O
at	O
least	O
five	O
times	O
higher	O
than	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
.	O

For	O
the	O
diagnosis	O
of	O
fatty	B
acid	I
oxidation	O
disorders	O
it	O
is	O
necessary	O
to	O
compare	O
the	O
relative	O
quantities	O
of	O
adipic	B
,	O
suberic	B
and	O
sebacic	B
acid	I
.	O

Due	O
to	O
different	O
response	O
factors	O
(	O
see	O
Table	O
3	O
)	O
this	O
can	O
only	O
be	O
done	O
by	O
dividing	O
the	O
areas	O
by	O
the	O
response	O
factor	O
.	O

The	O
results	O
for	O
adipic	B
,	O
suberic	B
and	O
sebacic	B
acid	I
in	O
the	O
last	O
patient	O
in	O
Table	O
5	O
are	O
2.0	O
,	O
4.2	O
and	O
14.6	O
,	O
respectively	O
,	O
and	O
are	O
consistent	O
with	O
dietary	O
medium	O
chain	O
triglycerides	B
.	O

4	O
Discussion	O
The	O
GC	O
/	O
MS	O
/	O
MS	O
screening	O
method	O
was	O
developed	O
as	O
a	O
fast	O
and	O
simple	O
method	O
to	O
identify	O
organic	O
acidurias	O
with	O
high	O
sensitivity	O
and	O
specificity	O
in	O
situations	O
where	O
a	O
fast	O
diagnosis	O
is	O
desirable	O
.	O

Fourteen	O
analytes	O
,	O
that	O
are	O
indicative	O
of	O
treatable	O
inborn	O
errors	O
of	O
metabolism	O
(	O
with	O
the	O
exception	O
of	O
fumarase	O
deficiency	O
)	O
,	O
were	O
chosen	O
for	O
the	O
screening	O
.	O

The	O
list	O
of	O
analytes	O
could	O
possibly	O
be	O
expanded	O
to	O
screen	O
for	O
other	O
disorders	O
.	O

A	O
GC	O
/	O
MS	O
run	O
in	O
the	O
full	O
scan	O
mode	O
is	O
performed	O
at	O
a	O
later	O
point	O
to	O
confirm	O
the	O
findings	O
of	O
the	O
screening	O
test	O
.	O

The	O
solid	O
-	O
phase	O
extraction	O
method	O
used	O
allows	O
sample	O
preparation	O
within	O
a	O
relatively	O
short	O
time	O
with	O
a	O
good	O
extraction	O
efficiency	O
for	O
all	O
marker	O
compounds	B
.	O

The	O
entire	O
sample	O
preparation	O
including	O
oximation	O
and	O
derivatization	O
can	O
be	O
accomplished	O
in	O
less	O
than	O
90	O
min	O
.	O

The	O
solid	O
-	O
phase	O
extraction	O
method	O
is	O
superior	O
to	O
a	O
liquid	O
–	O
liquid	O
extraction	O
with	O
ethylacetate	B
with	O
respect	O
to	O
both	O
time	O
and	O
extraction	O
efficiency	O
.	O

The	O
total	O
run	O
time	O
for	O
one	O
sample	O
is	O
10	O
min	O
.	O

Despite	O
the	O
short	O
run	O
time	O
,	O
the	O
method	O
achieves	O
high	O
specificity	O
.	O

A	O
high	O
specificity	O
is	O
inherent	O
to	O
tandem	O
MS	O
methods	O
,	O
due	O
to	O
the	O
isolation	O
of	O
a	O
characteristic	O
precursor	O
ion	O
in	O
the	O
first	O
step	O
,	O
that	O
gives	O
rise	O
to	O
characteristic	O
product	O
ions	O
in	O
the	O
second	O
step	O
.	O

Only	O
in	O
the	O
case	O
of	O
3-methylcrotonylglycine	B
and	O
tiglylglycine	B
,	O
which	O
are	O
structural	O
isomers	O
,	O
the	O
same	O
precursor	O
ion	O
had	O
to	O
be	O
chosen	O
because	O
of	O
very	O
similar	O
mass	O
spectra	O
of	O
the	O
two	O
compounds	O
.	O

The	O
product	O
ion	O
spectra	O
of	O
the	O
precursor	O
ion	O
m	O
/z	O
170	O
are	O
also	O
very	O
similar	O
for	O
both	O
organic	B
acids	I
.	O

The	O
most	O
abundant	O
ion	O
in	O
the	O
product	O
ion	O
spectrum	O
,	O
which	O
was	O
for	O
both	O
analytes	O
m	O
/z	O
96	O
,	O
was	O
chosen	O
for	O
the	O
detection	O
of	O
the	O
compounds	B
.	O

The	O
retention	O
time	O
in	O
comparison	O
to	O
the	O
standard	O
mixture	O
that	O
is	O
run	O
prior	O
to	O
the	O
patient	O
samples	O
has	O
to	O
be	O
used	O
for	O
the	O
identification	O
of	O
the	O
analyte	O
in	O
this	O
case	O
.	O

When	O
the	O
standard	O
mixture	O
is	O
run	O
,	O
the	O
two	O
peaks	O
are	O
always	O
clearly	O
distinguishable	O
.	O

A	O
high	O
sensitivity	O
is	O
also	O
achieved	O
by	O
MS	O
/	O
MS	O
.	O

Although	O
some	O
analytes	O
have	O
low	O
response	O
factors	O
,	O
this	O
is	O
more	O
than	O
compensated	O
for	O
by	O
the	O
exclusion	O
of	O
the	O
interfering	O
matrix	O
resulting	O
in	O
a	O
high	O
signal	O
to	O
noise	O
ratio	O
.	O

High	O
sensitivity	O
is	O
apparent	O
for	O
all	O
analytes	O
from	O
Table	O
4	O
.	O

All	O
14	O
organic	B
acid	I
markers	O
could	O
be	O
detected	O
in	O
the	O
majority	O
of	O
the	O
normal	O
control	O
samples	O
.	O

The	O
range	O
of	O
linearity	O
varies	O
for	O
the	O
14	O
compounds	O
.	O

While	O
the	O
majority	O
of	O
the	O
organic	B
acid	I
markers	O
showed	O
linearity	O
between	O
0.1	O
and	O
5	O
or	O
10	O
ng	O
/	O
μl	O
,	O
fumaric	B
acid	I
,	O
glutaric	B
acid	I
,	O
butyrylglycine	B
and	O
adipic	B
acid	I
gave	O
linear	O
standard	O
curves	O
only	O
up	O
to	O
1	O
ng	O
/	O
μl	O
.	O

The	O
limitations	O
in	O
some	O
of	O
the	O
linearity	O
ranges	O
is	O
not	O
surprising	O
since	O
the	O
standard	O
curves	O
were	O
obtained	O
over	O
a	O
concentration	O
range	O
of	O
four	O
orders	O
of	O
magnitude	O
.	O

They	O
are	O
in	O
part	O
due	O
to	O
the	O
different	O
response	O
factors	O
.	O

Therefore	O
,	O
at	O
the	O
same	O
analyte	O
concentration	O
different	O
amounts	O
of	O
product	O
ions	O
will	O
be	O
generated	O
and	O
detected	O
and	O
saturation	O
occurs	O
at	O
different	O
concentrations	O
.	O

For	O
the	O
screening	O
method	O
,	O
however	O
,	O
linear	O
standard	O
curves	O
are	O
not	O
necessarily	O
required	O
because	O
it	O
is	O
a	O
semiquantitative	O
method	O
.	O

Data	O
analysis	O
can	O
be	O
accomplished	O
quickly	O
,	O
by	O
simply	O
monitoring	O
the	O
characteristic	O
product	O
ion	O
chromatogram	O
for	O
each	O
of	O
the	O
14	O
organic	B
acid	I
markers	O
,	O
and	O
determining	O
the	O
peak	O
areas	O
and	O
retention	O
times	O
of	O
the	O
product	O
ion	O
peaks	O
.	O

The	O
retention	O
times	O
are	O
compared	O
with	O
the	O
retention	O
times	O
of	O
a	O
standard	O
mixture	O
that	O
includes	O
all	O
14	O
analytes	O
to	O
confirm	O
the	O
identity	O
of	O
the	O
detected	O
compound	B
.	O

The	O
determined	O
peak	O
areas	O
are	O
expressed	O
as	O
the	O
ratios	O
over	O
the	O
internal	O
standard	O
2-ketocaproic	B
acid	I
,	O
which	O
can	O
be	O
accomplished	O
with	O
the	O
fully	O
automated	O
software	O
version	O
for	O
Saturn	O
2000	O
GC	O
/	O
MS	O
instruments	O
,	O
and	O
are	O
then	O
compared	O
with	O
the	O
established	O
reference	O
values	O
.	O

Although	O
2-ketocaproic	B
acid	I
may	O
not	O
be	O
an	O
optimal	O
internal	O
standard	O
for	O
all	O
the	O
analytes	O
for	O
quantitative	O
purposes	O
,	O
it	O
is	O
a	O
satisfying	O
internal	O
standard	O
in	O
our	O
semiquantitative	O
method	O
.	O

There	O
is	O
very	O
good	O
reproducibility	O
from	O
one	O
injection	O
to	O
the	O
other	O
and	O
reasonable	O
reproducibility	O
from	O
one	O
extraction	O
to	O
the	O
other	O
.	O

We	O
determined	O
the	O
variation	O
coefficients	O
using	O
three	O
aliquots	O
of	O
a	O
standard	O
mixture	O
that	O
were	O
extracted	O
and	O
injected	O
on	O
the	O
same	O
day	O
or	O
on	O
different	O
days	O
.	O

The	O
same	O
day	O
variation	O
for	O
the	O
14	O
organic	B
acid	I
markers	O
was	O
between	O
0.5	O
and	O
8.5	O
%	O
,	O
the	O
day	O
to	O
day	O
variation	O
between	O
14.9	O
and	O
44.5	O
%	O
.	O

If	O
the	O
internal	O
standard	O
is	O
used	O
to	O
correct	O
for	O
variation	O
of	O
injection	O
and	O
extraction	O
,	O
the	O
day	O
to	O
day	O
variation	O
amounted	O
to	O
between	O
4.1	O
and	O
34.7	O
%	O
(	O
data	O
not	O
shown	O
)	O
.	O

Fig.	O
3	O
and	O
Table	O
5	O
show	O
that	O
organic	O
acidurias	O
can	O
be	O
easily	O
detected	O
with	O
this	O
method	O
.	O

We	O
therefore	O
conclude	O
that	O
the	O
method	O
can	O
be	O
used	O
as	O
a	O
quick	O
metabolic	O
screen	O
for	O
very	O
sick	O
patients	O
in	O
whom	O
there	O
is	O
concern	O
regarding	O
the	O
possibility	O
of	O
a	O
treatable	O
metabolic	O
disorder	O
.	O

Acknowledgements	O
TH	O
was	O
a	O
visiting	O
scientist	O
supported	O
by	O
a	O
postdoctoral	O
fellowship	O
grant	O
by	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
.	O

We	O
greatly	O
appreciate	O
the	O
advice	O
and	O
support	O
of	O
Frederic	O
C.	O
Glisson	O
from	O
Varian	O
.	O

A	O
clearer	O
understanding	O
of	O
the	O
role	O
of	O
vitamin	B
A	I
(	O
retinol	B
)	O
in	O
growth	O
and	O
development	O
was	O
achieved	O
when	O
it	O
was	O
discovered	O
that	O
retinoic	B
acid	I
,	O
the	O
carboxylic	B
acid	I
derivative	O
of	O
retinol	B
,	O
functions	O
as	O
a	O
ligand	O
controlling	O
a	O
nuclear	O
receptor	O
signaling	O
pathway	O
[	O
1,2	O
]	O
.	O

However	O
,	O
a	O
full	O
understanding	O
of	O
retinoid	B
signaling	O
will	O
only	O
come	O
when	O
the	O
mechanisms	O
regulating	O
conversion	O
of	O
retinol	O
to	O
the	O
active	O
ligand	O
retinoic	B
acid	I
are	O
elucidated	O
.	O

Enzyme	O
families	O
able	O
to	O
participate	O
in	O
retinol	B
metabolism	O
have	O
been	O
discovered	O
(	O
reviewed	O
in	O
[	O
3	O
]	O
)	O
.	O

In	O
particular	O
,	O
some	O
members	O
of	O
the	O
alcohol	O
dehydrogenase	O
(	O
ADH	O
)	O
and	O
short	O
-	O
chain	O
dehydrogenase	O
/	O
reductase	O
(	O
SDR	O
)	O
enzyme	O
families	O
are	O
capable	O
of	O
catalyzing	O
the	O
oxidation	O
of	O
retinol	B
to	O
retinal	B
,	O
and	O
some	O
forms	O
of	O
aldehyde	O
dehydrogenase	O
(	O
ALDH	O
)	O
and	O
cytochrome	O
P	O
-450	O
(	O
CYP	O
)	O
can	O
oxidize	O
retinal	B
to	O
retinoic	B
acid	I
.	O

Retinol	B
oxidation	O
is	O
catalyzed	O
by	O
several	O
distinct	O
classes	O
of	O
cytosolic	O
ADH	O
[	O
4–9	O
]	O
as	O
well	O
as	O
several	O
different	O
microsomal	O
SDRs	O
[	O
10–12	O
]	O
.	O

Further	O
studies	O
on	O
these	O
enzyme	O
families	O
should	O
reveal	O
the	O
mechanisms	O
of	O
retinol	B
oxidation	O
needed	O
to	O
properly	O
supply	O
retinoic	B
acid	I
for	O
retinoid	B
signaling	O
.	O

Vertebrate	O
ADH	O
(	O
EC	O
1.1.1.1	O
)	O
consists	O
of	O
a	O
family	O
of	O
cytosolic	O
,	O
NAD	B
-	O
dependent	O
,	O
zinc	B
-	O
containing	O
enzymes	O
[	O
13	O
]	O
and	O
a	O
nomenclature	O
based	O
upon	O
class	O
distinctions	O
has	O
been	O
described	O
[	O
14	O
]	O
.	O

ADHs	O
are	O
capable	O
of	O
oxidizing	O
a	O
wide	O
variety	O
of	O
aliphatic	B
alcohols	I
to	O
their	O
corresponding	O
aldehydes	B
[	O
4,15,16	O
]	O
,	O
and	O
these	O
aldehyde	B
products	O
act	O
as	O
substrates	O
for	O
members	O
of	O
the	O
ALDH	O
family	O
which	O
oxidize	O
them	O
to	O
their	O
corresponding	O
carboxylic	B
acids	I
[	O
17	O
]	O
.	O

The	O
ability	O
of	O
liver	O
ADH	O
,	O
now	O
known	O
to	O
consist	O
primarily	O
of	O
class	O
I	O
ADH	O
(	O
ADH1	O
)	O
,	O
to	O
utilize	O
retinol	B
as	O
a	O
substrate	O
has	O
been	O
appreciated	O
for	O
many	O
years	O
[	O
18,19	O
]	O
.	O

However	O
,	O
recent	O
studies	O
have	O
shown	O
that	O
human	O
class	O
IV	O
ADH	O
(	O
ADH4	O
)	O
has	O
even	O
higher	O
retinol	B
-	O
oxidizing	O
activity	O
than	O
human	O
ADH1	O
[	O
5,7–9	O
]	O
.	O

As	O
further	O
evidence	O
that	O
ADH1	O
and	O
ADH4	O
play	O
a	O
role	O
in	O
retinoid	B
signaling	O
,	O
the	O
mouse	O
homologs	O
for	O
these	O
enzymes	O
have	O
been	O
localized	O
in	O
numerous	O
retinoid	B
-	O
responsive	O
tissues	O
including	O
epidermis	O
[	O
20	O
]	O
,	O
testis	O
[	O
21	O
]	O
,	O
genitourinary	O
tract	O
[	O
22	O
]	O
,	O
digestive	O
tract	O
[	O
23	O
]	O
and	O
neurula	O
-	O
stage	O
embryos	O
[	O
24,25	O
]	O
.	O

ADH	O
may	O
also	O
participate	O
in	O
the	O
production	O
of	O
retinoic	B
acid	I
as	O
an	O
endocrine	O
hormone	B
as	O
demonstrated	O
by	O
the	O
discovery	O
of	O
high	O
levels	O
of	O
ADH1	O
,	O
ADH4	O
,	O
and	O
retinoic	B
acid	I
in	O
the	O
adrenal	O
cortex	O
[	O
26,27	O
]	O
.	O

In	O
addition	O
to	O
all	B
-	I
trans	I
-retinol	I
(	O
vitamin	B
A1	I
)	O
which	O
is	O
the	O
most	O
abundant	O
form	O
of	O
vitamin	B
A	I
in	O
mammals	O
it	O
has	O
been	O
demonstrated	O
that	O
several	O
additional	O
alcohol	B
forms	O
exist	O
which	O
play	O
biological	O
roles	O
in	O
retinoid	B
signaling	O
(	O
Fig.	O
1	O
)	O
.	O

In	O
human	O
epidermis	O
3,4-didehydroretinol	B
(	O
vitamin	B
A2	I
)	O
is	O
present	O
at	O
25	O
%	O
the	O
level	O
of	O
all	B
-	I
trans	I
-retinol	I
[	O
28	O
]	O
,	O
and	O
in	O
chick	O
embryos	O
[	O
29	O
]	O
and	O
Xenopus	O
embryos	O
[	O
30	O
]	O
the	O
level	O
of	O
3,4-didehydroretinol	B
is	O
comparable	O
to	O
that	O
of	O
all	B
-	I
trans	I
-retinol	I
.	O

Its	O
carboxylic	B
acid	I
derivative	O
3,4-didehydroretinoic	B
acid	I
is	O
produced	O
in	O
chick	O
embryos	O
[	O
29,31	O
]	O
and	O
Xenopus	O
embryos	O
[	O
32	O
]	O
,	O
and	O
has	O
been	O
shown	O
to	O
activate	O
retinoic	B
acid	I
receptors	O
[	O
33	O
]	O
and	O
have	O
biological	O
activity	O
[	O
34,35	O
]	O
.	O

Another	O
form	O
of	O
retinol	B
is	O
9-cis	B
-retinol	I
which	O
has	O
been	O
identified	O
in	O
rat	O
kidney	O
[	O
36	O
]	O
.	O

Its	O
carboxylic	B
acid	I
derivative	O
9-cis	B
-retinoic	I
acid	I
has	O
been	O
demonstrated	O
to	O
activate	O
retinoic	B
acid	I
receptors	O
as	O
well	O
as	O
retinoid	O
X	O
receptors	O
[	O
37,38	O
]	O
and	O
has	O
been	O
shown	O
to	O
have	O
biological	O
activity	O
[	O
39	O
]	O
.	O

In	O
addition	O
,	O
4-hydroxy	B
-	I
retinol	I
and	O
4-oxo	B
-	I
retinol	I
represent	O
two	O
additional	O
natural	O
forms	O
of	O
retinol	B
[	O
40	O
]	O
,	O
and	O
these	O
plus	O
4-oxo	B
-	I
retinal	I
and	O
4-oxo	B
-	I
retinoic	I
acid	I
have	O
been	O
demonstrated	O
to	O
activate	O
retinoic	B
acid	I
receptors	O
[	O
40,41	O
]	O
and	O
have	O
biological	O
activity	O
[	O
42,43	O
]	O
.	O

Little	O
is	O
known	O
about	O
the	O
enzymes	O
able	O
to	O
metabolize	O
these	O
additional	O
natural	O
retinols	B
except	O
in	O
the	O
case	O
of	O
9-cis	B
-retinol	I
which	O
is	O
a	O
substrate	O
for	O
ADH4	O
[	O
8	O
]	O
and	O
some	O
forms	O
of	O
SDR	O
[	O
12,44,45	O
]	O
.	O

X	O
-	O
Ray	O
crystallographic	O
structures	O
of	O
horse	O
class	O
I	O
ADH	O
EE	O
(	O
ADH1E	O
)	O
[	O
46	O
]	O
,	O
human	O
class	O
I	O
ADH	O
ββ	O
(	O
ADH1B	O
)	O
[	O
47,48	O
]	O
,	O
codfish	O
class	O
I	O
ADH	O
(	O
ADH1	O
)	O
[	O
49	O
]	O
,	O
human	O
class	O
III	O
ADH	O
(	O
ADH3	O
)	O
[	O
50	O
]	O
,	O
and	O
human	O
class	O
IV	O
ADH	O
(	O
ADH4	O
)	O
[	O
51	O
]	O
have	O
provided	O
several	O
well	O
-	O
defined	O
ADH	O
active	O
sites	O
.	O

The	O
structural	O
determinants	O
of	O
substrate	O
recognition	O
indicate	O
that	O
vertebrate	O
ADHs	O
are	O
best	O
suited	O
for	O
the	O
oxidation	O
of	O
long	B
-	I
chain	I
aliphatic	I
alcohols	I
.	O

Docking	O
studies	O
with	O
human	O
ADH1B	O
and	O
ADH4	O
,	O
which	O
share	O
69	O
%	O
amino	B
acid	I
sequence	O
identity	O
,	O
have	O
shown	O
that	O
the	O
active	O
sites	O
of	O
both	O
enzymes	O
can	O
accommodate	O
all	B
-	I
trans	I
-retinol	I
,	O
a	O
compound	O
containing	O
a	O
long	B
-	I
chain	I
aliphatic	I
alcohol	I
group	O
[	O
51–54	O
]	O
.	O

When	O
compared	O
with	O
the	O
crystal	O
structure	O
of	O
the	O
human	O
ADH1B	O
active	O
site	O
,	O
models	O
of	O
the	O
human	O
ADH4	O
active	O
site	O
(	O
prior	O
to	O
determination	O
of	O
its	O
crystal	O
structure	O
)	O
were	O
found	O
to	O
be	O
more	O
well	O
suited	O
for	O
binding	O
of	O
all	B
-	I
trans	I
-retinol	I
due	O
to	O
alterations	O
in	O
a	O
loop	O
from	O
amino	B
acid	I
residues	O
114	O
to	O
120	O
including	O
deletion	O
of	O
Gly117	B
which	O
increases	O
the	O
width	O
of	O
the	O
active	O
site	O
[	O
52,54	O
]	O
.	O

In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
the	O
role	O
of	O
ADHs	O
in	O
retinol	B
metabolism	O
we	O
have	O
taken	O
advantage	O
of	O
the	O
recently	O
determined	O
crystal	O
structure	O
of	O
human	O
ADH4	O
which	O
can	O
now	O
be	O
directly	O
compared	O
with	O
the	O
previously	O
known	O
crystal	O
structure	O
of	O
human	O
ADH1B	O
.	O

We	O
have	O
developed	O
a	O
computer	O
-	O
aided	O
molecular	O
docking	O
strategy	O
to	O
gauge	O
the	O
ability	O
of	O
all	O
five	O
natural	O
retinols	B
discussed	O
above	O
to	O
successfully	O
dock	O
to	O
the	O
human	O
ADH1B	O
and	O
ADH4	O
active	O
sites	O
.	O

These	O
binding	O
models	O
suggest	O
that	O
ADH	O
active	O
sites	O
are	O
well	O
suited	O
to	O
play	O
a	O
role	O
in	O
the	O
metabolism	O
of	O
a	O
wide	O
variety	O
of	O
natural	O
retinols	B
,	O
and	O
support	O
a	O
broad	O
role	O
for	O
ADH	O
in	O
retinoid	B
signaling	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Structural	O
preparation	O
Modeling	O
took	O
place	O
in	O
a	O
Silicon	B
Graphics	O
Power	O
Indigo	O
R8000	O
,	O
and	O
the	O
simulations	O
were	O
performed	O
in	O
a	O
Silicon	B
Graphics	O
Challenge	O
DM	O
4xR10000	O
.	O

All	O
structures	O
were	O
visually	O
inspected	O
using	O
molecular	O
modeling	O
program	O
QUANTA	O
version	O
97.0711	O
(	O
Molecular	O
Simulations	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
structural	O
preparation	O
of	O
ADH1B	O
,	O
ADH4	O
,	O
and	O
cellular	O
retinol	B
-	O
binding	O
protein	O
II	O
(	O
CRBPII	O
)	O
needed	O
to	O
perform	O
docking	O
simulations	O
was	O
based	O
upon	O
molecular	O
docking	O
computational	O
methods	O
(	O
DOCK	O
3.5	O
)	O
developed	O
by	O
Kuntz	O
and	O
co	O
-	O
workers	O
[	O
55,56	O
]	O
.	O

Starting	O
with	O
the	O
crystal	O
structures	O
of	O
human	O
ADH1B	O
(	O
i.e.	O
the	O
β1	O
β1	O
variant	O
)	O
[	O
48	O
]	O
,	O
human	O
ADH4	O
[	O
51	O
]	O
,	O
and	O
rat	O
CRBPII	O
[	O
57	O
]	O
,	O
ligands	O
and	O
all	O
water	B
molecules	O
were	O
removed	O
from	O
the	O
binding	O
pockets	O
except	O
for	O
the	O
structural	O
waters	B
that	O
are	O
part	O
of	O
the	O
binding	O
site	O
in	O
CRBPII	O
,	O
and	O
except	O
for	O
the	O
bound	O
coenzyme	O
NAD	B
and	O
catalytic	O
zinc	B
which	O
are	O
part	O
of	O
the	O
active	O
sites	O
of	O
ADH1B	O
and	O
ADH4	O
.	O

Amino	B
acid	I
residues	O
surrounding	O
the	O
active	O
site	O
(	O
ADHs	O
)	O
or	O
binding	O
site	O
(	O
CRBPII	O
)	O
were	O
extracted	O
using	O
DOCK3.5	O
.	O

These	O
truncated	O
structures	O
were	O
used	O
for	O
all	O
further	O
computational	O
work	O
.	O

A	O
Connolly	O
molecular	O
surface	O
for	O
each	O
binding	O
pocket	O
was	O
calculated	O
to	O
identify	O
grooves	O
and	O
invaginations	O
[	O
58	O
]	O
.	O

The	O
molecular	O
surfaces	O
of	O
each	O
binding	O
pocket	O
were	O
filled	O
with	O
a	O
set	O
of	O
overlapping	O
spheres	O
of	O
different	O
radii	O
using	O
DOCK3.5	O
.	O

These	O
sphere	O
centers	O
(	O
approx	O
.	O

60–80	O
spheres	O
per	O
binding	O
site	O
)	O
represented	O
the	O
negative	O
image	O
of	O
the	O
target	O
site	O
where	O
docking	O
simulations	O
and	O
evaluation	O
of	O
quality	O
of	O
fit	O
took	O
place	O
.	O

All	O
dockings	O
were	O
performed	O
with	O
the	O
protein	O
binding	O
site	O
as	O
described	O
above	O
remaining	O
rigid	O
.	O

Structures	O
for	O
all	B
-	I
trans	I
-retinol	I
,	O
9-cis	B
-retinol	I
,	O
3,4-didehydroretinol	B
,	I
4-oxo	B
-	I
retinol	I
,	O
and	O
4-hydroxy	B
-	I
retinol	I
were	O
also	O
modeled	O
.	O

To	O
overcome	O
the	O
rigid	O
-	O
body	O
docking	O
constraint	O
,	O
we	O
generated	O
different	O
conformations	O
of	O
each	O
retinol	B
as	O
follows	O
.	O

The	O
initial	O
structures	O
were	O
modeled	O
after	O
the	O
crystallographic	O
coordinates	O
of	O
all	B
-	I
trans	I
-retinol	I
in	O
holo	O
-	O
CRBPII	O
[	O
57	O
]	O
using	O
the	O
Quanta	O
molecular	O
editor	O
module	O
.	O

Partial	O
charges	O
were	O
calculated	O
and	O
the	O
structures	O
were	O
then	O
optimized	O
using	O
the	O
molecular	O
modeling	O
system	O
InsightII	O
version	O
97.0	O
builder	O
module	O
(	O
Molecular	O
Simulations	O
)	O
by	O
minimizing	O
the	O
initial	O
structure	O
applying	O
Steepest	O
Descents	O
and	O
Quasi	O
Newton	O
methods	O
(	O
1000	O
steps	O
)	O
.	O

The	O
optimized	O
retinols	B
were	O
then	O
used	O
as	O
the	O
initial	O
structures	O
to	O
generate	O
different	O
conformations	O
throughout	O
a	O
series	O
of	O
Monte	O
Carlo	O
random	O
sampling	O
runs	O
using	O
QUANTA	O
.	O

A	O
set	O
of	O
conformations	O
for	O
each	O
retinol	B
structure	O
was	O
saved	O
in	O
protein	O
databank	O
format	O
(	O
PDB	O
)	O
and	O
then	O
converted	O
into	O
DOCK3.5	O
format	O
.	O

2.2	O
Docking	O
simulations	O
In	O
order	O
to	O
evaluate	O
the	O
goodness	O
of	O
fit	O
subsequent	O
to	O
docking	O
,	O
each	O
orientation	O
was	O
evaluated	O
based	O
on	O
its	O
shape	O
complementary	O
(	O
contact	O
score	O
)	O
and	O
molecular	O
mechanics	O
interaction	O
energy	O
(	O
force	O
field	O
score	O
)	O
.	O

Contact	O
scoring	O
uses	O
a	O
loose	O
approximation	O
to	O
the	O
Lennard	O
-	O
Jones	O
potential	O
,	O
and	O
force	O
field	O
scoring	O
uses	O
the	O
AMBER	O
potential	O
.	O

For	O
all	O
our	O
experiments	O
,	O
we	O
used	O
both	O
scoring	O
functions	O
and	O
applied	O
the	O
DOCK3.5	O
rigid	O
-	O
body	O
minimization	O
algorithm	O
to	O
optimize	O
the	O
interaction	O
energies	O
.	O

Therefore	O
,	O
grids	O
containing	O
contact	O
limits	O
,	O
electrostatic	O
values	O
,	O
Van	O
der	O
Waals	O
attraction	O
and	O
repulsion	O
values	O
were	O
calculated	O
.	O

For	O
the	O
AMBER	O
force	O
-	O
field	O
potentials	O
of	O
coenzyme	O
NAD	B
,	O
the	O
explicit	O
parameters	O
of	O
each	O
atom	O
in	O
NAD	B
were	O
added	O
to	O
the	O
DOCK	O
AMBER	O
parameters	O
based	O
on	O
previous	O
studies	O
[	O
59,60	O
]	O
.	O

Additional	O
programs	O
in	O
the	O
DOCK	O
suite	O
allowed	O
us	O
to	O
calculate	O
root	O
-	O
mean	O
-	O
square	O
deviation	O
(	O
rmsd	O
)	O
and	O
least	O
-	O
squares	O
rmsd	O
values	O
,	O
close	O
contacts	O
,	O
number	O
of	O
bumps	O
,	O
and	O
to	O
recalculate	O
contact	O
scores	O
for	O
rigid	O
-	O
body	O
minimized	O
orientations	O
.	O

Initial	O
docking	O
was	O
performed	O
in	O
the	O
search	O
mode	O
for	O
each	O
retinol	B
using	O
the	O
set	O
of	O
different	O
conformations	O
generated	O
as	O
described	O
above	O
.	O

For	O
each	O
search	O
run	O
the	O
same	O
parameters	O
were	O
used	O
in	O
addition	O
to	O
the	O
usage	O
of	O
critical	O
clusters	O
,	O
rigid	O
-	O
body	O
minimization	O
,	O
contact	O
scoring	O
,	O
and	O
force	O
field	O
scoring	O
.	O

We	O
used	O
critical	O
clusters	O
to	O
define	O
critical	O
binding	O
regions	O
,	O
thus	O
constraining	O
DOCK	O
to	O
focus	O
on	O
the	O
site	O
near	O
the	O
catalytic	O
zinc	B
in	O
ADH	O
,	O
or	O
the	O
region	O
near	O
Glu108	B
in	O
CRBPII	O
.	O

In	O
order	O
to	O
define	O
critical	O
clusters	O
,	O
the	O
closest	O
sphere	O
center	O
to	O
the	O
catalytic	O
zinc	B
(	O
ADH	O
)	O
or	O
Glu108	B
(	O
CRBPII	O
)	O
was	O
assigned	O
as	O
the	O
critical	O
cluster	O
and	O
for	O
each	O
retinol	B
C-15	O
was	O
designated	O
the	O
critical	O
atom	O
.	O

Utilizing	O
critical	O
clusters	O
DOCK	O
eliminated	O
all	O
conformations	O
that	O
failed	O
to	O
achieve	O
a	O
distance	O
of	O
at	O
least	O
1.5	O
Å	O
between	O
the	O
critical	O
cluster	O
and	O
retinol	B
C-15	O
.	O

In	O
ADH1B	O
the	O
critical	O
region	O
was	O
equivalent	O
to	O
the	O
area	O
where	O
a	O
water	B
molecule	O
is	O
coordinated	O
by	O
the	O
catalytic	O
zinc	B
in	O
the	O
crystal	O
structure	O
[	O
47	O
]	O
.	O

For	O
retinol	B
orientations	O
having	O
a	O
contact	O
score	O
>	O
0	O
and	O
a	O
force	O
field	O
score	O
<	O
10	O
kcal	O
/	O
mol	O
,	O
the	O
orientation	O
was	O
rigid	O
-	O
body	O
minimized	O
and	O
evaluated	O
again	O
for	O
the	O
contact	O
score	O
and	O
force	O
field	O
score	O
.	O

Also	O
,	O
for	O
dockings	O
with	O
ADH1B	O
and	O
ADH4	O
,	O
the	O
NAD	B
,	O
zinc	B
,	O
and	O
Thr48	B
distances	O
were	O
calculated	O
,	O
i.e.	O
NAD	B
C-4	O
to	O
retinol	B
C-15	O
,	O
catalytic	O
zinc	O
to	O
retinol	B
hydroxyl	B
group	I
,	O
and	O
Thr48	B
hydroxyl	B
group	I
to	O
retinol	B
hydroxyl	B
group	I
,	O
respectively	O
.	O

In	O
the	O
case	O
of	O
CRBPII	O
dockings	O
,	O
the	O
Glu108	B
distance	O
was	O
calculated	O
,	O
i.e.	O
Glu108	B
amide	B
group	O
to	O
retinol	B
hydroxyl	B
group	I
.	O

The	O
results	O
were	O
analyzed	O
using	O
program	O
X	O
-	O
Motif	O
Graphics	O
to	O
determinate	O
which	O
retinol	B
conformation	O
achieved	O
the	O
best	O
orientation	O
for	O
each	O
protein	O
examined	O
.	O

Potential	O
candidates	O
were	O
visually	O
inspected	O
to	O
identify	O
location	O
of	O
bumps	O
and	O
potential	O
hydrogen	B
bonds	O
if	O
any	O
.	O

The	O
selected	O
retinol	B
conformation	O
with	O
the	O
best	O
orientation	O
inside	O
the	O
active	O
site	O
was	O
energy	O
minimized	O
using	O
QUANTA	O
CHARMm	O
module	O
.	O

To	O
do	O
this	O
we	O
constrained	O
all	O
non	O
-	O
hydrogen	B
atoms	O
in	O
the	O
protein	O
,	O
and	O
allowed	O
the	O
selected	O
conformation	O
to	O
be	O
optimized	O
by	O
applying	O
Steepest	O
Descents	O
(	O
1000	O
steps	O
)	O
.	O

As	O
a	O
final	O
step	O
the	O
optimized	O
conformation	O
determined	O
for	O
each	O
retinol	B
was	O
re	O
-	O
docked	O
to	O
gain	O
more	O
information	O
about	O
potential	O
orientations	O
within	O
each	O
protein	O
binding	O
site	O
.	O

The	O
final	O
docking	O
was	O
performed	O
using	O
single	O
mode	O
,	O
critical	O
clusters	O
,	O
rigid	O
-	O
body	O
minimization	O
,	O
contact	O
scoring	O
,	O
and	O
force	O
field	O
scoring	O
.	O

In	O
this	O
run	O
DOCK3.5	O
was	O
constrained	O
to	O
select	O
only	O
those	O
orientations	O
achieving	O
a	O
force	O
field	O
score	O
≤0	O
kcal	O
/	O
mol	O
and	O
no	O
more	O
than	O
one	O
bump	O
per	O
orientation	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Test	O
of	O
retinol	O
docking	O
strategy	O
The	O
three	O
-	O
dimensional	O
structure	O
of	O
a	O
high	O
-	O
affinity	O
complex	O
between	O
all	B
-	I
trans	I
-retinol	I
and	O
cellular	O
retinol	B
-	O
binding	O
protein	O
type	O
II	O
(	O
holo	O
-	O
CRBPII	O
)	O
has	O
been	O
determined	O
to	O
a	O
resolution	O
of	O
1.9	O
Å	O
[	O
57	O
]	O
.	O

As	O
a	O
test	O
of	O
our	O
molecular	O
docking	O
strategy	O
(	O
see	O
Section	O
2	O
)	O
all	B
-	I
trans	I
-retinol	I
was	O
removed	O
from	O
the	O
complex	O
and	O
docking	O
experiments	O
between	O
it	O
and	O
CRBPII	O
were	O
performed	O
using	O
DOCK3.5	O
.	O

The	O
unchanged	O
conformation	O
of	O
all	B
-	I
trans	I
-retinol	I
derived	O
from	O
the	O
crystal	O
structure	O
was	O
successfully	O
docked	O
to	O
CRBPII	O
as	O
determined	O
by	O
achieving	O
a	O
rmsd	O
of	O
0.19	O
Å	O
compared	O
to	O
the	O
crystal	O
structure	O
which	O
was	O
resolved	O
to	O
1.9	O
Å.	O
A	O
set	O
of	O
all	B
-	I
trans	I
-retinol	I
conformations	O
derived	O
by	O
Monte	O
Carlo	O
random	O
sampling	O
were	O
also	O
docked	O
to	O
CRBPII	O
,	O
resulting	O
in	O
an	O
orientation	O
with	O
a	O
rmsd	O
value	O
of	O
0.39	O
Å	O
relative	O
to	O
the	O
crystal	O
structure	O
.	O

The	O
conformation	O
of	O
all	B
-	I
trans	I
-retinol	I
present	O
in	O
this	O
latter	O
docked	O
orientation	O
was	O
quite	O
similar	O
to	O
that	O
in	O
the	O
crystal	O
structure	O
as	O
shown	O
by	O
a	O
least	O
-	O
squares	O
rmsd	O
value	O
of	O
0.37	O
Å.	O
Docking	O
to	O
CRBPII	O
was	O
also	O
performed	O
with	O
a	O
set	O
of	O
Monte	O
Carlo	O
random	O
sampling	O
conformations	O
generated	O
for	O
9-cis	B
-retinol	I
,	O
3,4-didehydroretinol	B
,	O
4-oxo	B
-	I
retinol	I
,	O
and	O
4-hydroxy	B
-	I
retinol	I
,	O
and	O
the	O
results	O
were	O
compared	O
to	O
those	O
for	O
all	B
-	I
trans	I
-retinol	I
(	O
Fig.	O
1	O
)	O
.	O

The	O
most	O
favorable	O
conformation	O
and	O
docked	O
orientation	O
for	O
each	O
retinol	B
structure	O
were	O
selected	O
using	O
the	O
criteria	O
of	O
force	O
field	O
score	O
,	O
contact	O
score	O
,	O
and	O
distance	O
to	O
amino	B
acid	I
residue	O
Gln108	B
(	O
Table	O
1	O
)	O
.	O

A	O
critical	O
measure	O
of	O
the	O
docking	O
efficiency	O
was	O
the	O
attainment	O
of	O
a	O
distance	O
of	O
2.98	O
Å	O
between	O
the	O
hydroxyl	B
group	I
of	O
all	B
-	I
trans	I
-retinol	I
and	O
the	O
side	O
chain	O
amide	B
group	O
of	O
Gln108	B
in	O
CRBPII	O
,	O
a	O
distance	O
nearly	O
identical	O
to	O
that	O
in	O
the	O
crystal	O
structure	O
of	O
holo	O
-	O
CRBPII	O
(	O
3.02	O
Å	O
)	O
.	O

This	O
close	O
proximity	O
allows	O
the	O
formation	O
of	O
a	O
hydrogen	B
bond	O
important	O
for	O
high	O
affinity	O
binding	O
in	O
holo	O
-	O
CRBPII	O
[	O
57	O
]	O
.	O

Also	O
,	O
the	O
docked	O
all	B
-	I
trans	I
-retinol	I
had	O
a	O
force	O
field	O
score	O
of	O
−29.9	O
kcal	O
/	O
mol	O
and	O
a	O
contact	O
score	O
of	O
110	O
,	O
values	O
nearly	O
identical	O
to	O
those	O
observed	O
in	O
the	O
holo	O
-	O
CRBPII	O
crystal	O
structure	O
(	O
−27.0	O
kcal	O
/	O
mol	O
and	O
105	O
,	O
respectively	O
)	O
(	O
Table	O
1	O
)	O
.	O

The	O
most	O
favorable	O
docking	O
obtained	O
with	O
9-cis	B
-retinol	I
gave	O
a	O
hydroxyl	B
-	O
Gln108	B
distance	O
of	O
3.52	O
Å	O
(	O
too	O
large	O
for	O
a	O
hydrogen	B
bond	O
)	O
,	O
whereas	O
the	O
most	O
favorable	O
docking	O
achieved	O
for	O
3,4-didehydroretinol	B
gave	O
a	O
hydroxyl	B
-	O
Gln108	B
distance	O
of	O
3.00	O
Å	O
,	O
nearly	O
identical	O
to	O
that	O
for	O
all	B
-	I
trans	I
-retinol	I
(	O
Table	O
1	O
)	O
.	O

Also	O
,	O
the	O
docked	O
9-cis	B
-retinol	I
had	O
a	O
significantly	O
higher	O
force	O
field	O
score	O
(	O
−21.0	O
kcal	O
/	O
mol	O
)	O
than	O
that	O
observed	O
for	O
3,4-didehydroretinol	B
(	O
−27.9	O
kcal	O
/	O
mol	O
)	O
or	O
all	B
-	I
trans	I
-retinol	I
(	O
−29.9	O
kcal	O
/	O
mol	O
)	O
,	O
further	O
indicating	O
that	O
the	O
9-cis	O
conformation	O
is	O
unfavorable	O
for	O
reaching	O
the	O
CRBPII	O
binding	O
site	O
.	O

These	O
results	O
provide	O
another	O
validation	O
of	O
our	O
docking	O
strategy	O
since	O
previous	O
in	O
vitro	O
binding	O
studies	O
have	O
clearly	O
shown	O
that	O
9-cis	B
-retinol	I
has	O
no	O
detectable	O
binding	O
to	O
CRBPII	O
whereas	O
3,4-didehydroretinol	B
does	O
bind	O
with	O
high	O
affinity	O
similar	O
to	O
all	B
-	I
trans	I
-retinol	I
[	O
61	O
]	O
.	O

Docking	O
of	O
4-oxo	B
-	I
retinol	I
and	O
4-hydroxy	B
-	I
retinol	I
to	O
CRBPII	O
resulted	O
in	O
hydroxyl	B
-	O
Gln108	B
distances	O
of	O
2.91	O
Å	O
and	O
2.90	O
Å	O
,	O
respectively	O
,	O
and	O
force	O
field	O
scores	O
of	O
−28.7	O
kcal	O
/	O
mol	O
and	O
−30.2	O
kcal	O
/	O
mol	O
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
docking	O
of	O
these	O
two	O
oxygenated	B
retinols	B
is	O
quite	O
favorable	O
.	O

No	O
in	O
vitro	O
binding	O
data	O
for	O
CRBPII	O
with	O
either	O
4-oxo	B
-	I
retinol	I
or	O
4-hydroxy	B
-	I
retinol	I
was	O
found	O
in	O
the	O
literature	O
.	O

Our	O
docking	O
models	O
predict	O
that	O
4-oxo	B
-	I
retinol	I
and	O
4-hydroxy	B
-	I
retinol	I
,	I
like	O
all	B
-	I
trans	I
-retinol	I
and	O
3,4-didehydroretinol	B
,	O
will	O
demonstrate	O
high	O
affinity	O
binding	O
to	O
CRBPII	O
.	O

3.2	O
Docking	O
of	O
retinols	B
to	O
human	O
ADH1B	O
and	O
ADH4	O
The	O
docking	O
methods	O
discussed	O
above	O
,	O
which	O
proved	O
successful	O
for	O
CRBPII	O
,	O
were	O
used	O
to	O
dock	O
all	B
-	I
trans	I
-retinol	I
,	O
9-cis	B
-retinol	I
,	O
3,4-didehydroretinol	B
,	O
4-oxo	B
-	I
retinol	I
,	I
and	O
4-hydroxy	B
-	I
retinol	I
to	O
the	O
active	O
sites	O
of	O
human	O
ADH1B	O
and	O
ADH4	O
.	O

The	O
three	O
-	O
dimensional	O
structures	O
for	O
each	O
active	O
site	O
were	O
based	O
upon	O
recent	O
X	O
-	O
ray	O
crystallographic	O
studies	O
of	O
ADH1B	O
determined	O
to	O
a	O
resolution	O
of	O
2.5	O
Å	O
[	O
48	O
]	O
and	O
ADH4	O
determined	O
to	O
a	O
resolution	O
of	O
3.0	O
Å	O
[	O
51	O
]	O
.	O

Docking	O
was	O
performed	O
with	O
the	O
same	O
set	O
of	O
Monte	O
Carlo	O
random	O
sampling	O
conformations	O
generated	O
for	O
each	O
retinol	B
structure	O
above	O
.	O

In	O
order	O
to	O
obtain	O
an	O
unbiased	O
view	O
of	O
the	O
success	O
of	O
docking	O
,	O
all	O
docked	O
orientations	O
with	O
force	O
field	O
scores	O
0	O
kcal	O
/	O
mol	O
and	O
contact	O
scores	O
>	O
0	O
were	O
examined	O
for	O
their	O
proximity	O
to	O
the	O
catalytic	O
zinc	B
atom	O
(	O
which	O
functions	O
in	O
orientation	O
of	O
the	O
alcohol	B
group	O
)	O
and	O
bound	O
NAD	B
coenzyme	O
(	O
which	O
functions	O
in	O
hydride	B
transfer	O
during	O
alcohol	B
oxidation	O
)	O
[	O
48,51	O
]	O
.	O

The	O
orientations	O
obtained	O
for	O
each	O
retinol	B
substrate	O
inside	O
the	O
active	O
sites	O
of	O
either	O
ADH1B	O
or	O
ADH4	O
were	O
plotted	O
with	O
respect	O
to	O
the	O
distances	O
between	O
the	O
catalytic	O
zinc	B
and	O
the	O
substrate	O
hydroxyl	B
oxygen	B
(	O
zinc	B
distance	O
)	O
versus	O
the	O
distances	O
between	O
NAD	B
C-4	O
and	O
substrate	O
C-15	O
which	O
donates	O
the	O
hydrogen	B
to	O
NAD	B
during	O
hydride	B
transfer	O
(	O
NAD	B
distance	O
)	O
.	O

Linear	O
regression	O
analysis	O
of	O
these	O
results	O
show	O
that	O
all	O
retinols	B
examined	O
(	O
each	O
approx	O
.	O

15	O
Å	O
in	O
length	O
)	O
can	O
enter	O
and	O
dock	O
along	O
at	O
least	O
some	O
portion	O
of	O
the	O
ADH1B	O
and	O
ADH4	O
active	O
sites	O
,	O
both	O
of	O
which	O
stretch	O
approx	O
.	O

16	O
Å	O
from	O
the	O
enzyme	O
surface	O
to	O
the	O
catalytic	O
zinc	B
(	O
Fig.	O
2	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
9-cis	B
-retinol	I
and	O
3,4-didehydroretinol	B
are	O
unable	O
to	O
dock	O
close	O
to	O
the	O
catalytic	O
zinc	B
of	O
ADH1B	O
since	O
their	O
closest	O
zinc	B
distances	O
ranged	O
from	O
5.3	O
to	O
5.9	O
Å	O
and	O
their	O
closest	O
NAD	B
distances	O
ranged	O
from	O
4.5	O
to	O
4.7	O
Å	O
(	O
Fig.	O
2B	O
,	O
C	O
)	O
.	O

However	O
,	O
all	O
other	O
retinol	B
-	O
ADH	O
combinations	O
underwent	O
much	O
more	O
favorable	O
docking	O
since	O
the	O
closest	O
zinc	B
distances	O
ranged	O
from	O
1.9	O
to	O
2.4	O
Å	O
and	O
the	O
closest	O
NAD	B
distances	O
ranged	O
from	O
3.2	O
to	O
3.6	O
Å	O
(	O
Fig.	O
2A	O
,	O
D	O
,	O
E	O
)	O
.	O

These	O
latter	O
distances	O
would	O
place	O
the	O
retinol	B
structure	O
in	O
a	O
favorable	O
position	O
for	O
hydride	B
transfer	O
as	O
shown	O
by	O
previous	O
ADH	B
crystallographic	O
studies	O
[	O
62	O
]	O
.	O

Logarithmic	O
regression	O
plots	O
of	O
the	O
zinc	B
distances	O
versus	O
the	O
contact	O
scores	O
for	O
each	O
retinol	B
-	O
ADH	O
combination	O
show	O
that	O
docked	O
orientations	O
which	O
are	O
closer	O
to	O
the	O
zinc	B
show	O
higher	O
,	O
more	O
favorable	O
contact	O
scores	O
for	O
both	O
enzyme	O
active	O
sites	O
(	O
Fig.	O
3	O
)	O
,	O
thus	O
illustrating	O
the	O
lock	O
-	O
and	O
-	O
key	O
concept	O
between	O
substrate	O
and	O
enzyme	O
.	O

Logarithmic	O
regression	O
plots	O
of	O
the	O
zinc	B
distances	O
versus	O
the	O
force	O
field	O
scores	O
show	O
that	O
ADH1B	O
and	O
ADH4	O
differ	O
markedly	O
in	O
the	O
energy	O
of	O
docked	O
orientations	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
the	O
case	O
of	O
all	B
-	I
trans	I
-retinol	I
docked	O
in	O
the	O
ADH1B	O
active	O
site	O
,	O
it	O
can	O
be	O
seen	O
that	O
docked	O
orientations	O
which	O
are	O
closer	O
to	O
the	O
catalytic	O
zinc	B
have	O
higher	O
(	O
less	O
favorable	O
)	O
energies	O
than	O
those	O
further	O
away	O
,	O
whereas	O
the	O
reverse	O
is	O
true	O
for	O
docking	O
in	O
the	O
ADH4	O
active	O
site	O
(	O
Fig.	O
4A	O
)	O
.	O

For	O
9-cis	B
-retinol	I
there	O
is	O
no	O
significant	O
change	O
in	O
energy	O
as	O
it	O
approaches	O
the	O
catalytic	O
zinc	B
of	O
ADH1B	O
,	O
but	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
energy	O
as	O
9-cis	B
-retinol	I
approaches	O
the	O
catalytic	O
zinc	B
of	O
ADH4	O
as	O
well	O
as	O
a	O
closer	O
approach	O
(	O
Fig.	O
4B	O
)	O
.	O

For	O
3,4-didehydroretinol	B
it	O
is	O
observed	O
that	O
force	O
field	O
scores	O
rise	O
sharply	O
for	O
docked	O
orientations	O
as	O
they	O
approach	O
the	O
catalytic	O
zinc	B
of	O
ADH1B	O
,	O
but	O
a	O
significant	O
decrease	O
in	O
force	O
field	O
scores	O
is	O
observed	O
for	O
ADH4	O
docking	O
(	O
Fig.	O
4C	O
)	O
.	O

In	O
contrast	O
,	O
4-oxo	B
-	I
retinol	I
and	O
4-hydroxy	B
-	I
retinol	I
docked	O
orientations	O
show	O
a	O
drop	O
in	O
their	O
force	O
field	O
scores	O
for	O
both	O
enzymes	O
as	O
these	O
substrates	O
approach	O
the	O
catalytic	O
zinc	B
(	O
Fig.	O
4D	O
,	O
E	O
)	O
.	O

3.3	O
Most	O
favorable	O
orientations	O
of	O
docked	O
retinols	B
relative	O
to	O
the	O
catalytic	O
zinc	B
,	O
NAD	B
,	O
and	O
Thr48	B
Docking	O
results	O
for	O
the	O
most	O
favorable	O
orientation	O
of	O
each	O
retinol	B
in	O
either	O
the	O
ADH1B	O
or	O
the	O
ADH4	O
active	O
sites	O
are	O
shown	O
(	O
Table	O
2	O
)	O
.	O

The	O
zinc	B
and	O
NAD	B
distances	O
are	O
indicated	O
as	O
well	O
as	O
the	O
distances	O
between	O
the	O
substrate	O
hydroxyl	B
group	I
and	O
Thr48	B
which	O
form	O
a	O
hydrogen	B
bond	O
[	O
62	O
]	O
.	O

With	O
the	O
exception	O
of	O
9-cis	B
-retinol	I
and	O
3,4-didehydroretinol	B
in	O
the	O
ADH1B	O
active	O
site	O
,	O
all	O
these	O
docked	O
structures	O
exhibit	O
distances	O
from	O
the	O
catalytic	O
zinc	B
(	O
1.9–2.4	O
Å	O
)	O
,	O
NAD	B
(	O
3.2–3.6	O
Å	O
)	O
,	O
and	O
Thr48	B
(	O
2.6–3.1	O
Å	O
)	O
which	O
favorably	O
orient	O
the	O
substrate	O
hydroxyl	B
group	I
and	O
adjacent	O
C-15	O
for	O
hydride	B
transfer	O
from	O
C-15	O
of	O
the	O
substrate	O
to	O
C-4	O
of	O
NAD	B
.	O

Docking	O
of	O
9-cis	B
-retinol	I
and	O
3,4-didehydroretinol	B
in	O
the	O
ADH1B	O
active	O
site	O
results	O
in	O
orientations	O
unfavorable	O
for	O
alcohol	B
oxidation	O
since	O
the	O
closest	O
distances	O
from	O
the	O
catalytic	O
zinc	B
(	O
5.3–5.9	O
Å	O
)	O
,	O
NAD	B
(	O
4.5–4.7	O
Å	O
)	O
,	O
and	O
Thr48	B
(	O
4.6–4.9	O
Å	O
)	O
were	O
too	O
far	O
to	O
promote	O
hydride	B
transfer	O
.	O

The	O
force	O
field	O
scores	O
and	O
contact	O
scores	O
for	O
these	O
most	O
favorable	O
orientations	O
provide	O
a	O
good	O
indication	O
of	O
the	O
relative	O
docking	O
abilities	O
of	O
ADH1B	O
and	O
ADH4	O
.	O

The	O
force	O
field	O
scores	O
for	O
all	O
five	O
retinols	B
examined	O
were	O
much	O
more	O
favorable	O
when	O
docked	O
to	O
ADH4	O
(	O
−22.3	O
to	O
−27.5	O
kcal	O
/	O
mol	O
)	O
as	O
opposed	O
to	O
ADH1B	O
(	O
−1.2	O
to	O
−14.0	O
kcal	O
/	O
mol	O
)	O
(	O
Table	O
2	O
)	O
.	O

Also	O
,	O
for	O
all	O
retinols	B
except	O
4-oxo	B
-	I
retinol	I
the	O
contact	O
scores	O
were	O
higher	O
when	O
docked	O
to	O
ADH4	O
rather	O
than	O
ADH1B	O
(	O
Table	O
2	O
)	O
.	O

Computer	O
-	O
generated	O
images	O
of	O
the	O
most	O
favorable	O
docked	O
orientations	O
for	O
all	B
-	I
trans	I
-retinol	I
,	O
9-cis	B
-retinol	I
,	O
3,4-didehydroretinol	B
,	O
and	O
4-oxo	B
-	I
retinol	I
are	O
shown	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
docked	O
structures	O
for	O
4-oxo	B
-	I
retinol	I
and	O
4-hydroxy	B
-	I
retinol	I
were	O
essentially	O
identical	O
(	O
image	O
not	O
shown	O
for	O
the	O
latter	O
)	O
.	O

It	O
is	O
seen	O
that	O
the	O
ADH4	O
active	O
site	O
is	O
wider	O
than	O
that	O
of	O
ADH1B	O
as	O
reported	O
previously	O
[	O
51	O
]	O
.	O

The	O
images	O
clearly	O
show	O
that	O
all	B
-	I
trans	I
-retinol	I
and	O
4-oxo	B
-	I
retinol	I
gain	O
close	O
access	O
to	O
the	O
ADH1B	O
catalytic	O
zinc	B
and	O
NAD	B
as	O
well	O
as	O
Thr48	B
which	O
is	O
hydrogen	B
-	O
bonded	O
to	O
the	O
substrate	O
hydroxyl	B
(	O
Fig.	O
5A	O
,	O
D	O
)	O
.	O

In	O
contrast	O
,	O
9-cis	B
-retinol	I
and	O
3,4-didehydroretinol	B
can	O
not	O
fully	O
enter	O
the	O
ADH1B	O
active	O
site	O
,	O
having	O
zinc	B
,	O
NAD	B
,	O
and	O
Thr48	B
distances	O
all	O
in	O
excess	O
of	O
4.5	O
Å	O
(	O
Fig.	O
5B	O
,	O
C	O
)	O
.	O

In	O
the	O
case	O
of	O
the	O
ADH4	O
active	O
site	O
it	O
is	O
seen	O
quite	O
clearly	O
that	O
all	O
four	O
retinol	B
structures	O
dock	O
closely	O
to	O
the	O
catalytic	O
zinc	B
,	O
NAD	B
,	O
and	O
Thr48	B
(	O
Fig.	O
5E	O
–	O
H	O
)	O
.	O

3.4	O
ADH4	O
has	O
a	O
more	O
favorable	O
retinol	B
-	O
binding	O
site	O
than	O
ADH1B	O
The	O
much	O
lower	O
force	O
field	O
scores	O
attained	O
for	O
docking	O
of	O
all	O
five	O
retinols	B
in	O
the	O
ADH4	O
active	O
site	O
relative	O
to	O
the	O
ADH1B	O
active	O
site	O
,	O
as	O
well	O
as	O
the	O
ability	O
of	O
9-cis	B
-retinol	I
and	O
3,4-didehydroretinol	B
to	O
closely	O
approach	O
the	O
catalytic	O
zinc	B
only	O
in	O
ADH4	O
,	O
indicate	O
that	O
ADH4	O
is	O
more	O
well	O
designed	O
for	O
binding	O
diverse	O
retinols	B
.	O

This	O
correlates	O
with	O
in	O
vitro	O
enzymatic	O
activity	O
assays	O
for	O
oxidation	O
of	O
all	B
-	I
trans	I
-retinol	I
indicating	O
catalytic	O
efficiencies	O
for	O
human	O
ADH4	O
of	O
1.9–4.5	O
μM−1	O
min−1	O
and	O
for	O
human	O
ADH1B	O
(	O
β1	O
β1	O
)	O
of	O
0.02–0.04	O
μM−1	O
min−1	O
,	O
a	O
difference	O
of	O
approx	O
.	O

100-fold	O
[	O
5,7	O
]	O
.	O

Interestingly	O
,	O
the	O
β2	O
β2	O
variant	O
of	O
human	O
ADH1B	O
(	O
which	O
differs	O
from	O
β1	O
β1	O
only	O
by	O
having	O
histidine	B
at	O
residue	O
47	O
rather	O
than	O
arginine	B
)	O
has	O
been	O
reported	O
to	O
have	O
a	O
catalytic	O
efficiency	O
for	O
retinol	B
oxidation	O
of	O
1.8	O
μM−1	O
min−1	O
,	O
thus	O
only	O
about	O
2-fold	O
less	O
than	O
ADH4	O
[	O
9	O
]	O
.	O

However	O
,	O
another	O
report	O
indicates	O
that	O
the	O
catalytic	O
efficiency	O
for	O
β2	O
β2	O
is	O
0.18	O
μM−1	O
min−1	O
using	O
different	O
assay	O
conditions	O
,	O
thus	O
still	O
about	O
20-fold	O
less	O
active	O
than	O
ADH4	O
[	O
7	O
]	O
.	O

In	O
either	O
case	O
the	O
β2	O
β2	O
variant	O
is	O
more	O
active	O
for	O
retinol	B
oxidation	O
than	O
the	O
β1	O
β1	O
variant	O
.	O

This	O
may	O
be	O
due	O
to	O
less	O
tight	O
binding	O
of	O
NAD	B
by	O
β2	O
β2	O
leading	O
to	O
a	O
faster	O
turnover	O
rate	O
since	O
residue	O
47	O
is	O
involved	O
in	O
coenzyme	O
binding	O
[	O
48	O
]	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
ability	O
of	O
ADHs	O
to	O
use	O
retinol	B
is	O
governed	O
not	O
only	O
by	O
the	O
overall	O
size	O
of	O
the	O
active	O
site	O
,	O
but	O
also	O
by	O
residue	O
47	O
lying	O
immediately	O
adjacent	O
to	O
the	O
active	O
site	O
residue	O
Thr48	B
.	O

Enzyme	O
activity	O
assays	O
with	O
9-cis	B
-retinol	I
and	O
9-cis	B
-retinal	I
have	O
shown	O
that	O
human	O
ADH4	O
is	O
very	O
active	O
with	O
these	O
substrates	O
demonstrating	O
catalytic	O
efficiencies	O
of	O
9.0–13.3	O
μM−1	O
min−1	O
[	O
8	O
]	O
,	O
whereas	O
human	O
ADH1B	O
has	O
nearly	O
undetectable	O
activity	O
for	O
9-cis	B
-retinal	I
demonstrating	O
a	O
catalytic	O
efficiency	O
of	O
only	O
0.0084	O
μM−1	O
min−1	O
[	O
5	O
]	O
.	O

Our	O
docking	O
models	O
predict	O
that	O
both	O
9-cis	B
-retinol	I
and	O
3,4-didehydroretinol	B
can	O
function	O
as	O
very	O
good	O
substrates	O
for	O
ADH4	O
,	O
but	O
not	O
for	O
ADH1B	O
.	O

Our	O
models	O
further	O
predict	O
that	O
4-oxo	B
-	I
retinol	I
and	O
4-hydroxy	B
-	I
retinol	I
can	O
function	O
as	O
substrates	O
for	O
both	O
enzymes	O
with	O
ADH4	O
having	O
a	O
much	O
higher	O
catalytic	O
efficiency	O
as	O
is	O
the	O
case	O
for	O
all	B
-	I
trans	I
-retinol	I
.	O

Our	O
findings	O
indicate	O
that	O
9-cis	B
-retinol	I
and	O
3,4-didehydroretinol	B
can	O
not	O
assume	O
conformations	O
which	O
allow	O
full	O
access	O
into	O
the	O
relatively	O
narrow	O
ADH1B	O
active	O
site	O
.	O

In	O
the	O
case	O
of	O
9-cis	B
-retinoids	I
it	O
is	O
already	O
clear	O
that	O
the	O
presence	O
of	O
a	O
cis	O
as	O
opposed	O
to	O
a	O
trans	O
double	O
bond	O
configuration	O
at	O
C-9	O
has	O
a	O
significant	O
effect	O
upon	O
the	O
ability	O
of	O
the	O
carboxylic	B
acid	I
forms	O
to	O
bind	O
to	O
retinoid	B
X	O
receptors	O
which	O
have	O
a	O
strong	O
selectivity	O
for	O
9-cis	B
-retinoic	I
acid	I
over	O
all	B
-	I
trans	I
-retinoic	I
acid	I
[	O
37,38	O
]	O
.	O

Our	O
docking	O
models	O
predict	O
that	O
ADH1B	O
has	O
a	O
selectivity	O
for	O
trans	B
as	O
opposed	O
to	O
cis	B
retinol	I
substrates	O
.	O

The	O
inability	O
of	O
9-cis	B
-retinol	I
to	O
enter	O
the	O
ADH1B	O
active	O
site	O
may	O
be	O
due	O
to	O
steric	O
hindrance	O
of	O
the	O
C-19	O
methyl	B
group	I
(	O
Fig.	O
5B	O
)	O
.	O

This	O
situation	O
is	O
not	O
true	O
for	O
ADH4	O
which	O
has	O
a	O
wider	O
active	O
site	O
than	O
ADH1B	O
due	O
to	O
deletion	O
of	O
Gly117	B
and	O
substitution	O
of	O
Leu	B
for	O
Tyr110	B
[	O
52,54	O
]	O
leading	O
to	O
an	O
accommodation	O
of	O
the	O
C-19	O
methyl	B
group	I
of	O
9-cis	B
-retinol	I
(	O
Fig.	O
5F	O
)	O
.	O

However	O
,	O
the	O
inability	O
of	O
3,4-didehydroretinol	B
to	O
fully	O
enter	O
the	O
ADH1B	O
active	O
site	O
is	O
less	O
obvious	O
.	O

We	O
suggest	O
that	O
the	O
presence	O
of	O
the	O
extra	O
double	O
bond	O
in	O
the	O
ring	O
structure	O
of	O
3,4-didehydroretinol	B
produces	O
a	O
smaller	O
ring	O
configuration	O
which	O
is	O
more	O
conformationally	O
restrictive	O
,	O
thus	O
placing	O
the	O
C-19	O
methyl	B
group	I
in	O
an	O
unfavorable	O
position	O
for	O
entry	O
into	O
the	O
narrow	O
ADH1B	O
active	O
site	O
(	O
Fig.	O
5C	O
)	O
but	O
without	O
restricting	O
access	O
to	O
the	O
wider	O
ADH4	O
active	O
site	O
(	O
Fig.	O
5	O
G	O
)	O
.	O

3.5	O
Conclusions	O
The	O
retinol	B
docking	O
strategy	O
described	O
here	O
has	O
provided	O
results	O
which	O
are	O
consistent	O
with	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
holo	O
-	O
CRBPII	O
[	O
57	O
]	O
,	O
with	O
the	O
known	O
binding	O
properties	O
of	O
CRBPII	O
for	O
all	B
-	I
trans	I
-retinol	I
,	O
9-cis	B
-retinol	I
,	I
and	O
3,4-didehydroretinol	B
[	O
61	O
]	O
,	O
and	O
with	O
the	O
enzymatic	O
properties	O
of	O
ADH1B	O
and	O
ADH4	O
for	O
all	B
-	I
trans	I
-retinol	I
and	O
9-cis	B
-retinol	I
[	O
5,8,52	O
]	O
.	O

The	O
studies	O
reported	O
here	O
use	O
the	O
known	O
crystal	O
structures	O
for	O
both	O
ADH1B	O
and	O
ADH4	O
,	O
and	O
demonstrate	O
that	O
the	O
ADH4	O
active	O
site	O
is	O
well	O
suited	O
to	O
bind	O
all	B
-	I
trans	I
-retinol	I
,	I
9-cis	B
-retinol	I
,	O
3,4-didehydroretinol	B
,	O
4-oxo	B
-	I
retinol	I
,	O
and	O
4-hydroxy	B
-	I
retinol	I
,	O
whereas	O
ADH1B	O
has	O
a	O
more	O
restrictive	O
active	O
site	O
which	O
will	O
accommodate	O
only	O
all	B
-	I
trans	I
-retinol	I
,	O
4-oxo	B
-	I
retinol	I
,	O
and	O
4-hydroxy	B
-	I
retinol	I
,	O
and	O
these	O
to	O
a	O
lesser	O
extent	O
than	O
ADH4	O
.	O

This	O
suggests	O
that	O
ADH4	O
plays	O
a	O
major	O
role	O
in	O
the	O
metabolism	O
of	O
a	O
diverse	O
array	O
of	O
natural	O
retinol	B
structures	O
implicated	O
as	O
precursors	O
for	O
the	O
active	O
retinoid	O
receptor	O
ligands	O
all	B
-	I
trans	I
-retinoic	I
acid	I
,	O
9-cis	B
-retinoic	I
acid	I
,	O
3,4-didehydroretinoic	B
acid	I
,	O
4-oxo	B
-	I
retinoic	I
acid	I
,	O
and	O
4-hydroxy	B
-	I
retinoic	I
acid	I
.	O

The	O
docking	O
models	O
suggest	O
that	O
ADH1B	O
plays	O
only	O
a	O
minor	O
role	O
if	O
any	O
in	O
the	O
metabolism	O
of	O
9-cis	B
-retinol	I
or	O
3,4-didehydroretinol	B
,	O
and	O
that	O
this	O
enzyme	O
is	O
more	O
likely	O
to	O
participate	O
in	O
the	O
metabolism	O
of	O
4-oxo	B
-	I
retinol	I
,	I
4-hydroxy	B
-	I
retinol	I
,	O
and	O
to	O
a	O
lesser	O
extent	O
all	B
-	I
trans	I
-retinol	I
.	O

The	O
ability	O
of	O
ADH1B	O
and	O
ADH4	O
active	O
sites	O
to	O
accommodate	O
various	O
retinol	B
substrates	O
provides	O
impetus	O
to	O
further	O
examine	O
how	O
broad	O
a	O
role	O
ADH	O
plays	O
in	O
the	O
production	O
of	O
active	O
ligands	O
for	O
retinoid	B
signaling	O
.	O

Acknowledgements	O

We	O
thank	O
H.L.	O
Ang	O
,	O
L.	O
Deltour	O
,	O
R.J.	O
Haselbeck	O
,	O
and	O
I.	O
Hoffmann	O
for	O
critical	O
discussions	O
,	O
and	O
D.	O
Zimmerman	O
in	O
the	O
Burnham	O
Institute	O
Computer	O
Resources	O
Department	O
for	O
computational	O
expertise	O
.	O

This	O
work	O
was	O
supported	O
by	O
National	O
Institutes	O
of	O
Health	O
Grant	O
AA07261	O
.	O

Pyrethroids	B
belong	O
to	O
the	O
most	O
frequently	O
used	O
pesticides	O
.	O

People	O
exposed	O
to	O
pyrethroids	B
do	O
not	O
only	O
include	O
workers	O
in	O
the	O
chemical	B
industry	O
(	O
production	O
,	O
filling	O
,	O
formulation	O
)	O
,	O
farmers	O
and	O
pest	O
control	O
operators	O
but	O
also	O
the	O
consumers	O
.	O

In	O
humans	O
,	O
pyrethroids	B
are	O
rapidly	O
metabolised	O
by	O
esterases	O
,	O
mainly	O
in	O
the	O
liver	O
.	O

The	O
detoxified	O
metabolites	B
are	O
renally	O
eliminated	O
,	O
the	O
elimination	O
half	O
-	O
life	O
time	O
(	O
t	O
1	O
/	O
2	O
)	O
for	O
the	O
metabolites	B
being	O
about	O
6	O
h	O
(	O
Leng	O
et	O
al.	O
,	O
1997a	O
)	O
.	O

After	O
cyfluthrin	B
exposure	O
93	O
%	O
of	O
the	O
metabolites	B
are	O
eliminated	O
during	O
the	O
first	O
24	O
h	O
(	O
Leng	O
et	O
al.	O
,	O
1997a	O
)	O
.	O

For	O
assessing	O
a	O
cyfluthrin	B
exposure	O
the	O
metabolites	B
are	O
routinely	O
determined	O
in	O
urine	O
(	O
Leng	O
et	O
al.	O
,	O
1996	O
,	O
1997b	O
)	O
.	O

Although	O
,	O
several	O
studies	O
have	O
shown	O
that	O
there	O
is	O
no	O
correlation	O
between	O
the	O
metabolite	B
concentration	O
in	O
urine	O
and	O
the	O
symptoms	O
mentioned	O
(	O
Kolmodin	O
-	O
Hedman	O
et	O
al.	O
,	O
1995	O
;	O
Leng	O
,	O
1998a	O
;	O
Wieseler	O
et	O
al.	O
,	O
1998	O
)	O
.	O

As	O
a	O
marker	O
of	O
biological	O
effects	O
the	O
unchanged	O
pyrethroid	B
has	O
to	O
be	O
determined	O
in	O
plasma	O
.	O

Here	O
,	O
the	O
problem	O
is	O
that	O
pyrethroids	B
are	O
only	O
present	O
for	O
a	O
few	O
hours	O
after	O
exposure	O
(	O
Leng	O
et	O
al.	O
,	O
1997b	O
;	O
Leng	O
and	O
Lewalter	O
,	O
1998b	O
)	O
.	O

As	O
local	O
symptoms	O
occurring	O
after	O
pyrethroid	B
exposure	O
mostly	O
skin	O
paresthesia	O
and	O
irritations	O
of	O
the	O
upper	O
respiratory	O
tract	O
are	O
reported	O
(	O
He	O
et	O
al.	O
,	O
1988	O
)	O
.	O

In	O
general	O
,	O
the	O
occurrence	O
,	O
kind	O
and	O
extend	O
of	O
a	O
symptom	O
depends	O
on	O
the	O
route	O
of	O
exposure	O
(	O
oral	O
or	O
inhalative	O
and	O
dermal	O
)	O
,	O
the	O
pyrethroid	B
dose	O
,	O
the	O
particle	O
size	O
or	O
the	O
local	O
concentration	O
of	O
the	O
pyrethroid	B
on	O
the	O
nerve	O
ending	O
.	O

But	O
the	O
individual	O
occurrence	O
or	O
even	O
the	O
severity	O
of	O
a	O
symptom	O
like	O
skin	O
paresthesia	O
can	O
not	O
be	O
explained	O
by	O
this	O
alone	O
.	O

Here	O
,	O
the	O
individual	O
metabolic	O
capacity	O
of	O
e.g.	O
the	O
skin	O
seems	O
to	O
play	O
a	O
very	O
important	O
role	O
.	O

For	O
pyrethroids	O
no	O
marker	O
of	O
susceptibility	O
is	O
known	O
yet	O
.	O

This	O
is	O
in	O
contrast	O
to	O
organophosphates	B
and	O
carbamates	B
.	O

Here	O
,	O
cholinesterase	O
variants	O
are	O
known	O
to	O
be	O
responsible	O
for	O
the	O
individual	O
susceptibility	O
regarding	O
the	O
occurrence	O
and	O
severity	O
of	O
the	O
related	O
symptom	O
.	O

Paraoxonase	O
present	O
in	O
human	O
plasma	O
was	O
shown	O
to	O
be	O
under	O
genetic	O
control	O
with	O
high	O
and	O
low	O
activities	O
.	O

Variations	O
in	O
plasma	O
paraoxonase	O
activity	O
may	O
contribute	O
to	O
interindividual	O
variations	O
in	O
susceptibility	O
(	O
McCracken	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Apart	O
from	O
the	O
cholinesterases	O
the	O
membrane	O
bound	O
non	O
-	O
specific	O
carboxylesterases	O
(	O
EC	O
3.1.1.1	O
,	O
systematic	O
name	O
:	O
carboxylic	O
-	O
ester	O
hydrolase	O
)	O
are	O
known	O
to	O
detoxify	O
xenobiotics	B
containing	O
aliphatic	B
esters	I
.	O

This	O
enzyme	O
is	O
inhibited	O
by	O
organophosphates	B
like	O
paraoxon	B
(	O
Junge	O
et	O
al.	O
,	O
1974	O
;	O
Tsujita	O
and	O
Okuda	O
,	O
1983	O
)	O
.	O

Carboxylesterases	O
are	O
present	O
e.g.	O
in	O
skin	O
,	O
muscle	O
,	O
kidney	O
,	O
brain	O
and	O
serum	O
with	O
the	O
highest	O
esterase	O
activity	O
found	O
in	O
the	O
liver	O
(	O
Satoh	O
,	O
1987	O
)	O
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
find	O
out	O
which	O
markers	O
correlate	O
with	O
pyrethroid	B
induced	O
adverse	O
effects	O
.	O

Therefore	O
,	O
the	O
use	O
of	O
determining	O
pyrethroids	B
in	O
plasma	O
,	O
pyrethroid	B
metabolites	B
in	O
urine	O
and	O
esterase	O
activities	O
was	O
evaluated	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Study	O
1—Pyrethroid	O
metabolites	B
in	O
urine	O
Twenty	O
-	O
two	O
pest	O
control	O
operators	O
regularly	O
exposed	O
to	O
the	O
pyrethroids	B
cyfluthrin	B
(	O
n	O
=	O
16	O
)	O
,	O
permethrin	B
(	O
n	O
=	O
3	O
)	O
,	O
deltamethrin	B
(	O
n	O
=	O
2	O
)	O
and	O
cypermethrin	B
(	O
n	O
=	O
1	O
)	O
as	O
well	O
as	O
a	O
non	O
-	O
exposed	O
control	O
group	O
of	O
20	O
subjects	O
were	O
investigated	O
.	O

At	O
the	O
end	O
of	O
the	O
working	O
week	O
24	O
h	O
urine	O
was	O
collected	O
and	O
the	O
concentration	O
of	O
the	O
metabolites	B
was	O
determined	O
by	O
GC	O
/	O
MS	O
(	O
LOD	O
:	O
0.5	O
μg	O
/	O
l	O
)	O
(	O
Kühn	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Moreover	O
,	O
a	O
medical	O
interview	O
was	O
performed	O
in	O
which	O
reported	O
symptoms	O
were	O
documented	O
(	O
Wieseler	O
et	O
al.	O
,	O
1998	O
)	O
.	O

2.2	O
Study	O
2—Half	O
-	O
life	O
time	O
of	O
cyfluthrin	B
metabolites	B
in	O
urine	O
Four	O
healthy	O
male	O
volunteers	O
were	O
exposed	O
for	O
60	O
min	O
to	O
a	O
mean	O
cyfluthrin	B
concentration	O
of	O
160	O
μg	O
/	O
m3	O
(	O
Leng	O
et	O
al.	O
,	O
1997a	O
)	O
.	O

The	O
study	O
design	O
and	O
the	O
medical	O
surveillance	O
of	O
the	O
volunteers	O
was	O
approved	O
by	O
an	O
independent	O
ethical	O
committee	O
after	O
a	O
review	O
of	O
data	O
on	O
animal	O
toxicity	O
and	O
consideration	O
of	O
the	O
dose	O
levels	O
in	O
relation	O
to	O
a	O
proposed	O
acceptable	O
daily	O
intake	O
(	O
ADI	O
)	O
of	O
0.02	O
mg	O
/	O
kg	O
per	O
day	O
cyfluthrin	B
.	O

Urine	O
was	O
collected	O
in	O
the	O
following	O
intervalls	O
:	O
before	O
and	O
immediately	O
after	O
the	O
exposure	O
,	O
1–2	O
h	O
/	O
2–3	O
h	O
/	O
3–4	O
h	O
/	O
4–5	O
h	O
/	O
5–6	O
h	O
/	O
6–12	O
and	O
12–24	O
h	O
after	O
exposure	O
.	O

Cyfluthrin	B
metabolites	B
cis	B
-	I
and	O
trans	B
-	I
3-	I
(	I
2,2-dichlorovinyl	I
)	I
-2,2-dimethylcyclopropanecarboxylic	I
acid	I
(	O
DCCA	B
)	O
and	O
fluorophenoxybenzoic	B
acid	I
(	O
FPBA	B
)	O
were	O
determined	O
in	O
urine	O
by	O
GC	O
/	O
MS	O
(	O
Kühn	O
et	O
al.	O
,	O
1996	O
)	O
.	O

As	O
a	O
first	O
order	O
kinetic	O
for	O
the	O
urinary	O
excretion	O
of	O
cyfluthrin	B
metabolites	B
was	O
assumed	O
,	O
a	O
linear	O
regression	O
analysis	O
was	O
performed	O
on	O
urinary	O
rate	O
versus	O
mid	O
-	O
point	O
time	O
from	O
peak	O
excretion	O
to	O
24	O
h	O
after	O
exposure	O
.	O

The	O
t	O
1	O
/	O
2	O
was	O
estimated	O
from	O
the	O
expression	O
0.693	O
/	O
(	O
slope	O
×	O
2.303	O
)	O
.	O

2.3	O
Study	O
3—Half	O
-	O
life	O
time	O
of	O
cyfluthrin	B
in	O
plasma	O
Eight	O
workers	O
in	O
the	O
chemical	B
industry	O
were	O
investigated	O
after	O
intoxications	O
(	O
Leng	O
and	O
Lewalter	O
,	O
1998b	O
)	O
.	O

Four	O
workers	O
were	O
exposed	O
to	O
cyfluthrin	B
and	O
four	O
were	O
exposed	O
to	O
cyfluthrin	B
and	O
methyl	B
-	I
parathion	I
.	O

Blood	O
was	O
drawn	O
30	O
min	O
after	O
exposure	O
and	O
3	O
h	O
later	O
.	O

Both	O
pesticides	O
were	O
determined	O
in	O
plasma	O
and	O
the	O
t	O
1	O
/	O
2	O
of	O
cyfluthrin	B
in	O
plasma	O
was	O
calculated	O
with	O
the	O
assumption	O
of	O
a	O
simple	O
first	O
order	O
decay	O
(	O
t	O
1	O
/	O
2	O
=	O
0.693	O
/	O
slope	O
×	O
2.303	O
)	O
.	O

2.4	O
Determination	O
of	O
transfluthrin	B
in	O
human	O
plasma	O
Native	O
human	O
plasma	O
naturally	O
containing	O
cholinesterase	O
and	O
carboxylesterase	O
was	O
dotated	O
with	O
transfluthrin	B
(	O
1	O
mg	O
/	O
l	O
)	O
.	O

The	O
change	O
of	O
transfluthrin	B
concentration	O
during	O
time	O
was	O
measured	O
.	O

In	O
another	O
experiment	O
,	O
2	O
U	O
/	O
ml	O
commercially	O
available	O
carboxylesterase	O
(	O
EC	O
3.1.1.1	O
from	O
porcine	O
liver	O
,	O
1000	O
units	O
,	O
Sigma	O
)	O
was	O
added	O
.	O

Transfluthrin	B
concentration	O
change	O
was	O
again	O
documented	O
.	O

The	O
method	O
for	O
the	O
determination	O
of	O
transfluthrin	B
in	O
plasma	O
is	O
described	O
elsewhere	O
(	O
Kühn	O
,	O
1997	O
)	O
.	O

2.5	O
Determination	O
of	O
carboxylesterase	O
activity	O
in	O
human	O
isolated	O
lymphocytes	O
A	O
total	O
of	O
5	O
ml	O
venous	O
blood	O
was	O
drawn	O
from	O
which	O
2–3	O
mio	O
(	O
theoretically	O
6–10	O
mio	O
)	O
lymphocytes	O
/	O
ml	O
were	O
isolated	O
and	O
quantified	O
on	O
slides	O
under	O
the	O
microscope	O
.	O

Lymphocytes	O
were	O
solved	O
in	O
1	O
ml	O
100	O
mM	O
buffer	O
(	O
pH	O
8)	O
containing	O
13.6	O
g	O
KH2	B
PO4	I
/l	O
and	O
17.4	O
g	O
K2	B
HPO4	I
/l	O
.	O

As	O
a	O
substrate	O
,	O
10	O
μl	O
of	O
a	O
cyfluthrin	B
solution	O
(	O
cyano	B
-	I
group	I
containing	O
pyrethroid	B
)	O
was	O
added	O
(	O
30	O
mg	O
cyfluthrin	B
/10	O
ml	O
DMF	B
)	O
.	O

As	O
a	O
positive	O
control	O
commercially	O
available	O
carboxylesterase	O
was	O
used	O
(	O
5	O
U	O
/	O
25	O
μl	O
buffer	O
)	O
.	O

The	O
sample	O
was	O
incubated	O
for	O
30	O
min	O
at	O
40	O
°	O
C	O
.	O

A	O
total	O
of	O
1	O
ml	O
of	O
the	O
lymphocyte	O
suspension	O
was	O
placed	O
in	O
a	O
glass	O
tube	O
with	O
screw	O
cap	O
.	O

The	O
applied	O
method	O
is	O
based	O
on	O
kryptate	B
formation	O
using	O
Kryptofix	B
222	I
B	I
polymer	I
as	O
a	O
phase	O
-	O
transfer	O
-	O
catalyst	O
to	O
transfer	O
the	O
cyanide	B
anion	O
formed	O
by	O
the	O
degradation	O
of	O
cyfluthrin	B
from	O
the	O
aqueous	O
alkaline	O
solution	O
to	O
the	O
organic	O
dichloromethane	B
phase	O
(	O
Chen	O
et	O
al.	O
,	O
1990	O
)	O
.	O

As	O
a	O
derivatization	O
agent	O
pentafluorobenzyl	B
bromide	I
was	O
used	O
and	O
the	O
formated	O
pentafluorobenzyl	B
cyanide	I
was	O
determined	O
by	O
GC	O
/	O
MS	O
.	O

2,3,5,6-tetrachloronitrobenzol	B
served	O
as	O
an	O
internal	O
standard	O
.	O

A	O
total	O
of	O
100	O
μl	O
of	O
the	O
organic	O
phase	O
was	O
removed	O
into	O
a	O
micro	O
vial	O
.	O

The	O
injection	O
vol	O
.	O

was	O
1	O
μl	O
.	O

Capillary	O
gas	O
chromatography	O
was	O
applied	O
using	O
a	O
Hewlett	O
-	O
Packard	O
MSD	O
with	O
a	O
GC	O
5890	O
,	O
an	O
autoinjector	O
HP	O
7673	O
and	O
a	O
HP	O
5973	O
mass	O
selective	O
detector	O
equipped	O
with	O
an	O
apolar	O
DB-5	O
MS	O
fused	O
silica	O
capillary	O
(	O
50	O
m	O
length	O
,	O
0.2	O
mm	O
i.d	O
.	O
,	O
0.33	O
μm	O
film	O
)	O
attached	O
to	O
a	O
retention	O
gap	O
with	O
helium	B
as	O
a	O
carrier	O
gas	O
at	O
a	O
pressure	O
of	O
160	O
kPa	O
.	O

The	O
split	O
was	O
open	O
during	O
injection	O
,	O
closed	O
after	O
0.2	O
min	O
for	O
1	O
min	O
and	O
remained	O
open	O
during	O
GC	O
run	O
.	O

The	O
following	O
GC	O
temperature	O
program	O
was	O
used	O
:	O
The	O
capillary	O
column	O
was	O
maintained	O
at	O
35	O
°	O
C	O
for	O
2	O
min	O
and	O
programmed	O
from	O
35	O
°	O
C	O
at	O
10	O
°	O
C	O
/	O
min	O
to	O
230	O
°	O
C	O
,	O
holding	O
for	O
2	O
min	O
and	O
then	O
programmed	O
from	O
230	O
°	O
C	O
at	O
20	O
°	O
C	O
/	O
min	O
to	O
280	O
°	O
C	O
.	O

The	O
injector	O
temperature	O
was	O
held	O
at	O
280	O
°	O
C	O
and	O
the	O
detector	O
temperature	O
was	O
set	O
at	O
300	O
°	O
C	O
(	O
MSD	O
-	O
transfere	O
line	O
)	O
.	O

For	O
identification	O
and	O
quantitation	O
mass	O
spectra	O
were	O
obtained	O
by	O
electron	O
impact	O
(	O
EI	O
,	O
70	O
eV	O
)	O
using	O
selected	O
ion	O
monitoring	O
(	O
SIM	O
)	O
(	O
Chen	O
et	O
al.	O
,	O
1990	O
)	O
.	O

The	O
signal	O
-	O
to	O
-	O
noise	O
value	O
of	O
pentafluorobenzyl	B
cyanide	I
at	O
a	O
concentration	O
level	O
of	O
25	O
μg	O
/	O
l	O
of	O
cyanide	B
was	O
3:1	O
.	O

The	O
average	O
in	O
run	O
-	O
coefficient	O
of	O
variation	O
was	O
10	O
%	O
(	O
50	O
μg	O
/	O
l	O
,	O
n	O
=	O
10	O
)	O
.	O

3	O
Results	O
3.1	O
Study	O
1—Pyrethroid	O
metabolites	B
in	O
urine	O
In	O
Fig.	O
1	O
the	O
symptoms	O
mentioned	O
by	O
22	O
pest	O
control	O
operators	O
and	O
20	O
control	O
subjects	O
are	O
presented	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
these	O
groups	O
.	O

Fig.	O
2	O
shows	O
that	O
there	O
was	O
no	O
correlation	O
between	O
the	O
concentration	O
of	O
pyrethroid	B
metabolites	B
in	O
urine	O
and	O
the	O
occurrence	O
of	O
symptoms	O
.	O

3.2	O
Study	O
2—Half	O
-	O
life	O
time	O
of	O
cyfluthrin	B
metabolites	B
in	O
urine	O
By	O
determining	O
the	O
interindividual	O
differences	O
in	O
cyfluthrin	B
metabolism	O
in	O
human	O
volunteers	O

it	O
was	O
obvious	O
that	O
there	O
were	O
subjects	O
with	O
a	O
slow	O
and	O
with	O
a	O
fast	O
rate	O
of	O
metabolism	O
(	O
Fig.	O
3	O
)	O
.	O

Overall	O
,	O
the	O
longer	O
the	O
t	O
1	O
/	O
2	O
,	O
the	O
more	O
the	O
symptom	O
.	O

3.3	O
Study	O
3—Half	O
-	O
life	O
time	O
of	O
cyfluthrin	B
in	O
plasma	O
Table	O
1	O
shows	O
the	O
interindividual	O
differences	O
in	O
cyfluthrin	B
metabolism	O
following	O
a	O
single	O
cyfluthrin	B
as	O
well	O
as	O
a	O
mixed	O
cyfluthrin	B
and	O
methyl	B
-	I
parathion	I
exposure	O
.	O

As	O
a	O
result	O
,	O
an	O
equal	O
amount	O
of	O
cyfluthrin	B
,	O
shown	O
by	O
nearly	O
identical	O
cyfluthrin	B
concentrations	O
in	O
plasma	O
,	O
leads	O
to	O
different	O
t	O
1	O
/	O
2	O
of	O
cyfluthrin	B
in	O
plasma	O
.	O

In	O
case	O
skin	O
paresthesia	O
occurred	O
,	O
a	O
comparable	O
long	O
cyfluthrin	B
t	O
1	O
/	O
2	O
was	O
found	O
.	O

Concerning	O
a	O
mixed	O
exposure	O
(	O
pyrethroid	B
plus	O
organophosphate	B
)	O
,	O
a	O
similar	O
amount	O
of	O
exposure	O
leads	O
to	O
t	O
1	O
/	O
2	O
of	O
cyfluthrin	B
variing	O
between	O
1	O
and	O
14	O
h.	O
In	O
general	O
,	O
in	O
case	O
of	O
a	O
mixed	O
exposure	O
there	O
was	O
a	O
tendency	O
of	O
a	O
longer	O
t	O
1	O
/	O
2	O
of	O
cyfluthrin	B
in	O
plasma	O
.	O

Skin	O
paresthesia	O
was	O
not	O
mentioned	O
in	O
case	O
of	O
a	O
short	O
t	O
1	O
/	O
2	O
.	O

3.4	O
Determination	O
of	O
transfluthrin	B
in	O
human	O
plasma	O
Transfluthrin	B
was	O
hydrolysed	O
very	O
slowly	O
(	O
>	O
60	O
h	O
)	O
in	O
human	O
plasma	O
,	O
i.e.	O
cholinesterase	O
does	O
not	O
seem	O
to	O
be	O
responsible	O
for	O
transfluthrin	B
metabolism	O
.	O

In	O
case	O
carboxylesterase	O
was	O
added	O
,	O
hydrolysis	O
was	O
much	O
faster	O
(	O
<	O
30	O
min	O
)	O
.	O

3.5	O
Determination	O
of	O
carboxylesterase	O
activity	O
in	O
human	O
isolated	O
lymphocytes	O
Fig.	O
4	O
shows	O
the	O
dependance	O
of	O
cyanic	B
acid	I
production	O
on	O
the	O
cyfluthrin	B
concentration	O
.	O

The	O
amount	O
of	O
carboxylesterase	O
was	O
constant	O
,	O
i.e.	O
1	O
U	O
/	O
ml	O
commercially	O
available	O
carboxylesterase	O
or	O
5	O
mio	O
isolated	O
lymphocytes	O
/	O
ml	O
.	O

Moreover	O
,	O
having	O
a	O
constant	O
substrate	O
concentration	O
,	O
the	O
amount	O
of	O
cyanic	B
acid	I
produced	O
was	O
dependant	O
on	O
the	O
amount	O
of	O
carboxylesterase	O
used	O
.	O

First	O
hints	O
for	O
interindividual	O
differences	O
in	O
cyanic	B
acid	I
production	O
are	O
demonstrated	O
in	O
Fig.	O
5	O
.	O

4	O
Discussion	O
This	O
study	O
demonstrates	O
that	O
the	O
individual	O
susceptibility	O
plays	O
a	O
major	O
role	O
in	O
pyrethroid	B
induced	O
adverse	O
effects	O
like	O
skin	O
paresthesia	O
.	O

In	O
humans	O
,	O
pyrethroids	B
are	O
assumed	O
to	O
be	O
rapidly	O
metabolized	O
by	O
a	O
hydrolytic	O
cleavage	O
(	O
esterases	O
)	O
into	O
their	O
corresponding	O
metabolites	B
cis	B
-	I
and	O
trans	B
-3-	I
(	I
2,2-dichlorovinyl	I
)	I
-2,2-dimethylcyclopropane	I
carboxylic	I
acid	I
or	O
cis	B
-3-	I
(	I
2,2-dibromovinyl	I
)	I
-2,2-dimethylcyclopropane	I
carboxylic	I
acid	I
.	O

The	O
alcohol	B
moiety	O
is	O
oxidised	O
(	O
mixed	O
-	O
functional	O
oxidases	O
)	O
to	O
4-fluoro-3-phenoxybenzoic	B
acid	I
or	O
3-phenoxybenzoic	B
acid	I
(	O
Kühn	O
et	O
al.	O
,	O
1996	O
)	O
.	O

The	O
acids	B
are	O
partly	O
conjugated	O
to	O
e.g.	O
glucuronic	B
acid	I
and	O
finally	O
renally	O
eliminated	O
(	O
Wollen	O
et	O
al.	O
,	O
1992	O
)	O
.	O

The	O
determination	O
of	O
the	O
t	O
1	O
/	O
2	O
of	O
eighter	O
pyrethroids	B
in	O
plasma	O
or	O
metabolites	B
in	O
urine	O
is	O
a	O
good	O
tool	O
to	O
get	O
indirect	O
information	O
about	O
individual	O
pyrethroid	B
metabolism	O
.	O

It	O
turned	O
out	O
that	O
only	O
in	O
case	O
of	O
a	O
long	O
t	O
1	O
/	O
2	O
of	O
cyfluthrin	B
in	O
plasma	O
skin	O
paresthesia	O
occurred	O
.	O

The	O
t	O
1	O
/	O
2	O
of	O
cyfluthrin	B
in	O
plasma	O
was	O
longer	O
in	O
case	O
of	O
a	O
mixed	O
exposure	O
than	O
in	O
case	O
of	O
a	O
single	O
one	O
.	O

This	O
might	O
be	O
explained	O
by	O
the	O
inhibition	O
of	O
the	O
cyfluthrin	B
degrading	O
esterase	O
by	O
the	O
organophosphate	B
methyl	B
-	I
parathion	I
.	O

In	O
case	O
of	O
a	O
direct	O
measurement	O
of	O
pyrethroid	B
susceptibility	O
the	O
activity	O
of	O
the	O
esterase	O
responsible	O
for	O
pyrethroid	B
metabolism	O
has	O
to	O
be	O
determined	O
.	O

In	O
contrast	O
to	O
organophosphates	B
and	O
carbamates	B
,	O
the	O
cholinesterase	O
does	O
not	O
seem	O
to	O
play	O
a	O
role	O
in	O
pyrethroid	B
metabolism	O
.	O

Apart	O
from	O
the	O
cholinesterase	O
the	O
carboxylesterase	O
is	O
a	O
widespread	O
esterase	O
as	O
well	O
.	O

It	O
is	O
known	O
that	O
several	O
carboxylesterases	O
exist	O
with	O
wide	O
and	O
overlapping	O
substrate	O
specifities	O
.	O

As	O
a	O
model	O
substrate	O
for	O
carboxylesterase	B
1-naphthyl	B
acetate	I
(	O
which	O
produces	O
1-naphtol	B
)	O
is	O
often	O
used	O
(	O
Williams	O
,	O
1985	O
)	O
.	O

After	O
pyrethroid	B
exposure	O
skin	O
paresthesia	O
is	O
frequently	O
reported	O
.	O

There	O
are	O
interindividual	O
differences	O
concerning	O
the	O
occurrence	O
and	O
the	O
severity	O
of	O
this	O
symptom	O
.	O

This	O
might	O
be	O
explained	O
by	O
individual	O
different	O
levels	O
of	O
carboxylesterase	O
activity	O
in	O
the	O
skin	O
as	O
it	O
is	O
known	O
that	O
the	O
human	O
skin	O
contains	O
at	O
least	O
four	O
different	O
carboxylesterases	O
(	O
Heymann	O
et	O
al.	O
,	O
1993	O
)	O
.	O

With	O
the	O
help	O
of	O
in	O
-	O
vitro	O
experiments	O
it	O
was	O
demonstrated	O
that	O
pyrethroids	B
are	O
hydrolyzed	O
by	O
carboxylesterases	O
.	O

As	O
in	O
comparison	O
to	O
rats	O
human	O
plasma	O
contains	O
only	O
very	O
little	O
carboxylesterase	O
(	O
McCracken	O
et	O
al.	O
,	O
1993	O
)	O
and	O
the	O
liver	O
is	O
not	O
easily	O
accessible	O
for	O
routine	O
measurements	O
,	O
we	O
wanted	O
to	O
find	O
out	O
if	O
there	O
is	O
a	O
measurable	O
carboxylesterase	O
activity	O
in	O
human	O
isolated	O
lymphocytes	O
.	O

Cyfluthrin	B
,	O
a	O
pyrethroid	B
containing	O
a	O
cyano	B
-	I
group	I
,	O
was	O
used	O
as	O
a	O
substrate	O
.	O

As	O
a	O
parameter	O
of	O
carboxylesterase	O
activity	O
the	O
production	O
of	O
cyanic	B
acid	I
was	O
measured	O
.	O

First	O
hints	O
showed	O
that	O
the	O
determination	O
of	O
carboxylesterase	O
acitivity	O
in	O
lymphocytes	O
is	O
a	O
most	O
promising	O
start	O
to	O
measure	O
the	O
individual	O
pyrethroid	B
susceptibility	O
.	O

5	O
Conclusion	O

The	O
determination	O
of	O
the	O
carboxylesterase	O
activity	O
in	O
human	O
isolated	O
lymphocytes	O
is	O
a	O
first	O
step	O
in	O
the	O
search	O
of	O
a	O
marker	O
of	O
pyrethroid	B
susceptibility	O
in	O
man	O
.	O

To	O
obtain	O
information	O
concerning	O
the	O
individual	O
rate	O
of	O
metabolism	O
,	O
the	O
t	O
1	O
/	O
2	O
of	O
the	O
pyrethroids	B
in	O
plasma	O
and	O
of	O
the	O
pyrethroid	B
metabolites	B
in	O
urine	O
should	O
be	O
determined	O
.	O

As	O
a	O
marker	O
of	O
exposure	O
the	O
determination	O
of	O
pyrethroid	B
metabolites	I
in	O
urine	O
is	O
indicated	O
.	O

Acknowledgements	O
The	O
authors	O
thank	O
Dr	O
K	O
.-	O
H.	O
Kühn	O
(	O
Institute	O
of	O
Hygiene	O
,	O
University	O
Duesseldorf	O
)	O
and	O
D.	O
Ellrich	O
(	O
Bayer	O
AG	O
,	O
Leverkusen	O
)	O
for	O
the	O
GC	O
/	O
MS	O
measurements	O
.	O

Cancer	O
in	O
various	O
forms	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	O
in	O
the	O
human	O
population	O
.	O

Chemoprevention	O
and	O
chemotherapy	O
are	O
employed	O
in	O
reducing	O
human	O
mortality	O
due	O
to	O
cancer	O
or	O
in	O
the	O
control	O
of	O
cancer	O
.	O

There	O
are	O
several	O
natural	B
products	I
of	O
plant	O
origin	O
(	O
phytochemicals	B
)	O
that	O
are	O
of	O
potential	O
value	O
as	O
chemopreventive	O
or	O
therapeutic	O
agents	O
.	O

As	O
therapeutic	O
agents	O
,	O
the	O
phytochemicals	B
kill	O
the	O
cancer	O
cells	O
or	O
stop	O
their	O
growth	O
,	O
leading	O
to	O
cancer	O
remission	O
.	O

Some	O
of	O
the	O
new	O
cancer	O
chemotherapeutic	O
agents	O
derived	O
from	O
plants	O
in	O
current	O
clinical	O
use	O
are	O
paclitaxel	B
(	O
Taxol	B
)	O
,	O
vincristine	B
(	O
Oncovin	B
)	O
,	O
podophyllotoxin	B
and	O
captothecin	B
(	O
Pezutto	O
,	O
1997	O
)	O
.	O

A	O
screening	O
test	O
using	O
human	O
cancer	O
cell	O
lines	O
is	O
usually	O
performed	O
as	O
an	O
initial	O
step	O
in	O
the	O
evaluation	O
of	O
chemicals	B
for	O
cancer	O
prevention	O
and	O
treatment	O
(	O
Skehan	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Those	O
compounds	O
that	O
are	O
found	O
to	O
be	O
potent	O
in	O
killing	O
cancer	O
cells	O
or	O
inhibiting	O
cell	O
growth	O
are	O
then	O
further	O
screened	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
growth	O
of	O
tumours	O
in	O
animal	O
models	O
.	O

One	O
group	O
of	O
compounds	O
with	O
potential	O
antitumour	O
activities	O
are	O
flavonoids	B
,	O
which	O
are	O
either	O
synthetic	B
or	O
natural	B
constituents	I
of	O
foods	O
or	O
drink	O
(	O
tea	O
and	O
fruit	O
juices	O
)	O
consumed	O
by	O
humans	O
.	O

Flavonoids	B
are	O
composed	O
of	O
different	O
chemical	B
classes	O
such	O
as	O
flavones	B
(	O
7,8-benzoflavone	B
or	O
α	B
-naphthoflavone	I
)	O
,	O
isoflavones	B
(	O
genistein	B
)	O
,	O
flavonols	B
(	O
quercetin	B
)	O
,	O
flavanols	B
[	O
(	B
+	I
)	I
-catechin	I
]	O
,	O
flavanones	B
(	O
naringenin	B
)	O
and	O
chalcones	B
(	O
xanthohumol	B
)	O
.	O

These	O
compounds	B
differ	O
in	O
the	O
level	O
of	O
oxidation	O
of	O
the	O
flavane	B
nucleus	O
and	O
in	O
the	O
number	O
and	O
position	O
of	O
hydroxyl	B
and	O
methoxyl	B
substituents	I
(	O
Lee	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Flavanones	B
lack	O
the	O
double	O
bond	O
in	O
the	O
2,3-position	O
of	O
the	O
C	O
ring	O
present	O
in	O
the	O
flavane	B
nucleus	O
.	O

Opening	O
of	O
the	O
C	O
-	O
ring	O
of	O
naringenin	B
yields	O
the	O
chalcone	B
,	O
chalconaringenin	B
.	O

Chalcones	B
are	O
open	O
C	O
-	O
ring	O
flavonoids	B
in	O
which	O
the	O
two	O
aromatic	B
rings	I
are	O
joined	O
by	O
a	O
three	O
-	O
carbon	B
α	B
,	I
β	I
-unsaturated	I
carbonyl	I
system	O
(	O
Bohm	O
,	O
1994	O
)	O
.	O

Chalcones	B
are	O
converted	O
to	O
flavanones	B
chemically	O
by	O
treatment	O
of	O
the	O
former	O
with	O
sodium	B
acetate	I
in	O
methanolic	B
solution	O
or	O
enzymatically	O
by	O
chalcone	B
isomerase	O
(	O
Stevens	O
et	O
al.	O
1997	O
,	O
1998	O
)	O
.	O

Flavonoids	B
,	O
including	O
chalcones	B
and	O
flavanones	B
,	O
have	O
been	O
shown	O
to	O
inhibit	O
the	O
proliferation	O
of	O
cancer	O
cells	O
and	O
inhibit	O
tumour	O
growth	O
(	O
Anto	O
et	O
al.	O
,	O
1995	O
;	O
De	O
Vincenzo	O
et	O
al.	O
,	O
1995	O
;	O
Middleton	O
and	O
Kandaswami	O
,	O
1994	O
;	O
Satomi	O
,	O
1993	O
;	O
Seo	O
et	O
al.	O
,	O
1997	O
;	O
Wattenberg	O
et	O
al.	O
,	O
1994	O
;	O
Yit	O
and	O
Das	O
,	O
1994	O
)	O
.	O

The	O
biological	O
effects	O
of	O
the	O
chalcones	B
depend	O
on	O
their	O
chemical	B
structure	O
.	O

For	O
example	O
,	O
methyl	B
and	O
hydroxy	B
substituted	I
chalcones	I
are	O
cytotoxic	O
in	O
Ehrlich	O
ascites	O
cells	O
and	O
Dalton	O
's	O
lymphoma	O
ascites	O
cells	O
,	O
whereas	O
only	O
hydroxy	B
substituted	I
chalcones	I
reduce	O
ascites	O
tumours	O
in	O
mice	O
(	O
Anto	O
et	O
al.	O
,	O
1995	O
)	O
.	O

Of	O
several	O
chalcones	B
studied	O
,	O
3′-methyl-3-hydroxy	B
-	I
chalcone	I
showed	O
the	O
strongest	O
antitumour	O
and	O
antitumour	O
-	O
promoting	O
activity	O
(	O
Nishino	O
et	O
al.	O
,	O
1993	O
;	O
Satomi	O
,	O
1993	O
;	O
Shibata	O
,	O
1994	O
)	O
.	O

This	O
compound	B
was	O
found	O
to	O
inhibit	O
the	O
proliferation	O
of	O
various	O
kinds	O
of	O
human	O
malignant	O
tumour	O
cells	O
representing	O
gastric	O
cancer	O
,	O
cervical	O
cancer	O
,	O
pancreatic	O
cancer	O
and	O
neuroblastoma	O
(	O
Satomi	O
,	O
1993	O
)	O
.	O

Thus	O
,	O
substitutions	O
on	O
the	O
chalcone	B
structure	O
have	O
a	O
profound	O
influence	O
on	O
the	O
anticarcinogenic	O
effects	O
of	O
chalcone	B
compounds	B
.	O

Recently	O
,	O
six	O
chalcones	B
(	O
xanthohumol	B
,	O
2′,4′,6′,4-tetrahydroxy-3′-prenylchalcone	B
,	O
2′,4′,6′,4-tetrahydroxy-3′-geranylchalcone	B
,	O
5′-prenylxanthohumol	B
,	O
dehydrocycloxanthohumol	B
and	O
dehydrocycloxanthohumol	B
hydrate	I
)	O
and	O
three	O
flavanones	B
(	O
isoxanthohumol	B
,	O
6-prenylnaringenin	B
and	O
8-prenylnaringenin	B
)	O
have	O
been	O
isolated	O
from	O
hops	O
by	O
Stevens	O
et	O
al.	O
(	O
1997	O
)	O
.	O

Four	O
of	O
the	O
hop	O
flavonoids	B
with	O
prenyl	B
groups	I
(	O
xanthohumol	B
,	O
isoxanthohumol	B
,	O
6-prenylnaringenin	B
and	O
8-prenylnaringenin	B
)	O
are	O
found	O
in	O
hopped	O
beers	O
(	O
Stevens	O
et	O
al.	O
1998	O
,	O
1999	O
)	O
.	O

Xanthohumol	B
is	O
the	O
most	O
abundant	O
prenylated	B
flavonoid	I
in	O
hops	O
whereas	O
isoxanthohumol	B
is	O
the	O
most	O
abundant	O
flavonoid	B
in	O
all	O
types	O
of	O
beer	O
tested	O
(	O
Stevens	O
et	O
al.	O
,	O
1998	O
,	O
1999	O
)	O
.	O

Isoxanthohumol	B
in	O
beer	O
is	O
produced	O
by	O
the	O
isomerization	O
of	O
xanthohumol	B
during	O
the	O
brewing	O
process	O
(	O
Stevens	O
et	O
al.	O
,	O
1999	O
)	O
.	O

The	O
potential	O
of	O
the	O
major	O
prenylated	B
hop	O
compounds	B
,	O
xanthohumol	B
and	O
isoxanthohumol	B
,	O
as	O
antineoplastic	O
agents	O
is	O
not	O
known	O
.	O

Other	O
prenylated	B
flavonoids	I
display	O
cytotoxic	O
activity	O
against	O
several	O
human	O
cancer	O
cell	O
lines	O
(	O
Seo	O
et	O
al.	O
,	O
1997	O
)	O
.	O

It	O
is	O
possible	O
that	O
the	O
prenylated	B
flavonoids	I
from	O
hops	O
and	O
beer	O
may	O
have	O
the	O
ability	O
to	O
inhibit	O
the	O
proliferation	O
of	O
cancer	O
cells	O
,	O
making	O
them	O
potentially	O
useful	O
as	O
cancer	O
chemopreventive	O
agents	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
this	O
research	O
project	O
was	O
to	O
examine	O
the	O
antiproliferative	O
and	O
cytotoxic	O
activities	O
of	O
prenylated	B
flavonoids	I
from	O
hops	O
(	O
Humulus	O
lupulus	O
)	O
in	O
human	O
breast	O
cancer	O
(	O
MCF-7	O
)	O
,	O
colon	O
cancer	O
(	O
HT-29	O
)	O
and	O
ovarian	O
cancer	O
(	O
A-2780	O
)	O
cells	O
in	O
vitro	O
.	O

The	O
cytotoxicity	O
of	O
these	O
hop	O
compounds	O
in	O
primary	O
cultures	O
of	O
rat	O
hepatocytes	O
was	O
also	O
evaluated	O
in	O
an	O
effort	O
to	O
determine	O
their	O
potential	O
to	O
cause	O
liver	O
toxicity	O
in	O
the	O
intact	O
animal	O
.	O

Hepatic	O
toxicity	O
is	O
one	O
of	O
the	O
early	O
issues	O
that	O
need	O
to	O
be	O
addressed	O
in	O
drug	B
development	O
and	O
is	O
therefore	O
pertinent	O
in	O
our	O
investigation	O
on	O
the	O
overall	O
evaluation	O
of	O
hop	O
flavonoids	B
as	O
potential	O
preventive	O
agents	O
for	O
cancer	O
in	O
humans	O
.	O

2	O
Materials	O
and	O
Methods	O
2.1	O
Chemicals	B
The	O
chalcone	B
compounds	B
(	O
Fig.	O
1	O
)	O
tested	O
for	O
their	O
growth	O
-	O
inhibitory	O
activities	O
were	O
xanthohumol	B
(	O
XN	B
)	O
,	O
2′,4′,6′,4-tetrahydroxy-3′-prenylchalcone	B
(	O
TP	B
)	O
,	O
2′,4′,6′,4-tetrahydroxy-3′-geranylchalcone	B
(	O
TG	B
)	O
,	O
dehydrocycloxanthohumol	B
(	O
DX	B
)	O
,	O
and	O
dehydrocycloxanthohumol	B
hydrate	I
(	O
DH	B
)	O
.	O

The	O
other	O
chalcone	B
,	O
5′-prenylxanthohumol	B
,	O
isolated	O
from	O
hops	O
was	O
not	O
available	O
in	O
sufficient	O
quantities	O
for	O
this	O
study	O
.	O

Isoxanthohumol	B
(	O
IX	B
)	O
,	O
a	O
flavanone	B
derivative	B
of	O
XN	B
which	O
is	O
present	O
in	O
hops	O
(	O
Stevens	O
et	O
al.	O
,	O
1997	O
)	O
,	O
was	O
also	O
examined	O
for	O
its	O
antiproliferative	O
activity	O
for	O
comparative	O
purposes	O
.	O

Sulforhodamine	B
B	I
(	O
SRB	B
)	O
was	O
obtained	O
from	O
Sigma	O
Chemical	O
Co.	O
(	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

Culture	O
media	O
and	O
supplements	O
were	O
purchased	O
from	O
Gibco	O
BRL	O
(	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Collagenase	O
(	O
Type	O
2	O
)	O
was	O
obtained	O
from	O
Worthington	O
Biochemical	O
Corporation	O
(	O
Freehold	O
,	O
NJ	O
)	O
.	O

[	O
Methyl	B
-3	I
H	I
]	I
thymidine	I
(	O
25	O
μ	O
Ci	O
/	O
μ	O
mol	O
)	O
was	O
purchased	O
from	O
Amersham	O
(	O
Arlington	O
Heights	O
,	O
IL	O
,	O
USA	O
)	O
.	O

2.2	O
Cell	O
cultures	O
Three	O
established	O
human	O
cancer	O
cell	O
lines	O
[	O
oestrogen	O
receptor	O
-	O
positive	O
breast	O
cancer	O
cells	O
(	O
MCF-7	O
)	O
,	O
human	O
colon	O
cancer	O
cells	O
(	O
HT-29	O
)	O
and	O
human	O
ovarian	O
cancer	O
cells	O
(	O
A-2780	O
)	O
]	O
were	O
used	O
for	O
the	O
cytotoxicity	O
studies	O
.	O

These	O
cell	O
lines	O
(	O
except	O
A-2780	O
)	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
)	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

The	O
ovarian	O
cancer	O
cell	O
line	O
,	O
A-2780	O
,	O
was	O
generously	O
provided	O
by	O
Dr	O
Raymond	O
Taetle	O
,	O
MD	O
,	O
Arizona	O
Cancer	O
Center	O
,	O
Tucson	O
,	O
AZ	O
.	O

2.3	O
Sulforhodamine	B
assay	O
The	O
sulforhodamine	B
B	I
(	O
SRB	B
)	O
assay	O
,	O
developed	O
by	O
the	O
National	O
Cancer	O
Institute	O
for	O
in	O
vitro	O
antitumour	O
screening	O
(	O
Rubinstein	O
et	O
al.	O
,	O
1990	O
;	O
Skehan	O
et	O
al.	O
,	O
1990	O
)	O
,	O
was	O
employed	O
to	O
determine	O
the	O
relative	O
potencies	O
of	O
the	O
individual	O
hop	B
compounds	I
in	O
inhibiting	O
the	O
growth	O
of	O
cancer	O
cells	O
and	O
in	O
determining	O
the	O
differential	O
sensitivities	O
of	O
three	O
human	O
cancer	O
cell	O
lines	O
to	O
the	O
antiproliferative	O
effects	O
of	O
the	O
individual	O
flavonoids	B
.	O

The	O
SRB	B
assay	O
measures	O
whole	O
-	O
culture	O
protein	O
content	O
as	O
an	O
index	O
of	O
tumour	O
cell	O
viability	O
.	O

Experimental	O
cell	O
cultures	O
were	O
plated	O
on	O
a	O
96-well	O
microtitre	O
plate	O
(	O
Costar	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
,	O
with	O
each	O
well	O
containing	O
0.2	O
ml	O
growth	O
medium	O
per	O
well	O
at	O
a	O
density	O
of	O
5	O
×	O
103	O
cells	O
/	O
well	O
.	O

After	O
1	O
or	O
2	O
days	O
of	O
incubation	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
atmosphere	O
of	O
95	O
%	O
air	O
/	O
5	O
%	O
CO2	B
,	O
the	O
cells	O
(	O
30–40	O
%	O
confluent	O
)	O
were	O
exposed	O
to	O
culture	O
medium	O
containing	O
the	O
hop	O
flavonoids	B
at	O
varying	O
concentrations	O
(	O
0.01	O
,	O
0.1	O
,	O
1.0	O
,	O
10	O
,	O
or	O
100	O
μ	O
m	O
)	O
.	O

The	O
flavonoids	B
were	O
initially	O
dissolved	O
in	O
ethanol	B
before	O
being	O
added	O
to	O
the	O
culture	O
media	O
.	O

Vehicle	O
-	O
treated	O
controls	O
contained	O
ethanol	B
at	O
the	O
same	O
concentration	O
(	O
0.1	O
%	O
)	O
as	O
in	O
the	O
treated	O
media	O
.	O

The	O
culture	O
medium	O
was	O
phenol	B
red	O
-	O
free	O
RPMI	O
(	O
for	O
HT-29	O
and	O
A-2780	O
)	O
or	O
Ham	O
's	O
F-12	O
/	O
DMEM	O
(	O
FD	O
)	O
(	O
for	O
MCF-7	O
)	O
supplemented	O
with	O
5	O
%	O
foetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
plus	O
penicillin	B
(	O
100	O
U	O
/	O
ml	O
)	O
and	O
streptomycin	B
(	O
100	O
μ	O
g	O
/	O
ml	O
)	O
.	O

The	O
cell	O
doubling	O
times	O
in	O
these	O
media	O
were	O
38	O
,	O
30	O
and	O
48	O
hr	O
for	O
MCF-7	O
,	O
HT-29	O
and	O
A-2780	O
cells	O
,	O
respectively	O
.	O

2	O
,	O
4	O
or	O
6	O
days	O
following	O
incubation	O
with	O
the	O
test	O
materials	O
or	O
ethanol	B
(	O
control	O
cultures	O
)	O
,	O
the	O
culture	O
medium	O
was	O
aspirated	O
and	O
the	O
cells	O
were	O
fixed	O
by	O
gentle	O
addition	O
of	O
200	O
μ	O
l	O
cold	O
10	O
%	O
trichloroacetic	B
acid	I
(	O
TCA	B
)	O
.	O

The	O
control	O
cells	O
were	O
in	O
the	O
proliferative	O
stage	O
during	O
the	O
6-day	O
period	O
and	O
were	O
semiconfluent	O
or	O
100	O
%	O
confluent	O
after	O
6	O
days	O
.	O

The	O
plates	O
were	O
incubated	O
for	O
1	O
hr	O
at	O
4	O
°	O
C	O
and	O
then	O
washed	O
five	O
times	O
with	O
tap	O
water	B
to	O
remove	O
TCA	B
.	O

Plates	O
were	O
air	O
-	O
dried	O
and	O
then	O
stained	O
for	O
30	O
min	O
with	O
0.4	O
%	O
(	O
w	O
/	O
v	O
)	O
SRB	B
dissolved	O
in	O
1	O
%	O
acetic	B
acid	I
.	O

SRB	B
was	O
removed	O
and	O
cultures	O
were	O
quickly	O
rinsed	O
four	O
times	O
with	O
1	O
%	O
acetic	B
acid	I
to	O
remove	O
unbound	O
dye	B
.	O

Residual	O
wash	O
solution	O
was	O
removed	O
and	O
the	O
cultures	O
were	O
air	O
-	O
dried	O
.	O

The	O
bound	O
dye	B
was	O
then	O
solubilized	O
with	O
200	O
μ	O
l	O
10	O
mm	O
unbuffered	O
Tris	B
base	I
(	O
pH	O
10.5	O
)	O
.	O

The	O
absorbance	O
of	O
each	O
well	O
at	O
564	O
nm	O
was	O
read	O
in	O
a	O
SpectraMax	O
250	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
,	O
Menlo	O
Park	O
,	O
CA	O
,	O
USA	O
)	O
.	O

At	O
day	O
zero	O
(	O
day	O
of	O
treatment	O
)	O
,	O
the	O
readings	O
of	O
the	O
control	O
wells	O
in	O
the	O
96-well	O
plates	O
ranged	O
from	O
0.4	O
to	O
0.6	O
OD	O
.	O

The	O
antiproliferative	O
activity	O
was	O
calculated	O
from	O
the	O
ratio	O
of	O
the	O
absorbance	O
readings	O
of	O
the	O
treated	O
wells	O
to	O
those	O
of	O
the	O
control	O
wells	O
.	O

Vehicle	O
-	O
treated	O
control	O
cells	O
were	O
grown	O
in	O
four	O
wells	O
in	O
every	O
96-well	O
plate	O
used	O
.	O

For	O
every	O
cell	O
line	O
,	O
all	O
the	O
flavonoids	B
were	O
tested	O
simultaneously	O
at	O
the	O
designated	O
times	O
to	O
avoid	O
day	O
-	O
to	O
-	O
day	O
variation	O
.	O

At	O
each	O
time	O
period	O
,	O
intra	O
-	O
assay	O
(	O
plate	O
to	O
plate	O
)	O
variation	O
in	O
vehicle	O
-	O
treated	O
cells	O
was	O
minimal	O
as	O
shown	O
by	O
standard	O
errors	O
of	O
4	O
%	O
or	O
less	O
from	O
three	O
individual	O
plates	O
.	O

For	O
example	O
,	O
the	O
absorbance	O
reading	O
(	O
mean±SEM	O
)	O
of	O
vehicle	O
-	O
treated	O
control	O
cells	O
in	O
three	O
plates	O
(	O
four	O
wells	O
per	O
plate	O
)	O
after	O
2	O
days	O
of	O
treatment	O
of	O
MCF-7	O
cells	O
was	O
1.53±0.03	O
.	O

The	O
average	O
of	O
four	O
wells	O
per	O
treatment	O
was	O
used	O
for	O
the	O
calculation	O
of	O
the	O
IC50	O
(	O
the	O
concentration	O
of	O
flavonoid	B
resulting	O
in	O
a	O
50	O
%	O
inhibition	O
of	O
cell	O
growth	O
)	O
using	O
the	O
Data	O
Analysis	O
and	O
Technical	O
Graphics	O
software	O
(	O
Origin	O
5.0	O
)	O
from	O
Microcal	O
Software	O
,	O
Inc.	O
,	O
Northampton	O
,	O
MA	O
,	O
USA	O
.	O

2.4	O
Effects	O
of	O
XN	B
and	O
IX	B
on	O
viability	O
of	O
MCF-7	O
cells	O
determined	O
by	O
the	O
trypan	B
blue	I
exclusion	O
method	O
MCF-7	O
cells	O
(	O
50,000	O
cells	O
/	O
well	O
)	O
were	O
seeded	O
into	O
12-well	O
plates	O
(	O
Corning	O
)	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
phenol	B
red	O
-	O
free	O
Ham	O
's	O
F-12	O
/	O
DMEM	O
containing	O
10	O
%	O
FBS	B
.	O

After	O
24	O
hr	O
in	O
culture	O
,	O
the	O
cells	O
were	O
treated	O
with	O
XN	B
or	O
IX	B
at	O
concentrations	O
of	O
0.01	O
,	O
0.1	O
,	O
1.0	O
,	O
10	O
and	O
100	O
μ	O
m	O
in	O
FD	O
medium	O
containing	O
5	O
%	O
FBS	B
.	O

Control	O
cells	O
were	O
incubated	O
under	O
identical	O
conditions	O
in	O
1	O
ml	O
culture	O
medium	O
containing	O
0.1	O
%	O
ethanol	B
.	O

After	O
8	O
,	O
24	O
and	O
48	O
hr	O
of	O
treatment	O
,	O
the	O
cells	O
were	O
trypsinized	O
and	O
cells	O
were	O
counted	O
in	O
a	O
haemacytometer	O
using	O
the	O
trypan	B
blue	I
exclusion	O
method	O
to	O
quantify	O
cell	O
viability	O
.	O

To	O
determine	O
population	O
doubling	O
time	O
,	O
untreated	O
cells	O
were	O
counted	O
in	O
a	O
haemacytometer	O
after	O
incubation	O
in	O
FD	O
medium	O
containing	O
5	O
%	O
FBS	B
for	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
and	O
6	O
days	O
.	O

The	O
cytotoxic	O
and	O
antiproliferative	O
activities	O
of	O
XN	B
and	O
IX	B
on	O
MCF-7	O
cells	O
were	O
determined	O
by	O
using	O
the	O
method	O
described	O
by	O
Jain	O
et	O
al.	O
(	O
1997	O
)	O
as	O
follows	O
:	O
Antiproliferative	O
activity	O
=	O
(	O
Viable	O
cells	O
control	O
−Viable	O
cells	O
treated	O
)	O
Viable	O
cells	O
control	O
×100	O
Cytotoxicity	O
=	O
%	O
cell	O
viability	O
control	O
−%	O
cell	O
viability	O
treated	O
)	O
%	O
cell	O
viability	O
control	O
×100	O
2.5	O
Effects	O
of	O
XN	B
and	O
IX	B
on	O
DNA	O
synthesis	O
in	O
MCF-7	O
cells	O
MCF-7	O
cells	O
(	O
5000	O
cells	O
/	O
well	O
)	O
were	O
seeded	O
into	O
96-well	O
plates	O
(	O
Corning	O
)	O
in	O
a	O
final	O
volume	O
of	O
0.2	O
ml	O
phenol	B
red	O
-	O
free	O
FD	O
medium	O
containing	O
10	O
%	O
FBS	B
.	O

After	O
a	O
24-hr	O
incubation	O
,	O
the	O
cells	O
were	O
treated	O
with	O
increasing	O
concentrations	O
of	O
XN	B
or	O
IX	B
in	O
FD	O
medium	O
containing	O
5	O
%	O
FBS	B
.	O

Control	O
cells	O
were	O
incubated	O
in	O
FD	O
medium	O
containing	O
0.1	O
%	O
ethanol	B
.	O

After	O
1	O
,	O
2	O
and	O
4	O
days	O
,	O
the	O
cells	O
were	O
washed	O
once	O
with	O
phenol	B
-	O
red	O
free	O
FD	O
medium	O
and	O
then	O
incubated	O
with	O
0.2	O
ml	O
of	O
[	B
methyl	I
-3	I
H	I
]	I
thymidine	I
(	O
1	O
μ	O
Ci	O
/	O
well	O
)	O
for	O
3	O
hr	O
.	O

The	O
medium	O
was	O
removed	O
and	O
the	O
cells	O
were	O
fixed	O
by	O
incubation	O
in	O
10	O
%	O
TCA	B
for	O
1	O
hr	O
at	O
4	O
°	O
C	O
.	O

The	O
cells	O
were	O
then	O
washed	O
twice	O
with	O
10	O
%	O
TCA	B
to	O
remove	O
unbound	O
radioactivity	O
.	O

The	O
plates	O
were	O
air	O
-	O
dried	O
and	O
the	O
cells	O
were	O
lysed	O
with	O
1	O
n	O
NaOH	B
(	O
0.2	O
ml	O
/	O
well	O
)	O
.	O

A	O
0.1-ml	O
aliquot	O
of	O
the	O
lysate	O
was	O
neutralized	O
with	O
HCl	B
prior	O
to	O
the	O
addition	O
of	O
scintillation	O
fluid	O
(	O
Opti	O
-	O
Fluor	O
)	O
.	O

The	O
radioactivity	O
of	O
the	O
samples	O
was	O
counted	O
in	O
a	O
liquid	O
scintillation	O
counter	O
(	O
Packard	O
Instrument	O
Company	O
,	O
Meriden	O
,	O
CT	O
,	O
USA	O
)	O
.	O

The	O
counts	O
(	O
disintegrations	O
per	O
min	O
)	O
of	O
four	O
wells	O
in	O
each	O
treatment	O
were	O
averaged	O
and	O
expressed	O
as	O
percent	O
of	O
controls	O
(	O
ethanol	B
-	O
treated	O
cells	O
)	O
.	O

2.6	O
Agarose	O
gel	O
analysis	O
of	O
DNA	O
fragmentation	O
This	O
experiment	O
was	O
performed	O
to	O
determine	O
whether	O
XN	B
and	O
IX	B
induce	O
apoptosis	O
in	O
MCF-7	O
cells	O
using	O
the	O
DNA	O
fragmentation	O
assay	O
on	O
agarose	B
gels	O
.	O

Semiconfluent	O
MCF-7	O
cells	O
growing	O
in	O
12-well	O
plates	O
were	O
incubated	O
in	O
FD	O
medium	O
containing	O
5	O
%	O
FBS	B
and	O
different	O
concentrations	O
(	O
0.1	O
,	O
0.5	O
,	O
1	O
,	O
5	O
,	O
10	O
,	O
40	O
and	O
100	O
μ	O
m	O
)	O
of	O
XN	B
or	O
IX	B
.	O

Control	O
wells	O
contained	O
0.1	O
%	O
ethanol	B
instead	O
of	O
flavonoids	B
.	O

After	O
8	O
or	O
24	O
hr	O
of	O
incubation	O
at	O
37	O
°	O
C	O
in	O
5	O
%	O
CO2	B
,	O
the	O
test	O
media	O
were	O
collected	O
in	O
microfuge	O
tubes	O
and	O
200	O
μ	O
l	O
lysis	O
buffer	O
(	O
DNAzol	O
Reagent	O
,	O
Gibco	O
/	O
BRL	O
)	O
was	O
added	O
to	O
each	O
well	O
.	O

The	O
tubes	O
containing	O
the	O
test	O
media	O
were	O
centrifuged	O
at	O
10,000	O
g	O
for	O
10	O
min	O
.	O

The	O
supernatant	O
was	O
removed	O
and	O
50	O
μ	O
l	O
lysis	O
buffer	O
was	O
added	O
to	O
each	O
tube	O
.	O

For	O
each	O
sample	O
,	O
the	O
lysate	O
from	O
the	O
wells	O
was	O
combined	O
with	O
lysate	O
in	O
the	O
microfuge	O
tube	O
.	O

Absolute	O
ethanol	B
(	O
150	O
μ	O
l	O
)	O
was	O
added	O
to	O
each	O
tube	O
containing	O
the	O
combined	O
lysate	O
to	O
precipitate	O
the	O
DNA	O
.	O

The	O
DNA	O
was	O
spooled	O
with	O
a	O
pipette	O
tip	O
and	O
attached	O
to	O
the	O
wall	O
near	O
the	O
top	O
of	O
the	O
tube	O
.	O

The	O
supernatant	O
was	O
carefully	O
aspirated	O
and	O
the	O
DNA	O
remaining	O
in	O
the	O
tube	O
was	O
washed	O
with	O
0.5	O
ml	O
of	O
95	O
%	O
ethanol	B
.	O

The	O
DNA	O
was	O
air	O
-	O
dried	O
,	O
dissolved	O
in	O
100	O
μ	O
l	O
sterile	O
water	B
and	O
an	O
aliquot	O
was	O
used	O
for	O
DNA	O
estimation	O
from	O
the	O
absorbance	O
reading	O
at	O
260	O
nm	O
.	O

The	O
isolated	O
DNA	O
(	O
6	O
μ	O
g	O
)	O
was	O
electrophoresed	O
on	O
a	O
1.5	O
%	O
agarose	B
gel	O
containing	O
ethidium	B
bromide	I
for	O
1.5	O
hr	O
in	O
TAE	B
buffer	O
(	O
40	O
mm	O
Tris	B
-	I
acetate	I
and	O
1	O
mm	O
EDTA	B
,	O
pH	O
8)	O
.	O

Gels	O
were	O
stained	O
with	O
ethidium	B
bromide	I
,	O
then	O
destained	O
in	O
water	B
containing	O
RNAse	O
A	O
and	O
viewed	O
on	O
a	O
UV	O
transilluminator	O
.	O

Photos	O
were	O
taken	O
using	O
a	O
digital	O
camera	O
attached	O
to	O
a	O
computer	O
with	O
a	O
video	O
processor	O
(	O
UVP	O
Image	O
Store	O
7500	O
,	O
Ultra	O
Violet	O
Products	O
,	O
Upland	O
,	O
CA	O
,	O
USA	O
)	O
.	O

2.7	O
Preparation	O
and	O
treatment	O
of	O
primary	O
cultures	O
of	O
rat	O
hepatocytes	O
Primary	O
cultures	O
of	O
rat	O
hepatocytes	O
were	O
obtained	O
from	O
8–11-day	O
-	O
old	O
Sprague	O
–	O
Dawley	O
rats	O
using	O
a	O
procedure	O
originally	O
described	O
by	O
Acosta	O
et	O
al.	O
(	O
1980	O
)	O
.	O

The	O
liver	O
was	O
perfused	O
by	O
retrograde	O
perfusion	O
of	O
the	O
portal	O
vein	O
with	O
a	O
modified	O
Hanks	O
'	O
calcium	B
-	O
free	O
balanced	O
salt	O
solution	O
containing	O
collagenase	O
Type	O
II	O
(	O
80	O
U	O
/	O
ml	O
)	O
.	O

The	O
pellet	O
(	O
hepatocytes	O
)	O
,	O
obtained	O
after	O
several	O
steps	O
of	O
mechanical	O
dissociation	O
and	O
low	O
-	O
speed	O
centrifugation	O
of	O
the	O
tissue	O
homogenates	O
,	O
was	O
resuspended	O
in	O
Williams	O
'	O
medium	O
E	O
containing	O
0.001	O
%	O
(	O
w	O
/	O
v	O
)	O
insulin	B
,	O
0.005	O
%	O
(	O
w	O
/	O
v	O
)	O
hydrocortisone	B
,	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
newborn	O
bovine	O
serum	O
,	O
potassium	B
penicillin	I
G	I
(	O
200	O
U	O
/	O
ml	O
)	O
streptomycin	B
sulfate	I
(	O
200	O
μ	O
g	O
/	O
ml	O
)	O
,	O
and	O
amphotericin	B
B	I
(	O
4	O
μ	O
g	O
/	O
ml	O
)	O
.	O

The	O
cell	O
suspension	O
was	O
strained	O
through	O
a	O
sterile	O
nylon	B
strainer	O
(	O
100	O
μ	O
m	O
)	O
into	O
a	O
50-ml	O
centrifuge	O
tube	O
.	O

Cell	O
viability	O
was	O
greater	O
than	O
95	O
%	O
as	O
determined	O
with	O
the	O
trypan	B
blue	I
dye	O
exclusion	O
test	O
.	O

The	O
cell	O
suspension	O
was	O
diluted	O
to	O
1.0	O
×	O
106	O
cells	O
/	O
ml	O
and	O
transferred	O
to	O
24-well	O
plates	O
at	O
0.5	O
ml	O
/	O
well	O
.	O

Hepatocyte	O
cultures	O
were	O
grown	O
in	O
a	O
CO2	B
incubator	O
with	O
95	O
%	O
air	O
and	O
5	O
%	O
CO2	B
at	O
37	O
°	O
C	O
and	O
maintained	O
at	O
a	O
pH	O
of	O
7.2–7.4	O
.	O

At	O
24	O
hr	O
from	O
the	O
initial	O
plating	O
,	O
the	O
culture	O
plate	O
was	O
shaken	O
in	O
a	O
circular	O
motion	O
,	O
cell	O
debris	O
was	O
removed	O
and	O
culture	O
medium	O
was	O
replaced	O
with	O
fresh	O
medium	O
.	O

The	O
incubation	O
medium	O
was	O
changed	O
every	O
24	O
hr	O
.	O

Hepatocytes	O
were	O
grown	O
in	O
culture	O
to	O
near	O
confluence	O
for	O
2	O
days	O
prior	O
to	O
treatment	O
with	O
the	O
hop	O
flavonoids	B
.	O

The	O
primary	O
hepatocyte	O
cultures	O
were	O
exposed	O
to	O
the	O
flavonoids	B
(	O
in	O
ethanol	B
)	O
at	O
concentrations	O
of	O
0	O
,	O
0.1	O
,	O
1.0	O
,	O
10	O
or	O
100	O
μ	O
m	O
(	O
only	O
XN	B
and	O
IX	B
were	O
used	O
at	O
the	O
highest	O
concentration	O
)	O
.	O

The	O
final	O
concentration	O
of	O
ethanol	B
in	O
the	O
incubation	O
medium	O
was	O
0.1	O
%	O
,	O
which	O
did	O
not	O
affect	O
the	O
viability	O
of	O
the	O
hepatocytes	O
.	O

Control	O
incubations	O
contained	O
ethanol	B
(	O
0.1	O
%	O
)	O
.	O

Untreated	O
cells	O
(	O
no	O
ethanol	B
)	O
were	O
also	O
incubated	O
to	O
help	O
assess	O
the	O
effect	O
of	O
ethanol	B
itself	O
on	O
the	O
viability	O
of	O
the	O
hepatocytes	O
.	O

After	O
1	O
,	O
6	O
,	O
24	O
and	O
48	O
hr	O
of	O
incubation	O
,	O
aliquots	O
of	O
the	O
cell	O
supernatants	O
(	O
after	O
centrifugation	O
)	O
were	O
analysed	O
for	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
activity	O
using	O
a	O
Sigma	O
diagnostic	O
kit	O
(	O
Cat	O
.	O

No.	O
500	O
)	O
in	O
a	O
96-well	O
microplate	O
reader	O
(	O
SpectraMax	O
250	O
,	O
Molecular	O
Devices	O
,	O
Sunnyvale	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Enzyme	B
activity	O
was	O
expressed	O
as	O
units	O
/	O
ml	O
of	O
culture	O
medium	O
.	O

2.8	O
Statistical	O
analysis	O
Statistical	O
significance	O
was	O
determined	O
by	O
Student	O
's	O
t	O
-test	O
.	O

In	O
all	O
cases	O
,	O
P	O
values	O
<	O
0.05	O
were	O
considered	O
statistically	O
significant	O
.	O

3	O
Results	O
3.1	O
Sulforhodamine	B
assay	O
The	O
SRB	B
assay	O
is	O
an	O
indirect	O
measure	O
of	O
cell	O
density	O
or	O
number	O
of	O
live	O
cells	O
attached	O
to	O
the	O
culture	O
plate	O
(	O
Skehan	O
et	O
al.	O
,	O
1990	O
)	O
.	O

As	O
shown	O
by	O
Skehan	O
et	O
al.	O
(	O
1990	O
)	O
,	O
the	O
SRB	B
results	O
are	O
linear	O
with	O
the	O
number	O
of	O
viable	O
cells	O
and	O
protein	O
content	O
in	O
the	O
wells	O
at	O
densities	O
from	O
sparse	O
subconfluence	O
to	O
multilayered	O
supraconfluence	O
.	O

In	O
agreement	O
with	O
these	O
results	O
,	O
we	O
found	O
that	O
dead	O
cells	O
detached	O
from	O
the	O
plate	O
and	O
were	O
removed	O
with	O
the	O
culture	O
media	O
during	O
the	O
SRB	B
assay	O
.	O

Microscopic	O
examination	O
of	O
the	O
individual	O
wells	O
of	O
the	O
culture	O
plate	O
showed	O
this	O
detachment	O
of	O
dead	O
cells	O
.	O

The	O
antiproliferative	O
activity	O
was	O
then	O
measured	O
as	O
a	O
ratio	O
of	O
the	O
number	O
of	O
viable	O
cells	O
(	O
expressed	O
as	O
OD	O
units	O
)	O
in	O
flavonoid	B
-	O
treated	O
wells	O
and	O
in	O
ethanol	B
(	O
vehicle	O
)	O
-treated	O
wells	O
.	O

Cytotoxicity	O
was	O
inferred	O
from	O
the	O
SRB	B
assay	O
by	O
comparing	O
the	O
OD	O
units	O
of	O
the	O
wells	O
with	O
flavonoid	B
-	O
treated	O
cells	O
at	O
designated	O
times	O
after	O
treatment	O
with	O
those	O
wells	O
with	O
untreated	O
cells	O
at	O
day	O
zero	O
(	O
cells	O
in	O
plates	O
before	O
treatment	O
with	O
flavonoid	B
or	O
ethanol	B
)	O
.	O

Lower	O
OD	O
readings	O
after	O
2	O
,	O
4	O
or	O
6	O
days	O
of	O
treatment	O
compared	O
with	O
OD	O
readings	O
at	O
day	O
zero	O
indicate	O
occurrence	O
of	O
cell	O
death	O
or	O
cytotoxicity	O
,	O
instead	O
of	O
growth	O
inhibition	O
or	O
antiproliferative	O
activity	O
.	O

With	O
this	O
method	O
,	O
our	O
results	O
showed	O
that	O
cell	O
death	O
occurred	O
in	O
the	O
MCF-7	O
,	O
HT-29	O
and	O
A-2780	O
cells	O
treated	O
with	O
any	O
of	O
the	O
hop	B
flavonoids	B
when	O
used	O
at	O
100	O
μ	O
m	O
concentration	O
(	O
data	O
not	O
shown	O
)	O
.	O

Cytotoxicity	O
of	O
the	O
flavonoids	B
at	O
this	O
concentration	O
was	O
verified	O
by	O
microscopic	O
examination	O
of	O
the	O
96-well	O
plates	O
.	O

Fig.	O
2	O
shows	O
the	O
dose	O
–	O
response	O
relationship	O
of	O
the	O
five	O
chalcones	B
and	O
one	O
flavanone	B
(	O
IX	B
)	O
with	O
the	O
growth	O
(	O
as	O
percent	O
of	O
control	O
)	O
of	O
human	O
breast	O
cancer	O
cells	O
(	O
MCF-7	O
)	O
after	O
a	O
2-day	O
(	O
A	O
)	O
or	O
4-day	O
(	O
B	O
)	O
period	O
of	O
treatment	O
.	O

At	O
0.1	O
and	O
1.0	O
μ	O
m	O
,	O
only	O
DX	B
caused	O
a	O
significant	O
inhibition	O
of	O
growth	O
of	O
breast	O
cancer	O
cells	O
after	O
2	O
days	O
of	O
exposure	O
(	O
Fig.	O
2	O
A	O
)	O
.	O

At	O
10	O
μ	O
m	O
,	O
XN	B
was	O
most	O
growth	O
-	O
inhibitory	O
followed	O
by	O
DX	B
,	O
IX	B
and	O
TG	B
in	O
that	O
order	O
.	O

At	O
100	O
μ	O
m	O
,	O
all	O
the	O
flavonoids	B
except	O
TP	B
almost	O
completely	O
inhibited	O
the	O
growth	O
of	O
breast	O
cancer	O
cells	O
.	O

A	O
greater	O
inhibition	O
of	O
growth	O
of	O
breast	O
cancer	O
cells	O
was	O
obtained	O
with	O
10	O
μ	O
m	O
XN	B
,	O
DX	B
and	O
IX	B
at	O
4	O
days	O
(	O
Fig.	O
2	O
B	O
)	O
than	O
at	O
2	O
days	O
of	O
exposure	O
and	O
XN	B
was	O
the	O
most	O
active	O
flavonoid	B
.	O

At	O
100	O
μ	O
m	O
,	O
all	O
the	O
flavonoids	B
almost	O
completely	O
inhibited	O
the	O
growth	O
of	O
breast	O
cancer	O
cells	O
after	O
4	O
days	O
of	O
treatment	O
(	O
Fig.	O
2	O
B	O
)	O
.	O

The	O
effects	O
of	O
the	O
hop	O
flavonoids	B
on	O
growth	O
of	O
human	O
colon	O
cancer	O
cells	O
(	O
HT-29	O
)	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

Unlike	O
MCF-7	O
cells	O
,	O
the	O
growth	O
of	O
human	O
colon	O
cancer	O
cells	O
(	O
HT-29	O
)	O
was	O
only	O
slightly	O
inhibited	O
(	O
less	O
than	O
11	O
%	O
inhibition	O
)	O
at	O
10	O
μ	O
m	O
of	O
XN	B
and	O
DX	B
after	O
2	O
days	O
of	O
treatment	O
(	O
Fig.	O
3	O
A	O
)	O
.	O

Approximately	O
8–12	O
%	O
of	O
the	O
HT-29	O
cells	O
exposed	O
to	O
100	O
μ	O
m	O
TP	B
,	O
DH	B
and	O
IX	B
survived	O
after	O
2	O
days	O
of	O
treatment	O
.	O

After	O
4	O
days	O
of	O
treatment	O
of	O
colon	O
cancer	O
cells	O
,	O
flavonoids	B
did	O
not	O
inhibit	O
cell	O
growth	O
at	O
10	O
μ	O
m	O
or	O
lower	O
concentration	O
.	O

However	O
,	O
all	O
the	O
flavonoids	B
almost	O
completely	O
inhibited	O
cell	O
growth	O
at	O
100	O
μ	O
m	O
(	O
Fig.	O
3	O
B	O
)	O
.	O

The	O
response	O
of	O
ovarian	O
cancer	O
cells	O
(	O
A-2780	O
)	O
to	O
the	O
antiproliferative	O
activity	O
of	O
hop	O
flavonoids	B
is	O
depicted	O
in	O
Fig.	O
4	O
.	O

The	O
growth	O
of	O
these	O
cancer	O
cells	O
was	O
significantly	O
inhibited	O
by	O
all	O
the	O
flavonoids	B
at	O
10	O
μ	O
m	O
and	O
by	O
XN	B
,	O
TP	B
and	O
TG	B
at	O
1	O
μ	O
m	O
after	O
2	O
days	O
of	O
treatment	O
(	O
Fig.	O
4	O
A	O
)	O
.	O

Significant	O
inhibition	O
of	O
cell	O
growth	O
was	O
observed	O
even	O
at	O
0.1	O
for	O
TP	B
and	O
TG	B
.	O

At	O
100	O
μ	O
m	O
,	O
all	O
the	O
flavonoids	B
were	O
highly	O
toxic	O
to	O
the	O
cells	O
.	O

After	O
4	O
days	O
,	O
none	O
of	O
the	O
flavonoids	B
(	O
at	O
0.1	O
,	O
1	O
or	O
10	O
μ	O
m	O
)	O
,	O
except	O
XN	B
(	O
10	O
μ	O
m	O
)	O
,	O
inhibited	O
the	O
growth	O
of	O
ovarian	O
cancer	O
cells	O
(	O
Fig.	O
4	O
B	O
)	O
but	O
at	O
100	O
μ	O
m	O
,	O
all	O
the	O
flavonoids	B
almost	O
completely	O
inhibited	O
their	O
growth	O
.	O

An	O
expanded	O
range	O
of	O
doses	O
(	O
0.01	O
,	O
0.1	O
,	O
1.0	O
,	O
2.5	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
,	O
60	O
and	O
100	O
μ	O
m	O
)	O
was	O
then	O
used	O
to	O
further	O
evaluate	O
the	O
relative	O
growth	O
-	O
inhibitory	O
activity	O
of	O
XN	B
,	O
DX	B
and	O
IX	B
in	O
A-2780	O
and	O
MCF-7	O
cells	O
by	O
calculating	O
and	O
comparing	O
their	O
IC50	O
values	O
.	O

These	O
three	O
flavonoids	B
were	O
chosen	O
for	O
further	O
evaluation	O
because	O
they	O
differed	O
widely	O
in	O
their	O
ability	O
to	O
inhibit	O
growth	O
of	O
A-2780	O
and	O
MCF-7	O
cells	O
.	O

The	O
dose	O
–	O
response	O
curve	O
revealed	O
that	O
the	O
antiproliferative	O
activity	O
of	O
XN	B
at	O
10	O
μ	O
m	O
or	O
greater	O
was	O
similar	O
at	O
2	O
,	O
4	O
and	O
6	O
days	O
in	O
human	O
ovarian	O
cancer	O
cells	O
(	O
A-2780	O
)	O
(	O
Fig.	O
5	O
)	O
.	O

However	O
,	O
at	O
lower	O
concentrations	O
,	O
the	O
growth	O
-	O
inhibitory	O
activity	O
of	O
XN	B
to	O
A-2780	O
cells	O
decreased	O
with	O
time	O
of	O
exposure	O
.	O

The	O
calculated	O
IC50	O
of	O
XN	B
at	O
2	O
,	O
4	O
and	O
6	O
days	O
of	O
exposure	O
were	O
0.52	O
,	O
5.2	O
and	O
6.7	O
μ	O
m	O
,	O
respectively	O
.	O

Similarly	O
to	O
XN	B
,	O
DX	B
and	O
IX	B
also	O
displayed	O
lower	O
IC50	O
values	O
in	O
A-2780	O
cells	O
at	O
2	O
days	O
than	O
at	O
4	O
days	O
of	O
treatment	O
(	O
Table	O
1	O
)	O
.	O

However	O
,	O
in	O
human	O
breast	O
cancer	O
cells	O
(	O
MCF-7	O
)	O
,	O
the	O
flavonoids	B
(	O
XN	B
,	O
DX	B
and	O
IX	B
)	O
were	O
more	O
inhibitory	O
(	O
lower	O
IC50	O
)	O
at	O
4	O
days	O
than	O
at	O
2	O
days	O
of	O
treatment	O
(	O
Table	O
1	O
)	O
.	O

XN	B
was	O
more	O
effective	O
than	O
DX	B
or	O
IX	B
in	O
inhibiting	O
the	O
growth	O
of	O
MCF-7	O
cells	O
at	O
both	O
times	O
of	O
exposure	O
.	O

3.2	O
Antiproliferative	O
effects	O
of	O
XN	B
and	O
IX	B
on	O
MCF-7	O
cells	O
as	O
determined	O
by	O
cell	O
counting	O
using	O
the	O
trypan	B
blue	I
exclusion	O
method	O
Another	O
method	O
to	O
determine	O
the	O
antiproliferative	O
activities	O
of	O
XN	B
and	O
IX	B
on	O
MCF-7	O
cells	O
is	O
to	O
use	O
a	O
haemacytometer	O
to	O
count	O
the	O
number	O
of	O
viable	O
cells	O
remaining	O
after	O
the	O
designated	O
treatment	O
period	O
.	O

Using	O
this	O
cell	O
counting	O
method	O
,	O
it	O
was	O
determined	O
that	O
XN	B
and	O
IX	B
,	O
at	O
0.01	O
to	O
10	O
μ	O
m	O
,	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
MCF-7	O
cells	O
after	O
8	O
hr	O
of	O
treatment	O
(	O
Fig.	O
6	O
A	O
)	O
.	O

However	O
,	O
at	O
100	O
μ	O
m	O
,	O
both	O
flavonoids	B
significantly	O
inhibited	O
the	O
growth	O
of	O
MCF-7	O
cells	O
during	O
the	O
same	O
period	O
.	O

After	O
1	O
day	O
of	O
treatment	O
,	O
XN	B
significantly	O
inhibited	O
the	O
proliferation	O
of	O
MCF-7	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
from	O
0.01	O
to	O
100	O
μ	O
m	O
(	O
Fig.	O
6	O
B	O
)	O
.	O

In	O
contrast	O
,	O
IX	B
was	O
only	O
inhibitory	O
at	O
100	O
μ	O
m	O
.	O

After	O
2	O
days	O
,	O
growth	O
inhibition	O
induced	O
by	O
XN	B
became	O
more	O
pronounced	O
(	O
Fig.	O
6	O
C	O
)	O
.	O

IX	B
became	O
inhibitory	O
at	O
10	O
μ	O
m	O
,	O
and	O
at	O
100	O
μ	O
m	O
,	O
both	O
XN	B
and	O
IX	B
produced	O
a	O
complete	O
inhibition	O
of	O
cell	O
growth	O
.	O

The	O
population	O
doubling	O
of	O
untreated	O
MCF-7	O
cells	O
in	O
FD	O
medium	O
containing	O
5	O
%	O
FBS	B
was	O
estimated	O
to	O
be	O
1.3	O
days	O
.	O

3.3	O
Cytotoxic	O
effects	O
of	O
XN	B
and	O
IX	B
on	O
MCF-7	O
cells	O
as	O
determined	O
by	O
cell	O
counting	O
using	O
the	O
trypan	B
blue	I
exclusion	O
method	O
Cytotoxicity	O
of	O
XN	B
and	O
IX	B
in	O
MCF-7	O
cells	O
was	O
investigated	O
using	O
the	O
trypan	B
blue	I
exclusion	O
method	O
.	O

Neither	O
XN	B
nor	O
IX	B
,	O
at	O
0.01–10	O
μ	O
m	O
,	O
produced	O
cytotoxicity	O
in	O
these	O
cells	O
after	O
8	O
hr	O
of	O
treatment	O
(	O
Fig.	O
7	O
A	O
)	O
.	O

At	O
100	O
μ	O
m	O
,	O
these	O
two	O
flavonoids	B
were	O
toxic	O
to	O
MCF-7	O
cells	O
.	O

After	O
24	O
hr	O
,	O
XN	B
but	O
not	O
IX	B
was	O
slightly	O
toxic	O
at	O
10	O
μ	O
m	O
(	O
Fig.	O
7	O
B	O
)	O
.	O

When	O
the	O
treatment	O
period	O
was	O
increased	O
to	O
2	O
days	O
,	O
XN	B
became	O
slightly	O
toxic	O
to	O
MCF-7	O
cells	O
at	O
0.01	O
μ	O
m	O
or	O
higher	O
(	O
Fig.	O
7	O
C	O
)	O
.	O

At	O
this	O
time	O
,	O
10	O
μ	O
m	O
IX	B
showed	O
significant	O
toxicity	O
to	O
MCF-7	O
cells	O
.	O

At	O
100	O
μ	O
m	O
XN	B
or	O
IX	B
,	O
virtually	O
all	O
the	O
cells	O
were	O
killed	O
after	O
2	O
days	O
of	O
exposure	O
.	O

Microscopic	O
examination	O
showed	O
that	O
most	O
of	O
the	O
dead	O
cells	O
were	O
in	O
the	O
culture	O
media	O
,	O
not	O
attached	O
to	O
the	O
culture	O
plate	O
.	O

3.4	O
Effects	O
of	O
XN	B
and	O
IX	B
on	O
DNA	O
synthesis	O
in	O
MCF-7	O
cells	O
The	O
effects	O
of	O
XN	B
and	O
IX	B
on	O
DNA	O
synthesis	O
,	O
as	O
determined	O
by	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
MCF-7	O
cells	O
,	O
are	O
shown	O
in	O
Fig.	O
8	O
.	O

Both	O
XN	B
and	O
IX	B
caused	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
DNA	O
synthesis	O
after	O
one	O
day	O
of	O
treatment	O
(	O
Fig.	O
8	O
A	O
)	O
.	O

XN	B
inhibited	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
at	O
much	O
lower	O
concentrations	O
than	O
IX	B
.	O

The	O
doses	O
at	O
which	O
a	O
significant	O
decrease	O
in	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
was	O
initially	O
observed	O
were	O
0.5	O
μ	O
m	O
for	O
XN	B
and	O
5	O
μ	O
m	O
for	O
IX	B
.	O

A	O
similar	O
pattern	O
of	O
inhibition	O
of	O
DNA	O
synthesis	O
was	O
obtained	O
after	O
2	O
days	O
of	O
exposure	O
(	O
Fig.	O
8	O
B	O
)	O
.	O

However	O
,	O
after	O
4	O
days	O
,	O
IX	B
was	O
more	O
effective	O
than	O
XN	B
in	O
inhibiting	O
thymidine	B
incorporation	O
at	O
5	O
μ	O
m	O
or	O
lower	O
(	O
Fig.	O
8	O
C	O
)	O
.	O

At	O
10	O
and	O
20	O
μ	O
m	O
,	O
XN	B
was	O
more	O
inhibitory	O
than	O
IX	B
.	O

XN	B
caused	O
an	O
unusual	O
pattern	O
of	O
inhibition	O
of	O
thymidine	B
incorporation	O
into	O
MCF-7	O
cells	O
in	O
that	O
a	O
significant	O
inhibition	O
was	O
observed	O
at	O
0.01	O
,	O
0.1	O
,	O
0.5	O
,	O
10	O
and	O
20	O
μ	O
m	O
but	O
not	O
at	O
1	O
or	O
2.5	O
μ	O
m	O
.	O

The	O
degree	O
of	O
inhibitory	O
effect	O
of	O
XN	B
at	O
5	O
and	O
10	O
μ	O
m	O
was	O
relatively	O
greater	O
at	O
2	O
days	O
than	O
at	O
4	O
days	O
of	O
treatment	O
.	O

3.5	O
Agarose	B
gel	O
analysis	O
of	O
DNA	O
fragmentation	O
One	O
of	O
the	O
hallmarks	O
of	O
apoptosis	O
is	O
the	O
production	O
of	O
characteristic	O
DNA	O
fragments	O
when	O
the	O
DNA	O
is	O
cleaved	O
by	O
Ca++	B
-dependent	O
endonucleases	O
at	O
the	O
linker	O
sites	O
between	O
nucleosomes	O
(	O
Arends	O
and	O
Wyllie	O
,	O
1991	O
)	O
.	O

The	O
ultimate	O
DNA	O
fragments	O
are	O
multimers	O
of	O
180-bp	O
fragments	O
that	O
resolve	O
into	O
a	O
""""	O
DNA	O
ladder	O
""""	O
during	O
electrophoresis	O
on	O
agarose	B
gels	O
.	O

Neither	O
XN	B
nor	O
IX	B
at	O
10	O
,	O
40	O
or	O
100	O
μ	O
m	O
induced	O
internucleosomal	O
DNA	O
fragmentation	O
in	O
MCF-7	O
cells	O
after	O
8	O
(	O
Plate	O
I	O
A	O
)	O
or	O
24	O
hr	O
(	O
Plate	O
I	O
B	O
)	O
of	O
treatment	O
.	O

3.6	O
Toxicity	O
of	O
hop	O
flavonoids	B
in	O
rat	O
hepatocyte	O
cultures	O
The	O
toxicity	O
of	O
XN	B
,	O
TP	B
,	O
TG	B
,	O
DH	B
and	O
IX	B
in	O
primary	O
cultures	O
of	O
rat	O
hepatocytes	O
was	O
measured	O
by	O
the	O
release	O
of	O
lactate	O
dehydrogenase	O
into	O
the	O
culture	O
medium	O
.	O

Cell	O
viability	O
was	O
not	O
significantly	O
affected	O
by	O
the	O
flavonoids	B
at	O
10	O
μ	O
m	O
or	O
lower	O
after	O
24	O
hr	O
of	O
treatment	O
(	O
Fig.	O
9	O
)	O
or	O
after	O
1	O
,	O
6	O
or	O
48	O
hr	O
of	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

At	O
100	O
μ	O
m	O
,	O
XN	B
and	O
IX	B
were	O
highly	O
toxic	O
to	O
the	O
hepatocytes	O
.	O

The	O
toxicity	O
of	O
TP	B
,	O
TG	B
and	O
DH	B
at	O
100	O
μ	O
m	O
was	O
not	O
evaluated	O
because	O
of	O
insufficient	O
supply	O
of	O
these	O
flavonoids	B
at	O
the	O
time	O
of	O
the	O
study	O
.	O

For	O
the	O
same	O
reason	O
,	O
no	O
toxicity	O
data	O
from	O
the	O
rat	O
hepatocyte	O
studies	O
for	O
DX	B
could	O
be	O
presented	O
in	O
this	O
report	O
.	O

Additional	O
preliminary	O
studies	O
showed	O
that	O
the	O
five	O
hop	O
flavonoids	B
do	O
not	O
inhibit	O
mitochondrial	O
respiration	O
and	O
do	O
not	O
uncouple	O
oxidative	O
phoshorylation	O
in	O
isolated	O
rat	O
liver	O
mitochondria	O
at	O
10	O
μ	O
m	O
or	O
lower	O
(	O
R.J.	O
Rodriguez	O
,	O
C.L.	O
Miranda	O
,	O
J.F.	O
Stevens	O
,	O
M.L.	O
Deinzer	O
and	O
D.R.	O
Buhler	O
,	O
unpublished	O
observations	O
)	O
.	O

4	O
Discussion	O
Previous	O
studies	O
have	O
shown	O
that	O
certain	O
synthesized	B
or	O
naturally	B
-	I
occurring	I
chalcone	I
compounds	I
(	O
not	O
found	O
in	O
hops	O
)	O
exhibit	O
antiproliferative	O
activities	O
in	O
human	O
cancer	O
cell	O
lines	O
(	O
De	O
Mello	O
et	O
al.	O
,	O
1974	O
;	O
Ramanathan	O
et	O
al.	O
,	O
1993	O
;	O
Satomi	O
,	O
1993	O
;	O
Yit	O
and	O
Das	O
,	O
1994	O
)	O
.	O

The	O
potency	O
of	O
the	O
chalcones	B
(	O
butein	B
,	O
2′-hydroxychalcone	B
,	O
2-hydroxychalcone	B
,	O
2′,6′-dihydroxy-4′-methoxychalcone	B
and	O
2′,4-dihydroxychalcone	B
)	O
as	O
inhibitors	O
of	O
growth	O
of	O
human	O
colon	O
adenocarcinoma	O
cell	O
line	O
,	O
CCL	O
220.1	O
,	O
was	O
dependent	O
on	O
the	O
position	O
and	O
number	O
of	O
hydroxyl	B
groups	I
in	O
the	O
chalcone	B
nucleus	O
(	O
Yit	O
and	O
Das	O
,	O
1994	O
)	O
.	O

In	O
both	O
primary	O
and	O
established	O
ovarian	O
cancer	O
cells	O
,	O
the	O
presence	O
of	O
an	O
α	O
-β	O
double	O
bond	O
,	O
the	O
hydroxylation	B
at	O
the	O
2	O
or	O
3	O
position	O
of	O
ring	O
B	O
and	O
the	O
absence	O
of	O
a	O
prenyl	B
group	I
were	O
important	O
to	O
the	O
antiproliferative	O
activity	O
of	O
chalcones	B
(	O
De	O
Vincenzo	O
et	O
al.	O
,	O
1995	O
)	O
.	O

Thus	O
,	O
it	O
was	O
of	O
interest	O
to	O
determine	O
whether	O
chalcone	B
compounds	I
found	O
in	O
hops	O
have	O
antiproliferative	O
effects	O
in	O
certain	O
human	O
cancer	O
cell	O
lines	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
using	O
the	O
sulforhodamine	B
assay	O
showed	O
that	O
of	O
the	O
five	O
hop	O
chalcones	B
tested	O
,	O
XN	B
was	O
the	O
most	O
effective	O
antiproliferative	O
agent	O
in	O
human	O
breast	O
cancer	O
cells	O
(	O
MCF-7	O
)	O
,	O
colon	O
cancer	O
cells	O
(	O
HT-29	O
)	O
and	O
ovarian	O
cancer	O
cells	O
(	O
A-2780	O
)	O
.	O

IX	B
was	O
the	O
least	O
effective	O
inhibitor	O
of	O
growth	O
of	O
A-2780	O
cells	O
whereas	O
TP	B
and	O
DH	B
were	O
least	O
active	O
in	O
MCF-7	O
cells	O
.	O

Of	O
the	O
three	O
cell	O
lines	O
studied	O
,	O
A-2780	O
was	O
more	O
sensitive	O
than	O
MCF-7	O
cells	O
to	O
the	O
antiproliferative	O
activities	O
of	O
all	O
five	O
hop	O
flavonoids	B
tested	O
.	O

The	O
differential	O
activity	O
of	O
the	O
chalcones	B
tested	O
in	O
this	O
study	O
can	O
be	O
ascribed	O
to	O
the	O
nature	O
and	O
position	O
of	O
substituents	O
in	O
the	O
chalcone	B
molecule	O
.	O

The	O
presence	O
of	O
a	O
methoxy	B
group	I
(	O
in	O
XN	B
)	O
,	O
instead	O
of	O
a	O
hydroxyl	B
group	I
(	O
in	O
TP	B
)	O
at	O
the	O
6′	O
position	O
in	O
the	O
A	O
ring	O
,	O
appeared	O
to	O
increase	O
the	O
growth	O
inhibitory	O
activity	O
of	O
the	O
chalcone	B
for	O
MCF-7	O
(	O
Fig.	O
2	O
)	O
and	O
HT-29	O
(	O
Fig.	O
3	O
)	O
cells	O
but	O
not	O
for	O
A-2780	O
cells	O
(	O
Fig.	O
4	O
)	O
.	O

Substitution	O
of	O
the	O
prenyl	B
group	I
with	O
a	O
geranyl	B
group	I
at	O
the	O
3′	O
position	O
(	O
TP	B
to	O
TG	B
)	O
resulted	O
in	O
reduced	O
growth	O
of	O
A-2780	O
but	O
not	O
of	O
MCF-7	O
cells	O
.	O

The	O
addition	O
of	O
a	O
hydroxyl	B
group	I
to	O
DX	B
,	O
as	O
in	O
DH	B
,	O
decreased	O
the	O
antiproliferative	O
activity	O
in	O
MCF-7	O
cells	O
,	O
but	O
not	O
in	O
A-2780	O
cells	O
.	O

Conversion	O
of	O
a	O
chalcone	B
to	O
a	O
flavanone	B
(	O
XN	B
to	O
IX	B
)	O
also	O
resulted	O
in	O
reduced	O
antiproliferative	O
activity	O
in	O
MCF-7	O
and	O
A-2780	O
cells	O
.	O

IX	B
is	O
a	O
trace	O
component	O
of	O
hops	O
but	O
is	O
the	O
most	O
abundant	O
flavonoid	B
in	O
hopped	O
beer	O
as	O
a	O
result	O
of	O
the	O
isomerization	O
of	O
XN	B
during	O
the	O
brewing	O
process	O
(	O
Stevens	O
et	O
al.	O
,	O
1999	O
)	O
.	O

The	O
ovarian	O
cancer	O
cell	O
line	O
(	O
A-2780	O
)	O
was	O
more	O
sensitive	O
than	O
the	O
colon	O
and	O
breast	O
cancer	O
cell	O
lines	O
to	O
the	O
toxic	O
effects	O
of	O
XN	B
,	O
TP	B
and	O
TG	B
after	O
2	O
days	O
of	O
exposure	O
.	O

In	O
A-2780	O
cells	O
,	O
these	O
chalcones	B
were	O
cytotoxic	O
at	O
concentrations	O
as	O
low	O
as	O
0.1	O
μ	O
m	O
.	O

However	O
,	O
a	O
4-day	O
treatment	O
with	O
TP	B
or	O
TG	B
at	O
concentrations	O
up	O
to	O
10	O
μ	O
m	O
did	O
not	O
inhibit	O
ovarian	O
cancer	O
cell	O
growth	O
.	O

Furthermore	O
,	O
the	O
IC50	O
of	O
XN	B
increased	O
from	O
0.5	O
μ	O
m	O
at	O
2	O
days	O
to	O
5.2	O
μ	O
m	O
at	O
4	O
days	O
in	O
A-2780	O
cells	O
.	O

The	O
increase	O
in	O
IC50	O
values	O
in	O
these	O
cells	O
at	O
4	O
days	O
was	O
also	O
observed	O
with	O
DX	B
and	O
IX	B
.	O

These	O
results	O
suggest	O
that	O
the	O
ovarian	O
cancer	O
cells	O
became	O
less	O
sensitive	O
to	O
the	O
hop	O
flavonoids	B
with	O
increased	O
length	O
of	O
exposure	O
.	O

There	O
are	O
several	O
possibilities	O
that	O
may	O
explain	O
the	O
decreased	O
sensitivity	O
of	O
the	O
ovarian	O
cancer	O
cells	O
with	O
increased	O
length	O
of	O
exposure	O
.	O

The	O
loss	O
of	O
antiproliferative	O
activity	O
of	O
the	O
hop	O
flavonoids	B
in	O
A-2780	O
cells	O
could	O
be	O
attributed	O
to	O
detoxification	O
of	O
the	O
flavonoids	B
by	O
the	O
ovarian	O
cancer	O
cells	O
.	O

During	O
the	O
4-day	O
exposure	O
,	O
the	O
culture	O
medium	O
was	O
not	O
replaced	O
with	O
fresh	O
medium	O
containing	O
the	O
flavonoids	B
.	O

The	O
concentration	O
of	O
the	O
flavonoids	B
or	O
their	O
inhibitory	O
metabolites	B
may	O
have	O
decreased	O
over	O
time	O
in	O
the	O
incubation	O
medium	O
due	O
to	O
detoxification	O
or	O
non	O
-	O
enzymatic	O
degradation	O
.	O

Nielsen	O
et	O
al.	O
(	O
1998	O
)	O
have	O
found	O
that	O
rat	O
P450	O
enzymes	O
are	O
capable	O
of	O
hydroxylating	B
and	O
demethylating	O
flavanones	B
,	O
flavones	B
or	O
flavonols	B
.	O

Preliminary	O
studies	O
in	O
our	O
laboratory	O
showed	O
that	O
cytochrome	O
P450	O
enzymes	O
are	O
involved	O
in	O
the	O
metabolism	O
of	O
XN	B
in	O
rat	O
liver	O
microsomes	O
(	O
unpublished	O
data	O
)	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
human	O
cancer	O
cells	O
can	O
detoxify	O
the	O
hop	O
flavonoids	B
.	O

Studies	O
on	O
the	O
metabolic	O
transformation	O
of	O
hop	O
flavonoids	B
by	O
the	O
human	O
cancer	O
cell	O
lines	O
may	O
help	O
explain	O
the	O
differential	O
sensitivity	O
of	O
the	O
three	O
human	O
cancer	O
cells	O
to	O
these	O
compounds	O
.	O

In	O
particular	O
,	O
these	O
metabolism	O
studies	O
may	O
explain	O
why	O
the	O
hop	O
chalcones	B
were	O
not	O
potent	O
in	O
inhibiting	O
the	O
growth	O
of	O
colon	O
cancer	O
cells	O
(	O
HT-29	O
)	O
despite	O
previous	O
studies	O
showing	O
that	O
other	O
chalcones	B
are	O
highly	O
effective	O
as	O
antiproliferative	O
agents	O
in	O
colon	O
cancer	O
cells	O
(	O
Yit	O
and	O
Das	O
,	O
1994	O
)	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
multidrug	O
resistant	O
A2780	O
cells	O
can	O
be	O
obtained	O
by	O
exposure	O
of	O
the	O
cells	O
to	O
drugs	B
that	O
are	O
substrates	O
for	O
the	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
drug	O
efflux	O
(	O
Chu	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Thus	O
,	O
after	O
4	O
days	O
,	O
the	O
A-2780	O
cells	O
,	O
as	O
well	O
as	O
HT-29	O
,	O
may	O
have	O
higher	O
levels	O
of	O
expression	O
of	O
P	O
-	O
glycoprotein	O
that	O
would	O
act	O
as	O
an	O
efflux	O
pump	O
to	O
move	O
XN	B
out	O
of	O
the	O
cells	O
,	O
making	O
the	O
cells	O
resistant	O
to	O
the	O
flavonoids	B
.	O

However	O
,	O
certain	O
prenylated	B
flavonoids	I
have	O
been	O
shown	O
to	O
inactivate	O
the	O
P	O
-	O
glycoprotein	O
by	O
bifunctional	O
interactions	O
at	O
vicinal	O
ATP	B
and	O
steroid	B
-	O
binding	O
sites	O
of	O
the	O
protein	O
(	O
Conseil	O
et	O
al.	O
,	O
1998	O
)	O
.	O

If	O
the	O
hop	O
flavonoids	B
block	O
the	O
action	O
of	O
this	O
protein	O
,	O
then	O
they	O
should	O
still	O
be	O
growth	O
-	O
inhibitory	O
after	O
4	O
days	O
in	O
A-2780	O
and	O
HT-29	O
cells	O
.	O

Studies	O
on	O
the	O
interaction	O
of	O
the	O
hop	O
flavonoids	B
with	O
P	O
-	O
glycoprotein	O
are	O
needed	O
to	O
further	O
understand	O
the	O
mechanism	O
for	O
the	O
development	O
of	O
resistance	O
of	O
cancer	O
cells	O
to	O
hop	O
flavonoids	B
with	O
increased	O
length	O
of	O
exposure	O
.	O

To	O
further	O
differentiate	O
the	O
antiproliferative	O
activity	O
from	O
the	O
cytotoxicity	O
of	O
XN	B
and	O
IX	B
in	O
MCF-7	O
cells	O
,	O
another	O
experiment	O
using	O
12-well	O
plates	O
was	O
performed	O
in	O
which	O
dead	O
and	O
viable	O
cells	O
in	O
each	O
well	O
were	O
counted	O
in	O
a	O
haemacytometer	O
after	O
trypan	B
blue	I
exclusion	O
staining	O
.	O

Cells	O
attached	O
to	O
the	O
plate	O
and	O
in	O
the	O
culture	O
medium	O
were	O
counted	O
at	O
time	O
zero	O
(	O
before	O
addition	O
of	O
flavonoids	O
)	O
and	O
at	O
various	O
times	O
(	O
8	O
,	O
24	O
and	O
48	O
hr	O
)	O
after	O
treatment	O
.	O

The	O
results	O
indicate	O
that	O
XN	B
inhibited	O
cell	O
growth	O
after	O
24	O
or	O
48	O
hr	O
at	O
concentrations	O
from	O
0.01	O
to	O
10	O
μ	O
m	O
but	O
caused	O
little	O
or	O
no	O
toxicity	O
(	O
cell	O
death	O
)	O
to	O
the	O
cells	O
(	O
Figs.	O
6	O
and	O
7	O
)	O
.	O

IX	B
was	O
growth	O
-	O
inhibitory	O
at	O
10	O
μ	O
m	O
after	O
48	O
hr	O
of	O
treatment	O
.	O

However	O
,	O
both	O
XN	B
and	O
IX	B
inhibited	O
the	O
growth	O
of	O
MCF-7	O
cells	O
by	O
more	O
than	O
50	O
%	O
after	O
8	O
hr	O
of	O
exposure	O
and	O
by	O
more	O
than	O
90	O
%	O
or	O
greater	O
after	O
24	O
and	O
48	O
hr	O
.	O

The	O
antiproliferative	O
activity	O
of	O
XN	B
and	O
IX	B
at	O
100	O
μ	O
m	O
after	O
8	O
hr	O
was	O
not	O
completely	O
attributed	O
to	O
the	O
cytotoxic	O
effects	O
of	O
these	O
flavonoids	B
at	O
this	O
concentration	O
since	O
percent	O
viability	O
was	O
greater	O
than	O
60	O
%	O
at	O
this	O
time	O
.	O

After	O
24	O
and	O
48	O
hr	O
,	O
the	O
antiproliferative	O
activity	O
of	O
XN	B
and	O
IX	B
at	O
100	O
μ	O
m	O
was	O
almost	O
completely	O
due	O
to	O
cell	O
killing	O
,	O
not	O
inhibition	O
of	O
cell	O
division	O
.	O

The	O
same	O
explanation	O
could	O
be	O
offered	O
for	O
the	O
effects	O
of	O
other	O
flavonoids	B
used	O
at	O
100	O
μ	O
m	O
in	O
the	O
three	O
human	O
cancer	O
cell	O
lines	O
since	O
the	O
number	O
of	O
viable	O
cells	O
(	O
based	O
on	O
sulforhodamine	B
assay	O
and	O
microscopic	O
examination	O
of	O
cell	O
cultures	O
)	O
remaining	O
after	O
treatment	O
was	O
less	O
than	O
that	O
obtained	O
before	O
treatment	O
at	O
time	O
zero	O
as	O
stated	O
above	O
.	O

Inhibition	O
of	O
DNA	O
synthesis	O
may	O
be	O
one	O
of	O
the	O
mechanisms	O
by	O
which	O
XN	B
and	O
IX	B
exert	O
their	O
antiproliferative	O
activity	O
in	O
MCF-7	O
cells	O
.	O

As	O
shown	O
in	O
Fig.	O
8	O
,	O
XN	B
and	O
IX	B
caused	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
DNA	O
synthesis	O
(	O
as	O
measured	O
by	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
)	O
in	O
MCF-7	O
cells	O
after	O
1	O
,	O
2	O
and	O
4	O
days	O
of	O
treatment	O
.	O

After	O
4	O
days	O
,	O
XN	B
was	O
surprisingly	O
less	O
active	O
than	O
IX	B
at	O
5	O
μ	O
m	O
or	O
lower	O
in	O
inhibiting	O
thymidine	O
incorporation	O
.	O

This	O
finding	O
was	O
not	O
consistent	O
with	O
the	O
greater	O
inhibition	O
of	O
cell	O
growth	O
by	O
XN	B
than	O
IX	B
(	O
Fig.	O
2	O
and	O
Table	O
1	O
)	O
.	O

Therefore	O
,	O
there	O
must	O
be	O
other	O
mechanisms	O
to	O
explain	O
the	O
differential	O
antiproliferative	O
activity	O
of	O
XN	B
and	O
IX	B
in	O
MCF-7	O
cells	O
.	O

The	O
isoflavone	B
genistein	B
induces	O
cytotoxicity	O
and	O
growth	O
inhibition	O
in	O
several	O
cancer	O
cell	O
lines	O
by	O
inhibition	O
of	O
DNA	O
synthesis	O
,	O
protein	O
tyrosine	O
kinases	O
,	O
inhibition	O
of	O
DNA	O
topoisomerases	O
,	O
inhibition	O
of	O
cell	O
cycle	O
events	O
,	O
and	O
induction	O
of	O
apoptosis	O
(	O
Barnes	O
et	O
al.	O
,	O
1995	O
)	O
.	O

The	O
synthetic	O
flavone	B
flavopiridol	B
induces	O
also	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
leukaemia	O
cells	O
(	O
Konig	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Consequently	O
,	O
it	O
is	O
possible	O
that	O
hop	O
flavonoids	B
may	O
cause	O
growth	O
arrest	O
at	O
more	O
than	O
one	O
stage	O
of	O
the	O
cell	O
cycle	O
.	O

Certain	O
prenylated	B
chalcones	I
have	O
been	O
shown	O
to	O
induce	O
apoptosis	O
in	O
MCF-7	O
cells	O
(	O
Pharmar	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Therefore	O
,	O
apoptosis	O
may	O
be	O
one	O
of	O
the	O
mechanisms	O
by	O
which	O
hop	O
flavonoids	B
such	O
as	O
XN	B
and	O
IX	B
cause	O
cell	O
death	O
in	O
MCF-7	O
cells	O
.	O

However	O
,	O
our	O
preliminary	O
work	O
showed	O
that	O
treatment	O
with	O
XN	B
and	O
IX	B
for	O
8	O
or	O
24	O
hr	O
did	O
not	O
induce	O
apoptosis	O
in	O
MCF-7	O
cells	O
based	O
on	O
the	O
DNA	O
laddering	O
assay	O
on	O
agarose	B
gels	O
(	O
Plate	O
Plate	O
I	O
)	O
.	O

Additional	O
studies	O
using	O
other	O
methods	O
to	O
assay	O
apoptosis	O
(	O
in	O
situ	O
TdT	B
labelling	O
,	O
morphological	O
examination	O
and	O
flow	O
cytometric	O
analysis	O
)	O
are	O
needed	O
to	O
confirm	O
that	O
XN	B
and	O
IX	B
do	O
not	O
induce	O
apoptosis	O
in	O
MCF-7	O
cells	O
.	O

The	O
potential	O
of	O
XN	B
as	O
anti	O
-	O
neoplastic	O
agent	O
for	O
breast	O
cancer	O
can	O
be	O
evaluated	O
further	O
by	O
comparing	O
its	O
ability	O
to	O
inhibit	O
growth	O
of	O
MCF-7	O
cells	O
in	O
vitro	O
with	O
that	O
of	O
other	O
flavonoids	B
such	O
as	O
genistein	B
.	O

Genistein	B
inhibited	O
the	O
growth	O
of	O
MCF-7	O
cells	O
(	O
based	O
on	O
SRB	B
assay	O
)	O
with	O
an	O
estimated	O
IC50	O
greater	O
than	O
40	O
μ	O
m	O
after	O
4	O
days	O
of	O
exposure	O
(	O
Hoffman	O
,	O
1995	O
)	O
.	O

Shao	O
et	O
al.	O
(	O
1998	O
)	O
reported	O
an	O
IC50	O
of	O
20	O
μ	O
m	O
for	O
genistein	B
in	O
MCF-7	O
cells	O
after	O
6	O
days	O
of	O
treatment	O
.	O

In	O
the	O
present	O
study	O
,	O
XN	B
gave	O
an	O
IC50	O
of	O
3.47	O
μ	O
m	O
in	O
MCF-7	O
cells	O
after	O
4	O
days	O
of	O
treatment	O
.	O

As	O
an	O
inhibitor	O
of	O
DNA	O
synthesis	O
in	O
MCF-7	O
cells	O
,	O
genistein	B
has	O
an	O
IC50	O
of	O
12.6	O
μ	O
m	O
at	O
2	O
days	O
(	O
Hoffman	O
,	O
1995	O
)	O
whereas	O
XN	B
has	O
an	O
IC50	O
of	O
1.5	O
μ	O
m	O
(	O
calculated	O
from	O
Fig.	O
8	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
XN	B
is	O
several	O
fold	O
more	O
potent	O
as	O
an	O
antiproliferative	O
agent	O
than	O
genistein	B
,	O
a	O
flavonoid	B
currently	O
used	O
in	O
clinical	O
trials	O
as	O
a	O
chemopreventive	O
agent	O
for	O
breast	O
cancer	O
in	O
humans	O
.	O

Two	O
citrus	O
flavanones	B
,	O
naringenin	B
and	O
hesperetin	B
,	O
have	O
been	O
shown	O
to	O
inhibit	O
the	O
proliferation	O
of	O
oestrogen	O
receptor	O
-	O
negative	O
MDA	O
-	O
MB-235	O
and	O
oestrogen	O
receptor	O
-	O
positive	O
MCF-7	O
human	O
breast	O
cancer	O
cells	O
as	O
determined	O
by	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
growing	O
cells	O
.	O

After	O
2	O
days	O
of	O
treatment	O
of	O
MDA	O
-	O
MB-435	O
,	O
both	O
flavanones	B
gave	O
an	O
IC50	O
of	O
18	O
μ	O
g	O
/	O
ml	O
(	O

So	O
et	O
al.	O
,	O
1996	O
)	O
whereas	O
in	O
MCF-7	O
cells	O
,	O
the	O
IC50	O
for	O
naringenin	B
and	O
hesperetin	B
were	O
18	O
and	O
12	O
μ	O
g	O
/	O
ml	O
,	O
respectively	O
(	O
So	O
et	O
al.	O
,	O
1997	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
IX	B
inhibited	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
in	O
MCF-7	O
cells	O
with	O
an	O
IC50	O
of	O
10	O
μ	O
m	O
(	O
or	O
3.54	O
μ	O
g	O
/	O
ml	O
)	O
suggesting	O
that	O
the	O
prenylated	B
flavanone	I
from	O
hops	O
and	O
beer	O
is	O
more	O
effective	O
than	O
the	O
citrus	O
flavanones	B
as	O
an	O
antiproliferative	O
agent	O
for	O
MCF-7	O
cells	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
demonstrate	O
whether	O
IX	B
will	O
inhibit	O
tumour	O
growth	O
of	O
MCF-7	O
cells	O
in	O
nude	O
mice	O
.	O

In	O
conclusion	O
,	O
XN	B
appeared	O
to	O
be	O
the	O
most	O
potent	O
of	O
the	O
five	O
hop	O
flavonoid	B
tested	O
in	O
inhibiting	O
the	O
proliferation	O
of	O
three	O
human	O
cancer	O
cell	O
lines	O
(	O
MCF-7	O
,	O
HT-29	O
and	O
A-2780	O
)	O
.	O

In	O
particular	O
,	O
XN	B
(	O
the	O
most	O
abundant	O
flavonoid	B
in	O
hops	O
)	O
was	O
highly	O
potent	O
in	O
suppressing	O
the	O
growth	O
of	O
human	O
breast	O
cancer	O
cells	O
(	O
MCF-7	O
)	O
and	O
ovarian	O
cancer	O
cells	O
(	O
A-2780	O
)	O
.	O

IX	B
,	O
the	O
flavanone	B
isomer	O
of	O
XN	B
and	O
the	O
most	O
abundant	O
prenylated	B
flavonoid	I
in	O
hopped	O
beers	O
,	O
was	O
also	O
a	O
potent	O
inhibitor	O
of	O
growth	O
of	O
MCF-7	O
cells	O
after	O
a	O
4-day	O
exposure	O
.	O

Inhibition	O
of	O
growth	O
of	O
MCF-7	O
cells	O
by	O
XN	B
and	O
IX	B
was	O
associated	O
with	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

These	O
findings	O
indicate	O
that	O
an	O
evaluation	O
of	O
the	O
potential	O
anticancer	O
properties	O
of	O
XN	B
and	O
IX	B
in	O
the	O
intact	O
animal	O
is	O
warranted	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
the	O
Hop	O
Research	O
Council	O
,	O
Medical	O
Research	O
Foundation	O
of	O
Oregon	O
,	O
and	O
NIEHS	O
grant	O
ES00210	O
.	O

This	O
manuscript	O
was	O
issued	O
by	O
the	O
Oregon	O
State	O
University	O
Agricultural	O
Experiment	O
Station	O
as	O
Technical	O
Paper	O
No.	O
11318	O
.	O

The	O
authors	O
thank	O
Sam	O
Bradford	O
and	O
Chelsea	O
Johnston	O
for	O
technical	O
assistance	O
.	O

The	O
tetrasaccharides	B
lacto	B
-	I
N	I
-tetraose	I
(	O
1	B
)	O
and	O
lacto	B
-	I
N	I
-neotetraose	I
(	O
2	B
)	O
are	O
amongst	O
the	O
oligosaccharides	B
isolated	O
from	O
human	O
milk	O
[	O
1,2	O
]	O

;	O
the	O
former	O
was	O
the	O
first	O
aminodeoxy	B
oligosaccharide	I
that	O
was	O
found	O
to	O
occur	O
free	O
in	O
nature	O
[	O
3–5	O
]	O
.	O

Oligosaccharides	B
1	B
and	O
2	B
represent	O
core	O
structural	O
elements	O
of	O
more	O
complex	O
oligosaccharides	B
in	O
human	O
milk	O
[	O
1,2	O
]	O
,	O
in	O
glycolipids	B
,	O
such	O
as	O
paragloboside	B
and	O
sialosylparagloboside	B
,	O
and	O
in	O
glycoproteins	O
.	O

These	O
oligosaccharides	B
are	O
useful	O
in	O
the	O
recognition	O
of	O
the	O
acceptor	O
specificity	O
of	O
glycosyltransferases	O
,	O
the	O
substrate	O
specificity	O
of	O
glycosidases	O
,	O
and	O
the	O
structure	O
of	O
antigenic	O
determinants	O
[	O
1	O
]	O
.	O

Thus	O
,	O
the	O
sequence	O
contained	O
in	O
lacto	B
-	I
N	I
-neotetraose	I
had	O
been	O
recognized	O
by	O
an	O
antibody	O
bound	O
to	O
granulocytes	O
that	O
was	O
obtained	O
by	O
immunization	O
with	O
normal	O
human	O
granulocytes	O
[	O
6	O
]	O
.	O

Paragloboside	B
,	O
a	O
lactoneotetraosyl	B
ceramide	I
,	O
was	O
first	O
isolated	O
from	O
human	O
erythrocytes	O
[	O
7	O
]	O
;	O
it	O
was	O
also	O
identified	O
as	O
a	O
specific	O
surface	O
component	O
of	O
virus	O
polyoma	O
-	O
transformed	O
hamster	O
embryo	O
fibroblast	O
cells	O
[	O
8	O
]	O
and	O
thus	O
it	O
may	O
act	O
as	O
surface	O
antigen	O
associated	O
with	O
this	O
tumor	O
[	O
9	O
]	O
.	O

The	O
Neu5Ac	B
α-	I
(	I
2→6	I
)	I
-lacto	I
-	I
N	I
-neotetraose	I
was	O
found	O
to	O
cause	O
inhibition	O
of	O
the	O
bacterial	O
infection	O
of	O
a	O
human	O
patient	O
suffering	O
from	O
pneumonia	O
[	O
10	O
]	O
.	O

Both	O
1	B
and	O
2	B
act	O
as	O
bacterial	O
receptors	O
for	O
pneumococci	O
[	O
11,12	O
]	O
.	O

The	O
pentasaccharide	B
HSO3	B
-3Gal	I
-	I
β-	I
(	I
1→3	I
)	I
-GlcNAc	I
-	I
β-	I
(	I
1→3	I
)	I
-Gal	I
-	I
β-	I
(	I
1→4	I
)	I
Glc	I
is	O
one	O
of	O
the	O
most	O
potent	O
oligosaccharide	B
ligands	O
for	O
human	O
E	O
-	O
selectin	O
[	O
13	O
]	O
.	O

It	O
is	O
a	O
strong	O
supporter	O
of	O
the	O
adhesion	O
of	O
E	O
-	O
selectin	O
-	O
expressing	O
cells	O
and	O
an	O
inhibitor	O
of	O
E	O
-	O
selectin	O
adhesion	O
.	O

Such	O
inhibitors	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
inflammation	O
and	O
for	O
minimizing	O
risk	O
of	O
metastasis	O
after	O
surgery	O
reactions	O
of	O
tumors	O
[	O
13–15	O
]	O
.	O

Partially	O
protected	O
lacto	B
-	I
N	I
-neotetraoses	I
were	O
prepared	O
as	O
intermediates	O
for	O
the	O
synthesis	O
of	O
blood	B
group	I
I	I
-	I
active	I
biantennary	I
neolacto	I
-	I
type	I
decaosyl	I
ceramide	I
[	O
16,17	O
]	O
.	O

One	O
of	O
the	O
crucial	O
points	O
in	O
the	O
syntheses	O
of	O
oligosaccharides	B
incorporating	O
2-amino-2-deoxy	B
-	I
d	I
-glucose	I
necessitates	O
its	O
availability	O
as	O
a	O
donor	O
that	O
requires	O
a	O
suitable	O
protection	O
of	O
the	O
amino	B
group	I
.	I

Various	O
protecting	O
groups	O
for	O
such	O
purposes	O
are	O
now	O
available	O
.	O

Thus	O
,	O
the	O
2-deoxy-2-phthalimido	B
sugars	I
were	O
used	O
as	O
glycosyl	B
donors	I
for	O
the	O
synthesis	O
of	O
lacto	B
-	I
N	I
-neotetraose	I
derivatives	I
[	O
16,17	O
]	O
,	O
of	O
p	B
-nitrophenyl	I
lacto	I
-	I
N	I
-tetraoside	I
[	O
18	O
]	O
,	O
and	O
of	O
benzyl	B
lacto	I
-	I
N	I
-neotetraoside	I
[	O
19	O
]	O
.	O

Also	O
lacto	B
-	I
N	I
-biose	I
was	O
prepared	O
by	O
the	O
phthalimide	B
method	O
[	O
20,21	O
]	O
.	O

The	O
benzyl	B
glycoside	I
of	I
2	I
[	O
22	O
]	O
as	O
well	O
as	O
the	O
ceramide	B
of	I
1	I
[	O
23	O
]	O
were	O
prepared	O
by	O
using	O
2-azido-2-deoxy	B
glucose	I
as	O
a	O
precursor	O
for	O
the	O
N	B
-acetylglucosamine	I
moiety	O
.	O

The	O
methyl	B
lacto	I
-	I
N	I
-neotetraoside	I
and	O
derivatives	B
thereof	O
were	O
prepared	O
by	O
the	O
phthalimide	B
method	O
[	O
24–26	O
]	O
and	O
the	O
oxazoline	B
method	O
[	O
27,28	O
]	O
.	O

The	O
latter	O
method	O
was	O
also	O
used	O
for	O
the	O
synthesis	O
of	O
lacto	B
-	I
N	I
-tetraose	I
by	O
a	O
route	O
utilizing	O
the	O
oxazoline	B
derivative	O
of	O
β	B
-	I
d	I
-galactopyranosyl-	I
(	I
1→3	I
)	I
-d	I
-glucosamine	I
(	O
lacto	B
-	I
N	I
-biose	I
I	I
)	O
as	O
a	O
donor	O
for	O
a	O
suitably	O
protected	O
lactose	B
acceptor	O
[	O
29–31	O
]	O
.	O

Also	O
the	O
2-O	B
-methyl	I
derivative	I
of	I
the	I
galactose	I
moiety	I
at	O
the	O
non	O
-	O
reducing	O
end	O
has	O
been	O
prepared	O
via	O
the	O
oxazoline	B
method	O
[	O
32	O
]	O
.	O

Recently	O
,	O
we	O
introduced	O
the	O
dimethylmaleoyl	B
(	O
DMM	B
)	O
group	B
as	O
a	O
new	O
amino	B
protecting	O
group	O
for	O
glucosamine	B
[	O
33	O
]	O
.	O

Its	O
ease	O
of	O
attachment	O
and	O
subsequent	O
cleavage	O
as	O
well	O
as	O
its	O
electron	O
-	O
withdrawing	O
property	O
make	O
the	O
d	B
-glucosamine	I
derivative	I
a	O
good	O
glycosyl	B
donor	I
with	O
an	O
enforced	O
capability	O
of	O
forming	O
a	O
β	O
-	O
linkage	O
.	O

Moreover	O
,	O
versatile	O
glycosyl	B
acceptors	I
containing	O
the	O
dimethylmaleoylamido	B
group	I
could	O
also	O
be	O
generated	O
and	O
successfully	O
employed	O
in	O
glycosylation	O
reactions	O
[	O
33	O
]	O
.	O

Owing	O
to	O
these	O
perspectives	O
of	O
the	O
DMM	B
group	I
,	O
we	O
report	O
herein	O
synthetic	O
routes	O
,	O
using	O
this	O
group	O
,	O
to	O
the	O
biologically	O
important	O
lacto	B
-	I
N	I
-neotetraose	I
(	O
2	B
)	O
and	O
lacto	B
-	I
N	I
-tetraose	I
(	O
1	B
)	O
.	O

The	O
generated	O
building	O
blocks	O
also	O
allow	O
their	O
further	O
use	O
as	O
donors	O
or	O
acceptors	O
for	O
the	O
preparation	O
of	O
various	O
oligosaccharides	B
.	O

2	O
2	O
.	O

Results	O
and	O
discussion	O
For	O
the	O
synthesis	O
of	O
the	O
target	O
tetrasaccharides	B
,	O
final	O
linkage	O
of	O
two	O
disaccharides	B
has	O
been	O
designed	O
.	O

Thus	O
,	O
the	O
disaccharide	B
donor	O
will	O
have	O
the	O
glucosamine	B
residue	O
containing	O
the	O
DMM	B
group	I
at	O
the	O
reducing	O
end	O
.	O

The	O
required	O
disaccharide	B
donor	O
7	B
was	O
synthesized	O
in	O
three	O
steps	O
from	O
known	O
acceptor	B
4	I
[	O
33	O
]	O
by	O
its	O
galactosidation	O
with	O
known	O
trichloroacetimidate	B
3	I
[	O
34	O
]	O
under	O
the	O
catalysis	O
of	O
trimethylsilyl	B
trifluoromethanesulfonate	I
(	O
Me3	B
SiOTf	I
)	I
to	O
give	O
the	O
β	B
-	I
linked	I
disaccharide	I
5	I
in	O
84	O
%	O
yield	O
.	O

Its	O
1	O
H	O
NMR	O
spectrum	O
supported	O
the	O
assignment	O
;	O
two	O
doublets	O
for	O
H-1	O
and	O
H-1′	O
at	O
δ	O
5.10	O
and	O
4.61	O
with	O
a	O
J	O
value	O
of	O
8.0	O
Hz	O
for	O
each	O
indicated	O
the	O
axial	O
nature	O
of	O
H-1	O
and	O
H-2	O
in	O
both	O
rings	O
.	O

The	O
tert	B
-butyldimethylsilyl	I
(	O
TBDMS	B
)	O
group	B
was	O
cleaved	O
from	O
5	B
with	O
tetrabutylammonium	B
fluoride	I
(	O
TBAF	B
)	O
to	O
give	O
6	B
,	O
which	O
can	O
be	O
readily	O
transformed	O
into	O
the	O
trichloroacetimidate	B
donor	O
7	B
.	O

Its	O
reaction	O
with	O
the	O
known	O
disaccharide	B
acceptor	O
benzyl	B
(	I
2,4,6-tri	I
-	I
O	I
-benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-2,3,6-tri	I
-	I
O	I
-benzyl	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
8	B
)	O
[	O
35	O
]	O
gave	O
the	O
desired	O
tetrasaccharide	B
9	I
;	O
the	O
13	O
C	O
NMR	O
spectrum	O
showed	O
the	O
presence	O
of	O
four	O
signals	O
at	O
δ	O
100.20	O
,	O
100.70	O
,	O
102.70	O
,	O
and	O
102.80	O
corresponding	O
to	O
the	O
four	O
β	O
-	O
linked	O
anomeric	O
carbons	O
.	O

Deblocking	O
of	O
the	O
DMM	B
group	I
from	O
9	B
with	O
NaOH	B
to	O
open	O
the	O
DMM	B
ring	O
followed	O
by	O
treatment	O
with	O
HCl	B
to	O
cleave	O
the	O
presumably	O
formed	O
butenolide	B
and	O
then	O
intermediate	O
acetylation	B
gave	O
10	B
in	O
71	O
%	O
yield	O
.	O

On	O
the	O
other	O
hand	O
,	O
using	O
hydrazine	B
hydrate	I
as	O
a	O
deblocking	O
agent	O
followed	O
by	O
acetylation	O
led	O
to	O
the	O
formation	O
of	O
10	B
in	O
54	O
%	O
yield	O
.	O

The	O
success	O
of	O
this	O
transformation	O
was	O
readily	O
confirmed	O
by	O
1	O
H	O
NMR	O
spectroscopy	O
,	O
which	O
exhibited	O
the	O
disappearance	O
of	O
the	O
methyl	B
signals	O
of	O
the	O
dimethylmaleoyl	B
group	I
and	O
the	O
appearance	O
of	O
an	O
NH	O
signal	O
at	O
δ	O
5.8	O
and	O
of	O
a	O
new	O
methyl	B
signal	O
.	O

Catalytic	O
hydrogenation	B
led	O
to	O
deblocking	O
of	O
the	O
benzyl	B
groups	I
which	O
,	O
upon	O
acetylation	B
,	O
gave	O
11	B
in	O
95	O
%	O
yield	O
as	O
the	O
peracetyl	B
derivative	I
of	I
2	I
.	O

The	O
1	O
H	O
NMR	O
spectrum	O
of	O
11	B
indicated	O
its	O
presence	O
as	O
a	O
mixture	O
of	O
α	B
(	O
δ	O
6.23	O
)	O
and	O
β	B
(	O
δ	O
5.64	O
)	O
anomers	B
in	O
a	O
ratio	O
of	O
3:2	O
.	O

Almost	O
the	O
same	O
ratio	O
was	O
also	O
reported	O
based	O
on	O
the	O
calculation	O
of	O
specific	O
rotations	O
[	O
28	O
]	O
and	O
1	O
H	O
NMR	O
spectroscopy	O
[	O
21	O
]	O
.	O

Deacylation	O
of	O
11	B
gave	O
2	B
in	O
91	O
%	O
yield	O
.	O

The	O
13	O
C	O
NMR	O
data	O
of	O
2	B
were	O
in	O
accordance	O
with	O
published	O
values	O
[	O
35	O
]	O
;	O
reacetylation	O
of	O
2	B
led	O
again	O
to	O
compound	O
11	B
,	O
thus	O
confirming	O
the	O
structure	O
of	O
2	B
(	O
Scheme	O
1	O
)	O
.	O

For	O
the	O
synthesis	O
of	O
the	O
lacto	B
-	I
N	I
-tetraose	I
1	I
,	O
two	O
approaches	O
were	O
designed	O
.	O

Both	O
methods	O
were	O
based	O
on	O
the	O
coupling	O
of	O
a	O
disaccharide	B
donor	O
with	O
the	O
disaccharide	B
acceptor	O
8	B
[	O
36	O
]	O
.	O

The	O
designation	O
of	O
these	O
two	O
routes	O
has	O
been	O
developed	O
in	O
order	O
to	O
allow	O
for	O
the	O
presence	O
of	O
temporary	O
blocking	O
groups	O
on	O
the	O
resulting	O
tetrasaccharide	B
thus	O
making	O
it	O
suitable	O
as	O
acceptor	O
for	O
other	O
mono-	B
and	O
oligosaccharide	B
donors	O
.	O

In	O
the	O
first	O
approach	O
known	O
donor	O
12	B
[	O
33	O
]	O
was	O
coupled	O
with	O
8	B
to	O
give	O
13	B
in	O
76	O
%	O
yield	O
.	O

Although	O
its	O
1	O
H	O
NMR	O
spectrum	O
showed	O
a	O
doublet	O
at	O
δ	O
5.27	O
for	O
the	O
newly	O
formed	O
glycosidic	O
bond	O
with	O
a	O
J	O
value	O
of	O
8.4	O
Hz	O
confirming	O
its	O
β	O
-	O
configuration	O
,	O
the	O
signals	O
for	O
the	O
anomeric	O
protons	O
are	O
hidden	O
under	O
other	O
signals	O
.	O

However	O
,	O
their	O
coupling	O
with	O
H-2	O
can	O
be	O
depicted	O
from	O
the	O
signals	O
for	O
H-2	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
13	O
C	O
NMR	O
spectrum	O
showed	O
signals	O
at	O
δ	O
c	O
100.30	O
,	O
100.50	O
,	O
and	O
102.80	O
corresponding	O
to	O
the	O
four	O
β	O
-	O
linked	O
anomeric	O
carbons	O
.	O

Debenzylidenation	O
of	O
13	O
with	O
p	B
-TsOH	I
gave	O
14	B
whose	O
NMR	O
spectra	O
showed	O
the	O
absence	O
of	O
the	O
benzylidene	B
CH	O
.	O

The	O
transformation	O
of	O
the	O
DMM	B
group	I
to	O
an	O
acetyl	B
group	I
was	O
achieved	O
by	O
the	O
action	O
of	O
alkali	B
and	O
then	O
acidification	O
followed	O
by	O
acetylation	B
to	O
give	O
15	B
in	O
76	O
%	O
yield	O
.	O

Catalytic	O
hydrogenation	B
of	O
15	B
,	O
followed	O
by	O
acetylation	B
,	O
gave	O
the	O
peracetyl	B
derivative	I
16	I
as	O
a	O
mixture	O
of	O
α	B
and	O
β	B
anomers	I
in	O
a	O
ratio	O
of	O
1:2	O
,	O
respectively	O
(	O
Scheme	O
2	O
)	O
.	O

Alternatively	O
,	O
the	O
required	O
disaccharide	B
donor	O
21	B
was	O
prepared	O
from	O
known	O
17	B
[	O
33	O
]	O
by	O
debenzylidenation	O
with	O
p	B
-TsOH	I
to	O
give	O
18	B
whose	O
O	O
-	O
acetylation	B
gave	O
19	B
.	O

Subsequent	O
removal	O
of	O
the	O
TBDMS	B
group	I
with	O
TBAF	B
gave	O
1-O	B
-	I
unprotected	I
20	I
,	O
thus	O
being	O
suitable	O
for	O
the	O
activation	O
with	O
trichloroacetonitrile	B
in	O
the	O
presence	O
of	O
DBU	B
to	O
give	O
trichloroacetimidate	B
21	I
.	O

Coupling	O
of	O
21	B
with	O
8	B
under	O
standard	O
conditions	O
gave	O
tetrasaccharide	B
22	I
in	O
75	O
%	O
yield	O
.	O

Its	O
1	O
H	O
NMR	O
spectrum	O
showed	O
for	O
the	O
H-1c	O
a	O
doublet	O
at	O
δ	O
5.16	O
with	O
a	O
coupling	O
constant	O
of	O
8.4	O
Hz	O
,	O
thus	O
confirming	O
the	O
β	O
-	O
configuration	O
.	O

Moreover	O
,	O
its	O
13	O
C	O
NMR	O
spectrum	O
showed	O
signals	O
at	O
δ	O
c	O
99.90	O
,	O
100.50	O
,	O
102.8	O
(	O
2C	O
)	O
,	O
confirming	O
the	O
presence	O
of	O
the	O
four	O
anomeric	O
centers	O
.	O

Removal	O
of	O
the	O
DMM	B
group	I
from	O
22	B
and	O
subsequent	O
acetylation	B
afforded	O
15	B
,	O
which	O
was	O
identical	O
to	O
the	O
material	O
obtained	O
via	O
the	O
first	O
approach	O
(	O
Scheme	O
3	O
)	O
.	O

In	O
conclusion	O
,	O
lacto	B
-	I
N	I
-tetraose	I
(	O
1	B
)	O
and	O
lacto	B
-	I
N	I
-neotetraose	I
(	O
2	B
)	O
were	O
successfully	O
synthesized	O
by	O
the	O
elaboration	O
of	O
the	O
newly	O
developed	O
protection	O
of	O
amino	B
sugars	I
with	O
dimethylmaleic	B
anhydride	I
providing	O
the	O
dimethylmaleimido	B
group	I
.	O

Cleavage	O
by	O
addition	O
of	O
alkali	B
followed	O
by	O
acid	B
can	O
be	O
successfully	O
performed	O
as	O
exhibited	O
in	O
our	O
first	O
report	O
[	O
33	O
]	O
,	O
using	O
this	O
group	O
for	O
amino	B
sugars	I
,	O
and	O
in	O
other	O
reports	O
,	O
using	O
it	O
for	O
amino	B
acids	I
and	O
proteins	O
[	O
37–41	O
]	O
.	O

Its	O
combination	O
with	O
the	O
trichloroacetimidate	B
leaving	O
group	B
[	O
42	O
]	O
at	O
C-1	O
of	O
a	O
glucosamine	B
residue	O
either	O
in	O
monomeric	O
form	O
or	O
as	O
part	O
of	O
an	O
oligosaccharide	B
provides	O
good	O
glycosyl	B
donors	I
in	O
order	O
to	O
form	O
β	O
-	O
linkages	O
.	O

Moreover	O
,	O
the	O
DMM	B
group	I
tolerates	O
manipulations	O
of	O
the	O
common	O
temporary	O
protective	O
groups	O
required	O
during	O
oligosaccharide	B
synthesis	O
and	O
,	O
in	O
addition	O
,	O
it	O
can	O
be	O
selectively	O
removed	O
under	O
quite	O
mild	O
conditions	O
.	O

The	O
partially	O
protected	O
target	O
tetrasaccharides	B
prepared	O
in	O
this	O
paper	O
,	O
as	O
well	O
as	O
their	O
precursors	O
,	O
can	O
be	O
used	O
for	O
the	O
elaboration	O
of	O
various	O
higher	O
oligosaccharides	B
.	O

3	O
3	O
.	O

Experimental	O
3.1	O
General	O
methods	O
Solvents	B
were	O
purified	O
in	O
the	O
usual	O
way	O
.	O

TLC	O
was	O
performed	O
on	O
plastic	O
plates	O
Silica	B
Gel	O
60	O
F254	O
and	O
on	O
HPTLC	O
plates	O
NH2	O
F254	O
S	O
(	O
E.	O
Merck	O
,	O
layer	O
thickness	O
0.2	O
mm	O
)	O
.	O

The	O
detection	O
was	O
achieved	O
by	O
treatment	O
with	O
a	O
solution	O
of	O
20	O
g	O
ammonium	B
molybdate	I
and	O
0.4	O
g	O
cerium	B
(	I
IV	I
)	I
sulfate	I
in	O
400	O
mL	O
10	O
%	O
H2	B
SO4	I
or	O
with	O
15	O
%	O
H2	B
SO4	I
,	O
and	O
heating	O
at	O
150	O
°	O
C	O
.	O

Flash	O
chromatography	O
was	O
carried	O
out	O
on	O
silica	B
gel	O
(	O
Baker	O
,	O
30–60	O
(	O
μm	O
)	O
and	O
Lichroprep	O
NH2	O
,	O
particle	O
size	O
40–63	O
μm	O
(	O
E.	O
Merck	O
)	O
.	O

Medium	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
MPLC	O
)	O
:	O
LiChroprep	O
Si	O
60	O
(	O
E.	O
Merck	O
;	O
size	O
15–25	O
μm	O
)	O
,	O
detection	O
by	O
differential	O
refractometer	O
.	O

Optical	O
rotations	O
were	O
determined	O
at	O
25	O
°	O
C	O
with	O
a	O
Perkin	O
–	O
Elmer	O
241	O
/	O
MC	O
polarimeter	O
(	O
1	O
dm	O
cell	O
)	O
.	O

NMR	O
spectra	O
were	O
recorded	O
with	O
Bruker	O
AC	O
250	O
and	O
600	O
DRX	O
instruments	O
,	O
using	O
tetramethylsilane	B
as	O
internal	O
standard	O
.	O

The	O
assignments	O
of	O
1	O
H	O
NMR	O
spectra	O
were	O
based	O
on	O
chemical	O
shift	O
correlation	O
(	O
DQFCOSY	O
)	O
and	O
rotating	O
frame	O
nuclear	O
Overhauser	O
effect	O
spectroscopy	O
(	O
ROESY	O
)	O
.	O

The	O
assignments	O
of	O
13	B
C	I
NMR	I
spectra	I
were	O
based	O
on	O
carbon	B
–	O
proton	O
shift	O
-	O
correlation	O
heteronuclear	O
multiple	O
quantum	O
coherence	O
(	O
HMQC	O
)	O
.	O

MS	O
spectra	O
were	O
recorded	O
with	O
MALDI	O
-	O
Kompakt	O
(	O
Kratos	O
)	O
,	O
EI	O
and	O
FAB	O
with	O
Finningen	O
MAT	O
312	O
/	O
AMD	O
.	O

Microanalyses	O
were	O
performed	O
in	O
the	O
Microanalysis	O
Unit	O
at	O
the	O
Fakultät	O
für	O
Chemie	O
,	O
Universität	O
Konstanz	O
.	O

3.2	O
tert	B
-	I
Butyldimethylsilyl	I
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-3,6-di	I
-	I
O	I
-	I
benzyl-2-deoxy-2-dimethylmaleimido	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
5	B
)	O
A	O
solution	O
of	O
3	O
(	O
0.25	O
g	O
,	O
0.52	O
mmol	O
)	O
and	O
4	B
(	O
0.24	O
g	O
,	O
0.4	O
mmol	O
)	O
in	O
dry	O
CH2	B
Cl2	I
(	O
2	O
mL	O
)	O
was	O
stirred	O
under	O
nitrogen	B
at	O
rt	O
for	O
10	O
min	O
while	O
Me3	B
SiOTf	I
(	O
0.01	O
M	O
in	O
CH2	B
Cl2	I
,	O
0.46	O
mL	O
)	O
was	O
added	O
dropwise	O
.	O

After	O
45	O
min	O
,	O
the	O
reaction	O
mixture	O
was	O
neutralized	O
with	O
Et3	B
N	I
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
2:1	O
petroleum	O
EtOAc	B
)	O
to	O
yield	O
5	B
(	O
0.32	O
g	O
,	O
84	O
%	O
)	O
as	O
an	O
oil	O
.	O

TLC	O
(	O
2:1	O
petroleum	B
EtOAc	B
)	O
:	O
R	O
f	O
0.34	O
,	O
[	O
α	O
]	O
D	O
+	O
19.8	O
°	O
(	O
c	O
0.6	O
,	O
CHCl3	O
)	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.36–7.10	O
(	O
m	O
,	O
10	O
H	O
,	O
2	O
Ph	O
)	O
,	O
5.26	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3,4	O
2.9	O
Hz	O
,	O
H-4b	O
)	O
,	O
5.13	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.0	O
,	O
J	O
2,3	O
10.4	O
Hz	O
,	O
H-2b	O
)	O
,	O
5.10	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.0	O
Hz	O
,	O
H-1a	O
)	O
,	O
4.86	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-3b	O
)	O
,	O
4.61	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1b	O
)	O
,	O
4.73	O
,	O
4.50	O
(	O
2	O
d	O
,	O
2	O
H	O
,	O
J	O
gem	O
12.2	O
Hz	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.85	O
,	O
4.41	O
(	O
2	O
d	O
,	O
2	O
H	O
,	O
J	O
gem	O
12.4	O
Hz	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.12	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
10.8	O
,	O
J	O
3,4	O
8.8	O
Hz	O
,	O
H-3a	O
)	O
,	O
3.98–3.93	O
(	O
m	O
,	O
3	O
H	O
,	O
H-4a	O
,	O
H-6b	O
,	O
H-6′b	O
)	O
,	O
3.84	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2a	O
)	O
,	O
3.73	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.0	O
,	O
J	O
5,6′	O
3.4	O
Hz	O
,	O
H-6′a	O
)	O
,	O
3.68–3.65	O
(	O
m	O
,	O
2	O
H	O
,	O
H-5b	O
,	O
H-6a	O
)	O
,	O
3.44	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.05	O
,	O
1.99	O
,	O
1.98	O
,	O
1.95	O
(	O
4	O
s	O
,	O
12	O
H	O
,	O
4	O
CH3	O
CO	O
)	O
,	O
1.80	O
(	O
br.s	O
,	O
6	O
H	O
,	O
2	O
CH3	O
)	O
,	O
0.72	O
[	O
s	O
,	O
9	O
H	O
,	O
SiC	O
(	O
CH3	O
)	O
3	O
]	O
,	O
0.02	O
(	O
s	O
,	O
3	O
H	O
,	O
SiCH3	O
)	O
,	O
−0.09	O
(	O
s	O
,	O
3	O
H	O
,	O
SiCH3	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
170.31	O
,	O
170.20	O
,	O
170.03	O
,	O
169.17	O
(	O
4	O
CH3	O
C	O
O	O
,	O
2	O
CO	O
)	O
,	O
139.10–136.69	O
,	O
128.51–127.03	O
(	O
2	O
Ph	O
)	O
,	O
100.38	O
(	O
C-1b	O
)	O
,	O
93.43	O
(	O
C-1a	O
)	O
,	O
78.03	O
(	O
C-4a	O
)	O
,	O
74.76	O
(	O
C-3a	O
)	O
,	O
74.08	O
(	O
C-5a	O
)	O
,	O
73.58	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
71.03	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
70.48	O
(	O
C-3b	O
)	O
,	O
69.53	O
(	O
C-5b	O
)	O
,	O
67.72	O
(	O
C-2b	O
)	O
,	O
67.06	O
(	O
C-6a	O
)	O
,	O
66.95	O
(	O
C-4b	O
)	O
,	O
60.85	O
(	O
C-6b	O
)	O
,	O
57.54	O
(	O
C-2a	O
)	O
,	O
25.32	O
[	O
SiC	O
(	O
C	O
H3	O
)	O
3	O
]	O
,	O
20.75	O
,	O
20.64	O
,	O
20.59	O
,	O
20.54	O
(	O
4	O
C	O
H3	O
CO	O
)	O
,	O
17.57	O
[	O
SiC	O
(	O
CH3	O
)	O
]	O
,	O
8.00	O
(	O
2	O
CH3	O
)	O
,	O
−4.24	O
(	O
SiCH3	O
)	O
,	O
−5.62	O
(	O
SiCH3	O
)	O
.	O

FABMS	O
(	O
positive	O
mode	O
,	O
NBOH	O
/	O
NaI	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
934	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C46	O
H61	O
NO16	O
Si	O
(	O
912.04	O
)	O
:	O
C	O
,	O
60.57	O
;	O
H	O
,	O
6.74	O
;	O
N	O
,	O
1.53	O
.	O

Found	O
:	O
C	O
,	O
60.17	O
;	O
H	O
,	O
6.94	O
;	O
N	O
,	O
1.50	O
.	O

3.3	O
O-	B
[	I
(	I
2,3,4,6-Tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-3,6-di	I
-	I
O	I
-	I
benzyl-2-deoxy-2-dimethylmaleimido	I
-	I
α	I
,	I
β	I
-	I
d	I
-glucopyranosyl	I
trichloroacetimidate	I
(	O
7	B
)	O
A	O
solution	O
of	O
5	B
(	O
3.0	O
g	O
,	O
3.28	O
mmol	O
)	O
in	O
dry	O
THF	B
(	O
8	O
mL	O
)	O
in	O
an	O
ice	B
-	O
salt	O
bath	O
was	O
treated	O
with	O
glacial	O
AcOH	B
(	O
0.21	O
mL	O
,	O
3.54	O
mmol	O
)	O
and	O
TBAF	B
(	O
0.1	O
M	O
,	O
3.6	O
mL	O
,	O
3.6	O
mmol	O
)	O
with	O
stirring	O
.	O

After	O
1	O
h	O
,	O
the	O
ice	B
bath	O
was	O
removed	O
and	O
the	O
solution	O
was	O
stirred	O
overnight	O
then	O
diluted	O
with	O
a	O
saturated	O
NaCl	B
solution	O
(	O
20	O
mL	O
)	O
and	O
extracted	O
with	O
CH2	B
Cl2	I
(	O
3	O
×	O
20	O
mL	O
)	O
.	O

The	O
organic	O
layer	O
was	O
separated	O
,	O
dried	O
over	O
anhydrous	O
magnesium	B
sulfate	I
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1.5:1	O
EtOAc	B
–	O
petroleum	B
ether	I
)	O
to	O
yield	O
6	B
(	O
2.2	O
g	O
,	O
83	O
%	O
)	O
as	O
a	O
white	O
foam	O
.	O

A	O
mixture	O
of	O
6	B
(	O
2.2	O
g	O
,	O
2.75	O
mmol	O
)	O
,	O
trichloroacetonitrile	B
(	O
0.6	O
mL	O
,	O
5.8	O
mmol	O
)	O
and	O
1,8-diazabicyclo	B
(	I
5,4,0	I
)	I
undec-7-ene	I
(	O
0.02	O
mL	O
,	O
0.12	O
mmol	O
)	O
in	O
dry	O
CH2	B
Cl2	I
(	O
6	O
mL	O
)	O
was	O
stirred	O
at	O
rt	O
for	O
8	O
h	O
and	O
then	O
concentrated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc+1	B
%	O
triethylamine	B
)	O
to	O
yield	O
7	B
(	O
2.23	O
g	O
,	O
85	O
%	O
)	O
as	O
a	O
pale	O
yellow	O
foam	O
in	O
the	O
α	O
:	O
β	O
ratio	O
1:3	O
.	O

TLC	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc+1	B
%	O
triethylamine	B
)	I
:	O
R	O
f	O
0.5	O
(	O
β	O
-	O
form	O
)	O
and	O
R	O
f	O
0.6	O
(	O
α	O
-	O
form	O
)	O
;	O
1	O
H	O
NMR	O
(	O
250	O
MHz	O
,	O
d	B
6	I
-Me2	I
SO	I
)	O
:	O
δ	O
9.92	O
(	O
br.s	O
,	O
0.75	O
H	O
,	O
NHβ	O
)	O
,	O
8.92	O
(	O
s	O
,	O
0.25	O
H	O
,	O
NHα	O
)	O
,	O
7.40–7.06	O
(	O
m	O
,	O
10	O
H	O
,	O
2	O
Ph	O
)	O
,	O
6.11	O
(	O
d	O
,	O
0.75	O
H	O
,	O
J	O
1,2	O
8.5	O
Hz	O
,	O
H-1ab	O
)	O
,	O
5.84	O
(	O
d	O
,	O
0.25	O
H	O
,	O
J	O
1,2	O
4.5	O
Hz	O
,	O
H-1aa	O
)	O
,	O
5.25	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3,4	O
2.7	O
Hz	O
,	O
H-4b	O
)	O
,	O
5.10–3.41	O
(	O
m	O
,	O
16	O
H	O
)	O
,	O
2.07	O
,	O
2.00	O
,	O
1.96	O
,	O
1.92	O
,	O
1.75	O
(	O
5	O
s	O
,	O
18	O
H	O
,	O
2	O
CH3	O
,	O
4	O
COCH3	O
)	O
.	O

FABMS	O
(	O
positive	O
mode	O
,	O
NBOH	O
/	O
NaI	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
965	O
[	O
MNa+	O
]	O
,	O
1115	O
[	O
MNaI	O
]	O
Na+	O
.	O

Anal	O
.	O

Calcd	O
for	O
C42	O
H47	O
N2	O
O16	O
Cl3	O
(	O
942.18	O
)	O
:	O
C	O
,	O
53.53	O
;	O
H	O
,	O
5.02	O
;	O
N	O
,	O
2.97	O
.	O

Found	O
:	O
C	O
,	O
53.18	O
;	O
H	O
,	O
5.02	O
;	O
N	O
,	O
3.09	O
.	O

3.4	O
Benzyl	B
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-	I
(	I
3,6-di	I
-	I
O	I
-	I
benzyl-2-deoxy-2-dimethylmaleimido	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2,4,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-2,3,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
9	B
)	O
A	O
mixture	O
of	O
7	B
(	O
0.414	O
g	O
,	O
0.439	O
mmol	O
)	O
and	O
8	B
(	O
0.333	O
g	O
,	O
0.342	O
mmol	O
)	O
in	O
dry	O
MeCN	B
(	O
2	O
mL	O
)	O
was	O
stirred	O
under	O
nitrogen	B
at	O
rt	O
for	O
10	O
min	O
while	O
Me3	B
SiOTf	I
(	O
0.01	O
M	O
in	O
MeCN	B
,	O
0.4	O
mL	O
)	O
was	O
added	O
dropwise	O
.	O

After	O
2	O
h	O
,	O
the	O
solution	O
was	O
neutralized	O
with	O
triethylamine	B
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
2:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
to	O
yield	O
9	B
(	O
0.501	O
g	O
,	O
83	O
%	O
)	O
as	O
a	O
white	O
foam	O
.	O

TLC	O
(	O
2:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
:	O
R	O
f	O
0.14	O
;	O
[	O
α	O
]	O
D	O
+	O
11.2	O
°	O
(	O
c	O
0.4	O
,	O
CHCl3	B
)	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.34–7.07	O
(	O
m	O
,	O
45	O
H	O
,	O
9	O
Ph	O
)	O
,	O
5.26	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3,4	O
3.0	O
Hz	O
,	O
H-4d	O
)	O
,	O
5.21	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.4	O
Hz	O
,	O
H-1c	O
)	O
,	O
5.14	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.4	O
,	O
J	O
2,3	O
10.2	O
Hz	O
,	O
H-2d	O
)	O
,	O
5.04	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.4	O
Hz	O
,	O
CHH	O
Ph	O
)	O
,	O
4.92	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.5	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.88–4.82	O
(	O
m	O
,	O
4	O
H	O
,	O
H-3d	O
,	O
1.5	O
CH	O
2	O
Ph	O
)	O
,	O
4.69	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.8	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.66	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.8	O
Hz	O
,	O
CHH	O
Ph	O
)	O
,	O
4.60–4.56	O
(	O
m	O
,	O
3	O
H	O
,	O
H-1d	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.48	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.4	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.47	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
12.1	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.44	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.8	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.39–4.26	O
(	O
m	O
,	O
7	O
H	O
,	O
H-1b	O
,	O
H-1a	O
,	O
2.5	O
CH	O
2	O
Ph	O
)	O
,	O
4.21–4.17	O
(	O
m	O
,	O
2	O
H	O
,	O
H-3c	O
,	O
CH	O
HPh	O
)	O
,	O
4.03–4.01	O
(	O
m	O
,	O
3	O
H	O
,	O
H-2c	O
,	O
H-4b	O
,	O
H-4c	O
)	O
,	O
3.93	O
(	O
m	O
,	O
2	O
H	O
,	O
H-6d	O
,	O
H-6′d	O
)	O
,	O
3.88	O
(	O
m	O
,	O
1	O
H	O
,	O
H-4a	O
)	O
,	O
3.77–3.71	O
(	O
m	O
,	O
2	O
H	O
,	O
H-6c	O
,	O
H-6′c	O
)	O
,	O
3.63	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5d	O
)	O
,	O
3.55–3.51	O
(	O
m	O
,	O
5	O
H	O
,	O
H-5c	O
,	O
H-6′b	O
,	O
H-2b	O
,	O
H-3b	O
,	O
H-6′a	O
)	O
,	O
3.40–3.35	O
(	O
m	O
,	O
5	O
H	O
,	O
H-6b	O
,	O
H-6a	O
,	O
H-5b	O
,	O
H-2a	O
,	O
H-3a	O
)	O
,	O
3.01	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.07	O
,	O
1.99	O
,	O
1.98	O
,	O
1.97	O
(	O
4	O
s	O
,	O
12	O
H	O
,	O
4	O
CH3	O
CO	O
)	O
,	O
1.56	O
(	O
br.s	O
,	O
6	O
H	O
,	O
2	O
CH3	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
102.80	O
(	O
C-1a	O
)	O
,	O
102.70	O
(	O
C-1b	O
)	O
,	O
100.70	O
(	O
C-1d	O
)	O
,	O
100.20	O
(	O
C-1c	O
)	O
,	O
83.40	O
(	O
C-3a	O
)	O
,	O
82.50	O
(	O
C-3b	O
)	O
,	O
82.00	O
(	O
C-2a	O
)	O
,	O
79.30	O
(	O
C-2b	O
)	O
,	O
78.20	O
(	O
C-4c	O
)	O
,	O
77.30	O
(	O
C-3c	O
)	O
,	O
76.90	O
(	O
C-4b	O
)	O
,	O
76.40	O
(	O
C-4a	O
)	O
,	O
75.80	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
75.30	O
(	O
2	O
C	O
H2	O
Ph	O
)	O
,	O
75.20	O
(	O
C-5a	O
)	O
,	O
74.70	O
(	O
C-5	O
,	O
C	O
H2	O
Ph	O
)	O
,	O
74.60	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
74.20	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.80	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.50	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.30	O
(	O
C-5b	O
)	O
,	O
71.30	O
(	O
C	O
H2	O
Ph	O
,	O
C-3d	O
)	O
,	O
70.80	O
(	O
C-5d	O
)	O
,	O
69.90	O
(	O
C-2d	O
)	O
,	O
68.60	O
(	O
C-6b	O
)	O
,	O
68.30	O
(	O
C-6c	O
)	O
,	O
68.20	O
(	O
C-6a	O
)	O
,	O
67.20	O
(	O
C-4d	O
)	O
,	O
60.90	O
(	O
C-6d	O
)	O
,	O
56.40	O
(	O
C-2c	O
)	O
.	O

MALDI	O
-	O
MS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
THF	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
1776	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C101	O
H109	O
NO26	O
(	O
1752.89	O
)	O
:	O
C	O
,	O
69.20	O
;	O
H	O
,	O
6.26	O
;	O
N	O
,	O
0.79	O
.	O

Found	O
:	O
C	O
,	O
69.26	O
;	O
H	O
,	O
6.68	O
;	O
N	O
,	O
0.78	O
.	O

3.5	O
Benzyl	B
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-	I
(	I
2-acetamido-2-deoxy-3,6-di	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2,4,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-2,3,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
10	B
)	O
3.5.1	O
Method	O
A	O
A	O
mixture	O
of	O
9	B
(	O
0.542	O
g	O
,	O
0.309	O
mmol	O
)	O
and	O
NaOH	B
(	O
1.5	O
g	O
,	O
0.037	O
mol	O
)	O
in	O
MeOH	B
–	O
dioxane	B
–	O
water	B
(	O
5:2:1	O
,	O
16	O
mL	O
)	O
was	O
stirred	O
overnight	O
.	O

Then	O
,	O
the	O
solution	O
was	O
neutralized	O
with	O
1:1	O
concd	O
HCl	B
–	O
H2	B
O	I
and	O
the	O
pH	O
was	O
adjusted	O
to	O
5	O
by	O
N	O
HCl	B
.	O

After	O
24	O
h	O
,	O
the	O
solution	O
was	O
neutralized	O
with	O
ethanolamine	B
and	O
dried	O
well	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
treated	O
with	O
pyridine	B
–	O
AcOH	B
(	O
2:1	O
,	O
24	O
mL	O
)	O
.	O

After	O
20	O
h	O
,	O
the	O
reaction	O
mixture	O
was	O
co	O
-	O
evaporated	O
with	O
toluene	B
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
diluted	O
with	O
water	B
(	O
30	O
mL	O
)	O
and	O
extracted	O
with	O
CH2	B
Cl2	I
(	O
3	O
×	O
30	O
mL	O
)	O
.	O

The	O
organic	O
layers	O
were	O
combined	O
,	O
dried	O
over	O
MgSO4	B
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1.5:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
and	O
the	O
unreacted	O
material	O
was	O
treated	O
similarly	O
to	O
yield	O
10	B
(	O
0.370	O
g	O
,	O
71	O
%	O
)	O
as	O
a	O
colorless	O
oil	O
.	O

TLC	O
(	O
1.5:1	O
petroleum	O
ether	B
–	O
EtOAc	B
)	O
:	O
R	O
f	O
0.09	O
;	O
[	O
α	O
]	O
D	O
−6.2	O
°	O
(	O
c	O
0.93	O
,	O
chloroform	B
)	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.34–7.17	O
(	O
m	O
,	O
45	O
H	O
,	O
9	O
Ph	O
)	O
,	O
5.80	O
(	O
br.s	O
,	O
1	O
H	O
,	O
NH	O
)	O
,	O
5.28	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3,4	O
3.0	O
,	O
H-4d	O
)	O
,	O
5.12	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
1,2	O
=	O
J	O
2,3	O
9.0	O
Hz	O
,	O
H-2d	O
)	O
,	O
5.01	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.6	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.98	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.6	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.92–4.31	O
(	O
m	O
,	O
20	O
H	O
,	O
H-1b	O
,	O
H-1a	O
,	O
H-1d	O
,	O
H-3d	O
,	O
H-1c	O
,	O
7.5	O
CH	O
2	O
Ph	O
)	O
,	O
4.18	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.6	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.01–3.90	O
(	O
m	O
,	O
5	O
H	O
,	O
H-6d	O
,	O
H-4a	O
,	O
H-4b	O
,	O
H-6′d	O
,	O
H-4c	O
)	O
,	O
3.78–3.72	O
(	O
m	O
,	O
5	O
H	O
,	O
H-6′a	O
,	O
H-6c	O
,	O
H-6′c	O
,	O
H-3c	O
,	O
H-2c	O
)	O
,	O
3.67–3.58	O
(	O
m	O
,	O
4	O
H	O
,	O
H-3b	O
,	O
H-5d	O
,	O
H-6a	O
,	O
H-2b	O
)	O
,	O
3.52–3.49	O
(	O
m	O
,	O
3	O
H	O
,	O
H-3a	O
,	O
H-6′b	O
,	O
H-5c	O
)	O
,	O
3.45–3.41	O
(	O
m	O
,	O
2	O
H	O
,	O
H-5b	O
,	O
H-2a	O
)	O
,	O
3.35	O
(	O
m	O
,	O
1	O
H	O
,	O
H-6b	O
)	O
,	O
3.24	O
(	O
2	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.01	O
,	O
1.99	O
,	O
1.98	O
,	O
1.53	O
(	O
4	O
s	O
,	O
15	O
H	O
,	O
5	O
CH3	O
CO	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
102.40	O
(	O
C-1b	O
)	O
,	O
102.30	O
(	O
C-1a	O
)	O
,	O
101.70	O
(	O
C-1c	O
)	O
,	O
99.80	O
(	O
C-1d	O
)	O
,	O
82.70	O
(	O
C-3a	O
)	O
,	O
81.70	O
(	O
C-3b	O
)	O
,	O
81.60	O
(	O
C-2a	O
)	O
,	O
79.70	O
(	O
C-2b	O
)	O
,	O
78.40	O
(	O
C-3c	O
)	O
,	O
76.30	O
(	O
C-4c	O
)	O
,	O
76.10	O
(	O
C-4b	O
)	O
,	O
75.80	O
(	O
C-4a	O
)	O
,	O
75.30	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
74.90	O
(	O
C-5a	O
)	O
,	O
74.80	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
74.70	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
74.60	O
(	O
C-5c	O
)	O
,	O
74.50	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.60	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.30	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.20	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.10	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.00	O
(	O
C-5b	O
)	O
,	O
70.80	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
70.60	O
(	O
C-3d	O
)	O
,	O
70.40	O
(	O
C-5d	O
)	O
,	O
69.30	O
(	O
C-2d	O
)	O
,	O
68.30	O
(	O
C-6c	O
)	O
,	O
68.10	O
(	O
C-6b	O
)	O
,	O
68.00	O
(	O
C-6a	O
)	O
,	O
66.70	O
(	O
C-4d	O
)	O
,	O
60.50	O
(	O
C-6d	O
)	O
,	O
55.10	O
(	O
C-2c	O
)	O
.	O

MALDIMS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
THT	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
1711	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C97	O
H107	O
N	O
O25	O
(	O
1686.83	O
)	O
:	O
C	O
,	O
69.06	O
;	O
H	O
,	O
6.39	O
;	O
N	O
,	O
0.83	O
.	O

Found	O
:	O
C	O
,	O
68.64	O
;	O
H	O
,	O
6.55	O
;	O
N	O
,	O
0.71	O
.	O

3.5.2	O
Method	O
B	O
A	O
mixture	O
of	O
9	B
(	O
0.153	O
g	O
,	O
0.087	O
mmol	O
)	O
,	O
hydrazine	B
hydrate	I
(	O
3.096	O
g	O
,	O
0.06	O
mol	O
,	O
3.0	O
mL	O
)	O
in	O
dry	O
MeOH	B
(	O
6	O
mL	O
)	O
was	O
heated	O
under	O
reflux	O
.	O

After	O
9	O
h	O
,	O
the	O
solution	O
was	O
evaporated	O
under	O
reduced	O
pressure	O
and	O
treated	O
with	O
Ac2	B
O	I
and	O
pyridine	B
as	O
described	O
in	O
Method	O
A	O
to	O
yield	O
10	B
(	O
0.08	O
g	O
,	O
54	O
%	O
)	O
.	O

3.6	O
(	B
2,3,4,6-Tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-	I
(	I
2-acetamido-2-deoxy-3,6-di	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2,4,6-tri	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-1,2,3,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
α	I
,	I
β	I
-	I
d	I
-glucopyranose	I
(	O
11	B
)	O
A	O
solution	O
of	O
10	O
(	O
0.1	O
g	O
,	O
0.059	O
mmol	O
)	O
in	O
1:1:1	O
AcOH	B
–	O
MeOH	B
–	O
dioxane	B
(	O
6	O
mL	O
)	O
was	O
stirred	O
under	O
hydrogen	B
in	O
the	O
presence	O
of	O
palladium	B
on	O
carbon	B
(	O
10	O
%	O
Pd	B
,	O
0.1	O
g	O
)	O
at	O
rt	O
.	O

After	O
48	O
h	O
,	O
the	O
reaction	O
mixture	O
was	O
filtered	O
through	O
Celite	B
and	O
washed	O
with	O
MeOH	B
.	O

The	O
combined	O
filtrates	O
were	O
concentrated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
treated	O
with	O
pyridine	B
(	O
10	O
mL	O
)	O
,	O
Ac2	B
O	I
(	O
5	O
mL	O
)	O
and	O
stirred	O
at	O
rt	O
.	O

After	O
20	O
h	O
,	O
the	O
reaction	O
was	O
worked	O
up	O
as	O
described	O
for	O
10	B
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
2:1.5	O
toluene	B
–	O
acetone	B
)	O
to	O
yield	O
11	B
(	O
0.071	O
g	O
,	O
95	O
%	O
)	O
as	O
an	O
amorphous	O
mass	O
in	O
the	O
ratio	O
of	O
α	O
/	O
β	O
3:2	O
.	O

TLC	O
(	O
2:1.5	O
toluene	B
–	O
acetone	B
)	O
:	O
R	O
f	O
0.19	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
6.23	O
(	O
d	O
,	O
0.6	O
H	O
,	O
J	O
1,2	O
=	O
J	O
1,2	O
=	O
3.5	O
Hz	O
,	O
H-1aα	O
)	O
,	O
5.63	O
(	O
d	O
,	O
0.4	O
H	O
,	O
J	O
1,2	O
8.3	O
Hz	O
,	O
H-1aβ	O
)	O
,	O
5.4	O
(	O
t	O
,	O
0.6	O
Hz	O
,	O
J	O
2,3	O
=	O
J	O
3,4	O
9.7	O
Hz	O
,	O
H-3aα	O
)	O
,	O
5.32	O
(	O
m	O
,	O
2	O
H	O
,	O
H-4d	O
,	O
NH	O
)	O
,	O
5.28	O
(	O
m	O
,	O
1	O
H	O
,	O
J	O
3,4	O
3.3	O
Hz	O
,	O
H-4b	O
)	O
,	O
5.18–5.15	O
(	O
m	O
,	O
1.4	O
H	O
,	O
H-3c	O
,	O
H-3aβ	O
)	O
,	O
5.8	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
1,2	O
=	O
J	O
2,3	O
8.2	O
Hz	O
,	O
H-2d	O
)	O
,	O
5.02	O
(	O
dd	O
,	O
0.4	O
H	O
,	O
J	O
1,2	O
8.3	O
,	O
J	O
2,3	O
9.2	O
Hz	O
,	O
H-2aβ	O
)	O
,	O
4.99–4.95	O
(	O
m	O
,	O
2.63	O
H	O
,	O
H-3d	O
,	O
H-2b	O
,	O
H-2aα	O
)	O
,	O
4.76	O
(	O
m	O
,	O
1	O
H	O
,	O
H-6′c	O
)	O
,	O
4.65	O
(	O
m	O
,	O
1	O
H	O
,	O
H-1c	O
)	O
,	O
4.52	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
7.9	O
Hz	O
,	O
H-1d	O
)	O
,	O
4.39–4.37	O
(	O
m	O
,	O
1	O
H	O
,	O
H-6′aβ	O
,	O
H-6′aα	O
)	O
,	O
4.31	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
7.9	O
Hz	O
,	O
H-1b	O
)	O
,	O
4.13–4.02	O
(	O
m	O
,	O
5	O
H	O
,	O
H-6b	O
,	O
H-6′b	O
,	O
H-6d	O
,	O
H-6′d	O
,	O
H-6aβ	O
,	O
H-6aα	O
)	O
,	O
3.96–3.94	O
(	O
m	O
,	O
1.6	O
H	O
,	O
H-6c	O
,	O
H-5aα	O
)	O
,	O
3.85	O
(	O
br.t	O
,	O
1	O
H	O
,	O
H-5d	O
)	O
,	O
3.78–3.71	O
(	O
m	O
,	O
4.4	O
H	O
,	O
H-3b	O
,	O
H-5aβ	O
,	O
H-4aα	O
,	O
H-5b	O
,	O
H-4aβ	O
,	O
H-4c	O
)	O
,	O
3.49–3.47	O
(	O
m	O
,	O
2	O
H	O
,	O
H-5c	O
,	O
H-2c	O
)	O
,	O
2.16–1.88	O
(	O
several	O
s	O
,	O
42	O
H	O
,	O
14	O
CH3	O
CO	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	O
):	O
δ	O
101.40	O
(	O
C-1d	O
)	O
,	O
101.10	O
,	O
100.70	O
(	O
C-1b	O
)	O
,	O
100.50	O
(	O
C-1c	O
)	O
,	O
91.80	O
(	O
C-1aβ	O
)	O
,	O
89.20	O
(	O
C-1aα	O
)	O
,	O
76.00	O
(	O
C-3b	O
)	O
,	O
75.90	O
(	O
C-4c	O
)	O
,	O
75.40	O
(	O
C-4aα	O
)	O
,	O
75.30	O
(	O
C-4aβ	O
)	O
,	O
73.90	O
(	O
C-5aβ	O
)	O
,	O
73.00	O
(	O
C-5c	O
)	O
,	O
72.60	O
(	O
C-3aβ	O
)	O
,	O
72.10	O
(	O
C-3c	O
)	O
,	O
71.40	O
(	O
C-5b	O
)	O
,	O
71.30	O
(	O
C-2aα	O
)	O
,	O
71.10	O
(	O
C-3d	O
)	O
,	O
71.00	O
(	O
C-5d	O
)	O
,	O
70.70	O
(	O
C-2aβ	O
)	O
,	O
69.60	O
(	O
C-3aα	O
)	O
,	O
69.50	O
(	O
C-2b	O
)	O
,	O
69.40	O
(	O
C-2d	O
)	O
,	O
69.10	O
(	O
C-4b	O
)	O
,	O
66.90	O
(	O
C-4d	O
)	O
,	O
62.10	O
(	O
C-6aα	O
)	O
,	O
61.80	O
(	O
C-6aβ	O
,	O
C-6b	O
)	O
,	O
61.00	O
(	O
C-6d	O
)	O
,	O
60.50	O
(	O
C-6c	O
)	O
,	O
55.20	O
(	O
C-2c	O
)	O
.	O

MALDIMS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
THT	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
1277	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C52	O
H71	O
NO34	O
(	O
1254.09	O
)	O
:	O
C	O
,	O
49.79	O
;	O
H	O
,	O
5.70	O
;	O
N	O
,	O
1.11	O
.	O

Found	O
:	O
C	O
,	O
49.81	O
;	O
H	O
,	O
6.22	O
;	O
N	O
,	O
1.15	O
.	O

3.7	O
(	B
β	I
-	I
d	I
-Galactopysranosyl	I
)	I
(	I
1→4	I
)	I
-	I
(	I
2-acetamido-2-deoxy	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
(	I
1→3	I
)	I
-	I
(	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-d	I
-glucopyranose	I
(	O
2	B
)	O
A	O
mixture	O
of	O
11	B
(	O
0.041	O
g	O
,	O
0.0326	O
mmol	O
)	O
,	O
MeOH	B
(	O
6.85	O
mL	O
)	O
and	O
MeONa	B
soln	O
(	O
0.195	O
M	O
,	O
0.45	O
mL	O
,	O
0.087	O
mmol	O
)	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
3	O
days	O
,	O
the	O
mixture	O
was	O
neutralized	O
with	O
Amberlite	B
IR	I
120	I
resin	O
(	O
H+	O
form	O
)	O
,	O
filtered	O
,	O
evaporated	O
under	O
reduced	O
pressure	O
,	O
and	O
then	O
lyophilized	O
from	O
water	B
to	O
yield	O
2	B
(	O
0.021	O
g	O
,	O
91	O
%	O
)	O
.	O

TLC	O
(	O
1:1:0.5	O
CH2	B
Cl2	I
–MeOH	O
–	O
AcOH	B
)	O
,	O
R	O
f	O
0.08	O
;	O
HPTLC	O
(	O
4:1	O
EtOH	B
–	O
water	B
)	O
,	O
R	O
f	O
0.31	O
.	O

MALDIMS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
THF	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
732	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C26	O
H45	O
NO21	O
·	O
2H2	O
O	O
(	O
743.64	O
)	O
:	O
C	O
,	O
41.99	O
;	O
H	O
,	O
6.64	O
;	O
N	O
,	O
1.88	O
.	O

Found	O
:	O
C	O
,	O
41.94	O
;	O
H	O
,	O
6.64	O
;	O
N	O
,	O
1.68	O
.	O

The	O
1	O
H	O
NMR	O
spectroscopy	O
data	O
(	O
600	O
MHz	O
,	O
D2	B
O	I
)	O
are	O
in	O
accordance	O
with	O
literature	O
data	O
[	O
35	O
]	O
.	O

3.8	O
Benzyl	B
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
4,6-benzylidene-2-deoxy-2-dimethylmaleimido	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2,4,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-2,3,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
13	B
)	O
A	O
mixture	O
of	O
12	B
(	O
0.13	O
g	O
,	O
0.15	O
mmol	O
)	O
and	O
8	B
(	O
0.123	O
g	O
,	O
0.126	O
mmol	O
)	O
in	O
dry	O
CH2	B
Cl2	I
(	O
1	O
mL	O
)	O
was	O
stirred	O
under	O
nitrogen	B
at−30	O
°	O
C	O
for	O
10	O
min	O
while	O
Me3	B
SiOTf	I
(	O
0.01	O
M	O
in	O
CH2	B
Cl2	I
,	O
0.17	O
mL	O
)	O
was	O
added	O
dropwise	O
.	O

After	O
40	O
min	O
,	O
the	O
solution	O
was	O
neutralized	O
with	O
triethylamine	B
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
2:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
to	O
yield	O
13	B
(	O
0.16	O
g	O
,	O
76	O
%	O
)	O
as	O
a	O
colorless	O
oil	O
.	O

TLC	O
(	O
2:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
:	O
R	O
f	O
0.12	O
;	O
[	O
α	O
]	O
D	O
−8.6	O
°	O
(	O
c	O
0.5	O
,	O
CHCl3	B
):	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.40–7.10	O
(	O
m	O
,	O
40	O
H	O
,	O
8	O
Ph	O
)	O
,	O
5.57	O
(	O
s	O
,	O
1	O
H	O
,	O
CH	O
Ph	O
)	O
,	O
5.27	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.4	O
Hz	O
,	O
H-1c	O
)	O
,	O
5.22	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
3,4	O
2.6	O
Hz	O
,	O
H-4d	O
)	O
,	O
5.00	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.0	O
,	O
J	O
2,3	O
10.3	O
Hz	O
,	O
H-2d	O
)	O
,	O
4.94	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.3	O
Hz	O
,	O
CHH	O
Ph	O
)	O
,	O
4.92	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.5	O
Hz	O
,	O
CHH	O
Ph	O
)	O
,	O
4.86	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
12.1	O
Hz	O
,	O
CHH	O
Ph	O
)	O
,	O
4.85	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.8	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.81	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
3,4	O
3.4	O
Hz	O
,	O
H-3d	O
)	O
,	O
4.70	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.8	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.65	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
=	O
J	O
3,4	O
9.5	O
Hz	O
,	O
H-3c	O
)	O
,	O
4.61	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.5	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.57	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.5	O
Hz	O
,	O
CH	O
HPH	O
)	O
,	O
4.54–4.51	O
(	O
m	O
,	O
2	O
H	O
,	O
H-1d	O
,	O
CH	O
HPh	O
)	O
,	O
4.48	O
(	O
m	O
,	O
2	O
H	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.39	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.5	O
,	O
J	O
5,6′	O
4.8	O
Hz	O
,	O
H-6′c	O
)	O
,	O
4.36–4.28	O
(	O
m	O
,	O
4	O
H	O
,	O
H-1a	O
,	O
H-1b	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.27	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
12.1	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.22	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.8	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.14	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
9.5	O
Hz	O
,	O
H-2c	O
)	O
,	O
4.05	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.0	O
,	O
J	O
5,6′	O
8.1	O
Hz	O
,	O
H-6′d	O
)	O
,	O
3.91–3.83	O
(	O
m	O
,	O
4	O
H	O
,	O
H-6c	O
,	O
H-6d	O
,	O
H-4b	O
,	O
H-4a	O
)	O
,	O
3.77	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
3,4	O
=	O
J	O
4,5	O
9.5	O
Hz	O
,	O
H-4c	O
)	O
,	O
3.60–3.48	O
(	O
m	O
,	O
6	O
H	O
,	O
H-5d	O
,	O
H-6′b	O
,	O
H-6′a	O
,	O
H-2b	O
,	O
H-3b	O
,	O
H-5c	O
)	O
,	O
3.41–3.35	O
(	O
m	O
,	O
5	O
H	O
,	O
H-6a	O
,	O
H-6b	O
,	O
H-5b	O
,	O
H-3a	O
,	O
H-2a	O
)	O
,	O
2.98	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.09	O
,	O
1.93	O
,	O
1.90	O
,	O
1.81	O
(	O
4	O
s	O
,	O
12	O
H	O
,	O
4	O
CH3	O
CO	O
)	O
,	O
1.55	O
(	O
br.s	O
,	O
6	O
H	O
,	O
2	O
CH3	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
102.80	O
(	O
C-1a	O
,	O
C-1b	O
)	O
,	O
101.90	O
(	O
C	O
-	O
C	O
HPh	O
)	O
,	O
100.50	O
(	O
C-1d	O
)	O
,	O
100.30	O
(	O
C-1c	O
)	O
,	O
83.40	O
(	O
C-3a	O
)	O
,	O
82.10	O
(	O
C-2a	O
)	O
,	O
81.80	O
(	O
C-3b	O
)	O
,	O
81.20	O
(	O
C-4c	O
)	O
,	O
79.40	O
(	O
C-2b	O
)	O
,	O
76.80	O
(	O
C-4b	O
)	O
,	O
76.30	O
(	O
C-4a	O
)	O
,	O
75.70	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
75.40	O
(	O
C-3c	O
,	O
C	O
H2	O
Ph	O
)	O
,	O
75.30	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
75.20	O
(	O
C-5a	O
)	O
,	O
74.50	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.80	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.50	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.40	O
(	O
C-5b	O
)	O
,	O
71.40	O
(	O
C-3d	O
)	O
,	O
71.20	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
70.70	O
(	O
C-5d	O
)	O
,	O
69.50	O
(	O
C-2d	O
)	O
,	O
69.10	O
(	O
C-6c	O
)	O
,	O
68.50	O
(	O
C-6b	O
)	O
,	O
68.10	O
(	O
C-6a	O
)	O
,	O
67.00	O
(	O
C-4d	O
)	O
,	O
66.30	O
(	O
C-5c	O
)	O
,	O
61.20	O
(	O
C-6d	O
)	O
,	O
56.00	O
(	O
C-2c	O
)	O
.	O

MALDIMS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
THT	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
1684	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C94	O
H101	O
NO26	O
(	O
1660.75	O
)	O
:	O
C	O
,	O
67.97	O
;	O
H	O
,	O
6.13	O
;	O
N	O
,	O
0.84	O
.	O

Found	O
:	O
C	O
,	O
68.06	O
;	O
H	O
,	O
6.41	O
;	O
N	O
,	O
0.64	O
.	O

3.9	O
Benzyl	B
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2-acetamido-4,6-di	I
-	I
O	I
-	I
acetyl-2-deoxy	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2,4,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-2,3,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
15	B
)	O
(	O
a	O
)	O
From	O
13	B
.	O

A	O
mixture	O
of	O
13	B
(	O
0.165	O
g	O
,	O
0.099	O
mmol	O
)	O
,	O
p	B
-TsOH	I
(	O
0.005	O
g	O
,	O
0.026	O
mmol	O
)	O
and	O
ethanethiol	B
(	O
0.1	O
g	O
,	O
1.62	O
mmol	O
,	O
0.12	O
mL	O
)	O
in	O
dry	O
CH2	B
Cl2	I
(	O
1	O
mL	O
)	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
24	O
h	O
,	O
the	O
solution	O
was	O
neutralized	O
with	O
Et3	B
N	I
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
to	O
yield	O
14	O
(	O
0.118	O
g	O
,	O
75	O
%	O
)	O
as	O
an	O
oil	O
;	O
TLC	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
:	O
R	O
f	O
0.11	O
.	O

A	O
mixture	O
of	O
the	O
aforementioned	O
oil	O
(	O
0.118	O
g	O
,	O
0.075	O
mmol	O
)	O
and	O
NaOH	B
(	O
0.17	O
g	O
,	O
4.25	O
mmol	O
)	O
in	O
a	O
dioxane	B
–	O
water	B
mixture	O
(	O
5:0.5	O
,	O
5.5	O
mL	O
)	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
24	O
h	O
,	O
the	O
pH	O
of	O
the	O
solution	O
was	O
adjusted	O
and	O
kept	O
at	O
5	O
by	O
N	O
HCl	B
.	O

After	O
24	O
h	O
,	O
the	O
solution	O
was	O
neutralized	O
with	O
K2	B
CO3	I
and	O
dried	O
under	O
reduced	O
pressure	O
in	O
the	O
presence	O
of	O
ethanolamine	B
(	O
0.2	O
mL	O
)	O
.	O

The	O
residue	O
was	O
treated	O
with	O
Ac2	B
O	I
(	O
4	O
mL	O
)	O
and	O
pyridine	B
(	O
8	O
mL	O
)	O
and	O
stirred	O
at	O
rt	O
.	O

After	O
15	O
h	O
,	O
the	O
solution	O
was	O
worked	O
up	O
as	O
described	O
for	O
10	B
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
and	O
the	O
un	O
-	O
reacted	O
material	O
was	O
separated	O
and	O
deprotected	O
again	O
to	O
yield	O
15	B
(	O
0.091	O
g	O
,	O
76	O
%	O
)	O
as	O
a	O
colorless	O
oil	O
.	O

TLC	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
:	O
R	O
f	O
0.09	O
;	O
[	O
α	O
]	O
D	O
−12.0	O
°	O
(	O
c	O
0.15	O
,	O
CHCl3	B
)	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.40–7.10	O
(	O
m	O
,	O
35	O
H	O
,	O
7	O
Ph	O
)	O
,	O
5.33	O
(	O
br.s	O
,	O
1	O
H	O
,	O
H-4d	O
)	O
,	O
4.99–4.84	O
(	O
m	O
,	O
9	O
H	O
,	O
NH	O
,	O
H-4c	O
,	O
H-1c	O
,	O
H-3d	O
,	O
H-2d	O
,	O
2.5	O
CH	O
2	O
Ph	O
)	O
,	O
4.73	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.9	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.69	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
10.5	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.63–4.57	O
(	O
m	O
,	O
3	O
H	O
,	O
1.5	O
CH	O
2	O
Ph	O
)	O
,	O
4.50	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.7	O
Hz	O
,	O
CH	O
HPh	O
)	O
,	O
4.44–4.40	O
(	O
m	O
,	O
3	O
H	O
,	O
H-1b	O
,	O
H-1a	O
,	O
CH	O
HPh	O
)	O
,	O
4.34–4.33	O
(	O
m	O
,	O
2	O
H	O
,	O
H-1d	O
,	O
CH	O
HPh	O
)	O
,	O
4.21–4.15	O
(	O
m	O
,	O
5	O
H	O
,	O
H-3c	O
,	O
H-6′d	O
,	O
H-6c	O
,	O
H-6′c	O
,	O
CH	O
HPh	O
)	O
,	O
4.07	O
(	O
m	O
,	O
1	O
H	O
,	O
H-6d	O
)	O
,	O
3.98	O
(	O
m	O
,	O
1	O
H	O
,	O
H-4a	O
)	O
,	O
3.92	O
(	O
m	O
,	O
1	O
H	O
,	O
H-4b	O
)	O
,	O
3.83	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5d	O
)	O
,	O
3.76–3.74	O
(	O
m	O
,	O
2	O
H	O
,	O
H-5c	O
,	O
H-6′a	O
)	O
,	O
3.67–3.66	O
(	O
m	O
,	O
2	O
H	O
,	O
H-6a	O
,	O
H-2b	O
)	O
,	O
3.54–3.45	O
(	O
m	O
,	O
5	O
H	O
,	O
H-2c	O
,	O
H-2a	O
,	O
H-6′b	O
,	O
H-3a	O
,	O
H-3b	O
)	O
,	O
3.40	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5b	O
)	O
,	O
3.36	O
(	O
m	O
,	O
1	O
H	O
,	O
H-6b	O
)	O
,	O
3.28	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.13	O
,	O
2.10	O
,	O
2.05	O
,	O
1.99	O
,	O
1.95	O
,	O
1.52	O
(	O
6	O
s	O
,	O
21	O
H	O
,	O
7	O
CH3	O
CO	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
102.80	O
(	O
C-1a	O
,	O
C-1b	O
)	O
,	O
101.20	O
(	O
C-1c	O
)	O
,	O
101.10	O
(	O
C-1d	O
)	O
,	O
83.10	O
(	O
C-3a	O
)	O
,	O
82.10	O
(	O
C-2a	O
,	O
C-3b	O
)	O
,	O
80.70	O
(	O
C-2b	O
)	O
,	O
77.10	O
(	O
C-3c	O
)	O
,	O
76.70	O
(	O
C-4a	O
)	O
,	O
76.40	O
(	O
C-4b	O
)	O
,	O
75.50	O
(	O
C-5a	O
,	O
C	O
H2	O
Ph	O
)	O
,	O
75.40	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
75.20	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
75.10	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.70	O
(	O
2	O
C	O
H2	O
Ph	O
)	O
,	O
73.60	O
(	O
C-5b	O
)	O
,	O
72.10	O
(	O
C-5c	O
)	O
,	O
71.30	O
(	O
C-3d	O
,	O
C	O
H2	O
Ph	O
)	O
,	O
70.80	O
(	O
C-5d	O
)	O
,	O
69.80	O
(	O
C-4c	O
)	O
,	O
69.40	O
(	O
C-2d	O
)	O
,	O
68.60	O
(	O
C-6a	O
)	O
,	O
68.40	O
(	O
C-6b	O
)	O
,	O
67.20	O
(	O
C-4d	O
)	O
,	O
63.00	O
(	O
C-6c	O
)	O
,	O
61.40	O
(	O
C-6d	O
)	O
,	O
57.40	O
(	O
C-2c	O
)	O
.	O

FABMS	O
(	O
positive	O
mode	O
,	O
NBOH	O
/	O
NaI	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
1613	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C87	O
H99	O
NO27	O
(	O
1590.66	O
)	O
:	O
C	O
,	O
65.68	O
;	O
H	O
,	O
6.27	O
;	O
N	O
,	O
0.88	O
.	O

Found	O
:	O
C	O
,	O
65.77	O
;	O
H	O
,	O
6.58	O
;	O
N	O
,	O
0.71	O
.	O

(	O
b	O
)	O
From	O
22	O
.	O

Compound	B
22	I
(	O
0.169	O
g	O
,	O
0.102	O
mmol	O
)	O
was	O
treated	O
as	O
described	O
for	O
14	B
to	O
yield	O
15	B
(	O
0.116	O
g	O
,	O
71	O
%	O
)	O
.	O

3.10	O
(	B
2,3,4,6-Tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2-acetamido-2-deoxy-4,6-di	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2,4,6-tri	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-1,2,3,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
α	I
/	I
β	I
-	I
d	I
-glucopyranose	I
(	O
16	B
)	O
According	O
to	O
the	O
procedure	O
described	O
for	O
the	O
preparation	O
of	O
11	B
,	O
compound	B
15	I
(	O
0.111	O
g	O
,	O
0.07	O
mmol	O
)	O
was	O
dissolved	O
in	O
1:1:1	O
AcOH	B
–	O
MeOH	B
–	O
dioxane	B
(	O
4.5	O
mL	O
)	O
and	O
hydrogenolized	B
in	O
the	O
presence	O
of	O
Pd	B
/	O
C	B
(	O
10	O
%	O
Pd	B
,	O
0.1	O
g	O
)	O
at	O
rt	O
for	O
48	O
h	O
,	O
then	O
worked	O
up	O
and	O
the	O
residue	O
was	O
acetylated	B
.	O

The	O
residue	O
was	O
purified	O
by	O
MPLC	O
(	O
1.5:1	O
toluene	B
–	O
acetone	B
)	O
to	O
yield	O
16	B
(	O
0.075	O
g	O
,	O
86	O
%	O
)	O
as	O
an	O
amorphous	O
mass	O
in	O
the	O
ratio	O
of	O
α	O
:	O
β	O
1:2	O
.	O

TLC	O
(	O
1.5:1	O
toluene	B
–	O
acetone	O
)	O
:	O
R	O
f	O
0.18	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
6.23	O
(	O
d	O
,	O
0.33	O
H	O
,	O
J	O
1,2	O
3.5	O
Hz	O
,	O
H-1aa	O
)	O
,	O
5.65–5.63	O
(	O
m	O
,	O
1.7	O
H	O
,	O
NH	O
,	O
H-1aβ	O
)	O
,	O
5.41	O
(	O
t	O
,	O
0.3	O
H	O
,	O
J	O
2,3	O
=	O
J	O
3,4	O
9.8	O
Hz	O
,	O
H-3aα	O
)	O
,	O
5.32–5.31	O
(	O
m	O
,	O
2	O
H	O
,	O
H-4b	O
,	O
H-4d	O
)	O
,	O
5.20	O
(	O
t	O
,	O
0.7	O
H	O
,	O
H-3aβ	O
)	O
,	O
5.11	O
(	O
t	O
,	O
1	O
H	O
,	O
H-1c	O
)	O
,	O
5.02–4.91	O
(	O
m	O
,	O
5	O
H	O
,	O
H-4c	O
,	O
H-3d	O
,	O
H-2aα	O
,	O
H-2b	O
,	O
H-2d	O
,	O
H-2aβ	O
)	O
,	O
4.54	O
(	O
t	O
,	O
1	O
H	O
,	O
J	O
2,3	O
=	O
J	O
3,4	O
9.8	O
Hz	O
,	O
H-3c	O
)	O
,	O
4.44–4.38	O
(	O
m	O
,	O
3	O
H	O
,	O
H-6′aα	O
,	O
H-6′aβ	O
,	O
H-6′c	O
,	O
H-1d	O
)	O
,	O
4.33	O
,	O
4.32	O
(	O
2	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
7.8	O
Hz	O
,	O
H-1b	O
)	O
,	O
4.14	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
gem	O
12.1	O
,	O
J5,6	O
2.9	O
Hz	O
,	O
H-6aα	O
,	O
H-6aβ	O
)	O
,	O
4.07–4.01	O
(	O
m	O
,	O
4	O
H	O
,	O
H-6b	O
,	O
H-6′b	O
,	O
H-6d	O
,	O
H-6′d	O
)	O
,	O
3.98–3.96	O
(	O
m	O
,	O
1.3	O
H	O
,	O
H-5aα	O
,	O
H-6c	O
)	O
,	O
3.82	O
(	O
t	O
,	O
1	O
H	O
,	O
H-5d	O
)	O
,	O
3.77–3.73	O
(	O
m	O
,	O
3.7	O
H	O
,	O
H-3b	O
,	O
H-5aβ	O
,	O
H-5b	O
,	O
H-4aα	O
,	O
H-4aβ	O
)	O
,	O
3.59	O
(	O
br.d	O
,	O
1	O
H	O
,	O
H-5c	O
)	O
,	O
2.80	O
(	O
br.t	O
,	O
1	O
H	O
,	O
H-2c	O
)	O
,	O
2.16–1.94	O
(	O
several	O
s	O
,	O
42	O
H	O
,	O
14	O
CH3	O
CO	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
101.30	O
,	O
100.90	O
(	O
C-1b	O
)	O
,	O
101.00	O
(	O
C-1d	O
)	O
,	O
99.00	O
(	O
C-1c	O
)	O
,	O
91.90	O
(	O
C-1aβ	O
)	O
,	O
89.30	O
(	O
C-1aα	O
)	O
,	O
76.50	O
(	O
C-3b	O
)	O
,	O
76.30	O
(	O
C-3c	O
)	O
,	O
75.50	O
(	O
C-4aα	O
)	O
,	O
75.30	O
(	O
C-4aβ	O
)	O
,	O
74.00	O
(	O
C-5aβ	O
)	O
,	O
72.70	O
(	O
C-3aβ	O
)	O
,	O
72.20	O
,	O
71.60	O
(	O
C-5c	O
)	O
,	O
71.40	O
(	O
C-3d	O
)	O
,	O
71.20	O
(	O
C-2aα	O
)	O
71.10	O
(	O
C-5aα	O
)	O
,	O
70.90	O
(	O
C-5d	O
)	O
,	O
70.70	O
(	O
C-2aβ	O
)	O
,	O
69.90	O
(	O
C-2d	O
)	O
,	O
69.70	O
(	O
C-3aα	O
,	O
C-2b	O
)	O
,	O
69.50	O
(	O
C-4d	O
)	O
,	O
69.20	O
(	O
C-4c	O
)	O
,	O
67.20	O
(	O
C-4b	O
)	O
,	O
62.00	O
(	O
C-6a	O
)	O
,	O
61.80	O
(	O
C-6b	O
)	O
,	O
61.70	O
(	O
C-6c	O
)	O
,	O
61.20	O
(	O
C-6d	O
)	O
,	O
59.30	O
(	O
C-2c	O
)	O
.	O

MALDIMS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
THT	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
1278	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C52	O
H71	O
NO34	O
(	O
1254.09	O
)	O
:	O
C	O
,	O
49.79	O
;	O
H	O
,	O
5.70	O
;	O
N	O
,	O
1.11	O
.	O

Found	O
:	O
C	O
,	O
49.85	O
;	O
H	O
,	O
6.23	O
;	O
N	O
,	O
1.08	O
.	O

3.11	O
β	B
-	I
d	I
-Galactopyranosyl-	I
(	I
1→3	I
)	I
-2-acetamido-2-deoxy	I
-	I
β	I
-	I
d	I
-glucopyranosyl-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→4	I
)	I
-d	I
-glucopyranose	I
(	O
1	B
)	O
A	O
mixture	O
of	O
16	B
(	O
0.053	O
g	O
,	O
0.033	O
mmol	O
)	O
,	O
MeOH	B
(	O
3.4	O
mL	O
)	O
and	O
NaOMe	B
(	O
0.195	O
M	O
in	O
MeOH	B
,	O
0.45	O
mL	O
)	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
3	O
h	O
,	O
water	B
(	O
3.4	O
mL	O
)	O
and	O
NaOMe	B
(	O
0.195	O
M	O
,	O
0.90	O
mL	O
)	O
were	O
added	O
.	O

After	O
3	O
days	O
,	O
the	O
reaction	O
mixture	O
was	O
worked	O
up	O
as	O
described	O
for	O
2	B
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
on	O
amino	O
-	O
phase	O
Lichroprep	O
(	O
3:1	O
EtOH	B
–	O
water	B
)	O
to	O
yield	O
1	B
(	O
0.018	O
g	O
,	O
78	O
%	O
)	O
as	O
a	O
foam	O
.	O

HPTLC	O
(	O
4:1	O
EtOH	B
–	O
water	B
)	O
:	O
R	O
f	O
0.19	O
;	O
[	O
α	O
]	O
D	O
+	O
23.9	O
°	O
(	O
c	O
0.5	O
,	O
H	O
2	O
O	O
,	O
3	O
h	O
)	O
;	O
lit	O
.	O

[	O
α	O
]	O
D	O
24	O
+	O
25.2	O
°	O
(	O
final	O
value	O
)	O
(	O
c	O
1.5	O
,	O
H	B
2	I
O	I
)	O
[	O
5	O
]	O
.	O

MALDIMS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
NaI	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
731.6	O
[	O
MNa+	O
]	O
.	O

The	O
1	O
H	O
NMR	O
spectroscopy	O
data	O
(	O
600	O
MHz	O
,	O
D2	B
O	I
)	O
were	O
in	O
accordance	O
with	O
literature	O
data	O
[	O
35	O
]	O
.	O

3.12	O
tert	B
-	I
Butyldimethylsilyl	I
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-2-deoxy-2-dimethylmaleimido	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
18	B
)	O
A	O
mixture	O
of	O
17	B
(	O
1.51	O
g	O
,	O
1.84	O
mmol	O
)	O
,	O
p	B
-TsOH	I
(	O
0.008	O
g	O
,	O
0.42	O
mmol	O
)	O
and	O
ethanethiol	B
(	O
0.84	O
g	O
,	O
13.46	O
mmol	O
,	O
1.0	O
mL	O
)	O
in	O
dry	O
CH2	B
Cl2	I
(	O
15	O
mL	O
)	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
20	O
h	O
,	O
the	O
solution	O
was	O
neutralized	O
with	O
triethylamine	B
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
to	O
yield	O
18	B
(	O
1.096	O
g	O
,	O
81	O
%	O
)	O
as	O
a	O
white	O
foam	O
.	O

TLC	O
(	O
1:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
:	O
R	O
f	O
0.14	O
;	O
[	O
α	O
]	O
D	O
−6.4	O
°	O
(	O
c	O
0.7	O
,	O
chloroform	B
)	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
5.31	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3,4	O
2.6	O
Hz	O
,	O
H-4b	O
)	O
,	O
5.13	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.0	O
,	O
J	O
2,3	O
10.5	O
Hz	O
,	O
H-2b	O
)	O
,	O
5.07	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.1	O
Hz	O
,	O
H-1a	O
)	O
,	O
4.91	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
3,4	O
2.6	O
Hz	O
,	O
H-3b	O
)	O
,	O
4.35	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1b	O
)	O
,	O
4.32	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
10.8	O
,	O
J	O
3,4	O
8.4	O
Hz	O
,	O
H-3a	O
)	O
,	O
4.09	O
(	O
m	O
,	O
2	O
H	O
,	O
H-6b	O
,	O
H-6′b	O
)	O
,	O
3.95	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5b	O
)	O
,	O
3.91–3.88	O
(	O
m	O
,	O
2	O
H	O
,	O
H-6′a	O
,	O
H-2a	O
)	O
,	O
3.75	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.5	O
,	O
J	O
5,6	O
5.6	O
Hz	O
,	O
H-6a	O
)	O
,	O
3.54	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
3,4	O
8.4	O
,	O
J	O
4,5	O
9.2	O
Hz	O
,	O
H-4a	O
)	O
,	O
3.46	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.12	O
,	O
2.05	O
,	O
1.95	O
,	O
1.92	O
,	O
1.81	O
(	O
5	O
s	O
,	O
18	O
H	O
,	O
2	O
CH3	O
,	O
4	O
CH3	O
CO	O
)	O
,	O
0.73	O
[	O
s	O
,	O
9	O
H	O
,	O
SiC	O
(	O
CH3	O
)	O
3	O
]	O
,	O
0.02	O
(	O
s	O
,	O
3	O
H	O
SiCH3	O
)	O
,	O
−0.07	O
(	O
s	O
,	O
3	O
H	O
,	O
SiCH3	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
170.38	O
,	O
170.10	O
,	O
170.05	O
,	O
168.68	O
(	O
4	O
CH3	O
C	O
O	O
,	O
2	O
CO	O
)	O
,	O
137.41	O
(	O
2	O
C	O
-	O
DMM	O
)	O
,	O
101.03	O
(	O
C-1b	O
)	O
,	O
93.41	O
(	O
C-1a	O
)	O
,	O
81.78	O
(	O
C-3a	O
)	O
,	O
75.36	O
(	O
C-5a	O
)	O
,	O
71.20	O
(	O
C-5b	O
)	O
,	O
70.76	O
(	O
C-4a	O
)	O
,	O
70.64	O
(	O
C-3b	O
)	O
,	O
68.60	O
(	O
C-2b	O
)	O
,	O
66.87	O
(	O
C-4b	O
)	O
,	O
63.17	O
(	O
C-6a	O
)	O
,	O
61.48	O
(	O
C-6b	O
)	O
,	O
56.87	O
(	O
C-2a	O
)	O
,	O
25.24	O
[	O
SiC	O
(	O
C	O
H3	O
)	O
3	O
]	O
,	O
20.58	O
,	O
20.53	O
,	O
20.47	O
,	O
20.27	O
(	O
4	O
C	O
H3	O
CO	O
)	O
,	O
17.48	O
[	O
SiC	O
[	O
CH3	O
)	O
]	O
,	O
8.73	O
(	O
2	O
C	O
–	O
CH3	O
)	O
,	O
−4.10	O
(	O
SiCH3	O
)	O
,	O
−5.61	O
(	O
SiCH3	O
)	O
.	O

FABMS	O
(	O
positive	O
mode	O
,	O
NBOH	O
/	O
NaI	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
754	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C32	O
H49	O
NO16	O
Si	O
(	O
731.80	O
)	O
:	O
C	O
,	O
52.51	O
;	O
H	O
,	O
6.74	O
;	O
N	O
,	O
1.91	O
.	O

Found	O
:	O
C	O
,	O
52.63	O
;	O
H	O
,	O
6.91	O
;	O
N	O
,	O
1.77	O
.	O
3.13	O
tert	B
-	I
Butyldimethylsilyl	I
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-4,6-di	I
-	I
O	I
-	I
acetyl-2-deoxy-2-dimethylmaleimido	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
19	B
)	O
A	O
mixture	O
of	O
18	B
(	O
1.51	O
g	O
,	O
1.43	O
mmol	O
)	O
,	O
pyridine	B
(	O
15	O
mL	O
)	O
and	O
acetic	B
anhydride	I
(	O
7.5	O
mL	O
)	O
was	O
stirred	O
at	O
rt	O
.	O

After	O
18	O
h	O
,	O
the	O
solution	O
was	O
worked	O
up	O
as	O
described	O
for	O
10	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1.5:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
to	O
yield	O
19	B
(	O
1.141	O
g	O
,	O
97	O
%	O
)	O
as	O
a	O
white	O
foam	O
.	O

TLC	O
(	O
1.5:1	O
petroleum	B
ether	I
–	O
EtOAc	B
:	O
R	O
f	O
0.11	O
;	O
[	O
α	O
]	O
D	O
−6.6	O
°	O
(	O
c	O
0.5	O
,	O
CHCl3	B
)	O
,	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
5.26	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3,4	O
Hz	O
,	O
H-4b	O
)	O
,	O
5.06	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.1	O
Hz	O
,	O
H-1a	O
)	O
,	O
4.93	O
(	O
m	O
,	O
1	O
H	O
,	O
H-2b	O
)	O
,	O
4.92	O
(	O
m	O
,	O
1	O
H	O
,	O
H-4a	O
)	O
,	O
4.84	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
10.4	O
,	O
J	O
3,4	O
3.4	O
Hz	O
,	O
H-3b	O
)	O
,	O
4.54	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
10.8	O
,	O
J	O
3,4	O
9.3	O
Hz	O
,	O
H-3a	O
)	O
,	O
4.20	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
7.8	O
Hz	O
,	O
H-1b	O
)	O
,	O
4.13	O
(	O
m	O
,	O
2	O
H	O
,	O
H-6a	O
,	O
H-6′a	O
)	O
,	O
4.07	O
(	O
m	O
,	O
2	O
H	O
,	O
H-6b	O
,	O
H-6′b	O
)	O
,	O
3.95	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
10.8	O
Hz	O
,	O
H-2a	O
)	O
,	O
3.76	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5b	O
)	O
,	O
3.70	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.10	O
,	O
2.05	O
,	O
2.04	O
,	O
2.03	O
,	O
2.02	O
,	O
1.97	O
,	O
1.91	O
,	O
1.89	O
(	O
8	O
s	O
,	O
24	O
H	O
,	O
2	O
CH3	O
,	O
6	O
CH3	O
CO	O
)	O
,	O
0.73	O
[	O
s	O
,	O
9	O
H	O
,	O
SiC	O
(	O
CH3	O
)	O
3	O
]	O
,	O
0.02	O
(	O
s	O
,	O
3	O
H	O
,	O
SiCH3	O
)	O
,	O
−0.06	O
(	O
s	O
,	O
3	O
H	O
,	O
SiCH3	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
170.32	O
,	O
170.19	O
,	O
169.29	O
,	O
169.10	O
(	O
6	O
CH3	O
C	O
O	O
,	O
2	O
CO	O
)	O
,	O
100.37	O
(	O
C-1b	O
)	O
,	O
93.26	O
(	O
C-1a	O
)	O
,	O
75.08	O
(	O
C-3a	O
)	O
,	O
71.86	O
(	O
C-5a	O
)	O
,	O
70.84	O
(	O
C-3b	O
)	O
,	O
70.47	O
(	O
C-5b	O
)	O
,	O
69.70	O
(	O
C-4a	O
)	O
,	O
68.97	O
(	O
C-2b	O
)	O
,	O
66.76	O
(	O
C-4b	O
)	O
,	O
62.70	O
(	O
C-6a	O
)	O
,	O
60.76	O
(	O
C-6b	O
)	O
,	O
57.69	O
(	O
C-2a	O
)	O
,	O
25.27	O
[	O
SiC	O
(	O
C	O
H3	O
)	O
3	O
]	O
,	O
20.78	O
,	O
20.65	O
,	O
20.53	O
(	O
6	O
C	O
H3	O
CO	O
)	O
,	O
8.83	O
(	O
2	O
CH3	O
)	O
,	O
−4.24	O
(	O
SiCH3	O
)	O
,	O
−5.60	O
(	O
SiCH3	O
)	O
.	O

FAB	O
MS	O
(	O
positive	O
mode	O
,	O
NBOH	O
/	O
NaI	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
838	O
[	O
MNa+	O
]	O
,	O
988	O
[	O
MNaI	O
]	O
Na+	O
.	O

Anal	O
.	O

Calcd	O
for	O
C36	O
H53	O
NO18	O
Si	O
(	O
815.87	O
)	O
:	O
C	O
,	O
52.99	O
;	O
H	O
,	O
6.54	O
;	O
N	O
,	O
1.71	O
.	O

Found	O
:	O
C	O
,	O
52.87	O
;	O
H	O
,	O
6.73	O
;	O
N	O
,	O
1.32	O
.	O

3.14	O
O-	B
[	I
(	I
2,3,4,6-Tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-4,6-di	I
-	I
O	I
-	I
acetyl-2-deoxy-2-dimethylmaleimido	I
-	I
α	I
/	I
β	I
-	I
d	I
-glucopyranosyl	I
]	I
trichloroacetimidate	I
(	O
21	B
)	O
A	O
mixture	O
of	O
19	B
(	O
1.047	O
g	O
,	O
1.28	O
mmol	O
)	O
,	O
glacial	O
AcOH	B
(	O
0.084	O
g	O
,	O
1.408	O
mmol	O
,	O
85.0	O
μL	O
)	O
and	O
TBAF	B
(	O
0.368	O
g	O
,	O
1.41	O
mmol	O
)	O
in	O
dry	O
THF	B
(	O
10	O
mL	O
)	O
was	O
reacted	O
and	O
worked	O
up	O
as	O
described	O
for	O
6	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
2:1	O
EtOAc	B
–	O
petroleum	B
ether	I
)	O
to	O
yield	O
20	B
(	O
0.9	O
g	O
,	O
quantitative	O
)	O
as	O
a	O
white	O
foam	O
.	O

TLC	O
(	O
2:1	O
EtOAc	B
–	O
petroleum	B
ether	I
)	O
:	O
R	O
f	O
0.24	O
.	O

A	O
solution	O
of	O
the	O
aforementioned	O
foam	O
(	O
0.9	O
g	O
,	O
1.28	O
mmol	O
)	O
in	O
dry	O
CH2	B
Cl2	I
(	O
5	O
mL	O
)	O
was	O
treated	O
by	O
trichloroacetonitrile	B
(	O
0.83	O
mL	O
,	O
8.1	O
mmol	O
)	O
and	O
DBU	B
(	O
0.03	O
mL	O
,	O
1.8	O
mmol	O
)	O
with	O
stirring	O
.	O

After	O
9	O
h	O
,	O
the	O
solution	O
was	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1.5:1	O
EtOAc	B
–	O
petroleum	B
ether+1	I
%	O
Et3	B
N	I
)	O
to	O
yield	O
21	B
(	O
0.932	O
g	O
,	O
85	O
%	O
)	O
as	O
a	O
fluorescent	O
foam	O
in	O
the	O
ratio	O
of	O
α	O
:	O
β	O
1:5	O
.	O

TLC	O
(	O
1.5:1	O
EtOAc	B
–	O
petroleum	B
ether+1	I
%	O
Et3	B
N	I
)	O
:	O
R	O
f	O
0.28	O
;	O
1	O
H	O
NMR	O
(	O
250	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
8.66	O
(	O
s	O
,	O
0.15	O
H	O
,	O
NHα	O
)	O
,	O
8.62	O
(	O
s	O
,	O
0.85	O
H	O
,	O
NHβ	O
)	O
,	O
6.19	O
(	O
d	O
,	O
0.15	O
H	O
,	O
J	O
1,2	O
3.2	O
Hz	O
,	O
H-1aa	O
)	O
,	O
6.15	O
(	O
d	O
,	O
0.85	O
H	O
,	O
J	O
1,2	O
8.9	O
Hz	O
,	O
H-1aβ	O
)	O
,	O
5.31–3.76	O
(	O
m	O
,	O
13	O
H	O
)	O
,	O
2.13	O
,	O
2.11	O
,	O
2.08	O
,	O
2.07	O
,	O
1.98	O
,	O
1.94	O
,	O
1.81	O
(	O
7	O
s	O
,	O
24	O
H	O
,	O
2	O
CH3	O
,	O
6	O
CH3	O
CO	O
)	O
.	O

FABMS	O
(	O
positive	O
mode	O
,	O
NBOH	O
/	O
NaI	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
869	O
[	O
MNa+	O
]	O
,	O
1019	O
[	O
MNaI	O
]	O
Na+	O
.	O

Anal	O
.	O

Calcd	O
for	O
C32	O
H39	O
N2	O
Cl3	O
O18	O
(	O
846.02	O
)	O
:	O
C	O
,	O
45.42	O
;	O
H	O
,	O
4.64	O
;	O
N	O
,	O
3.31	O
.	O

Found	O
:	O
C	O
,	O
44.86	O
;	O
H	O
,	O
4.49	O
;	O
N	O
,	O
3.43	O
.	O

3.15	O
Benzyl	B
(	I
2,3,4,6-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
4,6-di	I
-	I
O	I
-	I
acetyl-2-deoxy-2-dimethylmaleimido	I
-	I
β	I
-	I
d	I
-glucopyranosyl	I
)	I
-	I
(	I
1→3	I
)	I
-	I
(	I
2,4,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-2,3,6-tri	I
-	I
O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
22	B
)	O
A	O
mixture	O
of	O
21	B
(	O
0.16	O
g	O
,	O
0.177	O
mmol	O
)	O
and	O
8	B
(	O
0.15	O
g	O
,	O
0.154	O
mmol	O
)	O
in	O
dry	O
MeCN	B
(	O
1	O
mL	O
)	O
was	O
stirred	O
under	O
nitrogen	B
at	O
rt	O
for	O
10	O
min	O
while	O
Me3	B
SiOTf	I
(	O
0.01	O
M	O
in	O
MeCN	B
,	O
0.2	O
mL	O
)	O
was	O
added	O
dropwise	O
and	O
the	O
mixture	O
was	O
stirred	O
overnight	O
,	O
then	O
neutralized	O
with	O
Et3	B
N	I
and	O
evaporated	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
purified	O
by	O
flash	O
chromatography	O
(	O
1.5:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
to	O
yield	O
22	B
(	O
0.192	O
g	O
,	O
75	O
%	O
)	O
as	O
a	O
white	O
foam	O
.	O

TLC	O
(	O
1.5:1	O
petroleum	B
ether	I
–	O
EtOAc	B
)	O
:	O
R	O
f	O
0.13	O
;	O
[	O
α	O
]	O
D	O
−12.3	O
°	O
(	O
c	O
0.33	O
,	O
CHCl3	B
)	O
;	O
1	O
H	O
NMR	O
(	O
600	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.30–7.10	O
(	O
m	O
,	O
35	O
H	O
,	O
7	O
Ph	O
)	O
,	O
5.27	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
3,4	O
3.5	O
Hz	O
,	O
H-4d	O
)	O
,	O
5.16	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
1,2	O
8.4	O
Hz	O
,	O
H-1c	O
)	O
,	O
4.97	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
3,4	O
=	O
J	O
4,5	O
9.5	O
Hz	O
,	O
H-4c	O
)	O
,	O
4.94–4.91	O
(	O
m	O
,	O
3	O
H	O
,	O
H-2d	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.86	O
,	O
4.27	O
(	O
2	O
d	O
,	O
2	O
H	O
,	O
J	O
gem	O
12.1	O
Hz	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.78	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
2,3	O
10.4	O
,	O
J	O
3,4	O
3.5	O
Hz	O
,	O
H-3d	O
)	O
,	O
4.85	O
,	O
4.70	O
(	O
2	O
d	O
,	O
2	O
H	O
,	O
J	O
gem	O
10.8	O
Hz	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.62–4.51	O
(	O
m	O
,	O
5	O
H	O
,	O
H-3c	O
,	O
2	O
CH	O
2	O
Ph	O
)	O
,	O
4.47	O
(	O
d	O
,	O
1	O
H	O
,	O
J	O
gem	O
11.5	O
Hz	O
,	O
1	O
H	O
,	O
CH	O
HPh	O
)	O
,	O
4.36–4.31	O
(	O
m	O
,	O
4	O
H	O
,	O
H-1b	O
,	O
H-1a	O
,	O
CH	O
2	O
Ph	O
)	O
,	O
4.21–4.18	O
(	O
m	O
,	O
3	O
H	O
,	O
H-6c	O
,	O
H-6′c	O
,	O
CH	O
HPh	O
)	O
,	O
4.11–4.08	O
(	O
m	O
,	O
4	O
H	O
,	O
H-1d	O
,	O
H-2c	O
,	O
H-6d	O
,	O
H-6′d	O
)	O
,	O
3.96	O
(	O
dd	O
,	O
1	O
H	O
,	O
J	O
3,4	O
2.6	O
Hz	O
,	O
H-4b	O
)	O
,	O
3.91	O
(	O
m	O
,	O
1	O
H	O
,	O
H-4a	O
)	O
,	O
3.75	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5c	O
)	O
,	O
3.71	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5d	O
)	O
,	O
3.60–3.50	O
(	O
m	O
,	O
4	O
H	O
,	O
H-6′b	O
,	O
H-3b	O
,	O
H-2b	O
,	O
H-6′a	O
)	O
,	O
3.41–3.36	O
(	O
m	O
,	O
5	O
H	O
,	O
H-6b	O
,	O
H-5b	O
,	O
H-6a	O
,	O
H-2a	O
,	O
H-3a	O
)	O
,	O
2.99	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5a	O
)	O
,	O
2.10–1.90	O
(	O
6	O
s	O
,	O
18	O
H	O
,	O
6	O
CH3	O
CO	O
)	O
,	O
1.70	O
(	O
br.s	O
,	O
3	O
H	O
,	O
CH3	O
)	O
,	O
1.50	O
(	O
br.s	O
,	O
3	O
H	O
,	O
CH3	O
)	O
.	O

13	O
C	O
NMR	O
(	O
150.9	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
102.80	O
(	O
C-1a	O
,	O
C-1b	O
)	O
,	O
100.50	O
(	O
C-1d	O
)	O
,	O
99.90	O
(	O
C-1c	O
)	O
,	O
83.30	O
(	O
C-3a	O
)	O
,	O
82.60	O
(	O
C-3b	O
)	O
,	O
82.00	O
(	O
C-2a	O
)	O
,	O
79.00	O
(	O
C-2b	O
)	O
,	O
76.70	O
(	O
C-4b	O
)	O
,	O
76.30	O
(	O
C-4a	O
)	O
,	O
75.70	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
74.50	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
75.20	O
(	O
C-5a	O
,	O
C	O
H2	O
Ph	O
)	O
,	O
74.60	O
(	O
C-3c	O
)	O
,	O
74.30	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.70	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.60	O
(	O
C	O
H2	O
Ph	O
)	O
,	O
73.40	O
(	O
C-5b	O
)	O
,	O
71.90	O
(	O
C-5c	O
)	O
,	O
71.10	O
(	O
C-3d	O
,	O
C	O
H2	O
Ph	O
)	O
,	O
70.80	O
(	O
C-5d	O
)	O
,	O
69.70	O
(	O
C-4c	O
)	O
,	O
69.30	O
(	O
C-2d	O
)	O
,	O
68.50	O
(	O
C-6b	O
)	O
,	O
68.10	O
(	O
C-6a	O
)	O
,	O
67.00	O
(	O
C-4d	O
)	O
,	O
62.80	O
(	O
C-6c	O
)	O
,	O
60.90	O
(	O
C-6d	O
)	O
,	O
56.20	O
(	O
C-2c	O
)	O
.	O

MALDIMS	O
(	O
positive	O
mode	O
,	O
DHB	B
/	O
THT	B
-	O
matrix	O
)	O
:	O
m	O
/z	O
1679	O
[	O
MNa+	O
]	O
.	O

Anal	O
.	O

Calcd	O
for	O
C91	O
H101	O
NO28	O
(	O
1656.72	O
)	O
:	O
C	O
,	O
65.96	O
;	O
H	O
,	O
6.14	O
;	O
N	O
,	O
0.84	O
.	O

Found	O
:	O
C	O
,	O
65.55	O
;	O
H	O
,	O
5.96	O
;	O
N	O
,	O
0.78	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
the	O
European	O
Community	O
(	O
grant	O
No.	O
ERB	O
4061	O
PL	O
95	O
-	O
0372	O
)	O
,	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
and	O
the	O
Fonds	O
der	O
Chemischen	O
Industrie	O
.	O

M.R.E.A.	O
is	O
grateful	O
for	O
a	O
stipend	O
within	O
the	O
channel	O
program	O
of	O
the	O
Egyptian	O
Government	O
.	O

The	O
help	O
of	O
Dr	O
Armin	O
Geyer	O
in	O
structural	O
assignments	O
is	O
gratefully	O
acknowledged	O
.	O

Cholinesterases	O
have	O
been	O
extensively	O
studied	O
for	O
several	O
years	O
.	O

They	O
have	O
two	O
known	O
actions	O
:	O
acetylcholinesterase	O
(	O
AChE	O
,	O
EC	O
3.1.1.7	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
nervous	O
system	O
where	O
it	O
terminates	O
the	O
neurotransmitter	O
action	O
of	O
acetylcholine	B
,	O
and	O
,	O
when	O
present	O
in	O
non	O
-	O
cholinergic	O
contexts	O
,	O
as	O
is	O
for	O
example	O
vertebrate	O
butyrylcholinesterase	O
,	O
(	O
EC	O
3.1.1.8	O
)	O
they	O
are	O
believed	O
to	O
metabolise	O
xenobiotics	B
.	O

These	O
enzymes	O
have	O
two	O
distinct	O
substrate	O
binding	O
sites	O
:	O
the	O
catalytic	O
site	O
which	O
lies	O
at	O
the	O
bottom	O
of	O
a	O
20	O
Å	O
-	O
deep	O
gorge	O
and	O
a	O
peripheral	O
site	O
composed	O
of	O
numerous	O
aromatic	B
residues	I
lining	O
the	O
active	O
site	O
gorge	O
[	O
1,2	O
]	O
.	O

The	O
catalytic	O
site	O
can	O
be	O
divided	O
into	O
two	O
subsites	O
,	O
the	O
esteratic	O
site	O
represented	O
by	O
Ser200	B
which	O
is	O
activated	O
by	O
a	O
catalytic	O
triad	O
and	O
the	O
catalytic	O
anionic	O
site	O
represented	O
by	O
Trp84	B
which	O
participates	O
in	O
the	O
recognising	O
the	O
positively	O
charged	O
choline	B
part	O
of	O
the	O
substrate	O
.	O

Very	O
efficient	O
metabolization	O
of	O
acyl	B
esters	I
by	O
cholinesterases	O
takes	O
place	O
at	O
the	O
bottom	O
of	O
the	O
gorge	O
.	O

The	O
hydrolysis	O
of	O
acetylcholine	B
which	O
is	O
nearly	O
as	O
fast	O
as	O
allowed	O
by	O
diffusion	O
[	O
3,4	O
]	O
proceeds	O
in	O
three	O
steps	O
:	O
the	O
reversible	O
formation	O
of	O
a	O
Michaelian	O
complex	O
,	O
followed	O
by	O
the	O
acylation	O
and	O
subsequently	O
by	O
the	O
deacetylation	O
of	O
Ser200	B
[	O
5	O
]	O
.	O

As	O
substrate	O
also	O
binds	O
to	O
the	O
peripheral	O
site	O
,	O
different	O
forms	O
of	O
the	O
enzyme	O
will	O
exist	O
depending	O
on	O
which	O
sites	O
are	O
occupied	O
.	O

In	O
the	O
insect	O
enzyme	O
,	O
hydrolysis	O
of	O
the	O
substrate	O
deviates	O
from	O
Michaelian	O
behaviour	O
,	O
with	O
activation	O
at	O
low	O
substrate	O
concentration	O
and	O
inhibition	O
at	O
high	O
concentration	O
[	O
6	O
]	O
.	O

To	O
describe	O
this	O
activity	O
,	O
we	O
recently	O
tested	O
various	O
kinetic	O
models	O
by	O
fitting	O
and	O
finally	O
proposed	O
a	O
putative	O
scheme	O
able	O
to	O
explain	O
all	O
our	O
data	O
sets	O
(	O
Scheme	O
1	O
simplified	O
in	O
Scheme	O
2	O
)	O
.	O

It	O
supports	O
a	O
secondary	O
substrate	O
binding	O
site	O
on	O
the	O
protein	O
distinct	O
from	O
the	O
catalytic	O
site	O
.	O

Binding	O
to	O
the	O
catalytic	O
site	O
located	O
at	O
the	O
bottom	O
of	O
the	O
gorge	O
seems	O
to	O
be	O
irreversible	O
,	O
suggesting	O
that	O
each	O
molecule	O
of	O
substrate	O
which	O
enters	O
the	O
active	O
site	O
gorge	O
is	O
metabolised	O
.	O

Reversible	O
binding	O
at	O
the	O
peripheral	O
site	O
is	O
high	O
affinity	O
in	O
the	O
free	O
enzyme	O
(	O
4	O
μM	O
)	O
,	O
suggesting	O
that	O
this	O
increases	O
the	O
probability	O
of	O
the	O
substrate	O
entering	O
the	O
active	O
site	O
gorge	O
.	O

Active	O
site	O
occupation	O
then	O
leads	O
to	O
a	O
decrease	O
in	O
peripheral	O
site	O
affinity	O
(	O
30	O
mM	O
)	O
.	O

Peripheral	O
site	O
occupation	O
decreases	O
the	O
rate	O
constant	O
for	O
a	O
entrance	O
of	O
the	O
second	O
substrate	O
molecule	O
into	O
the	O
catalytic	O
site	O
and	O
strongly	O
affects	O
the	O
catalytic	O
activity	O
of	O
the	O
enzyme	O
.	O

This	O
results	O
in	O
both	O
an	O
apparent	O
activation	O
at	O
low	O
substrate	O
concentration	O
and	O
a	O
general	O
inhibition	O
at	O
high	O
substrate	O
concentration	O
.	O

Certain	O
reversible	O
inhibitors	O
bind	O
to	O
all	O
enzymatic	O
forms	O
while	O
others	O
bind	O
only	O
to	O
some	O
of	O
them	O
,	O
such	O
as	O
the	O
free	O
or	O
the	O
acylated	O
enzyme	O
.	O

When	O
binding	O
occurs	O
at	O
the	O
catalytic	O
site	O
,	O
the	O
acetyl	O
–	O
enzyme	O
–	O
inhibitor	O
complex	O
usually	O
deacetylates	O
at	O
a	O
slower	O
rate	O
than	O
the	O
free	O
acetyl	O
-	O
enzyme	O
[	O
7,8	O
]	O
while	O
ligand	O
binding	O
at	O
the	O
peripheral	O
site	O
modulates	O
activity	O
[	O
9,10	O
]	O
by	O
destabilising	O
of	O
substrate	O
binding	O
at	O
the	O
catalytic	O
site	O
[	O
11	O
]	O
through	O
conformational	O
changes	O
[	O
12	O
]	O
.	O

Each	O
inhibitor	O
may	O
occupy	O
a	O
distinct	O
position	O
and	O
be	O
oriented	O
somewhat	O
differently	O
at	O
the	O
two	O
anionic	O
sites	O
as	O
evidenced	O
by	O
kinetics	O
[	O
13	O
]	O
,	O
in	O
vitro	O
mutagenesis	O
[	O
14	O
]	O
and	O
structural	O
data	O
[	O
15	O
]	O
.	O

Here	O
,	O
we	O
test	O
the	O
proposed	O
kinetic	O
model	O
for	O
insect	O
AChE	O
using	O
three	O
reversible	O
inhibitors	O
:	O
tetramethylammonium	B
(	O
TMA	B
)	O
,	O
edrophonium	B
and	O
choline	B
.	O

The	O
model	O
suggests	O
that	O
TMA	B
binds	O
to	O
two	O
sites	O
on	O
the	O
protein	O
including	O
the	O
catalytic	O
site	O
,	O
while	O
edrophonium	B
and	O
choline	B
bind	O
only	O
to	O
one	O
site	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
AChE	O
synthesis	O
and	O
purification	O
Drosophila	O
AChE	O
was	O
produced	O
in	O
baculovirus	O
infected	O
cells	O
,	O
purified	O
and	O
stabilized	O
according	O
to	O
Estrada	O
and	O
Fournier	O
[	O
16	O
]	O
.	O

Briefly	O
,	O
a	O
hydrophilic	O
protein	O
was	O
produced	O
by	O
cloning	O
a	O
cDNA	O
truncated	O
at	O
the	O
3′	O
end	O
encoding	O
an	O
hydrophobic	O
peptide	B
exchanged	O
to	O
a	O
glycolipid	B
anchor	O
.	O

The	O
AChE	O
was	O
secreted	O
in	O
the	O
culture	O
medium	O
and	O
purified	O
by	O
affinity	O
chromatography	O
followed	O
by	O
diafiltration	O
and	O
anion	O
exchange	O
chromatography	O
to	O
eliminate	O
copurified	O
proteases	O
.	O

As	O
drosophila	O
AChE	O
was	O
not	O
stable	O
when	O
diluted	O
,	O
bovine	O
serum	O
albumine	O
was	O
added	O
to	O
the	O
sample	O
to	O
1	O
mg	O
/	O
ml	O
.	O

2.2	O
Kinetics	O
of	O
substrate	O
hydrolysis	O
Kinetic	O
analysis	O
was	O
performed	O
at	O
25	O
°	O
C	O
in	O
25	O
mM	O
phosphate	B
buffer	I
pH	O
7.25	O
.	O

Hydrolysis	O
of	O
acetylthiocholine	B
iodide	I
was	O
followed	O
at	O
412	O
nm	O
using	O
the	O
method	O
of	O
Ellman	O
et	O
al.	O
[	O
17	O
]	O
,	O
with	O
substrate	O
concentrations	O
of	O
1	O
μM	O
to	O
200	O
mM.	O
Reversible	O
inhibitions	O
were	O
tested	O
from	O
0.25	O
to	O
80	O
mM	O
for	O
TMA	B
,	O
from	O
1	O
to	O
100	O
μM	O
for	O
edrophonium	B
and	O
from	O
0.01	O
to	O
10	O
mM	O
for	O
choline	B
.	O

2.3	O
Data	O
analysis	O
Initial	O
rate	O
constants	O
obtained	O
in	O
the	O
presence	O
of	O
inhibitor	O
at	O
various	O
concentrations	O
were	O
analysed	O
according	O
to	O
the	O
mechanistic	O
models	O
previously	O
described	O
[	O
18	O
]	O
considering	O
that	O
the	O
inhibitor	O
molecule	O
can	O
bind	O
to	O
a	O
peripheral	O
site	O
and/or	O
to	O
the	O
catalytic	O
site	O
.	O

The	O
corresponding	O
rate	O
equations	O
were	O
derived	O
and	O
fitted	O
simultaneously	O
to	O
the	O
complete	O
set	O
of	O
data	O
for	O
each	O
inhibitor	O
.	O

Among	O
the	O
models	O
tested	O
corresponding	O
to	O
the	O
different	O
binding	O
possibilities	O
,	O
we	O
chose	O
the	O
simplest	O
one	O
which	O
fitted	O
all	O
data	O
.	O

Indeed	O
,	O
it	O
was	O
found	O
,	O
in	O
each	O
inhibition	O
mechanism	O
,	O
that	O
not	O
all	O
the	O
reaction	O
steps	O
were	O
necessary	O
,	O
so	O
in	O
the	O
analysis	O
of	O
kinetic	O
data	O
,	O
were	O
left	O
out	O
.	O

For	O
each	O
inhibitor	O
all	O
the	O
kinetic	O
constants	O
valid	O
in	O
the	O
presence	O
of	O
the	O
substrate	O
were	O
determined	O
.	O

Their	O
evaluations	O
were	O
carried	O
out	O
by	O
means	O
of	O
a	O
non	O
-	O
linear	O
regression	O
program	O
[	O
19	O
]	O
and	O
according	O
to	O
general	O
criteria	O
for	O
the	O
goodness	O
of	O
fit	O
[	O
20	O
]	O
.	O

3	O
Results	O
and	O
discussion	O
Scheme	O
1	O
presents	O
a	O
putative	O
model	O
allowing	O
the	O
analysis	O
the	O
kinetic	O
data	O
of	O
insect	O
AChE.	O
However	O
,	O
some	O
of	O
the	O
eight	O
kinetic	O
parameters	O
proved	O
to	O
be	O
unstable	O
and	O
thus	O
were	O
not	O
evaluated	O
correctly	O
.	O

Therefore	O
,	O
the	O
three	O
-	O
step	O
model	O
was	O
reduced	O
to	O
a	O
two-	O
step	O
model	O
[	O
21	O
]	O
.	O

Several	O
simplifications	O
are	O
possible	O
.	O

One	O
possibility	O
is	O
to	O
combine	O
acylation	O
and	O
deacylation	O
into	O
a	O
single	O
rate	O
constant	O
[	O
22	O
]	O
.	O

Although	O
this	O
simplified	O
model	O
is	O
useful	O
and	O
currently	O
used	O
[	O
23	O
]	O
,	O
it	O
can	O
only	O
explain	O
biphasic	O
kinetics	O
with	O
either	O
activation	O
or	O
inhibition	O
and	O
so	O
can	O
not	O
be	O
used	O
to	O
explain	O
our	O
experimental	O
data	O
unless	O
it	O
is	O
extended	O
to	O
three	O
binding	O
sites	O
for	O
the	O
substrate	O
.	O

Two	O
other	O
simplifications	O
resulting	O
in	O
the	O
same	O
equation	O
were	O
operative	O
for	O
all	O
our	O
experimental	O
data	O
,	O
obtained	O
with	O
different	O
mutated	O
enzymes	O
and	O
in	O
different	O
experimental	O
conditions	O
.	O

In	O
the	O
first	O
simplification	O
,	O
we	O
assume	O
that	O
each	O
molecule	O
which	O
enters	O
the	O
active	O
site	O
gorge	O
is	O
metabolised	O
and	O
thus	O
that	O
ES	O
complex	O
formation	O
is	O
an	O
irreversible	O
step	O
[	O
24,25	O
]	O
(	O
Scheme	O
2	O
)	O
.	O

In	O
the	O
second	O
simplification	O
,	O
reversible	O
Michaelian	O
complex	O
formation	O
and	O
acylation	O
are	O
included	O
in	O
the	O
same	O
step	O
,	O
the	O
scheme	O
remains	O
identical	O
to	O
Scheme	O
2	O
with	O
EA	O
instead	O
of	O
ES	O
.	O

In	O
the	O
presence	O
of	O
a	O
reversible	O
inhibitor	O
,	O
hydrolysis	O
can	O
be	O
described	O
by	O
Scheme	O
3	O
assuming	O
that	O
two	O
binding	O
sites	O
exist	O
for	O
the	O
substrate	O
and	O
the	O
inhibitor	O
on	O
the	O
protein	O
(	O
the	O
catalytic	O
site	O
and	O
a	O
peripheral	O
site	O
)	O
.	O

From	O
this	O
scheme	O
,	O
the	O
kinetic	O
steady	O
-	O
state	O
rate	O
equation	O
was	O
derived:	O
(	O
1	O
)	O
v	O
E	O
t	O
=	O
k3	O
S	O
1+a	O
S	O
K4	O
+	O
c	O
I	O
K7	O
k3	O
ki	O
1+a	O
S	O
K4	O
+	O
c	O
I	O
K7	O
1	O
+	O
S	O
K3	O
+	O
I	O
K6	O
+	O
I	O
K1	O
+	O
S	O
I	O
K2	O
K3	O
+	O

I	O
2	O
K5	O
K6	O
1+b	O
S	O
K3	O
+	O
d	O
I	O
K6	O
+	O
S	O
1	O
+	O
S	O
K4	O
+	O
I	O
K7	O

The	O
values	O
of	O
all	O
relevant	O
kinetic	O
constants	O
are	O
presented	O
in	O
Scheme	O
4	O
and	O
in	O
graphical	O
form	O
along	O
with	O
the	O
corresponding	O
experimental	O
data	O
in	O
Fig.	O
1	O
.	O

The	O
analysis	O
of	O
experimental	O
data	O
obtained	O
in	O
the	O
presence	O
of	O
TMA	B
,	O
edrophonium	B
or	O
choline	B
was	O
performed	O
by	O
fitting	O
to	O
all	O
data	O
simultaneously	O
for	O
each	O
inhibitor	O
.	O

In	O
each	O
case	O
,	O
Eq.	O
(	O
1	O
)	O
fits	O
the	O
experimental	O
results	O
well	O
.	O

Meanwhile	O
,	O
for	O
choline	B
and	O
edrophonium	B
,	O
experimental	O
data	O
can	O
be	O
resolved	O
by	O
a	O
simplified	O
scheme	O
using	O
only	O
10	O
parameters	O
.	O

In	O
each	O
case	O
all	O
parameters	O
were	O
estimated	O
without	O
constraint	O
.	O

It	O
turned	O
out	O
that	O
the	O
values	O
of	O
the	O
six	O
parameters	O
corresponding	O
to	O
the	O
reaction	O
without	O
inhibitor	O
did	O
not	O
significantly	O
change	O
if	O
the	O
analysis	O
included	O
the	O
data	O
from	O
acetylcholinesterase	O
inhibition	O
.	O

For	O
edrophonium	B
and	O
choline	B
,	O
the	O
complex	O
IEI	O
is	O
not	O
necessary	O
to	O
describe	O
data	O
,	O
suggesting	O
that	O
there	O
is	O
only	O
one	O
binding	O
site	O
on	O
the	O
enzyme	O
.	O

The	O
binding	O
is	O
non-	O
competitive	O
for	O
the	O
peripheral	O
site	O
.	O

In	O
addition	O
,	O
the	O
complex	O
EIS	O
,	O
resulting	O
from	O
the	O
binding	O
of	O
an	O
inhibitor	O
molecule	O
to	O
ES	O
,	O
is	O
necessary	O
to	O
correctly	O
fit	O
the	O
kinetic	O
data	O
.	O

This	O
suggests	O
that	O
the	O
inhibitor	O
molecule	O
binds	O
at	O
the	O
catalytic	O
site	O
even	O
if	O
it	O
is	O
occupied	O
.	O

In	O
that	O
case	O
,	O
the	O
second	O
simplification	O
is	O
operative	O
and	O
ES	O
is	O
replaced	O
by	O
EA	O
in	O
Schemes	O
2–4	O
.	O

Kinetic	O
and	O
structural	O
data	O
obtained	O
for	O
vertebrate	O
AChE	O
are	O
in	O
accordance	O
with	O
this	O
binding	O
at	O
the	O
catalytic	O
site	O
[	O
15,26	O
]	O
.	O

In	O
a	O
second	O
hypothesis	O
,	O
the	O
inhibitor	O
can	O
bind	O
to	O
the	O
enzymatic	O
form	O
ES	O
,	O
suggesting	O
that	O
it	O
binds	O
on	O
a	O
peripheral	O
site	O
different	O
from	O
that	O
of	O
the	O
substrate	O
.	O

Following	O
the	O
two	O
hypothesis	O
,	O
the	O
inhibitor	O
binding	O
to	O
the	O
protein	O
prevents	O
the	O
substrate	O
becoming	O
positionned	O
at	O
the	O
catalytic	O
site	O
and	O
decreases	O
the	O
acylation	O
and/or	O
the	O
deacylation	O
step	O
(	O
c	O
=	O
0.14	O
and	O
0.23	O
for	O
choline	B
and	O
edrophonium	B
respectively	O
)	O
.	O

For	O
TMA	B
,	O
the	O
total	O
Scheme	O
3	O
must	O
be	O
used	O
since	O
all	O
simplifications	O
tested	O
resulted	O
in	O
a	O
decrease	O
of	O
the	O
correlation	O
coefficient	O
.	O

As	O
the	O
IEI	O
species	O
was	O
useful	O
to	O
describe	O
data	O
,	O
it	O
seems	O
that	O
the	O
TMA	B
competes	O
with	O
the	O
substrate	O
at	O
the	O
peripheral	O
and	O
the	O
catalytic	O
sites	O
.	O

Such	O
a	O
result	O
is	O
not	O
in	O
agreement	O
with	O
previous	O
reports	O
suggesting	O
that	O
TMA	B
binds	O
to	O
a	O
single	O
site	O
on	O
the	O
vertebrate	O
enzyme	O
[	O
27,28	O
]	O
but	O
could	O
be	O
related	O
to	O
the	O
enzyme	O
origin	O
which	O
shows	O
more	O
complex	O
kinetics	O
with	O
substrate	O
activation	O
and	O
inhibition	O
.	O

In	O
contrast	O
to	O
the	O
substrate	O
,	O
TMA	B
binding	O
at	O
the	O
peripheral	O
site	O
does	O
not	O
hinder	O
the	O
entrance	O
of	O
the	O
substrate	O
molecule	O
into	O
the	O
gorge	O
(	O
d	O
=	O
1	O
)	O
since	O
it	O
is	O
a	O
smaller	O
molecule	O
than	O
the	O
substrate	O
.	O

Analysis	O
of	O
constants	O
obtained	O
without	O
inhibitors	O
(	O
Scheme	O
2	O
)	O
suggests	O
that	O
binding	O
of	O
the	O
substrate	O
at	O
the	O
peripheral	O
site	O
decreases	O
the	O
rate	O
constant	O
of	O
substrate	O
entrance	O
into	O
the	O
active	O
site	O
gorge	O
(	O
123	O
/	O
21	O
μM−1	O
s−1	O
)	O
,	O
and	O
decreases	O
substrate	O
hydrolysis	O
(	O
995	O
/	O
6.7	O
s−1	O
)	O
.	O

For	O
inhibitors	O
,	O
the	O
same	O
relation	O
was	O
observed	O
:	O
peripheral	O
site	O
occupation	O
by	O
a	O
substrate	O
molecule	O
decreases	O
the	O
affinity	O
of	O
the	O
inhibitor	O
at	O
the	O
catalytic	O
site	O
(	O
K	O
2	O
is	O
always	O
greater	O
than	O
K	O
1	O
)	O
.	O

The	O
effect	O
,	O
however	O
,	O
depends	O
on	O
the	O
inhibitor	O
:	O
it	O
is	O
strong	O
with	O
choline	B
but	O
weaker	O
with	O
edrophonium	B
and	O
TMA	B
.	O

This	O
interplay	O
between	O
the	O
two	O
sites	O
is	O
in	O
accordance	O
with	O
other	O
studies	O
which	O
also	O
showed	O
that	O
peripheral	O
site	O
occupation	O
by	O
a	O
substrate	O
molecule	O
modulates	O
the	O
activity	O
of	O
the	O
enzyme	O
by	O
destabilization	O
of	O
substrate	O
at	O
the	O
catalytic	O
site	O
[	O
9–11,2,12,29	O
]	O
.	O

Destabilization	O
seems	O
to	O
originate	O
from	O
conformational	O
changes	O
-	O
a	O
movement	O
of	O
the	O
Ω	O
loop	O
-	O
hich	O
modifies	O
the	O
orientation	O
of	O
a	O
main	O
element	O
of	O
the	O
catalytic	O
site	O
,	O
Trp84	B
[	O
30,31	O
]	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
shows	O
that	O
the	O
simple	O
model	O
which	O
was	O
proposed	O
for	O
the	O
reaction	O
between	O
Drosophila	O
AChE	O
and	O
its	O
substrate	O
is	O
also	O
able	O
to	O
describe	O
kinetics	O
with	O
the	O
simultaneous	O
action	O
of	O
the	O
substrate	O
and	O
a	O
reversible	O
inhibitor	O
.	O

Acknowledgements	O

We	O
thank	O
Frédéric	O
Magné	O
for	O
technical	O
assistance	O
.	O

This	O
research	O
was	O
supported	O
by	O
grants	O
from	O
DGA	O
,	O
and	O
CNRS	O
(	O
GDR	O
1105	O
and	O
ACS.SV3	O
)	O
.	O

At	O
least	O
some	O
of	O
the	O
behavioral	O
stimulant	O
effects	O
of	O
caffeine	B
in	O
laboratory	O
animals	O
appear	O
to	O
be	O
due	O
to	O
competitive	O
blockade	O
of	O
adenosine	O
A1	O
and/or	O
A2A	O
receptors	O
.	O

These	O
include	O
increasing	O
the	O
locomotor	O
activity	O
of	O
rodents	O
(	O
Snyder	O
et	O
al.	O
,	O
1981	O
)	O
and	O
the	O
rate	O
of	O
lever	O
pressing	O
of	O
monkeys	O
(	O
Spealman	O
,	O
1988	O
)	O
.	O

In	O
addition	O
to	O
blocking	O
adenosine	O
receptors	O
,	O
caffeine	B
has	O
actions	O
on	O
intracellular	O
systems	O
;	O
for	O
example	O
,	O
it	O
inhibits	O
the	O
activity	O
of	O
cyclic	O
nucleotide	O
phosphodiesterases	O
.	O

These	O
actions	O
appear	O
to	O
contribute	O
to	O
the	O
behavioral	O
depressant	O
effects	O
of	O
high	O
doses	O
of	O
caffeine	B
and	O
might	O
limit	O
the	O
behavioral	O
stimulant	O
effects	O
of	O
lower	O
doses	O
(	O
Daly	O
,	O
1993	O
)	O
.	O

9-Chloro-2-	B
(	I
2-furyl	I
)	I
[	I
1,2,4	I
]	I
triazolol	I
[	I
1,5-c	I
]	I
quinazolin-5-amine	I
(	O
CGS	B
15943	I
)	O
,	O
a	O
triazoloquinazoline	B
derivative	O
,	O
is	O
a	O
potent	O
antagonist	O
at	O
adenosine	O
receptors	O
,	O
with	O
some	O
selectivity	O
(	O
i.e.	O
,	O
5-	O
to	O
10-fold	O
)	O
for	O
the	O
adenosine	O
A2A	O
receptor	O
over	O
the	O
adenosine	O
A1	O
receptor	O
(	O
Williams	O
et	O
al.	O
,	O
1987	O
;	O
Jarvis	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Like	O
caffeine	O
,	O
CGS	B
15943	I
is	O
a	O
behavioral	O
stimulant	O
in	O
animals	O
.	O

It	O
dose	O
-	O
dependently	O
increases	O
the	O
locomotor	O
activity	O
of	O
rats	O
(	O
Holtzman	O
,	O
1991	O
)	O
and	O
the	O
rate	O
at	O
which	O
squirrel	O
monkeys	O
press	O
a	O
lever	O
to	O
avoid	O
an	O
aversive	O
stimulus	O
(	O
Howell	O
and	O
Byrd	O
,	O
1993	O
)	O
,	O
and	O
is	O
10–30	O
times	O
more	O
potent	O
than	O
caffeine	B
in	O
doing	O
so	O
.	O

Unlike	O
caffeine	B
,	O
CGS	B
15943	I
does	O
not	O
inhibit	O
the	O
activity	O
of	O
cyclic	O
nucleotide	O
phosphodiesterases	O
(	O
Williams	O
et	O
al.	O
,	O
1987	O
)	O
,	O
increasing	O
the	O
likelihood	O
that	O
effects	O
that	O
the	O
two	O
drugs	B
have	O
in	O
common	O
are	O
mediated	O
by	O
the	O
blockade	O
of	O
adenosine	O
receptors	O
.	O

Adenosine	O
A2A	O
receptors	O
in	O
the	O
brain	O
are	O
localized	O
to	O
postsynaptic	O
neurons	O
of	O
the	O
basal	O
ganglia	O
,	O
often	O
co	O
-	O
expressed	O
with	O
dopamine	O
D2	O
receptors	O
(	O
Martiniz	O
-	O
Mir	O
et	O
al.	O
,	O
1991	O
;	O
Ferré	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Data	O
from	O
neurochemical	O
as	O
well	O
as	O
from	O
behavioral	O
studies	O
suggest	O
that	O
activation	O
of	O
these	O
receptors	O
reduces	O
neurotransmission	O
mediated	O
by	O
dopamine	O
D2	O
-like	O
receptors	O
(	O
Ferré	O
et	O
al.	O
1991a	O
,	O
b	O
)	O
.	O

Similar	O
types	O
of	O
experimental	O
evidence	O
indicates	O
that	O
activation	O
of	O
adenosine	O
A1	O
receptors	O
reduces	O
neurotransmission	O
mediated	O
by	O
dopamine	O
D1	O
-like	O
receptors	O
(	O
Ferré	O
et	O
al.	O
,	O
1996	O
)	O
.	O

These	O
observations	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
behavioral	O
stimulant	O
effects	O
of	O
caffeine	B
reflect	O
,	O
in	O
part	O
,	O
the	O
enhancement	O
of	O
dopamine	B
-	O
mediated	O
neurotransmission	O
that	O
occurs	O
when	O
the	O
negative	O
modulatory	O
influence	O
of	O
adenosine	B
is	O
blocked	O
(	O
Ferré	O
et	O
al.	O
,	O
1992	O
;	O
Ferré	O
,	O
1997	O
)	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
caffeine	B
-	O
induced	O
stimulation	O
of	O
the	O
locomotor	O
activity	O
of	O
rats	O
is	O
blocked	O
by	O
R	B
(	I
+	I
)	I
-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H	I
-3-benzazepine	I
(	O
SCH	B
23390	I
)	O
and	O
eticlopride	B
(	O
Garrett	O
and	O
Holtzman	O
,	O
1994	O
)	O
,	O
antagonists	O
selective	O
for	O
the	O
dopamine	O
D1	O
and	O
D2	O
families	O
of	O
receptors	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
rats	O
discriminating	O
a	O
low	O
dose	O
of	O
caffeine	B
(	O
i.e.	O
,	O
10	O
mg	O
/	O
kg	O
)	O
generalize	O
completely	O
to	O
nonxanthine	O
psychomotor	O
stimulants	O
,	O
such	O
as	O
cocaine	B
and	O
amphetamine	B
(	O
Mumford	O
and	O
Holtzman	O
,	O
1991	O
)	O
,	O
drugs	B
whose	O
discriminative	O
effects	O
have	O
a	O
prominent	O
and	O
well	O
-	O
documented	O
dopamine	B
component	O
(	O
Goudie	O
,	O
1991	O
;	O
Woolverton	O
,	O
1991	O
)	O
.	O

These	O
rats	O
also	O
generalize	O
completely	O
to	O
CGS	O
15943	O
.	O

Conversely	O
,	O
monkeys	O
discriminating	O
CGS	B
15943	I
generalize	O
completely	O
to	O
caffeine	B
(	O
Holtzman	O
,	O
1996	O
)	O
.	O

The	O
present	O
study	O
was	O
conducted	O
in	O
order	O
to	O
evaluate	O
the	O
role	O
of	O
dopamine	B
in	O
the	O
discriminative	O
stimulus	O
effects	O
of	O
CGS	B
15943	I
in	O
squirrel	O
monkeys	O
.	O

Monkeys	O
with	O
a	O
stable	O
history	O
of	O
CGS	B
15943	I
discrimination	O
were	O
tested	O
for	O
stimulus	O
generalization	O
to	O
dopamine	O
receptor	O
agonists	O
that	O
encompass	O
a	O
variety	O
of	O
mechanisms	O
and	O
sites	O
of	O
action	O
.	O

Some	O
of	O
those	O
drugs	B
,	O
notably	O
cocaine	B
and	O
amphetamine	B
,	O
interact	O
with	O
brain	O
monoamine	B
systems	O
in	O
addition	O
to	O
dopamine	B
.	O

Therefore	O
,	O
the	O
monkeys	O
also	O
were	O
tested	O
for	O
stimulus	O
generalization	O
to	O
selective	O
inhibitors	O
of	O
the	O
neuronal	O
uptake	O
of	O
norepinephrine	B
and	O
serotonin	B
.	O

The	O
ability	O
of	O
monoamine	O
-	O
receptor	O
antagonists	O
to	O
block	O
the	O
discriminative	O
effects	O
of	O
the	O
training	O
dose	O
of	O
CGS	B
15943	I
also	O
was	O
determined	O
.	O

Morphine	B
and	O
phencyclidine	B
,	O
discriminable	O
drugs	B
whose	O
primary	O
actions	O
are	O
on	O
nonmonoamine	B
neuronal	O
systems	O
,	O
served	O
as	O
controls	O
for	O
pharmacological	O
selectivity	O
.	O

2	O
Methods	O
2.1	O
Subjects	O
The	O
subjects	O
were	O
four	O
adult	O
male	O
squirrel	O
monkeys	O
(	O
Saimiri	O
sciureus	O
)	O
,	O
designated	O
S85	O
,	O
S88	O
,	O
S90	O
and	O
S92	O
.	O

They	O
had	O
been	O
trained	O
previously	O
to	O
discriminate	O
between	O
i.m	O
.	O

injections	O
of	O
CGS	B
15943	I
and	O
its	O
vehicle	O
and	O
had	O
undergone	O
generalization	O
testing	O
with	O
a	O
series	O
of	O
methylxanthine	B
derivatives	B
(	O
Holtzman	O
,	O
1996	O
)	O
.	O

Between	O
experimental	O
sessions	O
,	O
the	O
monkeys	O
were	O
housed	O
two	O
per	O
cage	O
in	O
a	O
vivarium	O
where	O
they	O
had	O
continuous	O
access	O
to	O
food	O
and	O
water	B
.	O

The	O
lights	O
in	O
the	O
vivarium	O
were	O
illuminated	O
from	O
0700	O
to	O
1900	O
h.	O

The	O
care	O
and	O
use	O
of	O
the	O
monkeys	O
conformed	O
to	O
the	O
National	O
Institutes	O
of	O
Health	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
,	O
and	O
experiments	O
were	O
performed	O
according	O
to	O
a	O
protocol	O
that	O
had	O
been	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Emory	O
University	O
.	O

2.2	O
Procedure	O
The	O
monkeys	O
were	O
trained	O
and	O
tested	O
in	O
a	O
discrete	O
-	O
trial	O
avoidance	O
/	O
escape	O
procedure	O
,	O
as	O
described	O
previously	O
(	O
Holtzman	O
,	O
1996	O
)	O
.	O

During	O
experiments	O
,	O
they	O
were	O
seated	O
in	O
a	O
testing	O
chamber	O
and	O
secured	O
by	O
a	O
Plexiglas	O
waist	O
plate	O
.	O

The	O
chamber	O
was	O
inside	O
of	O
ventilated	O
enclosure	O
that	O
was	O
sound	O
-	O
attenuating	O
.	O

The	O
monkey	O
sat	O
facing	O
two	O
levers	O
that	O
were	O
mounted	O
10	O
cm	O
apart	O
.	O

A	O
Plexiglas	O
barrier	O
separated	O
the	O
monkey	O
from	O
the	O
levers	O
.	O

The	O
barrier	O
had	O
2.5	O
×	O
4.0	O
cm	O
openings	O
on	O
each	O
end	O
;	O
a	O
monkey	O
could	O
press	O
a	O
lever	O
by	O
extending	O
its	O
arm	O
through	O
the	O
opening	O
on	O
the	O
same	O
side	O
as	O
that	O
lever	O
,	O
but	O
could	O
not	O
reach	O
both	O
levers	O
at	O
the	O
same	O
time	O
.	O

The	O
start	O
of	O
a	O
trial	O
was	O
signaled	O
by	O
illumination	O
of	O
the	O
house	O
light	O
in	O
the	O
testing	O
chamber	O
.	O

Beginning	O
5.0	O
s	O
later	O
,	O
an	O
electric	O
current	O
of	O
constant	O
intensity	O
(	O
3.0–5.0	O
mA	O
)	O
was	O
passed	O
through	O
a	O
pair	O
of	O
brass	O
electrodes	O
that	O
rested	O
lightly	O
on	O
a	O
shaved	O
portion	O
of	O
the	O
monkey	O
's	O
tail	O
.	O

The	O
current	O
was	O
applied	O
for	O
1.0	O
s	O
every	O
3.0	O
s.	O

In	O
training	O
sessions	O
,	O
a	O
response	O
on	O
the	O
correct	O
choice	O
lever	O
at	O
any	O
time	O
during	O
a	O
trial	O
ended	O
the	O
trial	O
,	O
extinguished	O
the	O
houselight	O
,	O
and	O
initiated	O
a	O
50-s	O
intertrial	O
interval	O
.	O

In	O
test	O
sessions	O
,	O
a	O
response	O
on	O
either	O
choice	O
lever	O
ended	O
the	O
trial	O
.	O

During	O
intertrial	O
intervals	O
a	O
yellow	O
stimulus	O
light	O
located	O
at	O
eye	O
level	O
between	O
the	O
two	O
lever	O
was	O
illuminated	O
and	O
each	O
response	O
resulted	O
in	O
the	O
delivery	O
of	O
a	O
30-ms	O
electrical	O
stimulus	O
to	O
the	O
tail	O
of	O
the	O
monkey	O
.	O

This	O
latter	O
contingency	O
helped	O
to	O
restrict	O
responding	O
to	O
the	O
period	O
when	O
a	O
trial	O
was	O
in	O
progress	O
.	O

A	O
response	O
on	O
the	O
incorrect	O
choice	O
lever	O
in	O
a	O
training	O
session	O
did	O
not	O
end	O
the	O
trial	O
and	O
that	O
trial	O
was	O
recorded	O
as	O
incorrect	O
.	O

In	O
the	O
absence	O
of	O
a	O
response	O
,	O
a	O
trial	O
ended	O
after	O
the	O
delivery	O
of	O
three	O
electrical	O
stimuli	O
and	O
was	O
recorded	O
as	O
an	O
incomplete	O
trial	O
.	O

Two	O
monkeys	O
had	O
been	O
trained	O
to	O
press	O
the	O
right	O
choice	O
lever	O
in	O
sessions	O
that	O
had	O
been	O
preceded	O
with	O
an	O
injection	O
of	O
1.0	O
mg	O
/	O
kg	O
CGS	O
15943	O
and	O
to	O
press	O
the	O
left	O
choice	O
lever	O
in	O
sessions	O
that	O
had	O
been	O
preceded	O
with	O
an	O
injection	O
of	O
drug	B
-	O
free	O
vehicle	O
.	O

The	O
other	O
two	O
monkeys	O
had	O
the	O
opposite	O
lever	O
assignments	O
.	O

Training	O
and	O
test	O
sessions	O
consisted	O
of	O
25	O
trials	O
.	O

Test	O
sessions	O
with	O
both	O
choice	O
lever	O
activated	O
usually	O
were	O
conducted	O
twice	O
weekly	O
,	O
3	O
to	O
4	O
days	O
apart	O
,	O
in	O
order	O
to	O
assess	O
stimulus	O
generalization	O
to	O
novel	O
drug	B
conditions	O
.	O

Training	O
sessions	O
with	O
only	O
the	O
correct	O
choice	O
lever	O
activated	O
were	O
conducted	O
at	O
least	O
three	O
times	O
each	O
week	O
to	O
maintain	O
stable	O
discrimination	O
performance	O
.	O

CGS	B
15943	I
,	O
1.0	O
mg	O
/	O
kg	O
,	O
suspended	O
in	O
1	O
%	O
methylcellulose	B
or	O
the	O
1	O
%	O
methylcellulose	B
vehicle	O
was	O
injected	O
i.m	O
.	O

30	O
min	O
before	O
a	O
training	O
session	O
;	O
drug	O
and	O
vehicle	O
were	O
administered	O
on	O
an	O
alternating	O
basis	O
.	O

If	O
a	O
monkey	O
failed	O
to	O
complete	O
correctly	O
at	O
least	O
22	O
of	O
the	O
25	O
trials	O
of	O
a	O
training	O
session	O
,	O
the	O
next	O
scheduled	O
test	O
session	O
was	O
postponed	O
until	O
correct	O
responding	O
in	O
22	O
of	O
25	O
trials	O
occurred	O
in	O
four	O
consecutive	O
training	O
sessions	O
.	O

Drugs	B
were	O
tested	O
for	O
stimulus	O
generalization	O
in	O
an	O
unsystematic	O
order	O
that	O
was	O
different	O
for	O
each	O
monkey	O
;	O
the	O
pretreatment	O
interval	O
was	O
30	O
min	O
.	O

Tests	O
of	O
potential	O
antagonists	O
of	O
the	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
were	O
conducted	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

The	O
potential	O
antagonists	O
were	O
administered	O
15	O
min	O
before	O
the	O
training	O
dose	O
of	O
CGS	B
15943	I
,	O
45	O
min	O
before	O
the	O
test	O
session	O
.	O

Doses	O
of	O
each	O
drug	B
initially	O
were	O
assigned	O
for	O
testing	O
in	O
a	O
random	O
sequence	O
that	O
also	O
included	O
the	O
vehicle	O
of	O
the	O
drug	B
being	O
tested	O
.	O

However	O
,	O
because	O
of	O
prominent	O
interanimal	O
differences	O
in	O
sensitivity	O
to	O
many	O
of	O
the	O
drugs	B
,	O
dose	O
ranges	O
often	O
were	O
readjusted	O
during	O
the	O
course	O
of	O
testing	O
a	O
particular	O
drug	B
in	O
a	O
particular	O
monkey	O
.	O

2.3	O
Drugs	B
The	O
following	O
drugs	B
were	O
purchased	O
from	O
RBI	O
(	O
Natick	O
,	O
MA	O
)	O
:	O
CGS	B
15943	I
,	I
apomorphine	B
hydrochloride	I
,	O
(	B
±	I
)	I
-1-phenyl-2,3,4,5-tetrahydro-	I
(	I
1H	I
)	I
-3-benzazepine-7,8-diol	I
HCl	I
(	O
SKF	B
38393	I
)	O
,	O
R	B
(	I
−	I
)	I
-propylnorapomorphine	I
hydrochloride	I
(	O
NPA	B
)	O
,	O
(	B
−	I
)	I
-quinpirole	I
hydrochloride	I
,	O
(	B
±	I
)	I
-N	I
-allyl-1-phenyl-2,3,4,5-tetrahydro-	I
(	I
1H	I
)	I
-3-benzazepine-7,8-diol	I
HBr	I
(	O
(	B
±	I
)	I
-SKF	I
77434	I
)	O
,	O
1-	B
[	I
2-	I
[	I
bis	I
(	I
4-fluorophenyl	I
)	I
methoxy	I
]	I
ethyl	I
]	I
-4-	I
[	I
3-phenylpropyl	I
]	I
piperazine	I
diHCl	I
(	O
GBR	B
12909	I
)	O
,	O
R	B
(	I
+	I
)	I
-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H	I
-3-benzazepine	I
HCl	I
(	O
R	B
(	I
+	I
)	I
-SCH	I
23390	I
)	O
,	O
S	B
(	I
−	I
)	I
-eticlopride	I
hydrochloride	I
and	O
ketanserin	B
tartrate	I
.	O

d	B
-Amphetamine	I
sulfate	I
and	O
phentolamine	B
methanesulfonate	I
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
,	O
morphine	B
sulfate	I
was	O
obtained	O
from	O
Penick	O
(	O
Newark	O
,	O
NJ	O
)	O
,	O
cocaine	B
hydrochloride	I
and	O
phencyclidine	B
hydrochloride	I
(	O
PCP	B
)	O
were	O
provided	O
by	O
the	O
National	O
Institute	O
on	O
Drug	B
Abuse	O
(	O
Rockville	O
,	O
MD	O
)	O
,	O
and	O
nisoxetine	B
hydrochloride	I
and	O
fluoxetine	B
hydrochloride	I
were	O
provided	O
by	O
Eli	O
Lilly	O
and	O
Company	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

CGS	B
15943	I
was	O
suspended	O
in	O
1	O
%	O
methylcellulose	B
and	O
was	O
sonicated	O
before	O
injection	O
.	O

Amphetamine	B
,	O
cocaine	B
,	O
NPA	B
,	O
quinpirole	B
,	O
eticlopride	B
,	O
SCH	B
23390	I
,	O
morphine	B
and	O
phencyclidine	B
were	O
dissolved	O
in	O
0.9	O
%	O
saline	B
solution	O
.	O

SKF	B
38393	I
,	O
SKF	B
77434	I
,	O
nisoxetine	B
,	O
fluoxetine	B
,	O
phentolamine	B
and	O
ketanserin	B
were	O
dissolved	O
in	O
distilled	O
water	B
.	O

Apomorphine	B
was	O
dissolved	O
in	O
distilled	O
water	B
containing	O
0.2	O
%	O
ascorbic	B
acid	I
and	O
GBR	B
12909	I
was	O
dissolved	O
in	O
one	O
part	O
dimethylsulfoxide	B
and	O
three	O
parts	O
distilled	O
water	B
.	O

Drugs	B
and	O
vehicles	O
were	O
injected	O
into	O
a	O
thigh	O
muscle	O
in	O
a	O
volume	O
of	O
0.5–1.0	O
ml	O
per	O
kg	O
of	O
body	O
.	O

All	O
drug	B
doses	O
refer	O
to	O
the	O
free	B
base	I
.	O

2.4	O
Data	O
analysis	O
Discrimination	O
data	O
are	O
presented	O
as	O
the	O
number	O
of	O
trials	O
completed	O
on	O
the	O
CGS	B
15943-appropriate	I
choice	O
lever	O
;	O
the	O
remaining	O
trials	O
of	O
a	O
session	O
were	O
completed	O
on	O
the	O
lever	O
appropriate	O
for	O
the	O
methylcellulose	B
vehicle	O
.	O

The	O
ED50	O
was	O
defined	O
as	O
the	O
drug	B
dose	O
that	O
would	O
have	O
resulted	O
in	O
selection	O
of	O
the	O
CGS	B
15943-appropriate	I
lever	O
in	O
12.5	O
trials	O
of	O
a	O
test	O
session	O
.	O

It	O
was	O
estimated	O
for	O
each	O
animal	O
by	O
linear	O
regression	O
of	O
the	O
ascending	O
part	O
of	O
the	O
stimulus	O
-	O
generalization	O
curve	O
when	O
at	O
least	O
three	O
points	O
were	O
available	O
and	O
by	O
simple	O
interpolation	O
when	O
there	O
were	O
only	O
two	O
points	O
to	O
use	O
;	O
doses	O
were	O
transformed	O
to	O
logarithm10	O
.	O

The	O
AD50	O
was	O
defined	O
as	O
the	O
dose	O
of	O
drug	B
that	O
when	O
administered	O
before	O
1.0	O
mg	O
/	O
kg	O
CGS	B
15943	I
reduced	O
selection	O
of	O
the	O
CGS	B
15943-appropriate	I
choice	O
lever	O
to	O
12.5	O
trials	O
per	O
session	O
.	O

It	O
was	O
calculated	O
in	O
the	O
same	O
manner	O
as	O
the	O
ED50	O
was	O
.	O

ED50	O
s	O
and	O
AD50	O
s	O
were	O
converted	O
from	O
mg	O
/	O
kg	O
to	O
μmol	O
/	O
kg	O
for	O
potency	O
comparisons	O
among	O
drugs	B
.	O

They	O
were	O
evaluated	O
by	O
analysis	O
of	O
variance	O
for	O
repeated	O
measures	O
,	O
followed	O
by	O
the	O
Student	O
–	O
Newman	O
–	O
Keuls	O
test	O
for	O
multiple	O
comparisons	O
among	O
all	O
means	O
.	O

3	O
Results	O
The	O
sensitivity	O
of	O
the	O
monkeys	O
to	O
the	O
training	O
drug	B
in	O
the	O
present	O
study	O
[	O
ED50	O
(	O
95	O
%	O
confidence	O
limits	O
)	O
:	O
0.38	O
(	O
0.22–0.64	O
)	O
mg	O
/	O
kg	O
]	O
was	O
similar	O
to	O
their	O
sensitivity	O
in	O
the	O
preceding	O
study	O
(	O
Holtzman	O
,	O
1996	O
)	O
in	O
which	O
they	O
were	O
tested	O
with	O
a	O
series	O
of	O
methylxanthine	B
derivatives	B
[	O
ED50	O
(	O
95	O
%	O
confidence	O
limits	O
)	O
:	O
0.43	O
(	O
0.27–0.67	O
)	O
mg	O
/	O
kg	O
]	O
.	O

Fig.	O
1	O
contains	O
the	O
stimulus	O
generalization	O
curves	O
for	O
CGS	B
15943	I
for	O
each	O
of	O
the	O
four	O
monkeys	O
.	O

Neither	O
the	O
vehicle	O
for	O
CGS	B
15943	I
nor	O
the	O
vehicles	O
for	O
the	O
other	O
drugs	B
examined	O
resulted	O
in	O
an	O
average	O
of	O
more	O
than	O
one	O
trial	O
per	O
session	O
being	O
completed	O
on	O
the	O
CGS	B
15943-appropriate	I
choice	O
lever	O
;	O
for	O
the	O
sake	O
of	O
simplicity	O
,	O
data	O
for	O
drug	B
vehicles	O
are	O
not	O
shown	O
in	O
the	O
figures	O
.	O

All	O
of	O
the	O
monkeys	O
generalized	O
completely	O
or	O
almost	O
completely	O
to	O
the	O
eight	O
dopamine	O
receptor	O
agonists	O
that	O
were	O
tested	O
:	O
apomorphine	B
,	O
amphetamine	B
and	O
cocaine	B
(	O
Fig.	O
1	O
)	O
,	O
SKF	B
38303	I
,	I
SKF	B
77434	I
,	O
quinpirole	B
and	O
NPA	B
(	O
Fig.	O
2	O
)	O
,	O
and	O
GBR	B
12909	I
(	O
Fig.	O
3	O
)	O
.	O

Of	O
these	O
,	O
the	O
dopamine	O
D1	O
receptor	O
agonist	O
SKF	B
77434	I
was	O
the	O
most	O
potent	O
(	O
Fig.	O
2	O
)	O
and	O
the	O
dopamine	O
uptake	O
inhibitor	O
GBR	B
12909	I
was	O
the	O
least	O
potent	O
(	O
Fig.	O
3	O
)	O
.	O

On	O
a	O
molar	O
basis	O
,	O
SKF	B
77434	I
was	O
19	O
times	O
more	O
potent	O
than	O
CGS	B
15943	I
whereas	O
GBR	B
12909	I
was	O
one	O
-	O
fifth	O
as	O
potent	O
(	O
Table	O
1	O
)	O
.	O

As	O
is	O
evident	O
in	O
the	O
figures	O
,	O
interanimal	O
variability	O
in	O
sensitivity	O
to	O
the	O
dopamine	O
receptor	O
agonists	O
was	O
considerable	O
.	O

S90	O
was	O
the	O
most	O
sensitive	O
monkey	O
in	O
tests	O
of	O
stimulus	O
generalization	O
to	O
six	O
of	O
the	O
eight	O
dopamine	O
receptor	O
agonists	O
and	O
monkey	O
S92	O
displayed	O
the	O
greatest	O
sensitivity	O
to	O
the	O
other	O
two	O
,	O
cocaine	B
(	O
Fig.	O
1	O
)	O
and	O
SKF	B
38393	I
(	O
Fig.	O
2	O
)	O
.	O

As	O
a	O
consequence	O
of	O
this	O
interanimal	O
variability	O
,	O
differences	O
in	O
potencies	O
among	O
apomorphine	B
,	O
agonists	O
selective	O
for	O
dopamine	O
D1	O
or	O
D2	O
receptors	O
,	O
amphetamine	B
and	O
cocaine	B
were	O
not	O
statistically	O
reliable	O
(	O
Table	O
1	O
)	O
.	O

However	O
,	O
all	O
of	O
these	O
drugs	B
were	O
significantly	O
more	O
potent	O
than	O
GBR	B
12909	I
,	O
and	O
SKF	B
77434	I
and	O
amphetamine	B
were	O
significantly	O
more	O
potent	O
than	O
CGS	B
15943	I
(	O
Table	O
1	O
)	O
.	O

The	O
monkeys	O
also	O
generalized	O
completely	O
or	O
almost	O
completely	O
to	O
two	O
drugs	B
that	O
act	O
on	O
monoamine	B
neurotransmitter	O
systems	O
other	O
than	O
dopamine	B
:	O
fluoxetine	B
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serotonin	B
neuronal	O
transporter	O
,	O
and	O
nisoxetine	B
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
norepinephrine	B
neuronal	O
transporter	O
(	O
Fig.	O
3	O
)	O
.	O

Nisoxetine	B
was	O
significantly	O
more	O
potent	O
than	O
GBR	B
12909	I
in	O
occasioning	O
selection	O
of	O
the	O
CGS	B
15943-appropriate	I
choice	O
lever	O
,	O
whereas	O
the	O
potency	O
of	O
fluoxetine	B
was	O
not	O
different	O
from	O
that	O
of	O
either	O
nisoxetine	B
or	O
GBR	B
12909	I
(	O
Table	O
1	O
)	O
.	O

In	O
contrast	O
,	O
neither	O
morphine	B
(	O
1.0–5.6	O
mg	O
/	O
kg	O
)	O
nor	O
phencyclidine	B
(	O
0.03–0.3	O
mg	O
/	O
kg	O
)	O
occasioned	O
substantial	O
CGS	B
15943-appropriate	I
responding	O
(	O
Fig.	O
4	O
)	O
,	O
even	O
though	O
each	O
drug	B
was	O
tested	O
up	O
to	O
a	O
dose	O
that	O
caused	O
slumping	O
body	O
postures	O
indicative	O
of	O
motor	O
impairment	O
in	O
all	O
of	O
the	O
monkeys	O
.	O

The	O
discriminative	O
effects	O
of	O
the	O
1.0	O
mg	O
/	O
kg	O
training	O
dose	O
of	O
CGS	B
15943	I
were	O
blocked	O
completely	O
by	O
pretreating	O
the	O
monkeys	O
with	O
either	O
the	O
dopamine	O
D1	O
receptor	O
antagonist	O
SCH	B
23390	I
,	O
the	O
dopamine	O
D2	O
receptor	O
antagonist	O
eticlopride	B
,	O
or	O
the	O
5-HT2	O
/5-HT1C	O
receptor	O
antagonist	O
ketanserin	B
(	O
Fig.	O
5	O
)	O
.	O

SCH	B
23390	I
was	O
,	O
by	O
far	O
,	O
the	O
most	O
potent	O
antagonist	O
of	O
the	O
three	O
,	O
blocking	O
the	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
completely	O
at	O
doses	O
of	O
only	O
1.0–10	O
μg	O
/	O
kg	O
,	O
depending	O
upon	O
the	O
individual	O
monkey	O
.	O

The	O
AD50	O
s	O
(	O
and	O
95	O
%	O
confidence	O
limits	O
)	O
of	O
the	O
antagonists	O
were	O
4.97	O
(	O
1.83–13.5	O
)	O
nmol	O
/	O
kg	O
for	O
SCH	B
23390	I
,	O
57.9	O
(	O
17.5–192	O
)	O
nmol	O
/	O
kg	O
for	O
eticlopride	B
and	O
1.09	O
(	O
0.27–4.46	O
)	O
μmol	O
/	O
kg	O
for	O
ketanserin	B
.	O

Thus	O
,	O
on	O
a	O
molar	O
basis	O
,	O
SCH	B
23390	I
was	O
11.6	O
times	O
more	O
potent	O
than	O
eticlopride	B
and	O
219	O
times	O
more	O
potent	O
than	O
ketanserin	B
in	O
antagonizing	O
the	O
discriminative	O
effects	O
of	O
the	O
training	O
dose	O
of	O
CGS	B
15943	I
.	O

In	O
contrast	O
,	O
pretreatment	O
with	O
the	O
α	O
-	O
adrenoceptor	O
antagonist	O
phentolamine	B
blocked	O
the	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
only	O
partially	O
and	O
inconsistently	O
,	O
even	O
at	O
a	O
dose	O
as	O
high	O
as	O
10	O
mg	O
(	O
36	O
μmol	O
)	O
/	O
kg	O
(	O
Fig.	O
5	O
)	O
.	O

4	O
Discussion	O
The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
there	O
is	O
a	O
prominent	O
dopamine	B
component	O
to	O
the	O
discriminative	O
stimulus	O
effects	O
of	O
CGS	B
15943	I
in	O
squirrel	O
monkeys	O
.	O

CGS	B
15943	I
generalized	O
with	O
a	O
variety	O
of	O
directly	O
and	O
indirectly	O
acting	O
dopamine	O
receptor	O
agonists	O
and	O
its	O
discriminative	O
effects	O
were	O
blocked	O
dose	O
-	O
dependently	O
and	O
completely	O
by	O
low	O
doses	O
of	O
dopamine	O
receptor	O
antagonists	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
reports	O
of	O
dopamine	B
involvement	O
in	O
the	O
discriminative	O
effects	O
of	O
a	O
low	O
training	O
dose	O
of	O
caffeine	B
and	O
in	O
the	O
stimulation	O
of	O
locomotor	O
activity	O
by	O
caffeine	B
in	O
rats	O
(	O
Mumford	O
and	O
Holtzman	O
,	O
1991	O
;	O
Garrett	O
and	O
Holtzman	O
,	O
1994	O
)	O
.	O

They	O
also	O
are	O
consistent	O
with	O
a	O
growing	O
body	O
of	O
literature	O
suggesting	O
there	O
is	O
an	O
inverse	O
relationship	O
between	O
adenosine	O
receptor	O
activation	O
in	O
basal	O
ganglia	O
and	O
dopamine	B
-	O
mediated	O
neurotransmission	O
(	O
see	O
Section	O
1	O
)	O
.	O

It	O
appears	O
that	O
activation	O
of	O
either	O
the	O
dopamine	O
D1	O
or	O
D2	O
families	O
of	O
receptors	O
is	O
sufficient	O
to	O
produce	O
CGS	B
15943-like	I
stimulus	O
control	O
of	O
behavior	O
.	O

The	O
dopamine	O
D1	O
receptor	O
agonists	O
SKF	B
77434	I
and	O
SKF	B
38393	I
and	O
the	O
dopamine	O
D2	O
receptor	O
agonists	O
quinpirole	B
and	O
NPA	B
were	O
equipotent	O
in	O
this	O
regard	O
.	O

In	O
addition	O
,	O
the	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
were	O
blocked	O
by	O
nanomolar	O
doses	O
of	O
either	O
the	O
dopamine	O
D1	O
receptor	O
antagonist	O
SCH	B
23390	I
or	O
the	O
dopamine	O
D2	O
receptor	O
antagonist	O
eticlopride	B
.	O

These	O
effects	O
of	O
the	O
dopamine	O
receptor	O
antagonists	O
were	O
not	O
a	O
consequence	O
of	O
nonspecific	O
suppression	O
or	O
disruption	O
of	O
the	O
ongoing	O
behavior	O
.	O

The	O
monkeys	O
completed	O
all	O
session	O
trials	O
but	O
shifted	O
their	O
responding	O
in	O
an	O
orderly	O
manner	O
from	O
the	O
CGS	B
15943-appropriate	I
choice	O
lever	O
to	O
the	O
vehicle	O
-	O
appropriate	O
choice	O
lever	O
.	O

Similar	O
patterns	O
of	O
stimulus	O
generalization	O
and	O
antagonism	O
occur	O
in	O
squirrel	O
monkeys	O
discriminating	O
indirectly	O
acting	O
dopamine	O
receptor	O
agonists	O
,	O
such	O
as	O
cocaine	B
(	O
Spealman	O
et	O
al.	O
,	O
1991	O
)	O
,	O
GBR	B
12909	I
(	O
Melia	O
and	O
Spealman	O
,	O
1991	O
)	O
and	O
methamphetamine	B
(	O
Tidey	O
and	O
Bergman	O
,	O
1998	O
)	O
.	O

Dopamine	B
is	O
not	O
the	O
only	O
monoamine	B
that	O
appears	O
to	O
be	O
involved	O
in	O
the	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
.	O

The	O
monkeys	O
in	O
this	O
study	O
generalized	O
completely	O
to	O
nisoxetine	B
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
neuronal	O
norepinephrine	B
transporter	O
.	O

This	O
finding	O
,	O
too	O
,	O
is	O
consistent	O
with	O
the	O
results	O
of	O
a	O
study	O
on	O
the	O
discriminative	O
effects	O
of	O
a	O
low	O
training	O
dose	O
of	O
caffeine	B
in	O
rats	O
,	O
indicating	O
an	O
important	O
noradrenergic	O
component	O
(	O
Holtzman	O
,	O
1986	O
)	O
.	O

Monkeys	O
discriminating	O
amphetamine	B
(	O
Kamien	O
and	O
Woolverton	O
,	O
1989	O
)	O
and	O
monkeys	O
(	O
Spealman	O
,	O
1995	O
)	O
and	O
rats	O
(	O
Terry	O
et	O
al.	O
,	O
1994	O
)	O
discriminating	O
a	O
low	O
dose	O
of	O
cocaine	B
(	O
Spealman	O
,	O
1995	O
)	O
also	O
generalize	O
completely	O
with	O
nisoxetine	B
.	O

Contrasting	O
with	O
the	O
substitution	O
of	O
nisoxetine	B
for	O
CGS	B
15943	I
is	O
the	O
failure	O
of	O
phentolamine	B
,	O
an	O
α	O
-	O
adrenoceptor	O
antagonist	O
,	O
to	O
block	O
the	O
discriminative	O
effects	O
of	O
the	O
training	O
drug	B
.	O

This	O
outcome	O
distinguishes	O
the	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
in	O
this	O
study	O
from	O
those	O
of	O
caffeine	B
in	O
rats	O
;	O
phentolamine	B
blocked	O
the	O
discriminative	O
effects	O
of	O
a	O
low	O
caffeine	B
training	O
dose	O
(	O
Holtzman	O
,	O
1986	O
)	O
.	O

However	O
,	O
consistent	O
with	O
the	O
results	O
of	O
the	O
current	O
study	O
,	O
phentolamine	B
did	O
not	O
block	O
the	O
discriminative	O
effects	O
of	O
either	O
amphetamine	B
or	O
cocaine	B
in	O
monkeys	O
,	O
despite	O
the	O
fact	O
that	O
nisoxetine	B
generalized	O
with	O
the	O
training	O
drugs	B
(	O
Kamien	O
and	O
Woolverton	O
,	O
1989	O
;	O
Spealman	O
,	O
1995	O
)	O
.	O

There	O
are	O
several	O
possible	O
explanations	O
for	O
these	O
apparent	O
discrepancies	O
,	O
species	O
difference	O
,	O
for	O
example	O
.	O

The	O
pharmacokinetics	O
of	O
phentolamine	B
in	O
rats	O
and	O
monkeys	O
might	O
differ	O
,	O
as	O
might	O
the	O
qualitative	O
nature	O
of	O
the	O
discriminative	O
effects	O
that	O
arise	O
from	O
blockade	O
of	O
adenosine	O
receptors	O
and/or	O
the	O
relative	O
contribution	O
to	O
those	O
effects	O
of	O
α-	O
vs.	O
β	O
-	O
adrenoceptor	O
activation	O
.	O

Differences	O
among	O
the	O
training	O
drugs	B
must	O
also	O
be	O
considered	O
.	O

The	O
unique	O
spectrum	O
of	O
activity	O
of	O
caffeine	B
,	O
which	O
includes	O
inhibition	O
of	O
phosphodiesterases	O
,	O
might	O
make	O
a	O
noradrenergic	O
component	O
essential	O
to	O
the	O
stimulus	O
control	O
of	O
behavior	O
by	O
that	O
drug	B
.	O

Enhancement	O
of	O
noradrenergically	O
mediated	O
neurotransmission	O
might	O
be	O
sufficient	O
to	O
mimic	O
the	O
stimulus	O
effects	O
of	O
CGS	B
15943	I
(	O
as	O
well	O
as	O
those	O
of	O
amphetamine	B
and	O
cocaine	B
)	O
but	O
not	O
be	O
essential	O
for	O
stimulus	O
control	O
of	O
behavior	O
by	O
CGS	B
15943	I
.	O

A	O
third	O
monoamine	B
that	O
appears	O
to	O
have	O
a	O
role	O
in	O
the	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
is	O
serotonin	B
.	O

The	O
discriminative	O
effects	O
of	O
CGS	B
15943	I
were	O
mimicked	O
(	O
completely	O
,	O
in	O
three	O
of	O
four	O
monkeys	O
)	O
by	O
fluoxetine	B
,	O
a	O
selective	O
inhibitor	O
of	O
serotonin	B
uptake	O
by	O
neurons	O
,	O
and	O
were	O
blocked	O
by	O
ketanserin	B
,	O
a	O
5-HT2	O
receptor	O
antagonist	O
.	O

The	O
literature	O
contains	O
abundant	O
evidence	O
of	O
serotonergic	O
modulation	O
of	O
brain	O
dopamine	B
systems	O
.	O

Activation	O
of	O
serotonin	O
receptors	O
can	O
stimulate	O
dopamine	B
release	O
(	O
Parsons	O
and	O
Justice	O
,	O
1993	O
;	O
Benloucif	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Furthermore	O
,	O
serotonergic	O
mechanisms	O
appear	O
to	O
contribute	O
to	O
the	O
discriminative	O
and	O
reinforcing	O
stimulus	O
effects	O
of	O
psychomotor	O
stimulant	O
drugs	B
,	O
such	O
as	O
cocaine	B
(	O
Walsh	O
and	O
Cunningham	O
,	O
1997	O
)	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
effects	O
of	O
fluoxetine	B
in	O
monkeys	O
discriminating	O
CGS	B
15943	I
,	O
selective	O
serotonin	B
reuptake	O
inhibitors	O
do	O
not	O
substitute	O
for	O
the	O
cocaine	B
cue	O
,	O
even	O
when	O
the	O
training	O
dose	O
of	O
cocaine	B
is	O
relatively	O
low	O
(	O
Terry	O
et	O
al.	O
,	O
1994	O
;	O
Spealman	O
,	O
1995	O
)	O
.	O

A	O
pattern	O
of	O
broad	O
stimulus	O
generalization	O
to	O
pharmacologically	O
diverse	O
drugs	B
can	O
be	O
the	O
consequence	O
of	O
a	O
functionally	O
low	O
training	O
dose	O
(	O
Holtzman	O
,	O
1983	O
;	O
Overton	O
,	O
1984	O
)	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
the	O
training	O
dose	O
of	O
CGS	B
15943	I
was	O
,	O
indeed	O
,	O
functionally	O
low	O
.	O

First	O
,	O
the	O
discrimination	O
was	O
acquired	O
slowly	O
,	O
in	O
a	O
median	O
of	O
174	O
(	O
range	O
:	O
82–222	O
)	O
training	O
sessions	O
(	O
Holtzman	O
,	O
1996	O
)	O
.	O

Second	O
,	O
SKF	B
38393	I
and	O
SKF	B
77494	I
,	I
which	O
are	O
low	O
-	O
efficacy	O
agonists	O
at	O
dopamine	O
D1	O
receptors	O
(	O
Izenwasser	O
and	O
Katz	O
,	O
1993	O
;	O
Weed	O
et	O
al.	O
,	O
1997	O
)	O
,	O
generalized	O
completely	O
with	O
CGS	B
15943	I
.	I

In	O
contrast	O
,	O
SKF	B
38393	I
occasioned	O
little	O
drug	B
-	O
appropriate	O
responding	O
in	O
squirrel	O
monkeys	O
trained	O
to	O
discriminate	O
SKF	B
81297	I
,	O
a	O
high	O
-	O
efficacy	O
dopamine	O
D1	O
receptor	O
agonist	O
(	O
Rosenzweig	O
-	O
Libson	O
and	O
Bergman	O
,	O
1993	O
)	O
.	O

Third	O
,	O
the	O
ED50	O
s	O
of	O
cocaine	B
,	O
nisoxetine	B
,	O
and	O
GBR	B
12909	I
in	O
this	O
study	O
(	O
Table	O
1	O
)	O
were	O
up	O
to	O
several	O
-	O
fold	O
lower	O
than	O
they	O
were	O
in	O
squirrel	O
monkeys	O
discriminating	O
a	O
""""	O
low	O
""""	O
dose	O
(	O
0.18–0.3	O
mg	O
/	O
kg	O
)	O
of	O
cocaine	B
(	O
Spealman	O
,	O
1995	O
)	O
.	O

The	O
ED50	O
of	O
a	O
drug	B
varies	O
directly	O
with	O
the	O
magnitude	O
of	O
the	O
discriminative	O
effects	O
of	O
the	O
training	O
drug	B
(	O
Holtzman	O
,	O
1983	O
)	O
.	O

Therefore	O
,	O
these	O
results	O
suggest	O
that	O
the	O
training	O
dose	O
of	O
CGS	B
15943	I
engendered	O
a	O
less	O
intense	O
stimulus	O
than	O
did	O
the	O
low	O
training	O
dose	O
of	O
cocaine	B
in	O
the	O
study	O
by	O
Spealman	O
(	O
1995	O
)	O
.	O

A	O
discriminative	O
stimulus	O
of	O
relatively	O
low	O
intensity	O
might	O
also	O
account	O
for	O
the	O
variability	O
among	O
animals	O
in	O
their	O
responses	O
to	O
the	O
various	O
test	O
drugs	B
.	O

Despite	O
the	O
breadth	O
of	O
drugs	B
sharing	O
discriminative	O
effects	O
with	O
CGS	B
15943	I
,	O
stimulus	O
control	O
of	O
behavior	O
by	O
the	O
training	O
drug	B
did	O
have	O
pharmacological	O
specificity	O
.	O

Morphine	B
,	O
a	O
μ	O
-	O
opioid	O
receptor	O
agonist	O
,	O
and	O
phencyclidine	B
,	O
a	O
noncompetitive	O
antagonist	O
at	O
the	O
N	O
-methyl	O
-	O
d	O
-aspartate	O
(	O
NMDA	O
)	O
glutamate	O
–	O
receptor	O
complex	O
,	O
occasioned	O
little	O
CGS	B
15943-appropriate	I
responding	O
,	O
even	O
though	O
they	O
were	O
tested	O
at	O
doses	O
that	O
are	O
discriminable	O
to	O
squirrel	O
monkeys	O
(	O
Schaefer	O
and	O
Holtzman	O
,	O
1977	O
;	O
Holtzman	O
,	O
1982	O
)	O
.	O

Rats	O
trained	O
to	O
discriminate	O
magnesium	B
chloride	I
from	O
saline	B
also	O
generalize	O
completely	O
to	O
cocaine	B
and	O
to	O
specific	O
inhibitors	O
of	O
the	O
uptake	O
of	O
dopamine	B
,	O
norepinephrine	B
and	O
serotonin	B
,	O
but	O
generalize	O
only	O
partially	O
to	O
PCP	B
and	O
other	O
NMDA	O
receptor	O
antagonists	O
(	O
Kantak	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
relationship	O
,	O
if	O
any	O
,	O
between	O
the	O
discriminative	O
effects	O
of	O
magnesium	B
chloride	I
and	O
those	O
arising	O
from	O
blockade	O
of	O
adenosine	O
receptors	O
is	O
obscure	O
.	O

In	O
conclusion	O
,	O
squirrel	O
monkeys	O
discriminating	O
an	O
adenosine	O
receptor	O
antagonist	O
that	O
does	O
not	O
inhibit	O
phosphodiesterase	O
activity	O
generalize	O
not	O
only	O
to	O
other	O
drugs	B
that	O
block	O
adenosine	O
receptors	O
(	O
Holtzman	O
,	O
1996	O
)	O
,	O
but	O
also	O
to	O
drugs	B
that	O
enhance	O
neurotransmission	O
mediated	O
by	O
dopamine	B
,	O
norepinephrine	B
,	O
and	O
serotonin	B
.	O

Therefore	O
,	O
this	O
type	O
of	O
drug	B
discrimination	O
procedure	O
might	O
be	O
useful	O
for	O
studying	O
the	O
relationships	O
among	O
brain	O
adenosine	B
and	O
monoamine	B
systems	O
.	O

Acknowledgements	O
Ms.	O
Lora	O
O'Keefe	O
provided	O
technical	O
assistance	O
and	O
was	O
responsible	O
for	O
daily	O
training	O
and	O
test	O
sessions	O
.	O

Eli	O
Lilly	O
and	O
Company	O
generously	O
provided	O
nisoxetine	B
and	O
fluoxetine	B
.	O

This	O
research	O
was	O
supported	O
by	O
Grants	O
DA00541	O
,	O
DA03413	O
and	O
KO5	O
DA00008	O
,	O
all	O
from	O
the	O
National	O
Institute	O
on	O
Drug	B
Abuse	O
,	O
National	O
Institutes	O
of	O
Health	O
.	O

Humans	O
are	O
continuously	O
exposed	O
to	O
a	O
wide	O
variety	O
of	O
xenobiotics	B
either	O
voluntarily	O
or	O
from	O
environmental	O
exposure	O
.	O

Pesticides	B
represent	O
a	O
high	O
volume	O
of	O
widely	O
used	O
,	O
environmental	B
chemicals	I
and	O
there	O
is	O
a	O
continuous	O
debate	O
concerning	O
their	O
possible	O
role	O
in	O
many	O
chronic	O
,	O
human	O
health	O
conditions	O
including	O
cancer	O
.	O

Hence	O
,	O
a	O
great	O
deal	O
of	O
studies	O
were	O
carried	O
out	O
to	O
evaluate	O
their	O
possible	O
effects	O
on	O
the	O
population	O
in	O
general	O
and	O
on	O
the	O
environment	O
.	O

Dithianon	B
(	O
DT	B
)	O
(	O
5,10-dihydro-5,10-dioxo	B
-	I
naphto-	I
[	I
2,3b	I
]	I
-p	I
-dithio-2,3-dicarbonitrile	I
)	O
,	O
a	O
non	B
-	I
chlorinated	I
quinone	I
derivative	I
(	O
Fig.	O
1	O
)	O
,	O
is	O
a	O
protective	O
fungicide	B
mainly	O
used	O
against	O
apple	O
and	O
pear	O
scab	O
and	O
leaf	O
spot	O
on	O
cherry	O
trees	O
[	O
1	O
]	O
.	O

Toxicological	O
data	O
on	O
this	O
fungicide	B
are	O
lacking	O
and	O
only	O
a	O
little	O
information	O
about	O
its	O
toxicity	O
,	O
mutagenicity	O
and	O
embryotoxicity	O
has	O
been	O
reported	O
in	O
literature	O
[	O
2	O
]	O
.	O

Even	O
though	O
a	O
short	O
-	O
term	O
test	O
of	O
DT	B
mutagenicity	O
showed	O
negative	O
results	O
on	O
microbial	O
systems	O
[	O
3	O
]	O
and	O
the	O
Joint	O
FAO	O
/	O
WHO	O
Meeting	O
on	O
Pesticide	B
Residues	O
(	O
JMPR	O
)	O
(	O
1992	O
)	O
concluded	O
that	O
the	O
chemical	O
was	O
not	O
carcinogenic	O
,	O
it	O
could	O
induce	O
in	O
vitro	O
cell	O
transformation	O
on	O
BALB	O
/	O
c	O
3T3	O
cells	O
[	O
4	O
]	O
,	O
indicating	O
a	O
possible	O
promoting	O
effect	O
of	O
this	O
pesticide	B
.	O

These	O
data	O
indicate	O
that	O
DT	B
could	O
exert	O
a	O
co	O
-	O
carcinogenic	O
action	O
through	O
epigenetic	O
mechanisms	O
.	O

A	O
number	O
of	O
investigators	O
have	O
suggested	O
that	O
tumorigenesis	O
can	O
be	O
mediated	O
by	O
non	O
-	O
genotoxic	O
mechanisms	O
,	O
of	O
which	O
the	O
most	O
representative	O
are	O
the	O
following	O
:	O
unspecific	O
toxic	O
effects	O
from	O
administration	O
of	O
high	O
doses	O
(	O
MTD	O
)	O
of	O
the	O
compound	O
,	O
leading	O
to	O
cell	O
death	O
,	O
and	O
therefore	O
,	O
to	O
subsequent	O
stimulation	O
of	O
mitosis	O
[	O
5	O
]	O
;	O
increase	O
of	O
tubular	O
concentration	O
of	O
the	O
protein	O
α2	O
microglobulin	O
and	O
disruption	O
of	O
calcium	B
reabsorption	O
in	O
renal	O
tumours	O
[	O
5	O
]	O
;	O
facilitation	O
of	O
biliary	O
clearance	O
of	O
thyroid	O
hormone	B
T4	B
,	O
with	O
increased	O
incidences	O
of	O
TSH	O
production	O
,	O
thyroid	O
hypertrophy	O
,	O
hyperplasia	O
and	O
probably	O
tumours	O
[	O
6	O
]	O
;	O
increase	O
of	O
peroxisome	O
proliferation	O
in	O
rodent	O
liver	O
[	O
7	O
]	O
;	O
promotion	O
and	O
induction	O
regulation	O
of	O
cell	O
proliferation	O
[	O
8,9	O
]	O
;	O
pleiotropic	O
response	O
,	O
oxidative	O
stress	O
,	O
co	O
-	O
carcinogenesis	O
and	O
promotion	O
all	O
correlated	O
with	O
CYP	O
induction	O
[	O
10–16	O
]	O
.	O

Thus	O
,	O
the	O
outstanding	O
problems	O
faced	O
in	O
the	O
prediction	O
of	O
potential	O
carcinogens	O
,	O
being	O
mainly	O
toxicologically	O
non	O
-	O
genetic	O
[	O
17	O
]	O
,	O
prompted	O
us	O
to	O
investigate	O
the	O
toxicological	O
effects	O
at	O
metabolic	O
level	O
.	O

Many	O
chemicals	O
are	O
unique	O
for	O
their	O
ability	O
to	O
affect	O
a	O
wide	O
range	O
of	O
CYP	O
isoforms	O
belonging	O
to	O
different	O
families	O
and	O
subfamilies	O
.	O

In	O
our	O
laboratories	O
we	O
are	O
interested	O
in	O
the	O
study	O
of	O
certain	O
toxicological	O
effects	O
derived	O
by	O
the	O
modulation	O
of	O
CYP	O
-	O
associated	O
activities	O
,	O
the	O
most	O
important	O
apparatus	O
involved	O
in	O
phase	O
-	O
I	O
biotransformation	O
of	O
xenobiotics	B
(	O
drugs	B
and	O
environmental	B
pollutants	I
)	O
.	O

CYP	O
changes	O
,	O
altering	O
the	O
overall	O
metabolic	O
status	O
(	O
activation	O
/	O
detoxication	B
ratio	O
)	O
,	O
can	O
affect	O
the	O
disposition	O
of	O
other	O
compounds	O
in	O
specific	O
organs	O
[	O
10,12,18	O
]	O
,	O
as	O
well	O
as	O
exert	O
co	O
-	O
carcinogenic	O
and	O
promoting	O
effects	O
[	O
13,15	O
]	O
.	O

Here	O
,	O
the	O
ability	O
of	O
DT	B
to	O
affect	O
various	O
microsomal	O
monooxygenases	O
in	O
murine	O
liver	O
,	O
kidney	O
and	O
lung	O
was	O
studied	O
,	O
using	O
the	O
regio-	O
and	O
stereo	O
-	O
selective	O
hydroxylation	O
of	O
testosterone	B
as	O
a	O
multibiomarker	O
of	O
effect	O
[	O
19	O
]	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O
NADP+	B
,	O
16α	B
-	I
hydroxytestosterone	I
(	O
16α	B
-	I
TH	I
)	O
,	O
corticosterone	B
,	O
testosterone	B
and	O
4-androsten-3,17-dione	B
(	O
17-TH	B
)	O
were	O
purchased	O
from	O
Sigma	O
Chemical	O
Co.	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
;	O
glucose	B
6-phosphate	I
and	O
glucose	O
6-phosphate	O
dehydrogenase	O
from	O
Boehringer	O
-	O
Mannheim	O
(	O
Germany	O
)	O
,	O
HPLC	O
grade	O
methanol	B
,	O
tetrahydrofuran	B
and	O
dichloromethane	B
from	O
BDH	O
(	O
Pooley	O
,	O
UK	O
)	O
;	O
7α-	B
,	O
6β-	B
and	O
16β	B
-	I
hydroxytestosterone	I
from	O
Steraloids	O
(	O
Wilton	O
,	O
NH	O
)	O
;	O
6α-	B
,	O
2α-	B
and	O
2β	B
-	I
hydroxytestosterone	I
were	O
generous	O
gifts	O
from	O
Dr.	O
P.G.	O
Gervasi	O
(	O
CNR	O
Pisa	O
,	O
Italy	O
)	O
;	O
DT	B
(	O
5,10-dihydro-5,10-dioxo	B
-	I
naphtho-	I
[	I
2,3b	I
]	I
-p	I
-dithio-2,3-dicarbonitrile	I
)	O
chemical	O
purity	O
99.6	O
%	O
,	O
was	O
purchased	O
from	O
Lab	O
Service	O
(	O
Bologna	O
,	O
Italy	O
)	O
;	O
rabbit	O
polyclonal	O
antibodies	O
anti	O
-	O
CYP3A1	O
/	O
2	O
were	O
purchased	O
from	O
Chemicon	O
International	O
Inc.	O
(	O
Temecula	O
,	O
CA	O
)	O
;	O
all	O
other	O
chemicals	O
and	O
solvents	O
were	O
of	O
the	O
highest	O
commercially	O
available	O
purity	O
.	O

2.2	O
Animal	O
treatment	O
and	O
preparation	O
of	O
subcellular	O
fractions	O
Male	O
and	O
female	O
Swiss	O
albino	O
CD1	O
mice	O
(	O
Harlan	O
-	O
Nossan	O
,	O
Correzzana	O
,	O
Milan	O
)	O
,	O
weighing	O
28–30	O
g	O
,	O
were	O
housed	O
under	O
controlled	O
conditions	O
(	O
12	O
h	O
light	O
–	O
dark	O
cycle	O
,	O
22	O
°	O
C	O
,	O
60	O
%	O
humidity	O
)	O
.	O

They	O
were	O
fed	O
a	O
standard	O
rodent	O
chow	O
and	O
had	O
tap	O
water	B
ad	O
libitum	O
.	O

DT	B
was	O
dissolved	O
in	O
corn	B
oil	I
and	O
administered	O
(	O
i.p	O
.	O
)	O
in	O
a	O
single	O
(	O
3	O
or	O
6	O
mg	O
/	O
kg	O
body	O
wt	O
.	O
)	O
or	O
repeated	O
(	O
3	O
mg	O
/	O
kg	O
body	O
wt	O
.	O
daily	O
for	O
3	O
consecutive	O
days	O
)	O
dose	O
.	O

Controls	O
received	O
the	O
vehicle	O
only	O
,	O
under	O
the	O
same	O
conditions	O
.	O

Mice	O
were	O
fasted	O
16	O
h	O
prior	O
to	O
death	O
and	O
killed	O
humanely	O
in	O
accordance	O
with	O
approved	O
Home	O
Office	O
procedures	O
appropriate	O
to	O
the	O
species	O
.	O

Liver	O
,	O
kidney	O
and	O
lung	O
were	O
homogenized	O
in	O
4	O
volumes	O
(	O
w	O
/	O
v	O
)	O
of	O
0.05	O
M	O
Tris	B
–	I
HCl	I
buffer	O
(	O
pH	O
7.4	O
)	O
with	O
a	O
Teflon	O
pestle	O
(	O
Potter	O
-	O
Elvehjem	O
)	O
and	O
centrifuged	O
at	O
9000	O
×	O
g	O
for	O
20	O
min	O
.	O

The	O
post	O
-	O
mitochondrial	O
supernatant	O
obtained	O
,	O
was	O
centrifuged	O
for	O
60	O
min	O
at	O
105	O
000	O
×	O
g	O
.	O

The	O
pellet	O
was	O
resuspended	O
in	O
0.1	O
M	O
K3	B
P2	I
O7	I
(	O
pH	O
7.4	O
)	O
,	O
1	O
mM	O
EDTA	B
and	O
20	O
nM	O
BHT	B
,	O
and	O
centrifuged	O
again	O
for	O
60	O
min	O
at	O
105	O
000	O
×	O
g	O
to	O
obtain	O
the	O
final	O
microsomal	O
fraction	O
.	O

The	O
resultant	O
washed	O
microsomes	O
were	O
then	O
resuspended	O
with	O
a	O
hand	O
-	O
driven	O
homogenizer	O
in	O
10	O
mM	O
Tris	B
–	I
HCl	I
buffer	O
(	O
pH	O
7.4	O
)	O
containing	O
1	O
mM	O
EDTA	B
and	O
20	O
%	O
glycerol	B
(	O
v	O
/	O
v	O
)	O
.	O

Subcellular	O
preparations	O
were	O
immediately	O
frozen	O
in	O
liquid	O
nitrogen	B
,	O
stored	O
at	O
−80	O
°	O
C	O
and	O
used	O
within	O
1	O
week	O
[	O
20	O
]	O
.	O

2.3	O
Testosterone	O
hydroxylase	O
activity	O
2.3.1	O
Incubation	O
and	O
isolation	O
Incubations	O
contained	O
microsomes	O
(	O
equivalent	O
to	O
1–2	O
mg	O
protein	O
)	O
,	O
0.6	O
mM	O
NADP+	O
,	O
8	O
mM	O
glucose	B
6-phosphate	I
,	O
1.4	O
units	O
glucose	O
6-phosphate	O
dehydrogenase	O
and	O
1	O
mM	O
MgCl2	B
,	O
in	O
a	O
final	O
volume	O
of	O
2	O
ml	O
0.1	O
M	O
phosphate	B
Na+	I
/K+	I
buffer	O
(	O
pH	O
7.4	O
)	O
.	O

The	O
mixture	O
was	O
preincubated	O
for	O
5	O
min	O
at	O
37	O
°	O
C	O
.	O

The	O
reaction	O
was	O
performed	O
at	O
37	O
°	O
C	O
by	O
shaking	O
and	O
started	O
by	O
the	O
addition	O
of	O
80	O
mM	O
testosterone	B
(	O
dissolved	O
in	O
methanol	B
)	O
.	O

After	O
10	O
min	O
,	O
the	O
reaction	O
was	O
stopped	O
with	O
the	O
addition	O
of	O
5	O
ml	O
ice	O
-	O
cold	O
dichloromethane	B
and	O
12	O
nmol	O
corticosterone	B
(	O
internal	O
standard	O
)	O
in	O
methanol	B
.	O

After	O
1	O
min	O
vortexing	O
,	O
phases	O
were	O
separated	O
by	O
centrifugation	O
at	O
2000	O
×	O
g	O
for	O
10	O
min	O
and	O
the	O
aqueous	O
phase	O
was	O
extracted	O
once	O
more	O
with	O
2	O
ml	O
dichloromethane	B
.	O

The	O
organic	O
phase	O
was	O
extracted	O
with	O
2	O
ml	O
0.02	O
N	O
NaOH	B
to	O
remove	O
lipid	B
constituents	O
,	O
dried	O
over	O
anhydrous	O
sodium	B
sulphate	I
and	O
transferred	O
to	O
a	O
small	O
tube	O
.	O

Dichloromethane	B
was	O
evaporated	O
at	O
37	O
°	O
C	O
under	O
nitrogen	B
and	O
the	O
dried	O
samples	O
stored	O
at	O
−20	O
°	O
C	O
.	O

The	O
samples	O
were	O
dissolved	O
in	O
100	O
μl	O
methanol	B
and	O
analyzed	O
by	O
high	O
performance	O
liquid	O
chromatography	O
[	O
21	O
]	O
.	O

2.3.2	O
HPLC	O
separation	O
and	O
quantification	O
Chromatographic	O
separations	O
were	O
performed	O
using	O
a	O
system	O
consisting	O
of	O
a	O
high	O
-	O
pressure	O
pump	O
(	O
Waters	B
Model	O
600E	O
,	O
Multisolvent	O
Delivery	O
System	O
)	O
,	O
a	O
sample	O
injection	O
valve	O
(	O
Rheodyne	O
Model	O
7121	O
,	O
Cotati	O
,	O
CA	O
)	O
with	O
a	O
20	O
μl	O
sample	O
loop	O
and	O
an	O
ultraviolet	O
detector	O
(	O
254	O
nm	O
,	O
Waters	B
Model	O
486	O
,	O
Tunable	O
Absorbance	O
Detector	O
)	O
connected	O
to	O
an	O
integrator	O
(	O
Millennium	O
2010	O
,	O
Chromatography	O
Manager	O
)	O
.	O

For	O
reverse	O
-	O
phase	O
separation	O
of	O
metabolites	B
,	O
NOVA	O
-	O
PACK	O
C18	O
analytical	O
column	O
(	O
60	O
Å	O
,	O
4	O
mm	O
,	O
3.9	O
×	O
150	O
mm	O
,	O
Waters	B
)	O
was	O
used	O
as	O
the	O
stationary	O
phase	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
a	O
mixture	O
of	O
solvent	O
A	O
(	O
7.5	O
%	O
(	O
v	O
/	O
v	O
)	O
tetrahydrofuran	B
in	O
water	B
)	O
and	O
solvent	O
B	O
(	O
7.5	O
%	O
(	O
v	O
/	O
v	O
)	O
tetrahydrofuran	B
and	O
60	O
%	O
(	O
v	O
/	O
v	O
)	O
methanol	B
in	O
water	B
)	O
at	O
a	O
1	O
ml	O
/	O
min	O
flow	O
rate	O
.	O

Metabolite	O
separation	O
was	O
performed	O
by	O
a	O
gradient	O
from	O
30	O
%	O
to	O
100	O
%	O
(	O
v	O
/	O
v	O
)	O
of	O
solvent	O
B	O
over	O
30	O
min	O
.	O

The	O
eluent	O
was	O
monitored	O
at	O
254	O
nm	O
and	O
the	O
area	O
under	O
the	O
absorption	O
band	O
was	O
integrated	O
.	O

The	O
concentration	O
of	O
metabolites	B
was	O
determined	O
by	O
the	O
ratio	O
between	O
respective	O
metabolite	B
peak	O
areas	O
and	O
corticosterone	B
(	O
internal	O
standard	O
)	O
and	O
the	O
calibration	O
curves	O
obtained	O
with	O
synthetic	B
testosterone	I
derivatives	I
[	O
22,23	O
]	O
.	O

2.4	O
Protein	O
concentrations	O
Protein	O
was	O
determined	O
according	O
to	O
the	O
method	O
described	O
by	O
Lowry	O
[	O
24	O
]	O
and	O
Bailey	O
[	O
25	O
]	O
,	O
using	O
bovine	O
serum	O
albumin	O
as	O
standard	O
.	O

Samples	O
were	O
diluted	O
200	O
times	O
to	O
provide	O
a	O
suitable	O
protein	O
concentration	O
.	O

2.5	O
Statistics	O
and	O
computer	O
analysis	O
Statistical	O
analysis	O
on	O
biochemical	O
data	O
was	O
performed	O
using	O
Wilcoxon	O
's	O
rank	O
method	O
as	O
reported	O
by	O
Box	O
and	O
Hunter	O
[	O
26	O
]	O
.	O

The	O
software	O
packages	O
used	O
were	O
Millennium	O
1.1	O
and	O
Windows	O
3.1	O
run	O
on	O
a	O
PC	O
486	O
IBM	O
-	O
compatible	O
computer	O
.	O

2.6	O
Electrophoresis	O
and	O
Western	O
immunoblot	O
Microsomes	O
from	O
both	O
control	O
and	O
DT	B
-	O
treated	O
mice	O
were	O
solubilized	O
in	O
SDS	B
and	O
resolved	O
by	O
PAGE	O
[	O
27,28	O
]	O
.	O

Western	O
blot	O
analysis	O
with	O
rabbit	O
polyclonal	O
antibodies	O
(	O
anti	O
-	O
CYP3A1	O
/	O
2	O
)	O
,	O
raised	O
against	O
purified	O
rat	O
hepatic	O
CYP3A	O
[	O
29	O
]	O
,	O
was	O
performed	O
using	O
hepatic	O
and	O
kidney	O
microsomes	O
(	O
0.025	O
mg	O
of	O
microsomal	O
protein	O
were	O
electrophoresed	O
each	O
time	O
)	O
and	O
visualized	O
with	O
4-chloro-1-naphthol	B
in	O
a	O
0.006	O
%	O
hydrogen	B
peroxide	I
solution	O
.	O

3	O
Results	O
The	O
expression	O
of	O
testosterone	O
hydroxylase	O
(	O
TH	O
)	O
activities	O
in	O
liver	O
microsomes	O
derived	O
from	O
male	O
and	O
female	O
mice	O
receiving	O
a	O
single	O
3	O
or	O
6	O
mg	O
/	O
kg	O
body	O
wt	O
.	O

dose	O
of	O
DT	B
is	O
shown	O
in	O
Table	O
1	O
.	O

In	O
males	O
DT	B
was	O
able	O
to	O
increase	O
(	O
mainly	O
at	O
the	O
lower	O
dose	O
)	O
the	O
different	O
TH	O
-	O
associated	O
activities	O
,	O
whereas	O
in	O
females	O
an	O
inactivating	O
effect	O
(	O
mainly	O
at	O
the	O
higher	O
dose	O
)	O
was	O
detected	O
.	O

At	O
the	O
lower	O
dose	O
,	O
all	O
TH	O
activities	O
were	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
from	O
∼2.8-fold	O
(	O
6β-	O
,	O
16α-	O
and	O
16β	O
-	O
TH	O
activities	O
)	O
to	O
16-fold	O
(	O
2β	O
-	O
TH	O
activity	O
)	O
in	O
males	O
.	O

In	O
particular	O
,	O
increases	O
of	O
6α-	O
(	O
3.7-fold	O
)	O
,	O
7α-	O
and	O
2α-	O
(	O
∼4.4-fold	O
)	O
and	O
17-TH	O
(	O
7.1-fold	O
)	O
activities	O
were	O
achieved	O
.	O

At	O
the	O
higher	O
dose	O
,	O
either	O
a	O
4-fold	O
increase	O
of	O
2β	O
-	O
TH	O
activity	O
or	O
a	O
65.2	O
%	O
reduction	O
of	O
16β	O
-	O
TH	O
activity	O
was	O
observed	O
.	O

In	O
females	O
an	O
inactivating	O
effect	O
was	O
observed	O
mainly	O
at	O
the	O
higher	O
dose	O
tested	O
.	O

A	O
reduction	O
ranging	O
from	O
about	O
35	O
%	O
(	O
7α-	O
and	O
17-TH	O
activities	O
,	O
higher	O
dose	O
,	O
and	O
16β	O
-	O
TH	O
activity	O
,	O
lower	O
dose	O
)	O
to	O
66.4	O
%	O
(	O
16β	O
-	O
TH	O
activity	O
,	O
higher	O
dose	O
)	O
was	O
recorded	O
in	O
females	O
.	O

A	O
52	O
%	O
suppression	O
was	O
seen	O
for	O
6α-	O
and	O
6β	O
-	O
TH	O
activities	O
at	O
higher	O
dose	O
,	O
whereas	O
a	O
42	O
%	O
loss	O
of	O
16α	O
-	O
TH	O
activity	O
(	O
averaged	O
between	O
two	O
doses	O
)	O
was	O
observed	O
.	O

In	O
kidney	O
,	O
DT	B
significantly	O
(	O
P	O
<	O
0.01	O
)	O
induced	O
6β	O
-	O
TH	O
activity	O
(	O
CYP3A	O
-	O
like	O
)	O
from	O
2.9-	O
to	O
4.8-fold	O
,	O
at	O
the	O
higher	O
and	O
lower	O
doses	O
,	O
respectively	O
,	O
and	O
2α	O
-	O
TH	O
activity	O
(	O
5.0-fold	O
)	O
at	O
the	O
lower	O
dose	O
in	O
male	O
mice	O
(	O
Table	O
2	O
)	O
.	O

However	O
,	O
in	O
females	O
16α-	O
,	O
2α	O
-	O
and	O
2β	O
-	O
TH	O
activities	O
were	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
reduced	O
up	O
to	O
50.2	O
%	O
(	O
2β	O
-	O
TH	O
activity	O
)	O
at	O
doses	O
of	O
either	O
3	O
or	O
6	O
mg	O
/	O
kg	O
body	O
wt	O
.	O

Expression	O
of	O
TH	O
activities	O
in	O
lung	O
microsomes	O
is	O
reported	O
in	O
Table	O
3	O
.	O

Both	O
16α-	O
and	O
2α	O
-	O
TH	O
activities	O
were	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
(	O
7.1-	O
and	O
29.3-fold	O
,	O
respectively	O
)	O
at	O
the	O
lower	O
dose	O
in	O
males	O
.	O

An	O
increase	O
of	O
2β	O
-	O
TH	O
activity	O
from	O
3.1-	O
to	O
7.0-fold	O
(	O
lower	O
and	O
higher	O
dose	O
,	O
respectively	O
)	O
was	O
achieved	O
in	O
females	O
.	O

Again	O
,	O
a	O
2-fold	O
increase	O
in	O
2α-	O
and	O
16α	O
-	O
hydroxylations	O
was	O
also	O
achieved	O
in	O
females	O
at	O
the	O
6	O
mg	O
/	O
kg	O
body	O
wt	O
.	O

dose	O
.	O

In	O
contrast	O
,	O
repeated	O
DT	B
administrations	O
(	O
3	O
mg	O
/	O
kg	O
body	O
wt	O
.	O
,	O
daily	O
for	O
3	O
consecutive	O
days	O
)	O
were	O
able	O
to	O
significantly	O
reduce	O
TH	O
activities	O
from	O
∼39	O
%	O
(	O
6β-	O
and	O
2α	O
-	O
TH	O
activities	O
)	O
to	O
∼60	O
%	O
(	O
16β-	O
and	O
2β	O
-	O
TH	O
activities	O
)	O
in	O
liver	O
microsomes	O
derived	O
from	O
male	O
animals	O
,	O
whereas	O
they	O
had	O
no	O
effect	O
in	O
females	O
(	O
Table	O
4	O
)	O
.	O

In	O
kidney	O
,	O
repeated	O
treatment	O
determined	O
a	O
generalized	O
increase	O
of	O
several	O
TH	O
-	O
dependent	O
monooxygenases	O
.	O

For	O
example	O
,	O
enhancements	O
of	O
7α-	O
(	O
4.8-fold	O
)	O
,	O
2α-	O
and	O
17-TH	O
(	O
3.1-fold	O
)	O
,	O
6β-	O
(	O
2.9-fold	O
)	O
as	O
well	O
as	O
2β	O
-	O
TH	O
(	O
2.8-fold	O
)	O
activities	O
were	O
recorded	O
in	O
males	O
(	O
Table	O
5	O
)	O
.	O

In	O
females	O
,	O
TH	O
activities	O
were	O
increased	O
from	O
2.8-	O
(	O
17-TH	O
activity	O
)	O
to	O
5.2-fold	O
(	O
2α	O
-	O
TH	O
activity	O
)	O
.	O

In	O
lung	O
,	O
an	O
increase	O
of	O
7α	O
-	O
TH	O
activity	O
(	O
7.9-	O
and	O
9.6-fold	O
,	O
males	O
and	O
females	O
,	O
respectively	O
)	O
was	O
observed	O
(	O
Table	O
6	O
)	O
.	O

DT	B
was	O
also	O
able	O
to	O
induce	O
6β-	O
and	O
2α	O
-	O
TH	O
activities	O
(	O
∼4.0-fold	O
)	O
,	O
2β	O
-	O
TH	O
(	O
4.6-fold	O
)	O
and	O
17-TH	O
activities	O
(	O
3.1-fold	O
)	O
in	O
males	O
,	O
whereas	O
2β-	O
,	O
16α-	O
and	O
16β	O
-	O
TH	O
activities	O
were	O
increased	O
up	O
to	O
2.3-fold	O
and	O
6β	O
-	O
TH	O
activity	O
up	O
to	O
1.8-fold	O
in	O
females	O
.	O

The	O
induction	O
of	O
the	O
CYP3A	O
-	O
dependent	O
monooxygenases	O
in	O
liver	O
and	O
kidney	O
microsomes	O
from	O
male	O
mice	O
treated	O
with	O
a	O
single	O
DT	B
dose	O
was	O
sustained	O
by	O
means	O
of	O
Western	O
immunoblotting	O
analysis	O
,	O
using	O
rabbit	O
polyclonal	O
antibodies	O
anti	O
CYP3A1	O
/	O
2	O
(	O
Fig.	O
2	O
)	O
.	O

The	O
signal	O
shows	O
that	O
the	O
amount	O
of	O
CYP3A	O
apoprotein	O
is	O
enhanced	O
after	O
exposure	O
to	O
the	O
lower	O
DT	B
dose	O
in	O
both	O
liver	O
(	O
lane	O
2	O
)	O
and	O
kidney	O
(	O
lane	O
4	O
)	O
with	O
respect	O
to	O
control	O
animals	O
(	O
lanes	O
3	O
and	O
5	O
)	O
,	O
due	O
to	O
increased	O
transcription	O
or	O
enzyme	O
stabilization	O
.	O

4	O
Discussion	O
In	O
investigating	O
whether	O
dithianon	B
was	O
able	O
to	O
interfere	O
with	O
non	O
-	O
genotoxic	O
mechanisms	O
,	O
changes	O
in	O
murine	O
CYP	O
isoforms	O
in	O
different	O
organs	O
of	O
both	O
sexes	O
were	O
detected	O
using	O
testosterone	O
hydroxylase	O
as	O
a	O
multibiomarker	O
of	O
effects	O
[	O
30	O
]	O
.	O

Testosterone	B
,	O
indeed	O
,	O
is	O
an	O
excellent	O
indicator	O
substrate	O
for	O
analysis	O
of	O
CYP	O
expression	O
,	O
since	O
it	O
undergoes	O
stereo-	O
and	O
regio	O
-	O
selective	O
hydroxylations	O
catalyzed	O
by	O
a	O
wide	O
variety	O
of	O
different	O
CYP	O
isozymes	O
[	O
19	O
]	O
.	O

Literature	O
shows	O
that	O
pesticides	B
are	O
,	O
in	O
general	O
,	O
poor	O
initiating	O
agents	O
and	O
their	O
carcinogenic	O
activity	O
is	O
due	O
mainly	O
to	O
epigenetic	O
mechanisms	O
.	O

In	O
the	O
present	O
investigation	O
we	O
,	O
therefore	O
,	O
considered	O
the	O
potentiality	O
of	O
DT	B
to	O
behave	O
as	O
a	O
toxic	O
/	O
co	O
-	O
toxic	O
co	O
-	O
carcinogen	O
and	O
promoter	O
by	O
means	O
of	O
the	O
ability	O
of	O
this	O
fungicide	B
to	O
affect	O
CYP	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
aforementioned	O
detrimental	O
phenomena	O
,	O
taken	O
together	O
,	O
can	O
increase	O
the	O
toxicological	O
risk	O
independently	O
of	O
the	O
possible	O
initiating	O
properties	O
of	O
the	O
chemical	O
.	O

DT	B
exhibited	O
a	O
complex	O
pattern	O
of	O
CYP	O
modulation	O
,	O
typical	O
of	O
pesticides	B
that	O
are	O
either	O
substrates	O
,	O
inducers	O
or	O
inhibitors	O
of	O
different	O
CYPs	O
.	O

Both	O
induction	O
and	O
suppression	O
may	O
be	O
isozyme-	O
,	O
organ-	O
and	O
sex	O
-	O
specific	O
,	O
and	O
different	O
CYPs	O
may	O
be	O
affected	O
in	O
different	O
ways	O
by	O
the	O
same	O
chemical	O
under	O
different	O
conditions	O
[	O
31–34	O
]	O
.	O

Results	O
show	O
that	O
DT	B
was	O
able	O
to	O
induce	O
or	O
suppress	O
various	O
CYPs	O
in	O
Swiss	O
albino	O
CD1	O
mice	O
depending	O
on	O
sex	O
and	O
organ	O
;	O
after	O
a	O
single	O
treatment	O
males	O
were	O
more	O
responsive	O
to	O
induction	O
in	O
all	O
organs	O
(	O
liver	O
,	O
kidney	O
and	O
lung	O
)	O
whereas	O
females	O
were	O
responsive	O
to	O
either	O
suppression	O
(	O
liver	O
and	O
kidney	O
)	O
or	O
induction	O
(	O
lung	O
)	O
.	O

In	O
contrast	O
,	O
after	O
repeated	O
injections	O
DT	B
was	O
able	O
to	O
decrease	O
various	O
CYP	O
activities	O
in	O
male	O
liver	O
but	O
to	O
increase	O
them	O
in	O
kidney	O
and	O
lung	O
of	O
both	O
sexes	O
.	O

An	O
interesting	O
result	O
was	O
the	O
selective	O
induction	O
(	O
sustained	O
by	O
immunoblotting	O
analysis	O
)	O
and	O
suppression	O
of	O
the	O
CYP3A	O
isoform	O
,	O
confirming	O
previous	O
data	O
where	O
aminopyrine	B
was	O
used	O
as	O
the	O
preferential	O
CYP3A	O
probe	O
[	O
2	O
]	O
.	O

This	O
is	O
of	O
great	O
importance	O
because	O
CYP3A	O
isoform	O
is	O
the	O
most	O
abundant	O
cytochrome	O
present	O
in	O
human	O
liver	O
.	O

Modulation	O
of	O
the	O
different	O
CYP	O
isozymes	O
could	O
be	O
explained	O
by	O
considering	O
the	O
possible	O
competition	O
of	O
individual	O
CYPs	O
for	O
reductase	O
[	O
35	O
]	O
,	O
the	O
direct	O
inhibiting	O
effects	O
of	O
DT	B
or	O
the	O
direct	O
toxicity	O
derived	O
from	O
CYP	O
induction	O
per	O
se	O
[	O
16,36	O
]	O
.	O

It	O
is	O
possible	O
that	O
the	O
different	O
levels	O
of	O
testosterone	B
metabolites	B
in	O
the	O
various	O
organs	O
reflect	O
the	O
balance	O
between	O
induction	O
and	O
toxicity	O
[	O
20	O
]	O
.	O

The	O
observed	O
different	O
expressions	O
between	O
the	O
various	O
tissues	O
and	O
sexes	O
could	O
imply	O
:	O
(	O
a	O
)	O
different	O
induction	O
mechanisms	O
;	O
(	O
b	O
)	O
alteration	O
in	O
competing	O
pathways	O
involved	O
in	O
the	O
disposition	O
of	O
either	O
parent	B
compound	I
and	O
metabolite	B
;	O
(	O
c	O
)	O
differences	O
in	O
substrate	O
specificity	O
;	O
CYPs	O
coming	O
from	O
different	O
organs	O
can	O
elicit	O
different	O
metabolic	O
responses	O
[	O
20	O
]	O
due	O
to	O
different	O
substrate	O
specificity	O
.	O

The	O
observed	O
sex	O
differences	O
in	O
enzyme	O
modulation	O
(	O
induction	O
in	O
males	O
,	O
suppression	O
in	O
females	O
)	O
could	O
be	O
explained	O
in	O
terms	O
of	O
quantitative	O
or	O
qualitative	O
differences	O
in	O
the	O
CYPs	O
under	O
control	O
of	O
the	O
sex	O
hormones	B
.	O

DT	B
appears	O
to	O
affect	O
a	O
unique	O
spectrum	O
of	O
isozymes	O
in	O
mice	O
;	O
the	O
complex	O
pattern	O
of	O
induction	O
and	O
suppression	O
of	O
CYP	O
isoforms	O
has	O
potentially	O
significant	O
toxicological	O
consequences	O
,	O
increasing	O
or	O
in	O
some	O
instances	O
reducing	O
the	O
bioactivation	O
of	O
specific	O
xenobiotics	B
,	O
and	O
co	O
-	O
administered	O
drugs	B
,	O
as	O
well	O
as	O
a	O
profound	O
effect	O
on	O
endogenous	O
metabolism	O
and	O
cellular	O
functions	O
[	O
37	O
]	O
.	O

CYP	O
induction	O
can	O
also	O
determine	O
an	O
overproduction	O
of	O
oxygen	B
centred	I
radicals	I
,	O
due	O
to	O
the	O
autooxidation	O
of	O
the	O
CYP	O
-	O
Fe	O
2	O
+	O
-O2	O
−	O
complex	O
[	O
16,36	O
]	O
,	O
and	O
a	O
pleitropic	O
response	O
,	O
with	O
the	O
increase	O
of	O
either	O
phase	O
I	O
,	O
phase	O
II	O
or	O
other	O
enzymes	O
[	O
10	O
]	O
,	O
correlated	O
to	O
both	O
co	O
-	O
carcinogenic	O
and	O
promoting	O
properties	O
[	O
38,39	O
]	O
.	O

It	O
is	O
significant	O
that	O
a	O
cell	O
transforming	O
activity	O
on	O
BALB	O
/	O
c	O
3T3	O
cells	O
induced	O
by	O
DT	B
was	O
found	O
by	O
Perocco	O
et	O
al.	O
[	O
4	O
]	O
.	O

Taken	O
as	O
a	O
whole	O
,	O
the	O
aforementioned	O
toxicological	O
properties	O
of	O
DT	B
indicate	O
that	O
a	O
potential	O
risk	O
could	O
be	O
associated	O
with	O
human	O
exposure	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Research	O
Council	O
of	O
Italy	O
(	O
CNR	O
)	O
,	O
by	O
the	O
Ministry	O
of	O
the	O
University	O
and	O
of	O
Scientific	O
and	O
Technological	O
Research	O
(	O
MURST	O
ex	O
40	O
%	O
and	O
60	O
%	O
)	O
and	O
by	O
Interuniversitary	O
Biotechnology	O
Center	O
(	O
CIB	O
)	O
Bologna	O
,	O
grants	O
.	O

Enterobacteria	O
of	O
the	O
genus	O

Proteus	O
are	O
a	O
common	O
cause	O
of	O
urinary	O
tract	O
infections	O
in	O
human	O
,	O
which	O
often	O
result	O
in	O
severe	O
complications	O
,	O
such	O
as	O
pyelonephritis	O
and	O
formation	O
of	O
bladder	O
and	O
kidney	O
stones	O
[	O
1	O
]	O
.	O

Lipopolysaccharide	B
(	O
LPS	B
,	O
endotoxin	B
)	O
is	O
considered	O
as	O
one	O
of	O
the	O
virulence	O
factors	O
of	O
Proteus	O
which	O
,	O
after	O
being	O
released	O
from	O
bacterial	O
cells	O
,	O
mediates	O
the	O
infectious	O
processes	O
[	O
1,2	O
]	O
.	O

The	O
LPS	B
consists	O
of	O
three	O
moieties	O
:	O
a	O
lipid	B
part	O
(	O
lipid	B
A	I
)	O
which	O
anchors	O
LPS	B
into	O
the	O
outer	O
membrane	O
and	O
is	O
responsible	O
for	O
the	O
endotoxicity	O
of	O
the	O
LPS	B
,	O
an	O
oligosaccharide	B
core	O
region	O
,	O
and	O
an	O
O	B
-	I
specific	I
polysaccharide	I
chain	O
(	O
OPS	B
,	O
O	B
-	I
antigen	I
)	O
which	O
defines	O
the	O
immunospecificity	O
of	O
the	O
bacterium	O
.	O

On	O
the	O
basis	O
of	O
the	O
O	B
-	I
antigens	I
,	O
strains	O
of	O
Proteus	O
are	O
classified	O
serologically	O
into	O
more	O
than	O
60	O
serogroups	O
[	O
3–5	O
]	O
.	O

A	O
serological	O
cross	O
-	O
reactivity	O
was	O
observed	O
for	O
strains	O
of	O
different	O
serogroups	O
[	O
5	O
]	O
,	O
thus	O
showing	O
that	O
the	O
existing	O
serogrouping	O
scheme	O
does	O
not	O
reflect	O
all	O
,	O
but	O
major	O
,	O
antigenic	O
relationships	O
between	O
Proteus	O
strains	O
.	O

Immunochemical	O
studies	O
of	O
LPSs	B
are	O
important	O
for	O
substantiation	O
of	O
the	O
serological	O
cross	O
-	O
reactivity	O
of	O
strains	O
on	O
the	O
molecular	O
level	O
and	O
for	O
improvement	O
of	O
the	O
classification	O
of	O
Proteus	O
on	O
the	O
chemical	O
basis	O
.	O

In	O
the	O
LPSs	B
of	O
most	O
Proteus	O
strains	O
studied	O
,	O
the	O
OPSs	B
are	O
acidic	O
due	O
to	O
the	O
presence	O
of	O
various	O
acidic	B
sugars	I
and	O
non	B
-	I
sugar	I
components	I
;	O
a	O
few	O
strains	O
of	O
Proteus	O
vulgaris	O
and	O
Proteus	O
penneri	O
have	O
neutral	O
OPSs	B
[	O
5	O
]	O
.	O

Now	O
,	O
we	O
report	O
the	O
structures	O
of	O
the	O
OPSs	B
of	O
two	O
serologically	O
cross	O
-	O
reactive	O
strains	O
of	O
Proteus	O
mirabilis	O
belonging	O
to	O
serogroups	O
O24	O
and	O
O29	O
.	O

Strains	O
of	O
these	O
serogroups	O
are	O
frequent	O
among	O
isolates	O
from	O
clinical	O
specimens	O
[	O
3	O
]	O
and	O
were	O
confirmed	O
in	O
this	O
work	O
to	O
play	O
a	O
role	O
in	O
human	O
pathology	O
.	O

Immunochemical	O
studies	O
of	O
the	O
OPSs	B
and	O
LPSs	B
were	O
performed	O
in	O
order	O
to	O
reveal	O
the	O
epitope	O
specificity	O
of	O
the	O
cross	O
-	O
reactive	O
anti	O
-	O
LPS	O
antibodies	O
.	O

Part	O
of	O
the	O
data	O
of	O
P.	O
mirabilis	O
O24	O
has	O
been	O
reported	O
[	O
6	O
]	O
.	O

2	O
Material	O
and	O
methods	O
2.1	O
Bacterial	O
strains	O
,	O
isolation	O
and	O
degradation	O
of	O
the	O
LPSs	B
P.	O
mirabilis	O
O24	O
and	O
O29	O
(	O
strains	O
PrK	O
47	O
/	O
57	O
and	O
52	O
/	O
57	O
,	O
respectively	O
)	O
came	O
from	O
the	O
Czech	O
National	O
Collection	O
of	O
Type	O
Cultures	O
(	O
Institute	O
of	O
Epidemiology	O
and	O
Microbiology	O
,	O
Prague	O
)	O
.	O

The	O
LPSs	B
were	O
isolated	O
using	O
the	O
phenol	B
-	O
water	B
procedure	O
[	O
7	O
]	O
and	O
purified	O
by	O
treatment	O
with	O
DNAse	O
and	O
RNAse	O
(	O
Sigma	O
,	O
USA	O
)	O
and	O
ultracentrifugation	O
as	O
described	O
[	O
7,8	O
]	O
.	O

The	O
isolated	O
LPSs	B
were	O
essentially	O
free	O
of	O
nucleic	B
acids	I
and	O
contained	O
<	O
2	O
%	O
proteins	O
.	O

Delipidation	O
of	O
the	O
LPSs	B
was	O
performed	O
with	O
aqueous	O
2	O
%	O
acetic	B
acid	I
at	O
100	O
°	O
C	O
,	O
the	O
precipitate	O
was	O
removed	O
by	O
centrifugation	O
(	O
13	O
000	O
×	O
g	O
,	O
20	O
min	O
)	O
,	O
and	O
the	O
supernatant	O
was	O
fractionated	O
on	O
a	O
column	O
(	O
2.5	O
×	O
65	O
cm	O
)	O
of	O
Sephadex	O
G-50	O
(	O
Pharmacia	O
,	O
Sweden	O
)	O
in	O
0.05	O
M	O
pyridinium	B
acetate	I
buffer	O
pH	O
4.5	O
with	O
monitoring	O
by	O
a	O
Knauer	O
differential	O
refractometer	O
(	O
Germany	O
)	O
to	O
give	O
the	O
corresponding	O
high	O
molecular	O
mass	O
OPS	B
and	O
core	O
oligosaccharide	B
fractions	O
.	O

Alkali	B
-	O
treated	O
LPSs	B
were	O
prepared	O
by	O
saponification	O
of	O
the	O
LPSs	B
with	O
aqueous	O
0.25	O
M	O
NaOH	B
(	O
56	O
°	O
C	O
,	O
2	O
h	O
)	O
.	O

Smith	O
degradation	O
of	O
the	O
alkali	B
-	O
treated	O
LPS	B
from	O
P.	O
mirabilis	O
O24	O
was	O
performed	O
with	O
0.1	O
M	O
NaIO4	B
(	O
20	O
°	O
C	O
,	O
48	O
h	O
,	O
in	O
the	O
dark	O
)	O
,	O
the	O
resultant	O
product	O
was	O
reduced	O
with	O
NaBH4	B
and	O
desalted	O
on	O
Sephadex	O
G-50	O
.	O

2.2	O
NMR	O
spectroscopy	O
NMR	O
spectra	O
were	O
recorded	O
with	O
a	O
Bruker	O
DRX-500	O
spectrometer	O
for	O
a	O
solution	O
in	O
D2	B
O	I
at	O
30	O
or	O
60	O
°	O
C	O
using	O
internal	O
acetone	B
(	O
δH	O
2.225	O
,	O
δC	O
31.45	O
)	O
as	O
reference	O
.	O

Standard	O
Bruker	O
software	O
(	O
XWINNMR	O
1.2	O
)	O
was	O
used	O
to	O
acquire	O
and	O
maintain	O
the	O
NMR	O
data	O
.	O

A	O
mixing	O
time	O
of	O
200	O
and	O
100	O
ms	O
was	O
used	O
in	O
two	O
-	O
dimensional	O
TOCSY	O
and	O
NOESY	O
experiments	O
with	O
P.	O
mirabilis	O
O29	O
OPS	B
,	O
respectively	O
,	O
or	O
300	O
ms	O
in	O
a	O
NOESY	O
experiment	O
with	O
P.	O
mirabilis	O
O24	O
OPS	B
.	O

The	O
1	O
H-	O
and	O
13	O
C	O
-	O
NMR	O
spectra	O
were	O
assigned	O
using	O
two	O
-	O
dimensional	O
COSY	O
,	O
TOCSY	O
,	O
and	O
H	O
-	O
detected	O
1	O
H,13	O
C	O
heteronuclear	O
multiple	O
-	O
quantum	O
coherence	O
(	O
HMQC	O
)	O
experiments	O
.	O

The	O
assignment	O
of	O
β	O
-	O
linked	O
sugars	B
was	O
confirmed	O
making	O
use	O
of	O
intraresidue	O
H1	O
/	O
H3	O
,	O
H5	O
correlations	O
revealed	O
by	O
a	O
NOESY	O
experiment	O
.	O

Spin	O
systems	O
of	O
monosaccharides	B
were	O
identified	O
based	O
on	O
the	O
typical	O
3	O
J	O
H	O
,	O
H	O
coupling	O
constant	O
values	O
.	O

Amino	B
sugars	I
were	O
distinguished	O
by	O
correlations	O
of	O
protons	O
at	O
carbons	B
bearing	O
nitrogen	B
to	O
the	O
corresponding	O
carbons	B
at	O
δ	O
50–57	O
,	O
which	O
were	O
revealed	O
by	O
a	O
1	O
H,13	O
C	O
HMQC	O
experiment	O
.	O

2.3	O
Sugar	B
analysis	O
The	O
OPSs	B
were	O
hydrolyzed	O
with	O
2	O
M	O
CF3	B
COOH	I
(	O
120	O
°	O
C	O
,	O
2	O
h	O
)	O
or	O
methanolyzed	B
with	O
1	O
M	O
HCl	B
/	O
MeOH	B
(	O
80	O
°	O
C	O
,	O
16	O
h	O
)	O
.	O

Amino	B
sugars	I
were	O
identified	O
on	O
a	O
Biotronik	O
LC-2000	O
amino	B
acid	I
analyser	O
(	O
Germany	O
)	O
equipped	O
with	O
a	O
column	O
(	O
0.4	O
×	O
22	O
cm	O
)	O
of	O
a	O
Ostion	O
LG	O
AN	O
B	O
cation	B
-	I
exchange	I
resin	I
using	O
0.35	O
M	O
sodium	B
citrate	I
buffer	O
pH	O
5.28	O
at	O
80	O
°	O
C	O
.	O

Neutral	B
sugars	I
were	O
analysed	O
with	O
a	O
Biotronik	O
LC-2000	O
sugar	B
analyser	O
,	O
using	O
a	O
column	O
(	O
0.4	O
×	O
15	O
cm	O
)	O
of	O
a	O
Dionex	O
A	O
×	O
8–11	O
anion	B
-	I
exchange	I
resin	I
and	O
0.5	O
M	O
sodium	B
borate	I
buffer	O
pH	O
8.0	O
at	O
65	O
°	O
C	O
.	O

Uronic	B
acids	I
were	O
analysed	O
by	O
GLC	O
as	O
acetylated	B
methyl	I
glycosides	I
using	O
a	O
Hewlett	O
-	O
Packard	O
Model	O
5890	O
chromatograph	O
with	O
an	O
Ultra	O
2	O
capillary	O
column	O
and	O
a	O
temperature	O
gradient	O
of	O
160	O
°	O
C	O
(	O
1	O
min	O
)	O
to	O
290	O
°	O
C	O
at	O
10	O
°	O
C	O
/	O
min	O
.	O

The	O
absolute	O
configurations	O
of	O
monosaccharides	B
were	O
determined	O
by	O
GLC	O
of	O
acetylated	B
(	I
S	I
)	I
-2-butyl	I
glycosides	I
according	O
to	O
the	O
published	O
method	O
[	O
9,10	O
]	O
modified	O
as	O
described	O
[	O
11	O
]	O
.	O

2.4	O
Preparation	O
of	O
sera	O
and	O
serological	O
assays	O
Rabbit	O
antisera	O
against	O
surface	O
heat	O
-	O
stabile	O
antigens	B
of	O
Proteus	O
were	O
obtained	O
as	O
described	O
[	O
12	O
]	O
.	O

Briefly	O
,	O
a	O
New	O
Zealand	O
rabbit	O
received	O
i.v	O
.	O

increasing	O
doses	O
of	O
heat	O
killed	O
bacteria	O
on	O
days	O
0	O
,	O
4	O
,	O
7	O
and	O
11	O
.	O

On	O
day	O
15	O
,	O
20	O
ml	O
blood	O
was	O
taken	O
by	O
cardiac	O
puncture	O
and	O
early	O
serum	O
was	O
prepared	O
.	O

After	O
a	O
single	O
booster	O
injection	O
on	O
day	O
50	O
,	O
the	O
rabbit	O
was	O
extinguished	O
on	O
day	O
58	O
to	O
give	O
late	O
serum	O
.	O

Unless	O
stated	O
otherwise	O
,	O
the	O
data	O
of	O
early	O
serum	O
are	O
given	O
.	O

Human	O
sera	O
were	O
collected	O
from	O
healthy	O
individuals	O
or	O
hospitalised	O
patients	O
who	O
gave	O
informed	O
consent	O
.	O

ELISA	O
and	O
passive	O
hemolysis	O
(	O
PH	O
)	O
were	O
performed	O
essentially	O
as	O
described	O
[	O
12	O
]	O
.	O

In	O
ELISA	O
,	O
human	O
or	O
rabbit	O
sera	O
were	O
dispensed	O
to	O
plates	O
containing	O
antigens	B
(	O
LPS	B
or	O
Proteus	O
whole	O
cells	O
)	O
,	O
and	O
fixed	O
antibodies	O
were	O
quantified	O
with	O
horseradish	B
peroxidase	I
-	O
conjugated	O
goat	O
anti	O
-	O
human	O
or	O
anti	O
-	O
rabbit	O
IgG	O
(	O
Sigma	O
)	O
.	O

Proteinase	O
K-	O
(	O
Sigma	O
)	O
treated	O
whole	O
bacterial	O
cells	O
or	O
LPSs	B
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
according	O
to	O
Laemmli	O
[	O
13	O
]	O
.	O

The	O
gels	O
were	O
silver	B
-	O
stained	O
according	O
to	O
Tsai	O
and	O
Frasch	O
[	O
14	O
]	O
or	O
electroblotted	O
onto	O
nitrocellulose	B
plates	O
(	O
Shleicher	O
and	O
Schull	O
,	O
Germany	O
)	O
,	O
which	O
were	O
incubated	O
with	O
diluted	O
(	O
1:100	O
)	O
immune	O
rabbit	O
sera	O
as	O
primary	O
antibodies	O
and	O
then	O
with	O
horseradish	O
peroxidase	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
(	O
Sigma	O
)	O
as	O
secondary	O
antibodies	O
[	O
15	O
]	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Elucidation	O
of	O
the	O
structure	O
of	O
the	O
OPS	B
of	O
P.	O
mirabilis	O
O24	O
Sugar	B
analysis	O
of	O
the	O
OPS	B
after	O
full	O
acid	B
hydrolysis	O
,	O
including	O
determination	O
of	O
the	O
absolute	O
configurations	O
of	O
monosaccharides	B
,	O
revealed	O
2-amino-2-deoxy	B
-	I
D	I
-glucose	I
and	O
2-amino-2-deoxy	B
-	I
D	I
-galactose	I
in	O
the	O
ratio	O
2:1	O
,	O
as	O
well	O
as	O
D	B
-galactose	I
.	O

The	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
OPS	B
[	O
6	O
]	O
(	O
Table	O
1	O
)	O
contained	O
signals	O
for	O
four	O
anomeric	O
carbons	B
in	O
the	O
region	O
δ	O
102.5–106.6	O
,	O
three	O
carbons	B
linked	O
to	O
nitrogen	B
(	O
C2	O
of	O
hexosamines	B
)	O
in	O
the	O
region	O
δ	O
53.0–56.2	O
,	O
four	O
HOC	O
H2	O
-C	O
groups	O
(	O
C6	O
of	O
galactose	B
and	O
hexosamines	B
)	O
at	O
δ	O
61.4–62.4	O
,	O
13	O
other	O
sugar	B
ring	O
carbons	B
in	O
the	O
region	O
δ	O
69.9–82.8	O
,	O
and	O
three	O
N	B
-acetyl	I
groups	I
at	O
δ	O
23.6–23.9	O
(	O
CH3	O
)	O
and	O
δ	O
175.4–175.7	O
(	O
CO	O
)	O
.	O

Accordingly	O
,	O
the	O
1	O
H	O
-	O
NMR	O
spectrum	O
of	O
the	O
OPS	B
(	O
Table	O
1	O
)	O
contained	O
,	O
inter	O
alia	O
,	O
signals	O
for	O
four	O
anomeric	O
protons	O
in	O
the	O
region	O
δ	O
4.44–4.91	O
and	O
three	O
N	B
-acetyl	I
groups	I
at	O
δ	O
2.04	O
(	O
6H	O
)	O
and	O
2.09	O
(	O
3H	O
)	O
.	O

Therefore	O
,	O
the	O
OPS	B
is	O
composed	O
of	O
tetrasaccharide	B
repeating	O
units	O
containing	O
one	O
residue	O
each	O
of	O
D	B
-galactose	I
and	O
2-acetamido-2-deoxy	B
-	I
D	I
-glucose	I
,	O
and	O
two	O
residues	O
of	O
2-acetamido-2-deoxy	B
-	I
D	I
-galactose	I
.	O

Relatively	O
large	O
coupling	O
constant	O
values	O
of	O
J	O
1,2	O
7–8	O
Hz	O
,	O
determined	O
from	O
the	O
1	O
H	O
-	O
NMR	O
spectrum	O
of	O
the	O
OPS	B
,	O
showed	O
that	O
all	O
monosaccharide	B
residues	O
are	O
in	O
the	O
pyranose	B
form	O
and	O
β	O
-	O
linked	O
.	O

In	O
the	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
OPS	B
,	O
the	O
positions	O
of	O
the	O
signals	O
for	O
C2–C6	O
of	O
Gal	B
at	O
δ	O
72.2	O
,	O
74.2	O
,	O
69.9	O
,	O
76.1	O
,	O
and	O
62.4	O
(	O
or	O
62.0	O
)	O
,	O
respectively	O
,	O
were	O
close	O
to	O
those	O
of	O
non	O
-	O
substituted	O
β	B
-	I
Galp	I
[	O
16	O
]	O
and	O
,	O
hence	O
,	O
Gal	B
occupies	O
the	O
terminal	O
position	O
in	O
the	O
side	O
chain	O
.	O

As	O
a	O
result	O
of	O
the	O
glycosylation	O
,	O
the	O
signals	O
for	O
C4	O
of	O
one	O
of	O
the	O
GlcNAc	B
residues	O
(	O
GlcNAcI	B
)	O
,	O
C3	O
of	O
the	O
other	O
residue	O
(	O
GlcNAcII	B
)	O
,	O
C3	O
and	O
C4	O
of	O
GalNAc	B
were	O
shifted	O
downfield	O
to	O
δ	O
81.0	O
,	O
82.8	O
,	O
81.8	O
,	O
and	O
75.6	O
,	O
respectively	O
,	O
compared	O
to	O
their	O
positions	O
in	O
the	O
spectra	O
of	O
the	O
corresponding	O
non	O
-	O
substituted	O
monosaccharides	B
[	O
16	O
]	O
.	O

These	O
data	O
showed	O
that	O
the	O
OPS	B
is	O
branched	O
and	O
allowed	O
determination	O
of	O
the	O
positions	O
of	O
substitution	O
of	O
the	O
monosaccharides	B
.	O

The	O
NOESY	O
spectrum	O
of	O
the	O
OPS	B
contained	O
interresidue	O
cross	O
-	O
peaks	O
between	O
the	O
following	O
protons	O
:	O
Gal	B
H1	O
/	O
GalNAc	B
H3	O
(	O
strong	O
)	O
and	O
H4	O
(	O
weak	O
)	O
,	O
GalNAc	B
H1	O
/	O
GlcNAcI	B
H4	O
,	O
GlcNAcI	B
H1	O
/	O
GlcNAcII	B
H3	O
,	O
and	O
GlcNAcII	B
H1	O
/	O
GalNAc	B
H4	O
(	O
strong	O
)	O
,	O
H3	O
and	O
H5	O
(	O
both	O
weak	O
)	O
.	O

These	O
data	O
confirmed	O
the	O
positions	O
of	O
substitution	O
of	O
the	O
monosaccharide	B
residues	O
,	O
showed	O
that	O
GlcNAcII	B
and	O
Gal	B
are	O
attached	O
to	O
GalNAc	B
at	O
positions	O
4	O
and	O
3	O
,	O
respectively	O
,	O
and	O
allowed	O
determination	O
of	O
the	O
full	O
monosaccharide	B
sequence	O
in	O
the	O
repeating	O
unit	O
.	O

Therefore	O
,	O
the	O
OPS	B
of	O
P.	O
mirabilis	O
O24	O
,	O
which	O
is	O
the	O
first	O
neutral	O
OPS	B
found	O
in	O
this	O
species	O
,	O
has	O
the	O
following	O
structure	O
:	O
3.2	O
Elucidation	O
of	O
the	O
structure	O
of	O
the	O
OPS	B
of	O
P.	O
mirabilis	O
O29	O
Sugar	B
analysis	O
showed	O
the	O
presence	O
of	O
2-amino-2-deoxy	B
-	I
D	I
-galactose	I
and	O
D	B
-glucuronic	I
acid	I
(	O
D	B
-GlcA	I
)	O
as	O
components	O
of	O
the	O
OPS	B
.	O

The	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
OPS	B
(	O
Fig.	O
1	O
,	O
Table	O
1	O
)	O
was	O
typical	O
of	O
a	O
regular	O
polymer	B
.	O

It	O
contained	O
signals	O
for	O
four	O
anomeric	O
carbons	B
at	O
δ	O
96.2–105.0	O
,	O
three	O
HOC	O
H2	O
-C	O
groups	O
(	O
C6	O
of	O
GalN	B
)	O
at	O
δ	O
61.9	O
,	O
three	O
carbons	B
bearing	O
nitrogen	B
(	O
C2	O
of	O
GalN	B
)	O
at	O
δ	O
50.5	O
,	O
51.5	O
and	O
53.8	O
,	O
13	O
other	O
sugar	B
ring	O
carbons	B
at	O
δ	O
68.6–81.5	O
,	O
and	O
N	B
-acetyl	I
groups	I
(	O
CH3	O
at	O
δ	O
23.6	O
,	O
CO	O
at	O
δ	O
175.2–176.2	O
)	O
.	O

Accordingly	O
,	O
the	O
1	O
H	O
-	O
NMR	O
spectrum	O
(	O
Table	O
1	O
)	O
contained	O
signals	O
for	O
four	O
anomeric	O
protons	O
at	O
δ	O
4.52–5.08	O
,	O
other	O
signals	O
of	O
sugar	B
ring	O
protons	O
at	O
δ	O
3.41–4.44	O
,	O
and	O
three	O
N	B
-acetyl	I
groups	I
at	O
δ	O
2.06–2.10	O
.	O

Therefore	O
,	O
the	O
OPS	B
has	O
a	O
tetrasaccharide	B
repeating	O
unit	O
containing	O
three	O
residues	O
of	O
2-acetamido-2-deoxy	B
-	I
D	I
-galactose	I
and	O
one	O
residue	O
of	O
D	B
-glucuronic	I
acid	I
.	O

The	O
coupling	O
constant	O
value	O
of	O
J	O
1,2	O
3	O
Hz	O
indicated	O
that	O
one	O
of	O
the	O
GalNAc	B
residues	O
(	O
GalNAcI	B
)	O
is	O
α	O
-	O
linked	O
,	O
whereas	O
the	O
values	O
of	O
J	O
1,2	O
8	O
Hz	O
showed	O
that	O
GlcA	B
and	O
two	O
other	O
GalNAc	B
residues	O
(	O
GalNAcII	B
and	O
GalNAcIII	B
)	O
are	O
β	O
-	O
linked	O
.	O

The	O
NOESY	O
spectrum	O
showed	O
GalNAcIII	B
H1	O
/	O
GalNAcII	B
H4	O
and	O
GalNAcII	B
H1	O
/	O
GlcA	B
H4	O
interresidue	O
cross	O
-	O
peaks	O
,	O
thus	O
demonstrating	O
a	O
GalNAcIII	B
(	I
1→4	I
)	I
GalNAcII	I
(	I
1→4	I
)	I
GlcA	I
sequence	O
.	O

H1	O
of	O
GalNAcI	B
gave	O
two	O
interresidue	O
cross	O
-	O
peaks	O
,	O
with	O
H3	O
and	O
H4	O
of	O
GalNAcII	B
,	O
that	O
is	O
typical	O
of	O
α-	B
(	I
1→3	I
)	I
-linked	I
disaccharides	I
with	O
the	O
same	O
absolute	O
configuration	O
of	O
the	O
constituent	O
monosaccharides	B
[	O
17	O
]	O
.	O

Likewise	O
,	O
H1	O
of	O
GlcA	B
gave	O
two	O
cross	O
-	O
peaks	O
with	O
H3	O
and	O
H4	O
of	O
GalNAcIII	B
.	O

In	O
the	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
OPS	B
,	O
the	O
positions	O
of	O
the	O
signals	O
for	O
C2–C6	O
of	O
GalNAcI	B
at	O
δ	O
50.5	O
,	O
68.6	O
,	O
69.4	O
,	O
72.1	O
,	O
and	O
61.9	O
,	O
respectively	O
,	O
were	O
typical	O
of	O
the	O
non	O
-	O
substituted	O
α	B
-	I
Galp	I
NAc	I
[	O
16	O
]	O
.	O

Relatively	O
low	O
-	O
field	O
positions	O
of	O
the	O
signals	O
for	O
C3	O
of	O
GalNAcIII	B
and	O
C4	O
of	O
GlcA	B
at	O
δ	O
79.2	O
and	O
81.5	O
,	O
as	O
compared	O
with	O
those	O
in	O
non	O
-	O
substituted	O
β	B
-	I
Galp	I
NAc	I
and	O
β	B
-	I
Glcp	I
A	I
[	O
16	O
]	O
,	O
resulted	O
from	O
the	O
substitution	O
at	O
O3	O
and	O
O4	O
,	O
respectively	O
.	O

Taking	O
into	O
account	O
the	O
NOESY	O
data	O
,	O
one	O
could	O
conclude	O
that	O
GlcA	B
is	O
attached	O
to	O
GalNAcIII	B
at	O
position	O
3	O
.	O

Of	O
the	O
signals	O
for	O
C3	O
and	O
C4	O
of	O
GalNAcII	B
,	O
only	O
that	O
for	O
C3	O
was	O
shifted	O
,	O
as	O
expected	O
,	O
downfield	O
to	O
δ	O
77.3	O
,	O
whereas	O
the	O
signal	O
for	O
C4	O
remained	O
almost	O
at	O
the	O
same	O
position	O
at	O
δ	O
69.0	O
as	O
in	O
non	O
-	O
substituted	O
β	B
-	I
Galp	I
NAc	I
[	O
16	O
]	O
.	O

This	O
could	O
be	O
accounted	O
for	O
by	O
strong	O
deviation	O
from	O
the	O
expected	O
regular	O
conformation	O
of	O
the	O
1→4-glycosidic	O
linkage	O
in	O
a	O
sterically	O
hindered	O
trisaccharide	B
fragment	O
of	O
three	O
GalNAc	B
residues	O
with	O
vicinal	O
substitution	O
at	O
positions	O
3	O
and	O
4	O
of	O
GalNAcII	B
(	O
compare	O
also	O
published	O
data	O
[	O
18	O
]	O
)	O
.	O

On	O
the	O
basis	O
of	O
the	O
data	O
obtained	O
,	O
it	O
was	O
concluded	O
that	O
the	O
OPS	B
of	O
P.	O
mirabilis	O
O29	O
has	O
the	O
following	O
structure	O
:	O
As	O
the	O
OPS	B
of	O
P.	O
mirabilis	O
O24	O
studied	O
in	O
this	O
work	O
and	O
most	O
other	O
Proteus	O
OPSs	B
with	O
known	O
structure	O
[	O
5	O
]	O
,	O
the	O
OPS	B
of	O
P.	O
mirabilis	O
O29	O
is	O
enriched	O
in	O
N	B
-acetylamino	I
sugars	I
.	O

Also	O
typical	O
of	O
Proteus	O
OPSs	B
,	O
this	O
is	O
an	O
acidic	B
polysaccharide	I
containing	O
D	B
-glucuronic	I
acid	I
,	O
a	O
component	O
of	O
OPSs	B
of	O
many	O
other	O
Proteus	O
serogroups	O
[	O
5	O
]	O
.	O

Although	O
different	O
in	O
sugar	B
composition	O
,	O
the	O
main	O
chains	O
of	O
the	O
OPSs	B
of	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
exhibit	O
some	O
degree	O
of	O
structural	O
similarity	O
.	O

3.3	O
Serological	O
studies	O
Sera	O
of	O
75	O
healthy	O
volunteers	O
and	O
56	O
hospitalised	O
patients	O
were	O
tested	O
in	O
ELISA	O
for	O
the	O
presence	O
of	O
IgG	O
class	O
antibodies	O
against	O
LPSs	B
of	O
P.	O
mirabilis	O
.	O

48.0	O
%	O
and	O
49.3	O
%	O
sera	O
of	O
volunteers	O
contain	O
anti	O
-	O
P.	O
mirabilis	O
O24	O
and	O
anti	O
-	O
P.	O
mirabilis	O
O29	O
antibodies	O
,	O
respectively	O
.	O

The	O
level	O
of	O
patients	O
'	O
sera	O
reacting	O
with	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
LPSs	B
was	O
significantly	O
higher	O
(	O
80.4	O
%	O
and	O
67.9	O
%	O
,	O
respectively	O
)	O
.	O

These	O
data	O
indicated	O
a	O
role	O
of	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
as	O
pathological	O
agents	O
in	O
humans	O
.	O

P.	O
mirabilis	O
O24	O
LPS	B
reacted	O
with	O
rabbit	O
anti	O
-	O
P.	O
mirabilis	O
O24	O
serum	O
at	O
high	O
titres	O
of	O
1:102	O
400	O
in	O
passive	O
hemolysis	O
(	O
PH	O
)	O
and	O
1:128	O
000	O
in	O
ELISA	O
.	O

Alkali	B
-	O
treated	O
LPS	B
demonstrated	O
the	O
same	O
reactivity	O
in	O
ELISA	O
as	O
LPS	B
,	O
whereas	O
P.	O
mirabilis	O
O24	O
OPS	B
was	O
less	O
active	O
(	O
titre	O
1:16	O
000	O
)	O
.	O

A	O
weaker	O
reactivity	O
of	O
the	O
OPS	B
could	O
be	O
accounted	O
for	O
by	O
the	O
importance	O
of	O
the	O
core	O
-	O
lipid	B
A	I
moiety	O
of	O
LPS	B
in	O
the	O
exposure	O
of	O
the	O
OPS	B
chain	O
optimal	O
for	O
antibodies	O
binding	O
or	O
by	O
the	O
specificity	O
of	O
a	O
significant	O
fraction	O
of	O
antibodies	O
to	O
the	O
LPS	B
core	O
(	O
see	O
below	O
)	O
.	O

A	O
Smith	O
-	O
degraded	O
LPS	B
and	O
a	O
core	O
oligosaccharide	B
,	O
obtained	O
by	O
mild	O
acid	O
degradation	O
of	O
the	O
LPS	B
,	O
were	O
inactive	O
.	O

The	O
intact	O
LPS	B
and	O
alkali	B
-	O
treated	O
LPS	B
at	O
doses	O
of	O
4.9	O
and	O
78	O
ng	O
,	O
respectively	O
,	O
inhibited	O
the	O
reaction	O
in	O
ELISA	O
and	O
PH	O
in	O
the	O
homologous	O
system	O
of	O
anti	O
-	O
P.	O
mirabilis	O
O24	O
serum	O
/	O
P.	O
mirabilis	O
O24	O
LPS	B
.	O

The	O
OPS	B
inhibited	O
the	O
reaction	O
only	O
in	O
ELISA	O
at	O
as	O
high	O
dose	O
as	O
625	O
ng	O
,	O
whereas	O
the	O
Smith	O
-	O
degraded	O
LPS	B
and	O
the	O
core	O
oligosaccharide	B
were	O
inactive	O
.	O

Therefore	O
,	O
the	O
lateral	O
Gal	B
residue	O
,	O
which	O
is	O
destroyed	O
by	O
Smith	O
degradation	O
,	O
is	O
crucial	O
for	O
manifesting	O
of	O
the	O
O24	O
specificity	O
.	O

LPSs	B
from	O
various	O
Proteus	O
strains	O
representing	O
more	O
than	O
30	O
O	O
-	O
serogroups	O
were	O
tested	O
in	O
ELISA	O
with	O
rabbit	O
anti	O
-	O
P.	O
mirabilis	O
O24	O
antiserum	O
.	O

A	O
strong	O
cross	O
-	O
reactivity	O
was	O
observed	O
between	O
anti	O
-	O
P.	O
mirabilis	O
O24	O
serum	O
and	O
P.	O
mirabilis	O
O29	O
LPS	B
(	O
titres	O
1:32	O
000	O
and	O
1:4000	O
with	O
late	O
and	O
early	O
sera	O
,	O
respectively	O
)	O
.	O

Vice	O
versa	O
,	O
from	O
rabbit	O
anti	O
-	O
O	O
sera	O
against	O
over	O
30	O
Proteus	O
strains	O
tested	O
,	O
only	O
that	O
to	O
P.	O
mirabilis	O
O29	O
cross	O
-	O
reacted	O
in	O
ELISA	O
with	O
P.	O
mirabilis	O
O24	O
LPS	B
to	O
a	O
high	O
dilution	O
of	O
1:16	O
000	O
.	O

The	O
close	O
serological	O
relatedness	O
of	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
LPSs	B
was	O
confirmed	O
by	O
PH	O
data	O
(	O
Table	O
2	O
)	O
.	O

Preincubation	O
of	O
anti	O
-	O
P.	O
mirabilis	O
O24	O
serum	O
with	O
the	O
homologous	O
LPS	B
abolished	O
the	O
reactivity	O
in	O
PH	O
with	O
both	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
LPSs	B
.	O

Preincubation	O
of	O
the	O
same	O
serum	O
with	O
the	O
heterologous	O
P.	O
mirabilis	O
O29	O
LPS	B
reduced	O
slightly	O
the	O
reactivity	O
with	O
P.	O
mirabilis	O
O24	O
LPS	B
and	O
abolished	O
the	O
reactivity	O
with	O
P.	O
mirabilis	O
O29	O
LPS	B
.	O

Absorption	O
of	O
anti	O
-	O
P.	O
mirabilis	O
O29	O
serum	O
by	O
the	O
LPS	B
of	O
P.	O
mirabilis	O
O29	O
or	O
O24	O
reduced	O
significantly	O
the	O
reactivity	O
with	O
both	O
antigens	B
.	O

Therefore	O
the	O
strong	O
two	O
-	O
way	O
cross	O
-	O
reactivity	O
of	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
is	O
due	O
to	O
the	O
presence	O
of	O
a	O
common	O
epitope	O
(	O
s	O
)	O
on	O
the	O
LPSs	B
.	O

A	O
cross	O
-	O
reactivity	O
of	O
Proteus	O
strains	O
belonging	O
to	O
different	O
O	O
-	O
serogroups	O
is	O
not	O
uncommon	O
[	O
5	O
]	O
.	O

Most	O
often	O
cross	O
-	O
reactive	O
antibodies	O
recognise	O
identical	O
or	O
similar	O
oligosaccharide	B
fragments	O
on	O
the	O
OPS	B
,	O
from	O
a	O
disaccharide	B
to	O
a	O
tetrasaccharide	B
.	O

The	O
main	O
chains	O
of	O
the	O
OPSs	B
of	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
are	O
structurally	O
similar	O
and	O
,	O
thus	O
,	O
might	O
share	O
a	O
cross	O
-	O
reactive	O
epitope	O
(	O
s	O
)	O
.	O

However	O
,	O
in	O
Western	O
immunoblotting	O
,	O
a	O
ladder	O
-	O
like	O
banding	O
typical	O
of	O
LPSs	B
with	O
variable	O
chain	O
length	O
OPSs	B
was	O
observed	O
only	O
with	O
homologous	O
anti	O
-	O
P.	O
mirabilis	O
O24	O
and	O
anti	O
-	O
P.	O
mirabilis	O
O29	O
sera	O
(	O
Fig.	O
2A	O
,	O
B	O
,	O
respectively	O
)	O
.	O

The	O
reaction	O
of	O
both	O
anti	O
-	O
O	O
sera	O
with	O
the	O
heterologous	O
LPSs	B
of	O
P.	O
mirabilis	O
O29	O
and	O
O24	O
was	O
limited	O
to	O
fast	O
-	O
migrating	O
bands	O
,	O
which	O
correspond	O
to	O
the	O
core	O
-	O
lipid	B
A	I
moiety	O
(	O
Fig.	O
2	O
,	O
lanes	O
1	O
and	O
3	O
)	O
.	O

The	O
corresponding	O
heterologous	O
whole	O
cells	O
did	O
not	O
react	O
(	O
Fig.	O
2	O
,	O
lanes	O
2	O
and	O
4	O
)	O
and	O
,	O
therefore	O
,	O
cross	O
-	O
reactive	O
epitopes	O
are	O
not	O
exposed	O
on	O
the	O
cell	O
surface	O
.	O

These	O
findings	O
suggested	O
that	O
antibodies	O
against	O
the	O
core	O
-	O
lipid	B
A	I
region	O
of	O
the	O
LPS	B
,	O
rather	O
than	O
those	O
against	O
the	O
OPS	B
,	O
are	O
responsible	O
for	O
the	O
cross	O
-	O
reactivity	O
observed	O
.	O

A	O
high	O
level	O
of	O
anti	O
-	O
core	O
-	O
lipid	B
A	I
antibodies	O
may	O
be	O
due	O
to	O
the	O
exposure	O
of	O
OPS	B
-	O
lacking	O
LPS	B
species	O
on	O
the	O
surface	O
of	O
P.	O
mirabilis	O
O24	O
and	O
O29	O
.	O

A	O
low	O
degree	O
of	O
substitution	O
of	O
the	O
core	O
by	O
the	O
OPS	B
has	O
been	O
demonstrated	O
for	O
P.	O
mirabilis	O
S1959	O
LPS	B
(	O
serogroup	O
O3	O
)	O
[	O
19	O
]	O
.	O

A	O
cross	O
-	O
reactivity	O
has	O
been	O
reported	O
for	O
some	O
other	O
Proteus	O
strains	O
with	O
structurally	O
different	O
OPSs	B
and	O
likewise	O
accounted	O
for	O
by	O
the	O
presence	O
of	O
antibodies	O
recognising	O
the	O
core	O
region	O
of	O
LPS	B
[	O
20,21	O
]	O
.	O

It	O
can	O
be	O
suggested	O
that	O
the	O
LPS	B
core	O
regions	O
in	O
the	O
cross	O
-	O
reactive	O
strains	O
are	O
similar	O
or	O
identical	O
,	O
but	O
their	O
exact	O
structures	O
remain	O
to	O
be	O
determined	O
.	O

Acknowledgments	O
This	O
work	O
was	O
supported	O
by	O
Grants	O
4-PO5A	O
from	O
the	O
Sciences	O
Research	O
Committee	O
(	O
KBN	O
,	O
Poland	O
)	O
for	O
W.K.	O
and	O
99	O
-	O
04	O
-	O
48279	O
from	O
the	O
Russian	O
Foundation	O
for	O
Basic	O
Research	O
for	O
Y.A.K.	O

Abscisic	B
acid	I
(	O
ABA	B
)	O
is	O
a	O
sequiterpene	B
plant	O
hormone	B
that	O
modulates	O
seed	O
development	O
,	O
dormancy	O
,	O
cell	O
division	O
and	O
responses	O
to	O
environmental	O
stresses	O
such	O
as	O
drought	O
,	O
cold	O
,	O
salt	O
,	O
pathogen	O
attack	O
and	O
UV	O
light	O
[	O
1–3	O
]	O
.	O

It	O
is	O
ubiquitous	O
in	O
higher	O
plants	O
and	O
acts	O
via	O
multiple	O
pathways	O
,	O
inducing	O
rapid	O
closure	O
of	O
stomatal	O
pores	O
by	O
ion	O
efflux	O
from	O
guard	O
cells	O
and	O
slower	O
changes	O
in	O
gene	O
expression	O
[	O
4	O
]	O
.	O

Molecular	O
genetic	O
studies	O
in	O
the	O
model	O
organisms	O
maize	O
and	O
Arabidopsis	O
have	O
resulted	O
in	O
the	O
identification	O
of	O
downstream	O
components	O
of	O
ABA	B
and	O
stress	O
signalling	O
,	O
including	O
protein	O
phosphatases	O
and	O
kinases	O
,	O
transcription	O
factors	O
and	O
a	O
subunit	O
of	O
farnesyl	O
transferase	O
[	O
4–10	O
]	O
.	O

Reverse	O
genetic	O
and	O
biochemical	O
approaches	O
have	O
led	O
to	O
the	O
characterization	O
of	O
ABA-	B
and	O
stress	O
-	O
responsive	O
cis	O
-promoter	O
elements	O
and	O
transcription	O
factors	O
,	O
the	O
functional	O
cloning	O
of	O
a	O
syntaxin	O
and	O
demonstration	O
of	O
the	O
involvement	O
of	O
secondary	O
messengers	O
such	O
as	O
cyclic	B
ADP	I
ribose	B
and	O
calcium	B
[	O
4,11–15	O
]	O
.	O

Despite	O
this	O
rapid	O
progress	O
in	O
understanding	O
the	O
molecular	O
details	O
of	O
ABA	B
signalling	O
,	O
little	O
is	O
known	O
of	O
the	O
mechanisms	O
of	O
ABA	B
perception	O
.	O

Indirect	O
evidence	O
suggests	O
the	O
existence	O
of	O
multiple	O
ABA	O
receptors	O
[	O
16,17	O
]	O
,	O
but	O
with	O
the	O
exception	O
of	O
an	O
unconfirmed	O
report	O
in	O
1984	O
[	O
18	O
]	O
no	O
such	O
receptors	O
have	O
yet	O
been	O
described	O
.	O

Although	O
ABA	B
binding	O
proteins	O
[	O
19,20	O
]	O
and	O
carrier-	O
mediated	O
uptake	O
of	O
ABA	B
have	O
been	O
reported	O
[	O
21,22	O
]	O
,	O
there	O
is	O
no	O
evidence	O
to	O
link	O
these	O
to	O
the	O
physiological	O
effects	O
of	O
ABA	B
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
innovative	O
uses	O
of	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
and	O
flow	O
cytometry	O
to	O
demonstrate	O
biochemical	O
and	O
functional	O
interactions	O
of	O
the	O
monoclonal	O
antibody	O
JIM19	O
with	O
plasma	O
membranes	O
(	O
PMs	O
)	O
and	O
protoplasts	O
derived	O
from	O
rice	O
embryonic	O
suspension	O
cultures	O
.	O

JIM19	O
is	O
one	O
of	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
previously	O
generated	O
against	O
pea	O
guard	O
cell	O
protoplasts	O
[	O
23	O
]	O
that	O
was	O
shown	O
to	O
modulate	O
ABA	B
responses	O
in	O
barley	O
aleurone	O
protoplasts	O
,	O
another	O
target	O
cell	O
for	O
ABA	B
[	O
24	O
]	O
.	O

Our	O
data	O
show	O
that	O
JIM19	O
binds	O
to	O
glycoproteins	O
(	O
GPs	O
)	O
in	O
rice	O
PMs	O
and	O
that	O
such	O
binding	O
is	O
antagonized	O
by	O
ABA	B
but	O
not	O
by	O
the	O
structurally	O
related	O
,	O
biologically	O
inactive	O
ABA	B
catabolite	B
,	O
phaseic	B
acid	I
(	O
PA	B
)	O
.	O

Transient	O
gene	O
expression	O
assays	O
using	O
β	O
-	O
glucuronidase	O
(	O
GUS	O
)	O
/	O
luciferase	O
and	O
novel	O
flow	O
cytometric	O
quantitation	O
of	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
demonstrate	O
that	O
ABA	B
but	O
not	O
PA	B
induces	O
Em	O
promoter	O
activity	O
;	O
such	O
ABA	B
-	O
induced	O
promoter	O
activity	O
is	O
antagonized	O
by	O
JIM19	O
.	O

These	O
results	O
support	O
a	O
model	O
of	O
ABA	B
signalling	O
through	O
a	O
PM	O
complex	O
that	O
includes	O
an	O
ABA	O
receptor	O
and	O
JIM19	O
epitope	O
-	O
presenting	O
GP	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Embryonic	O
rice	O
(	O
Oryza	O
sativa	O
)	O
callus	O
cultures	O
(	O
Radon	O
6	O
from	O
the	O
International	O
Rice	O
Research	O
Institute	O
,	O
Los	O
Baños	O
,	O
Phillipines	O
)	O
were	O
obtained	O
from	O
Dr.	O
Tom	O
Hodges	O
,	O
Purdue	O
University	O
,	O
West	O
Lafayette	O
,	O
IN	O
47909	O
,	O
USA	O
.	O

Cultures	O
were	O
propagated	O
and	O
digested	O
for	O
making	O
protoplasts	O
as	O
previously	O
described	O
[	O
25	O
]	O
except	O
that	O
10	O
mM	O
HEPES	B
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
,	O
pH	O
5.6	O
,	O
was	O
substituted	O
for	O
phosphate	B
in	O
the	O
Krens	O
'	O
F	O
medium	O
and	O
2	O
%	O
weight	O
/	O
volume	O
(	O
w	O
/	O
v	O
)	O
cellulase	O
YC	O
,	O
0.35	O
%	O
(	O
w	O
/	O
v	O
)	O
macerozyme	O
and	O
0.1	O
%	O
(	O
w	O
/	O
v	O
)	O
pectolyase	B
Y23	O
were	O
used	O
for	O
overnight	O
digestion	O
(	O
Karlan	O
Research	O
Products	O
,	O
Santa	O
Rosa	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Phaseic	B
acid	I
was	O
obtained	O
from	O
Dr.	O
Sue	O
Abrams	O
,	O
Institute	O
of	O
Plant	O
Biotechnology	O
,	O
Saskatoon	O
,	O
Canada	O
.	O

(	B
±	I
)	I
Cis	I
,	I
trans	I
-ABA	I
(	O
Sigma	O
)	O
and	O
phaseic	B
acid	I
were	O
quantified	O
by	O
spectrometry	O
[	O
26	O
]	O
and	O
their	O
purity	O
and	O
relative	O
quantities	O
confirmed	O
by	O
mass	O
spectrometry	O
using	O
a	O
Finnegan	O
(	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
GCQ	O
ion	O
trap	O
[	O
27	O
]	O
.	O

2.2	O
Immunological	O
studies	O
JIM19	O
and	O
JIM20	O
[	O
23	O
]	O
were	O
obtained	O
as	O
hybridoma	O
supernatants	O
from	O
Ms.	O
Jan	O
Peart	O
,	O
John	O
Innes	O
Centre	O
,	O
Norwich	O
,	O
UK	O
.	O

For	O
functional	O
assays	O
the	O
supernatants	O
were	O
desalted	O
by	O
passing	O
over	O
NAP-10	O
columns	O
(	O
Amersham	O
-	O
Pharmacia	O
Biotech	O
.	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
equilibrated	O
with	O
0.1	O
M	O
phosphate	B
-	I
buffered	I
saline	I
(	O
PBS	B
)	O
,	O
pH	O
7.4	O
,	O
or	O
dialyzed	O
against	O
PBS	B
to	O
remove	O
sodium	O
azide	O
and	O
low	O
molecular	O
weight	O
impurities	O
.	O

Immunoblotting	O
to	O
nitrocellulose	B
(	O
Schleicher	O
and	O
Schull	O
,	O
Dassel	O
,	O
Germany	O
)	O
of	O
PM	O
proteins	O
separated	O
by	O
SDS	O
-	O
PAGE	O
was	O
by	O
standard	O
methods	O
[	O
28	O
]	O
.	O

JIM19	O
hybridoma	O
supernatant	O
was	O
used	O
to	O
probe	O
immunoblots	O
at	O
1	O
/	O
100	O
dilution	O
;	O
JIM20	O
was	O
used	O
at	O
1	O
/	O
10	O
dilution	O
.	O

Rabbit	O
anti	O
-	O
rat	O
IgM	O
conjugated	O
to	O
alkaline	O
phosphatase	O
(	O
Zymed	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
and	O
the	O
chromogenic	O
substrates	O
nitroblue	B
tetrazolium	I
chloride	I
and	O
5-bromo-4-chloro-3-indolyl	B
-	I
phosphate	I
(	O
Sigma	O
)	O
were	O
used	O
to	O
visualize	O
JIM	O
-	O
bound	O
antigens	O
.	O

The	O
titer	O
of	O
JIM19	O
was	O
estimated	O
to	O
be	O
2-fold	O
higher	O
than	O
JIM20	O
by	O
immunoblot	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Sodium	B
periodate	I
(	O
25	O
mM	O
solution	O
in	O
50	O
mM	O
NaOAc	B
,	O
pH	O
4.3	O
)	O
was	O
applied	O
overnight	O
to	O
blotted	O
PM	O
proteins	O
to	O
oxidize	O
GP	O
carbohydrates	B
before	O
immunodetection	O
with	O
JIM	O
antibodies	O
.	O

Flow	O
cytometry	O
of	O
rice	O
protoplasts	O
was	O
performed	O
on	O
a	O
Becton	O
-	O
Dickinson	O
(	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
FACS	O
Vantage	O
dual	O
beam	O
instrument	O
equipped	O
with	O
a	O
200	O
μm	O
nozzle	O
and	O
Lysis	O
II	O
acquisition	O
and	O
analysis	O
software	O
.	O

The	O
excitation	O
wavelength	O
for	O
flow	O
cytometry	O
was	O
488	O
nm	O
.	O

Fluorescence	O
emission	O
detection	O
was	O
with	O
a	O
fluorescein	B
isothiocyanate	I
(	O
FITC	B
)	O
530	O
/	O
30	O
nm	O
filter	O
set	O
.	O

For	O
Aequoria	O
victoria	O
GFP	O
studies	O
,	O
live	O
cells	O
were	O
analyzed	O
.	O

Cell	O
viability	O
was	O
determined	O
by	O
flow	O
cytometry	O
of	O
an	O
aliquot	O
of	O
live	O
protoplasts	O
treated	O
five	O
min	O
with	O
0.01	O
%	O
(	O
w	O
/	O
v	O
)	O
fluorescein	B
diacetate	I
(	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
.	O

For	O
immunofluorescence	O
studies	O
,	O
protoplasts	O
at	O
a	O
density	O
of	O
106	O
/0.5	O
ml	O
were	O
incubated	O
for	O
30	O
min	O
in	O
Krens	O
-	O
HEPES	B
with	O
or	O
without	O
JIM19	O
or	O
JIM20	O
hybridoma	O
supernatant	O
(	O
1	O
/	O
10	O
dilution	O
)	O
.	O

After	O
two	O
washes	O
with	O
Krens	O
-	O
HEPES	B
,	O
the	O
protoplasts	O
were	O
incubated	O
for	O
20	O
min	O
with	O
goat	O
anti	O
-	O
rat	O
IgG	O
-	O
conjugated	O
FITC	B
(	O
1	O
/	O
20	O
dilution	O
,	O
Sigma	O
)	O
,	O
washed	O
two	O
times	O
with	O
Krens	O
-	O
HEPES	B
and	O
fixed	O
in	O
1	O
%	O
paraformaldehyde	B
in	O
0.1	O
M	O
PBS	B
,	O
pH	O
7.4	O
for	O
30	O
min	O
.	O

2.3	O
Plasma	O
membrane	O
preparation	O
by	O
aqueous	O
two	O
phase	O
partitioning	O
PMs	O
were	O
prepared	O
from	O
fresh	O
or	O
frozen	O
callus	O
cultures	O
according	O
to	O
Larsson	O
[	O
29	O
]	O
with	O
modifications	O
.	O

The	O
tissue	O
was	O
homogenized	O
by	O
sonication	O
in	O
50	O
mM	O
Tris	B
,	O
0.25	O
M	O
sucrose	B
,	O
3	O
mM	O
EDTA	B
(	O
Sigma	O
)	O
,	O
1	O
mM	O
MgSO4	B
,	O
2	O
mM	O
dithiothreitol	B
,	O
pH	O
7.8	O
.	O

PEG-1540	B
(	O
Polysciences	O
,	O
Warrington	O
,	O
PA	O
,	O
USA	O
)	O
was	O
used	O
instead	O
of	O
PEG-3350	B
as	O
the	O
upper	O
phase	O
.	O

Membrane	O
marker	O
enzyme	O
assays	O
[	O
30	O
]	O
for	O
the	O
PM	O
(	O
vanadate	B
-	O
sensitive	O
ATPase	O
)	O
,	O
endoplasmic	O
reticulum	O
and	O
mitochondria	O
(	O
antimycin	B
A	I
-	O
resistant	O
and	O
-sensitive	O
cytochrome	O
c	O
reductases	O
,	O
respectively	O
)	O
indicated	O
a	O
PM	O
-	O
enrichment	O
over	O
total	O
membranes	O
of	O
7-	O
to	O
20-fold	O
(	O
data	O
not	O
shown	O
)	O
.	O

Protein	O
concentations	O
were	O
determined	O
by	O
the	O
dye	B
binding	O
method	O
[	O
28	O
]	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

2.4	O
Surface	O
plasmon	O
resonance	O
biosensor	O
analysis	O
The	O
immunoaffinity	O
purification	O
of	O
JIM19	O
was	O
as	O
follows	O
.	O

Alkaline	O
phosphatase	O
-	O
conjugated	O
rabbit	O
anti	O
-	O
rat	O
IgM	O
(	O
15	O
mg	O
;	O
Zymed	O
)	O
,	O
dialyzed	O
against	O
10	O
mM	O
HEPES	B
,	O
pH	O
6.5	O
,	O
was	O
covalently	O
bound	O
to	O
0.5	O
ml	O
Affigel	B
-	I
Gel	I
10	I
support	O
(	O
Bio	O
-	O
Rad	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Active	O
esters	B
were	O
blocked	O
with	O
1	O
M	O
ethanolamide	B
,	O
pH	O
8	O
.	O

The	O
column	O
was	O
equilibrated	O
with	O
PBS	B
and	O
5	O
ml	O
JIM19	O
hybridoma	O
supernatant	O
passed	O
over	O
the	O
column	O
.	O

After	O
washing	O
with	O
10	O
bed	O
volumes	O
of	O
PBS	B
,	O
the	O
JIM19	O
antibody	O
was	O
eluted	O
with	O
2	O
ml	O
100	O
mM	O
Gly	B
,	O
pH	O
2.5	O
and	O
collected	O
in	O
0.1	O
volume	O
of	O
1	O
M	O
KH2	B
Pi	I
,	O
pH	O
8.0	O
.	O

The	O
purified	O
JIM19	O
was	O
dialyzed	O
against	O
PBS	B
and	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
further	O
use	O
.	O

Approximately	O
3	O
ng	O
immunoaffinity	O
-	O
purified	O
JIM19	O
was	O
immobilized	O
on	O
a	O
CM5	O
carboxymethylated	O
dextran	B
chip	O
(	O
Pharmacia	O
Biotech	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
by	O
amine	B
coupling	O
at	O
pH	O
4.6	O
in	O
10	O
mM	O
NaOAc	B
using	O
the	O
manufacturer	O
's	O
provided	O
kit	O
.	O

Detection	O
of	O
SPR	O
was	O
with	O
a	O
BIAcore	O
2000	O
(	O
Pharmacia	O
)	O
.	O

The	O
JIM19	O
chip	O
was	O
regenerated	O
after	O
PM	O
binding	O
by	O
passing	O
0.1	O
N	O
NaOH	B
over	O
the	O
chip	O
for	O
60	O
s.	O
The	O
concentration	O
of	O
immunoaffinity	O
-	O
purified	O
JIM19	O
used	O
in	O
solution	O
competition	O
experiments	O
was	O
estimated	O
to	O
be	O
1	O
ng	O
/	O
μl	O
by	O
NanoOrange	O
(	O
Molecular	O
Probes	O
)	O
fluorescent	B
dye	I
binding	O
and	O
detection	O
with	O
a	O
Cytofluor	O
II	O
microplate	O
spectrofluorometer	O
(	O
Molecular	O
Dynamics	O
,	O
Sunnyvale	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Rabbit	O
anti	O
-	O
GUS	O
antibody	O
was	O
from	O
Molecular	O
Probes	O
.	O

2.5	O
Functional	O
studies	O
Transformation	O
of	O
protoplasts	O
was	O
according	O
to	O
[	O
31	O
]	O
,	O
using	O
25	O
μg	O
each	O
of	O
pBM207	O
and	O
pAHC18	O
and	O
3	O
×	O
106	O
protoplasts	O
/	O
transformation	O
,	O
which	O
were	O
split	O
into	O
six	O
paired	O
samples	O
.	O

pBM207	O
[	O
32	O
]	O
contains	O
the	O
650	O
bp	O
wheat	O
Em	O
promoter	O
driving	O
uidA	O
expression	O
(	O
GUS	O
)	O
.	O

pAHC18	O
contains	O
the	O
2.0	O
kb	O
maize	O
ubiquitin	O
promoter	O
driving	O
firefly	O
luciferase	O
(	O
LUC	O
;	O
[	O
33	O
]	O
)	O
and	O
was	O
included	O
as	O
an	O
internal	O
reference	O
for	O
non	O
-	O
ABA	B
-	O
inducible	O
transient	O
transcription	O
.	O

pCR559	O
contains	O
the	O
Em	O
promoter	O
driving	O
a	O
modified	O
GFP	O
(	O
sGFP	O
)	O
with	O
preferred	O
codons	O
and	O
the	O
S65	O
T	O
mutation	O
that	O
gives	O
enhanced	O
fluorescence	O
,	O
faster	O
chromophore	O
formation	O
and	O
slower	O
photobleaching	O
[	O
34	O
]	O
.	O

It	O
was	O
made	O
by	O
ligation	O
of	O
the	O
3.3	O
kb	O
.	O

Nco	O
I	O
–	O
Eco	O
RI	O
fragment	O
of	O
pBM207	O
and	O
the	O
1.0	O
kb	O
.	O

Nco	O
I	O
–	O
Eco	O
RI	O
fragment	O
of	O
p35SC4PPDK	O
-	O
sGFP	O
(	O
S65	O
T	O
)	O
containing	O
the	O
nos	O
3′	O
terminator	O
[	O
34	O
]	O
.	O

Transformed	O
,	O
washed	O
protoplasts	O
were	O
first	O
treated	O
with	O
1	O
/	O
10	O
,	O
1	O
/	O
20	O
,	O
1	O
/	O
40	O
,	O
or	O
1	O
/	O
80	O
volumes	O
of	O
JIM	O
antibody	O
and	O
after	O
15	O
min	O
,	O
various	O
concentrations	O
of	O
ABA	B
added	O
to	O
give	O
a	O
final	O
volume	O
of	O
0.5	O
ml	O
Krens	O
-	O
HEPES	B
and	O
0.05	O
%	O
ethanol	B
.	O

For	O
enzyme	O
-	O
based	O
reporter	O
assays	O
,	O
after	O
18	O
h	O
incubation	O
,	O
protoplasts	O
were	O
lysed	O
in	O
Reporter	O
Lysis	O
Buffer	O
plus	O
10	O
mM	O
2-mercaptoethanol	B
and	O
LUC	O
activity	O
measured	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
on	O
a	O
Monolight	O
2010	O
bioluminescence	O
luminometer	O
(	O
Analytical	O
Luminescence	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
LUC	O
limit	O
of	O
detection	O
for	O
a	O
linear	O
response	O
of	O
the	O
detector	O
was	O
approximately	O
7000	O
relative	O
light	O
units	O
and	O
the	O
sample	O
activities	O
were	O
between	O
40	O
000	O
and	O
160	O
000	O
relative	O
light	O
units	O
/	O
20	O
μl	O
extract	O
.	O

GUS	O
activities	O
of	O
the	O
samples	O
were	O
determined	O
according	O
to	O
[	O
35	O
]	O
,	O
using	O
4-methylumbelliferone	B
glucuronide	I
(	O
Rose	O
Scientific	O
,	O
Edmonton	O
,	O
Alta	O
.	O
,	O
Canada	O
)	O
as	O
substrate	O
dissolved	O
in	O
50	O
mM	O
NaPi	B
,	O
pH	O
7.0	O
,	O
10	O
mM	O
EDTA	B
,	O
0.1	O
%	O
(	O
v	O
/	O
v	O
)	O
Triton	B
X-100	I
,	O
3.4	O
mM	O
N	B
-lauryl	I
sarcosine	I
and	O
10	O
mM	O
2-mercaptoethanol	B
.	O

Activities	O
ranged	O
between	O
4	O
and	O
140	O
pmol	O
4-methylumbelliferone	B
/	O
h	O
/	O
40	O
μl	O
extract	O
.	O

Data	O
presented	O
are	O
of	O
experiments	O
that	O
were	O
repeated	O
once	O
with	O
similar	O
results	O
.	O

3	O
Results	O
3.1	O
JIM19	O
and	O
JIM20	O
recognize	O
cell	O
surface	O
glycoproteins	O
in	O
rice	O
Flow	O
cytometry	O
is	O
a	O
powerful	O
tool	O
that	O
is	O
relatively	O
unexploited	O
in	O
plant	O
biology	O
.	O

The	O
application	O
of	O
this	O
technique	O
to	O
embryonic	O
rice	O
protoplasts	O
immunodecorated	O
with	O
the	O
JIM19	O
antibody	O
demonstrated	O
substantial	O
binding	O
to	O
the	O
cell	O
surface	O
,	O
i.e.	O
the	O
PM	O
(	O
Fig.	O
1	O
)	O
.	O

Fig.	O
1B	O
shows	O
the	O
extent	O
of	O
JIM19	O
binding	O
to	O
a	O
population	O
of	O
rice	O
protoplasts	O
measured	O
as	O
relative	O
fluorescence	O
intensity	O
of	O
FITC	B
-	O
labelled	O
anti	O
-	O
rat	O
IgG	O
secondary	O
antibody	O
.	O

Approximately	O
70	O
%	O
of	O
the	O
protoplasts	O
are	O
labelled	O
by	O
JIM19	O
,	O
based	O
on	O
a	O
threshold	O
of	O
background	O
fluorescence	O
of	O
control	O
protoplasts	O
labelled	O
with	O
secondary	O
antibody	O
alone	O
(	O
Fig.	O
1A	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
JIM20	O
(	O
Fig.	O
1C	O
)	O
,	O
except	O
the	O
intensity	O
of	O
the	O
fluorescence	O
signal	O
was	O
less	O
than	O
half	O
that	O
of	O
JIM19	O
.	O

JIM20	O
is	O
related	O
to	O
JIM19	O
[	O
23	O
]	O
but	O
had	O
no	O
biological	O
activity	O
[	O
24	O
]	O
.	O

Varying	O
the	O
concentration	O
of	O
JIM	O
antibodies	O
over	O
the	O
range	O
of	O
1	O
/	O
10	O
to	O
1	O
/	O
80	O
dilution	O
did	O
not	O
affect	O
significantly	O
the	O
percentage	O
of	O
cells	O
labelled	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
suggest	O
that	O
the	O
affinity	O
of	O
JIM19	O
for	O
rice	O
PM	O
epitopes	O
is	O
higher	O
than	O
that	O
of	O
JIM20	O
.	O

In	O
order	O
to	O
characterize	O
further	O
the	O
surface	O
antigens	O
recognized	O
by	O
JIM19	O
and	O
JIM20	O
,	O
SDS	O
-	O
PAGE	O
and	O
immunoblot	O
analysis	O
were	O
performed	O
on	O
PMs	O
purified	O
by	O
aqueous	O
two	O
phase	O
partitioning	O
.	O

The	O
lability	O
of	O
the	O
rice	O
PM	O
JIM	O
epitopes	O
to	O
sodium	B
periodate	I
,	O
which	O
oxidizes	O
carbohydrates	B
was	O
tested	O
,	O
as	O
previous	O
work	O
suggested	O
that	O
JIM19	O
and	O
JIM20	O
recognize	O
the	O
carbohydrate	B
moieties	O
of	O
GPs	O
[	O
23	O
]	O
.	O

JIM19	O
and	O
JIM20	O
recognized	O
exclusively	O
the	O
carbohydrate	B
moieties	O
of	O
multiple	O
PM	O
GPs	O
,	O
evidenced	O
by	O
loss	O
of	O
all	O
immunoreactive	O
signals	O
after	O
treatment	O
of	O
immunoblots	O
with	O
sodium	B
periodate	I
(	O
Fig.	O
2	O
)	O
.	O

Similar	O
treatment	O
of	O
an	O
electroblotted	O
non	O
-	O
GP	O
control	O
(	O
β	O
-	O
glucuronidase	O
)	O
had	O
no	O
effect	O
on	O
immunodetection	O
(	O
data	O
not	O
shown	O
)	O
.	O

At	O
least	O
five	O
GPs	O
ranging	O
in	O
relative	O
size	O
from	O
25	O
kDa	O
to	O
more	O
than	O
175	O
kDa	O
were	O
recognized	O
by	O
JIM19	O
.	O

JIM20	O
also	O
recognized	O
GPs	O
larger	O
than	O
approximately	O
100	O
kDa	O
and	O
of	O
similar	O
size	O
to	O
the	O
proteins	O
recognized	O
by	O
JIM19	O
.	O

However	O
,	O
there	O
are	O
also	O
unique	O
PM	O
proteins	O
in	O
the	O
range	O
of	O
25–60	O
kDa	O
which	O
react	O
only	O
with	O
JIM19	O
(	O
Fig.	O
2	O
)	O
.	O

A	O
10-fold	O
higher	O
concentration	O
of	O
JIM20	O
than	O
JIM19	O
did	O
not	O
result	O
in	O
a	O
stronger	O
signal	O
or	O
detection	O
of	O
other	O
epitopes	O
(	O
Fig.	O
2	O
)	O
,	O
consistent	O
with	O
the	O
flow	O
cytometry	O
data	O
(	O
Fig.	O
1	O
)	O
indicating	O
that	O
the	O
affinity	O
of	O
JIM19	O
for	O
PM	O
epitopes	O
is	O
higher	O
than	O
that	O
of	O
JIM20	O
.	O

3.2	O
Binding	O
of	O
plasma	O
membranes	O
to	O
JIM19	O
is	O
specifically	O
antagonized	O
by	O
abscisic	B
acid	I
We	O
used	O
an	O
SPR	O
biosensor	O
[	O
36	O
]	O
to	O
characterize	O
the	O
binding	O
of	O
PM	O
epitopes	O
to	O
JIM19	O
.	O

SPR	O
technology	O
allows	O
monitoring	O
of	O
specific	O
biomolecular	O
interactions	O
between	O
a	O
ligand	O
(	O
e.g.	O
antibody	O
)	O
and	O
an	O
analyte	O
(	O
e.g.	O
antigen	O
)	O
,	O
resulting	O
in	O
a	O
change	O
in	O
refractive	O
index	O
measured	O
as	O
arbitrary	O
resonance	O
output	O
units	O
.	O

A	O
major	O
strength	O
of	O
this	O
technology	O
is	O
the	O
sensitive	O
,	O
quantitative	O
,	O
direct	O
determination	O
of	O
real	O
time	O
binding	O
activity	O
in	O
crude	O
,	O
complex	O
mixtures	O
without	O
labelling	O
of	O
components	O
.	O

Three	O
ng	O
(	O
65	O
fmol	O
of	O
IgM	O
binding	O
sites	O
,	O
assuming	O
10	O
binding	O
sites	O
/	O
IgM	O
)	O
of	O
immunoaffinity	O
-	O
purified	O
JIM19	O
was	O
covalently	O
bound	O
to	O
a	O
carboxymethyl	B
dextran	I
-	O
coated	O
biosensor	O
chip	O
,	O
giving	O
a	O
baseline	O
SPR	O
signal	O
of	O
21	O
600	O
units	O
(	O
Fig.	O
3	O
,	O
stage	O
1	O
)	O
.	O

A	O
non	O
-	O
saturating	O
amount	O
of	O
PMs	O
(	O
5	O
μg	O
of	O
protein	O
,	O
or	O
100	O
pmol	O
of	O
'	O
average	O
'	O
[	O
50	O
kDa	O
]	O
sized	O
proteins	O
)	O
was	O
then	O
bound	O
to	O
the	O
JIM19	O
chip	O
over	O
a	O
period	O
of	O
400	O
s	O
,	O
after	O
which	O
time	O
the	O
binding	O
reaction	O
approached	O
steady	O
state	O
(	O
Fig.	O
3	O
,	O
stage	O
2	O
)	O
.	O

The	O
amount	O
of	O
PM	O
bound	O
to	O
the	O
chip	O
was	O
linearly	O
dependent	O
on	O
the	O
amount	O
injected	O
(	O
correlation	O
coefficient	O
r	O
=	O
0.98	O
,	O
n	O
=	O
7	O
;	O
data	O
not	O
shown	O
)	O
,	O
as	O
expected	O
for	O
concentrations	O
of	O
analyte	O
far	O
below	O
the	O
equilibrium	O
dissociation	O
constant	O
for	O
independent	O
ligand	O
sites	O
.	O

The	O
detection	O
limit	O
of	O
the	O
biosensor	O
for	O
PM	O
binding	O
was	O
calculated	O
as	O
three	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
baseline	O
SPR	O
signal	O
between	O
sample	O
injections	O
;	O
the	O
PM	O
binding	O
signal	O
was	O
on	O
average	O
more	O
than	O
six	O
times	O
higher	O
than	O
the	O
detection	O
limit	O
(	O
data	O
not	O
shown	O
)	O
.	O

About	O
400	O
SPR	O
units	O
of	O
specific	O
PM	O
binding	O
were	O
observed	O
under	O
the	O
standard	O
binding	O
conditions	O
(	O
Table	O
1	O
)	O
.	O

The	O
specificity	O
of	O
PM	O
binding	O
to	O
JIM19	O
was	O
investigated	O
using	O
three	O
solution	O
competition	O
assays	O
for	O
JIM	O
antibody	O
specificity	O
.	O

Binding	O
of	O
PMs	O
to	O
the	O
JIM19	O
chip	O
could	O
be	O
prevented	O
by	O
pre	O
-	O
incubation	O
of	O
PMs	O
with	O
increasing	O
amounts	O
of	O
JIM19	O
(	O
Table	O
1	O
)	O
.	O

JIM20	O
also	O
antagonized	O
PM	O
binding	O
to	O
JIM19	O
,	O
suggesting	O
that	O
JIM19	O
and	O
JIM20	O
do	O
indeed	O
share	O
specificity	O
for	O
the	O
high	O
molecular	O
weight	O
epitopes	O
observed	O
in	O
Fig.	O
2	O
.	O

Non	O
-	O
specific	O
interference	O
with	O
PM	O
binding	O
was	O
low	O
,	O
as	O
measured	O
by	O
pre	O
-	O
incubation	O
of	O
PMs	O
with	O
an	O
unrelated	O
antibody	O
(	O
anti	O
-	O
GUS	O
,	O
Table	O
1	O
)	O
.	O

Furthermore	O
,	O
JIM19	O
did	O
not	O
bind	O
to	O
bovine	O
serum	O
albumin	O
(	O
Table	O
1	O
)	O
or	O
to	O
human	O
neutrophil	O
membrane	O
proteins	O
as	O
detected	O
by	O
immunoblotting	O
(	O
data	O
not	O
shown	O
)	O
.	O

Assuming	O
the	O
SPR	O
signal	O
due	O
to	O
binding	O
of	O
PM	O
vesicles	O
(	O
average	O
diameter	O
,	O
100	O
nm	O
[	O
29	O
]	O
)	O
is	O
similar	O
to	O
that	O
of	O
other	O
cellular	O
ligands	O
(	O
Pharmacia	O
BIAtechnology	O
Note	O
#	O
105	O
;	O
Uppsala	O
,	O
Sweden	O
)	O
,	O
the	O
observed	O
amount	O
of	O
specific	O
binding	O
corresponds	O
to	O
a	O
maximum	O
of	O
28	O
fmol	O
of	O
average	O
-	O
sized	O
50	O
kDa	O
proteins	O
[	O
36	O
]	O
,	O
or	O
less	O
than	O
0.03	O
%	O
of	O
the	O
total	O
PM	O
proteins	O
applied	O
.	O

Because	O
previous	O
work	O
suggested	O
that	O
JIM19	O
may	O
interact	O
with	O
ABA	B
signalling	O
mechanisms	O
[	O
24	O
]	O
,	O
we	O
tested	O
in	O
a	O
solution	O
competition	O
assay	O
the	O
effect	O
of	O
ABA	B
on	O
binding	O
of	O
PMs	O
to	O
the	O
JIM19	O
chip	O
.	O

A	O
dose	O
-	O
dependent	O
partial	O
inhibition	O
by	O
ABA	B
of	O
PM	O
binding	O
to	O
JIM19	O
was	O
observed	O
(	O
Fig.	O
4	O
)	O
.	O

Statistical	O
analysis	O
of	O
the	O
ABA	B
treatments	O
showed	O
that	O
taken	O
together	O
,	O
the	O
three	O
highest	O
ABA	B
concentrations	O
(	O
>	O
10	O
μM	O
)	O
resulted	O
in	O
significantly	O
higher	O
inhibition	O
of	O
JIM19	O
binding	O
to	O
PMs	O
than	O
the	O
three	O
lowest	O
ABA	B
concentrations	O
(	O
<	O
0.1	O
μM	O
;	O
P	O
<	O
0.04	O
,	O
one	O
-	O
sided	O
t	O
-test	O
,	O
equal	O
variance	O
)	O
.	O

The	O
specificity	O
of	O
this	O
inhibition	O
by	O
ABA	B
was	O
demonstrated	O
by	O
control	O
experiments	O
with	O
phaseic	B
acid	I
(	O
PA	B
)	O
,	O
an	O
oxidized	O
catabolite	B
of	O
ABA	B
that	O
is	O
biologically	O
inactive	O
in	O
most	O
,	O
but	O
not	O
all	O
,	O
physiological	O
assays	O
[	O
17	O
]	O
.	O

Equivalent	O
concentrations	O
of	O
PA	B
did	O
not	O
affect	O
PM	O
binding	O
to	O
JIM19	O
(	O
Fig.	O
4	O
)	O
.	O

A	O
statistical	O
analysis	O
of	O
the	O
data	O
set	O
indicates	O
that	O
ABA	B
was	O
significantly	O
more	O
active	O
than	O
PA	B
in	O
antagonizing	O
the	O
binding	O
of	O
PMs	O
to	O
JIM19	O
(	O
one	O
-	O
tailed	O
paired	O
Student	O
's	O
t	O
-test	O
,	O
P	O
<	O
0.0008	O
,	O
n	O
=	O
16	O
)	O
.	O

3.3	O
Functional	O
analysis	O
of	O
JIM19	O
effects	O
on	O
ABA	B
-	O
inducible	O
gene	O
expression	O
In	O
order	O
to	O
explore	O
the	O
biological	O
relevance	O
of	O
the	O
in	O
vitro	O
JIM19	O
interaction	O
with	O
PMs	O
,	O
ABA	B
and	O
phaseic	B
acid	I
,	O
we	O
quantified	O
by	O
two	O
independent	O
methods	O
ABA	B
-	O
inducible	O
transient	O
expression	O
of	O
the	O
Em	O
promoter	O
[	O
25,32	O
]	O
in	O
rice	O
protoplasts	O
.	O

Fig.	O
5	O
shows	O
the	O
results	O
of	O
an	O
enzyme	O
-	O
based	O
reporter	O
gene	O
assay	O
in	O
transiently	O
transformed	O
rice	O
protoplasts	O
.	O

Exogenous	O
ABA	B
activated	O
the	O
Em	O
promoter	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
phaseic	B
acid	I
was	O
not	O
active	O
in	O
triggering	O
Em	O
-	O
GUS	O
expression	O
(	O
Fig.	O
5	O
)	O
.	O

Hill	O
et	O
al.	O
[	O
17	O
]	O
also	O
found	O
phaseic	B
acid	I
to	O
be	O
inactive	O
in	O
inducing	O
Em	O
gene	O
expression	O
in	O
cultured	O
barley	O
embryos	O
.	O

Thus	O
,	O
the	O
in	O
vivo	O
specificity	O
and	O
sensitivity	O
for	O
ABA	B
perception	O
leading	O
to	O
Em	O
gene	O
expression	O
(	O
Fig.	O
5	O
)	O
correlate	O
well	O
with	O
the	O
in	O
vitro	O
specificity	O
for	O
ABA	B
antagonism	O
of	O
PM	O
binding	O
to	O
JIM19	O
(	O
Fig.	O
4	O
)	O
.	O

Because	O
protoplasts	O
are	O
a	O
heterogeneous	O
population	O
with	O
potentially	O
different	O
characteristics	O
that	O
might	O
complicate	O
analysis	O
of	O
signalling	O
pathways	O
,	O
we	O
developed	O
a	O
novel	O
,	O
quantitative	O
,	O
ABA	B
-	O
inducible	O
reporter	O
gene	O
expression	O
system	O
based	O
on	O
GFP	O
and	O
flow	O
cytometry	O
.	O

An	O
ABA	B
dose	O
-	O
GFP	O
intensity	O
response	O
curve	O
for	O
populations	O
of	O
protoplasts	O
transiently	O
expressing	O
GFP	O
driven	O
by	O
the	O
Em	O
promoter	O
is	O
shown	O
in	O
Fig.	O
6	O
.	O

Transformation	O
efficiency	O
was	O
approximately	O
one	O
percent	O
(	O
data	O
not	O
shown	O
)	O
.	O

Cell	O
viability	O
of	O
the	O
population	O
was	O
affected	O
negatively	O
by	O
high	O
ABA	B
concentrations	O
(	O
Fig.	O
6	O
)	O
.	O

Nonetheless	O
,	O
a	O
typical	O
log	O
-	O
linear	O
relationship	O
between	O
ABA	B
dose	O
and	O
GFP	O
abundance	O
in	O
individual	O
cells	O
was	O
observed	O
(	O
Fig.	O
6	O
)	O
.	O

Therefore	O
,	O
flow	O
cytometry	O
allows	O
quantitative	O
analysis	O
of	O
Em	O
:	O
GFP	O
expression	O
on	O
a	O
per	O
cell	O
basis	O
.	O

The	O
concentrations	O
of	O
ABA	B
required	O
for	O
transactivation	O
of	O
the	O
Em	O
promoter	O
in	O
these	O
assays	O
(	O
Figs.	O
5	O
and	O
6	O
)	O
are	O
in	O
the	O
physiological	O
range	O
found	O
in	O
plant	O
tissues	O
[	O
3	O
]	O
and	O
correlate	O
well	O
with	O
concentrations	O
required	O
for	O
ABA	B
-	O
inhibition	O
of	O
PM	O
binding	O
to	O
JIM19	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
an	O
attempt	O
to	O
correlate	O
further	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
effects	O
of	O
JIM19	O
on	O
ABA	B
signalling	O
,	O
the	O
ability	O
of	O
JIM19	O
to	O
antagonize	O
ABA	B
-	O
inducible	O
transient	O
Em	O
:	O
GUS	O
and	O
Em	O
:	O
GFP	O
expression	O
was	O
measured	O
.	O

Initial	O
experiments	O
demonstrated	O
that	O
JIM19	O
inhibited	O
ABA	B
effects	O
,	O
but	O
that	O
JIM20	O
had	O
no	O
activity	O
,	O
as	O
reported	O
previously	O
[	O
24	O
]	O
.	O

Consequently	O
,	O
we	O
used	O
JIM20	O
as	O
a	O
control	O
to	O
account	O
for	O
any	O
non	O
-	O
specific	O
antibody	O
effects	O
.	O

The	O
inhibition	O
of	O
ABA	B
-	O
inducible	O
Em	O
promoter	O
activation	O
by	O
co	O
-	O
incubation	O
of	O
protoplasts	O
with	O
JIM19	O
,	O
relative	O
to	O
JIM20	O
treatment	O
,	O
was	O
low	O
but	O
highly	O
significant	O
(	O
Table	O
2	O
;	O
one	O
-	O
tailed	O
paired	O
Student	O
's	O
t	O
-test	O
,	O
0.0003	O
<	O
P	O
<	O
0.001	O
)	O
.	O

About	O
45	O
%	O
inhibition	O
of	O
the	O
ABA	B
-	O
inducible	O
expression	O
of	O
the	O
Em	O
-	O
GUS	O
reporter	O
gene	O
was	O
achieved	O
by	O
treatment	O
of	O
protoplasts	O
with	O
JIM19	O
at	O
various	O
low	O
ABA	B
concentrations	O
(	O
Table	O
2	O
)	O
.	O

The	O
inhibition	O
was	O
consistently	O
25	O
%	O
when	O
measured	O
by	O
flow	O
cytometry	O
of	O
GFP	O
(	O
Table	O
2	O
)	O
.	O

These	O
results	O
on	O
the	O
interaction	O
of	O
JIM19	O
with	O
ABA	B
perception	O
leading	O
to	O
Em	O
promoter	O
activation	O
correlate	O
well	O
with	O
the	O
ABA	B
/	O
PM	O
interaction	O
observed	O
in	O
vitro	O
(	O
Fig.	O
4	O
)	O
.	O

4	O
Discussion	O
The	O
techniques	O
of	O
SPR	O
and	O
flow	O
cytometry	O
have	O
allowed	O
us	O
to	O
probe	O
the	O
mechanisms	O
of	O
JIM19	O
bioactivity	O
in	O
rice	O
protoplasts	O
.	O

Our	O
working	O
hypothesis	O
and	O
model	O
,	O
based	O
on	O
results	O
presented	O
here	O
,	O
is	O
that	O
the	O
JIM19	O
antibody	O
recognizes	O
an	O
epitope	O
in	O
rice	O
PMs	O
that	O
interacts	O
with	O
an	O
ABA	O
receptor	O
.	O

It	O
may	O
be	O
that	O
interaction	O
of	O
JIM19	O
with	O
a	O
surface	O
GP	O
adjacent	O
to	O
,	O
or	O
interactive	O
with	O
,	O
an	O
ABA	O
receptor	O
,	O
particularly	O
masks	O
an	O
ABA	B
binding	O
site	O
and	O
thereby	O
inhibits	O
ABA	B
responses	O
.	O

We	O
speculate	O
that	O
the	O
binding	O
of	O
ABA	B
to	O
a	O
receptor	O
complex	O
in	O
PMs	O
may	O
induce	O
a	O
conformational	O
change	O
that	O
alters	O
the	O
affinity	O
of	O
an	O
O	O
-linked	O
GP	O
epitope	O
for	O
JIM19	O
.	O

In	O
this	O
context	O
it	O
is	O
interesting	O
to	O
note	O
that	O
a	O
putative	O
O	O
-glucosyl	O
transferase	O
(	O
SPY	O
)	O
,	O
when	O
overexpressed	O
in	O
barley	O
aleurone	O
cells	O
,	O
can	O
transactivate	O
the	O
ABA	B
-	O
inducible	O
DHN	O
promoter	O
[	O
37	O
]	O
.	O

There	O
are	O
at	O
least	O
five	O
different	O
GPs	O
that	O
are	O
bound	O
by	O
JIM19	O
(	O
Fig.	O
2	O
)	O
.	O

Solution	O
competition	O
assays	O
with	O
JIM20	O
showed	O
a	O
high	O
degree	O
of	O
antagonism	O
of	O
PM	O
binding	O
to	O
JIM19	O
(	O
Table	O
2	O
)	O
,	O
suggesting	O
that	O
JIM19	O
and	O
JIM20	O
both	O
recognize	O
the	O
high	O
molecular	O
weight	O
epitopes	O
visualized	O
by	O
immunoblots	O
of	O
PM	O
proteins	O
(	O
Fig.	O
2	O
)	O
.	O

Although	O
such	O
a	O
heterogeneous	O
system	O
complicates	O
biochemical	O
analyses	O
by	O
SPR	O
,	O
these	O
results	O
do	O
suggest	O
that	O
JIM19	O
interacts	O
,	O
possibly	O
indirectly	O
,	O
with	O
ABA	B
signalling	O
mechanisms	O
.	O

The	O
semi	O
-	O
quantitative	O
capability	O
of	O
the	O
SPR	O
biosensor	O
allows	O
an	O
assessment	O
of	O
traditional	O
saturable	O
binding	O
assays	O
applied	O
to	O
the	O
postulated	O
ABA	O
receptor	O
,	O
assuming	O
that	O
the	O
calibration	O
of	O
the	O
SPR	O
signal	O
for	O
protein	O
also	O
holds	O
for	O
vesicles	O
.	O

Assuming	O
the	O
observed	O
ABA	B
-	O
antagonized	O
binding	O
of	O
PMs	O
to	O
JIM19	O
is	O
due	O
to	O
stoichiometric	O
binding	O
of	O
ABA	B
to	O
an	O
ABA	O
receptor	O
which	O
interacts	O
with	O
one	O
of	O
the	O
GPs	O
,	O
then	O
the	O
observed	O
SPR	O
signal	O
corresponds	O
to	O
50	O
pCi	O
3	B
H	I
-	I
ABA	I
,	O
or	O
approximately	O
2	O
Bq	O
(	O
120	O
dpm	O
)	O
/	O
μg	O
PM	O
protein	O
.	O

This	O
amount	O
of	O
label	O
is	O
near	O
the	O
limit	O
of	O
detection	O
of	O
binding	O
assays	O
.	O

The	O
SPR	O
PM	O
-	O
JIM19	O
biosensor	O
assay	O
described	O
here	O
provides	O
a	O
novel	O
and	O
sensitive	O
method	O
for	O
characterization	O
of	O
an	O
activity	O
associated	O
with	O
ABA	B
perception	O
.	O

There	O
are	O
conserved	O
heterodimeric	O
GPs	O
in	O
plants	O
and	O
animals	O
,	O
viz	O
.	O
integrins	O
,	O
that	O
function	O
in	O
cell	O
surface	O
recognition	O
,	O
adhesion	O
and	O
signal	O
transduction	O
[	O
38,39	O
]	O
.	O

The	O
affinities	O
and	O
conformation	O
of	O
integrins	O
are	O
modulated	O
by	O
cations	O
and	O
receptor	O
activation	O
[	O
40	O
]	O
.	O

Consistent	O
with	O
an	O
integrin	O
model	O
of	O
ABA	B
signalling	O
is	O
the	O
agonistic	O
effect	O
of	O
multivalent	O
cations	O
on	O
ABA	B
-	O
regulated	O
gene	O
expression	O
[	O
15,41	O
]	O
.	O

In	O
addition	O
,	O
recent	O
reports	O
have	O
demonstrated	O
the	O
existence	O
in	O
plants	O
of	O
glycosylphosphatidylinositol	B
(	O
GPI	B
)	O
-anchored	O
arabinogalactan	B
proteins	O
[	O
42	O
]	O
,	O
with	O
exciting	O
implications	O
for	O
signal	O
transduction	O
pathways	O
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Dr.	O
Jen	O
Sheen	O
for	O
p35SC4PPDK	O
-	O
sGFP	O
(	O
S65	O
T	O
)	O
,	O
Patrick	O
Po	O
Fai	O
Ng	O
,	O
Leigh	O
Brian	O
and	O
Regina	O
Kit	O
Fong	O
Chak	O
for	O
assistance	O
with	O
rice	O
tissue	O
culture	O
and	O
protoplasts	O
,	O
Kim	O
Kam	O
-	O
Chi	O
Li	O
for	O
assistance	O
with	O
BIAcore	O
instrumentation	O
,	O
Frances	O
Shuk	O
-	O
Lan	O
Chan	O
for	O
assistance	O
with	O
flow	O
cytometry	O
,	O
Drs	O
.	O

Tom	O
Schultz	O
and	O
Ralph	O
Quatrano	O
for	O
sharing	O
unpublished	O
results	O
and	O
Drs	O
.	O

Yung	O
Hou	O
Wong	O
and	O
Kevin	O
Lee	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
and	O
helpful	O
discussions	O
.	O

This	O
work	O
was	O
supported	O
by	O
Grant	O
#	O
JRS96	O
/	O
33	O
from	O
the	O
United	O
Kingdom	O
/	O
Hong	O
Kong	O
Joint	O
Research	O
Scheme	O
to	O
C.D.R.	O
and	O
S.J.N.	O
and	O
by	O
Competitive	O
Earmarked	O
Research	O
Grant	O
#	O
HKUST	O
6173	O
/	O
97	O
M	O
from	O
the	O
Hong	O
Kong	O
Research	O
Grants	O
Council	O
to	O
C.D.R.	O

The	O
cytochrome	O
P450	O
(	O
CYP	O
,	O
EC	O
1.14.14.1	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
metabolism	O
of	O
various	O
drugs	B
,	O
steroids	B
,	O
mutagens	B
and	O
carcinogens	B
[	O
1	O
]	O
.	O

It	O
can	O
metabolize	O
chemicals	O
into	O
reactive	B
intermediates	I
binding	O
spontaneously	O
to	O
proteins	O
,	O
nucleic	O
acids	O
,	O
lipids	B
and	O
to	O
CYP	O
itself	O
[	O
2	O
]	O
.	O

Organic	B
compounds	I
can	O
cause	O
CYP	O
destruction	O
by	O
irreversible	O
binding	O
of	O
their	O
metabolites	B
to	O
the	O
CYP	O
heme	O
,	O
apoprotein	O
,	O
or	O
both	O
[	O
3–5	O
]	O
.	O

It	O
was	O
postulated	O
that	O
CYP	O
can	O
be	O
destroyed	O
by	O
superoxide	B
anionradical	I
,	O
H2	B
O2	I
or	O
other	O
reactive	B
oxygen	I
species	I
formed	O
during	O
the	O
futile	O
cycle	O
without	O
substrate	O
[	O
6	O
]	O
or	O
via	O
reactive	B
oxygen	I
species	I
-	O
initiated	O
lipid	B
peroxidation	O
[	O
7	O
]	O
.	O

Some	O
CYP	O
isoforms	O
appear	O
to	O
be	O
more	O
sensitive	O
to	O
certain	O
substrates	O
[	O
8–10	O
]	O
.	O

An	O
inhibition	O
or	O
destruction	O
of	O
CYP	O
may	O
cause	O
prolongation	O
of	O
xenobiotic	B
action	O
,	O
increase	O
or	O
decrease	O
in	O
xenobiotic	B
toxicity	O
,	O
and	O
even	O
affect	O
physiological	O
functions	O
,	O
e.g.	O
steroid	B
biosynthesis	O
[	O
11	O
]	O
.	O

Selective	O
destruction	O
of	O
various	O
CYP	O
isoforms	O
alters	O
the	O
activation	O
/	O
detoxification	O
ratio	O
of	O
procarcinogens	B
and	O
thus	O
may	O
increase	O
the	O
cancer	O
risk	O
in	O
conditions	O
of	O
combined	O
exposure	O
[	O
10,12	O
]	O
.	O

Benzene	B
is	O
an	O
established	O
human	O
and	O
animal	O
carcinogen	O
[	O
13	O
]	O
acting	O
through	O
an	O
epigenetic	O
mechanism	O
.	O

Benzene	B
-	O
induced	O
myelotoxic	O
and	O
carcinogenic	O
effects	O
are	O
supposed	O
to	O
be	O
caused	O
by	O
covalent	O
binding	O
of	O
its	O
metabolites	B
to	O
biomacromolecules	O
[	O
14,15	O
]	O
.	O

Exposure	O
to	O
benzene	B
was	O
reported	O
to	O
lower	O
the	O
cytochrome	O
P450	O
content	O
and	O
activity	O
in	O
rats	O
pretreated	O
by	O
phenobarbital	B
in	O
vivo	O
[	O
16	O
]	O
.	O

The	O
role	O
of	O
benzene	B
in	O
CYP	O
destruction	O
was	O
also	O
studied	O
in	O
vitro	O
,	O
and	O
preliminary	O
results	O
revealed	O
that	O
the	O
main	O
destructive	O
agent	O
may	O
be	O
benzoquinone	B
[	O
17	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
in	O
detail	O
the	O
mechanism	O
of	O
CYP	O
destruction	O
by	O
benzene	B
and	O
its	O
metabolites	B
.	O

Lipid	B
peroxidation	O
and	O
formation	O
of	O
reactive	B
oxygen	I
species	I
was	O
followed	O
up	O
as	O
well	O
as	O
the	O
concentration	O
of	O
superoxide	B
anionradical	I
.	O

Selectivity	O
in	O
destruction	O
of	O
inducible	O
and	O
constitutive	O
rat	O
CYP	O
isoforms	O
was	O
studied	O
and	O
a	O
comparison	O
of	O
the	O
sensitivity	O
of	O
human	O
and	O
rat	O
CYP	O
was	O
carried	O
out	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O

All	O
chemicals	O
used	O
were	O
of	O
analytical	O
grade	O
.	O

NADPH	B
,	O
NADP	B
,	O
glucose-6-phosphate	B
,	O
chlorzoxazone	B
,	O
7-pentoxyresorufin	B
,	O
7-ethoxyresorufin	B
,	I
resorufin	B
,	O
tolbutamide	B
,	O
nifedipine	B
,	O
β	B
-	I
naphtoflavone	I
,	O
pregnenolone	B
16α	I
-	I
carbonitrile	I
,	O
MgCl2	B
,	O
Tris	B
,	O
KCl	B
,	O
and	O
chemicals	O
for	O
electrophoresis	O
and	O
immunoblotting	O
were	O
obtained	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

Glucose-6-phosphate	O
dehydrogenase	O
was	O
obtained	O
from	O
Boehringer	O
(	O
Mannheim	O
,	O
Germany	O
)	O
.	O

Solvents	O
used	O
in	O
HPLC	O
methods	O
were	O
products	O
of	O
Merck	O
(	O
Darmstadt	O
,	O
Germany	O
)	O
.	O

6-Hydroxychlorzoxazone	B
was	O
synthetized	O
at	O
Research	O
Institute	O
of	O
Pharmacy	O
and	O
Biochemistry	O
,	O
Czech	O
Republic	O
.	O

Polyclonal	O
anti	O
rat	O
CYP1A1	O
/	O
2	O
,	O
2B1	O
,	O
2E1	O
,	O
and	O
3A1	O
/	O
2	O
antibodies	O
were	O
generous	O
gifts	O
of	O
Magnus	O
Ingelman	O
-	O
Sundberg	O
(	O
Berzelius	O
Laboratory	O
,	O
Karolinska	O
Institutet	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
.	O

Oxidized	O
nifedipine	B
and	O
hydroxytolbutamide	B
were	O
generous	O
gifts	O
of	O
F.	O
Peter	O
Guengerich	O
(	O
Center	O
in	O
Molecular	O
Toxicology	O
,	O
Vanderbilt	O
University	O
,	O
Nashville	O
,	O
TN	O
,	O
USA	O
)	O
.	O

Hydroquinone	B
and	O
catechol	B
was	O
purified	O
by	O
crystallization	O
and	O
benzoquinone	B
by	O
sublimation	O
before	O
use	O
.	O

2.2	O
Animals	O
and	O
pretreatments	O
Adult	O
male	O
Wistar	O
rats	O
(	O
200–260	O
g	O
,	O
VELAZ	O
,	O
Czech	O
Republic	O
)	O
were	O
fed	O
ad	O
libitum	O
on	O
pellet	O
chow	O
and	O
water	O
a	O
week	O
before	O
use	O
.	O

Four	O
groups	O
of	O
rats	O
(	O
n	O
=	O
3–8	O
)	O
were	O
specifically	O
pretreated	O
to	O
induce	O
certain	O
CYP	O
isoforms	O
in	O
rat	O
liver	O
.	O

Control	O
microsomes	O
were	O
prepared	O
from	O
untreated	O
rats	O
.	O

One	O
pretreated	O
group	O
was	O
exposed	O
to	O
benzene	B
by	O
inhalation	O
,	O
4	O
mg	O
/	O
l	O
,	O
20	O
h	O
/	O
day	O
for	O
3	O
days	O
as	O
described	O
before	O
[	O
16	O
]	O
to	O
induce	O
high	O
levels	O
of	O
CYP2E1	O
.	O

Another	O
group	O
was	O
pretreated	O
with	O
pregnenolone	B
16α	I
-	I
carbonitrile	I
for	O
CYP3A	O
induction	O
in	O
five	O
i.g	O
.	O

intubations	O
,	O
25	O
mg	O
/	O
kg	O
in	O
olive	B
oil	I
in	O
12-h	O
intervals	O
during	O
3	O
days	O
.	O

The	O
third	O
group	O
was	O
pretreated	O
with	O
sodium	B
phenobarbital	I
(	O
0.1	O
%	O
in	O
drinking	O
water	B
for	O
5	O
days	O
and	O
one	O
i.p	O
.	O

injection	O
,	O
80	O
mg	O
/	O
kg	O
,	O
24	O
h	O
before	O
killing	O
)	O
to	O
induce	O
CYP2B1	O
.	O

The	O
β	B
-	I
naphtoflavone	I
-	O
pretreated	O
rats	O
(	O
80	O
mg	O
/	O
kg	O
in	O
olive	B
oil	I
i.p	O
.	O

for	O
3	O
days	O
)	O
were	O
the	O
source	O
of	O
CYP1A1	O
/	O
2-induced	O
microsomes	O
.	O

The	O
animals	O
were	O
killed	O
24	O
h	O
after	O
the	O
last	O
inducer	O
dose	O
or	O
immediately	O
after	O
the	O
third	O
exposure	O
to	O
benzene	B
.	O

Livers	O
from	O
animals	O
in	O
particular	O
groups	O
were	O
pooled	O
for	O
preparation	O
of	O
microsomes	O
.	O

2.3	O
Human	O
liver	O
samples	O
Human	O
liver	O
samples	O
were	O
obtained	O
from	O
the	O
Transplantation	O
Center	O
IKEM	O
,	O
Czech	O
Republic	O
,	O
from	O
donors	O
who	O
died	O
accidentally	O
as	O
a	O
result	O
of	O
brain	O
injury	O
.	O

Liver	O
samples	O
were	O
obtained	O
at	O
most	O
30	O
min	O
after	O
death	O
and	O
were	O
stored	O
in	O
liquid	O
nitrogen	O
until	O
microsomes	O
were	O
isolated	O
.	O

Some	O
of	O
the	O
donors	O
were	O
subjected	O
to	O
therapy	O
including	O
antibiotics	B
(	O
chloramphenicol	B
,	O
penicillin	B
,	O
ampicillin	B
,	O
gentamycin	B
)	O
,	O
mannitol	B
,	O
or	O
hormones	B
(	O
hydrocortisone	B
,	O
dexamethasone	B
)	O
for	O
24–48	O
h	O
before	O
death	O
.	O

2.4	O
Isolation	O
of	O
microsomes	O
Microsomes	O
were	O
prepared	O
according	O
to	O
van	O
der	O
Hoeven	O
and	O
Coon	O
[	O
18	O
]	O
and	O
stored	O
in	O
aliquots	O
of	O
0.1	O
ml	O
at	O
−80	O
°	O
C	O
until	O
use	O
.	O

Protein	O
concentration	O
was	O
determined	O
immediately	O
after	O
preparation	O
of	O
microsomes	O
according	O
to	O
Lowry	O
et	O
al.	O
[	O
19	O
]	O
using	O
serum	O
albumin	O
as	O
a	O
standard	O
.	O

The	O
total	O
CYP	O
content	O
was	O
estimated	O
by	O
the	O
spectrophotometric	O
method	O
of	O
Omura	O
and	O
Sato	O
[	O
20	O
]	O
.	O

2.5	O
Microsomal	O
incubations	O
Microsomes	O
(	O
1	O
mg	O
protein	O
/	O
ml	O
)	O
were	O
preincubated	O
with	O
1	O
mM	O
catechol	B
,	O
hydroquinone	B
,	O
or	O
benzoquinone	B
without	O
NADPH	B
or	O
with	O
NADPH	B
generating	O
system	O
only	O
(	O
10	O
mM	O
MgCl2	B
,	O
10	O
mM	O
glucose-6-phosphate	B
,	O
1	O
mM	O
NADP	B
,	O
0.5	O
U	O
/	O
ml	O
glucose-6-phosphate	O
dehydrogenase	O
)	O
in	O
total	O
volume	O
of	O
2	O
ml	O
of	O
150	O
mM	O
KCl	B
/	O
50	O
mM	O
Tris	B
(	O
pH	O
7.4	O
)	O
buffer	O
.	O

Preincubation	O
proceeded	O
for	O
60	O
min	O
at	O
37	O
°	O
C	O
in	O
a	O
shaking	O
water	B
bath	O
in	O
the	O
dark	O
.	O

After	O
preincubation	O
the	O
content	O
of	O
total	O
CYP	O
was	O
measured	O
by	O
the	O
spectrophotometric	O
method	O
of	O
Omura	O
and	O
Sato	O
[	O
20	O
]	O
.	O

In	O
order	O
to	O
avoid	O
interference	O
of	O
quinones	B
with	O
subsequent	O
analysis	O
after	O
preincubation	O
,	O
microsomes	O
were	O
pelleted	O
by	O
centrifugation	O
for	O
20	O
min	O
at	O
180	O
000	O
×	O
g	O
at	O
4	O
°	O
C	O
.	O

Pellets	O
were	O
resuspended	O
in	O
0.5	O
ml	O
KCl	B
–	O
Tris	B
buffer	O
.	O

Determination	O
of	O
activity	O
and	O
apoprotein	O
level	O
of	O
CYP	O
isoforms	O
by	O
assay	O
of	O
metabolism	O
of	O
marker	O
substrates	O
and	O
immunoblotting	O
in	O
sample	O
aliquots	O
followed	O
as	O
well	O
as	O
estimation	O
of	O
concentration	O
of	O
OH	B
radicals	I
,	O
semiquinone	B
radicals	I
and	O
malondialdehyde	B
(	O
MDA	B
)	O
.	O

2.6	O
Electrophoresis	O
and	O
immunoblotting	O
SDS	B
–	O
polyacrylamide	B
gel	O
electrophoresis	O
of	O
microsomal	O
proteins	O
was	O
performed	O
according	O
to	O
Laemmli	O
[	O
21	O
]	O
using	O
a	O
MiniProtean	O
II	O
apparatus	O
(	O
BioRad	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

For	O
immunoblotting	O
10	O
%	O
polyacrylamide	B
gel	O
was	O
used	O
and	O
5	O
μg	O
microsomal	O
protein	O
per	O
lane	O
were	O
applied	O
.	O

Immunoblotting	O
was	O
then	O
done	O
as	O
described	O
by	O
Towbin	O
et	O
al.	O
[	O
22	O
]	O
using	O
a	O
Miniblotter	O
device	O
(	O
BioRad	O
)	O
.	O

Blots	O
were	O
incubated	O
with	O
primary	O
antibody	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
in	O
PBST	B
buffer	O
(	O
20	O
mM	O
potassium	B
phosphate	I
(	O
pH	O
7.4	O
)	O
/	O
150	O
mM	O
NaCl	B
/	O
0.05	O
%	O
Tween	B
80	I
)	O
Anti	O
-	O
rat	O
CYP1A1	O
/	O
2	O
,	O
2B1	O
,	O
2E1	O
,	O
or	O
3A1	O
/	O
2	O
polyclonal	O
antibodies	O
were	O
used	O
in	O
dilution	O
of	O
1	O
/	O
500	O
for	O
2E1	O
antiserum	O
and	O
1	O
/	O
2000	O
for	O
the	O
rest	O
of	O
antisera	O
.	O

The	O
next	O
incubation	O
was	O
with	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
coupled	O
to	O
horseradish	O
peroxidase	O
as	O
a	O
secondary	O
antibody	O
(	O
dilution	O
1	O
/	O
1000	O
for	O
1	O
h	O
at	O
room	O
temperature	O
)	O
.	O

For	O
visualization	O
of	O
the	O
bands	O
a	O
mixture	O
of	O
2.5	O
mM	O
1-chloro-4-naphthol	B
and	O
15	O
mM	O
H2	B
O2	I
in	O
PBS	B
buffer	O
was	O
used	O
.	O

2.7	O
Enzyme	O
assays	O
7-Ethoxyresorufin	B
O	O
-deethylation	O
and	O
7-pentoxyresorufin	B
O	O
-depentylation	O
were	O
assayed	O
according	O
to	O
Lubet	O
et	O
al.	O
[	O
23	O
]	O
with	O
1.75	O
or	O
5	O
μM	O
substrate	O
,	O
respectively	O
,	O
0.25	O
mM	O
NADPH	B
,	O
and	O
100	O
pmol	O
CYP	O
for	O
20	O
min	O
.	O

Coumarin	B
7-hydroxylation	O
was	O
assayed	O
as	O
described	O
by	O
Yun	O
et	O
al.	O
[	O
24	O
]	O
with	O
20	O
μM	O
substrate	O
,	O
100	O
pmol	O
of	O
total	O
CYP	O
for	O
20	O
min	O
.	O

Tolbutamide	B
methylhydroxylation	O
was	O
performed	O
according	O
to	O
Knodell	O
et	O
al.	O
[	O
25	O
]	O
with	O
2.5	O
mM	O
substrate	O
,	O
NADPH	B
-	O
generating	O
system	O
(	O
10	O
mM	O
MgCl2	B
,	O
10	O
mM	O
glucose-6-phosphate	B
,	O
1	O
mM	O
NADP	B
,	O
0.5	O
U	O
/	O
ml	O
glucose-6-phosphate	O
dehydrogenase	O
)	O
,	O
and	O
100	O
pmol	O
CYP	O
for	O
30	O
min	O
.	O

Chlorzoxazone	B
6-hydroxylation	O
was	O
followed	O
according	O
to	O
Peter	O
et	O
al.	O
[	O
26	O
]	O
with	O
0.1	O
mM	O
substrate	O
,	O
NADPH	B
generating	O
system	O
(	O
see	O
above	O
)	O
,	O
and	O
100	O
pmol	O
of	O
CYP	O
for	O
20	O
min	O
.	O

Oxidation	O
of	O
nifedipine	B
was	O
determined	O
after	O
Guengerich	O
et	O
al.	O
[	O
27	O
]	O
with	O
80	O
μM	O
substrate	O
,	O
NADPH	B
-	O
generating	O
system	O
(	O
see	O
above	O
)	O
,	O
and	O
100	O
pmol	O
CYP	O
for	O
15	O
min	O
.	O

All	O
incubations	O
were	O
carried	O
out	O
in	O
total	O
volume	O
of	O
0.5	O
ml	O
of	O
KCl	B
–	O
Tris	B
buffer	O
at	O
37	O
°	O
C	O
in	O
a	O
shaking	O
water	B
bath	O
.	O

2.8	O
Other	O
assays	O
Concentration	O
of	O
OH	B
radicals	I
was	O
measured	O
as	O
described	O
[	O
28	O
]	O
and	O
lipid	B
peroxidation	O
was	O
estimated	O
according	O
to	O
Buege	O
and	O
Aust	O
[	O
29	O
]	O
.	O

Semiquinone	B
anion	I
radical	I
formation	O
was	O
evaluated	O
as	O
described	O
by	O
Gut	O
et	O
al.	O
[	O
16	O
]	O
.	O

2.9	O
Statistics	O
All	O
results	O
are	O
expressed	O
as	O
the	O
average	O
of	O
two	O
measurements	O
,	O
means	O
(	O
±S.D.	O
or	O
subject	O
to	O
correlation	O
analysis	O
.	O

The	O
Student	O
's	O
t	O
-test	O
was	O
used	O
for	O
analysis	O
of	O
differences	O
between	O
groups	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
CYP	O
destruction	O
by	O
quinones	B
and	O
NADPH	B
:	O
spectrophotometric	O
evaluation	O
of	O
CYP	O
content	O
Microsomes	O
from	O
rats	O
pretreated	O
with	O
various	O
CYP	O
inducers	O
were	O
preincubated	O
with	O
either	O
NADPH	B
without	O
substrate	O
or	O
quinones	B
in	O
the	O
absence	O
of	O
NADPH	B
.	O

This	O
experiment	O
showed	O
that	O
various	O
rat	O
CYP	O
isoforms	O
differed	O
in	O
sensitivity	O
to	O
both	O
NADPH	B
and	O
benzoquinone	B
.	O

CYP	O
3A	O
isoforms	O
were	O
the	O
most	O
sensitive	O
to	O
destruction	O
by	O
the	O
futile	O
cycle	O
(	O
Fig.	O
1	O
A	O
)	O
.	O

CYP	O
3A	O
as	O
well	O
as	O
CYP	O
1A	O
isoforms	O
were	O
also	O
found	O
to	O
be	O
the	O
most	O
sensitive	O
to	O
the	O
deleterious	O
action	O
of	O
benzoquinone	B
(	O
Fig.	O
1	O
B	O
)	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
electrophoresis	O
of	O
preincubated	O
microsomes	O
with	O
subsequent	O
immunochemical	O
detection	O
of	O
specific	O
CYP	O
isoforms	O
by	O
immunoblotting	O
(	O
Fig.	O
2	O
)	O
.	O

Protein	O
bands	O
corresponding	O
to	O
rat	O
CYP	O
3A1	O
/	O
2	O
and	O
1A1	O
/	O
2	O
proteins	O
completely	O
disappeared	O
after	O
preincubation	O
of	O
microsomes	O
with	O
benzoquinone	B
while	O
that	O
of	O
CYP	O
2B1	O
remained	O
visible	O
.	O

Assays	O
of	O
CYP	O
activity	O
showed	O
that	O
CYP	O
1A	O
and	O
3A	O
marker	O
activities	O
were	O
completely	O
destroyed	O
by	O
benzoquinone	B
(	O
100	O
%	O
destruction	O
of	O
nifedipine	B
oxidation	O
and	O
99.5	O
%	O
destruction	O
of	O
EROD	O
;	O
see	O
Table	O
1	O
)	O
.	O

CYP	O
2B1	O
and	O
2E1	O
proteins	O
seemed	O
to	O
be	O
slightly	O
more	O
resistant	O
to	O
the	O
destructive	O
effect	O
of	O
benzoquinone	B
as	O
judged	O
by	O
comparison	O
of	O
measurement	O
of	O
total	O
CYP	O
content	O
,	O
immunochemical	O
detection	O
,	O
and	O
marker	O
activity	O
assays	O
(	O
96	O
%	O
destruction	O
of	O
PROD	O
and	O
93	O
%	O
destruction	O
of	O
chlorzoxazone	B
oxidation	O
)	O
.	O

Rat	O
constitutive	O
CYP	O
isoforms	O
present	O
in	O
untreated	O
microsomes	O
appeared	O
to	O
be	O
the	O
most	O
resistant	O
to	O
the	O
NADPH	B
-	O
mediated	O
futile	O
cycle	O
and	O
also	O
showed	O
higher	O
resistance	O
to	O
benzoquinone	B
than	O
highly	O
inducible	O
CYP	O
1A	O
and	O
3A	O
isoforms	O
(	O
Fig.	O
1	O
)	O
.	O

No	O
significant	O
difference	O
between	O
various	O
types	O
of	O
microsomes	O
was	O
observed	O
in	O
sensitivity	O
to	O
hydroquinone	B
(	O
40–60	O
%	O
destruction	O
of	O
total	O
CYP	O
)	O
.	O

It	O
seems	O
to	O
be	O
apparent	O
that	O
sensitivities	O
of	O
the	O
relevant	O
CYP	O
isoforms	O
(	O
particularly	O
CYP	O
1A	O
and	O
3A	O
isoforms	O
)	O
to	O
quinones	B
differ	O
(	O
Fig.	O
1	O
,	O
Fig.	O
2	O
,	O
and	O
Table	O
1	O
)	O
.	O

On	O
the	O
contrary	O
Belisario	O
et	O
al.	O
observed	O
a	O
significantly	O
higher	O
inhibition	O
of	O
CYP	O
2B1	O
than	O
CYP	O
1A	O
activity	O
by	O
avarol	B
-	I
sesquiterpenoid	I
hydroquinone	B
and	O
its	O
quinone	B
avarone	B
(	O
30	O
μM	O
)	O
in	O
vitro	O
[	O
30	O
]	O
.	O

A	O
selective	O
inhibition	O
of	O
PROD	O
activity	O
(	O
in	O
comparison	O
with	O
EROD	B
)	O
in	O
rat	O
lung	O
microsomes	O
after	O
inhalation	O
of	O
a	O
benzene	B
derivative	O
m	B
-xylene	I
was	O
reported	O
as	O
well	O
[	O
10	O
]	O
.	O

Data	O
presented	O
here	O
do	O
not	O
suggest	O
higher	O
sensitivity	O
of	O
PROD	O
to	O
quinones	B
in	O
comparison	O
with	O
EROD	O
in	O
rat	O
liver	O
microsomes	O
in	O
vitro	O
.	O

One	O
possible	O
explanation	O
for	O
this	O
discrepancy	O
may	O
be	O
differences	O
in	O
the	O
amounts	O
of	O
quinones	B
presented	O
to	O
microsomal	O
proteins	O
.	O

Differences	O
in	O
the	O
distribution	O
of	O
CYP	O
proteins	O
in	O
the	O
lung	O
and	O
liver	O
may	O
play	O
a	O
role	O
as	O
well	O
.	O

3.2	O
Mechanism	O
of	O
CYP	O
destruction	O
:	O
evaluation	O
of	O
the	O
role	O
of	O
OH	B
radicals	I
,	O
semiquinone	B
radical	I
,	O
and	O
lipid	B
peroxidation	O
OH	B
radical	I
formation	O
and	O
induction	O
of	O
lipid	B
peroxidation	O
was	O
measured	O
in	O
various	O
types	O
of	O
microsomes	O
after	O
preincubation	O
with	O
NADPH	B
without	O
substrate	O
,	O
hydroquinone	B
or	O
benzoquinone	B
in	O
the	O
absence	O
of	O
NADPH	B
(	O
Figs.	O
3	O
and	O
4	O
)	O
.	O

The	O
NADPH	B
-	O
mediated	O
futile	O
cycle	O
greatly	O
enhanced	O
production	O
of	O
both	O
OH	B
radicals	I
and	O
MDA	B
(	O
marker	O
of	O
lipid	O
peroxidation	O
)	O
in	O
all	O
kinds	O
of	O
microsomes	O
(	O
Fig.	O
3	O
B	O
and	O
Fig.	O
4	O
B	O
)	O
.	O

On	O
the	O
other	O
hand	O
both	O
quinones	B
significantly	O
decreased	O
production	O
of	O
OH	B
radicals	I
and	O
MDA	B
in	O
all	O
kinds	O
of	O
microsomes	O
(	O
Fig.	O
3	O
C	O
and	O
Fig.	O
4	O
C	O
)	O
.	O

Thus	O
it	O
seems	O
that	O
quinones	B
exerted	O
a	O
rather	O
protective	O
effect	O
against	O
OH	B
radical	I
production	O
and	O
lipid	B
peroxidation	O
.	O

Therefore	O
it	O
can	O
be	O
concluded	O
that	O
these	O
processes	O
do	O
not	O
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
CYP	O
destruction	O
by	O
quinones	B
.	O

Reactive	B
oxygen	I
species	I
-	O
scavenging	O
capacity	O
of	O
quinonic	O
substances	O
was	O
reported	O
[	O
31,32	O
]	O
.	O

The	O
protective	O
effect	O
of	O
quinones	B
against	O
reactive	B
oxygen	I
species	I
formation	O
and	O
induction	O
of	O
lipid	B
peroxidation	O
may	O
play	O
a	O
positive	O
role	O
in	O
the	O
antitumor	O
activity	O
of	O
various	O
cytostatics	B
of	O
a	O
quinone	B
nature	O
or	O
with	O
an	O
expected	O
formation	O
of	O
quinonic	B
metabolites	I
in	O
the	O
course	O
of	O
their	O
metabolic	O
pathways	O
(	O
e.g.	O
adriamycin	B
,	O
daunorubicin	B
,	O
etoposide	B
,	O
etc	O
)	O
.	O

The	O
level	O
of	O
OH	B
radicals	I
formation	O
did	O
not	O
correlate	O
with	O
total	O
CYP	O
destruction	O
mediated	O
by	O
NADPH	B
,	O
suggesting	O
that	O
OH	B
radicals	I
do	O
not	O
play	O
a	O
role	O
in	O
the	O
mechanism	O
of	O
CYP	O
destruction	O
by	O
NADPH	B
-	O
mediated	O
futile	O
cycle	O
.	O

Although	O
it	O
was	O
reported	O
that	O
CYP	O
2E1	O
is	O
able	O
to	O
produce	O
higher	O
amounts	O
of	O
reactive	B
oxygen	I
species	I
and	O
initiate	O
lipid	B
peroxidation	O
[	O
33	O
]	O
,	O
increased	O
amounts	O
of	O
OH	B
radicals	I
or	O
MDA	B
in	O
microsomes	O
with	O
induced	O
CYP	O
2E1	O
were	O
not	O
observed	O
(	O
Fig.	O
3	O
)	O
.	O

Nevertheless	O
,	O
the	O
assay	O
conditions	O
used	O
by	O
Ekstroem	O
and	O
Ingelman	O
-	O
Sundberg	O
[	O
33	O
]	O
markedly	O
differed	O
from	O
those	O
used	O
in	O
this	O
study	O
(	O
different	O
CYP	O
inducers	O
,	O
incubation	O
buffer	O
,	O
temperature	O
and	O
time	O
of	O
incubation	O
,	O
measurement	O
of	O
O2	B
−	I
and	O
H2	B
O2	I
)	O
.	O

On	O
the	O
other	O
hand	O
the	O
more	O
MDA	B
formed	O
in	O
the	O
presence	O
of	O
NADPH	B
without	O
substrate	O
,	O
the	O
higher	O
was	O
the	O
destruction	O
of	O
total	O
CYP	O
(	O
Fig.	O
1	O
A	O
and	O
Fig.	O
4	O
B	O
)	O
.	O

It	O
was	O
postulated	O
that	O
lipid	B
peroxidation	O
is	O
the	O
main	O
contributing	O
factor	O
in	O
CYP	O
destruction	O
by	O
the	O
NADPH	B
-	O
mediated	O
futile	O
cycle	O
[	O
7	O
]	O
and	O
data	O
obtained	O
in	O
this	O
study	O
further	O
support	O
this	O
conclusion	O
.	O

Semiquinone	B
radical	I
formation	O
(	O
Fig.	O
5	O
)	O
did	O
not	O
correlate	O
with	O
the	O
rapid	O
course	O
of	O
CYP	O
destruction	O
produced	O
by	O
quinones	B
in	O
microsomes	O
from	O
phenobarbital	B
-	O
pretreated	O
rats	O
observed	O
previously	O
[	O
17	O
]	O
.	O

Taken	O
together	O
these	O
data	O
provide	O
new	O
evidence	O
to	O
support	O
the	O
previously	O
reported	O
conclusion	O
[	O
17	O
]	O
that	O
CYP	O
destruction	O
proceeds	O
by	O
direct	O
binding	O
of	O
the	O
oxidized	B
form	I
of	I
quinone	I
(	O
in	O
this	O
case	O
benzoquinone	B
)	O
to	O
protein	O
and	O
heme	B
moieties	O
of	O
CYP	O
.	O

These	O
results	O
also	O
comply	O
with	O
the	O
data	O
of	O
Lunte	O
and	O
Kissinger	O
[	O
34	O
]	O
who	O
found	O
that	O
in	O
microsomal	O
in	O
vitro	O
incubations	O
,	O
hydroquinone	B
was	O
oxidized	O
to	O
benzoquinone	B
,	O
which	O
resulted	O
in	O
an	O
increased	O
rate	O
of	O
covalent	O
binding	O
.	O

3.3	O
CYP	O
destruction	O
in	O
human	O
liver	O
microsomes	O
Total	O
CYP	O
destruction	O
was	O
measured	O
in	O
microsomes	O
from	O
five	O
different	O
human	O
liver	O
samples	O
after	O
preincubation	O
with	O
NADPH	B
alone	O
or	O
quinone	B
without	O
NADPH	B
.	O

Microsomes	O
used	O
in	O
this	O
study	O
were	O
screened	O
for	O
activity	O
of	O
various	O
human	O
liver	O
CYP	O
isoforms	O
(	O
1A2	O
,	O
2A6	O
,	O
2C9	O
,	O
2E1	O
,	O
3A4-Table	O
2	O
)	O
.	O

Surprisingly	O
,	O
human	O
liver	O
CYP	O
was	O
significantly	O
more	O
resistant	O
to	O
the	O
destructive	O
effect	O
of	O
the	O
NADPH	B
-	O
mediated	O
futile	O
cycle	O
in	O
comparison	O
with	O
rat	O
CYP	O
.	O

Some	O
of	O
the	O
microsomes	O
even	O
did	O
not	O
show	O
any	O
decrease	O
of	O
the	O
total	O
CYP	O
content	O
after	O
1-h	O
preincubation	O
with	O
NADPH	B
alone	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
samples	O
of	O
human	O
liver	O
microsomes	O
showed	O
significantly	O
higher	O
sensitivity	O
to	O
the	O
deleterious	O
effect	O
of	O
benzoquinone	B
than	O
rat	O
microsomes	O
(	O
Fig.	O
6	O
)	O
.	O

The	O
destructive	O
effect	O
of	O
reduced	O
quinones	B
(	O
hydroquinone	B
and	O
catechol	B
)	O
was	O
lower	O
than	O
that	O
of	O
the	O
oxidized	O
form	O
(	O
benzoquinone	B
)	O
.	O

A	O
striking	O
interindividual	O
variability	O
(	O
higher	O
than	O
in	O
rats	O
pretreated	O
with	O
various	O
inducers	O
)	O
was	O
observed	O
.	O

Correlation	O
analysis	O
of	O
activity	O
of	O
various	O
CYP	O
isoforms	O
and	O
extent	O
of	O
CYP	O
destruction	O
by	O
quinones	B
revealed	O
that	O
hydroquinone	B
-	O
dependent	O
destruction	O
correlated	O
with	O
EROD	O
activity	O
(	O
r	O
=	O
0.5	O
)	O
and	O
benzoquinone	B
-	O
dependent	O
destruction	O
correlated	O
with	O
nifedipine	B
oxidation	O
(	O
r	O
=	O
0.74	O
)	O
.	O

Due	O
to	O
the	O
low	O
number	O
of	O
individuals	O
used	O
in	O
this	O
study	O
the	O
level	O
of	O
significance	O
of	O
these	O
correlations	O
was	O
P	O
>	O
0.2	O
and	O
thus	O
clearly	O
suggesting	O
a	O
non	O
-	O
significant	O
tendency	O
.	O

Similar	O
experiments	O
on	O
evaluation	O
of	O
CYP	O
destruction	O
in	O
human	O
liver	O
microsomes	O
have	O
not	O
been	O
published	O
and	O
thus	O
there	O
is	O
no	O
possibility	O
to	O
compare	O
these	O
results	O
with	O
data	O
in	O
the	O
literature	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
presented	O
here	O
suggest	O
that	O
humans	O
may	O
be	O
more	O
susceptible	O
to	O
xenobiotics	B
and	O
especially	O
those	O
of	O
quinonic	B
nature	O
.	O

This	O
fact	O
should	O
be	O
taken	O
into	O
consideration	O
where	O
extrapolations	O
from	O
animal	O
studies	O
to	O
humans	O
are	O
done	O
and	O
environmental	O
hazards	O
of	O
human	O
exposure	O
to	O
xenobiotics	B
with	O
expected	O
quinonic	B
metabolites	I
are	O
assessed	O
.	O

Further	O
studies	O
with	O
higher	O
numbers	O
of	O
human	O
liver	O
samples	O
are	O
necessary	O
to	O
assess	O
the	O
sensitivity	O
of	O
specific	O
CYP	O
isoforms	O
to	O
quinone	B
action	O
and	O
thus	O
evaluate	O
the	O
reason	O
for	O
the	O
great	O
interindividual	O
variability	O
observed	O
.	O

Acknowledgements	O
Author	O
would	O
like	O
to	O
express	O
sincere	O
thanks	O
to	O
F.	O
Peter	O
Guengerich	O
and	O
Magnus	O
Ingelman	O
-	O
Sundberg	O
for	O
their	O
generous	O
gifts	O
.	O

Financial	O
support	O
was	O
provided	O
by	O
grant	O
of	O
Internal	O
Grant	O
Agency	O
of	O
the	O
Czech	O
Ministry	O
of	O
Health	O
,	O
grant	O
No.	O
IGA	O
3505	O
-	O
3	O
.	O

Hydrangeae	O
Dulcis	O
Folium	O
,	O
a	O
natural	O
medicine	O
indigenous	O
to	O
Japan	O
,	O
is	O
prepared	O
from	O
the	O
leaves	O
of	O
Hydrangea	O
macrophylla	O
seringe	O
var	O
.	O

thunbergii	O
makino	O
(	O
Saxifragaceae	O
)	O
via	O
several	O
processing	O
steps	O
such	O
as	O
crumpling	O
,	O
fermentation	O
and	O
drying	O
.	O

This	O
natural	O
medicine	O
is	O
listed	O
in	O
the	O
Japanese	O
Pharmacopoeia	O
XIII	O
and	O
is	O
extensively	O
used	O
in	O
confectionery	O
,	O
drinks	O
and	O
food	O
as	O
an	O
oral	O
refrigerant	O
and	O
a	O
sweetening	O
.	O

Two	O
dihydroisocoumarins	B
,	O
phyllodulcin	B
(	O
1	B
)	O
and	O
hydrangenol	B
(	O
3	B
)	O
,	O
have	O
been	O
isolated	O
as	O
the	O
principal	O
constituents	O
of	O
this	O
natural	O
medicine	O
(	O
the	O
processed	O
leaves	O
)	O
,	O
while	O
their	O
8-O	B
-glucosides	I
(	O
2	O
,	O
4	O
)	O
were	O
isolated	O
from	O
the	O
dried	O
leaves	O
of	O
Hydrangea	O
macrophylla	O
var	O
.	O

thunbergii	O
.	O
[	O
1	O
]	O
As	O
part	O
of	O
our	O
studies	O
of	O
the	O
bioactive	O
constituents	O
of	O
Hydrangeae	O
Dulcis	O
Folium,	O
[	O
1	O
,	O
2	O
]	O
the	O
methanolic	B
extract	O
of	O
this	O
natural	O
medicine	O
was	O
found	O
to	O
show	O
potent	O
antiallergic	O
,	O
antibacterial	O
,	O
antioxidative	O
,	O
antiulcer	O
and	O
cholagoic	O
activities.	O
[	O
3	O
]	O

We	O
have	O
reported	O
the	O
isolation	O
and	O
structural	O
characterization	O
of	O
two	O
isocoumarins	B
[	O
thunberginols	B
A	B
(	O
11	B
)	O
and	O
B	B
(	O
12	B
)	O
]	O
,	O
[	O
4	O
,	O
5	O
]	O
three	O
dihydroisocoumarins	B
[	O
thunberginols	B
C	B
(	O
6	B
)	O
,	O
D	B
(	O
7	B
)	O
,	O
and	O
E	B
(	O
8	B
)	O
]	O
,	O
[	O
6	O
]	O
a	O
benzylideneph	B
-	I
thalide	I
[	O
thunberginol	B
F	I
(	O
17	B
)	O
]	O
,	O
[	O
4	O
]	O
three	O
dihydroisocoumarin	B
glucosides	I
[	O
thunberginol	B
G	I
3′-O	I
-glucoside	I
,	O
(	B
+	I
)	I
-	I
and	O
(	B
−	I
)	I
-hydrangenol	I
4′-O	I
-glucoside	I
(	O
5	O
)	O
]	O
,	O
[	O
6	O
]	O
and	O
two	O
phthalides	B
[	O
hydramacrophyllols	B
A	B
(	O
19	B
)	O
and	O
B	B
(	O
20	B
)	O
]	O
[	O
7	O
]	O
as	O
the	O
antiallergic	O
and	O
antibacterial	O
principles	O
of	O
this	O
natural	O
medicine	O
.	O

We	O
have	O
developed	O
an	O
efficient	O
method	O
for	O
transforming	O
dihydroisocoumarin	B
into	O
benzylidenephthalide	B
and	O
isocoumarin	B
using	O
regiospecific	O
lactonization	O
reaction	O
of	O
2-carboxystilbenes.	B
[	O
7	O
]	O
During	O
the	O
course	O
of	O
these	O
synthetic	O
studies	O
,	O
various	O
isocoumarins	B
,	O
phthalides	B
and	O
stilbenes	B
were	O
obtained	O
,	O
but	O
their	O
antiallergic	O
activities	O
have	O
not	O
been	O
clarified	O
.	O

In	O
this	O
paper	O
,	O
we	O
describe	O
the	O
inhibitory	O
activities	O
of	O
isocoumarins	B
,	O
phthalides	B
and	O
stilbenes	B
from	O
Hydrangeae	O
Dulcis	O
Folium	O
or	O
the	O
dried	O
leaves	O
of	O
Hydrangea	O
macrophylla	O
var	O
.	O

thunbergii	O
and	O
their	O
synthetic	B
derivatives	I
on	O
the	O
histamine	B
release	O
induced	O
by	O
antigen	B
-	O
antibody	O
reaction	O
other	O
than	O
compound	B
48	I
/	I
80	I
and	O
calcium	B
ionophore	O
A23187	B
,	O
which	O
were	O
partially	O
reported	O
previously.	O
[	O
4–7	O
]	O
Their	O
structural	O
requirements	O
for	O
the	O
inhibitory	O
activity	O
will	O
also	O
be	O
discussed	O
.	O

2	O
Results	O
and	O
Discussion	O
We	O
investigated	O
the	O
structure	O
–	O
activity	O
relationships	O
of	O
the	O
constituents	O
isolated	O
from	O
Hydrangeae	O
Dulcis	O
Folium	O
and	O
related	O
compounds	O
.	O

Table	O
1	O
Table	O
2	O
Table	O
3	O
Table	O
4	O
show	O
the	O
IC50	O
values	O
for	O
inhibition	O
of	O
histamine	B
release	O
by	O
15-min	O
pretreatment	O
.	O

Compound	B
48	I
/	I
80	I
,	O
widely	O
used	O
to	O
analyze	O
the	O
mechanism	O
of	O
mast	O
cell	O
degranulation	O
,	O
mobilizes	O
Ca2	B
+	I
from	O
intracellular	O
Ca2	B
+	I
storage	O
sites	O
followed	O
by	O
extracellular	O
Ca2	B
+	I
influx	O
.	O

This	O
increase	O
in	O
Ca2	B
+	I
concentration	O
is	O
almost	O
entirely	O
dependent	O
on	O
intracellular	O
Ca2	B
+	I
.	O

Compound	B
48	I
/	I
80	I
acts	O
to	O
a	O
pertussis	O
toxin	O
-	O
sensitive	O
GTP	O
binding	O
protein	O
and	O
activates	O
phospholipase	O
Cγ	O
(	O
PLCγ	O
)	O
.	O

As	O
a	O
result	O
,	O
the	O
level	O
of	O
inositol-1,3,5-triphosphate	B
(	O
IP3	B
)	O
increases	O
followed	O
by	O
Ca2	B
+	I
mobilization	O
from	O
the	O
endplasmic	O
reticulum.	O
[	O
8	O
]	O

This	O
intracellular	O
Ca2	B
+	I
-dependent	O
event	O
progresses	O
in	O
less	O
than	O
10	O
s	O
and	O
rapidly	O
induces	O
mast	O
cell	O
degranulation	O
.	O

The	O
percentage	O
of	O
compound	B
48	I
/	I
80-induced	I
histamine	B
release	O
was	O
in	O
the	O
range	O
of	O
14.6	O
to	O
34.0	O
%	O
.	O

Thunberginols	B
A	B
(	O
11	B
)	O
,	O
B	B
(	O
12	B
)	O
,	O
D	B
(	O
7	B
)	O
,	O
E	B
(	O
8	B
)	O
and	O
F	B
(	O
17	B
)	O
and	O
piceatannol	B
(	O
25	B
)	O
inhibited	O
the	O
histamine	B
release	O
with	O
IC	O
50	O
values	O
of	O
less	O
than	O
100	O
μM.	O
The	O
inhibitory	O
activities	O
of	O
isocoumarins	B
such	O
as	O
11	B
and	O
12	B
were	O
more	O
potent	O
than	O
those	O
of	O
dihydroisocoumarins	B
,	O
with	O
IC50	O
values	O
of	O
22	O
and	O
76	O
μM	O
,	O
respectively	O
.	O

The	O
inhibitory	O
activity	O
of	O
a	O
benzilidenephthalide	B
,	O
17	B
,	O
was	O
most	O
potent	O
among	O
the	O
examined	O
compounds	O
,	O
and	O
its	O
IC50	O
value	O
was	O
9.8	O
μM.	O
Other	O
than	O
hydrangenol	B
(	O
3	B
)	O
,	O
7	B
,	O
8	B
,	O
25	B
and	O
lunurarin	B
(	O
26	B
)	O
,	O
many	O
dihydroisocoumarins	B
and	O
stilbenes	B
lacked	O
the	O
activity	O
.	O

A	O
reference	O
drug	B
,	O
DSCG	B
,	O
suppressed	O
the	O
histamine	B
release	O
at	O
high	O
concentration	O
(	O
37.7	O
%	O
inhibition	O
at	O
1000	O
μM	O
)	O
.	O

The	O
calcium	B
ionophore	O
A23187	B
changes	O
cell	O
membrane	O
permeability	O
and	O
induces	O
transport	O
of	O
extracellular	O
Ca2	B
+	I
into	O
the	O
cells	O
.	O

This	O
dynamic	O
Ca2	B
+	I
influx	O
elevates	O
intracellular	O
Ca2	B
+	I
level	O
and	O
induces	O
mast	O
cell	O
degranulation.	O
[	O
9	O
]	O
The	O
percentage	O
of	O
A23187-induced	B
histamine	B
release	O
was	O
in	O
the	O
range	O
of	O
14.7	O
to	O
25.9	O
.	O

Thunberginols	B
A	B
(	O
11	B
)	O
,	O
B	B
(	O
12	B
)	O
,	O
C	B
(	O
6	B
)	O
and	O
F	B
(	O
17	B
)	O
and	O
lunurarin	B
(	O
26	B
)	O
inhibited	O
the	O
histamine	B
release	O
and	O
their	O
IC50	O
values	O
were	O
less	O
than	O
100	O
μM.	O
Thunberginols	B
A	B
(	O
11	B
)	O
and	O
F	B
(	O
17	B
)	O
strongly	O
inhibited	O
this	O
histamine	B
release	O
as	O
well	O
as	O
that	O
induced	O
by	O
compound	B
48	I
/	I
80	I
with	O
IC50	O
values	O
of	O
9	O
and	O
20	O
μM	O
,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
isocoumarin	B
,	O
12	B
,	O
showed	O
less	O
activity	O
than	O
11	B
and	O
17	B
.	O

Phyllodulcin	B
(	O
1	B
)	O
,	O
dehydrophyllodulcin	B
(	O
14	B
)	O
,	O
3′-hydoxyhydrangeaic	B
acid	I
(	O
22	B
)	O
,	O
5-hydroxyhydrangeaic	B
acid	I
(	O
23	B
)	O
and	O
piceatannol	B
(	O
25	B
)	O
slightly	O
inhibited	O
the	O
histamine	B
release	O
.	O

DSCG	B
showed	O
only	O
a	O
low	O
level	O
of	O
activity	O
(	O
16.7	O
%	O
inhibition	O
at	O
1000	O
μM	O
)	O
.	O

The	O
signal	O
transmission	O
pathway	O
via	O
antigen	B
-	O
antibody	O
reaction	O
is	O
initiated	O
by	O
IgE	O
cross	O
-	O
linking	O
by	O
a	O
specific	O
antigen	B
.	O

The	O
aggregation	O
of	O
high	O
affinity	O
IgE	O
receptors	O
(	O
FcεRI	O
)	O
induces	O
phosphorylation	O
of	O
the	O
β	O
and	O
γ	O
subunits	O
of	O
FcεRI	O
[	O
10	O
]	O
followed	O
by	O
activation	O
of	O
tyrosine	O
kinases	O
such	O
as	O
Lyn	O
and	O
Syk.	O
[	O
11	O
,	O
12	O
]	O
These	O
tyrosine	O
kinases	O
phosphorylate	O
phospholipase	O
Cγ	O
(	O
PLCγ	O
)	O
.	O
[	O
13	O
]	O
Subsequently	O
,	O
PLCγ	O
hydrolyzes	O
membrane	O
phospholipids	B
and	O
produces	O
diacyl	B
glycerol	I
(	O
DG	B
)	O
and	O
IP3	B
.	O

The	O
elevation	O
of	O
IP3	B
leads	O
to	O
Ca2	B
+	I
mobilization	O
from	O
intracellular	O
Ca2	B
+	I
storage	O
sites	O
[	O
14	O
]	O
followed	O
by	O
an	O
influx	O
of	O
extracellular	O
Ca2	B
+	I
.	O
[	O
15	O
]	O

The	O
rise	O
in	O
intracellular	O
Ca2	B
+	I
level	O
causes	O
mast	O
cell	O
degranulation	O
and	O
production	O
of	O
metabolic	O
arachidonate	B
mediators	O
.	O

The	O
percentage	O
of	O
IgE	O
-	O
mediated	O
histamine	B
release	O
was	O
in	O
the	O
range	O
of	O
15.0	O
to	O
32.4	O
%	O
.	O

Thunberginols	B
A	B
(	O
11	B
)	O
,	O
B	B
(	O
12	B
)	O
,	O
C	B
(	O
6	B
)	O
,	O
E	B
(	O
8	B
)	O
,	O
F	B
(	O
17	B
)	O
,	O
and	O
G	B
(	O
9	B
)	O
,	O
dehydrophyllodulcin	B
(	O
14	B
)	O
,	O
resveratrol	B
(	O
24	B
)	O
and	O
piceatannol	B
(	O
25	B
)	O
showed	O
inhibitory	O
activities	O
at	O
less	O
than	O
100	O
μM.	O
The	O
inhibitory	O
activity	O
of	O
11	B
on	O
antigen	B
-	O
induced	O
histamine	B
release	O
was	O
less	O
than	O
those	O
of	O
compound	B
48	I
/	I
80	I
or	O
calcium	B
ionophore	O
A23187	B
(	O
IC50	O
value	O
:	O
64	O
μM	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
12	O
showed	O
more	O
potent	O
activity	O
than	O
compound	B
48	I
/	I
80	I
or	O
the	O
calcium	B
ionophore	O
A23187	B
(	O
IC50	O
value	O
:	O
10	O
μM	O
)	O
.	O

Thunberginol	B
F	I
(	O
17	B
)	O
also	O
showed	O
potent	O
activity	O
with	O
an	O
IC50	O
value	O
of	O
10	O
μM.	O
Thunberginol	B
D	I
(	O
7	B
)	O
,	O
hydrangenol	B
(	O
3	B
)	O
,	O
hydramacrophyllols	B
A	B
and	O
B	B
(	O
19	B
and	O
20	B
)	O
and	O
lunurarin	B
(	O
26	B
)	O
slightly	O
inhibited	O
histamine	B
release	O
.	O

DSCG	B
showed	O
no	O
activity	O
under	O
these	O
conditions	O
.	O

In	O
comparison	O
of	O
the	O
inhibitory	O
effects	O
of	O
active	O
isocoumarins	B
(	O
11	B
,	O
12	B
)	O
or	O
their	O
3-dehydro	B
compounds	I
(	O
9	B
,	O
7	B
)	O
on	O
histamine	B
release	O
induced	O
by	O
various	O
stimuli	O
,	O
the	O
activities	O
of	O
isocoumarins	B
seemed	O
to	O
be	O
more	O
potent	O
than	O
those	O
of	O
dihydroisocoumarins	B
.	O

The	O
presence	O
of	O
a	O
double	O
bond	O
at	O
the	O
3-position	O
contributes	O
to	O
fixation	O
of	O
the	O
3-phenyl	O
group	B
to	O
the	O
lactone	B
moiety	O
,	O
so	O
that	O
isocoumarins	B
preserve	O
the	O
plane	O
structure	O
.	O

On	O
the	O
other	O
hand	O
,	O
as	O
the	O
3-phenyl	B
group	I
of	O
a	O
dihydroisocoumarin	B
is	O
not	O
fixed	O
to	O
the	O
lactone	B
moiety	O
,	O
its	O
position	O
was	O
suggested	O
to	O
be	O
crooked	O
or	O
rotated	O
relative	O
to	O
the	O
lactone	B
moiety	O
.	O

The	O
plane	O
structure	O
of	O
the	O
isocoumarin	B
was	O
presumed	O
to	O
contribute	O
to	O
the	O
expression	O
and	O
enhancement	O
of	O
the	O
activity	O
.	O

Thunberginol	B
A	I
(	O
11	B
)	O
more	O
potently	O
inhibited	O
histamine	B
release	O
induced	O
by	O
non	O
-	O
physiological	O
stimulants	O
than	O
by	O
antigen	B
-	O
antibody	O
reaction	O
.	O

The	O
effect	O
of	O
11	B
on	O
stimulation	O
by	O
the	O
calcium	B
ionophore	O
A23187	B
was	O
more	O
potent	O
than	O
on	O
that	O
by	O
compound	B
48	I
/	I
80	I
.	O

In	O
contrast	O
,	O
12	B
showed	O
more	O
potent	O
activity	O
on	O
histamine	B
release	O
via	O
antigen	B
-	O
antibody	O
reaction	O
than	O
those	O
mediated	O
by	O
non	O
-	O
physiological	O
stimulants	O
.	O

The	O
effects	O
of	O
12	B
on	O
stimulation	O
by	O
non	O
-	O
physiological	O
stimulants	O
were	O
similar	O
.	O

These	O
observations	O
suggested	O
that	O
11	B
mainly	O
inhibits	O
the	O
Ca2	B
+	I
increase	O
induced	O
by	O
non	O
-	O
physiological	O
Ca2	B
+	I
mobilizers	O
,	O
especially	O
extracellular	O
Ca2	B
+	I
influx	O
,	O
and	O
lower	O
pathways	O
leading	O
to	O
histamine	B
release	O
.	O

On	O
the	O
other	O
hand	O
,	O
12	B
seemed	O
to	O
suppress	O
the	O
intracellular	O
Ca2	B
+	I
increase	O
and	O
other	O
signal	O
transduction	O
pathways	O
initiated	O
by	O
antigen	B
-	O
antibody	O
reaction	O
such	O
as	O
tyrosine	B
phosphorylation	O
.	O

Kimura	O
et	O
al.	O
reported	O
the	O
inhibitory	O
effects	O
of	O
4-acyl	B
isocoumarins	I
such	O
as	O
oosponol	B
(	O
4-hydroxymethylketone-8-hydroxyisocoumarin	B
)	O
,	O
metabolic	B
products	I
isolated	O
from	O
Oospora	O
astringens	O
(	O
air	O
-	O
borne	O
fungi	O
originated	O
from	O
house	O
dust	O
)	O
,	O
on	O
compound	B
48	I
/	I
80-induced	I
histamine	B
release.	O
[	O
16	O
]	O

They	O
also	O
reported	O
the	O
structure	O
–	O
activity	O
relationships	O
which	O
an	O
acyl	B
group	I
at	O
the	O
4-position	O
was	O
important	O
for	O
inhibition	O
of	O
histamine	B
release	O
.	O

From	O
the	O
results	O
of	O
our	O
investigation	O
of	O
isocoumarins	B
and	O
dihydroisocoumarins	B
,	O
the	O
8-hydroxyl	O
group	B
appears	O
to	O
be	O
essential	O
for	O
the	O
activity	O
.	O

That	O
is	O
,	O
hydrangenol	B
(	O
3	B
)	O
and	O
thunberginol	B
A	I
(	O
11	B
)	O
suppressed	O
histamine	B
release	O
,	O
while	O
hydrangenol	B
8-O	I
-glucoside	I
(	O
4	B
)	O
and	O
8-deoxythunberginol	B
A	I
(	O
13	B
)	O
lacked	O
activity	O
.	O

The	O
reason	O
why	O
the	O
hydroxyl	B
group	I
at	O
the	O
8-position	O
is	O
essential	O
for	O
the	O
activity	O
is	O
unclear	O
.	O

However	O
,	O
it	O
may	O
be	O
important	O
for	O
the	O
proton	O
of	O
the	O
8-hydroxyl	O
group	B
to	O
form	O
a	O
hydrogen	B
bond	O
to	O
an	O
adjacent	O
carbonyl	B
group	I
at	O
the	O
1-position	O
.	O

The	O
4′-hydroxyl	O
group	B
seemed	O
to	O
be	O
essential	O
because	O
3	B
showed	O
inhibitory	O
activity	O
,	O
while	O
(	B
−	I
)	I
-hydrangenol	I
4′-O	I
-glucoside	I
(	O
5	B
)	O
and	O
hydrangenol	B
monomethyl	I
ether	I
(	O
10	B
)	O
did	O
not	O
.	O

Comparison	O
of	O
phyllodulcin	B
(	O
1	B
)	O
,	O
thunberginol	B
E	I
(	O
8	B
)	O
and	O
10	B
indicated	O
that	O
the	O
3′-hydroxyl	O
group	B
recovered	O
the	O
activity	O
of	O
the	O
inactive	O
compound	O
with	O
the	O
4′-methoxyl	O
group	B
.	O

Moreover	O
,	O
the	O
profile	O
of	O
the	O
activity	O
of	O
dehydrophyllodulcin	B
(	O
14	B
)	O
was	O
subtly	O
different	O
from	O
that	O
of	O
thunberginol	B
A	I
(	O
11	B
)	O
.	O

The	O
mechanisms	O
of	O
action	O
of	O
these	O
compounds	O
may	O
be	O
different	O
.	O

The	O
3′-hydroxyl	O
group	B
in	O
3-phenyl	B
isocoumarins	I
with	O
the	O
8-hydroxyl	O
group	B
seemed	O
to	O
be	O
essential	O
,	O
because	O
11	B
suppressed	O
histamine	B
release	O
,	O
while	O
3′-deoxythunberginol	B
A	I
(	O
15	B
)	O
did	O
not	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
6-hydroxyl	O
group	B
did	O
not	O
seem	O
to	O
be	O
important	O
for	O
the	O
activity	O
based	O
on	O
comparison	O
between	O
1	B
and	O
8	B
,	O
3	B
and	O
6	B
,	O
7	B
and	O
9	B
,	O
and	O
11	B
and	O
12	B
.	O

However	O
,	O
as	O
the	O
profile	O
of	O
the	O
activity	O
of	O
11	B
on	O
various	O
types	O
of	O
histamine	B
release	O
reactions	O
was	O
different	O
from	O
that	O
of	O
12	B
,	O
the	O
presence	O
of	O
the	O
6-hydroxyl	O
group	B
may	O
contribute	O
slightly	O
to	O
inhibition	O
of	O
signal	O
transmission	O
on	O
different	O
types	O
of	O
histamine	B
release	O
.	O

From	O
the	O
results	O
of	O
inhibitory	O
activities	O
of	O
phthalides	B
,	O
only	O
thunberginol	B
F	I
(	O
17	B
)	O
,	O
which	O
conforms	O
to	O
the	O
plane	O
structure	O
due	O
to	O
the	O
presence	O
of	O
a	O
double	O
bond	O
at	O
the	O
3-position	O
,	O
potently	O
inhibited	O
histamine	B
release	O
.	O

The	O
activities	O
of	O
hydramacrophyllols	B
(	O
19	B
,	O
20	B
)	O
,	O
in	O
which	O
the	O
8-phenyl	O
groups	B
do	O
not	O
conform	O
to	O
the	O
plane	O
structure	O
against	O
phthalides	B
rings	O
,	O
showed	O
less	O
activity	O
.	O

3′-Deoxythunberginol	B
F	I
(	O
18	B
)	O
lacking	O
the	O
3′-hydroxyl	O
group	B
showed	O
no	O
activity	O
.	O

These	O
results	O
suggested	O
that	O
the	O
plane	O
structure	O
and	O
the	O
3′-hydroxyl	O
group	B
are	O
essential	O
for	O
the	O
activity	O
similarly	O
to	O
the	O
case	O
of	O
isocoumarins	B
.	O

In	O
the	O
case	O
of	O
stilbenes	B
,	O
piceatannol	B
(	O
25	B
)	O
potently	O
inhibited	O
the	O
histamine	B
release	O
induced	O
by	O
antigen	B
–	O
antibody	O
reaction	O
.	O

Tsuruga	O
et	O
al.	O
reported	O
that	O
25	B
inhibited	O
histamine	B
release	O
from	O
rat	O
peritoneal	O
mast	O
cells	O
induced	O
by	O
compound	B
48	I
/	I
80	I
and	O
concanavalin	B
A.	I
[	O
17	B
]	O
Our	O
observations	O
for	O
25	B
using	O
antigen	B
–	O
antibody	O
reaction	O
agreed	O
with	O
this	O
report	O
,	O
although	O
the	O
structure	O
–	O
activity	O
relationships	O
were	O
not	O
clarified	O
.	O

The	O
time	O
courses	O
of	O
the	O
effects	O
of	O
the	O
active	O
compounds	O
,	O
thunberginols	B
A	B
(	O
11	B
)	O
,	O
B	B
(	O
12	B
)	O
and	O
F	B
(	O
17	B
)	O
,	O
and	O
DSCG	B
were	O
examined	O
(	O
Table	O
5	O
)	O
.	O

Thunberginols	B
A	B
(	O
11	B
)	O
,	O
B	B
(	O
12	B
)	O
and	O
F	B
(	O
17	B
)	O
potently	O
inhibited	O
the	O
histamine	B
release	O
by	O
1-	O
to	O
15-min	O
pretreatment	O
at	O
the	O
concentration	O
of	O
100	O
μM.	O
DSCG	B
showed	O
an	O
inhibitory	O
effect	O
after	O
only	O
1-min	O
pretreatment	O
at	O
the	O
concentration	O
of	O
1000	O
μM	O
,	O
and	O
no	O
inhibitory	O
effects	O
were	O
observed	O
following	O
by	O
5-	O
or	O
15-min	O
pretreatment	O
.	O

These	O
results	O
suggested	O
that	O
the	O
inhibitory	O
mechanism	O
of	O
thunberginols	B
is	O
different	O
from	O
that	O
of	O
DSCG	B
.	O

3	O
Conclusion	O

The	O
structural	O
requirements	O
of	O
constituents	O
of	O
Hydrangeae	O
Dulcis	O
Folium	O
and	O
related	O
compounds	O
for	O
inhibitory	O
activity	O
on	O
mast	O
cell	O
degranulation	O
were	O
clarified	O
as	O
follows	O
.	O

The	O
activities	O
of	O
isocoumarins	B
such	O
as	O
thunberginols	B
A	B
(	O
11	B
)	O
and	O
B	B
(	O
12	B
)	O
were	O
more	O
potent	O
than	O
those	O
of	O
dihydroisocoumarins	B
such	O
as	O
hydrangenol	B
(	O
3	B
)	O
or	O
thunberginol	B
G	I
(	O
9	B
)	O
.	O

The	O
double	O
bond	O
at	O
the	O
3-position	O
seemed	O
to	O
be	O
essential	O
for	O
the	O
activity	O
.	O

The	O
hydroxyl	B
groups	I
at	O
the	O
8-	O
,	O
3′-	O
and	O
4′-	O
positions	O
of	O
isocoumarin	B
were	O
essential	O
for	O
the	O
activity	O
,	O
while	O
the	O
hydroxyl	B
group	I
at	O
the	O
6-position	O
was	O
scarcely	O
needed	O
.	O

Since	O
the	O
activity	O
of	O
a	O
benzylidenephthalide	B
,	O
thunberginol	B
F	I
(	O
17	B
)	O
,	O
was	O
more	O
potent	O
than	O
those	O
of	O
hydramacrophyllols	B
(	O
19	B
,	O
20	B
)	O
,	O
the	O
existence	O
of	O
a	O
double	O
bond	O
at	O
the	O
3-position	O
appeared	O
to	O
be	O
necessary	O
to	O
increase	O
the	O
activity	O
.	O

Moreover	O
,	O
the	O
hydroxyl	B
group	I
at	O
the	O
8-position	O
was	O
essential	O
for	O
the	O
activity	O
.	O

The	O
inhibitory	O
mechanism	O
of	O
thunberginols	B
A	B
(	O
11	B
)	O
,	O
B	B
(	O
12	B
)	O
and	O
F	B
(	O
17	B
)	O
seemed	O
to	O
be	O
different	O
from	O
that	O
of	O
DSCG	B
.	O

4	O
Experimental	O
4.1	O
Animals	O
Rats	O
were	O
purchased	O
from	O
Kiwa	O
Laboratory	O
Animals	O
Co.	O
,	O
Ltd.	O
(	O
Wakayama	O
,	O
Japan	O
)	O
and	O
housed	O
in	O
an	O
air	O
-	O
conditioned	O
room	O
at	O
23±2	O
°	O
C	O
for	O
more	O
than	O
3	O
days	O
.	O

Standard	O
laboratory	O
chow	O
(	O
MF	O
,	O
Oriental	O
Yeast	O
Co.	O
,	O
Ltd.	O
)	O
and	O
tap	O
water	B
were	O
given	O
freely	O
.	O

4.2	O
Materials	O
Anti	O
-	O
dinitrophenyl	B
(	O
Anti	O
-	O
DNP	B
)	O
IgE	O
was	O
purchased	O
from	O
Seikagaku	O
Co.	O
,	O
Ltd.	O
,	O
and	O
divided	O
into	O
small	O
volumes	O
and	O
stocked	O
at	O
−20	O
°	O
C	O
.	O

Dinitrophenylated	B
bovine	O
serum	O
albumin	O
(	O
DNP	O
-	O
BSA	O
)	O
was	O
prepared	O
from	O
bovine	O
serum	O
albumin	O
fraction	O
V	O
(	O
Sigma	O
)	O
and	O
sodium	B
dinitrobenzenesulfonate	I
(	O
Tokyo	O
Kasei	O
Organic	O
Chemicals	O
Co.	O
,	O
Ltd.	O
)	O
according	O
to	O
the	O
method	O
of	O
Tada	O
et	O
al.	O
[	O
18	O
]	O
Disodium	B
cromoglycate	I
(	O
DSCG	B
)	O
was	O
obtained	O
from	O
Biomol	O
Res	O
.	O

Lab	O
.	O

Inc.	O
The	O
mast	O
cell	O
medium	O
(	O
MCM	O
)	O
consisted	O
of	O
150	O
mM	O
NaCl	B
,	O
2.7	O
mM	O
KCl	B
,	O
0.9	O
mM	O
CaCl2	B
,	O
5.6	O
mM	O
glucose	B
,	O
and	O
5	O
mM	O
HEPES	B
in	O
distilled	O
water	B
,	O
and	O
pH	O
was	O
adjusted	O
to	O
7.4	O
by	O
addition	O
of	O
3N	O
NaOH	B
.	O

The	O
test	O
samples	O
were	O
isolated	O
or	O
synthesized	O
according	O
to	O
previous	O
reports.	O
[	O
1–7	O
]	O
For	O
histamine	B
release	O
test	O
,	O
each	O
compound	O
was	O
diluted	O
in	O
DMSO	B
and	O
dispersed	O
with	O
MCM	O
.	O

The	O
final	O
concentration	O
of	O
DMSO	B
was	O
0.1	O
%	O
.	O

4.3	O
Histamine	B
release	O
from	O
rat	O
peritoneal	O
mast	O
cells	O
induced	O
by	O
compound	B
48	I
/	I
80	I
,	O
calcium	B
ionophore	O
A23187	B
,	O
and	O
antigen	B
–	O
antibody	O
reaction	O
Histamine	B
release	O
test	O
was	O
performed	O
according	O
to	O
a	O
slight	O
modification	O
of	O
the	O
method	O
reported	O
previously.	O
[	O
4–7	O
]	O
4.4	O
Collection	O
of	O
rat	O
peritoneal	O
exudate	O
cells	O
Male	O
Wistar	O
rats	O
weighing	O
300	O
to	O
400	O
g	O
were	O
sacrificed	O
,	O
and	O
10	O
mL	O
of	O
cooled	O
MCM	O
was	O
injected	O
into	O
the	O
abdominal	O
cavity	O
.	O

After	O
gentle	O
massage	O
of	O
their	O
belly	O
for	O
2	O
min	O
,	O
the	O
cavity	O
was	O
opened	O
and	O
the	O
exudate	O
fluid	O
was	O
removed	O
to	O
a	O
plastic	O
tube	O
using	O
a	O
plastic	O
pipette	O
.	O

The	O
abdominal	O
cavity	O
was	O
repeatedly	O
washed	O
with	O
10	O
mL	O
of	O
MCM	O
.	O

The	O
exudate	O
fluid	O
was	O
centrifuged	O
(	O
120	O
×	O
g	O
,	O
4	O
°	O
C	O
,	O
10	O
min	O
)	O
and	O
washed	O
3	O
times	O
with	O
MCM	O
.	O

The	O
peritoneal	O
exudate	O
cells	O
were	O
suspended	O
in	O
3	O
mL	O
of	O
MCM	O
.	O

After	O
staining	O
cells	O
with	O
0.5	O
%	O
toluidine	B
blue	I
in	O
0.1	O
M	O
citrate	B
buffer	O
(	O
pH	O
4.8	O
)	O
,	O
the	O
number	O
of	O
mast	O
cells	O
was	O
counted	O
under	O
a	O
microscope	O
.	O

The	O
viability	O
of	O
peritoneal	O
cells	O
was	O
determined	O
by	O
the	O
trypan	B
blue	I
exclusion	O
test	O
.	O

4.5	O
Purification	O
of	O
rat	O
peritoneal	O
mast	O
cells	O
and	O
histamine	B
releaser	O
-	O
induced	O
histamine	B
release	O
Mast	O
cells	O
were	O
purified	O
from	O
peritoneal	O
exudate	O
cells	O
by	O
the	O
Percoll	O
density	O
gradient	O
separation	O
method.	O
[	O
19	O
]	O
Percoll	O
fluid	O
(	O
Pharmacia	O
)	O
and	O
decuple	O
concentrated	O
HAM	O
F-10	O
medium	O
(	O
Gibco	O
)	O
were	O
mixed	O
at	O
a	O
ratio	O
of	O
9:1	O
,	O
and	O
7	O
mL	O
of	O
the	O
fluid	O
was	O
decanted	O
into	O
a	O
polycarbonate	B
centrifuge	O
tube	O
.	O

The	O
tube	O
was	O
centrifuged	O
(	O
17000	O
×	O
g	O
,	O
4	O
°	O
C	O
,	O
20	O
min	O
)	O
using	O
an	O
angle	O
rotor	O
.	O

One	O
mL	O
of	O
peritoneal	O
exudate	O
cells	O
suspension	O
was	O
applied	O
gently	O
on	O
top	O
of	O
the	O
Percoll	O
density	O
gradient	O
,	O
followed	O
by	O
centrifugation	O
(	O
200	O
×	O
g	O
,	O
4	O
°	O
C	O
,	O
20	O
min	O
)	O
in	O
a	O
swing	O
rotor	O
.	O

After	O
removal	O
of	O
the	O
erythrocyte	O
and	O
monocyte	O
layers	O
near	O
the	O
surface	O
of	O
the	O
gradient	O
fluid	O
,	O
the	O
mast	O
cell	O
fraction	O
was	O
collected	O
.	O

The	O
mast	O
cell	O
fraction	O
was	O
washed	O
3	O
times	O
with	O
MCM	O
(	O
200	O
×	O
g	O
,	O
4	O
°	O
C	O
,	O
10	O
min	O
)	O
,	O
and	O
suspended	O
in	O
3	O
mL	O
of	O
MCM	O
.	O

The	O
number	O
of	O
mast	O
cells	O
was	O
counted	O
after	O
toluidine	B
blue	I
staining	O
,	O
and	O
the	O
viability	O
of	O
cells	O
was	O
checked	O
by	O
the	O
trypan	B
blue	I
exclusion	O
test	O
.	O

The	O
mast	O
cell	O
suspension	O
(	O
104	O
cells	O
/	O
1.8	O
mL	O
)	O
in	O
a	O
plastic	O
tube	O
was	O
preincubated	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
,	O
and	O
200	O
μL	O
of	O
the	O
test	O
sample	O
diluted	O
in	O
MCM	O
was	O
added	O
.	O

After	O
incubation	O
for	O
15	O
min	O
,	O
222	O
μL	O
of	O
compound	B
48	I
/	I
80	I
(	O
5	O
μg	O
/	O
mL	O
)	O
or	O
calcium	B
ionophore	O
A23187	B
(	O
10	O
μg	O
/	O
mL	O
)	O
was	O
added	O
,	O
and	O
incubation	O
was	O
continued	O
for	O
10	O
min	O
.	O

The	O
plastic	O
tube	O
was	O
cooled	O
in	O
ice	B
water	B
for	O
more	O
than	O
10	O
min	O
and	O
centrifuged	O
(	O
120	O
×	O
g	O
)	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
released	O
histamine	B
in	O
supernatant	O
was	O
determined	O
by	O
the	O
o	B
-phthaldialdehyde	I
fluorescence	O
method	O
using	O
HPLC.	O
[	O
20	O
]	O
4.6	O
Sensitization	O
of	O
mast	O
cells	O
with	O
anti	O
-	O
DNP	O
IgE	O
and	O
antigen	B
–	O
antibody	O
reaction	O
induced	O
-	O
histamine	B
release	O
from	O
mast	O
cells	O
One	O
mL	O
of	O
anti	O
-	O
DNP	O
IgE	O
(	O
PCA	O
titer	O
:	O
×1000	O
,	O
diluted	O
in	O
MCM	O
)	O
was	O
added	O
to	O
3	O
mL	O
of	O
peritoneal	O
exudate	O
cell	O
suspension	O
in	O
a	O
plastic	O
tube	O
,	O
and	O
incubated	O
at	O
37	O
°	O
C	O
for	O
1	O
h.	O
After	O
sensitization	O
,	O
the	O
tube	O
was	O
cooled	O
in	O
ice	B
water	B
,	O
and	O
the	O
peritoneal	O
exudate	O
cells	O
were	O
washed	O
3	O
times	O
with	O
5	O
mL	O
of	O
MCM	O
.	O

The	O
mast	O
cells	O
in	O
peritoneal	O
exudate	O
cell	O
suspension	O
were	O
adjusted	O
to	O
104	O
cells	O
/	O
1.62	O
mL	O
,	O
and	O
incubated	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
.	O

The	O
test	O
sample	O
diluted	O
with	O
180	O
μL	O
of	O
MCM	O
was	O
added	O
and	O
incubated	O
for	O
15	O
min	O
.	O

One-	O
and	O
5-min	O
pretreatments	O
with	O
11	B
,	O
12	B
,	O
17	B
and	O
DSCG	B
were	O
also	O
performed	O
for	O
time	O
course	O
study	O
.	O

Antigen	B
–	O
antibody	O
reaction	O
was	O
initiated	O
by	O
simultaneous	O
addition	O
of	O
200	O
μL	O
of	O
phosphatidyl	B
l	I
-serine	I
(	O
1	O
mg	O
/	O
mL	O
)	O
and	O
222	O
μL	O
of	O
DNP	O
-	O
BSA	O
(	O
1	O
mg	O
/	O
mL	O
)	O
.	O

After	O
20	O
min	O
incubation	O
,	O
the	O
tube	O
was	O
cooled	O
in	O
ice	B
water	B
for	O
more	O
than	O
10	O
min	O
and	O
centrifuged	O
(	O
120	O
×	O
g	O
)	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
released	O
histamine	B
in	O
the	O
supernatant	O
was	O
determined	O
by	O
the	O
method	O
described	O
previously	O
.	O

The	O
inhibition	O
(	O
%	O
)	O
was	O
calculated	O
according	O
to	O
the	O
following	O
equation	O
.	O

Inhibition	O
(	O
%	O
)	O
=	O
1−	O
(	O
Histamine	B
released	O
by	O
reaction−Spontaneously	O
released	O
histamine	B
)	O
(	O
Total	O
histamine	B
in	O
mast	O
cells−Spontaneously	O
released	O
histamine	B
)	O
×100	O

Ribonucleotide	O
reductase	O
(	O
EC	O
1.17.4.1	O
;	O
RR	O
)	O
plays	O
a	O
central	O
role	O
in	O
the	O
de	O
novo	O
synthesis	O
of	O
deoxyribonucleotides	B
required	O
for	O
DNA	O
replication	O
and	O
repair	O
[	O
1	O
,	O
2	O
]	O
and	O
there	O
is	O
a	O
strong	O
correlation	O
between	O
the	O
activity	O
of	O
the	O
enzyme	O
and	O
the	O
rate	O
of	O
cellular	O
replication	O
[	O
3	O
,	O
4	O
]	O
.	O

As	O
such	O
,	O
RR	O
offers	O
a	O
particularly	O
attractive	O
target	O
for	O
neoplastic	O
agents	B
directed	O
against	O
rapidly	O
growing	O
tumors	O
.	O

The	O
mammalian	O
enzyme	O
is	O
composed	O
of	O
two	O
protein	O
dimer	O
subunits	O
,	O
referred	O
to	O
as	O
M1	O
and	O
M2	O
.	O

The	O
catalytic	O
core	O
of	O
the	O
M2	O
subunit	O
contains	O
a	O
tyrosyl	B
free	I
radical	I
that	O
is	O
stabilized	O
by	O
a	O
non	O
-	O
heme	B
iron	B
center	O
[	O
5	O
]	O
.	O

Both	O
the	O
iron	B
and	O
the	O
tyrosyl	B
group	I
are	O
essential	O
for	O
catalytic	O
activity	O
.	O

A	O
number	O
of	O
compounds	O
have	O
been	O
identified	O
which	O
destabilize	O
the	O
iron	B
center	O
thereby	O
inactivating	O
the	O
enzyme	O
.	O

Hydroxyurea	B
(	O
HUr	B
)	O
is	O
the	O
only	O
one	O
of	O
these	O
agents	B
that	O
has	O
found	O
clinical	O
utility	O
;	O
however	O
,	O
HUr	B
has	O
a	O
low	O
affinity	O
for	O
the	O
enzyme	O
[	O
6	O
]	O
,	O
a	O
short	O
half	O
-	O
life	O
in	O
man	O
[	O
7	O
]	O
and	O
one	O
of	O
the	O
limitations	O
of	O
HUr	B
therapy	O
is	O
the	O
development	O
of	O
resistance	O
which	O
may	O
occur	O
via	O
several	O
different	O
mechanisms	O
involving	O
both	O
quantitative	O
and	O
qualitative	O
changes	O
in	O
RR	O
(	O
see	O
[	O
8	O
]	O
and	O
[	O
9	O
]	O
for	O
references	O
)	O
.	O

Inhibitors	O
of	O
RR	O
which	O
circumvent	O
some	O
of	O
these	O
limitations	O
of	O
HUr	B
could	O
likely	O
contribute	O
to	O
improvements	O
in	O
cancer	O
chemotherapy	O
regimens	O
.	O

The	O
α-	B
(	I
N	I
)	I
-heterocyclic	I
carboxaldehyde	I
thiosemicarbazones	I
(	O
HCTs	B
)	O
represent	O
a	O
class	O
of	O
compounds	O
that	O
are	O
among	O
the	O
most	O
potent	O
known	O
inhibitors	O
of	O
RR	O
activity	O
identified	O
to	O
date	O
[	O
10	O
]	O
.	O

The	O
first	O
observation	O
of	O
anticancer	O
activity	O
of	O
HCTs	B
was	O
made	O
over	O
40	O
years	O
ago	O
with	O
the	O
demonstration	O
by	O
Brockman	O
and	O
colleagues	O
that	O
pyridine-2-carboxaldehyde	B
thiosemicarbazone	I
was	O
able	O
to	O
prolong	O
the	O
life	O
span	O
of	O
mice	O
bearing	O
the	O
L1210	O
leukemia	O
[	O
11	O
]	O
.	O

Since	O
that	O
time	O
many	O
HCT	B
derivatives	O
have	O
been	O
synthesized	O
with	O
modifications	O
in	O
the	O
heterocyclic	O
ring	O
system	O
,	O
the	O
thiosemicarbazone	B
side	O
chain	O
,	O
as	O
well	O
as	O
with	O
variations	O
in	O
ring	O
substituents	O
(	O
see	O
[	O
12–14	O
]	O
for	O
examples	O
and	O
references	O
)	O
.	O

Detailed	O
structure	O
activity	O
relationships	O
were	O
established	O
in	O
several	O
murine	O
tumor	O
systems	O
for	O
these	O
early	O
HCTs	B
(	O
[	O
15	O
]	O
and	O
references	O
therein	O
)	O
which	O
ultimately	O
led	O
to	O
clinical	O
trials	O
in	O
humans	O
of	O
5-hydroxy-2-formyl	B
pyridine	I
thiosemicarbazone	I
(	O
5-HP	B
)	O
.	O

These	O
agents	B
strongly	O
complex	O
transition	O
metals	O
such	O
as	O
iron	B
,	O
copper	B
,	O
and	O
zinc	O
and	O
some	O
HCTs	B
have	O
the	O
capacity	O
to	O
remove	O
iron	B
from	O
ferritin	O
,	O
presumably	O
by	O
chelation	O
[	O
16	O
]	O
.	O

It	O
was	O
initially	O
assumed	O
that	O
their	O
ability	O
to	O
chelate	O
iron	B
,	O
which	O
is	O
required	O
for	O
stabilization	O
of	O
the	O
tyrosyl	B
radical	I
in	O
the	O
active	O
site	O
of	O
the	O
M2	O
subunit	O
of	O
RR	O
,	O
was	O
responsible	O
for	O
the	O
inhibitory	O
activity	O
of	O
the	O
enzyme	O
.	O

Inhibition	O
could	O
occur	O
either	O
by	O
coordination	O
of	O
iron	B
in	O
the	O
metal	B
bound	O
enzyme	O
or	O
by	O
the	O
prior	O
formation	O
of	O
the	O
iron	B
-	B
HCT	I
chelate	O
which	O
then	O
interacts	O
with	O
the	O
enzyme	O
.	O

It	O
appears	O
likely	O
that	O
the	O
iron	B
-	O
thiosemicarbazone	B
complex	O
itself	O
is	O
the	O
inhibitory	O
species	O
[	O
17	O
]	O
.	O

Regardless	O
of	O
the	O
exact	O
mechanism	O
,	O
it	O
is	O
worth	O
noting	O
that	O
there	O
are	O
several	O
HCTs	B
which	O
are	O
greater	O
than	O
1000-fold	O
more	O
potent	O
than	O
HUr	B
as	O
inhibitors	O
of	O
RR	O
.	O

Of	O
the	O
many	O
members	O
of	O
this	O
class	O
that	O
have	O
been	O
synthesized	O
and	O
shown	O
to	O
be	O
effective	O
inhibitors	O
of	O
RR	O
activity	O
,	O
tumor	O
cell	O
growth	O
in	O
culture	O
,	O
and	O
animal	O
tumors	O
in	O
vivo	O
,	O
only	O
5-HP	B
has	O
been	O
evaluated	O
clinically	O
[	O
18	O
,	O
19	O
]	O
.	O

The	O
results	O
of	O
Phase	O
I	O
trials	O
with	O
this	O
agent	B
were	O
not	O
encouraging	O
to	O
a	O
large	O
extent	O
because	O
5-HP	B
has	O
a	O
short	O
half	O
-	O
life	O
in	O
man	O
,	O
being	O
eliminated	O
primarily	O
as	O
the	O
inactive	O
O	B
-glucuronide	I
conjugate	O
[	O
18	O
]	O
.	O

Other	O
potentially	O
more	O
active	O
drugs	B
designed	O
to	O
be	O
resistant	O
to	O
O	O
-glucuronidation	O
have	O
recently	O
been	O
synthesized	O
and	O
evaluated	O
as	O
antitumor	O
agents	B
[	O
20	O
]	O
.	O

This	O
review	O
focuses	O
on	O
one	O
of	O
the	O
most	O
promising	O
agents	B
to	O
emerge	O
from	O
these	O
efforts	O
,	O
3-aminopyridine	B
carboxaldehyde	I
thiosemicarbazone	I
(	O
3-AP	B
)	O
,	O
which	O
is	O
currently	O
undergoing	O
Phase	O
1	O
clinical	O
trials	O
.	O

2	O
Materials	O
and	O
methods	O
2.1.1	O
Preparation	O
of	O
3-AP	B
3-AP	B
was	O
synthesized	O
by	O
the	O
methodology	O
shown	O
in	O
Fig.	O
1	O
(	O
adapted	O
from	O
[	O
20	O
]	O
)	O
.	O

Oxidation	O
[	O
21	O
,	O
22	O
]	O
of	O
3-nitro-2-picoline	B
(	O
1	B
)	O
with	O
selenium	B
dioxide	I
in	O
refluxing	O
dioxane	B
gave	O
3-nitropyridine-2-carboxaldehyde	B
(	O
2	B
)	O
.	O

The	O
nitro	B
group	I
was	O
reduced	O
to	O
the	O
amino	B
function	I
by	O
protecting	O
the	O
aldehyde	B
by	O
conversion	O
to	O
the	O
cyclic	B
ethylene	I
acetal	I
(	O
3	B
)	O
,	O
which	O
was	O
then	O
reduced	O
by	O
catalytic	O
hydrogenation	B
using	O
Pd	B
/	I
C	I
as	O
a	O
catalyst	O
to	O
yield	O
the	O
amino	B
acetal	I
(	O
4	B
)	O
[	O
23	O
]	O
.	O

Compound	B
4	I
was	O
then	O
reacted	O
with	O
thiosemicarbazide	B
in	O
ethanol	B
containing	O
10	O
%	O
concentrated	O
hydrochloric	B
acid	I
to	O
form	O
3-aminopyridine-2-carboxaldehyde	B
thiosemicarbazone	I
hydrochloride	I
.	O

3-AP	B
(	O
5	B
)	O
was	O
then	O
liberated	O
by	O
treatment	O
with	O
aqueous	O
sodium	B
bicarbonate	I
solution	O
.	O

2.1.2	O
Animals	O
C3H	O
×	O
DBA2	O
(	O
CD2	O
F1	O
)	O
mice	O
of	O
8–10	O
weeks	O
of	O
age	O
were	O
obtained	O
from	O
the	O
National	O
Cancer	O
Institute	O
.	O

With	O
noted	O
exceptions	O
,	O
mice	B
were	O
treated	O
with	O
a	O
fine	O
suspension	O
of	O
3-AP	B
in	O
0.9	O
%	O
NaCl	B
by	O
i.p	O
.	O

bolus	O
injection	O
(	O
0.01	O
ml	O
/	O
g	O
of	O
mouse	O
body	O
weight	O
)	O
.	O

2.1.3	O
In	O
vivo	O
leukemia	O
studies	O
Female	O
CD2	O
F1	O
mice	O
were	O
inoculated	O
on	O
day	O
0	O
with	O
1	O
×	O
105	O
cells	O
of	O
the	O
murine	O
L1210	O
leukemia	O
.	O

Treatment	O
by	O
i.p	O
.	O

bolus	O
injection	O
was	O
initiated	O
24	O
hr	O
later	O
and	O
continued	O
for	O
6	O
consecutive	O
days	O
.	O

Post	O
inoculation	O
life	O
span	O
was	O
monitored	O
for	O
60	O
days	O
.	O

2.1.4	O
Growth	O
of	O
murine	O
L1210	O
leukemia	O
cells	O
in	O
culture	O
L1210	O
cells	O
were	O
maintained	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
atmosphere	O
containing	O
5	O
%	O
CO2	B
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
horse	O
serum	O
.	O

The	O
L1210	O
cells	O
resistant	O
to	O
HUr	B
,	O
generated	O
and	O
characterized	O
by	O
Carter	O
and	O
Cory	O
[	O
24	O
]	O
,	O
were	O
maintained	O
under	O
the	O
same	O
conditions	O
as	O
the	O
parental	O
cells	O
with	O
the	O
addition	O
of	O
0.75	O
mM	O
HUr	B
to	O
the	O
culture	O
medium	O
.	O

The	O
MTS	O
/	O
PMS	O
microtiter	O
assay	O
of	O
Cory	O
et	O
al.	O
[	O
25	O
]	O
was	O
utilized	O
for	O
assessment	O
of	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
.	O

2.1.5	O
Ribonucleotide	O
reductase	O
assay	O
The	O
non	O
-	O
heme	B
iron	B
and	O
effector	O
binding	O
subunits	O
of	O
RR	O
were	O
prepared	O
from	O
Ehrlich	O
ascites	O
tumor	O
cells	O
as	O
described	O
previously	O
[	O
26	O
,	O
27	O
]	O
.	O

CDP	O
reductase	O
activity	O
was	O
assayed	O
by	O
the	O
method	O
of	O
Steeper	O
and	O
Steuart	O
[	O
28	O
]	O
.	O

The	O
assay	O
mixture	O
contained	O
3.75	O
nmol	O
[	B
14	I
C	I
]	I
CDP	I
(	O
0.03	O
μCi	O
)	O
,	O
900	O
nmol	O
dithiothreitol	B
,	O
150	O
nmol	O
ATP	B
,	O
and	O
aliquots	O
of	O
the	O
non	O
-	O
heme	B
iron	B
and	O
effector	O
binding	O
subunit	O
fractions	O
of	O
RR	O
in	O
a	O
final	O
vol	O
of	O
0.02	O
ml	O
.	O

After	O
a	O
30	O
min	O
incubation	O
at	O
37	O
°	O
C	O
,	O
the	O
CDP	O
reductase	O
reactions	O
were	O
stopped	O
in	O
a	O
boiling	O
water	B
bath	O
.	O

The	O
nucleotides	B
were	O
converted	O
to	O
nucleosides	B
by	O
snake	O
venom	O
treatment	O
[	O
28	O
]	O
and	O
deoxycytidine	B
was	O
separated	O
from	O
cytidine	B
on	O
a	O
Dowex	O
1-borate	O
ion	O
-	O
exchange	O
column	O
.	O

2.1.6	O
[	B
3	I
H	I
]	I
Thymidine	I
and	O
[	B
3	I
H	I
]	I
uridine	I
incorporation	O
The	O
effects	O
of	O
3-AP	B
on	O
RNA	O
and	O
DNA	O
syntheses	O
were	O
determined	O
by	O
measuring	O
the	O
incorporation	O
of	O
radiolabeled	B
uridine	B
and	O
thymidine	B
into	O
the	O
nucleic	O
acids	O
of	O
L1210	O
cells	O
incubated	O
with	O
various	O
concentrations	O
of	O
the	O
drug	B
.	O

Cells	O
were	O
incubated	O
with	O
either	O
0.1	O
μM	O
[	B
3	I
H	I
]	I
thymidine	I
(	O
0.5	O
μCi	O
/	O
ml	O
)	O
or	O
0.01	O
μM	O
[	B
3	I
H	I
]	I
uridine	I
(	O
0.5	O
μM	O
/	O
ml	O
)	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
,	O
then	O
washed	O
with	O
ice	B
-	O
cold	O
PBS	B
.	O

The	O
nucleic	O
acids	O
were	O
precipitated	O
with	O
ice	B
-	O
cold	O
10	O
%	O
trichloroacetic	B
acid	I
(	O
TCA	B
)	O
and	O
collected	O
on	O
Whatman	O
GF	O
/	O
C	O
filters	O
.	O

The	O
filters	O
were	O
then	O
washed	O
3	O
times	O
with	O
5	O
ml	O
of	O
ice	B
-	O
cold	O
10	O
%	O
TCA	B
followed	O
by	O
2	O
washes	O
with	O
95	O
%	O
ethanol	B
,	O
dried	O
and	O
incubated	O
with	O
0.25	O
ml	O
of	O
4	O
N	O
HCl	B
at	O
65	O
°	O
C	O
for	O
1	O
hr	O
.	O

The	O
samples	O
were	O
then	O
neutralized	O
by	O
addition	O
of	O
0.4	O
ml	O
of	O
2.5	O
N	O
NaOH	B
.	O

After	O
addition	O
of	O
5	O
ml	O
of	O
scintillation	O
fluid	O
,	O
the	O
radioactivity	O
in	O
each	O
sample	O
was	O
quantified	O
by	O
scintillation	O
spectrometry	O
.	O

3	O
Results	O
and	O
discussion	O
Growth	O
inhibitory	O
activity	O
of	O
3-AP	B
for	O
wildtype	O
and	O
HUr	B
-	O
resistant	O
L1210	O
leukemia	O
cells	O
in	O
vitro	O
.	O

The	O
effectiveness	O
of	O
3-AP	B
as	O
an	O
inhibitor	O
of	O
the	O
growth	O
of	O
wildtype	O
and	O
HUr	B
-	O
resistant	O
L1210	O
cells	O
has	O
been	O
determined	O
,	O
and	O
the	O
results	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

L1210	O
cells	O
selected	O
for	O
resistance	O
to	O
HUr	B
did	O
not	O
exhibit	O
a	O
corresponding	O
decrease	O
in	O
sensitivity	O
to	O
3-AP	B
.	O

3-AP	B
also	O
exhibited	O
65-fold	O
greater	O
potency	O
than	O
HUr	B
against	O
the	O
parental	O
cells	O
.	O

These	O
properties	O
of	O
3-AP	B
may	O
impact	O
favorably	O
on	O
the	O
clinical	O
outcome	O
of	O
cancer	O
patients	O
requiring	O
inclusion	O
of	O
a	O
RR	O
inhibitor	O
in	O
their	O
treatment	O
regimen	O
if	O
3-AP	B
is	O
substituted	O
for	O
HUr	B
,	O
considering	O
the	O
likely	O
emergence	O
of	O
HUr	B
-	O
resistant	O
cancer	O
cells	O
and	O
the	O
suboptimal	O
pharmacologic	O
profile	O
of	O
HUr	B
that	O
limit	O
its	O
effectiveness	O
as	O
an	O
antineoplastic	O
agent	B
.	O

3.1.1	O
In	O
vivo	O
antileukemic	O
activity	O
of	O
3-AP	B
When	O
3-AP	B
was	O
administered	O
twice	O
daily	O
for	O
six	O
consecutive	O
days	O
to	O
mice	O
inoculated	O
i.p	O
.	O

with	O
the	O
L1210	O
leukemia	O
,	O
significant	O
increases	O
in	O
life	O
span	O
were	O
observed	O
with	O
each	O
dosage	O
employed	O
and	O
long	O
term	O
(	O
60	O
day	O
)	O
survivors	O
were	O
produced	O
at	O
drug	B
dosage	O
levels	O
that	O
were	O
well	O
tolerated	O
by	O
the	O
hosts	O
(	O
Table	O
2	O
)	O
.	O

Detailed	O
studies	O
to	O
optimize	O
the	O
treatment	O
regimen	O
/	O
schedule	O
in	O
this	O
tumor	O
model	O
have	O
not	O
been	O
undertaken	O
.	O

The	O
fact	O
that	O
3-AP	B
as	O
a	O
single	O
agent	B
was	O
active	O
against	O
the	O
L1210	O
leukemia	O
over	O
a	O
broad	O
range	O
of	O
dosages	O
and	O
was	O
curative	O
for	O
some	O
mice	O
suggests	O
that	O
this	O
agent	B
may	O
well	O
have	O
a	O
wide	O
range	O
of	O
therapeutic	O
utility	O
in	O
the	O
clinical	O
setting	O
.	O

3.1.2	O
Inhibition	O
of	O
RR	O
activity	O
by	O
3-AP	B
The	O
reduction	O
of	O
CDP	B
to	O
dCDP	B
by	O
purified	O
RR	O
from	O
Ehrlich	O
ascites	O
cells	O
was	O
effectively	O
inhibited	O
by	O
3-AP	B
with	O
an	O
IC50	O
of	O
0.3	O
μM.	O
Thus	O
,	O
3-AP	B
is	O
1000-fold	O
more	O
potent	O
as	O
an	O
inhibitor	O
of	O
mammalian	O
RR	O
than	O
has	O
been	O
reported	O
for	O
HUr	B
[	O
29	O
]	O
and	O
ranks	O
among	O
the	O
most	O
potent	O
HCTs	B
,	O
with	O
an	O
IC50	O
value	O
6-fold	O
lower	O
than	O
that	O
of	O
5-HP	B
.	O

3.1.3	O
Effects	O
of	O
3-AP	B
on	O
nucleic	O
acid	O
synthesis	O
3-AP	B
selectively	O
inhibited	O
the	O
incorporation	O
of	O
radiolabeled	B
thymidine	I
into	O
the	O
acid	B
-	O
insoluble	O
fraction	O
of	O
L1210	O
cells	O
compared	O
to	O
the	O
incorporation	O
of	O
radiolabeled	B
uridine	I
(	O
Fig.	O
2	O
)	O
.	O

These	O
results	O
indicate	O
that	O
inhibition	O
of	O
DNA	O
synthesis	O
is	O
the	O
primary	O
action	O
of	O
3-AP	B
on	O
nucleic	O
acid	O
synthesis	O
.	O

3.1.4	O
Role	O
of	O
iron	O
in	O
the	O
inhibitory	O
activity	O
of	O
3-AP	B
Although	O
interaction	O
with	O
the	O
iron	B
stabilized	O
tyrosyl	B
radical	I
is	O
involved	O
in	O
the	O
action	O
of	O
HUr	B
and	O
most	O
probably	O
in	O
the	O
action	O
of	O
3-AP	B
on	O
RR	O
,	O
the	O
exact	O
mechanisms	O
are	O
not	O
identical	O
.	O

This	O
is	O
evidenced	O
by	O
the	O
failure	O
of	O
the	O
iron	B
chelator	O
Desferal	B
to	O
augment	O
3-AP	O
induced	O
inhibition	O
of	O
RR	O
(	O
Table	O
3	O
)	O
,	O
whereas	O
addition	O
of	O
Desferal	B
to	O
Adenocarcinoma	O
755	O
cell	O
cultures	O
increased	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
and	O
growth	O
produced	O
by	O
HUr	B
[	O
30	O
]	O
.	O

In	O
fact	O
,	O
the	O
inhibition	O
of	O
RR	O
by	O
3-AP	B
was	O
almost	O
completely	O
abolished	O
by	O
Desferal	B
(	O
Table	O
3	O
)	O
.	O

Moreover	O
,	O
the	O
preformed	O
metal	B
chelates	O
of	O
3-AP	B
produced	O
by	O
addition	O
of	O
exogenous	O
iron	B
,	O
copper	B
,	O
or	O
zinc	B
were	O
more	O
potent	O
as	O
inhibitors	O
of	O
CDP	O
reductase	O
than	O
3-AP	B
itself	O
and	O
,	O
with	O
the	O
exception	O
of	O
the	O
3-AP	B
-	O
Cu	B
(	I
II	I
)	I
chelate	O
,	O
were	O
more	O
effective	O
than	O
3-AP	B
as	O
inhibitors	O
of	O
the	O
growth	O
of	O
L1210	O
cells	O
in	O
culture	O
(	O
Table	O
4	O
)	O
.	O

The	O
Fe	B
(	I
II	I
)	I
and	O
Fe	B
(	I
III	I
)	I
complexes	B
of	B
3-AP	I
were	O
superior	O
to	O
the	O
Cu	B
(	I
II	I
)	I
and	O
Zn	B
(	I
II	I
)	I
chelates	B
in	O
both	O
systems	O
.	O

These	O
findings	O
provide	O
support	O
for	O
the	O
concept	O
that	O
the	O
relevant	O
inhibitory	O
species	O
is	O
the	O
iron	B
-	I
HCT	I
complex	I
rather	O
than	O
the	O
free	O
HCT	B
.	O

Like	O
HUr	B
,	O
the	O
effects	O
of	O
the	O
HCTs	B
on	O
cellular	O
proliferation	O
are	O
more	O
pronounced	O
on	O
cells	O
in	O
the	O
S	O
-	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Thus	O
,	O
the	O
most	O
sensitive	O
cancers	O
to	O
the	O
cytotoxic	O
action	O
of	O
3-AP	B
when	O
used	O
alone	O
most	O
likely	O
are	O
those	O
with	O
high	O
growth	O
fractions	O
,	O
such	O
as	O
the	O
acute	O
leukemias	O
or	O
chronic	O
leukemias	O
in	O
blast	O
crisis	O
.	O

To	O
expand	O
the	O
applicability	O
of	O
3-AP	B
to	O
cancers	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
such	O
as	O
occurs	O
with	O
most	O
solid	O
tumors	O
,	O
it	O
may	O
be	O
necessary	O
to	O
use	O
combinations	O
of	O
chemotherapeutic	O
agents	O
,	O
taking	O
advantage	O
of	O
the	O
ability	O
of	O
3-AP	B
to	O
synergize	O
with	O
drugs	B
that	O
damage	O
the	O
DNA	O
(	O
presumably	O
due	O
to	O
the	O
capacity	O
of	O
3-AP	B
to	O
inhibit	O
the	O
repair	O
of	O
lesions	O
in	O
DNA	O
)	O
.	O

Preliminary	O
data	O
from	O
our	O
laboratory	O
indicate	O
that	O
3-AP	B
has	O
the	O
capacity	O
to	O
synergize	O
with	O
1-acetyl-1,2-bis	B
(	I
methylsulfonyl	I
)	I
-2-	I
(	I
2-chloroethyl	I
)	I
hydrazine	I
[	O
32	O
]	O
,	O
cis	B
-	I
platin	I
,	O
and	O
etoposide	B
against	O
the	O
L1210	O
leukemia	O
in	O
mice	O
.	O

These	O
findings	O
suggest	O
that	O
in	O
addition	O
to	O
the	O
activity	O
of	O
3-AP	B
as	O
a	O
single	B
agent	O
,	O
prevention	O
of	O
the	O
repair	O
of	O
DNA	O
lesions	O
by	O
3-AP	B
will	O
result	O
in	O
efficacious	O
drug	B
combinations	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Additional	O
information	O
on	O
the	O
timing	O
of	O
the	O
repair	O
of	O
DNA	O
of	O
cancer	O
cells	O
following	O
damage	O
by	O
an	O
agent	B
acting	O
at	O
the	O
level	O
of	O
preformed	O
DNA	O
may	O
be	O
useful	O
in	O
optimizing	O
the	O
schedule	O
of	O
administration	O
of	O
the	O
RR	O
inhibitor	O
relative	O
to	O
the	O
treatment	O
with	O
a	O
DNA	O
damaging	O
agent	B
.	O

The	O
centrality	O
of	O
RR	O
in	O
cellular	O
proliferation	O
emphasizes	O
the	O
importance	O
of	O
developing	O
more	O
effective	O
inhibitors	O
in	O
order	O
to	O
exploit	O
any	O
/	O
all	O
possible	O
needs	O
of	O
the	O
cancer	O
cell	O
.	O

HCTs	B
,	O
such	O
as	O
3-AP	B
,	O
with	O
insensitivity	O
to	O
O	O
-glucuronidation	O
,	O
a	O
major	O
factor	O
in	O
the	O
inactivity	O
as	O
an	O
anticancer	O
agent	O
in	O
humans	O
of	O
5-HP	B
,	O
may	O
prove	O
to	O
have	O
therapeutic	O
efficacy	O
.	O

In	O
preclinical	O
and	O
biochemical	O
studies	O
,	O
3-AP	B
appears	O
to	O
be	O
superior	O
to	O
any	O
of	O
the	O
other	O
HCTs	B
reported	O
to	O
date	O
and	O
,	O
therefore	O
,	O
its	O
consideration	O
as	O
a	O
candidate	O
for	O
clinical	O
trials	O
in	O
the	O
treatment	O
of	O
cancer	O
is	O
warranted	O
and	O
it	O
is	O
currently	O
undergoing	O
a	O
Phase	O
I	O
trial	O
.	O

4	O
Summary	O
The	O
enzyme	O
RR	O
catalyzes	O
the	O
conversion	O
of	O
ribonucleoside	B
diphosphates	I
to	O
their	O
deoxyribonucleotide	B
counterparts	O
.	O

RR	O
is	O
critical	O
for	O
the	O
generation	O
of	O
the	O
cytosine	B
,	O
adenine	B
,	O
and	O
guanine	B
deoxyribonucleotide	B
5′-triphosphate	I
building	O
blocks	O
of	O
DNA	O
,	O
which	O
are	O
present	O
in	O
cells	O
as	O
exceedingly	O
small	O
intracellular	O
pools	O
.	O

Therefore	O
,	O
interference	O
with	O
the	O
function	O
of	O
RR	O
might	O
well	O
result	O
in	O
an	O
agent	B
with	O
significant	O
antineoplastic	O
activity	O
,	O
particularly	O
against	O
rapidly	O
proliferating	O
tumor	O
cells	O
.	O

HUr	B
is	O
the	O
only	O
inhibitor	O
of	O
RR	O
in	O
clinical	O
usage	O
;	O
this	O
agent	B
,	O
however	O
,	O
is	O
a	O
relatively	O
poor	O
inhibitor	O
of	O
the	O
enzyme	O
and	O
has	O
a	O
short	O
serum	O
half	O
-	O
life	O
.	O

Consequently	O
,	O
HUr	B
is	O
a	O
relatively	O
weak	O
anticancer	O
agent	O
.	O

In	O
an	O
effort	O
to	O
develop	O
a	O
more	O
potent	O
inhibitor	O
of	O
RR	O
with	O
utility	O
as	O
an	O
anticancer	O
agent	O
,	O
we	O
have	O
synthesized	O
3-AP	B
and	O
demonstrated	O
(	O
a	O
)	O
potent	O
inhibition	O
of	O
L1210	O
leukemia	O
cells	O
in	O
vitro	O
,	O
(	O
b	O
)	O
curative	O
capacity	O
for	O
mice	O
bearing	O
the	O
L1210	O
leukemia	O
,	O
(	O
c	O
)	O
marked	O
inhibition	O
of	O
RR	O
,	O
and	O
(	O
d	O
)	O
sensitivity	O
of	O
HUr	B
-	O
resistant	O
cells	O
to	O
3-AP	B
.	O

These	O
findings	O
collectively	O
demonstrate	O
the	O
clinical	O
potential	O
of	O
3-AP	B
as	O
an	O
antineoplastic	O
agent	B
.	O

Acknowledgements	O
This	O
research	O
was	O
supported	O
by	O
U.S.	O
Public	O
Health	O
Service	O
Grants	O
CA-53340	O
(	O
ACS	O
)	O
and	O
CA-55540	O
(	O
JGC	O
)	O
from	O
the	O
National	O
Cancer	O
Institute	O
.	O

RAF	O
is	O
a	O
Special	O
Fellow	O
of	O
the	O
Leukemia	O
Society	O
of	O
America	O
.	O

There	O
has	O
been	O
apparent	O
controversy	O
as	O
to	O
the	O
roles	O
nitric	B
oxide	I
(	O
NO	B
)	O
has	O
in	O
different	O
physiological	O
and	O
pathophysiological	O
mechanisms	O
at	O
the	O
molecular	O
level	O
.	O

Some	O
studies	O
show	O
that	O
NO	B
has	O
cytotoxic	O
properties	O
whereas	O
other	O
reports	O
demonstrate	O
that	O
NO	B
prevents	O
or	O
ameliorates	O
injurious	O
conditions	O
;	O
this	O
apparent	O
controversy	O
seems	O
to	O
be	O
due	O
to	O
the	O
fact	O
that	O
both	O
the	O
chemical	O
biology	O
of	O
NO	B
as	O
well	O
as	O
its	O
transducing	O
pathways	O
are	O
not	O
only	O
adopted	O
to	O
cytotoxicity	O
but	O
they	O
also	O
refer	O
to	O
cell	O
protection	O
(	O
for	O
review	O
,	O
see	O
Brune	O
et	O
al.	O
,	O
1998	O
;	O
Wink	O
and	O
Mitchell	O
,	O
1998	O
)	O
.	O

NO	B
is	O
a	O
widespread	O
signalling	O
molecule	O
involved	O
in	O
the	O
regulation	O
of	O
multiple	O
cellular	O
functions	O
(	O
for	O
a	O
review	O
,	O
see	O
Moncada	O
et	O
al.	O
,	O
1991	O
)	O
,	O
most	O
of	O
which	O
are	O
exerted	O
by	O
increasing	O
cyclic	B
GMP	I
concentrations	O
via	O
activation	O
of	O
soluble	O
guanylate	O
cyclase	O
(	O
SGC	O
)	O
(	O
for	O
review	O
see	O
Ignarro	O
,	O
1990	O
;	O
McDonald	O
and	O
Murad	O
,	O
1996	O
)	O
,	O
although	O
direct	O
actions	O
of	O
the	O
NO	B
molecule	O
have	O
also	O
been	O
reported	O
.	O

In	O
the	O
case	O
of	O
oxidative	O
damage	O
,	O
NO	B
has	O
been	O
proposed	O
to	O
exert	O
direct	O
neuroprotective	O
actions	O
as	O
an	O
anti	O
-	O
oxidant	O
(	O
Wink	O
et	O
al.	O
,	O
1993	O
;	O
Rauhala	O
et	O
al.	O
,	O
1996	O
,	O
1998	O
)	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
cyclic	B
GMP	I
may	O
also	O
have	O
neuroprotective	O
actions	O
(	O
Weill	O
and	O
Greene	O
,	O
1984	O
;	O
Garthwaite	O
and	O
Garthwaite	O
,	O
1988	O
;	O
Barger	O
et	O
al.	O
,	O
1995	O
;	O
Furukawa	O
et	O
al.	O
,	O
1996	O
;	O
Barger	O
and	O
Mattson	O
,	O
1996	O
;	O
Thippeswamy	O
and	O
Morris	O
,	O
1997	O
;	O
Pantazis	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
this	O
context	O
,	O
we	O
have	O
recently	O
shown	O
that	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
potentiates	O
cell	O
death	O
caused	O
by	O
the	O
generator	O
of	O
NO	B
and	O
O2	B
−	O
SIN-1	O
,	O
an	O
effect	O
that	O
was	O
enhanced	O
by	O
the	O
NO	B
scavenger	O
HbO2	B
,	O
abolished	O
by	O
catalase	O
and	O
accompanied	O
by	O
the	O
formation	O
of	O
H2	B
O2	I
,	O
suggesting	O
that	O
this	O
reactive	B
oxygen	I
species	I
(	O
ROS	B
)	O
accounts	O
for	O
this	O
enhancing	O
effect	O
(	O
Moro	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
NO	B
released	O
in	O
these	O
conditions	O
,	O
via	O
cyclic	B
GMP	I
elevation	O
,	O
confers	O
selective	O
cytoprotection	O
against	O
this	O
oxidative	O
component	O
of	O
cell	O
death	O
.	O

In	O
the	O
current	O
report	O
we	O
decided	O
to	O
study	O
the	O
effects	O
of	O
an	O
NO	B
donor	O
,	O
DETA	B
-	I
NONOate	I
on	O
H2	B
O2	I
-induced	O
cell	O
death	O
in	O
1-week	O
-	O
old	O
rat	O
cortical	O
neurones	O
in	O
primary	O
culture	O
,	O
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
NO	B
as	O
a	O
neuroprotective	O
agent	O
in	O
oxidative	O
stress	O
.	O

We	O
have	O
used	O
also	O
used	O
1H	B
-	I
[	I
1,2,4	I
]	I
oxadiazolo	I
[	I
4,3-a	I
]	I
quinoxalin-1-one	I
(	O
ODQ	B
)	O
,	O
as	O
a	O
specific	O
and	O
potent	O
inhibitor	O
of	O
SGC	O
(	O
Garthwaite	O
et	O
al.	O
,	O
1995	O
;	O
Moro	O
et	O
al.	O
,	O
1996	O
)	O
,	O
and	O
8-	B
(	I
4-chlorophenylthio	I
)	I
guanosine-3′,5′-monophosphorothioate	I
,	I
Rp	I
-	I
isomer	I
(	O
Rp-8-pCPT	B
-	I
cGMPS	I
)	I
,	O
as	O
a	O
specific	O
inhibitor	O
of	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinases	O
(	O
Butt	O
et	O
al.	O
,	O
1994	O
;	O
Smolenski	O
et	O
al.	O
,	O
1998	O
)	O
,	O
to	O
determine	O
whether	O
these	O
NO	B
effects	O
are	O
dependent	O
on	O
cyclic	B
GMP	I
and	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinases	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Primary	O
culture	O
of	O
rat	O
cortical	O
neurones	O
Primary	O
cultures	O
of	O
cortical	O
cells	O
were	O
prepared	O
as	O
described	O
before	O
(	O
Fernández	O
-	O
Tomé	O
and	O
Segal	O
,	O
1987	O
;	O
Moro	O
et	O
al.	O
,	O
1998	O
)	O
.	O

On	O
day	O
4	O
,	O
the	O
medium	O
was	O
changed	O
to	O
a	O
defined	O
medium	O
(	O
serum	O
-	O
free	O
,	O
chemically	O
defined	O
medium	O
containing	O
30	O
nM	O
selenite	B
,	O
5	O
μg	O
/	O
ml	O
insulin	O
from	O
bovine	O
pancreas	O
,	O
5	O
μg	O
/	O
ml	O
transferrin	O
,	O
20	O
nM	O
progesterone	B
and	O
100	O
μM	O
putrescine	B
in	O
MEM	B
)	O
,	O
which	O
was	O
replaced	O
twice	O
weekly	O
.	O

Studies	O
were	O
performed	O
at	O
in	O
vitro	O
day	O
8	O
,	O
when	O
the	O
cultures	O
consisted	O
of	O
≥95	O
%	O
neurones	O
(	O
Moro	O
et	O
al.	O
,	O
1998	O
)	O
.	O

To	O
expose	O
the	O
cells	O
to	O
the	O
various	O
agents	B
,	O
culture	O
medium	O
was	O
replaced	O
by	O
MEM	B
supplemented	O
with	O
0.6	O
%	O
glucose	B
,	O
0.029	O
%	O
glutamine	B
and	O
16	O
mg	O
/	O
l	O
gentamicin	B
.	O

2.2	O
Cell	O
treatments	O
Cortical	O
cells	O
grown	O
in	O
96-multiwell	O
plates	O
(	O
50	O
000	O
cells	O
/	O
well	O
)	O
were	O
treated	O
at	O
in	O
vitro	O
days	O
8–9	O
.	O

Dilutions	O
of	O
H2	B
O2	I
were	O
made	O
fresh	O
from	O
a	O
30	O
%	O
stock	O
solution	O
(	O
V	O
/	O
V	O
)	O
into	O
culture	O
medium	O
immediately	O
before	O
each	O
experiment	O
and	O
exposures	O
were	O
performed	O
within	O
5	O
min	O
after	O
dilution	O
.	O

In	O
the	O
first	O
experiments	O
,	O
cells	O
were	O
incubated	O
with	O
increasing	O
concentrations	O
of	O
hydrogen	B
peroxide	I
(	O
H2	B
O2	I
,	O
10–100	O
μM	O
)	O
for	O
30	O
min	O
.	O

In	O
a	O
different	O
set	O
of	O
experiments	O
,	O
cells	O
were	O
incubated	O
with	O
the	O
SGC	O
inhibitor	O
ODQ	B
(	O
1–10	O
μM	O
)	O
,	O
DMSO	B
(	O
a	O
hydroxyl	B
radical	I
scavenger	O
;	O
0.5	O
%	O
)	O
,	O
the	O
inhibitor	O
of	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinase	O
Rp-8-pCPT	B
-	I
cGMPS	I
(	O
100	O
μM	O
)	O
or	O
vehicle	O
for	O
30	O
min	O
.	O

After	O
this	O
time	O
,	O
cells	O
were	O
treated	O
with	O
H2	B
O2	I
(	O
20–40	O
μM	O
)	O
plus	O
DETA	B
-	I
NONOate	I
(	O
0.1–30	O
μM	O
)	O
for	O
30	O
min	O
.	O

Except	O
for	O
H2	B
O2	I
,	O
the	O
other	O
molecules	O
were	O
included	O
both	O
during	O
and	O
after	O
H2	B
O2	I
treatment	O
.	O

Finally	O
,	O
in	O
other	O
experiments	O
,	O
cells	O
treated	O
with	O
H2	B
O2	I
(	O
20–40	O
μM	O
,	O
30	O
min	O
)	O
were	O
incubated	O
with	O
the	O
membrane	O
-	O
permeable	O
analogue	B
of	I
cyclic	I
GMP	I
8-bromoguanosine	B
3′:5′-cyclic	I
monophosphate	I
(	O
8-Br	B
-	I
cyclic	I
GMP	I
,	I
1	O
mM	O
)	O
and	O
the	O
cyclic	O
GMP	O
phosphodiesterase	O
inhibitor	O
3-isobutyl-1-methylxanthine	B
(	O
IBMX	B
,	O
100	O
μM	O
)	O
.	O

Cell	O
viability	O
was	O
evaluated	O
6–24	O
h	O
after	O
the	O
treatment	O
without	O
changing	O
the	O
medium	O
unless	O
indicated	O
.	O

2.3	O
Viability	O
studies	O
Cell	O
viability	O
was	O
monitored	O
by	O
the	O
colourimetric	O
MTT	B
(	O
3-	B
(	I
4,5-dimethylthiazol-2-yl	I
)	I
-2,5-diphenyl	I
tetrazolium	I
bromide	I
)	O
assay	O
as	O
previously	O
described	O
(	O
Mosmann	O
,	O
1983	O
;	O
Hansen	O
et	O
al.	O
,	O
1989	O
)	O
.	O

This	O
method	O
assesses	O
mitochondrial	O
activity	O
by	O
measuring	O
the	O
ability	O
of	O
cortical	O
cultures	O
to	O
reduce	O
MTT	B
to	O
a	O
coloured	O
formazan	B
,	O
using	O
a	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
)	O
.	O

In	O
all	O
these	O
assays	O
,	O
eight	O
wells	O
were	O
used	O
for	O
each	O
condition	O
,	O
and	O
each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
have	O
shown	O
that	O
results	O
from	O
MTT	B
assay	O
in	O
this	O
preparation	O
correlated	O
well	O
with	O
other	O
methods	O
of	O
quantifying	O
cell	O
viability	O
such	O
as	O
morphological	O
cell	O
counting	O
performed	O
by	O
Trypan	B
Blue	I
exclusion	O
(	O
Moro	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Viability	O
of	O
control	O
cultures	O
as	O
assessed	O
with	O
this	O
method	O
was	O
unaffected	O
during	O
the	O
duration	O
of	O
the	O
experiment	O
.	O

2.4	O
Cyclic	B
GMP	I
concentrations	O
in	O
cortical	O
neurones	O
Cortical	O
neurones	O
grown	O
on	O
24-multiwell	O
plates	O
(	O
0.3	O
×	O
106	O
cells	O
/	O
well	O
)	O
at	O
in	O
vitro	O
day	O
8	O
were	O
incubated	O
for	O
an	O
additional	O
period	O
of	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
the	O
absence	O
or	O
presence	O
of	O
ODQ	B
(	O
1	O
μM	O
)	O
in	O
fresh	O
MEM	B
containing	O
IBMX	B
(	O
1	O
mM	O
)	O
.	O

They	O
were	O
then	O
incubated	O
,	O
either	O
alone	O
or	O
in	O
the	O
presence	O
of	O
H2	B
O2	I
(	O
40	O
μM	O
)	O
±DETA	O
-	B
NONOate	I
(	O
1–3	O
μM	O
)	O
for	O
30	O
min	O
.	O

In	O
all	O
cases	O
,	O
the	O
final	O
volume	O
was	O
300	O
μl	O
.	O

The	O
incubation	O
was	O
stopped	O
by	O
aspiration	O
of	O
the	O
medium	O
and	O
addition	O
of	O
0.5	O
ml	O
of	O
ice	B
-	O
cold	O
ethanol	B
.	O

The	O
cyclic	B
GMP	I
concentrations	O
were	O
determined	O
by	O
enzyme	O
immunoassay	O
(	O
EIA	O
cyclic	B
GMP	I
assay	O
kit	O
,	O
Amersham	O
)	O
following	O
manufacturers	O
instructions	O
and	O
absorbance	O
was	O
measured	O
in	O
a	O
Molecular	O
Devices	O
microplate	O
reader	O
.	O

2.5	O
Reagents	O
ODQ	B
was	O
from	O
Alexis	O
,	O
DETA	B
-	I
NONOate	I
was	O
from	O
Alexis	O
,	O
Rp-8-pCPT	B
-	I
cGMPS	I
was	O
from	O
Biolog	O
,	O
cyclic	B
GMP	I
enzyme	O
immunoassay	O
was	O
from	O
Amersham	O
and	O
other	O
reagents	O
were	O
from	O
Sigma	O
.	O

2.6	O
Statistics	O
Results	O
are	O
mean±S.E.M.	O
of	O
at	O
least	O
3	O
separate	O
experiments	O
.	O

One	O
-	O
way	O
ANOVAs	O
were	O
used	O
to	O
test	O
for	O
significant	O
differences	O
between	O
group	O
means	O
.	O

Post	O
hoc	O
analyses	O
employed	O
Newman	O
–	O
Keuls	O
tests	O
to	O
establish	O
significant	O
differences	O
,	O
corresponding	O
F	O
values	O
are	O
presented	O
in	O
each	O
figure	O
legend	O
and	O
P	O
<	O
0.05	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O

3	O
Results	O
3.1	O
Characterisation	O
of	O
H2	B
O2	I
-induced	O
neurotoxicity	O
in	O
primary	O
cortical	O
cultures	O
from	O
rat	O
brain	O
Incubation	O
of	O
cortical	O
neurones	O
with	O
H2	B
O2	I
(	O
10–100	O
μM	O
)	O
resulted	O
in	O
a	O
concentration	O
-	O
dependent	O
neuronal	O
death	O
,	O
which	O
was	O
detectable	O
6	O
h	O
after	O
the	O
treatment	O
.	O

This	O
toxic	O
effect	O
was	O
maximal	O
after	O
24	O
h	O
(	O
LC50	O
=	O
41.8±1.9	O
μM	O
;	O
Fig.	O
1	O
)	O
,	O
as	O
cell	O
death	O
caused	O
by	O
100	O
μM	O
H2	B
O2	I
after	O
48	O
h	O
was	O
not	O
significantly	O
different	O
from	O
that	O
obtained	O
at	O
24	O
h	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
cell	O
viability	O
studies	O
were	O
performed	O
24	O
h	O
after	O
the	O
treatment	O
.	O

The	O
neurotoxicity	O
induced	O
by	O
40	O
μM	O
H2	B
O2	I
was	O
reversed	O
in	O
the	O
presence	O
of	O
DMSO	B
(	O
0.5	O
%	O
;	O
91.1±2.1	O
%	O
of	O
control	O
,	O
n	O
=3	O
,	O
P	O
<	O
0.05	O
)	O
.	O

3.2	O
Effect	O
of	O
the	O
NO	B
donor	O
DETA	B
-	I
NONOate	I
on	O
H2	B
O2	I
-induced	O
neuronal	O
death	O
To	O
study	O
the	O
effects	O
of	O
the	O
NO	B
donor	O
DETA	B
-	I
NONOate	I
on	O
H2	B
O2	I
-induced	O
neurotoxicity	O
,	O
the	O
concentrations	O
of	O
H2	B
O2	I
used	O
were	O
20	O
and	O
40	O
μM.	O
The	O
addition	O
of	O
1–10	O
μM	O
DETA	B
-	I
NONOate	I
(	O
P	O
<	O
0.01	O
,	O
n	O
=	O
3–8	O
;	O
Fig.	O
2	O
)	O
,	O
but	O
not	O
of	O
lower	O
concentrations	O
(	O
0.3	O
μM	O
;	O
P	O
>	O
0.05	O
,	O
n	O
=	O
3–4	O
;	O
Fig.	O
2	O
)	O
inhibited	O
H2	B
O2	I
-induced	O
neuronal	O
death	O
.	O

These	O
concentrations	O
of	O
DETA	B
-	I
NONOate	I
did	O
not	O
have	O
any	O
effect	O
per	O
se	O
on	O
cell	O
viability	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.3	O
Reversal	O
by	O
ODQ	B
and	O
Rp-8-pCPT	B
-	I
cGMPS	I
of	O
the	O
neuroprotection	O
caused	O
by	O
DETA	B
-	I
NONOate	I
on	O
H2	B
O2	I
-induced	O
neurotoxicity	O
To	O
study	O
the	O
effects	O
of	O
ODQ	B
and	O
Rp-8-pCPT	B
-	I
cGMPS	I
on	O
DETA	B
-	I
NONOate	I
-	O
induced	O
neuroprotective	O
effects	O
,	O
the	O
concentration	O
of	O
H2	B
O2	I
used	O
was	O
40	O
μM.	O
ODQ	B
(	O
1–10	O
μM	O
)	O
reversed	O
the	O
neuroprotective	O
effect	O
caused	O
by	O
DETA	B
-	I
NONOate	I
(	O
1–10	O
μM	O
)	O
on	O
H2	B
O2	I
-induced	O
neuronal	O
death	O
(	O
P	O
<	O
0.01	O
,	O
n	O
=	O
3–5	O
;	O
Fig.	O
3	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
Rp-8-pCPT	B
-	I
cGMPS	I
(	O
100	O
μM	O
)	O
also	O
reversed	O
the	O
neuroprotective	O
effect	O
induced	O
by	O
10	O
μM	O
DETA	B
-	I
NONOate	I
on	O
H2	B
O2	I
-induced	O
neurotoxicity	O
(	O
n	O
=3	O
,	O
P	O
<	O
0.05	O
;	O
Fig.	O
4	O
)	O
.	O

These	O
concentrations	O
of	O
ODQ	B
or	O
Rp-8-pCPT	B
-	I
cGMPS	I
by	O
themselves	O
did	O
not	O
affect	O
cell	O
viability	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.4	O
Effect	O
of	O
8-Br	B
-	I
cyclic	I
GMP	I
on	O
H2	B
O2	I
-induced	O
neuronal	O
death	O
The	O
decrease	O
in	O
cell	O
viability	O
caused	O
by	O
30	O
and	O
40	O
μM	O
H2	B
O2	I
was	O
significantly	O
reversed	O
when	O
cells	O
were	O
co	O
-	O
incubated	O
in	O
the	O
presence	O
of	O
8-Br	B
-	I
cyclic	I
GMP	I
(	O
1	O
mM	O
;	O
Fig.	O
5	O
;	O
n	O
=3	O
,	O
P	O
<	O
0.05	O
)	O
.	O

This	O
compound	O
did	O
not	O
affect	O
per	O
se	O
cell	O
viability	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.5	O
Effect	O
of	O
ODQ	B
and	O
H2	B
O2	I
on	O
DETA	B
-	I
NONOate	I
-	O
induced	O
increase	O
in	O
cyclic	B
GMP	I
The	O
basal	O
cyclic	B
GMP	I
concentration	O
of	O
cortical	O
neurones	O
(	O
0.3±0.1	O
pmol	O
/	O
0.3	O
×	O
106	O
cells	O
,	O
n	O
=	O
6	O
)	O
was	O
significantly	O
inhibited	O
by	O
ODQ	B
(	O
1	O
μM	O
,	O
not	O
detectable	O
,	O
n	O
=3	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Incubation	O
of	O
cortical	O
cells	O
for	O
30	O
min	O
with	O
1	O
and	O
3	O
μM	O
DETA	B
-	I
NONOate	I
increased	O
the	O
cyclic	B
GMP	I
concentration	O
to	O
2.3±0.4	O
and	O
to	O
2.5±0.5	O
pmol	O
/	O
0.3	O
×	O
106	O
cells	O
,	O
respectively	O
(	O
n	O
=3	O
,	O
Fig.	O
6	O
)	O
.	O

This	O
increase	O
was	O
inhibited	O
by	O
ODQ	B
(	O
1	O
μM	O
,	O
n	O
=3	O
,	O
Fig.	O
6	O
)	O
.	O

In	O
addition	O
,	O
H2	B
O2	I
(	O
40	O
μM	O
)	O
did	O
not	O
significantly	O
affect	O
either	O
basal	O
or	O
stimulated	O
cyclic	B
GMP	I
levels	O
(	O
n	O
=3	O
,	O
P	O
>	O
0.05	O
,	O
Fig.	O
6	O
)	O
.	O

4	O
Discussion	O
Our	O
results	O
show	O
that	O
H2	B
O2	I
causes	O
neurotoxicity	O
in	O
1-week	O
-	O
old	O
rat	O
cortical	O
neurones	O
in	O
primary	O
culture	O
and	O
that	O
the	O
NO	B
donor	O
DETA	B
-	I
NONOate	I
at	O
concentrations	O
in	O
the	O
low	O
micromolar	O
range	O
inhibits	O
this	O
effect	O
.	O

This	O
effect	O
of	O
DETA	B
-	I
NONOate	I
is	O
mimicked	O
by	O
the	O
cyclic	B
GMP	I
analogue	B
8-Br	B
-	I
cyclic	I
GMP	I
and	O
reversed	O
by	O
the	O
selective	O
inhibitor	O
of	O
SGC	O
ODQ	B
and	O
the	O
specific	O
inhibitor	O
of	O
the	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinase	O
inhibitor	O
Rp-8-pCPT	B
-	I
cGMPS	I
.	O

This	O
action	O
of	O
ODQ	B
is	O
parallel	O
to	O
the	O
inhibition	O
of	O
the	O
DETA	B
-	I
NONOate	I
-	O
induced	O
increase	O
in	O
cyclic	B
GMP	I
concentrations	O
and	O
is	O
reversed	O
in	O
the	O
presence	O
of	O
8-Br	B
-	I
cyclic	I
GMP	I
,	O
which	O
mimics	O
the	O
actions	O
of	O
cyclic	B
GMP	I
.	O

H2	B
O2	I
caused	O
a	O
concentration	O
-	O
dependent	O
neurotoxicity	O
on	O
rat	O
cortical	O
neurones	O
,	O
which	O
was	O
maximal	O
1	O
day	O
after	O
a	O
30-min	O
period	O
treatment	O
.	O

This	O
effect	O
was	O
reversed	O
in	O
the	O
presence	O
of	O
DMSO	B
,	O
suggesting	O
that	O
hydroxyl	B
radical	I
formation	O
is	O
involved	O
in	O
H2	B
O2	I
-induced	O
neurotoxicity	O
.	O

The	O
NO	B
donor	O
DETA	B
-	I
NONOate	I
causes	O
neuroprotection	O
from	O
H2	B
O2	I
(	O
20	O
and	O
40	O
μM	O
)	O
-induced	O
toxicity	O
which	O
is	O
maximal	O
at	O
1–3	O
μM.	O
Direct	O
antioxidant	O
effects	O
of	O
the	O
NO	B
molecule	O
might	O
account	O
for	O
this	O
neuroprotective	O
effect	O
,	O
as	O
it	O
has	O
been	O
shown	O
previously	O
with	O
neurotoxicity	O
induced	O
by	O
different	O
agents	B
in	O
which	O
the	O
hydroxyl	B
radical	I
is	O
involved	O
(	O
Wink	O
et	O
al.	O
,	O
1993	O
;	O
Rauhala	O
et	O
al.	O
,	O
1996	O
,	O
1998	O
;	O
Mohanakumar	O
et	O
al.	O
,	O
1998	O
)	O
.	O

However	O
,	O
we	O
have	O
shown	O
that	O
inhibition	O
of	O
SGC	O
with	O
ODQ	B
reverses	O
DETA	B
-	I
NONOate	I
protective	O
effects	O
on	O
H2	B
O2	I
-induced	O
cell	O
death	O
suggesting	O
that	O
NO	B
-	O
induced	O
cyclic	B
GMP	I
elevation	O
plays	O
a	O
protective	O
role	O
against	O
the	O
mechanism	O
causing	O
cell	O
death	O
in	O
these	O
conditions	O
.	O

This	O
was	O
corroborated	O
by	O
:	O
(	O
1	O
)	O
the	O
data	O
showing	O
that	O
ODQ	B
inhibits	O
the	O
increases	O
in	O
cyclic	B
GMP	I
induced	O
by	O
DETA	B
-	I
NONOate	I
in	O
cortical	O
neurones	O
in	O
primary	O
culture	O
;	O
and	O
(	O
2	O
)	O
the	O
experiments	O
in	O
which	O
8-Br	B
-	I
cyclic	I
GMP	I
,	O
a	O
membrane	O
-	O
permeant	O
cyclic	B
GMP	I
analogue	B
,	I
significantly	O
inhibits	O
H2	B
O2	I
-induced	O
neurotoxicity	O
.	O

It	O
has	O
been	O
suggested	O
that	O
part	O
of	O
the	O
neuronal	O
death	O
caused	O
by	O
H2	B
O2	I
may	O
be	O
associated	O
with	O
increases	O
in	O
intracellular	O
free	O
calcium	B
(	O
Whittemore	O
et	O
al.	O
,	O
1995	O
)	O
.	O

This	O
is	O
consistent	O
with	O
our	O
finding	O
showing	O
reversal	O
of	O
DETA	B
-	I
NONOate	I
-	I
induced	O
neuroprotective	O
effects	O
by	O
ODQ	B
,	O
since	O
a	O
general	O
functional	O
theme	O
for	O
cyclic	B
GMP	I
action	O
through	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinase	O
is	O
a	O
lowering	O
of	O
intracellular	O
calcium	O
concentration	O
(	O
for	O
a	O
review	O
,	O
see	O
Wang	O
and	O
Robinson	O
,	O
1997	O
)	O
.	O

Supporting	O
this	O
theory	O
,	O
our	O
data	O
show	O
that	O
the	O
reversal	O
by	O
ODQ	B
of	O
DETA	B
-	I
NONOate	I
-	O
induced	O
inhibition	O
of	O
the	O
toxicity	O
caused	O
by	O
H2	B
O2	I
is	O
similar	O
to	O
that	O
achieved	O
after	O
incubation	O
of	O
the	O
cells	O
with	O
Rp-8-pCPT	B
-	I
cGMPS	I
,	O
an	O
inhibitor	O
of	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
suggesting	O
that	O
the	O
pathway	O
affording	O
protection	O
involves	O
activation	O
of	O
this	O
kinase	O
.	O

This	O
is	O
in	O
agreement	O
with	O
previous	O
studies	O
providing	O
evidence	O
that	O
activation	O
of	O
cyclic	B
GMP	I
or	O
cyclic	B
GMP	I
analogues	I
can	O
protect	O
neurones	O
against	O
metabolic	O
,	O
excitotoxic	O
and	O
oxidative	O
injury	O
via	O
a	O
decrease	O
in	O
intraneuronal	O
Ca2	B
+	I
concentration	O
caused	O
by	O
activation	O
of	O
K+	B
channels	O
,	O
which	O
is	O
mediated	O
by	O
a	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinase	O
(	O
Barger	O
et	O
al.	O
,	O
1995	O
;	O
Furukawa	O
et	O
al.	O
,	O
1996	O
;	O
Barger	O
and	O
Mattson	O
,	O
1996	O
)	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
also	O
been	O
shown	O
that	O
the	O
neuroprotective	O
effect	O
of	O
somatostatin	B
on	O
NMDA	B
-	O
induced	O
neuronal	O
death	O
is	O
also	O
mediated	O
by	O
cyclic	O
GMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
presumably	O
by	O
regulation	O
of	O
the	O
intracellular	O
calcium	B
level	O
(	O
Forloni	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Higher	O
concentrations	O
of	O
DETA	B
-	I
NONOate	I
did	O
not	O
afford	O
any	O
further	O
protection	O
in	O
our	O
preparation	O
;	O
some	O
authors	O
have	O
suggested	O
that	O
the	O
hydroxyl	B
radical	I
results	O
from	O
the	O
interaction	O
between	O
NO	B
and	O
H2	B
O2	I
(	O
Nappi	O
and	O
Vass	O
,	O
1998	O
)	O
,	O
and	O
this	O
might	O
counteract	O
the	O
neuroprotective	O
effects	O
that	O
we	O
have	O
observed	O
at	O
lower	O
concentrations	O
.	O

The	O
activation	O
of	O
SGC	O
is	O
accepted	O
to	O
be	O
the	O
main	O
target	O
for	O
NO	B
actions	O
(	O
Ignarro	O
,	O
1990	O
;	O
McDonald	O
and	O
Murad	O
,	O
1996	O
)	O
and	O
NO	B
released	O
from	O
DETA	B
-	I
NONOate	I
is	O
likely	O
to	O
be	O
responsible	O
for	O
cyclic	B
GMP	I
elevations	O
.	O

In	O
addition	O
,	O
H2	B
O2	I
could	O
be	O
another	O
candidate	O
as	O
it	O
has	O
been	O
shown	O
that	O
this	O
molecule	O
is	O
able	O
to	O
cause	O
activation	O
of	O
SGC	O
and	O
accumulation	O
of	O
cyclic	B
GMP	I
(	O
Burke	O
-	O
Wolin	O
et	O
al.	O
,	O
1991	O
)	O
.	O

However	O
,	O
H2	B
O2	I
did	O
not	O
cause	O
any	O
change	O
in	O
cyclic	B
GMP	I
levels	O
in	O
our	O
system	O
.	O

In	O
summary	O
,	O
our	O
data	O
show	O
that	O
H2	B
O2	I
causes	O
neurotoxicity	O
and	O
that	O
NO	B
-	O
induced	O
cyclic	O
GMP	O
elevations	O
exert	O
a	O
neuroprotective	O
role	O
against	O
this	O
damage	O
in	O
primary	O
cultures	O
of	O
rat	O
cortical	O
neurones	O
.	O

In	O
addition	O
,	O
pharmacological	O
manipulation	O
of	O
the	O
NO	B
:	O
cyclic	B
GMP	I
pathway	O
may	O
provide	O
a	O
therapy	O
for	O
neurodegenerative	O
diseases	O
in	O
which	O
oxidative	O
stress	O
is	O
implicated	O
,	O
such	O
as	O
Alzheimer	O
's	O
and	O
Parkinson	O
diseases	O
,	O
amyothrophic	O
lateral	O
sclerosis	O
and	O
disorders	O
which	O
include	O
ischaemia	O
and	O
excitotoxicity	O
(	O
Coyle	O
and	O
Puttfarcken	O
,	O
1993	O
;	O
Gutteridge	O
,	O
1994	O
;	O
Bowling	O
and	O
Beal	O
,	O
1995	O
)	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
DGICYT	O
PM	O
95	O
-	O
0070	O
,	O
DGES	O
PM97	O
-	O
0054	O
/	O
97	O
and	O
Fundación	O
Central	O
Hispano	O
.	O

Carbohydrate	B
structures	O
containing	O
a	O
Galα1→3	B
Gal	I
terminus	O
,	O
namely	O
α	B
-	I
Gal	I
epitope	I
,	O
have	O
been	O
identified	O
as	O
xenoactive	O
antigens	B
and	O
are	O
considered	O
to	O
be	O
the	O
major	O
cause	O
for	O
hyperacute	O
rejection	O
in	O
xenotransplantation.1–6	O
Similar	O
to	O
ABO	O
blood	O
-	O
mismatched	O
organ	O
allotransplants	O
,	O
transplants	O
from	O
species	O
other	O
than	O
Old	O
World	O
primates	O
are	O
rejected	O
within	O
minutes	O
by	O
human	O
natural	O
antibodies	O
,	O
so	O
-	O
called	O
anti	O
-	O
Gal	O
.	O

The	O
anti	O
-	O
Gal	O
antibody	O
is	O
reported	O
at	O
levels	O
of	O
1–2	O
%	O
of	O
total	O
IgG	O
and	O
3–8	O
%	O
of	O
total	O
IgM	O
in	O
human	O
blood.2	O
They	O
bind	O
specifically	O
to	O
an	O
α	B
-	I
Gal	I
epitope	I
on	O
the	O
surface	O
of	O
the	O
xenograft	O
cells	O
to	O
initiate	O
complement	O
-	O
mediated	O
lysis	O
of	O
the	O
cells.7	O
Taking	O
advantage	O
of	O
this	O
humoral	O
response	O
from	O
the	O
human	O
body	O
,	O
we	O
report	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
binding	O
of	O
α	B
-	I
Gal	I
epitope	I
containing	O
glycoconjugates	B
for	O
targeting	O
bacterial	O
cells	O
with	O
naturally	O
occurring	O
human	O
anti	O
α	O
-	O
Gal	O
antibodies	O
.	O

The	O
feasibility	O
of	O
using	O
antibody	O
targeting	O
followed	O
by	O
mediated	O
immune	O
response	O
against	O
bacterial	O
cells	O
was	O
proved	O
by	O
Bertozzi	O
et	O
al.8,9	O
However	O
,	O
antibody	O
based	O
immunotherapy	O
is	O
often	O
limited	O
by	O
immunogenicity	O
.	O

Development	O
of	O
humanized	O
antibodies	O
is	O
a	O
complex	O
and	O
difficult	O
task	O
.	O

Recently	O
the	O
direct	O
use	O
of	O
human	O
natural	O
antibodies	O
such	O
as	O
anti	O
-	O
Gal	O
for	O
the	O
specific	O
deletion	O
of	O
target	O
cells	O
has	O
become	O
very	O
attractive.10,11	O
In	O
this	O
paper	O
,	O
we	O
chose	O
bacterial	O
cells	O
as	O
a	O
model	O
system	O
.	O

Numerous	O
bacterial	O
strains	O
produce	O
surface	O
lectins	O
which	O
are	O
in	O
the	O
form	O
of	O
fimbriae	O
(	O
or	O
pili	O
)	O
that	O
are	O
filamentous	O
appendages	O
of	O
protein	O
subunits	O
.	O

They	O
are	O
found	O
to	O
be	O
responsible	O
for	O
cell	O
–	O
cell	O
recognition	O
and	O
infectious	O
disease	O
.	O

However	O
,	O
many	O
bacteria	O
undergo	O
genetic	O
changes	O
to	O
eschew	O
the	O
host	O
immune	O
system	O
.	O

In	O
spite	O
of	O
these	O
changes	O
,	O
the	O
binding	O
specificity	O
of	O
bacterial	O
cell	O
-	O
surface	O
lectins	O
is	O
conserved.12	O
Many	O
of	O
the	O
bacterial	O
lectins	O
exhibit	O
distinct	O
sugar	B
specificities	O
.	O

Among	O
the	O
best	O
characterized	O
fimbrial	O
lectins	O
are	O
the	O
type	O
1	O
fimbrial	O
lectins	O
which	O
are	O
specific	O
for	O
α	B
-	I
mannosides.13,14	I
The	O
binding	O
affinity	O
of	O
the	O
mannose	O
receptor	O
to	O
a	O
mannose	B
ligand	O
falls	O
in	O
the	O
millimolar	O
range	O
.	O

Recently	O
it	O
has	O
been	O
found	O
that	O
the	O
avidity	O
of	O
carbohydrate	B
ligands	O
binding	O
to	O
proteins	O
can	O
be	O
increased	O
dramatically	O
when	O
carbohydrate	B
ligands	O
are	O
organized	O
as	O
multivalent	O
clusters.15–18	O
The	O
mannose	B
-	B
containing	I
glycopolymers	B
and	O
glycodendrimers	B
have	O
been	O
reported	O
to	O
have	O
ideal	O
inhibitory	O
effect	O
of	O
binding	O
of	O
yeast	O
mannan	B
to	O
Concanavalin	O
A	O
and	O
Pea	O
lectins.19	O

It	O
was	O
indicated	O
that	O
the	O
well	O
-	O
defined	O
glycodendrimers	B
were	O
not	O
as	O
effective	O
as	O
glycopolymer	B
.	O

We	O
synthesized	O
a	O
new	O
type	O
of	O
α	B
-	I
Gal	I
epitope	I
and	O
mannose	B
containing	I
glycopolymers	I
(	O
Fig.	O
1	O
)	O
.	O

Binding	O
of	O
such	O
glycopolymers	B
to	O
mannose	B
specific	O
bacteria	O
,	O
followed	O
by	O
treatment	O
with	O
human	O
natural	O
anti	O
-	O
Gal	O
should	O
result	O
in	O
complement	O
-	O
mediated	O
lysis	O
of	O
the	O
bacteria	O
.	O

The	O
binding	O
of	O
the	O
glycopolymers	B
to	O
bacteria	O
was	O
tested	O
for	O
inhibition	O
against	O
agglutination	O
of	O
yeast	O
mannan	B
(	O
S.	O
cerevisiae	O
)	O
to	O
E.	O
coli	O
.	O

Human	O
natural	O
anti	O
-	O
Gal	O
antibody	O
binding	O
to	O
the	O
α	B
-	I
Gal	I
containing	I
glycopolymers	I
was	O
demonstrated	O
by	O
an	O
ELISA	O
inhibition	O
assay	O
.	O

Results	O
and	O
Discussion	O
Preparation	O
of	O
monomers	B
bearing	O
a	O
hydrophilic	O
spacer	O
from	O
lactose	B
and	O
mannose	B
Scheme	O
1	O
shows	O
the	O
synthesis	O
of	O
β	B
-	I
lactosyl	I
acrylamide	I
(	O
5	B
)	O
.	O

We	O
chose	O
commercially	O
available	O
2-	B
[	I
2-	I
(	I
2-chloroethoxy	I
)	I
ethoxy	I
]	I
ethanol	I
(	O
1	B
)	O
as	O
a	O
spacer	O
building	O
block	O
.	O

Complete	O
transformation	O
of	O
chloride	B
to	O
azide	B
2	I
was	O
accomplished	O
in	O
DMF	B
at	O
80	O
°	O
C	O
according	O
to	O
a	O
known	O
procedure.20	O
Glycosylation	O
of	O
2	O
with	O
α	B
-	I
lactosyl	I
bromide	I
heptaacetate	I
using	O
Köenigs	O
–	O
Knorr	O
glycosylation	O
method	O
gave	O
compound	B
3	I
in	O
82	O
%	O
yield	O
.	O

The	O
desired	O
β	O
-	O
configuration	O
was	O
confirmed	O
by	O
the	O
coupling	O
constant	O
of	O
anomeric	O
proton	O
(	O
J	O
12	O
=	O
7.8	O
Hz	O
)	O
.	O

The	O
glycoside	B
3	I
was	O
deacetylated	O
by	O
the	O
Zemplén	O
method	O
to	O
give	O
water	B
soluble	O
4	O
in	O
good	O
yield	O
.	O

Hydrogenation	O
of	O
compound	B
4	I
,	O
followed	O
by	O
the	O
treatment	O
with	O
acryloyl	B
chloride	I
to	O
provide	O
monomer	B
precursor	I
5	I
in	O
71	O
%	O
yield	O
.	O

Scheme	O
2	O
shows	O
a	O
similar	O
glycosylation	O
approach	O
toward	O
the	O
synthesis	O
of	O
α	B
-	I
mannosyl	I
acrylamide	I
(	O
8	O
)	O
.	O

The	O
glycosylation	O
reaction	O
provided	O
compound	B
6	I
in	O
moderate	O
yield	O
(	O
49	O
%	O
)	O
.	O

The	O
α	O
-	O
configuration	O
was	O
determined	O
by	O
the	O
anomeric	O
proton	O
coupling	O
constant	O
(	O
J	O
12	O
=	O
1.5	O
Hz	O
)	O
along	O
with	O
a	O
characteristic	O
feature	O
that	O
no	O
carbon	O
chemical	O
shifts	O
around	O
76	O
ppm	O
(	O
In	O
peracetylated	B
mannoside	I
,	O
C-5	O
chemical	O
shift	O
is	O
76	O
ppm	O
for	O
β	B
-	I
anomer	I
,	O
while	O
70	O
ppm	O
for	O
α	B
-	I
anomer	I
)	O
.	O

Comparing	O
to	O
α	B
-	I
lactosyl	I
bromide	I
heptaacetate	I
,	O
α	B
-	I
mannosyl	I
bromide	I
tetraacetate	I
was	O
more	O
reactive	O
.	O

Consequently	O
,	O
more	O
by	B
-	I
products	I
were	O
observed	O
in	O
this	O
reaction	O
.	O

Enzymatic	O
synthesis	O
of	O
an	O
α	B
-	I
Gal	I
disaccharide	I
containing	O
monomer	O
precursor	O
Synthesis	O
of	O
Galα1→3Gal	B
acrylamide	I
monomer	O
precursor	O
11	O
was	O
accomplished	O
by	O
a	O
one	O
-	O
pot	O
enzymatic	O
transglycosylation	O
reaction	O
catalyzed	O
by	O
α	O
-	O
galactosidase	O
from	O
green	O
coffee	O
beans	O
(	O
Scheme	O
3	O
)	O
.21	O

Although	O
the	O
yield	O
of	O
this	O
enzymatic	O
reaction	O
,	O
like	O
the	O
conventional	O
transglycosylation	O
,	O
is	O
relatively	O
low	O
,	O
the	O
concise	O
synthetic	O
approach	O
is	O
still	O
more	O
attractive	O
than	O
the	O
typical	O
protecting	O
-	O
deprotecting	O
chemical	O
synthesis	O
.	O

Transformation	O
of	O
the	O
nitro	B
group	I
of	O
compound	B
9	I
to	O
the	O
N	B
-acryloyl	I
function	I
was	O
then	O
effected	O
by	O
hydrogenation	B
,	O
followed	O
by	O
the	O
treatment	O
with	O
acryloyl	B
chloride	I
in	O
methanol	B
to	O
give	O
compound	B
11	I
.	O

Radical	O
terpolymerization	O
and	O
enzymatic	O
preparation	O
of	O
glycopolymers	B
containing	O
lactose	B
and	O
mannose	B
The	O
glycopolymers	B
bearing	O
α	B
-	I
Gal	I
epitope	I
were	O
constructed	O
through	O
two	O
different	O
routes	O
.	O

The	O
first	O
one	O
is	O
to	O
use	O
the	O
epitope	B
11	I
to	O
copolymerize	O
with	O
mannose	B
monomer	B
precursor	I
8	I
and	O
acrylamide	B
in	O
an	O
established	O
terpolymerization	O
method22	O
(	O
Scheme	O
4	O
)	O
.	O

The	O
polymerization	O
was	O
initiated	O
by	O
ammonium	B
persulfate	I
and	O
N	B
,	I
N	I
,	I
N′,N′	I
-tetramethylethylenediamine	I
in	O
aqueous	O
solution	O
.	O

Thin	O
-	O
layer	O
chromatography	O
was	O
used	O
to	O
monitor	O
the	O
reaction	O
.	O

The	O
final	O
polymer	B
was	O
obtained	O
as	O
a	O
white	O
fluffy	O
material	O
after	O
separation	O
by	O
Bio	O
-	O
gel	O
P-2	O
permeation	O
column	O
and	O
freeze	O
-	O
drying	O
(	O
76	O
%	O
yield	O
)	O
.	O

The	O
1	O
H	O
NMR	O
in	O
D2	B
O	I
verified	O
the	O
incorporation	O
of	O
all	O
three	O
monomers	O
in	O
the	O
final	O
glycopolymer	B
12	I
.	O

We	O
have	O
developed	O
an	O
efficient	O
chemoenzymatic	O
synthesis	O
of	O
α	B
-	I
Gal	I
epitope	I
using	O
a	O
recombinant	O
α1	O
-	O
3	O
galactosyltransferase.23	O
The	O
second	O
route	O
is	O
to	O
use	O
the	O
recombinant	O
enzyme	O
to	O
transfer	O
a	O
galactose	B
from	O
uridine	B
5′	I
diphosphate	I
galactose	I
(	O
UDP	B
-	I
Gal	I
)	O
to	O
a	O
lactosyl	B
acceptor	I
in	O
a	O
glycopolymer	B
containing	O
other	O
sugar	B
moieties	O
such	O
as	O
mannose	B
which	O
is	O
not	O
an	O
acceptor	O
of	O
the	O
enzyme	O
(	O
Scheme	O
5	O
)	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
example	O
showing	O
the	O
selective	O
modification	O
of	O
glycopolymers	B
bearing	O
different	O
sugar	B
moieties	O
.	O

Similar	O
enzymatic	O
transformations	O
to	O
the	O
polymers	B
bearing	O
single	O
type	O
of	O
sugar	B
ligand	O
have	O
been	O
reported.24–26	O
In	O
order	O
to	O
enhance	O
the	O
transfer	O
efficiency	O
,	O
the	O
biocompatible	O
oligoethoxyl	B
group	I
was	O
employed	O
.	O

This	O
provided	O
the	O
lactosyl	B
acceptor	I
side	O
chains	O
with	O
adequate	O
space	O
away	O
from	O
the	O
bulky	O
polymer	B
main	O
chain	O
.	O

The	O
enzyme	O
then	O
can	O
bind	O
to	O
the	O
acceptor	O
completely	O
for	O
subsequent	O
transformation	O
.	O

As	O
anticipated	O
,	O
the	O
enzymatic	O
transformation	O
generated	O
the	O
modified	O
glycopolymers	B
15A	B
–B	B
in	O
nearly	O
quantitative	O
yield	O
(	O
confirmed	O
by	O
the	O
integration	O
ratio	O
of	O
anomeric	O
protons	O
)	O
.	O

It	O
is	O
noteworthy	O
that	O
all	O
the	O
glycopolymers	B
obtained	O
from	O
terpolymerization	O
have	O
a	O
high	O
molecular	O
weight	O
(	O
Mw	O
>	O
870	O
kD	O
)	O
with	O
mean	O
hydrodynamic	O
diameter	O
of	O
polymer	B
chain	O
in	O
aqueous	O
solution	O
greater	O
than	O
69	O
nm	O
at	O
ambient	O
temperature	O
.	O

The	O
choice	O
of	O
using	O
aromatic	B
13	I
and	O
non	B
-	I
aromatic	I
8	I
α	B
-	I
mannoside	I
ligands	O
for	O
the	O
glycopolymers	B
was	O
based	O
on	O
the	O
work	O
done	O
by	O
Firon	O
et	O
al.27,28	O
They	O
found	O
that	O
E.	O
coli	O
.	O
showed	O
a	O
hydrophobic	O
region	O
close	O
to	O
mannose	B
-	O
binding	O
sites	O
which	O
favored	O
aromatic	B
α	I
-mannosides	I
such	O
as	O
p	B
-nitrophenyl	I
-	I
α	I
-	I
d	I
-mannopyranoside	I
.	O

They	O
also	O
noticed	O
that	O
Salmonella	O
species	O
possessed	O
a	O
binding	O
site	O
which	O
was	O
smaller	O
than	O
that	O
of	O
E.	O
coli	O
.	O
,	O
and	O
devoid	O
of	O
a	O
hydrophobic	O
region	O
.	O

The	O
13	O
C	O
NMR	O
spectrum	O
of	O
glycopolymer	B
15B	I
is	O
shown	O
in	O
Figure	O
2	O
.	O

The	O
anomeric	O
region	O
is	O
expanded	O
and	O
clearly	O
shows	O
the	O
presence	O
of	O
lactose	B
with	O
103.5	O
and	O
102.7	O
ppm	O
,	O
mannose	B
with	O
99.1	O
ppm	O
,	O
and	O
newly	O
formed	O
α	B
-	I
galactose	I
anomeric	O
carbon	B
resonance	O
of	O
96.0	O
ppm	O
(	O
Fig.	O
3	O
)	O
.	O

Chemoenzymatic	O
synthesis	O
of	O
monovalent	O
α	B
-	I
Gal	I
-	I
mannose	I
conjugate	I
As	O
shown	O
in	O
Scheme	O
6	O
,	O
compound	B
19	I
with	O
two	O
single	O
ligands	O
of	O
α	B
-	I
Gal	I
epitope	I
and	O
α	B
-	I
mannoside	I
was	O
constructed	O
for	O
a	O
control	O
experiment	O
comparing	O
with	O
the	O
multivalent	O
counterpart	O
15B	O
.	O

Glycosylation	O
of	O
methyl	B
6-hydroxyhexanoate	I
with	O
α	B
-	I
lactosyl	I
bromide	I
heptaacetate	I
using	O
the	O
same	O
Köenigs	O
–	O
Knorr	O
glycosylation	O
condition	O
as	O
in	O
Scheme	O
1	O
afforded	O
compound	B
16	I
.	O

The	O
glycoside	B
16	I
was	O
deacetylated	O
by	O
the	O
Zemplén	O
method	O
,	O
followed	O
by	O
saponification	O
to	O
give	O
water	O
soluble	O
17	B
with	O
a	O
free	O
carboxylic	B
group	I
.	O

The	O
lactosyl	B
derivative	I
was	O
then	O
coupled	O
with	O
p	B
-aminophenyl	I
-	I
α	I
-	I
d	I
-mannopyranoside	I
using	O
diphenylphosphoryl	B
azide	I
(	O
DPPA	B
)	O
as	O
a	O
promoter	O
which	O
was	O
demonstrated	O
to	O
activate	O
glycopeptide	B
coupling	O
in	O
the	O
presence	O
of	O
free	O
hydroxyl	B
groups.29	I
The	O
reaction	O
was	O
conducted	O
in	O
DMF	B
at	O
room	O
temperature	O
to	O
give	O
conjugate	B
18	I
in	O
66	O
%	O
yield	O
.	O

Enzymatic	O
galactosylation	O
of	O
compound	B
18	I
using	O
α1	O
-	O
3	O
galactosyltransferase	O
provided	O
the	O
α	B
-	I
gal	I
epitope	I
containing	O
conjugate	B
19	I
.	O

Binding	O
studies	O
of	O
α	B
-	I
Gal	I
-	I
mannose	I
glycoconjugates	I
to	O
bacteria	O
The	O
α	B
-	I
Gal	I
-	I
mannose	I
glycopolymers	I
were	O
tested	O
for	O
their	O
ability	O
to	O
function	O
as	O
multivalent	O
ligands	O
for	O
the	O
binding	O
of	O
E.	O
coli	O
K-12	O
HB101	O
bacterial	O
cells	O
.	O

This	O
E.	O
coli	O
strain	O
contains	O
mannose	B
-	O
binding	O
sites	O
located	O
on	O
the	O
surface	O
of	O
the	O
bacteria	O
,	O
which	O
can	O
bind	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
,	O
resulting	O
in	O
visible	O
agglutination	O
.	O

To	O
evaluate	O
the	O
activity	O
of	O
our	O
glycopolymers	B
12	B
and	O
15A	B
–B	B
,	O
we	O
compared	O
their	O
inhibitory	O
effects	O
on	O
agglutination	O
with	O
several	O
controls	O
including	O
the	O
monovalent	O
methyl	B
-	I
α	I
-	I
d	I
-mannopyranoside	I
,	O
p	B
-nitrophenyl	I
α	I
-	I
d	I
-mannopyranoside	I
,	O
α	B
-	I
Gal	I
-	I
mannose	I
conjugate	I
19	I
,	O
polyvalent	O
mannose	B
copolymers	I
15C	B
–	O
D	B
.	O

The	O
results	O
indicated	O
that	O
the	O
glycopolymers	B
12	B
and	O
15A	B
–B	B
are	O
effective	O
in	O
preventing	O
agglutination	O
at	O
concentrations	O
as	O
low	O
as	O
100	O
μM.	O
Comparing	O
to	O
methyl	B
-	I
α	I
-	I
d	I
-mannopyranoside	I
,	O
dramatic	O
increase	O
in	O
the	O
inhibitory	O
efficacy	O
was	O
observed	O
with	O
polyvalent	O
mannose	B
.	O

However	O
,	O
p	B
-nitrophenyl	I
α	I
-	I
d	I
-mannopyranoside	I
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
inhibitor	O
.	O

This	O
compound	O
showed	O
strong	O
inhibition	O
at	O
concentrations	O
as	O
low	O
as	O
90	O
μM.	O
Monovalent	O
conjugate	B
19	I
and	O
polymer	B
15B	I
bearing	O
a	O
hydrophobic	O
aromatic	B
ring	I
had	O
comparable	O
inhibitory	O
effects	O
.	O

The	O
polyvalency	O
here	O
is	O
unexpectedly	O
overshadowed	O
by	O
van	O
der	O
Waals	O
forces	O
resulting	O
from	O
the	O
packing	O
of	O
the	O
aromatic	B
ring	I
againt	O
a	O
hydrophobic	O
binding	O
pocket	O
on	O
the	O
surface	O
of	O
the	O
bacteria	O
.	O

It	O
is	O
noteworthy	O
that	O
no	O
inhibition	O
was	O
observed	O
with	O
p	B
-nitrophenyl	I
α	I
-	I
d	I
-galactopyranoside	I
.	O

This	O
indicates	O
the	O
mannose	B
-	O
binding	O
sites	O
are	O
highly	O
specific	O
.	O

α	B
-	I
Gal	I
residue	I
is	O
not	O
able	O
to	O
compete	O
with	O
mannose	B
in	O
binding	O
to	O
the	O
bacterial	O
mannose	O
receptors	O
(	O
Table	O
1	O
)	O
.	O

Binding	O
studies	O
of	O
α	B
-	I
Gal	I
-	I
mannose	I
glycoconjugates	I
to	O
human	O
natural	O
anti	O
-	O
Gal	O
antibodies	O
using	O
an	O
ELISA	O
inhibition	O
assay	O
To	O
assess	O
the	O
activity	O
of	O
α	B
-	I
Gal	I
-	I
mannose	I
glycoconjugates	I
binding	O
to	O
the	O
anti	O
α	O
-	O
Gal	O
antibodies	O
,	O
we	O
applied	O
a	O
previously	O
reported	O
ELISA	O
inhibition	O
assay.30	O
Mouse	O
laminin	O
having	O
α	B
-	I
Gal	I
epitopes	I
were	O
fixed	O
on	O
ELISA	O
plate	O
as	O
solid	O
-	O
phase	O
antigens	O
.	O

Test	O
glycoconjugates	B
were	O
then	O
incubated	O
with	O
human	O
anti	O
-	O
Gal	O
antibodies	O
on	O
the	O
ELISA	O
plate	O
.	O

The	O
plate	O
was	O
washed	O
and	O
incubated	O
with	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
conjugated	O
anti	O
-	O
human	O
IgG	O
antibody	O
.	O

After	O
additional	O
washing	O
,	O
the	O
color	O
was	O
developed	O
by	O
HRP	O
reaction	O
using	O
a	O
chromogenic	B
compound	I
.	O

Monovalent	O
conjugate	B
19	I
and	O
polymer	B
15B	I
were	O
tested	O
with	O
two	O
controls	O
α	B
-	I
Gal	I
epitope	I
(	O
Galα1→3Galβ1→4Glc	B
)	O
and	O
mannose	B
copolymer	I
15D	I
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
conjugate	B
19	I
and	O
polymer	B
15B	I
bind	O
effectively	O
to	O
human	O
anti	O
-	O
Gal	O
antibody	O
.	O

The	O
polyvalency	O
of	O
α	B
-	I
Gal	I
epitope	I
on	O
polymer	B
15B	I
was	O
clearly	O
demonstrated	O
by	O
comparing	O
the	O
inhibition	O
of	O
compound	B
19	I
with	O
polymer	B
15B	I
at	O
the	O
same	O
concentration	O
of	O
α	B
-	I
Gal	I
epitopes	I
.	O

Polymer	B
15D	I
without	O
having	O
α	B
-	I
Gal	I
epitope	I
had	O
no	O
binding	O
to	O
human	O
anti	O
-	O
Gal	O
antibody	O
.	O

It	O
can	O
be	O
concluded	O
that	O
no	O
cross	O
reactivity	O
exists	O
between	O
mannose	B
and	O
human	O
natural	O
anti	O
-	O
Gal	O
antibodies	O
.	O

More	O
importantly	O
,	O
inhibition	O
stem	O
from	O
steric	O
stabilization31	O
of	O
antibody	O
surface	O
was	O
not	O
observed	O
under	O
our	O
experimental	O
conditions	O
.	O

Conclusion	O
In	O
summary	O
,	O
we	O
have	O
used	O
chemoenzymatic	O
synthesis	O
to	O
effectively	O
construct	O
monovalent	O
and	O
multivalent	O
α	B
-	I
Gal	I
conjugates	I
containing	O
mannose	B
ligands	O
.	O

The	O
α	B
-	I
Gal	I
and	O
mannose	B
containing	B
compounds	I
were	O
subsequently	O
proved	O
to	O
be	O
potent	O
inhibitors	O
against	O
the	O
bindings	O
of	O
both	O
yeast	O
mannan	B
to	O
E.	O
coli	O
.	O
,	O
K-12	O
and	O
human	O
natural	O
anti	O
-	O
Gal	O
antibodies	O
to	O
mouse	O
laminin	O
.	O

Cross	O
reactivities	O
of	O
mannose	B
binding	O
to	O
anti	O
-	O
Gal	O
antibodies	O
and	O
α	B
-	I
Gal	I
residue	I
binding	O
to	O
bacteria	O
were	O
not	O
observed	O
.	O

The	O
model	O
compounds	B
with	O
dual	O
binding	O
capacity	O
will	O
be	O
viable	O
ligands	O
to	O
redirect	O
human	O
natural	O
immunity	O
against	O
bacterial	O
pathogens	O
coated	O
with	O
xenoactive	O
epitopes	B
.	O

The	O
sandwiched	O
binding	O
motif	O
as	O
well	O
as	O
bacterial	O
killing	O
assay	O
will	O
be	O
further	O
reported	O
in	O
due	O
course	O
.	O

Experimental	O
General	O
1	O
H	O
and	O
13	O
C	O
spectra	O
were	O
recorded	O
on	O
a	O
300	O
MHz	O
GE	O
Gemini	O
and	O
500	O
MHz	O
Varian	O
Unity	O
spectrometers	O
.	O

Mass	O
spectra	O
(	O
FAB	O
or	O
ESI	O
)	O
were	O
run	O
on	O
the	O
mass	O
spectrometry	O
facility	O
at	O
the	O
University	O
of	O
California	O
,	O
Riverside	O
.	O

Molecular	O
weight	O
of	O
glycopolymers	B
were	O
measured	O
by	O
static	O
light	O
scattering	O
using	O
NICOMP	O
model	O
370	O
submicron	O
particle	O
sizer	O
.	O

Thin	O
-	O
layer	O
chromatography	O
was	O
conducted	O
on	O
Baker	O
Si250F	O
silica	B
gel	O
TLC	O
plates	O
with	O
a	O
fluorescent	O
indicator	O
.	O

Column	O
chromatography	O
was	O
conducted	O
with	O
silica	B
gel	O
,	O
grade	O
62	O
,	O
60–200	O
mesh	O
,	O
150	O
Å	O
and	O
Bio	O
-	O
Gel	O
P-2	O
.	O

Dialysis	O
was	O
performed	O
against	O
deionized	O
water	B
using	O
dialysis	O
tubing	O
(	O
8000	O
MW	O
cutoff	O
)	O
.	O

Mouse	O
laminin	O
(	O
L2020	O
)	O
and	O
human	O
serum	O
derived	O
from	O
sterile	O
-	O
filtered	O
male	O
AB	O
plasma	O
were	O
obtained	O
from	O
Sigma	O
Co.	O
,	O
St.	O
Louis	O
,	O
MO	O
.	O

E.	O
coli	O
K-12	O
HB101	O
was	O
obtained	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
)	O
Rockville	O
,	O
MD	O
.	O

2-	B
[	I
2-	I
(	I
2-Azidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
(	I
2,3,4,6-tetra	I
-	I
O	I
-acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
14	I
)	I
-2,3,6-tri	I
-	I
O	I
-acetyl	I
-	I
β	I
-	I
d	I
-glucopyranoside	I
(	O
3	B
)	O
2,3,4,6-Hepta	B
-	I
O	I
-acetyl	I
-	I
α	I
-	I
lactosyl	I
bromide	I
(	O
4.5	O
g	O
,	O
6.4	O
mmol	O
)	O
and	O
2-	B
[	I
2-	I
(	I
2-azidoethoxy	I
)	I
ethoxy	I
]	I
-ethanol	I
(	O
1.6	O
g	O
)	O
were	O
added	O
to	O
a	O
previously	O
flame	O
-	O
dried	O
flask	O
containing	O
6	O
g	O
MS	O
4	O
Å	O
and	O
50	O
mL	O
anhydrous	O
CHCl3	B
.	O

The	O
resulting	O
suspension	O
was	O
stirred	O
for	O
half	O
an	O
hour	O
.	O

HgO	B
(	O
1.4	O
g	O
)	O
and	O
HgBr2	B
(	O
cat	O
)	O
were	O
added	O
to	O
the	O
suspension	O
.	O

The	O
mixture	O
was	O
stirred	O
in	O
the	O
dark	O
at	O
ambient	O
temperature	O
for	O
48	O
h.	O
The	O
resulting	O
mixture	O
was	O
passed	O
through	O
a	O
Celite	B
packed	O
glass	B
funnel	O
,	O
and	O
washed	O
with	O
saturated	O
NaHCO3	B
and	O
water	B
.	O

The	O
organic	O
phase	O
was	O
dried	O
over	O
anhydrous	O
Na2	B
SO4	I
and	O
concentrated	O
in	O
vacuo	O
.	O

The	O
resulting	O
residue	O
was	O
chromatographed	O
(	O
hexane	B
:	O
EtOAc	B
,	O
1:1	O
)	O
to	O
afford	O
product	B
3	I
(	O
4.2	O
g	O
,	O
82	O
%	O
)	O
.	O

3	O
:	O
1	O
H	O
NMR	O
(	O
CDCl3	B
)	O
Selected	O
δ	O
5.31	O
(	O
d	O
,	O
J	O
=	O
2.4	O
Hz	O
,	O
1H	O
)	O
,	O
5.16	O
(	O
t	O
,	O
J	O
=	O
9.3	O
Hz	O
,	O
1H	O
)	O
,	O
5.07	O
(	O
dd	O
,	O
J	O
=	O
7.8	O
Hz	O
,	O
10.2	O
,	O
1H	O
)	O
,	O
4.85–4.94	O
(	O
m	O
,	O
2H	O
)	O
,	O
4.54	O
(	O
d	O
,	O
J	O
=	O
7.8	O
Hz	O
,	O
1H	O
)	O
,	O
4.48–4.44	O
(	O
m	O
,	O
2H	O
)	O
,	O
3.36–4.11	O
(	O
m	O
,	O
18	O
H	O
)	O
13	O
C	O
δ	O
170.3	O
,	O
170.1	O
,	O
170.0	O
,	O
169.7	O
,	O
169.6	O
,	O
169.0	O
,	O
101.0	O
,	O
100.5	O
,	O
76.2	O
,	O
72.7	O
,	O
72.6	O
,	O
71.6	O
,	O
70.9	O
,	O
70.6	O
,	O
70.6	O
,	O
70.3	O
,	O
69.9	O
,	O
69.1	O
,	O
69.0	O
,	O
66.6	O
,	O
61.9	O
,	O
60.8	O
,	O
50.6	O
,	O
20.5	O
-	O
20.8	O
.	O

MS	O
(	O
m	O
/	O
z	O
)	O
816	O
(	O
M+Na+	O
)	O
;	O
HRMS	O
calcd	O
for	O
C32	O
H47	O
N3	O
O20	O
Na+	O
816.2651	O
,	O
found	O
816.2648	O
.	O

2-	B
[	I
2-	I
(	I
2-Azidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-glucopyranoside	I
(	O
4	B
)	O
To	O
a	O
solution	O
of	O
3	B
(	O
3	O
g	O
)	O
in	O
anhydrous	O
methanol	B
(	O
200	O
mL	O
)	O
at	O
0	O
°	O
C	O
was	O
added	O
NaOMe	B
until	O
the	O
pH	O
was	O
10	O
.	O

The	O
solution	O
was	O
stirred	O
for	O
3	O
h.	O
Dowex	B
cation	I
exchange	I
resin	I
(	O
H	O
form	O
)	O
was	O
added	O
to	O
adjust	O
the	O
pH	O
to	O
6–7	O
and	O
filtered	O
.	O

The	O
filtrate	O
was	O
evaporated	O
to	O
give	O
a	O
syrup	O
4	B
in	O
quantitative	O
yield	O
.	O

4	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ4.35	O
(	O
s	O
,	O
J	O
=	O
8.1	O
Hz	O
,	O
1H	O
)	O
,	O
4.27	O
(	O
d	O
,	O
J	O
=	O
7.8	O
Hz	O
,	O
1H	O
)	O
,	O
3.32–3.91	O
(	O
m	O
,	O
23	O
H	O
)	O
,	O
3.17	O
(	O
t	O
,	O
J	O
=	O
7.5	O
Hz	O
,	O
1H	O
)	O
.	O

13	O
C	O
δ	O
103.4	O
,	O
102.5	O
,	O
78.9	O
,	O
75.8	O
,	O
75.2	O
,	O
74.8	O
,	O
73.3	O
,	O
73.0	O
,	O
71.4	O
,	O
70.0	O
,	O
70.0	O
,	O
69.9	O
,	O
69.6	O
,	O
69.2	O
,	O
69.0	O
,	O
61.5	O
,	O
60.5	O
,	O
50.6	O
.	O

2-	B
[	I
2-	I
(	I
2-N	I
-acryloyl	I
-	I
aminoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-glucopyranoside	I
(	O
5	B
)	O
In	O
the	O
presence	O
of	O
PtO2	B
(	O
160	O
mg	O
)	O
,	O
4	O
(	O
1.6	O
g	O
)	O
in	O
methanol	B
(	O
40	O
mL	O
)	O
was	O
charged	O
with	O
hydrogen	B
(	O
50	O
lb	O
/	O
in2	O
)	O
for	O
1	O
h.	O
After	O
the	O
reaction	O
,	O
the	O
Pt	B
black	I
was	O
filtered	O
and	O
the	O
filtrate	O
was	O
evaporated	O
to	O
give	O
a	O
residue	O
.	O

To	O
a	O
solution	O
of	O
the	O
residue	O
in	O
cold	O
MeOH	B
(	O
120	O
mL	O
)	O
was	O
added	O
TEA	B
(	O
2	O
mL	O
)	O
and	O
acryloyl	B
chloride	I
(	O
0.6	O
mL	O
in	O
20	O
mL	O
chloroform	B
)	O
dropwise	O
at	O
0	O
°	O
C	O
.	O

The	O
mixture	O
was	O
allowed	O
to	O
warm	O
to	O
room	O
temperature	O
and	O
stirred	O
for	O
2	O
h.	O
The	O
solution	O
was	O
washed	O
with	O
anionic	B
resin	I
(	O
OH−	O
)	O
and	O
cationic	B
resin	I
(	O
H+	O
)	O
successively	O
until	O
the	O
solution	O
reached	O
neutrality	O
.	O

The	O
solution	O
was	O
concentrated	O
and	O
purified	O
on	O
a	O
Bio	O
-	O
Gel	O
P2	O
column	O
and	O
lyophilized	O
to	O
give	O
5	B
(	O
1.2	O
g	O
,	O
71	O
%	O
)	O
.	O

5	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
6.04–6.12	O
(	O
m	O
,	O
1H	O
)	O
,	O
5.58–5.61	O
(	O
m	O
,	O
2H	O
)	O
,	O
4.27	O
(	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
1H	O
)	O
,	O
4.34	O
(	O
d	O
,	O
J	O
=	O
7.5	O
Hz	O
,	O
1H	O
)	O
,	O
3.15–3.91	O
(	O
m	O
,	O
23	O
H	O
)	O
3	O
C	O
δ	O
(	O
130.4	O
,	O
128.0	O
,	O
103.5	O
,	O
102.7	O
,	O
78.9	O
,	O
76.0	O
,	O
75.4	O
,	O
74.9	O
,	O
73.4	O
,	O
73.1	O
,	O
71.5	O
,	O
70.3	O
,	O
70.2	O
,	O
70.1	O
,	O
70.0	O
,	O
69.3	O
,	O
69.1	O
,	O
61.6	O
,	O
60.6	O
,	O
39.6	O
.	O

HRFABMS	O
calcd	O
for	O
C21	O
H37	O
NO14	O
Na+	O
550.2112	O
,	O
found	O
550.2104	O
.	O

2-	B
[	I
2-	I
(	I
2-Azidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
2,3,4,6-tetra	I
-	I
O	I
-acetyl	I
-	I
α	I
-	I
d	I
-mannopyranoside	I
(	O
6	B
)	O
2,3,4,6-Tetra	B
-	I
O	I
-acetyl	I
-	I
α	I
-	I
mannosyl	I
bromide	I
(	O
7	O
g	O
,	O
17	O
mmol	O
)	O
and	O
2-	B
[	I
2-	I
(	I
2-azidoethoxy	I
)	I
ethoxy	I
]	I
ethanol	I
1	O
(	O
3	O
g	O
)	O
were	O
added	O
to	O
a	O
previously	O
flame	O
-	O
dried	O
flask	O
containing	O
10	O
g	O
MS	O
4	O
Å	O
and	O
100	O
mL	O
anhydrous	O
CHCl3	B
.	O

The	O
resulting	O
suspension	O
was	O
stirred	O
for	O
half	O
an	O
hour	O
.	O

HgO	B
(	O
3.7	O
g	O
)	O
and	O
HgBr2	B
(	O
cat	O
)	O
were	O
added	O
to	O
the	O
suspension	O
.	O

The	O
mixture	O
was	O
stirred	O
in	O
the	O
dark	O
at	O
ambient	O
temperature	O
for	O
48	O
h.	O
The	O
resulting	O
mixture	O
was	O
passed	O
through	O
a	O
Celite	B
packed	O
glass	B
funnel	O
,	O
and	O
washed	O
with	O
saturated	O
NaHCO3	B
and	O
water	B
.	O

The	O
organic	O
phase	O
was	O
dried	O
over	O
anhydrous	O
Na2	B
SO4	I
and	O
concentrated	O
in	O
vacuo	O
.	O

The	O
resulting	O
residue	O
was	O
chromatographed	O
(	O
hexane	B
:	O
EtOAc	B
,	O
1:1	O
)	O
to	O
afford	O
compound	B
6	I
(	O
4.2	O
g	O
,	O
49	O
%	O
)	O
.	O

6	O
:	O
1	O
H	O
NMR	O
(	O
CDCl3	B
)	O
δ	O
5.21–5.34	O
(	O
m	O
,	O
3H	O
)	O
,	O
4.83	O
(	O
d	O
,	O
J	O
=	O
1.5	O
Hz	O
,	O
1H	O
)	O
,	O
4.25	O
(	O
dd	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
12.3	O
Hz	O
,	O
1H	O
)	O
,	O
4.00–4.07	O
(	O
m	O
,	O
2H	O
)	O
,	O
3.74–3.80	O
(	O
m	O
,	O
1H	O
)	O
,	O
3.67–3.61	O
(	O
m	O
,	O
9H	O
)	O
,	O
3.36	O
(	O
t	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
2H	O
)	O
,	O
2.11	O
(	O
s	O
,	O
3H	O
)	O
,	O
2.06	O
(	O
s	O
,	O
3H	O
)	O
,	O
2.00	O
(	O
s	O
,	O
3H	O
)	O
,	O
1.95	O
(	O
s	O
,	O
3H	O
)	O
13	O
C	O
δ	O
(	O
170.6	O
,	O
169.9	O
,	O
169.8	O
,	O
169.6	O
,	O
97.7	O
,	O
70.7	O
,	O
70.6	O
,	O
70.0	O
,	O
69.5	O
,	O
69.0	O
,	O
68.4	O
,	O
67.3	O
,	O
66.1	O
,	O
62.4	O
,	O
50.6	O
,	O
20.6	O
-	O
20.8	O
.	O

MS	O
(	O
m	O
/	O
z	O
)	O
528	O
(	O
M+Na+	O
)	O
;	O
HRMS	O
calcd	O
for	O
C20	O
H31	O
N3	O
O12	O
Na+	O
528.1805	O
,	O
found	O
528.1853	O
.	O

2-	B
[	I
2-	I
(	I
2-Azidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl-	I
(	I
-d	I
-mannopyranoside	I
(	O
7	B
)	O
To	O
a	O
solution	O
of	O
6	B
(	O
3.6	O
g	O
)	O
in	O
anhydrous	O
methanol	B
(	O
200	O
mL	O
)	O
at	O
0	O
°	O
C	O
was	O
added	O
NaOMe	B
until	O
pH	O
was	O
10	O
.	O

The	O
solution	O
was	O
stirred	O
for	O
3	O
h.	O
Dowex	B
cation	I
exchange	I
resin	I
(	O
H	O
form	O
)	O
was	O
added	O
to	O
adjust	O
the	O
pH	O
to	O
6–7	O
and	O
filtered	O
.	O

The	O
filtrate	O
was	O
evaporated	O
to	O
give	O
a	O
syrup	O
7	B
in	O
quantitative	O
yield	O
.	O

7	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
(	O
4.72	O
(	O
s	O
,	O
1H	O
)	O
,	O
3.33–3.80	O
(	O
m	O
,	O
18	O
H	O
)	O
13	O
C	O
δ	O
100.5	O
,	O
73.3	O
,	O
71.1	O
,	O
70.5	O
,	O
70.2	O
,	O
70.1	O
,	O
70.1	O
,	O
69.9	O
,	O
67.3	O
,	O
67	O
,	O
50.7	O
.	O

2-	B
[	I
2-	I
(	I
2-N	I
-acryloyl	I
-	I
aminoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl-	I
(	I
-d	I
-mannopyranoside	I
(	O
8	B
)	O
In	O
the	O
presence	O
of	O
PtO2	B
(	O
98	O
mg	O
)	O
,	O
7	O
(	O
1.5	O
g	O
)	O
in	O
methanol	B
(	O
40	O
mL	O
)	O
was	O
charged	O
with	O
hydrogen	B
(	O
50	O
lb	O
/	O
in2	O
)	O
for	O
3	O
h.	O
After	O
the	O
reaction	O
,	O
the	O
Pt	B
black	I
was	O
filtered	O
and	O
the	O
filtrate	O
was	O
evaporated	O
to	O
give	O
a	O
residue	O
.	O

To	O
a	O
solution	O
of	O
the	O
residue	O
in	O
cold	O
MeOH	B
(	O
120	O
mL	O
)	O
was	O
added	O
TEA	B
(	O
2	O
mL	O
)	O
and	O
acryloyl	B
chloride	I
(	O
0.5	O
mL	O
in	O
20	O
mL	O
chloroform	B
)	O
dropwise	O
at	O
0	O
°	O
C	O
.	O

The	O
mixture	O
was	O
allowed	O
to	O
warm	O
to	O
room	O
temperature	O
and	O
stirred	O
for	O
2	O
h.	O
The	O
solution	O
was	O
washed	O
with	O
anionic	B
resin	I
(	O
OH−	O
)	O
and	O
cationic	B
resin	I
(	O
H+	O
)	O
successively	O
until	O
the	O
solution	O
reached	O
neutrality	O
.	O

The	O
solution	O
was	O
concentrated	O
and	O
purified	O
on	O
a	O
Bio	O
-	O
Gel	O
P2	O
column	O
and	O
lyophilized	O
to	O
give	O
8	B
(	O
1.4	O
g	O
,	O
88	O
%	O
)	O
.	O

8	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
(	O
6.13–6.00	O
(	O
m	O
,	O
2H	O
)	O
,	O
5.59	O
(	O
d	O
,	O
J	O
=	O
10.5	O
Hz	O
,	O
1H	O
)	O
,	O
4.70	O
(	O
s	O
,	O
1H	O
)	O
,	O
3.30–3.78	O
(	O
m	O
,	O
18	O
H	O
)	O
13	O
C	O
δ	O
130.4	O
,	O
128.0	O
,	O
100.5	O
,	O
73.3	O
,	O
71.1	O
,	O
70.1	O
,	O
70.6	O
,	O
70.2	O
,	O
70.1	O
,	O
70.1	O
,	O
69.4	O
,	O
67.3	O
,	O
66.9	O
,	O
61.5	O
,	O
39.6	O
.	O

HRFABMS	O
calcd	O
for	O
C15	O
H27	O
NO9	O
Na+	O
388.1584	O
,	O
found	O
388.1589	O
.	O

p	B
-Aminophenyl	I
3-O	I
-α	I
-	I
d	I
-galactopyranosyl	I
-	I
α	I
-	I
d	I
-galactopyranoside	I
(	O
10	B
)	O
In	O
the	O
presence	O
of	O
10	O
%	O
Pd	B
/	I
C	I
(	O
20	O
mg	O
)	O
,	O
9	O
obtained	O
as	O
described	O
previously,21	O
(	O
220	O
mg	O
,	O
0.48	O
mmol	O
)	O
was	O
charged	O
with	O
hydrogen	B
(	O
50	O
lb	O
/	O
in2	O
)	O
in	O
methanol	B
(	O
25	O
mL	O
)	O
for	O
overnight	O
.	O

After	O
the	O
reaction	O
,	O
the	O
Pd	B
black	I
was	O
filtered	O
and	O
the	O
filtrate	O
was	O
evaporated	O
to	O
give	O
a	O
residue	O
10	B
(	O
200	O
mg	O
,	O
97	O
%	O
)	O
.	O

10	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
6.87	O
,	O
6.67	O
(	O
2d	O
,	O
each	O
2H	O
,	O
J	O
=	O
8.1	O
Hz	O
)	O
,	O
5.37	O
(	O
d	O
,	O
J	O
=	O
3.3	O
Hz	O
,	O
1H	O
)	O
,	O
5.03	O
(	O
d	O
,	O
J	O
=	O
3.3	O
Hz	O
,	O
1H	O
)	O
,	O
4.14–3.55	O
m	O
,	O
12	O
H	O
)	O
,	O
13	O
C	O
δ	O
150.2	O
,	O
141.4	O
,	O
119.5	O
,	O
118.3	O
,	O
98.9	O
,	O
95.6	O
,	O
74.6	O
,	O
71.8	O
,	O
71.5	O
,	O
69.8	O
,	O
69.7	O
,	O
68.7	O
,	O
67.0	O
,	O
65.9	O
,	O
61.6	O
,	O
61.5	O
.	O

N	B
-acryloyl	I
-	I
aminophenyl	I
3-O	I
-α	I
-	I
d	I
-galactopyranosyl	I
-	I
α	I
-	I
d	I
-galactopyranoside	I
(	O
11	B
)	O
To	O
a	O
solution	O
of	O
compound	B
10	I
(	O
100	O
mg	O
,	O
0.23	O
mmol	O
)	O
in	O
cold	O
MeOH	B
(	O
20	O
mL	O
)	O
was	O
added	O
TEA	B
(	O
0.6	O
mL	O
)	O
and	O
acryloyl	B
chloride	I
(	O
0.2	O
mL	O
)	O
dropwise	O
at	O
0	O
°	O
C	O
.	O

The	O
mixture	O
was	O
allowed	O
to	O
warm	O
to	O
room	O
temperature	O
and	O
stirred	O
for	O
2	O
h.	O
The	O
solution	O
was	O
washed	O
with	O
anionic	B
resin	I
(	O
OH−	O
)	O
and	O
cationic	B
resin	I
(	O
H+	O
)	O
successively	O
until	O
the	O
solution	O
reached	O
neutrality	O
.	O

The	O
solution	O
was	O
concentrated	O
and	O
purified	O
on	O
a	O
Bio	O
-	O
Gel	O
P-2	O
column	O
and	O
lyophilized	O
to	O
give	O
11	B
(	O
49	O
mg	O
,	O
44	O
%	O
)	O
.	O

11	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
7.29	O
,	O
7.03	O
(	O
2d	O
,	O
each	O
2H	O
,	O
J	O
=	O
8.5	O
Hz	O
)	O
,	O
6.28–6.14	O
(	O
m	O
,	O
2H	O
)	O
,	O
5.70	O
(	O
d	O
,	O
J	O
=	O
10.0	O
Hz	O
,	O
1H	O
)	O
,	O
5.53	O
(	O
d	O
,	O
J	O
=	O
4.0	O
Hz	O
,	O
1H	O
)	O
,	O
5.06	O
(	O
d	O
,	O
J	O
=	O
4.0	O
Hz	O
,	O
1H	O
)	O
,	O
4.15–3.57	O
(	O
m	O
,	O
12H	O
)	O
13	O
C	O
δ	O
130.2	O
,	O
128.0	O
,	O
123.5	O
,	O
117.8	O
,	O
97.4	O
,	O
95.1	O
,	O
74.1	O
,	O
71.5	O
,	O
71	O
,	O
69.3	O
,	O
69.2	O
,	O
68.2	O
,	O
66.5	O
,	O
65.4	O
,	O
61.2	O
,	O
61.2	O
.	O

HRFABMS	O
calcd	O
for	O
C21	O
H29	O
NO12	O
Na+	O
510.1587	O
,	O
found	O
510.1601	O
.	O

Poly	B
{	I
acrylamide	I
-	I
co	I
-2-	I
[	I
2-	I
(	I
2-N	I
-acrylamidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
α	I
-	I
d	I
-mannopyranoside	I
-	I
co	I
-N	I
-acrylamidophenyl	I
3-O	I
-α	I
-	I
d	I
-galactopyranosyl	I
-	I
α	I
-	I
d	I
-galactopyranoside	I
}	I
(	O
12	B
)	O
Compound	B
8	I
(	O
70	O
mg	O
)	O
,	O
compound	B
11	I
(	O
48	O
mg	O
)	O
and	O
acrylamide	B
(	O
80	O
mg	O
)	O
were	O
dissolved	O
in	O
deoxygenated	O
dd	O
water	B
(	O
2	O
mL	O
)	O
.	O

Ammonium	B
persulfate	I
(	O
40	O
μL	O
of	O
a	O
stock	O
solution	O
,	O
50	O
mg	O
/	O
mL	O
)	O
and	O
TMEDA	B
(	O
5	O
μL	O
)	O
were	O
then	O
added	O
.	O

The	O
reaction	O
mixture	O
was	O
stirred	O
under	O
argon	B
at	O
55	O
°	O
C	O
overnight	O
.	O

The	O
cooled	O
reaction	O
mixture	O
was	O
dialyzed	O
(	O
8000	O
MW	O
cutoff	O
)	O
exhaustively	O
against	O
deionized	O
water	B
.	O

The	O
aqueous	O
solution	O
of	O
the	O
polymer	B
was	O
lyophilized	O
to	O
afford	O
white	O
fluffy	O
powder	O
12	B
(	O
150	O
mg	O
,	O
76	O
%	O
)	O
.	O

12	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
7.24	O
(	O
s	O
,	O
2H	O
)	O
,	O
7.03	O
(	O
d	O
,	O
J	O
=	O
7.0	O
Hz	O
,	O
aromatic	O
proton	O
)	O
,	O
5.55	O
(	O
s	O
,	O
anomeric	O
proton	O
)	O
,	O
5.06	O
(	O
s	O
,	O
anomeric	O
proton	O
)	O
,	O
4.73	O
(	O
s	O
,	O
anomeric	O
proton	O
)	O
,	O
3.26–4.15	O
(	O
m	O
)	O
,	O
2.17	O
and	O
2.02	O
(	O
2bs	O
)	O
,	O
1.60	O
and	O
1.48	O
(	O
2bs	O
)	O
.	O

The	O
average	O
incorporation	O
molar	O
ratio	O
is	O
1	O
/	O
28	O
/	O
5	O
(	O
Gal	B
α1→3	I
Gal	I
/	O
acrylamide	B
/	O
mannose	B
)	O
.	O

Poly	B
{	I
acrylamide	I
-	I
co	I
-2-	I
[	I
2-	I
(	I
2-N	I
-acrylamidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
α	I
-	I
d	I
-mannopyranoside	I
-	I
co	I
-2-	I
[	I
2-	I
(	I
2-N	I
-acrylamidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
β	I
-	I
lactoside	I
}	I
(	O
14A	B
)	O
Compound	B
8	I
(	O
330	O
mg	O
)	O
,	O
compound	B
5	I
(	O
176	O
mg	O
)	O
and	O
acrylamide	B
(	O
214	O
mg	O
)	O
were	O
dissolved	O
in	O
deoxygenated	O
dd	O
water	B
(	O
6	O
mL	O
)	O
.	O

Ammonium	B
persulfate	I
(	O
100	O
μL	O
of	O
a	O
stock	O
solution	O
,	O
50	O
mg	O
/	O
mL	O
)	O
and	O
TMEDA	B
(	O
10	O
μL	O
)	O
were	O
then	O
added	O
.	O

The	O
reaction	O
mixture	O
was	O
stirred	O
under	O
argon	B
at	O
75	O
°	O
C	O
for	O
4	O
h.	O
The	O
cooled	O
reaction	O
mixture	O
was	O
dialyzed	O
(	O
8000	O
MW	O
cutoff	O
)	O
exhaustively	O
against	O
deionized	O
water	B
.	O

The	O
aqueous	O
solution	O
of	O
the	O
polymer	B
was	O
lyophilized	O
to	O
afford	O
white	O
fluffy	O
powder	O
14A	B
(	O
600	O
mg	O
)	O
.	O

14A	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
4.72	O
(	O
s	O
,	O
mannose	B
anomeric	O
proton	O
)	O
,	O
4.35	O
(	O
d	O
,	O
J	O
=	O
7.5	O
Hz	O
,	O
anomeric	O
proton	O
)	O
,	O
4.28	O
(	O
d	O
,	O
J	O
=	O
7.8	O
Hz	O
,	O
anomeric	O
proton	O
)	O
,	O
3.26–4.79	O
(	O
m	O
)	O
,	O
2.17	O
and	O
2.01	O
(	O
2bs	O
)	O
,	O
1.58	O
and	O
1.47	O
(	O
2bs	O
)	O
.	O

The	O
average	O
incorporation	O
molar	O
ratio	O
is	O
1:12:2	O
(	O
lactose	B
:	O
acrylamide	B
:	O
mannose	B
)	O
.	O

Poly	B
{	I
acrylamide	I
-	I
co	I
-N	I
-acryloyl	I
-	I
aminophenyl	I
α	I
-	I
d	I
-mannopyranoside	I
-	I
co	I
-2	I
-	I
[	I
2	I
-	I
(	I
2	I
-N	I
-	I
acrylamidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
β	I
-	I
lactoside	I
}	I
(	O
14B	B
)	O
Compound	B
13	I
obtained	O
as	O
described	O
previously	O
19	O
(	O
100	O
mg	O
)	O
,	O
compound	B
5	I
(	O
162	O
mg	O
)	O
and	O
acrylamide	B
(	O
131	O
mg	O
)	O
were	O
dissolved	O
in	O
deoxygenated	O
dd	O
water	B
(	O
4	O
mL	O
)	O
.	O

Ammonium	B
persulfate	I
(	O
40	O
μL	O
of	O
a	O
stock	O
solution	O
,	O
50	O
mg	O
/	O
mL	O
)	O
and	O
TMEDA	B
(	O
5	O
μL	O
)	O
were	O
then	O
added	O
.	O

The	O
reaction	O
mixture	O
was	O
stirred	O
under	O
argon	B
at	O
90	O
°	O
C	O
for	O
34	O
min	O
.	O

The	O
cooled	O
reaction	O
mixture	O
was	O
dialyzed	O
(	O
8000	O
MW	O
cutoff	O
)	O
exhaustively	O
against	O
deionized	O
water	B
.	O

The	O
aqueous	O
solution	O
of	O
the	O
polymer	B
was	O
lyophilized	O
to	O
afford	O
the	O
white	O
fluffy	O
powder	O
14B	B
(	O
320	O
mg	O
)	O
.	O

14B	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
(	O
m	O
,	O
aromatic	O
protons	O
)	O
,	O
5.42	O
(	O
bs	O
,	O
anomeric	O
proton	O
)	O
,	O
4.35	O
(	O
d	O
,	O
J	O
=	O
7.5	O
Hz	O
,	O
anomeric	O
proton	O
)	O
,	O
4.28	O
(	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
anomeric	O
proton	O
)	O
,	O
4.00–3.20	O
(	O
m	O
)	O
,	O
2.18	O
and	O
2.03	O
(	O
2bs	O
)	O
,	O
1.60	O
and	O
1.48	O
(	O
2bs	O
)	O
.	O

The	O
average	O
incorporation	O
molar	O
ratio	O
is	O
1:5.8:1	O
(	O
lactose	B
:	O
acrylamide	B
:	O
mannose	B
)	O
.	O

Polymer	B
(	O
15A	B
)	O
Acceptor	O
glycopolymer	B
14A	I
(	O
100	O
mg	O
,	O
47	O
μmol	O
of	O
lactose	B
)	O
,	O
UDP	B
-	I
Gal	I
(	O
40	O
mg	O
)	O
and	O
rα1	O
-	O
3GalT	O
(	O
10	O
unit	O
)	O
were	O
incubated	O
in	O
a	O
solution	O
of	O
Tris	B
–	I
HCl	I
buffer	O
(	O
50	O
mM	O
,	O
pH	O
7	O
)	O
containing	O
Mn2	B
+	I
(	O
10	O
mM	O
)	O
for	O
48	O
h	O
at	O
ambient	O
temperature	O
.	O

The	O
mixture	O
was	O
directly	O
applied	O
to	O
Bio	O
-	O
Gel	O
P-2	O
with	O
water	B
as	O
the	O
eluent	O
.	O

The	O
fractions	O
containing	O
the	O
glycopolymer	B
were	O
collected	O
and	O
lyophilized	O
to	O
afford	O
the	O
white	O
powder	O
15A	B
in	O
quantitative	O
yield	O
.	O

15A	O
:	O
Selected	O
13	O
C	O
NMR	O
(	O
D2	B
O	I
)	O
103.5	O
,	O
102.7	O
,	O
99.1	O
(	O
mannose	B
anomeric	O
carbon	B
)	O
96.0	O
(	O
α	B
-	I
galactose	I
anomeric	O
carbon	B
)	O
,	O
79.2	O
(	O
C-4	O
of	O
glucose	B
)	O
,	O
77.8	O
(	O
C-3	O
of	O
β	B
-	I
galactose	I
)	O
.	O

Polymer	B
(	O
15B	B
)	O
Acceptor	O
glycopolymer	B
14B	I
(	O
120	O
mg	O
,	O
93	O
μmol	O
of	O
lactose	B
)	O
,	O
UDP	B
-	I
Gal	I
(	O
80	O
mg	O
)	O
and	O
rα1	O
-	O
3GalT	O
(	O
15	O
unit	O
)	O
were	O
incubated	O
in	O
a	O
solution	O
of	O
Tris	B
–	I
HCl	I
buffer	O
(	O
50	O
mM	O
,	O
pH	O
7	O
)	O
containing	O
Mn2	B
+	I
(	O
10	O
mM	O
)	O
for	O
48	O
h	O
at	O
ambient	O
temperature	O
.	O

The	O
mixture	O
was	O
directly	O
applied	O
to	O
Bio	O
-	O
Gel	O
P-2	O
with	O
water	B
as	O
the	O
eluent	O
.	O

The	O
fractions	O
containing	O
the	O
glycopolymer	B
were	O
collected	O
and	O
lyophilized	O
to	O
afford	O
the	O
white	O
powder	O
15B	B
in	O
quantitative	O
yield	O
.	O

15B	O
:	O
Selected	O
13	O
C	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
103.4	O
,	O
102.7	O
,	O
100.4	O
(	O
mannose	B
anomeric	O
carbon	B
)	O
95.9	O
(	O
α	B
-	I
galactose	I
anomeric	O
carbon	B
)	O
,	O
79.1	O
(	O
C-4	O
of	O
glucose	B
)	O
,	O
77.7	O
(	O
C-3	O
of	O
β	B
-	I
galactose	I
)	O
.	O

Poly	B
{	I
acrylamide	I
-	I
co	I
-2-	I
[	I
2-	I
(	I
2-N	I
-acrylamidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
α	I
-	I
d	I
-mannopyranoside	I
}	I
(	O
15C	B
)	O
Copolymer	B
15C	I
was	O
synthesized	O
using	O
compound	B
8	I
following	O
the	O
procedure	O
described	O
for	O
terpolymer	B
14A	I
.	O

The	O
average	O
incorporation	O
molar	O
ratio	O
is	O
3:1	O
(	O
acrylamide	B
:	O
mannose	B
)	O
.	O

Poly	B
{	I
acrylamide	I
-	I
co	I
-N	I
-acryloyl	I
-	I
aminophenyl	I
α	I
-	I
d	I
-mannopyranoside	I
}	I
(	O
15D	B
)	O
Copolymer	B
15D	I
was	O
synthesized	O
using	O
compound	B
13	I
following	O
the	O
procedure	O
described	O
before.8	O
The	O
average	O
incorporation	O
molar	O
ratio	O
is	O
6:1	O
(	O
acrylamide	B
:	O
mannose	B
)	O
.	O

Poly	B
{	I
acrylamide	I
-	I
co	I
-2-	I
[	I
2-	I
(	I
2-N	I
-acrylamidoethoxy	I
)	I
ethoxy	I
]	I
ethoxyl	I
-	I
β	I
-	I
lactoside	I
}	I
(	O
15E	B
)	O
Copolymer	B
15E	I
was	O
synthesized	O
using	O
compound	B
5	I
following	O
the	O
procedure	O
described	O
for	O
terpolymer	B
14A	I
.	O

The	O
average	O
incorporation	O
molar	O
ratio	O
is	O
1:12	O
(	O
lactose	B
:	O
acrylamide	B
)	O
.	O

Polymer	B
(	O
15F	B
)	O
Copolymer	B
15F	I
was	O
synthesized	O
following	O
the	O
procedure	O
described	O
for	O
polymer	B
15A	I
.	O

The	O
enzymatic	O
reaction	O
afforded	O
white	O
powder	O
15F	B
in	O
quantitative	O
yield	O
.	O

Compound	B
16	I
2,3,4,6-Hepta	B
-	I
O	I
-acetyl	I
-	I
α	I
-	I
lactosyl	I
bromide	I
(	O
5	O
g	O
,	O
7.1	O
mmol	O
)	O
and	O
methyl	B
6-hydroxyhexanoate	I
(	O
1.3	O
g	O
,	O
8.9	O
mmol	O
)	O
were	O
added	O
to	O
a	O
previously	O
flame	O
-	O
dried	O
flask	O
containing	O
7	O
g	O
MS	O
4	O
Å	O
and	O
30	O
mL	O
anhydrous	O
CHCl3	B
.	O

The	O
resulting	O
suspension	O
was	O
stirred	O
for	O
half	O
an	O
hour	O
.	O

HgO	B
(	O
1.5	O
g	O
)	O
and	O
HgBr2	B
(	O
257	O
mg	O
)	O
were	O
added	O
to	O
the	O
suspension	O
.	O

The	O
mixture	O
was	O
stirred	O
in	O
the	O
dark	O
at	O
ambient	O
temperature	O
for	O
48	O
h.	O
The	O
resulting	O
mixture	O
was	O
passed	O
through	O
a	O
Celite	B
packed	O
glass	B
funnel	O
,	O
and	O
washed	O
with	O
saturated	O
NaHCO3	B
and	O
water	B
.	O

The	O
organic	O
phase	O
was	O
dried	O
over	O
anhydrous	O
Na2	B
SO4	I
and	O
concentrated	O
in	O
vacuo	O
.	O

The	O
resulting	O
residue	O
was	O
chromatographed	O
(	O
hexane	B
:	O
EtOAc	B
,	O
1:1	O
)	O
to	O
afford	O
product	O
16	B
(	O
4.0	O
g	O
,	O
74	O
%	O
)	O
.	O

16	O
:	O
1	O
H	O
NMR	O
(	O
CDCl3	B
)	O
δ	O
5.32	O
(	O
d	O
,	O
J	O
=	O
2.5	O
Hz	O
,	O
1H	O
)	O
,	O
5.17	O
(	O
t	O
,	O
J	O
=	O
9.0	O
Hz	O
,	O
1H	O
)	O
,	O
5.08	O
(	O
dd	O
,	O
J	O
=	O
8.0	O
,	O
10.5	O
,	O
1H	O
)	O
,	O
4.93	O
(	O
dd	O
,	O
J	O
=	O
3.5	O
,	O
10.5	O
,	O
1H	O
)	O
,	O
4.85	O
(	O
dd	O
,	O
J	O
=	O
8.0	O
,	O
10.5	O
,	O
1H	O
)	O
,	O
4.47–4.44	O
(	O
m	O
,	O
2H	O
)	O
,	O
4.42	O
(	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
1H	O
)	O
,	O
4.11–4.04	O
(	O
m	O
,	O
3H	O
)	O
,	O
3.87–3.80	O
(	O
m	O
,	O
2H	O
)	O
,	O
3.77	O
(	O
t	O
,	O
J	O
=	O
9.5	O
Hz	O
,	O
1H	O
)	O
,	O
3.64	O
(	O
s	O
,	O
3H	O
)	O
,	O
3.59–3.55	O
(	O
m	O
,	O
1H	O
)	O
,	O
3.46–3.41	O
(	O
m	O
,	O
1H	O
)	O
,	O
2.27	O
(	O
t	O
,	O
J	O
=	O
7.5	O
Hz	O
,	O
2H	O
)	O
,	O
2.13	O
,	O
2.10	O
,	O
2.04	O
,	O
2.021	O
,	O
2.020	O
,	O
2.01	O
,	O
1.94	O
(	O
7s	O
,	O
7	O
acetyl	O
groups	O
)	O
,	O
1.64–1.50	O
(	O
m	O
,	O
4H	O
)	O
,	O
1.38–1.28	O
(	O
m	O
,	O
2H	O
)	O
.	O

13	O
C	O
δ174.7	O
,	O
171.1	O
,	O
171.0	O
,	O
170.8	O
,	O
170.7	O
,	O
170.5	O
,	O
170.3	O
,	O
169.8	O
,	O
101.7	O
,	O
101.2	O
,	O
77.0	O
,	O
73.5	O
,	O
73.3	O
,	O
72.4	O
,	O
71.7	O
,	O
71.3	O
,	O
70.5	O
,	O
69.8	O
,	O
67.3	O
,	O
62.7	O
,	O
61.5	O
,	O
34.6	O
,	O
29.7	O
,	O
26.0	O
,	O
25.2	O
,	O
21.54	O
,	O
21.49	O
,	O
21.4	O
(	O
b	O
)	O
,	O
21.3	O
(	O
b	O
)	O
,	O
21.2	O
(	O
b	O
)	O
.	O

HRFABMS	O
calcd	O
for	O
C33	O
H48	O
O20	O
Na+	O
787.2637	O
,	O
found	O
787.2618	O
.	O

Compound	O
17	O
To	O
a	O
solution	O
of	O
16	O
(	O
3	O
g	O
)	O
in	O
anhydrous	O
methanol	O
(	O
200	O
mL	O
)	O
at	O
0	O
°	O
C	O
was	O
added	O
NaOMe	O
until	O
pH	O
10	O
.	O

The	O
solution	O
was	O
stirred	O
for	O
3	O
h.	O
Dowex	B
cation	I
exchange	I
resin	I
(	O
H	O
form	O
)	O
was	O
added	O
to	O
adjust	O
the	O
pH	O
to	O
6–7	O
and	O
filtered	O
.	O

The	O
filtrate	O
was	O
evaporated	O
to	O
give	O
a	O
residue	O
which	O
was	O
dissolved	O
in	O
MeOH	B
:	O
H2	B
O	I
(	O
1:1	O
)	O
.	O

To	O
the	O
above	O
solution	O
was	O
added	O
LiOH	B
until	O
pH	O
11	O
.	O

The	O
solution	O
was	O
stirred	O
for	O
1	O
h.	O
Dowex	B
cation	I
exchange	I
resin	I
(	O
H	O
form	O
)	O
was	O
used	O
to	O
neutralize	O
the	O
above	O
solution	O
which	O
was	O
concentrated	O
to	O
afford	O
a	O
syrup	O
17	B
in	O
quantitative	O
yield	O
.	O

17	O
:	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
4.45	O
(	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
1H	O
)	O
,	O
4.41	O
(	O
d	O
,	O
J	O
=	O
7.6	O
Hz	O
,	O
1H	O
)	O
,	O
3.96–3.49	O
(	O
m	O
,	O
13	O
H	O
)	O
,	O
3.26	O
(	O
t	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
1H	O
)	O
,	O
2.22	O
(	O
t	O
,	O
J	O
=	O
7.2	O
Hz	O
,	O
2H	O
)	O
,	O
1.64–1.53	O
(	O
m	O
,	O
4H	O
)	O
,	O
1.38–1.32	O
(	O
m	O
,	O
2H	O
)	O
13	O
C	O
δ183.3	O
,	O
103.5	O
,	O
102.6	O
,	O
79.0	O
,	O
76.0	O
,	O
75.4	O
,	O
75.1	O
,	O
73.5	O
,	O
73.1	O
,	O
71.6	O
,	O
71.1	O
,	O
69.2	O
,	O
61.6	O
,	O
60.7	O
,	O
37.1	O
,	O
29.1	O
,	O
25.8	O
,	O
25.5	O
.	O

HRFABMS	O
calcd	O
for	O
C18	O
H32	O
O13	O
Na+	O
479.1741	O
,	O
found	O
479.1762	O
.	O

Compound	B
18	I
To	O
a	O
solution	O
of	O
17	B
(	O
612	O
mg	O
)	O
and	O
p	B
-aminophenyl	I
-	I
α	I
-	I
d	I
-mannopyranoside	I
(	O
400	O
mg	O
)	O
in	O
DMF	B
(	O
10	O
mL	O
)	O
at	O
0	O
°	O
C	O
was	O
added	O
DPPA	B
(	O
328	O
μL	O
)	O
and	O
TEA	B
(	O
400	O
μL	O
)	O
.	O

The	O
solution	O
was	O
stirred	O
vigorously	O
overnight	O
.	O

The	O
solution	O
was	O
concentrated	O
in	O
vacuo	O
,	O
followed	O
by	O
gel	O
filtration	O
through	O
Bio	O
-	O
Gel	O
P-2	O
column	O
eluted	O
by	O
water	B
.	O

The	O
fractions	O
containing	O
the	O
glycoconjugate	B
were	O
collected	O
and	O
lyophilized	O
to	O
afford	O
18	B
628	O
mg	O
(	O
66	O
%	O
yield	O
)	O
.	O

Selected	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ5.39	O
(	O
s	O
,	O
1H	O
,	O
anomeric	O
proton	O
of	O
mannose	B
)	O
,	O
4.26	O
(	O
d	O
,	O
J	O
=	O
7.5	O
Hz	O
,	O
2H	O
,	O
two	O
anomeric	O
protons	O
of	O
lactose	B
)	O
.	O

18	O
:	O
Selected	O
13	O
C	O
(	O
103.4	O
(	O
C-1	O
of	O
glucose	B
)	O
,	O
102.5	O
(	O
C-1	O
of	O
galactose	B
)	O
,	O
99.0	O
(	O
C-1	O
of	O
mannose	B
)	O
.	O

HRFABMS	O
calcd	O
for	O
C30	O
H47	O
NO18	O
Na+	O
732.2691	O
,	O
found	O
732.2665	O
.	O

Compound	B
19	I
Acceptor	O
glycoconjugate	B
18	I
(	O
250	O
mg	O
)	O
,	O
UDP	B
-	I
Gal	I
(	O
256	O
mg	O
)	O
,	O
0.1	O
%	O
BSA	B
and	O
rα1	O
-	O
3GalT	O
(	O
15	O
unit	O
)	O
were	O
incubated	O
in	O
a	O
solution	O
of	O
Tris	B
–	I
HCl	I
buffer	O
(	O
50	O
mM	O
,	O
pH	O
7	O
)	O
containing	O
Mn2	B
+	I
(	O
10	O
mM	O
)	O
for	O
48	O
h	O
at	O
ambient	O
temperature	O
.	O

The	O
mixture	O
was	O
directly	O
applied	O
to	O
Bio	O
-	O
Gel	O
P-2	O
with	O
water	B
as	O
the	O
eluent	O
.	O

The	O
fractions	O
containing	O
the	O
product	O
were	O
collected	O
and	O
lyophilized	O
to	O
afford	O
the	O
white	O
powder	O
19	B
187	O
mg	O
(	O
61	O
%	O
yield	O
)	O
.	O

19	O
:	O
Selected	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
)	O
δ	O
5.52	O
(	O
s	O
,	O
1H	O
,	O
anomeric	O
proton	O
of	O
mannose	B
)	O
,	O
5.09	O
,	O
(	O
d	O
,	O
J	O
=	O
3.2	O
Hz	O
,	O
1H	O
,	O
anomeric	O
proton	O
of	O
α	B
-	I
galactose	I
)	O
,	O
4.45	O
(	O
d	O
,	O
J	O
=	O
7.6	O
Hz	O
,	O
1H	O
,	O
anomeric	O
proton	O
)	O
,	O
4.40	O
(	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
1H	O
,	O
anomeric	O
proton	O
)	O
.	O

Selected	O
13	O
C	O
δ	O
103.9	O
(	O
C-1	O
of	O
glucose	B
)	O
,	O
103.1	O
(	O
C-1	O
of	O
β	B
-	I
galactose	I
)	O
,	O
99.5	O
(	O
C-1	O
of	O
mannose	B
)	O
,	O
96.5	O
(	O
C-1	O
of	O
α	B
-	I
galactose	I
)	O
.	O

HRFABMS	O
calcd	O
for	O
C36	O
H57	O
NO23	O
Na+	O
894.3219	O
,	O
found	O
894.3223	O
.	O

Agglutination	O
assay	O
E.	O
coli	O
K12	O
HB101	O
was	O
grown	O
overnight	O
at	O
37	O
°	O
C	O
in	O
static	O
LB	O
media	O
,	O
washed	O
,	O
and	O
suspended	O
with	O
PBS	B
to	O
a	O
final	O
concentration	O
of	O
1	O
×	O
108	O
cells	O
/	O
mL.	O
Yeast	O
(	O
S.	O
cerevisiae	O
,	O
wild	O
type	O
)	O
was	O
incubated	O
on	O
YPD	O
media	O
at	O
25	O
°	O
C	O
for	O
48	O
h	O
,	O
washed	O
,	O
and	O
suspended	O
with	O
PBS	B
to	O
a	O
final	O
dilution	O
of	O
4	O
×	O
107	O
cells	O
/	O
mL.	O
Agglutination	O
assays	O
were	O
carried	O
out	O
on	O
a	O
9-well	O
spot	O
plate	O
.	O

Aliquots	O
of	O
90	O
μL	O
of	O
a	O
solution	O
of	O
the	O
test	O
compound	O
were	O
first	O
agitated	O
with	O
30	O
μL	O
bacterial	O
suspension	O
for	O
30	O
s.	O
After	O
that	O
,	O
30	O
μL	O
yeast	O
suspension	O
was	O
added	O
,	O
and	O
allowed	O
to	O
develop	O
with	O
agitation	O
for	O
at	O
least	O
3	O
min	O
.	O

Agglutination	O
was	O
observed	O
under	O
a	O
magnifying	O
glass	B
.	O

Purification	O
of	O
anti	O
-	O
Gal	O
IgG	O
from	O
human	O
serum	O
Polyclonal	O
anti	O
-	O
Gal	O
antibodies	O
were	O
isolated	O
from	O
the	O
human	O
serum	O
according	O
to	O
a	O
modified	O
protocol	O
as	O
reported	O
previously.32	O
Male	O
AB	O
type	O
serum	O
was	O
heat	O
-	O
inactivated	O
in	O
a	O
water	B
bath	O
at	O
56	O
°	O
C	O
for	O
30	O
min	O
.	O

The	O
α	B
-	I
Gal	I
Sepharose	B
affinity	O
column	O
was	O
washed	O
with	O
75	O
mL	O
PBS	B
buffer	O
.	O

The	O
heat	O
-	O
inactivated	O
serum	O
(	O
25	O
mL	O
)	O
was	O
run	O
over	O
the	O
column	O
three	O
times	O
,	O
and	O
the	O
flow	O
-	O
through	O
collected	O
.	O

The	O
column	O
was	O
washed	O
with	O
6	O
mL	O
PBS	B
14	O
times	O
until	O
an	O
OD280	O
nm	O
reading	O
less	O
than	O
0.01	O
of	O
the	O
flow	O
-	O
through	O
was	O
reached	O
.	O

The	O
anti	O
-	O
Gal	O
antibodies	O
was	O
eluted	O
from	O
the	O
column	O
with	O
5	O
mL	O
of	O
100	O
mM	O
glycine·HCl	B
buffer	O
(	O
pH	O
2.8	O
)	O
10	O
times	O
until	O
sufficiently	O
low	O
OD280	O
nm	O
readings	O
were	O
obtained	O
.	O

The	O
fractions	O
were	O
collected	O
,	O
neutralized	O
immediately	O
with	O
0.5	O
M	O
sodium	B
bicarbonate	I
,	O
and	O
determined	O
by	O
ELISA	O
assays	O
.	O

ELISA	O
inhibition	O
assay	O
Mouse	O
laminin	O
(	O
10	O
μg	O
/	O
mL	O
in	O
carbonate	B
buffer	O
)	O
as	O
solid	O
-	O
phase	O
antigen	B
was	O
added	O
to	O
a	O
96-well	O
ELISA	O
(	O
Immulon	O
4	O
)	O
microtiter	O
plate	O
,	O
and	O
incubated	O
overnight	O
at	O
4	O
°	O
C	O
.	O

Test	O
compound	O
(	O
0.1	O
or	O
1	O
mM	O
)	O
was	O
incubated	O
with	O
55	O
μL	O
of	O
a	O
PBS	B
solution	O
of	O
human	O
polyclonal	O
anti	O
-	O
Gal	O
IgG	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
with	O
slow	O
agitation	O
.	O

The	O
human	O
anti	O
-	O
Gal	O
IgG	O
concentration	O
used	O
was	O
adjusted	O
to	O
cause	O
50	O
%	O
of	O
maximal	O
binding	O
to	O
solid	O
-	O
phase	O
antigen	B
.	O

ELISA	O
plate	O
was	O
blocked	O
with	O
1	O
%	O
BSA	B
in	O
PBS	B
,	O
and	O
incubated	O
45	O
min	O
at	O
room	O
temperature	O
.	O

To	O
appropriate	O
wells	O
on	O
ELISA	O
plate	O
was	O
added	O
50	O
μL	O
of	O
the	O
test	O
compound	O
/	O
Ab	O
solution	O
.	O

The	O
solution	O
in	O
each	O
well	O
was	O
incubated	O
for	O
1.5	O
h	O
at	O
room	O
temperature	O
.	O

The	O
wells	O
were	O
subsequently	O
washed	O
with	O
PBS	B
/	O
0.05	O
%	O
Tween	B
and	O
incubated	O
with	O
goat	O
anti	O
-	O
human	O
IgG	O
-	O
peroxidase	O
conjugate	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

After	O
additional	O
washing	O
with	O
PBS	B
/	O
0.05%Tween	O
,	O
the	O
peroxidase	O
reaction	O
was	O
performed	O
with	O
100	O
μL	O
of	O
a	O
3,3′,5,5′-tetramethylbenzidine	B
(	B
TMB	I
)	I
/	I
H2	I
O2	I
(	O
9	O
1	O
)	O
solution	O
,	O
and	O
the	O
UV	O
absorbance	O
was	O
measured	O
at	O
655	O
nm	O
.	O

Acknowledgements	O

We	O
thank	O
Neose	O
Inc.	O
for	O
providing	O
uridine	B
5′	I
diphosphate	I
galactose	I
(	O
UDP	B
-	I
Gal	I
)	O
.	O

This	O
work	O
was	O
generously	O
supported	O
by	O
Hercules	O
Inc	O
,	O
NSF	O
(	O
BES-9728366	O
)	O
and	O
Herman	O
Frasch	O
Foundation	O
(	O
449-HF97	O
)	O
.	O

We	O
also	O
thank	O
Prof.	O
Esin	O
Gulari	O
of	O
Chemical	O
Engineering	O
Department	O
for	O
providing	O
us	O
with	O
light	O
scattering	O
measurement	O
.	O

n-	B
Hexane	I
is	O
metabolized	O
by	O
microsomal	O
enzymes	O
giving	O
rise	O
to	O
several	O
oxidation	O
intermediates	O
(	O
Phase	O
I	O
metabolites	B
)	O
,	O
including	O
1-hexanol	B
,	O
2-hexanol	B
,	O
3-hexanol	B
,	O
2-hexanone	B
,	O
5-hydroxy-2-hexanone	B
,	O
2,5-hexanediol	B
,	O
4,5-dihydroxy-2-hexanone	B
and	O
2,5-hexanedione	B
(	O
'	O
free	O
'	O
2,5-HD	B
)	O
,	O
the	O
last	O
one	O
being	O
regarded	O
as	O
the	O
ultimate	O
neurotoxic	O
agent	O
(	O
Perbellini	O
et	O
al.	O
,	O
1981	O
;	O
Mutti	O
et	O
al.	O
,	O
1984	O
;	O
IPCS	O
,	O
1991	O
)	O
.	O

Most	O
of	O
n-	B
hexane	I
metabolites	B
—	O
but	O
not	O
2,5-HD	B
and	O
2-hexanone	B
—	O
undergo	O
Phase	O
II	O
biotransformation	O
and	O
are	O
excreted	O
as	O
glucuronide	B
conjugates	I
(	O
-G	B
)	O
.	O

Their	O
determination	O
by	O
conventional	O
techniques	O
requires	O
preliminary	O
hydrolysis	O
(	O
Fedtke	O
and	O
Bolt	O
,	O
1987a	O
,	O
b	O
;	O
Kawai	O
et	O
al.	O
,	O
1990	O
;	O
Perbellini	O
et	O
al.	O
,	O
1990	O
;	O
Soriano	O
et	O
al.	O
,	O
1996	O
)	O
,	O
yielding	O
to	O
the	O
'	O
total	O
2,5-HD	B
'	I
but	O
also	O
a	O
number	O
of	O
analytical	O
artifacts	O
,	O
i.e.	O
γ	B
-	I
valerolactone	I
and	O
furan	B
derivatives	B
.	O

A	O
new	O
method	O
for	O
the	O
direct	O
determination	O
of	O
both	O
Phases	O
I	O
and	O
II	O
metabolites	B
of	I
n-	I
hexane	I
has	O
been	O
recently	O
developed	O
with	O
the	O
use	O
of	O
the	O
hyphenated	O
technique	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
;	O
Andreoli	O
et	O
al.	O
,	O
1998	O
;	O
Manini	O
et	O
al.	O
,	O
1998	O
)	O
.	O

The	O
role	O
of	O
this	O
new	O
technique	O
in	O
the	O
field	O
of	O
metabolism	O
studies	O
is	O
becoming	O
more	O
important	O
,	O
documented	O
by	O
the	O
increasing	O
number	O
of	O
studies	O
published	O
every	O
year	O
all	O
over	O
the	O
world	O
(	O
Niessen	O
,	O
1998	O
)	O
.	O

The	O
advantages	O
of	O
using	O
a	O
mass	O
spectrometer	O
,	O
a	O
system	O
sensitive	O
,	O
specific	O
and	O
selective	O
,	O
capable	O
of	O
analyte	O
identification	O
and	O
confirmation	O
,	O
as	O
a	O
detector	O
have	O
been	O
already	O
demonstrated	O
in	O
the	O
case	O
of	O
the	O
on	O
-	O
line	O
coupling	O
of	O
gas	O
chromatography	O
with	O
mass	O
spectrometry	O
.	O

The	O
application	O
field	O
of	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
is	O
still	O
limited	O
to	O
volatile	O
and	O
non	O
-	O
thermally	O
labile	O
substances	O
,	O
with	O
relatively	O
low	O
molecular	O
weight	O
,	O
approximately	O
10	O
%	O
of	O
all	O
the	O
organic	B
compounds	I
.	O

On	O
the	O
contrary	O
,	O
liquid	O
chromatography	O
is	O
suitable	O
for	O
the	O
analysis	O
of	O
polar	B
compounds	I
without	O
the	O
need	O
of	O
prior	O
derivatization	O
and	O
is	O
compatible	O
with	O
aqueous	O
matrices	O
,	O
such	O
as	O
urine	O
,	O
without	O
the	O
need	O
of	O
sample	O
pretreatment	O
.	O

These	O
peculiarities	O
make	O
chromatographic	O
techniques	O
coupled	O
with	O
mass	O
spectrometry	O
suitable	O
for	O
a	O
wide	O
range	O
of	O
applications	O
and	O
open	O
new	O
perspectives	O
in	O
the	O
study	O
of	O
the	O
metabolic	O
fate	O
of	O
drugs	B
,	O
pesticides	B
,	O
natural	B
substances	I
and	O
environmental	B
pollutants	I
.	O

LC	O
-	O
MS	O
allows	O
the	O
analysis	O
of	O
n-	B
hexane	I
metabolites	B
in	O
untreated	O
urine	O
samples	O
without	O
the	O
risk	O
of	O
artifact	O
generation	O
.	O

Objectives	O
of	O
this	O
study	O
were	O
:	O
(	O
i	O
)	O
to	O
assess	O
the	O
analytical	O
validity	O
of	O
conventional	O
techniques	O
and	O
related	O
assumptions	O
;	O
(	O
ii	O
)	O
to	O
evaluate	O
the	O
metabolic	O
pattern	O
of	O
conjugates	B
and	O
unconjugates	O
n-	B
hexane	I
metabolites	B
by	O
hyphenated	O
techniques	O
,	O
i.e.	O
LC	O
-	O
MS	O
and	O
GC	O
-	O
MS	O
;	O
and	O
(	O
iii	O
)	O
to	O
estimate	O
the	O
contribution	O
of	O
different	O
methods	O
of	O
sample	O
pretreatment	O
in	O
the	O
production	O
of	O
2,5-HD	B
and	O
analytical	O
artifacts	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Animals	O
and	O
chemicals	O
Sprague	O
Dawley	O
rats	O
(	O
200–250	O
g	O
)	O
were	O
obtained	O
from	O
Charles	O
River	O
Laboratories	O
(	O
Calco	O
,	O
Como	O
,	O
Italy	O
)	O
.	O

The	O
animals	O
were	O
housed	O
under	O
conditions	O
of	O
constant	O
temperature	O
and	O
humidity	O
,	O
and	O
automatic	O
photocyle	O
.	O

They	O
had	O
free	O
access	O
to	O
food	O
and	O
water	B
,	O
and	O
only	O
to	O
water	B
during	O
urine	O
collection	O
.	O

All	O
experiments	O
were	O
carried	O
out	O
in	O
compliance	O
with	O
the	O
European	O
Community	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
.	O

2-Hexanol	B
,	O
2-hexanone	B
,	O
2,5-hexanedione	B
,	O
γ	B
-	I
valerolactone	I
,	O
2,5-hexanediol	B
were	O
purchased	O
from	O
Merck	O
(	O
Darmstadt	O
,	O
Germany	O
)	O
;	O
3-hexanol	B
,	O
2,5-dimethylfuran	B
from	O
Fluka	O
(	O
Buchs	O
,	O
Switzerland	O
)	O
;	O
cyclohexanone	B
(	O
I.S.	B
)	O
from	O
Sigma	O
.	O

High	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
water	B
,	O
methanol	B
,	O
acetonitrile	B
and	O
dichloromethane	B
were	O
obtained	O
from	O
Lab	O
-	O
Scan	O
(	O
Dublin	O
,	O
Ireland	O
)	O
;	O
n-	B
hexane	I
,	I
sodium	B
chloride	I
,	O
hydrochloric	B
acid	I
and	O
sodium	B
hydroxide	I
from	O
Carlo	O
Erba	O
(	O
Milan	O
,	O
Italy	O
)	O
.	O

β	O
-	O
Glucuronidase	O
/	O
arylsulphatase	O
from	O
Helix	O
Pomatia	O
was	O
from	O
Boehringer	O
Mannheim	O
Italia	O
(	O
Monza	O
,	O
Italy	O
)	O
.	O

2.2	O
Animal	O
exposure	O
and	O
urine	O
collection	O
Rats	O
were	O
treated	O
with	O
1.4	O
mmol	O
of	O
pure	O
n-	B
hexane	I
by	O
subcutaneous	O
injection	O
of	O
the	O
solvent	B
once	O
a	O
day	O
on	O
3	O
consecutive	O
days	O
.	O

After	O
the	O
treatment	O
,	O
the	O
rats	O
were	O
placed	O
in	O
individual	O
metabolic	O
cages	O
provided	O
with	O
urine	O
-	O
feces	O
separators	O
and	O
15	O
h	O
urine	O
samples	O
(	O
17.8±3.8	O
ml	O
)	O
were	O
collected	O
over	O
NaN3	B
0.1	O
%	O
.	O

Urine	O
samples	O
were	O
stored	O
at	O
−20	O
°	O
C	O
until	O
analysis	O
.	O

2.3	O
Sample	O
preparation	O
Rat	O
urine	O
was	O
divided	O
into	O
four	O
aliquots	O
,	O
undergoing	O
different	O
preparation	O
prior	O
to	O
chromatographic	O
analysis	O
:	O
(	O
a	O
)	O
no	O
hydrolysis	O
;	O
(	O
b	O
)	O
enzymatic	O
hydrolysis	O
:	O
2	O
ml	O
of	O
urine	O
were	O
mixed	O
with	O
4	O
ml	O
of	O
0.5	O
M	O
acetate	B
buffer	O
,	O
pH	O
5.0	O
,	O
and	O
20	O
μl	O
of	O
β	O
-	O
glucuronidase	O
/	O
arylsulphatase	O
,	O
then	O
incubated	O
for	O
24	O
h	O
at	O
37	O
°	O
C	O
;	O
(	O
c	O
)	O
acid	B
hydrolysis	O
:	O
2	O
ml	O
of	O
urine	O
were	O
mixed	O
with	O
100	O
μl	O
of	O
HCl	B
37	O
%	O
,	O
pH<1.0	O
,	O
then	O
put	O
in	O
a	O
boiling	O
water	B
bath	O
for	O
30	O
min	O
;	O
and	O
(	O
d	O
)	O
enzymatic	O
hydrolysis	O
followed	O
by	O
acid	B
hydrolysis	O
.	O

Each	O
aliquot	O
was	O
ultrafiltered	O
before	O
LC	O
-	O
MS	O
analysis	O
.	O

Samples	O
for	O
GC	O
-	O
MS	O
analysis	O
were	O
extracted	O
with	O
a	O
solution	O
of	O
I.S.	B
in	O
dichloromethane	B
and	O
the	O
organic	O
phase	O
was	O
evaporated	O
to	O
small	O
volume	O
in	O
nitrogen	B
current	O
.	O

2.4	O
Sample	O
analyses	O
The	O
chromatographic	O
analyses	O
of	O
n-	B
hexane	I
metabolites	B
in	O
rat	O
urine	O
samples	O
were	O
carried	O
out	O
as	O
described	O
earlier	O
(	O
Andreoli	O
et	O
al.	O
,	O
1998	O
;	O
Manini	O
et	O
al.	O
,	O
1998	O
)	O
.	O

GC	O
-	O
MS	O
analysis	O
of	O
all	O
the	O
samples	O
,	O
prior	O
and	O
after	O
hydrolysis	O
was	O
performed	O
by	O
using	O
a	O
Hewlett	O
Packard	O
HP	O
6890	O
gas	O
chromatograph	O
coupled	O
with	O
a	O
HP	O
5973	O
Mass	O
Selective	O
Detector	O
(	O
MSD	O
)	O
.	O

Separations	O
were	O
obtained	O
on	O
a	O
HP-5MS	O
capillary	O
column	O
(	O
30	O
m	O
×	O
0.25	O
mm	O
,	O
0.25	O
μm	O
film	O
thickness	O
)	O
using	O
hydrogen	B
as	O
a	O
carrier	O
gas	O
.	O

Instrument	O
control	O
,	O
data	O
acquisition	O
and	O
processing	O
were	O
performed	O
with	O
a	O
Hewlett	O
Packard	O
ChemStation	O
(	O
Hewlett	O
Packard	O
,	O
Palo	O
Alto	O
,	O
CA	O
,	O
USA	O
)	O
.	O

LC	O
-	O
MS	O
analyses	O
were	O
carried	O
out	O
using	O
a	O
Perkin	O
Elmer	O
series	O
200	O
liquid	O
chromatograph	O
coupled	O
with	O
a	O
PE	O
-	O
Sciex	O
API	O
100	O
single	O
-	O
quadrupole	O
mass	O
spectrometer	O
(	O
Sciex	O
,	O
Thornhill	O
,	O
Canada	O
)	O
equipped	O
with	O
a	O
heated	O
nebulizer	O
(	O
HN	O
)	O
interface	O
for	O
atmospheric	O
pressure	O
chemical	O
ionization	O
(	O
APCI	O
)	O
and	O
an	O
ionspray	O
interface	O
for	O
electrospray	O
ionization	O
(	O
ES	O
)	O
.	O

A	O
Power	O
Macintosh	O
7200	O
/	O
120	O
computer	O
was	O
used	O
for	O
instrument	O
control	O
,	O
data	O
acquisition	O
and	O
processing	O
.	O

LC	O
-	O
MS	O
-	O
MS	O
experiments	O
were	O
performed	O
on	O
a	O
PE	O
-	O
Sciex	O
API	O
300	O
triple	O
quadrupole	O
mass	O
spectrometer	O
.	O

Chromatography	O
of	O
conjugates	B
was	O
obtained	O
under	O
ion	O
-	O
suppressed	O
reversed	O
-	O
phase	O
conditions	O
,	O
by	O
using	O
high	O
-	O
speed	O
(	O
3	O
cm	O
,	O
3	O
μm	O
)	O
columns	O
and	O
formic	B
acid	I
(	O
2	O
mM	O
)	O
as	O
modifier	O
in	O
the	O
mobile	O
phase	O
.	O

Glucuronides	B
were	O
identified	O
in	O
untreated	O
urine	O
samples	O
by	O
electrospray	O
(	O
ES	O
)	O
LC	O
-	O
MS	O
in	O
negative	O
-	O
ion	O
mode	O
and	O
peak	O
identity	O
was	O
confirmed	O
by	O
LC	O
-	O
MS	O
-	O
MS	O
experiments	O
.	O

For	O
the	O
analysis	O
of	O
free	O
metabolites	B
in	O
hydrolyzed	O
samples	O
,	O
the	O
APCI	O
interface	O
was	O
used	O
in	O
positive	O
-	O
ion	O
mode	O
after	O
separation	O
on	O
a	O
C-18	O
column	O
.	O

3	O
Results	O
In	O
untreated	O
urine	O
samples	O
,	O
four	O
glucuronides	B
were	O
identified	O
and	O
characterized	O
by	O
LC	O
-	O
MS	O
,	O
then	O
confirmed	O
by	O
LC	O
-	O
MS	O
-	O
MS	O
:	O
2-hexanol	B
-	I
G	I
and	O
5-hydroxy-2-hexanone	B
-	I
G	I
represented	O
the	O
main	O
conjugates	O
,	O
and	O
4,5-dihydroxy-2-hexanone	B
-	I
G	I
was	O
clearly	O
detectable	O
,	O
whereas	O
2,5-hexanediol	B
-	I
G	I
was	O
identified	O
only	O
in	O
trace	O
amount	O
.	O
'	O

Free	O
'	O
2,5-HD	B
was	O
detectable	O
in	O
non	O
-	O
hydrolyzed	O
samples	O
both	O
by	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
(	O
Fig.	O
1	O
)	O
.	O

Identification	O
and	O
analytical	O
basis	O
for	O
the	O
quantitation	O
of	O
n	B
-hexane	I
glucuronides	I
,	O
whose	O
authentic	O
reference	O
materials	O
are	O
not	O
available	O
,	O
have	O
been	O
reported	O
in	O
a	O
previous	O
paper	O
(	O
Manini	O
et	O
al.	O
,	O
1998	O
)	O
.	O

The	O
proportion	O
of	O
main	O
metabolites	B
(	O
μmol	O
excreted	O
in	O
the	O
15	O
h	O
following	O
administration	O
)	O
after	O
different	O
sample	O
treatments	O
is	O
shown	O
in	O
Table	O
1	O
.	O

Values	O
are	O
arithmetic	O
means	O
and	O
SEM	O
of	O
six	O
urine	O
samples	O
.	O

Enzymatic	O
hydrolysis	O
did	O
not	O
increase	O
the	O
amount	O
of	O
2,5-HD	B
as	O
compared	O
to	O
untreated	O
samples	O
,	O
nor	O
did	O
it	O
produce	O
γ	B
-	I
valerolactone	I
.	O

Moreover	O
,	O
LC	O
-	O
MS	O
analysis	O
of	O
hydrolyzates	O
allowed	O
the	O
identification	O
of	O
the	O
following	O
deconjugated	O
metabolites	B
,	O
i.e.	O
5-hydroxy-2-hexanone	B
,	O
4,5-dihydroxy-2-hexanone	B
and	O
2,5-hexanediol	B
.	O

On	O
the	O
contrary	O
,	O
acid	B
hydrolysis	O
led	O
to	O
substantial	O
increases	O
in	O
2,5-HD	B
(	O
the	O
so	O
called	O
'	O
total	O
'	O
2,5-HD	B
)	O
and	O
produced	O
γ	B
-	I
valerolactone	I
.	O

Owing	O
to	O
its	O
complete	O
transformation	O
into	O
2,5-HD	B
and	O
γ	B
-	I
valerolactone	I
,	O
4,5-dihydroxy-2-hexanone	B
was	O
no	O
longer	O
detectable	O
in	O
LC	O
-	O
MS	O
chromatograms	O
from	O
samples	O
undergone	O
acid	B
hydrolysis	O
,	O
while	O
such	O
a	O
treatment	O
also	O
reduced	O
(	O
by	O
70	O
%	O
)	O
the	O
concentration	O
of	O
5-hydroxy-2-hexanone	B
.	O

In	O
GC	O
-	O
MS	O
chromatograms	O
of	O
both	O
enzymatic	O
and	O
acid	B
hydrolyzates	O
,	O
measurable	O
amounts	O
of	O
2,5-dimethylfuran	B
were	O
found	O
.	O

No	O
differences	O
were	O
found	O
between	O
acid	B
and	O
enzymatic	O
followed	O
by	O
acid	B
hydrolysis	O
(	O
not	O
shown	O
)	O
.	O

The	O
effect	O
of	O
acid	B
hydrolysis	O
on	O
the	O
metabolite	B
proportions	O
in	O
the	O
second	O
aliquot	O
of	O
the	O
urine	O
of	O
rats	O
1	O
and	O
2	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

In	O
urine	O
from	O
rat	O
1	O
,	O
the	O
n	B
-hexanol	I
-	I
G	I
to	O
5-hydroxy-2-hexanone	B
-	I
G	I
ratio	O
was	O
2.85	O
,	O
whereas	O
such	O
metabolites	B
were	O
excreted	O
in	O
comparable	O
amounts	O
by	O
rat	O
2	O
.	O

Acid	B
hydrolysis	O
of	O
n	B
-hexanol	I
-	I
G	I
quantitatively	O
led	O
to	O
the	O
corresponding	O
n	B
-hexanols	I
.	O

The	O
hydrolysis	O
of	O
5-hydroxy-2-hexanone	B
was	O
not	O
complete	O
(	O
residual	O
conjugated	O
metabolite	B
35	O
%	O
)	O
,	O
giving	O
rise	O
to	O
a	O
variable	O
increase	O
in	O
2,5-HD	B
(	O
by	O
440	O
and	O
2330	O
%	O
in	O
rats	O
1	O
and	O
2	O
,	O
respectively	O
)	O
and	O
to	O
the	O
generation	O
of	O
γ	B
-	I
valerolactone	I
(	O
undetectable	O
in	O
untreated	O
samples	O
)	O
,	O
in	O
addition	O
to	O
a	O
considerable	O
amount	O
of	O
free	O
5-hydroxy-2-hexanone	B
,	O
especially	O
in	O
the	O
case	O
of	O
rat	O
2	O
.	O

As	O
a	O
result	O
,	O
whereas	O
'	O
free	O
'	O
2,5-HD	B
was	O
six	O
-	O
fold	O
higher	O
in	O
urine	O
from	O
rat	O
1	O
than	O
in	O
samples	O
from	O
rat	O
2	O
,	O
comparable	O
amounts	O
of	O
'	O
total	O
'	O
2,5-HD	B
were	O
found	O
after	O
extensive	O
acid	O
hydrolysis	O
.	O

4	O
Discussion	O
The	O
origin	O
of	O
2,5-HD	B
and	O
sources	O
of	O
analytical	O
artifacts	O
in	O
urine	O
samples	O
from	O
rats	O
treated	O
with	O
n-	B
hexane	I
were	O
identified	O
and	O
characterized	O
by	O
using	O
both	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
.	O

Complementary	O
information	O
obtained	O
from	O
such	O
techniques	O
was	O
useful	O
to	O
clarify	O
controversial	O
issues	O
concerning	O
n-	B
hexane	I
metabolism	O
.	O

The	O
proposed	O
scheme	O
of	O
n	B
-hexane	I
metabolism	O
is	O
shown	O
in	O
Fig.	O
1	O
.	O

In	O
a	O
previous	O
paper	O
,	O
we	O
demonstrated	O
that	O
the	O
total	O
2,5-HD	B
is	O
produced	O
during	O
acid	B
hydrolysis	O
starting	O
from	O
both	O
4,5-dihydroxy-2-hexanone	B
-	I
G	I
and	O
5-hydroxy-2-hexanone	B
-	I
G	I
and	O
that	O
the	O
artifact	O
γ	B
-	I
valerolactone	I
is	O
also	O
generated	O
from	O
the	O
same	O
conjugates	B
by	O
the	O
acid	B
treatment	O
(	O
Manini	O
et	O
al.	O
,	O
1998	O
)	O
.	O

By	O
contrast	O
,	O
during	O
enzymatic	O
hydrolysis	O
,	O
4,5-dihydroxy-2-hexanone	B
and	O
5-hydroxy-2-hexanone	B
are	O
deconjugated	O
,	O
but	O
neither	O
γ	B
-	I
valerolactone	I
nor	O
2,5-HD	B
increase	O
as	O
compared	O
to	O
untreated	O
samples	O
.	O

Already	O
in	O
1976	O
,	O
it	O
was	O
demonstrated	O
that	O
5-hydroxy-2-hexanone	B
undergoes	O
dehydration	O
and	O
cyclization	O
in	O
the	O
GC	O
inlet	O
to	O
2,5-dimethyl-2,3-dihydrofuran	B
and	O
therefore	O
is	O
never	O
detectable	O
by	O
GC	O
(	O
Di	O
Vincenzo	O
et	O
al.	O
,	O
1976	O
)	O
.	O

For	O
the	O
first	O
time	O
,	O
using	O
APCI	O
-	O
LC	O
-	O
MS	O
we	O
detected	O
considerable	O
amounts	O
of	O
free	O
5-hydroxy-2-hexanone	B
in	O
rat	O
urine	O
after	O
enzymatic	O
or	O
acid	B
hydrolysis	O
(	O
Andreoli	O
et	O
al.	O
,	O
1998	O
)	O
,	O
which	O
is	O
responsible	O
of	O
furans	B
in	O
GC	O
-	O
MS	O
chromatograms	O
of	O
hydrolyzates	O
(	O
both	O
acid	B
and	O
enzymatic	O
)	O
.	O

Because	O
5-hydroxy-2-hexanone	B
-	I
G	I
is	O
the	O
most	O
abundant	O
polioxygenated	O
metabolite	B
of	O
n-	B
hexane	I
in	O
rat	O
(	O
n	B
-hexanol	I
-	I
G	I
does	O
not	O
produce	O
artifacts	O
)	O
,	O
this	O
is	O
the	O
'	O
key	O
metabolite	B
'	O
generating	O
'	O
total	O
'	O
2,5-HD	B
,	O
γ	B
-	I
valerolactone	I
,	O
and	O
2,5-dimethylfuran	B
.	O

The	O
yield	O
of	O
hydrolysis	O
for	O
this	O
compound	O
is	O
variable	O
,	O
i.e.	O
33–38	O
and	O
61–63	O
%	O
after	O
enzymatic	O
and	O
acid	B
treatment	O
,	O
respectively	O
.	O

Thus	O
,	O
the	O
calculation	O
of	O
4,5-dihydroxy-2-hexanone	B
and	O
5-hydroxy-2-hexanone	B
by	O
the	O
difference	O
between	O
2,5-HD	B
and	O
γ	B
-	I
valerolactone	I
with	O
and	O
without	O
hydrolysis	O
(	O
Soriano	O
et	O
al.	O
,	O
1996	O
)	O
,	O
is	O
questionable	O
.	O

Although	O
based	O
on	O
animal	O
experiments	O
needing	O
further	O
validation	O
in	O
field	O
studies	O
,	O
the	O
present	O
investigation	O
gives	O
rise	O
to	O
some	O
conclusions	O
relevant	O
to	O
the	O
biomonitoring	O
of	O
n	B
-hexane	I
exposure	O
.	O

Since	O
the	O
variability	O
due	O
to	O
pre	O
-	O
analytical	O
(	O
hydrolysis	O
)	O
and	O
analytical	O
factor	O
should	O
be	O
kept	O
as	O
low	O
as	O
possible	O
,	O
we	O
suggest	O
not	O
to	O
use	O
acid	B
hydrolysis	O
,	O
but	O
rather	O
to	O
measure	O
'	O
free	O
'	O
2,5-HD	B
in	O
untreated	O
samples	O
.	O
'	O

Free	O
'	O
2,5-HD	B
is	O
meaningful	O
from	O
a	O
toxicological	O
point	O
of	O
view	O
,	O
since	O
it	O
is	O
thought	O
to	O
be	O
responsible	O
for	O
the	O
neurotoxic	O
effects	O
of	O
n-	B
hexane	I
and	O
methyl	B
-	I
n-	I
butyl	I
ketone	I
.	O

By	O
contrast	O
,	O
the	O
meaning	O
of	O
'	O
total	O
'	O
2,5-HD	B
is	O
also	O
questionable	O
for	O
toxicological	O
reasons	O
,	O
since	O
it	O
results	O
from	O
a	O
number	O
of	O
highly	O
soluble	O
glucuronated	B
compounds	I
rapidly	O
excreted	O
with	O
urine	O
and	O
meaningless	O
in	O
terms	O
of	O
toxic	O
risk	O
.	O

Although	O
'	O
total	O
'	O
2,5-HD	B
appears	O
correlated	O
with	O
airborne	O
n	B
-hexane	I
(	O
Kawai	O
et	O
al.	O
,	O
1991	O
)	O
,	O
the	O
contribution	O
of	O
endogenous	B
compounds	I
seems	O
not	O
to	O
be	O
negligible	O
at	O
low	O
levels	O
(	O
Perbellini	O
et	O
al.	O
,	O
1993	O
;	O
Mutti	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Since	O
'	O
total	O
'	O
2,5-HD	B
is	O
not	O
the	O
unique	O
product	O
of	O
hydrolysis	O
of	O
several	O
glucuronated	B
metabolites	I
,	O
reference	O
values	O
for	O
'	O
total	O
'	O
2,5-HD	B
(	O
Bavazzano	O
et	O
al.	O
,	O
1998	O
)	O
are	O
also	O
questionable	O
.	O

Despite	O
the	O
limited	O
number	O
of	O
rats	O
considered	O
in	O
these	O
experiments	O
,	O
two	O
rats	O
repeatedly	O
treated	O
with	O
the	O
same	O
dose	O
of	O
n	B
-hexane	I
produced	O
different	O
amounts	O
of	O
the	O
neurotoxic	O
metabolite	B
2,5-HD	B
.	O

From	O
the	O
visual	O
inspection	O
of	O
Fig.	O
2	O
,	O
it	O
can	O
be	O
argued	O
that	O
interindividual	O
differences	O
exist	O
in	O
the	O
biotransformation	O
of	O
n	B
-hexane	I
,	O
resulting	O
in	O
different	O
proportions	O
among	O
Phases	O
I	O
and	O
II	O
metabolites	B
.	O

Interindividual	O
metabolic	O
differences	O
are	O
ignored	O
when	O
exposure	O
and	O
the	O
subsequent	O
neurotoxic	O
risk	O
are	O
assessed	O
on	O
the	O
basis	O
of	O
'	O
total	O
'	O
2,5-HD	B
.	O

Indeed	O
,	O
as	O
shown	O
in	O
the	O
same	O
Fig.	O
2	O
,	O
the	O
urinary	O
concentrations	O
of	O
2,5-HD	B
from	O
both	O
rats	O
were	O
overlapping	O
.	O

Taking	O
into	O
account	O
that	O
the	O
risk	O
of	O
adverse	O
effects	O
is	O
attributable	O
not	O
only	O
to	O
the	O
intrinsic	O
properties	O
or	O
toxicity	O
of	O
a	O
chemical	B
agent	I
,	O
but	O
also	O
to	O
the	O
susceptibility	O
of	O
exposed	O
subjects	O
,	O
this	O
preliminary	O
and	O
partial	O
result	O
warrants	O
the	O
study	O
of	O
metabolic	O
profiles	O
from	O
n-	B
hexane	I
exposed	O
subjects	O
in	O
relation	O
to	O
relevant	O
polymorphic	O
drug	O
-	O
metabolizing	O
enzymes	O
.	O

Also	O
,	O
the	O
use	O
of	O
suitable	O
and	O
valid	O
techniques	O
is	O
a	O
pre	O
-	O
requisite	O
to	O
characterize	O
metabolic	O
interactions	O
among	O
components	O
of	O
complex	O
solvent	O
mixtures	O
.	O

Acknowledgements	O
This	O
work	O
was	O
financially	O
supported	O
by	O
the	O
European	O
Commission	O
(	O
ENV	O
-	O
CT-96	O
-	O
173	O
)	O
.	O

The	O
medical	O
use	O
of	O
the	O
extracts	O
of	O
Echinacea	O
purpurea	O
is	O
long	O
known	O
and	O
the	O
polysaccharide	B
components	O
of	O
these	O
extracts	O
have	O
been	O
systematically	O
investigated	O
by	O
Wagner	O
et	O
al.	O
[	O
1–3	O
]	O
.	O

As	O
a	O
result	O
of	O
these	O
studies	O
,	O
the	O
polysaccharides	B
of	O
Echinacea	O
purpurea	O
are	O
produced	O
in	O
industrial	O
scale	O
by	O
cell	O
cultures	O
[	O
4,5	O
]	O
.	O

These	O
polysaccharides	B
are	O
4-O-	B
methylglucuronoarabinoxylans	I
[	O
3	O
]	O
and	O
arabinorhamnogalactans	B
[	O
3	O
]	O
.	O

Most	O
recently	O
an	O
arabinogalactan	B
fraction	O
possessing	O
promising	O
biological	O
activity	O
was	O
isolated	O
[	O
6	O
]	O
(	O
Scheme	O
1	O
)	O
.	O

Structure	O
elucidation	O
suggested	O
that	O
all	O
third	O
or	O
fourth	O
galactose	B
units	O
of	O
the	O
β-	B
(	I
1→6	I
)	I
-linked	I
galactan	I
skeleton	O
contain	O
either	O
an	O
α	B
-	I
l	I
-arabinofuranosyl	I
or	O
an	O
α	B
-	I
l	I
-arabinofuranosyl-	I
(	I
1→5	I
)	I
-α	I
-	I
l	I
-arabinofuranosyl	I
side	O
chain	O
.	O

The	O
presence	O
of	O
a	O
rather	O
similar	O
structural	O
unit	O
is	O
supposed	O
by	O
Albersheim	O
et	O
al.	O
[	O
7	O
]	O
in	O
the	O
polysaccharide	B
isolated	O
from	O
suspension	O
-	O
cultured	O
sycamore	O
maple	O
(	O
Acer	O
pseudoplatanus	O
)	O
.	O

Three	O
different	O
tetrasaccharide	B
derivatives	O
were	O
synthesized	O
most	O
recently	O
by	O
van	O
Boom	O
et	O
al.	O
[	O
8	O
]	O
for	O
the	O
characterisation	O
of	O
several	O
monoclonal	O
antibodies	O
elucidated	O
by	O
the	O
epitopes	B
of	O
polysaccharides	B
isolated	O
from	O
Acer	O
pseudoplatanus	O
.	O

2	O
.	O

Results	O
and	O
discussion	O
The	O
aim	O
of	O
the	O
present	O
synthetic	O
work	O
was	O
to	O
establish	O
a	O
method	O
for	O
the	O
preparation	O
of	O
well	O
-	O
defined	O
parts	O
of	O
the	O
next	O
two	O
structural	O
units	O
and	O
employ	O
these	O
oligosaccharides	B
to	O
raise	O
monoclonal	O
antibodies	O
.	O

These	O
antibodies	O
might	O
be	O
suitable	O
tools	O
for	O
structure	O
elucidation	O
of	O
plant	O
polysaccharides	B
[	O
9	O
]	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
there	O
are	O
only	O
four	O
examples	O
in	O
the	O
literature	O
[	O
8,10–12	O
]	O
for	O
the	O
preparation	O
of	O
non	O
-	O
symmetrically	O
2,6-di	B
-	I
O-	I
glycosylated	I
β	I
-	I
d	I
-galactopyranosyl	I
derivatives	I
.	O

Now	O
we	O
report	O
our	O
first	O
results	O
obtained	O
with	O
some	O
oligosaccharides	B
having	O
the	O
desired	O
minimal	O
structural	O
unit	O
.	O

We	O
were	O
the	O
first	O
to	O
report	O
[	O
13	O
]	O
that	O
the	O
reaction	O
of	O
alkyl	B
β	I
-	I
d	I
-galactopyranosides	I
with	O
2,2-dimethoxypropane	B
in	O
the	O
presence	O
of	O
a	O
catalytic	O
amount	O
of	O
p	B
-toluenesulfonic	I
acid	I
resulted	O
in	O
alkyl	B
3,4-O-	I
isopropylidene-6-O	I
-	I
(	I
methoxydimethyl	I
)	I
methyl	I
-	I
β	I
-	I
d	I
-galactopyranosides	I
.	O

Other	O
authors	O
[	O
14–16	O
]	O
succesfully	O
used	O
this	O
procedure	O
for	O
the	O
preparation	O
of	O
different	O
galactopyranoside	B
derivatives	O
having	O
a	O
free	O
OH-2	O
group	O
,	O
and	O
abbreviated	O
the	O
(	B
methoxydimethyl	I
)	I
methyl	I
group	I
as	O
MIP	B
(	O
2-methoxy	B
-	I
isopropyl	I
)	O
.	O

In	O
the	O
knowledge	O
of	O
this	O
reaction	O
,	O
our	O
strategy	O
was	O
to	O
galactosylate	O
a	O
galactopyranos	B
(	I
e	I
)	I
yl	I
unit	O
having	O
free	O
OH-6	O
,	O
and	O
after	O
deprotection	O
of	O
the	O
second	O
galactosyl	B
unit	I
and	O
treatment	O
with	O
2,2-dimethoxypropane	O
,	O
a	O
partially	B
protected	I
digalactose	I
having	O
the	O
OH-2′	O
free	O
was	O
expected	O
to	O
be	O
obtained	O
.	O

This	O
should	O
be	O
amenable	O
to	O
direct	O
arabinosylation	O
.	O

Based	O
on	O
the	O
above	O
considerations	O
,	O
1,2:3,4-di	B
-	I
O-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
[	O
17	O
]	O
(	O
1	B
)	O
was	O
glycosylated	O
with	O
α	B
-	I
acetobromo	I
-	I
d	I
-galactose	I
under	O
Helferich	O
conditions	O
(	O
Schemes	O
2	O
and	O
3	O
)	O
and	O
the	O
known	O
6-O	B
-	I
(	I
2,3,4,6-tetra	I
-	I
O	I
-acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-1,2:3,4-di	I
-	I
O-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
[	O
18	O
]	O
(	O
2	B
)	O
was	O
obtained	O
.	O

Compound	B
2	I
was	O
deacetylated	O
to	O
give	O
6-O	B
-	I
(	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-1,2:3,4-di	I
-	I
O-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
[	O
19	O
]	O
(	O
3	B
)	O
,	O
and	O
this	O
disaccharide	B
was	O
treated	O
with	O
50	O
equivalents	O
of	O
neat	O
2,2-dimethoxypropane	B
in	O
the	O
presence	O
of	O
p	B
-toluenesulfonic	I
acid	I
.	O

A	O
nearly	O
quantitative	O
reaction	O
yielded	O
6-O-	B
(	I
3,4-O-	I
isopropropylidene-6-O-	I
(	I
methoxydimethyl	I
)	I
methyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-1,2:3,4-di	I
-	I
O-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
4	B
)	O
.	O

Compound	B
5	I
with	O
6′-OH	O
free	O
was	O
formed	O
only	O
as	O
a	O
side	O
product	O
.	O

The	O
direct	O
treatment	O
of	O
β	B
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-d	I
-galactose	I
(	O
6	B
)	O
with	O
2,2-dimethoxypropane	B
also	O
resulted	O
in	O
compound	B
4	I
.	O

The	O
MIP	B
derivatives	I
show	O
very	O
easily	O
characterisable	O
1	O
H	O
and	O
13	O
C	O
NMR	O
signals	O
:	O
in	O
compound	B
4	I
there	O
were	O
eight	O
C	O
-	O
methyl	O
signals	O
in	O
the	O
1	O
H	O
NMR	O
spectrum	O
between	O
1.50	O
and	O
1.30	O
ppm	O
;	O
the	O
OCH3	O
group	O
resonated	O
at	O
3.12	O
ppm	O
.	O

In	O
the	O
13	O
C	O
NMR	O
spectrum	O
the	O
quaternary	O
acetal	O
carbon	B
of	O
the	O
(	B
methoxydimethyl	I
)	I
methyl	I
group	I
resonated	O
at	O
100.1	O
ppm	O
,	O
the	O
C-6	O
showed	O
a	O
rather	O
strong	O
upfield	O
shift	O
at	O
60.26	O
ppm	O
,	O
and	O
the	O
OCH3	O
signal	O
appeared	O
at	O
48.53	O
ppm	O
.	O

These	O
signals	O
also	O
helped	O
the	O
structure	O
elucidation	O
of	O
other	O
,	O
more	O
complex	O
oligosaccharide	B
derivatives	I
.	O

To	O
synthesize	O
the	O
trisaccharide	B
repeating	O
unit	O
of	O
structure	B
I	I
,	O
compound	B
4	I
seemed	O
to	O
be	O
a	O
good	O
candidate	O
as	O
the	O
aglycone	B
.	O

Arabinosylation	O
of	O
4	B
with	O
2,3,5-tri	B
-	I
O-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl	I
bromide	I
[	O
20	O
]	O
(	O
7	B
)	O
using	O
Hg	B
(	I
CN	I
)	I
2	I
as	O
promoter	O
resulted	O
in	O
three	O
chromatographically	O
well	O
-	O
separable	O
substances	O
,	O
but	O
,	O
unfortunately	O
,	O
none	O
of	O
them	O
contained	O
the	O
MIP	B
group	I
.	O

The	O
fully	O
protected	O
compound	O
proved	O
to	O
be	O
6-O-	B
[	I
2,6-di	I
-	I
O-	I
(	I
2,3,5-tri	I
-	I
O-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl	I
)	I
-3,4-O-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
]	I
-1,2:3,4-di	I
-	I
O-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
8	B
)	O
.	O

The	O
presence	O
of	O
three	O
quaternary	O
acetalic	O
signals	O
(	O
110.24	O
,	O
108.99	O
and	O
108.21	O
ppm	O
)	O
,	O
the	O
four	O
anomeric	O
carbon	O
signals	O
(	O
105.67	O
,	O
103.73	O
,	O
101.19	O
and	O
95.94	O
ppm	O
)	O
,	O
the	O
absence	O
of	O
the	O
MIP	B
group	I
and	O
the	O
glycosylation	O
shift	O
at	O
the	O
carbon	B
C-6′	O
verified	O
the	O
structure	O
of	O
compound	B
8	I
.	O

The	O
second	O
product	O
in	O
the	O
reaction	O
mixture	O
proved	O
to	O
be	O
the	O
trisaccharide	B
9	I
.	O

The	O
three	O
anomeric	O
carbon	B
signals	O
resonated	O
at	O
105.60	O
,	O
103.36	O
and	O
96.14	O
ppm	O
,	O
the	O
C-6′	O
was	O
glycosylated	O
(	O
C-6′	O
:	O
65.72	O
ppm	O
)	O
,	O
and	O
three	O
dioxolane	B
-	O
type	O
isopropylidene	B
groups	I
were	O
present	O
(	O
109.89	O
,	O
109.35	O
and	O
108.64	O
ppm	O
)	O
.	O

Acetylation	O
of	O
9	B
gave	O
the	O
monoacetyl	B
derivative	I
(	O
10	B
)	O
and	O
one	O
proton	O
triplet	O
was	O
shifted	O
to	O
the	O
lower	O
field	O
.	O

The	O
acetylated	O
OH	B
group	I
was	O
assigned	O
as	O
OH-2′	O
,	O
having	O
the	O
triplet	O
at	O
5.08	O
ppm	O
,	O
and	O
8.5	O
Hz	O
coupling	O
constants	O
assignable	O
to	O
J	O
1′,2′	O
and	O
J	O
2′,3′	O
.	O

The	O
third	O
(	O
minor	O
)	O
component	O
was	O
also	O
a	O
trisaccharide	B
(	O
11	B
)	O
,	O
in	O
which	O
C-6′	O
(	O
62.38	O
ppm	O
)	O
was	O
free	O
,	O
three	O
acetal	B
rings	O
were	O
present	O
(	O
109.98	O
,	O
109.46	O
and	O
108.74	O
ppm	O
)	O
,	O
and	O
an	O
arabinofuranosyl	B
unit	I
was	O
anchored	O
at	O
C-2′.	O
This	O
compound	O
was	O
the	O
planned	O
trisaccharide	B
,	O
although	O
without	O
the	O
terminal	O
MIP	B
substitutent	O
:	O
6-O-	B
[	I
2-O-	I
(	I
2,3,5-tri	I
-	I
O-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl	I
)	I
-3,4-O-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
]	I
-1,2:3,4-di	I
-	I
O-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
11	B
)	O
.	O

In	O
the	O
knowledge	O
of	O
the	O
extreme	O
acid	B
-	O
sensitive	O
properties	O
of	O
the	O
MIP	B
derivatives	I
,	O
the	O
formation	O
of	O
the	O
above	O
oligosaccharides	B
(	O
8	B
,	O
9	B
and	O
11	B
)	O
can	O
be	O
easily	O
explained	O
.	O

In	O
the	O
initial	O
stage	O
of	O
the	O
glycosylation	O
reaction	O
the	O
OH-2′	O
is	O
the	O
only	O
nucleophilic	O
partner	O
and	O
the	O
MIP	B
-	O
containing	O
12	B
(	O
vide	O
infra	O
)	O
was	O
produced	O
.	O

During	O
this	O
reaction	O
mercury	B
bromide	I
was	O
also	O
formed	O
and	O
this	O
rather	O
strong	O
Lewis	B
acid	I
hydrolysed	O
the	O
acid	B
-	O
sensitive	O
MIP	B
blocking	O
group	B
.	O

Then	O
,	O
reaction	O
of	O
the	O
more	O
nucleophilic	O
OH-6′	O
resulted	O
in	O
the	O
trisaccharide	B
derivative	I
9	I
,	O
and	O
the	O
excess	O
of	O
the	O
glycosyl	B
donor	I
glycosylated	O
it	O
to	O
the	O
tetrasaccharide	B
main	O
product	O
8	B
.	O

The	O
small	O
amount	O
of	O
compound	B
11	I
formed	O
from	O
its	O
6-OMIP	B
derivative	I
(	O
12	B
)	O
,	O
which	O
did	O
not	O
lose	O
its	O
MIP	B
during	O
the	O
coupling	O
reaction	O
,	O
but	O
was	O
cleaved	O
during	O
the	O
work	O
-	O
up	O
procedure	O
.	O

Similar	O
reaction	O
mixtures	O
were	O
obtained	O
by	O
using	O
Ag2	B
O	I
or	O
Ag2	B
CO3	I
promoters	O
.	O

To	O
avoid	O
the	O
cleavage	O
of	O
the	O
MIP	B
group	I
we	O
executed	O
the	O
glycosylation	O
reaction	O
promoted	O
by	O
AgOTf	B
in	O
the	O
presence	O
of	O
sym	B
-collidine	I
(	O
2,4,6-trimethylpyridine	B
)	O
,	O
hoping	O
that	O
this	O
strong	O
base	O
can	O
prevent	O
the	O
hydrolysis	O
of	O
the	O
acid	B
-	O
sensitive	O
mixed	O
acetalic	O
protecting	B
group	I
.	O

The	O
reaction	O
proceeded	O
with	O
an	O
acceptable	O
rate	O
and	O
two	O
products	O
(	O
12	B
and	O
13	B
)	O
were	O
formed	O
.	O

It	O
was	O
also	O
observed	O
that	O
the	O
chromatographically	O
faster	O
-	O
moving	O
component	O
(	O
12	B
)	O
was	O
transformed	O
into	O
the	O
slower	O
-	O
moving	O
one	O
(	O
13	B
)	O
.	O

Although	O
the	O
two	O
products	O
showed	O
very	O
similar	O
chromatographic	O
mobility	O
,	O
their	O
separation	O
could	O
be	O
achieved	O
rather	O
easily	O
.	O

The	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
of	O
the	O
faster	O
-	O
moving	O
component	O
showed	O
the	O
presence	O
of	O
the	O
MIP	B
group	I
(	O
δ	O
:	O
3.2	O
ppm	O
,	O
OCH	O
3	O
,	O
24	O
H	O
was	O
integrated	O
between	O
δ	O
:	O
1.18–1.62	O
ppm	O
)	O
,	O
and	O
three	O
benzoyl	B
moieties	I
were	O
also	O
present	O
.	O

The	O
13	O
C	O
NMR	O
spectrum	O
was	O
more	O
informative	O
;	O
three	O
dioxolane	B
-	O
type	O
acetalic	O
carbon	B
signals	O
could	O
be	O
assigned	O
(	O
δ	O
:	O
110.15	O
,	O
109.06	O
and	O
108.31	O
)	O
,	O
the	O
three	O
anomeric	O
carbon	B
atoms	O
resonated	O
at	O
103.82	O
,	O
101.28	O
and	O
96.04	O
ppm	O
,	O
and	O
the	O
quaternary	O
acetalic	O
carbon	B
atom	O
of	O
the	O
MIP	B
appeared	O
at	O
100.10	O
ppm	O
.	O

The	O
O-6′	O
contained	O
the	O
-O-	B
C	I
(	I
CH3	I
)	I
2	I
-OCH3	I
group	I
,	O
an	O
upfield	O
shift	O
of	O
∼2	O
ppm	O
could	O
be	O
detected	O
(	O
δ	O
:	O
60.08	O
ppm	O
)	O
and	O
the	O
OC	B
H3	I
group	I
resonated	O
at	O
48.49	O
ppm	O
.	O

Mild	O
acid	B
hydrolysis	O
of	O
the	O
MIP	B
group	I
in	O
compound	B
12	B
resulted	O
in	O
11	B
in	O
a	O
quantitative	O
yield	O
.	O

The	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
of	O
the	O
second	O
,	O
slower	O
-	O
moving	O
compound	B
(	O
13	B
)	O
showed	O
a	O
trisaccharide	B
character	O
.	O

The	O
spectra	O
did	O
not	O
contain	O
OCH3	B
signal	O
(	O
s	O
)	O
,	O
but	O
there	O
was	O
a	O
quaternary	O
carbon	B
signal	O
at	O
100.5	O
ppm	O
which	O
could	O
be	O
an	O
acetalic	O
carbon	B
resonance	O
.	O

The	O
C-6′	O
also	O
appeared	O
at	O
high	O
field	O
(	O
δ	O
:	O
60.18	O
ppm	O
)	O
,	O
and	O
there	O
were	O
21	O
hydrogens	B
in	O
the	O
methyl	B
-	O
proton	O
region	O
.	O

These	O
spectral	O
data	O
suggested	O
a	O
symmetrical	O
isopropylidene	B
acetal	I
structure	O
in	O
which	O
the	O
alcoholic	B
components	O
were	O
the	O
two	O
trisaccharide	B
molecules	O
;	O
its	O
composition	O
can	O
be	O
depicted	O
by	O
structure	O
13	B
.	O

Formation	O
of	O
symmetrical	O
dimerization	O
products	O
of	O
monosaccharides	B
having	O
similar	O
structure	O
to	O
13	O
was	O
reported	O
by	O
Barresi	O
and	O
Hindsgaul	O
[	O
21	O
]	O
in	O
a	O
publication	O
dealing	O
with	O
synthesis	O
of	O
β	B
-	I
mannopyranosides	I
by	O
intramolecular	O
aglycone	B
delivery	O
.	O

The	O
assumed	O
structure	O
of	O
13	B
was	O
verified	O
by	O
MALDI	O
-	O
TOF	O
MS	O
measurement	O
giving	O
m	O
/z	O
:	O
1853.9	O
.	O

In	O
the	O
spectrum	O
of	O
compound	B
13	I
two	O
additional	O
fragments	O
appeared	O
with	O
m	O
/z	O
:	O
906.5	O
and	O
946.5	O
;	O
the	O
first	O
could	O
be	O
assigned	O
to	O
11	B
and	O
the	O
second	O
to	O
the	O
6-O-	O
isopropenyl	B
ether	I
of	O
11	B
.	O

The	O
symmetrical	O
acetalic	O
bond	O
in	O
compound	B
13	I
is	O
more	O
stable	O
than	O
the	O
bonds	O
of	O
the	O
mixed	O
acetals	B
(	O
MIP	B
)	O
but	O
more	O
sensitive	O
than	O
the	O
cyclic	O
dioxolane	B
-	O
type	O
isopropylidene	B
acetals	I
.	O

Mild	O
acid	B
hydrolysis	O
of	O
13	B
resulted	O
in	O
11	B
with	O
a	O
quantitative	O
yield	O
.	O

Compound	B
11	I
can	O
be	O
a	O
choice	O
as	O
the	O
aglycone	B
for	O
additional	O
glycosylation	O
,	O
or	O
even	O
an	O
aglycone	B
for	O
dimerisation	O
into	O
the	O
hexasaccharide	B
I	I
.	O

These	O
results	O
demonstrate	O
that	O
the	O
easily	O
available	O
MIP	B
derivatives	I
can	O
serve	O
as	O
aglycones	B
in	O
glycosylation	O
reactions	O
,	O
but	O
basic	O
or	O
neutral	O
conditions	O
are	O
required	O
for	O
the	O
coupling	O
reactions	O
and	O
also	O
for	O
the	O
work	O
-	O
up	O
procedure	O
.	O

It	O
is	O
known	O
that	O
the	O
MIP	B
derivatives	I
can	O
be	O
successfully	O
etherified	O
under	O
basic	O
conditions	O
[	O
15	O
]	O
(	O
Scheme	O
4	O
)	O
.	O

Benzylation	O
of	O
compound	B
4	I
gave	O
the	O
fully	O
protected	O
crystalline	O
disaccharide	B
14	I
(	O
Scheme	O
2	O
)	O
.	O

Selective	O
hydrolysis	O
of	O
the	O
MIP	B
fgroup	O
resulted	O
in	O
the	O
crystalline	O
6-O-	B
(	I
2-O-	I
benzyl-3,4-O-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-1,2:3,4-di	I
-	I
O-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
15	B
)	O
.	O

Complete	O
hydrolysis	O
of	O
the	O
isopropylidene	B
acetals	I
either	O
of	O
14	B
or	O
15	B
gave	O
6-O-	B
(	I
2-O-	I
benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-d	I
-galactose	I
(	O
16	B
)	O
.	O

Acetylation	O
of	O
16	B
afforded	O
the	O
peracetylated	B
derivative	I
(	O
17	B
)	O
from	O
which	O
,	O
after	O
hydrogenolysis	O
,	O
6-O-	B
(	I
3,4,6-tri	I
-	I
O-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl	I
)	I
-1,2,3,4-tetra	I
-	I
O-	I
acetyl	I
-	I
α	I
,	I
β	I
-	I
d	I
-galactopyranose	I
(	O
18	B
)	O
was	O
obtained	O
.	O

Compound	B
18	I
could	O
be	O
arabinosylated	O
with	O
7	B
and	O
the	O
persubstituted	O
trisaccharide	B
19	I
was	O
isolated	O
.	O

For	O
the	O
removal	O
of	O
the	O
isopropylidene	B
groups	I
of	O
the	O
oligosaccharides	B
8	B
,	O
9	B
,	O
11	B
and	O
13	B
aqueous	O
90	O
%	O
trifluoroacetic	B
acid	I
was	O
used	O
.	O

The	O
acyl	B
groups	I
were	O
removed	O
by	O
Zemplén	O
transesterification	O
to	O
furnish	O
the	O
tetrasaccharide	B
20	I
from	O
compound	B
8	I
and	O
the	O
trisaccharide	B
21	I
from	O
the	O
protected	O
9	B
.	O

The	O
target	O
trisaccharide	B
22	I
was	O
obtained	O
from	O
three	O
different	O
protected	O
intermediates	O
:	O
11	B
,	O
13	B
and	O
19	B
(	O
Scheme	O
5	O
)	O
.	O

Detailed	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
1	O
H	O
and	O
13	O
C	O
NMR	O
studies	O
resulted	O
in	O
the	O
pertinent	O
spectral	O
assignments	O
.	O

The	O
13	O
C	O
NMR	O
data	O
of	O
the	O
protected	O
derivatives	O
are	O
collected	O
in	O
Table	O
1	O
.	O

Similar	O
measurements	O
were	O
done	O
in	O
the	O
case	O
of	O
the	O
free	O
oligosaccharides	B
,	O
too	O
.	O

These	O
trisaccharides	B
,	O
in	O
aqueous	O
solutions	O
,	O
occur	O
as	O
mixture	O
of	O
two	O
anomers	O
,	O
but	O
in	O
the	O
case	O
of	O
the	O
branched	O
tetrasaccharide	B
20	I
,	O
the	O
reducing	O
d	B
-galactose	I
unit	O
existed	O
in	O
four	O
isomeric	O
forms	O
(	O
α-	B
,	O
β	B
-	I
pyranose	I
and	O
α-	B
,	O
and	O
β	B
-	I
furanose	I
forms	O
)	O
and	O
in	O
the	O
equilibrium	O
mixture	O
the	O
quadruplication	O
of	O
some	O
individual	O
carbon-13	B
signals	O
could	O
be	O
detected	O
.	O

Similar	O
spectral	O
behaviours	O
have	O
been	O
reported	O
earlier	O
from	O
our	O
laboratory	O
[	O
22,23	O
]	O
(	O
Scheme	O
6	O
)	O
.	O

3	O
.	O

Experimental	O
3.1	O
General	O
methods	O
Optical	O
rotations	O
were	O
measured	O
at	O
room	O
temperature	O
with	O
a	O
Perkin	O
–	O
Elmer	O
241	O
automatic	O
polarimeter	O
.	O

Melting	O
points	O
were	O
determined	O
on	O
a	O
Kofler	O
apparatus	O
and	O
are	O
uncorrected	O
.	O

TLC	O
was	O
performed	O
on	O
Kieselgel	B
60	O
F254	O
(	O
E.	O
Merck	O
)	O
with	O
detection	O
by	O
charring	O
with	O
50	O
%	O
of	O
aqueous	O
sulfuric	B
acid	I
.	I

Column	O
chromatography	O
was	O
performed	O
on	O
Silica	B
Gel	O
60	O
(	O
E.	O
Merck	O
0.063–0.200	O
mm	O
)	O
.	O

The	O
organic	O
solution	O
was	O
dried	O
over	O
MgSO4	B
,	O
and	O
concentrated	O
in	O
a	O
vacuum	O
.	O

The	O
1	O
H	O
(	O
200	O
,	O
360	O
and	O
500	O
MHz	O
)	O
and	O
13	O
C	O
NMR	O
(	O
50.3	O
,	O
90.54	O
,	O
125.76	O
MHz	O
)	O
spectra	O
were	O
recorded	O
with	O
Bruker	O
WP-200	O
SY	O
,	O
Bruker	O
AM-360	O
and	O
Bruker	O
DRX-500	O
spectrometers	O
in	O
CDCl3	B
solutions	O
.	O

Internal	O
references	O
:	O
TMS	B
(	O
0.000	O
ppm	O
for	O
1	O
H	O
)	O
,	O
CDCl3	B
(	O
77.00	O
ppm	O
for	O
13	O
C	O
)	O
.	O

3.2	O
2,3,4,6-Tetra	B
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
2	B
)	O
Powdered	O
Hg	B
(	I
CN	I
)	I
2	I
(	O
16.4	O
g	O
,	O
0.065	O
mol	O
)	O
and	O
4	B
Å	I
molecular	I
sieves	I
(	O
10	O
g	O
)	O
were	O
added	O
to	O
a	O
solution	O
of	O
1	O
(	O
13.0	O
g	O
,	O
0.050	O
mol	O
)	O
in	O
120	O
mL	O
of	O
dry	O
CH3	B
CN	I
,	O
and	O
the	O
mixture	O
was	O
stirred	O
overnight	O
.	O

To	O
the	O
mixture	O
was	O
added	O
2,3,4,6-tetra	B
-	I
O	I
-acetyl	I
-	I
α	I
-	I
d	I
-galactopyranosyl	I
bromide	I
(	O
24.6	O
g	O
,	O
0.060	O
mol	O
)	O
in	O
five	O
portions	O
.	O

After	O
2	O
h	O
the	O
reaction	O
was	O
complete	O
(	O
TLC	O
,	O
23:2	O
CH2	B
Cl2	I
–acetone	O
,	O
R	O
f	O
0.5	O
)	O
.	O

The	O
mixture	O
was	O
diluted	O
with	O
500	O
mL	O
of	O
CH2	B
Cl2	I
,	O
the	O
inorganic	O
salts	B
were	O
filtered	O
off	O
,	O
and	O
the	O
filtrate	O
was	O
concentrated	O
in	O
vacuo	O
.	O

The	O
residue	O
was	O
dissolved	O
in	O
1000	O
mL	O
of	O
CH2	B
Cl2	I
,	O
the	O
inorganic	O
salts	B
were	O
filtered	O
off	O
again	O
,	O
the	O
filtrate	O
was	O
washed	O
with	O
aq	O
5	O
%	O
KI	B
solution	O
(	O
4	O
×	O
250	O
mL	O
)	O
,	O
and	O
water	B
(	O
2	O
×	O
250	O
mL	O
)	O
.	O

The	O
organic	O
layer	O
was	O
dried	O
and	O
evaporated	O
.	O

The	O
syrupy	O
residue	O
was	O
purified	O
by	O
column	O
chromatography	O
(	O
CH2	B
Cl2	I
–acetone	O
,	O
96:4→92:8	O
)	O
to	O
yield	O
2	B
(	O
19.0	O
g	O
,	O
64.4	O
%	O
)	O
:	O
[	O
α	O
]	O
D	O
22	O
−44.2	O
°	O
(	O
c	O
1.0	O
,	O
CHCl3	B
)	O
lit	O
.	O

−44	O
°	O
[	O
18	O
]	O
;	O
1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
5.51	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1	O
,	O
J	O
1,2	O
4.9	O
Hz	O
)	O
,	O
5.39	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-4′	O
,	O
J	O
3′,4′	O
3.4	O
Hz	O
,	O
J	O
4′,5′	O
1.0	O
Hz	O
)	O
,	O
5.22	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2′	O
,	O
J	O
1′,2′	O
7.9	O
Hz	O
,	O
J	O
2′,3′	O
10.5	O
Hz	O
)	O
,	O
5.03	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-3′	O
)	O
,	O
4.59	O
(	O
2	O
d	O
,	O
2	O
H	O
,	O
H-1′	O
,	O
H-3	O
,	O
J	O
3,4	O
8.0	O
Hz	O
)	O
,	O
4.30	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2	O
,	O
J	O
2,3	O
2.5	O
Hz	O
)	O
,	O
4.16	O
(	O
m	O
,	O
3	O
H	O
,	O
H-5′	O
,	O
H-6′a	O
,	O
b	O
,	O
J	O
gem	O
11.1	O
Hz	O
)	O
,	O
4.04	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-6a	O
,	O
J	O
5,6a	O
3.2	O
Hz	O
,	O
J	O
gem	O
11.5	O
Hz	O
)	O
,	O
3.95–3.85	O
(	O
m	O
,	O
2	O
H	O
,	O
H-4	O
,	O
H-5	O
)	O
,	O
3.69	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-6b	O
,	O
J	O
5,6b	O
7.6	O
Hz	O
)	O
,	O
2.15–1.95	O
(	O
4	O
s	O
,	O
each	O
3	O
H	O
,	O
4	O
CH3acetyl	O
)	O
,	O
1.55–1.30	O
(	O
4s	O
,	O
each	O
3	O
H	O
,	O
4	O
CH3ip	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C26	O
H38	O
O15	O
(	O
590.57	O
)	O
:	O
C	O
,	O
52.87	O
;	O
H	O
,	O
6.48	O
.	O

Found	O
:	O
C	O
,	O
52.90	O
;	O
H	O
,	O
6.51	O
.	O
3.3	O
β	B
-	I
d	I
-Galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
3	B
)	O
To	O
a	O
stirred	O
solution	O
of	O
2	B
(	O
16.5	O
g	O
,	O
0.028	O
mol	O
)	O
in	O
200	O
mL	O
of	O
dry	O
MeOH	B
NaOMe	B
(	O
100	O
mg	O
)	O
was	O
added	O
(	O
pH	O
∼8	O
)	O
.	O

After	O
2.5	O
h	O
the	O
TLC	O
(	O
85:15	O
CH2	B
Cl2	I
–MeOH	O
,	O
R	O
f	O
0.5	O
)	O
showed	O
complete	O
conversion	O
.	O

The	O
solution	O
was	O
neutralized	O
with	O
Amberlite	B
IR-120	I
H+	I
ion	I
-	I
exchange	I
resin	I
,	O
filtered	O
and	O
evaporated	O
to	O
yield	O
3	B
as	O
a	O
white	O
foam	O
(	O
11.7	O
g	O
,	O
98.8	O
%	O
)	O
:	O
[	O
α	O
]	O
D	O
22	O
−63.1	O
°	O
(	O
c	O
1.0	O
,	O
CHCl3	B
)	O
lit	O
.	O

−49.7	O
°	O
(	O
c	O
2	O
,	O
aq	O
0.5	O
M	O
TRIS	B
)	O
[	O
19	O
]	O
;	O
1	O
H	O
NMR	O
(	O
360	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
5.50	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1	O
,	O
J	O
1,2	O
5	O
Hz	O
)	O
,	O
4.62	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1′	O
,	O
J	O
1′,2′	O
8	O
Hz	O
)	O
,	O
4.40–3.45	O
(	O
m	O
,	O
14	O
skeleton	O
H	O
)	O
,	O
1.45	O
(	O
m	O
,	O
12	O
H	O
,	O
4	O
CH3ip	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C18	O
H30	O
O11	O
(	O
422.43	O
)	O
:	O
C	O
,	O
51.17	O
;	O
H	O
,	O
7.16	O
.	O

Found	O
:	O
C	O
,	O
51.32	O
;	O
H	O
,	O
7.13	O
.	O

3.4	O
3,4-O	B
-	I
Isopropylidene-6-O-	I
(	I
methoxydimethyl	I
)	I
methyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
4	B
)	O
and	O
3,4-O	B
-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
5	B
)	O
To	O
a	O
solution	O
of	O
3	B
(	O
11.5	O
g	O
,	O
0.027	O
mol	O
)	O
in	O
2,2-dimethoxypropane	B
(	O
170	O
mL	O
,	O
1.36	O
mol	O
)	O
was	O
added	O
400	O
mg	O
of	O
p	B
-toluenesulfonic	I
acid	I
,	O
and	O
the	O
mixture	O
was	O
stirred	O
overnight	O
.	O

By	O
TLC	O
(	O
4:1	O
CH2	B
Cl2	I
–acetone	O
;	O
+	O
0.1	O
%	O
Et3	B
N	I
)	O
the	O
starting	O
material	O
disappeared	O
,	O
compounds	B
4	B
(	O
R	O
f	O
0.54	O
)	O
and	O
5	B
(	O
R	O
f	O
0.25	O
)	O
were	O
formed	O
in	O
a	O
ratio	O
of	O
4:1	O
.	O

After	O
addition	O
of	O
Et3	B
N	I
(	O
2	O
mL	O
)	O
the	O
reaction	O
mixture	O
was	O
diluted	O
with	O
1	O
L	O
of	O
CH2	B
Cl2	I
,	O
washed	O
with	O
water	B
(	O
3	O
×	O
400	O
mL	O
)	O
,	O
dried	O
and	O
evaporated	O
.	O

The	O
residue	O
was	O
chromatographed	O
with	O
CH2	B
Cl2	I
–acetone	O
,	O
9:1→8:2	O
,	O
containing	O
1	O
%	O
Et3	B
N	I
to	O
give	O
4	B
(	O
10.6	O
g	O
,	O
72.5	O
%	O
)	O
and	O
5	B
(	O
2.5	O
g	O
,	O
19.7	O
%	O
)	O
.	O

The	O
same	O
products	O
in	O
similar	O
ratio	O
were	O
obtained	O
from	O
6	B
by	O
treatment	O
of	O
50	O
equivalents	O
of	O
2,2-dimethoxy	B
-	I
propane	I
and	O
catalytic	O
amount	O
of	O
p	B
-toluenesulfonic	I
acid	I
.	O

Compound	B
4	I
:	O
[	O
α	O
]	O
D	O
22	O
−35.6	O
°	O
(	O
c	O
1.3	O
,	O
CHCl3	B
)	O
;	O
1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
5.54	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1	O
,	O
J	O
1,2	O
5.0	O
Hz	O
)	O
,	O
4.60	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-3	O
,	O
J	O
2,3	O
2.4	O
Hz	O
,	O
J	O
3,4	O
7.9	O
Hz	O
)	O
,	O
4.31	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2	O
)	O
,	O
4.28	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-1′	O
,	O
J	O
1′,2′	O
8.4	O
Hz	O
)	O
,	O
4.24	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-4	O
,	O
J	O
4,5	O
1.7	O
Hz	O
)	O
,	O
4.16	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-4′	O
,	O
J	O
3′,4′	O
5.4	O
Hz	O
,	O
J	O
4′,5′	O
2.1	O
Hz	O
)	O
,	O
4.06	O
(	O
m	O
,	O
2	O
H	O
,	O
H-3′	O
,	O
H-6a	O
,	O
J	O
2′,3′	O
7.8	O
Hz	O
)	O
,	O
4.00	O
(	O
m	O
,	O
1	O
H	O
,	O
H-5	O
)	O
,	O
3.85	O
(	O
dt	O
,	O
1	O
H	O
,	O
H-5′	O
,	O
J	O
5′,6a′	O
=	O
J	O
5′,6b′	O
6.2	O
Hz	O
)	O
,	O
3.75–3.69	O
(	O
m	O
,	O
3	O
H	O
,	O
H-6a	O
,	O
H-6′a	O
,	O
b	O
)	O
,	O
3.59	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2′	O
)	O
,	O
3.25	O
(	O
s	O
,	O
3	O
H	O
,	O
OCH3	O
)	O
,	O
1.50–1.27	O
(	O
8	O
s	O
,	O
each	O
3	O
H	O
,	O
8	O
CH3ip	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C25	O
H42	O
O12	O
(	O
534.58	O
)	O
:	O
C	O
,	O
56.17	O
;	O
H	O
,	O
7.91	O
.	O

Found	O
:	O
C	O
,	O
56.31	O
;	O
H	O
,	O
8.00	O
.	O

Compound	B
5	I
:	O
[	O
α	O
]	O
D	O
22	O
−29.6	O
°	O
(	O
c	O
1.0	O
,	O
CHCl3	B
)	O
;	O
1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
5.48	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1	O
,	O
J	O
1,2	O
5.0	O
Hz	O
)	O
,	O
4.55	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-3	O
,	O
J	O
2,3	O
2.4	O
Hz	O
,	O
J	O
3,4	O
7.9	O
Hz	O
)	O
,	O
4.26	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2	O
)	O
,	O
4.22	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-1′	O
,	O
J	O
1′,2′	O
8.0	O
Hz	O
)	O
,	O
4.20	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-4	O
,	O
J	O
4,5	O
1.7	O
Hz	O
)	O
,	O
4.09–3.66	O
(	O
m	O
,	O
8	O
H	O
)	O
,	O
3.49	O
(	O
t	O
,	O
1	O
H	O
,	O
H-2′	O
J	O
2′,3′	O
8.0	O
Hz	O
)	O
,	O
1.50–1.27	O
(	O
m	O
,	O
18	O
H	O
,	O
6	O
CH3ip	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C21	O
H34	O
O11	O
(	O
462.49	O
)	O
:	O
C	O
,	O
54.53	O
;	O
H	O
,	O
7.40	O
,	O
.	O

Found	O
:	O
C	O
,	O
54.31	O
;	O
H	O
,	O
7.37	O
.	O

3.5	O
β	B
-	I
d	I
-Galactopyranosyl-	I
(	I
1→6	I
)	I
-d	I
-galactose	I
(	O
6	B
)	O
A	O
solution	O
of	O
4	B
(	O
50	O
mg	O
,	O
0.090	O
mmol	O
)	O
in	O
1	O
mL	O
of	O
90	O
%	O
trifluoroacetic	B
acid	I
was	O
stirred	O
for	O
15	O
min	O
,	O
and	O
concentrated	O
at	O
20	O
°	O
C	O
in	O
vacuo	O
.	O

Ethyl	B
acetate	I
(	O
6	O
mL	O
)	O
was	O
added	O
to	O
the	O
residue	O
,	O
and	O
the	O
precipitate	O
formed	O
was	O
washed	O
three	O
times	O
with	O
ethyl	B
acetate	I
to	O
yield	O
6	B
(	O
20	O
mg	O
,	O
64	O
%	O
)	O
:	O

[	O
α	O
]	O
D	O
22	O
+	O
17.3	O
°	O
(	O
c	O
0.19	O
,	O
H2	B
O	I
)	O
;	O
R	O
f	O
0.4	O
(	O
dichloromethane	B
:	O
methanol	B
:	O
H2	B
O	I
,	O
80:50:13	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C12	O
H22	O
O11	O
(	O
342.29	O
)	O
:	O
C	O
,	O
41.10	O
;	O
H	O
,	O
6.47	O
.	O

Found	O
:	O
C	O
,	O
41.44	O
;	O
H	O
,	O
6.48	O
.	O
3.6	O
2,3,5-Tri	B
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→2	I
)	I
-	I
[	I
2,3,5-tri	I
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→6	I
)	I
]	I
-3,4-O	I
-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
8	B
)	O
,	O
2,3,5-tri	B
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→6	I
)	I
-3,4-O	I
-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
9	B
)	O
and	O
2,3,5-tri	B
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→2	I
)	I
-3,4-O	I
-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
11	B
)	O
To	O
a	O
solution	O
of	O
4	B
(	O
390	O
mg	O
,	O
0.84	O
mmol	O
)	O
in	O
5	O
mL	O
of	O
dry	O
CH3	B
CN	I
were	O
added	O
powdered	O
Hg	B
(	I
CN	I
)	I
2	I
(	O
512	O
mg	O
,	O
2.4	O
equiv	O
)	O
and	O
4	B
Å	I
molecular	I
sieves	I
(	O
0.5	O
g	O
)	O
,	O
the	O
mixture	O
was	O
stirred	O
for	O
3	O
h	O
and	O
1.0	O
g	O
(	O
1.9	O
mmol	O
)	O
of	O
7	B
[	O
20	O
]	O
was	O
added	O
.	O

After	O
2	O
h	O
the	O
TLC	O
(	O
49:1	O
CH2	B
CL2	I
–acetone	O
)	O
showed	O
∼50	O
%	O
conversion	O
of	O
4	O
,	O
100	O
mg	O
of	O
Hg	B
(	I
CN	I
)	I
2	I
was	O
added	O
and	O
the	O
mixture	O
was	O
kept	O
at	O
50	O
°	O
C	O
for	O
6	O
h.	O
The	O
work	O
-	O
up	O
procedure	O
was	O
the	O
same	O
as	O
that	O
described	O
for	O
compound	B
2	I
.	O

The	O
crude	O
product	O
was	O
purified	O
by	O
coloumn	O
chromatography	O
to	O
give	O
8	B
(	O
280	O
mg	O
,	O
24.7	O
%	O
)	O
,	O
9	B
(	O
190	O
mg	O
,	O
24.8	O
%	O
)	O
and	O
11	B
(	O
40	O
mg	O
,	O
5.3	O
%	O
)	O
.	O

Compound	B
8	I
:	O
[	O
α	O
]	O
D	O
22	O
+	O
2.7	O
°	O
(	O
c	O
1.0	O
,	O
CHCl3	B
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C73	O
H74	O
O25	O
(	O
1351.36	O
)	O
:	O
C	O
,	O
64.88	O
;	O
H	O
,	O
5.51	O
.	O

Found	O
:	O
C	O
,	O
64.57	O
;	O
H	O
,	O
5.53	O
.	O

Compound	B
9	I
:	O
[	O
α	O
]	O
D	O
22	O
−15.5	O
°	O
(	O
c	O
1.0	O
,	O
CHCl3	B
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C47	O
H54	O
O18	O
(	O
906.94	O
)	O
:	O
C	O
,	O
62.24	O
;	O
H	O
,	O
6.00	O
.	O

Found	O
:	O
C	O
,	O
62.44	O
;	O
H	O
,	O
6.04	O
.	O

Compound	B
11	I
:	O
[	O
α	O
]	O
D	O
22	O
−3.17	O
°	O
(	O
c	O
0.82	O
,	O
CHCl3	B
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C47	O
H54	O
O18	O
(	O
906.94	O
)	O
:	O
C	O
,	O
62.24	O
;	O
H	O
,	O
6.00	O
.	O

Found	O
:	O
C	O
,	O
62.11	O
;	O
H	O
,	O
5.97	O
.	O

3.7	O
2,3,5-Tri	B
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→6	I
)	I
-2-O	I
-	I
acetyl-3,4-O	I
-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
10	B
)	O
To	O
a	O
solution	O
of	O
9	B
(	O
50	O
mg	O
)	O
in	O
pyridine	B
(	O
1	O
mL	O
)	O
was	O
treated	O
with	O
acetic	B
anhydride	I
(	O
1	O
mL	O
)	O
.	O

The	O
solution	O
was	O
evaporated	O
with	O
toluene	B
to	O
yield	O
10	B
,	O
which	O
was	O
used	O
for	O
NMR	O
measurements	O
only	O
.	O

3.8	O
2,3,5-Tri	B
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→2	I
)	I
-3,4-O	I
-	I
isopropylidene-6-O-	I
(	I
methoxydimethyl	I
)	I
methyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
12	B
)	O
and	O
2-propanone	B
bis-	I
[	I
2,3,5-tri	I
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→2	I
)	I
-3,4-O	I
-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
]	I
-6,6	I
acetale	I
(	O
13	B
)	O
Powdered	O
4	B
Å	I
molecular	I
sieves	I
(	O
1.2	O
g	O
)	O
were	O
added	O
to	O
a	O
solution	O
of	O
4	B
(	O
534	O
mg	O
,	O
1.0	O
mmol	O
)	O
and	O
7	O
[	O
20	O
]	O
(	O
630	O
mg	O
,	O
1.2	O
mmol	O
)	O
in	O
dry	O
CH2	O
Cl2	O
(	O
20	O
mL	O
)	O
,	O
and	O
the	O
mixture	O
was	O
stirred	O
in	O
dark	O
.	O

After	O
2	O
h	O
,	O
the	O
reaction	O
mixture	O
was	O
cooled	O
to	O
−25	O
°	O
C	O
,	O
sym	B
-collidine	I
(	O
0.29	O
mL	O
,	O
2	O
equiv	O
)	O
,	O
and	O
silver	B
triflate	I
(	O
514	O
mg	O
,	O
2	O
equiv	O
)	O
in	O
dry	O
toluene	B
(	O
4	O
mL	O
)	O
were	O
added	O
.	O

After	O
2	O
h	O
,	O
the	O
TLC	O
showed	O
complete	O
conversion	O
and	O
formation	O
of	O
two	O
products	O
,	O
Et3	B
N	I
(	O
1	O
mL	O
)	O
was	O
added	O
,	O
the	O
mixture	O
was	O
diluted	O
with	O
CH2	B
Cl2	I
and	O
filtered	O
through	O
a	O
pad	O
of	O
Celite	B
.	O

The	O
filtrate	O
was	O
washed	O
with	O
aq	O
10	O
%	O
Na2	B
S2	I
O3	I
and	O
water	B
,	O
dried	O
and	O
evaporated	O
.	O

The	O
products	O
were	O
separated	O
by	O
column	O
chromatography	O
(	O
23:2	O
CH2	B
Cl2	I
–acetone	O
,	O
+	O
1	O
%	O
Et3	B
N	I
)	O
to	O
give	O
12	B
(	O
280	O
mg	O
,	O
28.6	O
%	O
)	O
and	O
13	B
(	O
430	O
mg	O
,	O
23.1	O
%	O
)	O
.	O

Compound	B
12	I
:	O
[	O
α	O
]	O
D	O
22	O
−13.4	O
°	O
(	O
c	O
0.48	O
,	O
CHCl3	B
)	O
;	O
R	O
f	O
0.45	O
(	O
in	O
the	O
chromatographic	O
eluent	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C51	O
H62	O
O19	O
(	O
979.0	O
)	O
:	O
C	O
,	O
62.56	O
;	O
H	O
,	O
6.38	O
.	O

Found	O
:	O
C	O
,	O
62.81	O
;	O
H	O
6.33	O
.	O

Compound	B
13	I
:	O
[	O
α	O
]	O
D	O
22	O
−8.9	O
°	O
(	O
c	O
0.76	O
,	O
CHCl3	B
)	O
;	O
R	O
f	O
0.40	O
;	O
MALDI	O
-	O
TOF	O
MS	O
:	O
m	O
/z	O
[	O
M+Na	O
]	O
+	O
1876.9	O
;	O
Anal	O
.	O

Calcd	O
for	O
C97	O
H112	O
O36	O
(	O
1853.9	O
)	O
:	O
C	O
,	O
62.84	O
;	O
H	O
,	O
6.08	O
.	O

Found	O
:	O
C	O
,	O
63.11	O
;	O
H	O
,	O
6.07	O
.	O

3.9	O
2-O	B
-	I
Benzyl-3,4-O	I
-	I
isopropylidene-6-O-	I
(	I
methoxydimethyl	I
)	I
methyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
14	B
)	O
To	O
a	O
stirred	O
solution	O
of	O
4	B
(	O
10.0	O
g	O
,	O
0.018	O
mol	O
)	O
in	O
dry	O
N	B
,	I
N	I
-dimethyl	I
formamide	I
(	O
15	O
mL	O
)	O
80	O
%	O
NaH	B
(	O
672	O
mg	O
,	O
0.022	O
mol	O
)	O
was	O
added	O
at	O
0	O
°	O
C	O
.	O

After	O
30	O
min	O
benzyl	B
bromide	I
(	O
2.4	O
mL	O
,	O
0.220	O
mol	O
)	O
was	O
added	O
dropwise	O
,	O
and	O
the	O
mixture	O
was	O
stirred	O
for	O
3	O
h.	O
The	O
mixture	O
was	O
diluted	O
with	O
400	O
mL	O
of	O
CH2	B
Cl2	I
,	O
washed	O
with	O
water	O
until	O
neutral	O
,	O
dried	O
and	O
evaporated	O
.	O

The	O
crude	O
product	O
was	O
purified	O
by	O
column	O
chromatography	O
(	O
24:1	O
CH2	B
Cl2	I
–acetone	O
)	O
to	O
yield	O
14	B
(	O
8.2	O
g	O
,	O
70.1	O
%	O
)	O
;	O
mp	O
116–117	O
°	O
C	O
(	O
MeOH	B
)	O
;	O
[	O
α	O
]	O
D	O
22	O
−7.09	O
°	O
(	O
c	O
1.0	O
,	O
CHCl3	B
)	O
;	O
1	O
H	O
NMR	O
(	O
360	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
7.53–7.28	O
(	O
m	O
,	O
5	O
H	O
,	O
Ph	O
)	O
,	O
5.63	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1	O
,	O
J	O
1,2	O
5	O
Hz	O
)	O
,	O
4.93	O
(	O
dd	O
,	O
2	O
H	O
,	O
CH2	O
-Ph	O
,	O
J	O
gem	O
12	O
Hz	O
)	O
,	O
4.67	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-3	O
,	O
J	O
2,3	O
8	O
Hz	O
,	O
J	O
3,4	O
2.1	O
Hz	O
)	O
,	O
4.44	O
(	O
d	O
,	O
1	O
H	O
,	O
H-1′	O
,	O
J	O
1′,2′	O
8	O
Hz	O
)	O
,	O
4.38	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2	O
)	O
,	O
4.32	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-4	O
,	O
J	O
4,5	O
1.7	O
Hz	O
)	O
,	O
4.21–4.10	O
(	O
m	O
,	O
4	O
H	O
,	O
H-3′	O
,	O
H-4′	O
,	O
H-5	O
,	O
H-6	O
)	O
,	O
3.86	O
(	O
dt	O
,	O
1	O
H	O
,	O
H-5′	O
,	O
J	O
4′,5′	O
2	O
Hz	O
,	O
J	O
5′,6a′	O
=	O
J	O
5′,6b′	O
6	O
Hz	O
)	O
,	O
3.77	O
(	O
m	O
,	O
3	O
H	O
,	O
H-6	O
,	O
H-6′ab	O
)	O
,	O
3.43	O
(	O
dd	O
,	O
1	O
H	O
,	O
H-2′	O
,	O
J	O
2′,3′	O
6	O
Hz	O
)	O
,	O
3.28	O
(	O
s	O
,	O
3	O
H	O
,	O
OCH3	O
)	O
,	O
1.61–1.32	O
(	O
4	O
s	O
,	O
each	O
3	O
H	O
,	O
4	O
CH3ip	O
.	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C32	O
H48	O
O12	O
(	O
624,73	O
)	O
:	O
C	O
,	O
61.52	O
;	O
H	O
,	O
7.74	O
.	O

Found	O
:	O
C	O
,	O
61.37	O
;	O
H	O
,	O
7.72	O
.	O

3.10	O
2-O	B
-	I
Benzyl-3,4-O	I
-	I
isopropylidene	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2:3,4-di	I
-	I
O	I
-	I
isopropylidene	I
-	I
α	I
-	I
d	I
-galactopyranose	I
(	O
15	B
)	O
To	O
a	O
solution	O
of	O
14	B
(	O
3.0	O
g	O
,	O
4.8	O
mmol	O
)	O
in	O
50	O
mL	O
of	O
CH2	B
Cl2	I
,	O
2	O
mL	O
of	O
96	O
%	O
acetic	B
acid	I
and	O
two	O
drops	O
of	O
water	B
were	O
added	O
,	O
and	O
the	O
solution	O
was	O
heated	O
at	O
reflux	O
temperature	O
for	O
3	O
h.	O
The	O
mixture	O
was	O
diluted	O
with	O
CH2	B
Cl2	I
,	O
washed	O
with	O
aq	O
NaHCO3	B
and	O
water	B
,	O
dried	O
and	O
evaporated	O
.	O

The	O
solid	O
residue	O
(	O
2.7	O
g	O
)	O
was	O
crystallized	O
from	O
c	B
-hexane	I
to	O
yield	O
15	B
(	O
2.4	O
g	O
,	O
90.1	O
%	O
)	O
;	O
mp	O
128–129	O
°	O
C	O
;	O
R	O
f	O
0.45	O
(	O
17:3	O
CH2	B
Cl2	I
–acetone	O
)	O
;	O
[	O
α	O
]	O
D	O
22	O
−2.6	O
°	O
(	O
c	O
1.3	O
,	O
CHCl3	B
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C28	O
H40	O
O11	O
(	O
552.62	O
)	O
:	O
C	O
,	O
60.85	O
;	O
H	O
,	O
7.29	O
.	O

Found	O
:	O
C	O
,	O
61.01	O
;	O
H	O
,	O
7.27	O
.	O

3.11	O
3,4,6-Tri	B
-	I
O	I
-	I
acetyl-2-O	I
-	I
benzyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2,3,4-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
α	I
,	I
β	I
-	I
d	I
-galactopyranose	I
(	O
17	B
)	O
To	O
a	O
stirred	O
solution	O
of	O
14	B
(	O
300	O
mg	O
,	O
0.48	O
mmol	O
)	O
in	O
30	O
mL	O
of	O
CH2	B
Cl2	I
,	O
3	O
mL	O
of	O
trifluoroacetic	B
acid	I
and	O
one	O
drop	O
of	O
water	B
were	O
added	O
.	O

After	O
16	O
h	O
triethylamine	B
was	O
added	O
,	O
and	O
the	O
mixture	O
was	O
evaporated	O
to	O
give	O
16	B
(	O
R	O
f	O
0.53	O
,	O
8:5:1	O
CH2	B
Cl2	I
–acetone	O
–	O
water	B
)	O
which	O
was	O
acetylated	O
without	O
purification	O
in	O
a	O
mixture	O
of	O
5	O
mL	O
of	O
pyridine	B
and	O
5	O
mL	O
of	O
acetic	B
anhydride	I
to	O
give	O
17	B
.	O

The	O
crude	O
product	O
was	O
purified	O
by	O
column	O
chromatography	O
(	O
93:7	O
CH2	B
Cl2	I
–acetone	O
,	O
R	O
f	O
0.40	O
)	O
to	O
yield	O
17	O
(	O
230	O
mg	O
,	O
74.5	O
%	O
for	O
two	O
steps	O
)	O
;	O
[	O
α	O
]	O
D	O
22	O
+	O
25.2	O
°	O
(	O
c	O
1.0	O
,	O
CHCl3	B
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C26	O
H42	O
O18	O
(	O
642.61	O
)	O
:	O
C	O
,	O
48.59	O
;	O
H	O
,	O
6.58	O
.	O

Found	O
:	O
C	O
,	O
48.81	O
;	O
H	O
,	O
6.61	O
.	O

3.12	O
3,4,6-Tri	B
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2,3,4-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
α	I
,	I
β	I
-	I
d	I
-galactopyranose	I
(	O
18	B
)	O
Palladium	B
on	O
activated	O
carbon	B
(	O
30	O
mg	O
)	O
was	O
added	O
to	O
a	O
solution	O
of	O
17	B
(	O
300	O
mg	O
)	O
in	O
ethyl	B
acetate	I
(	O
3	O
mL	O
)	O
and	O
the	O
mixture	O
was	O
stirred	O
under	O
H2	B
.	O

After	O
4	O
h	O
the	O
mixture	O
was	O
diluted	O
with	O
ethyl	B
acetate	I
,	O
filtered	O
through	O
a	O
layer	O
of	O
Celite	B
,	O
and	O
evaporated	O
to	O
yield	O
18	B
(	O
260	O
mg	O
)	O
,	O
which	O
was	O
used	O
for	O
further	O
conversion	O
without	O
purification	O
.	O

3.13	O
2,3,5-Tri	B
-	I
O	I
-	I
benzoyl	I
-	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→2	I
)	I
-3,4,6-tri	I
-	I
O	I
-	I
acetyl	I
-	I
β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-1,2,3,4-tetra	I
-	I
O	I
-	I
acetyl	I
-	I
α	I
,	I
β	I
-	I
d	I
-galactopyranose	I
(	O
19	B
)	O
A	O
mixture	O
of	O
18	B
(	O
130	O
mg	O
,	O
0.200	O
mmol	O
)	O
,	O
powdered	O
Hg	B
(	I
CN	I
)	I
2	I
(	O
110	O
mg	O
,	O
2.2	O
equivalents	O
)	O
,	O
and	O
4	B
Å	I
molecular	I
sieves	I
(	O
500	O
mg	O
)	O
in	O
dry	O
CH3	B
CN	I
(	O
3	O
mL	O
)	O
was	O
stirred	O
for	O
30	O
min	O
.	O
,	O
compound	O
7	B
(	O
200	O
mg	O
,	O
0.380	O
mmol	O
)	O
in	O
1	O
mL	O
of	O
dry	O
CH3	B
CN	I
was	O
added	O
and	O
the	O
mixture	O
was	O
stirred	O
overnight	O
.	O

The	O
work	O
-	O
up	O
procedure	O
was	O
the	O
same	O
as	O
that	O
described	O
for	O
compound	B
2	I
.	O

The	O
residue	O
was	O
purified	O
by	O
column	O
chromatography	O
(	O
93:7	O
CH2	B
Cl2	I
–acetone	O
,	O
R	O
f	O
0.55	O
)	O
to	O
yield	O
19	B
(	O
152	O
mg	O
,	O
70.1	O
%	O
)	O
,	O
which	O
was	O
characterized	O
after	O
deprotection	O
.	O

3.14	O
α	B
-	I
l	I
-Arabinofuranosyl-	I
(	I
1→2	I
)	I
-	I
[	I
α	I
-	I
l	I
-arabinofuranosyl-	I
(	I
1→6	I
)	I
]	I
-β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-d	I
-galactose	I
(	O
20	B
)	O
To	O
a	O
solution	O
of	O
8	B
(	O
370	O
mg	O
,	O
0.270	O
mmol	O
)	O
in	O
dry	O
MeOH	B
(	O
10	O
mL	O
)	O
a	O
catalytic	O
amount	O
of	O
NaOMe	B
was	O
added	O
and	O
was	O
stirred	O
overnight	O
.	O

The	O
solution	O
was	O
neutralized	O
with	O
Amberlite	B
IR-120	I
H+	I
ion	I
-	I
exchange	I
resin	I
,	O
filtered	O
and	O
evaporated	O
.	O

The	O
residue	O
was	O
treated	O
with	O
aq	O
90	O
%	O
trifluoroacetic	B
acid	I
for	O
15	O
min	O
,	O
the	O
product	O
was	O
precipitated	O
by	O
addition	O
of	O
diethyl	B
ether	I
,	O
filtered	O
,	O
and	O
washed	O
twice	O
with	O
diethyl	B
ether	I
to	O
yield	O
20	B
(	O
120	O
mg	O
,	O
73.3	O
%	O
for	O
two	O
steps	O
)	O
;	O
[	O
α	O
]	O
D	O
22	O
−26.38	O
(	O
c	O
0.29	O
,	O
H2	O
O	O
)	O
;	O
13	O
C	O
NMR	O
(	O
90	O
MHz	O
)	O
δ	O
108.79	O
(	O
C-1″1″→2″	O
)	O
,	O
108.49	O
(	O
C-1″1″→6″	O
)	O
,	O
103.75	O
,	O
102.53	O
(	O
C-1′	O
)	O
,	O
97.32	O
,	O
96.96	O
(	O
C-1β	O
)	O
,	O
93.13	O
,	O
92.93	O
(	O
C-1α	O
)	O
,	O
70.06	O
(	O
C-6α	O
)	O
,	O
69.95	O
(	O
C-6β	O
)	O
,	O
67.87	O
(	O
C-6′	O
)	O
,	O
61.95	O
,	O
61.75	O
(	O
2	O
×	O
C-5″	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C22	O
H38	O
O19	O
(	O
606.52	O
)	O
:	O
C	O
,	O
43.56	O
;	O
H	O
,	O
6.31	O
.	O

Found	O
:	O
C	O
,	O
43.81	O
;	O
H	O
,	O
6.33	O
.	O

3.15	O
α	B
-	I
l	I
-Arabinofuranosyl-	I
(	I
1→6	I
)	I
-β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-d	I
-galactose	I
(	O
21	B
)	O
Compound	B
21	I
was	O
prepared	O
from	O
9	B
by	O
the	O
same	O
method	O
as	O
described	O
for	O
20	B
.	O

Compound	B
21	I
:	O
[	O
α	O
]	O
D	O
22	O
−13.6	O
(	O
c	O
0.35	O
,	O
H2	B
O	I
)	O
;	O
13	O
C	O
NMR	O
(	O
90	O
MHz	O
)	O
δ	O
108.54	O
(	O
C-1″	O
)	O
,	O
103.80	O
(	O
C-1′	O
)	O
,	O
97.05	O
(	O
C-1β	O
)	O
,	O
92.96	O
(	O
C-1α	O
)	O
,	O
84.45	O
(	O
C-4″	O
)	O
,	O
81.63	O
(	O
C-2	O
)	O
,	O
77.03	O
(	O
C-3″	O
)	O
,	O
74.45	O
(	O
C-5β	O
,	O
C-5′	O
)	O
,	O
73.17	O
(	O
C-3β	O
,	O
C-3′	O
)	O
,	O
72.40	O
(	O
C-2′	O
)	O
,	O
71.31	O
(	O
C-2β	O
)	O
,	O
70.13	O
(	O
C-6α	O
)	O
,	O
70.11	O
(	O
C-4α	O
)	O
,	O
69.86	O
(	O
C-6β	O
,	O
C-3α	O
,	O
C-5α	O
)	O
,	O
69.38	O
(	O
C-4β	O
,	O
C-4′	O
)	O
,	O
68.89	O
(	O
C-2α	O
)	O
,	O
67.99	O
(	O
C-6′	O
)	O
,	O
61.94	O
(	O
C-5″	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C17	O
H30	O
O15	O
(	O
474.42	O
)	O
:	O
C	O
,	O
43.03	O
;	O
H	O
,	O
6.37	O
.	O

Found	O
:	O
C	O
,	O
43.31	O
;	O
H	O
,	O
6.36	O
.	O

3.16	O
α	B
-	I
l	I
-Arabinofuranosyl-	I
(	I
1→2	I
)	I
-β	I
-	I
d	I
-galactopyranosyl-	I
(	I
1→6	I
)	I
-d	I
-galactose	I
(	O
22	B
)	O
To	O
a	O
solution	O
of	O
19	O
(	O
90	O
mg	O
,	O
0.083	O
mmol	O
)	O
in	O
dry	O
MeOH	B
(	O
5	O
mL	O
)	O
NaOMe	B
was	O
added	O
and	O
the	O
solution	O
was	O
stirred	O
overnight	O
.	O

The	O
solution	O
was	O
neutralized	O
with	O
Amberlite	B
IR-120	I
H+	I
ion	I
-	I
exchange	I
resin	I
,	O
filtered	O
and	O
evaporated	O
to	O
give	O
22	B
(	O
36	O
mg	O
,	O
91.4	O
%	O
)	O
.	O

Compound	B
22	I
was	O
also	O
prepared	O
starting	O
from	O
11	B
and	O
from	O
13	B
,	O
respectively	O
,	O
by	O
the	O
same	O
method	O
as	O
described	O
for	O
20	B
.	O

Compound	B
22	I
:	O
[	O
α	O
]	O
D	O
22	O
−17.5	O
(	O
c	O
0.16	O
,	O
H2	O
O	O
)	O
;	O
13	O
C	O
NMR	O
(	O
90	O
MHz	O
)	O
:	O
δ	O
108.81	O
(	O
C-1″	O
)	O
,	O
102.51	O
(	O
C-1′	O
)	O
,	O
97.00	O
(	O
C-1β	O
)	O
,	O
92.96	O
(	O
C-1α	O
)	O
,	O
84.80	O
(	O
C-4″	O
)	O
,	O
81.49	O
(	O
C-2″	O
)	O
,	O
77.44	O
(	O
C-3″	O
)	O
,	O
76.57	O
(	O
C-2′	O
)	O
,	O
75.66	O
(	O
C-5′	O
)	O
,	O
74.28	O
(	O
C-5β	O
)	O
,	O
73.50	O
(	O
C-3β	O
)	O
,	O
73.21	O
(	O
C-2β	O
)	O
,	O
72.37	O
(	O
C-3′	O
)	O
,	O
69.94	O
(	O
C-4α	O
)	O
,	O
69.87	O
(	O
C-6α	O
)	O
,	O
69.86	O
(	O
C-3α	O
)	O
,	O
69.74	O
(	O
C-5α	O
)	O
,	O
69.59	O
(	O
C-6β	O
)	O
,	O
69.39	O
(	O
C-4β	O
,	O
C-4′	O
)	O
,	O
68.86	O
(	O
C-2α	O
)	O
,	O
61.94	O
(	O
C-5″	O
)	O
,	O
61.48	O
(	O
C-6′	O
)	O
.	O

Anal	O
.	O

Calcd	O
for	O
C17	O
H30	O
O15	O
(	O
474.42	O
)	O
:	O
C	O
,	O
43.03	O
;	O
H	O
,	O
6.37	O
.	O

Found	O
:	O
C	O
,	O
43.37	O
;	O
H	O
,	O
6.40	O
.	O

Acknowledgements	O
This	O
research	O
was	O
supported	O
by	O
the	O
Hungarian	O
Scientific	O
Research	O
Fund	O
(	O
OTKA	O
T025244	O
)	O
.	O

It	O
has	O
become	O
increasingly	O
evident	O
from	O
epidemiologic	O
as	O
well	O
as	O
laboratory	O
studies	O
that	O
a	O
vast	O
variety	O
of	O
dietary	O
or	O
medicinal	O
phytochemicals	B
have	O
substantial	O
chemopreventive	O
properties	O
[	O
1–3	O
]	O
.	O

Curcumin	B
,	O
a	O
yellow	O
colouring	O
ingredient	O
present	O
in	O
turmeric	O
(	O
Curcuma	O
longa	O
Linn	O
,	O
Zingiberaceae	O
)	O
,	O
has	O
been	O
shown	O
to	O
exert	O
anti	O
-	O
carcinogenic	O
or	O
anti	O
-	O
mutagenic	O
effects	O
in	O
diverse	O
animal	O
models	O
and	O
also	O
in	O
cultured	O
cells	O
[	O
4–10	O
]	O
.	O

One	O
of	O
the	O
biochemical	O
mechanisms	O
of	O
cancer	O
chemopreventive	O
activities	O
of	O
curcumin	B
has	O
been	O
attributed	O
to	O
its	O
inhibition	O
of	O
tumor	O
promotion	O
(	O
reviewed	O
in	O
Ref	O
.	O

[	O
6	O
]	O
and	O
references	O
therein	O
)	O
.	O

Alpinia	O
oxyphylla	O
Miquel	O
that	O
also	O
belongs	O
to	O
the	O
ginger	O
family	O
(	O
Zingiberaceae	O
)	O
has	O
been	O
used	O
in	O
Oriental	O
herbal	O
medicine	O
.	O

Yakuchinone	B
A	I
(	O
1-	B
[	I
4′-hydroxy-3′-methoxyphenyl	I
]	I
-7-phenyl-3-heptanone	I
)	O
and	O
yakuchinone	B
B	I
(	O
1-	B
[	I
4′-hydroxy-3′-methoxyphenyl	I
]	I
-7-phenylhept-1-en-3-one	I
)	O
which	O
are	O
present	O
in	O
A.	O
oxyphylla	O
have	O
been	O
reported	O
to	O
be	O
strong	O
inhibitors	O
of	O
prostaglandin	B
biosynthesis	O
in	O
vitro	O
.	O

Like	O
curcumin	B
,	O
these	O
substances	O
have	O
a	O
diarylheptanoid	B
moiety	I
with	O
a	O
carbonyl	B
functional	O
group	B
(	O
see	O
structures	O
in	O
Fig.	O
1	O
)	O
and	O
are	O
hence	O
anticipated	O
to	O
exhibit	O
the	O
cancer	O
chemopreventive	O
activity	O
.	O

Since	O
tumor	O
promotion	O
is	O
closely	O
linked	O
to	O
inflammation	O
and	O
oxidative	O
stress	O
[	O
11	O
,	O
12	O
]	O
,	O
it	O
is	O
likely	O
that	O
compounds	O
with	O
strong	O
anti	O
-	O
oxidative	O
and	O
anti	O
-	O
inflammatory	O
activities	O
can	O
act	O
as	O
anti	O
-	O
tumor	O
promoters	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
evaluated	O
an	O
anti	O
-	O
tumor	O
promoting	O
potential	O
of	O
aforementioned	O
diarylheptanoids	B
derived	O
from	O
A.	O
oxyphylla	O
in	O
terms	O
of	O
their	O
capability	O
to	O
suppress	O
papilloma	O
formation	O
and	O
epidermal	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
activity	O
induced	O
by	O
the	O
tumor	O
promoter	O
,	O
12-O	B
-tetradecanoylphorbol-13-acetate	I
(	O
TPA	B
)	O
in	O
mouse	O
skin	O
.	O

Their	O
effects	O
on	O
TPA	B
-	O
stimulated	O
superoxide	B
generation	O
and	O
tumor	O
necrosis	O
factor	O
-	O
α	O
production	O
in	O
human	O
promyelocytic	O
leukemia	O
(	O
HL-60	O
)	O
cells	O
and	O
on	O
DNA	O
binding	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
in	O
NIH3T3	O
cells	O
were	O
also	O
examined	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
TPA	B
was	O
a	O
product	O
of	O
Alex	O
Biochemicals	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Thiobarbituric	B
acid	I
(	O
TBA	B
)	O
,	O
cytochrome	O
c	O
,	O
sodium	B
ascorbate	I
and	O
l	B
-ornithine	I
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

dl	B
-	I
[	I
1−14	I
C	I
]	I
Ornithine	I
was	O
a	O
product	O
of	O
Dupont	O
/	O
NEN	O
Research	O
Products	O
(	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
.	O

RPMI	O
1640	O
and	O
fetal	O
bovine	O
serum	O
were	O
obtained	O
from	O
Gibco	O
BRL	O
(	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Other	O
chemicals	O
and	O
solvents	O
used	O
were	O
of	O
highest	O
analytical	O
grade	O
.	O

Human	O
promyelocytic	O
leukemia	O
(	O
HL-60	O
)	O
and	O
NIH3T3	O
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

2.2	O
ODC	O
assay	O
The	O
ODC	O
activity	O
in	O
epidermal	O
soluble	O
fraction	O
was	O
assessed	O
by	O
measuring	O
the	O
release	O
of	O
14	B
CO	I
2	I
from	O
dl	B
-	I
[	I
1−14	I
C	I
]	I
ornithine	I
(	O
40–60	O
mCi	O
/	O
mmol	O
)	O
as	O
reported	O
previously	O
[	O
13	O
]	O
.	O

The	O
protein	O
concentration	O
was	O
determined	O
by	O
the	O
Bradford	O
method	O
[	O
14	O
]	O
using	O
bovine	O
serum	O
albumin	O
as	O
a	O
standard	O
.	O

2.3	O
ELISA	O
assay	O
for	O
TNF	O
-	O
α	O
production	O
in	O
HL-60	O
cells	O
The	O
exponentially	O
growing	O
HL-60	O
cells	O
(	O
2.5	O
×	O
105	O
cells	O
/	O
ml	O
)	O
maintained	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
fetal	O
bovine	O
serum	O
were	O
exposed	O
to	O
either	O
yakuchinone	B
A	I
or	O
yakuchinone	B
B	I
in	O
the	O
presence	O
of	O
3	O
nM	O
TPA	B
at	O
37	O
°	O
C	O
for	O
16	O
h.	O
The	O
cells	O
were	O
collected	O
by	O
centrifugation	O
(	O
2000	O
rpm	O
for	O
10	O
min	O
)	O
and	O
the	O
amount	O
of	O
TNF	O
-	O
α	O
in	O
supernatant	O
was	O
measured	O
by	O
use	O
of	O
a	O
human	O
TNF	O
-	O
α	O
ELISA	O
kit	O
from	O
Amersham	O
Life	O
Science	O
(	O
Buckinghamshire	O
,	O
UK	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instruction	O
.	O

2.4	O
Measurement	O
of	O
superoxide	B
generation	O
in	O
differentiated	O
HL-60	O
cells	O
HL-60	O
cells	O
were	O
maintained	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
bovine	O
serum	O
and	O
5	O
μg	O
/	O
ml	O
gentamicin	B
as	O
described	O
previously	O
[	O
15	O
]	O
.	O

The	O
cells	O
were	O
suspended	O
at	O
a	O
density	O
of	O
5	O
×	O
105	O
cells	O
/	O
ml	O
in	O
RPMI	O
medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
1.3	O
%	O
DMSO	B
and	O
incubated	O
for	O
6	O
days	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
atmosphere	O
of	O
5	O
%	O
CO2	B
.	O

Cells	O
were	O
harvested	O
by	O
centrifugation	O
,	O
washed	O
with	O
and	O
resuspended	O
in	O
phosphate	B
-	I
buffered	I
saline	I
(	O
1	O
×	O
106	O
cells	O
/	O
ml	O
)	O
.	O

Cells	O
were	O
preincubated	O
for	O
10	O
min	O
with	O
and	O
without	O
a	O
test	O
compound	O
,	O
and	O
TPA	B
(	O
8	O
μM	O
)	O
and	O
cytochrome	O
c	O
(	O
60	O
μM	O
)	O
were	O
added	O
to	O
the	O
reaction	O
mixture	O
.	O

After	O
30	O
min	O
incubation	O
at	O
37	O
°	O
C	O
,	O
absorbance	O
at	O
550	O
nm	O
was	O
read	O
.	O

2.5	O
Lipid	B
peroxidation	O
in	O
rat	O
brain	O
homogenates	O
Brain	O
homogenates	O
from	O
young	O
adult	O
male	O
Sprague	O
–	O
Dawley	O
rats	O
were	O
prepared	O
in	O
0.15	O
M	O
KCl	B
(	O
10	O
%	O
,	O
w	O
/	O
v	O
)	O
and	O
centrifuged	O
at	O
800	O
×	O
g	O
for	O
10	O
min	O
,	O
and	O
the	O
supernatant	O
was	O
used	O
for	O
in	O
vitro	O
lipid	O
peroxidation	O
assays	O
.	O

The	O
incubation	O
mixture	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
contained	O
brain	O
homogenate	O
(	O
0.5	O
ml	O
)	O
,	O
0.15	O
M	O
KCl	B
,	O
and	O
varying	O
amounts	O
of	O
test	O
compounds	O
.	O

Lipid	B
peroxidation	O
was	O
initiated	O
by	O
addition	O
of	O
ferric	B
chloride	I
(	O
100	O
μM	O
)	O
alone	O
or	O
in	O
combination	O
with	O
ascorbic	B
acid	I
(	O
100	O
μM	O
)	O
.	O

After	O
incubation	O
for	O
20	O
min	O
at	O
37	O
°	O
C	O
,	O
the	O
reaction	O
was	O
terminated	O
by	O
addition	O
of	O
0.5	O
ml	O
cold	O
trichloroacetic	B
acid	I
(	O
5.5	O
%	O
)	O
and	O
the	O
equal	O
volume	O
of	O
TBA	B
(	O
2	O
%	O
in	O
0.05	O
M	O
NaOH	B
)	O
followed	O
by	O
heating	O
at	O
100	O
°	O
C	O
for	O
10	O
min	O
.	O

The	O
mixtures	O
were	O
then	O
centrifuged	O
at	O
1000	O
×	O
g	O
for	O
10	O
min	O
and	O
the	O
absorbance	O
of	O
the	O
supernatant	O
was	O
measured	O
at	O
532	O
nm	O
.	O

2.6	O
Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
for	O
determining	O
AP-1	O
activation	O
NIH	O
3T3	O
cells	O
were	O
maintained	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
bovine	O
serum	O
and	O
penicillin	B
(	O
100	O
unit	O
/	O
l	O
)	O
and	O
streptomycin	B
(	O
100	O
μg	O
/	O
l	O
)	O
in	O
a	O
humidified	O
atmosphere	O
of	O
5	O
%	O
CO2	B
–95	O
%	O
air	O
.	O

Nuclear	O
proteins	O
were	O
isolated	O
according	O
to	O
the	O
method	O
of	O
Dignam	O
et	O
al.	O
[	O
16	O
]	O
.	O

In	O
brief	O
,	O
cells	O
were	O
lysed	O
with	O
ice	B
-	O
cold	O
buffer	O
A	O
(	O
10	O
mM	O
HEPES	B
,	O
pH	O
7.9	O
;	O
10	O
mM	O
KCl	B
;	O
0.1	O
mM	O
EDTA	B
;	O
1	O
mM	O
dithiothreitol	B
;	O
0.6	O
%	O
NP-40	B
)	O
containing	O
protease	O
inhibitor	O
cocktail	O
(	O
Boeringer	O
Mannheim	O
,	O
Mannheim	O
,	O
Germany	O
)	O
and	O
centrifuged	O
.	O

The	O
supernatant	O
was	O
removed	O
and	O
the	O
pellets	O
were	O
resuspended	O
in	O
buffer	O
C	O
(	O
20	O
mM	O
HEPES	B
,	O
pH	O
7.9	O
;	O
0.4	O
M	O
NaCl	B
;	O
1	O
mM	O
EDTA	B
;	O
1	O
mM	O
dithiothreitol	B
)	O
containing	O
protease	O
inhibitor	O
cocktail	O
and	O
incubated	O
on	O
ice	B
for	O
1	O
h.	O
After	O
centrifugation	O
,	O
the	O
supernatant	O
was	O
harvested	O
and	O
used	O
as	O
nuclear	O
extracts	O
.	O

The	O
protein	O
concentrations	O
of	O
nuclear	O
extracts	O
were	O
measured	O
by	O
the	O
Bradford	O
method	O
[	O
14	O
]	O
.	O

The	O
AP-1	O
oligonucleotide	B
probe	O
was	O
prepared	O
by	O
labeling	O
a	O
double	O
-	O
strand	O
oligonucleotide	B
(	O
5′-CGC	B
TTG	I
ATG	I
ACT	I
CA	I
G	I
CCG	I
GAA-3′	I
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
containing	O
AP-1	O
binding	O
sites	O
(	O
underlined	O
)	O
with	O
[	B
α−32	I
P	I
]	I
CTP	I
and	O
Klenow	O
enzyme	O
.	O

Five	O
micrograms	O
of	O
nuclear	O
proteins	B
were	O
incubated	O
with	O
equal	O
amounts	O
of	O
the	O
probe	O
in	O
the	O
presence	O
of	O
1	O
μg	O
of	O
poly	B
(	I
dI	I
–	I
dC	I
)	I
(	O
Pharmacia	O
,	O
Piscataway	O
,	O
NJ	O
,	O
USA	O
)	O
at	O
room	O
temperature	O
for	O
15	O
min	O
and	O
the	O
mixtures	O
were	O
loaded	O
onto	O
a	O
6	O
%	O
polyacrylamide	B
gel	O
at	O
80	O
V	O
in	O
0.5	O
×	O
TBE	B
buffer	O
.	O

The	O
gel	O
was	O
dried	O
,	O
autoradiographed	O
and	O
exposed	O
to	O
an	O
X	O
-	O
ray	O
film	O
at	O
−75	O
°	O
C	O
.	O

3	O
Results	O
and	O
discussion	O
Results	O
of	O
our	O
previous	O
study	O
revealed	O
that	O
topical	O
application	O
of	O
the	O
methanol	B
extract	O
of	O
A.	O
oxyphylla	O
to	O
the	O
dorsal	O
epidermis	O
of	O
mice	O
during	O
the	O
process	O
of	O
tumor	O
promotion	O
markedly	O
suppressed	O
the	O
papilloma	O
formation	O
[	O
15	O
]	O
.	O

The	O
extract	O
also	O
attenuated	O
the	O
mouse	O
ear	O
edema	O
induced	O
by	O
the	O
tumor	O
promoter	O
,	O
TPA	B
[	O
15	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
found	O
that	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
,	O
major	O
pungent	O
ingredients	O
derived	O
from	O
A.	O
oxyphylla	O
,	O
have	O
the	O
anti	O
-	O
tumor	O
promoting	O
potential	O
as	O
determined	O
by	O
their	O
inhibition	O
of	O
phorbol	B
ester	I
-	O
induced	O
ODC	O
activity	O
.	O

ODC	O
is	O
a	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
synthesis	O
of	O
polyamines	B
that	O
play	O
pivotal	O
roles	O
in	O
cell	O
growth	O
and	O
proliferation	O
.	O

ODC	O
is	O
rapidly	O
induced	O
by	O
many	O
mitogenic	O
stimuli	O
including	O
TPA	B
and	O
has	O
been	O
regarded	O
as	O
a	O
biochemical	O
hallmark	O
of	O
tumor	O
promotion	O
[	O
17–20	O
]	O
.	O

Conversely	O
,	O
various	O
anti	O
-	O
tumor	O
promoting	O
agents	O
exhibit	O
inhibitory	O
effects	O
on	O
the	O
catalytic	O
activity	O
of	O
this	O
enzyme	O
and	O
its	O
mRNA	O
expression	O
[	O
21–29	O
]	O
.	O

When	O
applied	O
topically	O
onto	O
shaven	O
backs	O
of	O
mice	O
30	O
min	O
prior	O
to	O
TPA	B
at	O
a	O
dose	O
of	O
50	O
μmol	O
,	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
inhibited	O
the	O
epidermal	O
ODC	O
activity	O
by	O
52	O
%	O
and	O
81	O
%	O
,	O
respectively	O
(	O
Fig.	O
2	O
)	O
5	O
h	O
after	O
the	O
treatment	O
,	O
which	O
was	O
in	O
good	O
agreement	O
with	O
their	O
inhibition	O
of	O
skin	O
tumor	O
promotion	O
(	O
K	O
.-	O
S.	O
Chun	O
et	O
al.	O
,	O
manuscript	O
in	O
preparation	O
)	O
.	O

Inflammation	O
is	O
closely	O
associated	O
with	O
the	O
tumor	O
promotion	O
process	O
and	O
the	O
production	O
of	O
such	O
cytokines	O
as	O
IL-1α	O
and	O
TNF	O
-	O
α	O
that	O
mediate	O
inflammatory	O
processes	O
has	O
been	O
shown	O
to	O
be	O
stimulated	O
by	O
phorbol	B
ester	I
[	O
30–32	O
]	O
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
topical	O
application	O
of	O
TPA	B
to	O
mouse	O
skin	O
induces	O
elevated	O
expression	O
of	O
TNF	O
-	O
α	O
in	O
the	O
epidermis	O
[	O
33–35	O
]	O
,	O
suggesting	O
that	O
this	O
pleiotropic	O
cytokine	O
directly	O
or	O
indirectly	O
mediates	O
the	O
inflammatory	O
and	O
hyperplastic	O
responses	O
elicited	O
by	O
the	O
tumor	O
promoter	O
.	O

Furthermore	O
,	O
TNF	O
-	O
α	O
markedly	O
stimulated	O
transformation	O
of	O
BALB	O
/	O
3T3	O
cells	O
induced	O
by	O
3-methylcholanthrene	B
[	O
36	O
]	O
and	O
is	O
hence	O
considered	O
as	O
an	O
endogenous	O
tumor	O
promoter	O
.	O

Epigallocatechin	B
gallate	I
,	O
a	O
chemopreventive	O
polyphenol	B
present	O
in	O
green	O
tea	O
,	O
has	O
been	O
shown	O
to	O
suppress	O
TNF	O
-	O
α	O
mRNA	O
expression	O
in	O
BALB	O
/	O
3T3	O
cells	O
treated	O
with	O
the	O
tumor	O
promoter	O
okadaic	B
acid	I
[	O
31	O
]	O
.	O

When	O
HL-60	O
cells	O
were	O
treated	O
with	O
TPA	B
(	O
3	O
nM	O
)	O
,	O
the	O
production	O
of	O
TNF	O
-	O
α	O
increased	O
steadily	O
up	O
to	O
16	O
h	O
after	O
the	O
treatment	O
(	O
Fig.	O
3	O
)	O
.	O

Treatment	O
of	O
either	O
yakuchinone	B
A	I
or	O
yakuchinone	B
B	I
at	O
50	O
or	O
100	O
μM	O
significantly	O
suppressed	O
the	O
TPA	B
-	O
stimulated	O
production	O
of	O
TNF	O
-	O
α	O
in	O
HL-60	O
cells	O
at	O
12	O
h	O
(	O
Fig.	O
4	O
)	O
.	O

Likewise	O
,	O
TPA	B
-	O
induced	O
expression	O
of	O
TNF	O
-	O
α	O
mRNA	O
in	O
HL-60	O
cells	O
or	O
mouse	O
skin	O
was	O
also	O
attenuated	O
by	O
these	O
diarylheptanoids	B
(	O
K	O
.-	O
S.	O
Chun	O
and	O
Y	O
.-	O
J.	O
Surh	O
,	O
unpublished	O
data	O
)	O
.	O

There	O
has	O
been	O
increasing	O
evidence	O
that	O
oxidative	O
stress	O
caused	O
by	O
reactive	B
oxygen	I
species	I
(	O
ROS	B
)	O
can	O
contribute	O
to	O
multi	O
-	O
stage	O
carcinogenesis	O
[	O
37–41	O
]	O
,	O
particularly	O
in	O
the	O
promotion	O
stage	O
and	O
a	O
variety	O
of	O
anti	O
-	O
oxidants	O
have	O
been	O
shown	O
to	O
be	O
effective	O
anti	O
-	O
tumor	O
promoters	O
[	O
42–44	O
]	O
.	O

Curcumin	B
,	O
for	O
instance	O
,	O
has	O
been	O
reported	O
to	O
alleviate	O
the	O
TPA	B
-	O
induced	O
oxidative	O
DNA	O
damage	O
in	O
mouse	O
epidermis	O
[	O
45	O
]	O
and	O
also	O
cultured	O
mouse	O
fibroblast	O
cells	O
[	O
46	O
]	O
.	O

The	O
compound	O
also	O
suppressed	O
superoxide	B
production	O
in	O
macrophages	O
activated	O
by	O
TPA	B
[	O
47	O
]	O
.	O

Likewise	O
,	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
attenuated	O
the	O
TPA	B
-	O
stimulated	O
generation	O
of	O
superoxide	B
anion	I
in	O
differentiated	O
HL-60	O
cells	O
(	O
Fig.	O
5	O
)	O
.	O

In	O
another	O
experiment	O
,	O
both	O
compounds	O
suppressed	O
lipid	B
peroxidation	O
in	O
rat	O
brain	O
homogenates	O
(	O
Table	O
1	O
)	O
.	O

AP-1	O
is	O
a	O
well	O
-	O
defined	O
transcription	O
factor	O
that	O
is	O
known	O
to	O
be	O
regulated	O
by	O
the	O
intracellular	O
redox	O
state	O
and	O
is	O
hence	O
implicated	O
in	O
the	O
inducible	O
expression	O
of	O
a	O
wide	O
variety	O
of	O
genes	O
involved	O
in	O
oxidative	O
stress	O
and	O
cellular	O
response	O
mechanisms	O
[	O
48	O
,	O
49	O
]	O
.	O

Functional	O
activation	O
of	O
AP-1	O
is	O
believed	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
signal	O
transduction	O
mediating	O
TPA	B
-	O
induced	O
tumor	O
promotion	O
.	O

Enhanced	O
binding	O
of	O
AP-1	O
to	O
the	O
TPA	B
response	O
element	O
(	O
TRE	O
)	O
in	O
TPA	B
-	O
stimulated	O
cells	O
has	O
been	O
associated	O
with	O
the	O
increased	O
transcription	O
of	O
different	O
responsive	O
genes	O
.	O

According	O
to	O
a	O
recent	O
study	O
by	O
Huang	O
et	O
al.	O
[	O
50	O
]	O
,	O
curcumin	B
suppresses	O
TPA	B
-	O
induced	O
TRE	O
-	O
binding	O
activity	O
of	O
c	O
-	O
Jun	O
/	O
AP-1	O
,	O
which	O
may	O
account	O
for	O
the	O
anti	O
-	O
tumor	O
promoting	O
effect	O
of	O
this	O
chemopreventive	B
agent	I
.	O

More	O
recently	O
,	O
curcumin	B
has	O
been	O
reported	O
to	O
inhibit	O
TNF	O
-	O
α	O
-	O
induced	O
binding	O
of	O
AP-1	O
to	O
DNA	O
in	O
bovine	O
aortic	O
endothelial	O
cells	O
[	O
51	O
]	O
.	O

When	O
treated	O
to	O
mouse	O
fibroblast	O
cells	O
in	O
culture	O
at	O
a	O
concentration	O
of	O
100	O
μM	O
for	O
1	O
h	O
,	O
both	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
mitigated	O
the	O
TPA	B
-	O
induced	O
binding	O
of	O
AP-1	O
to	O
TRE	O
(	O
Fig.	O
6	O
)	O
.	O

Mitogen	O
-	O
induced	O
AP-1	O
activation	O
has	O
been	O
shown	O
to	O
be	O
inhibited	O
by	O
anti	O
-	O
oxidants	O
,	O
suggesting	O
the	O
involvement	O
of	O
ROS	B
in	O
this	O
process	O
.	O

Based	O
on	O
these	O
findings	O
,	O
it	O
seems	O
likely	O
that	O
the	O
suppression	O
of	O
AP-1	O
activation	O
by	O
yakuchinones	B
is	O
attributable	O
,	O
in	O
part	O
,	O
to	O
their	O
anti	O
-	O
oxidant	O
activity	O
.	O

In	O
early	O
studies	O
,	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
were	O
found	O
to	O
be	O
potent	O
anti	B
-	I
inflammatory	I
agents	I
as	O
determined	O
by	O
their	O
strong	O
inhibition	O
of	O
prostaglandin	B
biosynthesis	O
by	O
bovine	O
seminal	O
vesicle	O
cyclooxygenase	O
[	O
52	O
]	O
and	O
a	O
rabbit	O
renal	O
medulla	O
microsomal	O
fraction	O
[	O
53	O
,	O
54	O
]	O
.	O

In	O
recent	O
years	O
,	O
there	O
is	O
an	O
expanding	O
body	O
of	O
data	O
supporting	O
that	O
suppression	O
of	O
prostaglandin	B
synthesis	O
through	O
selective	O
inhibition	O
of	O
cyclooxygenase	O
,	O
particularly	O
cyclooxygenase-2	O
which	O
is	O
inducible	O
by	O
various	O
extracellular	O
stimuli	O
,	O
is	O
regarded	O
as	O
an	O
important	O
strategy	O
for	O
cancer	O
chemoprevention	O
[	O
55	O
]	O
.	O

Inhibitors	O
of	O
arachidonic	B
acid	I
metabolism	O
have	O
been	O
found	O
to	O
induce	O
programmed	O
death	O
or	O
apoptosis	O
in	O
certain	O
types	O
of	O
tumor	O
cells	O
[	O
56–59	O
]	O
.	O

Thus	O
,	O
some	O
nonsteroidal	B
anti	I
-	I
inflammatory	I
drugs	I
,	O
including	O
sulindac	B
and	O
aspirin	B
,	O
exhibit	O
growth	O
-	O
inhibitory	O
and	O
anti	O
-	O
proliferative	O
properties	O
in	O
tumor	O
cells	O
via	O
induction	O
of	O
apoptosis	O
[	O
60–62	O
]	O
.	O

In	O
line	O
with	O
the	O
findings	O
on	O
the	O
capability	O
of	O
inhibitors	O
of	O
arachidonic	B
acid	I
metabolism	O
to	O
induce	O
apoptosis	O
or	O
suppress	O
proliferation	O
of	O
selected	O
malignant	O
or	O
transformed	O
cells	O
,	O
treatment	O
of	O
human	O
colon	O
cancer	O
(	O
HCA-7	O
)	O
cells	O
with	O
prostaglandin	B
E2	I
inhibited	O
apoptosis	O
via	O
induction	O
of	O
death	O
suppressing	O
protein	O
Bcl-2	O
[	O
63	O
]	O
.	O

We	O
have	O
recently	O
reported	O
that	O
both	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
induce	O
apoptotic	O
death	O
in	O
HL-60	O
cells	O
,	O
which	O
accounts	O
for	O
their	O
anti	O
-	O
proliferative	O
activity	O
[	O
64	O
]	O
.	O

Although	O
it	O
remains	O
unclear	O
whether	O
these	O
diarylheptanoids	B
induce	O
apoptosis	O
selectively	O
in	O
cancer	O
cells	O
,	O
they	O
appear	O
to	O
be	O
relatively	O
less	O
cytotoxic	O
in	O
normal	O
cells	O
.	O

In	O
this	O
context	O
,	O
it	O
is	O
of	O
interest	O
to	O
note	O
that	O
curcumin	B
induces	O
apoptosis	O
in	O
various	O
types	O
of	O
cell	O
lines	O
[	O
9	O
,	O
65	O
,	O
66	O
]	O
derived	O
from	O
human	O
tumors	O
,	O
but	O
the	O
compound	B
was	O
inactive	O
for	O
the	O
normal	O
cells	O
in	O
primary	O
culture	O
[	O
66	O
]	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
demonstrates	O
that	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B	I
derived	O
from	O
A.	O
oxyphylla	O
Miquel	O
,	O
inhibit	O
promotion	O
of	O
skin	O
tumorigenesis	O
and	O
tumor	O
promoter	O
-	O
induced	O
epidermal	O
ODC	O
activity	O
in	O
mice	O
.	O

These	O
diarylheptanoids	B
also	O
suppressed	O
TPA	B
-	O
stimulated	O
production	O
of	O
TNF	O
-	O
α	O
and	O
superoxide	B
in	O
cultured	O
HL-60	O
cells	O
.	O

Furthermore	O
,	O
TPA	B
-	O
induced	O
c	O
-	O
Jun	O
/	O
AP-1	O
activation	O
was	O
also	O
attenuated	O
by	O
the	O
above	O
substances	O
.	O

Additional	O
studies	O
are	O
in	O
progress	O
to	O
elucidate	O
the	O
detailed	O
molecular	O
mechanisms	O
underlying	O
anti	O
-	O
tumor	O
promoting	O
effects	O
of	O
yakuchinone	B
A	I
and	O
yakuchinone	B
B.	I
Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
the	O
G-7	O
project	O
(	O
1541	O
-	O
211	O
)	O
sponsored	O
by	O
the	O
Ministry	O
of	O
Science	O
and	O
Technology	O
,	O
Republic	O
of	O
Korea	O
and	O
a	O
grant	O
from	O
Korea	O
Ministry	O
of	O
Health	O
and	O
Welfare	O
(	O
Grant	O
No.	O
,	O
HMP-96-D-2	O
-	O
1034	O
)	O
.	O

Heterocyclic	B
amines	I
are	O
potent	O
bacterial	O
mutagens	O
[	O
1	O
]	O
,	O
rodent	O
carcinogens	B
[	O
2	O
]	O
,	O
and	O
suspected	O
human	O
carcinogens	B
[	O
3	O
]	O
.	O

Formation	O
of	O
heterocyclic	B
amines	I
during	O
cooking	O
processes	O
(	O
reviewed	O
in	O
Refs	O
.	O

[	O
4	O
,	O
5	O
]	O
)	O
suggests	O
that	O
exposure	O
to	O
these	O
compounds	O
is	O
largely	O
unavoidable	O
[	O
6	O
]	O
.	O

Therefore	O
,	O
other	O
means	O
of	O
controlling	O
heterocyclic	B
amine	I
-	O
induced	O
cancer	O
risk	O
need	O
to	O
be	O
considered	O
.	O

Numerous	O
dietary	O
components	O
have	O
been	O
shown	O
to	O
substantially	O
decrease	O
the	O
bacterial	O
mutagenicity	O
of	O
heterocyclic	B
amines	I
,	O
including	O
chlorophyllin	B
[	O
7	O
,	O
8	O
]	O
,	O
extracts	O
and	O
isolated	O
polyphenolic	B
components	I
from	O
tea	O
,	O
coffee	O
and	O
other	O
plant	O
sources	O
[	O
8–14	O
]	O
,	O
isothiocyanates	B
[	O
15	O
]	O
and	O
1-O	B
-hexyl-2,3,5-trimethylhydroquinone	I
[	O
16	O
]	O
.	O

Extract	O
of	O
madder	O
root	O
(	O
Rubia	O
tinctorum	O
)	O
contains	O
a	O
number	O
of	O
hydroxyanthraquinones	B
and	O
has	O
been	O
used	O
as	O
a	O
treatment	O
for	O
kidney	O
and	O
bladder	O
stones	O
[	O
17	O
]	O
and	O
as	O
a	O
food	O
colouring	O
.	O

Purpurin	B
(	O
1,2,4-trihydroxy-9,10-anthraquinone	B
)	O
(	O
Fig.	O
1	O
)	O
is	O
present	O
at	O
trace	O
amounts	O
in	O
R.	O
tinctorum	O
[	O
18	O
]	O
and	O
as	O
a	O
major	O
anthraquinone	B
component	O
of	O
R.	O
akane	O
,	O
Japanese	O
madder	O
(	O
communication	O
from	O
The	O
San	O
-	O
Ei	O
Gen	O
Foundation	O
for	O
Food	O
and	O
Chemical	O
Research	O
,	O
Osaka	O
)	O
.	O

Purpurin	B
is	O
non	O
-	O
mutagenic	O
in	O
the	O
majority	O
of	O
Ames	O
tester	O
strains	O
[	O
18	O
,	O
19	O
]	O
and	O
is	O
only	O
weakly	O
mutagenic	O
in	O
TA1537	O
[	O
19	O
]	O
.	O

We	O
have	O
investigated	O
the	O
possible	O
protective	O
role	O
of	O
this	O
polyphenolic	B
compound	O
against	O
bacterial	O
mutagenesis	O
induced	O
by	O
a	O
number	O
of	O
food	O
-	O
derived	O
heterocyclic	B
amines	I
,	O
particularly	O
3-amino-1-methyl-5H	B
-pyrido	I
[	I
4,3-b	I
]	I
indole	I
(	O
Trp	B
-	I
P-2	I
)	O
,	O
in	O
the	O
Ames	O
test	O
using	O
TA98	O
.	O

The	O
metabolism	O
of	O
heterocyclic	B
amines	I
to	O
mutagenic	O
intermediates	O
is	O
catalyzed	O
mainly	O
by	O
the	O
cytochrome	O
P	O
4501A	O
(	O
CYP1A	O
)	O
isoforms	O
,	O
in	O
particular	O
CYP1A2	O
(	O
Ref	O
.	O

[	O
20	O
]	O
and	O
references	O
therein	O
)	O
.	O

In	O
extrahepatic	O
tissues	O
there	O
is	O
also	O
some	O
contribution	O
to	O
bioactivation	O
by	O
prostaglandin	O
H	O
synthase	O
[	O
21	O
]	O
.	O

In	O
addition	O
,	O
there	O
is	O
some	O
evidence	O
for	O
a	O
free	B
radical	I
mechanism	O
involving	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
[	O
22	O
]	O
.	O

Previously	O
,	O
it	O
has	O
been	O
reported	O
that	O
chlorophyllin	B
[	O
23	O
]	O
and	O
several	O
anti	O
-	O
mutagenic	O
polyphenols	B
[	O
10	O
,	O
13	O
,	O
16	O
]	O
exert	O
their	O
effect	O
,	O
in	O
vitro	O
,	O
by	O
inhibition	O
of	O
CYP	O
-	O
dependent	O
metabolism	O
of	O
heterocyclic	B
amines	I
to	O
their	O
active	O
hydroxylamine	B
metabolites	I
.	O

Therefore	O
,	O
in	O
addition	O
to	O
the	O
regular	O
Ames	O
tester	O
strain	O
(	O
TA98	O
)	O
,	O
we	O
investigated	O
the	O
anti	O
-	O
mutagenic	O
potential	O
of	O
purpurin	B
in	O
bacteria	O
expressing	O
human	O
drug	O
metabolizing	O
enzymes	O
(	O
human	O
CYP1A2	O
,	O
human	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
,	O
and	O
Salmonella	O
O	O
-acetyltransferase	O
)	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O
Reagent	O
grade	O
purpurin	B
(	O
1,2,4-trihydroxy-9,10-anthraquinone	B
)	O
(	O
86	O
%	O
pure	O
,	O
as	O
determined	O
by	O
reversed	O
-	O
phase	O
HPLC	O
)	O
and	O
all	O
heterocyclic	B
amines	I
were	O
obtained	O
from	O
Wako	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Pure	O
grade	O
chlorophyllin	B
(	O
Cu	B
–	I
Na	I
salt	I
)	O
was	O
obtained	O
from	O
Nakalai	O
Tesque	O
(	O
Kyoto	O
,	O
Japan	O
)	O
and	O
epigallocatechin	B
gallate	I
(	O
EGCG	B
)	O
(	O
95	O
%	O
pure	O
)	O
was	O
a	O
kind	O
gift	O
from	O
Dr.	O
I.	O
Sakata	O
(	O
Toyo	O
Hakka	O
Satasho	O
,	O
Okayama	O
)	O
.	O

Activated	O
heterocyclic	B
amines	I
were	O
prepared	O
by	O
incubation	O
of	O
the	O
parent	O
amine	B
with	O
rat	O
hepatic	O
S9	O
mix	O
for	O
20	O
min	O
at	O
37	O
°	O
C	O
,	O
protein	O
precipitation	O
with	O
acetone	B
and	O
freeze	O
drying	O
of	O
the	O
supernatant	O
as	O
described	O
previously	O
[	O
24	O
]	O
.	O

Finally	O
,	O
purified	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
was	O
synthesized	O
from	O
Trp	B
-	I
P-2	I
via	O
Trp	B
-	I
P-2	I
(	I
NO2	I
)	I
as	O
described	O
by	O
Saito	O
et	O
al.	O
[	O
25	O
]	O
.	O

2.2	O
Animals	O
and	O
treatment	O
Induced	O
S9	O
used	O
in	O
the	O
assay	O
systems	O
was	O
obtained	O
from	O
male	O
rats	O
pre	O
-	O
treated	O
with	O
PCB-54	B
(	O
a	O
commercial	O
mixture	O
of	O
polychlorinated	B
biphenyls	I
,	O
Tokyo	O
Kasei	O
Chemical	O
)	O
as	O
described	O
previously	O
[	O
26	O
]	O
.	O

2.3	O
Bacterial	O
strains	O
and	O
mutation	O
assays	O
Bacterial	O
strains	O
TA98	O
,	O
and	O
TA98	O
-	O
1,8-DNP6	O
,	O
were	O
kind	O
gifts	O
from	O
Prof.	O
B.N.	O
Ames	O
(	O
University	O
of	O
California	O
,	O
Berkeley	O
)	O
,	O
and	O
Prof.	O
H.	O
Rosenkranz	O
(	O
Case	O
Western	O
Reserve	O
University	O
,	O
Cleveland	O
,	O
OH	O
)	O
,	O
respectively	O
.	O

Strains	O
TA1538R	O
,	O
TA1538AR	O
and	O
TA1538ARO	O
,	O
which	O
express	O
human	O
drug	O
metabolizing	O
enzymes	O
,	O
were	O
established	O
as	O
described	O
by	O
Suzuki	O
et	O
al.	O
[	O
27	O
]	O
.	O

Mutagenicity	O
assays	O
were	O
performed	O
using	O
the	O
methods	O
of	O
Maron	O
and	O
Ames	O
[	O
28	O
]	O
with	O
modifications	O
for	O
strains	O
expressing	O
recombinant	O
human	O
enzymes	O
as	O
described	O
previously	O
[	O
27	O
]	O
.	O

To	O
demonstrate	O
the	O
anti	O
-	O
mutagenic	O
activities	O
of	O
purpurin	B
,	O
the	O
mutagenic	O
heterocyclic	B
amines	I
were	O
assayed	O
with	O
the	O
use	O
of	O
the	O
pre	O
-	O
incubation	O
technique	O
of	O
Yahagi	O
et	O
al.	O
[	O
29	O
]	O
,	O
with	O
purpurin	B
added	O
before	O
the	O
pre	O
-	O
incubation	O
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
anti	O
-	O
mutagenesis	O
,	O
a	O
two	O
-	O
stage	O
test	O
was	O
performed	O
,	O
in	O
which	O
an	O
initial	O
incubation	O
of	O
TA1538ARO	O
(	O
a	O
strain	O
expressing	O
human	O
CYP1A2	O
,	O
human	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
,	O
and	O
bacterial	O
O	O
-acetyltransferase	O
)	O
bacterial	O
culture	O
(	O
100	O
ml	O
)	O
with	O
or	O
without	O
the	O
addition	O
of	O
purpurin	B
with	O
shaking	O
at	O
20	O
°	O
C	O
.	O

After	O
20	O
min	O
,	O
aliquots	O
were	O
taken	O
and	O
centrifuged	O
to	O
harvest	O
the	O
bacteria	O
.	O

The	O
bacteria	O
were	O
washed	O
twice	O
by	O
resuspending	O
in	O
nutrient	B
broth	O
followed	O
by	O
centrifugation	O
.	O

The	O
final	O
bacterial	O
pellet	O
was	O
gently	O
resuspended	O
in	O
nutrient	B
broth	O
and	O
incorporated	O
into	O
the	O
Ames	O
test	O
.	O

2.4	O
Measurement	O
of	O
CYP	O
and	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
Total	O
cytochrome	O
P	O
450	O
content	O
was	O
measured	O
by	O
the	O
method	O
of	O
Omura	O
and	O
Sato	O
[	O
30	O
]	O
and	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
activity	O
was	O
determined	O
by	O
the	O
reduction	O
of	O
cytochrome	O
c	O
according	O
to	O
the	O
method	O
of	O
Phillips	O
and	O
Langdon	O
[	O
31	O
]	O
.	O

3	O
Results	O
Fig.	O
2	O
demonstrates	O
the	O
anti	O
-	O
mutagenic	O
potential	O
of	O
purpurin	B
against	O
heterocyclic	B
amine	I
-	O
induced	O
mutagenicity	O
using	O
Salmonella	O
typhimurium	O
TA98	O
.	O

Purpurin	B
was	O
able	O
to	O
significantly	O
inhibit	O
the	O
mutagenicity	O
of	O
each	O
activated	O
heterocyclic	B
amine	I
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
inhibitory	O
effect	O
was	O
most	O
marked	O
for	O
Trp	B
-	I
P-1	I
(	O
0.5	O
nmol	O
)	O
and	O
Trp	B
-	I
P-2	I
(	O
0.06	O
nmol	O
)	O
with	O
greater	O
than	O
90	O
%	O
inhibition	O
(	O
Fig.	O
2	O
)	O
but	O
was	O
also	O
greater	O
than	O
60	O
%	O
for	O
MeIQ	B
(	O
0.2	O
nmol	O
)	O
,	O
IQ	B
(	O
0.1	O
nmol	O
)	O
and	O
Glu	B
-	I
P-1	I
(	O
5.0	O
nmol	O
)	O
.	O

The	O
inhibition	O
of	O
Trp	B
-	I
P-2-dependent	I
mutagenicity	O
by	O
purpurin	B
and	O
two	O
other	O
established	O
anti	O
-	O
mutagens	O
,	O
EGCG	B
and	O
chlorophyllin	B
clearly	O
showed	O
that	O
purpurin	B
is	O
an	O
effective	O
inhibitor	O
of	O
mutagenicity	O
(	O
Fig.	O
3	O
)	O
.	O

Even	O
when	O
the	O
molarities	O
of	O
the	O
added	O
compounds	O
are	O
taken	O
into	O
account	O
,	O
purpurin	B
(	O
17	O
%	O
inhibition	O
per	O
nmol	O
added	O
)	O
is	O
comparable	O
to	O
the	O
other	O
two	O
anti	O
-	O
mutagens	O
(	O
EGCG	B
,	O
16	O
%	O
per	O
nmol	O
and	O
chlorophyllin	B
,	O
13	O
%	O
per	O
nmol	O
)	O
.	O

Inhibition	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
mutagenicity	O
was	O
investigated	O
at	O
pH	O
5	O
and	O
pH	O
7.4	O
.	O

At	O
neutral	O
pH	O
the	O
anti	O
-	O
mutagenic	O
effect	O
was	O
considerably	O
greater	O
(	O
94	O
%	O
)	O
than	O
at	O
pH	O
5	O
(	O
54	O
%	O
)	O
.	O

However	O
,	O
the	O
mutagenic	O
response	O
at	O
pH	O
5	O
was	O
only	O
25	O
%	O
of	O
that	O
observed	O
at	O
pH	O
7.4	O
(	O
Table	O
1	O
)	O
.	O

TA98	O
-	O
1,8-DNP6	O
is	O
a	O
bacterial	O
strain	O
deficient	O
in	O
N	O
,	O
O	O
-acetyltransferase	O
[	O
32	O
]	O
.	O

In	O
aryl	B
amines	I
,	O
O	O
-acetylation	O
is	O
considered	O
a	O
bioactivation	O
pathway	O
and	O
consequently	O
,	O
it	O
is	O
possible	O
that	O
purpurin	B
exerts	O
its	O
anti	O
-	O
mutagenic	O
effect	O
by	O
having	O
an	O
influence	O
upon	O
acetylation	O
of	O
the	O
N	B
-hydroxylamine	I
.	O

However	O
,	O
the	O
mutagenic	O
response	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
in	O
TA98	O
-	O
1,8-DNP6	O
and	O
the	O
parent	O
TA98	O
strains	O
were	O
very	O
similar	O
(	O
Table	O
2	O
)	O
.	O

The	O
degree	O
of	O
inhibition	O
by	O
purpurin	B
was	O
the	O
same	O
in	O
both	O
strains	O
(	O
Table	O
2	O
)	O
.	O

In	O
both	O
the	O
presence	O
and	O
absence	O
of	O
rat	O
hepatic	O
S9	O
,	O
purpurin	B
did	O
not	O
affect	O
the	O
mutagenic	O
response	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
if	O
the	O
reaction	O
mixtures	O
were	O
not	O
pre	O
-	O
incubated	O
.	O

In	O
contrast	O
,	O
if	O
assay	O
mixtures	O
were	O
pre	O
-	O
incubated	O
for	O
40	O
min	O
at	O
37	O
°	O
C	O
,	O
purpurin	B
inhibited	O
the	O
mutagenic	O
response	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
S9	O
.	O

Both	O
the	O
mutagenicity	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
and	O
the	O
inhibition	O
by	O
purpurin	B
were	O
more	O
marked	O
in	O
the	O
absence	O
of	O
S9	O
mix	O
(	O
Fig.	O
4	O
)	O
.	O

Purpurin	B
was	O
non	O
-	O
mutagenic	O
in	O
Salmonella	O
strains	O
TA1538R	O
,	O
TA1538AR	O
and	O
TA1538ARO	O
which	O
express	O
human	O
drug	O
metabolizing	O
enzymes	O
(	O
Table	O
3	O
)	O
.	O

Some	O
cytotoxicity	O
was	O
observed	O
in	O
TA1538ARO	O
(	O
Table	O
3	O
)	O
.	O

A	O
dose	O
-	O
dependent	O
inhibition	O
of	O
the	O
mutagenicity	O
of	O
Trp	B
-	I
P-2	I
was	O
observed	O
for	O
purpurin	B
in	O
strain	O
TA1538ARO	O
with	O
a	O
10-fold	O
excess	O
of	O
purpurin	B
almost	O
entirely	O
removing	O
the	O
mutagenic	O
response	O
(	O
Fig.	O
5	O
)	O
.	O

During	O
the	O
two	O
-	O
stage	O
mutagenicity	O
test	O
,	O
a	O
20-min	O
incubation	O
of	O
the	O
TA1538ARO	O
bacterial	O
culture	O
with	O
purpurin	B
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
and	O
a	O
dose	O
-	O
dependent	O
degradation	O
of	O
CYP	O
(	O
Fig.	O
6	O
)	O
.	O

Consequently	O
,	O
when	O
these	O
bacteria	O
were	O
employed	O
in	O
the	O
Ames	O
test	O
,	O
the	O
mutagenic	O
response	O
obtained	O
with	O
a	O
range	O
of	O
Trp	B
-	I
P-2	I
concentrations	O
also	O
decreased	O
dose	O
-	O
dependently	O
(	O
Fig.	O
7	O
)	O
.	O

4	O
Discussion	O
We	O
have	O
presented	O
here	O
the	O
possible	O
advantage	O
of	O
purpurin	B
as	O
an	O
inhibitor	O
of	O
heterocyclic	B
amine	I
-	O
induced	O
mutations	O
,	O
using	O
the	O
Ames	O
bacterial	O
test	O
system	O
.	O

Purpurin	B
markedly	O
inhibited	O
the	O
mutagenic	O
response	O
of	O
a	O
range	O
of	O
heterocyclic	B
amines	I
with	O
an	O
apparent	O
preference	O
for	O
inhibition	O
of	O
the	O
activated	O
pyrido	B
indoles	I
,	O
Trp	B
-	I
P-1	I
and	O
Trp	B
-	I
P-2	I
(	O
Fig.	O
2	O
)	O
.	O

At	O
a	O
mutagen	O
:	O
purpurin	B
ratio	O
of	O
only	O
1:4	O
a	O
90	O
%	O
inhibition	O
of	O
Trp	B
-	I
P-1	I
mutagenicity	O
was	O
observed	O
(	O
Fig.	O
2	O
)	O
.	O

When	O
a	O
purified	O
sample	O
of	O
purpurin	B
was	O
used	O
(	O
purity	O
100	O
%	O
,	O
a	O
kind	O
gift	O
from	O
The	O
San	O
-	O
Ei	O
Gen	O
Foundation	O
for	O
Food	O
Chemical	O
Research	O
,	O
Osaka	O
)	O
,	O
identical	O
results	O
were	O
obtained	O
(	O
data	O
not	O
shown	O
)	O
.	O

When	O
the	O
protective	O
effect	O
of	O
purpurin	B
against	O
activated	O
Trp	B
-	I
P-2	I
was	O
compared	O
to	O
that	O
observed	O
with	O
the	O
established	O
anti	O
-	O
mutagens	O
,	O
EGCG	B
and	O
chlorophyllin	B
,	O
purpurin	B
was	O
found	O
to	O
be	O
equally	O
potent	O
(	O
Fig.	O
3	O
)	O
.	O

Solutions	O
of	O
purpurin	B
at	O
different	O
pH	O
values	O
have	O
markedly	O
different	O
physical	O
appearances	O
.	O

At	O
pH	O
5	O
,	O
a	O
purpurin	B
solution	O
is	O
orange	O
while	O
at	O
neutral	O
pH	O
and	O
alkaline	B
conditions	O
,	O
solutions	O
are	O
purple	O
.	O

The	O
inhibition	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
mutagenicity	O
was	O
investigated	O
at	O
neutral	O
(	O
7.4	O
)	O
and	O
acidic	B
(	O
5	O
)	O
pH	O
(	O
Table	O
1	O
)	O
.	O

At	O
neutral	O
pH	O
,	O
addition	O
of	O
a	O
30-fold	O
excess	O
of	O
purpurin	B
almost	O
entirely	O
inhibited	O
the	O
mutagenic	O
response	O
,	O
but	O
at	O
pH	O
5	O
the	O
decrease	O
in	O
revertant	O
colonies	O
was	O
only	O
60	O
%	O
(	O
Table	O
1	O
)	O
.	O

This	O
infers	O
that	O
whatever	O
change	O
there	O
may	O
be	O
in	O
the	O
structure	O
of	O
purpurin	B
occurring	O
in	O
acidic	B
solutions	O
blocks	O
the	O
anti	O
-	O
mutagenic	O
potential	O
.	O

However	O
,	O
at	O
pH	O
5	O
the	O
mutagenicity	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
is	O
also	O
considerably	O
decreased	O
in	O
the	O
absence	O
of	O
purpurin	B
(	O
Table	O
1	O
)	O
.	O

This	O
may	O
be	O
because	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
is	O
considerably	O
more	O
stable	O
under	O
acidic	B
conditions	O
and	O
consequently	O
,	O
does	O
not	O
degrade	O
so	O
readily	O
to	O
the	O
nitrenium	B
ion	I
.	O

Purpurin	B
could	O
act	O
at	O
neutral	O
pH	O
by	O
increasing	O
the	O
rate	O
of	O
degradation	O
of	O
the	O
hydroxylamine	B
to	O
a	O
non	O
-	O
mutagenic	O
intermediate	O
.	O

Degradation	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
to	O
less	O
mutagenic	O
intermediates	O
has	O
been	O
observed	O
previously	O
in	O
our	O
laboratory	O
for	O
other	O
natural	O
pigments	B
such	O
as	O
Monascus	B
red	I
and	O
Monascus	B
yellow	I
[	O
33	O
]	O
and	O
chlorophyllin	B
[	O
34	O
]	O
.	O

Many	O
aromatic	B
N	I
-hydroxylamines	I
undergo	O
further	O
metabolism	O
by	O
bacterial	O
N	O
,	O
O	O
-acetyltransferases	O
to	O
more	O
mutagenic	O
N	B
-acetoxyamines	I
.	O

To	O
determine	O
whether	O
purpurin	B
exerts	O
its	O
effect	O
upon	O
the	O
N	B
-hydroxylamine	I
or	O
the	O
N	B
-acetoxyamine	I
,	O
the	O
inhibition	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
mutagenicity	O
was	O
observed	O
in	O
TA98	O
and	O
the	O
N	O
,	O
O	O
-acetyltransferase	O
-	O
deficient	O
TA98	O
-	O
1,8-DNP6	O
strains	O
.	O

Both	O
the	O
mutagenic	O
response	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
and	O
its	O
inhibition	O
by	O
purpurin	B
were	O
comparable	O
in	O
both	O
strains	O
(	O
Table	O
2	O
)	O
.	O

The	O
absence	O
of	O
any	O
decrease	O
in	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
-induced	O
mutations	O
in	O
the	O
N	O
,	O
O	O
-acetyltransferase	O
-	O
deficient	O
strain	O
is	O
in	O
agreement	O
with	O
previous	O
investigations	O
[	O
35–37	O
]	O
.	O

It	O
has	O
been	O
suggested	O
that	O
this	O
is	O
because	O
the	O
N	B
-hydroxylamine	I
and	O
the	O
N	B
-acetoxyamine	I
of	O
Trp	B
-	I
P-2	I
are	O
equally	O
capable	O
of	O
forming	O
the	O
nitrenium	B
ion	I
[	O
37	O
]	O
.	O

Consequently	O
,	O
these	O
results	O
demonstrate	O
that	O
purpurin	B
can	O
express	O
a	O
potent	O
anti	O
-	O
mutagenic	O
effect	O
by	O
interaction	O
with	O
the	O
N	B
-hydroxylamine	I
.	O

In	O
both	O
the	O
presence	O
and	O
the	O
absence	O
of	O
S9	O
,	O
purpurin	B
had	O
no	O
effect	O
on	O
the	O
mutagenicity	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
if	O
the	O
direct	O
plate	O
-	O
incorporation	O
assay	O
was	O
employed	O
,	O
but	O
purpurin	B
acted	O
as	O
an	O
anti	O
-	O
mutagen	O
when	O
using	O
the	O
pre	O
-	O
incubation	O
method	O
(	O
Fig.	O
4	O
)	O
.	O

This	O
observation	O
implies	O
that	O
pre	O
-	O
incubation	O
is	O
essential	O
for	O
an	O
inhibitory	O
response	O
but	O
a	O
simple	O
dilution	O
effect	O
can	O
not	O
be	O
ruled	O
out	O
.	O

In	O
the	O
presence	O
of	O
S9	O
,	O
the	O
mutagenic	O
response	O
is	O
considerably	O
lower	O
,	O
probably	O
as	O
a	O
consequence	O
of	O
non	O
-	O
specific	O
binding	O
of	O
reactive	O
intermediates	O
to	O
protein	O
.	O

Even	O
in	O
the	O
absence	O
of	O
purpurin	B
,	O
pre	O
-	O
incubation	O
is	O
responsible	O
for	O
a	O
decrease	O
in	O
revertants	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
S9	O
.	O

This	O
is	O
a	O
consequence	O
of	O
the	O
time	O
-	O
dependent	O
degradation	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
[	O
38	O
]	O
under	O
aerobic	O
conditions	O
.	O

However	O
,	O
the	O
presence	O
of	O
purpurin	B
is	O
responsible	O
for	O
a	O
significant	O
decrease	O
in	O
revertants	O
in	O
addition	O
to	O
the	O
aerobic	O
degradation	O
(	O
Fig.	O
4	O
)	O
.	O

The	O
effect	O
of	O
purpurin	B
was	O
less	O
marked	O
in	O
the	O
presence	O
of	O
S9	O
,	O
suggesting	O
that	O
enzymes	O
within	O
the	O
S9	O
may	O
act	O
either	O
by	O
metabolizing	O
purpurin	B
to	O
a	O
less	O
effective	O
inhibitor	O
or	O
by	O
reversing	O
any	O
direct	O
effect	O
of	O
purpurin	B
on	O
the	O
mutagen	B
.	O

Several	O
hydroxyanthraquinones	B
,	O
including	O
purpurin	B
,	O
have	O
been	O
proposed	O
as	O
carcinogens	B
and	O
bacterial	O
mutagens	B
[	O
18	O
,	O
19	O
,	O
39–44	O
]	O
.	O

Chronic	O
feeding	O
of	O
a	O
high	O
dose	O
of	O
purpurin	B
(	O
1	O
%	O
diet	O
,	O
520	O
days	O
)	O
to	O
rats	O
was	O
responsible	O
for	O
increased	O
hyperplasia	O
of	O
the	O
renal	O
,	O
pelvic	O
epithelium	O
and	O
papilloma	O
and	O
carcinoma	O
development	O
in	O
the	O
urinary	O
bladder	O
[	O
41	O
]	O
.	O

These	O
effects	O
have	O
been	O
attributed	O
to	O
crystallization	O
of	O
purpurin	B
[	O
41	O
]	O
.	O

However	O
,	O
unlike	O
1-hydroxyanthraquinone	B
[	O
40	O
]	O
,	O
no	O
tumorigenic	O
or	O
toxicological	O
effects	O
were	O
observed	O
in	O
the	O
intestines	O
[	O
41	O
]	O
.	O

Therefore	O
,	O
lower	O
doses	O
,	O
which	O
may	O
avoid	O
crystallization	O
in	O
urinary	O
tract	O
,	O
may	O
not	O
be	O
tumorigenic	O
.	O

From	O
the	O
structure	O
of	O
purpurin	B
,	O
it	O
is	O
conceivable	O
that	O
it	O
forms	O
free	B
radicals	I
in	O
the	O
presence	O
of	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
.	O

Therefore	O
,	O
the	O
mutagenicity	O
of	O
purpurin	B
was	O
investigated	O
in	O
bacterial	O
strains	O
expressing	O
recombinant	O
enzymes	O
TA1538R	O
(	O
human	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
)	O
,	O
TA1538AR	O
(	O
human	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
and	O
human	O
CYP1A2	O
)	O
,	O
and	O
TA1438ARO	O
(	O
human	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
,	O
human	O
CYP1A2	O
,	O
and	O
bacterial	O
O	O
-acetyltransferase	O
)	O
[	O
27	O
]	O
.	O

At	O
the	O
concentrations	O
under	O
investigation	O
,	O
no	O
mutagenicity	O
was	O
detected	O
in	O
any	O
of	O
these	O
strains	O
(	O
Table	O
3	O
)	O
.	O

Purpurin	B
did	O
display	O
some	O
cytotoxicity	O
in	O
TA1538R	O
and	O
,	O
to	O
a	O
greater	O
degree	O
,	O
in	O
the	O
TA1538ARO	O
strain	O
.	O

The	O
cytotoxicity	O
in	O
the	O
TA1538ARO	O
strain	O
implies	O
that	O
O	O
-acetylation	O
of	O
purpurin	B
is	O
responsible	O
for	O
the	O
formation	O
of	O
a	O
cytotoxic	B
metabolite	I
.	O

However	O
,	O
the	O
spontaneous	O
reversion	O
rate	O
did	O
not	O
decrease	O
when	O
the	O
concentration	O
of	O
purpurin	B
was	O
raised	O
above	O
2500	O
pmol	O
(	O
Table	O
3	O
)	O
and	O
did	O
not	O
decrease	O
below	O
that	O
observed	O
for	O
the	O
TA1538R	O
and	O
TA1538AR	O
strains	O
.	O

An	O
increase	O
in	O
the	O
spontaneous	O
reversion	O
rate	O
observed	O
with	O
bacterial	O
strains	O
expressing	O
O	O
-acetyltransferase	O
has	O
been	O
reported	O
previously	O
[	O
45	O
]	O
but	O
the	O
reason	O
for	O
it	O
is	O
unknown	O
.	O

When	O
purpurin	B
was	O
present	O
,	O
the	O
mutagenicity	O
of	O
Trp	B
-	I
P-2	I
was	O
inhibited	O
dose	O
-	O
dependently	O
in	O
the	O
TA1538ARO	O
strain	O
,	O
with	O
the	O
addition	O
of	O
5	O
nmol	O
purpurin	B
responsible	O
for	O
the	O
complete	O
removal	O
of	O
mutagenic	O
response	O
(	O
Fig.	O
5	O
)	O
.	O

Similarly	O
,	O
use	O
of	O
a	O
two	O
-	O
stage	O
test	O
demonstrated	O
that	O
purpurin	B
successfully	O
enters	O
the	O
bacterial	O
cell	O
,	O
causes	O
a	O
concentration	O
-	O
dependent	O
degradation	O
of	O
CYP1A2	O
and	O
inhibition	O
of	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
(	O
Fig.	O
6	O
)	O
,	O
and	O
inhibited	O
the	O
bioactivation	O
of	O
Trp	B
-	I
P-2	I
(	O
Fig.	O
7	O
)	O
.	O

The	O
good	O
correlation	O
between	O
Trp	B
-	I
P-2	I
(	O
125	O
pmol	O
)	O
mutagenicity	O
and	O
CYP1A2	O
degradation	O
(	O
R	O
2	O
=	O
0.822	O
)	O
and	O
the	O
excellent	O
correlation	O
between	O
Trp	B
-	I
P-2	I
(	O
125	O
pmol	O
)	O
mutagenicity	O
and	O
the	O
inhibition	O
of	O
NADPH	O
-	O
cytochrome	O
P	O
450	O
reductase	O
(	O
R	O
2	O
=	O
0.981	O
)	O
demonstrates	O
that	O
purpurin	B
acts	O
by	O
inhibiting	O
the	O
bioactivation	O
of	O
Trp	B
-	I
P-2	I
by	O
CYP1A2	O
.	O

Whether	O
purpurin	B
truly	O
degrades	O
CYP1A2	O
or	O
simply	O
binds	O
to	O
the	O
haemoprotein	O
preventing	O
quantification	O
using	O
the	O
carbon	B
monoxide	I
-	O
difference	O
spectra	O
was	O
not	O
determined	O
.	O

Certainly	O
,	O
the	O
structure	O
of	O
purpurin	B
is	O
suggestive	O
of	O
a	O
substrate	O
for	O
CYP1A	O
isoforms	O
.	O

Consequently	O
,	O
purpurin	B
may	O
compete	O
with	O
Trp	B
-	I
P-2	I
for	O
access	O
to	O
the	O
active	O
site	O
of	O
CYP1A1	O
and	O
CYP1A2	O
.	O

To	O
conclude	O
,	O
purpurin	B
is	O
a	O
potent	O
inhibitor	O
of	O
heterocyclic	B
amine	I
-	O
induced	O
bacterial	O
mutagenesis	O
especially	O
that	O
of	O
activated	O
Trp	B
-	I
P-1	I
and	O
Trp	B
-	I
P-2	I
(	O
Fig.	O
2	O
)	O
.	O

This	O
anti	O
-	O
mutagenic	O
potential	O
of	O
purpurin	B
is	O
comparable	O
to	O
that	O
of	O
recognized	O
anti	O
-	O
mutagens	O
,	O
EGCG	B
and	O
chlorophyllin	B
.	O

The	O
mechanism	O
of	O
inhibition	O
was	O
partially	O
characterized	O
using	O
activated	O
Trp	B
-	I
P-2	I
and	O
was	O
found	O
to	O
be	O
dependent	O
upon	O
pH	O
,	O
being	O
more	O
effective	O
under	O
neutral	O
than	O
acidic	B
conditions	O
,	O
and	O
pre	O
-	O
incubation	O
.	O

The	O
mechanism	O
appears	O
to	O
constitute	O
,	O
at	O
least	O
in	O
part	O
,	O
an	O
inhibition	O
of	O
bioactivation	O
by	O
CYP1A2	O
.	O

The	O
use	O
of	O
bacteria	O
expressing	O
human	O
drug	O
metabolizing	O
enzymes	O
demonstrated	O
that	O
these	O
observations	O
may	O
have	O
some	O
relevance	O
for	O
anticarcinogenesis	O
in	O
humans	O
.	O

Purpurin	B
also	O
inhibits	O
the	O
direct	O
mutagenicity	O
of	O
Trp	B
-	I
P-2	I
(	I
NHOH	I
)	I
,	O
implying	O
that	O
it	O
has	O
a	O
second	O
,	O
so	O
far	O
unidentified	O
,	O
protective	O
mechanism	O
.	O

These	O
are	O
only	O
initial	O
observations	O
obtained	O
using	O
bacteria	O
.	O

Purpurin	B
has	O
been	O
proposed	O
as	O
a	O
possible	O
rodent	O
carcinogen	B
in	O
long	O
-	O
term	O
feeding	O
studies	O
[	O
41	O
]	O
.	O

Consequently	O
,	O
in	O
depth	O
in	O
vivo	O
investigations	O
in	O
suitable	O
animal	O
models	O
need	O
to	O
be	O
performed	O
before	O
purpurin	B
can	O
be	O
considered	O
a	O
true	O
chemopreventive	B
agent	I
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
express	O
their	O
thanks	O
to	O
The	O
Japanese	O
Society	O
for	O
the	O
Promotion	O
of	O
Science	O
(	O
JSPS	O
)	O
for	O
their	O
generous	O
stipend	O
for	O
one	O
of	O
them	O
(	O
T.M	O
)	O
,	O
to	O
The	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
for	O
funding	O
the	O
research	O
through	O
the	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
JSPS	O
Fellows	O
(	O
No.	O
97439	O
)	O
and	O
to	O
The	O
San	O
-	O
Ei	O
Gen	O
Foundation	O
for	O
Food	O
Chemical	O
Research	O
,	O
Osaka	O
,	O
for	O
their	O
funding	O
and	O
gift	O
of	O
pure	O
purpurin	B
.	O

Odorants	B
are	O
usually	O
small	O
hydrophobic	O
,	O
highly	O
volatile	O
molecules	O
which	O
have	O
great	O
importance	O
in	O
the	O
sensory	O
guidance	O
of	O
higher	O
animals	O
and	O
man	O
.	O

Their	O
receptors	O
belong	O
to	O
the	O
large	O
class	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
with	O
seven	O
transmembrane	O
helices	O
.	O

These	O
proteins	O
are	O
selectively	O
expressed	O
on	O
the	O
cilia	O
of	O
olfactory	O
neurons	O
in	O
the	O
olfactory	O
epithelium	O
(	O
Schild	O
&	O
Restrepo	O
,	O
1998	O
;	O
Buck	O
,	O
1996	O
;	O
Mombaerts	O
,	O
1996	O
;	O
Buck	O
&	O
Axel	O
,	O
1991	O
)	O
.	O

The	O
odorant	O
receptors	O
have	O
been	O
identified	O
as	O
constituting	O
a	O
large	O
family	O
of	O
homologous	O
receptors	O
(	O
approximately	O
1000	O
genes	O
)	O
,	O
allowing	O
exquisitely	O
specific	O
interactions	O
of	O
each	O
odorant	B
with	O
a	O
small	O
set	O
of	O
receptors	O
and	O
thus	O
odorant	B
identification	O
in	O
the	O
brain	O
.	O

Very	O
little	O
is	O
known	O
about	O
the	O
structure	O
of	O
the	O
binding	O
sites	O
and	O
,	O
consequently	O
,	O
of	O
the	O
molecular	O
basis	O
of	O
the	O
recognition	O
specificity	O
.	O

The	O
integral	O
transmembrane	O
nature	O
of	O
the	O
receptor	O
makes	O
experimentation	O
very	O
difficult	O
.	O

There	O
are	O
a	O
few	O
reported	O
examples	O
of	O
expression	O
of	O
small	O
amounts	O
of	O
odorant	O
receptors	O
in	O
insect	O
cells	O
(	O
Nekrasova	O
et	O
al	O
.	O
,	O
1996	O
;	O
Raming	O
et	O
al	O
.	O
,	O
1993	O
)	O
and	O
in	O
bacteria	O
(	O
Kiefer	O
et	O
al	O
.	O
,	O
1996	O
)	O
,	O
but	O
only	O
recently	O
the	O
functionality	O
of	O
a	O
cloned	O
mammalian	O
receptor	O
has	O
been	O
clearly	O
proven	O
in	O
the	O
rat	O
(	O
Zhao	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Small	O
carrier	O
proteins	O
have	O
been	O
shown	O
to	O
exist	O
in	O
insects	O
and	O
mammals	O
,	O
which	O
serve	O
to	O
shuttle	O
odor	O
or	O
pheromone	B
molecules	O
between	O
air	O
and	O
the	O
receptor	O
through	O
the	O
nasal	O
mucus	O
or	O
the	O
sensory	O
lymph	O
(	O
Pelosi	O
,	O
1994	O
)	O
.	O

These	O
proteins	O
are	O
called	O
odorant	O
or	O
pheromone	O
-	O
binding	O
proteins	O
(	O
OBP	O
,	O
PBP	O
)	O
.	O

In	O
insects	O
,	O
the	O
PBP	O
/	O
pheromone	B
specificity	O
is	O
very	O
strict	O
,	O
but	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
these	O
proteins	O
is	O
still	O
unknown	O
.	O

In	O
mammals	O
,	O
OBPs	O
display	O
apparently	O
very	O
little	O
specificity	O
,	O
since	O
they	O
were	O
found	O
to	O
be	O
able	O
to	O
bind	O
any	O
one	O
of	O
tens	O
of	O
different	O
odor	B
molecules	I
with	O
micromolar	O
affinities	O
(	O
Pelosi	O
,	O
1994	O
)	O
.	O

The	O
structure	O
of	O
two	O
OBPs	O
,	O
alone	O
or	O
in	O
complex	O
,	O
have	O
been	O
solved	O
(	O
Tegoni	O
et	O
al	O
.	O
,	O
1996	O
;	O
Bianchet	O
et	O
al	O
.	O
,	O
1996	O
;	O
Spinelli	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Antibodies	O
with	O
narrow	O
specificity	O
may	O
seem	O
an	O
ideal	O
surrogate	O
receptor	O
system	O
,	O
with	O
which	O
many	O
fundamental	O
features	O
of	O
highly	O
specific	O
interactions	O
of	O
such	O
small	O
hydrophobic	O
molecules	O
can	O
be	O
studied	O
,	O
even	O
though	O
the	O
topology	O
of	O
the	O
seven	O
-	O
helix	O
transmembrane	O
protein	O
will	O
almost	O
certainly	O
be	O
entirely	O
different	O
.	O

Furthermore	O
,	O
a	O
surrogate	O
receptor	O
system	O
such	O
as	O
antibodies	O
might	O
have	O
direct	O
biotechnological	O
applications	O
,	O
such	O
as	O
in	O
high	O
-	O
throughput	O
screening	O
for	O
odorants	B
,	O
or	O
as	O
a	O
controlled	O
release	O
system	O
,	O
in	O
which	O
the	O
odorant	B
is	O
given	O
off	O
once	O
the	O
protein	O
is	O
denatured	O
.	O

To	O
begin	O
to	O
study	O
such	O
questions	O
,	O
we	O
have	O
chosen	O
the	O
musk	O
odorant	B
traseolide	B
(	O
6-acetyl-1-isopropyl-2,3,3,5-tetramethyl	B
-	I
indane	I
)	O
as	O
a	O
model	O
system	O
.	O

Natural	O
musk	O
was	O
first	O
discovered	O
in	O
the	O
exocrine	O
scent	O
glands	O
of	O
the	O
deer	O
-	O
like	O
Moschus	O
animal	O
Moschus	O
moschiferus	O
,	O
which	O
lives	O
in	O
the	O
Himalayas	O
.	O

It	O
functions	O
as	O
territorial	O
marker	O
and	O
attracts	O
the	O
female	O
counterpart	O
(	O
Walbaum	O
,	O
1906	O
;	O
Ohloff	O
,	O
1990	O
)	O
.	O

Since	O
ca	O
1930	O
,	O
compounds	O
with	O
moschus	O
(	O
musk	O
)	O
-like	O
odor	O
have	O
been	O
synthetically	O
manufactured	O
in	O
large	O
amounts	O
and	O
are	O
used	O
in	O
fragrances	B
for	O
cosmetic	B
and	O
household	O
products	O
(	O
Kevekordes	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
antibodies	O
against	O
traseolide	B
,	O
their	O
fine	O
specificity	O
against	O
analogs	B
and	O
the	O
structural	O
basis	O
for	O
their	O
specificity	O
as	O
deduced	O
from	O
the	O
crystal	O
structure	O
of	O
a	O
Fab	O
fragment	O
,	O
complexed	O
with	O
traseolide	B
,	O
at	O
2.6	O
Å	O
resolution	O
.	O

By	O
expressing	O
a	O
representative	O
member	O
of	O
each	O
family	O
of	O
the	O
anti	O
-	O
traseolide	B
immune	O
response	O
as	O
scFv	O
fragments	O
in	O
Escherichia	O
coli	O
,	O
the	O
foundations	O
for	O
further	O
controlled	O
release	O
applications	O
and	O
structure	O
activity	O
relationships	O
can	O
be	O
laid	O
.	O

Results	O
Production	O
and	O
screening	O
of	O
cell	O
lines	O
Mice	O
were	O
immunized	O
with	O
the	O
succinyl	B
derivative	I
of	I
the	O
traseolide	B
hapten	B
,	O
coupled	O
to	O
keyhole	O
limpet	O
haemocyanin	O
(	O
KLH	O
)	O
at	O
position	O
R1	O
(	O
Figure	O
1	O
)	O
.	O

Supernatants	O
of	O
stable	O
cell	O
lines	O
were	O
screened	O
in	O
ELISA	O
for	O
the	O
production	O
of	O
monoclonal	O
antibodies	O
recognizing	O
the	O
odor	O
molecule	O
traseolide	B
.	O

Most	O
of	O
the	O
heavy	O
chains	O
were	O
determined	O
to	O
be	O
of	O
subclass	O
IgG1	O
,	O
while	O
light	O
chains	O
were	O
mostly	O
κ	O
-	O
chains	O
.	O

Antibody	O
variable	O
region	O
sequences	O
From	O
the	O
panel	O
of	O
antibody	O
-	O
producing	O
cells	O
,	O
eight	O
cell	O
lines	O
were	O
selected	O
for	O
sequence	O
determination	O
of	O
the	O
variable	O
regions	O
.	O

The	O
choice	O
depended	O
on	O
isotype	O
,	O
binding	O
and	O
production	O
levels	O
.	O

The	O
fragments	O
encoding	O
the	O
heavy	O
and	O
light	O
chain	O
variable	O
domains	O
were	O
cloned	O
and	O
sequenced	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
alignment	O
of	O
the	O
amino	B
acid	I
sequences	O
of	O
the	O
anti	O
-	O
traseolide	B
antibodies	O
reveals	O
that	O
six	O
sequences	O
are	O
highly	O
homologous	O
(	O
<	O
5	O
%	O
differences	O
in	O
VH	O
and	O
in	O
VL	O
coding	O
sequences	O
)	O
.	O

They	O
are	O
using	O
the	O
same	O
Vκ	O
,	O
Jκ	O
,	O
VH	O
,	O
D	O
and	O
JH	O
elements	O
,	O
and	O
were	O
thus	O
most	O
likely	O
derived	O
from	O
the	O
same	O
B	O
-	O
cell	O
.	O

The	O
two	O
other	O
sequences	O
differ	O
considerably	O
in	O
both	O
framework	O
and	O
CDR	O
residues	O
(	O
Figure	O
2	O
)	O
.	O

These	O
two	O
sequences	O
and	O
one	O
member	O
of	O
the	O
group	O
of	O
six	O
were	O
thus	O
chosen	O
for	O
further	O
characterization	O
as	O
scFv	O
fragments	O
(	O
M02	O
/	O
01	O
/	O
01	O
,	O
M02	O
/	O
11	O
/	O
01	O
and	O
M03	O
/	O
01	O
/	O
01	O
)	O
.	O

For	O
convenience	O
the	O
scFv	O
fragments	O
were	O
given	O
shorter	O
names	O
:	O
M02	O
/	O
01	O
/	O
01	O
,	O
scFv	O
Tras	O
-	O
X	O
;	O
M03	O
/	O
01	O
/	O
01	O
,	O
scFv	O
Tras	O
-	O
S	O
(	O
for	O
its	O
serine	B
at	O
position	O
H92	O
;	O
numbering	O
according	O
to	O
Kabat	O
et	O
al	O
.	O
,	O
1991	O
)	O
;	O
M02	O
/	O
11	O
/	O
01	O
,	O
scFv	O
Tras	O
-	O
L	O
(	O
for	O
its	O
lambda	O
light	O
chain	O
)	O
.	O

The	O
cell	O
line	O
expressing	O
monoclonal	O
antibody	O
M02	O
/	O
05	O
/	O
01	O
yielded	O
more	O
protein	O
than	O
the	O
cell	O
line	O
expressing	O
the	O
homologous	O
M02	O
/	O
01	O
/	O
01	O
sequence	O
.	O

Therefore	O
,	O
the	O
M02	O
/	O
05	O
/	O
01	O
variant	O
was	O
chosen	O
for	O
crystallization	O
as	O
a	O
Fab	O
fragment	O
.	O

The	O
variable	O
regions	O
of	O
the	O
antibodies	O
M02	O
/	O
01	O
/	O
01	O
and	O
M02	O
/	O
05	O
/	O
01	O
vary	O
in	O
eight	O
amino	B
acid	I
residue	O
positions	O
(	O
Figure	O
2	O
)	O
.	O

M02	O
/	O
05	O
/	O
01	O
contains	O
one	O
somatic	O
mutation	O
located	O
in	O
the	O
binding	O
pocket	O
,	O
Ala	B
H93	O
Val	B
,	O
as	O
became	O
apparent	O
from	O
the	O
X	O
-	O
ray	O
structure	O
of	O
the	O
complex	O
(	O
see	O
below	O
)	O
.	O

The	O
germline	O
sequence	O
(	O
Figure	O
2	O
)	O
has	O
Ala	B
H93	O
,	O
as	O
deduced	O
from	O
sequence	O
statistics	O
with	O
the	O
40	O
most	O
closely	O
related	O
antibody	O
sequences	O
of	O
the	O
Kabat	O
database	O
(	O
for	O
details	O
,	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
other	O
somatic	O
point	O
mutations	O
do	O
not	O
appear	O
functionally	O
significant	O
,	O
as	O
they	O
are	O
not	O
in	O
the	O
binding	O
pocket	O
and	O
do	O
not	O
directly	O
contact	O
the	O
antigen	B
,	O
but	O
rather	O
simply	O
reflect	O
the	O
background	O
mutation	O
rate	O
.	O

Expression	O
,	O
isolation	O
and	O
detection	O
of	O
scFv	O
fragments	O
The	O
VH	O
and	O
VL	O
genes	O
were	O
cloned	O
in	O
scFv	O
format	O
(	O
VH	O
-linker	O
-	O
VL	O
)	O
with	O
a	O
N	O
-	O
terminal	O
FLAG	O
-	O
tag	O
and	O
a	O
C	O
-	O
terminal	O
Myc	O
and	O
His	B
-	O
tag	O
in	O
the	O
vector	O
pIG6	O
(	O
Ge	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

The	O
scFv	O
fragments	O
were	O
expressed	O
in	O
the	O
periplasm	O
of	O
E.	O
coli	O
.	O

In	O
the	O
soluble	O
,	O
periplasmic	O
fraction	O
scFv	O
Tras	O
-	O
S	O
(	O
from	O
the	O
mAb	O
M03	O
/	O
01	O
/	O
01	O
)	O
and	O
scFv	O
Tras	O
-	O
L	O
(	O
from	O
the	O
mAb	O
M02	O
/	O
11	O
/	O
01	O
)	O
were	O
detected	O
in	O
reasonable	O
amounts	O
(	O
ca	O
1	O
mg	O
/	O
l	O
E.	O
coli	O
)	O
,	O
while	O
only	O
a	O
small	O
amount	O
of	O
scFv	O
Tras	O
-	O
X	O
(	O
from	O
the	O
mAb	O
M02	O
/	O
01	O
/	O
01	O
)	O
was	O
found	O
(	O
Figure	O
3	O
(	O
a	O
)	O
)	O
.	O

In	O
the	O
insoluble	O
fraction	O
a	O
double	O
band	O
for	O
scFv	O
Tras	O
-	O
X	O
was	O
observed	O
(	O
data	O
not	O
shown	O
;	O
cf	O
.	O

Figure	O
3	O
(	O
b	O
)	O
)	O
.	O

Examination	O
of	O
the	O
amino	B
acid	I
sequence	O
of	O
scFv	O
Tras	O
-	O
X	O
showed	O
a	O
rare	O
sequence	O
of	O
four	O
positively	O
charged	O
residues	O
in	O
CDR3	O
of	O
the	O
heavy	O
chain	O
.	O

To	O
check	O
whether	O
these	O
residues	O
were	O
causing	O
the	O
problems	O
in	O
the	O
periplasmic	O
production	O
of	O
the	O
fragment	O
,	O
two	O
mutations	O
were	O
introduced	O
to	O
give	O
the	O
mutant	O
Tras	O
-	O
P	O
,	O
which	O
substituted	O
the	O
charged	O
residues	O
by	O
neutral	O
amino	B
acids	I
:	O
Arg	B
H100a	O
Leu	B
and	O
Lys	B
H100c	O
Gln	B
.	O

These	O
residues	O
were	O
selected	O
with	O
the	O
help	O
of	O
a	O
preliminary	O
model	O
structure	O
of	O
the	O
antibody	O
variable	O
fragment	O
,	O
applying	O
the	O
criterion	O
that	O
the	O
backbone	O
conformation	O
of	O
CDRH3	O
would	O
stay	O
intact	O
(	O
A.	O
van	O
Beusekom	O
,	O
data	O
not	O
shown	O
)	O
.	O

The	O
subsequently	O
obtained	O
crystal	O
structure	O
(	O
see	O
below	O
)	O
showed	O
this	O
assumption	O
to	O
be	O
correct	O
.	O

The	O
CDRH3	O
mutations	O
indeed	O
led	O
to	O
a	O
much	O
higher	O
yield	O
of	O
soluble	O
scFv	O
in	O
the	O
periplasm	O
(	O
Figure	O
3	O
(	O
a	O
)	O
,	O
mutant	O
Tras	O
-	O
P	O
versus	O
Tras	O
-	O
X	O
)	O
.	O

On	O
a	O
Western	O
blot	O
developed	O
with	O
antibodies	O
recognizing	O
a	O
C	O
-	O
terminal	O
His	B
-	O
tag	O
,	O
the	O
insoluble	O
fraction	O
of	O
the	O
scFv	O
Tras	O
-	O
X	O
shows	O
a	O
double	O
band	O
(	O
Figure	O
3	O
(	O
b	O
)	O
)	O
.	O

One	O
band	O
has	O
the	O
identical	O
molecular	O
mass	O
as	O
mutant	O
scFv	O
Tras	O
-	O
P	O
,	O
presumably	O
the	O
correctly	O
processed	O
scFv	O
protein	O
,	O
while	O
the	O
second	O
band	O
has	O
a	O
slightly	O
higher	O
molecular	O
mass	O
.	O

Only	O
the	O
lower	O
one	O
is	O
detected	O
in	O
the	O
Western	O
blot	O
developed	O
with	O
antibodies	O
recognizing	O
the	O
N	O
-	O
terminal	O
FLAG	O
sequence	O
(	O
Figure	O
3	O
(	O
c	O
)	O
)	O
.	O

This	O
means	O
that	O
the	O
FLAG	O
sequence	O
is	O
not	O
at	O
the	O
N	O
terminus	O
in	O
the	O
upper	O
band	O
(	O
Knappik	O
&	O
Plückthun	O
,	O
1994	O
)	O
,	O
and	O
is	O
therefore	O
not	O
recognized	O
by	O
this	O
anti	O
-	O
FLAG	O
antibody	O
,	O
but	O
Tras	O
-	O
X	O
must	O
carry	O
an	O
N	O
-	O
terminal	O
extension	O
,	O
most	O
likely	O
the	O
signal	O
sequence	O
.	O

Positive	O
charges	O
have	O
been	O
observed	O
before	O
to	O
interfere	O
with	O
transport	O
through	O
the	O
membrane	O
(	O
Ayala	O
et	O
al	O
.	O
,	O
1995	O
;	O
Summers	O
et	O
al	O
.	O
,	O
1989	O
;	O
von	O
Heijne	O
,	O
1986	O
)	O
.	O

Thus	O
,	O
the	O
removal	O
of	O
two	O
positive	O
charges	O
in	O
CDRH3	O
(	O
to	O
interrupt	O
the	O
positive	O
charge	O
cluster	O
)	O
improved	O
the	O
amount	O
of	O
periplasmic	O
protein	O
,	O
presumably	O
at	O
least	O
in	O
part	O
because	O
of	O
more	O
efficient	O
membrane	O
transport	O
.	O

Additionally	O
,	O
the	O
positively	O
charged	O
cluster	O
may	O
have	O
provided	O
a	O
protease	O
target	O
(	O
Volkin	O
&	O
Klibanov	O
,	O
1989	O
;	O
Hammarberg	O
et	O
al	O
.	O
,	O
1990	O
)	O
and	O
thus	O
the	O
mutations	O
may	O
have	O
stabilized	O
the	O
protein	O
,	O
once	O
it	O
is	O
in	O
the	O
periplasm	O
.	O

The	O
functionality	O
of	O
the	O
scFv	O
Tras	O
-	O
P	O
,	O
Tras	O
-	O
L	O
and	O
Tras	O
-	O
S	O
fragments	O
was	O
checked	O
qualitatively	O
by	O
an	O
inhibition	O
ELISA	O
assay	O
.	O

Equal	O
amounts	O
of	O
soluble	O
periplasmic	O
fractions	O
were	O
applied	O
to	O
microtiter	O
plates	O
coated	O
with	O
the	O
traseolide	B
antigen	I
,	O
and	O
the	O
inhibition	O
by	O
soluble	O
traseolide	B
was	O
determined	O
.	O

All	O
showed	O
specific	O
ELISA	O
signals	O
of	O
the	O
same	O
order	O
of	O
magnitude	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
quantitatively	O
investigate	O
the	O
effect	O
of	O
the	O
CDRH3	O
mutations	O
on	O
the	O
binding	O
properties	O
of	O
the	O
antibody	O
fragment	O
,	O
the	O
K	O
D	O
values	O
of	O
scFv	O
Tras	O
-	O
X	O
and	O
the	O
mutant	O
Tras	O
-	O
P	O
were	O
determined	O
by	O
fluorescence	O
titration	O
.	O

Both	O
fragments	O
were	O
produced	O
as	O
cytoplasmic	O
inclusion	O
bodies	O
in	O
E.	O
coli	O
,	O
refolded	O
and	O
purified	O
by	O
affinity	O
chromatography	O
with	O
the	O
hapten	B
traseolide	B
.	O

Using	O
this	O
method	O
,	O
the	O
positive	O
charges	O
could	O
not	O
affect	O
the	O
expression	O
of	O
the	O
scFv	O
fragment	O
.	O

The	O
binding	O
constant	O
was	O
determined	O
by	O
a	O
direct	O
fit	O
of	O
the	O
protein	O
fluorescence	O
signal	O
as	O
a	O
function	O
of	O
the	O
hapten	B
concentration	O
(	O
Jung	O
&	O
Plückthun	O
,	O
1997	O
)	O
.	O

The	O
scFv	O
Tras	O
-	O
X	O
has	O
a	O
K	O
D	O
of	O
2.0	O
×	O
10−7	O
M	O
and	O
the	O
scFv	O
Tras	O
-	O
P	O
a	O
K	O
D	O
of	O
3.5	O
×	O
10−7	O
M	O
,	O
which	O
is	O
within	O
the	O
range	O
of	O
error	O
and	O
also	O
not	O
significantly	O
different	O
from	O
the	O
parent	O
antibody	O
(	O
see	O
below	O
)	O
.	O

Binding	O
assays	O
:	O
competition	O
BIAcore	O
and	O
fluorescence	O
titration	O
Fluorescence	O
titration	O
of	O
M02	O
/	O
05	O
/	O
01	O
and	O
M02	O
/	O
01	O
/	O
01	O
Fluorescence	O
titration	O
experiments	O
were	O
performed	O
with	O
the	O
mAb	O
and	O
the	O
scFv	O
Tras	O
-	O
X	O
fragment	O
of	O
M02	O
/	O
01	O
/	O
01	O
and	O
the	O
mAb	O
and	O
Fab	O
fragments	O
of	O
M02	O
/	O
05	O
/	O
01	O
.	O

M02	O
/	O
05	O
/	O
01	O
is	O
the	O
antibody	O
for	O
which	O
the	O
X	O
-	O
ray	O
structure	O
of	O
the	O
Fab	O
fragment	O
was	O
determined	O
(	O
see	O
below	O
)	O
,	O
and	O
M02	O
/	O
01	O
/	O
01	O
is	O
closely	O
related	O
,	O
but	O
carries	O
the	O
germline	O
amino	O
acid	O
Ala	B
H93	O
in	O
the	O
binding	O
pocket	O
.	O

The	O
binding	O
specificity	O
of	O
the	O
antibodies	O
M02	O
/	O
05	O
/	O
01	O
(	O
Val	O
H93	O
)	O
and	O
M02	O
/	O
01	O
/	O
01	O
(	O
Ala	O
H93	O
)	O
was	O
investigated	O
quantitatively	O
by	O
determining	O
the	O
binding	O
constants	O
of	O
three	O
structurally	O
related	O
traseolide	B
variants	B
.	O

The	O
traseolide	B
variants	B
used	O
were	O
the	O
succinyl	B
derivatives	I
of	B
T+	B
,	O
T−	B
and	O
Teth	B
(	O
Figure	O
1	O
)	O
.	O

The	O
comparison	O
of	O
the	O
binding	O
characteristics	O
of	O
the	O
two	O
related	O
antibodies	O
M02	O
/	O
05	O
/	O
01	O
and	O
M02	O
/	O
01	O
/	O
01	O
showed	O
that	O
the	O
binding	O
to	O
the	O
original	O
hapten	B
differs	O
significantly	O
:	O
the	O
K	O
D	O
of	O
the	O
antibody	O
M02	O
/	O
05	O
/	O
01	O
(	O
Val	O
H93	O
)	O
is	O
2.7	O
×	O
10−9	O
M	O
,	O
while	O
the	O
antibody	O
M02	O
/	O
01	O
/	O
01	O
(	O
Ala	O
H93	O
)	O
shows	O
a	O
K	O
D	O
of	O
1.6	O
×	O
10−7	O
M	O
for	O
the	O
same	O
hapten	B
,	O
which	O
corresponds	O
to	O
a	O
difference	O
in	O
dissociation	O
constant	O
of	O
a	O
factor	O
of	O
ca	O
75	O
(	O
Table	O
1	O
)	O
.	O

Another	O
remarkable	O
finding	O
is	O
that	O
for	O
M02	O
/	O
01	O
/	O
01	O
(	O
Ala	O
H93	O
)	O
no	O
significant	O
differences	O
were	O
found	O
in	O
binding	O
constant	O
between	O
the	O
three	O
closely	O
related	O
traseolide	B
variants	B
.	O

For	O
M02	O
/	O
05	O
/	O
01	O
(	O
Val	O
H93	O
)	O
,	O
however	O
,	O
the	O
odorless	O
variant	O
T−	B
,	O
lacking	O
one	O
methyl	B
group	I
(	O
Figure	O
1	O
)	O
,	O
showed	O
a	O
tenfold	O
lower	O
affinity	O
than	O
the	O
original	O
T+	B
hapten	I
.	O

The	O
Teth	B
variant	I
,	O
which	O
has	O
an	O
ethyl	B
group	I
instead	O
of	O
a	O
methyl	B
group	I
at	O
this	O
position	O
(	O
Figure	O
1	O
)	O
,	O
bound	O
with	O
about	O
the	O
same	O
affinity	O
as	O
the	O
original	O
hapten	B
T+	I
.	O

As	O
expected	O
,	O
the	O
Fab	O
fragment	O
of	O
M02	O
/	O
05	O
/	O
01	O
and	O
the	O
recombinant	O
scFv	O
Tras	O
-	O
X	O
(	O
from	O
M02	O
/	O
01	O
/	O
01	O
)	O
fragment	O
have	O
very	O
similar	O
binding	O
behavior	O
as	O
their	O
parent	O
mAb	O
to	O
monomeric	O
soluble	O
hapten	B
,	O
and	O
the	O
small	O
differences	O
may	O
indicate	O
the	O
limits	O
of	O
the	O
accuracy	O
of	O
the	O
measurements	O
.	O

BIAcore	O
measurements	O
of	O
M02	O
/	O
11	O
/	O
01	O
and	O
M03	O
/	O
01	O
/	O
01	O
Purified	O
monoclonal	O
antibodies	O
M02	O
/	O
11	O
/	O
01	O
and	O
M03	O
/	O
01	O
/	O
01	O
(	O
the	O
parent	O
mAbs	O
of	O
scFv	O
Tras	O
-	O
L	O
and	O
Tras	O
-	O
S	O
)	O
were	O
used	O
for	O
K	O
D	O
determination	O
in	O
solution	O
by	O
competition	O
BIAcore	O
analysis	O
(	O
Karlsson	O
,	O
1994	O
;	O
Nieba	O
et	O
al	O
.	O
,	O
1996	O
;	O
Hanes	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

In	O
this	O
experiment	O
,	O
the	O
monoclonal	O
antibody	O
was	O
incubated	O
with	O
the	O
soluble	O
succinyl	B
derivative	I
of	I
traseolide	I
,	O
and	O
the	O
mixture	O
was	O
injected	O
on	O
a	O
BIAcore	O
chip	O
containing	O
immobilized	O
BSA	O
-	O
traseolide	B
conjugate	O
at	O
high	O
density	O
.	O

Only	O
free	O
antibody	O
,	O
but	O
not	O
hapten	B
-	O
bound	O
antibody	O
,	O
can	O
bind	O
to	O
hapten	B
on	O
the	O
surface	O
,	O
analogous	O
to	O
the	O
Friguet	O
-	O
Goldberg	O
ELISA	O
(	O
Friguet	O
et	O
al	O
.	O
,	O
1985	O
)	O
.	O

The	O
observed	O
mass	O
-	O
transfer	O
limited	O
rates	O
therefore	O
indicated	O
the	O
amount	O
of	O
free	O
antibody	O
in	O
solution	O
as	O
a	O
function	O
of	O
hapten	B
concentration	O
.	O

In	O
this	O
way	O
,	O
the	O
correct	O
dissociation	O
constant	O
in	O
solution	O
could	O
be	O
obtained	O
,	O
independent	O
of	O
any	O
BIAcore	O
rebinding	O
errors	O
(	O
Schuck	O
,	O
1997	O
)	O
.	O

The	O
slopes	O
of	O
the	O
BIAcore	O
signal	O
,	O
which	O
correspond	O
to	O
the	O
initial	O
binding	O
rates	O
(	O
k	O
obs	O
)	O
,	O
were	O
plotted	O
against	O
the	O
corresponding	O
total	O
hapten	B
concentration	O
,	O
and	O
fitted	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Hanes	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

The	O
K	O
D	O
of	O
M02	O
/	O
11	O
/	O
01	O
was	O
calculated	O
as	O
2.1	O
×	O
10−9	O
M	O
and	O
that	O
of	O
M03	O
/	O
01	O
/	O
01	O
as	O
1.8	O
×	O
10−8	O
M	O
(	O
Table	O
1	O
)	O
.	O

X	O
-	O
ray	O
structure	O
of	O
bound	O
and	O
unbound	O
Fab	O
M02	O
/	O
05	O
/	O
01	O
The	O
three	O
-	O
dimensional	O
structures	O
of	O
Fab	O
M02	O
/	O
05	O
/	O
01	O
complexed	O
with	O
the	O
succinyl	B
derivative	I
of	I
the	O
traseolide	B
hapten	B
was	O
solved	O
at	O
2.6	O
Å	O
resolution	O
.	O

The	O
quality	O
of	O
the	O
Fab	O
-	O
hapten	O
structure	O
can	O
be	O
estimated	O
from	O
the	O
diffraction	O
and	O
refinement	O
data	O
(	O
Table	O
2	O
)	O
,	O
from	O
the	O
electron	O
density	O
map	O
(	O
Figure	O
4	O
)	O
and	O
from	O
the	O
Ramachandran	O
plot	O
,	O
in	O
which	O
85	O
%	O
of	O
the	O
residues	O
are	O
located	O
in	O
the	O
most	O
favorable	O
areas	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
""""	O
elbow	O
""""	O
angle	O
,	O
made	O
by	O
the	O
pseudo-2-fold	O
axes	O
relating	O
VH	O
to	O
VL	O
and	O
CH1	O
to	O
CL	O
is	O
∼169	O
°	O
,	O
giving	O
an	O
elongated	O
Fab	O
structure	O
with	O
few	O
intra	O
-	O
chain	O
,	O
interdomain	O
contacts	O
.	O

A	O
total	O
of	O
120	O
water	B
molecules	O
were	O
fitted	O
to	O
the	O
Fab	O
-	O
hapten	O
model	O
.	O

The	O
electron	O
density	O
for	O
the	O
predominantly	O
bound	O
(	B
S	I
,	I
S	I
)	I
-traseolide	I
is	O
of	O
high	O
quality	O
,	O
making	O
it	O
possible	O
to	O
position	O
it	O
with	O
good	O
precision	O
(	O
Figure	O
4	O
)	O
.	O

We	O
can	O
not	O
exclude	O
the	O
presence	O
of	O
some	O
minor	O
fraction	O
of	O
(	B
R	I
,	I
R	I
)	I
-traseolide	I
in	O
the	O
binding	O
site	O
.	O

At	O
a	O
contour	O
level	O
of	O
1.2σ	O
all	O
hapten	B
atoms	O
are	O
associated	O
with	O
electron	O
density	O
.	O

Accordingly	O
,	O
the	O
B	O
-factors	O
of	O
25.0	O
Å2	O
for	O
the	O
hapten	B
are	O
relatively	O
low	O
compared	O
to	O
the	O
average	O
(	O
40.5	O
Å2	O
;	O
Table	O
2	O
)	O
.	O

The	O
variable	O
domains	O
have	O
very	O
long	O
complementarity	O
-	O
determing	O
regions	O
(	O
CDRs	O
)	O
,	O
especially	O
H3	O
and	O
L1	O
,	O
which	O
protrude	O
from	O
the	O
combining	O
site	O
and	O
form	O
a	O
very	O
deep	O
cleft	O
between	O
each	O
other	O
(	O
Figure	O
5	O
)	O
.	O

The	O
long	O
CDRH3	O
runs	O
in	O
the	O
middle	O
of	O
the	O
cleft	O
and	O
folds	O
back	O
,	O
forming	O
a	O
flat	O
floor	O
for	O
the	O
combining	O
site	O
.	O

The	O
traseolide	B
hapten	B
is	O
located	O
in	O
a	O
deep	O
hydrophobic	O
pocket	O
(	O
Figure	O
6	O
)	O
involving	O
part	O
of	O
the	O
β	O
-	O
sheets	O
and	O
both	O
CDR3	O
of	O
the	O
heavy	O
and	O
light	O
chain	O
(	O
H3	O
and	O
L3	O
)	O
(	O
Figure	O
5	O
and	O
Table	O
3	O
)	O
.	O

The	O
binding	O
pocket	O
is	O
approximately	O
12	O
Å	O
deep	O
and	O
7	O
Å	O
wide	O
,	O
which	O
is	O
sufficient	O
to	O
bury	O
in	O
the	O
complex	O
450	O
Å2	O
of	O
the	O
water	B
-	O
accessible	O
surface	O
area	O
of	O
traseolide	B
(	O
of	O
531	O
Å2	O
in	O
total	O
)	O
(	O
Figure	O
6	O
)	O
.	O

As	O
expected	O
for	O
a	O
hydrophobic	O
hapten	B
,	O
the	O
nature	O
of	O
the	O
combining	O
site	O
is	O
hydrophobic	O
(	O
Figure	O
7	O
and	O
Table	O
3	O
)	O
.	O

The	O
hydrophobic	O
ring	O
system	O
is	O
contained	O
in	O
the	O
cavity	O
,	O
while	O
the	O
succinyl	B
moiety	I
is	O
directed	O
towards	O
the	O
solvent	O
and	O
is	O
hydrogen	B
-	O
bonded	O
to	O
two	O
water	B
molecules	O
,	O
W42	O
and	O
W52	O
,	O
located	O
at	O
2.5	O
Å	O
and	O
3.9	O
Å	O
,	O
respectively	O
(	O
Figure	O
7	O
)	O
.	O

The	O
majority	O
of	O
aromatic	B
residues	I
are	O
found	O
within	O
6	O
Å	O
of	O
the	O
hapten	O
:	O
Trp	B
H47	O
,	O
Tyr	B
H50	O
,	O
Trp	B
H103	O
from	O
the	O
heavy	O
chain	O
,	O
and	O
Tyr	B
L49	O
,	O
Tyr	B
L91	O
,	O
Phe	B
L94	O
,	O
Phe	B
L96	O
,	O
Phe	B
L98	O
from	O
the	O
light	O
chain	O
.	O

A	O
few	O
aliphatic	B
(	O
Ile	B
H37	O
,	O
Val	B
H93	O
,	O
Leu	B
H96	O
,	O
Leu	B
L36	O
and	O
Val	B
L89	O
)	O
and	O
polar	B
non	I
-	I
charged	I
amino	I
acid	I
residues	I
(	O
Asn	B
H35a	O
,	O
Thr	B
H94	O
,	O
Ser	B
H95	O
,	O
Ser	B
H101	O
and	O
Gly	B
L34	O
)	O
complete	O
the	O
active	O
site	O
(	O
Figure	O
7	O
)	O
.	O

Two	O
charged	B
residues	I
are	O
found	O
in	O
the	O
vicinity	O
of	O
the	O
hapten	B
.	O

Lys	B
H100c	O
is	O
located	O
at	O
4.5	O
Å	O
from	O
the	O
carboxylate	B
of	O
the	O
succinyl	B
moiety	I
,	O
while	O
Glu	B
L55	O
is	O
located	O
on	O
a	O
side	O
of	O
the	O
cavity	O
,	O
at	O
4.8	O
Å	O
from	O
one	O
of	O
the	O
methyl	B
group	I
of	O
the	O
isopropyl	B
motif	O
of	O
the	O
hapten	B
.	O

This	O
is	O
not	O
a	O
close	O
distance	O
,	O
however	O
,	O
and	O
the	O
charge	O
of	O
Glu	B
L55	O
is	O
compensated	O
by	O
Arg	B
H100d	O
and	O
Lys	B
L45	O
.	O

The	O
shape	O
of	O
the	O
cavity	O
is	O
not	O
fully	O
complementary	O
to	O
that	O
of	O
the	O
ligand	O
.	O

There	O
is	O
enough	O
room	O
for	O
larger	O
substituents	O
of	O
the	O
cyclopentane	B
ring	O
.	O

Discussion	O
Variability	O
in	O
antibodies	O
directed	O
to	O
a	O
small	O
hapten	B
The	O
alignment	O
of	O
the	O
amino	B
acid	I
sequences	O
of	O
the	O
variable	O
domains	O
of	O
the	O
anti	O
-	O
traseolide	B
antibodies	O
(	O
Figure	O
2	O
)	O
showed	O
that	O
antibodies	O
of	O
three	O
types	O
were	O
obtained	O
.	O

A	O
group	O
of	O
six	O
antibodies	O
,	O
derived	O
from	O
Kabat	O
subgroup	O
VH	O
IB	O
,	O
and	O
Vκ	O
II	O
,	O
M02	O
/	O
11	O
/	O
01	O
derived	O
from	O
VH	O
IB	O
,	O
and	O
Vλ	O
and	O
M03	B
/	I
01	I
/	I
01	I
derived	O
from	O
VH	O
IIB	O
and	O
Vκ	O
II	O
.	O

The	O
heavy	O
chain	O
of	O
M03	O
/	O
01	O
/	O
01	O
contains	O
a	O
very	O
peculiar	O
mutation	O
,	O
the	O
highly	O
conserved	O
Cys	B
H92	O
is	O
substituted	O
for	O
a	O
Ser	B
residue	O
,	O
and	O
thus	O
the	O
disulfide	B
bridge	O
in	O
the	O
heavy	O
chain	O
of	O
this	O
variable	O
domain	O
can	O
not	O
be	O
formed	O
.	O

The	O
consequences	O
for	O
stability	O
have	O
been	O
investigated	O
in	O
detail	O
elsewhere	O
(	O
Langedijk	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

The	O
sequence	O
diversification	O
by	O
somatic	O
mutations	O
has	O
been	O
studied	O
in	O
several	O
anti	O
-	O
hapten	B
systems	O
.	O

It	O
has	O
been	O
reported	O
that	O
mAbs	O
produced	O
against	O
small	O
ligands	O
such	O
as	O
arsonate	B
(	O
Wysocki	O
et	O
al	O
.	O
,	O
1987	O
)	O
,	O
morphine	B
(	O
Kussie	O
et	O
al	O
.	O
,	O
1989	O
)	O
,	O
cyclosporine	B
(	O
Schmitter	O
et	O
al	O
.	O
,	O
1990	O
)	O
,	O
oxazolone	B
(	O
Solin	O
et	O
al	O
.	O
,	O
1992	O
)	O
and	O
progesterone	B
(	O
Arevalo	O
et	O
al	O
.	O
,	O
1993	O
)	O
tend	O
to	O
show	O
a	O
high	O
degree	O
of	O
restriction	O
in	O
the	O
germline	O
V	O
-	O
region	O
gene	O
usage	O
.	O

In	O
contrast	O
,	O
the	O
antibodies	B
raised	O
against	O
the	O
small	O
hapten	B
traseolide	B
show	O
some	O
diversity	O
in	O
the	O
heavy	O
and	O
light	O
chain	O
subclasses	O
used	O
.	O

Also	O
for	O
dioxin	B
(	O
Recinos	O
et	O
al	O
.	O
,	O
1994	O
)	O
and	O
for	O
N	B
-	I
(	I
p	I
-cyanophenyl	I
)	I
-N	I
′-	I
(	I
diphenylmethyl	I
)	I
guanidineacetic	I
acid	I
,	O
a	O
high	O
potency	O
sweetener	O
(	O
Anchin	O
&	O
Linthicum	O
,	O
1993	O
)	O
,	O
diverse	O
structural	O
solutions	O
for	O
the	O
recognition	O
problem	O
of	O
a	O
small	O
molecule	O
were	O
noted	O
.	O

Thus	O
,	O
for	O
small	O
compounds	O
both	O
restricted	O
and	O
diverse	O
immune	O
response	O
have	O
been	O
found	O
.	O

The	O
dissociation	O
constants	O
of	O
the	O
antibodies	O
from	O
the	O
different	O
sequence	O
groups	O
to	O
the	O
traseolide	B
hapten	B
were	O
determined	O
,	O
using	O
either	O
fluorescence	O
titration	O
or	O
competition	O
BIAcore	O
(	O
Table	O
1	O
)	O
.	O

Although	O
small	O
differences	O
in	O
experimental	O
parameters	O
like	O
pH	O
and	O
temperature	O
will	O
always	O
be	O
present	O
,	O
the	O
data	O
may	O
be	O
compared	O
because	O
both	O
methods	O
are	O
based	O
on	O
measurements	O
in	O
solution	O
(	O
Nieba	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O

M02	O
/	O
05	O
/	O
01	O
and	O
M02	O
/	O
11	O
/	O
01	O
bind	O
to	O
the	O
hapten	B
with	O
similar	O
free	O
energy	O
,	O
while	O
M02	O
/	O
01	O
/	O
01	O
and	O
M03	O
/	O
01	O
/	O
01	O
have	O
dissociation	O
constants	O
that	O
are	O
one	O
to	O
two	O
orders	O
of	O
magnitude	O
higher	O
.	O

Binding	O
sites	O
for	O
small	O
hydrophobic	O
ligands	O
There	O
are	O
two	O
driving	O
forces	O
to	O
antigen	B
binding	O
:	O
entropic	O
forces	O
by	O
the	O
hydrophobic	O
effect	O
(	O
liberation	O
of	O
water	B
molecules	O
from	O
apolar	O
protein	O
surfaces	O
upon	O
complex	O
formation	O
)	O
and	O
enthalpic	O
forces	O
(	O
Mariuzza	O
et	O
al	O
.	O
,	O
1994	O
)	O
.	O

Antibodies	O
,	O
even	O
directed	O
to	O
the	O
same	O
target	O
,	O
differ	O
greatly	O
in	O
the	O
relative	O
contribution	O
of	O
each	O
component	O
,	O
and	O
no	O
general	O
rules	O
can	O
be	O
drawn	O
(	O
Malby	O
et	O
al	O
.	O
,	O
1994	O
)	O
.	O

In	O
general	O
,	O
the	O
specificity	O
of	O
antibodies	O
is	O
dependent	O
on	O
the	O
precise	O
nature	O
of	O
the	O
binding	O
surface	O
and	O
the	O
presence	O
or	O
absence	O
of	O
hydrogen	B
bonds	O
and	O
charge	O
-	O
charge	O
interactions	O
.	O

Binding	O
of	O
small	O
hydrophobic	O
haptens	B
to	O
antibodies	O
usually	O
occurs	O
deep	O
in	O
the	O
hydrophobic	O
cleft	O
of	O
the	O
antibody	O
,	O
and	O
thus	O
involves	O
framework	O
residues	O
.	O

Specificity	O
is	O
generally	O
achieved	O
by	O
involving	O
charged	B
residues	I
and	O
hydrogen	B
-	O
bond	O
interactions	O
(	O
Webster	O
et	O
al	O
.	O
,	O
1994	O
)	O
,	O
e.g.	O
steroid	B
hormones	I
(	O
Trinh	O
et	O
al	O
.	O
,	O
1997	O
;	O
Arevalo	O
et	O
al	O
.	O
,	O
1994	O
)	O
or	O
fluorescein	B
(	O
Omelyanenko	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

There	O
are	O
,	O
however	O
,	O
also	O
examples	O
of	O
specific	O
binding	B
devoid	O
of	O
these	O
polar	O
group	O
interactions	O
.	O

The	O
high	O
affinity	O
binding	O
of	O
antibody	O
26	O
-	O
10	O
for	O
digoxin	B
is	O
solely	O
derived	O
from	O
shape	O
complementarity	O
(	O
Jeffrey	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

The	O
traseolide	B
hapten	B
is	O
also	O
a	O
small	O
hydrophobic	O
molecule	O
,	O
and	O
binding	O
is	O
almost	O
entirely	O
due	O
to	O
van	O
der	O
Waals	O
forces	O
and	O
the	O
hydrophobic	O
effect	O
.	O

Both	O
the	O
keto	B
moiety	I
and	O
the	O
carboxylate	B
terminus	O
of	O
traseolide	B
do	O
not	O
seem	O
to	O
have	O
possibilities	O
for	O
hydrogen	B
bonding	O
in	O
close	O
vicinity	O
,	O
since	O
Lys	B
H100c	O
,	O
the	O
closest	O
charge	O
,	O
is	O
found	O
at	O
4.5	O
Å	O
from	O
the	O
carboxylate	B
group	I
of	O
traseolide	B
(	O
Table	O
3	O
)	O
.	O

This	O
was	O
expected	O
for	O
the	O
carboxylate	B
moiety	I
,	O
because	O
during	O
immunization	O
it	O
was	O
not	O
freely	O
accessible	O
,	O
but	O
coupled	O
to	O
KLH	O
.	O

Binding	O
specificity	O
:	O
affinity	O
for	O
related	O
hapten	B
variants	O
From	O
the	O
crystal	O
structure	O
of	O
Fab	O
M02	O
/	O
05	O
/	O
01	O
,	O
the	O
fit	O
of	O
the	O
hapten	B
-	O
antibody	O
contacting	O
surface	O
seems	O
remarkably	O
good	O
.	O

The	O
traseolide	B
hapten	B
has	O
been	O
found	O
in	O
a	O
deep	O
hydrophobic	O
pocket	O
lined	O
with	O
many	O
aromatic	B
residues	I
(	O
Figures	O
6	O
and	O
7	O
)	O
.	O

However	O
,	O
there	O
are	O
some	O
imperfections	O
in	O
that	O
cavities	O
remain	O
in	O
the	O
complex	O
.	O

The	O
side	O
of	O
the	O
binding	O
pocket	O
fits	O
well	O
with	O
the	O
hapten	B
,	O
while	O
the	O
bottom	O
of	O
it	O
is	O
not	O
that	O
close	O
to	O
the	O
molecular	O
surface	O
of	O
the	O
hapten	B
.	O

Visual	O
inspection	O
of	O
the	O
crystal	O
structure	O
showed	O
that	O
different	O
musk	O
molecules	O
could	O
be	O
fitted	O
as	O
well	O
.	O

Substituting	O
ethyl	B
for	O
methyl	B
in	O
the	O
R2	O
position	O
(	O
Figure	O
1	O
)	O
results	O
in	O
slightly	O
better	O
contacts	O
with	O
Leu	B
L36	O
and	O
Trp	B
H103	O
.	O

Substituting	O
a	O
methyl	B
group	I
by	O
an	O
hydrogen	B
atom	O
in	O
R2	O
,	O
however	O
,	O
might	O
be	O
unfavorable	O
,	O
as	O
a	O
cavity	O
would	O
be	O
generated	O
unless	O
the	O
van	O
der	O
Waals	O
contact	O
is	O
maintained	O
by	O
rotation	O
of	O
the	O
whole	O
hapten	B
.	O

These	O
findings	O
fit	O
well	O
with	O
the	O
experimental	O
data	O
(	O
Table	O
1	O
)	O
.	O

Filling	O
up	O
a	O
stable	O
empty	O
cavity	O
in	O
the	O
binding	O
pocket	O
by	O
the	O
ligand	O
might	O
be	O
a	O
general	O
strategy	O
to	O
improve	O
binding	O
energy	O
.	O

An	O
additional	O
4-methyl	O
group	B
attached	O
to	O
the	O
piperidine	B
ring	O
of	O
3-amidinophenylalanine	B
-	O
derived	O
inhibitors	O
to	O
thrombin	O
gave	O
rise	O
to	O
a	O
17-fold	O
better	O
binding	O
(	O
Bergner	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

The	O
more	O
complete	O
spatial	O
occupancy	O
of	O
the	O
hydrophobic	O
S2	O
cavity	O
probably	O
accounts	O
for	O
an	O
increase	O
in	O
free	O
binding	O
energy	O
by	O
1.5	O
kcal	O
/	O
mol	O
.	O

Recently	O
,	O
Dougan	O
et	O
al	O
.	O

(	O
1998	O
)	O
attempted	O
to	O
increase	O
the	O
binding	O
affinity	O
of	O
the	O
scFv	O
antibody	O
NC10	O
for	O
its	O
anti	O
-	O
influenza	O
virus	O
antigen	B
.	O

A	O
cavity	O
in	O
the	O
binding	O
interface	O
was	O
filled	O
with	O
a	O
larger	O
antibody	O
side	O
-	O
chain	O
.	O

However	O
,	O
the	O
replacement	O
of	O
Leu	B
L94	O
with	O
Tyr	B
or	O
Trp	B
abolished	O
binding	O
,	O
while	O
a	O
valine	B
residue	O
led	O
to	O
a	O
reduction	O
in	O
Gibbs	O
free	O
energy	O
(	O
ΔΔG	O
=	O
0.9	O
kcal	O
/	O
mol	O
)	O
.	O

The	O
cavity	O
creating	O
mutation	O
Leu	B
L94	O
Ala	B
abolished	O
binding	O
completely	O
.	O

Effects	O
of	O
somatic	O
mutations	O
in	O
M02	O
/	O
05	O
/	O
01	O
The	O
variable	O
regions	O
of	O
the	O
monoclonal	O
antibodies	O
M02	O
/	O
01	O
/	O
01	O
and	O
M02	O
/	O
05	O
/	O
01	O
vary	O
in	O
eight	O
amino	B
acid	I
positions	O
.	O

M02	O
/	O
05	O
/	O
01	O
contains	O
one	O
somatic	O
mutation	O
that	O
makes	O
direct	O
van	O
der	O
Waals	O
contact	O
to	O
the	O
traseolide	B
hapten	B
:	O
Ala	B
H93	O
Val	B
.	O

Apart	O
from	O
an	O
about	O
75-fold	O
improved	O
binding	O
energy	O
of	O
M02	O
/	O
05	O
/	O
01	O
compared	O
to	O
M02	O
/	O
01	O
/	O
01	O
for	O
traseolide	B
,	O
the	O
antibody	O
shows	O
also	O
an	O
increased	O
binding	O
specificity	O
as	O
it	O
discriminates	O
traseolide	B
better	O
from	O
its	O
non	O
-	O
smelling	O
derivative	O
(	O
Table	O
1	O
)	O
.	O

Although	O
it	O
can	O
not	O
be	O
excluded	O
that	O
the	O
other	O
somatic	O
mutations	O
contribute	O
to	O
the	O
altered	O
binding	O
characteristics	O
of	O
M02	O
/	O
05	O
/	O
01	O
,	O
the	O
Ala	B
H93	O
Val	B
mutation	O
is	O
the	O
one	O
most	O
likely	O
to	O
be	O
responsible	O
.	O

The	O
presence	O
of	O
Ala	B
H93	O
in	O
M02	O
/	O
01	O
/	O
01	O
will	O
enlarge	O
the	O
cavity	O
compared	O
to	O
the	O
Val	B
H93	O
in	O
the	O
structure	O
of	O
M02	O
/	O
05	O
/	O
01	O
solved	O
here	O
.	O

This	O
may	O
explain	O
the	O
difference	O
in	O
fine	O
-	O
specificity	O
for	O
traseolide	B
variants	B
:	O
M02	O
/	O
05	O
/	O
01	O
(	O
Val	B
H93	O
)	O
has	O
a	O
slightly	O
higher	O
affinity	O
for	O
Teth	B
then	O
for	O
T+	B
,	O
while	O
T−	B
binds	O
considerably	O
less	O
well	O
(	O
by	O
1.2	O
(	O
±0.1	O
)	O
kcal	O
/	O
mol	O
;	O
Table	O
1	O
)	O
.	O

For	O
M02	O
/	O
01	O
/	O
01	O
(	O
Ala	O
H93	O
)	O
no	O
substantial	O
differences	O
in	O
binding	O
affinity	O
were	O
found	O
between	O
the	O
three	O
traseolide	B
variants	B
(	O
Table	O
1	O
)	O
.	O

By	O
filling	O
an	O
existing	O
cavity	O
Val	B
H93	O
provides	O
a	O
tighter	O
association	O
to	O
the	O
traseolide	B
hapten	B
,	O
leading	O
to	O
better	O
binding	O
affinities	O
and	O
fine	O
specificity	O
for	O
traseolide	B
variants	B
(	O
Figure	O
8)	O
.	O

This	O
binding	O
energy	O
is	O
lost	O
by	O
creating	O
a	O
cavity	O
,	O
either	O
by	O
removing	O
the	O
side	O
-	O
chain	O
of	O
Val	B
H93	O
,	O
or	O
by	O
removing	O
the	O
methyl	B
group	I
on	O
C2	O
of	O
traseolide	B
.	O

This	O
illustrates	O
how	O
increase	O
in	O
binding	O
energy	O
is	O
coupled	O
to	O
specificity	O
.	O

The	O
importance	O
of	O
FR3	O
residue	O
H93	O
was	O
described	O
before	O
for	O
VH	O
Ox1	O
antibodies	O
,	O
where	O
Ala	B
H93	O
plays	O
a	O
critical	O
role	O
in	O
the	O
formation	O
of	O
the	O
hydrophobic	O
phOx	O
binding	O
pocket	O
(	O
Alzari	O
et	O
al	O
.	O
,	O
1990	O
)	O
.	O

In	O
the	O
Brookhaven	O
database	O
(	O
http://www.rcsb.org/pdb/	O
)	O
very	O
few	O
structures	O
are	O
found	O
in	O
which	O
H93	O
makes	O
contact	O
to	O
the	O
antigen	B
:	O
the	O
catalytic	O
antibodies	O
1eap	O
and	O
1kno	O
and	O
the	O
fluorescein	B
binding	O
Fab	O
fragment	O
4fab	O
.	O

As	O
residue	O
H93	O
is	O
located	O
deep	O
in	O
the	O
binding	O
pocket	O
,	O
only	O
small	O
haptens	B
are	O
able	O
to	O
make	O
contact	O
to	O
it	O
.	O

The	O
increase	O
in	O
binding	O
due	O
to	O
the	O
somatic	O
Ala	B
-	I
Val	I
mutation	O
in	O
the	O
binding	O
pocket	O
of	O
M02	O
/	O
05	O
/	O
01	O
corresponds	O
to	O
an	O
increase	O
in	O
free	O
energy	O
of	O
2.3	O
kcal	O
/	O
mol	O
(	O
Table	O
1	O
)	O
.	O

This	O
value	O
is	O
in	O
the	O
range	O
that	O
is	O
generally	O
observed	O
for	O
such	O
a	O
change	O
.	O

Studies	O
on	O
enzyme	O
-	O
substrate	O
interactions	O
have	O
shown	O
that	O
the	O
contribution	O
of	O
hydrophobic	O
groups	O
to	O
binding	O
can	O
be	O
large	O
and	O
variable	O
,	O
up	O
to	O
3.5	O
kcal	O
/	O
mol	O
per	O
methylene	B
group	I
(	O
Fersht	O
,	O
1985	O
)	O
.	O

For	O
comparison	O
,	O
the	O
contribution	O
of	O
a	O
buried	O
methylene	B
group	I
to	O
protein	O
stability	O
was	O
found	O
to	O
depend	O
on	O
its	O
local	O
environment	O
and	O
averages	O
ca	O
1.5	O
(	O
±0.6	O
)	O
kcal	O
/	O
mol	O
(	O
Serrano	O
et	O
al	O
.	O
,	O
1992	O
;	O
Jackson	O
et	O
al	O
.	O
,	O
1993	O
)	O
,	O
and	O
this	O
can	O
be	O
a	O
decisive	O
contribution	O
to	O
the	O
free	O
energy	O
of	O
folding	O
,	O
which	O
is	O
generally	O
quite	O
small	O
,	O
typically	O
5	O
-	O
15	O
kcal	O
/	O
mol	O
(	O
Privalov	O
,	O
1979	O
)	O
.	O

Bode	O
(	O
1979	O
)	O
measured	O
the	O
difference	O
in	O
free	O
-	O
energy	O
for	O
the	O
binding	O
of	O
dipeptides	B
to	O
p	B
-guanidinobenzoate	I
-	O
trypsinogen	O
.	O

Upon	O
substituting	O
a	O
Val	B
for	O
an	O
Ala	B
in	O
the	O
dipeptide	B
(	O
and	O
leaving	O
the	O
second	O
residue	O
identical	O
)	O
an	O
increase	O
of	O
2.9	O
-	O
3.1	O
kcal	O
/	O
mol	O
in	O
binding	O
energy	O
was	O
found	O
.	O

Force	O
-	O
field	O
calculations	O
were	O
performed	O
to	O
rationalize	O
the	O
experimentally	O
observed	O
differences	O
in	O
ligand	O
binding	O
energies	O
of	O
the	O
closely	O
related	O
antibodies	O
M02	O
/	O
01	O
/	O
01	O
(	O
Ala	O
H93	O
)	O
and	O
M02	O
/	O
05	O
/	O
01	O
(	O
Val	O
H93	O
)	O
,	O
and	O
to	O
provide	O
a	O
microscopic	O
description	O
of	O
the	O
processes	O
involved	O
.	O

The	O
binding	O
energies	O
of	O
M02	O
/	O
05	O
/	O
01	O
(	O
Val	O
H93	O
)	O
and	O
M02	O
/	O
01	O
/	O
01	O
(	O
Ala	O
H93	O
)	O
to	O
the	O
traseolide	B
variants	B
T+	B
and	O
T−	B
were	O
calculated	O
using	O
the	O
TAFF	O
force	O
-	O
field	O
(	O
Clark	O
et	O
al	O
.	O
,	O
1989	O
)	O
after	O
energy	O
minimization	O
of	O
the	O
complex	O
.	O

The	O
inter	O
-	O
molecular	O
van	O
der	O
Waals	O
energy	O
showed	O
the	O
same	O
trend	O
as	O
the	O
experimental	O
data	O
,	O
underlining	O
the	O
importance	O
of	O
the	O
surface	O
complementarity	O
.	O

However	O
,	O
the	O
absolute	O
binding	O
energies	O
were	O
not	O
predictive	O
,	O
probably	O
due	O
to	O
the	O
approximate	O
method	O
used	O
(	O
M.	O
Scarsi	O
,	O
unpublished	O
data	O
)	O
.	O

Receptor	O
mimicry	O
The	O
molecular	O
basis	O
for	O
the	O
mimicry	O
between	O
antibodies	O
and	O
receptors	O
has	O
been	O
questioned	O
;	O
the	O
observation	O
that	O
two	O
proteins	O
recognize	O
the	O
same	O
ligand	O
does	O
not	O
imply	O
that	O
they	O
share	O
common	O
structure	O
in	O
their	O
binding	O
sites	O
(	O
Amati	O
et	O
al	O
.	O
,	O
1995	O
;	O
Ducancel	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O

Nevertheless	O
,	O
the	O
working	O
concept	O
of	O
using	O
mAbs	O
as	O
""""	O
surrogate	O
receptors	O
""""	O
has	O
proved	O
useful	O
in	O
the	O
discovery	O
of	O
lead	O
compounds	O
for	O
pharmaceutical	O
and	O
related	O
purposes	O
,	O
because	O
antibodies	O
raised	O
against	O
receptor	O
-	O
specific	O
ligands	O
share	O
binding	O
properties	O
with	O
the	O
receptors	O
(	O
Cook	O
&	O
Drayer	O
,	O
1988	O
;	O
Döring	O
et	O
al	O
.	O
,	O
1994	O
)	O
.	O

The	O
binding	O
specificity	O
profile	O
of	O
monoclonal	O
antibody	O
NC6.8	O
appears	O
to	O
correlate	O
with	O
the	O
sweetness	O
potencies	O
of	O
the	O
superpotent	O
sweetener	O
ligand	O
(	O
Anchin	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
and	O
the	O
antibody	O
1B7	O
raised	O
against	O
the	O
β	O
-	O
adrenergic	O
receptor	O
ligand	O
alprenolol	B
demonstrated	O
high	O
affinity	O
and	O
stereoselectivity	O
for	O
both	O
β	O
-	O
adrenergic	O
agonists	O
and	O
antagonists	O
,	O
which	O
makes	O
it	O
an	O
ideal	O
model	O
of	O
the	O
receptor	O
's	O
binding	O
site	O
(	O
Sawutz	O
et	O
al	O
.	O
,	O
1985	O
)	O
.	O

Also	O
,	O
the	O
Tras	O
antibodies	O
may	O
exhibit	O
some	O
chemical	O
and	O
structural	O
interaction	O
motifs	O
as	O
found	O
in	O
the	O
natural	O
biological	O
odorant	O
receptor	O
.	O

For	O
the	O
monoclonal	O
antibody	O
M02	O
/	O
05	O
/	O
01	O
used	O
in	O
this	O
study	O
it	O
was	O
found	O
that	O
musk	O
odorant	B
T+	B
binds	O
better	O
than	O
the	O
odorless	O
T−	B
(	O
Table	O
1	O
)	O
.	O

From	O
the	O
crystal	O
structure	O
of	O
Fab	O
M02	O
/	O
05	O
/	O
01	O
it	O
is	O
clear	O
that	O
a	O
methyl	B
group	I
connected	O
to	O
the	O
indane	B
ring	O
of	O
traseolide	B
will	O
give	O
a	O
better	O
shape	O
complementarity	O
.	O

The	O
affinity	O
for	O
Teth	B
(	O
very	O
weak	O
musk	O
)	O
seems	O
to	O
correlate	O
less	O
well	O
with	O
the	O
olfactive	O
description	O
and	O
is	O
antibody	O
dependent	O
:	O
M02	O
/	O
05	O
/	O
01	O
bound	O
Teth	B
and	O
T+	B
in	O
a	O
comparabe	O
manner	O
.	O

To	O
be	O
able	O
to	O
distinguish	O
such	O
an	O
enormous	O
variability	O
of	O
odorants	B
,	O
we	O
predict	O
that	O
the	O
ligand	O
would	O
have	O
to	O
fit	O
very	O
precisely	O
to	O
the	O
odorant	O
receptor	O
.	O

If	O
they	O
leave	O
a	O
cavity	O
,	O
the	O
specificity	O
would	O
be	O
lost	O
.	O

In	O
analogy	O
to	O
the	O
traseolide	B
binding	O
pocket	O
odorant	B
molecules	O
might	O
bind	O
deeply	O
in	O
a	O
binding	O
pocket	O
,	O
between	O
adjacent	O
trans	O
-	O
membrane	O
helices	O
,	O
but	O
probably	O
also	O
contacting	O
the	O
loops	O
connecting	O
the	O
helices	O
.	O

Very	O
recently	O
more	O
evidence	O
for	O
this	O
hypothesis	O
was	O
found	O
by	O
Krautwurst	O
et	O
al	O
.	O

(	O
1998	O
)	O
.	O

They	O
expressed	O
full	O
-	O
length	O
odorant	O
receptors	O
in	O
HEK-293	O
cells	O
and	O
found	O
that	O
the	O
mouse	O
17	O
receptor	O
,	O
unlike	O
the	O
highly	O
homologous	O
rat	O
17	O
receptor	O
,	O
prefers	O
heptanal	B
instead	O
of	O
octanal	B
.	O

Both	O
receptors	O
differ	O
by	O
a	O
single	O
valine	B
to	O
isoleucine	B
substitution	O
in	O
transmembrane	O
region	O
V	O
of	O
the	O
odorant	O
receptor	O
.	O

In	O
addition	O
,	O
the	O
preservation	O
of	O
complementarity	O
between	O
the	O
receptor	O
and	O
the	O
ligand	O
seems	O
to	O
play	O
a	O
key	O
role	O
in	O
odorant	B
recognition	O
.	O

Conclusions	O
A	O
small	O
hapten	B
like	O
the	O
musk	O
odorant	B
traseolide	B
is	O
able	O
to	O
create	O
an	O
antibody	O
response	O
of	O
significant	O
sequence	O
diversity	O
in	O
the	O
mouse	O
.	O

Obviously	O
,	O
binding	O
of	O
an	O
odorant	B
to	O
a	O
protein	O
can	O
occur	O
in	O
different	O
binding	O
modes	O
.	O

Fine	O
specificity	O
of	O
a	O
monoclonal	O
antibody	O
for	O
the	O
musk	O
odorant	B
traseolide	B
is	O
regulated	O
primarily	O
by	O
shape	O
complementarity	O
and	O
the	O
concomitant	O
desolvation	O
of	O
the	O
complementary	O
surfaces	O
;	O
there	O
are	O
no	O
apparent	O
energetic	O
contributions	O
from	O
ionic	O
or	O
hydrogen	B
-	O
bonding	O
interactions	O
.	O

The	O
increase	O
in	O
binding	O
energy	O
is	O
coupled	O
to	O
an	O
increase	O
in	O
specificity	O
:	O
a	O
single	O
somatic	O
mutation	O
in	O
the	O
binding	O
pocket	O
of	O
M02	O
/	O
05	O
/	O
01	O
led	O
to	O
a	O
considerably	O
better	O
binding	O
of	O
the	O
traseolide	B
hapten	B
(	O
ΔΔG	O
=	O
−	O
2.3	O
(	O
±0.1	O
)	O
kcal	O
/	O
mol	O
)	O
.	O

At	O
the	O
same	O
time	O
the	O
Ala	B
-	I
Val	I
mutation	O
caused	O
more	O
specificity	O
for	O
hapten	B
variants	O
:	O
the	O
non	O
-	O
smelling	O
traseolide	B
odorant	B
lacking	O
a	O
methyl	B
group	I
was	O
binding	O
about	O
a	O
factor	O
10	O
less	O
tightly	O
than	O
the	O
original	O
traseolide	B
.	O

Materials	O
and	O
methods	O
Materials	O
and	O
strains	O
For	O
all	O
cloning	O
experiments	O
the	O
E.	O
coli	O
K12	O
strain	O
JM83	O
(	O
λ−	O
,	O
ara	O
,	O
Δ	O
(	O
lac	O
,	O
pro	O
AB	O
)	O
,	O
rpsL	O
,	O
thi	O
,	O
φ80	O
,	O
dlac	O
ZΔM15	O
)	O
(	O
Yanisch	O
-	O
Perron	O
et	O
al	O
.	O
,	O
1985	O
)	O
was	O
used	O
.	O

The	O
scFv	O
proteins	O
were	O
expressed	O
as	O
soluble	O
proteins	O
in	O
the	O
periplasm	O
in	O
the	O
E.	O
coli	O
strain	O
JM83	O
,	O
or	O
as	O
cytoplasmic	O
inclusion	O
bodies	O
in	O
the	O
E.	O
coli	O
strain	O
BL21	O
(	O
DE3	O
)	O
(	O
F−	O
,	O
ompT	O
−	O
,	O
rB	O
−	O
rB	O
−	O
,	O
(	O
λimm21	O
,	O
lac	O
I	O
,	O
lac	O
UV5	O
,	O
T7pol	O
,	O
int	O
)	O
)	O
with	O
the	O
T7	O
polymerase	O
-	O
based	O
system	O
(	O
Studier	O
&	O
Moffatt	O
,	O
1986	O
)	O
.	O

Immunization	O
,	O
fusion	O
and	O
subcloning	O
The	O
commercial	O
musk	O
odorant	B
traseolide	B
(	O
Quest	O
International	O
,	O
the	O
Netherlands	O
)	O
was	O
used	O
as	O
hapten	B
(	O
Figure	O
1	O
)	O
.	O

Immunization	O
,	O
production	O
of	O
monoclonal	O
antibodies	O
,	O
screening	O
for	O
hapten	B
specificity	O
,	O
mRNA	O
isolation	O
and	O
subcloning	O
was	O
performed	O
as	O
described	O
(	O
Langedijk	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Antibody	O
germline	O
determinations	O
The	O
40	O
sequences	O
of	O
the	O
Kabat	O
database	O
(	O
http://immuno.bme.nwu.edu	O
)	O
most	O
closely	O
related	O
to	O
the	O
heavy	O
or	O
light	O
chain	O
sequence	O
of	O
interest	O
were	O
aligned	O
with	O
the	O
""""	O
FASTA	O
""""	O
option	O
of	O
the	O
GCG	O
package	O
(	O
Genetics	O
Computer	O
Group	O
,	O
1991	O
;	O
Markiewcz	O
,	O
1991	O
)	O
.	O

The	O
data	O
were	O
aligned	O
with	O
""""	O
PILEUP	O
""""	O
and	O
reformatted	O
with	O
the	O
""""	O
PRETTY	O
""""	O
command	O
,	O
using	O
the	O
same	O
package	O
.	O

Subsequently	O
the	O
data	O
were	O
imported	O
in	O
an	O
Excel	O
macro	O
,	O
to	O
highlight	O
deviations	O
from	O
the	O
consensus	O
sequence	O
(	O
developed	O
by	O
A.	O
Honegger	O
)	O
.	O

A	O
prerequisite	O
for	O
the	O
analysis	O
is	O
that	O
the	O
database	O
contains	O
enough	O
sequences	O
of	O
the	O
germline	O
corresponding	O
to	O
the	O
input	O
sequence	O
.	O

For	O
the	O
heavy	O
chain	O
of	O
M02	O
/	O
05	O
/	O
01	O
the	O
germline	O
consensus	O
sequence	O
could	O
be	O
determined	O
,	O
because	O
24	O
sequences	O
of	O
the	O
same	O
germline	O
were	O
present	O
in	O
the	O
database	O
.	O

The	O
light	O
chain	O
of	O
M02	O
/	O
05	O
/	O
01	O
,	O
however	O
,	O
could	O
not	O
be	O
classified	O
,	O
because	O
no	O
sequences	O
of	O
antibodies	O
with	O
the	O
same	O
germline	O
were	O
found	O
(	O
data	O
not	O
shown	O
)	O
.	O

Construction	O
of	O
plasmids	O
The	O
VH	O
-	O
(	O
Gly4	B
Ser	B
)	O
3	O
-VL	O
construct	O
was	O
obtained	O
by	O
cloning	O
VH	O
and	O
VL	O
in	O
the	O
vector	O
pHJ300	O
(	O
Knappik	O
&	O
Plückthun	O
,	O
1994	O
)	O
.	O

Overlap	O
-	O
PCR	O
was	O
used	O
for	O
subcloning	O
the	O
scFv	O
gene	O
in	O
the	O
vector	O
containing	O
N	O
-	O
terminal	O
FLAG	O
and	O
C	O
-	O
terminal	O
Myc	B
and	O
His	B
-	O
tags	O
.	O

The	O
overlap	O
was	O
used	O
to	O
introduce	O
a	O
N	O
-	O
terminal	O
Eco	O
RV	O
site	O
and	O
a	O
C	O
-	O
terminal	O
Eco	O
RI	O
site	O
,	O
corresponding	O
to	O
the	O
vectors	O
used	O
.	O

For	O
periplasmic	O
expression	O
the	O
gene	O
was	O
subcloned	O
in	O
pIG6	O
(	O
Ge	O
et	O
al	O
.	O
,	O
1995	O
)	O
and	O
for	O
cytoplasmic	O
expression	O
,	O
the	O
gene	O
was	O
subcloned	O
in	O
pTFT74	O
(	O
Freund	O
et	O
al	O
.	O
,	O
1993	O
;	O
Ge	O
et	O
al	O
.	O
,	O
1995	O
)	O
which	O
places	O
expression	O
under	O
control	O
of	O
the	O
T7	O
promoter	O
.	O

The	O
mutant	O
antibody	O
fragment	O
Tras	O
-	O
P	O
was	O
constructed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
using	O
PCR	O
with	O
primers	O
containing	O
the	O
desired	O
mutation	O
.	O

After	O
sequencing	O
the	O
mutated	O
part	O
,	O
the	O
gene	O
was	O
digested	O
and	O
ligated	O
in	O
the	O
original	O
plasmid	O
.	O

Periplasmic	O
scFv	O
expression	O
and	O
fractionation	O
LB	O
medium	O
(	O
25	O
ml	O
)	O
containing	O
100	O
μg	O
/	O
ml	O
ampicillin	B
was	O
inoculated	O
with	O
an	O
E.	O
coli	O
overnight	O
culture	O
harboring	O
the	O
plasmid	O
encoding	O
the	O
respective	O
antibody	O
fragment	O
.	O

Cultures	O
were	O
incubated	O
at	O
room	O
temperature	O
(	O
RT	O
,	O
25	O
°	O
C	O
)	O
until	O
an	O
A	O
600	O
of	O
0.5	O
was	O
reached	O
.	O

Then	O
IPTG	B
(	O
isopropyl	B
β	I
-	I
d	I
-thiogalactopyranoside	I
)	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
0.5	O
mM	O
and	O
the	O
incubation	O
was	O
continued	O
for	O
three	O
hours	O
.	O

After	O
induction	O
,	O
aliquots	O
of	O
the	O
cell	O
cultures	O
(	O
with	O
an	O
equal	O
amount	O
of	O
E.	O
coli	O
cells	O
as	O
calculated	O
according	O
to	O
the	O
A	O
600	O
-value	O
,	O
usually	O
20	O
A	O
units	O
)	O
were	O
removed	O
,	O
and	O
the	O
cells	O
were	O
fractionated	O
with	O
an	O
osmotic	O
shock	O
according	O
to	O
a	O
modification	O
of	O
the	O
procedure	O
by	O
Witholt	O
et	O
al	O
.	O

(	O
1976	O
)	O
.	O

After	O
centrifuging	O
the	O
cells	O
at	O
4500	O
rpm	O
for	O
ten	O
minutes	O
,	O
the	O
cell	O
pellet	O
was	O
resuspended	O
in	O
0.5	O
ml	O
spheroplast	O
buffer	O
(	O
200	O
mM	O
Tris	B
-	I
HCl	I
,	I
0.5	O
mM	O
EDTA	B
,	O
0.5	O
M	O
sucrose	B
,	O
pH	O
8.0	O
)	O
at	O
4	O
°	O
C	O
.	O

The	O
suspension	O
was	O
gently	O
mixed	O
,	O
incubated	O
for	O
30	O
minutes	O
on	O
ice	B
and	O
centrifuged	O
for	O
ten	O
minutes	O
at	O
4500	O
rpm	O
at	O
4	O
°	O
C	O
.	O

The	O
pellet	O
was	O
resuspended	O
in	O
the	O
same	O
volume	O
as	O
the	O
spheroplasts	O
,	O
0.5	O
ml	O
of	O
mM	O
MgCl2	O
,	O
and	O
incubated	O
on	O
ice	O
for	O
another	O
30	O
minutes	O
and	O
centrifuged	O
as	O
above	O
.	O

Both	O
supernatant	O
fractions	O
were	O
pooled	O
as	O
the	O
soluble	O
periplasmic	O
fraction	O
,	O
whereas	O
the	O
pellet	O
was	O
dissolved	O
in	O
1	O
ml	O
PBS	O
.	O

Cytoplasmic	O
scFv	O
expression	O
Inclusion	O
body	O
protein	O
was	O
produced	O
as	O
described	O
and	O
was	O
isolated	O
following	O
a	O
standard	O
protocol	O
(	O
Buchner	O
&	O
Rudolph	O
,	O
1991	O
;	O
Langedijk	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Purification	O
of	O
inclusion	O
body	O
protein	O
and	O
refolding	O
were	O
carried	O
out	O
as	O
described	O
by	O
Proba	O
et	O
al	O
.	O

(	O
1997	O
)	O
,	O
except	O
that	O
the	O
formation	O
of	O
disulfide	B
bonds	O
was	O
allowed	O
by	O
the	O
presence	O
of	O
both	O
0.5	O
mM	O
of	O
reduced	B
and	O
0.5	O
mM	O
oxidized	B
glutathione	I
in	O
the	O
refolding	O
buffer	O
.	O

After	O
incubation	O
of	O
one	O
to	O
four	O
days	O
at	O
4	O
°	O
C	O
the	O
refolding	O
mixture	O
was	O
applied	O
to	O
a	O
hapten	B
-	O
affinity	O
column	O
.	O

Hapten	B
-	O
affinity	O
chromatography	O
Refolded	O
,	O
functional	O
protein	O
was	O
purified	O
using	O
affinity	O
chromatography	O
with	O
non	O
-	O
specific	O
elution	O
with	O
acidic	B
buffer	O
(	O
100	O
mM	O
glycine	B
,	O
pH	O
2.7	O
)	O
and	O
immediate	O
neutralization	O
with	O
one	O
-	O
quarter	O
volume	O
of	O
1	O
M	O
Tris	B
(	O
pH	O
8.0	O
)	O
(	O
Langedijk	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Purity	O
of	O
the	O
protein	O
was	O
controlled	O
by	O
Coomassie	O
-	O
stained	O
SDS	O
-	O
PAGE	O
.	O

If	O
necessary	O
the	O
purified	O
scFv	O
was	O
concentrated	O
by	O
centrifugal	O
filtration	O
with	O
an	O
Ultrafree	O
concentrator	O
(	O
Millipore	O
)	O
.	O

Yields	O
were	O
calculated	O
by	O
absorption	O
at	O
280	O
nm	O
,	O
using	O
calculated	O
extinction	O
coefficients	O
(	O
Gill	O
&	O
von	O
Hippel	O
,	O
1989	O
)	O
.	O

Protein	O
-	O
gel	O
electrophoresis	O
and	O
Western	O
blots	O
The	O
antibody	O
fragments	O
were	O
detected	O
by	O
reducing	O
SDS	O
-	O
PAGE	O
(	O
Laemmli	O
,	O
1970	O
)	O
and	O
subsequent	O
Coomassie	O
staining	O
or	O
Western	O
blotting	O
.	O

For	O
periplasmically	O
expressed	O
proteins	O
,	O
the	O
samples	O
were	O
normalized	O
to	O
the	O
amount	O
of	O
cells	O
.	O

Polyacrylamide	B
gels	O
were	O
blotted	O
on	O
PVDF	O
membrane	O
(	O
Immobilon	O
-	O
P	O
,	O
Millipore	O
;	O
Tovay	O
&	O
Baldo	O
,	O
1987	O
)	O
and	O
after	O
blotting	O
the	O
gel	O
was	O
immuno	O
-	O
stained	O
using	O
the	O
anti	O
-	O
FLAG	O
antibody	O
M1	O
(	O
Kodak	O
)	O
(	O
Prickett	O
et	O
al	O
.	O
,	O
1989	O
)	O
,	O
or	O
the	O
anti	O
-	O
His	O
tag	O
antibody	O
(	O
Lindner	O
et	O
al	O
.	O
,	O
1997	O
)	O
as	O
the	O
first	O
antibody	O
,	O
and	O
then	O
an	O
Fc	O
-	O
specific	O
goat	O
anti	O
-	O
mouse	O
antiserum	O
conjugated	O
to	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
as	O
second	O
antibody	O
(	O
Pierce	O
)	O
.	O

Luminescence	O
was	O
detected	O
with	O
the	O
ECL	O
™	O
kit	O
(	O
Amersham	O
)	O
,	O
or	O
color	O
was	O
developed	O
with	O
BM	O
-	O
blue	O
peroxidase	O
precipitating	O
substrate	O
(	O
Boehringer	O
Mannheim	O
)	O
.	O

BIAcore	O
measurements	O
Competition	O
BIAcore	O
analysis	O
was	O
performed	O
under	O
mass	O
-	O
transport	O
limitation	O
as	O
described	O
(	O
Karlsson	O
,	O
1994	O
;	O
Nieba	O
et	O
al	O
.	O
,	O
1996	O
)	O
,	O
using	O
a	O
sensor	O
chip	O
CM5	O
(	O
Pharmacia	O
)	O
coated	O
with	O
10,000	O
RU	O
of	O
BSA	O
-	O
traseolide	B
conjugate	O
or	O
with	O
only	O
BSA	O
as	O
a	O
control	O
.	O

Immobilization	O
of	O
BSA	O
was	O
performed	O
as	O
follows	O
:	O
35	O
μl	O
of	O
a	O
1:1	O
mixture	O
of	O
0.1	O
M	O
N	B
-hydroxysuccinimide	I
(	O
NHS	B
,	O
Fluka	O
)	O
and	O
0.2	O
M	O
N	B
-	I
(	I
3-dimethylaminopropyl	I
)	I
-N	I
′-ethylcarbodiimide	I
hydrochloride	I
(	O
EDC	B
,	O
Fluka	O
)	O
was	O
pumped	O
across	O
the	O
chip	O
to	O
activate	O
the	O
carboxmethylated	B
dextran	I
surface	O
.	O

Subsequently	O
30	O
μl	O
of	O
3	O
μM	O
BSA	O
-	O
traseolide	B
(	O
or	O
BSA	O
)	O
solubilized	O
in	O
NH4	B
Ac	I
(	O
pH	O
4.5	O
)	O
was	O
pumped	O
across	O
the	O
activated	O
surface	O
.	O

After	O
coating	O
sufficient	O
protein	O
(	O
which	O
was	O
followed	O
by	O
the	O
increasing	O
resonance	O
units	O
)	O
the	O
residual	O
NHS	B
esters	B
were	O
inactivated	O
with	O
ethanolamine	B
.	O

Each	O
binding	O
-	O
regeneration	O
cycle	O
was	O
performed	O
with	O
a	O
constant	O
flow	O
rate	O
of	O
20	O
μl	O
/	O
minute	O
using	O
20	O
mM	O
Hepes	O
(	O
pH	O
7.6	O
)	O
,	O
150	O
mM	O
NaCl	B
,	O
0.005	O
%	O
(	O
v	O
/	O
v	O
)	O
Tween-20	B
(	O
HBST	B
)	O
.	O

Samples	O
of	O
200	O
(	O
μl	O
of	O
antibody	O
in	O
HBST	B
,	O
containing	O
various	O
amounts	O
of	O
succinyl	B
derivatives	I
of	I
the	O
traseolide	B
hapten	B
and	O
preincubated	O
for	O
at	O
least	O
one	O
hour	O
at	O
4	O
°	O
C	O
,	O
were	O
injected	O
via	O
the	O
sample	O
loop	O
of	O
the	O
system	O
,	O
followed	O
by	O
regeneration	O
of	O
the	O
surface	O
by	O
injection	O
of	O
15	O
μl	O
of	O
100	O
mM	O
glycine	B
(	O
pH	O
2.3	O
)	O
.	O

Data	O
were	O
evaluated	O
using	O
BIAevaluation	O
software	O
(	O
Pharmacia	O
)	O
and	O
Kaleidagraph	O
(	O
Synergy	O
Software	O
,	O
USA	O
)	O
.	O

Slopes	O
of	O
the	O
association	O
phase	O
of	O
linear	O
sensograms	O
were	O
plotted	O
against	O
the	O
corresponding	O
total	O
hapten	B
concentrations	O
,	O
and	O
the	O
dissociation	O
constant	O
was	O
calculated	O
.	O

Fluorescence	O
titration	O
A	O
2	O
ml	O
sample	O
of	O
20	O
mM	O
Tris	B
,	O
100	O
mM	O
NaCl	B
(	O
pH	O
7.6	O
)	O
,	O
containing	O
0.1	O
-	O
0.5	O
μM	O
active	O
scFv	O
Tras	O
was	O
placed	O
in	O
a	O
cuvette	O
with	O
an	O
integrated	O
stirrer	O
,	O
equilibrated	O
at	O
17	O
°	O
C	O
.	O

Aliquots	O
of	O
concentrated	O
traseolide	B
stock	O
(	O
0.6	O
mM	O
)	O
were	O
added	O
and	O
after	O
ten	O
minutes	O
of	O
equilibration	O
a	O
spectrum	O
was	O
recorded	O
from	O
315	O
to	O
360	O
nm	O
(	O
excitation	O
wavelength	O
280	O
nm	O
)	O
on	O
a	O
Timemaster	O
™	O
fluorescence	O
spectrometer	O
(	O
Photon	O
Technology	O
Int	O
.	O
,	O
Brunswick	O
,	O
NJ	O
)	O
.	O

Fluorescence	O
emission	O
spectra	O
of	O
scFv	O
Tras	O
fragments	O
showed	O
quenching	O
of	O
fluorescence	O
upon	O
formation	O
of	O
a	O
complex	O
of	O
scFv	O
Tras	O
with	O
the	O
hapten	B
traseolide	I
.	O

The	O
emission	O
intensity	O
at	O
335	O
nm	O
was	O
used	O
for	O
determining	O
the	O
degree	O
of	O
complexation	O
as	O
a	O
function	O
of	O
traseolide	B
concentration	O
.	O

The	O
K	O
D	O
value	O
was	O
determined	O
by	O
a	O
direct	O
fit	O
of	O
emission	O
intensity	O
versus	O
hapten	B
concentration	O
(	O
Jung	O
&	O
Plückthun	O
,	O
1997	O
)	O
.	O

Papain	O
digestion	O
and	O
purification	O
of	O
Fab	O
fragments	O
Mouse	O
monoclonal	O
antibody	O
M02	O
/	O
05	O
/	O
01	O
(	O
IgG1	O
)	O
was	O
obtained	O
from	O
tissue	O
culture	O
of	O
the	O
relevant	O
hybridoma	O
cell	O
culture	O
medium	O
and	O
purified	O
by	O
Protein	O
A	O
affinity	O
chromatography	O
(	O
MCA	O
,	O
Groningen	O
)	O
.	O

The	O
following	O
stock	O
solutions	O
in	O
PBS	B
were	O
added	O
to	O
10	O
ml	O
of	O
a	O
M02	O
/	O
05	O
/	O
01	O
solution	O
(	O
4.4	O
mg	O
/	O
ml	O
in	O
PBS	B
)	O
:	O
250	O
μl	O
of	O
0.4	O
M	O
l	B
-cysteine	I
-	I
HCl	I
(	O
Sigma	O
,	O
C-1276	O
)	O
adjusted	O
to	O
pH	O
7.4	O
with	O
5	O
N	O
NaOH	B
,	O
500	O
μl	O
of	O
0.04	O
M	O
EDTA	B
(	O
Merck	O
,	O
108418	O
)	O
and	O
440	O
μl	O
of	O
1	O
mg	O
/	O
ml	O
papain	O
(	O
Boehringer	O
Mannheim	O
,	O
108014	O
)	O
.	O

Papain	O
digestion	O
was	O
allowed	O
for	O
three	O
hours	O
in	O
an	O
incubator	O
shaker	O
at	O
150	O
rpm	O
at	O
37	O
°	O
C	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
addition	O
of	O
500	O
μl	O
of	O
0.15	O
M	O
iodacetamide	B
(	O
Sigma	O
,	O
I-6125	O
)	O
to	O
the	O
reaction	O
mixture	O
.	O

Fab	O
fragments	O
were	O
purified	O
by	O
ion	O
-	O
exchange	O
chromatography	O
.	O

The	O
digested	O
antibody	O
sample	O
was	O
dialyzed	O
against	O
running	O
buffer	O
(	O
20	O
mM	O
Tris	B
-	I
HCl	I
(	O
pH	O
8.25	O
)	O
)	O
and	O
subsequently	O
applied	O
onto	O
a	O
Q	O
-	O
Sepharose	B
Fast	O
Flow	O
column	O
(	O
Pharmacia	O
)	O
equilibrated	O
with	O
running	O
buffer	O
at	O
1	O
ml	O
/	O
minute	O
.	O

A	O
salt	B
gradient	O
was	O
run	O
in	O
order	O
to	O
separate	O
Fab	O
fragments	O
from	O
non	O
-	O
digested	O
antibodies	O
and	O
Fc	O
fragments	O
(	O
gradient	O
:	O
2	O
mM	O
NaCl	B
/	O
ml	O
in	O
20	O
mM	O
Tris	B
-	I
HCl	I
(	O
pH	O
8.25	O
)	O
at	O
1	O
ml	O
/	O
minute	O
)	O
.	O

Fab	O
fragments	O
were	O
eluted	O
into	O
two	O
major	O
protein	O
peaks	O
named	O
Fab-1	O
and	O
Fab-2	O
,	O
respectively	O
.	O

By	O
iso	O
-	O
electric	O
focusing	O
(	O
Fast	O
-	O
System	O
,	O
Pharmacia	O
)	O
the	O
pI	O
values	O
of	O
Fab-1	O
and	O
Fab-2	O
were	O
determined	O
and	O
found	O
to	O
be	O
7.4	O
and	O
6.9	O
,	O
respectively	O
.	O

In	O
order	O
to	O
obtain	O
highly	O
pure	O
Fab	O
fractions	O
,	O
both	O
samples	O
were	O
dialyzed	O
against	O
running	O
buffer	O
and	O
subsequently	O
applied	O
onto	O
a	O
Mono	O
-	O
Q	O
column	O
(	O
Pharmacia	O
,	O
1	O
ml	O
)	O
as	O
described	O
above	O
.	O

A	O
salt	B
gradient	O
was	O
used	O
to	O
elute	O
the	O
Fab-1	O
and	O
Fab-2	O
samples	O
(	O
gradient	O
:	O
1	O
mM	O
NaCl	B
/	O
ml	O
at	O
1	O
ml	O
/	O
minute	O
)	O
.	O

One	O
major	O
Fab	O
fraction	O
was	O
identified	O
after	O
purification	O
of	O
the	O
Fab-1	O
sample	O
.	O

The	O
Fab-2	O
sample	O
,	O
however	O
,	O
was	O
separated	O
into	O
three	O
peaks	O
named	O
Fab-2	O
,	O
Fab-2′	O
and	O
Fab-2″	O
,	O
respectively	O
.	O

The	O
four	O
Fab	O
fractions	O
were	O
collected	O
separately	O
and	O
dialyzed	O
against	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
100	O
mM	O
NaCl	B
(	O
pH	O
7.5	O
)	O
.	O

In	O
an	O
ELISA	O
assay	O
all	O
four	O
Fab	O
fractions	O
showed	O
similar	O
specific	O
activities	O
towards	O
the	O
traseolide	B
molecule	O
.	O

Crystallization	O
studies	O
showed	O
that	O
best	O
crystals	O
were	O
obtained	O
with	O
Fab	O
fragments	O
from	O
the	O
Fab-1	O
subclass	O
.	O

All	O
further	O
studies	O
were	O
done	O
with	O
the	O
latter	O
fragment	O
.	O

Crystallization	O
and	O
data	O
collection	O
Prismatic	O
crystals	O
were	O
obtained	O
using	O
the	O
hanging	O
-	O
drop	O
vapor	O
diffusion	O
method	O
at	O
20	O
°	O
C	O
.	O

Drops	O
consisting	O
of	O
2	O
μl	O
of	O
a	O
protein	O
solution	O
with	O
or	O
without	O
hapten	B
(	O
5	O
mM	O
hapten	B
and	O
12	O
mg	O
Fab	O
per	O
ml	O
in	O
100	O
mM	O
Tris	B
,	O
pH	O
7.0	O
)	O
were	O
mixed	O
with	O
2	O
μl	O
of	O
the	O
well	O
solution	O
(	O
18	O
-	O
19	O
%	O
(	O
w	O
/	O
v	O
)	O
PEG8000	B
,	O
75	O
-	O
200	O
mM	O
sodium	B
acetate	I
(	O
pH	O
4.0	O
)	O
)	O
.	O

Crystals	O
belong	O
to	O
space	O
group	O
P	O
21	O
21	O
2	O
with	O
cell	O
dimensions	O
a	O
=	O
134.42	O
Å	O
,	O
b	O
=	O
84.5	O
Å	O
and	O
c	O
=	O
40.5	O
Å.	O
With	O
one	O
molecule	O
in	O
the	O
asymmetric	O
unit	O
(	O
assuming	O
a	O
molecular	O
mass	O
of	O
50	O
kDa	O
)	O
the	O
specific	O
protein	O
volume	O
is	O
V	O
m	O
=	O
2.3	O
Å3	O
/Da	O
,	O
which	O
corresponds	O
to	O
a	O
solvent	B
content	O
of	O
47	O
%	O
(	O
Matthews	O
,	O
1968	O
)	O
.	O

The	O
diffraction	O
data	O
were	O
collected	O
on	O
a	O
MAR	O
-	O
Research	O
Imaging	O
Plate	O
(	O
MAR	O
,	O
Hamburg	O
,	O
Germany	O
)	O
placed	O
on	O
a	O
Rigaku	O
RU200	O
rotating	O
anode	O
using	O
the	O
CuKα	O
radiation	O
.	O

Reflection	O
intensities	O
were	O
indexed	O
using	O
MARXDS	O
(	O
Kabsch	O
,	O
1988a	O
)	O
and	O
merged	O
/	O
scaled	O
using	O
MARSCALE	O
(	O
Kabsch	O
,	O
1988b	O
)	O
.	O

Details	O
of	O
the	O
data	O
processing	O
are	O
given	O
in	O
Table	O
2	O
.	O

Structure	O
determination	O
and	O
refinement	O
Both	O
rotational	O
and	O
translational	O
searches	O
for	O
the	O
Fab	O
fragment	O
were	O
performed	O
with	O
the	O
program	O
AMoRe	O
(	O
Navaza	O
,	O
1994	O
)	O
.	O

Because	O
of	O
the	O
flexibility	O
of	O
the	O
elbow	O
region	O
,	O
two	O
rotation	O
functions	O
were	O
performed	O
,	O
one	O
for	O
the	O
VH	O
:	O
VL	O
and	O
one	O
for	O
the	O
CH	O
1	O
:	O
CL	O
domains	O
.	O

The	O
search	O
model	O
consisted	O
of	O
the	O
variable	O
domains	O
of	O
an	O
anti	O
-	O
arsonate	B
antibody	O
(	O
PDB	O
file	O
2f19	O
;	O
Lascombe	O
et	O
al	O
.	O
,	O
1989	O
)	O
and	O
the	O
constant	O
domains	O
of	O
an	O
anti	O
-	O
oxazolone	B
antibody	O
(	O
P.M.	O
Alzari	O
&	O
S.	O
Spinelli	O
,	O
unpublished	O
results	O
;	O
Alzari	O
et	O
al	O
.	O
,	O
1990	O
)	O
.	O

The	O
orientation	O
of	O
the	O
variable	O
and	O
the	O
constant	O
domains	O
were	O
given	O
by	O
the	O
two	O
highest	O
peaks	O
in	O
the	O
corresponding	O
rotation	O
functions	O
calculated	O
with	O
data	O
between	O
10.0	O
and	O
3.5	O
Å.	O
The	O
resulting	O
model	O
had	O
a	O
R	O
-factor	O
of	O
0.40	O
and	O
a	O
correlation	O
coefficient	O
of	O
0.30	O
.	O

All	O
maps	O
were	O
constructed	O
using	O
the	O
CCP4	O
suite	O
of	O
programs	O
(	O
Collaborative	O
Computational	O
Project	O
Number	O
4	O
1994	O
)	O
,	O
side	O
-	O
chains	O
were	O
substituted	O
,	O
inserted	O
or	O
deleted	O
on	O
the	O
computer	O
graphics	O
according	O
to	O
the	O
sequence	O
of	O
the	O
authentic	O
anti	O
-	O
traseolide	B
Fab	O
with	O
the	O
program	O
Turbo	O
-	O
Frodo	O
(	O
Roussel	O
&	O
Cambillau	O
,	O
1989	O
)	O
.	O

The	O
refined	O
structure	O
of	O
the	O
Fab	O
M02	O
/	O
05	O
/	O
01	O
,	O
complexed	O
with	O
traseolide	B
,	O
was	O
obtained	O
by	O
cycles	O
of	O
model	O
building	O
alternated	O
with	O
refinement	O
of	O
the	O
atomic	O
coordinates	O
by	O
standard	O
slow	O
-	O
cooling	O
protocol	O
using	O
data	O
between	O
12.0	O
and	O
2.6	O
Å	O
(	O
Brünger	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O

As	O
the	O
low	O
-	O
resolution	O
data	O
were	O
employed	O
in	O
the	O
refinement	O
,	O
a	O
low	O
-	O
resolution	O
bulk	O
solvent	B
correction	O
,	O
as	O
implemented	O
in	O
the	O
XPLOR	O
program	O
version	O
3.843	O
(	O
Brünger	O
,	O
1996	O
)	O
was	O
applied	O
.	O

The	O
behavior	O
of	O
the	O
free	O
R	O
-factor	O
(	O
R	O
free	O
)	O
was	O
monitored	O
all	O
along	O
the	O
refinement	O
procedure	O
(	O
Brünger	O
,	O
1992	O
)	O
.	O

Details	O
of	O
the	O
refinement	O
and	O
model	O
statistic	O
are	O
listed	O
in	O
Table	O
2	O
.	O

Synthesis	O
of	O
musk	O
odorant	B
molecules	O
The	O
commercial	O
odorant	B
traseolide	B
(	O
6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane	B
)	O
is	O
a	O
musk	O
type	O
odorant	B
,	O
synthesized	O
by	O
Quest	O
International	O
(	O
Naarden	O
,	O
the	O
Netherlands	O
)	O
.	O

By	O
using	O
different	O
starting	O
materials	O
,	O
a	O
series	O
of	O
traseolide	B
analogs	B
was	O
synthesized	O
at	O
Quest	O
International	O
and	O
the	O
fragrance	O
of	O
these	O
analogs	B
was	O
evaluated	O
(	O
Figure	O
1	O
;	O
Traas	O
et	O
al	O
.	O
,	O
1982	O
)	O
.	O

In	O
order	O
to	O
be	O
able	O
to	O
raise	O
antibodies	O
against	O
traseolide	B
or	O
use	O
it	O
in	O
biological	O
assays	O
,	O
a	O
covalent	O
hydrophilic	O
linker	O
was	O
added	O
to	O
the	O
hydrophobic	O
odorant	B
.	O

This	O
allowed	O
attachment	O
to	O
a	O
carrier	O
protein	O
and	O
,	O
at	O
the	O
same	O
time	O
,	O
made	O
the	O
compound	O
better	O
soluble	O
in	O
aqueous	O
solutions	O
.	O

The	O
linker	O
should	O
preferably	O
not	O
interfere	O
with	O
the	O
structurally	O
important	O
parts	O
of	O
the	O
traseolide	O
,	O
so	O
that	O
antibodies	O
could	O
be	O
obtained	O
with	O
structures	O
resembling	O
the	O
olfactory	O
receptor	O
as	O
closely	O
as	O
possible	O
.	O

From	O
olfactive	O
studies	O
it	O
was	O
known	O
that	O
elongation	O
of	O
the	O
R1	O
chain	O
did	O
not	O
have	O
a	O
significant	O
influence	O
on	O
the	O
fragrance	O
(	O
Quest	O
International	O
,	O
the	O
Netherlands	O
)	O
.	O

Therefore	O
it	O
was	O
decided	O
to	O
introduce	O
a	O
carboxylic	O
substituent	O
in	O
R1	O
as	O
reactive	O
group	O
for	O
binding	O
to	O
the	O
carrier	O
proteins	O
(	O
the	O
succinyl	O
derivative	O
of	O
traseolide	O
;	O
Figure	O
1	O
)	O
.	O

The	O
succinyl	O
derivative	O
of	O
the	O
original	O
traseolide	O
hapten	O
was	O
available	O
from	O
Unilever	O
Research	O
Vlaardingen	O
(	O
the	O
Netherlands	O
)	O
,	O
while	O
the	O
succinyl	O
derivatives	O
of	O
the	O
other	O
traseolide	O
variants	O
had	O
to	O
be	O
synthesized	O
from	O
traseolide	O
-	O
alcohol	O
1-	O
(	O
2-hydroxy-3-methylpropyl	O
)	O
-4-methylbenzene	O
(	O
Traas	O
et	O
al	O
.	O
,	O
1982	O
)	O
.	O

First	O
isobutylene	O
,	O
or	O
2-methyl-2-pentene	O
respectively	O
,	O
was	O
allowed	O
to	O
react	O
with	O
traseolide	O
-	O
alcohol	O
in	O
a	O
[	O
3	O
+	O
2	O
]	O
cycloaddition	O
using	O
AlCl3	O
as	O
Lewis	O
base	O
to	O
form	O
the	O
traseolide	O
-	O
indane	O
(	O
Angle	O
&	O
Arnaiz	O
,	O
1992	O
)	O
.	O

Secondly	O
,	O
the	O
succinyl	O
derivative	O
was	O
formed	O
using	O
the	O
Friedel	O
Crafts	O
acylation	O
conditions	O
for	O
musk	O
odorants	B
(	O
Weber	O
et	O
al	O
.	O
,	O
1955	O
)	O
.	O

The	O
purity	O
of	O
the	O
newly	O
synthesized	O
traseolide	B
succinyl	B
derivatives	I
was	O
checked	O
by	O
TLC	O
,	O
NMR	O
and	O
absorption	O
spectroscopy	O
(	O
estimated	O
purity	O
:	O
Teth	B
⩾	O
95	O
%	O
and	O
T−	B
⩾	O
85	O
%	O
pure	O
;	O
data	O
not	O
shown	O
)	O
.	O

NMR	O
spectra	O
of	O
traseolide	B
indicated	O
that	O
the	O
substituents	O
in	O
C1	O
and	O
C2	O
are	O
in	O
trans	O
(	O
Figure	O
1	O
)	O
(	O
R.	O
Pepermans	O
,	O
unpublished	O
results	O
)	O
,	O
and	O
the	O
absolute	O
stereochemistry	O
is	O
deduced	O
from	O
the	O
electron	O
density	O
map	O
of	O
Fab	O
M02	O
/	O
05	O
/	O
01	O
complexed	O
with	O
the	O
traseolide	B
hapten	B
.	O

The	O
(	B
S	I
,	I
S	I
)	I
enantiomer	I
is	O
predominantly	O
occupying	O
the	O
binding	O
pocket	O
,	O
but	O
it	O
can	O
not	O
be	O
excluded	O
that	O
some	O
(	B
R	I
,	I
R	I
)	I
enantiomer	I
is	O
also	O
present	O
.	O

Protein	O
Data	O
Bank	O
accession	O
number	O
Coordinates	O
of	O
the	O
complexed	O
Fab	O
M05	O
/	O
01	O
/	O
01	O
have	O
been	O
deposited	O
in	O
the	O
Brookhaven	O
Protein	O
Data	O
bank	O
with	O
accession	O
number	O
1C12	O
.	O

Acknowledgements	O
The	O
authors	O
thank	O
J.A.M.	O
Laan	O
for	O
synthesis	O
of	O
the	O
succinyl	B
derivative	I
of	I
traseolide	I
,	O
E.A.	O
de	O
Ron	O
for	O
production	O
of	O
monoclonal	O
antibodies	O
,	O
W.J.	O
Bos	O
for	O
sequencing	O
of	O
cDNA	O
,	O
L.F.	O
Frenken	O
for	O
suggesting	O
the	O
Tras	O
-	O
P	O
mutant	O
,	O
M.	O
Scarsi	O
for	O
performing	O
theoretical	O
calculations	O
of	O
binding	O
energies	O
and	O
preparing	O
Figure	O
8	O
,	O
T.	O
Carell	O
of	O
the	O
ETH	O
for	O
the	O
opportunity	O
to	O
work	O
in	O
his	O
lab	O
,	O
and	O
J.	O
Maat	O
and	O
P.	O
de	O
Geus	O
for	O
initiating	O
the	O
project	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
EC	O
-	O
grant	O
BIOCT-920367	O
.	O

Piroxicam	B
(	O
PXM	B
)	O
(	O
Fig.	O
1	O
)	O
,	O
a	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drug	I
,	O
is	O
widely	O
used	O
in	O
the	O
therapy	O
of	O
osteoarthritis	O
and	O
rheumatoid	O
arthritis	O
,	O
and	O
it	O
has	O
been	O
known	O
to	O
induce	O
photosensitivity	O
as	O
one	O
of	O
its	O
side	O
-	O
effects	O
[	O
1	O
]	O
.	O

The	O
photosensitive	O
eruption	O
occurs	O
within	O
a	O
few	O
days	O
after	O
starting	O
the	O
treatment	O
with	O
this	O
drug	B
,	O
suggesting	O
a	O
phototoxic	O
reaction	O
[	O
2–4	O
]	O
.	O

However	O
,	O
there	O
are	O
some	O
reports	O
that	O
PXM	B
-	O
induced	O
photosensitivity	O
is	O
mainly	O
due	O
to	O
photoallergy	O
[	O
5–7	O
]	O
.	O

Ampiroxicam	B
(	O
APX	B
)	O
is	O
a	O
prodrug	B
of	O
PXM	B
and	O
is	O
developed	O
to	O
minimize	O
gastric	O
side	O
-	O
effects	O
[	O
8,9	O
]	O
.	O

Inactive	O
APX	B
is	O
hydrolyzed	O
to	O
active	O
PXM	B
by	O
an	O
intestinal	O
esterase	O
during	O
absorption	O
through	O
the	O
intestinal	O
wall	O
[	O
10	O
]	O
.	O

Hence	O
,	O
the	O
mechanism	O
of	O
photosensitivity	O
induced	O
by	O
both	O
PXM	B
and	O
APX	B
has	O
been	O
considered	O
to	O
be	O
similar	O
[	O
11–13	O
]	O
.	O

However	O
,	O
we	O
have	O
recently	O
experienced	O
a	O
patient	O
with	O
photosensitivity	O
induced	O
by	O
APX	B
who	O
showed	O
positive	O
patch	O
testing	O
to	O
UVA	O
-	O
irradiated	O
APX	B
and	O
thiosalicylate	B
(	O
TOS	B
)	O
,	O
but	O
was	O
negative	O
to	O
UVA	O
-	O
irradiated	O
PXM	B
.	O

In	O
order	O
to	O
elucidate	O
the	O
mechanism	O
of	O
APX-	B
and	O
PXM	B
-	O
induced	O
photosensitivity	O
further	O
,	O
antigenicity	O
of	O
UVA	O
-	O
irradiated	O
APX	B
and	O
its	O
cross	O
-	O
reactivity	O
to	O
APX	B
and	O
TOS	B
,	O
which	O
is	O
thought	O
to	O
be	O
an	O
active	O
hapten	B
of	O
PXM	B
,	O
were	O
examined	O
using	O
an	O
in	O
vivo	O
model	O
of	O
contact	O
hypersensitivity	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Animals	O
Female	O
Hartley	O
strain	O
guinea	O
pigs	O
(	O
380–450	O
g	O
weight	O
)	O
were	O
purchased	O
from	O
Saitama	O
Experimental	O
Animals	O
Supply	O
(	O
Saitama	O
,	O
Japan	O
)	O
.	O

2.2	O
Reagents	B
and	O
chemicals	B
APX	B
and	O
PXM	B
were	O
kindly	O
provided	O
by	O
Toyama	O
Chemical	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

TOS	B
and	O
Freund	O
's	O
complete	O
adjuvant	O
were	O
obtained	O
from	O
Wako	O
Pure	O
Chemical	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Other	O
chemicals	B
were	O
of	O
the	O
highest	O
grade	O
commercially	O
available	O
.	O

2.3	O
Absorption	O
spectra	O
APX	B
(	O
0.01	O
%	O
)	O
and	O
TOS	B
(	O
0.01	O
%	O
)	O
were	O
dissolved	O
in	O
acetone	B
and	O
phosphate	B
buffer	O
(	O
pH	O
7.4	O
)	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
solutions	O
of	O
APX	B
UVA	O
-	O
irradiated	O
or	O
non	O
-	O
irradiated	O
(	O
10	O
J	O
/	O
cm2	O
)	O
were	O
taken	O
to	O
dryness	O
under	O
a	O
stream	O
of	O
nitrogen	B
,	O
and	O
the	O
residues	O
were	O
reconstituted	O
with	O
phosphate	B
buffer	O
(	O
pH	O
7.4	O
)	O
.	O

Absorption	O
spectra	O
of	O
these	O
compounds	O
were	O
measured	O
using	O
an	O
automatic	O
spectrophotometer	O
(	O
U-2000	O
;	O
Hitachi	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

2.4	O
UVA	O
irradiation	O
procedure	O
Black	O
light	O
tubes	O
(	O
FL40S	O
BLB	O
;	O
Toshiba	O
,	O
Tokyo	O
,	O
Japan	O
)	O
were	O
set	O
15	O
cm	O
distance	O
from	O
each	O
solution	O
.	O

The	O
light	O
passed	O
through	O
3-mm	O
thick	O
glass	B
.	O

In	O
vitro	O
irradiation	O
was	O
carried	O
out	O
at	O
12.5–25.5	O
J	O
/	O
cm2	O
of	O
UVA	O
in	O
a	O
glass	B
tube	O
at	O
room	O
temperature	O
.	O

The	O
irradiation	O
dose	O
was	O
measured	O
with	O
a	O
UV	O
radiometer	O
(	O
UVR305	O
/	O
365DII	O
;	O
Toshiba	O
)	O
.	O

2.5	O
Sensitization	O
Antigenecity	O
of	O
APX	B
and	O
PXM	B
were	O
evaluated	O
by	O
the	O
adjuvant	O
patch	O
test	O
method	O
,	O
i.e.	O
a	O
modified	O
maximization	O
test	O
for	O
detection	O
of	O
contact	O
hypersensitivity	O
allergens	B
in	O
guinea	O
pig	O
[	O
14	O
]	O
.	O

Each	O
animal	O
was	O
sensitized	O
with	O
UVA	O
(	O
12.5	O
J	O
/	O
cm2	O
)	O
-irradiated	O
1	O
%	O
APX	B
in	O
acetone	B
/	O
olive	B
oil	I
(	O
A	B
/	I
O	I
)	O
(	O
1	O
:	O
4	O
)	O
,	O
1	O
%	O
PXM	B
in	O
A	B
/	I
O	I
,	O
1	O
%	O
TOS	B
in	O
ethanol	B
,	O
or	O
control	O
vehicle	O
.	O

At	O
the	O
first	O
induction	O
,	O
100	O
μl	O
of	O
each	O
chemical	B
was	O
applied	O
with	O
a	O
patch	O
tested	O
occlusively	O
on	O
a	O
shaved	O
and	O
abraded	O
nuchal	O
skin	O
area	O
(	O
3	O
×	O
4	O
cm2	O
)	O
,	O
which	O
was	O
defined	O
by	O
intradermal	O
injections	O
(	O
0.1ml	O
×	O
4	O
)	O
of	O
emulsified	O
Freund	O
's	O
complete	O
adjuvant	O
at	O
the	O
corners	O
.	O

The	O
patch	O
tests	O
were	O
repeated	O
daily	O
for	O
3	O
days	O
.	O

At	O
the	O
second	O
induction	O
,	O
10	O
%	O
sodium	B
laulyl	I
sulfate	I
in	O
petrolatum	B
was	O
applied	O
topically	O
on	O
the	O
eighth	O
day	O
,	O
and	O
each	O
sample	O
was	O
patch	O
tested	O
occlusively	O
again	O
on	O
the	O
ninth	O
day	O
.	O

2.6	O
Elicitation	O
and	O
evaluation	O
All	O
solutions	O
were	O
prepared	O
at	O
1	O
%	O
concentration	O
by	O
mixing	O
with	O
A	B
/	I
O.	I
Animals	O
were	O
tested	O
on	O
day	O
21	O
by	O
applying	O
20	O
μl	O
of	O
the	O
solution	O
,	O
which	O
was	O
open	O
application	O
on	O
the	O
shaved	O
skin	O
of	O
the	O
flank	O
.	O

Reading	O
was	O
scored	O
48	O
h	O
later	O
according	O
to	O
the	O
following	O
scale	O
for	O
scoring	O
skin	O
reactions	O
.	O

(	O
A	O
)	O
Scale	O
for	O
erythema	O
:	O
0	O
,	O
no	O
erythema	O
;	O
1	O
,	O
very	O
slight	O
erythema	O
(	O
barely	O
perceptible	O
)	O
;	O
2	O
,	O
well	O
-	O
defined	O
erythema	O
;	O
3	O
,	O
moderate	O
to	O
severe	O
erythema	O
;	O
4	O
,	O
severe	O
erythema	O
.	O

(	O
B	O
)	O
Scale	O
for	O
edema	O
:	O
0	O
,	O
no	O
edema	O
;	O
1	O
,	O
slight	O
edema	O
;	O
2	O
,	O
moderate	O
edema	O
;	O
3	O
,	O
severe	O
edema	O
(	O
raised	O
more	O
than	O
1	O
mm	O
and	O
extending	O
beyond	O
the	O
area	O
of	O
exposure	O
)	O
.	O

The	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
score	O
were	O
totalled	O
.	O

A	O
total	O
score	O
greater	O
than	O
2	O
was	O
expressed	O
as	O
positive	O
,	O
according	O
to	O
the	O
criteria	O
of	O
the	O
International	O
Contact	O
Dermatitis	O
Research	O
Group	O
(	O
ICDRG	O
)	O
[	O
15	O
]	O
.	O

2.7	O
High	O
-	O
performance	O
liquid	O
chromatography	O
condition	O
and	O
apparatus	O
High	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analysis	O
was	O
performed	O
on	O
a	O
capcell	O
pak	O
column	O
(	O
250	O
mm	O
,	O
i.d	O
.	O

4.6	O
cm	O
,	O
particle	O
size	O
5	O
μm	O
)	O
type	O
SG120	O
(	O
Shiseido	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
using	O
a	O
solvent	O
mixture	O
(	O
methanol	B
:	O
acetonitrile	B
:	O
distilled	B
water=2:3:5	I
,	O
v	O
/	O
v	O
)	O
as	O
the	O
mobile	O
phase	O
at	O
a	O
flow	O
-	O
rate	O
of	O
0.7	O
ml	O
/	O
min	O
.	O

The	O
apparatus	O
(	O
TOSOH	O
,	O
Tokyo	O
,	O
Japan	O
)	O
used	O
for	O
this	O
work	O
consisted	O
of	O
HPLC	O
pump	O
(	O
CCPD	O
)	O
and	O
a	O
UV	O
monitor	O
(	O
UV8020	O
)	O
set	O
at	O
a	O
wavelength	O
of	O
250	O
nm	O
.	O

The	O
sample	O
was	O
introduced	O
through	O
a	O
fixed	O
20	O
μl	O
loop	O
injector	O
(	O
AS-8000	O
)	O
and	O
the	O
peak	O
area	O
was	O
measured	O
on	O
an	O
integrator	O
(	O
chromatocorder	O
21	O
)	O
.	O

The	O
UVA	O
-	O
irradiated	O
APX	B
and	O
PXM	B
were	O
prepared	O
in	O
acetone	B
.	O

The	O
solutions	O
were	O
evaporated	O
to	O
dryness	O
and	O
then	O
reconstituted	O
in	O
the	O
mobile	O
phase	O
.	O

3	O
Results	O
3.1	O
In	O
vivo	O
study	O
As	O
shown	O
in	O
Tables	O
1	O
and	O
2	O
,	O
contact	O
hypersensitivities	O
among	O
UVA	O
-	O
irradiated	O
APX	B
,	O
UVA	O
-	O
irradiated	O
PXM	B
and	O
TOS	B
were	O
examined	O
.	O

Animals	O
sensitized	O
with	O
UVA	O
-	O
irradiated	O
1	O
%	O
APX	B
showed	O
positive	O
patch	O
testing	O
to	O
UVA	B
-	O
irradiated	O
APX	B
and	O
TOS	B
,	O
while	O
they	O
were	O
negative	O
in	O
challenge	O
by	O
UVA	O
-	O
irradiated	O
PXM	B
,	O
APX	B
and	O
PXM	B
.	O

None	O
of	O
the	O
UVA	O
-	O
irradiated	O
or	O
non	O
-	O
irradiated	O
APX	B
and	O
PXM	B
showed	O
positive	O
patch	O
testing	O
in	O
animals	O
sensitized	O
with	O
either	O
UVA	O
-	O
irradiated	O
PXM	B
or	O
control	O
vehicles	O
(	O
Table	O
1	O
)	O
.	O

Animals	O
immunized	O
with	O
TOS	B
were	O
successfully	O
challenged	O
by	O
TOS	B
and	O
cross	O
-	O
reacted	O
to	O
UVA	O
-	O
irradiated	O
APX	B
;	O
however	O
,	O
they	O
failed	O
to	O
react	O
to	O
UVA	O
-	O
irradiated	O
PXM	B
,	O
APX	B
and	O
PXM	B
(	O
Table	O
2	O
)	O
.	O

3.2	O
In	O
vitro	O
study	O
The	O
absorption	O
spectra	O
of	O
APX	B
,	O
TOS	B
and	O
UVA	O
-	O
irradiated	O
APX	B
are	O
shown	O
in	O
Fig.	O
2	O
.	O

The	O
maximal	O
absorption	O
of	O
APX	B
was	O
320	O
nm	O
,	O
and	O
alternation	O
of	O
the	O
absorbance	O
spectrum	O
was	O
detected	O
after	O
irradiation	O
.	O

The	O
absorption	O
peak	O
shifted	O
to	O
shorter	O
wavelength	O
.	O

The	O
UVA	O
-	O
irradiated	O
APX	B
spectrum	O
resembles	O
that	O
of	O
TOS	B
.	O

The	O
maximal	O
absorbance	O
of	O
the	O
PXM	B
was	O
360	O
nm	O
(	O
data	O
not	O
shown	O
)	O
.	O

Solutions	O
irradiated	O
with	O
UVA	O
were	O
submitted	O
to	O
HPLC	O
for	O
the	O
quantification	O
of	O
undegradated	O
compounds	O
.	O

Concentration	O
of	O
APX	B
was	O
easily	O
reduced	O
by	O
the	O
increase	O
in	O
UVA	O
irradiation	O
doses	O
,	O
as	O
compared	O
with	O
that	O
of	O
PXM	B
.	O

Finally	O
,	O
APX	B
almost	O
disappeared	O
at	O
the	O
UVA	O
irradiation	O
dose	O
of	O
12.5	O
J	O
/	O
cm2	O
(	O
Fig.	O
3	O
)	O
.	O

4	O
Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
succeeded	O
in	O
the	O
development	O
of	O
a	O
novel	O
animal	O
model	O
reflecting	O
clinical	O
observations	O
that	O
a	O
patient	O
with	O
photosensitivity	O
induced	O
by	O
APX	B
showed	O
positive	O
patch	O
testing	O
to	O
UVA	O
-	O
irradiated	O
APX	B
and	O
TOS	B
,	O
but	O
negative	O
for	O
UVA	O
-	O
irradiated	O
PXM	B
.	O

The	O
animals	O
sensitized	O
with	O
UVA	O
-	O
irradiated	O
APX	B
might	O
be	O
a	O
useful	O
model	O
to	O
examine	O
the	O
common	O
antigenic	O
properties	O
of	O
drugs	B
that	O
develop	O
photosensitivity	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
contact	O
hypersensitivity	O
induced	O
by	O
UVA	O
-	O
irradiated	O
APX	B
could	O
be	O
developed	O
by	O
photoproducts	O
of	O
APX	B
itself	O
,	O
but	O
not	O
by	O
the	O
biotransformation	O
of	O
APX	B
to	O
PXM	B
.	O

Actually	O
,	O
it	O
is	O
better	O
that	O
sensitized	O
animals	O
are	O
challenged	O
with	O
systemic	O
administration	O
of	O
APX	B
and	O
following	O
UVA	O
irradiation	O
to	O
skin	O
for	O
evaluating	O
the	O
clinical	O
phenomena	O
.	O

However	O
,	O
we	O
have	O
a	O
final	O
plan	O
to	O
detect	O
the	O
antigenic	O
photoproducts	O
of	O
APX	B
in	O
a	O
future	O
study	O
.	O

Hence	O
,	O
UVA	O
irradiation	O
was	O
performed	O
in	O
vitro	O
in	O
the	O
present	O
experiments	O
.	O

It	O
has	O
been	O
reported	O
that	O
several	O
kinds	O
of	O
photoproducts	O
of	O
PXM	B
are	O
formed	O
by	O
UVA	O
irradiation	O
in	O
different	O
conditions	O
[	O
4,16	O
]	O
.	O

Ikezawa	O
et	O
al.	O
have	O
reported	O
that	O
,	O
in	O
the	O
animals	O
sensitized	O
with	O
TOS	B
,	O
patch	O
testing	O
is	O
positive	O
to	O
PXM	B
under	O
the	O
condition	O
that	O
UVA	O
is	O
irradiated	O
after	O
a	O
patch	O
of	O
PXM	B
to	O
the	O
skin	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
carrier	O
protein	O
would	O
be	O
necessary	O
to	O
become	O
an	O
active	O
hapten	B
possessing	O
antigenic	O
property	O
,	O
as	O
irradiated	O
UVA	O
in	O
the	O
case	O
of	O
PXM	B
differed	O
from	O
that	O
of	O
APX	B
[	O
17	O
]	O
.	O

Furthermore	O
,	O
they	O
have	O
also	O
shown	O
that	O
patch	O
testing	O
was	O
negative	O
to	O
UVA	O
-	O
irradiated	O
PXM	B
without	O
patch	O
to	O
the	O
skin	O
in	O
the	O
animals	O
sensitized	O
with	O
TOS	B
in	O
agreement	O
with	O
our	O
result	O
.	O

Indeed	O
,	O
we	O
directly	O
confirmed	O
that	O
PXM	B
was	O
not	O
affected	O
with	O
UVA	O
irradiation	O
under	O
conditions	O
used	O
in	O
this	O
study	O
.	O

As	O
one	O
of	O
reasons	O
for	O
this	O
result	O
,	O
it	O
is	O
thought	O
that	O
the	O
intensity	O
of	O
UVA	O
exposure	O
used	O
here	O
is	O
relatively	O
low	O
judging	O
from	O
other	O
reports	O
[	O
16,17	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
APX	B
was	O
easily	O
decomposed	O
by	O
the	O
same	O
treatment	O
with	O
UVA	O
,	O
indicating	O
the	O
difference	O
of	O
character	O
between	O
APX	B
and	O
PXM	B
.	O

Interestingly	O
,	O
absorption	O
spectrum	O
of	O
UVA	O
-	O
irradiated	O
APX	B
was	O
similar	O
to	O
that	O
of	O
TOS	B
.	O

This	O
result	O
suggests	O
that	O
a	O
part	O
of	O
photoproducts	O
of	O
APX	B
might	O
have	O
common	O
chemical	O
structure	O
of	O
TOS	B
.	O

In	O
facts	O
,	O
TOS	B
showed	O
positive	O
reaction	O
in	O
the	O
animals	O
sensitized	O
with	O
UVA	O
-	O
irradiated	O
APX	B
,	O
and	O
vice	O
versa	O
,	O
i.e.	O
cross	O
-	O
reactivity	O
was	O
developed	O
between	O
UVA	O
-	O
irradiated	O
APX	B
and	O
TOS	B
.	O

Further	O
experiments	O
regarding	O
the	O
detection	O
of	O
photoproducts	O
of	O
APX	B
should	O
be	O
the	O
next	O
subject	O
.	O

Kurumaji	O
[	O
11	O
]	O
has	O
shown	O
that	O
the	O
positive	O
photo	O
-	O
patch	O
testing	O
is	O
due	O
to	O
biotransformation	O
of	O
APX	B
to	O
PXM	B
in	O
the	O
skin	O
.	O

However	O
,	O
taking	O
the	O
results	O
in	O
this	O
study	O
into	O
consideration	O
,	O
the	O
possibility	O
of	O
the	O
biotransformation	O
of	O
APX	B
to	O
PXM	B
in	O
contact	O
hypersensitivity	O
reactions	O
is	O
quite	O
low	O
.	O

Taken	O
together	O
,	O
it	O
appears	O
that	O
photoproducts	O
of	O
UVA	O
-	O
irradiated	O
APX	B
actually	O
contain	O
cross	O
-	O
reactive	O
substances	O
to	O
itself	O
or	O
TOS	B
,	O
and	O
that	O
contact	O
sensitivity	O
reaction	O
induced	O
by	O
APX	B
may	O
be	O
due	O
to	O
photoproducts	O
of	O
this	O
compound	O
,	O
but	O
not	O
that	O
of	O
PXM	B
.	O

In	O
conclusion	O
,	O
we	O
established	O
an	O
animal	O
model	O
reflecting	O
clinical	O
observation	O
in	O
a	O
patient	O
with	O
APX	B
-	O
induced	O
photosensitivity	O
.	O

The	O
data	O
shown	O
here	O
suggest	O
that	O
photoproducts	O
of	O
APX	B
possess	O
an	O
antigenic	O
property	O
.	O

In	O
addition	O
,	O
patch	O
of	O
APX	B
to	O
the	O
skin	O
before	O
UVA	O
irradiation	O
is	O
not	O
necessary	O
to	O
obtain	O
the	O
antigenic	O
photoproducts	O
of	O
APX	B
in	O
this	O
method	O
,	O
indicating	O
that	O
it	O
is	O
easy	O
to	O
recover	O
and	O
examine	O
the	O
antigenic	O
substances	O
of	O
APX	B
.	O

Therefore	O
,	O
the	O
detection	O
of	O
products	O
induced	O
by	O
irradiation	O
of	O
UVA	O
to	O
APX	B
might	O
assist	O
the	O
elucidation	O
of	O
the	O
mechanism	O
for	O
photoallergy	O
with	O
PXM	B
.	O

MDMA	B
,	O
or	O
'	O
Ecstasy	B
'	O
,	O
and	O
3,4-methylenedioxyethylamphetamine	B
(	O
MDEA	B
,	O
or	O
'	O
Eve	B
'	O
)	O
have	O
emerged	O
as	O
popular	O
recreational	O
drugs	B
of	O
abuse	O
over	O
the	O
last	O
decade	O
.	O

In	O
Western	O
Europe	O
,	O
due	O
to	O
the	O
erroneous	O
belief	O
that	O
these	O
are	O
relatively	O
safe	O
hallucinogens	O
,	O
the	O
use	O
of	O
such	O
substances	O
as	O
mood	O
enhancers	O
has	O
steadily	O
increased	O
,	O
especially	O
in	O
discotheques	O
,	O
during	O
the	O
1990s	O
[	O
1	O
]	O
.	O

Recreational	O
use	O
of	O
these	O
drugs	B
has	O
spread	O
in	O
Italy	O
in	O
the	O
last	O
few	O
years	O
[	O
2	O
]	O
.	O

Pharmacological	O
studies	O
indicate	O
that	O
these	O
substances	O
produce	O
a	O
mixture	O
of	O
central	O
stimulant	O
and	O
psychedelic	O
effects	O
,	O
many	O
of	O
which	O
appear	O
to	O
be	O
mediated	O
by	O
brain	O
monoamines	B
,	O
particularly	O
serotonin	B
and	O
dopamine	B
[	O
3	O
]	O
.	O

Recent	O
well	O
-	O
publicised	O
reports	O
of	O
deaths	O
resulting	O
from	O
MDMA	B
/	O
MDEA	B
abuse	O
at	O
'	O
rave	O
'	O
parties	O
have	O
led	O
to	O
an	O
increased	O
understanding	O
of	O
the	O
pathology	O
of	O
their	O
misuse	O
.	O

Toxic	O
effects	O
and	O
the	O
occasional	O
death	O
following	O
ring	O
substituted	O
amphetamine	O
misuse	O
have	O
been	O
reported	O
but	O
postmortem	O
data	O
are	O
lacking	O
[	O
4	O
]	O
previous	O
to	O
a	O
recent	O
review	O
which	O
illustrates	O
seven	O
fatal	O
cases	O
with	O
a	O
detailed	O
examination	O
of	O
the	O
post	O
-	O
mortem	O
findings	O
[	O
5	O
]	O
.	O

Additionally	O
,	O
while	O
deaths	O
due	O
to	O
MDMA	B
/	O
MDEA	O
have	O
been	O
reported	O
,	O
none	O
of	O
these	O
reports	O
have	O
on	O
focused	O
on	O
immunohistochemical	O
investigation	O
.	O

Three	O
cases	O
of	O
death	O
following	O
the	O
ingestion	O
of	O
these	O
substances	O
have	O
been	O
here	O
examined	O
to	O
better	O
define	O
the	O
histopathological	O
findings	O
related	O
to	O
MDMA	B
/	O
MDEA	B
intoxication	O
.	O

One	O
case	O
has	O
been	O
reported	O
previously	O
[	O
2	O
]	O
.	O

In	O
all	O
cases	O
we	O
were	O
able	O
to	O
carry	O
out	O
a	O
complete	O
immunohistochemical	O
studies	O
on	O
autopsy	O
specimens	O
.	O

2	O
Methods	O
2.1	O
Case	O
1	O
B.F.	O
,	O
19	O
years	O
of	O
age	O
,	O
was	O
seen	O
ingesting	O
numerous	O
tablets	O
of	O
Ecstasy	B
in	O
a	O
discotheque	O
the	O
night	O
of	O
June	O
15th	O
,	O
1996	O
,	O
for	O
the	O
entire	O
duration	O
of	O
the	O
party	O
until	O
early	O
morning	O
.	O

On	O
June	O
16th	O
,	O
in	O
the	O
late	O
morning	O
,	O
he	O
began	O
to	O
experience	O
respiratory	O
difficulty	O
,	O
uncoordinated	O
movements	O
,	O
generalised	O
hypertonia	O
and	O
hyperpyrexia	O
(	O
40.6	O
°	O
C	O
)	O
.	O

He	O
was	O
transported	O
to	O
the	O
local	O
hospital	O
where	O
the	O
following	O
hematochemical	O
values	O
were	O
registered	O
at	O
18:00	O
h	O
:	O
PT	O
50	O
%	O
;	O
PTT	O
52.7″	O
;	O
TT	O
24″	O
;	O
AT	O
III	O
102	O
%	O
;	O
fibrinogen	O
172	O
mg%	O
;	O
WBC	O
15	O
900	O
/	O
mm3	O
;	O
RBC	O
5	O
410	O
000	O
/	O
mm3	O
;	O
PLT	O
191	O
000	O
/	O
mm3	O
;	O
HB	O
15.2	O
g	O
/	O
dl	O
;	O
HCT	O
46	O
%	O
;	O
BP	O
100	O
/	O
50	O
mmHg	O
;	O
cardiac	O
rate	O
165	O
/	O
min	O
.	O

The	O
patient	O
was	O
given	O
artificial	O
ventilation	O
;	O
an	O
arterial	O
blood	O
gas	O
analysis	O
at	O
19:33	O
h	O
revealed	O
:	O
pH	O
7.326	O
;	O
p	O
CO2	O
37	O
mmHg	O
;	O
p	O
O2	O
89,8	O
mmHg	O
;	O
HCO3	B
18.8	O
mmol	O
/	O
l	O
;	O
SBC	O
19.4	O
mmol	O
/	O
l	O
;	O
So2	O
96.3	O
%	O
.	O

He	O
was	O
diagnosed	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
)	O
and	O
received	O
therapy	O
with	O
heparin	B
bolus	O
2000	O
IU	O
(	O
25	O
IU	O
/	O
kg	O
)	O
and	O
heparin	B
infusion	O
at	O
7	O
IU	O
/	O
kg	O
/	O
h	O
(	O
12	O
500	O
IU	O
for	O
24	O
h	O
)	O
together	O
with	O
the	O
administration	O
of	O
three	O
bags	O
of	O
plasma	O
.	O

At	O
23:30	O
h	O
he	O
suffered	O
a	O
severe	O
loss	O
of	O
blood	O
from	O
the	O
oral	O
cavity	O
and	O
injection	O
wounds	O
:	O
BP	O
60	O
/	O
30	O
mmHg	O
,	O
PR	O
40	O
/	O
min	O
.	O
,	O
PT	O
21	O
%	O
,	O
PTT	O
227.9″	O
,	O
TT	O
199.4″	O
,	O
AT	O
III	O
75	O
%	O
,	O
fibrinogen	O
2	O
mg%	O
,	O
WBC	O
17	O
000	O
/	O
mm3	O
,	O
RBC	O
3	O
230	O
000	O
/	O
mm3	O
,	O
HB	O
9.1	O
g	O
/	O
dl	O
,	O
HCT	O
28	O
%	O
,	O
PLT	O
74	O
000	O
/	O
mm3	O
,	O
uraemia	O
58.3	O
mg	O
/	O
dl	O
,	O
creatinine	B
level	O
3.83	O
mg	O
/	O
dl	O
,	O
K	B
5.37	O
mEq	O
/	O
l	O
,	O
Na	B
141	O
mEq	O
/	O
l	O
,	O
CPK	O
7395	O
,	O
CPK	O
MB	O
50	O
,	O
AST	O
222	O
,	O
ALT	O
112	O
.	O

At	O
01:50	O
h	O
he	O
suffered	O
a	O
cardiac	O
arrest	O
unresponsive	O
to	O
cardiopulmonary	O
resuscitation	O
.	O

2.2	O
Case	O
2	O
C.C.	O
,	O
20	O
years	O
of	O
age	O
,	O
went	O
with	O
some	O
friends	O
to	O
a	O
discotheque	O
,	O
where	O
he	O
remained	O
for	O
some	O
hours	O
and	O
where	O
he	O
was	O
seen	O
to	O
ingest	O
numerous	O
tablets	O
of	O
Ecstasy	B
.	O

When	O
he	O
returned	O
home	O
around	O
02:00	O
h	O
on	O
December	O
26th	O
,	O
he	O
told	O
his	O
mother	O
that	O
he	O
felt	O
feverish	O
.	O

The	O
armpit	O
temperature	O
was	O
established	O
at	O
40	O
°	O
C	O
and	O
he	O
immediately	O
went	O
to	O
bed	O
.	O

At	O
12:00	O
h	O
he	O
was	O
found	O
dead	O
,	O
his	O
pillow	O
soaked	O
with	O
blood	O
.	O

2.3	O
Case	O
3	O

On	O
May	O
19th,1996	O
at	O
15:00	O
h	O
,	O
R.L.	O
,	O
19	O
years	O
of	O
age	O
,	O
was	O
found	O
unconscious	O
near	O
a	O
discotheque	O
.	O

After	O
being	O
carried	O
to	O
the	O
Intensive	O
Care	O
Unit	O
of	O
the	O
local	O
hospital	O
,	O
the	O
following	O
clinical	O
and	O
laboratory	O
data	O
were	O
established	O
:	O
PT	O
52	O
%	O
;	O
PTT	O
55,4″	O
;	O
TT	O
29″	O
;	O
fibrinogen	O
150	O
mg%	O
;	O
WBC	O
11	O
200	O
/	O
mm3	O
;	O
RBC	O
5	O
220	O
000	O
/	O
mm3	O
;	O
PLT	O
180	O
000	O
/	O
mm3	O
;	O
HB	O
14g	O
/	O
dl	O
;	O
HCT	O
43	O
%	O
;	O
BP	O
90	O
/	O
50	O
mmHg	O
;	O
PR	O
170	O
/	O
min	O
;	O
T	O
40.5	O
°	O
C	O
.	O

The	O
clinical	O
course	O
progressively	O
worsened	O
and	O
at	O
15:00	O
h	O
on	O
May	O
20th	O
diffused	O
subcutaneous	O
petechiae	O
appeared	O
;	O
the	O
patient	O
sustained	O
convulsions	O
and	O
treatment	O
with	O
dopamine	B
was	O
started	O
because	O
of	O
progressive	O
hypotension	O
:	O
BP	O
60	O
/	O
40	O
mmHg	O
;	O
PR	O
60	O
/	O
min	O
;	O
PT	O
20	O
%	O
;	O
PTT	O
210″	O
;	O
TT	O
195″	O
;	O
fibrinogen	O
5	O
mg%	O
;	O
WBC	O
15	O
000	O
/	O
mm3	O
;	O
RBC	O
3	O
200	O
000	O
/	O
mm3	O
;	O
HB	O
9.8	O
g	O
/	O
dl	O
;	O
HCT	O
30	O
%	O
;	O
PLT	O
90	O
000	O
/	O
mm3	O
;	O
uraemia	O
74	O
mg	O
/	O
dl	O
;	O
creatinine	B
level	O
5.05	O
mg	O
/	O
dl	O
;	O
K	B
5.6	O
mEq	O
/	O
l	O
;	O
Na	B
138	O
mEq	O
/	O
l	O
;	O
CPK	O
8200	O
;	O
CPK	O
MB	O
40	O
;	O
AST	O
110	O
;	O
ALT	O
90	O
;	O
T	O
40.9	O
°	O
C	O
.	O

At	O
19:00	O
h	O
on	O
May	O
20th	O
he	O
was	O
pronounced	O
dead	O
.	O

Amphetamines	B
were	O
detected	O
in	O
the	O
urine	O
of	O
the	O
subjects	O
by	O
immunoenzymatic	O
screening	O
.	O

Toxicological	O
analyses	O
by	O
solid	O
–	O
liquid	O
extraction	O
and	O
gas	O
chromatography	O
–	O
mass	O
spectrometry	O
analysis	O
were	O
therefore	O
carried	O
out	O
to	O
identify	O
and	O
quantify	O
the	O
individual	O
substances	O
present	O
in	O
the	O
biological	O
fluids	O
and	O
organs	O
.	O

Table	O
1	O
shows	O
the	O
concentrations	O
of	O
MDMA	B
,	O
MDEA	B
and	O
MDA	B
(	O
metabolite	B
of	O
MDMA	B
)	O
in	O
current	O
cases	O
.	O

2.4	O
Immunohistochemical	O
staining	O
Immunohistochemical	O
investigation	O
of	O
the	O
kidney	O
and	O
the	O
muscle	O
structures	O
was	O
performed	O
utilising	O
polyclonal	O
anti	O
-	O
myoglobin	O
antibodies	O
(	O
Dako	O
,	O
Germany	O
)	O
[	O
6,7	O
]	O
.	O

Lungs	O
were	O
examined	O
utilising	O
polyclonal	O
anti	O
-	O
fibrinogen	O
antibodies	O
(	O
Calbiochem	O
,	O
USA	O
)	O
.	O

Liver	O
structures	O
were	O
examined	O
utilising	O
polyclonal	O
anti	O
-	O
fibrinogen	O
antibodies	O
(	O
Calbiochem	O
,	O
USA	O
)	O
,	O
anti	O
-	O
FDP	O
-	O
D	O
(	O
AGC	O
,	O
USA	O
)	O
,	O
and	O
anti	O
-	O
FDP	O
-	O
E	O
antibodies	O
(	O
ICN	O
Biomedicals	O
,	O
USA	O
)	O
[	O
8	O
]	O
.	O

Sections	O
were	O
counterstained	O
,	O
dehydrated	O
,	O
coverslipped	O
and	O
observed	O
in	O
a	O
Leitz	O
Aristoplan	O
optical	O
microscope	O
.	O

2.5	O
Other	O
tests	O
A	O
routine	O
microscopic	O
histopathological	O
study	O
was	O
performed	O
by	O
using	O
formalin	B
-	O
fixed	O
paraffin	B
embedded	O
tissue	O
sectioned	O
at	O
4	O
μm	O
and	O
stained	O
with	O
haematoxylin	B
–	O
eosin	B
,	O
periodic	B
acid	I
-	O
Schiff	O
and	O
phosphotungstic	B
acid	I
–	O
haematoxylin	B
(	O
PTAH	B
)	O
.	O

3	O
Results	O
3.1	O
Pathological	O
findings	O
The	O
morphological	O
data	O
together	O
with	O
the	O
autopsy	O
findings	O
revealed	O
diffused	O
subserous	O
petechiae	O
,	O
polyvisceral	O
stasis	O
and	O
the	O
following	O
histo	O
-	O
pathological	O
alterations	O
:	O
3.1.1	O
Brain	O
Massive	O
oedema	O
and	O
signs	O
of	O
neuronal	O
hypoxia	O
were	O
present	O
in	O
all	O
cases	O
;	O
in	O
one	O
case	O
perivascular	O
ring	O
haemorrhages	O
,	O
especially	O
in	O
the	O
cortical	O
zone	O
,	O
were	O
observed	O
.	O

3.1.2	O
Heart	O
Coagulative	O
myocytolysis	O
was	O
present	O
in	O
two	O
cases	O
.	O

We	O
observed	O
plurifocal	O
foci	O
of	O
myocells	O
with	O
hypercontraction	O
of	O
the	O
whole	O
myocell	O
and	O
myofibrillar	O
rhexis	O
with	O
anomalous	O
deeply	O
eosinophilic	O
cross	O
-	O
bands	O
formed	O
by	O
hypercontracted	O
sarcomeres	O
.	O

More	O
advanced	O
stages	O
of	O
coagulative	O
myocytolysis	O
(	O
alveolar	O
or	O
healing	O
patterns	O
)	O
and	O
old	O
myocardial	O
fibrosis	O
were	O
absent	O
or	O
minimal	O
.	O

In	O
one	O
case	O
areas	O
of	O
subendocardial	O
haemorrhage	O
were	O
also	O
noticed	O
.	O

3.1.3	O
Lung	O
All	O
cases	O
revealed	O
subpleural	O
and	O
intra	O
-	O
alveolar	O
haemorrhage	O
with	O
severe	O
oedema	O
and	O
,	O
in	O
two	O
cases	O
,	O
microthrombotic	O
formations	O
inside	O
lung	O
capillaries	O
.	O

3.1.4	O
Liver	O
In	O
two	O
cases	O
there	O
was	O
evidence	O
of	O
microvescicular	O
steatosis	O
and	O
in	O
one	O
case	O
clear	O
centrilobular	O
necrosis	O
around	O
the	O
central	O
veins	O
.	O

Liver	O
cells	O
in	O
the	O
central	O
zones	O
revealed	O
coagulation	O
necrosis	O
with	O
precipitation	O
of	O
fibrin	O
in	O
the	O
whole	O
area	O
affected	O
by	O
necrosis	O
.	O

There	O
were	O
occasionally	O
fibrillar	O
or	O
fine	O
granular	O
fibrin	O
thrombi	O
and	O
Kupffer	O
cells	O
ingesting	O
fibrin	O
in	O
sinusoids	O
around	O
the	O
area	O
of	O
necrosis	O
.	O

The	O
PTAH	O
staining	O
method	O
was	O
revealed	O
to	O
be	O
suitable	O
for	O
organized	O
fibrin	O
molecules	O
,	O
but	O
not	O
for	O
fibrin	O
molecules	O
during	O
the	O
process	O
of	O
either	O
polymerization	O
or	O
degradation	O
.	O

In	O
contrast	O
an	O
indirect	O
peroxidase	O
antibody	O
method	O
using	O
anti	O
-	O
fibrinogen	O
,	O
anti	O
-	O
FDP	O
-	O
D	O
and	O
anti	O
-	O
FDP	O
-	O
E	O
antibodies	O
was	O
suitable	O
for	O
the	O
latter	O
,	O
but	O
not	O
for	O
the	O
former	O
[	O
8	O
]	O
.	O

Post	O
-	O
mortem	O
virology	O
was	O
not	O
performed	O
in	O
these	O
cases	O
.	O

3.1.5	O
Kidney	O
Fibrin	O
thrombi	O
in	O
the	O
renal	O
glomeruli	O
were	O
observed	O
in	O
two	O
cases	O
.	O

All	O
glomeruli	O
thrombi	O
were	O
already	O
organised	O
and	O
were	O
stained	O
prominently	O
by	O
PTAH	O
.	O

In	O
one	O
case	O
acute	O
tubular	O
necrosis	O
was	O
observed	O
.	O

H&E	O
examination	O
revealed	O
numerous	O
reddish	O
-	O
brown	O
granular	O
and	O
amorphous	O
casts	O
within	O
the	O
renal	O
tubules	O
.	O

In	O
all	O
the	O
cases	O
the	O
presence	O
of	O
tubular	O
casts	O
was	O
studied	O
with	O
immunohistochemical	O
technique	O
,	O
thus	O
demonstrating	O
their	O
myoglobinic	O
nature	O
(	O
Figs.	O
1	O
and	O
2	O
)	O
.	O

3.1.6	O
Muscle	O
In	O
two	O
cases	O
hypercontracted	O
fibers	O
with	O
an	O
absence	O
of	O
the	O
striations	O
and	O
cystic	O
cavities	O
adjacent	O
to	O
zones	O
of	O
fiber	O
ruptures	O
were	O
present	O
(	O
Fig.	O
3a	O
)	O
.	O

The	O
immunohistochemical	O
investigation	O
for	O
myoglobin	O
performed	O
according	O
to	O
Fechner	O
and	O
co	O
-	O
workers	O
[	O
7,9	O
]	O
showed	O
accumulation	O
of	O
the	O
protein	O
in	O
the	O
breakage	O
areas	O
of	O
the	O
fibres	O
especially	O
on	O
the	O
surface	O
of	O
the	O
contraction	O
caps	O
(	O
Fig.	O
3b	O
)	O
.	O

4	O
Discussion	O
There	O
are	O
substantial	O
similarities	O
in	O
the	O
clinical	O
and	O
histopathological	O
findings	O
of	O
the	O
fatal	O
cases	O
herein	O
presented	O
.	O

Two	O
deaths	O
were	O
caused	O
by	O
single	O
intoxication	O
,	O
respectively	O
,	O
from	O
MDMA	B
and	O
MDEA	B
and	O
the	O
third	O
from	O
both	O
MDMA	B
and	O
MDEA	B
.	O

No	O
other	O
drugs	B
were	O
detected	O
.	O

In	O
the	O
present	O
study	O
the	O
pathological	O
data	O
are	O
in	O
accordance	O
with	O
a	O
well	O
studied	O
and	O
documented	O
clinical	O
entity	O
,	O
i.e.	O
hyperthermia	O
and	O
disseminated	O
intravascular	O
coagulation	O
[	O
10–12	O
]	O
;	O
however	O
the	O
macro	O
and	O
microscopic	O
findings	O
have	O
not	O
been	O
definitively	O
classified	O
or	O
defined	O
yet	O
.	O

After	O
the	O
onset	O
of	O
deaths	O
related	O
to	O
MDMA	B
ingestion	O
[	O
13	O
]	O
,	O
reports	O
have	O
been	O
compiled	O
about	O
fatal	O
arrhythmia	O
caused	O
by	O
the	O
ingestion	O
of	O
MDMA	B
[	O
14	O
]	O
or	O
cases	O
of	O
hyperthermia	O
followed	O
by	O
DIC	O
[	O
15–19	O
]	O
.	O

Clinical	O
proofs	O
of	O
hyperthermia	O
,	O
rhabdomyolysis	O
and	O
DIC	O
are	O
also	O
evident	O
in	O
deaths	O
caused	O
by	O
MDEA	O
intoxication	O
with	O
findings	O
of	O
subserous	O
haemorrhage	O
and	O
severe	O
polyvisceral	O
stasis	O
[	O
20–24	O
]	O
.	O

Similar	O
pathological	O
findings	O
are	O
described	O
in	O
the	O
cases	O
of	O
death	O
due	O
to	O
combined	O
intoxication	O
of	O
MDMA	B
and	O
MDEA	B
[	O
2,25,26	O
]	O
.	O

A	O
report	O
describes	O
acute	O
myocardial	O
infarction	O
associated	O
with	O
amphetamine	B
abuse	O
[	O
27	O
]	O
.	O

Potential	O
explanations	O
include	O
coronary	O
vasospasm	O
,	O
excessive	O
catecholamine	B
discharge	O
resulting	O
in	O
ischemic	O
myocardial	O
necrosis	O
,	O
and	O
catecholamine	B
mediated	O
platelet	O
aggregation	O
with	O
subsequent	O
thrombus	O
formation	O
.	O

The	O
syndrome	O
closely	O
resembles	O
acute	O
myocardial	O
infarction	O
due	O
to	O
cocaine	B
abuse	O
[	O
3	O
]	O
.	O

A	O
comparison	O
of	O
our	O
findings	O
with	O
presently	O
available	O
related	O
literature	O
reveals	O
slight	O
differences	O
in	O
histopathological	O
findings	O
,	O
particularly	O
of	O
the	O
heart	O
,	O
liver	O
and	O
kidneys	O
as	O
compared	O
to	O
those	O
described	O
in	O
previous	O
reports	O
.	O

The	O
types	O
of	O
myocardial	O
necrosis	O
found	O
in	O
our	O
cases	O
were	O
coagulative	O
myocytolysis	O
.	O

No	O
histological	O
signs	O
of	O
infarct	O
necrosis	O
were	O
detected	O
.	O

Coagulative	O
myocytolysis	O
,	O
even	O
if	O
confined	O
to	O
few	O
myocells	O
,	O
can	O
be	O
interpreted	O
as	O
a	O
histological	O
sign	O
of	O
adrenergic	O
overdrive	O
[	O
28	O
]	O
.	O

Coagulative	O
myocytolytic	O
changes	O
may	O
be	O
related	O
to	O
the	O
type	O
and	O
length	O
of	O
survival	O
,	O
particularly	O
in	O
subjects	O
predisposed	O
to	O
cardiac	O
adrenergic	O
response	O
.	O

It	O
remains	O
to	O
be	O
established	O
if	O
coagulative	O
myocytolysis	O
is	O
due	O
to	O
unspecific	O
agonal	O
stimuli	O
or	O
drug	B
action	O
.	O

In	O
other	O
words	O
,	O
any	O
attempt	O
to	O
evaluate	O
its	O
meaning	O
requires	O
the	O
recognition	O
of	O
older	O
stages	O
,	O
the	O
determination	O
of	O
survival	O
time	O
,	O
and	O
the	O
exclusion	O
of	O
reanimative	O
procedures	O
.	O

In	O
two	O
cases	O
,	O
the	O
study	O
of	O
muscle	O
samples	O
revealed	O
hypercontracted	O
fibers	O
with	O
disruption	O
of	O
the	O
cell	O
architecture	O
,	O
typical	O
pathological	O
changes	O
observed	O
in	O
deaths	O
due	O
to	O
malignant	O
hyperpyrexia	O
[	O
29	O
]	O
.	O

Malignant	O
hyperthermia	O
is	O
a	O
rare	O
,	O
inherited	O
abnormal	O
susceptibility	O
to	O
certain	O
drugs	B
,	O
mostly	O
inhalational	O
anaesthetics	B
[	O
30	O
]	O
.	O

It	O
is	O
possible	O
that	O
individual	O
susceptibility	O
to	O
the	O
adverse	O
effects	O
of	O
the	O
amphetamine	B
derivatives	B
exists	O
,	O
with	O
deficient	O
demethylation	O
of	O
MDMA	B
by	O
debrisoquine	O
hydroylase	O
(	O
CYP2D6	O
)	O
,	O
being	O
shown	O
in	O
certain	O
individuals	O
.	O

The	O
absence	O
of	O
CYP2D6	O
,	O
a	O
member	O
of	O
the	O
cytochrome	O
P450	O
superfamily	O
of	O
enzymes	O
,	O
in	O
5–9	O
%	O
of	O
whites	O
,	O
may	O
be	O
another	O
factor	O
explaining	O
apparently	O
idiosyncratic	O
or	O
severe	O
responses	O
to	O
the	O
drug	B
[	O
31	O
]	O
.	O

Rhabdomyolysis	O
and	O
myoglobinuria	O
are	O
often	O
described	O
[	O
10,32	O
]	O
.	O

The	O
presence	O
of	O
myoglobin	O
in	O
the	O
kidney	O
has	O
been	O
reported	O
in	O
a	O
histopathological	O
study	O
only	O
[	O
2	O
]	O
.	O

In	O
a	O
recent	O
review	O
,	O
myoglobin	O
was	O
not	O
detected	O
in	O
the	O
only	O
two	O
cases	O
in	O
which	O
the	O
kidneys	O
were	O
examined	O
[	O
5	O
]	O
.	O

We	O
were	O
able	O
to	O
demonstrate	O
the	O
presence	O
of	O
myoglobin	O
in	O
the	O
proximal	O
tubules	O
in	O
all	O
the	O
three	O
cases	O
here	O
examined	O
.	O

Two	O
cases	O
presented	O
microthrombosis	O
of	O
the	O
pulmonary	O
and	O
renal	O
microcirculation	O
related	O
to	O
DIC	O
.	O

Finally	O
,	O
in	O
two	O
cases	O
has	O
been	O
possible	O
to	O
demonstrate	O
a	O
hepatic	O
microvescicular	O
steatosis	O
and	O
aspects	O
of	O
centrilobular	O
necrosis	O
related	O
to	O
DIC	O
in	O
one	O
case	O
.	O

The	O
genesis	O
of	O
the	O
hepatic	O
damage	O
caused	O
by	O
MDMA	B
/	O
MDEA	B
still	O
remains	O
unexplained	O
and	O
does	O
not	O
seem	O
to	O
be	O
related	O
to	O
the	O
dose	O
or	O
frequency	O
of	O
drug	B
ingestion	O
.	O

Idiosyncratic	O
reactions	O
or	O
individual	O
susceptibility	O
are	O
likely	O
pathogenic	O
causes	O
of	O
the	O
hepatic	O
pictures	O
described	O
[	O
33,34	O
]	O
.	O

The	O
quality	O
of	O
Ecstasy	B
tablets	O
should	O
also	O
be	O
considered	O
due	O
to	O
the	O
established	O
and	O
documented	O
presence	O
of	O
toxic	O
contaminants	O
[	O
5	O
]	O
.	O

The	O
increase	O
in	O
cases	O
of	O
toxicity	O
due	O
to	O
MDMA	B
and	O
drugs	B
sold	O
as	O
'	O
Ecstasy	B
'	O
deserves	O
to	O
be	O
publicised	O
for	O
various	O
reasons	O
.	O

First	O
,	O
it	O
is	O
not	O
possible	O
to	O
establish	O
the	O
cause	O
of	O
severe	O
or	O
fatal	O
complications	O
following	O
the	O
ingestion	O
of	O
Ecstasy	B
with	O
the	O
data	O
available	O
at	O
present	O
.	O

Individuals	O
who	O
experience	O
such	O
an	O
adverse	O
reaction	O
have	O
often	O
used	O
the	O
drug	B
previously	O
without	O
problems	O
[	O
10	O
]	O
.	O

Chemical	O
and	O
toxicological	O
analysis	O
of	O
post	O
-	O
mortem	O
biological	O
material	O
shows	O
variable	O
concentrations	O
of	O
amphetamines	B
,	O
suggesting	O
hypersensitivity	O
in	O
the	O
cases	O
of	O
low	O
doses	O
.	O

Individual	O
susceptibility	O
to	O
ring	O
substituted	O
amphetamines	B
may	O
be	O
related	O
to	O
its	O
metabolism	O
in	O
the	O
liver	O
[	O
35	O
]	O
and	O
can	O
explain	O
severe	O
or	O
fatal	O
responses	O
to	O
the	O
drug	B
[	O
31	O
]	O
.	O

Second	O
,	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
pattern	O
of	O
toxicity	O
so	O
as	O
to	O
be	O
able	O
to	O
perform	O
correct	O
diagnoses	O
and	O
treatments	O
.	O

Finally	O
,	O
from	O
a	O
diagnostic	O
standpoint	O
,	O
in	O
all	O
ring	O
-	O
substituted	O
amphetamines	B
-	O
related	O
deaths	O
,	O
a	O
complete	O
immunohistochemical	O
study	O
should	O
be	O
performed	O
especially	O
on	O
muscle	O
[	O
36	O
]	O
and	O
kidney	O
[	O
37	O
]	O
samples	O
.	O

Chlozolinate	B
[	O
structure	O
and	O
chemical	B
names	O
in	O
Fig.	O
1	O
,	O
log	O
octanol	B
–	O
water	B
partition	O
coefficient	O
(	O
log	O
P	O
o	O
/	O
w	O
)	O
=	O
3.15	O
,	O
solubility	O
in	O
water=32	B
mg	O
/	O
l	O
at	O
25	O
°	O
C	O
]	O
is	O
a	O
fungicide	B
belonging	O
to	O
the	O
dicarboximide	B
group	O
which	O
is	O
used	O
on	O
a	O
variety	O
of	O
crops	O
:	O
fruiting	O
vegetables	O
,	O
stone	O
fruits	O
,	O
artichokes	O
,	O
carrots	O
,	O
grapes	O
,	O
potatoes	O
and	O
strawberries	O
.	O

It	O
was	O
included	O
in	O
the	O
first	O
list	O
of	O
compounds	O
re	O
-	O
evaluated	O
within	O
the	O
European	O
Union	O
in	O
the	O
framework	O
of	O
directive	O
91	O
/	O
414	O
/	O
EEC	O
[	O
1,2	O
]	O
.	O

Although	O
its	O
use	O
on	O
edible	O
crops	O
to	O
be	O
supported	O
in	O
the	O
future	O
will	O
be	O
restricted	O
to	O
stone	O
fruits	O
and	O
grapes	O
,	O
the	O
necessity	O
to	O
monitor	O
all	O
produce	O
for	O
residues	O
remains	O
.	O

Methods	O
published	O
in	O
the	O
literature	O
are	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
methods	O
based	O
on	O
that	O
of	O
Cabras	O
et	O
al.	O
[	O
3	O
]	O
,	O
which	O
enables	O
the	O
simultaneous	O
determination	O
of	O
dicarboximide	B
fungicides	B
and	O
their	O
degradation	O
product	O
3,5-dichloroaniline	B
,	O
and	O
are	O
,	O
therefore	O
,	O
group	O
specific	O
.	O

Although	O
chlozolinate	B
degrades	O
to	O
a	O
number	O
of	O
metabolites	B
,	O
the	O
residue	O
definition	O
proposed	O
includes	O
only	O
the	O
parent	B
compound	I
.	O

Two	O
gas	O
chromatography	O
(	O
GC	O
)	O
methods	O
specific	O
for	O
chlozolinate	B
which	O
use	O
thermionic	O
specific	O
detection	O
(	O
TSD	O
)	O
have	O
been	O
developed	O
by	O
the	O
manufacturing	O
company	O
ISAGRO	O
,	O
Milan	O
,	O
Italy	O
,	O
and	O
validated	O
satisfactorily	O
for	O
peaches	O
,	O
apricots	O
and	O
grapes	O
[	O
4	O
]	O
and	O
for	O
grapes	O
and	O
wine	O
[	O
5	O
]	O
.	O

However	O
,	O
for	O
routine	O
residue	O
control	O
it	O
is	O
desirable	O
to	O
be	O
able	O
to	O
analyse	O
residues	O
of	O
as	O
many	O
compounds	O
as	O
possible	O
simultaneously	O
and	O
it	O
is	O
,	O
therefore	O
,	O
important	O
to	O
examine	O
the	O
possibility	O
of	O
including	O
chlozolinate	B
in	O
multiresidue	O
methods	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
possibility	O
of	O
determining	O
residues	O
of	O
chlozolinate	B
in	O
several	O
crops	O
using	O
a	O
routinely	O
applied	O
multiresidue	O
method	O
and	O
to	O
validate	O
this	O
method	O
for	O
the	O
fungicide	B
according	O
to	O
the	O
relevant	O
international	O
guidelines	O
[	O
6–9	O
]	O
.	O

2	O
Experimental	O
2.1	O
Analytical	O
method	O
Since	O
chlozolinate	B
contains	O
two	O
chlorine	B
atoms	O
compared	O
to	O
only	O
one	O
nitrogen	B
atom	O
,	O
greater	O
sensitivity	O
would	O
be	O
expected	O
with	O
electron	O
-	O
capture	O
detection	O
(	O
ECD	O
)	O
than	O
with	O
TSD	O
.	O

The	O
method	O
selected	O
for	O
this	O
study	O
was	O
a	O
simple	O
,	O
low	O
-	O
cost	O
,	O
multiresidue	O
method	O
for	O
electron	O
-	O
capturing	O
compounds	O
[	O
10	O
]	O
which	O
is	O
already	O
used	O
routinely	O
in	O
our	O
laboratory	O
for	O
monitoring	O
purposes	O
.	O

All	O
solvents	O
and	O
reagents	B
used	O
were	O
of	O
high	O
purity	O
and	O
suitable	O
for	O
pesticide	B
residue	O
analysis	O
.	O

A	O
25-g	O
homogenized	O
sample	O
(	O
reduced	O
from	O
50	O
g	O
in	O
the	O
original	O
method	O
)	O
is	O
extracted	O
with	O
a	O
mixture	O
of	O
50	O
ml	O
toluene	B
and	O
25	O
ml	O
propan-2-ol	B
using	O
an	O
Ultra	O
-	O
Turrax	O
homogenizer	O
for	O
3	O
min	O
.	O

The	O
upper	O
toluene	B
phase	O
is	O
decanted	O
through	O
a	O
funnel	O
with	O
a	O
plug	O
of	O
quartz	B
-	O
wool	O
into	O
a	O
separatory	O
funnel	O
and	O
clean	O
-	O
up	O
is	O
effected	O
in	O
two	O
stages	O
through	O
(	O
a	O
)	O
liquid	O
–	O
liquid	O
partitioning	O
with	O
two	O
125-ml	O
portions	O
of	O
an	O
aqueous	O
solution	O
of	O
2	O
%	O
Na2	B
SO4	I
and	O
(	O
b	O
)	O
vigorous	O
shaking	O
for	O
1–2	O
min	O
of	O
a	O
10-ml	O
aliquot	O
of	O
the	O
toluene	B
phase	O
with	O
1	O
g	O
of	O
a	O
mixture	O
of	O
adsorbents	O
(	O
activated	O
charcoal	B
Altec	O
6	O
/	O
16	O
granular	O
–	O
Celite	B
545	O
;	O
3:1	O
,	O
w	O
/	O
w	O
)	O
followed	O
by	O
filtration	O
through	O
a	O
fluted	O
filter	O
paper	O
to	O
obtain	O
the	O
final	O
extract	O
.	O

2.2	O
Matrices	O
and	O
fortification	O
levels	O
The	O
four	O
most	O
important	O
crops	O
,	O
grapes	O
,	O
peaches	O
,	O
apricots	O
and	O
plums	O
,	O
were	O
fortified	O
at	O
four	O
concentrations	O
(	O
1	O
,	O
0.4	O
,	O
0.1	O
and	O
0.04	O
mg	O
/	O
kg	O
)	O
with	O
five	O
replicate	O
samples	O
at	O
each	O
level	O
.	O

Two	O
additional	O
levels	O
,	O
5	O
and	O
0.004	O
mg	O
/	O
kg	O
,	O
were	O
included	O
for	O
grapes	O
in	O
order	O
to	O
test	O
the	O
method	O
at	O
residue	O
concentrations	O
around	O
the	O
proposed	O
maximum	O
residue	O
level	O
(	O
MRL	O
)	O
of	O
5	O
mg	O
/	O
kg	O
and	O
at	O
the	O
estimated	O
limit	O
of	O
quantitation	O
(	O
LOQ	O
)	O
.	O

Plums	O
,	O
as	O
representative	O
of	O
stone	O
fruits	O
,	O
were	O
also	O
fortified	O
at	O
0.004	O
mg	O
/	O
kg	O
.	O

A	O
second	O
set	O
of	O
measurements	O
was	O
carried	O
out	O
on	O
seven	O
crops	O
for	O
which	O
the	O
use	O
of	O
chlozolinate	B
is	O
still	O
authorised	O
but	O
is	O
likely	O
to	O
be	O
withdrawn	O
in	O
the	O
future	O
,	O
and	O
on	O
one	O
further	O
crop	O
,	O
apples	O
,	O
for	O
which	O
there	O
is	O
no	O
approved	O
use	O
.	O

Fortification	O
was	O
at	O
the	O
expected	O
residue	O
level	O
of	O
1	O
mg	O
/	O
kg	O
(	O
8	O
to	O
12	O
replicates	O
)	O
.	O

Extension	O
of	O
the	O
study	O
to	O
include	O
these	O
crops	O
covers	O
the	O
need	O
to	O
ensure	O
that	O
monitoring	O
programmes	O
will	O
detect	O
illegal	O
use	O
of	O
the	O
pesticide	B
.	O

In	O
addition	O
,	O
the	O
method	O
was	O
tested	O
for	O
grape	O
samples	O
with	O
incurred	O
residues	O
,	O
using	O
grapes	O
of	O
varieties	O
Cardinal	O
and	O
Victoria	O
from	O
plots	O
of	O
vineyards	O
of	O
table	O
grapes	O
which	O
had	O
been	O
treated	O
with	O
a	O
commercial	O
formulation	O
of	O
chlozolinate	B
,	O
as	O
described	O
elsewhere	O
[	O
11	O
]	O
.	O

2.3	O
GC	O
determination	O
The	O
GC	O
determinations	O
were	O
carried	O
out	O
using	O
a	O
Hewlett	O
-	O
Packard	O
5890	O
Series	O
II	O
gas	O
chromatograph	O
fitted	O
with	O
an	O
ECD	O
system	O
operated	O
at	O
300	O
°	O
C	O
,	O
a	O
Hewlett	O
-	O
Packard	O
7673	O
autosampler	O
and	O
a	O
split	O
–	O
splitless	O
injector	O
operated	O
in	O
the	O
splitless	O
mode	O
(	O
250	O
°	O
C	O
,	O
60	O
s	O
,	O
1	O
μl	O
)	O
.	O

The	O
carrier	O
and	O
make	O
-	O
up	O
gases	O
were	O
helium	B
and	O
nitrogen	B
(	O
50	O
ml	O
/	O
min	O
)	O
,	O
respectively	O
,	O
and	O
two	O
fused	O
-	O
silica	B
chromatographic	O
columns	O
were	O
employed	O
:	O
an	O
Rtx-5	O
column	O
(	O
5	O
%	O
diphenyl–95	B
%	O
dimethylpolysiloxane	B
stationary	O
phase	O
,	O
30	O
m	O
×	O
0.250	O
mm	O
I.D.	O
,	O
0.25	O
μm	O
film	O
thickness	O
)	O
with	O
a	O
He	B
pressure	O
of	O
95	O
kPa	O
and	O
an	O
HP608	O
column	O
(	O
30	O
m	O
×	O
0.530	O
mm	O
I.D.	O
,	O
0.5	O
μm	O
film	O
thickness	O
)	O
with	O
a	O
He	B
pressure	O
of	O
37	O
kPa	O
.	O

The	O
following	O
oven	O
temperature	O
programme	O
was	O
used	O
:	O
80	O
°	O
C	O
,	O
hold	O
1	O
min	O
;	O
15	O
°	O
C	O
/	O
min	O
to	O
190	O
°	O
C	O
;	O
3	O
°	O
C	O
/	O
min	O
to	O
280	O
°	O
C	O
,	O
hold	O
5	O
min	O
.	O

Quantification	O
was	O
carried	O
out	O
using	O
calibration	O
curves	O
with	O
three	O
to	O
five	O
levels	O
which	O
covered	O
relatively	O
small	O
concentration	O
ranges	O
(	O
typically	O
a	O
factor	O
of	O
10	O
)	O
.	O

The	O
lowest	O
calibrated	O
level	O
and	O
highest	O
calibrated	O
level	O
were	O
chosen	O
in	O
each	O
case	O
so	O
as	O
to	O
ensure	O
that	O
the	O
range	O
of	O
pesticide	B
concentration	O
in	O
the	O
samples	O
of	O
the	O
batch	O
was	O
covered	O
,	O
and	O
bracketing	O
injections	O
of	O
standards	O
were	O
used	O
,	O
i.e.	O
,	O
standard	O
injections	O
were	O
made	O
both	O
preceding	O
and	O
following	O
each	O
batch	O
of	O
samples	O
.	O

Recoveries	O
for	O
grapes	O
,	O
plums	O
,	O
apricots	O
and	O
peaches	O
at	O
all	O
fortification	O
levels	O
and	O
for	O
apples	O
and	O
aubergines	O
at	O
1	O
mg	O
/	O
kg	O
were	O
determined	O
with	O
matrix	O
-	O
matched	O
standards	O
.	O

The	O
blank	O
commodity	O
used	O
for	O
matrix	O
-	O
matching	O
was	O
identical	O
to	O
that	O
used	O
for	O
preparation	O
of	O
the	O
spiked	O
samples	O
.	O

Recoveries	O
at	O
1	O
mg	O
/	O
kg	O
for	O
these	O
matrices	O
and	O
for	O
the	O
other	O
crops	O
included	O
in	O
the	O
study	O
were	O
determined	O
with	O
non	O
matrix	O
-	O
matched	O
standards	O
since	O
,	O
at	O
the	O
time	O
these	O
measurements	O
were	O
made	O
,	O
matrix	O
-	O
matching	O
of	O
GC	O
standards	O
was	O
not	O
routine	O
practice	O
in	O
our	O
laboratory	O
.	O

2.4	O
Method	O
validation	O
The	O
validation	O
of	O
an	O
analytical	O
method	O
in	O
individual	O
laboratories	O
,	O
i.e.	O
,	O
in	O
-	O
laboratory	O
validation	O
,	O
generally	O
includes	O
testing	O
it	O
for	O
accuracy	O
,	O
precision	O
,	O
the	O
limits	O
of	O
detection	O
(	O
LOD	O
)	O
and	O
quantitation	O
(	O
LOQ	O
)	O
,	O
specificity	O
,	O
sensitivity	O
,	O
linearity	O
,	O
ruggedness	O
and	O
practicability	O
[	O
6–9	O
]	O
.	O

More	O
recent	O
requirements	O
involve	O
the	O
examination	O
of	O
matrix	O
effects	O
and	O
verification	O
of	O
the	O
stability	O
of	O
an	O
analyte	O
in	O
both	O
calibration	O
solutions	O
and	O
sample	O
extracts	O
[	O
6,7	O
]	O
.	O

The	O
basic	O
criteria	O
which	O
must	O
be	O
met	O
in	O
order	O
for	O
a	O
method	O
to	O
be	O
considered	O
quantitative	O
are	O
satisfactory	O
accuracy	O
and	O
precision	O
,	O
i.e.	O
,	O
a	O
recovery	O
in	O
the	O
range	O
70	O
to	O
110	O
%	O
(	O
mean	O
recovery	O
80–100	O
%	O
)	O
and	O
a	O
relative	O
standard	O
deviation	O
(	O
RSD	O
)	O
within	O
±10	O
%	O
.	O

Precision	O
is	O
characterised	O
through	O
data	O
on	O
(	O
a	O
)	O
repeatability	O
,	O
which	O
estimates	O
within	O
-	O
batch	O
variation	O
(	O
same	O
analyst	O
,	O
test	O
material	O
and	O
equipment	O
over	O
a	O
short	O
time	O
interval	O
)	O
,	O
and	O
(	O
b	O
)	O
internal	O
reproducibility	O
,	O
(	O
preferably	O
different	O
analysts	O
,	O
batches	O
of	O
reagents	O
,	O
and	O
possibly	O
the	O
use	O
of	O
different	O
equipment	O
over	O
a	O
longer	O
time	O
interval	O
)	O
.	O

Most	O
series	O
of	O
replicates	O
for	O
a	O
given	O
fortification	O
level	O
and	O
crop	O
were	O
carried	O
out	O
on	O
the	O
same	O
day	O
by	O
the	O
same	O
analyst	O
,	O
thus	O
providing	O
extensive	O
data	O
for	O
testing	O
the	O
repeatability	O
of	O
the	O
method	O
.	O

Internal	O
reproducibility	O
is	O
indicated	O
by	O
the	O
RSD	O
values	O
of	O
the	O
mean	O
recoveries	O
for	O
different	O
crops	O
fortified	O
at	O
1	O
mg	O
/	O
kg	O
.	O

These	O
were	O
carried	O
out	O
over	O
a	O
period	O
of	O
many	O
months	O
,	O
and	O
extracts	O
were	O
prepared	O
by	O
several	O
different	O
laboratory	O
assistants	O
,	O
some	O
of	O
whom	O
were	O
short	O
-	O
term	O
temporary	O
staff	O
with	O
no	O
previous	O
training	O
in	O
the	O
field	O
.	O

These	O
data	O
,	O
therefore	O
,	O
also	O
provide	O
a	O
test	O
of	O
the	O
ruggedness	O
and	O
practicability	O
of	O
the	O
method	O
.	O

The	O
calculation	O
of	O
the	O
LOD	O
was	O
made	O
based	O
on	O
three	O
-	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
chlozolinate	B
concentration	O
found	O
for	O
ten	O
repeat	O
injections	O
of	O
the	O
extract	O
of	O
a	O
sample	O
fortified	O
at	O
the	O
estimated	O
LOQ	O
.	O

Measurements	O
were	O
made	O
for	O
both	O
grape	O
and	O
plum	O
extracts	O
.	O

The	O
LOQ	O
was	O
confirmed	O
by	O
calculation	O
of	O
the	O
RSD	O
of	O
the	O
recoveries	O
for	O
five	O
replicate	O
samples	O
each	O
of	O
grapes	O
and	O
plums	O
fortified	O
at	O
this	O
level	O
[	O
7	O
]	O
.	O

For	O
specificity	O
,	O
blanks	O
of	O
at	O
least	O
two	O
samples	O
of	O
each	O
crop	O
were	O
checked	O
for	O
interfering	O
peaks	O
on	O
the	O
two	O
chromatographic	O
columns	O
used	O
,	O
and	O
the	O
retention	O
times	O
of	O
a	O
wide	O
range	O
of	O
other	O
electron	O
-	O
capturing	O
compounds	O
were	O
checked	O
against	O
that	O
of	O
chlozolinate	B
.	O

Sensitivity	O
and	O
the	O
linearity	O
of	O
the	O
detector	O
response	O
to	O
the	O
analyte	O
were	O
examined	O
by	O
the	O
injection	O
of	O
matrix	O
-	O
matched	O
standard	O
solutions	O
of	O
chlozolinate	B
at	O
12	O
concentrations	O
in	O
the	O
range	O
0.002	O
to	O
10	O
μg	O
/	O
ml	O
.	O

The	O
effect	O
of	O
matrix	O
-	O
matching	O
on	O
recoveries	O
was	O
evaluated	O
by	O
repeating	O
some	O
of	O
the	O
earlier	O
analyses	O
for	O
which	O
matrix	O
-	O
matched	O
standards	O
had	O
not	O
been	O
used	O
.	O

Measurements	O
were	O
made	O
for	O
six	O
different	O
crops	O
at	O
the	O
1	O
mg	O
/	O
kg	O
fortification	O
level	O
.	O

In	O
order	O
to	O
test	O
the	O
stability	O
of	O
chlozolinate	B
,	O
the	O
extracts	O
from	O
samples	O
of	O
grapes	O
obtained	O
from	O
field	O
trials	O
with	O
the	O
pesticide	O
were	O
stored	O
at	O
−20	O
°	O
C	O
and	O
reanalysed	O
after	O
six	O
months	O
.	O

The	O
stability	O
of	O
the	O
matrix	O
-	O
matched	O
calibration	O
standards	O
during	O
GC	O
analysis	O
was	O
assessed	O
by	O
comparison	O
of	O
the	O
detector	O
response	O
to	O
standards	O
left	O
on	O
the	O
instrument	O
for	O
three	O
days	O
with	O
that	O
of	O
freshly	O
-	O
prepared	O
standards	O
.	O

3	O
Results	O
and	O
discussion	O
Table	O
1	O
gives	O
the	O
percentage	O
recoveries	O
for	O
the	O
four	O
main	O
crops	O
(	O
grapes	O
,	O
plums	O
,	O
apricots	O
and	O
peaches	O
)	O
at	O
four	O
to	O
six	O
fortification	O
levels	O
and	O
for	O
apples	O
and	O
aubergines	O
fortified	O
at	O
1	O
mg	O
/	O
kg	O
.	O

All	O
the	O
mean	O
recoveries	O
lie	O
within	O
the	O
range	O
86	O
to	O
99	O
%	O
,	O
with	O
an	O
overall	O
recovery	O
of	O
94	O
%	O
and	O
RSD	O
of	O
5	O
%	O
.	O

The	O
repeatability	O
of	O
the	O
measurements	O
is	O
good	O
,	O
with	O
values	O
for	O
the	O
RSD	O
of	O
within	O
-	O
batch	O
measurements	O
lying	O
between	O
1	O
and	O
8	O
%	O
.	O

Table	O
2	O
presents	O
recoveries	O
for	O
analyses	O
carried	O
out	O
without	O
matrix	O
-	O
matching	O
.	O

These	O
include	O
measurements	O
for	O
the	O
above	O
crops	O
fortified	O
only	O
at	O
1	O
mg	O
/	O
kg	O
in	O
addition	O
to	O
data	O
for	O
the	O
other	O
crops	O
included	O
in	O
the	O
study	O
.	O

The	O
range	O
of	O
RSD	O
values	O
for	O
within	O
-	O
batch	O
analyses	O
is	O
comparable	O
to	O
that	O
obtained	O
for	O
the	O
equivalent	O
matrix	O
-	O
matched	O
determinations	O
.	O

However	O
,	O
recoveries	O
for	O
individual	O
samples	O
are	O
sometimes	O
high	O
,	O
reaching	O
a	O
maximum	O
of	O
119	O
%	O
compared	O
to	O
102	O
%	O
when	O
matrix	O
-	O
matched	O
standards	O
are	O
used	O
.	O

Where	O
a	O
direct	O
comparison	O
can	O
be	O
made	O
(	O
for	O
six	O
crops	O
fortified	O
at	O
1	O
mg	O
/	O
kg	O
)	O
,	O
it	O
can	O
be	O
seen	O
that	O
an	O
increased	O
recovery	O
is	O
sometimes	O
,	O
but	O
not	O
always	O
,	O
observed	O
when	O
standards	O
are	O
not	O
matrix	O
-	O
matched	O
.	O

Internal	O
reproducibility	O
is	O
indicated	O
by	O
the	O
RSD	O
values	O
for	O
the	O
mean	O
recoveries	O
for	O
each	O
crop	O
in	O
Table	O
2	O
.	O

These	O
range	O
from	O
4	O
to	O
12	O
%	O
,	O
with	O
all	O
except	O
one	O
value	O
below	O
10	O
%	O
.	O

With	O
the	O
procedures	O
described	O
above	O
,	O
values	O
for	O
the	O
LOD	O
and	O
LOQ	O
of	O
the	O
method	O
were	O
0.001	O
mg	O
/	O
kg	O
and	O
0.004	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

The	O
lowest	O
calibrated	O
level	O
routinely	O
achieved	O
was	O
0.002	O
μg	O
/	O
ml	O
,	O
corresponding	O
to	O
a	O
concentration	O
in	O
the	O
crop	O
of	O
0.004	O
mg	O
/	O
kg	O
.	O

No	O
coextractives	O
from	O
the	O
crops	O
tested	O
were	O
found	O
to	O
interfere	O
with	O
the	O
quantification	O
of	O
chlozolinate	B
.	O

Fig.	O
2	O
shows	O
chromatograms	O
of	O
(	O
A	O
)	O
a	O
typical	O
grape	O
control	O
sample	O
and	O
(	O
B	O
)	O
chlozolinate	B
standard	O
in	O
grape	O
extract	O
.	O

Of	O
the	O
50	O
pesticides	B
routinely	O
sought	O
using	O
this	O
multiresidue	O
method	O
in	O
our	O
laboratory	O
,	O
those	O
giving	O
a	O
retention	O
time	O
within	O
0.2	O
min	O
of	O
the	O
chlozolinate	B
peak	O
on	O
either	O
of	O
the	O
analytical	O
columns	O
used	O
are	O
given	O
in	O
Table	O
3	O
.	O

Only	O
two	O
compounds	O
,	O
penconazole	B
and	O
heptachlor	B
epoxide	I
,	O
give	O
peaks	O
which	O
are	O
only	O
partially	O
resolved	O
from	O
that	O
of	O
chlozolinate	B
on	O
both	O
columns	O
.	O

Heptachlor	B
epoxide	I
is	O
a	O
superseded	O
compound	O
,	O
which	O
is	O
most	O
unlikely	O
to	O
occur	O
in	O
samples	O
monitored	O
for	O
chlozolinate	B
.	O

Although	O
the	O
partial	O
resolution	O
of	O
the	O
penconazole	B
and	O
chlozolinate	B
peaks	O
should	O
be	O
sufficient	O
to	O
prevent	O
confusion	O
of	O
the	O
two	O
compounds	O
,	O
the	O
identity	O
of	O
any	O
residue	O
would	O
be	O
better	O
confirmed	O
,	O
in	O
the	O
absence	O
of	O
GC	O
–	O
MS	O
capabilities	O
,	O
with	O
a	O
different	O
GC	O
column	O
.	O

For	O
example	O
,	O
with	O
an	O
Rtx-50	O
column	O
(	O
50	O
%	O
diphenyl–50	B
%	O
dimethylpolysiloxane	B
stationary	O
phase	O
,	O
30	O
m	O
×	O
0.250	O
mm	O
I.D.	O
,	O
0.25	O
μm	O
film	O
thickness	O
)	O
retention	O
times	O
are	O
22.68	O
and	O
23.03	O
min	O
for	O
chlozolinate	B
and	O
penconazole	B
,	O
respectively	O
.	O

Excellent	O
linearity	O
was	O
observed	O
over	O
a	O
wide	O
concentration	O
range	O
,	O
as	O
shown	O
in	O
Fig.	O
3A	O
.	O

The	O
detector	O
response	O
began	O
to	O
fall	O
off	O
only	O
above	O
5	O
μg	O
/	O
ml	O
.	O

Despite	O
the	O
regression	O
line	O
correlation	O
of	O
r	O
2	O
=	O
1.000	O
,	O
it	O
is	O
desirable	O
to	O
carry	O
out	O
quantification	O
with	O
a	O
calibration	O
curve	O
of	O
limited	O
range	O
because	O
of	O
very	O
slight	O
curvature	O
observed	O
when	O
concentrations	O
of	O
more	O
than	O
a	O
factor	O
of	O
ten	O
are	O
covered	O
.	O

This	O
is	O
particularly	O
important	O
for	O
low	O
concentrations	O
,	O
since	O
a	O
small	O
change	O
in	O
the	O
intercept	O
of	O
the	O
regression	O
line	O
may	O
have	O
a	O
relatively	O
large	O
effect	O
on	O
the	O
concentration	O
calculated	O
.	O

Fig.	O
3B	O
gives	O
the	O
regression	O
line	O
for	O
the	O
concentration	O
range	O
0.002	O
to	O
0.02	O
μg	O
/	O
ml	O
for	O
comparison	O
with	O
that	O
for	O
the	O
full	O
concentration	O
range	O
.	O

The	O
results	O
obtained	O
for	O
the	O
study	O
of	O
the	O
stability	O
of	O
chlozolinate	B
in	O
the	O
extracts	O
of	O
grape	O
samples	O
with	O
incurred	O
residues	O
are	O
shown	O
in	O
Fig.	O
4	O
.	O

There	O
is	O
no	O
indication	O
of	O
degradation	O
in	O
sample	O
extracts	O
stored	O
at	O
−20	O
°	O
C	O
over	O
six	O
months	O
.	O

Similarly	O
,	O
no	O
instances	O
of	O
degradation	O
of	O
chlozolinate	B
in	O
calibration	O
solutions	O
were	O
observed	O
.	O

4	O
Conclusions	O
The	O
multiresidue	O
method	O
tested	O
gives	O
good	O
accuracy	O
and	O
precision	O
for	O
the	O
analysis	O
of	O
chlozolinate	B
residues	O
in	O
all	O
the	O
crops	O
tested	O
.	O

In	O
addition	O
,	O
it	O
shows	O
good	O
sensitivity	O
and	O
specificity	O
and	O
the	O
sample	O
extracts	O
are	O
stable	O
under	O
the	O
conditions	O
required	O
for	O
GC	O
analysis	O
.	O

Although	O
the	O
effect	O
of	O
crop	O
enhancement	O
is	O
not	O
large	O
,	O
the	O
use	O
of	O
non	O
matrix	O
-	O
matched	O
calibration	O
standards	O
tends	O
to	O
lead	O
to	O
randomly	O
higher	O
recoveries	O
.	O

The	O
analytical	O
method	O
is	O
,	O
therefore	O
,	O
shown	O
to	O
be	O
suitable	O
for	O
the	O
monitoring	O
of	O
chlozolinate	B
residues	O
in	O
fruits	O
and	O
vegetables	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Agricultural	O
Research	O
Foundation	O
(	O
N.AG.RE.F.	O
)	O
within	O
the	O
framework	O
of	O
the	O
""""	O
DIMITRA	O
""""	O
project	O
.	O

The	O
authors	O
are	O
grateful	O
to	O
Kalliopi	O
Kokkinaki	O
for	O
assistance	O
with	O
preparation	O
of	O
the	O
manuscript	O
.	O

Five	O
muscarinic	O
receptors	O
have	O
been	O
cloned	O
thus	O
far	O
(	O
for	O
a	O
recent	O
review	O
Wess	O
,	O
1996	O
)	O
.	O

All	O
are	O
members	O
of	O
the	O
seven	O
-	O
transmembrane	O
G	O
-	O
protein	O
coupled	O
receptor	O
family	O
with	O
the	O
muscarinic	O
M1	O
,	O
M3	O
and	O
M5	O
sub	O
-	O
types	O
linked	O
to	O
Gq	O
/	O
11	O
proteins	O
and	O
the	O
production	O
of	O
inositides	B
,	O
whereas	O
the	O
muscarinic	O
M2	O
and	O
M4	O
receptors	O
are	O
associated	O
with	O
the	O
Gi	O
proteins	O
and	O
adenylate	O
cyclase	O
activity	O
.	O

Most	O
of	O
these	O
receptors	O
are	O
widely	O
expressed	O
throughout	O
the	O
body	O
including	O
the	O
brain	O
.	O

However	O
,	O
their	O
respective	O
physiological	O
roles	O
remain	O
to	O
be	O
fully	O
established	O
,	O
primarily	O
because	O
of	O
the	O
limited	O
availability	O
of	O
truly	O
receptor	O
sub	O
-	O
type	O
selective	O
agonists	O
and	O
antagonists	O
.	O

Among	O
the	O
putative	O
roles	O
of	O
the	O
muscarinic	O
receptor	O
sub	O
-	O
groups	O
,	O
an	O
action	O
as	O
inhibitory	O
autoreceptors	O
regulating	O
the	O
release	O
of	O
acetylcholine	B
has	O
been	O
suggested	O
on	O
the	O
basis	O
of	O
anatomical	O
(	O
Levey	O
et	O
al.	O
,	O
1995	O
)	O
,	O
pharmacological	O
(	O
Raiteri	O
et	O
al.	O
,	O
1984	O
;	O
Quirion	O
et	O
al.	O
,	O
1995	O
)	O
and	O
behavioral	O
(	O
Quirion	O
et	O
al.	O
,	O
1995	O
)	O
data	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
if	O
these	O
autoreceptors	O
are	O
of	O
the	O
muscarinic	O
M2	O
(	O
Raiteri	O
et	O
al.	O
,	O
1984	O
;	O
Quirion	O
et	O
al.	O
,	O
1995	O
)	O
or	O
M4	O
(	O
McKinney	O
et	O
al.	O
,	O
1993	O
)	O
sub	O
-	O
type	O
because	O
of	O
the	O
lack	O
of	O
selective	O
antagonists	O
to	O
distinguish	O
between	O
these	O
two	O
related	O
receptor	O
sub	O
-	O
types	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
BIBN-99	B
,	O
a	O
muscarinic	O
M2	O
receptor	O
antagonist	O
unable	O
to	O
fully	O
distinguish	O
between	O
muscarinic	O
M2	O
and	O
M4	O
receptors	O
,	O
is	O
capable	O
of	O
potently	O
reversing	O
cognitive	O
deficits	O
in	O
aged	O
memory	O
impaired	O
rats	O
(	O
Quirion	O
et	O
al.	O
,	O
1995	O
)	O
.	O

This	O
information	O
suggests	O
the	O
possibility	O
of	O
targeting	O
muscarinic	O
M2	O
receptors	O
as	O
a	O
means	O
of	O
alleviating	O
learning	O
deficits	O
.	O

It	O
is	O
thus	O
of	O
major	O
importance	O
to	O
clearly	O
establish	O
the	O
identity	O
of	O
the	O
muscarinic	O
receptor	O
sub	O
-	O
type	O
on	O
which	O
such	O
antagonists	O
are	O
likely	O
to	O
act	O
,	O
in	O
order	O
to	O
facilitate	O
acetylcholine	B
release	O
and	O
be	O
of	O
potential	O
clinical	O
relevance	O
in	O
diseases	O
associated	O
with	O
altered	O
cognition	O
.	O

Recently	O
,	O
PD102807	B
has	O
been	O
developed	O
as	O
one	O
of	O
the	O
very	O
first	O
selective	O
muscarinic	O
M4	O
receptor	O
antagonists	O
(	O
Nelson	O
et	O
al	O
,	O
1996	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
this	O
molecule	O
in	O
addition	O
to	O
the	O
purported	O
muscarinic	O
M2	O
receptor	O
antagonists	O
AF	B
-	I
DX	I
384	I
and	O
BIBN-161	B
(	O
Doods	O
et	O
al.	O
,	O
1993	O
)	O
to	O
further	O
investigate	O
the	O
exact	O
nature	O
of	O
the	O
autoreceptor	O
sub	O
-	O
type	O
(	O
s	O
)	O
regulating	O
acetylcholine	B
release	O
in	O
the	O
rat	O
hippocampus	O
,	O
as	O
assessed	O
by	O
in	O
vivo	O
dialysis	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Animals	O
and	O
drugs	O
Male	O
Sprague	O
–	O
Dawley	O
rats	O
(	O
270–300	O
g	O
)	O
were	O
purchased	O
from	O
Charles	O
River	O
Canada	O
(	O
St.	O
Constant	O
,	O
Quebec	O
)	O
.	O

Animals	O
were	O
kept	O
in	O
a	O
temperature-	O
(	O
22–24	O
°	O
C	O
)	O
,	O
humidity	O
(	O
55±5	O
%	O
)	O
and	O
light-	O
(	O
12	O
h	O
light	O
–	O
dark	O
cycle	O
,	O
lights	O
on	O
at	O
07:00	O
)	O
regulated	O
room	O
with	O
food	O
and	O
water	B
available	O
ad	O
libitum	O
for	O
at	O
least	O
3	O
days	O
before	O
surgery	O
.	O

The	O
procedures	O
involving	O
animals	O
and	O
their	O
care	O
were	O
conducted	O
in	O
accordance	O
with	O
the	O
McGill	O
University	O
Animal	O
Care	O
Committee	O
and	O
the	O
Canadian	O
Council	O
on	O
Animal	O
Care	O
.	O

BIBN-161	B
and	O
AF	B
-	I
DX	I
384	I
were	O
obtained	O
from	O
Dr.	O
H.	O
Doods	O
,	O
Boehringer	O
Ingelheim	O
,	O
Germany	O
,	O
while	O
PD102807	B
was	O
obtained	O
from	O
Dr.	O
R.	O
Schwarz	O
,	O
Parke	O
-	O
Davis	O
,	O
USA	O
.	O

AF	B
-	I
DX	I
384	I
was	O
dissolved	O
in	O
water	B
,	O
whereas	O
BIBN-161	B
and	O
PD102807	B
were	O
dissolved	O
in	O
0.1	O
N	O
HCl	B
and	O
brought	O
to	O
pH	O
5–6	O
with	O
0.1	O
N	O
NaOH	B
.	O

These	O
stock	O
solutions	O
were	O
then	O
diluted	O
appropriately	O
in	O
the	O
buffered	O
perfusate	O
(	O
see	O
below	O
)	O
.	O

2.2	O
Surgery	O
and	O
in	O
vivo	O
dialysis	O
Animals	O
were	O
anesthetized	O
by	O
intramuscular	O
injection	O
of	O
acepromazine	B
(	O
0.5	O
mg	O
/	O
kg	O
,	O
Ayerst	O
Laboratories	O
,	O
Montreal	O
,	O
Quebec	O
)	O
,	O
xylazine	B
(	O
5	O
mg	O
/	O
kg	O
,	O
Miles	O
Canada	O
,	O
Etobicoke	O
,	O
Ontario	O
)	O
and	O
ketamine	B
(	O
50	O
mg	O
/	O
kg	O
,	O
MTC	O
Pharmaceuticals	O
,	O
Cambridge	O
,	O
Ontario	O
)	O
.	O

Transverse	O
probes	O
(	O
AN69	O
hollow	O
fibers	O
,	O
molecular	O
weight	O
cut	O
off	O
<	O
60,000	O
,	O
i.d.=220	O
μm	O
,	O
o.d.=310	O
μm	O
,	O
Hospal	O
-	O
Gambro	O
,	O
St	O
-	O
Leonard	O
,	O
Quebec	O
)	O
were	O
placed	O
in	O
the	O
dorsal	O
hippocampus	O
(	O
3.8	O
mm	O
posterior	O
to	O
bregma	O
;	O
3.5	O
mm	O
ventral	O
to	O
the	O
surface	O
of	O
the	O
skull	O
)	O
,	O
according	O
to	O
coordinates	O
obtained	O
from	O
the	O
atlas	O
of	O
Paxinos	O
and	O
Watson	O
(	O
1987	O
)	O
.	O

Two	O
days	O
after	O
surgery	O
,	O
in	O
vivo	O
dialysis	O
was	O
performed	O
to	O
monitor	O
acetylcholine	B
release	O
,	O
as	O
described	O
in	O
detail	O
elsewhere	O
with	O
minor	O
modifications	O
(	O
Kitaichi	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Briefly	O
,	O
probes	O
were	O
perfused	O
at	O
a	O
flow	O
rate	O
of	O
2.34	O
μl	O
/	O
min	O
with	O
a	O
perfusate	O
containing	O
:	O
NaCl	B
(	O
125	O
mM	O
)	O
,	O
KCl	B
(	O
3	O
mM	O
)	O
,	O
CaCl2	B
(	O
1.3	O
mM	O
)	O
,	O
MgCl2	B
(	O
1.0	O
mM	O
)	O
,	O
NaHCO3	B
(	O
23	O
mM	O
)	O
in	O
aqueous	O
phosphate	B
buffer	I
(	O
1	O
mM	O
,	O
pH	O
7.3	O
)	O
,	O
100	O
nM	O
neostigmine	B
(	O
RBI	O
,	O
Watick	O
,	O
MA	O
)	O
was	O
included	O
to	O
prevent	O
the	O
degradation	O
of	O
acetylcholine	B
.	O

After	O
a	O
1	O
h	O
equilibration	O
period	O
,	O
dialysates	O
were	O
collected	O
every	O
10	O
min	O
.	O

Immediately	O
after	O
basal	O
acetylcholine	B
release	O
stabilized	O
,	O
perfusate	O
containing	O
different	O
concentrations	O
of	O
AF	B
-	I
DX	I
384	I
,	O
BIBN-161	B
or	O
PD102807	B
was	O
perfused	O
through	O
the	O
probes	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

The	O
precise	O
location	O
of	O
the	O
probes	O
was	O
verified	O
by	O
standard	O
histological	O
examination	O
.	O

2.3	O
High	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analysis	O
of	O
acetylcholine	B
The	O
concentration	O
of	O
acetylcholine	B
in	O
dialysates	O
was	O
measured	O
on	O
-	O
line	O
using	O
HPLC	O
coupled	O
with	O
post	O
-	O
column	O
enzymatic	O
reaction	O
and	O
electrochemical	O
detection	O
,	O
as	O
described	O
elsewhere	O
(	O
Day	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Acetylcholine	B
release	O
was	O
expressed	O
as	O
a	O
percentage	O
of	O
each	O
animal	O
individual	O
baseline	O
release	O
value	O
(	O
the	O
average	O
amount	O
of	O
acetylcholine	B
in	O
six	O
samples	O
collected	O
immediately	O
preceding	O
drug	B
treatment	O
)	O
.	O

All	O
data	O
are	O
expressed	O
as	O
mean±S.E.M.	O
3	O
Results	O
As	O
shown	O
in	O
Fig.	O
1A	O
and	O
Table	O
1	O
,	O
the	O
two	O
muscarinic	O
M2	O
receptor	O
antagonists	O
AF	B
-	I
DX	I
384	I
and	O
BIBN-161	B
facilitated	O
acetylcholine	B
release	O
in	O
the	O
rat	O
hippocampus	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

Both	O
drugs	B
yielded	O
a	O
significant	O
effect	O
at	O
100	O
nM	O
(	O
Table	O
1	O
)	O
but	O
AF	B
-	I
DX384	I
was	O
slightly	O
more	O
potent	O
than	O
BIBN-161	B
,	O
as	O
shown	O
in	O
Fig.	O
1C	O
.	O

Both	O
AF	B
-	I
DX	I
384	I
(	O
10	O
μM	O
)	O
and	O
BIBN-161	B
(	O
50	O
μM	O
)	O
were	O
able	O
to	O
potently	O
stimulate	O
acetylcholine	B
release	O
,	O
with	O
5–6	O
fold	O
increments	O
in	O
release	O
seen	O
at	O
these	O
concentrations	O
.	O

In	O
contrast	O
,	O
the	O
purported	O
muscarinic	O
M4	O
receptor	O
antagonist	O
PD102807	B
was	O
unable	O
to	O
modulate	O
release	O
at	O
concentrations	O
lower	O
than	O
50	O
μM	O
,	O
with	O
only	O
minimal	O
effects	O
(	O
1.6–1.7-fold	O
over	O
baseline	O
)	O
being	O
observed	O
at	O
very	O
high	O
concentrations	O
(	O
Fig.	O
1B	O
,	O
Table	O
1	O
)	O
.	O

The	O
lack	O
of	O
significant	O
effects	O
of	O
PD102807	B
on	O
hippocampal	O
acetylcholine	B
release	O
is	O
also	O
evident	O
in	O
the	O
graphed	O
representation	O
of	O
the	O
regression	O
analysis	O
performed	O
for	O
the	O
three	O
antagonists	O
tested	O
here	O
(	O
Fig.	O
1C	O
)	O
.	O

4	O
Discussion	O
In	O
vivo	O
acetylcholine	B
release	O
in	O
the	O
adult	O
rat	O
hippocampus	O
was	O
clearly	O
stimulated	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
by	O
AF	B
-	I
DX384	I
>	O
BIBN-161⋙PD102807	B
.	O

The	O
first	O
two	O
molecules	O
have	O
higher	O
or	O
equal	O
affinities	O
for	O
the	O
cloned	O
muscarinic	O
M2	O
than	O
the	O
M4	O
receptor	O
sub	O
-	O
types	O
while	O
the	O
reverse	O
is	O
true	O
for	O
the	O
newly	O
developed	O
muscarinic	O
M4	O
receptor	O
antagonist	O
PD102807	B
(	O
Doods	O
et	O
al.	O
,	O
1993	O
;	O
Nelson	O
et	O
al.	O
,	O
1996	O
)	O
.	O

In	O
fact	O
,	O
the	O
apparent	O
IC50	O
(	O
nM	O
)	O
values	O
of	O
AF	B
-	I
DX384	I
are	O
325	O
,	O
16	O
,	O
150	O
,	O
10	O
,	O
and	O
1860	O
for	O
the	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
M4	O
and	O
M5	O
sub	O
-	O
type	O
,	O
respectively	O
,	O
and	O
285	O
,	O
15	O
,	O
360	O
,	O
52	O
,	O
and	O
220	O
for	O
BIBN-161	B
.	O

In	O
contrast	O
,	O
PD102807	B
has	O
its	O
highest	O
affinity	O
for	O
the	O
muscarinic	O
M4	O
receptor	O
with	O
IC50	O
(	O
nM	O
)	O
values	O
of	O
6600	O
,	O
3400	O
,	O
950	O
,	O
90	O
,	O
and	O
7400	O
for	O
the	O
transfected	O
human	O
muscarinic	O
M1	O
to	O
M5	O
sub	O
-	O
types	O
(	O
Nelson	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Taken	O
together	O
,	O
those	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
muscarinic	O
receptor	O
regulating	O
acetylcholine	B
release	O
is	O
of	O
the	O
M2	O
and	O
not	O
the	O
M4	O
sub	O
-	O
type	O
,	O
at	O
least	O
in	O
the	O
rat	O
hippocampus	O
.	O

Earlier	O
anatomical	O
(	O
Levey	O
et	O
al.	O
,	O
1995	O
)	O
and	O
functional	O
(	O
Raiteri	O
et	O
al.	O
,	O
1984	O
;	O
Quirion	O
et	O
al.	O
,	O
1995	O
)	O
data	O
also	O
suggested	O
the	O
preferential	O
role	O
of	O
the	O
muscarinic	O
M2	O
receptor	O
as	O
a	O
negative	O
autoreceptor	O
regulating	O
acetylcholine	B
release	O
.	O

However	O
,	O
another	O
study	O
proposed	O
that	O
the	O
M4	O
sub	O
-	O
type	O
was	O
in	O
fact	O
acting	O
as	O
the	O
autoreceptor	O
(	O
McKinney	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
lack	O
of	O
adequately	O
selective	O
tools	O
to	O
distinguish	O
between	O
muscarinic	O
M2	O
and	O
M4	O
receptors	O
likely	O
explains	O
this	O
apparent	O
discrepancy	O
.	O

Recently	O
,	O
we	O
obtained	O
molecular	O
evidence	O
of	O
the	O
role	O
of	O
muscarinic	O
M2	O
receptors	O
in	O
the	O
regulation	O
of	O
acetylcholine	B
release	O
(	O
Kitaichi	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Using	O
an	O
antisense	O
approach	O
combined	O
with	O
in	O
vivo	O
dialysis	O
,	O
we	O
have	O
shown	O
that	O
a	O
treatment	O
with	O
antisense	O
directed	O
against	O
the	O
muscarinic	O
M2	O
receptor	O
blocked	O
the	O
ability	O
of	O
antagonists	O
such	O
as	O
AF	B
-	I
DX	I
384	I
to	O
facilitate	O
acetylcholine	B
release	O
,	O
whereas	O
treatment	O
with	O
a	O
specific	O
muscarinic	O
M4	O
receptor	O
antisense	O
(	O
or	O
missense	O
oligodeoxynucleotides	O
)	O
failed	O
to	O
alter	O
AF	B
-	I
DX	I
384	I
's	O
ability	O
to	O
modulate	O
acetylcholine	B
release	O
in	O
the	O
rat	O
hippocampus	O
.	O

Hence	O
,	O
the	O
data	O
reported	O
in	O
the	O
present	O
study	O
are	O
in	O
agreement	O
with	O
those	O
obtained	O
using	O
a	O
molecular	O
approach	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
an	O
M.R.C.	O
of	O
Canada	O
grant	O
to	O
R.	O
Quirion	O
,	O
a	O
chercheur	O
-	O
boursier	O
of	O
the	O
F.R.S.Q.	O
J.	O
Day	O
holds	O
a	O
fellowship	O
award	O
from	O
the	O
M.R.C.C.	O
K.	O
Kitaichi	O
is	O
now	O
at	O
the	O
Department	O
of	O
Medical	O
Technology	O
,	O
Nagoya	O
University	O
School	O
of	O
Health	O
Sciences	O
,	O
Nagoya	O
,	O
Japan	O
.	O

Gangliosides	B
are	O
distributed	O
mainly	O
on	O
the	O
outer	O
surface	O
of	O
cell	O
membranes	O
and	O
play	O
important	O
roles	O
in	O
various	O
cellular	O
functions	O
including	O
adhesion	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
signal	O
transduction	O
[	O
1–3	O
]	O
.	O

C	B
-	I
series	I
gangliosides	I
are	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
trisialosyl	B
residue	I
at	O
the	O
inner	O
galactose	B
of	O
the	O
hemato-	B
or	O
ganglio	B
-	I
oligosaccharide	I
structure	O
[	O
4	O
]	O
.	O

This	O
ganglioside	B
species	O
is	O
present	O
in	O
adult	O
fish	O
brain	O
of	O
certain	O
species	O
in	O
high	O
concentrations	O
[	O
5	O
]	O
.	O

In	O
avian	O
and	O
mammalian	O
brain	O
,	O
though	O
c	B
-	I
series	I
gangliosides	I
and	O
their	O
O	B
-acetyl	I
derivatives	I
are	O
temporarily	O
expressed	O
at	O
embryonic	O
stages	O
,	O
they	O
are	O
hardly	O
detected	O
at	O
adult	O
ages	O
[	O
6–9	O
]	O
.	O

Evidence	O
has	O
been	O
provided	O
suggesting	O
that	O
they	O
may	O
be	O
involved	O
in	O
growth	O
,	O
differentiation	O
and	O
migration	O
of	O
neuronal	O
cells	O
[	O
10–12	O
]	O
.	O

C	B
-	I
series	I
gangliosides	I
have	O
also	O
been	O
detected	O
in	O
tissues	O
and	O
cells	O
of	O
extra	O
-	O
neural	O
origin	O
,	O
including	O
swine	O
kidney	O
[	O
13	O
]	O
,	O
human	O
lung	O
[	O
14	O
]	O
,	O
bovine	O
buttermilk	O
[	O
15	O
]	O
,	O
cat	O
erythrocytes	O
[	O
16	O
]	O
,	O
pancreatic	O
islet	O
cells	O
[	O
17	O
]	O
,	O
and	O
different	O
types	O
of	O
cancer	O
cells	O
[	O
18–20	O
]	O
.	O

Expression	O
of	O
c	B
-	I
series	I
gangliosides	I
may	O
be	O
cell	O
-	O
specific	O
.	O

Our	O
recent	O
study	O
suggested	O
their	O
specific	O
localization	O
in	O
pancreatic	O
B	O
cells	O
among	O
islet	O
and	O
non	O
-	O
islet	O
cells	O
of	O
rat	O
pancreatic	O
tissue	O
[	O
21	O
]	O
.	O

Information	O
,	O
however	O
,	O
is	O
still	O
limited	O
about	O
the	O
distribution	O
and	O
function	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
extra	O
-	O
neural	O
tissues	O
and	O
cell	O
types	O
.	O

Iber	O
et	O
al.	O
[	O
22	O
]	O
investigated	O
sialyltransferase	O
activities	O
in	O
Golgi	O
preparations	O
from	O
rat	O
liver	O
and	O
reported	O
that	O
c	B
-	I
series	I
gangliosides	I
are	O
formed	O
by	O
the	O
same	O
set	O
of	O
glycosyltransferases	O
catalyzing	O
the	O
biosynthesis	O
of	O
asialo-	B
,	O
a-	B
and	O
b	B
-	I
series	I
gangliosides	I
.	O

This	O
finding	O
led	O
to	O
an	O
assumption	O
that	O
c	B
-	I
series	I
gangliosides	I
are	O
expressed	O
in	O
hepatocytes	O
and	O
carry	O
a	O
function	O
(	O
s	O
)	O
in	O
the	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
c	B
-	I
series	I
gangliosides	I
in	O
rat	O
hepatocytes	O
in	O
primary	O
culture	O
and	O
liver	O
tissues	O
from	O
rats	O
of	O
various	O
ages	O
using	O
a	O
specific	O
monoclonal	O
antibody	O
,	O
A2B5	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
purchased	O
from	O
a	O
commercial	O
breeder	O
.	O

An	O
A2B5-producing	O
hybridoma	O
CRL	O
1520	O
was	O
obtained	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
,	O
USA	O
)	O
and	O
cultured	O
in	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
,	O
Sigma	O
)	O
.	O

Culture	O
medium	O
containing	O
the	O
monoclonal	O
antibody	O
A2B5	O
(	O
IgM	O
-	O
type	O
)	O
was	O
used	O
for	O
this	O
study	O
.	O

Another	O
monoclonal	O
antibody	O
,	O
D1.1	O
(	O
IgG3-type	O
)	O
,	O
which	O
specifically	O
recognizes	O
9-O	B
-acetyl	I
GD3	I
,	O
was	O
a	O
kind	O
gift	O
of	O
Dr.	O
Robert	O
K.	O
Yu	O
(	O
Virginia	O
Commonwealth	O
University	O
,	O
Richmond	O
,	O
VA	O
,	O
USA	O
)	O
.	O

An	O
antibody	O
against	O
GM1	B
or	O
asialo	B
-	I
GM1	I
(	O
IgG	O
-	O
type	O
for	O
both	O
)	O
was	O
prepared	O
by	O
immunizing	O
rabbits	O
with	O
purified	O
glycolipid	B
by	O
a	O
method	O
reported	O
previously	O
[	O
23	O
]	O
.	O

Other	O
chemicals	B
were	O
purchased	O
from	O
the	O
following	O
companies	O
:	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
,	O
fluorescein	B
isothiocyanate	I
(	O
FITC	B
)	O
-	O
or	O
peroxidase	O
-	O
conjugated	O
antibodies	O
against	O
mouse	O
IgM	O
or	O
rabbit	O
IgG	O
,	O
and	O
Arthrobacter	O
ureafaciens	O
sialidase	O
(	O
Sigma	O
)	O
,	O
Block	O
-	O
Ace	O
(	O
blocking	O
solution	O
,	O
Dainihon	O
-	O
Seiyaku	O
Co.	O
,	O
Japan	O
)	O
,	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
)	O
Western	O
blotting	O
detection	O
kit	O
(	O
Amersham	O
)	O
,	O
cell	O
proliferation	O
MTT	O
and	O
ELISA	O
bromodeoxyuridine	B
(	O
BrdU	B
)	O
kits	O
(	O
Boehringer	O
-	O
Mannheim	O
)	O
,	O
thin	O
-	O
layer	O
chromatographic	O
(	O
TLC	O
)	O
plates	O
(	O
nanoplates	O
,	O
E.	O
Merck	O
)	O
,	O
and	O
purified	O
GD3	B
and	O
bovine	O
brain	O
ganglioside	B
mixture	O
(	O
Matreya	O
,	O
USA	O
)	O
.	O

2.2	O
Primary	O
culture	O
of	O
rat	O
hepatocytes	O
Hepatocytes	O
were	O
isolated	O
from	O
7-week	O
-	O
old	O
rat	O
liver	O
using	O
a	O
perfusion	O
method	O
reported	O
by	O
Seglen	O
[	O
24	O
]	O
.	O

The	O
purity	O
of	O
isolated	O
parenchymal	O
hepatocytes	O
was	O
judged	O
to	O
be	O
more	O
than	O
98	O
%	O
under	O
microscopy	O
.	O

The	O
isolated	O
cells	O
were	O
suspended	O
in	O
L-15	O
medium	O
,	O
seeded	O
in	O
collagen	B
-	O
coated	O
culture	O
dishes	O
,	O
and	O
incubated	O
at	O
37	O
°	O
C	O
for	O
24	O
h	O
under	O
1	O
%	O
CO2	B
-99	O
%	O
air	O
.	O

After	O
replacing	O
the	O
medium	O
with	O
media	O
containing	O
10	O
%	O
FBS	B
,	O
10	O
μg	O
/	O
ml	O
of	O
insulin	O
,	O
10	O
μM	O
dexamethasone	B
,	O
and	O
20	O
ng	O
/	O
ml	O
of	O
EGF	O
,	O
the	O
cells	O
were	O
cultured	O
for	O
5	O
days	O
(	O
day	O
0	O
to	O
day	O
5	O
)	O
.	O

Practically	O
no	O
growth	O
of	O
non	O
-	O
parenchymal	O
cells	O
was	O
observed	O
throughout	O
culture	O
.	O

For	O
assessment	O
of	O
hepatocyte	O
proliferation	O
rates	O
,	O
either	O
the	O
MTT	O
or	O
the	O
BrdU	O
incorporation	O
assay	O
could	O
be	O
used	O
,	O
providing	O
comparable	O
proliferation	O
curves	O
(	O
data	O
not	O
shown	O
)	O
.	O

An	O
MTT	O
assay	O
was	O
used	O
in	O
the	O
present	O
study	O
.	O

2.3	O
Immunofluorescence	O
of	O
cultured	O
hepatocytes	O
Primary	O
cultures	O
of	O
rat	O
hepatocytes	O
on	O
day	O
5	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	B
,	O
followed	O
by	O
incubation	O
with	O
a	O
blocking	O
solution	O
(	O
Block	O
-	O
Ace	O
)	O
at	O
37	O
°	O
C	O
for	O
1.5	O
h.	O
The	O
fixed	O
cells	O
were	O
incubated	O
consecutively	O
with	O
an	O
anti	O
-	O
ganglioside	O
antibody	O
and	O
FITC	B
-	O
conjugated	O
second	O
antibody	O
at	O
37	O
°	O
C	O
for	O
1.5	O
h	O
,	O
followed	O
by	O
examination	O
under	O
fluorescence	O
microscopy	O
.	O

For	O
control	O
,	O
the	O
primary	O
antibody	O
was	O
replaced	O
by	O
diluted	O
culture	O
medium	O
(	O
for	O
A2B5	O
or	O
D1.1	O
)	O
or	O
preimmune	O
serum	O
(	O
for	O
anti	O
-	O
GM1	O
antibody	O
)	O
.	O

2.4	O
Isolation	O
of	O
gangliosides	B
Total	O
lipids	B
were	O
extracted	O
from	O
cultured	O
cells	O
or	O
liver	O
tissues	O
with	O
chloroform	B
/	O
methanol	B
(	O
1:1	O
)	O
and	O
separated	O
into	O
neutral	B
and	O
acidic	B
lipids	I
by	O
DEAE	B
-	O
Sephadex	O
column	O
chromatography	O
.	O

Acidic	B
lipids	I
were	O
treated	O
with	O
methanolic	B
0.2	O
M	O
NaOH	B
at	O
37	O
°	O
C	O
for	O
1	O
h	O
,	O
followed	O
by	O
neutralization	O
with	O
acetic	B
acid	I
.	O

Purified	O
gangliosides	B
were	O
obtained	O
by	O
desalting	O
the	O
neutralized	O
sample	O
by	O
Sephadex	O
LH-20	O
column	O
chromatography	O
.	O

Chicken	O
brain	O
gangliosides	B
were	O
purified	O
from	O
13-day	O
-	O
old	O
embryos	O
by	O
a	O
similar	O
method	O
.	O

2.5	O
TLC	O
immunostaining	O
of	O
gangliosides	B
TLC	O
immunostaining	O
was	O
carried	O
out	O
based	O
upon	O
a	O
method	O
reported	O
previously	O
[	O
25	O
]	O
.	O

Gangliosides	B
were	O
developed	O
on	O
a	O
TLC	O
plate	O
with	O
a	O
solvent	B
system	O
of	O
chloroform	B
/	O
methanol	B
/	O
0.2	O
%	O
CaCl2	B
·	I
2H2	I
O	I
(	O
45:40:10	O
)	O
.	O

After	O
coating	O
with	O
a	O
0.4	O
%	O
polyisobutylmethacrylate	B
solution	O
,	O
the	O
plate	O
was	O
overlaid	O
consecutively	O
with	O
an	O
anti	O
-	O
ganglioside	O
antibody	O
and	O
peroxidase	O
-	O
conjugated	O
second	O
antibody	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O
The	O
responsive	O
band	O
(	O
s	O
)	O
were	O
detected	O
on	O
X	O
-	O
ray	O
film	O
by	O
an	O
ECL	O
Western	O
blotting	O
detection	O
kit	O
.	O

Gangliosides	B
on	O
the	O
plate	O
were	O
visualized	O
with	O
resorcinol	B
-	I
HCl	I
reagent	B
[	O
26	O
]	O
.	O

2.6	O
Detection	O
of	O
gangliosides	B
having	O
a	O
gangliotetraose	B
oligosaccharide	B
structure	O
Core	O
structures	O
of	O
oligosaccharides	B
of	O
gangliosides	B
were	O
analyzed	O
using	O
TLC	O
immunostaining	O
with	O
in	O
situ	O
hydrolysis	O
of	O
gangliosides	B
by	O
sialidase	O
[	O
27	O
]	O
.	O

In	O
brief	O
,	O
gangliosides	B
were	O
developed	O
on	O
TLC	O
and	O
treated	O
in	O
situ	O
with	O
A.	O
ureafaciens	O
sialidase	O
(	O
100	O
mU	O
/	O
ml	O
,	O
pH	O
4.8	O
)	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O
Asialo	B
-	I
GM1	I
,	O
which	O
was	O
generated	O
from	O
gangliotetraose	B
ganglioside	B
species	O
,	O
was	O
detected	O
by	O
TLC	O
immunostaining	O
with	O
an	O
anti	O
-	O
asialo	O
-	O
GM1	O
antibody	O
.	O

The	O
antibody	O
used	O
was	O
shown	O
to	O
have	O
strict	O
specificity	O
for	O
asialo	B
-	I
GM1	I
with	O
no	O
cross	O
-	O
reactivity	O
with	O
any	O
bovine	O
brain	O
gangliosides	B
[	O
27	O
]	O
.	O

3	O
Results	O
3.1	O
Detection	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
rat	O
hepatocytes	O
in	O
culture	O
The	O
specificity	O
of	O
the	O
antibody	O
preparation	O
used	O
in	O
this	O
study	O
was	O
examined	O
first	O
by	O
TLC	O
immunostaining	O
with	O
ganglioside	B
preparations	O
from	O
embryonic	O
chicken	O
brain	O
and	O
bovine	O
brain	O
;	O
the	O
former	O
is	O
known	O
to	O
express	O
c	B
-	I
series	I
gangliosides	I
at	O
higher	O
concentrations	O
[	O
7,9	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
1A	O
,	O
the	O
antibody	O
did	O
not	O
react	O
with	O
a-	B
and	O
b	B
-	I
series	I
gangliosides	I
in	O
bovine	O
brain	O
gangliosides	B
(	O
lane	O
2	O
)	O
,	O
but	O
selectively	O
immunostained	O
three	O
ganglioside	B
species	O
among	O
chicken	O
brain	O
gangliosides	B
(	O
lane	O
1	O
)	O
.	O

Based	O
upon	O
their	O
mobilities	O
on	O
TLC	O
,	O
these	O
gangliosides	B
were	O
assigned	O
to	O
GT3	B
,	O
GQ1c	B
,	O
and	O
GP1c	B
[	O
5	O
]	O
.	O

Using	O
this	O
A2B5	O
preparation	O
and	O
other	O
anti	O
-	O
ganglioside	O
antibodies	O
,	O
primary	O
cultures	O
of	O
adult	O
rat	O
hepatocytes	O
on	O
day	O
5	O
were	O
examined	O
by	O
an	O
immunofluorescence	O
method	O
.	O

Rat	O
hepatocytes	O
were	O
stained	O
positively	O
with	O
A2B5	O
(	O
Fig.	O
2	O
)	O
.	O

The	O
cells	O
were	O
also	O
immunostained	O
with	O
an	O
anti	O
-	O
GM1	O
antibody	O
,	O
but	O
hardly	O
stained	O
with	O
D1.1	O
,	O
which	O
is	O
specific	O
for	O
9-O	B
-acetyl	I
GD3	I
.	O

To	O
confirm	O
the	O
presence	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
rat	O
hepatocytes	O
,	O
gangliosides	B
were	O
isolated	O
from	O
cells	O
and	O
examined	O
for	O
their	O
reactivity	O
to	O
A2B5	O
.	O

Five	O
positive	O
bands	O
(	O
i.e.	O
,	O
bands	O
a	O
,	O
b	O
,	O
c	O
,	O
d	O
,	O
and	O
X	O
)	O
were	O
observed	O
with	O
TLC	O
immunostaining	O
with	O
A2B5	O
(	O
Fig.	O
1B	O
,	O
lane	O
1	O
)	O
.	O

Of	O
these	O
acidic	B
lipid	I
bands	O
,	O
bands	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
had	O
chromatographic	O
mobilities	O
that	O
corresponded	O
respectively	O
to	O
GT3	B
,	O
GT1c	B
,	O
GQ1c	B
,	O
and	O
GP1c	B
[	O
5	O
]	O
.	O

Gangliosides	B
of	O
rat	O
hepatocytes	O
were	O
further	O
characterized	O
using	O
TLC	O
immunostaining	O
with	O
in	O
situ	O
treatment	O
by	O
sialidase	O
.	O

Gangliosides	B
having	O
the	O
gangliotetraose	B
(	O
i.e.	O
,	O
GgOse4	B
)	O
structure	O
can	O
be	O
detected	O
by	O
this	O
method	O
[	O
27	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
3	O
,	O
GM1	B
,	O
GD1a	B
,	O
GD1b	B
,	O
GT1b	B
,	O
and	O
GQ1b	B
,	O
but	O
not	O
GD3	B
,	O
were	O
stained	O
positively	O
,	O
confirming	O
the	O
validity	O
of	O
this	O
method	O
.	O

In	O
addition	O
,	O
three	O
minor	O
gangliosides	B
with	O
a	O
gangliotetraose	B
backbone	O
were	O
detected	O
below	O
GT1b	B
,	O
below	O
GQ1b	B
,	O
and	O
far	O
below	O
GQ1b	B
on	O
TLC	O
;	O
their	O
mobilities	O
were	O
identical	O
to	O
A2B5-positive	O
bands	O
b	O
,	O
c	O
,	O
and	O
d	O
,	O
respectively	O
.	O

The	O
anti	O
-	O
asialo	O
-	O
GM1	O
antibody	O
did	O
not	O
stain	O
any	O
hepatocyte	O
gangliosides	B
without	O
in	O
situ	O
sialidase	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

Based	O
upon	O
these	O
findings	O
,	O
A2B5-reactive	O
bands	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
were	O
respectively	O
identified	O
as	O
GT3	B
,	O
GT1c	B
,	O
GQ1c	B
,	O
and	O
GP1c	B
.	O

In	O
addition	O
to	O
these	O
c	B
-	I
series	I
gangliosides	I
,	O
an	O
acidic	B
lipid	I
(	O
band	O
X	O
)	O
,	O
which	O
migrated	O
between	O
GD3	B
and	O
GD1a	B
on	O
TLC	O
,	O
was	O
observed	O
on	O
TLC	O
immunostaining	O
with	O
A2B5	O
.	O

Since	O
the	O
ganglioside	B
preparation	O
had	O
already	O
been	O
subjected	O
to	O
base	O
treatment	O
during	O
isolation	O
,	O
it	O
is	O
unlikely	O
that	O
band	O
X	O
is	O
alkali	B
-	O
labile	O
O	B
-acetyl	I
GT3	I
,	O
which	O
migrates	O
near	O
GD3	B
[	O
28	O
]	O
.	O

The	O
possibility	O
that	O
band	O
X	O
is	O
GD3	B
was	O
also	O
ruled	O
out	O
by	O
the	O
lack	O
of	O
reactivity	O
of	O
A2B5	O
to	O
authentic	O
GD3	B
(	O
data	O
not	O
shown	O
)	O
.	O

While	O
band	O
X	O
remained	O
positive	O
on	O
TLC	O
immunostaining	O
by	O
further	O
treatment	O
of	O
the	O
ganglioside	B
preparation	O
with	O
a	O
mild	O
base	B
(	O
0.2	O
M	O
methanolic	B
NaOH	B
,	O
37	O
°	O
C	O
for	O
1	O
h	O
)	O
,	O
it	O
was	O
not	O
detected	O
when	O
the	O
lipid	B
was	O
purified	O
by	O
preparative	O
TLC	O
and	O
subjected	O
to	O
the	O
same	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
thus	O
was	O
suggested	O
that	O
band	O
X	O
may	O
be	O
a	O
non	B
-	I
ganglioside	I
acidic	I
lipid	I
.	O

3.2	O
Effects	O
of	O
EGF	O
on	O
the	O
expression	O
of	O
c	B
-	I
series	I
gangliosides	I
The	O
effects	O
of	O
EGF	O
on	O
the	O
expression	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
cultured	O
hepatocytes	O
were	O
examined	O
.	O

In	O
the	O
presence	O
of	O
EGF	O
,	O
hepatocytes	O
proliferated	O
actively	O
up	O
to	O
day	O
3	O
and	O
ceased	O
proliferation	O
(	O
Fig.	O
4A	O
)	O
.	O

While	O
the	O
total	O
amount	O
of	O
c	B
-	I
series	I
gangliosides	I
increased	O
throughout	O
the	O
period	O
of	O
culture	O
,	O
individual	O
ganglioside	B
species	O
showed	O
different	O
time	O
-	O
course	O
profiles	O
(	O
Fig.	O
5A	O
)	O
.	O

The	O
content	O
of	O
GT3	B
rapidly	O
increased	O
up	O
to	O
day	O
3	O
and	O
reached	O
a	O
plateau	O
,	O
showing	O
a	O
profile	O
similar	O
to	O
the	O
growth	O
pattern	O
of	O
the	O
cells	O
.	O

The	O
concentrations	O
of	O
polysialo	B
species	O
such	O
as	O
GT1c	B
,	O
GQ1c	B
,	O
and	O
GP1c	B
exhibited	O
only	O
moderate	O
changes	O
during	O
the	O
period	O
of	O
active	O
proliferation	O
(	O
i.e.	O
,	O
up	O
to	O
day	O
1	O
)	O
,	O
but	O
rapidly	O
increased	O
as	O
the	O
cells	O
became	O
confluent	O
.	O

When	O
EGF	O
was	O
removed	O
from	O
the	O
culture	O
medium	O
,	O
rat	O
hepatocytes	O
proliferated	O
only	O
on	O
the	O
first	O
day	O
of	O
culture	O
(	O
Fig.	O
4A	O
)	O
.	O

While	O
the	O
expression	O
of	O
GT3	B
was	O
reduced	O
significantly	O
,	O
the	O
amounts	O
of	O
polysialo	B
species	O
at	O
day	O
5	O
were	O
almost	O
the	O
same	O
as	O
observed	O
with	O
EGF	O
(	O
Fig.	O
5B	O
)	O
.	O

3.3	O
Effects	O
of	O
cell	O
density	O
on	O
the	O
expression	O
of	O
c	B
-	I
series	I
gangliosides	I
Expression	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
rat	O
hepatocytes	O
was	O
also	O
modulated	O
by	O
cell	O
density	O
in	O
culture	O
.	O

Growth	O
rates	O
decreased	O
as	O
cells	O
were	O
cultured	O
at	O
higher	O
density	O
(	O
Fig.	O
4B	O
)	O
.	O

While	O
the	O
expression	O
of	O
GT3	B
was	O
less	O
influenced	O
by	O
changes	O
in	O
cell	O
density	O
,	O
the	O
contents	O
of	O
polysialo	B
species	O
such	O
as	O
GT1c	B
,	O
GQ1c	B
,	O
and	O
GP1c	B
significantly	O
increased	O
at	O
higher	O
cell	O
density	O
(	O
Fig.	O
6	O
)	O
.	O

3.4	O
Developmental	O
changes	O
in	O
the	O
composition	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
liver	O
tissues	O
C	B
-	I
series	I
gangliosides	I
in	O
liver	O
tissues	O
were	O
examined	O
using	O
rats	O
of	O
ages	O
ranging	O
from	O
16	O
embryonic	O
days	O
(	O
E16	O
)	O
to	O
7	O
postnatal	O
weeks	O
.	O

As	O
shown	O
in	O
Fig.	O
7	O
,	O
the	O
composition	O
of	O
c	B
-	I
series	I
gangliosides	I
demonstrated	O
a	O
unique	O
developmental	O
pattern	O
.	O

While	O
GT3	B
were	O
the	O
major	O
species	O
at	O
E16	O
,	O
they	O
were	O
replaced	O
by	O
GQ1c	B
at	O
E19	O
.	O

In	O
the	O
postnatal	O
period	O
,	O
polysialo	B
gangliosides	I
including	O
GP1c	B
became	O
dominant	O
with	O
advancing	O
age	O
.	O

In	O
addition	O
,	O
another	O
positive	O
band	O
(	O
band	O
Y	O
)	O
,	O
which	O
migrated	O
above	O
GM3	B
on	O
TLC	O
,	O
was	O
observed	O
in	O
the	O
adult	O
stage	O
.	O

Band	O
Y	O
became	O
negative	O
on	O
TLC	O
immunostaining	O
after	O
further	O
treatment	O
of	O
the	O
ganglioside	B
preparation	O
with	O
a	O
mild	O
base	B
,	O
suggesting	O
that	O
this	O
band	O
is	O
not	O
a	O
c	B
-	I
series	I
ganglioside	I
or	O
derivative	O
(	O
data	O
not	O
shown	O
)	O
.	O

4	O
Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
employed	O
monoclonal	O
antibody	O
A2B5	O
for	O
analyzing	O
c	B
-	I
series	I
gangliosides	I
in	O
rat	O
hepatocytes	O
and	O
liver	O
tissues	O
.	O

Since	O
c	B
-	I
series	I
gangliosides	I
exist	O
as	O
minor	O
ganglioside	B
components	O
in	O
mammalian	O
tissues	O
,	O
they	O
are	O
difficult	O
to	O
analyze	O
by	O
conventional	O
visualization	O
methods	O
after	O
separation	O
on	O
TLC	O
.	O

Accordingly	O
,	O
specific	O
antibodies	O
for	O
c	B
-	I
series	I
gangliosides	I
have	O
been	O
developed	O
and	O
used	O
as	O
valuable	O
analytical	O
tools	O
[	O
6,7,29,30	O
]	O
.	O

Monoclonal	O
antibody	O
A2B5	O
was	O
originally	O
prepared	O
by	O
immunizing	O
chicken	O
embryonic	O
retinal	O
cells	O
[	O
29	O
]	O
.	O

While	O
there	O
was	O
some	O
controversy	O
about	O
its	O
specificity	O
[	O
31	O
]	O
,	O
recent	O
studies	O
have	O
reported	O
strict	O
specificity	O
of	O
A2B5	O
to	O
c	B
-	I
series	I
gangliosides	I
using	O
embryonic	O
chicken	O
brain	O
[	O
9	O
]	O
and	O
cod	O
fish	O
brain	O
[	O
32	O
]	O
.	O

The	O
present	O
study	O
has	O
provided	O
further	O
evidence	O
for	O
the	O
validity	O
of	O
this	O
monoclonal	O
antibody	O
's	O
specificity	O
.	O

Five	O
positive	O
bands	O
were	O
observed	O
on	O
TLC	O
immunostaining	O
of	O
hepatocyte	O
gangliosides	B
with	O
A2B5	O
.	O

Among	O
these	O
bands	O
,	O
band	O
X	O
seemed	O
unaffected	O
by	O
mild	O
base	B
treatment	O
of	O
ganglioside	B
preparations	O
,	O
but	O
became	O
susceptible	O
to	O
the	O
same	O
treatment	O
after	O
purification	O
by	O
preparative	O
TLC	O
.	O

Band	O
Y	O
was	O
also	O
shown	O
to	O
be	O
alkali	B
-	O
labile	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
bands	O
X	O
and	O
Y	O
are	O
non	B
-	I
ganglioside	I
acidic	I
lipids	I
.	O

Gangliosides	B
of	O
hepatocytes	O
and	O
liver	O
tissues	O
are	O
considerably	O
low	O
in	O
their	O
contents	O
and	O
need	O
to	O
be	O
concentrated	O
extensively	O
before	O
analysis	O
.	O

These	O
non	B
-	I
ganglioside	I
lipids	I
may	O
also	O
be	O
concentrated	O
concomitantly	O
and	O
stained	O
non	O
-	O
specifically	O
on	O
TLC	O
immunostaining	O
.	O

Regarding	O
bands	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
,	O
evidence	O
has	O
been	O
provided	O
suggesting	O
that	O
they	O
belong	O
to	O
c	B
-	I
series	I
gangliosides	I
.	O

They	O
exhibited	O
chromatographic	O
mobilities	O
corresponding	O
to	O
GT3	B
,	O
GT1c	B
,	O
GQ1c	B
,	O
or	O
GP1c	B
,	O
respectively	O
.	O

Structural	O
analysis	O
of	O
core	O
oligosaccharides	O
provided	O
evidence	O
suggesting	O
that	O
bands	O
b	O
,	O
c	O
,	O
and	O
d	O
share	O
the	O
gangliotetraose	B
oligosaccharide	B
backbone	O
.	O

From	O
these	O
data	O
,	O
it	O
was	O
concluded	O
that	O
bands	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
were	O
GT3	B
,	O
GT1c	B
,	O
GQ1c	B
,	O
and	O
GP1c	B
,	O
respectively	O
.	O

The	O
presence	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
rat	O
hepatocytes	O
was	O
further	O
supported	O
by	O
positive	O
immunofluorescence	O
of	O
cultured	O
cells	O
with	O
this	O
A2B5	O
preparation	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
rat	O
hepatocytes	O
express	O
c	B
-	I
series	I
gangliosides	I
.	O

TLC	O
immunostaining	O
of	O
rat	O
hepatocyte	O
gangliosides	B
with	O
A2B5	O
demonstrated	O
that	O
the	O
content	O
and	O
composition	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
cells	O
were	O
influenced	O
by	O
EGF	O
or	O
cell	O
density	O
in	O
culture	O
.	O

Since	O
there	O
was	O
no	O
recognizable	O
growth	O
of	O
non	O
-	O
parenchymal	O
cells	O
,	O
it	O
was	O
concluded	O
that	O
hepatocytes	O
were	O
responsible	O
for	O
the	O
observed	O
ganglioside	B
changes	O
.	O

It	O
is	O
known	O
that	O
EGF	O
can	O
modulate	O
the	O
expression	O
of	O
major	O
gangliosides	B
in	O
different	O
cell	O
types	O
[	O
33–36	O
]	O
.	O

Treatment	O
of	O
rat	O
hepatocytes	O
with	O
EGF	O
produced	O
a	O
significant	O
increase	O
in	O
the	O
total	O
amount	O
of	O
c	B
-	I
series	I
gangliosides	I
.	O

Enhanced	O
expression	O
of	O
c	B
-	I
series	I
gangliosides	I
by	O
EGF	O
has	O
also	O
been	O
reported	O
with	O
cerebellar	O
neuronal	O
cells	O
[	O
37	O
]	O
and	O
neoplastic	O
glial	O
cells	O
[	O
38	O
]	O
.	O

Interestingly	O
,	O
the	O
effect	O
of	O
EGF	O
on	O
the	O
expression	O
of	O
c	B
-	I
series	I
gangliosides	I
was	O
differential	O
;	O
it	O
caused	O
significant	O
increases	O
in	O
the	O
amount	O
of	O
GT3	B
,	O
but	O
affected	O
the	O
contents	O
of	O
polysialo	B
species	O
only	O
moderately	O
.	O

Since	O
the	O
amount	O
of	O
GT3	B
and	O
growth	O
rate	O
of	O
cells	O
display	O
similar	O
time	O
courses	O
,	O
one	O
can	O
question	O
the	O
possibility	O
that	O
the	O
increased	O
expression	O
of	O
GT3	B
may	O
reflect	O
the	O
growth	O
activity	O
of	O
rat	O
hepatocytes	O
in	O
culture	O
.	O

This	O
assumption	O
,	O
however	O
,	O
is	O
not	O
supported	O
;	O
no	O
correlation	O
was	O
observed	O
between	O
the	O
content	O
of	O
GT3	B
and	O
growth	O
activity	O
of	O
cells	O
when	O
cells	O
were	O
cultured	O
at	O
different	O
cell	O
densities	O
.	O

We	O
have	O
recently	O
examined	O
the	O
effects	O
of	O
EGF	O
on	O
the	O
composition	O
of	O
major	O
gangliosides	B
in	O
rat	O
hepatocytes	O
in	O
primary	O
cultures	O
and	O
demonstrated	O
that	O
EGF	O
causes	O
augmented	O
expression	O
of	O
GM3	B
and	O
GD3	B
,	O
but	O
has	O
a	O
lesser	O
effect	O
on	O
other	O
ganglioside	B
species	O
including	O
GM1	B
,	O
GD1a	B
,	O
GD1b	B
,	O
and	O
GT1b	B
[	O
36	O
]	O
.	O

As	O
described	O
in	O
Section	O
1	O
,	O
the	O
sialylation	O
processes	O
of	O
a-	B
,	O
b-	B
,	O
and	O
c	B
-	I
series	I
gangliosides	I
are	O
catalyzed	O
by	O
the	O
same	O
set	O
of	O
sialyltransferases	O
[	O
22	O
]	O
.	O

Based	O
upon	O
these	O
results	O
about	O
major	O
gangliosides	B
in	O
cultured	O
hepatocytes	O
and	O
the	O
present	O
work	O
,	O
it	O
is	O
assumed	O
that	O
EGF	O
may	O
accelerate	O
the	O
steps	O
from	O
lactosylceramide	B
to	O
GM3	B
,	O
from	O
GM3	B
to	O
GD3	B
,	O
and	O
from	O
GD3	B
to	O
GT3	B
,	O
but	O
have	O
less	O
influence	O
on	O
the	O
further	O
steps	O
for	O
the	O
biosynthesis	O
of	O
gangliosides	B
in	O
rat	O
hepatocytes	O
(	O
see	O
Fig.	O
8	O
)	O
.	O

Thus	O
the	O
expression	O
of	O
GT3	B
may	O
be	O
connected	O
to	O
a	O
specific	O
process	O
(	O
es	O
)	O
governed	O
by	O
EGF	O
.	O

In	O
this	O
context	O
,	O
it	O
is	O
noteworthy	O
that	O
GT3	B
are	O
expressed	O
in	O
liver	O
tissues	O
only	O
in	O
the	O
early	O
embryonic	O
stage	O
,	O
in	O
which	O
EGF	O
may	O
function	O
as	O
a	O
dominant	O
growth	O
factor	O
for	O
hepatocytes	O
[	O
39	O
]	O
.	O

Expression	O
of	O
polysialo	B
species	O
was	O
less	O
affected	O
by	O
EGF	O
,	O
but	O
was	O
significantly	O
enhanced	O
by	O
higher	O
cell	O
density	O
.	O

This	O
finding	O
appears	O
to	O
be	O
in	O
harmony	O
with	O
previous	O
reports	O
that	O
the	O
proportion	O
of	O
polysialo	B
species	O
among	O
major	O
gangliosides	B
in	O
some	O
cell	O
types	O
increases	O
as	O
cells	O
become	O
confluent	O
[	O
36,40–44	O
]	O
.	O

Analysis	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
rat	O
liver	O
tissues	O
demonstrated	O
a	O
unique	O
developmental	O
profile	O
with	O
a	O
switch	O
from	O
a	O
GT3-dominant	B
composition	O
to	O
polysialo	B
species	O
-	O
dominant	O
patterns	O
at	O
late	O
embryonic	O
stages	O
.	O

Such	O
a	O
swift	O
and	O
complete	O
switch	O
in	O
the	O
composition	O
(	O
and	O
metabolism	O
)	O
of	O
c	B
-	I
series	I
gangliosides	I
has	O
not	O
been	O
observed	O
with	O
embryonic	O
neural	O
tissues	O
including	O
chicken	O
optic	O
lobes	O
[	O
7	O
]	O
or	O
rat	O
cerebral	O
cortex	O
[	O
8	O
]	O
.	O

While	O
these	O
neural	O
tissues	O
contain	O
many	O
different	O
cell	O
types	O
,	O
liver	O
tissues	O
are	O
more	O
homogeneous	O
,	O
largely	O
consisting	O
of	O
parenchymal	O
hepatocytes	O
.	O

The	O
changes	O
in	O
the	O
expression	O
of	O
c	B
-	I
series	I
gangliosides	I
in	O
this	O
period	O
may	O
closely	O
reflect	O
underlying	O
cellular	O
events	O
within	O
rat	O
hepatocytes	O
.	O

In	O
summary	O
,	O
we	O
have	O
demonstrated	O
that	O
rat	O
hepatocytes	O
express	O
c	B
-	I
series	I
gangliosides	I
in	O
a	O
growth-	O
and	O
development	O
-	O
dependent	O
manner	O
.	O

The	O
results	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
suggest	O
that	O
the	O
GT3	B
and	O
polysialo	B
species	O
may	O
have	O
a	O
distinct	O
role	O
(	O
s	O
)	O
in	O
cellular	O
function	O
of	O
rat	O
hepatocytes	O
.	O

A	O
further	O
study	O
on	O
the	O
regulatory	O
mechanism	O
for	O
the	O
expression	O
of	O
c	B
-	I
series	I
gangliosides	I
is	O
being	O
undertaken	O
.	O

Acknowledgements	O

We	O
would	O
like	O
to	O
thank	O
Mr.	O
Harunari	O
Tanaka	O
and	O
Ms.	O
Hisayo	O
Kitamura	O
for	O
their	O
technical	O
assistance	O
throughout	O
this	O
work	O
.	O

α	B
-	I
l	I
-Fucose	I
is	O
an	O
important	O
constituent	O
of	O
the	O
carbohydrate	B
chains	O
of	O
glycoconjugates	B
involved	O
in	O
a	O
variety	O
of	O
biological	O
events	O
,	O
such	O
as	O
cell	O
–	O
cell	O
recognition	O
and	O
antigenicity	O
[	O
1	O
]	O
.	O

For	O
example	O
,	O
immunological	O
determinants	O
of	O
the	O
ABH	O
(	O
O	O
)	O
type	O
are	O
known	O
to	O
be	O
oligosaccharides	B
having	O
the	O
common	O
structure	O
of	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→2	I
)	I
-β	I
-	I
d	I
-Gal	I
-	I
R.	I
Furthermore	O
,	O
(	B
1→2	I
)	I
-linked	I
α	I
-	I
l	I
-fucosyllactose	I
is	O
a	O
major	O
component	O
of	O
human	O
milk	O
oligosaccharides	B
[	O
2	O
]	O
.	O

Great	O
attention	O
,	O
therefore	O
,	O
has	O
been	O
paid	O
to	O
chemical	O
and	O
enzymatic	O
syntheses	O
of	O
such	O
oligosaccharides	B
.	O

Chemical	O
procedures	O
have	O
been	O
extensively	O
developed	O
[	O
3–6	O
]	O
,	O
but	O
they	O
are	O
frequently	O
cumbersome	O
because	O
of	O
many	O
protection	O
and	O
deprotection	O
steps	O
.	O

The	O
enzymatic	O
approach	O
has	O
utilized	O
various	O
glycosyltransferases	O
and	O
glycosidases	O
.	O

Fucosylated	B
di-	B
and	O
trisaccharides	B
of	O
the	O
type	O
2	O
ABO	O
blood	O
group	O
have	O
been	O
obtained	O
with	O
porcine	O
β	O
-	O
d	O
-galactoside	O
α-	O
(	O
1→2	O
)	O
fucosyltransferase	O
[	O
7	O
]	O
.	O

From	O
a	O
practical	O
viewpoint	O
,	O
the	O
use	O
of	O
glycosidases	O
is	O
attractive	O
for	O
synthesizing	O
oligosaccharides	B
,	O
because	O
these	O
enzymes	O
are	O
generally	O
more	O
available	O
,	O
and	O
less	O
expensive	O
than	O
glycosyltransferases	O
,	O
and	O
do	O
not	O
require	O
expensive	O
sugar	B
nucleotide	I
donors	O
[	O
8	O
]	O
.	O

Svensson	O
and	O
Thiem	O
reported	O
an	O
enzymatic	O
synthesis	O
of	O
methyl	B
(	I
1→2	I
)	I
-	I
and	I
(	I
1→6	I
)	I
-linked	I
α	I
-	I
l	I
-fucopyranosyl	I
-	I
β	I
-	I
d	I
-galactosides	I
in	O
the	O
ratio	O
of	O
2:3	O
with	O
an	O
α	O
-	O
l	O
-fucosidase	O
from	O
porcine	O
liver	O
[	O
9	O
]	O
.	O

Ajisaka	O
and	O
Shirakabe	O
developed	O
the	O
regioselective	O
synthesis	O
of	O
disaccharides	B
containing	O
(	B
1→2	I
)	I
-	I
,	O
(	B
1→3	I
)	I
-	I
,	O
and	O
(	B
1→6	I
)	I
-linked	I
α	I
-	I
l	I
-fucosyl	I
groups	I
by	O
use	O
of	O
α	O
-	O
l	O
-fucosidases	O
from	O
various	O
microorganisms	O
[	O
10	O
]	O
.	O

The	O
object	O
of	O
the	O
present	O
investigation	O
was	O
to	O
develop	O
a	O
system	O
for	O
the	O
enzymatic	O
synthesis	O
of	O
fucosylated	B
trisaccharide	I
1	I
of	O
the	O
determinant	O
of	O
type	O
2	O
blood	O
group	O
H	O
substance	O
,	O
utilizing	O
β	B
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-GlcNAc	I
(	I
LacNAc	I
)	I
,	O
which	O
has	O
been	O
readily	O
obtained	O
on	O
a	O
gram	O
-	O
scale	O
by	O
our	O
method	O
[	O
11,12	O
]	O
.	O

The	O
present	O
paper	O
reports	O
a	O
synthetic	O
procedure	O
for	O
α	B
-	I
l	I
-fucosyl	I
-	I
N	I
-acetyllactosamine	I
and	O
3′-O	B
-α	I
-	I
l	I
-fucosyllactose	I
through	O
α	B
-	I
l	I
-fucosidase	I
-	O
catalyzed	O
transglycosylation	O
.	O

2	O
2	O
.	O

Materials	O
and	O
methods	O
2.1	O
Materials	O
α	O
-	O
l	O
-Fucosidase	O
from	O
Alcaligenes	O
sp.	O
was	O
kindly	O
supplied	O
by	O
Kumiai	O
Chemical	O
Industry	O
Co.	O
Ltd.	O
,	O
(	O
Shizuoka	O
,	O
Japan	O
)	O
.	O

Porcine	O
liver	O
extract	O
(	O
Catalase	O
L	O
'	O
Amano	O
'	O
)	O
was	O
kindly	O
supplied	O
by	O
Amano	O
Pharmaceutical	O
Co.	O
Ltd.	O
,	O
(	O
Nagoya	O
,	O
Japan	O
)	O
.	O

LacNAc	B
,	O
β	B
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-Glc	I
-	I
OMe	I
,	O
β	B
-	I
d	I
-Gal-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Glc	I
-	I
OMe	I
,	O
and	O
β	B
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-GlcNAc	I
-	I
OMe	I
were	O
prepared	O
by	O
our	O
methods	O
[	O
11,12	O
]	O
.	O

p	B
-Nitrophenyl	I
α	I
-	I
l	I
-fucopyranoside	I
(	O
Fucα	B
-	I
p	I
NP	I
)	O
and	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→2	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-Glc	I
(	O
2′-O	B
-α	I
-	I
l	I
-fucosyllactose	I
)	O
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

All	O
other	O
chemicals	B
were	O
obtained	O
from	O
commercial	O
sources	O
.	O

2.2	O
Enzyme	O
assay	O
The	O
activity	O
of	O
α	O
-	O
l	O
-fucosidase	O
from	O
the	O
porcine	O
liver	O
extract	O
was	O
assayed	O
as	O
follows	O
:	O
a	O
mixture	O
containing	O
0.4	O
mM	O
Fucα	B
-	I
p	I
NP	I
in	O
0.9	O
mL	O
of	O
50	O
mM	O
NaOAc	B
buffer	O
(	O
pH	O
4.8	O
)	O
and	O
an	O
appropriate	O
amount	O
of	O
enzyme	O
in	O
total	O
volume	O
of	O
1	O
mL	O
was	O
incubated	O
for	O
10	O
min	O
at	O
37	O
°	O
C	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
adding	O
0.5	O
mL	O
of	O
1	O
M	O
Na2	B
CO3	I
solution	O
,	O
and	O
the	O
liberated	O
p	B
-nitrophenol	I
was	O
determined	O
spectrophotometrically	O
at	O
410	O
nm	O
.	O

The	O
activity	O
of	O
α	O
-	O
l	O
-fucosidase	O
from	O
Alcaligenes	O
sp.	O
was	O
assayed	O
in	O
a	O
similar	O
manner	O
with	O
50	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
and	O
incubation	O
at	O
50	O
°	O
C	O
.	O

One	O
unit	O
of	O
activity	O
was	O
defined	O
as	O
the	O
amount	O
of	O
enzyme	O
that	O
hydrolyzes	O
1	O
μmol	O
of	O
Fucα	B
-	I
p	I
NP	I
per	O
min	O
.	O

β	O
-	O
d	O
-Galactosidase	O
activity	O
was	O
assayed	O
as	O
follows	O
:	O
a	O
mixture	O
containing	O
2	O
mM	O
o	B
-nitrophenyl	I
β	I
-	I
d	I
-galactopyranoside	I
(	O
Galβ	B
-	I
o	I
NP	I
)	O
in	O
0.9	O
mL	O
of	O
50	O
mM	O
NaOAc	B
buffer	O
(	O
pH	O
4.8	O
)	O
and	O
an	O
appropriate	O
amount	O
of	O
enzyme	O
in	O
a	O
total	O
volume	O
of	O
1	O
mL	O
was	O
incubated	O
for	O
10	O
min	O
at	O
37	O
°	O
C	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
adding	O
0.5	O
mL	O
of	O
1	O
M	O
Na2	B
CO3	I
solution	O
,	O
and	O
liberated	O
o	B
-nitrophenol	I
was	O
determined	O
spectrophotometrically	O
at	O
420	O
nm	O
.	O

One	O
unit	O
of	O
enzyme	O
activity	O
was	O
defined	O
as	O
the	O
amount	O
of	O
the	O
enzyme	O
hydrolyzing	O
1	O
μmol	O
of	O
Galβ	B
-	I
o	I
NP	I
per	O
min	O
.	O

2.3	O
Analytical	O
methods	O
HPLC	O
was	O
performed	O
with	O
a	O
Hitachi	O
6000	O
liquid	O
chromatograph	O
with	O
a	O
Shodex	O
Asahipak	O
NH2P-50	O
column	O
(	O
4.6	O
mm	O
diameter	O
×	O
250	O
mm	O
,	O
Showadenko	O
Corp.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
developed	O
with	O
1:3	O
or	O
9:41	O
water	B
–	O
MeCN	B
at	O
a	O
flow	O
rate	O
of	O
0.8	O
mL	O
/	O
min	O
with	O
an	O
L-4000	O
UV	O
detector	O
and	O
an	O
L-3350	O
RI	O
monitor	O
.	O

1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
were	O
recorded	O
with	O
a	O
Jeol	O
JNM	O
-	O
EX	O
270	O
FT	O
-	O
NMR	O
spectrometer	O
.	O

Chemical	O
shifts	O
are	O
expressed	O
in	O
δ	O
values	O
relative	O
to	O
sodium	B
4,4-dimethyl-4-silapentanoate	I
as	O
the	O
external	O
standard	O
.	O

FABMS	O
analyses	O
were	O
carried	O
out	O
in	O
the	O
positive	O
ion	O
mode	O
using	O
a	O
Jeol	O
JMS	O
DS303HF	O
mass	O
spectrometer	O
,	O
coupled	O
to	O
a	O
Jeol	O
DA-800	O
mass	O
-	O
data	O
system	O
.	O

An	O
accelerating	O
voltage	O
of	O
10	O
kV	O
and	O
mass	O
resolution	O
of	O
1000	O
were	O
employed	O
.	O

A	O
sample	O
of	O
1	O
μL	O
in	O
distilled	B
water	I
was	O
loaded	O
onto	O
a	O
probe	O
tip	O
and	O
mixed	O
with	O
1	O
μL	O
of	O
glycerol	B
as	O
a	O
matrix	O
.	O

Mass	O
calibration	O
was	O
done	O
with	O
Ultramark	O
.	O

2.4	O
Preparation	O
of	O
α	O
-	O
l	O
-fucosidase	O
from	O
porcine	O
liver	O
The	O
porcine	O
liver	O
extract	O
(	O
400	O
mL	O
)	O
was	O
brought	O
to	O
20	O
%	O
saturation	O
with	O
(	B
NH4	I
)	I
2	I
SO4	I
,	O
stirred	O
for	O
30	O
min	O
,	O
and	O
kept	O
for	O
9	O
h	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatant	O
obtained	O
by	O
centrifugation	O
was	O
brought	O
to	O
60	O
%	O
saturation	O
with	O
(	B
NH4	I
)	I
2	I
SO4	I
and	O
stirred	O
for	O
1	O
h.	O
The	O
precipitate	O
was	O
recovered	O
by	O
centrifugation	O
,	O
dissolved	O
in	O
200	O
mL	O
of	O
50	O
mM	O
NaOAc	B
buffer	O
(	O
pH	O
6	O
)	O
,	O
and	O
dialyzed	O
overnight	O
against	O
the	O
same	O
buffer	O
.	O

The	O
dialyzed	O
enzyme	O
solution	O
was	O
then	O
charged	O
onto	O
a	O
CM	O
-	O
Sepharose	O
Fast	O
Flow	O
column	O
(	O
3.2	O
cm	O
diameter	O
×	O
24	O
cm	O
)	O
equilibrated	O
with	O
50	O
mM	O
NaOAc	B
buffer	O
(	O
pH	O
6	O
)	O
.	O

After	O
applying	O
the	O
sample	O
,	O
the	O
column	O
was	O
washed	O
with	O
400	O
mL	O
of	O
the	O
same	O
buffer	O
.	O

The	O
column	O
was	O
then	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
NaCl	B
concentration	O
from	O
0	O
(	O
400	O
mL	O
)	O
to	O
1	O
M	O
(	O
400	O
mL	O
)	O
and	O
the	O
eluate	O
was	O
collected	O
in	O
20-mL	O
fractions	O
.	O

Fractions	O
(	O
F.	O
nos.	O
21–27	O
)	O
containing	O
α	B
-	I
l	I
-fucosidase	I
,	O
which	O
did	O
not	O
show	O
β	O
-	O
d	O
-galactosidase	O
activity	O
,	O
were	O
combined	O
and	O
concentrated	O
to	O
low	O
volume	O
with	O
an	O
Amicon	O
Diaflo	O
unit	O
equipped	O
with	O
a	O
PM-10	O
membrane	O
operating	O
at	O
2	O
kg	O
/	O
cm2	O
,	O
giving	O
a	O
specific	O
activity	O
of	O
0.04	O
U	O
/	O
mg	O
protein	O
.	O

2.5	O
Preparation	O
of	O
α	B
-	I
l	I
-fucosidase	I
from	O
Alcaligenes	O
sp	O
Strain	O
KSF-9687	O
,	O
which	O
has	O
been	O
deposited	O
in	O
the	O
National	O
Institute	O
of	O
Bioscience	O
and	O
Human	O
Technology	O
,	O
Ministry	O
of	O
International	O
Trade	O
and	O
Industry	O
,	O
Tsukuba	O
,	O
Japan	O
,	O
under	O
accession	O
no.	O
P-16944	O
,	O
was	O
grown	O
in	O
a	O
medium	O
of	O
nutrient	O
broth	O
(	O
NB	O
)	O
.	O

The	O
culture	O
was	O
transferred	O
from	O
the	O
NB	O
to	O
a	O
500-mL	O
Erlenmeyer	O
flask	O
containing	O
100	O
mL	O
of	O
0.25	O
%	O
yeast	O
extract	O
,	O
0.5	O
%	O
polypeptone	B
,	O
0.1	O
%	O
KH2	B
PO4	I
,	O
and	O
0.05	O
%	O
MgSO4	B
·	I
7	I
H2	I
O	I
(	O
adjusted	O
to	O
pH	O
7	O
with	O
0.2	O
N	O
NaOH	B
before	O
the	O
sterilization	O
)	O
.	O

The	O
flask	O
was	O
shaken	O
on	O
a	O
rotary	O
shaker	O
for	O
48	O
h	O
at	O
37	O
°	O
C	O
at	O
200	O
rpm	O
.	O

2.5.1	O
Step	O
1	O
:	O

Streamline	O
-	O
DEAE	O
A	O
4-L	O
broth	O
containing	O
the	O
cells	O
was	O
adjusted	O
to	O
pH	O
7	O
with	O
0.5	O
M	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
.	O

The	O
broth	O
was	O
applied	O
on	O
a	O
Streamline	O
-	O
DEAE	B
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
column	O
(	O
5.0	O
cm	O
diameter	O
×	O
20	O
cm	O
)	O
equilibrated	O
with	O
10	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
at	O
room	O
temperature	O
.	O

After	O
the	O
column	O
had	O
been	O
washed	O
with	O
the	O
same	O
buffer	O
,	O
the	O
α	O
-	O
l	O
-fucosidase	O
activity	O
was	O
eluted	O
with	O
the	O
same	O
buffer	O
containing	O
0.2	O
M	O
NaCl	B
.	O

2.5.2	O
Step	O
2	O
:	O
Column	O
chromatography	O
on	O
Butyl	O
-	O
Toyopearl	O
650	O
M	O
Solid	O
(	B
NH4	I
)	I
2	I
SO4	I
was	O
added	O
to	O
make	O
1.5	O
L	O
of	O
the	O
active	O
fraction	O
from	O
Step	O
1	O
up	O
to	O
1	O
M	O
in	O
final	O
concentration	O
.	O

The	O
enzyme	O
solution	O
was	O
put	O
onto	O
a	O
Butyl	O
-	O
Toyopearl	O
650	O
M	O
column	O
(	O
2.6	O
cm	O
diameter	O
×	O
30	O
cm	O
)	O
equilibrated	O
with	O
10	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
containing	O
1	O
M	O
(	B
NH4	I
)	I
2	I
SO4	I
,	O
and	O
the	O
column	O
was	O
washed	O
with	O
the	O
same	O
buffer	O
at	O
4	O
°	O
C	O
.	O

The	O
column	O
was	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
(	B
NH4	I
)	I
2	I
SO4	I
from	O
1	O
M	O
(	O
300	O
mL	O
)	O
to	O
0	O
M	O
(	O
300	O
mL	O
)	O
.	O

The	O
active	O
fractions	O
were	O
pooled	O
and	O
dialyzed	O
against	O
50	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
.	O

2.5.3	O
Step	O
3	O
:	O
Fucose	O
–	O
Cellulofine	O
column	O
chromatography	O
The	O
dialyzed	O
enzyme	O
solution	O
was	O
charged	O
onto	O
a	O
Fucose	O
–	O
Cellulofine	O
[	O
13	O
]	O
column	O
(	O
1.6	O
cm	O
diameter	O
×	O
10	O
cm	O
)	O
equilibrated	O
with	O
50	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
;	O
the	O
column	O
was	O
washed	O
with	O
the	O
same	O
buffer	O
,	O
and	O
the	O
enzyme	O
activity	O
was	O
then	O
eluted	O
with	O
50	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
containing	O
50	O
mM	O
l	B
-fucose	I
at	O
4	O
°	O
C	O
.	O

The	O
active	O
fractions	O
were	O
dialyzed	O
against	O
10	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
total	O
activity	O
,	O
56	O
U	O
;	O
specific	O
activity	O
,	O
19.7	O
U	O
/	O
mg	O
)	O
.	O

2.6	O
Preparation	O
of	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→2	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-GlcNAc	I
(	O
1	B
)	O
and	O
its	O
isomers	B
α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-GlcNAc	I
(	O
2	B
)	O
and	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→6	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-GlcNAc	I
(	O
3	B
)	O
,	O
utilizing	O
porcine	O
liver	O
α	O
-	O
l	O
-fucosidase	O
(	O
Scheme	O
1	O
)	O
To	O
a	O
solution	O
of	O
Fucα	B
-	I
p	I
NP	I
(	O
70	O
mg	O
)	O
and	O
LacNAc	B
(	O
1.2	O
g	O
)	O
in	O
9	O
mL	O
of	O
50	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
4.8	O
)	O
containing	O
0.5	O
mL	O
of	O
MeOH	O
was	O
added	O
partially	O
purified	O
α	O
-	O
l	O
-fucosidase	O
from	O
porcine	O
liver	O
(	O
0.45	O
U	O
)	O
.	O

The	O
mixture	O
was	O
incubated	O
for	O
30	O
h	O
at	O
40	O
°	O
C	O
,	O
and	O
the	O
reaction	O
was	O
terminated	O
by	O
boiling	O
for	O
5	O
min	O
.	O

The	O
resulting	O
insoluble	O
material	O
was	O
filtered	O
and	O
the	O
filtrate	O
was	O
placed	O
directly	O
onto	O
an	O
activated	O
charcoal	B
–	O
Celite	B
column	O
(	O
2.6	O
cm	O
diameter	O
×	O
25	O
cm	O
)	O
.	O

The	O
column	O
was	O
eluted	O
successively	O
with	O
500	O
mL	O
of	O
water	B
and	O
500	O
mL	O
of	O
12	O
%	O
EtOH	B
,	O
and	O
then	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
12	O
%	O
(	O
500	O
mL	O
)	O
to	O
40	O
%	O
(	O
500	O
mL	O
)	O
EtOH	B
.	O

The	O
elution	O
was	O
monitored	O
by	O
measuring	O
the	O
absorbance	O
at	O
210	O
nm	O
for	O
the	O
characteristic	O
absorption	O
of	O
the	O
N	B
-acetyl	I
group	I
and	O
at	O
485	O
nm	O
(	O
carbohydrate	B
content	O
,	O
determined	O
by	O
the	O
phenol	B
–	O
H2	B
SO4	I
method	O
)	O
.	O

The	O
chromatogram	O
(	O
Fig.	O
1	O
)	O
showed	O
four	O
peaks	O
displaying	O
coincident	O
absorbance	O
at	O
210	O
and	O
485	O
nm	O
.	O

Fraction	O
F-1	O
contained	O
LacNAc	B
used	O
as	O
the	O
acceptor	O
.	O

F-2	O
,	O
F-3	O
,	O
and	O
F-4	O
were	O
collected	O
,	O
concentrated	O
,	O
and	O
lyophilized	O
to	O
afford	O
1	B
(	O
6.8	O
mg	O
)	O
,	O
2	B
(	O
6.4	O
mg	O
)	O
,	O
and	O
3	B
(	O
3.9	O
mg	O
)	O
,	O
respectively	O
.	O

Compound	B
1	I
had	O
m	O
/	O
z	O
530	O
[	O
M+H	O
]	O
+	O
;	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
,	O
30	O
°	O
C	O
)	O
:	O
δ	O
5.31	O
(	O
H-1α	O
)	O
,	O
5.21	O
(	O
d	O
,	O
J	O
1,2	O
2.97	O
Hz	O
,	O
H-1′′	O
)	O
,	O
4.72	O
(	O
d	O
,	O
J	O
1,2	O
8.1	O
Hz	O
,	O
H-1β	O
)	O
,	O
4.55	O
(	O
d	O
,	O
J	O
1,2	O
7.56	O
Hz	O
,	O
H-1′α	O
)	O
,	O
4.48	O
(	O
d	O
,	O
J	O
1,2	O
8.1	O
Hz	O
,	O
H-1′β	O
)	O
,	O
2.05	O
(	O
s	O
,	O
3	O
H	O
,	O
NAc	O
)	O
,	O
and	O
1.23	O
(	O
d	O
,	O
J	O
5,6	O
6.7	O
Hz	O
,	O
H-6′′	O
)	O
.	O

Compound	B
2	I
had	O
m	O
/	O
z	O
530	O
[	O
M+H	O
]	O
+	O
;	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
,	O
30	O
°	O
C	O
)	O
:	O
δ	O
5.23	O
(	O
d	O
,	O
J	O
1,2	O
2.43	O
Hz	O
,	O
H-1α	O
)	O
,	O
5.20	O
(	O
d	O
,	O
J	O
1,2	O
4.05	O
Hz	O
,	O
H-1′′	O
)	O
,	O
4.56	O
(	O
t	O
,	O
H-1′	O
)	O
,	O
2.07	O
(	O
s	O
,	O
3	O
H	O
,	O
NAc	O
)	O
,	O
and	O
1.23	O
(	O
d	O
,	O
J	O
5,6	O
6.48	O
Hz	O
,	O
H-6′′	O
)	O
.	O

Compound	B
3	I
had	O
m	O
/	O
z	O
530	O
[	O
M+H	O
]	O
+	O
;	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
,	I
30	O
°	O
C	O
)	O
:	O
δ	O
5.16	O
(	O
d	O
,	O
J	O
1,2	O
2.45	O
Hz	O
,	O
H-1α	O
)	O
,	O
4.89	O
(	O
d	O
,	O
J	O
1,2	O
3.65	O
Hz	O
,	O
H-1α′′	O
)	O
,	O
4.88	O
(	O
d	O
,	O
J	O
1,2	O
3.95	O
Hz	O
,	O
H-1β′′	O
)	O
,	O
4.44	O
(	O
d	O
,	O
J	O
1,2	O
7.6	O
Hz	O
,	O
H-1′	O
)	O
,	O
2.03	O
(	O
s	O
,	O
3	O
H	O
,	O
NAc	O
)	O
,	O
and	O
1.27	O
(	O
d	O
,	O
J	O
5,6	O
6.7	O
Hz	O
,	O
H-6′′	O
)	O
.	O

2.7	O
Preparation	O
of	O
compound	B
2	I
and	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-Glc	I
(	O
4	B
)	O
and	O
other	O
related	O
compounds	O
utilizing	O
Alcaligenes	O
sp.	O
α	O
-	O
l	O
-fucosidase	O
(	O
Scheme	O
2	O
)	O
2.7.1	O
Compound	B
2	I
Fucα	B
-	I
p	I
NP	I
(	O
60	O
mg	O
)	O
and	O
LacNAc	B
(	O
2	O
g	O
)	O
were	O
dissolved	O
in	O
20	O
mL	O
of	O
20	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
,	O
and	O
α	O
-	O
l	O
-fucosidase	O
from	O
Alcaligenes	O
sp.	O
(	O
0.6	O
U	O
)	O
was	O
added	O
.	O

The	O
mixture	O
was	O
incubated	O
for	O
24	O
h	O
at	O
50	O
°	O
C	O
and	O
the	O
reaction	O
was	O
terminated	O
by	O
boiling	O
for	O
5	O
min	O
.	O

The	O
resulting	O
insoluble	O
material	O
was	O
centrifuged	O
and	O
the	O
filtrate	O
was	O
put	O
directly	O
onto	O
an	O
activated	O
charcoal	B
–	O
Celite	B
column	O
(	O
2.2	O
cm	O
diameter	O
×	O
95	O
cm	O
)	O
.	O

The	O
column	O
was	O
eluted	O
successively	O
with	O
1	O
L	O
of	O
water	B
and	O
1	O
L	O
of	O
10	O
%	O
EtOH	B
,	O
and	O
then	O
with	O
a	O
linear	O
gradient	O
of	O
10	O
%	O
(	O
1	O
L	O
)	O
to	O
40	O
%	O
(	O
1	O
L	O
)	O
EtOH	O
.	O

The	O
eluate	O
was	O
collected	O
in	O
20-mL	O
fractions	O
and	O
showed	O
one	O
main	O
peak	O
(	O
3100–3400	O
mL	O
)	O
as	O
the	O
transfer	O
product	O
.	O

The	O
fraction	O
was	O
collected	O
,	O
concentrated	O
,	O
and	O
lyophilized	O
to	O
afford	O
2	B
(	O
60.8	O
mg	O
)	O
in	O
54	O
%	O
yield	O
,	O
based	O
on	O
the	O
donor	O
added	O
.	O

2.7.2	O
Compound	B
4	I
Fucα	B
-	I
p	I
NP	I
(	O
60	O
mg	O
)	O
and	O
lactose	B
(	O
1.4	O
g	O
)	O
were	O
dissolved	O
in	O
20	O
mL	O
of	O
20	O
mM	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
)	O
,	O
and	O
the	O
same	O
enzyme	O
(	O
0.6	O
U	O
)	O
was	O
then	O
added	O
.	O

The	O
mixture	O
was	O
then	O
applied	O
to	O
an	O
activated	O
charcoal	B
–	O
Celite	B
column	O
as	O
already	O
described	O
,	O
with	O
the	O
same	O
elution	O
conditions	O
.	O

The	O
eluate	O
,	O
collected	O
in	O
20-mL	O
fractions	O
,	O
showed	O
one	O
main	O
peak	O
(	O
2020–2220	O
mL	O
)	O
as	O
the	O
transfer	O
product	O
.	O

The	O
fraction	O
was	O
collected	O
,	O
concentrated	O
,	O
and	O
lyophilized	O
,	O
giving	O
4	B
(	O
35.2	O
mg	O
)	O
in	O
34	O
%	O
yield	O
,	O
based	O
on	O
the	O
donor	O
.	O

Compound	B
4	I
had	O
m	O
/	O
z	O
489	O
[	O
M+H	O
]	O
+	O
;	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
,	O
26	O
°	O
C	O
)	O
:	O
δ	O
5.23	O
(	O
d	O
,	O
J	O
1,2	O
3.96	O
Hz	O
,	O
H-1α	O
)	O
,	O
5.18	O
(	O
d	O
,	O
J	O
1,2	O
3	O
96	O
Hz	O
,	O
H-1′′	O
)	O
,	O
4.68	O
(	O
d	O
,	O
J	O
1,2	O
8.25	O
Hz	O
,	O
H-1β	O
)	O
,	O
4.52	O
(	O
t	O
,	O
H-1′	O
)	O
,	O
and	O
1.26	O
(	O
H-6′′	O
)	O
;	O
13	O
C	O
NMR	O
(	O
D2	B
O	I
)	O
:	O
δ	O
105.33	O
(	O
C-1′	O
)	O
,	O
103.74	O
(	O
C-1′′	O
)	O
,	O
98.60	O
(	O
C-1α	O
)	O
,	O
94.64	O
(	O
C-1β	O
)	O
,	O
83.16	O
(	O
C-3′	O
)	O
,	O
81.31	O
(	O
C-4α	O
)	O
,	O
8l.19	O
(	O
C-4β	O
)	O
,	O
78.09	O
(	O
C-5′	O
)	O
,	O
77.61	O
(	O
C-5β	O
)	O
,	O
77.23	O
(	O
C-3β	O
)	O
,	O
76.64	O
(	O
C-2β	O
)	O
,	O
74.59	O
(	O
C-4′′	O
)	O
,	O
74.29	O
(	O
C-3α	O
)	O
,	O
73.98	O
(	O
C-2α	O
)	O
,	O
73.24	O
(	O
C-2′	O
)	O
,	O
72.92	O
(	O
C-5α	O
)	O
,	O
72.24	O
(	O
C-3′′	O
)	O
,	O
71.46	O
(	O
C-4′	O
)	O
,	O
71.27	O
(	O
C-2′′	O
)	O
,	O
69.99	O
(	O
C-5′′	O
)	O
,	O
63.77	O
(	O
C-6′	O
)	O
,	O
62.93	O
(	O
C-6β	O
)	O
,	O
62.80	O
(	O
C-6α	O
)	O
,	O
and	O
18.17	O
(	O
C-6′′	O
)	O
.	O

Other	O
related	O
compounds	O
,	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-Glc	I
-	I
OMe	I
,	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Glc	I
-	I
OMe	I
,	O
and	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-GlcNAc	I
-	I
OMe	I
,	O
were	O
prepared	O
according	O
to	O
the	O
same	O
method	O
as	O
already	O
described	O
.	O

The	O
yields	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-Glc	I
-	I
OMe	I
had	O
m	O
/	O
z	O
503	O
[	O
M+H	O
]	O
+	O
;	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
,	O
26	O
°	O
C	O
)	O
:	O
δ	O
5.18	O
(	O
d	O
,	O
J	O
1,2	O
3.96	O
Hz	O
,	O
H-1′′	O
)	O
,	O
4.51	O
(	O
t	O
,	O
H-1′	O
)	O
,	O
4.41	O
(	O
d	O
,	O
J	O
1,2	O
7.92	O
Hz	O
,	O
H-1	O
)	O
,	O
and	O
1.22	O
(	O
H-6′′	O
)	O
;	O
13	O
C	O
NMR	O
(	O
D2	B
O	I
)	O
:	O
δ	O
105.91	O
(	O
C-1′	O
)	O
,	O
105.55	O
(	O
C-1	O
)	O
,	O
103.74	O
(	O
C-1′′	O
)	O
,	O
83.14	O
(	O
C-3′	O
)	O
,	O
81.22	O
(	O
C-4	O
)	O
,	O
78.09	O
(	O
C-5′	O
)	O
,	O
77.57	O
(	O
C-5	O
)	O
,	O
77.25	O
(	O
C-3	O
)	O
,	O
75.61	O
(	O
C-2	O
)	O
,	O
74.59	O
(	O
C-4′′	O
)	O
,	O
73.22	O
(	O
C-2′	O
)	O
,	O
72.22	O
(	O
C-3′′	O
)	O
,	O
71.45	O
(	O
C-4′	O
)	O
,	O
71.25	O
(	O
C-2′′	O
)	O
,	O
69.99	O
(	O
C-5′′	O
)	O
,	O
63.76	O
(	O
C-6′	O
)	O
,	O
62.89	O
(	O
C-6	O
)	O
,	O
60.04	O
(	O
OC	O
H3	O
)	O
,	O
and	O
18.15	O
(	O
C-6′′	O
)	O
.	O

α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Glc	I
-	I
OMe	I
had	O
m	O
/	O
z	O
503	O
[	O
M+H	O
]	O
+	O
;	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
,	O
26	O
°	O
C	O
)	O
:	O
δ	O
5.19	O
(	O
d	O
,	O
J	O
1,2	O
3.96	O
Hz	O
,	O
H-1′′	O
)	O
,	O
4.74	O
(	O
d	O
,	O
J	O
1,2	O
7.26	O
Hz	O
,	O
H-1	O
)	O
,	O
4.43	O
(	O
d	O
,	O
J	O
1,2	O
8.25	O
Hz	O
,	O
H-1′	O
)	O
,	O
and	O
1.22	O
(	O
H-6′′	O
)	O
;	O
13	O
C	O
NMR	O
(	O
D2	B
O	I
)	O
:	O
δ	O
105.87	O
(	O
C-1′	O
)	O
,	O
105.77	O
(	O
C-1	O
)	O
,	O
103.74	O
(	O
C-1′′	O
)	O
,	O
87.31	O
(	O
C-3	O
)	O
,	O
83.38	O
(	O
C-3′	O
)	O
,	O
78.31	O
(	O
C-5	O
)	O
,	O
78.08	O
(	O
C-5′	O
)	O
,	O
75.58	O
(	O
C-2	O
)	O
,	O
74.57	O
(	O
C-4′′	O
)	O
,	O
73.44	O
(	O
C-2′	O
)	O
,	O
72.22	O
(	O
C-3′′	O
)	O
,	O
71.45	O
(	O
C-2′′	O
)	O
,	O
71.25	O
(	O
C-4′	O
)	O
,	O
71.09	O
(	O
C-4	O
)	O
,	O
70.01	O
(	O
C-5′′	O
)	O
,	O
63.76	O
(	O
C-6′	O
)	O
,	O
62.89	O
(	O
C-6	O
)	O
,	O
60.04	O
(	O
OCH3	O
)	O
,	O
and	O
18.15	O
(	O
C-6′′	O
)	O
.	O

α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-GlcNAc	I
-	I
OMe	I
had	O
m	O
/	O
z	O
544	O
[	O
M+H	O
]	O
+	O
;	O
1	O
H	O
NMR	O
(	O
D2	B
O	I
,	O
26	O
°	O
C	O
)	O
:	O
δ	O
5.15	O
(	O
d	O
,	O
J	O
1,2	O
3	O
96	O
Hz	O
,	O
H-1′′	O
)	O
,	O
4.51	O
(	O
t	O
,	O
H-1′	O
)	O
,	O
4.44	O
(	O
d	O
,	O
J	O
1,2	O
7.26	O
Hz	O
,	O
H-1	O
)	O
,	O
and	O
1.22	O
(	O
H-6′′	O
)	O
;	O
13	O
C	O
NMR	O
(	O
D2	B
O	I
)	O
:	O
δ	O
177.55	O
(	O
CO	O
)	O
,	O
105.55	O
(	O
C-1′	O
)	O
,	O
104.76	O
(	O
C-1	O
)	O
,	O
103.79	O
(	O
C-1′′	O
)	O
,	O
83.22	O
(	O
C-3′	O
)	O
,	O
81.38	O
(	O
C-4	O
)	O
,	O
78.15	O
(	O
C-5′	O
)	O
,	O
77.65	O
(	O
C-5	O
)	O
,	O
75.45	O
(	O
C-3	O
)	O
,	O
74.64	O
(	O
C-4′′	O
)	O
,	O
73.31	O
(	O
C-2′	O
)	O
,	O
72.29	O
(	O
C-3′′	O
)	O
,	O
71.50	O
(	O
C-4′	O
)	O
,	O
71.30	O
(	O
C-2′′	O
)	O
,	O
70.06	O
(	O
C-5′′	O
)	O
,	O
63.81	O
(	O
C-6′	O
)	O
,	O
62.95	O
(	O
C-6	O
)	O
,	O
59.98	O
(	O
OCH3	O
)	O
,	O
57.86	O
(	O
C-2	O
)	O
,	O
25.05	O
(	O
COC	O
H3	O
)	O
and	O
18.22	O
(	O
C-6′′	O
)	O
.	O

2.8	O
Hydrolysis	O
reaction	O
of	O
Alcaligenes	O
sp.	O
α	O
-	O
l	O
-fucosidase	O
on	O
O	B
-	I
α	I
-	I
l	I
-fucosyllactose	I
To	O
a	O
200	O
μL	O
solution	O
containing	O
5	O
mM	O
of	O
4	O
or	O
2′-O	B
-α	I
-	I
l	I
-fucosyllactose	I
in	O
0.1	O
M	O
sodium	B
phosphate	I
buffer	O
(	O
pH	O
8)	O
,	O
44	O
mU	O
of	O
α	B
-	I
l	I
-fucosidase	I
from	O
Alcaligenes	O
sp.	O
was	O
added	O
.	O

The	O
solution	O
was	O
incubated	O
at	O
50	O
°	O
C	O
and	O
samples	O
(	O
10	O
μL	O
)	O
were	O
taken	O
out	O
at	O
appropriate	O
time	O
intervals	O
(	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
and	O
15	O
min	O
)	O
during	O
the	O
incubation	O
.	O

After	O
boiling	O
for	O
5	O
min	O
,	O
the	O
mono-	B
and	O
oligosaccharides	B
were	O
derivatized	O
with	O
ethyl	B
p	I
-aminobenzoate	I
according	O
to	O
the	O
published	O
methods	O
[	O
14,15	O
]	O
.	O

The	O
derivatized	O
sugars	B
were	O
analyzed	O
on	O
a	O
Hitachi	O
F-1050	O
fluorescence	O
spectrophotometer	O
by	O
HPLC	O
with	O
a	O
Wakosil	O
-	O
II	O
5C18	O
HG	O
column	O
(	O
4.6	O
cm	O
diameter	O
×	O
150	O
mm	O
,	O
Wako	O
Pure	O
Chemical	O
Industries	O
,	O
Ltd.	O
,	O
Osaka	O
,	O
Japan	O
)	O
eluted	O
with	O
1:9	O
MeCN–0.02	B
%	O
trifluoroacetic	B
acid	I
at	O
a	O
flow	O
rate	O
of	O
1	O
mL	O
/	O
min	O
.	O

3	O
3	O
.	O

Results	O
and	O
discussion	O
3.1	O
Transglycosylation	O
reaction	O
using	O
α	O
-	O
l	O
-fucosidase	O
from	O
porcine	O
liver	O
A	O
crude	O
α	O
-	O
l	O
-fucosidase	O
preparation	O
from	O
porcine	O
liver	O
,	O
prepared	O
by	O
precipitation	O
with	O
20–65	O
%	O
saturated	O
ammonium	B
sulfate	I
,	O
was	O
applied	O
to	O
a	O
CM	O
-	O
Sepharose	O
Fast	O
Flow	O
column	O
.	O

Most	O
of	O
the	O
β	O
-	O
d	O
-galactosidase	O
,	O
which	O
hydrolyzes	O
the	O
LacNAc	B
used	O
as	O
acceptor	O
,	O
was	O
not	O
absorbed	O
by	O
the	O
gel	O
and	O
eluted	O
out	O
with	O
50	O
mM	O
NaOAc	B
buffer	O
(	O
pH	O
6	O
)	O
,	O
and	O
the	O
adsorbed	O
part	O
of	O
α	O
-	O
l	O
-fucosidase	O
was	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
NaCl	B
from	O
0	O
to	O
1	O
M.	O
The	O
partially	O
purified	O
enzyme	O
preparation	O
,	O
almost	O
devoid	O
of	O
β	O
-	O
d	O
-galactosidase	O
activity	O
,	O
was	O
used	O
for	O
the	O
fucosylation	O
reaction	O
without	O
further	O
purification	O
.	O

Transglycosylation	O
of	O
α	O
-	O
l	O
-fucosidase	O
from	O
porcine	O
liver	O
was	O
performed	O
with	O
Fucα	B
-	I
p	I
NP	I
and	O
LacNAc	B
for	O
30	O
h	O
at	O
40	O
°	O
C	O
.	O

Compounds	B
1	I
–3	I
were	O
isolated	O
from	O
the	O
reaction	O
mixture	O
by	O
an	O
activated	O
charcoal	B
–	O
Celite	B
column	O
(	O
Fig.	O
1	O
)	O
in	O
the	O
ratio	O
of	O
40:37:23	O
.	O

These	O
products	O
were	O
obtained	O
in	O
13	O
%	O
total	O
yield	O
,	O
based	O
on	O
the	O
donor	O
added	O
.	O

Compounds	B
1	I
–3	I
all	O
showed	O
molecular	O
ions	O
at	O
m	O
/	O
z	O
530	O
for	O
[	O
M+H	O
]	O
+	O
by	O
FABMS	O
,	O
together	O
with	O
fragment	O
ions	O
at	O
m	O
/	O
z	O
204	O
,	O
222	O
,	O
366	O
,	O
384	O
,	O
and	O
512	O
(	O
HexNAc	B
–	O
water	B
,	O
HexNAc	B
,	O
deoxyHex	B
-	I
HexNAc	I
,	O
Hex	B
-	I
HexNAc	I
,	O
and	O
deoxyHex	B
-	I
Hex	I
-	I
HexNAc	I
–	O
water	B
,	O
respectively	O
)	O
.	O

These	O
data	O
show	O
the	O
trisaccharides	B
to	O
consist	O
of	O
deoxyHex	B
-	I
Hex	I
-	I
HexNAc	I
.	I

Further	O
,	O
the	O
structures	O
of	O
1	O
–3	O
were	O
elucidated	O
by	O
1	O
H	O
and	O
13	O
C	O
NMR	O
.	O

Table	O
1	O
summarizes	O
13	O
C	O
NMR	O
spectral	O
data	O
of	O
these	O
compounds	O
.	O

Compounds	B
1	I
–3	I
were	O
thus	O
identified	O
as	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→2	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-GlcNAc	I
,	I
α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-GlcNAc	I
,	O
and	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→6	I
)	I
-β	I
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-d	I
-GlcNAc	I
,	O
respectively	O
.	O

Fig.	O
2	O
shows	O
the	O
transglycosylation	O
profile	O
induced	O
by	O
the	O
α	O
-	O
l	O
-fucosidase	O
in	O
a	O
reaction	O
system	O
containing	O
LacNAc	B
acceptor	O
.	O

The	O
transfer	O
products	O
formed	O
were	O
analyzed	O
by	O
HPLC	O
.	O

The	O
time	O
at	O
which	O
maximal	O
production	O
of	O
the	O
total	O
amount	O
of	O
1	O
–3	O
was	O
24	O
h	O
,	O
and	O
the	O
proportions	O
of	O
the	O
three	O
compounds	O
varied	O
little	O
during	O
reaction	O
.	O

The	O
fucosylation	O
shows	O
only	O
low	O
regioselectivity	O
,	O
because	O
it	O
occurs	O
without	O
discrimination	O
at	O
the	O
O-2	O
,	O
O-3	O
,	O
and	O
O-6	O
positions	O
of	O
the	O
Gal	B
moiety	I
,	O
as	O
shown	O
in	O
Fig.	O
3	O
.	O

As	O
a	O
result	O
,	O
the	O
desired	O
compound	B
1	I
was	O
obtained	O
in	O
a	O
low	O
yield	O
of	O
5	O
%	O
based	O
on	O
the	O
donor	O
.	O

No	O
transfer	O
product	O
was	O
observed	O
when	O
lactose	B
instead	O
of	O
LacNAc	B
was	O
used	O
as	O
an	O
acceptor	O
,	O
which	O
was	O
consistent	O
with	O
the	O
result	O
reported	O
by	O
Svensson	O
and	O
Thiem	O
[	O
9	O
]	O
.	O

The	O
porcine	O
liver	O
α	O
-	O
l	O
-fucosidase	O
-	O
mediated	O
fucosylation	O
seems	O
to	O
recognize	O
subtle	O
differences	O
in	O
the	O
acceptor	O
structure	O
.	O

3.2	O
Transglycosylation	O
reaction	O
utilizing	O
α	O
-	O
l	O
-fucosidase	O
from	O
Alcaligenes	O
sp	O
An	O
α	O
-	O
l	O
-fucosidase	O
from	O
the	O
culture	O
of	O
Alcaligenes	O
sp.	O
was	O
partially	O
purified	O
by	O
successive	O
chromatography	O
on	O
Streamline	O
-	O
DEAE	B
and	O
Butyl	O
-	O
Toyopearl	O
650	O
M	O
columns	O
,	O
and	O
by	O
affinity	O
chromatography	O
on	O
a	O
Fucose	B
–	O
Cellulofine	O
column	O
.	O

The	O
partially	O
purified	O
enzyme	O
,	O
completely	O
devoid	O
of	O
β	O
-	O
d	O
-galactosidase	O
activity	O
,	O
was	O
used	O
for	O
the	O
enzyme	O
synthesis	O
.	O

Compound	B
2	I
has	O
been	O
synthesized	O
by	O
a	O
chemical	B
method	O
[	O
16	O
]	O
.	O

However	O
,	O
it	O
involved	O
elaborate	O
procedures	O
for	O
protection	O
,	O
glycosylation	O
,	O
and	O
deprotection	O
[	O
16	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
compound	O
2	O
was	O
efficiently	O
synthesized	O
from	O
LacNAc	B
and	O
Fucα	B
-	I
p	I
NP	I
on	O
a	O
100-mmol	O
scale	O
by	O
transglycosylation	O
utilizing	O
the	O
α	O
-	O
l	O
-fucosidase	O
.	O

It	O
was	O
conveniently	O
isolated	O
by	O
activated	O
charcoal	B
–	O
Celite	B
chromatography	O
in	O
high	O
yield	O
(	O
54	O
%	O
)	O
,	O
based	O
on	O
the	O
donor	O
added	O
.	O

In	O
this	O
case	O
,	O
the	O
molar	O
ratio	O
of	O
the	O
donor	O
to	O
acceptor	O
was	O
1:25	O
and	O
the	O
total	O
substrate	O
concentration	O
was	O
∼10	O
%	O
.	O

The	O
production	O
of	O
compound	B
2	I
as	O
a	O
function	O
of	O
time	O
was	O
monitored	O
by	O
HPLC	O
with	O
an	O
Asahipak	O
NH2P-50	O
column	O
.	O

The	O
chromatogram	O
showed	O
that	O
only	O
one	O
transfer	O
product	O
was	O
formed	O
during	O
the	O
entire	O
course	O
of	O
reaction	O
(	O
50	O
h	O
)	O
.	O

This	O
is	O
also	O
the	O
case	O
for	O
the	O
formation	O
of	O
4	B
in	O
the	O
reaction	O
with	O
lactose	B
as	O
the	O
acceptor	O
.	O

Compound	B
4	I
was	O
obtained	O
as	O
a	O
single	O
transfer	O
-	O
product	O
in	O
high	O
yield	O
(	O
34	O
%	O
)	O
,	O
based	O
on	O
the	O
donor	O
.	O

This	O
trisaccharide	B
has	O
been	O
synthesized	O
by	O
Baer	O
and	O
Abbas	O
[	O
17	O
]	O
.	O

Use	O
of	O
other	O
acceptors	O
,	O
β	B
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-GlcNAcOMe	I
,	O
β	B
-	I
d	I
-Gal-	I
(	I
1→4	I
)	I
-β	I
-	I
d	I
-GlcOMe	I
,	O
and	O
β	B
-	I
d	I
-Gal-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-GlcOMe	I
,	O
also	O
resulted	O
in	O
highly	O
regioselective	O
transglycosylation	O
from	O
Fucα	B
-	I
p	I
NP	I
to	O
the	O
3-position	O
of	O
the	O
Gal	B
moiety	I
by	O
use	O
of	O
the	O
α	O
-	O
l	O
-fucosidase	O
(	O
Table	O
2	O
)	O
.	O

This	O
result	O
indicates	O
that	O
introduction	O
of	O
the	O
methyl	B
group	I
at	O
the	O
β	O
anomeric	O
position	O
of	O
the	O
acceptors	O
enhanced	O
the	O
yield	O
of	O
transfer	O
products	O
.	O

These	O
reactions	O
were	O
efficient	O
enough	O
to	O
permit	O
one	O
-	O
pot	O
preparations	O
of	O
compound	B
2	I
and	O
its	O
analogues	B
.	O

In	O
this	O
way	O
,	O
the	O
enzyme	O
fucosylated	O
the	O
O-3′	O
position	O
of	O
the	O
galactose	B
-	I
containing	I
disaccharide	I
acceptors	O
regioselectively	O
,	O
in	O
contrast	O
with	O
the	O
porcine	O
liver	O
enzyme	O
,	O
and	O
generated	O
an	O
unusual	O
carbohydrate	B
linkage	O
.	O

The	O
α	B
-	I
l	I
-Fuc-	I
(	I
1→3	I
)	I
-d	I
-Gal	I
linkage	O
is	O
not	O
found	O
in	O
glycoconjugates	B
isolated	O
from	O
diverse	O
sources	O
,	O
but	O
its	O
presence	O
has	O
been	O
reported	O
as	O
part	O
of	O
higher	O
homologues	O
of	O
oligosaccharides	B
from	O
human	O
milk	O
[	O
18	O
]	O
.	O

Miyauchi	O
et	O
al.	O
have	O
reported	O
that	O
antiserum	O
against	O
3′-O	B
-α	I
-	I
l	I
-fucosyllactose	I
–	I
p	I
-isothiocyanato	I
-	I
phenethylamine	I
–	O
BSA	O
preferentially	O
reacts	O
with	O
adenocarcinoma	O
and	O
embryonal	O
carcinoma	O
cells	O
[	O
19	O
]	O
.	O

It	O
was	O
shown	O
that	O
the	O
unusual	O
oligosaccharide	B
4	I
is	O
useful	O
as	O
a	O
probe	O
for	O
investigating	O
biological	O
functions	O
.	O

In	O
a	O
separate	O
experiment	O
,	O
the	O
relative	O
rates	O
of	O
hydrolysis	O
of	O
2′-O	B
-α	I
-	I
l	I
-fucosyllactose	I
and	O
4	B
were	O
examined	O
using	O
the	O
α	O
-	O
l	O
-fucosidase	O
from	O
Alcaligenes	O
sp.	O

The	O
reactions	O
were	O
linear	O
from	O
3	O
to	O
15	O
min	O
,	O
and	O
the	O
rate	O
of	O
attack	O
on	O
4	B
was	O
arbitrarily	O
set	O
at	O
100	O
.	O

The	O
relative	O
hydrolysis	O
rate	O
of	O
2′-fucosyllactose	B
was	O
77.5	O
as	O
compared	O
with	O
that	O
of	O
4	O
,	O
a	O
difference	O
of	O
only	O
one	O
-	O
fourth	O
.	O

Thus	O
,	O
2′-O	B
-α	I
-	I
l	I
-fucosyllactose	I
seems	O
to	O
be	O
a	O
good	O
substrate	O
for	O
hydrolysis	O
.	O

In	O
general	O
,	O
glycosidases	O
are	O
known	O
to	O
be	O
responsible	O
for	O
both	O
hydrolytic	O
and	O
transfer	O
activities	O
.	O

Therefore	O
,	O
the	O
α	O
-	O
l	O
-fucosidase	O
was	O
also	O
expected	O
to	O
produce	O
a	O
trisaccharide	B
substituted	O
by	O
an	O
α	B
-	I
l	I
-fucosyl	I
group	I
at	O
the	O
O-2′	O
of	O
lactose	B
,	O
in	O
addition	O
to	O
the	O
O-3′	B
substituted	I
product	I
.	O

However	O
,	O
the	O
enzyme	O
induced	O
highly	O
regioselective	O
transglycosylation	O
to	O
the	O
3-position	O
of	O
the	O
Gal	B
moiety	I
from	O
Fucα	B
-	I
p	I
NP	I
and	O
no	O
2′-O	B
-α	I
-	I
l	I
-fucosyllactose	I
was	O
detected	O
during	O
the	O
entire	O
reaction	O
,	O
as	O
already	O
mentioned	O
.	O

There	O
may	O
be	O
other	O
factors	O
affecting	O
the	O
regioselectivity	O
of	O
this	O
transglycosylation	O
reaction	O
.	O

In	O
conclusion	O
,	O
a	O
fucosylated	B
trisaccharide	I
1	I
of	O
the	O
type	O
2	O
blood	O
group	O
H	O
substance	O
was	O
prepared	O
by	O
using	O
porcine	O
liver	O
α	O
-	O
l	O
-fucosidase	O
-	O
mediated	O
transglycosylation	O
.	O

We	O
have	O
also	O
developed	O
a	O
practical	O
synthetic	O
method	O
for	O
obtaining	O
fucosylated	B
trisaccharides	I
2	B
and	O
4	B
,	O
which	O
contain	O
the	O
unusual	O
α-	O
(	O
1→3	O
)	O
linkage	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
Grants	O
-	O
in	O
-	O
Aid	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
,	O
and	O
Culture	O
,	O
Japan	O
,	O
by	O
the	O
Research	O
Grant	O
for	O
Leading	O
Research	O
Utilizing	O
Potential	O
of	O
Regional	O
Science	O
and	O
Technology	O
from	O
Science	O
and	O
Technology	O
Agency	O
,	O
Japan	O
,	O
and	O

by	O
a	O
Research	O
Grant	O
from	O
the	O
Ministry	O
of	O
Agriculture	O
,	O
Forestry	O
and	O
Fisheries	O
,	O
Japan	O
.	O

Cytochrome	O
P450	O
(	O
CYP	O
)	O
enzymes	O
are	O
heme	O
-	O
thiolate	O
proteins	O
that	O
are	O
responsible	O
for	O
the	O
oxidative	O
metabolism	O
of	O
a	O
wide	O
variety	O
of	O
xenobiotics	B
[	O
1	O
]	O
.	O

They	O
comprise	O
a	O
superfamily	O
of	O
related	O
enzymes	O
that	O
are	O
grouped	O
into	O
families	O
and	O
subfamilies	O
based	O
on	O
similarities	O
in	O
amino	B
acid	I
sequences	O
.	O

The	O
determination	O
of	O
the	O
CYP	O
enzymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
new	O
chemical	B
entities	I
(	O
NCE	O
)	O
and	O
the	O
identification	O
of	O
interactions	O
with	O
a	O
specific	O
CYP	O
isozyme	O
(	O
e.g.	O
inhibition	O
of	O
that	O
isozyme	O
)	O
can	O
aid	O
in	O
predicting	O
clinical	O
drug	B
interactions	O
[	O
2	O
]	O
.	O

The	O
CYP	O
family	O
of	O
enzymes	O
has	O
been	O
shown	O
to	O
be	O
responsible	O
for	O
the	O
hydroxylation	O
of	O
steroids	B
and	O
related	B
compounds	I
.	O

Specifically	O
,	O
the	O
6β	O
-	O
hydroxylation	O
of	O
testosterone	B
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
CYP3A	O
family	O
of	O
CYP	O
enzymes	O
in	O
a	O
variety	O
of	O
species	O
[	O
3	O
]	O
.	O

By	O
measuring	O
the	O
rate	O
of	O
formation	O
of	O
the	O
testosterone	B
metabolite	I
,	O
6β	B
-	I
hydroxytestosterone	I
,	O
the	O
CYP3A	O
activity	O
of	O
a	O
preparation	O
of	O
hepatic	O
microsomes	O
can	O
be	O
determined	O
.	O

Several	O
HPLC	O
methods	O
have	O
been	O
reported	O
for	O
the	O
separation	O
of	O
testosterone	B
and	O
its	O
many	O
hydroxylated	B
metabolites	I
[	O
3–9	O
]	O
.	O

Most	O
use	O
gradient	O
elution	O
with	O
run	O
times	O
greater	O
than	O
30	O
min	O
followed	O
by	O
an	O
additional	O
between	O
-	O
run	O
reequilibration	O
.	O

Some	O
of	O
these	O
methods	O
require	O
complex	O
gradient	O
systems	O
that	O
often	O
cause	O
significant	O
changes	O
in	O
the	O
baseline	O
that	O
affect	O
resolution	O
and	O
detection	O
of	O
later	O
-	O
eluting	O
peaks	O
.	O

In	O
an	O
attempt	O
to	O
alleviate	O
some	O
of	O
these	O
problems	O
,	O
an	O
isocratic	O
HPLC	O
method	O
has	O
been	O
developed	O
[	O
8	O
]	O
,	O
however	O
,	O
the	O
total	O
run	O
time	O
for	O
this	O
method	O
is	O
still	O
greater	O
than	O
30	O
min	O
.	O

A	O
slightly	O
faster	O
capillary	O
electrophoretic	O
method	O
has	O
recently	O
been	O
reported	O
[	O
10	O
]	O
with	O
a	O
run	O
time	O
of	O
20	O
min	O
and	O
two	O
between	O
-	O
run	O
rinses	O
totaling	O
5	O
min	O
.	O

This	O
method	O
,	O
however	O
,	O
suffers	O
from	O
poor	O
sensitivity	O
and	O
poor	O
inter	O
-	O
day	O
migration	O
time	O
reproducibility	O
.	O

Watanabe	O
et	O
al.	O
have	O
reported	O
a	O
more	O
rapid	O
gas	O
chromatography	O
–	O
mass	O
spectrometry	O
(	O
GC	O
–	O
MS	O
)	O
method	O
[	O
11	O
]	O
,	O
but	O
it	O
requires	O
an	O
extraction	O
step	O
and	O
a	O
timely	O
multi	O
-	O
step	O
derivatization	O
of	O
the	O
hydroxylated	B
metabolites	I
.	O

In	O
addition	O
,	O
separable	O
syn	B
-	I
and	O
anti	B
-isomers	I
of	I
some	O
of	O
the	O
derivatized	B
metabolites	I
are	O
formed	O
.	O

A	O
rapid	O
non	O
-	O
chromatographic	O
procedure	O
employing	O
tritium	B
-	I
labeled	I
testosterone	I
was	O
also	O
recently	O
published	O
[	O
12	O
]	O
.	O

Safety	O
and	O
cost	O
considerations	O
make	O
this	O
method	O
far	O
from	O
ideal	O
.	O

Herein	O
is	O
described	O
a	O
method	O
for	O
the	O
determination	O
of	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
employing	O
gas	O
chromatography	O
with	O
selected	O
ion	O
monitoring	O
mass	O
spectrometric	O
detection	O
(	O
GC	O
–	O
SIM	O
–	O
MS	O
)	O
.	O

The	O
method	O
does	O
not	O
require	O
derivatization	O
and	O
testosterone	B
and	O
its	O
metabolites	B
are	O
separated	O
in	O
less	O
than	O
15	O
min	O
.	O

In	O
addition	O
,	O
the	O
selectivity	O
and	O
specificity	O
of	O
the	O
mass	O
spectrometer	O
helps	O
eliminate	O
interferences	O
from	O
compounds	O
being	O
evaluated	O
using	O
this	O
methodology	O
which	O
is	O
occasionally	O
a	O
problem	O
when	O
using	O
the	O
HPLC	O
–	O
UV	O
or	O
CE	O
–	O
UV	O
methods	O
previously	O
reported	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
Testosterone	B
,	O
17α	B
-	I
methyltestosterone	I
,	O
androstenedione	B
,	O
2β	B
-	I
hydroxytestosterone	I
phenylmethylsulfonyl	B
fluoride	I
(	O
PMSF	B
)	O
,	O
butylated	B
hydroxytoluene	I
(	O
BHT	B
)	O
,	O
and	O
Sigma	O
Ultra	O
grade	O
potassium	B
chloride	I
,	O
EDTA	B
,	O
HEPES	B
,	O
glycerol	B
,	O
and	O
magnesium	B
chloride	I
were	O
obtained	O
from	O
Sigma	O
Chemical	O
Co.	O
(	O
St.	O

Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

2α-	B
,	O
6β-	B
,	O
7α-	B
,	O
16α-	B
,	O
and	O
16β	B
-	I
hydroxytestosterone	I
were	O
obtained	O
from	O
Steraloids	O
,	O
Inc.	O
(	O
Wilton	O
,	O
NH	O
,	O
USA	O
)	O
.	O

HPLC	O
-	O
grade	O
methylene	B
chloride	I
(	O
J.T.	O
Baker	O
)	O
,	O
GC	O
–	O
MS	O
-	O
grade	O
methanol	B
(	O
Burdick	O
and	O
Jackson	O
)	O
,	O
and	O
UV	O
-	O
grade	O
acetonitrile	B
(	O
Burdick	O
and	O
Jackson	O
)	O
were	O
purchased	O
from	O
VWR	O
Scientific	O
Products	O
(	O
Suwanee	O
,	O
GA	O
,	O
USA	O
)	O
.	O

Bovine	O
serum	O
albumin	O
and	O
other	O
materials	O
for	O
determining	O
microsomal	O
protein	O
content	O
were	O
obtained	O
from	O
BioRad	O
(	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

2.2	O
Isolation	O
of	O
hepatic	O
microsomes	O
Human	O
liver	O
microsomes	O
were	O
prepared	O
using	O
a	O
differential	O
centrifugation	O
method	O
as	O
follows	O
:	O
Human	O
livers	O
rejected	O
for	O
transplant	O
were	O
received	O
fresh	O
from	O
the	O
International	O
Institute	O
for	O
the	O
Advancement	O
of	O
Medicine	O
(	O
Exton	O
,	O
PA	O
,	O
USA	O
)	O
in	O
less	O
than	O
36	O
h	O
post	O
-	O
clamp	O
time	O
or	O
frozen	O
from	O
the	O
Association	O
of	O
Human	O
Tissue	O
Users	O
(	O
Tucson	O
,	O
AZ	O
,	O
USA	O
)	O
.	O

The	O
liver	O
tissue	O
was	O
minced	O
and	O
rinsed	O
in	O
a	O
1.15	O
%	O
(	O
w	O
/	O
v	O
)	O
KCl	B
solution	O
.	O

The	O
tissue	O
was	O
weighed	O
,	O
washed	O
in	O
three	O
volumes	O
of	O
a	O
homogenization	O
buffer	O
(	O
100	O
mM	O
Tris	B
acetate	I
,	O
1	O
mM	O
EDTA	B
,	O
100	O
mM	O
KCl	B
,	O
20	O
μM	O
BHT	B
,	O
pH	O
7.4	O
)	O
and	O
then	O
homogenized	O
in	O
a	O
motorized	O
homogenizer	O
(	O
Omni	O
International	O
,	O
Atlanta	O
,	O
GA	O
,	O
USA	O
)	O
with	O
two	O
20	O
s	O
bursts	O
.	O

The	O
homogenate	O
was	O
centrifuged	O
at	O
approximately	O
10	O
000	O
g	O
for	O
30	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatant	O
(	O
s9	O
)	O
was	O
transferred	O
to	O
fresh	O
centrifuge	O
tubes	O
and	O
then	O
centrifuged	O
at	O
approximately	O
100	O
000	O
g	O
for	O
70	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
pellet	O
was	O
washed	O
once	O
in	O
1.5	O
volumes	O
of	O
a	O
buffer	O
containing	O
100	O
mM	O
tetrapotassium	B
pyrophosphate	I
,	O
1	O
mM	O
EDTA	B
,	O
and	O
20	O
μM	O
BHT	B
(	O
adjusted	O
to	O
pH	O
7.4	O
with	O
6	O
M	O
HCl	B
)	O
by	O
resuspending	O
and	O
homogenizing	O
in	O
a	O
glass	B
dounce	O
homogenizer	O
.	O

The	O
resuspended	O
pellet	O
was	O
centrifuged	O
again	O
at	O
100	O
000	O
g	O
for	O
70	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
resulting	O
pellet	O
was	O
resuspended	O
in	O
a	O
storage	O
buffer	O
(	O
10	O
mM	O
Tris	B
acetate	I
,	O
1	O
mM	O
EDTA	B
,	O
100	O
μM	O
PMSF	B
,	O
and	O
20	O
%	O
glycerol	B
,	O
pH	O
7.4	O
)	O
using	O
the	O
glass	B
dounce	O
homogenizer	O
,	O
aliquoted	O
(	O
1	O
ml	O
)	O
into	O
screw	O
-	O
cap	O
cryovials	O
,	O
and	O
stored	O
at	O
−80	O
°	O
C	O
until	O
use	O
.	O

Microsomal	O
protein	O
content	O
was	O
determined	O
using	O
the	O
Bradford	O
method	O
[	O
13	O
]	O
and	O
total	O
CYP	O
content	O
was	O
determined	O
spectrophotometrically	O
using	O
the	O
method	O
of	O
Omura	O
and	O
Sato	O
[	O
14	O
]	O
.	O

2.3	O
Microsomal	O
incubations	O
A	O
total	O
incubation	O
volume	O
of	O
500	O
μl	O
of	O
HEPES	B
buffer	O
(	O
50	O
mM	O
HEPES	B
,	O
15	O
mM	O
MgCl2	B
,	O
0.1	O
mM	O
EDTA	B
,	O
pH	O
7.6	O
)	O
containing	O
an	O
NADPH	B
regeneration	O
system	O
(	O
1	O
mM	O
NADP+	B
,	O
10	O
mM	O
glucose	B
6-phosphate	I
,	O
and	O
1	O
IU	O
glucose	B
6-phosphate	I
dehydrogenase	I
)	O
and	O
hepatic	O
microsomes	O
(	O
0.5	O
mg	O
protein	O
)	O
was	O
pre	O
-	O
incubated	O
at	O
37	O
°	O
C	O
for	O
3	O
min	O
.	O

The	O
enzymatic	O
reaction	O
was	O
initiated	O
upon	O
addition	O
of	O
testosterone	B
(	O
100	O
μM	O
,	O
from	O
10	O
mM	O
stock	O
in	O
MeOH	B
)	O
.	O

Blank	O
incubations	O
were	O
prepared	O
in	O
the	O
absence	O
of	O
the	O
NADPH	B
-	O
regeneration	O
system	O
.	O

Following	O
a	O
30	O
min	O
incubation	O
at	O
37	O
°	O
C	O
,	O
the	O
reaction	O
was	O
terminated	O
with	O
3	O
ml	O
of	O
methylene	B
chloride	I
.	O

After	O
the	O
addition	O
of	O
50	O
μl	O
of	O
methyltestosterone	B
internal	O
standard	O
solution	O
(	O
100	O
μM	O
)	O
,	O
the	O
samples	O
were	O
vortexed	O
for	O
about	O
30	O
s	O
and	O
then	O
centrifuged	O
at	O
1400	O
g	O
for	O
2	O
min	O
.	O

The	O
top	O
aqueous	O
layer	O
and	O
any	O
precipitate	O
at	O
the	O
phase	O
interface	O
was	O
aspirated	O
.	O

The	O
remaining	O
methylene	B
chloride	I
layer	O
was	O
evaporated	O
to	O
dryness	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	B
.	O

Acetonitrile	B
(	O
0.5	O
ml	O
)	O
was	O
added	O
,	O
and	O
each	O
tube	O
was	O
vortexed	O
briefly	O
.	O

Finally	O
,	O
the	O
content	O
of	O
each	O
tube	O
was	O
transferred	O
to	O
an	O
autosampler	O
vial	O
for	O
GC	O
–	O
SIM	O
–	O
MS	O
analysis	O
.	O

2.4	O
Calibration	O
standard	O
preparation	O
A	O
stock	O
solution	O
containing	O
testosterone	B
(	O
1	O
mM	O
)	O
and	O
6β	B
-	I
hydroxytestosterone	I
(	O
1	O
mM	O
)	O
was	O
prepared	O
in	O
methanol	B
and	O
stored	O
at	O
4	O
°	O
C	O
.	O

Working	O
solutions	O
of	O
varying	O
concentrations	O
down	O
to	O
2.5	O
μM	O
were	O
prepared	O
from	O
dilutions	O
of	O
the	O
stock	O
solution	O
with	O
methanol	B
.	O

Calibration	O
standard	O
samples	O
(	O
0.25	O
μM	O
,	O
0.50	O
μM	O
,	O
1.0	O
μM	O
,	O
5.0	O
μM	O
,	O
10	O
μM	O
,	O
50	O
μM	O
,	O
and	O
100	O
μM	O
)	O
covering	O
a	O
calibration	O
range	O
of	O
0.25	O
to	O
100	O
μM	O
were	O
prepared	O
by	O
adding	O
50	O
μl	O
of	O
each	O
working	O
solution	O
to	O
400	O
μl	O
water	B
and	O
50	O
μl	O
of	O
HEPES	B
buffer	O
.	O

The	O
samples	O
were	O
spiked	O
with	O
50	O
μl	O
of	O
methyltestosterone	B
internal	O
standard	O
solution	O
(	O
100	O
μM	O
)	O
and	O
extracted	O
as	O
described	O
above	O
for	O
the	O
microsomal	O
incubates	O
.	O

2.5	O
GC	O
–	O
MS	O
conditions	O
The	O
samples	O
were	O
analyzed	O
on	O
a	O
HP5890	O
Series	O
II	O
Gas	O
Chromatograph	O
interfaced	O
to	O
a	O
HP5971A	O
Mass	O
Selective	O
Detector	O
(	O
Hewlett	O
-	O
Packard	O
,	O
Palo	O
Alto	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Testosterone	B
,	O
its	O
metabolites	B
,	O
and	O
the	O
internal	O
standard	O
were	O
separated	O
on	O
a	O
HP-5MS	O
capillary	O
column	O
(	O
30	O
m	O
×	O
0.25	O
mm	O
,	O
0.25	O
μm	O
film	O
thickness	O
)	O
that	O
was	O
introduced	O
directly	O
into	O
the	O
source	O
of	O
the	O
mass	O
spectrometer	O
.	O

The	O
capillary	O
column	O
flow	O
-	O
rate	O
(	O
He	O
)	O
was	O
kept	O
constant	O
at	O
approximately	O
1	O
ml	O
/	O
min	O
.	O

using	O
electronic	O
pressure	O
control	O
.	O

A	O
1	O
μl	O
splitless	O
injection	O
was	O
made	O
using	O
a	O
purge	O
activation	O
time	O
of	O
1	O
min	O
.	O

The	O
injection	O
port	O
temperature	O
was	O
280	O
°	O
C	O
.	O

The	O
oven	O
was	O
held	O
at	O
80	O
°	O
C	O
for	O
1	O
min	O
and	O
then	O
ramped	O
at	O
20	O
°	O
C	O
per	O
min	O
to	O
a	O
final	O
temperature	O
of	O
300	O
°	O
C	O
and	O
held	O
for	O
3	O
min	O
.	O

Positive	O
-	O
ion	O
electron	O
ionization	O
mass	O
spectra	O
were	O
acquired	O
at	O
an	O
electron	O
energy	O
of	O
70	O
eV	O
with	O
an	O
ion	O
source	O
temperature	O
of	O
170	O
°	O
C	O
and	O
an	O
interface	O
temperature	O
of	O
280	O
°	O
C	O
.	O

For	O
quantitation	O
,	O
the	O
mass	O
spectrometer	O
was	O
operated	O
in	O
the	O
selected	O
ion	O
monitoring	O
mode	O
and	O
set	O
to	O
monitor	O
ions	O
at	O
m	O
/	O
z	O
288	O
,	O
304	O
,	O
and	O
302	O
(	O
100	O
ms	O
per	O
ion	O
)	O
for	O
testosterone	B
,	O
6β	B
-	I
hydroxytestosterone	I
,	O
and	O
methyltestosterone	B
,	O
respectively	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Method	O
development	O
Full	O
scan	O
positive	O
ion	O
electron	O
impact	O
mass	O
spectra	O
(	O
50–350	O
amu	O
)	O
of	O
testosterone	B
,	O
methyltestosterone	B
,	O
and	O
6β	B
-	I
hydroxytestosterone	I
were	O
acquired	O
to	O
determine	O
the	O
ions	O
to	O
monitor	O
in	O
the	O
SIM	O
mode	O
.	O

Representative	O
spectra	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

The	O
base	O
peak	O
in	O
the	O
mass	O
spectrum	O
of	O
testosterone	B
was	O
a	O
common	O
steroid	B
fragment	O
,	O
m	O
/	O
z	O
124	O
.	O

Therefore	O
,	O
the	O
molecular	O
ion	O
(	O
m	O
/	O
z	O
288	O
)	O
,	O
which	O
is	O
less	O
abundant	O
but	O
more	O
specific	O
,	O
was	O
chosen	O
for	O
testosterone	B
.	O

The	O
base	O
peaks	O
for	O
methyltestosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
were	O
the	O
molecular	O
ions	O
,	O
m	O
/	O
z	O
302	O
and	O
m	O
/	O
z	O
304	O
,	O
respectively	O
.	O

These	O
ions	O
were	O
selected	O
for	O
the	O
GC	O
–	O
SIM	O
–	O
MS	O
method	O
.	O

A	O
representative	O
chromatogram	O
from	O
a	O
sample	O
containing	O
testosterone	B
after	O
incubation	O
with	O
human	O
liver	O
microsomes	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

The	O
retention	O
times	O
of	O
testosterone	B
,	O
methyltestosterone	B
,	O
and	O
6β	B
-	I
hydroxytestosterone	I
were	O
approximately	O
12.7	O
,	O
12.8	O
,	O
and	O
13.4	O
min	O
,	O
respectively	O
.	O

Even	O
without	O
derivatization	O
,	O
no	O
significant	O
tailing	O
of	O
the	O
chromatographic	O
peaks	O
occurred	O
.	O

In	O
addition	O
,	O
no	O
thermal	O
degradation	O
of	O
the	O
steroids	B
was	O
observed	O
.	O

3.2	O
Specificity	O
The	O
method	O
was	O
evaluated	O
for	O
possible	O
interferences	O
from	O
other	O
known	O
CYP450	O
metabolites	B
of	I
testosterone	I
.	O

Androstenedione	B
(	O
12.6	O
min	O
)	O
,	O
2α	B
-	I
hydroxy-	I
(	O
13.1	O
min	O
)	O
,	O
2β	B
-	I
hydroxy-	I
(	O
13.0	O
min	O
)	O
,	O
7α	B
-	I
hydroxy-	I
(	O
13.6	O
min	O
)	O
,	O
16α	B
-	I
hydroxy-	I
(	O
13.8	O
min	O
)	O
,	O
and	O
16β	B
-	I
hydroxytestosterone	I
(	O
13.9	O
min	O
)	O
,	O
were	O
fully	O
resolved	O
from	O
testosterone	B
,	O
6β	B
-	I
hydroxytestosterone	I
,	O
and	O
methyltestosterone	B
.	O

In	O
addition	O
,	O
the	O
inherent	O
selectivity	O
and	O
specificity	O
of	O
the	O
mass	O
spectrometric	O
detector	O
has	O
eliminated	O
interferences	O
from	O
compounds	O
evaluated	O
using	O
this	O
methodology	O
.	O

3.3	O
Linearity	O
Seven	O
calibration	O
standards	O
ranging	O
in	O
concentration	O
from	O
0.25	O
to	O
100	O
μM	O
for	O
both	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
were	O
interspersed	O
with	O
samples	O
for	O
each	O
analytical	O
run	O
.	O

Weighted	O
(	O
1	O
/	O
x	O
2	O
)	O
linear	O
regressions	O
of	O
peak	O
area	O
ratios	O
of	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
to	O
the	O
internal	O
standard	O
,	O
methyltestosterone	B
,	O
as	O
a	O
function	O
of	O
concentration	O
were	O
performed	O
to	O
obtain	O
a	O
standard	O
curve	O
from	O
which	O
unknowns	O
were	O
quantified	O
.	O

Weighted	O
regressions	O
were	O
used	O
to	O
provide	O
homogeneity	O
of	O
variance	O
across	O
the	O
calibration	O
range	O
.	O

The	O
method	O
was	O
linear	O
from	O
0.25	O
to	O
100	O
μM	O
for	O
both	O
compounds	O
.	O

Regression	O
data	O
(	O
slope	O
,	O
intercept	O
,	O
and	O
correlation	O
coefficient	O
)	O
from	O
five	O
successive	O
analytical	O
runs	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Excellent	O
correlation	O
and	O
slope	O
reproducibility	O
was	O
observed	O
for	O
each	O
compound	O
.	O

3.4	O
Precision	O
and	O
accuracy	O
Inter	O
-	O
day	O
precision	O
and	O
accuracy	O
of	O
the	O
method	O
were	O
determined	O
from	O
the	O
back	O
-	O
calculated	O
results	O
for	O
the	O
seven	O
calibration	O
standards	O
for	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
from	O
the	O
five	O
runs	O
listed	O
in	O
Table	O
1	O
.	O

Within	O
-	O
day	O
precision	O
was	O
determined	O
by	O
assaying	O
six	O
replicates	O
at	O
each	O
of	O
three	O
different	O
concentrations	O
of	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
in	O
one	O
analytical	O
run	O
.	O

The	O
results	O
are	O
shown	O
in	O
Table	O
2	O
.	O

Within	O
-	O
day	O
and	O
inter	O
-	O
day	O
precision	O
(	O
expressed	O
as	O
relative	O
standard	O
deviation	O
)	O
was	O
less	O
than	O
5	O
%	O
for	O
all	O
concentrations	O
of	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
.	O

Accuracies	O
ranged	O
from	O
95.8	O
to	O
105.8	O
%	O
for	O
testosterone	B
and	O
94.6	O
to	O
104.2	O
%	O
for	O
6β	B
-	I
hydroxytestosterone	I
.	O

3.5	O
Extraction	O
recovery	O
The	O
extraction	O
recovery	O
of	O
the	O
analytes	O
and	O
internal	O
standard	O
was	O
determined	O
by	O
comparing	O
the	O
peak	O
areas	O
of	O
spiked	O
microsomal	O
samples	O
extracted	O
with	O
methylene	B
chloride	I
to	O
the	O
peak	O
areas	O
of	O
standard	O
solutions	O
at	O
the	O
same	O
concentration	O
not	O
carried	O
through	O
the	O
extraction	O
procedure	O
.	O

Recovery	O
was	O
determined	O
at	O
three	O
concentrations	O
(	O
0.5	O
μM	O
,	O
5	O
μM	O
,	O
and	O
50	O
μM	O
)	O
across	O
the	O
concentration	O
range	O
for	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
,	O
and	O
at	O
10	O
μM	O
for	O
methyltestosterone	B
.	O

Mean	O
percentage	O
recoveries	O
for	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
were	O
95%±2	O
%	O
(	O
n	O
=	O
18	O
)	O
and	O
98%±7	O
%	O
(	O
n	O
=	O
18	O
)	O
,	O
respectively	O
.	O

Mean	O
percentage	O
recovery	O
for	O
methyltestosterone	B
was	O
98%±3	O
%	O
(	O
n	O
=	O
6	O
)	O
.	O

3.6	O
Applications	O
The	O
method	O
has	O
been	O
used	O
to	O
analyze	O
over	O
2500	O
samples	O
for	O
6β	B
-	I
hydroxytestosterone	I
and	O
testosterone	B
.	O

It	O
has	O
been	O
used	O
to	O
characterize	O
the	O
CYP3A	O
metabolic	O
activity	O
of	O
multiple	O
preparations	O
of	O
human	O
,	O
rat	O
,	O
and	O
dog	O
hepatic	O
microsomes	O
,	O
precision	O
-	O
cut	O
slices	O
,	O
and	O
tissue	O
homogenates	O
.	O

The	O
method	O
has	O
also	O
been	O
used	O
to	O
screen	O
drugs	B
and	O
NCEs	B
for	O
inhibitory	O
effects	O
on	O
human	O
CYP3A4	O
.	O

The	O
effect	O
of	O
troleandomycin	B
(	O
TAO	B
)	O
,	O
a	O
known	O
CYP3A4	O
inhibitor	O
,	O
on	O
testosterone	B
6β	O
-	O
hydroxylation	O
has	O
been	O
determined	O
using	O
this	O
method	O
.	O

The	O
percent	O
inhibition	O
of	O
testosterone	B
6β	O
-	O
hydroxylation	O
(	O
as	O
compared	O
to	O
control	O
samples	O
with	O
no	O
TAO	B
present	O
)	O
was	O
plotted	O
as	O
a	O
function	O
of	O
TAO	B
concentration	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
inhibition	O
of	O
testosterone	B
6β	O
-	O
hydroxylation	O
by	O
TAO	B
determined	O
using	O
this	O
method	O
compares	O
favorably	O
to	O
results	O
reported	O
previously	O
[	O
15	O
]	O
.	O

Because	O
other	O
testosterone	B
metabolites	I
are	O
resolved	O
using	O
this	O
method	O
,	O
it	O
can	O
also	O
be	O
used	O
to	O
monitor	O
the	O
activity	O
of	O
other	O
CYP	O
enzymes	O
that	O
have	O
been	O
shown	O
to	O
produce	O
specific	O
hydroxylated	B
testosterone	I
metabolites	I
[	O
3	O
]	O
.	O

Chromatograms	O
from	O
incubations	O
of	O
testosterone	B
with	O
rat	O
liver	O
microsomes	O
with	O
and	O
without	O
NADPH	B
are	O
shown	O
in	O
Fig.	O
4	O
.	O

The	O
reconstructed	O
ion	O
chromatogram	O
(	O
m	O
/	O
z	O
304	O
)	O
from	O
the	O
sample	O
of	O
testosterone	B
incubated	O
with	O
rat	O
liver	O
microsomes	O
and	O
NADPH	B
shows	O
evidence	O
for	O
2α-	B
,	O
2β-	B
,	O
6β-	B
,	O
7α-	B
,	O
and	O
16α	B
-	I
hydroxytestosterone	I
.	O

The	O
method	O
could	O
be	O
further	O
optimized	O
for	O
these	O
additional	O
metabolites	B
by	O
monitoring	O
the	O
most	O
abundant	O
ions	O
in	O
the	O
full	O
scan	O
mass	O
spectra	O
of	O
these	O
compounds	O
.	O

4	O
Conclusions	O
A	O
method	O
has	O
been	O
developed	O
for	O
the	O
determination	O
of	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
using	O
GC	O
–	O
SIM	O
–	O
MS	O
.	O

The	O
run	O
time	O
of	O
the	O
method	O
(	O
15	O
min	O
)	O
is	O
half	O
that	O
of	O
previously	O
reported	O
HPLC	O
and	O
CE	O
methods	O
.	O

The	O
method	O
displays	O
excellent	O
precision	O
and	O
accuracy	O
over	O
a	O
linear	O
range	O
of	O
0.25	O
to	O
100	O
μM	O
for	O
testosterone	B
and	O
6β	B
-	I
hydroxytestosterone	I
.	O

The	O
selectivity	O
of	O
the	O
mass	O
spectrometric	O
detector	O
helps	O
eliminate	O
possible	O
interferences	O
from	O
compounds	O
evaluated	O
using	O
this	O
methodology	O
.	O

The	O
assay	O
has	O
been	O
used	O
to	O
characterize	O
the	O
CYP3A	O
activity	O
of	O
preparations	O
of	O
hepatic	O
microsomes	O
,	O
precision	O
-	O
cut	O
slices	O
,	O
and	O
tissue	O
homogenates	O
from	O
a	O
variety	O
of	O
species	O
.	O

The	O
platinum	B
coordination	B
complexes	I
cisplatin	B
,	O
and	O
its	O
less	O
toxic	O
analog	O
,	O
carboplatin	B
represent	O
two	O
of	O
the	O
major	O
drugs	B
currently	O
used	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

However	O
,	O
for	O
some	O
time	O
it	O
has	O
been	O
recognised	O
that	O
these	O
two	O
drugs	B
are	O
active	O
against	O
broadly	O
the	O
same	O
types	O
of	O
tumour	O
[	O
1	O
]	O
.	O

Thus	O
one	O
major	O
theme	O
of	O
analog	O
development	O
has	O
involved	O
attempting	O
to	O
widen	O
the	O
spectrum	O
of	O
antitumour	O
activity	O
to	O
tumours	O
that	O
are	O
initially	O
,	O
or	O
have	O
become	O
,	O
unresponsive	O
to	O
cisplatin	B
/	O
carboplatin	B
.	O

Despite	O
considerable	O
effort	O
illustrated	O
by	O
the	O
description	O
of	O
hundreds	O
of	O
analogs	O
,	O
and	O
the	O
phase	O
I	O
clinical	O
evaluation	O
of	O
around	O
25	O
compounds	O
,	O
only	O
one	O
,	O
carboplatin	B
,	O
is	O
widely	O
registered	O
for	O
use	O
[	O
2	O
for	O
a	O
review	O
]	O
.	O

While	O
carboplatin	B
,	O
and	O
the	O
orally	O
active	O
platinum	B
drug	B
,	O
JM216	B
[	O
3,4	O
]	O
have	O
addressed	O
issues	O
of	O
patient	O
quality	O
of	O
life	O
,	O
in	O
terms	O
of	O
circumvention	O
of	O
tumour	O
resistance	O
to	O
cisplatin	B
,	O
there	O
has	O
been	O
less	O
progress	O
.	O

Current	O
platinum	B
drugs	B
undergoing	O
clinical	O
trial	O
such	O
as	O
oxaliplatin	B
(	O
which	O
has	O
exhibited	O
some	O
activity	O
in	O
colorectal	O
cancer	O
,	O
especially	O
in	O
combination	O
with	O
5-fluorouracil	B
[	O
5	O
]	O
,	O
and	O
the	O
sterically	O
hindered	O
drug	B
,	O
AMD473	B
(	O
ZD0473	B
)	O
,	O
which	O
demonstrated	O
in	O
vivo	O
circumvention	O
of	O
acquired	O
cisplatin	B
resistance	O
in	O
human	O
tumour	O
xenografts	O
[	O
6	O
]	O
may	O
provide	O
some	O
widening	O
of	O
the	O
spectrum	O
of	O
antitumor	O
activity	O
obtained	O
with	O
the	O
parent	O
drugs	B
.	O

One	O
rational	O
approach	O
to	O
the	O
discovery	O
of	O
more	O
broad	O
-	O
spectrum	O
third	O
generation	O
platinum	B
drugs	B
is	O
to	O
design	O
novel	O
platinum	B
agents	B
which	O
bind	O
to	O
DNA	O
in	O
a	O
manner	O
distinct	O
from	O
that	O
of	O
cisplatin	B
and	O
carboplatin	B
,	O
which	O
both	O
ultimately	O
form	O
a	O
similar	O
spectrum	O
of	O
DNA	O
adducts	O
[	O
7	O
]	O
.	O

This	O
strategy	O
is	O
probably	O
best	O
exemplified	O
by	O
the	O
discovery	O
of	O
active	O
trans	B
platinum	I
complexes	I
,	O
initially	O
by	O
Farrell	O
and	O
co	O
-	O
workers	O
[	O
8–10	O
]	O
.	O

This	O
surprising	O
finding	O
broke	O
one	O
of	O
the	O
original	O
structure	O
-	O
activity	O
rules	O
for	O
platinum	B
complexes	B
,	O
namely	O
that	O
only	O
the	O
cis	B
isomers	I
were	O
endowed	O
with	O
antitumor	O
activity	O
[	O
11	O
]	O
.	O

Active	O
trans	B
platinum	I
complexes	I
have	O
also	O
been	O
described	O
based	O
on	O
platinum	B
(	B
II	I
)	I
iminoether	I
complexes	I
[	O
12–14	O
]	O
and	O
as	O
part	O
of	O
our	O
collaboration	O
with	O
the	O
Johnson	O
Matthey	O
Technology	O
Centre	O
,	O
namely	O
JM335	B
[	O
trans	B
ammine	I
(	I
cyclohexylaminedichlorodihydroxo	I
)	I
platinum	I
(	I
IV	I
)	I
]	O
[	O
15	O
]	O
.	O

Some	O
of	O
the	O
preclinical	O
antitumor	O
properties	O
of	O
JM335	B
have	O
been	O
previously	O
described	O
[	O
15–18	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
undertake	O
a	O
detailed	O
comparative	O
analysis	O
of	O
the	O
cellular	O
pharmacological	O
properties	O
of	O
JM335	B
,	O
its	O
cis	B
isomer	I
,	O
JM149	B
and	O
their	O
respective	O
platinum	B
(	I
II	I
)	I
counterparts	O
,	O
trans	B
ammine	I
(	I
cyclohexylamine	I
)	I
dichloro	I
platinum	I
(	I
II	I
)	I
JM334	B
,	O
and	O
its	O
cis	B
isomer	I
JM118	B
(	O
which	O
,	O
notably	O
,	O
has	O
also	O
been	O
shown	O
to	O
be	O
the	O
major	O
in	O
vivo	O
metabolite	B
of	O
the	O
oral	O
platinum	B
drug	B
JM216	B
[	O
19,21	O
]	O
)	O
.	O

The	O
study	O
has	O
used	O
three	O
human	O
ovarian	O
carcinoma	O
cell	O
lines	O
,	O
the	O
parent	O
relatively	O
cisplatin	B
-	O
sensitive	O
,	O
CH1	O
,	O
an	O
acquired	O
cisplatin	B
-	O
resistant	O
subline	O
,	O
CH1cisR	O
,	O
and	O
the	O
relatively	O
intrinsically	O
resistant	O
,	O
SKOV-3	O
.	O

Growth	O
inhibition	O
,	O
cellular	O
transport	O
,	O
DNA	O
platination	O
,	O
gene	O
-	O
specific	O
repair	O
of	O
platinum	B
drug	B
induced	O
DNA	O
adducts	O
and	O
induction	O
of	O
p53	O
and	O
apoptosis	O
has	O
been	O
determined	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Cell	O
lines	O
Two	O
parent	O
human	O
ovarian	O
carcinoma	O
cell	O
lines	O
,	O
the	O
relatively	O
cisplatin	B
sensitive	O
CH1	O
and	O
the	O
relatively	O
resistant	O
SKOV-3	O
,	O
have	O
been	O
used	O
[	O
22	O
]	O
.	O

In	O
addition	O
,	O
a	O
subline	O
of	O
CH1	O
possessing	O
acquired	O
resistance	O
to	O
cisplatin	B
,	O
CH1cisR	O
,	O
has	O
been	O
included	O
.	O

This	O
was	O
derived	O
through	O
in	O
vitro	O
exposure	O
as	O
described	O
previously	O
[	O
23	O
]	O
.	O

These	O
three	O
lines	O
have	O
been	O
used	O
by	O
us	O
previously	O
in	O
studies	O
of	O
cisplatin	B
-	O
induced	O
DNA	O
platination	O
[	O
24	O
]	O
and	O
apoptosis	O
[	O
25	O
]	O
.	O

Lines	O
were	O
grown	O
as	O
monolayers	O
in	O
Dulbecco	O
's	O
Modified	O
Eagle	O
's	O
Medium	O
containing	O
10	O
%	O
heat	O
inactivated	O
foetal	O
bovine	O
serum	O
,	O
2	O
mM	O
l	B
-glutamine	I
and	O
0.5	O
μg	O
/	O
ml	O
hydrocortisone	B
in	O
6	O
%	O
CO2	B
/94	O
%	O
air	O
.	O

Cells	O
were	O
periodically	O
checked	O
and	O
confirmed	O
to	O
be	O
free	O
of	O
Mycoplasma	O
.	O

2.2	O
Platinum	B
drugs	B
Cisplatin	O
,	O
JM118	B
,	O
JM149	B
,	O
JM334	B
,	O
and	O
JM335	B
were	O
synthesised	O
and	O
obtained	O
from	O
The	O
Johnson	O
Matthey	O
Technology	O
Centre	O
(	O
Reading	O
,	O
Berkshire	O
,	O
UK	O
)	O
.	O

Structures	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

All	O
drugs	B
were	O
dissolved	O
in	O
sterile	O
0.9	O
%	O
NaCl	B
solution	O
at	O
between	O
0.5	O
and	O
1	O
mM	O
and	O
sterile	O
filtered	O
prior	O
to	O
use	O
.	O

2.3	O
Assessment	O
of	O
growth	O
inhibition	O
This	O
was	O
assessed	O
using	O
the	O
sulforhodamine	B
B	I
(	O
SRB	B
)	O
assay	O
as	O
used	O
previously	O
by	O
us	O
for	O
platinum	B
drugs	B
with	O
these	O
cell	O
lines	O
[	O
3,16,23	O
]	O
.	O

Briefly	O
,	O
aliquots	O
of	O
a	O
single	O
cell	O
suspension	O
were	O
seeded	O
into	O
96-well	O
microtitre	O
plates	O
(	O
4000	O
per	O
well	O
)	O
and	O
allowed	O
to	O
attach	O
overnight	O
in	O
160	O
μ1	O
of	O
the	O
above	O
-	O
described	O
growth	O
medium	O
.	O

Platinum	B
drugs	B
(	O
made	O
up	O
fresh	O
immediately	O
before	O
)	O
were	O
then	O
added	O
to	O
the	O
wells	O
(	O
four	O
wells	O
per	O
concentration	O
)	O
at	O
up	O
to	O
ten	O
different	O
concentrations	O
.	O

Platinum	B
drug	B
exposure	O
was	O
for	O
2	O
h.	O
Thereafter	O
,	O
drug	B
was	O
carefully	O
washed	O
out	O
using	O
phosphate	B
buffered	I
saline	I
(	O
PBS	B
)	O
and	O
growth	O
medium	O
replaced	O
.	O

After	O
4	O
days	O
incubation	O
,	O
the	O
number	O
of	O
remaining	O
cells	O
was	O
compared	O
in	O
drug	B
-	O
exposed	O
versus	O
untreated	O
wells	O
using	O
0.4	O
%	O
SRB	B
(	O
Sigma	O
Chemicals	B
,	O
Poole	O
,	O
UK	O
)	O
dissolved	O
in	O
1	O
%	O
acetic	B
acid	I
.	O

Growth	O
inhibition	O
is	O
expressed	O
as	O
an	O
IC50	O
—	O
the	O
concentration	O
required	O
to	O
reduce	O
the	O
absorbance	O
(	O
cell	O
number	O
)	O
in	O
control	O
wells	O
by	O
50	O
%	O
.	O

2.4	O
Platinum	B
uptake	O
and	O
DNA	O
binding	O
Intracellular	O
platinum	B
uptake	O
and	O
DNA	O
binding	O
(	O
total	O
platination	O
)	O
was	O
measured	O
in	O
each	O
cell	O
line	O
following	O
2	O
h	O
drug	B
exposure	O
to	O
10	O
,	O
25	O
,	O
50	O
and	O
100	O
μM.	O
For	O
uptake	O
experiments	O
,	O
following	O
drug	B
exposure	O
,	O
cells	O
were	O
washed	O
twice	O
with	O
PBS	B
,	O
detached	O
by	O
scraping	O
into	O
2	O
ml	O
ice	B
-	O
cold	O
PBS	B
and	O
sonicated	O
.	O

Results	O
from	O
the	O
uptake	O
experiments	O
are	O
expressed	O
as	O
nmoles	O
Pt	B
(	O
measured	O
using	O
flameless	O
atomic	O
absorption	O
spectroscopy	O
;	O
FAAS	O
,	O
Perkin	O
Elmer	O
1100b	O
/	O
HGA	O
700	O
,	O
Beaconsfield	O
,	O
UK	O
)	O
per	O
mg	O
protein	O
(	O
using	O
the	O
Lowry	O
assay	O
)	O
.	O

For	O
DNA	O
binding	O
experiments	O
,	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
800	O
×	O
g	O
for	O
5	O
min	O
)	O
and	O
pellets	O
washed	O
twice	O
with	O
ice	B
cold	O
PBS	B
and	O
then	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	B
.	O

DNA	O
was	O
then	O
extracted	O
using	O
phenol	B
and	O
ethanol	B
precipitation	O
as	O
described	O
previously	O
[	O
24	O
]	O
.	O

Dried	O
DNA	O
pellets	O
were	O
dissolved	O
overnight	O
at	O
37	O
°	O
C	O
in	O
0.2	O
%	O
nitric	B
acid	I
and	O
platinum	B
content	O
measured	O
by	O
FAAS	O
and	O
results	O
expressed	O
as	O
nmoles	O
of	O
platinum	B
per	O
gram	O
of	O
DNA	O
.	O

2.5	O
Measurement	O
of	O
Pt	B
/	O
DNA	O
lesions	O
using	O
quantitative	O
PCR	O
Formation	O
and	O
removal	O
of	O
platinum	B
induced	O
lesions	O
was	O
measured	O
in	O
the	O
N	O
-	O
ras	O
gene	O
by	O
QPCR	O
as	O
described	O
previously	O
[	O
26,27	O
]	O
.	O

Cells	O
in	O
midlog	O
phase	O
(	O
approximately	O
106	O
)	O
were	O
incubated	O
for	O
5	O
h	O
with	O
2	O
×	O
IC50	O
of	O
drug	B
and	O
harvested	O
by	O
trypsinisation	O
either	O
immediately	O
after	O
removal	O
of	O
drug	B
or	O
following	O
a	O
24	O
h	O
incubation	O
in	O
drug	B
free	O
medium	O
.	O

Cells	O
were	O
lysed	O
in	O
340	O
μl	O
of	O
solution	O
(	O
400	O
mM	O
Tris	B
–	I
HCl	I
pH	O
8	O
,	O
60	O
mM	O
EDTA	B
,	O
150	O
mM	O
NaCl	B
,	O
and	O
1	O
%	O
w	O
/	O
v	O
SDS	B
)	O
plus	O
100	O
μl	O
5	O
M	O
sodium	B
perchlorate	I
by	O
mixing	O
at	O
37	O
°	O
C	O
for	O
20	O
min	O
and	O
then	O
at	O
65	O
°	O
C	O
for	O
a	O
further	O
20	O
min	O
.	O

A	O
total	O
of	O
580	O
μl	O
of	O
chloroform	B
was	O
added	O
to	O
the	O
lysate	O
,	O
the	O
solution	O
mixed	O
on	O
a	O
rotary	O
mixer	O
for	O
20	O
min	O
at	O
room	O
temperature	O
followed	O
by	O
centrifugation	O
in	O
a	O
microfuge	O
at	O
top	O
speed	O
for	O
12	O
min	O
.	O

Following	O
centrifugation	O
,	O
330	O
μl	O
of	O
the	O
upper	O
layer	O
was	O
aliquoted	O
into	O
a	O
new	O
microtube	O
and	O
nuclear	O
material	O
precipitated	O
in	O
two	O
volumes	O
of	O
absolute	O
ethanol	B
.	O

The	O
precipitate	O
was	O
washed	O
twice	O
in	O
70	O
%	O
ethanol	B
,	O
dried	O
in	O
an	O
incubator	O
over	O
night	O
at	O
37	O
°	O
C	O
and	O
dissolved	O
in	O
400	O
μl	O
H2	B
O.	I
PCR	O
was	O
performed	O
using	O
25	O
μl	O
of	O
DNA	O
sample	O
in	O
a	O
final	O
volume	O
of	O
100	O
μl	O
containing	O
;	O
2	O
units	O
(	O
0.2	O
μl	O
)	O
of	O
Taq	O
polymerase	O
(	O
red	O
hot	O
)	O
,	O
4.8	O
μl	O
of	O
a	O
dATP	B
,	O
dCTP	B
,	O
dGTP	B
,	O
dTTP	B
mix	O
(	O
120	O
μM	O
each	O
)	O
,	O
3	O
μl	O
(	O
0.75	O
mM	O
)	O
MgCl2	B
10	O
μl	O
,	O
buffer	O
IV	O
(	O
Advanced	O
Biotechnologies	O
)	O
,	O
5	O
μl	O
DMSO	B
,	O
1	O
μl	O
each	O
of	O
3′	O
and	O
5′	O
primer	O
sequence	O
,	O
and	O
1	O
μCi	O
(	O
α-32	B
P	I
)	O
dCTP	B
.	O

The	O
amplification	O
of	O
the	O
N	O
-	O
ras	O
fragment	O
was	O
performed	O
using	O
the	O
forward	O
primer	O
5′–GCC	B
TGG	I
TTA	I
CTG	I
TGT	I
CCT	I
GT–3′	I
and	O
the	O
reverse	O
primer	O
5′–GCC	B
AGC	I
CAC	I
ATC	I
TAC	I
AGT	I
AC–3′.	I
PCR	O
was	O
carried	O
out	O
using	O
a	O
Hybaid	O
Thermal	O
cycler	O
using	O
an	O
initial	O
2	O
min	O
denaturation	O
step	O
at	O
94	O
°	O
C	O
followed	O
by	O
25	O
cycles	O
of	O
94	O
°	O
C	O
for	O
1	O
min	O
,	O
55	O
°	O
C	O
for	O
1	O
min	O
and	O
72	O
°	O
C	O
for	O
1	O
min	O
with	O
a	O
final	O
incubation	O
of	O
4	O
min	O
at	O
72	O
°	O
C	O
at	O
the	O
end	O
of	O
the	O
cycling	O
.	O

These	O
conditions	O
were	O
chosen	O
to	O
ensure	O
that	O
the	O
PCR	O
reaction	O
was	O
still	O
in	O
the	O
exponential	O
phase	O
when	O
the	O
reaction	O
had	O
stopped	O
.	O

PCR	O
products	O
were	O
quantified	O
by	O
precipitation	O
of	O
aliquots	O
of	O
40	O
μl	O
of	O
reaction	O
mixture	O
with	O
1	O
ml	O
ice	B
cold	O
5	O
%	O
w	O
/	O
v	O
trichloroacetic	B
acid	I
20	O
mM	O
tetra	B
sodium	I
pyrophosphate	I
(	O
TCA	B
)	O
and	O
the	O
precipitate	O
captured	O
on	O
Whatman	O
GF	O
/	O
C	O
filters	O
with	O
unincorporated	O
α-32	B
P	I
-	I
dCTP	I
washed	O
through	O
with	O
10	O
ml	O
of	O
the	O
TCA	B
and	O
10	O
ml	O
of	O
absolute	O
ethanol	B
.	O

The	O
filters	O
were	O
placed	O
in	O
scintillation	O
fluid	O
and	O
the	O
PCR	O
product	O
quantitated	O
by	O
measuring	O
cpms	O
per	O
minute	O
.	O

Lesions	O
per	O
region	O
(	O
lesion	O
index	O
)	O
were	O
calculated	O
using	O
the	O
formula	O
:	O
−ln	O
Ad	O
/A	O
,	O
where	O
A	O
represents	O
PCR	O
product	O
(	O
cpm	O
)	O
from	O
control	O
sample	O
and	O
Ad	O
represents	O
cpm	O
from	O
treated	O
samples	O
.	O

Controls	O
containing	O
25	O
and	O
50	O
%	O
of	O
the	O
control	O
sample	O
were	O
included	O
to	O
ensure	O
that	O
the	O
PCR	O
was	O
quantitative	O
.	O

2.6	O
Microscopy	O
Cells	O
were	O
collected	O
24	O
h	O
following	O
a	O
2	O
h	O
incubation	O
with	O
drug	B
.	O

Detached	O
cells	O
were	O
aspirated	O
from	O
the	O
tissue	O
culture	O
flasks	O
and	O
collected	O
from	O
the	O
culture	O
medium	O
by	O
centrifugation	O
.	O

Attached	O
cells	O
were	O
washed	O
twice	O
with	O
ice	B
cold	O
PBS	B
and	O
removed	O
by	O
incubation	O
with	O
0.25	O
%	O
trypsin	O
for	O
5	O
min	O
prior	O
to	O
collection	O
by	O
centrifugation	O
.	O

For	O
fluorescent	O
microscopy	O
,	O
cells	O
were	O
incubated	O
with	O
propridium	B
iodide	I
(	O
PI	B
)	O
1	O
mg	O
/	O
ml	O
for	O
10	O
min	O
on	O
ice	B
and	O
nuclei	O
detected	O
by	O
red	O
fluorescence	O
.	O

2.7	O
Field	O
inverted	O
gel	O
electrophoresis	O
(	O
FIGE	O
)	O
of	O
DNA	O
Cells	O
were	O
incubated	O
with	O
equitoxic	O
concentrations	O
of	O
agents	O
(	O
2	O
×	O
,	O
5	O
×	O
,	O
10	O
×	O
IC50	O
)	O
for	O
2	O
h	O
and	O
then	O
at	O
24	O
h	O
(	O
for	O
CH1	O
and	O
CH1cisR	O
)	O
or	O
48	O
h	O
(	O
for	O
SKOV-3	O
)	O
attached	O
and	O
detached	O
cells	O
were	O
collected	O
by	O
centrifugation	O
.	O

Cell	O
pellets	O
of	O
approximately	O
5	O
×	O
105	O
were	O
then	O
incubated	O
in	O
lysis	O
buffer	O
[	O
200	O
mM	O
Tris	B
,	O
100	O
mM	O
EDTA	B
,	O
2	O
%	O
sodium	B
dodecyl	I
sulphate	I
]	O
containing	O
1	O
mg	O
/	O
ml	O
proteinase	O
K	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

RNA	O
was	O
removed	O
by	O
a	O
further	O
1	O
h	O
incubation	O
following	O
the	O
addition	O
of	O
10	O
μl	O
of	O
a	O
1	O
mg	O
/	O
ml	O
solution	O
of	O
RNAase	O
to	O
each	O
50	O
μl	O
sample	O
.	O

Aliquots	O
of	O
cell	O
lysate	O
were	O
then	O
added	O
directly	O
to	O
the	O
gel	O
,	O
the	O
wells	O
being	O
sealed	O
with	O
1	O
%	O
low	O
melting	O
point	O
agarose	B
.	O

FIGE	O
was	O
performed	O
with	O
1	O
×	O
TAE	O
(	O
40	O
mM	O
Tris	B
,	O
20	O
mM	O
sodium	B
acetate	I
,	O
1	O
mM	O
EDTA	B
)	O
using	O
a	O
Biorad	O
FIGE	O
mapper	O
.	O

Horizontal	O
gels	O
were	O
run	O
for	O
20	O
h	O
in	O
1	O
×	O
TAE	O
buffer	O
with	O
a	O
forward	O
voltage	O
of	O
10	O
V	O
/	O
cm	O
and	O
reverse	O
of	O
7	O
V	O
/	O
cm	O
with	O
linear	O
ramping	O
T	O
1	O
=	O
1	O
s	O
and	O
T	O
2	O
=	O
12	O
s.	O
The	O
temperature	O
of	O
the	O
TAE	O
buffer	O
was	O
controlled	O
at	O
14	O
°	O
C	O
using	O
a	O
Biorad	O
1000	O
mini	O
-	O
chiller	O
.	O

2.8	O
Western	O
blot	O
analysis	O
Cells	O
(	O
8	O
×	O
106	O
)	O
were	O
incubated	O
with	O
equitoxic	O
concentrations	O
(	O
2	O
×	O
IC50	O
)	O
of	O
drug	B
for	O
2	O
h	O
and	O
attached	O
cells	O
harvested	O
by	O
trypsinisation	O
at	O
various	O
time	O
points	O
following	O
drug	B
exposure	O
.	O

The	O
resulting	O
cell	O
pellets	O
were	O
resuspended	O
in	O
300	O
μl	O
of	O
lysis	O
buffer	O
containing	O
150	O
mM	O
NaCl	B
,	O
50	O
mM	O
Tris	B
–	I
HCl	I
,	O
to	O
which	O
was	O
added	O
;	O
500	O
μl	O
pf	O
20	O
mM	O
phenylmethylsulphonylfluoride	B
(	O
PMSF	B
)	O
100	O
μl	O
Na	B
orthovanadate	I
(	O
10	O
mM	O
stock	O
)	O
,	O
100	O
μl	O
NP40	B
,	O
100	O
μl	O
20	O
%	O
SDS	B
,	O
2	O
μl	O
aprotinin	O
(	O
10	O
mg	O
/	O
ml	O
stock	O
)	O
and	O
2	O
μl	O
leupeptin	B
(	O
10	O
mg	O
/	O
ml	O
stock	O
)	O
and	O
incubated	O
on	O
ice	B
for	O
1	O
h	O
)	O
.	O

The	O
lysed	O
samples	O
were	O
centrifuged	O
at	O
12	O
000	O
rpm	O
at	O
4	O
°	O
C	O
for	O
15	O
min	O
,	O
and	O
the	O
supernatant	O
collected	O
.	O

Samples	O
,	O
adjusted	O
to	O
contain	O
equal	O
protein	O
(	O
50	O
μg	O
)	O
,	O
were	O
diluted	O
50	O
/	O
50	O
with	O
Laemmli	O
buffer	O
and	O
incubated	O
at	O
95	O
°	O
C	O
for	O
3	O
min	O
.	O

Approximately	O
25	O
μl	O
of	O
sample	O
and	O
3	O
μl	O
of	O
standard	O
rainbow	O
marker	O
were	O
loaded	O
onto	O
8–16	O
%	O
Novex	O
precast	O
PAGE	O
gels	O
and	O
run	O
at	O
30	O
mA	O
per	O
gel	O
for	O
1	O
h	O
and	O
then	O
transferred	O
to	O
nitrocellulose	B
membrane	O
at	O
300	O
mA	O
for	O
2	O
h.	O
Following	O
transfer	O
,	O
the	O
membranes	O
were	O
stained	O
with	O
Ponceau	B
S	I
to	O
check	O
the	O
efficiency	O
of	O
the	O
transfer	O
.	O

The	O
membranes	O
were	O
washed	O
twice	O
with	O
PBS	B
containing	O
0.1	O
%	O
Tween	B
20	I
(	O
PBST	B
)	O
,	O
excess	O
liquid	O
was	O
drained	O
off	O
and	O
then	O
placed	O
in	O
blocking	O
buffer	O
(	O
154	O
mM	O
NaCl	B
,	O
10	O
mM	O
Tris	B
,	O
0.5	O
%	O
caesin	O
and	O
0.02	O
%	O
thimerosal	B
,	O
at	O
pH	O
7.6	O
)	O
and	O
agitated	O
for	O
1	O
h.	O
The	O
membranes	O
were	O
subsequently	O
washed	O
in	O
PBST	B
for	O
5	O
min	O
and	O
probed	O
for	O
the	O
protein	O
of	O
interest	O
with	O
primary	O
antibody	O
diluted	O
in	O
blocking	O
buffer	O
for	O
a	O
specified	O
time	O
.	O

For	O
example	O
,	O
1	O
h	O
for	O
p53	O
and	O
5	O
h	O
for	O
bcl-2	O
and	O
then	O
washed	O
thrice	O
for	O
10	O
min	O
with	O
PBST	B
.	O

The	O
membranes	O
were	O
incubated	O
with	O
secondary	O
antibody	O
linked	O
with	O
horse	O
radish	O
peroxidase	O
for	O
at	O
least	O
1	O
h	O
and	O
then	O
detected	O
with	O
ECL	O
reagents	B
(	O
Amersham	O
)	O
by	O
autoradiography	O
.	O

2.9	O
Statistical	O
analysis	O
Where	O
appropriate	O
,	O
statistical	O
significance	O
was	O
evaluated	O
using	O
the	O
Student	O
's	O
t	O
-test	O
(	O
two	O
tailed	O
)	O
.	O

A	O
P	O
-value	O
of	O
<	O
0.05	O
was	O
considered	O
significant	O
.	O

3	O
Results	O
3.1	O
Growth	O
inhibition	O
The	O
growth	O
inhibitory	O
properties	O
of	O
the	O
two	O
pairs	O
of	O
cis	B
and	O
trans	B
isomers	I
following	O
2	O
h	O
exposure	O
to	O
the	O
three	O
ovarian	O
carcinoma	O
cell	O
lines	O
,	O
are	O
shown	O
in	O
Fig.	O
2	O
.	O

Mean	O
IC50	O
values	O
in	O
μM	O
against	O
CH1	O
cells	O
were	O
1.3	O
for	O
JM118	B
,	O
3.4	O
for	O
JM334	B
,	O
35.3	O
for	O
JM149	B
and	O
18.6	O
for	O
JM335	B
.	O

A	O
degree	O
of	O
resistance	O
was	O
observed	O
in	O
CH1cisR	O
cells	O
to	O
all	O
four	O
agents	B
;	O
resistance	O
factors	O
(	O
Rf	O
;	O
IC50	O
resistant	O
/	O
IC50	O
CH1	O
cells	O
)	O
were	O
2.5	O
for	O
JM118	B
(	O
IC50	O
3.3	O
)	O
,	O
1.5	O
for	O
JM334	B
(	O
IC50	O
5.1	O
)	O
,	O
2.3	O
for	O
JM149	B
(	O
IC50	O
83	O
)	O
and	O
1.6	O
for	O
JM335	B
(	O
IC50	O
31	O
)	O
.	O

A	O
similar	O
effect	O
was	O
observed	O
with	O
the	O
SKOV-3	O
cell	O
line	O
but	O
with	O
Rf	O
values	O
being	O
lower	O
for	O
the	O
two	O
trans	B
compounds	I
:	O

Rf	O
values	O
of	O
20.5	O
for	O
JM118	B
(	O
IC50	O
27	O
)	O
and	O
10	O
for	O
,	O
JM149	B
(	O
IC50	O
350	O
)	O
but	O
only	O
4.5	O
for	O
JM334	B
(	O
IC50	O
15	O
)	O
and	O
4.4	O
for	O
JM335	B
(	O
IC50	O
83	O
)	O
.	O

The	O
curves	O
are	O
generally	O
similar	O
in	O
shape	O
:	O
At	O
2	O
×	O
IC50	O
concentrations	O
,	O
the	O
range	O
in	O
cell	O
kill	O
observed	O
across	O
all	O
four	O
drugs	B
was	O
from	O
83	O
to	O
90	O
%	O
.	O

Typical	O
IC50	O
values	O
for	O
cisplatin	B
[	O
24	O
]	O
are	O
CH1	O
2.5	O
μM	O
,	O
CH1cisR	O
7.5	O
μM	O
(	O
Rf	O
of	O
3	O
)	O
and	O
SKOV-3	O
33	O
μM	O
(	O
Rf	O
of	O
13	O
)	O
.	O

Several	O
points	O
emerge	O
:	O
(	O
1	O
)	O
the	O
Pt	B
(	I
II	I
)	I
compounds	B
JM118	B
and	O
JM334	B
are	O
more	O
potent	O
than	O
their	O
platinum	B
(	I
IV	I
)	I
counterparts	O
;	O
(	O
2	O
)	O
the	O
trans	B
isomer	I
JM335	B
was	O
more	O
potent	O
than	O
its	O
corresponding	O
cis	B
isomer	I
,	O
especially	O
in	O
the	O
relatively	O
cisplatin	B
-	O
resistant	O
SKOV-3	O
cell	O
line	O
.	O

However	O
,	O
with	O
the	O
platinum	B
(	I
II	I
)	I
pair	O
,	O
the	O
cis	B
compound	I
JM118	B
was	O
more	O
potent	O
that	O
the	O
trans	O
JM334	B
in	O
the	O
CH1	O
and	O
CH1cisR	O
lines	O
.	O

(	O
3	O
)	O
In	O
terms	O
of	O
resistance	O
factors	O
,	O
the	O
trans	B
compounds	I
showed	O
better	O
circumvention	O
of	O
cisplatin	B
resistance	O
(	O
lower	O
Rf	O
values	O
)	O
than	O
the	O
cis	B
compounds	I
;	O
this	O
was	O
most	O
apparent	O
with	O
the	O
intrinsically	O
resistant	O
SKOV-3	O
cell	O
line	O
(	O
e.g.	O
>	O
4-fold	O
lower	O
Rf	O
value	O
for	O
JM334	B
versus	O
JM118	B
)	O
.	O

3.2	O
Platinum	B
accumulation	O
and	O
DNA	O
binding	O
Full	O
dose	O
–	O
response	O
curves	O
(	O
10–100	O
μM	O
;	O
2	O
h	O
exposure	O
)	O
were	O
obtained	O
for	O
each	O
drug	B
using	O
all	O
three	O
cell	O
lines	O
.	O

A	O
generally	O
linear	O
relationship	O
between	O
concentration	O
and	O
platinum	O
accumulation	O
(	O
expressed	O
as	O
nmoles	O
Pt	B
/	O
mg	O
protein	O
)	O
was	O
obtained	O
(	O
data	O
not	O
shown	O
)	O
.	O

Comparative	O
accumulation	O
data	O
at	O
a	O
concentration	O
of	O
50	O
μM	O
are	O
shown	O
in	O
Fig.	O
3	O
A.	O
Platinum	B
accumulation	O
was	O
significantly	O
higher	O
following	O
exposure	O
to	O
the	O
trans	B
Pt	I
(	I
II	I
)	I
compound	I
JM334	B
compared	O
to	O
both	O
its	O
cis	B
isomer	I
JM118	B
(	O
e.g.	O
7-fold	O
higher	O
in	O
CH1	O
and	O
CH1cisR	O
;	O
P	O
<	O
0.005	O
)	O
and	O
compared	O
to	O
its	O
platinum	B
(	I
IV	I
)	I
homolog	B
,	O
JM335	B
.	O

There	O
was	O
little	O
to	O
suggest	O
that	O
reduced	O
accumulation	O
contributed	O
to	O
either	O
the	O
acquired	O
resistance	O
of	O
CH1cisR	O
or	O
the	O
intrinsic	O
resistance	O
of	O
SKOV-3	O
compared	O
to	O
the	O
parent	O
CH1	O
line	O
;	O
uptake	O
values	O
were	O
similar	O
for	O
JM118	B
across	O
all	O
three	O
cell	O
lines	O
,	O
uptake	O
was	O
higher	O
in	O
the	O
resistant	O
lines	O
following	O
exposure	O
to	O
JM149	B
(	O
13-fold	O
;	O
P	O
<	O
0.005	O
compared	O
to	O
CH1	O
)	O
.	O

Platinum	B
uptake	O
for	O
the	O
two	O
trans	B
compounds	I
JM334	B
and	O
JM335	B
was	O
a	O
little	O
lower	O
in	O
SKOV-3	O
compared	O
to	O
CH1	O
.	O

Similarly	O
to	O
the	O
accumulation	O
data	O
,	O
representative	O
total	O
DNA	O
platination	O
for	O
the	O
four	O
compounds	O
in	O
the	O
three	O
cell	O
lines	O
are	O
shown	O
in	O
Fig.	O
3	O
B	O
(	O
50	O
μM	O
,	O
2	O
h	O
drug	B
exposure	O
)	O
.	O

As	O
for	O
the	O
uptake	O
data	O
,	O
there	O
was	O
little	O
difference	O
in	O
DNA	O
platination	O
for	O
JM118	B
across	O
the	O
three	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
the	O
very	O
high	O
uptake	O
values	O
observed	O
with	O
the	O
trans	B
Pt	I
(	I
II	I
)	I
compound	I
JM334	B
compared	O
to	O
JM118	B
and	O
its	O
platinum	B
(	I
IV	I
)	I
homolog	B
JM335	B
(	O
especially	O
in	O
the	O
CH1	O
and	O
CH1cisR	O
cell	O
lines	O
)	O
did	O
not	O
result	O
in	O
higher	O
DNA	O
platination	O
.	O

Indeed	O
,	O
platination	O
was	O
significantly	O
lower	O
for	O
JM334	B
versus	O
JM118	B
in	O
the	O
CH1	O
and	O
CH1cisR	O
lines	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
higher	O
platination	O
(	O
3-fold	O
,	O
P	O
<	O
0.05	O
compared	O
to	O
CH1	O
)	O
was	O
observed	O
in	O
the	O
intrinsically	O
cisplatin	B
resistant	O
SKOV-3	O
cell	O
line	O
with	O
JM334	B
.	O

For	O
the	O
two	O
Pt	B
(	I
IV	I
)	I
compounds	B
,	O
DNA	O
platination	O
was	O
higher	O
(	O
around	O
2–3-fold	O
)	O
for	O
the	O
trans	B
compound	I
compared	O
to	O
its	O
cis	B
isomer	I
.	O

3.3	O
Gene	O
-	O
specific	O
repair	O
using	O
QPCR	O
As	O
a	O
further	O
means	O
of	O
studying	O
the	O
cellular	O
pharmacology	O
of	O
these	O
cis	B
and	O
trans	B
platinum	I
compounds	I
,	O
the	O
ability	O
of	O
the	O
CH1	O
,	O
CH1cisR	O
and	O
SKOV-3	O
cell	O
lines	O
to	O
remove	O
/	O
repair	O
lesions	O
induced	O
by	O
the	O
compounds	B
(	O
and	O
cisplatin	B
)	O
has	O
been	O
studied	O
in	O
the	O
N	O
-	O
ras	O
gene	O
using	O
QPCR	O
.	O

In	O
keeping	O
with	O
published	O
studies	O
using	O
cisplatin	B
[	O
27	O
]	O
an	O
exposure	O
time	O
of	O
5	O
h	O
was	O
used	O
and	O
removal	O
assessed	O
at	O
24	O
h	O
post	O
drug	B
removal	O
.	O

Fig.	O
4	O
A	O
shows	O
results	O
with	O
the	O
platinum	B
(	I
IV	I
)	I
cis	B
/trans	I
pair	I
using	O
a	O
concentration	O
of	O
2	O
×	O
2	O
h	O
-	O
IC50	O
.	O

Notably	O
,	O
the	O
parent	O
,	O
cisplatin	B
-	O
sensitive	O
cell	O
line	O
CH1	O
,	O
could	O
not	O
remove	O
lesions	O
by	O
either	O
of	O
the	O
two	O
platinum	B
drugs	B
(	O
illustrated	O
by	O
an	O
increase	O
in	O
lesion	O
index	O
at	O
24	O
h	O
compared	O
to	O
5	O
h	O
)	O
.	O

Similarly	O
,	O
the	O
CH1cisR	O
line	O
could	O
not	O
remove	O
lesions	O
induced	O
by	O
JM149	B
.	O

In	O
contrast	O
,	O
the	O
intrinsically	O
cisplatin	B
resistant	O
SKOV-3	O
cell	O
line	O
was	O
able	O
to	O
remove	O
adducts	B
formed	O
by	O
the	O
cis	B
compound	I
(	O
JM149	B
)	O
but	O
not	O
by	O
the	O
trans	B
compound	I
,	O
JM335	B
.	O

Results	O
for	O
the	O
Pt	B
(	I
II	I
)	I
pair	O
of	O
compounds	B
are	O
shown	O
in	O
Fig.	O
4	O
B.	O
In	O
common	O
with	O
observations	O
made	O
with	O
the	O
Pt	B
(	I
IV	I
)	I
compounds	I
,	O
the	O
CH1	O
cell	O
line	O
(	O
and	O
CH1cisR	O
line	O
)	O
was	O
unable	O
to	O
remove	O
adducts	B
formed	O
by	O
the	O
cis	B
Pt	I
(	I
II	I
)	I
compound	I
JM118	B
.	O

As	O
for	O
the	O
Pt	B
(	I
IV	I
)	I
pair	O
,	O
notably	O
the	O
SKOV-3	O
cell	O
line	O
removed	O
adducts	B
formed	O
by	O
the	O
cis	B
compound	I
JM118	B
but	O
was	O
unable	O
to	O
remove	O
adducts	B
formed	O
by	O
the	O
trans	B
isomer	I
,	O
JM334	B
.	O

Data	O
for	O
cisplatin	B
are	O
shown	O
in	O
Table	O
1	O
.	O

Results	O
showed	O
a	O
similar	O
pattern	O
of	O
response	O
to	O
that	O
observed	O
for	O
the	O
cis	B
compounds	I
JM118	B
and	O
JM149	B
with	O
removal	O
from	O
DNA	O
of	O
SKOV-3	O
cells	O
but	O
not	O
the	O
CH1	O
parental	O
line	O
.	O

In	O
contrast	O
,	O
however	O
,	O
removal	O
of	O
cisplatin	B
-	O
induced	O
lesions	O
was	O
apparent	O
in	O
CH1cisR	O
cells	O
.	O

3.4	O
Cell	O
death	O
induced	O
by	O
cis	B
and	O
trans	B
platinum	I
compounds	I
As	O
described	O
previously	O
[	O
20,25	O
]	O
,	O
we	O
initially	O
determined	O
the	O
rates	O
of	O
cell	O
death	O
induced	O
by	O
the	O
compounds	B
by	O
measuring	O
cellular	O
detachment	O
from	O
the	O
monolayer	O
over	O
time	O
following	O
2	O
h	O
drug	B
exposure	O
.	O

Results	O
for	O
the	O
CH1cisR	O
cell	O
line	O
for	O
all	O
four	O
compounds	B
used	O
at	O
an	O
equitoxic	O
(	O
2	O
×	O
IC50	O
)	O
concentration	O
are	O
shown	O
(	O
Fig.	O
5	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
the	O
CH1	O
and	O
SKOV-3	O
cell	O
lines	O
(	O
data	O
not	O
shown	O
and	O
20	O
for	O
JM149	B
and	O
JM335	B
in	O
the	O
CH1	O
cell	O
line	O
)	O
.	O

Notably	O
,	O
a	O
slower	O
rate	O
of	O
detachment	O
was	O
induced	O
by	O
the	O
two	O
cis	B
isomers	I
JM118	B
and	O
JM149	B
compared	O
to	O
their	O
trans	O
counterparts	O
.	O

While	O
the	O
time	O
taken	O
for	O
50	O
%	O
detachment	O
to	O
occur	O
with	O
the	O
trans	B
compounds	I
was	O
around	O
24	O
h	O
,	O
for	O
the	O
two	O
cis	B
compounds	I
,	O
this	O
was	O
around	O
72	O
h.	O
Detection	O
of	O
apoptosis	O
induced	O
by	O
cis	B
and	O
trans	B
platinum	I
compounds	I
.	O

To	O
determine	O
whether	O
the	O
cellular	O
detachment	O
and	O
cell	O
death	O
observed	O
in	O
the	O
cell	O
lines	O
.	O

occurred	O
through	O
apoptosis	O
,	O
two	O
complementary	O
means	O
of	O
detecting	O
apoptotic	O
cells	O
was	O
employed	O
;	O
fluorescence	O
microscopy	O
and	O
FIGE	O
of	O
DNA	O
.	O

Fig.	O
6	O
shows	O
fluorescent	O
microscopy	O
of	O
detached	O
CH1	O
cells	O
harvested	O
24	O
h	O
after	O
exposure	O
for	O
2	O
h	O
to	O
2	O
×	O
or	O
10	O
×	O
IC50	O
of	O
either	O
the	O
cis	B
Pt	I
(	I
II	I
)	I
compound	I
JM118	B
or	O
its	O
trans	O
counterpart	O
,	O
JM334	B
.	O

Using	O
2	O
×	O
IC50	O
of	O
the	O
cis	B
isomer	I
JM118	B
,	O
the	O
majority	O
of	O
detached	O
cells	O
exhibited	O
the	O
classical	O
morphology	O
of	O
apoptosis	O
(	O
condensation	O
and	O
fragmentation	O
pattern	O
of	O
chromatin	O
around	O
the	O
periphery	O
of	O
the	O
nucleus	O
—	O
6c	O
)	O
.	O

While	O
a	O
similar	O
appearance	O
was	O
seen	O
in	O
cells	O
exposed	O
to	O
either	O
10	O
×	O
IC50	O
of	O
JM118	B
(	O
6d	O
)	O
or	O
2	O
×	O
IC50	O
of	O
JM334	B
(	O
6e	O
)	O
,	O
cells	O
detaching	O
following	O
exposure	O
to	O
10	O
×	O
IC50	O
concentration	O
of	O
JM334	B
exhibited	O
a	O
different	O
morphological	O
appearance	O
(	O
6f	O
)	O
.	O

In	O
contrast	O
,	O
the	O
chromatin	O
was	O
not	O
condensed	O
and	O
resembled	O
that	O
of	O
control	O
untreated	O
cells	O
(	O
6b	O
)	O
.	O

Moreover	O
,	O
there	O
was	O
evidence	O
of	O
extensive	O
vesiculation	O
in	O
these	O
cells	O
.	O

The	O
morphological	O
appearance	O
of	O
CH1cisR	O
or	O
SKOV-3	O
cells	O
detaching	O
after	O
a	O
2	O
h	O
exposure	O
to	O
2	O
×	O
IC50	O
concentrations	O
of	O
all	O
four	O
compounds	B
showed	O
that	O
,	O
in	O
each	O
case	O
,	O
the	O
detached	O
cells	O
exhibited	O
the	O
appearance	O
of	O
apoptotic	O
cells	O
.	O

Hence	O
,	O
at	O
2	O
×	O
IC50	O
concentrations	O
,	O
all	O
four	O
compounds	B
induced	O
apoptosis	O
in	O
all	O
three	O
cell	O
lines	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
results	O
of	O
FIGE	O
of	O
DNA	O
from	O
pooled	O
attached	O
and	O
detached	O
cells	O
of	O
all	O
three	O
cell	O
lines	O
exposed	O
to	O
2	O
×	O
,	O
5	O
×	O
,	O
or	O
10	O
×	O
IC50	O
of	O
all	O
four	O
compounds	B
is	O
shown	O
in	O
Fig.	O
7	O
A	O
,	O
B	O
for	O
CH1	O
and	O
for	O
CH1cisR	O
and	O
SKOV-3	O
,	O
respectively	O
.	O

FIGE	O
was	O
used	O
in	O
preference	O
to	O
the	O
detection	O
of	O
DNA	O
laddering	O
by	O
gel	O
electrophoresis	O
since	O
previous	O
studies	O
using	O
these	O
lines	O
with	O
cisplatin	B
had	O
shown	O
that	O
internucleosomal	O
cleavage	O
could	O
not	O
be	O
detected	O
in	O
cells	O
undergoing	O
apoptosis	O
[	O
25	O
]	O
.	O

The	O
FIGE	O
results	O
indicate	O
that	O
none	O
of	O
the	O
attached	O
cell	O
populations	O
(	O
lanes	O
A3–5	O
for	O
JM118	O
,	O
A6–8	O
for	O
JM334	O
in	O
CH1	O
cells	O
;	O
lanes	O
B1	O
and	O
2	O
for	O
CH1cisR	O
JM118	O
and	O
JM334	O
,	O
respectively	O
and	O
lanes	O
B3	O
and	O
4	O
for	O
SKOV3	O
,	O
JM118	O
and	O
JM334	O
,	O
respectively	O
)	O
revealed	O
any	O
DNA	O
fragmentation	O
indicative	O
of	O
apoptosis	O
.	O

In	O
contrast	O
,	O
all	O
the	O
detached	O
cell	O
populations	O
of	O
cell	O
lines	O
following	O
exposure	O
to	O
the	O
cis	B
platinum	I
compounds	I
JM118	B
(	O
lanes	O
A9–11	O
for	O
CH1	O
;	O
B5	O
for	O
CH1cisR	O
and	O
B9	O
for	O
SKOV-3	O
)	O
and	O
JM149	B
(	O
B7	O
for	O
CH1cisR	O
and	O
B11	O
for	O
SKOV-3	O
)	O
revealed	O
the	O
presence	O
of	O
a	O
fragment	O
approximately	O
50	O
kb	O
in	O
size	O
.	O

For	O
the	O
detached	O
cell	O
populations	O
exposed	O
to	O
the	O
trans	B
compounds	I
,	O
the	O
observed	O
fragmentation	O
was	O
concentration	O
dependent	O
.	O

At	O
low	O
(	O
2	O
×	O
IC50	O
)	O
concentrations	O
the	O
50	O
kb	O
fragment	O
was	O
apparent	O
in	O
all	O
cases	O
(	O
lane	O
A12	O
for	O
JM334	B
in	O
CH1	O
cells	O
,	O
lane	O
B6	O
and	O
8	O
for	O
JM334	B
and	O
JM335	B
,	O
respectively	O
in	O
CH1cisR	O
and	O
lane	O
B10	O
and	O
12	O
for	O
JM334	B
and	O
JM335	B
,	O
respectively	O
in	O
SKOV-3	O
)	O
.	O

However	O
,	O
at	O
the	O
high	O
(	O
10	O
×	O
IC50	O
)	O
concentration	O
of	O
JM334	B
in	O
the	O
CH1	O
cells	O
(	O
lane	O
A14	O
)	O
the	O
50	O
kb	O
fragment	O
seen	O
at	O
lower	O
drug	B
concentrations	O
was	O
not	O
present	O
.	O

3.5	O
Induction	O
of	O
P53	O
protein	O
by	O
cis	B
and	O
trans	B
platinum	I
compounds	I
Our	O
studies	O
have	O
shown	O
that	O
the	O
CH1	O
cell	O
lines	O
are	O
wild	O
type	O
in	O
terms	O
of	O
p53	O
status	O
,	O
while	O
the	O
SKOV-3	O
is	O
null	O
[	O
28,29	O
]	O
.	O

Therefore	O
,	O
in	O
order	O
to	O
the	O
study	O
the	O
induction	O
of	O
p53	O
following	O
DNA	O
damage	O
induced	O
by	O
the	O
cis	B
and	O
trans	B
platinum	I
compounds	I
,	O
and	O
the	O
possible	O
correlation	O
to	O
the	O
apoptosis	O
observed	O
above	O
,	O
the	O
CH1	O
and	O
CH1cisR	O
cell	O
lines	O
were	O
selected	O
for	O
study	O
.	O

Representative	O
results	O
for	O
the	O
CH1	O
cell	O
line	O
using	O
the	O
JM149	B
/	O
JM335	B
pair	O
of	O
isomers	B
(	O
similar	O
results	O
were	O
observed	O
with	O
CH1cisR	O
)	O
are	O
shown	O
in	O
Fig.	O
8	O
A	O
and	O
B.	O
Results	O
indicate	O
that	O
,	O
following	O
2	O
h	O
drug	B
exposure	O
at	O
2	O
×	O
IC50	O
concentrations	O
,	O
p53	O
was	O
induced	O
by	O
5	O
h	O
and	O
levels	O
remained	O
high	O
at	O
16	O
and	O
24	O
h	O
post	O
exposure	O
.	O

The	O
degree	O
of	O
induction	O
was	O
somewhat	O
higher	O
with	O
the	O
trans	B
compound	I
JM335	B
compared	O
to	O
its	O
cis	O
counterpart	O
.	O

4	O
Discussion	O
In	O
recent	O
years	O
within	O
the	O
platinum	B
drug	B
development	O
field	O
there	O
has	O
been	O
a	O
burgeoning	O
interest	O
in	O
trans	B
platinum	I
complexes	I
exemplified	O
by	O
the	O
discovery	O
of	O
active	O
trans	B
platinum	I
complexes	I
by	O
at	O
least	O
three	O
independent	O
Groups	O
.	O

Within	O
our	O
collaboration	O
with	O
the	O
Johnson	O
Matthey	O
technology	O
Company	O
,	O
we	O
previously	O
described	O
some	O
of	O
the	O
antitumor	O
and	O
pharmacological	O
properties	O
of	O
the	O
JM	O
mixed	O
amine	B
class	O
of	O
trans	B
platinum	I
compounds	I
exemplified	O
by	O
JM335	B
[	O
16–20	O
]	O
.	O

These	O
studies	O
showed	O
that	O
JM335	B
was	O
capable	O
of	O
circumventing	O
acquired	O
cisplatin	B
resistance	O
in	O
vitro	O
.	O

Furthermore	O
,	O
JM335	B
produced	O
growth	O
delays	O
in	O
excess	O
of	O
15	O
days	O
against	O
four	O
human	O
ovarian	O
xenografts	O
in	O
vivo	O
.	O

In	O
contrast	O
the	O
platinum	B
(	I
II	I
)	I
trans	O
counterpart	O
JM334	B
was	O
not	O
active	O
in	O
vivo	O
probably	O
as	O
a	O
result	O
of	O
high	O
reactivity	O
/	O
poor	O
pharmacokinetic	O
properties	O
[	O
17	O
]	O
.	O

The	O
underlying	O
reasons	O
for	O
the	O
promising	O
in	O
vitro	O
potency	O
of	O
JM335	B
against	O
cisplatin	B
-	O
resistant	O
human	O
tumour	O
cell	O
lines	O
has	O
not	O
been	O
fully	O
elucidated	O
,	O
however	O
,	O
and	O
has	O
been	O
further	O
addressed	O
herein	O
.	O

This	O
study	O
describes	O
a	O
comparison	O
of	O
the	O
cellular	O
effects	O
of	O
two	O
pairs	O
of	O
cis	B
and	O
trans	B
platinum	I
isomers	I
in	O
an	O
intrinsically	O
cisplatin	B
resistant	O
human	O
ovarian	O
carcinoma	O
cell	O
line	O
(	O
SKOV-3	O
)	O
versus	O
a	O
pair	O
of	O
ovarian	O
cell	O
lines	O
(	O
CH1	O
and	O
a	O
subline	O
possessing	O
acquired	O
resistance	O
to	O
cisplatin	B
)	O
,	O
in	O
terms	O
of	O
growth	O
inhibition	O
,	O
drug	O
uptake	O
,	O
binding	O
to	O
DNA	O
,	O
gene	O
-	O
specific	O
DNA	O
repair	O
and	O
induction	O
of	O
cell	O
death	O
.	O

A	O
notable	O
feature	O
of	O
the	O
growth	O
inhibition	O
studies	O
was	O
the	O
improved	O
circumvention	O
of	O
both	O
acquired	O
and	O
intrinsic	O
cisplatin	B
resistance	O
by	O
the	O
two	O
trans	B
compounds	I
when	O
compared	O
to	O
their	O
cis	O
counterparts	O
.	O

This	O
interesting	O
effect	O
was	O
most	O
prominent	O
in	O
the	O
SKOV-3	O
cell	O
line	O
where	O
the	O
level	O
of	O
cross	O
-	O
resistance	O
(	O
compared	O
to	O
the	O
CH1	O
parent	O
line	O
)	O
to	O
the	O
cis	B
compounds	I
(	O
including	O
cisplatin	B
)	O
was	O
greater	O
than	O
10-fold	O
but	O
was	O
only	O
around	O
4-fold	O
for	O
the	O
two	O
trans	B
compounds	I
.	O

The	O
relative	O
potency	O
of	O
the	O
trans	B
Pt	I
compounds	I
against	O
the	O
SKOV-3	O
cells	O
is	O
surprising	O
in	O
terms	O
of	O
the	O
relative	O
levels	O
of	O
glutathione	B
in	O
the	O
CH1	O
versus	O
the	O
SKOV-3	O
cell	O
line	O
(	O
GSH	B
levels	O
are	O
3-fold	O
higher	O
in	O
SKOV-3	O
[	O
30	O
]	O
)	O
and	O
combined	O
with	O
the	O
previous	O
observation	O
that	O
the	O
trans	B
compound	I
JM335	B
is	O
much	O
more	O
susceptible	O
to	O
inactivation	O
by	O
intracellular	O
GSH	B
than	O
its	O
cis	O
counterpart	O
[	O
16	O
]	O
.	O

The	O
explanation	O
for	O
the	O
promising	O
selective	O
activity	O
of	O
the	O
trans	B
compounds	I
against	O
the	O
intrinsically	O
cisplatin	B
resistant	O
SKOV-3	O
appears	O
to	O
lie	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
and	O
repair	O
.	O

The	O
most	O
striking	O
difference	O
between	O
the	O
cell	O
lines	O
and	O
the	O
trans	B
versus	O
cis	B
compounds	I
was	O
how	O
the	O
SKOV-3	O
cell	O
line	O
handled	O
DNA	O
damage	O
induced	O
by	O
the	O
compounds	O
at	O
the	O
level	O
of	O
gene	O
-	O
specific	O
repair	O
.	O

Whereas	O
this	O
line	O
was	O
able	O
to	O
remove	O
adducts	B
from	O
a	O
fragment	O
of	O
the	O
N	O
-	O
ras	O
gene	O
within	O
24	O
h	O
formed	O
by	O
both	O
cis	B
platinum	I
compounds	I
JM118	B
and	O
JM149	B
,	O
there	O
was	O
an	O
increase	O
in	O
measured	O
adducts	B
following	O
exposure	O
to	O
their	O
trans	O
counterparts	O
,	O
JM334	B
and	O
JM335	B
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
small	O
increase	O
in	O
overall	O
DNA	O
platination	O
observed	O
immediately	O
following	O
a	O
2	O
h	O
drug	B
exposure	O
for	O
the	O
two	O
trans	B
compounds	I
relative	O
to	O
their	O
cis	O
counterparts	O
in	O
the	O
SKOV-3	O
cell	O
line	O
.	O

Interestingly	O
,	O
total	O
intracellular	O
platinum	B
accumulation	O
measurements	O
made	O
immediately	O
after	O
2	O
h	O
drug	O
exposure	O
did	O
not	O
correlate	O
with	O
either	O
the	O
potencies	O
observed	O
in	O
the	O
growth	O
inhibition	O
studies	O
or	O
the	O
levels	O
of	O
binding	O
to	O
DNA	O
.	O

In	O
particular	O
,	O
the	O
trans	O
Pt	B
(	I
II	I
)	I
compound	B
JM334	O
was	O
rapidly	O
taken	O
up	O
into	O
cells	O
resulting	O
in	O
significantly	O
higher	O
intracellular	O
platinum	B
levels	O
at	O
2	O
h	O
drug	B
exposure	O
in	O
all	O
three	O
cell	O
lines	O
but	O
this	O
was	O
not	O
reflected	O
in	O
significantly	O
higher	O
DNA	O
platination	O
,	O
especially	O
in	O
the	O
CH1	O
and	O
CH1cisR	O
cell	O
lines	O
.	O

This	O
is	O
probably	O
due	O
to	O
the	O
high	O
reactivity	O
of	O
JM334	B
[	O
17	O
]	O
resulting	O
in	O
avid	O
binding	O
to	O
cytoplasmic	O
thiol	B
-	O
containing	O
species	O
.	O

While	O
the	O
SKOV-3	O
cell	O
line	O
appeared	O
to	O
discriminate	O
at	O
the	O
level	O
of	O
gene	O
specific	O
repair	O
between	O
adducts	B
formed	O
by	O
cis	B
versus	O
trans	B
platinum	I
compounds	I
,	O
the	O
CH1	O
appeared	O
repair	O
-	O
deficient	O
in	O
not	O
being	O
capable	O
of	O
removing	O
adducts	B
from	O
the	O
N	O
-	O
ras	O
gene	O
formed	O
by	O
any	O
of	O
the	O
compounds	B
.	O

This	O
repair	O
deficiency	O
probably	O
contributes	O
to	O
the	O
relative	O
sensitivity	O
of	O
the	O
CH1	O
cell	O
line	O
compared	O
to	O
SKOV-3	O
to	O
all	O
four	O
compounds	B
and	O
underlines	O
the	O
possible	O
importance	O
of	O
gene	O
-	O
specific	O
repair	O
in	O
determining	O
the	O
cytotoxicity	O
of	O
platinum	B
compounds	B
.	O

The	O
CH1	O
line	O
has	O
also	O
been	O
shown	O
to	O
be	O
unable	O
to	O
remove	O
adducts	B
formed	O
by	O
JM216	B
(	O
unpublished	O
observations	O
)	O
.	O

These	O
observations	O
support	O
those	O
of	O
others	O
using	O
cisplatin	B
who	O
have	O
correlated	O
increased	O
gene	O
specific	O
repair	O
,	O
especially	O
of	O
interstrand	O
cross	O
-	O
links	O
,	O
with	O
resistance	O
of	O
human	O
ovarian	O
cancer	O
cell	O
lines	O
[	O
31–34	O
]	O
.	O

Levels	O
of	O
platinum	B
bound	O
to	O
DNA	O
were	O
similar	O
in	O
the	O
CH1	O
versus	O
CH1cisR	O
line	O
following	O
exposure	O
to	O
both	O
pairs	O
of	O
compounds	B
and	O
no	O
differences	O
could	O
be	O
measured	O
between	O
the	O
lines	O
in	O
terms	O
of	O
gene	O
specific	O
repair	O
,	O
induction	O
of	O
apoptosis	O
and	O
induction	O
of	O
p53	O
protein	O
.	O

Hence	O
,	O
as	O
with	O
resistance	O
to	O
JM216	B
in	O
the	O
acquired	O
JM216	B
resistant	O
subline	O
of	O
CH1	O
[	O
35	O
]	O
,	O
increased	O
tolerance	O
to	O
platinum	B
–	O
DNA	O
adducts	B
appears	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
resistance	O
to	O
these	O
cis	B
and	O
trans	B
compounds	I
in	O
CH1cisR.	O
All	O
four	O
platinum	B
compounds	B
induced	O
cell	O
death	O
by	O
apoptosis	O
in	O
the	O
three	O
lines	O
studied	O
.	O

The	O
presence	O
of	O
apoptotic	O
cells	O
following	O
drug	B
exposure	O
was	O
confirmed	O
by	O
both	O
fluorescence	O
microscopy	O
and	O
by	O
DNA	O
fragmentation	O
into	O
50	O
kb	O
fragments	O
.	O

As	O
observed	O
previously	O
using	O
cisplatin	B
in	O
these	O
three	O
cell	O
lines	O
[	O
25	O
]	O
DNA	O
fragmentation	O
into	O
internucleosomal	O
DNA	O
ladders	O
was	O
not	O
observed	O
in	O
apoptotic	O
cells	O
.	O

One	O
notable	O
difference	O
between	O
the	O
cis	B
and	O
trans	B
platinum	I
compounds	I
was	O
in	O
the	O
kinetics	O
of	O
apoptosis	O
.	O

As	O
observed	O
previously	O
with	O
CH1	O
cells	O
exposed	O
to	O
JM335	B
and	O
JM149	B
[	O
20	O
]	O
apoptosis	O
occurred	O
markedly	O
faster	O
in	O
CH1cisR	O
cells	O
exposed	O
to	O
JM334	B
or	O
JM335	B
when	O
compared	O
to	O
their	O
respective	O
cis	B
isomers	I
.	O

Interestingly	O
,	O
JM334	B
induced	O
a	O
non	O
-	O
apoptotic	O
death	O
at	O
high	O
drug	B
concentrations	O
with	O
cells	O
neither	O
displaying	O
apoptotic	O
morphology	O
(	O
extensive	O
vesiculation	O
occurring	O
)	O
nor	O
a	O
50	O
kb	O
fragment	O
by	O
FIGE	O
.	O

In	O
the	O
two	O
CH1	O
cell	O
lines	O
possessing	O
wild	O
-	O
type	O
p53	O
,	O
this	O
protein	O
was	O
induced	O
following	O
exposure	O
to	O
either	O
JM149	B
or	O
JM335	B
,	O
the	O
induction	O
being	O
somewhat	O
greater	O
with	O
the	O
trans	B
isomer	I
.	O

However	O
,	O
p53	O
induction	O
was	O
not	O
essential	O
for	O
apoptosis	O
at	O
least	O
in	O
the	O
SKOV-3	O
cells	O
which	O
is	O
null	O
for	O
p53	O
but	O
where	O
apoptosis	O
clearly	O
occurred	O
.	O

In	O
terms	O
of	O
the	O
cell	O
cycle	O
response	O
to	O
the	O
compounds	B
,	O
all	O
induced	O
a	O
general	O
slowdown	O
in	O
S	O
-	O
phase	O
and	O
effects	O
similar	O
to	O
those	O
reported	O
previously	O
by	O
us	O
in	O
these	O
lines	O
using	O
cisplatin	B
[	O
25	O
]	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
cellular	O
data	O
provide	O
further	O
evidence	O
previously	O
obtained	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
with	O
these	O
compounds	B
[	O
16,18	O
]	O
and	O
other	O
trans	B
compounds	I
[	O
13–15,36,37	O
]	O
that	O
trans	B
compounds	I
all	O
behave	O
differently	O
to	O
cis	B
-oriented	I
platinum	I
compounds	I
.	O

For	O
example	O
,	O
we	O
showed	O
that	O
JM335	B
formed	O
DNA	O
adducts	B
in	O
cells	O
which	O
were	O
not	O
recognised	O
by	O
a	O
monoclonal	O
antibody	O
raised	O
against	O
DNA	O
platinated	O
by	O
cisplatin	B
(	O
adducts	B
induced	O
by	O
JM149	B
and	O
JM	B
118	I
were	O
recognised	O
)	O
[	O
18	O
]	O
.	O

Also	O
,	O
while	O
JM335	B
was	O
capable	O
of	O
forming	O
DNA	O
interstrand	O
cross	O
-	O
links	O
in	O
SKOV-3	O
cells	O
,	O
in	O
CH1	O
cells	O
,	O
unusually	O
for	O
platinum	B
complexes	B
,	O
DNA	O
single	O
strand	O
breaks	O
were	O
detected	O
[	O
16,18	O
]	O
.	O

The	O
trans	B
iminoethers	I
have	O
been	O
shown	O
to	O
preferentially	O
form	O
monofunctional	O
adducts	B
at	O
guanine	B
residues	O
when	O
incubated	O
in	O
cell	O
-	O
free	O
conditions	O
with	O
doublestranded	O
DNA	O
causing	O
unique	O
local	O
distortions	O
in	O
DNA	O
[	O
13–15,36	O
]	O
.	O

The	O
trans	B
-pyridine	I
complexes	I
resulted	O
in	O
greatly	O
increased	O
DNA	O
–	O
DNA	O
interstrand	O
cross	O
-	O
linking	O
and	O
conformational	O
changes	O
shown	O
by	O
increased	O
unwinding	O
of	O
supercoiled	O
DNA	O
[	O
37	O
]	O
.	O

Another	O
trans	B
compound	I
(	B
PtCl2	I
(	I
NH3	I
)	I
(	I
quinoline	I
)	I
)	I
has	O
also	O
recently	O
been	O
shown	O
to	O
form	O
more	O
interstrand	O
cross	O
-	O
links	O
than	O
transplatin	B
when	O
incubated	O
with	O
DNA	O
for	O
48	O
h	O
[	O
38	O
]	O
.	O

In	O
summary	O
,	O
these	O
data	O
,	O
along	O
with	O
our	O
previous	O
studies	O
,	O
indicate	O
that	O
the	O
trans	B
platinum	I
complexes	I
JM334	B
and	O
JM335	B
possess	O
unique	O
cellular	O
pharmacological	O
properties	O
in	O
comparison	O
to	O
their	O
cis	O
counterparts	O
.	O

While	O
all	O
four	O
compounds	B
studied	O
induced	O
apoptosis	O
in	O
all	O
three	O
cell	O
lines	O
,	O
the	O
kinetics	O
of	O
cell	O
death	O
were	O
faster	O
for	O
the	O
trans	B
compounds	I
.	O

Their	O
selective	O
potency	O
against	O
the	O
intrinsically	O
cisplatin	B
resistant	O
SKOV-3	O
cell	O
line	O
appears	O
to	O
be	O
due	O
mainly	O
to	O
a	O
slower	O
rate	O
of	O
removal	O
or	O
even	O
a	O
failure	O
to	O
remove	O
the	O
DNA	O
adducts	B
at	O
the	O
level	O
of	O
actively	O
transcribed	O
genes	O
.	O

T	O
cell	O
activation	O
,	O
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
both	O
normal	O
and	O
pathogenic	O
immune	O
responses	O
,	O
involves	O
multiple	O
intracellular	O
signaling	O
events	O
emanating	O
from	O
the	O
cell	O
surface	O
TCR	O
/	O
CD3	O
complex	O
and	O
costimulatory	O
molecules	O
(	O
Cantrell	O
,	O
1996	O
;	O
Alberola	O
-	O
Ila	O
et	O
al.	O
,	O
1997	O
)	O
.	O

These	O
signaling	O
events	O
can	O
be	O
largely	O
mimicked	O
by	O
artificial	O
stimulation	O
of	O
the	O
T	O
cells	O
,	O
such	O
as	O
combined	O
treatment	O
with	O
anti	O
-	O
CD3	O
mAb	O
and	O
the	O
PKC	O
activator	O
,	O
PMA	B
(	O
Cantrell	O
,	O
1996	O
;	O
Alberola	O
-	O
Ila	O
et	O
al.	O
,	O
1997	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
under	O
both	O
physiological	O
and	O
artificial	O
conditions	O
of	O
stimulation	O
,	O
at	O
least	O
three	O
signal	O
transduction	O
pathways	O
,	O
dependent	O
respectively	O
on	O
the	O
activation	O
of	O
calcineurin	O
(	O
O'Keefe	O
et	O
al.	O
,	O
1992	O
)	O
,	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
and	O
its	O
upstream	O
regulator	O
MEK1	O
(	O
Seger	O
and	O
Krebs	O
,	O
1995	O
)	O
,	O
and	O
of	O
the	O
c	O
-	O
Jun	O
-	O
N	O
terminal	O
kinase	O
(	O
JNK	O
)	O
(	O
Su	O
et	O
al.	O
,	O
1994	O
)	O
ultimately	O
integrate	O
(	O
Cantrell	O
,	O
1996	O
;	O
Alberola	O
-	O
Ila	O
et	O
al.	O
,	O
1997	O
)	O
,	O
leading	O
to	O
the	O
secretion	O
of	O
cytokines	O
and	O
the	O
acquisition	O
of	O
effector	O
functions	O
by	O
the	O
T	O
cells	O
.	O

In	O
particular	O
,	O
these	O
pathways	O
are	O
essential	O
for	O
the	O
production	O
of	O
IL-2	O
(	O
O'Keefe	O
et	O
al.	O
,	O
1992	O
;	O
Li	O
et	O
al.	O
,	O
1996	O
;	O
Dumont	O
et	O
al.	O
,	O
1998	O
;	O
Powell	O
et	O
al.	O
,	O
1998	O
;	O
Werlen	O
et	O
al.	O
,	O
1998	O
)	O
,	O
the	O
major	O
T	O
cell	O
growth	O
factor	O
that	O
is	O
required	O
for	O
driving	O
T	O
cells	O
into	O
the	O
proliferation	O
cycle	O
.	O

Because	O
of	O
its	O
pivotal	O
immunoregulatory	O
function	O
,	O
T	O
cell	O
activation	O
provides	O
a	O
target	O
for	O
pharmacologic	O
modulation	O
aimed	O
at	O
achieving	O
clinically	O
useful	O
immunosuppression	O
.	O

This	O
is	O
well	O
demonstrated	O
by	O
the	O
therapeutic	O
efficacy	O
of	O
cyclosporin	B
A	I
(	O
CsA	B
)	O
and	O
FK506	B
(	O
reviewed	O
in	O
Dumont	O
,	O
1996	O
)	O
,	O
which	O
selectively	O
block	O
calcineurin	O
-	O
dependent	O
signaling	O
(	O
O'Keefe	O
et	O
al.	O
,	O
1992	O
)	O
,	O
and	O
represent	O
the	O
mainstays	O
of	O
the	O
immunosuppressive	O
regimen	O
currently	O
available	O
for	O
the	O
management	O
of	O
graft	O
rejection	O
and	O
autoimmune	O
diseases	O
.	O

However	O
,	O
these	O
agents	B
are	O
less	O
than	O
perfect	O
as	O
their	O
use	O
is	O
often	O
associated	O
with	O
significant	O
and	O
limiting	O
side	O
-	O
effects	O
(	O
Dumont	O
,	O
1996	O
)	O
,	O
and	O
there	O
is	O
a	O
pressing	O
need	O
for	O
novel	O
inhibitors	O
of	O
T	O
cell	O
activation	O
in	O
order	O
to	O
expand	O
the	O
immunosuppressive	O
therapeutic	O
armamentareum	O
.	O

Intense	O
screening	O
effort	O
of	O
natural	B
product	I
or	O
synthetic	B
compounds	I
are	O
therefore	O
ongoing	O
to	O
identify	O
such	O
inhibitors	O
.	O

This	O
search	O
led	O
us	O
to	O
discover	O
that	O
hypothemycin	B
,	O
a	O
resorcylic	B
acid	I
lactone	B
natural	B
product	I
,	O
previously	O
described	O
as	O
an	O
antibiotic	O
(	O
Nair	O
and	O
Carey	O
,	O
1980	O
;	O
Nair	O
et	O
al.	O
,	O
1981	O
;	O
Agatsuma	O
et	O
al.	O
,	O
1993	O
)	O
,	O
exerts	O
potent	O
suppressive	O
activity	O
on	O
T	O
cell	O
activation	O
.	O

The	O
present	O
studies	O
characterized	O
the	O
effect	O
of	O
hypothemycin	B
on	O
several	O
parameters	O
of	O
mouse	O
and	O
human	O
T	O
cell	O
activation	O
in	O
vitro	O
.	O

We	O
showed	O
that	O
this	O
compound	B
inhibits	O
the	O
proliferation	O
of	O
T	O
cells	O
induced	O
by	O
anti	O
-	O
CD3	O
mAb	O
treatment	O
and	O
PMA	B
in	O
a	O
manner	O
partially	O
reversed	O
by	O
exogenous	O
IL-2	O
.	O

Moreover	O
,	O
hypothemycin	B
was	O
found	O
to	O
inhibit	O
the	O
production	O
of	O
IL-2	O
,	O
IL-6	O
,	O
IL-10	O
,	O
IFN	O
-	O
γ	O
and	O
TNF	O
-	O
α	O
while	O
enhancing	O
the	O
production	O
of	O
IL-4	O
,	O
IL-5	O
and	O
IL-13	O
,	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
secretion	O
levels	O
.	O

Further	O
analyses	O
suggested	O
that	O
hypothemycin	B
disrupts	O
calcineurin	O
-	O
independent	O
signaling	O
,	O
through	O
an	O
inhibition	O
of	O
the	O
ERK	O
pathway	O
.	O

This	O
compound	B
therefore	O
represents	O
a	O
novel	O
type	O
of	O
T	O
cell	O
inhibitor	O
with	O
a	O
mode	O
of	O
action	O
distinct	O
from	O
that	O
of	O
CsA	B
or	O
FK506	B
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Isolation	O
of	O
hypothemycin	B
Hypothemycin	B
was	O
isolated	O
from	O
fermentations	O
of	O
an	O
unidentified	O
fungal	O
culture	O
that	O
was	O
found	O
active	O
in	O
a	O
screen	O
for	O
inhibitors	O
of	O
T	O
cell	O
activation	O
.	O

The	O
dried	O
2-butanone	B
extract	O
of	O
the	O
fermentation	O
was	O
purified	O
by	O
silica	B
gel	O
column	O
chromatography	O
developed	O
with	O
a	O
step	O
gradient	O
of	O
methanol	B
in	O
dichloromethane	B
.	O

The	O
fractions	O
containing	O
hypothemycin	B
were	O
pooled	O
and	O
dried	O
.	O

Pure	O
(	O
>	O
98	O
%	O
)	O
hypothemycin	B
was	O
obtained	O
by	O
crystallization	O
of	O
this	O
material	O
from	O
a	O
mixture	O
of	O
acetone	B
and	O
hexanes	B
.	O

The	O
compound	O
was	O
identified	O
based	O
on	O
comparison	O
of	O
spectroscopic	O
data	O
(	O
mass	O
spectrometry	O
,	O
UV	O
absorption	O
,	O
and	O
nuclear	O
magnetic	O
resonance	O
)	O
to	O
those	O
previously	O
published	O
for	O
hypothemycin	B
(	O
Nair	O
and	O
Carey	O
,	O
1980	O
;	O
Nair	O
et	O
al.	O
,	O
1981	O
;	O
Agatsuma	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Hypothemycin	B
was	O
dissolved	O
at	O
10	O
mg	O
/	O
ml	O
in	O
DMSO	B
and	O
stored	O
in	O
aliquots	O
at	O
−70	O
°	O
C	O
.	O

2.2	O
Other	O
reagents	O
Zearalenone	B
(	O
Kuiper	O
-	O
Goodman	O
et	O
al.	O
,	O
1987	O
)	O
was	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
and	O
stored	O
in	O
aliquots	O
(	O
10	O
mg	O
/	O
ml	O
,	O
DMSO	B
)	O
at	O
−70	O
°	O
C	O
.	O

PD98059	B
(	O
Dudley	O
et	O
al.	O
,	O
1995	O
)	O
was	O
obtained	O
from	O
Biomol	O
(	O
Plymouth	O
Meeting	O
,	O
PA	O
)	O
.	O

PMA	B
,	O
ionomycin	B
and	O
anisomycin	B
were	O
obtained	O
from	O
Sigma	O
.	O

Anti	O
-	O
mouse	O
CD3	O
mAb	O
(	O
2C11	O
)	O
and	O
anti	O
-	O
human	O
CD3	O
mAb	O
(	O
1XE	O
)	O
were	O
obtained	O
from	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
Research	O
Diagnostics	O
(	O
Flanders	O
,	O
NJ	O
)	O
,	O
respectively	O
.	O

Human	O
recombinant	O
IL-2	O
was	O
purchased	O
from	O
Biosource	O
International	O
(	O
Camarillo	O
,	O
CA	O
)	O
.	O

Human	O
PHA	O
-	O
conditioned	O
media	O
(	O
T	O
-	O
stim	O
,	O
without	O
PHA	O
)	O
was	O
obtained	O
from	O
Fisher	O
Scientific	O
(	O
Springfield	O
,	O
NJ	O
)	O
.	O

Fluoresceinated	O
mAb	O
to	O
mouse	O
CD69	O
was	O
obtained	O
from	O
Pharmingen	O
.	O

Unconjugated	O
and	O
biotin	B
-	O
conjugated	O
,	O
matched	O
anti	O
-	O
cytokine	O
antibody	O
pairs	O
for	O
quantitation	O
of	O
human	O
cytokines	O
by	O
ELISA	O
were	O
obtained	O
from	O
Genzyme	O
(	O
Cambridge	O
,	O
MA	O
)	O
(	O
IL-2	O
)	O
,	O
Research	O
Diagnostics	O
(	O
IL-4	O
,	O
IL-13	O
)	O
,	O
or	O
Pharmingen	O
(	O
IL-5	O
,	O
IL-10	O
,	O
IFN	O
-	O
γ	O
,	O
TNF	O
-	O
α	O
)	O
.	O

Poly	O
-	O
HRP	O
-	O
streptavidin	O
was	O
obtained	O
from	O
Research	O
Diagnostics	O
.	O

Polyclonal	O
antibodies	O
to	O
ERK1	O
/	O
2	O
and	O
phosphospecific	O
antibodies	O
recognizing	O
the	O
catalytically	O
activated	O
forms	O
of	O
ERK1	O
/	O
2	O
(	O
phosphorylation	O
at	O
Thr202	B
/	O
Tyr204	B
)	O
were	O
obtained	O
from	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
.	O

2.3	O
Cell	O
isolation	O
Mouse	O
splenic	O
T	O
cells	O
were	O
isolated	O
from	O
C57Bl	O
/	O
6Tac	O
mice	O
by	O
nylon	B
wool	B
separation	O
.	O

Human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
separated	O
from	O
venous	O
whole	O
or	O
leukophoresed	O
blood	O
from	O
healthy	O
volunteers	O
(	O
New	O
York	O
Blood	O
Bank	O
or	O
University	O
of	O
Pennsylvania	O
Medical	O
Center	O
)	O
by	O
ficoll	O
/	O
hypaque	O
centrifugation	O
(	O
LSM	O
,	O
Organon	O
Teknika	O
)	O
.	O

Highly	O
purified	O
T	O
cells	O
(	O
93–96	O
%	O
CD3	O
+	O
)	O
were	O
isolated	O
by	O
E	O
-	O
rosetting	O
of	O
PBMC	O
with	O
neuraminidase	O
-	O
treated	O
sheep	O
red	O
blood	O
cells	O
followed	O
by	O
overnight	O
incubation	O
at	O
37	O
°	O
C	O
in	O
plastic	B
flasks	O
to	O
remove	O
contaminating	O
adherent	O
cells	O
.	O

Mouse	O
or	O
human	O
cells	O
were	O
washed	O
and	O
resuspended	O
in	O
complete	O
culture	O
medium	O
made	O
of	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
,	O
2	O
mM	O
glutamine	B
,	O
1	O
mM	O
sodium	B
pyruvate	I
,	O
2	O
×	O
10−5	O
M	O
2-mercaptoethanol	B
and	O
20	O
ng	O
/	O
ml	O
gentamycin	B
.	O

2.4	O
Cell	O
cultures	O
Cell	O
cultures	O
were	O
set	O
up	O
in	O
flat	O
-	O
bottom	O
96-well	O
plates	O
;	O
each	O
well	O
receiving	O
200	O
μl	O
of	O
cell	O
suspension	O
.	O

Purified	O
mouse	O
or	O
human	O
T	O
cells	O
were	O
seeded	O
at	O
a	O
concentration	O
of	O
5	O
×	O
105	O
cells	O
/	O
ml	O
and	O
PBMC	O
at	O
a	O
concentration	O
of	O
106	O
cells	O
/	O
ml	O
.	O

For	O
stimulation	O
of	O
T	O
cells	O
,	O
the	O
appropriate	O
anti	O
-	O
CD3	O
mAb	O
(	O
2C11	O
:	O
100	O
ng	O
/	O
ml	O
;	O
1X2	O
:	O
0.4	O
μg	O
/	O
ml	O
)	O
was	O
added	O
with	O
PMA	B
(	O
0.1	O
,	O
1	O
or	O
10	O
ng	O
/	O
ml	O
,	O
as	O
indicated	O
)	O
and	O
with	O
or	O
without	O
IL-2	O
(	O
50	O
U	O
/	O
ml	O
)	O
.	O

For	O
stimulation	O
of	O
human	O
PBMC	O
,	O
the	O
1X2	O
mAb	O
was	O
used	O
at	O
0.4	O
μg	O
/	O
ml	O
and	O
cultures	O
were	O
set	O
up	O
without	O
or	O
with	O
10	O
%	O
T	O
-	O
stim	O
media	O
.	O

CTTL-2	O
cells	O
(	O
American	O
Type	O
Culture	O
Collection	O
,	O
Rockville	O
,	O
MD	O
)	O
were	O
washed	O
extensively	O
and	O
incubated	O
for	O
3	O
h	O
at	O
37	O
°	O
C	O
in	O
the	O
absence	O
of	O
IL-2	O
,	O
washed	O
again	O
and	O
resuspended	O
at	O
104	O
cells	O
/	O
ml	O
in	O
culture	O
medium	O
containing	O
100	O
U	O
/	O
ml	O
IL-2	O
.	O

The	O
cell	O
suspension	O
was	O
then	O
distributed	O
at	O
200	O
μl	O
/	O
well	O
in	O
culture	O
plates	O
.	O

Working	O
solutions	O
of	O
compounds	B
were	O
prepared	O
extemporaneously	O
in	O
culture	O
medium	O
from	O
their	O
stock	O
solutions	O
and	O
added	O
1:10	O
in	O
at	O
least	O
triplicate	O
wells	O
,	O
at	O
the	O
initiation	O
of	O
the	O
cultures	O
.	O

Plates	O
were	O
incubated	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
atmosphere	O
with	O
5	O
%	O
CO2	B
.	O

2.5	O
Measurement	O
of	O
proliferation	O
T	O
cell	O
cultures	O
were	O
pulsed	O
with	O
2	O
μCi	O
/	O
well	O
[	B
3	I
H	I
]	I
-TdR	I
(	O
specific	O
activity	O
:	O
5	O
Ci	O
/	O
mmole	O
,	O
Amersham	O
)	O
for	O
4	O
h	O
on	O
day	O
2	O
of	O
culture	O
(	O
mouse	O
)	O
or	O
for	O
8	O
h	O
on	O
day	O
3	O
of	O
culture	O
(	O
human	O
)	O
.	O

Cultures	O
were	O
harvested	O
in	O
a	O
Tomteck	O
harvester	O
(	O
Wallac	O
-	O
LKB	O
,	O
Gaithersburg	O
,	O
MD	O
)	O
.	O

Incorporated	O
radioactivity	O
was	O
measured	O
in	O
a	O
Betaplate	O
(	O
Wallac	O
-	O
LKB	O
)	O
liquid	O
scintillation	O
spectrometer	O
.	O

Results	O
were	O
calculated	O
as	O
means	O
of	O
replicate	O
wells	O
and	O
expressed	O
as	O
percent	O
of	O
the	O
control	O
response	O
of	O
cultures	O
stimulated	O
in	O
absence	O
of	O
compound	B
.	O

2.6	O
Quantitation	O
of	O
cytokine	O
concentration	O
in	O
culture	O
supernatants	O
For	O
cytokine	O
measurements	O
,	O
supernatants	O
from	O
human	O
T	O
cells	O
were	O
collected	O
after	O
24	O
or	O
48	O
h	O
of	O
culture	O
and	O
stored	O
at	O
4	O
°	O
C	O
or	O
at	O
−70	O
°	O
C	O
until	O
analysis	O
.	O

Cytokine	O
levels	O
were	O
quantitated	O
by	O
sandwich	O
ELISA	O
using	O
matched	O
antibody	O
pairs	O
.	O

ELISA	O
plates	O
(	O
Maxisorb	O
,	O
Nunc	O
)	O
were	O
coated	O
overnight	O
with	O
anti	O
-	O
cytokine	O
mAb	O
in	O
0.1	O
M	O
carbonate	O
/	O
bicarbonate	O
buffer	O
,	O
pH	O
9.6	O
.	O

After	O
washing	O
,	O
plates	O
were	O
blocked	O
with	O
casein	O
-	O
containing	O
blocking	O
buffer	O
(	O
Research	O
Diagnostics	O
)	O
,	O
and	O
washed	O
again	O
.	O

Appropriately	O
diluted	O
supernatant	O
samples	O
and	O
standards	O
were	O
distributed	O
in	O
duplicate	O
and	O
the	O
plates	O
were	O
incubated	O
for	O
2	O
h	O
at	O
room	O
temperature	O
on	O
a	O
horizontal	O
shaker	O
.	O

Plates	O
were	O
washed	O
,	O
incubated	O
for	O
1	O
h	O
with	O
biotinylated	O
anti	O
-	O
cytokine	O
Ab	O
and	O
washed	O
again	O
.	O

Plates	O
were	O
then	O
incubated	O
with	O
poly	O
-	O
HRP	O
streptavidin	O
for	O
30	O
min	O
at	O
room	O
temperature	O
with	O
shaking	O
.	O

After	O
a	O
final	O
wash	O
,	O
substrate	O
was	O
added	O
(	O
DAKO	O
TMP	O
One	O
-	O
Step	O
Substrate	O
System	O
,	O
DAKO	O
,	O
Carpinteria	O
,	O
CA	O
)	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
addition	O
of	O
0.2	O
M	O
sulfuric	B
acid	I
.	O

Plates	O
were	O
read	O
at	O
450	O
nm	O
in	O
a	O
Molecular	O
Devices	O
UVmax	O
plate	O
reader	O
(	O
Menlo	O
Park	O
,	O
CA	O
)	O
,	O
and	O
the	O
data	O
were	O
calculated	O
using	O
the	O
SOFTtmax	O
program	O
from	O
Molecular	O
Devices	O
.	O

The	O
results	O
were	O
expressed	O
as	O
percent	O
of	O
the	O
control	O
level	O
of	O
cytokine	O
production	O
by	O
cells	O
stimulated	O
in	O
the	O
absence	O
of	O
compound	B
.	O

The	O
50	O
%	O
inhibitory	O
concentration	O
of	O
compound	B
(	O
IC50	O
)	O
was	O
calculated	O
by	O
linear	O
regression	O
analysis	O
.	O

2.7	O
Analysis	O
of	O
cytokine	O
mRNA	O
expression	O
by	O
RNase	O
protection	O
assay	O
(	O
RPA	O
)	O
Purified	O
human	O
T	O
cells	O
were	O
cultured	O
in	O
T25	O
flasks	O
(	O
106	O
/ml	O
,	O
20	O
ml	O
/	O
flask	O
)	O
maintained	O
in	O
an	O
upright	O
position	O
.	O

The	O
cells	O
were	O
incubated	O
at	O
37	O
°	O
C	O
for	O
19	O
h	O
in	O
the	O
presence	O
of	O
the	O
various	O
stimuli	O
,	O
with	O
or	O
without	O
compound	O
,	O
as	O
indicated	O
.	O

Cells	O
were	O
then	O
harvested	O
,	O
centrifuged	O
,	O
transferred	O
to	O
microtubes	O
,	O
and	O
washed	O
with	O
PBS	B
.	O

Cell	O
pellets	O
were	O
frozen	O
at	O
−70	O
°	O
C	O
.	O

Total	O
RNA	O
was	O
extracted	O
using	O
RNAqueous	O
™	O
RNA	O
isolation	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
and	O
quantitated	O
by	O
absorbance	O
at	O
260	O
nm	O
.	O

Cytokine	O
mRNAs	O
were	O
detected	O
with	O
the	O
RiboQuant	O
™	O
Multi	O
-	O
Probe	O
RPA	O
system	O
from	O
PharMingen	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
using	O
the	O
hCK-1	O
multiprobe	O
-	O
template	O
.	O

Riboprobes	O
were	O
[	O
32	B
P	I
]	O
-labeled	O
and	O
hybridized	O
overnight	O
with	O
20	O
μg	O
of	O
the	O
RNA	O
samples	O
.	O

The	O
hybridized	O
RNA	O
was	O
treated	O
with	O
RNase	O
and	O
purified	O
according	O
to	O
the	O
RiboQuant	O
™	O
protocol	O
.	O

The	O
samples	O
were	O
then	O
electrophoresed	O
in	O
6	O
%	O
polyacrylamide	B
Tris	B
–	O
borate	B
–	O
EDTA	B
–	O
urea	B
mini	O
-	O
gels	O
(	O
Novex	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
gels	O
were	O
dried	O
,	O
exposed	O
and	O
quantitated	O
in	O
a	O
PhosphorImager	O
(	O
Molecular	O
Dynamics	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

2.8	O
Flow	O
cytometry	O
(	O
FCM	O
)	O
analysis	O
of	O
CD69	O
expression	O
Cultures	O
of	O
mouse	O
T	O
cells	O
(	O
106	O
/ml	O
)	O
for	O
assessment	O
of	O
CD69	O
induction	O
were	O
set	O
up	O
at	O
1	O
ml	O
/	O
well	O
in	O
24-well	O
plates	O
.	O

Cells	O
received	O
hypothemycin	B
or	O
FK506	B
and	O
were	O
stimulated	O
with	O
PMA	B
(	O
10	O
ng	O
/	O
ml	O
)	O
or	O
ionomycin	B
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

The	O
culture	O
plates	O
were	O
incubated	O
for	O
14	O
h	O
at	O
37	O
°	O
C	O
.	O

At	O
the	O
time	O
of	O
harvesting	O
,	O
the	O
plates	O
were	O
placed	O
on	O
ice	B
for	O
30	O
min	O
and	O
the	O
cells	O
were	O
collected	O
using	O
pasteur	O
pipettes	O
.	O

The	O
cells	O
were	O
stained	O
with	O
fluoresceinated	O
anti	O
-	O
CD69	O
mAb	O
and	O
washed	O
.	O

FCM	O
analysis	O
(	O
10,000	O
cells	O
/	O
sample	O
)	O
was	O
performed	O
in	O
a	O
FACScan	O
(	O
Becton	O
Dickinson	O
)	O
using	O
propidium	B
iodide	I
and	O
light	O
scatter	O
signals	O
to	O
gate	O
out	O
dead	O
cells	O
and	O
debris	O
.	O

2.9	O
Western	O
blot	O
analysis	O
of	O
ERK1	O
/	O
2	O
phosphorylation	O
Mouse	O
or	O
human	O
T	O
cells	O
(	O
107	O
in	O
1	O
ml	O
culture	O
medium	O
)	O
were	O
preincubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
in	O
absence	O
or	O
presence	O
of	O
compound	B
.	O

The	O
cells	O
were	O
treated	O
with	O
PMA	B
for	O
ERK1	O
/	O
2	O
stimulation	O
and	O
harvested	O
10	O
min	O
thereafter	O
.	O

Samples	O
were	O
placed	O
on	O
ice	B
and	O
spun	O
.	O

Pellets	O
were	O
resuspended	O
in	O
lysing	O
buffer	O
and	O
frozen	O
until	O
analysis	O
.	O

Samples	O
were	O
electrophoresed	O
in	O
10	O
%	O
tris	B
–	O
glycine	B
polyacrylamide	B
gels	O
.	O

Proteins	O
were	O
transferred	O
from	O
the	O
gels	O
to	O
PVDF	O
membranes	O
by	O
electroblotting	O
in	O
a	O
Milliblot	O
apparatus	O
(	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
)	O
.	O

The	O
membranes	O
were	O
reacted	O
with	O
antibodies	O
to	O
ERK1	O
/	O
2	O
(	O
New	O
England	O
Biolabs	O
)	O
.	O

The	O
reaction	O
was	O
detected	O
by	O
chemiluminescence	O
on	O
Hyperfilm	O
-	O
ECL	O
(	O
Amersham	O
,	O
Arlington	O
Heights	O
,	O
IL	O
)	O
.	O

3	O
Results	O
3.1	O
Hypothemycin	B
inhibits	O
T	O
cell	O
proliferation	O
in	O
a	O
manner	O
partially	O
reversible	O
by	O
exogenous	O
IL-2	O
We	O
first	O
identified	O
hypothemycin	B
(	O
Fig.	O
1	O
)	O
,	O
as	O
the	O
active	O
component	O
of	O
a	O
fungal	O
culture	O
broth	O
,	O
in	O
a	O
screen	O
for	O
inhibitors	O
of	O
T	O
cell	O
activation	O
using	O
murine	O
T	O
cells	O
activated	O
with	O
anti	O
-	O
CD3	O
mAb+PMA	O
.	O

As	O
shown	O
in	O
Fig.	O
2	O
a	O
,	O
hypothemycin	B
was	O
found	O
to	O
inhibit	O
the	O
proliferative	O
response	O
in	O
such	O
cultures	O
with	O
an	O
IC50	O
of	O
27.6±3.8	O
nM	O
(	O
n	O
=	O
5	O
)	O
.	O

A	O
control	O
compound	B
,	O
zearalenone	B
(	O
Kuiper	O
-	O
Goodman	O
et	O
al.	O
,	O
1987	O
)	O
,	O
which	O
is	O
structurally	O
related	O
to	O
hypothemycin	B
(	O
Fig.	O
1	O
)	O
,	O
failed	O
to	O
affect	O
proliferation	O
under	O
the	O
same	O
conditions	O
.	O

Hypothemycin	B
also	O
potently	O
inhibited	O
the	O
proliferation	O
of	O
purified	O
human	O
T	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
in	O
the	O
presence	O
of	O
a	O
low	O
concentration	O
of	O
PMA	B
(	O
0.1	O
ng	O
/	O
ml	O
)	O
,	O
with	O
an	O
IC50	O
=	O
25.8±8.9	O
nM	O
(	O
n	O
=	O
6	O
)	O
(	O
Fig.	O
2	O
b	O
)	O
.	O

The	O
proliferation	O
of	O
human	O
PBMC	O
(	O
T	O
cells+accessory	O
cells	O
:	O
monocytes	O
and	O
B	O
cells	O
)	O
induced	O
by	O
anti	O
-	O
CD3	O
mAb	O
in	O
the	O
absence	O
of	O
PMA	B
was	O
also	O
potently	O
inhibited	O
by	O
the	O
compound	B
,	O
with	O
an	O
IC50	O
=	O
57.1±5.5	O
nM	O
(	O
n	O
=3	O
)	O
(	O
Fig.	O
2	O
c	O
)	O
.	O

However	O
,	O
stimulation	O
of	O
purified	O
T	O
cells	O
in	O
the	O
presence	O
of	O
PMA	B
at	O
1	O
ng	O
/	O
ml	O
,	O
rendered	O
the	O
proliferative	O
response	O
less	O
sensitive	O
to	O
the	O
effect	O
of	O
hypothemycin	B
(	O
IC50	O
=	O
269.8±58.1	O
nM	O
,	O
n	O
=	O
5	O
)	O
(	O
Fig.	O
2	O
d	O
)	O
.	O

The	O
addition	O
of	O
exogenous	O
IL-2	O
(	O
50	O
U	O
/	O
ml	O
)	O
was	O
used	O
to	O
determine	O
whether	O
the	O
inhibitory	O
activity	O
of	O
hypothemycin	B
in	O
these	O
cultures	O
reflects	O
non	O
-	O
specific	O
toxicity	O
or	O
a	O
more	O
selective	O
effect	O
.	O

Fig.	O
2	O
shows	O
that	O
such	O
an	O
addition	O
resulted	O
in	O
a	O
significant	O
reversal	O
of	O
the	O
inhibition	O
by	O
the	O
compound	B
.	O

In	O
the	O
case	O
of	O
mouse	O
T	O
cells	O
,	O
the	O
IC50	O
increased	O
to	O
182.6±17.1	O
nM	O
(	O
n	O
=	O
5	O
)	O
(	O
Fig.	O
2	O
a	O
)	O
.	O

For	O
human	O
T	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb+PMA	O
at	O
0.1	O
ng	O
/	O
ml	O
,	O
the	O
IC50	O
in	O
presence	O
of	O
exogenous	O
IL-2	O
was	O
236.0±66.1	O
nM	O
(	O
n	O
=	O
6	O
)	O
(	O
Fig.	O
2	O
b	O
)	O
.	O

Moreover	O
,	O
in	O
the	O
case	O
of	O
human	O
PBMC	O
activated	O
by	O
anti	O
-	O
CD3	O
mAb	O
alone	O
,	O
the	O
addition	O
of	O
10	O
%	O
IL-2-containing	O
conditioned	O
medium	O
(	O
T	O
-	O
stim	O
)	O
completely	O
reversed	O
the	O
inhibitory	O
effect	O
of	O
hypothemycin	B
at	O
the	O
concentrations	O
tested	O
here	O
(	O
Fig.	O
2	O
c	O
)	O
.	O

Addition	O
of	O
exogenous	O
IL-2	O
to	O
purified	O
T	O
cell	O
cultures	O
stimulated	O
in	O
presence	O
of	O
PMA	B
at	O
1	O
ng	O
/	O
ml	O
did	O
not	O
appreciably	O
reduce	O
the	O
sensitivity	O
to	O
hypothemycin	B
,	O
suggesting	O
that	O
IL-2	O
produced	O
endogenously	O
is	O
not	O
limiting	O
for	O
proliferation	O
under	O
these	O
conditions	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.2	O
Hypothemycin	B
potently	O
inhibits	O
the	O
secretion	O
of	O
IL-2	O
but	O
affects	O
to	O
a	O
lesser	O
extent	O
the	O
response	O
to	O
IL-2	O
The	O
finding	O
that	O
the	O
inhibitory	O
effects	O
of	O
hypothemycin	B
can	O
be	O
reversed	O
by	O
exogeneous	O
IL-2	O
suggested	O
that	O
the	O
compound	B
may	O
act	O
by	O
interfering	O
with	O
the	O
production	O
of	O
IL-2	O
.	O

We	O
therefore	O
measured	O
IL-2	O
production	O
in	O
the	O
presence	O
of	O
hypothemycin	B
.	O

These	O
studies	O
were	O
conducted	O
in	O
human	O
T	O
cells	O
.	O

Pilot	O
experiments	O
using	O
cultures	O
stimulated	O
with	O
anti	O
-	O
CD3+PMA	O
at	O
0.1	O
ng	O
/	O
ml	O
showed	O
that	O
hypothemycin	B
suppressed	O
IL-2	O
production	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
the	O
level	O
of	O
IL-2	O
released	O
under	O
these	O
conditions	O
was	O
very	O
low	O
and	O
could	O
not	O
be	O
measured	O
accurately	O
enough	O
by	O
ELISA	O
to	O
permit	O
an	O
estimation	O
of	O
the	O
potency	O
of	O
the	O
inhibition	O
by	O
the	O
compound	B
.	O

Further	O
studies	O
were	O
therefore	O
done	O
on	O
cultures	O
activated	O
with	O
anti	O
-	O
CD3+PMA	O
at	O
1	O
ng	O
/	O
ml	O
.	O

With	O
such	O
a	O
strong	O
stimulation	O
,	O
high	O
levels	O
of	O
IL-2	O
(	O
10–30	O
ng	O
/	O
ml	O
)	O
were	O
detectable	O
in	O
the	O
supernatants	O
after	O
24	O
h	O
of	O
culture	O
.	O

As	O
shown	O
in	O
Fig.	O
3	O
a	O
,	O
hypothemycin	B
inhibited	O
this	O
production	O
of	O
the	O
cytokine	O
with	O
an	O
IC50	O
of	O
9.2±1.1	O
nM	O
(	O
n	O
=	O
5	O
)	O
,	O
even	O
though	O
under	O
these	O
conditions	O
the	O
proliferation	O
was	O
not	O
potently	O
suppressed	O
(	O
Fig.	O
2	O
d	O
)	O
possibly	O
because	O
the	O
residual	O
level	O
of	O
IL-2	O
still	O
produced	O
in	O
presence	O
of	O
the	O
compound	B
was	O
sufficient	O
to	O
support	O
T	O
cell	O
growth	O
.	O

It	O
was	O
also	O
important	O
to	O
determine	O
the	O
effect	O
of	O
hypothemycin	B
on	O
the	O
responsiveness	O
of	O
T	O
cells	O
to	O
IL-2	O
.	O

For	O
that	O
purpose	O
,	O
we	O
used	O
the	O
IL-2-dependent	O
murine	O
CTLL-2	O
cell	O
line	O
.	O

As	O
shown	O
in	O
Fig.	O
3	O
b	O
,	O
hypothemycin	B
did	O
inhibit	O
the	O
proliferation	O
induced	O
by	O
IL-2	O
in	O
these	O
cells	O
but	O
with	O
a	O
potency	O
approximately	O
20-fold	O
lower	O
(	O
IC50	O
=	O
194.2±13.2	O
nM	O
,	O
n	O
=	O
8)	O
than	O
for	O
inhibition	O
of	O
IL-2	O
production	O
by	O
normal	O
T	O
cells	O
.	O

This	O
degree	O
of	O
inhibition	O
of	O
cell	O
proliferation	O
by	O
the	O
compound	O
was	O
actually	O
similar	O
to	O
that	O
observed	O
with	O
normal	O
T	O
cells	O
stimulated	O
in	O
the	O
presence	O
of	O
exogeneous	O
IL-2	O
(	O
Fig.	O
2	O
)	O
.	O

3.3	O
Hypothemycin	B
differentially	O
modulates	O
the	O
production	O
of	O
various	O
cytokines	O
Having	O
established	O
that	O
hypothemycin	B
inhibits	O
IL-2	O
production	O
,	O
it	O
was	O
interesting	O
to	O
determine	O
the	O
effect	O
of	O
this	O
compound	B
on	O
other	O
cytokines	O
known	O
to	O
be	O
secreted	O
by	O
T	O
cells	O
upon	O
activation	O
.	O

This	O
was	O
done	O
using	O
human	O
T	O
cells	O
activated	O
for	O
2	O
days	O
with	O
anti	O
-	O
CD3+PMA	O
at	O
1	O
ng	O
/	O
ml	O
,	O
such	O
that	O
the	O
levels	O
of	O
various	O
cytokines	O
released	O
in	O
the	O
supernatants	O
were	O
within	O
the	O
range	O
of	O
sensitivity	O
of	O
ELISA	O
measurements	O
.	O

At	O
this	O
time	O
-	O
point	O
,	O
hypothemycin	B
still	O
potently	O
inhibited	O
the	O
production	O
of	O
IL-2	O
(	O
IC50	O
=	O
12.9±1.8	O
nM	O
,	O
n	O
=	O
10	O
,	O
Fig.	O
4	O
a	O
and	O
data	O
not	O
shown	O
)	O
.	O

The	O
data	O
in	O
Fig.	O
4	O
demonstrate	O
that	O
hypothemycin	B
also	O
strongly	O
suppressed	O
the	O
production	O
of	O
IL-6	O
(	O
IC50	O
=	O
9.5±1.1	O
nM	O
)	O
,	O
IL-10	O
(	O
IC50	O
=	O
18.5±2.6	O
nM	O
)	O
,	O
IFN	O
-	O
γ	O
(	O
IC50	O
=	O
17.7±3.7	O
nM	O
)	O
and	O
TNF	O
-	O
α	O
(	O
IC50	O
=	O
10.8±1.6	O
nM	O
)	O
.	O

However	O
,	O
in	O
the	O
same	O
cultures	O
,	O
the	O
compound	B
was	O
found	O
to	O
exert	O
a	O
strikingly	O
different	O
dose	O
-	O
dependent	O
effect	O
on	O
the	O
levels	O
of	O
IL-4	O
,	O
IL-5	O
and	O
IL-13	O
.	O

Although	O
completely	O
suppressed	O
at	O
264	O
nM	O
,	O
the	O
production	O
of	O
all	O
three	O
of	O
these	O
cytokines	O
was	O
markedly	O
augmented	O
,	O
by	O
up	O
to	O
8-fold	O
,	O
in	O
the	O
presence	O
of	O
33–66	O
nM	O
hypothemycin	B
(	O
EC50	O
∼10	O
nM	O
)	O
.	O

In	O
these	O
experiments	O
,	O
zearalenone	B
did	O
not	O
substantially	O
alter	O
the	O
production	O
of	O
any	O
of	O
the	O
cytokines	O
tested	O
.	O

3.4	O
Hypothemycin	B
affects	O
cytokine	O
production	O
at	O
the	O
mRNA	O
level	O
To	O
define	O
at	O
which	O
stage	O
of	O
the	O
induction	O
process	O
hypothemycin	B
alters	O
the	O
production	O
of	O
cytokines	O
,	O
we	O
next	O
examined	O
its	O
effect	O
on	O
cytokine	O
mRNA	O
expression	O
.	O

Human	O
T	O
cells	O
(	O
106	O
/ml	O
)	O
were	O
activated	O
with	O
anti	O
-	O
CD3	O
mAb+PMA	O
(	O
1	O
ng	O
/	O
ml	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
hypothemycin	B
,	O
or	O
zearalenone	B
.	O

After	O
19	O
h	O
of	O
culture	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
the	O
expression	O
of	O
transcripts	O
for	O
multiple	O
cytokines	O
was	O
detected	O
by	O
multiprobe	O
RPA	O
analysis	O
.	O

As	O
shown	O
in	O
Fig.	O
5	O
,	O
hypothemycin	B
strongly	O
suppressed	O
IL-2	O
mRNA	O
induction	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
while	O
zearalenone	B
had	O
no	O
effect	O
.	O

Hypothemycin	B
also	O
clearly	O
inhibited	O
the	O
expression	O
of	O
transcripts	O
for	O
IL-10	O
and	O
IFN	O
-	O
γ	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
transcripts	O
for	O
IL-4	O
,	O
IL-5	O
and	O
IL-13	O
was	O
enhanced	O
,	O
with	O
a	O
maximal	O
effect	O
in	O
the	O
presence	O
of	O
66	O
nM	O
hypothemycin	B
.	O

Again	O
,	O
zearalone	B
did	O
not	O
alter	O
this	O
expression	O
.	O

Therefore	O
,	O
for	O
these	O
particular	O
cytokines	O
,	O
the	O
modulation	O
of	O
mRNA	O
expression	O
parallels	O
that	O
of	O
protein	O
secretion	O
as	O
detected	O
in	O
culture	O
supernatants	O
(	O
Fig.	O
4	O
)	O
,	O
suggesting	O
that	O
hypothemycin	B
affects	O
predominantly	O
gene	O
transcription	O
and/or	O
transcript	O
stability	O
.	O

Note	O
that	O
hypothemycin	B
was	O
also	O
found	O
to	O
inhibit	O
IL-9	O
mRNA	O
expression	O
in	O
these	O
experiments	O
(	O
Fig.	O
5	O
)	O
.	O

3.5	O
Hypothemycin	B
inhibits	O
more	O
strongly	O
CD69	O
expression	O
induced	O
by	O
PMA	B
than	O
by	O
ionomycin	B
As	O
mentioned	O
before	O
,	O
cytokine	O
induction	O
upon	O
T	O
cell	O
activation	O
depends	O
on	O
multiple	O
signaling	O
pathways	O
(	O
Cantrell	O
,	O
1996	O
;	O
Alberola	O
-	O
Ila	O
et	O
al.	O
,	O
1997	O
)	O
.	O

As	O
an	O
approach	O
to	O
start	O
delineating	O
the	O
site	O
of	O
action	O
of	O
hypothemycin	B
within	O
T	O
cell	O
signaling	O
events	O
,	O
we	O
used	O
an	O
artificial	O
model	O
where	O
the	O
activation	O
of	O
the	O
T	O
cells	O
is	O
monitored	O
by	O
induction	O
of	O
expression	O
of	O
the	O
cell	O
surface	O
molecule	O
CD69	O
.	O

This	O
induction	O
can	O
be	O
promoted	O
upon	O
treatment	O
either	O
by	O
PMA	B
,	O
which	O
recruits	O
PKC	O
-	O
dependent	O
,	O
calcineurin	O
-	O
independent	O
signaling	O
,	O
including	O
the	O
ERK1	O
/	O
2	O
kinase	O
pathway	O
,	O
or	O
by	O
the	O
Ca2	B
+	I
ionophore	O
,	O
ionomycin	B
,	O
which	O
mimics	O
Ca2	B
+	I
signaling	O
and	O
activates	O
calcineurin	O
(	O
Taylor	O
-	O
Fishwick	O
and	O
Siegel	O
,	O
1995	O
)	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
PD98059	B
,	O
a	O
selective	O
inhibitor	O
of	O
MEK1	O
(	O
Dudley	O
et	O
al.	O
,	O
1995	O
)	O
,	O
markedly	O
suppresses	O
the	O
CD69	O
response	O
induced	O
by	O
PMA	B
but	O
not	O
by	O
ionomycin	B
,	O
while	O
the	O
reverse	O
is	O
true	O
for	O
the	O
calcineurin	O
inhibitor	O
,	O
FK506	B
(	O
Dumont	O
et	O
al.	O
,	O
1998	O
)	O
.	O

The	O
data	O
in	O
Fig.	O
6	O
demonstrate	O
that	O
incubation	O
of	O
mouse	O
T	O
cells	O
for	O
14	O
h	O
in	O
the	O
presence	O
of	O
PMA	B
(	O
10	O
ng	O
/	O
ml	O
)	O
induced	O
a	O
high	O
level	O
of	O
CD69	O
cell	O
surface	O
expression	O
.	O

This	O
induction	O
was	O
suppressed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
hypothemycin	B
,	O
whereas	O
FK506	B
(	O
10	O
nM	O
)	O
had	O
little	O
effect	O
.	O

In	O
contrast	O
,	O
CD69	O
expression	O
elicited	O
by	O
treatment	O
with	O
ionomycin	B
(	O
2	O
μg	O
/	O
ml	O
)	O
was	O
less	O
inhibited	O
by	O
hypothemycin	B
than	O
by	O
FK506	B
.	O

Therefore	O
,	O
hypothemycin	B
appears	O
to	O
preferentially	O
disrupt	O
CD69-induction	O
events	O
driven	O
by	O
PKC	O
activation	O
while	O
leaving	O
relatively	O
unaffected	O
those	O
driven	O
by	O
calcineurin	O
activation	O
.	O

3.6	O
Effects	O
of	O
hypothemycin	B
on	O
ERK1	O
/	O
2	O
activation	O
in	O
T	O
cells	O
Since	O
one	O
of	O
the	O
signaling	O
pathways	O
activated	O
by	O
PMA	B
in	O
T	O
cells	O
is	O
the	O
ERK1	O
/	O
2	O
MAP	O
kinase	O
,	O
through	O
activation	O
of	O
its	O
upstream	O
kinase	O
,	O
MEK	O
(	O
Dumont	O
et	O
al.	O
,	O
1998	O
)	O
,	O
the	O
CD69	O
data	O
mentioned	O
above	O
led	O
us	O
to	O
investigate	O
the	O
effect	O
of	O
hypothemycin	B
on	O
this	O
cascade	O
at	O
the	O
biochemical	O
level	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
ERK1	O
/	O
2	O
MAP	O
kinase	O
is	O
known	O
to	O
be	O
reflected	O
by	O
selective	O
phosphorylation	O
of	O
these	O
enzymes	O
which	O
can	O
be	O
detected	O
using	O
phosphospecific	O
antibodies	O
.	O

The	O
data	O
in	O
Fig.	O
7	O
a	O
show	O
that	O
PMA	B
treatment	O
of	O
human	O
T	O
cells	O
(	O
107	O
cells	O
/	O
ml	O
)	O
resulted	O
within	O
10	O
min	O
in	O
the	O
emergence	O
of	O
the	O
phosphorylated	O
forms	O
of	O
ERK1	O
/	O
2	O
as	O
seen	O
by	O
immunoblot	O
analysis	O
of	O
the	O
cell	O
lysates	O
.	O

This	O
was	O
inhibited	O
by	O
hypothemycin	B
at	O
3	O
and	O
0.3	O
μM	O
but	O
not	O
by	O
zearalenone	B
at	O
3	O
μM.	O
PD98059	B
,	O
used	O
here	O
as	O
a	O
positive	O
control	O
,	O
also	O
inhibited	O
ERK1	O
/	O
2	O
phosphorylation	O
.	O

These	O
compounds	O
did	O
not	O
affect	O
the	O
levels	O
of	O
ERK1	O
/	O
2	O
protein	O
detectable	O
with	O
a	O
phosphorylation	O
-	O
independent	O
antibody	O
(	O
Fig.	O
7	O
b	O
)	O
.	O

Similar	O
data	O
were	O
obtained	O
in	O
murine	O
T	O
cells	O
activated	O
with	O
PMA	B
at	O
10	O
ng	O
/	O
ml	O
(	O
data	O
not	O
shown	O
)	O
.	O

4	O
Discussion	O
Through	O
screening	O
of	O
microbial	O
broths	O
,	O
we	O
have	O
identified	O
the	O
immunosuppressive	O
activity	O
of	O
hypothemycin	B
,	O
a	O
compound	O
previously	O
known	O
for	O
its	O
antibiotic	O
activity	O
(	O
Nair	O
and	O
Carey	O
,	O
1980	O
;	O
Nair	O
et	O
al.	O
,	O
1981	O
;	O
Agatsuma	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
present	O
study	O
provides	O
evidence	O
that	O
hypothemycin	B
affects	O
certain	O
events	O
of	O
T	O
cell	O
activation	O
that	O
lead	O
to	O
cytokine	O
production	O
and	O
proliferation	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
while	O
the	O
antibiotic	O
/	O
cytotoxic	O
properties	O
of	O
hypothemycin	B
were	O
seen	O
only	O
in	O
the	O
high	O
micromolar	O
range	O
(	O
Nair	O
and	O
Carey	O
,	O
1980	O
;	O
Nair	O
et	O
al.	O
,	O
1981	O
;	O
Agatsuma	O
et	O
al.	O
,	O
1993	O
)	O
,	O
the	O
effects	O
on	O
T	O
cells	O
reported	O
here	O
occurred	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
compound	B
.	O

Furthermore	O
,	O
a	O
structurally	O
related	O
compound	B
,	O
zearalenone	B
,	O
which	O
has	O
estrogenic	O
activity	O
in	O
vivo	O
(	O
Kuiper	O
-	O
Goodman	O
et	O
al.	O
,	O
1987	O
)	O
had	O
no	O
discernable	O
effect	O
at	O
micromolar	O
concentrations	O
in	O
our	O
experimental	O
system	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
mostly	O
utilized	O
artificial	O
modes	O
of	O
stimulation	O
of	O
the	O
T	O
cells	O
,	O
through	O
anti	O
-	O
CD3	O
mAb	O
and	O
PMA	B
co	O
-	O
treatments	O
,	O
causing	O
a	O
vigorous	O
polyclonal	O
activation	O
of	O
the	O
T	O
cells	O
.	O

Under	O
these	O
conditions	O
,	O
hypothemycin	B
was	O
found	O
to	O
inhibit	O
the	O
proliferative	O
response	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
,	O
in	O
fact	O
,	O
this	O
inhibitory	O
activity	O
did	O
not	O
require	O
PMA	B
costimulation	O
since	O
it	O
was	O
also	O
observed	O
with	O
human	O
PBMC	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
alone	O
.	O

Moreover	O
,	O
the	O
inhibition	O
of	O
T	O
cell	O
proliferation	O
by	O
hypothemycin	B
was	O
partially	O
reversed	O
by	O
exogeneous	O
IL-2	O
,	O
a	O
feature	O
similar	O
to	O
the	O
inhibition	O
by	O
agents	B
known	O
to	O
suppress	O
IL-2	O
production	O
rather	O
than	O
IL-2-responsiveness	O
,	O
such	O
as	O
CsA	B
and	O
FK506	B
(	O
Dumont	O
,	O
1996	O
)	O
.	O

Accordingly	O
,	O
hypothemycin	B
inhibited	O
potently	O
the	O
production	O
of	O
IL-2	O
both	O
at	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

This	O
production	O
was	O
found	O
to	O
be	O
affected	O
even	O
under	O
conditions	O
where	O
hypothemycin	B
had	O
reduced	O
activity	O
on	O
the	O
proliferation	O
,	O
namely	O
upon	O
activation	O
of	O
human	O
T	O
cells	O
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
PMA	B
.	O

It	O
is	O
likely	O
that	O
,	O
in	O
this	O
situation	O
,	O
the	O
residual	O
amount	O
of	O
IL-2	O
secreted	O
in	O
the	O
presence	O
of	O
hypothemycin	B
was	O
high	O
enough	O
to	O
support	O
the	O
proliferation	O
of	O
the	O
cells	O
.	O

Indeed	O
,	O
the	O
fact	O
that	O
the	O
antiproliferative	O
effect	O
of	O
hypothemycin	B
in	O
activated	O
T	O
cells	O
is	O
dependent	O
on	O
the	O
strength	O
of	O
the	O
stimulation	O
further	O
argues	O
in	O
favor	O
of	O
a	O
selective	O
mode	O
of	O
action	O
for	O
the	O
compound	B
.	O

The	O
T	O
cell	O
stimulation	O
modality	O
utilized	O
here	O
,	O
leading	O
to	O
an	O
array	O
of	O
cytokines	O
being	O
produced	O
in	O
sufficient	O
amounts	O
for	O
accurate	O
quantitation	O
enabled	O
us	O
to	O
examine	O
the	O
effect	O
of	O
hypothemycin	B
on	O
this	O
production	O
.	O

Besides	O
IL-2	O
,	O
the	O
production	O
of	O
IL-6	O
,	O
IL-9	O
(	O
detected	O
at	O
the	O
mRNA	O
level	O
)	O
,	O
IL-10	O
,	O
IFN	O
-	O
γ	O
and	O
TNF	O
-	O
α	O
,	O
was	O
found	O
to	O
be	O
strongly	O
inhibited	O
by	O
hypothemycin	B
.	O

Therefore	O
,	O
this	O
compound	B
interrupts	O
signaling	O
events	O
of	O
T	O
cell	O
activation	O
that	O
are	O
required	O
for	O
the	O
positive	O
regulation	O
of	O
these	O
cytokines	O
.	O

In	O
marked	O
contrast	O
,	O
there	O
was	O
a	O
pronounced	O
augmentation	O
of	O
secretion	O
of	O
IL-4	O
,	O
IL-5	O
and	O
IL-13	O
in	O
presence	O
of	O
certain	O
concentrations	O
of	O
the	O
compound	B
.	O

RPA	O
analysis	O
further	O
demonstrated	O
that	O
hypothemycin	B
affects	O
gene	O
regulation	O
rather	O
than	O
translational	O
events	O
governing	O
the	O
synthesis	O
of	O
these	O
cytokines	O
.	O

Since	O
IL-4	O
,	O
IL-5	O
and	O
IL-13	O
are	O
mainly	O
produced	O
by	O
Th2	O
cells	O
(	O
Muraille	O
and	O
Leo	O
,	O
1998	O
)	O
,	O
their	O
up	O
-	O
regulation	O
under	O
conditions	O
where	O
the	O
other	O
cytokines	O
were	O
suppressed	O
is	O
particularly	O
intriguing	O
.	O

Such	O
a	O
differential	O
modulation	O
by	O
hypothemycin	B
may	O
point	O
to	O
distinct	O
signaling	O
mechanisms	O
for	O
induction	O
of	O
certain	O
Th2	O
versus	O
Th1	O
cytokines	O
,	O
as	O
indicated	O
by	O
a	O
number	O
of	O
recent	O
studies	O
(	O
Zheng	O
and	O
Flavell	O
,	O
1997	O
;	O
Ranganath	O
et	O
al.	O
,	O
1998	O
;	O
Dong	O
et	O
al.	O
,	O
1998	O
;	O
Kuo	O
and	O
Leiden	O
,	O
1999	O
;	O
Li	O
et	O
al.	O
,	O
1999	O
)	O
.	O

In	O
this	O
respect	O
,	O
hypothemycin	B
may	O
provide	O
a	O
useful	O
probe	O
to	O
explore	O
these	O
mechanisms	O
.	O

It	O
is	O
also	O
striking	O
that	O
the	O
differential	O
modulation	O
of	O
cytokine	O
production	O
by	O
hypothemycin	B
shown	O
here	O
differs	O
from	O
the	O
modulation	O
exerted	O
by	O
FK506	B
under	O
similar	O
conditions	O
but	O
resembles	O
what	O
we	O
previously	O
disclosed	O
in	O
the	O
case	O
of	O
the	O
MEK1	O
inhibitor	O
,	O
PD98059	B
(	O
Dumont	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Further	O
evidence	O
that	O
hypothemycin	B
may	O
affect	O
T	O
cell	O
signaling	O
events	O
in	O
a	O
manner	O
distinct	O
from	O
FK5065	B
and	O
similar	O
to	O
PD98059	B
was	O
obtained	O
by	O
studying	O
the	O
effect	O
of	O
the	O
compounds	B
on	O
CD69	O
induction	O
.	O

Although	O
CD69	O
induction	O
may	O
occur	O
independently	O
from	O
cytokine	O
induction	O
(	O
Castellanos	O
et	O
al.	O
,	O
1997	O
)	O
,	O
it	O
provides	O
a	O
convenient	O
model	O
to	O
probe	O
for	O
the	O
site	O
of	O
action	O
of	O
T	O
cell	O
inhibitors	O
as	O
it	O
can	O
be	O
elicited	O
either	O
through	O
PKC	O
-	O
dependent	O
,	O
calcineurin	O
-	O
independent	O
mechanisms	O
by	O
PMA	B
or	O
through	O
Ca2	B
+	I
/calcineurin	O
-	O
dependent	O
mechanisms	O
by	O
ionomycin	B
(	O
Taylor	O
-	O
Fishwick	O
and	O
Siegel	O
,	O
1995	O
)	O
.	O

Hypothemycin	B
inhibited	O
markedly	O
the	O
PMA	B
-	O
induced	O
response	O
but	O
to	O
a	O
lesser	O
extend	O
the	O
ionomycin	B
-	O
induced	O
response	O
,	O
whereas	O
FK506	B
exerted	O
an	O
opposite	O
pattern	O
of	O
inhibition	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
had	O
shown	O
that	O
PD98059	B
also	O
is	O
able	O
to	O
inhibit	O
CD69	O
induction	O
by	O
PMA	B
but	O
not	O
by	O
ionomycin	B
(	O
Dumont	O
et	O
al.	O
,	O
1998	O
)	O
.	O

The	O
similarities	O
between	O
the	O
cellular	O
effects	O
of	O
hypothemycin	B
and	O
of	O
PD98059	B
led	O
us	O
to	O
examine	O
whether	O
hypothemycin	B
would	O
prevent	O
activation	O
of	O
the	O
MAP	O
kinases	O
ERK1	O
/	O
2	O
in	O
T	O
cells	O
.	O

Our	O
data	O
demonstrated	O
that	O
hypothemycin	B
does	O
reduce	O
the	O
phosphorylation	O
of	O
these	O
enzymes	O
when	O
induced	O
by	O
PMA	B
treatment	O
in	O
T	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
hypothemycin	B
is	O
capable	O
of	O
disrupting	O
the	O
ERK1	O
/	O
2	O
cascade	O
in	O
T	O
cells	O
,	O
even	O
though	O
it	O
is	O
difficult	O
to	O
relate	O
directly	O
this	O
biochemical	O
alteration	O
to	O
the	O
effects	O
of	O
the	O
compound	B
on	O
proliferation	O
and	O
cytokine	O
production	O
,	O
because	O
of	O
the	O
artificial	O
stimulus	O
utilized	O
(	O
PMA	B
)	O
,	O
and	O
also	O
because	O
the	O
cell	O
concentrations	O
were	O
different	O
(	O
107	O
/ml	O
vs.	O
5	O
×	O
105	O
/ml	O
)	O
in	O
the	O
two	O
systems	O
.	O

Nevertheless	O
,	O
our	O
observations	O
are	O
consistent	O
with	O
a	O
recent	O
studies	O
revealing	O
that	O
hypothemycin	B
potently	O
inhibits	O
the	O
enzymatic	O
activity	O
MEK1	O
in	O
vitro	O
,	O
with	O
an	O
IC50	O
of	O
15	O
nM	O
(	O
Zhao	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Furthermore	O
,	O
analysis	O
of	O
several	O
hypothemycin	B
analogs	B
revealed	O
a	O
correlation	O
between	O
their	O
abilities	O
to	O
inhibit	O
MEK1	O
in	O
vitro	O
and	O
to	O
inhibit	O
IL-2	O
and	O
up	O
-	O
regulate	O
IL-4	O
production	O
in	O
T	O
cells	O
(	O
Camacho	O
and	O
Dumont	O
,	O
unpublished	O
observations	O
)	O
.	O

A	O
close	O
structural	O
relative	O
of	O
hypothemycin	B
,	O
Ro	B
09	I
-	I
2210	I
,	O
was	O
also	O
reported	O
to	O
suppress	O
T	O
cell	O
proliferation	O
and	O
to	O
inhibit	O
MEK1	O
with	O
an	O
IC50	O
of	O
59	O
nM	O
(	O
Williams	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Importantly	O
,	O
these	O
latter	O
studies	O
have	O
also	O
shown	O
that	O
neither	O
hypothemycin	B
(	O
Zhao	O
et	O
al.	O
,	O
1999	O
)	O
nor	O
Ro	O
09	O
-	O
2210	O
(	O
Williams	O
et	O
al.	O
,	O
1998	O
)	O
alter	O
the	O
enzymatic	O
activity	O
of	O
PKC	O
in	O
vitro	O
.	O

Therefore	O
,	O
the	O
inhibitory	O
effect	O
of	O
hypothemycin	B
on	O
T	O
cell	O
activation	O
may	O
be	O
attributed	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
blockade	O
of	O
MEK1	O
function	O
,	O
rather	O
than	O
a	O
direct	O
effect	O
on	O
PKC	O
.	O

However	O
,	O
in	O
experiments	O
not	O
shown	O
here	O
,	O
we	O
obtained	O
preliminary	O
evidence	O
that	O
MEK	O
may	O
not	O
be	O
the	O
only	O
biochemical	O
target	O
for	O
hypothemycin	B
in	O
T	O
cells	O
since	O
JNK	O
activation	O
by	O
anisomycin	B
was	O
also	O
affected	O
by	O
this	O
compound	O
.	O

In	O
this	O
respect	O
,	O
hypothemycin	B
appears	O
to	O
differ	O
from	O
PD98059	B
,	O
which	O
does	O
not	O
inhibit	O
JNK	O
activation	O
(	O
Dudley	O
et	O
al.	O
,	O
1995	O
)	O
.	O

At	O
the	O
moment	O
,	O
we	O
can	O
not	O
rule	O
out	O
that	O
hypothemycin	B
alters	O
other	O
targets	O
,	O
in	O
addition	O
to	O
the	O
ERK	O
and	O
JNK	O
pathways	O
.	O

This	O
might	O
well	O
be	O
the	O
case	O
at	O
micromolar	O
concentrations	O
of	O
the	O
compound	B
where	O
its	O
inhibitory	O
effect	O
on	O
proliferation	O
is	O
no	O
longer	O
reversed	O
by	O
exogeneous	O
IL-2	O
.	O

Additional	O
biochemical	O
analyses	O
of	O
the	O
effect	O
of	O
hypothemycin	B
in	O
T	O
cells	O
,	O
especially	O
when	O
stimulated	O
through	O
the	O
CD3	O
/	O
TCR	O
complex	O
,	O
will	O
be	O
required	O
to	O
better	O
delineate	O
the	O
selectivity	O
of	O
this	O
compound	B
.	O

While	O
the	O
precise	O
mechanism	O
of	O
action	O
of	O
hypothemycin	B
remains	O
to	O
be	O
defined	O
,	O
the	O
present	O
studies	O
demonstrated	O
that	O
it	O
acts	O
as	O
a	O
potent	O
,	O
non	O
cytotoxic	O
inhibitor	O
of	O
T	O
cell	O
activation	O
,	O
in	O
a	O
manner	O
different	O
from	O
a	O
calcineurin	O
inhibitor	O
.	O

Further	O
evaluation	O
of	O
the	O
immunosuppressive	O
activity	O
of	O
hypothemycin	B
and	O
of	O
its	O
potential	O
ability	O
to	O
promote	O
T	O
cell	O
anergy	O
(	O
DeSilva	O
et	O
al.	O
,	O
1996	O
;	O
Li	O
et	O
al.	O
,	O
1996	O
;	O
Powell	O
et	O
al.	O
,	O
1998	O
)	O
therefore	O
appears	O
justified	O
.	O

Acknowledgements	O

We	O
wish	O
to	O
thank	O
Jeanine	O
Regenthal	O
and	O
Paul	O
Fischer	O
for	O
assistance	O
with	O
the	O
FCM	O
analysis	O
experiments	O
.	O

Actin	O
is	O
present	O
at	O
high	O
concentrations	O
in	O
virtually	O
every	O
eukaryotic	O
cell	O
.	O

About	O
half	O
of	O
the	O
intracellular	O
actin	O
is	O
stabilized	O
in	O
its	O
monomeric	O
form	O
(	O
G	O
-	O
actin	O
)	O
by	O
interaction	O
with	O
sequestering	O
factors	O
[	O
1	O
]	O
.	O

This	O
monomeric	O
actin	O
can	O
be	O
used	O
for	O
fast	O
generation	O
of	O
new	O
actin	O
filaments	O
after	O
an	O
appropriate	O
intra-	O
or	O
extracellular	O
signal	O
[	O
2	O
]	O
.	O

The	O
β	B
-	I
thymosins	I
are	O
a	O
family	O
of	O
highly	O
conserved	O
polar	O
5	O
kDa	O
peptides	B
that	O
are	O
present	O
in	O
many	O
tissues	O
and	O
cells	O
of	O
different	O
vertebrates	O
except	O
human	O
and	O
chicken	O
erythrocytes	O
(	O
[	O
3	O
]	O
,	O
unpublished	O
data	O
)	O
.	O

The	O
most	O
abundant	O
species	O
of	O
β	B
-	I
thymosins	I
in	O
mammalian	O
tissues	O
is	O
thymosin	B
β4	I
,	O
which	O
was	O
originally	O
supposed	O
to	O
be	O
a	O
thymic	O
hormone	O
[	O
4,5	O
]	O
.	O

Safer	O
and	O
coworkers	O
demonstrated	O
in	O
1991	O
that	O
thymosin	B
β4	I
is	O
identical	O
to	O
the	O
actin	O
-	O
sequestering	O
factor	O
Fx	O
[	O
6,7	O
]	O
.	O

Thymosin	B
β4	I
is	O
now	O
regarded	O
as	O
the	O
main	O
intracellular	O
G	O
-	O
actin	O
-	O
sequestering	O
peptide	B
in	O
most	O
mammalian	O
cells	O
[	O
8–10	O
]	O
and	O
it	O
forms	O
a	O
1:1	O
complex	O
with	O
G	O
-	O
actin	O
,	O
thereby	O
inhibiting	O
salt	O
-	O
induced	O
polymerization	O
to	O
F	O
-	O
actin	O
[	O
11–15	O
]	O
.	O

We	O
had	O
found	O
that	O
thymosin	B
β4	I
is	O
present	O
in	O
very	O
high	O
concentrations	O
in	O
blood	O
cells	O
,	O
with	O
the	O
exception	O
of	O
erythrocytes	O
[	O
3	O
]	O
.	O

The	O
concentration	O
of	O
thymosin	B
β4	I
in	O
serum	O
is	O
normally	O
low	O
,	O
but	O
increases	O
if	O
the	O
serum	O
is	O
not	O
immediately	O
removed	O
from	O
clotted	O
blood	O
.	O

Cassimeris	O
et	O
al.	O
[	O
16	O
]	O
showed	O
first	O
that	O
thymosin	B
β4	I
is	O
the	O
main	O
G	O
-	O
actin	O
sequestering	O
peptide	B
in	O
resting	O
human	O
platelets	O
and	O
later	O
the	O
same	O
group	O
showed	O
that	O
it	O
is	O
involved	O
in	O
cellular	O
events	O
after	O
activation	O
of	O
platelets	O
[	O
17	O
]	O
.	O

In	O
1995	O
Grant	O
et	O
al.	O
reported	O
a	O
5-fold	O
increase	O
of	O
thymosin	B
β4	I
mRNA	O
during	O
morphological	O
differentiation	O
of	O
endothelial	O
cells	O
into	O
capillary	O
-	O
like	O
tubes	O
[	O
18	O
]	O
.	O

The	O
peptide	B
itself	O
increases	O
the	O
migration	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
4–6-fold	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
19	O
]	O
.	O

Frohm	O
and	O
coworkers	O
reported	O
high	O
concentrations	O
of	O
thymosin	B
β4	I
in	O
wound	O
and	O
blister	O
fluids	O
[	O
20	O
]	O
.	O

It	O
was	O
also	O
postulated	O
that	O
β	B
-	I
thymosins	I
may	O
play	O
a	O
role	O
in	O
apoptosis	O
[	O
21	O
]	O
.	O

Transglutaminases	O
are	O
Ca2	B
+	I
-dependent	O
enzymes	O
,	O
which	O
catalyze	O
the	O
posttranslational	O
modification	O
of	O
proteins	O
through	O
the	O
exchange	O
of	O
primary	B
amines	I
for	O
ammonia	B
at	O
the	O
carboxamide	B
group	I
of	O
glutamine	B
residues	I
.	O

Peptide	O
-	O
bound	O
lysine	B
residues	I
or	O
naturally	O
occurring	O
polyamines	B
serve	O
quite	O
unspecifically	O
as	O
primary	B
amine	I
substrates	O
[	O
22,23	O
]	O
.	O

In	O
the	O
case	O
of	O
peptide	O
-	O
bound	O
lysine	B
residues	I
covalent	O
isopeptide	B
bonds	O
were	O
formed	O
,	O
which	O
are	O
resistant	O
against	O
proteolysis	O
.	O

Transglutaminases	O
have	O
a	O
broad	O
specificity	O
for	O
primary	B
amine	I
substrates	O
,	O
whereas	O
the	O
number	O
of	O
proteins	O
which	O
serve	O
as	O
glutaminyl	B
substrates	O
is	O
highly	O
restricted	O
.	O

It	O
is	O
now	O
well	O
established	O
that	O
transglutaminases	O
are	O
implicated	O
in	O
a	O
wide	O
range	O
of	O
biological	O
phenomena	O
like	O
blood	O
coagulation	O
(	O
factor	O
XIIIa	O
)	O
,	O
wound	O
healing	O
,	O
terminal	O
differentiation	O
,	O
and	O
apoptosis	O
[	O
22,23	O
]	O
.	O

Safer	O
et	O
al.	O
described	O
cross	O
-	O
linking	O
of	O
Lys-38	B
of	O
thymosin	B
β4	I
to	O
Gln-41	B
of	O
actin	O
by	O
reaction	O
with	O
transglutaminase	O
[	O
24	O
]	O
.	O

However	O
,	O
in	O
this	O
transglutamination	O
thymosin	B
β4	I
served	O
as	O
an	O
aminyl	O
substrate	O
.	O

When	O
we	O
further	O
analyzed	O
the	O
possible	O
role	O
of	O
thymosin	B
β4	I
as	O
a	O
substrate	O
of	O
transglutaminases	O
we	O
found	O
that	O
thymosin	B
β4	I
was	O
labeled	O
with	O
dansylcadaverine	B
by	O
transglutaminase	O
,	O
hence	O
reacting	O
as	O
a	O
specific	O
glutaminyl	B
substrate	O
.	O

Here	O
,	O
we	O
describe	O
the	O
molecular	O
properties	O
of	O
the	O
products	O
formed	O
.	O

Additionally	O
,	O
we	O
show	O
that	O
labeling	O
of	O
thymosin	B
β4	I
does	O
not	O
interfere	O
with	O
G	O
-	O
actin	O
-	O
sequestering	O
activity	O
and	O
,	O
therefore	O
,	O
may	O
serve	O
as	O
a	O
useful	O
tool	O
for	O
further	O
investigations	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Reagents	O
were	O
obtained	O
from	O
the	O
following	O
sources	O
:	O
LiChroprep	B
RP-18	I
(	O
40–63	O
μm	O
)	O
and	O
trifluoroacetic	B
acid	I
(	O
TFA	B
,	O
Uvasol	O
)	O
from	O
Merck	O
(	O
Darmstadt	O
,	O
Germany	O
)	O
;	O
1-ethyl-3-	B
[	I
3-	I
(	I
dimethylamino	I
)	I
propyl	I
]	I
carbodiimide	I
(	O
EDC	B
)	O
,	O
monodansylcadaverine	B
[	O
N	B
-	I
(	I
5-aminopentyl	I
)	I
-5-	I
(	I
dimethylamino	I
)	I
naphthalene-1-sulfonamide	I
]	O
(	O
DNC	B
)	O
,	O
and	O
guinea	O
pig	O
liver	O
transglutaminase	O
from	O
Sigma	O
;	O
AsnC	O
proteinase	O
from	O
PanVera	O
Corporation	O
(	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
and	O
trypsin	O
from	O
Boehringer	O
Mannheim	O
(	O
Mannheim	O
,	O
Germany	O
)	O
.	O

2.2	O
Proteins	O
and	O
peptides	O
Actin	O
was	O
prepared	O
from	O
bovine	O
heart	O
or	O
rabbit	O
skeletal	O
muscle	O
by	O
the	O
method	O
of	O
Pardee	O
and	O
Spudich	O
[	O
25	O
]	O
and	O
further	O
purified	O
by	O
gel	O
filtration	O
[	O
26	O
]	O
on	O
a	O
Sephacryl	B
S300	I
column	O
(	O
Pharmacia	O
)	O
equilibrated	O
with	O
G	B
buffer	I
(	O
2	O
mM	O
Tris	B
–	I
HCl	I
,	O
0.2	O
mM	O
ATP	B
,	O
0.2	O
mM	O
CaCl2	B
,	O
0.5	O
mM	O
mercaptoethanol	B
,	O
0.05	O
%	O
NaN3	B
,	O
pH	O
8.0	O
)	O
.	O

G	O
-	O
actin	O
was	O
stored	O
in	O
G	B
buffer	I
at	O
0	O
°	O
C	O
.	O

Rabbit	O
skeletal	O
muscle	O
actin	O
was	O
pyrenylated	O
following	O
the	O
procedure	O
given	O
in	O
[	O
27	O
]	O
.	O

Thymosin	B
β4	I
was	O
isolated	O
from	O
bovine	O
spleen	O
as	O
described	O
[	O
28	O
]	O
.	O

The	O
purity	O
of	O
the	O
preparations	O
was	O
demonstrated	O
by	O
reverse	O
phase	O
HPLC	O
.	O

The	O
concentrations	O
of	O
thymosin	B
β4	I
and	O
actin	O
were	O
determined	O
by	O
amino	B
acid	I
analysis	O
after	O
acid	B
hydrolysis	O
(	O
6	O
M	O
HCl	B
,	O
155	O
°	O
C	O
,	O
1	O
h	O
)	O
and	O
precolumn	O
derivatization	O
with	O
o	B
-phthaldialdehyde	I
/	O
3-mercaptopropionic	B
acid	I
[	O
29	O
]	O
.	O

Proteolytic	O
fragments	O
of	O
peptides	B
(	O
thymosin	B
β4	I
and	O
modified	B
thymosin	I
β4	I
)	O
were	O
prepared	O
by	O
the	O
following	O
procedures	O
:	O
AsnC	O
endoproteinase	O
:	O
1	O
μg	O
of	O
peptide	B
was	O
incubated	O
with	O
1	O
μg	O
protease	O
in	O
10	O
μl	O
reaction	O
buffer	O
(	O
50	O
mM	O
sodium	B
acetate	I
,	O
pH	O
5.0	O
,	O
0.2	O
mM	O
DTT	B
,	O
0.2	O
mM	O
EDTA	B
)	O
;	O
trypsin	O
:	O
50	O
μg	O
peptide	B
TG51	O
was	O
digested	O
with	O
2	O
μg	O
trypsin	O
in	O
50	O
μl	O
1	O
%	O
NH4	B
HCO3	I
.	O

All	O
digestions	O
were	O
incubated	O
for	O
16	O
h	O
at	O
room	O
temperature	O
.	O

Thereafter	O
,	O
reactions	O
were	O
stopped	O
by	O
adding	O
an	O
equal	O
volume	O
of	O
10	O
%	O
TFA	B
.	O

Prior	O
to	O
analysis	O
by	O
MALDI	O
-	O
TOF	O
-	O
MS	O
the	O
samples	O
were	O
concentrated	O
in	O
vacuo	O
.	O

2.3	O
HPLC	O
Chromatographic	O
conditions	O
were	O
controlled	O
by	O
a	O
Merck	O
-	O
Hitachi	O
L-6200	O
system	O
supplemented	O
with	O
a	O
diode	O
array	O
UV	O
detector	O
(	O
L-7450A	O
,	O
Merck	O
-	O
Hitachi	O
)	O
and	O
with	O
a	O
fluorometer	O
(	O
F-1050	O
,	O
Merck	O
-	O
Hitachi	O
)	O
.	O

The	O
diode	O
array	O
detector	O
signal	O
was	O
recorded	O
on	O
a	O
computer	O
using	O
D-7000	O
HSM	O
software	O
(	O
Merck	O
)	O
and	O
the	O
fluorescence	O
signal	O
on	O
an	O
integrator	O
(	O
D-2500	O
,	O
Merck	O
-	O
Hitachi	O
)	O
.	O

For	O
high	O
sensitivity	O
detection	O
of	O
peptides	O
,	O
a	O
postcolumn	O
derivatization	O
system	O
was	O
used	O
[	O
30	O
]	O
.	O

Analytical	O
separations	O
.	O

Flow	O
rate	O
:	O
0.75	O
ml	O
/	O
min	O
;	O
buffer	O
:	O
0.1	O
%	O
TFA	B
;	O
gradient	O
:	O
linear	O
from	O
0	O
to	O
40	O
%	O
acetonitrile	B
in	O
60	O
min	O
;	O
column	O
:	O
Beckman	O
ODS	O
Ultrasphere	O
(	O
5	O
μm	O
,	O
4.6	O
×	O
250	O
mm	O
)	O
;	O
detection	O
:	O
UV	O
at	O
205	O
nm	O
or	O
fluorescence	O
after	O
postcolumn	O
derivatization	O
with	O
fluorescamine	B
.	O

Preparative	O
separation	O
of	O
the	O
peptides	O
.	O

Flow	O
rate	O
:	O
0.75	O
ml	O
/	O
min	O
;	O
buffer	O
:	O
0.1	O
%	O
trifluoroacetic	B
acid	I
;	O
gradient	O
:	O
linear	O
from	O
0	O
to	O
40	O
%	O
acetonitrile	B
in	O
120	O
min	O
;	O
column	O
:	O
Pharmacia	O
SuperPac	O
Pep	O
-	O
S	O
(	O
5	O
μm	O
,	O
4	O
×	O
250	O
mm	O
)	O
;	O
detection	O
:	O
UV	O
(	O
215	O
nm	O
)	O
or	O
dansyl	O
fluorescence	O
(	O
λ	O
ex	O
=	O
290	O
nm	O
,	O
λ	O
em	O
=	O
540	O
nm	O
)	O
.	O

2.4	O
Gel	O
electrophoretic	O
procedures	O
SDS	B
polyacrylamide	I
gel	I
electrophoresis	O
was	O
performed	O
either	O
by	O
the	O
method	O
of	O
Laemmli	O
[	O
31	O
]	O
or	O
using	O
Pharmacia	O
PhastGel	O
Gradient	O
10–15	O
.	O

Native	O
gel	O
electrophoresis	O
was	O
performed	O
as	O
detailed	O
previously	O
[	O
32	O
]	O
.	O

2.5	O
Transglutamination	O
of	O
thymosin	B
β4	I
with	O
dansylcadaverine	B
To	O
determine	O
the	O
time	O
course	O
of	O
transglutamination	O
,	O
thymosin	B
β4	I
(	O
120	O
μM	O
)	O
was	O
incubated	O
with	O
dansylcadaverine	B
(	O
5	O
mM	O
)	O
in	O
70	O
μl	O
buffer	O
consisting	O
of	O
10	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
7.4	O
,	O
15	O
mM	O
CaCl2	B
,	O
3	O
mM	O
DTT	B
.	O

The	O
reaction	O
was	O
started	O
by	O
addition	O
of	O
0.1	O
U	O
transglutaminase	O
.	O

Immediately	O
after	O
addition	O
of	O
the	O
enzyme	O
(	O
t	O
=	O
0	O
)	O
and	O
at	O
indicated	O
times	O
,	O
10	O
μl	O
were	O
taken	O
from	O
the	O
mixture	O
,	O
diluted	O
in	O
490	O
μl	O
0.1	O
%	O
TFA	B
to	O
stop	O
the	O
reaction	O
and	O
analyzed	O
by	O
HPLC	O
.	O

For	O
preparative	O
separation	O
of	O
labeled	O
peptides	O
,	O
500	O
μg	O
thymosin	B
β4	I
(	O
200	O
μM	O
)	O
was	O
incubated	O
at	O
room	O
temperature	O
with	O
500	O
μg	O
dansylcadaverine	B
(	O
3	O
mM	O
)	O
and	O
0.5	O
U	O
transglutaminase	O
in	O
500	O
μl	O
of	O
the	O
buffer	O
described	O
above	O
.	O

After	O
1	O
and	O
2	O
h	O
,	O
10	O
μl	O
was	O
subjected	O
to	O
analysis	O
by	O
HPLC	O
.	O

The	O
reaction	O
was	O
stopped	O
after	O
4	O
h	O
by	O
addition	O
of	O
5	O
μl	O
TFA	B
.	O

Thereafter	O
,	O
the	O
reaction	O
mixture	O
was	O
subjected	O
to	O
preparative	O
HPLC	O
.	O

Separated	O
peptides	O
were	O
concentrated	O
in	O
vacuo	O
and	O
then	O
characterized	O
by	O
amino	B
acid	I
analysis	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
.	O

2.6	O
Matrix	O
-	O
assisted	O
laser	O
desorption	O
mass	O
spectrometry	O
Mass	O
determinations	O
were	O
performed	O
with	O
a	O
Biflex	O
™	O
III	O
MALDI	O
-	O
TOF	O
mass	O
spectrometer	O
(	O
Bruker	O
Daltonics	O
,	O
Germany	O
)	O
.	O

The	O
instrument	O
is	O
equipped	O
with	O
a	O
nitrogen	O
laser	O
(	O
λ	O
=	O
337	O
nm	O
)	O
and	O
a	O
reflectron	O
.	O

Laser	O
-	O
desorbed	O
positive	O
ions	O
were	O
analyzed	O
after	O
being	O
accelerated	O
by	O
19	O
kV	O
in	O
the	O
reflection	O
mode	O
.	O

External	O
calibration	O
was	O
performed	O
by	O
use	O
of	O
a	O
standard	O
peptide	O
mixture	O
.	O

Usually	O
,	O
30	O
individual	O
spectra	O
were	O
averaged	O
to	O
produce	O
a	O
mass	O
spectrum	O
.	O

Dried	O
peptide	O
samples	O
were	O
dissolved	O
in	O
0.1	O
%	O
TFA	B
containing	O
33	O
%	O
acetonitrile	B
to	O
a	O
final	O
concentration	O
of	O
about	O
20	O
ng	O
/	O
μl	O
.	O

Each	O
sample	O
(	O
1	O
μl	O
)	O
was	O
mixed	O
with	O
2	O
μl	O
of	O
a	O
saturated	O
solution	O
of	O
α	B
-	I
cyano-4-hydroxycinnamic	I
acid	I
(	O
Sigma	O
,	O
Germany	O
)	O
in	O
0.1	O
%	O
TFA	B
,	O
33	O
%	O
acetonitrile	B
and	O
1	O
μl	O
of	O
this	O
mixture	O
was	O
spotted	O
onto	O
a	O
stainless	O
steel	O
target	O
.	O

2.7	O
Viscosimetry	O
and	O
EDC	B
cross	O
-	O
linking	O
Viscosimetric	O
measurements	O
were	O
done	O
with	O
a	O
falling	O
-	O
ball	O
viscometer	O
according	O
to	O
Cooper	O
and	O
Pollard	O
[	O
33	O
]	O
,	O
at	O
an	O
angle	O
of	O
40	O
°	O
relative	O
to	O
horizontal	O
,	O
distance	O
of	O
fall	O
:	O
45	O
mm	O
;	O
ball	O
diameter	O
:	O
0.794	O
mm	O
.	O

G	O
-	O
actin	O
solution	O
(	O
48	O
μl	O
;	O
0.18	O
mg	O
/	O
ml	O
in	O
G	B
buffer	I
)	O
was	O
incubated	O
with	O
or	O
without	O
thymosin	B
β4	I
or	O
dansylcadaverine	B
-	O
labeled	O
peptides	B
for	O
15	O
min	O
at	O
room	O
temperature	O
and	O
thereafter	O
2	O
μl	O
50	O
mM	O
MgCl2	B
was	O
added	O
.	O

The	O
mixture	O
was	O
filled	O
into	O
a	O
glass	O
capillary	O
(	O
diameter	O
0.92	O
mm	O
,	O
50	O
μl	O
micropipettes	O
,	O
Brand	O
No.	O
708733	O
)	O
,	O
sealed	O
at	O
one	O
end	O
and	O
incubated	O
for	O
4	O
h	O
before	O
measuring	O
time	O
of	O
fall	O
.	O

Thereafter	O
,	O
mixtures	O
were	O
removed	O
by	O
centrifugation	O
from	O
the	O
capillaries	O
and	O
incubated	O
with	O
5	O
μl	O
of	O
an	O
EDC	B
solution	O
(	O
36	O
mg	O
/	O
ml	O
)	O
.	O

After	O
2	O
h	O
,	O
an	O
additional	O
5	O
μl	O
EDC	B
solution	O
was	O
added	O
for	O
another	O
2	O
h	O
incubation	O
period	O
.	O

The	O
reaction	O
mixtures	O
were	O
dialyzed	O
overnight	O
in	O
microcollodion	O
bags	O
(	O
Sartorius	O
)	O
against	O
G	B
buffer	I
.	O

Prior	O
to	O
SDS	B
gel	I
electrophoresis	O
,	O
the	O
solutions	O
were	O
concentrated	O
in	O
vacuo	O
.	O

2.8	O
Transglutamination	O
of	O
thymosin	B
β4	I
in	O
the	O
presence	O
of	O
G	O
-	O
actin	O
G	O
-	O
actin	O
and	O
thymosin	B
β4	I
were	O
incubated	O
with	O
transglutaminase	O
in	O
the	O
presence	O
or	O
absence	O
of	O
dansylcadaverine	B
in	O
a	O
buffer	O
consisting	O
of	O
10	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
8.0	O
,	O
1	O
mM	O
CaCl2	B
,	O
5	O
mM	O
DTE	B
,	O
0.5	O
mM	O
ATP	B
,	O
0.2	O
mM	O
NaN3	B
overnight	O
at	O
room	O
temperature	O
.	O

3	O
Results	O
3.1	O
Derivatization	O
of	O
thymosin	B
β4	I
with	O
dansylcadaverine	B
by	O
transglutaminase	O
To	O
elucidate	O
whether	O
thymosin	B
β4	I
could	O
serve	O
as	O
a	O
glutaminyl	B
substrate	O
for	O
guinea	O
pig	O
transglutaminase	O
we	O
incubated	O
the	O
peptide	B
with	O
dansylcadaverine	B
,	O
a	O
well	O
-	O
known	O
fluorescent	O
aminyl	O
substrate	O
of	O
transglutaminase	O
.	O

HPLC	O
analyses	O
taken	O
directly	O
after	O
addition	O
of	O
the	O
enzyme	O
(	O
t	O
=	O
0	O
)	O
and	O
after	O
2	O
h	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

At	O
the	O
beginning	O
of	O
the	O
reaction	O
(	O
A	O
)	O
,	O
the	O
chromatogram	O
showed	O
a	O
large	O
peak	O
for	O
thymosin	B
β4	I
and	O
a	O
very	O
small	O
signal	O
for	O
its	O
sulfoxide	B
(	O
Tβ4	B
(	I
o	I
)	I
)	O
.	O

After	O
2	O
h	O
(	O
B	O
)	O
,	O
the	O
amounts	O
of	O
thymosin	B
β4	I
sulfoxide	I
and	O
thymosin	B
β4	I
were	O
diminished	O
while	O
five	O
new	O
peaks	O
arose	O
.	O

Because	O
of	O
the	O
presence	O
of	O
several	O
new	O
peaks	O
we	O
were	O
interested	O
to	O
elucidate	O
which	O
and	O
whether	O
more	O
than	O
one	O
of	O
the	O
three	O
possible	O
Gln	B
residues	I
were	O
derivatized	O
.	O

Therefore	O
we	O
measured	O
the	O
kinetics	O
of	O
the	O
derivatization	O
reaction	O
by	O
HPLC	O
analysis	O
as	O
described	O
in	O
Section	O
2	O
.	O

Fig.	O
2	O
shows	O
the	O
time	O
course	O
of	O
the	O
derivatization	O
reaction	O
,	O
where	O
the	O
amount	O
of	O
thymosin	B
β4	I
(	O
•	O
)	O
decreased	O
in	O
a	O
logarithmic	O
manner	O
.	O

The	O
products	O
TG47	B
(	O
○	O
)	O
and	O
TG48	B
(	O
■	O
)	O
increased	O
during	O
the	O
first	O
30	O
min	O
and	O
decreased	O
thereafter	O
.	O

The	O
third	O
product	O
TG49	B
(	O
not	O
shown	O
in	O
Fig.	O
2	O
)	O
increased	O
to	O
the	O
same	O
extent	O
as	O
thymosin	B
β4	I
sulfoxide	I
decreased	O
(	O
Fig.	O
1	O
)	O
.	O

Product	O
TG51	B
(	O
▴	O
)	O
first	O
developed	O
nearly	O
parallel	O
to	O
TG47	B
and	O
TG48	B
,	O
but	O
increased	O
further	O
and	O
constituted	O
the	O
main	O
product	O
.	O

After	O
about	O
2	O
h	O
another	O
product	O
(	O
TG55	B
,	O
▵	O
)	O
was	O
detected	O
which	O
was	O
only	O
formed	O
to	O
a	O
small	O
extent	O
during	O
the	O
incubation	O
period	O
.	O

3.2	O
Isolation	O
and	O
characterization	O
of	O
products	O
formed	O
For	O
isolation	O
and	O
characterization	O
of	O
the	O
products	O
,	O
we	O
carried	O
out	O
the	O
reaction	O
in	O
a	O
preparative	O
manner	O
as	O
described	O
in	O
Section	O
2	O
.	O

After	O
preparative	O
HPLC	O
,	O
we	O
isolated	O
six	O
products	O
.	O

Amino	B
acid	I
analysis	O
of	O
the	O
isolated	O
peptides	O
showed	O
identical	O
amino	B
acid	I
compositions	O
for	O
all	O
isolated	O
products	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
peptides	O
were	O
then	O
characterized	O
by	O
mass	O
spectroscopy	O
.	O

Table	O
1	O
summarizes	O
the	O
observed	O
molecular	O
masses	O
,	O
assigned	O
molecular	O
formulas	O
,	O
calculated	O
masses	O
and	O
their	O
deviations	O
.	O

These	O
data	O
showed	O
that	O
there	O
was	O
still	O
unreacted	O
thymosin	B
β4	I
(	O
Tβ4	B
)	O
,	O
two	O
mono	O
-	O
DNC	B
derivatives	O
(	O
[	O
Tβ4	B
∗	I
(	I
DNC	I
)	I
1	I
]	O
;	O
TG47	B
and	O
TG48	B
)	O
,	O
a	O
very	O
low	O
amount	O
of	O
bis	B
-	I
DNC	I
thymosin	I
β4	I
sulfoxide	I
(	O
[	O
Tβ4	B
(	I
o	I
)	I
∗	I
(	I
DNC	I
)	I
2	I
]	O
;	O
TG49	B
)	O
.	O

In	O
addition	O
to	O
a	O
small	O
amount	O
of	O
tris	O
-	O
DNC	O
thymosin	O
β4	O
(	O
[	O
Tβ4	O
∗	O
(	O
DNC	O
)	O
3	O
]	O
;	O
TG55	O
)	O
,	O
a	O
bis	O
-	O
DNC	O
thymosin	O
β4	O
(	O
[	O
Tβ4	O
∗	O
(	O
DNC	O
)	O
2	O
]	O
;	O
TG51	O
)	O
was	O
identified	O
as	O
the	O
main	O
product	O
.	O

3.3	O
Localization	O
of	O
derivatized	O
Gln	B
residues	I
To	O
further	O
elaborate	O
which	O
of	O
the	O
three	O
possible	O
Gln	B
residues	I
were	O
modified	O
,	O
we	O
digested	O
thymosin	B
β4	I
as	O
well	O
as	O
peptides	O
TG47	B
,	O
TG48	B
,	O
and	O
TG51	B
with	O
AsnC	O
proteinase	O
and	O
analyzed	O
the	O
samples	O
by	O
MALDI	O
-	O
TOF	O
-	O
MS	O
.	O

Because	O
thymosin	B
β4	I
possesses	O
only	O
one	O
Asn	B
residue	I
,	O
at	O
position	O
26	O
,	O
this	O
digestion	O
produces	O
two	O
fragments	O
,	O
Tβ4	B
1–26	I
and	O
Tβ4	B
27–43	I
,	O
containing	O
one	O
and	O
two	O
of	O
the	O
Gln	B
residues	I
,	O
respectively	O
.	O

In	O
the	O
case	O
of	O
thymosin	B
β4	I
,	O
the	O
two	O
expected	O
fragments	O
appeared	O
at	O
molecular	O
masses	O
of	O
3109.7	O
(	O
m	O
/z	O
)	O
and	O
1871.7	O
(	O
m	O
/z	O
)	O
(	O
Table	O
2	O
)	O
.	O

In	O
the	O
MALDI	O
mass	O
spectra	O
of	O
digested	O
TG47	B
the	O
C	O
-	O
terminal	O
fragment	O
was	O
shifted	O
to	O
2189.6	O
(	O
m	O
/z	O
)	O
,	O
whereas	O
in	O
the	O
case	O
of	O
TG48	B
the	O
signal	O
for	O
the	O
N	O
-	O
terminal	O
fragment	O
appeared	O
at	O
3430.8	O
(	O
m	O
/z	O
)	O
corresponding	O
to	O
the	O
addition	O
of	O
one	O
DNC	O
(	O
335.5	O
Da	O
)	O
.	O

This	O
indicated	O
that	O
Gln-23	B
of	O
TG48	B
and	O
either	O
Gln-36	B
or	O
39	B
of	O
TG47	B
were	O
derivatized	O
.	O

In	O
the	O
case	O
of	O
digested	O
TG51	B
,	O
both	O
peaks	O
were	O
shifted	O
.	O

Thus	O
,	O
we	O
concluded	O
that	O
Gln-23	B
and	O
also	O
one	O
of	O
the	O
two	O
Gln	B
residues	I
close	O
to	O
the	O
C	O
-	O
terminus	O
had	O
been	O
derivatized	O
in	O
this	O
peptide	O
.	O

To	O
elucidate	O
which	O
of	O
these	O
two	O
residues	O
was	O
derivatized	O
,	O
we	O
digested	O
TG51	B
with	O
trypsin	O
.	O

HPLC	O
analysis	O
of	O
TG51	B
digested	O
with	O
trypsin	O
yielded	O
two	O
major	O
and	O
two	O
minor	O
fluorescent	O
peaks	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
two	O
major	O
peaks	O
were	O
identified	O
by	O
amino	B
acid	I
analysis	O
and	O
MALDI	O
-	O
TOF	O
-	O
MS	O
as	O
DNC	B
-	O
labeled	O
tryptic	O
fragments	O
TG5119–25	B
(	O
m	O
/z	O
=	O
1181.4	O
;	O
expected	O
1182.4	O
)	O
and	O
TG5132–38	B
(	O
m	O
/z	O
=	O
1194.6	O
;	O
expected	O
1195.3	O
)	O
.	O

The	O
two	O
minor	O
fluorescent	O
fragments	O
represented	O
amino	B
acid	I
residues	I
20–25	B
(	O
m	O
/z	O
=	O
1053.3	O
;	O
expected	O
1054.3	O
)	O
and	O
20–31	B
(	O
m	O
/z	O
=	O
1690.0	O
;	O
expected	O
1691.0	O
)	O
of	B
TG51	I
.	O

No	O
DNC	B
-	O
labeled	O
fragment	O
corresponding	O
to	O
TG5139–43	B
was	O
detected	O
.	O

Therefore	O
,	O
Gln-36	B
is	O
the	O
second	O
residue	O
which	O
was	O
readily	O
modified	O
by	O
transglutaminase	O
.	O

3.4	O
Interaction	O
of	O
modified	O
thymosin	B
β4	I
with	O
G	O
-	O
actin	O
After	O
isolation	O
and	O
characterization	O
of	O
the	O
labeled	O
peptides	B
,	O
we	O
asked	O
how	O
these	O
modifications	O
of	O
thymosin	B
β4	I
influenced	O
the	O
interaction	O
with	O
G	O
-	O
actin	O
.	O

We	O
first	O
studied	O
the	O
polymerization	O
-	O
inhibiting	O
capacity	O
of	O
the	O
peptides	B
using	O
viscosimetry	O
.	O

The	O
time	O
of	O
fall	O
for	O
polymerized	O
actin	O
was	O
55±5	O
s	O
(	O
means±S.D.	O
,	O
n	O
=	O
6	O
)	O
.	O

In	O
the	O
presence	O
of	O
an	O
equal	O
amount	O
of	O
thymosin	B
β4	I
,	O
this	O
value	O
decreased	O
to	O
7±1.5	O
s	O
(	O
n	O
=	O
6	O
)	O
,	O
which	O
equaled	O
the	O
value	O
for	O
the	O
buffer	O
solution	O
and	O
represented	O
complete	O
inhibition	O
of	O
polymerization	O
.	O

Using	O
equimolar	O
amounts	O
of	O
thymosin	B
β4	I
sulfoxide	I
(	O
Tβ4	B
(	I
o	I
)	I
)	O
,	O
which	O
is	O
known	O
to	O
inhibit	O
the	O
polymerization	O
only	O
when	O
present	O
in	O
a	O
20-fold	O
excess	O
to	O
G	O
-	O
actin	O
,	O
but	O
not	O
at	O
equimolar	O
concentrations	O
to	O
actin	O
[	O
13	O
]	O
,	O
we	O
determined	O
a	O
value	O
of	O
40±3	O
s	O
(	O
n	O
=	O
4	O
)	O
.	O

For	O
all	O
labeled	O
peptides	O
,	O
values	O
in	O
the	O
range	O
of	O
7–10	O
s	O
were	O
determined	O
at	O
equimolar	O
ratios	O
to	O
G	O
-	O
actin	O
.	O

This	O
indicates	O
that	O
the	O
modification	O
of	O
neither	O
a	O
single	O
nor	O
all	O
glutamyl	B
residues	I
of	O
thymosin	B
β4	I
impaired	O
the	O
inhibition	O
of	O
the	O
salt	O
-	O
induced	O
polymerization	O
.	O

To	O
verify	O
these	O
results	O
,	O
we	O
further	O
analyzed	O
the	O
samples	O
by	O
cross	O
-	O
linking	O
with	O
the	O
zero	O
-	O
length	O
cross	O
-	O
linker	O
EDC	B
and	O
subsequent	O
SDS	B
-	I
PAGE	I
analysis	O
using	O
Pharmacia	O
PhastGel	O
Gradient	O
10–15	O
.	O

Following	O
UV	O
analysis	O
(	O
365	O
nm	O
)	O
of	O
fluorescent	O
bands	O
(	O
Fig.	O
4A	O
)	O
,	O
gel	O
was	O
stained	O
with	O
Coomassie	B
blue	I
(	O
Fig.	O
4B	O
)	O
.	O

Indeed	O
,	O
the	O
expected	O
fluorescent	O
bands	O
appeared	O
when	O
actin	O
was	O
cross	O
-	O
linked	O
with	O
labeled	O
peptides	B
.	O

Coomassie	O
blue	O
staining	O
indicated	O
that	O
all	O
peptides	O
were	O
cross	O
-	O
linked	O
to	O
G	O
-	O
actin	O
to	O
the	O
same	O
extent	O
.	O

Typically	O
,	O
about	O
50	O
%	O
of	O
actin	O
was	O
cross	O
-	O
linked	O
by	O
EDC	B
to	O
β	B
-	I
thymosins	I
.	O

3.5	O
Transglutamination	O
of	O
thymosin	B
β4	I
in	O
the	O
presence	O
of	O
G	O
-	O
actin	O
G	O
-	O
actin	O
has	O
been	O
described	O
as	O
a	O
glutaminyl	B
substrate	O
of	O
transglutaminase	O
[	O
34	O
]	O
and	O
the	O
transglutaminase	O
reaction	O
has	O
been	O
used	O
to	O
cross	O
-	O
link	O
G	O
-	O
actin	O
and	O
thymosin	B
β4	I
[	O
24	O
]	O
.	O

Therefore	O
we	O
studied	O
transglutamination	O
of	O
G	O
-	O
actin	O
in	O
the	O
presence	O
of	O
thymosin	B
β4	I
and	O
dansylcadaverine	B
(	O
Fig.	O
5	O
)	O
.	O

Detection	O
of	O
dansylcadaverine	B
fluorescence	O
after	O
SDS	B
-	I
PAGE	I
(	O
A	O
)	O
showed	O
that	O
the	O
amount	O
of	O
actin	O
–	O
thymosin	B
β4	I
crosslink	O
was	O
very	O
low	O
in	O
the	O
presence	O
of	O
dansylcadaverine	B
and	O
transglutaminase	O
(	O
lane	O
5	O
)	O
,	O
while	O
there	O
were	O
large	O
amounts	O
of	O
dansylcadaverine	B
-	I
labeled	I
thymosin	I
β4	I
(	O
lane	O
5	O
)	O
and	O
actin	O
(	O
lanes	O
3–5	O
)	O
.	O

Subsequent	O
Coomassie	B
blue	I
staining	O
(	O
B	O
)	O
demonstrated	O
that	O
actin	O
and	O
thymosin	B
β4	I
were	O
inefficiently	O
cross	O
-	O
linked	O
by	O
transglutaminase	O
(	O
lanes	O
1	O
and	O
2	O
)	O
.	O

The	O
amount	O
of	O
cross	O
-	O
link	O
further	O
decreased	O
in	O
the	O
presence	O
of	O
dansylcadaverine	B
competing	O
for	O
Lys	B
residues	I
of	O
either	O
G	O
-	O
actin	O
or	O
thymosin	B
β4	I
(	O
100	O
μM	O
,	O
lane	O
5	O
)	O
.	O

In	O
the	O
absence	O
of	O
thymosin	B
β4	I
,	O
dansylcadaverine	B
-	O
labeled	O
actin	O
polymerized	O
to	O
F	O
-	O
actin	O
as	O
revealed	O
by	O
fluorescence	O
detection	O
after	O
native	O
PAGE	O
(	O
Fig.	O
5A	O
,	O
lanes	O
3	O
and	O
4	O
)	O
.	O

This	O
was	O
caused	O
by	O
the	O
calcium	B
concentration	O
needed	O
for	O
activation	O
of	O
transglutaminase	O
(	O
1	O
mM	O
)	O
.	O

In	O
contrast	O
,	O
actin	O
polymerization	O
was	O
drastically	O
inhibited	O
in	O
the	O
presence	O
of	O
100	O
μM	O
thymosin	B
β4	I
,	O
due	O
to	O
complex	O
formation	O
with	O
thymosin	B
β4	I
(	O
lane	O
5	O
)	O
.	O

Coomassie	B
blue	I
staining	O
of	O
native	O
gels	O
(	O
Fig.	O
5B	O
)	O
showed	O
that	O
both	O
G	O
-	O
actin	O
and	O
its	O
complex	O
with	O
thymosin	B
β4	I
were	O
present	O
regardless	O
of	O
whether	O
dansylcadaverine	B
was	O
present	O
or	O
not	O
(	O
lanes	O
1	O
,	O
2	O
and	O
5	O
)	O
.	O

4	O
Discussion	O
In	O
this	O
work	O
,	O
we	O
demonstrated	O
that	O
thymosin	B
β4	I
could	O
serve	O
as	O
a	O
glutaminyl	B
substrate	O
for	O
guinea	O
pig	O
liver	O
transglutaminase	O
at	O
concentrations	O
that	O
are	O
present	O
inside	O
cells	O
.	O

Using	O
proteolytic	O
fragmentation	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectroscopy	O
,	O
we	O
elucidated	O
that	O
Gln	B
residues	I
23	B
and	O
36	B
are	O
easily	O
available	O
for	O
transglutamination	O
,	O
whereas	O
Gln-39	B
reacts	O
very	O
slowly	O
and	O
to	O
a	O
very	O
low	O
extent	O
.	O

Moreover	O
,	O
with	O
this	O
reaction	O
we	O
were	O
able	O
to	O
label	O
thymosin	B
β4	I
with	O
dansylcadaverine	B
as	O
a	O
fluorescent	O
marker	O
without	O
abolishing	O
its	O
interaction	O
with	O
G	O
-	O
actin	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
whether	O
thymosin	B
β4	I
could	O
serve	O
as	O
a	O
specific	O
glutaminyl	B
substrate	O
for	O
the	O
transglutaminase	O
reaction	O
.	O

In	O
recent	O
years	O
it	O
has	O
been	O
shown	O
that	O
thymosin	B
β4	I
may	O
be	O
involved	O
in	O
cellular	O
events	O
like	O
angiogenesis	O
[	O
18,19	O
]	O
,	O
wound	O
healing	O
[	O
20	O
]	O
,	O
apoptosis	O
[	O
21	O
]	O
and	O
blood	O
coagulation	O
[	O
3,16,17	O
]	O
.	O

Because	O
transglutaminases	O
also	O
participate	O
in	O
all	O
these	O
cellular	O
reactions	O
we	O
investigated	O
whether	O
thymosin	B
β4	I
and	O
transglutaminase	O
may	O
interact	O
.	O

Our	O
results	O
clearly	O
show	O
that	O
thymosin	B
β4	I
could	O
serve	O
as	O
a	O
glutaminyl	B
substrate	O
for	O
guinea	O
pig	O
transglutaminase	O
at	O
concentrations	O
which	O
are	O
present	O
inside	O
cells	O
(	O
Fig.	O
1	O
)	O
.	O

Consequently	O
it	O
is	O
likely	O
that	O
thymosin	B
β4	I
,	O
which	O
is	O
present	O
in	O
human	O
platelets	O
in	O
a	O
concentration	O
of	O
about	O
500	O
μM	O
[	O
3,35	O
]	O
,	O
serves	O
as	O
a	O
glutaminyl	B
substrate	O
for	O
factor	O
XIIIa	O
.	O

Our	O
data	O
also	O
verify	O
that	O
not	O
all	O
Gln	B
residues	I
of	O
thymosin	B
β4	I
are	O
readily	O
accessible	O
for	O
the	O
transglutaminase	O
reaction	O
.	O

Gorman	O
and	O
Folk	O
have	O
studied	O
the	O
glutaminyl	B
substrate	O
specificity	O
of	O
factor	O
XIIIa	O
and	O
guinea	O
pig	O
liver	O
transglutaminase	O
[	O
36	O
]	O
.	O

They	O
performed	O
single	O
and	O
multiple	O
amino	B
acid	I
substitutions	O
of	O
a	O
synthetic	O
peptide	B
substrate	O
corresponding	O
to	O
amino	B
acid	I
residues	I
161–175	I
of	I
β	I
-	I
casein	I
,	O
a	O
well	O
-	O
known	O
substrate	O
for	O
factor	O
XIIIa	O
(	O
Fig.	O
6	O
)	O
.	O

It	O
was	O
found	O
that	O
substitution	O
of	O
Lys	B
by	O
a	O
Gly	B
residue	I
at	O
position	O
+	O
2	O
results	O
in	O
a	O
distinct	O
decrease	O
of	O
its	O
glutaminyl	B
donor	O
property	O
with	O
transglutaminase	O
,	O
which	O
is	O
even	O
more	O
pronounced	O
with	O
factor	O
XIIIa	O
.	O

In	O
the	O
case	O
of	O
Gln-23	B
and	O
Gln-36	B
of	B
thymosin	I
β4	I
a	O
Lys	B
residue	I
follows	O
at	O
the	O
+	O
2	O
position	O
,	O
while	O
in	O
the	O
case	O
of	O
Gln-39	B
a	O
Gly	B
residue	I
is	O
at	O
this	O
position	O
.	O

This	O
may	O
partly	O
explain	O
why	O
Gln-39	B
of	I
thymosin	I
β4	I
is	O
only	O
labeled	O
to	O
a	O
very	O
low	O
extent	O
.	O

Activity	O
of	O
both	O
enzymes	O
showed	O
a	O
distinct	O
or	O
drastic	O
decrease	O
by	O
truncation	O
of	O
four	O
C-	B
or	O
N	B
-	I
terminal	I
residues	I
.	O

This	O
may	O
be	O
an	O
additional	O
reason	O
for	O
the	O
low	O
derivatization	O
of	O
Gln-39	B
.	O

The	O
environment	O
of	O
Gln-23	B
is	O
highly	O
conserved	O
throughout	O
all	O
mammalian	O
β	B
-	I
thymosins	I
except	O
thymosin	B
β15	I
(	O
Fig.	O
7	O
)	O
,	O
which	O
has	O
been	O
described	O
to	O
be	O
highly	O
expressed	O
in	O
human	O
cancer	O
cells	O
with	O
high	O
metastatic	O
activity	O
[	O
37	O
]	O
.	O

Safer	O
et	O
al.	O
[	O
6	O
]	O
proposed	O
that	O
the	O
sequence	O
17	O
LKKTETQEK25	B
of	O
thymosin	B
β4	I
may	O
be	O
involved	O
in	O
actin	O
sequestering	O
because	O
of	O
its	O
high	O
homology	O
with	O
the	O
well	O
-	O
known	O
actin	O
-	O
binding	O
sequence	O
of	O
actobindin	O
[	O
38	O
]	O
.	O

In	O
accordance	O
with	O
their	O
proposal	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
truncation	O
of	O
up	O
to	O
13	O
N	B
-	I
terminal	I
amino	I
acid	I
residues	I
does	O
not	O
abolish	O
chemical	O
cross	O
-	O
linking	O
to	O
G	O
-	O
actin	O
,	O
while	O
truncation	O
of	O
the	O
first	O
23	O
amino	B
acid	I
residues	I
completely	O
destroys	O
interaction	O
[	O
13	O
]	O
.	O

Surprisingly	O
,	O
as	O
demonstrated	O
here	O
,	O
derivatization	O
of	O
Gln-23	B
with	O
dansylcadaverine	B
did	O
not	O
abolish	O
G	O
-	O
actin	O
binding	O
,	O
suggesting	O
that	O
this	O
particular	O
position	O
may	O
not	O
be	O
essential	O
for	O
actin	O
binding	O
.	O

Indeed	O
,	O
Gln-23	B
is	O
not	O
conserved	O
in	O
the	O
corresponding	O
sequences	O
of	O
actobindin	O
[	O
38	O
]	O
.	O

There	O
are	O
several	O
reports	O
dealing	O
with	O
G	O
-	O
actin	O
as	O
a	O
glutaminyl	B
substrate	O
for	O
the	O
transglutaminase	O
reaction	O
.	O

Takashi	O
has	O
shown	O
that	O
dansylcadaverine	B
can	O
be	O
cross	O
-	O
linked	O
to	O
Gln-41	B
of	I
G	I
-	I
actin	I
and	O
that	O
this	O
leads	O
to	O
a	O
decrease	O
of	O
the	O
critical	O
concentration	O
and	O
faster	O
polymerization	O
of	O
labeled	O
G	O
-	O
actin	O
[	O
34	O
]	O
.	O

It	O
has	O
also	O
been	O
reported	O
that	O
actin	O
from	O
human	O
blood	O
platelets	O
and	O
rabbit	O
skeletal	O
muscle	O
actin	O
serves	O
as	O
a	O
substrate	O
for	O
factor	O
XIIIa	O
[	O
39	O
]	O
.	O

Moreover	O
,	O
the	O
cross	O
-	O
linked	O
matrix	O
from	O
platelets	O
formed	O
by	O
the	O
transglutaminase	O
reaction	O
contains	O
actin	O
[	O
40	O
]	O
.	O

Previously	O
,	O
Nemes	O
et	O
al.	O
[	O
41	O
]	O
have	O
shown	O
that	O
actin	O
seems	O
to	O
be	O
the	O
main	O
endogenous	O
substrate	O
for	O
tissue	O
transglutaminase	O
in	O
HL60	O
and	O
U937	O
cells	O
undergoing	O
apoptosis	O
.	O

For	O
detection	O
of	O
substrate	O
proteins	O
,	O
they	O
used	O
a	O
synthetic	O
hapten	B
-	I
labeled	I
lysine	I
derivative	O
,	O
which	O
is	O
able	O
to	O
cross	O
the	O
cell	O
membrane	O
.	O

After	O
inducing	O
apoptosis	O
,	O
they	O
detected	O
actin	O
as	O
the	O
major	O
protein	O
transglutaminated	O
with	O
hapten	B
-	I
labeled	I
lysine	I
by	O
Western	O
blot	O
analysis	O
.	O

Our	O
results	O
prove	O
that	O
,	O
at	O
least	O
under	O
the	O
conditions	O
used	O
in	O
our	O
assay	O
,	O
thymosin	B
β4	I
serves	O
equally	O
well	O
as	O
a	O
substrate	O
for	O
guinea	O
pig	O
transglutaminase	O
compared	O
to	O
actin	O
(	O
Fig.	O
5	O
)	O
.	O

Because	O
of	O
its	O
low	O
molecular	O
weight	O
and	O
high	O
solubility	O
thymosin	B
β4	I
may	O
have	O
escaped	O
their	O
SDS	B
-	I
PAGE	I
analysis	O
.	O

Therefore	O
,	O
it	O
will	O
be	O
interesting	O
to	O
look	O
for	O
transglutamination	O
of	O
thymosin	B
β4	I
during	O
apoptosis	O
using	O
HPLC	O
techniques	O
.	O

Taking	O
these	O
data	O
together	O
,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
thymosin	B
β4	I
may	O
serve	O
as	O
a	O
glutaminyl	B
substrate	O
for	O
transglutaminases	O
in	O
vivo	O
and	O
thus	O
may	O
possibly	O
play	O
an	O
important	O
role	O
in	O
transglutaminase	O
-	O
related	O
processes	O
.	O

Acknowledgments	O
We	O
express	O
our	O
appreciation	O
to	O
Doris	O
Jaegers	O
for	O
her	O
excellent	O
technical	O
assistance	O
.	O

The	O
most	O
common	O
octadecatrienoic	B
fatty	I
acid	I
in	O
plants	O
is	O
α	B
-	I
linoleic	I
acid	I
(	O
9Z	B
,	I
12Z	I
,	I
15Z	I
-18:3	I
)	O
,	O
which	O
is	O
the	O
main	O
constituent	O
of	O
chloroplastic	O
membranes	O
[	O
1	O
]	O
.	O

Moreover	O
,	O
triacylglycerols	B
from	O
seeds	O
provide	O
an	O
easily	O
accessible	O
source	O
of	O
additional	O
conjugated	B
octadecatrienoic	I
acids	I
having	O
(	O
Z	O
,	O
E	O
,	O
E	O
)	O
or	O
(	O
Z	O
,	O
E	O
,	O
Z	O
)	O
geometries	O
[	O
2	O
]	O
.	O

At	O
least	O
five	O
different	O
regio	O
isomers	O
have	O
been	O
reported	O
within	O
plants	O
with	O
double	B
bond	I
systems	O
in	O
the	O
following	O
positions	O
:	O
(	B
Z	I
,	I
E	I
,	I
Z	I
)	I
-	I
and	O
(	B
E	I
,	I
E	I
,	I
Z	I
)	I
-8,10,12	I
-	I
18:3	I
and	O
(	B
Z	I
,	I
E	I
,	I
Z	I
)	I
-	I
,	O
(	B
Z	I
,	I
E	I
,	I
E	I
)	I
-	I
and	O
(	B
E	I
,	I
E	I
,	I
Z	I
)	I
-9,11,13	I
-	I
18:3	I
.	O

One	O
of	O
these	O
,	O
calendic	B
acid	I
(	B
8E	I
,	I
10E	I
,	I
12Z	I
-18:3	I
)	I
,	O
is	O
the	O
major	O
constituent	O
of	O
the	O
seed	O
oil	O
of	O
Calendula	O
officinalis	O
,	O
Calendula	O
stellata	O
,	O
Osteospermum	O
spinescens	O
and	O
Osteospermum	O
hyoseroides	O
[	O
1	O
]	O
.	O

These	O
seed	O
oils	O
are	O
of	O
industrial	O
interest	O
,	O
because	O
the	O
oil	O
is	O
used	O
for	O
cosmetic	O
purposes	O
and	O
may	O
be	O
used	O
as	O
a	O
drying	O
oil	O
in	O
paintings	O
.	O

A	O
number	O
of	O
chemical	O
mechanisms	O
have	O
been	O
proposed	O
to	O
describe	O
the	O
biosynthesis	O
of	O
conjugated	B
octadecatrienoic	I
acids	I
.	O

These	O
include	O
the	O
formation	O
of	O
an	O
epoxy	B
derivative	I
of	I
linoleic	I
acid	I
as	O
an	O
intermediate	O
[	O
3	O
]	O
,	O
the	O
oxidation	O
of	O
linoleic	B
acid	I
[	O
4	O
]	O
,	O
the	O
isomerization	O
of	O
linolenic	B
acid	I
[	O
5	O
]	O
and	O
the	O
formation	O
of	O
a	O
radical	B
of	I
linoleic	I
acid	I
due	O
to	O
a	O
lipoxygenase	O
-	O
type	O
reaction	O
[	O
6–8	O
]	O
.	O

However	O
,	O
in	O
a	O
recent	O
publication	O
on	O
the	O
biosynthesis	O
of	O
α	B
-	I
eleostearic	I
acid	I
(	O
9Z	B
,	I
11E	I
,	I
13E	I
-18:3	I
)	O
,	O
which	O
is	O
a	O
regio	O
isomer	O
of	O
calendic	B
acid	I
,	I
it	O
was	O
shown	O
that	O
the	O
conversion	O
of	O
linoleic	B
acid	I
to	O
this	O
conjugated	O
octadecatrienoic	B
acid	I
occurs	O
while	O
this	O
acyl	B
moiety	I
is	O
esterified	O
to	O
phosphatidylcholine	B
[	O
9	O
]	O
.	O

Based	O
on	O
these	O
data	O
one	O
may	O
assume	O
that	O
the	O
conversion	O
of	O
esterified	B
linoleic	I
acid	I
to	O
conjugated	B
octadecatrienoic	I
acids	I
is	O
catalyzed	O
by	O
a	O
new	O
type	O
of	O
(	O
1,4	O
)	O
-linoleoyl	O
acyl	O
lipid	O
desaturase	O
.	O

To	O
obtain	O
additional	O
information	O
on	O
the	O
biosynthesis	O
of	O
conjugated	O
octadecatrienoic	B
acids	I
we	O
decided	O
to	O
continue	O
the	O
analysis	O
of	O
the	O
biosynthesis	O
of	O
calendic	B
acid	I
(	O
8E	B
,	I
10E	I
,	I
12Z	I
-18:3	I
)	O
in	O
the	O
developing	O
seeds	O
of	O
C.	O
officinalis	O
.	O

This	O
species	O
is	O
amenable	O
to	O
such	O
studies	O
,	O
because	O
it	O
is	O
easy	O
to	O
grow	O
,	O
its	O
seeds	O
contain	O
large	O
quantities	O
of	O
calendic	B
acid	I
,	O
and	O
most	O
of	O
the	O
studies	O
on	O
the	O
biosynthesis	O
of	O
conjugated	B
octadecatrienoic	I
acids	I
have	O
been	O
performed	O
with	O
seeds	O
from	O
this	O
plant	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
a	O
new	O
type	O
of	O
(	O
1,4	O
)	O
-acyl	O
lipid	O
desaturase	O
,	O
a	O
(	O
8,11	O
)	O
-linoleoyl	O
desaturase	O
that	O
catalyzes	O
the	O
formation	O
of	O
a	O
conjugated	B
triene	I
,	O
calendic	B
acid	I
.	O

2	O
Materials	O
and	O
methods	O
C.	O
officinalis	O
was	O
grown	O
from	O
seeds	O
in	O
a	O
greenhouse	O
under	O
16	O
h	O
of	O
artificially	O
supplemented	O
illumination	O
at	O
a	O
temperature	O
ranging	O
between	O
22	O
and	O
30	O
°	O
C	O
.	O

For	O
all	O
experiments	O
developing	O
seeds	O
at	O
a	O
fully	O
expanded	O
green	O
stage	O
were	O
used	O
.	O

For	O
RNA	O
isolation	O
20	O
g	O
of	O
plant	O
material	O
was	O
ground	O
in	O
liquid	O
nitrogen	B
,	O
100	O
ml	O
of	O
extraction	O
buffer	O
I	O
(	O
100	O
mM	O
Tris	B
-	I
HCl	I
,	O
pH	O
7.5	O
,	O
25	O
mM	O
EDTA	B
,	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
laurylsarcosyl	B
,	O
4	O
M	O
guanidinium	B
thiocyanate	I
,	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
PVPP	O
,	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
β	B
-	I
mercaptoethanol	I
)	O
was	O
added	O
and	O
the	O
homogenate	O
was	O
shaken	O
for	O
15	O
min	O
.	O

After	O
centrifugation	O
at	O
4000	O
×	O
g	O
for	O
15	O
min	O
the	O
floating	O
solid	O
lipid	O
phase	O
was	O
discarded	O
and	O
the	O
remaining	O
liquid	O
phase	O
was	O
extracted	O
twice	O
for	O
15	O
min	O
with	O
PCI	B
(	O
phenol	B
:	O
chloroform	B
:	O
isoamyl	B
alcohol	I
,	O
25:24:1	O
)	O
.	O

After	O
centrifugation	O
at	O
4000	O
×	O
g	O
for	O
15	O
min	O
the	O
upper	O
hydrophilic	O
phase	O
was	O
loaded	O
on	O
a	O
CsCl	B
cushion	O
(	O
5	O
M	O
CsCl	B
)	O
of	O
8	O
ml	O
and	O
centrifuged	O
at	O
18	O
°	O
C	O
and	O
100	O
000	O
×	O
g	O
for	O
18	O
h.	O
After	O
discarding	O
the	O
supernatant	O
the	O
RNA	O
precipitate	O
was	O
dried	O
,	O
washed	O
with	O
70	O
%	O
ethanol	B
and	O
extracted	O
for	O
15	O
min	O
with	O
a	O
mixture	O
consisting	O
of	O
7.5	O
ml	O
of	O
extraction	O
buffer	O
II	O
(	O
100	O
mM	O
Tris	B
-	I
HCl	I
,	O
pH	O
8.8	O
,	O
100	O
mM	O
NaCl	B
,	O
5	O
mM	O
EDTA	B
,	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
SDS	B
)	O
and	O
10	O
ml	O
PCI	B
.	O

After	O
centrifugation	O
at	O
4000	O
×	O
g	O
for	O
15	O
min	O
the	O
upper	O
hydrophilic	O
phase	O
was	O
washed	O
with	O
chloroform	B
and	O
the	O
remaining	O
RNA	B
was	O
precipitated	O
overnight	O
at	O
4	O
°	O
C	O
by	O
adding	O
an	O
equal	O
volume	O
of	O
5	O
M	O
LiCl	B
.	O

After	O
centrifugation	O
for	O
60	O
min	O
at	O
12	O
000	O
×	O
g	O
at	O
4	O
°	O
C	O
the	O
precipitate	O
was	O
washed	O
twice	O
with	O
70	O
%	O
ethanol	B
,	O
dried	O
and	O
dissolved	O
in	O
500	O
μl	O
water	B
.	O

From	O
this	O
total	O
RNA	O
fraction	O
mRNA	O
was	O
isolated	O
using	O
the	O
Poly	O
-	O
Attract	O
-	O
Kit	O
(	O
Promega	O
,	O
Mannheim	O
,	O
Germany	O
)	O
.	O

Single	O
stranded	O
cDNA	O
(	O
ss	O
-	O
cDNA	O
)	O
was	O
isolated	O
from	O
mRNA	O
of	O
developing	O
marigold	O
seeds	O
by	O
reversed	O
transcription	O
with	O
SuperscriptII	O
(	O
Gibco	O
BRL	O
,	O
Eggenstein	O
,	O
Germany	O
)	O
.	O

This	O
ss	O
-	O
cDNA	O
was	O
used	O
as	O
template	O
for	O
PCR	O
-	O
based	O
cloning	O
.	O

A	O
470	O
bp	O
PCR	O
fragment	O
was	O
amplified	O
with	O
the	O
degenerate	O
sense	O
primer	O
A	O
5′-CCD	O
TAY	O
TTC	O
TCI	O
TGG	O
AAR	O
WWH	O
AGY	O
CAY	O
CG-3′	O
and	O
antisense	O
primer	O
B	O
5′-CCA	O
RTY	O
CCA	O
YTC	O
IGW	O
BGA	O
RTC	O
RTA	O
RTG-3′	O
derived	O
from	O
the	O
amino	O
acid	O
sequences	O
PYFSWK	B
(	I
Y	I
/	I
I	I
)	I
SHR	I
and	O
HYDS	B
(	I
S	I
/	I
T	I
)	I
EW	I
(	I
D	I
/	I
N	I
)	I
W	I
,	O
respectively	O
.	O

The	O
PCR	O
reaction	O
was	O
carried	O
out	O
with	O
TfI	O
-	O
DNA	O
-	O
Polymerase	O
(	O
Biozym	O
,	O
Hess	O
.	O

Oldendorf	O
,	O
Germany	O
)	O
using	O
an	O
amplification	O
program	O
of	O
2	O
min	O
denaturation	O
at	O
94	O
°	O
C	O
,	O
followed	O
by	O
10	O
cycles	O
of	O
30	O
s	O
at	O
94	O
°	O
C	O
,	O
45	O
s	O
at	O
50	O
°	O
C	O
,	O
1	O
min	O
at	O
72	O
°	O
C	O
,	O
followed	O
by	O
20	O
cycles	O
of	O
30	O
s	O
at	O
94	O
°	O
C	O
,	O
45	O
s	O
at	O
50	O
°	O
C	O
,	O
1	O
min	O
at	O
72	O
°	O
C	O
(	O
time	O
increment	O
5	O
s	O
)	O
and	O
terminated	O
by	O
2	O
min	O
extension	O
at	O
72	O
°	O
C	O
.	O

PCR	O
products	O
of	O
the	O
expected	O
length	O
were	O
cloned	O
in	O
pCR2.1-TOPO	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
and	O
sequenced	O
.	O

The	O
fragment	O
CoDes2.2	O
was	O
chosen	O
for	O
the	O
isolation	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
clone	O
using	O
the	O
Marathon	O
cDNA	O
amplification	O
kit	O
(	O
Clontech	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

To	O
amplify	O
the	O
5′-	O
and	O
3′-ends	O
of	O
CoDes2.2	O
by	O
PCR	O
specific	O
primers	O
were	O
used	O
:	O
5′-race	O
:	O
primer	O
C	O
5′-GTG	O
AGG	O
GAG	O
TGA	O
GAG	O
ATG	O
GGT	O
GTG	O
GTG	O
C-3′	O
,	O
primer	O
D	O
5′-AAC	O
ACA	O
CTT	O
ACA	O
CCT	O
AGT	O
ACT	O
GGA	O
ATT-3′	O
;	O
3′-race	O
:	O
primer	O
E	O
5′-TAT	O
TCC	O
AAA	O
CTT	O
CTT	O
AAC	O
AAT	O
CCA	O
CCC	O
G-3′	O
,	O
primer	O
F	O
5′-CAA	O
TTC	O
CAG	O
TAC	O
TAG	O
GTG	O
TAA	O
GTG	O
TGT	O
T-3′.	O
The	O
PCR	O
reaction	O
was	O
carried	O
out	O
according	O
to	O
the	O
supplier	O
's	O
instructions	O
.	O

The	O
fragments	O
were	O
cloned	O
in	O
pCR2.1-TOPO	O
and	O
sequenced	O
.	O

To	O
obtain	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
by	O
PCR	O
,	O
specific	O
primers	O
of	O
the	O
expected	O
open	O
reading	O
frame	O
of	O
the	O
entire	O
cDNA	O
of	O
1.2	O
kb	O
were	O
used	O
for	O
amplification	O
:	O
sense	O
primer	O
G	O
5′-ATT	O
AGA	O
GCT	O
CAT	O
GGG	O
TGC	O
TGG	O
TGG	O
TCG	O
GAT	O
GTC	O
G-3′	O
and	O
antisense	O
primer	O
H	O
5′-ATT	O
ACT	O
CGA	O
GTG	O
ACA	O
TAC	O
ACC	O
TTT	O
TTG	O
ATT	O
ACA	O
TCT	O
TG-3′.	O
The	O
PCR	O
reaction	O
was	O
carried	O
out	O
with	O
the	O
Expand	O
High	O
Fidelity	O
System	O
(	O
Boehringer	O
,	O
Mannheim	O
,	O
Germany	O
)	O
using	O
an	O
amplification	O
program	O
of	O
2	O
min	O
denaturation	O
at	O
94	O
°	O
C	O
,	O
followed	O
by	O
10	O
cycles	O
of	O
30	O
s	O
at	O
94	O
°	O
C	O
,	O
35	O
s	O
at	O
63	O
°	O
C	O
,	O
2	O
min	O
at	O
72	O
°	O
C	O
,	O
followed	O
by	O
15	O
cycles	O
of	O
30	O
s	O
at	O
94	O
°	O
C	O
,	O
35	O
s	O
at	O
63	O
°	O
C	O
,	O
1	O
min	O
at	O
72	O
°	O
C	O
(	O
time	O
increment	O
5	O
s	O
)	O
and	O
terminated	O
by	O
2	O
min	O
extension	O
at	O
72	O
°	O
C	O
.	O

The	O
fragment	O
was	O
cloned	O
into	O
pGEM	O
-	O
T	O
and	O
the	O
resulting	O
plasmid	O
pCoDes8.11	O
was	O
sequenced	O
.	O

For	O
expression	O
in	O
Sacharomyces	O
cerevisiae	O
the	O
open	O
reading	O
frame	O
of	O
pCoDes8.11	O
was	O
cloned	O
as	O
a	O
Sac	O
I	O
/	O
Xho	O
I	O
fragment	O
behind	O
the	O
galactose	B
-	O
inducible	O
promoter	O
GAL1	O
into	O
the	O
shuttle	O
vector	O
pYES2	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
to	O
yield	O
plasmid	O
pYESDes8.11	O
.	O

Plasmid	O
pYESDes8.11	O
was	O
transformed	O
into	O
the	O
yeast	O
strain	O
INVSC1	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
by	O
the	O
polyethylene	B
glycol	I
method	O
[	O
10	O
]	O
.	O

The	O
expression	O
of	O
cells	O
harboring	O
plasmid	O
pYESDes8.11	O
was	O
performed	O
essentially	O
as	O
described	O
before	O
including	O
the	O
exogenous	O
application	O
of	O
linoleic	B
acid	I
[	O
11	O
]	O
.	O

Cells	O
reaching	O
the	O
stationary	O
phase	O
were	O
washed	O
with	O
minimal	O
medium	O
,	O
harvested	O
by	O
centrifugation	O
and	O
stored	O
at	O
−20	O
°	O
C	O
until	O
they	O
were	O
analyzed	O
.	O

For	O
analysis	O
of	O
the	O
calendic	O
acid	O
content	O
of	O
transformed	O
yeast	O
cells	O
,	O
the	O
cell	O
pellets	O
were	O
disrupted	O
using	O
a	O
sonifier	O
tip	O
and	O
lipids	B
were	O
extracted	O
with	O
hexane	B
/	O
isopropanol	B
according	O
to	O
[	O
12	O
]	O
.	O

After	O
recovery	O
of	O
the	O
organic	O
phase	O
,	O
solvents	O
were	O
evaporated	O
by	O
vacuum	O
and	O
the	O
lipids	B
were	O
reconstituted	O
in	O
methanol	B
,	O
then	O
either	O
directly	O
analyzed	O
by	O
HPLC	O
or	O
subjected	O
to	O
alkaline	O
hydrolysis	O
as	O
described	O
[	O
13	O
]	O
.	O

HPLC	O
analysis	O
of	O
the	O
free	O
fatty	B
acid	I
derivatives	I
was	O
carried	O
out	O
by	O
RP	O
-	O
HPLC	O
as	O
described	O
before	O
[	O
13	O
]	O
.	O

Calendic	B
acid	I
eluted	O
with	O
an	O
retention	O
time	O
of	O
11.8	O
min	O
exhibiting	O
the	O
characteristic	O
conjutriene	O
UV	O
spectrum	O
with	O
a	O
maximum	O
at	O
268	O
nm	O
[	O
14	O
]	O
.	O

Linoleic	B
acid	I
eluted	O
with	O
a	O
retention	O
time	O
of	O
12.7	O
min	O
exhibiting	O
maximal	O
absorbance	O
at	O
202	O
nm	O
.	O

Co	O
-	O
injections	O
with	O
authentic	O
standards	O
were	O
performed	O
.	O

The	O
standard	O
of	O
calendic	B
acid	I
was	O
prepared	O
from	O
the	O
triacylglycerol	B
fraction	O
of	O
lipid	B
extracts	O
from	O
marigold	O
seeds	O
by	O
alkaline	B
hydrolysis	O
.	O

Alternatively	O
,	O
the	O
corresponding	O
fatty	B
acid	I
methyl	I
esters	I
were	O
analyzed	O
by	O
gas	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
GC	O
/	O
MS	O
)	O
.	O

For	O
derivation	O
the	O
free	B
fatty	I
acid	I
derivatives	I
were	O
incubated	O
with	O
diazomethane	B
.	O

GC	O
/	O
MS	O
analysis	O
was	O
performed	O
with	O
a	O
Finigan	O
GCQ	O
GC	O
/	O
MS	O
system	O
equipped	O
with	O
a	O
capillary	O
Rtx-5	O
column	O
(	O
5	O
%	O
diphenyl-95	O
%	O
polydimethyl	O
siloxane	O
,	O
30	O
m	O
×	O
0.25	O
mm	O
;	O
0.25	O
μm	O
coating	O
thickness	O
;	O
Restek	O
,	O
Germany	O
)	O
.	O

Helium	O
was	O
used	O
as	O
carrier	O
gas	O
(	O
40	O
cm	O
/	O
s	O
)	O
.	O

An	O
electron	O
energy	O
of	O
70	O
eV	O
,	O
an	O
ion	O
source	O
temperature	O
of	O
150	O
°	O
C	O
,	O
and	O
a	O
temperature	O
of	O
275	O
°	O
C	O
for	O
the	O
transfer	O
line	O
were	O
used	O
.	O

The	O
samples	O
were	O
measured	O
in	O
the	O
EI	O
mode	O
,	O
and	O
the	O
splitless	O
injection	O
mode	O
(	O
opened	O
after	O
1	O
min	O
)	O
with	O
an	O
injector	O
temperature	O
of	O
250	O
°	O
C	O
.	O

The	O
temperature	O
gradient	O
was	O
60	O
°	O
C–110	O
°	O
C	O
at	O
25	O
°	O
C	O
/	O
min	O
,	O
110	O
°	O
C	O
for	O
1	O
min	O
,	O
110	O
°	O
C–270	O
°	O
C	O
at	O
10	O
°	O
C	O
/	O
min	O
,	O
and	O
270	O
°	O
C	O
for	O
10	O
min	O
.	O

Calendic	B
acid	I
eluted	O
with	O
a	O
retention	O
time	O
of	O
17.16	O
min	O
,	O
linoleic	B
acid	I
eluted	O
with	O
a	O
retention	O
time	O
of	O
15.92	O
min	O
,	O
and	O
α	B
-	I
linolenic	I
acid	I
eluted	O
with	O
a	O
retention	O
time	O
of	O
15.97	O
min	O
.	O

3	O
Results	O
3.1	O
PCR	O
-	O
based	O
cloning	O
and	O
isolation	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
For	O
PCR	O
-	O
based	O
cloning	O
degenerate	O
primers	O
,	O
deduced	O
from	O
conserved	O
regions	O
of	O
acyl	O
lipid	O
desaturases	O
,	O
were	O
synthesized	O
according	O
to	O
[	O
11,15,16	O
]	O
.	O

The	O
template	O
used	O
was	O
ss	O
-	O
cDNA	O
from	O
C.	O
officinalis	O
,	O
which	O
was	O
reverse	O
-	O
transcribed	O
from	O
mRNA	O
of	O
developing	O
seeds	O
at	O
a	O
fully	O
expanded	O
green	O
stage	O
.	O

PCR	O
products	O
of	O
the	O
expected	O
length	O
were	O
cloned	O
and	O
sequenced	O
.	O

Data	O
base	O
searches	O
and	O
alignments	O
with	O
these	O
fragments	O
indicated	O
similarities	O
to	O
plant	O
acyl	O
lipid	O
desaturases	O
with	O
different	O
regio	O
specificities	O
.	O

Except	O
for	O
one	O
(	O
CD2.2	O
)	O
,	O
all	O
were	O
classified	O
either	O
as	O
putative	O
members	O
of	O
the	O
classical	O
Δ12	O
desaturases	O
or	O
as	O
putative	O
sphingolipid	O
desaturases	O
based	O
on	O
identities	O
more	O
than	O
75	O
%	O
[	O
16	O
]	O
.	O

However	O
,	O
the	O
470	O
bp	O
fragment	O
CD2.2	O
exhibited	O
highest	O
identities	O
to	O
the	O
Δ12	O
fatty	O
acid	O
acetylenase	O
from	O
Crepis	O
alpina	O
and	O
the	O
Δ12	O
fatty	O
acid	O
epoxygenase	O
from	O
Crepis	O
palaestina	O
[	O
15	O
]	O
.	O

To	O
isolate	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
,	O
PCR	O
with	O
specific	O
primers	O
was	O
used	O
to	O
amplify	O
the	O
5′-	O
and	O
3′-ends	O
of	O
CD2.2	O
.	O

The	O
fragments	O
were	O
cloned	O
and	O
sequenced	O
.	O

With	O
specific	O
primers	O
for	O
the	O
expected	O
open	O
reading	O
frame	O
the	O
entire	O
cDNA	O
of	O
1.2	O
kb	O
was	O
amplified	O
by	O
PCR	O
and	O
cloned	O
into	O
pGEM	O
-	O
T.	O
The	O
resulting	O
fragment	O
CoDes8.11	O
was	O
sequenced	O
.	O

The	O
full	O
-	O
length	O
cDNA	O
had	O
a	O
length	O
of	O
1131	O
bp	O
encoding	O
a	O
protein	O
of	O
377	O
amino	O
acids	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
43.6	O
kDa	O
.	O

This	O
desaturase	O
sequence	O
showed	O
highest	O
identities	O
with	O
the	O
Δ12	O
acetylenase	O
from	O
C.	O
alpina	O
(	O
74	O
%	O
)	O
[	O
15	O
]	O
,	O
the	O
Δ12	O
epoxygenase	O
from	O
C.	O
palaestina	O
(	O
73	O
%	O
)	O
[	O
15	O
]	O
,	O
and	O
the	O
Δ12	O
desaturase	O
from	O
borage	O
(	O
62	O
%	O
)	O
[	O
17	O
]	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
three	O
characteristic	O
and	O
highly	O
conserved	O
histidine	B
regions	O
of	O
the	O
active	O
site	O
of	O
the	O
Δ12	O
acyl	O
lipid	O
desaturases	O
are	O
indicated	O
by	O
boxes	O
.	O

These	O
findings	O
were	O
further	O
supported	O
by	O
phylogenetic	O
analysis	O
according	O
to	O
[	O
17	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
2	O
,	O
the	O
newly	O
identified	O
(	O
8,11	O
)	O
-linoleoyl	O
desaturase	O
groups	O
with	O
the	O
Δ12	O
acyl	O
lipid	O
desaturase	O
family	O
.	O

However	O
,	O
it	O
forms	O
one	O
subfamily	O
with	O
the	O
Δ12	O
acetylenase	O
and	O
the	O
Δ12	O
epoxygenase	O
.	O

All	O
members	O
of	O
this	O
subfamily	O
are	O
clearly	O
separated	O
from	O
the	O
classical	O
Δ12	O
desaturases	O
and	O
12-hydroxylases	O
.	O

3.2	O
Functional	O
expression	O
in	O
S.	O
cerevisiae	O
and	O
fatty	B
acid	I
analysis	O
In	O
order	O
to	O
elucidate	O
the	O
catalytic	O
properties	O
of	O
this	O
new	O
desaturase	O
,	O
CoDes8.11	O
was	O
expressed	O
in	O
yeast	O
cells	O
under	O
the	O
control	O
of	O
the	O
galactose	B
-	O
inducible	O
promoter	O
GAL1	O
.	O

Since	O
yeast	O
cells	O
do	O
not	O
contain	O
dienoic	B
fatty	I
acids	I
as	O
substrates	O
for	O
the	O
(	O
8,11	O
)	O
-linoleoyl	O
desaturase	O
[	O
8	O
]	O
,	O
the	O
expression	O
was	O
performed	O
with	O
supplementation	O
of	O
linoleic	B
acid	I
.	O

Galactose	B
-	O
induced	O
yeast	O
cells	O
were	O
used	O
for	O
the	O
analysis	O
either	O
of	O
fatty	B
acid	I
methyl	I
esters	I
by	O
GC	O
/	O
MS	O
or	O
of	O
free	B
fatty	I
acids	I
by	O
HPLC	O
.	O

The	O
methyl	B
ester	I
of	I
calendic	I
acid	I
was	O
separated	O
from	O
the	O
classical	B
dienoic	B
and	O
trienoic	B
fatty	I
acids	I
by	O
GC	O
/	O
MS	O
.	O

It	O
eluted	O
with	O
a	O
retention	O
time	O
of	O
17.16	O
min	O
,	O
whereas	O
the	O
methyl	B
ester	I
of	I
linoleic	B
acid	I
eluted	O
with	O
a	O
retention	O
time	O
of	O
15.92	O
min	O
,	O
and	O
that	O
of	O
α	B
-	I
linolenic	I
acid	I
eluted	O
with	O
a	O
retention	O
time	O
of	O
15.97	O
min	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
using	O
this	O
method	O
calendic	B
acid	I
was	O
only	O
identified	O
by	O
its	O
characteristic	O
retention	O
time	O
,	O
because	O
the	O
corresponding	O
mass	O
spectra	O
of	O
the	O
methyl	B
esters	I
of	B
calendic	B
acid	I
and	O
α	B
-	I
linolenic	I
acid	I
showed	O
no	O
characteristic	O
fragmentation	O
patterns	O
when	O
compared	O
against	O
each	O
other	O
.	O

The	O
spectra	O
differed	O
only	O
in	O
their	O
relative	O
intensities	O
of	O
the	O
obtained	O
fragments	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
we	O
decided	O
to	O
analyze	O
the	O
formation	O
of	O
calendic	B
acid	I
within	O
yeast	O
cells	O
overexpressing	O
CoDes8.11	O
by	O
RP	O
-	O
HPLC	O
,	O
because	O
of	O
the	O
characteristic	O
UV	O
spectrum	O
of	O
calendic	B
acid	I
and	O
the	O
substantial	O
loss	O
of	O
calendic	B
acid	I
during	O
derivation	O
into	O
its	O
methyl	B
ester	I
for	O
GC	O
/	O
MS	O
analysis	O
.	O

As	O
a	O
standard	O
calendic	B
acid	I
was	O
isolated	O
from	O
the	O
triacylglycerol	B
fraction	O
of	O
marigold	O
seeds	O
and	O
analyzed	O
by	O
RP	O
-	O
HPLC	O
(	O
Fig.	O
3	O
,	O
upper	O
panel	O
)	O
.	O

The	O
retention	O
time	O
of	O
calendic	B
acid	I
was	O
11.8	O
min	O
and	O
as	O
shown	O
in	O
the	O
inset	O
it	O
exhibited	O
a	O
characteristic	O
UV	O
spectrum	O
of	O
conjutrienes	O
with	O
the	O
three	O
relative	O
maxima	O
at	O
262	O
nm	O
,	O
268	O
nm	O
and	O
282	O
nm	O
[	O
14	O
]	O
.	O

Yeast	O
cells	O
harboring	O
only	O
the	O
empty	O
vector	O
synthesized	O
no	O
calendic	B
acid	I
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
S.	O
cerevisiae	O
cells	O
expressing	O
the	O
CoDes8.11	O
cDNA	O
were	O
capable	O
of	O
forming	O
a	O
fatty	B
acid	I
which	O
co	O
-	O
elutes	O
with	O
calendic	B
acid	I
at	O
11.8	O
min	O
and	O
exhibits	O
the	O
characteristic	O
UV	O
spectrum	O
of	O
conjutrienes	O
(	O
Fig.	O
3	O
,	O
lower	O
panel	O
,	O
first	O
peak	O
at	O
11.8	O
min	O
)	O
.	O

The	O
second	O
peak	O
,	O
eluting	O
close	O
behind	O
calendic	B
acid	I
at	O
12.7	O
min	O
,	O
was	O
identified	O
as	O
linoleic	B
acid	I
.	O

This	O
indicates	O
that	O
the	O
newly	O
isolated	O
cDNA	O
encodes	O
a	O
desaturase	O
which	O
is	O
capable	O
of	O
converting	O
linoleic	B
acid	I
into	O
calendic	B
acid	I
upon	O
expression	O
in	O
yeast	O
cells	O
.	O

Moreover	O
,	O
no	O
calendic	B
acid	I
was	O
found	O
in	O
the	O
fraction	O
of	O
free	B
fatty	I
acids	I
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
supports	O
the	O
idea	O
that	O
calendic	B
acid	I
formation	O
may	O
occur	O
while	O
the	O
acyl	B
moiety	I
is	O
esterified	O
to	O
phosphatidylcholine	B
,	O
as	O
has	O
been	O
suggested	O
before	O
[	O
9	O
]	O
.	O

4	O
Discussion	O
Here	O
,	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
encoding	O
a	O
new	O
type	O
of	O
desaturase	O
catalyzing	O
a	O
(	O
1,4	O
)	O
-dehydrogenation	O
reaction	O
.	O

The	O
cDNA	O
encoding	O
an	O
(	O
8,11	O
)	O
-linoleoyl	O
desaturase	O
was	O
cloned	O
by	O
a	O
PCR	O
-	O
based	O
approach	O
as	O
has	O
been	O
described	O
before	O
[	O
11,16	O
]	O
.	O

So	O
far	O
,	O
this	O
cDNA	O
could	O
not	O
be	O
identified	O
by	O
EST	O
sequencing	O
of	O
cDNA	O
libraries	O
from	O
developing	O
marigold	O
seeds	O
,	O
indicating	O
that	O
the	O
expression	O
of	O
this	O
(	O
8,11	O
)	O
-linoleoyl	O
desaturase	O
gene	O
is	O
either	O
very	O
low	O
or	O
developmentally	O
regulated	O
.	O

The	O
deduced	O
protein	O
shared	O
highest	O
homologies	O
with	O
the	O
recently	O
identified	O
Δ12	O
acetylenase	O
and	O
Δ12	O
epoxygenase	O
from	O
Crepis	O
[	O
15	O
]	O
.	O

All	O
three	O
enzymes	O
convert	O
the	O
double	B
bond	I
in	O
the	O
Δ12	O
position	O
of	O
linoleic	B
acid	I
esterified	O
to	O
phosphatidylcholine	B
into	O
groups	O
with	O
new	O
functionalities	O
.	O

In	O
addition	O
,	O
within	O
a	O
phylogenetic	O
analysis	O
these	O
three	O
enzymes	O
could	O
be	O
clearly	O
separated	O
from	O
the	O
other	O
members	O
of	O
the	O
Δ12	O
acyl	O
lipid	O
desaturase	O
family	O
(	O
Fig.	O
2	O
)	O
.	O

As	O
shown	O
by	O
heterologous	O
expression	O
in	O
yeast	O
cells	O
,	O
the	O
enzyme	O
converts	O
linoleic	B
acid	I
into	O
a	O
conjugated	B
octadecatrienoic	I
acid	I
(	O
Fig.	O
3	O
)	O
.	O

Based	O
on	O
the	O
observation	O
that	O
linoleic	B
acid	I
is	O
the	O
precursor	O
of	O
calendic	B
acid	I
one	O
may	O
propose	O
a	O
new	O
reaction	O
mechanism	O
for	O
this	O
Δ12	O
-type	O
desaturase	O
.	O

Whereas	O
within	O
the	O
classical	O
Δ12	O
acyl	O
lipid	O
desaturases	O
a	O
(	O
1,2	O
)	O
-syn	O
dehydrogenation	O
at	O
the	O
carbon	B
atoms	I
C-12	O
and	O
C-13	O
of	O
oleic	B
acid	I
may	O
occur	O
[	O
18	O
]	O
,	O
one	O
may	O
assume	O
in	O
the	O
case	O
of	O
this	O
new	O
desaturase	O
a	O
(	O
1,4	O
)	O
-dehydrogenation	O
at	O
the	O
carbon	B
atoms	I
C-8	O
and	O
C-11	O
of	O
linoleic	B
acid	I
as	O
shown	O
in	O
a	O
speculative	O
reaction	O
scheme	O
in	O
Fig.	O
4	O
.	O

Within	O
linoleic	B
acid	I
the	O
elimination	O
of	O
protons	B
at	O
these	O
two	O
positions	O
might	O
be	O
sterically	O
favored	O
,	O
because	O
the	O
carbon	B
atoms	I
at	O
the	O
positions	O
C-8	O
and	O
C-11	O
are	O
localized	O
near	O
each	O
other	O
in	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
fatty	B
acid	I
molecule	O
.	O

For	O
the	O
conversion	O
of	O
linoleic	B
acid	I
into	O
α	B
-	I
eleostearic	I
acid	I
one	O
may	O
assume	O
a	O
homologous	O
enzyme	O
catalyzing	O
a	O
(	O
1,4	O
)	O
-dehydrogenation	O
at	O
the	O
carbon	B
atoms	I
C-14	O
and	O
C-11	O
of	O
linoleic	B
acid	I
.	O

Structural	O
determinants	O
which	O
point	O
to	O
this	O
new	O
regio	O
specificity	O
in	O
proton	B
abstraction	O
can	O
hardly	O
be	O
determined	O
by	O
sequence	O
comparison	O
.	O

However	O
,	O
conjugated	B
octadecatrienoic	I
acids	I
are	O
widespread	O
in	O
plant	O
seed	O
oils	O
[	O
19	O
]	O
.	O

Therefore	O
,	O
sequence	O
comparisons	O
between	O
this	O
enzyme	O
and	O
novel	O
yet	O
to	O
be	O
isolated	O
(	O
1,4	O
)	O
-acyl	O
lipid	O
desaturases	O
might	O
help	O
to	O
identify	O
structural	O
characteristics	O
or	O
differences	O
in	O
these	O
enzymes	O
which	O
lead	O
to	O
the	O
observed	O
regio	O
and	O
stereochemical	O
specificities	O
within	O
this	O
subfamily	O
of	O
Δ12	O
desaturases	O
.	O

Even	O
the	O
differences	O
between	O
this	O
(	O
8,11	O
)	O
-linoleoyl	O
desaturase	O
catalyzing	O
the	O
formation	O
of	O
calendic	B
acid	I
(	O
8E	B
,	I
10E	I
,	I
12Z	I
-18:3	I
)	O
and	O
the	O
corresponding	O
(	O
8,11	O
)	O
-linoleoyl	O
desaturase	O
catalyzing	O
the	O
formation	O
of	O
jacaric	B
acid	I
(	O
8Z	B
,	I
10E	I
,	I
12Z	I
-18:3	I
)	O
from	O
Jacaranda	O
mimosifolia	O
[	O
1	O
]	O
is	O
an	O
interesting	O
but	O
open	O
question	O
.	O

With	O
the	O
isolation	O
of	O
this	O
enzyme	O
the	O
first	O
example	O
has	O
been	O
given	O
for	O
a	O
(	O
1,4	O
)	O
-dehydrogenation	O
reaction	O
catalyzed	O
by	O
a	O
desaturase	O
on	O
a	O
dienoic	B
fatty	I
acid	I
.	O

However	O
,	O
this	O
reaction	O
has	O
been	O
suggested	O
recently	O
for	O
a	O
slightly	O
different	O
substrate	O
as	O
well	O
,	O
the	O
conversion	O
of	O
a	O
monoenoic	B
fatty	I
acid	I
into	O
a	O
conjudienoic	B
fatty	I
acid	I
within	O
the	O
biosynthesis	O
of	O
bombykol	B
,	O
a	O
sex	O
pheromone	O
of	O
the	O
female	O
moth	O
Bombyx	O
mori	O
[	O
20	O
]	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
grateful	O
to	O
S.	O
Barth	O
and	O
A.	O
Zeuner	O
for	O
expert	O
technical	O
assistance	O
.	O

The	O
authors	O
thank	O
M.A.	O
Fuller	O
and	O
Prof.	O
Dr.	O
C.	O
Wasternack	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
BASF	O
AG	O
.	O

Cisplatin	B
is	O
one	O
of	O
the	O
most	O
active	O
chemotherapeutic	O
agents	O
available	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
malignancies	O
,	O
especially	O
testicular	O
and	O
ovarian	O
carcinoma	O
.	O

However	O
,	O
the	O
drug	B
's	O
clinical	O
utility	O
is	O
restricted	O
by	O
both	O
toxicological	O
and	O
especially	O
tumour	O
resistance	O
considerations	O
.	O

For	O
example	O
,	O
while	O
high	O
response	O
rates	O
can	O
be	O
achieved	O
in	O
ovarian	O
cancer	O
,	O
the	O
long	O
-	O
term	O
results	O
are	O
disappointing	O
due	O
to	O
the	O
development	O
of	O
drug	O
resistance	O
leading	O
to	O
recurrence	O
and	O
subsequent	O
death	O
of	O
most	O
of	O
these	O
patients	O
[	O
1	O
]	O
.	O

Shortly	O
after	O
the	O
introduction	O
of	O
cisplatin	B
into	O
widespread	O
clinical	O
use	O
in	O
the	O
early	O
-	O
mid	O
1970s	O
,	O
a	O
collaborative	O
programme	O
of	O
analogue	O
development	O
was	O
begun	O
between	O
the	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Sutton	O
,	O
and	O
Johnson	O
Matthey	O
to	O
address	O
these	O
limitations	O
.	O

Initially	O
,	O
the	O
focus	O
was	O
aimed	O
at	O
the	O
discovery	O
of	O
a	O
less	O
toxic	O
but	O
equally	O
efficacious	O
cisplatin	B
analogue	B
.	O

As	O
part	O
of	O
these	O
analogue	O
studies	O
,	O
important	O
structure	O
–	O
activity	O
rules	O
to	O
define	O
the	O
requirements	O
for	O
antitumour	O
activity	O
of	O
platinum	B
compounds	I
were	O
established	O
[	O
2	O
]	O
.	O

More	O
than	O
300	O
complexes	O
were	O
examined	O
and	O
approximately	O
40	O
identified	O
as	O
active	O
at	O
the	O
preclinical	O
level	O
.	O

From	O
a	O
shortlist	O
of	O
eight	O
candidates	O
,	O
two	O
,	O
i.e.	O
,	O
JM8	B
(	O
diammine	B
(	I
1,1-cyclobutane	I
dicarboxylato	I
)	I
platinum	I
(	I
II	I
)	I
;	O
carboplatin	B
,	O
CBDCA	B
,	O
Paraplatin	B
®	I
)	O
and	O
JM9	B
(	O
cis	B
-dichloro	I
-	I
trans	I
-dihydroxo	I
-	I
cis	I
-bis	I
(	I
isopropylamine	I
)	I
platinum	I
(	I
IV	I
)	I
,	O
CHIP	B
,	O
iproplatin	B
)	O
,	O
entered	O
clinical	O
trial	O
[	O
3	O
]	O
.	O

Structures	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

Carboplatin	B
was	O
shown	O
to	O
be	O
less	O
toxic	O
(	O
myelosuppression	O
being	O
dose	O
-	O
limiting	O
)	O
than	O
cisplatin	B
(	O
or	O
iproplatin	B
)	O
,	O
equally	O
active	O
to	O
cisplatin	B
and	O
more	O
active	O
than	O
iproplatin	B
(	O
see	O
[	O
4	O
]	O
for	O
a	O
review	O
)	O
.	O

Carboplatin	B
is	O
now	O
registered	O
worldwide	O
,	O
and	O
has	O
emerged	O
as	O
the	O
first	O
-	O
line	O
treatment	O
of	O
choice	O
(	O
along	O
with	O
paclitaxel	B
)	O
for	O
patients	O
with	O
advanced	O
ovarian	O
cancer	O
.	O

The	O
next	O
phase	O
of	O
analogue	O
development	O
(	O
also	O
in	O
collaboration	O
with	O
Bristol	O
Myers	O
,	O
later	O
Bristol	O
Myers	O
Squibb	O
)	O
concerned	O
the	O
search	O
for	O
platinum	B
compounds	I
possessing	O
sufficient	O
oral	O
bioavailability	O
as	O
to	O
be	O
available	O
to	O
patients	O
as	O
tablets	O
/	O
capsules	O
.	O

To	O
overcome	O
the	O
poor	O
bioavailability	O
of	O
cisplatin	B
and	O
carboplatin	B
,	O
a	O
new	O
series	O
of	O
platinum	B
(	I
IV	I
)	I
complexes	O
with	O
lipophilic	O
axial	O
ligands	O
,	O
the	O
platinum	B
(	I
IV	I
)	I
ammine	B
/	O
amine	B
dicarboxylates	I
,	O
were	O
developed	O
.	O

From	O
around	O
50	O
dicarboxylates	B
exhibiting	O
oral	O
antitumour	O
activity	O
against	O
the	O
murine	O
ADJ	O
/	O
PC6	O
subcutaneous	O
plasmacytoma	O
tumour	O
,	O
ten	O
,	O
including	O
JM221	B
(	O
bis	B
-	I
butyrato	I
amminedichloro	I
(	I
cyclohexylamine	I
)	I
platinum	I
(	I
IV	I
)	I
)	O
and	O
JM216	B
(	O
bis	B
-	I
acetato	I
amminedichloro	I
(	I
cyclohexylamine	I
)	I
platinum	I
(	I
IV	I
)	I
,	O
BMS	B
182751	I
)	O
(	O
Fig.	O
1	O
for	O
structures	O
)	O
were	O
selected	O
for	O
further	O
antitumour	O
evaluation	O
against	O
human	O
ovarian	O
carcinoma	O
xenografts	O
[	O
5	O
]	O
.	O

Parallel	O
in	O
vitro	O
studies	O
had	O
also	O
shown	O
that	O
the	O
platinum	B
(	I
IV	I
)	I
ammine	B
/	O
amine	B
dicarboxylates	I
,	O
JM221	B
[	O
6	O
]	O
and	O
JM216	B
[	O
7	O
]	O
,	O
retained	O
activity	O
against	O
some	O
acquired	O
cisplatin	B
-	O
resistant	O
human	O
ovarian	O
carcinoma	O
cell	O
lines	O
and	O
that	O
longer	O
chain	O
dicarboxylates	B
such	O
as	O
JM221	B
were	O
considerably	O
more	O
potent	O
than	O
cisplatin	B
.	O

A	O
consideration	O
of	O
oral	O
absorption	O
properties	O
,	O
antitumour	O
activity	O
and	O
toxicological	O
characteristics	O
(	O
especially	O
emetogenic	O
potential	O
in	O
the	O
ferret	O
)	O
led	O
to	O
JM216	B
being	O
selected	O
for	O
clinical	O
trial	O
.	O

JM216	B
entered	O
clinical	O
trial	O
at	O
the	O
Royal	O
Marsden	O
Hospital	O
,	O
Sutton	O
,	O
in	O
1992	O
,	O
initially	O
given	O
as	O
a	O
single	O
oral	O
dose	O
every	O
3	O
weeks	O
.	O

Subsequent	O
phase	O
I	O
trials	O
established	O
that	O
a	O
schedule	O
daily	O
for	O
5	O
days	O
was	O
optimal	O
;	O
myelosuppression	O
(	O
thrombocytopenia	O
and	O
leucopenia	O
)	O
was	O
dose	O
-	O
limiting	O
[	O
8	O
]	O
.	O

The	O
drug	B
is	O
now	O
undergoing	O
various	O
phase	O
II	O
/	O
III	O
trials	O
.	O

In	O
the	O
1990s	O
,	O
the	O
focus	O
of	O
the	O
collaboration	O
has	O
been	O
to	O
discover	O
platinum	B
analogues	O
capable	O
of	O
circumventing	O
cisplatin	B
resistance	O
.	O

The	O
mechanisms	O
underlying	O
tumour	O
resistance	O
to	O
cisplatin	B
are	O
known	O
to	O
be	O
multifactorial	O
and	O
include	O
decreased	O
drug	O
transport	O
,	O
increased	O
cellular	O
detoxification	O
due	O
to	O
increased	O
glutathione	B
and	O
metallothionein	O
,	O
changes	O
in	O
DNA	O
repair	O
involving	O
increased	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and/or	O
loss	O
of	O
mismatch	O
repair	O
(	O
MMR	O
)	O
,	O
increased	O
tolerance	O
of	O
DNA	O
adducts	O
and	O
alterations	O
in	O
the	O
apoptotic	O
cell	O
death	O
pathway	O
[	O
9	O
]	O
.	O

The	O
relative	O
importance	O
of	O
these	O
factors	O
clinically	O
is	O
not	O
known	O
but	O
strategies	O
to	O
overcome	O
cisplatin	B
resistance	O
could	O
improve	O
the	O
outcome	O
of	O
patients	O
with	O
ovarian	O
carcinoma	O
.	O

One	O
strategy	O
to	O
overcome	O
cisplatin	B
resistance	O
is	O
to	O
design	O
new	O
platinum	B
analogues	O
that	O
specifically	O
address	O
some	O
,	O
or	O
ideally	O
all	O
,	O
of	O
the	O
above	O
known	O
resistance	O
mechanisms	O
.	O

To	O
assist	O
in	O
the	O
identification	O
of	O
analogues	O
capable	O
of	O
circumventing	O
cisplatin	B
resistance	O
,	O
we	O
established	O
panels	O
of	O
human	O
ovarian	O
carcinoma	O
cell	O
lines	O
,	O
sensitive	O
and	O
resistant	O
to	O
cisplatin	B
and	O
analogues	B
[	O
10,11	O
]	O
.	O

A	O
key	O
feature	O
of	O
this	O
platinum	B
drug	O
discovery	O
cascade	O
was	O
the	O
inclusion	O
of	O
'	O
mechanism	O
-	O
directed	O
'	O
models	O
of	O
acquired	O
cisplatin	B
resistance	O
[	O
11	O
]	O
;	O
with	O
a	O
pair	O
of	O
lines	O
(	O
41M	O
/	O
41Mcis	O
R	O
)	O
exhibiting	O
resistance	O
due	O
to	O
decreased	O
drug	B
transport	O
,	O
another	O
pair	O
(	O
CH1	O
/	O
CH1cis	O
R	O
)	O
with	O
resistance	O
mediated	O
at	O
the	O
level	O
of	O
DNA	O
repair	O
and	O
a	O
third	O
(	O
A2780	O
/	O
A2780cis	O
R	O
)	O
with	O
multifactorial	O
resistance	O
mechanisms	O
of	O
decreased	O
uptake	O
,	O
increased	O
glutathione	B
and	O
increased	O
DNA	O
repair	O
.	O

For	O
many	O
of	O
the	O
cell	O
lines	O
,	O
xenograft	O
counterparts	O
were	O
established	O
[	O
12–14	O
]	O
thereby	O
allowing	O
downstream	O
in	O
vivo	O
antitumour	O
evaluation	O
of	O
lead	O
molecules	O
(	O
i.e.	O
,	O
those	O
circumventing	O
cisplatin	B
resistance	O
in	O
vitro	O
)	O
.	O

Further	O
details	O
of	O
the	O
cascade	O
have	O
been	O
published	O
previously	O
[	O
4	O
]	O
.	O

From	O
an	O
in	O
vitro	O
evaluation	O
of	O
several	O
hundred	O
analogues	O
,	O
two	O
compounds	O
,	O
JM335	B
(	O
trans	B
-ammine	I
(	I
cyclohexylaminedichlorodihydroxo	I
)	I
platinum	I
(	I
IV	I
)	I
)	O
and	O
ZD0473	B
(	O
cis	B
-amminedichloro	I
(	I
2-methylpyridine	I
)	I
platinum	I
(	I
II	I
)	I
)	O
,	O
have	O
been	O
identified	O
as	O
lead	O
molecules	O
(	O
Fig.	O
1	O
for	O
structures	O
)	O
.	O

The	O
latest	O
findings	O
with	O
these	O
drugs	O
form	O
the	O
basis	O
of	O
the	O
remainder	O
of	O
this	O
review	O
.	O

2	O
JM335	B
:	O
preclinical	O
studies	O
with	O
an	O
active	O
trans	B
platinum	I
complex	I
JM335	B
represents	O
one	O
of	O
three	O
independent	O
classes	O
of	O
'	O
active	O
'	O
trans	B
platinum	I
complex	I
discovered	O
during	O
the	O
1990s	O
[	O
15–17	O
]	O
.	O

The	O
trans	B
-platinum	I
complexes	I
contravene	O
the	O
original	O
structure	O
–	O
activity	O
rules	O
assigned	O
to	O
platinum	B
complexes	I
[	O
2	O
]	O
and	O
represent	O
rationally	O
designed	O
molecules	O
aimed	O
at	O
inducing	O
a	O
different	O
spectrum	O
of	O
adducts	O
on	O
DNA	O
.	O

Early	O
studies	O
with	O
JM335	B
showed	O
circumvention	O
of	O
acquired	O
cisplatin	B
resistance	O
in	O
vitro	O
against	O
at	O
least	O
some	O
cell	O
lines	O
(	O
e.g.	O
,	O
41Mcis	O
R	O
and	O
CH1cis	O
R	O
)	O
[	O
15	O
]	O
and	O
a	O
good	O
measure	O
of	O
in	O
vivo	O
antitumour	O
activity	O
against	O
both	O
human	O
ovarian	O
carcinoma	O
xenografts	O
[	O
15,18	O
]	O
(	O
but	O
less	O
than	O
that	O
observed	O
for	O
cisplatin	B
)	O
and	O
against	O
acquired	O
cisplatin	B
-	O
resistant	O
murine	O
ADJ	O
/	O
PC6	O
plasmacytoma	O
and	O
L1210	O
leukaemia	O
models	O
[	O
19	O
]	O
.	O

Of	O
interest	O
was	O
that	O
the	O
platinum	B
(	I
II	I
)	I
counterpart	O
of	O
JM335	B
(	O
JM334	B
)	O
did	O
not	O
show	O
in	O
vivo	O
antitumour	O
activity	O
[	O
18	O
]	O
.	O

JM335	B
has	O
been	O
shown	O
to	O
induce	O
lesions	O
on	O
DNA	O
distinct	O
from	O
those	O
induced	O
by	O
cisplatin	B
illustrated	O
by	O
the	O
lack	O
of	O
recognition	O
of	O
JM335-induced	B
adducts	O
on	O
DNA	O
extracted	O
from	O
treated	O
tumour	O
cells	O
by	O
a	O
monoclonal	O
antibody	O
raised	O
against	O
cisplatinated	B
-	O
DNA	O
[	O
20	O
]	O
.	O

Other	O
studies	O
revealed	O
that	O
JM335	B
induced	O
apoptosis	O
in	O
the	O
CH1	O
cell	O
line	O
[	O
21	O
]	O
.	O

Recent	O
studies	O
have	O
focused	O
on	O
gene	O
-	O
specific	O
repair	O
of	O
DNA	O
lesions	O
formed	O
by	O
JM335	B
versus	O
its	O
cis	O
isomer	O
JM149	B
and	O
cisplatin	B
in	O
two	O
human	O
ovarian	O
carcinoma	O
cell	O
lines	O
;	O
the	O
intrinsically	O
cisplatin	B
-	O
sensitive	O
CH1	O
and	O
the	O
relatively	O
resistant	O
SKOV-3	O
.	O

Fig.	O
2	O
illustrates	O
the	O
ability	O
of	O
these	O
two	O
cell	O
lines	O
to	O
remove	O
DNA	O
lesions	O
induced	O
by	O
JM335	B
,	O
JM149	B
and	O
cisplatin	B
from	O
a	O
region	O
of	O
the	O
N	O
-	O
ras	O
gene	O
,	O
as	O
assayed	O
by	O
quantitative	O
-	O
PCR	O
.	O

Results	O
showed	O
that	O
the	O
CH1	O
cell	O
line	O
was	O
unable	O
to	O
remove	O
adducts	O
at	O
24	O
h	O
post	O
5	O
h	O
drug	O
exposure	O
formed	O
by	O
any	O
of	O
the	O
three	O
agents	O
.	O

In	O
contrast	O
,	O
SKOV-3	O
removed	O
adducts	O
formed	O
by	O
the	O
two	O
cis	O
-oriented	O
compounds	O
cisplatin	B
and	O
JM149	B
but	O
not	O
adducts	O
formed	O
by	O
the	O
trans	O
compound	O
JM335	B
.	O

Other	O
studies	O
investigating	O
the	O
ability	O
of	O
these	O
compounds	O
to	O
induce	O
cell	O
death	O
showed	O
that	O
all	O
three	O
compounds	O
induce	O
apoptosis	O
in	O
both	O
cell	O
lines	O
but	O
the	O
rate	O
of	O
death	O
was	O
markedly	O
faster	O
for	O
the	O
trans	O
isomer	O
(	O
e.g.	O
,	O
following	O
a	O
2	O
h	O
exposure	O
to	O
2	O
×	O
IC50	O
concentrations	O
,	O
the	O
time	O
for	O
50	O
%	O
of	O
cells	O
to	O
undergo	O
apoptotic	O
detachment	O
was	O
around	O
24	O
h	O
for	O
JM335	B
,	O
but	O
around	O
72	O
h	O
for	O
JM149	B
)	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
that	O
the	O
cellular	O
pharmacological	O
properties	O
of	O
the	O
trans	O
compound	O
JM335	B
differ	O
from	O
those	O
of	O
cisplatin	B
and	O
even	O
its	O
cis	O
isomer	O
.	O

The	O
future	O
challenge	O
is	O
to	O
achieve	O
adequate	O
delivery	O
of	O
these	O
intrinsically	O
relatively	O
reactive	O
platinum	B
drugs	I
to	O
tumours	O
in	O
vivo	O
.	O

To	O
date	O
,	O
including	O
JM335	B
[	O
18	O
]	O
,	O
the	O
level	O
of	O
in	O
vivo	O
antitumour	O
activity	O
against	O
human	O
solid	O
tumours	O
has	O
not	O
matched	O
their	O
promising	O
in	O
vitro	O
and	O
cellular	O
pharmacological	O
properties	O
.	O

3	O
ZD0473	B
:	O
studies	O
with	O
a	O
sterically	O
hindered	O
platinum	B
drug	I
Many	O
previous	O
studies	O
of	O
platinum	B
drug	I
resistance	O
,	O
including	O
our	O
own	O
using	O
the	O
panel	O
of	O
human	O
ovarian	O
carcinoma	O
cell	O
lines	O
[	O
22	O
]	O
,	O
have	O
indicated	O
that	O
drug	O
inactivation	O
by	O
cytoplasmic	O
thiol	B
-	O
containing	O
species	O
,	O
principally	O
glutathione	B
(	O
GSH	B
)	O
and	O
metallothionein	O
(	O
MT	O
)	O
,	O
contributes	O
to	O
resistance	O
[	O
9	O
]	O
.	O

The	O
rational	O
design	O
of	O
a	O
platinum	B
drug	I
possessing	O
a	O
reduced	O
susceptibility	O
to	O
binding	O
to	O
thiols	B
would	O
offer	O
the	O
potential	O
to	O
lessen	O
the	O
impact	O
of	O
this	O
commonly	O
described	O
mechanism	O
of	O
resistance	O
.	O

This	O
was	O
achieved	O
in	O
ZD0473	B
(	O
formerly	O
known	O
as	O
JM473	B
and	O
AMD473	B
)	O
by	O
increasing	O
the	O
steric	O
bulk	O
at	O
the	O
platinum	B
centre	O
using	O
the	O
2-methylpyridine	B
carrier	O
ligand	O
.	O

As	O
predicted	O
by	O
chemical	O
considerations	O
,	O
ZD0473	B
was	O
shown	O
to	O
be	O
relatively	O
less	O
reactive	O
than	O
cisplatin	B
to	O
the	O
thiol	B
-	O
containing	O
molecules	O
,	O
methionine	B
and	O
GSH	B
[	O
23,24	O
]	O
.	O

The	O
drug	B
also	O
possesses	O
a	O
two	O
-	O
fold	O
slower	O
aquation	O
rate	O
in	O
water	B
than	O
that	O
of	O
cisplatin	B
[	O
23	O
]	O
.	O

ZD0473	B
exhibited	O
a	O
promising	O
level	O
of	O
in	O
vitro	O
potency	O
against	O
the	O
41Mcis	O
R	O
,	O
CH1cis	O
R	O
and	O
A2780cis	O
R	O
acquired	O
cisplatin	B
-	O
resistant	O
cell	O
lines	O
[	O
24	O
]	O
.	O

At	O
the	O
level	O
of	O
DNA	O
binding	O
,	O
ZD0473	B
was	O
shown	O
to	O
form	O
some	O
unique	O
adducts	O
when	O
compared	O
to	O
cisplatin	B
(	O
e.g.	O
,	O
novel	O
sites	O
on	O
naked	O
plasmid	O
DNA	O
)	O
and	O
displayed	O
a	O
much	O
slower	O
rate	O
of	O
formation	O
of	O
interstrand	O
crosslinks	O
[	O
23,24	O
]	O
.	O

ZD0473	B
also	O
showed	O
in	O
vivo	O
antitumour	O
activity	O
by	O
both	O
the	O
intraperitoneal	O
and	O
oral	O
routes	O
,	O
including	O
against	O
some	O
models	O
of	O
acquired	O
cisplatin	B
resistance	O
[	O
25,26	O
]	O
.	O

In	O
rodents	O
,	O
ZD0473	B
possesses	O
a	O
toxicity	O
profile	O
similar	O
to	O
carboplatin	B
with	O
myelosuppression	O
the	O
dose	O
-	O
limiting	O
toxicity	O
[	O
25	O
]	O
.	O

AMD473	B
entered	O
clinical	O
trial	O
at	O
the	O
Royal	O
Marsden	O
NHS	O
Trust	O
Hospital	O
in	O
November	O
1997	O
under	O
the	O
auspices	O
of	O
the	O
UK	O
Cancer	O
Research	O
Campaign	O
.	O

In	O
April	O
1998	O
,	O
the	O
drug	B
was	O
licenced	O
from	O
AnorMED	O
to	O
Zeneca	O
as	O
ZD0473	B
.	O

Using	O
an	O
intravenous	O
dosing	O
schedule	O
given	O
initially	O
every	O
3	O
weeks	O
,	O
and	O
pharmacokinetically	O
guided	O
dose	O
escalation	O
from	O
12	O
mg	O
/	O
m2	O
,	O
a	O
dose	O
-	O
limiting	O
toxicity	O
of	O
myelosuppression	O
(	O
thrombocytopenia	O
and	O
neutropenia	O
)	O
was	O
observed	O
at	O
the	O
130	O
mg	O
/	O
m2	O
dose	O
-	O
level	O
.	O

In	O
addition	O
,	O
some	O
patients	O
at	O
this	O
dose	O
-	O
level	O
were	O
unable	O
to	O
receive	O
repeated	O
dosing	O
every	O
3	O
weeks	O
.	O

Subsequent	O
investigations	O
of	O
lower	O
doses	O
,	O
110–120	O
mg	O
/	O
m2	O
at	O
which	O
serious	O
toxicity	O
was	O
not	O
observed	O
,	O
suggested	O
that	O
non	O
-	O
heavily	O
pre	O
-	O
treated	O
patients	O
might	O
tolerate	O
higher	O
doses	O
and	O
patients	O
are	O
currently	O
being	O
treated	O
at	O
150	O
mg	O
/	O
m2	O
.	O

There	O
has	O
been	O
no	O
nephro-	O
,	O
oto-	O
or	O
neuro	O
-	O
toxicity	O
noted	O
to	O
date	O
.	O

The	O
pharmacokinetics	O
of	O
total	O
and	O
free	O
platinum	B
were	O
linear	O
over	O
the	O
range	O
of	O
doses	O
used	O
with	O
free	O
platinum	B
decaying	O
in	O
a	O
tri	O
-	O
phasic	O
pattern	O
with	O
a	O
long	O
(	O
approx	O
.	O
72	O
h	O
)	O
terminal	O
t	O
1	O
/	O
2γ	O
.	O

There	O
has	O
been	O
evidence	O
of	O
antitumour	O
activity	O
in	O
a	O
patient	O
with	O
ovarian	O
cancer	O
.	O

Additional	O
laboratory	O
-	O
based	O
studies	O
with	O
ZD0473	B
have	O
focused	O
on	O
drug	B
metabolism	O
,	O
the	O
elucidation	O
of	O
mechanisms	O
of	O
resistance	O
to	O
ZD0473	B
in	O
ovarian	O
cancer	O
cell	O
lines	O
and	O
effects	O
on	O
growth	O
inhibition	O
of	O
manipulating	O
intracellular	O
GSH	B
and	O
metallothionein	O
levels	O
in	O
tumour	O
cells	O
.	O

Compared	O
to	O
previous	O
metabolism	O
studies	O
performed	O
with	O
the	O
platinum	B
(	I
IV	I
)	I
dicarboxylate	I
oral	O
drug	B
,	O
JM216	B
,	O
the	O
metabolism	O
of	O
ZD0473	B
is	O
relatively	O
simple	O
with	O
the	O
major	O
products	O
being	O
the	O
aquated	B
cis	B
and	O
trans	B
species	I
.	O

The	O
drug	B
is	O
relatively	O
stable	O
and	O
even	O
with	O
incubation	O
of	O
ZD0473	B
with	O
excess	O
glutathione	B
(	O
with	O
and	O
without	O
glutathione	O
-	O
S	O
-transferase	O
)	O
this	O
did	O
not	O
result	O
in	O
the	O
formation	O
of	O
any	O
glutathione	B
adducts	I
.	O

Similar	O
to	O
resistance	O
studies	O
performed	O
with	O
cisplatin	B
,	O
acquired	O
ZD0473-resistant	B
cell	O
lines	O
have	O
been	O
established	O
using	O
the	O
CH1	O
and	O
A2780	O
ovarian	O
lines	O
.	O

Both	O
the	O
CH1	O
(	O
3.3-fold	O
-	O
resistant	O
)	O
and	O
A2780	O
(	O
2.7-fold	O
-	O
resistant	O
)	O
ZD0473R	O
lines	O
showed	O
cross	O
-	O
resistance	O
to	O
cisplatin	B
and	O
carboplatin	B
.	O

Both	O
resistant	O
lines	O
showed	O
a	O
small	O
reduction	O
in	O
platinum	B
transport	O
following	O
exposure	O
to	O
ZD0473	B
,	O
reflected	O
in	O
similar	O
decreases	O
in	O
DNA	O
platination	O
.	O

Interestingly	O
,	O
when	O
compared	O
to	O
their	O
parent	O
lines	O
,	O
both	O
resistant	O
lines	O
showed	O
an	O
elevation	O
in	O
GSH	B
levels	O
(	O
1.5-fold	O
in	O
A2780ZD0473R	O
and	O
2.7-fold	O
in	O
CH1ZD0473R	O
)	O
.	O

Hence	O
,	O
at	O
least	O
some	O
mechanisms	O
of	O
resistance	O
to	O
ZD0473	B
are	O
shared	O
with	O
those	O
previously	O
described	O
in	O
many	O
lines	O
for	O
cisplatin	B
.	O

The	O
A2780ZD0473R	O
line	O
also	O
appears	O
to	O
possess	O
changes	O
in	O
proteins	O
associated	O
with	O
DNA	O
mismatch	O
repair	O
[	O
27	O
]	O
and	O
apoptosis	O
[	O
28	O
]	O
in	O
that	O
loss	O
of	O
hMLH1	O
and	O
a	O
marked	O
increase	O
in	O
the	O
antiapoptotic	O
protein	O
BCL2	O
in	O
comparison	O
to	O
A2780	O
were	O
observed	O
.	O

In	O
contrast	O
,	O
in	O
a	O
series	O
of	O
acquired	O
cisplatin	B
-	O
resistant	O
ovarian	O
cell	O
-	O
line	O
pairs	O
,	O
there	O
was	O
no	O
consistent	O
pattern	O
of	O
BCL2	O
expression	O
with	O
,	O
in	O
some	O
cases	O
,	O
levels	O
being	O
lower	O
in	O
resistant	O
versus	O
parent	O
lines	O
(	O
e.g.	O
,	O
41Mcis	O
R	O
/	O
41	O
M	O
)	O
,	O
whereas	O
levels	O
were	O
higher	O
in	O
CH1cis	O
R	O
versus	O
CH1	O
.	O

Intriguing	O
effects	O
on	O
growth	O
inhibition	O
induced	O
by	O
ZD0473	B
versus	O
cisplatin	B
have	O
been	O
obtained	O
by	O
manipulation	O
of	O
intracellular	O
thiol	B
levels	O
in	O
human	O
ovarian	O
cancer	O
cells	O
.	O

Fig.	O
3	O
shows	O
the	O
effect	O
in	O
terms	O
of	O
fold	O
-	O
change	O
in	O
growth	O
inhibition	O
(	O
IC50	O
)	O
of	O
(	O
a	O
)	O
increasing	O
GSH	B
levels	O
in	O
A2780	O
cells	O
using	O
pre	O
-	O
exposure	O
to	O
GSH	B
-	I
ester	I
,	O
(	O
b	O
)	O
increasing	O
MT	O
levels	O
using	O
an	O
A2780	O
subline	O
stably	O
transfected	O
with	O
MTIIA	O
cDNA	O
and	O
(	O
c	O
)	O
reducing	O
GSH	B
levels	O
by	O
approximately	O
80	O
%	O
using	O
pre	O
-	O
exposure	O
of	O
SKOV-3	O
cells	O
(	O
which	O
have	O
relatively	O
high	O
intrinsic	O
levels	O
)	O
to	O
buthionine	B
sulfoxamine	I
(	O
BSO	B
)	O
.	O

As	O
predicted	O
by	O
the	O
reduced	O
susceptibility	O
of	O
ZD0473	B
to	O
bind	O
to	O
thiols	B
when	O
compared	O
to	O
cisplatin	B
,	O
increasing	O
either	O
GSH	B
or	O
MT	O
levels	O
reduced	O
the	O
growth	O
inhibitory	O
properties	O
of	O
cisplatin	B
to	O
a	O
greater	O
extent	O
than	O
for	O
ZD0473	B
(	O
e.g.	O
,	O
with	O
increasing	O
MT	O
levels	O
;	O
7-fold	O
loss	O
in	O
potency	O
of	O
cisplatin	B
but	O
only	O
1.3-fold	O
loss	O
with	O
ZD0473	B
)	O
.	O

In	O
contrast	O
,	O
and	O
surprisingly	O
,	O
the	O
reduction	O
of	O
GSH	B
levels	O
using	O
BSO	B
in	O
SKOV-3	O
cells	O
resulted	O
in	O
a	O
greater	O
potentiation	O
with	O
ZD0473	O
(	O
2.5-fold	O
)	O
than	O
with	O
cisplatin	O
(	O
1.5-fold	O
)	O
.	O

Although	O
BSO	B
may	O
exert	O
additional	O
effects	O
on	O
cells	O
such	O
as	O
affecting	O
drug	B
transport	O
,	O
metabolism	O
or	O
DNA	O
repair	O
[	O
29	O
]	O
these	O
data	O
indicate	O
that	O
further	O
studies	O
are	O
required	O
to	O
fully	O
elucidate	O
the	O
interactions	O
between	O
ZD0473	B
and	O
sulphur	B
-	I
containing	I
molecules	I
in	O
tumour	O
cells	O
.	O

4	O
Conclusions	O
Over	O
a	O
period	O
of	O
almost	O
20	O
years	O
,	O
the	O
Institute	O
of	O
Cancer	O
Research	O
/	O
Johnson	O
Matthey	O
/	O
AnorMED	O
collaboration	O
has	O
resulted	O
in	O
three	O
platinum	B
complexes	I
entering	O
clinical	O
trial	O
:	O
carboplatin	B
is	O
registered	O
worldwide	O
,	O
the	O
oral	O
platinum	B
JM216	B
is	O
undergoing	O
phase	O
II	O
/	O
III	O
trials	O
and	O
ZD0473	B
is	O
currently	O
in	O
phase	O
I	O
studies	O
.	O

The	O
trans	B
platinum	I
complex	I
JM335	B
represents	O
one	O
of	O
a	O
small	O
series	O
of	O
trans	B
complexes	I
which	O
exhibits	O
promising	O
in	O
vitro	O
antitumour	O
properties	O
,	O
especially	O
against	O
acquired	O
cisplatin	B
-	O
resistant	O
cells	O
.	O

Acknowledgements	O
Laboratory	O
studies	O
at	O
the	O
CRC	O
Centre	O
for	O
Cancer	O
Therapeutics	O
,	O
formerly	O
the	O
Drug	O
Development	O
Section	O
,	O
of	O
the	O
Institute	O
of	O
Cancer	O
Research	O
were	O
supported	O
predominantly	O
by	O
grants	O
from	O
the	O
UK	O
Cancer	O
Research	O
Campaign	O
.	O

All	O
studies	O
were	O
conducted	O
in	O
collaboration	O
with	O
chemists	O
at	O
Johnson	O
Matthey	O
,	O
and	O
in	O
recent	O
years	O
,	O
AnorMED	O
.	O

Thanks	O
are	O
due	O
to	O
numerous	O
post	O
-	O
doctoral	O
scientists	O
,	O
scientific	O
officers	O
,	O
Ph.D.	O
students	O
,	O
clinical	O
fellows	O
and	O
research	O
nurses	O
who	O
have	O
contributed	O
over	O
the	O
20-plus	O
years	O
.	O

Special	O
recognition	O
is	O
reserved	O
for	O
Professor	O
Ken	O
Harrap	O
,	O
without	O
whose	O
leadership	O
little	O
of	O
this	O
research	O
would	O
have	O
occurred	O
.	O

Conformational	O
analysis	O
of	O
disaccharides	B
is	O
usually	O
accompanied	O
by	O
the	O
generation	O
of	O
a	O
Ramachandran	O
-	O
like	O
conformational	O
map	O
as	O
a	O
tool	O
in	O
understanding	O
oligosaccharide	B
conformational	O
structures	O
[	O
1–3	O
]	O
.	O

In	O
these	O
maps	O
the	O
energy	O
is	O
determined	O
for	O
all	O
mutual	O
orientations	O
of	O
the	O
two	O
monosaccharide	B
residues	I
,	O
expressed	O
by	O
the	O
glycosidic	O
angles	O
φ	O
and	O
ψ	O
.	O

First	O
studies	O
were	O
carried	O
out	O
by	O
rigid	O
residue	O
analysis	O
[	O
3	O
]	O
.	O

However	O
,	O
by	O
allowing	O
all	O
variables	O
to	O
relax	O
,	O
Melberg	O
and	O
Rasmussen	O
[	O
4–6	O
]	O
initiated	O
flexible	O
residue	O
analysis	O
by	O
1979	O
.	O

These	O
studies	O
were	O
extended	O
in	O
the	O
late	O
1980s	O
[	O
7–12	O
]	O
,	O
giving	O
rise	O
to	O
the	O
first	O
fully	O
relaxed	O
energy	O
maps	O
of	O
many	O
disaccharides	B
.	O

When	O
generating	O
these	O
Ramachandran	O
maps	O
,	O
it	O
should	O
be	O
borne	O
in	O
mind	O
that	O
the	O
actual	O
conformational	O
hypersurface	O
of	O
a	O
disaccharide	B
carries	O
,	O
for	O
each	O
φ	O
,	O
ψ	O
combination	O
,	O
the	O
influence	O
of	O
the	O
orientations	O
of	O
secondary	B
hydroxyl	I
groups	I
,	O
hydroxymethyl	B
groups	I
and	O
the	O
primary	B
hydroxyl	I
groups	I
,	O
all	O
of	O
which	O
may	O
affect	O
the	O
calculated	O
final	O
energy	O
by	O
several	O
kilocalories	O
(	O
the	O
'	O
multiple	O
minimum	O
problem	O
'	O
[	O
1–3	O
]	O
)	O
.	O

For	O
a	O
disaccharide	B
formed	O
by	O
two	O
hexopyranose	B
residues	I
and	O
considering	O
the	O
three	O
staggered	O
positions	O
for	O
the	O
ten	O
exocyclic	O
groups	O
,	O
59,049	O
(	O
310	O
)	O
different	O
starting	O
points	O
are	O
possible	O
for	O
the	O
construction	O
of	O
the	O
map	O
[	O
3,13,14	O
]	O
.	O

Thus	O
,	O
different	O
starting	O
points	O
will	O
yield	O
different	O
minima	O
after	O
geometry	O
optimization	O
.	O

An	O
'	O
adiabatic	O
'	O
map	O
is	O
generated	O
by	O
plotting	O
the	O
lower	O
-	O
energy	O
values	O
found	O
at	O
each	O
grid	O
point	O
[	O
15	O
]	O
.	O

The	O
outcome	O
is	O
that	O
,	O
at	O
least	O
theoretically	O
,	O
the	O
true	O
adiabatic	O
map	O
for	O
a	O
disaccharide	B
can	O
only	O
be	O
obtained	O
after	O
calculating	O
59,049	O
relaxed	O
maps	O
and	O
determining	O
,	O
for	O
each	O
φ	O
/ψ	O
combination	O
,	O
the	O
one	O
with	O
the	O
lowest	O
energy	O
.	O

Even	O
with	O
present	O
resources	O
,	O
and	O
using	O
a	O
fast	O
molecular	O
mechanics	O
method	O
,	O
this	O
task	O
is	O
very	O
difficult	O
(	O
one	O
adiabatic	O
map	O
in	O
a	O
20	O
×	O
20	O
°	O
grid	O
would	O
take	O
more	O
than	O
three	O
years	O
in	O
a	O
single	O
CPU	O
for	O
minimizations	O
taking	O
an	O
average	O
of	O
5	O
s	O
each	O
)	O
.	O

This	O
problem	O
has	O
been	O
extensively	O
recognized	O
since	O
the	O
early	O
flexible	O
residue	O
analyses	O
[	O
4–6,10–15	O
]	O
.	O

However	O
,	O
it	O
was	O
found	O
that	O
the	O
hydroxymethyl	B
groups	I
in	O
monosaccharides	B
show	O
a	O
marked	O
trend	O
to	O
stay	O
at	O
preferential	O
positions	O
(	O
usually	O
gg	O
and	O
gt	O
)	O
[	O
11,14	O
]	O
.	O

Furthermore	O
,	O
it	O
was	O
determined	O
that	O
the	O
secondary	B
hydroxyl	I
groups	I
are	O
likely	O
to	O
form	O
a	O
'	O
crown	O
'	O
of	O
cooperative	O
hydrogen	B
bonds	I
,	O
oriented	O
either	O
clockwise	O
(	O
c	O
)	O
or	O
reverse	O
clockwise	O
(	O
r	O
)	O
around	O
the	O
pyranose	B
ring	O
[	O
9	O
]	O
.	O

In	O
this	O
way	O
,	O
each	O
monosaccharidic	B
unit	I
was	O
considered	O
[	O
15,16	O
]	O
only	O
in	O
the	O
gt	O
r	O
,	O
gt	O
c	O
,	O
gg	O
c	O
and	O
gg	O
r	O
conformations	O
,	O
thus	O
leading	O
to	O
only	O
16	O
starting	O
points	O
for	O
the	O
disaccharide	B
.	O

This	O
approach	O
has	O
been	O
extensively	O
used	O
,	O
among	O
others	O
,	O
by	O
Dowd	O
et	O
al.	O
[	O
16–19	O
]	O
,	O
who	O
studied	O
different	O
disaccharides	B
using	O
MM3	O
.	O

Sometimes	O
the	O
starting	O
conformers	O
were	O
not	O
just	O
16	O
,	O
but	O
24	O
when	O
a	O
different	O
arrangement	O
of	O
hydroxyl	B
groups	I
was	O
added	O
[	O
17,18	O
]	O
,	O
36	O
when	O
the	O
hydroxymethyl	B
groups	I
were	O
considered	O
at	O
the	O
three	O
available	O
positions	O
[	O
20,21	O
]	O
or	O
some	O
other	O
figures	O
[	O
22	O
]	O
.	O

The	O
same	O
approach	O
was	O
even	O
adopted	O
to	O
emulate	O
aqueous	B
solutions	O
[	O
23,24	O
]	O
,	O
where	O
such	O
circuits	O
of	O
hydrogen	B
bonds	I
might	O
not	O
form	O
at	O
all	O
.	O

The	O
multiple	O
minimum	O
problem	O
was	O
also	O
tackled	O
with	O
less	O
systematic	O
procedures	O
,	O
such	O
as	O
iterative	O
manual	O
searches	O
[	O
11,15,25–27	O
]	O
.	O

Tvaroška	O
and	O
co	O
-	O
workers	O
tried	O
to	O
overcome	O
this	O
problem	O
with	O
the	O
program	O
ramm	O
,	O
which	O
finds	O
the	O
energetically	O
most	O
favorable	O
combinations	O
of	O
the	O
pendant	O
group	O
orientations	O
for	O
each	O
φ	O
,	O
ψ	O
pair	O
,	O
using	O
a	O
random	O
sampling	O
technique	O
[	O
13,22,28	O
]	O
.	O

Another	O
way	O
to	O
elude	O
the	O
multiple	O
minimum	O
problem	O
is	O
to	O
explore	O
the	O
conformational	O
space	O
of	O
disaccharides	B
by	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
[	O
22,29,30	O
]	O
,	O
an	O
expanding	O
methodology	O
.	O

These	O
simulations	O
were	O
also	O
combined	O
with	O
Monte	O
Carlo	O
techniques	O
in	O
order	O
to	O
increase	O
their	O
efficiency	O
to	O
cross	O
energy	O
barriers	O
[	O
31,32	O
]	O
.	O

French	O
and	O
co	O
-	O
workers	O
[	O
14,16	O
]	O
have	O
pointed	O
out	O
the	O
problems	O
arising	O
from	O
minimization	O
with	O
the	O
mm2	O
'	O
standard	O
driver	O
'	O
,	O
for	O
which	O
the	O
inelastic	O
deformations	O
are	O
transmitted	O
to	O
the	O
next	O
structure	O
,	O
and	O
thus	O
suggested	O
the	O
use	O
of	O
a	O
driver	O
in	O
which	O
each	O
point	O
of	O
each	O
relaxed	O
surface	O
is	O
generated	O
directly	O
from	O
the	O
same	O
starting	O
point	O
,	O
in	O
order	O
to	O
avoid	O
these	O
propagations	O
of	O
deformations	O
.	O

Herein	O
is	O
presented	O
the	O
mapping	O
of	O
the	O
disaccharide	B
α	B
-	I
d	I
-Galp	I
-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Galp	I
(	O
1	O
)	O
[	O
25–27	O
]	O
using	O
MM3	O
[	O
33	O
]	O
at	O
either	O
ε	O
=3	O
or	O
ε	O
=	O
80	O
.	O

The	O
influence	O
of	O
using	O
either	O
driver	O
systematically	O
,	O
and	O
of	O
an	O
iterative	O
manual	O
searching	O
procedure	O
,	O
on	O
the	O
adiabaticity	O
of	O
the	O
final	O
maps	O
is	O
discussed	O
.	O

2	O
2	O
.	O

Methods	O
Calculations	O
were	O
carried	O
out	O
on	O
a	O
Sun	O
SparcStation	O
10	O
computer	O
,	O
using	O
the	O
molecular	O
mechanics	O
program	O
MM3	O
(	O
92	O
)	O
(	O
QCPE	O
,	O
Indiana	O
University	O
,	O
USA	O
)	O
,	O
developed	O
by	O
Allinger	O
and	O
co	O
-	O
workers	O
[	O
33	O
]	O
.	O

The	O
MM3	O
routines	O
were	O
modified	O
as	O
suggested	O
[	O
34	O
]	O
by	O
changing	O
the	O
maximum	O
atomic	O
movement	O
from	O
0.25	O
to	O
0.10	O
Å.	O
Minimization	O
(	O
by	O
the	O
block	O
diagonal	O
Newton	O
–	O
Raphson	O
procedure	O
for	O
grid	O
points	O
,	O
using	O
the	O
full	O
-	O
matrix	O
procedure	O
for	O
the	O
minima	O
)	O
was	O
terminated	O
when	O
the	O
average	O
movement	O
converged	O
to	O
a	O
value	O
lower	O
than	O
10−4	O
Å.	O

The	O
dihedrals	O
φ	O
and	O
ψ	O
(	O
also	O
called	O
φ	O
H	O
and	O
ψ	O
H	O
)	O
are	O
defined	O
by	O
atoms	O
H-1′C-1′O-3C-3	O
and	O
H-3C-3O-3C-1′	O
,	O
respectively	O
,	O
with	O
the	O
usual	O
sign	O
conventions	O
[	O
27	O
]	O
.	O

NOE	O
theoretical	O
calculations	O
and	O
average	O
linkage	O
rotations	O
were	O
calculated	O
as	O
reported	O
elsewhere	O
[	O
25,27	O
]	O
.	O

Sixteen	O
starting	O
conformers	O
of	O
the	O
disaccharide	B
were	O
generated	O
by	O
minimization	O
of	O
structures	O
with	O
the	O
adequate	O
geometry	O
:	O
their	O
glycosidic	O
torsional	O
angles	O
were	O
around	O
φ	O
,	O
ψ	O
−40	O
°	O
,−40	O
°	O
(	O
minimum	O
B	O
)	O
[	O
27	O
]	O
,	O
their	O
monosaccharide	B
constituents	O
were	O
4	O
C	O
1	O
ring	O
conformers	O
with	O
either	O
gt	O
(	O
θO-5C-5C-6O-6	O
≈60	O
°	O
)	O
or	O
gg	O
(	O
θO-5C-5C-6O-6	O
≈−60	O
°	O
)	O
orientation	O
of	O
the	O
hydroxymethyl	B
groups	I
.	O

As	O
suggested	O
[	O
9	O
]	O
,	O
clockwise	O
(	O
c	O
)	O
or	O
reverse	O
clockwise	O
(	O
r	O
)	O
orientations	O
were	O
chosen	O
for	O
the	O
secondary	B
hydroxyl	I
groups	I
.	O

The	O
primary	O
hydroxyl	O
groups	O
were	O
also	O
settled	O
in	O
a	O
position	O
that	O
may	O
give	O
hydrogen	O
-	O
bonding	O
possibilities	O
(	O
Table	O
1	O
)	O
.	O

As	O
the	O
conformation	O
of	O
each	O
ring	O
is	O
,	O
a	O
priori	O
independent	O
from	O
that	O
of	O
the	O
other	O
,	O
four	O
orientations	O
of	O
hydroxyl	B
groups	I
and	O
four	O
of	O
hydroxymethyl	B
groups	I
are	O
possible	O
,	O
thus	O
leading	O
to	O
the	O
16	O
starting	O
conformations	O
.	O

Each	O
starting	O
conformer	O
led	O
to	O
a	O
different	O
φ	O
/ψ	O
relaxed	O
map	O
.	O

Using	O
both	O
dihedral	O
drivers	O
(	O
see	O
below	O
)	O
,	O
φ	O
and	O
ψ	O
were	O
fully	O
varied	O
(	O
through	O
the	O
whole	O
−180	O
to	O
180	O
°	O
grid	O
)	O
using	O
a	O
20	O
°	O
grid	O
step	O
.	O

At	O
each	O
point	O
,	O
energies	O
were	O
calculated	O
after	O
minimization	O
with	O
restraints	O
for	O
these	O
two	O
angles	O
but	O
allowing	O
the	O
other	O
variables	O
to	O
relax	O
.	O

Both	O
ε	O
=3	O
and	O
ε	O
=	O
80	O
were	O
applied	O
,	O
using	O
either	O
MM3	O
Driver	O
2	O
,	O
which	O
at	O
each	O
point	O
takes	O
the	O
previously	O
calculated	O
grid	O
point	O
as	O
the	O
starting	O
point	O
for	O
calculations	O
,	O
or	O
MM3	O
Driver	O
4	O
,	O
which	O
always	O
uses	O
the	O
same	O
starting	O
conformer	O
to	O
calculate	O
all	O
grid	O
points	O
directly	O
(	O
Fig.	O
1	O
)	O
.	O
'	O

Adiabatic	O
'	O
maps	O
[	O
15	O
]	O
were	O
constructed	O
in	O
each	O
case	O
using	O
,	O
for	O
each	O
grid	O
point	O
,	O
the	O
lowest	O
-	O
energy	O
value	O
for	O
each	O
set	O
of	O
16	O
relaxed	O
maps	O
.	O

The	O
contribution	O
of	O
each	O
relaxed	O
map	O
to	O
the	O
'	O
adiabatic	O
'	O
map	O
was	O
evaluated	O
from	O
their	O
probability	O
distributions	O
assuming	O
no	O
entropy	O
differences	O
:	O
Pi	O
=	O
∑φψ	O
exp	O
−Eφψ	O
/RT	O
∑i	O
∑φψ	O
exp	O
−Eφψ	O
/RT	O
In	O
a	O
different	O
procedure	O
,	O
another	O
'	O
adiabatic	O
'	O
map	O
was	O
generated	O
following	O
an	O
iterative	O
procedure	O
reported	O
elsewhere	O
[	O
15,25–27	O
]	O
.	O

Briefly	O
,	O
some	O
different	O
starting	O
geometries	O
were	O
chosen	O
,	O
using	O
the	O
lower	O
-	O
energy	O
conformations	O
for	O
α-	B
and	O
β	B
-	I
d	I
-galactose	I
[	O
35	O
]	O
and	O
checking	O
the	O
effects	O
of	O
rotations	O
of	O
alternate	O
pairs	O
of	O
hydroxymethyl	B
and	O
hydroxyl	B
groups	I
.	O

To	O
identify	O
the	O
lowest	O
energy	O
on	O
each	O
φ	O
,	O
ψ	O
grid	O
point	O
,	O
many	O
starting	O
conformations	O
were	O
minimized	O
.	O

The	O
generated	O
points	O
served	O
as	O
starting	O
points	O
for	O
the	O
next	O
ones	O
,	O
radially	O
from	O
each	O
starting	O
point	O
,	O
in	O
an	O
iterative	O
manner	O
.	O

As	O
it	O
was	O
pointed	O
out	O
[	O
15	O
]	O
,	O
the	O
amount	O
of	O
additional	O
searching	O
done	O
for	O
each	O
point	O
was	O
arbitrary	O
,	O
and	O
therefore	O
can	O
not	O
be	O
automated	O
.	O

3	O
3	O
.	O

Results	O
and	O
discussion	O
The	O
MM3-generated	O
conformational	O
maps	O
of	O
the	O
disaccharide	B
α	B
-	I
d	I
-Galp-	I
(	I
1→3	I
)	I
-β	I
-	I
d	I
-Galp	I
(	O
1	O
)	O
at	O
a	O
dielectric	O
constant	O
3.0	O
were	O
obtained	O
both	O
using	O
the	O
MM3	O
dihedral	O
drivers	O
2	O
and	O
4	O
(	O
Fig.	O
1	O
)	O
,	O
starting	O
from	O
16	O
different	O
initial	O
conformers	O
.	O

The	O
maps	O
with	O
the	O
lowest	O
-	O
energy	O
values	O
for	O
each	O
grid	O
point	O
are	O
shown	O
in	O
Fig.	O
2	O
(	O
a	O
)	O
for	O
dihedral	O
driver	O
2	O
and	O
Fig.	O
2	O
(	O
b	O
)	O
for	O
dihedral	O
driver	O
4	O
.	O

Fig.	O
2	O
(	O
c	O
)	O
shows	O
the	O
map	O
obtained	O
with	O
an	O
iterative	O
method	O
(	O
see	O
Section	O
2	O
)	O
.	O

With	O
those	O
three	O
'	O
adiabatic	O
'	O
maps	O
,	O
a	O
more	O
representative	O
'	O
true	O
'	O
adiabatic	O
map	O
was	O
constructed	O
(	O
Fig.	O
2	O
(	O
d	O
)	O
)	O
,	O
in	O
which	O
each	O
grid	O
point	O
takes	O
the	O
lower	O
value	O
.	O

Fig.	O
3	O
displays	O
the	O
energy	O
differences	O
between	O
the	O
'	O
adiabatic	O
'	O
map	O
obtained	O
by	O
each	O
method	O
and	O
the	O
'	O
true	O
'	O
adiabatic	O
map	O
.	O

As	O
shown	O
,	O
none	O
of	O
the	O
three	O
methods	O
produced	O
the	O
lower	O
-	O
energy	O
points	O
for	O
the	O
whole	O
grid	O
,	O
as	O
it	O
was	O
already	O
suggested	O
[	O
3	O
]	O
.	O

The	O
work	O
performed	O
with	O
Driver	O
4	O
yielded	O
lower	O
-	O
energy	O
values	O
than	O
that	O
carried	O
out	O
with	O
Driver	O
2	O
.	O

The	O
latter	O
gave	O
rise	O
to	O
many	O
high	O
-	O
energy	O
values	O
(	O
some	O
more	O
than	O
3	O
kcal	O
mol−1	O
above	O
those	O
obtained	O
by	O
other	O
methods	O
)	O
,	O
especially	O
for	O
the	O
strip	O
with	O
ψ	O
=	O
−60	O
°	O
,	O
close	O
to	O
the	O
termination	O
of	O
the	O
cycle	O
,	O
where	O
inelastic	O
deformations	O
[	O
14	O
]	O
led	O
to	O
high	O
-	O
energy	O
values	O
for	O
the	O
16	O
starting	O
conformers	O
.	O

Table	O
2	O
indicates	O
the	O
contributions	O
of	O
each	O
of	O
the	O
three	O
methods	O
to	O
the	O
'	O
true	O
'	O
adiabatic	O
map	O
.	O

As	O
shown	O
,	O
using	O
Driver	O
2	O
,	O
more	O
than	O
half	O
of	O
the	O
grid	O
points	O
have	O
energies	O
with	O
an	O
average	O
of	O
2.1	O
kcal	O
mol−1	O
above	O
their	O
minimum	O
values	O
.	O

Most	O
of	O
the	O
16	O
starting	O
conformations	O
yielded	O
points	O
that	O
were	O
used	O
to	O
construct	O
the	O
maps	O
,	O
but	O
more	O
than	O
two	O
-	O
thirds	O
of	O
their	O
population	O
arises	O
from	O
conformers	O
with	O
the	O
β	B
-	I
d	I
-galactose	I
unit	O
in	O
gt	O
orientation	O
.	O

Also	O
,	O
starting	O
conformers	O
with	O
alternate	O
configurations	O
of	O
secondary	O
hydroxyl	O
groups	O
(	O
rc	O
and	O
cr	O
)	O
double	O
the	O
population	O
of	O
those	O
with	O
the	O
same	O
configuration	O
(	O
cc	O
and	O
rr	O
)	O
.	O

The	O
actual	O
minimum	O
-	O
energy	O
starting	O
point	O
corresponds	O
to	O
a	O
gggt	O
cr	O
orientation	O
.	O

Table	O
3	O
shows	O
the	O
values	O
of	O
its	O
exocyclic	O
angles	O
.	O

The	O
same	O
procedures	O
were	O
repeated	O
with	O
ε	O
=	O
80	O
.	O

Fig.	O
4	O
shows	O
the	O
three	O
resulting	O
maps	O
,	O
Fig.	O
5	O
shows	O
the	O
energy	O
differences	O
of	O
each	O
map	O
from	O
the	O
'	O
true	O
'	O
adiabatic	O
map	O
(	O
Fig.	O
4	O
(	O
c	O
)	O
)	O
,	O
and	O
Table	O
4	O
indicates	O
their	O
contributions	O
to	O
this	O
true	O
adiabatic	O
map	O
.	O

In	O
this	O
instance	O
,	O
the	O
iterative	O
search	O
procedure	O
by	O
itself	O
yielded	O
the	O
true	O
adiabatic	O
map	O
(	O
Figs.	O
4	O
(	O
c	O
)	O
and	O
5	O
,	O
Table	O
4	O
)	O
.	O

Drivers	O
2	O
and	O
4	O
gave	O
rise	O
to	O
a	O
map	O
with	O
energies	O
averaging	O
0.6	O
and	O
0.9	O
kcal	O
mol−1	O
above	O
the	O
adiabatic	O
map	O
,	O
respectively	O
.	O

Even	O
considering	O
points	O
with	O
0.5	O
kcal	O
mol−1	O
difference	O
,	O
Driver	O
4	O
failed	O
to	O
find	O
true	O
minima	O
on	O
81	O
%	O
of	O
the	O
grid	O
.	O

As	O
expected	O
,	O
the	O
deficiency	O
of	O
the	O
systematic	O
methods	O
at	O
this	O
dielectric	O
constant	O
arises	O
from	O
the	O
fact	O
that	O
none	O
of	O
the	O
initial	O
16	O
starting	O
conformers	O
has	O
the	O
lower	O
-	O
energy	O
conformation	O
of	O
the	O
exocyclic	O
groups	O
.	O

This	O
is	O
obvious	O
when	O
using	O
a	O
method	O
where	O
the	O
electrostatic	O
contributions	O
were	O
intentionally	O
damped	O
[	O
2,22,25	O
]	O
by	O
using	O
a	O
dielectric	O
constant	O
of	O
80	O
,	O
for	O
which	O
hydrogen	B
bonding	I
has	O
almost	O
no	O
effect	O
,	O
and	O
thus	O
the	O
r	O
and	O
c	O
circuits	O
are	O
meaningless	O
.	O

The	O
geometry	O
of	O
the	O
actual	O
global	O
minimum	O
(	O
found	O
by	O
the	O
iterative	O
search	O
procedure	O
)	O
is	O
shown	O
in	O
Table	O
3	O
.	O

In	O
this	O
conformer	O
,	O
both	O
monosaccharide	B
units	O
had	O
hydroxymethyl	B
groups	I
in	O
gt	O
orientation	O
,	O
the	O
unit	O
of	O
β	B
-	I
galactose	I
had	O
their	O
secondary	B
hydroxyl	I
groups	I
in	O
an	O
r	O
arrangement	O
,	O
but	O
the	O
α	O
-	O
galactose	O
unit	O
has	O
no	O
recognizable	O
pattern	O
(	O
Table	O
3	O
)	O
.	O

Contrasting	O
the	O
maps	O
generated	O
at	O
a	O
low	O
dielectric	O
constant	O
,	O
here	O
the	O
lower	O
-	O
energy	O
points	O
(	O
within	O
a	O
15	O
kcal	O
mol−1	O
low	O
-	O
energy	O
window	O
)	O
arise	O
from	O
a	O
few	O
starting	O
conformers	O
.	O

More	O
than	O
80	O
%	O
of	O
the	O
population	O
of	O
the	O
Driver	O
4	O
map	O
arises	O
from	O
starting	O
conformers	O
in	O
which	O
both	O
hydroxymethyl	B
groups	I
carry	O
gt	O
orientation	O
(	O
mainly	O
gtgt	O
rr	O
)	O
,	O
while	O
less	O
than	O
1	O
%	O
arises	O
from	O
both	O
monosaccharidic	B
units	O
with	O
gg	O
orientation	O
.	O

No	O
major	O
effect	O
of	O
the	O
secondary	B
hydroxyl	I
group	I
arrangements	O
was	O
found	O
,	O
although	O
those	O
starting	O
with	O
r	O
orientation	O
yielded	O
a	O
higher	O
population	O
on	O
the	O
adiabatic	O
map	O
than	O
those	O
with	O
c	O
orientation	O
.	O

According	O
to	O
literature	O
[	O
23,35	O
]	O
,	O
the	O
hydroxymethyl	B
groups	I
of	B
galactose	I
are	O
oriented	O
gt	O
or	O
tg	O
rather	O
than	O
gg	O
.	O

However	O
,	O
in	O
this	O
calculation	O
gt	O
and	O
gg	O
orientations	O
were	O
used	O
,	O
because	O
it	O
was	O
found	O
that	O
tg	O
orientation	O
gives	O
abnormally	O
high	O
energy	O
values	O
in	O
molecular	O
mechanics	O
calculations	O
[	O
35	O
]	O
.	O

Table	O
5	O
shows	O
the	O
average	O
NOE	O
and	O
linkage	O
rotations	O
predicted	O
from	O
the	O
adiabatic	O
maps	O
at	O
both	O
dielectric	O
constants	O
.	O

Their	O
comparison	O
with	O
experimental	O
values	O
indicates	O
a	O
better	O
agreement	O
with	O
the	O
calculations	O
carried	O
out	O
at	O
ε	O
=	O
80	O
.	O

The	O
need	O
for	O
reliable	O
methods	O
for	O
generating	O
disaccharide	B
'	O
adiabatic	O
'	O
maps	O
was	O
recognized	O
at	O
an	O
earlier	O
time	O
[	O
1	O
]	O
and	O
discussed	O
extensively	O
[	O
3,11,13–15	O
]	O
.	O

French	O
and	O
co	O
-	O
workers	O
have	O
suggested	O
the	O
use	O
of	O
the	O
so	O
-	O
called	O
'	O
new	O
driver	O
'	O
[	O
14,16	O
]	O
(	O
later	O
brought	O
into	O
MM3	O
as	O
Driver	O
4	O
)	O
in	O
the	O
hope	O
of	O
arriving	O
at	O
better	O
results	O
,	O
together	O
with	O
a	O
combination	O
of	O
low	O
-	O
energy	O
starting	O
points	O
based	O
on	O
their	O
hydrogen	B
-	I
bonding	I
abilities	O
[	O
9	O
]	O
.	O

The	O
same	O
group	O
has	O
successfully	O
applied	O
the	O
method	O
to	O
the	O
MM3	O
analysis	O
of	O
many	O
disaccharides	B
[	O
16–19	O
]	O
at	O
dielectric	O
constants	O
close	O
to	O
four	O
.	O

In	O
more	O
recent	O
papers	O
[	O
23,24,37	O
]	O
,	O
the	O
method	O
was	O
extended	O
to	O
simulations	O
of	O
water	B
behavior	O
by	O
using	O
a	O
dielectric	O
constant	O
close	O
to	O
80	O
.	O

For	O
ionic	B
solutions	I
this	O
value	O
is	O
higher	O
than	O
that	O
of	O
the	O
water	B
in	O
the	O
first	O
solvation	O
shell	O
,	O
where	O
it	O
can	O
reach	O
values	O
as	O
low	O
[	O
38	O
]	O
as	O
six	O
.	O

The	O
effect	O
of	O
using	O
a	O
constant	O
close	O
to	O
80	O
is	O
equivalent	O
to	O
neglecting	O
electrostatic	O
and	O
hydrogen	B
-	I
bonding	I
interactions	O
[	O
22,25	O
]	O
.	O

However	O
,	O
it	O
has	O
been	O
used	O
in	O
order	O
to	O
obtain	O
better	O
agreement	O
with	O
experimental	O
values	O
in	O
aqueous	B
solutions	O
[	O
39	O
]	O
,	O
as	O
in	O
this	O
work	O
(	O
Table	O
5	O
)	O
.	O

This	O
paper	O
shows	O
that	O
,	O
at	O
least	O
with	O
the	O
disaccharide	B
under	O
study	O
,	O
high	O
-	O
dielectric	O
-	O
constant	O
MM3	O
calculations	O
with	O
Driver	O
4	O
exhibit	O
large	O
failures	O
to	O
produce	O
an	O
adiabatic	O
map	O
.	O

Furthermore	O
,	O
Driver	O
2	O
gives	O
rise	O
to	O
a	O
far	O
better	O
map	O
,	O
which	O
can	O
even	O
be	O
improved	O
if	O
this	O
option	O
is	O
also	O
used	O
backwards	O
(	O
i.e.	O
from	O
ψ	O
=	O
−40	O
°	O
to	O
lower	O
values	O
)	O
.	O

In	O
this	O
way	O
,	O
the	O
large	O
errors	O
appearing	O
in	O
the	O
regions	O
with	O
ψ	O
=	O
−60	O
to	O
−140	O
°	O
(	O
Fig.	O
5	O
)	O
,	O
where	O
the	O
inelastic	O
deformations	O
appearing	O
in	O
the	O
long	O
way	O
that	O
leads	O
to	O
them	O
,	O
generating	O
high	O
energy	O
values	O
,	O
are	O
avoided	O
.	O

Actually	O
,	O
the	O
'	O
true	O
'	O
adiabatic	O
map	O
was	O
obtained	O
in	O
the	O
present	O
work	O
by	O
a	O
non	O
-	O
systematic	O
,	O
iterative	O
procedure	O
that	O
has	O
encountered	O
a	O
better	O
approach	O
to	O
the	O
true	O
surface	O
.	O

As	O
it	O
has	O
been	O
pointed	O
out	O
,	O
without	O
a	O
full	O
conformational	O
search	O
of	O
the	O
59,049	O
starting	O
conformers	O
,	O
no	O
true	O
adiabatic	O
map	O
can	O
be	O
produced	O
[	O
3,10,14,15	O
]	O
.	O

However	O
,	O
it	O
is	O
possible	O
to	O
reach	O
near	O
adiabaticity	O
,	O
by	O
a	O
combination	O
of	O
the	O
three	O
methods	O
shown	O
previously	O
.	O

Certainly	O
,	O
it	O
is	O
impossible	O
to	O
automate	O
the	O
iterative	O
method	O
,	O
which	O
means	O
consuming	O
considerable	O
CPU	O
time	O
,	O
as	O
well	O
as	O
making	O
a	O
sizeable	O
demand	O
on	O
the	O
efforts	O
of	O
an	O
experienced	O
researcher	O
.	O

However	O
,	O
reports	O
of	O
adiabatic	O
maps	O
with	O
high	O
dielectric	O
constants	O
and	O
starting	O
conformers	O
with	O
the	O
classical	O
clockwise	O
–	O
anticlockwise	O
orientation	O
of	O
the	O
secondary	B
hydroxyl	I
groups	I
should	O
be	O
treated	O
with	O
due	O
care	O
.	O

There	O
are	O
alternative	O
approaches	O
for	O
the	O
creation	O
of	O
a	O
potential	O
-	O
energy	O
surface	O
,	O
like	O
the	O
use	O
of	O
random	O
sampling	O
techniques	O
[	O
22	O
]	O
such	O
as	O
ramm	O
[	O
13,28	O
]	O
,	O
the	O
use	O
of	O
heuristic	O
procedures	O
like	O
cicada	O
[	O
40,41	O
]	O
or	O
applications	O
of	O
simulations	O
based	O
on	O
molecular	O
dynamics	O
[	O
22,29,30	O
]	O
,	O
Monte	O
Carlo	O
[	O
42	O
]	O
,	O
or	O
combinations	O
of	O
both	O
[	O
31,32	O
]	O
.	O

Even	O
when	O
the	O
construction	O
of	O
an	O
adiabatic	O
map	O
is	O
not	O
attempted	O
[	O
43	O
]	O
,	O
the	O
generation	O
of	O
the	O
local	O
minima	O
is	O
usually	O
required	O
.	O

The	O
results	O
shown	O
in	O
this	O
paper	O
indicate	O
that	O
the	O
determination	O
of	O
the	O
local	O
minima	O
from	O
the	O
combination	O
of	O
a	O
small	O
number	O
of	O
relaxed	O
maps	O
may	O
fail	O
,	O
and	O
it	O
indeed	O
does	O
,	O
at	O
high	O
dielectric	O
constants	O
.	O

Although	O
the	O
conformational	O
maps	O
obtained	O
by	O
each	O
method	O
are	O
roughly	O
similar	O
(	O
Figs.	O
2	O
and	O
4	O
)	O
,	O
the	O
fact	O
that	O
many	O
properties	O
of	O
carbohydrates	B
depend	O
strongly	O
on	O
small	O
differences	O
in	O
energy	O
leads	O
to	O
a	O
struggle	O
for	O
the	O
greatest	O
possible	O
accuracy	O
[	O
3	O
]	O
on	O
the	O
actual	O
adiabatic	O
character	O
of	O
the	O
generated	O
maps	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
a	O
grant	O
from	O
UBA	O
(	O
TX-014	O
)	O
.	O

Helpful	O
discussions	O
with	O
Drs	O
A.S.	O
Cerezo	O
,	O
R.	O
Erra	O
-	O
Balsells	O
and	O
M.S.	O
Maier	O
are	O
also	O
acknowledged	O
.	O

Activated	O
macrophages	O
can	O
generate	O
large	O
amounts	O
of	O
NO	B
from	O
L	B
-arginine	I
by	O
the	O
action	O
of	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
)	O
.	O

NO	B
is	O
an	O
important	O
intracellular	O
and	O
intercellular	O
regulatory	O
molecule	O
of	O
multiple	O
biological	O
functions	O
,	O
including	O
macrophage	O
-	O
mediated	O
cytotoxicity	O
,	O
neurotransmission	O
,	O
and	O
smooth	O
muscle	O
relaxation	O
[	O
1,2	O
]	O
.	O

Overproduction	O
of	O
NO	B
has	O
been	O
associated	O
with	O
oxidative	O
stress	O
[	O
3,4	O
]	O
and	O
with	O
the	O
pathophysiology	O
of	O
various	O
diseases	O
such	O
as	O
arthritis	O
,	O
diabetes	O
,	O
stroke	O
,	O
septic	O
shock	O
,	O
autoimmune	O
disease	O
,	O
and	O
chronic	O
inflammation	O
[	O
5,6	O
]	O
.	O

Cytokines	O
such	O
as	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
,	O
interleukin	O
(	O
IL	O
)	O
-2	O
,	O
and	O
other	O
inflammatory	O
stimuli	O
such	O
as	O
bacterial	O
lipopolysaccharide	B
(	O
LPS	B
)	O
regulate	O
the	O
activity	O
of	O
iNOS	O
in	O
macrophages	O
[	O
7,8	O
]	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
the	O
production	O
of	O
tumor	O
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
is	O
crucial	O
for	O
the	O
synergistic	O
induction	O
of	O
NO	B
synthesis	O
in	O
IFN	O
-	O
γ	O
and/or	O
LPS	B
-	O
stimulated	O
macrophages	O
[	O
9,10	O
]	O
.	O

In	O
macrophages	O
,	O
nuclear	O
factor	O
κB	O
(	O
NF	O
-	O
κB	O
)	O
in	O
cooperation	O
with	O
other	O
transcription	O
factors	O
coordinates	O
the	O
expression	O
of	O
genes	O
encoding	O
both	O
iNOS	O
and	O
TNF	O
-	O
α	O
.	O

NF	O
-	O
κB	O
plays	O
a	O
critical	O
role	O
in	O
the	O
activation	O
of	O
immune	O
cells	O
by	O
upregulating	O
the	O
expression	O
of	O
many	O
cytokines	O
essential	O
to	O
the	O
immune	O
response	O
[	O
11	O
]	O
.	O

In	O
particular	O
,	O
NF	O
-	O
κB	O
stimulates	O
the	O
production	O
of	O
IL-1	O
,	O
IL-6	O
,	O
TNF	O
-	O
α	O
,	O
lymphotoxin	O
,	O
and	O
IFN	O
-	O
γ	O
.	O

Furthermore	O
,	O
some	O
of	O
these	O
cytokines	O
,	O
e.g.	O
IL-1	O
and	O
TNF	O
-	O
α	O
,	O
activate	O
NF	O
-	O
κB	O
themselves	O
,	O
thus	O
initiating	O
an	O
autoregulatory	O
feedback	O
loop	O
.	O

NF	O
-	O
κB	O
activation	O
by	O
various	O
stimuli	O
occurs	O
upon	O
its	O
dissociation	O
from	O
the	O
inhibitory	O
protein	O
IκB	O
and	O
its	O
subsequent	O
nuclear	O
translocation	O
.	O

Several	O
lines	O
of	O
evidence	O
,	O
including	O
the	O
inhibition	O
by	O
various	O
antioxidants	O
,	O
suggest	O
that	O
NF	O
-	O
κB	O
activation	O
is	O
subject	O
to	O
redox	O
regulation	O
[	O
12,13	O
]	O
.	O

Because	O
of	O
the	O
pivotal	O
role	O
of	O
NO	B
and	O
TNF	O
-	O
α	O
in	O
the	O
antimicrobial	O
and	O
tumoricidal	O
activities	O
of	O
macrophages	O
,	O
a	O
significant	O
effort	O
has	O
focused	O
on	O
developing	O
therapeutic	O
agents	O
that	O
regulate	O
NO	B
production	O
and	O
TNF	O
-	O
α	O
secretion	O
[	O
14	O
]	O
.	O

Epidemiological	O
reports	O
have	O
indicated	O
that	O
consumption	O
of	O
foods	O
rich	O
in	O
flavonoids	B
is	O
associated	O
with	O
a	O
lower	O
incidence	O
of	O
degenerative	O
diseases	O
.	O

Consistently	O
,	O
experimental	O
data	O
are	O
accumulating	O
regarding	O
phenolic	B
compounds	I
as	O
natural	O
phytochemical	O
antioxidants	O
that	O
possess	O
antiinflammatory	O
,	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
anticarcinogenic	O
properties	O
[	O
15,16	O
]	O
.	O

There	O
is	O
increasing	O
interest	O
in	O
the	O
biological	O
activities	O
of	O
plant	O
extracts	O
such	O
as	O
that	O
obtained	O
from	O
the	O
bark	O
of	O
the	O
French	O
maritime	O
pine	O
,	O
Pinus	O
maritima	O
.	O

Pine	B
bark	I
extract	I
(	O
Pycnogenol	B
,	O
PYC	B
)	O
is	O
a	O
unique	O
mixture	O
of	O
phenols	B
and	O
polyphenols	B
,	O
broadly	O
divided	O
into	O
monomers	B
(	O
e.g.	O
catechin	B
,	O
epicatechin	B
and	O
taxifolin	B
)	O
,	O
dimers	B
(	O
e.g.	O
procyanidin	B
B1	B
,	O
B2	B
,	O
B3	B
,	O
and	O
B7	B
)	O
,	O
trimers	B
(	O
e.g.	O
procyanidin	B
C1	B
,	O
C2	B
)	O
,	O
and	O
oligomers	B
up	O
to	O
5–7	O
units	O
.	O

PYC	B
also	O
contains	O
phenolic	B
acids	I
such	O
as	O
caffeic	B
,	O
ferulic	B
and	O
p	B
-hydroxybenzoic	I
acid	I
as	O
minor	O
constituents	O
[	O
17	O
]	O
.	O

Bioflavonoids	B
participate	O
in	O
an	O
antioxidant	O
network	O
[	O
18	O
]	O
and	O
likely	O
spare	O
endogenous	O
cellular	O
vitamin	B
E	I
[	O
19	O
]	O
and	O
glutathione	B
[	O
20	O
]	O
.	O

PYC	B
also	O
modulates	O
NO	B
metabolism	O
in	O
stimulated	O
macrophages	O
by	O
affecting	O
both	O
iNOS	O
mRNA	O
expression	O
and	O
iNOS	O
activity	O
[	O
21	O
]	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
which	O
particular	O
constituents	O
of	O
PYC	B
mediate	O
its	O
immunomodulatory	O
properties	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
purified	O
monomeric	B
,	O
dimeric	B
,	O
and	O
trimeric	B
flavonoids	I
in	O
comparison	O
to	O
PYC	B
can	O
modulate	O
NF	O
-	O
κB	O
activation	O
as	O
well	O
as	O
NO	B
production	O
and	O
TNF	O
-	O
α	O
secretion	O
in	O
RAW	O
264.7	O
macrophages	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Murine	O
recombinant	O
IFN	O
-	O
γ	O
(	O
1	O
×	O
106	O
U	O
/	O
mg	O
)	O
,	O
murine	O
recombinant	O
TNF	O
-	O
α	O
(	O
1	O
×	O
106	O
U	O
/	O
ml	O
)	O
,	O
rabbit	O
anti	O
-	O
murine	O
TNF	O
-	O
α	O
polyclonal	O
antibody	O
(	O
Ab	O
)	O
,	O
and	O
hamster	O
anti	O
-	O
murine	O
TNF	O
-	O
α	O
monoclonal	O
Ab	O
were	O
from	O
Genzyme	O
(	O
Munich	O
,	O
Germany	O
)	O
.	O

LPS	B
(	O
phenol	B
-	O
extracted	O
Salmonella	O
enteritidis	O
)	O
,	O
catechin	B
,	O
epicatechin	B
,	O
and	O
taxifolin	B
were	O
from	O
Sigma	O
Chemical	O
Co.	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

Fetal	O
calf	O
serum	O
and	O
antibiotics	O
were	O
from	O
the	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
Cell	O
Culture	O
Facility	O
.	O

RPMI	B
containing	O
L	B
-arginine	I
(	O
200	O
mg	O
/	O
l	O
)	O
,	O
Hanks	B
'	I
balanced	I
salt	I
solution	I
,	O
and	O
other	O
tissue	O
culture	O
reagents	O
were	O
purchased	O
from	O
Life	O
Technologies	O
(	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
.	O

Pycnogenol	B
was	O
a	O
gift	O
from	O
Horphag	O
Research	O
Ltd.	O
(	O
Guernsey	O
,	O
UK	O
)	O
.	O

Procyanidins	B
B1	B
,	O
B2	B
(	O
both	O
from	O
apples	O
,	O
98	O
%	O
purity	O
)	O
,	O
and	O
C2	B
(	O
from	O
barley	O
,	O
93	O
%	O
purity	O
)	O
were	O
a	O
gift	O
from	O
Tsukuba	O
Research	O
Laboratories	O
(	O
Kyowa	O
Hakko	O
Kogyo	O
,	O
Japan	O
)	O
.	O

2.2	O
Macrophage	O
culture	O
The	O
murine	O
monocyte	O
/	O
macrophage	O
cell	O
line	O
RAW	O
264.7	O
was	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

Cells	O
were	O
cultured	O
in	O
75-cm2	O
plastic	O
flasks	O
(	O
Falcon	O
-	O
Becton	O
Dickinson	O
Labwares	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
,	O
USA	O
)	O
and	O
maintained	O
in	O
RPMI	B
1640	I
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
fetal	O
calf	O
serum	O
and	O
antibiotics	O
(	O
100	O
U	O
/	O
ml	O
of	O
penicillin	B
,	O
100	O
μg	O
/	O
ml	O
of	O
streptomycin	B
)	O
.	O

For	O
experiments	O
,	O
macrophages	O
were	O
detached	O
by	O
vigorous	O
pipetting	O
and	O
,	O
after	O
centrifugation	O
,	O
incubated	O
with	O
fresh	O
medium	O
in	O
either	O
96-well	O
tissue	O
culture	O
plates	O
(	O
2	O
×	O
105	O
cells	O
/	O
well	O
)	O
or	O
24-well	O
tissue	O
culture	O
plates	O
(	O
5	O
×	O
105	O
cells	O
/	O
well	O
)	O
at	O
37	O
°	O
C	O
in	O
an	O
atmosphere	O
of	O
5	O
%	O
CO2	B
plus	O
air	O
.	O

Cells	O
were	O
supplemented	O
with	O
the	O
test	O
compounds	O
for	O
1	O
h	O
followed	O
by	O
their	O
stimulation	O
with	O
10	O
U	O
/	O
ml	O
IFN	O
-	O
γ	O
and	O
further	O
incubated	O
for	O
various	O
periods	O
as	O
described	O
in	O
Section	O
3	O
.	O

2.3	O
Neutral	B
red	I
assay	O
Uptake	O
of	O
the	O
dye	O
neutral	B
red	I
was	O
used	O
as	O
a	O
measure	O
of	O
cell	O
viability	O
[	O
22	O
]	O
.	O

Cells	O
were	O
plated	O
in	O
24-well	O
plates	O
,	O
and	O
samples	O
were	O
treated	O
for	O
24	O
h	O
in	O
500	O
μl	O
of	O
medium	O
.	O

Thereafter	O
,	O
the	O
medium	O
was	O
removed	O
and	O
replaced	O
with	O
500	O
μl	O
of	O
medium	O
containing	O
60	O
μg	O
/	O
ml	O
of	O
neutral	B
red	I
(	O
Fisher	O
Scientific	O
,	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
for	O
3	O
h	O
at	O
37	O
°	O
C	O
.	O

Following	O
incubation	O
with	O
the	O
neutral	B
red	I
dye	O
,	O
the	O
medium	O
was	O
removed	O
,	O
and	O
the	O
cells	O
were	O
extracted	O
with	O
500	O
μl	O
of	O
50	O
%	O
ethanol	B
,	O
49	O
%	O
H2	B
O	I
,	O
1	O
%	O
glacial	B
acetic	I
acid	I
,	O
pH	O
4.2	O
.	O

Quadruplicate	O
100-μl	O
samples	O
from	O
each	O
well	O
were	O
transferred	O
to	O
a	O
96-well	O
plate	O
,	O
and	O
the	O
absorbance	O
at	O
510	O
nm	O
was	O
measured	O
with	O
a	O
microplate	O
reader	O
(	O
CS-931	O
,	O
Shimadzu	O
Corporation	O
,	O
Columbia	O
,	O
MD	O
,	O
USA	O
)	O
.	O

2.4	O
Assay	O
of	O
TNF	O
-	O
α	O
secretion	O
TNF	O
-	O
α	O
secretion	O
was	O
measured	O
by	O
modification	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
as	O
described	O
earlier	O
[	O
23	O
]	O
.	O

For	O
the	O
ELISA	O
,	O
96-well	O
plates	O
were	O
coated	O
with	O
6.25	O
ng	O
/	O
well	O
of	O
murine	O
monoclonal	O
Ab	O
with	O
specificity	O
for	O
murine	O
TNF	O
-	O
α	O
.	O

Before	O
use	O
and	O
between	O
subsequent	O
steps	O
in	O
the	O
assay	O
,	O
coated	O
plates	O
were	O
washed	O
twice	O
with	O
phosphate	B
-	I
buufered	I
saline	I
(	O
PBS	B
)	O
containing	O
0.05	O
%	O
(	O
v	O
/	O
v	O
)	O
Tween-20	B
and	O
twice	O
with	O
PBS	B
alone	O
.	O

For	O
the	O
standard	O
curve	O
,	O
rTNF	O
-	O
α	O
was	O
added	O
to	O
serum	O
previously	O
determined	O
to	O
be	O
negative	O
for	O
endogenous	O
TNF	O
-	O
α	O
.	O

After	O
exposure	O
to	O
medium	O
,	O
assay	O
plates	O
were	O
sequentially	O
exposed	O
to	O
rabbit	O
anti	O
-	O
TNF	O
-	O
α	O
,	O
phosphatase	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
,	O
and	O
p	B
-nitrophenyl	I
phosphate	I
.	O

Optical	O
density	O
readings	O
at	O
410	O
nm	O
were	O
taken	O
using	O
a	O
microplate	O
reader	O
.	O

2.5	O
Measurement	O
of	O
nitrite	B
and	O
nitrate	B
concentration	O
NO	B
secretion	O
in	O
cultured	O
macrophages	O
was	O
measured	O
by	O
a	O
microplate	O
assay	O
method	O
,	O
as	O
described	O
earlier	O
[	O
24,25	O
]	O
.	O

To	O
measure	O
nitrite	B
(	O
NO2	B
−	I
)	O
,	O
100	O
μl	O
of	O
macrophage	O
culture	O
supernatant	O
was	O
collected	O
,	O
mixed	O
with	O
an	O
equal	O
volume	O
of	O
Griess	B
reagent	I
(	O
1	O
%	O
sulfanilamide	B
/	O
0.1	O
%	O
N	B
-	I
(	I
1-naphthyl	I
)	I
-ethylenediamine	I
dihydrochloride	I
/	O
2.5	O
%	O
H3	B
PO4	I
)	O
and	O
incubated	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

Nitrite	B
concentration	O
was	O
determined	O
by	O
measuring	O
the	O
absorbance	O
at	O
540	O
nm	O
.	O

NaNO2	B
was	O
used	O
for	O
external	O
calibration	O
.	O

Cell	O
-	O
free	O
medium	O
alone	O
contained	O
5–8	O
μM	O
of	O
nitrite	B
;	O
this	O
value	O
was	O
determined	O
in	O
each	O
experiment	O
and	O
subtracted	O
from	O
the	O
value	O
obtained	O
for	O
each	O
cell	O
sample	O
.	O

Nitrate	B
(	O
NO3	B
−	I
)	O
was	O
measured	O
by	O
reducing	O
nitrate	B
to	O
nitrite	B
with	O
bacterial	O
nitrate	O
reductase	O
,	O
then	O
measuring	O
nitrite	B
by	O
using	O
Griess	B
reagent	I
.	O

There	O
was	O
no	O
interference	O
of	O
the	O
test	O
compounds	O
either	O
with	O
the	O
ELISA	O
or	O
with	O
Griess	B
reagent	I
.	O

2.6	O
Cell	O
transfection	O
and	O
reporter	O
gene	O
assay	O
RAW	O
264.7	O
macrophages	O
were	O
plated	O
at	O
2	O
×	O
105	O
cells	O
per	O
cm2	O
in	O
12-well	O
plates	O
,	O
and	O
24	O
h	O
later	O
transiently	O
co	O
-	O
transfected	O
with	O
the	O
plasmids	O
pGL3	O
-	O
4κB	O
-	O
Luc	O
and	O
pRL	O
-	O
TK	O
(	O
reference	O
plasmid	O
containing	O
a	O
Renilla	O
luciferase	O
gene	O
driven	O
by	O
a	O
minimal	O
thymidine	O
kinase	O
promoter	O
,	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
using	O
Fugene	B
6	I
reagent	O
(	O
Roche	O
Molecular	O
Biochemicals	O
,	O
Indianapolis	O
,	O
IN	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Briefly	O
,	O
the	O
transfection	O
mixture	O
containing	O
0.35	O
μg	O
of	O
pGL3	O
-	O
4κB	O
-	O
Luc	O
and	O
0.15	O
μg	O
of	O
pRL	O
-	O
TK	O
was	O
mixed	O
with	O
the	O
Fugene	B
6	I
reagent	O
and	O
added	O
to	O
the	O
cells	O
.	O

Treatments	O
with	O
test	O
compounds	O
and	O
IFN	O
-	O
γ	O
were	O
started	O
18	O
h	O
after	O
transfection	O
.	O

Cell	O
lysis	O
was	O
performed	O
12	O
h	O
after	O
treatments	O
and	O
luciferase	O
activities	O
were	O
measured	O
using	O
the	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
system	O
(	O
Promega	O
)	O
with	O
an	O
LKB	O
/	O
Wallac	O
luminometer	O
1250	O
(	O
Wallac	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
.	O

The	O
dual	O
-	O
luciferase	O
system	O
is	O
based	O
on	O
the	O
subsequent	O
measurement	O
of	O
firefly	O
(	O
from	O
pGL3	O
-	O
4κB	O
-	O
Luc	O
)	O
and	O
Renilla	O
(	O
from	O
pRL	O
-	O
TK	O
)	O
luciferase	O
activities	O
in	O
the	O
same	O
tube	O
with	O
the	O
same	O
extract	O
.	O

The	O
firefly	O
luciferase	O
activity	O
was	O
normalized	O
in	O
that	O
system	O
with	O
the	O
Renilla	O
luciferase	O
activity	O
to	O
correct	O
for	O
differences	O
in	O
the	O
transfection	O
efficiency	O
[	O
26	O
]	O
.	O

2.7	O
Lipid	B
A	I
analysis	O
PYC	B
was	O
tested	O
for	O
the	O
presence	O
of	O
lipid	B
A.	I
Samples	O
and	O
reference	O
standard	O
(	O
deep	O
rough	O
chemotype	O
LPS	B
from	O
Escherichia	O
coli	O
D31m4	O
)	O
were	O
treated	O
with	O
EDTA	B
,	O
and	O
purified	O
by	O
a	O
DEAE	B
-	O
cellulose	B
column	O
chromatography	O
as	O
previously	O
described	O
[	O
27	O
]	O
.	O

Samples	O
were	O
hydrolyzed	O
in	O
2	O
ml	O
of	O
0.1	O
M	O
HCl	B
at	O
100	O
°	O
C	O
for	O
30	O
min	O
to	O
yield	O
monophosphoryl	B
lipid	I
A.	I
Then	O
5	O
ml	O
of	O
chloroform	B
/	O
methanol	B
(	O
2:1	O
,	O
v	O
/	O
v	O
)	O
was	O
added	O
,	O
mixed	O
and	O
centrifuged	O
.	O

The	O
lower	O
organic	O
layer	O
was	O
recovered	O
,	O
filtered	O
and	O
dried	O
.	O

The	O
extracted	O
samples	O
were	O
applied	O
in	O
chloroform	B
/	O
methanol	B
(	O
4:1	O
,	O
v	O
/	O
v	O
)	O
to	O
silica	B
gel	I
GHL	O
plate	O
(	O
250	O
μm	O
)	O
and	O
irrigated	O
with	O
chloroform	B
/	O
methanol	B
/	O
water	B
/	O
concentrated	O
ammonium	B
hydroxide	I
(	O
50:25:4:2	O
,	O
v	O
/	O
v	O
)	O
.	O

Spots	O
were	O
visualized	O
by	O
spraying	O
the	O
plate	O
with	O
dichromate	B
/	O
sulfuric	B
acid	I
reagent	O
and	O
charring	O
.	O

2.8	O
Statistics	O
or	O
reproducibility	O
Data	O
in	O
figures	O
are	O
the	O
mean±S.D.	O
of	O
at	O
least	O
three	O
different	O
experiments	O
performed	O
in	O
triplicate	O
.	O

3	O
Results	O
3.1	O
TNF	O
-	O
α	O
secretion	O
by	O
macrophages	O
is	O
modified	O
by	O
flavonoids	B
in	O
a	O
structure	O
-	O
dependent	O
manner	O
As	O
a	O
first	O
step	O
,	O
the	O
cytotoxic	O
activity	O
of	O
the	O
monomeric	B
,	O
dimeric	B
and	O
trimeric	B
flavonoids	I
as	O
well	O
as	O
PYC	B
in	O
the	O
absence	O
and	O
presence	O
of	O
IFN	O
-	O
γ	O
was	O
assessed	O
using	O
the	O
neutral	O
red	O
assay	O
.	O

Pretreatment	O
of	O
both	O
unstimulated	O
and	O
stimulated	O
RAW	O
264.7	O
macrophages	O
up	O
to	O
100	O
μg	O
/	O
ml	O
catechin	B
,	O
epicatechin	B
as	O
well	O
as	O
PCA	B
B1	I
,	O
PCA	B
B2	I
and	O
PCA	B
C2	I
did	O
not	O
significantly	O
affect	O
the	O
cell	O
viability	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
in	O
macrophages	O
treated	O
with	O
100	O
μg	O
/	O
ml	O
taxifolin	B
for	O
24	O
h	O
a	O
slight	O
although	O
significant	O
cytotoxic	O
effect	O
could	O
be	O
observed	O
.	O

In	O
unstimulated	O
macrophages	O
only	O
small	O
amounts	O
of	O
TNF	O
-	O
α	O
were	O
secreted	O
into	O
the	O
medium	O
(	O
Fig.	O
1A	O
)	O
.	O

Pretreatment	O
of	O
unstimulated	O
cells	O
with	O
monomeric	B
or	O
dimeric	B
flavonoids	I
over	O
24	O
h	O
did	O
not	O
result	O
in	O
any	O
change	O
in	O
the	O
secretion	O
of	O
TNF	O
-	O
α	O
into	O
the	O
medium	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
PCA	B
C2	I
or	O
PYC	B
the	O
secreted	O
levels	O
of	O
TNF	O
-	O
α	O
significantly	O
increased	O
.	O

The	O
stimulation	O
of	O
RAW	O
264.7	O
cells	O
with	O
IFN	O
-	O
γ	O
resulted	O
in	O
a	O
manifold	O
increase	O
in	O
TNF	O
-	O
α	O
secretion	O
monitored	O
24	O
h	O
after	O
administration	O
(	O
Fig.	O
1B	O
)	O
.	O

All	O
monomeric	B
flavonoids	I
tested	O
(	O
catechin	B
,	O
epicatechin	B
,	O
and	O
taxifolin	B
)	O
decreased	O
the	O
secretion	O
of	O
TNF	O
-	O
α	O
almost	O
down	O
to	O
the	O
baseline	O
levels	O
as	O
measured	O
in	O
the	O
unstimulated	O
control	O
cells	O
.	O

While	O
the	O
dimeric	B
flavonoids	I
PCA	B
B1	I
and	O
PCA	B
B2	I
slightly	O
inhibited	O
IFN	O
-	O
γ	O
-	O
induced	O
TNF	O
-	O
α	O
secretion	O
,	O
the	O
trimeric	B
flavonoid	I
PCA	B
C2	I
induced	O
about	O
a	O
two	O
-	O
fold	O
increase	O
in	O
the	O
secretion	O
of	O
TNF	O
-	O
α	O
in	O
IFN	O
-	O
γ	O
-	O
stimulated	O
macrophages	O
.	O

Similar	O
to	O
PCA	B
C2	I
,	O
PYC	B
potentiated	O
the	O
effect	O
of	O
IFN	O
-	O
γ	O
on	O
TNF	O
-	O
α	O
secretion	O
.	O

The	O
secretion	O
of	O
TNF	O
-	O
α	O
due	O
to	O
PCA	B
C2	I
and	O
PYC	B
increased	O
both	O
in	O
a	O
dose-	O
and	O
time	O
-	O
dependent	O
fashion	O
as	O
shown	O
in	O
Fig.	O
2A	O
,	O
B	O
,	O
respectively	O
.	O

3.2	O
Effect	O
of	O
monomeric	B
,	O
dimeric	B
,	O
and	O
trimeric	B
flavonoids	I
on	O
NO	B
production	O
in	O
IFN	O
-	O
γ	O
-	O
stimulated	O
macrophages	O
In	O
parallel	O
with	O
the	O
characterization	O
of	O
TNF	O
-	O
α	O
secretion	O
the	O
effect	O
of	O
the	O
different	O
flavonoids	B
on	O
NO	B
release	O
into	O
the	O
medium	O
measured	O
by	O
the	O
Griess	O
reaction	O
was	O
studied	O
.	O

Unstimulated	O
control	O
cells	O
produced	O
a	O
negligible	O
amount	O
of	O
NO	B
(	O
<	O
5	O
μM	O
)	O
.	O

However	O
,	O
in	O
IFN	O
-	O
γ	O
-	O
stimulated	O
cells	O
a	O
substantial	O
increase	O
in	O
the	O
production	O
of	O
NO	B
was	O
evident	O
(	O
Fig.	O
3	O
)	O
.	O

Pretreatment	O
of	O
macrophages	O
with	O
catechin	B
,	O
epicatechin	B
,	O
and	O
taxifolin	B
significantly	O
decreased	O
IFN	O
-	O
γ	O
-	O
induced	O
NO	B
production	O
by	O
40	O
,	O
60	O
,	O
and	O
75	O
%	O
,	O
respectively	O
,	O
as	O
compared	O
to	O
IFN	O
-	O
γ	O
-	O
treated	O
cells	O
.	O

The	O
dimeric	B
flavonoids	I
PCA	B
B1	I
and	O
PCA	B
B2	I
showed	O
a	O
moderate	O
inhibitory	O
effect	O
on	O
NO	B
production	O
.	O

In	O
contrast	O
to	O
the	O
monomeric	B
and	O
dimeric	B
procyanidins	I
pretreatment	O
of	O
IFN	O
-	O
γ	O
-	O
stimulated	O
macrophages	O
with	O
the	O
PCA	B
C2	I
as	O
well	O
as	O
PYC	B
significantly	O
increased	O
IFN	O
-	O
γ	O
-	O
induced	O
NO	B
production	O
.	O

3.3	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
in	O
IFN	O
-	O
γ	O
-	O
stimulated	O
macrophages	O
is	O
modulated	O
by	O
flavonoids	B
Induction	O
of	O
TNF	O
-	O
α	O
and	O
iNOS	O
is	O
modulated	O
,	O
in	O
part	O
through	O
the	O
activation	O
of	O
NF	O
-	O
κB.	O
Consequently	O
the	O
effect	O
of	O
different	O
flavonoids	B
on	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
using	O
the	O
dual	O
-	O
luciferase	O
reporter	O
gene	O
assay	O
was	O
studied	O
.	O

Nearly	O
a	O
two	O
-	O
fold	O
increase	O
in	O
luciferase	O
activity	O
was	O
observed	O
when	O
RAW	O
264.7	O
macrophages	O
were	O
stimulated	O
with	O
IFN	O
-	O
γ	O
as	O
compared	O
to	O
unstimulated	O
control	O
cells	O
(	O
Fig.	O
4A	O
)	O
.	O

Similar	O
to	O
the	O
data	O
for	O
TNF	O
-	O
α	O
secretion	O
and	O
NO	B
production	O
the	O
monomeric	B
flavonoids	I
catechin	B
,	O
epicatechin	B
and	O
taxifolin	B
completely	O
counteracted	O
IFN	O
-	O
γ	O
-	O
induced	O
NF	O
-	O
κB	O
transactivation	O
.	O

Pretreatment	O
of	O
macrophages	O
with	O
PCA	B
B1	I
and	O
PCA	B
B2	I
resulted	O
in	O
a	O
slight	O
decrease	O
in	O
the	O
luciferase	O
activity	O
.	O

However	O
,	O
different	O
to	O
the	O
monomers	B
and	O
dimers	B
,	O
PCA	B
C2	I
and	O
PYC	B
significantly	O
increased	O
luciferase	O
activity	O
in	O
IFN	O
-	O
γ	O
-	O
stimulated	O
cells	O
.	O

In	O
addition	O
both	O
PCA	B
C2-	I
and	O
PYC	B
-	O
induced	O
NF	O
-	O
κB	O
activation	O
was	O
totally	O
inhibited	O
by	O
the	O
use	O
of	O
a	O
anti	O
-	O
murine	O
TNF	O
-	O
α	O
-	O
neutralizing	O
Ab	O
,	O
indicating	O
that	O
PCA	B
C2	I
or	O
PYC	B
-	O
induced	O
TNF	O
-	O
α	O
secretion	O
is	O
crucial	O
for	O
NF	O
-	O
κB	O
activation	O
in	O
macrophages	O
(	O
Fig.	O
4B	O
)	O
.	O

4	O
Discussion	O
4.1	O
TNF	O
-	O
α	O
secretion	O
TNF	O
-	O
α	O
was	O
produced	O
in	O
vanishingly	O
small	O
quantities	O
in	O
unstimulated	O
cells	O
as	O
reported	O
previously	O
[	O
28	O
]	O
.	O

However	O
,	O
when	O
macrophages	O
were	O
stimulated	O
with	O
IFN	O
-	O
γ	O
,	O
a	O
manifold	O
increase	O
in	O
the	O
secretion	O
of	O
TNF	O
-	O
α	O
into	O
the	O
medium	O
was	O
observed	O
.	O

Interestingly	O
,	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
IFN	O
-	O
γ	O
,	O
pretreatment	O
of	O
macrophages	O
with	O
the	O
trimer	B
PCA	B
C2	I
as	O
well	O
as	O
PYC	B
substantially	O
elevated	O
TNF	O
-	O
α	O
release	O
from	O
undetectable	O
levels	O
up	O
to	O
2–4	O
ng	O
/	O
ml	O
.	O

Similar	O
to	O
PCA	B
C2	I
and	O
PYC	B
the	O
flavonoid	B
drug	O
flavone-8-acetic	B
acid	I
(	O
FAA	B
)	O
,	O
which	O
augments	O
mouse	O
natural	O
killer	O
activity	O
,	O
has	O
been	O
shown	O
to	O
induce	O
TNF	O
-	O
α	O
secretion	O
in	O
J774	O
cells	O
and	O
thereby	O
synergized	O
with	O
recombinant	O
IL-2	O
for	O
the	O
treatment	O
of	O
murine	O
renal	O
cancer	O
[	O
29	O
]	O
.	O

Moreover	O
,	O
the	O
red	O
wine	O
polyphenol	B
resveratrol	B
has	O
been	O
reported	O
to	O
have	O
a	O
potent	O
effect	O
to	O
increase	O
basal	O
TNF	O
-	O
α	O
mRNA	O
expression	O
with	O
a	O
concomitant	O
increase	O
in	O
TNF	O
-	O
α	O
secretion	O
in	O
RAW	O
264.7	O
macrophages	O
[	O
30	O
]	O
.	O

In	O
this	O
regard	O
it	O
is	O
hypothesized	O
that	O
TNF	O
-	O
α	O
induction	O
appears	O
to	O
be	O
one	O
critical	O
factor	O
in	O
the	O
antitumor	O
effects	O
of	O
this	O
class	O
of	O
compounds	O
.	O

However	O
,	O
in	O
contrast	O
to	O
PCA	B
C2	I
and	O
PYC	B
the	O
monomeric	B
flavonoids	I
(	O
catechin	B
,	O
epicatechin	B
,	O
and	O
taxifolin	B
)	O
tested	O
in	O
the	O
present	O
study	O
had	O
a	O
strong	O
and	O
the	O
dimeric	B
flavonoids	I
PCA	B
B1	I
and	O
PCA	B
B2	I
a	O
slight	O
inhibitory	O
effect	O
on	O
the	O
secretion	O
of	O
TNF	O
-	O
α	O
into	O
the	O
medium	O
.	O

Consistent	O
with	O
these	O
findings	O
green	O
tea	O
polyphenols	B
also	O
significantly	O
decreased	O
TNF	O
-	O
α	O
and	O
NO	B
synthesis	O
in	O
elicited	O
murine	O
peritoneal	O
macrophages	O
as	O
well	O
as	O
in	O
the	O
BALB	O
/	O
c	O
mouse	O
model	O
[	O
31	O
]	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
different	O
flavonoids	B
result	O
in	O
a	O
different	O
outcome	O
in	O
terms	O
of	O
TNF	O
-	O
α	O
secretion	O
and	O
NO	B
production	O
have	O
not	O
been	O
clarified	O
yet	O
.	O

4.2	O
NO	B
production	O
The	O
monomeric	B
flavonoids	I
catechin	B
,	O
epicatechin	B
,	O
and	O
taxifolin	B
significantly	O
inhibited	O
NO	B
production	O
in	O
IFN	O
-	O
γ	O
-	O
stimulated	O
cells	O
.	O

The	O
cellular	O
mechanisms	O
by	O
which	O
flavonoids	B
down	O
-	O
regulate	O
NO	B
production	O
are	O
not	O
completely	O
understood	O
.	O

It	O
is	O
suggested	O
that	O
this	O
effect	O
might	O
be	O
partially	O
mediated	O
due	O
to	O
the	O
combination	O
of	O
several	O
different	O
biological	O
activities	O
,	O
i.e.	O
NO	B
scavenging	O
activity	O
,	O
inhibition	O
of	O
iNOS	O
enzyme	O
activity	O
,	O
and	O
inhibition	O
of	O
iNOS	O
mRNA	O
expression	O
[	O
32	O
]	O
.	O

It	O
should	O
also	O
be	O
taken	O
into	O
consideration	O
that	O
macrophages	O
are	O
often	O
stimulated	O
with	O
LPS	B
in	O
order	O
to	O
ensure	O
a	O
high	O
production	O
of	O
NO	B
.	O

However	O
,	O
stimulation	O
of	O
macrophages	O
with	O
LPS	O
in	O
the	O
presence	O
of	O
flavonoids	B
seems	O
to	O
be	O
problematic	O
since	O
flavonoid	B
-	O
rich	O
extracts	O
have	O
been	O
recently	O
found	O
to	O
suppress	O
the	O
activity	O
of	O
LPS	B
and	O
lipid	B
A	I
preparations	O
regardless	O
of	O
the	O
origin	O
of	O
the	O
bacteria	O
in	O
the	O
Limulus	O
test	O
[	O
33	O
]	O
widely	O
used	O
for	O
diagnosis	O
of	O
Gram	O
-	O
negative	O
bacterial	O
endotoxins	O
.	O

It	O
is	O
suggested	O
that	O
an	O
inhibition	O
in	O
the	O
production	O
of	O
NO	B
is	O
not	O
exclusively	O
mediated	O
due	O
to	O
cellular	O
effects	O
of	O
the	O
flavonoids	B
per	O
se	O
but	O
might	O
also	O
be	O
partially	O
caused	O
by	O
a	O
direct	O
interaction	O
of	O
these	O
compound	O
with	O
the	O
LPS	B
molecule	O
.	O

Therefore	O
in	O
the	O
present	O
investigation	O
macrophages	O
were	O
stimulated	O
with	O
IFN	O
-	O
γ	O
only	O
.	O

In	O
contrast	O
to	O
the	O
monomeric	B
and	O
dimeric	B
flavonoids	I
,	O
PCA	B
C2	I
and	O
PYC	B
significantly	O
increased	O
the	O
production	O
of	O
NO	B
in	O
IFN	O
-	O
γ	O
-	O
stimulated	O
macrophages	O
.	O

Under	O
the	O
conditions	O
investigated	O
,	O
treatment	O
of	O
unstimulated	O
macrophages	O
with	O
PCA	B
C2	I
and	O
PYC	B
also	O
resulted	O
in	O
a	O
considerable	O
increase	O
in	O
TNF	O
-	O
α	O
secretion	O
into	O
the	O
medium	O
known	O
to	O
be	O
crucial	O
for	O
NO	B
synthesis	O
in	O
macrophages	O
.	O

Based	O
on	O
monophosphoryl	B
lipid	I
A	I
analysis	O
PYC	B
was	O
completely	O
devoid	O
of	O
lipid	B
A.	I
This	O
finding	O
suggests	O
that	O
PYC	B
contains	O
no	O
significant	O
amounts	O
of	O
Gram	O
-	O
negative	O
bacterial	O
-	O
type	O
LPS	B
to	O
contribute	O
to	O
its	O
biological	O
activities	O
in	O
terms	O
of	O
NO	B
production	O
,	O
TNF	O
-	O
α	O
secretion	O
and	O
NF	O
-	O
κB	O
activation	O
.	O

In	O
the	O
absence	O
of	O
IFN	O
-	O
γ	O
both	O
treatment	O
of	O
macrophages	O
with	O
PCA	B
C2	I
and	O
PYC	B
alone	O
resulted	O
in	O
a	O
considerable	O
activation	O
of	O
NF	O
-	O
κB	O
(	O
Fig.	O
4B	O
)	O
that	O
was	O
significantly	O
inhibited	O
by	O
the	O
use	O
of	O
anti	O
-	O
murine	O
TNF	O
-	O
α	O
Ab	O
.	O

These	O
data	O
indicate	O
that	O
PCA	B
C2-	I
and	O
PYC	B
-	O
induced	O
changes	O
in	O
TNF	O
-	O
α	O
secretion	O
are	O
at	O
least	O
partially	O
responsible	O
for	O
the	O
observed	O
difference	O
in	O
NF	O
-	O
κB	O
activation	O
which	O
again	O
can	O
affect	O
NO	B
synthesis	O
.	O

4.3	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
The	O
biosynthesis	O
of	O
TNF	O
-	O
α	O
is	O
tightly	O
controlled	O
by	O
different	O
molecular	O
events	O
regulating	O
the	O
TNF	O
-	O
α	O
gene	O
,	O
mRNA	O
and	O
protein	O
.	O

At	O
the	O
transcriptional	O
level	O
,	O
besides	O
a	O
TATA	O
box	O
promoter	O
located	O
20	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
a	O
number	O
of	O
regulatory	O
sequences	O
are	O
also	O
found	O
upstream	O
of	O
the	O
TNF	O
-	O
α	O
gene	O
,	O
including	O
three	O
NF	O
-	O
κB	O
sites	O
κ1	O
,	O
κ2	O
,	O
κ3	O
which	O
are	O
thought	O
to	O
be	O
implicated	O
in	O
the	O
mechanism	O
of	O
TNF	O
-	O
α	O
induction	O
.	O

Furthermore	O
,	O
two	O
upstream	O
DNA	O
regions	O
of	O
the	O
iNOS	O
promoter	O
,	O
the	O
RI	O
and	O
RII	O
domains	O
,	O
are	O
required	O
for	O
the	O
maximal	O
promoter	O
activation	O
by	O
LPS	B
,	O
and	O
the	O
RII	O
domain	O
mediates	O
promoter	O
trans	O
-activation	O
of	O
IFN	O
-	O
γ	O
.	O

Both	O
of	O
these	O
domains	O
comprise	O
multiple	O
sequences	O
homologous	O
to	O
those	O
of	O
cis	O
elements	O
involved	O
in	O
transcription	O
activation	O
,	O
such	O
as	O
NF	O
-	O
κB	O
binding	O
sites	O
,	O
IFN	O
-	O
γ	O
response	O
elements	O
,	O
and	O
IFN	O
-	O
γ	O
-	O
activated	O
factor	O
binding	O
[	O
34	O
]	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
study	O
the	O
effect	O
of	O
different	O
structure	O
-	O
related	O
flavonoids	B
in	O
terms	O
of	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
using	O
the	O
dual	O
-	O
luciferase	O
reporter	O
gene	O
assay	O
.	O

Consistent	O
with	O
data	O
for	O
both	O
TNF	O
-	O
α	O
and	O
NO	B
,	O
the	O
monomeric	B
flavonoids	I
decreased	O
whereas	O
PCA	B
C2	I
and	O
PYC	B
increased	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
indicating	O
that	O
differences	O
in	O
TNF	O
-	O
α	O
secretion	O
and	O
NO	B
production	O
might	O
be	O
partially	O
mediated	O
due	O
to	O
difference	O
in	O
the	O
activation	O
or	O
inhibition	O
of	O
NF	O
-	O
κB.	O
Although	O
no	O
common	O
second	O
messenger	O
has	O
been	O
identified	O
,	O
many	O
NF	O
-	O
κB	O
-	O
activating	O
signals	O
have	O
been	O
shown	O
to	O
be	O
inhibited	O
by	O
antioxidants	B
.	O

Plumb	O
et	O
al.	O
[	O
35	O
]	O
recently	O
studied	O
the	O
antioxidant	O
properties	O
of	O
catechin	B
,	O
epicatechin	B
as	O
well	O
as	O
structure	O
-	O
related	O
dimeric	B
and	O
trimeric	B
flavonoids	I
similar	O
to	O
those	O
used	O
in	O
the	O
present	O
study	O
.	O

Interestingly	O
,	O
the	O
antioxidant	O
activity	O
in	O
the	O
aqueous	B
phase	O
increased	O
from	O
monomeric	B
to	O
trimeric	B
flavonoids	I
.	O

However	O
,	O
in	O
the	O
present	O
study	O
the	O
trimeric	B
flavonoid	I
PCA	B
C2	I
as	O
well	O
as	O
PYC	B
induced	O
a	O
substantial	O
activation	O
of	O
NF	O
-	O
κB.	O
Hence	O
changes	O
in	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
due	O
to	O
flavonoids	B
do	O
not	O
necessarily	O
reflect	O
differences	O
in	O
the	O
antioxidant	O
properties	O
of	O
these	O
compounds	O
.	O

Virgili	O
et	O
al.	O
[	O
21	O
]	O
studied	O
the	O
effect	O
of	O
PYC	B
on	O
NF	O
-	O
κB	O
activation	O
and	O
NO	B
production	O
in	O
IFN	O
-	O
γ+LPS	O
-	O
stimulated	O
murine	O
macrophages	O
using	O
the	O
same	O
cell	O
line	O
.	O

In	O
IFN	O
-	O
γ+LPS	O
-	O
stimulated	O
RAW	O
264.7	O
cells	O
,	O
PYC	B
had	O
no	O
effect	O
on	O
NF	O
-	O
κB	O
activation	O
.	O

PYC	B
pretreatment	O
was	O
started	O
24	O
h	O
before	O
the	O
IFN	O
-	O
γ+LPS	O
administration	O
.	O

However	O
,	O
in	O
the	O
present	O
experiment	O
cells	O
were	O
pretreated	O
with	O
PYC	B
only	O
1	O
h	O
before	O
the	O
stimulation	O
with	O
IFN	O
-	O
γ	O
.	O

Possibly	O
,	O
both	O
the	O
duration	O
of	O
PYC	B
pretreatment	O
and	O
the	O
characteristic	O
of	O
the	O
activating	O
signal	O
(	O
IFN	O
-	O
γ+LPS	O
vs.	O
IFN	O
-	O
γ	O
)	O
are	O
important	O
in	O
terms	O
of	O
PYC	B
-	O
induced	O
changes	O
in	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
in	O
activated	O
murine	O
macrophages	O
.	O

4.4	O
Conclusion	O
Flavonoids	B
constitute	O
a	O
large	O
group	O
of	O
phenolic	B
phytochemicals	I
with	O
antioxidant	O
properties	O
in	O
vitro	O
.	O

Despite	O
an	O
increasing	O
number	O
of	O
publications	O
concerning	O
free	O
radical	O
-	O
scavenging	O
and	O
hydrogen	O
-	O
donating	O
activities	O
of	O
flavonoids	B
[	O
15	O
]	O
,	O
little	O
is	O
known	O
about	O
their	O
biological	O
activity	O
in	O
terms	O
of	O
cell	O
signaling	O
and	O
gene	O
expression	O
.	O

The	O
present	O
data	O
show	O
for	O
the	O
first	O
time	O
that	O
monomeric	B
,	O
dimeric	B
,	O
and	O
trimeric	B
flavonoids	I
as	O
well	O
as	O
PYC	B
display	O
a	O
selective	O
activity	O
in	O
terms	O
of	O
TNF	O
-	O
α	O
secretion	O
,	O
NO	B
production	O
and	O
NF	O
-	O
κB	O
-	O
dependent	O
gene	O
expression	O
in	O
RAW	O
264.7	O
macrophages	O
.	O

In	O
addition	O
,	O
the	O
present	O
findings	O
suggest	O
that	O
the	O
degree	O
of	O
polymerization	O
of	O
flavonoids	B
seems	O
to	O
be	O
important	O
in	O
determining	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
flavonoids	B
may	O
exert	O
their	O
immunomodulatory	O
and	O
antiinflammatory	O
activity	O
.	O

The	O
concentrations	O
of	O
flavonoids	B
used	O
in	O
the	O
present	O
study	O
are	O
higher	O
than	O
those	O
readily	O
available	O
in	O
food	O
sources	O
such	O
as	O
tea	O
[	O
31	O
]	O
or	O
chocolate	O
[	O
36	O
]	O
.	O

However	O
,	O
concentrated	O
forms	O
of	O
plant	O
extracts	O
are	O
now	O
being	O
made	O
available	O
thereby	O
opening	O
the	O
possibility	O
of	O
achieving	O
concentrations	O
equivalent	O
to	O
those	O
supplemented	O
in	O
the	O
present	O
investigation	O
.	O

Acknowledgements	O
G.R.	O
is	O
supported	O
by	O
a	O
grant	O
from	O
the	O
German	O
Research	O
Society	O
(	O
DFG	O
Forschungsstipendium	O
Ri	O
884	O
/	O
3	O
-	O
1	O
)	O
.	O

The	O
authors	O
are	O
grateful	O
to	O
Dr.	O
Kuni	O
Takayama	O
,	O
Mycobacteriology	O
Research	O
Laboratory	O
,	O
William	O
S.	O
Middleton	O
Memorial	O
Veterans	O
Hospital	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
for	O
providing	O
the	O
lipid	B
A	I
analysis	O
and	O
extend	O
their	O
gratitude	O
to	O
Dr.	O
Takashi	O
Okamoto	O
,	O
Department	O
of	O
Molecular	O
Genetics	O
,	O
Nagoya	O
City	O
University	O
,	O
Medical	O
School	O
,	O
Nagoya	O
,	O
Japan	O
for	O
providing	O
the	O
plasmid	O
pGL3	O
-	O
4κB	O
-	O
Luc	O
.	O

Little	O
efforts	O
have	O
been	O
made	O
in	O
the	O
past	O
to	O
identify	O
compounds	O
from	O
the	O
brown	O
-	O
rot	O
fungus	O
Daedalea	O
quercina	O
(	O
L.	O
)	O
Pers	O
.	O

[	O
syn	O
.	O

Trametes	O
quercina	O
(	O
L.	O
)	O
Pilát	O
]	O
,	O
which	O
grows	O
on	O
weak	O
or	O
dead	O
stumps	O
of	O
deciduous	O
trees	O
,	O
mainly	O
oak	O
trees	O
,	O
and	O
from	O
the	O
white	O
-	O
rot	O
species	O
Daedaleopsis	O
confragosa	O
var	O
.	O

tricolor	O
(	O
Bulliard	O
)	O
Bondarzew	O
[	O
syn	O
.	O

Lenzites	O
tricolor	O
(	O
Bulliard	O
)	O
]	O
,	O
which	O
grows	O
on	O
various	O
deciduous	O
trees	O
.	O

Only	O
ergosterol	B
,	O
ergosta-7	B
,	I
22-dien-3β	I
-	I
ol	I
,	O
ergosterol	B
peroxide	I
(	O
5α,8α	B
-	I
epidioxyergosta-6,22-dien-3β	I
-	I
ol	I
)	O
and	O
3α	B
-	I
carboxyacetoxyquercinic	I
acid	I
(	O
3α	B
-	I
carboxyacetoxy-24-methyl-23-oxolanost-8-en-26-oic	I
acid	I
)	O
have	O
been	O
isolated	O
from	O
fruiting	O
bodies	O
of	O
D.	O
quercina	O
(	O
Adam	O
et	O
al.	O
,	O
1967a	O
;	O
Turner	O
and	O
Aldridge	O
,	O
1983	O
)	O
.	O

Ergosterol	B
peroxide	I
is	O
believed	O
to	O
be	O
an	O
artefact	O
(	O
Adam	O
et	O
al.	O
,	O
1967b	O
)	O
.	O

From	O
D.	O
confragosa	O
var	O
.	O

tricolor	O
only	O
some	O
unusual	O
fatty	B
acids	I
have	O
been	O
described	O
earlier	O
(	O
Dembitsky	O
et	O
al.	O
,	O
1993	O
)	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
12	O
compounds	O
,	O
five	O
of	O
which	O
are	O
new	O
natural	O
products	O
.	O

2	O
Results	O
and	O
discussion	O
Fresh	O
fruiting	O
bodies	O
of	O
both	O
species	O
were	O
cut	O
in	O
small	O
pieces	O
and	O
crushed	O
in	O
liquid	B
nitrogen	I
.	O

The	O
resulting	O
powders	O
were	O
extracted	O
with	O
n	B
-hexane	I
.	O

After	O
removing	O
the	O
solvent	O
,	O
D.	O
quercina	O
was	O
first	O
extracted	O
with	O
methanol	B
and	O
the	O
obtained	O
solid	O
extract	O
finally	O
extracted	O
with	O
dichloromethane	B
.	O

D.	O
confragosa	O
var	O
.	O

tricolor	O
was	O
directly	O
extracted	O
with	O
dichloromethane	B
.	O

Both	O
dichloromethane	B
extracts	O
and	O
the	O
n	B
-hexane	I
extract	O
of	O
D.	O
quercina	O
were	O
repeatedly	O
chromatographed	O
on	O
silica	B
gel	I
with	O
step	O
-	O
gradients	O
of	O
petroleum	B
ether	I
–	O
ethyl	B
acetate	I
and	O
chloroform	B
–	O
methanol	B
.	O

2.1	O
Daedalea	O
quercina	O
Six	O
compounds	O
were	O
identified	O
by	O
one-	O
and	O
two	O
-	O
dimensional	O
NMR	O
spectroscopy	O
,	O
mass	O
spectrometry	O
and	O
comparison	O
with	O
literature	O
data	O
as	O
polyporenic	B
acid	I
C	I
(	O
1	O
)	O
,	O
16α	B
-	I
hydroxy-24-methylene-3-oxolanost-8-en-21-oic	I
acid	I
(	O
2	O
)	O
,	O
16-O	B
-acetylpolyporenic	I
acid	I
C	I
(	O
3	O
)	O
,	O
16α	B
-	I
acetoxy-24-methylene-3-oxolanost-8-en-21-oic	I
acid	I
(	O
4	O
)	O
,	O
3α	B
-	I
carboxyacetoxyquercinic	I
acid	I
(	O
5	O
)	O
and	O
ergosterol	B
peroxide	I
(	O
6	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
compounds	O
3	O
and	O
4	O
are	O
new	O
natural	O
products	O
.	O

In	O
addition	O
,	O
compounds	O
1	O
and	O
2	O
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
as	O
constituents	O
of	O
D.	O
quercina	O
,	O
and	O
the	O
NMR	O
data	O
of	O
compounds	O
2	O
and	O
4	O
were	O
not	O
reported	O
before	O
.	O

Compound	O
1	O
was	O
previously	O
isolated	O
from	O
various	O
fungi	O
,	O
e.g.	O
Fomitopsis	O
pinicola	O
,	O
and	O
converted	O
to	O
its	O
16-O	B
-acetyl	I
derivative	I
(	O
Keller	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Compound	O
2	O
was	O
isolated	O
previously	O
from	O
the	O
closely	O
related	O
fungus	O
Daedalea	O
dickinsii	O
(	O
Inouye	O
et	O
al.	O
,	O
1970	O
)	O
.	O

The	O
NMR	O
data	O
of	O
compound	O
5	O
was	O
described	O
earlier	O
(	O
Chairul	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Some	O
of	O
the	O
earlier	O
assignments	O
appeared	O
to	O
be	O
incorrect	O
.	O

Compound	O
7	O
showed	O
four	O
olefinic	O
carbons	O
(	O
δ	O
133.31	O
,	O
135.16	O
,	O
125.46	O
,	O
148.05	O
)	O
,	O
one	O
acid	O
(	O
δ	O
178.31	O
)	O
and	O
two	O
ketone	O
carbon	O
signals	O
(	O
δ	O
201.83	O
,	O
217.90	O
)	O
.	O

The	O
chemical	O
shifts	O
of	O
the	O
keto	O
function	O
at	O
δ	O
201.83	O
,	O
the	O
exocyclic	O
methylene	O
group	O
at	O
δ	O
125.46	O
and	O
observed	O
long	O
-	O
range	O
correlations	O
indicated	O
a	O
lanost-8-ene	O
structure	O
with	O
a	O
23-oxo-24-methylene	O
functionalized	O
side	O
-	O
chain	O
and	O
an	O
acid	O
function	O
in	O
position	O
26	O
which	O
is	O
common	O
to	O
previously	O
identified	O
triterpenic	O
acids	O
from	O
this	O
species	O
.	O

Analysis	O
of	O
the	O
NMR	O
spectra	O
(	O
DEPT	O
,	O
HMQC	O
,	O
HMBC	O
)	O
and	O
their	O
comparison	O
with	O
the	O
data	O
of	O
other	O
isolated	O
metabolites	O
indicated	O
the	O
structure	O
24-methylene-3,23-dioxolanost-8-en-26-oic	B
acid	I
for	O
which	O
we	O
propose	O
the	O
name	O
quercinic	B
acid	I
B.	I
Compound	O
8	O
showed	O
two	O
olefinic	O
(	O
δ	O
133.33	O
,	O
136.74	O
)	O
and	O
two	O
hydroxylic	O
methine	O
carbons	O
(	O
δ	O
71.57	O
,	O
74.64	O
)	O
as	O
well	O
as	O
one	O
ketone	O
(	O
δ	O
213.31	O
)	O
and	O
one	O
carboxylic	O
function	O
(	O
δ	O
178.04	O
)	O
.	O

The	O
hydroxylic	O
methine	O
proton	O
at	O
δ	O
71.57	O
showed	O
long	O
-	O
range	O
coupling	O
with	O
the	O
quaternary	O
carbons	O
13	O
and	O
14	O
(	O
δ	O
52.04	O
,	O
49.36	O
)	O
as	O
well	O
as	O
with	O
a	O
methylene	O
group	O
at	O
δ	O
34.62	O
.	O

Further	O
analysis	O
left	O
carbon	O
12	O
as	O
the	O
only	O
possible	O
position	O
for	O
this	O
hydroxy	O
function	O
.	O

The	O
other	O
hydroxyl	O
group	O
could	O
be	O
assigned	O
to	O
carbon	O
3	O
as	O
the	O
proton	O
showed	O
long	O
-	O
range	O
couplings	O
with	O
carbons	O
2	O
,	O
4	O
,	O
5	O
and	O
with	O
the	O
methyl	O
carbons	O
28	O
and	O
29	O
.	O

Futher	O
analysis	O
of	O
the	O
NMR	O
data	O
indicated	O
presence	O
of	O
a	O
24-methyl-23-oxo	O
side	O
chain	O
with	O
an	O
acid	O
function	O
in	O
position	O
26	O
.	O

In	O
the	O
NOESY	O
spectrum	O
,	O
the	O
hydroxylic	O
methine	O
proton	O
(	O
δ	O
4.39	O
)	O
only	O
showed	O
a	O
correlation	O
with	O
the	O
methyl	O
protons	O
at	O
carbon	O
30	O
(	O
δ	O
0.94	O
)	O
indicating	O
a	O
β	O
-	O
configuration	O
.	O

The	O
hydroxylic	O
methine	O
proton	O
at	O
carbon	O
3	O
(	O
δ	O
3.63	O
)	O
only	O
showed	O
a	O
correlation	O
with	O
the	O
protons	O
connected	O
to	O
carbon	O
28	O
(	O
δ	O
0.92	O
)	O
also	O
indicating	O
a	O
β	O
-	O
configuration	O
.	O

Therefore	O
,	O
this	O
compound	O
was	O
3β,12β	B
-	I
dihydroxy-24-methyl-23-oxolanost-8-en-26-oic	I
acid	I
for	O
which	O
we	O
propose	O
the	O
name	O
quercinic	B
acid	I
C.	I
Compound	O
9	O
showed	O
two	O
olefinic	O
(	O
δ	O
133.84	O
,	O
134.85	O
)	O
and	O
two	O
methine	O
carbon	O
signals	O
(	O
δ	O
75.79	O
,	O
79.73	O
)	O
as	O
well	O
as	O
one	O
carboxylic	O
carbon	O
at	O
δ	O
177.36	O
.	O

In	O
addition	O
,	O
a	O
quaternary	O
carbon	O
signal	O
at	O
δ	O
109.96	O
was	O
found	O
which	O
corresponds	O
to	O
a	O
semi	O
-	O
acetalic	O
carbon	O
atom	O
.	O

The	O
latter	O
showed	O
long	O
-	O
range	O
couplings	O
with	O
the	O
hydrogen	O
atoms	O
at	O
carbons	O
25	O
(	O
δ	O
2.22	O
)	O
,	O
24	O
(	O
δ	O
2.12	O
)	O
,	O
20	O
(	O
δ	O
2.24	O
)	O
and	O
with	O
the	O
hydroxylic	O
methine	O
proton	O
at	O
carbon	O
12	O
(	O
δ	O
4.34	O
)	O
(	O
HMBC	O
)	O
.	O

This	O
led	O
to	O
the	O
conclusion	O
that	O
formation	O
of	O
a	O
cyclic	O
acetal	O
had	O
taken	O
place	O
involving	O
the	O
oxygen	O
at	O
position	O
12	O
and	O
the	O
carbonyl	O
group	O
in	O
position	O
23	O
of	O
quercinic	B
acid	I
C	I
(	O
8	O
)	O
.	O

Comparison	O
of	O
the	O
chemical	O
shifts	O
of	O
the	O
carbons	O
in	O
ring	O
A	O
of	O
the	O
triterpene	O
skeleton	O
with	O
the	O
data	O
of	O
many	O
previously	O
identified	O
compounds	O
indicated	O
a	O
3α	O
-	O
configuration	O
,	O
so	O
that	O
this	O
compound	O
was	O
not	O
a	O
simple	O
artefact	O
of	O
compound	O
8	O
.	O

Analysis	O
of	O
all	O
spectral	O
data	O
led	O
to	O
the	O
conclusion	O
that	O
compound	O
9	O
was	O
12β,23-epoxy-3α,23-dihydroxy-24-methyllanost-8-en-26-oic	B
acid	I
for	O
which	O
we	O
propose	O
the	O
name	O
3α	B
-	I
oxepanoquercinic	I
acid	I
C.	I
From	O
the	O
n	B
-hexane	I
extract	O
,	O
a	O
15:1	O
mixture	O
of	O
(	B
E	I
)	I
-	I
(	O
10	O
)	O
and	O
(	B
Z	I
)	I
-methyl	I
4-methoxycinnamate	I
(	O
11	O
)	O
was	O
isolated	O
.	O

The	O
identification	O
was	O
carried	O
out	O
by	O
comparison	O
of	O
the	O
GC	O
-	O
MS	O
and	O
NMR	O
spectra	O
with	O
literature	O
data	O
(	O
10	O
:	O
van	O
Heerden	O
et	O
al.	O
,	O
1996	O
,	O
11	O
:	O
Jacobsen	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Compound	O
10	O
was	O
previously	O
isolated	O
from	O
the	O
fungus	O
Lentinus	O
lepideus	O
(	O
Wat	O
and	O
Towers	O
,	O
1977	O
)	O
.	O

A	O
reference	O
sample	O
of	O
methyl	O
(	B
E	I
)	I
-4-methoxycinnamate	I
was	O
prepared	O
by	O
treatment	O
of	O
authentic	O
(	B
E	I
)	I
-4-methoxycinnamic	I
acid	I
with	O
diazomethane	B
.	O

The	O
spectroscopic	O
data	O
corresponded	O
to	O
those	O
of	O
compound	O
10	O
.	O

2.2	O
Daedaleopsis	O
confragosa	O
var	O
.	O

tricolor	O
From	O
the	O
dichloromethane	B
extract	O
,	O
compounds	O
5	O
and	O
6	O
were	O
isolated	O
.	O

These	O
compounds	O
are	O
the	O
first	O
triterpene	B
derivatives	I
isolated	O
from	O
this	O
species	O
and	O
were	O
identified	O
by	O
comparison	O
of	O
their	O
spectral	O
data	O
with	O
literature	O
data	O
.	O

Furthermore	O
,	O
a	O
mixture	O
of	O
compound	O
5	O
and	O
a	O
very	O
similar	O
compound	O
was	O
obtained	O
.	O

The	O
latter	O
one	O
showed	O
different	O
carbon	O
shifts	O
for	O
the	O
side	O
chain	O
compared	O
with	O
compound	O
5	O
.	O

The	O
additional	O
presence	O
of	O
an	O
olefinic	O
methylene	O
carbon	O
at	O
δ	O
125.34	O
and	O
a	O
quaternary	O
carbon	O
at	O
δ	O
148.05	O
as	O
well	O
as	O
the	O
upfield	O
shift	O
of	O
the	O
carbonyl	O
carbon	O
to	O
δ	O
201.54	O
indicated	O
that	O
this	O
compound	O
was	O
3α	B
-	I
carboxyacetoxy-24-methylene-23-oxolanost-8-en-26-oic	I
acid	I
(	O
12	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
analysis	O
of	O
the	O
two	O
-	O
dimensional	O
NMR	O
spectra	O
.	O

This	O
compound	O
has	O
been	O
isolated	O
previously	O
from	O
an	O
unidentified	O
Indonesian	O
Ganoderma	O
species	O
(	O
Chairul	O
et	O
al.	O
,	O
1990	O
)	O
but	O
some	O
NMR	O
assignments	O
appeared	O
to	O
be	O
incorrect	O
.	O

3	O
Experimental	O
3.1	O
Plant	O
material	O
Fruiting	O
bodies	O
of	O
Daedalea	O
quercina	O
were	O
collected	O
in	O
October	O
1998	O
near	O
Salzgitter	O
in	O
the	O
Harz	O
Mountains	O
and	O
fruiting	O
bodies	O
of	O
Daedaleopsis	O
confragosa	O
var	O
.	O

tricolor	O
in	O
September	O
1999	O
in	O
the	O
Sachsenwald	O
near	O
Hamburg	O
(	O
both	O
in	O
northern	O
Germany	O
)	O
(	O
Gerhardt	O
,	O
1996	O
)	O
.	O

3.2	O
Extraction	O
3.2.1	O
Daedalea	O
quercina	O
One	O
kilogram	O
of	O
fresh	O
fruiting	O
bodies	O
were	O
crushed	O
in	O
liquid	B
nitrogen	I
.	O

The	O
resulting	O
powder	O
was	O
extracted	O
twice	O
with	O
n	B
-hexane	I
(	O
2	O
×	O
2	O
l	O
,	O
6	O
days	O
each	O
)	O
and	O
then	O
with	O
methanol	B
(	O
2	O
l	O
,	O
6	O
days	O
)	O
.	O

The	O
methanol	B
extract	O
(	O
5.3	O
g	O
of	O
a	O
green	O
solid	O
)	O
was	O
extracted	O
with	O
250	O
ml	O
of	O
dichloromethane	B
(	O
1	O
day	O
under	O
stirring	O
)	O
yielding	O
4.8	O
g	O
of	O
a	O
pale	O
green	O
solid	O
.	O

3.2.2	O
Daedaleopsis	O
confragosa	O
var	O
.	O

tricolor	O
750	O
g	O
of	O
fresh	O
fruiting	O
bodies	O
were	O
crushed	O
in	O
liquid	B
nitrogen	I
.	O

The	O
resulting	O
powder	O
was	O
extracted	O
twice	O
with	O
n	B
-hexane	I
(	O
2	O
×	O
2	O
l	O
,	O
6	O
days	O
each	O
)	O
,	O
with	O
dichloromethane	B
(	O
2	O
l	O
,	O
6	O
days	O
)	O
,	O
yielding	O
6.7	O
g	O
of	O
a	O
pale	O
green	O
solid	O
,	O
and	O
finally	O
with	O
methanol	B
(	O
2	O
l	O
,	O
6	O
days	O
)	O
.	O

3.3	O
Isolation	O
3.3.1	O
Daedalea	O
quercina	O
The	O
dichloromethane	B
extract	O
was	O
submitted	O
to	O
flash	O
column	O
chromatography	O
on	O
silica	B
gel	I
with	O
a	O
stepwise	O
gradient	O
of	O
petroleum	B
ether	I
–	O
ethyl	B
acetate	I
(	O
from	O
39:1	O
to	O
0:1	O
,	O
v	O
/	O
v	O
)	O
and	O
was	O
rechromatographed	O
several	O
times	O
on	O
silica	B
gel	I
using	O
stepwise	O
gradients	O
of	O
petroleum	B
ether	I
–	O
ethyl	B
acetate	I
(	O
from	O
39:1	O
to	O
0:1	O
,	O
v	O
/	O
v	O
)	O
and	O
chloroform	B
-	O
methanol	B
(	O
from	O
49:1	O
to	O
9:1	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
following	O
yields	O
were	O
obtained	O
:	O
1	O
(	O
see	O
below	O
)	O
,	O
2	O
(	O
15	O
mg	O
)	O
,	O
3	O
,	O
4	O
(	O
see	O
below	O
)	O
,	O
5	O
(	O
30	O
mg	O
)	O
,	O
6	O
(	O
55	O
mg	O
)	O
,	O
7	O
(	O
14	O
mg	O
)	O
,	O
8	O
(	O
10	O
mg	O
)	O
,	O
9	O
(	O
50	O
mg	O
)	O
.	O

compounds	O
3	O
and	O
4	O
were	O
obtained	O
only	O
as	O
a	O
mixture	O
and	O
1	O
was	O
only	O
obtained	O
admixed	O
with	O
2	O
,	O
but	O
because	O
of	O
the	O
existence	O
of	O
similar	O
reference	O
compounds	O
,	O
further	O
separation	O
was	O
not	O
necessary	O
.	O

The	O
n	B
-hexane	I
extract	O
was	O
chromatographed	O
in	O
the	O
same	O
manner	O
and	O
yielded	O
5	O
mg	O
of	O
a	O
15:1	O
mixture	O
of	O
10	O
and	O
11	O
.	O

3.3.2	O
Daedaleopsis	O
confragosa	O
var	O
.	O

tricolor	O
The	O
dichloromethane	B
extract	O
was	O
chromatographed	O
in	O
the	O
same	O
manner	O
as	O
described	O
for	O
the	O
extracts	O
of	O
D.	O
quercina	O
.	O

Yields	O
:	O
5	O
(	O
5	O
mg	O
)	O
,	O
a	O
3:1	O
mixture	O
of	O
5	O
and	O
12	O
(	O
100	O
mg	O
)	O
and	O
6	O
(	O
10	O
mg	O
)	O
.	O

3.4	O
TLC	O
Silica	B
gel	I
60F254	I
(	O
Merck	O
)	O
;	O
eluent	O
chloroform-2-propanol	B
9:1	O
,	O
v	O
/	O
v	O
and	O
petroleum	B
ether	I
–	O
ethyl	B
acetate	I
,	I
1:1	O
,	O
v	O
/	O
v	O
;	O
detection	O
by	O
spraying	O
with	O
sulphuric	B
acid	I
(	O
10	O
%	O
in	O
ethanol	B
)	O
.	O

3.5	O
Column	O
chromatography	O
Various	O
column	O
sizes	O
with	O
silica	B
gel	I
0.063–0.040	O
mm	O
(	O
Macherey	O
–	O
Nagel	O
)	O
.	O

3.6	O
Gas	O
chromatography	O
Carlo	O
Erba	O
HRGC	O
5300	O
Mega	O
Series	O
instrument	O
equipped	O
with	O
a	O
fused	O
silica	O
capillary	O
(	O
25	O
m	O
)	O
coated	O
with	O
CPSil-5CB	O
(	O
Chrompack	O
)	O
,	O
split	O
injector	O
and	O
FID	O
.	O

Temperature	O
program	O
:	O
110–230	O
°	O
C	O
,	O
3	O
°	O
C	O
/	O
min	O
.	O

Carrier	O
gas	O
:	O
hydrogen	B
.	O

3.7	O
GC	O
-	O
MS	O
VG	O
Analytical	O
VG	O
70	O
-	O
250S	O
mass	O
spectrometer	O
(	O
EI	O
,	O
70	O
eV	O
)	O
coupled	O
to	O
a	O
Hewlett	O
-	O
Packard	O
HP	O
5890	O
gas	O
chromatograph	O
.	O

Carrier	O
gas	O
:	O
helium	B
.	O

3.8	O
NMR	O
spectroscopy	O
Bruker	O
WM	O
400	O
at	O
400.16	O
(	O
1	O
H	O
)	O
and	O
100.61	O
MHz	O
(	O
13	O
C	O
)	O
and	O
Bruker	O
DRX	O
500	O
at	O
500.13	O
(	O
1	O
H	O
)	O
and	O
125.76	O
MHz	O
(	O
13	O
C	O
)	O
.	O

All	O
NMR	O
shifts	O
are	O
relative	O
to	O
TMS	B
.	O

3.9	O
Polarimetry	O
Perkin	O
–	O
Elmer	O
241	O
,	O
l	O
=	O
1	O
dm	O
,	O
λ	O
=	O
589	O
nm	O
.	O

3.10	O
EI	O
-	O
MS	O
70	O
eV	O
,	O
VG	O
Analytical	O
70	O
-	O
250S	O
,	O
exact	O
mass	O
measurement	O
at	O
resolution	O
10,000	O
,	O
direct	O
probe	O
sample	O
introduction	O
.	O

3.11	O
Compound	O
1	O
,	O
polyporenic	B
acid	I
C	I
,	O
16α	B
-	I
hydroxy-24-methylene-3-oxolanosta-7,9	I
(	I
11	I
)	I
-dien-21-oic	I
acid	I
Obtained	O
only	O
as	O
a	O
mixture	O
with	O
2	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
pyridine	B
-	I
d5	I
):	O
see	O
Table	O
1	O
.	O

3.12	O
Compound	O
2	O
,	O
16α	B
-	I
hydroxy-24-methylene-3-oxolanost-8-en-21-oic	I
acid	I
1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
pyridine	O
-	O
d5	O
):	O
δ	O
0.98	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
3.1	O
Hz	O
)	O
,	O
0.99	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
3.1	O
Hz	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
s	O
,	O
H-29	O
)	O
,	O
1.05	O
(	O
3H	O
,	O
s	O
,	O
H-18	O
)	O
,	O
1.13	O
(	O
3H	O
,	O
s	O
,	O
H-19	O
)	O
,	O
1.14	O
(	O
3H	O
,	O
s	O
,	O
H-28	O
)	O
,	O
1.46	O
(	O
3H	O
,	O
s	O
,	O
H-30	O
)	O
,	O
4.53	O
(	O
1H	O
,	O
dd	O
,	O
J=7.6	O
,	O
6.6	O
Hz	O
,	O
H-16	O
)	O
,	O
4.85	O
(	O
1H	O
,	O
s	O
,	O
H-31a	O
)	O
,	O
4.98	O
(	O
1H	O
,	O
s	O
,	O
H-31b	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
pyridine	B
-	I
d5	I
):	O
see	O
Table	O
1	O
.	O

3.13	O
Compound	O
3	O
,	O
16-O	B
-acetylpolyporenic	I
acid	I
C	I
,	O
16α	B
-	I
acetoxy-24-methylene-3-oxolanosta-7,9	I
(	I
11	I
)	I
-dien-21-oic	I
acid	I
Obtained	O
only	O
as	O
a	O
mixture	O
with	O
4	O
.	O
13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	B
):	O
see	O
Table	O
1	O
.	O

3.14	O
Compound	O
4	O
,	O
16α	B
-	I
acetoxy-24-methylene-3-oxolanost-8-en-21-oic	I
acid	I
Obtained	O
only	O
as	O
a	O
mixture	O
with	O
3	O
.	O
13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	B
):	O
see	O
Table	O
1	O
.	O

3.15	O
Compound	O
5	O
,	O
3α	B
-	I
carboxyacetoxyquercinic	I
acid	I
,	O
3α	B
-	I
carboxyacetoxy-24-methyl-23-oxolanost-8-en-26-oic	I
acid	I
1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
0.74	O
(	O
3H	O
,	O
s	O
,	O
H-18	O
)	O
,	O
0.87	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.6	O
Hz	O
,	O
H-21	O
)	O
,	O
0.89	O
(	O
3H	O
,	O
s	O
,	O
H-29	O
)	O
,	O
0.93	O
(	O
3H	O
,	O
s	O
,	O
H-30	O
)	O
,	O
0.94	O
(	O
3H	O
,	O
s	O
,	O
H-28	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
s	O
,	O
H-19	O
)	O
,	O
1.09	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.1	O
Hz	O
,	O
H-31	O
)	O
,	O
1.21	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.9	O
Hz	O
,	O
H-27	O
)	O
,	O
3.45	O
(	O
2H	O
,	O
s	O
,	O
H-2′	O
)	O
,	O
4.76	O
(	O
1H	O
,	O
br	O
.	O

s	O
,	O
H-3	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	B
):	O
see	O
Table	O
1	O
.	O

EI	O
-	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
528	O
[	O
M	O
−	O
CO2	O
]	O
+	O
(	O
9	O
)	O
,	O
513	O
[	O
M	O
−	O
CO2	O
−	O
Me	O
]	O
+	O
(	O
13	O
)	O
,	O
453	O
(	O
80	O
)	O
,	O
435	O
(	O
21	O
)	O
,	O
309	O
(	O
52	O
)	O
,	O
153	O
(	O
71	O
)	O
,	O
43	O
(	O
100	O
)	O
.	O

3.16	O
Compound	O
6	O
,	O
ergosterol	B
peroxide	I
,	O
5α,8α	B
-	I
epidioxyergosta-6,22-dien-3β	I
-	I
ol	I
Waxy	O
brown	O
solid	O
,	O
[	O
α	O
20	O
−20.0	O
]	O
(	O
CHCl3	B
,	O
c	O
0.2	O
)	O
.	O

1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
0.82	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
12.6	O
Hz	O
,	O
H-26	O
)	O
,	O
0.82	O
(	O
3H	O
,	O
s	O
,	O
H-18	O
)	O
,	O
0.83	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
17.1	O
Hz	O
,	O
H-27	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
s	O
,	O
H-19	O
)	O
,	O
0.91	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
,	O
H-21	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
,	O
H-28	O
)	O
,	O
3.97	O
(	O
1H	O
,	O
m	O
,	O
H-3	O
)	O
,	O
5.14	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
15.3	O
,	O
8.2	O
Hz	O
,	O
H-23	O
)	O
,	O
5.22	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
15.2	O
,	O
7.6	O
Hz	O
,	O
H-22	O
)	O
,	O
6.24	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.7	O
Hz	O
,	O
H-7	O
)	O
,	O
6.51	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.7	O
Hz	O
,	O
H-6	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	B
):	O
see	O
Table	O
1	O
.	O

EI	O
-	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
396	O
[	O
M	O
−	O
O2	O
]	O
+	O
(	O
30	O
)	O
,	O
363	O
(	O
15	O
)	O
,	O
81	O
(	O
41	O
)	O
,	O
69	O
(	O
100	O
)	O
.	O

3.17	O
Compound	O
7	O
,	O
quercinic	B
acid	I
B	I
,	O
24-methylene-3,23-dioxolanost-8-en-26-oic	B
acid	I
Waxy	O
yellow	O
solid	O
,	O
[	O
α	O
20	O
+	O
37.5	O
]	O
(	O
CHCl3	B
,	O
c	O
1.0	O
)	O
.	O

1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
0.77	O
(	O
3H	O
,	O
s	O
,	O
H-18	O
)	O
,	O
0.90	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
8.1	O
Hz	O
,	O
H-21	O
)	O
,	O
0.91	O
(	O
3H	O
,	O
s	O
,	O
H-30	O
)	O
,	O
1.07	O
(	O
3H	O
,	O
s	O
,	O
H-28	O
)	O
,	O
1.10	O
(	O
3H	O
,	O
s	O
,	O
H-29	O
)	O
,	O
1.13	O
(	O
3H	O
,	O
s	O
,	O
H-19	O
)	O
,	O
1.36	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.2	O
Hz	O
,	O
H-27	O
)	O
,	O
5.95	O
(	O
1H	O
,	O
s	O
,	O
H-31a	O
)	O
,	O
6.20	O
(	O
1H	O
,	O
s	O
,	O
H-31b	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	B
):	O
see	O
Table	O
1	O
.	O

EI	O
-	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
482	O
[	O
M	O
]	O
+	O
(	O
8)	O
,	O
467	O
[	O
M	O
−	O
Me	O
]	O
+	O
(	O
23	O
)	O
,	O
449	O
[	O
M	O
−	O
Me	O
−	O
H2	O
O	O
]	O
+	O
(	O
13	O
)	O
,	O
325	O
(	O
87	O
)	O
,	O
151	O
(	O
100	O
)	O
,	O
69	O
(	O
94	O
)	O
.	O

3.18	O
Compound	O
8	O
,	O
quercinic	B
acid	I
C	I
,	O
3β,12β	B
-	I
dihydroxy-24-methyl-23-oxolanost-8-en-26-oic	I
acid	I
Amorphous	O
light	O
brown	O
solid	O
,	O
[	O
α	O
20	O
+	O
86.0	O
]	O
(	O
CH2	O
Cl2	O
,	O
c	O
0.05	O
)	O
.	O

1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
pyridine	B
-	I
d5	I
):	O
δ	O
0.92	O
(	O
3H	O
,	O
s	O
,	O
H-28	O
)	O
,	O
0.94	O
(	O
3H	O
,	O
s	O
,	O
H-30	O
)	O
,	O
1.05	O
(	O
3H	O
,	O
s	O
,	O
H-18	O
)	O
,	O
1.08	O
(	O
3H	O
,	O
s	O
,	O
H-19	O
)	O
,	O
1.15	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.9	O
Hz	O
,	O
H-31	O
)	O
,	O
1.23	O
(	O
3H	O
,	O
s	O
,	O
H-29	O
)	O
,	O
1.34	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.2	O
Hz	O
,	O
H-27	O
)	O
,	O
1.35	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.3	O
Hz	O
,	O
H-21	O
)	O
,	O
2.57	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.3	O
,	O
10.1	O
Hz	O
,	O
H-20	O
)	O
,	O
2.86	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.6	O
,	O
6.9	O
Hz	O
,	O
H-22a	O
)	O
,	O
3.17	O
(	O
2H	O
,	O
m	O
,	O
H-24	O
,	O
H-25	O
)	O
,	O
3.63	O
(	O
1H	O
,	O
br	O
.	O

s	O
,	O
H-3	O
)	O
,	O
4.39	O
(	O
1H	O
,	O
t	O
,	O
J	O
=	O
7.9	O
Hz	O
,	O
H-12	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
pyridine	B
-	I
d5	I
):	O
see	O
Table	O
1	O
.	O

EI	O
-	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
502	O
[	O
M	O
]	O
+	O
(	O
7	O
)	O
,	O
484	O
[	O
M	O
−	O
H2	O
O	O
]	O
+	O
(	O
11	O
)	O
,	O
469	O
[	O
M	O
−	O
H2	O
O	O
−	O
Me	O
]	O
+	O
(	O
100	O
)	O
,	O
451	O
[	O
M	O
−	O
2	O
H2	O
O	O
−	O
Me	O
]	O
+	O
(	O
47	O
)	O
,	O
325	O
(	O
38	O
)	O
,	O
309	O
(	O
31	O
)	O
,	O
69	O
(	O
74	O
)	O
.	O

3.19	O
Compound	O
9	O
,	O
3α	B
-	I
oxepanoquercinic	I
acid	I
C	I
,	O
12β,23-epoxy-3α,23-dihydroxy-24-methyllanost-8-en-26-oic	B
acid	I
Amorphous	O
white	O
solid	O
.	O

1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
0.76	O
(	O
3H	O
,	O
s	O
,	O
H-18	O
)	O
,	O
0.84	O
(	O
3H	O
,	O
s	O
,	O
H-29	O
)	O
,	O
0.89	O
(	O
3H	O
,	O
s	O
,	O
H-28	O
)	O
,	O
0.98	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
8.2	O
Hz	O
,	O
H-21	O
)	O
,	O
0.99	O
(	O
3H	O
,	O
s	O
,	O
H-19	O
)	O
,	O
0.99	O
(	O
3H	O
,	O
s	O
,	O
H-30	O
)	O
,	O
1.10	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
Hz	O
,	O
H-31	O
)	O
,	O
1.24	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.1	O
Hz	O
,	O
H-27	O
)	O
,	O
2.65	O
(	O
1H	O
,	O
m	O
,	O
H-17	O
)	O
,	O
4.34	O
(	O
1H	O
,	O
t	O
,	O
J	O
=	O
8.1	O
Hz	O
,	O
H-12	O
)	O
,	O
4.74	O
(	O
1H	O
,	O
br	O
.	O

s	O
,	O
H-3	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	B
):	O
see	O
Table	O
1	O
.	O

3.20	O
Compound	O
10	O
,	O
methyl	B
(	I
E	I
)	I
-4-methoxycinnamate	I
Obtained	O
only	O
as	O
a	O
mixture	O
with	O
11	O
.	O

1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
3.80	O
(	O
3H	O
,	O
s	O
,	O
OMe	O
)	O
,	O
3.85	O
(	O
3H	O
,	O
s	O
,	O
COOMe	O
)	O
,	O
6.32	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
16.2	O
Hz	O
,	O
H-8	O
)	O
,	O
6.92	O
(	O
2H	O
,	O
dt	O
,	O
J	O
=	O
9.1	O
,	O
1.6	O
Hz	O
,	O
H-3	O
,	O
H-5	O
)	O
,	O
7.49	O
(	O
2H	O
,	O
dt	O
,	O
J	O
=	O
9.1	O
,	O
1.6	O
Hz	O
,	O
H-2	O
,	O
H-6	O
)	O
,	O
7.66	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
16.2	O
Hz	O
,	O
H-7	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	O
):	O
δ	O
51.61	O
(	O
q	O
,	O
COOMe	O
)	O
,	O
55.41	O
(	O
q	O
,	O
OMe	O
)	O
,	O
114.36	O
(	O
d	O
,	O
C-3	O
,	O
C-5	O
)	O
,	O
115.31	O
(	O
d	O
,	O
C-8	O
)	O
,	O
127.16	O
(	O
s	O
,	O
C-1	O
)	O
,	O
129.75	O
(	O
d	O
,	O
C-2	O
,	O
C-6	O
)	O
,	O
144.56	O
(	O
d	O
,	O
C-7	O
)	O
,	O
153.74	O
(	O
s	O
,	O
C-4	O
)	O
,	O
161.43	O
(	O
s	O
,	O
C-9	O
)	O
.	O

EI	O
-	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
192	O
[	O
M	O
]	O
+	O
(	O
72	O
)	O
,	O
161	O
[	O
M	O
−	O
OMe	O
]	O
+	O
(	O
100	O
)	O
,	O
133	O
[	O
M	O
−	O
COOMe	O
]	O
+	O
(	O
38	O
)	O
,	O
118	O
(	O
13	O
)	O
,	O
89	O
(	O
18	O
)	O
.	O

3.21	O
Preparation	O
of	O
methyl	B
(	I
E	I
)	I
-4-methoxycinnamate	I
Commercially	O
available	O
(	B
E	I
)	I
-4-methoxycinnamic	I
acid	I
was	O
recrystallized	O
from	O
chloroform	B
and	O
2	O
mg	O
were	O
treated	O
with	O
diazomethane	B
solution	O
until	O
a	O
yellow	O
colour	O
remained	O
,	O
indicating	O
an	O
excess	O
of	O
diazomethane	B
.	O

Finally	O
,	O
the	O
solvent	O
and	O
the	O
diazomethane	B
were	O
removed	O
in	O
a	O
stream	O
of	O
nitrogen	B
yielding	O
pure	O
methyl	B
(	I
E	I
)	I
-4-methoxycinnamate	I
.	O

3.22	O
Compound	O
11	O
,	O
methyl	B
(	I
Z	I
)	I
-4-methoxycinnamate	I
Obtained	O
only	O
as	O
a	O
mixture	O
with	O
10	O
.	O

1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
3.80	O
(	O
3H	O
,	O
s	O
,	O
OMe	O
)	O
,	O
3.85	O
(	O
3H	O
,	O
s	O
,	O
COOMe	O
)	O
,	O
5.85	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
12.7	O
Hz	O
,	O
H-8	O
)	O
,	O
6.86	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
12.7	O
Hz	O
,	O
H-7	O
)	O
,	O
6.90	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.7	O
Hz	O
,	O
H-3	O
,	O
H-5	O
)	O
,	O
7.70	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.7	O
Hz	O
,	O
H-2	O
,	O
H-6	O
)	O
.	O

EI	O
-	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
192	O
[	O
M	O
]	O
+	O
(	O
69	O
)	O
,	O
161	O
[	O
M	O
−	O
OMe	O
]	O
+	O
(	O
100	O
)	O
,	O
133	O
[	O
M	O
−	O
COOMe	O
]	O
+	O
(	O
44	O
)	O
,	O
118	O
(	O
21	O
)	O
,	O
89	O
(	O
32	O
)	O
.	O

3.23	O
Compound	O
12	O
,	O
3α	B
-	I
carboxyacetoxy-24-methylene-23-oxolanost-8-en-26-oic	I
acid	I
Obtained	O
only	O
as	O
a	O
mixture	O
with	O
5	O
.	O

1	O
H	O
-	O
NMR	O
(	O
400.13	O
MHz	O
,	O
CDCl3	B
):	O
δ	O
0.74	O
(	O
3H	O
,	O
s	O
,	O
H-18	O
)	O
,	O
0.89	O
(	O
3H	O
,	O
s	O
,	O
H-29	O
)	O
,	O
0.90	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.6	O
Hz	O
,	O
H-21	O
)	O
,	O
0.93	O
(	O
3H	O
,	O
s	O
,	O
H-30	O
)	O
,	O
0.94	O
(	O
3H	O
,	O
s	O
,	O
H-28	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
s	O
,	O
H-19	O
)	O
,	O
1.36	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.2	O
Hz	O
,	O
H-27	O
)	O
,	O
3.46	O
(	O
2H	O
,	O
s	O
,	O
H-2′	O
)	O
,	O
4.76	O
(	O
1H	O
,	O
br	O
.	O

s	O
,	O
H-3	O
)	O
,	O
5.94	O
(	O
1H	O
,	O
s	O
,	O
H-31a	O
)	O
,	O
6.20	O
(	O
1H	O
,	O
s	O
,	O
H-31b	O
)	O
.	O

13	O
C	O
-	O
NMR	O
(	O
100.61	O
MHz	O
,	O
CDCl3	B
):	O
see	O
Table	O
1	O
.	O

Acknowledgements	O

The	O
financial	O
support	O
of	O
the	O
Fonds	O
der	O
Chemischen	O
Industrie	O
is	O
gratefully	O
acknowledged	O
.	O

We	O
also	O
thank	O
Helmut	O
and	O
Gisela	O
Rösecke	O
for	O
collecting	O
the	O
fruiting	O
bodies	O
of	O
Daedalea	O
quercina	O
.	O

Piper	O
methysticum	O
Forst	O
.	O

f.	O
(	O
Kava	O
Kava	O
)	O
belongs	O
to	O
the	O
family	O
Piperaceae	O
,	O
and	O
grows	O
as	O
a	O
perennial	O
shrub	O
in	O
Fiji	O
and	O
other	O
South	O
Pacific	O
islands	O
(	O
Singh	O
and	O
Blumenthal	O
,	O
1997	O
)	O
.	O

The	O
South	O
Pacific	O
islanders	O
have	O
been	O
using	O
a	O
traditionally	O
prepared	O
beverage	O
from	O
kava	O
roots	O
for	O
thousands	O
of	O
years	O
in	O
social	O
,	O
recreational	O
and	O
ceremonial	O
events	O
,	O
and	O
also	O
as	O
a	O
remedy	O
for	O
stress	O
and	O
anxiety	O
(	O
Singh	O
and	O
Blumenthal	O
,	O
1997	O
)	O
.	O

Due	O
to	O
its	O
beneficial	O
health	O
effects	O
,	O
P.	O
methysticum	O
has	O
gained	O
popularity	O
recently	O
in	O
western	O
countries	O
as	O
an	O
alternative	O
medicine	O
especially	O
for	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
(	O
Singh	O
and	O
Blumenthal	O
,	O
1997	O
)	O
.	O

Placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
studies	O
have	O
shown	O
Kava	O
extract	O
to	O
be	O
as	O
effective	O
as	O
the	O
standard	O
therapy	O
for	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
with	O
a	O
more	O
favorable	O
toxicity	O
profile	O
and	O
minimal	O
physical	O
and	O
psychological	O
dependence	O
(	O
Singh	O
and	O
Blumenthal	O
,	O
1997	O
;	O
Volz	O
and	O
Kieser	O
,	O
1997	O
)	O
.	O

The	O
chemistry	O
of	O
P.	O
methysticum	O
has	O
been	O
extensively	O
studied	O
,	O
and	O
so	O
far	O
more	O
than	O
40	O
compounds	O
belonging	O
to	O
the	O
classes	O
of	O
kavapyrones	B
,	O
alkaloids	B
,	O
steroids	B
,	O
chalcones	B
,	O
long	B
-	I
chained	I
fatty	I
acids	I
and	O
alcohols	B
have	O
been	O
isolated	O
and	O
identified	O
(	O
Parmar	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Among	O
these	O
compounds	O
,	O
kavalactones	B
have	O
been	O
recognized	O
as	O
the	O
constituents	O
responsible	O
for	O
the	O
reported	O
biological	O
activities	O
in	O
Kava	O
(	O
Singh	O
and	O
Blumenthal	O
,	O
1997	O
)	O
.	O

Eighteen	O
different	O
kavalactones	B
have	O
been	O
reported	O
from	O
the	O
root	O
extracts	O
of	O
Kava	O
and	O
desmethoxyyangonin	B
(	O
1	O
)	O
,	O
yangonin	B
(	O
2	O
)	O
,	O
dihydrokawain	B
(	O
3	O
)	O
,	O
kawain	B
(	O
4	O
)	O
,	O
dihydromethysticin	B
(	O
5	O
)	O
and	O
methysticin	B
(	O
6	O
)	O
are	O
the	O
most	O
abundant	O
(	O
Ganzera	O
and	O
Khan	O
,	O
1999	O
)	O
.	O

Our	O
preliminary	O
investigation	O
on	O
anti	O
-	O
anxiolytic	O
properties	O
of	O
Kava	O
root	O
extract	O
and	O
of	O
the	O
six	O
major	O
kavalactones	B
in	O
an	O
animal	O
model	O
showed	O
that	O
the	O
activity	O
for	O
the	O
root	O
extract	O
was	O
higher	O
than	O
those	O
observed	O
for	O
each	O
major	O
individual	O
compound	O
(	O
Smith	O
et	O
al.	O
,	O
2001	O
)	O
.	O

This	O
suggested	O
that	O
synergism	O
or	O
other	O
compounds	O
may	O
be	O
responsible	O
for	O
the	O
higher	O
activity	O
of	O
the	O
extract	O
.	O

Prompted	O
by	O
this	O
observation	O
,	O
an	O
isolation	O
and	O
identification	O
of	O
compounds	O
in	O
the	O
Kava	O
root	O
extract	O
were	O
carried	O
out	O
.	O

Chromatographic	O
separations	O
of	O
the	O
methylene	B
chloride	I
extract	O
of	O
Kava	O
root	O
,	O
followed	O
by	O
recrystallization	O
led	O
to	O
the	O
isolation	O
and	O
identification	O
of	O
nine	O
kavalactones	B
(	O
1–9	B
)	O
,	O
together	O
with	O
three	O
chalcones	B
(	O
10–12	B
)	O
,	O
3,4-methylenedioxycinnamylideneacetone	B
(	O
13	O
)	O
and	O
stigmasterol	B
.	O

All	O
but	O
,	O
kavalactone	B
,	O
11-methoxy-5,6-dihydroyangonin	B
(	O
7	O
)	O
were	O
previously	O
reported	O
from	O
P.	O
methysticum	O
(	O
Parmar	O
et	O
al.	O
,	O
1997	O
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
11-methoxy-5,6-dihydroyangonin	B
(	O
7	O
)	O
.	O

Structural	O
elucidation	O
of	O
above	O
compounds	O
was	O
carried	O
out	O
by	O
spectroscopic	O
means	O
and	O
by	O
comparison	O
of	O
the	O
physical	O
spectroscopic	O
data	O
with	O
those	O
in	O
the	O
literature	O
.	O

Though	O
18	O
kavalactones	B
have	O
been	O
isolated	O
so	O
far	O
from	O
P.	O
methysticum	O
by	O
various	O
research	O
groups	O
(	O
Jössang	O
and	O
Molho	O
,	O
1967	O
;	O
Achenbach	O
et	O
al.	O
,	O
1973	O
;	O
Dutta	O
et	O
al.	O
,	O
1972	O
;	O
Lopez	O
-	O
Avila	O
and	O
Benedicto	O
,	O
1997	O
;	O
Parmar	O
et	O
al.	O
,	O
1997	O
;	O
Singh	O
and	O
Blumenthal	O
,	O
1997	O
;	O
Ganzera	O
and	O
Khan	O
.	O
,	O
1999	O
)	O
,	O
complete	O
physical	O
data	O
and	O
13	O
C	O
and	O
1	O
H	O
NMR	O
assignments	O
are	O
available	O
(	O
Banerji	O
et	O
al.	O
,	O
1980	O
)	O
only	O
for	O
kawain	B
(	O
4	O
)	O
,	O
methysticin	B
(	O
6	O
)	O
and	O
yangonin	B
(	O
2	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
structure	O
elucidation	O
of	O
the	O
new	O
compound	O
,	O
11-methoxy-5,6-dihydroyangonin	B
and	O
complete	O
13	O
C	O
and	O
1	O
H	O
NMR	O
assignments	O
of	O
other	O
kavalactones	B
were	O
carried	O
out	O
using	O
COSY	O
,	O
HMQC	O
and	O
HMBC	O
experiments	O
.	O

2	O
Results	O
and	O
discussion	O
Chromatographic	O
separation	O
of	O
the	O
methylene	B
chloride	I
extract	O
of	O
P.	O
methysticum	O
roots	O
yielded	O
fourteen	O
compounds	O
.	O

Preliminary	O
spectroscopic	O
analysis	O
indicated	O
that	O
these	O
fourteen	O
compounds	O
comprised	O
of	O
nine	O
kavalactones	B
,	O
three	O
chalcones	B
,	O
3,4-methylenedioxycinnamylideneacetone	B
and	O
stigmasterol	B
.	O

Detailed	O
NMR	O
spectroscopic	O
analysis	O
and	O
comparison	O
of	O
the	O
physical	O
and	O
spectroscopic	O
data	O
with	O
those	O
reported	O
confirmed	O
the	O
structures	O
of	O
3,4-methylenedioxycinnamylideneacetone	B
(	O
13	O
)	O
(	O
Jössang	O
and	O
Molho	O
,	O
1967	O
)	O
,	O
stigmasterol	B
and	O
the	O
chalcones	B
as	O
flavokawain	B
A	I
(	O
10	O
)	O
(	O
Zhili	O
,	O
1998	O
)	O
,	O
flavokawain	B
B	I
(	O
11	O
)	O
(	O
Itokava	O
et	O
al.	O
,	O
1981	O
)	O
and	O
flavokawain	B
C	I
(	O
12	O
)	O
(	O
Seeram	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Analysis	O
of	O
the	O
NMR	O
spectra	O
of	O
the	O
kavalactones	B
using	O
HMQC	O
and	O
HMBC	O
experiments	O
permitted	O
the	O
determination	O
of	O
the	O
structures	O
of	O
these	O
compounds	O
and	O
the	O
assignments	O
of	O
13	O
C	O
signals	O
.	O

These	O
compounds	O
were	O
identified	O
as	O
desmethoxyyangonin	B
(	O
1	O
)	O
,	O
yangonin	B
(	O
2	O
)	O
,	O
dihydrokawain	B
(	O
3	O
)	O
,	O
kawain	B
(	O
4	O
)	O
,	O
dihydromethysticin	B
(	O
5	O
)	O
,	O
methysticin	B
(	O
6	O
)	O
tetrahydroyangonin	B
(	O
8	O
)	O
and	O
1-methoxytetrahydroyangonin	B
(	O
9	O
)	O
(	O
Achenbach	O
et	O
al.	O
,	O
1973	O
)	O
,	O
previously	O
isolated	O
and	O
identified	O
from	O
P.	O
methysticum	O
.	O

Analysis	O
of	O
compound	O
7	O
by	O
HRMS	O
suggested	O
a	O
molecular	O
formula	O
C16	O
H18	O
O5	O
(	O
[	O
M+H	O
]	O
+	O
=	O
291.1154	O
)	O
.	O

The	O
1	O
H	O
NMR	O
spectrum	O
of	O
this	O
compound	O
showed	O
three	O
methoxy	O
groups	O
and	O
a	O
typical	O
set	O
of	O
peaks	O
due	O
to	O
the	O
5,6	O
-dihydrokavalactone	O
skeleton	O
(	O
see	O
Experimental	O
)	O
.	O

Further	O
analysis	O
of	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
7	O
showed	O
an	O
AB	O
doublet	O
for	O
H-13	O
.	O

The1	O
H	O
NMR	O
signals	O
for	O
H-10	O
and	O
H-14	O
appeared	O
close	O
together	O
(	O
δ	O
6.91	O
and	O
6.90	O
,	O
respectively	O
)	O
and	O
a	O
part	O
of	O
H-14	O
doublet	O
of	O
doublet	O
(	O
J	O
=	O
1.6	O
and	O
7.8	O
Hz	O
)	O
overlapped	O
with	O
the	O
H-10	O
signal	O
to	O
give	O
a	O
broad	O
signal	O
.	O

These	O
data	O
suggested	O
the	O
11-methoxy-5,6-dihydroyangonin	B
structure	O
for	O
this	O
compound	O
,	O
which	O
was	O
confirmed	O
by	O
HMQC	O
and	O
HMBC	O
experiments	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
11-methoxy-5,6-dihydroyangonin	B
.	O

The	O
(	B
6R	I
)	I
-absolute	I
stereochemistry	O
was	O
determined	O
by	O
comparison	O
with	O
the	O
CD	O
data	O
reported	O
for	O
this	O
class	O
of	O
compounds	O
(	O
Snatzke	O
and	O
Hänsel	O
,	O
1968	O
;	O
Achenbach	O
and	O
Theobald	O
,	O
1974	O
)	O
.	O

The	O
13	O
C	O
NMR	O
assignments	O
of	O
nine	O
kavalactones	B
were	O
made	O
using	O
HMQC	O
and	O
HMBC	O
experiments	O
.	O

The	O
assignments	O
for	O
compounds	O
2	O
,	O
4	O
and	O
6	O
were	O
consistent	O
with	O
those	O
previously	O
reported	O
for	O
these	O
compounds	O
(	O
Banerji	O
et	O
al.	O
,	O
1980	O
)	O
.	O

The	O
detailed	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectroscopic	O
data	O
for	O
these	O
compounds	O
are	O
presented	O
in	O
Table	O
1	O
and	O
in	O
the	O
Experimental	O
.	O

3	O
Experimental	O
Mps	O
(	O
uncorr	O
.	O
)	O
were	O
recorded	O
on	O
an	O
Electrothermal	O
9100	O
instrument	O
.	O

UV	O
spectra	O
were	O
obtained	O
in	O
CD3	B
OD	I
,	O
using	O
Hewlett	O
Packard	O
8452A	O
spectrometer	O
and	O
IR	O
spectra	O
were	O
taken	O
on	O
an	O
Ati	O
Mattson	O
(	O
Genesis	O
Series	O
)	O
FTIR	O
spectrophotometer	O
.	O

1	O
H	O
NMR	O
and	O
13	O
C	O
NMR	O
spectra	O
were	O
recorded	O
on	O
Bruker	O
Avance	O
DPX-300	O
(	O
300	O
MHz	O
for	O
1	O
H	O
NMR	O
and	O
75.45	O
MHz	O
for	O
13	O
C	O
NMR	O
)	O
and	O
Bruker	O
Avance	O
DRX-500	O
(	O
500	O
MHz	O
for	O
1	O
H	O
NMR	O
and	O
125	O
MHz	O
for	O
13	O
C	O
NMR	O
)	O
spectrometers	O
in	O
CDCl3	B
and	O
MeOH	B
-	I
D4	I
using	O
TMS	B
as	O
internal	O
standard	O
.	O

High	O
resolution	O
MS	O
(	O
HRMS	O
)	O
were	O
obtained	O
by	O
direct	O
probe	O
using	O
Bruker	O
Bioapex	O
-	O
FTMS	O
with	O
Electro	O
-	O
Spray	O
Ionization	O
.	O

Preparative	O
TLC	O
was	O
carried	O
out	O
using	O
silica	B
gel	I
F	I
254	I
plates	O
(	O
thickness	O
1	O
mm	O
)	O
.	O

3.1	O
Extraction	O
and	O
isolation	O
Piper	O
methysticum	O
(	O
Kava	O
Kava	O
)	O
root	O
extract	O
(	O
1	O
kg	O
)	O
(	O
Nutratech	O
,	O
Passaic	O
Avenue	O
,	O
Fairfield	O
,	O
NJ	O
07004	O
,	O
USA	O
:	O
Lot	O
No.	O
40493240	O
)	O
was	O
extracted	O
three	O
times	O
with	O
methylene	B
chloride	I
at	O
room	O
temperature	O
for	O
1	O
h	O
under	O
sonication	O
.	O

The	O
combined	O
methylene	B
chloride	I
extract	O
was	O
evaporated	O
to	O
give	O
a	O
dark	O
green	O
viscous	O
semisolid	O
.	O

This	O
semisolid	O
was	O
dissolved	O
in	O
methanol	B
,	O
diluted	O
with	O
diethyl	B
ether	I
and	O
kept	O
at	O
−10	O
°	O
C	O
for	O
12	O
h	O
to	O
give	O
30	O
g	O
of	O
a	O
crystalline	O
material	O
.	O

Recrystallization	O
of	O
this	O
material	O
from	O
methanol	B
yielded	O
yangonin	B
(	O
4.5	O
g	O
)	O
and	O
the	O
mother	O
liquor	O
was	O
subjected	O
to	O
silica	B
gel	I
column	O
chromatography	O
.	O

Elution	O
of	O
the	O
column	O
with	O
increasing	O
amounts	O
of	O
acetone	B
in	O
hexane	B
as	O
the	O
solvent	O
gave	O
fractions	O
with	O
desmethoxyyangonin	B
(	O
1	O
)	O
,	O
yangonin	B
(	O
2	O
)	O
(	O
0.6	O
g	O
)	O
,	O
dihydrokawain	B
(	O
3	O
)	O
(	O
1.3	O
g	O
)	O
,	O
kawain	B
(	O
4	O
)	O
(	O
1.35	O
g	O
)	O
,	O
dihydromethysticin	B
(	O
5	O
)	O
(	O
2.15	O
g	O
)	O
methysticin	B
(	O
6	O
)	O
(	O
1.25	O
g	O
)	O
,	O
stigmasterol	B
(	O
1.2	O
g	O
)	O
and	O
flavokawain	B
A	I
(	O
10	O
)	O
(	O
0.4	O
g	O
)	O
as	O
major	O
compounds	O
and	O
were	O
further	O
purified	O
by	O
crystallization	O
.	O

The	O
mother	O
liquor	O
from	O
the	O
original	O
extract	O
was	O
also	O
subjected	O
to	O
column	O
chromatography	O
on	O
silica	B
gel	I
using	O
the	O
same	O
solvent	O
system	O
to	O
give	O
in	O
addition	O
to	O
the	O
above	O
compounds	O
several	O
fractions	O
with	O
minor	O
constituents	O
.	O

Preparative	O
TLC	O
of	O
these	O
fractions	O
using	O
methanol	B
/	O
dichloromethane	B
or	O
hexane	B
/	O
ethyl	B
acetate	I
mixtures	O
yielded	O
the	O
minor	O
compounds	O
7	O
,	O
8	O
,	O
9	O
,	O
11	O
,	O
12	O
and	O
13	O
in	O
pure	O
form	O
.	O

3.1.1	O
Stigmasterol	B
Semisolid	O
,	O
identity	O
confirmed	O
by	O
1	O
H	O
NMR	O
and	O
co	O
-	O
TLC	O
with	O
an	O
authentic	O
sample	O
.	O

3.1.2	O
Desmethoxyyangonin	B
(	O
1	O
)	O
White	O
amorphous	O
solid	O
(	O
0.21	O
%	O
)	O
,	O
mp	O
138–140	O
°	O
C	O
(	O
lit	O
138–140	O
)	O
(	O
Rezende	O
et	O
al.	O
,	O
1971	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
7.48	O
(	O
2H	O
,	O
m	O
,	O
H-10	O
and	O
H-14	O
)	O
,	O
7.44	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.9	O
Hz	O
,	O
H-8	O
)	O
,	O
7.35–7.31	O
(	O
3H	O
,	O
m	O
,	O
H-11	O
,	O
H-12	O
and	O
H-13	O
)	O
,	O
6.54	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
16.0	O
Hz	O
,	O
H-7	O
)	O
,	O
5.90	O
(	O
1H	O
,	O
s	O
,	O
H-5	O
)	O
,	O
5.44	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
1.4	O
Hz	O
,	O
H-3	O
)	O
,	O
3.76	O
(	O
3H	O
,	O
s	O
,	O
H-15	O
)	O
.	O

3.1.3	O
Yangonin	B
(	O
2	O
)	O
Yellow	O
needles	O
(	O
0.4	O
%	O
)	O
,	O
mp	O
152–155	O
°	O
C	O
(	O
lit	O
.	O

153–154	O
)	O
(	O
Dutta	O
et	O
al.	O
,	O
1972	O
)	O
.	O

1	O
H	O
-	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
7.42	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.9	O
Hz	O
,	O
H-8	O
)	O
,	O
7.41	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.8	O
Hz	O
,	O
H-10	O
and	O
H-14	O
)	O
,	O
6.87	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.8	O
Hz	O
,	O
H-11	O
and	O
H-13	O
)	O
,	O
6.42	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
16.0	O
Hz	O
,	O
H-7	O
)	O
,	O
5.86	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
2.1	O
Hz	O
,	O
H-5	O
)	O
,	O
5.43	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
2.1	O
Hz	O
,	O
H-3	O
)	O
,	O
3.78	O
(	O
3H	O
,	O
s	O
,	O
H-17	O
)	O
,	O
3.76	O
(	O
3H	O
,	O
s	O
,	O
15-H	O
)	O
.	O

3.1.4	O
Dihydrokawain	B
(	O
3	O
)	O
White	O
crystals	O
(	O
1.17	O
%	O
)	O
,	O
mp	O
58–60	O
°	O
C	O
,	O
(	O
lit	O
.	O

56–60	O
)	O
(	O
Spino	O
et	O
al.	O
,	O
1996	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
7.27	O
(	O
2H	O
,	O
m	O
,	O
H-11	O
and	O
H-13	O
)	O
,	O
7.18	O
(	O
3H	O
,	O
m	O
,	O
H-10	O
,	O
H-12	O
and	O
H-14	O
)	O
,	O
5.12	O
(	O
1H	O
,	O
d	O
,	O
J=	O
1.3	O
Hz	O
,	O
H3	O
)	O
,	O
4.34	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
,	O
3.70	O
(	O
3H	O
,	O
s	O
,	O
4-OCH3	O
)	O
,	O
2.84	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.73	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.48	O
(	O
1H	O
,	O
ddd	O
,	O
J	O
=	O
1.3	O
,	O
11.9	O
,	O
17.0	O
Hz	O
,	O
H-5	O
)	O
,	O
2.28	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
3.9	O
,	O
17.0	O
Hz	O
,	O
H-5	O
)	O
,	O
2.11	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
1.91	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
.	O

3.1.5	O
Kawain	B
(	O
4	O
)	O
White	O
crystals	O
(	O
0.53	O
%	O
)	O
,	O
mp	O
108–110	O
°	O
C	O
,	O
(	O
lit	O
.	O

106–108	O
)	O
(	O
Dutta	O
et	O
al.	O
,	O
1972	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
7.32	O
(	O
2H	O
,	O
m	O
,	O
H-11	O
and	O
H-13	O
)	O
,	O
7.25	O
(	O
2H	O
,	O
m	O
,	O
H-10	O
and	O
H-14	O
)	O
,	O
7.20	O
(	O
1H	O
,	O
m	O
,	O
H-12	O
)	O
,	O
6.70	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.9	O
Hz	O
,	O
H-8	O
)	O
,	O
6.23	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
6.14	O
,	O
15.9	O
Hz	O
,	O
H-7	O
)	O
,	O
5.16	O
(	O
1H	O
,	O
s	O
,	O
H-3	O
)	O
,	O
5.02	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
,	O
3.72	O
(	O
3H	O
,	O
s	O
,	O
H-15	O
)	O
,	O
2.63	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.0	O
,	O
10.7	O
Hz	O
,	O
H-5	O
)	O
,	O
2.51	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.0	O
,	O
4.5	O
,	O
Hz	O
,	O
H-5	O
)	O
.	O

3.1.6	O
Dihydromethysticin	B
(	O
5	O
)	O
White	O
crystals	O
(	O
0.54	O
%	O
)	O
,	O
mp	O
117–118	O
°	O
C	O
(	O
lit	O
.	O

117–118	O
)	O
(	O
Anon	O
.	O
1999	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
6.70	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.9	O
Hz	O
,	O
H-13	O
)	O
,	O
6.66	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
1.2	O
Hz	O
,	O
H-10	O
)	O
,	O
6.63	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
7.9	O
,	O
1.2	O
Hz	O
,	O
H-14	O
)	O
,	O
5.89	O
(	O
2H	O
,	O
s	O
,	O
O	O
–	O
CH2	O
–O	O
)	O
,	O
5.11	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
1.2	O
Hz	O
,	O
H-3	O
)	O
,	O
4.33	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
,	O
3.70	O
(	O
3H	O
,	O
s	O
,	O
H-12	O
)	O
,	O
2.77	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.67	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.40	O
(	O
1H	O
,	O
ddd	O
,	O
J	O
=	O
17.0	O
,	O
12.0	O
,	O
1.2	O
Hz	O
,	O
H-5	O
)	O
,	O
2.28	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
7.0	O
,	O
3.8	O
Hz	O
,	O
H-5	O
)	O
,	O
2.04	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
1.85	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
.	O

3.1.7	O
Methysticin	B
(	O
6	O
)	O
White	O
crystals	O
(	O
0.44	O
%	O
)	O
,	O
mp	O
134–136	O
°	O
C	O
(	O
lit	O
.	O

134–136	O
)	O
(	O
Dutta	O
et	O
al.	O
,	O
1972	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
6.88	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
1.4	O
Hz	O
,	O
H-10	O
)	O
,	O
6.79	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
8.0	O
,	O
1.5	O
Hz	O
,	O
H-14	O
)	O
,	O
6.72	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
H-13	O
)	O
,	O
6.59	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.8	O
Hz	O
,	O
H-8	O
)	O
,	O
6.06	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
6.4	O
,	O
15.9	O
Hz	O
,	O
H-7	O
)	O
,	O
5.92	O
(	O
2H	O
,	O
s	O
,	O
O	O
–	O
CH2	O
–O	O
)	O
,	O
5.15	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
0.6	O
Hz	O
,	O
H-3	O
)	O
,	O
4.98	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
,	O
3.72	O
(	O
3H	O
,	O
s	O
,	O
H-12	O
)	O
,	O
2.61	O
(	O
1H	O
,	O
ddd	O
,	O
J	O
=	O
17.2	O
,	O
10.8	O
,	O
0.7	O
Hz	O
,	O
H-5	O
)	O
,	O
2.48	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.1	O
,	O
4.4	O
Hz	O
,	O
H-5	O
)	O
.	O

3.1.8	O
11-Methoxy-5,6-dihydroyangonin	B
(	O
7	O
)	O
Yellow	O
semi	O
-	O
solid	O
(	O
0.01	O
%	O
)	O
,	O
[	O
α	O
]	O
25	O
D	O
+	O
70.0	O
°	O
(	O
CHCl3	O
;	O
c	O
0.025	O
)	O
.	O

CD	O
:	O
(	O
MeOH	O
:	O
c	O
0.01	O
)	O
:	O
[	O
Ø	O
]	O
232	O
−2.98	O
,	O
[	O
Ø	O
]	O
240	O
+	O
6.6	O
,	O
[	O
Ø	O
]	O
246	O
+	O
6.9	O
.	O

UV	O
:	O
λmax	O
MeOH	O
nm	O
(	O
log	O
ε	O
228	O
(	O
4.04	O
)	O
,	O
266	O
(	O
3.87	O
)	O
.	O

IR	O
cm−1	O
νmax	O
(	O
neat	O
)	O
:	O
2924	O
,	O
1707	O
,	O
1623	O
,	O
1514	O
,	O
1462	O
,	O
1222	O
,	O
1025	O
,	O
822	O
.	O

HRMS	O
291.1154	O
(	O
[	O
M+H	O
]	O
+	O
)	O
(	O
calculated	O
for	O
C16	O
H18	O
O5	O
,	O
291.1154	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
6.91	O
(	O
1H	O
,	O
s	O
,	O
H-10	O
)	O
,	O
6.90	O
(	O
1H	O
,	O
d	O
,	O
J=	O
7.8	O
,	O
1.6	O
Hz	O
,	O
H-14	O
)	O
,	O
6.79	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
H-13	O
)	O
,	O
6.62	O
(	O
1H	O
,	O
d	O
,	O
J=	O
15.9	O
Hz	O
,	O
8-H	O
)	O
,	O
6.13	O
(	O
1H	O
,	O
dd	O
,	O
J=	O
15.9	O
,	O
6.6	O
Hz	O
,	O
H-7	O
)	O
,	O
5.15	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
0.7	O
Hz	O
,	O
H-3	O
)	O
,	O
5.00	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
,	O
3.89	O
(	O
3H	O
,	O
s	O
,	O
H-17	O
)	O
,	O
3.87	O
(	O
3H	O
,	O
s	O
,	O
H-16	O
)	O
,	O
3.76	O
(	O
3H	O
,	O
s	O
,	O
H-15	O
)	O
,	O
2.66	O
(	O
1H	O
,	O
ddd	O
,	O
J	O
=	O
17.1	O
,	O
11.0	O
,	O
0.8	O
Hz	O
,	O
H-5	O
)	O
,	O
2.54	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.0	O
,	O
4.2	O
Hz	O
,	O
H-5	O
)	O
.	O

3.1.9	O
Tetrahydroyangonin	B
(	O
8	O
)	O
(	O
Franca	O
et	O
al.	O
,	O
1973	O
)	O
Yellow	O
semi	O
-	O
solid	O
(	O
0.015	O
%	O
)	O
,	O
1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
7.12	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
,	O
H-10	O
and	O
H-14	O
)	O
,	O
6.83	O
(	O
2H	O
,	O
d	O
,	O
J=	O
8.4	O
Hz	O
,	O
H-11	O
and	O
H-13	O
)	O
,	O
5.14	O
(	O
1H	O
,	O
s	O
,	O
H-3	O
)	O
,	O
4.35	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
,	O
3.78	O
(	O
3H	O
,	O
s	O
,	O
H-17	O
)	O
,	O
3.72	O
(	O
3H	O
,	O
s	O
,	O
H-15	O
)	O
,	O
2.81	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.72	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.50	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
16.9	O
,	O
12.2	O
Hz	O
,	O
H-5	O
)	O
,	O
2.29	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.0	O
,	O
3.7	O
Hz	O
,	O
H-5	O
)	O
,	O
2.09	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
1.89	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
.	O

3.1.10	O
11-Methoxytetrahydroyangonin	B
(	O
9	O
)	O
White	O
solid	O
(	O
0.011	O
%	O
)	O
,	O
mp	O
121–123	O
°	O
C	O
(	O
lit	O
.	O

121–123	O
)	O
(	O
Franca	O
et	O
al.	O
,	O
1973	O
)	O
.	O

[	O
α	O
]	O
25	O
D	O
:	O
+	O
27.7	O
°	O
(	O
CHCl3	O
;	O
c	O
0.011	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
6.76	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.6	O
Hz	O
,	O
H-13	O
)	O
,	O
6.71	O
(	O
1H	O
,	O
s	O
,	O
H-10	O
)	O
,	O
6.70	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.6	O
Hz	O
,	O
H-14	O
)	O
,	O
5.09	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
0.7	O
Hz	O
,	O
H-3	O
)	O
,	O
4.31	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
,	O
3.82	O
(	O
3H	O
,	O
s	O
,	O
H-16	O
)	O
,	O
3.81	O
(	O
3H	O
,	O
s	O
,	O
H-17	O
)	O
,	O
3.68	O
(	O
3H	O
,	O
s	O
,	O
H-15	O
)	O
,	O
2.78	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.68	O
(	O
1H	O
,	O
m	O
,	O
H-8	O
)	O
,	O
2.46	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
17.1	O
,	O
12.2	O
Hz	O
,	O
H-5	O
)	O
,	O
2.26	O
(	O
1H	O
,	O
dd	O
,	O
J=	O
17.0	O
,	O
3.7	O
Hz	O
,	O
H-5	O
)	O
,	O
2.06	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
1.87	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
.	O

3.1.11	O
Flavokawain	B
A	I
(	O
10	O
)	O
Yellow	O
crystalline	O
compound	O
(	O
0.46	O
%	O
)	O
,	O
mp	O
111–115	O
°	O
C	O
(	O
lit	O
.	O
116	O
)	O
(	O
Jössang	O
and	O
Molho	O
,	O
1967	O
)	O
.	O

1	O
H	O
-	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
14.40	O
(	O
1H	O
,	O
s	O
,	O
HO-2′	O
)	O
,	O
7.79	O
(	O
2H	O
,	O
s	O
,	O
H	O
-	O
α	O
and	O
H	O
-	O
β	O
)	O
,	O
7.56	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.8	O
Hz	O
,	O
H-2	O
and	O
H-6	O
)	O
,	O
6.92	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.7	O
Hz	O
,	O
H-3	O
and	O
H-5	O
)	O
,	O
6.09	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-3′	O
)	O
,	O
5.95	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-5′	O
)	O
,	O
3.91	O
(	O
3H	O
,	O
s	O
,	O
6′-OCH3	O
)	O
,	O
3.84	O
(	O
3H	O
,	O
s	O
,	O
-OCH3	O
)	O
,	O
3.82	O
(	O
3H	O
,	O
s	O
,	O
4′-OCH3	O
)	O
3.1.12	O
Flavokawain	B
B	I
(	O
11	O
)	O
Yellow	O
crystalline	O
compound	O
(	O
0.015	O
%	O
)	O
,	O
mp	O
96–98	O
°	O
C	O
(	O
lit	O
.	O

92	O
)	O
(	O
Jössang	O
and	O
Molho	O
,	O
1967	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
14.29	O
(	O
1H	O
,	O
s	O
,	O
HO-2′	O
)	O
,	O
7.90	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.6	O
Hz	O
,	O
H	O
-	O
β	O
)	O
,	O
7.78	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.6	O
Hz	O
,	O
H	O
-	O
α	O
)	O
,	O
7.62–7.59	O
(	O
2H	O
,	O
m	O
,	O
H-2	O
and	O
H-6	O
)	O
,	O
7.44–7.39	O
(	O
3H	O
,	O
m	O
,	O
H-2	O
,	O
H-3	O
and	O
H-5	O
)	O
,	O
6.11	O
(	O
1H	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-3′	O
)	O
,	O
5.96	O
(	O
1H	O
,	O
d	O
,	O
J=	O
2.3	O
Hz	O
,	O
H-5′	O
)	O
,	O
3.91	O
(	O
3H	O
,	O
s	O
,	O
6′-OCH3	O
)	O
,	O
3.80	O
(	O
3H	O
,	O
s	O
,	O
4′-OCH3	O
)	O
3.1.13	O
Flavokawain	B
C	I
(	O
12	O
)	O
Yellow	O
crystalline	O
compound	O
(	O
0.012	O
%	O
)	O
,	O
mp	O
185–188	O
°	O
C	O
(	O
lit	O
.	O

194–195	O
)	O
(	O
Seeram	O
et	O
al.	O
,	O
1996	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CD3	O
OD	O
)	O
:δ	O
7.72	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
16.2	O
Hz	O
,	O
H	O
-	O
β	O
)	O
,	O
7.65	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.9	O
Hz	O
,	O
H	O
-	O
α	O
)	O
,	O
7.44	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.6	O
Hz	O
,	O
H-2	O
and	O
H-6	O
)	O
,	O
6.82	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
8.6	O
Hz	O
,	O
H-3	O
and	O
H-5	O
)	O
,	O
6.02	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-3′	O
)	O
,	O
5.94	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
2.2	O
Hz	O
,	O
H-5′	O
)	O
,	O
3.86	O
(	O
3H	O
,	O
s	O
,	O
6′-OCH3	O
)	O
,	O
3.77	O
(	O
3H	O
,	O
s	O
,	O
4′-OMe	O
)	O
3.1.14	O
3,4-Methylenedioxycinnamylideneacetone	B
(	O
13	O
)	O
(	O
Jössang	O
and	O
Molho	O
,	O
1967	O
)	O

Semi	O
solid	O
(	O
0.018	O
%	O
)	O
.	O

1	O
H	O
NMR	O
(	O
CDCl3	O
)	O
:	O
δ	O
7.18	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
15.4	O
,	O
10.8	O
Hz	O
,	O
H-3′	O
)	O
,	O
6.92	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
1.7	O
Hz	O
,	O
H-2	O
)	O
,	O
6.85	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
8.0	O
,	O
1.4	O
Hz	O
,	O
H-6	O
)	O
,	O
6.77	O
(	O
1H	O
,	O
d	O
,	O
J=	O
15.5	O
Hz	O
,	O
H-1′	O
)	O
,	O
6.72	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.0	O
Hz	O
,	O
H-5	O
)	O
,	O
6.62	O
(	O
1H	O
,	O
dd	O
,	O
J	O
=	O
15.5	O
,	O
10.8	O
Hz	O
,	O
H-2′	O
)	O
,	O
6.13	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
15.5	O
Hz	O
,	O
H-4′	O
)	O
,	O
5.91	O
(	O
2H	O
,	O
s	O
,	O
O	O
–	O
CH2	O
–O	O
)	O
,	O
2.23	O
(	O
3H	O
,	O
s	O
,	O
H-6′	O
)	O
.	O

13	O
H	O
NMR	O
(	O
CDCl3	O
):	O
δ	O
27.6	O
(	O
C-6′	O
)	O
,	O
101.8	O
(	O
O	O
–	O
CH2	O
–O	O
)	O
,	O
106.2	O
(	O
C-2	O
)	O
,	O
108.9	O
(	O
C-5	O
)	O
,	O
123.5	O
(	O
C-6	O
)	O
,	O
125.2	O
(	O
C-2′	O
)	O
,	O
130.1	O
(	O
C-4′	O
)	O
,	O
130.9	O
(	O
C-1	O
)	O
,	O
141.3	O
(	O
C-1′	O
)	O
,	O
143.9	O
(	O
C-3′	O
)	O
,	O
148.7	O
(	O
C-3	O
)	O
,	O
149.1	O
(	O
C-4	O
)	O
,	O
198.5	O
(	O
C-5′	O
)	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
the	O
United	O
States	O
Department	O
of	O
Agriculture	O
,	O
ARS	O
Specific	O
Cooperative	O
Agreement	O
No.	O
58	O
-	O
6408	O
-	O
7	O
-	O
012	O
.	O

The	O
authors	O
thank	O
Dr.	O
Chuck	O
Dunbar	O
for	O
performing	O
the	O
HRMS	O
analyses	O
and	O
Frank	O
Wiggers	O
for	O
obtaining	O
NMR	O
spectra	O
.	O

The	O
authors	O
also	O
thank	O
CromaDex	O
(	O
Irvine	O
,	O
CA	O
,	O
USA	O
)	O
for	O
financial	O
support	O
of	O
this	O
project	O
.	O

Solanum	O
torvum	O
Swartz	O
(	O
Solanaceae	O
)	O
is	O
a	O
small	O
shrub	O
distributed	O
widely	O
in	O
Thailand	O
.	O

Its	O
edible	O
fruits	O
,	O
commonly	O
available	O
in	O
the	O
markets	O
,	O
are	O
used	O
as	O
a	O
vegetable	O
and	O
are	O
regarded	O
as	O
an	O
essential	O
ingredient	O
in	O
Thai	O
cuisine	O
.	O

To	O
date	O
,	O
steroidal	B
glycosides	I
(	O
Mahmood	O
et	O
al.	O
,	O
1985	O
;	O
Agrawal	O
et	O
al.	O
,	O
1989	O
;	O
Cuervo	O
et	O
al.	O
,	O
1991	O
;	O
Yahara	O
et	O
al.	O
,	O
1996	O
;	O
Fayez	O
and	O
Saleh	O
,	O
1967	O
)	O
,	O
and	O
long	B
chain	I
hydrocarbons	I
and	O
steroids	B
(	O
Mahmood	O
et	O
al.	O
,	O
1983	O
)	O
have	O
been	O
previously	O
isolated	O
from	O
S.	O
torvum	O
.	O

However	O
,	O
little	O
is	O
known	O
on	O
the	O
biological	O
activities	O
of	O
these	O
isolated	O
compounds	O
.	O

We	O
report	O
herein	O
the	O
isolation	O
,	O
structure	O
elucidation	O
,	O
and	O
biological	O
activities	O
of	O
three	O
polar	O
constituents	O
(	O
1	O
–3	O
)	O
in	O
the	O
fruits	O
of	O
S.	O
torvum	O
.	O

A	O
new	O
isoflavonoid	B
sulfate	I
,	O
named	O
torvanol	B
A	I
(	O
1	O
)	O
,	O
and	O
a	O
new	O
steroidal	B
glycoside	I
,	O
named	O
torvoside	B
H	I
(	O
3	O
)	O
,	O
together	O
with	O
a	O
known	O
glycoside	B
,	O
torvoside	B
A	I
(	O
2	O
)	O
,	O
have	O
been	O
isolated	O
from	O
a	O
MeOH	B
extract	O
of	O
S.	O
torvum	O
fruits1	O
.	O

2	O
Results	O
and	O
discussion	O
Torvanol	B
A	I
(	O
1	O
)	O
was	O
obtained	O
from	O
a	O
MeOH	B
extract	O
of	O
S.	O
torvum	O
fruits	O
after	O
sequential	O
purification	O
with	O
gel	O
filtration	O
chromatography	O
on	O
Sephadex	B
LH-20	I
and	O
preparative	O
(	O
reversed	O
phase	O
C18	O
)	O
HPLC	O
.	O

Although	O
torvanol	B
A	I
(	O
1	O
)	O
possesses	O
hydrophobic	O
components	O
(	O
e.g.	O
two	O
aromatic	B
rings	I
and	O
two	O
methyl	B
ethers	I
,	O
it	O
dissolves	O
remarkably	O
well	O
in	O
water	O
.	O

The	O
1	O
H	O
NMR	O
spectrum	O
(	O
D2	B
O	I
)	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
showed	O
two	O
prominent	O
methyl	O
ether	O
singlets	O
(	O
δ	O
H	O
3.75	O
and	O
3.84	O
)	O
,	O
non	O
-	O
equivalent	O
methylene	O
protons	O
attached	O
to	O
a	O
carbon	O
bearing	O
an	O
oxygen	O
atom	O
(	O
δ	O
H	O
4.17	O
and	O
4.25	O
)	O
,	O
methine	O
protons	O
(	O
δ	O
H	O
3.50	O
and	O
5.53	O
)	O
,	O
two	O
trans	O
olefinic	O
protons	O
(	O
δ	O
H	O
6.31	O
and	O
7.24	O
)	O
,	O
and	O
five	O
aromatic	O
protons	O
(	O
δ	O
H	O
6.72–7.10	O
)	O
.	O

The	O
J	O
value	O
of	O
15.7	O
Hz	O
of	O
olefinic	O
protons	O
(	O
H-7′	O
and	O
H-8′	O
)	O
revealed	O
a	O
trans	O
geometry	O
of	O
the	O
double	O
bond	O
between	O
C-7′	O
and	O
C-8′.	O
The	O
13	O
C	O
NMR	O
spectrum	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
revealed	O
20	O
signals	O
which	O
were	O
classified	O
by	O
the	O
DEPT	O
technique	O
as	O
nine	O
methine	O
,	O
one	O
methylene	O
,	O
two	O
methyl	O
,	O
and	O
eight	O
quaternary	O
carbons	O
.	O

The	O
1	O
H–1	O
H	O
COSY	O
spectrum	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
revealed	O
a	O
partial	O
structure	O
from	O
H-2	O
to	O
H-4	O
,	O
and	O
the	O
existence	O
of	O
an	O
ABX	O
system	O
of	O
the	O
aromatic	O
ring	O
A	O
,	O
as	O
well	O
as	O
a	O
meta	O
coupling	O
between	O
aromatic	O
protons	O
H-2′	O
and	O
H-4′.	O
The	O
HMBC	O
spectral	O
data	O
(	O
optimized	O
for	O
n	O
J	O
HC	O
=	O
8.0	O
Hz	O
)	O
of	O
torvanol	B
(	O
1	O
)	O
showed	O
correlations	O
of	O
H-2	O
to	O
C-4	O
and	O
C-1′	O
;	O
H-3	O
to	O
C-4a	O
and	O
C-1′	O
;	O
H-4	O
to	O
C-2	O
and	O
C-5	O
;	O
H-5	O
to	O
C-4	O
,	O
C-7	O
and	O
C-8a	O
;	O
H-7	O
to	O
C-5	O
and	O
C-8a	O
;	O
H-8	O
to	O
C-4a	O
and	O
C-6	O
;	O
both	O
H-2′	O
and	O
H-4′	O
to	O
C-6′	O
and	O
C-7′	O
;	O
H-7′	O
to	O
C-2′	O
,	O
C-4′	O
and	O
C-9′	O
;	O
and	O
H-8′	O
to	O
C-3′.	O
These	O
1	O
H–1	O
H	O
COSY	O
and	O
HMBC	O
spectral	O
data	O
readily	O
revealed	O
that	O
torvanol	B
A	I
(	O
1	O
)	O
possesses	O
an	O
isoflavonoid	B
skeleton	I
.	O

Both	O
methoxy	B
groups	I
were	O
assigned	O
by	O
analyses	O
of	O
the	O
HMBC	O
and	O
NOESY	O
spectral	O
data	O
.	O

The	O
HMBC	O
spectrum	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
showed	O
correlation	O
of	O
6-OMe	O
protons	O
to	O
C-6	O
,	O
and	O
5′-OMe	O
protons	O
to	O
C-5′	O
,	O
while	O
the	O
NOESY	O
spectrum	O
of	O
(	O
1	O
)	O
revealed	O
cross	O
peaks	O
between	O
6-OMe	O
protons	O
and	O
H-5	O
,	O
as	O
well	O
as	O
between	O
5′-OMe	O
protons	O
and	O
H-4′.	O
The	O
chemical	O
shifts	O
at	O
C-4	O
(	O
δ	O
H	O
5.53	O
and	O
δ	O
C	O
88.3	O
)	O
suggested	O
the	O
presence	O
of	O
an	O
ester	O
in	O
torvanol	O
A	O
(	O
1	O
)	O
,	O
however	O
,	O
there	O
were	O
no	O
further	O
carbon	O
resonances	O
on	O
the	O
13	O
C	O
NMR	O
of	O
torvanol	O
A	O
(	O
1	O
)	O
,	O
implying	O
the	O
existence	O
of	O
an	O
inorganic	O
ester	O
in	O
1	O
.	O

The	O
accurate	O
mass	O
of	O
m	O
/z	O
451.0677	O
[	O
(	O
M	O
–	O
H	O
)	O
−	O
,	O
Δ−2.2	O
mmu	O
]	O
obtained	O
from	O
the	O
ESITOF	O
mass	O
spectrum	O
(	O
negative	O
ion	O
mode	O
)	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
revealed	O
a	O
molecular	O
formula	O
of	O
1	O
as	O
C20	O
H20	O
O10	O
S	O
,	O
suggesting	O
that	O
1	O
possessed	O
a	O
sulfate	B
ester	I
.	O

The	O
IR	O
spectrum	O
of	O
1	O
indicated	O
the	O
presence	O
of	O
hydroxyl	B
groups	I
(	O
ν	O
max	O
3448	O
cm−1	O
)	O
,	O
conjugated	B
carbonyl	I
(	O
ν	O
max	O
1638	O
cm−1	O
)	O
,	O
and	O
sulfate	B
ester	I
(	O
ν	O
max	O
1256	O
cm−1	O
)	O
.	O

The	O
presence	O
of	O
a	O
sulfate	B
ester	I
group	I
was	O
also	O
indicated	O
by	O
the	O
EIMS	O
spectrum	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
,	O
showing	O
the	O
prominent	O
peak	O
of	O
the	O
fragment	O
ion	O
at	O
m	O
/z	O
355	O
[	O
M-97	O
]	O
,	O
due	O
to	O
the	O
loss	O
of	O
[	O
HSO4	O
]	O
−	O
.	O

The	O
solubility	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
in	O
water	O
suggested	O
that	O
1	O
existed	O
in	O
the	O
form	O
of	O
a	O
sulfate	B
salt	I
.	O

Analysis	O
by	O
an	O
atomic	O
absorption	O
spectrophotometer	O
revealed	O
that	O
1	O
was	O
a	O
potassium	B
salt	I
,	O
showing	O
the	O
stoichiometric	O
ratio	O
ca	O
.	O

1:1	O
(	O
torvanol	B
A	I
(	O
1	O
)	O
and	O
K	B
)	O
.	O

On	O
the	O
basis	O
of	O
these	O
spectral	O
data	O
,	O
the	O
chemical	O
structure	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
was	O
therefore	O
secured	O
.	O

The	O
assignments	O
of	O
protons	O
and	O
carbons	O
of	O
torvanol	B
A	I
(	O
1	O
)	O
are	O
shown	O
in	O
Table	O
1	O
.	O

The	O
3	O
J	O
3,4	O
value	O
of	O
6.4	O
Hz	O
suggested	O
a	O
pseudo	O
axial	O
orientation	O
of	O
H-4	O
,	O
and	O
the	O
respective	O
J	O
H-2ax	O
,	O
H-3	O
and	O
J	O
H-2eq	O
,	O
H-3	O
of	O
7.0	O
and	O
4.7	O
Hz	O
revealed	O
that	O
H-3	O
was	O
also	O
pseudo	O
axial	O
.	O

The	O
NOESY	O
spectrum	O
of	O
torvanol	O
A	O
(	O
1	O
)	O
showed	O
correlations	O
between	O
H-4	O
and	O
H-2ax	O
,	O
and	O
H-3	O
and	O
H-2eq	O
,	O
supporting	O
the	O
proposed	O
relative	O
stereochemistry	O
.	O

The	O
1	O
H	O
NMR	O
spectrum	O
(	B
pyridine	I
-	I
d	I
5	I
)	O
of	O
torvoside	B
H	I
(	O
3	O
)	O
(	O
[	O
α	O
]	O
29	O
D	O
−58.15	O
°	O
,	O
c	O
0.114	O
in	O
MeOH	B
)	O
was	O
similar	O
to	O
that	O
of	O
the	O
known	O
glycoside	B
,	O
torvoside	B
A	I
(	O
2	O
)	O
(	O
[	O
α	O
]	O
29	O
D	O
−50.16	O
°	O
,	O
c	O
0.123	O
in	O
MeOH	O
)	O
.	O

The	O
13	O
C	O
NMR	O
spectrum	O
of	O
torvoside	B
H	I
(	O
3	O
)	O
and	O
that	O
of	O
2	O
were	O
also	O
similar	O
,	O
except	O
that	O
the	O
hydroxy	B
bearing	I
carbon	I
signal	O
at	O
δ	O
C	O
ca	O
.	O

71.0	O
(	O
C-3	O
)	O
in	O
2	O
was	O
replaced	O
by	O
a	O
signal	O
at	O
δ	O
C	O
210.7	O
in	O
3	O
,	O
characteristic	O
of	O
a	O
ketone	B
functionality	O
.	O

The	O
ketone	O
moiety	O
was	O
also	O
confirmed	O
by	O
an	O
absorption	O
peak	O
at	O
1702	O
cm−1	O
in	O
the	O
IR	O
spectrum	O
of	O
3	O
.	O

The	O
ESITOF	O
mass	O
spectral	O
data	O
(	O
negative	O
ion	O
mode	O
)	O
revealed	O
quasi	O
-	O
molecular	O
ions	O
at	O
m	O
/z	O
901	O
[	O
M	O
–	O
H	O
]	O
−	O
for	O
torvoside	B
H	I
(	O
3	O
)	O
and	O
903	O
[	O
M	O
–	O
H	O
]	O
−	O
for	O
torvoside	B
A	I
(	O
2	O
)	O
,	O
implying	O
the	O
hydroxyl	B
group	I
at	O
C-3	O
in	O
2	O
was	O
a	O
ketone	B
in	O
3	O
.	O

On	O
enzymatic	O
hydrolysis	O
with	O
β	O
-glucosidase	O
,	O
torvoside	B
H	I
(	O
3	O
)	O
gave	O
glucose	B
and	O
compound	O
5	O
,	O
suggesting	O
that	O
3	O
possessed	O
a	O
glucose	B
unit	I
at	O
C-26	O
,	O
which	O
is	O
the	O
same	O
as	O
that	O
of	O
torvoside	B
A	I
(	O
2	O
)	O
(	O
Yahara	O
et	O
al.	O
,	O
1996	O
)	O
.	O

The	O
ESITOF	O
mass	O
spectrum	O
(	O
negative	O
ion	O
mode	O
)	O
established	O
the	O
molecular	O
formula	O
of	O
compound	B
5	I
as	O
C39	O
H62	O
O12	O
,	O
showing	O
an	O
accurate	O
mass	O
at	O
m	O
/z	O
721.4155	O
[	O
(	O
M	O
–	O
H	O
)	O
−	O
,	O
Δ−0.8	O
mmu	O
]	O
.	O

The	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectral	O
data	O
of	O
5	O
were	O
less	O
complex	O
than	O
that	O
of	O
torvoside	B
H	I
(	O
3	O
)	O
,	O
particularly	O
in	O
the	O
sugar	O
's	O
resonances	O
,	O
which	O
enabled	O
the	O
assignment	O
of	O
protons	O
and	O
carbons	O
in	O
5	O
.	O

Analyses	O
of	O
DEPT	O
,	O
1	O
H–1	O
H	O
COSY	O
,	O
HMQC	O
and	O
HMBC	O
spectral	O
data	O
led	O
to	O
a	O
complete	O
assignment	O
of	O
both	O
protons	O
and	O
carbons	O
in	O
the	O
molecule	O
(	O
Table	O
2	O
)	O
.	O

Important	O
1	O
H–13	O
C	O
long	O
-	O
ranged	O
correlations	O
on	O
the	O
HMBC	O
spectrum	O
of	O
compound	B
5	I
were	O
as	O
follows	O
:	O
H-2	O
and	O
H-4	O
to	O
C-3	O
;	O
H-4	O
to	O
C-6	O
;	O
H-18	O
to	O
C-1	O
and	O
C-5	O
;	O
H-19	O
to	O
C-12	O
,	O
C-14	O
and	O
C-17	O
;	O
H-16	O
to	O
C-20	O
;	O
H-21	O
to	O
C-17	O
and	O
C-22	O
;	O
H-24	O
to	O
C-22	O
;	O
and	O
H-26	O
to	O
C-22	O
,	O
C-24	O
and	O
C-27	O
.	O

The	O
HMBC	O
spectrum	O
of	O
5	O
also	O
demonstrated	O
the	O
correlation	O
of	O
the	O
anomeric	O
proton	O
(	O
H	O
-	O
qui1	O
)	O
of	O
quinovose	B
to	O
C-6	O
and	O
that	O
of	O
the	O
anomeric	O
proton	O
(	O
H	O
-	O
rha1	O
)	O
of	O
rhamnose	B
to	O
C	O
-	O
qui3	O
.	O

These	O
HMBC	O
correlations	O
provided	O
useful	O
information	O
concerning	O
connectivities	O
between	O
quinovose	B
and	O
the	O
steroidal	B
aglycone	I
(	O
linkage	O
at	O
C-6	O
)	O
,	O
as	O
well	O
as	O
that	O
between	O
quinovose	B
and	O
rhamnose	B
(	I
1→3	I
linkage	I
)	I
.	O

The	O
downfield	O
shifts	O
of	O
H	O
-	O
qui3	O
(	O
at	O
δ	O
H	O
4.21	O
)	O
and	O
C	O
-	O
qui3	O
(	O
at	O
δ	O
C	O
83.7	O
)	O
in	O
the	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
of	O
5	O
also	O
indicated	O
the	O
connectivity	O
(	O
1→3	O
)	O
of	O
the	O
two	O
sugars	O
.	O

As	O
for	O
the	O
relative	O
configuration	O
of	O
the	O
sugars	O
in	O
5	O
,	O
the	O
J	O
H	O
-	O
qui1,H	O
-	O
qui2	O
(	O
7.8	O
Hz	O
)	O
,	O
J	O
H	O
-	O
qui2,H	O
-	O
qui3	O
(	O
9.0	O
Hz	O
)	O
and	O
J	O
H	O
-	O
qui3,H	O
-	O
qui4	O
(	O
9.0	O
Hz	O
)	O
,	O
revealed	O
axial	O
orientations	O
of	O
H	O
-	O
qui1	O
,	O
H	O
-	O
qui2	O
,	O
H	O
-	O
qui3	O
and	O
H	O
-	O
qui4	O
,	O
respectively	O
,	O
while	O
those	O
of	O
J	O
H	O
-	O
rha2,H	O
-	O
rha3	O
(	O
3.2	O
Hz	O
)	O
,	O
J	O
H	O
-	O
rha3,H	O
-	O
rha4	O
(	O
9.3	O
Hz	O
)	O
and	O
J	O
H	O
-	O
rha4,H	O
-	O
rha5	O
(	O
9.3	O
Hz	O
)	O
readily	O
indicated	O
the	O
respective	O
configurations	O
of	O
H-2	O
,	O
H-3	O
,	O
H-4	O
and	O
H-5	O
as	O
equatorial	O
,	O
axial	O
,	O
axial	O
and	O
axial	O
.	O

Finally	O
,	O
the	O
presence	O
of	O
quinovose	O
and	O
rhamnose	O
(	O
1→3	O
linkage	O
)	O
in	O
5	O
was	O
confirmed	O
by	O
comparison	O
of	O
the	O
13	O
C	O
signals	O
with	O
those	O
of	O
published	O
values	O
(	O
Yahara	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Torvoside	O
H	O
(	O
3	O
)	O
exhibited	O
a	O
negative	O
optical	O
rotation	O
similar	O
to	O
that	O
of	O
torvoside	O
A	O
(	O
2	O
)	O
,	O
it	O
is	O
therefore	O
not	O
unreasonable	O
to	O
assume	O
that	O
the	O
absolute	O
configurations	O
of	O
all	O
sugars	O
in	O
3	O
are	O
the	O
same	O
as	O
those	O
in	O
2	O
.	O

On	O
the	O
basis	O
of	O
these	O
spectral	O
data	O
,	O
compound	B
5	I
is	O
(	B
25S	I
)	I
-6α	I
-hydroxy-5α	I
-spirostan-3-one	I
6-O	I
-	I
[	I
α	I
-l	I
-rhamnopyranosyl-	I
(	I
1→3	I
)	I
-β	I
-d	I
-quinovopyranoside	I
]	I
,	O
and	O
torvoside	B
H	I
(	O
3	O
)	O
is	O
therefore	O
(	B
25S	I
)	I
-26-O	I
-	I
(	I
β	I
-d	I
-glucopyranosyl	I
)	I
-6α	I
,	I
26-dihydroxy-5α	I
-spirostan-3-one	I
6-O	I
-	I
[	I
α	I
-l	I
-rhamnopyranosyl-	I
(	I
1→3	I
)	I
-β	I
-D	I
-	I
quinovopyranoside	I
]	I
.	O

Torvanol	B
A	I
(	O
1	O
)	O
,	O
torvoside	B
H	I
(	O
3	O
)	O
and	O
compound	B
5	I
exhibited	O
antiviral	O
activity	O
(	O
herpes	O
simplex	O
virus	O
type	O
1	O
)	O
with	O
the	O
IC50	O
values	O
of	O
9.6	O
,	O
23.2	O
and	O
17.4	O
μg	O
/	O
ml	O
,	O
respectively	O
.	O

Compounds	O
1	O
–5	O
were	O
inactive	O
(	O
at	O
50	O
μg	O
/	O
ml	O
)	O
against	O
BC	O
,	O
KB	O
and	O
Vero	O
cell	O
lines	O
.	O

Recently	O
,	O
antiviral	O
activity	O
(	O
herpes	O
virus	O
)	O
of	O
Solanum	B
steroidal	I
glycosides	I
has	O
been	O
demonstrated	O
(	O
Ikeda	O
et	O
al.	O
,	O
2000	O
)	O
,	O
while	O
Chah	O
et	O
al.	O
(	O
2000	O
)	O
reported	O
an	O
antimicrobial	O
activity	O
of	O
the	O
methanolic	B
extract	O
of	O
S.	O
torvum	O
fruits	O
.	O

3	O
Experimental	O
3.1	O
General	O
The	O
1	B
H	I
,	O
13	B
C	I
,	O
DEPTs	O
,	O
1	O
H–1	O
H	O
COSY	O
,	O
NOESY	O
,	O
HMQC	O
(	O
optimized	O
for	O
1	O
J	O
HC	O
=	O
145	O
Hz	O
)	O
and	O
HMBC	O
(	O
optimized	O
for	O
n	O
J	O
HC	O
=	O
8.0	O
Hz	O
as	O
well	O
as	O
4.0	O
Hz	O
)	O
spectra	O
were	O
recorded	O
on	O
a	O
Bruker	O
DRX	O
400	O
,	O
operating	O
at	O
400.1	O
MHz	O
for	O
proton	B
and	O
100.6	O
MHz	O
for	O
carbon	B
.	O

The	O
ESITOF	O
mass	O
spectra	O
were	O
obtained	O
from	O
a	O
Micromass	O
LCT	O
mass	O
spectrometer	O
,	O
while	O
the	O
IR	O
spectra	O
were	O
measured	O
on	O
a	O
Perkin	O
-	O
Elmer	O
2000	O
spectrometer	O
.	O

An	O
HPLC	O
pump	O
(	O
Waters	O
600	O
)	O
was	O
equipped	O
with	O
a	O
UV	O
-	O
photodiode	O
array	O
detector	O
(	O
Waters	O
996	O
)	O
.	O

The	O
metal	B
composition	O
in	O
torvanol	B
A	I
(	O
1	O
)	O
was	O
analyzed	O
with	O
a	O
Perkin	O
Elmer	O
(	O
model	O
3100	O
)	O
flame	O
atomic	O
absorption	O
spectrometer	O
.	O

3.2	O
Plant	O
specimen	O
,	O
extraction	O
and	O
isolation	O
Fresh	O
fruits	O
(	O
2.5	O
kg	O
)	O
of	O
S.	O
torvum	O
Swartz	O
were	O
bought	O
from	O
Pak	O
Klong	O
Talad	O
Market	O
,	O
Bangkok	O
,	O
Thailand	O
.	O

Crushed	O
fruits	O
were	O
macerated	O
in	O
MeOH	B
(	O
6	O
l	O
)	O
for	O
2	O
days	O
at	O
room	O
temperature	O
.	O

The	O
extract	O
was	O
evaporated	O
,	O
and	O
dissolved	O
in	O
70	O
%	O
aqueous	O
MeOH	B
,	O
which	O
was	O
sequentially	O
extracted	O
with	O
hexane	B
and	O
EtOAc	B
(	O
equal	O
volume	O
,	O
three	O
times	O
)	O
.	O

Aqueous	O
MeOH	B
,	O
hexane	B
,	O
and	O
EtOAc	B
layers	O
were	O
evaporated	O
to	O
dryness	O
,	O
to	O
give	O
respective	O
yields	O
of	O
15.3	O
,	O
10.0	O
,	O
and	O
5.5	O
g.	O
A	O
crude	O
extract	O
of	O
the	O
aqueous	O
MeOH	B
layer	O
was	O
applied	O
to	O
a	O
Sephadex	B
LH-20	I
column	O
(	O
eluted	O
with	O
MeOH	B
)	O
.	O

Twenty	O
fractions	O
(	O
ca	O
.	O
100	O
ml	O
)	O
were	O
collected	O
and	O
evaporated	O
to	O
dryness	O
in	O
vacuo	O
.	O

Fractions	O
15–20	O
containing	O
torvanol	B
A	I
(	O
1	O
)	O
were	O
combined	O
,	O
and	O
subsequently	O
purified	O
by	O
preparative	O
HPLC	O
(	O
C18	O
reversed	O
phase	O
column	O
,	O
Prep	O
Nova	O
Pak	O
,	O
Waters	O
)	O
using	O
H2	B
O	I
:	O
MeOH	B
(	O
90:10	O
,	O
v	O
/	O
v	O
)	O
as	O
eluent	O
,	O
yielding	O
torvanol	B
A	I
(	O
1	O
)	O
(	O
25	O
mg	O
)	O
.	O

Fractions	O
3–6	O
obtaining	O
from	O
Sephadex	B
LH-20	I
column	O
were	O
further	O
purified	O
by	O
MPLC	O
(	O
C18	O
reversed	O
phase	O
column	O
)	O
using	O
H2	B
O	I
:	O
MeOH	B
(	O
60:40	O
,	O
v	O
/	O
v	O
)	O
as	O
eluent	O
,	O
to	O
yield	O
torvoside	B
A	I
(	O
2	O
)	O
(	O
2.1	O
g	O
)	O
and	O
torvoside	B
H	I
(	O
3	O
)	O
(	O
0.2	O
g	O
)	O
.	O

3.3	O
Bioassay	O
The	O
cytotoxic	O
assay	O
employed	O
the	O
colorimetric	O
method	O
(	O
Skehan	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Ellipticine	B
,	O
the	O
reference	O
substance	O
,	O
exhibited	O
activity	O
toward	O
BC	O
and	O
KB	O
cell	O
lines	O
,	O
both	O
with	O
the	O
IC50	O
of	O
0.3	O
μg	O
/	O
ml	O
.	O

Antiviral	O
activity	O
was	O
also	O
assessed	O
employing	O
the	O
colorimetric	O
method	O
(	O
Skehan	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
was	O
maintained	O
in	O
the	O
Vero	O
cell	O
line	O
(	O
kidney	O
fibroblast	O
of	O
an	O
African	O
green	O
monkey	O
)	O
,	O
which	O
was	O
cultured	O
in	O
Eagle	B
's	I
minimum	I
essential	I
medium	I
(	O
MEM	O
)	O
with	O
addition	O
of	O
heat	O
-	O
inactivated	O
fetal	B
bovine	I
serum	I
(	O
FBS	O
)	O
(	O
10	O
%	O
)	O
and	O
antibiotics	B
.	O

The	O
test	O
samples	O
were	O
put	O
into	O
wells	O
of	O
a	O
microtiter	O
plate	O
at	O
the	O
final	O
concentrations	O
ranging	O
from	O
20	O
to	O
50	O
μg	O
/	O
ml	O
.	O

The	O
viral	O
HSV-1	O
(	O
30	O
PFU	O
)	O
was	O
added	O
into	O
the	O
96-well	O
plate	O
,	O
followed	O
by	O
plating	O
of	O
Vero	O
cells	O
(	O
1	O
×	O
105	O
cells	O
/	O
ml	O
)	O
;	O
the	O
final	O
volume	O
was	O
200	O
μl	O
.	O

After	O
incubation	O
at	O
37	O
°	O
C	O
for	O
72	O
h	O
,	O
under	O
5	O
%	O
of	O
CO2	B
atmosphere	O
,	O
cells	O
were	O
fixed	O
and	O
stained	O
,	O
and	O
optical	O
density	O
was	O
measured	O
at	O
510	O
nm	O
.	O

Under	O
our	O
screening	O
conditions	O
,	O
the	O
reference	O
compound	O
,	O
Acyclovir	B
,	O
typically	O
exhibited	O
the	O
antiviral	O
HSV-1	O
with	O
the	O
IC50	O
of	O
2	O
-	O
5	O
μg	O
/	O
ml	O
.	O

3.4	O
Torvanol	B
A	I
(	O
1	O
)	O
Amorphous	O
powder	O
:	O
mp	O
>	O
300	O
°	O
C	O
[	O
α	O
]	O
29	O
D	O
−50	O
°	O
(	O
c	O
0.280	O
,	O
H2	O
O	O
)	O
;	O
IR	O
ν	O
max	O
cm−1	O
:	O
3448	O
,	O
2362	O
,	O
1638	O
,	O
1610	O
,	O
1545	O
,	O
1499	O
,	O
1389	O
,	O
1330	O
,	O
1256	O
,	O
1145	O
,	O
1065	O
,	O
985	O
,	O
851	O
,	O
822	O
,	O
761	O
;	O
UV	O
(	O
MeOH	O
)	O
λ	O
max	O
nm	O
:	O
203	O
,	O
234	O
,	O
283	O
;	O
ESITOF	O
MS	O
(	O
negative	O
ion	O
mode	O
)	O
:	O
m	O
/z	O
451.0677	O
,	O
calc	O
.	O

for	O
C20	O
H19	O
O10	O
S	O
(	O
M	O
–	O
H	O
)	O
−	O
,	O
free	O
acid	O
form	O
,	O
451.0699	O
;	O
for	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
(	O
Table	O
1	O
)	O
.	O

3.5	O
Torvoside	B
H	I
(	O
3	O
)	O
and	O
its	O
derivative	B
(	I
5	I
)	I
Torvoside	B
H	I
(	O
3	O
)	O
was	O
obtained	O
as	O
an	O
amorphous	O
powder	O
:	O
mp	O
170–172	O
°	O
C	O
[	O
α	O
]	O
29	O
D	O
−58.15	O
°	O
(	O
c	O
0.114	O
,	O
MeOH	O
)	O
;	O
IR	O
ν	O
max	O
cm−1	O
:	O
3422	O
,	O
2932	O
,	O
1702	O
,	O
1655	O
,	O
1648	O
,	O
1458	O
,	O
1420	O
,	O
1381	O
,	O
1074	O
;	O
ESITOF	O
MS	O
(	O
negative	O
ion	O
mode	O
)	O
:	O
m	O
/z	O
901.465	O
,	O
calc	O
.	O

for	O
C45	O
H73	O
O18	O
(	O
M	O
–	O
H	O
)	O
−	O
,	O
901.479	O
;	O
for	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
(	O
Table	O
2	O
)	O
.	O

Torvoside	B
H	I
(	O
3	O
)	O
(	O
70	O
mg	O
)	O
was	O
incubated	O
with	O
commercial	O
almond	O
β	O
-	O
glucosidase	O
(	O
7	O
mg	O
)	O
in	O
H2	B
O	I
(	O
12.5	O
ml	O
)	O
at	O
37	O
°	O
C	O
for	O
24	O
h.	O
After	O
evaporation	O
of	O
the	O
solvent	O
,	O
the	O
reaction	O
mixture	O
was	O
applied	O
to	O
a	O
silica	B
gel	I
column	O
,	O
eluted	O
with	O
CHCl3	B
:	O
MeOH	B
(	O
3:1	O
)	O
,	O
to	O
give	O
β	B
-	I
d	I
-glucose	I
and	O
a	O
derivative	B
5	I
(	O
mp	O
180–183	O
°	O
C	O
;	O
[	O
α	O
]	O
29	O
D	O
−63.72	O
°	O
,	O
c	O
0.113	O
in	O
MeOH	O
)	O
,	O
ESITOF	O
MS	O
(	O
negative	O
ion	O
mode	O
)	O
:	O
m	O
/z	O
721.4155	O
,	O
calc	O
.	O

for	O
C39	O
H61	O
O12	O
(	O
M	O
-	O
H	O
)	O
−	O
,	O
721.4163	O
;	O
1	O
H	O
and	O
13	O
C	O
NMR	O
(	O
Table	O
2	O
)	O
.	O

Acknowledgements	O
This	O
work	O
is	O
a	O
project	O
of	O
the	O
Center	O
for	O
Protein	O
Structure	O
and	O
Function	O
at	O
the	O
Faculty	O
of	O
Science	O
,	O
Mahidol	O
University	O
.	O

We	O
are	O
grateful	O
to	O
the	O
Biodiversity	O
Research	O
and	O
Training	O
Program	O
(	O
BRT	O
)	O
,	O
BIOTEC	O
/	O
NSTDA	O
for	O
financial	O
support	O
.	O

D.A.	O
received	O
a	O
scholarship	O
from	O
the	O
Chulabhorn	O
Research	O
Institute	O
.	O

Y.T.	O
thanks	O
the	O
National	O
Science	O
and	O
Technology	O
Development	O
Agency	O
(	O
NSTDA	O
)	O
for	O
the	O
Senior	O
Research	O
Fellowship	O
Award	O
.	O

J.S.	O
is	O
a	O
Senior	O
Research	O
Fellow	O
of	O
the	O
Thailand	O
Research	O
Fund	O
.	O

Since	O
arachidonic	B
acid	I
(	O
20:4n-6	B
,	O
AA	B
)	O
and	O
docosahexaenoic	B
acid	I
(	O
22:6n-3	B
,	O
DHA	B
)	O
compose	O
the	O
major	O
portion	O
of	O
polyunsaturated	B
fatty	I
acids	I
(	O
PUFA	B
)	O
in	O
brain	O
lipids	B
,	O
these	O
PUFAs	B
are	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
functions	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Most	O
importantly	O
,	O
DHA	B
has	O
been	O
demonstrated	O
to	O
be	O
essential	O
in	O
maintaining	O
normal	O
functions	O
of	O
CNS	O
,	O
which	O
has	O
been	O
demonstrated	O
by	O
the	O
impairment	O
of	O
memory	O
functions	O
occurring	O
in	O
experimental	O
rodents	O
with	O
n-3	B
PUFA	I
deficiency	O
[	O
1,2	O
]	O
.	O

However	O
,	O
the	O
biochemical	O
basis	O
of	O
the	O
essentiality	O
of	O
DHA	B
in	O
the	O
functions	O
of	O
CNS	O
has	O
not	O
been	O
defined	O
.	O

On	O
the	O
other	O
hand	O
,	O
AA	B
itself	O
or	O
AA	B
-	I
derived	I
eicosanoids	I
modulates	O
neurotransmission	O
[	O
3,4	O
]	O
.	O

Therefore	O
,	O
the	O
functions	O
of	O
CNS	O
may	O
be	O
modified	O
by	O
dietary	O
supplementation	O
with	O
n-3	B
PUFA	I
,	O
which	O
antagonizes	O
the	O
metabolism	O
and	O
actions	O
of	O
AA	B
[	O
5	O
]	O
.	O

Δ9	B
-Tetrahydrocannabinol	I
,	O
a	O
psychoactive	O
compound	O
derived	O
from	O
marijuana	O
,	O
acts	O
through	O
either	O
the	O
CB1	O
or	O
CB2	O
receptor	O
;	O
the	O
former	O
is	O
highly	O
expressed	O
in	O
areas	O
of	O
CNS	O
[	O
6	O
]	O
and	O
the	O
latter	O
is	O
localized	O
mainly	O
in	O
peripheral	O
immune	O
cells	O
[	O
7	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
discovery	O
of	O
endogenous	O
ligands	B
of	O
cannabinoid	O
receptors	O
in	O
the	O
brain	O
has	O
facilitated	O
the	O
progress	O
of	O
research	O
on	O
the	O
regulation	O
of	O
cannabinoid	O
-	O
receptor	O
-	O
mediated	O
neuronal	O
functions	O
.	O

Recently	O
,	O
two	O
arachidonic	B
acid	I
(	O
20:4n-6	B
,	I
AA	B
)	O
-containing	O
compounds	O
,	O
anandamide	B
,	O
(	O
N	B
-arachidonoylethanolamine	I
)	I
and	O
2-arachidonoylglycerol	B
(	O
2-AG	B
)	O
,	O
have	O
been	O
identified	O
as	O
the	O
endogenous	O
ligands	O
for	O
cannabinoid	O
receptors	O
and	O
these	O
molecules	O
have	O
been	O
detected	O
in	O
various	O
brain	O
regions	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
Sugiura	O
and	O
colleague	O
demonstrated	O
that	O
2-AG	B
is	O
the	O
major	O
monoacylglycerol	B
(	O
MG	B
)	O
molecular	O
species	O
in	O
the	O
rat	O
brain	O
and	O
its	O
potencies	O
for	O
CB1	O
and	O
CB2	O
receptors	O
are	O
much	O
greater	O
than	O
those	O
of	O
anandamide	B
[	O
9–11	O
]	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
reported	O
that	O
MG	B
molecular	O
species	O
containing	O
fatty	B
acids	I
other	O
than	O
AA	B
are	O
less	O
potent	O
for	O
both	O
CB1	O
and	O
CB2	O
receptors	O
[	O
10,11	O
]	O
.	O

Therefore	O
,	O
it	O
can	O
be	O
assumed	O
that	O
2-AG	B
plays	O
a	O
dominant	O
role	O
in	O
the	O
regulation	O
of	O
cannabinoid	O
receptor	O
functions	O
in	O
the	O
brain	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
sequential	O
hydrolysis	O
of	O
arachidonate	B
-	I
containing	I
phospholipids	I
is	O
one	O
of	O
the	O
major	O
biosynthetic	O
pathways	O
of	O
2-AG	B
in	O
the	O
brain	O
[	O
12,13	O
]	O
although	O
the	O
candidate	O
of	O
precursor	O
phospholipid	B
classes	O
as	O
well	O
as	O
the	O
enzymes	O
involved	O
in	O
2-AG	B
biosynthesis	O
have	O
not	O
been	O
identified	O
.	O

On	O
the	O
other	O
hand	O
,	O
MG	B
species	O
containing	O
EPA	B
and	O
DHA	B
were	O
demonstrated	O
to	O
be	O
less	O
potent	O
for	O
cannabinoid	O
receptors	O
than	O
2-AG	B
[	O
10,11	O
]	O
.	O

Therefore	O
,	O
the	O
manipulation	O
of	O
dietary	O
n-3	B
PUFA	I
status	O
may	O
change	O
the	O
levels	O
of	O
2-AG	B
as	O
well	O
as	O
n-3	B
PUFA	I
-	O
containing	O
MG	B
in	O
tissues	O
,	O
which	O
indicates	O
the	O
alteration	O
of	O
endogenous	O
ligand	O
activity	O
for	O
cannabinoid	O
receptors	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
determined	O
the	O
effects	O
of	O
chronic	O
n-3	B
PUFA	I
deficiency	O
and	O
short	O
-	O
term	O
supplementation	O
with	O
a	O
DHA	B
-	O
rich	O
diet	O
on	O
brain	O
2-AG	B
levels	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
fatty	B
acid	I
composition	O
of	O
brain	O
phospholipids	B
in	O
mice	O
under	O
different	O
dietary	O
n-3	B
PUFA	I
status	O
in	O
order	O
to	O
differentiate	O
the	O
levels	O
of	O
2-AG	B
in	O
their	O
brains	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Preparation	O
of	O
monoacylglycerol	B
standards	O
Triarachidonoylglycerol	B
,	O
trieicosapentaenoylglycerol	B
or	O
tridocosahexaenoylglycerol	B
(	O
Nu	O
-	O
Chek	O
-	O
Prep	O
Inc.	O
,	O
Elysian	O
,	O
MN	O
)	O
was	O
treated	O
with	O
lipase	O
from	O
Rhizopus	O
arrhizus	O
(	O
Type	O
XI	O
,	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
as	O
described	O
by	O
Schmid	O
et	O
al.	O
[	O
14	O
]	O
.	O

The	O
2-acyl	B
form	I
of	I
MG	I
was	O
the	O
primary	O
product	O
in	O
the	O
treatment	O
of	O
triacylglycerol	B
with	O
the	O
lipase	O
,	O
although	O
a	O
small	O
amount	O
of	O
the	O
1	B
(	I
3	I
)	I
-acyl	I
form	I
of	I
MG	I
was	O
generated	O
due	O
to	O
spontaneous	O
migration	O
of	O
the	O
acyl	B
moiety	O
from	O
the	O
Sn	O
-2	O
position	O
to	O
the	O
Sn	O
-1	O
(	O
3	O
)	O
position	O
.	O

The	O
1	B
(	I
3	I
)	I
-	I
and	O
2-acyl	B
forms	I
of	I
MG	I
generated	O
during	O
the	O
lipase	O
treatment	O
of	O
triacylglycerols	B
were	O
extracted	O
from	O
the	O
reaction	O
mixture	O
with	O
diethylether	B
and	O
separated	O
from	O
each	O
other	O
by	O
silica	B
gel	I
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
using	O
a	O
mixture	O
of	O
CHCl3	B
/ethylacetate	O
/	O
trimethoxyborane	B
(	O
100:20:7	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
[	O
15	O
]	O
as	O
a	O
developing	O
solvent	O
.	O

Each	O
MG	B
was	O
recovered	O
from	O
the	O
adsorbents	O
by	O
the	O
method	O
of	O
Bligh	O
and	O
Dyer	O
[	O
16	O
]	O
.	O

The	O
1	B
(	I
3	I
)	I
-	I
and	O
2-acyl	B
forms	I
of	B
monopalmitoylglycerol	B
and	O
monooleoylglycerol	B
were	O
purchased	O
from	O
Nu	O
-	O
Chek	O
-	O
Prep	O
and	O
Sigma	O
,	O
respectively	O
,	O
which	O
were	O
purified	O
by	O
the	O
above	O
-	O
mentioned	O
silica	B
gel	I
TLC	O
before	O
use	O
.	O

1-Heptadecanoylglycerol	B
(	O
Nu	O
-	O
Chek	O
-	O
Prep	O
Inc.	O
)	O
was	O
used	O
as	O
an	O
internal	O
standard	O
for	O
quantification	O
.	O

The	O
purity	O
and	O
quantity	O
of	O
all	O
the	O
MG	B
standards	O
used	O
were	O
determined	O
by	O
gas	O
–	O
liquid	O
chromatography	O
as	O
fatty	B
acid	I
methylesters	I
prepared	O
by	O
transmethylation	O
using	O
methanolic	B
HCl	B
(	O
5	O
%	O
,	O
w	O
/	O
v	O
)	O
in	O
the	O
presence	O
of	O
hepadecanoic	B
acid	I
(	O
17:0	B
)	O
.	O

2.2	O
Preparation	O
of	O
MG	B
dibenzoates	I
The	O
dried	O
MG	B
sample	O
was	O
treated	O
with	O
25	O
μl	O
of	O
benzoylchloride	B
(	O
Nakalai	O
Tesque	O
,	O
Tokyo	O
)	O
in	O
the	O
presence	O
of	O
200	O
μl	O
of	O
anhydrous	O
pyridine	B
(	O
Wako	O
Pure	O
Chem	O
.	O

Osaka	O
,	O
Japan	O
)	O
for	O
15	O
min	O
at	O
60	O
°	O
C	O
.	O

After	O
the	O
addition	O
of	O
1	O
ml	O
of	O
distilled	O
water	B
,	O
the	O
mixture	O
was	O
heated	O
for	O
another	O
15	O
min	O
and	O
then	O
1	O
ml	O
of	O
30	O
%	O
(	O
w	O
/	O
v	O
)	O
aqueous	B
ammonium	B
hydroxide	I
was	O
added	O
.	O

MG	B
dibenzoates	I
were	O
extracted	O
three	O
times	O
with	O
2	O
ml	O
of	O
n	B
-hexane	I
and	O
purified	O
by	O
silica	B
gel	I
TLC	O
using	O
a	O
solvent	O
system	O
of	O
benzene	B
/	O
petroleum	B
ether	I
/	O
diethyl	B
ether	I
(	O
50:45:5	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
[	O
17	O
]	O
.	O

A	O
spot	O
corresponding	O
to	O
MG	B
dibenzoates	I
(	O
R	O
f	O
=	O
0.26	O
)	O
[	O
17	O
]	O
was	O
visualized	O
under	O
an	O
ultraviolet	O
light	O
after	O
spraying	O
with	O
purimurine	B
(	O
Nakalai	O
Tesque	O
)	O
dissolved	O
in	O
acetone	B
/	O
water	B
(	O
4:1	O
)	O
.	O

MG	B
dibenzoate	I
was	O
recovered	O
from	O
the	O
adsorbent	O
by	O
the	O
method	O
of	O
Bligh	O
and	O
Dyer	O
[	O
16	O
]	O
and	O
reconstituted	O
in	O
100	O
μl	O
of	O
acetonitrile	B
for	O
subsequent	O
HPLC	O
analysis	O
.	O

2.3	O
HPLC	O
separation	O
and	O
quantification	O
of	O
MG	B
dibenzoates	I
MG	B
dibenzoates	I
with	O
different	O
acyl	B
chains	I
were	O
separated	O
and	O
quantified	O
by	O
reverse	O
-	O
phase	O
HPLC	O
with	O
an	O
octadecylsilica	B
column	O
(	O
4.6	O
×	O
150	O
mm	O
,	O
Senshu	O
Pak	O
,	O
Senshu	O
Scientific	O
Co.	O
,	O
Ltd.	O
,	O
Tokyo	O
)	O
equilibrated	O
with	O
85	O
%	O
aqueous	B
acetonitrile	B
at	O
a	O
flow	O
rate	O
of	O
1	O
ml	O
/	O
min	O
.	O

MG	B
dibenzoates	I
were	O
detected	O
by	O
ultraviolet	O
absorbance	O
at	O
230	O
nm	O
(	O
SPD-6A	O
,	O
Shimadzu	O
,	O
Tokyo	O
)	O
.	O

The	O
standard	O
MG	B
dibenzoates	I
were	O
used	O
to	O
confirm	O
the	O
retention	O
time	O
of	O
those	O
prepared	O
from	O
mouse	O
brain	O
by	O
the	O
HPLC	O
.	O

Quantification	O
of	O
MG	B
dibenzoates	I
was	O
carried	O
out	O
by	O
comparing	O
their	O
peak	O
area	O
with	O
that	O
of	O
1-heptadecanoylglycerol	B
(	O
17:0MG	B
)	O
dibenzoate	B
added	O
as	O
an	O
internal	O
standard	O
.	O

The	O
peaks	O
observed	O
in	O
the	O
HPLC	O
analysis	O
of	O
mouse	O
brain	O
MG	B
were	O
further	O
identified	O
by	O
on	O
-	O
line	O
atmospheric	O
-	O
pressure	O
chemical	O
ionization	O
-	O
mass	O
spectrometry	O
(	O
APCI	O
-	O
MS	O
)	O
(	O
HP1100MSD	O
,	O
Yokagawa	O
Analytical	O
Systems	O
,	O
Tokyo	O
)	O
operating	O
in	O
the	O
positive	O
-	O
ionization	O
mode	O
at	O
90	O
V.	O
2.4	O
Animals	O
and	O
dietary	O
protocols	O
The	O
experimental	O
protocol	O
was	O
approved	O
by	O
the	O
Committee	O
of	O
Animal	O
Care	O
and	O
Use	O
of	O
Toyama	O
Medical	O
and	O
Pharmaceutical	O
University	O
(	O
Protocol	O
No.	O
2001	O
-	O
31	O
)	O
.Experiment	O
1	O
Female	O
ddy	O
mice	O
at	O
4	O
weeks	O
of	O
age	O
(	O
SLC	O
)	O
were	O
fed	O
a	O
diet	O
supplemented	O
with	O
either	O
5	O
%	O
(	O
w	O
/	O
w	O
)	O
safflower	B
oil	I
(	O
n-3-deficient	O
diet	O
)	O
or	O
safflower	B
oil	I
plus	O
DHA	B
ethylester	I
(	O
99:1	O
)	O
(	O
n-3-sufficient	O
diet	O
)	O
for	O
23	O
weeks	O
before	O
mating	O
with	O
male	O
ddy	O
mice	O
.	O

Male	O
pups	O
weaned	O
at	O
4	O
weeks	O
old	O
were	O
fed	O
the	O
same	O
diet	O
as	O
their	O
dams	O
for	O
an	O
additional	O
6	O
weeks	O
prior	O
to	O
analysis	O
.	O

The	O
fatty	B
acid	I
composition	O
of	O
the	O
dietary	O
fat	O
is	O
shown	O
in	O
Table	O
1	O
.	O

Experiment	O
2	O
Male	O
ddy	O
mice	O
at	O
4	O
weeks	O
old	O
(	O
SLC	O
,	O
Shizuoka	O
,	O
Japan	O
)	O
were	O
divided	O
into	O
two	O
groups	O
.	O

Each	O
group	O
of	O
mice	O
was	O
assigned	O
to	O
an	O
AIN-76	O
powdered	O
diet	O
(	O
Nihon	O
Nosan	O
Kogyo	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
supplemented	O
with	O
either	O
10	O
%	O
(	O
w	O
/	O
w	O
)	O
linoleate	B
(	O
18:2n-6	B
,	O
LA	B
)	O
-rich	O
safflower	B
oil	I
(	O
Nippon	O
Oil	O
Industry	O
,	O
Tokyo	O
)	O
(	O
low	O
-	O
DHA	B
diet	O
)	O
or	O
10	O
%	O
DHA	B
-	O
rich	O
fish	O
oil	O
(	O
Nissui	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
(	O
high	O
-	O
DHA	B
diet	O
)	O
for	O
4	O
weeks	O
prior	O
to	O
analysis	O
.	O

The	O
fatty	O
acid	O
composition	O
of	O
the	O
dietary	O
fat	O
is	O
shown	O
in	O
Table	O
1	O
.	O

2.5	O
Lipid	B
extraction	O
from	O
mice	O
brain	O
Mice	O
lightly	O
anesthetized	O
with	O
diethylether	O
were	O
decapitated	O
and	O
their	O
heads	O
were	O
immediately	O
immersed	O
into	O
liquid	B
nitrogen	I
and	O
left	O
for	O
more	O
than	O
10	O
min	O
.	O

Frozen	O
whole	O
brains	O
were	O
dissected	O
from	O
the	O
skull	O
and	O
homogenized	O
using	O
a	O
blender	O
in	O
chloroform	B
/	O
methanol	B
(	O
1:2	O
,	O
v	O
/	O
v	O
)	O
in	O
the	O
presence	O
of	O
1-heptadecanoylglycerol	B
(	O
1.45	O
nmol	O
)	O
as	O
an	O
internal	O
standard	O
,	O
and	O
total	O
lipids	B
were	O
obtained	O
according	O
to	O
the	O
method	O
of	O
Bligh	O
and	O
Dyer	O
[	O
16	O
]	O
.	O

Total	O
lipids	B
were	O
applied	O
to	O
a	O
silica	B
gel	I
cartridge	O
column	O
(	O
Sep	O
-	O
Pak	O
Plus	O
Si	O
,	O
Waters	O
,	O
Milford	O
,	O
MA	O
,	O
USA	O
)	O
that	O
had	O
been	O
pre	O
-	O
equilibrated	O
with	O
chloroform	B
.	O

Chloroform	B
(	O
10	O
ml	O
)	O
was	O
loaded	O
onto	O
the	O
column	O
to	O
remove	O
almost	O
all	O
triacylglycerols	B
,	O
cholesterol	B
and	O
diacylglycerols	B
.	O

A	O
MG	B
-	O
rich	O
fraction	O
was	O
eluted	O
from	O
the	O
column	O
with	O
10	O
ml	O
of	O
chloroform	B
/	O
methanol	B
(	O
98:2	O
,	O
v	O
/	O
v	O
)	O
,	O
and	O
dried	O
using	O
nitrogen	B
gas	O
.	O

The	O
fraction	O
containing	O
total	O
phospholipids	B
was	O
then	O
eluted	O
from	O
the	O
column	O
with	O
20	O
ml	O
of	O
chloroform	B
/	O
methanol	B
/	O
distilled	B
water	I
(	O
1:2:0.8	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
,	O
and	O
the	O
eluate	O
was	O
processed	O
to	O
obtain	O
total	O
phospholipids	B
according	O
to	O
the	O
method	O
of	O
Bligh	O
and	O
Dyer	O
[	O
16	O
]	O
.	O

2.6	O
Analysis	O
of	O
fatty	B
acid	I
composition	O
of	O
phospholipids	B
in	O
mouse	O
brain	O
Phosphatidylcholine	B
(	O
PC	B
)	O
,	O
phosphatidylethanolamine	B
(	O
PE	B
)	O
,	O
phosphatidylserine	B
(	O
PS	B
)	O
and	O
phosphatidylinositol	B
(	O
PI	O
)	O
were	O
purified	O
from	O
the	O
total	O
phospholipids	B
by	O
two	O
-	O
dimensional	O
silica	B
gel	I
TLC	O
using	O
chloroform	B
/	O
methanol	B
/	O
formic	B
acid	I
/	O
distilled	B
water	I
(	O
60:30:8:2	O
,	O
v	O
/	O
v	O
/	O
v	O
/	O
v	O
)	O
and	O
chloroform	B
/	O
methanol	B
/	O
25	O
%	O
ammonium	B
hydroxide	I
solution	O
(	O
60:40:6	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
for	O
the	O
first	O
and	O
second	O
developments	O
,	O
respectively	O
.	O

Fatty	B
acids	I
in	O
each	O
phospholipid	B
class	O
were	O
converted	O
into	O
their	O
corresponding	O
methylesters	B
by	O
boiling	O
in	O
methanol	B
containing	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
hydrogen	B
chloride	I
,	O
and	O
analyzed	O
by	O
gas	O
–	O
liquid	O
chromatography	O
with	O
a	O
capillary	O
column	O
(	O
DB-225	O
,	O
J&B	O
Scientific	O
,	O
Folsom	O
,	O
CA	O
,	O
USA	O
)	O
.	O

2.7	O
Statistical	O
analysis	O
Statistical	O
analysis	O
was	O
performed	O
using	O
Student	O
's	O
t	O
-test	O
to	O
confirm	O
significance	O
between	O
the	O
dietary	O
groups	O
.	O

3	O
Results	O
3.1	O
Separation	O
of	O
authentic	O
MG	B
dibenzoates	I
by	O
HPLC	O
Fig.	O
1	O
presents	O
a	O
reverse	O
-	O
phase	O
HPLC	O
profile	O
of	O
the	O
dibenzoates	B
of	I
authentic	O
MG	B
.	O

Almost	O
all	O
1	B
(	I
3	I
)	I
-	I
and	O
2-acyl	B
isomers	I
of	I
MG	I
dibenzoates	I
with	O
different	O
acyl	O
groups	O
were	O
clearly	O
separated	O
,	O
except	O
that	O
the	O
derivatives	B
of	I
2-palmitoylglycerol	B
(	O
2	B
-	I
16:0MG	I
)	O
and	O
1-octadecenylglycerol	B
(	O
1	B
-	I
18:1MG	I
)	O
coeluted	O
.	O

When	O
1	O
nmol	O
each	O
of	O
MG	B
standards	O
was	O
derivatized	O
and	O
separated	O
by	O
HPLC	O
(	O
Fig.	O
1	O
)	O
,	O
the	O
peak	O
areas	O
obtained	O
were	O
almost	O
same	O
among	O
all	O
the	O
derivatives	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
we	O
calculated	O
the	O
amounts	O
of	O
MG	B
from	O
brain	O
extracts	O
using	O
the	O
following	O
equation	O
:	O
(	O
peak	O
area	O
of	O
dibenzoate	B
of	I
MG	I
interest	O
)	O
/	O
(	O
peak	O
area	O
of	O
dibenzoate	B
of	I
1	I
-	I
17:0MG	I
)	O
×	O
1.45	O
nmol	O
.	O

3.2	O
Identification	O
of	O
2-AG	B
and	O
other	O
MGs	B
in	O
mouse	O
brain	O
Dibenzoate	B
derivatives	I
of	O
mouse	O
brain	O
MG	O
were	O
separated	O
by	O
reverse	O
-	O
phase	O
HPLC	O
;	O
a	O
typical	O
HPLC	O
profile	O
is	O
shown	O
in	O
Fig.	O
2A	O
.	O

The	O
retention	O
time	O
of	O
peaks	O
I	O
and	O
II	O
were	O
identical	O
with	O
those	O
of	O
dibenzoates	B
of	B
1	B
(	I
3	I
)	I
-AG	I
and	O
2-AG	B
,	O
respectively	O
.	O

The	O
APCI	O
-	O
mass	O
spectrum	O
of	O
peak	O
II	O
included	O
several	O
signals	O
at	O
m	O
/z	O
604.4	O
and	O
m	O
/z	O
609.4	O
(	O
Fig.	O
2B	O
,	O
panel	O
a	O
)	O
;	O
these	O
signals	O
corresponded	O
to	O
mass	O
numbers	O
18	O
or	O
23	O
greater	O
than	O
the	O
predicted	O
molecular	O
weight	O
of	O
the	O
dibenzoate	B
of	I
monoarachidonoylglycerol	I
(	O
=	O
586.4	O
)	O
,	O
respectively	O
.	O

Therefore	O
,	O
these	O
ion	O
signals	O
can	O
be	O
assumed	O
as	O
[	O
M+NH4	O
]	O
+	O
and	O
[	O
M+Na	O
]	O
+	O
,	O
respectively	O
.	O

The	O
occurrence	O
of	O
[	O
M+NH4	O
]	O
+	O
can	O
be	O
accounted	O
for	O
by	O
MG	B
dibenzoates	B
having	O
been	O
were	O
washed	O
with	O
ammonium	B
hydroxide	I
solution	O
before	O
their	O
TLC	O
purification	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

In	O
this	O
APCI	O
mass	O
spectrum	O
,	O
another	O
ion	O
peak	O
at	O
m	O
/z	O
465.3	O
was	O
also	O
obtained	O
in	O
both	O
mass	O
spectra	O
,	O
which	O
indicates	O
the	O
formation	O
of	O
[	O
M	O
–	O
C6	O
H5	O
COO	O
]	O
+	O
.	O

The	O
APCI	O
-	O
mass	O
spectrum	O
of	O
peak	O
I	O
whose	O
retention	O
time	O
corresponded	O
to	O
that	O
of	O
1	B
(	I
3	I
)	I
-AG	I
-	B
dibenzoate	I
was	O
quite	O
similar	O
to	O
that	O
of	O
peak	O
II	O
(	O
Fig.	O
2B	O
,	O
panel	O
a	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
earlier	O
peaks	O
III	O
and	O
IV	O
were	O
detected	O
and	O
identified	O
by	O
APCI	O
-	O
MS	O
as	O
dibenzoates	B
of	B
1	B
(	I
3	I
)	I
-	I
and	O
2-monodocosahexaenoylglycerol	B
(	O
DHG	B
-	I
MG	I
)	O
based	O
in	O
the	O
demonstration	O
of	O
[	O
M+NH4	O
]	O
+	O
=	O
628.4	O
,	O
[	O
M+Na	O
]	O
+	O
=	O
633.4	O
and	O
[	O
M	O
–	O
C6	O
H5	O
COO	O
]	O
+	O
=	O
489.3	O
(	O
Fig.	O
2B	O
,	O
panels	O
c	O
and	O
d	O
)	O
.	O

Similarly	O
,	O
several	O
other	O
peaks	O
were	O
identified	O
as	O
dibenzoates	B
of	I
monopalmitoylglycerol	B
,	O
monooleoylglycerol	B
and	O
monostearoylglycerol	B
,	O
although	O
2-palmitoylglycerol	B
and	O
1	B
(	I
3	I
)	I
-oleoylglycerol	I
derivatives	B
were	O
found	O
to	O
coelute	O
as	O
shown	O
in	O
Fig.	O
1	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
the	O
major	O
MG	B
molecular	O
species	O
in	O
mouse	O
brain	O
extracts	O
could	O
be	O
separated	O
by	O
HPLC	O
as	O
their	O
dibenzoate	B
derivatives	I
and	O
identified	O
by	O
subsequent	O
APCI	O
-	O
MS	O
.	O

3.3	O
Effects	O
of	O
chronic	O
deficiency	O
of	O
n-3	B
PUFA	I
on	O
the	O
levels	O
of	O
AA	B
and	O
DHA	B
in	O
phospholipids	B
and	O
MG	B
levels	O
in	O
brain	O
In	O
the	O
n-3-deficient	O
group	O
,	O
the	O
DHA	B
levels	O
in	O
brain	O
PC	B
,	O
PE	B
and	O
PS	B
were	O
markedly	O
lower	O
than	O
those	O
in	O
the	O
n-3-sufficient	O
group	O
(	O
Table	O
2	O
)	O
.	O

As	O
reported	O
in	O
other	O
studies	O
[	O
1,2	O
]	O
,	O
the	O
decrease	O
in	O
the	O
DHA	B
level	O
in	O
brain	O
phospholipids	B
is	O
compensated	O
by	O
the	O
increase	O
in	O
22:5n-6	B
and	O
22:4n-6	B
levels	O
in	O
the	O
n-3	O
deficient	O
group	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
DHA	B
level	O
in	O
brain	O
PI	B
was	O
very	O
low	O
but	O
was	O
significantly	O
lower	O
in	O
the	O
n-3-deficient	O
group	O
than	O
in	O
the	O
n-3-sufficient	O
group	O
.	O

However	O
,	O
the	O
AA	B
levels	O
in	O
all	O
the	O
four	O
phospholipid	B
classes	O
were	O
similar	O
between	O
the	O
two	O
dietary	O
groups	O
.	O

As	O
shown	O
above	O
,	O
the	O
dietary	O
n-3	B
PUFA	I
deficiency	O
induced	O
a	O
marked	O
reduction	O
of	O
the	O
DHA	B
level	O
without	O
changing	O
the	O
AA	B
level	O
in	O
brain	O
phospholipids	O
in	O
mice	O
.	O

However	O
,	O
the	O
brain	O
2-AG	B
level	O
in	O
the	O
n-3-deficient	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
n-3-sufficient	O
group	O
(	O
Fig.	O
3	O
)	O
.	O

In	O
the	O
n-3-deficient	O
group	O
,	O
the	O
brain	O
2-DHG	B
MG	I
level	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
n-3-sufficient	O
group	O
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
2	B
-	I
16:0MG	I
plus	O
1	B
(	I
3	I
)	I
-18:1MG	I
as	O
well	O
as	O
2	B
-	I
18:1MG	I
were	O
higher	O
in	O
the	O
n-3-deficient	O
group	O
than	O
in	O
the	O
n-3-sufficient	O
group	O
.	O

1	B
-	I
16:0MG	I
levels	O
were	O
similar	O
between	O
the	O
two	O
dietary	O
groups	O
.	O

3.4	O
Effects	O
of	O
short	O
-	O
term	O
supplementation	O
with	O
DHA	B
rich	O
diet	O
on	O
AA	B
and	O
DHA	B
levels	O
in	O
phospholipids	O
and	O
on	O
MG	B
levels	O
in	O
brain	O
As	O
demonstrated	O
above	O
,	O
the	O
reduction	O
of	O
DHA	B
levels	O
in	O
brain	O
phospholipids	B
associated	O
with	O
dietary	O
n-3	B
PUFA	I
deficiency	O
led	O
to	O
the	O
increase	O
in	O
the	O
brain	O
2-AG	B
level	O
.	O

We	O
,	O
therefore	O
,	O
confirm	O
whether	O
or	O
not	O
the	O
enrichment	O
with	O
DHA	B
in	O
brain	O
phospholipids	B
could	O
alter	O
brain	O
2-AG	B
levels	O
in	O
mice	O
.	O

A	O
relatively	O
short	O
-	O
term	O
of	O
dietary	O
enrichment	O
with	O
DHA	B
-	O
induced	O
significant	O
changes	O
in	O
the	O
levels	O
of	O
DHA	B
as	O
well	O
as	O
AA	O
in	O
brain	O
phospholipids	B
(	O
Table	O
3	O
)	O
.	O

The	O
DHA	B
levels	O
in	O
brain	O
PC	B
and	O
PE	B
of	O
the	O
brain	O
were	O
significantly	O
higher	O
in	O
the	O
high	O
-	O
DHA	O
group	O
than	O
in	O
the	O
low	O
-	O
DHA	O
group	O
(	O
Table	O
3	O
)	O
.	O

The	O
DHA	O
level	O
in	O
brain	O
PI	B
was	O
slightly	O
but	O
significantly	O
higher	O
in	O
the	O
high	O
-	O
DHA	B
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
DHA	B
diet	O
group	O
.	O

By	O
contrast	O
,	O
the	O
AA	B
levels	O
in	O
brain	O
PC	B
and	O
PE	B
were	O
significantly	O
lower	O
in	O
the	O
high	O
-	O
DHA	B
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
DHA	B
group	O
,	O
although	O
those	O
in	O
PI	B
and	O
PS	B
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
dietary	O
groups	O
.	O

The	O
brain	O
2-AG	B
level	O
was	O
significantly	O
lower	O
in	O
the	O
high	O
-	O
DHA	B
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
DHA	B
diet	O
group	O
(	O
Fig.	O
4	O
)	O
.	O

Although	O
1	B
(	I
3	I
)	I
-AG	I
was	O
a	O
minor	O
constituent	O
of	O
brain	O
MG	B
relative	O
to	O
2-AG	B
,	O
its	O
level	O
was	O
also	O
lower	O
in	O
the	O
high	O
-	O
DHA	B
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
DHA	B
diet	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
the	O
two	O
DHA	B
-	I
containing	I
MG	I
isomers	O
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
1	B
-	I
16:0MG	I
and	O
2	B
-	I
18:1MG	I
were	O
similar	O
between	O
the	O
two	O
dietary	O
groups	O
,	O
although	O
the	O
level	O
of	O
2	B
-	I
16:0MG	I
plus	O
1	B
(	I
3	I
)	I
-18:1MG	I
was	O
lower	O
in	O
the	O
high	O
-	O
DHA	B
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
DHA	B
diet	O
group	O
.	O

4	O
Discussion	O
It	O
has	O
been	O
suggested	O
that	O
2-AG	B
is	O
generated	O
from	O
arachidonate	B
-	B
containing	I
phospholipids	I
through	O
their	O
sequential	O
hydrolysis	O
by	O
PLC	O
and	O
DG	O
lipase	O
[	O
12	O
]	O
.	O

Since	O
the	O
Sn	O
-2	O
position	O
of	O
the	O
PI	B
of	O
mammalian	O
tissues	O
is	O
esterified	O
mainly	O
with	O
AA	B
and	O
the	O
existence	O
of	O
families	O
of	O
PLC	O
isozymes	O
specific	O
for	O
PI	B
have	O
been	O
demonstrated	O
in	O
the	O
brain	O
[	O
18	O
]	O
,	O
it	O
can	O
be	O
hypothesized	O
that	O
PI	B
is	O
the	O
most	O
likely	O
phospholipid	B
class	O
utilized	O
for	O
2-AG	B
biosynthesis	O
.	O

However	O
,	O
Bisogno	O
et	O
al.	O
[	O
13	O
]	O
demonstrated	O
in	O
mouse	O
neuroblastoma	O
that	O
AA	B
-	B
containing	I
phospholipids	I
are	O
hydrolyzed	O
by	O
phospholipase	O
D	O
to	O
phosphatidic	B
acid	I
,	O
followed	O
by	O
phosphatidate	O
-	O
hydrolyzing	O
phosphatase	O
and	O
then	O
DG	O
lipase	O
to	O
form	O
2-AG	B
.	O

More	O
recently	O
,	O
Lee	O
et	O
al.	O
[	O
19	O
]	O
demonstrated	O
that	O
the	O
enzymatic	O
activity	O
for	O
esterifying	O
glycerol	B
with	O
a	O
fatty	B
acid	I
in	O
the	O
brain	O
is	O
also	O
a	O
possible	O
pathway	O
of	O
2-AG	B
biosynthesis	O
.	O

We	O
demonstrated	O
that	O
the	O
dietary	O
supplementation	O
with	O
a	O
high	O
-	O
DHA	B
diet	O
reduced	O
the	O
2-AG	B
level	O
in	O
the	O
absence	O
of	O
the	O
reduction	O
of	O
the	O
AA	B
level	O
in	O
PI	B
as	O
compared	O
with	O
the	O
low	O
-	O
DHA	B
diet	O
group	O
(	O
Fig.	O
4	O
and	O
Table	O
3	O
)	O
.	O

The	O
reduction	O
of	O
the	O
AA	B
level	O
in	O
PC	B
and	O
PE	B
as	O
well	O
as	O
PS	B
by	O
a	O
high	O
-	O
DHA	B
diet	O
as	O
compared	O
with	O
the	O
low	O
-	O
DHA	B
diet	O
group	O
can	O
be	O
due	O
to	O
the	O
difference	O
in	O
brain	O
2-AG	B
levels	O
between	O
the	O
two	O
dietary	O
groups	O
.	O

Therefore	O
,	O
the	O
pathway	O
that	O
involves	O
the	O
utilization	O
of	O
phosphatidic	B
acid	I
[	O
13	O
]	O
,	O
presumably	O
derived	O
from	O
PC	B
or	O
PE	B
,	O
more	O
likely	O
accounts	O
for	O
our	O
observations	O
.	O

However	O
,	O
the	O
changes	O
in	O
AA	B
level	O
in	O
phospholipids	B
alone	O
could	O
not	O
account	O
for	O
the	O
alteration	O
of	O
the	O
brain	O
2-AG	B
levels	O
,	O
because	O
we	O
found	O
the	O
elevation	O
of	O
the	O
2-AG	B
level	O
in	O
the	O
mouse	O
brain	O
with	O
reduced	O
DHA	B
level	O
without	O
affecting	O
the	O
AA	B
level	O
in	O
all	O
the	O
four	O
phospholipid	B
classes	O
.	O

These	O
results	O
enable	O
us	O
to	O
consider	O
that	O
DHA	B
has	O
an	O
inhibitory	O
properties	O
for	O
2-AG	B
biosynthesis	O
in	O
the	O
brain	O
.	O

For	O
example	O
,	O
DHA	B
-	B
containing	I
phospholipids	I
may	O
inhibit	O
the	O
enzymatic	O
step	O
(	O
s	O
)	O
for	O
the	O
hydrolysis	O
of	O
AA	B
-	B
containing	I
phospholipids	I
,	O
presumably	O
PLC	O
or	O
PLD	O
.	O

This	O
mechanism	O
,	O
if	O
any	O
,	O
may	O
also	O
account	O
for	O
the	O
reduction	O
of	O
the	O
2-AG	B
level	O
in	O
brain	O
phospholipids	B
of	O
mice	O
fed	O
with	O
the	O
high	O
-	O
DHA	B
diet	O
.	O

However	O
,	O
the	O
biochemical	O
role	O
of	O
DHA	B
-	B
containing	I
phospholipids	I
in	O
regard	O
to	O
the	O
interaction	O
with	O
2-AG	B
biosynthesis	O
should	O
be	O
further	O
investigated	O
.	O

Unlike	O
2-AG	B
,	O
DHA	B
-	B
containing	I
MGs	I
have	O
very	O
low	O
levels	O
despite	O
the	O
abundance	O
of	O
DHA	B
-	B
containing	I
phospholipids	I
in	O
the	O
brain	O
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

In	O
addition	O
,	O
the	O
2	B
-	I
22:6n-3MG	I
level	O
did	O
not	O
increase	O
even	O
when	O
the	O
DHA	B
level	O
in	O
brain	O
phospholipids	O
was	O
elevated	O
by	O
dietary	O
enrichment	O
with	O
DHA	B
(	O
Fig.	O
4	O
and	O
Table	O
3	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
enzymatic	O
system	O
(	O
s	O
)	O
preferentially	O
generate	O
2-AG	B
over	O
2	B
-	I
22:6n-3MG	I
.	O

If	O
AA	B
-	B
containing	I
phospholipids	I
are	O
indeed	O
the	O
precursors	O
of	O
2-AG	B
,	O
DHA	B
-	B
containing	I
phospholipids	I
would	O
not	O
be	O
efficiently	O
utilized	O
for	O
2	B
-	I
22:6n-3MG	I
synthesis	O
.	O

The	O
hydrolysis	O
of	O
DHA	B
-	B
containing	I
phospholipids	I
by	O
enzymes	O
such	O
as	O
PLC	O
or	O
PLD	O
should	O
be	O
examined	O
to	O
clarify	O
the	O
mechanism	O
of	O
preferential	O
generation	O
of	O
2-AG	B
over	O
2	B
-	I
22:6n-3MG	I
.	O

There	O
are	O
reports	O
showing	O
that	O
the	O
administration	O
of	O
a	O
CB1	O
antagonist	O
,	O
SR14716	B
,	O
enhances	O
memory	O
functions	O
in	O
mice	O
and	O
rats	O
[	O
20,21	O
]	O
.	O

In	O
addition	O
,	O
CB1	O
receptor	O
knockout	O
mice	O
retain	O
memory	O
longer	O
than	O
wild	O
-	O
type	O
controls	O
[	O
22,23	O
]	O
.	O

These	O
observations	O
suggest	O
that	O
endogenous	O
cannabinoid	B
ligands	O
exhibit	O
a	O
memory	O
-	O
disrupting	O
property	O
.	O

Furthermore	O
,	O
CB1	O
knockout	O
mice	O
show	O
increased	O
aggressive	O
and	O
anxiogenic	O
-	O
like	O
responses	O
as	O
well	O
as	O
a	O
higher	O
sensitivity	O
to	O
a	O
chronic	O
unpredictable	O
mild	O
stress	O
as	O
shown	O
by	O
their	O
enhanced	O
depressive	O
-	O
like	O
responses	O
[	O
24	O
]	O
.	O

The	O
pharmacological	O
and	O
genetic	O
manipulations	O
of	O
endogenous	O
cannabinoid	B
action	O
obviously	O
clarified	O
its	O
role	O
in	O
the	O
functions	O
of	O
CNS	O
.	O

Accordingly	O
,	O
the	O
elevation	O
of	O
the	O
2-AG	B
level	O
in	O
the	O
brain	O
of	O
mice	O
under	O
chronic	O
n-3	B
PUFA	I
deficiency	O
is	O
an	O
important	O
finding	O
which	O
could	O
elucidate	O
the	O
molecular	O
mechanism	O
of	O
their	O
abnormalities	O
in	O
memory	O
functions	O
[	O
1,2	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
reduction	O
of	O
2-AG	B
levels	O
in	O
the	O
brain	O
of	O
mice	O
fed	O
with	O
the	O
n-3	B
PUFA	I
-	O
rich	O
diet	O
suggests	O
a	O
possibility	O
that	O
this	O
dietary	O
manipulation	O
may	O
improve	O
memory	O
and	O
emotional	O
functions	O
.	O

Lim	O
and	O
Suzuki	O
[	O
25	O
]	O
reported	O
that	O
dietary	O
supplementation	O
with	O
a	O
high	O
-	O
DHA	B
diet	O
enhances	O
the	O
learning	O
ability	O
of	O
mice	O
tested	O
using	O
a	O
maze	O
task	O
as	O
compared	O
with	O
low	O
-	O
DHA	B
diet	O
.	O

Recently	O
,	O
Berger	O
et	O
al.	O
have	O
demonstrated	O
that	O
a	O
short	O
-	O
term	O
supplementation	O
of	O
both	O
AA	B
and	O
DHA	B
in	O
liquid	O
formula	O
increases	O
the	O
levels	O
of	O
anandamide	B
(	O
N	B
-arachidonoylethanolamine	I
)	O
and	O
its	O
DHA	B
-	O
containing	O
analogue	O
(	O
N	B
-docosahexaenoylethanolamine	I
)	O
in	O
newborn	O
piglet	O
brain	O
[	O
26	O
]	O
.	O

However	O
,	O
under	O
the	O
same	O
conditions	O
,	O
the	O
levels	O
of	O
MG	B
containing	O
AA	B
or	O
DHA	B
did	O
not	O
increase	O
.	O

They	O
demonstrated	O
the	O
elevation	O
of	O
the	O
AA-	B
and	O
DHA	B
-	O
containing	B
N	I
-acylethanolamime	I
level	O
even	O
after	O
the	O
supplementation	O
with	O
only	O
a	O
small	O
amount	O
(	O
below	O
1	O
%	O
of	O
total	O
fatty	O
acids	O
of	O
the	O
formula	O
)	O
of	O
these	O
PUFA	B
in	O
the	O
formula	O
for	O
newborn	O
piglets	O
for	O
a	O
relatively	O
short	O
period	O
(	O
18	O
days	O
)	O
.	O

Therefore	O
,	O
AA	B
and	O
DHA	B
would	O
be	O
incorporated	O
into	O
these	O
pathways	O
of	O
N	B
-acylethanolamide	I
biosynthesis	O
more	O
rapidly	O
than	O
into	O
the	O
2-AG	B
synthetic	O
pathways	O
.	O

There	O
are	O
two	O
proposed	O
biosynthetic	O
pathways	O
for	O
anandamide	B
,	O
which	O
involves	O
the	O
formation	O
of	O
a	O
unique	O
precursor	O
,	O
N	B
-acylphosphatidylethanolamine	I
[	O
27	O
]	O
or	O
direct	O
N	O
-acylation	O
of	O
ethanolamine	B
[	O
28	O
]	O
.	O

Bisogno	O
et	O
al.	O
[	O
29	O
]	O
have	O
already	O
shown	O
the	O
formation	O
of	O
N	B
-docosahexaenoylphosphatidylethanolamine	I
as	O
a	O
possible	O
precursor	O
for	O
the	O
biosynthesis	O
of	O
N	B
-docosahexaenoylethanolamide	I
in	O
bovine	O
retinal	O
tissues	O
.	O

Although	O
the	O
precise	O
mechanism	O
by	O
which	O
dietary	O
supplementation	O
with	O
AA	B
and	O
DHA	B
preferentially	O
leads	O
to	O
the	O
incorporation	O
of	O
these	O
PUFAs	B
into	O
N	B
-acylethanolamines	I
is	O
still	O
unknown	O
,	O
these	O
results	O
also	O
suggest	O
that	O
the	O
manipulation	O
of	O
dietary	O
PUFA	B
can	O
modify	O
the	O
psychoemotional	O
status	O
through	O
the	O
change	O
in	O
the	O
levels	O
of	O
endogenous	O
cannabinoid	B
ligands	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
dietary	O
n-3	B
PUFA	I
status	O
is	O
one	O
of	O
the	O
important	O
factors	O
that	O
influence	O
brain	O
2-AG	B
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
various	O
physiological	O
and	O
pathological	O
conditions	O
leading	O
to	O
the	O
alteration	O
of	O
endogenous	O
2-AG	B
levels	O
and	O
its	O
implication	O
to	O
these	O
events	O
have	O
been	O
reported	O
[	O
30–33	O
]	O
.	O

Therefore	O
,	O
our	O
findings	O
may	O
help	O
clarify	O
the	O
mechanism	O
by	O
which	O
the	O
manipulation	O
of	O
the	O
dietary	O
n-3	B
PUFA	I
status	O
modulates	O
the	O
CNS	O
function	O
under	O
physiological	O
and	O
pathological	O
conditions	O
.	O

Acknowledgements	O

We	O
thank	O
Dr.	O
Kengo	O
Akimoto	O
(	O
Institute	O
for	O
Health	O
Care	O
Science	O
,	O
Research	O
,	O
Suntory	O
Ltd.	O
)	O
for	O
conducting	O
APCI	O
-	O
MS	O
analysis	O
and	O
helpful	O
discussion	O
on	O
the	O
molecular	O
identification	O
of	O
MG	O
.	O

Extracts	O
of	O
the	O
creosote	O
bush	O
(	O
Larrea	O
tridentata	O
,	O
family	O
Zygophyllaceae	O
)	O
have	O
long	O
been	O
used	O
as	O
a	O
folk	O
remedy	O
for	O
Type	O
II	O
(	O
non	O
-	O
insulin	O
-	O
dependent	O
)	O
diabetes	O
by	O
native	O
Americans	O
in	O
southwestern	O
North	O
America	O
.	O

In	O
this	O
study	O
we	O
have	O
evaluated	O
the	O
metabolic	O
effects	O
of	O
masoprocol	B
,	O
a	O
pure	O
compound	O
isolated	O
from	O
the	O
creosote	O
bush	O
,	O
in	O
a	O
rat	O
model	O
of	O
Type	O
II	O
diabetes	O
.	O

Animals	O
were	O
fed	O
a	O
20	O
%	O
fat	O
(	O
by	O
weight	O
)	O
diet	O
for	O
2	O
weeks	O
prior	O
to	O
intravenous	O
injection	O
with	O
streptozotocin	B
(	O
STZ	B
,	O
0.19	O
mmol	O
/	O
kg	O
)	O
.	O

Diabetic	O
animals	O
(	O
glucose	B
16	O
-	O
33	O
mmol	O
/	O
l	O
)	O
were	O
treated	O
with	O
vehicle	O
,	O
metformin	B
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
or	O
masoprocol	B
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
twice	O
a	O
day	O
for	O
4	O
days	O
.	O

Masoprocol	B
treatment	O
lowered	O
glucose	B
concentrations	O
an	O
average	O
of	O
35	O
%	O
compared	O
with	O
vehicle	O
(	O
14.2+	O
/	O
-1.1	O
vs	O
21.7+	O
/	O
-1.0	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
similar	O
to	O
metformin	B
treatment	O
(	O
12.8+	O
/	O
-0.9	O
mmol	O
/	O
l	O
)	O
,	O
without	O
any	O
change	O
in	O
insulin	O
concentration	O
.	O

Masoprocol	B
treatment	O
also	O
lowered	O
triglyceride	B
concentrations	O
80	O
%	O
compared	O
with	O
vehicle	O
(	O
1.0+	O
/	O
-0.1	O
vs	O
4.8+	O
/	O
-0.3	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
far	O
greater	O
than	O
following	O
metformin	B
treatment	O
(	O
3.6+	O
/	O
-0.3	O
mmol	O
/	O
l	O
)	O
.	O

Non	O
-	O
esterified	O
fatty	B
acid	I
and	O
glycerol	B
concentration	O
were	O
decreased	O
by	O
approximately	O
65	O
%	O
by	O
masoprocol	B
compared	O
with	O
vehicle	O
,	O
a	O
reduction	O
approximately	O
twice	O
as	O
great	O
as	O
seen	O
with	O
metformin	B
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
effect	O
of	O
masoprocol	B
on	O
in	O
vivo	O
insulin	O
-	O
mediated	O
glucose	B
disposal	O
was	O
evaluated	O
by	O
infusing	O
fat	O
-	O
fed	O
/	O
STZ	B
rats	O
with	O
glucose	B
(	O
0.22	O
mmol	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
and	O
insulin	O
(	O
30	O
pmol	O
x	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
for	O
5	O
h.	O
In	O
response	O
to	O
the	O
infusion	O
,	O
steady	O
-	O
state	O
plasma	O
glucose	B
concentrations	O
were	O
reduced	O
30	O
%	O
in	O
masoprocol	B
-	O
treated	O
animals	O
compared	O
with	O
vehicle	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
with	O
no	O
change	O
noted	O
in	O
rats	O
treated	O
with	O
metformin	B
.	O

The	O
effect	O
of	O
masoprocol	B
treatment	O
was	O
also	O
tested	O
in	O
primary	O
adipocytes	O
isolated	O
from	O
normal	O
animals	O
.	O

Adipocytes	O
treated	O
with	O
masoprocol	B
(	O
30	O
micromol	O
/	O
l	O
)	O
had	O
higher	O
basal	O
and	O
insulin	O
-	O
stimulated	O
glucose	B
clearance	O
than	O
did	O
adipocytes	O
treated	O
with	O
vehicle	O
(	O
p	O
<	O
0.05	O
)	O
.	O

These	O
data	O
show	O
that	O
masoprocol	B
decreases	O
both	O
plasma	O
glucose	B
and	O
triglyceride	B
concentrations	O
in	O
fat	O
-	O
fed	O
/	O
STZ	B
rats	O
,	O
presumably	O
as	O
a	O
result	O
of	O
its	O
ability	O
to	O
both	O
increase	O
glucose	B
disposal	O
and	O
decrease	O
lipolysis	O
.	O

The	O
induction	O
of	O
micronucleated	O
erythrocytes	O
by	O
diisopropylcarbodiimide	B
(	O
DIC	B
)	O
and	O
dicyclohexylcarbodiimide	B
(	O
DCC	B
)	O
was	O
investigated	O
as	O
part	O
of	O
a	O
U.S.	O
National	O
Toxicology	O
Program	O
(	O
NTP	O
)	O
evaluation	O
of	O
the	O
subchronic	O
toxicity	O
of	O
these	O
chemicals	O
.	O

Analysis	O
of	O
peripheral	O
blood	O
smears	O
from	O
male	O
and	O
female	O
B6C3F1	O
mice	O
exposed	O
to	O
17.5	O
-	O
140.0	O
mg	O
DIC	B
/	O
kg	O
/	O
day	O
by	O
skin	O
painting	O
for	O
13	O
weeks	O
revealed	O
dose	O
-	O
related	O
increases	O
in	O
the	O
frequency	O
of	O
micronucleated	O
normochromatic	O
erythrocytes	O
(	O
MN	O
-	O
NCE	O
)	O
in	O
both	O
sexes	O
.	O

Results	O
of	O
a	O
similar	O
13-week	O
peripheral	O
blood	O
micronucleus	O
(	O
MN	O
)	O
test	O
with	O
DCC	B
(	O
1.5	O
-	O
12.0	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
also	O
positive	O
,	O
although	O
the	O
increases	O
in	O
MN	O
-	O
NCE	O
were	O
not	O
as	O
great	O
as	O
those	O
observed	O
with	O
DIC	B
.	O

In	O
contrast	O
to	O
the	O
positive	O
results	O
of	O
the	O
subchronic	O
skin	O
-	O
painting	O
studies	O
in	O
mice	O
,	O
acute	O
bone	O
marrow	O
MN	O
studies	O
with	O
DIC	B
and	O
DCC	B
in	O
male	O
F344	O
rats	O
,	O
using	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
,	O
yielded	O
negative	O
results	O
.	O

Both	O
the	O
acute	O
and	O
the	O
subchronic	O
exposures	O
included	O
doses	O
that	O
produced	O
clinical	O
signs	O
of	O
toxicity	O
.	O

Acute	O
mouse	O
bone	O
marrow	O
MN	O
tests	O
with	O
DIC	B
administered	O
in	O
single	O
or	O
triple	O
i.p	O
.	O

injection	O
protocols	O
were	O
subsequently	O
conducted	O
to	O
determine	O
if	O
the	O
differing	O
responses	O
between	O
mice	O
and	O
rats	O
were	O
due	O
to	O
species	O
or	O
protocol	O
differences	O
.	O

The	O
results	O
of	O
these	O
acute	O
tests	O
were	O
negative	O
or	O
equivocal	O
.	O

Because	O
the	O
subchronic	O
studies	O
produced	O
positive	O
results	O
,	O
it	O
was	O
hypothesized	O
that	O
these	O
carbodiimides	B
required	O
multiple	O
treatments	O
over	O
an	O
extended	O
period	O
of	O
time	O
to	O
produce	O
an	O
increase	O
in	O
MN	O
-	O
erythrocytes	O
.	O

To	O
confirm	O
the	O
original	O
response	O
,	O
a	O
second	O
dermal	O
subchronic	O
study	O
was	O
conducted	O
with	O
DIC	B
;	O
the	O
protocol	O
was	O
modified	O
to	O
include	O
sequential	O
blood	O
samplings	O
to	O
permit	O
monitoring	O
MN	O
frequencies	O
over	O
time	O
.	O

The	O
data	O
demonstrated	O
a	O
small	O
but	O
consistent	O
induction	O
of	O
micronucleated	O
erythrocytes	O
in	O
mice	O
treated	O
with	O
DIC	B
by	O
skin	O
painting	O
.	O

Antibacterial	O
antibiotics	O
,	O
diperamycin	B
(	O
1	O
)	O
was	O
produced	O
in	O
the	O
culture	O
broth	O
of	O
Streptomyces	O
griseoaurantiacus	O
MK393-AF2	O
.	O

Various	O
spectroscopic	O
analyses	O
of	O
1	O
suggested	O
that	O
1	O
belonged	O
to	O
a	O
member	O
of	O
cyclic	B
hexadepsipeptide	I
antibiotic	O
.	O

Antibiotic	B
1	I
had	O
potent	O
inhibitory	O
activity	O
against	O
various	O
Gram	O
-	O
positive	O
bacteria	O
including	O
Enterococcus	O
seriolicida	O
and	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

Subcutaneous	O
tumor	O
induction	O
with	O
three	O
dose	O
levels	O
of	O
3-methylcholanthrene	B
(	O
MCA	B
)	O
,	O
benzo	B
[	I
a	I
]	I
pyrene	I
(	O
BP	B
)	O
,	O
and	O
7,12-dimethylbenz	B
[	I
a	I
]	I
anthracene	I
(	O
DMBA	B
)	O
in	O
two	O
vehicles	O
was	O
studied	O
in	O
C3H	O
/	O
Anf	O
Cum	O
,	O
C57BL	O
/	O
6	O
Cum	O
,	O
DBA	O
/	O
2J	O
,	O
and	O
(	O
C57BLXC3H	O
/	O
Anf	O
)	O
F1	O
(	O
BC3F1	O
/	O
Cum	O
)	O
mice	O
.	O

Median	O
tumor	O
dose	O
levels	O
were	O
significantly	O
lower	O
when	O
the	O
three	O
carcinogens	O
were	O
suspended	O
in	O
trioctanoin	B
.	O

When	O
beeswax	B
:	I
trioctanoin	I
(	O
B	B
:	I
T	I
)	O
was	O
used	O
as	O
a	O
vehicle	O
,	O
the	O
three	O
carcinogens	O
differed	O
in	O
their	O
abilities	O
to	O
be	O
absorbed	O
or	O
solubilized	O
from	O
the	O
vehicle	O
by	O
the	O
three	O
strains	O
of	O
mice	O
and	O
the	O
hybrid	O
.	O

In	O
C3H	O
/	O
Anf	O
mice	O
,	O
BP	B
in	O
B	B
:	I
T	I
failed	O
to	O
produce	O
tumors	O
.	O

In	O
BC3F1	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
by	O
MCA	B
,	O
BP	B
,	O
or	O
DMBA	B
in	O
B	B
:	I
T.	I
In	O
C57BL	O
/	O
6	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
with	O
DMBA	B
or	O
MCA	B
in	O
B	B
:	I
T.	I
In	O
DBA	O
/	O
2	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
by	O
BP	B
or	O
MCA	B
in	O
B	B
:	I
T.	I
These	O
results	O
indicated	O
that	O
the	O
interpretation	O
of	O
tumor	O
induction	O
results	O
obtained	O
with	O
B	B
:	I
T	I
vehicle	O
may	O
be	O
related	O
to	O
the	O
conditions	O
of	O
bioassay	O
rather	O
than	O
to	O
the	O
carcinogenic	O
potential	O
of	O
a	O
compound	O
.	O

DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
and	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	O
(	O
PARP	O
)	O
are	O
activated	O
by	O
DNA	O
strand	O
breaks	O
and	O
participate	O
in	O
DNA	O
repair	O
.	O

We	O
investigated	O
the	O
interactive	O
effects	O
of	O
inhibitors	O
of	O
these	O
enzymes	O
[	O
wortmannin	B
(	O
WM	B
)	O
,	O
which	O
inhibits	O
DNA	O
-	O
PK	O
,	O
and	O
8-hydroxy-2-methylquinazolin-4-one	B
(	O
NU1025	B
)	O
,	O
a	O
PARP	O
inhibitor	O
]	O
on	O
cell	O
survival	O
and	O
DNA	O
double	O
-	O
strand	O
break	O
(	O
DSB	O
)	O
and	O
single	O
-	O
strand	O
break	O
(	O
SSB	O
)	O
rejoining	O
in	O
Chinese	O
hamster	O
ovary	O
-	O
K1	O
cells	O
following	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
or	O
temozolomide	B
.	O

WM	B
(	O
20	O
microM	O
)	O
or	O
NU1025	B
(	O
300	O
microM	O
)	O
potentiated	O
the	O
cytotoxicity	O
of	O
IR	O
with	O
dose	O
enhancement	O
factors	O
at	O
10	O
%	O
survival	O
(	O
DEF10	O
)	O
values	O
of	O
4.5	O
+	O
/-	O

0.6	O
and	O
1.7	O
+	O
/-	O

0.2	O
,	O
respectively	O
.	O

When	O
used	O
in	O
combination	O
,	O
a	O
DEF10	O
of	O
7.8	O
+	O
/-	O

1.5	O
was	O
obtained	O
.	O

WM	B
or	O
NU1025	B
potentiated	O
the	O
cytotoxicity	O
of	O
temozolomide	B
,	O
and	O
an	O
additive	O
effect	O
on	O
the	O
DEF10	O
value	O
was	O
obtained	O
with	O
the	O
combined	O
inhibitors	O
.	O

Using	O
the	O
same	O
inhibitor	O
concentrations	O
,	O
their	O
single	O
and	O
combined	O
effects	O
on	O
DSB	O
and	O
SSB	O
levels	O
following	O
IR	O
were	O
assessed	O
by	O
neutral	O
and	O
alkaline	O
elution	O
.	O

Cells	O
exposed	O
to	O
IR	O
were	O
post	O
-	O
incubated	O
for	O
30	O
min	O
to	O
allow	O
repair	O
to	O
occur	O
.	O

WM	B
or	O
NU1025	B
increased	O
net	O
DSB	O
levels	O
relative	O
to	O
IR	O
alone	O
(	O
DSB	O
levels	O
of	O
1.29	O
+	O
/-	O

0.04	O
and	O
1.20	O
+	O
/-	O

0.05	O
,	O
respectively	O
,	O
compared	O
with	O
1.01	O
+	O
/-	O

0.03	O
for	O
IR	O
alone	O
)	O
and	O
the	O
combination	O
had	O
an	O
additive	O
effect	O
.	O

WM	B
had	O
no	O
effect	O
on	O
SSB	O
levels	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
NU1025	B
.	O

SSB	O
levels	O
were	O
increased	O
to	O
1.27	O
+	O
/-	O

0.05	O
with	O
NU1025	B
compared	O
with	O
IR	O
alone	O
,	O
1.02	O
+	O
/-	O

0.04	O
.	O

The	O
dose	O
-	O
dependent	O
effects	O
of	O
the	O
inhibitors	O
on	O
DSB	O
levels	O
showed	O
that	O
they	O
were	O
near	O
maximal	O
by	O
20	O
microM	O
WM	O
and	O
300	O
microM	O
NU1025	O
.	O

DSB	O
repair	O
kinetics	O
were	O
studied	O
.	O

Both	O
inhibitors	O
increased	O
net	O
DSB	O
levels	O
over	O
a	O
3	O
h	O
time	O
period	O
;	O
when	O
they	O
were	O
combined	O
,	O
net	O
DSB	O
levels	O
at	O
3	O
h	O
were	O
identical	O
to	O
DSB	O
levels	O
immediately	O
post	O
-	O
IR	O
.	O

The	O
combined	O
use	O
of	O
DNA	O
repair	O
inhibitors	O
may	O
have	O
therapeutic	O
potential	O
.	O

Chemical	O
investigation	O
of	O
the	O
sponge	O
Spongia	O
matamata	O
collected	O
in	O
Yap	O
,	O
Micronesia	O
,	O
has	O
resulted	O
in	O
the	O
isolation	O
of	O
six	O
new	O
spongian	O
diterpenoids	B
,	O
2	O
-	O
7	O
,	O
along	O
with	O
the	O
known	O
compound	O
,	O
spongia-13	B
(	I
16	I
)	I
,	I
14-dien-19-oic	I
acid	I
(	O
1	O
)	O
.	O

The	O
structures	O
were	O
determined	O
by	O
spectroscopic	O
methods	O
.	O

Meloxicam	B
[	O
4-hydroxy-2-methyl	B
-	I
N-	I
(	I
5-methyl-2-thiazolyl	I
)	I
-2H-1,2-benzothiazine	I
-3-carboxamide-1	I
,	I
1-dioxide	I
]	O
is	O
a	O
nonsteroidal	B
anti	I
-	I
inflammatory	I
drug	I
(	O
NSAID	B
)	O
of	O
the	O
oxicam	B
class	O
which	O
shows	O
preferential	O
inhibition	O
of	O
cyclo	O
-	O
oxygenase-2	O
.	O

Meloxicam	B
has	O
a	O
plasma	O
half	O
-	O
life	O
of	O
approximately	O
20	O
hours	O
,	O
making	O
it	O
convenient	O
for	O
once	O
-	O
daily	O
administration	O
.	O

Meloxicam	B
is	O
eliminated	O
after	O
biotransformation	O
to	O
4	O
pharmacologically	O
inactive	O
metabolites	O
,	O
which	O
are	O
excreted	O
in	O
urine	O
and	O
faeces	O
.	O

Meloxicam	B
and	O
its	O
metabolites	B
bind	O
extensively	O
to	O
plasma	O
albumin	O
.	O

Substantial	O
concentrations	O
of	O
meloxicam	B
are	O
attained	O
in	O
synovial	O
fluid	O
,	O
the	O
proposed	O
site	O
of	O
action	O
in	O
chronic	O
inflammatory	O
arthropathies	O
.	O

Neither	O
moderate	O
renal	O
nor	O
hepatic	O
insufficiency	O
significantly	O
alter	O
the	O
pharmacokinetics	O
of	O
meloxicam	B
.	O

Dosage	O
adjustment	O
is	O
not	O
required	O
in	O
the	O
elderly	O
.	O

Drug	O
-	O
drug	O
interaction	O
studies	O
are	O
available	O
for	O
some	O
commonly	O
co	O
-	O
prescribed	O
medications	O
.	O

Concentration	O
-	O
dependent	O
therapeutic	O
and	O
toxicological	O
effects	O
have	O
yet	O
to	O
be	O
extensively	O
elucidated	O
for	O
this	O
NSAID	B
.	O

Recent	O
work	O
within	O
our	O
laboratory	O
has	O
focused	O
on	O
the	O
enzymes	O
we	O
hypothesize	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
bis	B
(	I
monoacylglycerol	I
)	I
phosphate	I
from	O
phosphatidylglycerol	B
.	O

Here	O
we	O
describe	O
a	O
transacylase	O
,	O
active	O
at	O
acidic	O
pH	O
values	O
,	O
isolated	O
from	O
a	O
macrophage	O
-	O
like	O
cell	O
line	O
,	O
RAW	O
264.7	O
.	O

This	O
enzyme	O
acylates	O
the	O
head	O
group	O
glycerol	B
of	O
sn-3	B
:	I
sn-1	I
'	I
lysophosphatidylglycerol	I
to	O
form	O
sn-3	B
:	I
sn-1	I
'	I
bis	I
(	I
monoacylglycerol	I
)	I
phosphate	I
.	O

Here	O
we	O
demonstrate	O
that	O
this	O
enzyme	O
uses	O
two	O
lysophosphatidylglycerol	B
molecules	O
,	O
one	O
as	O
an	O
acyl	O
donor	O
and	O
another	O
as	O
an	O
acyl	O
acceptor	O
,	O
and	O
that	O
the	O
acyl	O
contributions	O
from	O
all	O
other	O
lipids	B
tested	O
are	O
comparatively	O
minor	O
.	O

This	O
enzyme	O
prefers	O
saturated	O
acyl	O
chains	O
to	O
monounsaturates	B
,	O
16	B
and	O
18	B
carbon	I
fatty	I
acids	I
over	O
14	B
carbon	I
fatty	I
acids	I
,	O
and	O
saturated	O
acyl	B
chains	I
at	O
the	O
sn-1	O
position	O
to	O
monounsaturated	O
acyl	B
chains	I
on	O
the	O
sn-2	O
carbon	B
of	O
lysophosphatidylglycerol	O
.	O

We	O
present	O
data	O
which	O
show	O
the	O
transacylase	O
activity	O
depends	O
on	O
the	O
presence	O
of	O
a	O
lipid	B
-	O
water	B
interface	O
and	O
the	O
lipid	B
polymorphic	O
state	O
.	O

INTRODUCTION	O
We	O
have	O
recently	O
shown	O
that	O
rabbit	O
antibodies	O
to	O
the	O
p	B
-	I
azophenylphosphorylcholine	I
(	O
APPC	B
)	O
determinant	O
,	O
which	O
bears	O
2	O
charges	O
of	O
opposite	O
sign	O
,	O
have	O
both	O
positively	O
and	O
negatively	O
charged	O
groups	O
in	O
their	O
binding	O
sites	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
positive	O
charge	O
is	O
contributed	O
by	O
the	O
guanidinium	B
group	I
of	O
arginine	B
and	O
the	O
negative	O
charge	O
is	O
contributed	O
by	O
the	O
carboxylate	B
group	I
of	B
either	O
a	B
glutamyl	B
or	O
aspartyl	B
residue	I
.	O

We	O
have	O
also	O
previously	O
shown	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
that	O
the	O
phosphorylcholine	B
-	O
binding	O
mouse	O
myeloma	O
protein	O
,	O
HOPC-8	O
,	O
similarly	O
contains	O
gaunidinium	B
and	O
carboxylate	B
groups	I
in	O
its	O
binding	O
site	O
.	O

In	O
an	O
attempt	O
to	O
gain	O
further	O
insight	O
into	O
the	O
nature	O
of	O
these	O
binding	O
sites	O
we	O
have	O
measured	O
the	O
relative	O
binding	O
constants	O
of	O
several	O
structurally	O
related	O
small	O
molecules	O
with	O
anti	O
-	O
APPC	B
antibodies	O
and	O
with	O
HOPC-8	O
.	O

The	O
Krel	O
values	O
for	O
hapten	B
binding	O
to	O
the	O
rabbit	O
anti	O
-	O
APPC	B
antibodies	O
and	O
to	O
the	O
myeloma	O
protein	O
,	O
together	O
with	O
our	O
evidence	O
for	O
specific	O
functional	O
groups	O
in	O
the	O
binding	O
sites	O
,	O
have	O
allowed	O
us	O
to	O
draw	O
inferences	O
regarding	O
the	O
topography	O
of	O
the	O
binding	O
sites	O
of	O
anti	O
-	O
APPC	B
antibodies	O
and	O
HOPC-8	O
.	O

*	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
U.S.	O
Public	O
Health	O
Service	O
Research	O
Grants	O
CA-11656	O
and	O
AI-03962	O
from	O
the	O
National	O
Cancer	O
Institute	O
.	O

t	O
A	O
unit	O
of	O
the	O
New	O
York	O
State	O
Department	O
of	O
Health	O
.	O

$	O
Abbreviations	O
used	O
:	O
APPC	B
,	O
p	B
-	I
azophenylphosphorylcholine	I
;	O
NPPC	B
,	O
p	B
-	I
nitrophenylphosphorylcholine	I
;	O
PC	B
,	O
phosphorylcholine	B
;	O
GPC	B
,	O
L	B
-	I
a	I
-	I
glycerophosphorylcholine	I
;	O
AcC	B
,	O
acetylcholine	B
;	O
I	B
-	I
Ap	I
,	O
p	B
-	I
iodophenyltrimethylammonium	I
;	O
PO3	B
,	O
phenylphosphate	B
;	O
03	B
,	O
phenylphosphonate	B
;	O
BBS	B
,	O
borate	B
buffered	I
saline	I
.	O

901	O
MATERIALS	O
AND	O
METHODS	O
p	B
-	I
Diazonium	I
phenylphosphorylcholine	I
chloride	I
(	O
DPPC	B
)	O
This	O
was	O
prepared	O
according	O
to	O
Chesebro	O
&	O
Metzger	O
(	O
1972	O
)	O
with	O
the	O
exception	O
that	O
in	O
the	O
diazotization	O
step	O
1.0	O
N	O
HCl	B
rather	O
than	O
0.1	O
N	O
HCl	B
was	O
used	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

Haptens	B
Haptens	B
tested	O
were	O
reagent	O
grade	O
commercial	O
products	O
,	O
used	O
without	O
further	O
purification	O
.	O

Goat	O
anti	O
-	O
rabbit	O
IgG	O
This	O
serum	O
was	O
a	O
preparation	O
previously	O
described	O
(	O
Hoffman	O
et	O
al.	O
,	O
1971	O
)	O
.	O

Rabbit	O
anti	O
-	O
mouse	O
IgA	O
This	O
serum	O
was	O
obtained	O
from	O
Dr.	O
Oliver	O
A.	O
Roholt	O
of	O
our	O
Department	O
.	O

It	O
was	O
prepared	O
by	O
hyperimmunization	O
of	O
rabbits	O
with	O
MOPC-315	O
myeloma	O
protein	O
.	O

Anti	O
-	O
APPC	B
antibodies	O
The	O
preparation	O
of	O
rabbit	O
antisera	O
to	O
the	O
APPC	B
determinant	O
and	O
the	O
subsequent	O
isolation	O
and	O
purification	O
of	O
the	O
antibodies	O
from	O
individual	O
rabbits	O
by	O
specific	O
immunoadsorption	O
has	O
been	O
described	O
previously	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

In	O
the	O
present	O
work	O
preparations	O
from	O
rabbits	O
6055	O
and	O
6057	O
were	O
specifically	O
purified	O
anti	O
-	O
APPC	B
antibodies	O
and	O
the	O
preparation	O
from	O
rabbit	O
5920	O
was	O
a	O
gamma	O
globulin	O
fraction	O
of	O
anti	O
-	O
APPC	B
serum	O
.	O

HOPC-8	O
myeloma	O
protein	O
This	O
was	O
obtained	O
from	O
the	O
serum	O
of	O
tumor	O
-	O
bearing	O
mice	O
as	O
previously	O
described	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

The	O
myeloma	O
tumor	O
was	O
obtained	O
through	O
the	O
courtesy	O
of	O
Dr.	O
Michael	O
Potter	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
MD	O
.	O

L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
Rabbit	O
serum	O
albumin	O
(	O
RSA	O
)	O
This	O
was	O
Fraction	O
V	O
obtained	O
from	O
Pentex	O
,	O
Inc.	O
,	O
Kankakee	O
,	O
IL	O
.	O

RSA	O
-	O
APPC	B
This	O
was	O
prepared	O
by	O
reacting	O
160	O
mg	O
of	O
RSA	O
in	O
about	O
10	O
ml	O
of	O
pH	O
9.5	O
borate	B
buffer	I
with	O
90	O
umoles	O
of	O
DPPC	B
for	O
18	O
hr	O
.	O

The	O
solution	O
was	O
then	O
dialyzed	O
against	O
pH	O
8	O
z	O
BBS	B
,	O
stored	O
frozen	O
and	O
used	O
as	O
needed	O
.	O

The	O
entire	O
prep-	O
ae	O
aration	O
was	O
carried	O
out	O
at	O
4	O
.	O

Radioiodination	O
of	O
RSA	O
-	O
APPC	B
RSA	O
-	O
APPC	B
was	O
trace	O
labeled	O
with	O
'	B
251	I
by	O
a	O
modification	O
of	O
the	O
method	O
of	O
Greenwood	O
et	O
al.	O
(	O
1963	O
)	O
.	O

Iodination	O
was	O
carried	O
out	O
in	O
0.45	O
ml	O
of	O
pH	O
8	O
BBS	B
containing	O
200	O
Ug	O
(	O
ca	O
.	O

3	O
n	O
-	O
mole	O
)	O
RSA	O
-	O
APPC	B
,	O
1	O
n	O
-	O
mole	O
of	O
KI	B
,	O
0.4	O
mCi	O
of	O
'	B
ZSI	I
and	O
300	O
n	O
-	O
mole	O
of	O
chloromine	B
T.	I
The	O
reaction	O
was	O
allowed	O
to	O
proceed	O
for	O
30	O
min	O
,	O
stopped	O
with	O
300	O
n	O
-	O
mole	O
of	O
bisulfite	B
and	O
the	O
product	O
dialyzed	O
to	O
remove	O
free	O
""""	O
'	O
I	O
and	O
reagents	B
.	O

Measurement	O
of	O
K	O
,	O
e	O
,	O
The	O
method	O
used	O
to	O
obtain	O
the	O
relative	O
binding	O
constants	O
for	O
the	O
various	O
haptens	B
is	O
based	O
on	O
the	O
technique	O
originally	O
developed	O
by	O
Skom	O
&	O
Talmadge	O
(	O
1958	O
)	O
for	O
precipitating	O
antigen	O
-	O
antibody	O
complexes	O
with	O
antiglobulin	O
.	O

In	O
our	O
assay	O
the	O
primary	O
haptenic	O
determinant	O
,	O
p	B
-	I
azophenylphosphory1choline	I
,	O
was	O
coupled	O
to	O
rabbit	O
serum	O
albumin	O
which	O
was	O
then	O
trace	O
labeled	O
with	O
1251	B
.	O

Labeled	B
antigen	I
was	O
mixed	O
with	O
varying	O
amounts	O
of	O
antibody	O
and	O
the	O
amount	O
of	O
antigen	B
bound	O
was	O
determined	O
by	O
precipitating	O
all	O
the	O
gamma	O
globulin	O
(	O
i.e.	O
bound	O
and	O
unbound	O
antibody	O
as	O
well	O
as	O
non	O
-	O
specific	O
y	O
globulin	O
)	O
with	O
goat	O
antiglobulin	O
antibody	O
and	O
measuring	O
the	O
radioactivity	O
associated	O
with	O
the	O
precipitate	O
.	O

Relative	O
binding	O
constants	O
(	O
K	O
,	O
e	O
,	O
)	O
for	O
the	O
different	O
haptens	B
were	O
determined	O
by	O
measuring	O
their	O
ability	O
to	O
inhibit	O
the	O
reaction	O
of	O
labeled	O
antigen	B
with	O
antibody	O
.	O

The	O
amount	O
of	O
antibody	O
was	O
chosen	O
so	O
that	O
about	O
60	O
%	O
of	O
the	O
labeled	O
antigen	B
was	O
bound	O
by	O
antibody	O
in	O
the	O
absence	O
of	O
hapten	B
.	O

In	O
a	O
typical	O
determination	O
the	O
antigen	B
solution	O
was	O
made	O
to	O
contain	O
100	O
ng	O
per	O
ml	O
of	O
1251-RSA	O
-	O
APPC	B
and	O
1	O
mg	O
/	O
ml	O
of	O
RSA	O
in	O
pH	O
8	O
BBS	B
.	O

The	O
required	O
concentration	O
of	O
antibody	O
was	O
made	O
up	O
in	O
normal	O
rabbit	O
serum	O
diluted	O
1:5	O
with	O
pH	O
8	O
BBS	B
.	O

HOPC-8	O
myeloma	O
protein	O
was	O
made	O
up	O
in	O
normal	O
mouse	O
serum	O
diluted	O
1:5	O
.	O

To	O
0.1	O
ml	O
of	O
antibody	O
(	O
or	O
HOPC-8	O
)	O
solution	O
were	O
added	O
,	O
0.1	O
ml	O
'	O
251-RSA	O
-	O
APPC	O
solution	O
and	O
0.1	O
ml	O
hapten	B
solution	O
in	O
pH	O
8	O
BBS	B
.	O

Hapten	B
concentrations	O
ranged	O
from	O
10	O
'	O
to	O
10-'M.	O
In	O
one	O
sample	O
(	O
uninhibited	O
)	O
,	O
hapten	B
solution	O
was	O
replaced	O
by	O
buffer	B
to	O
determine	O
the	O
amount	O
of	O
antigen	B
precipitated	O
in	O
the	O
absence	O
of	O
hapten	B
.	O

Another	O
mixture	O
(	O
non	O
-	O
specific	O
control	O
)	O
contained	O
0.1	O
ml	O
1:5	O
diluted	O
normal	O
rabbit	O
(	O
or	O
mouse	O
)	O
serum	O
in	O
place	O
of	O
antibody	O
,	O
0.1	O
ml	O
of	O
antigen	B
and	O
0.1	O
ml	O
of	O
buffer	B
.	O

All	O
tubes	O
were	O
incubated	O
at	O
37	O
for	O
30	O
min	O
.	O

Then	O
0.2	O
ml	O
of	O
anti	O
-	O
globulin	O
antiserum	O
was	O
added	O
to	O
all	O
tubes	O
.	O

The	O
amount	O
added	O
was	O
that	O
determined	O
to	O
be	O
sufficient	O
to	O
precipitate	O
all	O
the	O
globulin	O
in	O
the	O
mixture	O
.	O

Goat	O
anti	O
-	O
rabbit	O
y	O
-	O
globulin	O
was	O
used	O
to	O
precipitate	O
the	O
rabbit	O
antibodies	O
and	O
rabbit	O
anti	O
-	O
mouse	O
IgA	O
was	O
used	O
to	O
precipitate	O
the	O
HOPC-8	O
myeloma	O
protein	O
.	O

The	O
reaction	O
mixtures	O
were	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
1	O
hr	O
,	O
and	O
then	O
stored	O
at	O
5	O
overnight	O
.	O

The	O
tubes	O
were	O
centrifuged	O
,	O
the	O
supernatants	O
discarded	O
and	O
the	O
precipitates	O
washed	O
twice	O
with	O
saline	B
.	O

Radioactivity	O
in	O
the	O
precipitates	O
was	O
determined	O
.	O

All	O
determinations	O
were	O
done	O
in	O
duplicate	O
.	O

Per	O
cent	O
inhibition	O
is	O
given	O
by	O
:	O
Inhibition	O
=	O
f	O
1	O
ANTI	O
-	O
APPC	O
#	O
6055	O
loo	O
50	O
01	O
10	O
-	O
6	O
10	O
-	O
5	O
NPPC	B
GPC	B
,	O
Pc	O
P03	O
I_AD	O
CHOLINE	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
Fig.	O
1	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	B
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	B
antigen	B
to	O
anti	O
-	O
APPC	O
antibody	O
from	O
rabbit	O
6055	O
.	O

Values	O
determined	O
in	O
this	O
manner	O
were	O
reproducible	O
to	O
within	O
%	O
.	O

RESULTS	O
Plots	O
of	O
effect	O
of	O
hapten	B
on	O
antigen	B
binding	O
are	O
given	O
in	O
Fig.	O
1	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	O
6055	O
and	O
in	O
Fig.	O
2	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	O
5920	O
.	O

The	O
plots	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	O
6057	O
,	O
were	O
essentially	O
identical	O
to	O
those	O
in	O
Fig.	O
1	O
.	O

From	O
these	O
data	O
,	O
K	O
,	O
el	O
values	O
were	O
calculated	O
relative	O
to	O
the	O
most	O
inhibitory	O
hapten	B
,	O
NPPC	B
,	O
according	O
to	O
the	O
formula	O
:	O
_	O
(	O
NPPC	B
)	O
at	O
50	O
%	O
inhibition	O
K	O
""""	O
'	O
(	O
HAPTEN	B
)	O
at	O
50	O
%	O
inhibition	O
The	O
values	O
of	O
K	O
,	O
e	O
,	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
only	O
effective	O
inhibitors	O
observed	O
are	O
those	O
listed	O
in	O
Table	O
1	O
,	O
having	O
K	O
,	O
e	O
,	O
values	O
>	O
0.0001	O
.	O

It	O
is	O
interesting	O
that	O
the	O
p	B
-	I
iodophenyltrimethylammonium	I
ion	I
gave	O
detectable	O
inhibition	O
in	O
2	O
instances	O
.	O

Twentyfive	O
other	O
haptens	B
were	O
tested	O
.	O

None	O
showed	O
appreciable	O
binding	O
to	O
anti	O
-	O
APPC	B
antibodies	O
.	O

Among	O
those	O
tested	O
were	O
negatively	O
and	O
positively	O
chargen	O
haptens	B
,	O
including	O
other	O
phenyltrimethylammonium	B
ions	I
and	O
ANTI	O
-	O
APPC	O
#	O
5920	O
loo	O
50	O
z	O
x	O
NPPC	B
,	O
GPC	O
I	O
-	O
AP	O
PC	O
CHOLINE	B
0	O
10	O
-	O
6	O
10	O
-	O
5	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10-I	O
INHIBITOR	O
CONC.	O
(	O
M	O
)	O
Fig.	O
2	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	B
antigen	O
to	O
anti	O
-	O
APPC	B
antibody	O
from	O
rabbit	O
5920	O
.	O

inhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
uninhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
x	O
100	O
.	O

Specificity	O
of	O
Anti	O
-	O
p	O
-	O
Azophenylphosphorylcholine	B
Antibodies	O
Table	O
1	O
.	O

Relative	O
binding	O
constants	O
of	O
haptens	B
for	O
anti	O
APPC	B
antibodies	O
Hapten	O
NPPC	O
t	I
.-	I
a	I
-	I
glycerophosphorylcholine	I
Phosphorylcholine	B
I	B
-	I
Ap	I
Choline	I
Phenylphosphonate	B
Phenylphosphate	B
Rabbit	O
No.	O
5920	O
6055	O
6057	O
K	O
1.0	O
0.015	O
0.0003	O
0.004	O
0.0007	O
0.0001	O
0.0001	O
1.0	O
1.0	O
0.019	O
0.016	O
0.0004	O
0.0005	O
0.0001	O
<	O
0.0001	O
0.00006	O
0.00006	O
0.0002	O
<	O
0.0001	O
0.0001	O
<	O
0.0001	O
several	O
phenylarsonates	B
and	O
sulfonates	B
.	O

A	O
representative	O
list	O
of	O
some	O
of	O
these	O
non	O
-	O
inhibitory	O
haptens	B
is	O
given	O
in	O
Table	O
2	O
.	O

The	O
results	O
of	O
inhibition	O
studies	O
with	O
the	O
mouse	O
myeloma	O
protein	O
HOPC-8	O
are	O
given	O
in	O
Fig.	O
3	O
where	O
the	O
inhibition	O
curves	O
are	O
drawn	O
only	O
for	O
those	O
haptens	B
showing	O
significant	O
ability	O
to	O
inhibit	O
.	O

K	O
,	O
e	O
,	O
values	O
were	O
calculated	O
as	O
described	O
above	O
and	O
are	O
listed	O
in	O
Table	O
3	O
.	O

For	O
comparison	O
,	O
Table	O
3	O
also	O
lists	O
values	O
of	O
K	O
,	O
el	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
TEPC-15	B
in	O
a	O
system	O
using	O
the	O
C	B
-	I
polysaccharide	I
of	O
pneumococcus	O
as	O
an	O
antigen	B
.	O

There	O
is	O
adequate	O
serological	O
and	O
chemical	O
evidence	O
showing	O
that	O
HOPC-8	O
and	O
TEPC-15	O
are	O
nearly	O
identical	O
proteins	O
(	O
Potter	O
&	O
Lieberman	O
,	O
1970	O
;	O
Hood	O
et	O
al.	O
,	O
1970	O
)	O
.	O

The	O
values	O
in	O
Table	O
3	O
show	O
the	O
close	O
correspondence	O
between	O
our	O
values	O
of	O
K	O
,	O
e	O
,	O
for	O
HOPC-8	O
and	O
those	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
for	O
TECP-15	O
.	O

The	O
K	O
,	O
e	O
,	O
values	O
for	O
anti	O
-	O
APPC	B
from	O
rabbit	O
6055	O
are	O
also	O
listed	O
in	O
Table	O
3	O
to	O
facilitate	O
comparisons	O
with	O
HOPC-8	O
.	O

In	O
order	O
to	O
assess	O
further	O
the	O
validity	O
of	O
the	O
inhibition	O
method	O
as	O
used	O
here	O
for	O
obtaining	O
Kre	O
,	O
values	O
,	O
we	O
have	O
compared	O
the	O
value	O
of	O
K	O
,	O
e	O
,	O
calculated	O
from	O
the	O
individual	O
binding	O
constants	O
of	O
HOPC-8	O
for	O
phosphory1choline	B
(	O
PC	B
)	O
and	O
p	B
-	I
nitrophenylphosphorylcholine	I
(	O
NPPC	B
)	O
as	O
determined	O
by	O
equilibrium	O
dialysis	O
,	O
to	O
the	O
Kre	O
,	O
values	O
calculated	O
from	O
the	O
inhibition	O
data	O
.	O

As	O
measured	O
by	O
equilibrium	O
dialysis	O
with	O
HOPC-8	O
the	O
binding	O
constant	O
for	O
PC	B
(	O
KPc	O
)	O
was	O
found	O
to	O
be	O
1.2	O
x	O
106	O
M-1	O
and	O
for	O
NPPC	B
the	O
KNPPC	O
was	O
0.43	O
x	O
106	O
M-1	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
ratio	O
of	O
the	O
two	O
is	O
:	O
1.20	O
x	O
106	O
_	O
KPCIKNPPC	O
-	O
0.43	O
x	O
106	O
-	O
2.8	O
.	O

Table	O
2	O
.	O

Haptens	B
unable	O
to	O
inhibit	O
binding	O
of	O
RSA	O
-	O
APPC	B
to	O
anti	O
-	O
APPC	B
antibodies	O
""""	O
Acetylcholine	B
Phenyltrimethylammonium	B
p	B
-	I
Aminophenyltrimethylammonium	I
chloride	I
Phenylarsonate	B
p	B
-	I
Nitrophenylarsonate	I
p	B
-	I
lodophenylarsonate	I
Hydroxyphenylazo	B
)	I
phenylarsonate	I
p	B
-	I
lodobenzenesulfonate	I
Naphthalene	B
-	I
l	I
-	I
sulfonate	I
5-Nitro-3-iodo-4-hydroxyphenylacetate	B
5-Nitro-4-hydroxyphenylacetate	B
Kre	O
,	O
<	O
0.0001	O
,	O
relative	O
to	O
NPPC	B
,	O
which	O
is	O
equivalent	O
to	O
<	O
50	O
%	O
inhibition	O
at	O
0.1	O
M	O
hapten	B
concentration	O
.	O

903	O
HOPC-8	O
100	O
PC	O
WPC	O
I	O
-	O
Ap	O
GPC	O
AcC	O
m	O
50	O
z	O
_	O
<	O
60P	O
Y	O
,	O
OOPO=3	O
~	O
OP	O
03	O
0	O
ITS	O
I	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
IT	O
2	O
IT	O
l	O
Fig.	O
3	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	B
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	B
antigen	B
to	O
mouse	O
myeloma	O
protein	O
HOPC-8	O
.	O

The	O
ratio	O
obtained	O
using	O
K	O
,	O
e	O
,	O
values	O
obtained	O
by	O
hapten	B
inhibition	O
(	O
Table	O
3	O
)	O
is	O
2.9	O
,	O
a	O
satisfactory	O
agreement	O
.	O

DISCUSSION	O
The	O
relative	O
binding	O
constants	O
(	O
K	O
,	O
,	O
,	O
)	O
for	O
haptens	B
to	O
anti	O
-	O
APPC	B
antibodies	O
were	O
determined	O
by	O
hapten	B
inhibition	O
.	O

About	O
30	O
potential	O
ligands	B
were	O
tested	O
and	O
only	O
5	O
of	O
these	O
were	O
shown	O
to	O
bind	O
significantly	O
(	O
NPPC	B
,	O
glycerophosphorylcholine	B
,	O
I	B
-	I
Ap	I
,	O
choline	B
and	O
phosphorylcholine	B
)	O
.	O

The	O
values	O
of	O
K	O
,	O
,	O
,	O
obtained	O
with	O
the	O
several	O
haptens	B
allow	O
inferences	O
as	O
to	O
the	O
relative	O
importance	O
of	O
the	O
particular	O
structural	O
features	O
of	O
each	O
hapten	B
in	O
contributing	O
to	O
the	O
binding	O
energy	O
.	O

The	O
rabbit	O
anti	O
-	O
APPC	B
antibodies	O
studied	O
here	O
were	O
raised	O
against	O
a	O
hapten	B
having	O
3	O
distinct	O
structural	O
features	O
-	O
a	O
p	B
-	I
azophenyl	I
group	I
,	O
a	O
negatively	O
charged	O
phosphoryl	B
ester	I
group	I
,	O
and	O
a	O
positively	O
charged	O
quarternary	B
ammonium	I
group	I
.	O

Of	O
these	O
,	O
the	O
one	O
apparently	O
very	O
important	O
for	O
binding	O
is	O
the	O
positively	B
charged	I
group	I
,	O
since	O
haptens	B
which	O
were	O
most	O
effective	O
in	O
inhibiting	O
the	O
binding	O
of	O
the	O
APPC	B
-	B
containing	I
antigen	I
to	O
antibody	O
contained	O
this	O
group	O
(	O
Table	O
1	O
)	O
and	O
those	O
least	O
effective	O
did	O
not	O
.	O

Thus	O
,	O
removal	O
of	O
the	O
choline	B
group	I
from	O
phenylphosphorylcholine	B
decreases	O
its	O
binding	O
strength	O
by	O
a	O
factor	O
of	O
about	O
Table	O
3	O
.	O

Comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
for	O
HOPC-8	O
,	O
TEPC-15	O
and	O
a	O
rabbit	O
anti	O
-	O
APPC	B
antibody	O
Hapten	B
HOPC-8	O
2.9	O
1.0	O
0.5	O
0.033	O
0.015	O
0.01	O
""""	O
0.001	O
<	O
0.0001	O
Rabbit	O
anti	O
APPC	B
-	O
No	O
.	O

6055	O
K	O
,	O
TEPC-15	O
Phosphorylcholine	B
NPPC	B
-a	O
-	B
glycerophosphorylchole	I
I	B
-	I
Ap	I
Acetylcholine	B
Choline	B
Phenylphosphate	B
Phenylphosphonate	B
2.9	O
0.0004	O
1.0	O
0.019	O
0.0001	O
0.0001	O
0.008	O
0.00006	O
0.005	O
0.0001	O
-	O
0.0002	O
-	O
0.27	O
Calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
the	O
inhibition	O
of	O
binding	O
of	O
c	B
-	I
polysaccharide	I
of	O
Pneumococcus	O
.	O

The	O
values	O
were	O
obtained	O
by	O
setting	O
the	O
Kre	O
,	O
value	O
for	O
phosphorylchole	B
at	O
2.9	O
and	O
calculating	O
the	O
other	O
values	O
relative	O
to	O
this	O
.	O

""""	O
Estimated	O
from	O
the	O
value	O
of	O
Kre	O
,	O
for	O
choline	B
with	O
TEPC-15	O
.	O

904	O
L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
10,000	O
since	O
K	O
,	O
e	O
,	O
for	O
phenylphosphate	B
was	O
at	O
least	O
this	O
much	O
smaller	O
than	O
the	O
K	O
,	O
e	O
,	O
for	O
NPPC	B
(	O
Table	O
1	O
)	O
.	O

Moreover	O
,	O
p	B
-	I
iodophenyltrimethylammonium	I
gave	O
detectable	O
inhibition	O
with	O
one	O
anti	O
-	O
APPC	B
preparation	O
,	O
although	O
its	O
structure	O
is	O
otherwise	O
rather	O
different	O
from	O
the	O
choline	B
inhibitors	O
.	O

The	O
p	B
-	I
nitrophenyl	I
group	I
of	O
NPPC	B
contributes	O
very	O
effectively	O
to	O
the	O
specific	O
interaction	O
,	O
since	O
replacing	O
it	O
by	O
the	O
glycerol	B
group	I
decreases	O
the	O
binding	O
by	O
a	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
.	O

Similarly	O
,	O
removing	O
the	O
p	B
-	I
nitrophenyl	I
group	I
,	O
to	O
give	O
phosphorylcholine	B
,	O
decreases	O
the	O
binding	O
by	O
another	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
so	O
that	O
phosphorylcholine	B
binds	O
2500	O
times	O
more	O
weakly	O
than	O
NPPC	B
.	O

The	O
negatively	O
charged	O
phosphoryl	B
group	I
apparently	O
interacts	O
only	O
to	O
a	O
small	O
extent	O
with	O
the	O
antibody	O
site	O
.	O

This	O
is	O
evident	O
from	O
the	O
fact	O
that	O
K	O
,	O
,	O
,	O
for	O
phosphorylcholine	B
is	O
only	O
6	O
-	O
8	O
times	O
greater	O
than	O
Kre	O
,	O
for	O
choline	B
for	O
2	O
antibody	O
preparations	O
studied	O
and	O
is	O
actually	O
smaller	O
than	O
that	O
for	O
choline	B
for	O
the	O
third	O
antibody	O
preparation	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
phenylphosphate	B
(	O
Table	O
2	O
)	O
and	O
phenylphosphonate	B
(	O
Table	O
1	O
)	O
show	O
only	O
weak	O
binding	O
to	O
the	O
antibodies	O
.	O

Thus	O
the	O
contribution	O
of	O
the	O
negative	O
charge	O
to	O
binding	O
is	O
not	O
great	O
,	O
in	O
spite	O
of	O
the	O
fact	O
that	O
we	O
have	O
previously	O
shown	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
that	O
a	O
positively	O
charged	O
arginyl	B
residue	I
is	O
present	O
in	O
the	O
anti	O
-	O
APPC	B
antibody	O
site	O
,	O
providing	O
a	O
basis	O
for	O
electrostatic	O
interaction	O
with	O
the	O
phosphoryl	B
group	I
.	O

When	O
the	O
rabbit	O
anti	O
-	O
APPC	B
antibodies	O
are	O
compared	O
to	O
the	O
mouse	O
myeloma	O
protein	O
,	O
HOPC-8	O
,	O
some	O
very	O
obvious	O
differences	O
in	O
specificity	O
are	O
apparent	O
.	O

In	O
general	O
HOPC-8	O
shows	O
broader	O
cross	O
-	O
reactivity	O
than	O
the	O
induced	O
rabbit	O
antibody	O
.	O

The	O
representative	O
comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
(	O
relative	O
to	O
NPPC	B
)	O
given	O
in	O
Table	O
3	O
,	O
indicates	O
that	O
many	O
more	O
of	O
the	O
compounds	O
listed	O
show	O
appreciable	O
binding	O
(	O
K	O
,	O
e	O
,	O
>	O
0.005	O
)	O
to	O
HOPC-8	O
than	O
to	O
rabbit	O
anti	O
-	O
APPC	B
.	O

In	O
addition	O
,	O
the	O
fine	O
specificity	O
of	O
HOPC-8	O
is	O
quite	O
different	O
from	O
that	O
of	O
the	O
rabbit	O
antibody	O
,	O
since	O
the	O
relative	O
binding	O
constant	O
for	O
phosphorylcholine	B
is	O
10	O
'	O
greater	O
with	O
HOPC-8	O
than	O
with	O
rabbit	O
anti	O
-	O
APPC	B
.	O

The	O
binding	O
to	O
the	O
2	O
proteins	O
differs	O
for	O
glycerophosphorylcholine	B
by	O
a	O
factor	O
of	O
25	O
,	O
for	O
chohne	B
by	O
a	O
factor	O
of	O
100	O
and	O
for	O
acetylcholine	B
by	O
a	O
factor	O
greater	O
than	O
100	O
.	O

The	O
negatively	O
charged	O
phosphoryl	B
group	I
appears	O
to	O
be	O
much	O
more	O
important	O
for	O
binding	O
to	O
HOPC-8	O
than	O
to	O
the	O
rabbit	O
antibody	O
,	O
since	O
the	O
K-	O
,	O
value	O
for	O
phosphorylcholine	B
is	O
greater	O
than	O
that	O
for	O
choline	B
by	O
a	O
factor	O
of	O
about	O
300	O
in	O
the	O
case	O
of	O
HOPC-8	O
.	O

For	O
rabbit	O
antibody	O
this	O
factor	O
is	O
only	O
about	O
10	O
(	O
Table	O
3	O
)	O
.	O

Moreover	O
,	O
phenylphosphate	B
binds	O
more	O
than	O
10	O
times	O
more	O
strongly	O
to	O
HOPC-8	O
than	O
to	O
anti	O
-	O
APPC	B
antibody	O
.	O

This	O
is	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
addition	O
of	O
the	O
p	B
-	I
nitrophenyl	I
group	I
to	O
phosphorylcholine	B
neither	O
adds	O
to	O
nor	O
subtracts	O
from	O
the	O
binding	O
energy	O
with	O
HOPC-8	O
,	O
whereas	O
it	O
adds	O
a	O
great	O
deal	O
to	O
the	O
binding	O
energy	O
with	O
anti	O
-	O
APPC	B
antibody	O
.	O

The	O
fact	O
that	O
the	O
HOPC-8	O
site	O
is	O
large	O
enough	O
to	O
accommodate	O
the	O
p	B
-	I
nitrophenyl	I
group	I
of	O
NPPC	B
with	O
little	O
steric	O
hindrance	O
is	O
of	O
interest	O
,	O
since	O
the	O
site	O
of	O
McPC-603	O
protein	O
,	O
which	O
also	O
binds	O
phosphorylcholine	B
analogues	I
with	O
similar	O
although	O
not	O
identical	O
specificity	O
(	O
Leon	O
&	O
Young	O
,	O
1971	O
)	O
also	O
can	O
accommodate	O
a	O
large	O
substituent	O
on	O
phosphorylcholine	B
.	O

Thus	O
,	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
studies	O
of	O
the	O
Fab	O
fragment	O
of	O
McPC-603	O
as	O
summarized	O
by	O
Segal	O
et	O
al.	O
(	O
1974	O
)	O
indicate	O
that	O
there	O
is	O
a	O
large	O
region	O
of	O
the	O
cleft	O
in	O
which	O
phosphorylcholine	B
is	O
bound	O
which	O
is	O
available	O
for	O
binding	O
additional	O
structure	O
.	O

Indeed	O
,	O
one	O
of	O
the	O
compounds	O
used	O
in	O
defining	O
the	O
site	O
region	O
was	O
2-	B
(	I
5'-acetoxy	I
-	I
mercury-2'-thiemyl	I
)	I
-ethylphosphory1choline	I
(	O
Padlan	O
et	O
al.	O
,	O
1973	O
)	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
large	O
compound	O
might	O
bind	O
equally	O
as	O
well	O
to	O
the	O
HOPC-8	O
site	O
as	O
to	O
the	O
McPC-603	O
site	O
.	O

The	O
differences	O
between	O
HOPC-8	O
sites	O
and	O
rabbit	O
anti	O
-	O
APPC	B
sites	O
are	O
interesting	O
in	O
view	O
of	O
the	O
fact	O
that	O
when	O
APPC	B
conjugated	O
to	O
protein	O
is	O
used	O
as	O
an	O
immunogen	O
in	O
the	O
BALB	O
/	O
c	O
mouse	O
,	O
the	O
IgM	O
antibodies	O
elicited	O
are	O
largely	O
of	O
the	O
HOPC-8-TEPC-15	O
idiotype	O
and	O
show	O
the	O
same	O
binding	O
characteristics	O
as	O
the	O
myeloma	O
proteins	O
(	O
Lee	O
it	O
al.	O
,	O
1974	O
)	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
receptor	O
sites	O
on	O
cells	O
responding	O
to	O
APPC	B
in	O
the	O
rabbits	O
we	O
used	O
are	O
quite	O
different	O
in	O
structure	O
from	O
sites	O
on	O
cells	O
which	O
respond	O
in	O
the	O
mouse	O
.	O

Furthermore	O
,	O
we	O
have	O
previously	O
observed	O
that	O
the	O
rabbit	O
antibodies	O
are	O
rather	O
heterogeneous	O
,	O
as	O
evidenced	O
by	O
their	O
non	O
-	O
linear	O
binding	O
curves	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
,	O
and	O
their	O
complex	O
isoelectric	O
focusing	O
patterns	O
(	O
Nutt	O
et	O
al.	O
,	O
1976	O
)	O
.	O

Populations	O
of	O
anti	O
-	O
APPC	B
antibodies	O
produced	O
also	O
differ	O
from	O
rabbit	O
to	O
rabbit	O
as	O
evidenced	O
by	O
the	O
differences	O
in	O
binding	O
strength	O
for	O
p	B
-	I
iodophenyltrimethylammonium	I
and	O
for	O
choline	B
shown	O
by	O
antibodies	O
from	O
rabbits	O
6055	O
and	O
5920	O
(	O
Table	O
1	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
induced	O
mouse	O
antibodies	O
appear	O
to	O
be	O
essentially	O
monoclonal	O
products	O
(	O
Lee	O
et	O
al.	O
,	O
1974	O
)	O
.	O

There	O
are	O
,	O
of	O
course	O
,	O
some	O
similarities	O
between	O
the	O
rabbit	O
antibodies	O
and	O
HOPC-8	O
.	O

The	O
major	O
of	O
these	O
is	O
that	O
for	O
both	O
binding	O
sites	O
the	O
positively	O
charged	O
quarternary	B
ammonium	I
group	I
appears	O
to	O
be	O
the	O
immunodominant	O
group	O
,	O
since	O
those	O
haptens	B
not	O
containing	O
this	O
group	O
are	O
bound	O
very	O
poorly	O
in	O
both	O
cases	O
(	O
Table	O
3	O
)	O
.	O

Thus	O
a	O
negatively	O
charged	O
carboxylate	B
group	I
which	O
would	O
interact	O
with	O
this	O
group	O
,	O
and	O
which	O
we	O
have	O
shown	O
to	O
be	O
present	O
in	O
the	O
combining	O
site	O
of	O
both	O
HOPC-8	O
and	O
anti	O
-	O
APPC	B
antibodies	O
,	O
is	O
probably	O
the	O
most	O
important	O
common	O
feature	O
of	O
both	O
sites	O
.	O

The	O
above	O
considerations	O
allow	O
us	O
to	O
make	O
the	O
following	O
inferences	O
about	O
the	O
topography	O
of	O
the	O
antiAPPC	O
and	O
HOPC-8	O
binding	O
sites	O
:	O
(	O
1	O
)	O
The	O
anti	O
-	O
APPC	B
site	O
contains	O
a	O
region	O
closely	O
complementary	O
to	O
the	O
phenyl	B
group	I
of	O
APPC	B
,	O
so	O
that	O
an	O
appreciable	O
part	O
ofAhe	O
binding	O
interaction	O
occurs	O
in	O
this	O
region	O
.	O

The	O
HOPC-8	O
site	O
accommodates	O
the	O
phenyl	B
group	I
with	O
little	O
interaction	O
energy	O
.	O

(	O
2	O
)	O
An	O
arginyl	B
residue	I
in	O
the	O
HOPC-8	O
site	O
contributes	O
a	O
positive	O
charge	O
which	O
interacts	O
strongly	O
with	O
the	O
negative	O
charge	O
on	O
the	O
phosphoryl	B
group	I
.	O

In	O
the	O
anti	O
-	O
APPC	B
site	O
,	O
which	O
also	O
contains	O
an	O
arginyl	B
residue	I
,	O
the	O
interaction	O
with	O
the	O
phosphoryl	B
group	I
is	O
much	O
weaker	O
,	O
and	O
therefore	O
the	O
2	O
groups	O
are	O
probably	O
farther	O
apart	O
than	O
in	O
the	O
HOPC-8	O
site	O
.	O

(	O
3	O
)	O
Both	O
sites	O
interact	O
strongly	O
with	O
the	O
quaternary	B
ammonium	I
group	I
of	O
choline	B
and	O
thus	O
this	O
group	O
probably	O
closely	O
approaches	O
a	O
carboxylate	B
group	I
present	O
in	O
both	O
sites	O
.	O

Acknowledgements	O
-	O
We	O
thank	O
Messrs.	O
Robert	O
Hewson	O
,	O
Leonard	O
Rendina	O
and	O
Arthur	O
Trott	O
for	O
expert	O
technical	O
assistance	O
.	O

Specificity	O
of	O
Anti	O
-	O
p	B
-	I
Azophenylphosphorylcholine	I
Antibodies	O

Manganous	B
chloride	I
and	O
Congo	B
red	I
incorporated	O
into	O
blotting	O
paper	O
discs	O
have	O
been	O
used	O
to	O
differentiate	O
gonococci	O
from	O
meningococci	O
.	O

The	O
new	O
technique	O
is	O
simple	O
and	O
reliable	O
;	O
the	O
materials	O
for	O
the	O
test	O
are	O
inexpensive	O
.	O

The	O
method	O
will	O
increase	O
the	O
efficiency	O
of	O
distinguishing	O
between	O
the	O
pathogenic	O
Neisseria	O
in	O
any	O
clinical	O
bacteriology	O
laboratory	O
and	O
especially	O
in	O
those	O
in	O
the	O
tropical	O
areas	O
.	O

A	O
methodology	O
to	O
determine	O
the	O
intrinsic	O
capacities	O
of	O
a	O
microflora	O
to	O
degrade	O
gasoline	B
was	O
developed	O
,	O
in	O
particular	O
for	O
assessing	O
the	O
potential	O
of	O
autochtonous	O
populations	O
of	O
polluted	O
and	O
non	O
polluted	O
soils	O
for	O
natural	O
attenuation	O
and	O
engineered	O
bioremediation	O
.	O

A	O
model	O
mixture	O
(	O
GM23	B
)	O
constituted	O
of	O
the	O
23	O
most	O
representative	O
hydrocarbons	B
of	O
a	O
commercial	O
gasoline	B
was	O
used	O
.	O

The	O
capacities	O
of	O
the	O
microflorae	O
(	O
kinetics	O
and	O
extent	O
of	O
biodegradation	O
)	O
were	O
assessed	O
by	O
chromatographic	O
analysis	O
of	O
hydrocarbon	B
consumption	O
and	O
of	O
CO2	B
production	O
.	O

The	O
degradation	O
of	O
the	O
components	O
of	O
GM23	B
was	O
assayed	O
in	O
separate	O
incubations	O
of	O
each	O
component	O
and	O
in	O
the	O
complete	O
mixture	O
.	O

For	O
the	O
microflora	O
of	O
an	O
unpolluted	O
spruce	O
forest	O
soil	O
,	O
all	O
hydrocarbons	B
of	O
GM23	B
except	O
cyclohexane	B
,	O
2,2,4-	B
and	O
2,3,4-trimethylpentane	B
isomers	O
were	O
degraded	O
to	O
below	O
detection	O
limit	O
in	O
28	O
days	O
.	O

This	O
microflora	O
was	O
reinforced	O
with	O
two	O
mixed	O
microbial	O
communities	O
selected	O
from	O
gasoline	B
-	O
polluted	O
sites	O
and	O
shown	O
to	O
degrade	O
cyclohexane	B
and	O
2,2,4-trimethylpentane	B
.	O

With	O
the	O
reinforced	O
microflora	O
,	O
complete	O
degradation	O
of	O
GM23	B
was	O
observed	O
.	O

The	O
degradation	O
patterns	O
of	O
individual	O
components	O
of	O
GM23	B
were	O
similar	O
when	O
the	O
compounds	O
were	O
present	O
individually	O
or	O
in	O
the	O
GM23	B
mixture	O
,	O
as	O
long	O
as	O
the	O
concentrations	O
of	O
2-ethyltoluene	B
and	O
trimethylbenzene	B
isomers	I
were	O
kept	O
sufficiently	O
low	O
(	O
<	O
or	O
=	O
35	O
mg.l-1	O
)	O
to	O
remain	O
below	O
their	O
inhibitory	O
level	O
.	O

The	O
first	O
acyclonucleosides	B
based	O
on	O
the	O
benzothiadiazine	B
dioxide	I
system	O
were	O
synthesized	O
following	O
the	O
silylation	O
procedure	O
.	O

Several	O
acyclic	B
moieties	I
,	O
including	O
acetoxyethoxymethyl	B
,	O
benzyloxymethyl	B
,	O
and	O
propargyloxymethyl	B
groups	I
,	O
were	O
introduced	O
.	O

Two	O
synthetic	O
strategies	O
were	O
designed	O
to	O
selectively	O
obtain	O
the	O
N-1	B
or	O
N-3	B
derivatives	I
.	O

Lipase	O
-	O
mediated	O
deacylation	O
was	O
used	O
for	O
the	O
deprotection	O
of	O
the	O
acyclonucleosides	B
.	O

Some	O
of	O
the	O
benzothiadiazine	B
dioxide	I
acyclonucleosides	I
,	O
in	O
particular	O
16	B
,	O
proved	O
active	O
against	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
at	O
concentrations	O
slightly	O
higher	O
than	O
that	O
found	O
for	O
ganciclovir	B
[	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
=	O
3	O
.	O
5	O
-	O
3.7	O
micrograms	O
/	O
mL	O
,	O
cytotoxicity	O
(	O
CC50	O
)	O
>	O
/=	O
40	O
micrograms	O
/	O
mL	O
,	O
MCC	O
=	O
20	O
micrograms	O
/	O
mL	O
]	O
.	O

Additionally	O
,	O
compound	B
16	I
inhibited	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
in	O
CEM	O
cells	O
at	O
concentrations	O
that	O
were	O
5-fold	O
lower	O
than	O
its	O
cytotoxic	O
concentration	O
.	O

To	O
examine	O
the	O
stereospecific	O
effects	O
of	O
lipoic	B
compounds	I
on	O
pyruvate	B
metabolism	O
,	O
the	O
effects	O
of	O
R	B
-	I
lipoic	I
acid	I
(	O
R	B
-	I
LA	I
)	O
,	O
S	B
-	I
lipoic	I
acid	I
(	O
S	B
-	I
LA	I
)	I
and	O
1,2-diselenolane-3-pentanoic	B
acid	I
(	O
Se	B
-	I
LA	I
)	O
on	O
the	O
activities	O
of	O
the	O
mammalian	O
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	O
)	O
and	O
its	O
catalytic	O
components	O
were	O
investigated	O
.	O

Both	O
S	B
-	I
LA	I
and	O
R	B
-	I
LA	I
markedly	O
inhibited	O
PDC	O
activity	O
;	O
whereas	O
Se	B
-	I
LA	I
displayed	O
inhibition	O
only	O
at	O
higher	O
concentrations	O
.	O

Examination	O
of	O
the	O
effects	O
on	O
the	O
individual	O
catalytic	O
components	O
indicated	O
that	O
Se	B
-	I
LA	I
inhibited	O
the	O
pyruvate	O
dehydrogenase	O
component	O
;	O
whereas	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
inhibited	O
the	O
dihydrolipoamide	O
acetyltransferase	O
component	O
.	O

The	O
three	O
lipoic	B
compounds	I
lowered	O
dihydrolipoamide	O
dehydrogrenase	O
(	O
E3	O
)	O
activity	O
in	O
the	O
forward	O
reaction	O
by	O
about	O
30	O
to	O
45	O
%	O
.	O

The	O
kinetic	O
data	O
of	O
E3	O
showed	O
that	O
both	O
R	B
-	I
LA	I
and	O
Se	B
-	I
LA	I
are	O
used	O
as	O
substrates	O
by	O
E3	O
for	O
the	O
reverse	O
reaction	O
.	O

Decarboxylation	O
of	O
[	B
1	I
-	I
14C	I
]	I
pyruvate	I
via	O
PDC	O
by	O
cultured	O
HepG2	O
cells	O
was	O
not	O
affected	O
by	O
R	B
-	I
LA	I
,	O
but	O
moderately	O
decreased	O
with	O
S	B
-	I
LA	I
and	O
Se	B
-	I
LA	I
.	O

These	O
findings	O
indicate	O
that	O
(	O
i	O
)	O
purified	O
PDC	O
and	O
its	O
catalytic	O
components	O
are	O
affected	O
by	O
lipoic	B
compounds	I
based	O
on	O
their	O
stereoselectivity	O
;	O
and	O
(	O
ii	O
)	O
the	O
oxidation	O
of	O
pyruvate	B
by	O
intact	O
HepG2	O
cells	O
is	O
not	O
inhibited	O
by	O
R	B
-	I
LA	I
.	O

The	O
later	O
finding	O
with	O
the	O
intact	O
cells	O
is	O
in	O
support	O
of	O
therapeutic	O
role	O
of	O
R	B
-	I
LA	I
as	O
an	O
antioxidant	O
.	O

A	O
highly	O
sensitive	O
pre	O
-	O
column	O
HPLC	O
method	O
for	O
simultaneous	O
determination	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
in	O
urine	O
was	O
developed	O
.	O

The	O
analytes	O
were	O
labelled	O
with	O
4-	B
(	I
5,6-dimethoxy-2-phthalimidinyl	I
)	I
-2-methoxyphenylsulfonyl	I
chloride	I
at	O
70	O
degrees	O
C	O
for	O
20	O
min	O
.	O

The	O
derivatives	O
separated	O
on	O
tandem	O
reversed	O
-	O
phase	O
columns	O
by	O
a	O
gradient	O
elution	O
and	O
were	O
monitored	O
with	O
fluorescence	O
detection	O
at	O
318	O
nm	O
(	O
excitation	O
)	O
and	O
392	O
nm	O
(	O
emission	O
)	O
.	O

The	O
detection	O
limits	O
for	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
were	O
1	O
-	O
5	O
fmol	O
/	O
injection	O
(	O
S	O
/	O
N	O
=	O
3	O
)	O
.	O

Urine	O
samples	O
were	O
treated	O
with	O
o	B
-	I
phthalaldehyde	I
,	O
followed	O
by	O
purification	O
on	O
a	O
Bond	O
Elut	O
C18	O
column	O
before	O
conducting	O
the	O
labelling	O
reaction	O
.	O

Pro	B
-	I
Hyp	I
,	O
Pro	B
-	I
Gly	I
and	O
Pro	B
-	I
Pro	I
were	O
identified	O
as	O
prolyl	B
dipeptides	I
in	O
urine	O
.	O

The	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
relative	O
standard	O
deviations	O
were	O
1.5	O
-	O
4.8	O
and	O
1.7	O
-	O
5.8	O
%	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
Pro	B
-	I
Hyp	I
,	O
Pro	B
-	I
Gly	I
,	O
Pro	B
-	I
Pro	I
,	O
Pro	B
and	O
Hyp	B
in	O
normal	O
human	O
urine	O
were	O
97.6	O
+	O
/-	O

28.2	O
,	O
2.74	O
+	O
/-	O

1.48	O
,	O
2.08	O
+	O
/-	O

1.13	O
,	O
6.71	O
+	O
/-	O

3.34	O
and	O
2.30	O
+	O
/-	O

1.59	O
nmol	O
/	O
mg	O
creatinine	B
,	O
respectively	O
.	O

An	O
enzyme	O
with	O
lipase	O
and	O
esterase	O
activity	O
was	O
purified	O
from	O
bovine	O
pancreas	O
.	O

Furthermore	O
,	O
a	O
non	O
-	O
radioactive	O
lipase	O
assay	O
was	O
developed	O
which	O
is	O
100	O
times	O
more	O
sensitive	O
than	O
the	O
conventional	O
methods	O
and	O
allowed	O
the	O
characterization	O
of	O
the	O
lipase	O
activity	O
of	O
the	O
enzyme	O
.	O

The	O
lipase	O
activity	O
increased	O
42	O
times	O
in	O
the	O
presence	O
of	O
10	O
mM	O
sodium	B
taurocholate	I
,	O
which	O
for	O
the	O
first	O
time	O
provides	O
direct	O
evidence	O
that	O
a	O
bile	O
salt	O
-	O
activated	O
lipase	O
(	O
bp	O
-	O
BAL	O
)	O
was	O
isolated	O
from	O
bovine	O
pancreas	O
.	O

This	O
conclusion	O
is	O
further	O
supported	O
by	O
the	O
fact	O
that	O
the	O
N	B
-	I
terminal	I
amino	I
acid	I
sequence	O
of	O
this	O
lipase	O
/	O
esterase	O
is	O
88	O
%	O
homologous	O
to	O
human	O
milk	O
BAL	O
and	O
human	O
pancreatic	O
BAL	O
.	O

Staining	O
with	O
various	O
lectins	O
showed	O
that	O
bp	O
-	O
BAL	O
is	O
a	O
glycoprotein	O
which	O
contains	O
fucose	B
residues	O
.	O

Previously	O
from	O
bovine	O
pancreas	O
a	O
lysophospholipase	O
has	O
been	O
purified	O
and	O
a	O
gene	O
was	O
cloned	O
and	O
sequenced	O
encoding	O
an	O
enzyme	O
with	O
cholesterol	O
esterase	O
/	O
lysophospholipase	O
activity	O
.	O

Comparison	O
of	O
the	O
N	B
-	I
terminal	I
amino	I
acid	I
sequence	O
of	O
bp	O
-	O
BAL	O
with	O
the	O
deduced	O
amino	B
acid	I
sequence	O
of	O
the	O
latter	O
revealed	O
that	O
they	O
are	O
identical	O
.	O

Furthermore	O
,	O
the	O
molecular	O
weight	O
of	O
the	O
purified	O
bp	O
-	O
BAL	O
of	O
63,000	O
,	O
as	O
estimated	O
by	O
SDS	O
-	O
PAGE	O
,	O
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
purified	O
lysophospholipase	O
(	O
65,000	O
)	O
and	O
to	O
the	O
theoretical	O
molecular	O
weight	O
of	O
65,147	O
of	O
the	O
cholesterol	O
esterase	O
/	O
lysophospholipase	O
.	O

These	O
data	O
suggest	O
that	O
these	O
three	O
enzymes	O
are	O
one	O
and	O
the	O
same	O
.	O

The	O
antioxidant	O
activity	O
of	O
Eriobotrya	O
japonica	O
was	O
determined	O
by	O
measuring	O
the	O
radical	O
scavenging	O
effect	O
on	O
DPPH	B
(	O
1,1-diphenyl-2-picrylhydrazyl	B
)	O
radical	B
and	O
lipid	B
peroxidation	O
produced	O
when	O
mouse	O
liver	O
homogenate	O
was	O
exposed	O
to	O
the	O
air	O
at	O
37	O
degrees	O
C	O
,	O
using	O
2-thiobarbituric	B
acid	I
(	O
TBA	B
)	O
.	O

The	O
methanol	B
extract	O
and	O
its	O
fractions	O
of	O
Eriobotrya	O
japonica	O
leaves	O
showed	O
strong	O
antioxidant	O
activity	O
.	O

The	O
antioxidant	O
activity	O
of	O
EtOAc	B
and	O
n	B
-	I
BuOH	I
soluble	O
fractions	O
were	O
stronger	O
than	O
the	O
others	O
,	O
and	O
were	O
further	O
purified	O
by	O
repeated	O
silica	B
gel	I
,	O
MCl	B
gel	I
CHP-20P	I
,	O
and	O
Sephadex	B
LH-20	I
column	O
chromatography	O
.	O

Antioxidant	O
chlorogenic	B
acid	I
,	O
quercetin-3-sambubioside	B
from	O
n	B
-	I
BuOH	I
fraction	O
,	O
and	O
methyl	B
chlorogenate	I
,	O
kaempferol-	B
and	O
quercetin-3-rhamnosides	B
,	O
together	O
with	O
the	O
inactive	O
ursolic	B
acid	I
and	O
2	B
alpha	I
-	I
hydroxyursolic	I
acid	I
from	O
EtOAc	B
fraction	O
were	O
isolated	O
.	O

Antioxidant	O
flavonoids	B
and	O
chlorogenic	B
acid	I
also	O
showed	O
prominent	O
inhibitory	O
activity	O
against	O
free	O
radical	O
generation	O
in	O
dichlorofluorescein	B
(	O
DCF	B
)	O
method	O
.	O

The	O
synthesis	O
and	O
the	O
antimicrobial	O
properties	O
of	O
a	O
new	O
series	O
of	O
cephalosporinic	B
beta	I
-	I
lactam	I
antibiotics	I
is	O
described	O
.	O

The	O
data	O
reported	O
in	O
the	O
present	O
paper	O
show	O
the	O
potential	O
of	O
this	O
type	O
of	O
substituted	B
cephalosporins	I
as	O
new	O
anti	B
Gram	I
-	I
positive	I
antibiotic	I
drugs	I
.	O

In	O
fact	O
,	O
all	O
compounds	B
tested	O
showed	O
a	O
good	O
in	O
vitro	O
antibacterial	O
activity	O
against	O
the	O
most	O
relevant	O
Gram	O
-	O
positive	O
pathogens	O
including	O
resistant	O
species	O
that	O
currently	O
represent	O
unmet	O
medical	O
need	O
.	O

On	O
the	O
contrary	O
,	O
the	O
new	O
synthesized	O
compounds	B
were	O
found	O
to	O
be	O
completely	O
devoid	O
of	O
any	O
activity	O
on	O
Gram	O
-	O
negative	O
bacteria	O
up	O
to	O
a	O
concentration	O
of	O
the	O
single	O
agent	O
of	O
128	O
microg	O
/	O
ml	O
.	O

The	O
hydroxylation	O
at	O
C-2	O
of	O
testosterone	B
and	O
5alpha	B
-	I
dihydrotestosterone	I
is	O
measured	O
by	O
isolation	O
of	O
HTO	B
after	O
incubating	O
""""	O
metabolically	O
labile	O
""""	O
tritium	B
labeled	I
steroids	I
with	O
the	O
enzymes	O
.	O

After	O
hydroxylation	O
of	O
testosterone	B
in	O
rat	O
liver	O
2alpha	B
-	I
hydroxytestosterone	I
was	O
isolated	O
and	O
identified	O
by	O
gaschromatography	O
and	O
mass	O
spectra	O
.	O

Oxamniquine	B
(	O
1,2,3,4-tetrahydro-2-	B
[	I
(	I
isopropylamino	I
)	I
methyl	I
]	I
-7-nitro-6-quinoline	I
methanol	I
)	I
is	O
an	O
antischistosomal	B
agent	I
that	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
S.	O
mansoni	O
(	O
intestinal	O
schistosomiasis	O
)	O
infection	O
.	O

It	O
has	O
been	O
shown	O
to	O
inhibit	O
DNA	B
,	O
RNA	B
and	O
protein	O
synthesis	O
in	O
schistosomes	O
.	O

The	O
oral	O
bioavailability	O
of	O
oxamniquine	B
is	O
good	O
,	O
effective	O
plasma	O
levels	O
are	O
achieved	O
in	O
1–1.5	O
h	O
[	O
1	O
]	O
.	O

Oxamniquine	B
is	O
the	O
subject	O
of	O
a	O
monograph	O
in	O
the	O
US	O
Pharmacopoeia	O
(	O
USP	O
XXIII	O
)	O
[	O
2	O
]	O
whereby	O
a	O
spectrophotometric	O
method	O
is	O
recommended	O
for	O
its	O
determination	O
,	O
whether	O
in	O
its	O
pure	O
form	O
or	O
in	O
capsules	O
.	O

Other	O
reported	O
methods	O
include	O
spectrophotometry	O
[	O
3,4	O
]	O
,	O
non	O
-	O
aqueous	O
titration	O
[	O
5	O
]	O
,	O
gas	O
chromatography	O
[	O
6	O
]	O
,	O
high	O
-	O
performance	O
liquid	O
chromatography	O
[	O
7–11	O
]	O
,	O
polarography	O
[	O
12	O
]	O
,	O
capillary	O
electrophoresis	O
[	O
9	O
]	O
,	O
flow	O
-	O
injection	O
analysis	O
[	O
13	O
]	O
and	O
cyclic	O
voltammetry	O
[	O
14	O
]	O
.	O

The	O
above	O
-	O
mentioned	O
methods	O
are	O
either	O
not	O
sufficiently	O
sensitive	O
or	O
are	O
tedious	O
and	O
require	O
highly	O
sophisticated	O
instrumentation	O
.	O

Therefore	O
,	O
there	O
is	O
still	O
a	O
need	O
for	O
a	O
much	O
more	O
sensitive	O
and	O
simple	O
method	O
for	O
the	O
determination	O
of	O
oxamniquine	B
,	O
especially	O
in	O
biological	O
fluids	O
.	O

Fluorimetry	O
,	O
by	O
virtue	O
of	O
its	O
high	O
sensitivity	O
,	O
meets	O
this	O
requirement	O
.	O

Reviewing	O
the	O
literature	O
revealed	O
that	O
no	O
fluorimetric	O
methods	O
were	O
reported	O
for	O
oxamniquine	B
.	O

As	O
for	O
2-cyanoacetamide	B
,	O
it	O
has	O
been	O
recently	O
used	O
for	O
the	O
determination	O
of	O
aminoglycosides	B
[	O
15	O
]	O
,	O
reducing	O
carbohydrates	B
[	O
16–18	O
]	O
,	O
enzymatic	O
degradation	O
products	O
of	O
reducing	O
polysaccharides	B
[	O
19	O
]	O
and	O
catecholamines	B
[	O
20,21	O
]	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
is	O
to	O
study	O
the	O
reaction	O
of	O
the	O
reduced	O
derivative	B
(	O
nitroso	B
)	O
of	B
oxamniquine	I
with	O
2-cyanoacetamide	B
in	O
an	O
attempt	O
to	O
develop	O
a	O
sensitive	O
fluorimetric	O
method	O
to	O
be	O
used	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
.	O

2	O
Experimental	O
2.1	O
Apparatus	O
An	O
Aminco	O
-	O
Bowman	O
Model	O
J4	O
-9860	O
spectrofluorometer	O
was	O
used	O
with	O
the	O
excitation	O
and	O
emission	O
slits	O
set	O
at	O
5	O
mm	O
.	O

A	O
1-cm	O
quartz	O
cell	O
was	O
used	O
for	O
all	O
measurements	O
.	O

2.2	O
Materials	O
and	O
reagents	O
All	O
the	O
chemicals	O
used	O
were	O
of	O
analytical	O
reagent	O
grade	O
,	O
while	O
the	O
solvents	B
were	O
of	O
the	O
spectroscopic	O
grade	O
.	O

A	O
pure	O
drug	B
sample	O
of	O
oxamniquine	B
was	O
kindly	O
supplied	O
by	O
Pfizer	O
(	O
Sandwich	O
,	O
UK	O
)	O
and	O
was	O
used	O
as	O
received	O
.	O

2-Cyanoacetamide	B
was	O
purchased	O
from	O
Aldrich	O
Chemical	O
Co.	O
Plasma	O
was	O
obtained	O
from	O
Mansoura	O
University	O
Hospital	O
,	O
Mansoura	O
(	O
Egypt	O
)	O
and	O
urine	O
was	O
obtained	O
from	O
healthy	O
volunteers	O
.	O

Freshly	O
prepared	O
10	O
%	O
aqueous	O
solution	O
of	O
calcium	B
chloride	I
and	O
4	O
%	O
aqueous	O
solution	O
of	O
2-cyanoacetamide	B
were	O
prepared	O
and	O
used	O
throughout	O
the	O
study	O
.	O

2.2.1	O
Stock	O
solution	O
Dissolve	O
20	O
mg	O
of	O
oxamniquine	B
in	O
100	O
of	O
methanol	B
.	O

Make	O
serial	O
dilutions	O
with	O
water	B
to	O
obtain	O
a	O
final	O
concentration	O
of	O
20	O
μg	O
/	O
ml	O
.	O

2.3	O
Procedure	O
2.3.1	O
Preparation	O
of	O
the	O
calibration	O
curve	O
Transfer	O
aliquots	O
of	O
oxamniquine	B
final	O
stock	O
solution	O
into	O
a	O
series	O
of	O
25	O
ml	O
standard	O
flasks	O
so	O
that	O
the	O
final	O
drug	B
concentration	O
is	O
in	O
the	O
range	O
0.08–0.88	O
μg	O
/	O
ml	O
.	O

Add	O
to	O
each	O
flask	O
120±5	O
mg	O
of	O
zinc	O
dust	O
and	O
12	O
ml	O
of	O
calcium	B
chloride	I
solution	O
.	O

Shake	O
well	O
and	O
leave	O
to	O
stand	O
for	O
20	O
min	O
.	O

Filter	O
the	O
excess	O
zinc	B
powder	O
.	O

Add	O
1	O
ml	O
of	O
2-cyanoacetamide	B
solution	O
to	O
the	O
filtrate	O
,	O
then	O
heat	O
on	O
a	O
boiling	O
water	B
bath	O
for	O
1	O
h.	O
Cool	O
and	O
fill	O
to	O
the	O
mark	O
in	O
25	O
ml	O
standard	O
flask	O
with	O
water	B
.	O

Measure	O
the	O
fluorescence	O
of	O
the	O
filtrate	O
using	O
370	O
nm	O
as	O
the	O
excitation	O
wavelength	O
and	O
450	O
nm	O
as	O
the	O
emission	O
wavelength	O
.	O

A	O
blank	O
reagent	B
is	O
prepared	O
simultaneously	O
.	O

Plot	O
the	O
values	O
of	O
the	O
%	O
relative	O
intensity	O
against	O
the	O
final	O
concentration	O
in	O
μg	O
/	O
ml	O
to	O
get	O
the	O
calibration	O
graph	O
.	O

Alternatively	O
,	O
the	O
regression	O
equation	O
is	O
derived	O
.	O

2.3.2	O
Determination	O
of	O
oxamniquine	B
in	O
spiked	O
human	O
plasma	O
and	O
urine	O
A	O
standard	O
calibration	O
curve	O
was	O
prepared	O
daily	O
by	O
spiking	O
blank	O
plasma	O
or	O
urine	O
with	O
varying	O
amounts	O
of	O
oxamniquine	B
.	O

A	O
stock	O
solution	O
containing	O
10	O
μg	O
/	O
ml	O
of	O
oxamniquine	B
was	O
freshly	O
prepared	O
.	O

Control	O
samples	O
of	O
plasma	O
or	O
urine	O
were	O
spiked	O
with	O
different	O
quantities	O
of	O
oxamniquine	B
to	O
give	O
a	O
final	O
drug	B
concentration	O
of	O
0.2–0.8	O
μg	O
/	O
ml	O
.	O

Add	O
0.8	O
ml	O
of	O
1	O
M	O
NaOH	B
with	O
gentle	O
shaking	O
to	O
1.0	O
ml	O
of	O
the	O
spiked	O
urine	O
or	O
plasma	O
.	O

The	O
solution	O
was	O
then	O
vortexed	O
with	O
3	O
×	O
5	O
ml	O
of	O
ether	O
for	O
2	O
min	O
then	O
centrifuged	O
at	O
2500	O
rpm	O
for	O
5	O
min	O
.	O

The	O
resulting	O
supernatant	O
was	O
then	O
evaporated	O
to	O
dryness	O
under	O
nitrogen	B
at	O
ambient	O
temperature	O
.	O

The	O
resulting	O
residue	O
was	O
dissolved	O
in	O
5	O
ml	O
of	O
methanol	B
and	O
then	O
made	O
up	O
to	O
10	O
ml	O
with	O
water	B
in	O
a	O
volumetric	O
flask	O
.	O

The	O
procedure	O
described	O
in	O
Section	O
2.3.1	O
was	O
then	O
applied	O
.	O

A	O
blank	O
experiment	O
using	O
plasma	O
or	O
urine	O
without	O
the	O
drug	B
was	O
carried	O
out	O
simultaneously	O
.	O

The	O
content	O
of	O
oxamniquine	B
was	O
then	O
determined	O
from	O
the	O
previously	O
plotted	O
calibration	O
graphs	O
.	O

3	O
Results	O
and	O
discussion	O
The	O
nitro	B
group	I
is	O
reported	O
to	O
be	O
reduced	O
into	O
the	O
corresponding	O
nitroso	B
group	I
upon	O
reduction	O
with	O
Zn	B
/	O
CaCl2	B
[	O
22	O
]	O
.	O

This	O
process	O
was	O
confirmed	O
by	O
testing	O
for	O
the	O
nitroso	B
group	I
using	O
sodium	B
nitroprusside	I
[	O
23	O
]	O
.	O

The	O
nitroso	B
compounds	I
were	O
reported	O
to	O
react	O
with	O
active	O
methylene	B
containing	I
compounds	I
with	O
the	O
production	O
of	O
the	O
corresponding	O
imines	B
[	O
24	O
]	O
.	O

The	O
latter	O
is	O
proposed	O
to	O
undergo	O
a	O
ring	O
-	O
closing	O
reaction	O
with	O
the	O
elimination	O
of	O
one	O
molecule	O
of	O
ammonia	B
and	O
the	O
production	O
of	O
the	O
3-cyanooxazazepin-2-one	B
derivative	I
,	O
which	O
is	O
the	O
fluorescent	B
product	I
.	O

A	O
proposal	O
of	O
reaction	O
pathway	O
is	O
suggested	O
in	O
Scheme	O
1	O
.	O

A	O
highly	O
fluorescent	B
product	I
with	O
λmax	O
excitation	O
at	O
370	O
nm	O
and	O
λmax	O
emission	O
of	O
450	O
nm	O
was	O
obtained	O
(	O
Fig.	O
1	O
)	O
.	O

3.1	O
Study	O
of	O
the	O
experimental	O
conditions	O
The	O
factors	O
affecting	O
the	O
production	O
of	O
nitroso	B
derivative	I
were	O
first	O
studied	O
.	O

All	O
factors	O
were	O
kept	O
constant	O
except	O
one	O
,	O
which	O
was	O
changed	O
in	O
turn	O
to	O
study	O
its	O
effect	O
.	O

Any	O
amount	O
of	O
zinc	B
powder	O
in	O
the	O
range	O
100–300	O
mg	O
was	O
found	O
to	O
give	O
the	O
same	O
results	O
;	O
therefore	O
120±5	O
mg	O
were	O
used	O
throughout	O
the	O
work	O
.	O

As	O
for	O
calcium	B
chloride	I
solution	O
12±1	O
ml	O
of	O
10	O
%	O
(	O
wt.	O
/	O
vol	O
.	O
)	O

aqueous	O
solution	O
was	O
found	O
to	O
give	O
maximum	O
fluorescence	O
.	O

Larger	O
volumes	O
caused	O
slight	O
decrease	O
in	O
fluorescence	O
.	O

Increasing	O
the	O
reduction	O
time	O
(	O
at	O
room	O
temperature	O
)	O
was	O
found	O
to	O
increase	O
the	O
fluorescence	O
up	O
to	O
20	O
min	O
,	O
after	O
which	O
time	O
the	O
fluorescence	O
intensity	O
remained	O
unchanged	O
.	O

3.2	O
Factors	O
affecting	O
the	O
development	O
of	O
the	O
fluorophore	B
The	O
effect	O
of	O
the	O
concentration	O
of	O
2-cyanoacetamide	B
was	O
studied	O
by	O
using	O
increasing	O
volumes	O
of	O
4	O
%	O
aqueous	O
solution	O
.	O

It	O
was	O
found	O
that	O
1.0±0.1	O
ml	O
is	O
appropriate	O
for	O
maximum	O
fluorescence	O
intensity	O
;	O
larger	O
volumes	O
caused	O
no	O
further	O
increase	O
in	O
fluorescence	O
.	O

The	O
temperature	O
and	O
time	O
of	O
heating	O
were	O
also	O
studied	O
.	O

It	O
was	O
concluded	O
that	O
heating	O
in	O
a	O
boiling	O
water	B
-	I
bath	O
for	O
1	O
h	O
gave	O
the	O
highest	O
fluorescence	O
readings	O
.	O

Longer	O
heating	O
time	O
caused	O
a	O
decrease	O
in	O
fluorescence	O
as	O
shown	O
in	O
Fig.	O
2	O
.	O

After	O
optimizing	O
the	O
conditions	O
,	O
it	O
was	O
found	O
that	O
the	O
relation	O
between	O
the	O
%	O
relative	O
intensity	O
(	O
%	O
RI	O
)	O
and	O
final	O
concentration	O
of	O
oxamniquine	B
was	O
rectilinear	O
over	O
the	O
range	O
0.08–0.88	O
μg	O
/	O
ml	O
with	O
a	O
minimum	O
detectability	O
(	O
S	O
/N	O
=	O
2	O
)	O
of	O
8	O
ng	O
/	O
ml	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
linear	O
regression	O
analysis	O
of	O
the	O
results	O
gave	O
the	O
following	O
equation:%	O
RI	O
=	O
0.0358	O
+	O
107.4C	O
(	O
r=0.9999	O
)	O
where	O
C	O
=	O
final	O
concentration	O
in	O
μg	O
/	O
ml	O
,	O
%	O
RI	O
=	O
relative	O
fluorescence	O
intensity	O
and	O
r	O
=	O
correlation	O
coefficient	O
.	O

Statistical	O
analysis	O
of	O
the	O
results	O
of	O
analysis	O
of	O
authentic	O
sample	O
of	O
oxamniquine	B
obtained	O
by	O
both	O
the	O
proposed	O
method	O
and	O
the	O
official	O
method	O
[	O
2	O
]	O
revealed	O
no	O
significant	O
difference	O
between	O
the	O
two	O
methods	O
regarding	O
the	O
accuracy	O
and	O
precision	O
,	O
as	O
indicated	O
by	O
the	O
F	O
-test	O
and	O
Student	O
's	O
t	O
-test	O
,	O
respectively	O
[	O
25	O
]	O
.	O

Oxamniquine	B
is	O
readily	O
absorbed	O
following	O
oral	O
ingestion	O
,	O
and	O
a	O
peak	O
concentration	O
in	O
plasma	O
occurs	O
within	O
about	O
3	O
h.	O
The	O
presence	O
of	O
food	O
significantly	O
delays	O
absorption	O
and	O
limits	O
the	O
concentration	O
achieved	O
in	O
plasma	O
during	O
the	O
first	O
several	O
hours	O
after	O
administration	O
.	O

Urinary	O
excretion	O
is	O
the	O
major	O
route	O
of	O
elimination	O
in	O
humans	O
[	O
26	O
]	O
.	O

Oxamniquine	B
is	O
given	O
orally	O
in	O
a	O
dose	O
of	O
250	O
mg	O
three	O
times	O
daily	O
;	O
this	O
leads	O
to	O
a	O
final	O
blood	O
level	O
concentration	O
of	O
about	O
5	O
μg	O
/	O
ml	O
,	O
i.e.	O
higher	O
than	O
the	O
upper	O
limit	O
of	O
the	O
working	O
range	O
of	O
the	O
proposed	O
method	O
.	O

Thus	O
,	O
the	O
high	O
sensitivity	O
of	O
the	O
proposed	O
method	O
allowed	O
the	O
determination	O
of	O
oxamniquine	B
in	O
biological	O
fluids	O
.	O

Table	O
1	O
shows	O
the	O
results	O
for	O
the	O
fluorimetric	O
determination	O
of	O
a	O
pure	O
sample	O
of	O
oxamniquine	B
,	O
while	O
Table	O
2	O
shows	O
the	O
results	O
of	O
the	O
fluorometric	O
determination	O
of	O
oxamniquine	B
in	O
spiked	O
urine	O
and	O
plasma	O
samples	O
,	O
respectively	O
.	O

The	O
extraction	O
procedure	O
described	O
by	O
Woolhouse	O
and	O
Wood	O
[	O
6	O
]	O
was	O
adopted	O
here	O
.	O

The	O
results	O
are	O
satisfactorily	O
accurate	O
and	O
precise	O
.	O

In	O
conclusion	O
,	O
a	O
highly	O
sensitive	O
and	O
accurate	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
oxamniquine	B
in	O
urine	O
and	O
plasma	O
.	O

Although	O
the	O
previously	O
reported	O
methods	O
[	O
6,7	O
]	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
may	O
be	O
less	O
time	O
-	O
consuming	O
,	O
the	O
proposed	O
method	O
is	O
,	O
however	O
,	O
more	O
sensitive	O
and	O
does	O
not	O
need	O
complicated	O
instrumentation	O
.	O

The	O
relationship	O
between	O
taurine	B
and	O
aging	O
of	O
brain	O
neural	O
cells	O
was	O
studied	O
by	O
using	O
primary	O
human	O
fetal	O
brain	O
neural	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
results	O
indicated	O
that	O
the	O
activity	O
of	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
was	O
significantly	O
higher	O
in	O
taurine	B
added	O
group	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
,	O
9	O
and	O
15	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

With	O
different	O
taurine	B
levels	O
,	O
the	O
SOD	O
activities	O
of	O
50	O
mg	O
/	O
L	O
and	O
200	O
mg	O
/	O
L	O
taurine	B
groups	O
were	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

After	O
3-day	O
culture	O
,	O
the	O
activity	O
of	O
glutathione	O
peroxidase	O
(	O
GSH	O
-	O
Px	O
)	O
in	O
the	O
taurine	O
added	O
group	O
was	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
membrane	O
lipid	B
fluidity	O
of	O
neural	O
cells	O
decreased	O
with	O
time	O
in	O
control	O
group	O
,	O
but	O
was	O
stable	O
in	O
the	O
group	O
treated	O
with	O
taurine	B
.	O

The	O
fluidity	O
was	O
more	O
stable	O
in	O
the	O
groups	O
treated	O
with	O
50	O
,	O
200	O
and	O
400	O
mg	O
/	O
L	O
groups	O
cultured	O
for	O
6	O
days	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
or	O
0.01	O
)	O
.	O

The	O
present	O
study	O
showed	O
that	O
taurine	B
is	O
necessary	O
for	O
maintaining	O
membrane	O
lipid	O
fluidity	O
of	O
neural	O
cells	O
in	O
proper	O
levels	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
postponing	O
the	O
aging	O
process	O
of	O
brain	O
neural	O
cells	O
.	O

A	O
combination	O
of	O
atovaquone	B
and	O
proguanil	B
has	O
been	O
found	O
to	O
be	O
quite	O
effective	O
in	O
treating	O
malaria	O
,	O
with	O
little	O
evidence	O
of	O
the	O
emergence	O
of	O
resistance	O
when	O
atovaquone	B
was	O
used	O
as	O
a	O
single	O
agent	O
.	O

We	O
have	O
examined	O
possible	O
mechanisms	O
for	O
the	O
synergy	O
between	O
these	O
two	O
drugs	B
.	O

While	O
proguanil	B
by	O
itself	O
had	O
no	O
effect	O
on	O
electron	O
transport	O
or	O
mitochondrial	O
membrane	O
potential	O
(	O
DeltaPsim	O
)	O
,	O
it	O
significantly	O
enhanced	O
the	O
ability	O
of	O
atovaquone	B
to	O
collapse	O
DeltaPsim	O
when	O
used	O
in	O
combination	O
.	O

This	O
enhancement	O
was	O
observed	O
at	O
pharmacologically	O
achievable	O
doses	O
.	O

Proguanil	B
acted	O
as	O
a	O
biguanide	B
rather	O
than	O
as	O
its	O
metabolite	B
cycloguanil	B
(	O
a	O
parasite	O
dihydrofolate	O
reductase	O
[	O
DHFR	O
]	O
inhibitor	O
)	O
to	O
enhance	O
the	O
atovaquone	B
effect	O
;	O
another	O
DHFR	O
inhibitor	O
,	O
pyrimethamine	B
,	O
also	O
had	O
no	O
enhancing	O
effect	O
.	O

Proguanil	B
-	O
mediated	O
enhancement	O
was	O
specific	O
for	O
atovaquone	B
,	O
since	O
the	O
effects	O
of	O
other	O
mitochondrial	O
electron	O
transport	O
inhibitors	O
,	O
such	O
as	O
myxothiazole	B
and	O
antimycin	B
,	O
were	O
not	O
altered	O
by	O
inclusion	O
of	O
proguanil	B
.	I

Surprisingly	O
,	O
proguanil	B
did	O
not	O
enhance	O
the	O
ability	O
of	O
atovaquone	B
to	O
inhibit	O
mitochondrial	O
electron	O
transport	O
in	O
malaria	O
parasites	O
.	O

These	O
results	O
suggest	O
that	O
proguanil	B
in	O
its	O
prodrug	O
form	O
acts	O
in	O
synergy	O
with	O
atovaquone	B
by	O
lowering	O
the	O
effective	O
concentration	O
at	O
which	O
atovaquone	B
collapses	O
DeltaPsim	O
in	O
malaria	O
parasites	O
.	O

This	O
could	O
explain	O
the	O
paradoxical	O
success	O
of	O
the	O
atovaquone	B
-	O
proguanil	B
combination	O
even	O
in	O
regions	O
where	O
proguanil	B
alone	O
is	O
ineffective	O
due	O
to	O
resistance	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
atovaquone	B
-	O
proguanil	B
combination	O
may	O
act	O
as	O
a	O
site	O
-	O
specific	O
uncoupler	O
of	O
parasite	O
mitochondria	O
in	O
a	O
selective	O
manner	O
.	O

To	O
develop	O
positron	O
-	O
emitting	O
tracers	O
for	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
studies	O
,	O
ex	O
vivo	O
autoradiography	O
(	O
ARG	O
)	O
is	O
a	O
useful	O
technique	O
to	O
demonstrate	O
the	O
distribution	O
of	O
the	O
tracer	O
in	O
the	O
brain	O
as	O
well	O
as	O
in	O
the	O
whole	O
body	O
.	O

A	O
recent	O
advent	O
of	O
radioluminography	O
using	O
phosphor	O
-	O
imaging	O
plates	O
(	O
12	O
,	O
14	O
)	O
has	O
enabled	O
the	O
ex	O
vivo	O
ARG	O
to	O
be	O
applied	O
to	O
ultrashort	O
-	O
lived	O
11	O
C	O
-	O
labeled	O
tracers	O
.	O

Yanai	O
et	O
al.	O
reported	O
a	O
potential	O
of	O
the	O
imaging	O
plates	O
for	O
receptor	O
ARG	O
with	O
11	B
C	I
-	O
labeled	O
ligands	O
compared	O
with	O
tritiated	O
ligands	O
(	O
25	O
)	O
.	O

Planas	O
et	O
al.	O
(	O
18	O
)	O
characterized	O
a	O
cholinesterase	O
inhibitor	O
[	B
11	I
C	I
]	I
physostigmine	I
using	O
a	O
similar	O
type	O
storage	O
phosphor	O
plates	O
.	O

We	O
also	O
used	O
imaging	O
plates	O
to	O
characterize	O
newly	O
developed	O
11	B
C	I
-	O
labeled	O
receptor	O
ligands	O
(	O
3	O
,	O
10	O
,	O
16	O
)	O
.	O

Because	O
the	O
intensity	O
of	O
photo	O
-	O
stimulated	O
-	O
luminescence	O
(	O
PSL	O
)	O
is	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
in	O
a	O
wide	O
range	O
,	O
ARG	O
images	O
expressed	O
as	O
PSL	O
is	O
considered	O
to	O
reflect	O
the	O
quantitative	O
distribution	O
of	O
radioactivity	O
.	O

Recently	O
,	O
Sihver	O
et	O
al.	O
(	O
21	O
)	O
have	O
quantitatively	O
evaluated	O
in	O
vitro	O
ARG	O
with	O
storage	O
phosphor	O
plates	O
and	O
11	B
C	I
-	I
flumazenil	I
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
describe	O
quantitative	O
evaluation	O
of	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
using	O
an	O
imaging	O
plate	O
and	O
a	O
11	B
C	I
-	O
labeled	O
dopamine	B
D2	O
-like	O
receptor	O
ligand	O
,	O
[	B
11	I
C	I
]	I
nemonapride	I
(	O
[	B
11	I
C	I
]	I
YM-09151	I
-	I
2	I
)	O
(	O
5	O
,	O
6	O
,	O
8	O
,	O
9	O
,	O
11	O
)	O
.	O

Its	O
tritiated	O
compound	O
has	O
been	O
used	O
widely	O
for	O
pharmacological	O
studies	O
as	O
one	O
of	O
representative	O
dopamine	B
D2	O
-like	O
receptor	O
ligands	O
.	O

We	O
report	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	B
11	I
C	I
]	I
nemonapride	I
in	O
the	O
cortex	O
beside	O
the	O
dopamine	B
D2	O
-like	O
receptors	O
in	O
the	O
striatum	O
both	O
ex	O
vivo	O
and	O
in	O
vitro	O
.	O

Materials	O
and	O
methods	O
[	B
11	I
C	I
]	I
Nemonapride	I
(	O
9	B
)	O
and	O
[	B
11	I
C	I
]	I
SCH	I
23390	I
(	O
4	B
)	O
were	O
synthesized	O
by	O
11	B
C	I
-	I
methylation	O
of	O
the	O
corresponding	O
desmethyl	B
compound	I
with	O
[	B
11	I
C	I
]	I
methyl	I
iodide	I
by	O
the	O
method	O
previously	O
described	O
.	O

The	O
specific	O
activity	O
of	O
the	O
compounds	O
was	O
measured	O
as	O
follows	O
.	O

The	O
radioactivity	O
(	O
MBq	O
)	O
of	O
an	O
appropriate	O
volume	O
of	O
tracer	O
solution	O
was	O
measured	O
by	O
a	O
radioisotope	O
calibrator	O
(	O
type	O
CRC-712	O
,	O
Capintec	O
Inc.	O
,	O
Ramsey	O
,	O
NJ	O
)	O
,	O
and	O
a	O
part	O
of	O
the	O
solution	O
was	O
applied	O
to	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
to	O
determine	O
the	O
mass	O
(	O
nmol	O
)	O
of	O
the	O
compounds	O
based	O
on	O
the	O
ultraviolet	O
(	O
UV	O
)	O
response	O
to	O
the	O
authentic	O
sample	O
.	O

Male	O
Wistar	O
rats	O
(	O
8–10	O
weeks	O
old	O
)	O
were	O
obtained	O
from	O
Tokyo	O
Laboratory	O
Animals	O
Company	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
animal	O
studies	O
were	O
approved	O
by	O
the	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Tokyo	O
Metropolitan	O
Institute	O
of	O
Gerontology	O
.	O

Calibration	O
of	O
PSL	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
A	O
solution	O
of	O
11	O
C	O
-	O
tracer	O
was	O
prepared	O
at	O
the	O
concentration	O
of	O
100	O
MBq	O
/	O
mL	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
t	O
=	O
0	O
min	O
,	O
26	O
min	O
after	O
end	O
of	O
bombardment	O
[	O
EOB	O
]	O
)	O
.	O

The	O
solution	O
was	O
diluted	O
to	O
0.03–10	O
MBq	O
/	O
mL	O
,	O
and	O
10	O
μL	O
of	O
each	O
diluted	O
solution	O
(	O
0.3–100	O
kBq	O
)	O
was	O
loaded	O
on	O
six	O
pieces	O
of	O
filter	O
paper	O
(	O
5	O
mm	O
×	O
5	O
mm	O
,	O
0.23	O
±	O
0.05	O
mm	O
thickness	O
,	O
Toyo	O
Roshi	O
Kaisha	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Three	O
pieces	O
of	O
the	O
filter	O
paper	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
of	O
type	O
IP	O
BAS	O
SR	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
until	O
the	O
decay	O
-	O
out	O
of	O
11	B
C	I
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
activity	O
at	O
the	O
start	O
of	O
contact	O
ranged	O
from	O
1.05	O
to	O
2990	O
Bq	O
(	O
t	O
=	O
35.5	O
min	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
other	O
three	O
pieces	O
of	O
the	O
filter	O
paper	O
was	O
measured	O
with	O
a	O
well	O
-	O
type	O
auto	O
-	O
gamma	O
counter	O
(	O
type	O
1282	O
Compugamma	O
CS	O
,	O
Wallac	O
Oy	O
,	O
Turku	O
,	O
Finland	O
)	O
for	O
15	O
s	O
,	O
and	O
the	O
cpm	O
/	O
Bq	O
was	O
computed	O
with	O
decay	O
correction	O
.	O

The	O
PSL	O
values	O
over	O
the	O
entire	O
piece	O
of	O
filter	O
paper	O
(	O
25	O
mm2	O
)	O
were	O
measured	O
with	O
a	O
bioimaging	O
analyzer	O
of	O
type	O
BAS	O
2500	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
to	O
compute	O
the	O
PSL	O
per	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
The	O
filter	O
paper	O
provided	O
with	O
the	O
11	O
C	O
-	O
radioactivity	O
as	O
described	O
above	O
and	O
the	O
autoradiographic	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
(	O
1.11–31.73	O
kBq	O
/	O
g	O
)	O
(	O
Amersham	O
International	O
plc	O
.	O
,	O
Buckinghamshire	O
,	O
England	O
)	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
of	O
the	O
same	O
type	O
for	O
4	O
h	O
to	O
examine	O
the	O
reproducibility	O
between	O
imaging	O
plates	O
;	O
the	O
PSL	O
of	O
the	O
micro	O
-	O
scales	O
were	O
measured	O
as	O
PSL	O
/	O
mm2	O
.	O

Ex	O
vivo	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
[	B
11	I
C	I
]	I
Nemonapride	I
(	O
143	O
MBq	O
/	O
4.3	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
a	O
rat	O
(	O
235	O
g	O
)	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
.	O

Fifteen	O
minutes	O
later	O
,	O
the	O
rat	O
was	O
killed	O
and	O
the	O
brain	O
was	O
removed	O
.	O

The	O
brain	O
at	O
the	O
bregma	O
(	O
17	O
)	O
was	O
cut	O
into	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thick	O
coronal	O
sections	O
using	O
a	O
cryotome	O
(	O
Bright	O
Instruments	O
Co.	O
Ltd.	O
,	O
UK	O
)	O
at	O
−15	O
°	O
C	O
.	O

The	O
brain	O
sections	O
were	O
thaw	O
-	O
mounted	O
on	O
glass	O
plates	O
(	O
20	O
×	O
32	O
mm2	O
)	O
that	O
were	O
precoated	O
with	O
3	O
%	O
3-aminopropyltriethoxysilane	B
in	O
acetone	B
.	O

The	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
°	O
C	O
and	O
apposed	O
placed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
110	O
min	O
)	O
.	O

The	O
tracer	O
uptake	O
was	O
visualized	O
as	O
described	O
above	O
.	O

Regions	O
of	O
interest	O
(	O
ROIs	O
)	O
were	O
placed	O
on	O
the	O
striatum	O
(	O
6–8	O
mm2	O
)	O
and	O
on	O
the	O
cerebral	O
cortex	O
(	O
6–8	O
mm2	O
)	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
were	O
measured	O
.	O

From	O
the	O
other	O
rat	O
(	O
230	O
g	O
)	O
given	O
[	B
11	I
C	I
]	I
nemonapride	I
(	O
136	O
MBq	O
/	O
4.4	O
nmol	O
)	O
,	O
the	O
coronal	O
brain	O
sections	O
with	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thickness	O
were	O
also	O
obtained	O
as	O
described	O
above	O
.	O

The	O
whole	O
section	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
for	O
15	O
s.	O

The	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
,	O
assuming	O
equal	O
radioactivity	O
concentration	O
between	O
corresponding	O
regions	O
or	O
whole	O
brains	O
in	O
neighboring	O
sections	O
at	O
the	O
bregma	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
To	O
obtain	O
coronal	O
brain	O
sections	O
having	O
a	O
wider	O
range	O
of	O
radioactivity	O
,	O
ex	O
vivo	O
ARG	O
was	O
performed	O
with	O
[	B
11	I
C	I
]	I
SCH	I
23390	I
,	O
which	O
is	O
more	O
concentrated	O
in	O
the	O
striatum	O
than	O
[	B
11	I
C	I
]	I
nemonapride	I
.	O

[	B
11	I
C	I
]	I
SCH	I
23390	I
(	O
236	O
MBq	O
/	O
11.1	O
nmol	O
and	O
47	O
MBq	O
/	O
2.2	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
two	O
rats	O
(	O
t	O
=	O
0	O
min	O
,	O
30	O
min	O
after	O
EOB	O
)	O
.	O

The	O
rats	O
were	O
killed	O
15	O
min	O
later	O
,	O
and	O
25	O
pairs	O
of	O
the	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
prepared	O
throughout	O
the	O
brain	O
as	O
described	O
above	O
.	O

One	O
set	O
of	O
the	O
brain	O
sections	O
was	O
applied	O
to	O
an	O
imaging	O
plate	O
until	O
decay	O
-	O
out	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
,	O
and	O
the	O
other	O
set	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
(	O
t	O
=	O
102	O
min	O
)	O
.	O

Then	O
the	O
PSL	O
/	O
cpm	O
was	O
calculated	O
for	O
each	O
brain	O
section	O
.	O

Regional	O
brain	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
method	O
[	B
11	I
C	I
]	I
Nemonapride	I
(	O
82.6–96.7	O
MBq	O
/	O
2.1–5.7	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
four	O
rats	O
(	O
260–290	O
g	O
)	O
.	O

They	O
were	O
killed	O
30	O
min	O
later	O
and	O
the	O
brains	O
were	O
removed	O
.	O

From	O
a	O
half	O
brain	O
hemisphere	O
,	O
three	O
pairs	O
of	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
cut	O
near	O
bregma	O
.	O

The	O
radioactivity	O
(	O
cpm	O
)	O
of	O
one	O
set	O
of	O
section	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
and	O
converted	O
to	O
Bq	O
.	O

The	O
other	O
section	O
was	O
exposed	O
to	O
an	O
imaging	O
plate	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
as	O
described	O
above	O
,	O
and	O
the	O
PSL	O
/	O
Bq	O
was	O
calculated	O
assuming	O
that	O
the	O
pair	O
of	O
adjacent	O
brain	O
sections	O
had	O
the	O
same	O
radioactivity	O
.	O

ROIs	O
were	O
placed	O
on	O
the	O
striatum	O
and	O
on	O
the	O
cortex	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
regional	O
brain	O
section	O
volume	O
(	O
mm2	O
×	O
0.02	O
mm	O
)	O
,	O
which	O
was	O
converted	O
to	O
Bq	O
/	O
mL.	O
Then	O
,	O
the	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
by	O
the	O
striatum	O
or	O
cortex	O
was	O
assessed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
milliliter	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
mL	O
)	O
.	O

From	O
the	O
other	O
hemisphere	O
the	O
striatum	O
and	O
cortex	O
were	O
dissected	O
and	O
weighed	O
,	O
and	O
the	O
radioactivity	O
of	O
the	O
tissues	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
.	O

The	O
uptake	O
was	O
expressed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
gram	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
g	O
)	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
measure	O
the	O
receptor	O
binding	O
capacity	O
quantitatively	O
in	O
ex	O
vivo	O
ARG	O
,	O
the	O
amount	O
of	O
injected	O
carrier	O
ligand	O
must	O
be	O
sufficiently	O
small	O
to	O
avoid	O
saturation	O
effect	O
.	O

To	O
determine	O
if	O
the	O
carrier	O
amount	O
of	O
nemonapride	B
meets	O
this	O
requirement	O
under	O
the	O
specific	O
activity	O
of	O
current	O
experimental	O
condition	O
,	O
the	O
effect	O
of	O
carrier	O
dose	O
on	O
the	O
regional	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
evaluated	O
by	O
tissue	O
sampling	O
.	O

[	B
11	I
C	I
]	I
Nemonapride	I
with	O
various	O
amount	O
of	O
carrier	O
(	O
10	O
MBq	O
/	O
0.027–500	O
nmol	O
)	O
was	O
injected	O
into	O
rats	O
(	O
227	O
±	O
12	O
g	O
)	O
,	O
and	O
the	O
uptake	O
(	O
%	O
ID	O
/	O
g	O
)	O
by	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
was	O
measured	O
at	O
30	O
min	O
after	O
the	O
injection	O
by	O
the	O
tissue	O
sampling	O
method	O
as	O
described	O
above	O
.	O

In	O
vitro	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
In	O
vitro	O
ARG	O
with	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
performed	O
according	O
to	O
the	O
method	O
of	O
Przedborski	O
et	O
al.	O
(	O
19	O
)	O
with	O
a	O
slight	O
modification	O
.	O

Coronal	O
rat	O
brain	O
sections	O
with	O
10-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-μm	O
thickness	O
near	O
the	O
bregma	O
(	O
17	O
)	O
were	O
prepared	O
.	O

The	O
brain	O
sections	O
were	O
pre	O
-	O
incubated	O
in	O
100	O
mL	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7.4	O
,	O
containing	O
120	O
mM	O
NaCl	B
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
the	O
same	O
buffer	O
containing	O
100	O
kBq	O
/	O
mL	O
(	O
25	O
TBq	O
/	O
mmol	O
)	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
,	O
in	O
which	O
all	O
the	O
sections	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

After	O
being	O
washed	O
with	O
ice	B
-	O
cold	O
50	O
mM	O
Tris	B
-	I
HCl	I
(	O
pH	O
7.4	O
)	O
containing	O
120	O
mM	O
NaCl	B
,	O
the	O
brain	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
°	O
C	O
,	O
and	O
then	O
contacted	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
58	O
min	O
)	O
until	O
the	O
activity	O
decayed	O
out	O
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
binding	O
of	O
11	B
C	I
was	O
measured	O
as	O
the	O
PSL	O
/	O
mm2	O
over	O
the	O
ROIs	O
placed	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
.	O

The	O
other	O
set	O
of	O
the	O
brain	O
section	O
was	O
also	O
assayed	O
as	O
described	O
above	O
and	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
whole	O
section	O
was	O
measured	O
with	O
a	O
gamma	O
counter	O
.	O

Saturation	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
binding	O
The	O
buffer	O
containing	O
various	O
concentrations	O
(	O
0.156	O
,	O
0.313	O
,	O
0.625	O
,	O
1.25	O
,	O
and	O
2.50	O
nM	O
)	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
(	O
21	O
TBq	O
/	O
mmol	O
)	O
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
40	O
min	O
after	O
EOB	O
)	O
,	O
and	O
six	O
brain	O
sections	O
with	O
20-μm	O
thickness	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
each	O
buffer	O
as	O
described	O
above	O
.	O

Nonspecific	O
binding	O
was	O
determined	O
by	O
incubating	O
adjacent	O
six	O
sections	O
in	O
the	O
medium	O
to	O
which	O
haloperidol	B
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
20	O
μM.	O
Three	O
brain	O
sections	O
in	O
each	O
assay	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
85	O
min	O
)	O
to	O
measure	O
the	O
PSL	O
values	O
,	O
and	O
the	O
adjacent	O
three	O
sections	O
were	O
measured	O
for	O
radioactivity	O
(	O
cpm	O
)	O
.	O

Then	O
,	O
the	O
PSL	O
/	O
Bq	O
calculated	O
as	O
described	O
above	O
was	O
converted	O
to	O
concentration	O
of	O
receptor	O
-	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
using	O
the	O
specific	O
activity	O
of	O
the	O
ligand	O
.	O

Scatchard	O
plot	O
,	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
versus	O
bound	O
ligand	O
/	O
free	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
/	O
nM	O
)	O
,	O
was	O
carried	O
out	O
.	O

Results	O
and	O
discussion	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
Figure	O
1	O
shows	O
the	O
PSL	O
values	O
of	O
the	O
standard	O
sample	O
on	O
filter	O
paper	O
.	O

The	O
PSL	O
values	O
were	O
linearly	O
proportional	O
to	O
the	O
11	B
C	I
radioactivity	O
(	O
Bq	O
)	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
Fig.	O
1A	O
)	O
,	O
and	O
the	O
ratio	O
was	O
10.7	O
PSL	O
/	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Because	O
each	O
sample	O
presented	O
uniform	O
activity	O
distribution	O
within	O
the	O
piece	O
of	O
filter	O
paper	O
,	O
the	O
PSL	O
of	O
the	O
standard	O
sample	O
on	O
the	O
filter	O
paper	O
was	O
expressed	O
as	O
a	O
linear	O
function	O
of	O
radioactivity	O
in	O
the	O
range	O
from	O
0.4	O
to	O
1110	O
PSL	O
/	O
mm2	O
(	O
0.04–104	O
Bq	O
/	O
mm2	O
)	O
in	O
the	O
present	O
study	O
.	O

The	O
linearity	O
between	O
the	O
radioisotope	O
calibrator	O
and	O
the	O
well	O
-	O
type	O
gamma	O
counter	O
was	O
also	O
confirmed	O
,	O
the	O
ratio	O
being	O
40.1	O
cpm	O
/	O
Bq	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
When	O
the	O
11	O
C	O
-	O
samples	O
on	O
filter	O
paper	O
and	O
standard	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
,	O
the	O
coefficient	O
variation	O
(	O
SD	O
/	O
mean	O
)	O
of	O
the	O
five	O
plates	O
for	O
11	B
C	I
-	O
sensitivity	O
and	O
14	B
C	I
-	O
sensitivity	O
was	O
2.4–3.2	O
%	O
at	O
17.4–164	O
PSL	O
/	O
mm2	O
and	O
2.6–6.9	O
%	O
at	O
5.2–36.6	O
PSL	O
/	O
mm2	O
,	O
respectively	O
.	O

The	O
variation	O
for	O
11	B
C	I
was	O
comparable	O
to	O
that	O
for	O
14	B
C	I
,	O
which	O
confirmed	O
the	O
reliability	O
of	O
our	O
homemade	O
standard	O
source	O
on	O
filter	O
paper	O
.	O

Effect	O
of	O
section	O
thickness	O
Figure	O
2	O
shows	O
representative	O
autoradiograms	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

High	O
11	B
C	I
density	O
was	O
observed	O
in	O
the	O
caudate	O
putamen	O
,	O
nucleus	O
accumbens	O
,	O
and	O
olfactory	O
tubercle	O
,	O
consistent	O
with	O
the	O
well	O
-	O
known	O
distribution	O
of	O
dopamine	B
D2	O
receptors	O
.	O

Figure	O
3	O
illustrates	O
the	O
relationship	O
between	O
brain	O
section	O
thickness	O
and	O
PSL	O
values	O
measured	O
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

The	O
PSL	O
/	O
mm2	O
value	O
for	O
ex	O
vivo	O
ARG	O
was	O
not	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
(	O
Fig.	O
3A	O
)	O
,	O
suggesting	O
that	O
the	O
absorption	O
of	O
radiation	O
increases	O
as	O
the	O
section	O
thickness	O
increases	O
,	O
because	O
it	O
is	O
reasonably	O
assumed	O
that	O
the	O
radioactivity	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
uniformly	O
distributed	O
throughout	O
the	O
thickness	O
in	O
the	O
striatum	O
and	O
cortex	O
near	O
the	O
bregma	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
deviation	O
from	O
the	O
linear	O
function	O
was	O
much	O
larger	O
for	O
the	O
in	O
vitro	O
ARG	O
than	O
for	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
reached	O
a	O
plateau	O
both	O
in	O
the	O
striatum	O
and	O
cortex	O
for	O
over	O
100-μm	O
thick	O
sections	O
.	O

This	O
finding	O
is	O
probably	O
because	O
diffusion	O
of	O
the	O
11	B
C	I
-	O
tracer	O
into	O
the	O
brain	O
tissue	O
was	O
not	O
completed	O
in	O
thick	O
brain	O
sections	O
during	O
the	O
incubation	O
period	O
,	O
and	O
the	O
binding	O
did	O
not	O
reach	O
an	O
equilibrium	O
state	O
.	O

The	O
explanation	O
was	O
approved	O
by	O
measurement	O
of	O
radioactivity	O
of	O
the	O
whole	O
brain	O
sections	O
with	O
a	O
gamma	O
counter	O
(	O
Fig.	O
3C	O
)	O
.	O

The	O
radioactivity	O
was	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
in	O
ex	O
vivo	O
ARG	O
,	O
but	O
not	O
in	O
in	O
vitro	O
ARG	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
Figure	O
4	O
shows	O
relationship	O
between	O
the	O
PSL	O
value	O
and	O
the	O
radioactivity	O
of	O
11	B
C	I
on	O
the	O
whole	O
section	O
with	O
20-μm	O
thickness	O
and	O
for	O
the	O
entire	O
piece	O
of	O
25-mm2	O
filter	O
paper	O
with	O
230-μm	O
thickness	O
.	O

The	O
PSL	O
was	O
found	O
to	O
be	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
within	O
the	O
brain	O
sections	O
or	O
filter	O
paper	O
,	O
although	O
the	O
coefficient	O
was	O
different	O
between	O
the	O
two	O
materials	O
because	O
of	O
different	O
thickness	O
as	O
suggested	O
from	O
Figure	O
2	O
.	O

Therefore	O
,	O
the	O
PSL	O
value	O
can	O
be	O
converted	O
to	O
the	O
radioactivity	O
expressed	O
as	O
Bq	O
unit	O
,	O
if	O
the	O
radioactivity	O
of	O
the	O
adjacent	O
brain	O
sections	O
with	O
the	O
same	O
thickness	O
is	O
measured	O
with	O
a	O
gamma	O
-	O
counter	O
.	O

Table	O
1	O
summarizes	O
the	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
by	O
the	O
striatum	O
and	O
cortex	O
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
by	O
the	O
tissue	O
sampling	O
.	O

Comparable	O
values	O
of	O
the	O
striatal	O
and	O
cortical	O
uptake	O
were	O
obtained	O
by	O
the	O
two	O
methods	O
,	O
nevertheless	O
the	O
technical	O
problem	O
that	O
the	O
nonstriatal	O
region	O
might	O
be	O
contaminated	O
with	O
the	O
striatal	O
sample	O
in	O
the	O
tissue	O
sampling	O
,	O
and	O
the	O
fact	O
that	O
the	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
is	O
less	O
homogeneous	O
in	O
the	O
striatum	O
than	O
in	O
the	O
cortex	O
.	O

Therefore	O
,	O
ex	O
vivo	O
ARG	O
may	O
be	O
a	O
suitable	O
method	O
to	O
quantitatively	O
evaluate	O
small	O
regions	O
such	O
as	O
nucleus	O
accumbens	O
and	O
olfactory	O
tubercles	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
evaluate	O
the	O
carrier	O
dose	O
on	O
the	O
regional	O
brain	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
,	O
the	O
uptake	O
was	O
measured	O
by	O
tissue	O
sampling	O
method	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
,	O
at	O
the	O
dose	O
of	O
22	O
nmol	O
/	O
kg	O
the	O
uptake	O
was	O
slightly	O
decreased	O
,	O
though	O
not	O
statistically	O
significant	O
.	O

In	O
the	O
regional	O
brain	O
distribution	O
study	O
with	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
(	O
Table	O
1	O
)	O
,	O
the	O
injected	O
doses	O
were	O
320–330	O
MBq	O
/	O
kg	O
as	O
radioactivity	O
and	O
8.1–20	O
nmol	O
/	O
kg	O
as	O
carrier	O
amounts	O
.	O

Therefore	O
,	O
the	O
injected	O
carrier	O
dose	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
slightly	O
exceeded	O
to	O
the	O
optimum	O
condition	O
.	O

However	O
,	O
because	O
the	O
PSL	O
/	O
mm2	O
values	O
measured	O
in	O
the	O
cortex	O
were	O
12–14	O
at	O
65–70	O
min	O
after	O
the	O
tracer	O
injection	O
(	O
at	O
35–40	O
min	O
after	O
the	O
exposing	O
time	O
)	O
in	O
the	O
study	O
described	O
in	O
Table	O
1	O
,	O
the	O
injected	O
dose	O
for	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
can	O
be	O
reasonably	O
reduced	O
to	O
approximately	O
one	O
-	O
tenth	O
within	O
the	O
linearity	O
range	O
for	O
the	O
PSL	O
/	O
mm2	O
(	O
>	O
0.4	O
in	O
Fig.	O
1	O
)	O
,	O
although	O
statistical	O
noise	O
is	O
increased	O
.	O

Therefore	O
,	O
the	O
quantitative	O
ex	O
vivo	O
ARG	O
method	O
using	O
imaging	O
plates	O
presented	O
in	O
this	O
study	O
is	O
applicable	O
to	O
quantitative	O
measurement	O
of	O
the	O
receptor	O
binding	O
capacity	O
with	O
[	B
11	I
C	I
]	I
nemonapride	I
.	O

It	O
can	O
also	O
be	O
applied	O
to	O
other	O
dopamine	O
receptor	O
ligands	O
such	O
as	O
[	B
11	I
C	I
]	I
raclopride	I
,	O
[	B
11	I
C	I
]	I
N	I
-methylspiperone	I
,	O
and	O
[	B
11	I
C	I
]	I
SCH	I
23390	I
(	O
data	O
not	O
shown	O
)	O
,	O
although	O
the	O
uptake	O
depends	O
in	O
the	O
ligand	O
.	O

Figure	O
5	O
also	O
showed	O
that	O
a	O
saturable	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
observed	O
in	O
the	O
cortex	O
and	O
cerebellum	O
besides	O
in	O
the	O
striatum	O
,	O
which	O
was	O
preliminarily	O
suggested	O
by	O
a	O
previous	O
report	O
(	O
5	O
)	O
.	O

In	O
vitro	O
[	B
11	I
C	I
]	I
Nemonapride	I
binding	O
to	O
the	O
striatum	O
and	O
cortex	O
In	O
previous	O
studies	O
on	O
in	O
vitro	O
binding	O
of	O
radiolabeled	O
nemonapride	B
(	B
[	I
3	I
H	I
]	I
YM-09151	I
-	I
2	I
)	O
at	O
room	O
temperature	O
,	O
the	O
tracer	O
binding	O
reached	O
equilibrium	O
after	O
90	O
min	O
(	O
2	O
,	O
15	O
,	O
24	O
)	O
.	O

In	O
our	O
preliminary	O
experiment	O
,	O
when	O
the	O
incubation	O
was	O
carried	O
out	O
at	O
37	O
°	O
C	O
to	O
accelerate	O
the	O
equilibration	O
,	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
binding	O
reached	O
a	O
maximal	O
level	O
at	O
30	O
min	O
(	O
data	O
not	O
shown	O
)	O
,	O
which	O
enabled	O
the	O
use	O
of	O
the	O
short	O
-	O
lived	O
11	B
C	I
-	O
ligand	O
.	O

The	O
specific	O
activity	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
reasonably	O
high	O
(	O
25	O
TBq	O
/	O
mmol	O
at	O
the	O
start	O
of	O
assay	O
in	O
the	O
present	O
study	O
)	O
compared	O
with	O
conventional	O
in	O
vitro	O
ARG	O
using	O
3	B
H	I
-	O
labeled	O
compounds	O
.	O

Thus	O
the	O
in	O
vitro	O
ARG	O
with	O
[	B
11	I
C	I
]	I
nemonapride	I
is	O
a	O
practicable	O
technique	O
.	O

The	O
period	O
required	O
from	O
the	O
end	O
of	O
radiosynthesis	O
to	O
the	O
exposing	O
the	O
brain	O
slice	O
to	O
imaging	O
plate	O
was	O
approximately	O
90	O
min	O
.	O

A	O
saturation	O
binding	O
experiment	O
showed	O
a	O
specific	O
binding	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
to	O
the	O
striatum	O
and	O
cortex	O
(	O
Fig.	O
6A	O
)	O
.	O

Scatchard	O
analysis	O
indicated	O
a	O
Kd	O
of	O
730	O
pM	O
and	O
an	O
apparent	O
Bmax	O
of	O
160	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
striatum	O
and	O
a	O
Kd	O
of	O
1.5	O
nM	O
and	O
a	O
Bmax	O
of	O
29	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
cortex	O
.	O

The	O
Kd	O
value	O
of	O
730	O
pM	O
for	O
the	O
striatum	O
is	O
in	O
the	O
same	O
order	O
as	O
those	O
obtained	O
with	O
in	O
vitro	O
ARG	O
by	O
Unis	O
et	O
al.	O
(	O
626	O
pM	O
)	O
(	O
24	O
)	O
and	O
Yokoyama	O
et	O
al.	O
(	O
315	O
pM	O
)	O
(	O
26	O
)	O
,	O
but	O
is	O
larger	O
than	O
those	O
(	O
21–82	O
pM	O
)	O
measured	O
by	O
the	O
membrane	O
binding	O
assay	O
(	O
1	O
,	O
13	O
,	O
15	O
,	O
23	O
)	O
or	O
with	O
in	O
vitro	O
ARG	O
(	O
2	O
)	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
the	O
assay	O
conditions	O
such	O
as	O
incubation	O
time	O
,	O
temperature	O
,	O
blockers	O
used	O
to	O
evaluate	O
the	O
nonspecific	O
binding	O
,	O
other	O
medium	O
components	O
,	O
and	O
slice	O
thickness	O
in	O
ARG	O
.	O

The	O
saturation	O
kinetics	O
may	O
also	O
be	O
different	O
between	O
the	O
membrane	O
homogenate	O
and	O
the	O
brain	O
slice	O
.	O

An	O
in	O
vivo	O
saturation	O
binding	O
experiment	O
in	O
Figure	O
6	O
revealed	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	B
11	I
C	I
]	I
nemonapride	I
in	O
the	O
cortex	O
and	O
striatum	O
.	O

This	O
finding	O
was	O
also	O
revealed	O
by	O
an	O
ex	O
vivo	O
study	O
(	O
Fig.	O
5	O
)	O
,	O
which	O
also	O
suggested	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
in	O
the	O
cerebellum	O
.	O

The	O
specific	O
binding	O
evaluated	O
with	O
a	O
haloperidol	B
-	O
blockade	O
was	O
lower	O
than	O
the	O
nonspecific	O
binding	O
in	O
the	O
cortex	O
(	O
Fig.	O
6A	O
-2	O
)	O
.	O

Kazawa	O
et	O
al.	O
(	O
13	O
)	O
demonstrated	O
that	O
[	B
3	I
H	I
]	I
nemonapride	I
binding	O
in	O
the	O
cortical	O
membrane	O
was	O
displaced	O
by	O
sulpiride	B
or	O
by	O
haloperidol	B
.	O

They	O
also	O
showed	O
that	O
these	O
binding	O
sites	O
were	O
apparently	O
different	O
from	O
serotonin-2	O
receptors	O
.	O

The	O
unknown	O
binding	O
sites	O
may	O
be	O
dopamine	B
D4	O
receptors	O
,	O
because	O
haloperidol	B
,	O
but	O
not	O
raclopride	B
,	O
displaced	O
the	O
uptake	O
(	O
20	O
)	O
.	O

Sigma	O
receptors	O
may	O
be	O
another	O
candidate	O
for	O
the	O
unknown	O
binding	O
sites	O
.	O

Helmeste	O
et	O
al.	O
(	O
7	O
)	O
suggested	O
that	O
nemonapride	B
also	O
has	O
an	O
affinity	O
for	O
sigma	O
receptors	O
,	O
which	O
was	O
evaluated	O
by	O
a	O
blocking	O
study	O
with	O
a	O
selective	O
sigma	O
receptor	O
ligand	O
,	O
R	B
(	I
−	I
)	I
-N	I
-	I
(	I
3-phenyl	I
-	I
n	I
-propyl	I
)	I
-1-phenyl-2-aminopropane	I
(	O
PPAP	B
)	O
.	O

Preliminary	O
findings	O
indicated	O
that	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
uptake	O
was	O
reduced	O
by	O
carrier	O
nemonapride	B
or	O
by	O
haloperidol	B
in	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
of	O
the	O
mouse	O
brain	O
,	O
but	O
that	O
other	O
sigma	O
receptor	O
ligands	O
such	O
as	O
PPAP	B
,	O
(	B
+	I
)	I
-SKF10047	I
,	O
R	B
(	I
+	I
)	I
-3-	I
(	I
3-hydroxyphenyl	I
)	I
-N	I
-propylpiperidine	I
hydrochloride	I
(	O
R	B
[	I
+	I
]	I
-3-PPP	I
)	O
and	O
NE-100	B
(	O
22	O
)	O
did	O
not	O
reduce	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
uptake	O
by	O
the	O
striatum	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
in	O
vivo	O
affinity	O
of	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
for	O
sigma	O
receptors	O
is	O
under	O
investigation	O
.	O

So	O
far	O
,	O
we	O
confirmed	O
in	O
ex	O
vivo	O
and	O
in	O
vitro	O
experiments	O
that	O
the	O
saturable	O
binding	O
sites	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
are	O
present	O
in	O
the	O
cortex	O
(	O
and	O
probably	O
in	O
the	O
cerebellum	O
)	O
although	O
their	O
characteristics	O
remain	O
unknown	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
No.	O
10558115	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Perillyl	B
alcohol	I
is	O
a	O
hydroxylated	B
metabolite	I
of	O
d	B
-limonene	I
[	O
1–3	O
]	O
,	O
which	O
is	O
the	O
major	O
,	O
naturally	O
occurring	O
monoterpene	B
present	O
in	O
orange	O
peel	O
oil	O
.	O

Perillyl	B
alcohol	I
is	O
also	O
found	O
in	O
lavender	O
,	O
mints	O
,	O
and	O
celery	O
seeds	O
.	O

It	O
has	O
been	O
shown	O
that	O
d	B
-limonene	I
and	O
metabolites	B
possess	O
chemopreventative	O
and	O
chemotherapeutic	O
activity	O
against	O
human	O
malignancies	O
with	O
low	O
toxicity	O
[	O
4–8	O
]	O
.	O

d	B
-Limonene	I
is	O
extensively	O
metabolized	O
(	O
Scheme	O
1	O
)	O
in	O
animals	O
[	O
1–5	O
]	O
and	O
in	O
humans	O
[	O
9,10	O
]	O
and	O
perillic	B
acid	I
and	O
dihydroperillic	B
acid	I
were	O
found	O
to	O
be	O
the	O
major	O
circulating	O
metabolites	B
[	O
1–3,5,6	O
]	O
and	O
for	O
perillyl	B
alcohol	I
[	O
11	O
]	O
.	O

Metabolites	B
of	O
limonene	B
with	O
intermediate	O
polarity	O
such	O
as	O
perillyl	B
alcohol	I
,	O
perillic	B
acid	I
methyl	I
ester	I
and	O
perillaldehyde	B
were	O
found	O
to	O
be	O
more	O
potent	O
inhibitors	O
of	O
isoprenylation	O
of	O
the	O
p21–26	O
kDa	O
protein	O
,	O
which	O
is	O
involved	O
in	O
cell	O
growth	O
and	O
proliferation	O
[	O
7	O
]	O
,	O
than	O
limonene	B
itself	O
.	O

In	O
vivo	O
,	O
perillyl	B
alcohol	I
was	O
also	O
found	O
to	O
be	O
more	O
active	O
than	O
d	B
-limonene	I
[	O
4–7,12–14	O
]	O
.	O

Phillips	O
et	O
al.	O
[	O
11	O
]	O
conducted	O
a	O
pharmacokinetic	O
study	O
of	O
perillyl	B
alcohol	I
in	O
dogs	O
using	O
a	O
GC	O
–	O
MS	O
method	O
with	O
a	O
sensitivity	O
limit	O
of	O
0.25	O
μg	O
/	O
ml	O
,	O
but	O
were	O
unable	O
to	O
detect	O
the	O
parent	O
drug	B
in	O
circulation	O
.	O

In	O
order	O
to	O
understand	O
the	O
pharmacokinetic	O
and	O
disposition	O
characteristics	O
of	O
perillyl	B
alcohol	I
,	O
the	O
development	O
of	O
a	O
more	O
sensitive	O
quantitation	O
assay	O
method	O
is	O
necessary	O
.	O

The	O
present	O
report	O
describes	O
a	O
sensitive	O
GC	O
–	O
MS	O
method	O
for	O
the	O
measurement	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
plasma	O
using	O
the	O
stable	O
isotope	B
-	I
labelled	I
analogs	I
as	O
the	O
internal	O
standards	O
.	O

A	O
derivatization	O
procedure	O
is	O
also	O
used	O
to	O
facilitate	O
the	O
GC	O
separation	O
and	O
mass	O
spectrometric	O
detection	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O
and	O
reagents	O
(	B
S	I
)	I
-	I
(	I
−	I
)	I
-Perillyl	I
alcohol	I
(	O
POH	B
)	O
was	O
purchased	O
from	O
Aldrich	O
(	O
Milwaukee	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Perillic	B
acid	I
(	O
PA	B
)	O
,	O
cis-	B
/trans-	I
dihydroperillic	I
acid	I
(	O
cis-	B
/trans-	I
DHPA	I
,	O
cis-	B
/trans-	I
4	I
(	I
1′-methylethenyl	I
)	I
cyclohexane-1-carboxylic	I
acid	I
)	O
,	O
perillyl	B
alcohol	I
-	I
d3	I
(	O
POH	B
-	I
d3	I
)	O
and	O
perillic	B
acid	I
-	I
d2	I
-13	I
C	I
(	O
13	B
C	I
-	I
PA	I
-	I
d2	I
)	O
(	O
Fig.	O
1	O
)	O
were	O
synthesized	O
according	O
to	O
the	O
literature	O
method	O
[	O
15	O
]	O
.	O

POH	B
-	I
d3	I
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
POH	B
,	O
whereas	O
13	B
C	I
-	I
PA	I
-	I
d2	I
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
PA	B
and	O
cis-	B
/	I
trans	I
-DHPA	I
.	O

Cis-	B
and	O
trans-	B
1-carboxy-4-methylcyclohexane	I
were	O
purchased	O
from	O
Aldrich	O
.	O

The	O
chemical	O
purity	O
of	O
all	O
these	O
synthetic	B
compounds	I
as	O
well	O
as	O
the	O
isotope	O
purity	O
of	O
labeled	B
compounds	I
was	O
99	O
%	O
.	O

N	B
,-	I
O	I
-Bis-	I
(	I
trimethylsilyl	I
)	I
silyltrifluoroacetamide	I
(	O
BSTFA	B
)	O
was	O
obtained	O
from	O
Pierce	O
(	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Acetonitrile	B
(	O
HPLC	O
grade	O
)	O
was	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

All	O
other	O
organic	B
solvents	I
and	O
reagents	B
purchased	O
from	O
Fisher	O
Scientific	O
were	O
of	O
reagent	O
grade	O
.	O

2.2	O
Sample	O
extraction	O
To	O
each	O
of	O
a	O
set	O
of	O
16	O
×	O
125-mm	O
disposable	O
tubes	O
was	O
added	O
appropriate	O
amounts	O
of	O
the	O
internal	O
standards	O
in	O
acetonitrile	B
followed	O
by	O
gentle	O
evaporation	O
of	O
the	O
solvent	O
with	O
a	O
stream	O
of	O
nitrogen	B
.	O

A	O
plasma	O
sample	O
(	O
0.5	O
ml	O
or	O
less	O
)	O
was	O
then	O
added	O
and	O
the	O
content	O
mixed	O
.	O

The	O
sample	O
volume	O
of	O
less	O
than	O
0.5	O
ml	O
was	O
made	O
up	O
to	O
0.5	O
ml	O
by	O
addition	O
of	O
blank	O
mouse	O
or	O
human	O
plasma	O
.	O

Acetonitrile	B
(	O
1.0	O
ml	O
)	O
was	O
added	O
to	O
precipitate	O
the	O
protein	O
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
set	O
of	O
disposable	O
tubes	O
and	O
was	O
acidified	O
by	O
addition	O
of	O
10	O
μl	O
of	O
3	O
M	O
HCl	B
.	I

The	O
extraction	O
was	O
accomplished	O
with	O
3	O
×	O
2	O
ml	O
methylene	B
chloride	I
by	O
vigorously	O
mixing	O
on	O
a	O
vortex	O
-	O
mixer	O
for	O
10	O
s	O
,	O
followed	O
by	O
centrifugation	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
methylene	B
chloride	I
extracts	O
were	O
combined	O
and	O
evaporated	O
to	O
dryness	O
by	O
a	O
stream	O
of	O
N2	O
.	O

Forty	O
μl	O
of	O
60	O
%	O
BSTFA	B
in	O
acetonitrile	B
was	O
then	O
added	O
.	O

The	O
content	O
was	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
5	O
min	O
before	O
analysis	O
by	O
GC	O
–	O
MS	O
.	O

2.3	O
GC	O
–	O
MS	O
analysis	O
GC	O
–	O
MS	O
analysis	O
of	O
the	O
analytes	O
was	O
performed	O
on	O
a	O
Finnigan	O
MAT	O
ITS40	O
(	O
Finnigan	O
MAT	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
coupled	O
to	O
a	O
3300	O
/	O
3400	O
Model	O
Varian	O
gas	O
chromatograph	O
(	O
Walnut	O
Creek	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
gas	O
chromatograph	O
was	O
equipped	O
with	O
a	O
DB-5	O
fused	O
-	O
silica	B
capillary	O
column	O
(	O
30	O
m	O
×	O
0.25	O
mm	O
)	O
wall	O
-	O
coated	O
with	O
0.25	O
mm	O
of	O
cross	O
-	O
linked	O
95	O
%	O
methyl-	B
and	O
5	O
%	O
phenyl	B
-	I
polysiloxane	I
(	O
J&W	O
Scientific	O
,	O
Folsom	O
,	O
CA	O
,	O
USA	O
)	O
and	O
an	O
autosampler	O
(	O
Finnigan	O
MAT	O
)	O
.	O

Ultra	O
-	O
high	O
purity	O
helium	B
was	O
used	O
as	O
the	O
carrier	O
gas	O
with	O
a	O
head	O
pressure	O
of	O
15	O
psi	O
(	O
ca	O
.	O

105	O
Pa	O
)	O
.	O

The	O
injection	O
port	O
and	O
the	O
transfer	O
line	O
were	O
set	O
at	O
270	O
°	O
C	O
.	O

The	O
oven	O
temperature	O
was	O
initiated	O
at	O
100	O
°	O
C	O
for	O
1	O
min	O
,	O
and	O
was	O
ramped	O
to	O
250	O
°	O
C	O
at	O
15	O
°	O
C	O
/	O
min	O
,	O
then	O
increased	O
to	O
280	O
°	O
C	O
at	O
30	O
°	O
C	O
/	O
min	O
.	O

The	O
column	O
was	O
held	O
at	O
250	O
°	O
C	O
for	O
1	O
min	O
.	O

Analysis	O
was	O
performed	O
using	O
chemical	O
ionization	O
mode	O
and	O
ammonia	B
was	O
used	O
as	O
the	O
reagent	B
gas	O
.	O

Quantitation	O
was	O
performed	O
in	O
the	O
selected	O
ion	O
monitor	O
mode	O
by	O
measuring	O
the	O
base	O
peak	O
of	O
either	O
MH+	O
or	O
the	O
fragment	O
ions	O
characteristic	O
of	O
the	O
trimethylsilylated	B
derivatives	I
of	O
the	O
analytes	O
and	O
their	O
respective	O
internal	O
standards	O
.	O

The	O
peak	O
area	O
ratio	O
method	O
was	O
used	O
in	O
construction	O
of	O
the	O
calibration	O
curves	O
.	O

2.4	O
13	O
C	O
-	O
NMR	O
analysis	O
13	O
C	O
-	O
NMR	O
spectra	O
were	O
recorded	O
on	O
either	O
a	O
Brucker	O
NR-250	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
62.89	O
MHz	O
or	O
a	O
Brucker	O
AM-500	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
125.77	O
MHz	O
with	O
tetramethylsilane	B
as	O
the	O
internal	O
standard	O
and	O
CDCl3	B
as	O
the	O
solvent	B
.	O

2.5	O
Separation	O
of	O
cis-	B
and	O
trans-	B
dihydroperillic	I
acid	I
A	O
mixture	O
of	O
synthetic	O
cis-	B
and	O
trans-	B
dihydroperillic	I
acids	I
was	O
separated	O
by	O
thin	O
-	O
layer	O
chromatography	O
.	O

The	O
mixture	O
(	O
10	O
mg	O
)	O
was	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
CH2	B
Cl2	I
and	O
the	O
solution	O
was	O
applied	O
onto	O
a	O
precoated	O
silica	B
gel	I
G	O
60	O
thin	O
-	O
layer	O
plate	O
(	O
EM	O
Merck	O
,	O
thickness	O
0.2	O
mm	O
,	O
20	O
×	O
20	O
cm	O
)	O
.	O

This	O
plate	O
was	O
developed	O
ascendingly	O
with	O
50:1	O
CH2	B
Cl2	I
–MeOH	O
on	O
a	O
lined	O
tank	O
for	O
one	O
full	O
-	O
length	O
.	O

Under	O
UV	O
light	O
visualization	O
,	O
two	O
overlapping	O
spots	O
(	O
ca	O
.	O
50	O
%	O
)	O
(	O
R	O
f	O
0.55–0.76	O
)	O
were	O
seen	O
and	O
the	O
upper	O
portion	O
of	O
the	O
faster	O
-	O
running	O
spot	O
(	O
R	O
f	O
0.72–0.76	O
)	O
was	O
scrapped	O
off	O
and	O
eluted	O
with	O
CH2	B
Cl2	I
.	O

The	O
collected	O
compound	O
(	O
ca	O
.	O

2	O
mg	O
)	O
was	O
found	O
to	O
be	O
the	O
pure	O
component	O
corresponding	O
to	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
on	O
GC	O
–	O
MS	O
using	O
the	O
condition	O
as	O
described	O
above	O
.	O

The	O
lower	O
portion	O
of	O
the	O
spot	O
was	O
also	O
collected	O
and	O
GC	O
–	O
MS	O
still	O
showed	O
a	O
mixture	O
of	O
cis	B
/	I
trans	I
-DHPA	I
with	O
retention	O
times	O
of	O
6.3	O
and	O
6.7	O
min	O
.	O

Attempts	O
to	O
further	O
resolve	O
these	O
components	O
were	O
unsuccessful	O
.	O

2.6	O
Assay	O
characterization	O
and	O
validation	O
Detection	O
limit	O
was	O
measured	O
by	O
reducing	O
the	O
amount	O
of	O
each	O
analyte	O
until	O
the	O
signal	O
-	O
to	O
-	O
noise	O
equaled	O
to	O
four	O
,	O
which	O
is	O
defined	O
as	O
the	O
detection	O
limit	O
.	O

The	O
recovery	O
was	O
estimated	O
by	O
comparing	O
the	O
ratio	O
of	O
the	O
extracted	O
analytes	O
to	O
the	O
unextracted	O
internal	O
standard	O
with	O
that	O
of	O
the	O
unextracted	O
pairs	O
.	O

Within	O
-	O
run	O
precision	O
for	O
POH	B
,	O
PA	B
,	O
cis-	B
and	O
trans-	B
DHPA	I
was	O
determined	O
by	O
analyzing	O
six	O
replicates	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
.	O

The	O
concentrations	O
used	O
were	O
:	O
for	O
POH	B
at	O
2	O
,	O
4	O
,	O
20	O
,	O
200	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	O
at	O
40	O
,	O
200	O
,	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	B
and	O
trans-	B
DHPA	I
each	O
at	O
20	O
,	O
100	O
,	O
and	O
1000	O
ng	O
/	O
ml	O
.	O

Between	O
-	O
run	O
precision	O
was	O
evaluated	O
by	O
analyzing	O
the	O
variation	O
of	O
the	O
slopes	O
of	O
six	O
standard	O
curves	O
for	O
each	O
analyte	O
obtained	O
on	O
six	O
different	O
days	O
.	O

2.7	O
Pilot	O
animal	O
study	O
The	O
femoral	O
and	O
jugular	O
veins	O
of	O
a	O
Sprague	O
-	O
Dawley	O
rat	O
weighing	O
350	O
g	O
were	O
cannulated	O
under	O
ether	O
anesthesia	O
.	O

Three	O
hours	O
after	O
recovery	O
,	O
the	O
animal	O
was	O
given	O
neat	O
perillyl	B
alcohol	I
(	O
ca	O
.	O

22	O
μl	O
)	O
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

via	O
the	O
femoral	O
cannula	O
over	O
30	O
s	O
followed	O
by	O
a	O
rinse	O
of	O
0.5	O
ml	O
normal	O
saline	B
.	O

At	O
the	O
time	O
schedule	O
of	O
0	O
,	O
3	O
,	O
5	O
,	O
10	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
180	O
,	O
240	O
,	O
300	O
,	O
360	O
,	O
480	O
,	O
720	O
,	O
960	O
,	O
1200	O
,	O
and	O
1440	O
min	O
following	O
dosing	O
,	O
approximately	O
0.2	O
ml	O
of	O
heparinized	O
blood	O
each	O
was	O
withdrawn	O
from	O
the	O
jugular	O
vein	O
cannula	O
.	O

Plasma	O
was	O
separated	O
by	O
centrifugation	O
.	O

An	O
aliquot	O
of	O
each	O
plasma	O
sample	O
was	O
appropriately	O
diluted	O
with	O
blank	O
rat	O
plasma	O
to	O
make	O
up	O
to	O
0.5	O
ml	O
.	O

Under	O
this	O
condition	O
,	O
the	O
measured	O
concentrations	O
were	O
in	O
the	O
range	O
of	O
the	O
calibration	O
-	O
curve	O
.	O

To	O
each	O
plasma	O
sample	O
was	O
added	O
200	O
ng	O
of	O
the	O
internal	O
standard	O
followed	O
by	O
an	O
addition	O
of	O
1.0	O
ml	O
acetonitrile	B
to	O
precipitate	O
the	O
protein	O
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
2000	O
g	O
for	O
5	O
m.	O
The	O
supernatant	O
was	O
removed	O
and	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
analysis	O
.	O

2.8	O
Preliminary	O
clinical	O
study	O
The	O
clinical	O
study	O
is	O
a	O
part	O
of	O
an	O
ongoing	O
Phase	O
I	O
evaluation	O
of	O
POH	B
as	O
a	O
chemopreventative	B
agent	I
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

The	O
Phase	O
I	O
protocol	O
was	O
approved	O
by	O
the	O
Institution	O
Review	O
Board	O
(	O
IRB	O
)	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

Subjects	O
with	O
a	O
personal	O
history	O
of	O
AJCC	O
Stage	O
I	O
–	O
IIIa	O
breast	O
cancer	O
who	O
have	O
undergone	O
definitive	O
resection	O
with	O
curative	O
intent	O
and	O
who	O
have	O
completed	O
all	O
adjuvant	O
radiation	O
therapy	O
,	O
chemotherapy	O
,	O
and	O
reversible	O
hormone	O
therapy	O
are	O
eligible	O
to	O
enroll	O
in	O
this	O
study	O
.	O

All	O
subjects	O
were	O
in	O
good	O
general	O
health	O
with	O
adequate	O
major	O
organ	O
functions	O
and	O
ECOG	O
Performance	O
Status	O
of	O
0–1	O
.	O

Patients	O
were	O
treated	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
,	O
Cleveland	O
,	O
Ohio	O
.	O

The	O
current	O
study	O
was	O
limited	O
to	O
patients	O
at	O
the	O
first	O
of	O
the	O
five	O
dose	O
levels	O
.	O

Dose	O
at	O
0.5	O
g	O
/	O
m2	O
was	O
given	O
as	O
capsules	O
,	O
which	O
were	O
supplied	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Following	O
dosing	O
,	O
blood	O
samples	O
were	O
drawn	O
at	O
0	O
(	O
predose	O
)	O
,	O
0.25	O
,	O
0.5	O
,	O
0.75	O
,	O
1.0	O
,	O
1.5	O
,	O
2.0	O
,	O
3.0	O
,	O
4.0	O
,	O
6.0	O
,	O
8.0	O
,	O
10.0	O
,	O
and	O
24	O
h.	O
Plasma	O
was	O
separated	O
from	O
red	O
blood	O
cells	O
by	O
centrifugation	O
and	O
kept	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
shipment	O
.	O

All	O
frozen	O
specimens	O
were	O
then	O
shipped	O
in	O
a	O
dry	B
-	I
ice	I
container	O
(	O
overnight	O
)	O
to	O
Dr.	O
Chan	O
's	O
Laboratory	O
at	O
the	O
Ohio	O
State	O
University	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
in	O
the	O
same	O
manner	O
as	O
the	O
rat	O
plasma	O
samples	O
.	O

2.9	O
Quality	O
control	O
and	O
stability	O
Two	O
sets	O
of	O
spiked	O
plasma	O
samples	O
consisting	O
of	O
three	O
concentration	O
levels	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ng	O
/	O
ml	O
of	O
POH	B
,	O
PA	B
,	I
cis-	B
/trans-	I
DHPA	I
were	O
prepared	O
and	O
frozen	O
at	O
−20	O
°	O
C	O
.	O

One	O
frozen	O
set	O
was	O
sent	O
to	O
the	O
Laboratory	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
by	O
overnight	O
courier	O
service	O
in	O
dry	B
-	I
ice	I
.	O

After	O
storage	O
for	O
approximately	O
one	O
week	O
at	O
−20	O
°	O
C	O
,	O
the	O
same	O
samples	O
were	O
returned	O
by	O
courier	O
service	O
to	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
.	O

Another	O
set	O
of	O
samples	O
were	O
maintained	O
frozen	O
at	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
for	O
the	O
same	O
duration	O
until	O
analysis	O
.	O

Drug	B
and	O
metabolite	B
levels	O
were	O
analyzed	O
in	O
these	O
two	O
sets	O
of	O
samples	O
at	O
the	O
same	O
time	O
and	O
the	O
results	O
were	O
compared	O
.	O

3	O
Results	O
3.1	O
Analysis	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
The	O
GC	O
–	O
MS	O
mass	O
spectra	O
of	O
POH	B
,	O
PA	B
and	O
cis-	B
/trans-	I
DHPA	I
and	O
their	O
internal	O
standards	O
,	O
POH	B
-	I
d3	I
and	O
13	B
C	I
-	I
PA	I
-	I
d2	I
are	O
shown	O
in	O
Fig.	O
1	O
.	O

As	O
shown	O
,	O
silylated	B
POH	I
and	O
its	O
internal	O
standard	O
each	O
showed	O
the	O
base	O
peak	O
at	O
m	O
/	O
z	O
135	O
and	O
138	O
corresponding	O
to	O
their	O
C	O
–	O
O	O
cleavages	O
.	O

MH+	O
ions	O
as	O
their	O
TMS	B
derivatives	I
at	O
m	O
/	O
z	O
239	O
and	O
m	O
/	O
z	O
242	O
,	O
respectively	O
,	O
were	O
detected	O
for	O
PA	B
and	O
13	B
C	I
-	I
PA	I
-	I
d2	I
as	O
the	O
base	O
peak	O
,	O
and	O
also	O
for	O
cis-	B
/trans-	I
DHPA	I
at	O
m	O
/	O
z	O
241	O
at	O
55	O
%	O
relative	O
abundance	O
.	O

These	O
ions	O
were	O
used	O
for	O
subsequent	O
quantitation	O
.	O

On	O
this	O
basis	O
,	O
a	O
typical	O
set	O
of	O
GC	O
mass	O
chromatograms	O
of	O
human	O
and	O
rat	O
plasma	O
extracts	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

As	O
shown	O
,	O
all	O
analytes	O
were	O
detected	O
as	O
symmetrical	O
peaks	O
and	O
cis-	B
and	O
trans-	B
DHPA	I
were	O
well	O
resolved	O
.	O

The	O
retention	O
times	O
of	O
the	O
analytes	O
were	O
:	O
POH	B
/	O
POH	B
-	I
d3	I
at	O
6.2	O
min	O
,	O
PA	B
/	O
13	B
C	I
-	I
PA	I
-	I
d2	I
at	O
7.3	O
min	O
,	O
cis-	B
DHPA	I
at	O
6.3	O
min	O
,	O
and	O
trans-	B
DHPA	I
at	O
6.7	O
min	O
.	O

The	O
assignments	O
of	O
cis-	B
and	O
trans-	B
DHPA	I
are	O
described	O
below	O
and	O
coincided	O
with	O
those	O
of	O
Phillips	O
et	O
al.	O
[	O
11	O
]	O
.	O

No	O
interference	O
peaks	O
at	O
the	O
selected	O
ion	O
regions	O
were	O
found	O
in	O
the	O
human	O
or	O
rat	O
plasma	O
blank	O
,	O
except	O
for	O
low	O
levels	O
of	O
signal	O
contributed	O
by	O
the	O
internal	O
standards	O
.	O

These	O
interference	O
contributions	O
were	O
due	O
to	O
incomplete	O
isotope	O
labeling	O
and	O
were	O
all	O
<	O
2	O
%	O
.	O

Thus	O
,	O
the	O
ions	O
monitored	O
at	O
m	O
/	O
z	O
135	O
,	O
138	O
,	O
239	O
,	O
242	O
and	O
241	O
were	O
considered	O
to	O
be	O
highly	O
specific	O
and	O
sensitive	O
for	O
detecting	O
POH	B
and	O
its	O
metabolites	B
.	O

3.2	O
Assignments	O
of	O
cis-	B
and	O
trans-	O
DHPA	B
Phillips	O
et	O
al.	O
[	O
11	O
]	O
using	O
GC	O
–	O
MS	O
method	O
with	O
electron	O
-	O
impact	O
ionization	O
partially	O
resolved	O
the	O
underivatized	O
cis-	B
and	O
trans-	B
DHPA	I
.	O

On	O
the	O
basis	O
of	O
the	O
different	O
mass	O
spectral	O
fragmentation	O
patterns	O
of	O
these	O
two	O
isomers	B
augmented	O
by	O
a	O
quantum	O
mechanical	O
calculation	O
to	O
correlate	O
the	O
configuration	O
and	O
mass	O
fragmentation	O
preference	O
,	O
they	O
assigned	O
the	O
smaller	O
component	O
with	O
a	O
shorter	O
retention	O
time	O
as	O
the	O
cis-	B
isomer	I
and	O
the	O
larger	O
slower	O
-	O
eluting	O
component	O
as	O
the	O
trans-	B
isomer	I
.	O

Since	O
we	O
employed	O
derivatization	O
in	O
our	O
GC	O
–	O
MS	O
assay	O
,	O
direct	O
correlation	O
of	O
our	O
system	O
with	O
those	O
of	O
Philips	O
et	O
al.	O
was	O
difficult	O
.	O

Therefore	O
,	O
we	O
resorted	O
to	O
use	O
an	O
alternative	O
method	O
for	O
the	O
assignment	O
of	O
these	O
isomers	B
.	O

Using	O
thin	O
layer	O
chromatographic	O
separation	O
,	O
we	O
were	O
able	O
to	O
partially	O
resolve	O
the	O
two	O
isomers	B
.	O

The	O
faster	O
running	O
spot	O
was	O
enriched	O
and	O
accumulated	O
.	O

The	O
GC	O
–	O
MS	O
showed	O
that	O
the	O
enriched	O
component	O
had	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
.	O

The	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
synthetic	O
mixture	O
of	O
cis-	B
and	O
trans-	B
DHPA	I
showed	O
sets	O
of	O
doublets	O
at	O
180.97	O
and	O
181.65	O
ppm	O
corresponding	O
to	O
the	O
-COOH	O
signals	O
,	O
at	O
149.76	O
and	O
149.96	O
ppm	O
corresponding	O
to	O
C-1′	O
,	O
at	O
108.54	O
and	O
108.75	O
ppm	O
corresponding	O
to	O
C-2′	O
,	O
at	O
44.15	O
and	O
44.55	O
ppm	O
corresponding	O
to	O
C-4	O
,	O
at	O
39.37	O
and	O
42.98	O
ppm	O
corresponding	O
to	O
C-1	O
,	O
and	O
at	O
above	O
40	O
ppm	O
for	O
the	O
remaining	O
carbons	B
and	O
the	O
side	O
chain	O
methyl	B
.	O

The	O
carbon	B
chemical	O
shift	O
assignments	O
were	O
based	O
on	O
the	O
H	O
-	O
coupling	O
,	O
H	O
-	O
decoupling	O
data	O
,	O
and	O
comparison	O
with	O
known	O
assignments	O
of	O
several	O
monoterpenes	B
and	O
cyclohexane	B
systems	O
[	O
16–18	O
]	O
.	O

However	O
,	O
the	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
above	O
described	O
enriched	O
component	O
failed	O
to	O
show	O
signals	O
with	O
adequate	O
intensity	O
at	O
the	O
downfield	O
region	O
(	O
180	O
ppm	O
)	O
but	O
signals	O
above	O
120	O
ppm	O
were	O
clearly	O
discernible	O
with	O
unequal	O
intensity	O
,	O
consistent	O
with	O
the	O
enrichment	O
.	O

Based	O
on	O
the	O
cyclohexanol	B
system	O
,	O
chemical	O
shift	O
of	O
C-1	O
appears	O
to	O
be	O
most	O
sensitive	O
to	O
cis-	O
/trans-	O
isomerism	O
[	O
18	O
]	O
.	O

Thus	O
,	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
cis-	B
and	O
trans-	B
1,4-methyl	I
cyclohexanol	I
show	O
C-1	O
at	O
66.2	O
and	O
70.0	O
ppm	O
,	O
respectively	O
,	O
and	O
cis-	B
and	O
trans-	B
1,4-t	I
-	I
butylcyclohexanol	I
show	O
C-1	O
at	O
65.0	O
and	O
70.4	O
ppm	O
,	O
respectively	O
.	O

In	O
both	O
cases	O
C-1s	O
for	O
the	O
cis-	B
isomer	I
are	O
several	O
ppm	O
upfield	O
from	O
the	O
trans-	B
isomer	I
.	O

The	O
enriched	O
DHPA	B
isomer	I
showed	O
only	O
a	O
singlet	O
at	O
39.36	O
ppm	O
of	O
C-1	O
with	O
the	O
more	O
downfield	O
signal	O
missing	O
.	O

This	O
suggests	O
that	O
the	O
enriched	O
DHPA	B
isomer	I
may	O
be	O
the	O
cis-	B
isomer	I
.	O

This	O
possibility	O
was	O
further	O
supported	O
by	O
examination	O
of	O
the	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
synthetic	O
cis-	B
and	O
trans-	B
1-carboxyl-4-methylcyclohexanes	I
which	O
showed	O
C-1	O
chemical	O
shifts	O
at	O
31.32	O
and	O
34.21	O
ppm	O
,	O
respectively	O
.	O

Again	O
,	O
the	O
C-1	O
of	O
cis-	B
isomer	I
shows	O
nearly	O
3	O
ppm	O
upfield	O
from	O
that	O
of	O
the	O
trans-	B
isomer	I
.	O

In	O
order	O
to	O
correlate	O
the	O
GC	O
–	O
MS	O
retention	O
times	O
of	O
the	O
silyl	B
derivatives	I
of	I
these	O
cyclohexane	B
isomers	I
with	O
their	O
stereochemistry	O
,	O
cis-	B
and	O
trans-	B
1-carboxyl-4-methylcyclohexane	I
were	O
silylated	O
with	O
BSTFA	B
.	I

The	O
GC	O
–	O
MS	O
showed	O
that	O
the	O
cis-	B
isomer	I
gave	O
a	O
retention	O
time	O
of	O
4.12	O
min	O
while	O
the	O
trans-	B
isomer	I
gave	O
a	O
retention	O
time	O
of	O
4.28	O
min	O
using	O
the	O
similar	O
temperature	O
programming	O
and	O
column	O
as	O
those	O
of	O
DHPA	B
.	O

On	O
this	O
basis	O
,	O
it	O
was	O
concluded	O
that	O
the	O
DHPA	B
isomer	I
with	O
the	O
shorter	O
retention	O
time	O
was	O
the	O
cis-	B
isomer	I
and	O
that	O
with	O
the	O
longer	O
retention	O
time	O
was	O
the	O
isomer	B
with	I
trans-	I
configuration	I
.	O

Interestingly	O
,	O
the	O
assignment	O
appeared	O
to	O
be	O
the	O
same	O
as	O
those	O
of	O
Philips	O
et	O
al.	O
[	O
11	O
]	O
,	O
based	O
on	O
the	O
relative	O
retention	O
times	O
of	O
the	O
underivatized	O
compounds	O
and	O
the	O
relative	O
amount	O
of	O
the	O
DHPA	B
found	O
as	O
metabolite	B
in	O
vivo	O
.	O

3.3	O
Within	O
-	O
run	O
validation	O
When	O
plotting	O
the	O
peak	O
area	O
ratios	O
between	O
the	O
analyte	O
and	O
the	O
internal	O
standard	O
against	O
the	O
added	O
concentrations	O
of	O
the	O
analytes	O
a	O
linear	O
relationship	O
was	O
obtained	O
within	O
the	O
concentration	O
ranges	O
monitored	O
for	O
all	O
analytes	O
.	O

In	O
both	O
human	O
and	O
rat	O
plasma	O
,	O
for	O
POH	B
linearity	O
was	O
demonstrated	O
from	O
2	O
to	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	B
and	O
trans-	B
DHPA	I
from	O
10	O
to	O
1000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	B
DHPA	I
20	O
to1000	O
ng	O
/	O
ml	O
.	O

The	O
routine	O
sensitivity	O
limit	O
was	O
found	O
to	O
be	O
2	O
ng	O
/	O
ml	O
for	O
POH	B
,	O
10	O
ng	O
/	O
ml	O
for	O
PA	O
and	O
trans-	B
DHPA	I
,	O
and	O
20	O
ng	O
/	O
ml	O
for	O
cis-	B
DHPA	I
.	O

The	O
within	O
-	O
run	O
validation	O
data	O
for	O
POH	B
and	O
metabolites	B
in	O
rat	O
and	O
human	O
plasma	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Also	O
shown	O
in	O
the	O
same	O
table	O
are	O
the	O
accuracy	O
data	O
.	O

As	O
shown	O
,	O
the	O
%	O
C.V.	O
values	O
ranged	O
from	O
0.5	O
to	O
8	O
%	O
with	O
the	O
majority	O
falling	O
below	O
5	O
%	O
and	O
a	O
mean	O
accuracy	O
value	O
of	O
98.6	O
%	O
.	O

3.4	O
Between	O
-	O
run	O
validation	O
The	O
between	O
-	O
run	O
variation	O
for	O
POH	B
in	O
human	O
plasma	O
was	O
5.5	O
%	O
and	O
6.3	O
%	O
in	O
rat	O
plasma	O
as	O
measured	O
by	O
the	O
slopes	O
of	O
six	O
calibration	O
curves	O
in	O
each	O
medium	O
at	O
six	O
different	O
occasions	O
(	O
Table	O
2	O
)	O
.	O

At	O
each	O
case	O
,	O
the	O
mean	O
intercept	O
is	O
less	O
than	O
2	O
ng	O
/	O
ml	O
equivalent	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
PA	B
by	O
similar	O
measurements	O
were	O
5.5	O
%	O
in	O
human	O
plasma	O
and	O
3.4	O
%	O
in	O
rat	O
plasma	O
,	O
all	O
n	O
=	O
6	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
cis-	B
DHPA	I
in	O
human	O
and	O
rat	O
plasma	O
were	O
6.9	O
%	O
and	O
5.1	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
trans-	B
DHPA	I
were	O
5.0	O
and	O
6.3	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
(	O
Table	O
2	O
)	O
.	O

In	O
these	O
cases	O
,	O
the	O
mean	O
intercepts	O
for	O
the	O
calibration	O
curves	O
of	O
the	O
metabolites	B
were	O
less	O
than	O
5	O
ng	O
/	O
ml	O
analyte	O
equivalent	O
.	O

3.5	O
Recovery	O
and	O
quality	O
control	O
The	O
recovery	O
values	O
of	O
POH	B
,	O
PA	B
,	O
cis-	B
and	O
trans-	B
DHPA	I
from	O
the	O
entire	O
procedure	O
were	O
:	O
98	O
%	O
,	O
59	O
%	O
,	O
64	O
%	O
and	O
72	O
%	O
in	O
human	O
plasma	O
and	O
90	O
%	O
,	O
77	O
%	O
,	O
69	O
%	O
and	O
76	O
%	O
in	O
rat	O
plasma	O
,	O
respectively	O
.	O

There	O
was	O
less	O
than	O
3	O
%	O
variation	O
for	O
POH	B
and	O
metabolite	B
levels	O
in	O
plasma	O
samples	O
kept	O
at	O
−20	O
°	O
C	O
over	O
the	O
course	O
of	O
four	O
weeks	O
and	O
there	O
was	O
no	O
appreciable	O
difference	O
in	O
the	O
samples	O
tested	O
through	O
mailing	O
via	O
the	O
courier	O
service	O
.	O

3.6	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
a	O
rat	O
Fig.	O
3	O
shows	O
a	O
plasma	O
concentration	O
–	O
time	O
profile	O
of	O
POH	B
and	O
metabolites	B
in	O
the	O
rat	O
given	O
POH	B
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

As	O
shown	O
,	O
POH	B
was	O
detected	O
in	O
circulation	O
up	O
to	O
360	O
min	O
with	O
the	O
initial	O
concentration	O
at	O
2089	O
ng	O
/	O
ml	O
.	O

The	O
concentrations	O
declined	O
biexponentially	O
with	O
a	O
terminal	O
half	O
-	O
life	O
of	O
approximately	O
135	O
min	O
.	O

PA	B
appeared	O
in	O
plasma	O
in	O
the	O
first	O
sample	O
at	O
3	O
min	O
and	O
peaked	O
at	O
10	O
at	O
8893	O
ng	O
/	O
ml	O
and	O
declined	O
approximately	O
monoexponentially	O
to	O
about	O
35	O
ng	O
/	O
ml	O
at	O
720	O
min	O
.	O

Cis	B
-	I
and	O
trans-	B
DHPA	I
appeared	O
in	O
plasma	O
at	O
about	O
10	O
min	O
and	O
peaked	O
at	O
about	O
60	O
min	O
and	O
also	O
declined	O
monoexponentially	O
.	O

The	O
plasma	O
levels	O
of	O
the	O
trans-	B
metabolite	I
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
cis-	B
isomer	I
.	I

An	O
unknown	O
metabolite	B
,	O
labeled	O
as	O
M2	B
,	O
was	O
also	O
detected	O
in	O
plasma	O
at	O
high	O
levels	O
and	O
this	O
metabolite	B
has	O
the	O
same	O
m	O
/	O
z	O
value	O
as	O
PA	B
but	O
with	O
a	O
retention	O
time	O
of	O
8.3	O
min	O
.	O

M2	B
appeared	O
in	O
plasma	O
at	O
3	O
min	O
at	O
2070	O
ng	O
/	O
ml	O
PA	B
equivalent	O
and	O
peaked	O
at	O
10	O
min	O
at	O
levels	O
over	O
6000	O
ng	O
/	O
ml	O
.	O

Although	O
the	O
initial	O
levels	O
of	O
this	O
metabolite	B
were	O
slightly	O
lower	O
than	O
those	O
of	O
PA	B
,	O
the	O
levels	O
after	O
2	O
h	O
exceeded	O
those	O
of	O
PA	B
after	O
and	O
were	O
detectable	O
even	O
at	O
1440	O
min	O
.	O

The	O
plasma	O
half	O
-	O
life	O
was	O
approximately	O
3	O
h.	O
3.7	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
a	O
patient	O
The	O
plasma	O
concentration	O
–	O
time	O
profiles	O
of	O
POH	B
and	O
its	O
metabolites	B
were	O
measured	O
in	O
a	O
patient	O
who	O
received	O
a	O
p.o	O
.	O

dose	O
at	O
500	O
mg	O
/	O
m2	O
and	O
the	O
results	O
are	O
shown	O
in	O
Fig.	O
4	O
.	O

As	O
shown	O
,	O
POH	B
,	O
PA	B
,	O
cis-	B
and	O
trans-	B
DHPA	I
were	O
all	O
detectable	O
in	O
plasma	O
.	O

POH	B
was	O
detectable	O
at	O
3.5	O
ng	O
/	O
ml	O
at	O
0.75	O
h	O
and	O
peaked	O
at	O
5.0	O
ng	O
/	O
ml	O
at	O
1.5	O
h.	O
The	O
levels	O
then	O
declined	O
monoexponentially	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
2.3	O
h.	O
The	O
AUC	O
value	O
was	O
22	O
ng	O
/	O
ml	O
h.	O
The	O
most	O
abundant	O
metabolite	B
in	O
circulation	O
was	O
PA	B
which	O
peaked	O
slowly	O
at	O
11400	O
ng	O
/	O
ml	O
at	O
about	O
1.5	O
h.	O
PA	B
was	O
formed	O
rapidly	O
following	O
the	O
POH	B
administration	O
,	O
and	O
remained	O
at	O
a	O
steady	O
-	O
state	O
for	O
1–2	O
h	O
before	O
declining	O
.	O

The	O
level	O
then	O
declined	O
monoexponentially	O
to	O
about	O
40	O
ng	O
/	O
ml	O
at	O
8	O
h	O
and	O
became	O
undetectable	O
thereafter	O
.	O

Similar	O
to	O
the	O
case	O
in	O
the	O
rat	O
,	O
cis-	B
DHPA	I
levels	O
were	O
lower	O
than	O
those	O
of	O
trans	O
.	O

Two	O
previously	O
undescribed	O
metabolites	B
were	O
detected	O
in	O
circulation	O
.	O

M1	B
gave	O
a	O
retention	O
time	O
of	O
7.7	O
min	O
and	O
M2	B
gave	O
a	O
retention	O
of	O
8.3	O
min	O
,	O
which	O
appears	O
identical	O
to	O
the	O
one	O
described	O
in	O
the	O
rat	O
.	O

Both	O
of	O
these	O
metabolites	O
gave	O
the	O
MH+	O
ion	O
identical	O
to	O
that	O
of	O
PA	B
.	O

Levels	O
of	O
M2	B
were	O
lower	O
than	O
those	O
of	O
PA	B
but	O
higher	O
than	O
those	O
of	O
M1	B
.	O

M2	B
peaked	O
at	O
over	O
1000	O
ng	O
/	O
ml	O
at	O
3	O
h	O
,	O
and	O
M1	B
peaked	O
at	O
76	O
ng	O
/	O
ml	O
at	O
1	O
h.	O
4	O
Discussion	O
Previous	O
GC	O
and	O
GC	O
–	O
MS	O
methods	O
failed	O
to	O
detect	O
POH	B
in	O
plasma	O
presumably	O
because	O
of	O
inadequate	O
sensitivity	O
[	O
11	O
]	O
.	O

The	O
reason	O
for	O
the	O
low	O
sensitivity	O
may	O
be	O
due	O
to	O
the	O
use	O
of	O
electron	O
impact	O
mass	O
spectrometry	O
for	O
detection	O
.	O

Excess	O
fragmentation	O
under	O
the	O
EI	O
condition	O
significantly	O
reduced	O
the	O
assay	O
sensitivity	O
.	O

Moreover	O
,	O
POH	B
and	O
its	O
metabolites	B
such	O
as	O
PA	B
are	O
still	O
rather	O
polar	O
.	O

Tailing	O
of	O
their	O
GC	O
peaks	O
may	O
also	O
reduce	O
the	O
assay	O
sensitivity	O
.	O

The	O
present	O
method	O
used	O
a	O
soft	O
ammonia	B
chemical	O
ionization	O
,	O
which	O
could	O
reduce	O
fragmentation	O
and	O
increase	O
the	O
relative	O
abundance	O
of	O
the	O
ion	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
that	O
BSTFA	B
derivatization	O
of	O
POH	B
and	O
its	O
metabolites	B
reduced	O
tailing	O
and	O
further	O
reduced	O
fragmentation	O
and	O
enhanced	O
sensitivity	O
.	O

Another	O
improvement	O
of	O
our	O
analytical	O
method	O
was	O
to	O
use	O
the	O
stable	O
isotopically	O
labeled	O
POH	B
and	O
PA	B
as	O
the	O
internal	O
standard	O
that	O
provided	O
the	O
excellent	O
C.V.s	O
obtained	O
.	O

Thus	O
,	O
the	O
current	O
assay	O
provided	O
more	O
than	O
a	O
hundred	O
-	O
fold	O
improvement	O
in	O
sensitivity	O
over	O
the	O
previous	O
GC	O
–	O
MS	O
method	O
,	O
and	O
made	O
it	O
possible	O
to	O
detect	O
circulating	O
POH	B
following	O
POH	B
administration	O
.	O

The	O
use	O
of	O
derivatization	O
and	O
a	O
capillary	O
column	O
in	O
this	O
method	O
also	O
permitted	O
the	O
complete	O
separation	O
of	O
cis-	B
and	O
trans-	B
DHPA	I
(	O
Fig.	O
3	O
)	O
.	O

The	O
earlier	O
eluting	O
peak	O
(	O
6.3	O
min	O
)	O
was	O
assigned	O
to	O
be	O
the	O
cis-	B
isomer	I
,	O
based	O
on	O
the	O
NMR	O
method	O
and	O
this	O
assignment	O
is	O
identical	O
to	O
those	O
of	O
Philip	O
et	O
al.	O
[	O
11	O
]	O
who	O
assigned	O
their	O
earlier	O
eluting	O
component	O
in	O
the	O
partially	O
resolved	O
pair	O
as	O
the	O
cis-	B
isomer	I
.	O

Both	O
the	O
preliminary	O
rat	O
and	O
human	O
pharmacokinetic	O
data	O
show	O
that	O
POH	B
was	O
detectable	O
in	O
circulation	O
for	O
the	O
first	O
time	O
following	O
POH	B
administration	O
.	O

Metabolites	B
of	O
POH	B
were	O
detected	O
in	O
high	O
levels	O
in	O
both	O
rat	O
and	O
human	O
plasma	O
.	O

PA	B
appeared	O
very	O
rapidly	O
in	O
circulation	O
and	O
rose	O
to	O
high	O
concentrations	O
,	O
suggesting	O
that	O
POH	B
underwent	O
rapid	O
metabolism	O
.	O

Both	O
cis-	B
and	O
trans-	B
DHPA	I
were	O
unequivocally	O
detected	O
in	O
the	O
human	O
and	O
in	O
the	O
rat	O
and	O
their	O
formation	O
as	O
a	O
mixture	O
was	O
previously	O
under	O
debate	O
[	O
11	O
]	O
.	O

Two	O
previously	O
undescribed	O
metabolites	B
were	O
detected	O
in	O
significant	O
levels	O
in	O
human	O
plasma	O
and	O
one	O
also	O
in	O
the	O
rat	O
.	O

These	O
two	O
metabolites	B
as	O
their	O
silylated	B
derivatives	I
gave	O
the	O
parent	O
ion	O
(	O
MH+	O
)	O
at	O
m	O
/	O
z	O
239	O
identical	O
to	O
that	O
of	O
silylated	B
PA	I
but	O
with	O
different	O
retention	O
times	O
.	O

Characterization	O
of	O
these	O
metabolites	B
is	O
currently	O
underway	O
.	O

Thus	O
,	O
the	O
current	O
method	O
is	O
useful	O
to	O
support	O
preclinical	O
and	O
clinical	O
investigations	O
of	O
disposition	O
of	O
perillyl	B
alcohol	I
.	O

5	O
Conclusion	O
A	O
GC	O
–	O
MS	O
stable	O
isotope	O
-	O
dilution	O
method	O
has	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
human	O
and	O
animal	O
plasma	O
and	O
the	O
method	O
has	O
been	O
validated	O
.	O

Unchanged	O
perillyl	B
alcohol	I
in	O
plasma	O
was	O
detected	O
in	O
human	O
and	O
animal	O
circulation	O
for	O
the	O
first	O
time	O
.	O

Isomers	O
of	O
a	O
reduced	O
metabolite	B
DHPA	B
have	O
been	O
total	O
resolved	O
and	O
detected	O
and	O
their	O
previous	O
cis-	O
and	O
trans-	O
assignments	O
verified	O
by	O
alternate	O
techniques	O
.	O

Two	O
new	O
metabolites	B
were	O
also	O
detected	O
.	O

This	O
GC	O
–	O
MS	O
can	O
be	O
applied	O
to	O
investigate	O
preclinical	O
and	O
clinical	O
pharmacokinetics	O
of	O
perillyl	B
alcohol	I
both	O
as	O
a	O
chemopreventative	B
and	O
chemotherapeutical	B
agent	I
.	O

Acknowledgments	O
This	O
study	O
was	O
in	O
part	O
supported	O
by	O
PHS	O
Contract	O
NCI	O
-	O
CN-55083070	O
,	O
Task	O
22	O
,	O
awarded	O
to	O
the	O
Cleveland	O
Clinic	O
Foundation	O
subcontracted	O
to	O
the	O
Ohio	O
State	O
University	O
and	O
by	O
P30	O
CA16058	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Eosinophils	O
may	O
play	O
important	O
roles	O
in	O
allergic	O
diseases	O
such	O
as	O
asthma	O
and	O
atopic	O
dermatitis	O
)	O
'	O
2	O
In	O
such	O
diseases	O
,	O
eosinophiis	O
migrate	O
to	O
inflammatory	O
sites	O
and	O
degranulate	O
eytotoxic	O
proteins	O
such	O
as	O
major	O
basic	O
protein	O
and	O
eosinophil	O
-	O
derived	O
neurotoxin	O
(	O
EDN	O
)	O
.	O

The	O
cytotoxic	O
proteins	O
damage	O
tissues	O
and	O
cause	O
physiologic	O
abnormalities	O
in	O
patients	O
with	O
allergic	O
diseases	O
.	O

Therefore	O
,	O
cosinophil	O
degranulation	O
inhibitors	O
may	O
be	O
anti	O
-	O
allergic	O
drugs	B
.	O

Recently	O
,	O
we	O
found	O
that	O
sulochrin	B
(	O
6	B
)	O
,	O
a	O
metabolite	B
of	O
fungi	O
,	O
was	O
a	O
specific	O
inhibitor	O
of	O
eosinophil	O
degranulation3	O
and	O
also	O
inhibited	O
eosinophll	O
activation	O
and	O
chemotaxis	O
.	O

*	O
We	O
report	O
here	O
the	O
effects	O
of	O
ortho-	O
substituent	O
groups	O
on	O
inhibitory	O
activity	O
to	O
eosinophil	O
degranulation	O
.	O

Chemistry	O
Sulochrin	B
(	O
6	B
)	O
was	O
synthesized	O
as	O
shown	O
in	O
scheme	O
1	O
.	O

Benzoic	B
acid	I
benzyl	I
ester	I
(	O
5	B
)	O
was	O
obtained	O
by	O
the	O
condensation	O
of	O
2-bromo	B
benzyl	I
alcohol	I
(	O
2	B
)	O
and	O
benzoic	B
acid	I
(	O
4	O
)	O
.	O

Anion	O
induced	O
rearrangement	O
of	O
(	O
5	B
)	O
gave	O
1-	B
benzoyl	I
benzyl	I
alcohol	I
,	O
which	O
was	O
oxidized	O
to	O
benzoyl	B
benzoic	I
acid	I
without	O
isolation.5	O
'	O
6	O
Esterification	O
of	O
the	O
benzoyl	B
benzoic	I
acid	I
followed	O
by	O
debenzylatinn	O
afforded	O
sulochrin	B
(	O
6	B
)	O
.7	O
All	O
other	O
sulochrin	B
derivatives	B
except	O
for	O
(	O
9	B
)	O
were	O
obtained	O
through	O
a	O
modified	O
methodology	O
.	O

Compound	B
9	I
was	O
prepared	O
as	O
shown	O
in	O
scheme	O
2	O
.	O

Results	O
and	O
Discussion	O
The	O
derivatives	B
of	I
sulochrin	I
(	O
6	B
)	O
were	O
examined	O
for	O
their	O
"inba""oitory"	O
activity	O
against	O
eosinophil	O
degranulation	O
as	O
descn'bed	O
previously.3	O
At	O
first	O
,	O
ester	B
derivatives	B
were	O
synthesized	O
to	O
examine	O
the	O
structure	O
-	O
activity	O
relationship	O
.	O

As	O
shown	O
in	O
Table	O
la	O
,	O
alkyl	B
esters	I
(	O
11	O
-	O
15	O
)	O
retained	O
activity	O
,	O
and	O
in	O
particular	O
,	O
n	B
-	I
butyl	I
and	O
see	B
-	I
butyl	I
esters	I
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

Pll	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00305	O
-	O
4	O
1946	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O

Scheme	O
I	O
OH	O
OBn	O
a	O
,	O
b	O
,	O
c	O
,	O
d	O
Br	O
Me	O
""""	O
<	O
~	O
OH	O
Me	O
""""	O
""""	O
~	O
OBn	O
COOMe	O
""""	O
~OH	O
e	O
,	O
f	O
1	O
2	O
3	O
4	O
O	O
OBn	O
7	O
~	O
-~	O
OMe	O
QH13	O
!	O

r	O
2	O
+	O
4	O
P	O
5~	O
15	O
T	O
""""	O
Br	O
BnO	O
""""	O
-	O
..	O

:	O
I	O
""""	O
Me	O
h	O
,	O
i	O
,	O
j	O
,	O
k	O
,	O
I	O
I	O
""""	O
~1	O
-	O
1	O
""""	O
g	O
OMe	O
MeOOC	O
O	O
OH	O
9	O
8	O
5	O
6	O
(	O
Sulochrln	B
)	O
(	O
a	O
)	O
BnBr	B
,	O
K	O
~	O
O~	O
/	O
CH3CN	B
/	O
reflux,33	O
%	O
;	O
(	O
b	O
)	O
Me	O
zSO4,K	O
~	O
CO3	O
/	O
CHaCN	O
/	O
reflux,96	O
%	O
;	O
(	O
c	O
)	O
UAIH4	O
/	O
I'HF,96	O
%	O
;	O
(	O
d	O
)	O
NBS	B
/	O
CCI4,43	B
%	O
;	O
(	O
e	O
)	O
BnBr	B
,	O
l	O
~	O
COa	O
/	O
DMF	B
/	O
reflux,74	O
%	O
;	O
(	O
f	O
)	O
t	O
-	O
BuOWiPr	O
=	O
O	O
/	O
reflux,93	O
%	O
;	O
(	O
g	O
)	O
DEAD	B
/	O
PPh	O
.	O

VrHF,82	O
%	O
;	O
(	O
h	O
)	O
n	B
-	I
BuLi	I
/	O
"1""HF,-78""C,45"	O
%	O
;	O
(	O
i	O
)	O
PDC	B
/	O
DMF,54	B
%	O
;	O
(	O
j	O
)	O
BudNH4	O
)	O
KMnO,~=yddlne,81	O
%	O
;	O
(	O
k	O
)	O
Mel	B
K2CO	O
~	O
JDMF	O
;	O
(	O
I	O
)	O
Pd	B
(	I
OH	I
)	I
rCarbon	O
/	B
EtOH	B
/	O
Cyclohexene	B
/	O
refiux	O
81	O
%	O
Scheme	O
2	O
Me	O
~	O
OMe	O
o~	O
OMe	O
OH	O
MeO	O
~	O
OMe	O
~	O
MeO'~OMe	O
.	O

HO	O
~	O
Me	O
""""	O
COOH	O
m	O
""""	O
~	O
""""	O
COCI	O
n	O
,	O
p	O
7	O
8	O
O	O
OH	O
(	O
m	O
)	O
SOCle	O
;	O
(	O
n	O
)	O
n	B
-	I
BuLi	I
/	O
THF	B
,	O
-4YC,15	O
%	O
;	O
(	O
P	O
)	O
BBrdCH	O
=	O
Cle,64	O
%	O
(	O
13	O
and	O
14	O
)	O
showed	O
more	O
potent	O
activity	O
than	O
sulochrin	B
(	O
6	B
)	O
.	O

On	O
thc	O
other	O
hand	O
,	O
decarboxyl	O
and	O
flee	O
carboxylic	B
acid	I
derivatives	O
(	O
9	O
and	O
10	O
)	O
did	O
not	O
show	O
any	O
activity	O
even	O
at	O
10	O
pM.	O
These	O
results	O
suggest	O
that	O
the	O
existence	O
of	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
1947	O
Table	O
la	O
Effects	O
of	O
alkylester	B
on	O
eoslnophll	O
degranulation	O
OMe	O
OH	O
R1	O
O	O
OH	O
Compound	O
R	O
,	O
ICso	O
(	O
mlcroM	O
)	O
Sulochrin	B
(	O
6	B
)	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
COOCHa	O
H	O
COOH	O
COOCH2CHa	O
COOCH	O
=	O
CH	O
=	O
CHa	O
COOCH	O
=	O
CH2CH	O
=	O
CHa	O
COO	O
(	O
CH	O
)	O
CHaCH	O
=	O
CHa	O
COO	O
(	O
CH=	O
)	O
sCH.~	O
0.1	O
>	O
10	O
>	O
10	O
0.1	O
0.1	O
0.04	O
0.03	O
0.3	O
Table	O
lb	O
Effects	O
of	O
phenolic	B
hydroxyl	B
groups	I
on	O
eoslnophil	O
degranulation	O
Sulochdn	B
(	O
6	B
)	O
HO-,~zFtz	O
12~	O
16	O
17	O
MeOOC	O
O	O
OR	O
,	O
19	O
2O	O
Compound	O
R2	O
FL~	O
P~	O
ICs0	O
(	O
microM	O
)	O
H	O
Me	O
H	O
Me	O
H	O
H	O
Me	O
H	O
Me	O
Me	O
Me	O
H	O
(	O
CH2	O
)	O
2OH	O
H	O
H	O
Me	O
H	O
(	O
CH=	O
)	O
=OH	O
0.1	O
0.4	O
0.3	O
>	O
10	O
>	O
10	O
>	O
10	O
alkyl	B
ester	I
at	O
C-6	O
position	O
is	O
essential	O
and	O
see	B
-	I
butyl	I
ester	I
is	O
most	O
suitable	O
for	O
activity	O
.	O

Next	O
,	O
we	O
examined	O
the	O
importance	O
of	O
methoxy	B
and	O
hydroxyl	B
groups	I
at	O
C-2	O
,	O
C-12	O
and	O
C-16	O
positions	O
(	O
Table	O
lb	O
)	O
.	O

Compared	O
to	O
sulochrin	B
(	O
6	B
)	O
,	O
19	B
showed	O
much	O
less	O
activity	O
.	O

Activity	O
of	O
16	B
approached	O
that	O
of	O
sulochrin	B
(	O
6	B
)	O
after	O
methylation	O
of	O
hydroxyl	B
group	I
at	O
C-12	O
position	O
in	O
19	B
.	O

Furthermore	O
,	O
compound	O
17	B
also	O
showed	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
methoxy	B
group	I
at	O
C-2	O
or	O
(	O
2	O
-	O
12	O
position	O
is	O
required	O
for	O
activity	O
.	O

Compound	B
18	I
,	O
in	O
which	O
two	O
methoxy	B
groups	I
at	O
C-12	O
and	O
(	O
2	O
-	O
16	O
positions	O
on	O
the	O
ring	O
B	O
were	O
introduced	O
,	O
showed	O
much	O
less	O
activity	O
than	O
16	B
or	O
17	B
.	O

Furthermore	O
,	O
compound	B
20	I
also	O
lost	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
free	O
hydroxyl	B
group	I
at	O
ortho	O
-	O
position	O
on	O
the	O
ring	O
B	O
is	O
required	O
for	O
activity	O
,	O
suggesting	O
that	O
hydrogen	B
bond	O
between	O
16-OH	O
and	O
carbunyl	O
at	O
(	O
2	O
-	O
10	O
might	O
contn'bute	O
to	O
activity	O
.	O

We	O
have	O
recently	O
shown	O
that	O
substituents	O
at	O
ortho	O
-	O
positions	O
showed	O
effect	O
on	O
the	O
conformation	O
from	O
the	O
analysis	O
of	O
crystal	O
structures	O
of	O
suiochrin	B
derivatives	B
,	O
a	O
The	O
hydrogen	B
bond	O
between	O
16-OH	O
and	O
earbonyl	O
at	O
C-10	O
may	O
contribute	O
to	O
the	O
conformation	O
where	O
the	O
ring	O
B	O
and	O
the	O
central	O
carbunyl	O
planes	O
are	O
co	O
-	O
planner	O
and	O
cross	O
at	O
a	O
right	O
angle	O
to	O
the	O
1948	O
1	O
t	O
.	O

Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
ring	O
A.	O
This	O
conformation	O
would	O
be	O
inaccess	O
~	O
le	O
to	O
the	O
less	O
active	O
compounds	O
that	O
lack	O
the	O
hydrogen	B
bond	O
,	O
supporting	O
the	O
speculation	O
.	O

Compounds	B
10	B
and	O
19	B
,	O
which	O
have	O
more	O
hydrophilic	O
substitution	O
at	O
ortho	O
-	O
positions	O
,	O
lost	O
activity	O
.	O

Therefore	O
,	O
hydrophobicity	O
is	O
also	O
important	O
for	O
activity	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
that	O
i	O
)	O
alkylester	B
at	O
C-6	O
position	O
is	O
required	O
;	O
ii	O
)	O
see	B
-	I
butyl	I
ester	I
at	O
C-6	O
position	O
is	O
optimal	O
for	O
activity	O
;	O
ill	O
)	O
optimal	O
hydrophobicity	O
of	O
the	O
ortho	O
-	O
substituents	O
may	O
exist	O
;	O
and	O
iv	O
)	O
the	O
conformation	O
of	O
sulochrin	B
may	O
influence	O
to	O
the	O
inlu'bitory	O
activity	O
against	O
eosinophil	O
degranulation	O
.	O

Acknowledgements	O

We	O
thank	O
to	O
Dr.	O
Masakazu	O
Sakalo'bara	O
for	O
critical	O
reading	O
of	O
this	O
manuscript	O
.	O

An	O
accurate	O
estimation	O
of	O
the	O
onset	O
of	O
oestrus	O
in	O
cows	O
is	O
vital	O
to	O
the	O
cost	O
-	O
efficient	O
application	O
of	O
artificial	O
insemination	O
(	O
AI	O
)	O
procedures	O
(	O
Ball	O
,	O
1982	O
)	O
.	O

The	O
steroid	B
hormone	O
progesterone	B
,	O
which	O
is	O
secreted	O
by	O
the	O
corpus	O
luteum	O
,	O
functions	O
to	O
prepare	O
the	O
uterus	O
for	O
pregnancy	O
and	O
to	O
maintain	O
pregnancy	O
following	O
conception	O
.	O

Fluctuations	O
in	O
the	O
level	O
of	O
secreted	O
progesterone	B
are	O
reflected	O
throughout	O
the	O
oestrus	O
cycle	O
by	O
the	O
concentration	O
of	O
the	O
hormone	O
present	O
in	O
cows	O
'	O
milk	O
.	O

It	O
follows	O
that	O
by	O
monitoring	O
milk	O
progesterone	B
concentration	O
it	O
has	O
been	O
possible	O
accurately	O
to	O
predict	O
the	O
onset	O
of	O
oestrus	O
;	O
using	O
enzyme	O
immunoassay	O
methodology	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982a	O
)	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
optimum	O
fertility	O
rates	O
can	O
be	O
achieved	O
when	O
AI	O
is	O
performed	O
on	O
the	O
third	O
day	O
of	O
sustained	O
low	O
milk	O
progesterone	B
concentration	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982b	O
;	O
Foulkes	O
and	O
Goodey	O
,	O
1988	O
)	O
.	O

The	O
search	O
for	O
a	O
rapid	O
,	O
convenient	O
and	O
inexpensive	O
means	O
of	O
frequently	O
monitoring	O
milk	O
progesterone	B
levels	O
in	O
a	O
herd	O
of	O
animals	O
has	O
led	O
into	O
research	O
toward	O
a	O
user	O
-	O
friendly	O
on	O
-	O
the	O
-	O
farm	O
device	O
.	O

One	O
such	O
approach	O
is	O
a	O
disposable	O
screen	O
-	O
printed	O
amperometric	O
biosensor	O
.	O

Previously	O
,	O
we	O
described	O
the	O
development	O
of	O
a	O
prototype	O
progesterone	B
biosensor	O
comprising	O
mAb	O
immobilised	O
on	O
the	O
working	O
surface	O
of	O
a	O
screen	O
-	O
printed	O
carbon	B
electrode	O
(	O
SPCE	O
)	O
.	O

It	O
operated	O
in	O
a	O
competitive	O
immunoassay	O
format	O
,	O
relying	O
upon	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
enzyme	O
-	O
labelled	O
progesterone	B
in	O
the	O
presence	O
of	O
endogenous	O
milk	O
progesterone	B
.	O

Initial	O
proof	O
-	O
of	O
-	O
principle	O
was	O
provided	O
from	O
experiments	O
conducted	O
in	O
aqueous	O
buffer	O
solution	O
using	O
phenyl	B
phosphate	I
as	O
substrate	O
for	O
the	O
enzyme	O
alkaline	O
phosphatase	O
,	O
with	O
a	O
chronoamperometric	O
readout	O
dependent	O
on	O
the	O
oxidation	O
of	O
phenol	B
at	O
a	O
potential	O
of	O
+	O
700	O
mV	O
versus	O
SCE	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Operating	O
at	O
this	O
relatively	O
high	O
electrode	O
potential	O
,	O
however	O
,	O
it	O
was	O
not	O
possible	O
to	O
obtain	O
a	O
calibration	O
in	O
milk	O
,	O
due	O
to	O
variable	O
adsorption	O
,	O
at	O
the	O
electrode	O
surface	O
,	O
of	O
electroactive	O
species	O
present	O
within	O
this	O
complex	O
matrix	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
;	O
even	O
washing	O
with	O
solvents	O
of	O
varying	O
polarity	O
did	O
not	O
remove	O
the	O
interferent	O
.	O

For	O
this	O
reason	O
,	O
it	O
is	O
desirable	O
to	O
reduce	O
the	O
operating	O
potential	O
to	O
below	O
that	O
required	O
to	O
oxidise	O
the	O
interferent	O
.	O

In	O
order	O
to	O
achieve	O
this	O
objective	O
,	O
two	O
potentially	O
useful	O
enzyme	O
substrates	O
,	O
1-naphthyl	B
phosphate	I
(	O
1-NP	B
)	O
and	O
4-aminophenyl	B
phosphate	I
(	O
4-APP	B
)	O
,	O
may	O
be	O
considered	O
.	O

These	O
are	O
hydrolysed	O
to	O
their	O
corresponding	O
phenols	B
,	O
1-naphthol	B
and	O
4-aminophenol	B
,	O
on	O
reaction	O
with	O
alkaline	B
phosphatase	I
.	O

Both	O
4-APP	B
(	O
Tang	O
et	O
al.	O
,	O
1988	O
;	O
Pemberton	O
et	O
al.	O
,	O
1998	O
;	O
Schreiber	O
et	O
al.	O
,	O
1997	O
)	O
and	O
1-NP	B
(	O
Athey	O
et	O
al.	O
,	O
1993	O
;	O
Fernandez	O
-	O
Sanchez	O
and	O
Costa	O
-	O
Garcia	O
,	O
1997	O
)	O
have	O
been	O
investigated	O
previously	O
in	O
immunoassay	O
systems	O
,	O
but	O
no	O
detailed	O
comparative	O
studies	O
of	O
their	O
performance	O
have	O
been	O
reported	O
at	O
SPCEs	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
electrochemical	O
behaviour	O
of	O
1-naphthol	B
and	O
4-aminophenol	B
at	O
bare	O
and	O
antibody	O
-	O
coated	O
SPCEs	O
and	O
to	O
determine	O
which	O
phenol	B
would	O
be	O
the	O
more	O
compatible	O
with	O
biosensor	O
operation	O
.	O

Their	O
phosphorylated	B
derivatives	I
were	O
then	O
evaluated	O
as	O
substrates	O
for	O
use	O
with	O
a	O
milk	O
progesterone	B
immunosensor	O
.	O

This	O
paper	O
describes	O
the	O
results	O
of	O
these	O
studies	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
and	O
reagents	O
Chemicals	O
used	O
were	O
of	O
AR	O
-	O
grade	O
and	O
were	O
purchased	O
from	O
Merck	O
(	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
.	O

Water	B
for	O
the	O
preparation	O
of	O
buffer	O
solutions	O
was	O
drawn	O
from	O
a	O
Milli	O
-	O
Q	O
Water	O
Purification	O
System	O
(	O
Millipore	O
UK	O
,	O
Watford	O
,	O
UK	O
)	O
.	O

Carbonate	B
coating	O
buffer	O
(	O
CB	O
)	O
comprised	O
0.015	O
mol	O
/	O
dm	O
Na2	B
CO3	I
and	O
0.035	O
mol	O
/	O
dm3	O
NaHCO3	B
at	O
a	O
pH	O
of	O
9.6	O
.	O

Diethanolamine	B
-	I
HCl	I
buffer	O
(	O
DB	O
;	O
0.1	O
mol	O
/	O
dm3	O
)	O
was	O
adjusted	O
to	O
a	O
final	O
pH	O
of	O
7.2	O
or	O
9.8	O
.	O

MgCl2	B
at	O
a	O
concentration	O
of	O
0.01	O
mol	O
/	O
dm3	O
was	O
included	O
in	O
pH9.8	O
DB	O
as	O
a	O
cofactor	O
for	O
alkaline	O
phosphatase	O
.	O

Before	O
final	O
dilution	O
in	O
DB	O
,	O
4-aminophenol	B
(	O
Sigma	O
-	O
Aldrich	O
Company	O
,	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
was	O
dissolved	O
in	O
0.1	O
mol	O
/	O
dm3	O
NaOH	B
;	O
1-naphthol	B
(	O
Acros	O
Organics	O
,	O
Loughborough	O
,	O
Leics	O
,	O
UK	O
)	O
was	O
dissolved	O
directly	O
in	O
DB	O
.	O

A	O
polyclonal	O
rabbit	O
antibody	O
(	O
IgG	O
fraction	O
)	O
against	O
sheep	O
IgG	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
rIg	O
)	O
.	O

Sheep	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
against	O
progesterone	B
(	O
Groves	O
et	O
al.	O
,	O
1990	O
)	O
was	O
kindly	O
provided	O
by	O
Ridgeway	O
Science	O
Ltd.	O
in	O
the	O
form	O
of	O
culture	O
supernatant	O
.	O

A	O
solution	O
containing	O
alkaline	O
-	O
phosphatase	O
-	O
labelled	O
progesterone	B
(	O
AP	O
-	O
prog	O
)	O
was	O
obtained	O
from	O
the	O
same	O
source	O
.	O

Unlabelled	O
progesterone	B
(	O
f.wt.=314.5	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

4-APP	B
(	O
monosodium	B
salt	I
)	O
and	O
1-NP	B
were	O
purchased	O
from	O
ICN	O
Biomedicals	O
Ltd.	O
,	O
Thame	O
,	O
Oxon	O
,	O
UK	O
and	O
Acros	O
Organics	O
,	O
respectively	O
.	O

Whole	O
milk	O
test	O
samples	O
from	O
six	O
different	O
Fresian	O
Holstein	O
dairy	O
cows	O
at	O
various	O
stages	O
of	O
their	O
oestrus	O
cycles	O
were	O
obtained	O
from	O
Ridgeway	O
Science	O
Ltd.	O
These	O
samples	O
were	O
collected	O
following	O
agitation	O
of	O
the	O
complete	O
milking	O
jar	O
after	O
morning	O
milking	O
of	O
cows	O
.	O

One	O
Lactab	O
MkIII	O
tablet	O
(	O
Thompson	O
and	O
Capper	O
Ltd.	O
,	O
Runcorn	O
,	O
Cheshire	O
,	O
UK	O
)	O
containing	O
30	O
mg	O
potassium	B
dichromate	I
was	O
added	O
to	O
every	O
25	O
ml	O
milk	O
as	O
a	O
preservative	O
.	O

Samples	O
were	O
then	O
stored	O
at	O
4	O
°	O
C	O
where	O
they	O
were	O
stable	O
for	O
up	O
to	O
3	O
months	O
.	O

In	O
the	O
present	O
study	O
,	O
assays	O
were	O
performed	O
after	O
21	O
days	O
of	O
storage	O
.	O

Standards	O
containing	O
known	O
concentrations	O
of	O
progesterone	B
were	O
prepared	O
by	O
dissolving	O
progesterone	B
in	O
methanol	B
at	O
1	O
mg	O
/	O
ml	O
,	O
aliquoting	O
a	O
known	O
volume	O
into	O
a	O
glass	O
tube	O
and	O
evaporating	O
the	O
methanol	B
under	O
N2	B
before	O
adding	O
to	O
whole	O
milk	O
(	O
sampled	O
and	O
preserved	O
as	O
above	O
)	O
from	O
an	O
oestrus	O
cow	O
(	O
containing	O
<	O
1	O
ng	O
/	O
ml	O
progesterone	B
)	O
.	O

Serial	O
dilutions	O
were	O
then	O
performed	O
in	O
the	O
same	O
milk	O
over	O
the	O
desired	O
concentration	O
range	O
.	O

2.2	O
Biosensor	O
preparation	O
Carbon	B
electrodes	O
(	O
3	O
×	O
3	O
mm	O
working	O
area	O
)	O
were	O
screen	O
-	O
printed	O
using	O
code	O
D14	O
ink	O
formulation	O
onto	O
PVC	B
backing	O
card	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
Mamhilad	O
,	O
Gwent	O
,	O
UK	O
)	O
as	O
described	O
elsewhere	O
(	O
Sprules	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Individual	O
screen	O
-	O
printed	O
electrodes	O
(	O
SPCEs	O
)	O
were	O
coated	O
with	O
rIg	O
(	O
to	O
capture	O
and	O
orientate	O
the	O
mAb	O
)	O
and	O
mAb	O
as	O
described	O
previously	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

For	O
these	O
studies	O
,	O
a	O
1	O
/	O
20	O
dilution	O
of	O
mAb	O
was	O
applied	O
to	O
the	O
electrodes	O
,	O
being	O
chosen	O
empirically	O
as	O
the	O
highest	O
dilution	O
giving	O
an	O
optimum	O
sigmoidal	O
calibration	O
plot	O
for	O
progesterone	B
measured	O
colorimetrically	O
(	O
see	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

These	O
are	O
referred	O
to	O
as	O
mAb	O
-	O
SPCEs	O
.	O

2.3	O
Instrumentation	O
Electrochemical	O
procedures	O
were	O
carried	O
out	O
using	O
an	O
E612	O
VA	O
Scanner	O
and	O
an	O
E611	O
VA	O
Detector	O
(	O
Metrohm	O
,	O
Herisau	O
,	O
Switzerland	O
)	O
attached	O
to	O
a	O
Linseis	O
LY18100	O
x	O
–y	O
plotter	O
(	O
Recorder	O
Laboratory	O
Services	O
,	O
Sutton	O
,	O
Surrey	O
,	O
UK	O
)	O
.	O

A	O
Viglen	O
486	O
Sx	O
computer	O
was	O
used	O
for	O
simulation	O
of	O
cyclic	O
voltammograms	O
using	O
the	O
simulation	O
program	O
CVSIM	O
(	O
Gosser	O
,	O
1993	O
)	O
.	O

The	O
simple	O
'	O
E	O
r	O
'	O
,	O
mechanism	O
for	O
a	O
one	O
-	O
electron	O
oxidation	O
of	O
a	O
solution	O
species	O
at	O
the	O
working	O
electrode	O
was	O
used	O
to	O
estimate	O
values	O
for	O
k	O
het	O
from	O
simulations	O
of	O
the	O
oxidation	O
of	O
4-aminophenol	B
at	O
bare	O
and	O
mAb	O
-	O
coated	O
SPCEs	O
.	O

Common	O
electroactive	O
species	O
parameters	O
were	O
:	O
C	O
red	O
=	O
1	O
mM	O
,	O
C	O
ox	O
=	O
0.0	O
mM	O
,	O
D	O
=	O
5	O
×	O
10−6	O
cm2	O
/s	O
;	O
and	O
common	O
experimental	O
settings	O
were	O
:	O
number	O
of	O
half	O
cycles=2	O
,	O
A	O
=	O
0.09	O
cm2	O
,	O
E	O
i	O
=	O
−0.3	O
V	O
,	O
E	O
s	O
=	O
+	O
1.0	O
V	O
,	O
E	O
f	O
=	O
−0.3	O
V	O
,	O
v	O
=	O
0.05	O
vs−1	O
.	O

Parameters	O
specific	O
for	O
reaction	O
at	O
a	O
bare	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
−0.050	O
V	O
,	O
α	O
=	O
0.533	O
and	O
for	O
reaction	O
at	O
a	O
mAb	O
-	O
coated	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
−0.037	O
V	O
,	O
α	O
=	O
0.400	O
.	O

2.4	O
Cyclic	O
voltammetry	O
and	O
chronoamperometry	O
Cyclic	O
voltammetric	O
studies	O
were	O
conducted	O
using	O
10	O
ml	O
analyte	O
volumes	O
in	O
a	O
glass	O
voltammetric	O
cell	O
.	O

Individual	O
working	O
SPCEs	O
or	O
mAb	O
-	O
SPCEs	O
were	O
used	O
in	O
a	O
3-electrode	O
configuration	O
in	O
conjunction	O
with	O
a	O
saturated	O
calomel	B
reference	O
and	O
platinum	B
counter	O
electrode	O
.	O

Chronoamperometric	O
measurements	O
were	O
made	O
by	O
using	O
individual	O
working	O
mAb	O
-	O
SPCEs	O
,	O
together	O
with	O
a	O
saturated	O
calomel	B
electrode	O
functioning	O
as	O
a	O
combined	O
counter	O
/	O
reference	O
electrode	O
in	O
a	O
two	O
electrode	O
configuration	O
.	O

In	O
this	O
way	O
it	O
was	O
possible	O
to	O
perform	O
measurements	O
using	O
a	O
small	O
(	O
0.5	O
ml	O
)	O
volume	O
of	O
enzyme	O
substrate	O
solution	O
in	O
a	O
conical	O
polypropylene	B
cell	O
.	O

2.5	O
Electrochemical	O
immunoassay	O
procedure	O
Milk	O
samples	O
were	O
mixed	O
with	O
AP	O
-	O
prog	O
solution	O
in	O
the	O
ratio	O
3:5	O
(	O
this	O
combination	O
gave	O
a	O
maximum	O
signal	O
:	O
noise	O
ratio	O
)	O
.	O

Eight	O
microlitre	O
volumes	O
of	O
these	O
mixtures	O
were	O
added	O
to	O
the	O
surface	O
of	O
individual	O
mAb	O
-	O
SPCEs	O
.	O

After	O
30	O
min	O
at	O
room	O
temperature	O
(	O
18–25	O
°	O
C	O
;	O
RT	O
)	O
,	O
the	O
electrodes	O
were	O
washed	O
three	O
times	O
in	O
DB	O
,	O
pH	O
9.8	O
,	O
then	O
placed	O
in	O
0.5	O
ml	O
DB	O
,	O
pH	O
9.8	O
or	O
the	O
same	O
buffer	O
containing	O
5	O
mmol	O
/	O
dm3	O
4-APP	B
or	O
1-NP	B
.	O

After	O
5	O
min	O
(	O
a	O
compromise	O
between	O
maximum	O
enzyme	O
activity	O
and	O
speed	O
of	O
assay	O
for	O
multiple	O
samples	O
)	O
,	O
the	O
working	O
electrode	O
potential	O
was	O
stepped	O
from	O
open	O
circuit	O
to	O
+	O
200	O
or	O
+	O
300	O
mV	O
versus	O
SCE	O
,	O
respectively	O
and	O
the	O
peak	O
current	O
(	O
i	O
p	O
)	O
response	O
was	O
recorded	O
.	O

Calibration	O
graphs	O
were	O
obtained	O
by	O
plotting	O
i	O
p	O
values	O
in	O
the	O
presence	O
of	O
an	O
enzyme	O
substrate	O
minus	O
background	O
i	O
p	O
values	O
in	O
buffer	O
only	O
for	O
each	O
known	O
standard	O
progesterone	B
concentration	O
(	O
y	O
-axis	O
)	O
against	O
progesterone	B
concentration	O
(	O
x	O
-axis	O
)	O
.	O

For	O
each	O
unknown	O
cow	O
sample	O
,	O
a	O
similar	O
subtraction	O
of	O
the	O
buffer	O
blank	O
i	O
p	O
value	O
was	O
performed	O
before	O
using	O
the	O
calibration	O
plot	O
by	O
interpolation	O
to	O
obtain	O
an	O
estimate	O
of	O
progesterone	B
concentration	O
.	O

The	O
relationship	O
between	O
readings	O
obtained	O
by	O
EIA	O
and	O
electrochemical	O
assays	O
was	O
investigated	O
using	O
linear	O
regression	O
analysis	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Electrochemistry	O
of	O
4-aminophenol	B
,	O
1-naphthol	B
and	O
corresponding	O
monophosphates	B
The	O
electrochemical	O
behaviour	O
of	O
the	O
enzyme	O
substrates	O
4-APP	B
and	O
1-NP	B
,	O
and	O
their	O
hydrolysis	O
products	O
,	O
4-aminophenol	B
and	O
1-naphthol	B
,	O
was	O
examined	O
by	O
cyclic	O
voltammetry	O
at	O
unmodified	O
SPCEs	O
(	O
Fig.	O
1	O
)	O
.	O

4-Aminophenol	B
showed	O
well	O
-	O
defined	O
oxidation	O
and	O
reduction	O
peaks	O
and	O
the	O
ΔE	O
p	O
value	O
indicated	O
that	O
the	O
electrode	O
reaction	O
was	O
quasi	O
-	O
reversible	O
(	O
Fig.	O
1	O
(	O
a	O
)	O
)	O
.	O

The	O
anodic	O
potential	O
(	O
E	O
pa	O
)	O
was	O
well	O
below	O
that	O
required	O
for	O
the	O
oxidation	O
of	O
the	O
corresponding	O
monophosphate	B
,	O
4-APP	B
(	O
Fig.	O
1	O
(	O
b	O
)	O
)	O
.	O

In	O
contrast	O
,	O
1-naphthol	B
gave	O
only	O
an	O
oxidation	O
peak	O
at	O
+	O
230	O
mV	O
(	O
Fig.	O
1	O
(	O
c	O
)	O
)	O
,	O
which	O
could	O
be	O
due	O
to	O
the	O
electrode	O
reaction	O
itself	O
giving	O
an	O
electro	O
-	O
inactive	O
product	O
,	O
or	O
to	O
the	O
oxidised	O
naphthol	B
product	O
undergoing	O
an	O
irreversible	O
chemical	O
reaction	O
.	O

1-NP	B
(	O
Fig.	O
1	O
(	O
d	O
)	O
)	O
was	O
not	O
electrochemically	O
active	O
over	O
the	O
potential	O
range	O
studied	O
.	O

At	O
this	O
stage	O
,	O
it	O
appeared	O
that	O
the	O
anodic	O
signals	O
for	O
either	O
4-aminophenol	B
or	O
1-naphthol	B
could	O
be	O
used	O
as	O
the	O
basis	O
for	O
an	O
immunoassay	O
for	O
progesterone	B
.	O

Further	O
studies	O
were	O
therefore	O
performed	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
voltammetric	O
behaviour	O
of	O
these	O
two	O
phenols	B
.	O

The	O
cyclic	O
voltammetric	O
behaviour	O
of	O
4-aminophenol	B
and	O
1-naphthol	B
was	O
next	O
compared	O
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
(	O
Fig.	O
2	O
)	O
.	O

For	O
both	O
analytes	O
,	O
the	O
presence	O
of	O
the	O
antibodies	O
increased	O
the	O
background	O
oxidation	O
signal	O
at	O
potentials	O
above	O
+	O
0.5	O
V	O
(	O
Fig.	O
2	O
(	O
b	O
,	O
d	O
)	O
)	O
,	O
but	O
the	O
magnitude	O
of	O
the	O
overall	O
peak	O
currents	O
were	O
the	O
same	O
as	O
obtained	O
at	O
naked	O
SPCEs	O
(	O
Fig.	O
2	O
(	O
a	O
,	O
c	O
)	O
)	O
.	O

However	O
,	O
in	O
the	O
case	O
of	O
4aminophenol	B
,	O
the	O
oxidation	O
peak	O
became	O
broader	O
in	O
the	O
presence	O
of	O
the	O
antibodies	O
and	O
showed	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
∼30	O
mV	O
,	O
Fig.	O
2	O
(	O
a	O
,	O
b	O
)	O
)	O
.	O

In	O
the	O
case	O
of	O
1-naphthol	B
,	O
there	O
was	O
also	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
∼10	O
mV	O
)	O
in	O
the	O
presence	O
of	O
the	O
antibodies	O
(	O
Fig.	O
2	O
(	O
c	O
,	O
d	O
)	O
)	O
.	O

Further	O
comparison	O
of	O
the	O
electrochemistry	O
of	O
4-aminophenol	B
and	O
1-naphthol	B
,	O
at	O
naked	O
and	O
mAb	O
-	O
coated	O
SPCEs	O
,	O
was	O
obtained	O
by	O
performing	O
cyclic	O
voltammetry	O
at	O
various	O
scan	O
rates	O
.	O

The	O
relationship	O
produced	O
during	O
cyclic	O
voltammetry	O
between	O
peak	O
current	O
(	O
i	O
p	O
)	O
and	O
v	O
1	O
/	O
2	O
is	O
described	O
by	O
the	O
Randles	O
-	O
Sevcik	O
equation	O
,	O
modified	O
for	O
irreversible	O
systems	O
:	O

Cv	O
1	O
/	O
2	O
ip	O
=	O
(	O
2.99	O
×	O
10	O
5	O
)	O
·	O
n	O
(	O
αna	O
)	O
1	O
/	O
2	O
AD1	O
/	O
2	O
(	O
Heineman	O
and	O
Kissinger	O
,	O
1984	O
)	O
where	O
i	O
p	O
=	O
peak	O
current	O
(	O
μA	O
)	O
,	O
n	O
=	O
number	O
of	O
electrons	O
,	O
αn	O
a	O
=	O
electron	O
transfer	O
coefficient	O
,	O
A	O
=	O
working	O
electrode	O
area	O
(	O
cm2	O
)	O
,	O
D	O
=	O
diffusion	O
coefficient	O
(	O
cm2	O
/s	O
)	O
,	O
C=	O
bulk	O
concentration	O
of	O
analyte	O
(	O
mmoles	O
/	O
ml	O
)	O
and	O
v	O
=	O
scan	O
rate	O
(	O
mV	O
/	O
s	O
)	O
.	O

Plots	O
of	O
i	O
p	O
versus	O
v	O
1	O
/	O
2	O
for	O
both	O
analytes	O
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

In	O
the	O
case	O
of	O
4-aminophenol	B
,	O
there	O
is	O
evidence	O
that	O
the	O
presence	O
of	O
the	O
mAb	O
results	O
in	O
lower	O
i	O
p	O
values	O
at	O
all	O
scan	O
rates	O
compared	O
with	O
naked	O
SPCEs	O
(	O
Fig.	O
3	O
(	O
a	O
)	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
mAb	O
may	O
slow	O
the	O
diffusion	O
of	O
4-AP	B
towards	O
the	O
electrode	O
surface	O
,	O
and	O
may	O
combine	O
with	O
polyphenols	B
to	O
reduce	O
the	O
working	O
area	O
available	O
for	O
the	O
oxidation	O
of	O
4-AP	B
.	O

In	O
contrast	O
,	O
ip	O
values	O
obtained	O
for	O
1-naphthol	B
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
are	O
almost	O
superimposed	O
for	O
scan	O
rates	O
up	O
to	O
200	O
mVs−1	O
(	O
Fig.	O
3	O
(	O
b	O
)	O
)	O
.	O

This	O
suggests	O
that	O
the	O
antibody	O
coating	O
has	O
little	O
effect	O
on	O
the	O
diffusional	O
characteristics	O
of	O
1-naphthol	B
.	O

Electron	O
transfer	O
coefficients	O
(	O
αn	O
a	O
)	O
were	O
calculated	O
for	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
as	O
described	O
previously	O
(	O
Galus	O
,	O
1976	O
)	O
.	O

For	O
4-aminophenol	B
,	O
these	O
values	O
were	O
0.533	O
and	O
0.400	O
,	O
respectively	O
;	O
this	O
decrease	O
indicates	O
that	O
the	O
antibody	O
layer	O
partially	O
inhibits	O
the	O
electron	O
transfer	O
step	O
,	O
possibly	O
due	O
to	O
steric	O
hindrance	O
.	O

A	O
computer	O
simulation	O
program	O
(	O
CVSIM	O
,	O
Gosser	O
,	O
1993	O
)	O
was	O
used	O
to	O
simulate	O
cyclic	O
voltammograms	O
for	O
4-aminophenol	B
in	O
order	O
to	O
obtain	O
values	O
for	O
the	O
electrochemical	O
rate	O
constant	O
.	O

Using	O
the	O
above	O
αn	O
a	O
values	O
,	O
it	O
was	O
found	O
that	O
the	O
heterogeneous	O
rate	O
constant	O
(	O
k	O
het	O
)	O
for	O
the	O
mAb	O
-	O
SPCEs	O
was	O
3.0	O
×	O
10−4	O
/cm	O
s−1	O
,	O
whereas	O
k	O
het	O
for	O
a	O
naked	O
SPCE	O
was	O
calculated	O
to	O
be	O
6.5	O
×	O
10−4	O
cm	O
s−1	O
.	O

The	O
slower	O
rate	O
constant	O
obtained	O
with	O
the	O
mAb	O
-	O
SPCEs	O
supports	O
the	O
suggestion	O
of	O
partial	O
inhibition	O
discussed	O
above	O
.	O

Finally	O
,	O
the	O
αn	O
a	O
values	O
were	O
calculated	O
for	O
1-naphthol	B
at	O
naked-	O
and	O
mAb	O
-	O
SPCEs	O
,	O
to	O
be	O
0.53	O
and	O
0.60	O
,	O
respectively	O
.	O

These	O
values	O
suggest	O
that	O
the	O
antibody	O
coating	O
does	O
not	O
inhibit	O
the	O
rate	O
of	O
electron	O
transfer	O
during	O
the	O
oxidation	O
of	O
this	O
phenol	B
.	O

Fig.	O
4	O
(	O
a	O
)	O
shows	O
the	O
effect	O
of	O
scan	O
rate	O
on	O
the	O
anodic	O
peak	O
potential	O
for	O
4-aminophenol	B
,	O
at	O
naked	O
and	O
antibody	O
-	O
coated	O
SPCEs	O
.	O

True	O
reversible	O
reactions	O
do	O
not	O
show	O
shifts	O
of	O
E	O
p	O
with	O
scan	O
rate	O
,	O
inferring	O
that	O
the	O
oxidation	O
reactions	O
at	O
both	O
types	O
of	O
SPCE	O
appear	O
to	O
be	O
quasi	O
-	O
reversible	O
over	O
the	O
range	O
studied	O
.	O

In	O
contrast	O
,	O
at	O
scan	O
rates	O
above	O
100	O
mVs−1	O
,	O
1-naphthol	B
appears	O
to	O
show	O
more	O
reversible	O
behaviour	O
at	O
both	O
SPCEs	O
than	O
4-aminophenol	B
.	O

This	O
may	O
be	O
explained	O
by	O
a	O
slow	O
chemical	O
follow	O
-	O
up	O
reaction	O
(	O
possibly	O
polymerisation	O
)	O
for	O
1-naphthol	B
after	O
the	O
initial	O
electron	O
transfer	O
step	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
the	O
peak	O
potential	O
for	O
the	O
oxidation	O
of	O
1-naphthol	B
obtained	O
at	O
the	O
mAb	O
-	O
SPCE	O
at	O
200	O
mVs−1	O
is	O
+	O
0.38	O
V	O
;	O
for	O
4-aminophenol	B
at	O
this	O
electrode	O
the	O
E	O
p	O
value	O
was	O
+	O
0.28	O
V.	O
All	O
of	O
the	O
above	O
observations	O
using	O
cyclic	O
voltammetry	O
suggested	O
that	O
1-NP	B
would	O
be	O
a	O
suitable	O
candidate	O
for	O
the	O
chronoamperometric	O
immunoassay	O
.	O

Although	O
the	O
magnitude	O
of	O
the	O
anodic	O
response	O
was	O
lower	O
than	O
that	O
seen	O
for	O
4-aminophenol	B
at	O
equivalent	O
concentration	O
,	O
the	O
hydrolysis	O
product	O
,	O
1-naphthol	B
,	O
appeared	O
capable	O
of	O
producing	O
a	O
significant	O
and	O
unimpeded	O
oxidation	O
signal	O
at	O
mAb	O
-	O
SPCEs	O
.	O

3.2	O
Establishing	O
the	O
operating	O
potential	O
for	O
chronoamperometric	O
detection	O
of	O
l	B
-	I
naphthol	I
Previous	O
cyclic	O
voltammograms	O
with	O
SPCEs	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
have	O
demonstrated	O
the	O
presence	O
,	O
in	O
milk	O
,	O
of	O
electroactive	O
species	O
capable	O
of	O
adsorbing	O
onto	O
the	O
electrode	O
surface	O
and	O
being	O
oxidised	O
to	O
produce	O
anodic	O
signals	O
capable	O
of	O
interfering	O
with	O
the	O
operation	O
of	O
the	O
immunosensor	O
by	O
chronoamperometry	O
.	O

Using	O
4-APP	B
as	O
enzyme	O
substrate	O
it	O
was	O
possible	O
to	O
select	O
an	O
operating	O
potential	O
of	O
+	O
200	O
mV	O
,	O
well	O
below	O
the	O
potential	O
required	O
to	O
oxidise	O
adsorbed	O
milk	O
species	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
order	O
to	O
confirm	O
that	O
1-naphthol	B
could	O
be	O
detected	O
amperometrically	O
and	O
to	O
establish	O
an	O
operating	O
potential	O
for	O
use	O
in	O
the	O
assay	O
,	O
chronoamperometric	O
measurement	O
of	O
a	O
1	O
mM	O
1-naphthol	B
solution	O
was	O
performed	O
over	O
a	O
range	O
of	O
operating	O
potentials	O
at	O
mAb	O
-	O
SPCEs	O
which	O
had	O
been	O
incubated	O
with	O
enzyme	O
-	O
labelled	O
progesterone	B
either	O
in	O
buffer	O
solution	O
or	O
in	O
milk	O
.	O

Fig.	O
5	O
shows	O
that	O
in	O
order	O
to	O
avoid	O
signals	O
due	O
to	O
the	O
oxidation	O
of	O
electroactive	O
species	O
within	O
milk	O
,	O
it	O
would	O
be	O
necessary	O
to	O
operate	O
below	O
+	O
400	O
mV.	O
It	O
was	O
necessary	O
to	O
operate	O
at	O
+	O
600	O
mV	O
to	O
achieve	O
the	O
maximum	O
current	O
signal	O
from	O
chronoamperometry	O
of	O
1-naphthol	B
.	O

However	O
,	O
it	O
was	O
still	O
possible	O
to	O
obtain	O
over	O
50	O
%	O
of	O
this	O
response	O
at	O
+	O
300	O
mV	O
which	O
was	O
therefore	O
chosen	O
as	O
the	O
operating	O
potential	O
for	O
the	O
biosensor	O
.	O

3.3	O
Analysis	O
of	O
cows	O
'	O
milk	O
-	O
comparison	O
of	O
enzyme	O
substrates	O
4-APP	B
and	O
1-NP	B
In	O
order	O
to	O
compare	O
the	O
performance	O
of	O
the	O
immunosensor	O
using	O
1-NP	B
as	O
an	O
enzyme	O
substrate	O
with	O
its	O
performance	O
using	O
4-APP	B
,	O
milk	O
samples	O
obtained	O
from	O
a	O
number	O
of	O
different	O
cows	O
were	O
analysed	O
for	O
progesterone	B
content	O
using	O
both	O
approaches	O
.	O

The	O
results	O
were	O
then	O
compared	O
with	O
those	O
obtained	O
using	O
a	O
commercial	O
EIA	O
(	O
Ridgeway	O
Science	O
Ltd.	O
;	O
accuracy=±8	O
%	O
inter	O
-	O
assay	O
C.V.	O
,	O
sensitivity=0.6	O
ng	O
/	O
ml	O
)	O
by	O
reference	O
to	O
a	O
standard	O
curve	O
of	O
absorbance	O
reading	O
versus	O
progesterone	O
concentration	O
(	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Fig.	O
6	O
(	O
a	O
)	O
shows	O
the	O
calibration	O
curve	O
obtained	O
using	O
4-APP	B
as	O
substrate	O
to	O
measure	O
progesterone	B
milk	O
standards	O
over	O
the	O
concentration	O
range	O
,	O
0–50	O
ng	O
/	O
ml	O
,	O
before	O
and	O
after	O
background	O
subtraction	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
ranged	O
from	O
5.3	O
to	O
18.3	O
%	O
.	O

The	O
readings	O
obtained	O
for	O
six	O
cows	O
'	O
milk	O
samples	O
,	O
together	O
with	O
those	O
obtained	O
using	O
the	O
standard	O
EIA	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
for	O
the	O
two	O
sets	O
of	O
values	O
(	O
Fig.	O
6	O
(	O
b	O
)	O
)	O
.	O

Reasonable	O
agreement	O
(	O
r	O
=	O
0.840	O
)	O
was	O
obtained	O
between	O
the	O
two	O
methods	O
.	O

One	O
calibration	O
curve	O
obtained	O
using	O
1-NP	B
is	O
shown	O
in	O
Fig.	O
7	O
(	O
a	O
)	O
,	O
before	O
and	O
after	O
adjustment	O
for	O
background	O
current	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
was	O
improved	O
compared	O
with	O
the	O
4-APP	B
assay	O
and	O
ranged	O
from	O
4.1	O
to	O
12.4	O
%	O
;	O
this	O
may	O
have	O
been	O
due	O
to	O
the	O
improved	O
solubility	O
of	O
the	O
1-naphthyl	B
phosphate	I
over	O
the	O
4-APP	B
.	O

Readings	O
obtained	O
for	O
the	O
same	O
six	O
cows	O
'	O
milk	O
samples	O
tested	O
above	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
comparing	O
these	O
values	O
with	O
those	O
obtained	O
by	O
EIA	O
(	O
Fig.	O
7	O
(	O
b	O
)	O
)	O
.	O

The	O
result	O
was	O
a	O
close	O
agreement	O
between	O
the	O
two	O
sets	O
of	O
readings	O
and	O
an	O
improved	O
correlation	O
(	O
r	O
=	O
0.946	O
)	O
over	O
the	O
4-APP	B
assay	O
.	O

4	O
Conclusion	O
In	O
summary	O
,	O
the	O
above	O
results	O
have	O
demonstrated	O
that	O
by	O
using	O
1-naphthyl	B
phosphate	I
(	O
1-NP	B
)	O
as	O
enzyme	O
substrate	O
,	O
it	O
is	O
possible	O
to	O
develop	O
an	O
amperometric	O
screen	O
-	O
printed	O
immunosensor	O
for	O
milk	O
progesterone	B
based	O
on	O
the	O
detection	O
of	O
the	O
product	O
,	O
1-naphthol	B
at	O
an	O
operating	O
potential	O
of	O
+	O
300	O
mV.	O
The	O
required	O
detection	O
limit	O
of	O
2–5	O
ng	O
/	O
ml	O
(	O
Bulman	O
,	O
1979	O
;	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
was	O
achieved	O
using	O
this	O
approach	O
.	O

Examination	O
of	O
the	O
electrochemistry	O
of	O
1-naphthol	B
itself	O
indicated	O
that	O
it	O
was	O
readily	O
oxidisable	O
at	O
the	O
surface	O
of	O
an	O
SPCE	O
in	O
the	O
presence	O
or	O
absence	O
of	O
immobilised	O
antibody	O
.	O

This	O
was	O
a	O
potential	O
advantage	O
over	O
4-aminophenol	B
which	O
appeared	O
to	O
suffer	O
from	O
a	O
diffusional	O
barrier	O
,	O
most	O
probably	O
as	O
a	O
result	O
of	O
the	O
formation	O
of	O
polyphenols	B
at	O
the	O
electrode	O
surface	O
.	O

Although	O
the	O
operating	O
potential	O
required	O
for	O
oxidation	O
of	O
1-naphthol	B
was	O
100	O
mV	O
higher	O
than	O
that	O
used	O
for	O
the	O
detection	O
of	O
4-aminophenol	B
,	O
the	O
1-naphthol	B
assay	O
operated	O
below	O
the	O
oxidation	O
potential	O
of	O
milkborne	O
interferents	O
and	O
did	O
not	O
suffer	O
from	O
a	O
loss	O
of	O
sensitivity	O
.	O

Indeed	O
,	O
a	O
closer	O
agreement	O
than	O
that	O
achieved	O
using	O
4-APP	B
was	O
obtained	O
with	O
an	O
established	O
EIA	O
method	O
for	O
milk	O
samples	O
taken	O
from	O
different	O
cows	O
having	O
varying	O
background	O
responses	O
.	O

Furthermore	O
,	O
this	O
correlation	O
was	O
also	O
better	O
than	O
that	O
obtained	O
using	O
4-APP	B
in	O
a	O
previous	O
study	O
on	O
milk	O
samples	O
taken	O
from	O
a	O
single	O
animal	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Since	O
1-NP	B
is	O
inexpensive	O
,	O
readily	O
soluble	O
and	O
easy	O
to	O
obtain	O
,	O
the	O
screenprinted	O
immunosensor	O
when	O
used	O
in	O
combination	O
with	O
this	O
substrate	O
may	O
hold	O
promise	O
for	O
future	O
development	O
into	O
a	O
device	O
for	O
large	O
-	O
scale	O
milk	O
monitoring	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
R.	O
Pittson	O
and	O
his	O
staff	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
GEM	O
)	O
,	O
Mamhilad	O
,	O
Gwent	O
for	O
supplying	O
the	O
SPCEs	O
.	O

Drs	O
D.J.	O
Groves	O
and	O
B.A.	O
Morris	O
from	O
the	O
Heterohybridoma	O
Antibody	O
Group	O
,	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Surrey	O
are	O
gratefully	O
acknowledged	O
as	O
the	O
originators	O
of	O
the	O
mAb	O
.	O

Financial	O
support	O
for	O
this	O
project	O
was	O
provided	O
by	O
the	O
HEFCE	O
.	O

Ferbam	B
[	O
iron	B
(	I
III	I
)	I
dimethyldithiocarbamate	I
]	O
is	O
a	O
well	O
known	O
dithiocarbamate	B
effective	O
fungicide	B
widely	O
used	O
against	O
a	O
variety	O
of	O
plant	O
pathogenic	O
fungi	O
.	O

Ferbam	B
is	O
generally	O
determined	O
by	O
the	O
carbon	B
disulphide	I
evolution	O
method	O
based	O
on	O
its	O
decomposition	O
by	O
hot	O
mineral	O
acids	B
to	O
amine	B
and	O
carbon	B
disulfide	I
using	O
different	O
approaches	O
[	O
1	O
]	O
.	O

Ferbam	B
is	O
also	O
determined	O
by	O
converting	O
it	O
into	O
moybdenum	B
[	O
2	O
]	O
,	O
copper	B
[	O
3	O
]	O
and	O
1,10-phenanthroline	B
[	O
4	O
]	O
complexes	B
.	O

McLeod	O
and	O
McCulley	O
[	O
5	O
]	O
determined	O
dithiocarbamate	B
fungicides	B
by	O
headspace	O
gas	O
chromatography	O
of	O
the	O
carbon	B
disulphide	I
evolved	O
in	O
controlled	O
conditions	O
from	O
foodstuffs	O
and	O
similar	O
methods	O
were	O
also	O
given	O
by	O
the	O
Committee	O
for	O
Analytical	O
Methods	O
[	O
6	O
]	O
.	O

However	O
,	O
all	O
these	O
methods	O
suffer	O
from	O
the	O
following	O
disadvantages	O
:	O
(	O
a	O
)	O
Methods	O
other	O
than	O
gas	O
chromatography	O
are	O
indirect	O
,	O
time	O
consuming	O
and	O
sensitivity	O
is	O
low	O
.	O

(	O
b	O
)	O
Gas	O
chromatographic	O
methods	O
are	O
sensitive	O
but	O
suffer	O
from	O
lack	O
of	O
the	O
selectivity	O
since	O
all	O
dithiocarbamate	B
fungicides	B
evolve	O
carbon	B
disulphide	I
on	O
acid	B
hydrolysis	O
.	O

(	O
c	O
)	O
Spectrophotometric	O
methods	O
suffer	O
the	O
interference	O
of	O
various	O
ions	O
.	O

Capillary	O
electrophoresis	O
[	O
7,8	O
]	O
,	O
is	O
a	O
microvolume	O
separation	O
technique	O
increasingly	O
achieving	O
recognition	O
for	O
its	O
use	O
in	O
the	O
separation	O
of	O
inorganic	B
and	O
organic	B
compounds	I
.	O

The	O
key	O
features	O
of	O
this	O
technique	O
are	O
its	O
very	O
short	O
analysis	O
time	O
and	O
small	O
sample	O
volumes	O
in	O
the	O
nanoliter	O
and	O
picoliter	O
range	O
.	O

Capillary	O
electrophoresis	O
has	O
been	O
used	O
for	O
the	O
determination	O
of	O
sodium	B
dimethyldithiocarbamate	I
using	O
sulphonic	B
acid	I
polymer	B
coated	O
capillary	O
columns	O
at	O
pH	O
6.5	O
using	O
sodium	B
phosphate	I
buffer	O
[	O
9	O
]	O
.	O

Liang	O
et	O
al.	O
used	O
diode	O
array	O
detection	O
and	O
factor	O
analysis	O
for	O
the	O
determination	O
of	O
dithiocarbamates	B
[	O
10	O
]	O
.	O

In	O
another	O
approach	O
,	O
solid	O
-	O
phase	O
extraction	O
was	O
used	O
to	O
separate	O
dithiocarbamates	B
with	O
other	O
pesticides	B
[	O
11	O
]	O
.	O

The	O
extensive	O
studies	O
of	O
metal	B
–	I
aminopolycarboxylate	I
complexes	I
are	O
reviewed	O
by	O
Timerbaev	O
[	O
12	O
]	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
investigation	O
of	O
the	O
potential	O
of	O
capillary	O
electrophoresis	O
in	O
the	O
determination	O
of	O
Ferbam	B
.	O

As	O
will	O
be	O
demonstrated	O
in	O
this	O
report	O
,	O
capillary	O
electrophoresis	O
with	O
its	O
precision	O
instrumentation	O
and	O
small	O
sample	O
requirements	O
is	O
well	O
suited	O
for	O
the	O
determination	O
of	O
Ferbam	B
.	O

Here	O
,	O
we	O
present	O
a	O
relatively	O
simple	O
and	O
selective	O
capillary	O
electrophoretic	O
method	O
by	O
converting	O
Fe	B
(	I
III	I
)	I
present	O
in	O
Ferbam	B
into	O
Fe	B
(	I
III	I
)	I
–EDTA−	I
complex	I
.	O

The	O
chemical	O
structure	O
of	O
Ferbam	B
is	O
as	O
follows	O
:	O
[	O
(	O
CH3	O
)	O
2	O
–NC	O
(	O
S	O
)	O
2	O
]	O
3	O
Fe	O
.	O

2	O
Experimental	O
2.1	O
Instrumentation	O
Separations	O
were	O
performed	O
on	O
a	O
Thermo	O
Separation	O
Products	O
100	O
CE	O
-	O
system	O
equipped	O
with	O
an	O
UV	O
absorbance	O
detector	O
.	O

Fused	O
silica	B
capillaries	O
of	O
75	O
cm	O
long	O
(	O
45	O
cm	O
to	O
the	O
detector	O
)	O
×	O
100	O
μm	O
I.D.	O
were	O
used	O
.	O

The	O
solutes	O
were	O
injected	O
in	O
the	O
hydrodynamic	O
mode	O
by	O
vacuum	O
injection	O
for	O
2	O
s.	O
TSP	O
1000	O
software	O
was	O
used	O
for	O
the	O
data	O
acquisition	O
.	O

Detection	O
was	O
performed	O
by	O
direct	O
UV	O
absorbance	O
at	O
254	O
nm	O
.	O

All	O
experiments	O
were	O
conducted	O
at	O
25±1	O
°	O
C	O
.	O

2.2	O
Reagents	B
and	O
solutions	O
All	O
chemicals	B
used	O
were	O
of	O
analytical	O
-	O
reagent	B
grade	O
and	O
doubly	O
distilled	B
water	I
was	O
used	O
for	O
the	O
preparation	O
of	O
solutions	O
and	O
all	O
dilutions	O
.	O

2.2.1	O
Ferbam	B
solution	O
Ferbam	B
was	O
obtained	O
from	O
Riedel	O
-	O
de	O
Haën	O
(	O
Germany	O
)	O
and	O
used	O
as	O
received	O
.	O

Ferbam	B
solution	O
was	O
prepared	O
by	O
decomposing	O
its	O
20	O
mg	O
with	O
concentrated	O
nitric	B
acid	I
(	O
5–10	O
ml	O
)	O
and	O
heated	O
till	O
all	O
the	O
fumes	O
were	O
ceased	O
(	O
almost	O
to	O
dryness	O
)	O
and	O
dissolved	O
the	O
residue	O
in	O
1–2	O
ml	O
of	O
concentrated	O
HCl	B
and	O
diluted	O
upto	O
30–40	O
ml	O
and	O
pH	O
adjusted	O
in	O
the	O
range	O
2–3	O
using	O
dilute	O
NaOH	B
and	O
finally	O
diluted	O
to	O
100	O
ml	O
in	O
a	O
calibrated	O
flask	O
.	O

The	O
recovery	O
of	O
iron	B
(	I
III	I
)	I
from	O
Ferbam	B
was	O
checked	O
by	O
titrating	O
it	O
using	O
Variamine	B
Blue	I
B	I
as	O
indicator	O
[	O
13	O
]	O
.	O

Working	O
solutions	O
of	O
lower	O
concentrations	O
were	O
prepared	O
by	O
appropriate	O
dilutions	O
with	O
distilled	B
water	I
.	O

2.2.2	O
EDTA	B
solution	O
Stock	O
solution	O
of	O
EDTA	B
(	O
0.5	O
mM	O
)	O
as	O
disodium	B
salt	I
was	O
prepared	O
in	O
distilled	B
water	I
.	O

2.2.3	O
Buffer	O
solution	O
Electrophoretic	O
buffer	O
solution	O
was	O
prepared	O
from	O
boric	B
acid	I
50	O
mM	O
and	O
adjusting	O
the	O
desired	O
pH	O
by	O
adding	O
0.1	O
M	O
NaOH	B
solution	O
.	O

2.3	O
Procedures	O
2.3.1	O
Basic	O
procedure	O
The	O
capillary	O
was	O
rinsed	O
with	O
1	O
M	O
NaOH	B
,	O
0.1	O
M	O
NaOH	B
and	O
water	B
for	O
2	O
min	O
,	O
respectively	O
,	O
then	O
equilibrated	O
with	O
the	O
carrier	O
electrolyte	O
for	O
2	O
min	O
.	O

Between	O
all	O
electrophoretic	O
separations	O
the	O
capillary	O
was	O
rinsed	O
for	O
2	O
min	O
with	O
carrier	O
electrolyte	B
.	O

All	O
electrolyte	B
solutions	O
were	O
filtered	O
through	O
a	O
0.45	O
μm	O
membrane	O
filter	O
.	O

2.3.2	O
Preparation	O
of	O
standard	O
calibration	O
graph	O
A	O
series	O
of	O
standard	O
solutions	O
of	O
Ferbam	B
were	O
mixed	O
with	O
EDTA	B
(	O
1	O
ml	O
)	O
and	O
diluted	O
to	O
2	O
ml	O
with	O
distilled	B
water	I
and	O
injected	O
into	O
the	O
capillary	O
under	O
the	O
optimised	O
conditions	O
to	O
test	O
the	O
linearity	O
of	O
the	O
calibration	O
graph	O
.	O

2.3.3	O
Determination	O
of	O
Ferbam	B
in	O
grains	O
The	O
method	O
was	O
applied	O
for	O
the	O
determination	O
of	O
Ferbam	B
from	O
wheat	O
grains	O
.	O

A	O
known	O
amount	O
of	O
Ferbam	B
in	O
acetonitrile	B
was	O
crushed	O
with	O
10	O
g	O
of	O
wheat	B
grains	O
and	O
shaken	O
mechanically	O
with	O
chloroform	B
(	O
100	O
ml	O
)	O
for	O
1	O
h.	O
The	O
mixture	O
was	O
filtered	O
and	O
the	O
residue	O
in	O
the	O
funnel	O
was	O
washed	O
with	O
chloroform	B
(	O
3	O
×	O
10	O
ml	O
)	O
.	O

The	O
extracts	O
were	O
evaporated	O
to	O
dryness	O
and	O
solution	O
was	O
prepared	O
as	O
discussed	O
above	O
and	O
determined	O
by	O
the	O
general	O
procedure	O
.	O

Untreated	O
samples	O
were	O
taken	O
as	O
reference	O
and	O
the	O
results	O
indicated	O
good	O
recoveries	O
in	O
all	O
cases	O
.	O

The	O
results	O
of	O
the	O
determinations	O
are	O
given	O
in	O
Table	O
1	O
.	O

3	O
Results	O
and	O
discussion	O
A	O
typical	O
capillary	O
electropherogram	O
of	O
Ferbam	B
at	O
pH	O
9.0	O
is	O
shown	O
in	O
Fig.	O
1	O
.	O

It	O
shows	O
a	O
sharp	O
peak	O
with	O
baseline	O
resolution	O
.	O

In	O
order	O
to	O
determine	O
the	O
best	O
experimental	O
conditions	O
(	O
peak	O
efficiency	O
,	O
analysis	O
time	O
)	O
borate	B
,	O
phosphate	B
and	O
acetate	B
buffer	O
of	O
pH	O
9.0	O
,	O
7.0	O
and	O
4.5	O
,	O
respectively	O
of	O
1.25–50	O
mM	O
were	O
investigated	O
and	O
compared	O
.	O

It	O
was	O
observed	O
that	O
below	O
pH	O
7.0	O
in	O
phosphate	B
and	O
acetate	B
buffer	O
good	O
peak	O
were	O
not	O
observed	O
.	O

A	O
well	O
defined	O
peak	O
was	O
obtained	O
in	O
between	O
25	O
and	O
50	O
mM	O
borate	B
buffer	O
of	O
pH	O
9.0	O
.	O

It	O
was	O
observed	O
that	O
the	O
migration	O
time	O
was	O
more	O
at	O
the	O
higher	O
concentrations	O
of	O
the	O
borate	B
buffer	O
.	O

Above	O
25	O
mM	O
concentration	O
of	O
borate	B
buffer	O
there	O
was	O
a	O
considerable	O
increase	O
in	O
the	O
migration	O
time	O
of	O
the	O
both	O
analytes	O
,	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
analysis	O
time	O
.	O

Therefore	O
,	O
25	O
mM	O
of	O
borate	B
buffer	O
concentration	O
was	O
preferred	O
.	O

The	O
influence	O
of	O
the	O
applied	O
voltage	O
was	O
also	O
studied	O
by	O
increasing	O
the	O
applied	O
voltage	O
.	O

The	O
retention	O
time	O
decreases	O
with	O
increasing	O
voltage	O
.	O

Therefore	O
,	O
+	O
30	O
kV	O
was	O
applied	O
to	O
get	O
the	O
shortest	O
time	O
.	O

A	O
linear	O
relationship	O
between	O
peak	O
height	O
and	O
concentrations	O
were	O
obtained	O
in	O
the	O
range	O
3.5–500	O
μg	O
/	O
ml	O
with	O
an	O
correlation	O
coefficient	O
of	O
0.9994	O
.	O

The	O
linear	O
regression	O
equation	O
for	O
the	O
calibration	O
curve	O
is	O
y	O
=	O
0.0001x	O
+	O
0.0003	O
.	O

Aliquots	O
containing	O
50	O
μg	O
/	O
ml	O
of	O
give	O
a	O
relative	O
standard	O
deviation	O
of	O
2.9	O
%	O
in	O
analysis	O
.	O

Ferbam	B
,	O
if	O
present	O
with	O
other	O
water	B
soluble	O
dithiocarbamates	B
such	O
as	O
nabam	B
,	O
metham	B
,	O
sodium	B
diethyldithiocarbamate	I
,	O
etc	O
.	O
,	O
can	O
easily	O
be	O
separated	O
by	O
extraction	O
with	O
chloroform	B
;	O
Nabam	B
and	O
others	O
will	O
remain	O
in	O
the	O
aqueous	O
phase	O
which	O
can	O
then	O
be	O
analysed	O
by	O
the	O
basic	O
procedure	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
our	O
experiments	O
have	O
shown	O
that	O
Ferbam	B
can	O
be	O
determined	O
directly	O
in	O
the	O
presence	O
of	O
metal	B
ions	I
like	O
Co	B
(	I
II	I
)	I
,	O
Zn	B
(	I
II	I
)	I
,	O
Cu	B
(	I
II	I
)	I
and	O
Ni	B
(	I
II	I
)	I
without	O
any	O
interference	O
,	O
whereas	O
,	O
these	O
metal	B
ions	I
strongly	O
interfere	O
in	O
the	O
spectrophotometric	O
methods	O
[	O
2,3	O
]	O
.	O

These	O
results	O
are	O
similar	O
to	O
as	O
reported	O
by	O
earlier	O
workers	O
[	O
12,15	O
]	O
.	O

4	O
Conclusions	O
Capillary	O
electrophoresis	O
provides	O
an	O
important	O
tool	O
in	O
the	O
hands	O
of	O
the	O
analytical	O
chemists	O
for	O
the	O
determination	O
of	O
Ferbam	B
.	O

The	O
detection	O
limit	O
(	O
S	O
/N	O
=3	O
)	O
using	O
this	O
method	O
is	O
0.7	O
μg	O
/	O
ml	O
(	O
0.7	O
mg	O
/	O
kg	O
)	O
of	O
Ferbam	B
which	O
is	O
better	O
than	O
1	O
μg	O
/	O
ml	O
of	O
Nitowski	O
et	O
al.	O
's	O
[	O
9	O
]	O
method	O
reported	O
for	O
dimethyldithiocarbamate	B
using	O
sulphonic	B
acid	I
polymer	B
-	O
coated	O
capillary	O
columns	O
.	O

As	O
most	O
of	O
the	O
cations	B
and	O
anions	B
do	O
not	O
interfere	O
in	O
the	O
determination	O
of	O
Ferbam	B
,	O
moreover	O
,	O
the	O
simplicity	O
and	O
small	O
sample	O
volume	O
requirements	O
makes	O
it	O
advantageous	O
to	O
other	O
chromatographic	O
techniques	O
.	O

Thus	O
,	O
the	O
usefulness	O
of	O
capillary	O
electrophoresis	O
as	O
a	O
tool	O
for	O
checking	O
the	O
amount	O
of	O
Ferbam	B
is	O
successfully	O
demonstrated	O
.	O

Acknowledgements	O
One	O
of	O
the	O
authors	O
(	O
A.K.M.	O
)	O
thanks	O
the	O
AvH	O
Foundation	O
,	O
Bonn	O
,	O
Germany	O
for	O
financial	O
assistance	O
.	O

l	B
-cis	I
Diltiazem	I
,	O
the	O
enantiomer	O
of	O
diltiazem	B
(	O
d	B
-cis	I
diltiazem	I
)	O
,	O
has	O
100	O
times	O
less	O
Ca2	B
+	I
channel	O
blocking	O
activity	O
than	O
diltiazem	B
(	O
Ikeda	O
et	O
al.	O
,	O
1991	O
)	O
.	O

l	B
-cis	I
Diltiazem	I
is	O
not	O
a	O
simple	O
inactive	O
stereoisomer	O
but	O
has	O
been	O
established	O
as	O
a	O
unique	O
pharmacological	O
tool	O
(	O
Caretta	O
et	O
al.	O
,	O
1979	O
)	O
.	O

For	O
example	O
,	O
l	B
-cis	I
diltiazem	I
,	O
but	O
not	O
diltiazem	B
,	O
inhibits	O
the	O
cGMP	O
-	O
gated	O
cation	O
channel	O
in	O
rod	O
cells	O
(	O
Stern	O
et	O
al.	O
,	O
1986	O
;	O
Quandt	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Interestingly	O
,	O
there	O
have	O
been	O
several	O
reports	O
indicating	O
that	O
l	B
-cis	I
diltiazem	I
protects	O
against	O
ischemic	O
cardiac	O
injury	O
.	O

For	O
example	O
,	O
l	B
-cis	I
diltiazem	I
produces	O
a	O
high	O
recovery	O
of	O
cardiac	O
function	O
after	O
ischemia	O
/	O
reperfusion	O
and	O
inhibits	O
the	O
increase	O
of	O
non	O
-	O
esterified	O
fatty	B
acids	I
during	O
ischemia	O
in	O
isolated	O
,	O
perfused	O
working	O
rat	O
heart	O
(	O
Nasa	O
et	O
al.	O
,	O
1990	O
;	O
Xiao	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Recently	O
,	O
our	O
laboratory	O
has	O
reported	O
that	O
treatment	O
with	O
l	B
-cis	I
diltiazem	I
reduced	O
infarct	O
size	O
without	O
affecting	O
any	O
hemodynamic	O
parameter	O
in	O
rabbit	O
heart	O
in	O
vivo	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Since	O
l	B
-cis	I
diltiazem	I
has	O
a	O
much	O
less	O
potent	O
Ca2	O
+	O
channel	O
blocking	O
action	O
than	O
diltiazem	B
,	O
it	O
has	O
been	O
suggested	O
that	O
l	B
-cis	I
diltiazem	I
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
with	O
a	O
mechanism	O
other	O
than	O
Ca2	O
+	O
channel	O
blockade	O
.	O

We	O
have	O
also	O
demonstrated	O
that	O
treatment	O
with	O
l	B
-cis	I
diltiazem	I
before	O
reperfusion	O
also	O
reduced	O
infarct	O
size	O
in	O
ischemic	O
rabbit	O
heart	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Ca2	B
+	I
overload	O
at	O
reperfusion	O
after	O
ischemia	O
(	O
Allen	O
and	O
Orchard	O
,	O
1983	O
)	O
and	O
reoxygenation	O
after	O
hypoxia	O
(	O
Poole	O
-	O
Wilson	O
et	O
al.	O
,	O
1984	O
)	O
have	O
been	O
considered	O
to	O
be	O
involved	O
in	O
the	O
final	O
stage	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
of	O
cardiac	O
myocytes	O
(	O
Nayler	O
,	O
1981	O
;	O
Farber	O
,	O
1982	O
;	O
Steenbergen	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Thus	O
,	O
it	O
is	O
postulated	O
that	O
l	B
-cis	I
diltiazem	I
elicits	O
a	O
cardioprotective	O
action	O
via	O
the	O
attenuation	O
of	O
Ca2	O
+	O
overload	O
after	O
reperfusion	O
.	O

In	O
terms	O
of	O
energy	O
metabolism	O
,	O
ischemic	O
insults	O
can	O
be	O
simulated	O
,	O
in	O
part	O
,	O
by	O
controlled	O
metabolic	O
inhibition	O
.	O

Li	O
et	O
al.	O
(	O
1989	O
)	O
has	O
reported	O
that	O
the	O
myocytes	O
were	O
reversibly	O
ATP	B
-	O
depleted	O
by	O
metabolic	O
inhibitors	O
.	O

Thus	O
,	O
myocardial	O
Ca2	B
+	I
overload	O
induced	O
by	O
ischemia	O
and	O
reperfusion	O
is	O
considered	O
to	O
be	O
simply	O
mimicked	O
,	O
in	O
part	O
,	O
by	O
treatment	O
with	O
carbonyl	B
cyanide	I
m	I
-chrolophenylhydrazone	I
(	O
CCCP	B
)	O
,	O
a	O
mitochondrial	O
uncoupler	O
,	O
followed	O
by	O
washout	O
of	O
CCCP	B
.	O

In	O
order	O
to	O
assess	O
the	O
effect	O
of	O
l	B
-cis	I
diltiazem	I
on	O
reperfusion	O
-	O
induced	O
Ca2	B
+	I
overload	O
,	O
we	O
used	O
a	O
model	O
for	O
Ca2	B
+	I
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
isolated	O
guinea	O
pig	O
cardiomyocytes	O
.	O

We	O
also	O
assessed	O
the	O
effect	O
of	O
other	O
drugs	O
,	O
Ca2	O
+	O
channel	O
blockers	O
and	O
Na+	B
/Ca2	O
+	B
exchanger	O
blockers	O
,	O
to	O
clarify	O
the	O
mechanism	O
for	O
Ca2	B
+	I
overload	O
in	O
this	O
model	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Preparation	O
of	O
single	O
cells	O
Ventricular	O
myocytes	O
were	O
isolated	O
enzymatically	O
from	O
the	O
hearts	O
of	O
male	O
Hartley	O
guinea	O
pigs	O
(	O
weight	O
250–500	O
g	O
)	O
according	O
to	O
the	O
method	O
described	O
(	O
Kurokawa	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
animals	O
were	O
anaesthetized	O
with	O
sodium	B
pentobarbital	I
(	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
and	O
the	O
ascending	O
aorta	O
was	O
cannulated	O
in	O
situ	O
under	O
artificial	O
respiration	O
.	O

The	O
heart	O
was	O
perfused	O
with	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
for	O
10	O
min	O
,	O
followed	O
by	O
the	O
same	O
solution	O
containing	O
collagenase	O
for	O
7–14	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
8–10	O
ml	O
/	O
min	O
via	O
a	O
Langendorff	O
apparatus	O
at	O
37	O
°	O
C	O
.	O

Subsequently	O
,	O
the	O
enzyme	O
solution	O
was	O
washed	O
out	O
with	O
a	O
high	O
K+	B
,	O
Ca2	B
+	I
-free	O
solution	O
(	O
Kraftbrühe	B
(	O
KB	B
)	O
solution	B
,	O
Isenberg	O
and	O
Klöckner	O
,	O
1982	O
)	O
.	O

The	O
ventricular	O
myocytes	O
were	O
dissociated	O
by	O
gentle	O
stirring	O
of	O
the	O
tissue	O
fragments	O
at	O
37	O
°	O
C	O
.	O

The	O
dissociated	O
cells	O
were	O
stored	O
in	O
KB	B
solution	I
at	O
4	O
°	O
C	O
,	O
and	O
were	O
used	O
up	O
to	O
10	O
h	O
after	O
isolation	O
.	O

Nominally	O
Ca2	B
+	I
-free	O
solution	O
had	O
the	O
following	O
composition	O
(	O
mM	O
)	O
:	O
NaCl	B
135	O
,	O
KCl	B
5.4	O
,	O
MgCl2	B
1	O
,	O
glucose	B
5.8	O
,	O
HEPES	B
5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
tris	B
)	O
.	O

Normal	O
Tyrode	B
solution	I
was	O
made	O
by	O
adding	O
1.8	O
mM	O
CaCl2	B
to	O
nominally	O
Ca2	B
+	I
-free	O
solution	O
.	O

The	O
collagenase	O
solutions	O
were	O
prepared	O
by	O
adding	O
collagenase	O
(	O
110	O
units	O
/	O
ml	O
Collagenase	O
S-1	O
,	O
Nitta	O
Gelatin	O
,	O
Osaka	O
,	O
Japan	O
;	O
200–220	O
units	O
/	O
ml	O
collagenase	O
,	O
Yakult	O
,	O
Tokyo	O
.	O

Japan	O
)	O
and	O
10.8	O
nM	O
CaCl2	B
to	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
,	O
or	O
by	O
combining	O
collagenase	O
(	O
0.145	O
U	O
/	O
ml	O
collagenase	O
A	O
,	O
Boehringer	O
Mannheim	O
,	O
Japan	O
)	O
and	O
protease	O
(	O
0.156	O
units	O
/	O
ml	O
protease	O
type	O
IX	O
,	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
to	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
.	O

The	O
KB	B
solution	I
contained	O
(	O
mM	O
)	O
:	O
potassium	B
glutamate	I
70	O
,	O
KCl	B
20	O
,	O
oxalic	B
acid	I
10	O
,	O
KH2	B
PO4	I
10	O
,	O
taurine	B
10	O
,	O
glucose	B
5.8	O
,	O
HEPES	B
5	O
,	O
EGTA	B
0.5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
KOH	B
)	O
.	O

2.2	O
Measurement	O
of	O
fluorescence	O
ratio	O
of	O
fura-2	B
in	O
cardiac	O
myocytes	O
For	O
measurement	O
of	O
a	O
change	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
of	O
cardiac	O
myocytes	O
,	O
a	O
Ca2	B
+	I
-sensitive	O
fluorescent	O
dye	O
,	O
fura-2	B
/	I
acetoxymethylester	I
(	O
fura-2	B
/	I
AM	I
)	O
,	O
was	O
used	O
.	O

Fura-2	B
/	I
AM	I
(	O
1	O
mM	O
,	O
dissolved	O
in	O
dimethylsulfoxide	B
,	O
DMSO	B
)	O
was	O
prepared	O
in	O
KB	B
solution	I
and	O
applied	O
to	O
isolated	O
myocytes	O
at	O
a	O
final	O
concentration	O
of	O
10	O
μM.	O
After	O
the	O
cell	O
suspension	O
had	O
been	O
incubated	O
for	O
10	O
min	O
at	O
37	O
°	O
C	O
,	O
the	O
cells	O
settled	O
out	O
and	O
became	O
loosely	O
attached	O
to	O
the	O
bottom	O
of	O
the	O
chamber	O
.	O

Then	O
the	O
fura-2-loaded	B
myocytes	O
were	O
washed	O
and	O
superfused	O
(	O
4–5	O
ml	O
/	O
min	O
,	O
37	O
°	O
C	O
)	O
with	O
normal	O
Tyrode	B
solution	I
containing	O
1.8	O
mM	O
Ca2	B
+	I
for	O
30	O
min	O
.	O

The	O
myocytes	O
were	O
illuminated	O
with	O
a	O
dual	O
wavelength	O
fluorometer	O
(	O
CAM-230	O
,	O
Japan	O
Spectroscopic	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Video	O
images	O
were	O
digitized	O
,	O
using	O
an	O
Argus-50	O
/	O
Ca	O
system	O
(	O
Hamamatsu	O
Photonics	O
)	O
.	O

The	O
fluorescence	O
ratio	O
was	O
calculated	O
from	O
the	O
value	O
of	O
the	O
fluorescence	O
intensity	O
at	O
500	O
nm	O
with	O
340-	O
and	O
380-nm	O
excitation	O
.	O

The	O
digital	O
images	O
were	O
obtained	O
every	O
5	O
min	O
from	O
just	O
before	O
treatment	O
with	O
CCCP	B
till	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.3	O
Evaluation	O
of	O
morphological	O
changes	O
of	O
cardiac	O
myocytes	O
Cells	O
lightly	O
attached	O
to	O
the	O
perfusion	O
chamber	O
were	O
superfused	O
with	O
normal	O
Tyrode	B
solution	I
at	O
37	O
°	O
C	O
.	O

After	O
30	O
min	O
of	O
stabilization	O
,	O
a	O
rod	O
-	O
shaped	O
cell	O
was	O
selected	O
randomly	O
from	O
those	O
within	O
the	O
microscopic	O
field	O
of	O
the	O
chamber	O
.	O

Caffeine	B
(	O
5	O
mM	O
)	O
was	O
added	O
for	O
1	O
min	O
to	O
the	O
chamber	O
in	O
order	O
to	O
confirm	O
that	O
the	O
function	O
of	O
the	O
intracellular	O
Ca2	B
+	I
store	O
of	O
the	O
myocyte	O
was	O
maintained	O
.	O

After	O
washing	O
out	O
of	O
the	O
caffeine	B
for	O
5	O
min	O
,	O
the	O
morphology	O
of	O
the	O
myocyte	O
was	O
recorded	O
as	O
a	O
digital	O
image	O
using	O
the	O
Argus-50	O
/	O
Ca	O
system	O
.	O

To	O
examine	O
the	O
morphological	O
change	O
of	O
the	O
myocyte	O
,	O
the	O
morphology	O
of	O
the	O
same	O
cell	O
was	O
also	O
recorded	O
at	O
the	O
end	O
of	O
chemical	O
ischemia	O
and	O
also	O
at	O
the	O
end	O
of	O
30-min	O
reperfusion	O
.	O

After	O
Ca2	B
+	I
measurement	O
,	O
the	O
morphological	O
change	O
was	O
analyzed	O
by	O
measuring	O
the	O
area	O
of	O
the	O
myocyte	O
.	O

The	O
cell	O
surface	O
area	O
was	O
calculated	O
from	O
the	O
digitized	O
image	O
of	O
the	O
cell	O
and	O
the	O
post	O
-	O
ischemic	O
value	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
pre	O
-	O
ischemic	O
value	O
.	O

2.4	O
Experimental	O
protocols	O
In	O
order	O
to	O
determine	O
the	O
optimal	O
condition	O
of	O
the	O
Ca2	B
+	I
overload	O
model	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
,	O
we	O
performed	O
some	O
preliminary	O
experiments	O
.	O

We	O
first	O
followed	O
a	O
protocol	O
for	O
metabolic	O
inhibition	O
,	O
using	O
Tyrode	B
solution	I
containing	O
normal	O
Ca2	B
+	I
and	O
1	O
μM	O
of	O
CCCP	B
.	O

However	O
,	O
the	O
myocytes	O
exposed	O
to	O
CCCP	B
for	O
10–15	O
min	O
showed	O
a	O
rigor	O
contraction	O
with	O
an	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
but	O
failed	O
to	O
show	O
Ca2	O
+	O
overload	O
on	O
washout	O
of	O
CCCP	B
(	O
energy	O
repletion	O
)	O
after	O
the	O
transition	O
to	O
rigor	O
contraction	O
(	O
the	O
sign	O
of	O
ATP	B
depletion	O
)	O
.	O

These	O
cells	O
showed	O
neither	O
further	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
nor	O
morphological	O
changes	O
after	O
energy	O
repletion	O
.	O

To	O
improve	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
,	O
we	O
used	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
for	O
metabolic	O
inhibition	O
,	O
since	O
it	O
was	O
reported	O
that	O
cells	O
in	O
the	O
low	O
Ca2	B
+	I
solution	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
)	O
.	O

We	O
also	O
examined	O
the	O
dose	O
-	O
dependent	O
effects	O
of	O
CCCP	B
(	O
100	O
nM	O
,	O
1	O
and	O
3	O
μM	O
)	O
,	O
and	O
confirmed	O
that	O
1	O
μM	O
of	O
CCCP	B
was	O
the	O
most	O
stable	O
to	O
induce	O
Ca2	B
+	I
overload	O
after	O
energy	O
repletion	O
.	O

Based	O
on	O
these	O
experiments	O
,	O
we	O
established	O
the	O
standard	O
procedure	O
as	O
follows	O
.	O

After	O
confirmation	O
of	O
the	O
integrity	O
of	O
the	O
myocardial	O
store	O
functions	O
described	O
in	O
the	O
previous	O
section	O
,	O
Ca2	B
+	I
-free	O
Tyrode	O
containing	O
CCCP	B
(	O
1	O
μM	O
)	O
was	O
perfused	O
for	O
40	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
2–3	O
ml	O
/	O
min	O
.	O

Ca2	B
+	I
overload	O
was	O
induced	O
by	O
washout	O
of	O
CCCP	B
with	O
normal	O
Tyrode	B
solution	I
for	O
30	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
4–5	O
ml	O
/	O
min	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
the	O
following	O
two	O
protocols	O
:	O
(	O
A	O
)	O
before	O
metabolic	O
inhibition	O
,	O
in	O
which	O
drugs	O
were	O
included	O
throughout	O
the	O
experiment	O
,	O
and	O
(	O
B	O
)	O
before	O
energy	O
repletion	O
,	O
in	O
which	O
drugs	O
were	O
included	O
from	O
5	O
min	O
before	O
energy	O
repletion	O
to	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.5	O
Calibration	O
for	O
Ca2	B
+	I
concentration	O
The	O
maximum	O
ratio	O
(	O
R	O
max	O
)	O
unique	O
to	O
individual	O
cells	O
was	O
obtained	O
at	O
the	O
end	O
of	O
each	O
experiment	O
by	O
applying	O
ionomycin	B
(	O
2	O
μM	O
)	O
to	O
the	O
normal	O
Tyrode	B
solution	I
.	O

The	O
minimum	O
ratio	O
(	O
R	O
min	O
)	O
was	O
obtained	O
by	O
applying	O
EGTA	B
(	O
10	O
mM	O
)	O
to	O
the	O
ionomycin	B
containing	O
Tyrode	B
solution	I
.	O

Both	O
R	O
max	O
and	O
R	O
min	O
values	O
were	O
obtained	O
under	O
steady	O
state	O
conditions	O
.	O

[	O
Ca2	B
+	I
]	O
i	O
was	O
calculated	O
from	O
the	O
following	O
formula	O
:	O
[	O
Ca2	B
+	I
]	O
i	O
(	O
nM	O
)	O
=	O
(	O
R	O
−R	O
min	O
)	O
×K	O
d	O
×F	O
min	O
/	O
(	O
(	O
R	O
max	O
−R	O
)	O
×F	O
max	O
)	O
)	O
,	O
where	O
R	O
is	O
the	O
ratio	O
obtained	O
from	O
the	O
experiment	O
,	O
F	O
means	O
the	O
fluorescence	O
intensity	O
at	O
380-nm	O
excitation	O
,	O
and	O
K	O
d	O
is	O
the	O
dissociation	O
constant	O
defined	O
as	O
224	O
nM.	O
2.6	O
Chemicals	O
l	B
-cis	I
Diltiazem	I
and	O
diltiazem	B
were	O
kind	O
gifts	O
from	O
Tanabe	O
Seiyaku	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

A	O
specific	O
inhibitor	O
of	O
Na+	B
/Ca2	O
+	B
exchanger	O
,	O
2-	B
[	I
2-	I
[	I
4-	I
(	I
4-nitrobenzyloxy	I
)	I
phenyl	I
]	I
ethyl	I
]	I
isothiourea	I
methanesulphonate	I
(	O
KB	B
-	I
R7943	I
)	O
,	O
was	O
a	O
kind	O
gift	O
from	O
Kanebo	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

CCCP	B
was	O
purchased	O
from	O
Sigma	O
.	O

2.7	O
Statistical	O
analysis	O
All	O
data	O
were	O
expressed	O
as	O
means±S.E.M.	O
The	O
time	O
course	O
data	O
(	O
Ca2	B
+	I
measurement	O
)	O
were	O
divided	O
into	O
two	O
events	O
,	O
during	O
40	O
min	O
of	O
metabolic	O
inhibition	O
and	O
during	O
30-min	O
energy	O
repletion	O
,	O
and	O
repeated	O
measures	O
two	O
-	O
way	O
analysis	O
of	O
variance	O
was	O
used	O
.	O

If	O
there	O
was	O
no	O
interaction	O
between	O
the	O
drug	O
factor	O
and	O
the	O
time	O
factor	O
,	O
Bonferroni	O
/	O
Dunn	O
(	O
Dunn	O
's	O
Procedure	O
for	O
Comparing	O
a	O
Control	O
to	O
All	O
other	O
Means	O
)	O
post	O
-	O
hoc	O
test	O
was	O
done	O
thereafter	O
.	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
the	O
Bonferroni	O
/	O
Dunn	O
post	O
-	O
hoc	O
test	O
was	O
used	O
for	O
the	O
cell	O
size	O
data	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
Super	O
ANOVA	O
™	O
(	O
Abacus	O
Concepts	O
,	O
Berkeley	O
,	O
CA	O
)	O
.	O

Differences	O
were	O
considered	O
to	O
be	O
statistically	O
significant	O
when	O
the	O
P	O
value	O
was	O
less	O
than	O
0.05	O
.	O

3	O
Results	O
3.1	O
Cell	O
selection	O
In	O
all	O
the	O
experiments	O
,	O
rod	O
-	O
shaped	O
myocytes	O
as	O
shown	O
in	O
Fig.	O
1A	O
were	O
selected	O
.	O

A	O
single	O
myocyte	O
was	O
further	O
selected	O
for	O
the	O
ischemia	O
experiment	O
,	O
based	O
on	O
the	O
criterion	O
that	O
it	O
showed	O
a	O
transient	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
on	O
treatment	O
with	O
5	O
mM	O
caffeine	B
(	O
Fig.	O
1B	O
)	O
.	O

The	O
cells	O
,	O
which	O
did	O
not	O
satisfy	O
these	O
criteria	O
,	O
or	O
which	O
changed	O
morphologically	O
after	O
the	O
treatment	O
with	O
caffeine	B
,	O
were	O
excluded	O
.	O

3.2	O
Changes	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
Fig.	O
2	O
represents	O
the	O
change	O
in	O
time	O
course	O
of	O
[	O
Ca2	B
+	I
]	O

i	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
.	O

Before	O
CCCP	B
treatment	O
,	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
of	O
all	O
cells	O
used	O
were	O
almost	O
identical	O
in	O
level	O
(	O
about	O
100	O
nM	O
)	O
.	O

In	O
the	O
control	O
myocytes	O
,	O
[	O
Ca2	B
+	I
]	O
i	O
did	O
not	O
change	O
during	O
40	O
min	O
of	O
CCCP	B
treatment	O
.	O

After	O
washout	O
of	O
CCCP	B
,	O
[	O
Ca2	B
+	I
]	O
i	O
increased	O
dramatically	O
within	O
5	O
min	O
and	O
continued	O
to	O
increase	O
until	O
the	O
end	O
of	O
energy	O
repletion	O
.	O

In	O
order	O
to	O
confirm	O
that	O
this	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
was	O
not	O
due	O
to	O
the	O
simple	O
entry	O
of	O
extracellular	O
Ca2	B
+	I
when	O
Ca2	B
+	I
-free	O
Tyrode	B
was	O
replaced	O
by	O
normal	O
Tyrode	B
,	O
we	O
performed	O
the	O
same	O
perfusion	O
protocol	O
without	O
CCCP	B
treatment	O
.	O

We	O
observed	O
that	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
showed	O
a	O
small	O
(	O
20–30	O
nM	O
)	O
,	O
but	O
not	O
significant	O
,	O
increase	O
at	O
5	O
min	O
after	O
energy	O
repletion	O
.	O

Therefore	O
,	O
the	O
Ca2	B
+	I
overload	O
observed	O
here	O
is	O
considered	O
to	O
be	O
induced	O
by	O
the	O
injury	O
due	O
to	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

Furthermore	O
,	O
Ni2	B
+	I
(	O
5	O
mM	O
)	O
and	O
KB	B
-	I
R7943	I
(	O
10	O
μM	O
)	O
,	O
known	O
as	O
inhibitors	O
of	O
the	O
Na+	B
/Ca2	B
+	I
exchanger	O
,	O
completely	O
blocked	O
the	O
initial	O
rise	O
of	O
[	O
Ca2	B
+	I
]	O
i	O
after	O
washout	O
of	O
CCCP	B
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
and	O
continued	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
during	O
30	O
min	O
of	O
energy	O
repletion	O
.	O

However	O
,	O
nitrendipine	B
(	O
10	O
μM	O
)	O
,	O
a	O
dihydropyridine	B
Ca2	B
+	I
channel	O
blocker	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
after	O
washout	O
of	O
CCCP	B
.	O

Nicardipine	B
(	O
10	O
μM	O
)	O
,	O
another	O
dihydropyridine	B
Ca2	B
+	I
channel	O
blocker	O
,	O
also	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
(	O
see	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
in	O
this	O
model	O
was	O
suggested	O
to	O
be	O
mediated	O
,	O
not	O
by	O
L	O
-	O
type	O
Ca2	B
+	I
channels	O
but	O
by	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
before	O
metabolic	O
inhibition	O
(	O
protocol	O
(	O
A	O
)	O
)	O
,	O
diltiazem	B
(	O
3	O
μM	O
)	O
and	O
l	B
-cis	I
diltiazem	I
(	O
10	O
μM	O
)	O
,	O
but	O
not	O
l	B
-cis	I
diltiazem	I
(	O
3	O
μM	O
)	O
significantly	O
attenuated	O
the	O
[	B
Ca2	I
+	I
]	O
i	O
increase	O
during	O
energy	O
repletion	O
(	O
Fig.	O
3A	O
)	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
5	O
min	O
before	O
washout	O
of	O
CCCP	B
(	O
protocol	O
(	O
B	O
)	O
)	O
,	O
3	O
μM	O
of	O
diltiazem	B
,	O
which	O
was	O
effective	O
in	O
protocol	O
(	O
A	O
)	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
.	O

However	O
,	O
a	O
higher	O
concentration	O
of	O
diltiazem	B
(	O
10	O
μM	O
)	O
could	O
significantly	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

l	B
-cis	I
Diltiazem	I
(	O
10	O
μM	O
)	O
also	O
attenuated	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
.	O

3.3	O
Morphological	O
change	O
of	O
the	O
cell	O
after	O
energy	O
repletion	O
Cells	O
,	O
which	O
showed	O
a	O
rigor	O
contraction	O
during	O
CCCP	B
treatment	O
,	O
were	O
all	O
excluded	O
from	O
the	O
experiments	O
.	O

Table	O
1	O
represents	O
the	O
morphological	O
change	O
in	O
cell	O
size	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
,	O
accompanied	O
by	O
[	O
Ca2	B
+	I
]	O
i	O
.	O

Compared	O
with	O
the	O
control	O
,	O
l	B
-cis	I
diltiazem	I
(	O
10	O
μM	O
)	O
,	O
diltiazem	B
(	O
10	O
μM	O
)	O
,	O
Ni2	B
+	I
(	O
5	O
mM	O
)	O
and	O
KB	B
-	I
R7943	I
(	O
10	O
μM	O
)	O
,	O
added	O
5	O
min	O
before	O
washout	O
of	O
CCCP	B
,	O
all	O
reduced	O
the	O
cell	O
shortening	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
these	O
effects	O
correlated	O
well	O
with	O
the	O
attenuation	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
.	O

Treatment	O
with	O
diltiazem	B
(	O
3	O
μM	O
)	O
failed	O
to	O
reduce	O
the	O
contraction	O
,	O
which	O
correlated	O
with	O
the	O
increase	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
.	O

Neither	O
nitrendipine	B
(	O
10	O
μM	O
)	O
nor	O
nicardipine	B
(	O
10	O
μM	O
)	O
attenuated	O
the	O
contraction	O
or	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
after	O
energy	O
repletion	O
.	O

4	O
Discussion	O
4.1	O
Increase	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	O
pig	O
isolated	O
myocytes	O
Isolated	O
cardiomyocytes	O
are	O
reversibly	O
made	O
ATP	B
-	O
depleted	O
by	O
CCCP	B
,	O
a	O
reversible	O
inhibitor	O
of	O
mitochondrial	O
oxidative	O
phosphorylation	O
(	O
Li	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
myocytes	O
,	O
which	O
show	O
a	O
rigor	O
contraction	O
on	O
metabolic	O
inhibition	O
are	O
reported	O
to	O
have	O
depressed	O
Ca2	B
+	I
overload	O
,	O
because	O
the	O
activity	O
of	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
is	O
inhibited	O
by	O
energy	O
depletion	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
;	O
Collins	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Li	O
et	O
al.	O
(	O
1988	O
)	O
have	O
also	O
reported	O
that	O
cells	O
maintaining	O
a	O
low	O
[	O
Ca2	B
+	I
]	O
i	O
level	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
.	O

Since	O
our	O
aim	O
was	O
to	O
assess	O
the	O
effect	O
of	O
l	B
-cis	I
diltiazem	I
on	O
reperfusion	O
-	O
induced	O
Ca2	B
+	I
overload	O
in	O
vitro	O
,	O
we	O
followed	O
a	O
protocol	O
with	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
,	O
which	O
improves	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
.	O

Using	O
this	O
type	O
of	O
model	O
,	O
we	O
could	O
partially	O
simulate	O
the	O
ischemia	O
/	O
reperfusion	O
-	O
induced	O
Ca2	B
+	I
overload	O
in	O
vitro	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
marked	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
was	O
observed	O
after	O
washout	O
of	O
CCCP	B
with	O
Ca2	B
+	I
-containing	O
Tyrode	B
solution	I
.	O

This	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
was	O
suppressed	O
by	O
Ni2	B
+	I
or	O
KB	B
-	I
R7943	I
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
,	O
but	O
was	O
not	O
suppressed	O
by	O
nitrendipine	B
or	O
nicardipine	B
(	O
Fig.	O
2	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
by	O
energy	O
repletion	O
occurred	O
via	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
,	O
but	O
not	O
through	O
the	O
dihydropyridine	B
-	O
sensitive	O
Ca2	B
+	I
channel	O
in	O
this	O
model	O
.	O

4.2	O
Cardioprotective	O
effect	O
of	O
l	B
-cis	I
diltiazem	I
on	O
Ca2	B
+	I
overload	O
in	O
guinea	O
pig	O
myocytes	O
In	O
the	O
present	O
study	O
,	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
attenuated	O
both	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
and	O
the	O
cell	O
shortening	O
induced	O
by	O
CCCP	B
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
demonstrated	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
attenuated	O
veratridine	B
-	O
induced	O
Ca2	B
+	I
overload	O
and	O
hypercontracture	O
in	O
isolated	O
rat	O
hearts	O
.	O

However	O
,	O
this	O
is	O
not	O
direct	O
evidence	O
that	O
l	B
-cis	I
diltiazem	I
actually	O
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
by	O
inhibiting	O
Ca2	B
+	I
overload	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
mimicked	O
the	O
phenomenon	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
in	O
the	O
chamber	O
and	O
our	O
data	O
are	O
the	O
first	O
demonstration	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
protect	O
against	O
the	O
Ca2	B
+	I
overload	O
induced	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
same	O
concentration	O
range	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
observation	O
that	O
nitrendipine	B
and	O
nicardipine	B
were	O
without	O
effect	O
,	O
suggests	O
that	O
their	O
effects	O
are	O
independent	O
of	O
L	O
-	O
type	O
Ca2	B
+	I
channel	O
blocking	O
.	O

This	O
possibility	O
is	O
also	O
supported	O
by	O
the	O
results	O
of	O
a	O
previous	O
study	O
in	O
our	O
laboratory	O
showing	O
that	O
l	B
-cis	I
diltiazem	I
(	O
10	O
μM	O
)	O
as	O
well	O
as	O
diltiazem	B
(	O
3	O
μM	O
)	O
worked	O
to	O
preserve	O
high	O
-	O
energy	O
phosphates	B
in	O
the	O
ischemia	O
–	O
reperfusion	O
model	O
of	O
isolated	O
guinea	O
pig	O
hearts	O
(	O
submitted	O
for	O
publication	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
inclusion	O
of	O
diltiazem	B
(	O
3	O
μM	O
)	O
throughout	O
the	O
experiment	O
attenuated	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
during	O
reperfusion	O
(	O
Fig.	O
3A	O
)	O
.	O

However	O
,	O
the	O
addition	O
of	O
diltiazem	B
(	O
3	O
μM	O
)	O
,	O
started	O
5	O
min	O
before	O
reperfusion	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
we	O
suggest	O
that	O
some	O
events	O
during	O
chemical	O
ischemia	O
,	O
which	O
could	O
be	O
affected	O
by	O
diltiazem	B
,	O
might	O
be	O
involved	O
in	O
the	O
Ca2	B
+	I
overload	O
during	O
reperfusion	O
(	O
Watts	O
et	O
al.	O
,	O
1990	O
;	O
Sakamoto	O
et	O
al.	O
,	O
1997	O
)	O
.	O

4.3	O
Cardioprotective	O
mechanism	O
by	O
l	B
-cis	I
diltiazem	I
on	O
Ca2	B
+	I
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
In	O
the	O
present	O
model	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
was	O
inhibited	O
by	O
both	O
Ni2	B
+	I
and	O
KB	B
-	I
R7943	I
(	O
Fig.	O
2	O
)	O
.	O

Concerning	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
in	O
this	O
model	O
,	O
the	O
L	O
-	O
type	O
Ca2	B
+	I
channel	O
does	O
not	O
seem	O
to	O
be	O
involved	O
.	O

This	O
is	O
because	O
the	O
dihydropyridine	B
Ca2	B
+	I
channel	O
blockers	O
,	O
nitrendipine	B
and	O
nicardipine	B
,	O
affected	O
neither	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
nor	O
cell	O
shortening	O
(	O
Table	O
1	O
)	O
.	O

The	O
inhibition	O
of	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
may	O
afford	O
protection	O
from	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
previous	O
report	O
has	O
demonstrated	O
that	O
the	O
intracellular	O
Na+	B
concentration	O
(	O
[	O
Na+	B
]	O
i	O
)	O
is	O
increased	O
by	O
metabolic	O
inhibition	O
in	O
guinea	O
pig	O
myocytes	O
(	O
Satoh	O
et	O
al.	O
,	O
1995	O
)	O
.	O

This	O
indicates	O
that	O
Na+	B
overload	O
caused	O
during	O
metabolic	O
inhibition	O
is	O
important	O
in	O
this	O
model	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
previously	O
reported	O
that	O
l	B
-cis	I
diltiazem	I
inhibited	O
veratridine	B
-	O
induced	O
Na+	B
overload	O
in	O
rat	O
cardiac	O
myocytes	O
.	O

Haigney	O
et	O
al.	O
(	O
1992	O
)	O
reported	O
that	O
the	O
[	O
Na+	B
]	O
i	O
increase	O
seen	O
during	O
hypoxia	O
is	O
potentiated	O
after	O
rigor	O
contraction	O
in	O
isolated	O
rat	O
myocytes	O
.	O

They	O
also	O
suggested	O
that	O
inactivation	O
-	O
resistant	O
Na+	B
channels	O
were	O
involved	O
in	O
this	O
[	O
Na+	B
]	O
i	O
increase	O
.	O

We	O
demonstrated	O
in	O
the	O
present	O
study	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
at	O
10	O
μM	O
,	O
when	O
introduced	O
5	O
min	O
before	O
washout	O
of	O
CCCP	B
,	O
attenuated	O
cell	O
shortening	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
it	O
is	O
speculated	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
attenuate	O
Ca2	B
+	I
overload	O
by	O
inhibiting	O
the	O
[	O
Na+	B
]	O
i	O
accumulation	O
early	O
after	O
energy	O
repletion	O
.	O

In	O
conclusion	O
,	O
we	O
first	O
demonstrated	O
that	O
l	B
-cis	I
diltiazem	I
attenuated	O
the	O
Ca2	B
+	I
overload	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	O
pig	O
myocytes	O
.	O

The	O
cardioprotective	O
action	O
of	O
l	B
-cis	I
diltiazem	I
evidenced	O
in	O
the	O
present	O
work	O
merits	O
further	O
research	O
,	O
since	O
l	B
-cis	I
diltiazem	I
could	O
become	O
a	O
lead	O
compound	O
for	O
investigating	O
protection	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
Dr.	O
Satomi	O
Adachi	O
-	O
Akahane	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
helpful	O
discussions	O
and	O
Mr.	O
Shoichi	O
Kanda	O
,	O
Ms.	O
Maki	O
Urata	O
,	O
and	O
Mr.	O
Taichiro	O
Tomida	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
kind	O
assistance	O
with	O
cell	O
preparation	O
.	O

We	O
thank	O
Tanabe	O
Seiyaku	O
for	O
the	O
kind	O
gift	O
of	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
.	O

We	O
thank	O
Kanebo	O
for	O
the	O
kind	O
gift	O
of	O
KB	B
-	I
R	I
7943	I
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Dopamine	B
(	O
DA	B
)	O
is	O
a	O
neurotransmitter	O
that	O
plays	O
a	O
fundamental	O
role	O
in	O
the	O
control	O
of	O
a	O
variety	O
of	O
physiological	O
functions	O
including	O
locomotor	O
movement	O
,	O
learning	O
,	O
reward	O
behavior	O
,	O
and	O
hormone	O
synthesis	O
and	O
release	O
[	O
40	O
]	O
.	O

However	O
,	O
overflow	O
of	O
DA	B
in	O
the	O
brain	O
has	O
been	O
suggested	O
to	O
participate	O
in	O
certain	O
neurodegenerative	O
processes	O
.	O

These	O
include	O
ischemia	O
[	O
6	O
]	O
,	O
hypoxia	O
[	O
2	O
]	O
,	O
and	O
neurotoxicities	O
induced	O
by	O
excitatory	O
amino	B
acids	I
[	O
16	O
]	O
and	O
methamphetamine	B
[	O
38	O
]	O
.	O

In	O
all	O
of	O
the	O
above	O
cases	O
,	O
striatal	O
DA	B
availability	O
in	O
the	O
brain	O
is	O
significantly	O
increased	O
.	O

For	O
example	O
,	O
the	O
striatal	O
DA	B
concentration	O
rapidly	O
reaches	O
concentrations	O
as	O
high	O
as	O
0.2	O
mM	O
after	O
ligation	O
of	O
the	O
cervical	O
artery	O
in	O
the	O
gerbil	O
ischemic	O
model	O
[	O
45	O
]	O
.	O

Depletion	O
of	O
endogenous	O
DA	B
by	O
chemical	O
lesion	O
of	O
the	O
nigrostriatal	O
dopaminergic	O
pathway	O
reduces	O
ischemic	O
insult	O
to	O
the	O
striatum	O
[	O
17	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
DA	B
result	O
in	O
apoptosis	O
and	O
neurodegeneration	O
[	O
18	O
,	O
19	O
]	O
.	O

This	O
DA	B
neurotoxicity	O
is	O
believed	O
to	O
be	O
mediated	O
through	O
a	O
DA	B
-	O
oxidation	O
-	O
associated	O
pathway	O
.	O

DA	B
oxidative	O
stress	O
is	O
also	O
assumed	O
to	O
be	O
a	O
major	O
pathological	O
factor	O
that	O
contributes	O
to	O
dopaminergic	O
neuronal	O
degeneration	O
in	O
Parkinson	O
's	O
disease	O
[	O
14	O
]	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
DA	B
induces	O
apoptosis	O
involving	O
the	O
oxidation	O
–	O
JNK	O
–	O
c	O
-	O
Jun	O
activation	O
pathway	O
in	O
in	O
vitro	O
cell	O
cultures	O
[	O
32	O
]	O
and	O
activation	O
of	O
transcription	O
factors	O
AP-1	O
and	O
NF	O
-	O
κB	O
in	O
an	O
in	O
vivo	O
rat	O
model	O
[	O
29	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
high	O
concentrations	O
of	O
DA	B
in	O
rats	O
also	O
result	O
in	O
activation	O
of	O
astrocytes	O
as	O
indicated	O
by	O
an	O
increase	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
immunocytochemical	O
staining	O
and	O
astrocyte	O
proliferation	O
determined	O
by	O
[	B
3	I
H	I
]	I
R05	I
-	I
4864	I
binding	O
to	O
peripheral	O
benzodiazepine	O
receptors	O
on	O
astrocytes	O
[	O
15	O
]	O
.	O

Astrocytes	O
are	O
the	O
intimate	O
partners	O
of	O
neurons	O
and	O
play	O
important	O
physiological	O
roles	O
in	O
the	O
maintenance	O
of	O
the	O
microenvironment	O
of	O
neurons	O
,	O
including	O
sequestration	O
and	O
metabolism	O
of	O
various	O
neurotransmitters	O
,	O
and	O
production	O
of	O
proinflammatory	O
and	O
immunomodulatory	O
cytokines	O
and	O
neuropeptides	B
[	O
50	O
]	O
.	O

In	O
the	O
rat	O
ischemic	O
model	O
,	O
activated	O
striatal	O
astrocytes	O
appear	O
to	O
play	O
a	O
protective	O
role	O
for	O
DA	O
-	O
innervated	O
neurons	O
[	O
51	O
]	O
.	O

In	O
a	O
cell	O
culture	O
system	O
,	O
striatal	O
astrocytes	O
were	O
also	O
shown	O
to	O
have	O
a	O
protective	O
effect	O
against	O
hydrogen	B
peroxide	I
toxicity	O
in	O
dopaminergic	O
neurons	O
[	O
24	O
]	O
.	O

Nevertheless	O
,	O
the	O
mechanism	O
by	O
which	O
DA	B
activates	O
astrocytes	O
is	O
unknown	O
.	O

To	O
investigate	O
potential	O
signaling	O
of	O
activation	O
of	O
astrocytes	O
by	O
DA	B
,	O
we	O
have	O
chosen	O
a	O
rat	O
C6	O
glioma	O
cell	O
line	O
stably	O
expressing	O
DA	O
D2L	O
receptors	O
based	O
on	O
the	O
following	O
reasons	O
.	O

(	O
1	O
)	O
C6	O
glioma	O
cells	O
have	O
been	O
widely	O
used	O
as	O
a	O
model	O
of	O
glial	O
phenotype	O
[	O
5	O
,	O
39	O
]	O
.	O

(	O
2	O
)	O
Recent	O
evidence	O
suggests	O
that	O
D2	O
receptors	O
are	O
expressed	O
in	O
striatal	O
astrocytes	O
.	O

Physiologically	O
,	O
DA	B
can	O
induce	O
membrane	O
hyperpolarization	O
in	O
the	O
majority	O
of	O
astrocytes	O
from	O
the	O
striatum	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
application	O
of	O
domperidone	B
,	O
a	O
D2	O
receptor	O
antagonist	O
[	O
21	O
]	O
.	O

D2	O
antagonists	O
,	O
[	B
3	I
H	I
]	I
domperidone	I
and	O
[	B
3	I
H	I
]	I
spiperone	I
,	O
can	O
specifically	O
label	O
striatal	O
astrocytes	O
[	O
20	O
]	O
.	O

D2	O
receptor	O
mRNA	O
can	O
be	O
detected	O
by	O
either	O
in	O
situ	O
hybridization	O
or	O
polymerase	O
chain	O
reaction	O
from	O
astrocytes	O
in	O
striatum	O
,	O
an	O
area	O
enriched	O
with	O
dopaminergic	O
termini	O
,	O
but	O
not	O
astrocytes	O
in	O
cerebellum	O
,	O
which	O
receives	O
little	O
dopaminergic	O
innervation	O
[	O
4	O
]	O
.	O

This	O
region	O
-	O
specific	O
expression	O
of	O
D2	O
receptors	O
suggests	O
that	O
dopaminergic	O
neurons	O
may	O
physiologically	O
influence	O
astrocyte	O
functions	O
.	O

(	O
3	O
)	O
C6-D2L	O
cells	O
stably	O
express	O
recombinant	O
D2L	O
DA	O
receptors	O
[	O
36	O
]	O
.	O

The	O
expression	O
level	O
of	O
D2	O
receptors	O
in	O
C6-D2L	O
cells	O
is	O
about	O
188	O
fmol	O
/	O
mg	O
protein	O
,	O
which	O
is	O
close	O
to	O
that	O
in	O
striatal	O
membranes	O
(	O
∼400	O
fmol	O
/	O
mg	O
protein	O
)	O
[	O
30	O
,	O
37	O
]	O
.	O

(	O
4	O
)	O
Like	O
native	O
neuronal	O
D2	O
receptors	O
,	O
the	O
binding	O
of	O
agonist	O
to	O
D2	O
receptors	O
in	O
the	O
C6-D2L	O
cells	O
is	O
functionally	O
coupled	O
to	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
,	O
resulting	O
in	O
inhibition	O
of	O
adenylate	O
cyclase	O
[	O
49	O
]	O
and	O
activation	O
of	O
both	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
(	O
ERKs	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
[	O
30	O
]	O
.	O

Given	O
the	O
fact	O
of	O
C6	O
glial	O
phenotype	O
and	O
D2	O
receptors	O
in	O
striatal	O
astrocytes	O
,	O
the	O
biological	O
functions	O
stimulated	O
by	O
D2	O
receptors	O
observed	O
in	O
C6-D2L	O
cells	O
may	O
mimic	O
those	O
produced	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
C6-D2L	O
cell	O
line	O
may	O
serve	O
as	O
a	O
good	O
in	O
vitro	O
cell	O
culture	O
model	O
for	O
studies	O
of	O
DA	B
regulation	O
of	O
glial	O
response	O
.	O

Using	O
this	O
C6-D2L	O
cell	O
line	O
,	O
we	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	B
stimulate	O
cell	O
proliferation	O
through	O
activation	O
of	O
both	O
ERKs	O
and	O
JNK	O
[	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
found	O
that	O
high	O
concentrations	O
(	O
micromolar	O
levels	O
)	O
of	O
DA	B
stimulate	O
a	O
delayed	O
mitogenesis	O
compared	O
to	O
that	O
induced	O
by	O
the	O
nanomolar	O
levels	O
of	O
DA	B
.	O

This	O
DA	B
-	O
stimulated	O
mitogenesis	O
requires	O
D2-receptor	O
-	O
mediated	O
intracellular	O
redox	O
–	O
tyrosine	O
kinase	O
cascade	O
,	O
but	O
does	O
not	O
need	O
ERK	O
activation	O
.	O

In	O
addition	O
,	O
micromolar	O
levels	O
of	O
DA	B
also	O
increase	O
GFAP	O
expression	O
,	O
which	O
is	O
linked	O
to	O
a	O
D2-receptor	O
-	O
independent	O
p38	O
MAPK	O
activation	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Antibodies	O
against	O
phosphorylated	B
tyrosine	I
(	O
PY99	B
)	O
and	O
ERK2	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Antibodies	O
against	O
phospho	O
-	O
specific	O
ERK	O
and	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
were	O
from	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
.	O

DA	B
,	O
(	B
+	I
)	I
-	I
and	O
(	B
−	I
)	I
-butaclamol	I
hydrochloride	I
,	O
and	O
(	B
−	I
)	I
-quinpirole	I
hydrochloride	I
were	O
from	O
Research	O
Biochemicals	O
International	O
(	O
Natick	O
,	O
MA	O
)	O
.	O

PD098059	B
,	O
p38	O
inhibitor	O
SB	B
203580	I
,	O
diphenyleneiodonium	B
chloride	I
(	O
DPI	B
)	O
,	O
Herbimycin	B
A	I
,	O
Wortmannin	B
,	O
H7	B
,	O
and	O
staurosporine	B
were	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Pertussis	O
toxin	O
(	O
PTX	O
)	O
and	O
N	B
-acetyl	I
-	I
l	I
-cysteine	I
(	O
NAC	B
)	O
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
.	O

[	B
3	I
H	I
]	I
Thymidine	I
was	O
purchased	O
form	O
Amersham	O
(	O
Arlington	O
Heights	O
,	O
IL	O
)	O
.	O

Genistein	B
was	O
from	O
Gibco	O
BRL	O
(	O
Gaithersburg	O
,	O
MD	O
)	O
.	O

Hoechst	B
33342	I
was	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O

2.2	O
Cell	O
culture	O
and	O
treatments	O
Stably	O
transfected	O
C6-D2L	O
cells	O
were	O
prepared	O
as	O
described	O
[	O
46	O
]	O
and	O
maintained	O
in	O
Dulbecco	B
's	I
modified	I
Eagle	I
's	I
medium	I
(	O
DMEM	B
)	O
supplemented	O
with	O
5	O
%	O
fetal	O
bovine	O
serum	O
and	O
5	O
%	O
donor	O
calf	O
serum	O
with	O
penicillin	B
/	O
streptomycin	B
and	O
puromycin	B
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

The	O
wild	O
-	O
type	O
C6	O
cells	O
were	O
maintained	O
in	O
the	O
above	O
medium	O
without	O
puromycin	B
.	O

For	O
tyrosine	B
phosphorylation	O
and	O
GFAP	O
studies	O
,	O
the	O
cells	O
were	O
starved	O
with	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	B
acid	I
for	O
6–8	O
h	O
and	O
then	O
stimulated	O
with	O
indicated	O
reagents	O
.	O

All	O
reagents	O
were	O
prepared	O
or	O
diluted	O
with	O
DMEM	B
plus	O
0.025	O
%	O
ascorbic	B
acid	I
.	O

For	O
inhibitory	O
experiments	O
,	O
all	O
inhibitory	O
reagents	O
except	O
PTX	O
were	O
added	O
0.5	O
h	O
(	O
PTX	O
for	O
6	O
h	O
)	O
prior	O
to	O
stimulation	O
with	O
DA	B
.	O

2.3	O
Lysate	O
preparation	O
After	O
stimulation	O
,	O
the	O
cells	O
were	O
immediately	O
washed	O
twice	O
using	O
cold	O
PBS	B
and	O
then	O
solubilized	O
with	O
ice	O
-	O
cold	O
buffer	O
consisting	O
of	O
25	O
mM	O
Hepes	B
,	O
pH	O
7.5	O
,	O
300	O
mM	O
NaCl	B
,	O
1.5	O
mM	O
MgCl2	B
,	O
0.2	O
mM	O
EDTA	B
,	O
0.1	O
%	O
Triton	B
X-100	I
,	O
20	O
mM	O
β	B
-	I
glycerophosphate	I
,	O
0.1	O
mM	O
sodium	B
orthovanadate	I
,	O
0.5	O
mM	O
DTT	B
,	O
100	O
μg	O
/	O
ml	O
PMSF	B
,	O
and	O
2	O
μg	O
/	O
ml	O
leupeptin	B
.	O

Cellular	O
extracts	O
were	O
cleared	O
by	O
centrifugation	O
for	O
30	O
min	O
at	O
14,000	O
rpm	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatants	O
were	O
saved	O
and	O
the	O
protein	O
concentration	O
was	O
determined	O
using	O
Bio	B
-	I
Rad	I
protein	I
reagent	I
.	O

For	O
determination	O
of	O
GFAP	O
,	O
the	O
cell	O
lysates	O
were	O
prepared	O
as	O
follows	O
.	O

Stimulated	O
cells	O
were	O
scraped	O
and	O
collected	O
by	O
centrifugation	O
for	O
5	O
min	O
at	O
3000	O
rpm	O
.	O

The	O
cell	O
pellets	O
were	O
washed	O
once	O
with	O
cold	O
PBS	B
,	O
pH	O
7.4	O
,	O
solubilized	O
with	O
hot	O
lysis	O
buffer	O
(	O
80–90	O
°	O
C	O
)	O
containing	O
10	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
7.6	O
,	O
150	O
mM	O
NaCl	B
,	O
0.5	O
mm	O
EDTA	B
,	O
1	O
mM	O
EGTA	B
,	O
1	O
%	O
sodium	B
dodecyl	I
sulfate	I
(	O
SDS	B
)	O
,	O
1	O
mM	O
sodium	O
orthovanadate	O
,	O
1	O
mM	O
PMSF	B
,	O
1	O
μg	O
/	O
ml	O
pepstatin	B
A	I
,	O
and	O
2	O
μg	O
/	O
ml	O
aprotinin	O
,	O
and	O
heated	O
for	O
20	O
min	O
at	O
90	O
°	O
C	O
.	O

The	O
protein	O
concentration	O
of	O
the	O
lysates	O
was	O
determined	O
by	O
using	O
Micro	B
BCA	I
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
.	O

All	O
lysates	O
were	O
used	O
immediately	O
or	O
aliquoted	O
and	O
stored	O
at	O
−70	O
°	O
C	O
for	O
further	O
use	O
.	O

2.4	O
Immunoblotting	O
Equal	O
amounts	O
of	O
lysate	O
protein	O
(	O
40	O
μg	O
/	O
lane	O
)	O
were	O
run	O
on	O
8–16	O
%	O
SDS	O
-	O
PAGE	O
and	O
electrophoretically	O
transferred	O
to	O
nitrocellulose	B
.	O

The	O
nitrocellulose	B
blot	O
was	O
blocked	O
with	O
10	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
in	O
TBST	B
buffer	I
(	O
20	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
7.4	O
,	O
500	O
mM	O
NaCl	B
,	O
and	O
0.01	O
%	O
Tween-20	B
)	O
and	O
then	O
incubated	O
with	O
primary	O
antibodies	O
(	O
phospho	O
-	O
specific	O
ERK	O
,	O
ERK2	O
,	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
,	O
or	O
PY99	O
,	O
1:1000	O
)	O
in	O
TBST	B
containing	O
5	O
%	O
BSA	O
overnight	O
at	O
4	O
°	O
C	O
.	O

The	O
immunoreactive	O
bands	O
were	O
detected	O
by	O
sequential	O
incubation	O
with	O
horseradish	O
-	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
1:5000	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
)	O
and	O
Renaissance	O
substrate	O
(	O
DuPont	O
;	O
Boston	O
,	O
MA	O
)	O
.	O

For	O
control	O
of	O
protein	O
loading	O
,	O
immunoblotting	O
with	O
ERK2	O
was	O
performed	O
using	O
either	O
a	O
sister	O
gel	O
or	O
a	O
stripped	O
blot	O
.	O

For	O
quantitative	O
studies	O
,	O
the	O
band	O
was	O
quantified	O
with	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
results	O
were	O
normalized	O
to	O
fold	O
of	O
control	O
and	O
presented	O
as	O
means±S.E.M.	O
2.5	O
Measurement	O
of	O
mitogenesis	O
The	O
procedures	O
were	O
described	O
elsewhere	O
[	O
31	O
]	O
.	O

C6-D2L	O
cells	O
(	O
1	O
×	O
105	O
/ml	O
,	O
0.2	O
ml	O
/	O
well	O
)	O
were	O
plated	O
in	O
a	O
96-well	O
plate	O
and	O
grown	O
for	O
24	O
h.	O
The	O
cells	O
were	O
rinsed	O
twice	O
with	O
serum	O
-	O
free	O
DMEM	B
and	O
starved	O
for	O
8	O
h	O
in	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	B
acid	I
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
incubated	O
with	O
DA	B
for	O
23	O
h	O
and	O
pulsed	O
with	O
2	O
μCi	O
[	B
3	I
H	I
]	I
thymidine	I
per	O
well	O
for	O
an	O
additional	O
6	O
h.	O
The	O
cells	O
in	O
each	O
well	O
were	O
fixed	O
with	O
ice	O
-	O
cold	O
5	O
%	O
trichloroacetic	B
acid	I
,	O
washed	O
three	O
times	O
with	O
cold	O
STE	B
buffer	I
(	O
150	O
mM	O
NaCl	B
,	O
50	O
mM	O
Tris	B
–	I
HCl	I
,	O
pH	O
7.2	O
,	O
1	O
mM	O
EDTA	B
)	O
,	O
and	O
solubilized	O
with	O
0.1	O
ml	O
of	O
a	O
mixture	O
of	O
0.1	O
%	O
SDS	B
and	O
0.01	O
N	O
NaOH	B
.	O

Incorporated	O
[	B
3	I
H	I
]	I
thymidine	I
was	O
counted	O
with	O
a	O
Beckman	O
liquid	O
scintillation	O
counter	O
and	O
expressed	O
as	O
counts	O
per	O
minute	O
per	O
well	O
(	O
cpm	O
/	O
well	O
)	O
.	O

2.6	O
Cell	O
cycle	O
analysis	O
by	O
flow	O
cytometry	O
Cell	O
cycle	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
method	O
by	O
Chrest	O
et	O
al.	O
[	O
9	O
]	O
.	O

Briefly	O
,	O
C6-D2L	O
cells	O
were	O
plated	O
in	O
35	O
mm	O
dishes	O
,	O
and	O
seeded	O
overnight	O
.	O

The	O
cells	O
were	O
starved	O
for	O
8	O
h	O
by	O
replacing	O
the	O
mixture	O
of	O
DMEM	B
plus	O
0.025	O
%	O
ascorbic	B
acid	I
and	O
stimulated	O
for	O
29	O
h.	O
The	O
cells	O
were	O
then	O
collected	O
and	O
suspended	O
in	O
complete	O
cell	O
culture	O
medium	O
.	O

The	O
cells	O
(	O
1	O
×	O
106	O
cells	O
/	O
ml	O
)	O
were	O
treated	O
with	O
1	O
μM	O
Hoechst	B
33342	I
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

Cells	O
were	O
analyzed	O
for	O
DNA	O
content	O
using	O
a	O
FACStarplus	O
flow	O
cytometer	O
(	O
Becton	O
Dickinson	O
Immunocytometry	O
System	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
equipped	O
with	O
argon	B
and	O
krypton	B
lasers	O
.	O

Hoechst	B
33342	I
stained	O
cells	O
were	O
excited	O
with	O
350–356	O
nm	O
wavelength	O
UV	O
light	O
from	O
the	O
krypton	B
laser	O
and	O
the	O
fluorescence	O
emission	O
was	O
collected	O
with	O
a	O
424-nm	O
filter	O
.	O

DNA	O
histograms	O
were	O
acquired	O
by	O
collecting	O
a	O
total	O
of	O
10,000	O
events	O
.	O

Cell	O
compartments	O
,	O
including	O
G1	O
,	O
S	O
,	O
and	O
G2	O
/M	O
phases	O
,	O
were	O
determined	O
using	O
the	O
Multicycle	O
software	O
(	O
Phoenix	O
Flow	O
Systems	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

3	O
Results	O
3.1	O
DA	B
stimulates	O
mitogenesis	O
We	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	B
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
[	O
30	O
]	O
.	O

The	O
maximal	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
occurs	O
at	O
17	O
h	O
after	O
exposure	O
to	O
100	O
nM	O
DA	B
concentration	O
.	O

We	O
extended	O
this	O
study	O
by	O
observing	O
the	O
cell	O
response	O
at	O
high	O
DA	B
concentrations	O
and	O
longer	O
exposure	O
.	O

Interestingly	O
,	O
micromolar	O
levels	O
of	O
DA	B
also	O
stimulate	O
DNA	O
synthesis	O
but	O
with	O
a	O
slower	O
time	O
course	O
(	O
about	O
29	O
h	O
after	O
DA	B
stimulation	O
,	O
data	O
not	O
shown	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
DA	B
stimulated	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

The	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
was	O
linearly	O
increased	O
from	O
0.1	O
to	O
500	O
μM	O
DA	B
.	O

The	O
mitogenic	O
activity	O
at	O
500	O
μM	O
DA	B
was	O
about	O
3.2±0.2	O
times	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

This	O
DA	B
-	O
induced	O
mitogenesis	O
could	O
be	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
aphidicoline	B
(	O
20	O
μg	O
/	O
ml	O
,	O
data	O
not	O
shown	O
)	O
,	O
a	O
potent	O
DNA	O
polymerase	O
a	O
inhibitor	O
.	O

To	O
confirm	O
the	O
DA	B
mitogenic	O
activation	O
,	O
we	O
also	O
determined	O
the	O
cell	O
cycle	O
distribution	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
200	O
μM	O
DA	B
increased	O
the	O
percentage	O
of	O
the	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
of	O
cells	O
in	O
G1	O
phase	O
,	O
suggesting	O
that	O
DA	B
promotes	O
progression	O
through	O
the	O
cell	O
cycle	O
.	O

Next	O
,	O
we	O
tested	O
whether	O
this	O
DA	B
-	O
stimulated	O
mitogenesis	O
requires	O
activation	O
of	O
D2	O
receptors	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
10	O
μM	O
(	B
+	I
)	I
-butaclamol	I
,	O
a	O
potent	O
D2	O
receptor	O
antagonist	O
,	O
completely	O
inhibited	O
DA	B
-	O
induced	O
DNA	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
,	O
while	O
10	O
μM	O
(	B
−	I
)	I
-butaclamol	I
,	O
an	O
inactive	O
form	O
of	O
(	B
+	I
)	I
-butaclamol	I
,	O
had	O
no	O
effect	O
on	O
the	O
DA	B
-	O
stimulated	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

To	O
confirm	O
these	O
results	O
,	O
we	O
determined	O
the	O
effect	O
of	O
quinpirole	B
,	O
a	O
specific	O
D2	O
receptor	O
agonist	O
,	O
on	O
cell	O
cycling	O
.	O

Like	O
the	O
effect	O
of	O
micromolar	O
levels	O
of	O
DA	B
,	O
micromolar	O
levels	O
of	O
quinpirole	B
promoted	O
cell	O
proliferation	O
.	O

Quinpirole	B
increased	O
the	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
in	O
G1	O
phase	O
(	O
Table	O
1	O
)	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
mitogenic	O
effect	O
within	O
a	O
DA	B
concentration	O
range	O
of	O
0–500	O
μM	O
in	O
wild	O
-	O
type	O
C6	O
cells	O
without	O
expression	O
of	O
D2L	O
receptors	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

Instead	O
,	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
of	O
wild	O
-	O
type	O
C6	O
cells	O
was	O
decreased	O
about	O
20–26	O
%	O
at	O
DA	B
concentrations	O
from	O
10	O
to	O
500	O
μM	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	O
,	O
a	O
G	O
protein	O
-	O
receptor	O
uncoupler	O
,	O
partially	O
blocked	O
DA	B
-	O
stimulated	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
this	O
DA	B
-	O
stimulated	O
mitogenesis	O
requires	O
DA	B
D2	O
receptor	O
activation	O
.	O

3.2	O
Effects	O
of	O
kinase	O
inhibitors	O
on	O
DA	B
-	O
induced	O
mitogenesis	O
In	O
order	O
to	O
examine	O
the	O
signaling	O
that	O
mediates	O
the	O
DA	B
-	O
stimulated	O
mitogenesis	O
,	O
we	O
first	O
tested	O
the	O
effect	O
of	O
DA	B
on	O
the	O
activity	O
of	O
ERK	O
,	O
a	O
protein	O
serine	O
kinase	O
that	O
is	O
linked	O
to	O
cell	O
proliferation	O
stimulated	O
by	O
growth	O
factors	O
,	O
cytokines	O
and	O
neurotransmitters	O
[	O
11	O
,	O
34	O
]	O
.	O

As	O
shown	O
in	O
the	O
phospho	O
-	O
specific	O
ERK	O
immunoblot	O
of	O
Fig.	O
2	O
a	O
,	O
DA	B
had	O
little	O
or	O
no	O
effect	O
on	O
ERK	O
phosphorylation	O
at	O
concentrations	O
corresponding	O
to	O
its	O
mitogenic	O
effect	O
(	O
10–500	O
μM	O
)	O
,	O
although	O
DA	B
at	O
lower	O
concentrations	O
did	O
stimulate	O
ERK	O
phosphorylation	O
and	O
activity	O
[	O
30	O
]	O
.	O

The	O
bottom	O
panel	O
in	O
Fig.	O
2	O
a	O
shows	O
ERK2	O
immunoblot	O
of	O
a	O
sister	O
gel	O
,	O
indicating	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
.	O

To	O
confirm	O
that	O
ERK	O
was	O
not	O
involved	O
in	O
DA	B
-	O
induced	O
mitogenesis	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
PD098059	B
,	O
a	O
selective	O
MEK1	O
inhibitor	O
[	O
3	O
]	O
,	O
on	O
DA	B
-	O
induced	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
2	O
b	O
,	O
the	O
DA	B
-	O
stimulated	O
DNA	O
synthesis	O
was	O
only	O
partially	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
PD	B
098059	I
(	O
10–50	O
μM	O
)	O
(	O
Fig.	O
2	O
b	O
)	O
.	O

With	O
application	O
of	O
either	O
10	O
or	O
50	O
μM	O
PD	B
098059	I
,	O
bFGF	O
-	O
stimulated	O
ERK	O
activity	O
,	O
as	O
indicated	O
by	O
ERK	O
phosphorylation	O
,	O
was	O
greatly	O
or	O
completely	O
inhibited	O
,	O
respectively	O
(	O
Fig.	O
2	O
c	O
)	O
,	O
which	O
serves	O
as	O
a	O
positive	O
control	O
of	O
the	O
inhibitory	O
effect	O
of	O
PD098059	B
on	O
MEK1–ERK	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
mitogenesis	O
induced	O
by	O
micromolar	O
levels	O
of	O
DA	B
is	O
not	O
mediated	O
by	O
a	O
MEK	O
–	O
ERK	O
activation	O
pathway	O
.	O

We	O
have	O
also	O
tested	O
other	O
kinase	O
inhibitors	O
on	O
DA	B
-	O
stimulated	O
mitogenesis	O
.	O

These	O
inhibitors	O
included	O
Wortmannin	B
for	O
PI3	O
kinase	O
,	O
rapamycin	B
for	O
S6	O
kinase	O
,	O
and	O
SB203580	B
for	O
p38	O
MAP	O
kinase	O
.	O

Staurosporine	O
and	O
H7	O
are	O
inhibitors	O
for	O
a	O
broad	O
spectrum	O
of	O
protein	O
kinases	O
,	O
which	O
include	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
G	O
,	O
CaM	O
kinase	O
,	O
and	O
myosin	O
light	O
chain	O
kinase	O
.	O

The	O
effect	O
of	O
depletion	O
of	O
PKC	O
on	O
DA	B
-	O
stimulated	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
was	O
also	O
examined	O
by	O
prolonged	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
.	O

The	O
data	O
are	O
summarized	O
on	O
Table	O
2	O
.	O

All	O
these	O
treatments	O
had	O
no	O
effect	O
on	O
DA	B
-	O
induced	O
DNA	O
synthesis	O
.	O

3.3	O
DA	B
stimulates	O
mitogenesis	O
-	O
associated	O
protein	O
tyrosine	B
phosphorylation	O
DA	B
stimulated	O
protein	O
tyrosine	B
phosphorylation	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
3	O
a	O
and	O
b	O
)	O
.	O

The	O
phosphorylated	B
tyrosine	I
-	O
containing	O
proteins	O
were	O
easily	O
immunodetected	O
with	O
monoclonal	O
anti	O
-	O
phosphotyrosine	O
IgG	O
(	O
PY99	O
)	O
.	O

When	O
C6-D2L	O
cells	O
were	O
treated	O
with	O
200	O
μM	O
DA	B
,	O
protein	O
tyrosine	B
phosphorylation	O
rapidly	O
increased	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
between	O
15	O
and	O
30	O
min	O
,	O
then	O
decreased	O
by	O
1	O
h	O
(	O
Fig.	O
3	O
a	O
)	O
.	O

A	O
majority	O
of	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
were	O
located	O
within	O
the	O
molecular	O
size	O
range	O
of	O
50–200	O
kDa	O
,	O
some	O
of	O
which	O
are	O
indicated	O
by	O
arrows	O
in	O
Fig.	O
3	O
a.	O
DA	B
-	O
stimulated	O
tyrosine	B
phosphorylation	O
was	O
evident	O
within	O
DA	B
concentrations	O
ranging	O
from	O
10	O
to	O
500	O
μM	O
(	O
Fig.	O
3	O
b	O
)	O
,	O
which	O
paralleled	O
the	O
DA	B
concentrations	O
for	O
stimulation	O
of	O
mitogenesis	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

To	O
monitor	O
the	O
amounts	O
of	O
protein	O
loaded	O
,	O
all	O
blots	O
were	O
stripped	O
and	O
then	O
immunoblotted	O
with	O
anti	O
-	O
ERK2	O
.	O

The	O
lower	O
anti	O
-	O
ERK2	O
immunoblottings	O
in	O
Fig.	O
3	O
a	O
and	O
b	O
show	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
.	O

This	O
protein	O
tyrosine	B
phosphorylation	O
,	O
mostly	O
at	O
molecular	O
sizes	O
between	O
50	O
and	O
150	O
kDa	O
,	O
required	O
D2	O
receptor	O
activation	O
.	O

Preincubation	O
of	O
C6-D2L	O
cells	O
30	O
min	O
with	O
(	B
+	I
)	I
-butaclamol	I
,	O
a	O
specific	O
D2	O
receptor	O
antagonist	O
,	O
could	O
block	O
DA	B
-	O
induced	O
protein	O
tyrosine	B
phosphorylation	O
(	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
antagonistic	O
effect	O
was	O
concentration	O
-	O
dependent	O
.	O

Increasing	O
(	B
+	I
)	I
-butaclamol	I
from	O
1	O
to	O
100	O
μM	O
resulted	O
in	O
significant	O
inhibition	O
of	O
protein	O
tyrosine	B
phosphorylation	O
.	O

Especially	O
in	O
the	O
presence	O
of	O
100	O
μM	O
(	B
+	I
)	I
-butaclamol	I
,	O
the	O
cells	O
failed	O
to	O
respond	O
to	O
200	O
μM	O
DA	B
stimulation	O
(	O
upper	O
left	O
panel	O
,	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
blocking	O
effect	O
was	O
specific	O
to	O
D2	O
receptors	O
since	O
application	O
of	O
the	O
same	O
amount	O
of	O
(	B
−	I
)	I
-butaclamol	I
,	O
an	O
inactive	O
form	O
of	O
(	B
+	I
)	I
-butaclamol	I
,	O
did	O
not	O
show	O
any	O
effect	O
on	O
DA	B
-	O
stimulated	O
tyrosine	B
phosphorylation	O
.	O

We	O
have	O
also	O
directly	O
tested	O
the	O
effect	O
of	O
quinpirole	B
,	O
a	O
D2	O
receptor	O
agonist	O
,	O
on	O
protein	O
tyrosine	B
phosphorylation	O
.	O

As	O
shown	O
in	O
the	O
right	O
panel	O
of	O
Fig.	O
3	O
c	O
,	O
increasing	O
quinpirole	B
from	O
10	O
to	O
200	O
μM	O
resulted	O
in	O
a	O
great	O
increase	O
in	O
the	O
amount	O
of	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
.	O

Furthermore	O
,	O
we	O
could	O
not	O
observe	O
significant	O
changes	O
in	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
in	O
wild	O
-	O
type	O
C6	O
cells	O
treated	O
with	O
DA	B
concentrations	O
from	O
10	O
to	O
500	O
μM	O
(	O
data	O
not	O
shown	O
)	O
.	O

Inactivation	O
of	O
cellular	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
by	O
PTX	O
partially	O
blocked	O
DA	B
-	O
induced	O
protein	O
tyrosine	B
phosphorylation	O
.	O

We	O
have	O
quantified	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
between	O
50	O
and	O
150	O
kDa	O
by	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
500	O
ng	O
/	O
ml	O
PTX	O
inhibited	O
DA	B
(	O
200	O
μM	O
)	O
-stimulated	O
tyrosine	B
phosphorylation	O
by	O
57±15	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

PTX	O
at	O
a	O
concentration	O
of	O
100	O
ng	O
/	O
ml	O
also	O
reduced	O
the	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
by	O
24±13	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

Coincidentally	O
,	O
this	O
percentage	O
of	O
reduction	O
of	O
tyrosine	B
phosphorylation	O
by	O
100	O
ng	O
/	O
ml	O
PTX	O
is	O
close	O
to	O
its	O
inhibitory	O
ability	O
(	O
32±10	O
%	O
,	O
n	O
=3	O
,	O
Fig.	O
1	O
b	O
)	O
to	O
DA	B
-	O
stimulated	O
mitogenesis	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
D2	O
receptor	O
activation	O
is	O
associated	O
with	O
protein	O
tyrosine	O
kinase	O
activity	O
.	O

In	O
order	O
to	O
test	O
the	O
idea	O
that	O
tyrosine	O
kinase	O
is	O
involved	O
in	O
DA	B
-	O
stimulated	O
mitogenesis	O
,	O
we	O
examined	O
the	O
effect	O
of	O
genistein	B
,	O
a	O
potent	O
tyrosine	O
kinase	O
inhibitor	O
,	O
on	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
a	O
,	O
preincubation	O
of	O
either	O
genistein	B
or	O
herbimycin	B
(	O
another	O
tyrosine	O
kinase	O
inhibitor	O
)	O
significantly	O
blocked	O
the	O
protein	O
tyrosine	B
phosphorylation	O
stimulated	O
by	O
200	O
μM	O
DA	B
.	O

Application	O
of	O
10	O
μM	O
genistein	B
completely	O
inhibited	O
the	O
DNA	O
synthesis	O
induced	O
by	O
DA	B
(	O
Fig.	O
4	O
b	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
activation	O
of	O
protein	O
tyrosine	O
kinase	O
is	O
required	O
for	O
the	O
promotion	O
of	O
mitogenesis	O
induced	O
by	O
DA	B
.	O

3.4	O
DA	B
-	O
induced	O
mitogenesis	O
is	O
involved	O
in	O
an	O
intracellular	O
redox	O
–	O
tyrosine	B
phosphorylation	O
pathway	O
Although	O
reactive	B
oxygen	I
species	I
(	O
ROS	B
)	O
are	O
implicated	O
in	O
pathological	O
cellular	O
processes	O
,	O
including	O
oxidative	O
stress	O
damage	O
[	O
47	O
]	O
and	O
ischemic	O
neuronal	O
injury	O
[	O
10	O
]	O
,	O
recent	O
evidence	O
suggests	O
that	O
ROS	B
are	O
involved	O
in	O
cell	O
signaling	O
that	O
regulates	O
proliferation	O
and	O
DNA	O
synthesis	O
[	O
22	O
]	O
.	O

To	O
test	O
the	O
idea	O
that	O
D2	O
receptors	O
stimulate	O
mitogenesis	O
through	O
regulation	O
of	O
an	O
intracellular	O
redox	O
–	O
tyrosine	O
kinase	O
cascade	O
,	O
we	O
examined	O
the	O
effect	O
of	O
diphenylene	B
iodonium	I
(	O
DPI	B
)	O
and	O
N	B
-acetyl	I
cysteine	I
(	O
NAC	B
)	O
on	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
.	O

DPI	B
is	O
an	O
inhibitor	O
of	O
flavonoid	B
-	O
containing	O
oxidases	O
that	O
can	O
catalyze	O
the	O
formation	O
of	O
superoxide	B
from	O
oxygen	B
with	O
NADH	B
/	O
NADPH	B
as	O
an	O
electron	O
donor	O
[	O
28	O
,	O
43	O
]	O
.	O

Some	O
flavonoid	B
-	O
containing	O
oxidases	O
,	O
such	O
as	O
NADPH	B
-	O
dependent	O
oxidase	O
,	O
have	O
been	O
shown	O
to	O
be	O
regulated	O
by	O
a	O
variety	O
of	O
membrane	O
receptors	O
,	O
such	O
as	O
intrinsic	O
tyrosine	O
-	O
kinase	O
-	O
containing	O
receptors	O
and	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
[	O
22	O
,	O
23	O
]	O
.	O

NAC	B
is	O
an	O
antioxidant	O
that	O
can	O
scavenge	O
free	B
radicals	I
.	O

Pretreatment	O
of	O
C6-D2L	O
cells	O
with	O
either	O
1	O
μM	O
DPI	B
or	O
20	O
mM	O
NAC	B
greatly	O
reduced	O
tyrosine	B
phosphorylation	O
and	O
consequent	O
mitogenesis	O
induced	O
by	O
DA	B
(	O
Fig.	O
5	O
a	O
and	O
b	O
)	O
.	O

Either	O
DPI	B
or	O
NAC	B
itself	O
has	O
no	O
effect	O
on	O
tyrosine	B
phosphorylation	O
of	O
proteins	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
anti	O
-	O
ERK2	O
immunoblotting	O
of	O
same	O
stripped	O
blot	O
shows	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
in	O
each	O
lane	O
(	O
lower	O
panel	O
,	O
Fig.	O
5	O
a	O
)	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
the	O
protein	O
tyrosine	O
kinase	O
and	O
consequent	O
mitogenesis	O
may	O
be	O
regulated	O
by	O
intracellular	O
ROS	B
,	O
which	O
are	O
assumed	O
to	O
be	O
produced	O
by	O
flavonoid	B
-	O
containing	O
oxidases	O
.	O

Next	O
,	O
we	O
tested	O
the	O
roles	O
of	O
ROS	B
in	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
by	O
application	O
of	O
exogenous	O
H2	B
O2	I
.	O

We	O
assumed	O
that	O
the	O
protein	O
tyrosine	O
kinase	O
could	O
be	O
activated	O
by	O
DA	B
-	O
stimulated	O
increase	O
of	O
intracellular	O
ROS	B
.	O

If	O
this	O
is	O
the	O
case	O
,	O
exogenous	O
application	O
of	O
low	O
concentrations	O
of	O
H2	B
O2	I
may	O
enhance	O
protein	O
kinase	O
activity	O
and	O
subsequent	O
mitogenesis	O
induced	O
by	O
DA	B
.	O

As	O
shown	O
in	O
Fig.	O
6	O
a	O
,	O
increasing	O
extracellular	O
H2	B
O2	I
concentrations	O
did	O
result	O
in	O
increase	O
of	O
DA	B
-	O
induced	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
.	O

The	O
upper	O
panel	O
shows	O
anti	O
-	O
phosphotyrosine	O
immunoblotting	O
,	O
while	O
the	O
lower	O
panel	O
is	O
a	O
quantified	O
data	O
(	O
from	O
50	O
to	O
150	O
kDa	O
)	O
of	O
at	O
least	O
three	O
experiments	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
sister	O
gel	O
was	O
run	O
and	O
immunostained	O
with	O
anti	O
-	O
ERK2	O
to	O
monitor	O
protein	O
loading	O
.	O

The	O
nanomolar	O
levels	O
of	O
H2	B
O2	I
enhanced	O
by	O
about	O
2.7-fold	O
amounts	O
of	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
stimulated	O
by	O
10	O
μM	O
DA	B
,	O
although	O
H2	B
O2	I
levels	O
below	O
1	O
nM	O
show	O
only	O
a	O
small	O
effect	O
(	O
Fig.	O
6	O
a	O
)	O
.	O

Furthermore	O
,	O
an	O
enhancement	O
effect	O
of	O
H2	B
O2	I
on	O
DA	B
-	O
stimulated	O
mitogenesis	O
was	O
also	O
observed	O
(	O
Fig.	O
6	O
b	O
)	O
.	O

However	O
,	O
the	O
capability	O
of	O
increasing	O
DA	B
-	O
induced	O
mitogenesis	O
at	O
nanomolar	O
levels	O
of	O
H2	B
O2	I
was	O
reduced	O
when	O
compared	O
with	O
that	O
at	O
0.1	O
pM	O
H2	B
O2	I
(	O
Fig.	O
6	O
b	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
a	O
dual	O
effect	O
of	O
ROS	O
in	O
cell	O
proliferation	O
:	O
a	O
stimulatory	O
effect	O
at	O
low	O
concentrations	O
and	O
a	O
toxic	O
effect	O
at	O
high	O
concentrations	O
[	O
22	O
]	O
.	O

With	O
the	O
application	O
of	O
H2	B
O2	I
alone	O
without	O
DA	B
,	O
C6-D2L	O
cells	O
did	O
exhibit	O
such	O
a	O
dual	O
mitogenic	O
effect	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.5	O
DA	B
increases	O
GFAP	O
expression	O
In	O
addition	O
to	O
stimulating	O
DNA	O
synthesis	O
,	O
DA	B
at	O
micromolar	O
levels	O
also	O
significantly	O
increased	O
the	O
expression	O
of	O
GFAP	O
,	O
a	O
sensitive	O
parameter	O
serving	O
as	O
another	O
criterion	O
of	O
reactive	O
astrocytes	O
[	O
33	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
7	O
a	O
,	O
C6-D2L	O
cells	O
responded	O
to	O
DA	B
(	O
200	O
μM	O
)	O
treatment	O
with	O
an	O
increase	O
in	O
GFAP	O
expression	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Between	O
0	O
and	O
48	O
h	O
after	O
stimulation	O
,	O
the	O
amount	O
of	O
GFAP	O
was	O
increased	O
about	O
2.1±0.1-fold	O
(	O
Fig.	O
7	O
a	O
)	O
.	O

Concentration	O
dependence	O
studies	O
carried	O
out	O
at	O
24	O
h	O
showed	O
that	O
maximal	O
stimulation	O
of	O
GFAP	O
expression	O
occurred	O
at	O
200	O
μM	O
DA	B
(	O
Fig.	O
7	O
b	O
)	O
.	O

Interestingly	O
,	O
GFAP	O
production	O
was	O
decreased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
500	O
μM	O
DA	B
for	O
24	O
h	O
(	O
Fig.	O
7	O
b	O
)	O
,	O
which	O
differs	O
from	O
the	O
dose	O
–	O
response	O
data	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
)	O
.	O

This	O
observation	O
suggests	O
that	O
DA	B
stimulatory	O
GFAP	O
synthesis	O
may	O
be	O
regulated	O
by	O
a	O
different	O
pathway	O
from	O
mitogenesis	O
.	O

Alternatively	O
,	O
this	O
decrease	O
of	O
GFAP	O
expression	O
at	O
500	O
μM	O
DA	B
may	O
be	O
due	O
to	O
widespread	O
mitogenesis	O
since	O
immature	O
astrocytes	O
have	O
a	O
less	O
amount	O
of	O
GFAP	O
expression	O
.	O

3.6	O
DA	B
-	O
induced	O
GFAP	O
generation	O
involves	O
activation	O
of	O
p38	O
MAPK	O
It	O
became	O
important	O
to	O
determine	O
whether	O
DA	B
-	O
stimulated	O
GFAP	O
production	O
might	O
also	O
be	O
required	O
to	O
activate	O
the	O
D2	O
receptor	O
–	O
tyrosine	O
kinase	O
pathway	O
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
used	O
a	O
paradigm	O
similar	O
to	O
that	O
for	O
DA	B
-	O
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
(	O
Fig.	O
1	O
)	O
.	O

Surprisingly	O
,	O
the	O
GFAP	O
stimulation	O
did	O
not	O
appear	O
to	O
be	O
regulated	O
by	O
D2	O
receptors	O
since	O
it	O
was	O
not	O
influenced	O
by	O
the	O
D2	O
receptor	O
antagonist	O
,	O
(	B
+	I
)	I
-butaclamol	I
(	O
Fig.	O
8	O
a	O
)	O
.	O

Application	O
of	O
DA	B
to	O
wild	O
-	O
type	O
C6	O
cells	O
also	O
resulted	O
in	O
a	O
similar	O
increase	O
in	O
GFAP	O
expression	O
as	O
that	O
in	O
C6-D2L	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
direct	O
application	O
of	O
quinpirole	B
(	O
200	O
μM	O
)	O
,	O
a	O
D2	O
receptor	O
agonist	O
,	O
had	O
no	O
effect	O
on	O
GFAP	O
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
PTX	O
for	O
6	O
h	O
had	O
no	O
effect	O
on	O
DA	B
-	O
stimulated	O
GFAP	O
generation	O
(	O
Fig.	O
8	O
a	O
)	O
,	O
suggesting	O
that	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
might	O
also	O
not	O
be	O
involved	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
either	O
10	O
μM	O
genistein	B
or	O
20	O
mM	O
NAC	B
also	O
had	O
no	O
effect	O
on	O
GFAP	O
expression	O
due	O
to	O
DA	B
(	O
Fig.	O
8	O
a	O
)	O
,	O
while	O
the	O
identical	O
treatments	O
resulted	O
in	O
the	O
blocking	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
4	O
b	O
,	O
Fig.	O
5	O
b	O
)	O
.	O

PD098059	B
also	O
had	O
no	O
effect	O
on	O
DA	B
-	O
stimulated	O
GFAP	O
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Thus	O
,	O
unlike	O
DA	B
-	O
induced	O
mitogenesis	O
,	O
GFAP	O
stimulation	O
does	O
not	O
seem	O
to	O
involve	O
the	O
D2	O
receptor	O
–	O
tyrosine	O
kinase	O
pathway	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
GFAP	O
expression	O
stimulated	O
by	O
DA	B
could	O
be	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	B
,	O
a	O
selective	O
p38	O
MAPK	O
inhibitor	O
[	O
13	O
,	O
27	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
8	O
b	O
,	O
application	O
of	O
10	O
μM	O
SB	B
203580	I
completely	O
blocked	O
the	O
increases	O
in	O
GFAP	O
generation	O
stimulated	O
by	O
DA	B
at	O
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
μM	O
,	O
suggesting	O
that	O
activation	O
of	O
p38	O
MAPK	O
might	O
be	O
required	O
for	O
the	O
regulation	O
of	O
GFAP	O
generation	O
.	O

By	O
using	O
anti	O
-	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
immunoblotting	O
,	O
we	O
examined	O
the	O
effect	O
of	O
DA	B
on	O
p38	O
MAPK	O
phosphorylation	O
,	O
a	O
requirement	O
for	O
p38	O
MAPK	O
activity	O
[	O
42	O
]	O
.	O

With	O
the	O
application	O
of	O
100	O
μM	O
DA	B
to	O
C6-D2L	O
cells	O
,	O
p38	O
MAPK	O
was	O
rapidly	O
phosphorylated	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
at	O
15	O
min	O
,	O
then	O
gradually	O
decreased	O
to	O
basal	O
level	O
by	O
about	O
1	O
h	O
(	O
Fig.	O
9	O
a	O
)	O
.	O

The	O
p38	O
MAPK	O
phosphorylation	O
was	O
greatly	O
increased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
DA	B
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
μM	O
for	O
15	O
min	O
(	O
Fig.	O
9	O
b	O
)	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
(	B
+	I
)	I
-butaclamol	I
had	O
no	O
effect	O
on	O
DA	B
-	O
stimulated	O
phosphorylation	O
of	O
p38	O
MAPK	O
(	O
Fig.	O
9	O
c	O
)	O
.	O

These	O
data	O
suggest	O
that	O
DA	B
-	O
activated	O
p38	O
MAPK	O
may	O
not	O
be	O
mediated	O
by	O
D2	O
receptors	O
.	O

4	O
Discussion	O
In	O
this	O
paper	O
,	O
we	O
report	O
that	O
micromolar	O
levels	O
of	O
DA	B
stimulate	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
.	O

In	O
contrast	O
with	O
our	O
previous	O
report	O
for	O
earlier	O
mitogenesis	O
(	O
peaking	O
at	O
17	O
h	O
)	O
induced	O
by	O
nanomolar	O
levels	O
of	O
DA	B
[	O
30	O
]	O
,	O
this	O
mitogenesis	O
stimulated	O
by	O
micromolar	O
levels	O
of	O
DA	B
occurs	O
at	O
about	O
29	O
h.	O
Biochemically	O
,	O
the	O
earlier	O
phase	O
of	O
mitogenesis	O
requires	O
D2	O
receptor	O
–	O
MAPK	O
signaling	O
,	O
while	O
the	O
later	O
phase	O
requires	O
the	O
D2-receptor	O
–	O
tyrosine	O
kinase	O
pathway	O
.	O

Although	O
relationship	O
of	O
the	O
two	O
phases	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
is	O
not	O
clear	O
,	O
the	O
different	O
signaling	O
mechanisms	O
suggest	O
that	O
they	O
are	O
not	O
likely	O
to	O
be	O
dependent	O
on	O
each	O
other	O
.	O

For	O
example	O
,	O
nanomolar	O
levels	O
of	O
DA	B
strongly	O
stimulate	O
MAPK	O
without	O
significant	O
protein	O
tyrosine	B
phosphorylation	O
and	O
the	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
blockers	O
of	O
MAPK	O
pathway	O
.	O

Micromolar	O
levels	O
of	O
DA	B
strongly	O
stimulate	O
protein	O
tyrosine	O
kinase	O
without	O
effect	O
on	O
MAPK	O
,	O
and	O
the	O
consequent	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
tyrosine	B
kinase	I
inhibitors	I
but	O
not	O
by	O
blockers	O
of	O
the	O
MAPK	O
pathway	O
.	O

Under	O
normal	O
physiological	O
conditions	O
,	O
striatal	O
astrocytes	O
surround	O
dopaminergic	O
neurons	O
.	O

Although	O
the	O
astrocytes	O
do	O
not	O
have	O
synaptic	O
contact	O
with	O
dopaminergic	O
neurons	O
,	O
D2	O
receptors	O
in	O
astrocytes	O
may	O
sense	O
DA	B
(	O
low	O
concentrations	O
)	O
that	O
might	O
escape	O
from	O
the	O
synapse	O
and	O
play	O
a	O
physiological	O
role	O
via	O
the	O
MAPK	O
pathway	O
.	O

In	O
pathologic	O
conditions	O
,	O
such	O
as	O
ischemia	O
,	O
hypoxia	O
and	O
excitatory	B
amino	I
acid	I
-	O
induced	O
neurotoxicity	O
,	O
the	O
extracellular	O
DA	B
concentration	O
in	O
striata	O
is	O
significantly	O
increased	O
to	O
micromolar	O
levels	O
[	O
2	O
,	O
6	O
,	O
45	O
]	O
.	O

Although	O
the	O
length	O
of	O
DA	B
exposure	O
in	O
our	O
cell	O
culture	O
was	O
relatively	O
long	O
,	O
the	O
signaling	O
responses	O
,	O
such	O
as	O
protein	O
tyrosine	B
phosphorylation	O
and	O
p38	O
MAPK	O
phosphorylation	O
,	O
were	O
rapid	O
,	O
within	O
a	O
few	O
minutes	O
(	O
Fig.	O
3	O
a	O
,	O
Fig.	O
9	O
a	O
)	O
.	O

Thus	O
,	O
the	O
micromolar	O
level	O
DA	B
-	O
induced	O
activation	O
of	O
astrocytes	O
may	O
be	O
implicated	O
in	O
these	O
pathologic	O
conditions	O
.	O

Our	O
results	O
suggest	O
that	O
micromolar	O
levels	O
of	O
DA	B
activate	O
C6-D2L	O
cells	O
through	O
an	O
interaction	O
with	O
receptors	O
.	O

This	O
is	O
evident	O
since	O
DA	B
-	O
stimulated	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
(	B
+	I
)	I
-butaclamol	I
,	O
a	O
selective	O
D2	O
DA	B
receptor	O
antagonist	O
,	O
with	O
no	O
effect	O
of	O
(	B
−	I
)	I
-butaclamol	I
,	O
an	O
inactive	O
isoform	O
of	O
(	B
+	I
)	I
-butaclamol	I
.	O

Quinpirole	B
,	O
a	O
specific	O
D2	O
receptor	O
agonist	O
,	O
also	O
promotes	O
cell	O
cycle	O
progression	O
.	O

Furthermore	O
,	O
wild	O
-	O
type	O
C6	O
cells	O
,	O
lacking	O
the	O
expression	O
of	O
D2	O
receptors	O
,	O
exhibit	O
no	O
mitogenic	O
response	O
to	O
stimulation	O
by	O
DA	B
.	O

This	O
also	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
mitogenesis	O
might	O
be	O
mediated	O
by	O
ROS	B
produced	O
by	O
DA	B
autoxidation	O
.	O

However	O
,	O
considering	O
the	O
fact	O
that	O
C6	O
cells	O
contain	O
other	O
monoamine	B
receptors	O
,	O
such	O
as	O
β	O
adrenergic	O
receptors	O
[	O
35	O
]	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
micromolar	O
levels	O
of	O
DA	B
may	O
also	O
non	O
-	O
specifically	O
stimulate	O
these	O
receptors	O
and	O
may	O
cooperate	O
with	O
DA	B
receptors	O
.	O

A	O
receptor	O
-	O
mediated	O
mechanism	O
may	O
also	O
be	O
involved	O
in	O
GFAP	O
upregulation	O
stimulated	O
by	O
DA	B
since	O
GFAP	O
synthesis	O
could	O
not	O
be	O
prevented	O
by	O
preincubation	O
with	O
20	O
mM	O
NAC	B
,	O
which	O
can	O
scavenge	O
ROS	B
generated	O
either	O
by	O
DA	B
oxidation	O
or	O
through	O
a	O
D2-receptor	O
-	O
mediated	O
redox	O
system	O
.	O

Although	O
the	O
type	O
of	O
receptor	O
involved	O
in	O
DA	B
-	O
stimulated	O
GFAP	O
expression	O
is	O
currently	O
unknown	O
,	O
it	O
would	O
appear	O
not	O
to	O
be	O
D2	O
receptors	O
since	O
both	O
wild	O
-	O
type	O
C6	O
and	O
C6-D2L	O
cells	O
gave	O
a	O
similar	O
GFAP	O
regulatory	O
response	O
to	O
DA	B
stimulation	O
.	O

One	O
potential	O
candidate	O
would	O
be	O
β	O
adrenergic	O
receptors	O
,	O
shown	O
to	O
stimulate	O
GFAP	O
expression	O
through	O
cAMP	O
[	O
44	O
]	O
.	O

High	O
-	O
concentration	O
DA	B
-	O
stimulated	O
mitogenesis	O
appears	O
to	O
involve	O
the	O
intracellular	O
production	O
of	O
ROS	B
as	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

First	O
,	O
DA	B
-	O
stimulated	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
DPI	B
.	O

DPI	B
has	O
been	O
demonstrated	O
to	O
be	O
a	O
potent	O
and	O
selective	O
inhibitor	O
for	O
membrane	O
-	O
bound	O
NADPH	B
-	O
dependent	O
oxidase	O
through	O
a	O
binding	O
to	O
the	O
flavoprotein	O
component	O
of	O
the	O
oxidase	O
[	O
12	O
,	O
28	O
,	O
43	O
]	O
.	O

This	O
intracellular	O
NADPH	B
-	O
dependent	O
oxidase	O
can	O
directly	O
catalyze	O
substrate	B
oxygen	I
conversion	O
to	O
the	O
superoxide	B
anion	I
,	O
which	O
can	O
in	O
turn	O
generate	O
other	O
reactive	B
oxygen	I
intermediates	I
.	O

Secondly	O
,	O
DA	B
-	O
induced	O
mitogenesis	O
is	O
prevented	O
by	O
the	O
membrane	O
-	O
permeable	O
antioxidant	O
,	O
NAC	B
.	O

Finally	O
,	O
application	O
of	O
very	O
low	O
concentrations	O
of	O
H2	B
O2	I
can	O
enhance	O
both	O
DA	B
-	O
induced	O
protein	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
.	O

These	O
observations	O
suggest	O
that	O
ROS	B
may	O
serve	O
as	O
a	O
second	O
messenger	O
in	O
the	O
signaling	O
of	O
DA	B
-	O
stimulated	O
mitogenesis	O
,	O
adding	O
evidence	O
in	O
support	O
of	O
the	O
recent	O
notion	O
that	O
ROS	B
act	O
as	O
intracellular	O
messengers	O
of	O
cell	O
proliferation	O
[	O
22	O
]	O
.	O

Like	O
other	O
astrocyte	O
mitogens	B
,	O
such	O
as	O
endothelin	B
[	O
7	O
,	O
26	O
]	O
,	O
micromolar	O
level	O
DA	B
-	O
induced	O
mitogenesis	O
requires	O
tyrosine	B
phosphorylation	O
.	O

Application	O
of	O
DA	B
to	O
C6-D2L	O
cells	O
rapidly	O
increases	O
protein	O
tyrosine	B
phosphorylation	O
.	O

Concentration	O
-	O
dependent	O
tyrosine	B
phosphorylation	O
studies	O
show	O
a	O
similar	O
profile	O
to	O
that	O
of	O
DA	B
-	O
induced	O
DNA	O
synthesis	O
.	O

Both	O
protein	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
can	O
be	O
effectively	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
genistein	B
,	O
a	O
potent	O
protein	O
tyrosine	O
kinase	O
inhibitor	O
[	O
1	O
]	O
.	O

However	O
,	O
unlike	O
for	O
the	O
mitogen	B
endothelin	B
,	O
DA	B
-	O
stimulated	O
mitogenesis	O
is	O
not	O
linked	O
to	O
the	O
tyrosine	O
kinase	O
–	O
ERK	O
pathway	O
since	O
DA	B
at	O
micromolar	O
levels	O
has	O
no	O
stimulatory	O
effect	O
on	O
ERK	O
activation	O
.	O

Furthermore	O
,	O
PD098095	B
,	O
the	O
MEK1	O
inhibitor	O
,	O
has	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
high	O
concentration	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
although	O
it	O
does	O
have	O
some	O
inhibitory	O
effects	O
on	O
basal	O
DNA	O
synthesis	O
.	O

DA	B
-	O
stimulated	O
mitogenesis	O
at	O
micromolar	O
levels	O
is	O
partially	O
mediated	O
by	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
.	O

This	O
is	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

(	O
1	O
)	O
Pretreatment	O
of	O
the	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	O
only	O
inhibits	O
DA	B
-	O
stimulated	O
mitogenesis	O
by	O
about	O
24–50	O
%	O
,	O
depending	O
on	O
concentrations	O
of	O
DA	B
(	O
Fig.	O
1	O
b	O
)	O
.	O

(	O
2	O
)	O
Application	O
of	O
PTX	O
,	O
even	O
in	O
a	O
very	O
high	O
concentration	O
(	O
500	O
ng	O
/	O
ml	O
)	O
,	O
only	O
partially	O
blocks	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
.	O

(	O
3	O
)	O
The	O
ability	O
of	O
PTX	O
to	O
inhibit	O
protein	O
tyrosine	B
phosphorylation	O
is	O
correlated	O
with	O
that	O
to	O
inhibit	O
DA	B
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

These	O
observations	O
raise	O
the	O
possibility	O
that	O
PTX	O
-	O
resistant	O
G	O
proteins	O
may	O
participate	O
in	O
the	O
signaling	O
of	O
high	O
concentration	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
,	O
although	O
further	O
studies	O
are	O
required	O
.	O

Some	O
literature	O
reports	O
suggest	O
that	O
receptors	O
coupled	O
to	O
PTX	O
-	O
insensitive	O
G	O
proteins	O
or	O
the	O
small	O
G	O
protein	O
Ras	O
can	O
regulate	O
cell	O
proliferation	O
.	O

For	O
example	O
,	O
thrombin	O
,	O
an	O
astrocytic	O
mitogen	O
,	O
has	O
been	O
shown	O
to	O
stimulate	O
DNA	O
synthesis	O
in	O
1321N1	O
astrocytoma	O
cells	O
through	O
coupling	O
with	O
G12	O
,	O
a	O
Gq	O
subtype	O
of	O
GTP	O
binding	O
proteins	O
[	O
41	O
]	O
.	O

Recently	O
,	O
D2	O
receptors	O
were	O
also	O
reported	O
to	O
stimulate	O
prolactin	O
release	O
via	O
coupling	O
of	O
a	O
PTX	O
-	O
insensitive	O
G	O
protein	O
pathway	O
[	O
8	O
]	O
.	O

Whether	O
or	O
not	O
D2	O
receptors	O
might	O
be	O
coupled	O
to	O
PTX	O
-	O
insensitive	O
G	O
proteins	O
or	O
Ras	O
small	O
G	O
proteins	O
in	O
response	O
to	O
high	O
concentrations	O
of	O
DA	B
needs	O
further	O
study	O
.	O

Our	O
data	O
suggest	O
that	O
activation	O
of	O
p38	O
MAPK	O
is	O
required	O
for	O
upregulation	O
of	O
GFAP	O
synthesis	O
following	O
high	O
concentrations	O
of	O
DA	B
stimulation	O
.	O

This	O
is	O
based	O
on	O
the	O
following	O
observations	O
.	O

(	O
1	O
)	O
Micromolar	O
level	O
DA	B
-	O
stimulated	O
GFAP	O
production	O
can	O
be	O
completely	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	B
,	O
a	O
highly	O
selective	O
inhibitor	O
of	O
p38	O
MAPK	O
[	O
13	O
,	O
27	O
]	O
.	O

Inhibition	O
of	O
a	O
parallel	O
MAPK	O
pathway	O
by	O
PD098059	B
has	O
no	O
effect	O
on	O
DA	B
-	O
induced	O
GFAP	O
expression	O
,	O
suggesting	O
that	O
a	O
relative	O
specificity	O
of	O
p38	O
MAPK	O
may	O
play	O
a	O
role	O
in	O
GFAP	O
generation	O
.	O

(	O
2	O
)	O
DA	B
activates	O
p38	O
MAPK	O
activity	O
at	O
concentrations	O
similar	O
to	O
those	O
of	O
DA	B
-	O
induced	O
GFAP	O
expression	O
.	O

(	O
3	O
)	O
Both	O
activation	O
of	O
p38	O
MAPK	O
and	O
GFAP	O
synthesis	O
are	O
not	O
regulated	O
by	O
D2	O
receptors	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
the	O
regulation	O
of	O
GFAP	O
by	O
p38	O
MAPK	O
.	O

In	O
C6	O
cells	O
,	O
an	O
increase	O
in	O
intracellular	O
cAMP	B
,	O
either	O
by	O
stimulation	O
of	O
β	O
-	O
adrenergic	O
receptors	O
[	O
44	O
]	O
or	O
by	O
stimulation	O
of	O
adenylate	O
cyclase	O
by	O
forskolin	B
[	O
44	O
]	O
,	O
is	O
capable	O
of	O
stimulating	O
GFAP	O
.	O

The	O
relationship	O
of	O
cAMP	B
to	O
p38	O
MAPK	O
deserves	O
further	O
investigation	O
.	O

In	O
our	O
cell	O
culture	O
studies	O
,	O
at	O
least	O
two	O
pathways	O
have	O
been	O
demonstrated	O
to	O
activate	O
C6-D2L	O
glioma	O
cells	O
.	O

One	O
is	O
the	O
D2-receptor	O
-	O
required	O
intracellular	O
redox	O
–	O
protein	O
tyrosine	O
kinase	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
cell	O
mitogenesis	O
.	O

Another	O
is	O
the	O
D2	O
receptor	O
-	O
independent	O
p38	O
MAPK	O
cascade	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
GFAP	O
synthesis	O
.	O

Interestingly	O
,	O
in	O
an	O
in	O
vivo	O
rat	O
model	O
,	O
reactive	O
astrocytes	O
in	O
the	O
brain	O
respond	O
differently	O
to	O
brain	O
injury	O
.	O

Some	O
astrocytes	O
undergo	O
proliferation	O
as	O
indicated	O
only	O
by	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
;	O
some	O
exhibit	O
hypertrophy	O
labeled	O
only	O
by	O
GFAP	O
;	O
some	O
are	O
labeled	O
by	O
both	O
GFAP	O
and	O
[	B
3	I
H	I
]	I
thymidine	I
[	O
25	O
,	O
48	O
]	O
.	O

This	O
observation	O
suggests	O
that	O
these	O
two	O
separate	O
pathways	O
may	O
operate	O
in	O
the	O
in	O
vivo	O
situation	O
.	O

Taken	O
together	O
,	O
the	O
information	O
from	O
our	O
in	O
vitro	O
cell	O
culture	O
studies	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
in	O
vivo	O
striatal	O
astrocytic	O
response	O
and	O
help	O
to	O
elucidate	O
potential	O
roles	O
of	O
astrocytes	O
in	O
neurodegeneration	O
.	O

Acknowledgements	O

We	O
thank	O
Dr.	O
K.A.	O
Neve	O
for	O
providing	O
C6-D2L	O
cells	O
.	O

Malaria	O
is	O
still	O
the	O
most	O
important	O
parasitic	O
disease	O
in	O
the	O
world	O
,	O
causing	O
2–3	O
million	O
deaths	O
every	O
year	O
(	O
WHO	O
,	O
1997	O
)	O
.	O

The	O
rising	O
resistance	O
of	O
Plasmodium	O
spp	O
.	O
,	O
especially	O
Plasmodium	O
falciparum	O
,	O
to	O
known	O
antimalarials	O
such	O
as	O
chloroquine	B
makes	O
the	O
search	O
for	O
new	O
antimalarial	B
drugs	I
increasingly	O
important	O
.	O

Therefore	O
,	O
we	O
investigated	O
several	O
medicinal	O
plants	O
,	O
which	O
are	O
traditionally	O
used	O
as	O
antimalarial	O
or	O
antipyretic	O
remedies	O
by	O
the	O
indigenous	O
population	O
in	O
Latin	O
America	O
(	O
Duke	O
,	O
1975	O
;	O
Hirschhorn	O
,	O
1981	O
;	O
Joly	O
et	O
al.	O
,	O
1987	O
;	O
Gupta	O
et	O
al.	O
,	O
1993	O
)	O
.	O

During	O
a	O
screening	O
program	O
,	O
we	O
obtained	O
lipophilic	O
and	O
hydrophilic	O
extracts	O
of	O
these	O
plants	O
with	O
antiplasmodial	O
activity	O
and	O
we	O
selected	O
the	O
most	O
active	O
ones	O
for	O
further	O
investigation	O
(	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Andira	O
inermis	O
(	O
W.	O
Wright	O
)	O
H.B.K.	O
(	O
Fabaceae	O
)	O
is	O
a	O
tall	O
tree	O
characterised	O
by	O
a	O
thick	O
trunk	O
and	O
red	O
-	O
purple	O
flowers	O
,	O
native	O
from	O
southern	O
Mexico	O
to	O
northern	O
South	O
America	O
.	O

As	O
a	O
febrifuge	O
,	O
the	O
bark	O
is	O
boiled	O
in	O
milk	O
,	O
sweetened	O
water	B
or	O
performed	O
in	O
pills	O
.	O

It	O
is	O
also	O
used	O
as	O
a	O
purgative	O
,	O
vermifuge	O
,	O
or	O
for	O
dermal	O
irritations	O
.	O

The	O
seeds	O
have	O
similar	O
uses	O
.	O

Large	O
doses	O
of	O
the	O
stem	O
bark	O
or	O
seeds	O
caused	O
vomiting	O
and	O
violent	O
diarrhoea	O
;	O
in	O
some	O
cases	O
they	O
were	O
even	O
fatal	O
(	O
Hirschhorn	O
,	O
1981	O
;	O
Morton	O
,	O
1981	O
)	O
.	O

From	O
this	O
species	O
,	O
several	O
isoflavones	B
and	O
related	O
structures	O
have	O
been	O
reported	O
(	O
Cocker	O
et	O
al.	O
,	O
1962	O
;	O
Lock	O
de	O
Ugaz	O
et	O
al.	O
,	O
1991	O
)	O
.	O

The	O
lipophilic	O
extracts	O
of	O
stems	O
and	O
leaves	O
showed	O
moderate	O
in	O
vitro	O
activity	O
against	O
P.	O
falciparum	O
in	O
this	O
screening	O
program	O
and	O
were	O
further	O
analysed	O
by	O
bioassay	O
-	O
guided	O
fractionation	O
to	O
isolate	O
the	O
active	O
compounds	O
.	O

2	O
Material	O
and	O
methods	O
2.1	O
General	O
For	O
fractionation	O
,	O
silica	B
gel	I
60	I
(	O
70–230	O
mesh	O
)	O
was	O
utilised	O
.	O

Preparative	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
performed	O
on	O
a	O
Knauer	O
Eurochrom	O
2000	O
equipped	O
with	O
a	O
Nucleosil	B
P	I
300	I
C-18	I
(	O
10	O
μm	O
)	O
column	O
.	O

Mass	O
spectra	O
were	O
determined	O
with	O
a	O
Finnigan	O
MAT	O
CH7A	O
(	O
220	O
°	O
C	O
,	O
ionisation	O
70	O
eV	O
)	O
and	O
1	O
H	O
-	O
NMR	O
spectra	O
were	O
obtained	O
using	O
acetone	B
-	I
D6	I
as	O
a	O
solvent	O
with	O
a	O
Bruker	O
AVANCE	O
DPX	O
400	O
(	O
400	O
MHz	O
,	O
TMS	B
as	O
internal	O
standard	O
)	O
.	O

The	O
erythrocytes	O
were	O
harvested	O
with	O
an	O
Inotech	O
cell	O
harvester	O
and	O
the	O
β	O
-	O
radiation	O
of	O
the	O
incorporated	O
[	B
3	I
H	I
]	I
hypoxanthine	I
was	O
measured	O
with	O
a	O
Wallac	O
1450	O
MicroBeta	O
plus	O
liquid	O
scintillation	O
counter	O
.	O

2.2	O
Plant	O
material	O
Leaves	O
and	O
stems	O
of	O
A.	O
inermis	O
were	O
collected	O
in	O
the	O
area	O
of	O
Panama	O
City	O
(	O
at	O
the	O
road	O
El	O
Llano	O
-	O
Carti	O
)	O
,	O
Panama	O
,	O
during	O
March	O
1997	O
.	O

Voucher	O
specimens	O
(	O
FLORPAN	O
2758	O
)	O
were	O
identified	O
by	O
Professor	O
M.D.	O
Correa	O
A.	O
and	O
deposited	O
at	O
the	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
.	O

2.3	O
Extraction	O
and	O
isolation	O
In	O
the	O
screening	O
program	O
,	O
the	O
air	O
-	O
dried	O
stem	O
bark	O
and	O
leaves	O
(	O
20	O
g	O
)	O
were	O
extracted	O
three	O
times	O
for	O
2	O
h	O
with	O
150	O
ml	O
petroleum	B
ether	I
/	O
ethyl	B
acetate	I
(	O
1:1	O
)	O
at	O
room	O
temperature	O
.	O

Then	O
the	O
plant	O
material	O
was	O
air	O
dried	O
again	O
and	O
treated	O
three	O
times	O
with	O
150	O
ml	O
methanol	B
/	O
water	B
(	O
8:2	O
)	O
to	O
yield	O
the	O
hydrophilic	O
extracts	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
°	O
C	O
.	O

For	O
further	O
investigations	O
,	O
the	O
crushed	O
stems	O
(	O
600	O
g	O
)	O
were	O
air	O
dried	O
and	O
extracted	O
three	O
times	O
with	O
2	O
l	O
of	O
petroleum	B
ether	I
/	O
ethyl	B
acetate	I
(	O
1:1	O
)	O
for	O
24	O
h	O
at	O
room	O
temperature	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
°	O
C	O
.	O

The	O
oily	O
residue	O
(	O
3.3	O
g	O
)	O
was	O
subjected	O
to	O
column	O
chromatography	O
on	O
silica	B
gel	I
60	I
(	O
45	O
g	O
)	O
and	O
eluted	O
with	O
cyclohexane	B
,	O
cyclohexane	B
/	O
ethyl	B
acetate	I
mixtures	O
,	O
and	O
methanol	B
to	O
yield	O
seven	O
fractions	O
,	O
which	O
were	O
tested	O
against	O
P.	O
falciparum	O
.	O

Fraction	O
5	O
and	O
6	O
,	O
which	O
were	O
eluted	O
with	O
cyclohexane	B
/	O
ethyl	B
acetate	I
(	O
8:2	O
and	O
7:3	O
,	O
respectively	O
)	O
,	O
proved	O
to	O
be	O
most	O
active	O
.	O

Further	O
separation	O
of	O
fraction	O
5	O
(	O
150	O
mg	O
)	O
by	O
HPLC	O
at	O
a	O
5	O
ml	O
/	O
min	O
flow	O
rate	O
of	O
methanol	B
/	O
water	B
(	O
55:45	O
)	O
yielded	O
the	O
compounds	O
1	O
(	O
2.4	O
mg	O
)	O
,	O
2	O
(	O
6.1	O
mg	O
)	O
,	O
and	O
3	O
(	O
6.6	O
mg	O
)	O
.	O

Fraction	O
6	O
was	O
separated	O
with	O
methanol	B
/	O
water	B
(	O
45:55	O
)	O
to	O
give	O
the	O
compounds	O
4	O
(	O
8.3	O
mg	O
)	O
,	O
5	O
(	O
8.5	O
mg	O
)	O
,	O
and	O
6	O
(	O
1.6	O
mg	O
)	O
.	O

Compound	O
2	O
(	O
prunetin	B
)	O
:	O
EI	O
-	O
MS	O
:	O
m	O
/z	O
(	O
rel	O
.	O

int.	O
)	O
=284	O
(	O
M+	O
,	O
100	O
)	O
,	O
166	O
(	O
35	O
)	O
,	O
138	O
(	O
22	O
)	O
,	O
118	O
(	O
15	O
)	O
,	O
110	O
(	O
10	O
)	O
,	O
95	O
(	O
13	O
)	O
;	O
1	O
H	O
-	O
NMR	O
(	O
400	O
MHz	O
,	O
acetone	O
-	O
D6	O
):	O
δ	O
(	O
ppm	O
)	O
=3.93	O
(	O
3	O
H	O
,	O
s	O
,	O
CH3	O
O-7	O
)	O
,	O
6.36	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-6	O
)	O
,	O
6.55	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.4	O
Hz	O
,	O
H-8	O
)	O
,	O
6.91	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-3′,5′	O
)	O
,	O
7.47	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-2′,6′	O
)	O
,	O
8.22	O
(	O
1	O
H	O
,	O
s	O
,	O
H-2	O
)	O
,	O
13.4	O
(	O
1	O
H	O
,	O
s	O
,	O
OH-5	O
)	O
.	O

2.4	O
Antiplasmodial	O
bioassay	O
In	O
this	O
study	O
,	O
the	O
chloroquine	B
-	O
sensitive	O
strain	O
of	O
P.	O
falciparum	O
poW	O
(	O
IC50	O
=	O
0.015	O
μM	O
)	O
and	O
the	O
chloroquine	B
-	O
resistant	O
clone	O
Dd2	O
(	O
IC50	O
=	O
0.14	O
μM	O
)	O
were	O
used	O
.	O

They	O
were	O
maintained	O
in	O
continuous	O
culture	O
in	O
human	O
red	O
blood	O
cells	O
(	O
A+	O
)	O
diluted	O
to	O
5	O
%	O
haematocrit	O
in	O
RPMI	B
1640	I
medium	I
supplemented	O
with	O
25	O
mM	O
Hepes	B
,	O
30	O
mM	O
NaHCO3	B
,	O
and	O
10	O
%	O
human	O
A+	O
serum	O
.	O

Crude	O
extracts	O
and	O
isolated	O
compounds	O
were	O
dissolved	O
in	O
DMSO	B
(	O
1	O
mg	O
/	O
50	O
μl	O
)	O
and	O
diluted	O
in	O
RPMI	B
1640	I
medium	I
(	O
Trager	O
and	O
Jensen	O
,	O
1976	O
)	O
.	O

The	O
tests	O
were	O
performed	O
in	O
96-well	O
microtiter	O
plates	O
(	O
Desjardins	O
et	O
al.	O
,	O
1979	O
)	O
which	O
contained	O
150	O
μl	O
of	O
a	O
parasitized	O
red	O
blood	O
suspension	O
(	O
A+	O
,	O
2.5	O
%	O
haematocrit	O
,	O
0.5	O
%	O
parasitaemia	O
)	O
.	O

The	O
samples	O
were	O
added	O
to	O
give	O
final	O
concentrations	O
between	O
1.56	O
and	O
100	O
μg	O
/	O
ml	O
.	O

After	O
incubation	O
in	O
a	O
candle	O
jar	O
for	O
24	O
h	O
,	O
0.5	O
μCi	O
[	B
3	I
H	I
]	I
hypoxanthine	I
(	O
1	O
mCi	O
/	O
ml	O
,	O
ICN	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
for	O
another	O
18	O
h.	O
Incorporation	O
of	O
[	B
3	I
H	I
]	I
hypoxanthine	I
was	O
measured	O
by	O
liquid	O
scintillation	O
after	O
harvesting	O
the	O
cells	O
on	O
glass	O
fibre	O
filters	O
with	O
the	O
cell	O
harvester	O
.	O

All	O
tests	O
were	O
performed	O
in	O
triplicate	O
.	O

The	O
percentage	O
of	O
growth	O
inhibition	O
was	O
calculated	O
as	O
follows	O
:	O
(	O
1−	O
[	O
cpm	O
in	O
drug	O
treated	O
cultures	O
/	O
cpm	O
in	O
untreated	O
cultures	O
]	O
)	O
×	O
100	O
.	O

The	O
concentration	O
at	O
which	O
growth	O
was	O
inhibited	O
by	O
50	O
%	O
(	O
IC50	O
)	O
was	O
estimated	O
by	O
interpolation	O
.	O

Extracts	O
with	O
IC50	O
values	O
above	O
50	O
μg	O
/	O
ml	O
were	O
considered	O
to	O
be	O
inactive	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
)	O
.	O

3	O
Results	O
The	O
isolated	O
compounds	O
1–6	O
(	O
Fig.	O
1	O
)	O
turned	O
out	O
to	O
be	O
isoflavones	B
.	O

Compound	O
1	O
,	O
isolated	O
from	O
both	O
stems	O
and	O
leaves	O
was	O
identified	O
as	O
formononetin	B
by	O
comparison	O
with	O
an	O
authentic	O
sample	O
.	O

According	O
to	O
the	O
spectral	O
data	O
(	O
1	O
H	O
-	O
NMR	O
,	O
EI	O
-	O
MS	O
)	O
,	O
compound	O
2	O
proved	O
to	O
be	O
prunetin	B
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
1	O
H	O
-	O
NMR	O
values	O
for	O
prunetin	B
have	O
been	O
published	O
so	O
far	O
,	O
therefore	O
they	O
are	O
given	O
in	O
Section	O
2.3	O
.	O

The	O
isoflavones	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
were	O
identified	O
as	O
biochanin	B
A	I
,	O
calycosin	B
,	O
genistein	B
,	O
and	O
pratensein	B
,	O
respectively	O
,	O
by	O
comparison	O
of	O
1	O
H	O
-	O
NMR	O
and	O
EI	O
-	O
MS	O
with	O
published	O
data	O
(	O
Asres	O
et	O
al.	O
,	O
1985	O
;	O
Kobayashi	O
et	O
al.	O
,	O
1985	O
)	O
.	O

Prunetin	B
(	O
2	O
)	O
,	O
calycosin	B
(	O
4	O
)	O
,	O
and	O
pratensein	B
(	O
6	O
)	O
were	O
detected	O
for	O
the	O
first	O
time	O
from	O
the	O
genus	O
Andira	O
.	O

The	O
lipophilic	O
extracts	O
of	O
A.	O
inermis	O
exhibited	O
IC50	O
values	O
from	O
56.0	O
μg	O
/	O
ml	O
(	O
leaves	O
)	O
to	O
108.7	O
μg	O
/	O
ml	O
(	O
stems	O
)	O
against	O
P.	O
falciparum	O
in	O
vitro	O
(	O
Table	O
1	O
)	O
.	O

The	O
hydrophilic	O
extracts	O
proved	O
to	O
be	O
inactive	O
.	O

For	O
all	O
tested	O
substances	O
the	O
antiparasitic	O
activity	O
against	O
the	O
chloroquine	B
-	O
sensitive	O
strain	O
poW	O
was	O
higher	O
(	O
factor	O
two	O
)	O
than	O
against	O
the	O
chloroquine	B
-	O
resistant	O
clone	O
Dd2	O
.	O

Calycosin	B
(	O
IC50	O
4.2	O
μg	O
/	O
ml	O
for	O
poW	O
;	O
9.8	O
μg	O
/	O
ml	O
for	O
Dd2	O
)	O
and	O
genistein	B
(	O
IC50	O
2.0	O
μg	O
/	O
ml	O
for	O
poW	O
;	O
4.1	O
μg	O
/	O
ml	O
for	O
Dd2	O
)	O
proved	O
to	O
be	O
most	O
active	O
.	O

The	O
other	O
four	O
compounds	O
were	O
considered	O
to	O
be	O
inactive	O
.	O

4	O
Discussion	O
Although	O
the	O
lipophilic	O
extracts	O
of	O
A.	O
inermis	O
showed	O
only	O
moderate	O
antiplasmodial	O
activity	O
compared	O
to	O
those	O
known	O
for	O
other	O
plant	O
remedies	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
;	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
they	O
afforded	O
two	O
active	O
isoflavones	B
.	O

This	O
is	O
the	O
first	O
report	O
on	O
antiplasmodial	O
activity	O
of	O
isoflavones	B
against	O
P.	O
falciparum	O
.	O

The	O
low	O
concentration	O
of	O
calycosin	B
and	O
genistein	B
(	O
<	O
0.01	O
%	O
w	O
/	O
w	O
)	O
may	O
be	O
the	O
explanation	O
for	O
the	O
low	O
antiplasmodial	O
activity	O
of	O
the	O
crude	O
extract	O
.	O

It	O
is	O
known	O
that	O
calycosin	B
also	O
proved	O
to	O
be	O
active	O
against	O
Giardia	O
intestinalis	O
,	O
a	O
potent	O
protozoan	O
agent	O
for	O
enteric	O
diseases	O
(	O
ElSohly	O
et	O
al.	O
,	O
1999	O
)	O
.	O

During	O
the	O
preparation	O
of	O
this	O
paper	O
a	O
patent	O
application	O
was	O
published	O
(	O
Khan	O
et	O
al.	O
,	O
1999	O
)	O
,	O
which	O
claimed	O
a	O
method	O
of	O
treating	O
giardiasis	O
and/or	O
malaria	O
comprising	O
the	O
use	O
of	O
isoflavones	B
,	O
but	O
mentioning	O
no	O
data	O
,	O
proving	O
their	O
antiplasmodial	O
activity	O
against	O
P.	O
falciparum	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
focused	O
on	O
the	O
investigation	O
of	O
the	O
lipophilic	O
extract	O
.	O

The	O
indigenous	O
population	O
,	O
e.g.	O
in	O
Brazil	O
(	O
Morton	O
,	O
1981	O
)	O
,	O
prefer	O
to	O
boil	O
the	O
stem	O
bark	O
with	O
milk	O
.	O

This	O
procedure	O
covers	O
the	O
bitter	O
taste	O
and	O
probably	O
causes	O
the	O
extraction	O
of	O
lipophilic	O
constituents	O
.	O

Interestingly	O
,	O
hydrophilic	O
extracts	O
(	O
methanol	B
/	O
water	B
8:2	O
)	O
from	O
A.	O
inermis	O
did	O
not	O
show	O
antiplasmodial	O
activity	O
in	O
our	O
test	O
system	O
.	O

The	O
evaluation	O
of	O
extracts	O
obtained	O
with	O
water	B
or	O
milk	O
is	O
still	O
in	O
progress	O
and	O
might	O
be	O
interesting	O
with	O
regard	O
to	O
the	O
ethnobotanical	O
use	O
of	O
this	O
species	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
indebted	O
to	O
C.	O
Guerra	O
,	O
for	O
his	O
support	O
in	O
collecting	O
the	O
plant	O
material	O
,	O
and	O
to	O
Professor	O
M.D.	O
Correa	O
A.	O
,	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
,	O
Republic	O
of	O
Panama	O
,	O
for	O
her	O
identification	O
of	O
the	O
species	O
.	O

We	O
thank	O
Drs	O
D.S.	O
Kim	O
and	O
B.	O
Kleuser	O
,	O
Institut	O
für	O
Pharmazie	O
,	O
Freie	O
Universität	O
Berlin	O
,	O
Germany	O
,	O
for	O
their	O
advice	O
concerning	O
determination	O
of	O
radioactivity	O
.	O

This	O
study	O
was	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Deutsche	O
Pharmazeutische	O
Gesellschaft	O
to	O
K.	O
Jenett	O
-	O
Siems	O
and	O
by	O
Charité	O
Grant	O
Nr	O
.	O

98	O
-	O
700	O
.	O

CIFLORPAN	O
acknowledges	O
the	O
Fundation	O
Natura	O
and	O
the	O
Organization	O
of	O
American	O
States	O
(	O
OAS	O
)	O
for	O
financial	O
support	O
.	O

